FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Proverbio, AM
AF Proverbio, Alice Mado
TI Sex Differences in Social Cognition: The Case of Face Processing
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE gender differences; empathy; females; emotions; theory of mind;
   affective response
ID INFANT FACIAL EXPRESSIONS; EVENT-RELATED POTENTIALS; HIGH-FUNCTIONING
   AUTISM; GENDER-DIFFERENCES; NEURAL ACTIVATION; BABY SCHEMA; HORMONAL
   CONTRACEPTIVES; ORBITOFRONTAL CORTEX; NONHUMAN-PRIMATES;
   ASPERGER-SYNDROME
AB Several studies have demonstrated that women show a greater interest for social information and empathic attitude than men. This article reviews studies on sex differences in the brain, with particular reference to how males and females process faces and facial expressions, social interactions, pain of others, infant faces, faces in things (pareidolia phenomenon), opposite-sex faces, humans vs. landscapes, incongruent behavior, motor actions, biological motion, erotic pictures, and emotional information. Sex differences in oxytocin-based attachment response and emotional memory are also mentioned. In addition, we investigated how 400 different human faces were evaluated for arousal and valence dimensions by a group of healthy male and female University students. Stimuli were carefully balanced for sensory and perceptual characteristics, age, facial expression, and sex. As a whole, women judged all human faces as more positive and more arousing than men. Furthermore, they showed a preference for the faces of children and the elderly in the arousal evaluation. Regardless of face aesthetics, age, or facial expression, women rated human faces higher than men. The preference for opposite-vs. same-sex faces strongly interacted with facial age. Overall, both women and men exhibited differences in facial processing that could be interpreted in the light of evolutionary psychobiology. (C) 2016 Wiley Periodicals, Inc.
C1 [Proverbio, Alice Mado] Univ Milano Bicocca, Dept Psychol, Milan Mi Ctr Neurosci, Milan, Italy.
RP Proverbio, AM (reprint author), Univ Milano Bicocca, Dept Psychol, Piazza Ateneo Nuovo 1,U6 Bldg, I-20126 Milan, Italy.
EM mado.proverbio@unimib.it
FU University of Milano-Bicocca [13974 2015-ATE-0052]
FX Contract grant sponsor: University of Milano-Bicocca; Contract grant
   number: 13974 2015-ATE-0052.
CR Alexander GM, 2002, EVOL HUM BEHAV, V23, P467, DOI 10.1016/S1090-5138(02)00107-1
   ALLEY TR, 1981, DEV PSYCHOL, V17, P650, DOI 10.1037//0012-1649.17.5.650
   Anderson LC, 2013, NEUROIMAGE, V83, P751, DOI 10.1016/j.neuroimage.2013.07.040
   BABCHUK WA, 1985, ETHOL SOCIOBIOL, V6, P89, DOI 10.1016/0162-3095(85)90002-0
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   BERMAN PW, 1980, PSYCHOL BULL, V88, P668, DOI 10.1037/0033-2909.88.3.668
   BERMAN PW, 1975, SEX ROLES, V1, P311
   BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9
   Brosch T, 2007, EMOTION, V7, P685, DOI 10.1037/1528-3542.7.3.685
   Caldara R, 2004, NEUROREPORT, V15, P905, DOI 10.1097/01.wnr.0000119729.93564.3e
   Canessa N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042347
   Cardenas RA, 2013, EVOL HUM BEHAV, V34, P280, DOI 10.1016/j.evolhumbehav.2013.04.001
   Cloutier J, 2008, J COGNITIVE NEUROSCI, V20, P941, DOI 10.1162/jocn.2008.20062
   Conway C, 2008, P ROY SOC LOND B BIO, V7, P63
   Cornwell RE, 2004, P ROY SOC LOND B BIO, V22, P635
   DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebner NC, 2008, BEHAV RES METHODS, V40, P130, DOI [10.3758/BRM.40.1.130, 10.3738/BRM.40.1.130]
   Fischer H, 2004, NEUROREPORT, V15, P235, DOI 10.1097/00001756-200402090-00004
   Fischer H, 2004, COGN AFFECT BEHAV NE, V4, P326, DOI 10.3758/CABN.4.3.326
   Forte AJ, 2015, AESTHET PLAST SURG, V39, P856, DOI 10.1007/s00266-015-0553-1
   Galvan A, 2005, J NEUROSCI, V25, P8650, DOI 10.1523/JNEUROSCI.2431-05.2005
   Gard MG, 2007, EMOTION, V7, P429, DOI 10.1037/1528-3542.7.2.429
   Glocker ML, 2009, P NATL ACAD SCI USA, V106, P9115, DOI 10.1073/pnas.0811620106
   Glocker ML, 2009, ETHOLOGY, V115, P257, DOI 10.1111/j.1439-0310.2008.01603.x
   Griksiene R, 2011, PSYCHONEUROENDOCRINO, V36, P1239, DOI 10.1016/j.psyneuen.2011.03.001
   Hahn AC, 2014, NEUROSCI BIOBEHAV R, V46, P591, DOI 10.1016/j.neubiorev.2014.08.015
   Hahn AC, 2013, Q J EXP PSYCHOL, V66, P200, DOI 10.1080/17470218.2012.705860
   HALL JA, 1978, PSYCHOL BULL, V85, P845, DOI 10.1037//0033-2909.85.4.845
   Hall JK, 2010, COGNITION EMOTION, V24, P629, DOI 10.1080/02699930902906882
   Harmon-Jones E, 2011, PSYCHOL BULL, V137, P508, DOI 10.1037/a0022744
   Herman RA, 2003, HORM BEHAV, V43, P573, DOI 10.1016/S0018-506X(03)00067-9
   Huynh HK, 2012, J SEX MED, V9, P1579, DOI 10.1111/j.1743-6109.2012.02706.x
   Jack RE, 2015, CURR BIOL, V25, pR621, DOI 10.1016/j.cub.2015.05.052
   Klein S, 2003, PHARMACOPSYCHIATRY, V36, pS191
   Kranz F, 2006, CURR BIOL, V16, P63, DOI 10.1016/j.cub.2005.10.070
   Kringelbach ML, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001664
   Kuhn SL, 2006, CURR ANTHROPOL, V47, P953, DOI 10.1086/507197
   Lane RD, 1999, NEUROPSYCHOLOGIA, V37, P989, DOI 10.1016/S0028-3932(99)00017-2
   Lang PJ, 2010, BIOL PSYCHOL, V84, P437, DOI 10.1016/j.biopsycho.2009.10.007
   Lang PJ, 1988, INT AFFECTIVE PICTUR
   Lang P. J., 1997, INT AFFECTIVE PICTUR
   Law-Smith MJ, 2006, P ROY SOC B-BIOL SCI, V273, P135, DOI 10.1098/rspb.2005.3296
   Leibenluft E, 2004, BIOL PSYCHIAT, V56, P225, DOI 10.1016/j.biopsych.2004.05.017
   Leveroni CL, 1998, DEV NEUROPSYCHOL, V14, P321
   Little AC, 2002, P ROY SOC B-BIOL SCI, V269, P1095, DOI 10.1098/rspb.2002.1984
   Lu HJ, 2012, EVOL PSYCHOL-US, V10, P120
   Lundqvist D, 2005, VIS COGN, V12, P51, DOI 10.1080/13506280444000085
   Lundqvist D, 2015, COGNITION EMOTION, V29, P621, DOI 10.1080/02699931.2014.927352
   Lundqvist D, 2014, COGNITION EMOTION, V28, P1012, DOI 10.1080/02699931.2013.867479
   Luo LZ, 2011, J EXP CHILD PSYCHOL, V110, P115, DOI 10.1016/j.jecp.2011.04.002
   Maestripieri D, 2006, DEV REV, V26, P120, DOI 10.1016/j.dr.2006.02.006
   Maestripieri D, 2002, HUM NATURE-INT BIOS, V13, P327, DOI 10.1007/s12110-002-1018-1
   MCKELVIE SJ, 1993, J SOC BEHAV PERS, V8, P297
   Mordecai KL, 2008, HORM BEHAV, V54, P286, DOI 10.1016/j.yhbeh.2008.03.006
   Nielsen SE, 2014, BEHAV NEUROSCI, V128, P482, DOI 10.1037/a0036687
   Nielsen SE, 2011, NEUROBIOL LEARN MEM, V96, P378, DOI 10.1016/j.nlm.2011.06.013
   Nitschke JB, 2004, NEUROIMAGE, V21, P583, DOI 10.1016/j.neuroimaging.2003.10.005
   Oberman LM, 2007, SOC COGN AFFECT NEUR, V2, P62, DOI 10.1093/scan/nsl022
   Osgood Charles, 1957, MEASUREMENT MEANING
   Parsons CE, 2011, PLOS ONE, V6
   Parsons CE, 2013, SOC NEUROSCI-UK, V8, P525, DOI 10.1080/17470919.2013.842610
   Pavlova MA, 2015, PLOS ONE, V8
   Pavlova MA, 2015, CEREB CORTEX, V25, P3468, DOI 10.1093/cercor/bhu175
   Peltola MJ, 2014, EMOTION, V14, P469, DOI 10.1037/a0035959
   Penton-Voak IS, 2001, P ROY SOC B-BIOL SCI, V268, P1617, DOI 10.1098/rspb.2001.1703
   Perrett DI, 1998, NATURE, V394, P884, DOI 10.1038/29772
   Petersen N, 2015, HUM BRAIN MAPP, V36, P2644, DOI 10.1002/hbm.22797
   Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025
   Proverbio AM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-44
   Proverbio AM, 2016, SOC COGN AFFECT NEUR, V11, P1501, DOI 10.1093/scan/nsw064
   Proverbio AM, 2007, SCAND J PSYCHOL, V48, P477, DOI 10.1111/j.1467-9450.2007.00616.x
   Proverbio AM, 2006, NEUROPSYCHOLOGIA, V44, P2987, DOI 10.1016/j.neuropsychologia.2006.06.015
   Proverbio AM, 2012, NEUROPSYCHOLOGIA, V50, P2325, DOI 10.1016/j.neuropsychologia.2012.05.036
   Proverbio AM, 2011, J COGNITIVE NEUROSCI, V23, P3197, DOI 10.1162/jocn_a_00041
   Proverbio AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022026
   Proverbio AM, 2010, NEUROPSYCHOLOGIA, V48, P1454, DOI 10.1016/j.neuropsychologia.2010.01.015
   Proverbio AM, 2009, NEUROPSYCHOLOGIA, V47, P2374, DOI 10.1016/j.neuropsychologia.2008.10.030
   Proverbio A.M., 2011, PSYCHOLOGY, V02, P931, DOI DOI 10.4236/PSYCH.2011.29140
   Proverbio AM, 2008, BMC NEUROSCI, V30, P56
   Proverbio AM, 2010, FRONT PSYCHOL, V18, P169
   Proverbio AM, 2010, PLOS ONE, V21, P5
   Ramirez SM, 2004, HORM BEHAV, V46, P520, DOI 10.1016/j.yhbeh.2004.05.009
   Rhodes G, 2006, ANNU REV PSYCHOL, V57, P199, DOI 10.1146/annurev.psych.57.102904.190208
   Rhodes MG, 2012, PSYCHOL BULL, V138, P146, DOI 10.1037/a0025750
   Russell JA, 2003, BRAIN RES, V110, P145
   Sabatinelli D, 2004, NEUROREPORT, V15, P1109, DOI 10.1097/01.wnr.0000126558.41468.3d
   Sander K, 2007, HUM BRAIN MAPP, V28, P1007, DOI 10.1002/hbm.20333
   Seifritz E, 2003, BIOL PSYCHIAT, V54, P1367, DOI 10.1016/S0006-3223(03)00697-8
   Spreckelmeyer KN, 2013, NEUROIMAGE, V66, P223, DOI 10.1016/j.neuroimage.2012.10.068
   Strathearn L, 2008, PEDIATRICS, V122, P40, DOI 10.1542/peds.2007-1566
   Suyama N, 2008, INT J NEUROSCI, V118, P1227, DOI 10.1080/00207450601047176
   Thompson AE, 2014, COGNITION EMOTION, V28, P1164, DOI 10.1080/02699931.2013.875889
   Tiedt HO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069107
   Turk DJ, 2004, NEUROIMAGE, V22, P1281, DOI 10.1016/j.neuroimage.2004.02.037
   Walker PM, 2003, PERCEPTION, V32, P1117, DOI 10.1068/p5098
   Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004
NR 99
TC 0
Z9 0
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0360-4012
EI 1097-4547
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD JAN-FEB
PY 2017
VL 95
IS 1-2
BP 222
EP 234
DI 10.1002/jnr.23817
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA EC9DI
UT WOS:000388443900023
PM 27870403
ER

PT J
AU Rubin, LH
   Yao, L
   Keedy, SK
   Reilly, JL
   Bishop, JR
   Carter, CS
   Pournajafi-Nazarloo, H
   Drogos, LL
   Tamminga, CA
   Pearlson, GD
   Keshavan, MS
   Clementz, BA
   Hill, SK
   Liao, W
   Ji, GJ
   Lui, S
   Sweeney, JA
AF Rubin, Leah H.
   Yao, Li
   Keedy, Sarah K.
   Reilly, James L.
   Bishop, Jeffrey R.
   Carter, C. Sue
   Pournajafi-Nazarloo, Hossein
   Drogos, Lauren L.
   Tamminga, Carol A.
   Pearlson, Godfrey D.
   Keshavan, Matcheri S.
   Clementz, Brett A.
   Hill, Scot K.
   Liao, Wei
   Ji, Gong-Jun
   Lui, Su
   Sweeney, John A.
TI Sex Differences in Associations of Arginine Vasopressin and Oxytocin
   With Resting-State Functional Brain Connectivity
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE sex differences; oxytocin; vasopressin; resting state; brain function
ID MEDIAL PREFRONTAL CORTEX; VERBAL FLUENCY TASKS; NETWORKS; AMYGDALA;
   METAANALYSIS; EMOTION; HUMANS; NEUROPEPTIDES; SCHIZOPHRENIA;
   NEUROBIOLOGY
AB Oxytocin (OT) and arginine vasopressin (AVP) exert robust and sexually dimorphic influences on cognition and emotion. How these hormones regulate relevant functional brain systems is not well understood. OT and AVP serum concentrations were assayed in 60 healthy individuals (36 women). Brain functional networks assessed with resting-state functional magnetic resonance imaging (rs-fMRI) were constructed with graph theory-based approaches that characterize brain networks as connected nodes. Sex differences were demonstrated in rs-fMRI. Men showed higher nodal degree (connectedness) and efficiency (information propagation capacity) in left inferior frontal gyrus (IFG) and bilateral superior temporal gyrus (STG) and higher nodal degree in left rolandic operculum. Women showed higher nodal betweenness (being part of paths between nodes) in right putamen and left inferior parietal gyrus (IPG). Higher hormone levels were associated with less intrinsic connectivity. In men, higher AVP was associated with lower nodal degree and efficiency in left IFG (pars orbitalis) and left STG and less efficiency in left IFG (pars triangularis). In women, higher AVP was associated with lower betweenness in left IPG, and higher OT was associated with lower nodal degree in left IFG (pars orbitalis). Hormones differentially correlate with brain networks that are important for emotion processing and cognition in men and women. AVP in men and OT in women may regulate orbital frontal cortex connectivity, which is important in emotion processing. Hormone associations with STG and pars triangularis in men and parietal cortex in women may account for well-established sex differences in verbal and visuospatial abilities, respectively. (C) 2016 Wiley Periodicals, Inc.
C1 [Rubin, Leah H.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
   [Yao, Li; Lui, Su; Sweeney, John A.] Sichuan Univ, West China Hosp, Dept Radiol, 37 Guoxue Xiang, Chengdu 610041, Sichuan, Peoples R China.
   [Keedy, Sarah K.] Univ Chicago, Psychiat, Chicago, IL 60637 USA.
   [Reilly, James L.] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
   [Bishop, Jeffrey R.] Univ Minnesota, Pharm & Psychiat, Minneapolis, MN USA.
   [Carter, C. Sue; Pournajafi-Nazarloo, Hossein] Kinsey Inst, Bloomington, IN USA.
   [Drogos, Lauren L.] Univ Calgary, Hotchkiss Brain Inst, Dept Physiol, Calgary, AB, Canada.
   [Drogos, Lauren L.] Univ Calgary, Hotchkiss Brain Inst, Dept Pharmacol, Calgary, AB, Canada.
   [Tamminga, Carol A.; Sweeney, John A.] Univ Texas Southwestern Med Ctr Dallas, Psychiat, Dallas, TX 75390 USA.
   [Pearlson, Godfrey D.] Yale Univ, Dept Psychiat, Hartford, CT USA.
   [Pearlson, Godfrey D.] Yale Univ, Dept Neurobiol, Hartford, CT USA.
   [Pearlson, Godfrey D.] Olin Neuropsychiat Res Ctr, Hartford, CT USA.
   [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
   [Keshavan, Matcheri S.] Harvard Med Sch, Boston, MA USA.
   [Clementz, Brett A.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
   [Hill, Scot K.] Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL USA.
   [Liao, Wei] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Minist Educ, Ctr Informat Biomed,Key Lab Neuroinformat, Chengdu, Peoples R China.
   [Ji, Gong-Jun] Anhui Med Univ, Dept Med Psychol, Lab Cognit Neuropsychol, Hefei, Peoples R China.
RP Lui, S (reprint author), Sichuan Univ, West China Hosp, Dept Radiol, 37 Guoxue Xiang, Chengdu 610041, Sichuan, Peoples R China.
EM lusuwcums@hotmail.com
FU Brain and Behavior Research Foundation; National Institutes of Health
   [K12HD055892, K08MH083888, MH083126, MH077851, MH078113, MH077945,
   MH077852, MH077862]; National Natural Science Foundation of China
   [81371527]; Program for Changjiang Scholars and Innovative Research Team
   in University of China
FX Contract grant sponsor: Brain and Behavior Research Foundation (to
   L.H.R.); Contract grant sponsor: National Institutes of Health; Contract
   grant number: #K12HD055892; Contract grant number: #K08MH083888;
   Contract grant number: #MH083126; Contract grant number: #MH077851;
   Contract grant number: #MH078113; Contract grant number: #MH077945;
   Contract grant number: #MH077852; Contract grant number: MH077862;
   Contract grant sponsor: National Natural Science Foundation of China;
   Contract grant number: 81371527; Contract grant sponsor: Program for
   Changjiang Scholars and Innovative Research Team in University of China.
CR Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017
   Allen Elena A, 2011, Front Syst Neurosci, V5, P2, DOI 10.3389/fnsys.2011.00002
   Andreano JM, 2009, LEARN MEMORY, V16, P248, DOI 10.1101/lm.918309
   Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107
   Bluhm RL, 2008, NEUROREPORT, V19, P887, DOI 10.1097/WNR.0b013e328300ebbf
   Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253
   Cahill L, 2003, ANN NY ACAD SCI, V985, P163
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Carter CS, 2007, ANN NY ACAD SCI, V1098, P312, DOI 10.1196/annals.1384.006
   Carter CS, 2009, DEV NEUROSCI-BASEL, V31, P332, DOI 10.1159/000216544
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Costafreda SG, 2006, HUM BRAIN MAPP, V27, P799, DOI 10.1002/hbm.20221
   De Vries GJ, 2006, NEUROSCIENCE, V138, P947, DOI 10.1016/j.neuroscience.2005.07.050
   de Frias C.M., 2006, NEUROPSYCHOL DEV C B, V13, P574
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Ebner NC, 2016, PSYCHONEUROENDOCRINO, V69, P50, DOI 10.1016/j.psyneuen.2016.03.013
   Fernandez-Guasti A, 2000, J COMP NEUROL, V425, P422, DOI 10.1002/1096-9861(20000925)425:3<422::AID-CNE7>3.0.CO;2-H
   Filippi M, 2013, HUM BRAIN MAPP, V34, P1330, DOI 10.1002/hbm.21514
   Frederikse ME, 1999, CEREB CORTEX, V9, P896, DOI 10.1093/cercor/9.8.896
   FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312
   Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490
   Goldstein JM, 2002, ARCH GEN PSYCHIAT, V59, P480
   Gur Raquel E, 2002, Dialogues Clin Neurosci, V4, P197
   Gur RC, 2002, J NEUROSCI METH, V115, P137, DOI 10.1016/S0165-0270(02)00006-7
   Gur Ruben C, 2013, Dialogues Clin Neurosci, V15, P399
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hjelmervik H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103492
   Kimura D., 1999, SEX COGNITION
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kong J, 2010, BEHAV BRAIN RES, V211, P215, DOI 10.1016/j.bbr.2010.03.042
   KRAMER JH, 1988, J CLIN PSYCHOL, V44, P907, DOI 10.1002/1097-4679(198811)44:6<907::AID-JCLP2270440610>3.0.CO;2-8
   Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577
   Kumar J, 2015, INT J NEUROPSYCHOPH, V18
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701
   Lee Royce J, 2013, Front Syst Neurosci, V7, P100, DOI 10.3389/fnsys.2013.00100
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Liu HS, 2009, P NATL ACAD SCI USA, V106, P20499, DOI 10.1073/pnas.0908073106
   MANN VA, 1990, NEUROPSYCHOLOGIA, V28, P1063, DOI 10.1016/0028-3932(90)90141-A
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Motoki K, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00480
   Ochsner KN, 2004, NEUROIMAGE, V23, P483, DOI 10.1016/j.neuroimage.2004.06.030
   Onnela JP, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.065103
   Petersen N, 2014, NEUROIMAGE, V90, P24, DOI 10.1016/j.neuroimage.2013.12.016
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Power JD, 2010, NEURON, V67, P735, DOI 10.1016/j.neuron.2010.08.017
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Ross CA, 1996, TRENDS NEUROSCI, V19, P171, DOI 10.1016/S0166-2236(96)10022-9
   Rubin LH, 2014, SCHIZOPHRENIA BULL, V40, P1374, DOI 10.1093/schbul/sbu027
   Rubin LH, 2011, SCHIZOPHR RES, V130, P266, DOI 10.1016/j.schres.2011.06.002
   Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003
   Ruigrok ANV, 2014, NEUROSCI BIOBEHAV R, V39, P34, DOI 10.1016/j.neubiorev.2013.12.004
   Sacher J, 2013, MAGN RESON IMAGING, V31, P366, DOI 10.1016/j.mri.2012.06.007
   Satterthwaite TD, 2013, NEUROIMAGE, V64, P240, DOI 10.1016/j.neuroimage.2012.08.052
   Singer T, 2008, EMOTION, V8, P781, DOI 10.1037/a0014195
   Smeltzer MD, 2006, NEUROSCI LETT, V394, P146, DOI 10.1016/j.neulet.2005.10.019
   Sripada CS, 2013, INT J NEUROPSYCHOPH, V16, P255, DOI 10.1017/S1461145712000533
   Stevens JS, 2012, NEUROPSYCHOLOGIA, V50, P1578, DOI 10.1016/j.neuropsychologia.2012.03.011
   Tomasino Barbara, 2015, Front Hum Neurosci, V9, P693, DOI 10.3389/fnhum.2015.00693
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250
   Wagner S, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-19
   Wang J, 2014, NEUROIMAGE, V91, P91, DOI 10.1016/j.neuroimage.2014.01.003
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Weiss EM, 2006, J INT NEUROPSYCH SOC, V12, P502, DOI 10.1017/S1355617706060656
   Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X
   Weissman-Fogel I, 2010, HUM BRAIN MAPP, V31, P1713, DOI 10.1002/hbm.20968
   Welton Thomas, 2015, Brain Connect, V5, P193, DOI 10.1089/brain.2014.0313
   Whittle S, 2011, BIOL PSYCHOL, V87, P319, DOI 10.1016/j.biopsycho.2011.05.003
   Wig GS, 2011, ANN NY ACAD SCI, V1224, P126, DOI 10.1111/j.1749-6632.2010.05947.x
   Williams LM, 2009, J CLIN EXP NEUROPSYC, V31, P257, DOI 10.1080/13803390802255635
   Yan CG, 2013, NEUROIMAGE, V76, P183, DOI 10.1016/j.neuroimage.2013.03.004
   Zhang JR, 2011, BIOL PSYCHIAT, V70, P334, DOI 10.1016/j.biopsych.2011.05.018
   Zink CF, 2010, J NEUROSCI, V30, P7017, DOI 10.1523/JNEUROSCI.4899-09.2010
   Zuo XN, 2010, J NEUROSCI, V30, P15034, DOI 10.1523/JNEUROSCI.2612-10.2010
NR 79
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0360-4012
EI 1097-4547
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD JAN-FEB
PY 2017
VL 95
IS 1-2
BP 576
EP 586
DI 10.1002/jnr.23820
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA EC9DI
UT WOS:000388443900054
PM 27870395
ER

PT J
AU Poromaa, IS
   Comasco, E
   Georgakis, MK
   Skalkidou, A
AF Poromaa, Inger Sundstrom
   Comasco, Erika
   Georgakis, Marios K.
   Skalkidou, Alkistis
TI Sex Differences in Depression During Pregnancy and the Postpartum Period
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Review
DE peripartum depression; sex; testosterone; cortisol; oxytocin;
   neuroimaging
ID CORTICOTROPIN-RELEASING HORMONE; PROGENITOR-CELL PROLIFERATION; NEWLY
   GENERATED NEURONS; MATERNAL-BEHAVIOR; ADULT NEUROGENESIS; HIPPOCAMPAL
   NEUROGENESIS; PATERNAL BEHAVIOR; MENTAL-HEALTH; PRAIRIE VOLE; HUMAN
   BRAIN
AB Women have a lifetime risk of major depression double that of men but only during their reproductive years. This sex difference has been attributed partially to activational effects of female sex steroids and also to the burdens of pregnancy, childbirth, and parenting. Men, in contrast, have a reproductive period difficult to delineate, and research on the mental health of men has rarely considered the effects of fatherhood. However, the couple goes through a number of potentially stressing events during the reproductive period, and both mothers and fathers are at risk of developing peripartum depression. This Review discusses the literature on maternal and paternal depression and the endocrine changes that may predispose a person to depression at this stage of life, with specific focus on the hypothalamus-pituitary axis, oxytocin, and testosterone levels in men. Important findings on sex differences in the neural correlates of maternal and paternal behavior have emerged, highlighting the relevance of the emotional brain in mothers and the socio-cognitive brain in fathers and pointing toward the presence of a common parents' brain. Additionally, sex differences in neurogenesis and brain plasticity are described in relation to peripartum depression. (C) 2016 The Authors. Journal of Neuroscience Research Published by Wiley Periodicals, Inc.
C1 [Poromaa, Inger Sundstrom; Georgakis, Marios K.; Skalkidou, Alkistis] Uppsala Univ, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden.
   [Comasco, Erika] Uppsala Univ, Dept Neurosci, Uppsala, Sweden.
   [Georgakis, Marios K.] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece.
RP Poromaa, IS (reprint author), Uppsala Univ, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden.
EM inger.sundstrom@kbh.uu.se
FU Swedish Research Council [523-2014-2342, 521-2013-2339, VR: 2015-00495];
   Uppsala University Hospital; Marta Lundqvist Foundation [2013, 2014];
   Tore Nilson Foundation [2014]; Swedish Society of Medicine [SLS-331991,
   SLS-332691]; Marie Sklodowska Curie Fellowship; EU FP7-People-Cofund
   [INCA 600398]
FX Contract grant sponsor: Swedish Research Council; Contract grant number:
   523-2014-2342 (to A.S.); Contract grant number: 521-2013-2339 (to
   I.S.P.); Contract grant sponsor: Uppsala University Hospital (to A.S.,
   I.S.P.); Contract grant sponsor: Marta Lundqvist Foundation; Contract
   grant number: 2013; Contract grant number: 2014; Contract grant sponsor:
   Tore Nilson Foundation; Contract grant number: 2014; Contract grant
   sponsor: Swedish Society of Medicine; Contract grant number: SLS-331991
   (to E.C.); Contract grant number: SLS-332691 (to E.C.); Contract grant
   sponsor: Marie Sklodowska Curie Fellowship (to E.C.); Contract grant
   sponsor: Swedish Research Council; Contract grant number: VR: 2015-00495
   (to E.C.); Contract grant sponsor: EU FP7-People-Cofund; Contract grant
   number: INCA 600398 (to E.C.).
CR Abraham E, 2014, P NATL ACAD SCI USA, V111, P9792, DOI 10.1073/pnas.1402569111
   Akbari EM, 2007, BEHAV NEUROSCI, V121, P1001, DOI 10.1037/0735-7044.121.5.1001
   Amanatkar HR, 2014, ANN CLIN PSYCHIATRY, V26, P19
   Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Archer J, 2006, NEUROSCI BIOBEHAV R, V30, P319, DOI 10.1016/j.neubiorev.2004.12.007
   Atzil S, 2012, J AM ACAD CHILD PSY, V51, P798, DOI 10.1016/j.jaac.2012.06.008
   Bales KL, 2004, HORM BEHAV, V45, P354, DOI 10.1016/j.yhbeh.2004.01.004
   Bannbers E, 2013, BEHAV BRAIN RES, V241, P132, DOI 10.1016/j.bbr.2012.12.003
   Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004
   Bedard A, 2002, NEUROSCI LETT, V328, P213, DOI 10.1016/S0304-3940(02)00530-X
   Bedard A, 2006, EXP BRAIN RES, V170, P501, DOI 10.1007/s00221-005-0233-5
   Berg SJ, 2001, MAYO CLIN PROC, V76, P582
   Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999
   Biaggi A, 2016, J AFFECT DISORDERS, V191, P62, DOI 10.1016/j.jad.2015.11.014
   Bloch M, 2000, AM J PSYCHIAT, V157, P924, DOI 10.1176/appi.ajp.157.6.924
   Blom EA, 2010, BJOG-INT J OBSTET GY, V117, P1390, DOI 10.1111/j.1471-0528.2010.02660.x
   Boldrini M, 2012, BIOL PSYCHIAT, V72, P562, DOI 10.1016/j.biopsych.2012.04.024
   BRIDGES RS, 1985, SCIENCE, V227, P782, DOI 10.1126/science.3969568
   BRIDGES RS, 1978, ENDOCRINOLOGY, V102, P258
   Bromet E, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-90
   Cheng YH, 2000, J CLIN ENDOCR METAB, V85, P1937, DOI 10.1210/jc.85.5.1937
   Chrousos George P., 1998, Annals of Internal Medicine, V129, P229
   Cohen LS, 2006, JAMA-J AM MED ASSOC, V295, P499, DOI 10.1001/jama.295.5.499
   Comasco E, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0619-4
   Comasco E, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00388
   Comasco E, 2011, ARCH WOMEN MENT HLTH, V14, P453, DOI 10.1007/s00737-011-0239-x
   Cox EQ, 2015, PSYCHONEUROENDOCRINO, V55, P164, DOI 10.1016/j.psyneuen.2015.02.009
   Darnaudery M, 2007, PSYCHONEUROENDOCRINO, V32, P803, DOI 10.1016/j.psyneuen.2007.05.012
   Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053
   De Dreu CKW, 2012, HORM BEHAV, V61, P419, DOI 10.1016/j.yhbeh.2011.12.009
   Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961
   Dias CC, 2015, J AFFECT DISORDERS, V171, P142, DOI 10.1016/j.jad.2014.09.022
   DORR HG, 1989, J CLIN ENDOCR METAB, V68, P863
   Duke SA, 2014, J ADOLESCENT HEALTH, V55, P315, DOI 10.1016/j.jadohealth.2014.05.007
   Edelstein RS, 2015, AM J HUM BIOL, V27, P317, DOI 10.1002/ajhb.22670
   Edward KL, 2015, AM J MENS HEALTH, V9, P26, DOI 10.1177/1557988314526614
   Endendijk JJ, 2016, HORM BEHAV, V80, P68, DOI 10.1016/j.yhbeh.2016.01.016
   Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044
   Escriba-Aguir V, 2011, J EPIDEMIOL COMMUN H, V65, P320, DOI 10.1136/jech.2008.085894
   Esscher A, 2016, BRIT J PSYCHIAT, V208, P462, DOI 10.1192/bjp.bp.114.161711
   Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2015, TRENDS NEUROSCI, V38, P387, DOI 10.1016/j.tins.2015.04.004
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Figueiredo B, 2011, ARCH WOMEN MENT HLTH, V14, P247, DOI 10.1007/s00737-011-0217-3
   Fleming AS, 1997, HORM BEHAV, V32, P85, DOI 10.1006/hbeh.1997.1407
   Fleming AS, 1997, HORM BEHAV, V31, P145, DOI 10.1006/hbeh.1997.1376
   FLEMING AS, 1989, PHYSIOL BEHAV, V46, P449, DOI 10.1016/0031-9384(89)90019-X
   Fowler CD, 2002, J NEUROBIOL, V51, P115, DOI 10.1002/neu.10042
   Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db
   Gettler LT, 2011, HORM BEHAV, V60, P599, DOI 10.1016/j.yhbeh.2011.08.009
   Gettler LT, 2011, P NATL ACAD SCI USA, V108, P16194, DOI 10.1073/pnas.1105403108
   Gingnell M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128964
   Glasper ER, 2011, J COMP NEUROL, V519, P2271, DOI 10.1002/cne.22628
   Glynn LM, 2014, PSYCHOSOM MED, V76, P355, DOI 10.1097/PSY.0000000000000066
   Goldstein JM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00247
   Goodman JH, 2004, J ADV NURS, V45, P26, DOI 10.1046/j.1365-2648.2003.02857.x
   Gordon I, 2010, PHYSIOL BEHAV, V101, P679, DOI 10.1016/j.physbeh.2010.08.008
   Gordon I, 2010, HORM BEHAV, V58, P513, DOI 10.1016/j.yhbeh.2010.04.007
   Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548
   Gutierrez-Galve L, 2015, PEDIATRICS, V135, pE339, DOI 10.1542/peds.2014-2411
   Hahn-Holbrook Jennifer, 2013, Clin Psychol Sci, V1, P253
   Haines HM, 2015, SEX REPROD HEALTHC, V6, P204, DOI 10.1016/j.srhc.2015.05.002
   Hannerfors AK, 2015, PSYCHONEUROENDOCRINO, V58, P104, DOI 10.1016/j.psyneuen.2015.04.009
   HARRIS B, 1994, BRIT MED J, V308, P949
   Hellgren C, 2013, PSYCHONEUROENDOCRINO, V38, P3150, DOI 10.1016/j.psyneuen.2013.08.007
   Hillerer KM, 2014, HIPPOCAMPUS, V24, P673, DOI 10.1002/hipo.22258
   Huang LY, 1998, J NEUROBIOL, V36, P410, DOI 10.1002/(SICI)1097-4695(19980905)36:3<410::AID-NEU8>3.0.CO;2-Z
   Hunter Theresa, 2014, Health Promot Perspect, V4, P132, DOI 10.5681/hpp.2014.017
   Iliadis S, 2015, PSYCHONEUROENDOCRINO, V61, P61, DOI 10.1016/j.psyneuen.2015.07.556
   Iliadis SI, 2016, DEPRESS ANXIETY, V33, P1023, DOI 10.1002/da.22529
   Inta D, 2008, P NATL ACAD SCI USA, V105, P20994, DOI 10.1073/pnas.0807059105
   Ito J, 2013, J HUM LACT, V29, P491, DOI 10.1177/0890334413488680
   Jung C, 2011, J CLIN ENDOCR METAB, V96, P1533, DOI 10.1210/jc.2010-2395
   Kempton MJ, 2011, ARCH GEN PSYCHIAT, V68, P675, DOI 10.1001/archgenpsychiatry.2011.60
   Kersting Anette, 2012, Dialogues Clin Neurosci, V14, P187
   Kerstis B, 2016, ARCH WOMEN MENT HLTH, V19, P87, DOI 10.1007/s00737-015-0522-3
   KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G
   Kim P, 2015, FRONT PSYCHOL, V6, DOI [10.3389/fpsyg.2015.01772, 10.3389/fpsyg2015.01772]
   Kim P, 2014, SOC NEUROSCI-UK, V9, P522, DOI 10.1080/17470919.2014.933713
   Kim P, 2010, BEHAV NEUROSCI, V124, P695, DOI 10.1037/a0020884
   Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360
   Kronmuller KT, 2008, BRIT J PSYCHIAT, V192, P472, DOI 10.1192/bjp.bp.107.040378
   Kuijper EAM, 2013, REPROD BIOMED ONLINE, V27, P33, DOI 10.1016/j.rbmo.2013.03.009
   Kuo PX, 2012, BIOL PSYCHOL, V91, P302, DOI 10.1016/j.biopsycho.2012.08.002
   Kuzawa CW, 2009, HORM BEHAV, V56, P429, DOI 10.1016/j.yhbeh.2009.07.010
   Leckman JF, 2004, J NEURAL TRANSM, V111, P753, DOI 10.1007/s00702-003-0067-x
   Lee Margherita M, 2013, Curr Top Behav Neurosci, V14, P153, DOI 10.1007/7854_2012_226
   Leuner B, 2006, HORM BEHAV, V50, P38, DOI 10.1016/j.yhbeh.2006.01.002
   Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153
   Leuner B, 2007, HIPPOCAMPUS, V17, P434, DOI 10.1002/hipo.20278
   Leuner B, 2016, FRONT NEUROENDOCRIN, V41, P99, DOI 10.1016/j.yfrne.2016.02.004
   Leuner B, 2010, TRENDS NEUROSCI, V33, P465, DOI 10.1016/j.tins.2010.07.003
   Li WQ, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00074
   Lieberwirth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00171
   Lieberwirth C, 2013, EUR J NEUROSCI, V38, P3345, DOI 10.1111/ejn.12323
   Lindahl V, 2005, ARCH WOMEN MENT HLTH, V8, P77, DOI 10.1007/s00737-005-0080-1
   Lonstein JS, 2015, HORM BEHAV, V73, P156, DOI 10.1016/j.yhbeh.2015.06.011
   Lorberbaum JP, 1999, DEPRESS ANXIETY, V10, P99, DOI 10.1002/(SICI)1520-6394(1999)10:3<99::AID-DA2>3.0.CO;2-#
   Luzzati F, 2006, J NEUROSCI, V26, P609, DOI 10.1523/JNEUROSCI.4371-05.2006
   MacKinnon AL, 2014, PSYCHONEUROENDOCRINO, V48, P52, DOI 10.1016/j.psyneuen.2014.06.003
   Magiakou MA, 1996, J CLIN ENDOCR METAB, V81, P1912, DOI 10.1210/jc.81.5.1912
   Martin JL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008758
   Martins MV, 2016, HUM REPROD UPDATE, V22, P466, DOI 10.1093/humupd/dmw009
   Mascaro JS, 2014, SOC COGN AFFECT NEUR, V9, P1704, DOI 10.1093/scan/nst166
   Matthey S, 2000, J AFFECT DISORDERS, V60, P75, DOI 10.1016/S0165-0327(99)00159-7
   Mehta D, 2012, J AFFECT DISORDERS, V136, P1192, DOI 10.1016/j.jad.2011.11.042
   Mitchell C, 2011, P NATL ACAD SCI USA, V108, P8189, DOI 10.1073/pnas.1014129108
   Morse CA, 2000, J PSYCHOSOM OBST GYN, V21, P109, DOI 10.3109/01674820009075616
   Moses-Kolko EL, 2014, J NEUROENDOCRINOL, V26, P665, DOI 10.1111/jne.12183
   Muller MN, 2009, P R SOC B, V276, P347, DOI 10.1098/rspb.2008.1028
   Munk-Olsen T, 2009, ARCH GEN PSYCHIAT, V66, P189, DOI 10.1001/archgenpsychiatry.2008.528
   Norhayati MN, 2015, J AFFECT DISORDERS, V175, P34, DOI 10.1016/j.jad.2014.12.041
   Nunes S, 2001, HORM BEHAV, V39, P70, DOI 10.1006/hbeh.2000.1631
   Nunes-Costa RA, 2014, PSICOL-REFLEX CRIT, V27, P794, DOI 10.1590/1678-7153.201427420
   O'Hara MW, 2013, ANNU REV CLIN PSYCHO, V9, P379, DOI 10.1146/annurev-clinpsy-050212-185612
   OHARA MW, 1982, J ABNORM PSYCHOL, V91, P457, DOI 10.1037//0021-843X.91.6.457
   OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801
   Okuda H, 2009, J NEUROSCI RES, V87, P3546, DOI 10.1002/jnr.22160
   Parker KJ, 2001, HORM BEHAV, V39, P285, DOI 10.1006/hbeh.2001.1655
   Paulson JF, 2016, ARCH WOMEN MENT HLTH, V19, P655, DOI 10.1007/s00737-016-0598-4
   Paulson JF, 2010, JAMA-J AM MED ASSOC, V303, P1961, DOI 10.1001/jama.2010.605
   Pawlby S, 2009, J AFFECT DISORDERS, V113, P236, DOI 10.1016/j.jad.2008.05.018
   Pawluski JL, 2007, NEUROSCIENCE, V149, P53, DOI 10.1016/j.neuroscience.2007.07.031
   Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x
   Perheentupa A, 2004, FERTIL STERIL, V82, P903, DOI 10.1016/j.fertnstert.2004.02.141
   Pope CJ, 2016, DEPRESS RES TREAT, V2016
   Poromaa IS, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00380
   Poromaa IS, 2012, ACTA OBSTET GYN SCAN, V91, P420, DOI 10.1111/j.1600-0412.2011.01333.x
   Raisanen S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-004047
   Raymond AD, 2006, BRAIN RES, V1102, P44, DOI 10.1016/j.brainres.2006.04.113
   Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006
   Ruscio MG, 2008, BEHAV BRAIN RES, V187, P9, DOI 10.1016/j.bbr.2007.08.028
   Saaltink DJ, 2014, CELL MOL LIFE SCI, V71, P2499, DOI 10.1007/s00018-014-1568-5
   Saltzman W, 2011, PROG NEURO-PSYCHOPH, V35, P1192, DOI 10.1016/j.pnpbp.2010.09.017
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Seifritz E, 2003, BIOL PSYCHIAT, V54, P1367, DOI 10.1016/S0006-3223(03)00697-8
   Sherriff Nigel, 2014, Community Pract, V87, P20
   Shors TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep18960
   SIEGEL HI, 1978, HORM BEHAV, V11, P12, DOI 10.1016/0018-506X(78)90054-5
   Skalkidou Alkistis, 2012, Womens Health (Lond), V8, P659, DOI 10.2217/whe.12.55
   Soares CN, 2008, J PSYCHIATR NEUROSCI, V33, P331
   Soares CN, 2014, MENOPAUSE, V21, P198, DOI 10.1097/GME.0000000000000193
   STALLA GK, 1989, GYNECOL ENDOCRINOL, V3, P1, DOI 10.3109/09513598909152447
   Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0
   Storey AE, 2000, EVOL HUM BEHAV, V21, P79, DOI 10.1016/S1090-5138(99)00042-2
   Storey AE, 2011, HORM BEHAV, V60, P353, DOI 10.1016/j.yhbeh.2011.07.001
   Swain JE, 2014, INFANT MENT HEALTH J, V35, P394, DOI 10.1002/imhj.21471
   Swain JE, 2014, BRAIN RES, V1580, P78, DOI 10.1016/j.brainres.2014.03.007
   Swain JE, 2007, J CHILD PSYCHOL PSYC, V48, P262, DOI 10.1111/j.1469-7610.2007.01731.x
   Swain JE, 2012, BEHAV BRAIN SCI, V35, P378, DOI 10.1017/S0140525X12001112
   Tanapat P, 2005, J COMP NEUROL, V481, P252, DOI 10.1002/cne.20385
   Toffoletto S, 2014, PSYCHONEUROENDOCRINO, V50, P28, DOI 10.1016/j.psyneuen.2014.07.025
   Tuohy Alan, 2008, Psychol Health Med, V13, P43, DOI 10.1080/13548500701294531
   van Anders SM, 2012, HORM BEHAV, V61, P31, DOI 10.1016/j.yhbeh.2011.09.012
   Vesga-Lopez O, 2008, ARCH GEN PSYCHIAT, V65, P805, DOI 10.1001/archpsyc.65.7.805
   Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957
   Vigod SN, 2013, CAN MED ASSOC J, V185, P1129, DOI 10.1503/cmaj.122028
   Volgsten H, 2008, HUM REPROD, V23, P2056, DOI 10.1093/humrep/den154
   Wee KY, 2011, J AFFECT DISORDERS, V130, P358, DOI 10.1016/j.jad.2010.06.019
   Wilson S, 2010, CLIN PSYCHOL REV, V30, P167, DOI 10.1016/j.cpr.2009.10.007
   Wittfoth-Schardt D, 2012, NEUROPSYCHOPHARMACOL, V37, P1799, DOI 10.1038/npp.2012.47
   Wynne-Edwards KE, 2007, HORM BEHAV, V52, P114, DOI 10.1016/j.yhbeh.2007.03.018
   Wynne-Edwards KE, 2001, HORM BEHAV, V40, P139, DOI 10.1006/hbeh.2001.1699
   Yee LM, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.10.029
   Yim IS, 2009, ARCH GEN PSYCHIAT, V66, P162, DOI 10.1001/archgenpsychiatry.2008.533
NR 166
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0360-4012
EI 1097-4547
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD JAN-FEB
PY 2017
VL 95
IS 1-2
BP 719
EP 730
DI 10.1002/jnr.23859
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA EC9DI
UT WOS:000388443900069
ER

PT J
AU Ozalp, RG
   Yavuz, A
   Orman, A
   Seker, I
   Kucuksen, DU
   Risvanli, A
   Demiral, OO
   Wehrend, A
AF Ozalp, R. G.
   Yavuz, A.
   Orman, A.
   Seker, I.
   Kucuksen, D. Udum
   Risvanli, A.
   Demiral, O. O.
   Wehrend, A.
TI Parturition induction in ewes by a progesterone receptor blocker,
   aglepristone, and subsequent neonatal survival: Preliminary results
SO THERIOGENOLOGY
LA English
DT Article
DE Ewe; Aglepristone; Parturition induction; Lambs
ID DEXAMETHASONE-INDUCED PARTURITION; MIDGESTATION PREGNANCY TERMINATION;
   ANTAGONIST AGLEPRISTONE; BIRTH-WEIGHT; BODY-TEMPERATURE; LITTER SIZE;
   SHEEP; BITCHES; METABOLISM; FETAL
AB The clinical effects of aglepristone treatment to induce parturition in ewes and their newborns were reported. Three experimental groups were defined: group AG5 (n = 5), group AG10 (n = 5), and group CG (n = 5) in which ewes were injected twice with 5, 10 mg/kg of aglepristone, and saline solution of ewes, respectively. Different parameters associated with parturition in ewes and their newborns were investigated. Serum progesterone, oxytocin, and free and conjugated total estrogens were measured after treatments until parturition. No statistical difference was found from first aglepristone administration to onset of lambing between AG5 and AG10 (23.90 +/- 6.20, 40.00 +/- 6.71 hours). Parturition induction in two groups shortened the gestational length significantly compared with the control group (P = 0.003). Dystocia was observed in two ewes in group AG10. The placental weight showed statistically significant difference only between the AG10 and CG (P = 0.039), but no difference was observed in the placental expulsion period between the groups. Decrease in food consumption 24 to 36 hours after parturition in all ewes and skin necrosis in an ewe in group AG5 were observed. Progesterone concentration was significantly lower in AG5 than that in ewes in group AG10 and CG (P < 0.05). No difference was observed in concentrations of free total estrogens and oxytocin between groups. The body temperature of lambs was significantly different between AG10 and CG groups both right after (P = 0.011) and 12 hours after parturition (P = 0.014). The lambs in CG had the highest mean birth weight (4.29 +/- 0.28 kg), which was significantly different from the induced groups. No significant difference of blood pH and blood gases values between groups was identified both at birth and 12 hours after parturition for lambs. Significant differences could clearly be observed in total protein and blood urea nitrogen and total protein findings 12 hours after parturition (P < 0.05), whereas no difference was found in blood glucose, albumin, inorganic phosphor, triglyceride, or total cholesterol parameters. The results of this study show that the administration of aglepristone to induce parturition can precisely control lambing time without any side effects in either mothers or lambs. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ozalp, R. G.; Yavuz, A.] Uludag Univ, Dept Obstet & Gynecol, Fac Vet Med, Bursa, Turkey.
   [Orman, A.] Uludag Univ, Dept Zootech, Fac Vet Med, Bursa, Turkey.
   [Seker, I.] Firat Univ, Fac Vet Med, Dept Zootech, Elazig, Turkey.
   [Kucuksen, D. Udum] Uludag Univ, Dept Biochem, Fac Vet Med, Bursa, Turkey.
   [Risvanli, A.] Firat Univ, Fac Vet Med, Dept Obstet & Gynecol, Elazig, Turkey.
   [Demiral, O. O.] Erciyes Univ, Dept Reprod & Artificial Inseminat, Fac Vet Med, Kayseri, Turkey.
   [Wehrend, A.] Justus Liebig Univ, Clin Obstet Gynecol & Androl Large & Small Anim, Giessen, Germany.
RP Ozalp, RG (reprint author), Uludag Univ, Dept Obstet & Gynecol, Fac Vet Med, Bursa, Turkey.
EM rgozalp@uludag.edu.tr
FU Uludag University Scientific Research Projects Unit (BAP) [UAP
   (V)-2011/22]
FX This work was supported by the Uludag University Scientific Research
   Projects Unit (BAP) (project number UAP (V)-2011/22). The manuscript was
   edited by American Journal Experts and Akademik Makale Tercume. The
   authors would like to thank E.Sinem Ozdemir Salci for her help to
   collect blood samples of ewes in group AG5.
CR ALEXANDER G., 1958, AUSTRALIAN JOUR AGRIC RES, V9, P339, DOI 10.1071/AR9580339
   Baan M, 2005, THERIOGENOLOGY, V63, P1958, DOI 10.1016/j.theriogenology.2004.09.008
   Balios SA, 2008, EGYPT J SHEEP GOAT S, V3, P65
   Batista M, 2011, REPROD DOMEST ANIM, V46, P882, DOI 10.1111/j.1439-0531.2011.01759.x
   CHALLIS JRG, 1976, PROSTAGLANDINS, V11, P1041, DOI 10.1016/0090-6980(76)90011-3
   Corrada Y, 2005, ANIM REPROD SCI, V87, P295, DOI 10.1016/j.anireprosci.2004.11.012
   Crespi EJ, 2006, J PHYSIOL-LONDON, V572, P119, DOI 10.1113/jphysiol.2005.103929
   Dwyer CM, 2006, J ANIM SCI, V84, P1093
   EDEY TN, 1985, AUST VET J, V62, P104, DOI 10.1111/j.1751-0813.1985.tb14152.x
   Fieni F, 2009, REPROD DOMEST ANIM, V44, P167, DOI 10.1111/j.1439-0531.2009.01419.x
   Fieni F, 2001, J REP FER S, P243
   Fieni F, 2006, THERIOGENOLOGY, V66, P1721, DOI 10.1016/j.theriogenology.2006.02.026
   FLINT APF, 1976, J ENDOCRINOL, V69, P433, DOI 10.1677/joe.0.0690433
   Fontbonne A, 2009, REPROD DOMEST ANIM, V44, P170, DOI 10.1111/j.1439-0531.2009.01377.x
   Galac S, 2000, THERIOGENOLOGY, V53, P941, DOI 10.1016/S0093-691X(00)00241-7
   GAZAL OS, 1993, J REPROD FERTIL, V97, P233
   Georgiev P, 2006, THERIOGENOLOGY, V65, P1401, DOI 10.1016/j.theriogenology.2005.08.011
   Georgiev P, 2010, REPROD DOMEST ANIM, V45, pE161, DOI 10.1111/j.1439-0531.2009.01540.x
   Greenwood PL, 2002, J ANIM SCI, V80, P2850
   Greenwood PL, 2000, REPROD FERT DEVELOP, V12, P149, DOI 10.1071/RD00053
   HARMAN EL, 1980, J ANIM SCI, V50, P391
   HARRISON FA, 1982, BRIT VET J, V138, P402
   Ingoldby L, 2001, IN PRACTICE, V23, P228
   JENKINSON CMC, 1995, NEW ZEAL J AGR RES, V38, P337
   Kastelic JP, 1996, CAN VET J, V37, P101
   KOENIG MV, 1984, ARCH MED VET, V16, P7
   Konyali A, 2007, ANIM REPROD SCI, V97, P394, DOI 10.1016/j.anireprosci.2006.09.008
   LIGGINS GC, 1971, NATURE, V232, P629, DOI 10.1038/232629a0
   Liggins GC, 1973, MEM SOC ENDOCR, V30, P119
   LINZELL JL, 1968, J ENDOCRINOL, V41, P433, DOI 10.1677/joe.0.0410433
   Miller DR, 2009, J ANIM SCI, V87, P3167, DOI 10.2527/jas.2009-1825
   Mota-Rojas D, 2005, ANIM REPROD SCI, V86, P131, DOI 10.1016/j.anireprosci.2004.06.004
   OAKES G, 1973, P SOC EXP BIOL MED, V142, P194
   Ozalp GR, 2008, THERIOGENOLOGY, V69, P1056, DOI 10.1016/j.theriogenology.2008.01.016
   Pastor J, 2001, PEQUENOS RUMINANTES, V2, P18
   Piccione G, 2013, LARGE ANIM REV, V19, P133
   RESTALL BJ, 1976, AUST J EXP AGR, V16, P462, DOI 10.1071/EA9760462
   RUBIANES E, 1991, THERIOGENOLOGY, V36, P329, DOI 10.1016/0093-691X(91)90390-Y
   Shenavai S, 2012, REPRODUCTION, V144, P279, DOI 10.1530/REP-11-0471
   Shenavai S, 2010, REPRODUCTION, V140, P623, DOI 10.1530/REP-10-0182
   SHEVAH Y, 1974, ANIM PROD, V18, P89
   Sir C, 2010, LIVEST SCI, V131, P119, DOI 10.1016/j.livsci.2010.03.011
   Tontis A, 1987, Tierarztl Prax, V15, P25
   Tsiligianni T, 2008, ACTA VET HUNG, V56, P393, DOI 10.1556/AVet.56.2008.3.12
   WEBSTER GM, 1981, ANIM PROD, V32, P341
   Wehrend A, 2005, J VET MED A, V52, P472, DOI 10.1111/j.1439-0442.2005.00759.x
   WORSFOLD AI, 1986, BRIT VET J, V142, P195
NR 47
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD JAN 1
PY 2017
VL 87
BP 141
EP 147
DI 10.1016/j.theriogenology.2016.08.016
PG 7
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA ED0PJ
UT WOS:000388544100017
PM 27658744
ER

PT J
AU Rebordao, MR
   Galvao, A
   Pinto-Bravo, P
   Pinheiro, J
   Gamboa, S
   Silva, E
   Mateus, L
   Ferreira-Dias, G
AF Rebordao, Maria R.
   Galvao, Antonio
   Pinto-Bravo, Pedro
   Pinheiro, Joana
   Gamboa, Sandra
   Silva, Elisabete
   Mateus, Luisa
   Ferreira-Dias, Graca
TI Endometrial prostaglandin synthases, ovarian steroids, and oxytocin
   receptors in mares with oxytocin-induced luteal maintenance
SO THERIOGENOLOGY
LA English
DT Article
DE Mare; Luteal phase; Oxytocin; Endometrium; Steroids receptors; Oxytocin
   receptor
ID EARLY-PREGNANCY; ESTROUS-CYCLE; EQUINE ENDOMETRIUM;
   PROGESTERONE-RECEPTOR; CORPUS-LUTEUM; CORPORA-LUTEA; SEX STEROIDS; F-2
   ALPHA; IN-VITRO; EXPRESSION
AB Oxytocin (OXT) has been used to prolong the luteal phase in mares, but its mechanism of action is unknown. The aim of this study was to evaluate the effect of chronic exogenous OXT administration to mid-luteal phase mares on luteal maintenance: Also, endometrial expression of prostaglandin endoperoxide synthase 2 (PTGS2), prostaglandin F-2 alpha, E-2 and I-2 synthases (AKR1C3, PTGES, and PTGIS), oxytocin receptor (OXTR), progesterone receptor (PGR), and estrogen receptors 1 (ESR1) and 2 (ESR2) were assessed in mares experiencing luteal maintenance 2 weeks after chronic exogenous OXT administration. Control mares (n = 5; C group) received 6 mL of saline im, whereas OXT (60 units/mare) was administered im (n = 6; OXT group), every 12 hours, on days 7 to 14 postovulation. After endometrial biopsy in groups C (Day 10) and OXT (Day 24), luteolysis occurred within 3 or 6 days, respectively. Luteal maintenance took place in 4 of 6 (67%) of OXT-treated mares. Progesterone in C group was the highest on biopsy day (P < 0.05). In OXT mares, PTGS2, ESR1 (P < 0.05), PTGES, PTGIS, PGR, and ESR2 (P < 0.01) gene transcription decreased, whereas OXTR increased (P < 0.05) in comparison with the C group. In OXT-treated mares, endometrial ESR2 protein expression decreased (P < 0.05), but OXTR increased (P < 0.05) compared with control animals. In both experimental groups, PTGS2 was mainly immunolocalized in surface epithelium, whereas AKR1C3, PTGES, PTGIS, and PGR were in surface and glandular epithelia. ESR1 and ESR2 were found in glandular epithelium and OXTR in stromal cells. High immunolabeling for PTGES, PTGIS, PGR, and OXTR and low for ESR2 was detected in endometrium of OXT-group mares with extended diestrus. Prolonged luteal function associated with chronic OXT treatment may be related to different spatial expression of OXTR and PGR in the endometrium. The observed reduction of endometrial ESR2 may be responsible for the maintenance of PGR in luminal and glandular epithelium. Also, ESR2 may attenuate the transcriptional activity of ESR1 in mare endometrium. This study offers new knowledge on the endometrial expression of ovarian steroids and OXT receptors in OXT pharmacologically induced luteal maintenance in the mare. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Rebordao, Maria R.; Galvao, Antonio; Pinto-Bravo, Pedro; Silva, Elisabete; Mateus, Luisa; Ferreira-Dias, Graca] Univ Lisbon, CIISA, Fac Vet Med, Lisbon, Portugal.
   [Rebordao, Maria R.; Pinto-Bravo, Pedro; Pinheiro, Joana; Gamboa, Sandra] Coimbra Coll Agr, Dept Anim Sci, Coimbra, Portugal.
   [Galvao, Antonio] Inst Anim Reprod & Food Res PAS, Dept Reprod Immunol & Pathol, Olsztyn, Poland.
RP Ferreira-Dias, G (reprint author), Univ Lisbon, CIISA, Fac Vet Med, Lisbon, Portugal.
EM gmlfdias@fmv.ulisboa.pt
RI Galvao, Antonio/F-7040-2014; CIISA, FMV/D-2242-2016
OI Galvao, Antonio/0000-0002-7990-3071; 
FU Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/CVT/121805/2010,
   PTDC/CVT-REP/4202/2014]
FX This work was supported by Fundacao para a Ciencia e a Tecnologia,
   Portugal (grant numbers: PTDC/CVT/121805/2010; PTDC/CVT-REP/4202/2014).
   The authors would like to thank Professor Sheryl S. King, former
   Professor of Animal Science, Southern Illinois University at Carbondale,
   Carbondale, IL, USA, for kindly proofreading the document. The authors
   also would like to thank Mrs Maria do Rosario Luis for assistance on
   histology preparations.
CR Asselin E, 1996, BIOL REPROD, V54, P371, DOI 10.1095/biolreprod54.2.371
   Atli MO, 2010, ANIM REPROD SCI, V122, P124, DOI 10.1016/j.anireprosci.2010.08.007
   Bae SE, 2003, THERIOGENOLOGY, V60, P909, DOI 10.1016/S0093-691X(02)01362-6
   BAKER CB, 1981, AM J VET RES, V42, P1816
   Behrendt-Adam CY, 1999, DOMEST ANIM ENDOCRIN, V16, P183, DOI 10.1016/S0739-7240(99)00008-9
   Bishop CV, 2008, VET J, V176, P270, DOI 10.1016/j.tvjl.2007.05.014
   Boerboom D, 2004, BIOL REPROD, V70, P391, DOI 10.1095/biolreprod.103.020800
   Catalano RD, 2011, MOL HUM REPROD, V17, P182, DOI 10.1093/molehr/gaq094
   Conneely OM, 2000, STEROIDS, V65, P571, DOI 10.1016/S0039-128X(00)00115-X
   Dheda K, 2004, BIOTECHNIQUES, V37, P112
   Ferreira-Dias G, 2006, DOMEST ANIM ENDOCRIN, V30, P247, DOI 10.1016/j.domaniend.2005.07.007
   Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI [10.1210/en.2005-1120, 10.1210/en.2006-0349]
   Galvao A, 2013, REPROD FERT DEVELOP, V25, P985, DOI 10.1071/RD12153
   Galvao A, 2016, ENDOCRINOLOGY, V157, P858, DOI 10.1210/en.2015-1362
   Galvao A, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.097147
   Galvao AM, 2010, BIOL REPROD, V83, P901, DOI 10.1095/biolreprod.110.084699
   Gebhardt S, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103226
   Gee EK, 2012, NEW ZEAL VET J, V60, P189, DOI 10.1080/00480169.2011.651095
   Ginther OJ, 2011, DOMEST ANIM ENDOCRIN, V41, P174, DOI 10.1016/j.domaniend.2011.06.003
   Ginther OJ, 2005, BIOL REPROD, V73, P315, DOI 10.1095/biolreprod.105.040253
   Hapangama DK, 2015, HUM REPROD UPDATE, V21, P174, DOI 10.1093/humupd/dmu053
   Hartt LS, 2005, REPRODUCTION, V130, P241, DOI 10.1530/rep.1.00596
   Honnens A, 2011, J REPROD DEVELOP, V57, P43, DOI 10.1262/jrd.10-023T
   Katila T, 2011, PFERDEHEILKUNDE, V27, P261
   Keith L, 2013, THERIOGENOLOGY, V79, P616, DOI 10.1016/j.theriogenology.2012.11.015
   KENNEY RM, 1978, J AM VET MED ASSOC, V172, P241
   Kimura T, 2003, J MOL ENDOCRINOL, V30, P109, DOI 10.1677/jme.0.0300109
   King SS, 2010, ANIM REPROD SCI, V117, P232, DOI 10.1016/j.anireprosci.2009.04.012
   Kurita T, 2006, BIOL REPROD, V6, P821
   Large MJ, 2012, MOL CELL ENDOCRINOL, V358, P155, DOI 10.1016/j.mce.2011.07.027
   Lee J, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.112.106427
   McDowell KJ, 1999, J REPROD FERTIL, V117, P135
   Merkl M, 2010, BIOL REPROD, V83, P874, DOI 10.1095/biolreprod.110.085233
   Miller L., ANAL GELS W BLOTS IM
   NEELY DP, 1979, J REPROD FERTIL, V55, P303
   Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965
   Ruijter-Villani M, 2015, REPROD FERT DEVELOP, V27, P834
   Sharp DC, 1997, J REPROD FERTIL, V109, P137
   Silva ESM, 2014, ANIM REPROD SCI, V151, P169, DOI 10.1016/j.anireprosci.2014.11.001
   Soloff MS, 2000, EXP PHYSIOL, V85, p51S, DOI 10.1111/j.1469-445X.2000.tb00007.x
   Starbuck GR, 1998, J REPROD FERTIL, V113, P173
   Stout TAE, 2002, REPRODUCTION, V123, P261, DOI 10.1530/rep.0.1230261
   Stout TAE, 1999, J REPROD FERTIL, V116, P315
   Vanderwall DK, 2007, JAVMA-J AM VET MED A, V231, P1864, DOI 10.2460/javma.231.12.1864
   Vanderwall DK, 2016, J EQUINE VET SCI, V36, P1, DOI 10.1016/j.jevs.2015.09.007
   Vanderwall DK, 2012, J EQUINE VET SCI, V32, P536, DOI 10.1016/j.jevs.2011.12.011
   Vanderwall DK, 1998, J REPROD FERTIL, V112, P337
   Vrachnis N, 2011, INT J ENDOCRINOL, DOI 10.1155/2011/350546
   Watson E D, 2000, J Reprod Fertil Suppl, P289
   WATSON ED, 1992, THERIOGENOLOGY, V38, P575, DOI 10.1016/0093-691X(92)90020-R
   Weihua Z, 2000, Proc Natl Acad Sci U S A, V97, P5936, DOI 10.1073/pnas.97.11.5936
   Wilsher S, 2011, ANIM REPROD SCI, V129, P200, DOI 10.1016/j.anireprosci.2011.11.004
   Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047
NR 53
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD JAN 1
PY 2017
VL 87
BP 193
EP 204
DI 10.1016/j.theriogenology.2016.08.028
PG 12
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA ED0PJ
UT WOS:000388544100025
PM 27773348
ER

PT J
AU Arai, A
   Hirota, Y
   Miyase, N
   Miyata, S
   Young, LJ
   Osako, Y
   Yuri, K
   Mitsui, S
AF Arai, Aki
   Hirota, Yu
   Miyase, Naoki
   Miyata, Shiori
   Young, Larry J.
   Osako, Yoji
   Yuri, Kazunari
   Mitsui, Shinichi
TI A single prolonged stress paradigm produces enduring impairments in
   social bonding in monogamous prairie voles
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE PTSD; Partner preference; Social behavior; Serotonin; SSRI; Paroxetine
ID POSTTRAUMATIC-STRESS; MICROTUS-OCHROGASTER; PARTNER PREFERENCE;
   MESSENGER-RNA; FAST FEEDBACK; RAT MODEL; OXYTOCIN; VASOPRESSIN;
   EXPRESSION; DISORDER
AB Traumatic events such as natural disasters, violent crimes, tragic accidents, and war, can have devastating impacts on social relationships, including marital partnerships. We developed a single prolonged stress (SPS) paradigm, which consisted of restraint, forced swimming, and ether anesthesia, to establish an animal model relevant to post-traumatic stress disorder. We applied a SPS paradigm to a monogamous rodent, the prairie vole (Microtus ochrogaster) in order to determine whether a traumatic event affects the establishment of pair bonds. We did not detect effects of the SPS treatment on anhedonic or anxiety-like behavior. Sham-treated male voles huddled with their partner females, following a 6 day cohabitation, for a longer duration than with a novel female, indicative of a pair bond. In contrast, SPS-treated voles indiscriminately huddled with the novel and partner females. Interestingly, the impairment of pair bonding was rescued by oral administration of paroxetine, a selective serotonin reuptake inhibitor (SSRI), after the SPS treatment. Immunohistochemical analyses revealed that oxytocin immunoreactivity (IR) was significantly decreased in the supraoptic nucleus (SON), but not in the paraventricular nucleus (PVN), 7 days after SPS treatment, and recovered 14 days after SPS treatment. After the presentation of a partner female, oxytocin neurons labeled with Fos IR was significantly increased in SPS-treated voles compared with sham-treated voles regardless of paroxetine administration.
   Our results suggest that traumatic events disturb the formation of pair bond possibly through an interaction with the serotonergic system, and that SSRIs are candidates for the treatment of social problems caused by traumatic events. Further, a vole SPS model may be useful for understanding mechanisms underlying the impairment of social bonding by traumatic events. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Arai, Aki; Hirota, Yu; Mitsui, Shinichi] Gunma Univ, Grad Sch Hlth Sci, Dept Rehabil Sci, 3-39-22 Showa Machi, Maebashi, Gumma 3718514, Japan.
   [Miyase, Naoki; Miyata, Shiori; Mitsui, Shinichi] Gunma Univ, Dept Occupat Therapy, 3-39-22 Showa Machi, Maebashi, Gumma 3718514, Japan.
   [Young, Larry J.] Emory Univ, Sch Med, Silvio O Conte Ctr Oxytocin & Social Cognit,Yerke, Ctr Translat Social Neurosci,Dept Psychiat & Beha, 954 Gatewood Rd, Atlanta, GA 30329 USA.
   [Osako, Yoji; Yuri, Kazunari] Kochi Univ, Kochi Med Sch, Dept Neurobiol & Anat, Oko Cho, Nankoku, Kochi 7838505, Japan.
RP Mitsui, S (reprint author), Gunma Univ, Grad Sch Hlth Sci, Dept Rehabil Sci, 3-39-22 Showa Machi, Maebashi, Gumma 3718514, Japan.
EM smitsui@gunma-u.ac.jp
FU JSPS KAKENHI Grant [26461734]; NIH [R01MH096983, 1P50MH100023, OD
   P51OD11132]
FX SM was supported by JSPS KAKENHI Grant Number 26461734. The contribution
   of LJY was supported by NIH grants R01MH096983, 1P50MH100023 and OD
   P51OD11132.
CR Ahern TH, 2009, J NEUROSCI METH, V182, P180, DOI 10.1016/j.jneumeth.2009.06.010
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Ask H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-413
   Barrett CE, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.73
   Bosch OJ, 2016, PSYCHONEUROENDOCRINO, V64, P66, DOI 10.1016/j.psyneuen.2015.11.011
   BRONSON FH, 1979, Q REV BIOL, V54, P265, DOI 10.1086/411295
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   Calhoun J. B., 1963, ECOLOGY SOCIOLOGY NO
   Collimore KC, 2010, DEPRESS ANXIETY, V27, P1017, DOI [10.1002/da.20728, 10.1002/da.20759]
   DeVries AC, 1996, P NATL ACAD SCI USA, V93, P11980, DOI 10.1073/pnas.93.21.11980
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Donaldson ZR, 2010, BEHAV NEUROSCI, V124, P159, DOI 10.1037/a0018094
   Eagle AL, 2013, BEHAV BRAIN RES, V256, P591, DOI 10.1016/j.bbr.2013.09.014
   Eaton JL, 2012, DEV PSYCHOBIOL, V54, P92, DOI 10.1002/dev.20566
   Enman NM, 2015, BIOL PSYCHIAT, V78, P871, DOI 10.1016/j.biopsych.2015.04.024
   Gobrogge K.L., 2016, BIOL PSYCHI IN PRESS
   Gobrogge K, 2016, CURR OPIN NEUROBIOL, V38, P80, DOI 10.1016/j.conb.2016.04.011
   Gobrogge KL, 2007, J COMP NEUROL, V502, P1109, DOI 10.1002/cne.21364
   Icerace A., 2016, NEURAL PLAST, V2016
   Imanaka A, 2006, BEHAV BRAIN RES, V173, P129, DOI 10.1016/j.bbr.2006.06.012
   Johnson ZV, 2016, HORM BEHAV, V79, P8, DOI 10.1016/j.yhbeh.2015.11.011
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P564
   Kazan D, 2016, J AFFECT DISORDERS, V190, P585, DOI 10.1016/j.jad.2015.11.003
   Kelly AM, 2014, FRONT NEUROENDOCRIN, V35, P512, DOI 10.1016/j.yfrne.2014.04.005
   King LB, 2016, BIOL PSYCHIAT, V80, P160, DOI 10.1016/j.biopsych.2015.12.008
   Knox D, 2012, LEARN MEMORY, V19, P43, DOI 10.1101/lm.024356.111
   Liberzon I, 1999, J NEUROENDOCRINOL, V11, P11
   Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9
   Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   Martin MM, 2012, PHYSIOL BEHAV, V105, P529, DOI 10.1016/j.physbeh.2011.09.015
   McGraw LA, 2010, TRENDS NEUROSCI, V33, P103, DOI 10.1016/j.tins.2009.11.006
   McMillan KA, 2014, J TRAUMA STRESS, V27, P602, DOI 10.1002/jts.21952
   Melvin KC, 2012, RES NURS HEALTH, V35, P164, DOI 10.1002/nur.21459
   Miller MW, 2013, J ANXIETY DISORD, V27, P240, DOI 10.1016/j.janxdis.2013.02.005
   Mitsui S, 2009, EUR J NEUROSCI, V30, P2368, DOI 10.1111/j.1460-9568.2009.07029.x
   Nakamura K, 2015, BEHAV BRAIN RES, V281, P24, DOI 10.1016/j.bbr.2014.11.022
   Northcutt KV, 2007, J COMP NEUROL, V500, P103, DOI 10.1002/cne.21148
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   Perrine SA, 2016, BEHAV BRAIN RES, V303, P228, DOI 10.1016/j.bbr.2016.01.056
   Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339
   Resendez SL, 2013, J NEUROSCI, V33, P9140, DOI 10.1523/JNEUROSCI.4123-12.2013
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Sezgin A.U., 2014, STRESS HLTH
   Takahashi T, 2006, PSYCHOPHARMACOLOGY, V189, P165, DOI 10.1007/s00213-006-0545-6
   Villalba C, 1997, HORM BEHAV, V32, P184, DOI 10.1006/hbeh.1997.1420
   WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F
   WORTH CB, 1950, J MAMMAL, V31, P293, DOI 10.2307/1375298
   Yamamoto S, 2008, NEUROPSYCHOPHARMACOL, V33, P2108, DOI 10.1038/sj.npp.1301605
   Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Yoshii T, 2008, NEUROSCIENCE, V156, P466, DOI 10.1016/j.neuroscience.2008.07.049
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
   Zhe D, 2008, ACTA HISTOCHEM CYTOC, V41, P89, DOI 10.1267/ahc.08013
NR 59
TC 1
Z9 1
U1 49
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD DEC 15
PY 2016
VL 315
BP 83
EP 93
DI 10.1016/j.bbr.2016.08.022
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DW8YS
UT WOS:000383942000010
PM 27522019
ER

PT J
AU Mayorova, TD
   Tian, S
   Cai, W
   Semmens, DC
   Odekunle, EA
   Zandawala, M
   Badi, Y
   Rowe, ML
   Egertova, M
   Elphick, MR
AF Mayorova, Tatiana D.
   Tian, Shi
   Cai, Weigang
   Semmens, Dean C.
   Odekunle, Esther A.
   Zandawala, Meet
   Badi, Yusef
   Rowe, Matthew L.
   Egertova, Michaela
   Elphick, Maurice R.
TI Localization of Neuropeptide Gene Expression in Larvae of an Echinoderm,
   the Starfish Asterias rubens
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE neuropeptide precursor; mRNA in situ hybridization; larval nervous
   system; bipinnaria; brachiolaria; attachment complex; Echinodermata
ID URCHIN STRONGYLOCENTROTUS-PURPURATUS; NERVOUS-SYSTEM; SEA-STAR;
   BRACHIOLARIA LARVAE; HYDRACTINIA-ECHINATA; SALMFAMIDE NEUROPEPTIDE;
   DENDRASTER-EXCENTRICUS; RFAMIDE NEUROPEPTIDES; NEURAL ARCHITECTURE;
   ILYANASSA-OBSOLETA
AB Neuropeptides are an ancient class of neuronal signaling molecules that regulate a variety of physiological and behavioral processes in animals. The life cycle of many animals includes a larval stage(s) that precedes metamorphic transition to a reproductively active adult stage but, with the exception of Drosophila melanogaster and other insects, research on neuropeptide signaling has hitherto largely focused on adult animals. However, recent advances in genome/transcriptome sequencing have facilitated investigation of neuropeptide expression/function in the larvae of protostomian (e.g., the annelid Platynereis durnerilii) and deuterostomian (e.g., the urochordate Ciona intestinalis) invertebrates. Accordingly, here we report the first multi-gene investigation of larval neuropeptide precursor expression in a species belonging to the phylum Echinodermata the starfish Asterias rubens. Whole-mount mRNA in situ hybridization was used to visualize in bipinnaria and brachiolaria stage larvae the expression of eight neuropeptide precursors: L-type SALMFamide (Si), F-type SALMFamide (S2), vasopressin/oxytocin-type, NGFFYamide, thyrotropin-releasing hormone-type, gonadotropin-releasing hormone-type, calcitonin-type and corticotropin-releasing hormone-type. Expression of only three of the precursors (Si, S2, NGFFYamide) was observed in bipinnaria larvae but by the brachiolaria stage expression of all eight precursors was detected. An evolutionarily conserved feature of larval nervous systems is the apical organ and in starfish larvae this comprises the bilaterally symmetrical lateral ganglia, but only the Si and S2 precursors were found to be expressed in these ganglia. A prominent feature of brachiolaria larvae is the attachment complex, comprising the brachia and adhesive disk, which mediates larval attachment to a substratum prior to metamorphosis. Interestingly, all of the neuropeptide precursors examined here are expressed in the attachment complex, with distinctive patterns of expression suggesting potential roles for neuropeptides in the attachment process. Lastly, expression of several neuropeptide precursors is associated with ciliary bands, suggesting potential roles for the neuropeptides derived from these precursors in control of larval locomotion and/or feeding. In conclusion, our findings provide novel perspectives on the evolution and development of neuropeptide signaling systems and neuroanatomical insights into neuropeptide function in echinoderm larvae.
C1 [Mayorova, Tatiana D.; Tian, Shi; Cai, Weigang; Semmens, Dean C.; Odekunle, Esther A.; Zandawala, Meet; Badi, Yusef; Rowe, Matthew L.; Egertova, Michaela; Elphick, Maurice R.] Queen Mary Univ London, Sch Biol & Chem Sci, Dept Oranismal Biol, London, England.
   [Mayorova, Tatiana D.] Russian Acad Sci, Koltzov Inst Dev Biol, Dev Neurobiol Lab, Moscow, Russia.
   [Mayorova, Tatiana D.] NINDS, Neurobiol Lab, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Elphick, MR (reprint author), Queen Mary Univ London, Sch Biol & Chem Sci, Dept Oranismal Biol, London, England.
EM m.relphick@qmul.ac.uk
FU European Molecular Biology Organization fellowship [ASTF 168-2014];
   Russian Foundation for Basic Research [15-04-04298]; BBSRC
   [BB/M001644/1]; Leverhulme Trust [RGP-2013-351]; China Scholarship
   Council; Society for Experimental Biology
FX This study was supported by a European Molecular Biology Organization
   fellowship awarded to TM (ASTF 168-2014), Russian Foundation for Basic
   Research (grant 15-04-04298 awarded to TM), BBSRC (grant BB/M001644/1),
   the Leverhulme Trust (grant RGP-2013-351), the China Scholarship Council
   and the Society for Experimental Biology.
CR BARKER MF, 1978, J EXP MAR BIOL ECOL, V33, P1, DOI 10.1016/0022-0981(78)90040-0
   BARLOW LA, 1992, J NEUROBIOL, V23, P829, DOI 10.1002/neu.480230705
   Beer AJ, 2001, BIOL BULL, V200, P268, DOI 10.2307/1543509
   Braubach OR, 2006, J EXP BIOL, V209, P4676, DOI 10.1242/jeb.02556
   Burke RD, 2006, DEV BIOL, V300, P434, DOI 10.1016/j.ydbio.2006.08.007
   BURKE RD, 1983, CELL TISSUE RES, V229, P145
   Byrne M, 2005, DEV GENES EVOL, V215, P608, DOI 10.1007/s00427-005-0018-7
   Byrne M, 2001, DEV GROWTH DIFFER, V43, P459
   Byrne M, 2002, J COMP NEUROL, V451, P101, DOI 10.1002/cne.10315
   Byrne M, 2007, EVOL DEV, V9, P432
   Chee F, 1999, INVERTEBR REPROD DEV, V36, P111, DOI 10.1080/07924259.1999.9652685
   Chia F.-S., 1978, P219
   Conzelmann M, 2013, P NATL ACAD SCI USA, V110, P8224, DOI 10.1073/pnas.1220285110
   Conzelmann M, 2012, EVODEVO, V3, DOI 10.1186/2041-9139-3-23
   Conzelmann M, 2011, P NATL ACAD SCI USA, V108, pE1174, DOI 10.1073/pnas.1109085108
   Croll RP, 1996, DEV BIOL, V173, P344, DOI 10.1006/dbio.1996.0028
   Cummins SF, 2011, J COMP NEUROL, V519, P2043, DOI 10.1002/cne.22621
   Cummins SF, 2009, INT J DEV BIOL, V53, P1081, DOI 10.1387/ijdb.082791sc
   Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049
   Dickinson AJG, 1999, ZOOMORPHOLOGY, V119, P49, DOI 10.1007/s004350050080
   Dickinson AJG, 2003, J COMP NEUROL, V466, P197, DOI 10.1002/cne.10863
   Dickinson AJG, 2000, BIOL BULL, V199, P305, DOI 10.2307/1543187
   Dyachuk V, 2009, DEV GROWTH DIFFER, V51, P69, DOI 10.1111/j.1440-169X.2008.01081.x
   Elia L, 2009, BIOL BULL-US, V216, P322
   Elphick MR, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00002
   Elphick MR, 2014, GEN COMP ENDOCR, V205, P23, DOI 10.1016/j.ygcen.2014.02.012
   ELPHICK MR, 1991, P ROY SOC B-BIOL SCI, V243, P121, DOI 10.1098/rspb.1991.0020
   Erwin DH, 2002, DEVELOPMENT, V129, P3021
   Furuya K, 2000, P NATL ACAD SCI USA, V97, P6469, DOI 10.1073/pnas.97.12.6469
   Galliot B, 2011, EUR J NEUROSCI, V34, P847, DOI 10.1111/j.1460-9568.2011.07829.x
   Groger H, 2001, GENESIS, V29, P110, DOI 10.1002/gene.1013
   Haesaerts D, 2005, ZOOMORPHOLOGY, V124, P67, DOI 10.1007/s00435-005-0112-4
   Hamada M, 2011, DEV BIOL, V352, P202, DOI 10.1016/j.ydbio.2011.01.006
   Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901
   Jekely G, 2013, P NATL ACAD SCI USA, V110, P8702, DOI 10.1073/pnas.1221833110
   Jones CE, 2016, BBA-GEN SUBJECTS, V1860, P57, DOI [10.1016/j.bbagen.2015.10.008, 10.1016/j.bbagen2015.10.008]
   KATAOKA H, 1989, P NATL ACAD SCI USA, V86, P2976, DOI 10.1073/pnas.86.8.2976
   Katsukura Y, 2004, J EXP BIOL, V207, P1803, DOI 10.1242/jeb.00974
   Katsukura Y, 2003, DEV GENES EVOL, V213, P579, DOI 10.1007/s00427-003-0361-5
   KEMPF SC, 1987, J NEUROBIOL, V18, P217, DOI 10.1002/neu.480180207
   LEITZ T, 1994, DEV BIOL, V163, P440, DOI 10.1006/dbio.1994.1160
   Marlow HQ, 2009, DEV NEUROBIOL, V69, P235, DOI 10.1002/dneu.20698
   Mayorova T, 2013, ZOOLOGY, V116, P9, DOI 10.1016/j.zool.2012.07.002
   McEdward LR, 2001, CAN J ZOOL, V79, P1125, DOI 10.1139/cjz-79-7-1125
   Middleton A, 2001, BIOCHEM PHARMACOL, V62, P171, DOI 10.1016/S0006-2952(01)00641-4
   Mirabeau O, 2013, P NATL ACAD SCI USA, V110, pE2028, DOI 10.1073/pnas.1219956110
   Morris VB, 2011, ACTA ZOOL-STOCKHOLM, V92, P266, DOI 10.1111/j.1463-6395.2010.00468.x
   MOSS C, 1994, J MAR BIOL ASSOC UK, V74, P61
   Murabe N, 2008, J COMP NEUROL, V509, P271, DOI 10.1002/cne.21742
   Murabe N, 2007, DEV GROWTH DIFFER, V49, P647, DOI 10.1111/j.1440-169x.2007.00959.x
   Murphy TH, 2001, J NEUROCHEM, V76, P1670, DOI 10.1046/j.1471-4159.2001.00157.x
   Nakajima Y, 2004, EVOL DEV, V6, P95, DOI 10.1111/j.1525-142X.2004.04011.x
   Nassel DR, 2010, PROG NEUROBIOL, V92, P42, DOI 10.1016/j.pneurobio.2010.04.010
   Nikitin M, 2015, GEN COMP ENDOCR, V212, P145, DOI 10.1016/j.ygcen.2014.03.049
   OGURO C, 1976, BIOL BULL, V151, P560, DOI 10.2307/1540506
   OKON E, 1976, NATURE, V263, P345, DOI 10.1038/263345a0
   Perillo M, 2014, GEN COMP ENDOCR, V205, P68, DOI 10.1016/j.ygcen.2014.06.014
   Piraino S, 2011, J COMP NEUROL, V519, P1931, DOI 10.1002/cne.22614
   Pisani D, 2012, MOL PHYLOGENET EVOL, V62, P27, DOI 10.1016/j.ympev.2011.08.028
   Rowe ML, 2012, GEN COMP ENDOCR, V179, P331, DOI 10.1016/j.ygcen.2012.09.009
   SAWCHENKO PE, 1984, J NEUROSCI, V4, P1118
   SCHUCHERT P, 1993, ACTA ZOOL-STOCKHOLM, V74, P115
   Semmens DC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150224
   Semmens DC, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150030
   Semmens DC, 2013, J EXP BIOL, V216, P4047, DOI 10.1242/jeb.092171
   Shifrin DA, 2012, CURR BIOL, V22, P627, DOI 10.1016/j.cub.2012.02.022
   Simakov O, 2015, NATURE, V527, P459, DOI 10.1038/nature16150
   Sodergren E, 2006, SCIENCE, V314, P941, DOI 10.1126/science.1133609
   SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4
   Strand F. L., 1999, NEUROPEPTIDES
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   THORNDYKE MC, 1992, ACTA ZOOL-STOCKHOLM, V73, P207
   Tian S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28788
   Veenstra JA, 2011, GEN COMP ENDOCR, V171, P160, DOI 10.1016/j.ygcen.2011.01.005
   Veenstra JA, 2010, GEN COMP ENDOCR, V167, P86, DOI 10.1016/j.ygcen.2010.02.010
   Voronezhskaya EE, 2008, ACTA BIOL HUNG, V59, P117, DOI 10.1556/ABiol.59.2008.Suppl.19
   Williams EA, 2015, FRONT ZOOL, V12, DOI 10.1186/s12983-014-0093-6
   Yu YY, 2007, J HISTOCHEM CYTOCHEM, V55, P223, DOI 10.1369/jhc.6A7032.2006
   Yuan D, 2008, DEV GENES EVOL, V218, P525, DOI 10.1007/s00427-008-0254-8
   Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745
NR 80
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD DEC 1
PY 2016
VL 10
AR 553
DI 10.3389/fnins.2016.00553
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA ED7TT
UT WOS:000389075000001
ER

PT J
AU Matsumoto, N
   Okamoto, K
   Takagi, Y
   Ikegaya, Y
AF Matsumoto, Nobuyoshi
   Okamoto, Kazuki
   Takagi, Yuki
   Ikegaya, Yuji
TI 3-Hz subthreshold oscillations of CA2 neurons In vivo
SO HIPPOCAMPUS
LA English
DT Article
DE CA2; 3 Hz; in vivo whole-cell recording; membrane potential; oscillation
ID HIPPOCAMPAL AREA CA2; THETA OSCILLATIONS; SOCIAL MEMORY; SUPRAMAMMILLARY
   NUCLEUS; SYNAPTIC PLASTICITY; ACTIVITY PATTERNS; PYRAMIDAL CELLS;
   FREQUENCY; DYNAMICS; BEHAVIOR
AB The CA2 region is unique in the hippocampus; it receives direct synaptic innervations from several hypothalamic nuclei and expresses various receptors of neuromodulators, including adenosine, vasopressin, and oxytocin. Furthermore, the CA2 region may have distinct brain functions, such as the control of instinctive and social behaviors; however, little is known about the dynamics of the subthreshold membrane potentials of CA2 neurons in vivo. We conducted whole-cell current-clamp recordings from CA2 pyramidal cells in urethane-anesthetized mice and monitored the intrinsic fluctuations in their membrane potentials. The CA2 pyramidal cells emitted spontaneous action potentials at mean firing rates of approximate to 0.8 Hz. In approximately half of the neurons, the subthreshold membrane potential oscillated at approximate to 3 Hz. In two neurons, we obtained simultaneous recordings of local field potentials from the CA1 stratum radiatum and demonstrated that the 3-Hz oscillations of CA2 neurons were not correlated with CA1 field potentials. In tetrodotoxin-perfused acute hippocampal slices, the membrane potentials of CA2 pyramidal cells were not preferentially entrained to 3-Hz sinusoidal current inputs, which suggest that intracellular 3-Hz oscillations reflect the neuronal dynamics of the surrounding networks. (c) 2016 Wiley Periodicals, Inc.
C1 [Matsumoto, Nobuyoshi; Okamoto, Kazuki; Takagi, Yuki; Ikegaya, Yuji] Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.
   [Ikegaya, Yuji] Natl Inst Informat & Communicat Technol, Ctr Informat & Neural Networks, Suita, Osaka, Japan.
RP Ikegaya, Y (reprint author), Univ Tokyo, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.
EM yuji@ikegaya.jp
FU  [26250003];  [25119004]
FX Grant sponsor: Grants-in-Aid for Science Research A; Grant number:
   26250003; Grant sponsor: Grants-in-Aid for Science Research on
   Innovative Areas "Mental Time"; Grant number: 25119004.
CR Abe R, 2014, NEUROREPORT, V25, P1013, DOI 10.1097/WNR.0000000000000206
   Amaral D, 2007, HIPPOCAMPUS BOOK, P37
   ANDERSEN P, 1971, EXP BRAIN RES, V13, P222
   Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X
   Caruana DA, 2012, LEARN MEMORY, V19, P391, DOI 10.1101/lm.025304.111
   Fujisawa S, 2011, NEURON, V72, P153, DOI 10.1016/j.neuron.2011.08.018
   Funayama K, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002231
   Harvey CD, 2009, NATURE, V461, P941, DOI 10.1038/nature08499
   Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028
   Ishikawa D, 2014, J NEUROSCI, V34, P5044, DOI 10.1523/JNEUROSCI.5298-13.2014
   Jones MW, 2011, TRENDS NEUROSCI, V34, P526, DOI 10.1016/j.tins.2011.07.007
   Karalis N, 2016, NAT NEUROSCI, V19, P605, DOI 10.1038/nn.4251
   Kay K, 2016, NATURE, V531, P185, DOI 10.1038/nature17144
   Kocsis B, 2006, HIPPOCAMPUS, V16, P531, DOI 10.1002/hipo.20180
   Kowalczyk T, 2014, HIPPOCAMPUS, V24, P7, DOI 10.1002/hipo.22167
   Kuga N, 2011, J NEUROSCI, V31, P2607, DOI 10.1523/JNEUROSCI.5319-10.2011
   Lubenov EV, 2009, NATURE, V459, P534, DOI 10.1038/nature08010
   Makino K, 2016, ANAT SCI INT, V91, P188, DOI 10.1007/s12565-015-0284-z
   Mankin EA, 2015, NEURON, V85, P190, DOI 10.1016/j.neuron.2014.12.001
   Mizunuma M, 2014, NAT NEUROSCI, V17, P503, DOI 10.1038/nn.3674
   Mizuseki K, 2009, NEURON, V64, P267, DOI 10.1016/j.neuron.2009.08.037
   Pagani JH, 2015, MOL PSYCHIATR, V20, P490, DOI 10.1038/mp.2014.47
   Penttonen M, 1998, EUR J NEUROSCI, V10, P718, DOI 10.1046/j.1460-9568.1998.00096.x
   Piskorowski RA, 2016, NEURON, V89, P163, DOI 10.1016/j.neuron.2015.11.036
   Sakaguchi T, 2012, NEUROREPORT, V23, P457, DOI 10.1097/WNR.0b013e32835375b6
   Smith AS, 2016, MOL PSYCHIATR, V21, P1137, DOI 10.1038/mp.2015.189
   SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97
   Valero M, 2015, NAT NEUROSCI, V18, P1281, DOI 10.1038/nn.4074
   Vertes RP, 2015, PROG BRAIN RES, V219, P121, DOI 10.1016/bs.pbr.2015.03.008
   YLINEN A, 1995, HIPPOCAMPUS, V5, P78, DOI 10.1002/hipo.450050110
   Zemankovics R, 2010, J PHYSIOL-LONDON, V588, P2109, DOI 10.1113/jphysiol.2009.185975
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1050-9631
EI 1098-1063
J9 HIPPOCAMPUS
JI Hippocampus
PD DEC
PY 2016
VL 26
IS 12
BP 1570
EP 1578
DI 10.1002/hipo.22657
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA EC9YX
UT WOS:000388501300009
PM 27650674
ER

PT J
AU Galfi, M
   Radacs, M
   Molnar, Z
   Budai, I
   Toth, G
   Posa, A
   Kupai, K
   Szalai, Z
   Szabo, R
   Molnar, HA
   Gardi, J
   Laszlo, FA
   Varga, C
AF Galfi, M.
   Radacs, M.
   Molnar, Zs.
   Budai, I.
   Toth, G.
   Posa, A.
   Kupai, K.
   Szalai, Z.
   Szabo, R.
   Molnar, H. A.
   Gardi, J.
   Laszlo, Ferenc A.
   Varga, Cs.
TI Ghrelin-Induced Enhancement of Vasopressin and Oxytocin Secretion in Rat
   Neurohypophyseal Cell Cultures
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Vasopressin; Oxytocin; Neurohypophyseal cell culture; Ghrelin; Ghrelin
   receptor antagonist
ID GROWTH-HORMONE SECRETAGOGUE; HYPOTHALAMIC 4B CELLS; GHS-R ANTAGONIST;
   TISSUE-CULTURES; DIABETES-INSIPIDUS; RECEPTOR; RELEASE; PEPTIDE;
   EXPRESSION; HISTAMINE
AB The effects of ghrelin on vasopressin and oxytocin secretion were studied in 13-14-day cell cultures of isolated rat neurohypophyseal tissue. The vasopressin and oxytocin contents of the supernatant were determined by radioimmunoassay after a 1- or 2-h incubation. Significantly increased levels of vasopressin and oxytocin production were detected in the cell culture media following ghrelin administration, depending on the ghrelin doses. The oxytocin level proved to be more elevated than that of vasopressin. The increase of vasopressin and oxytocin secretion could be totally blocked by previous administration of the ghrelin receptor antagonist ([D-Lys(3)]-growth hormone-releasing peptide-6). Application of the ghrelin receptor antagonist after ghrelin administration proved ineffective. The results indicate that vasopressin and oxytocin release is influenced directly by the ghrelin system, and the effects of ghrelin on vasopressin and oxytocin secretion from the neurohypophyseal tissue in rats can occur at the level of the posterior pituitary. Our observations lend support to the view that neurohypophysis contains ghrelin receptors.
C1 [Galfi, M.; Radacs, M.; Molnar, Zs.; Budai, I.] Univ Szeged, Inst Appl Sci, Gyula Juhasz Fac Educ, Dept Environm Biol & Educ, Szeged, Hungary.
   [Toth, G.] Univ Szeged, Dept Med Chem, Fac Med, Szeged, Hungary.
   [Posa, A.; Kupai, K.; Szalai, Z.; Szabo, R.; Laszlo, Ferenc A.; Varga, Cs.] Univ Szeged, Fac Sci & Informat, Dept Physiol Anat & Neurosci, Szeged, Hungary.
   [Molnar, H. A.] Univ Szeged, Inst Phys Educ & Sport Sci, Gyula Juhasz Fac Educ, Szeged, Hungary.
   [Gardi, J.] Univ Szeged, Dept Internal Med 1, Fac Med, Szeged, Hungary.
RP Laszlo, FA (reprint author), Univ Szeged, Fac Sci & Informat, Dept Physiol Anat & Neurosci, Szeged, Hungary.
EM laszlo.a.ferenc@freemail.hu
FU New National Excellence Program of The Ministry of Human Capacities
FX This study was supported through the New National Excellence Program of
   The Ministry of Human Capacities (Aniko Posa).
CR ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272
   Asakawa A, 2003, GUT, V52, P947, DOI 10.1136/gut.52.7.947
   Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827
   Beck B, 2004, LIFE SCI, V76, P473, DOI 10.1016/j.lfs.2004.09.001
   BOERSMA CJC, 1993, BRAIN RES, V611, P117, DOI 10.1016/0006-8993(93)91783-O
   Bowers CY, 1998, CELL MOL LIFE SCI, V54, P1316, DOI 10.1007/s000180050257
   DANIEL AR, 1967, J PHYSIOL-LONDON, V190, P171
   DOGTEROM J, 1978, AM J PHYSIOL, V234, pE463
   Galfi M, 2005, REGUL PEPTIDES, V127, P225, DOI 10.1016/j.regpep.2004.12.009
   Galfi M, 2001, REGUL PEPTIDES, V98, P49, DOI 10.1016/S0167-0115(00)00224-X
   Galfi M, 2002, REGUL PEPTIDES, V110, P17, DOI 10.1016/S0167-0115(02)00112-X
   Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5
   Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974
   HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0
   HUSZTI Z, 1990, GLIA, V3, P159, DOI 10.1002/glia.440030303
   JANAKY T, 1982, J LIQ CHROMATOGR, V5, P1499, DOI 10.1080/01483918208062847
   Janaky T, 1998, RAPID COMMUN MASS SP, V12, P1765, DOI 10.1002/(SICI)1097-0231(19981130)12:22<1765::AID-RCM359>3.0.CO;2-U
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P242, DOI 10.1046/j.1365-2826.2003.00978.x
   Jorgensen H, 2002, EUR J ENDOCRINOL, V147, P815, DOI 10.1530/eje.0.1470815
   JULESZ J, 1992, PROG BRAIN RES, V91, P89
   Kageyama K, 2012, REGUL PEPTIDES, V174, P12, DOI 10.1016/j.regpep.2011.11.003
   Kageyama K, 2011, STRESS, V14, P520, DOI 10.3109/10253890.2011.558605
   Kapoor JR, 2000, J NEUROSCI, V20, P8868
   Katugampola SD, 2001, BRIT J PHARMACOL, V134, P143, DOI 10.1038/sj.bjp.0704228
   KENNEDY PGE, 1980, LAB INVEST, V43, P342
   Knigge U, 1999, ENDOCRINOLOGY, V140, P3713, DOI 10.1210/en.140.8.3713
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kojima M, 2001, TRENDS ENDOCRIN MET, V12, P118, DOI 10.1016/S1043-2760(00)00362-3
   Korbonits M, 1999, J NEUROENDOCRINOL, V11, P521
   LACZI F, 1986, ACTA ENDOCRINOL-COP, V113, P168
   Laszlo FA, 1989, P 4 INT C NEUR NEW A, P87
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maletinska L, 2011, MOL CELL ENDOCRINOL, V343, P55, DOI 10.1016/j.mce.2011.06.006
   McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415
   MICHLERSTUKE A, 1982, J NEUROSCI RES, V7, P215, DOI 10.1002/jnr.490070212
   MOHR E, 1990, FEBS LETT, V263, P332, DOI 10.1016/0014-5793(90)81407-F
   Mozid AM, 2003, HORM METAB RES, V35, P455
   Nemoto T, 2011, PEPTIDES, V32, P1281, DOI 10.1016/j.peptides.2011.04.007
   Olszewski PK, 2007, NEUROREPORT, V18, P499, DOI 10.1097/WNR.0b013e328058684e
   PAP A, 1979, PFLUG ARCH EUR J PHY, V383, P19, DOI 10.1007/BF00584470
   Patel K, 2012, INT J BIOL SCI, V8, P108, DOI 10.7150/ijbs.8.108
   PEARSON D, 1975, ENDOCRINOLOGY, V96, P982
   Petersenn S, 2002, Minerva Endocrinol, V27, P243
   Radacs M, 2006, REGUL PEPTIDES, V134, P82, DOI 10.1016/j.regpep.2006.01.006
   ROKAEUS A, 1988, NEUROSCI LETT, V90, P45, DOI 10.1016/0304-3940(88)90784-7
   Shahryar HA, 2014, ARQ BRAS ENDOCRINOL, V58, P288, DOI 10.1590/0004-2730000002980
   SKOFITSCH G, 1989, NEUROENDOCRINOLOGY, V49, P419, DOI 10.1159/000125147
   SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009
   Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621
   Smith RG, 2001, ENDOCRINE, V14, P9, DOI 10.1385/ENDO:14:1:009
   STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7
   Torsello A, 1998, EUR J PHARMACOL, V360, P123, DOI 10.1016/S0014-2999(98)00677-3
   TWEEDLE CD, 1987, NEUROSCIENCE, V20, P241, DOI 10.1016/0306-4522(87)90016-9
   Vecsernyes M, 1994, Endocr Regul, V28, P145
   Wren AM, 2002, NEUROENDOCRINOLOGY, V76, P316, DOI 10.1159/000066629
   Yokoyama T, 2009, J NEUROENDOCRINOL, V21, P910, DOI 10.1111/j.1365-2826.2009.01911.x
   Zhu Y, 2003, J PHARMACOL SCI, V92, P259
NR 57
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD DEC
PY 2016
VL 60
IS 4
BP 525
EP 530
DI 10.1007/s12031-016-0850-4
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA ED1SS
UT WOS:000388625800012
PM 27752928
ER

PT J
AU McCue, PM
AF McCue, Patrick M.
TI Hormone Therapy in Clinical Equine Practice
SO VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE
LA English
DT Article
DE Equine hormone therapy; Equine reproductive management; Clinical equine
   practice
ID ANESTROUS MARES; OVULATION; OXYTOCIN
AB A wide variety of hormone therapies are used in clinical practice in the reproductive management of horses. The goal of this article is to review therapeutic options for a variety of clinical indications.
C1 [McCue, Patrick M.] Colorado State Univ, Coll Vet Med & Biomed Sci, Equine Reprod Lab, 3101 Rampart Rd, Ft Collins, CO 80523 USA.
RP McCue, PM (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Equine Reprod Lab, 3101 Rampart Rd, Ft Collins, CO 80523 USA.
EM pmccue@colostate.edu
CR Allen WR, 2006, EQUINE VET J, V38, P454, DOI 10.2746/042516406778400628
   Allen WR, 2001, REPROD DOMEST ANIM, V36, P121, DOI 10.1046/j.1439-0531.2001.00312.x
   Burden CA, 2015, J EQUINE VET SCI, V35, P531, DOI 10.1016/j.jevs.2015.02.011
   Coffman EA, 2014, THERIOGENOLOGY, V82, P1241, DOI 10.1016/j.theriogenology.2014.07.038
   Dascanio JJ, 2014, EQUINE REPRODUCTIVE PROCEDURES, P264
   Duchamp G, 2002, THERIOGENOLOGY, V58, P599, DOI 10.1016/S0093-691X(02)00850-6
   Ferris RA, 2012, J EQUINE VET SCI, V32, P285, DOI 10.1016/j.jevs.2011.11.007
   Ginther OJ, 1992, REPROD BIOL MARE BAS, P279
   Lindholm ARG, 2010, ANIM REPROD SCI, V121S, P68
   Macpherson ML, 1997, J AM VET MED ASSOC, V210, P799
   Mccue PM, 2007, EQUINE VET EDUC, V19, P215, DOI 10.2746/095777307X187793
   Mccue PM, 2008, J EQUINE VET SCI, V28, P91, DOI 10.1016/j.jevs.2008.01.005
   McCue PM, 2014, EQUINE REPRODUCTIVE PROCEDURES, P146
   McCue PM, 1997, J EQUINE VET SCI, V17, P327, DOI 10.1016/S0737-0806(97)80092-5
   Meijer M, 2015, P AM ASS EQUINE PRAC, V61, P478
   Meyers-Brown GA, 2013, THERIOGENOLOGY, V80, P456, DOI 10.1016/j.theriogenology.2013.04.029
   Niswender KD, 2004, J EQUINE VET SCI, V24, P37, DOI 10.1016/jevs.2003.12.011
   Stout TAE, 2004, ANIM REPROD SCI, V82-3, P633, DOI 10.1016/j.anireprosci.2004.04.009
   Taylor T B, 1982, J Reprod Fertil Suppl, V32, P219
   Tshewang U, 1997, AUST VET J, V75, P663, DOI 10.1111/j.1751-0813.1997.tb15366.x
   Tuener RM, 2015, EQUINE VET EDUC, V27, P340
   Vanderwall DK, 2007, JAVMA-J AM VET MED A, V231, P1864, DOI 10.2460/javma.231.12.1864
NR 22
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0739
EI 1558-4224
J9 VET CLIN N AM-EQUINE
JI Vet. Clin. N. Am.-Equine Pract.
PD DEC
PY 2016
VL 32
IS 3
BP 425
EP +
DI 10.1016/j.cveq.2016.07.001
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA ED8KI
UT WOS:000389120000005
PM 27810035
ER

PT J
AU Nakajima, M
   Watanabe, T
   Aoki, R
   Shimizu, R
   Okuyama, S
   Furukawa, Y
AF Nakajima, Mitsunari
   Watanabe, Takashi
   Aoki, Rui
   Shimizu, Risei
   Okuyama, Satoshi
   Furukawa, Yoshiko
TI Phenotypes associated with psychiatric disorders are sex-specific in a
   mutant mouse line
SO BRAIN RESEARCH
LA English
DT Article
DE Sex; Psychiatric disorder; Autism; Schizophrenia; Oxytocin
ID DOUBLE-TRANSGENIC MICE; ABNORMAL-BEHAVIOR; SCHIZOPHRENIA; AUTISM;
   PROLACTIN; OXYTOCIN; KNOCKOUT; MODEL; VASOPRESSIN; CLOZAPINE
AB Wnt1-Cre- and Wnt1-GAL4 double transgenic (dTg) mice are used to study neural crest cell lineages by utilizing either the Cre/loxP or the GAL4/UAS system. We have previously shown that these mice exhibit behavioral abnormalities that resemble certain behaviors of psychiatric disorders and histologic alterations in the cholinergic and glutamatergic systems in the brain. The objective of the current study was to extend the behavioral analyses in these mice and to determine whether there were any sex-specific differences in the prevalence or severity of these behaviors. In the present study, we demonstrate additional behavioral abnormalities in dTg mice, such as increased locomotor activity, decreased social behavior, and an increased frequency in vertical jumping. Of these, the proclivity for vertical jumping was observed only in male dTg mice. In contrast, MK-801 administration induced increased locomotion in only female dTg mice. Furthermore, the concentrations of prolactin in the sera and oxytocin in the hypothalamus were both reduced only in female dTg mice, compared to controls. These sex-dependent behavioral and hormonal abnormalities in the dTG mice suggest that the phenotype of certain psychiatric disorders may be influenced by both genetic and sex-specific factors.
C1 [Nakajima, Mitsunari; Watanabe, Takashi; Aoki, Rui; Shimizu, Risei; Okuyama, Satoshi; Furukawa, Yoshiko] Matsuyama Univ, Coll Pharmaceut Sci, Sch Clin Pharm, Dept Pharmaceut Pharmacol, 4-2 Bunkyo Cho, Matsuyama, Ehime 7908578, Japan.
RP Nakajima, M (reprint author), Matsuyama Univ, Coll Pharmaceut Sci, Sch Clin Pharm, Dept Pharmaceut Pharmacol, 4-2 Bunkyo Cho, Matsuyama, Ehime 7908578, Japan.
EM mnakajim@cc.matsuyama-u.ac.jp
FU JSPS KAKENHI [JP16K09977]
FX This work was supported by JSPS KAKENHI Grant number JP16K09977. We
   would like to thank Editage (www.editage.jp) for English language
   editing.
CR Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   BAILEY A, 1995, PSYCHOL MED, V25, P63
   Baron-Cohen S, 2002, TRENDS COGN SCI, V6, P248, DOI DOI 10.1016/S1364-6613(02)01904-6
   Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569
   Charoenphandhu N, 2010, TRENDS ENDOCRIN MET, V21, P395, DOI 10.1016/j.tem.2010.02.002
   Concolino D, 2008, J INHERIT METAB DIS, V31, pS193, DOI 10.1007/s10545-007-0788-3
   CORBETT R, 1995, PSYCHOPHARMACOLOGY, V120, P67, DOI 10.1007/BF02246146
   Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC), 2014, MMWR SURVEILL SUMM, V63, P1
   Gleason SD, 1997, PSYCHOPHARMACOLOGY, V129, P79, DOI 10.1007/s002130050165
   Gray L, 2009, INT J NEUROPSYCHOPH, V12, P45, DOI 10.1017/S1461145708009085
   Guilmatre A, 2009, ARCH GEN PSYCHIAT, V66, P947, DOI 10.1001/archgenpsychiatry.2009.80
   Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Ito S, 2013, NEUROBIOL DIS, V49, P29, DOI 10.1016/j.nbd.2012.08.003
   JABLENSKY A, 1992, PSYCHOL MED, P1
   Just MJ, 2015, NEUROPSYCH DIS TREAT, V11, P1655, DOI 10.2147/NDT.S84528
   Kennett JE, 2012, J NEUROENDOCRINOL, V24, P403, DOI 10.1111/j.1365-2826.2011.02263.x
   Kim Sung Koo, 2015, Korean J Pediatr, V58, P8, DOI 10.3345/kjp.2015.58.1.8
   Kirkovski M, 2013, J AUTISM DEV DISORD, V43, P2584, DOI 10.1007/s10803-013-1811-1
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Miyakawa T, 2003, P NATL ACAD SCI USA, V100, P8987, DOI 10.1073/pnas.1432926100
   Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349
   Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8
   Nakajima M, 2014, NEUROSCI LETT, V566, P236, DOI 10.1016/j.neulet.2014.02.061
   Nakajima M, 2013, J NEUROCHEM, V124, P241, DOI 10.1111/jnc.12085
   Nakatani J, 2009, CELL, V137, P1235, DOI 10.1016/j.cell.2009.04.024
   O'Tuathaigh CMP, 2007, NEUROSCIENCE, V147, P18, DOI 10.1016/j.neuroscience.2007.03.051
   ONSTAD S, 1991, ACTA PSYCHIAT SCAND, V83, P395, DOI 10.1111/j.1600-0447.1991.tb05563.x
   Rapoport J, 2009, J AM ACAD CHILD PSY, V48, P10, DOI 10.1097/CHI.0b013e31818b1c63
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Rowitch DH, 1999, J NEUROSCI, V19, P8954
   Ruigrok ANV, 2014, NEUROSCI BIOBEHAV R, V39, P34, DOI 10.1016/j.neubiorev.2013.12.004
   Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851
   Szatmari P, 2012, AM J MED GENET B, V159B, P5, DOI 10.1002/ajmg.b.31238
   Tandon R, 2009, SCHIZOPHR RES, V110, P1, DOI 10.1016/j.schres.2009.03.005
   Tanimura Y, 2008, BEHAV BRAIN RES, V189, P250, DOI 10.1016/j.bbr.2008.01.001
   Van Wijngaarden-Cremers PJM, 2014, J AUTISM DEV DISORD, V44, P627, DOI 10.1007/s10803-013-1913-9
   Yang M, 2012, J NEUROSCI, V32, P6525, DOI 10.1523/JNEUROSCI.6107-11.2012
   Yeung WL, 2006, BRAIN DEV-JPN, V28, P389, DOI 10.1016/j.braindev.2005.10.012
   [Anonymous], P NATL ACAD SCI US, P13355
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD DEC 1
PY 2016
VL 1652
BP 53
EP 61
DI 10.1016/j.brainres.2016.09.037
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA EC3XF
UT WOS:000388059700006
PM 27693417
ER

PT J
AU Mayasich, SA
   Bemis, LT
   Clarke, BL
AF Mayasich, Sally A.
   Bemis, Lynne T.
   Clarke, Benjamin L.
TI DNA methylation in a sea lamprey vasotocin receptor gene promoter
   correlates with tissue- and life-stage-specific mRNA expression
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
   BIOLOGY
LA English
DT Article
DE DNA methylation; Estrogen response element; Oxytocin receptor; Sea
   lamprey; Vasotocin receptor; Zinc-finger transcription factors
ID PETROMYZON-MARINUS; NEURAL CREST; TRANSCRIPTION; EVOLUTION; ORIGIN
AB The jawless vertebrate sea lamprey (Petromyzon marinus) genome has a different structure from both invertebrates and jawed vertebrates featuring high guanine-cytosine (GC) content. This raises the question of whether DNA methylation of cytosine-guanine (CpG) dinucleotides could function to regulate lamprey gene transcription. We previously characterized a lamprey arginine vasotocin (AVT) receptor gene (Pm807) possessing characteristics of both arginine vasopressin (AVP) VIA and oxytocin (OXT) receptor genes of jawed vertebrates. Lamprey Pm807 mRNA is highly expressed in adult heart and larval liver but not expressed in adult liver. Using high-resolution melt (HRM) PCR on bisulfite-converted DNA, we pinpointed a region with tissue specific differences in DNA melt characteristics, indicating differences in methylation level. Sequencing revealed a pattern of methylation at specific CpGs at consistently higher levels in adult heart and larval liver than adult liver. These CpGs are associated with putative transcription factor binding sequences organized similarly to functional OXTR promoters in mammals, suggesting functional similarity in lamprey gene transcription regulation. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Mayasich, Sally A.; Bemis, Lynne T.; Clarke, Benjamin L.] Univ Minnesota Duluth, Dept Biomed Sci, Sch Med, 1035 Univ Dr, Duluth, MN 55812 USA.
RP Mayasich, SA (reprint author), US EPA, Midcontinent Ecol Div, 6201 Congdon Blvd, Duluth, MN 55804 USA.
EM mayasich.sally@epa.gov
FU Office of the Vice President for Research, University of Minnesota
FX This research was supported by a Grant-in-Aid of Research, Artistry and
   Scholarship from the Office of the Vice President for Research,
   University of Minnesota. We thank Olivia Mayasich for technical
   assistance, Drs. Kevin Diebel and Aubie Shaw for experimental
   suggestions, and Drs. Sara Zimmer, Allen Mensinger, and Michael Hornung
   for review of the manuscript.
CR Boyd V.L., 2007, PROGR DNA METHYLATHO
   Covelo-Soto L, 2015, COMP BIOCHEM PHYS B, V185, P42, DOI 10.1016/j.cbpb.2015.03.007
   Dhakar MB, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P3
   Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200
   Green SA, 2014, DIFFERENTIATION, V87, P44, DOI 10.1016/j.diff.2014.02.001
   Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008
   Harony-Nicolas H, 2014, PSYCHONEUROENDOCRINO, V39, P121, DOI 10.1016/j.psyneuen.2013.10.004
   He M, 2015, FASEB J, V29, P4059, DOI 10.1096/fj.15-272658
   Holler M, 1988, GENE DEV, V2, P1127
   Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726
   Jones MJ, 2015, AGING CELL, V14, P924, DOI 10.1111/acel.12349
   Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206
   Kopf E, 2005, J THROMB HAEMOST, V3, P2057, DOI 10.1111/j.1538-7836.2005.01510.x
   Kusui C, 2001, BIOCHEM BIOPH RES CO, V289, P681, DOI 10.1006/bbrc.2001.6024
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu YY, 2014, J BIOL CHEM, V289, P4778, DOI 10.1074/jbc.M113.486290
   Liu YW, 2014, NUCLEIC ACIDS RES, V42, P4859, DOI 10.1093/nar/gku134
   Lotem J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080467
   Mamrut S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056869
   Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221
   MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284
   Mayasich SA, 2016, GEN COMP ENDOCR, V226, P88, DOI 10.1016/j.ygcen.2016.01.001
   Nah GSS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113445
   Okamura K, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S7-S2
   Paixao-Cortes VR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073560
   Paris M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-219
   Rojas AM, 2005, FEBS J, V272, P3505, DOI 10.1111/j.1742-4658.2005.04759.x
   Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537
   Sauka-Spengler T, 2007, DEV CELL, V13, P405, DOI 10.1016/j.devcel.2007.08.005
   Smith JJ, 2013, NAT GENET, V45, P415, DOI 10.1038/ng.2568
   Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622
   Tweedie S, 1997, MOL CELL BIOL, V17, P1469
   Zhang Z., 2015, BIORXIV
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1096-4959
EI 1879-1107
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD DEC
PY 2016
VL 202
BP 56
EP 66
DI 10.1016/j.cbpb.2016.07.007
PG 11
WC Biochemistry & Molecular Biology; Zoology
SC Biochemistry & Molecular Biology; Zoology
GA ED0OQ
UT WOS:000388542200008
ER

PT J
AU Happe, F
   Conway, JR
AF Happe, Francesca
   Conway, Jane R.
TI Recent progress in understanding skills and impairments in social
   cognition
SO CURRENT OPINION IN PEDIATRICS
LA English
DT Review
DE autism spectrum disorder; heterogeneity; social cognition; theory of
   mind
ID AUTISM SPECTRUM DISORDER; RIGHT TEMPOROPARIETAL JUNCTION; ATTACHMENT
   DISORDER; PERSPECTIVE-TAKING; ASPERGER-SYNDROME; EYES TEST; MIND;
   ALEXITHYMIA; CHILDREN; OXYTOCIN
AB Purpose of review
   Social interaction is affected in many different developmental disorders; indeed, the new Diagnostic and Statistical Manual of Mental Disorders has introduced social cognition as one of six core components of neurocognitive functioning. Social cognition is not one thing, but a wide range of putative processes, which may be differentially affected in different clinical groups. This review focuses on recent advances in one aspect of social cognition, 'theory of mind' (ToM, representing what people think), and one core clinical group, autism spectrum disorder (ASD).
   Recent findings
   It is 30 years since impaired ToM was proposed as an explanation for ASD social difficulties, and recently there has been a widening of interest to other clinical groups. ToM has been found to be distinct from emotion recognition and empathy. Recent research on ASD has focused increasingly on atypical sensory responses and commonly comorbid conditions. Interventions for social deficits, including ToM training and oxytocin, have shown mixed results to date.
   Summary
   Heterogeneity poses a major obstacle to current research. Theoretical and empirical refinements are needed to elucidate neurocognitive and aetiological underpinnings of sociocognitive processes and inform clinical advances.
C1 [Happe, Francesca; Conway, Jane R.] Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC Social Genet & Dev Psychiat Ctr, London, England.
RP Happe, F (reprint author), Inst Psychiat Psychol & Neurosci, Social Genet & Dev Psychiat Ctr MRC, PO80,De Crespigny Pk,Denmark Hill, London SE5 8AF, England.
EM francesca.happe@kcl.ac.uk
CR Bakopoulou I, 2016, RES DEV DISABIL, V49-50, P354, DOI 10.1016/j.ridd.2015.12.013
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8
   Baum SH, 2015, PROG NEUROBIOL, V134, P140, DOI 10.1016/j.pneurobio.2015.09.007
   Bird G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.61
   Blanken LME, 2015, AM J PSYCHIAT, V172, P479, DOI 10.1176/appi.ajp.2014.14040482
   Bolton PF, 2012, J AM ACAD CHILD ADOL, V51
   Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Colvert E, 2015, JAMA PSYCHIAT, V72, P415, DOI 10.1001/jamapsychiatry.2014.3028
   Cook R, 2013, PSYCHOL SCI, V24, P723, DOI 10.1177/0956797612463582
   Davidson C, 2015, RES DEV DISABIL, V40, P63, DOI 10.1016/j.ridd.2015.01.007
   Wilson CE, 2016, AUTISM, V20, P808, DOI 10.1177/1362361315611381
   Fletcher-Watson S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008785.pub2
   Frith U, AUTISM EXPLAINING EN
   Frye RE, 2016, CLIN MED INSIGHTS-PE, V10, P43, DOI 10.4137/CMPed.S38337
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Halladay AK, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0019-y
   Hansen SN, 2015, JAMA PEDIATR, V169, P56, DOI 10.1001/jamapediatrics.2014.1893
   Happe F, 2015, J BR ACAD, V3, P197
   Happe F, ANNU REV PS IN PRESS
   Happe F., 1995, SOC RES CHILD DEV, V66, P843, DOI DOI 10.1111/J.1467-8624.1995.TB00909.X
   Happe F, 2014, J CHILD PSYCHOL PSYC, V55, P553, DOI 10.1111/jcpp.12162
   Henry JD, 2015, NAT REV NEUROL, V12, P28
   Heyes C, 2014, DEVELOPMENTAL SCI, V17, P647, DOI 10.1111/desc.12148
   Hiller RM, 2016, AUTISM, V20, P75, DOI 10.1177/1362361314568899
   Jokiranta-Olkoniemi E, 2016, JAMA PSYCHIAT, V73, P622, DOI 10.1001/jamapsychiatry.2016.0495
   Jones AP, 2010, J CHILD PSYCHOL PSYC, V51, P1188, DOI 10.1111/j.1469-7610.2010.02280.x
   Kay CL, 2016, DEV PSYCHOPATHOL, V28, P73, DOI 10.1017/S0954579415000292
   Knutsen J, 2015, DEVELOPMENTAL SCI, DOI [10.1111/desc.12368, DOI 10.1111/DESC.12368]
   Krall SC, 2016, HUM BRAIN MAPP, V37, P796, DOI 10.1002/hbm.23068
   Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Maddox BB, 2015, J AUTISM DEV DISORD, V45, P3949, DOI 10.1007/s10803-015-2531-5
   Mai XQ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00380
   Mary A, 2015, CHILD NEUROPSYCHOL, V7049, P1
   Milosavljevic B, 2016, J AUTISM DEV DISORD, V46, P1354, DOI 10.1007/s10803-015-2670-8
   O'Nions E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134331
   Oakley BFM, 2016, J ABNORM PSYCHOL, V125, P818, DOI 10.1037/abn0000182
   Ozonoff S, 2010, J AM ACAD CHILD ADOL, V49
   Peterson C, 2016, DEV PSYCHOL, V52, P46, DOI 10.1037/a0039833
   Phillips J, 2015, PSYCHOL SCI, V26, P1353, DOI 10.1177/0956797614558717
   PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515
   Robertson CE, 2016, CURR BIOL, V26, P80, DOI 10.1016/j.cub.2015.11.019
   Robertson CE, 2013, J NEUROSCI, V 33, P16983, DOI 10.1523/JNEUROSCI.0448-13.2013
   Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729
   Santiesteban I, 2015, EUR J NEUROSCI, V42, P2527, DOI 10.1111/ejn.13036
   Santiesteban I, 2012, CURR BIOL, V22, P2274, DOI 10.1016/j.cub.2012.10.018
   Schaafsma SM, 2015, TRENDS COGN SCI, V19, P65, DOI 10.1016/j.tics.2014.11.007
   Schurz M, 2014, NEUROSCI BIOBEHAV R, V42, P9, DOI 10.1016/j.neubiorev.2014.01.009
   Senju A, 2009, SCIENCE, V325, P883, DOI 10.1126/science.1176170
   Spunt RP, 2015, PSYCHOL SCI, V26, P724, DOI 10.1177/0956797615569002
   Sutera S, 2007, J AUTISM DEV DISORD, V37, P98, DOI 10.1007/s10803-006-0340-6
   Telford EJ, 2016, J CHILD PSYCHOL PSYC, V57, P861, DOI 10.1111/jcpp.12546
   Tick B, 2016, J AM ACAD CHILD ADOL, V55
   Tick B, 2016, J CHILD PSYCHOL PSYC, V57, P585, DOI 10.1111/jcpp.12499
   Todd AR, 2015, J EXP PSYCHOL GEN, V144, P374, DOI 10.1037/xge0000048
   Wellman HM, 2014, MAKING MINDS THEORY
   WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5
NR 59
TC 1
Z9 1
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8703
EI 1531-698X
J9 CURR OPIN PEDIATR
JI CURR. OPIN. PEDIATR.
PD DEC
PY 2016
VL 28
IS 6
BP 736
EP 742
DI 10.1097/MOP.0000000000000417
PG 7
WC Pediatrics
SC Pediatrics
GA EC0JF
UT WOS:000387785900011
PM 27606956
ER

PT J
AU Kania, BF
   Wronska, D
AF Kania, Bogdan Feliks
   Wronska, Danuta
TI Role of L-glutamate in aggression
SO MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE
LA Polish
DT Review
DE glutamate; their receptors in CNS; role in aggression
ID NMDA RECEPTOR-CHANNEL; MONOAMINE-OXIDASE; AMPA RECEPTORS; MICE;
   BEHAVIOR; RATS; HYPOTHALAMUS; NEURONS; LOCALIZATION; ATTACK
AB L-glutamate is one of major excitatory transmitters (along with aspartic, kainate acids and glycine) in the central nervous system and/or the peripheral nervous system. It mediates interaction through the stimulation of various ionotropic receptors families (ligand gated cation channels) and metabotropic receptor families (G-protein coupled). In this review, we describe the molecular composition of these glutamatergic receptors and discuss their neuropharmacology, particularly with respect to their roles in animal social behaviors and, particularly, in aggression. It is also known, that during aggression different interactions occur in the nervous system among glutamate, serotonin, vasopressin, oxytocin, dopamine, GABA and steroid receptors.
C1 [Kania, Bogdan Feliks] Uniwersyteckie Ctr Med Weterynaryjnej UJ UR Krako, Al Mickiewicza 24-28, PL-30059 Krakow, Poland.
   [Wronska, Danuta] Agr Univ Krakow, Katedra Fizjol & Endokrynol Zwierzat, Wydzial Biol & Hodowli Zwierzat, Al Mickiewicza 24-28, PL-30059 Krakow, Poland.
RP Kania, BF (reprint author), Ul Nowoursynowska 133C, PL-02797 Warsaw, Poland.
EM bkania@ur.krakow.pl
CR Adamczyk A, 2012, BEHAV BRAIN RES, V229, P265, DOI 10.1016/j.bbr.2012.01.007
   Ago Y, 2012, J PHARMACOL SCI, V118, P295, DOI 10.1254/jphs.11200SC
   Audet MC, 2009, PHYSIOL BEHAV, V96, P394, DOI 10.1016/j.physbeh.2008.11.002
   Bedrosian Tracy A, 2014, Curr Top Behav Neurosci, V17, P131, DOI 10.1007/7854_2013_273
   Bortolato M, 2012, J NEUROSCI, V32, P8574, DOI 10.1523/JNEUROSCI.0225-12.2012
   BRODY JF, 1969, NATURE, V224, P1330, DOI 10.1038/2241330a0
   Carrillo M, 2011, BEHAV NEUROSCI, V125, P753, DOI 10.1037/a0025127
   Carrillo M, 2009, BRAIN RES, V1249, P118, DOI 10.1016/j.brainres.2008.10.053
   Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055
   Diano S, 1997, ENDOCRINOLOGY, V138, P778, DOI 10.1210/en.138.2.778
   Duncan GE, 2004, BEHAV BRAIN RES, V153, P507, DOI 10.1016/j.bbr.2004.01.008
   Fischer SG, 2007, BEHAV BRAIN RES, V180, P77, DOI 10.1016/j.bbr.2007.02.025
   Navarro JF, 2008, EUR J PHARMACOL, V586, P217, DOI 10.1016/j.ejphar.2008.02.070
   Navarro JF, 2009, PSICOTHEMA, V21, P475
   Garcia-Garcia AL, 2009, BIOL PSYCHIAT, V66, P275, DOI 10.1016/j.biopsych.2009.02.027
   Haller J, 1998, BEHAV PHARMACOL, V9, P469, DOI 10.1097/00008877-199809000-00010
   Hamshere ML, 2009, BRIT J PSYCHIAT, V195, P23, DOI 10.1192/bjp.bp.108.061424
   Kew JNC, 2005, PSYCHOPHARMACOLOGY, V179, P4, DOI 10.1007/s00213-005-2200-z
   KRUK MR, 1983, BRAIN RES, V260, P61, DOI 10.1016/0006-8993(83)90764-3
   KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0
   LANG A, 1995, N-S ARCH PHARMACOL, V351, P363
   LeGreves P, 1997, NEUROSCI LETT, V226, P61, DOI 10.1016/S0304-3940(97)00244-9
   Miczek KA, 2013, PSYCHOPHARMACOLOGY, V226, P445, DOI 10.1007/s00213-013-3008-x
   Newman EL, 2015, PSYCHOPHARMACOLOGY, V232, P4359, DOI 10.1007/s00213-015-4069-9
   Newman EL, 2012, PSYCHOPHARMACOLOGY, V224, P167, DOI 10.1007/s00213-012-2734-9
   Scott AL, 2008, NEUROREPORT, V19, P739, DOI 10.1097/WNR.0b013e3282fd6e88
   Shaltiel G, 2008, MOL PSYCHIATR, V13, P858, DOI 10.1038/mp.2008.20
   Shigemoto R, 1997, J NEUROSCI, V17, P7503
   Shimshek DR, 2006, MOL ENDOCRINOL, V20, P219, DOI 10.1210/me.2005-0262
   Sukhotina IA, 2000, PSYCHOPHARMACOLOGY, V149, P345, DOI 10.1007/s002130000386
   Takahashi Aki, 2014, Curr Top Behav Neurosci, V17, P3, DOI 10.1007/7854_2013_263
   Vekovischeva OY, 2004, GENES BRAIN BEHAV, V3, P253, DOI 10.1111/j.1601-183X.2004.00075.x
   Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951
   Yadav R., 2012, PLOS ONE, V7, P32969
   Zhao XH, 2009, PROG NEURO-PSYCHOPH, V33, P1173, DOI 10.1016/j.pnpbp.2009.06.016
NR 35
TC 0
Z9 0
U1 1
U2 1
PU POLISH SOC VETERINARY SCIENCES EDITORIAL OFFICE
PI LUBLIN
PA AKADEMICKA 12, 20-950 LUBLIN, POLAND
SN 0025-8628
J9 MED WETER
JI Med. Weter.
PD DEC
PY 2016
VL 72
IS 12
BP 740
EP 744
DI 10.21521/mw.5603
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA EC9FB
UT WOS:000388448700004
ER

PT J
AU Willner, P
   Bergman, J
   Vanderschuren, L
   Ellenbroek, B
AF Willner, Paul
   Bergman, Jack
   Vanderschuren, Louk
   Ellenbroek, Bart
TI The behavioural pharmacology of oxytocin
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Editorial Material
NR 0
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 637
EP 638
DI 10.1097/FBP.0000000000000274
PG 2
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900001
ER

PT J
AU Lee, MR
   Weerts, EM
AF Lee, Mary R.
   Weerts, Elise M.
TI Oxytocin for the treatment of drug and alcohol use disorders
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Review
DE addiction; alcoholism; dependence; oxytocin; substance-use disorder;
   treatment
ID CONDITIONED PLACE PREFERENCE; METHAMPHETAMINE-SEEKING BEHAVIOR; CHRONIC
   MORPHINE TREATMENT; MEDIAL PREFRONTAL CORTEX; SOCIAL ANXIETY DISORDER;
   PITUITARY-ADRENAL AXIS; NUCLEUS-ACCUMBENS CORE; LONG-TERM ABSTINENCE;
   BLOOD-BRAIN-BARRIER; PROLYL-D-LEUCINE
AB There is growing interest in the use of oxytocin (OT) as a potential treatment for alcohol and other substance-use disorders. OT is a neuropeptide that modulates adaptive processes associated with addiction including reward, tolerance, associative learning, memory, and stress responses. OT exerts its effects through interactions with the hypothalamic-pituitary-adrenal axis and multiple neurotransmitter systems including the dopamine mesolimbic reward and corticotrophin-releasing factor stress systems. The effects of OT on stress systems are of high interest, given the strong link between stress, drug use and relapse, and known dysregulation of hypothalamic-pituitary-adrenal-axis activity associated with substance-use disorders. At the same time, the OT system is itself altered by acute or chronic drug exposure. This review summarizes the preclinical and clinical literature on the OT system and its relevance to drug and alcohol addiction. In addition, findings from recent clinical trials conducted in participants with cocaine, cannabis, or alcohol use disorder are included and evidence that OT may help to normalize blunted stress responses, and attenuate withdrawal-associated hypercortisolism, negative mood, and withdrawal symptoms is summarized. (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Lee, Mary R.] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, Bethesda, MD USA.
   [Lee, Mary R.] NIDA, Bethesda, MD 20892 USA.
   [Weerts, Elise M.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA.
RP Weerts, EM (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA.
EM eweerts@jhmi.edu
FU Bench-to-Bedside (B2B) grant - NIH Office of Behavioral and Social
   Sciences Research (OBSSR); National Institute on Alcohol Abuse and
   Alcoholism (NIAAA) [R21 AA022679]
FX This work was supported by a Bench-to-Bedside (B2B) grant (PI: Mary R.
   Lee) funded by the NIH Office of Behavioral and Social Sciences Research
   (OBSSR) and by the National Institute on Alcohol Abuse and Alcoholism
   (NIAAA) R21 AA022679 (PI: Elise M. Weerts).
CR ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   Banks WA, 2015, PEPTIDES, V72, P16, DOI 10.1016/j.peptides.2015.03.010
   Baracz SJ, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12337
   Baracz SJ, 2016, ADDICT BIOL, V21, P316, DOI 10.1111/adb.12198
   Baracz SJ, 2013, HORM BEHAV, V63, P370, DOI 10.1016/j.yhbeh.2012.12.003
   Baracz SJ, 2012, BEHAV BRAIN RES, V228, P185, DOI 10.1016/j.bbr.2011.11.038
   Baracz SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136132
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Beets I, 2012, SCIENCE, V338, P543, DOI 10.1126/science.1226860
   BICKNELL RJ, 1988, J PHYSIOL-LONDON, V396, P297
   BOHUS B, 1978, BRAIN RES, V157, P414, DOI 10.1016/0006-8993(78)90052-5
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Boschloo L, 2011, DRUG ALCOHOL DEPEN, V116, P170, DOI 10.1016/j.drugalcdep.2010.12.006
   Bowen MT, 2015, P NATL ACAD SCI USA, V112, P3104, DOI 10.1073/pnas.1416900112
   Buisman-Pijlman FTA, 2014, PHARMACOL BIOCHEM BE, V119, P22, DOI 10.1016/j.pbb.2013.09.005
   Burri A, 2008, PSYCHONEUROENDOCRINO, V33, P591, DOI 10.1016/j.psyneuen.2008.01.014
   Butovsky E, 2006, MOL CELL NEUROSCI, V31, P795, DOI 10.1016/j.mcn.2006.01.008
   Carson DS, 2010, ADDICT BIOL, V15, P448, DOI 10.1111/j.1369-1600.2010.00247.x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Cruz FC, 2008, PSYCHOPHARMACOLOGY, V201, P459, DOI 10.1007/s00213-008-1307-4
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   Di Simplicio M, 2009, J PSYCHOPHARMACOL, V23, P241, DOI 10.1177/0269881108095705
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Ebner K, 2000, BRAIN RES, V872, P87, DOI 10.1016/S0006-8993(00)02464-1
   Epperson CN, 1996, BIOL PSYCHIAT, V40, P547, DOI 10.1016/0006-3223(96)00120-5
   ERMISCH A, 1985, J CEREBR BLOOD F MET, V5, P350
   ERRICO AL, 1993, J STUD ALCOHOL, V54, P393
   Fahlke C, 2000, ALCOHOL CLIN EXP RES, V24, P644, DOI 10.1111/j.1530-0277.2000.tb02035.x
   Fahlke C, 1996, PSYCHOPHARMACOLOGY, V127, P133, DOI 10.1007/BF02805986
   Fish EW, 2008, PSYCHOPHARMACOLOGY, V197, P145, DOI 10.1007/s00213-007-1017-3
   Flanagan JC, 2015, PSYCHIAT RES, V229, P94, DOI 10.1016/j.psychres.2015.07.064
   Foley P, 2010, NEUROSCI BIOBEHAV R, V35, P91, DOI 10.1016/j.neubiorev.2010.01.010
   Freeman SM, 2016, PSYCHONEUROENDOCRINO, V66, P185, DOI 10.1016/j.psyneuen.2016.01.014
   Funk D, 2004, PSYCHOPHARMACOLOGY, V176, P82, DOI 10.1007/s00213-004-1859-x
   Georgiou P, 2015, ADDICT BIOL, V20, P902, DOI 10.1111/adb.12208
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gossen A, 2012, NEUROPEPTIDES, V46, P211, DOI 10.1016/j.npep.2012.07.001
   Han WY, 2014, PHARMACOL BIOCHEM BE, V119, P80, DOI 10.1016/j.pbb.2013.11.014
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hicks C, 2016, ADDICT BIOL, V21, P304, DOI 10.1111/adb.12197
   Higley AE, 2011, PSYCHOPHARMACOLOGY, V218, P121, DOI 10.1007/s00213-011-2355-8
   Hoge EA, 2008, CNS NEUROSCI THER, V14, P165, DOI 10.1111/j.1755-5949.2008.00051.x
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   IBRAGIMOV R, 1987, LIFE SCI, V41, P1265, DOI 10.1016/0024-3205(87)90205-0
   INSEL TR, 1991, EUR J PHARMACOL, V203, P149, DOI 10.1016/0014-2999(91)90806-2
   Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3
   Jezova D, 1995, ANN NY ACAD SCI, V771, P192, DOI 10.1111/j.1749-6632.1995.tb44681.x
   Jong Trynke R de, 2015, Psychoneuroendocrinology, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027
   KEMPER A, 1990, DRUG ALCOHOL DEPEN, V25, P319, DOI 10.1016/0376-8716(90)90158-B
   KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI [10.1016/j.neuropharm.2013.05.024, 10.1016/j.neuropharm2013.05.024]
   KOVACS GL, 1985, NEUROPHARMACOLOGY, V24, P413, DOI 10.1016/0028-3908(85)90026-7
   KOVACS GL, 1985, LIFE SCI, V37, P17, DOI 10.1016/0024-3205(85)90620-4
   KOVACS GL, 1984, BEHAV BRAIN RES, V14, P1, DOI 10.1016/0166-4328(84)90014-7
   KOVACS GL, 1990, NEUROPHARMACOLOGY, V29, P365, DOI 10.1016/0028-3908(90)90095-9
   KOVACS GL, 1987, J PHARMACOL EXP THER, V241, P569
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Krueger F, 2013, SOC COGN AFFECT NEUR, V8, P494, DOI 10.1093/scan/nss026
   Kubzansky LD, 2012, BIOL PSYCHOL, V90, P1, DOI 10.1016/j.biopsycho.2012.02.010
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   LANG RE, 1983, NEUROENDOCRINOLOGY, V37, P314, DOI 10.1159/000123566
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   Leknes S, 2013, SOC COGN AFFECT NEUR, V8, P741, DOI 10.1093/scan/nss062
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   LUNDIN S, 1986, ACTA ENDOCRINOL-COP, V112, P465
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   MacFadyen K, 2016, PHARMACOL BIOCHEM BE, V140, P27, DOI 10.1016/j.pbb.2015.10.014
   Marchesi C, 1997, PROG NEURO-PSYCHOPH, V21, P797, DOI 10.1016/S0278-5846(97)00080-8
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Moaddab M, 2015, PSYCHONEUROENDOCRINO, V53, P159, DOI 10.1016/j.psyneuen.2015.01.003
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Morales-Rivera A, 2014, PSYCHOPHARMACOLOGY, V231, P4145, DOI 10.1007/s00213-014-3553-y
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 1998, J PHYSIOL-LONDON, V508, P289
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Ohlsson B, 2005, NEUROGASTROENT MOTIL, V17, P697, DOI 10.1111/j.1365-2982.2005.00679.x
   Onaka T, 2012, J NEUROENDOCRINOL, V24, P587, DOI 10.1111/j.1365-2826.2012.02300.x
   Ondrejcakova M, 2010, STRESS, V13, P315, DOI 10.3109/10253891003596822
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Peters S, 2013, ADDICT BIOL, V18, P66, DOI 10.1111/adb.12001
   Peters ST, 2016, ADDICT BIOL, DOI [10.1111/adb.12362, DOI 10.1111/ADB.12362]
   Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043
   PUCILOWSKI O, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90067-1
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   RIGTER H, 1980, PHARMACOL BIOCHEM BE, V13, P285
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   SARNYAI Z, 1991, NEUROPEPTIDES, V19, P51, DOI 10.1016/0143-4179(91)90073-R
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Sarnyai Z, 1990, Neuroreport, V1, P200, DOI 10.1097/00001756-199011000-00006
   Simeon D, 2011, PSYCHONEUROENDOCRINO, V36, P1418, DOI 10.1016/j.psyneuen.2011.03.013
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Sinha R, 2011, ARCH GEN PSYCHIAT, V68, P942, DOI 10.1001/archgenpsychiatry.2011.49
   Sivukhina EV, 2006, HORM METAB RES, V38, P382, DOI 10.1055/s-2006-944522
   Stoop R, 2014, CURR OPIN NEUROBIOL, V29, P187, DOI 10.1016/j.conb.2014.09.012
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   SZABO G, 1987, ALCOHOL ALCOHOLISM, V22, P71
   SZABO G, 1985, ALCOHOL, V2, P567, DOI 10.1016/0741-8329(85)90082-5
   SZABO G, 1989, ACTA PHYSIOL HUNG, V73, P97
   Tauber M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-47
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Uhart M, 2009, ADDICT BIOL, V14, P43, DOI 10.1111/j.1369-1600.2008.00131.x
   Vescovi PP, 1997, ALCOHOL CLIN EXP RES, V21, P1195, DOI 10.1097/00000374-199710000-00006
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Walter M, 2006, ADDICT BIOL, V11, P157, DOI 10.1111/j.1355-6215.2006.00018.x
   WAND GS, 1991, J CLIN ENDOCR METAB, V72, P1290
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   You ZD, 2000, NEUROREPORT, V11, P3113, DOI 10.1097/00001756-200009280-00015
   Zanos P, 2014, PHARMACOL BIOCHEM BE, V119, P72, DOI 10.1016/j.pbb.2013.05.009
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zhou L, 2014, INT J NEUROPSYCHOPH, V18
NR 122
TC 0
Z9 0
U1 10
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 640
EP 648
DI 10.1097/FBP.0000000000000258
PG 9
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900002
PM 27603752
ER

PT J
AU Parrott, AC
AF Parrott, Andrew C.
TI Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal
   aspects of recreational 'ecstasy'
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Review
DE cortisol; ecstasy; human; 3,4-methylenedioxymethamphetamine; mood;
   neurohormone; oxytocin; psychosocial; stress
ID (ECSTASY)-INDUCED SEROTONIN NEUROTOXICITY; PITUITARY-ADRENAL-AXIS; MDMA
   POLYDRUG USERS; INTRANASAL OXYTOCIN; EMPIRICAL-RESEARCH;
   CLINICAL-PHARMACOLOGY; TRANSPORTER BINDING; BIOENERGETIC STRESS; HUMAN
   PSYCHOBIOLOGY; PROSOCIAL FEELINGS
AB Most research into 3,4-methylenedioxymethamphetamine (MDMA) has debated its psychobiological effects in relation to neurotransmission. This article debates the contributory roles of the neurohormones oxytocin and cortisol for their psychobiological effects in humans. The empirical literature on these neurohormones is reviewed and suggestions for future research outlined. Acute MDMA or 'ecstasy' can generate increased levels of oxytocin and cortisol, and these neurohormonal changes may be important for its mood-enhancing and energy-activation effects in humans. However, an initial finding of enhanced sociability correlating with oxytocin levels has not been replicated. Potential reasons are debated. There may be dynamic interactions between the two neurohormones, with greater activation under cortisol, facilitating stronger positive feelings under oxytocin. Chronic regular use of MDMA can adversely affect cortisol in several ways. Regular users show increased cortisol in 3-month hair samples, changes to the cortisol awakening response, and indications of greater daily stress. Furthermore, these cortisol findings suggest changes to the hypothalamic-pituitary-adrenal axis. The effects of chronic MDMA usage on oxytocin still need to be investigated. It is concluded that the neurohormones oxytocin and cortisol contribute in various ways to the psychobiological effects of recreational ecstasy/MDMA. Behavioural Pharmacology 27:649-658 Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Parrott, Andrew C.] Swansea Univ, Dept Psychol, Swansea SA2 8PP, W Glam, Wales.
   [Parrott, Andrew C.] Swinburne Univ, Ctr Human Psychopharmacol, Melbourne, Vic, Australia.
RP Parrott, AC (reprint author), Swansea Univ, Dept Psychol, Swansea SA2 8PP, W Glam, Wales.
EM a.c.parrott@swansea.ac.uk
CR Backhaus J, 2006, BIOL PSYCHIAT, V60, P1324, DOI 10.1016/j.biopsych.2006.03.051
   Bedi G, 2010, BIOL PSYCHIAT, V68, P1134, DOI 10.1016/j.biopsych.2010.08.003
   Benningfield MM, 2013, NEUROPSYCHOPHARMACOL, V38, P253, DOI 10.1038/npp.2012.178
   Briere FN, 2012, J EPIDEMIOL COMMUN H, V66, P990, DOI 10.1136/jech-2011-200706
   Broadbear JH, 2014, PHARMACOL BIOCHEM BE, V119, P61, DOI 10.1016/j.pbb.2013.07.002
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Chaouloff F, 2000, J PSYCHOPHARMACOL, V14, P139
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cohen RS, 1998, LOVE DRUG MARCHING B
   Cruickshank CC, 2009, ADDICTION, V104, P1085, DOI 10.1111/j.1360-0443.2009.02564.x
   Doblin R, 2014, HUM PSYCHOPHARM CLIN, V29, P105, DOI 10.1002/hup.2389
   Downey LA, 2015, HUM PSYCHOPHARM CLIN, V30, P199, DOI 10.1002/hup.2474
   Dumont GJH, 2009, SOC NEUROSCI-UK, V4, P359, DOI 10.1080/17470910802649470
   Dumont GJH, 2006, J PSYCHOPHARMACOL, V20, P176, DOI 10.1177/0269881106063271
   Emanuele E, 2006, MED HYPOTHESES, V67, P1250, DOI 10.1016/j.mehy.2006.05.021
   Evans SL, 2014, BRAIN RES, V1580, P69, DOI 10.1016/j.brainres.2013.11.008
   Farre M, 2004, PSYCHOPHARMACOLOGY, V173, P364, DOI 10.1007/s00213-004-1789-7
   FISHBEIN DH, 1989, BIOL PSYCHIAT, V25, P1049, DOI 10.1016/0006-3223(89)90293-X
   Fisk JE, 2005, PSYCHOPHARMACOLOGY, V181, P550, DOI 10.1007/s00213-005-0006-7
   Fox HC, 2002, PSYCHOPHARMACOLOGY, V162, P203, DOI 10.1002/s00213-002-1071-9
   Freedman RR, 2005, PSYCHOPHARMACOLOGY, V183, P248, DOI 10.1007/s00213-005-0149-6
   Fries E, 2009, INT J PSYCHOPHYSIOL, V72, P67, DOI 10.1016/j.ijpsycho.2008.03.014
   Frokjaer VG, 2014, INT J NEUROPSYCHOPH, V17, P1119, DOI 10.1017/S1461145714000066
   Gerra G, 2003, PSYCHIAT RES, V120, P115, DOI 10.1016/S0165-1781(03)00175-6
   Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3
   GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319
   Hall AP, 2006, BRIT J ANAESTH, V96, P678, DOI 10.1093/bja/ael078
   Harris DS, 2002, PSYCHOPHARMACOLOGY, V162, P396, DOI 10.1007/s00213-002-1131-1
   Herbert J, 2006, J NEUROENDOCRINOL, V18, P393, DOI 10.1111/j.1365-2826.2006.01429.x
   Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161
   Hysek CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036476
   Jacobsen LK, 2004, PSYCHOPHARMACOLOGY, V173, P383, DOI 10.1007/s00213-003-1679-4
   Kamilar-Britt P, 2015, NEUROSCI BIOBEHAV R, V57, P433, DOI 10.1016/j.neubiorev.2015.08.016
   Kemmerling K, 1996, NEUROPSYCHIATRIE, V10, P94
   Khoury JE, 2015, NEUROBIOL STRESS, V30, P34
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Kirkpatrick MG, 2014, NEUROPSYCHOPHARMACOL, V39, P1654, DOI 10.1038/npp.2014.12
   Kirkpatrick MG, 2012, PSYCHOPHARMACOLOGY, V219, P109, DOI 10.1007/s00213-011-2383-4
   Kirschbaum C, 2009, PSYCHONEUROENDOCRINO, V34, P32, DOI 10.1016/j.psyneuen.2008.08.024
   Kish SJ, 2010, BRAIN, V133, P1779, DOI 10.1093/brain/awq103
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Kuypers KPC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100719
   Laviola G, 1999, NEUROSCI BIOBEHAV R, V23, P993, DOI 10.1016/S0149-7634(99)00032-9
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Liechti ME, 2001, PSYCHOPHARMACOLOGY, V154, P161, DOI 10.1007/s002130000648
   Mas M, 1999, J PHARMACOL EXP THER, V290, P136
   May AL, 2015, HUM PSYCHOPHARM CLIN, V30, P272, DOI 10.1002/hup.2432
   McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665
   McCann UD, 2007, SCI WORLD J, V2, P231
   McCann UD, 2014, EFFECTS DRUG ABUSE H, P475
   McCann UD, 2011, PSYCHOPHARMACOLOGY, V217, P475, DOI 10.1007/s00213-011-2303-7
   McCann UD, 2009, NEUROLOGY, V73, P2011, DOI 10.1212/WNL.0b013e3181c51a62
   MCDOWELL DM, 1994, PSYCHIAT ANN, V24, P127
   McEwen BS, 2006, METABOLISM, V55, pS20, DOI 10.1016/j.metabol.2006.07.008
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McMorris T, 2006, INT J PSYCHOPHYSIOL, V61, P204, DOI 10.1016/j.ijpsycho.2005.10.002
   Meyer Jerrold S, 2013, Subst Abuse Rehabil, V4, P83, DOI 10.2147/SAR.S37258
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371
   Montgomery C, 2010, HUM PSYCHOPHARM CLIN, V25, P318, DOI 10.1002/hup.1119
   Morefield KM, 2009, NEUROPSYCHOBIOLOGY, V60, P216
   Nagaraja N, 2007, PSYCHOPHARMACOLOGY, V190, P73, DOI 10.1007/s00213-006-0593-y
   Nemeroff CB, 2005, J CLIN PSYCHIAT, V66, P5
   Nieuwenhuizen AG, 2008, PHYSIOL BEHAV, V94, P169, DOI 10.1016/j.physbeh.2007.12.011
   Oei NYL, 2006, STRESS, V9, P133, DOI 10.1080/10253890600965773
   Ogeil RP, 2013, DRUG ALCOHOL DEPEN, V132, P223, DOI 10.1016/j.drugalcdep.2013.02.002
   Ogeil RP, 2011, HUM PSYCHOPHARM CLIN, V26, P508, DOI 10.1002/hup.1233
   Pacifici R, 2001, LIFE SCI, V69, P2931, DOI 10.1016/S0024-3205(01)01373-X
   Parrott AC, 2008, NEUROPSYCHOBIOLOGY, V57, P165, DOI 10.1159/000147470
   Parrott AC, 2007, PSYCHOPHARMACOLOGY, V191, P181, DOI 10.1007/s00213-007-0703-5
   Parrott AC, 2006, HUM PSYCHOPHARM CLIN, V21, P285, DOI 10.1002/hup.773
   Parrott AC, 2014, EUR NEUROPSYCHOPHARM, V24, P369, DOI 10.1016/j.euroneuro.2013.11.006
   Parrott AC, 2013, J PSYCHOPHARMACOL, V27, P113, DOI 10.1177/0269881112454231
   Parrott AC, 2012, DRUG ALCOHOL DEPEN, V121, P1, DOI 10.1016/j.drugalcdep.2011.08.012
   Parrott AC, 2009, NEUROPSYCHOBIOLOGY, V60, P148, DOI 10.1159/000253551
   Parrott AC, 2006, J PSYCHOPHARMACOL, V20, P147, DOI 10.1177/026988110603268
   Parrott AC, 2005, J PSYCHOPHARMACOL, V19, P71, DOI 10.1177/0269881105048900
   Parrott AC, 2004, NEUROPSYCHOBIOLOGY, V50, P329, DOI 10.1159/000080961
   Parrott AC, 2001, HUM PSYCHOPHARM CLIN, V16, P557, DOI 10.1002/hup.351
   Parrott AC, 1998, PSYCHOPHARMACOLOGY, V139, P261, DOI 10.1007/s002130050714
   Parrott AC, 2007, J PSYCHOPHARMACOL, V21, pa35
   Parrott AC, 2014, TEMPERATURE AUSTIN, V1, P1
   Parrott AC, 2010, NEW HORIZONNEUROSC
   Parrott AC, 2016, HDB PSYCHOB IN PRESS
   Parrott AC, 2015, HUM PSYCHOPHARM CLIN, V30, P213, DOI 10.1002/hup.2468
   Parrott AC, 2014, BEHAV PHARMACOL, V25, P458, DOI 10.1097/FBP.0000000000000060
   Parrott AC, 2014, J PSYCHOACTIVE DRUGS, V46, P37, DOI 10.1080/02791072.2014.873690
   Parrott AC, 2014, HUM PSYCHOPHARM CLIN, V29, P109, DOI 10.1002/hup.2390
   Parrott AC, 2013, NEUROSCI BIOBEHAV R, V37, P1466, DOI 10.1016/j.neubiorev.2013.04.016
   Parrott AC, 2013, HUM PSYCHOPHARM CLIN, V28, P289, DOI 10.1002/hup.2318
   Parrott AC, 2011, PSYCHOPHARMACOLOGY, V215, P527, DOI 10.1007/s00213-011-2184-9
   Reay JL, 2006, J PSYCHOPHARMACOL, V20, P385, DOI 10.1177/0269881106063269
   Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664
   Rodgers J, 2003, J PSYCHOPHARMACOL, V17, P389, DOI 10.1177/0269881103174016
   Roger-Sanchez C, 2016, BEHAV PHARMACOL, V27, P116, DOI 10.1097/FBP.0000000000000210
   Schifano F, 1998, DRUG ALCOHOL DEPEN, V52, P85, DOI 10.1016/S0376-8716(98)00051-9
   Schmid Y, 2015, EUR NEUROPSYCHOPHARM, V25, P17, DOI 10.1016/j.euroneuro.2014.11.020
   Schmid Y, 2014, J PSYCHOPHARMACOL, V28, P847, DOI 10.1177/0269881114542454
   Scholey AB, 2011, NEUROPSYCHOBIOLOGY, V63, P15, DOI 10.1159/000321833
   Seibert J, 2014, NEUROENDOCRINOLOGY, V100, P17, DOI 10.1159/000364879
   Selye H, 1956, STRESS LIFE
   Singer LT, 2016, NEUROTOXICOL TERATOL, V54, P22, DOI 10.1016/j.ntt.2016.01.003
   Singer LT, 2012, PEDIATRICS, V130, P407, DOI 10.1542/peds.2012-0666
   Stalder T, 2016, PSYCHONEUROENDOCRINO, V63, P414, DOI 10.1016/j.psyneuen.2015.10.010
   Stalder T, 2012, BRAIN BEHAV IMMUN, V26, P1019, DOI 10.1016/j.bbi.2012.02.002
   Strohle A, 2003, PHARMACOPSYCHIATRY, V36, pS207
   Suy K, 1999, Eur J Emerg Med, V6, P249
   Taurah L, 2014, PSYCHOPHARMACOLOGY, V231, P737, DOI 10.1007/s00213-013-3288-1
   Theall KP, 2006, AIDS BEHAV, V10, P169, DOI 10.1007/s10461-005-9059-1
   Turner JJD, 1998, J PSYCHOPHARMACOL, V12, pa43
   Turner JJD, 2014, J PSYCHOPHARMACOL, V28, P55, DOI 10.1177/0269881113515061
   van Dijken GD, 2013, NEPHROL DIAL TRANSPL, V28, P2277, DOI 10.1093/ndt/gft023
   Wetherell MA, 2014, PSYCHOPHARMACOLOGY, V231, P1365, DOI 10.1007/s00213-013-3325-0
   Wetherell MA, 2012, HUM PSYCHOPHARM CLIN, V27, P167, DOI 10.1002/hup.1261
   White CM, 2014, J CLIN PHARMACOL, V54, P245, DOI 10.1002/jcph.266
   Wolf OT, 2005, NEUROBIOL AGING, V26, P1357, DOI 10.1016/j.neurobiolaging.2004.11.003
   Wolff K, 2006, J PSYCHOPHARMACOL, V20, P400, DOI 10.1177/0269881106061514
   Wolff K, 2013, J PSYCHOPHARMACOL, V27, P115, DOI 10.1177/0269881112455288
   Wolff K, 2012, J PSYCHOPHARMACOL, V26, P419, DOI 10.1177/0269881111415737
   Zhou JF, 2003, FREE RADICAL RES, V37, P491, DOI 10.1080/1071576031000076286
NR 120
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 649
EP 658
DI 10.1097/FBP.0000000000000262
PG 10
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900003
PM 27681116
ER

PT J
AU Johnson, JL
   Buisman-Pijlman, FTA
AF Johnson, Jacinta L.
   Buisman-Pijlman, Femke T. A.
TI Adversity impacting on oxytocin and behaviour: timing matters
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Review
DE addiction; adversity; animal; drug; human; lifespan; mental health;
   oxytocin; resilience; stress
ID VASOPRESSIN V1A RECEPTORS; STRESSFUL LIFE EVENTS; SOCIAL-BEHAVIOR;
   MATERNAL SEPARATION; PRENATAL STRESS; PLASMA OXYTOCIN; OLDER-ADULTS;
   NEUROSCIENCE PERSPECTIVE; CHILDHOOD MALTREATMENT; SUBSTANCE MISUSE
AB The endogenous oxytocin system plays a vital role in facilitating parturition, lactation and social interaction in humans and other mammals. It also impacts on a number of important endocrine, immune and neurotransmitter systems. A well-regulated oxytocin system has been proposed to increase resilience, and therefore reduce the likelihood of an individual developing mental illness or substance dependence. This review discusses the adverse external influences that can modulate oxytocin receptor and protein levels and impact on substance use and mental health. The paper highlights the impact of adversity such as poor maternal care, parental substance use and child abuse or neglect. We review clinical and preclinical data on the impact of adversity on the basis of the time of exposure from infancy and early childhood, to adolescence, adulthood to older age. Previous research suggests that dysregulation of the endogenous oxytocin system may be implicated in determining susceptibility to stress, anxiety, addiction and mental health conditions. The impact of external influence seems to be strongest in specific time periods where the system shows experience-based development or natural fluctuations in oxytocin levels. Interventions that target the oxytocin system during or soon after exposure to adversity may prove protective. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Johnson, Jacinta L.] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia.
   [Johnson, Jacinta L.] SA Hlth, SA Pharm, Flinders Med Ctr, Div Pharm, Adelaide, SA, Australia.
   [Buisman-Pijlman, Femke T. A.] Univ Adelaide, Adelaide Med Sch, Discipline Pharmacol, Adelaide, SA, Australia.
RP Buisman-Pijlman, FTA (reprint author), Univ Adelaide, North Med Sch, Adelaide Med Sch, Discipline Pharmacol, Frome Rd, Adelaide, SA 5005, Australia.
EM femke.buisman-pijlman@adelaide.edu.au
FU University of Adelaide
FX This study was funded by the University of Adelaide.
CR Alves E, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00032
   Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Babb JA, 2014, HORM BEHAV, V65, P386, DOI 10.1016/j.yhbeh.2014.03.005
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Bales KL, 2012, HORM BEHAV, V61, P313, DOI 10.1016/j.yhbeh.2011.12.013
   Bales KL, 2004, DEV PSYCHOBIOL, V44, P123, DOI 10.1002/dev.10165
   BAROWICZ T, 1979, J DAIRY RES, V46, P41
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Blow FC, 2012, CURR PSYCHIAT REP, V14, P310, DOI 10.1007/s11920-012-0292-9
   Bowen M, 2016, NEUROPATHOLOGY DRUG, P82
   Bowen MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027237
   Bradley B, 2011, DEV PSYCHOPATHOL, V23, P439, DOI 10.1017/S0954579411000162
   Branchi I, 2009, NEUROSCI BIOBEHAV R, V33, P551, DOI 10.1016/j.neubiorev.2008.03.011
   Brems C, 2004, AM J DRUG ALCOHOL AB, V30, P799, DOI 10.1081/ADA-200037546
   Broadbear JH, 2011, ADDICT BIOL, V16, P202, DOI 10.1111/j.1369-1600.2010.00267.x
   BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132
   Buisman-Pijlman FTA, 2014, PHARMACOL BIOCHEM BE, V119, P22, DOI 10.1016/j.pbb.2013.09.005
   Burns KA, 1997, J CLIN PSYCHOL, V53, P279, DOI 10.1002/(SICI)1097-4679(199704)53:3<279::AID-JCLP11>3.0.CO;2-F
   Calza L, 1997, J NEURAL TRANSM, V104, P1095, DOI 10.1007/BF01273321
   Carini LM, 2013, HORM BEHAV, V64, P634, DOI 10.1016/j.yhbeh.2013.08.011
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Carson DS, 2012, EXP CLIN PSYCHOPHARM, V20, P497, DOI 10.1037/a0029976
   Caughey SD, 2011, J NEUROENDOCRINOL, V23, P1113, DOI 10.1111/j.1365-2826.2011.02224.x
   CHIODERA P, 1994, REGUL PEPTIDES, V51, P169, DOI 10.1016/0167-0115(94)90206-2
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   de Souza MA, 2013, NEUROCHEM RES, V38, P1479, DOI 10.1007/s11064-013-1049-5
   Dumont GJH, 2009, SOC NEUROSCI-UK, V4, P359, DOI 10.1080/17470910802649470
   Ebner Natalie C, 2014, Front Psychol, V5, P1595, DOI 10.3389/fpsyg.2014.01595
   Ebner NC, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00487
   Emeny RT, 2015, PSYCHONEUROENDOCRINO, V56, P132, DOI 10.1016/j.psyneuen.2015.03.014
   Evans JJ, 1997, ENDOCRINOLOGY, V138, P2049, DOI 10.1210/en.138.5.2049
   Feldman R, 2010, HORM BEHAV, V58, P669, DOI 10.1016/j.yhbeh.2010.06.005
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   Freedman D, 2015, J AFFECT DISORDERS, V173, P65, DOI 10.1016/j.jad.2014.10.052
   Fries ABW, 2005, P NATL ACAD SCI USA, V102, P17237, DOI 10.1073/pnas.0504767102
   Galbally M, 2011, HARVARD REV PSYCHIAT, V19, P1, DOI 10.3109/10673229.2011.549771
   Gannon RL, 2014, EUR NEUROPSYCHOPHARM, V24, P964, DOI [10.1016/j.euroneuro.2013.12.007, 10.1016/j.euroneuro.2014.03.008]
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gouin JP, 2010, PSYCHONEUROENDOCRINO, V35, P1082, DOI 10.1016/j.psyneuen.2010.01.009
   HAN JS, 1993, AM J PHYSIOL, V265, pF26
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Huffmeijer R, 2013, GERONTOLOGY, V59, P32, DOI 10.1159/000341333
   Jankord R, 2011, ENDOCRINOLOGY, V152, P629, DOI 10.1210/en.2010-0658
   Jezova D, 1995, ANN NY ACAD SCI, V771, P192, DOI 10.1111/j.1749-6632.1995.tb44681.x
   Johns JM, 1997, NEUROPEPTIDES, V31, P439, DOI 10.1016/S0143-4179(97)90037-8
   Johns JM, 1998, ANN NY ACAD SCI, V846, P399, DOI 10.1111/j.1749-6632.1998.tb09765.x
   Johns JM, 2005, PHARMACOL BIOCHEM BE, V81, P769, DOI 10.1016/j.pbb.2005.06.001
   Johns JM, 2004, INT J DEV NEUROSCI, V22, P321, DOI 10.1016/j.ijdevneu.2004.03.002
   Johnson AL, 2002, J DEV BEHAV PEDIATR, V23
   Johnson JL, 2016, DETECTION MISUSED DR
   Kalinichev M, 2002, PHARMACOL BIOCHEM BE, V73, P131, DOI 10.1016/S0091-3057(02)00781-5
   Kim S, 2016, MATERNAL BRAIN PLAST, P59
   Knobloch HS, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00031
   Koenig JI, 2005, BEHAV BRAIN RES, V156, P251, DOI 10.1016/j.bbr.2004.05.030
   Koob GF, 2006, NEUROBIOLOGY ADDICTI
   Korosi A, 2010, DEV PSYCHOBIOL, V52, P661, DOI 10.1002/dev.20490
   Kramer KM, 2003, PHYSIOL BEHAV, V79, P775, DOI 10.1016/S0031-9384(03)00175-6
   Kumsta R, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00083
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Landry SH, 1998, PEDIATR RES, V43, P13, DOI 10.1203/00006450-199804001-00083
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   Levine S, 2005, PSYCHONEUROENDOCRINO, V30, P939, DOI 10.1016/j.psyneuen.2005.03.013
   LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405
   Light KC, 2005, BIOL PSYCHOL, V69, P5, DOI 10.1016/j.biopsycho.2004.11.002
   Lukas M, 2010, NEUROPHARMACOLOGY, V58, P78, DOI 10.1016/j.neuropharm.2009.06.020
   Magura S, 1996, CHILD YOUTH SERV REV, V18, P193, DOI 10.1016/0190-7409(96)00001-1
   Mairesse J, 2015, PSYCHONEUROENDOCRINO, V62, P36, DOI 10.1016/j.psyneuen.2015.07.005
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McMurray MS, 2008, NEUROTOXICOL TERATOL, V30, P475, DOI 10.1016/j.ntt.2008.07.001
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Miller TV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00076
   Millstein RA, 2007, NEUROSCI BIOBEHAV R, V31, P3, DOI 10.1016/j.neubiorev.2006.05.003
   Mizuki R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00138
   Moffett MC, 2007, BIOCHEM PHARMACOL, V73, P321, DOI 10.1016/j.bcp.2006.08.003
   Montag C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051882
   Myers AJ, 2014, J PSYCHIATR RES, V59, P93, DOI 10.1016/j.jpsychires.2014.08.021
   Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   Nishimori K, 2008, PROG BRAIN RES, V170, P79, DOI 10.1016/S0079-6123(08)00408-1
   Nissen E, 1996, EARLY HUM DEV, V45, P103, DOI 10.1016/0378-3782(96)01725-2
   Nissen E, 2009, J PSYCHOSOM OBST GYN, V19, P49
   Noonan L R, 1994, Brain Res Dev Brain Res, V80, P115
   Nylander I, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00077
   O'Donnell K, 2009, DEV NEUROSCI-BASEL, V31, P285, DOI 10.1159/000216539
   Opacka-Juffry J, 2012, STRESS, V15, P1, DOI 10.3109/10253890.2011.560309
   Oreland S, 2010, NEUROPEPTIDES, V44, P391, DOI 10.1016/j.npep.2010.06.001
   Ozsoy S, 2009, PSYCHIAT RES, V169, P249, DOI 10.1016/j.psychres.2008.06.034
   Patel N, 2015, PHYSIOL BEHAV, V139, P254, DOI 10.1016/j.physbeh.2014.11.018
   Pena CJ, 2013, BEHAV NEUROSCI, V127, P33, DOI 10.1037/a0031219
   Rault JL, 2013, PHYSIOL BEHAV, V112, P40, DOI 10.1016/j.physbeh.2013.02.007
   Reyes TL, 2014, J GERONTOL B-PSYCHOL, V69, pS229, DOI 10.1093/geronb/gbu104
   Romeo RD, 2003, HORM BEHAV, V43, P561, DOI 10.1016/S0018-506X(03)00063-1
   RUSSELL JT, 1980, ENDOCRINOLOGY, V107, P1880
   Rutherford Helena J V, 2011, Front Psychiatry, V2, P37, DOI 10.3389/fpsyt.2011.00037
   Salonia A, 2005, HORM BEHAV, V47, P164, DOI 10.1016/j.yhbeh.2004.10.002
   Samuel S, 2015, ATTACH HUM DEV, V17, P272, DOI 10.1080/14616734.2015.1029951
   Schonfeld L, 2015, AM J PUBLIC HEALTH, V105, P205, DOI 10.2105/AJPH.2013.301859
   Schulz KM, 2009, HORM BEHAV, V55, P597, DOI 10.1016/j.yhbeh.2009.03.010
   SHYKEN JM, 1995, CLIN OBSTET GYNECOL, V38, P232, DOI 10.1097/00003081-199506000-00006
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   SOFRONIEW MV, 1983, PROG BRAIN RES, V60, P101
   SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475
   SOFRONIEW MV, 1981, ACTA HISTOCHEM, P79
   Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002
   Suchman NE, 2010, ATTACH HUM DEV, V12, P483, DOI 10.1080/14616734.2010.501983
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Theodosis DT, 2002, FRONT NEUROENDOCRIN, V23, P101, DOI 10.1006/frne.2001.0226
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Tops M, 2014, PHARMACOL BIOCHEM BE, V119, P39, DOI 10.1016/j.pbb.2013.07.015
   Uvnas-Mobcrg K, 2009, J PSYCHOSOM OBST GYN, V11, P261
   Veenema AH, 2012, HORM BEHAV, V61, P304, DOI 10.1016/j.yhbeh.2011.12.002
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Wang P, 2015, J NEUROIMMUNOL, V289, P152, DOI 10.1016/j.jneuroim.2015.11.001
   Widom CS, 2007, J STUD ALCOHOL DRUGS, V68, P317
   WIERDA M, 1991, NEUROBIOL AGING, V12, P511, DOI 10.1016/0197-4580(91)90081-T
   Williams SK, 2014, PHARMACOL BIOCHEM BE, V119, P10, DOI 10.1016/j.pbb.2013.07.004
   Williams SK, 2011, CURR NEUROPHARMACOL, V9, P478, DOI 10.2174/157015911796557957
   Wolff K, 2006, J PSYCHOPHARMACOL, V20, P400, DOI 10.1177/0269881106061514
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
   Zoicas L, 2014, NEUROPSYCHOPHARMACOL, V39, P3027, DOI 10.1038/npp.2014.156
NR 125
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 659
EP 671
DI 10.1097/FBP.0000000000000269
PG 13
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900004
PM 27755016
ER

PT J
AU Yu, CJ
   Zhang, SW
   Tai, FD
AF Yu, Cheng J.
   Zhang, Shu W.
   Tai, Fa D.
TI Effects of nucleus accumbens oxytocin and its antagonist on social
   approach behavior
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE avoidance; mandarin voles; nucleus accumbens; oxytocin; oxytocin
   receptor antagonist; preference
ID VENTRAL TEGMENTAL AREA; FEMALE PRAIRIE VOLES; MALE-RATS; PARAVENTRICULAR
   NUCLEUS; MATERNAL-BEHAVIOR; BRAIN OXYTOCIN; LATENT INHIBITION;
   SEXUAL-BEHAVIOR; PENILE ERECTION; MANDARIN VOLES
AB Severe impairment of social interaction is a core symptom of numerous psychiatric disorders. Oxytocin (OT) has been shown to be involved in various aspects of social behavior related to reproduction, but little is known about its effects on nonreproductive social interaction between adults or the neuroanatomical location where OT exerts its action. Here, we examined the nucleus accumbens, a region of the brain containing high levels of the oxytocin receptor (OTR) and comprising an important node in the neural circuitry possibly related to social interaction. Behavioral effects of a local microinfusion of OT (0.1, 1, and 10 ng/side) and an oxytocin receptor antagonist (OTR-A) (1, 10, and 100 ng/side) were evaluated in naturally high social and low social female and male monogamous mandarin voles (Microtus mandarinus) using the social preference paradigm and open-field tests. The results showed that administration of 1 ng/side OT increased social preference; however, this effect was not apparent at lower or higher doses. OT did not alter anxiety-like behavior or total locomotion. Microinfusions of a selective OTR-A at 10 and 100 ng doses reduced social approach behavior; a dose of 1 ng had no effect. In conclusion, our results suggest that accumbal OT and OTR-A regulate social preferences in voles in a dose-Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Yu, Cheng J.; Zhang, Shu W.; Tai, Fa D.] Shaanxi Normal Univ, Coll Life Sci, Inst Brain & Behav Sci, Behav Neurosci Dept, Xian 710062, Shaanxi, Peoples R China.
   [Yu, Cheng J.] Ningxia Med Univ, Sch Basic Med, Physiol Dept, Yinchuan, Peoples R China.
RP Tai, FD (reprint author), Shaanxi Normal Univ, Coll Life Sci, Inst Brain & Behav Sci, Xian 710062, Shaanxi, Peoples R China.
EM taifadao@snnu.edu.cn
FU National Natural Science Foundation of China [31170377, 30970370];
   Fundamental Research Funds for Central University [GK201305009]
FX This study was supported by National Natural Science Foundation of China
   #31170377 and 30970370 and Fundamental Research Funds for Central
   University #GK201305009.
CR ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x
   ANNETT LE, 1989, BEHAV BRAIN RES, V31, P231, DOI 10.1016/0166-4328(89)90005-3
   ARGIOLAS A, 1989, PHARMACOL BIOCHEM BE, V33, P81, DOI 10.1016/0091-3057(89)90433-4
   ARGIOLAS A, 1988, ANN NY ACAD SCI, V525, P330, DOI 10.1111/j.1749-6632.1988.tb38617.x
   Argiolas A, 2013, PROG NEUROBIOL, V108, P80, DOI 10.1016/j.pneurobio.2013.06.006
   Bale TL, 2001, J NEUROSCI, V21, P2546
   Bales KL, 2007, HORM BEHAV, V52, P274, DOI 10.1016/j.yhbeh.2007.05.004
   BENELLI A, 1995, NEUROPEPTIDES, V28, P251, DOI 10.1016/0143-4179(95)90029-2
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   Blume A, 2008, EUR J NEUROSCI, V27, P1947, DOI 10.1111/j.1460-9568.2008.06184.x
   Bosch OJ, 2005, J NEUROSCI, V25, P6807, DOI 10.1523/JNEUROSCI.1342-05.2005
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Campbell A, 2010, PERS SOC PSYCHOL REV, V14, P281, DOI 10.1177/1088868310363594
   Cao Y, 2014, HORM BEHAV, V65, P57, DOI 10.1016/j.yhbeh.2013.11.005
   CARLSSON M, 1990, SCHIZOPHRENIA BULL, V16, P425
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Carter CS, 2008, NEUROBIOLOGY OF THE PARENTAL BRAIN, P417
   CARTER CS, 1995, NEUROSCI BIOBEHAV R, V19, P303
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   DAMSMA G, 1992, BEHAV NEUROSCI, V106, P181, DOI 10.1037//0735-7044.106.1.181
   Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   DRAGO F, 1986, PHARMACOL BIOCHEM BE, V24, P1185, DOI 10.1016/0091-3057(86)90168-1
   Ferrari PF, 2003, EUR J NEUROSCI, V17, P371, DOI 10.1046/j.1460-9568.2003.02447.x
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gargiulo PA, 1996, BRAZ J MED BIOL RES, V29, P805
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471
   Green EL, 1975, BIOL LAB MOUSE
   Groenewegen HJ, 2007, CNS SPECTRUMS, V12, P887
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Jeanblanc J, 2002, NEUROSCIENCE, V111, P315, DOI 10.1016/S0306-4522(02)00019-2
   Johnson K, 1996, J PHARMACOL EXP THER, V277, P1122
   Kalivas PW, 1999, CURR OPIN NEUROBIOL, V9, P223, DOI 10.1016/S0959-4388(99)80031-2
   Kendrick KM, 2000, EXP PHYSIOL, V85, p111S, DOI 10.1111/j.1469-445X.2000.tb00014.x
   KOOB GF, 1992, ANN NY ACAD SCI, V654, P171, DOI 10.1111/j.1749-6632.1992.tb25966.x
   KOVACS GL, 1990, NEUROPHARMACOLOGY, V29, P365, DOI 10.1016/0028-3908(90)90095-9
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Love T.M., 2013, PHARM BIOCH BEHAV, V119, P49
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Luo AH, 2011, SCIENCE, V333, P353, DOI 10.1126/science.1204622
   MALDONADOIRIZARRY CS, 1994, PSYCHOPHARMACOLOGY, V116, P65, DOI 10.1007/BF02244872
   MCCARTHY MM, 1990, HORM BEHAV, V24, P365, DOI 10.1016/0018-506X(90)90015-P
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   MOGENSON GJ, 1991, ADV EXP MED BIOL, V295, P267
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Parkinson JA, 1999, J NEUROSCI, V19, P2401
   Paxinos G., 2001, MOUSE BRAIN STEREOTA
   PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605
   Pliakas AM, 2001, J NEUROSCI, V21, P7397
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   Qiao XF, 2014, BEHAV BRAIN RES, V274, P226, DOI 10.1016/j.bbr.2014.08.020
   SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8
   SEAMANS JK, 1994, BEHAV NEUROSCI, V108, P456
   Setlow B, 1998, BEHAV NEUROSCI, V112, P603, DOI 10.1037/0735-7044.112.3.603
   Smith-Roe SL, 2000, J NEUROSCI, V20, P7737
   Tai Fadao, 2001, Acta Theriologica Sinica, V21, P50
   Tai F, 1998, J SHAANXI NORMAL U N, V26, P66
   Tai F, 2001, ACTA ZOOL SINICA, V47, P260
   Thompson RR, 2004, BEHAV NEUROSCI, V118, P620, DOI 10.1037/0735-7044.118.3.620
   Usiello A, 1998, PSYCHOPHARMACOLOGY, V137, P175, DOI 10.1007/s002130050607
   van Erp AMM, 2000, J NEUROSCI, V20, P9320
   VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275
   Waldherr M, 2007, P NATL ACAD SCI USA, V104, P16681, DOI 10.1073/pnas.0705860104
   Weiner I, 1996, BEHAV BRAIN RES, V81, P123, DOI 10.1016/S0166-4328(96)00051-4
   Young KA, 2014, J NEUROSCI, V34, P8499, DOI 10.1523/JNEUROSCI.4275-13.2014
   ZABORSZKY L, 1985, NEUROSCIENCE, V14, P427, DOI 10.1016/0306-4522(85)90302-1
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
NR 74
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 672
EP 680
DI 10.1097/FBP.0000000000000212
PG 9
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900005
PM 26960161
ER

PT J
AU Demirci, E
   Ozmen, S
   Kilic, E
   Oztop, DB
AF Demirci, Esra
   Ozmen, Sevgi
   Kilic, Eser
   Oztop, Didem B.
TI The relationship between aggression, empathy skills and serum oxytocin
   levels in male children and adolescents with attention deficit and
   hyperactivity disorder
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE aggression empathy; attention deficit and hyperactivity disorder;
   emotion recognition; human; oxytocin
ID DEFICIT/HYPERACTIVITY DISORDER; INTRANASAL OXYTOCIN; EMOTIONAL EMPATHY;
   SOCIAL COGNITION; NEURAL CIRCUITRY; EYES TEST; AUTISM; MIND; HUMANS;
   ADHD
AB Although attention deficit and hyperactivity disorder (ADHD) are recognized as neurodevelopmental disorders characterized by impairment in executive functions, impairments in social functioning are often accompanied by ADHD. Oxytocin (OT) has been investigated in a number of psychiatric disorders owing to its effects on social interactions. The aim of this study was to determine the relationship between aggression, empathy and OT levels in children with ADHD. Forty male patients with ADHD, ranging in age from 7 to 18 years, and 40 healthy age-matched and sex-matched individuals were included in this study. The patients and healthy controls filled in the Buss-Perry Aggression Questionnaire and Bryant's Empathy Index for Children and Adolescents; the Reading the Mind in the Eyes test was then completed. Blood samples were collected for OT at the beginning of the study. Lower serum OT levels were observed in patients with ADHD compared with the healthy controls. Moreover, there was a negative correlation between serum OT level and aggression scores and a positive correlation between the serum OT level and empathy scores in patients with ADHD. We conclude that OT may play a role in aggression and empathy skills, affecting the social life of those with ADHD. (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Demirci, Esra; Ozmen, Sevgi; Oztop, Didem B.] Erciyes Univ, Sch Med, Dept Child & Adolescent Psychiat, TR-38039 Kayseri, Turkey.
   [Kilic, Eser] Erciyes Univ, Sch Med, Dept Biochem, TR-38039 Kayseri, Turkey.
RP Demirci, E (reprint author), Erciyes Univ, Sch Med, Dept Child & Adolescent Psychiat, TR-38039 Kayseri, Turkey.
EM esra_z_d_r@hotmail.com
FU Erciyes University [TTU-2013-4260]
FX Research Fund of Erciyes University provided financial support for kit
   (project number: TTU-2013-4260). The funding source had no further role
   in the study design, the interpretation of data, the writing of the
   report, and the decision to submit the paper for publication.
CR Alcorn JL, 2015, BEHAV PHARMACOL, V26, P798, DOI 10.1097/FBP.0000000000000173
   Alcorn JL, 2015, PSYCHOL REC, V65, P691, DOI 10.1007/s40732-015-0139-y
   American Psychiatric Association, 2000, AM PSYCH ASS TASK FO
   Arnsten AFT, 2003, PEDIAT PSYCHOPHARMAC, P99
   Bagwell CL, 2001, J AM ACAD CHILD PSY, V40, P1285, DOI 10.1097/00004583-200111000-00008
   Barkley RA, 2006, ATTENTION DEFICIT HY, P297
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Boakes J, 2008, CHILD NEUROPSYCHOL, V14, P82, DOI 10.1080/09297040701503327
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Braaten EB, 2000, J CONSULT CLIN PSYCH, V68, P313, DOI 10.1037//0022-006X.68.2.313
   Buss AH, 2002, AGGRESSION QUESTIONN
   Campbell A, 2013, AGGRESSIVE BEHAV, V39, P316, DOI 10.1002/ab.21478
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Carter C S, 2001, Prog Brain Res, V133, P241
   Dalton KM, 2005, NAT NEUROSCI, V8, P519, DOI 10.1038/nn1421
   del Barrio V, 2004, PSYCHOL REP, V95, P257, DOI 10.2466/pr0.95.1.257-262
   Dereboy C, 2007, TURK PSIKIYATR DERG, V18, P48
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ende G, 2016, NEUROPSYCHOPHARMACOL, V41, P410, DOI 10.1038/npp.2015.153
   Feeser M, 2015, PSYCHONEUROENDOCRINO, V53, P223, DOI 10.1016/j.psyneuen.2014.12.015
   Fetissov SO, 2006, BIOL PSYCHIAT, V60, P799, DOI 10.1016/j.biopsych.2006.03.081
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hastings PD, 2000, DEV PSYCHOL, V36, P531, DOI 10.1037//0012-1649.36.5.531
   Hattori J, 2006, BRAIN DEV-JPN, V28, P371, DOI 10.1016/j.braindev.2005.11.009
   Hirotaka K, 2012, BMC PSYCHIATRY, V12, P110
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Insel TR, 1999, BIOL PSYCHIAT, V45, P145, DOI 10.1016/S0006-3223(98)00142-5
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kuehn BM, 2011, JAMA-J AM MED ASSOC, V305, P659, DOI 10.1001/jama.2011.117
   Lee PC, 2012, RES DEV DISABIL, V33, P2040, DOI 10.1016/j.ridd.2012.05.011
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Maoz H, 2014, J PSYCHOPHARMACOL, V28, P212, DOI 10.1177/0269881113492030
   Marton I, 2009, J ABNORM CHILD PSYCH, V37, P107, DOI 10.1007/s10802-008-9262-4
   Neumann ID, 2007, BIOCHEM SOC T, V35, P1252, DOI 10.1042/BST0351252
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Park J, 2010, PROG NEURO-PSYCHOPH, V34, P697, DOI 10.1016/j.pnpbp.2010.03.029
   Pelc K, 2006, PEDIATR NEUROL, V35, P93, DOI 10.1016/j.peidatrneurol.2006.01.014
   Radke S, 2015, PSYCHONEUROENDOCRINO, V60, P75, DOI 10.1016/j.psyneuen.2015.06.006
   Sasaki T, 2015, PSYCHIAT RES, V228, P746, DOI 10.1016/j.psychres.2015.05.029
   Schwenck C, 2011, Z KINDER JUG-PSYCH, V39, P265, DOI 10.1024/1422-4917/a000118
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268
   Sinzig J, 2008, EUR CHILD ADOLES PSY, V17, P63, DOI 10.1007/s00787-007-0637-9
   Succu S, 2007, NEUROPHARMACOLOGY, V52, P1034, DOI 10.1016/j.neuropharm.2006.10.019
   Taurines Regina, 2014, Atten Defic Hyperact Disord, V6, P231, DOI 10.1007/s12402-014-0145-y
   Turan T, 2013, PSYCHONEUROENDOCRINO, V38, P2890, DOI 10.1016/j.psyneuen.2013.07.017
   Van der Oord S, 2005, BEHAV RES THER, V43, P733, DOI 10.1016/j.brat.2004.06.004
   Voracek M, 2006, PERS INDIV DIFFER, V41, P1481, DOI 10.1016/j.paid.2006.06.009
   Wehmeier PM, 2010, J ADOLESCENT HEALTH, V46, P209, DOI 10.1016/j.jadohealth.2009.09.009
   Williams LM, 2008, BIOL PSYCHIAT, V63, P917, DOI 10.1016/j.biopsych.2007.11.022
   Zak PJ, 2006, ECON HUM BIOL, V4, P412, DOI 10.1016/j.ehb.2006.06.004
NR 54
TC 0
Z9 0
U1 10
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 681
EP 688
DI 10.1097/FBP.0000000000000234
PG 8
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900006
PM 27031167
ER

PT J
AU Ji, HY
   Su, WL
   Zhou, RC
   Feng, J
   Lin, Y
   Zhang, YM
   Wang, XM
   Chen, XY
   Li, J
AF Ji, Haoyi
   Su, Wenlong
   Zhou, Ruchen
   Feng, Jing
   Lin, Yue
   Zhang, Yumin
   Wang, Xinmei
   Chen, Xiaoyang
   Li, Jing
TI Intranasal oxytocin administration improves depression-like behaviors in
   adult rats that experienced neonatal maternal deprivation
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE depression; intranasal administration; neonatal maternal deprivation;
   neurogenesis rat; oxytocin
ID FORCED SWIMMING TEST; HIPPOCAMPAL NEUROGENESIS; ANTIDEPRESSANT
   TREATMENT; PLASMA OXYTOCIN; SEPARATION; STRESS; BRAIN; MODEL; RECEPTORS;
   MICE
AB Oxytocin( OT), a hypothalamic neuropeptide, has been implicated in the regulation of social behaviors in rodents and humans. This study assessed the effects of intranasal administration of OT on depressive-like behaviors and hippocampal neurogenesis in adult rats following neonatal maternal deprivation( NMD). Here, we show that NMD resulted in significant depression-like behaviors, as indicated by decreases in physical activity and emotional reactivity in a novel environment, in 2-month-old animals. Notably, the OT levels in the plasma, hypothalamus, and hippocampus were decreased in these animals. Intranasal administration of OT reduced the depressive-like behaviors in NMD rats and rescued hippocampal long-term plasticity impaired by NMD stress in rats by promoting hippocampal neurogenesis. These results indicate that OT alleviates the depressive-like behaviors in NMD adult rats, probably mediated by improving adult hippocampal neurogenesis. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Ji, Haoyi; Su, Wenlong; Zhou, Ruchen; Feng, Jing; Lin, Yue; Zhang, Yumin] Shandong Univ, Sch Med, Dept Physiol, Shandong Prov Key Lab Mental Disorders, Jinan, Peoples R China.
   [Ji, Haoyi; Chen, Xiaoyang] Shandong Univ, Sch Med, Dept Med Eth, Jinan, Peoples R China.
   [Wang, Xinmei; Li, Jing] Cent Hosp Zibo, Dept Pathol, Zibo 255000, Shandong, Peoples R China.
RP Li, J (reprint author), Cent Hosp Zibo, Dept Pathol, Zibo 255000, Shandong, Peoples R China.
EM sydft2014@163.com
FU Natural Science Foundation of Shandong Province [ZR2014HP069]
FX This research was supported by the Natural Science Foundation of
   Shandong Province (No. ZR2014HP069).
CR Badhan RKS, 2014, CURR DRUG DELIV, V11, P458, DOI 10.2174/1567201811666140321113555
   Blume A, 2008, EUR J NEUROSCI, V27, P1947, DOI 10.1111/j.1460-9568.2008.06184.x
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Branchi I, 2013, PSYCHONEUROENDOCRINO, V38, P522, DOI 10.1016/j.psyneuen.2012.07.010
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Cryan JF, 2000, J PHARMACOL EXP THER, V295, P1120
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Daniels WMU, 2004, METAB BRAIN DIS, V19, P3, DOI 10.1023/B:MEBR.0000027412.19664.b3
   DETKE MJ, 1995, PSYCHOPHARMACOLOGY, V121, P66, DOI 10.1007/BF02245592
   Duman CH, 2007, BIOL PSYCHIAT, V61, P661, DOI 10.1016/j.biopsych.2006.05.047
   El Khoury A, 2006, PROG NEURO-PSYCHOPH, V30, P535, DOI 10.1016/j.pnpbp.2005.11.011
   ERMISCH A, 1985, J CEREBR BLOOD F MET, V5, P350
   Ferigolo M, 1998, PHARMACOL BIOCHEM BE, V60, P431, DOI 10.1016/S0091-3057(98)00011-2
   KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1
   Kim HJ, 2005, NEUROPEPTIDES, V39, P587, DOI 10.1016/j.npep.2005.09.003
   Lajud N, 2012, PSYCHONEUROENDOCRINO, V37, P410, DOI 10.1016/j.psyneuen.2011.07.011
   Lee JH, 2007, NEUROSCI RES, V58, P32, DOI 10.1016/j.neures.2007.01.008
   Lee SY, 2015, SCI REP-UK, V5, DOI 10.1038/srep18540
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Lopez-Rubalcava C, 2000, NEUROPSYCHOPHARMACOL, V22, P191, DOI 10.1016/S0893-133X(99)00100-1
   Lucki I, 1997, BEHAV PHARMACOL, V8, P523, DOI 10.1097/00008877-199711000-00010
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Malberg JE, 2000, J NEUROSCI, V20, P9104
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Onaka T, 2003, EUR J NEUROSCI, V18, P3018, DOI 10.1046/j.1460-9568.2003.03037.x
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0
   Reneric JP, 1998, PSYCHOPHARMACOLOGY, V136, P190, DOI 10.1007/s002130050555
   Ryu V, 2008, INT J OBESITY, V32, P1355, DOI 10.1038/ijo.2008.108
   Ryu V, 2009, BRAIN RES, V1295, P127, DOI 10.1016/j.brainres.2009.08.006
   Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969
   van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427
   Vazquez DM, 2000, BRAIN RES, V855, P76, DOI 10.1016/S0006-8993(99)02307-0
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037//0033-2909.83.3.482
   Yuen KW, 2014, J PSYCHIATR RES, V51, P30, DOI 10.1016/j.jpsychires.2013.12.012
   Zhang Y, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-11
NR 40
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 689
EP 696
DI 10.1097/FBP.0000000000000248
PG 8
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900007
PM 27644094
ER

PT J
AU Miller, MA
   Bershad, A
   King, AC
   Lee, R
   de Wit, H
AF Miller, Melissa A.
   Bershad, Anya
   King, Andrea C.
   Lee, Royce
   de Wit, Harriet
TI Intranasal oxytocin dampens cue-elicited cigarette craving in daily
   smokers: a pilot study
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE craving; human; oxytocin; placebo-controlled trial; smoking
ID CONDITIONED PLACE PREFERENCE; SMOKING-BEHAVIOR; PLASMA OXYTOCIN;
   MENSTRUAL-CYCLE; ADDICTION; COCAINE; HUMANS; WITHDRAWAL; DEPENDENCE;
   RATS
AB Despite moderate success with pharmacological and behavioral treatments, smoking relapse rates remain high, and many smokers report that smoking cues lead to relapse. Therefore, treatments that target cue reactivity are needed. One candidate for reducing craving is the neuropeptide oxytocin (OT). Here, we investigated the effects of intranasal OT on two types of craving for cigarettes: craving following overnight abstinence and craving elicited by smoking-related cues. In this within-subject, placebo-controlled pilot study, smokers (N=17) abstained from smoking for 12 h before attending two sessions randomized to intranasal OT or placebo (i.e. saline nasal spray). On each session, participants received two doses of OT (20 IU) or placebo at 1-h intervals, and rated craving before and after each dose. Spontaneous cigarette craving was assessed after the first spray, and cue-elicited craving was assessed following the second spray. OT did not reduce levels of spontaneous craving after the first spray, but significantly dampened cue-induced smoking craving. These results provide preliminary evidence that OT can reduce cue-induced smoking craving in smokers. These findings provide an important link between preclinical and clinical studies aimed at examining the effectiveness of OT as a novel treatment for drug craving. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Miller, Melissa A.; Bershad, Anya; King, Andrea C.; Lee, Royce; de Wit, Harriet] Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC3077, Chicago, IL 60637 USA.
   [Bershad, Anya] Univ Chicago, Interdisciplinary Scientist Training Program, Chicago, IL 60637 USA.
RP de Wit, H (reprint author), Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC3077, Chicago, IL 60637 USA.
EM hdew@uchicago.edu
FU Comprehensive Cancer Center Pilot Grant - University of Chicago;
   National Institute of Mental Health [T32MH020065]
FX This research was supported by a Comprehensive Cancer Center Pilot Grant
   awarded by the University of Chicago (awarded to H.d.W., A.K., and
   R.L.). The research was also funded by a grant from the National
   Institute of Mental Health (T32MH020065) (awarded to M.A.M.).
CR Baker TB, 2004, PSYCHOL REV, V111, P33, DOI 10.1037/0033-295X.111.1.33
   Baracz SJ, 2012, BEHAV BRAIN RES, V228, P185, DOI 10.1016/j.bbr.2011.11.038
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Conklin CA, 2001, EXP CLIN PSYCHOPHARM, V9, P399, DOI 10.1037/1064-1297.9.4.399
   Cox L S, 2001, Nicotine Tob Res, V3, P7, DOI 10.1080/14622200020032051
   Cui SS, 2001, J NEUROSCI, V21, P9867
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Drobes DJ, 1997, J ABNORM PSYCHOL, V106, P15, DOI 10.1037/0021-843X.106.1.15
   Ferguson SG, 2009, J SUBST ABUSE TREAT, V36, P235, DOI 10.1016/j.jsat.2008.06.005
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GLAD W, 1976, J ABNORM PSYCHOL, V85, P119
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   Heishman SJ, 2008, NICOTINE TOB RES, V10, P643, DOI 10.1080/14622200801908174
   HERMAN CP, 1974, J PERS SOC PSYCHOL, V30, P664, DOI 10.1037/h0037440
   HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289
   Jarvik ME, 2000, PHARMACOL BIOCHEM BE, V66, P553, DOI 10.1016/S0091-3057(00)00261-6
   JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435
   JOHANSON CE, 1980, PSYCHOPHARMACOLOGY, V71, P275, DOI 10.1007/BF00433062
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   KOVACS GL, 1985, LIFE SCI, V37, P1895, DOI 10.1016/0024-3205(85)90007-4
   KOVACS GL, 1990, NEUROPHARMACOLOGY, V29, P365, DOI 10.1016/0028-3908(90)90095-9
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   LaRowe SD, 2007, ADDICT BEHAV, V32, P2888, DOI 10.1016/j.addbeh.2007.04.025
   Leischow SJ, 1997, EXP CLIN PSYCHOPHARM, V5, P54, DOI 10.1037/1064-1297.5.1.54
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Maarcher Ann, 2011, Morbidity and Mortality Weekly Report, V60, P1513
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Mucha RF, 1998, CAN J PHYSIOL PHARM, V76, P259, DOI 10.1139/cjpp-76-3-259
   Payne T J, 1990, J Subst Abuse, V2, P113
   PAYNE TJ, 1991, ADDICT BEHAV, V16, P467, DOI 10.1016/0306-4603(91)90054-L
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Rostron B, 2013, NICOTINE TOB RES, V15, P1722, DOI 10.1093/ntr/ntt051
   Salonia A, 2005, HORM BEHAV, V47, P164, DOI 10.1016/j.yhbeh.2004.10.002
   Substance Abuse and Mental Health Services Administration (SAMHSA), 2011, ADVISORY, V10
   SARNYAI Z, 1992, NEUROPHARMACOLOGY, V31, P593, DOI 10.1016/0028-3908(92)90192-R
   SARNYAI Z, 1991, NEUROPEPTIDES, V19, P51, DOI 10.1016/0143-4179(91)90073-R
   SARNYAI Z, 1992, PHARMACOL BIOCHEM BE, V43, P491, DOI 10.1016/0091-3057(92)90182-F
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Sarnyai Z, 2011, ADDICT BIOL, V16, P199, DOI 10.1111/j.1369-1600.2011.00332.x
   SHUKOVSKI L, 1989, J CLIN ENDOCR METAB, V68, P455
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   SURAWY C, 1985, BRIT J ADDICT, V80, P207
   SZABO G, 1987, ALCOHOL ALCOHOLISM, V22, P71
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Wetter DW, 2004, PREV MED, V39, P1156, DOI 10.1016/j.ypmed.2004.04.028
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213
   You ZD, 2001, NEUROSCI RES, V41, P143, DOI 10.1016/S0168-0102(01)00272-3
NR 56
TC 0
Z9 0
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 697
EP 703
DI 10.1097/FBP.0000000000000260
PG 7
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900008
PM 27661192
ER

PT J
AU Janezic, EM
   Uppalapati, S
   Nagl, S
   Contreras, M
   French, ED
   Fellous, JM
AF Janezic, Eric M.
   Uppalapati, Swetha
   Nagl, Stephanie
   Contreras, Marco
   French, Edward D.
   Fellous, Jean-Marc
TI Beneficial effects of chronic oxytocin administration and social
   co-housing in a rodent model of post-traumatic stress disorder
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE anxiety; oxytocin; prosocial; rat; stress
ID POTENTIATED STARTLE PARADIGM; NATIONAL COMORBIDITY SURVEY; REDUCES
   BACKGROUND ANXIETY; VENTRAL TEGMENTAL AREA; INJECTED CAGE MATE;
   MALE-RATS; BRAIN OXYTOCIN; FEMALE RATS; SITUATIONAL REMINDERS;
   ENERGY-CONSERVATION
AB Post-traumatic stress disorder (PTSD) is in part due to a deficit in memory consolidation and extinction. Oxytocin (OXT) has anxiolytic effects and promotes prosocial behaviors in both rodents and humans, and evidence suggests that it plays a role in memory consolidation. We studied the effects of administered OXT and social co-housing in a rodent model of PTSD. Acute OXT yielded a short-term increase in the recall of the traumatic memory if administered immediately after trauma. Low doses of OXT delivered chronically had a cumulating anxiolytic effect that became apparent after 4 days and persisted. Repeated injections of OXT after short re-exposures to the trauma apparatus yielded a long-term reduction in anxiety. Co-housing with naive nonshocked animals decreased the memory of the traumatic context compared with single-housed animals. In the long term, these animals showed less thigmotaxis and increased interest in novel objects, and a low OXT plasma level. Co-housed PTSD animals showed an increase in risk-taking behavior. These results suggest beneficial effects of OXT if administered chronically through increases in memory consolidation after re-exposure to a safe trauma context. We also show differences between the benefits of social co-housing with naive rats and co-housing with other shocked animals on trauma-induced long-term anxiety. (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Janezic, Eric M.; Uppalapati, Swetha; Nagl, Stephanie; Contreras, Marco; Fellous, Jean-Marc] Univ Arizona, Computat & Expt Neurosci Lab, Tucson, AZ USA.
   [Nagl, Stephanie; Contreras, Marco; Fellous, Jean-Marc] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA.
   [French, Edward D.] Univ Arizona, Dept Pharmacol, Tucson, AZ USA.
RP Fellous, JM (reprint author), Dept Psychol, Room 312,1503 E Univ Blvd, Tucson, AZ 85721 USA.
EM fellous@email.arizona.edu
FU ONR-MURI Grant [N000141310672]; Pew Latin Fellowship
FX This work was supported in part by ONR-MURI Grant N000141310672 (J.M.F.)
   and a Pew Latin Fellowship (M.C.). The authors wish to thank Zachary
   Trahan and Blaine Harper for their help.
CR Acheson D, 2013, PSYCHOPHARMACOLOGY, V229, P199, DOI 10.1007/s00213-013-3099-4
   Agren G, 2002, NEUROREPORT, V13, P1415
   Agren G, 2002, NEUROREPORT, V13, P1453
   Arai A, 2016, BEHAV BRAIN RES, V315, P83, DOI 10.1016/j.bbr.2016.08.022
   Ayers LW, 2011, NEUROPSYCHOPHARMACOL, V36, P2488, DOI 10.1038/npp.2011.138
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004
   Bisson J, 2007, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.C0003388.PUB3
   BOHUS B, 1978, BRAIN RES, V157, P414, DOI 10.1016/0006-8993(78)90052-5
   BOHUS B, 1978, NEUROPHARMACOLOGY, V17, P239, DOI 10.1016/0028-3908(78)90107-7
   Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   Carson DS, 2010, ADDICT BIOL, V15, P448, DOI 10.1111/j.1369-1600.2010.00247.x
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Charuvastra A, 2008, ANNU REV PSYCHOL, V59, P301, DOI 10.1146/annurev.psych.58.110405.085650
   Chini B, 2014, BIOL PSYCHIAT, V76, P360, DOI 10.1016/j.biopsych.2013.08.029
   Cloitre M, 2009, CNS SPECTRUMS, V14, P32
   Corral-Frias NS, 2013, NEUROPSYCHOPHARMACOL, V38, P350, DOI 10.1038/npp.2012.189
   COSTALL B, 1989, PHARMACOL BIOCHEM BE, V32, P777, DOI 10.1016/0091-3057(89)90033-6
   Davis M, 2006, BIOL PSYCHIAT, V60, P369, DOI 10.1016/j.biopsych.2006.03.084
   Devarajan K, 2004, NEUROSCI LETT, V367, P144, DOI 10.1016/j.neulet.2004.05.112
   DEWIED D, 1993, FRONT NEUROENDOCRIN, V14, P251, DOI 10.1006/frne.1993.1009
   Dudai Y, 2015, NEURON, V88, P20, DOI 10.1016/j.neuron.2015.09.004
   Eckstein M, 2015, BIOL PSYCHIAT, V78, P194, DOI 10.1016/j.biopsych.2014.10.015
   Elands J, 1988, J Chem Neuroanat, V1, P293
   Elklit Ask, 2012, Torture, V22, P11
   Eskandarian Sharaf, 2013, Basic Clin Neurosci, V4, P315
   Euston DR, 2007, SCIENCE, V318, P1147, DOI 10.1126/science.1148979
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Hicks C, 2012, J NEUROENDOCRINOL, V24, P1012, DOI 10.1111/j.1365-2826.2012.02311.x
   Hikind N, 2008, NEUROBIOL LEARN MEM, V90, P217, DOI 10.1016/j.nlm.2008.03.003
   Ho JM, 2014, ENDOCRINOLOGY, V155, P2845, DOI 10.1210/en.2014-1148
   Huzard D, 2015, PHYSIOL BEHAV, V151, P238, DOI 10.1016/j.physbeh.2015.07.018
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kofoed Lial, 1993, Psychiatric Quarterly (New York), V64, P151, DOI 10.1007/BF01065867
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kudrimoti HS, 1999, J NEUROSCI, V19, P4090
   Lahoud N, 2013, PSYCHONEUROENDOCRINO, V38, P2184, DOI 10.1016/j.psyneuen.2013.04.006
   Liberzon Israel, 2008, Prog Brain Res, V167, P151
   Louvart H, 2006, PSYCHONEUROENDOCRINO, V31, P92, DOI 10.1016/j.psyneuen.2005.05.014
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   MacDonald K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00035
   Maren S, 2013, NAT REV NEUROSCI, V14, P417, DOI 10.1038/nrn3492
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Missig G, 2010, NEUROPSYCHOPHARMACOL, V35, P2607, DOI 10.1038/npp.2010.155
   Muroy SE, 2016, NEUROPSYCHOPHARMACOL, V41, P2160, DOI 10.1038/npp.2016.16
   Neumann I, 1996, J NEUROENDOCRINOL, V8, P227, DOI 10.1046/j.1365-2826.1996.04557.x
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Olff M, 2010, CNS SPECTRUMS, V15, P522, DOI 10.1017/S109285290000047X
   Parsons RG, 2013, NAT NEUROSCI, V16, P146, DOI 10.1038/nn.3296
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Petersson M, 2003, NEUROSCI LETT, V343, P97, DOI 10.1016/S0304-3940(03)00334-3
   PITMAN RK, 1993, PSYCHIAT RES, V48, P107, DOI 10.1016/0165-1781(93)90035-F
   Pynoos RS, 1996, BIOL PSYCHIAT, V39, P129, DOI 10.1016/0006-3223(95)00088-7
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Stein MB, 2002, AM J PSYCHIAT, V159, P1777, DOI 10.1176/appi.ajp.159.10.1777
   Stidd DA, 2013, BRAIN STIMUL, V6, P837, DOI 10.1016/j.brs.2013.05.008
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Toledo-Rodriguez M, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00017
   Toth I, 2012, PSYCHOPHARMACOLOGY, V223, P149, DOI 10.1007/s00213-012-2702-4
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Valdes JL, 2015, J NEUROPHYSIOL, V114, P1183, DOI 10.1152/jn.00758.2014
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Williams LM, 2006, NEUROIMAGE, V29, P347, DOI 10.1016/j.neuroimage.2005.03.047
   WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517
NR 75
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 704
EP 717
DI 10.1097/FBP.0000000000000270
PG 14
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900009
PM 27740964
ER

PT J
AU Boulet, NP
   Cloutier, CJ
   Ossenkopp, KP
   Kavaliers, M
AF Boulet, Nathalie P.
   Cloutier, Caylen J.
   Ossenkopp, Klaus-Peter
   Kavaliers, Martin
TI Oxytocin, social factors, and the expression of conditioned disgust
   (anticipatory nausea) in male rats
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE malaise; rat; social conditioning; social recognition; toxin
ID TASTE AVOIDANCE; GAPING RESPONSES; RODENT MODEL; RECOGNITION; AVERSION;
   VASOPRESSIN; STIMULI; LICL; EXPOSURE; BEHAVIOR
AB Disgust has been proposed to have evolved as a means to rid the body and mouth of noxious substances and toxins, as well as to motivate and facilitate avoidance of contact with disease-causing organisms and infectious materials. Nonemetic species, such as the rat, show distinctive facial expressions, including the gaping reaction, indicative of nausea-based disgust. These conditioned disgust responses can be used to model anticipatory nausea in humans, which is a learned response observed following chemotherapy treatment. As social factors play a role in the modulation and expression of conditioned disgust responses in rats, and the nonapeptide, oxytocin (OT), is involved in the modulation of social behavior, the present study examined the effects of an OT antagonist, L-368 899, on the development and expression of socially mediated conditioned disgust in male rats. When administered 10 min before testing in a distinct context (different from the original conditioning context), L-368 899 (5 mg/kg) significantly decreased gaping behavior in rats that were conditioned with a social partner. LiCl-treated rats administered L-368 899 before testing also showed decreased social initiations toward their social partner. These findings suggest that OT may play a role in the modulation and expression of socially mediated conditioned disgust in rats. (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Cloutier, Caylen J.; Ossenkopp, Klaus-Peter; Kavaliers, Martin] Western Univ, Dept Psychol, London, ON N6A 5C1, Canada.
   [Boulet, Nathalie P.; Ossenkopp, Klaus-Peter; Kavaliers, Martin] Western Univ, Grad Program Neurosci, London, ON N6A 5C1, Canada.
RP Kavaliers, M (reprint author), Western Univ, Dept Psychol, Fac Social Sci, London, ON N6A 5C1, Canada.
EM kavalier@uwo.ca
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
FX This research was supported by Natural Sciences and Engineering Research
   Council of Canada (NSERC) Discovery grants to M.K. and K.-P.O.
CR Arakawa H, 2011, NEUROSCI BIOBEHAV R, V35, P1916, DOI 10.1016/j.neubiorev.2011.03.007
   BENELLI A, 1995, NEUROPEPTIDES, V28, P251, DOI 10.1016/0143-4179(95)90029-2
   BEST MR, 1986, ANIM LEARN BEHAV, V14, P1, DOI 10.3758/BF03200030
   BOAKES RA, 1993, EUR J CANCER, V29A, P866, DOI 10.1016/S0959-8049(05)80427-7
   Boulet N, 2015, SOC NEUR ABSTR, V26
   Chapman HA, 2012, ANN NY ACAD SCI, V1251, P62, DOI 10.1111/j.1749-6632.2011.06369.x
   Choleris E, 2009, FRONT NEUROENDOCRIN, V30, P442, DOI 10.1016/j.yfrne.2009.05.003
   Cloutier CJ, 2012, BEHAV BRAIN RES, V232, P278, DOI 10.1016/j.bbr.2012.04.021
   Cloutier CJ, 2011, NEUROSCI LETT, V502, P76, DOI 10.1016/j.neulet.2011.07.003
   Cloutier CJ, 2016, PHARM BIOCH BEHAV
   Curtis V, 2011, PHILOS T R SOC B, V366, P389, DOI 10.1098/rstb.2010.0117
   DIVGI AB, 1989, NEW ENGL J MED, V320, P189
   Dluzen DE, 2000, EUR J NEUROSCI, V12, P760, DOI 10.1046/j.1460-9568.2000.00952.x
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dumais KM, 2016, FRONT NEUROENDOCRIN, V40, P1, DOI 10.1016/j.yfrne.2015.04.003
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   GARCIA J, 1974, SCIENCE, V185, P824, DOI 10.1126/science.185.4154.824
   GRILL HJ, 1978, BRAIN RES, V143, P263, DOI 10.1016/0006-8993(78)90568-1
   Guzman YF, 2014, PSYCHOPHARMACOLOGY, V231, P2097, DOI 10.1007/s00213-013-3356-6
   Hennessy MB, 2014, BRAIN BEHAV IMMUN, V37, P15, DOI 10.1016/j.bbi.2013.10.021
   Herisson FM, 2014, NEUROREPORT, V25, P909, DOI 10.1097/WNR.0000000000000201
   Horn CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060537
   Jacobs GH, 2001, J EXP BIOL, V204, P2439
   Kavaliers M, 2004, HORM BEHAV, V46, P272, DOI 10.1016/j.yhbeh.2004.03.005
   Kavaliers M, 2014, ANIM BEHAV, V97, P105, DOI 10.1016/j.anbehav.2014.09.006
   Kavaliers M, 2011, PSYCHOL SCI, V22, P1367, DOI 10.1177/0956797611420576
   Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI 10.1016/j.biopsych.2009.12.012
   Limebeer CL, 2008, BEHAV BRAIN RES, V187, P33, DOI 10.1016/j.bbr.2007.08.024
   Limebeer CL, 2006, PHYSIOL BEHAV, V88, P398, DOI 10.1016/j.physbeh.2006.04.014
   Lopes PC, 2012, BEHAV ECOL SOCIOBIOL, V66, P1421, DOI 10.1007/s00265-012-1397-1
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Matteson S, 2002, AM J OBSTET GYNECOL, V186, pS239, DOI 10.1067/mob.2002.122597
   Morrow GR, 1997, MED MANAGEMENT CANC, P149
   Moshkin M, 2012, J SEX MED, V9, P3211, DOI 10.1111/j.1743-6109.2011.02562.x
   Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111
   NESSE RM, 1980, PSYCHOSOM MED, V42, P33
   OCONNOR EF, 1987, PHYSIOL BEHAV, V40, P91, DOI 10.1016/0031-9384(87)90189-2
   Oettl LL, 2016, NEURON, V90, P609, DOI 10.1016/j.neuron.2016.03.033
   Olszewski PK, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12376
   Olszewski PK, 2013, PEPTIDES, V50, P36, DOI 10.1016/j.peptides.2013.09.008
   Olszewski PK, 2000, AM J PHYSIOL-REG I, V279, pR1504
   Ossenkopp KP, 2011, EUR J PHARMACOL, V660, P358, DOI 10.1016/j.ejphar.2011.03.049
   OSSENKOPP KP, 1985, NEUROBEH TOXICOL TER, V7, P95
   OSSENKOPP KP, 1995, NEUROSCI BIOBEHAV R, V19, P99, DOI 10.1016/0149-7634(94)00024-U
   Parker LA, 2003, LEARN BEHAV, V31, P165
   Parker LA, 2008, CAN J EXP PSYCHOL, V62, P198, DOI 10.1037/a0012531
   Pellis SM, 1997, NEUROSCI BIOBEHAV R, V21, P105, DOI 10.1016/0149-7634(95)00060-7
   Pettibone DJ, 1997, BIOCHEM SOC T, V25, P1051
   PETTIJOHN TF, 1981, J COMP PHYSIOL PSYCH, V95, P228, DOI 10.1037/h0077766
   Popik P, 1991, Eur Neuropsychopharmacol, V1, P555, DOI 10.1016/0924-977X(91)90010-R
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   ROZIN P, 1987, PSYCHOL REV, V94, P23, DOI 10.1037//0033-295X.94.1.23
   Rozin P., 2008, HDB EMOTIONS, P757
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Song Z, 2016, SOC BEHAV NEUROENDOC, V81, P20
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Theodoridou A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058113
   Tomoyasu N, 1996, PHYSIOL BEHAV, V59, P273, DOI 10.1016/0031-9384(95)02072-1
   Toth I, 2012, PSYCHOPHARMACOLOGY, V223, P149, DOI 10.1007/s00213-012-2702-4
   TRAVERS JB, 1986, BEHAV NEUROSCI, V100, P544, DOI 10.1037//0735-7044.100.4.544
   Tuerke KJ, 2012, J NEUROSCI, V32, P13709, DOI 10.1523/JNEUROSCI.2042-12.2012
   Tybur JM, 2013, PSYCHOL REV, V120, P65, DOI 10.1037/a0030778
   VERBALIS JG, 1986, BEHAV NEUROSCI, V100, P466, DOI 10.1037//0735-7044.100.4.466
   Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2
   Wirth MM, 2002, NEUROREPORT, V13, P1355, DOI 10.1097/00001756-200207190-00028
   YIRMIYA R, 1987, PHYSIOL BEHAV, V39, P489, DOI 10.1016/0031-9384(87)90378-7
   Zoicas L, 2014, NEUROPSYCHOPHARMACOL, V39, P3027, DOI 10.1038/npp.2014.156
NR 67
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD DEC
PY 2016
VL 27
IS 8
BP 718
EP 725
DI 10.1097/FBP.0000000000000271
PG 8
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA EB9KD
UT WOS:000387711900010
PM 27740965
ER

PT J
AU Maejima, Y
   Kumamoto, K
   Takenoshita, S
   Shimomura, K
AF Maejima, Yuko
   Kumamoto, Kensuke
   Takenoshita, Seiichi
   Shimomura, Kenju
TI Projections from a single NUCB2/nesfatin-1 neuron in the paraventricular
   nucleus to different brain regions involved in feeding
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Arcuate nucleus; Axon collateral; Dorsal vagal complex;
   NUCB2/nesfatin-1; Nucleus of the solitary tract; Hypothalamic
   paraventricular nucleus
ID MELANOCORTIN SYSTEM; SUPRAOPTIC NUCLEI; FOOD-INTAKE; NESFATIN-1;
   HYPOTHALAMUS; RAT; IMMUNOREACTIVITY; IDENTIFICATION; SUPPRESSION;
   OXYTOCIN
AB The anorexigenic neuropeptide NEFA/nucleobindin 2 (NUCB2)/nesfatin-1-containing neurons are distributed in the brain regions involved in feeding regulation, including the hypothalamic paraventricular nucleus (PVN). Functionally, NUCB2/nesfatin-1 neurons in the PVN regulate feeding through the hypothalamus and brain stem. However, the neural network of PVN NUCB2/nesfatin-1 neurons has yet to be elucidated. Axon collateral branches allow individual neurons to target multiple neurons. In some cases, each target neuron can be located in different nuclei. Here we show that a single neuron in the PVN projects axonal collaterals to both the dorsal vagal complex (DVC) and the arcuate nucleus (ARC), which are important brain regions for feeding regulation. In this study, after injection of different retrograde tracers into the DVC and ARC, both tracer-labeled neurons were detected in the identical PVN neuron, indicating the axon collateral projections from the single PVN neuron to the DVC and ARC. Furthermore, immunohistochemical analysis revealed that approximately 50 % of the neurons with axon collateral projections from the PVN to the DVC and ARC were found to be NUCB2/nesfatin-1 neurons. Our data suggest that a single NUCB2/nesfatin-1 neuron in the PVN projects to both the ARC and the DVC with axon collateral projection. Although the physiological significance remains to be elucidated, our data offer new perspectives on NUCB2/nesfatin-1 function at the neural network level and food intake regulation.
C1 [Maejima, Yuko; Shimomura, Kenju] Fukushima Med Univ, Dept Electrophysiol & Oncol, Sch Med, 1 Hikarigaoka, Fukushima 9601295, Japan.
   [Kumamoto, Kensuke; Takenoshita, Seiichi] Fukushima Med Univ, Dept Organ Regulatory Surg, Sch Med, Fukushima 9601295, Japan.
RP Maejima, Y (reprint author), Fukushima Med Univ, Dept Electrophysiol & Oncol, Sch Med, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM maejimay@fmu.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [24591341, 15K09395];
   Takeda Science Foundation
FX The authors would like to thank Prof. Kazuto Kobayashi and Dr. Nozomu
   Yoshioka (Fukushima Medical University) for their critical comments on
   this paper. The authors also would like to thank Mr. Yoshimasa Kiyomatsu
   and Mr. Shunsuke Onodera (Olympus Co.), Mr. Shiro Mizogami (KEYENCE Co.)
   for their technical support. This work was supported by Grant-in-Aid for
   Scientific Research (C) (24591341, 15K09395) from the Japan Society for
   the Promotion of Science (JSPS), Takeda Science Foundation to YM.
CR Browning KN, 2011, AUTON NEUROSCI-BASIC, V161, P6, DOI 10.1016/j.autneu.2010.11.001
   CONRAD LCA, 1976, J COMP NEUROL, V169, P221, DOI 10.1002/cne.901690206
   Conte WL, 2009, BRAIN STRUCT FUNCT, V213, P367, DOI 10.1007/s00429-009-0212-x
   Conte WL, 2009, NAT PROTOC, V4, P1157, DOI 10.1038/nprot.2009.93
   Fan W, 2004, NAT NEUROSCI, V7, P335, DOI 10.1038/nn1214
   Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054
   Gallo G, 2011, DEV NEUROBIOL, V71, P201, DOI 10.1002/dneu.20852
   Gonzalez R, 2009, BIOCHEM BIOPH RES CO, V381, P643, DOI 10.1016/j.bbrc.2009.02.104
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kohno D, 2008, ENDOCRINOLOGY, V149, P1295, DOI 10.1210/en.2007-1276
   Krashes MJ, 2014, NATURE, V507, P238, DOI 10.1038/nature12956
   Maejima Y, 2014, FEBS LETT, V588, P4404, DOI 10.1016/j.febslet.2014.10.010
   Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002
   Oh SW, 2014, NATURE, V508, P207, DOI 10.1038/nature13186
   Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162
   Oldfield BJ, 2007, EUR J NEUROSCI, V25, P2404, DOI 10.1111/j.1460-9568.2007.05429.x
   Ramanjaneya M, 2010, ENDOCRINOLOGY, V151, P3169, DOI 10.1210/en.2009-1358
   Schwartz MW, 2000, NATURE, V404, P661
   Sedbazar U, 2013, BIOCHEM BIOPH RES CO, V434, P434, DOI 10.1016/j.bbrc.2013.03.090
   Stengel A, 2013, OBES REV, V14, P859, DOI 10.1111/obr.12063
   Stengel A, 2009, ENDOCRINOLOGY, V150, P232, DOI 10.1210/en.2008-0747
   Vas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059809
   Yoshida N, 2010, AGING-US, V2, P775
   Yosten GLC, 2009, AM J PHYSIOL-REG I, V297, pR330, DOI 10.1152/ajpregu.90867.2008
NR 24
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD DEC
PY 2016
VL 221
IS 9
BP 4723
EP 4731
DI 10.1007/s00429-015-1150-4
PG 9
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA EB8QZ
UT WOS:000387657200027
PM 26639940
ER

PT J
AU Jardine, JE
   Law, P
   Hogg, M
   Murphy, D
   Khan, KS
AF Jardine, Jennifer E.
   Law, Penny
   Hogg, Matthew
   Murphy, Deirdre
   Khan, Khalid S.
CA C-SAFETY
TI Haemorrhage at caesarean section: a framework for prevention and
   research
SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
LA English
DT Review
DE blood transfusion; caesarean section; intrapartum care; major obstetric
   haemorrhage; postpartum haemorrhage
ID DOUBLE-BLIND; POSTPARTUM HEMORRHAGE; RANDOMIZED-TRIAL; TRANEXAMIC ACID;
   BLOOD-LOSS; OXYTOCIN; CARBETOCIN; WOMEN
AB Purpose of review
   Caesarean section rates are increasing across the world. Postpartum haemorrhage is a major cause of morbidity and mortality; major haemorrhage is more common after caesarean delivery. There is a wide range of practice in the prevention and treatment of postpartum haemorrhage at caesarean section. The aim of this review is to summarize current opinion in the management of postpartum haemorrhage at caesarean section.
   Recent findings
   Recent large randomized controlled trials have shown a possible effect from the routine use of tranexamic acid and ergometrine. Small randomized controlled trials have shown a possible benefit from using carbetocin.
   Summary
   The impact of postpartum haemorrhage can be reduced by antenatal correction of anaemia. Intraoperative medical management consists of oxytocinon, additional oxytocics+/- tranexamic acid, with at present limited evidence as to the order in which these should be considered. Trials of routine use of cell salvage and tranexamic acid are currently underway.
C1 [Jardine, Jennifer E.; Hogg, Matthew] Barts Hlth NHS Trust, Royal London Hosp, London, England.
   [Jardine, Jennifer E.] Queen Mary Univ London, Womens Hlth Res Unit, Barts & London Sch Med, London, England.
   [Law, Penny] Hillingdon Hosp, London, England.
   [Murphy, Deirdre] Univ Dublin, Dept Obstet & Gynaecol, Trinity Coll, Dublin, Ireland.
   [Khan, Khalid S.] UCL, London, England.
RP Jardine, JE (reprint author), Queen Mary Univ London, Obstet & Gynaecol, London, England.
EM j.e.jardine@qmul.ac.uk
FU Ferring Pharmaceuticals
FX Funding for the initial meeting and for writing, editorial and
   administrative support was provided by Ferring Pharmaceuticals. Although
   Ferring Pharmaceuticals had the opportunity to review and comment on the
   medical content and technical accuracy of the content, the
   recommendations were not influenced by the sponsor and the authors
   retained final editorial control.
CR Attilakos G, 2010, BJOG-INT J OBSTET GY, V117, P929, DOI 10.1111/j.1471-0528.2010.02585.x
   Betran AP, 2007, PAEDIATR PERINAT EP, V21, P98, DOI 10.1111/j.1365-3016.2007.00786.x
   Brocklehurst P, 2010, BJOG-INT J OBSTET GY, V117, P1366, DOI 10.1111/j.1471-0528.2010.02686.x
   Dansereau J, 1999, AM J OBSTET GYNECOL, V180, P670, DOI 10.1016/S0002-9378(99)70271-1
   DeAndrade D, 2016, TRANSFUSION
   Dhariwal SK, 2014, CURR OPIN OBSTET GYN, V26, P425, DOI 10.1097/GCO.0000000000000116
   Dilauro MD, 2012, CLIN RADIOL, V67, P515, DOI 10.1016/j.crad.2011.10.031
   Gallos ID, UTEROTONIC AGENTS PR
   International Federation of Gynaecologists and Obstetricians (FIGO), 2009, MOIST CONT DET, P1
   Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55
   McDonald SJ, 2013, EFFECT TIMING UMBILI
   National Institute for Care Excellence, 2011, COAL FIR POW PLANTS, P56
   National Institute for Care Excellence, 2008, ANT CAR UNC PREGN CL, P1
   Patel RR, 2005, INT J EPIDEMIOL, V34, P353, DOI 10.1093/ije/dyh401
   Razali N, 2016, EUR J OBSTET GYN R B, V198, P35, DOI 10.1016/j.ejogrb.2015.12.017
   Reveiz L, 2007, TREATMENTS IRON DEFI
   Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X
   [Anonymous], 2011, PREV MAN POSTP HAEM, P24
   Shakur H, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-40
   Sheehan SR, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4661
   Sheehan SR, 2010, EUR J OBSTET GYN R B, V148, P121, DOI 10.1016/j.ejogrb.2009.10.004
   Simonazzi G, 2016, ACTA OBSTET GYN SCAN, V95, P28, DOI 10.1111/aogs.12798
   Spector JM, 2013, INT J GYNECOL OBSTET, V122, P164, DOI 10.1016/j.ijgo.2013.03.022
   [Anonymous], 2011, GREEN TOP, P1
NR 24
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-872X
EI 1473-656X
J9 CURR OPIN OBSTET GYN
JI Curr. Opin. Obstet. Gynecol.
PD DEC
PY 2016
VL 28
IS 6
BP 492
EP 498
DI 10.1097/GCO.0000000000000328
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EC3DD
UT WOS:000388004100006
PM 27787286
ER

PT J
AU Kikusui, T
   Ishio, Y
   Nagasawa, M
   Mogil, JS
   Mogi, K
AF Kikusui, Takefumi
   Ishio, Yukino
   Nagasawa, Miho
   Mogil, Jeffrey S.
   Mogi, Kazutaka
TI Early weaning impairs a social contagion of pain-related stretching
   behavior in mice
SO DEVELOPMENTAL PSYCHOBIOLOGY
LA English
DT Article
DE early weaning; empathy; mice; pain contagion
ID MATERNAL-DEPRIVATION; BASOLATERAL AMYGDALA; TACTILE STIMULATION;
   EMPATHY; ANXIETY; STRESS; OXYTOCIN; MOUSE; RATS; SENSITIVITY
AB Pain sensitivity in mice can be modulated through exposure to familiar individuals. This phenomenon is considered a form of emotional contagion, thought to be an evolutionary precursor of empathy in mammals. In particular, mother-infant interactions early in life can considerably alter empathy development. Here, we demonstrated that pairs of mice that were simultaneously administered with a noxious stimulus (acetic acid) exhibited more pain-related behaviors than when one of the pair was treated with a noxious stimulus. However, these differences disappeared when mice were separated from the dam 1 week earlier than the typical weaning age. Even when mice were alone, when treated with acetic acid, early weaning decreased their pain response. These results suggested that the disruption of mother-infant bonding through early weaning impairs pain contagion and modulates sensitivity to pain.
C1 [Kikusui, Takefumi; Ishio, Yukino; Nagasawa, Miho; Mogi, Kazutaka] Azabu Univ, Dept Anim Sci & Biotechnol, Sagamihara, Kanagawa, Japan.
   [Nagasawa, Miho] Jichi Med Univ, Dept Physiol, Shimotsuke, Tochigi, Japan.
   [Mogil, Jeffrey S.] McGill Univ, Dept Psychol, Montreal, PQ, Canada.
RP Mogi, K (reprint author), Azabu Univ, Dept Anim Sci & Biotechnol, Chuoh Ku, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 2525201, Japan.
EM mogik@azabu-u.ac.jp
FU Japan Society for the Promotion of Science; Ministry of Education,
   Culture, Sports, Science, and Technology of Japan [26292167, 23248049,
   25118007]; Azabu University
FX This research was supported by Japan Society for the Promotion of
   Science, Ministry of Education, Culture, Sports, Science, and Technology
   of Japan (26292167), (23248049), and (25118007), Grant-in-Aid for
   Scientific Research on Innovative Areas (25118007), and Azabu
   University.
CR Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Branchi I, 2006, BIOL PSYCHIAT, V60, P690, DOI 10.1016/j.biopsych.2006.01.005
   Brechuhl J, 2013, P NATL ACAD SCI USA, V110, P4762, DOI 10.1073/pnas.1214249110
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hoffman L. M., 1991, HDB MORAL BEHAV DEV, P275
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Imanaka A, 2008, BEHAV BRAIN RES, V186, P91, DOI 10.1016/j.bbr.2007.07.039
   Inagaki Hideaki, 2008, Physiol Behav, V93, P606, DOI 10.1016/j.physbeh.2007.10.021
   Jeon D, 2010, NAT NEUROSCI, V13, P482, DOI 10.1038/nn.2504
   Kanari K, 2005, BEHAV BRAIN RES, V156, P45, DOI 10.1016/j.bbr.2004.05.008
   Kikusui T, 2004, PHYSIOL BEHAV, V81, P37, DOI 10.1016/j.physbeh.2003.12.016
   Kikusui T, 2009, J NEUROENDOCRINOL, V21, P427, DOI 10.1111/j.1365-2826.2009.01837.x
   Kikusui T, 2006, BEHAV BRAIN RES, V175, P96, DOI 10.1016/j.bbr.2006.08.007
   Kikusui T, 2006, PHILOS T R SOC B, V361, P2215, DOI 10.1098/rstb.2006.1941
   Kikusui T, 2009, PSYCHONEUROENDOCRINO, V34, P762, DOI 10.1016/j.psyneuen.2008.12.009
   Kiyokawa Y, 2004, BEHAV NEUROSCI, V118, P798, DOI 10.1037/0935-7044.118.4.798
   Langford DJ, 2014, PAIN, V155, P1183, DOI 10.1016/j.pain.2014.03.026
   Langford DJ, 2006, SCIENCE, V312, P1967, DOI 10.1126/science.1128322
   Martin LJ, 2015, CURR BIOL, V25, P326, DOI 10.1016/j.cub.2014.11.028
   Nakamura K, 2008, BEHAV BRAIN RES, V187, P442, DOI 10.1016/j.bbr.2007.10.002
   Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010
   Ono M, 2008, NEUROSCIENCE, V156, P1103, DOI 10.1016/j.neuroscience.2008.07.078
   Pollak SD, 2003, J ABNORM PSYCHOL, V112, P323, DOI 10.1037/0021-843X.112.3.323
   Pollak SD, 2000, DEV PSYCHOL, V36, P679, DOI 10.1037//0012-1649.36.5.679
   Preston SD, 2002, BEHAV BRAIN SCI, V25, P1
   Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535
   Stephan M, 2002, BEHAV BRAIN RES, V133, P149, DOI 10.1016/S0166-4328(01)00468-5
   STRAKER G, 1981, DEV PSYCHOL, V17, P762, DOI 10.1037//0012-1649.17.6.762
   Takita M, 2016, NEUROSCI RES, V103, P48, DOI 10.1016/j.neures.2015.08.003
   Terranova ML, 1998, J COMP PSYCHOL, V112, P3, DOI 10.1037/0735-7036.112.1.3
   Weaver SA, 2007, J PAIN, V8, P962, DOI 10.1016/j.jpain.2007.07.001
   Winslow JT, 2003, NEUROPSYCHOPHARMACOL, V28, P910, DOI 10.1038/sj.npp.1300128
NR 32
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1630
EI 1098-2302
J9 DEV PSYCHOBIOL
JI Dev. Psychobiol.
PD DEC
PY 2016
VL 58
IS 8
BP 1101
EP 1107
DI 10.1002/dev.21443
PG 7
WC Developmental Biology; Psychology
SC Developmental Biology; Psychology
GA EC1LU
UT WOS:000387867500016
PM 27364014
ER

PT J
AU Striepens, N
   Schroter, F
   Stoffel-Wagner, B
   Maier, W
   Hurlemann, R
   Scheele, D
AF Striepens, Nadine
   Schroeter, Franziska
   Stoffel-Wagner, Birgit
   Maier, Wolfgang
   Hurlemann, Rene
   Scheele, Dirk
TI Oxytocin enhances cognitive control of food craving in women
SO HUMAN BRAIN MAPPING
LA English
DT Article
DE craving; emotion regulation; food; functional magnetic resonance
   imaging; oxytocin; women
ID BINGE-EATING DISORDER; HUMAN BRAIN; PARAVENTRICULAR NUCLEUS; APPROACH
   BEHAVIOR; DEFICIENT MICE; WEIGHT-LOSS; OBESITY; REWARD; RESPONSES;
   ACTIVATION
AB In developed countries, obesity has become an epidemic resulting in enormous health care costs for society and serious medical complications for individuals. The homeostatic regulation of food intake is critically dependent on top-down control of reward-driven food craving. There is accumulating evidence from animal studies that the neuropeptide oxytocin (OXT) is involved in regulating hunger states and eating behavior, but whether OXT also contributes to cognitive control of food craving in humans is still unclear. We conducted a counter-balanced, double-blind, within-subject, pharmacological magnetic resonance imaging experiment involving 31 healthy women who received 24 IU of intranasal OXT or placebo and were scanned twice while they were exposed to pictures of palatable food. The participants were instructed either to imagine the immediate consumption or to cognitively control the urge to eat the food. Our results show a trend that OXT specifically reduced food craving in the cognitive control condition. On the neural level, these findings were paralleled by an increase of activity in the middle and superior frontal gyrus, precuneus, and cingulate cortex under OXT. Interestingly, the behavioral OXT effect correlated with the OXT-induced changes in the prefrontal cortex and precuneus. Collectively, the present study provides first evidence that OXT plays a key role in the cognitive regulation of food craving in women by strengthening activity in a broad neurocircuitry implicated in top-down control and self-referential processing. Hum Brain Mapp 37:4276-4285, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Striepens, Nadine; Schroeter, Franziska; Maier, Wolfgang; Hurlemann, Rene; Scheele, Dirk] Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany.
   [Striepens, Nadine; Schroeter, Franziska; Hurlemann, Rene; Scheele, Dirk] Univ Bonn, Div Med Psychol, D-53105 Bonn, Germany.
   [Stoffel-Wagner, Birgit] Univ Bonn, Dept Clin Chem & Clin Pharmacol, D-53105 Bonn, Germany.
   [Maier, Wolfgang] German Ctr Neurodegenerat Dis DZNE, D-53175 Bonn, Germany.
RP Scheele, D (reprint author), Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany.; Scheele, D (reprint author), Univ Bonn, Div Med Psychol, D-53105 Bonn, Germany.
EM Dirk-Scheele@gmx.de
FU German Research Foundation (Deutsche Forschungsgemeinschaft [DFG])
   [HU1202/4-1, BE 5465/2-1]
FX Contract grant sponsor: German Research Foundation (Deutsche
   Forschungsgemeinschaft [DFG]); Contract grant numbers: HU1202/4-1 and BE
   5465/2-1 (to R.H. and D.S.).
CR ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   Atasoy D, 2012, NATURE, V488, P172, DOI 10.1038/nature11270
   Barness LA, 2007, AM J MED GENET A, V143A, P3016, DOI 10.1002/ajmg.a.32035
   Blevins JE, 2004, AM J PHYSIOL-REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Brody AL, 2007, BIOL PSYCHIAT, V62, P642, DOI 10.1016/j.biopsych.2006.10.026
   Camerino C, 2009, OBESITY, V17, P980, DOI 10.1038/oby.2009.12
   Caspers S, 2010, NEUROIMAGE, V50, P1148, DOI 10.1016/j.neuroimage.2009.12.112
   Childress AR, 1999, AM J PSYCHIAT, V156, P11
   Cohen DA, 2008, DIABETES, V57, P1768, DOI 10.2337/db08-0163
   De Coster L, 2014, PSYCHONEUROENDOCRINO, V50, P220, DOI 10.1016/j.psyneuen.2014.08.021
   Delahanty L, 2002, DIABETES CARE, V25, P1992, DOI 10.2337/diacare.25.11.1992
   Dinkel A, 2005, DIAGNOSTICA, V51, P67, DOI 10.1026/0012-1924.51.2.67
   Eckstein M, 2016, NEUROPSYCHOPHARMACOL, V41, P932, DOI 10.1038/npp.2015.245
   Eckstein M, 2015, BIOL PSYCHIAT, V78, P194, DOI 10.1016/j.biopsych.2014.10.015
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Goldman RL, 2013, OBESITY, V21, P2189, DOI 10.1002/oby.20575
   Gould BR, 2003, NEUROSCIENCE, V122, P155, DOI 10.1016/S0306-4522(03)00283-5
   Hartwell KJ, 2011, ADDICT BIOL, V16, P654, DOI 10.1111/j.1369-1600.2011.00340.x
   Hollmann M, 2012, INT J OBESITY, V36, P648, DOI 10.1038/ijo.2011.125
   Hurlemann R, 2016, BIOL PSYCHIAT, V79, P185, DOI 10.1016/j.biopsych.2015.05.013
   Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024
   Karch S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133034
   Kekic M, 2014, APPETITE, V78, P55, DOI 10.1016/j.appet.2014.03.010
   Kenny PJ, 2011, NEURON, V69, P664, DOI 10.1016/j.neuron.2011.02.016
   Kessler RC, 2013, BIOL PSYCHIAT, V73, P904, DOI 10.1016/j.biopsych.2012.11.020
   Kober H, 2010, P NATL ACAD SCI USA, V107, P14811, DOI 10.1073/pnas.1007779107
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Leehr EJ, 2015, NEUROSCI BIOBEHAV R, V49, P125, DOI 10.1016/j.neubiorev.2014.12.008
   Maas LC, 1998, AM J PSYCHIAT, V155, P124
   Maejima Y, 2011, AGING-US, V3, P1169
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Mitchell JM, 2016, J ADDICT MED, V10, P182, DOI 10.1097/ADM.0000000000000213
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Pelchat ML, 2004, NEUROIMAGE, V23, P1486, DOI 10.1016/j.neuroimage.2004.08.023
   Perry A, 2010, PSYCHONEUROENDOCRINO, V35, P1446, DOI 10.1016/j.psyneuen.2010.04.011
   Potenza Marc N, 2014, Front Psychiatry, V5, P164, DOI 10.3389/fpsyt.2014.00164
   Poulton AS, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00014
   Preckel K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00191
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   Sabatier Nancy, 2013, Front Endocrinol (Lausanne), V4, P35, DOI 10.3389/fendo.2013.00035
   Scheele D, 2016, SOC COGN AFFECT NEUR, V11, P767, DOI 10.1093/scan/nsv157
   Scheele D, 2015, EUR NEUROPSYCHOPHARM, V25, P1817, DOI 10.1016/j.euroneuro.2015.05.009
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720
   Small DM, 2002, NEURON, V33, P668, DOI 10.1016/S0896-6273(02)00620-7
   Suplicy H, 2014, INT J OBESITY, V38, P1097, DOI 10.1038/ijo.2013.225
   SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jc.80.2.573
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Uher R, 2005, BIOL PSYCHIAT, V58, P840, DOI 10.1016/j.biopsych.2005.05.043
   Volkow ND, 2013, BIOL PSYCHIAT, V73, P811, DOI 10.1016/j.biopsych.2012.12.020
   von Deneen KM, 2011, MATURITAS, V68, P342, DOI 10.1016/j.maturitas.2011.01.018
   Webber L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004787
   WEINGARTEN HP, 1991, APPETITE, V17, P167, DOI 10.1016/0195-6663(91)90019-O
   WEINGARTEN HP, 1990, APPETITE, V15, P231, DOI 10.1016/0195-6663(90)90023-2
   WILLIAMS TDM, 1986, J ENDOCRINOL, V108, P163, DOI 10.1677/joe.0.1080163
   Woolley JD, 2016, PSYCHOPHARMACOLOGY B
   Wu ZF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045167
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
NR 67
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
EI 1097-0193
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD DEC
PY 2016
VL 37
IS 12
BP 4276
EP 4285
DI 10.1002/hbm.23308
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA EB5FL
UT WOS:000387399200005
PM 27381253
ER

PT J
AU Monasterio, E
   Mei-Dan, O
   Hackney, AC
   Lane, AR
   Zwir, I
   Rozsa, S
   Cloninger, CR
AF Monasterio, Erik
   Mei-Dan, Omer
   Hackney, Anthony C.
   Lane, Amy R.
   Zwir, Igor
   Rozsa, Sandor
   Cloninger, C. Robert
TI Stress reactivity and personality in extreme sport athletes: The
   psychobiology of BASE jumpers
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Extreme sports; BASE jumping; Resilience; Stress reactivity;
   Temperament; Character
ID PITUITARY-ADRENAL SYSTEM; AIR-TRAFFIC CONTROLLERS; SALIVARY
   ALPHA-AMYLASE; CORTISOL REACTIVITY; PLASMA OXYTOCIN; HARM AVOIDANCE;
   TEMPERAMENT; RESPONSES; NEUROTICISM; CHARACTER
AB This is the first report of the psychobiology of stress in BASE jumpers, one of the most dangerous forms of extreme sport. We tested the hypotheses that indicators of emotional style (temperament) predict salivary cortisol reactivity, whereas indicators of intentional goal-setting (persistence and character) predict salivary alpha-amylase reactivity during BASE jumping. Ninety-eight subjects completed the Temperament and Character Inventory (TCI) the day before the jump, and 77 also gave salivary samples at baseline, pre-jump on the bridge over the New River Gorge, and post jump upon landing. Overall BASE jumpers are highly resilient individuals who are highly self-directed, persistent, and risk-taldng, but they are heterogeneous in their motives and stress reactivity in the Hypothalamic-Pituitary-Adrenal (HPA) stress system (cortisol reactivity) and the sympathetic arousal system (alpha-amylase reactivity). Three classes of jumpers were identified using latent class analysis based on their personality profiles, prior jumping experience, and levels of cortisol and alpha-amylase at all three time points. "Masterful" jumpers (class 1) had a strong sense of self-directedness and mastery, extensive prior experience, and had little alpha-amylase reactivity and average cortisol reactivity. "Trustful' jumpers (class 2) were highly cooperative and trustful individuals who had little cortisol reactivity coincident with the social support they experienced prior to jumping. "Courageous" jumpers (class 3) were determined despite anxiety and inexperience, and they had high sympathetic reactivity but average cortisol activation. We conclude that trusting social attachment (Reward Dependence) and not jumping experience predicted low cortisol reactivity, whereas persistence (determination) and not jumping experience predicted high alpha-amylase reactivity. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
C1 [Monasterio, Erik] Univ Otago, Hillmorton Hosp, Christchurch 4733, New Zealand.
   [Mei-Dan, Omer] Univ Colorado, Dept Orthoped, CU Sports Med & Performance Ctr, Boulder, CO 80309 USA.
   [Hackney, Anthony C.; Lane, Amy R.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA.
   [Zwir, Igor; Rozsa, Sandor; Cloninger, C. Robert] Washington Univ, Sch Med, Dept Psychiat, Campus Box 8134,660 South Euclid Ave, St Louis, MO 63110 USA.
RP Cloninger, CR (reprint author), Washington Univ, Sch Med, Dept Psychiat, Campus Box 8134,660 South Euclid Ave, St Louis, MO 63110 USA.
EM Erik.Monasterio@cdhb.health.edu; omer.meidan@ucdenver.edu;
   ach@email.unc.edu; crcloninger44@gmail.com
CR Ali N, 2012, PHYSIOL BEHAV, V106, P65, DOI 10.1016/j.physbeh.2011.10.003
   Bell CJ, 2006, J PSYCHOPHARMACOL, V20, P656, DOI 10.1177/0269881106060512
   Campanella F, 2014, COMPR PSYCHIAT, V55, P1269, DOI 10.1016/j.comppsych.2014.03.009
   Cloninger C, 1994, TEMPERAMENT CHARACTE
   Cloninger C Robert, 2011, Int J Pers Cent Med, V1, P43
   Cloninger CR, 2012, J AFFECT DISORDERS, V136, P758, DOI 10.1016/j.jad.2011.09.046
   Cloninger CR, 2011, J AFFECT DISORDERS, V128, P24, DOI 10.1016/j.jad.2010.06.012
   CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573
   CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975
   DABBS JM, 1991, PHYSIOL BEHAV, V49, P815, DOI 10.1016/0031-9384(91)90323-G
   Deinzer R, 1997, PHYSIOL BEHAV, V61, P507
   Deuschle M, 1997, LIFE SCI, V61, P2239, DOI 10.1016/S0024-3205(97)00926-0
   Deuschle M, 1997, J CLIN ENDOCR METAB, V82, P234, DOI 10.1210/jc.82.1.234
   Dorn LD, 2007, ANN CLIN BIOCHEM, V44, P281, DOI 10.1258/000456307780480954
   Francis B., 2004, USING HOMICIDE DATA
   Gillespie NA, 2003, PERS INDIV DIFFER, V35, P1931, DOI 10.1016/S0191-8869(03)00042-4
   Grucza RA, 2007, J PERS ASSESS, V89, P167
   Gusnard DA, 2003, P NATL ACAD SCI USA, V100, P3479, DOI 10.1073/pnas.0538050100
   Hackney AC, 2008, J ATHL TRAINING, V43, P631, DOI 10.4085/1062-6050-43.6.631
   Haimerl CJ, 2001, J TRANSPERS PSYCHOL, V33, P37
   Hare OA, 2013, PHYSIOL BEHAV, V118, P40, DOI 10.1016/j.physbeh.2013.05.011
   Hayes AF, 2013, PSYCHOL SCI, V24, P1918, DOI 10.1177/0956797613480187
   Kline R. B., 2005, PRINCIPLES PRACTICE
   LEE DJ, 1989, J PSYCHOSOM RES, V33, P177, DOI 10.1016/0022-3999(89)90045-7
   McCleery JM, 2001, BIOL PSYCHIAT, V49, P410, DOI 10.1016/S0006-3223(00)01056-8
   McCraty R, 2003, J ALTERN COMPLEM MED, V9, P355, DOI 10.1089/107555303765551589
   Mei-Dan O, 2012, CLIN J SPORT MED, V22, P262, DOI 10.1097/JSM.0b013e31824bd53a
   Monasterio E., 2013, ADVENTURE EXTREME SP, P303
   Monasterio E, 2014, WILD ENVIRON MED, V25, P214, DOI 10.1016/j.wem.2013.12.028
   Monasterio E, 2012, J APPL SPORT PSYCHOL, V24, P391, DOI 10.1080/10413200.2012.666710
   Monasterio Erik, 2008, N Z Med J, V121, P70
   Nater UM, 2007, PSYCHONEUROENDOCRINO, V32, P392, DOI 10.1016/j.psyneuen.2007.02.007
   Nater UM, 2013, PSYCHONEUROENDOCRINO, V38, P3167, DOI 10.1016/j.psyneuen.2013.09.008
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535
   Oswald LM, 2006, NEUROPSYCHOPHARMACOL, V31, P1583, DOI 10.1038/sj.npp.1301012
   Paulus MP, 2003, NEUROIMAGE, V19, P1439, DOI 10.1016/S1053-8119(03)00251-9
   Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463
   Phillips AC, 2005, PSYCHOPHYSIOLOGY, V42, P232, DOI 10.1111/j.1469-8986.2005.00281.x
   Polk DE, 2005, PSYCHONEUROENDOCRINO, V30, P261, DOI 10.1016/j.psyneuen.2004.08.004
   Raff H, 2013, ENDOCR CONNECT, V2, P24, DOI 10.1530/EC-12-0058
   Rogers RD, 1999, J NEUROSCI, V19, P9029
   ROSE RM, 1982, PSYCHONEUROENDOCRINO, V7, P113, DOI 10.1016/0306-4530(82)90003-8
   Soreide K, 2007, J TRAUMA, V62, P1113, DOI 10.1097/01.ta.0000239815.73858.88
   Tops M, 2007, PSYCHOPHYSIOLOGY, V44, P444, DOI 10.1111/j.1469-8986.2007.00510.x
   Tops M, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00021
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Tyrka AR, 2007, ACTA PSYCHIAT SCAND, V115, P395, DOI 10.1111/j.1600-0447.2006.00941.x
   Tyrka AR, 2008, HORM BEHAV, V53, P518, DOI 10.1016/j.yhbeh.2007.12.004
   Uebersax J., 2009, LATENT STRUCTURE ANA
   Van Schuerbeek P, 2014, BEHAV BRAIN FUNCT, V10, DOI 10.1186/1744-9081-10-18
   Van Schuerbeek P, 2011, BRAIN RES, V1371, P32, DOI 10.1016/j.brainres.2010.11.073
   Wolf JM, 2008, BIOL PSYCHOL, V78, P20, DOI 10.1016/j.biopsycho.2007.12.004
   Wolfe T., 1979, RIGHT STUFF FARRAR S
   Wust S., 2000, NOISE HEALTH, V2, P79
   McCraty R., 2013, OPEN J SOC SCI, V1, P32, DOI [10.4236/jss.2013.16007, DOI 10.4236/JSS.2013.16007]
NR 55
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD DEC 1
PY 2016
VL 167
BP 289
EP 297
DI 10.1016/j.physbeh.2016.09.025
PG 9
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA EC3SX
UT WOS:000388047700033
PM 27693575
ER

PT J
AU Mickey, B
   Heffernan, J
   Heisel, C
   Pecina, M
   Hsu, DT
   Zubieta, JK
   Love, TM
AF Mickey, Brian J.
   Heffernan, Joseph
   Heisel, Curtis
   Pecina, Marta
   Hsu, David T.
   Zubieta, Jon-Kar
   Love, Tiffany M.
TI Oxytocin modulates hemodynamic responses to monetary incentives in
   humans
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Oxytocin; Reward; FMRI
ID VENTRAL TEGMENTAL AREA; INCREASES EXTRACELLULAR DOPAMINE; EVENT-RELATED
   FMRI; NUCLEUS-ACCUMBENS; INTRANASAL OXYTOCIN; HUMAN BRAIN; REWARD
   ANTICIPATION; PENILE ERECTION; SEX-DIFFERENCES; MALE RATS
AB Oxytocin is a neuropeptide widely recognized for its role in regulating social and reproductive behavior. Increasing evidence from animal models suggests that oxytocin also modulates reward circuitry in non-social contexts, but evidence in humans is lacking.
   We examined the effects of oxytocin administration on reward circuit function in 18 healthy men as they performed a monetary incentive task.
   The blood oxygenation level-dependent (BOLD) signal was measured using functional magnetic resonance imaging in the context of a randomized, double-blind, placebo-controlled, crossover trial of intranasal oxytocin.
   We found that oxytocin increases the BOLD signal in the midbrain (substantia nigra and ventral tegmental area) during the late phase of the hemodynamic response to incentive stimuli. Oxytocin's effects on midbrain responses correlated positively with its effects on positive emotional state. We did not detect an effect of oxytocin on responses in the nucleus accumbens. Whole-brain analyses revealed that oxytocin attenuated medial prefrontal cortical deactivation specifically during anticipation of loss.
   Our findings demonstrate that intranasal administration of oxytocin modulates human midbrain and medial prefrontal function during motivated behavior. These findings suggest that endogenous oxytocin is a neurochemical mediator of reward behaviors in humans-even in a non-social context-and that the oxytocinergic system is a potential target of pharmacotherapy for psychiatric disorders that involve dysfunction of reward circuitry.
C1 [Mickey, Brian J.; Pecina, Marta; Hsu, David T.; Zubieta, Jon-Kar; Love, Tiffany M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA.
   [Mickey, Brian J.; Heffernan, Joseph; Heisel, Curtis; Pecina, Marta; Hsu, David T.; Zubieta, Jon-Kar; Love, Tiffany M.] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.
   [Mickey, Brian J.; Zubieta, Jon-Kar; Love, Tiffany M.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA.
   [Hsu, David T.] Stony Brook Sch Med, Dept Psychiat, Stony Brook, NY USA.
RP Love, TM (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA.; Love, TM (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.; Love, TM (reprint author), Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA.
EM tiffany.love@hsc.utah.edu
FU National Center for Advancing Translational Sciences [UL1 RR 024986, UL1
   TR 000433]; NIMH [K23 MH 092648]
FX This research was supported by the National Center for Research
   Resources (UL1 RR 024986), now the National Center for Advancing
   Translational Sciences (UL1 TR 000433). BJM was supported by the NIMH
   (K23 MH 092648). The authors thank Thomas Chenevert, PhD, for his help
   and advice in scanning; technologists Suzan Lowe BA, RT(R)(MR), and Sara
   Easler BA, RT(R)(MR), for their assistance in collecting imaging data;
   and Amy Skyles, PharmD, and Mona Moore, MS, RAC, at the Michigan
   Institute for Clinical and Health Research for providing regulatory
   support and guidance.
CR ADAN RAH, 1995, ENDOCRINOLOGY, V136, P4022, DOI 10.1210/en.136.9.4022
   Bartz JA, 2011, TRENDS COGN SCI
   Becker JB, 2008, SEX DIFFERENCES BRAI, P177
   Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042
   Bjork JM, 2004, J NEUROSCI, V24, P1793, DOI 10.1523/JNEUROSCI.4862-03.2004
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Carter RM, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.021.2009
   Cooper JC, 2008, NEUROIMAGE, V39, P538, DOI 10.1016/j.neuroimage.2007.08.009
   Costa P. T., 1992, PSYCHOL ASSESSMENT, V4, P5, DOI [10.1037/1040-3590.4.1.5, DOI 10.1037/1040-3590.4.1.5]
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Di Simplicio M, 2009, J PSYCHOPHARMACOL, V23, P241, DOI 10.1177/0269881108095705
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Domes G, 2013, PSYCHOL MED, V43, P1747, DOI 10.1017/S0033291712002565
   Domes G, 2013, PSYCHONEUROENDOCRINO, V38, P1198, DOI 10.1016/j.psyneuen.2012.10.002
   Dumais KM, 2013, HORM BEHAV, V64, P693, DOI 10.1016/j.yhbeh.2013.08.012
   Eapen M, 2011, AM J NEURORADIOL, V32, P688, DOI 10.3174/ajnr.A2355
   Ellenbogen MA, 2012, PSYCHOPHYSIOLOGY, V49, P128, DOI 10.1111/j.1469-8986.2011.01278.x
   Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306
   Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209
   Gamer M, 2012, PSYCHONEUROENDOCRINO, V37, P87, DOI 10.1016/j.psyneuen.2011.05.007
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Gordon I, 2011, DEV COGN NEUROS-NETH, V1, P471, DOI 10.1016/j.dcn.2011.07.007
   Gregory R, 2015, HORM BEHAV, V69, P82, DOI 10.1016/j.yhbeh.2014.12.009
   Groppe SE, 2013, BIOL PSYCHIAT, V74, P172, DOI 10.1016/j.biopsych.2012.12.023
   Helfinstein SM, 2013, SOC COGN AFFECT NEUR, V8, P720, DOI 10.1093/scan/nss057
   Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547
   Kim YR, 2014, PSYCHIAT INVEST, V11, P160, DOI 10.4306/pi.2014.11.2.160
   Kis A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00532
   Knutson B, 2001, J Neurosci, V21, pRC159
   Knutson B, 2004, NEURON, V43, P261, DOI 10.1016/j.neuron.2004.06.030
   Knutson B, 2005, CURR OPIN NEUROL, V18, P411, DOI 10.1097/01.wco.0000173463.24758.f6
   Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016
   Krebs RM, 2011, NEUROIMAGE, V58, P647, DOI 10.1016/j.neuroimage.2011.06.038
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   Leng G, 2015, BIOL PSYCHIAT
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Love TM, 2014, PHARMACOL BIOCHEM BE, V119, P49, DOI 10.1016/j.pbb.2013.06.011
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Melis MR, 2009, EUR J NEUROSCI, V30, P1349, DOI 10.1111/j.1460-9568.2009.06912.x
   Mullinger KJ, 2014, NEUROIMAGE, V94, P263, DOI 10.1016/j.neuroimage.2014.02.029
   Nakajima M, 2014, CELL, V159, P295, DOI 10.1016/j.cell.2014.09.020
   Nawijn L, 2016, PSYCHONEUROENDOCRINO, V66, P228, DOI 10.1016/j.psyneuen.2016.01.020
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Qi J, 2007, ARCH PHARM, V376, P441
   Quintana DS, 2016, MOL PSYCHIATR, V21, P29, DOI 10.1038/mp.2015.166
   Riem MME, 2012, NEUROPSYCHOPHARMACOL, V37, P1257, DOI 10.1038/npp.2011.313
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009
   Samanez-Larkin GR, 2007, NAT NEUROSCI, V10, P787, DOI 10.1038/nn1894
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Schott BH, 2008, J NEUROSCI, V28, P14311, DOI 10.1523/JNEUROSCI.2058-08.2008
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Tang YM, 2014, NEUROPHARMACOLOGY, V77, P277, DOI 10.1016/j.neuropharm.2013.10.004
   Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181
   Watson D., 1994, PANAS X MANUAL POSIT
   Wittfoth-Schardt D, 2012, NEUROPSYCHOPHARMACOL, V37, P1799, DOI 10.1038/npp.2012.47
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
NR 65
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD DEC
PY 2016
VL 233
IS 23-24
BP 3905
EP 3919
DI 10.1007/s00213-016-4423-6
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA EB8RW
UT WOS:000387659500008
PM 27614896
ER

PT J
AU Koda, N
   Watanabe, G
   Miyaji, Y
   Kuniyoshi, M
   Miyaji, C
   Hirata, T
AF Koda, Naoko
   Watanabe, Gen
   Miyaji, Yoshio
   Kuniyoshi, Miyako
   Miyaji, Chiemi
   Hirata, Terufumi
TI Effects of a Dog-Assisted Intervention Assessed by Salivary Cortisol
   Concentrations in Inmates of a Japanese Prison
SO ASIAN JOURNAL OF CRIMINOLOGY
LA English
DT Article
DE Dog-assisted intervention; Mood; Prison inmates; Salivary cortisol;
   Stress management
ID BEHAVIORAL STRESS-MANAGEMENT; SOCIAL SUPPORT; HEALTHY-SUBJECTS; THERAPY;
   RESPONSES; CHILDREN; DEPRESSION; DISORDERS; OXYTOCIN; PROGRAM
AB Physiological effects of a dog-assisted, stress management and communication training program conducted in a prison were investigated by assessing salivary cortisol concentrations of prison inmates before and after the sessions. The program was conducted with groups of inmates with psychiatric and/or developmental disorders. In the program, male inmates interacted with trained pet dogs and their volunteer handlers. Inmates evaluated their mood states before and after each session by using a questionnaire. Moreover, handlers evaluated the quality of the interaction with inmates after each session. Results indicated that the inmates' cortisol values in most cases decreased following their participation in the sessions. The inmates who demonstrated stress reduction by decreasing cortisol values were diagnosed only psychiatric disorders, were aware of their mood improvement, and were evaluated by the handlers as having interacted well during the sessions. This indicated the validity of psychiatrists' diagnoses, inmates' self-evaluation, and handlers' evaluation of inmates. Also, inmates who experienced a medium mood without mood changes had decreased cortisol values. It is suggested that these results are useful for predicting and selecting inmates who are expected to obtain effects by participating in the program. Moreover, it is suggested that providing feedback to inmates about changes in their salivary cortisol levels could help them better understand their psychophysical state, which could result in more effective stress management.
C1 [Koda, Naoko; Watanabe, Gen] Tokyo Univ Agr & Technol, Sch Agr, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.
   [Miyaji, Yoshio; Miyaji, Chiemi] Japan Anim Assisted Therapy Council, 441-10 Shimokusadani, Inami, Hyogo 6751101, Japan.
   [Kuniyoshi, Miyako; Hirata, Terufumi] Harima Rehabil Program Ctr, 544 Sosa, Kakogawa, Hyogo 6751201, Japan.
RP Koda, N (reprint author), Tokyo Univ Agr & Technol, Sch Agr, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.
EM koda@cc.tuat.ac.jp
CR Endenburg N., 1995, WALTHAM BOOK HUMAN A, P7
   Fine A. H., 2006, HDB ANIMAL ASSISTED
   FOLSE EB, 1994, ANTHROZOOS, V7, P188
   Fournier A. K., 2007, BEHAV SOCIAL ISSUES, V16, P89
   Fredrickson M., 1995, WALTHAM BOOK HUMAN A, P60
   Friedmann E., 1995, WALTHAM BOOK HUMAN A, P33
   Fryers T, 1998, BRIT MED J, V317, P1025
   Furst G., 2011, ANIMAL PROGRAMS PRIS
   Gaab J, 2003, PSYCHONEUROENDOCRINO, V28, P767, DOI 10.1016/S0306-4530(02)00069-0
   Hammerfald K, 2006, PSYCHONEUROENDOCRINO, V31, P333, DOI 10.1016/j.psyneuen.2005.08.007
   Handlin L, 2012, ANTHROZOOS, V25, P215, DOI 10.2752/175303712X13316289505468
   Harkrader T., 2004, CORRECTIONS TODAY, V66, P74
   Hart L. A., 1995, WALTHAM BOOK HUMAN A, P19
   Heaney JLJ, 2010, INT J PSYCHOPHYSIOL, V78, P201, DOI 10.1016/j.ijpsycho.2010.07.009
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hoffmann AOM, 2009, EUR J INTEGR MED, V1, P145, DOI 10.1016/j.eujim.2009.08.002
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   Hucklebridge F, 2005, PSYCHONEUROENDOCRINO, V30, P51, DOI 10.1016/j.psyneuen.2004.04.007
   Inatani F., 2006, STRESS MANAGEMENT RE, V3, P3
   Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045
   Kim E., 2009, JAPANESE J HLTH PROM, V11, P25
   KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004
   Koda N, 2015, ANIM WELFARE, V24, P203, DOI 10.7120/09627286.24.2.203
   Koda N, 2015, ASIAN J CRIMINOL, V10, P193, DOI 10.1007/s11417-015-9204-3
   Kovacs Z, 2006, ANTHROZOOS, V19, P353, DOI 10.2752/089279306785415475
   Lang UE, 2010, EUR J INTEGR MED, V2, P123, DOI 10.1016/j.eujim.2010.07.002
   Leskela U, 2006, PSYCHOL MED, V36, P779, DOI 10.1017/S0033291706007276
   Martin F, 2002, WESTERN J NURS RES, V24, P657, DOI 10.1177/019394502236639
   McCraty R, 1998, INTEGR PHYS BEH SCI, V33, P151, DOI 10.1007/BF02688660
   McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006
   Ministry of Justice, 2012, WHIT PAP CRIM 2012
   Moneymaker JM, 1991, J OFFENDER REHABILIT, V16, P133, DOI 10.1300/J076v16n03_09
   Moroto K., 2008, KYOSEI KYOIKU KENKYU, V53, P50
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Prothmann A, 2009, ANTHROZOOS, V22, P161, DOI 10.2752/175303709X434185
   REDEFER LA, 1989, J AUTISM DEV DISORD, V19, P461, DOI 10.1007/BF02212943
   Saxena S, 2006, WORLD PSYCHIATRY, V5, P179
   Taya K, 1985, ANIM REPROD, V31, P186, DOI [10.1262/jrd1977.31.186, DOI 10.1262/JRD1977.31.186]
   VINING RF, 1983, ANN CLIN BIOCHEM, V20, P329
   VORMBROCK JK, 1988, J BEHAV MED, V11, P509, DOI 10.1007/BF00844843
   Wesley MC, 2009, ANTHROZOOS, V22, P137, DOI 10.2752/175303709X434167
   [Anonymous], 1991, THE JOURNAL OF NERVO
NR 42
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1871-0131
EI 1871-014X
J9 ASIAN J CRIMINOL
JI Asian J. Criminol.
PD DEC
PY 2016
VL 11
IS 4
BP 309
EP 319
DI 10.1007/s11417-016-9232-7
PG 11
WC Criminology & Penology
SC Criminology & Penology
GA EB2YS
UT WOS:000387229100004
ER

PT J
AU Sui, QQ
   Zhu, J
   Li, XN
   Knight, GE
   He, C
   Burnstock, G
   Yuan, HB
   Xiang, ZH
AF Sui, Qian-qian
   Zhu, Jiao
   Li, Xiangnan
   Knight, Gillian E.
   He, Cheng
   Burnstock, Geoffrey
   Yuan, Hongbin
   Xiang, Zhenghua
TI A modified protocol for the detection of three different mRNAs with a
   new-generation in situ hybridization chain reaction on frozen sections
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE Multiple fluorescence in situ hybridization; Hybridization chain
   reaction; Brain section
ID FLUORESCENCE INSITU HYBRIDIZATION; EMBRYONIC ZEBRAFISH BRAIN;
   CHROMOSOME-ABERRATIONS; GENE-EXPRESSION; DNA; MULTIPLE; AMPLIFICATION;
   SEQUENCES; PLATFORM; LABEL
AB A new multiple fluorescence in situ hybridization method based on hybridization chain reaction was recently reported, enabling simultaneous mapping of multiple target mRNAs within intact zebrafish and mouse embryos. With this approach, DNA probes complementary to target mRNAs trigger chain reactions in which metastable fluorophore-labeled DNA hairpins self-assemble into fluorescent amplification polymers. The formation of the specific polymers enhances greatly the sensitivity of multiple fluorescence in situ hybridization. In this study we describe the optimal parameters (hybridization chain reaction time and temperature, hairpin and salt concentration) for multiple fluorescence in situ hybridization via amplification of hybridization chain reaction for frozen tissue sections. The combined use of fluorescence in situ hybridization and immunofluorescence, together with other control experiments (sense probe, neutralization and competition, RNase treatment, and anti-sense probe without initiator) confirmed the high specificity of the fluorescence in situ hybridization used in this study. Two sets of three different mRNAs for oxytocin, vasopressin and somatostatin or oxytocin, vasopressin and thyrotropin releasing hormone were successfully visualized via this new method. We believe that this modified protocol for multiple fluorescence in situ hybridization via hybridization chain reaction would allow researchers to visualize multiple target nucleic acids in the future.
C1 [Sui, Qian-qian; Zhu, Jiao; He, Cheng; Xiang, Zhenghua] Second Mil Med Univ, Dept Neurobiol, Key Lab Mol Neurobiol, Minist Educ, Shanghai 200433, Peoples R China.
   [Li, Xiangnan; Yuan, Hongbin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China.
   [Li, Xiangnan] Third Peoples Hosp Yancheng, Dept Anesthesiol, Yancheng 224001, Peoples R China.
   [Knight, Gillian E.; Burnstock, Geoffrey] UCL, Auton Neurosci Ctr, Sch Med, Rowland Hill St, London NW3 2PF, England.
   [Burnstock, Geoffrey] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia.
RP Xiang, ZH (reprint author), Second Mil Med Univ, Dept Neurobiol, Key Lab Mol Neurobiol, Minist Educ, Shanghai 200433, Peoples R China.
EM jfjczyy@aliyun.com; zhxiang@hotmail.com
FU National Natural Science Foundation of the People's Republic of China
   [81471260]
FX This work was supported by the National Natural Science Foundation of
   the People's Republic of China (81471260 to Z. Xiang).
CR BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1
   Chan PM, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni162
   Choi HMT, 2014, ACS NANO, V8, P4284, DOI 10.1021/nn405717p
   Choi HMT, 2010, NAT BIOTECHNOL, V28, P1208, DOI 10.1038/nbt.1692
   CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484
   Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101
   Grabinski TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120120
   HAASE AT, 1985, SCIENCE, V227, P189, DOI 10.1126/science.2981430
   Han J, 2013, ANAL CHIM ACTA, V790, P24, DOI 10.1016/j.aca.2013.06.025
   HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631
   HOPMAN AHN, 1986, HISTOCHEMISTRY, V85, P1, DOI 10.1007/BF00508646
   Huss David, 2015, Cold Spring Harb Protoc, V2015, P259, DOI 10.1101/pdb.prot083832
   Kenny D, 2002, J HISTOCHEM CYTOCHEM, V50, P1219
   Koos B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8294
   Kosman D, 2004, SCIENCE, V305, P846, DOI 10.1126/science.1099247
   Lauter G, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-43
   Lauter G, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-10
   NEDERLOF PM, 1989, CYTOMETRY, V10, P20, DOI 10.1002/cyto.990100105
   NEDERLOF PM, 1990, CYTOMETRY, V11, P126, DOI 10.1002/cyto.990110115
   Nguyen MH, 2016, J AM CHEM SOC, V138, P3675, DOI 10.1021/jacs.6b01731
   PARDUE ML, 1969, P NATL ACAD SCI USA, V64, P600, DOI 10.1073/pnas.64.2.600
   Player AN, 2001, J HISTOCHEM CYTOCHEM, V49, P603
   Raj A, 2008, NAT METHODS, V5, P877, DOI [10.1038/nmeth.1253, 10.1038/NMETH.1253]
   Schwarzkopf M, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw503
   Shimron S, 2012, ANAL CHEM, V84, P1042, DOI 10.1021/ac202643y
   Song WQ, 2012, ANALYST, V137, P1396, DOI 10.1039/c2an16232f
   Sylwestrak EL, 2016, CELL, V164, P792, DOI 10.1016/j.cell.2016.01.038
   Tang W, 2012, CHEM COMMUN, V48, P6678, DOI 10.1039/c2cc32747c
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Wang HW, 2014, JOVE-J VIS EXP, DOI 10.3791/51426
   Wang X, 2013, ANALYST, V138, P2691, DOI 10.1039/c3an36885h
   WIEGANT J, 1993, CYTOGENET CELL GENET, V63, P73, DOI 10.1159/000133507
   Xiang Z, 2001, Brain Res Dev Brain Res, V128, P25
   Xu QF, 2013, ANAL CHEM, V85, P6915, DOI 10.1021/ac401334r
   Zhao JJ, 2012, BIOSENS BIOELECTRON, V36, P129, DOI 10.1016/j.bios.2012.04.013
   Zhu GZ, 2013, P NATL ACAD SCI USA, V110, P7998, DOI 10.1073/pnas.1220817110
   Zhuang JY, 2013, BIOSENS BIOELECTRON, V45, P52, DOI 10.1016/j.bios.2013.01.039
NR 37
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD DEC
PY 2016
VL 47
IS 6
BP 511
EP 529
DI 10.1007/s10735-016-9696-x
PG 19
WC Cell Biology
SC Cell Biology
GA EB7QM
UT WOS:000387584400001
PM 27722791
ER

PT J
AU Francis, SM
   Kirkpatrick, MG
   de Wit, H
   Jacob, S
AF Francis, Sunday M.
   Kirkpatrick, Matthew G.
   de Wit, Harriet
   Jacob, Suma
TI Urinary and plasma oxytocin changes in response to MDMA or intranasal
   oxytocin administration
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; MDMA; Intranasal oxytocin; Plasma; Urine
ID AUTISM SPECTRUM DISORDERS; CEREBROSPINAL-FLUID; SOCIAL-BEHAVIOR;
   VASOPRESSIN; HUMANS; SCHIZOPHRENIA; CORTISOL; CHILDREN; WOMEN;
   ASSOCIATIONS
AB Background: The neuropeptide oxytocin (OT) has received increased experimental attention for its putative role in both normal social functioning and several psychiatric disorders that are partially characterized by social dysfunction (e.g., autism spectrum disorders: ASD). Many human experimental studies measure circulating plasma levels of OT in order to examine the relationship between the hormone and behavior. Urinary OT (uOT) assays offer a simple, easy, and non-invasive method to measure peripheral hormone levels, but the correspondence between uOT and plasma OT (pOT) levels is unclear. Here, we conducted two within-subjects, double-blind studies exploring changes in uOT and pOT levels following administration of two drugs: MDMA, an oxytocin-releasing drug (Study 1), and intranasal oxytocin (INOT: Study 1 and 2).
   Methods: In Study 1, 14 adult participants (2 females) were each administered either oral 1.5 mg/kg MDMA or 40 IU INOT across two different study sessions. In Study 2, 10 male participants (adolescents and young adults) diagnosed with ASD received either 40 IU INOT or placebo across two different sessions. In both studies, blood and urine samples were collected before and after drug administration at each study session. For Study 1,10 participants provided valid plasma and urine samples for the MDMA session, and 8 provided valid samples for the INOT session. For Study 2, all 10 participants provided valid samples for both INOT and placebo sessions. Pre- and post-administration levels of pOT and uOT were compared. Additionally, correlations between percent change from baseline uOT and pOT levels were examined.
   Results: Study 1: Plasma OT and uOT levels significantly increased after administration of MDMA and INOT. Furthermore, uOT levels were positively correlated with pOT levels following administration of MDMA (r= 0.57, p = 0.042) but not INOT (r = 0.51, p=0.097). Study 2: There was a significant increase in uOT levels after administration of INOT, but not after administration of placebo. Under both conditions, INOT and placebo, significant increases in pOT levels were not observed. Additionally, change from baseline uOT and pOT levels were positively correlated (r = 0.57, p=0.021). There was no significant correlation between uOT and pOT levels following placebo administration.
   Conclusion: Our results show a measurable and significant increase in pOT and uOT levels after the administration of MDMA (Study 1) and INOT (Study 1 and Study 2). Additionally, a positive correlation between uOT and pOT levels was observed in both samples (healthy adults and ASD patients) in at least one condition. However, uOT and pOT levels were not correlated under all conditions, suggesting that uOT levels do not fully correspond to pOT levels in the time windows we measured. Future studies should further examine the relationship between levels of pOT and uOT in healthy and clinical populations on measures of social behavior because uOT may serve as an additional non-invasive method to measure peripheral OT changes. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Francis, Sunday M.; Jacob, Suma] Univ Illinois, Dept Psychiat, Inst Juvenile Res, 1747 West Roosevelt Rd, Chicago, IL 60608 USA.
   [Kirkpatrick, Matthew G.; de Wit, Harriet] Univ Chicago, Dept Psychiat & Behav Neurosci, A27 South Maryland Ave, Chicago, IL 60637 USA.
   [Jacob, Suma] Univ Minnesota, Dept Psychiat, 717 Delaware St SE,Room 516, Minneapolis, MN 55414 USA.
   [Kirkpatrick, Matthew G.] Univ Southern Calif, Dept Prevent Med, 2001 North Soto St, Los Angeles, CA 90032 USA.
RP Jacob, S (reprint author), Univ Minnesota, Dept Psychiat, 717 Delaware St SE,Room 516, Minneapolis, MN 55414 USA.
EM sfrancis@umn.edu; mgkirkpa@usc.edu; hdew@uchicago.edu; sjacob@umn.edu
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Anestis SF, 2010, EVOL ANTHROPOL, V19, P66, DOI 10.1002/evan.20253
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   Bedi G, 2010, J PSYCHOPHARMACOL, V24, P233, DOI 10.1177/0269881108097631
   Bedi G, 2009, PSYCHOPHARMACOLOGY, V207, P73, DOI 10.1007/s00213-009-1635-z
   Bick J, 2010, DEV PSYCHOBIOL, V52, P100, DOI 10.1002/dev.20411
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bos PA, 2012, FRONT NEUROENDOCRIN, V33, P17, DOI 10.1016/j.yfrne.2011.01.002
   Broadbear JH, 1999, J PHARMACOL EXP THER, V289, P1641
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Carter CS, 2007, ANN NY ACAD SCI, V1098, P312, DOI 10.1196/annals.1384.006
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Christensen JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116172
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dumont GJH, 2009, SOC NEUROSCI-UK, V4, P359, DOI 10.1080/17470910802649470
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Francis SM, 2014, BRAIN RES, V1580, P199, DOI 10.1016/j.brainres.2014.01.021
   Freeman SM, 2016, PSYCHONEUROENDOCRINO, V66, P185, DOI 10.1016/j.psyneuen.2016.01.014
   Gossen A, 2012, NEUROPEPTIDES, V46, P211, DOI 10.1016/j.npep.2012.07.001
   Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1
   Gray PB, 2007, HORM BEHAV, V52, P499, DOI 10.1016/j.yhbeh.2007.07.005
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Hammock E, 2012, J AM ACAD CHILD PSY, V51, P712, DOI 10.1016/j.jaac.2012.04.010
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Hoffman ER, 2012, EAT BEHAV, V13, P256, DOI 10.1016/j.eatbeh.2012.02.004
   HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289
   Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161
   Hysek CM, 2012, PSYCHOPHARMACOLOGY, V222, P293, DOI 10.1007/s00213-012-2645-9
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   Jacob S., 2011, NEUROPSYCHOLOGY AUTI, P451
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Kirkpatrick MG, 2014, NEUROPSYCHOPHARMACOL, V39, P1654, DOI 10.1038/npp.2014.12
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Lord C., 1999, AUTISM DIAGNOSTIC OB
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   Reyes TL, 2014, J GERONTOL B-PSYCHOL, V69, pS229, DOI 10.1093/geronb/gbu104
   Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e
   Rutter M., 2003, AUTISM DIAGNOSTIC IN
   Saito A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00217
   Schmid Y, 2014, J PSYCHOPHARMACOL, V28, P847, DOI 10.1177/0269881114542454
   Seltzer LJ, 2007, HORM BEHAV, V51, P436, DOI 10.1016/j.yhbeh.2006.12.012
   Seltzer LJ, 2010, P ROY SOC B-BIOL SCI, V277, P2661, DOI 10.1098/rspb.2010.0567
   Snowdon CT, 2010, HORM BEHAV, V58, P614, DOI 10.1016/j.yhbeh.2010.06.014
   Souza RP, 2010, SCHIZOPHR RES, V121, P279, DOI 10.1016/j.schres.2010.04.019
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Teltsh O, 2012, INT J NEUROPSYCHOPH, V15, P309, DOI 10.1017/S1461145711001374
   Weisman O, 2013, PSYCHONEUROENDOCRINO, V38, P694, DOI 10.1016/j.psyneuen.2012.08.011
   White TL, 2002, PHARMACOL BIOCHEM BE, V73, P729, DOI 10.1016/S0091-3057(02)00818-3
   Ziegler T., 2005, P NATL ACAD SCI USA, V102, P237, DOI DOI 10.1073/PNAS.0504767102
   Yuen KW, 2014, J PSYCHIATR RES, V51, P30, DOI 10.1016/j.jpsychires.2013.12.012
   ZIEGLER TE, 1995, HORM BEHAV, V29, P407, DOI 10.1006/hbeh.1995.1028
NR 67
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 92
EP 100
DI 10.1016/j.psyneuen.2016.08.011
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700011
ER

PT J
AU Engert, V
   Koester, AM
   Riepenhausen, A
   Singer, T
AF Engert, Veronika
   Koester, Anna M.
   Riepenhausen, Antje
   Singer, Tania
TI Boosting recovery rather than buffering reactivity: Higher
   stress-induced oxytocin secretion is associated with increased cortisol
   reactivity and faster vagal recovery after acute psychosocial stress
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Stress; Reactivity; Recovery; Plasma oxytocin; Cortisol; Heart rate
   variability
ID PITUITARY-ADRENAL AXIS; RESPIRATORY SINUS ARRHYTHMIA;
   HEART-RATE-VARIABILITY; SALIVARY CORTISOL; ALPHA-AMYLASE; PSYCHOLOGICAL
   STRESS; PLASMA OXYTOCIN; SOCIAL STRESS; CARDIOVASCULAR RECOVERY;
   PERIPHERAL OXYTOCIN
AB Animal models and human studies using paradigms designed to stimulate endogenous oxytocin release suggest a stress-buffering role of oxytocin. We here examined the involvement of stress-induced peripheral oxytocin secretion in reactivity and recovery phases of the human psychosocial stress response. Healthy male and female participants (N = 114) were subjected to a standardized laboratory stressor, the Trier Social Stress Test. In addition to plasma oxytocin, cortisol was assessed as a marker of hypothalamic pituitary-adrenal (HPA-) axis activity, alpha-amylase and heart rate as markers of sympathetic activity, high frequency heart rate variability as a marker of vagal tone and self-rated anxiety as an indicator of subjective stress experience. On average, oxytocin levels increased by 51% following psychosocial stress. The stress-induced oxytocin secretion, however, did not reduce stress reactivity. To the contrary, higher oxytocin secretion was associated with greater cortisol reactivity and peak cortisol levels in both sexes. In the second phase of the stress response the opposite pattern was observed, with higher oxytocin secretion associated with faster vagal recovery. We suggest that after an early stage of oxytocin and HPA-axis co-activation, the stress-reducing action of oxytocin unfolds. Due to the time lag it manifests as a recovery-boosting rather than a reactivity-buffering effect. By reinforcing parasympathetic autonomic activity, specifically during stress recovery, oxytocin may provide an important protective function against the health-compromising effects of sustained stress. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Engert, Veronika; Koester, Anna M.; Riepenhausen, Antje; Singer, Tania] Max Planck Inst Human Cognit & Brain Sci, Dept Social Neurosci, Stephanstr 1a, D-04103 Leipzig, Germany.
RP Engert, V (reprint author), Max Planck Inst Human Cognit & Brain Sci, Dept Social Neurosci, Stephanstr 1a, D-04103 Leipzig, Germany.
EM engert@cbs.mpg.de
CR ALTEMUS M, 1995, J CLIN ENDOCR METAB, V80, P2954, DOI 10.1210/jc.80.10.2954
   Altemus M, 2001, PSYCHOSOM MED, V63, P814
   ARAI Y, 1989, AM J PHYSIOL, V256, pH132
   Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x
   BERNTSON GG, 1993, PSYCHOPHYSIOLOGY, V30, P183, DOI 10.1111/j.1469-8986.1993.tb01731.x
   Borenstein M., 2009, CONVERTING EFFECT SI
   Braga DC, 2000, AM J PHYSIOL-REG I, V278, pR1474
   Brosschot JF, 2005, PSYCHONEUROENDOCRINO, V30, P1043, DOI 10.1016/j.psyneuen.2005.04.008
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Campbell J., 2012, ACUTE PSYCHOSOCIAL S
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   Dabrowska J, 2011, PSYCHONEUROENDOCRINO, V36, P1312, DOI 10.1016/j.psyneuen.2011.03.003
   Dallman M.F., 2000, ENCY STRESS
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   Denver JW, 2007, BIOL PSYCHOL, V74, P286, DOI 10.1016/j.biopsycho.2005.09.005
   Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355
   Ditzen B, 2013, SOC COGN AFFECT NEUR, V8, P897, DOI 10.1093/scan/nss083
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   DRESSENDORFER RA, 1992, J STEROID BIOCHEM, V43, P683, DOI 10.1016/0960-0760(92)90294-S
   Engelmann M, 2004, FRONT NEUROENDOCRIN, V25, P132, DOI 10.1016/j.yfrne.2004.09.001
   Engert V, 2011, PSYCHONEUROENDOCRINO, V36, P1294, DOI 10.1016/j.psyneuen.2011.02.018
   First M.B., 1997, STRUCTURED CLIN INTE
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GROSSMAN P, 1991, PSYCHOPHYSIOLOGY, V28, P201, DOI 10.1111/j.1469-8986.1991.tb00412.x
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2001, J CLIN ENDOCR METAB, V86, P4798, DOI 10.1210/jc.86.10.4798
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Higa KT, 2002, AM J PHYSIOL-REG I, V282, pR537
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   Jong Trynke R de, 2015, Psychoneuroendocrinology, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027
   Kaufmann T, 2011, BEHAV RES METHODS, V43, P1161, DOI 10.3758/s13428-011-0107-7
   Kelly MM, 2008, J BEHAV THER EXP PSY, V39, P87, DOI 10.1016/j.jbtep.2007.02.003
   KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004
   KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611
   Kubzansky LD, 2012, BIOL PSYCHOL, V90, P1, DOI 10.1016/j.biopsycho.2012.02.010
   Kudielka BM, 2005, BIOL PSYCHOL, V69, P113, DOI 10.1016/j.biopsycho.2004.11.009
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   LEGROS JJ, 1988, NEUROENDOCRINOLOGY, V48, P204, DOI 10.1159/000125009
   Light KC, 2000, HEALTH PSYCHOL, V19, P560, DOI 10.1037//0278-6133.19.6.560
   Linden W, 1997, J PSYCHOSOM RES, V42, P117, DOI 10.1016/S0022-3999(96)00240-1
   Lorentz K, 1999, CLIN CHEM LAB MED, V37, P1053, DOI 10.1515/CCLM.1999.154
   MacDonald K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00035
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mezzacappa ES, 2001, PSYCHOSOM MED, V63, P650
   Michelini LC, 2001, ANN NY ACAD SCI, V940, P206
   Miller R, 2013, PSYCHOSOM MED, V75, P832, DOI 10.1097/PSY.0000000000000002
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Patisaul HB, 2003, J NEUROENDOCRINOL, V15, P787, DOI 10.1046/j.1365-2826.2003.01061.x
   Pierrehumbert B, 2010, NEUROSCIENCE, V166, P168, DOI 10.1016/j.neuroscience.2009.12.016
   Porges SW, 2003, PHYSIOL BEHAV, V79, P503, DOI 10.1016/S0031-9384(03)00156-2
   Quirin M., 2011, OXYTOCIN BUFFERS COR
   RICHARD S, 1990, J BIOL CHEM, V265, P6098
   Rohleder N, 2009, PSYCHONEUROENDOCRINO, V34, P469, DOI 10.1016/j.psyneuen.2008.12.004
   SANDERS G, 1990, PSYCHONEUROENDOCRINO, V15, P47, DOI 10.1016/0306-4530(90)90046-C
   Schielzeth H, 2009, BEHAV ECOL, V20, P416, DOI 10.1093/beheco/arn145
   Schlotz W, 2008, PSYCHOSOM MED, V70, P787, DOI 10.1097/PSY.0b013e3181810658
   Singer T., 2016, RESOURCE PROJECT BAC
   SOFRONIEW MV, 1981, NEUROSCI LETT, V22, P211, DOI 10.1016/0304-3940(81)90108-7
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Steptoe A, 2005, J HYPERTENS, V23, P529, DOI 10.1097/01.hjh.0000160208.66405.a8
   Stewart JC, 2001, BIOL PSYCHOL, V58, P105, DOI 10.1016/S0301-0511(01)00105-3
   STOCK S, 1989, ACTA OBSTET GYN SCAN, V68, P75, DOI 10.3109/00016348909087694
   Taylor S.E., 2006, RELATION OXYTOCIN PS
   Taylor SE, 2006, CURR DIR PSYCHOL SCI, V15, P273, DOI 10.1111/j.1467-8721.2006.00451.x
   Thayer JF, 2007, BIOL PSYCHOL, V74, P224, DOI 10.1016/j.biopsycho.2005.11.013
   Thayer JF, 2010, INT J CARDIOL, V141, P122, DOI 10.1016/j.ijcard.2009.09.543
   Tops M, 2007, BIOL PSYCHOL, V75, P119, DOI 10.1016/j.biopsycho.2007.01.001
   Ursin H, 2004, PSYCHONEUROENDOCRINO, V29, P567, DOI 10.1016/S0306-4530(03)00091-X
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   WILDER J, 1957, J NERV MENT DIS, V125, P73, DOI 10.1097/00005053-195701000-00009
   WINNDEEN ES, 1988, CLIN CHEM, V34, P2005
   Winslow JT, 2004, CURR OPIN NEUROBIOL, V14, P248, DOI 10.1016/j.conb.2004.03.009
   Wittchen H-U, 1997, SKID STRUKTURIERTES
   Wittchen H.U., 1997, DIAGN EXPERTENSYSTEM
NR 84
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 111
EP 120
DI 10.1016/j.psyneuen.2016.08.029
PG 10
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700013
ER

PT J
AU Parr, LA
   Brooks, JM
   Jonesteller, T
   Moss, S
   Jordano, JO
   Heitz, TR
AF Parr, Lisa A.
   Brooks, Jenna M.
   Jonesteller, Trina
   Moss, Shannon
   Jordano, James O.
   Heitz, Thomas R.
TI Effects of chronic oxytocin on attention to dynamic facial expressions
   in infant macaques
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Development; Oxytocin; Facial expression; Infant macaque; Gaze;
   Eye-tracking
ID AUTISM SPECTRUM DISORDERS; INTRANASAL OXYTOCIN; SOCIAL-BEHAVIOR;
   RHESUS-MONKEYS; MACACA-MULATTA; CEREBROSPINAL-FLUID; EYE REGION; MALE
   RATS; FACES; GAZE
AB Studies in a variety of species have reported enhanced prosocial effects after an acute administration of the neuromodulating hormone, oxytocin (OT). Although the exact mechanisms underlying these effects are not fully understood, there is broad interest in developing OT into a treatment for social deficits. Only a few studies, however, have examined the effects of OT if given repeatedly during early development, the period when early intervention is likely to have the greatest benefits for reversing the progression towards social impairment. Those studies, exclusively in rodents, report mixed results. Some have shown enhancement of prosocial behavior, including increased social exploration, but others have shown antisocial effects, including increased aggression. In the present study, infant rhesus macaques were treated with a high-frequency (3 x per week) or low-frequency (1 x per week) dose of intranasal oxytocin (IN-OT) or placebo (IN-saline) between two and six months of age, after which their reactions to dynamic facial expressions (neutral, lipsmacking and threats) were measured. Results showed that IN-OT, compared to placebo, increased the time monkeys spent viewing the expression videos, but selectively reduced attention to the eyes in neutral faces in a dose dependent manner. The mechanism for this non-prosocial effect may be that repeated IN-OT administration down-regulates the expression of OT receptors in brain regions important for regulating social attention. Consequently, our results raise questions about the efficacy of implementing chronic IN-OT as a pharmacotherapy for the treatment of social deficits, particularly if given early in development. More work is needed, not only to identify optimal treatment schedules, but also to understand how IN-OT exerts its influences on the brain and behavior. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Parr, Lisa A.; Brooks, Jenna M.; Jonesteller, Trina; Moss, Shannon; Heitz, Thomas R.] Yerkes Natl Primate Res Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.
   [Parr, Lisa A.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Parr, Lisa A.] Emory Univ, Ctr Translat Social Neurosci, Atlanta, GA 30329 USA.
   [Jordano, James O.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA.
RP Parr, LA (reprint author), 954 Gatewood Rd, Atlanta, GA 30329 USA.
EM lparr@emory.edu
FU NIMH NIH HHS [R01 MH104534]
CR Alves E, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00032
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Bales KL, 2012, HORM BEHAV, V61, P313, DOI 10.1016/j.yhbeh.2011.12.013
   BOOTHE RG, 1982, DEV PSYCHOL, V18, P665
   Bowen MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027237
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   Calcagnoli F, 2014, HORM BEHAV, V65, P427, DOI 10.1016/j.yhbeh.2014.03.008
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Clark-Elford R, 2014, INT J NEUROPSYCHOPH, V17, P199, DOI 10.1017/S1461145713001120
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Dal Monte O, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00041
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebitz RB, 2013, P NATL ACAD SCI USA, V110, P11630, DOI 10.1073/pnas.1305230110
   Ferrari PF, 2009, CURR BIOL, V19, P1768, DOI 10.1016/j.cub.2009.08.055
   Field A., 2013, DISCOVERING STAT USI
   Freeman SM, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12382
   Freeman SM, 2016, PSYCHONEUROENDOCRINO, V66, P185, DOI 10.1016/j.psyneuen.2016.01.014
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gothard KM, 2007, J NEUROPHYSIOL, V97, P1671, DOI 10.1152/jn.00714.2006
   Gothard KM, 2004, ANIM COGN, V7, P25, DOI 10.1007/s10071-003-0179-6
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guo K, 2003, EXP BRAIN RES, V150, P363, DOI 10.1007/s00221-003-1429-1
   Hammock EAD, 2015, NEUROPSYCHOPHARMACOL, V40, P24, DOI 10.1038/npp.2014.120
   HINDE R. A., 1962, PROC ZOOL SOC LONDON, V138, P1
   Hoffman KL, 2007, CURR BIOL, V17, P766, DOI 10.1016/j.cub.2007.03.040
   Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310
   INSEL TR, 1992, ENDOCRINOLOGY, V130, P2602, DOI 10.1210/en.130.5.2602
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Landman R, 2014, P NATL ACAD SCI USA, V111, P18037, DOI 10.1073/pnas.1420167111
   Lefevre A, 2016, NEUROSCI BIOBEHAV R, V63, P168, DOI 10.1016/j.neubiorev.2016.01.011
   Leonard TK, 2012, BEHAV NEUROSCI, V126, P781, DOI 10.1037/a0030348
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Miller TV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00076
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Mosher CP, 2014, CURR BIOL, V24, P2459, DOI 10.1016/j.cub.2014.08.063
   Mosher CP, 2011, BEHAV NEUROSCI, V125, P639, DOI 10.1037/a0024264
   Muschinski J., 2016, DEV PSYCHOBIOL
   Nahm FKD, 1997, J COGNITIVE NEUROSCI, V9, P611, DOI 10.1162/jocn.1997.9.5.611
   Parr L.A., 2016, DEV PSYCHOBIOL
   Parr LA, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00278
   Parr LA, 2013, PSYCHONEUROENDOCRINO, V38, P1748, DOI 10.1016/j.psyneuen.2013.02.011
   Putnam PT, 2016, PSYCHONEUROENDOCRINO, V72, P47, DOI 10.1016/j.psyneuen.2016.05.016
   Rault JL, 2013, PHYSIOL BEHAV, V112, P40, DOI 10.1016/j.physbeh.2013.02.007
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Simpson EA, 2014, P NATL ACAD SCI USA, V111, P6922, DOI 10.1073/pnas.1402471111
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Veenema AH, 2012, HORM BEHAV, V61, P304, DOI 10.1016/j.yhbeh.2011.12.002
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Yatawara C.J., 2015, MOL PSYCHIAT
NR 56
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 149
EP 157
DI 10.1016/j.psyneuen.2016.08.028
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700017
PM 27621197
ER

PT J
AU Song, ZM
   Borland, JM
   Larkin, TE
   O'Malley, M
   Albers, HE
AF Song, Zhimin
   Borland, Johnathan M.
   Larkin, Tony E.
   O'Malley, Maureen
   Albers, H. Elliott
TI Activation of oxytocin receptors, but not arginine-vasopressin V1a
   receptors, in the ventral tegmental area of male Syrian hamsters is
   essential for the reward-like properties of social interactions
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Social interaction; Social behavior; Social salience; Social motivation;
   Conditioned place preference; Neuropeptides; Mesolimbic dopamine system;
   Dopamine
ID CONDITIONED PLACE PREFERENCE; NUCLEUS-ACCUMBENS DOPAMINE; BEHAVIOR
   NEURAL-NETWORK; MALE PRAIRIE VOLES; MESOCRICETUS-AURATUS;
   PSYCHIATRIC-DISORDERS; MATERNAL-BEHAVIOR; MALE RATS; AGGRESSION;
   COMMUNICATION
AB Social reward plays a fundamental role in shaping human and animal behavior. The rewarding nature of many forms of social behavior including sexual behavior, parental behavior, and social play has been revealed using well-established procedures such as the conditioned place preference test. Many motivated social behaviors are regulated by the nonapeptides oxytocin (OT) and arginine vasopressin (AVP) through their actions in multiple brain structures. Interestingly, there are few data on whether OT or AVP might contribute to the rewarding properties of social interaction by their actions within brain structures that play a key role in reward mechanisms such as the ventral tegmental area (VTA). The goal of the present study was to investigate the role of OT and AVP in the VTA in regulating the reward-like properties of social interactions. Social interactions between two male hamsters reduced a spontaneous place avoidance in hamsters injected with saline control. Interestingly, however, OT and AVP injected into the VTA induced a significant two-fold reduction in place avoidance for the social interaction chamber when compared to control injections of vehicle. Finally, because OT and AVP can act on each other's receptors to influence social behavior, we also injected highly selective OTR and V1aR agonists and antagonists to determine whether OT or AVP V1a receptors were responsible for mediating the effects of these neuropeptides on social reward. Our results not only demonstrated that OT and AVP activate OTRs and not Vi aRs to mediate social reward, they also demonstrated that the activation of OT receptors in the VTA is essential for the expression of the rewarding properties of social interactions. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Song, Zhimin; Borland, Johnathan M.; Larkin, Tony E.; O'Malley, Maureen; Albers, H. Elliott] Georgia State Univ, Ctr Behav Neurosci, Neurosci Inst, Atlanta, GA 30303 USA.
RP Albers, HE (reprint author), Georgia State Univ, Neurosci Inst, POB 5030, Atlanta, GA 30302 USA.
EM biohea@gsu.edu
CR Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007
   ALBERS HE, 1986, J NEUROSCI, V6, P2085
   Albers HE, 2006, BRAIN RES, V1073, P425, DOI 10.1016/j.brainres.2005.12.081
   Albers H.E., 2002, HORMONES BRAIN BEHAV, P393, DOI DOI 10.1016/B978-012532104-4/50008-1
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aragona BJ, 2003, J NEUROSCI, V23, P3483
   Aragona BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.015.2009
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Bora E, 2009, CURR OPIN PSYCHIATR, V22, P320, DOI 10.1097/YCO.0b013e328329e970
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Caldwell H.K., 2016, CURR TOP BEHAV NEURO, P51
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   Crews D, 1997, ANN NY ACAD SCI, V807, P1, DOI 10.1111/j.1749-6632.1997.tb51910.x
   Curtis JT, 2005, PHYSIOL BEHAV, V86, P338, DOI 10.1016/j.physbeh.2005.08.022
   Dhakar MB, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P3
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   DRICKAMER LC, 1973, ANIM BEHAV, V21, P557, DOI 10.1016/S0003-3472(73)80016-8
   DRICKAMER LC, 1973, ANIM BEHAV, V21, P564, DOI 10.1016/S0003-3472(73)80017-X
   Dumais K.M., 2015, FRONT NEUROENDOCRINO
   Gil M, 2013, EUR J NEUROSCI, V38, P2308, DOI 10.1111/ejn.12216
   Goodson JL, 2013, HORM BEHAV, V64, P103, DOI 10.1016/j.yhbeh.2013.05.006
   Groppe SE, 2013, BIOL PSYCHIAT, V74, P172, DOI 10.1016/j.biopsych.2012.12.023
   Gutzler SJ, 2010, EUR J NEUROSCI, V31, P1655, DOI 10.1111/j.1460-9568.2010.07190.x
   Hammock EAD, 2015, NEUROPSYCHOPHARMACOL, V40, P24, DOI 10.1038/npp.2014.120
   Harmon AC, 2002, J NEUROENDOCRINOL, V14, P963, DOI 10.1046/j.1365-2826.2002.00863.x
   HUGUENIN RL, 1964, HELV CHIM ACTA, V47, P1934, DOI 10.1002/hlca.19640470733
   Huhman KL, 2006, HORM BEHAV, V50, P640, DOI 10.1016/j.yhbeh.2006.06.022
   Insel T.R., 1992, OXYTOCIN A NEUROPEPT
   IsHak WW, 2011, J AFFECT DISORDERS, V130, P1, DOI 10.1016/j.jad.2010.06.001
   Kelly AM, 2014, FRONT NEUROENDOCRIN, V35, P512, DOI 10.1016/j.yfrne.2014.04.005
   KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Love TM, 2014, PHARMACOL BIOCHEM BE, V119, P49, DOI 10.1016/j.pbb.2013.06.011
   LOWBRIDGE J, 1977, J MED CHEM, V20, P120, DOI 10.1021/jm00211a025
   MANNING M, 1995, INT J PEPT PROT RES, V46, P244
   Manning M., 2012, OXYTOCIN VASOPRESSIN
   Mattson BJ, 2005, NEUROSCIENCE, V135, P315, DOI 10.1016/j.neuroscience.2005.06.045
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Meisel RL, 1996, EUR J PHARMACOL, V309, P21, DOI 10.1016/0014-2999(96)00389-5
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Morin L., 2001, STEREOTAXIC ATLAS BR
   Nephew BC, 2008, PHARMACOL BIOCHEM BE, V91, P77, DOI 10.1016/j.pbb.2008.06.013
   Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x
   Numan M., 2015, HORM BEHAV
   O'Connell LA, 2011, J COMP NEUROL, V519, P3599, DOI 10.1002/cne.22735
   O'Connell LA, 2011, FRONT NEUROENDOCRIN, V32, P320, DOI 10.1016/j.yfrne.2010.12.004
   Peartree NA, 2012, PHYSIOL BEHAV, V105, P749, DOI 10.1016/j.physbeh.2011.10.001
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Song Z, 2016, SOC BEHAV NEUROENDOC, V81, P20
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   Trezza V, 2011, DEV COGN NEUROS-NETH, V1, P444, DOI 10.1016/j.dcn.2011.05.007
   Wagner U, 2015, SOC COGN AFFECT NEUR, V10, P801, DOI 10.1093/scan/nsu121
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 59
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 164
EP 172
DI 10.1016/j.psyneuen.2016.09.001
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700019
PM 27632574
ER

PT J
AU Kovacs, K
   Kis, A
   Pogany, A
   Koller, D
   Topal, J
AF Kovacs, Krisztina
   Kis, Anna
   Pogany, Akos
   Koller, Dora
   Topal, Jozsef
TI Differential effects of oxytocin on social sensitivity in two distinct
   breeds of dogs (Canis familiaris)
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Dog (Canis familiaris); Breed differences; Social
   responsiveness
ID COMMUNICATIVE SIGNALS; RECEPTOR GENE; HUMAN INFANTS; DOMESTIC DOG; PET
   DOGS; BEHAVIOR; HUMANS; COMPREHENSION; COOPERATION; CORTISOL
AB Dogs have been proven to show several human-analogue social behaviors, and recent research raises the possibility that the oxytocin system is related to these. However, despite dogs' general tendency to excel in the domain of social cognition, there is increasing evidence that dogs' ability to utilize human signals may vary with breed. Moreover, breeds may show differences not only in their 'inborn' communicative abilities, but also in their learning skills related to these. The aim of the present study was to explore breed differences and breed-specific effects of oxytocin administration on different aspects of social responsiveness. Dogs from two markedly different breeds, Border Collies (cooperative workers) and Siberian Huskies (independent workers) were tested. After having received intranasal administration of oxytocin or placebo, subjects participated in three behavioral tests measuring social responsiveness. Our results show that there are several behavioral differences between the two breeds and also that there are differential effects of the oxytocin treatment. Border Collies were in general more susceptible to the 'social' effects of oxytocin compared to Siberian Huskies: after oxytocin administration they (1) looked more at the experimenter in the 'Unreachable food' situation, (2) looked more at the owner and shifted their gaze more between the sound source and the owner in a potentially dangerous situation, and (3) looked longer at the experimenter's eyes in the 'Tolerance of prolonged eye contact' test. These findings suggest that selection for enhanced cooperative abilities, possibly complemented by the effect of different social environments the two breeds experience, affects dogs' performance in several behavioral tests and that the neurohormonal background differently modulates social behavior in different working breeds. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kovacs, Krisztina; Kis, Anna; Topal, Jozsef] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Cognit Neurosci & Psychol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary.
   [Kovacs, Krisztina; Pogany, Akos] Eotvos Lorand Univ, Dept Ethol, Pazmany Ps 1-C, H-1117 Budapest, Hungary.
   [Koller, Dora] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1085 Budapest, Hungary.
RP Kovacs, K (reprint author), Hungarian Acad Sci, Res Ctr Nat Sci, Inst Cognit Neurosci & Psychol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary.
EM kovacskrisztinabea@gmail.com
CR Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bence M, 2013, BEHAV GENET, V43, P509
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Chen FS, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00200
   Choleris E, 2008, PROG BRAIN RES, V170, P291, DOI 10.1016/S0079-6123(08)00424-X
   Christov-Moore L, 2014, NEUROSCI BIOBEHAV R, V46, P604, DOI 10.1016/j.neubiorev.2014.09.001
   Coppinger R, 2001, DOGS STARTLING NEW U
   Duranton C, 2015, J COMP PSYCHOL, V129, P84, DOI 10.1037/a0037825
   Farago T, 2010, ANIM BEHAV, V79, P917, DOI 10.1016/j.anbehav.2010.01.005
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Feng C, 2015, GENES BRAIN BEHAV, V14, P516, DOI 10.1111/gbb.12234
   Gacsi M, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-31
   Gaunet F, 2008, ANIM COGN, V11, P475, DOI 10.1007/s10071-008-0138-3
   Gaunet F, 2011, ANIM COGN, V14, P849, DOI 10.1007/s10071-011-0418-1
   Gimpl G, 2002, PROG BRAIN RES, P43
   Gordon I, 2010, PHYSIOL BEHAV, V101, P679, DOI 10.1016/j.physbeh.2010.08.008
   Handlin L, 2011, ANTHROZOOS, V24, P301, DOI 10.2752/175303711X13045914865385
   Hare B, 2005, TRENDS COGN SCI, V9, P439, DOI 10.1016/j.tics.2005.07.003
   Hernadi A, 2015, BEHAV PROCESS, V119, P1, DOI 10.1016/j.beproc.2015.07.001
   Hernadi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043267
   Herzmann G, 2013, PSYCHONEUROENDOCRINO, V38, P2140, DOI 10.1016/j.psyneuen.2013.04.002
   Hori Y., 2013, Open Journal of Animal Sciences, V3, P54
   Horn L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065296
   Jackman S., 2015, PSCL CLASSES METHODS
   Jakovcevic A, 2010, BEHAV PROCESS, V84, P602, DOI 10.1016/j.beproc.2010.04.003
   Kit A., 2014, J VET BEHAV, V9, pe15, DOI DOI 10.1016/J.JVEB.2014.09.050
   Kis A, 2015, HORM BEHAV, V69, P1, DOI 10.1016/j.yhbeh.2014.12.004
   Kis A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083993
   Kovacs K., 2016, ANIM COGN, V18, P1
   Kumsta R, 2013, FRONT NEUROSCI, V7, P1
   Lakatos G, 2009, ANIM COGN, V12, P621, DOI 10.1007/s10071-009-0221-4
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   Marshall-Pescini S, 2016, ANIM COGN, V19, P571, DOI 10.1007/s10071-016-0960-y
   Merola I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047653
   Miklosi A, 2005, J COMP PSYCHOL, V119, P179, DOI 10.1037/0735-7036.119.2.179
   Miklosi A, 2004, ANIM BEHAV, V67, P995, DOI 10.1016/j.anbehav.2003.10.008
   Miklosi A, 2003, CURR BIOL, V13, P763, DOI 10.1016/S0960-9822(03)00263-X
   Miklosi A., 2012, OXFORD HDB COMP EVOL, P194
   Miklosi A, 2000, ANIM COGN, V3, P159, DOI DOI 10.1007/S100710000072
   Muller C., 2011, BIOL LETT, V7
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Parker HG, 2004, SCIENCE, V304, P1160, DOI 10.1126/science.1097406
   Passalacqua C, 2011, ANIM BEHAV, V82, P1043, DOI 10.1016/j.anbehav.2011.07.039
   Romero T, 2014, P NATL ACAD SCI USA, V111, P9085, DOI 10.1073/pnas.1322868111
   Scott J.P., 1965, GENETICS SOCIAL BEHA
   Smyth G., 2016, STATMOD STAT MODELIN
   Soproni K, 2001, J COMP PSYCHOL, V115, P122, DOI 10.1037//0735-7036.115.2.122
   Svartberg K, 2006, APPL ANIM BEHAV SCI, V96, P293, DOI 10.1016/j.applanim.2005.06.014
   Team R.C. A Language and Environment for Statistical Computing, 2012, LANG ENV STAT COMP
   Therneau T., 2015, PACKAGE SURVIVAL ANA
   Therneau T. M, 2015, COXME MIXED EFFECTS
   Thielke L.E., 2015, BIOL REV
   Topal J, 2009, ADV STUD BEHAV, V39, P71, DOI 10.1016/S0065-3454(09)39003-8
   Venables W.N., 2002, MODERN APPL STAT R
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   Wobber V, 2009, INTERACT STUD, V10, P206, DOI 10.1075/is.10.2.06wob
NR 58
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 212
EP 220
DI 10.1016/j.psyneuen.2016.09.010
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700025
ER

PT J
AU Vaht, M
   Kurrikoff, T
   Laas, K
   Veidebaum, T
   Harro, J
AF Vaht, Mariliis
   Kurrikoff, Triin
   Laas, Kariina
   Veidebaum, Toomas
   Harro, Jaanus
TI Oxytocin receptor gene variation rs53576 and alcohol abuse in a
   longitudinal population representative study
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE OXTR; rs53576; Alcohol; Addiction; Longitudinal study; Social
   interactions
ID FUNCTIONAL CONNECTIVITY; AGGRESSIVE-BEHAVIOR; ETHANOL-CONSUMPTION; OXTR
   POLYMORPHISMS; DRINKING MOTIVES; DRUG-ADDICTION; DSM-IV; STRESS; HUMANS;
   VICTIMIZATION
AB Background: Oxytocin is an important regulator of social relationships and has been implicated in development of substance use and addiction. We examined the association of a variance in the oxytocin receptor gene (OXTR rs53576 polymorphism) with alcohol use in a population-representative sample, and potential moderation by social functioning.
   Methods: The analysis was carried out on the older birth cohort of the longitudinal Estonian Children Personality Behaviour and Health Study (ECPBHS), a cohort of initially 15 years old children (original n=593) recalled at ages 18 and 25. In all data collection waves the participants reported the frequency of consuming alcoholic beverages. Psychiatric interview was carried out at age 25 to assess the lifetime prevalence of substance use disorders. Adverse social interactions with teachers, classmates and family members were self-reported at ages 15 and 18. The minor (A) allele frequency was 0.37.
   Results: Males homozygous for the A allele (suggested to be associated with less efficient oxytocinergic functioning) were more frequent alcohol consumers at ages 15 and 18 and also more likely to have had alcohol abuse or addiction by age 25 compared to male G allele carriers. Alcohol use was not associated with the OXTR genotype in females. Both male and female AA homozygotes who had reported less favourable relations with their teachers at age 15 more likely had alcohol use disorder.
   Conclusions: OXTR rs53576 polymorphism is associated with alcohol use and prevalence of alcohol use disorders in males, and this may be moderated by inferior interpersonal relationships. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Vaht, Mariliis; Laas, Kariina; Harro, Jaanus] Univ Tartu, Estonian Ctr Behav & Hlth Sci, Dept Psychol, Div Neuropsychopharmacol, Tartu, Estonia.
   [Kurrikoff, Triin] Univ Tartu, Dept Social Studies, Div Sociol, Tartu, Estonia.
   [Veidebaum, Toomas] Estonian Ctr Behav & Hlth Sci, Natl Inst Hlth Dev, Tallinn, Estonia.
RP Harro, J (reprint author), Univ Tartu, Estonian Ctr Behav & Hlth Sci, Dept Psychol, Div Neuropsychopharmacol, Tartu, Estonia.
EM jaanus.harro@ut.ee
CR Archimi A, 2014, ADDICT BEHAV, V39, P713, DOI 10.1016/j.addbeh.2013.11.011
   Bahi A, 2015, PHYSIOL BEHAV, V139, P321, DOI 10.1016/j.physbeh.2014.11.046
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Boschloo L, 2013, J CLIN PSYCHIAT, V74, P1233, DOI 10.4088/JCP.12m08159
   Buhs ES, 2006, J EDUC PSYCHOL, V98, P1, DOI 10.1037/0022-0663.98.1.1
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Crawford AM, 2011, J ANXIETY DISORD, V25, P924, DOI 10.1016/j.janxdis.2011.05.005
   de Graaf R, 2012, SOC PSYCH PSYCH EPID, V47, P203, DOI 10.1007/s00127-010-0334-8
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   Erol A, 2015, DRUG ALCOHOL DEPEN, V156, P1, DOI 10.1016/j.drugalcdep.2015.08.023
   Feng C, 2015, GENES BRAIN BEHAV, V14, P516, DOI 10.1111/gbb.12234
   Garcia FD, 2011, PROG NEURO-PSYCHOPH, V35, P118, DOI 10.1016/j.pnpbp.2010.09.021
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gorka SM, 2015, NEUROPSYCHOPHARMACOL, V40, P278, DOI 10.1038/npp.2014.168
   Grinevich V, 2016, BIOL PSYCHIAT, V79, P155, DOI 10.1016/j.biopsych.2015.04.013
   Harro M, 2001, PROG NEURO-PSYCHOPH, V25, P1497, DOI 10.1016/S0278-5846(01)00212-3
   Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830
   INOUE T, 1994, J BIOL CHEM, V269, P32451
   Johansson A, 2012, GENES BRAIN BEHAV, V11, P214, DOI 10.1111/j.1601-183X.2011.00744.x
   Johansson A, 2012, PSYCHONEUROENDOCRINO, V37, P1546, DOI 10.1016/j.psyneuen.2012.02.009
   Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Li JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131820
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   Little T. D., 2006, STRUCTURAL EQUATION, V13, P479
   LoParo D, 2016, AM J MED GENET B, V171, P589, DOI 10.1002/ajmg.b.32359
   Lucht MJ, 2009, PROG NEURO-PSYCHOPH, V33, P860, DOI 10.1016/j.pnpbp.2009.04.004
   MacFadyen K, 2016, PHARMACOL BIOCHEM BE, V140, P27, DOI 10.1016/j.pbb.2015.10.014
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McInnis OA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01133
   Merenakk L, 2003, ADDICT BEHAV, V28, P1507, DOI 10.1016/S0306-4603(02)00270-8
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mitchell IJ, 2015, NEUROSCI BIOBEHAV R, V55, P98, DOI 10.1016/j.neubiorev.2015.04.018
   Paaver M, 2008, PROG NEURO-PSYCHOPH, V32, P1263, DOI 10.1016/j.pnpbp.2008.03.021
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Peters S, 2013, ADDICT BIOL, V18, P66, DOI 10.1111/adb.12001
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Rospenda KM, 2013, J ADDICT DIS, V32, P325, DOI 10.1080/10550887.2013.849971
   Saphire-Bernstein S, 2011, P NATL ACAD SCI USA, V108, P15118, DOI 10.1073/pnas.1113137108
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Sarnyai Z, 2011, ADDICT BIOL, V16, P199, DOI 10.1111/j.1369-1600.2011.00332.x
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Shlik J., 1999, MINI 5 0 0 MINI RAHV
   Tang YM, 2014, NEUROPHARMACOLOGY, V77, P277, DOI 10.1016/j.neuropharm.2013.10.004
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Volkow ND, 2013, JAMA PSYCHIAT, V70, P661, DOI 10.1001/jamapsychiatry.2013.1141
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   Wang JP, 2013, NEUROIMAGE, V81, P199, DOI 10.1016/j.neuroimage.2013.05.029
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Young KA, 2014, J NEUROSCI, V34, P8499, DOI 10.1523/JNEUROSCI.4275-13.2014
NR 56
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2016
VL 74
BP 333
EP 341
DI 10.1016/j.psyneuen.2016.09.018
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA EB6VW
UT WOS:000387524700039
PM 27716573
ER

PT J
AU Bhome, R
   Howard, R
AF Bhome, Rohan
   Howard, Robert
TI Oxytocin, trust and very late-onset schizophrenia-like psychosis
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Letter
ID BEHAVIOR
C1 [Bhome, Rohan; Howard, Robert] UCL, Div Psychiat, London, England.
RP Bhome, R (reprint author), UCL, Div Psychiat, London, England.
EM rohan.bhome@ucl.ac.uk
FU UCL Division of Psychiatry Scholarship
FX R. B. is the recipient of a UCL Division of Psychiatry Scholarship.
CR Cesarini D, 2008, P NATL ACAD SCI USA, V105, P3721, DOI 10.1073/pnas.0710069105
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krueger F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00004
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Zak PJ, 2005, HORM BEHAV, V48, P522, DOI 10.1016/j.yhbeh.2005.07.009
NR 5
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD DEC
PY 2016
VL 31
IS 12
BP 1373
EP 1374
DI 10.1002/gps.4520
PG 2
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA EB0KQ
UT WOS:000387033100014
PM 27272342
ER

PT J
AU Kaser, R
   Bruckmaier, RM
   Thomas, S
   Sieme, H
   Wedekind, C
   Burger, D
AF Kaser, R.
   Bruckmaier, R. M.
   Thomas, S.
   Sieme, H.
   Wedekind, C.
   Burger, D.
TI High interindividual and intraindividual variation of oxytocin secretion
   in estrous mares exposed to stallions, but no significant link to mate
   preferences
SO THERIOGENOLOGY
LA English
DT Article
DE Equine; Mate preference; Teasing; Oxytocin; Estradiol; Cortisol
ID AFFILIATIVE BEHAVIOR; PLASMA OXYTOCIN; SEXUAL-BEHAVIOR; RELEASE;
   CORTISOL; STIMULATION; INCREASES; CATTLE; COWS; RADIOIMMUNOASSAY
AB Oxytocin is a hormone that may not only influence reproductive mechanisms in mammals but also their social behavior, including pair bonding. We therefore tested if the concentrations of oxytocin and other hormones reveal mate preferences of 13 mares in estrus. Each mare was first exposed to two stallions (haphazardly selected out of seven) and her behavior recorded. The mare was then returned to her box (i.e., no contact to stallions during that time). Approximately 4.5 hours later, venous blood samples were collected every minute during 30 minutes preceding exposure to one of the two previously used stallions, 6 minutes during exposure, and 30 minutes after exposure back in the mare's box. The procedure was repeated in the consecutive estrus cycle, with the difference that the mare was each exposed to the other of the two stallions during oxytocin measurements. In 20 of the 26 trials, oxytocin concentrations were significantly elevated during exposure to the stallion, without significant associations to cortisol and estradiol concentrations. We found no significant association between oxytocin secretion and preferences in the previous choice situation. While estradiol concentration showed a high repeatability over the two cycles, we found considerable intraindividual differences in oxytocin and cortisol plasma concentration among the two cycles. Partially, the variation in oxytocin concentrations could be linked to the time of ovulation, with lower oxytocin plasma concentrations in mares which ovulated later than expected. In conclusion, when teasing under experimental conditions, we found high interindividual and intraindividual variation among mares in the increase of oxytocin plasma concentrations, depending on the timing of ovulation. However, oxytocin levels seemed to be no predictor of mare preference. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Kaser, R.; Thomas, S.; Burger, D.] Agroscope, Swiss Inst Equine Med, Avenches, Switzerland.
   [Kaser, R.; Thomas, S.; Burger, D.] Univ Bern, Avenches, Switzerland.
   [Bruckmaier, R. M.] Univ Bern, Vetsuisse Fac, Vet Physiol, Bern, Switzerland.
   [Thomas, S.; Wedekind, C.] Univ Lausanne, Dept Ecol & Evolut, Biophore, Lausanne, Switzerland.
   [Sieme, H.] Univ Vet Med Hanover, Reprod Med Unit, Clin Horses, Hannover, Germany.
RP Burger, D (reprint author), Agroscope, Swiss Inst Equine Med, Avenches, Switzerland.; Burger, D (reprint author), Univ Bern, Avenches, Switzerland.
EM dominik.burger@vetsuisse.unibe.ch
RI Wedekind, Claus/S-3353-2016
OI Wedekind, Claus/0000-0001-6143-4716
FU ISMEquine Research
FX The authors thank the Swiss National Stud for providing infrastructures
   and animals, and they gratefully appreciate the laboratory assistance of
   Yolande Zbinden, Veterinary Physiology, Vetsuisse Faculty University of
   Berne. This work was supported by ISMEquine Research.
CR Ababneh MM, 2013, REPROD DOMEST ANIM, V48, P223, DOI 10.1111/j.1439-0531.2012.02136.x
   Alexander SL, 1995, EQUINE REPROD, VVI, P361
   Aurich C, 2011, ANIM REPROD SCI, V124, P220, DOI 10.1016/j.anireprosci.2011.02.005
   BACK DG, 1974, J AM VET MED ASSOC, V165, P717
   Bauer C, 2006, VETERINARMEDIZINISCH, P89
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Blaicher W, 1999, GYNECOL OBSTET INVES, V47, P125, DOI 10.1159/000010075
   Blanks AM, 2003, BJOG-INT J OBSTET GY, V110, P46, DOI 10.1016/S1470-0328(03)00024-7
   BRUCKMAIER RM, 1992, J DAIRY RES, V59, P479
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Clutton-Brock T, 2009, Q REV BIOL, V84, P3
   Crowell-Davis SL, 2007, HORM BEHAV, V52, P12, DOI 10.1016/j.yhbeh.2007.03.020
   DEBACKERE M, 1961, J ENDOCRINOL, V22, P321, DOI 10.1677/joe.0.0220321
   Domes G, 2013, PSYCHONEUROENDOCRINO, V38, P1198, DOI 10.1016/j.psyneuen.2012.10.002
   FUCHS AR, 1981, J ENDOCRINOL, V90, P245, DOI 10.1677/joe.0.0900245
   GILBERT CL, 1991, J REPROD FERTIL, V91, P337
   Gutjahr S, 2000, THERIOGENOLOGY, V54, P447, DOI 10.1016/S0093-691X(00)00361-7
   Handler J, 2003, THERIOGENOLOGY, V59, P1381, DOI 10.1016/S0093-691X(02)01189-5
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heitor F, 2006, BEHAV PROCESS, V73, P231, DOI 10.1016/j.beproc.2006.05.005
   Klingel H, 1982, J Reprod Fertil Suppl, V32, P89
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Langendijk P, 2003, THERIOGENOLOGY, V59, P849, DOI 10.1016/S0093-691X(02)01157-3
   Linklater WL, 2000, BIOL REV, V75, P1, DOI 10.1017/S0006323199005411
   Lyimo ZC, 2000, THERIOGENOLOGY, V53, P1783, DOI 10.1016/S0093-691X(00)00314-9
   Madill S, 2000, J REPROD FERTILITY S, V56, P351
   Marazziti D, 2004, PSYCHONEUROENDOCRINO, V29, P931, DOI 10.1016/j.psyneuen.2003.08.006
   MATTIOLI M, 1986, THERIOGENOLOGY, V25, P399, DOI 10.1016/0093-691X(86)90047-6
   McCue PM, 2004, AAEP P, V50, P510
   McDonnell SM, 2000, ANIM REPROD SCI, V60, P211, DOI 10.1016/S0378-4320(00)00136-6
   Nikolakopoulos E, 2000, ANIM REPROD SCI, V63, P89, DOI 10.1016/S0378-4320(00)00149-4
   PICKEREL TM, 1993, APPL ANIM BEHAV SCI, V38, P1, DOI 10.1016/0168-1591(93)90037-P
   Porter RH, 2002, PHYSIOL BEHAV, V77, P151, DOI 10.1016/S0031-9384(02)00819-3
   RABB MH, 1989, J ANIM SCI, V67, P2724
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   SCHAMS D, 1982, ACTA ENDOCRINOL-COP, V99, P218
   SCHAMS D, 1983, ACTA ENDOCRINOL-COP, V103, P180
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   SHARMA OP, 1974, J REPROD FERTIL, V37, P421
   Smith AS, 2010, HORM BEHAV, V57, P255, DOI 10.1016/j.yhbeh.2009.12.004
   Snowdon CT, 2010, HORM BEHAV, V58, P614, DOI 10.1016/j.yhbeh.2010.06.014
   Squires EL, 2008, J EQUINE VET SCI, V28, P627, DOI 10.1016/j.jevs.2008.10.010
   Stecco R, 2003, THERIOGENOLOGY, V60, P727, DOI 10.1016/S0093-691X(03)00076-1
   TAMANINI C, 1983, ACTA ENDOCRINOL-COP, V102, P447
   Turner RA, 1999, PSYCHIATRY, V62, P97
   Vanderwall DK, 1998, J REPROD FERTIL, V112, P337
   Veening JG, 2015, EUR J PHARMACOL, V753, P209, DOI 10.1016/j.ejphar.2014.07.045
   Veronesi MC, 2010, THERIOGENOLOGY, V73, P460, DOI 10.1016/j.theriogenology.2009.09.028
NR 50
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD DEC
PY 2016
VL 86
IS 9
BP 2222
EP 2229
DI 10.1016/j.theriogenology.2016.07.017
PG 8
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA EA3XC
UT WOS:000386541600015
PM 27587272
ER

PT J
AU de Barros, NR
   Miranda, MCR
   Borges, FA
   de Mendonca, RJ
   Cilli, EM
   Herculano, RD
AF de Barros, Natan Roberto
   Romeiro Miranda, Matheus Carlos
   Borges, Felipe Azevedo
   de Mendonca, Ricardo Jose
   Cilli, Eduardo Maffud
   Herculano, Rondinelli Donizetti
TI Oxytocin Sustained Release Using Natural Rubber Latex Membranes
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Oxytocin; Natural rubber latex; Peptide; Sustained release; Biomaterial
ID CARRIER
AB The demand for biomaterials with properties that provide sustained release of substances with pharmacological interest is constant. One candidate for applications in this area is the Natural Rubber Latex (NRL) extracted from the rubber tree Hevea brasiliensis. Recent studies indicate the NRL as a matrix for sustained release, showing promising results for biomedical applications such as: can stimulate natural angiogenesis and is capable of adhering cells on its surface, promoting the replacement and regeneration of tissue. So, the NRL is an excellent candidate to propitiate the sustained release of peptides of pharmacological interest such as oxytocin, a hormonal peptide which has the function to promote uterine muscle contractions and reduce bleeding during childbirth, and stimulate the release of breast milk. Results demonstrated that 90 mu g mL(-1) (45 %) of the incorporated peptide in Natural Rubber Latex Biomedical (NRLb) functionalized membranes was released at 10 h in phosphate-buffered saline (PBS) solution. Swelling kinetics assay showed that the NRLb membranes are able to absorb over a period of 16 h up to 1.08 grams of water per grams of membrane. Scanning electron microscopy showed that the peptide was adsorbed on the surface and within NRLb membrane. Fourier transform infrared and Derivative Thermogravimetric analysis indicated that oxytocin did not interacted chemically with the membrane. Furthermore, hemolysis of erythrocytes, quantified spectrophotometrically using materials (Oxytocin, NRLb, and NRLb + Oxytocin) showed no hemolytic effects up to 100 mu g mL(-1) (compounds and mixtures), indicating no detectable disturbance of the red blood cell membranes. Based on these results it was possible to conclude that the NRLb has shown effectiveness as a model in the release of peptides with pharmacological interest.
C1 [de Barros, Natan Roberto; Romeiro Miranda, Matheus Carlos; Borges, Felipe Azevedo; Cilli, Eduardo Maffud] Sao Paulo State Univ, Inst Chem, 55 Prof Francisco Degni St, BR-14800060 Araraquara, SP, Brazil.
   [de Mendonca, Ricardo Jose] UFTM ICBN, Biochem Sect, 330 Manoel Mendes Sq, BR-38015050 Uberaba, MG, Brazil.
   [Herculano, Rondinelli Donizetti] Sao Paulo State Univ, Fac Pharmaceut Sci, Km01 Araraquara Jau Rd, BR-14801902 Araraquara, SP, Brazil.
RP de Barros, NR (reprint author), Sao Paulo State Univ, Inst Chem, 55 Prof Francisco Degni St, BR-14800060 Araraquara, SP, Brazil.
EM natan501@hotmail.com
FU CAPES; CNPq; FAPESP [2014/17526-8, 2015/02343-8]
FX This work was supported by CAPES, CNPq and FAPESP (Processes
   2014/17526-8, 2015/02343-8).
CR Aielo PB, 2014, MATER RES-IBERO-AM J, V17, P146, DOI [10.1590/S1516-14392014005000010, 10.1590/S1516-14392014000700024]
   Allarcon Jorge Barrios, 2003, Rev Bras Anestesiol, V53, P89, DOI 10.1590/S0034-70942003000100012
   Alves COM, 2003, TESTE ANGIOGENESE ES
   Barros NR, 2015, J MAT, DOI [10.1155/2015/807948, DOI 10.1155/2015/807948]
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Blaabjerg MSB, 2015, CONTACT DERMATITIS, V73, P21, DOI 10.1111/cod.12386
   Borges FA, 2014, ISRN POLYM SCI, DOI [10.1155/2014/241297, DOI 10.1155/2014/241297]
   Borges FA, 2015, J BIOMAT SCI-POLYM E, V26, P1256, DOI 10.1080/09205063.2015.1086945
   Bozkurt O, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.076023
   Costa PJC, 2002, BRAS CIENC FARM REV, DOI [10.1590/S1516-93322002000200003, DOI 10.1590/S1516-93322002000200003]
   D'Auzac J, 1989, PHYSL RUBBER TREE CO
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   Ereno C, 2010, J BIOMED MATER RES A, V95A, P932, DOI 10.1002/jbm.a.32919
   Ferreira M, 2009, BRAZ J PHYS, V39, P564, DOI 10.1590/S0103-97332009000500010
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Frade MAC, 2004, MED CUTAN IBER LAT A, V32, P157
   Guidelli EJ, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1536-2
   HASMA H, 1986, Journal of Natural Rubber Research, V1, P30
   Herculano RD, 2011, MAT SCI ENG C-MATER, V31, P272, DOI 10.1016/j.msec.2010.09.007
   Herculano RD, 2010, MATER RES-IBERO-AM J, V13, P57, DOI 10.1590/S1516-14392010000100013
   Herculano RD, 2009, MATER RES-IBERO-AM J, V12, P253, DOI 10.1590/S1516-14392009000200023
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168-3659(01)00248-6
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   McMahan C, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.42051
   Mendonca RJ, 2010, PHYTOTHER RES, V24, P764, DOI 10.1002/ptr.3043
   Miranda M., 2014, THESIS
   Mrue Fatima, 2004, Mat. Res., V7, P277, DOI 10.1590/S1516-14392004000200010
   Murbach HD, 2014, INT J BIOMATER, DOI [10.1155/2014/157952, DOI 10.1155/2014/157952]
   Neda I, 2012, PEPTIDE AMINO ACIDS, DOI [10.5772/51619, DOI 10.5772/51619]
   Onuma Y, 1999, TOXICON, V37, P55, DOI 10.1016/S0041-0101(98)00133-0
   Pichayakorn W, 2012, J MEMBRANE SCI, V411, P81, DOI 10.1016/j.memsci.2012.04.017
   Pinho Erika Christina Canarim M. de, 2004, Arq. Bras. Oftalmol., V67, P27, DOI 10.1590/S0004-27492004000100005
   Romeira K. M., 2012, Journal of Applied Sciences, V12, P693, DOI 10.3923/jas.2012.693.697
   Salamon BF, 2011, THESIS
   Steingräber Talita, 2008, Rev. colomb. cienc. quim. farm., V37, P122
   Thote AJ, 2005, DRUG DEV IND PHARM, V31, P43, DOI 10.1081/DDC-200043985
   Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x
   WHO, 2015, WHO MOD LIST ESS MED
NR 38
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1573-3149
EI 1573-3904
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
PD DEC
PY 2016
VL 22
IS 4
BP 435
EP 444
DI 10.1007/s10989-016-9523-y
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DZ7VP
UT WOS:000386076400001
ER

PT J
AU Stauffer, CS
   Musinipally, V
   Suen, A
   Lynch, KL
   Shapiro, B
   Woolley, JD
AF Stauffer, Christopher S.
   Musinipally, Vivek
   Suen, Angela
   Lynch, Kara L.
   Shapiro, Brad
   Woolley, Joshua D.
TI A two-week pilot study of intranasal oxytocin for cocaine-dependent
   individuals receiving methadone maintenance treatment for opioid use
   disorder
SO ADDICTION RESEARCH & THEORY
LA English
DT Article
DE Cocaine; social; addiction; methadone; oxytocin
ID TREATMENT RETENTION; SOCIAL ATTACHMENT; OPIATE ADDICTION; DRUG-USERS;
   STRESS; SEEKING; ASSOCIATION; IMPLICIT; BEHAVIOR; HEROIN
AB About 30-60% of the patients receiving methadone for opioid use disorder (OUD) actively use cocaine. Cocaine use disorder (CUD) has no FDA-approved pharmacological treatment; existing psychosocial treatments are inadequate. Oxytocin (OT), a social neuropeptide, has preclinical promise as an adjunctive treatment for both OUD and CUD. Twenty-two individuals receiving methadone for OUD with co-occurring CUD were randomized to receive OT or placebo intranasally 40IU twice daily for two weeks. A priori aims were feasibility and safety. Exploratory effectiveness aims included laboratory-based measures of drug craving, drug-related implicit cognition, and drug use. High retention rates (93.5%), the absence of study-related adverse events, and the fact that OT was well tolerated in this population support the feasibility of larger trials. Two weeks of OT (but not placebo) significantly reduced cocaine craving at day 15 compared to baseline (mean change +/- SD: OT=-0.23 +/- 0.19, p=0.004; PL=-0.16 +/- 0.29, p=0.114). For heroin craving, the placebo group reported a trend-level increase over time while the OT group remained unchanged - with medium to large effect sizes between the groups (Cohen's d=0.71-0.90). OT led to a significant switch from implicit self-association with drugs to implicitly associating drugs with others (mean change +/- SD: 0.25 +/- 0.35, p=0.037) and a trend-level reduction in self-reported cocaine use over time (Z=-1.78, p=0.075). Furthermore, OT significantly increased the accuracy of self-reported cocaine use when correlated with quantitative urine levels of cocaine metabolite. This proof-of-concept study provides promising early evidence that OT may be an effective adjunct to the treatment of co-occurring CUD and OUD. Further investigation with larger trials is warranted.
C1 [Stauffer, Christopher S.; Shapiro, Brad; Woolley, Joshua D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Stauffer, Christopher S.; Musinipally, Vivek; Woolley, Joshua D.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA.
   [Musinipally, Vivek; Suen, Angela] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   [Lynch, Kara L.] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA 94143 USA.
RP Stauffer, CS (reprint author), 4150 Clement St 116-C, San Francisco, CA 94121 USA.
EM christopher.stauffer@ucsf.edu
FU San Francisco Treatment Research Center at the University of California,
   San Francisco from National Institute on Drug Abuse [P50 DA009253];
   National Institute of Mental Health [R25 MH060482]
FX This project was supported by the San Francisco Treatment Research
   Center at the University of California, San Francisco via grant number
   P50 DA009253 from the National Institute on Drug Abuse. Additional
   support was provided by the National Institute of Mental Health via
   grant number R25 MH060482.
CR ALEXANDER BK, 1982, PSYCHOL BULL, V92, P367, DOI 10.1037/0033-2909.92.2.367
   Bart G, 2012, J ADDICT DIS, V31, P207, DOI 10.1080/10550887.2012.694598
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bentzley BS, 2014, P NATL ACAD SCI USA, V111, P11822, DOI 10.1073/pnas.1406324111
   Best D, 2016, ADDICT RES THEORY, V24, P111, DOI 10.3109/16066359.2015.1075980
   Bisagno V, 2014, BEHAV PHARMACOL, V25, P445, DOI 10.1097/FBP.0000000000000049
   Cacciola JS, 2007, DRUG ALCOHOL DEPEN, V87, P297, DOI 10.1016/j.drugalcdep.2006.09.002
   Cardoso C, 2014, PSYCHONEUROENDOCRINO, V49, P161, DOI 10.1016/j.psyneuen.2014.07.014
   CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561
   de la Fuente L, 2014, J SUBST ABUSE TREAT, V46, P219, DOI 10.1016/j.jsat.2013.07.001
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   Everitt BJ, 2014, EUR J NEUROSCI, V40, P2163, DOI 10.1111/ejn.12644
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Greenwald AG, 2003, J PERS SOC PSYCHOL, V85, P197, DOI 10.1037/0022-3514.85.2.197
   Grillon C, 2013, MOL PSYCHIATR, V18, P958, DOI 10.1038/mp.2012.156
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Heinz AJ, 2006, J SUBST ABUSE TREAT, V31, P355, DOI 10.1016/j.jsat.2006.05.009
   Hofmann SG, 2015, PSYCHIAT RES, V228, P708, DOI 10.1016/j.psychres.2015.05.039
   Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3
   Lan KC, 2009, J NEUROCHEM, V109, P382, DOI 10.1111/j.1471-4159.2009.05998.x
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   Lieberwirth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00171
   Lin SH, 2015, NEUROPSYCHOBIOLOGY, V71, P65, DOI 10.1159/000371637
   Lynch KL, 2011, J ANAL TOXICOL, V35, P176
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Mantsch JR, 2016, NEUROPSYCHOPHARMACOL, V41, P335, DOI 10.1038/npp.2015.142
   Marhe R, 2013, J CONSULT CLIN PSYCH, V81, P1, DOI 10.1037/a0030754
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Morales-Rivera A, 2014, PSYCHOPHARMACOLOGY, V231, P4145, DOI 10.1007/s00213-014-3553-y
   Myers AJ, 2014, J PSYCHIATR RES, V59, P93, DOI 10.1016/j.jpsychires.2014.08.021
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Preston KL, 1996, PSYCHOPHARMACOLOGY, V123, P15, DOI 10.1007/BF02246276
   Robins LN, 2010, AM J ADDICTION, V19, P203, DOI 10.1111/j.1521-0391.2010.00046.x
   Rooke SE, 2008, ADDICT BEHAV, V33, P1314, DOI 10.1016/j.addbeh.2008.06.009
   Rowan-Szal GA, 2000, ADDICT RES, V8, P51, DOI 10.3109/16066350009004409
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   Siqueland L, 2002, AM J ADDICTION, V11, P24, DOI 10.1080/10550490252801611
   Stauffer CS, 2014, J CLIN PSYCHIAT, V75, P1028, DOI 10.4088/JCP.14ac09437
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   Tops M, 2014, PHARMACOL BIOCHEM BE, V119, P39, DOI 10.1016/j.pbb.2013.07.015
   Weinstock J, 2010, PSYCHOL ADDICT BEHAV, V24, P282, DOI 10.1037/a0017542
   White WL, 2014, J PSYCHOACTIVE DRUGS, V46, P114, DOI 10.1080/02791072.2014.901587
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
NR 46
TC 0
Z9 0
U1 6
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1606-6359
EI 1476-7392
J9 ADDICT RES THEORY
JI Addict. Res. Theory
PD DEC
PY 2016
VL 24
IS 6
BP 490
EP 498
DI 10.3109/16066359.2016.1173682
PG 9
WC Substance Abuse; Social Issues
SC Substance Abuse; Social Issues
GA DZ4RW
UT WOS:000385848200008
ER

PT J
AU Hamou, B
   Wainstock, T
   Mastrolia, SA
   Beer-Weisel, R
   Staretz-Chacham, O
   Dukler, D
   Rafaeli-Yehudai, T
   Mazor, M
   Erez, O
AF Hamou, Batel
   Wainstock, Tamar
   Mastrolia, Salvatore Andrea
   Beer-Weisel, Ruthy
   Staretz-Chacham, Orna
   Dukler, Doron
   Rafaeli-Yehudai, Tal
   Mazor, Moshe
   Erez, Offer
TI Induction of labor in twin gestation: lessons from a population based
   study
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Cesarean delivery; Foley catheter; oxytocin; prostaglandins; term
   pregnancy
ID PERINATAL-MORTALITY; CESAREAN DELIVERY; ELECTIVE INDUCTION;
   RANDOMIZED-TRIAL; PREGNANCIES; TERM; WOMEN; COMPLICATIONS; MORBIDITY;
   SINGLETON
AB Introduction: The route of delivery and the role of induction of labor in twin gestations are controversial. The aim of this study was to determine the efficacy of induction of labor in twin gestations.Methods: This retrospective population based cohort study included 4605 twin gestations divided into following groups: 1) spontaneous parturition (n=2937, 63.78%); 2) induction of labor (n=653, 14.2%) and 3) elective cesarean delivery (n=1015, 22.04%).Results: The rate of vaginal delivery in the labor induction group was 81% (529/653). In comparison to the other study groups, induction of labor in twins was independently associated with a 77% reduction in the risk of cesarean delivery (OR 0.23; 95% CI 0.18-0.31) and a 78% reduction in the risk of postpartum death for the second twin (OR 0.22; 95% CI 0.05-0.94). The rate of nulliparity, term delivery and labor dystocia was higher in the induction of labor group (p<0.001 in all comparisons).Conclusions: Our results suggest that induction of labor in twin gestation is successful and is independently associated with substantial reduction in the risk of cesarean delivery and postpartum death of the second twin.
C1 [Hamou, Batel; Mastrolia, Salvatore Andrea; Beer-Weisel, Ruthy; Dukler, Doron; Rafaeli-Yehudai, Tal; Mazor, Moshe] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Obstet & Gynecol, Sch Med,Fac Hlth Sci, Beer Sheva, Israel.
   [Wainstock, Tamar] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Epidemiol, Beer Sheva, Israel.
   [Mastrolia, Salvatore Andrea] Univ Bari Aldo Moro, Azienda Osped Univ Policlin Bari, Sch Med, Dept Obstet & Gynecol, Bari, Italy.
   [Staretz-Chacham, Orna] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Fac Hlth Sci, Dept Neonatol,Sch Med, Beer Sheva, Israel.
   [Erez, Offer] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Fac Hlth Sci, Matern Dept D,Obstet Day Care Unit, Beer Sheva, Israel.
RP Erez, O (reprint author), Soroka Univ Med Ctr, Obstet Day Care Unit, Matern Dept D, POB 151, IL-84101 Beer Sheva, Israel.
EM erezof@bgu.ac.il
CR Ananth C V, 2004, J Matern Fetal Neonatal Med, V15, P380, DOI 10.1080/14767058410001727413
   Barrett JFR, 2013, NEW ENGL J MED, V369, P1295, DOI 10.1056/NEJMoa1214939
   Chauhan SP, 2010, AM J OBSTET GYNECOL, V203, P305, DOI 10.1016/j.ajog.2010.04.031
   Cheung YB, 2000, AM J EPIDEMIOL, V152, P1107, DOI 10.1093/aje/152.12.1107
   Cincotta RP, 2001, SCIENCE, V294, P525, DOI 10.1126/science.1063403
   Clarke J., 1786, REGISTER PHIL T R SO, V76, P349
   Crosignani PG, 2000, HUM REPROD, V15, P1856
   Dawood MY, 1996, AM J OBSTET GYNECOL, V174, P1208, DOI 10.1016/S0002-9378(96)70663-4
   Denbow ML, 2000, AM J OBSTET GYNECOL, V182, P417, DOI 10.1016/S0002-9378(00)70233-X
   Dodd JM, 2012, BJOG-INT J OBSTET GY, V119, P964, DOI 10.1111/j.1471-0528.2012.03356.x
   Dodd JM, 2003, AM J OBSTET GYNECOL, V189, P1731, DOI 10.1016/S0002-9378(03)00854-8
   Fellman J, 2009, TWIN RES HUM GENET, V12, P183, DOI 10.1375/twin.12.2.183
   Hack KE, 2008, BJOG-INT J OBSTET GY, V115, P58, DOI 10.1111/j.1471-0528.2007.01556.x
   Hack KEA, 2011, BJOG-INT J OBSTET GY, V118, P1090, DOI 10.1111/j.1471-0528.2011.02955.x
   Hamilton BE, 2007, NATL VITAL STAT REPO, V57
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Hartley RS, 2001, AM J OBSTET GYNECOL, V184, P451, DOI 10.1067/mob.2001.109399
   Joseph KS, 2003, OBSTET GYNECOL, V102, P791, DOI 10.1016/S0029-7844(03)00620-3
   LUKE B, 1993, AM J OBSTET GYNECOL, V169, P588
   Martin JA, 2012, NCHS DATA BRIEF, V80, P1
   Martin Joyce A, 2003, Natl Vital Stat Rep, V52, P1
   Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753
   Maslow AS, 2000, OBSTET GYNECOL, V95, P917, DOI 10.1016/S0029-7844(00)00794-8
   Minakami H, 1996, JAMA-J AM MED ASSOC, V275, P1432, DOI 10.1001/jama.275.18.1432
   Mizrahi M, 1999, EUR J OBSTET GYN R B, V87, P55, DOI 10.1016/S0301-2115(99)00075-5
   Onyiriuka AN, 2003, NIG Q J HOSP MED, V16, P88
   PRN-foundation, 2004, PER CAR NETH 2004
   Rao A, 2004, BEST PRACT RES CL OB, V18, P557, DOI 10.1016/j.bpobgyn.2004.04.007
   Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4
   Spong CY, 2011, OBSTET GYNECOL, V118, P323, DOI 10.1097/AOG.0b013e3182255999
   Tan TYT, 2003, ULTRASOUND OBST GYN, V22, P409, DOI 10.1002/uog.224
   Taylor M, 2012, OBSTET GYNECOL, V120, P297, DOI 10.1097/AOG.0b013e31825f3643
   Warner BB, 2000, CLIN PERINATOL, V27, P347, DOI 10.1016/S0095-5108(05)70025-7
   [Anonymous], 2013, OBSTET GYNECOL, V121, P908
NR 34
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD DEC
PY 2016
VL 29
IS 24
BP 3999
EP 4007
DI 10.3109/14767058.2016.1152252
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX8ZF
UT WOS:000384680900013
PM 26864351
ER

PT J
AU Bershad, AK
   Weafer, JJ
   Kirkpatrick, MG
   Wardle, MC
   Miller, MA
   de Wit, H
AF Bershad, Anya K.
   Weafer, Jessica J.
   Kirkpatrick, Matthew G.
   Wardle, Margaret C.
   Miller, Melissa A.
   de Wit, Harriet
TI Oxytocin receptor gene variation predicts subjective responses to MDMA
SO SOCIAL NEUROSCIENCE
LA English
DT Article
DE MDMA; oxytocin; OXTR; social behavior
ID POSTTRAUMATIC-STRESS-DISORDER;
   3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; OXTR; HUMANS;
   ECSTASY; POLYMORPHISM; SUPPORT; INTERACT; DISTRESS; DRUGS
AB 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) enhances desire to socialize and feelings of empathy, which are thought to be related to increased oxytocin levels. Thus, variation in the oxytocin receptor gene (OXTR) may influence responses to the drug. Here, we examined the influence of a single OXTR nucleotide polymorphism (SNP) on responses to MDMA in humans. Based on findings that carriers of the A allele at rs53576 exhibit reduced sensitivity to oxytocin-induced social behavior, we hypothesized that these individuals would show reduced subjective responses to MDMA, including sociability. In this three-session, double blind, within-subjects study, healthy volunteers with past MDMA experience (N=68) received a MDMA (0, 0.75mg/kg, and 1.5mg/kg) and provided self-report ratings of sociability, anxiety, and drug effects. These responses were examined in relation to rs53576. MDMA (1.5mg/kg) did not increase sociability in individuals with the A/A genotype as it did in G allele carriers. The genotypic groups did not differ in responses at the lower MDMA dose, or in cardiovascular or other subjective responses. These findings are consistent with the idea that MDMA-induced sociability is mediated by oxytocin, and that variation in the oxytocin receptor gene may influence responses to the drug.
C1 [Bershad, Anya K.; Weafer, Jessica J.; Miller, Melissa A.; de Wit, Harriet] Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC3077, Chicago, IL 60637 USA.
   [Bershad, Anya K.] Univ Chicago, Interdisciplinary Scientist Training Program, Chicago, IL 60637 USA.
   [Kirkpatrick, Matthew G.] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA.
   [Wardle, Margaret C.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP de Wit, H (reprint author), Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave,MC3077, Chicago, IL 60637 USA.
EM hdew@uchicago.edu
FU National Institute on Drug Abuse [R01 DA002182, R21 DA026570]; National
   Institute of General Medical Sciences [2T32GM007281]
FX This work was supported by grants from the National Institute on Drug
   Abuse [grant numbers R01 DA002182 and R21 DA026570] to H. de Wit. Anya
   K. Bershad was supported by a grant from the National Institute of
   General Medical Sciences [2T32GM007281].
CR Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Bedi G, 2009, PSYCHOPHARMACOLOGY, V207, P73, DOI 10.1007/s00213-009-1635-z
   Bravo G. L., 2001, ECSTASY COMPLETE GUI
   Chen FS, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.163
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Doblin R, 2002, J PSYCHOACTIVE DRUGS, V34, P185
   Dumont GJH, 2009, SOC NEUROSCI-UK, V4, P359, DOI 10.1080/17470910802649470
   First MB, 1996, STRUCTURED CLIN INTE
   FISCHMAN MW, 1991, BRIT J ADDICT, V86, P1563
   GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319
   Grewen KM, 2005, PSYCHOSOM MED, V67, P531, DOI 10.1097/01.psy.0000170341.88395.47
   GRINSPOON L, 1986, AM J PSYCHOTHER, V40, P393
   Han Dawn D., 2006, BMC Pharmacology, V6, P6, DOI 10.1186/1471-2210-6-6
   Hart AB, 2013, NEUROPSYCHOPHARMACOL, V38, P802, DOI 10.1038/npp.2012.245
   Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161
   Hysek CM, 2012, PSYCHOPHARMACOLOGY, V222, P293, DOI 10.1007/s00213-012-2645-9
   Jostins L, 2012, P NATL ACAD SCI USA, V109, pE1048, DOI 10.1073/pnas.1202539109
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krueger F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00004
   Kuypers KPC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100719
   Lucht MJ, 2009, PROG NEURO-PSYCHOPH, V33, P860, DOI 10.1016/j.pnpbp.2009.04.004
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   McQuaid RJ, 2015, SOC COGN AFFECT NEUR, V10, P1153, DOI 10.1093/scan/nsu166
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371
   Norman GJ, 2011, J PSYCHOPHARMACOL, V25, P1313, DOI 10.1177/0269881110367452
   Riedlinger J., 2001, ECSTASY COMPLETE GUI
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Sumnall HR, 2006, J PSYCHOPHARMACOL, V20, P670, DOI 10.1177/0269881106060764
   Ter Bogt TFM, 2005, SUBST USE MISUSE, V40, P1479, DOI 10.1081/JA-200066822
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   Thompson MR, 2009, SOC NEUROSCI, V4, P60, DOI 10.1080/17470910802045042
   Tops Mattie, 2011, Front Psychiatry, V2, P60, DOI 10.3389/fpsyt.2011.00060
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Verrico CD, 2007, PSYCHOPHARMACOLOGY, V189, P489, DOI 10.1007/s00213-005-0174-5
   Wardle MC, 2014, SOC COGN AFFECT NEUR, V9, P1076, DOI 10.1093/scan/nsu035
   Wardle MC, 2014, PSYCHOPHARMACOLOGY B, V231, P1
   White TL, 2002, PHARMACOL BIOCHEM BE, V73, P729, DOI 10.1016/S0091-3057(02)00818-3
NR 43
TC 0
Z9 0
U1 8
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1747-0919
EI 1747-0927
J9 SOC NEUROSCI-UK
JI Soc. Neurosci.
PD DEC
PY 2016
VL 11
IS 6
BP 592
EP 599
DI 10.1080/17470919.2016.1143026
PG 8
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA DX9DW
UT WOS:000384694800003
PM 26787430
ER

PT J
AU Li, YW
   Shi, YH
   Lu, JQ
   Ji, WH
   Wang, ZL
AF Li, Yangwei
   Shi, Yuhua
   Lu, Jiqi
   Ji, Weihong
   Wang, Zhenlong
TI Sequence and phylogenetic analysis of the complete mitochondrial genome
   of Lasiopodomys mandarinus mandarinus (Arvicolinae, Rodentia)
SO GENE
LA English
DT Article
DE Mitochondrial genome; Mandarin voles; Phylogenetic relationships
ID CYTOCHROME-B; MICROTUS-MANDARINUS; MAXIMUM-LIKELIHOOD; VOLES; DNA;
   EVOLUTION; RADIATION; OXYTOCIN; RNA; DIVERSIFICATION
AB Mandarin vole (Lasiopodomys mandarinus) is a subterranean rodent that is often used as a model for studying subterranean hypoxic stress in mammals. However the taxonomy of this species is still in dispute. Mitochondrial DNA (mtDNA) has long been used for phylogenetic reconstruction and, in this study, the complete mitochondria! genome of L mandarinus mandarinus was sequenced. Our results showed that the mitochondrial genome of L m. mandarinus is a circular molecule of 16,367 bp, which contains 13 protein-coding genes, 22 tRNA and 2 rRNA genes. Except for the 8 tRNA and ND6 genes, all other mitochondrial genes are encoded on the heavy strand. We also analyzed the phylogenetic position of L mandarinus in respect to the tribe Arvicolini using the sequence of complete Cytb gene, 2rRNA genes and 12 protein-coding genes, and maximum likelihood and Bayesian methods. Our results gave further support to the species status of L mandarinus and the generic status of Lasiopodomys. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Li, Yangwei; Shi, Yuhua; Lu, Jiqi; Wang, Zhenlong] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China.
   [Ji, Weihong] Massey Univ, Inst Nat Sci, North Shore Mail Ctr, Auckland 0632, New Zealand.
RP Wang, ZL (reprint author), Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China.
EM wzl@zzu.edu.cn
FU National Natural Science Foundation of China [31372193]; Foundation of
   Henan Educational Committee [13A180717]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 31372193), and the Foundation of Henan Educational
   Committee (Grant No. 13A180717).
CR Allen G. M., 1938, MAMMALS CHINA MONGOL
   Altekar G, 2004, BIOINFORMATICS, V20, P407, DOI 10.1093/bioinformatics/btg427
   AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.ecolsys.18.1.489
   Bannikova AA, 2010, BIOL J LINN SOC, V99, P595
   Cong H., 2014, MITOCHONDR DNA, P1
   Corbet G. B., 1978, MAMMALS PALAEARCTIC
   Cunha RL, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-210
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Fernandez-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Fink S, 2010, SYST BIOL, V59, P548, DOI 10.1093/sysbio/syq042
   Galewski T, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-80
   Goodson JL, 2015, PHYSIOL BEHAV, V141, P154, DOI 10.1016/j.physbeh.2015.01.016
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hinton M. A. C., 1926, MONOGRAPH VOLES LEMM
   HIXSON JE, 1986, J BIOL CHEM, V261, P2384
   IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385
   Jia R, 2008, PHYSIOL BEHAV, V95, P56, DOI 10.1016/j.physbeh.2008.04.015
   Krebs C, 2014, INTEGR ZOOL, V9, P229, DOI 10.1111/1749-4877.12090
   Lanfear R, 2012, MOL BIOL EVOL, V29, P1695, DOI 10.1093/molbev/mss020
   Liu B, 2010, COMP BIOCHEM PHYS A, V156, P469, DOI 10.1016/j.cbpa.2010.03.034
   Liu ZJ, 2011, MITOCHONDR DNA, V22, P174, DOI 10.3109/19401736.2011.636438
   Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955
   Lu XF, 2014, INTEGR ZOOL, V9, P231, DOI 10.1111/1749-4877.12035
   Mardulyn P, 1999, MOL PHYLOGENET EVOL, V12, P282, DOI 10.1006/mpev.1999.0618
   Martinkova N, 2012, FOLIA ZOOL, V61, P254
   May-Collado L, 2006, MOL PHYLOGENET EVOL, V38, P344, DOI 10.1016/j.ympev.2005.09.019
   Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550
   Nowak RM, 1983, WALKERS MAMMALS WORL
   O'Leary MA, 2013, SCIENCE, V339, P662, DOI 10.1126/science.1229237
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   Palombo MR, 2014, INTEGR ZOOL, V9, P107, DOI 10.1111/1749-4877.12088
   Perea-Rodriguez JP, 2015, J NEUROENDOCRINOL, V27, P245, DOI 10.1111/jne.12264
   Pereira SL, 2000, GENET MOL BIOL, V23, P745, DOI 10.1590/S1415-47572000000400008
   Petrova TV, 2015, J ZOOL SYST EVOL RES, V53, P97, DOI 10.1111/jzs.12082
   Robovsky J, 2008, ZOOL SCR, V37, P571, DOI 10.1111/j.1463-6409.2008.00342.x
   Ronquist F., 2011, MRBAYES VER IN PRESS
   Shenbrot G.I., 2005, ATLAS GEOGRAPHIC DIS
   Sulaiman ZH, 2006, INTEGR ZOOL, V1, P12, DOI 10.1111/j.1749-4877.2006.00005.x
   Tai FD, 2000, CAN J ZOOL, V78, P2119
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Wang JX, 2003, HEREDITAS, V138, P47, DOI 10.1034/j.1601-5223.2003.01615.x
   Wang Tingzheng, 1995, Acta Theriologica Sinica, V15, P302
   Wu RY, 2014, NEUROENDOCRINOLOGY, V100, P119, DOI 10.1159/000366441
   Wyman SK, 2004, BIOINFORMATICS, V20, P3252, DOI 10.1093/bioinformatics/bth352
   Zhang Yue, 1997, Zoological Research, V18, P397
   Zhang Z. B., 1998, ECOLOGY MANAGEMENT R, P64
NR 46
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD NOV 30
PY 2016
VL 593
IS 2
BP 302
EP 307
DI 10.1016/j.gene.2016.08.035
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA DY7RS
UT WOS:000385327600008
PM 27562081
ER

PT J
AU Brugada-Ramentol, V
   de Polavieja, GG
   Roman, AC
AF Brugada-Ramentol, Victoria
   de Polavieja, Gonzalo G.
   Roman, Angel-Carlos
TI Toward a Molecular Profile of Self-Representation
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE self-representation; OMICS techniques; sense of agency; sense of
   ownership; proteomics
ID RUBBER HAND ILLUSION; MULTISENSORY BRAIN; ANOREXIA-NERVOSA;
   VIRTUAL-REALITY; BODY OWNERSHIP; OXYTOCIN; EMBODIMENT; PERCEPTION;
   MUTATIONS; ARM
AB Feeling embodiment over our body or body part has a major role in the understanding of the self and control of self-actions. Even though it is crucial in our daily life, embodiment is not an homogenous phenotype across population, as quantified by implicit and explicit measures (i.e., neuroimaging or self-reports). Studies have shown differences in neuropathological conditions compared to healthy controls, but also across healthy individuals. We discuss examples of self-perception differences, and the molecular origin of embodiment, focusing on clinical cases, during the first and second section. We then discuss two important questions in this molecular-to-embodiment relationship: (i) which are the molecular levels (and their associated techniques) that can be relevant to embodiment, and (ii) which are the most adequate experiments to correlate molecular profiles and embodiment quantification across individuals. Potential answers for both questions will be outlined during the third and fourth sections, respectively, in order to design a framework to study the molecular profile of body embodiment.
C1 [Brugada-Ramentol, Victoria; de Polavieja, Gonzalo G.; Roman, Angel-Carlos] Fundacao Champalimaud, Collect Behav Lab, Champailmaud Res, Lisbon, Portugal.
RP de Polavieja, GG; Roman, AC (reprint author), Fundacao Champalimaud, Collect Behav Lab, Champailmaud Res, Lisbon, Portugal.
EM gonzalo.polavieja@neuro.fchampalimaud.org;
   angelfoman@neuro.fchampalimaud.org
FU Fundacao para a Ciencia e Tecnologia [PTDC/NEU-SCC/0948/2014];
   Champalimaud Research (Portugal); FEBS long-term postdoctoral
   fellowship; Fundacao para a Ciencia e Tecnologia Ph.D. fellowship
   [SFRH/BD/52201/2013]
FX We acknowledge funding from the Fundacao para a Ciencia e Tecnologia
   (PTDC/NEU-SCC/0948/2014) and the Champalimaud Research (Portugal) to
   GGdP, from a FEBS long-term postdoctoral fellowship to ACR, and from
   Fundacao para a Ciencia e Tecnologia Ph.D. fellowship to VBR
   SFRH/BD/52201/2013).
CR Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bond RL, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00097
   Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784
   Conson M, 2015, AUTISM RES, V8, P454, DOI 10.1002/aur.1460
   Cui HX, 2013, J CLIN INVEST, V123, P4706, DOI 10.1172/JCI71400
   Downey LE, 2014, J NEUROL NEUROSUR PS, V85, P1016, DOI 10.1136/jnnp-2013-306995
   Ehrsson HH, 2005, J NEUROSCI, V25, P10564, DOI 10.1523/JNEUROSCI.0800-05.2005
   Gallagher S, 2000, TRENDS COGN SCI, V4, P14, DOI 10.1016/S1364-6613(99)01417-5
   Garbarini F, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00043
   Garbarini F, 2015, NEUROPSYCHOLOGIA, V70, P402, DOI 10.1016/j.neuropsychologia.2014.11.008
   Ge H, 2003, TRENDS GENET, V19, P551, DOI 10.1016/j.tig.2003.08.009
   Haans A, 2008, BODY IMAGE, V5, P389, DOI 10.1016/j.bodyim.2008.04.003
   Heinzen EL, 2012, NAT GENET, V44, P1030, DOI 10.1038/ng.2358
   Ivanisevic J, 2014, CHEM BIOL, V21, P1575, DOI 10.1016/j.chembiol.2014.09.016
   Keizer A, 2012, PSYCHIAT RES, V200, P530, DOI 10.1016/j.psychres.2012.05.001
   Keizer A, 2011, PSYCHIAT RES, V190, P115, DOI 10.1016/j.psychres.2011.04.031
   Kilteni K, 2012, PRESENCE-TELEOP VIRT, V21, P373
   Lenggenhager B, 2007, SCIENCE, V317, P1096, DOI 10.1126/science.1143439
   Lenzenweger MF, 2000, SCHIZOPHR RES, V42, P111, DOI 10.1016/S0920-9964(99)00120-6
   Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4
   Miles E, 2011, J PSYCHOSOM RES, V71, P240, DOI 10.1016/j.jpsychores.2011.04.002
   Palmer CJ, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.1557
   Parsons TD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00660
   Petkova VI, 2011, CURR BIOL, V21, P1118, DOI 10.1016/j.cub.2011.05.022
   Piomelli D, 2007, NAT REV NEUROSCI, V8, P743, DOI 10.1038/nrn2233
   Puglia MH, 2015, P NATL ACAD SCI USA, V112, P3308, DOI 10.1073/pnas.1422096112
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549
   Slater M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010564
   Slater M, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.006.2008
   Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948
   Tsakiris M, 2005, J EXP PSYCHOL HUMAN, V31, P80, DOI 10.1037/0096-1523.31.1.80
   Wey HY, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7551
   Wu Y, 2013, BIOL PSYCHOL, V92, P179, DOI 10.1016/j.biopsycho.2012.11.011
   Yeh HH, 2013, NEUROIMAGE, V64, P630, DOI 10.1016/j.neuroimage.2012.09.019
NR 35
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD NOV 28
PY 2016
VL 10
AR 602
DI 10.3389/fnhum.2016.00602
PG 5
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA EC9ZG
UT WOS:000388502200001
ER

PT J
AU Trofimova, IN
   Sulis, W
AF Trofimova, Irina N.
   Sulis, William
TI A Study of the Coupling of FET Temperament Traits with Major Depression
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE Major Depression; temperament profiles; DSM/ICD descriptors; FET
   framework; sex differences; age differences
ID OPIOID-RECEPTOR GENE; PERSONALITY-TRAITS; ANXIETY DISORDERS; GENDER
   DIFFERENCES; TEMPORAL COURSE; MOOD DISORDERS; MODEL; CHARACTER;
   OXYTOCIN; BEHAVIOR
AB Objective: Temperament and mental illness have been linked to the same systems of behavioral regulation. A temperament model, carefully structured to respond to subtle differences within systems of behavior regulation, should exhibit distinct temperament patterns in the presence of mental illness. Previous comparisons of temperament profiles in mental disorders used mostly emotionality-related traits. In contrast, the Functional Ensemble of Temperament (FET) model differentiates not only between emotionality traits, but also between traits related to physical, verbal, and mental aspects of behavior and maps 12 functional aspects of behavior to temperament traits as well as to symptoms of mental illnesses. This article reports on the coupling of sex, age, and temperament traits with Major Depression (MD) using the FET framework.
   Method: Intake records of 467 subjects, ages 1724, 2545, 4665, 6684 were examined, with temperament assessed by the Structure of Temperament Questionnaire (based on the FET).
   Results: The presence of MD was associated with changes in mean temperament scores on 9 of the 12 traits. The results were in line with the DSM-5 criteria of fatigue (patients with MD reported a significant decrease in three types of endurance motor-physical, social-verbal, and mental), of psychomotor retardation (a significant decrease in physical and social-verbal tempo) and of worthlessness (as low Self-Confidence). The results also showed that three new symptoms, high Impulsivity, high Neuroticism, and diminished Plasticity, should be considered as depressive symptoms in future versions of the DSM. As a significant negative result, no interaction of age or sex (with the exception of the Self-Confidence scale) with MD was found for temperament traits.
   Conclusion: The value of differentiating between physical, social, and mental aspects of behavior is demonstrated in the differential effects of major depression and gender. The value of differentiating between endurance, dynamical and orientation-related aspects of behavior is also demonstrated. The deleterious impact of MD on temperament scores appeared to be similar across all age groups. The appearance of high impulsivity, neuroticism, and low plasticity deserve further study as associated factors in future versions of the DSM/ICD.
C1 [Trofimova, Irina N.; Sulis, William] McMaster Univ, Dept Psychiat & Behav Neurosci, Collect Intelligence Lab, Hamilton, ON, Canada.
RP Sulis, W (reprint author), McMaster Univ, Dept Psychiat & Behav Neurosci, Collect Intelligence Lab, Hamilton, ON, Canada.
EM sulisw@mcmaster.ca
CR Akiskal H. S., 1989, VALIDITY PSYCHIAT DI, P217
   Al-Halabi S, 2011, PSYCHIAT RES, V186, P397, DOI 10.1016/j.psychres.2010.07.021
   ALEXOPOULOS GS, 1993, AM J PSYCHIAT, V150, P1693
   Ball S. A., 1999, PERSONALITY, V106, P545, DOI [10.1037/0021-843X-1064545, DOI 10.1037/0021-843X.106.4.545]
   Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105
   Barraza JA, 2009, ANN NY ACAD SCI, V1167, P182, DOI 10.1111/j.1749-6632.2009.04504.x
   Bates J. E., 1994, TEMPERAMENT INDIVIDU
   Bennabi D., 2013, BIOMED RES INT, V2013, DOI [10.1155/2013/158746, DOI 10.1155/2013/158746]
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   Birren J., 2001, HDB PSYCHOL AGING
   Blazer D., 2009, TXB GERIATRIC PSYCHI
   BLOOM FE, 1983, PSYCHIAT CLIN N AM, V6, P365
   Bodnar RJ, 2010, PEPTIDES, V31, P2325, DOI 10.1016/j.peptides.2010.09.016
   Broom DC, 2002, NEUROPSYCHOPHARMACOL, V26, P744, DOI 10.1016/S0893-133X(01)00413-4
   Brown TA, 2007, J ABNORM PSYCHOL, V116, P313, DOI 10.1037/0021-843X.116.2.313
   Charmandari E, 2005, ANNU REV PHYSIOL, V67, P259, DOI 10.1146/annurev.physiol.67.040403.120816
   CLARK LA, 1994, J ABNORM PSYCHOL, V103, P103, DOI 10.1037//0021-843X.103.1.103
   Clark LA, 2005, J ABNORM PSYCHOL, V114, P505, DOI 10.1037/0021-843X.114.4.505
   Clark LA, 2006, BRIT J PSYCHIAT, V189, P481, DOI 10.1192/bjp.bp.106.03825
   CLONINGER CR, 1986, PSYCHIAT DEV, V4, P167
   COMER SD, 1993, J PHARMACOL EXP THER, V267, P888
   Costa PT, 2001, J PERS SOC PSYCHOL, V81, P322, DOI 10.1037/0022-3514.81.2.322
   Costa PT, 2005, J AFFECT DISORDERS, V89, P45, DOI 10.1016/j.jad.2005.06.010
   degli Uberti E C, 1995, J Endocrinol Invest, V18, P1
   Depue RA, 2005, BEHAV BRAIN SCI, V28, P313
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Elovainio M, 2004, J AFFECT DISORDERS, V83, P227, DOI 10.1016/j.jad.2004.06.005
   Filliol D, 2000, NAT GENET, V25, P195
   Gray J. A., 1982, NEUROPSYCHOLOGY ANXI
   Hansenne M, 1999, J PSYCHIAT RES, V33, P31, DOI 10.1016/S0022-3956(98)00036-3
   Harrington ME, 2012, PROG NEUROBIOL, V99, P93, DOI 10.1016/j.pneurobio.2012.07.004
   HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762
   Insel TR, 2014, AM J PSYCHIAT, V171, P395, DOI 10.1176/appi.ajp.2014.14020138
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452
   Josefsson K, 2013, DEV PSYCHOPATHOL, V25, P713, DOI 10.1017/S0954579413000126
   Jutkiewicz EM, 2005, PSYCHOPHARMACOLOGY, V182, P588, DOI 10.1007/s00213-005-0138-9
   Kagan J., 1994, GALENS PROPHECY TEMP
   Kampman O, 2012, EUR PSYCHIAT, V27, P245, DOI 10.1016/j.eurpsy.2010.07.006
   Kampman O, 2011, J AFFECT DISORDERS, V135, P20, DOI 10.1016/j.jad.2010.12.021
   Kandler C, 2013, DEV PSYCHOL, V49, P1739, DOI 10.1037/a0030744
   Karam EG, 2010, WORLD PSYCHIATRY, V9, P103
   Keverne EB, 2004, CURR OPIN NEUROBIOL, V14, P777, DOI 10.1016/j.conb.2004.10.006
   Klein W., 2011, ANNU REV CLIN PSYCHO, V7, P209
   Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI 10.1037/a0020327
   Krishnan V, 2010, AM J PSYCHIAT, V167, P1305, DOI 10.1176/appi.ajp.2009.10030434
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   Lu X., 2012, DEPRESS RES TREAT, V2012, DOI 10.1155/2012/604684
   Lutz PE, 2013, TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002
   Mehrabian A., 1995, IMAGINATION COGNITIO, V15, P133, DOI [10.2190/JB3J-U.1E-GYGY-DORJ, DOI 10.2190/JB3J-LL1E-GYGY-D0RJ]
   Mineka S, 1998, ANNU REV PSYCHOL, V49, P377, DOI 10.1146/annurev.psych.49.1.377
   Mochcovitch MD, 2012, REV BRAS PSIQUIATR, V34, P342, DOI 10.1016/j.rbp.2012.03.002
   Naragon-Gainey K, 2013, J ABNORM PSYCHOL, V122, P611, DOI 10.1037/a0032997
   Nery FG, 2009, DEPRESS ANXIETY, V26, P382, DOI 10.1002/da.20478
   Noftle EE, 2010, PSYCHOL AGING, V25, P95, DOI 10.1037/a0018199
   Nolen-Hoeksema S, 2001, CURR DIR PSYCHOL SCI, V10, P173, DOI 10.1111/1467-8721.00142
   Olmstead MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004410
   Parker G, 2001, PSYCHOL MED, V31, P1231
   Pelissolo A, 2002, ENCEPHALE, V28, P363
   Pradhan AA, 2011, TRENDS PHARMACOL SCI, V32, P581, DOI 10.1016/j.tips.2011.06.008
   Rihmer Z, 2010, CURR OPIN PSYCHIATR, V23, P12, DOI 10.1097/YCO.0b013e32833299d4
   Robbins TW, 2007, PHILOS T R SOC B, V362, P917, DOI 10.1098/rstb.2007.2097
   Roberts BW, 2000, PSYCHOL BULL, V126, P3, DOI 10.1037/0033-2909.126.1.3
   Roberts BW, 2006, PSYCHOL BULL, V132, P1, DOI 10.1037/0033-2909.132.1.1
   ROTHBART MK, 1988, CHILD DEV, V59, P1241, DOI 10.1111/j.1467-8624.1988.tb01493.x
   Rovai L, 2013, EUR REV MED PHARMACO, V17, P2065
   RUSALOV VM, 1989, PERS INDIV DIFFER, V10, P817, DOI 10.1016/0191-8869(89)90017-2
   Rusalov V. M., 1979, BIOLOGICHESKIYE OSNO
   Rusalov V. M., 2007, STUCTURE TEMPERAMENT
   Schwarzer C, 2009, PHARMACOL THERAPEUT, V123, P353, DOI 10.1016/j.pharmthera.2009.05.006
   Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886
   Strelau J., 1998, TEMPERAMENT PSYCHOL
   Struder HK, 2001, INT J SPORTS MED, V22, P467, DOI 10.1055/s-2001-17605
   TAKAHASHI M, 1990, JPN J PHARMACOL, V53, P487, DOI 10.1254/jjp.53.487
   Taylor SE, 2006, PSYCHOSOM MED, V68, P238, DOI 10.1097/01.psy.0000203242.95990.74
   Terraccion A., 2006, J GERONTOL B-PSYCHOL, V61, P108, DOI 10.1093/geronb/61.2.P108
   Trofimova I., 2010, OPEN BEHAV SCI PSYCH, V4, P1, DOI [10.2174/1874230001004010001, DOI 10.2174/1874230001004010001]
   Trofimova I., 2011, INT J PSYCHOL PSYCHO, V11, P389
   Trofimova I., 2010, ADV BIOSCI BIOTECHNO, V1, P190, DOI [10.4236/abb.2010.13027, DOI 10.4236/ABB.2010.13027]
   Trofimova I., 2016, TEMPERAMENTS INDIVID, P77
   Trofimova I., 2016, PLOS ONE IN PRESS
   Trofimova I, 2016, NEUROSCI BIOBEHAV R, V64, P382, DOI 10.1016/j.neubiorev.2016.03.008
   Trofimova I, 2016, PSYCHOL REP, V118, P387, DOI 10.1177/0033294116639430
   Trofimova I, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00338
   Trofimova I, 2015, AM J PSYCHOL, V128, P485, DOI 10.5406/amerjpsyc.128.4.0485
   Trofimova I, 2010, AM J PSYCHOL, V123, P467
   WATSON D, 1988, J ABNORM PSYCHOL, V97, P346, DOI 10.1037/0021-843X.97.3.346
   Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106
   Weinstock LM, 2006, J ABNORM PSYCHOL, V115, P68, DOI 10.1037/0021-843X.115.1.68
   Weiss A, 2009, AM J GERIAT PSYCHIAT, V17, P591
   Zentner M., 2012, HDB TEMPERAMENT
   Zuckerman M., 1994, BEHAV EXPRESSIONS BI
NR 92
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD NOV 25
PY 2016
VL 7
AR 1848
DI 10.3389/fpsyg.2016.01848
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA ED0FV
UT WOS:000388519300001
ER

PT J
AU Zierer, J
   Pallister, T
   Tsai, PC
   Krumsiek, J
   Bell, JT
   Lauc, G
   Spector, TD
   Menni, C
   Kastenmuller, G
AF Zierer, Jonas
   Pallister, Tess
   Tsai, Pei-Chien
   Krumsiek, Jan
   Bell, Jordana T.
   Lauc, Gordan
   Spector, Tim D.
   Menni, Cristina
   Kastenmueller, Gabi
TI Exploring the molecular basis of age-related disease comorbidities using
   a multi-omics graphical model
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; GENE-EXPRESSION CHANGES; CHRONIC
   KIDNEY-DISEASE; ADIPOSE-TISSUE; URIC-ACID; METABOLIC SYNDROME;
   DEHYDROEPIANDROSTERONE DHEA; VISCERAL FAT; INFLAMMATION; OXYTOCIN
AB Although association studies have unveiled numerous correlations of biochemical markers with age and age-related diseases, we still lack an understanding of their mutual dependencies. To find molecular pathways that underlie age-related diseases as well as their comorbidities, we integrated aging markers from four different high-throughput omics datasets, namely epigenomics, transcriptomics, glycomics and metabolomics, with a comprehensive set of disease phenotypes from 510 participants of the TwinsUK cohort. We used graphical random forests to assess conditional dependencies between omics markers and phenotypes while eliminating mediated associations. Applying this novel approach for multi-omics data integration yields a model consisting of seven modules that represent distinct aspects of aging. These modules are connected by hubs that potentially trigger comorbidities of age-related diseases. As an example, we identified urate as one of these key players mediating the comorbidity of renal disease with body composition and obesity. Body composition variables are in turn associated with inflammatory IgG markers, mediated by the expression of the hormone oxytocin. Thus, oxytocin potentially contributes to the development of chronic low-grade inflammation, which often accompanies obesity. Our multi-omics graphical model demonstrates the interconnectivity of age-related diseases and highlights molecular markers of the aging process that might drive disease comorbidities.
C1 [Zierer, Jonas; Pallister, Tess; Tsai, Pei-Chien; Bell, Jordana T.; Lauc, Gordan; Spector, Tim D.; Menni, Cristina; Kastenmueller, Gabi] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
   [Zierer, Jonas; Kastenmueller, Gabi] Helmholtz Zentrum Munchen, Inst Bioinformat & Syst Biol, Neuherberg, Germany.
   [Krumsiek, Jan] Helmholtz Zentrum Munchen, Inst Computat Biol, Neuherberg, Germany.
   [Krumsiek, Jan; Kastenmueller, Gabi] German Ctr Diabet Res DZD, Neuherberg, Germany.
   [Lauc, Gordan] Genos Glycosci Res Lab, Zagreb, Croatia.
RP Kastenmuller, G (reprint author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.; Kastenmuller, G (reprint author), Helmholtz Zentrum Munchen, Inst Bioinformat & Syst Biol, Neuherberg, Germany.; Kastenmuller, G (reprint author), German Ctr Diabet Res DZD, Neuherberg, Germany.
EM g.kastenmueller@helmholtz-muenchen.de
FU Wellcome Trust; European Community; National Institute for Health
   Research (NIHR)-BioResource, Clinical Research Facility and Biomedical
   Research Centre at Guy's and St Thomas' NHS Foundation Trust; King's
   College London; MRC AimHy [MR/M016560/1]
FX We thank Kerrin Small for her advice on the analysis of transcriptomics
   data. The study was funded by the Wellcome Trust; European Community's
   Seventh Framework Programme (FP7/2007-2013). The study also receives
   support from the National Institute for Health Research (NIHR)-funded
   BioResource, Clinical Research Facility and Biomedical Research Centre
   based at Guy's and St Thomas' NHS Foundation Trust in partnership with
   King's College London. TDS is an ERC Advanced Researcher CM is funded by
   the MRC AimHy (MR/M016560/1) project grant.
CR Arca M, 2007, AM J CARDIOL, V100, P1511, DOI 10.1016/j.amjcard.2007.06.049
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Barrios C, 2016, J AM SOC NEPHROL, V27, P933, DOI 10.1681/ASN.2015010109
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279
   Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102
   Bonnet S, 2003, P NATL ACAD SCI USA, V100, P9488, DOI 10.1073/pnas/1633724100
   Brandes U, 2008, IEEE T KNOWL DATA EN, V20, P172, DOI 10.1109/TKDE.2007.190689
   Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197
   Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1
   Chaves VE, 2013, PEPTIDES, V45, P9, DOI 10.1016/j.peptides.2013.04.010
   Civelek M, 2014, NAT REV GENET, V15, P34, DOI 10.1038/nrg3575
   Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007
   Csardi G., 2006, INT J COMPLEX SYST, V1695, P1695, DOI DOI 10.1080/01621459.1951.10500769
   Dall'Olio F, 2013, AGEING RES REV, V12, P685, DOI 10.1016/j.arr.2012.02.002
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   DeBosch BJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5642
   Driver JA, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2467
   Esser N, 2014, DIABETES RES CLIN PR, V105, P141, DOI 10.1016/j.diabres.2014.04.006
   Fellinghauer B, 2013, COMPUT STAT DATA AN, V64, P132, DOI 10.1016/j.csda.2013.02.022
   Fogarty AW, 2008, AM J CLIN NUTR, V87, P30
   Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002
   Giacomello A, 1997, METABOLISM, V46, P1085, DOI 10.1016/S0026-0495(97)90283-3
   Glass D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r75
   Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104
   Grundberg E, 2013, AM J HUM GENET, V93, P876, DOI 10.1016/j.ajhg.2013.10.004
   Grundberg E, 2012, NAT GENET, V44, P1084, DOI 10.1038/ng.2394
   Gustafsson M, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0082-6
   Hauner H, 2004, PHYSIOL BEHAV, V83, P653, DOI 10.1016/j.physbeh.2004.09.016
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Huan Tianxiao, 2015, Mol Syst Biol, V11, P799, DOI 10.15252/msb.20145399
   HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075
   Humphries MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002051
   Johnson RJ, 2013, NEPHROL DIAL TRANSPL, V28, P2221, DOI 10.1093/ndt/gft029
   Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862
   Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190
   Krumsiek J, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-21
   Lauritzen S.L., 1996, GRAPHICAL MODELS
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Lee DS, 2008, P NATL ACAD SCI USA, V105, P9880, DOI 10.1073/pnas.0802208105
   Levey AS, 2009, ANN INTERN MED, V150, P604
   Maeda K, 2010, BLOOD, V115, P4699, DOI 10.1182/blood-2009-07-230631
   Masuo K, 2003, HYPERTENSION, V42, P474, DOI 10.1161/01.HYP.0000091371.53502.D3
   Menni C, 2016, OBESITY, V24, P1380, DOI 10.1002/oby.21488
   Menni C, 2015, J GERONTOL A-BIOL, V70, P809, DOI 10.1093/gerona/glu121
   Menni C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082558
   Menni C, 2013, INT J EPIDEMIOL, V42, P1111, DOI 10.1093/ije/dyt094
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Nakanishi N, 2003, DIABETES CARE, V26, P48, DOI 10.2337/diacare.26.1.48
   Nihlen U, 2001, SCAND J CLIN LAB INV, V61, P341, DOI 10.1080/003655101316911378
   [Office for National Statistics Population Estimates for UK England and Wales Scotland and Northern Ireland], 2016, POP EST UK ENGL WAL
   OKEEFFE S, 1991, EUR RESPIR J, V4, P932
   ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002
   Oti M, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.041376
   Parekh PJ, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.16
   Park J, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.16
   Pucic M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010090
   Shah RD, 2013, J R STAT SOC B, V75, P55, DOI 10.1111/j.1467-9868.2011.01034.x
   Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008
   Takahashi S, 1997, METABOLISM, V46, P1162, DOI 10.1016/S0026-0495(97)90210-9
   Tang HF, 2006, BBA-MOL BASIS DIS, V1762, P525, DOI 10.1016/j.bbadis.2005.12.009
   Teucher B, 2007, TWIN RES HUM GENET, V10, P734, DOI 10.1375/twin.10.5.734
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Vaziri ND, 2013, KIDNEY INT, V83, P308, DOI 10.1038/ki.2012.345
   Weidner CI, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r24
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Yang JL, 2015, SCI REP-UK, V5, DOI 10.1038/srep15145
   Zhang B, 2005, STAT APPL GENET MO B, V4, DOI 10.2202/1544-6115.1128
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
   Zierer J, 2015, AGING CELL, V14, P933, DOI 10.1111/acel.12386
NR 71
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 25
PY 2016
VL 6
AR 37646
DI 10.1038/srep37646
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC9ST
UT WOS:000388485200001
ER

PT J
AU Witchey, SK
   Stevenson, EL
   Caldwell, HK
AF Witchey, Shannah K.
   Stevenson, Erica L.
   Caldwell, Heather K.
TI Genotypic differences in intruder-evoked immediate early gene activation
   in male, but not female, vasopressin 1b receptor knockout mice
SO BMC NEUROSCIENCE
LA English
DT Article
DE Intermale aggression; Resident intruder test; Maternal aggression;
   c-FOS; EGR-1
ID BEHAVIOR NEURAL-NETWORK; HIPPOCAMPAL AREA CA2; SOCIAL-BEHAVIOR;
   AGGRESSIVE-BEHAVIOR; MATERNAL AGGRESSION; INTERMALE AGGRESSION;
   AGONISTIC BEHAVIOR; RAT HIPPOCAMPUS; OESTROUS CYCLE; OXYTOCIN
AB Background: The neuropeptide arginine vasopressin (Avp) modulates social behaviors via its two centrally expressed receptors, the Avp 1a receptor and the Avp 1b receptor (Avpr1b). Recent work suggests that, at least in mice, Avp signaling through Avpr1b within the CA2 region of the hippocampus is critical for normal aggressive behaviors and social recognition memory. However, this brain area is just one part of a larger neural circuit that is likely to be impacted in Avpr1b knockout (-/-) mice. To identify other brain areas that are affected by altered Avpr1b signaling, genotypic differences in immediate early gene activation, i. e. c-FOS and early growth response factor 1 (EGR-1), were quantified using immunocytochemistry following a single exposure to an intruder.
   Results: In females, no genotypic differences in intruder-evoked c-FOS or EGR-1 immunoreactivity were observed in any of the brain areas measured. In males, while there were no intruder-evoked genotypic differences in c-FOS immunoreactivity, genotypic differences were observed in EGR-1 immunoreactivity within the ventral bed nucleus of the stria terminalis and the anterior hypothalamus; with Avpr1b -/- males having less EGR-1 immunoreactivity in these regions than controls.
   Conclusions: These data are the first to identify specific brain areas that may be a part of a neural circuit that includes Avpr1b-expressing cells in the CA2 region of the hippocampus. It is thought that this circuit, when working properly, plays a role in how an animal evaluates its social context.
C1 [Witchey, Shannah K.; Stevenson, Erica L.; Caldwell, Heather K.] Kent State Univ, Dept Biol Sci, Neuroendocrinol & Behav Lab, 256 Cunningham Hall, Kent, OH 44242 USA.
   [Stevenson, Erica L.; Caldwell, Heather K.] Kent State Univ, Sch Biomed Sci, Neuroendocrinol & Behav Lab, Kent, OH USA.
RP Caldwell, HK (reprint author), Kent State Univ, Dept Biol Sci, Neuroendocrinol & Behav Lab, 256 Cunningham Hall, Kent, OH 44242 USA.; Caldwell, HK (reprint author), Kent State Univ, Sch Biomed Sci, Neuroendocrinol & Behav Lab, Kent, OH USA.
EM hcaldwel@kent.edu
FU NIH [R21 MH083963]
FX This work was supported by NIH R21 MH083963 to H.K.C.
CR Adkins-Regan E, 2009, ILAR J, V50, P5
   Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007
   Bartesaghi R, 2006, NEUROSCIENCE, V142, P247, DOI 10.1016/j.neuroscience.2006.06.001
   Bartesaghi R, 2004, HIPPOCAMPUS, V14, P948, DOI 10.1002/hipo.20011
   Beiderbeck DI, 2007, EUR J NEUROSCI, V26, P3597, DOI 10.1111/j.1460-9568.2007.05974.x
   Borhegyi Z, 1997, EXP BRAIN RES, V115, P369, DOI 10.1007/PL00005706
   BRUCE HM, 1960, SCIENCE, V131, P1526, DOI 10.1126/science.131.3412.1526
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Caldwell Heather K, 2016, Curr Top Behav Neurosci, V27, P51
   Caldwell HK, 2012, ADV EXP MED BIOL, V739, P187, DOI 10.1007/978-1-4614-1704-0_12
   Caldwell HK, 2010, HORM BEHAV, V58, P257, DOI 10.1016/j.yhbeh.2010.03.008
   Caldwell HK, 2009, PHYSIOL BEHAV, V97, P131, DOI 10.1016/j.physbeh.2009.02.006
   Caldwell HK, 2008, PROG BRAIN RES, V170, P65, DOI 10.1016/S0079-6123(08)00406-8
   Caughey SD, 2011, J NEUROENDOCRINOL, V23, P1113, DOI 10.1111/j.1365-2826.2011.02224.x
   Cui ZZ, 2013, J COMP NEUROL, V521, P1844, DOI 10.1002/cne.23263
   de No RL, 1934, J PSYCHOL NEUROL, V46, P113
   de Vries GJ, 2012, J NEUROENDOCRINOL, V24, P527, DOI 10.1111/j.1365-2826.2012.02305.x
   Delville Y, 2000, BRAIN BEHAV EVOLUT, V55, P53, DOI 10.1159/000006642
   DeVito LM, 2009, J NEUROSCI, V29, P2676, DOI 10.1523/JNEUROSCI.5488-08.2009
   Dhakar MB, 2012, HORM BEHAV, V62, P86, DOI 10.1016/j.yhbeh.2012.05.007
   ELY DL, 1977, PHYSIOL BEHAV, V18, P1075, DOI 10.1016/0031-9384(77)90014-2
   Everts HGJ, 1997, HORM BEHAV, V31, P136, DOI 10.1006/hbeh.1997.1375
   Franklin K., 2007, MOUSE BRAIN STEREOTA
   Gammie SC, 2001, BRAIN RES, V898, P232, DOI 10.1016/S0006-8993(01)02189-8
   Goodson JL, 2013, HORM BEHAV, V64, P103, DOI 10.1016/j.yhbeh.2013.05.006
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Hasen NS, 2006, BRAIN RES, V1108, P147, DOI 10.1016/j.brainres.2006.06.007
   Hasen NS, 2005, PHYSIOL BEHAV, V84, P681, DOI 10.1016/j.physbeh.2005.02.010
   Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028
   Jennings JH, 2013, NATURE, V496, P224, DOI 10.1038/nature12041
   Kelly AM, 2014, FRONT NEUROENDOCRIN, V35, P512, DOI 10.1016/j.yfrne.2014.04.005
   KOLLACKWALKER S, 1995, NEUROSCIENCE, V66, P721, DOI 10.1016/0306-4522(94)00563-K
   KRUK MR, 1991, NEUROSCI BIOBEHAV R, V15, P527, DOI 10.1016/S0149-7634(05)80144-7
   Lein ES, 2004, J NEUROSCI, V24, P3879, DOI 10.1523/JNEUROSCI.4710-03.2004
   Lein ES, 2005, J COMP NEUROL, V485, P1, DOI 10.1002/cne.20426
   Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3
   MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9
   Nelson RJ, 2007, NAT REV NEUROSCI, V8, P536, DOI 10.1038/nrn2174
   O'Connell LA, 2011, J COMP NEUROL, V519, P3599, DOI 10.1002/cne.22735
   Pagani JH, 2015, MOL PSYCHIATR, V20, P490, DOI 10.1038/mp.2014.47
   Rich ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098839
   Sekino Y, 1997, J NEUROPHYSIOL, V78, P1662
   Smith AS, 2016, MOL PSYCHIATR, V21, P1137, DOI 10.1038/mp.2015.189
   Stevenson EL, 2014, EUR J NEUROSCI, V40, P3294, DOI 10.1111/ejn.12689
   Stevenson EL, 2012, HORM BEHAV, V61, P277, DOI 10.1016/j.yhbeh.2011.11.009
   TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3
   Trainor BC, 2010, NEUROSCIENCE, V165, P325, DOI 10.1016/j.neuroscience.2009.10.050
   Uekita T, 2011, BEHAV BRAIN RES, V219, P302, DOI 10.1016/j.bbr.2011.01.042
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   Veenema AH, 2008, PROG BRAIN RES, V170, P261, DOI 10.1016/S0079-6123(08)00422-6
   Vertes RP, 2000, SYNAPSE, V38, P281, DOI 10.1002/1098-2396(20001201)38:3<281::AID-SYN7>3.0.CO;2-6
   Vigers AJ, 2000, J COMP NEUROL, V416, P398, DOI 10.1002/(SICI)1096-9861(20000117)416:3<398::AID-CNE10>3.0.CO;2-P
   Wersinger SR, 2007, GENES BRAIN BEHAV, V6, P653, DOI 10.1111/j.1601-183X.2006.00294.x
   Wersinger SR, 2008, ENDOCRINOLOGY, V149, P116, DOI 10.1210/en.2007-1056
   Wersinger SR, 2002, MOL PSYCHIATR, V7, P975, DOI 10.1038/sj.mp.4001195
   Wersinger SR, 2004, HORM BEHAV, V46, P638, DOI 10.1016/j.yhbeh.2004.07.004
   WHITTEN WK, 1956, J ENDOCRINOL, V13, P399, DOI 10.1677/joe.0.0130399
   WHITTEN WK, 1958, J ENDOCRINOL, V17, P307, DOI 10.1677/joe.0.0170307
   Williams TE, 1996, J COMP NEUROL, V370, P147, DOI 10.1002/(SICI)1096-9861(19960624)370:2<147::AID-CNE2>3.0.CO;2-2
   Young WS, 2006, NEUROSCIENCE, V143, P1031, DOI 10.1016/j.neuroscience.2006.08.040
NR 61
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD NOV 24
PY 2016
VL 17
AR 75
DI 10.1186/s12868-016-0310-7
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA ED0NZ
UT WOS:000388540500001
ER

PT J
AU Francis, SM
   Kim, SJ
   Kistner-Griffin, E
   Guter, S
   Cook, EH
   Jacobi, S
AF Francis, Sunday M.
   Kim, Soo-Jeong
   Kistner-Griffin, Emily
   Guter, Stephen
   Cook, Edwin H.
   Jacobi, Suma
TI ASD and Genetic Associations with Receptors for Oxytocin and
   Vasopressin-AVPR1A, AVPR1B, and OXTR
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE neuropeptides; oxytocin; vasopressin; receptors; social behaviors;
   repetitive behaviors
ID AUTISM SPECTRUM DISORDER; SIMONS SIMPLEX COLLECTION; ONSET MOOD
   DISORDERS; ARGININE-VASOPRESSIN; PROMOTER REGION; 1B RECEPTOR;
   REPETITIVE BEHAVIOR; ASPERGER SYNDROME; UNIFIED APPROACH;
   SOCIAL-BEHAVIOR
AB Background: There are limited treatments available for autism spectrum disorder (ASD). Studies have reported significant associations between the receptor genes of oxytocin (OT) and vasopressin (AVP) and ASD diagnosis, as well as ASD-related phenotypes. Researchers have also found the manipulation of these systems affects social and repetitive behaviors, core characteristics of ASD. Consequently, research involving the oxytocin/vasopressin pathways as intervention targets has increased. Therefore, further examination into the relationship between these neuropeptides and ASD was undertaken. In this study, we examined associations between variants in the receptor genes of vasopressin (AVPR1A, AVPR1B), oxytocin (OXTR), and ASD diagnosis along with related subphenotypes.
   Methods: Probands were assessed using Autism Diagnostic Interview-Revised, Autism Diagnostic Observation Schedule, and clinical DSM-IV-TR criteria. Single nucleotide polymorphisms (SNPs) in AVPR1B and OXTR, and microsatellites in AVPR1A were genotyped in similar to 200 families with a proband with ASD. Family based association testing (FBAT) was utilized to determine associations between variants and ASD. Haplotypes composed of OXTR SNPs (i.e., rs53576-rs2254298-rs2268493) were also analyzed due to previously published associations.
   Results: Using the additive inheritance model in FBAT we found associations between AVPR1B SNPs (rs28632197, p = 0.005, rs35369693, p = 0.025) and diagnosis. As in other studies, OXTR rs2268493 (p = 0.050) was associated with diagnosis. rs2268493 was also associated with ASD subphenotypes of social withdrawal (p = 0.013) and Insistence on Sameness (p = 0.039). Further analyses demonstrated that the haplotype, rs2254298 rs2268493 was found to be significantly associated with diagnosis (A-T; p = 0.026). FBAT was also used to analyze AVPR1A microsatellites (RS1 and RS3). Both length variants were found to be associated with restrictive, repetitive behaviors, but not overall diagnosis. Correction for multiple comparisons was performed for SNPs tested in each gene region, only AVPR1B SNPs remained significantly associated with ASD diagnosis.
   Conclusions: Autism is a heterogeneous disorder with many genes and pathways that contribute to its development. SNPs and microsatellites in the receptor genes of OT and AVP are associated with ASD diagnosis and measures of social behavior as well as restricted repetitive behaviors. We reported a novel association with ASD and AVPR1B SNPs. Understanding of genotype-phenotype relationships may be helpful in the development of pharmacological interventions for the OT/AVP system.
C1 [Francis, Sunday M.; Jacobi, Suma] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   [Kim, Soo-Jeong] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Kistner-Griffin, Emily] Med Univ South Carolina, Hollings Canc Ctr, Biostat Shared Resource, Charleston, SC USA.
   [Guter, Stephen; Cook, Edwin H.] Univ Illinois, Inst Juvenile Res, Dept Psychiat, Chicago, IL USA.
RP Jacobi, S (reprint author), Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
EM sjacob@umn.edu
FU NIMH [K23MH082121]; NARSAD Young Investigator Award [3K23MH082121-03S1];
   Leadership Education in Neurodevelopmental and Related Disorders
   Training Program [T73MC12835]; NICHD/NINDS/NIEHS [P50HD055751]
FX This work was supported by NIMH K23MH082121 and NARSAD Young
   Investigator Award (SJ), 3K23MH082121-03S1 and Leadership Education in
   Neurodevelopmental and Related Disorders Training Program T73MC12835
   (SF) and NICHD/NINDS/NIEHS P50HD055751 (EC, EK, SG). We acknowledge Dr.
   Sue C. Carter for her ongoing support and contributions to our study of
   the oxytocin and vasopressin systems. We value laboratory assistance
   from Kathy Hennessy, Kelly Moore, and Zenping Hao. Shravan Sarvepalli
   and Elena Guerra also helped with genotyping a subset of samples. Also,
   the authors would like to thank Emma Shankland, Diksha Srishyla, and
   Lucinda Wasserburg for their assistance in reviewing the manuscript.
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   AMAN MG, 1985, AM J MENT DEF, V89, P492
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Anney R, 2012, HUM MOL GENET, V21, P4781, DOI 10.1093/hmg/dds301
   Appenrodt E, 1998, PHYSIOL BEHAV, V64, P543, DOI 10.1016/S0031-9384(98)00119-X
   Bal VH, 2015, AUTISM RES, V8, P583, DOI 10.1002/aur.1474
   Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855
   Bowen MT, 2014, INT J NEUROPSYCHOPH, V17, P1621, DOI 10.1017/S1461145714000388
   Caldwell HK, 2010, HORM BEHAV, V58, P257, DOI 10.1016/j.yhbeh.2010.03.008
   Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Chakrabarti B, 2009, AUTISM RES, V2, P157, DOI 10.1002/aur.80
   Chakrabarti S, 2005, AM J PSYCHIAT, V162, P1133, DOI 10.1176/appi.ajp.162.6.1133
   Chang SC, 2014, PSYCHONEUROENDOCRINO, V39, P257, DOI 10.1016/j.psyneuen.2013.09.024
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Chaste P, 2015, BIOL PSYCHIAT, V77, P775, DOI 10.1016/j.biopsych.2014.09.017
   Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0
   Damiano CR, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-7
   Davis MC, 2014, SCHIZOPHR RES, V159, P353, DOI 10.1016/j.schres.2014.09.006
   De Dreu CKW, 2014, SOC COGN AFFECT NEUR, V9, P1159, DOI 10.1093/scan/nst094
   Dempster EL, 2007, ARCH GEN PSYCHIAT, V64, P1189, DOI 10.1001/archpsyc.64.10.1189
   Dempster EL, 2009, EUR J NEUROSCI, V30, P1615, DOI 10.1111/j.1460-9568.2009.06930.x
   Di Napoli A, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-48
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Francis SM, 2014, BRAIN RES, V1580, P199, DOI 10.1016/j.brainres.2014.01.021
   Giles LL, 2016, ACAD PEDIATR, V16, P508, DOI 10.1016/j.acap.2016.03.011
   Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1
   Guastella AJ, 2011, PSYCHONEUROENDOCRINO, V36, P294, DOI 10.1016/j.psyneuen.2010.07.023
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Haram M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00009
   Hus V, 2007, BIOL PSYCHIAT, V61, P438, DOI 10.1016/j.biopsych.2006.08.044
   Hus V, 2014, J AUTISM DEV DISORD, V44, P2400, DOI 10.1007/s10803-012-1719-1
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Kantojarvi K, 2015, AUTISM RES, V8, P634, DOI 10.1002/aur.1473
   Keck ME, 2008, AM J MED GENET B, V147B, P1196, DOI 10.1002/ajmg.b.30750
   Kenkel WM, 2012, J NEUROENDOCRINOL, V24, P874, DOI 10.1111/j.1365-2826.2012.02301.x
   Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125
   Knafo A, 2008, GENES BRAIN BEHAV, V7, P266, DOI 10.1111/j.1601-183X.2007.00341.x
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kranz TM, 2016, AUTISM RES, V9, P1036, DOI 10.1002/aur.1597
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M
   Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z
   Landgraf R, 2003, STRESS, V6, P111, DOI 10.1080/102589031000104193
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Leszczynska-Rodziewicz A, 2012, J AFFECT DISORDERS, V138, P490, DOI 10.1016/j.jad.2012.01.025
   Levin R, 2009, PSYCHONEUROENDOCRINO, V34, P901, DOI 10.1016/j.psyneuen.2008.12.014
   Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   Lord C., 1999, AUTISM DIAGNOSTIC OB
   Luppino D, 2014, PSYCHIAT GENET, V24, P185, DOI 10.1097/YPG.0000000000000036
   Meyer-Lindenberg A, 2009, MOL PSYCHIATR, V14, P968, DOI 10.1038/mp.2008.54
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Pagani JH, 2015, MOL PSYCHIATR, V20, P490, DOI 10.1038/mp.2014.47
   Pare P, 2016, GENET MOL BIOL, V39, P646, DOI [10.1590/1678-4685-GMB-2015-0323, 10.1590/1678-4685-gmb-2015-0323]
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918
   Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e
   Russell AJ, 2016, AUTISM, V20, P623, DOI 10.1177/1362361315604271
   Rutter M., 2003, AUTISM DIAGNOSTIC IN
   SAWCHENKO PE, 1985, FED PROC, V44, P221
   Scattoni ML, 2008, BEHAV BRAIN RES, V187, P371, DOI 10.1016/j.bbr.2007.09.034
   Seltzer LJ, 2010, P ROY SOC B-BIOL SCI, V277, P2661, DOI 10.1098/rspb.2010.0567
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Szczepankiewicz A, 2013, PSYCHIAT GENET, V23, P239, DOI 10.1097/YPG.0000000000000007
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Tansey KE, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-3
   Van der Kooij M. A., 2015, CURR OPIN BEHAV SCI, V2, P52, DOI [10.1016/j.cobeha.2014.09.001, DOI 10.1016/J.COBEHA.2014.09.001]
   Wang JP, 2016, HUM BRAIN MAPP, V37, P2700, DOI 10.1002/hbm.23203
   Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503
   Wermter AK, 2010, AM J MED GENET B, V153B, P629, DOI 10.1002/ajmg.b.31032
   Wu Nan, 2015, Psych J, V4, P160, DOI 10.1002/pchj.102
   Wu N, 2012, J AFFECT DISORDERS, V138, P468, DOI 10.1016/j.jad.2012.01.009
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Yang SY, 2010, NEUROSCI LETT, V479, P197, DOI 10.1016/j.neulet.2010.05.050
   Yang SY, 2010, PSYCHIAT RES, V178, P199, DOI 10.1016/j.psychres.2009.11.007
   Yrigollen CM, 2008, BIOL PSYCHIAT, V63, P911, DOI 10.1016/j.biopsych.2007.11.015
   Zai CC, 2012, PSYCHIAT RES, V200, P784, DOI 10.1016/j.psychres.2012.07.031
   Zink CF, 2012, HORM BEHAV, V61, P400, DOI 10.1016/j.yhbeh.2012.01.016
NR 82
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD NOV 22
PY 2016
VL 10
AR 516
DI 10.3389/fnins.2016.00516
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA ED0LA
UT WOS:000388532800001
ER

PT J
AU Rebo, J
   Mehdipour, M
   Gathwala, R
   Causey, K
   Liu, Y
   Conboy, MJ
   Conboy, IM
AF Rebo, Justin
   Mehdipour, Melod
   Gathwala, Ranveer
   Causey, Keith
   Liu, Yan
   Conboy, Michael J.
   Conboy, Irina M.
TI A single heterochronic blood exchange reveals rapid inhibition of
   multiple tissues by old blood
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MUSCLE STEM-CELLS; SKELETAL-MUSCLE; HIPPOCAMPAL NEUROGENESIS; COGNITIVE
   FUNCTION; REGENERATION; REJUVENATION; OXYTOCIN; OSTEOPONTIN;
   TRANSFUSION; MYOGENESIS
AB Heterochronic parabiosis rejuvenates the performance of old tissue stem cells at some expense to the young, but whether this is through shared circulation or shared organs is unclear. Here we show that heterochronic blood exchange between young and old mice without sharing other organs, affects tissues within a few days, and leads to different outcomes than heterochronic parabiosis. Investigating muscle, liver and brain hippocampus, in the presence or absence of muscle injury, we find that, in many cases, the inhibitory effects of old blood are more pronounced than the benefits of young, and that peripheral tissue injury compounds the negative effects. We also explore mechanistic explanations, including the role of B2M and TGF-beta. We conclude that, compared with heterochronic parabiosis, heterochronic blood exchange in small animals is less invasive and enables better-controlled studies with more immediate translation to therapies for humans.
C1 [Rebo, Justin; Mehdipour, Melod; Gathwala, Ranveer; Liu, Yan; Conboy, Michael J.; Conboy, Irina M.] Univ Calif Berkeley, Dept Bioengn, 174 Stanley Hall, Berkeley, CA 94720 USA.
   [Rebo, Justin; Mehdipour, Melod; Gathwala, Ranveer; Liu, Yan; Conboy, Michael J.; Conboy, Irina M.] Univ Calif Berkeley, Inst QB3, 174 Stanley Hall, Berkeley, CA 94720 USA.
   [Causey, Keith] SENS Res Fdn, 110 Pioneer Way,Suite J, Mountain View, CA 94041 USA.
RP Conboy, MJ; Conboy, IM (reprint author), Univ Calif Berkeley, Dept Bioengn, 174 Stanley Hall, Berkeley, CA 94720 USA.; Conboy, MJ; Conboy, IM (reprint author), Univ Calif Berkeley, Inst QB3, 174 Stanley Hall, Berkeley, CA 94720 USA.
EM conboymj@berkeley.edu; iconboy@berkeley.edu
FU NIH [R56]; Rogers' Family; Calico; SENS Research Foundation; Life
   Extension Foundation
FX This work was supported by the following grants: NIH R56 to I.M.C.,
   Rogers' Family to I.M.C., Calico to I.M.C., the SENS Research Foundation
   to J.R. and K.C., and the Life Extension Foundation to J.R. and K.C.
CR Aartsma-Rus A., 2014, J VIS EXP, V27
   Auer-Hackenberg L, 2012, WIEN KLIN WOCHENSCHR, V124, P23, DOI 10.1007/s00508-012-0238-6
   Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131
   Bardelmeijer HA, 2003, LAB ANIM-UK, V37, P181, DOI 10.1258/002367703766453010
   Barraza JA, 2013, EXP CLIN PSYCHOPHARM, V21, P85, DOI 10.1037/a0031581
   Beranger GE, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00081
   Beranger GE, 2014, ENDOCRINOLOGY, V155, P1340, DOI 10.1210/en.2013-1688
   Bohatschek M, 2004, J COMP NEUROL, V470, P382, DOI 10.1002/cne.20017
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008
   Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034
   Carlson ME, 2009, EMBO MOL MED, V1, P381, DOI 10.1002/emmm.200900045
   Carlson ME, 2009, AGING CELL, V8, P676, DOI 10.1111/j.1474-9726.2009.00517.x
   Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Cho YK, 2007, LAB CHIP, V7, P565, DOI 10.1039/b616115d
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Conboy IM, 2015, AGING-US, V7, P754
   Conboy IM, 2012, CELL CYCLE, V11, P2260, DOI 10.4161/cc.20437
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   Elabd C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5082
   Flaherman VJ, 2012, J PEDIATR-US, V160, P796, DOI 10.1016/j.jpeds.2011.09.063
   Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x
   Pagel CN, 2014, J CELL COMMUN SIGNAL, V8, P95, DOI 10.1007/s12079-013-0217-3
   Paliwal P, 2012, AGING-US, V4, P553
   Rebo J, 2010, REJUV RES, V13, P298, DOI 10.1089/rej.2009.0964
   Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019
   Schaffer DV, 2004, NEUROMOL MED, V5, P1, DOI 10.1385/NMM:5:1:001
   Smits-Wintjens VEHJ, 2013, NEONATOLOGY, V103, P141, DOI 10.1159/000343261
   Tsai HM, 2006, ANNU REV MED, V57, P419, DOI 10.1146/annurev.med.57.061804.084505
   Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   von Baeyer H, 2003, THER APHER DIAL, V7, P127, DOI 10.1046/j.1526-0968.2003.00004.x
   Yousef H, 2015, ONCOTARGET, V6, P11959
   Yousef H, 2015, STEM CELLS, V33, P1577, DOI 10.1002/stem.1943
NR 36
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 22
PY 2016
VL 7
AR 13363
DI 10.1038/ncomms13363
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC6XX
UT WOS:000388281100001
PM 27874859
ER

PT J
AU Krahe, C
   Drabek, MM
   Paloyelis, Y
   Fotopoulou, A
AF Krahe, Charlotte
   Drabek, Marianne M.
   Paloyelis, Yannis
   Fotopoulou, Aikaterini
TI Affective touch and attachment style modulate pain: a laser-evoked
   potentials study
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE affective touch; pain; laser-evoked potentials; attachment style;
   interoception
ID OPIOID-RECEPTOR GENE; SOCIAL SUPPORT; PLEASANT TOUCH; HAIRY SKIN;
   OXYTOCIN; STRESS; HUMANS; OTHERS; RATS; INTEROCEPTION
AB Affective touch and cutaneous pain are two sub-modalities of interoception with contrasting affective qualities (pleasantness/unpleasantness) and social meanings (care/harm), yet their direct relationship has not been investigated. In 50 women, taking into account individual attachment styles, we assessed the role of affective touch and particularly the contribution of the C tactile (CT) system in subjective and electrophysiological responses to noxious skin stimulation, namely N1 and N2-P2 laser-evoked potentials. When pleasant, slow (versus fast) velocity touch was administered to the (non-CT-containing) palm of the hand, higher attachment anxiety predicted increased subjective pain ratings, in the same direction as changes in N2 amplitude. By contrast, when pleasant touch was administered to CT-containing skin of the arm, higher attachment anxiety predicted attenuated N1 and N2 amplitudes. Higher attachment avoidance predicted opposite results. Thus, CT-based affective touch can modulate pain in early and late processing stages (N1 and N2 components), with the direction of effects depending on attachment style. Affective touch not involving the CT system seems to affect predominately the conscious perception of pain, possibly reflecting socio-cognitive factors further up the neurocognitive hierarchy. Affective touch may thus convey information about available social resources and gate pain responses depending on individual expectations of social support.
   This article is part of the themed issue 'Interoception beyond homeostasis: affect, cognition and mental health'.
C1 [Krahe, Charlotte; Paloyelis, Yannis] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, London, England.
   [Drabek, Marianne M.] Univ Nottingham, Arthrit Res UK Pain Ctr, Nottingham, England.
   [Fotopoulou, Aikaterini] UCL, Res Dept Clin Educ & Hlth Psychol, London, England.
RP Krahe, C (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, London, England.
EM charlotte.krahe@kcl.ac.uk
FU Volkswagen Foundation 'European Platform for Life Sciences, Mind
   Sciences and Humanities' [II/85 069]; European Research Council Starting
   Investigator Award [ERC-2012-STG GA313755]; Economic and Social Research
   Council [ES/K009400/1]
FX This study was supported by a project grant no. (II/85 069) from the
   Volkswagen Foundation 'European Platform for Life Sciences, Mind
   Sciences and Humanities' and a European Research Council Starting
   Investigator Award (ERC-2012-STG GA313755) (to A.F.). Y.P. was supported
   by an Economic and Social Research Council fellowship (grant no.
   ES/K009400/1).
CR Acock Alan C., 2013, DISCOVERING STRUCTUR
   AGREN G, 1995, NEUROSCI LETT, V187, P49, DOI 10.1016/0304-3940(95)11335-T
   Aiken Leona S., 1991, MULTIPLE REGRESSION
   Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105
   Bjornsdotter M, 2010, EXP BRAIN RES, V207, P149, DOI 10.1007/s00221-010-2408-y
   BOWLBY J, 1977, BRIT J PSYCHIAT, V130, P201, DOI 10.1192/bjp.130.3.201
   Case L. K., 2016, ENEURO, V3, P1
   Coan JA, 2006, PSYCHOL SCI, V17, P1032, DOI 10.1111/j.1467-9280.2006.01832.x
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4
   Crucianelli Laura, 2013, Front Psychol, V4, P703, DOI 10.3389/fpsyg.2013.00703
   Decety J, 2015, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fobeh.2014.00457
   Dworkin JD, 2016, J CLIN EPIDEMIOL, V72, P56, DOI 10.1016/j.jclinepi.2015.10.019
   Eisenberger NI, 2011, P NATL ACAD SCI USA, V108, P11721, DOI 10.1073/pnas.1108239108
   Essick GK, 2010, NEUROSCI BIOBEHAV R, V34, P192, DOI 10.1016/j.neubiorev.2009.02.003
   Field T, 2014, COMPLEMENT THER CLIN, V20, P224, DOI 10.1016/j.ctcp.2014.07.002
   Fraley RC, 2000, J PERS SOC PSYCHOL, V78, P350, DOI 10.1037/0022-3514.78.2.350
   Gentsch A, 2015, CURR BIOL, V25, P2392, DOI 10.1016/j.cub.2015.07.049
   Hathaway Elizabeth E, 2015, Glob Adv Health Med, V4, P32, DOI 10.7453/gahmj.2015.029
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hertenstein MJ, 2006, EMOTION, V6, P528, DOI 10.1037/1528-3542.6.3.528
   HIGGINS JD, 1971, SCIENCE, V172, P866, DOI 10.1126/science.172.3985.866
   Hurter S, 2014, J PAIN, V15, P934, DOI 10.1016/j.jpain.2014.06.004
   Insel T. R., 2000, REV GEN PSYCHOL, V4, P176, DOI 10.1037/1089-2680.4.2.176
   Inui K, 2006, CEREB CORTEX, V16, P355, DOI 10.1093/cercor.bhi114
   JOHANSSON RS, 1979, J PHYSIOL-LONDON, V286, P283
   Johnston C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008435.pub2
   KEHOE P, 1986, BEHAV NEUROSCI, V100, P624, DOI 10.1037/0735-7044.100.5.624
   Korosi A, 2010, DEV PSYCHOBIOL, V52, P661, DOI 10.1002/dev.20490
   Krahe C, 2015, SOC COGN AFFECT NEUR, V10, P1030, DOI 10.1093/scan/nsu156
   Krahe C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00386
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lamm C, 2015, CORTEX, V70, P79, DOI 10.1016/j.cortex.2015.01.021
   Lee MC, 2009, J NEUROSCI, V29, P7909, DOI 10.1523/JNEUROSCI.0014-09.2009
   Legrain V, 2002, PAIN, V99, P21, DOI 10.1016/S0304-3959(02)00051-9
   Legrain V, 2011, PROG NEUROBIOL, V93, P111, DOI 10.1016/j.pneurobio.2010.10.005
   Loken LS, 2011, BRAIN RES, V1417, P9, DOI 10.1016/j.brainres.2011.08.011
   Loken LS, 2009, NAT NEUROSCI, V12, P547, DOI 10.1038/nn.2312
   LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
   Mancini F, 2015, PAIN, V156, P1936, DOI 10.1097/j.pain.0000000000000253
   Mancini F, 2014, PAIN, V155, P635, DOI 10.1016/j.pain.2013.12.024
   Master SL, 2009, PSYCHOL SCI, V20, P1316, DOI 10.1111/j.1467-9280.2009.02444.x
   McGlone F, 2012, EUR J NEUROSCI, V35, P1782, DOI 10.1111/j.1460-9568.2012.08092.x
   McGlone F, 2014, NEURON, V82, P737, DOI 10.1016/j.neuron.2014.05.001
   Meredith PJ, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0326-y
   Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943
   Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3
   Paloyelis Y, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12347
   Ravitz P, 2010, J PSYCHOSOM RES, V69, P419, DOI 10.1016/j.jpsychores.2009.08.006
   Rolls ET, 2010, NEUROSCI BIOBEHAV R, V34, P237, DOI 10.1016/j.neubiorev.2008.03.010
   Sambo CF, 2010, PAIN, V151, P687, DOI 10.1016/j.pain.2010.08.035
   StataCorp, 2013, STATA STAT SOFTW REL
   Troisi A, 2012, SOC COGN AFFECT NEUR, V7, P542, DOI 10.1093/scan/nsr037
   Uchino BN, 2006, J BEHAV MED, V29, P377, DOI 10.1007/s10865-006-9056-5
   Uvnas-Moberg Kerstin, 2014, Front Psychol, V5, P1529, DOI 10.3389/fpsyg.2014.01529
   Valeriani M, 2008, NEUROIMAGE, V40, P1419, DOI 10.1016/j.neuroimage.2007.12.056
   Weaver A, 2004, AM J PRIMATOL, V62, P243, DOI 10.1002/ajp.20019
NR 57
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD NOV 19
PY 2016
VL 371
IS 1708
AR 20160009
DI 10.1098/rstb.2016.0009
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA EC0CU
UT WOS:000387766300007
ER

PT J
AU Holtfrerich, SKC
   Schwarz, KA
   Sprenger, C
   Reimers, L
   Diekhof, EK
AF Holtfrerich, Sarah K. C.
   Schwarz, Katharine A.
   Sprenger, Christian
   Reimers, Luise
   Diekhof, Esther K.
TI Endogenous Testosterone and Exogenous Oxytocin Modulate Attentional
   Processing of Infant Faces
SO PLOS ONE
LA English
DT Article
ID BABY SCHEMA; SALIVARY TESTOSTERONE; CUTENESS PERCEPTION; COGNITIVE
   EMPATHY; BEHAVIOR; BRAIN; RECEPTOR; AUTISM; WOMEN; VASOPRESSIN
AB Evidence indicates that hormones modulate the intensity of maternal care. Oxytocin is known for its positive influence on maternal behavior and its important role for childbirth. In contrast, testosterone promotes egocentric choices and reduces empathy. Further, testosterone decreases during parenthood which could be an adaptation to increased parental investment. The present study investigated the interaction between testosterone and oxytocin in attentional control and their influence on attention to baby schema in women. Higher endogenous testosterone was expected to decrease selective attention to child portraits in a face-in-the-crowd-paradigm, while oxytocin was expected to counteract this effect. As predicted, women with higher salivary testosterone were slower in orienting attention to infant targets in the context of adult distractors. Interestingly, reaction times to infant and adult stimuli decreased after oxytocin administration, but only in women with high endogenous testosterone. These results suggest that oxytocin may counteract the adverse effects of testosterone on a central aspect of social behavior and maternal caretaking.
C1 [Holtfrerich, Sarah K. C.; Reimers, Luise; Diekhof, Esther K.] Univ Hamburg, Bioctr Grindel, Hamburg, Germany.
   [Holtfrerich, Sarah K. C.; Reimers, Luise; Diekhof, Esther K.] Inst Human Biol, Zool Museum, Neuroendocrinol Unit, Hamburg, Germany.
   [Schwarz, Katharine A.; Sprenger, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Hamburg, Germany.
   [Schwarz, Katharine A.] Univ Wurzburg, Inst Psychol, Wurzburg, Germany.
RP Holtfrerich, SKC (reprint author), Univ Hamburg, Bioctr Grindel, Hamburg, Germany.; Holtfrerich, SKC (reprint author), Inst Human Biol, Zool Museum, Neuroendocrinol Unit, Hamburg, Germany.
EM sarah.holtfrerich@gmx.de
FU European Research Council [ERC-2010-AdG_20100407]
FX KAS was supported by the European Research Council,
   ERC-2010-AdG_20100407. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alley T.R., 1983, J DEV PSYCHOL, V29, P411
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Baron-Cohen S, 2002, TRENDS COGN SCI, V6, P248, DOI 10.1016/S1364-6613(02)01904-6
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Bate S, 2014, CORTEX, V50, P55, DOI 10.1016/j.cortex.2013.08.006
   BAUCOM DH, 1985, J PERS SOC PSYCHOL, V48, P1218
   Borgi M, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00411
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bos PA, 2010, PSYCHONEUROENDOCRINO, V35, P114, DOI 10.1016/j.psyneuen.2009.09.013
   Bridges RS, 1997, ENDOCRINOLOGY, V138, P756, DOI 10.1210/en.138.2.756
   Brosch T, 2007, EMOTION, V7, P685, DOI 10.1037/1528-3542.7.3.685
   Cameron NM, 2008, HORM BEHAV, V54, P178, DOI 10.1016/j.yhbeh.2008.02.013
   Cardenas RA, 2013, EVOL HUM BEHAV, V34, P280, DOI 10.1016/j.evolhumbehav.2013.04.001
   Chapman E, 2006, SOC NEUROSCI, V1, P135, DOI 10.1080/17470910600992239
   Crespi BJ., 2015, BIOL REV CAMB PHILOS, V91, P390
   Diekhof EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098977
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebner NC, 2010, BEHAV RES METHODS, V42, P351, DOI 10.3758/BRM.42.1.351
   Eisenegger C, 2010, NATURE, V463, P356, DOI 10.1038/nature08711
   Ewert JP, 1997, TRENDS NEUROSCI, V20, P332
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   FRAYNE J, 1995, BIOL REPROD, V52, P1268, DOI 10.1095/biolreprod52.6.1268
   Geary DC, 2000, PSYCHOL BULL, V126, P55, DOI 10.1037/0033-2909.126.1.55
   Gettler LT, 2011, P NATL ACAD SCI USA, V108, P16194, DOI 10.1073/pnas.1105403108
   Glocker ML, 2009, P NATL ACAD SCI USA, V106, P9115, DOI 10.1073/pnas.0811620106
   Glocker ML, 2009, ETHOLOGY, V115, P257, DOI 10.1111/j.1439-0310.2008.01603.x
   Golle J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121554
   Golle J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058248
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Hahn AC, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2014.0978
   Hahn AC, 2015, HORM BEHAV, V67, P54, DOI 10.1016/j.yhbeh.2014.11.010
   Han SJ, 2007, ERNST SCHERING FDN S, V1, P25
   Harris JA, 1996, AGGRESSIVE BEHAV, P22
   Herrero S., 1990, BEARS THEIR BIOL MAN, V8, P25, DOI 10.2307/3872900
   Hildebrandt K. A., 1981, INFANT MENT HEALTH J, V2, P56, DOI 10.1002/1097-0355(198121)2:1<56::AID-IMHJ2280020109>3.0.CO;2-G
   Hodsoll J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012509
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Jaeggi AV, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0058
   Kringelbach ML, 2016, TRENDS IN PRESS 0519
   Kuzawa CW, 2010, HORM BEHAV, V57, P441, DOI 10.1016/j.yhbeh.2010.01.014
   Kuzawa CW, 2009, HORM BEHAV, V56, P429, DOI 10.1016/j.yhbeh.2009.07.010
   Lewis John G, 2006, Clin Biochem Rev, V27, P139
   Liening S.H., 2010, SOCIAL PERSONALITY P, V4, P982, DOI DOI 10.1111/J.1751-9004.2010.00316.X
   Little AC, 2012, ETHOLOGY, V118, P775, DOI 10.1111/j.1439-0310.2012.02068.x
   Lorenz K., 1943, Zeitschrift fuer Tierpsychologie Berlin, V5, P235
   Mazur A, 1998, BEHAV BRAIN SCI, V21, P353
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   Naber FBA, 2013, J AUTISM DEV DISORD, V43, P224, DOI 10.1007/s10803-012-1536-6
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466
   PRINS HHT, 1989, BEHAVIOUR, V108, P262, DOI 10.1163/156853989X00330
   Reimers L, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00183
   Rilling JK, 2013, NEUROPSYCHOLOGIA, V51, P731, DOI 10.1016/j.neuropsychologia.2012.12.017
   Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009
   Saltzman W, 2011, PROG NEURO-PSYCHOPH, V35, P1192, DOI 10.1016/j.pnpbp.2010.09.017
   Savaskan E, 2008, PSYCHONEUROENDOCRINO, V33, P368, DOI 10.1016/j.psyneuen.2007.12.004
   Sherman GD, 2009, EMOTION, V9, P282, DOI 10.1037/a0014904
   Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703
   SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972
   Spindler P, 1961, ANTHROPOL ANZ, V25, P60
   Sprengelmeyer R, 2009, PSYCHOL SCI, V20, P149, DOI 10.1111/j.1467-9280.2009.02272.x
   van Anders SM, 2011, PSYCHONEUROENDOCRINO, V36, P1265, DOI 10.1016/j.psyneuen.2011.06.001
   van Honka J, 2011, P NATL ACAD SCI USA, V108, P3448, DOI 10.1073/pnas.1011891108
   Weisman O, 2015, PSYCHONEUROENDOCRINO, V58, P23, DOI 10.1016/j.psyneuen.2015.04.007
   Weisman O, 2014, PROG NEURO-PSYCHOPH, V49, P47, DOI 10.1016/j.pnpbp.2013.11.006
   WINGFIELD JC, 1990, AM NAT, V136, P829, DOI 10.1086/285134
   WINSLOW JT, 1991, J NEUROSCI, V11, P2032
   Wittfoth-Schardt D, 2012, NEUROPSYCHOPHARMACOL, V37, P1799, DOI 10.1038/npp.2012.47
   Wright ND, 2012, P ROY SOC B-BIOL SCI, V279, P2275, DOI 10.1098/rspb.2011.2523
   Zink CF, 2003, J NEUROSCI, V23, P8092
NR 73
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2016
VL 11
IS 11
AR e0166617
DI 10.1371/journal.pone.0166617
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC7WC
UT WOS:000388350300079
ER

PT J
AU Liu, XX
   Ishimatsu, K
   Sotoyama, M
   Iwakiri, K
AF Liu, Xinxin
   Ishimatsu, Kazuma
   Sotoyama, Midori
   Iwakiri, Kazuyuki
TI Positive emotion inducement modulates cardiovascular responses caused by
   mental work
SO JOURNAL OF PHYSIOLOGICAL ANTHROPOLOGY
LA English
DT Article
DE Positive emotion; Mental work; Blood pressure; Total peripheral
   resistance
ID WHITE-COLLAR WORKERS; BLOOD-PRESSURE; JOB STRAIN; STRESS; HEALTH; TASKS;
   HYPERTENSION; OXYTOCIN; HUMANS; RISK
AB Background: Positive emotion is considered as an important factor related to health-relevant biological processes, including cardiovascular responses. To explore the possibility of using positive emotion as a tool to manage cardiovascular response of white-collar workers, we examined the influence on cardiovascular response of positive emotion inducement before a mental work.
   Method: Seventeen healthy males participated and performed a 10-min, PC-based Stroop color word task as their mental work. Before the task, 60 pleasant pictures chosen from the International Affective Picture System were presented in a random order under a positive emotion inducement condition while a gray screen was presented under a control condition. A 30-min relaxation period after completing the task was provided to examine the aftereffects of positive emotion inducement. Throughout these periods, systolic and diastolic blood pressure, mean arterial blood pressure, heart rate, stroke volume, cardiac output, and total peripheral resistance were measured continuously.
   Results: Blood pressure and total peripheral resistance were lower during the picture presentation period under the positive emotion inducement period compared to the control condition. All indices did not differ during the color word task period. During the relaxation period after the task, however, blood pressure and total peripheral resistance were lower under the positive emotion inducement condition compared to the control condition.
   Conclusion: Positive emotion inducement before a mental work beneficially modulates cardiovascular responses, suggesting that positive emotion inducement may be a useful tool to manage the cardiovascular response to mental work.
C1 [Liu, Xinxin; Sotoyama, Midori; Iwakiri, Kazuyuki] Natl Inst Occupat Safety & Hlth, Tama Ku, 6-21-1 Nagao, Kawasaki, Kanagawa 2148585, Japan.
   [Ishimatsu, Kazuma] Jikei Inst, Grad Sch Hlth Care Sci, Yodogawa Ku, 1-2-8 Miyahara, Osaka 5320003, Japan.
RP Liu, XX (reprint author), Natl Inst Occupat Safety & Hlth, Tama Ku, 6-21-1 Nagao, Kawasaki, Kanagawa 2148585, Japan.
EM liu@h.jniosh.johas.go.jp
FU Japan Society for the Promotion of Science [24700746]
FX This study was partly supported by a Grant-in-Aid for Young Scientists
   (B) (No. 24700746) from the Japan Society for the Promotion of Science.
   This funding partly supported the measuring equipment and necessary
   materials.
CR Baumgartner T, 2006, INT J PSYCHOPHYSIOL, V60, P34, DOI 10.1016/j.ijpsycho.2005.04.007
   Chida Y, 2008, PSYCHOL BULL, V134, P829, DOI 10.1037/a0013342
   Chida Y, 2010, HYPERTENSION, V55, P1026, DOI 10.1161/HYPERTENSIONAHA.109.146621
   Fredrickson BL, 1998, COGNITION EMOTION, V12, P191
   Fredrickson BL, 2004, PHILOS T ROY SOC B, V359, P1367, DOI 10.1098/rstb.2004.1512
   Fredrickson BL, 2000, MOTIV EMOTION, V24, P237, DOI 10.1023/A:1010796329158
   GEENEN V, 1988, PSYCHONEUROENDOCRINO, V13, P367, DOI 10.1016/0306-4530(88)90043-1
   Guimont C, 2006, AM J PUBLIC HEALTH, V96, P1436, DOI 10.2105/AJPH.2004.057679
   Gutkowska J, 2014, BRAZ J MED BIOL RES, V47, P206, DOI 10.1590/1414-431X20133309
   Key BL, 2009, ANN BEHAV MED, V38, P154, DOI 10.1007/s12160-009-9104-9
   Kop WJ, 2011, BIOL PSYCHOL, V86, P230, DOI 10.1016/j.biopsycho.2010.12.003
   Laflamme N, 1998, SCAND J WORK ENV HEA, V24, P334
   Lang PJ, 2005, A6 U FLOR
   Lang P. J., 1980, TECHNOLOGY MENTAL HL, P119
   LEVENSON RW, 1990, PSYCHOPHYSIOLOGY, V27, P363, DOI 10.1111/j.1469-8986.1990.tb02330.x
   LEVENSON RW, 1991, PSYCHOL AGING, V6, P28, DOI 10.1037/0882-7974.6.1.28
   LIGHT KC, 1989, HEALTH PSYCHOL, V8, P577, DOI 10.1037/0278-6133.8.5.577
   Liu Xinxin, 2007, Journal of Physiological Anthropology, V26, P165, DOI 10.2114/jpa2.26.165
   Liu XX, 2011, IND HEALTH, V49, P265
   Liu XX, 2010, J PHYSIOL ANTHROPOL, V29, P35, DOI 10.2114/jpa2.29.35
   Liu Xinxin, 2007, Journal of Physiological Anthropology, V26, P355, DOI 10.2114/jpa2.26.355
   Marrero AF, 1997, INT J PSYCHOPHYSIOL, V25, P185, DOI 10.1016/S0167-8760(96)00737-4
   McClelland AB, 2009, INT J PSYCHOPHYSIOL, V74, P166, DOI 10.1016/j.ijpsycho.2009.08.008
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   ROSE RM, 1978, PSYCHOSOM MED, V40, P142
   Sakairi Y., 2003, B I HLTH SPORT SCI U, V26, P27
   Steptoe A, 2005, P NATL ACAD SCI USA, V102, P6508, DOI 10.1073/pnas.0409174102
   Steptoe A, 2009, J PERS, V77, P1747, DOI 10.1111/j.1467-6494.2009.00599.x
   WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566
NR 29
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1880-6805
J9 J PHYSIOL ANTHROPOL
JI J. Physiol. Anthropol.
PD NOV 16
PY 2016
VL 35
AR 27
DI 10.1186/s40101-016-0116-4
PG 8
WC Physiology
SC Physiology
GA EC4TY
UT WOS:000388128100001
PM 27852306
ER

PT J
AU Gordon, I
   Jack, A
   Pretzsch, CM
   Vander Wyk, B
   Leckman, JF
   Feldman, R
   Pelphrey, KA
AF Gordon, Ilanit
   Jack, Allison
   Pretzsch, Charlotte M.
   Vander Wyk, Brent
   Leckman, James F.
   Feldman, Ruth
   Pelphrey, Kevin A.
TI Intranasal Oxytocin Enhances Connectivity in the Neural Circuitry
   Supporting Social Motivation and Social Perception in Children with
   Autism
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FUNCTIONAL CONNECTIVITY; SPECTRUM DISORDERS; MULTISENSORY INTERACTIONS;
   PSYCHOTROPIC MEDICATION; BIOLOGICAL-MOTION; MATERNAL-BEHAVIOR;
   NUCLEUS-ACCUMBENS; BRAIN MECHANISMS; HUMANS; FMRI
AB Oxytocin (OT) has become a focus in investigations of autism spectrum disorder (ASD). The social deficits that characterize ASD may relate to reduced connectivity between brain sites on the mesolimbic reward pathway (nucleus accumbens; amygdala) that receive OT projections and contribute to social motivation, and cortical sites involved in social perception. Using functional magnetic resonance imaging and a randomized, double blind, placebo-controlled crossover design, we show that OT administration in ASD increases activity in brain regions important for perceiving social-emotional information. Further, OT enhances connectivity between nodes of the brain's reward and socioemotional processing systems, and does so preferentially for social (versus nonsocial) stimuli. This effect is observed both while viewing coherent versus scrambled biological motion, and while listening to happy versus angry voices. Our findings suggest a mechanism by which intranasal OT may bolster social motivation-one that could, in future, be harnessed to augment behavioral treatments for ASD.
C1 [Gordon, Ilanit; Pretzsch, Charlotte M.; Vander Wyk, Brent; Leckman, James F.; Feldman, Ruth] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
   [Gordon, Ilanit; Feldman, Ruth] Bar Ilan Univ, Dept Psychol, IL-5290002 Ramat Gan, Israel.
   [Jack, Allison; Pelphrey, Kevin A.] George Washington Univ, Autism & Neurodev Disorders Inst, Ashburn, VA 20147 USA.
RP Gordon, I (reprint author), Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.; Gordon, I (reprint author), Bar Ilan Univ, Dept Psychol, IL-5290002 Ramat Gan, Israel.; Jack, A (reprint author), George Washington Univ, Autism & Neurodev Disorders Inst, Ashburn, VA 20147 USA.
EM ilush.gordon@gmail.com; allisonjack@gwu.edu
FU US-Israel Bi-National Science Foundation; Harris Family Professorship;
   Lee Foundation; Brown-Coxe Postdoctoral Award; NIH [T32 MH018268-31]
FX We are grateful to the children and families who participated in this
   study. We would like to thank Osama Abdelghany from the Yale New Haven
   Hospital Investigational Drug Pharmacy for his work in providing the
   active compound and placebo. We also thank Randi Bennett, Molly Lucas
   and Cara Cordeaux for their help in data collection. This research was
   supported by the US-Israel Bi-National Science Foundation (Feldman,
   Pelphrey, Gordon, and Leckman), the Harris Family Professorship
   (Pelphrey), a Lee Foundation Postdoctoral Award (Gordon), the Brown-Coxe
   Postdoctoral Award (Jack), and NIH Grant T32 MH018268-31 Training
   Program in Childhood Neuropsychiatric Disorders (Jack).
CR Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Atzil S, 2011, NEUROPSYCHOPHARMACOL, V36, P2603, DOI 10.1038/npp.2011.172
   Baribeau DA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00335
   Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Belin P, 2008, BEHAV RES METHODS, V40, P531, DOI 10.3758/BRM.40.2.531
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Brothers L., 1990, CONCEPTS NEUROSCIENC, V1, P27, DOI DOI 10.1093/SCHBUL/SBQ012
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Castelli F, 2002, BRAIN, V125, P1839, DOI 10.1093/brain/awf189
   Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004
   Chevallier C, 2012, TRENDS COGN SCI, V16, P231, DOI 10.1016/j.tics.2012.02.007
   Constantino J. N, 2005, SOCIAL RESPONSIVENES
   Coury DL, 2012, PEDIATRICS, V130, pS69, DOI 10.1542/peds.2012-0900D
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dawson G, 2005, DEV NEUROPSYCHOL, V27, P403, DOI 10.1207/s15326942dn2703_6
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Gordon I, 2011, DEV COGN NEUROS-NETH, V1, P471, DOI 10.1016/j.dcn.2011.07.007
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hertz U, 2010, NEUROIMAGE, V52, P617, DOI 10.1016/j.neuroimage.2010.04.186
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   Kaiser MD, 2010, P NATL ACAD SCI USA, V107, P21223, DOI 10.1073/pnas.1010412107
   Kanwisher N, 1997, J NEUROSCI, V17, P4302
   Keri S, 2009, COGN AFFECT BEHAV NE, V9, P237, DOI 10.3758/CABN.9.3.237
   Kohls G, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-10
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lamy D, 2008, CONSCIOUS COGN, V17, P688, DOI 10.1016/j.concog.2007.11.001
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   Love TM, 2014, PHARMACOL BIOCHEM BE, V119, P49, DOI 10.1016/j.pbb.2013.06.011
   Martuzzi R, 2007, CEREB CORTEX, V17, P1672, DOI 10.1093/cercor/bhl077
   Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053
   Miller G, 2013, SCIENCE, V339, P267, DOI 10.1126/science.339.6117.267
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   Morris JP, 2006, NEUROPSYCHOLOGIA, V44, P1919, DOI 10.1016/j.neuropsychologia.2006.01.035
   Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005
   O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046
   Paz R, 2013, CURR OPIN NEUROBIOL, V23, P381, DOI [10.1016/j.conb.2013.01.008, 10.1016/j.conb.2013.1.008]
   Pelphrey KA, 2006, CURR DIR PSYCHOL SCI, V15, P136, DOI 10.1111/j.0963-7214.2006.00423.x
   Pelphrey KA, 2003, J NEUROSCI, V23, P6819
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018
   Raij T, 2010, EUR J NEUROSCI, V31, P1772, DOI 10.1111/j.1460-9568.2010.07213.x
   ROSS HE, 2009, THE JOURNAL OF NEURO, V29, P1312, DOI DOI 10.1523/JNEUR0SCI.5039-08.2009
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014
   Salimpoor VN, 2013, SCIENCE, V340, P216, DOI 10.1126/science.1231059
   Sander D, 2005, NEUROIMAGE, V28, P848, DOI 10.1016/j.neuroimage.2005.06.023
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Schubart JR, 2014, AUTISM, V18, P631, DOI 10.1177/1362361313497537
   Scott-Van Zeeland AA, 2010, AUTISM RES, V3, P53, DOI 10.1002/aur.122
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   Taylor AE, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00360
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Wong DF, 2009, NEUROPSYCHOPHARMACOL, V34, P187, DOI 10.1038/npp.2008.166
   Woolrich M, 2008, NEUROIMAGE, V41, P286, DOI 10.1016/j.neuroimage.2008.02.042
   Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023
   Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931
   Xiao ZW, 2005, HUM BRAIN MAPP, V25, P212, DOI 10.1002/hbm.20105
   Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162
NR 78
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 15
PY 2016
VL 6
AR 35054
DI 10.1038/srep35054
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EB8OX
UT WOS:000387651700001
PM 27845765
ER

PT J
AU Hinde, K
   Muth, C
   Maninger, N
   Ragen, BJ
   Larke, RH
   Jarcho, MR
   Mendoza, SP
   Mason, WA
   Ferrer, E
   Cherry, SR
   Fisher-Phelps, ML
   Bales, KL
AF Hinde, Katie
   Muth, Chelsea
   Maninger, Nicole
   Ragen, Benjamin J.
   Larke, Rebecca H.
   Jarcho, Michael R.
   Mendoza, Sally P.
   Mason, William A.
   Ferrer, Emilio
   Cherry, Simon R.
   Fisher-Phelps, Marina L.
   Bales, Karen L.
TI Challenges to the Pair Bond: Neural and Hormonal Effects of Separation
   and Reunion in a Monogamous Primate
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE attachment; separation; stress; cortisol; oxytocin; vasopressin
ID MALE PRAIRIE VOLES; MONKEY CALLICEBUS-CUPREUS; NEW-WORLD MONKEYS;
   SOCIAL-BEHAVIOR; TITI MONKEYS; OXYTOCIN RECEPTORS; SAGUINUS-OEDIPUS;
   PATERNAL CARE; RESPONSES; VASOPRESSIN
AB Social monogamy at its most basic is a group structure in which two adults form a unit and share a territory. However, many socially monogamous pairs display attachment relationships known as pair bonds, in which there is a mutual preference for the partner and distress upon separation. The neural and hormonal basis of this response to separation from the adult pair mate is under-studied. In this project, we examined this response in male titi monkeys (Callicebus cupreus), a socially monogamous New World primate. Males underwent a baseline scan, a short separation (48 h), a long separation (approximately 2 weeks), a reunion with the female pair mate and an encounter with a female stranger (with nine males completing all five conditions). Regional cerebral glucose metabolism was measured via positron emission tomography (PET) imaging using [18F]-fluorodeoxyglucose (FDG) co-registered with structural magnetic resonance imaging (MRI), and region of interest (ROI) analysis was carried out. In addition, plasma was collected and assayed for cortisol, oxytocin (OT), vasopressin (AVP), glucose and insulin concentrations. Cerebrospinal fluid (CSF) was collected and assayed for OT and AVP. We used generalized estimating equations (GEE) to examine significant changes from baseline. Short separations were characterized by decreases in FDG uptake, in comparison to baseline, in the lateral septum (LS), ventral pallidum (VP), paraventricular nucleus of the hypothalamus (PVN), periaqueductal gray (PAG), and cerebellum, as well as increases in CSF OT, and plasma cortisol and insulin. Long separations differed from baseline in reduced FDG uptake in the central amygdala (CeA), reduced whole brain FDG uptake, increased CSF OT and increased plasma insulin. The response on encounter with a stranger female depended on whether or not the male had previously reproduced with his pair mate, suggesting that transitions to fatherhood contribute to the neurobiology underlying response to a novel female. Reunion with the partner appeared to stimulate coordinated release of central and peripheral OT. The observed changes suggest the involvement of OT and AVP systems, as well as limbic and striatal areas, during separation and reunion from the pair mate.
C1 [Hinde, Katie; Maninger, Nicole; Ragen, Benjamin J.; Larke, Rebecca H.; Mendoza, Sally P.; Mason, William A.; Fisher-Phelps, Marina L.; Bales, Karen L.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.
   [Hinde, Katie] Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ USA.
   [Hinde, Katie] Arizona State Univ, Ctr Evolut & Med, Tempe, AZ USA.
   [Muth, Chelsea; Ragen, Benjamin J.; Larke, Rebecca H.; Mendoza, Sally P.; Mason, William A.; Ferrer, Emilio; Bales, Karen L.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.
   [Muth, Chelsea] Penn State Univ, Human Dev & Family Studies, University Pk, PA 16802 USA.
   [Jarcho, Michael R.] Siena Coll, Dept Psychol, Loudonville, NY USA.
   [Cherry, Simon R.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
   [Fisher-Phelps, Marina L.] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA.
RP Bales, KL (reprint author), Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.; Bales, KL (reprint author), Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.
EM klbales@ucdavis.edu
FU NIH [HD053555]; Office of Research Infrastructure Programs
   [P51OD011107]; Good Nature Institute
FX This research was supported by NIH HD053555 to KLB, Office of Research
   Infrastructure Programs grant P51OD011107 to CNPRC, and Good Nature
   Institute to KLB. We also gratefully acknowledge the following for
   research assistance: Luana Griffin, Thomas Schaefer, Carlos Almeida and
   Bales lab undergraduate volunteers; Jaleh Janatpour and Kevin Theis for
   animal care; Dr. Angela Colagross-Schouten, Dr. Kari Christe, Dr. Laura.
   Summers and the veterinary staff for care and assistance with the PET
   scans; Vanessa Bakula, Sarah Grisso, Deborah Kent and Research Services
   at CNPRC; Michelle Connell, Jennifer Fung and Doug Rowland at the Center
   for Molecular and Genomic Imaging; and Richard Larson and the Center for
   Imaging Sciences at UC Davis.
CR Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Bales KL, 2005, AM J PRIMATOL, V66, P73
   Bales KL, 2007, BRAIN RES, V1184, P245, DOI 10.1016/j.brainres.2007.09.087
   Bales KL, 2016, HORM BEHAV, V77, P249, DOI 10.1016/j.yhbeh.2015.05.021
   Bales K. L., 2011, NEW DIRECTIONS RELAT, P91
   Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bosch OJ, 2016, PSYCHONEUROENDOCRINO, V64, P66, DOI 10.1016/j.psyneuen.2015.11.011
   Bosch OJ, 2009, NEUROPSYCHOPHARMACOL, V34, P1406, DOI 10.1038/npp.2008.154
   Bowlby J., 1969, ATTACHMENT LOSS
   Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Cacioppo JT, 2015, PERSPECT PSYCHOL SCI, V10, P202, DOI 10.1177/1745691614564876
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Campbell JC, 2009, PHYSIOL BEHAV, V98, P367, DOI 10.1016/j.physbeh.2009.06.014
   Carp SB, 2016, AM J PRIMATOL, V78, P326, DOI 10.1002/ajp.22450
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Conley O. G, 2012, NEUROBIOLOGICAL BASI
   Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607
   Eisenberger NI, 2015, ANNU REV PSYCHOL, V66, P601, DOI 10.1146/annurev-psych-010213-115146
   Engh AL, 2006, P ROY SOC B-BIOL SCI, V273, P707, DOI 10.1098/rspb.2005.3378
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Fernandez-Duque E, 2009, ANNU REV ANTHROPOL, V38, P115, DOI 10.1146/annurev-anthro-091908-164334
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12382
   Freeman SM, 2016, PSYCHONEUROENDOCRINO, V66, P185, DOI 10.1016/j.psyneuen.2016.01.014
   Freeman S. M., 2016, SOC NEUROSCI, V20, P1, DOI [10.1080/17470919.2016.1156570, DOI 10.1080/17470919.2016.1156570]
   Ge Y, 2002, BRAIN RES, V927, P204, DOI 10.1016/S0006-8993(01)03346-7
   Gettler LT, 2014, EVOL ANTHROPOL, V23, P146, DOI 10.1002/evan.21412
   Gobrogge K, 2015, HORM BEHAV, V76, P91, DOI 10.1016/j.yhbeh.2015.08.010
   Gold PW, 2015, MOL PSYCHIATR, V20, P32, DOI 10.1038/mp.2014.163
   Gordon I, 2008, PSYCHOPHYSIOLOGY, V45, P349, DOI 10.1111/j.1469-8986.2008.00649.x
   Grippo AJ, 2007, PSYCHONEUROENDOCRINO, V32, P966, DOI 10.1016/j.psyneuen.2007.07.004
   Gundel H, 2003, AM J PSYCHIAT, V160, P1946, DOI 10.1176/appi.ajp.160.11.1946
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   Hedeker D., 2006, LONGITUDINAL DATA AN, V451
   HENNESSY MB, 1995, PHYSIOL BEHAV, V57, P331, DOI 10.1016/0031-9384(94)00250-9
   Johnson ZV, 2016, HORM BEHAV, V79, P8, DOI 10.1016/j.yhbeh.2015.11.011
   Kenkel WM, 2012, J NEUROENDOCRINOL, V24, P874, DOI 10.1111/j.1365-2826.2012.02301.x
   Kersting A, 2009, AM J PSYCHIAT, V166, P1402, DOI 10.1176/appi.ajp.2009.08121875
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Laugero KD, 2011, PROSTAG LEUKOTR ESS, V84, P71, DOI 10.1016/j.plefa.2010.12.003
   Mason WA, 1998, PSYCHONEUROENDOCRINO, V23, P765
   McNeal N, 2014, AUTON NEUROSCI-BASIC, V180, P9, DOI 10.1016/j.autneu.2013.10.001
   Mendoza S.P., 1991, P311
   Mendoza SP, 2000, BIOLOGY OF ANIMAL STRESS, P227, DOI 10.1079/9780851993591.0227
   MENDOZA SP, 1986, PHYSIOL BEHAV, V38, P795, DOI 10.1016/0031-9384(86)90045-4
   MENDOZA SP, 1986, ANIM BEHAV, V34, P1336, DOI 10.1016/S0003-3472(86)80205-6
   Mendoza S. P., HORMONES BRAIN BEHAV
   Mendoza SP, 1999, UFAW HDB CARE MANAGE, V1, P591
   Muth C, 2016, EDUC PSYCHOL MEAS, V76, P64, DOI 10.1177/0013164415580432
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   O'Connor MF, 2008, NEUROIMAGE, V42, P969, DOI 10.1016/j.neuroimage.2008.04.256
   Ragen BJ, 2015, NEUROSCIENCE, V290, P421, DOI 10.1016/j.neuroscience.2015.01.023
   Ragen BJ, 2015, NEUROSCIENCE, V287, P32, DOI 10.1016/j.neuroscience.2014.11.053
   Ragen BJ, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P288
   Ragen BJ, 2012, AM J PRIMATOL, V74, P758, DOI 10.1002/ajp.22026
   Resendez SL, 2016, ELIFE, V5, DOI 10.7554/eLife.15325
   Resendez SL, 2013, REV NEUROSCIENCE, V24, P51, DOI 10.1515/revneuro-2012-0068
   Resendez SL, 2012, J NEUROSCI, V32, P6771, DOI 10.1523/JNEUROSCI.5779-11.2012
   Roitman MF, 2005, NEURON, V45, P587, DOI 10.1016/j.neuron.2004.12.055
   Saga Y., 2016, CEREB CORTEX, DOI [10.1093/cercor/bhw107, DOI 10.1093/CERCOR/BHW107]
   Saltzman W, 2015, J ZOOL, V296, P23, DOI 10.1111/jzo.12211
   Saltzman W, 2014, J NEUROENDOCRINOL, V26, P685, DOI 10.1111/jne.12176
   Sanchez S, 1999, AM J PRIMATOL, V48, P99, DOI 10.1002/(SICI)1098-2345(1999)48:2<99::AID-AJP2>3.0.CO;2-6
   Sanchez S, 2008, FOLIA PRIMATOL, V79, P458, DOI 10.1159/000151718
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Schneiderman I, 2014, SOC COGN AFFECT NEUR, V9, P1524, DOI 10.1093/scan/nst142
   Sheehan TP, 2004, BRAIN RES REV, V46, P71, DOI 10.1016/j.brainresrev.2004.04.009
   Soares-Cunha C, 2016, NEUROSCI BIOBEHAV R, V68, P370, DOI 10.1016/j.neubiorev.2016.05.021
   Sun P, 2014, BEHAV BRAIN RES, V265, P22, DOI 10.1016/j.bbr.2014.02.016
   Tardif S, 2006, ILAR J, V47, P307
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Uchino BN, 2006, J BEHAV MED, V29, P377, DOI 10.1007/s10865-006-9056-5
   Valeggia CR, 1999, AM J PRIMATOL, V47, P183, DOI 10.1002/(SICI)1098-2345(1999)47:3<183::AID-AJP1>3.0.CO;2-J
   Valtorta NK, 2016, HEART, V102, P1009, DOI 10.1136/heartjnl-2015-308790
   Van Belle S, 2016, AM J PRIMATOL, V78, P204, DOI 10.1002/ajp.22493
   Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Yang J, 2011, PEPTIDES, V32, P1255, DOI 10.1016/j.peptides.2011.03.007
   Yokoyama R., 2016, NEUROIMAGE, DOI [10.1016/j.neuroimage.2016.09.052, DOI 10.1016/J.NEUROIMAGE.2016.09.052]
   Young LJ, 2005, J COMP NEUROL, V493, P51, DOI 10.1002/cne.20771
   Ziegler TE, 2006, BIOL LETT-UK, V2, P181, DOI 10.1098/rsbl.2005.0426
   Zingg H. H., 2002, HORMONES BRAIN BEHAV, P779
NR 84
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD NOV 14
PY 2016
VL 10
AR 221
DI 10.3389/fnbeh.2016.00221
PG 15
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA EB9OE
UT WOS:000387724000001
ER

PT J
AU Maaloe, N
   Housseine, N
   Bygbjerg, IC
   Meguid, T
   Khamis, RS
   Mohamed, AG
   Nielsen, BB
   van Roosmalen, J
AF Maaloe, Nanna
   Housseine, Natasha
   Bygbjerg, Ib Christian
   Meguid, Tarek
   Khamis, Rashid Saleh
   Mohamed, Ali Gharib
   Nielsen, Birgitte Bruun
   van Roosmalen, Jos
TI Stillbirths and quality of care during labour at the low resource
   referral hospital of Zanzibar: a case-control study
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Tanzania; Low resource; Stillbirths; Labour; Quality of care; PartoMa;
   Caesarean section; Severe hypertensive disorders; Oxytocin;
   Criterion-based audit; Case-control study; Guidelines; Partograph
ID MIDDLE-INCOME COUNTRIES; CRITERION-BASED AUDIT; DAR-ES-SALAAM; OBSTETRIC
   FISTULA; CESAREAN DELIVERY; PROLONGED LABOR; RURAL HOSPITALS; NEONATAL
   DEATH; RISK-FACTORS; TANZANIA
AB Background: To study determinants of stillbirths as indicators of quality of care during labour in an East African low resource referral hospital.
   Methods: A criterion-based unmatched unblinded case-control study of singleton stillbirths with birthweight >= 2000 g (n = 139), compared to controls with birthweight >= 2000 g and Apgar score >= 7 (n = 249).
   Results: The overall facility-based stillbirth rate was 59 per 1000 total births, of which 25 % was not reported in the hospital's registers. The majority of singletons had birthweight >= 2000 g (n = 139; 79 %), and foetal heart rate was present on admission in 72 (52 %) of these (intra-hospital stillbirths). Overall, poor quality of care during labour was the prevailing determinant of 71 (99 %) intra-hospital stillbirths, and median time from last foetal heart assessment till diagnosis of foetal death or delivery was 210 min. (interquartile range: 75-315 min.). Of intra-hospital stillbirths, 26 (36 %) received oxytocin augmentation (23 % among controls; odds ratio (OR) 1.86, 95 % confidential interval (CI) 1.06-3.27); 15 (58 %) on doubtful indication where either labour progress was normal or less dangerous interventions could have been effective, e.g. rupture of membranes. Substandard management of prolonged labour frequently led to unnecessary caesarean sections. The caesarean section rate among all stillbirths was 26 % (11 % among controls; OR 2.94, 95 % CI 1.68-5.14), and vacuum extraction was hardly ever done. Of women experiencing stillbirth, 27 (19 %) had severe hypertensive disorders (4 % among controls; OR 5.76, 95 % CI 2.70-12.31), but 18 (67 %) of these did not receive antihypertensives. An additional 33 (24 %) did not have blood pressure recorded during active labour. When compared to controls, stillbirths were characterized by longer admissions during labour. However, substandard care was prevalent in both cases and controls and caused potential risks for the entire population. Notably, women with foetal death on admission were in the biggest danger of neglect.
   Conclusions: Intrapartum management of women experiencing stillbirth was a simple yet strong indicator of quality of care. Substandard care led to perinatal as well as maternal risks, which furthermore were related to unnecessary complex, time consuming, and costly interventions. Improvement of obstetric care is warranted to end preventable birth-related deaths and disabilities.
C1 [Maaloe, Nanna; Bygbjerg, Ib Christian] Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, Oster Farimagsgade 5,Bldg 9, DK-1353 Copenhagen K, Denmark.
   [Housseine, Natasha; Meguid, Tarek; Khamis, Rashid Saleh; Mohamed, Ali Gharib] Mnazi Mmoja Hosp, Zanzibar, Tanzania.
   [Housseine, Natasha] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Meguid, Tarek] State Univ Zanzibar, Sch Hlth & Med Sci, POB 146, Zanzibar, Tanzania.
   [Nielsen, Birgitte Bruun] Copenhagen Univ Hosp, Rigshosp, Dept Obstet, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
   [van Roosmalen, Jos] Vrije Univ Amsterdam, Athena Inst, De Boelelaan 1105, NL-1081 HV Amsterdam, Netherlands.
RP Maaloe, N (reprint author), Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, Oster Farimagsgade 5,Bldg 9, DK-1353 Copenhagen K, Denmark.
EM nannamaaloe@outlook.com
FU Lundbeck foundation; Laerdal foundation; Augustinus foundation
FX The present study was funded by grants from the Lundbeck, Laerdal, and
   Augustinus foundations.
CR Afnan-Holmes H, 2015, LANCET GLOB HEALTH, V3, pE396, DOI 10.1016/S2214-109X(15)00059-5
   Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7
   Ameh CA, 2012, MATERN CHILD HLTH J, V16, P941, DOI 10.1007/s10995-011-0832-7
   Aminu M, 2014, BJOG-INT J OBSTET GY, V121, P141, DOI 10.1111/1471-0528.12995
   Ayres-De-Campos D, 2015, INT J GYNECOL OBSTET, V131, P13, DOI 10.1016/j.ijgo.2015.06.020
   Baxley E, 2014, ALSO ADV LIFE SUPPOR
   Begum B, 2010, Mymensingh Med J, V19, P340
   Braddick L, 2016, INT J GYNECOL OBSTET, V132, P89, DOI 10.1016/j.ijgo.2015.06.047
   Cowgill KD, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0592-2
   Drost E, 2010, BJOG-INT J OBSTET GY, V117, P1553, DOI 10.1111/j.1471-0528.2010.02691.x
   Gans-Lartey F, 2013, MIDWIFERY, V29, P461, DOI 10.1016/j.midw.2012.03.002
   Geelhoed D, 2015, INT J GYNECOL OBSTET, V130, P148, DOI 10.1016/j.ijgo.2015.03.027
   Gold KJ, 2014, INT J GYNECOL OBSTET, V125, P223, DOI 10.1016/j.ijgo.2013.12.006
   Goldenberg RL, 2013, INT J GYNECOL OBSTET, V122, P230, DOI 10.1016/j.ijgo.2013.04.008
   Guerrier Gilles, 2013, Int J Womens Health, V5, P495, DOI 10.2147/IJWH.S48179
   Harrison MS, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S9
   HMIS Z, 2012, ZANZIBAR ANN HLTH B, V2011
   Jonsson M., 2009, USE MISUSE OXYTOCIN
   Kerber KJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S9
   Kidanto HL, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-45
   KWAST BE, 1994, LANCET, V343, P1399
   Lavender T, 2013, COCHRANE DB SYST REV, V7
   Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5
   Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7
   Lewis D, 2015, J GYNECOL OBSTET, V131, P9
   Litorp H, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-107
   Maaloe N, 2012, BJOG-INT J OBSTET GY, V119, P605, DOI 10.1111/j.1471-0528.2012.03284.x
   Maaloe N, 2012, ACTA OBSTET GYN SCAN, V91, P1069, DOI 10.1111/j.1600-0412.2012.01474.x
   McClure EM, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S7
   National Bureau of Statistics, 2010, TANZ DEM HLTH SURV
   Nyamtema AS, 2008, INT J GYNECOL OBSTET, V100, P37, DOI 10.1016/j.ijgo.2007.06.049
   O'Neill SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054588
   ODRISCOLL K, 1973, BMJ-BRIT MED J, V3, P135
   Oladapo O, 2015, BJOG, V123, P928
   Requejo J, 2012, BUILDING FUTURE WOME
   Ridgeway JJ, 2004, OBSTET GYNECOL, V103, P506, DOI 10.1097/01.AOG.0000113619.67704.99
   Puchalski Ritchie LM, 2016, J CLIN EPID IN PRESS
   Shah S, 2016, INT HEALTH, V8, P89, DOI 10.1093/inthealth/ihv051
   Souza JP, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0029-4
   Stanton C, 2008, BIRTH-ISS PERINAT C, V35, P204, DOI 10.1111/j.1523-536X.2008.00241.x
   Tebeu PM, 2012, INT UROGYNECOL J, V23, P387, DOI 10.1007/s00192-011-1622-x
   UNICEF, 2015, LEV TRENDS CHILD MOR
   VANROOSMALEN J, 1989, BRIT J OBSTET GYNAEC, V96, P827
   Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55
   von Dadelszen Peter, 2012, J Obstet Gynaecol Can, V34, P917
   WHO MoH Z, 2007, MILL DEV GOALS PROGR
   World Health Organization, 2007, MAN COMPL PREGN CHIL
   World Health Organization, 2010, INT CLASS DIS 10 REV
NR 48
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD NOV 10
PY 2016
VL 16
AR 351
DI 10.1186/s12884-016-1142-2
PG 12
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EB7YS
UT WOS:000387608100002
PM 27832753
ER

PT J
AU Corriveau, S
   Blouin, S
   Burt, E
   Rousseau, E
   Pasquier, JC
AF Corriveau, Stephanie
   Blouin, Simon
   Burt, Elyse
   Rousseau, Eric
   Pasquier, Jean-Charles
TI Antenatal montelukast treatment reduces uterine activity associated with
   inflammation in a pregnant rat model
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Inflammation; Leukotrienes; Montelukast; Pregnant rats; Tocolytics;
   Uterine contractions
ID LEUKOTRIENE-RECEPTOR ANTAGONISTS; PRETERM DELIVERY; AMNIOTIC-FLUID;
   IN-VITRO; PROSTAGLANDINS; PARTURITION; MYOMETRIUM; CONTRACTILITY;
   INFECTION; 5-LIPOXYGENASE
AB Objective: The potency of acute montelukast treatment, a leukotriene receptor antagonist, has been demonstrated as tocolytic on in vitro myometrial contractility. This study assessed the ability of a 48 h montelukast treatment to modify in vitro contractions under inflammatory conditions in a pregnant rat model.
   Study design: Pregnant Sprague-Dawley rats were injected intraperitoneally (gestational days 20-22) with lipopolysaccharides (LPS) 200 mu g/kg (4 treatments at 12 h intervals) alone or combined with montelukast 10 mg/kg/day or a saline solution for a 48 h period. Uterine rings (n = 72) were obtained by median laparotomy at day 22. Spontaneous contractile activities were compared using pharmacological compounds (oxytocin, nifedipine) along with assessment of contractile parameters. Myometrial subcellular fractions were also analyzed by Western blot to quantify oxytocin, cysteinyl leukotriene receptors and inflammation markers.
   Results: In in vitro experiments, the area under the curve, the amplitude and the duration of phasic contractions were significantly reduced following 48 h of LPS + montelukast treatment comparatively to the LPS group. Moreover, in this same group, oxytocin (10(-9)-10(-7) M) largely decreased uterine sensitivity (p = 0.04). Following LPS and montelukast treatment, the tocolytic effectiveness of nifedipine (10(-9)-10(-7) M) was increased (p < 0.01). Western blot analysis confirmed the presence of type 1 CysLT receptors in all treated groups. Hence, montelukast treatment restored TNF-alpha. and COX-2 basal levels.
   Conclusion: Our results strongly suggest that montelukast treatment could facilitate a relative uterine quiescence by decreasing its sensitivity to uterotonic agent or by increasing tocolytic efficiency under proinflammatory conditions. Published by Elsevier Ireland Ltd.
C1 [Corriveau, Stephanie; Blouin, Simon; Burt, Elyse; Rousseau, Eric; Pasquier, Jean-Charles] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Obstet & Gynecol, Sherbrooke, PQ, Canada.
RP Pasquier, JC (reprint author), Univ Sherbrooke, Fac Med & Hlth Sci, Obstet & Gynecol, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada.
EM jean-charles.pasquier@usherbrooke.ca
FU Foundation of Stars
FX Foundation of Stars.
CR Bakhireva LN, 2007, J ALLERGY CLIN IMMUN, V119, P618, DOI 10.1016/j.jaci.2006.12.618
   BERNAL AL, 1989, BRIT J OBSTET GYNAEC, V96, P568, DOI 10.1111/j.1471-0528.1989.tb03258.x
   Bezold KY, 2013, GENOME MED, V5, DOI 10.1186/gm438
   Brown NL, 1999, MOL HUM REPROD, V5, P668, DOI 10.1093/molehr/5.7.668
   Corriveau S, 2014, EUR J OBSTET GYN R B, V177, P77, DOI 10.1016/j.ejogrb.2014.02.042
   Corriveau S, 2014, J OBSTET GYNAECOL RE, V40, P661, DOI 10.1111/jog.12247
   Corriveau S, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.009
   Cotechini T, 2014, J EXP MED, V211, P165, DOI 10.1084/jem.20130295
   Ghiani CA, 2011, ASN NEURO, V3
   Gibb W, 1998, ANN MED, V30, P235, DOI 10.3109/07853899809005850
   Girard S, 2008, CYTOKINE, V43, P54, DOI 10.1016/j.cyto.2008.04.007
   Girard S, 2012, BRAIN BEHAV IMMUN, V26, P1331, DOI 10.1016/j.bbi.2012.09.001
   Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500
   Hertelendy F, 2004, PROSTAG LEUKOTR ESS, V70, P207, DOI 10.1016/j.plefa.2003.04.009
   HILLIER SL, 1993, OBSTET GYNECOL, V81, P941
   Kahnt AS, 2013, BIOCHEM PHARMACOL, V86, P286, DOI 10.1016/j.bcp.2013.05.005
   Khanprakob T, 2012, COCHRANE DATABASE SY
   Koren G, 2010, CAN FAM PHYSICIAN, V56, P881
   Lim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034707
   Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9
   Maclntyre D. A., 2014, FASEB J, V28, P2358
   Maeba S, 2005, ANN ALLERG ASTHMA IM, V94, P670
   Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367
   Olson DM, 2003, BEST PRACT RES CL OB, V17, P717, DOI 10.1016/S1521-6934(03)00069-5
   PLISKA V, 1986, J BIOL CHEM, V261, P6984
   Ramires R, 2004, BIOCHEM BIOPH RES CO, V324, P815, DOI 10.1016/j.bbrc.2004.09.125
   Rauk PN, 2000, AM J REPROD IMMUNOL, V43, P152, DOI 10.1111/j.8755-8920.2000.430304.x
   Romero R, 2006, BJOG-INT J OBSTET GY, V113, P17, DOI 10.1111/j.1471-0528.2006.01120.x
   ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006
   ROMERO R, 1987, OBSTET GYNECOL, V70, P849
   Ross RG, 2004, AM J OBSTET GYNECOL, V190, P532, DOI 10.1016/S0002-9378(03)00949-9
   Sarkar M, 2009, EUR J CLIN PHARMACOL, V65, P1259, DOI 10.1007/s00228-009-0713-9
   Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669
   Tintinger Gregory R, 2010, ScientificWorldJournal, V10, P2403, DOI 10.1100/tsw.2010.229
   Tomari S, 2001, ANN ALLERG ASTHMA IM, V87, P156
   Wierzbicki M, 2009, MICROBIOL IMMUNOL, V53, P694, DOI 10.1111/j.1348-0421.2009.00174.x
   WORD RA, 1992, J CLIN ENDOCR METAB, V75, P1027, DOI 10.1210/jc.75.4.1027
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD NOV
PY 2016
VL 206
BP 92
EP 98
DI 10.1016/j.ejogrb.2016.08.003
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA ED3VG
UT WOS:000388776000017
PM 27649459
ER

PT J
AU Umehara, H
   Fabbri, R
   Provensi, G
   Passani, MB
AF Umehara, Hayato
   Fabbri, Roberta
   Provensi, Gustavo
   Passani, M. Beatrice
TI The hypophagic factor oleoylethanolamide differentially increases c-fos
   expression in appetite regulating centres in the brain of wild type and
   histamine deficient mice
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Histidine decarboxylase; Tuberomamillary nucleus; Hypophagia; c-Fos;
   Feeding behavior
ID RAT HYPOTHALAMIC NEURONS; FOOD-INTAKE; BASOLATERAL AMYGDALA; H-1
   RECEPTOR; WEIGHT-GAIN; NUCLEUS; ACTIVATION; BEHAVIOR; FAT; HETEROGENEITY
AB Histaminergic neurons in the hypothalamic tuberomamillary nucleus (TMN) establish connections with virtually all brain areas. Recent evidence suggests that feeding-related motivation is correlated with the activation of a subpopulation of histamine neurons in the ventral TMN that project to hypothalamic and subcortical areas controlling feeding behaviour. Oleoylethanolamide (OEA) is a hypophagic lipid-amide released by the small intestine in response to daily fat intake that indirectly activates hypothalamic oxytocin-neurons in the paraventricular (PVN) and supraoptic (SON) nuclei. We recently showed that OEA requires the integrity of neuronal histamine to fully display its hypophagic effect. Here we aimed to investigate if differences exist in OEA-induced c-Fos expression in several brain regions of fasted, histidine decarboxylase (HDC)-KO mice that do not synthesize histamine, and wild type (WT) littermates. All the brain regions examined receive histaminergic innervation and are involved in different aspects of feeding behaviour. We found that OEA increased c-Fos expression in the SON, arcuate nucleus (ARC) and the amygdala of WT mice, but not HDC-KO mice, whereas neither genotype nor treatment differences were observed in the lateral and dorsomedial hypothalamus. Furthermore, oxytocin-immunostaining was markedly increased in the neurohypophysis of WT and not in HDC-KO mice. Of note, OEA increased c-Fos expression in the nucleus of solitary tract of both genotypes. Our findings suggest that the TMN serves as a relay station to elaborate peripheral signals that control homeostatic and adaptive behavioural responses. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Umehara, Hayato; Fabbri, Roberta; Provensi, Gustavo] Univ Firenze, NEUROFARBA Sect Pharmacol & Toxicol, Viale Pieraccini 6, I-50139 Florence, Italy.
   [Passani, M. Beatrice] Univ Firenze, Dipartimento Sci Salute, Viale Pieraccini 6, I-50139 Florence, Italy.
   [Umehara, Hayato] Niigata Univ, Grad Sch Med & Dent Sci, Div Pharmacol, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.
RP Passani, MB (reprint author), Univ Firenze, Dipartimento Sci Salute, Viale Pieraccini 6, I-50139 Florence, Italy.
EM beatrice.passani@unifi.it
FU Programmi di Ricerca di Rilevante Interesse Nazionale Grant [2009
   2009ESX7T3_003 E 55.921]
FX We are grateful to Adele Romano and Silvana Gaetani for technical help.
   Funding: Programmi di Ricerca di Rilevante Interesse Nazionale Grant
   2009 2009ESX7T3_003 E 55.921.
CR Acosta-Galvan G, 2011, P NATL ACAD SCI USA, V108, P5813, DOI 10.1073/pnas.1015551108
   Anaclet C, 2009, J NEUROSCI, V29, P14423, DOI 10.1523/JNEUROSCI.2604-09.2009
   Arora S, 2006, NEUROPEPTIDES, V40, P375, DOI 10.1016/j.npep.2006.07.001
   Baumgartner I, 2010, J NEUROENDOCRINOL, V22, P557, DOI 10.1111/j.1365-2826.2010.01995.x
   Beckman TR, 2009, PHYSIOL BEHAV, V96, P568, DOI 10.1016/j.physbeh.2008.12.007
   Blandina Patrizio, 2012, Front Syst Neurosci, V6, P33, DOI 10.3389/fnsys.2012.00033
   Cai HJ, 2014, NAT NEUROSCI, V17, P1240, DOI 10.1038/nn.3767
   Campolongo P, 2009, P NATL ACAD SCI USA, V106, P8027, DOI 10.1073/pnas.0903038106
   de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582
   Deng C., 2012, BIOL PSYCHIAT, V34, P1
   Fekete E, 2002, BRAIN RES, V955, P55, DOI 10.1016/S0006-8993(02)03362-0
   Fekete EM, 2007, BRAIN RES BULL, V71, P386, DOI 10.1016/j.brainresbull.2006.10.007
   Franklin R., 2007, MOUSE BRAIN STEREOTA
   Furini C, 2014, NEUROSCI BIOBEHAV R, V47, P670, DOI 10.1016/j.neubiorev.2014.10.016
   Gaetani S, 2010, J NEUROSCI, V30, P8096, DOI 10.1523/JNEUROSCI.0036-10.2010
   Giannoni P, 2009, EUR J NEUROSCI, V29, P2363, DOI 10.1111/j.1460-9568.2009.06765.x
   Gotoh K, 2013, J NEUROCHEM, V125, P588, DOI 10.1111/jnc.12213
   Hansen HS, 2014, PHARMACOL RES, V86, P18, DOI 10.1016/j.phrs.2014.03.006
   Kask A, 2000, BRAIN RES, V887, P460, DOI 10.1016/S0006-8993(00)03034-1
   Kim SF, 2007, P NATL ACAD SCI USA, V104, P3456, DOI 10.1073/pnas.0611417104
   Kovacs A, 2012, BRAIN RES BULL, V88, P589, DOI 10.1016/j.brainresbull.2012.06.001
   Kroeze WK, 2003, NEUROPSYCHOPHARMACOL, V28, P519, DOI 10.1038/sj.npp.1300027
   Lecklin A, 1998, PHARMACOL BIOCHEM BE, V59, P753, DOI 10.1016/S0091-3057(97)00465-6
   Masaki T, 2004, DIABETES, V53, P2250, DOI 10.2337/diabetes.53.9.2250
   Munari L, 2013, NEUROPHARMACOLOGY, V70, P131, DOI 10.1016/j.neuropharm.2013.01.021
   OOKUMA K, 1989, BRAIN RES, V490, P268, DOI 10.1016/0006-8993(89)90244-8
   Ookuma K., 1993, BRAIN RES, V27, P135
   Panula P., 2014, NATURE REV NEUROSCI, V14, P72
   Parker JA, 2013, INT J OBESITY, V37, P1391, DOI 10.1038/ijo.2012.227
   Parks GS, 2014, J PHYSIOL-LONDON, V592, P2183, DOI 10.1113/jphysiol.2013.268771
   Passani MB, 2011, J PHARMACOL EXP THER, V336, P24, DOI 10.1124/jpet.110.171306
   Piomelli D, 2013, TRENDS ENDOCRIN MET, V24, P332, DOI 10.1016/j.tem.2013.03.001
   Provensi G, 2015, INFLAMM RES, V64, pS19
   Provensi G., 2015, NEUROPHARMACOLOGY
   Provensi G, 2014, P NATL ACAD SCI USA, V111, P11527, DOI 10.1073/pnas.1322016111
   Romano A, 2013, PEPTIDES, V49, P21, DOI 10.1016/j.peptides.2013.08.006
   Sakurai T, 2014, NAT REV NEUROSCI, V15, P719, DOI 10.1038/nrn3837
   Schone C, 2012, J NEUROSCI, V32, P12437, DOI 10.1523/JNEUROSCI.0706-12.2012
   Sergeeva OA, 2005, J NEUROSCI, V25, P88, DOI 10.1523/JNEUROSCI.3209-04.2005
   Soria-Gomez E, 2010, PHARMACOL RES, V61, P379, DOI 10.1016/j.phrs.2010.01.010
   Toftegaard CL, 2003, REGUL PEPTIDES, V111, P83, DOI 10.1016/S0167-0115(02)00260-4
   Umehara H, 2010, METHOD FIND EXP CLIN, V32, P733, DOI 10.1358/mf.2010.32.10.1545781
   Umehara H, 2012, NEUROCHEM INT, V61, P942, DOI 10.1016/j.neuint.2012.05.022
   Valdes JL, 2006, EUR J NEUROSCI, V23, P1352, DOI 10.1111/j.1460-9568.2006.04659.x
   West EA, 2012, BEHAV NEUROSCI, V126, P563, DOI 10.1037/a0029080
NR 45
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 2016
VL 113
BP 100
EP 107
DI 10.1016/j.phrs.2016.08.020
PN A
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ED7XU
UT WOS:000389086800010
PM 27543461
ER

PT J
AU Honceriu, C
   Ciobica, A
   Stoica, B
   Chirazi, M
   Padurariu, M
AF Honceriu, Cezar
   Ciobica, Alin
   Stoica, Bogdan
   Chirazi, Marin
   Padurariu, Manuela
TI Oxytocin Antioxidant Effects on Wistar Rats
SO REVISTA DE CHIMIE
LA English
DT Article
DE oxytocin; oxidative stress; glutathione peroxidase; malondiadehyde;
   serum
ID NEUTROPHIL-DEPENDENT MECHANISM; OXIDATIVE STRESS STATUS;
   LIPID-PEROXIDATION; RELEASE; MEMORY; INTERLEUKIN-1-BETA; DISEASE;
   PLASMA; INFLAMMATION; VASOPRESSIN
AB There are very few studies regarding the influence of oxytocin on the oxidative stress status modifications. Even more, the very few studies that exist in this area of research are suggesting controversial results, with reports stating antioxidant, pro-oxidant or sometimes no modifications at all for the specific oxidative stress determined. In this context, in the current study we decided to preliminary study the relevance of 10 days intraperitoneally oxytocin administration on one antioxidant enzyme (glutathione peroxidase-GPX) and one lipid peroxidation marker (malondialdehyde-MDA) in Wistar rats total serum, as compared to a control group of rats which received saline. Thus, we report here a significant antioxidant activity for the administration of oxytocin, as demonstrated by a significant decrease of the specific enzymatic activity of GPX and an increase of MDA concentration in the serum of Wistar rats. This could be relevant in the context of the increased awareness regarding the relevance of oxytocin in the treatment of the main neuropsychiatric disorders, especially when administrated through the intranasal route, considering also that oxidative stress represent an important landmark in these deficiencies.
C1 [Honceriu, Cezar; Ciobica, Alin; Chirazi, Marin] Alexandru Ioan Cuza Univ, Dept Mol & Expt Biol, 11 Carol I Blvd, Iasi 700506, Romania.
   [Ciobica, Alin] Romanian Acad, Iasi Branch, 8 Carol I, Iasi 700505, Romania.
   [Stoica, Bogdan; Padurariu, Manuela] Grigore T Popa Univ Med & Pharm, 16 Univ Str, Iasi 700115, Romania.
RP Honceriu, C (reprint author), Alexandru Ioan Cuza Univ, Dept Mol & Expt Biol, 11 Carol I Blvd, Iasi 700506, Romania.
EM chonceri@yahoo.fr
FU CNCS-UEFISCDI [PN-II-RU-TE-2014-4-1886]
FX The present paper is supported by a grant offered through CNCS-UEFISCDI,
   project number PN-II-RU-TE-2014-4-1886, "A complex study regarding the
   relevance of oxytocin administration in some animal models of
   neuropsychiatric disorders", 120 from 01/10/2015.
CR Balmus IM, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/3975101
   Balmus IM, 2016, SAUDI J GASTROENTERO, V22, P3, DOI 10.4103/1319-3767.173753
   Bild W, 2013, PROG NEURO-PSYCHOPH, V43, P79, DOI 10.1016/j.pnpbp.2012.12.009
   Bild W, 2013, J AFFECT DISORDERS, V145, P165, DOI 10.1016/j.jad.2012.07.024
   Bild W, 2013, J PHYSIOL BIOCHEM, V69, P147, DOI 10.1007/s13105-012-0162-2
   Biyikli NK, 2006, PEPTIDES, V27, P2249, DOI 10.1016/j.peptides.2006.03.029
   Cantemir A, 2016, REV CHIM-BUCHAREST, V67, P1725
   Cantemir A, 2016, REV CHIM-BUCHAREST, V67, P1538
   Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576
   Ciobica A, 2016, ACTA ENDOCRINOL-BUCH, V12, P65, DOI 10.4183/aeb.2016.65
   Ciobica A, 2012, PSYCHIAT DANUB, V24, P194
   Ciobica A, 2012, J MED BIOCHEM, V31, P83, DOI 10.2478/v10011-011-0053-z
   Ciobica A, 2011, J MED BIOCHEM, V30, P109, DOI 10.2478/v10011-011-0009-3
   Deing V, 2013, EXP DERMATOL, V22, P399, DOI 10.1111/exd.12155
   Dobrin R, 2016, REV CHIM-BUCHAREST, V67, P1778
   Dusunceli F, 2008, PEPTIDES, V29, P1216, DOI 10.1016/j.peptides.2008.02.010
   Finger EC, 2015, NEUROLOGY, V84, P174, DOI 10.1212/WNL.0000000000001133
   Garcia Fortea P, 2014, J MATERN-FETAL NEO M, V27, P1598
   Gavrilenko V G, 2003, Morfologiia, V124, P24
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Guastella AJ, 2015, SCHIZOPHR RES, V168, P628, DOI 10.1016/j.schres.2015.06.005
   Gurzu C, 2008, CENT EUR J BIOL, V3, P39, DOI 10.2478/s11535-008-0003-z
   HANIF K, 1982, SCIENCE, V216, P1010, DOI 10.1126/science.7079746
   Hritcu L, 2009, CENT EUR J BIOL, V4, P335, DOI 10.2478/s11535-009-0029-x
   IQBAL Z., 2013, BMC VET RES, V27, P169
   Iseri SO, 2005, PEPTIDES, V26, P483, DOI 10.1016/j.peptides.2004.10.005
   Karelina K, 2011, STROKE, V42, P3606, DOI 10.1161/STROKEAHA.111.628008
   KASTING NW, 1986, NEUROENDOCRINOLOGY, V42, P285, DOI 10.1159/000124453
   Kim SH, 2015, MOL CELL ENDOCRINOL, V403, P64, DOI 10.1016/j.mce.2014.11.008
   Kis A, 2015, HORM BEHAV, V69, P1, DOI 10.1016/j.yhbeh.2014.12.004
   LANDGRAF R, 1995, EUR J NEUROSCI, V7, P592, DOI 10.1111/j.1460-9568.1995.tb00663.x
   Mostafa T, 2015, ANDROLOGIA, V47, P209, DOI 10.1111/and.12248
   NAITO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1189, DOI 10.1016/0006-291X(91)91547-P
   NAPIERALA M., 2016, HUM EXP TOXICOL
   Nation DA, 2010, PSYCHOSOM MED, V72, P376, DOI 10.1097/PSY.0b013e3181d74c48
   Oliveira-Pelegrin GR, 2013, NEUROIMMUNOMODULAT, V20, P65, DOI 10.1159/000345044
   Padurariu M, 2013, PSYCHIAT DANUB, V25, P401
   Padurariu M, 2010, NEUROSCI LETT, V479, P317, DOI 10.1016/j.neulet.2010.05.088
   Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0
   Salzano S, 2014, P NATL ACAD SCI USA, V111, P12157, DOI 10.1073/pnas.1401712111
   Schmid B, 2001, ENDOCRINOLOGY, V142, P1380, DOI 10.1210/en.142.4.1380
   SPANGELO BL, 1994, ENDOCRINOLOGY, V135, P556, DOI 10.1210/en.135.2.556
   Stanic D, 2016, CHEM-BIOL INTERACT, V256, P134, DOI 10.1016/j.cbi.2016.07.006
   Stefanescu C, 2012, J AFFECT DISORDERS, V143, P34, DOI 10.1016/j.jad.2012.05.022
   Stoica BA, 2011, J BIOL INORG CHEM, V16, P753, DOI 10.1007/s00775-011-0777-8
   Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008
   Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301
   TUDTEPE H., 2007, REGUL PEPTIDES, V140, P101
NR 48
TC 0
Z9 0
U1 0
U2 0
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R-77131, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD NOV
PY 2016
VL 67
IS 11
BP 2246
EP 2249
PG 4
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA EC8AI
UT WOS:000388361900025
ER

PT J
AU Harrison, F
   Aerts, L
   Brodaty, H
AF Harrison, Fleur
   Aerts, Liesbeth
   Brodaty, Henry
TI Apathy in Dementia: Systematic Review of Recent Evidence on
   Pharmacological Treatments
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Review
DE Apathy; Dementia; Alzheimer's disease; BPSD; Neuropsychiatric symptoms;
   Pharmacotherapy
ID PLACEBO-CONTROLLED TRIAL; OPEN-LABEL TRIAL; ALZHEIMERS-DISEASE;
   PSYCHOLOGICAL SYMPTOMS; FRONTOTEMPORAL DEMENTIA; NEUROPSYCHIATRIC
   SYMPTOMS; LEWY BODIES; NEURODEGENERATIVE DISEASES; COGNITIVE IMPAIRMENT;
   DIAGNOSTIC-CRITERIA
AB Increasing recognition that apathy is one of the most prevalent behavioral and psychological symptoms of dementia and causes substantial caregiver distress has led to trials evaluating psychosocial and pharmacological treatments of apathy in dementia. We evaluated evidence of the efficacy of pharmacotherapies for apathy in dementia from studies since 2013. Previously reported benefits of acetylcholinesterase inhibitors and memantine were not replicated in recent studies. Antidepressants had mixed results with positive effects for apathy shown only for agomelatine, while stimulants, analgesics, and oxytocin study results were inconclusive. For some approaches, such as antipsychotic review, positive effects were found only in combination with non-pharmacological approaches. Relatively few studies assessed apathy outcomes specifically, complicating interpretation of potentially positive treatment effects; none dissected outcomes for emotional, motivational and behavioral components of apathy. Better trial design and more detailed analysis are needed in order to evaluate outcomes of pharmacological treatments for apathy.
C1 [Harrison, Fleur; Aerts, Liesbeth; Brodaty, Henry] Univ New South Wales Australia, Dementia Collaborat Res Ctr, Assessment & Better Care, Sch Psychiat, Sydney, NSW 2052, Australia.
   [Harrison, Fleur; Brodaty, Henry] Univ New South Wales Australia, Ctr Hlth Brain Ageing, Sch Psychiat, Sydney, NSW 2052, Australia.
   [Brodaty, Henry] Prince Wales Hosp, Acad Dept Old Age Psychiat, Randwick, NSW 2031, Australia.
RP Brodaty, H (reprint author), Univ New South Wales Australia, Dementia Collaborat Res Ctr, Assessment & Better Care, Sch Psychiat, Sydney, NSW 2052, Australia.; Brodaty, H (reprint author), Univ New South Wales Australia, Ctr Hlth Brain Ageing, Sch Psychiat, Sydney, NSW 2052, Australia.; Brodaty, H (reprint author), Prince Wales Hosp, Acad Dept Old Age Psychiat, Randwick, NSW 2031, Australia.
EM f.harrison@unsw.edu.au; l.aerts@unsw.edu.au; h.brodaty@unsw.edu.au
FU Sanofi; Servier; Tau Therapeutics
FX Fleur Harrison and Liesbeth Aerts declare that they have no conflict of
   interests. Henry Brodaty is on the advisory board and acted as a
   consultant for Nutricia and his department has received payment to
   participate in drug trials for AD from Sanofi, Servier, and Tau
   Therapeutics.
CR Aguera-Ortiz L, 2016, INT J GERIATR PSYCHI
   Arciniegas DB, 2013, J NEUROPSYCH CLIN N, V25, pE25, DOI 10.1176/appi.neuropsych.12060158
   Ballard Clive, 2011, Int J Palliat Nurs, V17, P424
   Barnhart W Jason, 2004, J Psychiatr Pract, V10, P196, DOI 10.1097/00131746-200405000-00010
   Berman K, 2012, AM J GERIAT PSYCHIAT, V20, P104, DOI 10.1097/JGP.0b013e31822001a6
   Borsje P, 2015, INT PSYCHOGERIATR, V27, P385, DOI 10.1017/S1041610214002282
   Brodaty H, 2013, J NEUROPSYCH CLIN N, V25, P283, DOI 10.1176/appi.neuropsych.12040080
   Brodaty H, 2012, AM J GERIAT PSYCHIAT, V20, P549, DOI 10.1097/JGP.0b013e31822be242
   Callegari I, 2016, NEURODEGENER DIS, V16, P352, DOI 10.1159/000445873
   Cipriani G, 2014, J NERV MENT DIS, V202, P718, DOI 10.1097/NMD.0000000000000190
   Clarke DE, 2011, J PSYCHOSOM RES, V70, P73, DOI 10.1016/j.jpsychores.2010.01.012
   Cumbo E, 2014, J ALZHEIMERS DIS, V39, P477, DOI 10.3233/JAD-131190
   Cummings J, 2015, J GERIATR PSYCH NEUR, V28, P159, DOI 10.1177/0891988715573534
   Cummings JL, 1997, NEUROLOGY, V48, pS10
   CUMMINGS JL, 1994, NEUROLOGY, V44, P2308
   David R, 2008, CLIN NEUROL NEUROSUR, V110, P19, DOI 10.1016/j.clineuro.2007.08.007
   Eurelings LSM, 2016, INT PSYCHOGERIATR, V28, P669, DOI 10.1017/S1041610215001751
   Ferre S, 2016, PSYCHOPHARMACOLOGY, V233, P1963, DOI 10.1007/s00213-016-4212-2
   Finger EC, 2015, NEUROLOGY, V84, P174, DOI 10.1212/WNL.0000000000001133
   FORSTL H, 1993, BRIT J PSYCHIAT, V163, P364, DOI 10.1192/bjp.163.3.364
   Freund-Levi Y, 2014, AM J GERIAT PSYCHIAT, V22, P341, DOI 10.1016/j.jagp.2013.05.005
   Dykstra Goris E, 2016, J ADV NURS, P1
   Groeneweg-Koolhoven I, 2016, J GERIATR PSYCH NEUR, V29, P178, DOI 10.1177/0891988716632914
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Guercio BJ, 2015, J ALZHEIMERS DIS, V47, P421, DOI 10.3233/JAD-150146
   Herrmann N, 2008, J CLIN PSYCHOPHARM, V28, P296, DOI 10.1097/JCP.0b013e318172b479
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huang SS, 2012, ARCH GERONTOL GERIAT, V55, P55, DOI 10.1016/j.archger.2011.04.009
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Husebo BS, 2014, INT J GERIATR PSYCH, V29, P828, DOI 10.1002/gps.4063
   Ikeda M, 2013, DEMENT GERIATR COGN, V36, P229, DOI 10.1159/000351672
   Ishii S, 2009, J AM MED DIR ASSOC, V10, P381, DOI 10.1016/j.jamda.2009.03.007
   Jesso S, 2011, BRAIN, V134, P2493, DOI 10.1093/brain/awr171
   Kaufer D, 1998, DEMENT GERIATR COGN, V9, P8, DOI 10.1159/000051193
   Kim JS, 2016, J MOV DISORD, V9, P97, DOI 10.14802/jmd.16001
   Kimura T, 2013, GERIATR GERONTOL INT, V13, P516, DOI 10.1111/ggi.12025
   Kimura T, 2013, GERIATR GERONTOL INT, V13, P506, DOI 10.1111/j.1447-0594.2012.00956.x
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kromhout MA, 2014, J NUTR HEALTH AGING, V18, P407, DOI 10.1007/s12603-013-0417-9
   Kung FC, 2012, CLIN INTERV AGING, V7, P393, DOI 10.2147/CIA.S36509
   Lanctot KL, 2016, ALZHEIMERS DEMENT
   Lanctot KL, 2007, INT PSYCHOGERIATR, V19, P151, DOI 10.1017/S1041610206003899
   Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x
   Laudon M, 2014, INT J MOL SCI, V15, P15924, DOI 10.3390/ijms150915924
   Lee DR, 2013, INT J GERIATR PSYCH, V28, P135, DOI 10.1002/gps.3799
   Leontjevas R, 2013, INT PSYCHOGERIATR, V25, P1941, DOI 10.1017/S1041610213001440
   Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043
   Levy R, 2012, REV NEUROL-FRANCE, V168, P585, DOI 10.1016/j.neurol.2012.05.003
   Ligthart SA, 2012, ARCH GEN PSYCHIAT AM, V69, P243
   Links KA, 2013, NEUROCASE, V19, P256, DOI 10.1080/13554794.2012.667120
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V
   MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Matsuzono K, 2015, J ALZHEIMERS DIS, V48, P757, DOI 10.3233/JAD-150518
   Matsuzono K, 2015, J ALZHEIMERS DIS, V45, P771, DOI 10.3233/JAD-143084
   Mendez MF, 2007, AM J GERIAT PSYCHIAT, V15, P84, DOI 10.1097/01.JGP.0000231744.69631.33
   Mitchell RA, 2011, CNS NEUROSCI THER, V17, P411, DOI 10.1111/j.1755-5949.2010.00161.x
   Mori E, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-014-0081-2
   Mori E, 2012, ANN NEUROL, V72, P41, DOI 10.1002/ana.23557
   Mulin E, 2011, INT J GERIATR PSYCH, V26, P158, DOI 10.1002/gps.2508
   PERRY EK, 1994, NEUROREPORT, V5, P747, DOI 10.1097/00001756-199403000-00002
   Racagni G, 2011, WORLD J BIOL PSYCHIA, V12, P574, DOI 10.3109/15622975.2011.595823
   Rajkumar AP, 2016, J AM MED DIR ASSOC, V17, P741, DOI 10.1016/j.jamda.2016.04.006
   Rea R, 2015, J ALZHEIMERS DIS, V48, P377, DOI 10.3233/JAD-141983
   Robert P, 2009, EUR PSYCHIAT, V24, P98, DOI 10.1016/j.eurpsy.2008.09.001
   Rosdinom R, 2013, PREV MED, V57, pS67, DOI 10.1016/j.ypmed.2012.12.025
   Rosenberg PB, 2013, J CLIN PSYCHIAT, V74, P810, DOI 10.4088/JCP.12m08099
   Ruthirakuhan M, 2016, COCHRANE DATABSE SYS
   Selbaek G, 2013, J AM MED DIR ASSOC, V14, P161, DOI 10.1016/j.jamda.2012.09.027
   Settle EC, 1998, J CLIN PSYCHIAT, V59, P25
   Shelef A, 2016, J ALZHEIMERS DIS, V51, P15, DOI 10.3233/JAD-150915
   Shimizu S, 2015, DEMENT GERIATR COG D, V5, P135, DOI 10.1159/000375527
   Skogseth R, 2008, DEMENT GERIATR COGN, V25, P559, DOI 10.1159/000137671
   Smith A, 2002, FOOD CHEM TOXICOL, V40, P1243, DOI 10.1016/S0278-6915(02)00096-0
   Spalletta G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089216
   Stanton BR, 2013, J NEUROL, V260, P2481, DOI 10.1007/s00415-013-6989-9
   STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134
   Tagariello P, 2009, ARCH GERONTOL GERIAT, V49, P246, DOI 10.1016/j.archger.2008.09.002
   Tampi RR, 2016, THER ADV CHRONIC DIS
   Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72
   Teranishi M, 2013, J CLIN PSYCHOPHARM, V33, P600, DOI 10.1097/JCP.0b013e31829798d5
   Tokuchi R, 2015, GERIATR GERONTOL INT
   Yao H, 2009, HYPERTENS RES, V32, P586, DOI 10.1038/hr.2009.65
   Zhang N, 2015, DEMENT GERIATR COGN, V40, P85, DOI 10.1159/000430808
NR 85
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
EI 1535-1645
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD NOV
PY 2016
VL 18
IS 11
AR 103
DI 10.1007/s11920-016-0737-7
PG 12
WC Psychiatry
SC Psychiatry
GA EC5II
UT WOS:000388167600006
PM 27726067
ER

PT J
AU Thienel, M
   Fritsche, A
   Heinrichs, M
   Peter, A
   Ewers, M
   Lehnert, H
   Born, J
   Hallschmid, M
AF Thienel, M.
   Fritsche, A.
   Heinrichs, M.
   Peter, A.
   Ewers, M.
   Lehnert, H.
   Born, J.
   Hallschmid, M.
TI Oxytocin's inhibitory effect on food intake is stronger in obese than
   normal-weight men
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID INTRANASAL OXYTOCIN; BRAIN; REWARD; STRESS; RATS; PATHWAYS; NUCLEUS;
   NEURONS; HUMANS; SAFETY
AB BACKGROUND/OBJECTIVES: Animal studies and pilot experiments in men indicate that the hypothalamic neuropeptide oxytocin limits food intake, and raise the question of its potential to improve metabolic control in obesity.
   SUBJECTS/METHODS: We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men. In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake. Energy expenditure was repeatedly assessed by indirect calorimetry and blood was sampled to determine concentrations of blood glucose and hormones.
   RESULTS: Oxytocin markedly reduced hunger-driven food intake in the fasted state in obese but not in normal-weight men, and led to a reduction in snack consumption in both groups, whereas energy expenditure remained generally unaffected. Hypothalamic-pituitary-adrenal axis secretion and the postprandial rise in plasma glucose were blunted by oxytocin in both groups.
   CONCLUSIONS: Oxytocin exerts an acutely inhibitory impact on food intake that is enhanced rather than decreased in obese compared with normal-weight men. This pattern puts it in contrast to other metabolically active neuropeptides and bodes well for clinical applications of oxytocin in the treatment of metabolic disorders.
C1 [Thienel, M.; Ewers, M.; Born, J.; Hallschmid, M.] Univ Tubingen, Dept Med Psychol & Behav Neurobiol, Otfried Muller Str 25, D-72076 Tubingen, Germany.
   [Fritsche, A.; Peter, A.; Born, J.; Hallschmid, M.] German Ctr Diabet Res DZD, Tubingen, Germany.
   [Fritsche, A.; Peter, A.; Born, J.; Hallschmid, M.] Univ Tubingen, Helmholtz Ctr Munich, Inst Diabet Res & Metab Dis, Tubingen, Germany.
   [Fritsche, A.; Peter, A.] Univ Hosp Tubingen, Div Endocrinol Diabetol Angiol Nephrol & Clin Che, Dept Internal Med, Tubingen, Germany.
   [Heinrichs, M.] Univ Freiburg, Lab Biol & Personal Psychol, Dept Psychol, Freiburg, Germany.
   [Heinrichs, M.] Univ Freiburg, Univ Med Ctr, Freiburg Brain Imaging Ctr, Freiburg, Germany.
   [Lehnert, H.] Univ Lubeck, Dept Internal Med 1, Lubeck, Germany.
RP Hallschmid, M (reprint author), Univ Tubingen, Dept Med Psychol & Behav Neurobiol, Otfried Muller Str 25, D-72076 Tubingen, Germany.
EM manfred.hallschmid@uni-tuebingen.de
FU Deutsche Forschungsgemeinschaft [SFB 654]; German Federal Ministry of
   Education and Research (BMBF) [01GI0925]; Helmholtz Alliance Imaging and
   Curing Environmental Metabolic Diseases (ICEMED), through the Initiative
   and Networking Fund of the Helmholtz Association
FX This study was supported by grants from the Deutsche
   Forschungsgemeinschaft (SFB 654), from the German Federal Ministry of
   Education and Research (BMBF) to the German Center for Diabetes Research
   (DZD e.V.; 01GI0925), and from the Helmholtz Alliance Imaging and Curing
   Environmental Metabolic Diseases (ICEMED), through the Initiative and
   Networking Fund of the Helmholtz Association. The funding sources had no
   input in the design and conduct of this study; in the collection,
   analysis and interpretation of the data, or in the preparation, review
   or approval of the manuscript. We thank Yvonne Riexinger and Miryam Lex
   (Department of Medical Psychology and Behavioural Neurobiology,
   University of Tubingen, Tubingen, Germany) for their invaluable
   laboratory work, and all the volunteers who participated in this study.
   German Clinical Trial Register number: DRKS00010728.
CR ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   Begg DP, 2013, NAT REV ENDOCRINOL, V9, P584, DOI 10.1038/nrendo.2013.136
   Berthoud HR, 2011, AM J PHYSIOL-REG I, V300, pR1266, DOI 10.1152/ajpregu.00028.2011
   Blevins JE, 2015, PHYSIOL BEHAV, V152, P438, DOI 10.1016/j.physbeh.2015.05.023
   Blevins JE, 2015, AM J PHYSIOL-REG I, V308, pR431, DOI 10.1152/ajpregu.00441.2014
   Blevins JE, 2004, AM J PHYSIOL-REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI 10.1073/pnas.1934666100
   Diekelmann S, 2011, NAT NEUROSCI, V14, P381, DOI 10.1038/nn.2744
   Gibson EL, 2006, PHYSIOL BEHAV, V89, P53, DOI 10.1016/j.physbeh.2006.01.024
   Hallschmid M, 2012, DIABETES, V61, P782, DOI 10.2337/db11-1390
   Hallschmid M, 2010, DIABETES, V59, P1101, DOI 10.2337/db09-1493
   Halpern B, 2015, EXPERT OPIN DRUG SAF, V14, P305, DOI 10.1517/14740338.2015.994502
   Higgs S, 2008, PHYSIOL BEHAV, V94, P454, DOI 10.1016/j.physbeh.2008.02.011
   Ho JM, 2013, ENDOCRINOLOGY, V154, P589, DOI 10.1210/en.2012-1751
   Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0
   Jeukendrup AE, 2005, INT J SPORTS MED, V26, pS28, DOI 10.1055/s-2004-830512
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Lowe MR, 2009, APPETITE, V53, P114, DOI 10.1016/j.appet.2009.05.016
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Maejima Y, 2015, NEUROENDOCRINOLOGY, V101, P35, DOI 10.1159/000371636
   Maejima Y, 2011, AGING-US, V3, P1169
   Melis MR, 2009, EUR J NEUROSCI, V30, P1349, DOI 10.1111/j.1460-9568.2009.06912.x
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Miras AD, 2014, INT J OBESITY, V38, P325, DOI 10.1038/ijo.2013.205
   Morton GJ, 2014, NAT REV NEUROSCI, V15, P367, DOI 10.1038/nrn3745
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Nummenmaa L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031089
   OLSON BR, 1991, AM J PHYSIOL, V260, pR448
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   Sabatier N, 2003, J NEUROSCI, V23, P10351
   Schultes B, 2005, DIABETES CARE, V28, P2884, DOI 10.2337/diacare.28.12.2884
   Steyer R, 1997, MEHRDIMENSIONALE BEF
   Stunkard AJ, 1985, PSYCHOSOM RES, V29, P71, DOI DOI 10.1016/0022-3999(85)90010-8
   Ulrich-Lai YM, 2010, P NATL ACAD SCI USA, V107, P20529, DOI 10.1073/pnas.1007740107
   VANSTRIEN T, 1986, INT J EAT DISORDER, V5, P747, DOI 10.1002/1098-108X(198605)5:4<747::AID-EAT2260050413>3.0.CO;2-6
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
   Ziauddeen H, 2012, NAT REV NEUROSCI, V13, P279, DOI 10.1038/nrn3212
NR 40
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD NOV
PY 2016
VL 40
IS 11
BP 1707
EP 1714
DI 10.1038/ijo.2016.149
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EC4TT
UT WOS:000388127600015
PM 27553712
ER

PT J
AU Eul, J
   Verres, R
AF Eul, J.
   Verres, R.
TI Effects of Psychoactive Substances on the Desire For Love and for Sex
   and on Sexual Performance - Results of a Questionnaire-Study with 1 616
   People - Mostly with Multiple Drug Use Experience
SO SUCHTTHERAPIE
LA German
DT Article
DE psychoactive substances; feelings of love; libido; sexual performance;
   MDMA
ID PROTECTIVE FACTORS; ALCOHOL; RISK; CONSUMPTION; BEHAVIOR; MDMA;
   INTOXICATION; COHERENCE; OXYTOCIN; PATTERNS
AB Anonymous questionnaires were distributed to 1616 drug using individuals to enquire about changes in (A) the need for love and affection, (B) the desire for sexual experiences, and (C) the sexual performance after consuming drugs. The questionnaire assessed the effects of 9 main drugs, as well as 25 other psychoactive substances. The highest increase in need for love, together with a significantly elevated libido, was reported after the use of ecstasy (MDMA), followed by cannabis. Cocaine was associated with the highest libido and the most intense sexual performance, although with no significant increase in feeling of love and affection. Poppers and cocaine were often consumed to increase sexual desire. However, with regard to eliciting feelings of love and affection, Poppers take the penultimate place among all drugs. Alcohol, psyilocybin mushrooms, amphetamines, LSD, and heroin are not considered important with regard to sexuality. The consumption of high doses of drugs compared to moderate doses has inhibiting effects (except for ecstasy/MDMA) with regard to the study's 3 parameters. Drug use, as described in the study, may be viewed as an act of self-medication. A better understanding of the link between moderate drug use and satisfying sexual experiences could lead to a more mindful use of psychoactive substances.
C1 [Eul, J.] Inst Empir & Interdisziplinare Drogen Forsch, Berlin, Germany.
   [Verres, R.] Heidelberg Univ, Inst Med Psychol, Heidelberg, Germany.
RP Verres, R (reprint author), Klinikum Univ Heidelberg, Inst Med Psychol, Bergheimer Str 20, D-69115 Heidelberg, Germany.
EM rolf.verres@hotmail.de
CR Aguilar-Raab C, 2011, SUCHTTHERAPIE, V12, P125, DOI 10.1055/s-0031-1271728
   Aguilar-Raab C, 2014, HDB HEIDELBERGER DRO
   Bellis MA, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-155
   Cacioppo S, 2012, J SEX MED, V9, P1048, DOI 10.1111/j.1743-6109.2012.02651.x
   Calafat A, 2008, ADICCIONES, V20, P37
   Castilla J, 1999, DRUG ALCOHOL DEPEN, V56, P47, DOI 10.1016/S0376-8716(99)00008-3
   Crenshaw TL, 1993, GOLDBERG JP SEXUAL P
   Drumright LN, 2006, SUBST USE MISUSE, V41, P1551, DOI 10.1080/10826080600847894
   Meckel Fischer F, 2015, THERAPY SUBSTANCE
   Foxman B, 2006, SEX TRANSM DIS, V33, P156, DOI 10.1097/01.olq.0000187210.53010.10
   Gallagher KE, 2010, AGGRESSIVE BEHAV, V36, P405, DOI 10.1002/ab.20351
   GAY GR, 1982, J PSYCHOACTIVE DRUGS, V14, P111
   George WH, 2011, HORM BEHAV, V59, P730, DOI 10.1016/j.yhbeh.2011.03.006
   Grof S., 2008, LSD PSYCHOTHERAPY
   Gudelsky GA, 2008, PHARMACOL BIOCHEM BE, V90, P198, DOI 10.1016/j.pbb.2007.10.003
   Hagenbach D, 2011, ALBERT HOFMANN SEIN
   Hermle L, 2015, FORTSCHR NEUROL PSYC, V83, P506, DOI 10.1055/s-0035-1553717
   Hobson A., 2010, OPTIMIERTE GEHIRN
   Jovanovic H, 2008, NEUROIMAGE, V39, P1408, DOI 10.1016/j.neuroimage.2007.10.016
   Jungaberle H, 2008, THERAPIE PSYCHOAKTIV
   Klee H, 1998, J DRUG ISSUES, V28, P33
   Kyung-Hee C, 2005, AIDS EDUC PREV, V17, P418
   Luchters S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-384
   MALATESTA VJ, 1982, J SEX RES, V18, P1
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   Palha AP, 2008, ADV PSYCHOSOM MED, V29, P131, DOI 10.1159/000126628
   Passie T, 2005, MED HYPOTHESES, V64, P899, DOI 10.1016/j.mehy.2004.11.044
   Pfeiffer-Genschel T, 2012, BERICHT 2012 NATL RE
   Rawson RA, 2002, J SUBST ABUSE TREAT, V22, P103, DOI 10.1016/S0740-5472(01)00215-X
   Riley AJ, 1993, SEXUAL PHARMACOLOGY
   Romanelli Frank, 2003, Top HIV Med, V11, P25
   Ross M W, 2001, Annu Rev Sex Res, V12, P290
   Rusch M, 2004, SEX TRANSM DIS, V31, P492, DOI 10.1097/01.olq.0000135991.21755.18
   Schmid Y, 2015, EUR NEUROPSYCHOPHARM, V25, P17, DOI 10.1016/j.euroneuro.2014.11.020
   Schuster RM, 2012, J INT NEUROPSYCH SOC, V18, P827, DOI 10.1017/S1355617712000586
   Sumnall HR, 2007, J PSYCHOPHARMACOL, V21, P525, DOI 10.1177/0269881106075590
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   Ullrich-Kleinmanns J, 2008, SUCHTTHERAPIE, V9, P12, DOI 10.1055/s-2008-1046795
   Vallejo-Medina P, 2013, J SEX MED, V10, P333, DOI 10.1111/j.1743-6109.2012.02977.x
   Wippermann CEM, 2015, Z GESUNDHEITSPSYCHOL, V23, P31, DOI 10.1026/0943-8149/a000133
NR 40
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 1439-9903
EI 1439-989X
J9 SUCHTTHERAPIE
JI Suchttherapie
PD NOV
PY 2016
VL 17
IS 4
BP 153
EP 160
DI 10.1055/s-0042-115228
PG 8
WC Psychiatry
SC Psychiatry
GA EC9ZX
UT WOS:000388503900005
ER

PT J
AU del Razo, RA
   Bales, KL
AF del Razo, Rocio Arias
   Bales, Karen L.
TI Exploration in a dispersal task: Effects of early experience and
   correlation with other behaviors in prairie voles (Microtus ochrogaster)
SO BEHAVIOURAL PROCESSES
LA English
DT Article
DE Dispersal; Individual variation; Parental care; Natural variation; Vole
ID SPONTANEOUS MATERNAL-BEHAVIOR; EARLY REARING EXPERIENCE; NATAL
   DISPERSAL; INDIVIDUAL-DIFFERENCES; ALLOPARENTAL BEHAVIOR; NATURAL
   VARIATION; GENE-EXPRESSION; SEX-DIFFERENCES; CARE; OXYTOCIN
AB Socially monogamous prairie voles (Microtus ochrogaster) display remarkable individual variation in social behaviors, which has been associated with differences in early life experience and neuropeptide receptor densities. These differences are also seen in the wild, where approximately 70% of young voles remain in their natal group as non-breeding alloparents, while the other 30% disperse. We investigated whether natural variation in early parental care could contribute to offspring's willingness to "disperse" (willingness to explore) in a laboratory context. Behavioral differences between dispersers and residents could also provide a way to interpret individual variation in other behaviors commonly observed under laboratory conditions. Breeder pairs ranked as high, medium or low-contact, according to the amount of early parental care they provided to offspring, were used to produce and rear experimental subjects. Effects of early parental care on the offspring's willingness to disperse were seen at post-natal day 21, with high-contact offspring spending more time in the start cage and low-contact offspring spending more time exploring. Variations in parental care were also associated with differences in juvenile and adult behaviors that could potentially encourage philopatry or dispersal behavior in the wild. High-contact offspring displayed less anxiety-like behavior compared to low-contact animals. Low-contact offspring displayed the lowest amount of alloparental care. High-contact offspring spent more time in side-by-side contact with a potential partner compared to medium and low-contact offspring. These results suggest that variations in early parental care can impact weanlings' exploratory behavior, but that philopatry is not driven by high anxiety. (C) 2016 Elsevier B.V. All rights reserved.
C1 [del Razo, Rocio Arias; Bales, Karen L.] Univ Calif Davis, Dept Psychol, One Shields Ave, Davis, CA 95616 USA.
RP Bales, KL (reprint author), Univ Calif Davis, Dept Psychol, One Shields Ave, Davis, CA 95616 USA.
EM klbales@ucdavis.edu
FU National Institutes of Health [HD060117]
FX This research was supported by funding from National Institutes of
   Health HD060117 to KLB.
CR Ahern TH, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.017.2009
   Alter MD, 2009, BIOL PSYCHIAT, V66, P1061, DOI 10.1016/j.biopsych.2009.05.026
   Bales KL, 2007, DEV PSYCHOBIOL, V49, P335, DOI 10.1002/dev.20216
   Bales KL, 2012, HORM BEHAV, V61, P313, DOI 10.1016/j.yhbeh.2011.12.013
   Bales Karen L, 2011, Front Psychiatry, V2, P24, DOI 10.3389/fpsyt.2011.00024
   Bales KL, 2004, DEV PSYCHOBIOL, V44, P123, DOI 10.1002/dev.10165
   BEKOFF M, 1977, AM NAT, V111, P715, DOI 10.1086/283201
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   CARTER CS, 1993, SCI AM, V268, P100
   Champagne FA, 2003, ENDOCRINOLOGY, V144, P4720, DOI 10.1210/en.2003-0564
   DeVries AC, 1999, CAN J ZOOL, V77, P885, DOI 10.1139/cjz-77-6-885
   Dingemanse NJ, 2003, P ROY SOC B-BIOL SCI, V270, P741, DOI 10.1098/rspb.2002.2300
   Ellingsen DM, 2016, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01986
   Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155
   Francis DD, 1999, BIOL PSYCHIAT, V46, P1153, DOI 10.1016/S0006-3223(99)00237-1
   Francis DD, 2000, J NEUROENDOCRINOL, V12, P1145, DOI 10.1046/j.1365-2826.2000.00599.x
   GETZ LL, 1994, ETHOL ECOL EVOL, V6, P267
   GETZ LL, 1987, AM ZOOL, V27, P909
   GETZ LL, 1992, AM MIDL NAT, V128, P197, DOI 10.2307/2426425
   Getz LL, 1997, AM MIDL NAT, V138, P412, DOI 10.2307/2426833
   Getz LL, 1996, AM SCI, V84, P56
   Hoset KS, 2011, BEHAV ECOL, V22, P176, DOI 10.1093/beheco/arq188
   Lin YK, 2006, J MAMMAL, V87, P446, DOI 10.1644/05-MAMM-A-201R1.1
   Liu D, 2000, J NEUROENDOCRINOL, V12, P5
   Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659
   Liu RY, 2000, J NEUROPATH EXP NEUR, V59, P314
   Lonstein JS, 2001, J COMP PSYCHOL, V115, P53, DOI 10.1037//0735-7036.115.1.53
   Lucia KE, 2008, BEHAV ECOL, V19, P774, DOI 10.1093/beheco/arn028
   Maruyama K, 2012, J PHYSIOL SCI, V62, P259, DOI 10.1007/s12576-012-0205-z
   MCGUIRE B, 1993, BEHAV ECOL SOCIOBIOL, V32, P293
   McGuire B, 2013, J MAMMAL, V94, P40, DOI 10.1644/11-MAMM-A-387.1
   Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Olazabal DE, 2005, DEV PSYCHOBIOL, V47, P166, DOI 10.1002/dev.20077
   Ophir AG, 2008, P NATL ACAD SCI USA, V105, P1249, DOI 10.1073/pnas.0709116105
   Perkeybile AM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00191
   Perkeybile AM, 2015, PHYSIOL BEHAV, V147, P149, DOI 10.1016/j.physbeh.2015.04.024
   Perkeybile AM, 2015, BEHAV BRAIN RES, V283, P37, DOI 10.1016/j.bbr.2015.01.025
   Perkeybile AM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00021
   Roberts RL, 1998, CAN J ZOOL, V76, P1862, DOI 10.1139/cjz-76-10-1862
   Sailer U, 2016, NEUROIMAGE, V139, P360, DOI 10.1016/j.neuroimage.2016.06.031
   Seelke A. M. H., 2015, J COMP NEUROL
   Starr-Phillips EJ, 2014, DEV PSYCHOBIOL, V56, P1017, DOI 10.1002/dev.21182
   Stone AI, 2010, BEHAV PROCESS, V83, P8, DOI 10.1016/j.beproc.2009.08.008
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F
   Yoder JM, 2004, BEHAV ECOL, V15, P469, DOI 10.1093/beheco/arh037
NR 48
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-6357
EI 1872-8308
J9 BEHAV PROCESS
JI Behav. Processes
PD NOV
PY 2016
VL 132
BP 66
EP 75
DI 10.1016/j.beproc.2016.10.002
PG 10
WC Psychology, Biological; Behavioral Sciences; Zoology
SC Psychology; Behavioral Sciences; Zoology
GA EB6VY
UT WOS:000387524900010
ER

PT J
AU Litvin, Y
   Turner, CA
   Rios, MB
   Maras, PM
   Chaudhury, S
   Baker, MR
   Blandino, P
   Watson, SJ
   Akil, H
   McEwen, B
AF Litvin, Yoav
   Turner, Cortney A.
   Rios, Mariel B.
   Maras, Pamela M.
   Chaudhury, Sraboni
   Baker, Miriam R.
   Blandino, Peter, Jr.
   Watson, Stanley J., Jr.
   Akil, Huda
   McEwen, Bruce
TI Fibroblast growth factor 2 alters the oxytocin receptor in a
   developmental model of anxiety-like behavior in male rat pups
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Anxiety; Fear; Stress; FGF2; Oxytocin; Depression
ID EXTENDED AMYGDALA; SOCIAL-BEHAVIOR; BRAIN; VASOPRESSIN; ANTIDEPRESSANT;
   FGF-2
AB We aimed to determine the short-term effects of early-life stress in the form of maternal separation (MS) on anxiety-like behavior in male rat pups. In order to assess anxiety, we measured 40 kHz separation-induced ultrasonic vocalizations (USV) on postnatal day (PND) 11. We further aimed to evaluate the potential involvement of two neurochemical systems known to regulate social and anxiety-like behaviors throughout life: oxytocin (OT) and fibroblast growth factor 2 (FGF2). For these purposes, we tested the effects of neonatal administration (on PND1) of an acute dose of FGF2 on USV and its potential interaction with MS. In addition, we validated the anxiolytic effects of OT and measured oxytocin receptor (OTR) gene expression, binding and epigenetic regulation via histone acetylation. Our results show that MS potentiated USV while acute administration of OT and FGF2 attenuated them. Further, we found that both FGF2 and MS increased OTR gene expression and the association of acH3K14 with the OTR promoter in the bed nucleus of the stria terminalis (BNST). Comparable changes, though not as pronounced, were also found for the central amygdala (CeA). Our findings suggest that FGF2 may exert its anxiolytic effects in male MS rats by a compensatory increase in the acetylation of the OTR promoter to overcome reduced OT levels in the BNST. (C) 2016 Published by Elsevier Inc.
C1 [Litvin, Yoav; Rios, Mariel B.; Baker, Miriam R.; McEwen, Bruce] Rockefeller Univ, Neuroendocrinol Lab, 1230 York Ave,Box 165, New York, NY 10065 USA.
   [Turner, Cortney A.; Maras, Pamela M.; Chaudhury, Sraboni; Blandino, Peter, Jr.; Watson, Stanley J., Jr.; Akil, Huda] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.
RP McEwen, B (reprint author), Rockefeller Univ, Neuroendocrinol Lab, 1230 York Ave,Box 165, New York, NY 10065 USA.
EM mcewen@rockefeller.edu
FU Hope for Depression Research Foundation (HDRF); NIDA [5 P01 DA021633];
   ONR [N00014-09-1-0598, N00014-12-1-0366]; Pritzker Neuropsychiatric
   Disorders Research Consortium
FX The authors declare no competing financial interests. The authors would
   like to thank James Stewart and Angela Koelsch for the technical help.
   The studies detailed herein were made possible by funding from the Hope
   for Depression Research Foundation (HDRF; RGA# DTF Phase II (D) (McEwen-
   PI)). This work was also supported by NIDA (grant number 5 P01
   DA021633), ONR (grant numbers N00014-09-1-0598 and N00014-12-1-0366) and
   the Pritzker Neuropsychiatric Disorders Research Consortium.
CR Alheid GF, 1998, NEUROSCIENCE, V84, P967, DOI 10.1016/S0306-4522(97)00560-5
   Beery AK, 2010, NEUROSCIENCE, V169, P665, DOI 10.1016/j.neuroscience.2010.05.023
   Calcagnoli F, 2014, HORM BEHAV, V65, P427, DOI 10.1016/j.yhbeh.2014.03.008
   Calcagnoli F, 2014, BEHAV BRAIN RES, V261, P315, DOI 10.1016/j.bbr.2013.12.050
   Caldji C, 2000, NEUROPSYCHOPHARMACOL, V22, P219, DOI 10.1016/S0893-133X(99)00110-4
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Chaudhury S, 2014, P NATL ACAD SCI USA, V111, P11834, DOI 10.1073/pnas.1411618111
   Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109
   Eiland L, 2012, HIPPOCAMPUS, V22, P82, DOI 10.1002/hipo.20862
   Emiliano ABF, 2007, NEUROPSYCHOPHARMACOL, V32, P977, DOI 10.1038/sj.npp.1301206
   Ferris Craig, 2005, Novartis Foundation Symposium, V268, P190
   Gomez-Pinilla F, 2000, BRAIN RES BULL, V53, P283, DOI 10.1016/S0361-9230(00)00342-7
   GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hofer M. A., 2002, CURR PROTOC NEUROSCI, V8, P14
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   INSEL TR, 1991, EUR J PHARMACOL, V203, P149, DOI 10.1016/0014-2999(91)90806-2
   Jennings JH, 2013, NATURE, V496, P224, DOI 10.1038/nature12041
   Lehmann J, 2000, REV NEUROSCIENCE, V11, P383
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Lukas M, 2010, NEUROPHARMACOLOGY, V58, P78, DOI 10.1016/j.neuropharm.2009.06.020
   Lukas M., 2011, NEUROPSYCHOPHARMACOL
   Murgatroyd C, 2004, J NEUROSCI, V24, P7762, DOI 10.1523/JNEUROSCI.1614-04.2004
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Oreland S, 2010, NEUROPEPTIDES, V44, P391, DOI 10.1016/j.npep.2010.06.001
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Perez JA, 2009, J NEUROSCI, V29, P6379, DOI 10.1523/JNEUROSCI.4829-08.2009
   Sanchez MM, 2001, DEV PSYCHOPATHOL, V13, P419, DOI 10.1017/S0954579401003029
   Turner CA, 2012, NEURON, V76, P160, DOI 10.1016/j.neuron.2012.08.037
   Turner CA, 2012, BIOL PSYCHIAT, V72, P254, DOI 10.1016/j.biopsych.2012.05.025
   Turner CA, 2011, P NATL ACAD SCI USA, V108, P8021, DOI 10.1073/pnas.1103732108
   Uvnas-Moberg K, 1999, PSYCHOPHARMACOLOGY, V142, P95, DOI 10.1007/s002130050867
   Wagner JP, 1999, J NEUROSCI, V19, P6006
   Wang H, 2013, NAT NEUROSCI, V16, P919, DOI 10.1038/nn.3420
   WINSLOW JT, 1993, PSYCHOPHARMACOL BULL, V29, P409
   Zorrilla EP, 2014, FRONT NEUROENDOCRIN, V35, P234, DOI 10.1016/j.yfrne.2014.01.001
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD NOV
PY 2016
VL 86
BP 64
EP 70
DI 10.1016/j.yhbeh.2016.09.009
PG 7
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA EC3WA
UT WOS:000388056600008
PM 27693608
ER

PT J
AU Larke, RH
   Maninger, N
   Ragen, BJ
   Mendoza, SP
   Bales, KL
AF Larke, Rebecca H.
   Maninger, Nicole
   Ragen, Benjamin J.
   Mendoza, Sally P.
   Bales, Karen L.
TI Serotonin 1A agonism decreases affiliative behavior in pair-bonded titi
   monkeys
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Pair-bonding; Oxytocin; Vasopressin; Cortisol; Monogamy; 8-OH-DPAT;
   Social behavior; Primate
ID FEMALE PRAIRIE VOLES; MU-OPIOID RECEPTORS; SOCIAL ATTACHMENT;
   NUCLEUS-ACCUMBENS; MICROTUS-OCHROGASTER; CALLICEBUS-CUPREUS; OXYTOCIN
   RECEPTOR; VASOPRESSIN; CORTICOSTERONE; RAT
AB Relatively little is known about serotonergic involvement in pair-bonding despite its putative role in regulating social behavior. Here we sought to determine if pharmacological elevation of serotonin 1A (5-HT1A) receptor activity would lead to changes in social behavior in pair-bonded male titi monkeys (Callicebus cupreus). Adult males in established heterosexual pairs were injected daily with the selective 5-HT1A agonist 8-OH-DPAT or saline for 15 days using a within-subjects design. Social behavior with the female pair-mate was quantified, and plasma concentrations of oxytocin, vasopressin, and cortisol were measured. When treated with saline, subjects showed reduced plasma oxytocin concentrations, while 8-OH-DPAT treatment buffered this decrease. Treatment with 8-OH-DPAT also led to decreased plasma cortisol 15 minutes post-injection and decreased social behavior directed toward the pair-mate including approaching, initiating contact, lipsmacking, and grooming. The reduction in affiliative behavior seen with increased activity at 5-HT1A receptors indicates a substantial role of serotonin activity in the expression of social behavior. In addition, results indicate that the effects of 5-HT1A agonism on social behavior in adulthood differ between rodents and primates. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Larke, Rebecca H.; Ragen, Benjamin J.; Mendoza, Sally P.; Bales, Karen L.] Univ Calif Davis, Dept Psychol, One Shields Ave, Davis, CA 95616 USA.
   [Larke, Rebecca H.; Maninger, Nicole; Ragen, Benjamin J.; Mendoza, Sally P.; Bales, Karen L.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.
   [Ragen, Benjamin J.] NYU, Dept Anthropol, New York, NY 10003 USA.
RP Larke, RH (reprint author), Univ Calif Davis, Dept Psychol, One Shields Ave, Davis, CA 95616 USA.
EM rhlarke@ucdavis.edu
FU NICHD [HD053555]; Good Nature Institute; NIH [P51OD011107]; Autism
   Science Foundation
FX NICHD HD053555, Good Nature Institute, Autism Science Foundation, and
   NIH P51OD011107 to the California National Primate Research Center.
CR Aragona BJ, 2004, ILAR J, V45, P35
   Aragona BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.015.2009
   Aubert Y, 2013, J SEX MED, V10, P1461, DOI 10.1111/jsm.12131
   BAGDY G, 1993, BRAIN RES, V611, P330, DOI 10.1016/0006-8993(93)90521-N
   Bales KL, 2005, AM J PRIMATOL, V66, P73
   Bales KL, 2007, BRAIN RES, V1184, P245, DOI 10.1016/j.brainres.2007.09.087
   Bales KL, 2007, HORM BEHAV, V52, P274, DOI 10.1016/j.yhbeh.2007.05.004
   BARD JA, 1993, J BIOL CHEM, V268, P23422
   BELL R, 1994, NEUROSCI BIOBEHAV R, V18, P325, DOI 10.1016/0149-7634(94)90046-9
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Brambilla A, 1999, EUR NEUROPSYCHOPHARM, V10, P63, DOI 10.1016/S0924-977X(99)00056-5
   Burkett JP, 2011, NEUROPSYCHOPHARMACOL, V36, P2200, DOI 10.1038/npp.2011.117
   Carp SB, 2016, AM J PRIMATOL, V78, P326, DOI 10.1002/ajp.22450
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Cheeta S, 2001, BRAIN RES, V915, P170, DOI 10.1016/S0006-8993(01)02846-3
   DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
   Eaton JL, 2012, DEV PSYCHOBIOL, V54, P92, DOI 10.1002/dev.20566
   FEIGHNER JP, 1989, PSYCHOPATHOLOGY, V22, P21
   Feir-Walsh B. J., 1974, EDUC PSYCHOL MEAS, P789
   FULLER RW, 1990, NEUROENDOCRINOLOGY, V52, P206, DOI 10.1159/000125586
   Gehlert DR, 2014, EUR J PHARMACOL, V745, P91, DOI 10.1016/j.ejphar.2014.10.010
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   Hennessy MB, 1997, NEUROSCI BIOBEHAV R, V21, P11, DOI 10.1016/S0149-7634(96)00013-9
   HENNESSY MB, 1995, PHYSIOL BEHAV, V57, P331, DOI 10.1016/0031-9384(94)00250-9
   HOFFMAN KA, 1995, DEV PSYCHOBIOL, V28, P399, DOI 10.1002/dev.420280705
   Hostetler CM, 2011, BEHAV PHARMACOL, V22, P703, DOI 10.1097/FBP.0b013e32834affd2
   Insel TR, 1998, ADV EXP MED BIOL, V449, P215
   Jarcho MR, 2011, GENES BRAIN BEHAV, V10, P375, DOI 10.1111/j.1601-183X.2010.00677.x
   Jordan BA, 2000, NEUROPSYCHOPHARMACOL, V23, pS5, DOI 10.1016/S0893-133X(00)00143-3
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P242, DOI 10.1046/j.1365-2826.2003.00978.x
   Keebaugh AC, 2015, SOC NEUROSCI-UK, V10, P561, DOI 10.1080/17470919.2015.1040893
   Kiser D, 2012, NEUROSCI BIOBEHAV R, V36, P786, DOI 10.1016/j.neubiorev.2011.12.009
   Lim MM, 2004, J NEUROENDOCRINOL, V16, P325, DOI 10.1111/j.0953-8194.2004.01162.x
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Martin MM, 2012, PHYSIOL BEHAV, V105, P529, DOI 10.1016/j.physbeh.2011.09.015
   Mason WA, 1998, PSYCHONEUROENDOCRINO, V23, P765
   Mason W.A., 1966, TULANE STUD ZOOL, V5
   McDevitt RA, 2011, J CHEM NEUROANAT, V41, P234, DOI 10.1016/j.jchemneu.2011.05.001
   Mendoza S. P., 1999, UFAW HDB CARE MANAGE, P591
   Olivier B, 2015, EUR J PHARMACOL, V753, P2, DOI 10.1016/j.ejphar.2014.10.031
   Osei-Owusu P, 2005, J PHARMACOL EXP THER, V313, P1324, DOI 10.1124/jpet.104.082073
   Phillips KA, 2014, AM J PRIMATOL, V76, P801, DOI 10.1002/ajp.22281
   PICAZO O, 1995, BRAIN RES BULL, V37, P169, DOI 10.1016/0361-9230(94)00273-4
   Pitkow LJ, 2001, J NEUROSCI, V21, P7392
   PRZEGALINSKI E, 1989, PHARMACOL BIOCHEM BE, V33, P329, DOI 10.1016/0091-3057(89)90509-1
   Ragen BJ, 2013, PSYCHONEUROENDOCRINO, V38, P2448, DOI 10.1016/j.psyneuen.2013.05.009
   Resendez SL, 2016, ELIFE, V5, DOI 10.7554/eLife.15325
   Resendez SL, 2013, J NEUROSCI, V33, P9140, DOI 10.1523/JNEUROSCI.4123-12.2013
   Resendez SL, 2012, J NEUROSCI, V32, P6771, DOI 10.1523/JNEUROSCI.5779-11.2012
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   UvnasMoberg K, 1996, NEUROPHARMACOLOGY, V35, P1635
   Valeggia CR, 1999, AM J PRIMATOL, V47, P183, DOI 10.1002/(SICI)1098-2345(1999)47:3<183::AID-AJP1>3.0.CO;2-J
   Vicentic A, 1998, EUR J PHARMACOL, V346, P261, DOI 10.1016/S0014-2999(97)01607-5
   Whitaker-Azmitia PM, 2005, INT J DEV NEUROSCI, V23, P75, DOI 10.1016/j.ijdevneu.2004.07.022
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 58
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD NOV
PY 2016
VL 86
BP 71
EP 77
DI 10.1016/j.yhbeh.2016.10.001
PG 7
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA EC3WA
UT WOS:000388056600009
PM 27712925
ER

PT J
AU Shahid, R
   Qureshi, ZI
   Lodhi, LA
   Zia-ur-Rahman
AF Shahid, Rehmatullah
   Qureshi, Zafar Iqbal
   Lodhi, Laeeq Akbar
   Zia-ur-Rahman
TI EFFECT OF RECOMBINANT BOVINE SOMATOTROPIN (rbST) AND OXYTOCIN ON HEALTH
   BIOMARKERS, REPRODUCTIVE PERFORMANCE AND MILK COMPOSITION OF NILI-RAVI
   BUFFALOES (Bubalus bubalis) DURING SPRING AND SUMMER SEASONS
SO PAKISTAN JOURNAL OF AGRICULTURAL SCIENCES
LA English
DT Article
DE rbST and oxytocin; buffaloes; milk composition; health indicators;
   reproductive performance
ID LACTATING DAIRY-COWS
AB Bovine somatotropin (rbST) and oxytocin are used to increase milk production and for milk letdown respectively in dairy animals. The study was conducted to determine the effects of rbST and oxytocin on various health biomarkers, reproductive performance and milk composition of buffaloes during spring and hot summer. A total of 100 buffaloes were divided into four groups, A (control), B (oxytocin), C (rbST) and D (rbST+ oxytocin), with (n=15) animals in each group during spring and (n=10) during summer. Animals of respective groups received rbST (Boostin-250) 35mg on alternate days and oxytocin 10 IU before each milking, starting on day 70 postpartum till the end of lactation. Blood sample was collected to determine TOS, TAC, ALT and AST. Milk sample were analyzed for fat, protein, lactose and SNF contents. Reproductive performance parameters were assessed by rectal palpation and from farm record. Results revealed that oxytocin decreased the activities of ALT, AST, TOS and milk yield, while TAC was increased than controls. Buffaloes administered with rbST showed lower values of ALT, TOS and higher TAC than control. Milk fat, protein and lactose contents decreased due to rbST, oxytocin or rbST+ oxytocin treatment. Milk yield increased after rbST treatment and decreased with oxytocin during spring.
C1 [Shahid, Rehmatullah; Qureshi, Zafar Iqbal; Lodhi, Laeeq Akbar] Univ Agr Faisalabad, Dept Theriogenol, Fac Vet Sci, Faisalabad, Pakistan.
   [Zia-ur-Rahman] Univ Agr Faisalabad, Inst Pharm Physiol & Pharmacol, Fac Vet Sci, Faisalabad, Pakistan.
RP Shahid, R (reprint author), Univ Agr Faisalabad, Dept Theriogenol, Fac Vet Sci, Faisalabad, Pakistan.
EM rehmatdr@yahoo.com
CR Chalupa W, 1996, J DAIRY SCI, V79, P800
   CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141
   David C.L, 1977, LAB GUIDE DAIRY CHEM
   Egan H., 1981, PERSONS CHEM ANAL FO
   Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.1015
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   ESTEBAN E, 1994, J DAIRY SCI, V77, P3371
   GRAF F, 1991, J VET MED A, V38, P621
   Hafez E.S.E, 1987, REPROD FARM ANIMALS
   Hanafi EM, 2008, AM EURASIAN J AGR EN, V4, P530
   Lasheen M. A., 2008, J AGR ENV SCI, V3, P771
   HODGKINSON SC, 1991, DOMEST ANIM ENDOCRIN, V8, P343, DOI 10.1016/0739-7240(91)90002-2
   Jousan FD, 2007, J DAIRY SCI, V90, P341
   Khan B.B., 1983, PRACTICAL MANUAL INT
   LUDRI RS, 1989, J DAIRY SCI, V72, P2283, DOI 10.3168/jds.S0022-0302(89)79359-0
   Miesner MD, 2008, VET CLIN N AM-FOOD A, V24, P409, DOI 10.1016/j.cvfa.2008.02.008
   Noakes D.E., 2001, ARTHUR VET REPROD OB, P333
   Shyam K.S., 2003, J VET MED SCI, V65, P1213
   St-Pierre NR, 2014, JAVMA-J AM VET MED A, V245, P550, DOI 10.2460/javma.245.5.550
   Steen A, 2001, ACTA VET SCAND, V42, P219, DOI 10.1186/1751-0147-42-219
   Zafar I, 2013, BMC VET RES, V9, P169
   Zafar Iqbal, 2015, Tropical Animal Health and Production, V47, P21, DOI 10.1007/s11250-014-0676-4
   Zwald NR, 2004, J DAIRY SCI, V87, P4287
NR 23
TC 0
Z9 0
U1 1
U2 1
PU UNIV AGRICULTURE, FAC VETERINARY SCIENCE
PI FAISALABAD
PA UNIV AGRICULTURE, FAC VETERINARY SCIENCE, FAISALABAD, 00000, PAKISTAN
SN 0552-9034
EI 2076-0906
J9 PAK J AGR SCI
JI Pak. J. Agric. Sci.
PD NOV
PY 2016
VL 53
IS 4
BP 985
EP 990
DI 10.21162/PAKJAS/16.5538
PG 6
WC Agriculture, Multidisciplinary
SC Agriculture
GA EC0HP
UT WOS:000387780500028
ER

PT J
AU Roth, G
AF Roth, Gerhard
TI Why long-lasting therapeutic changes in the brain need time
SO PSYCHOTHERAPEUT
LA German
DT Article
DE Mental disorders; Long-term therapy; Therapeutic alliance;
   Therapy-induced neuronal reorganization; Adult neurogenesis
ID PREFRONTAL CORTEX; ADULT NEUROGENESIS; MAJOR DEPRESSION; STRESS;
   EXTINCTION; OXYTOCIN; BEHAVIOR; FEAR
AB Successful psychotherapy requires structural and functional changes in limbic brain centers; however, these differ in manner, effectiveness and dynamics. One primary factor is the therapeutic alliance, i. e. the mutual trust between patient and therapist. This factor reduces the level of stress hormones via release of the "bonding hormone" oxytocin and increases the production of serotonin and endogenous opioids. As a consequence, a rapid improvement of the mental emotional state of the patient often occurs; however, this is not accompanied by the deeper and longer lasting neuronal changes necessary to treat severe mental illnesses. This occurs only when dysfunctional habits of feeling, thinking and acting residing primarily in the basal ganglia (striatopallidum and nucleus accumbens) and amygdala are reorganized. Rather than being an explicit cognitive process this represents an implicit procedural process, which after an extensive search for resources requires a sufficient length of time and frequent rehearsal of more adaptive emotional attitudes and patterns of behavior. Apparently, this is promoted by the generation of new nerve cells from neural stem cells induced by oxytocin and neurotrophins, such as brain-derived neurotrophic factor (BDNF), taking place in the hippocampus and the basal ganglia. All these facts are in favor of a long-term psychotherapy at least in cases of severe mental diseases.
C1 [Roth, Gerhard] Univ Bremen, Inst Hirnforsch, Postfach 330440, D-28334 Bremen, Germany.
RP Roth, G (reprint author), Univ Bremen, Inst Hirnforsch, Postfach 330440, D-28334 Bremen, Germany.
EM Gerhard.Roth@uni-bremen.de
CR Benecke C, 2014, KLINISCHE PSYCHOL PS
   Benish SG, 2008, CLIN PSYCHOL REV, V28, P746, DOI 10.1016/j.cpr.2007.10.005
   Brody AL, 2001, ARCH GEN PSYCHIAT, V58, P631, DOI 10.1001/archpsyc.58.7.631
   Buchheim A, 2012, PLOS ONE, V7, P33745
   Clark DA, 2010, TRENDS COGN SCI, V14, P418, DOI 10.1016/j.tics.2010.06.007
   Curtis MA, 2007, CLIN EXP PHARMACOL P, V34, P528, DOI 10.1111/j.1440-1681.2007.04609.x
   de Weerth C, 2003, EARLY HUM DEV, V73, P39, DOI 10.1016/S0378-3782(03)00074-4
   Freud S, 1915, GW, V10, P263
   Freud S, 1923, GW, V13, P237
   Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34
   Grawe K., 2004, NEUROPSYCHOTHERAPIE
   Gray J. A., 1991, EXPLORATIONS TEMPERA, pS105
   Hautzinger M, 2000, KOGNITIVE VERHALTENS
   Holtzheimer PE, 2011, TRENDS NEUROSCI, V34, P1, DOI 10.1016/j.tins.2010.10.004
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138
   Nagai Y, 2004, NEUROIMAGE, V22, P243, DOI 10.1016/j.neuroimage.2004.01.019
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Pape HC, 2010, PHYSIOL REV, V90, P419, DOI 10.1152/physrev.00037.2009
   Ray RD, 2012, NEUROSCI BIOBEHAV R, V36, P479, DOI 10.1016/j.neubiorev.2011.08.005
   Roth G, 2016, COACHING BERATUNG GE
   Roth G, 2014, WIE GEHIRN SEELE MAC
   Rudolf G, 2012, STRUKTURBEZOGENE PSY
   Ruegg JC, 2014, GEHIRN PSYCHEUNDKORP
   Shapley CF, 2010, PSYCHOTHERTHEORRESPR, V47, P603
   Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287
   Struber N, 2014, NEUROSCI BIOBEHAV R, V38, P17, DOI 10.1016/j.neubiorev.2013.10.015
   Wampold Bruce, 2001, GREAT PSYCHOTHERAPY
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0935-6185
EI 1432-2080
J9 PSYCHOTHERAPEUT
JI Psychotherapeut
PD NOV
PY 2016
VL 61
IS 6
BP 455
EP 461
DI 10.1007/s00278-016-0142-z
PG 7
WC Psychology, Clinical; Psychology, Psychoanalysis
SC Psychology
GA EB8RY
UT WOS:000387659700005
ER

PT J
AU Strauss, GP
   Gold, JM
AF Strauss, Gregory P.
   Gold, James M.
TI A Psychometric Comparison of the Clinical Assessment Interview for
   Negative Symptoms and the Brief Negative Symptom Scale
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE psychosis; negative symptoms; assessment
ID OXYTOCIN LEVELS; LARGE-SAMPLE; SCHIZOPHRENIA; VALIDATION; CAINS;
   DEFICITS; SPEECH; INDIVIDUALS; IMPAIRMENT; EXPRESSION
AB In 2005, the National Institute of Mental Health held a consensus development conference on negative symptoms of schizophrenia. Among the important conclusions of this meeting were that there are at least 5 commonly accepted domains of negative symptoms (blunted affect, alogia, avolition, anhedonia, asociality) and that new rating scales were needed to adequately assess these constructs. Two next-generation negative symptom scales resulted from this meeting: the Brief Negative Symptom Scale (BNSS) and Clinical Assessment Interview for Negative Symptoms (CAINS). Both measures are becoming widely used and studies have demonstrated good psychometric properties for each scale. The current study provides the first direct psychometric comparison of these scales. Participants included 65 outpatients diagnosed with schizophrenia or schizoaffective disorder who completed clinical interviews, questionnaires, and neuropsychological testing. Separate raters completed the BNSS and CAINS within the same week. Results indicated that both measures had good internal consistency, convergent validity, and discriminant validity. High correspondence was observed between CAINS and BNSS blunted affect and alogia items. Moderate convergence occurred for avolition and asociality items, and low convergence was seen among anhedonia items. Findings suggest that both scales have good psychometric properties, but that there are important distinctions among the items related to motivation and pleasure.
C1 [Strauss, Gregory P.] SUNY Binghamton, Dept Psychol, POB 6000, Binghamton, NY 13902 USA.
   [Gold, James M.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.
   [Gold, James M.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA.
RP Strauss, GP (reprint author), SUNY Binghamton, Dept Psychol, POB 6000, Binghamton, NY 13902 USA.
EM gstrauss@binghamton.edu
FU National Institute of Mental Health (NIMH) [K23MH092530, R01MH080066]
FX This work was supported by National Institute of Mental Health (NIMH)
   grants K23MH092530 to G.P.S. and R01MH080066 to J.M.G.
CR Alpert M, 2002, J PSYCHIAT RES, V36, P347, DOI 10.1016/S0022-3956(02)00016-X
   ALPERT M, 1993, PSYCHIAT RES, V48, P181, DOI 10.1016/0165-1781(93)90070-W
   Alpert M, 1997, SCHIZOPHRENIA BULL, V23, P171
   Andreasen NC, 1983, SCALE ASSESSMENT NEG
   Blanchard JJ, 2011, SCHIZOPHRENIA BULL, V37, P291, DOI 10.1093/schbul/sbq104
   Buchanan RW, 2007, AM J PSYCHIAT, V164, P1593, DOI 10.1176/appi.ajp.2007.06081358
   Carpenter WT, 2016, SCHIZOPHRENIA BULL, V42, P1, DOI 10.1093/schbul/sbv160
   Chan RCK, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00007
   CHAPMAN LJ, 1976, J ABNORM PSYCHOL, V85, P374, DOI 10.1037//0021-843X.85.4.374
   Chieffi M, 2015, EUR PSYCHIAT, V30
   Cohen AS, 2008, J PSYCHIATR RES, V42, P827, DOI 10.1016/j.jpsychires.2007.08.008
   Cohen AS, 2016, J ABNORM PSYCHOL, V125, P299, DOI 10.1037/abn0000136
   Cohen AS, 2014, SCHIZOPHR RES, V160, P173, DOI 10.1016/j.schres.2014.10.032
   Cohen AS, 2010, SCHIZOPHRENIA BULL, V36, P143, DOI 10.1093/schbul/sbn061
   Engel M, 2014, PSYCHIAT RES, V220, P659, DOI 10.1016/j.psychres.2014.07.070
   First MB, 2001, COMMUNICATION
   Forbes C, 2010, SCHIZOPHR RES, V124, P36, DOI 10.1016/j.schres.2010.08.039
   Garcia-Portilla Maria Paz, 2015, Schizophr Res, V166, P115, DOI 10.1016/j.schres.2015.05.003
   Gold JM, 2013, BIOL PSYCHIAT, V74, P130, DOI 10.1016/j.biopsych.2012.12.022
   Grant PM, 2009, SCHIZOPHRENIA BULL, V35, P798, DOI 10.1093/schbul/sbn008
   Harvey PD, 2006, SCHIZOPHRENIA BULL, V32, P250, DOI 10.1093/schbul/sbj011
   HAWK AB, 1975, ARCH GEN PSYCHIAT, V32, P343
   Heerey EA, 2007, J ABNORM PSYCHOL, V116, P268, DOI 10.1037/0021-843X.116.2.268
   Horan WP, 2011, SCHIZOPHR RES, V132, P140, DOI 10.1016/j.schres.2011.06.030
   Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165
   Kirkpatrick B, 2006, SCHIZOPHRENIA BULL, V32, P214, DOI 10.1093/schbul/sbj053
   Kirkpatrick B, 2011, SCHIZOPHRENIA BULL, V37, P300, DOI 10.1093/schbul/sbq059
   KRING AM, 1994, PSYCHIAT RES, V54, P211, DOI 10.1016/0165-1781(94)90008-6
   Kring AM, 2008, SCHIZOPHRENIA BULL, V34, P819, DOI 10.1093/schbul/sbn071
   Kring Ann M, 2014, Clin Psychol Sci, V2, P443
   Kring AM, 2014, EUR NEUROPSYCHOPHARM, V24, P725, DOI 10.1016/j.euroneuro.2013.06.007
   Kring AM, 2013, AM J PSYCHIAT, V170, P165, DOI 10.1176/appi.ajp.2012.12010109
   Llerena K, 2012, SCHIZOPHR RES, V142, P65, DOI 10.1016/j.schres.2012.09.005
   Mane A, 2014, COMPR PSYCHIAT, V55, P1726, DOI 10.1016/j.comppsych.2014.05.024
   Merlotti E, 2014, J PSYCHOPATHOL, V20, P199
   Mucci A, 2015, EUR PSYCHIAT, V30, P641, DOI 10.1016/j.eurpsy.2015.01.014
   Nuechterlein KH, 2006, MATRICS CONSENSUS CO
   OVERALL JE, 1962, PSYCHOL REP, V10, P799
   Strauss GP, 2015, NEUROPSYCHOLOGY, V29, P282, DOI 10.1037/neu0000113
   Strauss GP, 2015, SCHIZOPHR RES, V162, P52, DOI 10.1016/j.schres.2015.01.022
   Strauss GP, 2015, SCHIZOPHR RES, V162, P47, DOI 10.1016/j.schres.2015.01.034
   Strauss GP, 2015, SCHIZOPHR RES, V162, P57, DOI 10.1016/j.schres.2014.12.023
   Strauss GP, 2013, J PSYCHIATR RES, V47, P783, DOI 10.1016/j.jpsychires.2013.01.015
   Strauss GP, 2012, SCHIZOPHR RES, V142, P88, DOI 10.1016/j.schres.2012.10.012
   Strauss GP, 2012, SCHIZOPHR RES, V142, P96, DOI 10.1016/j.schres.2012.09.007
   Strauss GP, 2012, AM J PSYCHIAT, V169, P364, DOI 10.1176/appi.ajp.2011.11030447
   Valiente-Gomez A, 2015, SCHIZOPHR RES, V166, P104, DOI 10.1016/j.schres.2015.06.006
   Wolf DH, 2014, SCHIZOPHRENIA BULL, V40, P1328, DOI 10.1093/schbul/sbu026
NR 48
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD NOV
PY 2016
VL 42
IS 6
BP 1384
EP 1394
DI 10.1093/schbul/sbw046
PG 11
WC Psychiatry
SC Psychiatry
GA EC3MA
UT WOS:000388029100014
PM 27174556
ER

PT J
AU Uhrig, S
   Hirth, N
   Broccoli, L
   von Wilmsdorff, M
   Bauer, M
   Sommer, C
   Zink, M
   Steiner, J
   Frodl, T
   Malchow, B
   Falkai, P
   Spanagel, R
   Hansson, AC
   Schmitt, A
AF Uhrig, Stefanie
   Hirth, Natalie
   Broccoli, Laura
   von Wilmsdorff, Martina
   Bauer, Manfred
   Sommer, Clemens
   Zink, Mathias
   Steiner, Johann
   Frodl, Thomas
   Malchow, Berend
   Falkai, Peter
   Spanagel, Rainer
   Hansson, Anita C.
   Schmitt, Andrea
TI Reduced oxytocin receptor gene expression and binding sites in different
   brain regions in schizophrenia: A post-mortem study
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Post-mortem; Oxytocin receptor; Gene expression; Receptor
   autoradiography; Antipsychotics
ID NEUROANATOMICAL DISTRIBUTION; 1ST-EPISODE SCHIZOPHRENIA; EMOTION
   RECOGNITION; SOCIAL-PERCEPTION; DEFICITS; BEHAVIOR; VASOPRESSIN; MIND;
   METAANALYSIS; CLOZAPINE
AB Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain.
   Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([I-125]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left prefrontal and middle temporal cortex, left nucleus caudatus, and right posterior superior vermis in 10 schizophrenia patients and 6 healthy controls. Furthermore, to investigate confounding effects of long-term antipsychotic medication we treated rats with clozapine or haloperidol for 12 weeks and assessed expression of the oxytocin receptor in cortical and subcortical brain regions.
   In schizophrenia patients, we found a downregulation of oxytocin receptor mRNA in the temporal cortex and a decrease in receptor binding in the vermis. In the other regions, the results showed trends in the same direction, without reaching statistical significance. We found no differences between antipsychotic-treated rats and controls.
   Downregulated expression and binding of the oxytocin receptor in brain regions involved in social cognition may lead to a dysfunction of oxytocin signaling. Our results support a dysfunction of the oxytocin receptor in schizophrenia, which may contribute to deficits of social cognition. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Uhrig, Stefanie; Hirth, Natalie; Broccoli, Laura; Spanagel, Rainer; Hansson, Anita C.] Heidelberg Univ, Med Fac Mannheim, Neuroanat Res Grp, Inst Psychopharmacol,Cent Inst Mental Hlth, D-68159 Heidelberg, Germany.
   [von Wilmsdorff, Martina] Heinrich Heine Univ, Fac Med, Dept Psychiat & Psychotherapy, Berg Landstr 2, D-40629 Dusseldorf, Germany.
   [Bauer, Manfred] Univ Leipzig, Dept Neuropathol, Liebigstr 24, D-04103 Leipzig, Germany.
   [Sommer, Clemens] Johannes Gutenberg Univ Mainz, Inst Neuropathol, Langenbeckstr 1, D-55131 Mainz, Germany.
   [Zink, Mathias] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Psychiat & Psychotherapy, D-68159 Heidelberg, Germany.
   [Steiner, Johann; Frodl, Thomas] Univ Magdeburg, Dept Psychiat & Psychotherapy, Leipziger Str 44, D-39120 Magdeburg, Germany.
   [Malchow, Berend; Falkai, Peter; Schmitt, Andrea] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
   [Schmitt, Andrea] Univ Sao Paulo, Inst Psychiat, Lab Neurosci LIM27, Rua Dr Ovidio Pires de Campos 785, BR-05453010 Sao Paulo, SP, Brazil.
RP Schmitt, A (reprint author), Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
EM Andrea.Schmitt@med.uni-muenchen.de
FU European Commission [LSHM-CT-2004-503039, Marie-Curie IN-SENS
   FP7-2013-PEOPLE 607616]; German Federal Ministry of Education and
   Research (BMBF) through the Integrated Network IntegraMent (Integrated
   Understanding of Causes and Mechanisms in Mental Disorders) under e:Med
   Programme [01ZX1314I SP6, 01ZX1311A SP3]; Deutsche
   Forschungsgemeinschaft [DFG HA6102/1-1, SFB1134]
FX The study was supported by the European Commission under the Sixth
   Framework Programme (BrainNet Europe II, LSHM-CT-2004-503039) and under
   the Seventh Framework Programme (Marie-Curie IN-SENS FP7-2013-PEOPLE
   607616). Furthermore, this work was funded by the German Federal
   Ministry of Education and Research (BMBF) through the Integrated Network
   IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental
   Disorders) under the auspices of the e:Med Programme (grant number
   01ZX1314I SP6 to Peter Falkai and 01ZX1311A SP3 to AC Hansson) and
   Deutsche Forschungsgemeinschaft (DFG HA6102/1-1, DFG center grant
   (SFB1134) to AC Hansson and R Spanagel).
CR Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056
   Andreasen NC, 2008, SCHIZOPHRENIA BULL, V34, P708, DOI 10.1093/schbul/sbn034
   Andreasen NC, 1999, BIOL PSYCHIAT, V46, P908, DOI 10.1016/S0006-3223(99)00152-3
   Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Bartholomeusz CF, 2015, SCHIZOPHR RES, V168, P614, DOI 10.1016/j.schres.2015.06.007
   Bicks LK, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01805
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Bosia M, 2012, CURR TOP MED CHEM, V12, P2284
   Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z
   Caldwell HK, 2009, MOL PSYCHIATR, V14, P190, DOI 10.1038/sj.mp.4002150
   Chini B, 2014, BIOL PSYCHIAT, V76, P360, DOI 10.1016/j.biopsych.2013.08.029
   Cohen M, 2012, INT J NEUROPSYCHOPH, V15, P297, DOI 10.1017/S146114571100068X
   Davis MC, 2014, SCHIZOPHR RES, V159, P353, DOI 10.1016/j.schres.2014.09.006
   Elands J, 1988, J Chem Neuroanat, V1, P293
   Falkai P., 2011, SCHIZOPHRENIA CURREN, P31
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Green MF, 1996, AM J PSYCHIAT, V153, P321
   Green MF, 2015, NAT REV NEUROSCI, V16, P620, DOI 10.1038/nrn4005
   Gromann PM, 2013, BRAIN, V136, P1968, DOI 10.1093/brain/awt076
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Haijma SV, 2013, SCHIZOPHRENIA BULL, V39, P1129, DOI 10.1093/schbul/sbs118
   Haram M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00009
   Hirth N., 2016, P NATL ACAD SCI US
   HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383
   Hurlemann R, 2016, BIOL PSYCHIAT, V79, P185, DOI 10.1016/j.biopsych.2015.05.013
   Insel TR, 2016, BIOL PSYCHIAT, V79, P153, DOI 10.1016/j.biopsych.2015.02.002
   Kantrowitz JT, 2015, J NEUROSCI, V35, P14909, DOI 10.1523/JNEUROSCI.4603-14.2015
   Kemp J, 2013, CORTEX, V49, P559, DOI 10.1016/j.cortex.2012.01.004
   King L. B., 2016, BIOL PSYCHIAT
   Lambert Martin, 2010, Dialogues Clin Neurosci, V12, P393
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   Lee PR, 2005, NEUROPSYCHOPHARMACOL, V30, P1883, DOI 10.1038/sj.npp.1300722
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   MARENGO J, 1994, SCHIZOPHRENIA BULL, V20, P519
   Meinhardt MW, 2013, J NEUROSCI, V33, P2794, DOI 10.1523/JNEUROSCI.4062-12.2013
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mier D., 2016, CURR TOP BEHAV NEURO
   Montag C, 2013, WORLD J BIOL PSYCHIA, V14, P500, DOI 10.3109/15622975.2012.677547
   Mothersill O., 2015, CEREBELLUM
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Nieuwenhuys R, 2008, HUMAN CENTRAL NERVOU
   Okugawa G, 2007, NEUROPSYCHOBIOLOGY, V56, P216, DOI 10.1159/000122268
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Oya K., 2015, EUR ARCH PSYCHIAT CL
   Paxinos G., 2013, RAT BRAIN STEREOTAXI
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Peters S, 2014, PSYCHONEUROENDOCRINO, V42, P225, DOI 10.1016/j.psyneuen.2014.01.021
   REY MJ, 1989, INT CLIN PSYCHOPHARM, V4, P95, DOI 10.1097/00004850-198904000-00001
   Rich ME, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00090
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Rosenfeld AJ, 2011, SCHIZOPHRENIA BULL, V37, P1077, DOI 10.1093/schbul/sbq015
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Schneider M, 2014, AM J PSYCHIAT, V171, P627, DOI 10.1176/appi.ajp.2013.13070864
   Segarra N, 2008, NEUROREPORT, V19, P1513, DOI 10.1097/WNR.0b013e3283108bd8
   Shepherd AM, 2012, NEUROSCI BIOBEHAV R, V36, P1342, DOI 10.1016/j.neubiorev.2011.12.015
   Shin NY, 2015, NEUROPSYCHOPHARMACOL, V40, P1919, DOI 10.1038/npp.2015.41
   SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545
   Sommer Wolfgang H, 2014, Front Integr Neurosci, V8, P87, DOI 10.3389/fnint.2014.00087
   Sommer WH, 2010, HUM MUTAT, V31, pE1594, DOI 10.1002/humu.21299
   Souza RP, 2010, SCHIZOPHR RES, V121, P279, DOI 10.1016/j.schres.2010.04.019
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Takei Y, 2013, J PSYCHIATR RES, V47, P1581, DOI 10.1016/j.jpsychires.2013.07.029
   Tavano A, 2007, BRAIN, V130, P2646, DOI 10.1093/brain/awm201
   Teltsh O, 2012, INT J NEUROPSYCHOPH, V15, P309, DOI 10.1017/S1461145711001374
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   UVNASMOBERG K, 1992, PSYCHOPHARMACOLOGY, V109, P473, DOI 10.1007/BF02247726
   van Veluw SJ, 2014, BRAIN IMAGING BEHAV, V8, P24, DOI 10.1007/s11682-013-9266-8
   von Wilmsdorff M, 2013, PHARMACOPSYCHIATRY, V46, P1, DOI 10.1055/s-0032-1321907
   Wigton R, 2015, J PSYCHIATR NEUROSCI, V40, pE1, DOI 10.1503/jpn.130289
   Woods SW, 2003, J CLIN PSYCHIAT, V64, P663
   Yeganeh-Doost P, 2011, CLINICS, V66, P71, DOI 10.1590/S1807-59322011001300009
   Zik JB, 2015, PSYCHIAT RES, V226, P31, DOI 10.1016/j.psychres.2014.11.048
NR 75
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2016
VL 177
IS 1-3
BP 59
EP 66
DI 10.1016/j.schres.2016.04.019
PG 8
WC Psychiatry
SC Psychiatry
GA EC2OR
UT WOS:000387963200009
PM 27132494
ER

PT J
AU Daubenbuchel, AMM
   Hoffmann, A
   Eveslage, M
   Ouml;zyurt, J
   Lohle, K
   Reichel, J
   Thiel, CM
   Martens, H
   Geenen, V
   Muller, HL
AF Daubenbuechel, Anna M. M.
   Hoffmann, Anika
   Eveslage, Maria
   Oezyurt, Jale
   Lohle, Kristin
   Reichel, Julia
   Thiel, Christiane M.
   Martens, Henri
   Geenen, Vincent
   Mueller, Hermann L.
TI Oxytocin in survivors of childhood-onset craniopharyngioma
SO ENDOCRINE
LA English
DT Article
DE Craniopharyngioma; Hypothalamus; Obesity; Oxytocin; Behavior
ID FOOD-INTAKE; PERIPHERAL OXYTOCIN; BODY-WEIGHT; HYPOTHALAMIC OBESITY;
   ENERGY-BALANCE; VASOPRESSIN; BEHAVIOR; CHILDREN; EXOCYTOSIS; RECEPTORS
AB Quality of survival of childhood-onset craniopharyngioma patients is frequently impaired by hypothalamic involvement or surgical lesions sequelae such as obesity and neuropsychological deficits. Oxytocin, a peptide hormone produced in the hypothalamus and secreted by posterior pituitary gland, plays a major role in regulation of behavior and body composition. In a cross-sectional study, oxytocin saliva concentrations were analyzed in 34 long-term craniopharyngioma survivors with and without hypothalamic involvement or treatment-related damage, recruited in the German Childhood Craniopharyngioma Registry, and in 73 healthy controls, attending the Craniopharyngioma Support Group Meeting 2014. Oxytocin was measured in saliva of craniopharyngioma patients and controls before and after standardized breakfast and associations with gender, body mass index, hypothalamic involvement, diabetes insipidus, and irradiation were analyzed. Patients with preoperative hypothalamic involvement showed similar oxytocin levels compared to patients without hypothalamic involvement and controls. However, patients with surgical hypothalamic lesions grade 1 (anterior hypothalamic area) presented with lower levels (p = 0.017) of oxytocin under fasting condition compared to patients with surgical lesion of posterior hypothalamic areas (grade 2) and patients without hypothalamic lesions (grade 0). Craniopharyngioma patients' changes in oxytocin levels before and after breakfast correlated (p = 0.02) with their body mass index. Craniopharyngioma patients continue to secrete oxytocin, especially when anterior hypothalamic areas are not involved or damaged, but oxytocin shows less variation due to nutrition. Oxytocin supplementation should be explored as a therapeutic option in craniopharyngioma patients with hypothalamic obesity and/or behavioral pathologies due to lesions of specific anterior hypothalamic areas. Clinical trial number: KRANIOPHARYNGEOM 2000/2007(NCT00258453; NCT01272622).
C1 [Daubenbuechel, Anna M. M.; Hoffmann, Anika; Lohle, Kristin; Reichel, Julia; Mueller, Hermann L.] Med Campus Univ Oldenburg, Dept Pediat, Klinikum Oldenburg AoR, D-26133 Oldenburg, Germany.
   [Daubenbuechel, Anna M. M.] Univ Groningen, Univ Med Ctr Groningen, NL-9712 Groningen, Netherlands.
   [Eveslage, Maria] Univ Munster, Inst Biostat & Clin Res, D-48149 Munster, Germany.
   [Oezyurt, Jale] Carl Ossietzky Univ, Dept Psychol, Biol Psychol Lab, Fac Med & Hlth Sci, D-26129 Oldenburg, Germany.
   [Thiel, Christiane M.] Carl Ossietzky Univ, Res Ctr Neurosensory Sci & Cluster Excellence Hea, D-26129 Oldenburg, Germany.
   [Martens, Henri; Geenen, Vincent] Univ Liege Liege Sart Tilman, GIGA I3 Ctr Immunoendocrinol, B-4000 Liege, Belgium.
RP Muller, HL (reprint author), Med Campus Univ Oldenburg, Dept Pediat, Klinikum Oldenburg AoR, D-26133 Oldenburg, Germany.
EM mueller.hermann@klinikum-oldenburg.de
FU German Childhood Cancer Foundation, Bonn, Germany
FX We thank all patients who participated in this study. We are grateful
   for the help of Margarita Neff-Heinrich, Gottingen, Germany, in
   proofreading and editing the manuscript. H. L. Muller is supported by
   the German Childhood Cancer Foundation, Bonn, Germany.
CR Acevedo-Rodriguez A, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00160
   Baribeau DA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00335
   BAUER HG, 1954, J CLIN ENDOCR METAB, V14, P13
   Bereket A, 2012, OBES REV, V13, P780, DOI 10.1111/j.1467-789X.2012.01004.x
   Blevins JE, 2013, REV ENDOCR METAB DIS, V14, P311, DOI 10.1007/s11154-013-9260-x
   Cai Dongsheng, 2013, Drug Discov Today Dis Mech, V10, pe63
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cook N, 2016, J PEDIATR ENDOCR MET, V29, P995, DOI 10.1515/jpem-2015-0445
   Dekkers OM, 2006, EUR J ENDOCRINOL, V154, P483, DOI 10.1530/eje.1.02114
   Frank E, 2008, EUR J PHARMACOL, V583, P226, DOI 10.1016/j.ejphar.2007.11.063
   Ho JM, 2013, ENDOCRINOLOGY, V154, P589, DOI 10.1210/en.2012-1751
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lippi G, 2006, CLIN CHEM LAB MED, V44, P358, DOI 10.1515/CCLM.2006.073
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Muller HL, 2016, CURR OPIN ENDOCRINOL, V23, P81, DOI 10.1097/MED.0000000000000214
   Muller HL, 2014, ENDOCR REV, V35, P513, DOI 10.1210/er.2013-1115
   Muller HL, 2012, J CLIN ENDOCR METAB, V97, P3935, DOI 10.1210/jc.2012-2069
   Muller HL, 2011, J CLIN ENDOCR METAB, V96, P1981, DOI 10.1210/jc.2011-0174
   Muller HL, 2011, EUR J ENDOCRINOL, V165, P17, DOI 10.1530/EJE-11-0158
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Pequeux C, 2001, SCAND J CLIN LAB INV, V61, P407, DOI 10.1080/003655101316911468
   POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Sobota R, 2015, BEHAV NEUROSCI, V129, P389, DOI 10.1037/bne0000074
   Sterkenburg AS, 2015, NEURO-ONCOLOGY, V17, P1029, DOI 10.1093/neuonc/nov044
   Tauber M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-47
   Wu Y, 2013, BIOL PSYCHOL, V92, P179, DOI 10.1016/j.biopsycho.2012.11.011
   Young WS, 2003, NEUROENDOCRINOLOGY, V78, P185, DOI 10.1159/000073702
   Zada G, 2010, HORM RES PAEDIAT, V74, P62, DOI 10.1159/000309349
   Zhang G, 2011, NEURON, V69, P523, DOI 10.1016/j.neuron.2010.12.036
NR 41
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD NOV
PY 2016
VL 54
IS 2
BP 524
EP 531
DI 10.1007/s12020-016-1084-5
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EB3BD
UT WOS:000387235500025
PM 27585663
ER

PT J
AU Sentilhes, L
   Merlot, B
   Madar, H
   Sztark, F
   Brun, S
   Deneux-Tharaux, C
AF Sentilhes, Loic
   Merlot, Benjamin
   Madar, Hugo
   Sztark, Francois
   Brun, Stephanie
   Deneux-Tharaux, Catherine
TI Postpartum haemorrhage: prevention and treatment
SO EXPERT REVIEW OF HEMATOLOGY
LA English
DT Review
DE Postpartum hemorrhage; prevention; treatment; guidelines; oxytocin;
   active management of third stage of labor; sulprostone; tranexamic acid;
   transfusion; hysterectomy
ID RANDOMIZED-CONTROLLED-TRIAL; ELECTIVE CESAREAN DELIVERY;
   PLACEBO-CONTROLLED TRIAL; STEPWISE UTERINE DEVASCULARIZATION; PELVIC
   ARTERIAL EMBOLIZATION; CONTROLLED CORD TRACTION; DOSE TRANEXAMIC ACID;
   REDUCE BLOOD-LOSS; VAGINAL DELIVERY; DOUBLE-BLIND
AB Introduction: Postpartum hemorrhage (PPH) is one of the leading causes of maternal death and severe maternal morbidity worldwide and strategies to prevent and treat PPH vary among international authorities.Areas covered: This review seeks to provide a global overview of PPH (incidence, causes, risk factors), prevention (active management of the third stage of labor and prohemostatic agents), treatment (first, second and third-line measures to control PPH), by also underlining recommendations elaborated by international authorities and using algorithms.Expert commentary: When available, oxytocin is considered the drug of first choice for both prevention and treatment of PPH, while peripartum hysterectomy remains the ultimate life-saving procedure if pharmacological and resuscitation measures fail. Nevertheless, the level of evidence for preventing and treating PPH is globally low. The emergency nature of PPH makes randomized controlled trials (RCT) logistically difficult. Population-based observational studies should be encouraged as they can usefully strengthen the evidence base, particularly for components of PPH treatment that are difficult or impossible to assess through RCT.
C1 [Sentilhes, Loic; Merlot, Benjamin; Madar, Hugo; Brun, Stephanie] Univ Bordeaux, Bordeaux Univ Hosp, Dept Obstet & Gynecol, Bordeaux, France.
   [Sztark, Francois] Univ Bordeaux, Bordeaux Univ Hosp, Dept Anesthesiol, Bordeaux, France.
   [Deneux-Tharaux, Catherine] Paris Descartes Univ, Sorbonne Paris Cite, Ctr Epidemiol & Stat,INSERM,U1153, Obstet Perinatal & Pediat Epidemiol Res Team, Paris, France.
RP Sentilhes, L (reprint author), Bordeaux Univ Hosp, Dept Obstet & Gynecol, Pl Amelie Raba Leon, F-33076 Bordeaux, France.
EM loicsentilhes@hotmail.com
CR ACOG practice bulletin, 2006, OBSTET GYNECOL, V108, P806
   Akladios CY, 2014, J GYNECOL OBST BIO R, V43, P1161, DOI 10.1016/j.jgyn.2014.10.008
   Al-Zirqi I, 2008, BJOG-INT J OBSTET GY, V115, P1265, DOI 10.1111/j.1471-0528.2008.01859.x
   Alam A, 2015, TRANSFUS MED REV, V29, P231, DOI 10.1016/j.tmrv.2015.07.002
   Al-Zirqi I, 2009, AM J OBSTET GYNECOL, V201, P273
   Anorlu RI, 2008, COCHRANE DB SYST REV, V3
   Askar A, 2011, ARCH GYNECOL OBSTET, V284, P1359, DOI 10.1007/s00404-011-1851-8
   Bateman BT, 2014, ANESTH ANALG, V119, P1344, DOI 10.1213/ANE.0000000000000398
   Bateman BT, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.07.001
   Bateman BT, 2010, ANESTH ANALG, V110, P1368, DOI 10.1213/ANE.0b013e3181d74898
   Bates SM, 2008, CHEST, V133, p844S, DOI 10.1378/chest.08-0761
   Begley CM, 2015, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD007412.PUB4
   Belghiti J, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000514
   Blum J, 2010, LANCET, V375, P217, DOI 10.1016/S0140-6736(09)61923-1
   Boer K, 2007, J THROMB HAEMOST, V5, P2415, DOI 10.1111/j.1538-7836.2007.02767.x
   Bohlmann MK, 2014, ARCH GYNECOL OBSTET, V289, P555, DOI 10.1007/s00404-013-3016-4
   BONNAR J, 1970, BRIT MED J, V2, P200
   Bonnet MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066882
   Bose P, 2006, BJOG-INT J OBSTET GY, V113, P919, DOI 10.1111/j.1471-0528.2006.01018.x
   Boucher Marc, 2004, J Obstet Gynaecol Can, V26, P481
   Bouet PE, 2015, BRIT J ANAESTH, V114, P339, DOI 10.1093/bja/aeu468
   Bouet PE, 2015, J MATERN-FETAL NEO M, V29, P1
   Bouet PE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30342
   BRANT HA, 1967, BRIT MED J, V1, P398
   BULLOUGH CHW, 1989, LANCET, V2, P522
   Butwick AJ, 2014, BRIT J ANAESTH, V113, P661, DOI 10.1093/bja/aeu150
   Butwick AJ, 2010, BRIT J ANAESTH, V104, P338, DOI 10.1093/bja/aeq004
   Butwick AJ, 2015, CURR OPIN ANESTHESIO, V28, P275, DOI 10.1097/ACO.0000000000000180
   Butwick AJ, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.01.008
   Callaghan WM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.011
   Calvert C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041114
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Charbit B, 2007, J THROMB HAEMOST, V5, P266, DOI 10.1111/j.1538-7836.2007.02297.x
   Chen M, 2013, OBSTET GYNECOL, V122, P290, DOI 10.1097/AOG.0b013e3182999085
   COMBS CA, 1991, OBSTET GYNECOL, V77, P69
   Cortet M, 2012, BRIT J ANAESTH, V108, P984, DOI 10.1093/bja/aes096
   Cunningham FG, 2001, WILLIAMS OBSTET
   D'Alton ME, 2014, OBSTET GYNECOL, V123, P973, DOI 10.1097/AOG.0000000000000219
   Dahlke JD, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.02.023
   deGroot ANJA, 1996, ACTA OBSTET GYN SCAN, V75, P464, DOI 10.3109/00016349609033355
   Deneux-Tharaux C, 2014, J GYNECOL OBST BIO R, V43, P936, DOI 10.1016/j.jgyn.2014.09.023
   Deneux-Tharaux C, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1541
   Dua S, 2006, INT J OBSTET ANESTH, V15, P250, DOI 10.1016/j.ijoa.2005.10.016
   Ducloy-Bouthors AS, 2011, CRIT CARE, V15, DOI 10.1186/cc10143
   Dupont C, 2014, J GYNECOL OBST BIO R, V43, P244, DOI 10.1016/j.jgyn.2013.05.003
   Dyer RA, 2011, CURR OPIN ANESTHESIO, V24, P255, DOI 10.1097/ACO.0b013e328345331c
   Fournet-Fayard A, 2014, J GYNECOL OBST BIO R, V43, P951, DOI 10.1016/j.jgyn.2014.09.024
   Gibbins KJ, 2013, AM J OBSTET GYNECOL, V208, P181, DOI 10.1016/j.ajog.2012.07.034
   Goffinet F., 1995, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V24, P209
   Grotegut CA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.023
   Gulmezoglu AM, 2012, LANCET, V379, P1721, DOI 10.1016/S0140-6736(12)60206-2
   Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4
   Gungorduk K, 2010, AUST NZ J OBSTET GYN, V50, P36, DOI 10.1111/j.1479-828X.2009.01106.x
   HAHN L, 1975, ACTA OBSTET GYN SCAN, V54, P49
   Hancock A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0653-6
   Heesen M, 2014, ACTA ANAESTH SCAND, V58, P1075, DOI 10.1111/aas.12341
   Hellgren M, 2003, SEMIN THROMB HEMOST, V29, P125, DOI 10.1055/s-2003-38897
   Hofmeyr GJ, 2001, BEST PRACT RES CL OB, V15, P645, DOI 10.1053/beog.2001.0205
   Hofmeyr GJ, 2013, COCHRANE DB SYST REV, V7
   Hofmeyr GJ, 2016, BEST PRACT RES CLIN
   HOWARD WF, 1964, JAMA-J AM MED ASSOC, V189, P411
   Hutton EK, 2007, JAMA-J AM MED ASSOC, V297, P1241, DOI 10.1001/jama.297.11.1241
   Joseph KS, 2007, BJOG-INT J OBSTET GY, V114, P751, DOI 10.1111/j.1471-0528.2007.01316.x
   Kayem G, 2016, BJOG-INT J OBSTET GY, V123, P598, DOI 10.1111/1471-0528.13477
   Kayem G, 2011, BJOG-INT J OBSTET GY, V118, P856, DOI 10.1111/j.1471-0528.2011.02921.x
   Kayem G, 2011, OBSTET GYNECOL, V117, P14, DOI 10.1097/AOG.0b013e318202c596
   Ker K, 2016, BJOG-INT J OBSTET GY, V123, P1745, DOI 10.1111/1471-0528.14267
   Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9
   Khan M, 2014, CAN J ANESTH, V61, P242, DOI 10.1007/s12630-013-0082-9
   Khan RU, 2012, COMPREHENSIVE TXB PO, P94
   KOELBL H, 1989, J PERINAT MED, V17, P107, DOI 10.1515/jpme.1989.17.2.107
   Kovacheva VP, 2015, ANESTHESIOLOGY, V123, P92, DOI 10.1097/ALN.0000000000000682
   Kramer MS, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.07.007
   KRUITHOF EKO, 1987, BLOOD, V69, P460
   Laas E, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.08.028
   Lalonde A, 2012, INT J GYNECOL OBSTET, V117, P108, DOI 10.1016/j.ijgo.2012.03.001
   Lavigne-Lissalde G, 2015, J THROMB HAEMOST, V13, P520, DOI 10.1111/jth.12844
   Leduc Dean, 2009, J Obstet Gynaecol Can, V31, P980
   Legendre G, 2016, J MATERN-FETAL NEO M, V26, P1
   Liabsuetrakul T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005456.pub2
   LOUDEN KA, 1992, BRIT J OBSTET GYNAEC, V99, P371, DOI 10.1111/j.1471-0528.1992.tb13751.x
   LUDWIG H, 1971, AM J OBSTET GYNECOL, V111, P328
   Lutomski JE, 2012, BJOG-INT J OBSTET GY, V119, P306, DOI 10.1111/j.1471-0528.2011.03198.x
   Martin E, 2015, ACTA OBSTET GYN SCAN, V94, P399, DOI 10.1111/aogs.12591
   Mathai M, 2013, COCHRANE DB SYST REV, V5
   McDonald S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000201.PUB2
   Mehrabadi A, 2013, BJOG-INT J OBSTET GY, V120, P853, DOI 10.1111/1471-0528.12149
   Misme H, 2016, J GYNECOL OBST BIO R, V45, P71, DOI 10.1016/j.jgyn.2015.01.004
   Nardin JM, 2011, COCHRANE DB SYST REV, V5
   NEWTON M, 1961, OBSTET GYNECOL, V17, P9
   Nordstrom L, 1997, BRIT J OBSTET GYNAEC, V104, P781, DOI 10.1111/j.1471-0528.1997.tb12020.x
   Novikova N, 2015, COCHRANE DB SYST REV, V6
   Oberg AS, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.872
   [Anonymous], 2014, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.G4984
   Oladapo OT, 2012, COCHRANE DB SYST REV, V2
   POESCHMANN RP, 1991, BRIT J OBSTET GYNAEC, V98, P528, DOI 10.1111/j.1471-0528.1991.tb10364.x
   Purwosunu Y, 2016, OBSTET GYNECOL, V128, P33, DOI 10.1097/AOG.0000000000001473
   Quibel Ghout I, 2016, OBSTET GYNECOL, V128, P805
   Rabe H, 2008, NEONATOLOGY, V93, P138, DOI 10.1159/000108764
   Rouse DJ, 2005, AM J OBSTET GYNECOL, V193, P1056, DOI 10.1016/j.ajog.2005.07.077
   Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2011, MAN POSTP HEM
   Royal College of Obstetrician and Gynaecologists, 2011, POSTP HEM PREV MAN
   Saucedo M, 2013, OBSTET GYNECOL, V122, P752, DOI 10.1097/AOG.0b013e31829fc38c
   Schmitz T, 2011, OBSTET GYNECOL, V118, P257, DOI 10.1097/AOG.0b013e3182255335
   Sentilhes L, 2010, BJOG-INT J OBSTET GY, V117, P84, DOI 10.1111/j.1471-0528.2009.02381.x
   Sentilhes L, BJOG IN PRESS
   Sentilhes L, 2016, BJOG, DOI [10.1111/1471-0528.14305, DOI 10.1111/1471-0528.14305]
   Sentilhes L, 2008, ACTA OBSTET GYN SCAN, V87, P1020, DOI 10.1080/00016340802380750
   Sentilhes L, 2008, HUM REPROD, V23, P1087, DOI 10.1093/humrep/den049
   Sentilhes L, 2016, OBSTET GYNECOL, V128, P909, DOI 10.1097/AOG.0000000000001663
   Sentilhes L, 2016, ACTA OBSTET GYN SCAN, V95, P836, DOI 10.1111/aogs.12864
   Sentilhes Loic, 2016, Evid Based Med, V21, P97, DOI 10.1136/ebmed-2016-110382
   Sentilhes L, 2016, TRANSFUS MED REV, V30, P100, DOI 10.1016/j.tmrv.2016.01.003
   Sentilhes L, 2016, EUR J OBSTET GYN R B, V198, P12, DOI 10.1016/j.ejogrb.2015.12.012
   Sentilhes L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0573-5
   Sentilhes L, 2011, ACTA OBSTET GYN SCAN, V90, P615, DOI 10.1111/j.1600-0412.2011.01119.x
   Sentilhes L, 2009, ACTA OBSTET GYN SCAN, V88, P490, DOI 10.1080/00016340902792441
   Sentilhes L, 2009, OBSTET GYNECOL, V113, P992, DOI 10.1097/AOG.0b013e3181a114f7
   Sentithes L, 2015, BRIT J ANAESTH, V114, P576, DOI 10.1093/bja/aeu448
   Shakur H, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-40
   Sheehan SR, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4661
   Shields LE, 2015, AM J OBSTET GYNECOL, V212, P272, DOI 10.1016/j.ajog.2014.07.012
   Shields LE, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.084
   SHIMADA H, 1989, THROMB RES, V54, P91, DOI 10.1016/0049-3848(89)90039-X
   Simonazzi G, 2016, ACTA OBSTET GYN SCAN, V95, P28, DOI 10.1111/aogs.12798
   Solomon C, 2012, BRIT J ANAESTH, V109, P851, DOI 10.1093/bja/aes361
   Soltani H, 2010, COCHRANE DB SYST REV, V8
   Soltani H, 2011, COCHRANE DB SYST REV, V9
   Sosa CG, 2009, OBSTET GYNECOL, V113, P1313, DOI 10.1097/AOG.0b013e3181a66b05
   Stafford I, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.049
   Su LL, 2009, BJOG-INT J OBSTET GY, V116, P1461, DOI 10.1111/j.1471-0528.2009.02226.x
   Su LL, 2012, COCHRANE DB SYST REV, V4
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
   TATUM HJ, 1953, AM J OBSTET GYNECOL, V66, P27
   TAYLOR GJ, 1985, OBSTET GYNECOL, V66, P821
   Thomas TA, 2002, BRIT J ANAESTH, V89, P499, DOI 10.1093/bja/aef193
   Torloni MR, 2016, BJOG, V2016, DOI [10.1111/1471-0528.13998, DOI 10.1111/1471-0528.13998]
   Tuncalp O, 2012, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD000494.PUB4
   Westhoff G, 2013, COCHRANE DB SYST REV, V10, DOI [DOI 10.1002/14651858.CD001808.PUB2, 10.1002/14651858.CD001808.pub2]
   Wetta LA, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.03.011
   [Anonymous], 2012, WHO REC PREV POSTP H
   Widmer M, 2010, LANCET, V375, P1808, DOI 10.1016/S0140-6736(10)60348-0
   Wikkelso AJ, 2015, BRIT J ANAESTH, V114, P623, DOI 10.1093/bja/aeu444
   WILCOX CF, 1959, AM J OBSTET GYNECOL, V77, P772
   Zhang WH, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c293
NR 145
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4086
EI 1747-4094
J9 EXPERT REV HEMATOL
JI Expert Rev. Hematol.
PD NOV
PY 2016
VL 9
IS 11
BP 1043
EP 1061
DI 10.1080/17474086.2016.1245135
PG 19
WC Hematology
SC Hematology
GA EB6QU
UT WOS:000387510600006
PM 27701915
ER

PT J
AU Sowden, S
   Brewer, R
   Catmur, C
   Bird, G
AF Sowden, Sophie
   Brewer, Rebecca
   Catmur, Caroline
   Bird, Geoffrey
TI The Specificity of the Link Between Alexithymia, Interoception, and
   Imitation
SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-HUMAN PERCEPTION AND PERFORMANCE
LA English
DT Article
DE alexithymia; interoception; imitation-inhibition; self-other processing
ID AUTISM SPECTRUM DISORDERS; TEMPOROPARIETAL JUNCTION; AUTOMATIC
   IMITATION; SOCIAL COGNITION; QUOTIENT AQ; COMPATIBILITY; POPULATION;
   INHIBITION; AWARENESS; OXYTOCIN
AB Alexithymia is a subclinical condition traditionally characterized by difficulties identifying and describing one's own emotions. Recent formulations of alexithymia, however, suggest that the condition may result from a generalized impairment in the perception of all bodily signals ("interoception"). Interoceptive accuracy has been associated with a variety of deficits in social cognition, but recently with an improved ability to inhibit the automatic tendency to imitate the actions of others. The current study tested the consequences for social cognition of the hypothesized association between alexithymia and impaired interoception by examining the relationship between alexithymia and the ability to inhibit imitation. If alexithymia is best characterized as a general interoceptive impairment, then one would predict that alexithymia would have the same relationship with the ability to control imitation as does interoceptive accuracy. Forty-three healthy adults completed measures of alexithymia, imitation-inhibition, and as a control, inhibition of nonimitative spatial compatibility. Results revealed the predicted relationship, such that increasing alexithymia was associated with an improved ability to inhibit imitation, and that this relationship was specific to imitation-inhibition. These results support the characterization of alexithymia as a general interoceptive impairment and shed light on the social ability of alexithymic individuals-with implications for the multitude of psychiatric, neurological, and neuro-developmental disorders associated with high rates of alexithymia.
C1 [Sowden, Sophie; Bird, Geoffrey] Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England.
   [Brewer, Rebecca] Univ East London, Sch Psychol, London E15 4LZ, England.
   [Catmur, Caroline] Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London, England.
   [Bird, Geoffrey] UCL, Inst Cognit Neurosci, London WC1E 6BT, England.
RP Sowden, S (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, 16 Crespigny Pk, London SE5 8AF, England.
EM sophie.sowden@kcl.ac.uk
FU Medical Research Council; Baily Thomas Charitable Trust
FX Sophie Sowden is supported by a doctoral studentship from the Medical
   Research Council, which provided the funds for participant payments in
   this study. Geoffrey Bird is supported by the Baily Thomas Charitable
   Trust.
CR Aaron RV, 2015, PERS INDIV DIFFER, V77, P215, DOI 10.1016/j.paid.2014.12.032
   Ainley V, 2014, NEUROPSYCHOLOGIA, V60, P21, DOI 10.1016/j.neuropsychologia.2014.05.010
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Bird G, 2014, NEUROSCI BIOBEHAV R, V47, P520, DOI 10.1016/j.neubiorev.2014.09.021
   Brass M, 2005, NEUROPSYCHOLOGIA, V43, P89, DOI 10.1016/j.neuropsychologia.2004.06.018
   Brass M, 2009, PHILOS T R SOC B, V364, P2359, DOI 10.1098/rstb.2009.0066
   Brewer R., ALEXITHYMIA GEN DEFI
   Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Catmur C, 2011, J EXP PSYCHOL HUMAN, V37, P409, DOI 10.1037/a0019325
   Chartrand TL, 1999, J PERS SOC PSYCHOL, V76, P893, DOI 10.1037//0022-3514.76.6.893
   Cho YS, 2004, PERCEPT PSYCHOPHYS, V66, P1003, DOI 10.3758/BF03194991
   de Guzman M, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0079
   Gaigg S. B., AUTISM INT J RES PRA
   Happe F., ANN REV PSYCHOL
   Harms MB, 2010, NEUROPSYCHOL REV, V20, P290, DOI 10.1007/s11065-010-9138-6
   Herbert BM, 2011, J PERS, V79, P1149, DOI 10.1111/j.1467-6494.2011.00717.x
   Hogeveen J, 2015, SOC COGN AFFECT NEUR, V10, P1003, DOI 10.1093/scan/nsu148
   LAFRANCE M, 1985, PERS SOC PSYCHOL B, V11, P207, DOI 10.1177/0146167285112008
   Marsh LE, 2016, NEUROIMAGE, V139, P368, DOI 10.1016/j.neuroimage.2016.06.050
   Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0
   Press C, 2005, COGNITIVE BRAIN RES, V25, P632, DOI 10.1016/j.cogbrainres.2005.08.020
   Quattrocki E, 2014, NEUROSCI BIOBEHAV R, V47, P410, DOI 10.1016/j.neubiorev.2014.09.012
   Ruzich E, 2015, MOL AUTISM, V6, DOI 10.1186/2040-2392-6-2
   Santiesteban I, 2012, COGNITION, V122, P228, DOI 10.1016/j.cognition.2011.11.004
   Seth AK, 2013, TRENDS COGN SCI, V17, P565, DOI 10.1016/j.tics.2013.09.007
   Shah P, 2016, CORTEX, V81, P215, DOI 10.1016/j.cortex.2016.03.021
   SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255
   Sowden S, 2016, AUTISM RES, V9, P292, DOI 10.1002/aur.1511
   Sowden S, 2015, CEREB CORTEX, V25, P1107, DOI 10.1093/cercor/bht306
   Sowden S, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00789
   Spengler S, 2010, BIOL PSYCHIAT, V68, P1148, DOI 10.1016/j.biopsych.2010.09.017
   Spengler S, 2010, CONSCIOUS COGN, V19, P98, DOI 10.1016/j.concog.2009.12.014
NR 33
TC 0
Z9 0
U1 7
U2 7
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0096-1523
EI 1939-1277
J9 J EXP PSYCHOL HUMAN
JI J. Exp. Psychol.-Hum. Percept. Perform.
PD NOV
PY 2016
VL 42
IS 11
BP 1687
EP 1692
DI 10.1037/xhp0000310
PG 6
WC Psychology; Psychology, Experimental
SC Psychology
GA EB1XQ
UT WOS:000387150100001
PM 27786535
ER

PT J
AU Lai, PF
   Tribe, RM
   Johnson, MR
AF Lai, Pei F.
   Tribe, Rachel M.
   Johnson, Mark R.
TI Differential impact of acute and prolonged cAMP agonist exposure on
   protein kinase A activation and human myometrium contractile activity
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
DE cyclic adenosine monophosphate; parturition; uterine smooth muscle
ID SMOOTH-MUSCLE-CELLS; PREGNANT HUMAN MYOMETRIUM; CYCLIC-AMP; IN-VIVO;
   PROGESTERONE ACTION; SIGNALING PATHWAYS; PROSTAGLANDIN E-2; ANCHORING
   PROTEIN; PLASMA-MEMBRANE; PRETERM LABOR
AB Acute cAMP elevation inhibits myometrial contractility, but the mechanisms responsible are not fully elucidated and the long-term effects are uncertain. Both need to be defined in pregnant human myometrium before the therapeutic potential of cAMP-elevating agents in the prevention of preterm labour can be realised. In the present study, we tested the hypotheses that PKA activity is necessary for cAMP-induced myometrial relaxation, and that prolonged cAMP elevation can prevent myometrial contractions. Myometrial tissues obtained from term, pre-labour elective Caesarean sections were exposed to receptor-independent cAMP agonists to determine the relationship between myometrial contractility (spontaneous and oxytocin-induced), PKA activity, HSP20 phosphorylation and expression of contraction-associated and cAMP signalling proteins. Acute (1h) application of cAMP agonists promoted myometrial relaxation, but this was weakly related to PKA activation. A PKA-specific activator, 6-Bnz-cAMP, increased PKA activity (6.82.0 mean fold versus vehicle; P=0.0313) without inducing myometrial relaxation. Spontaneous myometrial contractility declined after 24h but was less marked when tissues were constantly exposed to cAMP agonists, especially for 8-bromo-cAMP (4.31.2mean fold versus vehicle; P=0.0043); this was associated with changes to calponin, cofilin and HSP20 phosphorylated/total protein levels. Oxytocin-induced contractions were unaffected by pre-incubation with cAMP agonists despite treatments being able to enhance PKA activity and HSP20 phosphorylation. These data suggest that cAMP-induced myometrial relaxation is not solely dependent on PKA activity and the ability of cAMP agonists to repress myometrial contractility is lost with prolonged exposure. We conclude that cAMP agonist treatment alone may not prevent preterm labour.
C1 [Lai, Pei F.; Johnson, Mark R.] Imperial Coll London, Acad Dept Obstet & Gynaecol, London SW10 9NH, England.
   [Tribe, Rachel M.] Kings Coll London, Div Womens Hlth, London SE1 7EH, England.
   [Tribe, Rachel M.] Kings Hlth Partners, Womens Hlth Acad Ctr, London SE1 7EH, England.
RP Johnson, MR (reprint author), Imperial Coll, Chelsea & Westminster Hosp, Acad Dept Obstet & Gynaecol, Parturit Res Grp, 369 Fulham Rd, London SW10 9NH, England.
EM mark.johnson@imperial.ac.uk
FU Action Medical Research [208701, SP4573]; Borne sub-charity of the
   Chelsea & Westminster Hospital Health Charity [1067412-7]; Tommy's
   charity [1060508]
FX P.F.L. was funded by Action Medical Research (No. 208701; project grant
   SP4573) and Borne (No. 1067412-7; a sub-charity of the Chelsea &
   Westminster Hospital Health Charity). R.M.T. receives funding from
   Tommy's charity (No. 1060508).
CR Allerston CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057644
   ANWER K, 1990, BIOL REPROD, V43, P851, DOI 10.1095/biolreprod43.5.851
   Astle S, 2007, MOL HUM REPROD, V13, P69, DOI 10.1093/molehr/gal093
   Astle S, 2005, MOL HUM REPROD, V11, P279, DOI 10.1093/molehr/gah158
   Ayres AW, 2003, J SOC GYNECOL INVEST, V10, P428, DOI 10.1016/S1071-5576(03)00136-9
   Beall AC, 1997, J BIOL CHEM, V272, P11283
   Billington CK, 2013, PULM PHARMACOL THER, V26, P112, DOI 10.1016/j.pupt.2012.05.007
   Bogard AS, 2011, J PHARMACOL EXP THER, V337, P209, DOI 10.1124/jpet.110.177923
   Butler T, 2013, AM J PHYSIOL-CELL PH, V304, pC485, DOI 10.1152/ajpcell.00161.2012
   Chan YW, 2014, EXP PHYSIOL, V99, P510, DOI 10.1113/expphysiol.2013.072868
   Chen L, 2014, MOL CELL ENDOCRINOL, V382, P334, DOI 10.1016/j.mce.2013.10.018
   Chen L, 2012, J CELL MOL MED, V16, P1447, DOI 10.1111/j.1582-4934.2011.01413.x
   Chik CL, 1996, FASEB J, V10, P1310
   Cooper DMF, 2014, BIOCHEM J, V462, P199, DOI 10.1042/BJ20140560
   Cordeaux Y, 2010, J CLIN ENDOCR METAB, V95, pE437, DOI 10.1210/jc.2010-1541
   Crankshaw DJ, 2014, EUR J PHARMACOL, V738, P245, DOI 10.1016/j.ejphar.2014.05.037
   Croci T, 2007, J PHARMACOL EXP THER, V321, P1118, DOI 10.1124/jpet.106.119123
   Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200
   Dao KK, 2006, J BIOL CHEM, V281, P21500, DOI 10.1074/jbc.M603116200
   Delpy E, 1996, BRIT J PHARMACOL, V119, P471
   Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265
   Dodge KL, 1999, ENDOCRINOLOGY, V140, P5165, DOI 10.1210/en.140.11.5165
   Edwards HV, 2012, BIOCHEM SOC T, V40, P210, DOI 10.1042/BST20110673
   Eid AH, 2012, CELL PHYSIOL BIOCHEM, V30, P247, DOI 10.1159/000339061
   EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835
   Fetalvero Kristina M, 2008, J Clin Invest, V118, P3966, DOI 10.1172/JCI33800
   Frambach T, 2005, J CLIN ENDOCR METAB, V90, P2882, DOI 10.1210/jc.2004-1732
   Gerthoffer WT, 2013, CURR OPIN PHARMACOL, V13, P324, DOI 10.1016/j.coph.2013.04.002
   Hay A, 2010, MOL HUM REPROD, V16, P752, DOI 10.1093/molehr/gaq046
   HERLIHY JT, 1973, CIRC RES, V33, P275
   Herman SB, 2000, MOL PHARMACOL, V57, P991
   Hewer RC, 2011, J MOL CELL CARDIOL, V50, P87, DOI 10.1016/j.yjmcc.2010.10.010
   Hocking J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073382
   Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007
   Hudson CA, 2012, MOL HUM REPROD, V18, P265, DOI 10.1093/molehr/gar078
   Kandola MK, 2014, ENDOCRINOLOGY, V155, P605, DOI 10.1210/en.2013-1761
   Karolczak-Bayatti M, 2011, J BIOL CHEM, V286, P34346, DOI 10.1074/jbc.M111.278549
   Kassel KM, 2008, AM J PHYSIOL-LUNG C, V294, pL131, DOI 10.1152/ajplung.00381.2007
   Kimura T, 1996, ENDOCRINOLOGY, V137, P780, DOI 10.1210/en.137.2.780
   Ku CY, 2005, J SOC GYNECOL INVEST, V12, P421, DOI 10.1016/j.jsgi.2005.04.002
   Lei K, 2011, J CLIN ENDOCR METAB, V96, pE1013, DOI 10.1210/jc.2010-2310
   Li LS, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-37
   Longo M, 2003, MOL HUM REPROD, V9, P159, DOI 10.1093/molehr/gag023
   MacDougall MWJ, 2003, J CLIN ENDOCR METAB, V88, P2194, DOI 10.1210/jc.2002-021862
   MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41
   March of Dimes, 2012, BORN TOO SOON GLOBAL
   Mehats C, 2000, J PHARMACOL EXP THER, V292, P817
   Mehats C, 1999, ENDOCRINOLOGY, V140, P3228, DOI 10.1210/en.140.7.3228
   MICHEL MC, 1989, CLIN PHARMACOL THER, V45, P1
   Morgado M, 2012, CELL MOL LIFE SCI, V69, P247, DOI 10.1007/s00018-011-0815-2
   Murthy KS, 2003, AM J PHYSIOL-GASTR L, V284, pG1006, DOI 10.1152/ajpgi.00465.2002
   Patel BS, 2015, AM J RESP CELL MOL, V52, P634, DOI 10.1165/rcmb.2014-0344OC
   Phillips RJ, 2002, J CLIN ENDOCR METAB, V87, P5675, DOI 10.1210/jc.2002-020640
   Poppe H, 2008, NAT METHODS, V5, P277, DOI 10.1038/nmeth0408-277
   Purves GI, 2009, J PHYSIOL-LONDON, V587, P3639, DOI 10.1113/jphysiol.2009.173534
   Roscioni SS, 2011, BRIT J PHARMACOL, V164, P958, DOI 10.1111/j.1476-5381.2011.01354.x
   Roscioni SS, 2011, BRIT J PHARMACOL, V162, P193, DOI 10.1111/j.1476-5381.2010.01011.x
   SCHULTZ C, 1994, MOL PHARMACOL, V46, P702
   Seternes OM, 1999, CELL SIGNAL, V11, P211, DOI 10.1016/S0898-6568(98)00069-2
   Sin YY, 2011, J MOL CELL CARDIOL, V50, P872, DOI 10.1016/j.yjmcc.2011.02.006
   Slater DM, 2006, MOL HUM REPROD, V12, P89, DOI 10.1093/molehr/gal005
   Sparey C, 1999, J CLIN ENDOCR METAB, V84, P1705, DOI 10.1210/jc.84.5.1705
   Sprenger JU, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7965
   Tribe RM, 2000, BIOL REPROD, V63, P748, DOI 10.1095/biolreprod63.3.748
   Tribe RM, 2001, EXP PHYSIOL, V86, P247, DOI 10.1113/eph8602180
   Tyson EK, 2008, ENDOCRINOLOGY, V149, P6157, DOI 10.1210/en.2008-0593
   Verli J, 2013, J OBSTET GYNAECOL RE, V39, P31, DOI 10.1111/j.1447-0756.2012.01929.x
   WATSON EL, 1990, MOL PHARMACOL, V38, P547
   Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040
   Yuan Wei, 2007, BMC Pregnancy Childbirth, V7 Suppl 1, pS10, DOI 10.1186/1471-2393-7-S1-S10
   YUSTA B, 1988, J NEUROCHEM, V51, P1807
   Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982
   Zhao R, 2008, J BIOL CHEM, V283, P36522, DOI 10.1074/jbc.M805294200
   Zhong JM, 1999, AM J PHYSIOL-CELL PH, V277, pC840
NR 74
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD NOV
PY 2016
VL 594
IS 21
BP 6369
EP 6393
DI 10.1113/JP272320
PG 25
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA EB1CO
UT WOS:000387084200023
PM 27328735
ER

PT J
AU Hurlemann, R
   Marsh, N
AF Hurlemann, R.
   Marsh, N.
TI New insights into the neuroscience of human altruism
SO NERVENARZT
LA German
DT Article
DE Altruism; Punishment; Empathy; Oxytocin; Evolution
ID PAROCHIAL ALTRUISM; OXYTOCIN; RESPONSES; BIAS; EVOLUTION; TRUST
AB Numerous honorary initiatives for humanitarian aid towards refugees illustrate the high prevalence of altruistic behavior in the population. In medicine, an exquisite example of a human propensity for altruism is organ donation. Current perspectives on the neurobiology of altruism suggest that it is deeply rooted in the motivational architecture of the social brain. This is reflected by the social evolution of cooperation and parochialism, both of which are modulated by the evolutionarily conserved peptide hormone oxytocin. From a psychiatric perspective, altruism varies along a dimensional spectrum, with pathological hyperaltruism resulting in unexpected harm for oneself and others.
C1 [Hurlemann, R.; Marsh, N.] Univ Klinikum Bonn, Abt Med Psychol, D-53105 Bonn, Germany.
   [Hurlemann, R.] Univ Klinikum Bonn, Klin & Poliklin Psychiat & Psychotherapie, Sigmund Freud Str 25, D-53105 Bonn, Germany.
RP Hurlemann, R (reprint author), Univ Klinikum Bonn, Klin & Poliklin Psychiat & Psychotherapie, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM renehurlemann@icloud.com
CR Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Bernhard H, 2006, NATURE, V442, P912, DOI 10.1038/nature04981
   Blaffer-Hrdy S, MOTHERS OTHERS EVOLU
   Comte A, 1966, REDE GEIST POSITIVIS, P261
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735
   DIE ZEIT, 2008, ESS S BOWL WAS IST M
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Downie RS, 2002, J MED ETHICS, V28, P75, DOI 10.1136/jme.28.2.75
   Eckstein M, 2013, NERVENARZT, V84, P1321, DOI 10.1007/s00115-013-3832-6
   Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a
   Freeman SM, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12382
   HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114
   Hein G, 2016, SCIENCE, V351, P1074, DOI 10.1126/science.aac7992
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hurlemann R, 2016, BIOL PSYCHIAT, V79, P185, DOI 10.1016/j.biopsych.2015.05.013
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Karakayali Serhat, 2015, STRUKTUREN MOTIVE EH
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lee HH, 2010, NATURE, V467, P82, DOI 10.1038/nature09354
   Liu N, 2015, P NATL ACAD SCI USA, V112, pE3123, DOI 10.1073/pnas.1508097112
   Marsh AA, 2016, WIRES COGN SCI, V7, P59, DOI 10.1002/wcs.1377
   Marsh AA, 2014, P NATL ACAD SCI USA, V111, P15036, DOI 10.1073/pnas.1408440111
   Marsh N, 2015, J NEUROSCI, V35, P15696, DOI 10.1523/JNEUROSCI.3199-15.2015
   Meffert H, 2013, BRAIN, V136, P2550, DOI 10.1093/brain/awt190
   Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755
   Oakley BA, 2013, P NATL ACAD SCI USA, V110, P10408, DOI 10.1073/pnas.1302547110
   Post SG, 2005, INT J BEHAV MED, V12, P66, DOI 10.1207/s15327558ijbm1202_4
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Scheele D, 2013, EUR ARCH PSY CLIN N, V263, P675, DOI 10.1007/s00406-013-0392-5
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Scheele D, 2012, BIOL PSYCHIAT, V72, pE5, DOI 10.1016/j.biopsych.2012.01.028
   Scheuer E, 2003, PSYCHOSOZIALE MED, P72
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Wu CC, 2013, P NATL ACAD SCI USA, V110, P2217, DOI 10.1073/pnas.1220885110
   Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128
   ZEITmagazin, 2010, ZEITMAGAZIN
NR 38
TC 0
Z9 0
U1 12
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028-2804
EI 1433-0407
J9 NERVENARZT
JI Nervenarzt
PD NOV
PY 2016
VL 87
IS 11
BP 1131
EP 1135
DI 10.1007/s00115-016-0229-3
PG 5
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA EB6LJ
UT WOS:000387494500002
PM 27752721
ER

PT J
AU De Dreu, CKW
   Kret, ME
   Sauter, DA
AF De Dreu, Carsten K. W.
   Kret, Mariska E.
   Sauter, Disa A.
TI Assessing Emotional Vocalizations From Cultural In-Group and Out-Group
   Depends on Oxytocin
SO SOCIAL PSYCHOLOGICAL AND PERSONALITY SCIENCE
LA English
DT Article
DE emotions; group living; communication; hormones; evolution
ID INTRANASAL OXYTOCIN; NEURAL CIRCUITRY; HUMANS; PERCEPTION; BRAIN;
   RECOGNITION; EXPRESSIONS; VASOPRESSIN; AGGRESSION; ADAPTATION
AB Group-living animals, humans included, produce vocalizations like screams, growls, laughs, and victory calls. Accurately decoding such emotional vocalizations serves both individual and group functioning, suggesting that (i) vocalizations from in-group members may be privileged, in terms of speed and accuracy of processing, and (ii) such processing may depend on evolutionary ancient neural circuitries that sustain and enable cooperation with and protection of the in-group against outside threat. Here, we examined this possibility and focused on the neuropeptide oxytocin. Dutch participants self-administered oxytocin or placebo (double-blind, placebo-controlled study design) and responded to emotional vocalizations produced by cultural in-group members (Native Dutch) and cultural out-group members (Namibian Himba). In-group vocalizations were recognized faster and more accurately than out-group vocalizations, and oxytocin enhanced accurate decoding of specific vocalizations from one's cultural out-grouptriumph and anger. We discuss possible explanations and suggest avenues for new research.
C1 [De Dreu, Carsten K. W.; Kret, Mariska E.] Leiden Univ, Inst Psychol, POB 9555, NL-2300 RB Leiden, Netherlands.
   [De Dreu, Carsten K. W.] Univ Amsterdam, Ctr Expt Econ & Polit Decis Making CREED, NL-1012 WX Amsterdam, Netherlands.
   [Sauter, Disa A.] Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands.
RP De Dreu, CKW (reprint author), Leiden Univ, Inst Psychol, POB 9555, NL-2300 RB Leiden, Netherlands.
EM c.k.w.de.dreu@fsw.leidenuniv.nl
FU Grant NWO [275-70-033, NWO 016-155-082]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Financial
   support was provided by Grant NWO 275-70-033 (to DAS) and NWO
   016-155-082 (to MEK).
CR Amodio DM, 2004, J EXP SOC PSYCHOL, V40, P225, DOI 10.1016/S0022-1031(03)00100-8
   Baas M., 2008, PSYCHOL BULL, V134, P739
   Baas M, 2011, J PERS SOC PSYCHOL, V100, P794, DOI 10.1037/a0022981
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Belin P, 2008, P ROY SOC B-BIOL SCI, V275, P473, DOI 10.1098/rspb.2007.1460
   Bestelmeyer PEG, 2014, J NEUROSCI, V34, P8098, DOI 10.1523/JNEUROSCI.4820-13.2014
   Blasi A, 2011, CURR BIOL, V21, P1220, DOI 10.1016/j.cub.2011.06.009
   Bos PA, 2012, FRONT NEUROENDOCRIN, V33, P17, DOI 10.1016/j.yfrne.2011.01.002
   Bosch OJ, 2005, J NEUROSCI, V25, P6807, DOI 10.1523/JNEUROSCI.1342-05.2005
   Burgdorf J, 2008, J COMP PSYCHOL, V122, P357, DOI 10.1037/a0012889
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carver CS, 2009, J PERS, V77, P125, DOI 10.1111/j.1467-6494.2008.00540.x
   Darwin C., 1872, EXPRESSION EMOTIONS
   Davis JE, 2003, ANN NY ACAD SCI, V1000, P91, DOI 10.1196/annals.1280.019
   De Dreu CKW, 2016, BIOL PSYCHIAT, V79, P165, DOI 10.1016/j.biopsych.2015.03.020
   De Dreu CKW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046751
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   de Gelder B, 2010, NEUROSCI BIOBEHAV R, V34, P513, DOI 10.1016/j.neubiorev.2009.10.008
   De Marco A, 2011, AM J PHYS ANTHROPOL, V146, P457, DOI 10.1002/ajpa.21606
   DECASPER AJ, 1980, SCIENCE, V208, P1174, DOI 10.1126/science.7375928
   De Dreu C. K. W, 2014, SOCIAL COGNITIVE AFF, V9
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ebitz RB, 2013, P NATL ACAD SCI USA, V110, P11630, DOI 10.1073/pnas.1305230110
   Fecteau S, 2007, NEUROIMAGE, V36, P480, DOI 10.1016/j.neuroimage.2007.02.043
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Frijda N.H., 1986, EMOTIONS
   GURSKI JC, 1980, DEV PSYCHOBIOL, V13, P463, DOI 10.1002/dev.420130504
   Harari-Dahan O, 2014, NEUROSCI BIOBEHAV R, V47, P506, DOI 10.1016/j.neubiorev.2014.10.007
   Higgins ET, 1997, AM PSYCHOL, V52, P1280, DOI 10.1037/0003-066X.52.12.1280
   Idson LC, 2000, J EXP SOC PSYCHOL, V36, P252, DOI 10.1006/jesp.1999.1402
   Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Lambert B, 2014, PSYCHONEUROENDOCRINO, V40, P60, DOI 10.1016/j.psyneuen.2013.10.015
   Laukka P, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00353
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Marler P, 1988, PRIMATE VOCAL COMMUN
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Melchers M, 2015, SOC NEUROSCI-UK, V10, P345, DOI 10.1080/17470919.2015.1008646
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mouterde SC, 2012, ANIM BEHAV, V83, P605, DOI 10.1016/j.anbehav.2011.11.032
   Mowrer O. H., 1960, LEARNING THEORY BEHA
   Murphy D, 2013, ANIM BEHAV, V85, P119, DOI 10.1016/j.anbehav.2012.10.015
   Noordewier MK, 2013, COGNITION EMOTION, V27, P1326, DOI 10.1080/02699931.2013.777660
   Pell MD, 2015, BIOL PSYCHOL, V111, P14, DOI 10.1016/j.biopsycho.2015.08.008
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Ross MD, 2009, CURR BIOL, V19, P1106, DOI 10.1016/j.cub.2009.05.028
   Sauter DA, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00814
   Sauter DA, 2010, P NATL ACAD SCI USA, V107, P2408, DOI 10.1073/pnas.0908239106
   Sauter DA, 2010, J COGNITIVE NEUROSCI, V22, P474, DOI 10.1162/jocn.2009.21215
   Scheumann M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091192
   Seltzer LJ, 2010, P ROY SOC B-BIOL SCI, V277, P2661, DOI 10.1098/rspb.2010.0567
   van Ijzendoorn MH, 2012, PSYCHONEUROENDOCRINO, V37, P438, DOI 10.1016/j.psyneuen.2011.07.008
   Van Kleef GA, 2010, ADV EXP SOC PSYCHOL, V42, P45, DOI 10.1016/S0065-2601(10)42002-X
   Wittig RM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.3096
NR 57
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1948-5506
EI 1948-5514
J9 SOC PSYCHOL PERS SCI
JI Soc. Psychol. Personal Sci.
PD NOV
PY 2016
VL 7
IS 8
BP 837
EP 846
DI 10.1177/1948550616657596
PG 10
WC Psychology, Social
SC Psychology
GA EB5YW
UT WOS:000387458000009
ER

PT J
AU Chen, HH
   Zhao, BX
   Porges, EC
   Cohen, RA
   Ebner, NC
AF Chen, Huaihou
   Zhao, Bingxin
   Porges, Eric C.
   Cohen, Ronald A.
   Ebner, Natalie C.
TI Edgewise and subgraph-level tests for brain networks
SO STATISTICS IN MEDICINE
LA English
DT Article
DE network-based statistics; graphical structure; resting-state brain
   functional connectivity
ID PERMUTATION TESTS; SELECTION; MODELS; TRAJECTORIES; DISORDERS;
   COGNITION; GRAPHS; SEX
AB Resting-state functional magnetic resonance image is a useful technique for investigating brain functional connectivity at rest. In this work, we develop flexible regression models and methods for determining differences in resting-state functional connectivity as a function of age, gender, drug intervention, or neuropsychiatric disorders. We propose two complementary methods for identifying changes of edges and subgraphs. (i) For detecting changes of edges, we select the optimal model at each edge and then conduct contrast tests to identify the effects of the important variables while controlling the familywise error rate. (ii) We adopt the network-based statistics method to improve power by incorporating the graph topological structure. Both methods have wide applications for low signal-to-noise ratio data. We propose stability criteria for the choice of threshold in the network-based statistics procedure and utilize efficient massive parallel procedure to speed up the estimation and inference procedure. Results from our simulation studies show that the thresholds chosen by the proposed stability criteria outperform the Bonferroni threshold. To demonstrate applicability, we use both methods in the context of the Oxytocin and Aging Study to determine effects of age, gender, and drug treatment on resting-state functional connectivity, as well as in the context of the Autism Brain Imaging Data Exchange Study to determine effects of autism spectrum disorder on functional connectivity at rest. Copyright (C) 2016 John Wiley & Sons, Ltd.
C1 [Chen, Huaihou; Zhao, Bingxin] Univ Florida, Dept Biostat, Gainesville, FL 32611 USA.
   [Chen, Huaihou; Porges, Eric C.; Cohen, Ronald A.; Ebner, Natalie C.] Univ Florida, Inst Aging, McKnight Brain Inst, Ctr Cognit Aging & Memory CAM,Dept Aging Geriatr, Gainesville, FL USA.
   [Ebner, Natalie C.] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
RP Chen, HH (reprint author), Univ Florida, Dept Biostat, Gainesville, FL 32611 USA.
EM huaihouchen@ufl.edu
FU Center for Cognitive Aging and Memory at the University of Florida;
   McKnight Brain Research Foundation; Claude D. Pepper Center at the
   University of Florida [P30 AG028740]
FX The authors thank Dr. Kai Yu at National Cancer Institute for discussion
   and suggestions on the edgewise regression and Harold Rocha for
   editorial assistance. This work was supported by the Center for
   Cognitive Aging and Memory at the University of Florida, the McKnight
   Brain Research Foundation, and the Claude D. Pepper Center at the
   University of Florida (P30 AG028740).
CR Chen HH, 2015, NEUROIMAGE, V111, P454, DOI 10.1016/j.neuroimage.2014.12.082
   Csardi G., 2006, INT J COMPLEX SYST, V1695, P1695, DOI DOI 10.1080/01621459.1951.10500769
   Di Martino A, 2014, MOL PSYCHIATR, V19, P659, DOI 10.1038/mp.2013.78
   Ebner NC, 2016, PSYCHONEUROENDOCRINO, V69, P50, DOI 10.1016/j.psyneuen.2016.03.013
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Fang YX, 2012, COMPUT STAT DATA AN, V56, P468, DOI 10.1016/j.csda.2011.09.003
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Friedman J, GLMNET LASSO ELASTIC
   Gartner T., 2003, ACM SIGKDD EXPLORATI, V5, P49, DOI DOI 10.1145/959242.959248
   HASTIE T, 1993, J ROY STAT SOC B MET, V55, P757
   Insel TR, 2014, JAMA-J AM MED ASSOC, V311, P1727, DOI 10.1001/jama.2014.1193
   Kennedy DN, 1998, CEREB CORTEX, V8, P372, DOI 10.1093/cercor/8.4.372
   Kim JH, 2014, NEUROIMAGE, V101, P681, DOI 10.1016/j.neuroimage.2014.07.031
   Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8
   Lauritzen S.L., 1996, GRAPHICAL MODELS
   Liu H, 2010, ADV NEURAL INFORM PR, P1432
   McArdle BH, 2001, ECOLOGY, V82, P290, DOI 10.1890/0012-9658(2001)082[0290:FMMTCD]2.0.CO;2
   Meinshausen N, 2006, ANN STAT, V34, P1436, DOI 10.1214/009053606000000281
   Meinshausen N, 2010, J R STAT SOC B, V72, P417
   Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013
   Middleton FA, 2000, BRAIN COGNITION, V42, P183, DOI 10.1006/brcg.1999.1099
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Narayan M, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00108
   Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058
   Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018
   Reiss PT, 2014, J COMPUT GRAPH STAT, V23, P232, DOI 10.1080/10618600.2012.733549
   Reiss PT, 2010, BIOMETRICS, V66, P636, DOI 10.1111/j.1541-0420.2009.01300.x
   Rudie JD, 2012, CEREB CORTEX, V22, P1025, DOI 10.1093/cercor/bhr171
   Westfall P., 1993, RESAMPLING BASED MUL
   Whitfield-Gabrieli Susan, 2012, Brain Connect, V2, P125, DOI 10.1089/brain.2012.0073
   Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910
   Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041
   Zhang L, 2016, J AM STAT ASSOC, V111, P772, DOI 10.1080/01621459.2015.1042581
   Zhu YZ, 2014, J AM STAT ASSOC, V109, P1683, DOI 10.1080/01621459.2014.921182
   Zuo XN, 2010, J NEUROSCI, V30, P15034, DOI 10.1523/JNEUROSCI.2612-10.2010
NR 35
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD NOV
PY 2016
VL 35
IS 27
BP 4994
EP 5008
DI 10.1002/sim.7039
PG 15
WC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Medicine, Research &
   Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Research & Experimental
   Medicine; Mathematics
GA EB4NA
UT WOS:000387347400007
PM 27397632
ER

PT J
AU Yulia, A
   Singh, N
   Lei, KY
   Sooranna, SR
   Johnson, MR
AF Yulia, Angela
   Singh, Natasha
   Lei, Kaiyu
   Sooranna, Suren R.
   Johnson, Mark R.
TI Cyclic AMP Effectors Regulate Myometrial Oxytocin Receptor Expression
SO ENDOCRINOLOGY
LA English
DT Article
ID PROTEIN-KINASE-A; FACTOR-KAPPA-B; MESSENGER-RIBONUCLEIC-ACID; PREGNANT
   HUMAN MYOMETRIUM; SMOOTH-MUSCLE-CELLS; G-ALPHA-S; PROGESTERONE-RECEPTOR;
   PHOSPHODIESTERASE ACTIVITY; DIFFERENTIAL EXPRESSION;
   ADENOSINE-MONOPHOSPHATE
AB The factors that initiate human labor are poorly understood. We have tested the hypothesis that a decline in cAMP/protein kinaseA (PKA) function leads to the onset of labor. Initially, we identified myometrial cAMP/PKA-responsive genes (six up-regulated and five down-regulated genes) and assessed their expression in myometrial samples taken from different stages of pregnancy and labor. We found that the oxytocin receptor (OTR) was one of the cAMP-repressed genes, and, given the importance of OTR in the labor process, we studied the mechanisms involved in greater detail using small interfering RNA, chemical agonists, and antagonists of the cAMP effectors. We found that cAMP-repressed genes, including OTR, increased with the onset of labor. Our in vitro studies showed that cAMP acting via PKA reduced OTR expression but that in the absence of PKA, cAMP acts via exchange protein activated by cAMP (EPAC) to increase OTR expression. In early labor myometrial samples, PKA levels and activity declined and Epac1 levels increased, perhaps accounting for the increase in myometrial OTR mRNA and protein levels at this time. In vitro exposure of myometrial cells to stretch and IL-1 beta increased OTR levels and reduced basal and forskolin-stimulated cAMP and PKA activity, as judged by phospho-cAMP response element-binding protein levels, but neither stretch nor IL-1 beta had any effect on PKA or EPAC1 levels. In summary, there is a reduction in the activity of the cAMP/PKA pathway with the onset of human labor potentially playing a critical role in regulating OTR expression and the transition from myometrial quiescence to activation.
C1 [Yulia, Angela; Singh, Natasha; Lei, Kaiyu; Sooranna, Suren R.; Johnson, Mark R.] Chelsea & Westminster Hosp, London SW10 9NH, England.
   [Yulia, Angela; Singh, Natasha; Lei, Kaiyu; Sooranna, Suren R.; Johnson, Mark R.] Inst Reprod & Dev Biol, London W12 0NN, England.
RP Johnson, MR (reprint author), Imperial Coll, Chelsea & Westminster Hosp, Acad Dept Obstet & Gynaecol, 369 Fulham Rd, London SW10 9NH, England.
EM mark.johnson@imperial.ac.uk
FU Action Medical Research, Borne; National Institute for Health Research
   Biomedical Research Centre
FX This work was supported by Action Medical Research, Borne, and the
   National Institute for Health Research Biomedical Research Centre.
CR ADOLFS MJP, 1985, PROSTA LEUKOTR MED, V18, P217, DOI 10.1016/0262-1746(85)90021-6
   Arulkumaran S, 2012, J CLIN ENDOCR METAB, V97, P489, DOI 10.1210/jc.2011-1991
   Bailey J, 2000, MOL HUM REPROD, V6, P648, DOI 10.1093/molehr/6.7.648
   BENEDETTO MT, 1990, J STEROID BIOCHEM, V35, P205, DOI 10.1016/0022-4731(90)90276-X
   Chapman NR, 2005, ENDOCRINOLOGY, V146, P4994, DOI 10.1210/en.2005-0533
   Chen L, 2014, MOL CELL ENDOCRINOL, V382, P334, DOI 10.1016/j.mce.2013.10.018
   EGARTER CH, 1990, AM J OBSTET GYNECOL, V163, P794
   Ekholm D, 1997, BBA-MOL CELL RES, V1356, P64, DOI 10.1016/S0167-4889(96)00159-0
   EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484
   EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835
   Fang X, 2000, AM J REPROD IMMUNOL, V44, P65, DOI 10.1111/j.8755-8920.2000.440201.x
   Fetalvero Kristina M, 2008, J Clin Invest, V118, P3966, DOI 10.1172/JCI33800
   FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734
   FUCHS AR, 1991, AM J OBSTET GYNECOL, V165, P1515
   Ghosh M, 2015, BIOMED RES INT, V2015
   Ghosh M, 2012, GLIA, V60, P1839, DOI 10.1002/glia.22401
   Groom KM, 2005, BJOG-INT J OBSTET GY, V112, P725, DOI 10.1111/j.1471-0528.2005.00539.x
   Hardy DB, 2006, MOL ENDOCRINOL, V20, P2724, DOI 10.1210/me.2006-0112
   Kalkhoven E, 1996, J BIOL CHEM, V271, P6217
   Keelan JA, 1997, CLIN OBSTET GYNECOL, V40, P460, DOI 10.1097/00003081-199709000-00004
   Kimura T., 1996, Journal of Endocrinology, V148, pS19
   Kimura T, 1996, ENDOCRINOLOGY, V137, P780, DOI 10.1210/en.137.2.780
   KOFINAS AD, 1990, J REPROD MED, V35, P1045
   KOFINAS AD, 1987, AM J OBSTET GYNECOL, V157, P733
   Ku CY, 2005, J SOC GYNECOL INVEST, V12, P421, DOI 10.1016/j.jsgi.2005.04.002
   Lei K, 2015, MOL ENDOCRINOL, V29, P1454, DOI 10.1210/me.2015-1122
   Lei K, 2011, J CLIN ENDOCR METAB, V96, pE1013, DOI 10.1210/jc.2010-2310
   Lei KY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050167
   Liggins G C, 1973, Recent Prog Horm Res, V29, P111
   MacDougall MWJ, 2003, J CLIN ENDOCR METAB, V88, P2194, DOI 10.1210/jc.2002-021862
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Neilson JP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004352.pub3
   Ou CW, 1998, BIOL REPROD, V59, P1055, DOI 10.1095/biolreprod59.5.1055
   Parry LJ, 2000, EXP PHYSIOL, V85, p91S, DOI 10.1111/j.1469-445X.2000.tb00012.x
   Price SA, 2001, EXP PHYSIOL, V86, P265, DOI 10.1113/eph8602182
   Price SA, 2000, J ENDOCRINOL, V164, P21, DOI 10.1677/joe.0.1640021
   Renthal NE, 2015, COLD SPRING HARB PER, V5
   RIVERA J, 1990, ENDOCRINOLOGY, V127, P155
   Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898
   Slater DM, 2006, MOL HUM REPROD, V12, P89, DOI 10.1093/molehr/gal005
   SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972
   Tan HQ, 2012, J CLIN ENDOCR METAB, V97, pE719, DOI 10.1210/jc.2011-3251
   Terzidou V, 2005, J CLIN ENDOCR METAB, V90, P237, DOI 10.1210/jc.2004-0277
   Terzidou V, 2006, J CLIN ENDOCR METAB, V91, P2317, DOI 10.1210/jc.2005.2649
   Thota C, 2005, BIOL REPROD, V72, P416, DOI 10.1095/biolreprod.104.033779
   Wathes DC, 1999, J ENDOCRINOL, V161, P143, DOI 10.1677/joe.0.1610143
   Winkler M, 2003, MICROSC RES TECHNIQ, V60, P430, DOI 10.1002/jemt.10281
   Wu WX, 1999, ENDOCRINOLOGY, V140, P5712, DOI 10.1210/en.140.12.5712
   Young IR, 2001, FRONT HORM RES, V27, P10
NR 49
TC 0
Z9 0
U1 2
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD NOV
PY 2016
VL 157
IS 11
BP 4411
EP 4422
DI 10.1210/en.2016-1514
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EA6YF
UT WOS:000386774400033
PM 27673556
ER

PT J
AU Jiang, CX
   Cheng, ZP
AF Jiang, Caixia
   Cheng, Zhongping
TI Update of recent studies of adenomyosis-associated dysmenorrhea
SO GYNECOLOGY AND MINIMALLY INVASIVE THERAPY-GMIT
LA English
DT Review
DE adenomyosis; dysmenorrhea; inflammatory factors; neuroendocrine; pelvic
   splanchnic nerves
ID UTEROSACRAL LIGAMENT; RADICAL HYSTERECTOMY; WOMEN; SEVERITY; SURGERY
AB Adenomyosis is characterized by invasion of endometrial glands and stromal cells into the myometrium. It is a common gynecological disorder that usually occurs in women during their reproductive years. The primary clinical manifestations of adenomyosis are menorrhagia and progressive dysmenorrhea. The pathogenesis of adenomyosis-associated dysmenorrhea is complicated. However, it is predicted that oxytocin, inflammatory factors, and prostaglandin F2 alpha are responsible for adenomyosis-associated dysmenorrhea via the induction of uterine smooth muscle contractions. Additionally, the pain conductivity of the pelvic viscera (internal organs) involves both the sympathetic (T10-L1) and parasympathetic (S2-4) nervous systems located in the abdominal region. This article provides a review of the pathophysiology of dysmenorrhea in adenomyosis and the nociceptive afferent pathway of the pelvic splanchnic nerves. Copyright (C) 2016, The Asia-Pacific Association for Gynecologic Endoscopy and Minimally Invasive Therapy. Published by Elsevier Taiwan LLC.
C1 [Jiang, Caixia; Cheng, Zhongping] Tongji Univ, Yangpu Hosp, Sch Med, Dept Obstet & Gynecol, Shanghai, Peoples R China.
RP Cheng, ZP (reprint author), Tongji Univ, Yangpu Hosp, Sch Med, 450 Teng Yue Rd, Shanghai 200090, Peoples R China.
EM mdcheng18@263.net
CR Benagiano G, 2012, FERTIL STERIL, V98, P572, DOI 10.1016/j.fertnstert.2012.06.044
   Chen CL, 2014, EUR J OBSTET GYN R B, V172, P74, DOI 10.1016/j.ejogrb.2013.09.035
   Fujii M, 2002, GYNECOL OBSTET INVES, V54, P11, DOI 10.1159/000066289
   Fujii S, 2007, GYNECOL ONCOL, V107, P4, DOI 10.1016/j.ygyno.2007.08.076
   Garcia L, 2011, J MINIM INVAS GYN, V18, P428, DOI 10.1016/j.jmig.2011.04.004
   Guo SW, 2013, FERTIL STERIL, V99, P231, DOI 10.1016/j.fertnstert.2012.08.038
   Holloran-Schwartz MB, 2014, OBSTET GYN CLIN N AM, V41, P357, DOI 10.1016/j.ogc.2014.05.003
   Horng HC, 2014, TAIWAN J OBSTET GYNE, V53, P3, DOI 10.1016/j.tjog.2014.01.001
   Jarrell John F, 2005, J Obstet Gynaecol Can, V27, P781
   Latthe PM, 2007, ACTA OBSTET GYN SCAN, V86, P4, DOI 10.1080/00016340600753117
   Li B, 2013, FERTIL STERIL, V100, P568, DOI 10.1016/j.fertnstert.2013.04.028
   Liu XS, 2011, HUM REPROD, V26, P337, DOI 10.1093/humrep/deq311
   Mechsner S, 2010, FERTIL STERIL, V94, P2541, DOI 10.1016/j.fertnstert.2010.03.015
   Nie JC, 2011, FERTIL STERIL, V95, P1164, DOI 10.1016/j.fertnstert.2010.09.027
   Nie J, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.035
   Proctor ML, 2005, COCHRANE DB SYST REV, pD1896
   Ramanah R, 2012, INT UROGYNECOL J, V23, P1483, DOI 10.1007/s00192-012-1819-7
   Tokushige N, 2006, HUM REPROD, V21, P782, DOI 10.1063/humrep/dei368
   Zhang XM, 2010, FERTIL STERIL, V94, P730, DOI 10.1016/j.fertnstert.2009.03.026
   Zhang XM, 2009, FERTIL STERIL, V92, P1799, DOI 10.1016/j.fertnstert.2009.05.016
   Zhang Y, 2015, ACTA OBSTET GYN SCAN, V94, P412, DOI 10.1111/aogs.12595
   Zullo F, 2003, AM J OBSTET GYNECOL, V189, P5, DOI 10.1067/mob.2003.358
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-3070
EI 2213-3089
J9 GYNECOL MINIM INVASI
JI Gynecol. Minim. Invasive Ther.-GMIT
PD NOV
PY 2016
VL 5
IS 4
BP 137
EP 140
DI 10.1016/j.gmit.2016.06.002
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA8KN
UT WOS:000386883800001
ER

PT J
AU Freeman, MD
   Porat, N
   Rojansky, N
   Elami-Suzin, M
   Winograd, O
   Ben-Meir, A
AF Freeman, Martine D.
   Porat, Nurit
   Rojansky, Nathan
   Elami-Suzin, Matan
   Winograd, Orit
   Ben-Meir, Assaf
TI Physical symptoms and emotional responses among women undergoing induced
   abortion protocols during the second trimester
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Emotions; Induced abortion; Mifepristone; Misoprostol; Oxytocin; Second
   trimester
ID POSTTRAUMATIC-STRESS; MISOPROSTOL; ANALGESIA; OXYTOCIN; TRIAL; PAIN
AB Objective: To compare the physical and emotional effects of two medical protocols for induced abortion during the second trimester. Methods: The present study was part of a prospective randomized controlled trial comparing mifepristone followed by oxytocin or misoprostol that was conducted at the Hadassah Hebrew University Medical Center, Jerusalem, Israel, from January 10, 2009, to February 22, 2012. Inclusion criteria were pregnancy (14-24 weeks), epidural analgesia, and medical induction of abortion (either elective or following missed abortion). A structured questionnaire was used to assess the participants' physical symptoms and emotional responses. The primary outcome for the present analysis was the degree of physical symptoms reported. Results: Overall, 68 women in the oxytocin group and 67 in the misoprostol group received epidural analgesia and completed the questionnaire. As assessed using a five-point Likert scale, women in the misoprostol group were more likely than those in the oxytocin group to experience diarrhea (1.34 +/- 0.84 vs 1.10 +/- 0.55; P = 0.05) and shivers (3.03 +/- 1.75 vs 1.75 +/- 1.21; P < 0.001). No other between-group differences were detected for the physical or emotional variables evaluated. Conclusion: Differences in physical symptoms experienced by the two treatment groups did not influence the participants' subsequent emotional response. ClinicalTrials.gov: NCF00784797 (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Freeman, Martine D.; Rojansky, Nathan; Elami-Suzin, Matan; Winograd, Orit; Ben-Meir, Assaf] Hadassah Hebrew Univ, Med Ctr, Obstet & Gynecol, Jerusalem, Israel.
   [Porat, Nurit] Hebrew Univ Jerusalem, Med Ctr, Qual Safety & Accreditat Unit, Jerusalem, Israel.
RP Freeman, MD (reprint author), Hadassah Hebrew Univ, Obstet & Gynecol, Ein Kerem Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.
EM martinef09@gmail.com
CR Andersson IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115957
   Ben-Meir A, 2009, J REPROD MED, V54, P511
   Borgatta L, 2011, CONTRACEPTION, V84, P4, DOI 10.1016/j.contraception.2011.02.005
   Brouns JFGM, 2010, CONTRACEPTION, V82, P266, DOI 10.1016/j.contraception.2010.03.006
   Coleman PK, 2011, BRIT J PSYCHIAT, V199, P180, DOI 10.1192/bjp.bp.110.077230
   Ding T, 2014, ANESTH ANALG, V119, P383, DOI 10.1213/ANE.0000000000000107
   Elami-Suzin M, 2013, OBSTET GYNECOL, V122, P815, DOI 10.1097/AOG.0b013e3182a2dcb7
   Elul B, 1999, CONTRACEPTION, V59, P107, DOI 10.1016/S0010-7824(99)00003-7
   Finer LB, 2005, PERSPECT SEX REPRO H, V37, P110, DOI 10.1363/3711005
   Hamoda H, 2004, BJOG-INT J OBSTET GY, V111, P996, DOI 10.1111/j.1471-0528.2004.00235.x
   Kersting Anette, 2012, Dialogues Clin Neurosci, V14, P187
   Lalitkumar S, 2007, HUM REPROD UPDATE, V13, P37, DOI 10.1093/humupd/dml049
   Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330
   Lohr PA, 2008, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD006714.PUB2
   Lundell IW, 2015, EUR J CONTRACEP REPR, V20, P211, DOI 10.3109/13625187.2014.1002032
   Major B, 2009, AM PSYCHOL, V64, P863, DOI 10.1037/a0017497
   Michels TC, 2007, AM FAM PHYSICIAN, V76, P1341
   Olde E, 2006, CLIN PSYCHOL REV, V26, P1, DOI 10.1016/j.cpr.2005.07.002
   Rue VM, 2004, MED SCI MONITOR, V10, pSR5
   Sedgh G, 2012, LANCET, V379, P625, DOI 10.1016/S0140-6736(11)61786-8
   SHALEV AY, 1993, BRIT J CLIN PSYCHOL, V32, P247
   Tedstone JE, 2003, CLIN PSYCHOL REV, V23, P409, DOI 10.1016/S0272-7358(03)00031-X
   Turner JA, 2002, PAIN, V98, P127, DOI 10.1016/S0304-3959(02)00045-3
NR 23
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD NOV
PY 2016
VL 135
IS 2
BP 154
EP 157
DI 10.1016/j.ijgo.2016.05.008
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA5EW
UT WOS:000386643200007
PM 27539053
ER

PT J
AU Ahmed, WAS
   Ibrahim, ZM
   Ashor, OE
   Mohamed, ML
   Ahmed, MR
   Elshahat, AM
AF Ahmed, Waleed Ali Sayed
   Ibrahim, Zakia Mahdy
   Ashor, Osama Elsayed
   Mohamed, Mariam Lotfi
   Ahmed, Magdy Refaat
   Elshahat, Amal Mohamed
TI Use of the Foley catheter versus a double balloon cervical ripening
   catheter in pre-induction cervical ripening in postdate primigravidae
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE cervical ripening; Cook cervical ripening balloon; Foley catheter;
   induction of labor
ID UNFAVORABLE CERVIX; MECHANICAL METHODS; LABOR INDUCTION; TRIAL
AB AimTo compare the efficacy of two mechanical devices for pre-induction of labor cervical ripening: the Foley catheter and the Cook cervical ripening balloon.
   MethodsThis interventional study included 78 postdate primigravid women randomly allocated into two groups: the Foley or Cook balloon catheter. Removal of the catheters was planned approximately 12 h after insertion if spontaneous expulsion had not occurred. The main outcome measures included changes in Bishop score, insertion to delivery time, mode of delivery and occurrence of adverse effects.
   ResultsSpontaneous expulsion of the Foley catheter was encountered more frequently than the Cook (89.2% vs 78.4%; P = 0.03). However, the median Bishop score was significantly higher when using the Cook compared with the Foley catheter after balloon removal (6 vs 5; P = 0.03). The duration from balloon insertion to expulsion and from insertion to delivery was significantly shorter in the Foley group compared with the Cook balloon group (6:19 2:1 vs 7:26 +/- 2:25 h; P = 0.03 and 13:50 +/- 4:00 vs 15:16 +/- 4:30 h; P = 0.03, respectively). There were no significant differences in other outcomes, such as the amount of oxytocin units used, mode of delivery, pain encountered during or after insertion and overall patient satisfaction.
   ConclusionsUse of the Cook cervical ripening catheter results in greater cervical ripening compared with the Foley catheter. However, the duration from balloon insertion to expulsion and then delivery were significantly shorter when using the Foley catheter; therefore, we recommend its use, particularly in low resource settings.
C1 [Ahmed, Waleed Ali Sayed; Ibrahim, Zakia Mahdy; Ashor, Osama Elsayed; Mohamed, Mariam Lotfi; Ahmed, Magdy Refaat; Elshahat, Amal Mohamed] Suez Canal Univ, Dept Obstet & Gynecol, Fac Med, Round Rd, Ismailia 41111, Egypt.
RP Ahmed, WAS (reprint author), Suez Canal Univ, Dept Obstet & Gynecol, Fac Med, Round Rd, Ismailia 41111, Egypt.
EM waleed.asa@gmail.com
CR American College of Obstetricians and Gynecologists, 2009, ACOG PRACT B, V107
   Atad J, 1997, BRIT J OBSTET GYNAEC, V104, P29, DOI 10.1111/j.1471-0528.1997.tb10644.x
   Cookmedical.com, 2014, COOK CERV RIP BALL
   Cunningham F, 2014, WILLIAMS OBSTET, P231
   Fleiss J. L, 1981, STAT METHODS RATES P
   Gelber S, 2006, CLIN OBSTET GYNECOL, V49, P642, DOI 10.1097/00003081-200609000-00022
   Jozwiak M, 2010, BJOG-INT J OBSTET GY, V117, P892, DOI 10.1111/j.1471-0528.2010.02556.x
   KRAMMER J, 1995, CLIN OBSTET GYNECOL, V38, P280, DOI 10.1097/00003081-199506000-00010
   Mei-Dan E, 2012, J MATERN-FETAL NEO M, V25, P723, DOI 10.3109/14767058.2011.591459
   Rouse DJ, 2000, OBSTET GYNECOL, V96, P671, DOI 10.1016/S0029-7844(00)01010-3
   Salim R, 2011, OBSTET GYNECOL, V118, P79, DOI 10.1097/AOG.0b013e318220e4b7
   Sherman D J, 1996, Obstet Gynecol Surv, V51, P621, DOI 10.1097/00006254-199610000-00022
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD NOV
PY 2016
VL 42
IS 11
BP 1489
EP 1494
DI 10.1111/jog.13086
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA9EQ
UT WOS:000386944600010
ER

PT J
AU Choi, GB
   Choe, HK
   Reed, MD
AF Choi, Gloria B.
   Choe, Han K.
   Reed, Michael D.
TI Oxytocin mediates entrainment of sensory stimuli to social cues of
   opposing valence
SO CHEMICAL SENSES
LA English
DT Meeting Abstract
CT 17th International Symposium on Olfaction and Taste (ISOT)
CY JUN 05-09, 2016
CL Yokohama, JAPAN
C1 [Choi, Gloria B.; Choe, Han K.; Reed, Michael D.] MIT, McGovern Inst Brain & Cognit Sci, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0379-864X
EI 1464-3553
J9 CHEM SENSES
JI Chem. Senses
PD NOV
PY 2016
VL 41
IS 9
MA PA16-5
BP E135
EP E135
PG 1
WC Behavioral Sciences; Food Science & Technology; Neurosciences;
   Physiology
SC Behavioral Sciences; Food Science & Technology; Neurosciences &
   Neurology; Physiology
GA DZ8NB
UT WOS:000386126000075
ER

PT J
AU Golub, Y
   Canneva, F
   Funke, R
   Frey, S
   Distler, J
   von Horsten, S
   Freitag, CM
   Kratz, O
   Moll, GH
   Solati, J
AF Golub, Y.
   Canneva, F.
   Funke, R.
   Frey, S.
   Distler, J.
   von Hoersten, S.
   Freitag, C. M.
   Kratz, O.
   Moll, G. H.
   Solati, J.
TI Effects of In utero environment and maternal behavior on neuroendocrine
   and behavioral alterations in a mouse model of prenatal trauma
SO DEVELOPMENTAL NEUROBIOLOGY
LA English
DT Article
DE prenatal trauma; PTBS; corticosterone; prolactin; maternal behavior
ID POSTTRAUMATIC-STRESS-DISORDER; ULTRASONIC VOCALIZATIONS; HOLOCAUST
   SURVIVORS; ANIMAL-MODELS; OXYTOCIN; RATS; DEPRESSION; CHILDREN; ANXIETY;
   GROWTH
AB Maternal posttraumatic stress disorder (PTSD) following trauma exposure during pregnancy is associated with an increased risk of affective disorders in children. To investigate the mechanisms by which prenatal trauma and/or maternal PTSD affect brain development and behavior we established a mouse model of prenatal traumatic (PT) experience based on the application of an electric foot shock to C57Bl/6N female mice on the gestational day 12 during their pregnancy. The model is based on a previously validated animal model of PTSD. We found high anxiety levels and poor maternal care along with reduced serum prolactin and increased corticosterone levels in dams following maternal trauma (MT). PT-pups were born smaller and stayed smaller throughout their life. We show increased time and frequency of ultrasonic calls in PT-pups when separated from the mothers on the postnatal day (PND) 9. Cross-fostering experiments reveal lower anxiety levels in PT pups raised by healthy mothers as compared to trauma-naive pups raised by MT-dams. Importantly, the combination of prenatal trauma and being raised by a traumatized mother leads to: (1) the highest corticosterone levels in pups, (2) longest USV-call time and (3) highest anxiety levels in comparison to other experimental groups. Our data indicates a distinct change in maternal care following MT which is possibly associated with trauma-induced decrease in prolactin levels. Furthermore, we show that maternal behavior is crucial for the development of the offspring anxiety and specific aspects in maternal care overwrite to a significant extend the effects of in utero and postnatal environment. (c) 2016 Wiley Periodicals, Inc. Develop Neurobiol 76: 1254-1265, 2016
C1 [Golub, Y.; Funke, R.; Frey, S.; Distler, J.; Kratz, O.; Moll, G. H.; Solati, J.] Univ Clin Erlangen, Dept Child & Adolescent Mental Hlth, Schwabachanlage 6 & 10, D-91054 Erlangen, Germany.
   [Golub, Y.; Freitag, C. M.] Goethe Univ Hosp Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany.
   [Canneva, F.; von Hoersten, S.] Univ Erlangen Nurnberg, Dept Expt Therapy, Preclin Expt Anim Ctr, Palmsanlage 5, D-91054 Erlangen, Germany.
RP Golub, Y; Solati, J (reprint author), Univ Clin Erlangen, Dept Child & Adolescent Mental Hlth, Schwabachanlage 6 & 10, D-91054 Erlangen, Germany.; Golub, Y (reprint author), Goethe Univ Hosp Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany.
EM yulia.golub@uk-erlangen.de; jsolati@gmail.com
FU "Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung,"
   University of Erlangen
FX Grant sponsor: "Erlanger Leistungsbezogene Anschubfinanzierung und
   Nachwuchsforderung," University of Erlangen.
CR Barker DJP, 2005, NEW ENGL J MED, V353, P1802, DOI 10.1056/NEJMoa044160
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Chemtob CM, 2010, CHILD DEV, V81, P1129, DOI 10.1111/j.1467-8624.2010.01458.x
   Chokchaloemwong D, 2015, GEN COMP ENDOCR, V212, P131, DOI 10.1016/j.ygcen.2014.03.046
   desBoo HA, 2006, AUST NZ J OBSTET GYN, V46, P4
   Eriksson J, 2001, INT J OBESITY, V25, P735, DOI 10.1038/sj.ijo.0801602
   Field T, 2011, INFANT BEHAV DEV, V34, P1, DOI 10.1016/j.infbeh.2010.09.008
   Fish EW, 2004, ANN NY ACAD SCI, V1036, P167, DOI 10.1196/annals.1330.011
   Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155
   Gluckman P, 2005, J ROY SOC MED, V98, P130
   Golub Y, 2011, J PSYCHIATR RES, V45, P650, DOI 10.1016/j.jpsychires.2010.10.014
   Golub Y, 2009, BEHAV BRAIN RES, V205, P544, DOI 10.1016/j.bbr.2009.08.019
   Harris A, 2011, HORM BEHAV, V59, P279, DOI 10.1016/j.yhbeh.2010.06.007
   Harville EW, 2010, WOMEN HEALTH ISS, V20, P20, DOI 10.1016/j.whi.2009.10.002
   Lehrner A, 2014, PSYCHONEUROENDOCRINO, V40, P213, DOI 10.1016/j.psyneuen.2013.11.019
   Maccari S, 2003, NEUROSCI BIOBEHAV R, V27, P119, DOI 10.1016/S0149-7634(03)00014-9
   Marco EM, 2011, NEUROTOX RES, V19, P286, DOI 10.1007/s12640-010-9205-z
   McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003
   Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161
   Meek LR, 2001, PHYSIOL BEHAV, V72, P473, DOI 10.1016/S0031-9384(00)00431-5
   NAGY G, 1983, NEUROENDOCRINOLOGY, V37, P459, DOI 10.1159/000123593
   Palosaari E, 2013, CHILD ABUSE NEGLECT, V37, P955, DOI 10.1016/j.chiabu.2013.04.006
   PEDERSEN CA, 1991, LIFE SCI, V48, P1537, DOI 10.1016/0024-3205(91)90278-J
   PEDERSEN CA, 1979, P NATL ACAD SCI USA, V76, P6661, DOI 10.1073/pnas.76.12.6661
   PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605
   Pedersen CA, 2003, PHYSIOL BEHAV, V80, P233, DOI 10.1016/j.physbeh.2003.07.011
   Perez-Edgar K, 2005, CHILD ADOL PSYCH CL, V14, P681, DOI 10.1016/j.chc.2005.05.008
   Pike KC, 2008, BJOG-INT J OBSTET GY, V115, P149, DOI 10.1111/j.1471-0528.2007.01603.x
   Portfors CV, 2014, CURR OPIN NEUROBIOL, V28, P115, DOI 10.1016/j.conb.2014.07.002
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Shair HN, 2003, DEV PSYCHOBIOL, V42, P206, DOI 10.1002/dev.10087
   Siegmund A, 2007, J PSYCHIATR RES, V41, P848, DOI 10.1016/j.jpsychires.2006.07.017
   Solati J, 2015, PHYSIOL BEHAV, V139, P369, DOI 10.1016/j.physbeh.2014.10.016
   Solati J, 2010, PSYCHIAT CLIN NEUROS, V64, P634, DOI 10.1111/j.1440-1819.2010.02143.x
   Vaughan OR, 2012, J PHYSIOL-LONDON, V590, P5529, DOI 10.1113/jphysiol.2012.239426
   Walf AA, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00040
   Weems CF, 2013, J ANXIETY DISORD, V27, P140, DOI 10.1016/j.janxdis.2012.11.003
   YEHUDA R, 1993, BIOL PSYCHIAT, V33, P479, DOI 10.1016/0006-3223(93)90001-T
   Yehuda R, 2001, DEV PSYCHOPATHOL, V13, P733, DOI 10.1017/S0954579401003170
   Yehuda R, 2014, AM J PSYCHIAT, V9, P1163
   Yehuda R, 2007, ARCH GEN PSYCHIAT, V64, P1040, DOI 10.1001/archpsyc.64.9.1040
   Yehuda R, 2006, ANN NY ACAD SCI, V1071, P137, DOI 10.1196/annals.1364.012
   Zerach G, 2012, J FAM PSYCHOL, V26, P274, DOI 10.1037/a0027159
NR 44
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-8451
EI 1932-846X
J9 DEV NEUROBIOL
JI Dev. Neurobiol.
PD NOV
PY 2016
VL 76
IS 11
BP 1254
EP 1265
DI 10.1002/dneu.22387
PG 12
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA DZ4LA
UT WOS:000385828800006
PM 26899175
ER

PT J
AU Wall, SK
   Wellnitz, O
   Hernandez-Castellano, LE
   Ahmadpour, A
   Bruckmaier, RM
AF Wall, Samantha K.
   Wellnitz, Olga
   Hernandez-Castellano, Lorenzo E.
   Ahmadpour, Amir
   Bruckmaier, Rupert M.
TI Supraphysiological oxytocin increases the transfer of immunoglobulins
   and other blood components to milk during lipopolysaccharide- and
   lipoteichoic acid-induced mastitis in dairy cows
SO JOURNAL OF DAIRY SCIENCE
LA English
DT Article
DE mastitis; blood-milk barrier; endotoxin; oxytocin
ID BOVINE MAMMARY-GLAND; SOMATIC-CELL COUNT; STAPHYLOCOCCUS-AUREUS;
   ESCHERICHIA-COLI; LACTATE-DEHYDROGENASE; BACTERIOLOGICAL CURE; CLINICAL
   MASTITIS; IMMUNE-RESPONSES; TIGHT JUNCTIONS; INFLAMMATION
AB Bacterial mastitis causes pathogen-dependent changes of the blood-milk barrier, and these changes can influence the differential transfer of blood components to milk. It is well known that gram-negative pathogens such as Escherichia coli can cause a greater activation of the immune system and thus a more comprehensive transfer of blood components including IgG than gram-positive pathogens such as Staphylococcus aureus. Supraphysiological doses of oxytocin (OT) have been shown to increase the permeability of the blood-milk barrier; however, the effect of OT during experimentally induced mastitis has not been investigated. Therefore, the objective of this study was to examine if intravenous administration of OT during lipopolysaccharide (LPS)- or lipoteichoic acid (LTA)-induced mastitis could influence the transfer of blood components to milk. The hypothesis was that OT could induce a greater transfer of blood components during mastitis. Twenty-seven dairy cows were injected via the teat canal with LPS, LTA, or a saline control followed by an intravenous injection of OT 2 h following intra-mammary challenge. Milk samples were collected every half hour and analyzed for somatic cell count (SCC), IgG, lactate dehydrogenase (LDH), and serum albumin (SA). Due to the chosen dosage of LPS and LTA, there was no difference in SCC between quarters challenged with only LPS or LTA. Quarters challenged with LPS and OT had a higher SCC and a greater transfer of IgG, LDH, and SA compared with quarters challenged with only LPS. Quarters challenged with LTA and OT had a greater transfer of IgG, LDH, and SA, whereas the SCC increase did not differ from quarters only treated with LTA. In quarters treated only with OT, SCC, LDH, and SA increased, but no difference was observed in IgG concentration from untreated control quarters. In conclusion, there are pathogen-specific changes in the blood-milk barrier and OT can induce a greater transfer of blood components to milk in both LPS- and LTA-induced mastitis. Oxytocin could have implications for use as a mastitis therapy, as there was an increased transfer of IgG into the milk.
C1 [Wall, Samantha K.; Wellnitz, Olga; Hernandez-Castellano, Lorenzo E.; Ahmadpour, Amir; Bruckmaier, Rupert M.] Univ Bern, Vetsuisse Fac, Vet Physiol, CH-3001 Bern, Switzerland.
   [Wall, Samantha K.] Univ Bern, Grad Sch Cellular & Biomed Sci, CH-3012 Bern, Switzerland.
   [Ahmadpour, Amir] Bu Ali Sina Univ, Fac Agr, Dept Anim Sci, Hamadan 651783313, Iran.
RP Bruckmaier, RM (reprint author), Univ Bern, Vetsuisse Fac, Vet Physiol, CH-3001 Bern, Switzerland.
EM rupert.bruckmaier@vetsuisse.unibe.ch
FU Swiss National Science Foundation [149460]
FX The authors thank Yolande Zbinden, Anna-Lena Neuheuser, and Denisa Dan
   (Veterinary Physiology, Vetsuisse Faculty University of Bern,
   Switzerland) for technical assistance. We are grateful to Kerst
   Stelwagen (SciLactis Ltd., New Zealand) for participating in discussions
   about experimental design and treatments. This study was supported by
   the Swiss National Science Foundation (grant no. 149460).
CR Akers RM, 2011, J MAMMARY GLAND BIOL, V16, P275, DOI 10.1007/s10911-011-9231-3
   ALLEN JC, 1990, J DAIRY SCI, V73, P975
   Bannerman DD, 2004, CLIN DIAGN LAB IMMUN, V11, P463, DOI 10.1128/CDLI.11.3.463-472.2004
   BOGIN E, 1977, RES VET SCI, V22, P198
   Burton JL, 2003, VET CLIN N AM-FOOD A, V19, P1, DOI 10.1016/0749-0720(02)00073-7
   GUTERBOCK WM, 1993, J DAIRY SCI, V76, P3437, DOI 10.3168/jds.S0022-0302(93)77682-1
   Hebert A, 2000, FEMS MICROBIOL LETT, V193, P57, DOI 10.1016/S0378-1097(00)00455-9
   Hogan J., 1999, LAB HDB BOVINE MASTI
   Kandasamy S, 2011, J DAIRY SCI, V94, P5963, DOI 10.3168/jds.2011-4288
   Knight CH, 2000, VET REC, V146, P311
   Lehmann M, 2013, J DAIRY SCI, V96, P889, DOI 10.3168/jds.2012-5410
   Lehmann M, 2015, J DAIRY RES, V82, P129, DOI 10.1017/S002202991400065X
   McDonald B, 2011, J MOL MED, V89, P1079, DOI 10.1007/s00109-011-0784-9
   Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361
   NICKERSON SC, 1993, VET MED-US, V88, P375
   Pyorala S, 1997, J DAIRY SCI, V80, P2820
   Rainard P, 1997, VET RES, V28, P231
   Sol J, 1997, J DAIRY SCI, V80, P2803
   STELWAGEN K, 1994, J DAIRY SCI, V77, P3577
   Stelwagen K, 2014, J MAMMARY GLAND BIOL, V19, P131, DOI 10.1007/s10911-013-9309-1
   SUTRA L, 1994, J MED MICROBIOL, V40, P79
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Wall SK, 2016, J DAIRY SCI, V99, P7544, DOI 10.3168/jds.2016-11093
   Wall SK, 2015, J DAIRY SCI, V98, P7748, DOI 10.3168/jds.2015-9440
   Wellnitz O, 2013, J DAIRY SCI, V96, P1681, DOI 10.3168/jds.2012-6150
   Wellnitz O, 2011, J DAIRY SCI, V94, P5405, DOI 10.3168/jds.2010-3931
   Wellnitz O, 2016, J DAIRY SCI, V99, P4851, DOI 10.3168/jds.2016-10927
   Wellnitz O, 2015, J DAIRY RES, V82, P322, DOI 10.1017/S0022029915000345
   Wellnitz O, 2012, VET J, V192, P148, DOI 10.1016/j.tvjl.2011.09.013
NR 29
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-0302
EI 1525-3198
J9 J DAIRY SCI
JI J. Dairy Sci.
PD NOV
PY 2016
VL 99
IS 11
BP 9165
EP 9173
DI 10.3168/jds.2016-11548
PG 9
WC Agriculture, Dairy & Animal Science; Food Science & Technology
SC Agriculture; Food Science & Technology
GA DZ1PQ
UT WOS:000385610700062
PM 27592421
ER

PT J
AU Vilhena-Franco, T
   Mecawi, AS
   Elias, LLK
   Antunes-Rodrigues, J
AF Vilhena-Franco, Tatiane
   Mecawi, Andre Souza
   Kagohara Elias, Lucila Leico
   Antunes-Rodrigues, Jose
TI Oestradiol effects on neuroendocrine responses induced by water
   deprivation in rats
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE oestradiol; water deprivation; vasopressin; oxytocin; angiotensin
ID VASOPRESSIN GENE-EXPRESSION; GONADAL-STEROID MODULATION; MEDIAN PREOPTIC
   NUCLEUS; OXYTOCIN MESSENGER-RNA; FEMALE RATS; SUBFORNICAL ORGAN;
   SUPRAOPTIC NUCLEUS; ESTROGEN-RECEPTOR; FOS IMMUNOREACTIVITY; OSMOTIC
   STIMULATION
AB Water deprivation (WD) induces changes in plasma volume and osmolality, which in turn activate several responses, including thirst, the activation of the renin-angiotensin system (RAS) and vasopressin (AVP) and oxytocin (OT) secretion. These systems seem to be influenced by oestradiol, as evidenced by the expression of its receptor in brain areas that control fluid balance. Thus, we investigated the effects of oestradiol treatment on behavioural and neuroendocrine changes of ovariectomized rats in response to WD. We observed that in response to WD, oestradiol treatment attenuated water intake, plasma osmolality and haematocrit but did not change urinary volume or osmolality. Moreover, oestradiol potentiated WD-induced AVP secretion, but did not alter the plasma OT or angiotensin II (Ang II) concentrations. Immunohistochemical data showed that oestradiol potentiated vasopressinergic neuronal activation in the lateral magnocellular PVN (PaLM) and supraoptic (SON) nuclei but did not induce further changes in Fos expression in the median preoptic nucleus (MnPO) or subfornical organ (SFO) or in oxytocinergic neuronal activation in the SON and PVN of WD rats. Regarding mRNA expression, oestradiol increased OT mRNA expression in the SON and PVN under basal conditions and after WD, but did not induce additional changes in the mRNA expression for AVP in the SON or PVN. It also did not affect the mRNA expression of RAS components in the PVN. In conclusion, our results show that oestradiol acts mainly on the vasopressinergic system in response to WD, potentiating vasopressinergic neuronal activation and AVP secretion without altering AVP mRNA expression.
C1 [Vilhena-Franco, Tatiane; Kagohara Elias, Lucila Leico; Antunes-Rodrigues, Jose] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Physiol, Sao Paulo, Brazil.
   [Mecawi, Andre Souza] Univ Fed Rural Rio de Janeiro, Inst Biol & Hlth Sci, Dept Physiol Sci, Rio De Janeiro, Brazil.
   [Mecawi, Andre Souza] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur, Malaysia.
RP Vilhena-Franco, T (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Physiol, Sao Paulo, Brazil.
EM tativilhenafranco@gmail.com
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/05436-3]; University of Malaya
   [UM.C/625/1/HIR/MOHE/MED/22H-20001-E000086]
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP, #2010/05436-3). Dr Mecawi is also funded by a High
   Impact Research grant from the University of Malaya
   (UM.C/625/1/HIR/MOHE/MED/22H-20001-E000086).
CR Aitken JM, 1974, MOL MED, V47, P179, DOI [10.1042/cs0470179), DOI 10.1042/CS0470179]
   Amico JA, 1995, ADV EXP MED BIOL, V395, P23
   Amico JA, 1997, ENDOCR RES, V23, P69
   AMICO JA, 1981, J CLIN ENDOCR METAB, V52, P988
   Antunes-Rodrigues J, 2004, PHYSIOL REV, V84, P169, DOI 10.1152/physrev.00017.2003
   Araujo IG, 2013, PHYSIOL BEHAV, V122, P104, DOI 10.1016/j.physbeh.2013.08.018
   BARRON WM, 1986, AM J PHYSIOL, V250, pE352
   BOTELHO LMO, 1994, PEPTIDES, V15, P723, DOI 10.1016/0196-9781(94)90103-1
   Brown CH, 2013, J NEUROENDOCRINOL, V25, P678, DOI 10.1111/jne.12051
   Caligioni CS, 2002, LIFE SCI, V71, P2821, DOI 10.1016/S0024-3205(02)02139-2
   CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267
   CARTER DA, 1991, NEUROENDOCRINOLOGY, V53, P1, DOI 10.1159/000125689
   CARTER DA, 1989, J BIOL CHEM, V264, P6601
   CROFTON JT, 1985, ENDOCRINOLOGY, V117, P1195
   CROWLEY RS, 1993, ENDOCRINOLOGY, V133, P2711, DOI 10.1210/en.133.6.2711
   CROWLEY RS, 1993, ENDOCRINOLOGY, V133, P2704, DOI 10.1210/en.133.6.2704
   Culman J, 2001, J RENIN-ANGIO-ALDO S, V2, P96
   Dalmasso C, 2015, PHYSIOL BEHAV, V151, P494, DOI 10.1016/j.physbeh.2015.08.020
   Dalmasso C, 2011, PHYSIOL BEHAV, V104, P398, DOI 10.1016/j.physbeh.2011.04.029
   Davison JM, 2000, AM J PHYSIOL, V246, P105, DOI [10.1152/ajpregu.00295.2000, DOI 10.1152/AJPREGU.00295.2000]
   De Luca LA, 2002, AM J PHYSIOL-REG I, V282, pR552
   Fitzsimons JT, 1998, PHYSIOL REV, V78, P583
   Fujisawa S, 2001, BEHAV BRAIN RES, V122, P33, DOI 10.1016/S0166-4328(01)00176-0
   da Silveira LTG, 2007, CELL MOL NEUROBIOL, V27, P575, DOI 10.1007/s10571-007-9144-2
   Gottlieb HB, 2006, AM J PHYSIOL-REG I, V290, pR1251, DOI 10.1152/ajpregu.00727.2005
   Greenwood MP, 2015, AM J PHYSIOL-REG I, V308, pR559, DOI 10.1152/ajpregu.00444.2014
   HAANWINCKEL MA, 1991, HORM METAB RES, V23, P318, DOI 10.1055/s-2007-1003686
   Hartley DE, 2004, J NEUROENDOCRINOL, V16, P191, DOI 10.1111/j.0953-8194.2004.01150.x
   Haywood SA, 1999, ENDOCRINOLOGY, V140, P3255, DOI 10.1210/en.140.7.3255
   Hrabovszky E, 2004, J COMP NEUROL, V473, P315, DOI 10.1002/cne.20127
   Huang W, 1996, AM J PHYSIOL-REG I, V270, pR427
   HUSAIN MK, 1973, J CLIN ENDOCR METAB, V37, P616
   Kisley LR, 1999, BRAIN RES, V844, P34, DOI 10.1016/S0006-8993(99)01815-6
   Krause EG, 2006, J PHYSIOL-LONDON, V573, P251, DOI 10.1113/jphysiol.2006.106740
   Krause EG, 2003, PHYSIOL BEHAV, V79, P267, DOI 10.1016/S0031-9384(03)00095-7
   Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lucio-Oliveira F, 2012, J ENDOCRINOL, V212, P129, DOI 10.1530/JOE-11-0272
   Mecawi AD, 2015, COMPR PHYSIOL, V5, P1465, DOI 10.1002/cphy.c140031
   Mecawi AS, 2011, AM J PHYSIOL-REG I, V301, pR905, DOI 10.1152/ajpregu.00800.2010
   Mecawi AS, 2008, EXPT PHYSL, V93, P1002, DOI [10.1113/expphysiol.2008.042713, DOI 10.1113/EXPPHYSIOL.2008.042713]
   MILLER FD, 1989, P NATL ACAD SCI USA, V86, P2468, DOI 10.1073/pnas.86.7.2468
   Morien A, 1999, BRAIN RES, V816, P1, DOI 10.1016/S0006-8993(98)00828-2
   OLDFIELD BJ, 1991, BRAIN RES, V558, P13, DOI 10.1016/0006-8993(91)90708-4
   OLIET SHR, 1993, AM J PHYSIOL, V265, pR1475
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Rosas-Arellano MP, 1999, BRAIN RES, V837, P254, DOI 10.1016/S0006-8993(99)01672-8
   SHARE L, 1988, PHYSIOL REV, V68, P1248
   Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
   Simonian SX, 1997, NEUROSCIENCE, V76, P517, DOI 10.1016/S0306-4522(96)00406-X
   SKOWSKY WR, 1979, ENDOCRINOLOGY, V104, P105
   Sladek CD, 1998, J NEUROENDOCRINOL, V10, P897
   Smejkalova T, 2010, J NEUROSCI, V30, P16137, DOI 10.1523/JNEUROSCI.4161-10.2010
   Stachenfeld NS, 2004, J APPL PHYSIOL, V96, P1011, DOI 10.1152/japplphysiol.01032.2003
   Stachenfeld NS, 2002, AM J PHYSIOL-ENDOC M, V283, pE711, DOI 10.1152/ajpendo.00192.2002
   Stachenfeld NS, 1998, AM J PHYSIOL-REG I, V274, pR187
   Stickery EM, 2002, PHYSIOL BEHAV, V77, P731, DOI [10.1016/S0031-9384(02)00926-5, DOI 10.1016/S0031-9384(02)00926-5]
   Summy-Long JY, 2001, CLIN EXP PHARMACOL P, V28, P590, DOI 10.1046/j.1440-1681.2001.03491.x
   Swenson KL, 1997, ENDOCRINOLOGY, V138, P2089, DOI 10.1210/en.138.5.2089
   Tanaka J, 2003, EXP NEUROL, V179, P83, DOI 10.1006/exnr.2002.8054
   THRASHER TN, 1994, FRONT NEUROENDOCRIN, V15, P157, DOI 10.1006/frne.1994.1007
   VANTOL HHM, 1988, ENDOCRINOLOGY, V122, P945
   VEILLE JC, 1986, J CLIN ENDOCR METAB, V63, P721
   Vilhena-Franco T, 2011, J NEUROENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2826.2011.02133.x
   Voisin DL, 1997, NEUROSCIENCE, V78, P215, DOI 10.1016/S0306-4522(96)00551-9
   WINDLE RJ, 1993, J ENDOCRINOL, V137, P311, DOI 10.1677/joe.0.1370311
   Zingg HH, 1989, ENDOCRINOLOGY, V65, P59, DOI [10.1016/0303-7207(89)90165-2, DOI 10.1016/0303-7207(89)90165-2]
NR 67
TC 0
Z9 0
U1 0
U2 0
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022-0795
EI 1479-6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD NOV
PY 2016
VL 231
IS 2
BP 167
EP 180
DI 10.1530/JOE-16-0311
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DZ6DK
UT WOS:000385951600008
ER

PT J
AU Duque-Wilckens, N
   Steinman, MQ
   Laredo, SA
   Hao, R
   Perkeybile, AM
   Bales, KL
   Trainor, BC
AF Duque-Wilckens, Natalia
   Steinman, Michael Q.
   Laredo, Sarah A.
   Hao, Rebecca
   Perkeybile, Allison M.
   Bales, Karen L.
   Trainor, Brian C.
TI Inhibition of vasopressin V1a receptors in the medioventral bed nucleus
   of the stria terminalis has sex- and context-specific anxiogenic effects
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Oxytocin; Stress; Social defeat; Anxiety; Extended amygdala
ID FEMALE CALIFORNIA MICE; MU-OPIOID RECEPTOR; CONDITIONED DEFEAT;
   NEUROANATOMICAL DISTRIBUTION; PEROMYSCUS-CALIFORNICUS; SYRIAN-HAMSTERS;
   MESSENGER-RNA; SOCIAL DEFEAT; IMMOBILIZATION STRESS; PREFRONTAL CORTEX
AB Vasopressin V1a receptors (V1aR) are thought to contribute to the pathophysiology of psychiatric disorders such as anxiety and depression, sparking interest in V1aR as a therapeutic target. Although the global effects of V1aR have been documented, less is known about the specific neural circuits mediating these effects. Moreover, few studies have examined context-specific V1aR function in both males and females. By using the California mouse, we first studied the effects of sex and social defeat stress on V1aR binding in the forebrain. In females but not males, V1aR binding in the bed nucleus of the stria terminalis (BNST) was negatively correlated to social interaction behavior. In females stress also increased V1aR binding in the nucleus accumbens (NAc). Infusions of V1aR antagonist in to the medioventral BNST (BNSTmv) had anxiogenic effects only in animals naive to defeat. For males, inhibition of V1aR in BNSTmv had anxiogenic effects in social and nonsocial contexts, but for females, anxiogenic effects were limited to social contexts. In stressed females, inhibition of V1aR in the NAc shell had no effect on social interaction behavior, but had an anxiogenic effect in an open field test. These data suggest that V1aR in BNSTmv have anxiolytic and prosocial effects in males, and that in females, prosocial and anxiolytic effects of V1aR appear to be mediated independently by receptors in the BNSTmv and NAc shell, respectively. These findings suggest that males have more overlap in neural circuits modulating anxiety in social and nonsocial contexts than females. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Duque-Wilckens, Natalia; Laredo, Sarah A.; Bales, Karen L.; Trainor, Brian C.] Univ Calif Davis, Anim Behav Grad Grp, Davis, CA 95616 USA.
   [Steinman, Michael Q.] Univ Calif Davis, Mol Cellular & Integrat Physiol Grad Grp, Davis, CA 95616 USA.
   [Hao, Rebecca; Perkeybile, Allison M.; Bales, Karen L.; Trainor, Brian C.] Univ Calif Davis, Dept Psychol, 1 Shields Ave, Davis, CA 95616 USA.
RP Trainor, BC (reprint author), Univ Calif Davis, Dept Psychol, 1 Shields Ave, Davis, CA 95616 USA.
EM bctrainor@ucdavis.edu
FU NIH [R01 MH103322, F31 MH095253]; NSF GRF; Becas Chile CONICYT
FX Special thanks to Sae Yokoyama who helped with experiments, and to
   Emilio Ferrer for suggestions on statistical analyses. Supported by NIH
   R01 MH103322 to BCT, F31 MH095253 to MQS, NSF GRF to SAL, Becas Chile
   CONICYT to NDW.
CR ALBERS HE, 1986, J NEUROSCI, V6, P2085
   Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130
   Avery SN, 2016, NEUROPSYCHOPHARMACOL, V41, P126, DOI 10.1038/npp.2015.185
   Bales KL, 2007, NEUROSCIENCE, V144, P38, DOI 10.1016/j.neuroscience.2006.09.009
   Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972
   Bester-Meredith JK, 2001, HORM BEHAV, V40, P51, DOI 10.1006/hbeh.2001.1666
   Bester-Meredith JK, 1999, HORM BEHAV, V36, P25, DOI 10.1006/hbeh.1999.1522
   Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360
   Bosch OJ, 2010, J NEUROENDOCRINOL, V22, P420, DOI 10.1111/j.1365-2826.2010.01984.x
   Campi KL, 2014, NEUROPHARMACOLOGY, V77, P208, DOI 10.1016/j.neuropharm.2013.09.026
   Campi KL, 2013, BRAIN BEHAV EVOLUT, V81, P236, DOI 10.1159/000353260
   Cecchi M, 2002, NEUROPHARMACOLOGY, V43, P1139, DOI 10.1016/S0028-3908(02)00292-7
   Clinard CT, 2015, NEUROPHARMACOLOGY, V90, P102, DOI 10.1016/j.neuropharm.2014.11.016
   Coria-Avila GA, 2014, NEUROSCI BIOBEHAV R, V43, P173, DOI 10.1016/j.neubiorev.2014.04.004
   Curtis AL, 1997, J PHARMACOL EXP THER, V281, P163
   Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109
   Egashira N, 2007, BEHAV BRAIN RES, V178, P123, DOI 10.1016/j.bbr.2006.12.009
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gray CL, 2015, PHYSIOL BEHAV, V152, P56, DOI 10.1016/j.physbeh.2015.09.010
   Gray M, 2012, NEUROPSYCHOPHARMACOL, V37, P2712, DOI 10.1038/npp.2012.136
   Greenberg GD, 2015, EUR J NEUROSCI, V42, P3081, DOI 10.1111/ejn.13099
   Greenberg GD, 2014, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00223
   Hammack SE, 2012, NEUROPHARMACOLOGY, V62, P565, DOI 10.1016/j.neuropharm.2011.02.024
   Hammock EAD, 2006, PHILOS T R SOC B, V361, P2187, DOI 10.1098/rstb.2006.1939
   Inoue K, 2013, NEUROSCIENCE, V244, P122, DOI 10.1016/j.neuroscience.2013.03.035
   Jedema HP, 2004, J NEUROSCI, V24, P9703, DOI 10.1523/JNEUROSCI.2830-04.2004
   JOHNSON AE, 1993, BRAIN RES, V622, P9, DOI 10.1016/0006-8993(93)90795-O
   Kawahara H, 2000, EUR J PHARMACOL, V387, P279, DOI 10.1016/S0014-2999(99)00793-1
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048
   Laredo SA, 2015, EUR J NEUROSCI, V41, P434, DOI 10.1111/ejn.12824
   Lebow MA, 2016, MOL PSYCHIATR, V21, P450, DOI 10.1038/mp.2016.1
   Lee Royce J, 2013, Front Syst Neurosci, V7, P100, DOI 10.3389/fnsys.2013.00100
   Linfoot I, 2009, PROG NEURO-PSYCHOPH, V33, P1129, DOI 10.1016/j.pnpbp.2009.06.008
   Litvin Y, 2007, AGGRESSIVE BEHAV, V33, P545, DOI 10.1002/ab.20222
   Lukas M, 2015, PSYCHONEUROENDOCRINO, V56, P35, DOI 10.1016/j.psyneuen.2015.03.005
   Mak P, 2012, J PSYCHOPHARMACOL, V26, P532, DOI 10.1177/0269881111416687
   Markham CM, 2009, BEHAV BRAIN RES, V198, P69, DOI 10.1016/j.bbr.2008.10.022
   Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663
   O'Connell LA, 2011, J COMP NEUROL, V519, P3599, DOI 10.1002/cne.22735
   Perkeybile AM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00191
   Pitkow LJ, 2001, J NEUROSCI, V21, P7392
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   Reber SO, 2007, ENDOCRINOLOGY, V148, P670, DOI 10.1210/en.2006-0983
   Reyes B. A., 2015, ENEURO, V2
   RIBBLE DO, 1990, BEHAV ECOL SOCIOBIOL, V26, P9
   Silva AL, 2010, BEHAV BRAIN RES, V208, P528, DOI 10.1016/j.bbr.2009.12.038
   Smagin GN, 1997, BRAIN RES BULL, V42, P431, DOI 10.1016/S0361-9230(96)00368-1
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   Steinman MQ, 2015, PSYCHONEUROENDOCRINO, V51, P122, DOI 10.1016/j.psyneuen.2014.09.009
   Steinman M. Q., 2016, BIOL PSYCHIAT
   Trainor BC, 2010, NEUROSCIENCE, V165, P325, DOI 10.1016/j.neuroscience.2009.10.050
   Trainor BC, 2013, HORM BEHAV, V63, P543, DOI 10.1016/j.yhbeh.2013.01.011
   Trainor BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017405
   Varlinskaya EI, 2012, PHARMACOL BIOCHEM BE, V100, P440, DOI 10.1016/j.pbb.2011.10.010
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   Walker DL, 2008, BRAIN STRUCT FUNCT, V213, P29, DOI 10.1007/s00429-008-0183-3
   Young LJ, 1999, J NEUROENDOCRINOL, V11, P291
NR 58
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD NOV
PY 2016
VL 110
BP 59
EP 68
DI 10.1016/j.neuropharm.2016.07.018
PN A
PG 10
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DY7OF
UT WOS:000385318100006
PM 27452721
ER

PT J
AU Pfundmair, M
   Lamprecht, F
   von Wedemeyer, FM
   Frey, D
AF Pfundmair, Michaela
   Lamprecht, Franziska
   von Wedemeyer, Florentine M.
   Frey, Dieter
TI Your word is my command: Oxytocin facilitates the understanding of
   appeal in verbal communication
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Verbal communication; Appeal; Four-ear model
ID HUMANS
AB The hormone oxytocin is known to facilitate positive communication behaviors. In the current study, we aimed to examine how it affects the interpretation of verbal information during communication. We predicted oxytocin to promote the understanding of the socially most effortful dimension of appeal. After intranasal administration of oxytocin or a placebo, participants responded to a "four-ear communication" questionnaire. Results revealed that participants under oxytocin not only chose the dimension of appeal as first choice significantly more often than participants under placebo but also preferred it over most of the other dimensions of interpretation. The findings add to our knowledge of oxytocin as a facilitator of social approach and indicate how oxytocin might work in communicative settings. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Pfundmair, Michaela; Lamprecht, Franziska; von Wedemeyer, Florentine M.; Frey, Dieter] Univ Munich, Leopoldstr 13, D-80802 Munich, Germany.
RP Pfundmair, M (reprint author), Univ Munich, Dept Psychol, Leopoldstr 13, D-80802 Munich, Germany.
EM michaela.pfundmair@psy.lmu.de; franziksa.lamprecht@psy.lmu.de;
   florentine.wedemeyer@psy.lmu.de; dieter.frey@psy.lmu.de
CR Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Dietrich W, 2013, MANY PEACE SER, P1, DOI 10.1057/9781137035066
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   GOULDNER AW, 1960, AM SOCIOL REV, V25, P161, DOI 10.2307/2092623
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Hoge EA, 2014, HUM PSYCHOPHARM CLIN, V29, P299, DOI 10.1002/hup.2402
   Jiang L., 2015, TRANSLATION CROSS CU, P301
   Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547
   Preckel K, 2015, SOC COGN AFFECT NEUR, V10, P987, DOI 10.1093/scan/nsu147
   Risius M, 2014, P ANN HICSS, P540, DOI 10.1109/HICSS.2014.74
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Unkelbach C, 2008, PSYCHOL SCI, V19, P1092, DOI 10.1111/j.1467-9280.2008.02206.x
   Schulz von Thun F., 1981, MITEINANDER REDEN 1
   Schulz von Thun F., 2011, MITEINANDER REDEN 1
NR 18
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD NOV
PY 2016
VL 73
BP 63
EP 66
DI 10.1016/j.psyneuen.2016.07.213
PG 4
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DY7QQ
UT WOS:000385324800008
PM 27472166
ER

PT J
AU Isgett, SF
   Algoe, SB
   Boulton, AJ
   Way, BM
   Fredrickson, BL
AF Isgett, Suzannah F.
   Algoe, Sara B.
   Boulton, Aaron J.
   Way, Baldwin M.
   Fredrickson, Barbara L.
TI Common variant in OXTR predicts growth in positive emotions from
   loving-kindness training
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Affective science; Positive psychology; Genetics; Meditation;
   Vantage sensitivity
ID OXYTOCIN RECEPTOR GENE; SOCIAL CUES; ASSOCIATION; BEHAVIOR; AUTISM;
   POLYMORPHISM; STRESS; BUILD; CD38; TEMPERAMENT
AB Ample research suggests that social connection reliably generates positive emotions. Oxytocin, a neuropeptide implicated in social cognition and behavior, is one biological mechanism that may influence an individual's capacity to extract positive emotions from social contexts. Because variation in certain genes may indicate underlying neurobiological differences, we tested whether several SNPs in two genes related to oxytocin signaling would show effects on positive emotions that were context-specific, depending on sociality. For six weeks, a sample of mid-life adults (N = 122) participated in either socially-focused loving kindness training or mindfulness training. During this timespan they reported their positive emotions daily. Five SNPs within OXTR and CD38 were assayed, and each was tested for its individual effect on daily emotions. The hypothesized three-way interaction between time, training type, and genetic variability emerged: Individuals homozygous for the G allele of OXTR rs1042778 experienced gains in daily positive emotions from loving-kindness training, whereas individuals with the T allele did not experience gains in positive emotions with either training. These findings are among the first to show how genetic differences in oxytocin signaling may influence an individual's capacity to experience positive emotions as a result of a socially-focused intervention. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Isgett, Suzannah F.; Algoe, Sara B.; Boulton, Aaron J.; Fredrickson, Barbara L.] Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, CB 3270, Chapel Hill, NC 27599 USA.
   [Way, Baldwin M.] Ohio State Univ, Dept Psychol, 100G Lazenby Hall,1827 Neil Ave, Columbus, OH 43210 USA.
   [Way, Baldwin M.] Ohio State Univ, Inst Behav Med Res, 100G Lazenby Hall,1827 Neil Ave, Columbus, OH 43210 USA.
RP Fredrickson, BL (reprint author), Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, CB 3270, Chapel Hill, NC 27599 USA.
EM blf@unc.edu
FU National Institutes of Health [R01NR012899, R01CA170128, R01AT007884];
   National Science Foundation Graduate Research Fellowship [DGE-1144081]
FX Barbara L. Fredrickson was supported by grants from the National
   Institutes of Health (grant Nos. R01NR012899, R01CA170128, and
   R01AT007884). Suzannah F. Isgett was supported by the National Science
   Foundation Graduate Research Fellowship (grant No. DGE-1144081). Funding
   sources had no involvement in any part of conducting research, analyzing
   data, or writing the manuscript.
CR Algoe SB, 2014, SOC COGN AFFECT NEUR, V9, P1855, DOI 10.1093/scan/nst182
   Bakermans-Kranenburg MJ, 2014, PSYCHIAT GENET, V24, P45, DOI 10.1097/YPG.0b013e3283643684
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Belsky J, 2009, PSYCHOL BULL, V135, P885, DOI 10.1037/a0017376
   Black A. C., 2012, HDB RES METHODS STUD, P339
   Bolger N., 2013, INTRO DIARY EXPERIEN
   Bower JE, 2013, J CLIN ONCOL, V31, P1656, DOI 10.1200/JCO.2012.46.2143
   Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Chen FS, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00200
   Chida Y, 2008, PSYCHOSOM MED, V70, P741, DOI 10.1097/PSY.0b013e31818105ba
   Choe HK, 2015, NEURON, V87, P152, DOI 10.1016/j.neuron.2015.06.022
   Creswell KG, 2015, SOC COGN AFFECT NEUR, V10, P869, DOI 10.1093/scan/nsu132
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Domes G, 2013, PSYCHOL MED, V43, P1747, DOI 10.1017/S0033291712002565
   Feingold A, 2013, REV GEN PSYCHOL, V17, P111, DOI 10.1037/a0030048
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Fredrickson BL, 2008, J PERS SOC PSYCHOL, V95, P1045, DOI 10.1037/a0013262
   Fredrickson Barbara L, 1998, Rev Gen Psychol, V2, P300, DOI 10.1037/1089-2680.2.3.300
   Fredrickson BL, 2013, ADV EXP SOC PSYCHOL, V47, P1, DOI 10.1016/B978-0-12-407236-7.00001-2
   Furman DJ, 2011, PSYCHONEUROENDOCRINO, V36, P891, DOI 10.1016/j.psyneuen.2010.12.004
   Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7
   Howell R., 2007, HLTH PSYCHOL REV, V1, P83, DOI [10.1080/17437190701492486, DOI 10.1080/17437190701492486]
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Israel S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005535
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Kahneman D, 2004, SCIENCE, V306, P1776, DOI 10.1126/science.1103572
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Michalska K. J., 2014, FRONT BEHAV NEUROSCI, V8
   Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004
   Muthen L.K., 1998, MPLUS USERS GUIDE
   Otake Keiko, 2006, J Happiness Stud, V7, P361, DOI 10.1007/s10902-005-3650-z
   Pluess M, 2013, PSYCHOL BULL, V139, P901, DOI 10.1037/a0030196
   Poulin MJ, 2012, PSYCHOL SCI, V23, P446, DOI 10.1177/0956797611428471
   Preacher KJ, 2006, J EDUC BEHAV STAT, V31, P437, DOI 10.3102/10769986031004437
   Salzberg Sharon, 2011, REAL HAPPINESS POWER
   Seidlmeier P., 2012, PSYCHOL BULL, V138, P1129
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Steptoe A, 2012, ARCH INTERN MED, V172, P273, DOI 10.1001/archinternmed.2011.1028
   Stone AA, 2012, J POSIT PSYCHOL, V7, P306, DOI 10.1080/17439760.2012.691980
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   Van Cappellen P., 2016, SOC COGN AFFECT NEUR
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
NR 56
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD NOV
PY 2016
VL 73
BP 244
EP 251
DI 10.1016/j.psyneuen.2016.08.010
PG 8
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DY7QQ
UT WOS:000385324800027
PM 27543885
ER

PT J
AU Martins, D
   Paloyelis, Y
   Prata, D
AF Martins, Daniel
   Paloyelis, Yannis
   Prata, Diana
TI "Shedding light on a dark question": Peripheral oxytocin signalling and
   neurobehavioral responses to intranasal oxytocin in humans
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Letter
ID CEREBROSPINAL-FLUID
C1 [Martins, Daniel; Prata, Diana] Univ Lisbon, Fac Med, Inst Med Mol, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal.
   [Paloyelis, Yannis; Prata, Diana] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, Crespigny Pk, London SE5 8AF, England.
RP Prata, D (reprint author), Univ Lisbon, Fac Med, Inst Med Mol, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal.
EM diana.prata@medicina.ulisboa.pt
CR Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Evans SL, 2014, BRAIN RES, V1580, P69, DOI 10.1016/j.brainres.2013.11.008
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Paloyelis Y, 2016, BIOL PSYCHIAT, V79, P693, DOI 10.1016/j.biopsych.2014.10.005
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
NR 5
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD NOV
PY 2016
VL 73
BP 271
EP 272
DI 10.1016/j.psyneuen.2016.08.008
PG 2
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DY7QQ
UT WOS:000385324800030
PM 27613568
ER

PT J
AU Dagdeviren, H
   Cengiz, H
   Heydarova, U
   Caypinar, SS
   Kanawati, A
   Guven, E
   Ekin, M
AF Dagdeviren, Hediye
   Cengiz, Huseyin
   Heydarova, Ulkar
   Caypinar, Sema Suzen
   Kanawati, Ammar
   Guven, Ender
   Ekin, Murat
TI Intramuscular versus intravenous prophylactic oxytocin for postpartum
   hemorrhage after vaginal delivery: a randomized controlled study
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Oxytocin; Postpartum haemorrhage; Randomized controlled trial; Vaginal
   delivery
ID CONTROLLED-TRIAL; CESAREAN-SECTION; PREVENTION; LABOR
AB Prevention of postpartum haemorrhage (PPH) is essential in the pursuit of improved health care for women. Oxytocin, the most commonly used uterotonic agent to prevent PPH, has no established the route of administration. In this study we aimed to compare whether the mode of oxytocin administration, i.e., intravenous and intramuscular administration, has an effect on the potential benefits and side effects.
   A total of 256 women were randomised into two groups: intramuscular group (128) or intravenous group (128).
   Estimated blood loss during the third stage of labour was similar between the two groups (p = 0.572). Further there were no statistically significant difference was noted between the two groups in terms of the mean duration of labor, duration of the third stage of labor, manual removal of the placenta, need for instrumental delivery, need for blood transfusion, PPH aeyen500 mL, PPH aeyen1000 mL, or length of hospital stay.
   Using oxytocin by intravenous and intramuscular route has a similar efficacy and adverse effects.
C1 [Dagdeviren, Hediye; Cengiz, Huseyin; Heydarova, Ulkar; Caypinar, Sema Suzen; Kanawati, Ammar; Guven, Ender; Ekin, Murat] Bakirkoy Dr Sadi Konuk Teaching & Res Hosp, Dept Obstet & Gynaecol, Tevfik Saglam St 11, Istanbul, Turkey.
RP Dagdeviren, H (reprint author), Bakirkoy Dr Sadi Konuk Teaching & Res Hosp, Dept Obstet & Gynaecol, Tevfik Saglam St 11, Istanbul, Turkey.
EM hediyedagdeviren@gmail.com
CR Bouwmeester FW, 2005, CURR PHARM DESIGN, V11, P759, DOI 10.2174/1381612053381882
   Breathnach F, 2006, TXB POSTPARTUM HAEMO, P256
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Charbit B, 2007, CLIN PHARMACOL THER, V76, P359
   Chong YS, 2004, CURR OPIN OBSTET GYN, V16, P143, DOI 10.1097/01.gco.0000124170.64477cd
   Davies GA, 2011, OBSTET GYNECOLOGY, V105, P294
   Davies GAL, 2005, OBSTET GYNECOL, V105, P294, DOI 10.1097/01.AOG.0000148264.20909.bb
   Jackson KW, 2001, AM J OBSTET GYNECOL, V185, P873, DOI 10.1067/mob.2001.117363
   Kaul Virochana, 2006, Indian J Med Sci, V60, P233
   Lewis G, 2007, CONFIDENTIAL ENQUIRY
   Miller S, 2004, J MIDWIFERY WOM HEAL, V49, P283, DOI 10.1016/j.jmwh.2004.04.001
   Priya GP, 2015, ARCH GYNECOL OBSTET, V292, P1231, DOI 10.1007/s00404-015-3763-5
   Rouse DJ, 2000, OBSTET GYNECOL, V96, P671, DOI 10.1016/S0029-7844(00)01010-3
   Soltani H, 2006, COCHRANE DATABASE SY
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
   Wedisinghe L, 2008, EUR J OBSTET GYN R B, V137, P27, DOI 10.1016/j.ejogrb.2007.04.007
   Westhoff G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001808.pub2
   World Health Organization, 2009, WHO GUID MAN POSTP H
   Ming Ying Gai, 2004, EUR J OBSTET GYN R B, V112, P154
NR 19
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD NOV
PY 2016
VL 294
IS 5
BP 911
EP 916
DI 10.1007/s00404-016-4060-7
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DY5KO
UT WOS:000385138700004
PM 26980230
ER

PT J
AU Zondag, DC
   Gross, MM
   Grylka-Baeschlin, S
   Poat, A
   Petersen, A
AF Zondag, Dirkje C.
   Gross, Mechthild M.
   Grylka-Baeschlin, Susanne
   Poat, Angela
   Petersen, Antje
TI The dynamics of epidural and opioid analgesia during labour
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Combined analgesia; Labour duration; Spontaneous birth; Cox regression;
   Longitudinal studies; Timing of interventions
ID NEURAXIAL ANALGESIA; CESAREAN DELIVERY; RISK-FACTORS; PAIN; COHORT;
   BIRTH; DURATION; PROGRESSION; EXPERIENCE; OXYTOCIN
AB To investigate the association of analgesia, opioids or epidural, or the combination of both with labour duration and spontaneous birth in nulliparous women.
   A secondary data analysis of an existing cohort study was performed and included nulliparous women (n = 2074). Durations of total labour and first and second labour stage were calculated with Kaplan-Meier estimation for the four different study groups: no analgesia (n = 620), opioid analgesia (n = 743), epidural analgesia (n = 482), and combined application (n = 229). Labour duration was compared by Cox regression while adjusting for confounders and censoring for operative births. Logistic regression was used to investigate the association between the administration of different types of analgesia and mode of birth.
   Most women in the combined application group were first to receive opioid analgesia. Women with no analgesia had the shortest duration of labour (log rank p < 0.001) and highest chance of a spontaneous birth (p < 0.001). If analgesia was administered, women with opioids had a shorter first stage (p = 0.018), compared to women with epidural (p < 0.001) or women with combined application (p < 0.001). Women with opioids had an increased chance to reach full cervical dilatation (p = 0.006). Women with epidural analgesia (p < 0.001) and women with combined application (p < 0.001) had a prolonged second stage and decreased chance of spontaneous birth compared to women without analgesia.
   Women with opioids had a prolonged first stage, but increased chance to reach full cervical dilatation. Women with epidural analgesia and women with both opioid and epidural analgesia had a prolonged first and second stage and a decreased chance of a spontaneous birth.
C1 [Zondag, Dirkje C.; Gross, Mechthild M.; Grylka-Baeschlin, Susanne; Petersen, Antje] Hannover Med Sch, Midwifery Res & Educ Unit, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Poat, Angela] Univ Hull, Fac Hlth & Social Care, Kingston Upon Hull HU6 7RX, N Humberside, England.
RP Petersen, A (reprint author), Hannover Med Sch, Midwifery Res & Educ Unit, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM Petersen.Antje@mh-hannover.de
FU German Research Council (DFG) [GR 1917/4-1]
FX This study was funded by the German Research Council (DFG; Grant number
   GR 1917/4-1).
CR Anim-Somuah M, 2011, COCHRANE DB SYST REV, V7, P12
   Bernitz S, 2014, MIDWIFERY, V30, P364, DOI 10.1016/j.midw.2013.03.010
   Bhattacharya S, 2006, BMC PREGNANCY CHILDB, V19, P14, DOI DOI 10.1186/1471-2393-6-14
   Bland JM, 2004, BRIT MED J, V328, P1073, DOI 10.1136/bmj.328.7447.1073
   Caughey AB, 2006, AM J OBSTET GYNECOL, V195, P700, DOI 10.1016/j.ajog.2006.07.003
   Caughey AB, 2009, EVID REP TECHNOL ASS, P1
   Davey MA, 2013, MIDWIFERY, V29, P1297, DOI 10.1016/j.midw.2013.05.014
   German Society of Obstetrics and Gynaecology (DGGG), 2010, 015025 DGGG AWMF
   Eley VA, 2015, ANAESTH INTENS CARE, V43, P12
   Grant EN, 2015, BJOG-INT J OBSTET GY, V122, P288, DOI 10.1111/1471-0528.12966
   Green JM, 2003, BIRTH-ISS PERINAT C, V30, P235, DOI 10.1046/j.1523-536X.2003.00253.x
   Gross MM, 2014, ARCH GYNECOL OBSTET, V289, P41, DOI 10.1007/s00404-013-2916-7
   Gross MM, 2009, ARCH GYNECOL OBSTET, V280, P899, DOI 10.1007/s00404-009-0990-7
   Gross MM, 2005, BIRTH-ISS PERINAT C, V32, P122, DOI 10.1111/j.0730-7659.2005.00355.x
   Hasegawa J, 2013, J ANESTH, V27, P43, DOI 10.1007/s00540-012-1480-9
   Hatem M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004667.pub2
   Hodnett ED, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003766.pub2
   Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   Janssen PA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-182
   Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2
   Kemp E, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008070.pub2
   Lawrence A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003934.pub2
   Leap N, 2004, NORMAL CHILDBIRTH EV, P25
   Leap N, 2010, J MIDWIFERY WOM HEAL, V55, P234, DOI 10.1016/j.jmwh.2010.02.001
   Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427
   Nowotzek A, 2007, GEBURTSH FRAUENHEILK, V67, P906
   O'Hara MW, 2013, ANNU REV CLIN PSYCHO, V9, P379, DOI 10.1146/annurev-clinpsy-050212-185612
   Petersen A, 2013, ARCH GYNECOL OBSTET, V288, P245, DOI 10.1007/s00404-013-2737-8
   Petersen A, 2011, MIDWIFERY, V27, pE267, DOI 10.1016/j.midw.2010.10.017
   Rohwer AC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009243.pub3
   Sandall J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004667.pub5
   Schiessl B, 2005, EUR J OBSTET GYN R B, V118, P17, DOI 10.1016/j.ejogrb.2004.01.045
   Shintani AK, 2009, CRIT CARE MED, V37, P2939, DOI 10.1097/CCM.0b013e3181b7fbbb
   Simkin P, 2004, J MIDWIFERY WOM HEAL, V49, P489, DOI 10.1016/j.jmwh.2004.07.007
   Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009514
   Stewart DE, 2003, POSTPARTUM DEPRESSIO
   Tracy Sally K, 2007, Women Birth, V20, P41, DOI 10.1016/j.wombi.2007.03.005
   Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2
   Vahratian A, 2005, OBSTET GYNECOL, V105, P698, DOI 10.1097/01.AOG.0000157436.68847.3b
   Van der Gucht N, 2015, MIDWIFERY, V31, P349, DOI 10.1016/j.midw.2014.12.005
   van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008
   van Cranenburgh B, 2009, PIJN VANUIT NEUROWET
   Waldenstrom U, 2004, BIRTH-ISS PERINAT C, V31, P17, DOI 10.1111/j.0730-7659.2004.0270.x
   Wassen MMLH, 2014, EUR J OBSTET GYN R B, V183, P125, DOI 10.1016/j.ejogrb.2014.10.023
   Worstell T, 2014, OBSTET GYNECOL, V123, p84S
NR 46
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD NOV
PY 2016
VL 294
IS 5
BP 967
EP 977
DI 10.1007/s00404-016-4110-1
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DY5KO
UT WOS:000385138700012
PM 27194036
ER

PT J
AU de la Mora, MP
   Perez-Carrera, D
   Crespo-Ramirez, M
   Tarakanov, A
   Fuxe, K
   Borroto-Escuela, DO
AF Perez de la Mora, Miguel
   Perez-Carrera, Diana
   Crespo-Ramirez, Minerva
   Tarakanov, Alexander
   Fuxe, Kjell
   Borroto-Escuela, Dasiel O.
TI Signaling in dopamine D2 receptor-oxytocin receptor heterocomplexes and
   its relevance for the anxiolytic effects of dopamine and oxytocin
   interactions in the amygdala of the rat
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Anxiety; Fear; Amygdala; Dopamine D2 receptor; Oxytocin receptor;
   Receptor-receptor interactions; Raclopride; Oxytocin; Heteroreceptor
   complexes
ID INTEGRIN TRIPLETS; RESPONSE ELEMENT; MARINE SPONGES; PROTEIN-KINASE;
   FEAR; VASOPRESSIN; BEHAVIOR; HETEROMERS; ANXIETY; BINDING
AB Dopamine D2 receptor (D2R)-oxytocin receptor (OTR) interactions exist within heterocomplexes with facilitatory effects on D2R recognition and Gi/o coupling. In this work the hypothesis is tested using cotransfected HEK293 cells whether allosteric reciprocal D2R-OTR interactions can enhance signaling of D2R-OTR heterocomplexes along the CREB, MAPK and PLC pathways and whether the anxiolytic effects of OT may involve facilitatory D2R-OTR interactions within the central amygdaloid nucleus (CeA). Oxytocin enhanced the D2-like agonist quinpirole induced inhibition of the AC-PKA-pCREB signaling cascade and increased its signaling over the RAS-MAPK-pELK pathway. Quinpirole enhanced the oxytocin induced increases in the activity of the PLCbeta-IP3-calcineurin and RAS-MAPK-pELK cascades. Bilateral infusion of oxytocin (0.9-150 ng/side) into the CeA of the rat elicited anxiolytic effects in the Shock-Probe Burying test, an unconditioned model of fear/anxiety. This action was not observed when oxytocin (25 ng/side) was simultaneously co-infused with raclopride (neither 250 nor 500 ng/side), a D2/D3 antagonist, into the CeA. Based on the current findings, the blockade of the anxiolytic effects of oxytocin by the simultaneous intra-CeA administration of raclopride can be explained by a lack of facilitatory protomer interactions in D2R-OTR heterocomplexes. Dysfunction and/or disruption of such interactions in the central amygdala may lead to anxiety development. Restoration of such interactions may represent a new strategy for development of novel anxiolytic drugs. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Perez de la Mora, Miguel; Perez-Carrera, Diana; Crespo-Ramirez, Minerva] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City, DF, Mexico.
   [Tarakanov, Alexander] Russian Acad Sci, St Petersburg Inst Informat & Automat, St Petersburg, Russia.
   [Fuxe, Kjell; Borroto-Escuela, Dasiel O.] Karolinska Inst, Dept Neurosci, Retzius Vag 8, S-17177 Stockholm, Sweden.
   [Borroto-Escuela, Dasiel O.] Univ Urbino, Physiol Sect, Dept Biomol Sci, Campus Sci Enrico Mattei,Via Ca Le Suore 2, I-61029 Urbino, Italy.
RP de la Mora, MP (reprint author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City, DF, Mexico.; Borroto-Escuela, DO (reprint author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, S-17177 Stockholm, Sweden.
EM mperez@ifc.unam.mx; dianaperezcarrera@hotmail.com; mcrespo@ifc.unam.mx;
   sasha_tar@hotmail.com; kjell.fuxe@ki.se; dasiel.borroto.escuela@ki.se
FU Vetenskaspsradet from Swedish Research Council with Mexico
   [348-2014-4396]; Direction General de Asuntos del Personal Academic
   (DGAPA) de la Universidad Nacional Autonoma de Mexico [IN204314];
   Consejo Nacional de Ciencia y Tecnologia (CONACYT) [220173]; Swedish
   Medical Research Council [04X-715]; AFA Forsakring [130328]; Computing
   Unit from Institute de Fisiologia Celular, Universidad Nacional Autonoma
   de Mexico
FX This work was supported by Vetenskaspsradet in year 2015-2017 (No
   348-2014-4396) as an international collaborative research grant from the
   Swedish Research Council (2015-2017) with Mexico (M. Perez de la Mora),
   and by the grants IN204314 from the Direction General de Asuntos del
   Personal Academic (DGAPA) de la Universidad Nacional Autonoma de Mexico
   and 220173 from Consejo Nacional de Ciencia y Tecnologia (CONACYT), the
   Swedish Medical Research Council (04X-715) to KF, and by AFA Forsakring
   (130328) to KF and D.O.B.-E. We are indebted with the Computing Unit
   from Institute de Fisiologia Celular, Universidad Nacional Autonoma de
   Mexico and in particular to Francisco Perez-Eugenio for their support
   during this work. Alexander O. Tarakanov has not received any support
   for this work. D.O.B.-E. belongs to Academia de Biologos Cubanos. The
   authors have no affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript
CR Bale TL, 2001, J NEUROSCI, V21, P2546
   Baskerville TA, 2008, PROG BRAIN RES, V170, P277, DOI 10.1016/S0079-6123(08)00423-8
   Borroto-Escuela DO, 2014, INT J MOL SCI, V15, P8570, DOI 10.3390/ijms15058570
   Borroto-Escuela DO, 2013, BIOCHEM BIOPH RES CO, V435, P140, DOI 10.1016/j.bbrc.2013.04.058
   Borroto-Escuela DO, 2010, BIOCHEM BIOPH RES CO, V401, P605, DOI 10.1016/j.bbrc.2010.09.110
   Borroto-Escuela DO, 2010, BIOCHEM BIOPH RES CO, V394, P222, DOI 10.1016/j.bbrc.2010.02.168
   Borroto-Escuela DO, 2010, BIOCHEM BIOPH RES CO, V393, P767, DOI 10.1016/j.bbrc.2010.02.078
   Borroto-Escuela D.O., 2016, PSYCHOPHARMACOLOGY, V6, P77
   Chang WH, 2014, PSYCHONEUROENDOCRINO, V47, P212, DOI 10.1016/j.psyneuen.2014.05.020
   CONDESLARA M, 1994, BRAIN RES, V637, P277, DOI 10.1016/0006-8993(94)91245-9
   de la Mora MP, 2006, EUR J NEUROSCI, V23, P2749, DOI 10.1111/j.1460-9568.2006.04798.x
   Perez de la Mora M., 2011, 10 C BIOL PSYCH PRAG
   Devost D, 2008, PROG BRAIN RES, V170, P167, DOI 10.1016/S0079-6123(08)00415-9
   DEWIED D, 1991, P NATL ACAD SCI USA, V88, P1494, DOI 10.1073/pnas.88.4.1494
   Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026
   Engin E, 2008, PROG NEURO-PSYCHOPH, V32, P1399, DOI 10.1016/j.pnpbp.2008.03.020
   Fuxe K, 2014, PROG BRAIN RES, V211, P113, DOI 10.1016/B978-0-444-63425-2.00005-2
   Fuxe K, 2012, BRAIN RES, V1476, P119, DOI 10.1016/j.brainres.2012.01.062
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006
   Hicks C, 2012, J NEUROENDOCRINOL, V24, P1012, DOI 10.1111/j.1365-2826.2012.02311.x
   Ho GY, 2007, PHARMACOLOGY, V79, P114, DOI 10.1159/000098097
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   JAMES TA, 1978, J PHARMACOL METHOD, V1, P197, DOI 10.1016/0160-5402(78)90049-9
   Jarrett TM, 2006, NEUROPEPTIDES, V40, P161, DOI 10.1016/j.npep.2006.03.002
   Kanat M, 2015, NEUROPSYCHOPHARMACOL, V40, P2632, DOI 10.1038/npp.2015.111
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Lahoud N, 2013, PSYCHONEUROENDOCRINO, V38, P2184, DOI 10.1016/j.psyneuen.2013.04.006
   Laszlo K, 2016, BEHAV BRAIN RES, V296, P279, DOI 10.1016/j.bbr.2015.09.021
   LeDoux J, 2007, CURR BIOL, V17, pR868, DOI 10.1016/j.cub.2007.08.005
   Love TM, 2014, PHARMACOL BIOCHEM BE, V119, P49, DOI 10.1016/j.pbb.2013.06.011
   Love TM, 2012, BIOL PSYCHIAT, V72, P198, DOI 10.1016/j.biopsych.2012.01.033
   MacDonald K, 2014, BRAIN RES, V1580, P22, DOI 10.1016/j.brainres.2014.01.025
   Mak P, 2012, J PSYCHOPHARMACOL, V26, P532, DOI 10.1177/0269881111416687
   McCarthy MM, 1996, PHYSIOL BEHAV, V60, P1209
   Miyamoto S, 2013, CURR OPIN PSYCHIATR, V26, P158, DOI 10.1097/YCO.0b013e32835d8296
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004
   Paxinos G., 1986, RAT BRAIN STEREOTAXI
   Perez de la Mora M, 2012, Neuroscience, V201, P252, DOI 10.1016/j.neuroscience.2011.10.045
   de la Mora MP, 2010, PROG NEUROBIOL, V90, P198, DOI 10.1016/j.pneurobio.2009.10.010
   Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.009.004
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   ROOZENDAAL B, 1992, BRAIN RES, V596, P35, DOI 10.1016/0006-8993(92)91529-N
   Rosenfeld AJ, 2011, SCHIZOPHRENIA BULL, V37, P1077, DOI 10.1093/schbul/sbq015
   Sauer C, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00045
   SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Smeltzer MD, 2006, NEUROSCI LETT, V394, P146, DOI 10.1016/j.neulet.2005.10.019
   Sobota R, 2015, BEHAV NEUROSCI, V129, P389, DOI 10.1037/bne0000074
   STOEHR JD, 1992, PSYCHONEUROENDOCRINO, V17, P267, DOI 10.1016/0306-4530(92)90067-H
   Stoop R, 2015, ANNU REV NEUROSCI, V38, P369, DOI 10.1146/annurev-neuro-071714-033904
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Tarakanov AO, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-128
   Tarakanov AO, 2012, J RECEPT SIG TRANSD, V32, P202, DOI 10.3109/10799893.2012.692119
   Tarakanov AO, 2010, J MOL NEUROSCI, V41, P294, DOI 10.1007/s12031-009-9313-5
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   VOORN P, 1983, BRAIN RES, V270, P169, DOI 10.1016/0006-8993(83)90809-0
   Wang ZX, 2004, PHYSIOL BEHAV, V83, P319, DOI 10.1016/j.physbeh.2004.08.024
   Wouters Elien, 2014, BMC Res Notes, V7, P357, DOI 10.1186/1756-0500-7-357
   Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 65
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD NOV
PY 2016
VL 1862
IS 11
BP 2075
EP 2085
DI 10.1016/j.bbadis.2016.07.004
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DY1MX
UT WOS:000384860200006
ER

PT J
AU Jamei, M
   Sadeghi, AA
AF Jamei, Matin
   Sadeghi, Ali Asghar
TI Effect of Quercetin on Cortisol and Oxytocin Levels, Oxytocin Receptor
   Gene Expression and Morphometry of Uterus in Rats Exposed to Bisphenol A
SO KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI
LA English
DT Article
DE Bisphenol; Oxidative stress; Oxytocin; Quercetin; Rat
ID UTERINE CONTRACTION; IN-VIVO; ESTROGEN; STRESS; ENDOMETRIOSIS;
   CYTOTOXICITY; ASSOCIATION
AB This study was carried out to evaluate effects of quercetin and bisphenol A (BPA), alone and in combination, on plasma cortisol and oxytocin levels, oxytocin receptor gene expression and morphometry of uterus in rat. After one week of acclimatization, twenty female rats were divided into four treatments as: control, received ethanol saline as injection intraperitoneally and gavaged hydroxypropylmethylcellulose (HPMC). The second group injected with 50 mu g BPA per kg body weight dissolved in ethanol saline two times per week for 4 weeks. The third group gavaged 30 mg quercetin per kg body weight suspended in aqueous solution of HPMC two times per week for 4 weeks, while the fourth group was treated with quercetin along with BPA. Two days after final injection and gavage, rats were anesthetized and uterine and blood samples were collected. BPA alone increased plasma MDA level, decreased total antioxidant capacity (TCA) and had no effect (P>0.05) on oxytocin and cortisol levels in the plasma compared with control group. Quercetin along with BPA decreased MDA level, but had no effect (P>0.05) on TCA, oxytocin and cortisol levels compared to control. Quercetin and BPA, alone or in combination, resulted in increase (P<0.05) oxytocin receptor gene expression. Treatment with quercetin along with BPA increased (P<0.05) endometrium, but had no effect (P>0.05) on myometrium and epimetrium. It was indicated that quercetin may be a potential compound for reducing oxidative stress damages in uterus layer and increasing blood oxytocin level and its receptor in uterine, but cannot completely ameliorate the negative effects of BPA.
C1 [Jamei, Matin; Sadeghi, Ali Asghar] Islamic Azad Univ, Dept Anim Sci, Sci & Res Branch, Tehran, Iran.
RP Sadeghi, AA (reprint author), Islamic Azad Univ, Dept Anim Sci, Sci & Res Branch, Tehran, Iran.
EM a.sadeghi@srbiau.ac.ir
FU Islamic Azad University
FX The authors are grateful to the Islamic Azad University for research
   funding support. We also thank all staffs in the animal house, for the
   assistance in the care and feeding of the rats used in this research.
CR An BS, 2013, MOL CELL ENDOCRINOL, V375, P27, DOI 10.1016/j.mce.2013.04.025
   Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   Bhutada P, 2010, PROG NEURO-PSYCHOPH, V34, P955, DOI 10.1016/j.pnpbp.2010.04.025
   Bulletti C, 2002, FERTIL STERIL, V77, P1156, DOI 10.1016/S0015-0282(02)03087-X
   Bulletti C, 2001, HUM REPROD, V16, P2676, DOI 10.1093/humrep/16.12.2676
   Cheng LC, 2012, TOXICOL APPL PHARM, V258, P343, DOI 10.1016/j.taap.2011.11.017
   DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S
   Dusza Luiza, 2006, Reprod Biol, V6 Suppl 1, P151
   Edwards KM, 2008, MATURITAS, V61, P330, DOI 10.1016/j.maturitas.2008.09.024
   Erden I.M., 2001, CLIN EXP DERMATOL, V26, P536
   Aboul Ezz HS, 2013, CYTOTECHNOLOGY, V67, P145, DOI 10.1007/s10616-013-9672-1
   Harnly JM, 2006, J AGR FOOD CHEM, V54, P9966, DOI 10.1021/jf061478a
   Hassan ZK, 2012, OXID MED CELL LONGEV, DOI 10.1155/2012/194829
   Huang H, 2012, REPROD TOXICOL, V34, P317, DOI 10.1016/j.reprotox.2012.04.008
   Kabuto H, 2003, ENVIRON RES, V93, P31, DOI 10.1016/S0013-9351(03)00062-8
   Kawabata K, 2010, J NUTR BIOCHEM, V21, P374, DOI 10.1016/j.jnutbio.2009.01.008
   Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303
   Lejonklou MH, 2014, TOXICOL LETT, V229, pS243, DOI [10.1016/j.toxlet.2014.06.811, 10.1016/j.toxlet.2014.06.810]
   Nakagawa Y, 2000, ARCH TOXICOL, V74, P99, DOI 10.1007/s002040050659
   Panagiotidou E, 2014, J ENDOCRINOL, V220, P207, DOI 10.1530/JOE-13-0416
   Patisaul HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043890
   Poimenova A, 2010, NEUROSCIENCE, V167, P741, DOI 10.1016/j.neuroscience.2010.02.051
   SANGAI NP, 2012, TOXICOL IND HEALTH, V30, P581
   Szego EM, 2006, J NEUROSCI, V26, P4104, DOI 10.1523/JNEUROSCI.0222-06.2006
   Veiga-Lopez A, 2015, ENDOCRINOLOGY, V156, P911, DOI 10.1210/en.2014-1863
   Verma RJ, 2009, ACTA POL PHARM, V66, P41
   Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195
   Wolstenholme JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025448
   Wu CH, 2015, J FUNCT FOODS, V19, P495, DOI 10.1016/j.jff.2015.09.028
NR 29
TC 0
Z9 0
U1 9
U2 9
PU KAFKAS UNIV, VETERINER FAKULTESI DERGISI
PI KARS
PA KAFKAS UNIV, VETERINER FAKULTESI DERGISI, KARS, 36040, TURKEY
SN 1300-6045
J9 KAFKAS UNIV VET FAK
JI Kafkas Univ. Vet. Fak. Derg.
PD NOV-DEC
PY 2016
VL 22
IS 6
BP 823
EP 828
DI 10.9775/kvfd.2016.15397
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA DU3MB
UT WOS:000382113800003
ER

PT J
AU Lawson, SK
   Gray, AC
   Woehrle, NS
AF Lawson, Sarah K.
   Gray, Andrew C.
   Woehrle, Nancy S.
TI Effects of oxytocin on serotonin 1B agonist-induced autism-like behavior
   in mice
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Autism spectrum disorder; Mouse model; Serotonin 1B receptor; Oxytocin;
   Three-chambered social test; Non-selective attention
ID OBSESSIVE-COMPULSIVE DISORDER; DEFICIT HYPERACTIVITY DISORDER; PERVASIVE
   DEVELOPMENTAL DISORDERS; CONDITIONED PLACE PREFERENCE; GROWTH-HORMONE
   RESPONSE; SPECTRUM DISORDERS; ATTENTION-DEFICIT; SOCIAL-BEHAVIOR;
   NONSELECTIVE ATTENTION; REPETITIVE BEHAVIORS
AB Social impairments in autism remain poorly understood and without approved pharmacotherapies. Novel animals models are needed to elucidate mechanisms and evaluate novel treatments for the social deficits in autism. Recently, serotonin 1B receptor (5-HT1B) agonist challenge in mice was shown to induce autism-like behaviors including perseveration, reduced prepulse inhibition, and delayed alternation deficits. However, the effects of 5-HT1B agonists on autism-related social behaviors in mice remain unknown. Here, we examine the effects of 5-HT1B agonist challenge on sociability and preference for social novelty in mice. We also examine the effects of 5-HT1B agonist treatment on average rearing duration, a putative rodent measure of non-selective attention. Non-selective attention is an associated feature of autism that is also not well understood. We show that 5-HT1B receptor activation reduces sociability, preference for social novelty, and rearing in mice. In addition, we examine the ability of oxytocin, an off-label treatment for the social impairments in autism, to reverse 5-HT1B agonist-induced social and attention deficits in mice. We show that oxytocin restores social novelty preference in mice treated with a 5-HT1B agonist. We also show that oxytocin attenuates 5-HT1B agonist-induced sociability and rearing deficits in mice. Our results suggest that 5-HT1B agonist challenge provides a useful pharmacological mouse model for aspects of autism, and implicate 5-HT1B in autism social and attention deficits. Moreover, our findings suggest that oxytocin may treat the social deficits in autism through a mechanism involving 5-HT1B. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Lawson, Sarah K.; Gray, Andrew C.; Woehrle, Nancy S.] Wittenberg Univ, Dept Psychol, 225 N Fountain Ave, Springfield, OH 45501 USA.
   [Woehrle, Nancy S.] Wittenberg Univ, Neurosci Program, Springfield, OH 45501 USA.
RP Woehrle, NS (reprint author), Wittenberg Univ, Dept Psychol, 225 N Fountain Ave, Springfield, OH 45501 USA.
EM woehrlen@wittenberg.edu
OI Woehrle, Nancy/0000-0002-0516-9310
FU  [FRF 14-1314]
FX This work was supported by institutional funding grant FRF 14-1314.
CR ABBRUZZESE M, 1995, BRAIN COGNITION, V27, P202, DOI 10.1006/brcg.1995.1017
   Abbruzzese M, 1997, NEUROPSYCHOLOGIA, V35, P907, DOI 10.1016/S0028-3932(96)00095-4
   Adham N, 1997, NEUROPHARMACOLOGY, V36, P569, DOI 10.1016/S0028-3908(97)00020-8
   Allen G, 2001, FRONT BIOSCI-LANDMRK, V6, pD105, DOI 10.2741/allen
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   ANDERSON GM, 1987, J CHILD PSYCHOL PSYC, V28, P885, DOI 10.1111/j.1469-7610.1987.tb00677.x
   Aspide R, 1998, BEHAV BRAIN RES, V95, P123, DOI 10.1016/S0166-4328(97)00217-9
   Aspide R, 2000, NEUROSCI BIOBEHAV R, V24, P59, DOI 10.1016/S0149-7634(99)00045-7
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   BARDO MT, 1984, PHARMACOL BIOCHEM BE, V21, P545
   Bejerot S, 2007, AUTISM, V11, P101, DOI 10.1177/1362361307075699
   Bergqvist PBF, 1999, BIOL PSYCHIAT, V45, P164, DOI 10.1016/S0006-3223(98)00154-1
   Bolton PF, 1998, PSYCHOL MED, V28, P385, DOI 10.1017/S0033291797006004
   Brodkin ES, 1997, J CHILD ADOL PSYCHOP, V7, P109, DOI 10.1089/cap.1997.7.109
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   CHEETHAM SC, 1993, BRIT J PHARMACOL, V110, P1621
   Copping N.A., 2016, NEUROSCIENCE
   Coutinho AM, 2004, MOL PSYCHIATR, V9, P264, DOI 10.1038/sj.mp.4001409
   Crawley JN, 2004, MENT RETARD DEV D R, V10, P248, DOI 10.1002/mrdd.20039
   Dalton KM, 2005, NAT NEUROSCI, V8, P519, DOI 10.1038/nn1421
   DeLorey TM, 2008, BEHAV BRAIN RES, V187, P207, DOI 10.1016/j.bbr.2007.09.009
   DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Domes G, 2014, NEUROPSYCHOPHARMACOL, V39, P698, DOI 10.1038/npp.2013.254
   Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007
   DOUCET E, 1995, SYNAPSE, V19, P18, DOI 10.1002/syn.890190104
   Dulawa SC, 2000, NEUROPHARMACOLOGY, V39, P2170, DOI 10.1016/S0028-3908(00)00030-7
   Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433
   Duncan GE, 2004, BEHAV BRAIN RES, V153, P507, DOI 10.1016/j.bbr.2004.01.008
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Gabis LV, 2014, ISR MED ASSOC J, V16, P295
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Glennon R.A., 2000, PSYCHOPHARMACOLOGY 4
   Goldstein S, 2004, J AUTISM DEV DISORD, V34, P329, DOI 10.1023/B:JADD.0000029554.46570.68
   GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441
   Grippo AJ, 2009, PSYCHONEUROENDOCRINO, V34, P1542, DOI 10.1016/j.psyneuen.2009.05.017
   Gross-Isseroff R, 2004, NEUROPSYCHOBIOLOGY, V50, P200, DOI 10.1159/000079970
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   HAMON M, 1990, NEUROPSYCHOPHARMACOL, V3, P349
   Ho E.V., 2016, PSYCHOPHARMACOLOGY B, P2015
   Hoenig K, 2005, BIOL PSYCHIAT, V57, P1153, DOI 10.1016/j.biopsych.2005.01.040
   Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627
   Hollander E, 2003, PSYCHIAT RES, V117, P11, DOI 10.1016/S0165-1781(02)00304-9
   Hollander E, 2000, NEUROPSYCHOPHARMACOL, V22, P163, DOI 10.1016/S0893-133X(99)00121-9
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   INSEL TR, 1991, EUR J PHARMACOL, V203, P149, DOI 10.1016/0014-2999(91)90806-2
   Insel TR, 1997, AM J PSYCHIAT, V154, P726
   JIN H, 1992, J BIOL CHEM, V267, P5735
   Kirshenbaum GS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060141
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   LABERGE D, 1989, PSYCHOL REV, V96, P101, DOI 10.1037//0033-295X.96.1.101
   Landry R, 2004, J CHILD PSYCHOL PSYC, V45, P1115, DOI 10.1111/j.1469-7610.2004.00304.x
   Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5
   Lefevre A, 2016, NEUROSCI BIOBEHAV R, V63, P168, DOI 10.1016/j.neubiorev.2016.01.011
   Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0
   List A, 2007, J EXP PSYCHOL HUMAN, V33, P1322, DOI 10.1037/0096-1523.33.6.1322
   Lo SC, 2016, SCI REP-UK, V6, DOI 10.1038/srep18335
   Loveland KA, 2008, NEUROPSYCHOLOGIA, V46, P49, DOI 10.1016/j.neuropsychologia.2007.08.017
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   McAlonan GM, 2002, BRAIN, V125, P1594, DOI 10.1093/brain/awf150
   McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001
   McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x
   McTighe SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062189
   Meng ZQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007742
   Micali N, 2004, AUTISM, V8, P21, DOI 10.1177/1362361304040636
   Miles JH, 2005, AM J MED GENET A, V135A, P171, DOI 10.1002/ajmg.a.30590
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Monk CS, 2010, J PSYCHIATR NEUROSCI, V35, P105, DOI 10.1503/jpn.090085
   MONTGOMERY SA, 1993, EUR NEUROPSYCHOPHARM, V3, P153
   Moritz S, 2001, J NERV MENT DIS, V189, P562, DOI 10.1097/00005053-200108000-00012
   Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030
   Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-183X.2004.00076.x
   Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Novotny S, 2000, PSYCHIAT RES, V94, P173, DOI 10.1016/S0165-1781(00)00134-7
   Novotny S, 2004, INT J NEUROPSYCHOPH, V7, P249, DOI 10.1017/S146114570400433X
   OBERLANDER C, 1987, EUR J PHARMACOL, V139, P205, DOI 10.1016/0014-2999(87)90253-6
   OBERLANDER C, 1986, NEUROSCI LETT, V67, P113, DOI 10.1016/0304-3940(86)90382-4
   OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0
   Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365
   PARKER EM, 1993, J NEUROCHEM, V60, P380, DOI 10.1111/j.1471-4159.1993.tb05865.x
   PAULUS MP, 1993, PSYCHOPHARMACOLOGY, V113, P177, DOI 10.1007/BF02245695
   PAULUS MP, 1993, PSYCHOPHARMACOLOGY, V113, P187, DOI 10.1007/BF02245696
   PEROUTKA SJ, 1989, EUR J PHARMACOL, V163, P133, DOI 10.1016/0014-2999(89)90406-8
   PEROUTKA SJ, 1986, J NEUROCHEM, V47, P529
   Perry W, 2007, BIOL PSYCHIAT, V61, P482, DOI 10.1016/j.biopsych.2005.09.025
   Piggot J, 2009, NEUROSCIENCE, V164, P247, DOI 10.1016/j.neuroscience.2009.05.054
   Pobbe RLH, 2011, BEHAV BRAIN RES, V216, P446, DOI 10.1016/j.bbr.2010.08.039
   Quintana DS, 2015, NEUROSCI BIOBEHAV R, V49, P182, DOI 10.1016/j.neubiorev.2014.12.011
   Radyushkin K, 2009, GENES BRAIN BEHAV, V8, P416, DOI 10.1111/j.1601-183X.2009.00487.x
   Ramos L, 2015, PSYCHOPHARMACOLOGY, V232, P2631, DOI 10.1007/s00213-015-3899-9
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   RITVO ER, 1970, ARCH GEN PSYCHIAT, V23, P566
   Ryan BC, 2010, BEHAV BRAIN RES, V208, P178, DOI 10.1016/j.bbr.2009.11.031
   Sasaki T, 2015, PSYCHIAT RES, V228, P746, DOI 10.1016/j.psychres.2015.05.029
   SCHAIN RJ, 1961, J PEDIATR-US, V58, P315, DOI 10.1016/S0022-3476(61)80261-8
   Shanahan NA, 2011, BIOL PSYCHIAT, V70, P1039, DOI 10.1016/j.biopsych.2011.07.032
   Shanahan NA, 2009, BIOL PSYCHIAT, V65, P401, DOI 10.1016/j.biopsych.2008.09.026
   Silverman JL, 2011, BRAIN RES, V1380, P120, DOI 10.1016/j.brainres.2010.09.026
   Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201
   Simpson HB, 2010, CURR TOP BEHAV NEURO, V2, P527, DOI 10.1007/7854_2009_12
   SIPES TA, 1994, NEUROPHARMACOLOGY, V33, P441, DOI 10.1016/0028-3908(94)90074-4
   Sizoo B, 2009, J NERV MENT DIS, V197, P450, DOI 10.1097/NMD.0b013e3181a61dd0
   Sprengelmeyer R, 1997, P ROY SOC B-BIOL SCI, V264, P1767
   Srivastava AK, 2014, NEUROSCI BIOBEHAV R, V46, P161, DOI 10.1016/j.neubiorev.2014.02.015
   SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3
   Tanda K, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-19
   Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038
   Veenstra-VanderWeele J, 2012, P NATL ACAD SCI USA, V109, P5469, DOI 10.1073/pnas.1112345109
   Weng SJ, 2011, J CHILD PSYCHOL PSYC, V52, P296, DOI 10.1111/j.1469-7610.2010.02317.x
   Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   Woehrle NS, 2013, PSYCHOPHARMACOLOGY, V227, P545, DOI 10.1007/s00213-013-2985-0
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
NR 116
TC 0
Z9 0
U1 43
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD NOV 1
PY 2016
VL 314
BP 52
EP 64
DI 10.1016/j.bbr.2016.07.027
PG 13
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DU7TY
UT WOS:000382418700008
PM 27439030
ER

PT J
AU Bolten, N
   De Jonge, A
   Zwagerman, E
   Zwagerman, P
   Klomp, T
   Zwart, JJ
   Geerts, CC
AF Bolten, N.
   De Jonge, A.
   Zwagerman, E.
   Zwagerman, P.
   Klomp, T.
   Zwart, J. J.
   Geerts, C. C.
TI Effect of planned place of birth on obstetric interventions and maternal
   outcomes among low-risk women: a cohort study in the Netherlands
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Midwifery; Caesarean section; Instrumental birth; Obstetrical; Perineal
   damage; Postpartum haemorrhage; Home childbirth
ID HOME BIRTHS; HOSPITAL BIRTHS; DELIVERY; CARE; LABOR; EPISIOTOMY;
   PREGNANCIES; MORBIDITY; 2ND-STAGE; TEARS
AB Background: The use of interventions in childbirth has increased the past decades. There is concern that some women might receive more interventions than they really need. For low-risk women, midwife-led birth settings may be of importance as a counterbalance towards the increasing rate of interventions. The effect of planned place of birth on interventions in the Netherlands is not yet clear. This study aims to give insight into differences in obstetric interventions and maternal outcomes for planned home versus planned hospital birth among women in midwife-led care.
   Methods: Women from twenty practices across the Netherlands were included in 2009 and 2010. Of these, 3495 were low-risk and in midwife-led care at the onset of labour. Information about planned place of birth and outcomes, including instrumental birth (caesarean section, vacuum or forceps birth), labour augmentation, episiotomy, oxytocin in third stage, postpartum haemorrhage > 1000 ml and perineal damage, came from the national midwife-led care perinatal database, and a postpartum questionnaire.
   Results: Women who planned home birth more often had spontaneous birth (nulliparous women aOR 1.38, 95 % CI 1.08-1.76, parous women aOR 2.29, 95 % CI 1.21-4.36) and less often episiotomy (nulliparous women aOR 0.73, 0.58-0. 91, parous women aOR 0.47, 0.33-0.68) and use of oxytocin in the third stage (nulliparous women aOR 0.58, 0.42-0.80, parous women aOR 0.47, 0.37-0.60) compared to women who planned hospital birth. Nulliparous women more often had anal sphincter damage (aOR 1.75, 1.01-3.03), but the difference was not statistically significant if women who had caesarean sections were excluded. Parous women less often had labour augmentation (aOR 0.55, 0.36-0.82) and more often an intact perineum (aOR 1.65, 1.34-2.03). There were no differences in rates of vacuum/forceps birth, unplanned caesarean section and postpartum haemorrhage > 1000 ml.
   Conclusions: Women who planned home birth were more likely to give birth spontaneously and had fewer medical interventions.
C1 [Bolten, N.; De Jonge, A.; Klomp, T.; Geerts, C. C.] Vrije Univ Amsterdam, Med Ctr, Dept Midwifery Sci, AVAG, Amsterdam, Netherlands.
   [Bolten, N.; De Jonge, A.; Klomp, T.; Geerts, C. C.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
   [Zwagerman, E.; Zwagerman, P.] AVAG, Midwife Acad Amsterdam, Amsterdam, Netherlands.
   [Zwart, J. J.] Deventer Hosp, Dept Obstet & Gynaecol, Deventer, Netherlands.
RP Bolten, N (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Midwifery Sci, AVAG, Amsterdam, Netherlands.; Bolten, N (reprint author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
EM nienkebolten@hotmail.com
FU ZonMw [91611016]
FX The research described in this article was funded by ZonMw (grant number
   91611016).
CR Alfirevic Z, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006066.pub2
   Allen VM, 2003, OBSTET GYNECOL, V102, P477, DOI 10.1016/S0029-7844(03)00570-2
   Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3
   Anthony S, 2008, Ned Tijdschr Geneeskd, V152, P2514
   Anthony S, 2005, BJOG-INT J OBSTET GY, V112, P748, DOI 10.1111/j.1471-0528.2004.00520.x
   Barber EL, 2011, OBSTET GYNECOL, V118, P29, DOI 10.1097/AOG.0b013e31821e5f65
   Bernitz S, 2011, BJOG-INT J OBSTET GY, V118, P1357, DOI 10.1111/j.1471-0528.2011.03043.x
   Blix E, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-179
   Brocklehurst P, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7400
   Carroli G, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000081.pub2
   Cheng YW, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.08.008
   Cheyney M, 2014, J MIDWIFERY WOM HEAL, V59, P17, DOI 10.1111/jmwh.12172
   Christianson LM, 2003, AM J OBSTET GYNECOL, V189, P255, DOI 10.1067/mob.2003.547
   CNATTINGIUS S, 1993, AM J OBSTET GYNECOL, V168, P16
   Davis D, 2011, BIRTH-ISS PERINAT C, V38, P111, DOI 10.1111/j.1523-536X.2010.00458.x
   de Jonge A, 2015, BJOG-INT J OBSTET GY, V122, P720, DOI 10.1111/1471-0528.13084
   De Jonge A, 2004, J PSYCHOSOM OBST GYN, V25, P35, DOI 10.1080/01674820410001737423
   de Jonge A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126266
   de Jonge A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3263
   Doherty DA, 2006, INT J GYNECOL OBSTET, V95, P242, DOI 10.1016/j.ijgo.2006.06.021
   Gerdin E, 2007, AUST NZ J OBSTET GYN, V47, P286, DOI 10.1111/j.1479-828X.2007.00739.x
   Gottfredsdottir H, 2015, SEX REPROD HEALTHC, V6, P138, DOI 10.1016/j.srhc.2015.05.004
   Gupta JK, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002006.pub3
   Hendrix M, 2009, BJOG-INT J OBSTET GY, V116, P537, DOI 10.1111/j.1471-0528.2008.02103.x
   Hingstman L, 2011, NEDERLANDS I ONDERZO
   Hutton EK, 2016, CAN MED ASSOC J, V188, pE80, DOI 10.1503/cmaj.150564
   Jain Deepika, 2012, J Obstet Gynaecol India, V62, P429, DOI 10.1007/s13224-012-0225-x
   Kiran TSU, 2005, BJOG-INT J OBSTET GY, V112, P768, DOI 10.1111/j.1471-0528.2004.00546.x
   KLEIVERDA G, 1990, EUR J OBSTET GYN R B, V36, P1, DOI 10.1016/0028-2243(90)90043-Z
   Klomp T, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-230
   Leushuis E, 2009, BJOG-INT J OBSTET GY, V116, P1773, DOI 10.1111/j.1471-0528.2009.02378.x
   Lindgren HE, 2008, ACTA OBSTET GYN SCAN, V87, P751, DOI 10.1080/00016340802199903
   Lotgering FK, 2005, RICHTLIJN VAGINALE K
   Malin M, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-84
   Mannien J, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-69
   Minsart AF, 2013, ACTA OBSTET GYN SCAN, V92, P204, DOI 10.1111/aogs.12003
   Offerhaus PM, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0471-x
   Offerhaus PM, 2015, MIDWIFERY, V31, P648, DOI [10.1016/j.midw.2013.06.013, 10.1016/j.midw.2015.01.013]
   Perdok H, 2015, BIRTH-ISS PERINAT C, V42, P156, DOI 10.1111/birt.12160
   Poen AC, 1997, BRIT J OBSTET GYNAEC, V104, P563, DOI 10.1111/j.1471-0528.1997.tb11533.x
   Poeran J, 2013, SOC SCI MED, V83, P42, DOI 10.1016/j.socscimed.2013.02.008
   Raisanen SH, 2009, ACTA OBSTET GYN SCAN, V88, P1365, DOI 10.3109/00016340903295626
   Roberts CL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001725
   Schutte JM, 2010, BJOG-INT J OBSTET GY, V117, P399, DOI 10.1111/j.1471-0528.2009.02382.x
   Stichting Perinatale Registratie Nederland, 2014, PER ZORG NED 2013
   Stichting Perinatale Registratie Nederland, 2006, PER ZORG NED 2003
   van der Hulst LAM, 2004, BIRTH-ISS PERINAT C, V31, P28, DOI 10.1111/j.0730-7659.2004.0271.x
   van Dillen J, 2010, ACTA OBSTET GYN SCAN, V89, P1460, DOI 10.3109/00016349.2010.519018
   Verloskundige Indicatielijst, 2003, VERL IND COMM VERL C
   Vogel JP, 2015, LANCET GLOB HEALTH, V3, pE260, DOI 10.1016/S2214-109X(15)70094-X
   World Health Organisation, 2015, WHO STAT CES SECT RA
   Wiegers TA, 1996, BRIT MED J, V313, P1309
   Zielinski Ruth, 2015, Int J Womens Health, V7, P361, DOI 10.2147/IJWH.S55561
NR 53
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD OCT 28
PY 2016
VL 16
AR 329
DI 10.1186/s12884-016-1130-6
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA2AC
UT WOS:000386392400001
PM 27793112
ER

PT J
AU Khazardoost, S
   Vahdani, FG
   Latifi, S
   Borna, S
   Tahani, M
   Rezaei, MA
   Shafaat, M
AF Khazardoost, Soghra
   Vahdani, Fahimeh Ghotbizadeh
   Latifi, Sahar
   Borna, Sedighe
   Tahani, Maryam
   Rezaei, Mohammad Ali
   Shafaat, Masoomeh
TI Pre-induction translabial ultrasound measurements in predicting mode of
   delivery compared to bishop score: a cross-sectional study
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Ultrasound; Cesarean section; Bishop
ID TRANSVAGINAL DIGITAL EXAMINATION; FETAL HEAD POSITION; SUCCESSFUL LABOR
   INDUCTION; CERVICAL LENGTH; SONOGRAPHIC MEASUREMENT; CESAREAN DELIVERY;
   ELECTIVE INDUCTION; TERM; STATION; RELIABILITY
AB Background: By increased concerns about the accuracy of the traditional methods to predict outcomes after induction of labor, developing new standards has a great clinical importance. Here, we compared the predictive value of translabial ultrasound measurements with Bishop Score to determine the suitability of induction of labor.
   Methods: A homogenous population of primigravid women was recruited. Induction of labor was performed with low-dose infusion of oxytocin. Translabial ultrasound and assessment of Bishop Score were performed by two different obstetricians. Receiver-operating characteristics curves were obtained to measure area under curve and subsequently, test sensitivity of each method.
   Results: One hundred women entered the investigation. Maternal body mass index was significantly higher among candidates of Cesarean section (P: 0.02). Maternal age and fetus weight, gender and occiput position were not determinants of outcomes of induction of labor. Cervical length and fetal head-pubis symphysis distance measured by translabial ultrasound had a test sensitivity of 90 and 88 %, respectively which were slightly higher than sensitivity of Bishop score (84 %).
   Conclusion: This study demonstrates that translabial measurements can be a suitable alternative method to monitor labor progress with an admissible predictive value compared with Bishop Score. It is a non-invasive method which provides valuable objective measurements and can be better accepted by women when considering the painful process which is required in evaluating Bishop Score.
C1 [Khazardoost, Soghra; Vahdani, Fahimeh Ghotbizadeh; Borna, Sedighe; Tahani, Maryam] Univ Tehran Med Sci, Vali Asr Hosp, Dept Obstet & Gynecol, Imam Khomeini Hosp Complex,Keshavarz Blvd, Tehran 1419733141, Iran.
   [Latifi, Sahar; Rezaei, Mohammad Ali; Shafaat, Masoomeh] Univ Tehran Med Sci, Tehran, Iran.
   [Vahdani, Fahimeh Ghotbizadeh] Univ Tehran Med Sci, Vali Asr Hosp, Maternal Fetal & Neonatal Res Ctr, Tehran, Iran.
RP Vahdani, FG (reprint author), Univ Tehran Med Sci, Vali Asr Hosp, Dept Obstet & Gynecol, Imam Khomeini Hosp Complex,Keshavarz Blvd, Tehran 1419733141, Iran.; Vahdani, FG (reprint author), Univ Tehran Med Sci, Vali Asr Hosp, Maternal Fetal & Neonatal Res Ctr, Tehran, Iran.
EM fghotbi@yahoo.com
CR ACOG Committee on Practice Bulletins-Obstetrics, 2009, OBSTET GYNECOL, V114, P386
   Akmal S, 2003, ULTRASOUND OBST GYN, V21, P437, DOI 10.1002/uog.103
   Akmal S, 2002, J Matern Fetal Neonatal Med, V12, P172, DOI 10.1080/713605646
   Arrieta A, 2011, HEALTH POLICY, V99, P124, DOI 10.1016/j.healthpol.2010.07.016
   Bartha JL, 2005, ULTRASOUND OBST GYN, V25, P155, DOI 10.1002/uog.1813
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Buchmann E, 2008, INT J GYNECOL OBSTET, V101, P285, DOI 10.1016/j.ijgo.2007.11.020
   Crowley P, 2000, COCHRANE DB SYST REV, V2
   Cunningham FG, 2014, WILLIAMS OBSTET, P456
   Dietz HP, 2006, ULTRASOUND OBST GYN, V27, P409, DOI 10.1002/uog.2731
   Dupuis O, 2005, AM J OBSTET GYNECOL, V192, P868, DOI 10.1016/j.ajog.2004.09.028
   Eggebo TM, 2008, ULTRASOUND OBST GYN, V32, P199, DOI 10.1002/uog.5360
   Eggebo TM, 2006, ULTRASOUND OBST GYN, V27, P387, DOI 10.1002/uog.2744
   Faltin-Traub EF, 2004, EUR J OBSTET GYN R B, V112, P178, DOI 10.1016/S0301-2115(03)00336-1
   FRIEDMAN EA, 1954, AM J OBSTET GYNECOL, V68, P1568
   Gabriel R, 2002, ULTRASOUND OBST GYN, V19, P254, DOI 10.1046/j.1469-0705.2002.00643.x
   Laencina AMG, 2007, ACTA OBSTET GYN SCAN, V86, P799, DOI 10.1080/00016340701409858
   Gonen R, 1998, Eur J Ultrasound, V7, P183, DOI 10.1016/S0929-8266(98)00042-1
   Hamilton Brady E, 2010, Natl Vital Stat Rep, V59, P1
   Heffner LJ, 2003, OBSTET GYNECOL, V102, P287, DOI 10.1016/S0029-7844(03)00531-3
   Ho D, 2005, ULTRASOUND OBST GYN, V25, P165
   HOLCOMB WL, 1991, OBSTET GYNECOL, V78, P43
   JACKSON GM, 1992, OBSTET GYNECOL, V79, P214
   Kreiser D, 2001, J Matern Fetal Med, V10, P283, DOI 10.1080/714904341
   Maslow AS, 2000, OBSTET GYNECOL, V95, P917, DOI 10.1016/S0029-7844(00)00794-8
   Mikulandra F, 1996, Zentralbl Gynakol, V118, P441
   Nader R, 2010, AUST NZ J OBSTET GYN, V50, P329, DOI 10.1111/j.1479-828X.2010.01169.x
   Newman RB, 2008, OBSTET GYNECOL, V112, P508, DOI 10.1097/AOG.0b013e3181842087
   Niino Y, 2011, BIOSCI TRENDS, V5, P139, DOI 10.5582/bst.2011.v5.4.139
   Pandis GK, 2001, ULTRASOUND OBST GYN, V18, P623, DOI 10.1046/j.0960-7692.2001.00580.x
   Peregrine E, 2006, OBSTET GYNECOL, V107, P227, DOI 10.1097/01.AOG.0000196508.11431.c0
   Rane SM, 2005, J MATERN-FETAL NEO M, V17, P315, DOI 10.1080/14767050500127690
   Rane SM, 2004, ULTRASOUND OBST GYN, V24, P538, DOI 10.1002/uog.1100
   Rane SM, 2003, ULTRASOUND OBST GYN, V22, P40, DOI 10.1002/uog.165
   Rozenberg P, 2005, Gynecol Obstet Fertil, V33, P17, DOI 10.1016/j.gyobfe.2004.11.006
   Rozenberg P, 2005, BJOG-INT J OBSTET GY, V112, P192, DOI 10.1111/j.1471-0528.2004.00549.x
   SADOUL G, 1981, J GYNECOL OBST BIO R, V10, P269
   Sherer DM, 2007, ULTRASOUND OBST GYN, V30, P123, DOI 10.1002/uog.4096
   Sherer DM, 2002, ULTRASOUND OBST GYN, V19, P258
   Sherer DM, 2002, ULTRASOUND OBST GYN, V19, P264, DOI 10.1046/j.1469-0705.2002.00656.x
   Souka A P, 2003, J Matern Fetal Neonatal Med, V13, P59, DOI 10.1080/jmf.13.1.59.63
   STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313
   Tan PC, 2007, ULTRASOUND OBST GYN, V29, P568, DOI 10.1002/uog.4018
   Tenore JL, 2003, AM FAM PHYSICIAN, V67, P2123
   Tutschek B, 2011, BJOG-INT J OBSTET GY, V118, P62, DOI 10.1111/j.1471-0528.2010.02775.x
   Uyar Y, 2009, ARCH GYNECOL OBSTET, V280, P357, DOI 10.1007/s00404-008-0915-x
   Valentin L, 2002, ULTRASOUND OBST GYN, V20, P256, DOI 10.1046/j.1469-0705.2002.00765.x
   Ware V, 2000, AM J OBSTET GYNECOL, V182, P1030, DOI 10.1067/mob.2000.105399
NR 48
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD OCT 28
PY 2016
VL 16
AR 330
DI 10.1186/s12884-016-1090-x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA1YT
UT WOS:000386388900001
PM 27793113
ER

PT J
AU Gahbauer, S
   Bockmann, RA
AF Gahbauer, Stefan
   Boeckmann, Rainer A.
TI Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its
   Implications for GPCR Function
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Review
DE GPCR; dimerization; oligomerization; membrane; cholesterol;
   palmitoylation; FRET; molecular dynamics simulation
ID MOLECULAR-DYNAMICS SIMULATIONS; INDUCED CONFORMATIONAL-CHANGES; A(2A)
   ADENOSINE RECEPTOR; COARSE-GRAINED MODEL; BETA(2)-ADRENERGIC RECEPTOR;
   LIPID RAFTS; OXYTOCIN RECEPTOR; CRYSTAL-STRUCTURE; SEROTONIN(1A)
   RECEPTOR; CARDIAC MYOCYTES
AB The dimerization or even oligomerization of G protein coupled receptors (GPCRs) causes ongoing, controversial debates about its functional role and the coupled biophysical, biochemical or biomedical implications. A continously growing number of studies hints to a relation between oligomerization and function of GPCRs and strengthens the assumption that receptor assembly plays a key role in the regulation of protein function. Additionally, progress in the structural analysis of GPCR-G protein and GPCR-ligand interactions allows to distinguish between actively functional and non-signaling complexes. Recent findings further suggest that the surrounding membrane, i.e., its lipid composition may modulate the preferred dimerization interface and as a result the abundance of distinct dimeric conformations. In this review, the association of GPCRs and the role of the membrane in oligomerization will be discussed. An overview of the different reported oligomeric interfaces is provided and their capability for signaling discussed. The currently available data is summarized with regard to the formation of GPCR oligomers, their structures and dependency on the membrane microenvironment as well as the coupling of oligomerization to receptor function.
C1 [Gahbauer, Stefan; Boeckmann, Rainer A.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Biol, Computat Biol, Erlangen, Germany.
RP Bockmann, RA (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Dept Biol, Computat Biol, Erlangen, Germany.
EM rainer.boeckmann@fau.de
FU DFG Research Training Group "Dynamic Interactions at Biological
   Membranes: From Single Molecules to Tissue" [1962/1]
FX This work was funded by the DFG Research Training Group 1962/1, "Dynamic
   Interactions at Biological Membranes: From Single Molecules to Tissue."
CR Alemany R, 2007, BBA-BIOMEMBRANES, V1768, P964, DOI 10.1016/j.bbamem.2006.09.024
   Alves ID, 2005, BIOCHEMISTRY-US, V44, P9168, DOI 10.1021/bi050207a
   Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697
   Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314
   Ayoub MA, 2010, CURR OPIN PHARMACOL, V10, P44, DOI 10.1016/j.coph.2009.09.012
   Baier CJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00069
   Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200
   Bhatnagar A, 2004, J BIOL CHEM, V279, P34614, DOI 10.1074/jbc.M404673200
   Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200
   Botelho AV, 2006, BIOPHYS J, V91, P4464, DOI 10.1529/biophysj.106.082776
   Broussard JA, 2013, NAT PROTOC, V8, P265, DOI 10.1038/nprot.2012.147
   BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5
   Calebiro D, 2013, P NATL ACAD SCI USA, V110, P743, DOI 10.1073/pnas.1205798110
   Chavent M, 2014, BIOCHEMISTRY-US, V53, P6641, DOI 10.1021/bi500800x
   CHEETHAM JJ, 1989, BIOCHEMISTRY-US, V28, P8928, DOI 10.1021/bi00448a036
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Chini B, 2009, J MOL ENDOCRINOL, V42, P371, DOI 10.1677/JME-08-0114
   Cordomi A, 2015, TRENDS BIOCHEM SCI, V40, P548, DOI 10.1016/j.tibs.2015.07.007
   Cottet Martin, 2012, Front Endocrinol (Lausanne), V3, P92, DOI 10.3389/fendo.2012.00092
   de Jong DH, 2013, J CHEM THEORY COMPUT, V9, P687, DOI 10.1021/ct300646g
   de Meyer F, 2009, P NATL ACAD SCI USA, V106, P3654, DOI 10.1073/pnas.0809959106
   Devost D, 2004, J NEUROENDOCRINOL, V16, P372, DOI 10.1111/j.0953-8194.2004.01188.x
   Escriba PV, 2007, BBA-BIOMEMBRANES, V1768, P836, DOI 10.1016/j.bbamem.2006.09.001
   Fallahi-Sichani M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006604
   Feller SE, 2005, CURR OPIN STRUC BIOL, V15, P416, DOI 10.1016/j.sbi.2005.07.002
   Feller SE, 2003, J AM CHEM SOC, V125, P4434, DOI 10.1021/ja0345874
   FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55
   Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a
   Gawrisch K, 2008, PROSTAG LEUKOTR ESS, V79, P131, DOI 10.1016/j.plefa.2008.09.002
   Ghosh E, 2015, NAT REV MOL CELL BIO, V16, P69, DOI 10.1038/nrm3933
   Gimpl G, 2002, BBA-BIOMEMBRANES, V1564, P384, DOI 10.1016/S0005-2736(02)00475-3
   Gimpl G, 2016, CHEM PHYS LIPIDS, V199, P61, DOI 10.1016/j.chemphyslip.2016.04.006
   Goddard Alan D., 2012, Biophysical Reviews, V4, P291, DOI 10.1007/s12551-012-0073-z
   Goddard AD, 2013, METHOD CELL BIOL, V117, P341, DOI 10.1016/B978-0-12-408143-7.00018-9
   Goddard AD, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-27
   Gorinski N, 2012, MOL PHARMACOL, V82, P448, DOI 10.1124/mol.112.079137
   Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269
   Grossfield A, 2006, J PHYS CHEM B, V110, P8907, DOI 10.1021/jp060405r
   Grossfield A, 2006, P NATL ACAD SCI USA, V103, P4888, DOI 10.1073/pnas.0508352103
   Guixa-Gonzalez R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19839
   Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102
   Han J, 2015, BIOPHYS J, V109, P760, DOI 10.1016/j.bpj.2015.06.049
   Hanson MA, 2008, STRUCTURE, V16, P897, DOI 10.1016/j.str.2008.05.001
   Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200
   Hipser C, 2010, MT SINAI J MED, V77, P374, DOI 10.1002/msj.20199
   Huang P, 2007, BRAIN RES, V1184, P46, DOI 10.1016/j.brainres.2007.09.096
   Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886
   Ianoul A, 2005, NAT CHEM BIOL, V1, P196, DOI 10.1038/nchembio726
   Insel PA, 2005, BIOCHEM SOC T, V33, P1131
   Ishizaka N, 1998, HYPERTENSION, V32, P459
   Jafurulla M, 2014, BBA-BIOMEMBRANES, V1838, P158, DOI 10.1016/j.bbamem.2013.08.015
   Jafurulla M, 2011, BIOCHEM BIOPH RES CO, V404, P569, DOI 10.1016/j.bbrc.2010.12.031
   Jastrzebska B, 2015, J BIOL CHEM, V290, P25728, DOI 10.1074/jbc.M115.662684
   Jordan BA, 1999, NATURE, V399, P697
   Kaczor AA, 2015, MOL INFORM, V34, P246, DOI 10.1002/minf.201400088
   Kasai RS, 2014, CURR OPIN CELL BIOL, V27, P78, DOI 10.1016/j.ceb.2013.11.008
   Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003
   Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3
   Kimata N, 2015, J MAGN RESON, V253, P111, DOI 10.1016/j.jmr.2014.12.014
   KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009
   Kniazeff J, 2011, PHARMACOL THERAPEUT, V130, P9, DOI 10.1016/j.pharmthera.2011.01.006
   Kobe F, 2008, BBA-MOL CELL RES, V1783, P1503, DOI 10.1016/j.bbamcr.2008.02.021
   Kobilka BK, 2007, BBA-BIOMEMBRANES, V1768, P794, DOI 10.1016/j.bbamem.2006.10.021
   KRALCHEVSKY PA, 1995, J CHEM SOC FARADAY T, V91, P3415, DOI 10.1039/ft9959103415
   Larisch N, 2016, CELL MOL LIFE SCI, V73, P2565, DOI 10.1007/s00018-016-2131-3
   Li LBB, 2012, BBA-BIOMEMBRANES, V1818, P135, DOI 10.1016/j.bbamem.2011.10.026
   Li-Wei Chen, 2002, Protein and Peptide Letters, V9, P145, DOI 10.2174/0929866023408850
   Liu JJ, 2012, SCIENCE, V335, P1106, DOI 10.1126/science.1215802
   Liu W, 2012, SCIENCE, V337, P232, DOI 10.1126/science.1219218
   Lohse MJ, 2012, PHARMACOL REV, V64, P299, DOI 10.1124/pr.110.004309
   Lyman E, 2009, STRUCTURE, V17, P1660, DOI 10.1016/j.str.2009.10.010
   Mancia F, 2008, EMBO REP, V9, P363, DOI 10.1038/embor.2008.27
   Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954
   Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f
   Marrink SJ, 2013, CHEM SOC REV, V42, P6801, DOI 10.1039/c3cs60093a
   Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g
   Meng XY, 2014, CURR PHARM BIOTECHNO, V15, P996
   Mitchell DC, 1998, BIOPHYS J, V74, P879
   Mitchell DC, 2003, LIPIDS, V38, P437, DOI 10.1007/s11745-003-1081-1
   Mondal S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02909
   Mondal S, 2011, BIOPHYS J, V101, P2092, DOI 10.1016/j.bpj.2011.09.037
   Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x
   Mouritsen O. G., 2013, COMPREHENSIVE BIOPHY, V5, P245
   Muth S, 2011, BIOCHEM J, V437, P541, DOI 10.1042/BJ20101795
   Ng Stephanie Y L, 2012, Front Endocrinol (Lausanne), V3, P175, DOI 10.3389/fendo.2012.00175
   Nguyen DH, 2003, EXP CELL RES, V291, P36, DOI 10.1016/S0014-4827(03)00345-8
   Nguyen DH, 2002, J IMMUNOL, V168, P4121
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   Oates J, 2011, CURR OPIN STRUC BIOL, V21, P802, DOI 10.1016/j.sbi.2011.09.007
   Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407
   Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930
   Paila YD, 2011, J PHYS CHEM B, V115, P11439, DOI 10.1021/jp201458h
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Papoucheva E, 2004, J BIOL CHEM, V279, P3280, DOI 10.1074/jbc.M308177200
   Pawson AJ, 2003, ENDOCRINOLOGY, V144, P3860, DOI 10.1210/en.2003-0028
   Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200
   Perez-Aguilar JM, 2014, J AM CHEM SOC, V136, P16044, DOI 10.1021/ja508394x
   Periole X, 2007, J AM CHEM SOC, V129, P10126, DOI 10.1021/ja0706246
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Pitman MC, 2005, J AM CHEM SOC, V127, P4576, DOI 10.1021/ja042715y
   Pluhackova K., 2016, PLOS COMPUT BIOL, V12
   Pluhackova K, 2015, J PHYS-CONDENS MAT, V27, DOI 10.1088/0953-8984/27/32/323103
   Pluhackova K, 2015, J PHYS CHEM B, V119, P4396, DOI 10.1021/acs.jpcb.5b00434
   Pluhackova K, 2013, METHODS MOL BIOL, V1033, P85, DOI 10.1007/978-1-62703-487-6_6
   Ponimaskin EG, 2002, J BIOL CHEM, V277, P2534, DOI 10.1074/jbc.M106529200
   Pontier SM, 2008, J BIOL CHEM, V283, P24659, DOI 10.1074/jbc.M800778200
   Prakash A, 2010, BIOPHYS J, V99, P3657, DOI 10.1016/j.bpj.2010.10.023
   Prasanna X, 2014, BIOPHYS J, V106, P1290, DOI 10.1016/j.bpj.2014.02.002
   Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1
   Provasi D, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004148
   Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5
   Qiu Y, 2011, MOL PHARMACOL, V80, P210, DOI 10.1124/mol.110.070870
   Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325
   Renner U, 2007, MOL PHARMACOL, V72, P502, DOI 10.1124/mol.107.037085
   Rog T, 2014, CHEM PHYS LIPIDS, V184, P82, DOI 10.1016/j.chemphyslip.2014.10.004
   Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144
   Sabbadin D, 2014, J CHEM INF MODEL, V54, P169, DOI 10.1021/ci400532b
   Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546
   Sadiq SK, 2013, CURR MED CHEM, V20, P22
   Salahpour A, 2003, BIOL CHEM, V384, P117, DOI 10.1515/BC.2003.012
   Salom D, 2013, METHOD CELL BIOL, V117, P451, DOI 10.1016/B978-0-12-408143-7.00024-4
   Sandoval A, 2016, BIOPHYS J, V111, P79, DOI 10.1016/j.bpj.2016.06.004
   Savi P, 2006, P NATL ACAD SCI USA, V103, P11069, DOI 10.1073/pnas.0510446103
   Schneider EH, 2010, J PHARMACOL EXP THER, V333, P382, DOI 10.1124/jpet.109.163220
   Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.3.CO;2-C
   Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140
   Sengupta D, 2015, BBA-BIOMEMBRANES, V1848, P1775, DOI 10.1016/j.bbamem.2015.03.018
   Sengupta D, 2012, J PHYS CHEM B, V116, P12991, DOI 10.1021/jp309888u
   SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302
   Stark AC, 2013, J CHEM THEORY COMPUT, V9, P4176, DOI 10.1021/ct400008p
   Szidonya L, 2008, J ENDOCRINOL, V196, P435, DOI 10.1677/JOE-07-0573
   Tautermann CS, 2015, COMPUT STRUCT BIOTEC, V13, P111, DOI 10.1016/j.csbj.2014.12.002
   Vafabakhsh R, 2015, NATURE, V524, P497, DOI 10.1038/nature14679
   Villar VM, 2016, METHOD CELL BIOL, V132, P3, DOI 10.1016/bs.mcb.2015.11.008
   Vischer HF, 2015, MOL PHARMACOL, V88, P561, DOI 10.1124/mol.115.099440
   Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905
   Wacker D, 2013, SCIENCE, V340, P615, DOI 10.1126/science.1232808
   Wang JH, 2006, MOL CANCER THER, V5, P2474, DOI 10.1158/1535-7163.MCT-05-0261
   Wassenaar TA, 2015, J CHEM THEORY COMPUT, V11, P2278, DOI 10.1021/ct5010092
   Wassenaar TA, 2015, J CHEM THEORY COMPUT, V11, P2144, DOI 10.1021/acs.jctc.5b00209
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu HX, 2014, SCIENCE, V344, P58, DOI 10.1126/science.1249489
   Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200
   Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507
   Zezula J, 2008, BRIT J PHARMACOL, V153, pS184, DOI 10.1038/sj.bjp.0707674
   Zhang DD, 2015, NATURE, V520, P317, DOI 10.1038/nature14287
   Zhang KH, 2014, NATURE, V509, P115, DOI 10.1038/nature13083
   Zheng H, 2012, J LIPID RES, V53, P1153, DOI 10.1194/jlr.M024455
   Zheng H, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-6
   Zocher M, 2012, P NATL ACAD SCI USA, V109, pE3463, DOI 10.1073/pnas.1210373109
NR 151
TC 0
Z9 0
U1 10
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 25
PY 2016
VL 7
AR 494
DI 10.3389/fphys.2016.00494
PG 17
WC Physiology
SC Physiology
GA DZ8CF
UT WOS:000386095600001
PM 27826255
ER

PT J
AU Olah, K
   Elekes, F
   Turcsan, B
   Kis, O
   Topal, J
AF Olah, Katalin
   Elekes, Fruzsina
   Turcsan, Borbala
   Kis, Orsolya
   Topal, Jozsef
TI Social Pre-treatment Modulates Attention Allocation to Transient and
   Stable Object Properties
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE social pre-treatment; communication; change detection; object; location;
   identity
ID COMMUNICATIVE SIGNALS; PREVERBAL INFANTS; OXYTOCIN; HUMANS; COGNITION;
   PEDAGOGY; BEHAVIOR; CHILDREN
AB Increasing evidence suggests that ostensive-communicative signals in social learning situations enable observers to focus their attention on the intrinsic features of an object (e.g., color) at the expense of ignoring transient object properties (e.g., location). Here we investigated whether off-line social cues, presented as social primes, have the same power to modulate attention allocation to stable and transient object properties as on-line ostensive-communicative cues. The first part of the experiment consisted of a pre-treatment phase, where adult male participants either received intensive social stimulation or were asked to perform non-social actions. Then, they participated in a change detection test, where they watched pairs of pictures depicting an array of five objects. On the second picture, a change occurred compared to the first picture. One object changed either its location (moving forward or backward) or was replaced by another object, and participants were required to indicate where the change had happened. We found that participants detected the change more successfully if it had happened in the location of the object; however, this difference was reduced following a socially intense pre-treatment phase. The results are discussed in relation to the claims of the natural pedagogy theory.
C1 [Olah, Katalin; Turcsan, Borbala; Kis, Orsolya; Topal, Jozsef] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Cognit Neurosci & Psychol, Budapest, Hungary.
   [Olah, Katalin; Elekes, Fruzsina] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary.
   [Elekes, Fruzsina] Cent European Univ, Cognit Dev Ctr, Budapest, Hungary.
   [Kis, Orsolya] Budapest Univ Technol & Econ, Dept Cognit Sci, Budapest, Hungary.
RP Olah, K (reprint author), Hungarian Acad Sci, Res Ctr Nat Sci, Inst Cognit Neurosci & Psychol, Budapest, Hungary.; Olah, K (reprint author), Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary.
EM olah.katalin@ppk.elte.hu
FU Hungarian Scientific Research Fund [K-112138, K-409352]
FX Financial support for this research was provided by the Hungarian
   Scientific Research Fund under the following grant numbers: K-112138 and
   K-409352.
CR Bandura Albert, 1977, SOCIAL LEARNING THEO
   Bargh JA, 2006, EUR J SOC PSYCHOL, V36, P147, DOI 10.1002/ejsp.336
   Bargh JA, 1996, J PERS SOC PSYCHOL, V71, P230, DOI 10.1037//0022-3514.71.2.230
   Broadbent D. E., 1958, PERCEPTION COMMUNICA
   Butler LP, 2012, CHILD DEV, V83, P1416, DOI 10.1111/j.1467-8624.2012.01775.x
   Butler PD, 2005, CURR OPIN PSYCHIATR, V18, P151, DOI 10.1097/00001504-200503000-00008
   Csibra G, 2006, ATTENTION PERFORM, P249
   Csibra G, 2011, PHILOS T R SOC B, V366, P1149, DOI 10.1098/rstb.2010.0319
   Csibra G, 2009, TRENDS COGN SCI, V13, P148, DOI 10.1016/j.tics.2009.01.005
   Feldman R, 2010, HORM BEHAV, V58, P669, DOI 10.1016/j.yhbeh.2010.06.005
   Futo J, 2010, COGNITION, V117, P1, DOI 10.1016/j.cognition.2010.06.003
   Gergely G, 2006, ROOTS HUMAN SOCIALIT, P229
   Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008
   Kiraly I, 2013, J EXP CHILD PSYCHOL, V116, P471, DOI 10.1016/j.jecp.2012.12.003
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kis A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00532
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Mareschal D, 2003, COGNITION, V88, P259, DOI 10.1016/S0010-0277(03)00039-8
   Marno H, 2014, J EXP PSYCHOL HUMAN, V40, P752, DOI 10.1037/a0035113
   MISHKIN M, 1982, BEHAV BRAIN RES, V6, P57, DOI 10.1016/0166-4328(82)90081-X
   NAGELL K, 1993, J COMP PSYCHOL, V107, P174, DOI 10.1037/0735-7036.107.2.174
   Over H, 2012, J COMP PSYCHOL, V126, P182, DOI 10.1037/a0024555
   Over H, 2009, PSYCHOL SCI, V20, P1189, DOI 10.1111/j.1467-9280.2009.02419.x
   Parise E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072360
   Senju A, 2008, CURR BIOL, V18, P668, DOI 10.1016/j.cub.2008.03.059
   Southgate V, 2009, DEVELOPMENTAL SCI, V12, P1013, DOI 10.1111/j.1467-7687.2009.00861.x
   Topal J, 2008, SCIENCE, V321, P1831, DOI 10.1126/science.1161437
   Yoon JMD, 2008, P NATL ACAD SCI USA, V105, P13690, DOI 10.1073/pnas.0804388105
NR 28
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 25
PY 2016
VL 7
AR 1619
DI 10.3380/fpsyg.2010.01619
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA DZ8CO
UT WOS:000386096500001
PM 27826267
ER

PT J
AU Song, SS
   Zou, ZL
   Song, HW
   Wang, YM
   Uquillas, FD
   Wang, HJ
   Chen, H
AF Song, Sensen
   Zou, Zhiling
   Song, Hongwen
   Wang, Yongming
   Uquillas, Federico d'Oleire
   Wang, Huijun
   Chen, Hong
TI Romantic Love Is Associated with Enhanced Inhibitory Control in an
   Emotional Stop-Signal Task
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE romantic love; inhibitory control; emotional stop signal task; sadness
ID MONOGAMOUS PRAIRIE VOLE; RESPONSE-INHIBITION; AUTONOMIC REACTIVITY;
   PREFRONTAL CORTEX; BRAIN RESPONSES; ATTENTION; DEPRESSION; ADDICTION;
   OXYTOCIN; AMYGDALA
AB Purpose: This study explored whether romantic lovers differ in emotion-related inhibitory control capacity from those who are single.
   Methods: 88 healthy undergraduate college students participated in the study. Half were currently in love and in a romantic relationship (love group, LG), and half were single and had never been in a romantic relationship (single group, SG). Based on duration of romantic relationship (i.e., love duration), the LG were further divided into two subgroups: early stage love and longer periods of love. All participants completed an emotional Stop Signal Task, consisting of a variety of human face stimuli displaying either sad or neutral affect.
   Results: Results found that relative to SG, lovers showed greater inhibitory control [shorter stop-signal reaction time (SSRT)] during negative emotion condition trials. Furthermore, in early stages of love, SSRT for negative emotion condition trials was significantly shorter compared to that in longer periods of love or SG individuals, with no significant differences between the two latter groups.
   Conclusion: Compared with individuals who were single, early stage lovers showed greater capacity for inhibiting action during presentation of negative emotional stimuli. Within a greater social context, greater inhibitory control capacity during early stages of love may be related to the successful formation of romantic relationships, particularly to the ability to persevere in goal-directed action despite negative emotional contexts such as that of sadness.
C1 [Song, Sensen; Zou, Zhiling; Wang, Huijun; Chen, Hong] Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
   [Song, Hongwen] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Anhui, Peoples R China.
   [Wang, Yongming] Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China.
   [Uquillas, Federico d'Oleire] Harrard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA.
RP Zou, ZL (reprint author), Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
EM zouzl@swu.edu.cn
FU Fundamental Research Funds organization for the Central University of
   China [SWU15091.34]; Chongqing Educational Funds [2015-JC-005]; Chinese
   National Social Science Foundation [12XSH018]
FX This work was supported by grants from the Fundamental Research Funds
   organization for the Central University of China (SWU15091.34),
   Chongqing Educational Funds (2015-JC-005) and the Chinese National
   Social Science Foundation (12XSH018).
CR Acevedo BP, 2012, SOC COGN AFFECT NEUR, V7, P145, DOI 10.1093/scan/nsq092
   Acevedo BP, 2009, REV GEN PSYCHOL, V13, P59, DOI 10.1037/a0014226
   Aldhafeeri FM, 2012, NEUROSCI LETT, V512, P94, DOI 10.1016/j.neulet.2012.01.064
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Aron A., 1991, LOVE AND SEXUALITY
   Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006
   Bai L., 2006, CHIN MENT HLTH J, V19, P719
   Baumeister R.F., 2003, HDB SELF IDENTITY, V1, P197
   Berscheid E, 2010, ANNU REV PSYCHOL, V61, P1, DOI 10.1146/annurev.psych.093008.100318
   Bianchi-Demicheli F, 2006, SOC NEUROSCI, V1, P90, DOI 10.1080/17470910600976547
   Bodenhausen GV, 2000, PSYCHOL SCI, V11, P320, DOI 10.1111/1467-9280.00263
   Boehler CN, 2012, BEHAV BRAIN RES, V229, P123, DOI 10.1016/j.bbr.2012.01.003
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Cacioppo S., 2012, CLIN NEUROPSYCHIATRY, V9, P3
   CAMRAS LA, 1989, MOTIV EMOTION, V13, P53, DOI 10.1007/BF00995544
   Carretie L, 2014, COGN AFFECT BEHAV NE, V14, P1228, DOI 10.3758/s13415-014-0270-2
   CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9
   Damasio A, 2005, DESCARTES ERROR EMOT
   de Boer A, 2012, NEUROSCIENCE, V201, P114, DOI 10.1016/j.neuroscience.2011.11.017
   DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193
   Diamond LM, 2012, CLIN NEUROPSYCHIATRY, V9, P39
   ELLSWORTH PC, 1988, MOTIV EMOTION, V12, P271, DOI 10.1007/BF00993115
   Emanuele E, 2006, PSYCHONEUROENDOCRINO, V31, P288, DOI 10.1016/j.psyneuen.2005.09.002
   Esch T, 2005, NEUROENDOCRINOL LETT, V26, P264
   Fisher H., 2004, WHY WE LOVE NATURE C
   Fisher HE, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00687
   Fox E, 2002, COGNITION EMOTION, V16, P355, DOI 10.1080/02699930143000527
   Frascella J, 2010, ANN NY ACAD SCI, V1187, P294, DOI 10.1111/j.1749-6632.2009.05420.x
   Frewen PA, 2006, ANN NY ACAD SCI, V1071, P110, DOI 10.1196/annals.1364.010
   Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6
   Garcia C. Y., 1998, PSYCHOL SPAIN, V2, P76
   Gasper K, 2004, COGNITION EMOTION, V18, P405, DOI 10.1080/02699930341000068
   Goldstein M, 2007, NEUROIMAGE, V36, P1026, DOI 10.1016/j.neuroimage.2007.01.056
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   GOTLIB IH, 1984, J PERS SOC PSYCHOL, V47, P427, DOI 10.1037/0022-3514.47.2.427
   GOTTMAN JM, 1992, J PERS SOC PSYCHOL, V63, P221, DOI 10.1037/0022-3514.63.2.221
   Habel U, 2005, NEUROIMAGE, V26, P206, DOI 10.1016/j.neuroimage.2005.01.014
   Hare TA, 2005, BIOL PSYCHIAT, V57, P624, DOI 10.1016/j.biopsych.2004.12.038
   HATFIELD E, 1986, J ADOLESCENCE, V9, P383, DOI 10.1016/S0140-1971(86)80043-4
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   Herbert C., 2011, J BEHAV BRAIN SCI, V1, P153, DOI [10.4236/jbbs.2011.13020, DOI 10.4236/JBBS.2011.13020]
   Johnstone T, 2007, J NEUROSCI, V27, P8877, DOI 10.1523/JNEUROSCI.2063-07.2007
   Joormann J, 2007, J ABNORM PSYCHOL, V116, P80, DOI 10.1037/0021-843X.116.1.80
   Joormann J, 2010, COGNITION EMOTION, V24, P281, DOI 10.1080/02699930903407948
   Kalanthroff E, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00078
   Lerner Y, 2012, J COGNITIVE NEUROSCI, V24, P531, DOI 10.1162/jocn_a_00165
   LEVENSON RW, 1985, J PERS SOC PSYCHOL, V49, P85, DOI 10.1037/0022-3514.49.1.85
   LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Lim MM, 2004, J COMP NEUROL, V468, P555, DOI 10.1002/cne.10973
   Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X
   LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037//0033-295X.91.3.295
   Logan GD, 1994, INHIBITORY PROCESSES
   Marazziti D, 2004, PSYCHONEUROENDOCRINO, V29, P931, DOI 10.1016/j.psyneuen.2003.08.006
   Marazziti D, 1999, PSYCHOL MED, V29, P741, DOI 10.1017/S0033291798007946
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Nilakantan A, 2014, PAIN MED, V15, P947, DOI 10.1111/pme.12422
   Okon-Singer H, 2007, EMOTION, V7, P147, DOI 10.1037/1528-3542.7.1.147
   Ortigue S, 2007, J COGNITIVE NEUROSCI, V19, P1218, DOI 10.1162/jocn.2007.19.7.1218
   Pawliczek CM, 2013, NEUROIMAGE, V79, P264, DOI 10.1016/j.neuroimage.2013.04.104
   Pessoa L, 2012, EMOTION, V12, P192, DOI 10.1037/a0024109
   Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006
   Potts R., 1989, COGNITION EMOTION, V3, P197, DOI DOI 10.1080/02699938908415241
   Pourtois G, 2013, BIOL PSYCHOL, V92, P492, DOI 10.1016/j.biopsycho.2012.02.007
   Pronk TM, 2011, J PERS SOC PSYCHOL, V100, P827, DOI 10.1037/a0021993
   Pronk TM, 2010, J PERS SOC PSYCHOL, V98, P119, DOI 10.1037/a0017875
   Rebetez MML, 2015, COGNITION EMOTION, V29, P559, DOI 10.1080/02699931.2014.922054
   Riehl-Emde A, 2003, FAM PROCESS, V42, P253, DOI 10.1111/j.1545-5300.2003.42205.x
   Roisman GI, 2007, DEV PSYCHOL, V43, P39, DOI 10.1037/0012-1649.43.1.39
   Sagaspe P, 2011, NEUROIMAGE, V55, P1825, DOI 10.1016/j.neuroimage.2011.01.027
   Schneider W., 2002, E PRIME USERS GUIDE
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   Schneiderman I, 2011, EMOTION, V11, P1314, DOI 10.1037/a0024090
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, V2, P385
   Sehlmeyer C, 2010, NEUROPSYCHOLOGIA, V48, P2488, DOI 10.1016/j.neuropsychologia.2010.04.022
   SIMPSON JA, 1986, PERS SOC PSYCHOL B, V12, P363, DOI 10.1177/0146167286123011
   Song HW, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00071
   Starka L, 2007, Prague Med Rep, V108, P297
   STERNBERG RJ, 1986, PSYCHOL REV, V93, P119, DOI 10.1037/0033-295X.93.2.119
   Suslow T, 2013, PSYCHIAT RES-NEUROIM, V211, P239, DOI 10.1016/j.pscychresns.2012.09.008
   Verbruggen F, 2007, COGNITION EMOTION, V21, P391, DOI 10.1080/02699930600625081
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Vuilleumier P, 2009, CURR DIR PSYCHOL SCI, V18, P148
   Wang LH, 2005, EMOTION, V5, P12, DOI 10.1037/1528-3542.5.1.12
   WILLIAMS JR, 1992, ANN NY ACAD SCI, V652, P487, DOI 10.1111/j.1749-6632.1992.tb34393.x
   Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   Wlodarski R, 2014, REV GEN PSYCHOL, V18, P313, DOI 10.1037/gpr0000020
   Xu XM, 2011, HUM BRAIN MAPP, V32, P249, DOI 10.1002/hbm.21017
   Yin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076294
NR 90
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 25
PY 2016
VL 7
AR 1574
DI 10.3389/fpsyg.2016.01574
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA DZ8BY
UT WOS:000386094800001
PM 27826260
ER

PT J
AU Kalisa, R
   Rulisa, S
   van den Akker, T
   van Roosmalen, J
AF Kalisa, Richard
   Rulisa, Stephen
   van den Akker, Thomas
   van Roosmalen, Jos
TI Maternal Near Miss and quality of care in a rural Rwandan hospital
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Audit; Maternal morbidity; Maternal mortality; Maternal near miss;
   Obstetrics; Quality of care
ID NEAR-MISS; MORTALITY; SERVICES; AUDIT; SUDAN
AB Background: The WHO Maternal Near Miss (MNM) approach was developed to evaluate and improve quality of obstetric care worldwide. This study aimed to study the incidence of MNM and quality of care at a district hospital in rural Rwanda by applying this approach.
   Methods: A facility based, prospective cohort study conducted at a district hospital in rural Rwanda between June 2013 and December 2014. Subjects were followed from time of admission to discharge or death.
   Results: In 3979 deliveries, 3827 singletons and 152 twins pairs were born. Among the 4131 neonates, there were 3994 live births and 137 stillbirths. Ninety-nine women suffered severe maternal outcome (SMO): 86 maternal near misses and 13 deaths. This adds up to a maternal near miss ratio of 21.5 per 1000 live births (95 % CI 17.3-26.5), a maternal mortality ratio of 325 per 100 000 live births (95 % CI 181-543) and a mortality index of 13.1 % (95 % CI 7.3-21.9). Hemorrhage (n = 49, 57 %) and hypertensive disorders (n = 27, 31.4 %) were the commonest MNM conditions. Eclampsia (n = 4/13; 30.7 %) was the leading cause of maternal mortality, while sepsis/peritonitis following cesarean section (n = 2/6; 33.3 %) had the highest mortality index. Seventy-seven out of 99 SMO cases (77.9 %) were referred from other facilities with critical conditions and 28 out of 99 SMO cases (28.3 %) were admitted into the Intensive Care Unit. Several indicators such as administration of oxytocin, magnesium sulfate and antibiotics were found to be suboptimal.
   Conclusions: MNM is common at district level in Rwanda. The MNM approach enabled us to identify shortfalls in clinical practice and the referral system.
C1 [Kalisa, Richard] Ruhengeri Hosp, Dept Obstet & Gynecol, Musanze, Rwanda.
   [Kalisa, Richard; van Roosmalen, Jos] Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands.
   [Rulisa, Stephen] Univ Rwanda, Dept Obstet & Gynecol, Kigali, Rwanda.
   [van den Akker, Thomas; van Roosmalen, Jos] Leiden Univ, Dept Obstet, Med Ctr, Leiden, Netherlands.
RP Kalisa, R (reprint author), Ruhengeri Hosp, Dept Obstet & Gynecol, Musanze, Rwanda.; Kalisa, R (reprint author), Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands.
EM kalichard@gmail.com
CR Adisasmita Asri, 2008, BMC Pregnancy Childbirth, V8, P10, DOI 10.1186/1471-2393-8-10
   Ali AA, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-48
   Binagwaho A, 2013, NEW ENGL J MED, V369, P2054, DOI 10.1056/NEJMsr1302176
   Borchert M, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-109
   David E, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0401-3
   Filippi V, 2005, ACTA OBSTET GYN SCAN, V84, P11, DOI 10.1111/j.0001-6349.2005.00636.x
   Maternal Health Division, 2014, MAT NEAR MISS REV OP
   Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1
   Mivumbi VN, 2014, INT J GYNECOL OBSTET, V124, P244, DOI 10.1016/j.ijgo.2013.09.017
   National Institute of Statistics of Rwanda, 2014, RWAND DEM HLTH SURV
   National Institute of Statistics of Rwanda Ministry of Health and ICF International, 2006, RWAND DEM HLTH SURV
   Nelissen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061248
   Nyamtema AS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-94
   Oladapo Olufemi T, 2005, Reprod Health, V2, P9, DOI 10.1186/1742-4755-2-9
   Pearson L, 2005, INT J GYNECOL OBSTET, V88, P208, DOI 10.1016/j.ijgo.2004.09.027
   Rijken MJ, 2015, LANCET, V386, P1941, DOI 10.1016/S0140-6736(15)00828-4
   Rulisa S, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0619-8
   Rusa L, 2009, TROP MED INT HEALTH, V14, P830, DOI 10.1111/j.1365-3156.2009.02292.x
   Say L, 2004, REPROD HLTH, V1, P3, DOI DOI 10.1186/1742-4755-1-3
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Say L, 2009, BEST PRACT RES CL OB, V23, P287, DOI 10.1016/j.bpobgyn.2009.01.007
   Souza JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044129
   THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7
   Tuncalp O, 2012, BJOG-INT J OBSTET GY, V119, P653, DOI 10.1111/j.1471-0528.2012.03294.x
   Tuncalp O, 2013, INT J GYNECOL OBSTET, V123, P58, DOI 10.1016/j.ijgo.2013.06.003
   van den Akker T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054805
   van den Akker T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020776
   WHO, 2011, EV QUAL CAR SEV PREG
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD OCT 21
PY 2016
VL 16
AR 324
DI 10.1186/s12884-016-1119-1
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DZ5CP
UT WOS:000385879900007
PM 27769193
ER

PT J
AU Kaneko, Y
   Pappas, C
   Tajiri, N
   Borlongan, CV
AF Kaneko, Yuji
   Pappas, Colleen
   Tajiri, Naoki
   Borlongan, Cesar V.
TI Oxytocin modulates GABA(A)R subunits to confer neuroprotection in stroke
   in vitro
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NEURONAL INHIBITION; ISCHEMIC-STROKE; RECEPTOR; CELLS; BRAIN; HMGB1;
   DIFFERENTIATION; MITOCHONDRIA; EXPRESSION; CHLORIDE
AB Oxytocin protects against ischemia-induced inflammation and oxidative stress, and is associated with GABA (gamma-aminobutyric acid, an inhibitory neurotransmitter) signaling transduction in neurons. However, the molecular mechanism by which oxytocin affords neuroprotection, especially the interaction between oxytocin receptor and GABA(A) receptor (GABA(A)R), remains to be elucidated. Primary rat neural cells were exposed to oxytocin before induction of experimental acute stroke model via oxygen-glucose deprivation-reperfusion (OGD/R) injury. Pretreatment with oxytocin increased cell viability, decreased the cell damage against oxidative stress, and prevented the release of high mobility group box1 during OGD/R. However, introduction of oxytocin during OGD/R did not induce neuroprotection. Although oxytocin did not affect the glutathione-related cellular metabolism before OGD, oxytocin modulated the expression levels of GABA(A)R subunits, which function to remove excessive neuronal excitability via chloride ion influx. Oxytocin-pretreated cells significantly increased the chloride ion influx in response to GABA and THIP (delta-GABA(A)R specific agonist). This study provides evidence that oxytocin regulated GABA(A)R subunits in affording neuroprotection against OGD/R injury.
C1 [Kaneko, Yuji; Tajiri, Naoki; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.
   [Pappas, Colleen] Univ S Florida, Sch Aging Studies, 13301 Bruce B Downs Blvd, Tampa, FL 33612 USA.
RP Kaneko, Y; Borlongan, CV (reprint author), Univ S Florida, Coll Med, Ctr Excellence Aging & Brain, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.
EM ykaneko@health.usf.edu; cborlong@health.usf.edu
FU USF ORI [HSC-18330, COM HSC-18300]; NIH NINDS [RO1 1R01NS071956-01]; USF
   Department of Neurosurgery and Brain Repair Funds
FX This work was supported by USF OR&I HSC-18330 & COM HSC-18300 (YK), NIH
   NINDS RO1 1R01NS071956-01 (CVB), and USF Department of Neurosurgery and
   Brain Repair Funds (CVB). Part of this manuscript was presented at the
   American Society for Neural Therapy and Repair 23d Annual Conference,
   April 28-30, 2016, Clearwater Beach, Florida.
CR Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Bowen MT, 2015, P NATL ACAD SCI USA, V112, P3104, DOI 10.1073/pnas.1416900112
   Brickley SG, 2012, NEURON, V73, P23, DOI 10.1016/j.neuron.2011.12.012
   Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511
   Dienel GA, 2006, NEUROCHEM INT, V48, P586, DOI 10.1016/j.neuint.2006.01.004
   Dugladze T, 2012, SCIENCE, V336, P1458, DOI 10.1126/science.1222017
   Duveau V, 2011, EUR J NEUROSCI, V34, P362, DOI 10.1111/j.1460-9568.2011.07782.x
   Eckertova M, 2011, BRIT J PHARMACOL, V162, P452, DOI 10.1111/j.1476-5381.2010.01037.x
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008-0127
   Evans SL, 2014, BRAIN RES, V1580, P69, DOI 10.1016/j.brainres.2013.11.008
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Hashida K, 2002, BBA-GEN SUBJECTS, V1572, P85, DOI 10.1016/S0304-4165(02)00282-9
   Hengen KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030608
   Hinman JD, 2014, CURR OPIN NEUROL, V27, P615, DOI 10.1097/WCO.0000000000000149
   Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370
   Jickling GC, 2014, J CEREBR BLOOD F MET, V34, P185, DOI 10.1038/jcbfm.2013.203
   Jo S, 2014, NAT MED, V20, P886, DOI 10.1038/nm.3639
   Johnston GAR, 1996, PHARMACOL THERAPEUT, V69, P173, DOI 10.1016/0163-7258(95)02043-8
   Kaneko Y, 2016, MOL NEUROBIOL, V53, P1874, DOI 10.1007/s12035-015-9126-1
   Kaneko Y, 2014, CNS NEUROSCI THER, V20, P275, DOI 10.1111/cns.12208
   Kang HJ, 2009, LAB INVEST, V89, P948, DOI 10.1038/labinvest.2009.47
   Karelina K, 2011, STROKE, V42, P3606, DOI 10.1161/STROKEAHA.111.628008
   Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056
   Koksma JJ, 2003, J NEUROSCI, V23, P788
   Kuner T, 2000, NEURON, V27, P447, DOI 10.1016/S0896-6273(00)00056-8
   Laschet JJ, 2004, J NEUROSCI, V24, P7614, DOI 10.1523/JNEUROSCI.0868-04.2004
   Lee S, 2010, SCIENCE, V330, P790, DOI 10.1126/science.1184334
   Liu BS, 2010, STROKE, V41, P1018, DOI 10.1161/STROKEAHA.110.579011
   Meera P, 2011, J NEUROPHYSIOL, V106, P2057, DOI 10.1152/jn.00450.2011
   Mele M, 2014, NEUROBIOL DIS, V65, P220, DOI 10.1016/j.nbd.2014.01.019
   Mielke JG, 2005, J NEUROCHEM, V92, P103, DOI 10.1111/j.1471-4159.2004.02841.x
   Pond BB, 2006, J NEUROSCI, V26, P1396, DOI 10.1523/JNEUROSCI.1421-05.2006
   Ralser Markus, 2007, J Biol, V6, P10, DOI 10.1186/jbiol61
   Rudolph U, 2014, ANNU REV PHARMACOL, V54, P483, DOI 10.1146/annurev-pharmtox-011613-135947
   Sergeeva OA, 2005, J NEUROSCI, V25, P88, DOI 10.1523/JNEUROSCI.3209-04.2005
   Shojo H, 2000, MOL GENET METAB, V71, P552, DOI 10.1006/mgme.2000.3094
   Tajiri N., 2016, CNS NEUROSCI THER
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Tyzio R, 2006, SCIENCE, V314, P1788, DOI 10.1126/science.1133212
   Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190
   Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334
   Zhang XH, 2008, J IMMUNOL, V181, P5015
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
NR 43
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 21
PY 2016
VL 6
AR 35659
DI 10.1038/srep35659
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ4LW
UT WOS:000385831200002
PM 27767042
ER

PT J
AU Chatterjee, S
   Sarkar, A
   Rao, KD
AF Chatterjee, Susmita
   Sarkar, Anupam
   Rao, Krishna D.
TI Using Misoprostol for Primary versus Secondary Prevention of Postpartum
   Haemorrhage - Do Costs Matter?
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; MANAGEMENT; LABOR
AB Background
   Postpartum heammorrhage (PPH), defined as blood loss greater than or equal to 500 ml within 24 hours after birth, is the leading cause of maternal deaths globally and in India. Misoprostol is an important option for PPH management in setting where oxytocin (the gold standard for PPH prevention and treatment) in not available or not feasible to use. For the substantial number of deliveries which take place at home or at lower level heatlh facilities in India, misoprostol pills can be adminstered to prevent PPH. The standard approach using misoprostol is to administer it prophylactically as primary prevention (600 mcg). An alternative strategy could be to administer misoprostol only to those who are at high risk of having PPH i.e. as secondary prevention.
   Methods
   This study reports on the relative cost per person of a strategy involving primary versus secondary prevention of PPH using misoprostol. It is based on a randomized cluster trial that was conducted in Bijapur district in Karnataka, India between December 2011 and March 2014 among pregnant women to compare two community-level strategies for the prevention of PPH: primary and secondary. The analysis was conducted from the government perspective using an ingredient approach.
   Results
   The cluster trial showed that there were no significant differences in clinical outcomes between the two study arms. However, the results of the cost analysis show that there is a difference of INR 6 (US$ 0.1) per birth for implementing the strategies primary versus secondary prevention. In India where 14.9 million births take place at sub-centres and at home, this additional cost of INR 6 per birth translates to an additional cost of INR 94 (US$ 1.6) million to the government to implement the primary prevention compared to the secondary prevention strategy.
   Conclusion
   As clinical outcomes did not differ significantly between the two arms in the trial, taking into account the difference in costs and potential issues with sustainability, secondary prevention might be a more strategic option.
C1 [Chatterjee, Susmita; Sarkar, Anupam] Publ Hlth Fdn India, New Delhi, India.
   [Rao, Krishna D.] Johns Hopkins Univ, Baltimore, MD USA.
RP Chatterjee, S (reprint author), Publ Hlth Fdn India, New Delhi, India.
EM susmita.c@phfi.org
FU Gynuity Health Projects, USA; Gynuity Health projects
FX This work was supported by Gynuity Health Projects, USA. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; We sincerely thank Gynuity
   Health projects for providing funding support of this study. We are
   thankful to the partner institutes: University of Chicago, Illinois and
   University of California, San Francisco. We are grateful to KLE
   University, BLDE University and the ANMs of the sub-centres for their
   support and co-operation during field data collection.
CR Bellad MB, 2012, COMPREHENSIVE TXB PO, P275
   Bradley SEK, 2007, INT J GYNECOL OBSTET, V97, P52, DOI 10.1016/j.ijgo.2006.12.005
   Dabash R, 2012, COMPREHENSIVE TXB PO, P296
   Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6
   Drummond MF, 2005, COST ANAL METHODS EC, P55
   International Institute for Population Sciences (IIPS), 2010, DISTR LEV HOUS FAC S, Patent No. Mumabi
   Mobeen N, 2011, BJOG-INT J OBSTET GY, V118, P353, DOI 10.1111/j.1471-0528.2010.02807.x
   Montgomery AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083331
   Prata N, 2006, INT J GYNECOL OBSTET, V94, P149, DOI 10.1016/j.ijgo.2006.05.027
   Raghavan S, 2016, BJOG-INT J OBSTET GY, V123, P120, DOI 10.1111/1471-0528.13540
   Walker D, 2002, HEALTH POLICY PLANN, V17, P112, DOI 10.1093/heapol/17.1.112
   Walraven G, 2005, BJOG-INT J OBSTET GY, V112, P1277, DOI 10.1111/j.1471-0528.2005.00711.x
   World Health Organisation (WHO), 2009, WHO GUID MAN POSTP H, V1
   World Health Organization, 2012, WHO REC PREV TREATM
NR 14
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2016
VL 11
IS 10
AR e0164718
DI 10.1371/journal.pone.0164718
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ9NV
UT WOS:000386203800029
PM 27755601
ER

PT J
AU Lombardo, MV
   Lai, MC
   Auyeung, B
   Holt, RJ
   Allison, C
   Smith, P
   Chakrabarti, B
   Ruigrok, ANV
   Suckling, J
   Bullmore, ET
   Ecker, C
   Craig, MC
   Murphy, DGM
   Happe, F
   Baron-Cohen, S
AF Lombardo, Michael V.
   Lai, Meng-Chuan
   Auyeung, Bonnie
   Holt, Rosemary J.
   Allison, Carrie
   Smith, Paula
   Chakrabarti, Bhismadev
   Ruigrok, Amber N. V.
   Suckling, John
   Bullmore, Edward T.
   Ecker, Christine
   Craig, Michael C.
   Murphy, Declan G. M.
   Happe, Francesca
   Baron-Cohen, Simon
CA MRC AIMS Consortium
TI Unsupervised data-driven stratification of mentalizing heterogeneity in
   autism
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH-FUNCTIONING AUTISM; RANDOMIZED CONTROLLED-TRIAL; OXYTOCIN NASAL
   SPRAY; DOMAIN CRITERIA RDOC; ASPERGER-SYNDROME; SPECTRUM DISORDERS;
   SOCIAL COGNITION; NETWORK ANALYSIS; DIAGNOSTIC INTERVIEW; PRECISION
   MEDICINE
AB Individuals affected by autism spectrum conditions (ASC) are considerably heterogeneous. Novel approaches are needed to parse this heterogeneity to enhance precision in clinical and translational research. Applying a clustering approach taken from genomics and systems biology on two large independent cognitive datasets of adults with and without ASC (n = 694; n = 249), we find replicable evidence for 5 discrete ASC subgroups that are highly differentiated in item-level performance on an explicit mentalizing task tapping ability to read complex emotion and mental states from the eye region of the face (Reading the Mind in the Eyes Test; RMET). Three subgroups comprising 45-62% of ASC adults show evidence for large impairments (Cohen's d = -1.03 to -11.21), while other subgroups are effectively unimpaired. These findings delineate robust natural subdivisions within the ASC population that may allow for more individualized inferences and accelerate research towards precision medicine goals.
C1 [Lombardo, Michael V.] Univ Cyprus, Dept Psychol, Ctr Appl Neurosci, Nicosia, Cyprus.
   [Lombardo, Michael V.; Lai, Meng-Chuan; Auyeung, Bonnie; Holt, Rosemary J.; Allison, Carrie; Smith, Paula; Chakrabarti, Bhismadev; Ruigrok, Amber N. V.; Baron-Cohen, Simon] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England.
   [Lai, Meng-Chuan] Univ Toronto, Ctr Addict & Mental Hlth, Child & Youth Mental Hlth Collaborat, Toronto, ON, Canada.
   [Lai, Meng-Chuan] Univ Toronto, Dept Psychiat, Hosp Sick Children, Toronto, ON, Canada.
   [Lai, Meng-Chuan] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan.
   [Lai, Meng-Chuan] Coll Med, Taipei, Taiwan.
   [Auyeung, Bonnie] Univ Edinburgh, Dept Psychol, Sch Philosophy Psychol & Language Sci, Edinburgh, Midlothian, Scotland.
   [Chakrabarti, Bhismadev] Univ Reading, Sch Psychol & Clin Language Sci, Ctr Integrat Neurosci & Neurodynam, Reading, Berks, England.
   [Suckling, John; Bullmore, Edward T.] Univ Cambridge, Dept Psychiat, Brain Mapping Unit, Cambridge, England.
   [Suckling, John; Bullmore, Edward T.; Baron-Cohen, Simon] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England.
   [Ecker, Christine; Craig, Michael C.; Murphy, Declan G. M.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, Sackler Inst Translat Neurodev, London, England.
   Univ Oxford, Dept Psychiat, Autism Res Grp, Oxford OX1 2JD, England.
   [Happe, Francesca; MRC AIMS Consortium] Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC Social Genet & Dev Psychiat Ctr, London, England.
   [Ecker, Christine] Goethe Univ Frankfurt, Univ Hosp Frankfurt Main, Dept Child & Adolescent Psychiat Psychosomat & Ps, Frankfurt, Germany.
   [Craig, Michael C.] Bethlem Royal & Maudsley Hosp, SLAM NHS Fdn Trust, Natl Autism Unit, Beckenham, Kent, England.
RP Lombardo, MV (reprint author), Univ Cyprus, Dept Psychol, Ctr Appl Neurosci, Nicosia, Cyprus.; Lombardo, MV (reprint author), Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England.
EM mvlombardo@gmail.com
FU National Institute for Health Research (NIHR) Collaboration for
   Leadership in Applied Health Research and Care (CLAHRC) East of England
   at Cambridgeshire and Peterborough NHS Foundation Trust; Innovative
   Medicines Initiative Joint Undertaking [115300]; European Union; EFPIA
   companies; Autism Speaks; UK Medical Research Council (MRC) [G0600977];
   Wellcome Trust [091774/Z/10/Z]; Autism Research Trust (ART); William
   Binks Autism Neuroscience Fellowship at the University of Cambridge;
   O'Brien Scholars Program within the Child and Youth Mental Health
   Collaborative at the Centre for Addiction and Mental Health and The
   Hospital for Sick Children, Toronto
FX This study was supported by the National Institute for Health Research
   (NIHR) Collaboration for Leadership in Applied Health Research and Care
   (CLAHRC) East of England at Cambridgeshire and Peterborough NHS
   Foundation Trust. The views expressed are those of the authors and not
   necessarily those of the NHS, the NIHR, or the Department of Health.
   This study was also conducted in association with the European Autism
   Interventions-A Multicentre Study for Developing New Medications
   (EU-AIMS) consortium; EU-AIMS receives support from the Innovative
   Medicines Initiative Joint Undertaking under grant agreement number
   115300, resources of which are composed of financial contribution from
   the European Union's Seventh Framework Programme (FP7/2007-2013), EFPIA
   companies, and Autism Speaks. This study was also supported by grants
   from the UK Medical Research Council (MRC) (G0600977), the Wellcome
   Trust (091774/Z/10/Z), and the Autism Research Trust (ART). M-CL and AR
   received support from the William Binks Autism Neuroscience Fellowship
   at the University of Cambridge. M-CL received support from the O'Brien
   Scholars Program within the Child and Youth Mental Health Collaborative
   at the Centre for Addiction and Mental Health and The Hospital for Sick
   Children, Toronto. We would also like to thank Karen Pierce, Eric
   Courchesne, Tiziano Pramparo, Jon Brock, and Aja Murray for valuable
   discussion and comments.
CR Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Baribeau DA, 2015, J AM ACAD CHILD PSY, V54, P479, DOI 10.1016/j.jaac.2015.03.016
   Barnes JL, 2009, AUTISM RES, V2, P148, DOI 10.1002/aur.79
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00
   Baron-Cohen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136521
   BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8
   Baron-Cohen S., 1995, MINDBLINDNESS ESSAY
   Bernier R, 2014, CELL, V158, P263, DOI 10.1016/j.cell.2014.06.017
   Brunsdon VEA, 2014, AUTISM, V18, P17, DOI 10.1177/1362361313499456
   Byrge L, 2015, J NEUROSCI, V35, P5837, DOI 10.1523/JNEUROSCI.5182-14.2015
   Cacciotti-Saija C, 2015, SCHIZOPHRENIA BULL, V41, P483, DOI 10.1093/schbul/sbu094
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Daniels AM, 2012, J AUTISM DEV DISORD, V42, P257, DOI 10.1007/s10803-011-1236-7
   Dufour N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075468
   Dziobek I, 2006, J AUTISM DEV DISORD, V36, P623, DOI 10.1007/s10803-006-0107-0
   Einfeld SL, 2014, AM J MED GENET A, V164, P2232, DOI 10.1002/ajmg.a.36653
   Ellegood J, 2015, MOL PSYCHIATR, V20, P118, DOI 10.1038/mp.2014.98
   Fletcher- Watson S., 2014, COCHRANE DB SYST REV, V3
   Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504
   Frick C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041650
   Frith U, 2001, NEURON, V32, P969, DOI 10.1016/S0896-6273(01)00552-9
   Geschwind DH, 2007, CURR OPIN NEUROBIOL, V17, P103, DOI 10.1016/j.conb.2007.01.009
   Geschwind D. H., 2015, LANCET NEUROL
   Gillberg C, 2014, J AUTISM DEV DISORD, V44, P3274, DOI 10.1007/s10803-014-2163-1
   Golan O, 2006, SOC NEUROSCI-UK, V1, P111, DOI 10.1080/17470910600980986
   Gupta S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6748
   Haar S., 2014, CEREB CORTEX
   Hahamy A, 2015, NAT NEUROSCI, V18, P302, DOI 10.1038/nn.3919
   Happe F., 1995, SOC RES CHILD DEV, V66, P843, DOI DOI 10.1111/J.1467-8624.1995.TB00909.X
   Hu VW, 2009, AUTISM RES, V2, P67, DOI 10.1002/aur.72
   Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379
   Insel TR, 2014, AM J PSYCHIAT, V171, P395, DOI 10.1176/appi.ajp.2014.14020138
   Kapur S, 2012, MOL PSYCHIATR, V17, P1174, DOI 10.1038/mp.2012.105
   Kim ES, 2011, STRUCT EQU MODELING, V18, P212, DOI 10.1080/10705511.2011.557337
   Lai M. C., 2012, PLOS ONE
   Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003
   Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1
   Lai MC, 2013, BRAIN, V136, P2799, DOI 10.1093/brain/awt216
   Lai MC, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001544
   Lai MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020835
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Leekam S, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0082
   Lefebvre A, 2015, BIOL PSYCHIAT, V78, P126, DOI 10.1016/j.biopsych.2015.02.010
   Lombardo MV, 2015, NEURON, V86, P567, DOI 10.1016/j.neuron.2015.03.023
   Lombardo MV, 2011, NEUROIMAGE, V56, P1832, DOI 10.1016/j.neuroimage.2011.02.067
   Lombardo M. V., 2016, BIORXIV
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   Lord C, 2012, J CONSULT CLIN PSYCH, V80, P477, DOI 10.1037/a0027214
   Lugnegard T, 2013, SCHIZOPHR RES, V143, P277, DOI 10.1016/j.schres.2012.12.001
   Moran JM, 2011, P NATL ACAD SCI USA, V108, P2688, DOI 10.1073/pnas.1011734108
   Mumford JA, 2010, NEUROIMAGE, V52, P1465, DOI 10.1016/j.neuroimage.2010.05.047
   Pantelis PC, 2015, SOC COGN AFFECT NEUR, V10, P1348, DOI 10.1093/scan/nsv021
   Parikshak NN, 2015, NAT REV GENET, V16, P441, DOI 10.1038/nrg3934
   Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031
   Peterson E, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00220
   Pickles A, 2014, J CHILD PSYCHOL PSYC, V55, P1354, DOI 10.1111/jcpp.12269
   Pramparo T, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20156108
   Pramparo T, 2015, JAMA PSYCHIAT, V72, P386, DOI 10.1001/jamapsychiatry.2014.3008
   Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374
   Sandvik AM, 2014, SCAND J PSYCHOL, V55, P585, DOI 10.1111/sjop.12138
   Schaafsma SM, 2015, TRENDS COGN SCI, V19, P65, DOI 10.1016/j.tics.2014.11.007
   Senju A, 2009, SCIENCE, V325, P883, DOI 10.1126/science.1176170
   Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f
   Soorya LV, 2015, J AM ACAD CHILD PSY, V54, P208, DOI 10.1016/j.jaac.2014.12.005
   Szatmari P, 2015, JAMA PSYCHIAT, V72, P276, DOI 10.1001/jamapsychiatry.2014.2463
   Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110
   Wechsler D., 1999, WECHSLER ABBREVIATED
   Wilson CE, 2014, AUTISM RES, V7, P568, DOI 10.1002/aur.1394
   Zhang B, 2005, STAT APPL GENET MO B, V4, DOI 10.2202/1544-6115.1128
NR 74
TC 0
Z9 0
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 18
PY 2016
VL 6
AR 35333
DI 10.1038/srep35333
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ0DR
UT WOS:000385508100001
PM 27752054
ER

PT J
AU Morrison, JJ
   Crosby, DA
   Crankshaw, DJ
AF Morrison, John J.
   Crosby, David A.
   Crankshaw, Denis J.
TI In vitro contractile effects of agents used in the clinical management
   of postpartum haemorrhage
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Human myometrium; Postpartum haemorrhage; Uterotonic; Oxytocin;
   Misoprostol; Carbetocin
ID HUMAN MYOMETRIUM; PROSTANOID RECEPTORS; OXYTOCIN; CARBETOCIN; PREGNANCY;
   EPIDEMIOLOGY; MISOPROSTOL; STRIPS
AB Uterine atony is a major cause of postpartum haemorrhage and maternal mortality. However, the comparative pharmacology of agents used to treat this condition is poorly understood. This study evaluates, using human pregnant myometrium in vitro, a range of contractile parameters for agents used in the clinical treatment of atonic postpartum haemorrhage. The effects of oxytocin, carbetocin, ergometrine, carboprost, syntometrine and misoprostol were investigated in 146 myometrial strips from 19 donors. The potency and maximal response values were obtained, and compared, using both maximal amplitude and mean contractile force as indices of contraction. Single, EC50 concentrations of the agents were administered and both force and contraction peak parameters were compared during a 15-min exposure. Differences were considered significant when P < 0.05. There were no significant differences in the peak amplitude of response between agents, except for misoprostol, which was inactive. There was a wide difference in potencies using both measures of contractility, with oxytocin and carbetocin being the most potent. The most important difference between the agents was in their ability to increase the mean contractile force, with oxytocin superior to all agents except syntometrine. In single dose experiments, mean contractile force was the parameter that separated the agents. In this respect, oxytocin was not statistically different from carboprost or syntometrine, but was superior to all other agents. These findings support a clear role for oxytocin as the first line agent for treatment of postpartum haemorrhage and raise doubts about the potential clinical usefulness of misoprostol. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Morrison, John J.; Crosby, David A.; Crankshaw, Denis J.] Natl Univ Ireland Galway, Dept Obstet & Gynaecol, Galway, Ireland.
RP Morrison, JJ (reprint author), Natl Univ Ireland Galway, Dept Obstet & Gynaecol, Galway, Ireland.
EM John.Morrison@nuigalway.ie
FU Galway University Hospital Perinatal Fund
FX This work was supported by the Galway University Hospital Perinatal
   Fund. We thank the theatre nursing staff who assisted with the biopsy
   collection procedure. The authors report no conflict of interest in the
   performance or reporting of this study.
CR Astle S, 2005, MOL HUM REPROD, V11, P279, DOI 10.1093/molehr/gah158
   Balki M., 2014, CAN J ANAESTH
   Balki M, 2015, ANESTH ANALG, V120, P1074, DOI 10.1213/ANE.0000000000000682
   Bateman BT, 2010, ANESTH ANALG, V110, P1368, DOI 10.1213/ANE.0b013e3181d74898
   Bohlmann MK, 2014, ARCH GYNECOL OBSTET, V289, P555, DOI 10.1007/s00404-013-3016-4
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Chan CL, 2000, BRIT J PHARMACOL, V129, P589, DOI 10.1038/sj.bjp.0703072
   Cole NM, 2016, ANESTHESIOLOGY, V124, P378, DOI 10.1097/ALN.0000000000000940
   Crankshaw DJ, 2015, REPROD SCI, V22, P1229, DOI 10.1177/1933719115572483
   Crankshaw DJ, 2014, EUR J PHARMACOL, V738, P245, DOI 10.1016/j.ejphar.2014.05.037
   Crankshaw DJ, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.014
   Engstrom T, 1998, EUR J PHARMACOL, V355, P203, DOI 10.1016/S0014-2999(98)00513-5
   Gibbins KJ, 2013, AM J OBSTET GYNECOL, V208, P181, DOI 10.1016/j.ajog.2012.07.034
   Gizzo S, 2013, REPROD SCI, V20, P1011, DOI 10.1177/1933719112468951
   Mousa HA, 2014, COCHRANE DB SYST REV, V2
   SENIOR J, 1993, BRIT J PHARMACOL, V108, P501
   Shields LE, 2015, AM J OBSTET GYNECOL, V212, P272, DOI 10.1016/j.ajog.2014.07.012
   SWEENEY G, 1990, CURR THER RES CLIN E, V47, P528
   Voigt F, 2015, EUR J OBSTET GYN R B, V187, P85, DOI 10.1016/j.ejogrb.2014.11.026
   World Health Organization, 2012, WHO REC PREV TREATM
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2016
VL 789
BP 328
EP 333
DI 10.1016/j.ejphar.2016.07.025
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DY7RR
UT WOS:000385327500038
PM 27423315
ER

PT J
AU Kovacs, L
   Kezer, FL
   Ruff, F
   Szenci, O
AF Kovacs, Levente
   Kezer, Fruzsina Luca
   Ruff, Ferenc
   Szenci, Otto
TI Timing of obstetrical assistance affects peripartal cardiac autonomic
   function and early maternal behavior of dairy cows
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Obstetrical assistance; Cardiac autonomic function; Stress; Early
   maternal behavior; Heart rate variability; Dairy cows
ID HEART-RATE-VARIABILITY; WELFARE; CATTLE; CALF; INDICATORS; RESPONSES;
   OXYTOCIN; DYSTOCIA; PROGRESS; MILKING
AB Peripartal autonomic nervous system function and early maternal behavior were investigated in 79 multiparous Holstein-Friesian cows. Animals were allocated into four groups based on the technology of calving management: 1) unassisted calving in a group pen (UCG; N = 19), 2) unassisted calving in an individual pen (UCI; N= 21), 3) assisted calving with appropriately timed obstetrical assistance (ACA; N = 20), and 4) assisted calving with premature obstetrical assistance (ACP; N = 19). Heart rate;the high frequency (HF) component of heart rate variability (HRV) as a measure of vagal activity and the ratio between the low frequency (LF) and HF components (LF/HF ratio) as a parameter of sympathetic nervous system activity were calculated. Heart rate and HRV parameters were presented as areas under the curves (AUC) for the following periods: 1) prepartum period (between 96 h before the onset of calving restlessness and the onset of restlessness), 2) parturition (between the onset calving restlessness and delivery), and 3) postpartum period (during a 48-h period after delivery). Pain-related behaviors were recorded during parturition (i.e., the occurrence of vocalization and stretching the neck towards the abdomen) and during a 2-h observation period after calving (i.e., the occurrence of vocalization, stretching the neck towards the abdomen and the duration of standing with an arched back). Early maternal behavior was observed during the first 2 h following calving as follows: 1) latency and duration of sniffing calf's head/body, and 2) latency and duration of licking calf's head/body. No difference was found across groups in autonomic function before the onset of calving restlessness. Area under the heart rate curve was higher in ACP cows during parturition (39.6 +/- 2.5 beats/min x h) compared to UCG, UCI and ACA animals (AUC = 13.1 +/- 0.9 beats/min x h, AUC = 22.3 +/- 1.4 beats/min x h and AUC = 25.0 +/- 2.1 beats/min x h, respectively). Area under the heart rate curve did not differ across the UCG, UCI and ACA groups during the postpartum period (AUC = 65.2 +/- 16.7 beats/min x h, AUC = 58.0 +/- 14.2 beats/min x h and AUC = 62.9 +/- 12.1 beats/min x h, respectively) but it was higher in ACP cows compared to the former groups (AUC = 269.1 +/- 36.3 beats/min x h). During parturition, area under the HF curve reflected a lower vagal tone (AUC = 305 +/- 1.6 n.u. x h) in cows with premature obstetrical assistance than in animals that calved individually without farmer assistance (AUC = 2.7 +/- 0.4 n.u. x h) or with appropriately timed assistance (AUC = 3.2 +/- 1.2 n.u. x h). During parturition, LF/HF ratio showed greater sympathetic activity in ACP cows than in animals from any other group. Area under the HF curve was similar across UCG, UCI and ACA cows (AUC = -232.1 +/- 42.0 n.u. x h, AUC = 163.4 +/- 35.6 n.u. x h and AUC = -331.4 +/- 562 n.u. x h, respectively) during the postpartum period and was the lowest in ACP cows (AUC = -1025.6 +/- 44.2 n.u, x h) reflecting a long-term stress load in the latter group. During parturition, both vocalization and stretching the neck towards the abdomen occurred more often in UCG cows than in cows from any other groups, and the incidence of both behaviors was statistically higher in ACP cows than in UCI and ACA animals. There were no significant differences across groups in these behaviors during the 2-h postpartum observation.
   UCG cows had a shorter latency and a longer duration of maternal grooming during the first 2 h following delivery compared to any other groups. UCI and ACA dams spent more time with licking the calf within the 2-h period after calving and had a shorter latency to sniff and lick the offspring compared to cows that received premature assistance. Group calving is less stressful for cows than calving in an individual pen either with or without obstetrical assistance. Calving in a group or with appropriately timed farmer assistance supports the expression of early maternal behavior and lead to a rapid post-partum recovery of the autonomic nervous system. Premature obstetrical assistance means stress for cows during parturition, leads to a prolonged postpartum recovery of the autonomic nervous system and inhibits the expression of early maternal behavior. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Kovacs, Levente; Kezer, Fruzsina Luca; Szenci, Otto] MTA SZIE Large Anim Clin Res Grp, H-2225 Ullo Dora Major, Hungary.
   [Kovacs, Levente; Kezer, Fruzsina Luca] Szent Istvan Univ, Fac Agr & Environm Sci, Inst Anim Husb, Pater Karoly Utca 1, H-2100 Godollo, Hungary.
   [Ruff, Ferenc] Hungarian Cent Stat Off, Dept Methodol, Keleti Karoly Utca 5-7, H-1024 Budapest, Hungary.
   [Szenci, Otto] Szent Istvan Univ, Fac Vet Sci, Dept & Clin Prod Anim, H-2225 Ullo Dora Major, Hungary.
RP Kovacs, L (reprint author), MTA SZIE Large Anim Clin Res Grp, H-2225 Ullo Dora Major, Hungary.
EM Kovacs.Levente@mkk.szie.hu
FU Research Center of Excellence [9878-3/2016/FEKUT]
FX The authors would like to thank Ferenc Bodo, the owner of the farm and
   to Agoston Bodo farm manager for supporting the study and the farm staff
   of Prograg Agrarcentrum Ltd. at Rackeresztur, Laszlopuszta for taking
   care of the animals during the experiment. Dr. Levente Kovacs was
   supported by the Research Center of Excellence - 9878-3/2016/FEKUT
   project.
CR AKSELROD S, 1985, AM J PHYSIOL, V249, pH867
   Barrier AC, 2012, PREV VET MED, V103, P248, DOI 10.1016/j.prevetmed.2011.09.001
   Barrier AC, 2012, APPL ANIM BEHAV SCI, V139, P209, DOI 10.1016/j.applanim.2012.03.003
   Broom D.M., 1981, BIOLIGY BEHAV MECH F, P320
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Despres G, 2002, PHYSIOL RES, V51, P347
   DUFTY JH, 1981, NEW ZEAL VET J, V29, P44, DOI 10.1080/00480169.1981.34796
   Dwyer CM, 2001, ANIM SCI, V72, P555
   Fisher MW, 2002, ANIM WELFARE, V11, P157
   Garry FB, 2004, BOVINE PR, V38, P1
   Gleerup KB, 2015, APPL ANIM BEHAV SCI, V171, P25, DOI 10.1016/j.applanim.2015.08.023
   Hagen K, 2005, PHYSIOL BEHAV, V85, P195, DOI 10.1016/j.physbeh.2005.03.019
   Hamner JW, 2001, J APPL PHYSIOL, V90, P1559
   Houle MS, 1994, AM J PHYSIOL, V276, P215
   Jensen MB, 2012, APPL ANIM BEHAV SCI, V139, P195, DOI 10.1016/j.applanim.2012.04.002
   Kolkman I, 2010, REPROD DOMEST ANIM, V45, P160, DOI 10.1111/j.1439-0531.2008.01295.x
   Kovacs L, 2015, PHYSIOL BEHAV, V139, P281, DOI 10.1016/j.physbeh.2014.11.039
   Kovacs L, 2014, J DAIRY SCI, V97, P6955, DOI 10.3168/jds.2014-8327
   Kovacs L, 2014, ANIMAL, V8, P316, DOI 10.1017/S1751731113002140
   Kovacs L, 2013, J DAIRY SCI, V96, P7743, DOI 10.3168/jds.2013-7030
   Kovacs L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145313
   Kovacs L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134792
   Lay DC, 1996, J ANIM SCI, V74, P1806
   LIDFORS LM, 1994, APPL ANIM BEHAV SCI, V42, P11, DOI 10.1016/0168-1591(94)90003-5
   Margulis L., 1991, SYMBIOSISOURCE EVO, P486
   Mee JF, 2004, VET CLIN N AM-FOOD A, V20, P521, DOI 10.1016/j.cvfa.2004.06.001
   Miedema HM, 2011, APPL ANIM BEHAV SCI, V132, P14, DOI 10.1016/j.applanim.2011.03.003
   Mohr E, 2002, PHYSIOL BEHAV, V75, P251, DOI 10.1016/S0031-9384(01)00651-5
   Nielsen SS, 2009, IN PRACTICE, V31, P150
   OWENS JL, 1985, APPL ANIM BEHAV SCI, V13, P321, DOI 10.1016/0168-1591(85)90012-7
   Pilz M, 2012, APPL ANIM BEHAV SCI, V138, P18, DOI 10.1016/j.applanim.2012.01.011
   R Core Team, 2013, R LANG ENV STAT COMP
   Raussi S, 2003, APPL ANIM BEHAV SCI, V80, P245, DOI 10.1016/S0168-1591(02)00213-7
   Schuenemann GM, 2011, J DAIRY SCI, V94, P5494, DOI 10.3168/jds.2011-4436
   Scott PR, 2005, VET J, V170, P33, DOI 10.1016/j.tvjl.2004.03.010
   Stafford K.J., 2010, IMPROVING ANIMAL WEL, P88
   Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024
   Thomsen P.T., 2005, P ANN C BOV PRACT PR, P109
   Uvnas-Moberg K, 2005, Z PSYCHOSOM MED PSYC, V51, P57
   Vannucchi CI, 2015, VET J, V203, P228, DOI 10.1016/j.tvjl.2014.12.018
   von Borell E, 2007, PHYSIOL BEHAV, V92, P293, DOI 10.1016/j.physbeh.2007.01.007
   von Keyserlingk MAG, 2007, HORM BEHAV, V52, P106, DOI 10.1016/j.yhbeh.2007.03.015
   Watamura SE, 2004, DEV PSYCHOBIOL, V45, P125, DOI 10.1002/dev.20026
NR 43
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD OCT 15
PY 2016
VL 165
BP 202
EP 210
DI 10.1016/j.physbeh.2016.08.001
PG 9
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DY0LS
UT WOS:000384788900025
PM 27494992
ER

PT J
AU Reyes-Lagos, JJ
   Hadamitzky, M
   Pena-Castillo, MA
   Echeverria, JC
   Bosche, K
   Luckemann, L
   Schedlowski, M
   Pacheco-Lopez, G
AF Reyes-Lagos, Jose Javier
   Hadamitzky, Martin
   Pena-Castillo, Miguel Angel
   Echeverria, Juan Carlos
   Bosche, Katharina
   Luckemann, Laura
   Schedlowski, Manfred
   Pacheco-Lopez, Gustavo
TI Exogenous oxytocin reduces signs of sickness behavior and modifies heart
   rate fluctuations of endotoxemic rats
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Heart rate variability; Sickness behavior; Autonomic activity;
   Anti-inflammatory cholinergic pathway; Oxytocin; LPS
ID CHOLINERGIC ANTIINFLAMMATORY PATHWAY; RATE-VARIABILITY; TIME-SERIES;
   BLOOD-PRESSURE; LOCOMOTOR-ACTIVITY; LIPOPOLYSACCHARIDE; INFLAMMATION;
   MICE; TOLERANCE; CYTOKINE
AB Besides the well-known roles of oxytocin on birth, maternal bonding, and lactation, recent evidence shows that this hypothalamic hormone possesses cardioprotective, anti-inflammatory and parasympathetic neuromodulation properties. In this study, we explore the heart rate fluctuations (HRF) in an endotoxemic rodent model that was accompanied by the administration of exogenous oxytocin. The assessment of HRF has been widely used as an indirect measure of the cardiac autonomic function. In this context, adult male Dark Agouti rats were equipped with a telemetric transmitter to continuously and remotely measure the electrocardiogram, temperature, and locomotion. In a between-subjects experimental design, rats received the following peripheral treatment: saline solution as a vehicle (V); lipopolysaccharide (LPS); oxytocin (Ox); lipopolysaccharide + oxytocin (LPS + Ox). Linear and non-linear parameters of HRF were estimated starting 3 h before to 24 h after treatments. Our results showed that exogenous oxytocin does not modify by itself the HRF of oxytocin-treated rats in comparison to vehicle-treated rats. However, in animals undergoing endotoxemia it: a) provokes a less anticorrelated pattern in HRF, b) decreased mean heart rate, c) moderated the magnitude and duration of the LPS-induced hyperthermia, and d) increased locomotion, up to 6 h after the LPS injection. The less anticorrelated pattern in the HRF and decreased mean heart rate may reflect a cardiac pacemaker coupling with cholinergic influences mediated by oxytocin during LPS-induced endotoxemia. Finally, the anti-lethargic and long-term temperature moderating effects of the administration of oxytocin during endotoxemia could be a consequence of the systemic anti-inflammatory properties of oxytocin. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Reyes-Lagos, Jose Javier; Pena-Castillo, Miguel Angel; Echeverria, Juan Carlos] Metropolitan Univ UAM, Basic Sci & Engn Div, Campus Iztapalapa, Mexico City 09340, DF, Mexico.
   [Hadamitzky, Martin; Bosche, Katharina; Luckemann, Laura; Schedlowski, Manfred] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Psychol & Behav Immunobiol, D-45122 Essen, Germany.
   [Pacheco-Lopez, Gustavo] Metropolitan Univ UAM, Biol & Hlth Sci Div, Campus Lerma, Lerma 52005, Mexico.
   [Pacheco-Lopez, Gustavo] Leiden Univ, Fac Social & Behav Sci, Hlth Med & Neuropsychol Unit, NL-2333 AK Leiden, Netherlands.
RP Pacheco-Lopez, G (reprint author), Univ Autonoma Metropolitana, Unidad Lerma, Div Ciencias Biol & Salud, Dept Ciencias Salud, Ave Garzas 10, Lerma 52005, Edo Mex, Mexico.
EM g.pacheco@correo.ler.uam.mx
FU Mexican Council for Science and Technology (CONACyT) [381983/253449];
   Metropolitan University (UAM)-Mexico; University Hospital of
   Essen-Germany
FX J. Javier Reyes-Lagos thanks the Mexican Council for Science and
   Technology (CONACyT) for providing scholarship (CVU/Scholarship number:
   381983/253449). This work was partially funded by the Metropolitan
   University (UAM)-Mexico research and mobility funds to GPL, MAPC and
   JCE, as well as institutional funds of the University Hospital of
   Essen-Germany.
CR Ashkenazy Y, 2003, PHYSICA A, V323, P19, DOI 10.1016/S0378-4371(03)00008-6
   Ashkenazy Y, 2000, COMPUT CARDIOL, V27, P139, DOI 10.1109/CIC.2000.898475
   Barraza JA, 2013, EXP CLIN PSYCHOPHARM, V21, P85, DOI 10.1037/a0031581
   Camm AJ, 1996, EUR HEART J, V17, P354
   Carpenter J.W., 2004, EXOTIC ANIMAL FORMUL
   Cicutti NJ, 1999, CAN J CARDIOL, V15, P1267
   Clodi M, 2008, AM J PHYSIOL-ENDOC M, V295, pE686, DOI 10.1152/ajpendo.90263.2008
   Diaz-Cabiale Z, 2000, BRAIN RES, V887, P421, DOI 10.1016/S0006-8993(00)03017-1
   Durosier LD, 2015, PHYSIOL MEAS, V36, DOI 10.1088/0967-3334/36/10/2089
   Ehrentraut S, 2007, ARTERIOSCL THROM VAS, V27, P2170, DOI 10.1161/ATVBAHA.107.146100
   Engeland CG, 2001, PHYSIOL BEHAV, V72, P481, DOI 10.1016/S0031-9384(00)00436-4
   Engler H, 2011, BRAIN BEHAV IMMUN, V25, P1384, DOI 10.1016/j.bbi.2011.04.005
   Engler H, 2009, BRAIN BEHAV IMMUN, V23, P518, DOI 10.1016/j.bbi.2009.01.018
   Fairchild KD, 2011, AM J PHYSIOL-REG I, V300, pR330, DOI 10.1152/ajpregu.00487.2010
   Fairchild KD, 2009, AM J PHYSIOL-REG I, V297, pR1019, DOI 10.1152/ajpregu.00132.2009
   Gamer M, 2012, PSYCHONEUROENDOCRINO, V37, P87, DOI 10.1016/j.psyneuen.2011.05.007
   Gholami M, 2012, SHOCK, V37, P219, DOI 10.1097/SHK.0b013e318240b4be
   Glass L, 2009, CHAOS, V19, DOI 10.1063/1.3156832
   Godin P.J., 1996, EXPT HUMAN ENDOTOXEM
   Higa KT, 2002, AM J PHYSIOL-REG I, V282, pR537
   Huang JA, 2010, J NEURAL TRANSM, V117, P729, DOI 10.1007/s00702-010-0407-6
   Huston JM, 2011, J INTERN MED, V269, P45, DOI 10.1111/j.1365-2796.2010.02321.x
   Jankowski M, 2000, P NATL ACAD SCI USA, V97, P6207, DOI 10.1073/pnas.110137497
   Jankowski M, 2010, BASIC RES CARDIOL, V105, P205, DOI 10.1007/s00395-009-0076-5
   Reyes-Lagos JJ, 2015, PHYSIOL BEHAV, V149, P255, DOI 10.1016/j.physbeh.2015.05.041
   Kemp A.H., 2012, PLOS ONE, V7, P3
   Kit A., 2014, J VET BEHAV, V9, pe15, DOI DOI 10.1016/J.JVEB.2014.09.050
   Lutfi MF, 2011, KHARTOUM MED J, V4, P548
   Mazloom R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082251
   Nikolic VN, 2013, J CARDIOL, V62, P37, DOI 10.1016/j.jjcc.2013.02.013
   Norman GJ, 2011, BIOL PSYCHOL, V86, P174, DOI 10.1016/j.biopsycho.2010.11.006
   Pacheco-Lopez G, 2008, PHYSIOL BEHAV, V93, P261, DOI 10.1016/j.physbeh.2007.08.022
   Pavlov VA, 2003, MOL MED, V9, P125
   Pavlov VA, 2008, INT J CLIN EXP MED, V1, P203
   PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141
   Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005
   Petersson M, 1996, PHYSIOL BEHAV, V60, P1311
   Petersson M, 2001, PEPTIDES, V22, P1479, DOI 10.1016/S0196-9781(01)00469-7
   Petersson M, 1999, J AUTONOM NERV SYST, V78, P49, DOI 10.1016/S0165-1838(99)00061-2
   Radaelli A, 2010, J HYPERTENS, V28, pE528
   Reid ED, 2012, J ANIM SCI, V90, P4788, DOI 10.2527/jas.2011-4705
   Reyes-Lagos J. J., 2014, ADV NEUROIMMUNE BIOL, V5, P75, DOI DOI 10.3233/NIB-140085
   Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039
   Schmid B, 2011, J BIOL RHYTHM, V26, P464, DOI 10.1177/0748730411414264
   Thireau J, 2008, EXP PHYSIOL, V93, P83, DOI 10.1113/expphysiol.2007.040733
   Vela C, 2010, J PHYSIOL PHARMACOL, V61, P59
   Wessel N., 2000, HERZSCHR ELEKTROPHYS, V11, P159, DOI DOI 10.1007/S003990070035)
   Yuan L, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0541-7
   Zila I, 2015, PHYSIOL RES, V64, pS669
NR 49
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD OCT 15
PY 2016
VL 165
BP 223
EP 230
DI 10.1016/j.physbeh.2016.07.013
PG 8
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DY0LS
UT WOS:000384788900028
PM 27450414
ER

PT J
AU Amano, T
   Anzai, M
   Matsumoto, K
AF Amano, Tomoko
   Anzai, Masayuki
   Matsumoto, Kazuya
TI The Clock mutation reduces reproductive performance of mice by affecting
   the implantation capacity: Maternal Clock mutation is not the only
   factor affecting implantation
SO THERIOGENOLOGY
LA English
DT Article
DE Circadian gene; Mouse; Implantation
ID MAMMALIAN CIRCADIAN CLOCK; EMBRYO IMPLANTATION; MUTANT MICE; MOUSE;
   PREGNANCY; OXYTOCIN; RHYTHMS
AB Here, we showed that the Clock gene was important for reproductive performance in mice. We compared outcomes from the four possible mating combinations between wild-type mice (WT) and mice homozygous for the Clock delta-19 mutation (CL). We found that the only significant differences were between the WT male x WT female and CL male x CL female mating groups; these groups differed with regard to elongation of the pregnancy period (19.3 vs. 20.5 days, respectively, P < 0.05) and the number of newborn pups (13.4 +/- 0.8 vs. 8.6 +/- 1.5, respectively, P < 0.05). Because CL dams impregnated by male CLs exhibited normal continuous increases in body weight during the entire gestation period and did not show any signs of spontaneous abortion from mid to late gestation, we reasoned that some embryos were lost before or at the time of implantation. Immediately before implantation (88 hours after fertilization), neither the number of embryos collected from uteri nor the percentage of the embryos that reached the blastocyst stage differed significantly among mating groups. In contrast, immediately after implantation (160 hours after fertilization), the average number of implantation sites was significantly lower for the CL male x CL female mating group than that for the WT male' x WT female mating group (7.0 vs.13.0, P < 0.05); this decrease was accompanied by a significant lowering of the positions of implantation sites in uteri, and this lowering of the implantation sites was more severe when mothers and embryos bore more CL alleles (WT male x WT female > CL male x WT female > WT male x CL female > CL male x CL female), suggesting that the Clock mutation reduced the reproduction performance of the parents by affecting the implantation capacity via such as embryos' ability to implant. (C) 2016 The Author(s). Published by Elsevier Inc.
C1 [Amano, Tomoko; Matsumoto, Kazuya] Kindai Univ, Dept Genet Engn, Coll Biol Oriented Sci & Technol, Wakayama, Japan.
   [Amano, Tomoko] Rakuno Gakuen Univ, Coll Agr Food & Environm Sci, Dept Sustainable Agr, Lab Anim Genet, Ebetsu, Hokkaido, Japan.
   [Anzai, Masayuki] Kindai Univ, Inst Adv Technol, Wakayama, Japan.
RP Amano, T (reprint author), Kindai Univ, Dept Genet Engn, Coll Biol Oriented Sci & Technol, Wakayama, Japan.; Amano, T (reprint author), Rakuno Gakuen Univ, Coll Agr Food & Environm Sci, Dept Sustainable Agr, Lab Anim Genet, Ebetsu, Hokkaido, Japan.
EM amano@rakuno.ac.jp
FU Kanzawa Medical Research Foundation; Japanese Ministry of Education,
   Culture, Sports, and Technology [23780280, 26450383]
FX This work was supported by a grant from the Kanzawa Medical Research
   Foundation, a Grant-in-Aid for Young Scientists (23780280), and a
   Grant-in-Aid for Scientific Research (26450383) from the Japanese
   Ministry of Education, Culture, Sports, and Technology. The funding
   sources had no involvement in study design, data collection, data
   analysis, data interpretation, or writing of the article.
CR Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001
   BOSSMAR T, 1994, AM J OBSTET GYNECOL, V171, P1634
   Chen Q, 2013, MOL ASPECTS MED, V34, P1024, DOI 10.1016/j.mam.2012.07.017
   Cheng TC, 2004, CHINESE J PHYSIOL, V47, P43
   Dolatshad H, 2006, HUM REPROD, V21, P68, DOI 10.1093/humrep/dei313
   Gluckman Peter D, 2004, Semin Fetal Neonatal Med, V9, P419, DOI 10.1016/j.siny.2004.03.001
   Hama K, 2007, BIOL REPROD, V77, P954, DOI 10.1095/biolreprod.107.060293
   Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215
   Hogan B, 1986, MANIPULATING MOUSE E
   Hoshino K, 2006, ENDOCRINOLOGY, V147, P1916, DOI 10.1210/en.2005-1343
   Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9
   King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   MCLAREN A, 1976, J EMBRYOL EXP MORPH, V35, P191
   Miller BH, 2004, CURR BIOL, V14, P1367, DOI 10.1016/j.cub.2004.07.055
   Ochedalski T, 2004, NEUROENDOCRINOL LETT, V25, P278
   Ochi M, 2003, NEUROSCI LETT, V347, P163, DOI 10.1016/S0304-3940(03)00688-8
   Oishi K, 2002, BIOCHEM BIOPH RES CO, V298, P198, DOI 10.1016/S0006-291X(02)02427-0
   QUINN P, 1982, J REPROD FERTIL, V66, P161
   Ratajczak CK, 2012, REPROD FERT DEVELOP, V24, P759, DOI 10.1071/RD11164
   Ratajczak CK, 2009, ENDOCRINOLOGY, V150, P1879, DOI 10.1210/en.2008-1021
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Roizen J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000922
   Sei H, 2001, NEUROREPORT, V12, P1461, DOI 10.1097/00001756-200105250-00033
   Song H, 2002, DEVELOPMENT, V129, P2879
   Sudhansu D, 2006, PHYSL REPROD
   Thouas G. A., 2001, REPROD BIOMED ONLINE, V3, P25, DOI [10.1016/S1472-6483(10)61960-8, DOI 10.1016/S1472-6483(10)61960-8]
   Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505
NR 28
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD OCT 15
PY 2016
VL 86
IS 7
BP 1670
EP 1684
DI 10.1016/j.theriogenology.2016.05.027
PG 15
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DW8WF
UT WOS:000383935500006
PM 27520292
ER

PT J
AU Nagel, C
   Trenk, L
   Aurich, J
   Wulf, M
   Aurich, C
AF Nagel, Christina
   Trenk, Lisa
   Aurich, Joerg
   Wulf, Manuela
   Aurich, Christine
TI Changes in blood pressure, heart rate, and blood profile in mares during
   the last 3 months of gestation and the peripartum period
SO THERIOGENOLOGY
LA English
DT Article
DE Horse; Parturition; Blood pressure; Blood count; Plasma electrolyte
ID RATE-VARIABILITY; NATRIURETIC-PEPTIDE; PLASMA-VOLUME; PREGNANCY;
   OXYTOCIN; HORSES; PARTURITION; POSTPARTUM; SYSTEM; PROGESTERONE
AB In this study, peripartum changes in complete blood count, plasma electrolyte concentrations, blood pressure, heart rate, and heart rate variability (HRV) were determined in pregnant Warmblood mares (n = 10). Blood was collected from Days 245 to 330 of gestation (phase A), 2Days 3 to 1 before foaling (phase B), repeatedly within 12 hours after foaling (phase C), and on Days 1 to 3 postpartum (phase D). On the same days as blood collection, blood pressure and cardiac beat-to-beat intervals were measured and time domain HRV variables were calculated. Blood pressure decreased during the past 3 months of gestation, reached a nadir at foaling and increased rapidly thereafter (P < 0.001). Heart rate increased in phase A, reached a maximum in phase B, and decreased directly after foaling (P < 0.001) while HRV increased transiently after foaling (P < 0.001). The number of polymorphonuclear granulocytes was higher during phases B, C, and D than that during phase A (P < 0.001) and total leukocyte numbers peaked in phase C (P < 0.001). Erythrocyte counts and hematocrit increased immediately after foaling with a rapid decrease thereafter (P < 0.001), while plasma total protein was highest 1 hour after foaling (P < 0.001). Sodium and chloride concentrations increased from phases A to C and decreased in phase D (P < 0.001). Calcium concentrations were lowest immediately after foaling. In conclusion, changes in cardiovascular function and a transient hemoconcentration occur in peripartum mares. These changes may favor adequate uterine perfusion. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Nagel, Christina; Wulf, Manuela] Vetmeduni Vienna, Graf Lehndorff Inst Equine Sci, Neustadt, Germany.
   [Trenk, Lisa; Aurich, Christine] Vetmeduni Vienna, Dept Small Anim & Horses, Ctr Artificial Inseminat & Embryo Transfer, Vienna, Austria.
   [Aurich, Joerg] Vetmeduni Vienna, Dept Small Anim & Horses, Sect Obstet Gynecol & Androl, Vienna, Austria.
RP Nagel, C (reprint author), Vetmeduni Vienna, Graf Lehndorff Inst Equine Sci, Neustadt, Germany.
EM christina.nagel@vetmeduni.ac.at
FU Profillinien grant of the Vetmeduni Vienna [PP 09211432]
FX This study was funded by an internal Profillinien grant of the Vetmeduni
   Vienna (grant number PP 09211432).
CR Andruskevich SM, 2013, PHYSIOL BEHAV, V122, P155, DOI 10.1016/j.physbeh.2013.09.005
   ATHERTON JC, 1982, J PHYSIOL-LONDON, V330, P81
   Bazzano M, 2014, ANIM REPROD SCI, V149, P199, DOI 10.1016/j.anireprosci.2014.07.005
   Beausejour A, 2003, AM J PHYSIOL-HEART C, V285, pH375, DOI 10.1152/ajpheart.01132.2002
   Bedard S, 2005, J PHYSIOL-LONDON, V562, P937, DOI 10.1113/jphysiol.2004.064683
   Bernstein IM, 2001, OBSTET GYNECOL, V97, P669, DOI 10.1016/S0029-7844(00)01222-9
   BLANCHARD TL, 1986, THERIOGENOLOGY, V25, P347, DOI 10.1016/0093-691X(86)90070-1
   Bollwein H, 2004, THERIOGENOLOGY, V61, P499, DOI 10.1016/S0093-691X(03)00225-5
   Brunton PJ, 2008, J PHYSIOL PHARMACOL, V59, P27
   CORUZZI G, 1989, J VET PHARMACOL THER, V12, P404, DOI 10.1111/j.1365-2885.1989.tb00691.x
   Favaretto AIV, 1997, PEPTIDES, V18, P1377, DOI 10.1016/S0196-9781(97)00209-X
   Ginther OJ, 1996, J EQUINE VET SCI, V16, P159, DOI 10.1016/S0737-0806(96)80131-6
   HALUSKA GJ, 1988, J REPROD FERTIL, V84, P635
   Harvey JW, 2005, VET CLIN PATH, V34, P248, DOI 10.1111/j.1939-165X.2005.tb00049.x
   HILLMAN RB, 1975, J REPROD FERTIL, P641
   HOLMES J. R., 1966, CAN VETERINARY J, V7, P280
   HUNTER S, 1992, BRIT HEART J, V68, P540
   Ille N, 2014, J VET BEHAV, V9, P341, DOI 10.1016/j.jveb.2014.07.006
   Klewitz J, 2015, THERIOGENOLOGY, V83, P721, DOI 10.1016/j.theriogenology.2014.11.007
   Lumbers ER, 2014, AM J PHYSIOL-REG I, V306, pR91, DOI 10.1152/ajpregu.00034.2013
   Magdesian KG, 2004, VET CLIN N AM-EQUINE, V20, P11, DOI 10.1016/j.cveq.2003.12.001
   Mariella J, 2014, THERIOGENOLOGY, V81, P526, DOI 10.1016/j.theriogenology.2013.11.001
   Moll W, 2001, Z KARDIOL, V90, P2
   MOSELEY G, 1973, J AGR SCI, V81, P403
   Mukaddam-Daher S, 2001, HYPERTENSION, V38, P292
   Mukaddam-Daher S, 2002, J ENDOCRINOL, V175, P211, DOI 10.1677/joe.0.1750211
   Nagel C, 2012, THERIOGENOLOGY, V78, P759, DOI 10.1016/j.theriogenology.2012.03.023
   Nagel C, 2010, THERIOGENOLOGY, V73, P973, DOI 10.1016/j.theriogenology.2009.11.026
   Nagel C, 2014, THERIOGENOLOGY, V82, P160, DOI 10.1016/j.theriogenology.2014.03.015
   PARRY BW, 1982, AM J VET RES, V43, P50
   Pearsson SGB, 1973, ZENTRALBL VET A, V20, P456
   Broughton Pipkin F, 1982, J REPROD FERTIL S, V32, P555
   Rosseland LA, 2013, ANESTHESIOLOGY, V119, P541, DOI 10.1097/ALN.0b013e31829416dd
   Satue K, 2011, THERIOGENOLOGY, V76, P1404, DOI 10.1016/j.theriogenology.2011.06.009
   Schmidt A, 2010, HORM BEHAV, V57, P209, DOI 10.1016/j.yhbeh.2009.11.003
   Stull CL, 2002, EQUINE VET J, V34, P550, DOI 10.2746/042516402776180214
   SULLIVAN CA, 1994, CLIN OBSTET GYNECOL, V37, P558, DOI 10.1097/00003081-199409000-00009
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
   Toyoshima Masafumi, 2015, J Med Case Rep, V9, P84, DOI 10.1186/s13256-015-0553-4
   Ueno T, 2010, EQUINE VET J, V42, P529, DOI 10.1111/j.2042-3306.2010.00090.x
   Vivrette SL, 2000, J REPROD FERTIL, V119, P347, DOI 10.1530/reprod/119.2.347
   WEIS FR, 1975, OBSTET GYNECOL, V46, P211
   Williams NM, 2012, J EQUINE VET SCI, V32, P281, DOI 10.1016/j.jevs.2011.11.002
NR 43
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD OCT 15
PY 2016
VL 86
IS 7
BP 1856
EP 1864
DI 10.1016/j.theriogenology.2016.06.001
PG 9
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DW8WF
UT WOS:000383935500025
PM 27393220
ER

PT J
AU De Molo, VU
   Saldanha, RRM
   Dos Santos, CR
   Cruz, JD
   Lira, VA
   Santana, VJ
   Michelini, LC
AF De Molo, Vitor U.
   Saldanha, Rayssa R. M.
   Dos Santos, Carla R.
   Cruz, Josiane De Campos
   Lira, Vitor A.
   Santana-Filho, Valter J.
   Michelini, Lisete C.
TI Ovarian Hormone Deprivation Reduces Oxytocin Expression in
   Paraventricular Nucleus Preautonomic Neurons and Correlates with
   Baroreflex Impairment in Rats
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE baroreflex; oxytocin; arterial pressure; autonomic nervous system;
   ovariectomy
ID ESTROGEN-RECEPTOR-BETA; TRAINING-INDUCED PLASTICITY;
   CONGESTIVE-HEART-FAILURE; AUTONOMIC NERVOUS-SYSTEM; SYMPATHOVAGAL
   BALANCE; OVARIECTOMIZED RATS; OXIDATIVE STRESS; BLOOD-PRESSURE;
   BRAIN-STEM; EXERCISE
AB The prevalence of cardiovascular diseases including hypertension increases dramatically in women after menopause, however the mechanisms involved remain incompletely understood. Oxytocinergic (OTergic) neurons are largely present within the paraventricular nucleus of the hypothalamus (PVN). Several studies have shown that OTergic drive from PVN to brainstem increases baroreflex sensitivity and improves autonomic control of the circulation. Since preautonomic PVN neurons express different types of estrogen receptors, we hypothesize that ovarian hormone deprivation causes baroreflex impairment, autonomic imbalance and hypertension by negatively impacting OTergic drive and oxytocin levels in pre-autonomic neurons. Here, we assessed oxytocin gene and protein expression (qPCR and immunohistochemistry) within PVN subnuclei in sham-operated and ovariectomized Wistar rats. Conscious hemodynamic recordings were used to assess resting blood pressure and heart rate and the autonomic modulation of heart and vessels was estimated by power spectral analysis. We observed that the ovarian hormone deprivation in ovariectomized rats decreased baroreflex sensitivity, increased sympathetic and reduced vagal outflows to the heart and augmented the resting blood pressure. Of note, ovariectomized rats had reduced PVN oxytocin mRNA and protein expression in all pre-autonomic PVN subnuclei. Furthermore, reduced PVN oxytocin protein levels were positively correlated with decreased baroreflex sensitivity and negatively correlated with increased LF/HF ratio. These findings suggest that reduced oxytocin expression in OTergic neurons of the PVN contributes to the baroreflex dysfunction and autonomic dysregulation observed with ovarian hormone deprivation.
C1 [De Molo, Vitor U.; Saldanha, Rayssa R. M.; Santana-Filho, Valter J.] Univ Fed Sergipe, Dept Physiol, Sao Cristovao, Brazil.
   [De Molo, Vitor U.; Lira, Vitor A.] Univ Iowa, Pappajohn Biomed Inst, Fraternal Order Eagles Diabet Res Ctr,Abboud Card, Obes Res & Educ Initiat,Dept Hlth & Human Physiol, Iowa City, IA 52242 USA.
   [Dos Santos, Carla R.; Michelini, Lisete C.] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil.
   [Cruz, Josiane De Campos] Univ Fed Paraiba, Dept Biotechnol, Joao Pessoa, Paraiba, Brazil.
RP Michelini, LC (reprint author), Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil.
EM michelin@usp.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [BEX
   6292/15-1]; Fundacao de Apoio a Pesquisa e Inovacao Tecnologica do
   Estado de Sergipe (FAPITEC-SE); Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2011/51410-9]
FX This work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES/ Proc BEX 6292/15-1), Fundacao de Apoio a Pesquisa
   e Inovacao Tecnologica do Estado de Sergipe (FAPITEC-SE) and Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, proc 2011/51410-9). LM
   is a Research Fellow of CNPq.
CR ADAMOPOULOS S, 1992, AM J CARDIOL, V70, P1576, DOI 10.1016/0002-9149(92)90460-G
   Alves SE, 1998, P NATL ACAD SCI USA, V95, P3281, DOI 10.1073/pnas.95.6.3281
   APPEL ML, 1989, J AM COLL CARDIOL, V14, P1139, DOI 10.1016/0735-1097(89)90408-7
   BECKER RC, 1990, CARDIOLOGY, V77, P6, DOI 10.1159/000174648
   BILLMAN GE, 1982, CIRCULATION, V66, P874
   Braga DC, 2000, AM J PHYSIOL-REG I, V278, pR1474
   Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017
   BUIJS RM, 1978, CELL TISSUE RES, V192, P423
   Burr RL, 2007, SLEEP, V30, P913
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Cavalleri MT, 2011, AM J PHYSIOL-REG I, V301, pR958, DOI 10.1152/ajpregu.00104.2011
   Cruz JC, 2013, EXP PHYSIOL, V98, P386, DOI 10.1113/expphysiol.2012.065888
   DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323
   Dias DPM, 2010, BRAZ J MED BIOL RES, V43, P969, DOI 10.1590/S0100-879X2010001000008
   Eisenhofer G, 1996, CIRCULATION, V93, P1667
   Flues K, 2010, MATURITAS, V65, P267, DOI 10.1016/j.maturitas.2009.11.007
   Geerling JC, 2010, J COMP NEUROL, V518, P1460, DOI 10.1002/cne.22283
   Golden SH, 2002, AM J EPIDEMIOL, V155, P437, DOI 10.1093/aje/155.5.437
   GUZZETTI S, 1995, EUR HEART J, V16, P1100
   Hernandez I, 2000, AM J PHYSIOL-REG I, V279, pR1599
   Higa KT, 2002, AM J PHYSIOL-REG I, V282, pR537
   Higa-Taniguchi KT, 2007, AM J PHYSIOL-REG I, V292, pR1717, DOI 10.1152/ajpregu.00613.2006
   Higa-Taniguchi KT, 2009, EXP PHYSIOL, V94, P1103, DOI 10.1113/expphysiol.2009.049262
   Hrabovszky E, 1998, ENDOCRINOLOGY, V139, P2600, DOI 10.1210/en.139.5.2600
   Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b
   JANSSEN BJA, 1995, AM J PHYSIOL-HEART C, V269, pH62
   JENSEN J, 1990, MATURITAS, V12, P321, DOI 10.1016/0378-5122(90)90012-U
   Lizcano F, 2014, BIOMED RES INT, V2014, DOI [DOI 10.1155/2014/757461, 10.1155/2014/757461]
   MALLIANI A, 1991, CIRCULATION, V84, P482
   Mercuro G, 2000, AM J CARDIOL, V85, P787, DOI 10.1016/S0002-9149(99)00865-6
   Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449
   Michelini LC, 2007, CLIN EXP PHARMACOL P, V34, P369, DOI 10.1111/j.1440-1681.2007.04589.x
   MILLER FD, 1989, P NATL ACAD SCI USA, V86, P2468, DOI 10.1073/pnas.86.7.2468
   Moak JP, 2007, HEART RHYTHM, V4, P1523, DOI 10.1016/j.hrthm.2007.07.019
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A
   Nickenig G, 1998, CIRCULATION, V97, P2197
   Oliveira LR, 2012, AUTON NEUROSCI-BASIC, V167, P45, DOI 10.1016/j.autneu.2011.12.004
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Patisaul HB, 2003, J NEUROENDOCRINOL, V15, P787, DOI 10.1046/j.1365-2826.2003.01061.x
   Paxinos G, 2006, RAT BRAIN STEREOTAXI
   Peters JH, 2008, J NEUROSCI, V28, P11731, DOI 10.1523/JNEUROSCI.3419-08.2008
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pinol RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112138
   Re Richard N, 2009, Ochsner J, V9, P133
   Rienzo M. D., 1995, COMPUTER ANAL CARDIO
   Skrapari I, 2007, OBESITY, V15, P1685, DOI 10.1038/oby.2007.201
   Sladek CD, 2015, COMPR PHYSIOL, V5, P1281, DOI 10.1002/cphy.c140028
   Stauss HM, 2007, CLIN EXP PHARMACOL P, V34, P362, DOI 10.1111/j.1440-1681.2007.04588.x
   Stern JE, 2003, BRAIN RES, V975, P99, DOI 10.1016/S0006-8993(03)02594-0
   Taddei S, 1996, HYPERTENSION, V28, P576
   TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583
   WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406
NR 54
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 13
PY 2016
VL 7
AR 461
DI 10.3389/fphys.2016.00461
PG 9
WC Physiology
SC Physiology
GA DY7IR
UT WOS:000385303500001
ER

PT J
AU Shah, P
   Catmur, C
   Bird, G
AF Shah, Punit
   Catmur, Caroline
   Bird, Geoffrey
TI Emotional decision-making in autism spectrum disorder: the roles of
   interoception and alexithymia
SO MOLECULAR AUTISM
LA English
DT Article
DE Autism; Emotion; Replication; Insula; Alexithymia; Interoception;
   Framing effect; Decision-making
ID FUNCTIONAL CONNECTIVITY; ANXIETY; AWARENESS; BRAIN; PERCEPTION; INSULA;
   HEART; DEPRESSION; EXPERIENCE; OXYTOCIN
AB The way choices are framed influences decision-making. These "framing effects" emerge through the integration of emotional responses into decision-making under uncertainty. It was previously reported that susceptibility to the framing effect was reduced in individuals with autism spectrum disorder (ASD) due to a reduced tendency to incorporate emotional information into the decision-making process. However, recent research indicates that, where observed, emotional processing impairments in ASD may be due to co-occurring alexithymia. Alexithymia is thought to arise due to impaired interoception (the ability to perceive the internal state of one's body), raising the possibility that emotional signals are not perceived and thus not integrated into decision-making in those with alexithymia and that therefore reduced framing effects in ASD are a product of co-occurring alexithymia rather than ASD per se. Accordingly, the present study compared framing effects in autistic individuals with neurotypical controls matched for alexithymia. Results showed a marked deviation between groups. The framing effect was, in line with previous data, significantly smaller in autistic individuals, and there was no relationship between alexithymia or interoception and decision-making in the ASD group. In the neurotypical group, however, the size of the framing effect was associated with alexithymia and interoception, even after controlling for autistic traits. These results demonstrate that although framing effects are associated with interoception and alexithymia in the neurotypical population, emotional and interoceptive signals have less impact upon the decision-making process in ASD.
C1 [Shah, Punit] Univ London, Kings Coll London, Dept Neuroimaging, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England.
   [Catmur, Caroline] Univ London, Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England.
   [Bird, Geoffrey] UCL, Inst Cognit Neurosci, London, England.
   [Bird, Geoffrey] Univ London, Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC SGDP Ctr, London, England.
RP Shah, P (reprint author), Univ London, Kings Coll London, Dept Neuroimaging, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England.
EM punit.shah@kcl.ac.uk
FU Medical Research Council; Baily Thomas Charitable Fund "Interoception
   and Autism Spectrum Disorders"
FX P.S. is supported by the Medical Research Council. G.B. is supported by
   a grant from the Baily Thomas Charitable Fund "Interoception and Autism
   Spectrum Disorders."
CR Ainley V, 2014, NEUROPSYCHOLOGIA, V60, P21, DOI 10.1016/j.neuropsychologia.2014.05.010
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Barrett LF, 2015, NAT REV NEUROSCI, V16, P419, DOI 10.1038/nrn3950
   Bernhardt BC, 2014, CEREB CORTEX, V24, P3258, DOI 10.1093/cercor/bht182
   Berthoz S, 1999, EUR PSYCHIAT, V14, P372, DOI 10.1016/S0924-9338(99)00233-3
   Bird G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.61
   Bird G, 2011, J AUTISM DEV DISORD, V41, P1556, DOI 10.1007/s10803-011-1183-3
   Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060
   Brewer R, 2015, R SOC OPEN SCI, V2
   Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Brewer R, 2015, J ABNORM PSYCHOL, V124, P589, DOI 10.1037/abn0000076
   Brosnan M, 2016, J AUTISM DEV DISORD, V46, P2115, DOI 10.1007/s10803-016-2742-4
   Cook R, 2013, PSYCHOL SCI, V24, P723, DOI 10.1177/0956797612463582
   Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176
   Dawson M, 2007, PSYCHOL SCI, V18, P657, DOI 10.1111/j.1467-9280.2007.01954.x
   De Martino B, 2008, J NEUROSCI, V28, P10746, DOI 10.1523/JNEUROSCI.2895-08.2008
   De Martino B, 2006, SCIENCE, V313, P684, DOI 10.1126/science.1128356
   De Martino B, 2012, NEUROSCIENCE OF PREFERENCE AND CHOICE: COGNITIVE AND NEURAL MECHANISMS, P93, DOI 10.1016/B978-0-12-381431-9.00005-X
   DuBois D, 2016, INT J DEV NEUROSCI, V52, P104, DOI 10.1016/j.ijdevneu.2016.05.001
   Dunn BD, 2010, PSYCHOL SCI, V21, P1835, DOI 10.1177/0956797610389191
   Eizaguirre AE, 2004, PERS INDIV DIFFER, V36, P321, DOI 10.1016/S0191-8869(03)00099-0
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149
   Fiene L, 2015, AUTISM RES, V8, P709, DOI 10.1002/aur.1486
   Fitzgerald M, 2004, AM J PSYCHIAT, V161, P2134, DOI 10.1176/appi.ajp.161.11.2134
   Foulkes L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121018
   Frith CD, 2008, PHILOS T R SOC B, V363, P3875, DOI 10.1098/rstb.2008.0156
   Gaigg S, AUTISM IN PRESS
   Garfinkel SN, 2016, BIOL PSYCHOL, V114, P117, DOI 10.1016/j.biopsycho.2015.12.003
   Garfinkel SN, 2015, BIOL PSYCHOL, V104, P65, DOI 10.1016/j.biopsycho.2014.11.004
   Garfinkel SN, 2013, SOC COGN AFFECT NEUR, V8, P231, DOI 10.1093/scan/nss140
   Griffin C, 2016, AUTISM RES, V9, P773, DOI 10.1002/aur.1569
   Hartley CA, 2012, BIOL PSYCHIAT, V72, P113, DOI 10.1016/j.biopsych.2011.12.027
   Herbert BM, 2011, J PERS, V79, P1149, DOI 10.1111/j.1467-6494.2011.00717.x
   Hill E, 2004, J AUTISM DEV DISORD, V34, P229, DOI 10.1023/B:JADD.0000022613.41399.14
   Hogeveen J, 2016, NEUROPSYCHOLOGIA, V82, P142, DOI 10.1016/j.neuropsychologia.2016.01.021
   Jorgensen MM, 2007, PSYCHOTHER PSYCHOSOM, V76, P369, DOI 10.1159/000107565
   Kahneman D, 2007, TRENDS COGN SCI, V11, P45, DOI 10.1016/j.tics.2006.11.007
   Kelley K, 2007, BEHAV RES METHODS, V39, P979, DOI 10.3758/BF03192993
   Kenny L, 2015, AUTISM, P55
   Livingston LA, 2016, FRONT PSYCHOL, V7, DOI [10.3389/fpsyg.2016.01103, 10.3389/fpsyci.2016.01103]
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   Maximo JO, 2014, NEUROPSYCHOL REV, V24, P16, DOI 10.1007/s11065-014-9250-0
   Meissner K, 2011, BIOL PSYCHOL, V86, P289, DOI 10.1016/j.biopsycho.2011.01.001
   Mottron L, 2006, J AUTISM DEV DISORD, V36, P27, DOI 10.1007/s10803-005-0040-7
   Patil I, 2016, SCI REP-UK, V6, DOI 10.1038/srep23637
   Paulus MP, 2010, BRAIN STRUCT FUNCT, V214, P451, DOI 10.1007/s00429-010-0258-9
   Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017
   Peirce Jonathan W, 2008, Front Neuroinform, V2, P10, DOI 10.3389/neuro.11.010.2008
   Preuschoff K, 2008, J NEUROSCI, V28, P2745, DOI 10.1523/JNEUROSCI.4286-07.2008
   Quattrocki E, 2014, NEUROSCI BIOBEHAV R, V47, P410, DOI 10.1016/j.neubiorev.2014.09.012
   Rausch A, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-015-0060-x
   Reyna VF, 2015, CHILD DEV PERSPECT, V9, P122, DOI 10.1111/cdep.12117
   Roiser JP, 2009, J NEUROSCI, V29, P5985, DOI 10.1523/JNEUROSCI.0407-09.2009
   SCHANDRY R, 1981, PSYCHOPHYSIOLOGY, V18, P483, DOI 10.1111/j.1469-8986.1981.tb02486.x
   Schauder KB, 2015, J EXP CHILD PSYCHOL, V131, P193, DOI 10.1016/j.jecp.2014.11.002
   Seth AK, 2013, TRENDS COGN SCI, V17, P565, DOI 10.1016/j.tics.2013.09.007
   Shah P, 2016, J AUTISM DEV DISORD, V46, P3193, DOI 10.1007/s10803-016-2848-8
   Shah P, 2016, CORTEX, V81, P215, DOI 10.1016/j.cortex.2016.03.021
   Silani G, 2008, SOC NEUROSCI, V3, P97, DOI 10.1080/17470910701577020
   Singer T, 2009, TRENDS COGN SCI, V13, P334, DOI 10.1016/j.tics.2009.05.001
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Stevenson JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059329
   Sutterlin S, 2013, COGNITIVE SCI, V37, P922, DOI 10.1111/cogs.12036
   Swartz JR, 2013, J AM ACAD CHILD PSY, V52, P84, DOI 10.1016/j.jaac.2012.10.012
   TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683
   Wallace GL, 2008, RES AUTISM SPECT DIS, V2, P447, DOI 10.1016/j.rasd.2007.09.005
   Wechsler D, 2013, WASI 2 WECHSLER ABBR
   Wechsler D., 1997, WECHSLER ADULT INTEL
   Wechsler D., 2008, WECHSLER ADULT INTEL
   Xu PF, 2013, J NEUROSCI, V33, P18641, DOI 10.1523/JNEUROSCI.1253-13.2013
NR 72
TC 0
Z9 0
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2040-2392
J9 MOL AUTISM
JI Mol. Autism
PD OCT 13
PY 2016
VL 7
AR 43
DI 10.1186/s13229-016-0104-x
PG 10
WC Genetics & Heredity; Neurosciences
SC Genetics & Heredity; Neurosciences & Neurology
GA DZ3FT
UT WOS:000385731300001
PM 27777716
ER

PT J
AU Refuerzo, JS
   Leonard, F
   Bulayeva, N
   Gorenstein, D
   Chiossi, G
   Ontiveros, A
   Longo, M
   Godin, B
AF Refuerzo, Jerrie S.
   Leonard, Fransisca
   Bulayeva, Nataliya
   Gorenstein, David
   Chiossi, Giuseppe
   Ontiveros, Alejandra
   Longo, Monica
   Godin, Biana
TI Uterus-targeted liposomes for preterm labor management: studies in
   pregnant mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN MYOMETRIAL CONTRACTILITY; ADVANCING GESTATIONAL-AGE;
   OVER-THE-COUNTER; DUCTUS-ARTERIOSUS; INDOMETHACIN TOCOLYSIS; DRUG
   TRANSFER; CYCLOOXYGENASE INHIBITORS; CLINICAL-TRIAL; HUMAN PLACENTA;
   DOUBLE-BLIND
AB Preterm labor caused by uterine contractions is a major contributor to neonatal morbidity and mortality. Treatment intended to reduce uterine contractions include tocolytic agents, such as indomethacin. Unfortunately, clinically used tocolytics are frequently inefficient and cross the placenta causing fetal side effects. Here we show for the first time in obstetrics the use of a targeted nanoparticle directed to the pregnant uterus and loaded with a tocolytic for reducing its placental passage and sustaining its efficacy. Nanoliposomes encapsulating indomethacin and decorated with clinically used oxytocin receptor antagonist were designed and evaluated in-vitro, ex-vivo and in-vivo. The proposed approach resulted in targeting uterine cells in-vitro, inhibiting uterine contractions ex-vivo, while doubling uterine drug concentration, decreasing fetal levels, and maintaining the preterm birth rate in vivo in a pregnant mouse model. This promising approach opens new horizons for drug development in obstetrics that could greatly impact preterm birth, which currently has no successful treatments.
C1 [Refuerzo, Jerrie S.; Ontiveros, Alejandra; Longo, Monica] Univ Texas Hlth Sci Ctr Houston, Dept Obstet Gynecol & Reprod Sci, Div Maternal Fetal Med, Houston, TX 77030 USA.
   [Leonard, Fransisca; Godin, Biana] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA.
   [Bulayeva, Nataliya; Gorenstein, David] Univ Texas Hlth Sci Ctr Houston, Dept NanoMed & Biomed Engn, Houston, TX 77030 USA.
   [Chiossi, Giuseppe] Univ Texas Med Branch, Dept Obstet & Gynecol, Div Maternal Fetal Med, Galveston, TX 77555 USA.
RP Refuerzo, JS (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Obstet Gynecol & Reprod Sci, Div Maternal Fetal Med, Houston, TX 77030 USA.; Godin, B (reprint author), Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA.
EM Jerrie.S.Refuerzo@uth.tmc.edu; bianagodinv@gmail.com
FU Eunice Kennedy Shriver National Institute of Child Health & Human
   Development of the National Institutes of Health [R21HD08947]
FX Research reported in this publication was supported by the Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   of the National Institutes of Health under Award Number R21HD08947. We
   would also like to thank Francesca Ferrari, M.D., Esther Tamayo, and Lan
   Yongsheng for assisting in the conduction of the in vivo, ex vivo and in
   vitro experiments.
CR Abramovici A, 2012, OBSTET GYN CLIN N AM, V39, P77, DOI 10.1016/j.ogc.2011.12.003
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   BESINGER RE, 1991, AM J OBSTET GYNECOL, V164, P981
   Chioss G, 2012, AM J PERINAT, V29, P699, DOI 10.1055/s-0032-1314891
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Flenady V, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004452.pub3
   Garland M, 1998, OBSTET GYN CLIN N AM, V25, P21, DOI 10.1016/S0889-8545(05)70356-9
   Glover DD, 2003, AM J OBSTET GYNECOL, V188, P1039, DOI 10.1067/mob.2003.223
   HALLAK M, 1993, AM J OBSTET GYNECOL, V168, P865
   HALLAK M, 1992, AM J OBSTET GYNECOL, V167, P1059
   Harrod JS, 2011, AM J PHYSIOL-ENDOC M, V301, pE362, DOI 10.1152/ajpendo.00696.2010
   HENDRICKS SK, 1990, BRIT J OBSTET GYNAEC, V97, P312, DOI 10.1111/j.1471-0528.1990.tb01807.x
   Karadas B, 2004, EUR J PHARMACOL, V485, P289, DOI 10.1016/j.ejphar.2003.11.055
   Keelan JA, 2015, NANOMEDICINE-UK, V10, P2229, DOI [10.2217/nnm.15.48, 10.2217/NNM.15.48]
   King A, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600349
   KIRSHON B, 1991, AM J PERINAT, V8, P86, DOI 10.1055/s-2007-999349
   Klauser CK, 2014, J MATERN-FETAL NEO M, V27, P801, DOI 10.3109/14767058.2013.847416
   KURKI T, 1991, OBSTET GYNECOL, V78, P1093
   Lee PR, 2003, AM J OBSTET GYNECOL, V189, P261, DOI 10.1067/mob.2003.485
   Longo M, 2003, MOL HUM REPROD, V9, P159, DOI 10.1093/molehr/gag023
   MAJOR CA, 1994, AM J OBSTET GYNECOL, V170, P102
   March of Dimes, 2015, PREM BIRTH REP CARD
   Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1
   Matthews T J, 2015, Natl Vital Stat Rep, V64, P1
   McCallum LA, 2011, J CELL MOL MED, V15, P577, DOI 10.1111/j.1582-4934.2010.01021.x
   McCloskey C, 2014, EMBO MOL MED, V6, P1161, DOI 10.15252/emmm.201403944
   MOISE KJ, 1993, AM J OBSTET GYNECOL, V168, P1350
   MOISE KJ, 1990, AM J OBSTET GYNECOL, V162, P549
   MOMMA K, 1987, PEDIATR RES, V22, P567, DOI 10.1203/00006450-198711000-00018
   Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095/biolreprod55.2.427
   MORALES WJ, 1993, AM J OBSTET GYNECOL, V169, P97
   NIEBYL JR, 1980, AM J OBSTET GYNECOL, V136, P1014
   Ohmichi M, 1997, ENDOCRINOLOGY, V138, P3103, DOI 10.1210/en.138.8.3103
   Panter KR, 1999, BRIT J OBSTET GYNAEC, V106, P467, DOI 10.1111/j.1471-0528.1999.tb08300.x
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Refuerzo JS, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.02.006
   Refuerzo JS, 2005, AM J PERINAT, V22, P321, DOI 10.1055/s2005-873235
   Reinebrant HE, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001992.pub3
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Sakai M, 2001, MOL HUM REPROD, V7, P595, DOI 10.1093/molehr/7.6.595
   Sawdy R, 1998, BRIT J PHARMACOL, V125, P1212, DOI 10.1038/sj.bjp.0702211
   Sawdy RJ, 2003, EUR J OBSTET GYN R B, V109, P33, DOI 10.1016/S0301-2115(02)00481-5
   SCHROCK A, 1989, AM J PERINAT, V6, P191, DOI 10.1055/s-2007-999574
   Slattery MM, 2001, OBSTET GYNECOL, V98, P563, DOI 10.1016/S0029-7844(01)01522-8
   Srinath P, 2000, DRUG DEV IND PHARM, V26, P313, DOI 10.1081/DDC-100100359
   Suarez RD, 2001, OBSTET GYNECOL, V97, P921, DOI 10.1016/S0029-7844(01)01356-4
   Suarez VR, 2002, AM J OBSTET GYNECOL, V187, P886, DOI 10.1067/mob.2002.127464
   Syme MR, 2004, CLIN PHARMACOKINET, V43, P487, DOI 10.2165/00003088-200443080-00001
   Tasciotti E, 2011, MOL IMAGING, V10, P56, DOI 10.2310/7290.2011.00011
   Touitou E., 2006, ENHANCEMENT DRUG DEL, P255
   van der Aa EM, 1998, PHARM WORLD SCI, V20, P139, DOI 10.1023/A:1008656928861
   Vermillion ST, 1997, AM J OBSTET GYNECOL, V177, P256, DOI 10.1016/S0002-9378(97)70184-4
   [Anonymous], PRET BIRTH
   WIKLAND M, 1982, ACTA OBSTET GYN SCAN, V61, P467
   [Anonymous], 2016, OBSTET GYNECOL, V127, pe39
   [Anonymous], 2016, OBSTET GYNECOL, V127, pe29
NR 56
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 11
PY 2016
VL 6
AR 34710
DI 10.1038/srep34710
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DY6MT
UT WOS:000385242100001
PM 27725717
ER

PT J
AU Day, LT
   Hruschka, D
   Mussell, F
   Jeffers, E
   Saha, SL
   Alam, S
AF Day, Louise T.
   Hruschka, Daniel
   Mussell, Felicity
   Jeffers, Eva
   Saha, Stacy L.
   Alam, Shafiul
TI Perinatal mortality associated with use of uterotonics outside of
   Comprehensive Emergency Obstetric and Neonatal Care: a cross-sectional
   study
SO REPRODUCTIVE HEALTH
LA English
DT Article
DE Perinatal mortality; Uterotonics; Bangladesh; Stillbirth; Neonatal
   death; Child survival; Under-five mortality
ID OXYTOCIN; INDIA; LABOR
AB Background: Prior studies have shown that using uterotonics to augment or induce labor before arrival at comprehensive Emergency Obstetric and Neonatal Care (CEmONC) settings (henceforth, "outside uterotonics") may contribute to perinatal mortality in low-and middle-income countries. We estimate its effect on perinatal mortality in rural Bangladesh.
   Methods: Using hospital records (23986 singleton term births, Jan 1, 2009-Dec 31, 2015) from rural Bangladesh, we use a logistic regression model to estimate the increased risk of perinatal death from uterotonics administered outside a CEmONC facility.
   Results: Among term births (>= 37 weeks gestation), the risk of perinatal death adjusted for key confounders is significantly increased among women reporting uterotonic use outside of CEmONC (OR = 3.0, 95 % CI = 2.4,3.7). This increased risk is particularly high for fresh stillbirths (OR = 4.0, 95 % CI = 3.0,5.3) and intrapartum-related causes of early neonatal deaths (birth asphyxia) (OR = 3.1, 95 % CI = 2.2,4.5).
   Conclusions: In this sample, outside uterotonic use was associated with substantially increased risk of fresh stillbirths, deaths due to birth asphyxia, and all perinatal deaths. In settings of high uterotonic use outside of controlled settings, substantial improvement in both stillbirth and early neonatal mortality may be made by reducing such use.
C1 [Day, Louise T.; Saha, Stacy L.; Alam, Shafiul] LAMB MIS Res Dept, Parbatipur 5250, Dinajpur, Bangladesh.
   [Day, Louise T.] LAMB Hosp, Dept Pediat, Parbatipur 5250, Dinajpur, Bangladesh.
   [Hruschka, Daniel; Jeffers, Eva] Arizona State Univ, Tempe, AZ 85287 USA.
   [Mussell, Felicity] LAMB Hosp, Dept Obstet, Parbatipur 5250, Dinajpur, Bangladesh.
RP Day, LT (reprint author), LAMB MIS Res Dept, Parbatipur 5250, Dinajpur, Bangladesh.; Day, LT (reprint author), LAMB Hosp, Dept Pediat, Parbatipur 5250, Dinajpur, Bangladesh.
EM louisetday@gmail.com
CR Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2
   Brhlikova P, 2009, J HLTH STUDIES, V2, P33
   Darmstadt GL, 2014, LANCET, V384, P174, DOI 10.1016/S0140-6736(14)60458-X
   Day LT, 2011, ASCON ANN SCI C INT
   de Bernis L, LANCET
   FINNSTROM O, 1977, ACTA PAEDIATR SCAND, V66, P601, DOI 10.1111/j.1651-2227.1977.tb07954.x
   Flandermeyer D, 2010, INT J GYNECOL OBSTET, V108, P269, DOI 10.1016/j.ijgo.2009.12.001
   Iyengar SD, 2009, J HEALTH POPUL NUTR, V27, P303
   Jeffery P, 2008, CONTRIB INDIAN SOC, V42, P59, DOI 10.1177/006996670704200104
   Jeffery P, 2007, REPROD HEALTH MATTER, V15, P172, DOI 10.1016/S0968-8080(07)30320-0
   Jeffery P, 2010, SOC SCI MED, V71, P1711, DOI 10.1016/j.socscimed.2010.05.002
   Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5
   Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3
   Liu L., 2014, LANCET
   Lovold A, 2008, INT J GYNECOL OBSTET, V103, P276, DOI 10.1016/j.ijgo.2008.08.009
   Moran AC, 2010, BJOG-INT J OBSTET GY, V117, P1608, DOI 10.1111/j.1471-0528.2010.02714.x
   Mullany LC, 2013, INT J GYNECOL OBSTET, V122, P22, DOI 10.1016/j.ijgo.2013.02.013
   Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080
   Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15
NR 19
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4755
J9 REPROD HEALTH
JI Reprod. Health
PD OCT 6
PY 2016
VL 13
AR 129
DI 10.1186/s12978-016-0241-x
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY2VH
UT WOS:000384949700001
PM 27716260
ER

PT J
AU Hicks, C
   Ramos, L
   Dampney, B
   Baracz, SJ
   McGregor, IS
   Hunt, GE
AF Hicks, Callum
   Ramos, Linnet
   Dampney, Bruno
   Baracz, Sarah J.
   McGregor, Iain S.
   Hunt, Glenn E.
TI Regional c-Fos expression induced by peripheral oxytocin administration
   is prevented by the vasopressin 1A receptor antagonist SR49059
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Oxytocin; Vasopressin 1A receptor; SR49059; c-Fos; Locomotor activity;
   Hypothalamus
ID RANDOMIZED CONTROLLED-TRIAL; MALE-RATS; INTRANASAL OXYTOCIN;
   PARAVENTRICULAR NUCLEUS; ADMINISTERED OXYTOCIN; SOCIAL RECOGNITION;
   LOCOMOTOR-ACTIVITY; STRIA TERMINALIS; CENTRAL AMYGDALA; BED NUCLEUS
AB Peripherally administered oxytocin induces a wide range of behavioural and physiological effects that are thought to be mediated by the oxytocin receptor (OTR). However, oxytocin also has considerable affinity for the vasopressin 1A receptor (VAR), such that various oxytocinergic effects may in fact be mediated by the VAR rather than the OTR. Here we used c-Fos immunohistochemistry to determine the extent to which the regional pattern of neuronal activation produced by peripheral oxytocin involves the V1AR. Male Wistar rats were administered oxytocin (1 mg/kg, IP) alone, or following pre-treatment with the V1AR antagonist SR49059 (1 mg/kg, IP), and were assessed for locomotor activity changes and for c-Fos expression across a number of brain regions. Oxytocin reduced the distance travelled by rats during a 70 min test session, and this inhibitory behavioural effect was prevented by SR49059. Consistent with previous reports, oxytocin increased c-Fos expression in a number of brain regions. In several of these regions the supraoptic and paraventricular (PVN) nuclei of the hypothalamus, locus coeruleus and nucleus of the solitary tract the c-Fos response was prevented by SR49059 pre-treatment. Notably, SR49059 inhibited the c-Fos activation in oxytocin-synthesising magnocellular neurons in the PVN. However, c-Fos expression in the central amygdala to oxytocin was unaffected by SR49059. The current findings add to an increasing body of research suggesting that many of the functional effects of oxytocin may be V1AR mediated. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hicks, Callum; Ramos, Linnet; Baracz, Sarah J.; McGregor, Iain S.] Univ Sydney, Sch Psychol, Brennan MacCallum Bldg, Sydney, NSW 2006, Australia.
   [Dampney, Bruno] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia.
   [Hunt, Glenn E.] Univ Sydney, Concord Hosp, Sydney Med Sch, Discipline Psychiat, Concord, NSW 2139, Australia.
RP Hunt, GE (reprint author), Univ Sydney, Concord Hosp, Sydney Med Sch, Discipline Psychiat, Concord, NSW 2139, Australia.
EM chicks0333@gmail.com; lramos1984@gmail.com; b.dampney@unsw.edu.au;
   Sarah.Baracz@sydney.edu.au; lain.McGregor@sydney.edu.au;
   glenn.hunt@sydney.edu.au
FU National Health and Medical Research Council [1033444, 1011518,
   1088711]; NHMRC Principal Research Fellowship from the National Health
   and Medical Research Council of Australia
FX Research was funded by two National Health and Medical Research Council
   grants to ISM and GEH (1033444, 1011518 and 1088711). ISM is supported
   by an NHMRC Principal Research Fellowship from the National Health and
   Medical Research Council of Australia.
CR ANDREWS JS, 1983, NEUROPEPTIDES, V4, P17, DOI 10.1016/0143-4179(83)90004-5
   ANTONIJEVIC IA, 1995, ENDOCRINOLOGY, V136, P154, DOI 10.1210/en.136.1.154
   Bale TL, 2001, J NEUROSCI, V21, P2546
   Bernal A, 2007, HORM BEHAV, V52, P289, DOI 10.1016/j.yhbeh.2007.05.005
   Berridge CW, 2003, BRAIN RES REV, V42, P33, DOI 10.1016/S0165-0173(03)00143-7
   Borrow AP, 2012, HORM BEHAV, V61, P266, DOI 10.1016/j.yhbeh.2011.11.001
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Bowen MT, 2014, INT J NEUROPSYCHOPH, V17, P1621, DOI 10.1017/S1461145714000388
   Bowen MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027237
   Braga DC, 2000, AM J PHYSIOL-REG I, V278, pR1474
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Campbell-Smith EJ, 2015, LEARN MEMORY, V22, P247, DOI 10.1101/lm.036962.114
   Carson DS, 2010, ADDICT BIOL, V15, P448, DOI 10.1111/j.1369-1600.2010.00247.x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Consiglio AR, 2005, PHYSIOL BEHAV, V85, P354, DOI 10.1016/j.physbeh.2005.05.002
   Costa-e-Sousa RH, 2005, REGUL PEPTIDES, V132, P107, DOI 10.1016/j.regpep.2005.09.011
   Dumais KM, 2013, HORM BEHAV, V64, P693, DOI 10.1016/j.yhbeh.2013.08.012
   Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607
   Egashira N, 2007, BEHAV BRAIN RES, V178, P123, DOI 10.1016/j.bbr.2006.12.009
   Einfeld SL, 2014, AM J MED GENET A, V164, P2232, DOI 10.1002/ajmg.a.36653
   Feifel D, 1999, PSYCHOPHARMACOLOGY, V141, P93, DOI 10.1007/s002130050811
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Gaykema RPA, 2007, BRAIN RES, V1130, P130, DOI 10.1016/j.brainres.2006.10.084
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   Gupta J., 2009, BRIT J PHARMACOL, V155, P118
   Gutkowska J, 2012, J NEUROENDOCRINOL, V24, P599, DOI 10.1111/j.1365-2826.2011.02235.x
   Hicks C, 2014, BRIT J PHARMACOL, V171, P2868, DOI 10.1111/bph.12613
   Hicks C, 2012, J NEUROENDOCRINOL, V24, P1012, DOI 10.1111/j.1365-2826.2012.02311.x
   Hicks C, 2016, ADDICT BIOL, V21, P304, DOI 10.1111/adb.12197
   Hicks C, 2015, PSYCHOPHARMACOLOGY, V232, P2659, DOI 10.1007/s00213-015-3902-5
   Higa KT, 2002, AM J PHYSIOL-REG I, V282, pR537
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hunt GE, 2011, BRAIN RES BULL, V86, P65, DOI 10.1016/j.brainresbull.2011.06.011
   Hurbin A, 1998, ENDOCRINOLOGY, V139, P4701, DOI 10.1210/en.139.11.4701
   Iwasaki Y, 2015, AM J PHYSIOL-REG I, V308, pR360, DOI 10.1152/ajpregu.00344.2014
   JACOB SW, 1967, AM J SURG, V114, P414, DOI 10.1016/0002-9610(67)90166-3
   Karanges EA, 2016, BRAIN RES BULL, V121, P246, DOI 10.1016/j.brainresbull.2016.02.008
   Kita I, 2006, NEUROSCI RES, V54, P269, DOI 10.1016/j.neures.2005.12.005
   Klenerova V, 2009, NEUROENDOCRINOL LETT, V30, P335
   KREJCI I, 1979, EUR J PHARMACOL, V56, P347, DOI 10.1016/0014-2999(79)90265-6
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   LIN MT, 1983, NEUROPHARMACOLOGY, V22, P1007, DOI 10.1016/0028-3908(83)90217-4
   Loyens E, 2012, BRAIN RES, V1436, P43, DOI 10.1016/j.brainres.2011.11.059
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   MacDonald K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00035
   MacDonald K, 2012, J SEX MED, V9, P1407, DOI 10.1111/j.1743-6109.2012.02703.x
   Maejima Y, 2015, NEUROENDOCRINOLOGY, V101, P35, DOI 10.1159/000371636
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Neumann ID, 2006, AM J PHYSIOL-REG I, V291, pR29, DOI 10.1152/ajpregu.00763.2005
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   OLSON BR, 1993, MOL CELL NEUROSCI, V4, P93, DOI 10.1006/mcne.1993.1011
   Olszewski PK, 2010, PHARMACOL BIOCHEM BE, V97, P47, DOI 10.1016/j.pbb.2010.05.026
   Paxinos G., 1997, RAT BRAIN STEREOTAXI
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Petersson M, 1998, NEUROSCI LETT, V255, P115, DOI 10.1016/S0304-3940(98)00729-0
   PETTY MA, 1985, EUR J PHARMACOL, V112, P203, DOI 10.1016/0014-2999(85)90497-2
   Pitkow LJ, 2001, J NEUROSCI, V21, P7392
   Popeski N, 2001, J NEUROENDOCRINOL, V13, P596, DOI 10.1046/j.1365-2826.2001.00673.x
   RAGGENBASS M, 1992, J PHYSIOL-LONDON, V457, P131
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z
   Ring RH, 2011, BIOL PSYCHIAT, V69, P818, DOI 10.1016/j.biopsych.2011.03.020
   ROGERS RC, 1985, PEPTIDES, V6, P1143, DOI 10.1016/0196-9781(85)90441-3
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   SARNYAI Z, 1991, NEUROPEPTIDES, V19, P51, DOI 10.1016/0143-4179(91)90073-R
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Serradeil-Le Gal C, 2002, PROG BRAIN RES, V139, P197
   SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554
   SERRADEILLEGAL C, 1995, AM J PHYSIOL-HEART C, V268, pH404
   Stojicic S, 2008, NEUROPHARMACOLOGY, V54, P824, DOI 10.1016/j.neuropharm.2007.12.013
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413
   Trandafir CC, 2004, CLIN EXP PHARMACOL P, V31, P261, DOI 10.1111/j.1440-1681.2004.03986.x
   Uvnas-Moberg K, 2005, INT J BEHAV MED, V12, P59, DOI 10.1207/s15327558ijbm1202_3
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   UVNASMOBERG K, 1992, ACTA PHYSIOL SCAND, V145, P429, DOI 10.1111/j.1748-1716.1992.tb09385.x
   Uvnas-Moberg K., 2006, ANN NY ACAD SCI, V807, P146
   van Nieuwenhuijzen PS, 2014, NEUROSCIENCE, V277, P700, DOI 10.1016/j.neuroscience.2014.07.056
   Van Nieuwenhuijzen PS, 2009, NEUROSCIENCE, V158, P441, DOI 10.1016/j.neuroscience.2008.10.011
   Veenema AH, 2008, PROG BRAIN RES, V170, P261, DOI 10.1016/S0079-6123(08)00422-6
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
NR 92
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD OCT
PY 2016
VL 127
BP 208
EP 218
DI 10.1016/j.brainresbull.2016.10.005
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA ED7YH
UT WOS:000389088100026
PM 27725169
ER

PT J
AU Pare, P
   Paixao-Cortes, VR
   Tovo-Rodrigues, L
   Vargas-Pinilla, P
   Viscardi, LH
   Salzano, FM
   Henkes, LE
   Bortolini, MC
AF Pare, Pamela
   Paixao-Cortes, Vanessa R.
   Tovo-Rodrigues, Luciana
   Vargas-Pinilla, Pedro
   Viscardi, Lucas Henriques
   Salzano, Francisco Mauro
   Henkes, Luiz E.
   Bortolini, Maria Catira
TI Oxytocin and arginine vasopressin receptor evolution: implications for
   adaptive novelties in placental mammals
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE Oxytocin receptor; Arginine vasopressin receptors; molecular evolution;
   protein disorder; interaction motifs
ID INTRINSICALLY DISORDERED REGIONS; PROTEIN-COUPLED RECEPTORS;
   EVOLVABILITY; ALIGNMENT; MUTATION; PEPTIDE; DOMAINS; DOCKING; SYSTEM;
   FAMILY
AB Oxytocin receptor (OXTR) and arginine vasopressin receptors (AVPR1a, AVPR1b, and AVPR2) are paralogous genes that emerged through duplication events; along the evolutionary timeline, owing to speciation, numerous orthologues emerged as well. In order to elucidate the evolutionary forces that shaped these four genes in placental mammals and to reveal specific aspects of their protein structures, 35 species were selected. Specifically, we investigated their molecular evolutionary history and intrinsic protein disorder content, and identified the presence of short linear interaction motifs. OXTR seems to be under evolutionary constraint in placental mammals, whereas AVPR1a, AVPR1b, and AVPR2 exhibit higher evolutionary rates, suggesting that they have been under relaxed or experienced positive selection. In addition, we describe here, for the first time, that the OXTR, AVPR1a, AVPR1b, and AVPR2 mammalian orthologues preserve their disorder content, while this condition varies among the paralogues. Finally, our results reveal the presence of short linear interaction motifs, indicating possible functional adaptations related to physiological and/or behavioral taxa-specific traits.
C1 [Pare, Pamela; Vargas-Pinilla, Pedro; Viscardi, Lucas Henriques; Salzano, Francisco Mauro; Bortolini, Maria Catira] Univ Fed Rio Grande do Sul, Dept Genet, Programa Posgrad Genet & Biol Mol, Porto Alegre, RS, Brazil.
   [Paixao-Cortes, Vanessa R.] Univ Fed Bahia UFBA, Inst Biol, Programa Posgrad Genet & Biodiversidade, Salvador, BA, Brazil.
   [Tovo-Rodrigues, Luciana] UFSC, Lab Fisiol Reprod Anim, Curitibanos, SC, Brazil.
   [Henkes, Luiz E.] Univ Fed Pelotas UFPEL, Programa Posgrad Epidemiol, Pelotas, RS, Brazil.
RP Bortolini, MC (reprint author), Univ Fed Rio Grande do Sul, Dept Genet, Caixa Postal 15053, BR-91501970 Porto Alegre, RS, Brazil.
EM maria.bortolini@ufrgs.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnolcgico (CNPq)
FX This research was financially supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnolcgico (CNPq).
CR Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Bselt I, 2009, PLOS ONE, V4
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Dinkel H, 2014, NUCLEIC ACIDS RES, V42, pD259, DOI 10.1093/nar/gkt1047
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448
   Fujino Y, 1999, J EXP ZOOL, V284, P401, DOI 10.1002/(SICI)1097-010X(19990901)284:4<401::AID-JEZ6>3.0.CO;2-U
   Gabaldon T, 2013, NAT REV GENET, V14, P360, DOI 10.1038/nrg3456
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862
   Gwee PC, 2008, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-47
   Huang H, 2012, COMPUT BIOL CHEM, V41, P51, DOI 10.1016/j.compbiolchem.2012.10.001
   Jaakola VP, 2005, PROTEIN ENG DES SEL, V18, P103, DOI 10.1093/protein/gzi004
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275
   Jordan GE, 2008, BIOINFORMATICS, V24, P1641, DOI 10.1093/bioinformatics/btn235
   Kimura T, 1998, HUM REPROD, V13, P2645, DOI 10.1093/humrep/13.9.2645
   Koehbach Johannes, 2013, Commun Integr Biol, V6, pe27583, DOI 10.4161/cib.27583
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   Kosiol C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000144
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583
   Lagman D, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-238
   Lee AG, 2011, BIOL LETTERS, V7, P584, DOI 10.1098/rsbl.2011.0107
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628
   Liu J, 1996, J BIOL CHEM, V271, P8772
   LUZIUS H, 1992, J RECEPTOR RES, V12, P351, DOI 10.3109/10799899209074800
   Marra NJ, 2012, COMP BIOCHEM PHYS D, V7, P328, DOI 10.1016/j.cbd.2012.07.001
   Meredith RW, 2011, SCIENCE, V334, P521, DOI 10.1126/science.1211028
   Neduva V, 2005, FEBS LETT, V579, P3342, DOI 10.1016/j.febslet.2005.04.005
   Ocampo Daza Daniel, 2012, General and Comparative Endocrinology, V175, P135, DOI 10.1016/j.ygcen.2011.10.011
   Oumi T, 1996, J EXP ZOOL, V276, P151, DOI 10.1002/(SICI)1097-010X(19961001)276:2<151::AID-JEZ8>3.3.CO;2-I
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Penn O, 2010, NUCLEIC ACIDS RES, V38, pW23, DOI 10.1093/nar/gkq443
   Perelman P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001342
   Pigliucci M, 2008, NAT REV GENET, V9, P75, DOI 10.1038/nrg2278
   Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030
   Ren DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125775
   Schlessinger A, 2011, CURR OPIN STRUC BIOL, V21, P412, DOI 10.1016/j.sbi.2011.03.014
   Slusarz MJ, 2013, J PEPT SCI, V19, P118, DOI 10.1002/psc.2485
   Song S, 2012, P NATL ACAD SCI USA, V109, P14942, DOI 10.1073/pnas.1211733109
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197
   Teyra J, 2012, FEBS LETT, V586, P2631, DOI 10.1016/j.febslet.2012.05.043
   Tovo-Rodrigues L, 2014, NEUROSCIENCE, V277, P764, DOI 10.1016/j.neuroscience.2014.06.049
   Uversky VN, 2015, FEBS J, V282, P1182, DOI 10.1111/febs.13202
   Maere S, 2009, NAT REV GENET, V10, P725, DOI DOI 10.1038/NRG2600
   Vargas-Pinilla P, 2015, P NATL ACAD SCI USA, V112, P88, DOI 10.1073/pnas.1419399112
   Wagner A, 2008, P R SOC B, V275, P91, DOI 10.1098/rspb.2007.1137
   Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920
   Xue B, 2013, BBA-PROTEINS PROTEOM, V1834, P725, DOI 10.1016/j.bbapap.2013.01.012
   Yamaguchi Y, 2012, GEN COMP ENDOCR, V178, P519, DOI 10.1016/j.ygcen.2012.07.008
   Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088
   Yedvabny E, 2015, J PHYS CHEM B, V119, P896, DOI 10.1021/jp505902m
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
NR 54
TC 1
Z9 1
U1 0
U2 0
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PD OCT-DEC
PY 2016
VL 39
IS 4
BP 646
EP 657
DI 10.1590/1678-4685-GMB-2015-0323
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA ED1QR
UT WOS:000388620500018
ER

PT J
AU Samson, WK
AF Samson, Willis K.
TI Oxytocin redux
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY
LA English
DT Editorial Material
ID HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; CORTICOTROPIN-RELEASING HORMONE;
   INCREASES ENERGY-EXPENDITURE; FOOD-INTAKE; PROLACTIN SECRETION;
   DEFICIENT MICE; SALT APPETITE; SPINAL-CORD; ANOREXIA-NERVOSA;
   GASTRIC-MOTILITY
C1 [Samson, Willis K.] St Louis Univ, Sch Med, Dept Physiol & Pharmacol, St Louis, MO USA.
RP Samson, WK (reprint author), St Louis Univ, 1402 South Grand Blvd, St Louis, MO 63104 USA.
EM samsonwk@slu.edu
CR Amico JA, 2005, AM J PHYSIOL-REG I, V280, pR1789
   ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   BLACKBURN RE, 1993, P NATL ACAD SCI USA, V90, P10380, DOI 10.1073/pnas.90.21.10380
   BLACKBURN RE, 1995, AM J PHYSIOL-REG I, V269, pR245
   Blevins JE, 2016, AM J PHYSIOL-REG I, V310, pR640, DOI 10.1152/ajpregu.00220.2015
   Blevins JE, 2015, PHYSIOL BEHAV, V152, P438, DOI 10.1016/j.physbeh.2015.05.023
   Blevins JE, 2015, AM J PHYSIOL-REG I, V308, pR431, DOI 10.1152/ajpregu.00441.2014
   Blevins JE, 2004, AM J PHYSIOL-REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003
   BUIJS RM, 1978, CELL TISSUE RES, V186, P423
   Camerino C, 2009, OBESITY, V17, P980, DOI 10.1038/oby.2009.12
   Dabrowska J, 2011, PSYCHONEUROENDOCRINO, V36, P1312, DOI 10.1016/j.psyneuen.2011.03.003
   Dale HH, 1909, BIOCHEM J, V4, P427
   DESAULLES E, 1995, BRAIN RES, V699, P139, DOI 10.1016/0006-8993(95)01019-R
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   FEUERSTEIN G, 1984, J PHARMACOL EXP THER, V228, P348
   FLANAGAN LM, 1992, BRAIN RES, V578, P256, DOI 10.1016/0006-8993(92)90255-8
   GIBBS DM, 1984, ENDOCRINOLOGY, V114, P1216
   Grinevich V, 2016, BIOL PSYCHIAT, V79, P155, DOI 10.1016/j.biopsych.2015.04.013
   Ho JM, 2014, ENDOCRINOLOGY, V155, P2845, DOI 10.1210/en.2014-1148
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Kublaoui BM, 2008, MOL ENDOCRINOL, V22, P1723, DOI 10.1210/me.2008-0067
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Lawson EA, 2013, J CLIN PSYCHIAT, V74, pE451, DOI 10.4088/JCP.12m08154
   Lawson EA, 2012, J CLIN ENDOCR METAB, V97, pE1898, DOI 10.1210/jc.2012-1702
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   LUMPKIN MD, 1983, ENDOCRINOLOGY, V112, P1711
   Mack SO, 2002, J APPL PHYSIOL, V92, P826
   Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Michelini LC, 2003, AM J PHYSIOL-HEART C, V284, pH2269, DOI 10.1152/ajpheart.00774.2002
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   NILAVER G, 1980, NEUROENDOCRINOLOGY, V30, P150, DOI 10.1159/000122991
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Noble EE, 2014, AM J PHYSIOL-REG I, V307, pR737, DOI 10.1152/ajpregu.00118.2014
   OLSON BR, 1991, ENDOCRINOLOGY, V129, P785
   OLSON BR, 1991, AM J PHYSIOL, V260, pR448
   OLSON BR, 1992, BRAIN RES, V569, P238, DOI 10.1016/0006-8993(92)90635-M
   Ong ZY, 2015, AM J PHYSIOL-REG I, V308, pR800, DOI 10.1152/ajpregu.00534.2014
   Petersson M, 1999, J CARDIOVASC PHARM, V33, P102, DOI 10.1097/00005344-199901000-00015
   PETTY MA, 1985, EUR J PHARMACOL, V112, P203, DOI 10.1016/0014-2999(85)90497-2
   Quintana DS, 2016, BIOL PSYCHIAT, V79, pE49, DOI 10.1016/j.biopsych.2015.06.021
   Rigatto K, 2003, HYPERTENSION, V42, P793, DOI 10.1161/01.HYP.0000090321.81218.7B
   Rinaman L, 2002, AM J PHYSIOL-REG I, V283, pR99, DOI 10.1152/ajpregu.00008.2002
   Rinaman L, 1998, J COMP NEUROL, V399, P101, DOI 10.1002/(SICI)1096-9861(19980914)399:1<101::AID-CNE8>3.0.CO;2-5
   ROGERS RC, 1987, PEPTIDES, V8, P505, DOI 10.1016/0196-9781(87)90017-9
   Sabatier Nancy, 2013, Front Endocrinol (Lausanne), V4, P35, DOI 10.3389/fendo.2013.00035
   SAMSON WK, 1992, ANN NY ACAD SCI, V652, P411, DOI 10.1111/j.1749-6632.1992.tb34371.x
   SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554
   SAMSON WK, 1989, ENDOCRINOLOGY, V124, P812
   SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306
   SHAPIRO LE, 1989, SYNAPSE, V4, P259, DOI 10.1002/syn.890040312
   Sladek CD, 2015, COMPR PHYSIOL, V5, P1281, DOI 10.1002/cphy.c140028
   SOFRONIEW MV, 1983, PROG BRAIN RES, V60, P101
   SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jc.80.2.573
   SWANSON LW, 1979, J COMP NEUROL, V188, P87, DOI 10.1002/cne.901880108
   Swarbrick MM, 2011, OBESITY, V19, P2394, DOI 10.1038/oby.2011.79
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Vaccari C, 1998, ENDOCRINOLOGY, V139, P5015, DOI 10.1210/en.139.12.5015
   VERBALIS JG, 1986, SCIENCE, V232, P1417, DOI 10.1126/science.3715453
   Welch MG, 2009, J COMP NEUROL, V512, P256, DOI 10.1002/cne.21872
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Yang Z, 2009, AUTON NEUROSCI-BASIC, V147, P80, DOI 10.1016/j.autneu.2009.01.013
   Yi KJ, 2015, J NEUROENDOCRINOL, V27, P335, DOI 10.1111/jne.12268
   Yosten GLC, 2014, AM J PHYSIOL-REG I, V306, pR722, DOI 10.1152/ajpregu.00396.2013
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 67
TC 0
Z9 0
U1 1
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD OCT 1
PY 2016
VL 311
IS 4
BP R710
EP R713
DI 10.1152/ajpregu.00307.2016
PG 4
WC Physiology
SC Physiology
GA EC9HX
UT WOS:000388456500010
ER

PT J
AU Pfeifer, AC
   Ditzen, B
   Neubauer, E
   Schiltenwolf, M
AF Pfeifer, A. -C.
   Ditzen, B.
   Neubauer, E.
   Schiltenwolf, M.
TI Effect of oxytocin on human pain perception
SO SCHMERZ
LA German
DT Article
DE Oxytocin; Pain perception; Therapeutic effectiveness; Attachment
   behavior; Treatment success
ID RECURRENT ABDOMINAL-PAIN; INTRANASAL OXYTOCIN; PLASMA OXYTOCIN;
   NOCICEPTIVE THRESHOLDS; CEREBROSPINAL-FLUID; INDUCED ANALGESIA;
   DOUBLE-BLIND; SPINAL-CORD; MALE RATS; VASOPRESSIN
AB Background. Over the years the effect of the neuropeptide oxytocin and its possible utilization for pain management has been increasingly more investigated and discussed. Initial results emphasized the effects of oxytocin with respect to labor and breastfeeding. Diverse animals studies were also able to demonstrate the effectiveness of the peptide in attachment behavior and pain perception; however, it is still unclear how oxytocin affects pain perception in humans. The potential therapeutic effectiveness of oxytocin could be particularly important for primary and secondary treatment of pain patients because chronification of pain can occur more frequently in this area.
   Methods. For this review the databases PubMed, Medline und PsycINFO were searched using the terms oxytocin, pain, human and analgesic. The search resulted in a total of 89 original articles after excluding articles regarding labor pain, breastfeeding and animal studies. Only those studies were included which were carried out between 1994 and 2015. A total of 17 articles remained for inclusion in this review and included 13 studies on the exogenous application of oxytocin and 4 on measurement of oxytocin levels in plasma.
   Conclusion. This review article gives a summary of the current state of research on oxytocin and its direct and indirect association with human pain perception and emphasizes its relevance for the multimodal management of pain.
C1 [Pfeifer, A. -C.; Neubauer, E.; Schiltenwolf, M.] Univ Klinikum Heidelberg, Klin Orthopadie & Unfallchirurg, Konservat Orthopadie, Tagesklin Schmerztherapie, Schlierbacher Landstr 200a, D-69118 Heidelberg, Germany.
   [Ditzen, B.] Univ Klinikum Heidelberg, ZPM, Inst Med Psychol, Heidelberg, Germany.
RP Pfeifer, AC (reprint author), Univ Klinikum Heidelberg, Klin Orthopadie & Unfallchirurg, Konservat Orthopadie, Tagesklin Schmerztherapie, Schlierbacher Landstr 200a, D-69118 Heidelberg, Germany.
EM Ann-Christin.Pfeifer@med.uni-heidelberg.de
CR Alfven G, 2004, J PEDIATR GASTR NUTR, V38, P513, DOI 10.1097/00005176-200405000-00010
   ALFVEN G, 1994, ACTA PAEDIATR, V83, P1076, DOI 10.1111/j.1651-2227.1994.tb12989.x
   Anderberg UM, 2000, Z RHEUMATOL, V59, P373, DOI 10.1007/s003930070045
   ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   ARLETTI R, 1993, NEUROPEPTIDES, V24, P125, DOI 10.1016/0143-4179(93)90075-L
   BECKMANN H, 1985, PSYCHONEUROENDOCRINO, V10, P187, DOI 10.1016/0306-4530(85)90056-3
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   BODNAR RJ, 1984, INT J NEUROSCI, V24, P149, DOI 10.3109/00207458409089803
   Bouchon M, 2010, LOW DOSE OXYTOCIN ST
   Breton JD, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-19
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Crock LW, 2012, J NEUROSCI, V32, P14217, DOI 10.1523/JNEUROSCI.1473-12.2012
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Eisenach JC, 2015, ANESTHESIOLOGY, V122, P407, DOI 10.1097/ALN.0000000000000539
   Eisenberger NI, 2007, BIOL PSYCHIAT, V61, P1100, DOI 10.1016/j.biopsych.2006.08.007
   Eliava M, 2016, NEURON ACCEPT, V89, DOI [10.1016/j.neuron.2016.01.041, DOI 10.1016/J.NEURON.2016.01.041]
   Frasch A, 1995, ADV EXP MED BIOL, V395, P257
   Ge Y, 2002, BRAIN RES, V927, P204, DOI 10.1016/S0006-8993(01)03346-7
   Goodin BR, 2015, CURR PHARM DESIGN, V21, P906
   Grewen KM, 2008, ETHNIC HEALTH, V13, P219, DOI 10.1080/13557850701837310
   Holt-Lunstad J, 2014, J SOC PERS RELAT, V5
   Kessner S, 2013, JAMA-J AM MED ASSOC, V310, P1733, DOI 10.1001/jama.2013.277446
   Kirsch P, 2005, NEUROSCIENCE, V25, P11489
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   LINKOWSKI P, 1984, EUR ARCH PSY CLIN N, V234, P162, DOI 10.1007/BF00461555
   Liu W, 1990, Zhen Ci Yan Jiu, V15, P24
   Louvel D, 1996, GUT, V39, P741, DOI 10.1136/gut.39.5.741
   LUPPI P, 1993, NEUROREPORT, V4, P1063
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   Mameli S, 2014, RHEUMATOL INT, V34, P1047, DOI 10.1007/s00296-014-2953-y
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   MILLAN MJ, 1984, BRAIN RES, V309, P384
   Neumann ID, 2000, REGUL PEPTIDES, V96, P31, DOI 10.1016/S0167-0115(00)00197-X
   Ohlsson B, 2005, NEUROGASTROENT MOTIL, V17, P697, DOI 10.1111/j.1365-2982.2005.00679.x
   Paloyelis Y, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12347
   Parker KJ, 2005, PSYCHONEUROENDOCRINO, V30, P924, DOI 10.1016/j.psyneuen.2005.04.002
   Petersson M, 1999, NEUROSCI LETT, V264, P41, DOI 10.1016/S0304-3940(99)00159-7
   Petersson M, 1996, NEUROSCI LETT, V212, P87, DOI 10.1016/0304-3940(96)12773-7
   Phillips William J, 2006, J Pain Palliat Care Pharmacother, V20, P25, DOI 10.1300/J354v20n03_05
   Quevedo AS, 2007, J NEUROSCI, V27, P11635, DOI 10.1523/JNEUROSCI.3356-07.2007
   Rash JA, 2014, PSYCHOSOM MED, V76, P422, DOI 10.1097/PSY.0000000000000068
   Rash JA, 2014, CLIN J PAIN, V30, P453, DOI 10.1097/AJP.0b013e31829f57df
   Reeta K, 2006, REGUL PEPTIDES, V135, P85, DOI 10.1016/j.regpep.2006.04.004
   RUSSELL JA, 1995, EXP PHYSIOL, V80, P307
   Schandry R, 2006, BIOL PSYCHOL
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Singer T, 2008, EMOTION, V8, P781, DOI 10.1037/a0014195
   Tracy LM, 2015, NEUROSCI BIOBEHAV R, V55, P53, DOI 10.1016/j.neubiorev.2015.04.013
   Uvnas-Moberg K, 2005, Z PSYCHOSOM MED PSYC, V51, P57
   Uvnas-Moberg K, 1998, PEDIATR RES, V43, P344
   Uvnas-Moberg K, 2000, REGUL PEPTIDES, V88, P27, DOI 10.1016/S0167-0115(99)00112-3
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Wang YL, 2013, NEUROPEPTIDES, V47, P93, DOI 10.1016/j.npep.2012.12.003
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yang J, 2011, REGUL PEPTIDES, V169, P39, DOI 10.1016/j.regpep.2011.04.007
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   YUNUS MB, 1991, ARTHRITIS RHEUM, V34, P15, DOI 10.1002/art.1780340104
   Zunhammer M, 2015, PSYCHOSOM MED, V77, P156, DOI 10.1097/PSY.0000000000000142
NR 61
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-433X
EI 1432-2129
J9 SCHMERZ
JI Schmerz
PD OCT
PY 2016
VL 30
IS 5
BP 457
EP 469
DI 10.1007/s00482-016-0164-z
PG 13
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA EC6TG
UT WOS:000388269000010
PM 27681779
ER

PT J
AU Fluegge, K
AF Fluegge, Keith
TI Does environmental exposure to the greenhouse gas, N2O, contribute to
   etiological factors in neurodevelopmental disorders? A mini-review of
   the evidence
SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
LA English
DT Review
DE Autism spectrum disorders; ADHD; Air pollution; Nitrous oxide; Kappa
   opioid receptor; Dynorphin; Nitrogen fertilizers; Glyphosate; NMDA
   receptor; Dopamine; Methionine synthase; Alpha 7 nicotinic acetylcholine
   receptor; Oxytocin; Estrogen; Nitric oxide; Optimal outcomes; Maternal
   immune activation; Thimerosal; Ophthalmology; Gastrointestinal
ID AUTISM SPECTRUM DISORDERS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;
   KAPPA-OPIOID RECEPTOR; DEFICIT HYPERACTIVITY DISORDER; NICOTINIC
   ACETYLCHOLINE-RECEPTOR; NITRIC-OXIDE SYNTHASE; MATERNAL IMMUNE
   ACTIVATION; RAT NUCLEUS-ACCUMBENS; MIDDLE-EAR PRESSURE; NITROUS-OXIDE
AB Background: Neurodevelopmental disorders are increasing in prevalence worldwide. Previous work suggests that exposure to the environmental air pollutant and greenhouse gas- nitrous oxide (N2O)- may be an etiological factor in neurodevelopmental disorders through the targeting of several neural correlates.
   Methodology: While a number of recent systematic reviews have addressed the role of general anesthesia in the surgical setting and neurodevelopmental outcomes, a narrative mini-review was conducted to first define and characterize the relevant variables (i.e., N2O, attention-deficit hyperactivity disorder [ADHD] and autism spectrum disorders [ASD]) and their potential interactions into a coherent, hypothesis-generating work. The narrative mini-review merges basic principles in environmental science, anesthesiology, and psychiatry to more fully develop the novel hypotheses that neurodevelopmental impairment found in conditions like ADHD and ASD may be due to exposure to the increasing air pollutant, N2O.
   Results: The results of the present mini-review indicate that exposure to N2O, even at non-toxic doses, may modulate central neurotransmission and target many neural substrates directly implicated in neurodevelopmental disorders, including the glutamatergic, opioidergic, cholinergic, and dopaminergic systems. Epidemiological studies also indicate that early and repeated exposure to general anesthesia, including N2O, may contribute to later adverse neurodevelopmental outcomes in children.
   Conclusions: The current evidence and subsequent hypotheses suggest that a renewed interest be taken in the toxicological assessment of environmental N2O exposure using validated biomarkers and psychiatric endpoints. Given the relevance of N2O as a greenhouse gas, societies may also wish to engage in a more robust monitoring and reporting of N2O levels in the environment for climactic benefit as well. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Fluegge, Keith] Inst Hlth & Environm Res, Cleveland, OH 44118 USA.
RP Fluegge, K (reprint author), Inst Hlth & Environm Res, Cleveland, OH 44118 USA.
EM keithfluegge@gmail.com
CR ABDULKAREEM HS, 1991, TOXICOL IND HEALTH, V7, P97
   Akca O, 2004, ACTA ANAESTH SCAND, V48, P894, DOI 10.1111/j.1399-6576.2004.00427.x
   Anderson C, 2012, PEDIATRICS, V130, P870, DOI 10.1542/peds.2012-0762
   Archer Trevor, 2016, Curr Top Behav Neurosci, V29, P295, DOI 10.1007/7854_2015_415
   ARMSTRONG PJ, 1995, PSYCHOPHARMACOLOGY, V117, P486, DOI 10.1007/BF02246223
   Atladottir HO, 2012, PEDIATRICS, V130, pE1447, DOI 10.1542/peds.2012-1107
   BADEN JM, 1991, BRIT J ANAESTH, V66, P500, DOI 10.1093/bja/66.4.500
   Baumeister R. F., 1997, REV GEN PSYCHOL, V1, P311, DOI DOI 10.1037/1089-2680.1.3.311
   Beaulieu JJ, 2011, P NATL ACAD SCI USA, V108, P214, DOI 10.1073/pnas.1011464108
   Becker Daniel E, 2008, Anesth Prog, V55, P124, DOI 10.2344/0003-3006-55.4.124
   Becker JAJ, 2014, NEUROPSYCHOPHARMACOL, V39, P2049, DOI 10.1038/npp.2014.59
   Benturquia N, 2008, NEUROSCIENCE, V155, P341, DOI 10.1016/j.neuroscience.2008.05.015
   Berenguer-Forner C, 2015, REV NEUROLOGIA, V60, pS37
   Bershad AK, 2016, PSYCHONEUROENDOCRINO, V63, P43, DOI 10.1016/j.psyneuen.2015.09.011
   Bicks LK, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01805
   Bilkei-Gorzo A, 2014, NEUROPHARMACOLOGY, V77, P406, DOI 10.1016/j.neuropharm.2013.10.023
   Billeci L, 2015, AM J CLIN DERMATOL, V16, P371, DOI 10.1007/s40257-015-0145-5
   Biscaldi M, 2016, BIOL PSYCHOL, V118, P25, DOI 10.1016/j.biopsycho.2016.04.064
   Black Kelsey, 2013, Strabismus, V21, P98, DOI 10.3109/09273972.2013.786733
   Block R I, 1990, Anesth Prog, V37, P271
   BONDY CA, 1988, ENDOCRINOLOGY, V122, P1321
   Branda EM, 2000, PHARMACOL BIOCHEM BE, V65, P217, DOI 10.1016/S0091-3057(99)00202-6
   Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003
   BRODSKY JB, 1986, MED TOXICOL ADV DRUG, V1, P362
   BRUCE DL, 1974, ANESTHESIOLOGY, V40, P453, DOI 10.1097/00000542-197405000-00010
   Brunzell DH, 2012, NEUROPSYCHOPHARMACOL, V37, P1134, DOI 10.1038/npp.2011.299
   Butterbach-Bahl K, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0122
   Cadman T, 2012, J AM ACAD CHILD PSY, V51, P879, DOI 10.1016/j.jaac.2012.06.017
   Cahill FJ, 2000, J BIOMED SCI, V7, P299, DOI 10.1007/BF02253248
   Carey AN, 2009, J NEUROSCI, V29, P4293, DOI 10.1523/JNEUROSCI.6146-08.2009
   Castelo-Branco G, 2014, NEUROBIOL DIS, V71, P220, DOI 10.1016/j.nbd.2014.08.019
   Centers for Disease Control and Prevention, 2014, SURVEILLANCE SUMMARI, V63, P1
   Centeno ML, 2006, J COMP NEUROL, V497, P489, DOI 10.1002/cne.21026
   Ceylan M, 2010, PROG NEURO-PSYCHOPH, V34, P1491, DOI 10.1016/j.pnpbp.2010.08.010
   Ceylan MF, 2012, PSYCHIAT CLIN NEUROS, V66, P220, DOI 10.1111/j.1440-1819.2012.02330.x
   Chang JPC, 2014, CURR PHARM DESIGN, V20, P5180
   Chao CC, 1996, P NATL ACAD SCI USA, V93, P8051, DOI 10.1073/pnas.93.15.8051
   Chartoff EH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00466
   Chinn K, 1997, LARYNGOSCOPE, V107, P357, DOI 10.1097/00005537-199703000-00015
   Chiu YHM, 2016, ENVIRON INT, V87, P56, DOI 10.1016/j.envint.2015.11.010
   Choi GB, 2016, SCIENCE, V351, P933, DOI 10.1126/science.aad0314
   CHRISTENSEN B, 1993, J PHARMACOL EXP THER, V267, P1298
   Clifford A, 2016, ENVIRON RES, V147, P383, DOI 10.1016/j.envres.2016.01.018
   Cunningham AB, 2008, RES AUTISM SPECT DIS, V2, P469, DOI 10.1016/j.rasd.2007.09.006
   Curran LK, 2007, PEDIATRICS, V120, pE1386, DOI 10.1542/peds.2007-0360
   Damin V., 2008, SCI AGR, V65, P4
   Davidson EA, 2009, NAT GEOSCI, V2, P659, DOI 10.1038/NGEO608
   de Araujo JSA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3153-3
   de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264
   Demopoulos C., 2015, AUTISM RES
   Di Martino A, 2009, BIOL PSYCHIAT, V65, P63, DOI 10.1016/j.biopsych.2008.09.022
   Dickerson M. S., 2012, RES AUTISM SPECT DIS, V6, P277
   Dissanayake C, 2006, DEV PSYCHOPATHOL, V18, P381, DOI 10.1017/S0954579406060202
   DOHRN CS, 1992, BEHAV PHARMACOL, V3, P19
   DOHRN CS, 1993, PHARMACOL BIOCHEM BE, V46, P927, DOI 10.1016/0091-3057(93)90224-H
   Eigsti IM, 2016, NEUROIMAGE-CLIN, V10, P182, DOI 10.1016/j.nicl.2015.11.014
   El-Bakri NK, 2004, J CELL MOL MED, V8, P537, DOI 10.1111/j.1582-4934.2004.tb00478.x
   ElChaar GM, 2006, ANN PHARMACOTHER, V40, P1086, DOI 10.1345/aph.1G499
   Ende G, 2016, NEUROPSYCHOPHARMACOL, V41, P410, DOI 10.1038/npp.2015.153
   Environmental Protection Agency, 2014, OV GREENH GAS NITR O
   FAGAN D, 1994, PSYCHOPHARMACOLOGY, V116, P333, DOI 10.1007/BF02245337
   Fink G, 1996, CELL MOL NEUROBIOL, V16, P325, DOI 10.1007/BF02088099
   Fluegge K, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.24
   Fluegge K., 2016, J CHILD ADO IN PRESS
   Fluegge K., 2016, ENV INT
   Fluegge K., 2016, J CHILD ADOLESC PSYC
   Fluegge K, 2016, POL J ENVIRON STUD, V25, P1489, DOI 10.15244/pjoes/61742
   Fluegge K, 2016, BRAIN BEHAV IMMUN, V57, P371, DOI 10.1016/j.bbi.2016.06.013
   Fluegge K, 2016, NUTRITION, V32, P1163, DOI 10.1016/j.nut.2016.02.017
   Fluegge K, 2016, PSYCHIAT RES, V242, P169, DOI 10.1016/j.psychres.2016.05.058
   Fluegge K, 2016, POSTGRAD MED, V128, P573, DOI 10.1080/00325481.2016.1189802
   Fluegge K, 2016, J CLIN PSYCHIAT, V77, pE903, DOI 10.4088/JCP.16lr10663
   Fluegge K, 2016, MED HYPOTHESES, V92, P18, DOI 10.1016/j.mehy.2016.04.020
   Fluegge K, 2016, J AM ACAD CHILD PSY, V55, P523, DOI 10.1016/j.jaac.2016.04.005
   Fluegge K, 2016, EPILEPSY BEHAV, V58, P143, DOI 10.1016/j.yebeh.2016.02.009
   Fluegge K, 2016, EUR CHILD ADOLES PSY, V25, P453, DOI 10.1007/s00787-015-0803-4
   Fluegge K, 2016, AM J CLIN DERMATOL, V17, P187, DOI 10.1007/s40257-016-0180-x
   Freudenberg F, 2015, GENES BRAIN BEHAV, V14, P46, DOI 10.1111/gbb.12193
   Frye Richard E, 2013, Front Public Health, V1, P31, DOI 10.3389/fpubh.2013.00031
   Fukagawa H, 2014, BRIT J ANAESTH, V113, P1032, DOI 10.1093/bja/aeu254
   Gandal MJ, 2012, GENES BRAIN BEHAV, V11, P740, DOI 10.1111/j.1601-183X.2012.00816.x
   Gao YD, 2015, BEHAV NEUROSCI, V129, P50, DOI 10.1037/bne0000031
   GARFIELD JM, 1975, PSYCHOPHARMACOLOGIA, V42, P5, DOI 10.1007/BF00428818
   Gigliucci Valentina, 2014, Front Pediatr, V2, P91, DOI 10.3389/fped.2014.00091
   Green BN, 2001, J SPORT CHIROPR REH, V15, P5
   Gutierrez MJF, 2005, WASTE MANAGE RES, V23, P133, DOI 10.1177/0734242X05052803
   Ha Sungji, 2015, Exp Neurobiol, V24, P273, DOI 10.5607/en.2015.24.4.273
   Haberberger RV, 2003, HISTOCHEM CELL BIOL, V120, P173, DOI 10.1007/s00418-003-0550-3
   Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76
   Hansen TG, 2015, PEDIATR ANESTH, V25, P65, DOI 10.1111/pan.12548
   Hara Y, 2015, PHYSIOL REV, V95, P785, DOI 10.1152/physrev.00036.2014
   Hertz-Picciotto I, 2006, ENVIRON HEALTH PERSP, V114, P1119, DOI 10.1289/ehp.8483
   Houpt MI, 2004, PEDIATR DENT, V26, P29
   Huerta M, 2012, PEDIATR CLIN N AM, V59, P103, DOI 10.1016/j.pcl.2011.10.018
   Ikeda J, 2013, J AUTISM DEV DISORD, V43, P1447, DOI 10.1007/s10803-012-1475-2
   Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460
   Joseph N, 2015, J ATTEN DISORD, V19, P915, DOI 10.1177/1087054713510354
   Jucaite A, 2005, BIOL PSYCHIAT, V57, P229, DOI 10.1016/j.biopsych.2004.11.009
   Kabatas EU, 2015, J AUTISM DEV DISORD, V45, P2578, DOI 10.1007/s10803-015-2428-3
   Kalkbrenner AE, 2015, EPIDEMIOLOGY, V26, P30, DOI 10.1097/EDE.0000000000000173
   Kang V, 2014, AUTISM RES, V7, P501, DOI 10.1002/aur.1386
   Kanner L, 1943, NERV CHILD, V2, P217
   Karabiyik L, 1996, EUR J ANAESTH, V13, P27
   Kern Janet K, 2015, Brain Connect, V5, P321, DOI 10.1089/brain.2014.0324
   Kiely B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148337
   Kirino E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132233
   Knuesel I, 2014, NAT REV NEUROL, V10, P643, DOI 10.1038/nrneurol.2014.187
   Kolpen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084353
   Konicarova J, 2014, NEUROPSYCH DIS TREAT, V10, P85, DOI 10.2147/NDT.S56017
   Koyama T, 2010, J ANESTH, V24, P297, DOI 10.1007/s00540-010-0886-5
   Koyanagi S, 2008, ANESTH ANALG, V106, P1904, DOI 10.1213/ane.0b013e318172b15b
   Kuhlmann L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056434
   Kunz PA, 2013, J NEUROSCI, V33, P7762, DOI 10.1523/JNEUROSCI.2482-12.2013
   Kuryatov A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062246
   Kutlu S, 2004, NEUROENDOCRINOLOGY, V79, P197, DOI 10.1159/000078101
   Lalanne Laurence, 2014, Front Psychiatry, V5, P170, DOI 10.3389/fpsyt.2014.00170
   Larson K, 2011, PEDIATRICS, V127, P462, DOI 10.1542/peds.2010-0165
   Lee C, 2013, PAIN, V9, P45, DOI DOI 10.1186/1744-8069-9-45
   Lee EJ, 2015, CURR OPIN PHARMACOL, V20, P8, DOI 10.1016/j.coph.2014.10.007
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Levin ED, 2012, CURR DRUG TARGETS, V13, P602
   Lipman TE, 2002, CLIMATIC CHANGE, V53, P477, DOI 10.1023/A:1015235211266
   Lyall K, 2014, INT J EPIDEMIOL, V43, P443, DOI 10.1093/ije/dyt282
   Madras BK, 2005, BIOL PSYCHIAT, V57, P1397, DOI 10.1016/j.biopsych.2004.10.011
   Magnuson KM, 2011, J DEV BEHAV PEDIATR, V32, P332, DOI 10.1097/DBP.0b013e318213f56c
   MAGNUSSON M, 1989, AVIAT SPACE ENVIR MD, V60, P977
   Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433
   Manicolo O, 2016, GAIT POSTURE, V44, P245, DOI 10.1016/j.gaitpost.2015.12.012
   MANZANARES J, 1992, NEUROENDOCRINOLOGY, V55, P301, DOI 10.1159/000126129
   Matsushita Y, 2013, CURR PHARM DESIGN, V19, P7355
   Matthes HWD, 1998, J NEUROSCI, V18, P7285
   McClernon FJ, 2008, ANN NY ACAD SCI, V1141, P131, DOI 10.1196/annals.1441.016
   McFadden KL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00553
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McNeill AM, 2002, STROKE, V33, P1685, DOI 10.1161/01.STR.0000016325.54374.93
   Megremi ASF, 2013, MED HYPOTHESES, V80, P391, DOI 10.1016/j.mehy.2013.01.007
   Mennerick S, 1998, J NEUROSCI, V18, P9716
   Meuwese JDI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079326
   Meyer U, 2014, BIOL PSYCHIAT, V75, P307, DOI 10.1016/j.biopsych.2013.07.011
   Mika J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104420
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Moore DJ, 2015, AUTISM, V19, P387, DOI 10.1177/1362361314527839
   Musser ED, 2014, J CHILD PSYCHOL PSYC, V55, P819, DOI 10.1111/jcpp.12201
   Nabipour S, 2014, IRAN J PUBLIC HEALTH, V43, P1022
   Nagele P, 2008, ANESTHESIOLOGY, V109, P36, DOI 10.1097/ALN.0b013e318178820b
   Negrao BL, 2011, NEUROPSYCHOBIOLOGY, V63, P82, DOI 10.1159/000317548
   Nelson Travis M, 2015, Spec Care Dentist, V35, P105, DOI 10.1111/scd.12101
   Niehus R, 2006, J DEV BEHAV PEDIATR, V27, pS120, DOI 10.1097/00004703-200604002-00010
   Nizri E, 2009, J IMMUNOL, V183, P6681, DOI 10.4049/jimmunol.0902212
   Orhan-Sungur M, 2005, CURR OPIN ANESTHESIO, V18, P620, DOI 10.1097/01.aco.0000188417.00011.78
   Orinstein AJ, 2015, J AUTISM DEV DISORD, V45, P2443, DOI 10.1007/s10803-015-2409-6
   Orinstein AJ, 2014, J DEV BEHAV PEDIATR, V35, P247, DOI 10.1097/DBP.0000000000000037
   Ornoy A, 2015, REPROD TOXICOL, V56, P155, DOI 10.1016/j.reprotox.2015.05.007
   Osterling JA, 2002, DEV PSYCHOPATHOL, V14, P239
   Outram FN, 2012, ENVIRON SCI TECHNOL, V46, P8156, DOI 10.1021/es3012244
   Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9
   Panju S, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0057-5
   Papadopoulos N, 2014, PSYCHIAT RES, V218, P319, DOI 10.1016/j.psychres.2014.04.037
   Park S, 2012, NAT GEOSCI, V5, P261, DOI [10.1038/ngeo1421, 10.1038/NGEO1421]
   Parker-Athill EC, 2010, NEUROSIGNALS, V18, P113, DOI 10.1159/000319828
   Perkins T.J., 2014, PSYCHIAT RES, V30, P119
   Plitt M, 2015, P NATL ACAD SCI USA, V112, pE6699, DOI 10.1073/pnas.1510098112
   Polderman TJC, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.84
   Presti MF, 2005, BEHAV BRAIN RES, V157, P363, DOI 10.1016/j.bbr.2004.08.003
   Ptacek R, 2011, MED SCI MONITOR, V17, pRA215
   Pu DH, 2013, AUTISM RES, V6, P384, DOI 10.1002/aur.1300
   Rai V, 2016, METAB BRAIN DIS, V31, P727, DOI 10.1007/s11011-016-9815-0
   Ramsay Douglas S, 2014, Temperature (Austin), V1, P257
   Ramsay Douglas S, 2014, Temperature (Austin), V1, P248
   Rao SP, 2003, PEPTIDES, V24, P745, DOI 10.1016/S0196-9781(03)00112-0
   Rawls Scott M, 2011, Front Biosci (Schol Ed), V3, P822
   Raz R, 2015, ENVIRON HEALTH PERSP, V123, P264, DOI 10.1289/ehp.1408133
   Reiersen AM, 2008, TWIN RES HUM GENET, V11, P579, DOI 10.1375/twin.11.6.579
   Reiprich P, 2005, CEREB CORTEX, V15, P349, DOI 10.1093/cercor/bhh137
   Richardson KJ, 2015, J PHARMACOL EXP THER, V352, P156, DOI 10.1124/jpet.114.218057
   Romero TRL, 2012, J NEUROSCI RES, V90, P1654, DOI 10.1002/jnr.23050
   Rommelse NNJ, 2011, NEUROSCI BIOBEHAV R, V35, P1363, DOI 10.1016/j.neubiorev.2011.02.015
   ROSENBERG P, 1974, ANN CHIR GYNAECOL FE, V63, P500
   Roullet FI, 2013, NEUROTOXICOL TERATOL, V36, P47, DOI 10.1016/j.ntt.2013.01.004
   Roy A, 2015, J INTELL DISABIL RES, V59, P293, DOI 10.1111/jir.12122
   Rucklidge JJ, 2010, PSYCHIAT CLIN N AM, V33, P357, DOI 10.1016/j.psc.2010.01.006
   RUSSELL JA, 1993, J PHYSIOL-LONDON, V469, P365
   Sakamoto S, 2006, ANESTH ANALG, V103, P1459, DOI 10.1213/01.ane.0000247792.03959.f1
   Salpekar JA, 2014, EPILEPSY BEHAV, V37, P310, DOI 10.1016/j.yebeh.2014.04.021
   Sasaki T, 2015, PSYCHIAT RES, V228, P746, DOI 10.1016/j.psychres.2015.05.029
   Schlussman SD, 2005, BRAIN RES BULL, V67, P169, DOI 10.1016/j.brainresbull.2005.04.018
   Schmitt LM, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-47
   Schreiber F, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-24
   Sealey LA, 2016, ENVIRON INT, V88, P288, DOI 10.1016/j.envint.2015.12.021
   Sedki F, 2015, ADDICT BIOL, V20, P423, DOI 10.1111/adb.12133
   Sharma A, 1999, MOL PSYCHIATR, V4, P235, DOI 10.1038/sj.mp.4000522
   Shattock Paul, 2002, Expert Opin Ther Targets, V6, P175
   Shavelle RM, 2001, J AUTISM DEV DISORD, V31, P569, DOI 10.1023/A:1013247011483
   Shcherbak I, 2014, P NATL ACAD SCI USA, V111, P9199, DOI 10.1073/pnas.1322434111
   Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x
   Sirohi S, 2015, J NEUROCHEM, V135, P659, DOI 10.1111/jnc.13279
   Smeets CJLM, 2015, BRAIN, V138, P2537, DOI 10.1093/brain/awv195
   Solomon O, 2013, SOC SCI MED, V94, P106, DOI 10.1016/j.socscimed.2013.06.034
   Spencer TJ, 2007, BIOL PSYCHIAT, V62, P1059, DOI 10.1016/j.biopsych.2006.12.008
   Sprung J, 2012, MAYO CLIN PROC, V87, P120, DOI 10.1016/j.mayocp.2011.11.008
   Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545
   Stray LL, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-18
   Strom M.A., 2016, BR J DERMATOL
   Suzuki T, 2003, ANESTH ANALG, V96, P443, DOI 10.1213/01.ANE.0000042447.84463.74
   Sweeten TL, 2004, BIOL PSYCHIAT, V55, P434, DOI 10.1016/j.biopsych.200309.001
   TASSINARI M S, 1986, Toxicology and Industrial Health, V2, P261
   Tejeda HA, 2013, NEUROPSYCHOPHARMACOL, V38, P1770, DOI 10.1038/npp.2013.76
   Treister R, 2015, PAIN PRACT, V15, P4, DOI 10.1111/papr.12129
   Turner PA, 2015, P NATL ACAD SCI USA, V112, P9839, DOI 10.1073/pnas.1503598112
   Tyson K, 2014, J AUTISM DEV DISORD, V44, P648, DOI 10.1007/s10803-013-1921-9
   Uddin LQ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00458
   van Rooij D, 2015, NEUROIMAGE-CLIN, V7, P325, DOI 10.1016/j.nicl.2015.01.004
   Van't Veer A, 2013, PSYCHOPHARMACOLOGY, V229, P435, DOI 10.1007/s00213-013-3195-5
   VANDEHEIJNING BJM, 1991, EUR J PHARMACOL, V209, P199, DOI 10.1016/0014-2999(91)90170-U
   VANDERSCHUREN LJMJ, 1995, EUR J PHARMACOL, V276, P257, DOI 10.1016/0014-2999(95)00040-R
   Verma A, 1996, J NEUROSCI, V16, P373
   Visser E, 2013, J PSYCHIATR NEUROSCI, V38, P398, DOI 10.1503/jpn.120177
   Volkow ND, 2007, ARCH GEN PSYCHIAT, V64, P932, DOI 10.1001/archpsyc.64.8.932
   Volkow ND, 2012, J NEUROSCI, V32, P841, DOI 10.1523/JNEUROSCI.4461-11.2012
   Vrijheid M, 2016, INT J HYG ENVIR HEAL, V219, P331, DOI 10.1016/j.ijheh.2016.05.001
   Wadenberg MLG, 2003, CNS DRUG REV, V9, P187
   Walker BM, 2013, NEUROPSYCHOPHARMACOL, V38, P2278, DOI 10.1038/npp.2013.129
   Wallace JM, 2005, J NEUROPHYSIOL, V93, P2279, DOI 10.1152/jn.01042.2004
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Wang TT, 2016, EUR CHILD ADOLES PSY, V25, P341, DOI 10.1007/s00787-015-0786-1
   Wang XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084954
   Wasilewska Jolanta, 2009, Pol Merkur Lekarski, V27, P40
   Wegiel J, 2010, ACTA NEUROPATHOL, V119, P755, DOI 10.1007/s00401-010-0655-4
   Weiss Michael J, 2013, Front Integr Neurosci, V7, P33, DOI 10.3389/fnint.2013.00033
   Werling DM, 2013, CURR OPIN NEUROL, V26, P146, DOI 10.1097/WCO.0b013e32835ee548
   World Health Organization-WHO, 2013, WHO MOD LIST ESS MED
   Wink LK, 2014, J CLIN PSYCHIAT, V75, P835, DOI 10.4088/JCP.13cr08917
   Wu J, 2012, MOL NEUROBIOL, V45, P605, DOI 10.1007/s12035-012-8278-5
   Wu WL, 2015, BRAIN BEHAV IMMUN, V46, P192, DOI 10.1016/j.bbi.2015.02.005
   Yatawara C.J., 2015, MOL PSYCHIAT
   Yui K, 2016, CNS NEUROL DISORD-DR, V15, P587, DOI 10.2174/1871527315666160413121751
   Yurtbasi P., 2015, J ATTEN DISORD
   Zacny JP, 2010, DRUG ALCOHOL DEPEN, V112, P251, DOI 10.1016/j.drugalcdep.2010.06.008
   Zacny JP, 1996, NEUROSCI LETT, V209, P73, DOI 10.1016/0304-3940(96)12626-4
   ZACNY JP, 1995, PHARMACOL BIOCHEM BE, V51, P815, DOI 10.1016/0091-3057(95)00039-Y
   Zayas RM, 2002, J NEUROCHEM, V83, P421, DOI 10.1046/j.1471-4159.2002.01147.x
   Zerbo O, 2013, J AUTISM DEV DISORD, V43, P25, DOI 10.1007/s10803-012-1540-x
   Zhang C, 1999, ANESTHESIOLOGY, V91, P1401, DOI 10.1097/00000542-199911000-00033
   Zhang HF, 2015, J ANESTH, V29, P749, DOI 10.1007/s00540-015-2030-z
   Zhang YT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146797
   Zhu SJ, 2016, CELL, V165, P704, DOI 10.1016/j.cell.2016.03.028
   Zittan E, 2007, AM J PHYSIOL-HEART C, V293, pH860, DOI 10.1152/ajpheart.01189.2006
NR 247
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1382-6689
EI 1872-7077
J9 ENVIRON TOXICOL PHAR
JI Environ. Toxicol. Pharmacol.
PD OCT
PY 2016
VL 47
BP 6
EP 18
DI 10.1016/j.etap.2016.08.013
PG 13
WC Environmental Sciences; Pharmacology & Pharmacy; Toxicology
SC Environmental Sciences & Ecology; Pharmacology & Pharmacy; Toxicology
GA EC2IZ
UT WOS:000387936700002
PM 27566494
ER

PT J
AU Wellmann, S
   Koslowski, A
   Spanaus, K
   Zimmermann, R
   Burkhardt, T
AF Wellmann, Sven
   Koslowski, Andrea
   Spanaus, Katharina
   Zimmermann, Roland
   Burkhardt, Tilo
TI Fetal Release of Copeptin in Response to Maternal Oxytocin
   Administration: A Randomized Controlled Trial
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID ARGININE-VASOPRESSIN; ANTENATAL BETAMETHASONE; CESAREAN DELIVERY; PLASMA
   COPEPTIN; DAYS GESTATION; CORD BLOOD; STRESS; SHEEP; MORBIDITY; INFANTS
AB OBJECTIVE:To test whether an oxytocin challenge test raises neonatal levels of copeptin, the C-terminal portion of proarginine vasopressin, a sensitive stress marker elevated in neonates born by vaginal delivery as opposed to elective cesarean delivery.METHODS:In a randomized controlled trial in women with a singleton pregnancy undergoing elective cesarean delivery at greater than 36 weeks of gestation and no contractions or rupture of membranes, we compared arterial umbilical cord plasma concentrations of copeptin between neonates exposed to an oxytocin challenge test before elective cesarean delivery and those administered saline infusion (placebo group). Women randomized to an oxytocin challenge test received 5 international units/500 mL oxytocin Ringer lactate infused at a rate of 12 mL/h and doubled every 10 minutes until it induced three uterine contractions per 10-minute interval, at which point it was discontinued. Neonatal copeptin levels were the primary endpoint. Secondary endpoints included biochemical and physiologic parameters of fetal and maternal well-being.RESULTS:From January 2012 to October 2012 and from September 2013 to January 2015, 78 women underwent an oxytocin challenge test and 78 placebo infusion, of whom 12 and 11, respectively, were excluded as a result of insufficient blood sample volume for analysis. Umbilical cord plasma copeptin levels [median (range)] were higher in neonates who underwent an oxytocin challenge test than those who underwent placebo infusion: 22.2 (3.22-2,319) compared with 7.39 (2.5-344.6) pmol/L (P<.001). There were no statistically significant differences between the two groups in secondary outcomes.CONCLUSION:Oxytocin challenge test-induced contractions before elective cesarean delivery trigger fetal copeptin release.CLINICAL TRIAL REGISTRATION:ClinicalTrials.gov, https://clinicaltrials.gov, NCT01962701.
C1 [Burkhardt, Tilo] Univ Zurich Hosp, Dept Obstet, Frauenklin Str 10, CH-8091 Zurich, Switzerland.
   Univ Zurich Hosp, Dept Neonatol, CH-8091 Zurich, Switzerland.
   Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland.
   Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland.
   Univ Basel, Childrens Hosp, Div Neonatol, Basel, Switzerland.
RP Burkhardt, T (reprint author), Univ Zurich Hosp, Dept Obstet, Frauenklin Str 10, CH-8091 Zurich, Switzerland.
EM tilo.burkhardt@usz.ch
FU Zurich Center for Integrative Human Physiology (ZIHP), University of
   Zurich, Zurich, Switzerland; Swiss National Science Foundation Career
   Award for Medical Scientists [33CM30-124101]
FX Supported by the Zurich Center for Integrative Human Physiology (ZIHP),
   University of Zurich, Zurich, Switzerland. S.W. was supported by a Swiss
   National Science Foundation Career Award for Medical Scientists
   (33CM30-124101).
CR Ahmed MR, 2015, J MATERN-FETAL NEO M, V28, P1486, DOI 10.3109/14767058.2014.958461
   Aiken CEM, 2014, JAMA PEDIATR, V168, P507, DOI 10.1001/jamapediatrics.2014.9
   Albuquerque C A, 1998, J Matern Fetal Med, V7, P177
   Bailit JL, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.051
   Benzing J, 2011, J CLIN ENDOCR METAB, V96, pE982, DOI 10.1210/jc.2010-2858
   BROWN LAS, 1990, AM J PHYSIOL, V258, pL301
   Burckhardt MA, 2014, J CLIN ENDOCR METAB, V99, pE1750, DOI 10.1210/jc.2014-2244
   Burkhardt T, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.09.024
   Carey LC, 2007, ENDOCRINOLOGY, V148, P1440, DOI 10.1210/en.2006-1185
   CUMMINGS JJ, 1995, PEDIATR RES, V38, P30, DOI 10.1203/00006450-199507000-00006
   De Luca R, 2009, PEDIATRICS, V123, pE1064, DOI 10.1542/peds.2008-2407
   DEVANE GW, 1982, PEDIATR RES, V16, P504
   GIBSON KJ, 1993, J DEV PHYSIOL, V19, P125
   Guetta J, 2012, AM J RESP CELL MOL, V47, P583, DOI 10.1165/rcmb.2012-0117OC
   Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783
   Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341
   KLINK F, 1981, OBSTET GYNECOL, V57, P437
   L'Abate P, 2013, RESP PHYSIOL NEUROBI, V185, P222, DOI 10.1016/j.resp.2012.10.011
   Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038
   Nageotte M, 2005, AM J OBSTET GYNECOL, V192, P1920
   Nickel CH, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-7
   Ostergaard Louise, 2014, Hypoxia (Auckl), V2, P143
   PERKS AM, 1993, J DEV PHYSIOL, V19, P203
   PIMENTEL G, 1989, AM J OBSTET GYNECOL, V160, P242
   ROOTH G, 1979, GYNECOL OBSTET INVES, V10, P265
   ROSS MG, 1984, AM J OBSTET GYNECOL, V150, P421
   RURAK DW, 1978, J PHYSIOL-LONDON, V277, P341
   Schlapbach LJ, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-38
   SCHMIDT S, 1985, ARCH GYNECOL, V236, P145, DOI 10.1007/BF02133957
   Schuetz P, 2007, CURR OPIN CRIT CARE, V13, P578, DOI 10.1097/MCC.0b013e3282c9ac2a
   Shinozuka N, 1999, AM J OBSTET GYNECOL, V180, P1202, DOI 10.1016/S0002-9378(99)70617-4
   Smith J, 2013, BIOMARK MED, V7, P139, DOI [10.2217/bmm.12.79, 10.2217/BMM.12.79]
   Stutchfield P, 2005, BRIT MED J, V331, P662, DOI 10.1136/bmj.38547.416493.06
   Stutchfield PR, 2013, ARCH DIS CHILD-FETAL, V98, pF195, DOI 10.1136/archdischild-2012-303157
   Wellmann S, 2010, J CLIN ENDOCR METAB, V95, P5091, DOI 10.1210/jc.2010-1331
   Wen SW, 2005, CAN MED ASSOC J, V173, P759, DOI 10.1503/cmaj.045156
   Wilmink FA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.052
NR 37
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD OCT
PY 2016
VL 128
IS 4
BP 699
EP 703
DI 10.1097/AOG.0000000000001594
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX6VT
UT WOS:000384523600004
PM 27607861
ER

PT J
AU Quibel, T
   Ghout, I
   Goffinet, F
   Salomon, LJ
   Fort, J
   Javoise, S
   Bussieres, L
   Aegerter, P
   Rozenberg, P
AF Quibel, Thibaud
   Ghout, Idir
   Goffinet, Francois
   Salomon, Laurent J.
   Fort, Julie
   Javoise, Sophie
   Bussieres, Laurence
   Aegerter, Philippe
   Rozenberg, Patrick
CA Grp Rech Obstet Gynecologie GROG
TI Active Management of the Third Stage of Labor With a Combination of
   Oxytocin and Misoprostol to Prevent Postpartum Hemorrhage: A Randomized
   Controlled Trial
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID ORAL MISOPROSTOL; MATERNAL MORTALITY; DOUBLE-BLIND; EPIDEMIOLOGY;
   MULTICENTER; UTEROTONICS; GUIDELINES; DEATH; RISK
AB OBJECTIVE:To evaluate the effectiveness and safety of misoprostol administered simultaneously with oxytocin as part of the active management of the third stage of labor.METHODS:This multicenter, double-blind, randomized, placebo-controlled trial recruited women in the first stage of labor with expected vaginal deliveries at 36-42 weeks of gestation. Exclusion criteria were multiple pregnancies, hypersensitivity to misoprostol, and cesarean delivery. Participants received routine intravenous oxytocin and were randomly allocated to receive 400 micrograms misoprostol or placebo orally immediately after delivery of the newborn. The primary outcome was postpartum hemorrhage (500 mL or greater within 2 hours of birth). Secondary outcomes included severe postpartum hemorrhage (1,000 mL or greater) and adverse maternal events such as fever, shivering, and nausea. Two groups of 1,550 women were required to demonstrate a 33% decrease of postpartum hemorrhage according to a two-tailed at 0.05 with 80% power. An interim analysis was planned after 50% enrollment.RESULTS:Participant enrollment occurred from April 2010 to September 2013. Baseline characteristics were similar in the two groups. The study was discontinued after the planned interim analysis including 1,721 patients showed that misoprostol was not effective and was associated with significantly more adverse effects. The rate of postpartum hemorrhage was 8.4% (68/806) in the misoprostol and 8.3% (66/797) in the placebo group (P=.98), and rates of severe postpartum hemorrhage were 1.8% and 2.4%, respectively (P=.57). Maternal adverse events occurred significantly more frequently in the misoprostol group (for fever 30.4% in the misoprostol group compared with 6.3% in the placebo group, P<.001; for shivering 10.8% in the misoprostol group compared with 0.6% in the placebo group, P<.001).CONCLUSION:Misoprostol administered with prophylactic routine oxytocin did not reduce the rate of postpartum hemorrhage risk and increased the rate of adverse events.CLINICAL TRIAL REGISTRATION:ClinicalTrials.gov, https://clinicaltrials.gov, NCT01113229.
C1 Versailles St Quentin Univ, Poissy St Germain Hosp, Dept Obstet & Gynecol, Res Unit EA 7285, Versailles, France.
   Ambroise Pare Hosp, AP HP, Dept Clin Res Paris Ouest, Boulogne, France.
   Descartes Univ, Port Royal Cochin Hosp, Dept Obstet, Paris, France.
   Descartes Univ, Port Royal Cochin Hosp, Dept Gynecol, Paris, France.
   Descartes Univ, Necker Hosp, AP HP, Paris, France.
   Necker Cochin Hosp, AP HP, Dept Clin Res Necker Cochin, Paris, France.
RP Quibel, T (reprint author), Ctr Hosp Poissy St Germain, Serv Gynecol Obstet, 10 Rue Champ Gaillard, F-78300 Poissy, France.
EM tquibel@chi-poissy-st-germain.fr
FU Programme Hospitalier de Recherche Clinique Clinique-PHRC (Ministere de
   la Sante) [AOR 09010]
FX Supported by a grant from Programme Hospitalier de Recherche Clinique
   Clinique-PHRC 2009 (Ministere de la Sante No AOR 09010).
CR Al-Zirqi I, 2008, BJOG-INT J OBSTET GY, V115, P1265, DOI 10.1111/j.1471-0528.2008.01859.x
   Bateman BT, 2010, ANESTH ANALG, V110, P1368, DOI 10.1213/ANE.0b013e3181d74898
   Begley CM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007412.pub4
   Caliskan E, 2003, OBSTET GYNECOL, V101, P921, DOI 10.1016/S0029-7844(03)00077-2
   Callaghan WM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.011
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Chong YS, 2001, BRIT J OBSTET GYNAEC, V108, P41
   [Anonymous], 2010, INT J GYNAECOL OBSTE
   Deneux-Tharaux C, 2010, BJOG-INT J OBSTET GY, V117, P1278, DOI 10.1111/j.1471-0528.2010.02648.x
   Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6
   Elati A, 2012, OBSTET GYNECOL, V120, P1140, DOI [http://10.1097/AOG.0b013e3182707341, 10.1097/AOG.0b013e3182707341]
   Fawole AO, 2011, INT J GYNECOL OBSTET, V112, P107, DOI 10.1016/j.ijgo.2010.08.023
   Gibbins KJ, 2013, AM J OBSTET GYNECOL, V208, P181, DOI 10.1016/j.ajog.2012.07.034
   Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4
   Hofmeyr GJ, 2011, INT J GYNECOL OBSTET, V112, P98, DOI 10.1016/j.ijgo.2010.08.019
   Joseph KS, 2007, BJOG-INT J OBSTET GY, V114, P751, DOI 10.1111/j.1471-0528.2007.01316.x
   Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9
   Lumbiganon P, 1999, BRIT J OBSTET GYNAEC, V106, P304, DOI 10.1111/j.1471-0528.1999.tb08266.x
   [Anonymous], 2006, OBSTET GYNECOL
   [Anonymous], 2016, MAN POSTP HEM
   [Anonymous], 2016, POSTP HEM PREV MAN
   Saucedo M, 2013, J GYNECOL OBST BIO R, V42, P613, DOI 10.1016/j.jgyn.2013.06.011
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Schulz KF, 2010, OBSTET GYNECOL, V115, P1063, DOI 10.1097/AOG.0b013e3181d9d421
   Sentithes L, 2014, J GYNECOL OBST BIO R, V43, P1170, DOI 10.1016/j.jgyn.2014.10.009
   Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8
   Toggweiler S, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13538
   [Anonymous], 2012, COCHRANE DATABASE SY
   Westhoff G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001808.pub2
   Widmer M, 2010, LANCET, V375, P1808, DOI 10.1016/S0140-6736(10)60348-0
NR 30
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD OCT
PY 2016
VL 128
IS 4
BP 805
EP 811
DI 10.1097/AOG.0000000000001626
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX6VT
UT WOS:000384523600017
PM 27607864
ER

PT J
AU Gram, A
   Trachsel, A
   Boos, A
   Kowalewski, MP
AF Gram, Aykut
   Trachsel, Alexandra
   Boos, Alois
   Kowalewski, Mariusz P.
TI Elevated utero/placental GR/NR3C1 is not required for the induction of
   parturition in the dog
SO REPRODUCTION
LA English
DT Article
ID PLACENTAL ESTROGEN SYNTHESIS; RECEPTOR GENE-EXPRESSION; CANINE
   CORPUS-LUTEUM; OXYTOCIN RECEPTOR; PROGESTERONE-RECEPTORS; INDUCED
   LUTEOLYSIS; PERIPHERAL PLASMA; BEAGLE BITCHES; LATE PREGNANCY; UTERUS
AB The endocrine mechanisms that lead to initiation of parturition in dogs are still not fully understood. The prepartum luteolysis is associated with increased prostaglandin (PG) F2 alpha secretion; however, there is no pregnancy-or parturition-related increase in estrogens. Moreover, unlike in other mammalian species, in the dog, increased peripartum levels of cortisol measured sporadically in maternal peripheral blood are not mandatory for normal parturition. Nevertheless, auto/paracrine effects of cortisol at the placental feto-maternal level cannot be excluded. Therefore, the aim of this study was to investigate the expression and localization of glucocorticoid receptor (GR/NR3C1) in canine utero/placental (Ut/Pl) units and uterine interplacental sites at selected time points during pregnancy (pre-implantation, post-implantation and mid-gestation), and at normal and antigestagen-induced parturition. The Ut/Pl expression of GR/NR3C1 did not change significantly from pre-implantation until mid-gestation; however, it was strongly induced during the prepartum luteolysis. Within the interplacental samples, expression of GR/NR3C1-mRNA was greater post-implantation than pre-implantation and did not change afterward, i.e. toward mid-gestation. Compartmentalization studies within the Ut/Pl units, involving placenta, endometrium and myometrium separately, performed at the prepartum luteolysis revealed the highest GR/NR3C1-mRNA levels in placenta compared with endometrium and myometrium. Interestingly, in antigestagen-treated mid-pregnancy dogs, Ut/Pl and interplacental GR/NR3C1-mRNA expression remained unaffected. At the cellular level, placental GR/NR3C1 was clearly detectable in placenta fetalis, i.e. in trophoblast cells. In conclusion, increased expression of GR/NR3C1 during normal parturition, but not following antigestagen-treatment, suggest that it is not required for initiating the signaling cascade of PG synthesis leading to the induction of parturition in the dog.
C1 [Gram, Aykut; Trachsel, Alexandra; Boos, Alois; Kowalewski, Mariusz P.] Univ Zurich, Inst Vet Anat, Vetsuisse Fac, Zurich, Switzerland.
RP Kowalewski, MP (reprint author), Univ Zurich, Inst Vet Anat, Vetsuisse Fac, Zurich, Switzerland.
EM kowalewski@vetanat.uzh.ch
FU Swiss National Science Foundation (SNSF) [31003A_160251]
FX This research was supported by the Swiss National Science Foundation
   (SNSF); research grant number 31003A_160251.
CR Amoroso EC, 1952, MARSHALLS PHYSL REPR, P127
   ASH RW, 1975, J ENDOCRINOL, V64, P141, DOI 10.1677/joe.0.0640141
   Bolt RJ, 2001, PEDIATR PULM, V32, P76, DOI 10.1002/ppul.1092
   Brown AG, 2004, UTERUS HUMAN REPROD, V1034, P36, DOI [10.1196/annals.1335.004, DOI 10.1196/ANNALS.1335.004]
   CHALLIS JRG, 1977, BIOL REPROD, V16, P57, DOI 10.1095/biolreprod16.1.57
   Chida D, 2011, ENDOCRINOLOGY, V152, P1652, DOI 10.1210/en.2010-0935
   CONCANNON PW, 1977, PROSTAGLANDINS, V13, P533, DOI 10.1016/0090-6980(77)90030-2
   CONCANNON PW, 1978, BIOL REPROD, V19, P1113, DOI 10.1095/biolreprod19.5.1113
   CONCANNON PW, 1975, BIOL REPROD, V13, P112, DOI 10.1095/biolreprod13.1.112
   CONCANNON PW, 1989, J REPROD FERTIL, P3
   Driver PM, 2001, MOL HUM REPROD, V7, P357, DOI 10.1093/molehr/7.4.357
   Fieni F, 2001, J REP FER S, P243
   FLINT APF, 1978, J ENDOCRINOL, V78, P367, DOI 10.1677/joe.0.0780367
   Fuchs AR, 1999, BIOL REPROD, V60, P341, DOI 10.1095/biolreprod60.2.341
   Gram A, 2014, REPROD DOMEST ANIM, V49, P41, DOI 10.1111/rda.12295
   Gram A, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.122929
   Gram A, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.109918
   Greven H, 2007, PLACENTA, V28, P889, DOI 10.1016/j.placenta.2007.01.008
   Gupta S, 2003, J SOC GYNECOL INVEST, V10, P136, DOI 10.1016/S1071-5576(03)00010-8
   HEAP RB, 1966, J ENDOCRINOL, V34, P417, DOI 10.1677/joe.0.0340417
   Helmer H, 1998, AM J OBSTET GYNECOL, V179, P1572, DOI 10.1016/S0002-9378(98)70027-4
   HOFFMANN B, 1973, HORM RES, V4, P302, DOI 10.1159/000178317
   Hoffmann B, 2002, DOMEST ANIM ENDOCRIN, V23, P309, DOI 10.1016/S0739-7240(02)00166-2
   HOFFMANN B, 1994, EXP CLIN ENDOCRINOL, V102, P185
   JANSZEN BPM, 1995, ANIM REPROD SCI, V37, P251, DOI 10.1016/0378-4320(94)01344-L
   Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556
   KEHRER A, 1973, Z ANAT ENTWICKLUNGS, V143, P25, DOI 10.1007/BF00519908
   Kota Sunil K, 2013, Indian J Endocrinol Metab, V17, P50, DOI 10.4103/2230-8210.107841
   Kowalewski MP, 2006, J STEROID BIOCHEM, V101, P254, DOI 10.1016/j.jsbmb.2006.06.029
   Kowalewski MP, 2012, REPROD DOMEST ANIM, V47, P19, DOI 10.1111/rda.12036
   Kowalewski MP, 2014, REPROD BIOL, V14, P89, DOI 10.1016/j.repbio.2013.11.004
   Kowalewski MP, 2006, THERIOGENOLOGY, V66, P1423, DOI 10.1016/j.theriogenology.2006.01.039
   Kowalewski MP, 2011, THERIOGENOLOGY, V75, P877, DOI 10.1016/j.theriogenology.2010.10.030
   Kowalewski MP, 2010, REPRODUCTION, V139, P655, DOI 10.1530/REP-09-0140
   Kowalewski MP, 2009, ANIM REPROD SCI, V116, P129, DOI 10.1016/j.anireprosci.2008.12.011
   LARCHER A, 1995, ENDOCRINOLOGY, V136, P5350, DOI 10.1210/en.136.12.5350
   Li XQ, 2014, PLACENTA, V35, P291, DOI 10.1016/j.placenta.2014.03.005
   MAGYAR DM, 1980, ENDOCRINOLOGY, V107, P155
   MASON JI, 1989, J ENDOCRINOL, V122, P351, DOI 10.1677/joe.0.1220351
   MEIER S, 1995, J REPROD FERTIL, V103, P233
   Mparmpakas D, 2014, OBSTET GYNECOL INT, V2014, DOI [10.1155/2014/239278, DOI 10.1155/2014/239278]
   Nishiyama T, 1999, ANAT HISTOL EMBRYOL, V28, P125, DOI 10.1046/j.1439-0264.1999.00170.x
   Nnamani Mauris C, 2013, Evol Med Public Health, V2013, P273, DOI 10.1093/emph/eot022
   Nohr B, 1993, J Reprod Fertil Suppl, V47, P542
   OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015
   Onclin K, 2002, THERIOGENOLOGY, V57, P1957, DOI 10.1016/S0093-691X(02)00644-1
   PHILIBERT D, 1991, FRONT HORM RES, V19, P1
   Ratajczak CK, 2008, PEDIATR RES, V64, P581, DOI 10.1203/PDR.0b013e31818718d2
   Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965
   Schuler G, 2006, REPRODUCTION, V131, P669, DOI 10.1530/rep.1.01033
   SCHULER G, 1994, EXP CLIN ENDOCRINOL, V102, P169
   SMITH VG, 1973, J ANIM SCI, V36, P391
   Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681
   Vermeirsch H, 2000, ANAT REC, V260, P42, DOI 10.1002/1097-0185(20000901)260:1<42::AID-AR50>3.0.CO;2-8
   VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0
   Wu WX, 1996, ENDOCRINOLOGY, V137, P722, DOI 10.1210/en.137.2.722
   Wyrwoll CS, 2014, HORMONES INTRAUTERIN, V12, P17, DOI [10.1007/978-3-319-02591-9, DOI 10.1007/978-3-319-02591-9]
   Zakar T, 2007, AM J OBSTET GYNECOL, V196, P289, DOI 10.1016/j.ajog.2006.09.005
   Zhang SM, 2007, STEROIDS, V72, P600, DOI 10.1016/j.steroids.2007.03.012
NR 59
TC 0
Z9 0
U1 0
U2 0
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD OCT
PY 2016
VL 152
IS 4
BP 303
EP 311
DI 10.1530/REP-16-0213
PG 9
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA DW4HN
UT WOS:000383603900008
PM 27530348
ER

PT J
AU Matheson, K
   McQuaid, RJ
   Anisman, H
AF Matheson, Kimberly
   McQuaid, Robyn J.
   Anisman, Hymie
TI Group identity, discrimination, and well-being: confluence of
   psychosocial and neurobiological factors
SO CURRENT OPINION IN PSYCHOLOGY
LA English
DT Article
ID DIURNAL CORTISOL RHYTHMS; OXYTOCIN RECEPTOR GENE; PERCEIVED
   DISCRIMINATION; INTRANASAL OXYTOCIN; INTERGENERATIONAL TRANSMISSION;
   DEPRESSIVE DISORDER; SOCIAL IDENTITY; STRESS; HEALTH; CONSEQUENCES
AB In this paper we examine the variability in the associations between discrimination/stigma and vulnerability to poor health outcomes in light of psychosocial and neurobiological processes that might contribute to these relations. Depending on the features of the discrimination or stigma, different neurobiological stress reactions occur (i.e., cortisol reactivity vs. blunting). The effects of discrimination and stigma on well-being may be moderated by oxytocin, as this hormone influences processes related to the salience of the social category. Emerging areas that may further illuminate the links between discrimination and health outcomes involve the inflammatory immune system, as well as intergenerational transmission of severe or chronic stressors.
C1 [Matheson, Kimberly; McQuaid, Robyn J.; Anisman, Hymie] Carleton Univ, Ottawa, ON K1S 5B6, Canada.
   [Matheson, Kimberly] Carleton Univ, Dept Neurosci, Ottawa, ON K1S 5B6, Canada.
RP Matheson, K (reprint author), Carleton Univ, Ottawa, ON K1S 5B6, Canada.; Matheson, K (reprint author), Carleton Univ, Dept Neurosci, Ottawa, ON K1S 5B6, Canada.
EM kim.matheson@carleton.ca
CR Aizer A, 2014, SCIENCE, V344, P856, DOI 10.1126/science.1251872
   Anisman H, 2008, PROG NEUROBIOL, V85, P1, DOI 10.1016/j.pneurobio.2008.01.004
   Audet MC, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00416
   Berger M, 2015, STRESS, V18, P1, DOI 10.3109/10253890.2014.989204
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bombay A, 2014, CULT DIVERS ETHN MIN, V20, P75, DOI 10.1037/a0033352
   Bowers ME, 2016, NEUROPSYCHOPHARMACOL, V41, P232, DOI 10.1038/npp.2015.247
   Brittian AS, 2015, CULT DIVERS ETHN MIN, V21, P41, DOI 10.1037/a0037531
   Brody GH, 2015, J ADOLESCENT HEALTH, V56, P496, DOI 10.1016/j.jadohealth.2015.01.017
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Cruwys T, 2014, PERS SOC PSYCHOL REV, V18, P215, DOI 10.1177/1088868314523839
   Daskalakis NP, 2013, ENDOCRIN METAB CLIN, V42, P503, DOI 10.1016/j.ecl.2013.05.004
   De Dreu CKW, 2012, HORM BEHAV, V61, P419, DOI 10.1016/j.yhbeh.2011.12.009
   Doyle DM, 2014, J BEHAV MED, V37, P1134, DOI 10.1007/s10865-014-9563-8
   Eisenberger NI, 2015, ANNU REV PSYCHOL, V66, P601, DOI 10.1146/annurev-psych-010213-115146
   Giamo LS, 2012, CULT DIVERS ETHN MIN, V18, P319, DOI 10.1037/a0029729
   Haslam SA, 2009, APPL PSYCHOL-INT REV, V58, P1, DOI 10.1111/j.1464-0597.2008.00379.x
   Heim C, 2010, DEV PSYCHOBIOL, V52, P671, DOI 10.1002/dev.20494
   Hollon NG, 2015, NAT NEUROSCI, V18, P1405, DOI 10.1038/nn.4114
   Jamieson JP, 2013, PSYCHOL SCI, V24, P131, DOI 10.1177/0956797612448194
   Jetten J, 2012, THE SOCIAL CURE
   Jetten J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124609
   Jones JM, 2011, SOC PSYCHOL PERS SCI, V2, P239, DOI 10.1177/1948550610386806
   Luo SY, 2015, NEUROIMAGE, V110, P22, DOI 10.1016/j.neuroimage.2015.01.042
   Marsh N, 2015, J NEUROSCI, V35, P15696, DOI 10.1523/JNEUROSCI.3199-15.2015
   Martin CG, 2012, HORM BEHAV, V61, P661, DOI 10.1016/j.yhbeh.2012.02.025
   Matheson K, 2014, HDB PSYCHONEUROIMMUN, P234
   Matheson K, 2012, THE SOCIAL CURE, P133
   McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7
   McQuaid RJ, 2015, SOC COGN AFFECT NEUR, V10, P1153, DOI 10.1093/scan/nsu166
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Merali Z, 2004, EUR J NEUROSCI, V20, P229, DOI 10.1111/j.1460-9568.2004.03468.x
   Paradies Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138511
   Priest N, 2013, SOC SCI MED, V95, P115, DOI 10.1016/j.socscimed.2012.11.031
   Quinn DM, 2015, PSYCHIATR REHABIL J, V38, P103, DOI 10.1037/prj0000136
   Quinn DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096977
   Raison CL, 2013, MOD TR PHARMACOPSYCH, V28, P33, DOI 10.1159/000343966
   Schmitt MT, 2014, PSYCHOL BULL, V140, P921, DOI 10.1037/a0035754
   Schvey NA, 2014, PSYCHOSOM MED, V76, P156, DOI 10.1097/PSY.0000000000000031
   Shalvi S, 2014, P NATL ACAD SCI USA, V111, P5503, DOI 10.1073/pnas.1400724111
   Sheng F, 2013, BIOL PSYCHOL, V92, P380, DOI 10.1016/j.biopsycho.2012.11.018
   Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302
   Slavich GM, 2010, P NATL ACAD SCI USA, V107, P14817, DOI 10.1073/pnas.1009164107
   Szyf M, 2015, TRENDS MOL MED, V21, P134, DOI 10.1016/j.molmed.2014.12.004
   Wei D, 2015, P NATL ACAD SCI USA, V112, P14084, DOI 10.1073/pnas.1509795112
   Yehuda R., 2015, BIOL PSYCHIAT
   Zeiders KH, 2014, PSYCHONEUROENDOCRINO, V50, P280, DOI 10.1016/j.psyneuen.2014.08.023
NR 49
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-250X
J9 CURR OPIN PSYCHOL
JI Curr. Opin. Psychol.
PD OCT
PY 2016
VL 11
BP 35
EP 39
DI 10.1016/j.copsyc.2016.05.005
PG 5
WC Psychology, Multidisciplinary
SC Psychology
GA EA8IQ
UT WOS:000386878900009
ER

PT J
AU Kranz, TM
   Kopp, M
   Waltes, R
   Sachse, M
   Duketis, E
   Jarczok, TA
   Degenhardt, F
   Gorgen, K
   Meyer, J
   Freitag, CM
   Chiocchetti, AG
AF Kranz, Thorsten M.
   Kopp, Marnie
   Waltes, Regina
   Sachse, Michael
   Duketis, Eftichia
   Jarczok, Tomasz A.
   Degenhardt, Franziska
   Goergen, Katharina
   Meyer, Jobst
   Freitag, Christine M.
   Chiocchetti, Andreas G.
TI Meta-analysis and association of two common polymorphisms of the human
   oxytocin receptor gene in autism spectrum disorder
SO AUTISM RESEARCH
LA English
DT Article
DE meta-analysis; autism spectrum disorder; oxytocin receptor; genotyping;
   social interaction; endophenotype; genetics; oxytocin
ID ARGININE-VASOPRESSIN; CANDIDATE GENES; OXTR GENE; BEHAVIOR; CHILDREN;
   POPULATION; COGNITION; ETIOLOGY; DEFICITS; SYSTEM
AB Neuropeptides such as oxytocin (OXT) are known facilitators of social behavior across species. Variants of the OXT receptor gene (OXTR) have been tested for association with autism spectrum disorder (ASD) across manifold ethnicities, yielding both positive and negative findings. A recent meta-analysis, comprising 16 single nucleotide polymorphisms (SNPs), has corroborated the implication of OXTR in the etiology of ASD. Here, we genotyped and tested two additional variants (rs237889 and rs237897) for association with ASD in two German predominantly high-functioning ASD samples. We found nominal over-transmission (OR=1.48, CI95=1.06-2.08, P=0.022) for the minor A allele of variant rs237889G>A in sample 1 (N=135 complete parent-offspring trios, 29 parent child duos), but not in sample 2 (362 trios, 69 duos). Still, in a meta-analysis comprising four different studies including the two unreported German data sets (N=542 families), this finding was confirmed (OR=1.12; CI95=1.01-1.24, random effects P=0.012). In addition, carriers of the minor risk allele rs237889-A showed significantly increased severity scores, as assessed through the autism diagnostic interview - revised (ADI-R), with highly significant increases in social interaction deficits. Our results corroborate the implication of common OXTR variants in the etiology of ASD. There is a need for functional studies to delineate the neurobiological implications of this and other association findings. (172/250). Autism Res2016, 9: 1036-1045. (c) 2016 International Society for Autism Research, Wiley Periodicals, Inc.
C1 [Kranz, Thorsten M.; Goergen, Katharina; Meyer, Jobst] Univ Trier, Dept Neurobehav Genet, Johanniterufer 15, D-54290 Trier, Germany.
   [Kopp, Marnie; Waltes, Regina; Sachse, Michael; Duketis, Eftichia; Jarczok, Tomasz A.; Freitag, Christine M.; Chiocchetti, Andreas G.] Goethe Univ Frankfurt, Dept Child & Adolescent Psychiat, Psychosomat & Psychotherapy, Deutschordenstr 50, D-60528 Frankfurt, Germany.
   [Degenhardt, Franziska] Univ Bonn, Inst Human Genet, Sigmund Freud Str 25, D-53127 Bonn, Germany.
RP Chiocchetti, AG (reprint author), Goethe Univ Frankfurt, Dept Child & Adolescent Psychiat, Psychosomat & Psychotherapy, Deutschordenstr 50, D-60528 Frankfurt, Germany.
EM andreas.chiocchetti@kgu.de
FU German Research Foundation (DFG) [ME 1923/5-1, ME 1632/5-3, GRK 1389/1];
   Saarland University [T6 03 10 00-45]; European Commission; German
   Bundesministerium fur Bildung und Forschung BMBF (ERA-NET NEURON
   project: EUHFAUTISM) [EUHFAUTISM-01EW1105]
FX German Research Foundation (DFG) (ME 1923/5-1, ME 1632/5-3, and GRK
   1389/1 to J.M.); Saarland University (T6 03 10 00-45 to C.M.F); The
   European Commission and the German Bundesministerium fur Bildung und
   Forschung BMBF (ERA-NET NEURON project: EUHFAUTISM; EUHFAUTISM-01EW1105
   to C.M.F).
CR Alves E, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00032
   Baribeau DA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00335
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Brune M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-38
   Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   de Krom M, 2009, BIOL PSYCHIAT, V65, P625, DOI 10.1016/j.biopsych.2008.09.035
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gauderman W. J., 2006, QUANTO 1 1 COMPUTER
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   INTERNATIONAL HAPMAP C, 2010, NATURE, V467, P52, DOI DOI 10.1038/NATURE09298
   Israel S, 2008, PROG BRAIN RES, V170, P435, DOI 10.1016/S0079-6123(08)00434-2
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Kelemenova S, 2010, PSYCHIAT GENET, V20, P137, DOI 10.1097/YPG.0b013e32833a1eb3
   Kleinhans NM, 2011, NEUROIMAGE, V54, P697, DOI 10.1016/j.neuroimage.2010.07.037
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Mosconi MW, 2009, ARCH GEN PSYCHIAT, V66, P509, DOI 10.1001/archgenpsychiatry.2009.19
   Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010
   Poelmans G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.48
   Ronald A, 2011, AM J MED GENET B, V156B, P255, DOI 10.1002/ajmg.b.31159
   Tansey KE, 2010, NEUROSCI LETT, V474, P163, DOI 10.1016/j.neulet.2010.03.035
   Terenzi MG, 2005, NEUROSCIENCE, V134, P345, DOI 10.1016/j.neuroscience.2005.04.004
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Waltes R, 2014, J NEURAL TRANSM, V121, P1107, DOI 10.1007/s00702-014-1230-2
   Wermter AK, 2010, AM J MED GENET B, V153B, P629, DOI 10.1002/ajmg.b.31032
   World Health Organization, 1993, ICD 10 CLASS MENT BE
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Yates D, 2012, NAT REV NEUROSCI, V13, DOI 10.1038/nrn3213
   Yrigollen CM, 2008, BIOL PSYCHIAT, V63, P911, DOI 10.1016/j.biopsych.2007.11.015
NR 45
TC 3
Z9 3
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-3792
EI 1939-3806
J9 AUTISM RES
JI Autism Res.
PD OCT
PY 2016
VL 9
IS 10
BP 1036
EP 1045
DI 10.1002/aur.1597
PG 10
WC Behavioral Sciences; Psychology, Developmental
SC Behavioral Sciences; Psychology
GA EA4IX
UT WOS:000386576100002
PM 26788924
ER

PT J
AU Lieberwirth, C
   Wang, ZX
AF Lieberwirth, Claudia
   Wang, Zuoxin
TI The neurobiology of pair bond formation, bond disruption, and social
   buffering
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Article
ID FEMALE PRAIRIE VOLES; PARTNER-PREFERENCE FORMATION; NUCLEUS-ACCUMBENS
   DOPAMINE; OXYTOCIN RECEPTOR DENSITY; MICROTUS-OCHROGASTER; MONOGAMOUS
   RODENT; SEXUAL FIDELITY; BEHAVIOR; VASOPRESSIN; AMPHETAMINE
AB Enduring social bonds play an essential role in human society. These bonds positively affect psychological, physiological, and behavioral functions. Here, we review the recent literature on the neurobiology, particularly the role of oxytocin and dopamine, of pair bond formation, bond disruption, and social buffering effects on stress responses, from studies utilizing the socially monogamous prairie vole (Microtus ochrogaster).
C1 [Lieberwirth, Claudia] Utah Valley Univ, Dept Behav Sci, Orem, UT 84057 USA.
   [Wang, Zuoxin] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
   [Wang, Zuoxin] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.
RP Lieberwirth, C (reprint author), Utah Valley Univ, Dept Behav Sci, Orem, UT 84057 USA.
EM Lieberwirth.c@gmail.com
FU NIH [MHR01-058616, MHR01-089852]
FX We thank Hans Jorgensen for the careful reading of the manuscript and
   Charles Badland for his assistance with the figure. This work was
   supported by NIH grants MHR01-058616 and MHR01-089852 to ZXW.
CR Acevedo BP, 2011, SOC COGN AFFECT NEUR, P1
   Anacker AMJ, 2014, P NATL ACAD SCI USA, V111, P6052, DOI 10.1073/pnas.1320879111
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aragona BJ, 2003, J NEUROSCI, V23, P3483
   Bales KL, 2007, BRAIN RES, V1184, P245, DOI 10.1016/j.brainres.2007.09.087
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Bosch OJ, 2009, NEUROPSYCHOPHARMACOL, V34, P1406, DOI 10.1038/npp.2008.154
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   CARTER CS, 1995, NEUROSCI BIOBEHAV R, V19, P303
   Carter CS, 1997, ANN NY ACAD SCI, V807, P260, DOI 10.1111/j.1749-6632.1997.tb51925.x
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Dewsbury DA, 1988, COMP PSYCHOL MONOGAM, V35
   Duclot F, 2016, HORM BEHAV, V81, P68, DOI 10.1016/j.yhbeh.2016.04.001
   Dunbar RIM, 2010, NEUROSCI BIOBEHAV R, V34, P260, DOI 10.1016/j.neubiorev.2008.07.001
   Fraser ON, 2008, P NATL ACAD SCI USA, V105, P8557, DOI 10.1073/pnas.0804141105
   Gingrich B, 2000, BEHAV NEUROSCI, V114, P173, DOI 10.1037/0735-7044.114.1.173
   Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106
   Grippo AJ, 2007, PSYCHONEUROENDOCRINO, V32, P966, DOI 10.1016/j.psyneuen.2007.07.004
   Grippo AJ, 2007, BIOL PSYCHIAT, V62, P1162, DOI 10.1016/j.biopsych.2007.04.011
   Grippo AJ, 2007, PSYCHOSOM MED, V69, P149, DOI 10.1097/PSY.0b013e31802f054b
   Grippo AJ, 2009, PSYCHONEUROENDOCRINO, V34, P1542, DOI 10.1016/j.psyneuen.2009.05.017
   Grippo Angela J, 2008, Depress Anxiety, V25, pE17, DOI 10.1002/da.20375
   Gunaydin LA, 2014, CELL, V157, P1535, DOI 10.1016/j.cell.2014.05.017
   Hostetler CM, 2014, PSYCHONEUROENDOCRINO, V39, P152, DOI 10.1016/j.psyneuen.2013.10.006
   INSEL TR, 1992, PSYCHONEUROENDOCRINO, V17, P3, DOI 10.1016/0306-4530(92)90073-G
   INSEL TR, 1995, PHYSIOL BEHAV, V57, P615, DOI 10.1016/0031-9384(94)00362-9
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Keebaugh AC, 2011, HORM BEHAV, V60, P498, DOI 10.1016/j.yhbeh.2011.07.018
   Kikusui T, 2006, PHILOS T R SOC B, V361, P2215, DOI 10.1098/rstb.2006.1941
   KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721
   Lieberwirth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00171
   Lieberwirth C, 2012, HORM BEHAV, V62, P357, DOI 10.1016/j.yhbeh.2012.03.005
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   Liu Y, 2011, J NEUROSCI, V31, P7960, DOI 10.1523/JNEUROSCI.1006-11.2011
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   McNeal N, 2014, AUTON NEUROSCI-BASIC, V180, P9, DOI 10.1016/j.autneu.2013.10.001
   Numan M, 2003, NEUROBIOLOGY PARENTA
   Okhovat M, 2015, SCIENCE, V350, P1371, DOI 10.1126/science.aac5791
   Ophir AG, 2008, P NATL ACAD SCI USA, V105, P1249, DOI 10.1073/pnas.0709116105
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Ortigue S, 2010, J SEX MED, V7, P3541, DOI 10.1111/j.1743-6109.2010.01999.x
   Pournajafi-Nazarloo H, 2013, PEPTIDES, V43, P20, DOI 10.1016/j.peptides.2013.02.007
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Smith AS, 2016, PSYCHONEUROENDOCRINO, V63, P50, DOI 10.1016/j.psyneuen.2015.09.017
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   Smith AS, 2012, HORM BEHAV, V61, P320, DOI 10.1016/j.yhbeh.2011.11.010
   Solomon NG, 2009, MOL ECOL, V18, P4680, DOI 10.1111/j.1365-294X.2009.04361.x
   Song HW, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00071
   Sun P, 2014, BEHAV BRAIN RES, V265, P22, DOI 10.1016/j.bbr.2014.02.016
   Swain JE, 2007, J CHILD PSYCHOL PSYC, V48, P262, DOI 10.1111/j.1469-7610.2007.01731.x
   Wang H, 2013, NAT NEUROSCI, V16, P919, DOI 10.1038/nn.3420
   Wang ZX, 1999, BEHAV NEUROSCI, V113, P602, DOI 10.1037/0735-7044.113.3.602
   WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F
   WILLIAMS JR, 1992, ANN NY ACAD SCI, V652, P487, DOI 10.1111/j.1749-6632.1992.tb34393.x
   Young KA, 2014, J NEUROSCI, V34, P8499, DOI 10.1523/JNEUROSCI.4275-13.2014
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young LJ, 2005, J COMP NEUROL, V493, P51, DOI 10.1002/cne.20771
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 62
TC 0
Z9 0
U1 4
U2 4
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD OCT
PY 2016
VL 40
BP 8
EP 13
DI 10.1016/j.conb.2016.05.006
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA EA2EO
UT WOS:000386405800003
PM 27290660
ER

PT J
AU Poklis, JL
   Mohs, AJ
   Wolf, CE
   Poklis, A
   Peace, MR
AF Poklis, Justin L.
   Mohs, Amanda J.
   Wolf, Carl E.
   Poklis, Alphonse
   Peace, Michelle R.
TI Identification of Drugs in Parenteral Pharmaceutical Preparations from a
   Quality Assurance and a Diversion Program by Direct Analysis in
   Real-Time AccuTOF(TM)-Mass Spectrometry (DART-MS)
SO JOURNAL OF ANALYTICAL TOXICOLOGY
LA English
DT Article
ID SUBSTANCE-ABUSE; ANESTHESIOLOGY; PHYSICIANS; ADDICTION
AB In healthcare settings drug diversion and impairment of physicians are major concerns requiring a rapid and efficient method for surveillance and detection. A Direct Analysis in Real Time ion source coupled to a JEOL AccuTOF(TM) time-of-flight mass spectrometer (DART-MS) method was developed to screen parenteral pharmaceutical formulations for potential drug diversion. Parenteral pharmaceutical formulations are also known as injectable formulations and are used with intravenous, subcutaneous, intramuscular and intra-articular administration. A library was created using the mass spectra data collected by a DART-MS operated in switching mode at 20, 60 and 90 V settings. This library contained 17 commonly encountered drugs in parenteral pharmaceutical formulations that included the surgical analgesic: fentanyl, hydromorphone and morphine; anesthetic: baclofen, bupivacaine, ketamine, midazolam, ropivacaine and succinylcholine; and a mixture of other drug classes: caffeine, clonidine, dexamethasone, ephedrine, heparin, methadone, oxytocin and phenylephrine. Randomly selected 200 de-identified parenteral pharmaceutical formulations containing one or more drugs were submitted for analysis to the FIRM Toxicology Laboratory at Virginia Commonwealth University Health and were screened using the DART-MS. The drug contents of the de-identified formulations were previously confirmed by a published high performance liquid chromatography (HPLC) method. The drugs in the formulations were rapidly and successfully identified using the generated library. The DART-MS and HPLC results were in complete agreement for all 200 parenteral pharmaceutical formulations.
C1 [Poklis, Justin L.; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Mohs, Amanda J.; Wolf, Carl E.; Poklis, Alphonse; Peace, Michelle R.] Virginia Commonwealth Univ, Dept Forens Sci, Med Coll Virginia Campus, Richmond, VA 23284 USA.
   [Wolf, Carl E.; Poklis, Alphonse] Virginia Commonwealth Univ, Dept Pathol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
RP Poklis, JL (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
EM justin.poklis@vcuhealth.org
FU National Institute on Health (NIH) Center for Drug Abuse [P30DA033934]
FX This project was supported in part by the National Institute on Health
   (NIH) Center for Drug Abuse grant P30DA033934.
CR Bell D M, 1999, AANA J, V67, P133
   Berge KH, 2012, MAYO CLIN PROC, V87, P674, DOI 10.1016/j.mayocp.2012.03.013
   Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB
   Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1
   Cody RB, 2005, ANAL CHEM, V77, P2297, DOI 10.1021/ac050162j
   Cody R. B., 2005, JEOL NEWS, V40, P8
   Danhelova H, 2012, ANAL BIOANAL CHEM, V403, P2883, DOI 10.1007/s00216-012-5820-2
   Devine B, 2012, AM J HEALTH-SYST PH, V69, P552, DOI 10.2146/ajhp120010
   HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333
   MCAULIFFE WE, 1987, AM J HOSP PHARM, V44, P311
   McClure SR, 2011, AM J HEALTH-SYST PH, V68, P689, DOI 10.2146/ajhp100212
   SILVERSTEIN JH, 1993, ANESTHESIOLOGY, V79, P354, DOI 10.1097/00000542-199308000-00022
   Wolf CE, 2005, J ANAL TOXICOL, V29, P711
NR 13
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0146-4760
EI 1945-2403
J9 J ANAL TOXICOL
JI J. Anal. Toxicol.
PD OCT
PY 2016
VL 40
IS 8
BP 608
EP 616
DI 10.1093/jat/bkw065
PG 9
WC Chemistry, Analytical; Toxicology
SC Chemistry; Toxicology
GA EA9IT
UT WOS:000386957100007
PM 27474362
ER

PT J
AU Donhoffner, ME
   Goings, SP
   Atabaki, K
   Wood, RI
AF Donhoffner, M. E.
   Goings, S. P.
   Atabaki, K.
   Wood, R. I.
TI Intracerebroventricular Oxytocin Self-Administration in Female Rats
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE oxytocin; self-administration; intracerebroventricular; operant
   behaviour; reinforcement; rats
ID CONDITIONED PLACE PREFERENCE; ANXIETY-RELATED BEHAVIOR;
   MICROTUS-OCHROGASTER; SEXUAL RECEPTIVITY; MATERNAL-BEHAVIOR; SOCIAL
   ATTACHMENT; ANIMAL-MODELS; ESTROGEN; MICE; SYSTEM
AB Oxytocin (OT) is a neuromodulator that facilitates pair-bonding, maternal care and social approach. OT is considered to promote these social behaviours by enhancing the salience and reinforcing effects of relevant social stimuli. There is the additional possibility that OT per se may be rewarding. To test this, we investigated whether female rats would voluntarily self-administer OT. Female Long-Evans rats were ovariectomised and then received an oestrogen implant and an i.c.v. cannula. Rats were tested in an operant chamber with active and inactive levers. They were initially tested for 4h/day on a fixed-ratio 5 schedule for self-administration of artificial cerebral spinal fluid (aCSF) for 5days, followed by aCSF, or OT, at 1 or 10ng/l for another 5days. Rats self-administering aCSF made 36.2 +/- 6.2 active lever responses/4h versus 14.9 +/- 3.4 inactive responses. Responses for 1ng/l OT were similar. However, rats self-administering 10ng/l OT made significantly more active lever responses (67.8 +/- 12.0 per 4h), and received 121.4 +/- 21.0ng OT/4h. To determine whether reduced anxiety contributes to the reinforcing effects of OT, rats received an infusion of aCSF or OT at 0.3 or 3.0g immediately before testing on the elevated plus maze. There was no effect of OT on anxiety as reflected by percentage time spent on the open arms, as well as no effect of OT on locomotion as measured either by the number of closed arm entries or the number of total arm entries. These results suggest that OT may be rewarding, and that this is not a result of the anxiolytic effects of OT.
C1 [Donhoffner, M. E.; Goings, S. P.] Univ Southern Calif, Grad Program Neurosci, Los Angeles, CA 90033 USA.
   [Atabaki, K.; Wood, R. I.] Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, 1333 San Pablo St,BMT 408a, Los Angeles, CA 90033 USA.
   [Atabaki, K.] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden.
RP Wood, RI (reprint author), Univ Southern Calif, Keck Sch Med, Dept Cell & Neurobiol, 1333 San Pablo St,BMT 408a, Los Angeles, CA 90033 USA.
EM riw@usc.edu
FU NIH [R21-AA020575]
FX The present study was supported by NIH (R21-AA020575) to RIW.
CR ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   ARLETTI R, 1985, NEUROPEPTIDES, V6, P247, DOI 10.1016/0143-4179(85)90095-2
   ARLETTI R, 1990, PHYSIOL BEHAV, V48, P825, DOI 10.1016/0031-9384(90)90234-U
   BALE TL, 1995, ENDOCRINOLOGY, V136, P27, DOI 10.1210/en.136.1.27
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   BENELLI A, 1994, NEUROPEPTIDES, V27, P245, DOI 10.1016/0143-4179(94)90005-1
   Bosch OJ, 2005, J NEUROSCI, V25, P6807, DOI 10.1523/JNEUROSCI.1342-05.2005
   CALDWELL JD, 1986, NEUROPEPTIDES, V7, P175, DOI 10.1016/0143-4179(86)90093-4
   Dumais KM, 2013, HORM BEHAV, V64, P693, DOI 10.1016/j.yhbeh.2013.08.012
   Dumont GJH, 2009, SOC NEUROSCI-UK, V4, P359, DOI 10.1080/17470910802649470
   ELLIS GB, 1980, NEUROENDOCRINOLOGY, V31, P205, DOI 10.1159/000123075
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Figueira RJ, 2008, BEHAV NEUROSCI, V122, P618, DOI 10.1037/0735-7044.122.3.618
   File S.E., 2004, CURR PROTOC NEUROSCI, V8, P3, DOI DOI 10.1002/0471142301.NS0803S26
   FLEMING AS, 1994, PSYCHOBIOLOGY, V22, P44
   Frye CA, 2006, BRAIN RES, V1067, P209, DOI 10.1016/j.brainres.2005.10.038
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gipson CD, 2011, EXP CLIN PSYCHOPHARM, V19, P409, DOI 10.1037/a0024682
   Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3
   Kent K, 2013, J NEUROENDOCRINOL, V25, P803, DOI 10.1111/jne.12075
   Lee A, 2000, BEHAV BRAIN RES, V108, P213
   Lynch WJ, 2010, COMPARATIVE MED, V60, P177
   Mantella RC, 2003, ENDOCRINOLOGY, V144, P2291, DOI 10.1210/en.2002-0197
   McCarthy MM, 1996, PHYSIOL BEHAV, V60, P1209
   McCarthy MM, 1995, ADV EXP MED BIOL, V395, P235
   NEUMANN I, 1993, NEUROSCIENCE, V53, P65, DOI 10.1016/0306-4522(93)90285-N
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   NEWMAN KS, 1988, ANIM BEHAV, V36, P1779, DOI 10.1016/S0003-3472(88)80117-9
   PEDERSEN CA, 1979, P NATL ACAD SCI USA, V76, P6661, DOI 10.1073/pnas.76.12.6661
   Perry AN, 2013, HORM BEHAV, V64, P573, DOI 10.1016/j.yhbeh.2013.08.007
   Peters ST, 2016, ADDICT BIOL, DOI [10.1111/adb.12362, DOI 10.1111/ADB.12362]
   PILOTTO R, 1984, PSYCHOPHARMACOLOGY, V84, P174, DOI 10.1007/BF00427442
   Pope HG, 2014, ENDOCR REV, V35, P341, DOI 10.1210/er.2013-1058
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Sato SM, 2010, PSYCHONEUROENDOCRINO, V35, P1063, DOI 10.1016/j.psyneuen.2010.01.007
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Silverman JL, 2007, HORM BEHAV, V52, P146, DOI 10.1016/j.yhbeh.2007.03.017
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI 10.1007/BF02246268
   SZOSTAK C, 1987, NEUROPHARMACOLOGY, V26, P1673, DOI 10.1016/0028-3908(87)90116-X
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Volman SF, 2013, J NEUROSCI, V33, P17569, DOI 10.1523/JNEUROSCI.3250-13.2013
   Walf AA, 2008, NEUROREPORT, V19, P789, DOI 10.1097/WNR.0b013e3282fe209c
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Wood RI, 2004, PSYCHOPHARMACOLOGY, V171, P298, DOI 10.1007/s00213-003-1587-7
   Young LJ, 2015, NEUROPSYCHOPHARMACOL, V40, P243, DOI 10.1038/npp.2014.186
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 54
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD OCT
PY 2016
VL 28
IS 10
DI 10.1111/jne.12416
PG 6
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA EB0WJ
UT WOS:000387066900005
ER

PT J
AU Leng, G
   Sabatier, N
AF Leng, G.
   Sabatier, N.
TI Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random
   Numbers
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Review
DE ELISA; radioimmunoassay; bioassay; oxytocin; vasopressin; sample matrix
ID METABOLIC-CLEARANCE RATE; PLASMA ARGININE-VASOPRESSIN; TANDEM
   MASS-SPECTROMETRY; ANTIDIURETIC-HORMONE; POSTERIOR PITUITARY; MILK
   EJECTION; NEUROHYPOPHYSEAL HORMONES; NEUROSECRETORY GRANULES;
   CEREBROSPINAL-FLUID; ENZYME-IMMUNOASSAY
AB In this review, we consider the ways in which vasopressin and oxytocin have been measured since their first discovery. Two different ways of measuring oxytocin in widespread use currently give values in human plasma that differ by two orders of magnitude, and the values measured by these two methods in the same samples show no correlation. The notion that we should accept this seems absurd. Either one (or both) methods is not measuring oxytocin, or, by oxytocin', the scientists that use these different methods mean something very different. If these communities are to talk to each other, it is important to validate one method and invalidate the other, or else to establish exactly what each community understands by oxytocin'. A similar issue concerns vasopressin: again, different ways of measuring vasopressin give values in human plasma that differ by two orders of magnitude, and it appears that the same explanation for discrepant oxytocin measurements applies to discrepant vasopressin measurements. The first assays for oxytocin and vasopressin measured biological activity directly. When immunoassays were introduced, they encountered problems: high molecular weight factors in raw plasma interfered with the binding of antibodies to the hormones, leading to high and erroneous readings. When these interfering factors were removed by extraction of plasma samples, immunoassays gave measurements consistent with bioassays, with measures of turnover and with the sensitivity of target tissues to exogenous hormone. However, many recent papers use an enzyme-linked immunoassay to measure plasma levels without extracting the samples. Like the first radioimmunassays of unextracted plasma, this generates impossibly high and wholly erroneous measurements.
C1 [Leng, G.; Sabatier, N.] Univ Edinburgh, Ctr Integrat Physiol, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.
RP Leng, G (reprint author), Univ Edinburgh, Ctr Integrat Physiol, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.
EM gareth.leng@ed.ac.uk
FU European Union [607310]
FX We thank Professors John Russell and Mike Ludwig for their helpful
   comments on earlier drafts of this manuscript. Research in Gareth Leng's
   laboratory is supported by the European Union's Seventh Framework
   Programme for research, technological development and demonstration
   (Grant No. 607310; Nudge-it).
CR ANDERSEN LJ, 1990, AM J PHYSIOL, V259, pR53
   Anderson GM, 2006, J AUTISM DEV DISORD, V36, P829, DOI 10.1007/s10803-006-0153-7
   ANG VTY, 1982, J ENDOCRINOL, V93, P319, DOI 10.1677/joe.0.0930319
   Apter-Levi Y, 2014, BRAIN RES, V1580, P124, DOI 10.1016/j.brainres.2013.10.052
   ARGENT NB, 1992, CLIN SCI, V83, P583
   Arrowsmith S, 2014, J NEUROENDOCRINOL, V26, P356, DOI 10.1111/jne.12154
   BAERWOLFF M, 1988, AM J PHYSIOL, V255, pR940
   Balanescu S, 2011, J CLIN ENDOCR METAB, V96, P1046, DOI 10.1210/jc.2010-2499
   BANGHAM D R, 1958, Bull World Health Organ, V19, P325
   BAYLIS PH, 1977, CLIN ENDOCRINOL, V7, P91, DOI 10.1111/j.1365-2265.1977.tb01300.x
   Bell WB, 1909, BRIT MED J, V1909, P1609
   BENMANSOUR M, 1982, EUR J CLIN INVEST, V12, P475, DOI 10.1111/j.1365-2362.1982.tb02228.x
   Bjerner J, 2005, CLIN CHEM, V51, P9, DOI 10.1373/clinchem.2004.042994
   Blanks AM, 2003, BJOG-INT J OBSTET GY, V110, P46, DOI 10.1016/S1470-0328(03)00024-7
   Budden A, 2014, COCHRANE DB SYST REV, V10
   BURD JM, 1985, J IMMUNOASSAY, V6, P227, DOI 10.1080/01971528508063031
   BURR IM, 1969, J CLIN ENDOCR METAB, V29, P948
   BYRNES DJ, 1976, HORM METAB RES, V8, P361
   CARATY A, 1980, REPROD NUTR DEV, V20, P1489, DOI 10.1051/rnd:19800808
   Carter CS, 2007, ANN NY ACAD SCI, V1098, P312, DOI 10.1196/annals.1384.006
   Chan WY, 2000, EXP PHYSIOL, V85, p7S, DOI 10.1111/j.1469-445X.2000.tb00003.x
   CHARD T, 1973, J ENDOCRINOL, V58, P143, DOI 10.1677/joe.0.0580143
   CHARD T, 1970, J ENDOCRINOL, V48, P223, DOI 10.1677/joe.0.0480223
   CHARD T, 1970, J ENDOCRINOL, V46, P533, DOI 10.1677/joe.0.0460533
   CHARD T, 1970, J ENDOCRINOL, V46, P269, DOI 10.1677/joe.0.0460269
   CHIODERA P, 1984, J ENDOCRINOL INVEST, V7, P287
   Christensen JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116172
   CHRISTENSEN MS, 1976, SCAND J CLIN LAB INV, V36, P313, DOI 10.3109/00365517609055266
   Cobo E, 1970, Rev Colomb Obstet Ginecol, V21, P455
   CZACZKES JW, 1964, J CLIN INVEST, V43, P1649, DOI 10.1172/JCI105040
   Dale HH, 1906, J PHYSIOL-LONDON, V34, P163
   DAVIES R, 1983, BRIT HEART J, V49, P528
   DAWOOD MY, 1989, AM J PERINAT, V6, P167, DOI 10.1055/s-2007-999569
   DAWOOD MY, 1978, J ENDOCRINOL, V76, P261, DOI 10.1677/joe.0.0760261
   DEKANSKI J, 1952, BRIT J PHARM CHEMOTH, V7, P567
   Schaffalitzky de Muckadell OB, 1977, SCAND J CLIN LAB INV, V37, P155
   Designs A, OXYTOCIN ENZYME IMMU
   DETTELBACH HR, 1958, AM J PHYSIOL, V192, P379
   Devarajan K, 2004, NEUROSCI LETT, V367, P144, DOI 10.1016/j.neulet.2004.05.112
   Dudley HW, 1919, J PHARMACOL EXP THER, V14, P295
   ELLENDORFF F, 1988, J ENDOCRINOL, V119, P219, DOI 10.1677/joe.0.1190219
   ELLENDORFF F, 1982, J PHYSIOL-LONDON, V333, P577
   FABIAN M, 1969, J PHYSIOL-LONDON, V204, P653
   FABIAN M, 1969, J ENDOCRINOL, V43, P175, DOI 10.1677/joe.0.0430175
   FABIAN M, 1969, ENDOCRINOLOGY, V85, P600
   FAHRENKRUG J, 1977, J LAB CLIN MED, V89, P1379
   Fenske W, 2016, BEST PRACT RES CL EN, V30, P219, DOI 10.1016/j.beem.2016.02.013
   Frijling JL, 2015, J NEUROENDOCRINOL, V27, P743, DOI 10.1111/jne.12300
   FYHRQUIST F, 1976, SCAND J CLIN LAB INV, V36, P841, DOI 10.3109/00365517609081947
   GAINER H, 1977, SCIENCE, V195, P1354, DOI 10.1126/science.65791
   GAINER H, 1977, J CELL BIOL, V73, P366, DOI 10.1083/jcb.73.2.366
   GAITAN E, 1964, J CLIN INVEST, V43, P2310, DOI 10.1172/JCI105105
   GINSBURG M, 1951, BRIT J PHARM CHEMOTH, V6, P411
   GINSBURG M, 1959, BRIT J PHARM CHEMOTH, V14, P327
   GINSBURG M, 1953, J ENDOCRINOL, V9, P283, DOI 10.1677/joe.0.0090283
   Gouin JP, 2015, PHYSIOL BEHAV, V139, P67, DOI 10.1016/j.physbeh.2014.11.021
   HARVEY RF, 1974, GUT, V15, P690, DOI 10.1136/gut.15.9.690
   HASAN SH, 1970, J ENDOCRINOL, V47, P135, DOI 10.1677/joe.0.0470135
   HELLER J, 1959, Cesk Fysiol, V8, P194
   HENNEBERRY HP, 1992, J HYPERTENS, V10, P221, DOI 10.1097/00004872-199203000-00004
   HIGUCHI T, 1986, J ENDOCRINOL, V110, P251, DOI 10.1677/joe.0.1100251
   HOLLANDER W, 1957, J CLIN INVEST, V36, P1059, DOI 10.1172/JCI103501
   Horvat-Gordon M, 2005, PHYSIOL BEHAV, V84, P445, DOI 10.1016/j.physbeh.2005.01.007
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Jenkins R, 2015, AAPS J, V17, P1, DOI 10.1208/s12248-014-9685-5
   Jobst A, 2014, ACTA NEUROPSYCHIATR, V26, P347, DOI 10.1017/neu.2014.20
   JONES CW, 1972, J PHYSIOL-LONDON, V227, P553
   Jong Trynke R de, 2015, Psychoneuroendocrinology, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027
   Jovanovic A, 1997, BRIT J PHARMACOL, V121, P1468, DOI 10.1038/sj.bjp.0701273
   Juul KV, 2014, AM J PHYSIOL-RENAL, V306, pF931, DOI 10.1152/ajprenal.00604.2013
   Kamm O, 1928, SCIENCE, V67, P199, DOI 10.1126/science.67.1729.199
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   Kowalski WB, 1998, AM J PHYSIOL-ENDOC M, V274, pE791
   Kramer KM, 2006, HORM BEHAV, V49, P206, DOI 10.1016/j.yhbeh.2005.07.001
   LANDGRAF R, 1985, EXP CLIN ENDOCRINOL, V85, P245
   LAUSON HD, 1961, AM J PHYSIOL, V200, P493
   LEAKE RD, 1981, J CLIN ENDOCR METAB, V53, P730
   LEAKE RD, 1980, OBSTET GYNECOL, V56, P701
   LEE HB, 1985, J NUCL MED, V26, P72
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Leng G, 1987, CIRCUMVENTRICULAR OR, VIII, P47
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Leng G, 2015, J ENDOCRINOL, V226, pT173, DOI 10.1530/JOE-15-0087
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   MARTIN MJ, 1972, J ENDOCRINOL, V52, P481, DOI 10.1677/joe.0.0520481
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   MORRIS JF, 1976, J ENDOCRINOL, V68, P209, DOI 10.1677/joe.0.0680209
   Nadeau A, 1971, HORM METAB RES S3, V3, P40
   NIBSC. WHO International Standard, 2013, OXYTOCIN 4 INT STAND
   NIBSC. WHO International Standard, 2013, ARGININE VASOPRESSIN
   Nomura S, 2005, BBA-PROTEINS PROTEOM, V1751, P19, DOI 10.1016/j.bbapap.2005.04.006
   NORDMANN JJ, 1984, P NATL ACAD SCI-BIOL, V81, P180, DOI 10.1073/pnas.81.1.180
   OS I, 1984, ACTA PHYSIOL SCAND, V122, P49, DOI 10.1111/j.1748-1716.1984.tb07480.x
   PAGE LB, 1971, CLIN CHIM ACTA, V34, P55, DOI 10.1016/0009-8981(71)90065-9
   Prakash BS, 1998, ANIM REPROD SCI, V51, P185, DOI 10.1016/S0378-4320(98)00069-4
   Qureshi S, 2014, ENDOCRINOLOGY, V155, P4605, DOI 10.1210/en.2014-1385
   RAISZ LG, 1958, J LAB CLIN MED, V52, P437
   ROBERTSO.GL, 1970, P NATL ACAD SCI USA, V66, P1298, DOI 10.1073/pnas.66.4.1298
   ROBINSON AG, 1973, METABOLISM, V22, P1047, DOI 10.1016/0026-0495(73)90224-2
   ROBINSON IC, 1974, BRIT J PHARMACOL, V50, P409
   Robinson KJ, 2014, J NEUROSCI METH, V226, P73, DOI 10.1016/j.jneumeth.2014.01.019
   RODBARD D, 1970, ACTA ENDOCRINOL-COP, P79
   Roper JA, 2011, STRESS, V14, P98, DOI 10.3109/10253890.2010.512376
   Rubin LH, 2014, SCHIZOPHRENIA BULL, V40, P1374, DOI 10.1093/schbul/sbu027
   Russell JA, 2003, FRONT NEUROENDOCRIN, V24, P27, DOI 10.1016/S0091-3022(02)00104-8
   Rutigliano Grazia, 2016, Psychiatry Res, V241, P207, DOI 10.1016/j.psychres.2016.04.117
   SAAMELI K, 1963, AM J OBSTET GYNECOL, V85, P186
   SALA NL, 1974, J APPL PHYSIOL, V36, P154
   SCHAMS D, 1983, ACTA ENDOCRINOL-COP, V103, P180
   SEGAR WE, 1968, J CLIN INVEST, V47, P2143, DOI 10.1172/JCI105900
   Shannon JA, 1942, J EXP MED, V76, P387, DOI 10.1084/jem.76.4.387
   SHARE L, 1967, AM J MED, V42, P701, DOI 10.1016/0002-9343(67)90090-3
   Sharif-Naeini R, 2008, NEURON, V58, P179, DOI 10.1016/j.neuron.2008.02.013
   SHELDRICK EL, 1981, PROSTAGLANDINS, V22, P631, DOI 10.1016/0090-6980(81)90072-1
   Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632
   SPENCER CA, 1977, CLIN CHEM, V23, P584
   STAHL WR, 1965, SCIENCE, V150, P1039, DOI 10.1126/science.150.3699.1039
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   TAKAMATA A, 1995, AM J PHYSIOL-REG I, V269, pR874
   Theobald G W, 1968, Obstet Gynecol Surv, V23, P109, DOI 10.1097/00006254-196802000-00001
   THEOBALD GW, 1959, J PHYSIOL-LONDON, V149, P443
   THORNTON S, 1990, AM J PHYSIOL, V259, pR21
   THORNTON S, 1992, ACTA ENDOCRINOL-COP, V126, P425
   Tsukazaki Y, 2016, ANAL SCI, V32, P153, DOI 10.2116/analsci.32.153
   UEDA T, 1994, OBSTET GYNECOL, V84, P259
   WAKERLEY JB, 1971, NATURE-NEW BIOL, V233, P180
   Watson BP, 1913, CAN MED ASSOC J, V3, P739
   Weeks A, 2015, BJOG-INT J OBSTET GY, V122, P202, DOI 10.1111/1471-0528.13098
   WEIR GC, 1973, HORM METAB RES, V5, P241
   Ziegler T., 2005, P NATL ACAD SCI USA, V102, P237, DOI DOI 10.1073/PNAS.0504767102
   YOSHIDA S, 1963, J LAB CLIN MED, V62, P279
   ZERBE RL, 1983, AM J MED, V74, P265, DOI 10.1016/0002-9343(83)90625-3
   Zhang DP, 2014, J PHARMACEUT BIOMED, V99, P67, DOI 10.1016/j.jpba.2014.07.001
   Zhang GD, 2011, ANAL BIOCHEM, V416, P45, DOI 10.1016/j.ab.2011.04.041
   [Anonymous], 1928, J AM MED ASS, V90, P618
NR 135
TC 0
Z9 0
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD OCT
PY 2016
VL 28
IS 10
DI 10.1111/jne.12413
PG 13
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA EB0WJ
UT WOS:000387066900002
ER

PT J
AU Jensen, P
   Persson, ME
   Wright, D
   Johnsson, M
   Sundman, AS
   Roth, LSV
AF Jensen, Per
   Persson, Mia E.
   Wright, Dominic
   Johnsson, Martin
   Sundman, Ann-Sofie
   Roth, Lina S. V.
TI The Genetics of How Dogs Became Our Social Allies
SO CURRENT DIRECTIONS IN PSYCHOLOGICAL SCIENCE
LA English
DT Article
DE genetics; social behavior; canids; breed; welfare
ID CANIS-FAMILIARIS; DOMESTIC DOG; OXYTOCIN; PERSONALITY; HUMANS
AB Dogs were domesticated from wolves about 15,000 years ago, and an important selection pressure (intentional or unintentional) has been their ability to communicate and cooperate with people. They show extensive human-directed sociability, which varies within as well as between breeds and is not shared by ancestral wolves. Hence, dogs are potentially ideal models for studying the genetics of social behavior. Here, we review some recent research carried out by us and others on this subject. We present results showing that recent selection of different breed types can be used as a model system for investigating the genetic architecture of personalities. Furthermore, we review data showing that human-directed social behavior is significantly related to a small number of genes that have known connections to human social disorders such as autism and schizophrenia. We suggest that dogs are excellent study subjects for analyzing the evolution and genetics of social behavior and can serve as probes for human health and welfare.
C1 [Jensen, Per; Persson, Mia E.; Wright, Dominic; Johnsson, Martin; Sundman, Ann-Sofie; Roth, Lina S. V.] Linkoping Univ, Dept Phys Chem & Biol, AVIAN Behav Genom & Physiol Grp, S-58183 Linkoping, Sweden.
RP Jensen, P (reprint author), Linkoping Univ, IFM Biol, AVIAN Behav Genom & Physiol Grp, S-58183 Linkoping, Sweden.
EM perje@ifm.liu.se
FU European Research Council [322206]
FX The research was funded by the European Research Council through
   Advanced Grant 322206: "Genetics and Epigenetics of Animal Welfare"
   (GENEWELL).
CR Chapman NH, 2015, HUM GENET, V134, P1055, DOI 10.1007/s00439-015-1585-y
   Ding ZL, 2012, HEREDITY, V108, P507, DOI 10.1038/hdy.2011.114
   Dodman NH, 2010, MOL PSYCHIATR, V15, P8, DOI 10.1038/mp.2009.111
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Feddersen-Petersen DU, 2000, ARCH TIERZUCHT, V43, P387
   Feng C, 2015, GENES BRAIN BEHAV, V14, P516, DOI 10.1111/gbb.12234
   Foyer P., 2015, SCI REPORTS, V6, DOI 10.1038/srep19253
   Foyer P, 2013, APPL ANIM BEHAV SCI, V146, P79, DOI 10.1016/j.applanim.2013.03.013
   German AJ, 2006, J NUTR, V136, p1940S
   Hall NJ, 2012, GENES BRAIN BEHAV, V11, P889, DOI 10.1111/j.1601-183X.2012.00851.x
   Hare B, 2002, SCIENCE, V298, P1634, DOI 10.1126/science.1072702
   Kaminski J, 2013, ANIM COGN, V16, P385, DOI 10.1007/s10071-012-0579-6
   Kis A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083993
   Kubinyi E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030271
   Larson G, 2012, P NATL ACAD SCI USA, V109, P8878, DOI 10.1073/pnas.1203005109
   Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338
   Maginnity ME, 2014, ANIM COGN, V17, P1375, DOI 10.1007/s10071-014-0773-9
   Masuda K, 2004, J VET MED SCI, V66, P183, DOI 10.1292/jvms.66.183
   Miklosi A., 2015, DOG BEHAV EVOLUTION
   Moore MC, 2011, J APPL PHYSIOL, V110, P458, DOI 10.1152/japplphysiol.00768.2010
   Morey DF, 2006, J ARCHAEOL SCI, V33, P158, DOI 10.1016/j.jas.2005.07.009
   Muller CA, 2015, CURR BIOL, V25, P601, DOI 10.1016/j.cub.2014.12.055
   Overall KL, 2000, PROG NEURO-PSYCHOPH, V24, P727, DOI 10.1016/S0278-5846(00)00104-4
   Persson M., 2016, DOG HUMAN INTE UNPUB
   Persson ME, 2015, GENES BRAIN BEHAV, V14, P337, DOI 10.1111/gbb.12194
   Persson M. E., SCI REPORTS IN PRESS
   Pilley JW, 2011, BEHAV PROCESS, V86, P184, DOI 10.1016/j.beproc.2010.11.007
   Pongracz P, 2005, J COMP PSYCHOL, V119, P136, DOI 10.1037/0735-7036.119.2.136
   Romero T, 2014, P NATL ACAD SCI USA, V111, P9085, DOI 10.1073/pnas.1322868111
   Roth LSV, 2016, SCI REP-UK, V6, DOI 10.1038/srep19631
   Saetre P, 2006, GENES BRAIN BEHAV, V5, P240, DOI 10.1111/j.1601-183X.2005.00155.x
   Sim K, 2012, J CLIN PSYCHIAT, V73, P320, DOI 10.4088/JCP.10m06491
   Sundman A-S, 2016, Genes Brain Behav, V15, P750, DOI 10.1111/gbb.12317
   Svartberg K, 2002, APPL ANIM BEHAV SCI, V79, P133, DOI 10.1016/S0168-1591(02)00121-1
   Udell MAR, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0489
   van Rooy Diane, 2014, Canine Genet Epidemiol, V1, P7, DOI 10.1186/2052-6687-1-7
   Viranyi Z, 2004, BEHAV PROCESS, V66, P161, DOI 10.1016/j.beproc.2004.01.012
   Wang GD, 2016, CELL RES, V26, P21, DOI 10.1038/cr.2015.147
NR 38
TC 0
Z9 0
U1 5
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963-7214
EI 1467-8721
J9 CURR DIR PSYCHOL SCI
JI Curr. Dir. Psychol.
PD OCT
PY 2016
VL 25
IS 5
SI SI
BP 334
EP 338
DI 10.1177/0963721416657050
PG 5
WC Psychology, Multidisciplinary
SC Psychology
GA DZ6DT
UT WOS:000385952500007
ER

PT J
AU Arambula, SE
   Belcher, SM
   Planchart, A
   Turner, SD
   Patisaul, HB
AF Arambula, Sheryl E.
   Belcher, Scott M.
   Planchart, Antonio
   Turner, Stephen D.
   Patisaul, Heather B.
TI Impact of Low Dose Oral Exposure to Bisphenol A (BPA) on the Neonatal
   Rat Hypothalamic and Hippocampal Transcriptome: A CLARITY-BPA Consortium
   Study
SO ENDOCRINOLOGY
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; SPRAGUE-DAWLEY RATS; GENE-EXPRESSION;
   MESSENGER-RNA; FEMALE RATS; SEX-DIFFERENCES; ESTRADIOL BENZOATE; ETHINYL
   ESTRADIOL; SYNAPTIC PLASTICITY; PRENATAL EXPOSURE
AB Bisphenol A (BPA) is an endocrine disrupting, high volume production chemical found in a variety of products. Evidence of prenatal exposure has raised concerns that developmental BPA may disrupt sex-specific brain organization and, consequently, induce lasting changes on neurophysiology and behavior. We and others have shown that exposure to BPA at doses below the no-observed-adverse-effect level can disrupt the sex-specific expression of estrogen-responsive genes in the neonatal rat brain including estrogen receptors (ERs). The present studies, conducted as part of the Consortium Linking Academic and Regulatory Insights of BPA Toxicity program, expanded this work by examining the hippocampal and hypothalamic transcriptome on postnatal day 1 with the hypothesis that genes sensitive to estrogen and/or sexually dimorphic in expression would be altered by prenatal BPA exposure. NCTR Sprague-Dawley dams were gavaged from gestational day 6 until parturition with BPA (0-, 2.5-, 25-, 250-, 2500-, or 25 000-mu g/kg body weight [bw]/d). Ethinyl estradiol was used as a reference estrogen (0.05- or 0.5-mu g/kg bw/d). Postnatal day 1 brains were microdissected and gene expression was assessed with RNA-sequencing (0-, 2.5-, and 2500-mu g/kg bw BPA groups only) and/or quantitative real-time PCR (all exposure groups). BPA-related transcriptional changes were mainly confined to the hypothalamus. Consistent with prior observations, BPA induced sex-specific effects on hypothalamic ER alpha and ER beta (Esr1 and Esr2) expression and hippocampal and hypothalamic oxytocin (Oxt) expression. These data demonstrate prenatal BPA exposure, even at doses below the current no-observed-adverse-effect level, can alter gene expression in the developing brain.
C1 [Arambula, Sheryl E.; Belcher, Scott M.; Planchart, Antonio; Patisaul, Heather B.] North Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA.
   [Arambula, Sheryl E.; Patisaul, Heather B.] North Carolina State Univ, Keck Ctr Behav Biol, Raleigh, NC 27695 USA.
   [Arambula, Sheryl E.; Belcher, Scott M.; Planchart, Antonio; Patisaul, Heather B.] North Carolina State Univ, Ctr Human Hlth & Environm, Raleigh, NC 27695 USA.
   [Turner, Stephen D.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA.
RP Patisaul, HB (reprint author), North Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA.
EM hbpatisa@ncsu.edu
FU NIEHS [U011ES020929]; NIEHS Interagency Agreement [AES12013 (FDA IAG
   224-12-0003)]
FX This study is part of the NIEHS CLARITY-BPA Consortium supported by
   NIEHS Grant U011ES020929 (to H.B.P.). The animal portion of this study
   is supported by NIEHS Interagency Agreement AES12013 (FDA IAG
   224-12-0003).
CR Adewale HB, 2011, NEUROTOXICOLOGY, V32, P38, DOI 10.1016/j.neuro.2010.07.008
   Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174
   Ali S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106245
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Andersen ME, 1999, ENV HLTH PERSPE S107, V4, P631
   Armoskus C, 2014, BRAIN RES, V1562, P23, DOI 10.1016/j.brainres.2014.03.017
   Auer PL, 2010, GENETICS, V185, P405, DOI 10.1534/genetics.110.114983
   Barkhem T, 1998, MOL PHARMACOL, V54, P105
   BAYER SA, 1974, J COMP NEUROL, V158, P55, DOI 10.1002/cne.901580105
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007
   Birnbaum LS, 2012, ENVIRON HEALTH PERSP, V120, P1640, DOI 10.1289/ehp.1205330
   Bourguignon JP, 2013, J NEUROENDOCRINOL, V25, P1079, DOI 10.1111/jne.12107
   Bowman RE, 2015, HORM BEHAV, V69, P89, DOI 10.1016/j.yhbeh.2014.12.007
   BUIJS RM, 1979, CELL TISSUE RES, V204, P355
   Cao JY, 2014, REPRODUCTION, V147, P537, DOI 10.1530/REP-13-0501
   Cao JY, 2013, TOXICOL SCI, V133, P157, DOI 10.1093/toxsci/kft035
   Cao JY, 2012, NEUROTOXICOLOGY, V33, P23, DOI 10.1016/j.neuro.2011.11.002
   Cao JY, 2011, J COMP NEUROL, V519, P2954, DOI 10.1002/cne.22648
   Cardoso N, 2011, J PHYSIOL BIOCHEM, V67, P559, DOI 10.1007/s13105-011-0102-6
   Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147
   Churchwell MI, 2014, TOXICOL SCI, V139, P4, DOI 10.1093/toxsci/kfu021
   Cohen H, 2010, J NEUROENDOCRINOL, V22, P889, DOI 10.1111/j.1365-2826.2010.02003.x
   Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171
   COX NM, 1987, THERIOGENOLOGY, V27, P395, DOI 10.1016/0093-691X(87)90228-7
   De Vries GJ, 2004, ENDOCRINOLOGY, V145, P1063, DOI 10.1210/en.2003-1504
   Delclos KB, 2014, TOXICOL SCI, V139, P174, DOI 10.1093/toxsci/kfu022
   Delclos KB, 2009, REPROD TOXICOL, V27, P117, DOI 10.1016/j.reprotox.2008.12.005
   Derveaux S, 2010, METHODS, V50, P227, DOI 10.1016/j.ymeth.2009.11.001
   Diel P, 2000, J STEROID BIOCHEM, V73, P1, DOI 10.1016/S0960-0760(00)00051-0
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doerge DR, 2011, TOXICOL APPL PHARM, V255, P261, DOI 10.1016/j.taap.2011.07.009
   DOHLER KD, 1991, INT REV CYTOL, V131, P1
   Dumas TC, 2005, HIPPOCAMPUS, V15, P562, DOI 10.1002/hipo.20077
   EFSA, 2015, EFSA J, V13, P3978, DOI DOI 10.2903/J.EFSA.2015.3978
   FAO/WHO, 2011, TOX HLTH ASP BISPH A
   Farabollino F, 2002, ENVIRON HEALTH PERSP, V110, P409
   Food and Drug Administration, 2012, BISPH A BPA US FOOD
   Gasnier B, 2004, PFLUG ARCH EUR J PHY, V447, P756, DOI 10.1007/s00424-003-1091-2
   Gillette R, 2014, ENDOCRINOLOGY, V155, P3853, DOI 10.1210/en.2014-1253
   Gioiosa L, 2015, DOSE-RESPONSE, V13, DOI 10.1177/1559325815610760
   Haseman JK, 2001, TOXICOL SCI, V61, P201, DOI 10.1093/toxsci/61.2.201
   Heindel JJ, 2015, REPROD TOXICOL, V58, P33, DOI 10.1016/j.reprotox.2015.07.075
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121
   Ivanova T, 2000, CELL TISSUE RES, V300, P231, DOI 10.1007/s004410000199
   JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400
   Johnson SA, 2016, HORM BEHAV, V80, P139, DOI 10.1016/j.yhbeh.2015.09.005
   Jung HS, 2012, NAT REV NEUROSCI, V13, P308, DOI 10.1038/nrn3210
   Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073
   Kanitz A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0702-5
   Khalaf-Nazzal R, 2013, NEUROSCIENCE, V248, P225, DOI 10.1016/j.neuroscience.2013.05.061
   Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849
   Kimura E, 2016, ARCH TOXICOL, V90, P691, DOI 10.1007/s00204-015-1485-x
   Knudsen EI, 2004, J COGNITIVE NEUROSCI, V16, P1412, DOI 10.1162/0898929042304796
   Kramer KM, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-71
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kumar D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110482
   Kundakovic M, 2015, P NATL ACAD SCI USA, V112, P6807, DOI 10.1073/pnas.1408355111
   Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110
   Leranth C, 2008, P NATL ACAD SCI USA, V105, P14187, DOI 10.1073/pnas.0806139105
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Liang XB, 2005, J NEUROCHEM, V92, P477, DOI 10.1111/j.1471-4159.2004.02870.x
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu S, 2011, NUCLEIC ACIDS RES, V39, P578, DOI 10.1093/nar/gkq817
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Love M. I., 2014, BIORXIV, V15, P550, DOI [10.1101/002832, DOI 10.1186/S13059-014-0550-8]
   Maciejewska B, 1998, ACTA NEUROBIOL EXP, V58, P23
   Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007
   McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Monje L, 2010, REPROD TOXICOL, V30, P625, DOI 10.1016/j.reprotox.2010.08.004
   Monje L, 2007, J ENDOCRINOL, V194, P201, DOI 10.1677/JOE-07-0014
   Mustieles V, 2015, NEUROTOXICOLOGY, V49, P174, DOI 10.1016/j.neuro.2015.06.002
   NTP, 2008, NTP CERHR MON POT HU
   Nugent BM, 2015, NAT NEUROSCI, V18, P690, DOI 10.1038/nn.3988
   Ogi H, 2015, BRAIN DEV-JPN, V37, P739, DOI 10.1016/j.braindev.2014.12.008
   Patisaul HB, 2006, NEUROTOXICOL TERATOL, V28, P111, DOI 10.1016/j.ntt.2005.11.004
   Patisaul HB, 2003, J NEUROENDOCRINOL, V15, P787, DOI 10.1046/j.1365-2826.2003.01061.x
   Patisaul HB, 2007, NEUROTOXICOLOGY, V28, P1, DOI 10.1016/j.neuro.2006.10.001
   Patisaul HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043890
   Paxinos G., 1991, ATLAS DEV RAT BRAIN
   Paxinos G, 2007, ATLAS DEV MOUSE BRAI
   Ptak A, 2012, TOXICOL LETT, V210, P332, DOI 10.1016/j.toxlet.2012.02.003
   Putz O, 2001, BIOL REPROD, V65, P1496, DOI 10.1095/biolreprod65.5.1496
   Putz O, 2001, BIOL REPROD, V65, P1506, DOI 10.1095/biolreprod65.5.1506
   Rebuli ME, 2016, J STEROID BIOCHEM, V160, P148, DOI 10.1016/j.jsbmb.2015.08.021
   Rebuli ME, 2015, TOXICOL SCI, V148, P341, DOI 10.1093/toxsci/kfv163
   Rebuli ME, 2014, TOXICOL SCI, V140, P190, DOI 10.1093/toxsci/kfu074
   Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804
   Sadowski RN, 2014, NEUROTOXICOL TERATOL, V42, P17, DOI [10.1016/j.ntt.2014.01.002, 10.1016/Intt.2014.01.002]
   Sakakibara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079437
   Wittfoht W, 2002, ENVIRON HEALTH PERSP, V110, P703
   Schug TT, 2015, ENDOCRINOLOGY, V156, P1941, DOI 10.1210/en.2014-1734
   Schug TT, 2013, REPROD TOXICOL, V40, P35, DOI 10.1016/j.reprotox.2013.05.010
   Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745
   SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475
   Steinmetz R, 1997, ENDOCRINOLOGY, V138, P1780, DOI 10.1210/en.138.5.1780
   Sullivan AW, 2014, ENDOCRINOLOGY, V155, P3867, DOI 10.1210/en.2014-1379
   Tiwari SK, 2015, MOL NEUROBIOL, V51, P1395, DOI 10.1007/s12035-014-8817-3
   Tyzio R, 1999, J NEUROSCI, V19, P10372
   Wang C, 2014, TOXICOLOGY, V322, P51, DOI 10.1016/j.tox.2014.05.001
   Wolfe CA, 2005, DEV BRAIN RES, V157, P34, DOI 10.1016/j.devbrainres.2005.03.001
   Wolstenholme JT, 2013, HORM BEHAV, V64, P833, DOI 10.1016/j.yhbeh.2013.09.007
   Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195
   Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001
   Wright CL, 2010, TRENDS ENDOCRIN MET, V21, P553, DOI 10.1016/j.tem.2010.05.004
NR 108
TC 0
Z9 0
U1 4
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2016
VL 157
IS 10
BP 3856
EP 3872
DI 10.1210/en.2016-1339
PG 17
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DZ7QT
UT WOS:000386061800019
PM 27571134
ER

PT J
AU Kim, JS
   Brown, CH
   Anderson, GM
AF Kim, Joon S.
   Brown, Colin H.
   Anderson, Greg M.
TI Anti-opioid Effects of RFRP-3 on Magnocellular Neuron Activity in
   Morphine-naive and Morphine-treated Female Rats
SO ENDOCRINOLOGY
LA English
DT Article
ID SUPRAOPTIC NUCLEUS OXYTOCIN; NEUROPEPTIDE-FF NPFF; CONDITIONED PLACE
   PREFERENCE; SPINAL GANGLION NEURONS; IN-VIVO; WITHDRAWAL EXCITATION;
   GENE-EXPRESSION; DORSAL RAPHE; PEPTIDE RFRP; RECEPTORS
AB Neuropeptide FF receptors (NPFFR1 and NPFFR2) have been proposed to possess anti-opioid properties, and be involved in the development of opiate tolerance and dependence. However, there is no evidence to date supporting such opioid effects at the cellular level in vivo. Using in vivo electrophysiological recordings from vasopressin and oxytocin neurons in the supraoptic nucleus, we aimed to determine the effects of NPFFRs on opiate inhibition, tolerance, and dependence at a cellular level. Both vasopressin and oxytocin neurons are acutely inhibited by opioids and develop opiate tolerance. Oxytocin neurons also develop cellular opiate dependence and undergo withdrawal hyperexcitation upon cessation of opiate administration. Here, the classical mu-opioid receptor agonist, morphine robustly inhibited the spontaneous firing rate of vasopressin and oxytocin neurons, and this inhibition was attenuated by pretreatment with the NPFFR1 agonist, RFamide-related peptide-3. In rats infused with morphine for 6 d, vasopressin neurons were unresponsive to morphine, indicating the development of cellular tolerance, but pretreatment with the NPFFR antagonist, GJ14, restored acute morphine inhibition. In morphine-infused rats, RFamide related peptide-3 did not induce withdrawal excitation in oxytocin neurons and GJ14 did not reverse naloxone-precipitated withdrawal excitation. This is the first evidence of anti-opioid effects of the NPFFR system at a cellular level in vivo. Our results suggest that the anti-opioid properties of the NPFFR system reduce morphine sensitivity during tolerance but that it is not involved in dependence.
C1 [Kim, Joon S.; Anderson, Greg M.] Univ Otago, Ctr Neuroendocrinol, Dunedin 9054, New Zealand.
   [Kim, Joon S.; Anderson, Greg M.] Univ Otago, Dept Anat, Dunedin 9054, New Zealand.
   [Brown, Colin H.] Univ Otago, Dept Physiol, Dunedin 9054, New Zealand.
RP Anderson, GM (reprint author), Univ Otago, Sch Med Sci, Ctr Neuroendocrinol, POB 56, Dunedin 9054, New Zealand.; Anderson, GM (reprint author), Univ Otago, Sch Med Sci, Dept Anat, POB 56, Dunedin 9054, New Zealand.
EM greg.anderson@otago.ac.nz
RI Brown, Colin/A-6235-2011
OI Brown, Colin/0000-0003-2305-846X
FU University of Otago School of Medical Sciences
FX This work was supported by the University of Otago School of Medical
   Sciences.
CR ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9
   BICKNELL RJ, 1988, J PHYSIOL-LONDON, V396, P297
   Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200
   Brown CH, 1998, J NEUROSCI, V18, P9480
   Brown CH, 2005, EUR J NEUROSCI, V21, P501, DOI 10.1111/j.1460-9568.2005.03885.x
   Brown CH, 2004, STRESS, V7, P97, DOI 10.1080/10253890410001727776
   Brown CH, 1998, J PHYSIOL-LONDON, V507, P831, DOI 10.1111/j.1469-7793.1998.831bs.x
   Brown CH, 1996, J PHYSIOL-LONDON, V496, P787
   Brown CH, 2000, NEUROSCI RES, V36, P97, DOI 10.1016/S0168-0102(99)00121-2
   Brown CH, 2014, NEUROPHYSIOLOGY NEUR, P63
   Doi N, 2001, BRIT J PHARMACOL, V132, P1136, DOI 10.1038/sj.bjp.0703911
   Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1
   Elhabazi K, 2012, BRIT J PHARMACOL, V165, P424, DOI 10.1111/j.1476-5381.2011.01563.x
   Elhabazi K, 2013, NEUROPHARMACOLOGY, V75, P164, DOI 10.1016/j.neuropharm.2013.07.012
   Findeisen M, 2011, PHARMACEUTICALS, V4, P1248
   Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009
   Gelot A, 1998, EUR J PHARMACOL, V358, P203, DOI 10.1016/S0014-2999(98)00625-6
   Goodman CB, 1996, PEPTIDES, V17, P389, DOI 10.1016/0196-9781(96)00002-2
   Gouarderes C, 2004, SYNAPSE, V51, P249, DOI 10.1002/syn.10305
   Hara K, 2002, ANESTH ANALG, V94, P313, DOI 10.1097/00000539-200202000-00015
   Henningsen JB, 2016, J COMP NEUROL, V524, P1825, DOI 10.1002/cne.23924
   Johnstone LE, 2000, J NEUROSCI, V20, P1272
   Kersante F, 2006, PEPTIDES, V27, P980, DOI 10.1016/j.peptides.2005.07.025
   Kersante F, 2011, NEUROSCI LETT, V488, P305, DOI 10.1016/j.neulet.2010.11.052
   Kim JS, 2015, ENDOCRINOLOGY, V156, P4152, DOI 10.1210/en.2015-1532
   KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550
   Kotlinska J, 2007, PEPTIDES, V28, P2235, DOI 10.1016/j.peptides.2007.08.006
   Leng G, 2008, NEUROENDOCRINOLOGY, V88, P160, DOI 10.1159/000149827
   Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200
   Ludwig M, 1997, J PHYSIOL-LONDON, V505, P145, DOI 10.1111/j.1469-7793.1997.145bc.x
   MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G
   MALIN DH, 1995, DRUG ALCOHOL DEPEN, V40, P37, DOI 10.1016/0376-8716(95)01178-1
   Marchand S, 2006, PEPTIDES, V27, P964, DOI 10.1016/j.peptides.2005.07.023
   Mollereau C, 2005, CURR TOP MED CHEM, V5, P341, DOI 10.2174/1568026053544515
   Mollereau C, 2005, MOL PHARMACOL, V67, P965, DOI 10.1124/mol.104.004614
   Murphy NP, 1997, NEUROSCIENCE, V80, P567, DOI 10.1016/S0306-4522(97)00142-5
   Nye HE, 1996, MOL PHARMACOL, V49, P636
   Pfleger KDG, 2005, BIOCHEM J, V385, P625
   Poling MC, 2012, ENDOCRINOLOGY, V153, P1827, DOI 10.1210/en.2011-2049
   PUMFORD KM, 1991, J PHYSIOL-LONDON, V440, P437
   Rebeyrolles S, 1996, NEUROREPORT, V7, P2979, DOI 10.1097/00001756-199611250-00036
   ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206
   Roumy M, 1999, BRAIN RES, V845, P208, DOI 10.1016/S0006-8993(99)01965-4
   Roumy M, 1996, EUR J PHARMACOL, V306, P291, DOI 10.1016/0014-2999(96)00210-5
   Roumy M, 2003, NEUROSCI LETT, V348, P159, DOI 10.1016/S0304-3940(03)00791-2
   Roumy M, 2007, J BIOL CHEM, V282, P8332, DOI 10.1074/jbc.M6096946200
   RUSSELL JA, 1995, EXP PHYSIOL, V80, P307
   Sabatier N, 2004, J PHYSIOL-LONDON, V558, P161, DOI 10.1113/jphysiol.2004.063982
   Serturner FW, 1806, J PHARM ARZTE APOTHE, V14, P47
   Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103
   SUMMERLEE AJS, 1981, J ENDOCRINOL, V90, P255, DOI 10.1677/joe.0.0900255
   SUMMERLEE AJS, 1981, J PHYSIOL-LONDON, V321, P1
   SUMNER BEH, 1990, NEUROSCIENCE, V37, P635, DOI 10.1016/0306-4522(90)90095-L
   Tan PPC, 1999, PEPTIDES, V20, P1211, DOI 10.1016/S0196-9781(99)00125-4
   Ueda H, 2009, FRONT BIOSCI, V14, P5260, DOI 10.2741/3596
   YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757
NR 56
TC 0
Z9 0
U1 1
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2016
VL 157
IS 10
BP 4003
EP 4011
DI 10.1210/en.2016-1374
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DZ7QT
UT WOS:000386061800031
PM 27533886
ER

PT J
AU Highley, LL
   Previs, RA
   Dotters-Katz, SK
   Brancazio, LR
   Grotegut, CA
AF Highley, Louise L.
   Previs, Rebecca A.
   Dotters-Katz, Sarah K.
   Brancazio, Leo R.
   Grotegut, Chad A.
TI Cesarean delivery among women with prolonged labor induction
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE Induction; labor; obesity; oxytocin; pregnancy
ID NULLIPAROUS WOMEN; ELECTIVE INDUCTION; UNFAVORABLE CERVIX;
   GESTATIONAL-AGE; FETAL WEIGHT; RISK; TERM; PREDICTION; DURATION
AB Objective: The objective of this study was to determine characteristics associated with cesarean delivery among women with labor induction lasting over 24 h.
   Study design: Women with live singleton pregnancies without prior cesarean delivery undergoing a labor induction lasting >24 h between September 2006 and March 2009 at Duke University Hospital were identified. Collected variables were compared between subjects by mode of delivery. A multivariate logistic regression model for the outcome cesarean delivery was constructed separately for nulliparous and parous women.
   Results: There were 303 women who met inclusion criteria. The overall cesarean delivery rate was 57% (n=172) and remained constant with time (P=0.15, test-for-trend). Nulliparous women having a cesarean delivery were more likely to be obese [adjusted OR (aOR) 2.00; 95% CI 1.05, 3.80] and have a larger fetus [aOR 1.11 (aOR for every 100 g increase in birthweight), 95% CI 1.03, 1.20] compared to those having a vaginal delivery.
   Conclusion: Increasing BMI and birthweight were independent predictors of cesarean delivery among nulliparous women with prolonged labor induction. Despite this, after 24 h of labor induction, the overall mean cesarean delivery rate remained constant at 57%, and did not change with time. Among women having a vaginal delivery following a prolonged labor induction, we saw high rates of shoulder dystocia, operative vaginal delivery and severe perineal laceration.
C1 [Grotegut, Chad A.] Duke Univ, Div Maternal Fetal Med, DUMC Box 3967, Durham, NC 27710 USA.
   [Highley, Louise L.; Previs, Rebecca A.; Dotters-Katz, Sarah K.; Brancazio, Leo R.] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA.
RP Grotegut, CA (reprint author), Duke Univ, Div Maternal Fetal Med, DUMC Box 3967, Durham, NC 27710 USA.
EM chad.grotegut@duke.edu
CR Ahmadzia HK, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.06.041
   Alexander JM, 2001, OBSTET GYNECOL, V97, P911, DOI 10.1016/S0029-7844(01)01354-0
   Bahn SA, 1998, OBSTET GYNECOL, V92, P403, DOI 10.1016/S0029-7844(98)00188-4
   Blackwell SC, 2008, AM J PERINAT, V25, P205, DOI 10.1055/s-2008-1064933
   Caughey AB, 2006, AM J OBSTET GYNECOL, V195, P700, DOI 10.1016/j.ajog.2006.07.003
   Dandolu V, 2005, J MATERN-FETAL NEO M, V18, P305, DOI 10.1080/14767050500312730
   Edwards H, 2006, J MATERN-FETAL NEO M, V19, P723, DOI 10.1080/14767050600921307
   Goetzinger KR, 2014, J MATERN-FETAL NEO M, V27, P89, DOI 10.3109/14767058.2013.806474
   Greenberg MB, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.058
   Grobman WA, 2007, EUR J OBSTET GYN R B, V132, P163, DOI 10.1016/j.ejogrb.2006.09.002
   Gull I, 2002, ULTRASOUND OBST GYN, V20, P57, DOI 10.1046/j.1469-0705.2002.00742.x
   Gunatilake RP, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.07.023
   Heffner LJ, 2003, OBSTET GYNECOL, V102, P287, DOI 10.1016/S0029-7844(03)00531-3
   Johnson DP, 2003, AM J OBSTET GYNECOL, V188, P1565, DOI 10.1067/mob.2003.458
   Laughon SK, 2011, OBSTET GYNECOL, V117, P805, DOI 10.1097/AOG.0b013e3182114ad2
   Martin Joyce A, 2010, Natl Vital Stat Rep, V58, P1
   Nuthalapaty FS, 2004, OBSTET GYNECOL, V103, P452
   Osmundson S, 2011, OBSTET GYNECOL, V117, P583, DOI 10.1097/AOG.0b013e31820caf12
   Rouse DJ, 2000, OBSTET GYNECOL, V96, P671, DOI 10.1016/S0029-7844(00)01010-3
   Schuit E, 2012, BJOG-INT J OBSTET GY, V119, P915, DOI 10.1111/j.1471-0528.2012.03334.x
   Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4
   Simon CE, 2005, OBSTET GYNECOL, V105, P705, DOI 10.1097/01.AOG.0000157437.10998.e7
   Vahratian A, 2005, ANN EPIDEMIOL, V15, P467, DOI 10.1016/j.annepidem.2005.02.005
   Vahratian A, 2005, OBSTET GYNECOL, V105, P698, DOI 10.1097/01.AOG.0000157436.68847.3b
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   Watson WJ, 1996, OBSTET GYNECOL, V88, P990
   Wing DA, 2002, AM J OBSTET GYNECOL, V186, P1237, DOI 10.1067/mob.2002.123740
NR 27
TC 1
Z9 1
U1 0
U2 0
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD OCT
PY 2016
VL 44
IS 7
BP 759
EP 766
DI 10.1515/jpm-2014-0357
PG 8
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DZ7MF
UT WOS:000386049300006
PM 26352059
ER

PT J
AU Patel, S
   Weierstahl, KL
   Shah, S
   Fidkowski, CW
AF Patel, Shaun
   Weierstahl, Krystal L.
   Shah, Sonalee
   Fidkowski, Christina W.
TI Anesthetic Management for Cesarean Delivery in a Patient With Pulmonary
   Emboli, Pulmonary Hypertension, and Right Ventricular Failure
SO A & A CASE REPORTS
LA English
DT Article
ID POSTDURAL PUNCTURE HEADACHE; ACCIDENTAL DURAL PUNCTURE; MORBIDLY OBESE
   PARTURIENTS; ARTERIAL-HYPERTENSION; PREGNANCY OUTCOMES; WOMEN; OXYTOCIN;
   SECTION; VASOPRESSIN
AB The maternal mortality rate for parturients with severe pulmonary hypertension is 30% to 50%. General, epidural, and combined low-dose spinal-epidural anesthesia have been used successfully for cesarean deliveries in patients with pulmonary hypertension. We describe a cesarean delivery performed using an intrathecal catheter in a 25-year-old morbidly obese (body mass index, 82 kg/m(2)) woman (gravida 3, para 2 at 32 weeks of gestation) who had severe pulmonary hypertension, right ventricular failure, pulmonary emboli, and obstructive sleep apnea. We discuss the anesthetic considerations for parturients with severe pulmonary hypertension undergoing cesarean delivery including the selection of anesthetic technique, vasopressors, and uterotonic agents.
C1 [Patel, Shaun; Weierstahl, Krystal L.; Shah, Sonalee; Fidkowski, Christina W.] Henry Ford Hosp, Dept Anesthesiol, 2799 W Grand Blvd, Detroit, MI 48202 USA.
   [Shah, Sonalee; Fidkowski, Christina W.] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Fidkowski, CW (reprint author), Henry Ford Hosp, Dept Anesthesiol, 2799 W Grand Blvd, Detroit, MI 48202 USA.
EM cfidkow1@hfhs.org
CR Angle P, 1999, CAN J ANAESTH, V46, P861
   Bedard E, 2009, EUR HEART J, V30, P256, DOI 10.1093/eurheartj/ehn597
   Bonnin M, 2005, ANESTHESIOLOGY, V102, P1133, DOI 10.1097/00000542-200506000-00012
   Bussieres JS, 2007, CURR OPIN ANESTHESIO, V20, P48, DOI 10.1097/ACO.0b013e32801158a9
   CHAUHAN S, 1995, REGION ANESTH, V20, P459
   Currigan DA, 2014, ANESTHESIOLOGY, V121, P930, DOI 10.1097/ALN.0000000000000430
   Dyer RA, 2010, INT J OBSTET ANESTH, V19, P313, DOI 10.1016/j.ijoa.2010.04.011
   FAURE E, 1994, REGION ANESTH, V19, P361
   George RB, 2010, CAN J ANAESTH, V57, P578, DOI 10.1007/s12630-010-9297-1
   Heesen M, 2013, INT J OBSTET ANESTH, V22, P26, DOI 10.1016/j.ijoa.2012.10.004
   HOOD DD, 1993, ANESTHESIOLOGY, V79, P1210, DOI 10.1097/00000542-199312000-00011
   Hosseinian L, 2014, J CARDIOTHOR VASC AN, V28, P1064, DOI 10.1053/j.jvca.2013.11.017
   Jais X, 2012, EUR RESPIR J, V40, P881, DOI 10.1183/09031936.00141211
   Kaddoum R, 2014, J ANESTH, V28, P628, DOI 10.1007/s00540-013-1761-y
   Kiely DG, 2010, BJOG-INT J OBSTET GY, V117, P565, DOI 10.1111/j.1471-0528.2009.02492.x
   Ma LL, 2011, INT J OBSTET ANESTH, V20, P198, DOI 10.1016/j.ijoa.2010.12.009
   Peralta F, 2015, ANESTH ANALG, V121, P451, DOI 10.1213/ANE.0000000000000802
   Pinder AJ, 2002, INT J OBSTET ANESTH, V11, P156, DOI 10.1054/ijoa.2002.0970
   Price LC, 2007, BRIT J ANAESTH, V99, P552, DOI 10.1093/bja/aem180
   Russell IF, 2012, INT J OBSTET ANESTH, V21, P7, DOI 10.1016/j.ijoa.2011.10.005
   Sarkar J, 2015, SHOCK, V43, P475, DOI 10.1097/SHK.0000000000000325
   SECHER NJ, 1978, ACTA OBSTET GYN SCAN, V57, P97
   SECHER NJ, 1982, ACTA OBSTET GYN SCAN, V61, P213
   Spitzer Y, 2015, A A CASE REP, V4, P166, DOI 10.1213/XAA.0000000000000152
   Tabarsi N, 2014, INT J CARDIOL, V177, P490, DOI 10.1016/j.ijcard.2014.08.059
   Thomas JS, 2007, BRIT J ANAESTH, V98, P116, DOI 10.1093/bja/ael302
   Verstraete S, 2014, ACTA ANAESTH SCAND, V58, P1233, DOI 10.1111/aas.12394
   Weiss BM, 1998, J AM COLL CARDIOL, V31, P1650, DOI 10.1016/S0735-1097(98)00162-4
NR 28
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2325-7237
J9 A A CASE REP
JI A A Case Rep.
PD OCT 1
PY 2016
VL 7
IS 7
BP 146
EP 149
DI 10.1213/XAA.0000000000000367
PG 4
WC Anesthesiology
SC Anesthesiology
GA DZ1UG
UT WOS:000385625800002
PM 27513968
ER

PT J
AU Ungerfeld, R
   Abril-Sanchez, S
   Toledano-Diaz, A
   Beracochea, F
   Castano, C
   Giriboni, J
   Santiago-Moreno, J
AF Ungerfeld, Rodolfo
   Abril-Sanchez, Silvia
   Toledano-Diaz, Adolfo
   Beracochea, Florencia
   Castano, Cristina
   Giriboni, Julia
   Santiago-Moreno, Julian
TI Oxytocin administration before sperm collection by transrectal
   ultrasonic-guided massage of the accessory sex glands in mouflons and
   bucks
SO ANIMAL REPRODUCTION SCIENCE
LA English
DT Article
DE Animal welfare; Pain; Ruminants; Semen; Stress
ID SEMEN CHARACTERISTICS; MALE LAMBS; ELECTROEJACULATION; BULLS; RAMS;
   STIMULATION; BEHAVIOR; OUTPUT
AB Transrectal ultrasonic-guided massage of the accessory sex glands (TUMASG) is an alternative technique for sperm collection which decreases negative animal welfare concerns of electroejaculation. However, quality of collected sperm with TUMASG is less than that collected by electroejaculation. Utilisation of TUMASG may not, however, induce strong muscular contractions, so administration of oxytocin before the procedure may improve sperm quality. Therefore, two studies were designed to determine if administration of oxytocin before TUMASG improves the procedure and quality of the collected semen. The first study was performed with anaesthetised mouflons, and the second with non-anaesthetised Gabon bucks. Time length, number of electric pulses applied and numbers of vocalizations were recorded, and sperm characteristics were analysed. The number of electrical pulses and sperm characteristics did not differ with oxytocin administration in mouflons. However, oxytocin administration decreased time length (P=0.02) and tended to decrease the number of electric pulses needed for induction of ejaculation (P = 0.08) in bucks. The number of vocalizations and sperm variables did not differ when the two procedures were used. In conclusion, oxytocin administration before TUMASG shortened the procedure and tended to decrease the number of electrical pulses needed to induce ejaculation in conscious bucks, thus, decreasing welfare concerns for the animals in which TUMASG is used. Therefore, its routine inclusion in this species should be considered. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ungerfeld, Rodolfo; Abril-Sanchez, Silvia; Beracochea, Florencia; Giriboni, Julia] Univ Republica, Fac Vet, Dept Fisiol, Montevideo, Uruguay.
   [Abril-Sanchez, Silvia] Univ Murcia, E-30001 Murcia, Spain.
   [Toledano-Diaz, Adolfo; Castano, Cristina; Santiago-Moreno, Julian] Inst Nacl Invest & Tecnol Agr & Alimentaria INIA, Dept Reprod Anim, Madrid, Spain.
RP Ungerfeld, R (reprint author), Univ Republica, Fac Vet, Dept Fisiol, Montevideo, Uruguay.
EM rungerfeld@gmail.com
FU MINECO [AGL2014-52081-R]; Comision Sectorial de Investigation Cientifica
   (CSIC), Universidad de la Repdblica, Uruguay
FX We acknowledge Milton Pintos for his help with animal management.
   Experiment 1 was supported by MINECO grant AGL2014-52081-R; Experiment 2
   by Comision Sectorial de Investigation Cientifica (CSIC), Universidad de
   la Repdblica, Uruguay.
CR BERNDTSON WE, 1988, J REPROD FERTIL, V82, P467
   Bozkurt T, 2007, TURK J VET ANIM SCI, V31, P303
   BRINDLEY GS, 1981, J NEUROL NEUROSUR PS, V44, P9, DOI 10.1136/jnnp.44.1.9
   Busso JM, 2005, RES VET SCI, V78, P93, DOI 10.1016/j.rvsc.2004.06.004
   CAMPBELL R. C., 1956, Journal of Agricultural Science, V48, P1
   Christensen BW, 2011, THERIOGENOLOGY, V76, P975, DOI 10.1016/j.theriogenology.2011.05.003
   Damian JP, 2011, REPROD DOMEST ANIM, V46, P646, DOI 10.1111/j.1439-0531.2010.01722.x
   IBRAHIM MAR, 1988, ACTA VET HUNG, V36, P3
   JEYENDRAN RS, 1984, J REPROD FERTIL, V70, P219
   KNIGHT TW, 1974, J REPROD FERTIL, V39, P329
   Mewe M, 2007, REPRODUCTION, V134, P493, DOI 10.1530/RFP-07-0220
   Nicholson HD, 1999, J REPROD FERTIL, V117, P299, DOI 10.1530/jrf.0.1170299
   Ortiz-de-Montellano M, 2007, SMALL RUMINANT RES, V69, P228, DOI 10.1016/j.smallrumres.2005.12.025
   Damian JP, 2015, PHYSIOL BEHAV, V147, P47, DOI 10.1016/j.physbeh.2015.04.004
   Palmer CW, 2004, ANIM REPROD SCI, V80, P213, DOI 10.1016/j.anireprosci.2003.07.003
   Palmer CW, 2005, THERIOGENOLOGY, V64, P469, DOI 10.1016/j.theriogenology.2005.05.032
   PEETERS G, 1983, J ENDOCRINOL, V99, P161, DOI 10.1677/joe.0.0990161
   Perumal P., 2015, INDIAN J APPL RES, V5, P548
   PURSEL V G, 1974, Theriogenology, V1, P63, DOI 10.1016/0093-691X(74)90008-9
   Saniger Marcela Arrazola, 2011, Drug Metab Lett, V5, P192
   Santiago-Moreno J, 2013, THERIOGENOLOGY, V79, P383, DOI 10.1016/j.theriogenology.2012.10.011
   Santiago-Moreno J, 2011, RES VET SCI, V90, P150, DOI 10.1016/j.rvsc.2010.05.011
   Stafford KJ, 1996, NEW ZEAL VET J, V44, P95, DOI 10.1080/00480169.1996.35943
   Tecirlioglu RT, 2002, REPROD FERT DEVELOP, V14, P363, DOI 10.1071/RD02015
   Ungerfeld R, 2012, REPROD DOMEST ANIM, V47, pe56, DOI 10.1111/j.1439-0531.2011.01926.x
   Ungerfeld R, 2008, ANIM REPROD SCI, V109, P161, DOI 10.1016/j.anireprosci.2007.12.006
   Ungerfeld R, 2015, THERIOGENOLOGY, V84, P1067, DOI 10.1016/j.theriogenology.2015.06.009
   Whittington K, 2001, REPRODUCTION, V122, P317, DOI 10.1530/rep.0.1220317
   Wrzal PK, 2012, CELL SIGNAL, V24, P333, DOI 10.1016/j.cellsig.2011.09.019
   Yeoman RR, 1998, HUM REPROD, V13, P2527, DOI 10.1093/humrep/13.9.2527
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4320
EI 1873-2232
J9 ANIM REPROD SCI
JI Anim. Reprod. Sci.
PD OCT
PY 2016
VL 173
BP 13
EP 17
DI 10.1016/j.anireprosci.2016.08.002
PG 5
WC Agriculture, Dairy & Animal Science; Reproductive Biology
SC Agriculture; Reproductive Biology
GA DY7SJ
UT WOS:000385329300003
PM 27530370
ER

PT J
AU Hollingworth, J
   Mcgurgan, P
AF Hollingworth, J.
   Mcgurgan, P.
TI Prolongation of Corrected Q-T Interval Associated with Oxytocin Infusion
   During Labour
SO AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY
LA English
DT Meeting Abstract
C1 [Hollingworth, J.; Mcgurgan, P.] King Edward Mem Hosp, Perth, WA, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-8666
EI 1479-828X
J9 AUST NZ J OBSTET GYN
JI Aust. N. Z. J. Obstet. Gynaecol.
PD OCT
PY 2016
VL 56
SU 1
BP 42
EP 42
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DZ0YZ
UT WOS:000385566900113
ER

PT J
AU Marchand, G
   Citrin, A
   Sainz, K
   Weeden, A
AF Marchand, G.
   Citrin, A.
   Sainz, K.
   Weeden, A.
TI MEDUSA PROTOCOL - Minimising the Blood Loss and Maximising the Efficacy
   of Oxytocin Sensitive Dilation and Curettage Procedures
SO AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY
LA English
DT Meeting Abstract
C1 [Marchand, G.; Citrin, A.; Weeden, A.] Marchand OBGYN PLLC, Mesa, AZ USA.
   [Sainz, K.] Washington Univ Hlth & Sci, Sch Med, San Pedro, Belize.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-8666
EI 1479-828X
J9 AUST NZ J OBSTET GYN
JI Aust. N. Z. J. Obstet. Gynaecol.
PD OCT
PY 2016
VL 56
SU 1
BP 47
EP 47
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DZ0YZ
UT WOS:000385566900127
ER

PT J
AU Engster, KM
   Kroczek, AL
   Rose, M
   Stengel, A
   Kobelt, P
AF Engster, Kim-Marie
   Kroczek, Arthur L.
   Rose, Matthias
   Stengel, Andreas
   Kobelt, Peter
TI Peripheral injection of bombesin induces c-Fos in NUCB2/nesfatin-1
   neurons
SO BRAIN RESEARCH
LA English
DT Article
DE Brain-gut-axis food intake hypothalamus nucleus of the solitary tract;
   Paraventricular nucleus; Rat
ID CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; REDUCES
   FOOD-INTAKE; RAT-BRAIN; PARAVENTRICULAR NUCLEUS; NESFATIN-1 NEURONS;
   LESIONED RATS; BINDING-SITES; MEAL SIZE; IMMUNOREACTIVITY
AB As anorexigenic hormones bombesin and nucleobindin2 (NUCB2)/nesfatin-1 decrease food intake in rodents. Both hormones have been described in brain nuclei that play a role in the modulation of hunger and satiety, like the paraventricular nucleus of the hypothalamus (PVN) and the nucleus of the solitary tract (NTS). However, the direct interaction of the two hormones is unknown so far. The aim of study was to elucidate whether bombesin directly interacts with NUCB2/nesfatin-1 neurons in the PVN and NTS. Therefore, we injected bombesin intraperitoneally (ip) at two doses (26 and 32 nmol/kg body weight) and assessed c-Fos activation in the PVN, arcuate nucleus (ARC) and NTS compared to vehicle treated rats (0.15 M NaCI). We also performed co-localization studies with oxytocin or tyrosine hydroxylase. Bombesin at both doses increased the number of c-Fos positive neurons in the PVN (p < 0.05) and NTS (p < 0.05) compared to vehicle, while in the ARC no modulation was observed (p > 0.05). In the PVN and NTS the number of c-Fos positive neurons colocalized with NUCB2/nesfatin-1 increased after bombesin injection compared to vehicle treatment (p <0.05). Moreover, an increase of activated NUCB2/nesfatin-1 immunoreactive neurons that co-expressed oxytocin in the PVN (p < 0.05) or tyrosine hydroxylase in the NTS (p <0.05) was observed compared to vehicle. Our results show that peripherally injected bombesin activates NUCB2/nesfatin-1 neurons in the PVN and NTS giving rise to a possible interaction between bombesin and NUCB2/nesfatin-1 in the modulation of food intake. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Engster, Kim-Marie; Kroczek, Arthur L.; Rose, Matthias; Stengel, Andreas; Kobelt, Peter] Charite, Dept Psychosomat Med, Charite Ctr Internal Med & Dermatol, Campus Mitte,Sauerbruchweg 5, D-10117 Berlin, Germany.
RP Kobelt, P (reprint author), Charite, Dept Psychosomat Med, Charite Ctr Internal Med & Dermatol, Campus Mitte,Sauerbruchweg 5, D-10117 Berlin, Germany.
EM peter.kobelt@charite.de
FU Charite-Universitatsmedizin Berlin [14/61071]
FX This work was supported by grants from the Charite-Universitatsmedizin
   Berlin (14/61071). We thank the Robert Koch-Institute in Berlin for
   access to the cLSM 760.
CR ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873
   Atsuchi K, 2010, NEUROREPORT, V21, P1008, DOI 10.1097/WNR.0b013e32833f7b96
   BELLINGER LL, 1984, PEPTIDES, V5, P547, DOI 10.1016/0196-9781(84)90085-8
   BONAZ B, 1993, BRAIN RES, V600, P353, DOI 10.1016/0006-8993(93)91397-B
   Bustos G, 2004, BRAIN RES REV, V47, P126, DOI 10.1016/j.brainresrev.2004.05.002
   Degen LP, 2001, GASTROENTEROLOGY, V120, P361, DOI 10.1053/gast.2001.21174
   DENBOW DM, 1989, PEPTIDES, V10, P275, DOI 10.1016/0196-9781(89)90030-2
   ERSPAMER V, 1974, BRIT J PHARMACOL, V52, P227
   ERSPAMER V, 1972, BRIT J PHARMACOL, V45, P442
   FLYNN FW, 1991, PEPTIDES, V12, P761, DOI 10.1016/0196-9781(91)90130-H
   Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054
   GEARY N, 1986, REGUL PEPTIDES, V15, P261, DOI 10.1016/0167-0115(86)90067-4
   Goebel M, 2011, PEPTIDES, V32, P36, DOI 10.1016/j.peptides.2010.09.027
   Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064
   Goebel-Stengel M, 2011, BRAIN RES, V1396, P20, DOI 10.1016/j.brainres.2011.04.031
   Gotoh K, 2013, J NEUROCHEM, V124, P90, DOI 10.1111/jnc.12066
   JANSEN JBMJ, 1984, SURGERY, V96, P55
   Johnston S A, 1988, Peptides, V9 Suppl 1, P245, DOI 10.1016/0196-9781(88)90250-1
   Kent P, 2001, NEUROENDOCRINOLOGY, V73, P203, DOI 10.1159/000054637
   Kent P, 2001, PEPTIDES, V22, P57, DOI 10.1016/S0196-9781(00)00355-7
   KIRCHGESSNER AL, 1988, PHYSIOL BEHAV, V42, P529, DOI 10.1016/0031-9384(88)90154-0
   Kobelt P, 2004, BRAIN RES PROTOC, V13, P45, DOI 10.1016/j.brainresprot.2004.01.003
   Kobelt P, 2006, AM J PHYSIOL-REG I, V291, pR903, DOI 10.1152/ajpregu.00681.2005
   Kohno D, 2008, ENDOCRINOLOGY, V149, P1295, DOI 10.1210/en.2007-1276
   Konczol K, 2010, NEUROCHEM INT, V57, P189, DOI 10.1016/j.neuint.2010.04.012
   KULKOSKY PJ, 1982, PHYSIOL BEHAV, V28, P505, DOI 10.1016/0031-9384(82)90147-0
   KYRKOULI SE, 1987, PEPTIDES, V8, P237, DOI 10.1016/0196-9781(87)90096-9
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Li BH, 1996, REGUL PEPTIDES, V62, P167, DOI 10.1016/0167-0115(96)00029-8
   LYNCH WC, 1993, PHYSIOL BEHAV, V53, P1223, DOI 10.1016/0031-9384(93)90384-R
   Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002
   Michaud D, 1999, AM J PHYSIOL-REG I, V276, pR1617
   Mohan H, 2012, REGUL PEPTIDES, V175, P61, DOI 10.1016/j.regpep.2012.02.006
   Moody TW, 2004, PEPTIDES, V25, P511, DOI 10.1016/j.peptides.2004.02.012
   MORAN TH, 1988, PEPTIDES, V9, P643, DOI 10.1016/0196-9781(88)90177-5
   Moreau JM, 2013, BEHAV BRAIN RES, V250, P343, DOI 10.1016/j.bbr.2013.05.036
   MUURAHAINEN NE, 1993, AM J PHYSIOL, V264, pR350
   Noetzel S, 2009, REGUL PEPTIDES, V157, P84, DOI 10.1016/j.regpep.2009.06.009
   Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162
   Okere B, 2010, BRAIN RES, V1317, P92, DOI 10.1016/j.brainres.2009.12.053
   Watson C., 1997, RAT BRAIN STEREOTAXI
   Plamondon H, 1997, EUR J PHARMACOL, V340, P99, DOI 10.1016/S0014-2999(97)01346-0
   Price CJ, 2008, J NEUROENDOCRINOL, V20, P245, DOI 10.1111/j.1365-2826.2007.01641.x
   SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879
   SAWCHENKO PE, 1981, SCIENCE, V214, P685, DOI 10.1126/science.7292008
   SAWCHENKO PE, 1982, BRAIN RES REV, V4, P275, DOI 10.1016/0165-0173(82)90010-8
   Sayegh AI, 2013, PROG MOL BIOL TRANSL, V114, P343, DOI 10.1016/B978-0-12-386933-3.00010-8
   SCARPIGNATO C, 1981, DIGESTION, V21, P104
   SCHUSDZIARRA V, 1986, DIABETES, V35, P791, DOI 10.2337/diabetes.35.7.791
   SCHUSDZIARRA V, 1986, NEUROPEPTIDES, V7, P51, DOI 10.1016/0143-4179(86)90079-X
   Schwartz GJ, 1997, AM J PHYSIOL-REG I, V272, pR1726
   Shimizu H, 2009, ENDOCRINOLOGY, V150, P662, DOI 10.1210/en.2008-0598
   Stengel A, 2013, HISTOCHEM CELL BIOL, V139, P909, DOI 10.1007/s00418-013-1087-8
   Stengel A, 2009, ENDOCRINOLOGY, V150, P4911, DOI 10.1210/en.2009-0578
   STUCKEY JA, 1982, BRAIN RES BULL, V8, P617, DOI 10.1016/0361-9230(82)90089-2
   STUCKEY JA, 1985, PEPTIDES, V6, P1249, DOI 10.1016/0196-9781(85)90458-9
   TAYLOR IL, 1985, AM J PHYSIOL, V248, pG277
   Thaw AK, 1998, PHYSIOL BEHAV, V64, P425, DOI 10.1016/S0031-9384(98)00073-0
   UETA Y, 1993, BRAIN RES BULL, V32, P453, DOI 10.1016/0361-9230(93)90290-R
   VERBALIS JG, 1988, PEPTIDES, V9, P1289, DOI 10.1016/0196-9781(88)90194-5
   WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4
   WEST DB, 1982, PEPTIDES, V3, P61, DOI 10.1016/0196-9781(82)90143-7
   WOODS SC, 1983, PEPTIDES, V4, P687, DOI 10.1016/0196-9781(83)90019-0
   Yamada K, 2002, EUR J PHARMACOL, V440, P281, DOI 10.1016/S0014-2999(02)01435-8
   Yoshida N, 2010, AGING-US, V2, P775
   YoshidaYoneda E, 1996, AM J PHYSIOL-REG I, V271, pR1584
   Yosten GLC, 2010, AM J PHYSIOL-REG I, V298, pR1642, DOI 10.1152/ajpregu.00804.2009
   ZARBIN MA, 1985, J NEUROSCI, V5, P429
NR 68
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD OCT 1
PY 2016
VL 1648
BP 46
EP 53
DI 10.1016/j.brainres.2016.07.006
PN A
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA DY7OI
UT WOS:000385318400006
PM 27396908
ER

PT J
AU Haram, M
   Bettella, F
   Brandt, CL
   Quintana, DS
   Nerhus, M
   Bjella, T
   Djurovic, S
   Westlye, LT
   Andreassen, OA
   Melle, I
   Tesli, M
AF Haram, Marit
   Bettella, Francesco
   Brandt, Christine Lycke
   Quintana, Daniel S.
   Nerhus, Mari
   Bjella, Thomas
   Djurovic, Srdjan
   Westlye, Lars T.
   Andreassen, Ole A.
   Melle, Ingrid
   Tesli, Martin
TI Contribution of Oxytocin Receptor Polymorphisms to Amygdala Activation
   in Schizophrenia Spectrum Disorders
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Haram, Marit; Bettella, Francesco; Brandt, Christine Lycke; Quintana, Daniel S.; Nerhus, Mari; Bjella, Thomas; Djurovic, Srdjan; Westlye, Lars T.; Andreassen, Ole A.; Melle, Ingrid; Tesli, Martin] Univ Oslo, Inst Clin Med, NORMENT KG Jebsen Ctr Psychosis Res, N-0316 Oslo, Norway.
   [Haram, Marit; Bettella, Francesco; Brandt, Christine Lycke; Quintana, Daniel S.; Nerhus, Mari; Bjella, Thomas; Djurovic, Srdjan; Westlye, Lars T.; Andreassen, Ole A.; Melle, Ingrid; Tesli, Martin] Oslo Univ Hosp, Div Mental Hlth & Addict, N-0450 Oslo, Norway.
   [Djurovic, Srdjan] Oslo Univ Hosp Ulleval, Dept Med Genet, Oslo, Norway.
   [Djurovic, Srdjan; Westlye, Lars T.] Univ Oslo, Dept Psychol, Oslo, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
EI 1751-7893
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2016
VL 10
SU 1
BP 85
EP 85
PG 1
WC Psychiatry
SC Psychiatry
GA DZ1EX
UT WOS:000385582800251
ER

PT J
AU de Girolamo, G
   Dagani, J
   Saviotti, FM
   Raimondi, S
AF de Girolamo, Giovanni
   Dagani, Jessica
   Saviotti, Francesco M.
   Raimondi, Sara
TI A Randomized Control Trial on Oxytocin as Adjunctive Therapy for the
   Treatment of Schizophrenia
SO EARLY INTERVENTION IN PSYCHIATRY
LA English
DT Meeting Abstract
C1 [de Girolamo, Giovanni; Dagani, Jessica] St John God Clin Res Ctr, Brescia, Italy.
   [Saviotti, Francesco M.; Raimondi, Sara] ASST, Dept Mental Hlth, Desenzano Del Garda, Italy.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7885
EI 1751-7893
J9 EARLY INTERV PSYCHIA
JI Early Interv. Psychiatry
PD OCT
PY 2016
VL 10
SU 1
MA B67
BP 175
EP 175
PG 1
WC Psychiatry
SC Psychiatry
GA DZ1EX
UT WOS:000385582800530
ER

PT J
AU Georgiou, P
   Zanos, P
   Hourani, S
   Kitchen, I
   Bailey, A
AF Georgiou, Polymnia
   Zanos, Panos
   Hourani, Susanna
   Kitchen, Ian
   Bailey, Alexis
TI Cocaine abstinence induces emotional impairment and brain
   region-specific upregulation of the oxytocin receptor binding
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE anhedonia; anxiety; cocaine withdrawal; corticosterone; mice
ID SOCIAL ANXIETY DISORDER; CHRONIC BINGE COCAINE; MU-OPIOID RECEPTOR;
   INDUCED REINSTATEMENT; SEEKING BEHAVIOR; RATS; MICE; METHAMPHETAMINE;
   ADDICTION; STRESS
AB The key problem in treating cocaine addiction is the maintenance of a drug-free state as negative emotional symptoms during abstinence often trigger relapse. The mechanisms underpinning the emotional dysregulation during abstinence are currently not well-understood. There is evidence suggesting a role of the neuropeptide oxytocin in the modulation of drug addiction processes. However, its involvement during long-term abstinence from cocaine use remains unclear. In this study, we aimed to behaviourally characterize a mouse model of long-term cocaine withdrawal and assess the effect of chronic cocaine administration and long-term cocaine abstinence on the central oxytocinergic system and the hypothalamic-pituitary-adrenal axis. Fourteen-day escalating-dose cocaine administration (3x15-30mg/kg/day) and 14-day withdrawal increased plasma corticosterone levels and oxytocin receptor (OTR) binding in piriform cortex, lateral septum and amygdala. A specific cocaine withdrawal-induced increase in OTR binding was observed in the medial septum. These biochemical alterations occurred concomitantly with the emergence of memory impairment, contextual psychomotor sensitization and an anhedonic and anxiogenic phenotype during withdrawal. Our study established a clear relationship between cocaine abstinence and emotional impairment in a novel translationally relevant model of cocaine withdrawal and demonstrated for the first time brain region-specific neuroadaptations of the oxytocin system, which may contribute to abstinence-induced negative emotional state.
C1 [Georgiou, Polymnia; Zanos, Panos; Hourani, Susanna; Kitchen, Ian; Bailey, Alexis] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Guildford GU2 5XH, Surrey, England.
   [Georgiou, Polymnia; Zanos, Panos] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.
   [Bailey, Alexis] St Georges Univ London, Inst Med & Biomed Educ, London SW17 0R, England.
RP Bailey, A (reprint author), St Georges Univ London, Inst Med & Biomed Educ, London SW17 0R, England.
EM abailey@sgul.ac.uk
FU Royal Society [RG120556]; European commission [LSHM-CT2004-005166]
FX This study was supported by grant a Royal Society grant (RG120556; P.I.
   Alexis Bailey) and European commission grant (contact number:
   LSHM-CT2004-005166). The sponsors had no involvement in the design of
   study and in the collection, analysis and interpretation of the data,
   nor in the writing of the manuscript and the decision to submit this
   article for publication. The authors thank Mrs Hannah Hobson for her
   help in brain dissection.
CR Bailey A, 2008, EUR J NEUROSCI, V28, P759, DOI 10.1111/j.1460-9568.2008.06369.x
   Bailey A, 2007, J NEUROCHEM, V102, P1817, DOI 10.1111/j.1471-4159.2007.04661.x
   Baracz SJ, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12337
   Busnelli M, 2013, J PHARMACOL EXP THER, V346, P318, DOI 10.1124/jpet.113.202994
   Contoreggi C, 2003, NEUROENDOCRINOLOGY, V78, P154, DOI 10.1159/000072797
   Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327
   Curley JP, 2012, HORM BEHAV, V61, P454, DOI 10.1016/j.yhbeh.2012.01.013
   GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107
   Georgiou P, 2016, NEUROPHARMACOLOGY, V105, P520, DOI 10.1016/j.neuropharm.2016.02.012
   Georgiou P, 2015, EUR NEUROPSYCHOPHARM, V25, P2459, DOI 10.1016/j.euroneuro.2015.09.015
   Georgiou P, 2015, ADDICT BIOL, V20, P902, DOI 10.1111/adb.12208
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   Johns JM, 1997, NEUROPEPTIDES, V31, P439, DOI 10.1016/S0143-4179(97)90037-8
   Kelley BJ, 2005, COGN BEHAV NEUROL, V18, P108, DOI 10.1097/01.wnn.0000160823.61201.20
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Leventhal AM, 2010, EXP CLIN PSYCHOPHARM, V18, P562, DOI 10.1037/a0021964
   Lever C, 2006, REV NEUROSCIENCE, V17, P111
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Metaxas A, 2012, BRIT J PHARMACOL, V167, P450, DOI 10.1111/j.1476-5381.2012.02023.x
   Morales-Rivera A, 2014, PSYCHOPHARMACOLOGY, V231, P4145, DOI 10.1007/s00213-014-3553-y
   Morton W. A, 1999, PRIMARY CARE COMPANI, V1, P109, DOI [10.4088/PCC.v01n0403, DOI 10.4088/PCC.V0]
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   PATCHEV VK, 1993, NEUROSCIENCE, V57, P537, DOI 10.1016/0306-4522(93)90003-X
   Petersson M, 1999, NEUROSCI LETT, V264, P41, DOI 10.1016/S0304-3940(99)00159-7
   Rich ME, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00090
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   SARNYAI Z, 1992, NEUROPEPTIDES, V23, P27, DOI 10.1016/0143-4179(92)90006-I
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Slattery David A, 2010, Pharmaceuticals (Basel), V3, P702
   Soyka M, 2016, PROG NEURO-PSYCHOPH, V70, P148, DOI 10.1016/j.pnpbp.2015.11.003
   WEDDINGTON WW, 1990, ARCH GEN PSYCHIAT, V47, P861
   Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112, DOI 10.1038/npp.2008.60
   Wolf ME, 2016, NAT REV NEUROSCI, V17, P351, DOI 10.1038/nrn.2016.39
   Wright SR, 2016, ADDICT BIOL, V21, P811, DOI 10.1111/adb.12259
   Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998
   Zanos P, 2015, J PHARMACOL EXP THER, V355, P76, DOI 10.1124/jpet.115.225664
   Zanos P, 2015, NEUROSCI LETT, V600, P33, DOI 10.1016/j.neulet.2015.05.054
   Zanos P, 2014, PHARMACOL BIOCHEM BE, V119, P72, DOI 10.1016/j.pbb.2013.05.009
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zhou LY, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu009
   Zhou Y, 2011, NEUROPSYCHOPHARMACOL, V36, P2062, DOI 10.1038/npp.2011.97
   Zubaran C, 2013, REV ASSOC MED BRAS, V59, P360, DOI 10.1016/j.ramb.2013.01.008
NR 45
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD OCT
PY 2016
VL 44
IS 7
BP 2446
EP 2454
DI 10.1111/ejn.13348
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA DY8QE
UT WOS:000385394100005
PM 27453431
ER

PT J
AU Vendittelli, F
   Barasinski, C
   Pereira, B
   Dreyfus, M
   Lemery, D
   Bouvier-Colle, MH
AF Vendittelli, Francoise
   Barasinski, Chloe
   Pereira, Bruno
   Dreyfus, Michel
   Lemery, Didier
   Bouvier-Colle, Marie-Helene
CA HERA Grp
TI Policies for management of postpartum haemorrhage: the HERA
   cross-sectional study in France
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Caesareans; Delivery; Immediate postpartum haemorrhage; Third stage of
   labour
ID SEVERE MATERNAL MORBIDITY; OBSTETRIC HEMORRHAGE; CLINICAL-PRACTICE;
   DELIVERY; GUIDELINES; EUROPE; LABOR
AB Objective: The principal objective of this study was to describe the policies reported by French maternity units for the prevention and early management of postpartum haemorrhage (PPH). The second objective was to assess their variation according to hospital level and status.
   Study design: Cross-sectional observational study of French maternity units, from January 2010 to April 2011. The medical supervisor (obstetrician or midwife) of participating maternity wards completed a questionnaire designed to ascertain the unit's protocol for preventing and managing PPH after both vaginal and caesarean deliveries at a gestational age >22 weeks (or a birth weight >500 g). The main outcome measure was the percentage of units reporting protocols adhering to the principal criteria for adequate management defined by the 2004 French guidelines for PPH.
   Results: 252 maternity units participated in the survey. Almost all units had a written protocol for PPH (97.2%). For vaginal deliveries, 82.5% of units had a definition of PPH (>500 ml) and 92.8% had a policy of preventive oxytocin use. For caesareans, only 23.8% defined PPH (as >1000 ml), 68.8% used manual delivery of the placenta, and 76.9% recommended oxytocin injection immediately after the birth. The first-line medication for PPH was oxytocin (96.3%) and the second-line treatment a prostaglandin (97.5%). Level III maternity units had a definition of haemorrhage for vaginal deliveries more often than did other levels of care (P=0.04). Manual removal of the placenta after caesareans was significantly more frequent in level I than level III units (P = 0.008) and in private than other types of maternity units. Medical management of haemorrhage did not differ according to level of care or maternity status.
   Conclusions: The responses by maternity unit supervisors showed significant improvement in the management of PPH accordingly to the 2004 French guidelines, especially for the third stage of labour. This improvement did not differ between hospitals by levels of care or legal status. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Vendittelli, Francoise; Barasinski, Chloe; Lemery, Didier] Ctr Hosp Univ Clermont Ferrand, Pole Femme & Enfant, Site Estaing,1 Pl Lucie & Raymond Aubrac, F-63003 Clermont Ferrand 1, France.
   [Vendittelli, Francoise; Barasinski, Chloe; Lemery, Didier] Univ Auvergne, Clermont Univ, EA 4681, PEPRADE Perinatal Grossesse Environm PRAt Med & D, Clermont Ferrand, France.
   [Vendittelli, Francoise; Lemery, Didier] RTH Laennec, Fac Med, AUDIPOG, Lyon, France.
   [Pereira, Bruno] Ctr Hosp Univ Clermont Ferrand, Direct Rech Clin, F-63003 Clermont Ferrand, France.
   [Dreyfus, Michel] CHU Caen, Gynecol Obstet & Med Reprod, Caen, France.
   [Dreyfus, Michel] Univ Caen, Caen, France.
   [Bouvier-Colle, Marie-Helene] Univ Paris 05, CRESS, Equipe Epope, Inserm,U1153, Paris, France.
RP Vendittelli, F (reprint author), Ctr Hosp Univ Clermont Ferrand, Pole Femme & Enfant, Site Estaing,1 Pl Lucie & Raymond Aubrac, F-63003 Clermont Ferrand 1, France.
EM fvendittelli@chu-clermontferrand.fr
FU French Ministry of Health (PHRCN) [05-05]
FX This study was supported by a grant from the French Ministry of Health
   (PHRCN 2009 No. 05-05).
CR Anorlu RI, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004737.pub2
   Batra P, 2014, OBSTET GYNECOL, V123, p136S
   Begley CM, COCHRANE DATABASE SY, V3
   Brace V, 2004, BJOG-INT J OBSTET GY, V111, P481, DOI 10.1111/j.1471-0528.2004.00101.x
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Deneux-Tharaux C, 2008, J GYNECOL OBST BIO R, V37, P237, DOI 10.1016/j.jgyn.2008.01.007
   Deneux-Tharaux C, 2009, BJOG-INT J OBSTET GY, V116, P119, DOI 10.1111/j.1471-0528.2008.01996.x
   Fowler SJ, 2005, ANAESTH INTENS CARE, V33, P784
   Goffinet F, 2005, Gynecol Obstet Fertil, V33, P268, DOI 10.1016/j.gyobfe.2005.03.016
   Hofmeyr GJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008020.pub2
   Hoveyda F, 2001, BRIT J OBSTET GYNAEC, V108, P927, DOI 10.1111/j.1471-0528.2001.00230.x
   International Confederation of Midwives International Federation of Gynecology and Obstetrics, 2003, J OBSTET GYNAECOL CA, V25, P952
   JacobsJokhan D, 2004, COCHRANE DB SYST REV
   Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9
   Liabsuetrakul T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005456.pub2
   McDonald SJ, 2014, COCHRANE DB SYST REV
   McDonald SJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004074.pub3
   Mousa HA, 2014, COCHRANE DB SYST REV
   Nadisauskiene RJ, 2014, EUR J OBSTET GYN R B, V178, P21, DOI 10.1016/j.ejogrb.2014.03.051
   Oladapo OT, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009332.pub2
   Omedo B, 2014, INT J GYNECOL OBSTET, V125, P162
   Pena-Marti G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005462.pub2
   Rath WH, 2011, ACTA OBSTET GYN SCAN, V90, P421, DOI 10.1111/j.1600-0412.2011.01107.x
   Roberts CL, 2008, INT J GYNECOL OBSTET, V103, P172, DOI 10.1016/j.ijgo.2008.05.025
   Saucedo M, 2013, J GYNECOL OBST BIO R, V42, P613, DOI 10.1016/j.jgyn.2013.06.011
   Saucedo M, 2013, OBSTET GYNECOL, V122, P752, DOI 10.1097/AOG.0b013e31829fc38c
   Sentilhes L, 2016, EUR J OBSTET GYN R B, V198, P12, DOI 10.1016/j.ejogrb.2015.12.012
   Shields LE, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.084
   Soltani H, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006173.pub2
   Su LL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005457.pub4
   Tuncalp O, 2012, DATABASE SYST REV
   Westhoff G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001808.pub2
   Wilman K, 2004, BJOG, V111, P164
   Winter C, 2007, BJOG-INT J OBSTET GY, V114, P845, DOI 10.1111/j.1471-0528.2007.01377.x
   Zhang WH, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c293
   Zhang WH, 2005, BJOG-INT J OBSTET GY, V112, P89, DOI 10.1111/j.1471-0528.2004.00303.x
   Zwart JJ, 2008, BJOG-INT J OBSTET GY, V115, P842, DOI 10.1111/j.1471-0528.2008.01713.x
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD OCT
PY 2016
VL 205
BP 21
EP 26
DI 10.1016/j.ejogrb.2016.08.008
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DY7QA
UT WOS:000385323100005
PM 27566217
ER

PT J
AU Bullens, LM
   Moors, S
   Heimel, PJV
   van der Hout-van der Jagt, MB
   Oei, SG
AF Bullens, Lauren M.
   Moors, Suzanne
   Heimel, Pieter J. van Runnard
   van der Hout-van der Jagt, M. Beatrijs
   Oei, S. Guid
TI Practice variation in the management of intrapartum fetal distress in
   The Netherlands and the Western world
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Fetal monitoring; Fetal distress; Intrauterine resuscitation; Guideline;
   Clinical practice
ID SCALP BLOOD LACTATE; INTRAUTERINE RESUSCITATION; TERM LABOR; TOCOLYSIS
AB Objective: Solid evidence on the effect of intrauterine resuscitation on neonatal outcome is limited, and superiority of one intervention over the others is not clear. We therefore surveyed the clinical practice variation in fetal monitoring and the management of fetal distress during labor, in Dutch labor wards. In addition, we have compared recommendations from international guidelines.
   Study design: We conducted a survey among all 86 Dutch hospitals, using a questionnaire on fetal monitoring and management of fetal distress. In addition, we requested international guidelines of 28 Western countries to study international recommendations regarding labor management.
   Results: The response rate of the national survey was 100%. Labor wards of all hospitals use CTG for fetal monitoring, 98% use additional fetal scalp blood sampling, and 23% use ST-analysis. When fetal distress is suspected, oxytocin is discontinued and tocolytic drugs are applied in all hospitals. Nearly all hospitals (98%) use maternal reposition for fetal resuscitation, 33% use amnioinfusion, and 58% provide maternal hyperoxygenation. Management is mainly based on the Dutch national guideline (58%) or on local guidelines (26%).
   Eight international guidelines on fetal monitoring were obtained for analysis. Fetal scalp blood sampling facilities are recommended in all the obtained guidelines. Use of ST-analysis is recommended in three guidelines and advised against in three guidelines. Five guidelines also advised on intrauterine resuscitation: discontinuation of oxytocin and use of tocolytic drugs was advised in all guidelines, amnioinfusion was recommended in two guidelines and advised against in two guidelines, whereas maternal hyperoxygenation was recommended in two guidelines and advised against in one guideline.
   Conclusion: Nationwide clinical practice, and recommendations from international guidelines agree on the use of fetal scalp blood sampling in addition to cardiotocography during labor. The opinion on the use of ST-analysis differs per clinic and per guideline. Discontinuation of oxytocin, administration of tocolytic drugs and maternal repositioning are rather uniform, on national and international level. However, there is a large variation in the use of amnioinfusion and maternal hyperoxygenation, which may be explained by the contradictory recommendations of the different guidelines. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Bullens, Lauren M.; Moors, Suzanne; Heimel, Pieter J. van Runnard; van der Hout-van der Jagt, M. Beatrijs; Oei, S. Guid] Maxima Med Ctr, Dept Obstet & Gynecol, Veldhoven, Netherlands.
   [Bullens, Lauren M.; van der Hout-van der Jagt, M. Beatrijs; Oei, S. Guid] Eindhoven Univ Technol, Dept Elect Engn, Eindhoven, Netherlands.
RP Bullens, LM (reprint author), POB 7777, NL-5500 MB Veldhoven, Netherlands.
EM laurenbullens@gmail.com
CR Allen RM, 2004, AUST NZ J OBSTET GYN, V44, P549, DOI 10.1111/j.1479-828X.2004.00306.x
   American College of Obstetricians and Gynecologists, 2010, OBSTET GYNECOL, V116, P1232
   Bakker JJH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006947.pub3
   Berg D, 1973, KARDIOTOKOGRAPHIE DI
   Briozzo L, 2007, J OBSTET GYNAECOL RE, V33, P266, DOI 10.1111/j.1447-0756.2007.00522.x
   Bullens LM, 2015, OBSTET GYNECOL SURV, V70, P524, DOI 10.1097/OGX.0000000000000215
   Palmgren Colov N, 2016, FOSTEROVERVAGNING FO
   de Heus R, 2008, EUR J OBSTET GYN R B, V139, P139, DOI 10.1016/j.ejogrb.2008.01.001
   Deutsche Gesellschaft fur Gynakologie und Guburtshilfe Arbeitsgemeischaft Materno-fetale Medizin Deutsche Gezellschaft fur Pranatal und Geburtzmedizin Deutsche Gesellschaft fur Perinatale Medizin, 2016, S1 LEITL ANW CTG WAH
   East CE, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006174.pub3
   Graca LM., 2012, MONITORIZACAO FETAL
   Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094
   Heinis AMF, 2011, ACTA OBSTET GYN SCAN, V90, P1107, DOI 10.1111/j.1600-0412.2011.01237.x
   Heintz E, 2008, BJOG-INT J OBSTET GY, V115, P1676, DOI 10.1111/j.1471-0528.2008.01935.x
   Institute of Obstetricians and Gynecologistst Royal College of Physicians of Ireland and Directorate of Stategy and Clinical Programmes Health Service Executive, 2016, CLIN PRACT GUID INTR
   Kruger K, 1999, AM J OBSTET GYNECOL, V181, P1072, DOI 10.1016/S0002-9378(99)70083-9
   Kulier R, 2000, COCHRANE DB SYST REV
   Nederlandse Vereniging voor Obstetric en Gynaecologie, 2016, RICHTL FOET BEW
   Parer JT, 1998, COMP BIOCHEM PHYS A, V119, P711, DOI 10.1016/S1095-6433(98)01009-5
   Ramanah R, 2010, FETAL DIAGN THER, V27, P14, DOI 10.1159/000262281
   The Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2016, INTR FET SURV CLIN G
   Simpson KR, 2008, SEMIN FETAL NEONAT M, V13, P362, DOI 10.1016/j.siny.2008.04.016
   The Society of Obstetricians and Gynaecologists of Canada, 2007, JOGC S4, V29
   National Collaborating Centre for Women's and Children's Health (UK), 2014, INTR CAR CAR HLTH WO
   Van 't Hooft J, 2016, J MATERN-FETAL NEO M, V14, P1
   Vijgen SMC, 2011, ACTA OBSTET GYN SCAN, V90, P772, DOI 10.1111/j.1600-0412.2011.01138.x
   Vlemminx Marion W C, 2015, Ned Tijdschr Geneeskd, V159, pA8535
   Brix Westergaard H, 2016, AMNIOINFUSION FODSLE
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD OCT
PY 2016
VL 205
BP 48
EP 53
DI 10.1016/j.ejogrb.2016.08.012
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DY7QA
UT WOS:000385323100010
PM 27566222
ER

PT J
AU Horn, SR
   Charney, DS
   Feder, A
AF Horn, Sarah R.
   Charney, Dennis S.
   Feder, Adriana
TI Understanding resilience: New approaches for preventing and treating
   PTSD
SO EXPERIMENTAL NEUROLOGY
LA English
DT Review
DE Resilience; Stress; Neurobiology; PTSD; Intervention; Prevention
ID POSTTRAUMATIC-STRESS-DISORDER; ATTENTION BIAS VARIABILITY; POSITIVE
   YOUTH DEVELOPMENT; RANDOMIZED CLINICAL-TRIAL; INTIMATE PARTNER VIOLENCE;
   NEUROPEPTIDE-Y CONCENTRATIONS; COGNITIVE-BEHAVIOR THERAPY; WAR-AFFECTED
   CHILDREN; C-REACTIVE PROTEIN; QUALITY-OF-LIFE
AB All individuals experience stressful life events, and up to 84% of the general population will experience at least one potentially traumatic event. In some cases, acute or chronic stressors lead to the development of posttraumatic stress disorder (PTSD) or other psychopathology; however, the majority of people are resilient to such effects. Resilience is the ability to adapt successfully in the face of stress and adversity. A wealth of research has begun to identify the genetic, epigenetic, neural, and environmental underpinnings of resilience, and has indicated that resilience is mediated by adaptive changes encompassing several environmental factors, neural circuits, numerous neurotransmitters, and molecular pathways. The first part of this review focuses on recent findings regarding the genetic, epigenetic, developmental, psychosocial, and neurochemical factors as well as neural circuits and molecular pathways that underlie the development of resilience. Emerging and exciting areas of research and novel methodological approaches, including genome-wide gene expression studies, immune, endocannabinoid, oxytocin, and glutamatergic systems, are explored to help delineate innovative mechanisms that may contribute to resilience. The second part reviews several interventions and preventative approaches designed to enhance resilience in both developmental and adult populations. Specifically, the review will delineate approaches aimed to bolster resilience in individuals with PTSD. Furthermore, we discuss novel pharmacologic approaches, including the N-methyl-D-aspartate (NMDA) receptor ketamine and neuropeptide Y (NPY), as exciting new prospects for not only the treatment of PTSD but as new targets to enhance resilience. Our growing understanding of resilience and interventions will hopefully lead to the development of new strategies for not just treating PTSD but also screening and early identification of at-risk youth and adults. Taken together, efforts aimed at dissemination and implementation of novel interventions to enhance resilience will have to keep pace with the growth of new preventive and treatment strategies. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Horn, Sarah R.; Charney, Dennis S.; Feder, Adriana] Icahn Sch Med, Dept Psychiat, New York, NY 10029 USA.
   [Charney, Dennis S.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
   [Charney, Dennis S.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
RP Feder, A (reprint author), Icahn Sch Med, Dept Psychiat, New York, NY 10029 USA.
EM adriana.feder@mssm.edu
CR Adler AB, 2009, MIL MED, V174, P21
   Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877
   Admon R, 2013, CEREB CORTEX, V23, P28, DOI 10.1093/cercor/bhr369
   Alim TN, 2008, AM J PSYCHIAT, V165, P1566, DOI 10.1176/appi.ajp.2008.07121939
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Amat J, 2016, J NEUROSCI, V36, P153, DOI 10.1523/JNEUROSCI.3114-15.2016
   Badura-Brack AS, 2015, AM J PSYCHIAT, V172, P1233, DOI 10.1176/appi.ajp.2015.14121578
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027
   Banks K, 2015, J CLIN PSYCHOL, V71, P935, DOI 10.1002/jclp.22200
   Bar-Shai M., 2015, ANONYMOUS FUTURE DIR, P3
   Bender K, 2015, J RES ADOLESCENCE, V25, P352, DOI 10.1111/jora.12123
   Benjet C, 2016, PSYCHOL MED, V46, P327, DOI 10.1017/S0033291715001981
   Benoit JD, 2015, BEHAV BRAIN RES, V281, P1, DOI 10.1016/j.bbr.2014.12.001
   Berkowitz SJ, 2011, J CHILD PSYCHOL PSYC, V52, P676, DOI 10.1111/j.1469-7610.2010.02321.x
   Bermudo-Soriano CR, 2012, PHARMACOL BIOCHEM BE, V100, P752, DOI 10.1016/j.pbb.2011.04.010
   Bernard K, 2015, JAMA PEDIATR, V169, P112, DOI 10.1001/jamapediatrics.2014.2369
   Binder EB, 2008, JAMA-J AM MED ASSOC, V299, P1291, DOI 10.1001/jama.299.11.1291
   Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552
   Bonanno GA, 2012, PSYCHOL TRAUMA-US, V4, P74, DOI 10.1037/a0017829
   Booth FW, 2002, J PHYSIOL-LONDON, V543, P399, DOI 10.1113/physiol2002019265
   BOYCE WT, 1990, J DEV BEHAV PEDIATR, V11, P105
   Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81
   Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626
   Breslau N, 1999, AM J PSYCHIAT, V156, P902
   Briscione Maria Anne, 2014, Front Psychiatry, V5, P88, DOI 10.3389/fpsyt.2014.00088
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231
   Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032
   Buhle JT, 2014, CEREB CORTEX, V24, P2981, DOI 10.1093/cercor/bht154
   Burt KB, 2012, DEV PSYCHOPATHOL, V24, P493, DOI 10.1017/S0954579412000119
   Burton M.S., 2015, J CONTEMP PSYCHOTHER, P1
   Cacioppo JT, 2015, J PERS SOC PSYCHOL, V109, P90, DOI 10.1037/pspi0000022
   CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0
   Catalano RF, 2004, ANN AM ACAD POLIT SS, V591, P98, DOI 10.1177/0002716203260102
   Chamey DS, 2004, AM J PSYCHIAT, V161, P195
   Charney DS, 2003, ACTA PSYCHIAT SCAND, V108, P38, DOI 10.1034/j.1600-0447.108.s417.3.x
   Cicchetti D., 2007, ANN NY ACAD SCI, V1094, P248
   Committee on Treatment of Posttraumatic Stress Disorder Board on Population Health and Public Health Practice Institute of Medicine, 2008, TREATM POSTTR STRESS
   Cornelis MC, 2010, CURR PSYCHIAT REP, V12, P313, DOI 10.1007/s11920-010-0126-6
   Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420
   Craun SW, 2015, J CHILD SEX ABUS, V24, P592, DOI 10.1080/10538712.2015.1042187
   Daskalakis NP, 2014, P NATL ACAD SCI USA, V111, P13529, DOI 10.1073/pnas.1401660111
   Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3
   Davis M, 2006, BIOL PSYCHIAT, V60, P369, DOI 10.1016/j.biopsych.2006.03.084
   De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1
   de Kloet ER, 2007, NAT CLIN PRACT ENDOC, V3, P168, DOI 10.1038/ncpendmet0403
   de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683
   Delgado MR, 2006, BIOL PSYCHOL, V73, P39, DOI 10.1016/j.biopsycho.2006.01.006
   Diab M, 2015, CHILD ABUSE NEGLECT, V40, P24, DOI 10.1016/j.chiabu.2014.12.002
   Diab M, 2014, SOC DEV, V23, P215, DOI 10.1111/sode.12052
   Difede J, 2014, NEUROPSYCHOPHARMACOL, V39, P1052, DOI 10.1038/npp.2013.317
   Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x
   Dozier Mary, 2009, Child Adolesc Social Work J, V26, P321
   Drabant EM, 2012, AM J PSYCHIAT, V169, P397, DOI 10.1176/appi.ajp.2011.10111699
   Drabant EM, 2009, BIOL PSYCHIAT, V65, P367, DOI 10.1016/j.biopsych.2008.09.007
   Dudley KJ, 2011, NEUROSCI BIOBEHAV R, V35, P1544, DOI 10.1016/j.neubiorev.2010.12.016
   Duman RS, 2014, DEPRESS ANXIETY, V31, P291, DOI 10.1002/da.22227
   Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013
   Duval ER, 2015, THER CLIN RISK MANAG, V11, P115, DOI 10.2147/TCRM.S48528
   Eidelman-Rothman M, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00165
   Elman I, 2009, BIOL PSYCHIAT, V66, P1083, DOI 10.1016/j.biopsych.2009.06.006
   Enman NM, 2015, BIOL PSYCHIAT, V78, P871, DOI 10.1016/j.biopsych.2015.04.024
   Eraly SA, 2014, JAMA PSYCHIAT, V71, P423, DOI 10.1001/jamapsychiatry.2013.4374
   Erickson KI, 2009, BRIT J SPORT MED, V43, P22, DOI 10.1136/bjsm.2008.052498
   Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504
   Fani N, 2012, PSYCHOL MED, V42, P533, DOI 10.1017/S0033291711001565
   Feder A., 2011, RESILIENCE MENTAL HL, P1
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62
   Feder A, 2013, J AFFECT DISORDERS, V147, P156, DOI 10.1016/j.jad.2012.10.027
   Feder A, 2009, NAT REV NEUROSCI, V10, P446, DOI 10.1038/nrn2649
   Felmingham K, 2007, PSYCHOL SCI, V18, P127, DOI 10.1111/j.1467-9280.2007.01860.x
   Felmingham KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103653
   Fish EW, 2004, ANN NY ACAD SCI, V1036, P167, DOI 10.1196/annals.1330.011
   Fisher PA, 2006, ANN NY ACAD SCI, V1094, P215, DOI 10.1196/annals.1376.023
   Fisher PA, 2007, PREV SCI, V8, P161, DOI 10.1007/s11121-007-0066-5
   Foa EB, 2000, J TRAUMA STRESS, V13, P539, DOI 10.1023/A:1007802031411
   Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449
   Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194
   Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953
   FONTANA AF, 1989, HEALTH PSYCHOL, V8, P175, DOI 10.1037//0278-6133.8.2.175
   Fredrickson BL, 2013, P NATL ACAD SCI USA, V110, P13684, DOI 10.1073/pnas.1305419110
   Fredrickson BL, 1998, COGNITION EMOTION, V12, P191
   Fredrickson BL, 2004, PHILOS T ROY SOC B, V359, P1367, DOI 10.1098/rstb.2004.1512
   Friedman M.J., 1995, RELATIONSHIP TRAUMA
   Gaali S, 2015, NAT CHEM BIOL, V11, P33, DOI 10.1038/nchembio.1699
   Garland EL, 2010, CLIN PSYCHOL REV, V30, P849, DOI 10.1016/j.cpr.2010.03.002
   Garmezy N., 1974, CHILD HIS FAMILY CHI
   Garmezy N., 1983, STRESS COPING DEV CH
   Gee Dylan G, 2015, Neurobiol Stress, V1, P184
   Geuze E, 2012, PSYCHONEUROENDOCRINO, V37, P1837, DOI 10.1016/j.psyneuen.2012.03.017
   Giannopoulou Ioanna, 2006, Clin Child Psychol Psychiatry, V11, P543, DOI 10.1177/1359104506067876
   Gidron Y, 2001, J TRAUMA STRESS, V14, P773, DOI 10.1023/A:1013046322993
   Gidron Y, 2007, J NERV MENT DIS, V195, P179, DOI 10.1097/01.nmd.0000254676.11987.5d
   Gill JM, 2013, J PSYCHOSOM RES, V74, P301, DOI 10.1016/j.jpsychores.2012.10.013
   Graham-Bermann SA, 2007, J CONSULT CLIN PSYCH, V75, P199, DOI 10.1037/0022-006X.75.2.199
   Groer MW, 2015, BIOL RES NURS, V17, P303, DOI 10.1177/1099800414544949
   Gross JJ, 2002, PSYCHOPHYSIOLOGY, V39, P281, DOI 10.1017/S0048577201393198
   Harvey BH, 2012, PHARMACOL BIOCHEM BE, V100, P775, DOI 10.1016/j.pbb.2011.06.014
   Heath NM, 2013, CYTOKINE, V63, P172, DOI 10.1016/j.cyto.2013.04.030
   Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X
   Heim C., 2013, ENCY BEHAV MED
   Hill MN, 2013, PSYCHONEUROENDOCRINO, V38, P2952, DOI 10.1016/j.psyneuen.2013.08.004
   Hill MN, 2005, NEUROPSYCHOPHARMACOL, V30, P508, DOI 10.1038/sj.npp.1300601
   Hobfoll Stevan E, 2007, Psychiatry, V70, P283, DOI 10.1521/psyc.2007.70.4.283
   Hobfoll SE, 2011, SOC SCI MED, V72, P1400, DOI 10.1016/j.socscimed.2011.02.022
   Hodes GE, 2014, P NATL ACAD SCI USA, V111, P16136, DOI 10.1073/pnas.1415191111
   Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326
   Hovens JGFM, 2010, ACTA PSYCHIAT SCAND, V122, P66, DOI 10.1111/j.1600-0447.2009.01491.x
   Howell KH, 2015, J INTERPERS VIOLENCE, V30, P232, DOI 10.1177/0886260514533155
   Howell KH, 2013, J AGGRESS MALTREAT T, V22, P425, DOI 10.1080/10926771.2013.775986
   Hyman SM, 2003, J FAM VIOLENCE, V18, P295, DOI 10.1023/A:1025117311660
   Iacoviello BM, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23970
   Iacoviello BM, 2014, J TRAUMA STRESS, V27, P232, DOI 10.1002/jts.21899
   Iribarren J, 2005, EVID-BASED COMPL ALT, V2, P503, DOI 10.1093/ecam/neh127
   Israel-Cohen Y, 2015, J POSIT PSYCHOL, V10, P99, DOI 10.1080/17439760.2014.927910
   JEVNING R, 1978, HORM BEHAV, V10, P54, DOI 10.1016/0018-506X(78)90024-7
   Jindani F, 2015, EVID-BASED COMPL ALT, DOI 10.1155/2015/351746
   Jovanovic T, 2013, CORTEX, V49, P1884, DOI 10.1016/j.cortex.2012.08.011
   Jung SH, 2015, BRAIN BEHAV IMMUN, V44, P195, DOI 10.1016/j.bbi.2014.09.015
   Kabat-Zinn J., 2003, CONSTRUCTIVISM HUMAN, V8, P73
   Karatsoreos IN, 2013, J CHILD PSYCHOL PSYC, V54, P337, DOI 10.1111/jcpp.12054
   Kearney DJ, 2012, J CLIN PSYCHOL, V68, P101, DOI 10.1002/jclp.20853
   Kearns MC, 2012, DEPRESS ANXIETY, V29, P833, DOI 10.1002/da.21997
   Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048
   Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007
   King DW, 2006, J APPL SOC PSYCHOL, V36, P2980, DOI 10.1111/j.0021-9029.2006.00138.x
   Klengel T, 2015, NEUROPSYCHOPHARMACOL, V40, P244, DOI 10.1038/npp.2014.208
   Knaevelsrud C, 2014, J NERV MENT DIS, V202, P651, DOI 10.1097/NMD.0000000000000178
   KOBASA SC, 1982, J PERS SOC PSYCHOL, V42, P168, DOI 10.1037//0022-3514.42.1.168
   Koch S.B., 2016, NEUROPSYCHOPHARMACOL, V10
   Koch S.B., 2015, NEUROPSYCHOPHARMACOL, V10, P1
   Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krishnan V, 2007, CELL, V131, P391, DOI 10.1016/j.cell.2007.09.018
   Krystal JH, 2009, BRAIN RES, V1293, P13, DOI 10.1016/j.brainres.2009.03.044
   Langley AK, 2015, J CONSULT CLIN PSYCH, V83, P853, DOI 10.1037/ccp0000051
   Leavitt L.A., 2014, PSYCHOL EFFECTS WAR
   LeDoux JE, 2002, AM J PSYCHIAT, V159, P171
   Lee H., 2015, REDUCTIONS SYMPTOM S
   Leontopoulou S., 2010, PSYCHOLOGY, V1, P377, DOI 10.4236/psych.2010.15047
   Lerner RM, 2005, J EARLY ADOLESCENCE, V25, P17, DOI 10.1177/0272431604272461
   Lerner RM, 2005, J EARLY ADOLESCENCE, V25, P10, DOI 10.1177/0272431604273211
   Leve LD, 2012, J CHILD PSYCHOL PSYC, V53, P1197, DOI 10.1111/j.1469-7610.2012.02594.x
   Li NX, 2011, BIOL PSYCHIAT, V69, P754, DOI 10.1016/j.biopsych.2010.12.015
   Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3
   Lierberman A.F., 2005, J AM ACAD CHILD ADOL, V44, P1241
   Logue MW, 2015, NEUROPSYCHOPHARMACOL, V40, P2287, DOI 10.1038/npp.2015.118
   Logue MW, 2015, PSYCHONEUROENDOCRINO, V57, P1, DOI 10.1016/j.psyneuen.2015.03.016
   Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164
   Lyons D.M., 2009, FRONT BEHAV NEUROSCI, V32, P1
   MacNamara A, 2016, NEUROPSYCHOPHARMACOL, V41, P611, DOI 10.1038/npp.2015.190
   Maddi SR, 2007, MIL PSYCHOL, V19, P61
   Mahabir M, 2015, J ANXIETY DISORD, V36, P127, DOI 10.1016/j.janxdis.2015.10.004
   Masten AS, 2012, ANNU REV PSYCHOL, V63, P227, DOI 10.1146/annurev-psych-120710-100356
   Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037//0003-066X.56.3.227
   Masten AS, 1999, DEV PSYCHOPATHOL, V11, P143, DOI 10.1017/S0954579499001996
   Masten A. S., 1990, DEV PSYCHOPATHOL, V2, P425, DOI DOI 10.1017/S0954579400005812
   McCormack K, 2006, DEV PSYCHOBIOL, V48, P537, DOI 10.1002/dev.20157
   McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157
   McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739
   McGrath H., 2012, BOUNCE BACK CLASSROO
   McRae K, 2012, EMOTION, V12, P250, DOI 10.1037/a0026351
   MEICHENBAUM DH, 1988, COUNS PSYCHOL, V16, P69, DOI 10.1177/0011000088161005
   Michopoulos V, 2015, AM J PSYCHIAT, V172, P353, DOI 10.1176/appi.ajp.2014.14020263
   Milad MR, 2005, P NATL ACAD SCI USA, V102, P10706, DOI 10.1073/pnas.050441102
   Mineka S, 2006, AM PSYCHOL, V61, P10, DOI 10.1037/0003-066X.61.1.10
   Moor A, 2007, WOMEN THER, V30, P19, DOI 10.1300/J015v30n01_02
   Moore SA, 2008, BEHAV RES THER, V46, P993, DOI 10.1016/j.brat.2008.05.001
   Morgan CA, 2000, BIOL PSYCHIAT, V47, P902, DOI 10.1016/S0006-3223(99)00239-5
   MRAZEK PJ, 1987, CHILD ABUSE NEGLECT, V11, P357, DOI 10.1016/0145-2134(87)90009-3
   Mueller PJ, 2007, CLIN EXP PHARMACOL P, V34, P377, DOI 10.1111/j.1440-1681.2007.04590.x
   Mulligan K, 2011, PSYCHOL MED, V41, P673, DOI 10.1017/S003329171000125X
   Murray H., 2015, BEHAV COGN PSYCHOTH, P1
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392
   Naim R, 2015, AM J PSYCHIAT, V172, P1242, DOI 10.1176/appi.ajp.2015.14121579
   Nemeroff CB, 2014, J AM ACAD CHILD PSY, V53, P395, DOI 10.1016/j.jaac.2014.02.004
   Neumeister A, 2015, PSYCHONEUROENDOCRINO, V51, P577, DOI 10.1016/j.psyneuen.2014.10.012
   New AS, 2009, BIOL PSYCHIAT, V66, P656, DOI 10.1016/j.biopsych.2009.05.020
   Neylan TC, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23938
   O'Donovan A, 2015, PSYCHONEUROENDOCRINO, V51, P557, DOI 10.1016/j.psyneuen.2014.11.010
   Ong AD, 2006, J PERS SOC PSYCHOL, V91, P730, DOI 10.1037/0022-3514.91.4.730
   OVERMIER JB, 1967, J COMP PHYSIOL PSYCH, V63, P28, DOI 10.1037/h0024166
   Pacella ML, 2013, J ANXIETY DISORD, V27, P33, DOI 10.1016/j.janxdis.2012.08.004
   Parcesepe AM, 2015, AGGRESS VIOLENT BEH, V25, P15, DOI 10.1016/j.avb.2015.06.004
   Park CL, 2010, PSYCHOL BULL, V136, P257, DOI 10.1037/a0018301
   Pastorelli C., 2015, J CHILD PSYCHOL PSYC, P1
   Patterson G. R., 1992, SOCIAL LEARNING APPR
   Pechtel P, 2011, PSYCHOPHARMACOLOGY, V214, P55, DOI 10.1007/s00213-010-2009-2
   Pfau Madeline L, 2015, Neurobiol Stress, V1, P66
   Pidgeon A.M., 2015, EUR SCI J, V11, P211
   Pidgeon A.M., 2014, J PSYCHOL, V1, P8
   Pietrzak RH, 2014, PSYCHOL MED, V44, P205, DOI 10.1017/S0033291713000597
   Pietrzak RH, 2010, J AFFECT DISORDERS, V120, P188, DOI 10.1016/j.jad.2009.04.015
   Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558
   Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3
   Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138
   Rabinak CA, 2014, DEPRESS ANXIETY, V31, P851, DOI 10.1002/da.22243
   Rapgay L, 2014, MINDFULNESS, V5, P742, DOI 10.1007/s12671-013-0231-9
   Ravindran LN, 2009, BRAIN RES, V1293, P24, DOI 10.1016/j.brainres.2009.03.037
   Resnick H, 2007, BEHAV RES THER, V45, P2432, DOI 10.1016/j.brat.2007.05.002
   Reynaud E, 2013, NEUROPSYCHOLOGIA, V51, P845, DOI 10.1016/j.neuropsychologia.2013.01.007
   Rose S., 2014, MILITARY BEHAV HLTH, V2, P264, DOI [10.1080/21635781.2014.963757, DOI 10.1080/21635781.2014.963757]
   Rothbaum BO, 2014, J CLIN PSYCHIAT, V75, P1380, DOI 10.4088/JCP.13m08715
   Rothbaum BO, 2014, AM J PSYCHIAT, V171, P640, DOI 10.1176/appi.ajp.2014.13121625
   Rothbaum BO, 2012, BIOL PSYCHIAT, V72, P957, DOI 10.1016/j.biopsych.2012.06.002
   Ruggiero KJ, 2009, PSYCHIATRY, V72, P195, DOI 10.1521/psyc.2009.72.2.195
   Russo SJ, 2012, NAT NEUROSCI, V15, P1475, DOI 10.1038/nn.3234
   Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236
   Rutter M, 2013, J CHILD PSYCHOL PSYC, V54, P474, DOI 10.1111/j.1469-7610.2012.02615.x
   Sabban E.L., 2015, NEUROPEPTIDES, V12
   Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI 10.1016/j.neuropsychologia.2008.05.022
   Sajdyk TJ, 2008, J NEUROSCI, V28, P893, DOI 10.1523/JNEUROSCI.0659-07.2008
   Sapienza JK, 2011, CURR OPIN PSYCHIATR, V24, P267, DOI 10.1097/YCO.0b013e32834776a8
   Sautter FJ, 2009, J MARITAL FAM THER, V35, P343, DOI 10.1111/j.1752-0606.2009.00125.x
   Scheeringa MS, 2006, AM J PSYCHIAT, V163, P644, DOI 10.1176/appi.ajp.163.4.644
   Schiller D, 2010, TRENDS COGN SCI, V14, P268, DOI 10.1016/j.tics.2010.04.002
   Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637
   Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820
   SELIGMAN ME, 1967, J EXP PSYCHOL, V74, P1, DOI 10.1037/h0024514
   Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410
   Seppala EM, 2014, J TRAUMA STRESS, V27, P397, DOI 10.1002/jts.21936
   Serova LI, 2013, NEUROSCIENCE, V236, P298, DOI 10.1016/j.neuroscience.2013.01.040
   Sharot T, 2007, NATURE, V450, P102, DOI 10.1038/nature06280
   Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235
   Silverman MN, 2005, VIRAL IMMUNOL, V18, P41, DOI 10.1089/vim.2005.18.41
   Singewald N, 2015, PHARMACOL THERAPEUT, V149, P150, DOI 10.1016/j.pharmthera.2014.12.004
   Sliter M, 2014, J ORGAN BEHAV, V35, P257, DOI 10.1002/job.1868
   Smith BW, 2011, J CONSULT CLIN PSYCH, V79, P613, DOI 10.1037/a0025189
   Smoller JW, 2016, NEUROPSYCHOPHARMACOL, V41, P297, DOI 10.1038/npp.2015.266
   Soeter M, 2015, BIOL PSYCHIAT, V78, P880, DOI 10.1016/j.biopsych.2015.04.006
   Solomon Z, 1990, MIL PSYCHOL, V2, P241, DOI 10.1207/s15327876mp0204_4
   Southwick SM, 2012, RESILIENCE: THE SCIENCE OF MASTERING LIFE'S GREATEST CHALLENGES, P1, DOI 10.1017/CBO9781139013857
   Southwick S.M., 2011, RESILIENCE MENTAL HL
   Southwick SM, 2012, IMPLICATIONS PREV BI, V71, P1068
   Southwick S.M., 2013, HDB PTSD SCI PRACTIC
   Southwick SM, 2005, ANNU REV CLIN PSYCHO, V1, P255, DOI 10.1146/annurev.clinpsy.1.102803.143948
   Southwick SM, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14001708
   Southwick SM, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.25338
   Southwick Steven M, 2006, Am J Psychother, V60, P161
   Spitzer C, 2010, J PSYCHIATR RES, V44, P15, DOI 10.1016/j.jpsychires.2009.06.002
   Stacey M., 1970, HOSP CHILDREN THEIR
   Stanley EA, 2011, COGN BEHAV PRACT, V18, P566, DOI 10.1016/j.cbpra.2010.08.002
   Stein MB, 2007, J TRAUMA STRESS, V20, P923, DOI 10.1002/jts.20270
   Stellar JE, 2015, EMOTION, V15, P129, DOI 10.1037/emo0000033
   Strange BA, 2004, P NATL ACAD SCI USA, V101, P11454, DOI 10.1073/pnas.0404282101
   Suris A, 2010, ANN CLIN PSYCHIATRY, V22, P274
   Swartz JR, 2015, NEURON, V85, P505, DOI 10.1016/j.neuron.2014.12.055
   Tenhula WN, 2014, PROF PSYCHOL-RES PR, V45, P416, DOI 10.1037/a0037150
   Thabet A, 2014, ARAB J PSYCHIAT, V25, P71
   Thompson RW, 2011, TRAUMA VIOLENCE ABUS, V12, P220, DOI 10.1177/1524838011416375
   Thorsell A, 2010, EXP BIOL MED, V235, P1163, DOI 10.1258/ebm.2010.009331
   Tol WA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-56
   Tottenham N, 2010, DEVELOPMENTAL SCI, V13, P46, DOI 10.1111/j.1467-7687.2009.00852.x
   Tsai J, 2015, PSYCHOL MED, V45, P165, DOI 10.1017/S0033291714001202
   Tsatsoulis A, 2006, ANN NY ACAD SCI, V1083, P196, DOI 10.1196/annals.1367.020
   Ullman SE, 2001, J TRAUMA STRESS, V14, P369, DOI 10.1023/A:1011125220522
   van Meijel EPM, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0492-z
   Vythilingam M., 2009, PSYCHIAT RES, V30, P75
   Walker C., 2015, NEUROENDOCRINOL STRE, P287
   Waugh CE, 2008, SOC COGN AFFECT NEUR, V3, P322, DOI 10.1093/scan/nsn024
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Werner E.E., 1971, CHILDREN KAUAI HONOL
   Werner EE, 1977, KAUAIS CHILDREN COME
   Werner EE, 2012, DEV PSYCHOPATHOL, V24, P553, DOI 10.1017/S0954579412000156
   Wethington HR, 2008, AM J PREV MED, V35, P287, DOI 10.1016/j.amepre.2008.06.024
   Whealin JM, 2008, TRAUMA VIOLENCE ABUS, V9, P100, DOI 10.1177/1524838008315869
   White J, 2015, EPIDEMIOL PSYCH SCI, V24, P249, DOI 10.1017/S2045796014000110
   Wolmer L, 2011, J TRAUMA STRESS, V24, P309, DOI 10.1002/jts.20638
   Wolmer L, 2011, J AM ACAD CHILD PSY, V50, P340, DOI 10.1016/j.jaac.2011.01.002
   Wu G, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00010
   WYMAN PA, 1991, AM J COMMUN PSYCHOL, V19, P405
   Yehuda R, 2006, BIOL PSYCHIAT, V59, P660, DOI 10.1016/j.biopsych.2005.08.027
   Yehuda R, 2001, J CLIN PSYCHIAT, V62, P41
   Yehuda R, 2006, ANN NY ACAD SCI, V1071, P379, DOI 10.1196/annals.1364.028
   Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015
   Zannas AS, 2015, BIOL PSYCHIAT, V78, P327, DOI 10.1016/j.biopsych.2015.04.003
   Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498
   Zatzick DF, 2009, PSYCHIATRY, V72, P346, DOI 10.1521/psyc.2009.72.4.346
   Zoellner LA, 1999, J TRAUMA STRESS, V12, P689, DOI 10.1023/A:1024777303848
   Zohar J, 2011, EUR NEUROPSYCHOPHARM, V21, P796, DOI 10.1016/j.euroneuro.2011.06.001
NR 282
TC 0
Z9 0
U1 15
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD OCT
PY 2016
VL 284
SI SI
BP 119
EP 132
DI 10.1016/j.expneurol.2016.07.002
PN B
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA DY7UJ
UT WOS:000385334500002
PM 27417856
ER

PT J
AU Cabral, KA
   Andrade, CAF
AF Cabral, K. A.
   Andrade, C. A. F.
TI Importance of the lateral parabrachial nucleus to sodium balance in
   fluid-depleted rats
SO NEUROSCIENCE RESEARCH
LA English
DT Article
DE Sodium; Dehydration; Natriuresis; Alpha(2)-adrenoceptor; Hindbrain
ID SALT APPETITE; ALPHA(2)-ADRENERGIC ACTIVATION; SEROTONERGIC MECHANISMS;
   HORMONAL RESPONSES; RECEPTORS MEDIATE; CENTRAL OXYTOCIN; NACL INTAKE;
   ANGIOTENSIN; MOXONIDINE; SITES
AB The lateral parabrachial nucleus (LPBN) exerts an important inhibitory influence for the control of sodium and water intake. However, the importance of LPBN on renal responses and cardiovascular changes during extracellular dehydration are still unknown. Here we investigated the effects of bilateral injections of moxonidine (alpha(2)-adrenergic and imidazoline receptor agonist) on renal and cardiovascular changes in fluid-depleted rats. Male Wistar rats (n = 4-8 per group) with bilateral stainless steel guide-cannulas implanted into the LPBN were treated with subcutaneous furosemide (10 mg/1<g) + captopril (5 mg/kg) to induce fluid depletion. Forty-five min later vehicle or moxonidine (0.5 nmol/0.21 mu 1) were bilaterally injected into the LPBN. In fluid-depleted rats, moxonidine produced strong 0.3 M NaCI and water intake without noticeable changes in cardiovascular parameters. Moxonidine did not change sodium excretion (488 +/- 135, vs. vehicle: 376 +/- 75 mu Eq/1 h) or urinary volume (2.5 +/- 0.7, vs. vehicle: 2.5 +/- 0.3 ml/1 h) in fluid-depleted rats without access to fluids for rehydration. However, moxonidine decreased natriuresis (462 +/- 127, vs. vehicle: 888 +/- 122 mu Eq/1 h) and diuresis (2.5 +/- 0.5, vs. vehicle: 4.5 +/- 0.5 ml/1 h) in fluid-depleted rats submitted to i.g. rehydration. These data suggest that alpha2-adrenergic mechanism of the LPBN facilitates sodium/water retention and body fluid volume expansion during extracellular dehydration. (C) 2016 Elsevier Ireland Ltd and Japan Neuroscience Society. All rights reserved.
C1 [Cabral, K. A.] Univ Fed Alfenas, Brazilian Physiol Soc, Grad Program Physiol, Alfenas, MG, Brazil.
   [Andrade, C. A. F.] UNESP, Sch Dent, Dept Physiol & Pathol, BR-14801903 Araraquara, SP, Brazil.
RP Andrade, CAF (reprint author), Rua Humaita 1680, BR-14801903 Araraquara, SP, Brazil.
EM carina.andrade@foar.unesp.br
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   CAPES
FX The authors thank MF Venancio and J dos Reis Pereira (Unifal-MG) for
   technical assistance. This research was supported by Brazilian public
   funding from Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) and CAPES. This work was part of the requirements to obtain a
   Master degree by Kriss A. Cabral in the Graduate Program in Physiology
   of the Brazilian Physiological Society (Programa Multicentrico de
   Pos-Graduacao em Ciencias Fisiologicas, Unifal-MG, Sociedade Brasileira
   de Fisiologia - SBFis), Brazil.
CR Andrade CAF, 2006, NEUROSCIENCE, V142, P21, DOI 10.1016/j.neuroscience.2006.04.015
   Andrade CAF, 2015, BEHAV BRAIN RES, V278, P535, DOI 10.1016/j.bbr.2014.10.007
   Andrade CAF, 2014, BRAZ J MED BIOL RES, V47, P11, DOI 10.1590/1414-431X20133308
   Andrade CAF, 2012, NEUROSCIENCE, V208, P69, DOI 10.1016/j.neuroscience.2012.02.013
   Andrade CAF, 2004, NEUROSCIENCE, V129, P25, DOI 10.1016/j.neuroscience.2004.07.042
   Andrade CAF, 2011, PHYSIOL BEHAV, V104, P702, DOI 10.1016/j.physbeh.2011.07.020
   Antunes-Rodrigues J, 2004, PHYSIOL REV, V84, P169, DOI 10.1152/physrev.00017.2003
   BLACKBURN RE, 1995, AM J PHYSIOL-REG I, V269, pR245
   BLACKBURN RE, 1992, AM J PHYSIOL, V263, pR1347
   CIRIELLO J, 1984, BRAIN RES, V322, P388, DOI 10.1016/0006-8993(84)90140-9
   ERNSBERGER P, 1993, J PHARMACOL EXP THER, V264, P172
   Ernsberger P, 1997, J HYPERTENS, V15, pS9
   FITTS DA, 1989, BEHAV NEUROSCI, V103, P865
   FULWILER CE, 1984, BRAIN RES REV, V7, P229, DOI 10.1016/0165-0173(84)90012-2
   Gasparini S, 2009, NEUROSCIENCE, V164, P370, DOI 10.1016/j.neuroscience.2009.08.048
   HAXHIU MA, 1994, J CARDIOVASC PHARM, V24, pS1, DOI 10.1097/00005344-199424001-00002
   HERBERT H, 1995, ANAT EMBRYOL, V192, P507
   HERBERT H, 1990, J COMP NEUROL, V293, P540, DOI 10.1002/cne.902930404
   JHAMANDAS JH, 1992, J NEUROENDOCRINOL, V4, P461, DOI 10.1111/j.1365-2826.1992.tb00194.x
   Jhamandas JH, 1996, BRAIN RES BULL, V39, P115, DOI 10.1016/0361-9230(95)02084-5
   Johnson A.K., 2007, HDB NEUROCHEMISTRY M, P641, DOI DOI 10.1007/978-0-387-30405-2_17
   KRUKOFF TL, 1993, BRAIN RES BULL, V30, P163, DOI 10.1016/0361-9230(93)90054-F
   LANCA AJ, 1985, NEUROSCIENCE, V14, P1117, DOI 10.1016/0306-4522(85)90281-7
   Margatho LO, 2007, AM J PHYSIOL-REG I, V292, pR1190, DOI 10.1152/ajpregu.00351.2006
   Menani JV, 2014, AM J PHYSIOL-REG I, V306, pR201, DOI 10.1152/ajpregu.00251.2012
   Menani JV, 1996, AM J PHYSIOL-REG I, V270, pR162
   Menani J., 2006, NEW TRENDS BRAIN RES, P95
   Norgren R., 1981, BRAIN MECH SENSATION, P143
   Paxinos G, 2004, RAT BRAIN STEREOTAXI
   Pereira DTB, 2010, PHYSIOL BEHAV, V99, P472, DOI 10.1016/j.physbeh.2009.12.009
   SALEH TM, 1994, AM J PHYSIOL, V266, pR1287
   Talley EM, 1996, J COMP NEUROL, V372, P111, DOI 10.1002/(SICI)1096-9861(19960812)372:1<111::AID-CNE8>3.0.CO;2-6
   THUNHORST RL, 1994, AM J PHYSIOL, V266, pR458
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD OCT
PY 2016
VL 111
BP 41
EP 47
DI 10.1016/j.neures.2016.05.003
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DY7QB
UT WOS:000385323200005
PM 27282217
ER

PT J
AU Bilgic, A
   Toker, A
   Uysal, S
AF Bilgic, Ayhan
   Toker, Aysun
   Uysal, Saliha
TI Exploratory study to evaluate plasma vasopressin and apelin-13 levels in
   children with attention-deficit hyperactivity disorder
SO PSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
DE apelin-13; attention-deficit hyperactivity disorder; children; plasma;
   vasopressin
ID CRITERION VALIDITY; RECEPTOR; RELIABILITY; OXYTOCIN; PATHWAY; MICE;
   ASSOCIATION; AGGRESSION; GENE
AB AimVasopressin exerts robust influences on social communication and behavior in humans. Apelin is a relatively novel neuropeptide that could counteract vasopressin's actions and has been shown to be closely related with a broad range of physiological functions. Abnormalities in vasopressin and apelin have been detected in a variety of psychiatric disorders, but their relation to attention-deficit hyperactivity disorder (ADHD) is unknown. In the present study, we explored the plasma levels of vasopressin and apelin-13 in children with ADHD.
   MethodsThirty-four children with ADHD and 36 healthy controls were enrolled in this study. The severity of ADHD symptoms was assessed via Conners' Parent Rating Scale and Conners' Teacher Rating Scale. Plasma levels of vasopressin and apelin-13 were measured using commercial enzyme-linked immunosorbent assay kits.
   ResultsThe mean plasma apelin-13 levels were significantly higher in male children with ADHD than in male control subjects; no significant difference was found between the groups for plasma apelin-13 levels in girls or in the entire subject cohort. Plasma vasopressin levels did not show any significant differences between groups. There were no significant correlations between plasma levels of these neuropeptides and scores for Conners' Parent Rating Scale and Conners' Teacher Rating Scale.
   ConclusionOur results suggest a sex-specific association between plasma apelin-13 levels and ADHD. Apelin-13 may play a role in the etiopathogenesis of ADHD either with a direct impact on the apelin receptor or via its opposing effect on the vasopressinergic system.
C1 [Bilgic, Ayhan] Necmettin Erbakan Univ, Meram Sch Med, Dept Child & Adolescent Psychiat, Konya, Turkey.
   [Toker, Aysun; Uysal, Saliha] Necmettin Erbakan Univ, Meram Sch Med, Dept Biochem, Konya, Turkey.
RP Bilgic, A (reprint author), Necmettin Erbakan Univ, Meram Sch Med, Dept Child & Adolescent Psychiat, Serinyol St, TR-42090 Meram Konya, Turkey.
EM bilgicayhan@yahoo.com
FU Scientific Research Project Coordination Unit of Necmettin Erbakan
   University [143018001]
FX Funding for this study was provided by a grant from the Scientific
   Research Project Coordination Unit of Necmettin Erbakan University
   (Project no: 143018001). The authors wish to thank the patients and
   families who participated in this study. We gratefully acknowledge the
   assistance of Dr Umit Isik in laboratory collections.
CR Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47
   Bertrand C, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00115
   Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2
   Boso M, 2007, ARCH MED RES, V38, P70, DOI 10.1016/j.arcmed.2006.08.003
   Buhler E, 2011, J AUTISM DEV DISORD, V41, P1718, DOI 10.1007/s10803-011-1205-1
   Carson DS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132224
   Cheng BH, 2012, PEPTIDES, V37, P171, DOI 10.1016/j.peptides.2012.07.012
   Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621
   Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P279, DOI 10.1023/A:1022606501530
   Davies W, 2014, FRONT NEUROENDOCRIN, V35, P331, DOI 10.1016/j.yfrne.2014.03.003
   DesMota N, 2004, P NATL ACAD SCI USA, V101, P10464
   desVries GJ, 2008, PROG BRAIN RES, V170, P17
   Donaldson ZR, 2010, BEHAV NEUROSCI, V124, P159, DOI 10.1037/a0018094
   Feng CL, 2015, BRAIN IMAGING BEHAV, V9, P754, DOI 10.1007/s11682-014-9333-9
   Fournel A, 2015, GUT, DOI [10.1136/gutjnl-2015-310230, DOI 10.1136/GUTJNL-2015-310230]
   Gokler B, 2004, COCUK GENCLIK RUH SA, V11, P109
   Jaszberenyi M, 2004, NEUROSCIENCE, V129, P811, DOI 10.1016/j.neuroscience.2004.08.007
   Kaner S, 2013, NOROPSIKIYATRI ARS, V50, P100, DOI 10.4274/npa.y6219
   Kaner S, 2013, EGIT BILIM, V38, P81
   Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021
   Luppino D, 2014, PSYCHIAT GENET, V24, P185, DOI 10.1097/YPG.0000000000000036
   Lv SY, 2012, BRAIN RES BULL, V88, P574, DOI 10.1016/j.brainresbull.2012.06.003
   Malik AI, 2014, PSYCHIAT GENET, V24, P201, DOI 10.1097/YPG.0000000000000044
   Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Park J, 2010, PROG NEURO-PSYCHOPH, V34, P697, DOI 10.1016/j.pnpbp.2010.03.029
   Qian QJ, 2003, AM J MED GENET B, V118B, P103, DOI 10.1002/ajmg.b.10064
   Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x
   Sasaki T, 2015, PSYCHIAT RES, V228, P746, DOI 10.1016/j.psychres.2015.05.029
   Savasr I, 1995, MANUAL WECHSLER INTE
   Telegdy G, 2014, BEHAV BRAIN RES, V263, P198, DOI 10.1016/j.bbr.2014.01.009
   Valle A, 2008, J NEUROENDOCRINOL, V20, P79, DOI 10.1111/j.1365-2826.2007.01617.x
   vansWest D, 2009, PSYCHIAT GENET, V19, P102
   Wechsler D, 1974, WISC R MANUAL WECHSL
   Yang SS, 2015, ARCH MED SCI, V11, P1065, DOI 10.5114/aoms.2015.54863
NR 35
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-1316
EI 1440-1819
J9 PSYCHIAT CLIN NEUROS
JI Psychiatry Clin. Neurosci.
PD OCT
PY 2016
VL 70
IS 10
BP 442
EP 447
DI 10.1111/pcn.12415
PG 6
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DZ0XU
UT WOS:000385563800004
PM 27283127
ER

PT J
AU Yenuberi, H
   Abraham, A
   Sebastian, A
   Benjamin, SJ
   Jeyaseelan, V
   Mathews, JE
AF Yenuberi, Hilda
   Abraham, Anuja
   Sebastian, Ajit
   Benjamin, Santosh J.
   Jeyaseelan, Visalakshi
   Mathews, Jiji E.
TI A randomised double-blind placebo-controlled trial comparing stepwise
   oral misoprostol with vaginal misoprostol for induction of labour
SO TROPICAL DOCTOR
LA English
DT Article
DE Oral; vaginal; misoprostol; oxytocin; induction; tachysystole
ID TERM
AB A comparison of induction of labour (IOL) using three doses of 25 mu g vaginal misoprostol inserted at intervals of 4h or more with a stepwise oral regime starting with 50 mu g followed by two doses of 100 mu g was studied in a double-blind placebo-controlled trial in a tertiary centre in South India. Primary outcome was vaginal delivery in 24h. Significantly more women in the first group required oxytocin augmentation and a third dose of the drug than women in the second group. Uterine tachysystole and other maternal and neonatal complications were similar. Thus it is concluded that women induced with oral, as compared to vaginal misoprostol are more likely to labour without oxytocin.
C1 [Yenuberi, Hilda; Abraham, Anuja; Sebastian, Ajit; Benjamin, Santosh J.; Mathews, Jiji E.] Christian Med Coll & Hosp, Dept Obstet & Gynaecol, Vellore, Tamil Nadu, India.
   [Jeyaseelan, Visalakshi] Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, India.
RP Mathews, JE (reprint author), Christian Med Coll & Hosp, Dept Obstet & Gynaecol, Unit 5, Ida Scudder Rd, Vellore 632004, Tamil Nadu, India.
EM coronistrial@yahoo.co.in
FU Christian Medical College and Hospital, Vellore [7598]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Christian
   Medical College and Hospital, Vellore (No. 7598 dated 07.09.2011).
CR [Anonymous], 2009, OBSTET GYNECOL, V114, P192, DOI DOI 10.1097/AOG.0B013E3181AEF106
   Adair CD, 1998, OBSTET GYNECOL, V92, P810, DOI 10.1016/S0029-7844(98)00278-6
   Alfirevic Z, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001338.pub2
   Bennett KA, 1998, OBSTET GYNECOL, V92, P481, DOI 10.1016/S0029-7844(98)00226-9
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Chen W, 2016, BJOG-INT J OBSTET GY, V123, P346, DOI 10.1111/1471-0528.13456
   Cheng SY, 2008, OBSTET GYNECOL, V111, P119, DOI 10.1097/01.AOG.0000297313.68644.71
   Colon I, 2005, AM J OBSTET GYNECOL, V192, P747, DOI 10.1016/j.ajog.2004.12.051
   Crane JMG, 2006, BJOG-INT J OBSTET GY, V113, P1366, DOI 10.1111/j.1471-0528.2006.01111.x
   Dodd JM, 2006, BRIT MED J, V332, P509, DOI 10.1136/bmj.38729.513819.63
   Fisher SA, 2001, AM J OBSTET GYNECOL, V185, P906, DOI 10.1067/mob.2001.117303
   Goldberg AB, 2001, NEW ENGL J MED, V344, P38
   Hofmeyr GJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000941.pub2
   Hofmeyr GJ, 2001, BRIT J OBSTET GYNAEC, V108, P952, DOI 10.1111/j.1471-0528.2001.00231.x
   Hogerzeil HV, STABILITY INJECTABLE
   Kwon JS, 2001, BRIT J OBSTET GYNAEC, V108, P23, DOI 10.1111/j.1471-0528.2001.00007.x
   Mathews JE, 2000, INT J GYNECOL OBSTET, V68, P43, DOI 10.1016/S0020-7292(99)00170-8
   OBrien WF, 1995, CLIN PERINATOL, V22, P973
   Olah KSJ, 2015, OBSTET GYNAECOLOGIST, V17, P265
   SanchezRamos L, 1997, OBSTET GYNECOL, V89, P633, DOI 10.1016/S0029-7844(96)00374-2
   Shetty A, 2001, BRIT J OBSTET GYNAEC, V108, P238, DOI 10.1111/j.1471-0528.2001.00073.x
   Spiby H., 1994, COCHRANE DATABASE SY
   Stewart RD, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.07.032
   Weeks A, 2007, INT J GYNECOL OBSTET, V99, pS194, DOI 10.1016/j.ijgo.2007.09.011
   World Health Organization, WHO REC IND LAB
   Wing DA, 2000, OBSTET GYNECOL, V95, P905, DOI 10.1016/S0029-7844(00)00815-2
   Zieman M, 1997, OBSTET GYNECOL, V90, P88, DOI 10.1016/S0029-7844(97)00111-7
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0049-4755
EI 1758-1133
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2016
VL 46
IS 4
BP 198
EP 205
DI 10.1177/0049475515624856
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DZ0GH
UT WOS:000385515000005
PM 26787644
ER

PT J
AU Manish, P
   Rathore, S
   Benjamin, SJ
   Abraham, A
   Jeyaseelan, V
   Mathews, JE
AF Manish, Pushplata
   Rathore, Swati
   Benjamin, Santosh J.
   Abraham, Anuja
   Jeyaseelan, Vishali
   Mathews, Jiji E.
TI A randomised controlled trial comparing 30mL and 80mL in Foley catheter
   for induction of labour after previous Caesarean section
SO TROPICAL DOCTOR
LA English
DT Article
DE Foley catheter induction of labour; 30mL or 80mL in catheter balloon;
   uterine rupture; caesarean section; trial of scar; Vaginal birth after
   caesarean section (VBAC)
ID VAGINAL BIRTH; SUCCESS; COHORT
AB Inducing labour with a Foley balloon catheter rather than using oxytocin or prostaglandins is considered to be less risky if the uterus is scarred.(1) It is not known if more fluid in the balloon is more effective without being more dangerous. Volumes of 80mL and 30mL were compared in 154 eligible women. Mode of delivery, duration of labour and delivery within 24h were similar in both groups. However, the second group required oxytocin more frequently. Though more scar dehiscences occurred in the first group, the difference was not significant.
C1 [Manish, Pushplata; Rathore, Swati; Benjamin, Santosh J.; Abraham, Anuja; Mathews, Jiji E.] Christian Med Coll & Hosp, Dept Obstet & Gynaecol, Vellore, Tamil Nadu, India.
   [Jeyaseelan, Vishali] Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, India.
RP Mathews, JE (reprint author), Christian Med Coll & Hosp, Dept Obstet & Gynaecol, Unit 5, Ida Scudder Rd, Vellore 632004, Tamil Nadu, India.
EM og5@cmcvellore.ac.in
FU Institutional Fluid Research Fund
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was funded by Institutional Fluid Research Fund.
CR Bujold E, 2004, OBSTET GYNECOL, V103, P18, DOI 10.1097/01.AOG.0000109148.23082.C1
   Cahill AG, 2008, OBSTET GYNECOL, V111, P654, DOI 10.1097/AOG.0b013e318163be22
   Heinemann J, 2008, AM J OBSTET GYNECOL, V199, P177, DOI 10.1016/j.ajog.2008.05.005
   Jozwiak M, 2014, ACTA OBSTET GYN SCAN, V93, P296, DOI 10.1111/aogs.12320
   Knight HE, 2014, BJOG-INT J OBSTET GY, V121, P183, DOI 10.1111/1471-0528.12508
   Ravasia DJ, 2000, AM J OBSTET GYNECOL, V183, P1176, DOI 10.1067/mob.2000.109037
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0049-4755
EI 1758-1133
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2016
VL 46
IS 4
BP 205
EP 211
DI 10.1177/0049475515626031
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DZ0GH
UT WOS:000385515000006
PM 26774112
ER

PT J
AU Massey, SH
   Schuette, SA
   Pournajafi-Nazarloo, H
   Wisner, KL
   Carter, CS
AF Massey, Suena H.
   Schuette, Stephanie A.
   Pournajafi-Nazarloo, Hossein
   Wisner, Katherine L.
   Carter, C. Sue
TI Interaction of oxytocin level and past depression may predict postpartum
   depressive symptom severity
SO ARCHIVES OF WOMENS MENTAL HEALTH
LA English
DT Article
DE Postpartum depression; Mood; Oxytocin; Biomarker; Hormone; Oxytocin
   receptor gene
ID PLASMA OXYTOCIN; DNA METHYLATION; INDIVIDUAL-DIFFERENCES; PERINATAL
   DEPRESSION; PSYCHOSOCIAL STRESS; PERIPHERAL OXYTOCIN; SOCIAL-BEHAVIOR;
   WOMEN; PREGNANCY; VALIDATION
AB We examined plasma oxytocin concentration and postpartum depression (PPD) symptom severity in women who were not depressed during pregnancy and whether this differed by major depressive disorder (MDD) history. We assessed psychiatric history and plasma oxytocin in 66 healthy pregnant women in the third trimester (M = 35 +/- 3 weeks) and depressive symptoms at 6 weeks postpartum (M = 5.9 +/- 0.8 weeks). Linear regression analysis was used to examine oxytocin and PPD symptom severity and moderation of oxytocin and PPD by past MDD. Women with (n = 13) and without (n = 53) past MDD differed in third trimester depressive symptom severity, but not oxytocin level, demographic factors, or birth outcomes. Controlling for third trimester depressive symptoms, oxytocin level was unrelated to PPD symptom severity [B(SE) = -.019 (.084); beta = -.025; t = -.227; p = .821]. However, oxytocin level interacted with past MDD to predict PPD symptom severity [B(SE) = 7.489 (2.429); beta = .328; t = 3.084; p = .003]. Higher oxytocin predicted greater PPD symptom severity in women with past MDD (p = .019), but not in women without (p = .216). Replication in a larger sample and methodologic challenges are discussed.
C1 [Massey, Suena H.; Schuette, Stephanie A.; Wisner, Katherine L.] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 676 North St Clair St,Suite 1000, Chicago, IL 60611 USA.
   [Massey, Suena H.; Schuette, Stephanie A.] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Pournajafi-Nazarloo, Hossein; Carter, C. Sue] Indiana Univ, Kinsey Inst, Bloomington, IN USA.
   [Pournajafi-Nazarloo, Hossein; Carter, C. Sue] Indiana Univ, Dept Biol, Bloomington, IN USA.
   [Wisner, Katherine L.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Massey, SH (reprint author), Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 676 North St Clair St,Suite 1000, Chicago, IL 60611 USA.; Massey, SH (reprint author), Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
EM suena.massey@northwestern.edu
FU Evergreen Invitational Women's Health Grant from the Northwestern
   Memorial Foundation; National Institute on Drug Abuse (NIDA) [K23
   DA037913]
FX This work was funded by the Evergreen Invitational Women's Health Grant
   from the Northwestern Memorial Foundation to Dr. Massey (9/12/13
   agreement date), and grant K23 DA037913 from the National Institute on
   Drug Abuse (NIDA) to Dr. Massey. The Evergreen Invitational,
   Northwestern Memorial Foundation, and NIDA had no role in the study
   design, collection, analysis or interpretation of data, writing the
   manuscript, or the decision to submit the paper for publication.
CR American College of Obstetricians and Gynecologists (ACOG), 2015, OBSTET GYNECOLOGY, V125, P1268
   Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Bell AF, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00243
   Carter C S, 2001, Prog Brain Res, V133, P241
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carter CS, 1997, ANN NY ACAD SCI, V807, P164, DOI 10.1111/j.1749-6632.1997.tb51918.x
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Cox JL, 1996, J AFFECT DISORDERS, V39, P185, DOI 10.1016/0165-0327(96)00008-0
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   Dennis CL, 2006, BIRTH-ISS PERINAT C, V33, P323, DOI 10.1111/j.1523-536X.2006.00130.x
   Eapen V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107745
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Frank E, 2008, EUR J PHARMACOL, V583, P226, DOI 10.1016/j.ejphar.2007.11.063
   GAINER H, 1983, PROG BRAIN RES, V60, P205
   Goldman M, 2008, SCHIZOPHR RES, V98, P247, DOI 10.1016/j.schres.2007.09.019
   Goodman JH, 2009, BIRTH-ISS PERINAT C, V36, P60, DOI 10.1111/j.1523-536X.2008.00296.x
   Gouin JP, 2010, PSYCHONEUROENDOCRINO, V35, P1082, DOI 10.1016/j.psyneuen.2010.01.009
   Hammock E, 2012, J AM ACAD CHILD PSY, V51, P712, DOI 10.1016/j.jaac.2012.04.010
   Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI 10.1176/appi.ajp.157.11.1873
   Kim S, 2014, BRAIN RES, V1580, P219, DOI 10.1016/j.brainres.2013.11.009
   Klengel T, 2014, NEUROPHARMACOLOGY, V80, P115, DOI 10.1016/j.neuropharm.2014.01.013
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   MacKinnon AL, 2014, PSYCHONEUROENDOCRINO, V48, P52, DOI 10.1016/j.psyneuen.2014.06.003
   Martin-Protean LLC, 2015, OX QUANT PROD
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McFarland J, 2011, ARCH WOMEN MENT HLTH, V14, P425, DOI 10.1007/s00737-011-0237-z
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Prevost M, 2014, FRONT PUB HLTH, V27, P1
   Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Rush AJ, 2005, NEUROPSYCHOPHARMACOL, V30, P405, DOI 10.1038/sj.npp.1300614
   Rush A.J., 2000, INT J METH PSYCH RES, V9, P45, DOI DOI 10.1002/MPR.79
   Seay JS, 2014, J APPL BIOBEHAV RES, V19, P70
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Sun HS, 2013, NEUROPSYCHOPHARMACOL, V38, P124, DOI 10.1038/npp.2012.73
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tops M, 2013, HDB RESILIENCE APPRO, P115
   Unternaehrer E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.77
   Weisman O, 2013, PSYCHONEUROENDOCRINO, V38, P694, DOI 10.1016/j.psyneuen.2012.08.011
   Wen SW, 2000, AM J EPIDEMIOL, V152, P1009, DOI 10.1093/aje/152.11.1009
   Wisner KL, 2006, JAMA-J AM MED ASSOC, V296, P2616, DOI 10.1001/jama.296.21.2616
   Wisner KL, 2013, JAMA PSYCHIAT, V70, P490, DOI 10.1001/jamapsychiatry.2013.87
   Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P403, DOI 10.1016/j.genhosppsych.2009.04.003
   Zelkowitz P, 2014, HORM BEHAV, V66, P351, DOI 10.1016/j.yhbeh.2014.06.014
   Zlotnick C, 2006, AM J PSYCHIAT, V163, P1443, DOI 10.1176/appi.ajp.163.8.1443
NR 48
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 1434-1816
EI 1435-1102
J9 ARCH WOMEN MENT HLTH
JI Arch. Womens Ment. Health
PD OCT
PY 2016
VL 19
IS 5
BP 799
EP 808
DI 10.1007/s00737-016-0616-6
PG 10
WC Psychiatry
SC Psychiatry
GA DW4JW
UT WOS:000383610000009
PM 26957508
ER

PT J
AU Brambilla, M
   Cotelli, M
   Manenti, R
   Dagani, J
   Sisti, D
   Rocchi, M
   Balestrieri, M
   Pini, S
   Raimondi, S
   Saviotti, FM
   Scocco, P
   de Girolamo, G
AF Brambilla, Michela
   Cotelli, Maria
   Manenti, Rosa
   Dagani, Jessica
   Sisti, Davide
   Rocchi, Marco
   Balestrieri, Matteo
   Pini, Stefano
   Raimondi, Sara
   Saviotti, Francesco Maria
   Scocco, Paolo
   de Girolamo, Giovanni
TI Oxytocin to modulate emotional processing in schizophrenia: A
   randomized, double-blind, cross-over clinical trial
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Pharmacological treatment; Psychosis; Social cognition
ID ADJUNCTIVE INTRANASAL OXYTOCIN; SOCIAL COGNITION; PLASMA OXYTOCIN;
   OLFACTORY IDENTIFICATION; NEGATIVE SYMPTOMS; PERCEPTION; PEOPLE;
   INTELLIGENCE; METAANALYSIS; SKILLS
AB Deficits in social cognition, including emotional processing, are hallmarks of schizophrenia and antipsychotic agents seem to be ineffectual to improve these symptoms. However, oxytocin does seem to have beneficial effects on social cognition. The aim of this study was to examine the effects of four months of treatment with intranasal oxytocin, in 31 patients with schizophrenia, on distinct aspects of social cognition. This was assessed using standardized and experimental tests in a randomized, double-blind, placebo-controlled, cross-over trial. All patients underwent clinical and experimental assessment before treatment, four months after treatment and at the end of treatment. Social cognition abilities were assessed with the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) and the Reading the Mind in the Eyes task (RMET). Furthermore, an Emotional Priming Paradigm (EPP) was developed to examine the effects of oxytocin on implicit perceptual sensitivity to affective information and explicit facial affect recognition.
   We found that oxytocin improved performance on MSCEIT compared to placebo in Branch 3 Understanding Emotion (p-value=0.004; Cohen's d=1.12). In the EPP task, we observed a significant reduction of reaction times for facial affect recognition (p-value=0.021; Cohen's d=0.88). No effects were found for implicit priming or for theory of mind abilities. Further study is required in order to highlight the potential for possible integration of oxytocin with antipsychotic agents as well as to evaluate psycho-social treatment as a multi-dimensional approach to increase explicit emotional processing abilities and compensate social cognition deficits related to schizophrenia. (C) 2016 Elsevier B.V. and ECNP. All rights reserved.
C1 [Brambilla, Michela; Cotelli, Maria; Manenti, Rosa] IRCCS St John God Clin Res Ctr, Neuropsychol Unit, Brescia, Italy.
   [Dagani, Jessica; de Girolamo, Giovanni] IRCCS St John God Clin Res Ctr, Psychiat Epidemiol & Evaluat Unit, Brescia, Italy.
   [Sisti, Davide; Rocchi, Marco] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy.
   [Balestrieri, Matteo] Univ Udine, DISM, Psychiat Clin, Udine, Italy.
   [Pini, Stefano] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Raimondi, Sara; Saviotti, Francesco Maria] ASST Garda Brescia, Dept Mental Hlth, Brescia, Italy.
   [Scocco, Paolo] Dept Mental Hlth ULSS 16, Padua, Italy.
RP Cotelli, M (reprint author), IRCCS Ctr San Giovanni Dio Fatebenefratelli, Via Pilastroni 4, I-25125 Brescia, Italy.
EM mcotelli@fatebenefratelli.eu
FU Italian Ministry of Health (Ministero della Salute) [RF2010-2311148]
FX This work was supported by the Italian Ministry of Health (Ministero
   della Salute) Grant (grant number RF2010-2311148 to G.D.G.). The Italian
   Ministry of Health had no further role in study design, in the
   collection, analysis and interpretation of data, in writing the report
   or in the decision to submit the paper for publication.
CR Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514
   Amminger GP, 2012, SCHIZOPHRENIA BULL, V38, P1030, DOI 10.1093/schbul/sbr015
   Anselmetti S, 2008, NEUROL SCI, V29, P85, DOI 10.1007/s10072-008-0866-9
   Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Bediou B, 2005, PSYCHIAT RES, V133, P149, DOI 10.1016/j.psychres.2004.08.008
   Bertinetto P. M., 2005, CORPUS LESSICO FREQU
   Bukovskaya O, 2016, PSYCHIAT QUART, V87, P521, DOI 10.1007/s11126-015-9407-x
   Cacciotti-Saija C, 2015, SCHIZOPHRENIA BULL, V41, P483, DOI 10.1093/schbul/sbu094
   Dagani J, 2016, SCHIZOPHR RES, V172, P158, DOI 10.1016/j.schres.2016.02.011
   Davis MC, 2014, NEUROPSYCHOPHARMACOL, V39, P2070, DOI 10.1038/npp.2014.68
   Davis MC, 2013, SCHIZOPHR RES, V147, P393, DOI 10.1016/j.schres.2013.04.023
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Eack SM, 2010, SCHIZOPHRENIA BULL, V36, P370, DOI 10.1093/schbul/sbn091
   Feifel D., 2015, BIOL PSYCHIAT
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Fischer-Shofty M, 2013, SCHIZOPHR RES, V146, P357, DOI 10.1016/j.schres.2013.01.006
   Gibson CM, 2014, SCHIZOPHR RES, V156, P261, DOI 10.1016/j.schres.2014.04.009
   Green MF, 2005, SCHIZOPHRENIA BULL, V31, P882, DOI 10.1093/schbul/sbi049
   Green MF, 2008, SCHIZOPHRENIA BULL, V34, P1211, DOI 10.1093/schbul/sbm145
   Green MF, 2015, NAT REV NEUROSCI, V16, P620, DOI 10.1038/nrn4005
   Green MF, 2012, SCHIZOPHRENIA BULL, V38, P854, DOI 10.1093/schbul/sbq171
   GRIZZLE JE, 1965, BIOMETRICS, V21, P467, DOI 10.2307/2528104
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guastella A. J., 2015, SCHIZOPHR RES
   Hofmann SG, 2015, PSYCHIAT RES, V228, P708, DOI 10.1016/j.psychres.2015.05.039
   Juckel G., 2009, EUR PSYCHIAT, V24
   Khan A, 2013, BIOL PSYCHIAT, V73, p266S
   Kucharska-Pietura K, 2013, CNS DRUGS, V27, P335, DOI 10.1007/s40263-013-0047-0
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   Lavoie MA, 2013, PSYCHIAT RES, V209, P129, DOI 10.1016/j.psychres.2012.11.037
   Lee MR, 2013, SCHIZOPHR RES, V145, P110, DOI 10.1016/j.schres.2013.01.001
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Martinez-Dominguez S., 2015, PSYCHIAT RES, V225, P374
   Mattavelli G, 2011, NEUROPSYCHOLOGIA, V49, P992, DOI 10.1016/j.neuropsychologia.2011.01.038
   Mayer JD, 2008, AM PSYCHOL, V63, P503, DOI 10.1037/0003-066X.63.6.503
   Mayer JD, 2003, EMOTION, V3, P97, DOI 10.1037/1528-3542.3.1.97
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modabbernia A, 2013, CNS DRUGS, V27, P57, DOI 10.1007/s40263-012-0022-1
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Pinkham AE, 2014, J CLIN PSYCHIAT, V75, P14, DOI 10.4088/JCP.13065su1.04
   Rich ME, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00090
   Savran A, 2008, 1 COST 2101 WORKSH B
   Shin NY, 2015, NEUROPSYCHOPHARMACOL, V40, P2286, DOI 10.1038/npp.2015.78
   Strauss GP, 2015, SCHIZOPHR RES, V162, P57, DOI 10.1016/j.schres.2014.12.023
   Suslow T, 2003, EUR ARCH PSY CLIN N, V253, P292, DOI 10.1007/s00406-003-0443-4
   Suslow T, 2003, PSYCHIAT RES, V120, P131, DOI 10.1016/S0165-1781(03)00173-2
   Vellante M, 2013, COGN NEUROPSYCHIATRY, V18, P326, DOI 10.1080/13546805.2012.721728
   Walss-Bass C, 2013, SCHIZOPHR RES, V147, P387, DOI 10.1016/j.schres.2013.04.003
NR 49
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
EI 1873-7862
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2016
VL 26
IS 10
BP 1619
EP 1628
DI 10.1016/j.euroneuro.2016.08.001
PG 10
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DY1QK
UT WOS:000384869300007
PM 27527256
ER

PT J
AU Raghuraman, N
   Stout, MJ
   Young, OM
   Tuuli, MG
   Lopez, JD
   Macones, GA
   Cahill, AG
AF Raghuraman, Nandini
   Stout, Molly J.
   Young, Omar M.
   Tuuli, Methodius G.
   Lopez, Julia D.
   Macones, George A.
   Cahill, Alison G.
TI Utility of the Simplified Bishop Score in Spontaneous Labor
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE Bishop score; cervical dilation; effacement; fetal station; labor
ID CESAREAN DELIVERY; NULLIPAROUS WOMEN; SUCCESSFUL INDUCTION; CERVICAL
   LENGTH; RISK; INDUCIBILITY; PREDICTION; TERM
AB Objective The objective of this study was to evaluate the relationship between the simplified Bishop score (SBS) on admission for labor and subsequent labor outcomes to identify women at higher risk for cesareans.
   Study Design This was a secondary analysis of a prospective cohort study of 4,733 singleton pregnancies. Adjusted odds ratios (aOR) were calculated comparing outcomes in women with an unfavorable SBS <= 5 to women with a favorable SBS > 5. A favorable SBS was compared with the individual parameters of dilation, effacement, and station. The primary outcome was vaginal delivery. Secondary outcomes were prolonged first stage, completion of first stage, oxytocin augmentation, and prolonged second stage.
   Results 47.8% of the patients admitted in labor had an unfavorable SBS. Nulliparous and multiparous patients with a favorable SBS were more likely to have a vaginal delivery (aOR 1.96, 95% confidence intervals [Cl] 1.49-2.57; aOR 1.91, 95% CI 1.44-2.53) and less likely to require oxytocin augmentation (aOR 0.34, 95% CI 0.28-0.42; aOR 0.26, 95% CI 0.22-0.30. Compared with dilation alone, the SBS in its entirety was associated with a higher likelihood of vaginal delivery in nulliparous.
   Conclusion An unfavorable SBS on admission for labor is associated with a decreased likelihood of having a vaginal delivery.
C1 [Raghuraman, Nandini; Stout, Molly J.; Young, Omar M.; Tuuli, Methodius G.; Lopez, Julia D.; Macones, George A.; Cahill, Alison G.] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, 660 S Euclid Ave,5th Floor Maternity Bldg, St Louis, MO 63103 USA.
RP Raghuraman, N (reprint author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, 660 S Euclid Ave,5th Floor Maternity Bldg, St Louis, MO 63103 USA.
EM raghuramann@wudosis.wustl.edu
CR Barber EL, 2011, OBSTET GYNECOL, V118, P29, DOI 10.1097/AOG.0b013e31821e5f65
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   BURNETT JE, 1966, OBSTET GYNECOL, V28, P479
   Caughey AB, 2014, AM J OBSTET GYNECOL, V210, P179, DOI 10.1016/j.ajog.2014.01.026
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   FRIEDMAN EA, 1966, OBSTET GYNECOL, V28, P495
   Johnson DP, 2003, AM J OBSTET GYNECOL, V188, P1565, DOI 10.1067/mob.2003.458
   Kehila M, 2015, Minerva Ginecol, V67, P499
   LANGE AP, 1982, OBSTET GYNECOL, V60, P137
   Laughon SK, 2011, OBSTET GYNECOL, V117, P805, DOI 10.1097/AOG.0b013e3182114ad2
   Pandis GK, 2001, ULTRASOUND OBST GYN, V18, P623, DOI 10.1046/j.0960-7692.2001.00580.x
   Park KH, 2011, ULTRASOUND OBST GYN, V38, P198, DOI 10.1002/uog.9020
   Reis FM, 2003, AM J OBSTET GYNECOL, V189, P1361, DOI 10.1067/S0002-9378(03)00725-7
   Segel SY, 2012, AM J PERINAT, V29, P723, DOI 10.1055/s-0032-1314895
   Vahratian A, 2005, OBSTET GYNECOL, V105, P698, DOI 10.1097/01.AOG.0000157436.68847.3b
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   Zhang J, 2010, OBSTET GYNECOL, V116, P1281, DOI 10.1097/AOG.0b013e3181fdef6e
NR 17
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
EI 1098-8785
J9 AM J PERINAT
JI Am. J. Perinatol.
PD OCT
PY 2016
VL 33
IS 12
BP 1176
EP 1181
DI 10.1055/s-0036-1585413
PG 6
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DY0LJ
UT WOS:000384788000010
PM 27398698
ER

PT J
AU Rehn, T
   Keeling, LJ
AF Rehn, Therese
   Keeling, Linda J.
TI Measuring dog-owner relationships: Crossing boundaries between animal
   behaviour and human psychology
SO APPLIED ANIMAL BEHAVIOUR SCIENCE
LA English
DT Review
DE Attachment; Reunion; Strange situation procedure; Animal welfare;
   Caregiving; Human-animal interaction
ID AINSWORTHS STRANGE SITUATION; HEART-RATE-VARIABILITY; CANIS-FAMILIARIS;
   GUIDE DOGS; ADULT ATTACHMENT; PLASMA-CORTISOL; WORKING DOGS; OXYTOCIN;
   RESPONSES; PET
AB Previous research suggests that dogs (Canis familiaris) form attachment bonds to their owners and that the strengths of the attachment can vary. However, it does not seem reasonable to believe that all dogs share the same attachment style, considering their differences in genetic background, their previous experiences and the many different caregiving strategies that are known to exist among humans. Rather, the level of security felt by dogs towards their owner probably varies, as seen in children towards their parent. The aim of this review is to highlight the strengths and weaknesses of current approaches of investigating the dog-human relationship in order to contribute to this rapidly developing field. The main focus is related to trying to increase our understanding about the dog's experience of the relationship. Current knowledge about the dog-human relationship is reviewed and discussed. Concepts from human psychology are used to clarify some of the terms that are also used in anthrozoology, thereby giving stronger theoretical support to our suggestions of how to adapt and apply methods to further develop assessments of dog-owner relationships. We highlight potential factors that deserve more attention in future studies to improve our understanding of the dog-human relationship, and we suggest a more coordinated approach, with a unified terminology, to develop an overarching framework. Suggestions for the future to achieve this include focusing on attachment styles at the individual dog level, rather than talking about the 'average' dog. Furthermore, a dyadic approach is suggested, where both the attributes of the dog (its attachment style) and the owner (its caregiving strategy) are incorporated when assessing the relationship. One way to do this is to focus on the balance between the dog's separation distress and how effective the owner's caregiving strategy is in calming the dog when reunited. The consequence, from an applied point of view, is owners becoming more aware of what type of attachment style their dog has and what caregiving strategy they have. Knowing this may contribute to identifying sources of conflict in past or present relationships, so helping owners form more successful and positive relationships in the future. It may also contribute to better matching when rehoming shelter dogs. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Rehn, Therese; Keeling, Linda J.] Swedish Univ Agr Sci, Dept Anim Environm & Hlth, POB 7068, SE-75007 Uppsala, Sweden.
RP Rehn, T (reprint author), Swedish Univ Agr Sci, Dept Anim Environm & Hlth, POB 7068, SE-75007 Uppsala, Sweden.
EM Therese.Rehn@slu.se
RI Rehn, Therese/C-5980-2014
OI Rehn, Therese/0000-0002-5687-1521
FU Swedish Research Council for Environment, Agricultural Sciences and
   Spatial Planning (FOR-MAS) [221-2013-329]
FX We would like to thank the Swedish Research Council for Environment,
   Agricultural Sciences and Spatial Planning (FOR-MAS, 221-2013-329) for
   financing this work. The work was carried out within the Centre of
   Excellence in Animal Welfare Science, a Swedish collaborative research
   environment.
CR AINSWORT.MD, 1970, CHILD DEV, V41, P49, DOI 10.1111/j.1467-8624.1970.tb00975.x
   AINSWORTH MDS, 1989, AM PSYCHOL, V44, P709, DOI 10.1037//0003-066X.44.4.709
   Ainsworth M. D. S., 1973, REV CHILD DEV RES, P1
   Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Appelhans BM, 2006, REV GEN PSYCHOL, V10, P229, DOI 10.1037/1089-2680.10.3.229
   Archer J, 1997, EVOL HUM BEHAV, V18, P237, DOI 10.1016/S0162-3095(99)80001-4
   Barker Randolph, 1988, J MENTAL HLTH COUNSE, V10, P46
   Bartholomew K., 1998, ATTACHMENT THEORY CL, P25
   Bell DC, 2000, PSYCHOL INQ, V11, P69, DOI 10.1207/S15327965PLI1102_01
   BOWLBY J, 1958, INT J PSYCHOANAL, V39, P350
   Bowlby J, 1969, ATTACHMENT LOSS, V1
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   CASSIDY J, 1988, CHILD DEV, V59, P121, DOI 10.2307/1130394
   Chen FS, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00200
   Creel S, 2001, TRENDS ECOL EVOL, V16, P491, DOI 10.1016/S0169-5347(01)02227-3
   Crowell J. A., 2008, HDB ATTACHMENT THEOR, P599
   Dilworth-Anderson P, 2002, GERONTOLOGIST, V42, P237
   Dwyer F, 2006, ANTHROZOOS, V19, P243, DOI 10.2752/089279306785415592
   Fallani G, 2007, PHYSIOL BEHAV, V90, P648, DOI 10.1016/j.physbeh.2006.12.001
   Fallani G, 2006, APPL ANIM BEHAV SCI, V100, P241, DOI 10.1016/j.applanim.2005.12.005
   Foyer P, 2016, SCI REP-UK, V6, DOI 10.1038/srep19253
   Foyer P, 2014, APPL ANIM BEHAV SCI, V155, P93, DOI 10.1016/j.applanim.2014.03.006
   Gacsi M, 2001, J COMP PSYCHOL, V115, P423, DOI 10.1037//0735-7036.115.4.423
   Gacsi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058475
   Gazzano A, 2008, J VET BEHAV, V3, P125, DOI 10.1016/j.jveb.2008.04.004
   Gazzano A, 2008, APPL ANIM BEHAV SCI, V110, P294, DOI 10.1016/j.applanim.2007.05.007
   GOLDBERG S, 1991, CAN J PSYCHIAT, V36, P393
   Gross J. J., 1998, REV GEN PSYCHOL, V2, P271, DOI DOI 10.1037/1089-2680.2.3.271
   Gunnar MR, 1998, PREV MED, V27, P208, DOI 10.1006/pmed.1998.0276
   Handlin L, 2012, ANTHROZOOS, V25, P215, DOI 10.2752/175303712X13316289505468
   Handlin L, 2011, ANTHROZOOS, V24, P301, DOI 10.2752/175303711X13045914865385
   Haverbeke A, 2008, PHYSIOL BEHAV, V93, P59, DOI 10.1016/j.physbeh.2007.07.014
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   HINDE RA, 1976, J CHILD PSYCHOL PSYC, V17, P1, DOI 10.1111/j.1469-7610.1976.tb00370.x
   HINDE RA, 1976, MAN, V11, P1, DOI 10.2307/2800384
   Horn L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065296
   Hydbring-Sandberg E, 2004, J ENDOCRINOL, V180, P439, DOI 10.1677/joe.0.1800439
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   Jagoe A, 1996, APPL ANIM BEHAV SCI, V47, P31, DOI 10.1016/0168-1591(95)01008-4
   JOHNSON TP, 1992, ANTHROZOOS, V5, P160
   Kerepesi A, 2015, BEHAV PROCESS, V110, P27, DOI 10.1016/j.beproc.2014.02.005
   KEVERNE EB, 1994, ACTA PAEDIATR, V83, P47
   Kis A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083993
   Kobak R, 2009, J FAM PSYCHOL, V23, P447, DOI 10.1037/a0015213
   Kobelt AJ, 2003, APPL ANIM BEHAV SCI, V82, P137, DOI 10.1016/S0168-1591(03)00062-5
   Koda N, 2001, BEHAV PROCESS, V53, P41, DOI 10.1016/S0376-6357(00)00146-7
   Konok V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118375
   Kotrschal K, 2009, BEHAV PROCESS, V81, P383, DOI 10.1016/j.beproc.2009.04.001
   KOVACS GL, 1987, J PHARMACOL EXP THER, V241, P569
   LINE S, 1986, APPL ANIM BEHAV SCI, V16, P77, DOI 10.1016/0168-1591(86)90042-0
   Main M, 2000, J AM PSYCHOANAL ASS, V48, P1055, DOI 10.1177/00030651000480041801
   MAIN M, 1990, HUM DEV, V33, P48
   Main M., 1986, DISCOVERY NONSECURE
   Marinelli L, 2007, APPL ANIM BEHAV SCI, V108, P143, DOI 10.1016/j.applanim.2006.11.018
   Mariti C., 2011, J VET BEHAV, V6, P90, DOI 10.1016/j.jveb.2010.08.026
   Mariti C, 2014, APPL ANIM BEHAV SCI, V152, P64, DOI 10.1016/j.applanim.2013.12.002
   Mariti C, 2013, J VET BEHAV, V8, P135, DOI 10.1016/j.jveb.2012.05.006
   Mikulincer M., 2007, ATTACHMENT ADULTHOOD, p[81, 324]
   Miller DD, 1996, J AM VET MED ASSOC, V209, P738
   Miller SC, 2009, ANTHROZOOS, V22, P31, DOI 10.2752/175303708X390455
   Mongillo P, 2013, PHYSIOL BEHAV, V120, P64, DOI 10.1016/j.physbeh.2013.07.011
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Odendaal JSJ, 2000, J PSYCHOSOM RES, V49, P275, DOI 10.1016/S0022-3999(00)00183-5
   Palestrini C, 2005, APPL ANIM BEHAV SCI, V94, P75, DOI 10.1016/j.applanim.2005.02.005
   Palmer R, 2008, APPL ANIM BEHAV SCI, V109, P306, DOI 10.1016/j.applanim.2007.04.002
   PANKSEPP J, 1994, ACTA PAEDIATR, V83, P40, DOI 10.1111/j.1651-2227.1994.tb13264.x
   Panksepp J., 1998, AFFECTIVE NEUROSCIEN
   Panksepp J, 2009, BIOL PSYCHIAT, V65, P725, DOI 10.1016/j.biopsych.2009.02.004
   Patronek GJ, 1996, J AM VET MED ASSOC, V209, P572
   Prato-Previde E, 2003, BEHAVIOUR, V140, P225, DOI 10.1163/156853903321671514
   Rehn T., 2013, THESIS
   Rehn T, 2014, APPL ANIM BEHAV SCI, V150, P65, DOI 10.1016/j.applanim.2013.10.008
   Rehn T, 2014, PHYSIOL BEHAV, V124, P45, DOI 10.1016/j.physbeh.2013.10.009
   Rehn T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056938
   Sachser N, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0344
   Salman M D, 1998, J Appl Anim Welf Sci, V1, P207, DOI 10.1207/s15327604jaws0103_2
   Schoberl I, 2016, J VET BEHAV, V11, P77, DOI 10.1016/j.jveb.2015.09.007
   Scott J.P., 1965, GENETICS SOCIAL BEHA
   Serpell JA, 2004, ANIM WELFARE, V13, pS145
   Shiverdecker MD, 2013, PHYSIOL BEHAV, V109, P75, DOI 10.1016/j.physbeh.2012.12.002
   Shore ER, 2006, ANTHROZOOS, V19, P325, DOI 10.2752/089279306785415466
   Siniscalchi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078455
   SROUFE LA, 1977, MERRILL PALMER QUART, V23, P3
   Steiss JE, 2007, APPL ANIM BEHAV SCI, V106, P96, DOI 10.1016/j.applanim.2006.06.018
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Svartberg K, 2006, APPL ANIM BEHAV SCI, V96, P293, DOI 10.1016/j.applanim.2005.06.014
   TEMPLER DI, 1981, PSYCHOL REC, V31, P343
   Tiira K., 2016, PLOS ONE, V10
   Topal J, 2005, ANIM BEHAV, V70, P1367, DOI 10.1016/j.anbehav.2005.03.025
   Topal J, 1998, J COMP PSYCHOL, V112, P219, DOI 10.1037/0735-7036.112.3.219
   Trivers R. L., 1972, SEXUAL SELECTION DES
   Tuber DS, 1996, J COMP PSYCHOL, V110, P103, DOI 10.1037/0735-7036.110.1.103
   Udell MAR, 2014, ANIM BEHAV, V89, P99, DOI 10.1016/j.anbehav.2013.12.012
   Valsecchi P, 2010, APPL ANIM BEHAV SCI, V123, P43, DOI 10.1016/j.applanim.2009.12.012
   VOITH VL, 1992, APPL ANIM BEHAV SCI, V34, P263, DOI 10.1016/S0168-1591(05)80121-2
   VOITH VL, 1985, VET CLIN N AM-SMALL, V15, P289
   von Borell E, 2007, PHYSIOL BEHAV, V92, P293, DOI 10.1016/j.physbeh.2007.01.007
   Wedl M, 2010, INTERACT STUD, V11, P482, DOI 10.1075/is.11.3.09wed
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   You HS, 2000, J CROSS CULT PSYCHOL, V31, P528, DOI 10.1177/0022022100031004006
NR 102
TC 0
Z9 0
U1 42
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1591
EI 1872-9045
J9 APPL ANIM BEHAV SCI
JI Appl. Anim. Behav. Sci.
PD OCT
PY 2016
VL 183
BP 1
EP 9
DI 10.1016/j.applanim.2016.07.003
PG 9
WC Agriculture, Dairy & Animal Science; Behavioral Sciences; Veterinary
   Sciences
SC Agriculture; Behavioral Sciences; Veterinary Sciences
GA DY1LR
UT WOS:000384857000001
ER

PT J
AU Tomaszycki, ML
   Richardson, KK
   Mann, KJ
AF Tomaszycki, Michelle L.
   Richardson, Kimberly K.
   Mann, Kyle J.
TI Sex and Pairing Status Explain Variations in the Activation of
   Nonapeptide Receptors in Song and Motivation Regions
SO BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE nonapeptide; V1aR; OTR; singing; pairing
ID MALE EUROPEAN STARLINGS; FINCHES TAENIOPYGIA-GUTTATA; VOLES
   MICROTUS-OCHROGASTER; MEDIAL PREOPTIC NUCLEUS; BEHAVIOR BRAIN-REGIONS;
   VENTRAL TEGMENTAL AREA; FEMALE ZEBRA FINCHES; EARLY GENE ZIF268;
   SOCIAL-BEHAVIOR; PRAIRIE VOLES
AB The nonapeptides oxytocin and vasopressin have been implicated in a variety of social behaviors. In zebra finches, oxytocin antagonists decrease pairing in both sexes, and pairing, in turn, increases expression of both mesotocin (the avian homologue of oxytocin) and vasotocin (the avian homologue of vasopressin). Increases in mesotocin and vasotocin mRNA are correlated with the amount of directed singing by males. Thus, in the present study, we examined the hypothesis that activation of cells containing nonapeptide receptors in song-related regions (ventral tegmental area, lateral septum, and medial preoptic nucleus) would also be correlated with directed singing in males. To rule out the possibility that these regions are involved in general pairing motivation, we also included females as subjects. In the ventral tegmental area, males had higher ZENK and V1aR than females and paired animals (regardless of sex) had higher ZENK and V1aR than did unpaired animals. In the medial preoptic nucleus, paired animals had higher ZENK than did unpaired animals, and there were no sex or pairing effects in the lateral septum. Only ZENK + V1aR in the medial preoptic nucleus was correlated with singing in males. These findings suggest that pairing is associated activation of nonapeptide receptors in the ventral tegmental area and the medial preoptic nucleus, but there is only partial evidence that courtship singing accounts for these findings.
C1 [Tomaszycki, Michelle L.; Richardson, Kimberly K.; Mann, Kyle J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA.
RP Tomaszycki, ML (reprint author), Lafayette Coll, Dept Psychol, 303 Oechsle Hall, Easton, PA 18042 USA.
EM tomaszym@lafayette.edu
CR Adar E, 2008, J NEUROSCI, V28, P5394, DOI 10.1523/JNEUROSCI.5706-07.2008
   Alger SJ, 2009, EUR J NEUROSCI, V29, P970, DOI 10.1111/j.1460-9568.2009.06637.x
   Alger SJ, 2011, J CHEM NEUROANAT, V42, P45, DOI 10.1016/j.jchemneu.2011.05.005
   Appeltants D, 2000, J CHEM NEUROANAT, V18, P117, DOI 10.1016/S0891-0618(99)00054-X
   Appeltants D, 2002, NEUROREPORT, V13, P649, DOI 10.1097/00001756-200204160-00023
   Bailey DJ, 2003, MOL BRAIN RES, V116, P147, DOI 10.1016/S0169-328X(03)00288-2
   Ball GF, 2002, FRONT NEUROENDOCRIN, V23, P137, DOI 10.1006/frne.2002.0230
   Barter JW, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00039
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Bester-Meredith JK, 1999, HORM BEHAV, V36, P25, DOI 10.1006/hbeh.1999.1522
   Bharati IS, 2006, NEUROSCIENCE, V143, P661, DOI 10.1016/j.neuroscience.2006.08.046
   Bolhuis JJ, 2000, P NATL ACAD SCI USA, V97, P2282, DOI 10.1073/pnas.030539097
   Bozon B, 2002, HIPPOCAMPUS, V12, P570, DOI 10.1002/hipo.10100
   Charlier TD, 2005, NEUROSCIENCE, V131, P13, DOI 10.1016/j.neuroscience.2004.09.068
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Curley JP, 2005, TRENDS ECOL EVOL, V20, P561, DOI 10.1016/j.tree.2005.05.018
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Gale SD, 2008, J COMP NEUROL, V508, P824, DOI 10.1002/cne.21700
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Goodson JL, 2009, P NATL ACAD SCI USA, V106, P8737, DOI 10.1073/pnas.0811821106
   Goodson JL, 2009, HORM BEHAV, V55, P197, DOI 10.1016/j.yhbeh.2008.10.007
   Goodson JL, 2004, HORM BEHAV, V45, P136, DOI 10.1016/j.yhbeh.2003.08.006
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Hall ZI, 2014, BEHAV BRAIN RES, V264, P26, DOI 10.1016/j.bbr.2014.01.043
   Heimovics SA, 2005, J NEUROBIOL, V65, P207, DOI 10.1002/neu.20181
   Heimovics SA, 2007, BEHAV BRAIN RES, V176, P333, DOI 10.1016/j.bbr.2006.10.023
   Heimovics SA, 2006, HORM BEHAV, V50, P726, DOI 10.1016/j.yhbeh.2006.06.013
   Hull EM, 2007, HORM BEHAV, V52, P45, DOI 10.1016/j.yhbeh.2007.03.030
   Jin X, 2010, NATURE, V466, P457, DOI 10.1038/nature09263
   Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138
   Kabelik D, 2009, HORM BEHAV, V56, P101, DOI 10.1016/j.yhbeh.2009.03.017
   Kelly AM, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00055
   Kelly AM, 2013, HORM BEHAV, V64, P840, DOI 10.1016/j.yhbeh.2013.09.006
   Kelly AM, 2011, HORM BEHAV, V60, P12, DOI 10.1016/j.yhbeh.2011.01.012
   Klatt JD, 2013, HORM BEHAV, V64, P818, DOI 10.1016/j.yhbeh.2013.10.001
   Klatt JD, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2396
   Leung CH, 2011, ENDOCRINOLOGY, V152, P4865, DOI 10.1210/en.2011-1394
   LEWIS JW, 1981, J COMP NEUROL, V196, P347, DOI 10.1002/cne.901960212
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Lowrey EM, 2014, BEHAV NEUROSCI, V128, P61, DOI 10.1037/a0035416
   Mabry KE, 2011, ANIM BEHAV, V81, P11, DOI 10.1016/j.anbehav.2010.09.021
   Maney DL, 2003, J NEUROBIOL, V56, P163, DOI 10.1002/neu.10227
   Maney DL, 2008, J COMP NEUROL, V511, P173, DOI 10.1002/cne.21830
   Mello CV, 2002, J COMP PHYSIOL A, V188, P943, DOI 10.1007/s00359-002-0347-1
   Panzica GC, 1996, FRONT NEUROENDOCRIN, V17, P51, DOI 10.1006/frne.1996.0002
   Patel MV, 2012, J EXP ZOOL PART B, V318B, P368, DOI 10.1002/jez.b.22453
   Pedersen A, 2012, HORM BEHAV, V62, P113, DOI 10.1016/j.yhbeh.2012.05.009
   Puryear CB, 2010, BEHAV NEUROSCI, V124, P234, DOI 10.1037/a0018865
   Remage-Healey L, 2012, J NEUROSCI, V32, P8231, DOI 10.1523/JNEUROSCI.1114-12.2012
   Riters LV, 2012, FRONT NEUROENDOCRIN, V33, P194, DOI 10.1016/j.yfrne.2012.04.002
   Riters LV, 2004, BEHAV BRAIN RES, V155, P307, DOI 10.1016/j.bbr.2004.05.002
   ROMO R, 1990, J NEUROPHYSIOL, V63, P592
   SILCOX AP, 1982, ANIM BEHAV, V30, P1237, DOI 10.1016/S0003-3472(82)80216-9
   Smiley KO, 2012, BEHAV PROCESS, V90, P210, DOI 10.1016/j.beproc.2012.01.008
   Tomaszycki ML, 2005, ANIM BEHAV, V70, P785, DOI 10.1016/j.anbehav.2005.01.010
   Vahaba DM, 2013, BEHAV BRAIN RES, V252, P164, DOI 10.1016/j.bbr.2013.05.056
   Wang DV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016528
   WANG ZX, 1994, BRAIN RES, V650, P212, DOI 10.1016/0006-8993(94)91784-1
   Wang ZX, 2004, PHYSIOL BEHAV, V83, P319, DOI 10.1016/j.physbeh.2004.08.024
   Woolley SC, 2008, PLOS BIOL, V6, P525, DOI 10.1371/journal.pbio.0060062
   Wu D, 2010, BRAIN RES, V1343, P104, DOI 10.1016/j.brainres.2010.04.084
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Yanagihara S, 2006, EUR J NEUROSCI, V24, P3619, DOI 10.1111/j.1460-9568.2006.05228.x
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Zann R. A., 1996, ZEBRA FINCH SYNTHESI
NR 66
TC 0
Z9 0
U1 2
U2 2
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7044
EI 1939-0084
J9 BEHAV NEUROSCI
JI Behav. Neurosci.
PD OCT
PY 2016
VL 130
IS 5
BP 479
EP 489
DI 10.1037/bne0000159
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DX6XR
UT WOS:000384529900003
PM 27504854
ER

PT J
AU Elmadih, A
   Wan, MW
   Downey, D
   Elliott, R
   Swain, JE
   Abel, KM
AF Elmadih, Alya
   Wan, Ming Wai
   Downey, Darragh
   Elliott, Rebecca
   Swain, James E.
   Abel, Kathryn M.
TI Natural Variation in Maternal Sensitivity Is Reflected in Maternal Brain
   Responses to Infant Stimuli
SO BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE functional magnetic resonance imaging (fMRI); blood oxygenation level
   dependent response (BOLD); maternal sensitivity; oxytocin
ID PLASMA OXYTOCIN; DEPRESSION SCALE; ATTACHMENT BRAIN; DECISION-MAKING;
   NEURAL BASIS; MOTHERS; EMOTION; AUTISM; RISK; FMRI
AB Increasing evidence suggests that discrete neural networks that mediate emotion processing are activated when mothers respond to infant's images or cries. Accumulating data also indicate that natural variation in maternal caregiving behavior is related to maternal oxytocin (OT) levels. However, brain activation to infant cues has not been studied comparing mothers at disparate ends of the "maternal sensitivity" spectrum. Based on observed mother-infant play interaction at 4-6 months postpartum in 80 antenatally recruited mothers, 15 mothers with the highest sensitivity (HSMs) and 15 mothers with the lowest sensitivity (LSMs) were followed at 7-9 months using functional magnetic resonance imaging (fMRI) to examine brain responses to viewing videos of their "own" versus an "unknown" infant in 3 affect states (neutral, happy, and sad). Plasma OT measurements were taken from mothers following play interactions with their infant. Compared with LSMs, HSMs showed significantly greater brain activation in right superior temporal gyrus (STG) in response to own versus unknown neutral infant and to own happy versus neutral control. Changes in brain activation were significantly negatively correlated with plasma OT responses in HSMs mothers. Conversely, compared with HSMs, LSMs showed no significant activation difference in response to own infant separately or in contrast to unknown infant. Activation of STG may index sensitive maternal response to own infant stimuli. Sensitive parenting may have its unique profile in relation to brain responses which can act as biomarkers for future intervention studies that enhance sensitivity of maternal care.
C1 [Elmadih, Alya; Wan, Ming Wai; Abel, Kathryn M.] Univ Manchester, Inst Brain Behav & Mental Hlth, Ctr Womens Mental Hlth, Manchester M13 9PL, Lancs, England.
   [Downey, Darragh; Elliott, Rebecca] Univ Manchester, Inst Brain Behav & Mental Hlth, Neurosci & Psychiat Unit, Manchester M13 9PL, Lancs, England.
   [Swain, James E.] Univ Michigan, Ctr Human Growth & Dev, Women & Infants Mental Hlth Program, Dept Psychiat,Psychol, Ann Arbor, MI 48109 USA.
RP Elmadih, A (reprint author), Univ Manchester, 3rd Floor East Jean McFarlane Bldg, Manchester M13 9PL, Lancs, England.
EM alyamadeh1@gmail.com
FU Magnetic Resonance Imaging Facility grant; Wellcome Trust Clinical
   Research Facility (Manchester); Centre for Women's Mental Health
   (University of Manchester, UK)
FX This study was supported by a Magnetic Resonance Imaging Facility grant,
   the Wellcome Trust Clinical Research Facility (Manchester), and the
   Centre for Women's Mental Health (University of Manchester, UK). Authors
   declare no conflict of interest.
CR Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X
   Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Alink L, 2008, PARENTING EARLY AGGR, V18, P99
   AMICO JA, 1985, J CLIN ENDOCR METAB, V60, P5
   Atzil S, 2012, J AM ACAD CHILD PSY, V51, P798, DOI 10.1016/j.jaac.2012.06.008
   Atzil S, 2011, NEUROPSYCHOPHARMACOL, V36, P2603, DOI 10.1038/npp.2011.172
   Bakermans-Kranenburg MJ, 2015, ANNU REV PSYCHOL, V66, P381, DOI 10.1146/annurev-psych-010814-015407
   Barlow J., 2008, RES REPORT, P9
   Barrett J, 2011, J CHILD PSYCHOL PSYC, V52, P368, DOI 10.1111/j.1469-7610.2010.02306.x
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Bick J, 2010, DEV PSYCHOBIOL, V52, P100, DOI 10.1002/dev.20411
   Bigelow AE, 2010, INFANT BEHAV DEV, V33, P50, DOI 10.1016/j.infbeh.2009.10.009
   Bolling DZ, 2011, NEUROIMAGE, V54, P2462, DOI 10.1016/j.neuroimage.2010.10.049
   Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525
   COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782
   Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904
   Crosnoe R, 2010, CHILD DEV, V81, P972, DOI 10.1111/j.1467-8624.2010.01446.x
   Downer JT, 2006, SCHOOL PSYCHOL REV, V35, P11
   Elmaolih A, 2014, BRAIN RES, V1580, P143, DOI 10.1016/j.brainres.2014.01.020
   Elsabbagh M, 2015, J AUTISM DEV DISORD, V45, P283, DOI 10.1007/s10803-014-2192-9
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, HORM BEHAV, V58, P669, DOI 10.1016/j.yhbeh.2010.06.005
   FONAGY P, 1994, J CHILD PSYCHOL PSYC, V35, P231, DOI 10.1111/j.1469-7610.1994.tb01160.x
   Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Green J, 2015, LANCET PSYCHIAT, V2, P133, DOI 10.1016/S2215-0366(14)00091-1
   Green J, 2013, J AUTISM DEV DISORD, V43, P2502, DOI 10.1007/s10803-013-1797-8
   Ho SS, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00152
   Ho SS, 2012, NEUROIMAGE, V63, P843, DOI 10.1016/j.neuroimage.2012.07.017
   Hoffman ER, 2012, EAT BEHAV, V13, P256, DOI 10.1016/j.eatbeh.2012.02.004
   Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Kim P, 2011, J CHILD PSYCHOL PSYC, V52, P907, DOI 10.1111/j.1469-7610.2011.02406.x
   Kochanska G, 2013, J CHILD PSYCHOL PSYC, V54, P323, DOI 10.1111/jcpp.12002
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lenzi D, 2009, CEREB CORTEX, V19, P1124, DOI 10.1093/cercor/bhn153
   Levine Ari, 2007, Peptides, V28, P1162, DOI 10.1016/j.peptides.2007.04.016
   Lorberbaum JP, 2002, BIOL PSYCHIAT, V51, P431, DOI 10.1016/S0006-3223(01)01284-7
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Marazziti Donatella, 2006, Clin Pract Epidemiol Ment Health, V2, P28, DOI 10.1186/1745-0179-2-28
   Meins E, 2001, J CHILD PSYCHOL PSYC, V42, P637, DOI 10.1017/S0021963001007302
   Musser ED, 2012, DEV COGN NEUROS-NETH, V2, P428, DOI 10.1016/j.dcn.2012.04.003
   Noriuchi M, 2008, BIOL PSYCHIAT, V63, P415, DOI 10.1016/j.biopsych.2007.05.018
   Numan M, 2010, BEHAV NEUROSCI, V124, P715, DOI 10.1037/a0021548
   PARKER G, 1979, BRIT J MED PSYCHOL, V52, P1
   Pearson RM, 2011, INFANT BEHAV DEV, V34, P525, DOI 10.1016/j.infbeh.2011.07.003
   Penny WD, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P156, DOI 10.1016/B978-012372560-8/50012-7
   Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   Ranote S, 2004, NEUROREPORT, V15, P1825, DOI 10.1097/01.wnr.0000137078.64128.6a
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Rizzolatti G, 2008, CURR OPIN NEUROBIOL, V18, P179, DOI 10.1016/j.conb.2008.08.001
   Sandler IN, 2011, ANNU REV PSYCHOL, V62, P299, DOI 10.1146/annurev.psych.121208.131619
   Seifritz E, 2003, BIOL PSYCHIAT, V54, P1367, DOI 10.1016/S0006-3223(03)00697-8
   Somerville LH, 2010, CEREB CORTEX, V20, P3005, DOI 10.1093/cercor/bhq049
   Sroufe LA, 2000, INFANT MENT HEALTH J, V21, P67, DOI 10.1002/(SICI)1097-0355(200001/04)21:1/2<67::AID-IMHJ8>3.0.CO;2-2
   Strathearn L, 2012, HORM BEHAV, V61, P429, DOI 10.1016/j.yhbeh.2012.01.014
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Swain JE, 2014, BRAIN RES, V1580, P78, DOI 10.1016/j.brainres.2014.03.007
   Swain JE, 2008, J CHILD PSYCHOL PSYC, V49, P1042, DOI 10.1111/j.1469-7610.2008.01963.x
   Swain JE, 2012, PARENT-SCI PRACT, V12, P115, DOI 10.1080/15295192.2012.680409
   Swain JE, 2004, BIOL PSYCHIAT, V55, p153S
   Swain J. E., 2014, 34 ANN M CAN AC CHIL
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tabak BA, 2011, PSYCHONEUROENDOCRINO, V36, P115, DOI 10.1016/j.psyneuen.2010.07.004
   Taylor SE, 2006, PSYCHOSOM MED, V68, P238, DOI 10.1097/01.psy.0000203242.95990.74
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Turner RA, 2002, STRESS, V5, P269
   Wan MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088436
   Wan MW, 2013, J CHILD PSYCHOL PSYC, V54, P763, DOI 10.1111/jcpp.12032
   Wan MW, 2012, RES DEV DISABIL, V33, P924, DOI 10.1016/j.ridd.2011.12.011
   Wan M. W., 2016, INT J BEHAV DEV
   Warren SL, 2005, INF MENTAL HLTH J, V26, P40, DOI 10.1002/imhj.20034
   Wittfoth-Schardt D, 2012, NEUROPSYCHOPHARMACOL, V37, P1799, DOI 10.1038/npp.2012.47
   Yoshimura S, 2014, SOC COGN AFFECT NEUR, V9, P487, DOI 10.1093/scan/nst009
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 77
TC 0
Z9 0
U1 8
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7044
EI 1939-0084
J9 BEHAV NEUROSCI
JI Behav. Neurosci.
PD OCT
PY 2016
VL 130
IS 5
BP 500
EP 510
DI 10.1037/bne0000161
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DX6XR
UT WOS:000384529900005
PM 27513806
ER

PT J
AU Eisenach, JC
   Yaksh, TL
AF Eisenach, James C.
   Yaksh, Tony L.
TI Ethical Concerns Regarding Human Study
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Letter
ID OXYTOCIN
C1 [Eisenach, James C.] Wake Forest Sch Med, Dept Anesthesiol, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.
   [Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA.
RP Eisenach, JC (reprint author), Wake Forest Sch Med, Dept Anesthesiol, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM jimeisenach@gmail.com
CR Condes-Lara M, 2016, CNS NEUROSCI THER, V22, P532, DOI 10.1111/cns.12551
   Eisenach JC, 2010, PAIN, V149, P417, DOI 10.1016/j.pain.2010.02.028
   Yaksh TL, 2014, ANESTHESIOLOGY, V120, P951, DOI 10.1097/ALN.0000000000000148
   Yaksh TL, 2010, SCIENCE, V328, P45, DOI 10.1126/science.328.5974.45-a
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
EI 1755-5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD OCT
PY 2016
VL 22
IS 10
BP 866
EP 866
DI 10.1111/cns.12604
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DW4QL
UT WOS:000383628000009
PM 27577599
ER

PT J
AU Condes-Lara, M
   Zayas-Gonzalez, H
   Manzano-Garcia, A
   Gonzalez-Hernandez, A
AF Condes-Lara, Miguel
   Zayas-Gonzalez, Hector
   Manzano-Garcia, Alfredo
   Gonzalez-Hernandez, Abimael
TI Response to Letter to the Editor by Eisenach and Yaksh on "Successful
   Pain Management with Epidural Oxytocin"
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Letter
C1 [Condes-Lara, Miguel; Zayas-Gonzalez, Hector; Manzano-Garcia, Alfredo; Gonzalez-Hernandez, Abimael] Univ Nacl Autonoma Mexico, Dept Neurobiol Desarrollo & Neurofisiol, Inst Neurobiol, Blvd Juriquilla 3001, Queretaro 76230, Mexico.
   [Zayas-Gonzalez, Hector] Hosp Reg Petroleos Mexicanos, Guanajuato, Mexico.
RP Gonzalez-Hernandez, A (reprint author), Univ Nacl Autonoma Mexico, Dept Neurobiol Desarrollo & Neurofisiol, Inst Neurobiol, Blvd Juriquilla 3001, Queretaro 76230, Mexico.
EM abimaelgh@gmail.com
RI Gonzalez-Hernandez, Abimael/B-4746-2013
OI Gonzalez-Hernandez, Abimael/0000-0002-6472-1419
CR Beauchamp Tom L., 2009, PRINCIPLES BIOMEDICA
   Ceballos A, 2000, PAIN, V87, P99, DOI 10.1016/S0304-3959(00)00266-9
   Condes-Lara M, 2016, CNS NEUROSCI THER, V22, P532, DOI 10.1111/cns.12551
   Eisenach J, 2016, ETHICAL REGARDING HU
   Elger CE, 2009, EPILEPSIA, V50, P79, DOI 10.1111/j.1528-1167.2009.02354.x
   Ruble James, 2012, J Pain Palliat Care Pharmacother, V26, P146, DOI 10.3109/15360288.2012.671243
NR 6
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
EI 1755-5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD OCT
PY 2016
VL 22
IS 10
BP 867
EP 868
DI 10.1111/cns.12601
PG 2
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DW4QL
UT WOS:000383628000010
PM 27577179
ER

PT J
AU Mobaraki, N
   Kahnamouei-Aghdam, F
   Amani, F
   Mahami, S
AF Mobaraki, Noushin
   Kahnamouei-Aghdam, Fariba
   Amani, Firouz
   Mahami, Sousan
TI Comparing the Effectiveness of Intravenous Oxytocin Versus Rectal
   Misoprostol in the Management of Third-Stage of Labour After
   Second-Trimester Abortion
SO INTERNATIONAL JOURNAL OF WOMENS HEALTH AND REPRODUCTION SCIENCES
LA English
DT Article
DE Abortion; Induced; Misoprostol; Oxytocin; Rectal administration
ID ORAL MISOPROSTOL; 3RD STAGE; ACTIVE MANAGEMENT; TERMINATION; PREGNANCY;
   INDUCTION; TRIAL
AB Objectives: To compare the efficacy of intravenous oxytocin versus rectal misoprostol in the management of the third stage of labor during pregnancy termination.
   Materials and Methods: In this randomized clinical trial, 100 pregnant women in active phase of labor and similar gestational age who had the inclusion criteria were randomly assigned into two groups of 50 patients each, for oxytocin (group 1) and misoprostol (group 2). Forty units of intravenous oxytocin was used as the standard regimen in the intervention group and compared with 400 mu g rectal misoprostol in the control group. Necessary outcomes were analyzed by statistical methods in SPP 20.
   Results: The frequency of retained placenta in the misoprostol group with 4 patients (8%) was less than the oxytocin group with 8 cases (16%), but not statistically significant. Decreasing hemoglobin concentration in the misoprostol group (0.54 mg/dL) was significantly lower than oxytocin group (0.8 mg/dL; P = 0.001).
   Conclusion: Results showed that using misoprostol in the third stage of labor in second-trimester abortions could reach a better outcome, regarding lower risks of hemorrhage and frequency of retained products of conception as compared to oxytocin.
C1 [Mobaraki, Noushin; Kahnamouei-Aghdam, Fariba; Amani, Firouz; Mahami, Sousan] Ardabil Univ Med Sci, Dept Obstet & Gynecol, Ardebil, Iran.
RP Kahnamouei-Aghdam, F (reprint author), Ardabil Univ Med Sci, Dept Obstet & Gynecol, Ardebil, Iran.
EM F.kahnamouei@arums.ac.ir
CR Aziz S, 2014, J PAK MED ASSOC, V64, P428
   Bhattacharjee N, 2008, AUST NZ J OBSTET GYN, V48, P165, DOI 10.1111/j.1479-828X.2008.00831.x
   Carbonell JL, 2008, CONTRACEPTION, V77, P50, DOI 10.1016/j.contraception.2007.09.007
   Chaudhuri P, 2010, INT J GYNECOL OBSTET, V109, P25, DOI 10.1016/j.ijgo.2009.11.009
   Clark K, 2006, AM J OBSTET GYNECOL, V194, P1391, DOI 10.1016/j.ajog.2005.11.026
   Cunningham FG, 2010, WILLIAMS OBSTET, P230
   Dickinson JE, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.044
   Green J, 2007, CONTRACEPTION, V76, P310, DOI 10.1016/j.contraception.2007.06.010
   Guzelogiu-Kayisli Z, 2009, SEMIN REPROD MED, V27, P62, DOI 10.1055/s-0028-1108011
   Hofmeyr GJ, 2009, B WORLD HEALTH ORGAN, V87, P666, DOI 10.2471/BLT.08.055715
   Karjane NW, 2006, OBSTET GYNECOL, V107, P234, DOI 10.1097/01.AOG.0000198629.44186.c8
   Karsidag AYK, 2009, INT J GYNECOL OBSTET, V106, P250, DOI 10.1016/j.ijgo.2009.04.001
   Leader J, 2002, OBSTET GYNECOL, V100, P689, DOI 10.1016/S0029-7844(02)02213-5
   Lohr PA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006714.pub2
   Mansouri HA, 2011, ARCH GYNECOL OBSTET, V283, P935, DOI 10.1007/s00404-010-1466-5
   Parsons Steven M, 2007, J Obstet Gynaecol Can, V29, P711
   Prata N, 2006, INT J GYNECOL OBSTET, V94, P149, DOI 10.1016/j.ijgo.2006.05.027
   Sundaram S, 2009, AM J OBSTET GYNECOL, V200, pE24, DOI 10.1016/j.ajog.2008.09.868
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ARAS PART MEDICAL INT PRESS
PI TABRIZ
PA NO 1, S SHAREATI ST, 5138815941, TABRIZ, 00000, IRAN
SN 2330-4456
J9 INT J WOMENS HEALTH
JI Int. J. Womens Health Reprod. Sci.
PD OCT
PY 2016
VL 4
IS 4
BP 181
EP 184
DI 10.15296/ijwhr.2016.40
PG 4
WC Reproductive Biology
SC Reproductive Biology
GA DX6YV
UT WOS:000384532900007
ER

PT J
AU Zhang, HF
   Dai, YC
   Wu, J
   Jia, MX
   Zhang, JS
   Shou, XJ
   Han, SP
   Zhang, R
   Han, JS
AF Zhang, Hong-Feng
   Dai, Yu-Chuan
   Wu, Jing
   Jia, Mei-Xiang
   Zhang, Ji-Shui
   Shou, Xiao-Jing
   Han, Song-Ping
   Zhang, Rong
   Han, Ji-Sheng
TI Plasma Oxytocin and Arginine-Vasopressin Levels in Children with Autism
   Spectrum Disorder in China: Associations with Symptoms
SO NEUROSCIENCE BULLETIN
LA English
DT Article
DE Autism spectrum disorder; Oxytocin; Vasopressin; Behavioral relevance
ID RECEPTOR GENE OXTR; RATING-SCALE CARS; SOCIAL-BEHAVIOR;
   CEREBROSPINAL-FLUID; CHILDHOOD AUTISM; MENSTRUAL-CYCLE; PERIPHERAL
   OXYTOCIN; HEALTHY WOMEN; MALE RATS; DEFICIENT
AB Autism spectrum disorder (ASD) is defined by impairments of social interaction and the presence of obsessive behaviors. The "twin" nonapeptides oxytocin (OXT) and arginine-vasopressin (AVP) are known to play regulatory roles in social behaviors. However, the plasma levels and behavioral relevance of OXT and AVP in children with ASD have seldom been investigated. It is also unknown whether their mothers have abnormal plasma peptide levels. Here, using well-established methods of neuropeptide measurement and a relatively large sample size, we determined the plasma levels of the two neuropeptides in 85 normal children, 84 children with ASD, and 31 mothers from each group of children. As expected, children with ASD had lower plasma OXT levels than gender-matched controls (P = 0.028). No such difference was found for plasma AVP concentrations. Correlation analysis showed that ASD children with higher plasma OXT concentrations tended to have less impairment of verbal communication (Rho = -0.22, P = 0.076), while those with higher plasma AVP levels tended to have lower levels of repetitive use of objects (Rho = -0.231, P = 0.079). Unlike the findings in children, maternal plasma OXT levels showed no group difference. However, plasma AVP levels in the mothers of ASD children tended to be lower than in the mothers of normal children (P = 0.072). In conclusion, our results suggest that the OXT system is dysregulated in children with ASD, and that OXT and AVP levels in plasma seem to be associated with specific autistic symptoms. The plasma levels of OXT or AVP in mothers and their ASD children did not seem to change in the same direction.
C1 [Zhang, Hong-Feng; Dai, Yu-Chuan; Shou, Xiao-Jing; Han, Song-Ping; Zhang, Rong; Han, Ji-Sheng] Peking Univ, Neurosci Res Inst, Beijing 100191, Peoples R China.
   [Zhang, Hong-Feng; Dai, Yu-Chuan; Shou, Xiao-Jing; Zhang, Rong; Han, Ji-Sheng] Peking Univ, Sch Basic Med Sci, Dept Neurobiol, Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Zhang, Hong-Feng; Dai, Yu-Chuan; Shou, Xiao-Jing; Zhang, Rong; Han, Ji-Sheng] Peking Univ, Key Lab Neurosci, Minist Educ, Natl Hlth & Family Planning Commiss, Beijing 100191, Peoples R China.
   [Wu, Jing] Peking Univ, Ctr Med & Hlth Anal, Beijing 100191, Peoples R China.
   [Jia, Mei-Xiang] Peking Univ, Mental Hlth Inst, Beijing 100191, Peoples R China.
   [Zhang, Ji-Shui] Capital Univ Med Sci, Beijing Childrens Hosp, Dept Neurol, Beijing 100045, Peoples R China.
   [Zhang, Ji-Shui] Capital Univ Med Sci, Beijing Childrens Hosp, Ctr Rehabil, Beijing 100045, Peoples R China.
RP Zhang, R; Han, JS (reprint author), Peking Univ, Neurosci Res Inst, Beijing 100191, Peoples R China.; Zhang, R; Han, JS (reprint author), Peking Univ, Sch Basic Med Sci, Dept Neurobiol, Hlth Sci Ctr, Beijing 100191, Peoples R China.; Zhang, R; Han, JS (reprint author), Peking Univ, Key Lab Neurosci, Minist Educ, Natl Hlth & Family Planning Commiss, Beijing 100191, Peoples R China.
EM zhangrong@bjmu.edu.cn; hanjisheng@bjmu.edu.cn
FU Research Special Fund for Public Welfare Industry of Health of China
   [201302002-11]; National Natural Science Foundation of China [81271507]
FX This work was supported by grants from the Research Special Fund for
   Public Welfare Industry of Health of China (201302002-11) and the
   National Natural Science Foundation of China (81271507).
CR Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47
   Alabdali A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-4
   Altemus M, 2004, BIOL PSYCHIAT, V56, P386, DOI 10.1016/j.biopsych.2004.06.002
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Boso M, 2007, ARCH MED RES, V38, P70, DOI 10.1016/j.arcmed.2006.08.003
   Calcagnoli F, 2014, HORM BEHAV, V65, P427, DOI 10.1016/j.yhbeh.2014.03.008
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Carson DS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132224
   Carson DS, 2014, PEPTIDES, V61, P12, DOI 10.1016/j.peptides.2014.08.003
   CHALLINOR SM, 1994, ENDOCR RES, V20, P117
   Cushing BS, 2001, HORM BEHAV, V39, P48, DOI 10.1006/hbeh.2000.1633
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Forsling ML, 1998, EXP PHYSIOL, V83, P409
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Insel TR, 1999, BIOL PSYCHIAT, V45, P145, DOI 10.1016/S0006-3223(98)00142-5
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Jacobson JD, 2014, PSYCHONEUROENDOCRINO, V40, P159, DOI 10.1016/j.psyneuen.2013.11.014
   Jansen LMC, 2006, J AUTISM DEV DISORD, V36, P891, DOI 10.1007/s10803-006-0124-z
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Kent K, 2013, J NEUROENDOCRINOL, V25, P803, DOI 10.1111/jne.12075
   Kose S, 2013, PSYCHIAT CLIN NEUROS, V67, P20, DOI 10.1111/pcn.12005
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Lukas M, 2011, PSYCHONEUROENDOCRINO, V36, P843, DOI 10.1016/j.psyneuen.2010.11.007
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Meziane H, 2015, BIOL PSYCHIAT, V78, P85, DOI 10.1016/j.biopsych.2014.11.010
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Moscovice LR, 2012, HORM BEHAV, V62, P592, DOI 10.1016/j.yhbeh.2012.08.011
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Park EY, 2016, PEDIATR INT, V58, P139, DOI 10.1111/ped.12770
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Ramos L, 2014, PSYCHONEUROENDOCRINO, V46, P46, DOI 10.1016/j.psyneuen.2014.04.013
   Rellini E, 2004, J AUTISM DEV DISORD, V34, P703, DOI 10.1007/s10803-004-5290-2
   Rubin LH, 2015, SCHIZOPHR RES, V166, P269, DOI 10.1016/j.schres.2015.04.039
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Salonia A, 2005, HORM BEHAV, V47, P164, DOI 10.1016/j.yhbeh.2004.10.002
   Schaller F, 2010, HUM MOL GENET, V19, P4895, DOI 10.1093/hmg/ddq424
   Schank JC, 2009, BEHAV BRAIN RES, V197, P166, DOI 10.1016/j.bbr.2008.08.019
   SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436
   Silverman JL, 2010, NEUROSCIENCE, V171, P1197, DOI 10.1016/j.neuroscience.2010.09.059
   Simpson EA, 2014, P NATL ACAD SCI USA, V111, P6922, DOI 10.1073/pnas.1402471111
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033
   Vaiserman AM, 2013, J DEV ORIG HLTH DIS, V4, P269, DOI 10.1017/S2040174413000123
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Wheelwright S, 2010, MOL AUTISM, V1, DOI 10.1186/2040-2392-1-10
   Ziegler T., 2005, P NATL ACAD SCI USA, V102, P237, DOI DOI 10.1073/PNAS.0504767102
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Xu XJ, 2015, PHYSIOL BEHAV, V138, P13, DOI 10.1016/j.physbeh.2014.09.014
   Xu XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074849
   Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162
   Zhang HF, 2015, PHYSIOL BEHAV, V151, P485, DOI 10.1016/j.physbeh.2015.08.014
NR 60
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1673-7067
EI 1995-8218
J9 NEUROSCI BULL
JI Neurosci. Bull.
PD OCT
PY 2016
VL 32
IS 5
BP 423
EP 432
DI 10.1007/s12264-016-0046-5
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA DX7XC
UT WOS:000384601700001
PM 27342432
ER

PT J
AU Lewis, L
   Hauck, YL
   Pemberton, A
   Crichton, C
   Conwell, M
AF Lewis, Lucy
   Hauck, Yvonne L.
   Pemberton, Alissa
   Crichton, Caroline
   Conwell, Marion
TI Titration of intravenous synthetic oxytocin post vaginal birth following
   induction or augmentation
SO SEXUAL & REPRODUCTIVE HEALTHCARE
LA English
DT Article
DE Induction of labour; Augmentation of labour; Intravenous oxytocin;
   Titration; Postpartum haemorrhage
ID LABOR
AB Evidence exists for titration of intravenous oxytocin during induction and augmentation, whereas no evidence was identified for titration of intravenous oxytocin following vaginal birth, where management excluded oxytocin for postpartum haemorrhage (PPH). This retrospective cohort study explored this issue through patient case notes and computerised perinatal data. Analysis included 335 women comparing induction (n = 226, 67%) to augmentation (n =109, 33%). The two groups differed in terms of: parity; oxytocin dosage; length of time on intravenous oxytocin; and the length of first and second stage labour. They had similar rates of PPH and titration of intravenous oxytocin following birth was rarely recorded. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Lewis, Lucy; Hauck, Yvonne L.] Curtin Univ, Sch Nursing Midwifery & Paramed, Perth, WA 6102, Australia.
   [Lewis, Lucy; Hauck, Yvonne L.; Pemberton, Alissa; Crichton, Caroline] King Edward Mem Hosp, Dept Nursing & Midwifery Educ & Res, Perth, WA 6009, Australia.
   [Conwell, Marion] King Edward Mem Hosp, Perth, WA, Australia.
RP Lewis, L (reprint author), Curtin Univ, Sch Nursing Midwifery & Paramed, Perth, WA 6102, Australia.; Lewis, L (reprint author), King Edward Mem Hosp, Dept Nursing & Midwifery Educ & Res, Perth, WA 6009, Australia.
EM Lucy.lewis@curtin.edu.au
FU King Edward Memorial Hospital
FX We would like to acknowledge King Edward Memorial Hospital who provided
   funding for the research midwives employed in this study. However, King
   Edward Memorial Hospital had no decision in relation to the: study
   design; data collection; analysis; interpretation of the data; writing
   of this paper; or submission.
CR Belghiti J, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000514
   Bell AF, 2014, J MIDWIFERY WOM HEAL, V59, P35, DOI 10.1111/jmwh.12101
   Bor P, 2016, BJOG-INT J OBSTET GY, V123, P129, DOI 10.1111/1471-0528.13589
   Budden A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009701.pub2
   Hilder L., 2014, PERINATAL STAT SERIE, V30
   Lewis L, 2016, WOMEN BIRTH, DOI [10.1016/j.wombi.2016.04.009, DOI 10.1016/J.WOMBI.2016.04.009]
NR 6
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1877-5756
EI 1877-5764
J9 SEX REPROD HEALTHC
JI Sex. Reprod. Healthc.
PD OCT
PY 2016
VL 9
BP 35
EP 37
DI 10.1016/j.srhc.2016.06.002
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DY0LA
UT WOS:000384787100006
PM 27634662
ER

PT J
AU Hegde, S
   Ji, H
   Oliver, D
   Patel, NS
   Poupore, N
   Shtutman, M
   Kelly, MP
AF Hegde, Shweta
   Ji, Hao
   Oliver, David
   Patel, Neema S.
   Poupore, Nicolas
   Shtutman, Michael
   Kelly, Michy P.
TI PDE11A REGULATES SOCIAL BEHAVIORS AND IS A KEY MECHANISM BY WHICH SOCIAL
   EXPERIENCE SCULPTS THE BRAIN
SO NEUROSCIENCE
LA English
DT Article
DE phosphodiesterase; hippocampus; social buffering; social approach;
   social odor recognition; social memory
ID BIPOLAR AFFECTIVE-DISORDER; CYCLIC-AMP PRODUCTION; PLATELET
   PROSTAGLANDIN-E1 HYPOSENSITIVITY; DIFFERENTIAL EXPRESSION ANALYSIS;
   ADRENERGIC-RECEPTOR FUNCTION; INBRED MOUSE STRAINS; EDINBURGH HIGH-RISK;
   G-PROTEIN MEASURES; POSTMORTEM BRAIN; MONONUCLEAR LEUKOCYTES
AB Despite the fact that appropriate social behaviors are vital to thriving in one's environment, little is understood of the molecular mechanisms controlling social behaviors or how social experience sculpts these signaling pathways. Here, we determine if Phosphodiesterase 11A (PDE11A), an enzyme that is enriched in the ventral hippocampal formation (VHIPP) and that breaks down cAMP and cGMP, regulates social behaviors. PDE11 wild-type (WT), heterozygous (HT), and knockout (KO) mice were tested in various social approach assays and gene expression differences were measured by RNA sequencing. The effect of social isolation on PDE11A4 compartmentalization and subsequent social interactions and social memory was also assessed. Deletion of PDE11A triggered age-and sex-dependent deficits in social approach in specific social contexts but not others. Mice appear to detect altered social behaviors of PDE11A KO mice, because C57BL/6J mice prefer to spend time with a sex-matched PDE11A WT vs. its KO littermate; whereas, a PDE11A KO prefers to spend time with a novel PDE11A KO vs. its WT littermate. Not only is PDE11A required for intact social interactions, we found that 1 month of social isolation vs. group housing decreased PDE11A4 protein expression specifically within the membrane fraction of VHIPP. This isolation-induced decrease in PDE11A4 expression appears functional because social isolation impairs subsequent social approach behavior and social memory in a PDE11A genotype-dependent manner. Pathway analyses following RNA sequencing suggests PDE11A is a key regulator of the oxytocin pathway and membrane signaling, consistent with its pivotal role in regulating social behavior. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Hegde, Shweta; Patel, Neema S.; Poupore, Nicolas; Kelly, Michy P.] Univ South Carolina, Dept Pharmacol Physiol & Neurosci, Sch Med, 6439 Garners Ferry Rd,VA Bldg 1,3rd Floor,D-12, Columbia, SC 29209 USA.
   [Ji, Hao; Oliver, David; Shtutman, Michael] Univ South Carolina, Dept Drug Discovery & Biomed Sci, South Carolina Coll Pharm, Columbia, SC 29208 USA.
RP Kelly, MP (reprint author), Univ South Carolina, Dept Pharmacol Physiol & Neurosci, Sch Med, 6439 Garners Ferry Rd,VA Bldg 1,3rd Floor,D-12, Columbia, SC 29209 USA.
FU NIGMS [1P20GM109091]; Research Starter Grant in Pharmacology &
   Toxicology from the PhRMA Foundation; ASPIRE award from the Office of
   the Vice President for Research from the University of South Carolina;
   Research Development Fund Award from the University of South Carolina
   School of Medicine; NARSAD Young Investigator Award from the Brain &
   Behavior Research Foundation; NIMH [1R01MH101130]; ASU-BIO, Inc.;
   Deallus
FX The authors would like to thank Marcelo Wood, Ted Abel, and Igor
   Roninson for helpful advice on RNA sequencing as well as Alex Gasparian
   for project management support. Research supported by 1P20GM109091 from
   NIGMS (Project 1, M. S.; Project 3, M. P. K.), a Research Starter Grant
   in Pharmacology & Toxicology from the PhRMA Foundation (M. P. K.), an
   ASPIRE award from the Office of the Vice President for Research from the
   University of South Carolina (individual awards to M. S. and M. P. K.),
   a Research Development Fund Award from the University of South Carolina
   School of Medicine (M. P. K.), a NARSAD Young Investigator Award from
   the Brain & Behavior Research Foundation (M. P. K.), and 1R01MH101130
   from NIMH (M. P. K.). M. P. K. receives consulting fees from ASU-BIO,
   Inc. and Deallus for projects unrelated to the current manuscript. S.H.,
   H.J., D.O., N.P. and M. S. have no financial conflicts to disclose.
CR Avissar S, 1997, J AFFECT DISORDERS, V43, P85, DOI 10.1016/S0165-0327(96)01400-0
   Avissar S, 2001, CELL MOL NEUROBIOL, V21, P799, DOI 10.1023/A:1015164423918
   Avissar S, 2001, SCHIZOPHR RES, V47, P37, DOI 10.1016/S0920-9964(00)00038-4
   Bacchelli E, 2003, MOL PSYCHIATR, V8, P916, DOI 10.1038/sj.mp.4001340
   Bartels SJ, 2009, CURR OPIN PSYCHIATR, V22, P381, DOI 10.1097/YCO.0b013e32832c9234
   BELMAKER RH, 1978, PSYCHOPHARMACOLOGY, V58, P307, DOI 10.1007/BF00427396
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Bickle J, 2008, CONSCIOUS COGN, V17, P468, DOI 10.1016/j.concog.2008.03.015
   Boess FG, 2004, NEUROPHARMACOLOGY, V47, P1081, DOI 10.1016/j.neuropharm.2004.07.040
   Bonkale WL, 1999, BRAIN RES, V818, P383, DOI 10.1016/S0006-8993(98)01307-9
   BOWERS MB, 1979, PSYCHOPHARMACOLOGY, V62, P17, DOI 10.1007/BF00426029
   Brightwell JJ, 2005, LEARN MEMORY, V12, P12, DOI 10.1101/lm.85005
   Brodkin ES, 2004, BRAIN RES, V1002, P151, DOI 10.1016/j.brainres.2003.12.013
   Cabanero M, 2009, PHARMACOGENET GENOM, V19, P235, DOI 10.1097/FPC.0b013e328320a3e2
   Cembrowski MS, 2016, NEURON
   Chang A, 2003, J NEUROCHEM, V84, P781, DOI 10.1046/j.0022-3042.2003.01605.x
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Cheng CYY, 2009, J MOL ENDOCRINOL, V43, P81, DOI 10.1677/JME-08-0123
   Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189
   Coon H, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.100
   Couzin J, 2008, SCIENCE, V319, P274, DOI 10.1126/science.319.5861.274
   COWBURN RF, 1994, BRAIN RES, V633, P297, DOI 10.1016/0006-8993(94)91552-0
   Dean M, 2014, J CHILD PSYCHOL PSYC, V55, P1218, DOI 10.1111/jcpp.12242
   Derntl B, 2011, SOC NEUROSCI-UK, V6, P482, DOI 10.1080/17470919.2011.579800
   Dickens AP, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-647
   Ditzen B, 2014, RESTOR NEUROL NEUROS, V32, P149, DOI 10.3233/RNN-139008
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   EBSTEIN RP, 1976, PSYCHOPHARMACOLOGY, V51, P71, DOI 10.1007/BF00426324
   Edmunds CE, 2008, MOL CELL, V30, P519, DOI 10.1016/j.molcel.2008.03.024
   Fairless AH, 2012, BEHAV BRAIN RES, V228, P299, DOI [10.1016/j.bbr.2011.12.001, 10.1016/j.bbr.2.011.12.001]
   Feldman R, 2015, BIOL PSYCHIAT
   Feleder C, 2010, BIOL PSYCHIAT, V67, P386, DOI 10.1016/j.biopsych.2009.09.028
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   Fields A, 1999, J NEUROCHEM, V73, P1704, DOI 10.1046/j.1471-4159.1999.731704.x
   Francis SH, 2011, PHYSIOL REV, V91, P651, DOI 10.1152/physrev.00030.2010
   GARVER DL, 1982, LIFE SCI, V31, P1987, DOI 10.1016/0024-3205(82)90037-6
   GATTAZ WF, 1983, BRIT J PSYCHIAT, V142, P288, DOI 10.1192/bjp.142.3.288
   Ghose S, 2009, SCHIZOPHR RES, V111, P131, DOI 10.1016/j.schres.2009.03.038
   Giacco D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050119
   Gobrogge K, 2015, HORM BEHAV
   GOLDBERG M, 1984, J AUTISM DEV DISORD, V14, P159, DOI 10.1007/BF02409658
   Goldman MB, 2011, BEHAV BRAIN RES, V218, P106, DOI 10.1016/j.bbr.2010.11.025
   Grauer SM, 2009, J PHARMACOL EXP THER, V331, P574, DOI 10.1124/jpet.109.155994
   Gregor T, 2010, SCIENCE, V328, P1021, DOI 10.1126/science.1183415
   Gurguis GNM, 1997, NEUROPSYCHOPHARMACOL, V16, P69, DOI 10.1016/S0893-133X(96)00161-3
   Gurguis GNM, 1999, PSYCHIAT RES, V85, P305, DOI 10.1016/S0165-1781(99)00004-9
   Gurguis GNM, 1999, J PSYCHIAT RES, V33, P309, DOI 10.1016/S0022-3956(99)00008-4
   Hall J, 2010, PSYCHOL MED, V40, P761, DOI 10.1017/S0033291709991000
   Hawton A, 2011, QUAL LIFE RES, V20, P57, DOI 10.1007/s11136-010-9717-2
   Hegde S, 2016, NEUROPSYCHOPHARMACOL
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   HOSHINO Y, 1980, FOLIA PSYCHIAT NEU J, V34, P9
   Hostinar CE, 2014, PSYCHOL BULL, V140, P256, DOI 10.1037/a0032671
   Hutson PH, 2011, NEUROPHARMACOLOGY, V61, P665, DOI 10.1016/j.neuropharm.2011.05.009
   Jager R, 2012, J BIOL CHEM, V287, P1210, DOI 10.1074/jbc.M111.263806
   Jahr E, 2007, AUTISM, V11, P349, DOI 10.1177/1362361307078134
   Jessen F, 2003, AM J PSYCHIAT, V160, P1305, DOI 10.1176/appi.ajp.160.7.1305
   Ji LN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023751
   Johnstone EC, 2005, BRIT J PSYCHIAT, V186, P18, DOI 10.1192/bjp.186.1.18
   KAFKA MS, 1983, ARCH GEN PSYCHIAT, V40, P264
   KAFKA MS, 1979, AM J PSYCHIAT, V136, P685
   Kafka MS, 1986, J CLIN PSYCHIAT, V8, P15
   KAIYA H, 1990, PSYCHOPHARMACOL BULL, V26, P381
   KAIYA H, 1992, PROSTAG LEUKOTR ESS, V46, P33, DOI 10.1016/0952-3278(92)90056-O
   Kang WH., 1990, ZHONGHUA SHEN JING J, V23, P318
   KANOF PD, 1989, BIOL PSYCHIAT, V25, P413, DOI 10.1016/0006-3223(89)90194-7
   KANOF PD, 1987, AM J PSYCHIAT, V144, P1556
   KANOF PD, 1986, ARCH GEN PSYCHIAT, V43, P987
   Kelley DJ, 2008, NEUROSCI BIOBEHAV R, V32, P1533, DOI 10.1016/j.neubiorev.2008.06.005
   Kelly MP, 2008, LEARN MEMORY, V15, P75, DOI 10.1101/lm.723708
   Kelly MP, 2010, P NATL ACAD SCI USA, V107, P8457, DOI 10.1073/pnas.1000730107
   Kelly MP, 2014, WILEY SER DRUG DISC, P47
   Kelly MP, 2015, CURR PHARM DESIGN, V21, P389
   Kelly MP, 2014, CELL SIGNAL, V26, P383, DOI 10.1016/j.cellsig.2013.10.007
   Kelsoe J, 2010, Method to predict response to treatment for psychiatric illnesses, P1, Patent No. 201002337021
   Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6
   Kondo N, 2013, INT J SOC PSYCHIATR, V59, P79, DOI 10.1177/0020764011423611
   Launay J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129688
   LAVIOLA G, 1994, PSYCHOPHARMACOLOGY, V113, P388, DOI 10.1007/BF02245214
   Lee JM, 2004, NEUROIMAGE, V22, P831, DOI 10.1016/j.neroimage.2004.02.004
   LERER B, 1987, AM J PSYCHIAT, V144, P1324
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Liebenberg N, 2012, METAB BRAIN DIS, V27, P337, DOI 10.1007/s11011-012-9284-z
   Locke J., 2010, J RES SPECIAL ED NEE, V10, P74, DOI [10.1111/j.1471-3802.2010.01148.x., DOI 10.1111/J.1471-3802.2010.01148.X, 10.1111/j.1471-3802.2010.01148.x]
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Luo HR, 2009, NEUROPSYCH DIS TREAT, V5, P163
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   MEMO M, 1983, SCIENCE, V221, P1304, DOI 10.1126/science.6310753
   Mertens J, 2015, NATURE, V527, P95, DOI 10.1038/nature15526
   Miller P, 2002, BRIT J PSYCHIAT, V180, P179, DOI 10.1192/bjp.180.2.179
   Nesvaderani M, 2009, AUST NZ J PSYCHIAT, V43, P310, DOI 10.1080/00048670902721103
   OFUJI M, 1989, LIFE SCI, V45, P2135, DOI 10.1016/0024-3205(89)90079-9
   Pathak G, 2015, NEUROPHARMACOLOGY, V95, P434, DOI 10.1016/j.neuropharm.2015.04.026
   Pathak G, MOL PSYCHIA IN PRESS
   Pegues MP, 2003, SCHIZOPHR RES, V60, P105, DOI 10.1016/S0920-9964(02)00288-8
   Pompili Maurizio, 2008, Expert Rev Neurother, V8, P51, DOI 10.1586/14737175.8.1.51
   Rahman S, 1997, J NEUROCHEM, V68, P297
   Rajarethinam R, 2001, PSYCHIAT RES-NEUROIM, V108, P79, DOI 10.1016/S0925-4927(01)00120-2
   Rametti G, 2007, SCHIZOPHR RES, V96, P62, DOI 10.1016/j.schres.2007.04.034
   Reidpath DD, 2005, SOCIOL HEALTH ILL, V27, P468, DOI 10.1111/j.1467-9566.2005.00452.x
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rusch N, 2008, SCHIZOPHR RES, V99, P155, DOI 10.1016/j.schres.2007.05.024
   Sankoorikal GMV, 2006, BIOL PSYCHIAT, V59, P415, DOI 10.1016/j.biopsych.2005.07.026
   Schobel SA, 2009, SCHIZOPHR RES, V114, P110, DOI 10.1016/j.schres.2009.07.016
   Schobel SA, 2009, ARCH GEN PSYCHIAT, V66, P938, DOI 10.1001/archgenpsychiatry.2009.115
   Shah CR, 2013, AUTISM RES, V6, P212, DOI 10.1002/aur.1280
   Shahar-Gold H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065085
   SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905
   Slavich George M, 2013, Clin Psychol Sci, V1, P331
   Srivastava DP, 2012, J NEUROSCI, V32, P11864, DOI 10.1523/JNEUROSCI.1349-12.2012
   Stoesz BM, 2013, NEUROSCI BIOBEHAV R, V37, P123, DOI 10.1016/j.neubiorev.2012.11.007
   SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tipton LA, 2013, J APPL RES INTELLECT, V26, P522, DOI 10.1111/jar.12051
   Tseng KY, 2009, BEHAV BRAIN RES, V204, P295, DOI 10.1016/j.bbr.2008.11.039
   Turetsky BI, 2009, AM J PSYCHIAT, V166, P226, DOI 10.1176/appi.ajp.2008.07071210
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Wong ML, 2006, P NATL ACAD SCI USA, V103, P15124, DOI 10.1073/pnas.0602795103
   Woolfrey KM, 2009, NAT NEUROSCI, V12, P1275, DOI 10.1038/nn.2386
   Yang YC, 2016, P NATL ACAD SCI US
   Yang Y, 2012, NEURON, V73, P774, DOI 10.1016/j.neuron.2012.02.003
   YOUNG LT, 1993, J NEUROCHEM, V61, P890, DOI 10.1111/j.1471-4159.1993.tb03600.x
   YOUNG LT, 1991, BRAIN RES, V553, P323, DOI 10.1016/0006-8993(91)90843-K
   YOUNG LT, 1994, AM J PSYCHIAT, V151, P594
   Young SN, 2008, J PSYCHIATR NEUROSCI, V33, P391
   Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200
   Zhang J, 2011, PSYCHIAT RES-NEUROIM, V192, P84, DOI 10.1016/j.pscychresns.2010.09.001
   Zhou XB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku310
   Zhou YA, 2008, SCHIZOPHR RES, V100, P120, DOI 10.1016/j.schres.2007.11.039
NR 130
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD OCT
PY 2016
VL 335
BP 151
EP 169
DI 10.1016/j.neuroscience.2016.08.019
PG 19
WC Neurosciences
SC Neurosciences & Neurology
GA DW9XR
UT WOS:000384016600014
PM 27544407
ER

PT J
AU Mizrachi, Y
   Levy, M
   Bar, J
   Kovo, M
AF Mizrachi, Yossi
   Levy, Michal
   Bar, Jacob
   Kovo, Michal
TI Induction of labor in nulliparous women with unfavorable cervix: a
   comparison of Foley catheter and vaginal prostaglandin E-2
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Labor induction; Foley catheter; Prostaglandins; Nulliparity
ID RANDOMIZED CONTROLLED-TRIAL; CESAREAN DELIVERY; ELECTIVE INDUCTION;
   TERM; MISOPROSTOL; RISK; GEL; OXYTOCIN
AB To compare maternal and neonatal outcomes of two methods of labor induction in nulliparous women with unfavorable cervix.
   A case-control study was performed on nulliparous women with a cervical Bishop score < 6, who underwent induction of labor with either extra-amniotic Foley catheter (Foley catheter study group) or vaginal tablets of prostaglandin E-2 (PGE(2) control group). The control group was matched for gestational age and for the indication to induce labor.
   A total of 346 nulliparous women were included. Similar rates of cesarean delivery were found in the Foley catheter and the PGE(2) groups (25.4 vs. 24.2 %, respectively, p = 0.8), without differences in maternal or neonatal adverse outcomes. In the Foley catheter group, induction to delivery interval was shorter compared with the PGE(2) group (25.1 vs. 36.6 h, respectively, p < 0.001), and more women delivered within 24 h (55.0 vs. 40.4 %, respectively, p = 0.01).
   Induction of labor with Foley catheter in nulliparous women with unfavorable cervix is associated with shorter induction to delivery interval, but with similar rates of cesarean deliveries and adverse pregnancy outcomes, as compared with vaginal tablets of PGE(2).
C1 [Mizrachi, Yossi; Levy, Michal; Bar, Jacob; Kovo, Michal] Edith Wolfson Med Ctr, Dept Obstet & Gynecol, POB 5, IL-58100 Holon, Israel.
   [Mizrachi, Yossi; Levy, Michal; Bar, Jacob; Kovo, Michal] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Mizrachi, Y (reprint author), Edith Wolfson Med Ctr, Dept Obstet & Gynecol, POB 5, IL-58100 Holon, Israel.; Mizrachi, Y (reprint author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
EM mizrachi.yossi@gmail.com
OI Mizrachi, Yossi/0000-0002-2533-6972
CR Abramovici D, 1999, AM J OBSTET GYNECOL, V181, P1108, DOI 10.1016/S0002-9378(99)70090-6
   Aghideh FK, 2014, J MATERN-FETAL NEO M, V27, P592, DOI 10.3109/14767058.2013.831066
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Coonrod DV, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.03.026
   Culver J, 2004, AM J PERINAT, V21, P139, DOI 10.1055/s-2004-823777
   Dollberg S, 2005, ISRAEL MED ASSOC J, V7, P311
   Ehrenthal DB, 2010, OBSTET GYNECOL, V116, P35, DOI 10.1097/AOG.0b013e3181e10c5c
   Fox NS, 2011, BJOG-INT J OBSTET GY, V118, P647, DOI 10.1111/j.1471-0528.2011.02905.x
   Heinemann J, 2008, AM J OBSTET GYNECOL, V199, P177, DOI 10.1016/j.ajog.2008.05.005
   Jozwiak M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001233.pub2
   Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1
   Maslow AS, 2000, OBSTET GYNECOL, V95, P917, DOI 10.1016/S0029-7844(00)00794-8
   Memon F, 2011, J OBSTET GYNAECOL, V31, P220, DOI 10.3109/01443615.2010.544424
   Parkes I, 2016, J MATERN-FETAL NEO M, V29, P224, DOI 10.3109/14767058.2014.993965
   Pennell CE, 2009, BJOG-INT J OBSTET GY, V116, P1443, DOI 10.1111/j.1471-0528.2009.02279.x
   Pevzner L, 2009, OBSTET GYNECOL, V114, P261, DOI 10.1097/AOG.0b013e3181ad9377
   Shetty A, 2005, EUR J OBSTET GYN R B, V123, P56, DOI 10.1016/j.ejogrb.2005.03.004
   Suffecool K, 2014, J PERINAT MED, V42, P213, DOI 10.1515/jpm-2013-0152
   Taher SE, 2011, BJOG-INT J OBSTET GY, V118, P719, DOI 10.1111/j.1471-0528.2011.02901.x
   Thomas J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003101.pub3
   Vahratian A, 2005, OBSTET GYNECOL, V105, P698, DOI 10.1097/01.AOG.0000157436.68847.3b
   van Baaren GJ, 2013, BJOG-INT J OBSTET GY, V120, P987, DOI 10.1111/1471-0528.12221
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   [Anonymous], 2009, OBSTET GYNECOL, V114, P192, DOI DOI 10.1097/AOG.0B013E3181AEF106
   [Anonymous], 2009, OBSTET GYNECOL, V114, P386, DOI DOI 10.1097/AOG.0B013E3181B48EF5
NR 25
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2016
VL 294
IS 4
BP 725
EP 730
DI 10.1007/s00404-016-4026-9
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV4UJ
UT WOS:000382920400007
PM 26837386
ER

PT J
AU Ragusa, A
   Gizzo, S
   Noventa, M
   Ferrazzi, E
   Deiana, S
   Svelato, A
AF Ragusa, Antonio
   Gizzo, Salvatore
   Noventa, Marco
   Ferrazzi, Enrico
   Deiana, Sara
   Svelato, Alessandro
TI Prevention of primary caesarean delivery: comprehensive management of
   dystocia in nulliparous patients at term
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Labor dystocia; Cesarean section; Partogram; Labor augmentation;
   Intrapartum strategy; Nulliparity
ID TRANSABDOMINAL ULTRASOUND ASSESSMENT; TRANSVAGINAL DIGITAL EXAMINATION;
   OCCIPUT POSTERIOR POSITION; HEAD POSITION; NEURAXIAL ANALGESIA;
   RISK-FACTORS; LABOR CURVE; FETAL SPINE; PREGNANCY; BIRTH
AB Dystocia is the leading indication for primary caesarean sections. Our aim is to compare two approaches in the management of dystocia in labor in nulliparous women with a singleton fetus in cephalic presentation at term in spontaneous or induced labor.
   Prospective cohort study. Four hundred and nineteen consecutive patients were divided into two groups: the standard management group (SM), in acceleration of labor was commenced at the "action line" in the case of arrested or protracted labor, and the comprehensive management group (CM) in which arrested or protracted labor was considered as a warning sign promoting further diagnostic assessment prior to considering intervention.
   Caesarean sections rate was 22.2 % in the SM group (216 patients) and 10.3 % in the CM group (203 patients) (p = 0.001). The rate of oxytocin use decreased from 33.3 % in SM group to 13.8 % in the CM group (p < 0.0005). The rate of amniotomy decreased from 41.7 % in the SM group to 7.4 % in the CM group (p < 0.0005). The percentage of newborns with 5-min Apgar score < 7 and/or umbilical cord arterial pH aecurrency sign 7.00 decreased from 2.3 % in SM cohort to 0.5 % in CM cohort (p = ns). The average length of labor did not differ between the two groups of patients (264 vs 277 min; p = ns).
   Comprehensive management of dystocia enabled us to achieve a reduction in iatrogenic interventions in labor while maintaining good neonatal outcomes.
C1 [Ragusa, Antonio] Massa Carrara Hosp, Dipartimento Materno Infantile, UOC Ginecol & Ostetricia, Via Enrico Mattei 21, I-54100 Massa Carrara, Italy.
   [Gizzo, Salvatore; Noventa, Marco] Univ Padua, Dipartimento Salute Donna & Bambino, UOC Ginecol & Ostetricia, Via Giustiniani 3, I-35128 Padua, Italy.
   [Ferrazzi, Enrico] Osped V Buzzi, Sch Med, Dept Woman Mother & Newborn, Milan, Italy.
   [Deiana, Sara] Univ Cagliari, San Giovanni di Dio Gen Hosp, Dept Obstet & Gynaecol, Cagliari, Italy.
   [Svelato, Alessandro] Carlo Poma Gen Hosp, Dept Obstet & Gynaecol, Mantua, Italy.
RP Ragusa, A (reprint author), Massa Carrara Hosp, Dipartimento Materno Infantile, UOC Ginecol & Ostetricia, Via Enrico Mattei 21, I-54100 Massa Carrara, Italy.
EM antonio.ragusa@gmail.com; ginecologia_padova@libero.it
CR American College of Obstetricians and Gynecologists; Society for Maternal- Fetal Medicine, 2014, OBSTET GYNECOL, V123, P693, DOI DOI 10.1097/01.AOG.0000444441.04111.1D
   American College of Obstetricians and Gynecologists, 2009, OBSTET GYNECOL, V114, P192, DOI DOI 10.1097/AOG.0B013E3181AEF106
   Berghella V, 2008, AM J OBSTET GYNECOL, V199, P445, DOI 10.1016/j.ajog.2008.06.093
   Blasi I, 2010, ULTRASOUND OBST GYN, V35, P210, DOI 10.1002/uog.7504
   Cohain JS, 2013, J MATERN-FETAL NEO M, V26, P1687, DOI 10.3109/14767058.2013.798286
   Cunningham F, 2010, WILLIAMS OBSTET
   Desbriere R, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.882
   Dupuis O, 2005, AM J OBSTET GYNECOL, V192, P868, DOI 10.1016/j.ajog.2004.09.028
   Frigo MG, 2011, J OBSTET GYNAECOL RE, V37, P1532, DOI 10.1111/j.1447-0756.2011.01568.x
   Gifford DS, 2000, OBSTET GYNECOL, V95, P589, DOI 10.1016/S0029-7844(99)00575-X
   Gizzo S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114190
   Gizzo S, 2014, OBSTET GYNECOL, V124, P837, DOI 10.1097/AOG.0000000000000487
   Gizzo S, 2014, BIOMED RES INT, DOI 10.1155/2014/783598
   Gizzo S, 2014, BIOMED RES INT, DOI 10.1155/2014/638093
   Gizzo S, 2014, J PERINAT MED, V42, P339, DOI 10.1515/jpm-2013-0160
   Gizzo S, 2013, SCI WORLD J, DOI 10.1155/2013/254901
   Gizzo S, 2013, REPROD SCI, V20, P1011, DOI 10.1177/1933719112468951
   Gizzo S, 2013, FERTIL STERIL, V99, P2097, DOI 10.1016/j.fertnstert.2013.02.013
   Gizzo S, 2013, ULTRASOUND MED BIOL, V39, P550, DOI 10.1016/j.ultrasmedbio.2012.07.016
   Gizzo S, 2013, FERTIL STERIL, V99, P496, DOI 10.1016/j.fertnstert.2012.10.019
   Gizzo S, 2012, BREASTFEED MED, V7, P262, DOI 10.1089/bfm.2011.0099
   Gregory KD, 1998, AM J PUBLIC HEALTH, V88, P1384, DOI 10.2105/AJPH.88.9.1384
   Gross MM, 2014, ARCH GYNECOL OBSTET, V289, P41, DOI 10.1007/s00404-013-2916-7
   Hayes BC, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.03.023
   Institute for Safe Medication Practices, 2014, LIST HIGH AL MED
   Ijaiya Munir'deen A, 2011, Ann Afr Med, V10, P115, DOI 10.4103/1596-3519.82074
   Jonsson M, 2008, ACTA OBSTET GYN SCAN, V87, P745, DOI 10.1080/00016340802220352
   Kenyon S, 2013, COCHRANE DB SYST REV, V7
   Kjaergaard Hanne, 2008, BMC Pregnancy Childbirth, V8, P45, DOI 10.1186/1471-2393-8-45
   Kominiarek MA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.014
   KWAST BE, 1994, LANCET, V343, P1399
   Le Ray C, 2007, OBSTET GYNECOL, V110, P873, DOI 10.1097/01.AOG.0000281666.04924.be
   Leap N, 2010, J MIDWIFERY WOM HEAL, V55, P234, DOI 10.1016/j.jmwh.2010.02.001
   Lee SM, 2010, EUR J OBSTET GYN R B, V148, P152, DOI 10.1016/j.ejogrb.2009.10.031
   Lowe NK, 2011, MED HYPOTHESES, V76, P755, DOI 10.1016/j.mehy.2011.02.018
   Marpeau L, 2002, Gynecol Obstet Fertil, V30, P282, DOI 10.1016/S1297-9589(02)00316-8
   Martin CJH, 2013, COMPLEMENT THER CLIN, V19, P44, DOI 10.1016/j.ctcp.2012.09.001
   Mittal P, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.09.025
   NICE, 2007, INTR CAR CAR HLTH WO
   Onyeije CI, 2001, AM J OBSTET GYNECOL, V184, P713, DOI 10.1067/mob.2001.111296
   Pascali-Bonaro D, 2004, J MIDWIFERY WOM HEAL, V49, P19, DOI 10.1016/j.jmwh.2004.01.017
   Patrelli TS, 2012, J ULTRAS MED, V31, P239
   PIQUARD F, 1988, OBSTET GYNECOL, V72, P746
   Racinet C, 2005, Gynecol Obstet Fertil, V33, P533, DOI 10.1016/j.gyobfe.2005.05.022
   Reichman O, 2008, EUR J OBSTET GYN R B, V136, P25, DOI 10.1016/j.ejogrb.2006.12.025
   Rosand GMB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-161
   Rouse DJK, 2001, OBSTET GYNECOL, V98, P550, DOI 10.1016/S0029-7844(01)01516-2
   Sherer DM, 2002, ULTRASOUND OBST GYN, V19, P258
   Sherer DM, 2002, ULTRASOUND OBST GYN, V19, P264, DOI 10.1046/j.1469-0705.2002.00656.x
   Simkin P, 2010, BIRTH-ISS PERINAT C, V37, P61, DOI 10.1111/j.1523-536X.2009.00380.x
   Stremler R, 2005, BIRTH-ISS PERINAT C, V32, P243, DOI 10.1111/j.0730-7659.2005.00382.x
   Zhang J, 2002, AM J OBSTET GYNECOL, V187, P824, DOI 10.1067/mob.2002.127142
   Zhang J, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.058
NR 53
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2016
VL 294
IS 4
BP 753
EP 761
DI 10.1007/s00404-016-4046-5
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV4UJ
UT WOS:000382920400011
PM 26924640
ER

PT J
AU Kennedy, GA
   Hudson, R
AF Kennedy, Gerard A.
   Hudson, Robyn
TI Phase response curve to 1 h light pulses for the European rabbit
   (Oryctolagus cuniculus)
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE Circadian rhythms; free-running rhythm; phase-response curve; phase
   advance; phase delay; rabbit; Oryctolagus cuniculus
ID CIRCADIAN ACTIVITY RHYTHM; MICE MUS-MUSCULUS; FUNCTIONAL-ANALYSIS;
   NOCTURNAL RODENTS; PACEMAKERS; ENTRAINMENT; OXYTOCIN; BEHAVIOR; PATTERN;
   SYSTEM
AB While much is known about the circadian systems of rodents, chronobiological studies of other mammalian groups have been limited. One of the most extensively studied nonrodent species, both in the laboratory and in the wild, is the European rabbit. The aim of this study was to extend knowledge of the rabbit circadian system by examining its phasic response to light. Twelve Dutch-Himalayan cross rabbits of both sexes were allowed to free-run in constant darkness and then administered 1 h light pulses (1000 lux) at multiple predetermined circadian times. Changes in the phase of the rabbits' circadian wheel-running rhythms were measured after each light pulse and used to construct a phase-response curve (PRC). The rabbits' PRC and free-running period (tau) conformed to the empirical regularities reported for other predominantly nocturnal animals, including rodents and predatory marsupials. The results of the study are thus consistent with reports that the rabbit is essentially a nocturnal animal and show that it can entrain to light/dark (LD) cycles via discrete phase shifts. Knowledge about the rabbit's circadian range of entrainment to LD cycles gained in this study will be useful for examining the putative circadian processes believed to underlie the unusual rhythm of very brief, once-daily nest visits by nursing rabbit mothers and other nursing lagomorphs.
C1 [Kennedy, Gerard A.] Cairnmillar Inst, Sch Psychol Counselling & Psychotherapy, 993 Burke Rd, Camberwell, Vic 3124, Australia.
   [Hudson, Robyn] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico.
RP Kennedy, GA (reprint author), Cairnmillar Inst, Sch Psychol Counselling & Psychotherapy, 993 Burke Rd, Camberwell, Vic 3124, Australia.
EM gerard.kennedy@cairnmillar.edu.au
CR ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11
   CASSONE V M, 1987, Journal of Biological Rhythms, V2, P261, DOI 10.1177/074873048700200402
   Comas M, 2008, J BIOL RHYTHM, V23, P425, DOI 10.1177/0748730408321567
   Comas M, 2007, J BIOL RHYTHM, V22, P432, DOI 10.1177/0748730407305728
   Comas M, 2006, J BIOL RHYTHM, V21, P362, DOI 10.1177/0748730406292446
   DAAN S, 1976, J COMP PHYSIOL, V106, P253
   DeCoursey P J, 1986, J Biol Rhythms, V1, P171, DOI 10.1177/074873048600100301
   DECOURSEY PJ, 1986, J COMP PHYSIOL A, V159, P161, DOI 10.1007/BF00612299
   DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33
   DECOURSEY PJ, 1961, Z VERGL PHYSIOL, V44, P331, DOI 10.1007/BF00388033
   Gonzalez-Mariscal G, 2016, HORM BEHAV, V77, P30, DOI 10.1016/j.yhbeh.2015.05.011
   HONMA K, 1985, JPN J PHYSIOL, V35, P643, DOI 10.2170/jjphysiol.35.643
   HORTON BJ, 1974, LIFE SCI, V15, P1895, DOI 10.1016/0024-3205(74)90040-X
   HUDSON R, 1995, BIOL REPROD, V53, P519, DOI 10.1095/biolreprod53.3.519
   JILGE B, 1980, LAB ANIM, V14, P3, DOI 10.1258/002367780780943042
   JILGE B, 1991, J EXP ANIM SCI, V34, P170
   Jilge B, 2001, CHRONOBIOL INT, V18, P1, DOI 10.1081/CBI-100001275
   Johnson CH, 1999, CHRONOBIOL INT, V16, P711, DOI 10.3109/07420529909016940
   KATZ RS, 1975, INVEST OPHTH VISUAL, V14, P775
   KENNEDY GA, 1994, PHYSIOL BEHAV, V55, P385, DOI 10.1016/0031-9384(94)90151-1
   KENNEDY GA, 1989, PHYSIOL BEHAV, V46, P667, DOI 10.1016/0031-9384(89)90349-1
   Lee, 1997, AM J PHYSIOL, V273, pR278
   MROSOVSKY N, 1988, J COMP PHYSIOL A, V162, P35, DOI 10.1007/BF01342701
   MYKYTOWYCZ R., 1958, C S I R O WILDLIFE RES, V3, P26
   Ninomiya-Alarcon JG, 2004, AM J PHYSIOL-REG I, V287, pR174, DOI 10.1152/ajpregu.00710.2003
   NUBOER JFW, 1983, J COMP PHYSIOL, V151, P359
   PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P223
   PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P333
   PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291
   PIVIK RT, 1986, BEHAV NEURAL BIOL, V45, P275, DOI 10.1016/S0163-1047(86)80016-4
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Rodel HG, 2012, MAMM BIOL, V77, P441, DOI 10.1016/j.mambio.2012.04.002
   Schlolaut W, 2013, WORLD RABBIT SCI, V21, P145, DOI 10.4995/wrs.2013.1029
   Slotten HA, 2005, BEHAV BRAIN RES, V165, P91, DOI 10.1016/j.bbr.2005.06.046
   SUMMER TL, 1984, AM J PHYSIOL, V246, pR299
   VILLAFUERTE R, 1993, MAMMALIA, V57, P341, DOI 10.1515/mamm.1993.57.3.341
   WALLAGEDREES JM, 1989, Z SAUGETIERKD, V54, P22
NR 37
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0742-0528
EI 1525-6073
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PD OCT
PY 2016
VL 33
IS 8
BP 1120
EP 1128
DI 10.1080/07420528.2016.1191506
PG 9
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA DV9GV
UT WOS:000383249600017
PM 27305519
ER

PT J
AU Mohan, S
   Khan, D
   Moffett, RC
   McKillop, AM
   Flatt, PR
AF Mohan, S.
   Khan, D.
   Moffett, R. C.
   McKillop, A. M.
   Flatt, P. R.
TI Oxytocin: improves glucose homeostasis, beta cell proliferation and
   survival
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Meeting Abstract
C1 [Mohan, S.; Khan, D.; Moffett, R. C.; McKillop, A. M.; Flatt, P. R.] Univ Ulster, Sch Biomed Sci, Coleraine, Londonderry, North Ireland.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD OCT
PY 2016
VL 185
SU 7
MA P14
BP 379
EP 379
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV7QG
UT WOS:000383130800034
ER

PT J
AU Sharma, C
   Soni, A
   Soni, PK
   Verma, S
   Verma, A
   Gupta, A
AF Sharma, Chanderdeep
   Soni, Anjali
   Soni, Pawan K.
   Verma, Suresh
   Verma, Ashok
   Gupta, Amit
TI A Retrospective Case-Control Study Evaluating the Role of Mifepristone
   for Induction of Labor in Women with Previous Cesarean Section
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Pregnancy; Mifepristone; Induction of labor; Prior cesarean delivery
ID CHORIONIC TISSUE; EARLY-PREGNANCY; RU486; TERM
AB To investigate the role of "mifepristone" for induction of labor (IOL) in pregnant women with prior cesarean section (CS).
   In this retrospective study, all pregnant women with prior CS who received oral mifepristone (400 mg) for IOL (as per clear obstetric indications) [group 1] were compared with pregnant women with prior CS who had spontaneous onset of labor (SOL) [group 2], with respect to incidence of vaginal delivery, CS, duration of labor, and various maternal and fetal outcomes.
   During the study period, 72 women received mifepristone (group 1) for IOL and 346 had SOL (group 2). In group 1 after mifepristone administration, 40 (55.6 %) women had labor onset, and 24 (33.3 %) women had cervical ripening (Bishop Score aeyen 8) within 48 h. There were no statistically significant differences with respect to duration of labor (p value: 0.681), mode of delivery (i.e., normal delivery or CS-p value: 0.076 or 0.120, respectively), or maternal (blood loss or scar dehiscence/rupture uterus), or fetal outcomes (NICU admission) compared to women with previous CS with SOL (group 2). However, the need of oxytocin (p value 0.020) and dose of oxytocin requirement (p value 0.008) were more statistically significant in group 1.
   Mifepristone may be considered as an agent for IOL in women with prior CS.
C1 [Sharma, Chanderdeep; Soni, Anjali; Soni, Pawan K.; Verma, Suresh; Verma, Ashok; Gupta, Amit] Dr Rajendra Prasad Govt Med Coll Dr RPGMC Kangra, Dept OBG, Set 112, Kangra 176001, HP, India.
RP Sharma, C (reprint author), Dr Rajendra Prasad Govt Med Coll Dr RPGMC Kangra, Dept OBG, Set 112, Kangra 176001, HP, India.
EM cdsharma2006@gmail.com
CR [Anonymous], 2010, OBSTET GYNECOL, V116, P450
   Arulkumaran S, 2013, BEST PRACT RES CL OB, V27, P151, DOI 10.1016/j.bpobgyn.2013.01.001
   Berkane N, 2005, AM J OBSTET GYNECOL, V192, P114, DOI 10.1016/j.ajog.2004.05.084
   BROGDEN RN, 1993, DRUGS, V45, P384
   CHENG L, 1993, HUM REPROD, V8, P705
   CHENG LN, 1993, J CLIN ENDOCR METAB, V77, P873, DOI 10.1210/jc.77.3.873
   Chwalisz K, 1998, HUM REPROD, V13, P245, DOI 10.1093/humrep/13.2.245
   Dodd J, 2004, AUST NZ J OBSTET GYN, V44, P392, DOI 10.1111/j.1479-828X.2004.00258.x
   Edwards MS, 1996, CLIN OBSTET GYNECOL, V39, P469, DOI 10.1097/00003081-199606000-00020
   Elliott CL, 1998, OBSTET GYNECOL, V92, P804, DOI 10.1016/S0029-7844(98)00284-1
   GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436
   Giacalone PL, 1998, OBSTET GYNECOL, V92, P487, DOI 10.1016/S0029-7844(98)00225-7
   Hapangama D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002865.pub2
   Jozwiak M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009792.pub2
   LELAIDIER C, 1994, BRIT J OBSTET GYNAEC, V101, P501, DOI 10.1111/j.1471-0528.1994.tb13150.x
   Lelaidier C., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P91
   Li L, 1996, Zhonghua Fu Chan Ke Za Zhi, V31, P681
   McGill J, 2007, INT J GYNECOL OBSTET, V96, P80, DOI 10.1016/j.ijgo.2006.09.030
   Niino Y, 2011, BIOSCI TRENDS, V5, P139, DOI 10.5582/bst.2011.v5.4.139
   Stenlund PM, 1999, ACTA OBSTET GYN SCAN, V78, P793, DOI 10.1034/j.1600-0412.1999.780910.x
   Su H, 1996, Zhonghua Fu Chan Ke Za Zhi, V31, P676
   Timor-Tritsch IE, 2012, AM J OBSTET GYNECOL, V207, P14, DOI 10.1016/j.ajog.2012.03.007
   Wing DA, 2000, OBSTET GYNECOL, V96, P543, DOI 10.1016/S0029-7844(00)00947-9
   Zhang N, 1999, Zhonghua Fu Chan Ke Za Zhi, V34, P751
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 30
EP 37
DI 10.1007/s13224-015-0760-3
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200006
PM 27651574
ER

PT J
AU Vernekar, M
   Rajib, R
AF Vernekar, Manisha
   Rajib, Roy
TI Unscarred Uterine Rupture: A Retrospective Analysis
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Uterine rupture; Unscarred uterine rupture; Obstructed labor; Induction
   of labor; Instrumental delivery
ID PLACENTA-PERCRETA; UTERUS
AB Uterine rupture is a catastrophic obstetrical emergency associated with a significant feto-maternal morbidity and mortality. Many risk factors for uterine rupture, as well as a wide range of clinical presentations, have been identified.
   To analyze the frequency, predisposing factors, and maternal and fetal outcomes of uterine rupture.
   A retrospective analysis of cases of unscarred uterine rupture was conducted at the Department of Obstetrics and Gynecology, RIMS, Imphal from June 1, 2010 to June 30, 2012.
   Our analysis comprised 13 cases. Of these, 30.8 % were booked cases. Most of the cases (46.2 %) were Para 2. Uterine rupture occurred at term in 10 cases. The rupture occurred due to mismanaged labor (30.8 %), the use of oxytocin (23 %), instrumental delivery (15.4 %), obstructed labor (15.4 %), induction by prostaglandin gel (7.7 %), and placenta percreta (7.7 %). Maternal deaths and perinatal deaths were 30.8 and 53.8 %, respectively. Sub-total hysterectomy was done in 8 cases and in 1 patient laparotomy with repair was performed.
   Ruptured uterus causes a high risk in patients. An unscarred uterus can undergo rupture even without etiological or risk factors. The patients with mismanaged labor, grand multiparas, and obstructed prolonged labor must be managed by properly trained personnel at a tertiary care center in order to avoid the morbidity or mortality.
C1 [Vernekar, Manisha; Rajib, Roy] ESIC & MC, ESI PGIMSR, Dept Obstet & Gynaecol, Kolkata, India.
   [Vernekar, Manisha] Care Of Roy R, Pailan Pk Housing Project, Plot 34-1, Kolkata 700104, India.
RP Vernekar, M (reprint author), ESIC & MC, ESI PGIMSR, Dept Obstet & Gynaecol, Kolkata, India.; Vernekar, M (reprint author), Care Of Roy R, Pailan Pk Housing Project, Plot 34-1, Kolkata 700104, India.
EM manu_1486@yahoo.co.in
CR Ahmadi S, 2003, Gynecol Obstet Fertil, V31, P713, DOI 10.1016/S1297-9589(03)00212-1
   Akhtar Y, 2010, PROF MED J, V17, P314
   Dane B, 2009, J EMERG MED, V37, P393, DOI 10.1016/j.jemermed.2007.10.040
   Dow M, 2009, AM J PERINAT, V26, P739, DOI 10.1055/s-0029-1223287
   Esmans A, 2004, HUM REPROD, V19, P2401, DOI 10.1093/humrep/deh421
   Hofmeyr GJ, 2005, BJOG-INT J OBSTET GY, V112, P1221, DOI 10.1111/j.1471-0528.2005.00725.x
   Imseis HM, 1998, J REPROD MED, V43, P233
   Mazzone Michael E, 2006, WMJ, V105, P64
   Miller DA, 1997, OBSTET GYNECOL, V89, P671, DOI 10.1016/S0029-7844(97)00073-2
   Nahum GG, 2011, UTERINE RUPTURE PREG
   Rashmi Radhakrishnan G, 2001, J INDIAN MED ASSOC, p[99, 634]
   Rizwan N, 2011, J PAK MED ASSOC, V61, P322
   Turner MJ, 2002, BEST PRACT RES CL OB, V16, P69, DOI 10.1053/beog.2002.0256
NR 13
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 51
EP 54
DI 10.1007/s13224-015-0769-7
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200009
PM 27651577
ER

PT J
AU Kumar, KSS
   Shyam, S
   Batakurki, P
AF Kumar, K. S. Sunil
   Shyam, Sundar
   Batakurki, Pavitra
TI Carboprost Versus Oxytocin for Active Management of Third Stage of
   Labor: A Prospective Randomized Control Study
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Active management of third stage of labor; Carboprost; Oxytocin; Third
   stage of labor; Postpartum hemorrhage; Brasss V drape
ID POSTPARTUM HEMORRHAGE; PREVENT
AB Postpartum hemorrhage is the single largest and leading cause of maternal morbidity and mortality not only in developing countries but also in developed countries. The present study is an attempt to evaluate the scope of using prophylactic intramuscular carboprost tromethamine 125 mu g in comparison with intramuscular oxytocin 10 units for the active management of third stage of labor.
   Two hundred pregnant women at term with spontaneous onset of labor were included in the study and were randomly divided into 2 groups of 100 women each. Group A and group B were given injection oxytocin 10 units and injection carboprost tromethamine 125 mu g intramuscularly, respectively, at the time of delivery of anterior shoulder. The main outcome measures with respect to third stage of labor were: duration, blood loss by volume, difference in hemoglobin, need for additional oxytocics and side effects.
   Subjects who received carboprost tromethamine 125 mu g showed a significant reduction in duration of third stage of labor (p < 0.05) and blood loss (p < 0.01) when compared to the subjects who received oxytocin 10 units. Likelihood of occurrence of postpartum hemorrhage was reduced without significant side effects except for diarrhea. Additional need for other uterotonics after carboprost was significantly less compared to oxytocin.
   Intramuscular carboprost 125 mu g is a better cost-effective alternative as compared to 10 units intramuscular oxytocin in active management of third stage of labor.
C1 [Kumar, K. S. Sunil; Shyam, Sundar] SDM Coll Med Sci & Hosp, Dept OBGYN, Dharwad 580009, Karnataka, India.
   [Batakurki, Pavitra] Ashirwada Hosp, Dept OBGYN, MIG 226, Hubli, Karnataka, India.
RP Kumar, KSS (reprint author), SDM Coll Med Sci & Hosp, Dept OBGYN, Dharwad 580009, Karnataka, India.
EM drsuneelks@gmail.com
CR ABDELALEEM H, 1993, INT J GYNECOL OBSTET, V42, P247, DOI 10.1016/0020-7292(93)90219-M
   Anjaneyulu R, 1988, ACTA OBSTET GYNECOL, V145, P9
   Bai J, 2014, EXP THER MED, V7, P46, DOI 10.3892/etm.2013.1379
   Begley CM, 2011, COCHRANE DB SYST REV, V11
   Bhattacharya P, 1988, ACTA OBSTET GYNECO S, V145, pS13
   BUTTINO L, 1986, AM J PERINAT, V3, P241, DOI 10.1055/s-2007-999875
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Chelmow D, 2011, BMJ
   Gizzo S, 2013, REPROD SCI, V20, P1011, DOI 10.1177/1933719112468951
   Hofmeyr GJ, 2000, RECENT ADV OBSTET GY, P56
   International Confederation of Midwives International Federation of Obstetrics and Gynecology, 2007, INT J GYNECOL OBSTET, V97, P160
   Kamalajayaram V, 1994, J OBSTET GYNAECOL IN, V44, P393
   Leduc Dean, 2009, J Obstet Gynaecol Can, V31, P980
   Nordstrom L, 1997, BRIT J OBSTET GYNAEC, V104, P781, DOI 10.1111/j.1471-0528.1997.tb12020.x
   Park K, 2013, TXB PREVENTIVE SOCIA, P516
   Roach MK, 2013, AM J PERINAT, V30, P523, DOI 10.1055/s-0032-1329184
   Shah D, 2006, TXB POSTPARTUM HEMOR, P434
   Vaid A, 2009, ARCH GYNECOL OBSTET, V280, P893, DOI 10.1007/s00404-009-1019-y
   World Health Organization, 2007, WHO REC PREV POSTP H
NR 19
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 229
EP 234
DI 10.1007/s13224-016-0842-x
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200041
ER

PT J
AU Roy, P
   Sujatha, MS
   Bhandiwad, A
   Biswas, B
AF Roy, Priyankur
   Sujatha, M. S.
   Bhandiwad, Ambarisha
   Biswas, Bivas
TI Role of Tranexamic Acid in Reducing Blood Loss in Vaginal Delivery
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Blood loss; Maternal morbidity; Tranexamic acid
ID POSTPARTUM HEMORRHAGE; CESAREAN-SECTION
AB Anti-fibrinolytic agents are used to reduce obstetric blood loss as the fibrinolytic system is known to get activated after placental delivery.
   To evaluate the efficacy of parenteral tranexamic acid in reducing blood loss during normal labour and to compare it with the amount of blood loss in patients who received placebo in the third stage of labour.
   Patients with spontaneous labour or planned for induction of labour and fulfilling the inclusion criteria were recruited for the study. In each patient, the pre-delivery pulse rate, blood pressure, Hb gm% and PCV% were noted. Labour was monitored carefully using a partogram. The study group received Inj. Oxytocin and Inj. Tranexamic acid. The control group received Inj. Oxytocin and Placebo injection. Immediately after delivery of the baby, when all the liquor was drained, the patient was placed over a blood drape-a disposable conical, graduated plastic collection bag. The amount of blood collected in the blood drape was measured. Then the patient was given pre-weighed pads, which were weighed 2 h post-partum. The blood loss was measured by measuring the blood collected in the drape and by weighing the swabs before and after delivery.
   The total number of patients studied was 100-equally distributed in both the groups. The age group of the patients and BMI were comparable. There was a significant increase in the pulse rate and decrease in blood pressure in the control group as compared with the study group. The post-delivery haemoglobin and haematocrit were significantly reduced in the control group as compared to the study group. The mean blood loss at the end of 2 h was 105 ml in the study group and 252 ml in the control group. There was a significant increase in the usage of uterotonics and also in the need for blood transfusion in the control group; 12 % of the patients in the control group had to stay for more than 3 days compared to 2 % in the study group.
   Tranexamic acid injection, an antifibrinolytic agent when given prophylactically after the delivery of the baby, by intravenous route appears to reduce the blood loss and maternal morbidity during normal labour effectively.
C1 [Roy, Priyankur] JSS Med Coll & Hosp, Dept Obstet & Gynaecol, Mysore, Karnataka, India.
   [Sujatha, M. S.] JSS Univ, JSS Med Coll & Hosp, Dept OBG Unit 2, Mysore, Karnataka, India.
   [Bhandiwad, Ambarisha] JSS Univ, JSS Med Coll & Hosp, Dept OBG, Mysore, Karnataka, India.
   [Biswas, Bivas] Kings Mill Hosp, Dept Obstet & Gynaecol, Sutton In Ashfield, Notts, England.
RP Roy, P (reprint author), JSS Med Coll & Hosp, Dept Obstet & Gynaecol, Mysore, Karnataka, India.
EM priyankurroy@hotmail.com
CR As AK, 1996, BRIT J OBSTET GYNAEC, V103, P1250, DOI 10.1111/j.1471-0528.1996.tb09638.x
   ASTEDT B, 1987, SCAND J GASTROENTERO, V22, P22, DOI 10.3109/00365528709089756
   Gai MY, 2004, EUR J OBSTET GYN R B, V112, P154, DOI 10.1016/S0301-2115(03)00287-2
   Gokhan, 2011, ROUTINE PRACTICE USI
   Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2
   Lalonde A, 2006, INT J GYNECOL OBSTET, V94, P243, DOI 10.1016/j.ijgo.2006.04.016
   Leduc Dean, 2009, J Obstet Gynaecol Can, V31, P980
   Lethaby A, 2000, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000249
   Litch JA, 2004, PROGRAM APPROPRIATE, P132
   Mac Mullen NJ, 2005, MCN AM J, V30, P40
   Novikova N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007872.pub2
   Pattinson RC, 2006, SAVING MOTHERS 3 REP
   Peitsidis P, 2011, EXPERT OPIN PHARMACO, V12, P503, DOI 10.1517/14656566.2011.545818
   Sekhavat L, 2009, J MATERN-FETAL NEO M, V22, P72, DOI 10.1080/14767050802353580
   Soltani H, 2010, COCHRANE DB SYST REV, V4
   Tesseir V, 2004, J GYNECOL OBST BIO R, V33, P4529
   Yang H, 2001, Zhonghua Fu Chan Ke Za Zhi, V36, P590
NR 17
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 246
EP 250
DI 10.1007/s13224-016-0856-4
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200044
PM 27651612
ER

PT J
AU Akkenapally, PL
AF Akkenapally, Prasanna Latha
TI A Comparative Study of Misoprostol Only and Mifepristone Plus
   Misoprostol in Second Trimester Termination of Pregnancy
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Misoprostol; Mifepristone; Second trimester; Termination
ID RANDOMIZED-CONTROLLED-TRIAL; ABORTION; INTERVALS; OXYTOCIN
AB To compare the effectiveness, success rate and induction to abortion interval between administration of misoprostol only and mifepristone with misoprostol in second trimester abortions (14-20 weeks) .
   The study was conducted by dividing women approaching for second trimester termination, into two groups each consisting of 100 women. Group-I received only misoprostol; 600 mcg initial vaginal insertion followed by 400 mcg sublingually every 3 h until termination. Women in Group-II received mifepristone 200 mg and after 24 h started with 600 mcg misoprostol, per vaginal followed by 400 mcg sublingually till abortion was completed, up to a maximum of five doses in both groups.
   The success rate in Group-I was 89 %, whereas in Group-II it was 96 %. The mean induction abortion interval in Group-I was 10.67 +/- 3.96 h compared to Group-II which was significantly less 6.19 +/- 2.70 h (p value < 0.01). The mean dose of misoprostol in Group-I was 1610 +/- 511.18 mcg and in Group-II, it was lesser 1046 +/- 392.71 mcg (p value < 0.01). There was significant difference in the mean blood loss also, 97.20 +/- 36.35 ml in Group-I and 52.55 +/- 27.96 ml in Group-II. Also among the individual groups multigravidae and lower gestational age (< 17 weeks), women had lesser IAI as well as lesser misoprostol dose was required.
   Pretreatment with mifepristone significantly reduces the induction abortion interval and the misoprostol dose along with minimal blood loss.
C1 [Akkenapally, Prasanna Latha] Kamineni Acad Med Sci & Res Ctr, Dept OBG, Hyderabad, Telangana, India.
   [Akkenapally, Prasanna Latha] Jyothi Matern & Infertil Ctr, Plot 18, Hyderabad 500060, Andhra Pradesh, India.
RP Akkenapally, PL (reprint author), Kamineni Acad Med Sci & Res Ctr, Dept OBG, Hyderabad, Telangana, India.
EM drlatasri@gmail.com
FU population health services of India (PHSI)
FX thank Dr A Sreenivasa Rao, retired deputy civil surgeon, Family Planning
   Department, Government Maternity Hospital, Petlaburz, Hyderabad,
   Telangana, India. At present he is working in PHSI. I also thank
   population health services of India (PHSI) for supporting to conduct the
   study.
CR Borgatta L, 2011, CONTRACEPTION, V84, P4, DOI 10.1016/j.contraception.2011.02.005
   Creinin MD, 1999, CLIN GUIDE MED SURG, P91
   Dabash R, 2015, INT J GYNECOL OBSTET, V130, P40, DOI 10.1016/j.ijgo.2015.02.023
   Dickinson JE, 2014, OBSTET GYNECOL, V123, P1162, DOI 10.1097/AOG.0000000000000290
   Elami-Suzin M, 2013, OBSTET GYNECOL, V122, P815, DOI 10.1097/AOG.0b013e3182a2dcb7
   Garg Geetika, 2015, J Obstet Gynaecol India, V65, P111, DOI 10.1007/s13224-014-0605-5
   Heini JM, 2010, ACTA OBSTET GYNAECOL, V89, P1552
   Hou SP, 2010, INT J GYNECOL OBSTET, V111, P126, DOI 10.1016/j.ijgo.2010.06.008
   Kulier R, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002855.pub4
   Mentula M, 2011, HUM REPROD, V26, P2690, DOI 10.1093/humrep/der218
   Modak R, 2014, OPEN J OBSTET GYNAEC, V4, P751
   Nagaria Tripti, 2011, J Obstet Gynaecol India, V61, P659, DOI 10.1007/s13224-011-0118-4
   Ngoc Nguyen Thi Nhu, 2011, Obstet Gynecol, V118, P601, DOI 10.1097/AOG.0b013e318227214e
   SWAHN ML, 1988, BRIT J OBSTET GYNAEC, V95, P126, DOI 10.1111/j.1471-0528.1988.tb06840.x
   World Health Organization, 2011, UNS AB GLOB REG EST
   Wildschut H, 2011, COCHRANE DB SYST REV, V19
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 251
EP 257
DI 10.1007/s13224-016-0869-z
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200045
PM 27651613
ER

PT J
AU Ray, I
   Bhattacharya, R
   Chakraborty, S
   Bagchi, C
   Mukhopadhyay, S
AF Ray, Irene
   Bhattacharya, Ratneshwar
   Chakraborty, Somajita
   Bagchi, Chiranjib
   Mukhopadhyay, Sima
TI Role of Intravenous Tranexamic Acid on Caesarean Blood Loss: A
   Prospective Randomised Study
SO JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
LA English
DT Article
DE Tranexamic acid; Anti-fibrinolytics; Blood loss; Caesarean delivery;
   Post-partum haemorrhage
ID POSTPARTUM HEMORRHAGE; DELIVERY; SECTION; EFFICACY; TRIAL
AB Post-partum haemorrhage (PPH) is a major cause of maternal mortality globally. Tranexamic acid, an anti-fibrinolytic agent, is a novel approach in an attempt to prevent this dreadful complication. This study aims to document the efficacy of intravenous (IV) tranexamic acid in reducing blood loss during and after caesarean section (CS).
   In this prospective randomised placebo-controlled open-label study, 100 mothers scheduled for elective CS were randomly selected and divided into two groups (study and control) of 50 each. The study group received 1 g IV tranexamic acid and the control group received IV placebo. Following delivery, all mothers received ten units of oxytocin in 500 ml of normal saline.
   The mean intra-operative and post-partum blood loss were significantly lower in the study group than the control group: 499.11 +/- 111.2 and 59.93 +/- 12.5 ml versus 690.85 +/- 198.41 and 110.06 +/- 13.47 ml, respectively, (p < 0.001). Total blood loss was 30 % less in the study group (p < 0.001). Six mothers had PPH in the control group, while none in the study group. The difference between the pre-operative and post-operative haemoglobin levels was significantly less in the study group than the control group, 0.26 +/- 0.22 versus 0.99 +/- 0.48 g% (p < 0.001).There was no significant difference with respect to other haematological parameters. There was no added adverse effect or need for NICU admission in the study group.
   Pre-operative IV tranexamic acid significantly reduced blood loss during elective CS without any significant adverse effects.
C1 [Ray, Irene; Chakraborty, Somajita] Med Coll Kolkata, Dept Obstet & Gynaecol, Kolkata, W Bengal, India.
   [Bhattacharya, Ratneshwar] Icare Inst Med Sci & Res, Dept Med, Haldia, W Bengal, India.
   [Bhattacharya, Ratneshwar; Mukhopadhyay, Sima] Dr BC Roy Hosp, Haldia, W Bengal, India.
   [Bagchi, Chiranjib] Sch Trop Med, Dept Clin & Expt Pharmacol, Kolkata, W Bengal, India.
   [Mukhopadhyay, Sima] Icare Inst Med Sci & Res, Dept Obstet & Gynaecol, Haldia, W Bengal, India.
RP Ray, I (reprint author), Med Coll Kolkata, Dept Obstet & Gynaecol, Kolkata, W Bengal, India.
EM dr.ireneray@gmail.com
CR AbouZahr C, 1998, ANTEPARTUM POSTPARTU
   COMBS CA, 1991, OBSTET GYNECOL, V77, P77
   Gai MY, 2004, EUR J OBSTET GYN R B, V112, P154, DOI 10.1016/S0301-2115(03)00287-2
   Gungorduk K, 2011, AM J PERINAT, V28, P233, DOI 10.1055/s-0030-1268238
   Hofmeyr GJ, 2005, BJOG-INT J OBSTET GY, V112, P547, DOI 10.1111/j.1471-0528.2004.00512.x
   Magann EF, 2005, SOUTH MED J, V98, P681, DOI 10.1097/01.SMJ.0000163309.53317.B8
   Movafegh A, 2011, INT J GYNECOL OBSTET, V115, P224, DOI 10.1016/j.ijgo.2011.07.015
   Munn MB, 2001, OBSTET GYNECOL, V98, P386, DOI 10.1016/S0029-7844(01)01479-X
   Sekhavat L, 2009, J MATERN-FETAL NEO M, V22, P72, DOI 10.1080/14767050802353580
   Shakur H, 2010, TRIALS, V16, P40
   SVANBERG L, 1980, ACTA OBSTET GYN SCAN, V59, P127
   THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9
NR 12
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0971-9202
EI 0975-6434
J9 J OBSTET GYNECOL IND
JI J. Obstet. Gynecol. India
PD OCT
PY 2016
VL 66
SU 1
BP 347
EP 352
DI 10.1007/s13224-016-0915-x
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV6CK
UT WOS:000383018200060
PM 27651628
ER

PT J
AU Felten, A
   Reuter, M
AF Felten, A.
   Reuter, M.
TI How to clone a SNP? Oxytocin receptor single nucleotide polymorphism
   rs2268498: From association towards functionality
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD OCT
PY 2016
VL 101
BP 477
EP 477
DI 10.1016/j.paid.2016.05.133
PG 1
WC Psychology, Social
SC Psychology
GA DV5XF
UT WOS:000383003300143
ER

PT J
AU Melchers, M
AF Melchers, M.
TI The Genetics of Oxytocin and Social Cognition
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD OCT
PY 2016
VL 101
BP 499
EP 499
DI 10.1016/j.paid.2016.05.228
PG 1
WC Psychology, Social
SC Psychology
GA DV5XF
UT WOS:000383003300238
ER

PT J
AU Eriksen, JLK
   Melamed, A
   Clapp, MA
   Little, SE
   Zera, C
AF Eriksen, Jennifer L. Katz
   Melamed, Alexander
   Clapp, Mark A.
   Little, Sarah E.
   Zera, Chloe
TI Cesarean Delivery in Adolescents
SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY
LA English
DT Article
DE Pregnancy; Adolescents; Pregnancy in adolescence; Cesarean section;
   Obstetric delivery
ID MATERNAL AGE; MORBIDITY
AB Study Objective: To examine the effect of maternal age on indication for primary cesarean delivery in low-risk nulliparous women.
   Design: Retrospective cohort study.
   Setting: Urban academic tertiary care center.
   Participants: Nulliparous women younger than 35 years of age delivering vertex-presenting singletons at term.
   Interventions: Participants underwent spontaneous, operative or cesarean delivery.
   Main Outcome Measures: Mode of delivery, indication, and timing of cesarean delivery.
   Results: Adolescents were half as likely to undergo cesarean delivery overall (odds ratio [OR], 0.48; 95% confidence interval [CI], 0.43-0.54), and more than one-third less likely to undergo cesarean delivery in labor (OR, 0.59; 95% CI, 0.53-0.66). Adjustment for potential confounders did not alter the strength of these associations. Adolescents were half as likely to undergo cesarean delivery for failure to progress (OR, 0.49; 95% CI, 0.43-0.54). There was no difference in the odds of cesarean delivery for nonreassuring fetal status (OR, 0.91; 95% CI, 0.77-1.06), or genital herpes (OR, 1.44; 95% Cl, 0.57-3.68). Induction, macrosomia, oxytocin augmentation, and any labor complication were all associated with increased risk of cesarean delivery. There was no difference in the duration of second stage for adolescents who delivered by cesarean delivery compared with adults (240.0 vs 237.7 minutes; P = .84), but adolescents who delivered vaginally had a second stage that was one-third shorter than adults (62.5 vs 100.3 minutes; P < .001).
   Conclusion: Adolescents are half as likely to undergo primary cesarean delivery overall, and 40% less likely to undergo a primary cesarean delivery in labor, even after adjustment for multiple maternal, neonatal, and labor characteristics. This difference is not explained by differences in the duration of the second stage of labor.
C1 [Eriksen, Jennifer L. Katz; Melamed, Alexander; Clapp, Mark A.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.
   [Little, Sarah E.; Zera, Chloe] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Maternal Fetal Med, 75 Francis St, Boston, MA 02115 USA.
RP Eriksen, JLK (reprint author), Brigham & Womens Hosp, CWN 3,75 Francis St, Boston, MA 02115 USA.
EM jkatzeriksen@partners.org
CR Baicker K, 2006, HEALTH AFFAIR, V25, pW355, DOI 10.1377/hlthaff.25.w355
   Boyle A, 2013, OBSTET GYNECOL, V122, P33, DOI 10.1097/AOG.0b013e3182952242
   Hamilton BE, 2015, BIRTHS FINAL DATA 20
   KONJE JC, 1992, BRIT J OBSTET GYNAEC, V99, P969, DOI 10.1111/j.1471-0528.1992.tb13699.x
   Malabarey OT, 2012, J PEDIATR ADOL GYNEC, V25, P190, DOI 10.1016/j.jpag.2012.01.002
   Marshall NE, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.035
   Menacker F, 2005, NATL VITAL STAT REPO, V54
   MOERMAN ML, 1982, AM J OBSTET GYNECOL, V143, P528
   Penfield CA, 2011, AM J OBSTET GYNECOL, V204, pS219, DOI 10.1016/j.ajog.2010.10.566
   Silver RM, 2006, OBSTET GYNECOL, V107, P1226, DOI 10.1097/01.AOG.0000219750.79480.84
   Spong CY, 2012, OBSTET GYNECOL, V120, P1181, DOI [http://10.1097/AOG.0b013e3182704880, 10.1097/AOG.0b013e3182704880]
   Timofeev J, 2013, OBSTET GYNECOL, V122, P1184, DOI 10.1097/AOG.0000000000000017
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-3188
EI 1873-4332
J9 J PEDIATR ADOL GYNEC
JI J. Pediatr Adolesc. Gynecol.
PD OCT
PY 2016
VL 29
IS 5
BP 443
EP 447
DI 10.1016/j.jpag.2016.01.123
PG 5
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DV0EX
UT WOS:000382591900008
ER

PT J
AU Narita, K
   Murata, T
   Matsuoka, S
AF Narita, Kazumi
   Murata, Takuya
   Matsuoka, Satoshi
TI The ventromedial hypothalamus oxytocin induces locomotor behavior
   regulated by estrogen
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Ventromedial hypothalamus; Locomotor activity; Oxytocin; Oxytocin
   receptor; Estrogen; Estrus cycle
ID RECEPTOR MESSENGER-RNA; RAT-BRAIN; RUNNING ACTIVITY; GENE-EXPRESSION;
   SEXUAL-BEHAVIOR; MAMMARY-GLAND; BINDING-SITES; MOUSE STRAINS; NUCLEUS;
   CYCLE
AB Our previous studies demonstrated that excitation of neurons in the rat ventromedial hypothalamus (VMH) induced locomotor activity. An oxytocin receptor (Oxtr) exists in the VMH and plays a role in regulating sexual behavior. However, the role of Oxtr in the VMH in locomotor activity is not clear. In this study we examined the roles of oxytocin in the VMH in running behavior, and also investigated the involvement of estrogen in this behavioral change. Microinjection of oxytocin into the VMH induced a dose-dependent increase in the running behavior in male rats. The oxytocin-induced running activity was inhibited by simultaneous injection of Oxtrantagonist, (d(CH2)(1/5)Try(Me)(2),Om(8))-oxytocin. Oxytocin injection also induced running behavior in ovariectomized (OVX) female rats. Pretreatment of the OVX rats with estrogen augmented the oxytocin-induced running activity twofold, and increased the Oxtr mRNA in the VMH threefold. During the estrus cycle locomotor activity spontaneously increased in the dark period of proestrus. The Oxtr mRNA was up-regulated in the proestrus afternoon. Blockade of oxytocin neurotransmission by its antagonist before the onset of the dark period of proestrus decreased the following nocturnal locomotor activity. These findings demonstrate that Oxtr in the VMH is involved in the induction of running behavior and that estrogen facilitates this effect by means of Oxtr up regulation, suggesting the involvement of oxytocin in the locomotor activity of proestrus female rats. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Narita, Kazumi; Murata, Takuya; Matsuoka, Satoshi] Univ Fukui, Fac Med Sci, Dept Integrat & Syst Physiol, Matsuoka, Fukui 9101193, Japan.
RP Narita, K (reprint author), Univ Fukui, Fac Med Sci, Dept Integrat & Syst Physiol, Matsuoka, Fukui 9101193, Japan.
EM knarita@u-fukui.ac.jp; murata@u-fukui.ac.jp; smatsuok@u-fukui.ac.jp
FU JSPS KAKENHI [26670101, 15K08204]
FX This study was supported in part by a JSPS KAKENHI Grant Number 26670101
   and 15K08204.
CR ADAN RAH, 1995, ENDOCRINOLOGY, V136, P4022, DOI 10.1210/en.136.9.4022
   Bale TL, 1995, ADV EXP MED BIOL, V395, P269
   BALE TL, 1995, J NEUROSCI, V15, P5058
   BALE TL, 1995, ENDOCRINOLOGY, V136, P27, DOI 10.1210/en.136.1.27
   Bale TL, 2001, J NEUROSCI, V21, P2546
   Bosch OJ, 2008, P NATL ACAD SCI USA, V105, P17139, DOI 10.1073/pnas.0807412105
   Chan O, 2013, TRENDS ENDOCRIN MET, V24, P616, DOI 10.1016/j.tem.2013.08.005
   Correa SM, 2015, CELL REP, V10, P62, DOI 10.1016/j.celrep.2014.12.011
   Flanagan-Cato LM, 2011, FRONT NEUROENDOCRIN, V32, P124, DOI 10.1016/j.yfrne.2011.02.008
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gould BR, 2003, NEUROSCIENCE, V122, P155, DOI 10.1016/S0306-4522(03)00283-5
   Griffin GD, 2010, J COMP NEUROL, V518, P4531, DOI 10.1002/cne.22470
   Jarrett TM, 2006, NEUROPEPTIDES, V40, P161, DOI 10.1016/j.npep.2006.03.002
   KELLY J, 1980, BRAIN RES, V197, P1, DOI 10.1016/0006-8993(80)90430-8
   Kimura T, 2003, J MOL ENDOCRINOL, V30, P109, DOI 10.1677/jme.0.0300109
   King BA, 2006, PHYSIOL BEHAV, V87, P221, DOI 10.1016/j.physbeh.2005.10.007
   Kopp C, 2006, BEHAV BRAIN RES, V167, P165, DOI 10.1016/j.bbr.2005.09.001
   LUITEN P G M, 1987, Progress in Neurobiology (Oxford), V28, P1, DOI 10.1016/0301-0082(87)90004-9
   Maejima Y, 2015, NEUROENDOCRINOLOGY, V101, P35, DOI 10.1159/000371636
   MCCARTHY MM, 1994, NEUROENDOCRINOLOGY, V59, P432, DOI 10.1159/000126689
   Meddle SL, 2007, ENDOCRINOLOGY, V148, P5095, DOI 10.1210/en.2007-0615
   Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9
   Murata T, 2003, ENDOCR J, V50, P579, DOI 10.1507/endocrj.50.579
   Murata T, 2003, J VET MED SCI, V65, P707, DOI 10.1292/jvms.65.707
   Murata T, 2008, J VET MED SCI, V70, P1253, DOI 10.1292/jvms.70.1253
   Murata T, 2014, J REPROD DEVELOP, V60, P55, DOI 10.1262/jrd.2012-139
   Musatov S, 2007, P NATL ACAD SCI USA, V104, P2501, DOI 10.1073/pnas.0610787104
   Narita K, 1998, ANN NY ACAD SCI, V860, P556, DOI 10.1111/j.1749-6632.1998.tb09103.x
   Narita K, 2002, BEHAV BRAIN RES, V134, P275, DOI 10.1016/S0166-4328(02)00041-4
   NARITA K, 1993, BRAIN RES, V603, P243, DOI 10.1016/0006-8993(93)91243-L
   NARITA K, 1994, BRAIN RES, V642, P290, DOI 10.1016/0006-8993(94)90933-4
   Narita K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028136
   Nestor Casey C, 2014, Horm Mol Biol Clin Investig, V17, P109, DOI 10.1515/hmbci-2013-0050
   Noble EE, 2014, AM J PHYSIOL-REG I, V307, pR737, DOI 10.1152/ajpregu.00118.2014
   Paxinos G., 1986, RAT BRAIN STEREOTAXI
   Pedersen CA, 2006, NEUROSCIENCE, V139, P843, DOI 10.1016/j.neuroscience.2006.01.002
   Pfaff D, 2011, ENDOCRINOLOGY, V152, P1209, DOI 10.1210/en.2010-1007
   Rich ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098839
   Rosen GJ, 2008, NEUROSCIENCE, V155, P809, DOI 10.1016/j.neuroscience.2008.05.039
   Saffroy M, 2003, NEUROSCIENCE, V116, P761, DOI 10.1016/S0306-4522(02)00748-0
   Sherwin CM, 1998, ANIM BEHAV, V56, P11, DOI 10.1006/anbe.1998.0836
   TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0
   Uphouse L, 2015, BEHAV BRAIN RES, V282, P95, DOI 10.1016/j.bbr.2015.01.004
   VANTOL HHM, 1988, ENDOCRINOLOGY, V122, P945
   Veening JG, 2015, EUR J PHARMACOL, V753, P209, DOI 10.1016/j.ejphar.2014.07.045
   Xu Y, 2011, CELL METAB, V14, P453, DOI 10.1016/j.cmet.2011.08.009
   YOKAWA T, 1990, PHYSIOL BEHAV, V47, P1261, DOI 10.1016/0031-9384(90)90380-M
   Young LJ, 1997, J NEUROENDOCRINOL, V9, P859, DOI 10.1046/j.1365-2826.1997.00654.x
   Yuno K, 2014, J TOXICOL SCI, V39, P507
   Zingg HH, 1995, ADV EXP MED BIOL, V395, P395
NR 50
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD OCT 1
PY 2016
VL 164
BP 107
EP 112
DI 10.1016/j.physbeh.2016.05.047
PN A
PG 6
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DU6QM
UT WOS:000382339700014
PM 27237044
ER

PT J
AU Bahi, A
   Al Mansouri, S
   Al Maamari, E
AF Bahi, Amine
   Al Mansouri, Shamma
   Al Maamari, Elyazia
TI Nucleus accumbens lentiviral-mediated gain of function of the oxytocin
   receptor regulates anxiety- and ethanol-related behaviors in adult mice
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Anxiety; Elevated-plus maze; Lentivirus; LORR; Marbles burying;
   Open-field; Oxytocin receptor; Two-bottle choice
ID CONDITIONED-PLACE PREFERENCE; VOLUNTARY ALCOHOL-CONSUMPTION; CHRONIC
   PSYCHOSOCIAL STRESS; ELEVATED PLUS-MAZE; INDUCED PSYCHOMOTOR
   SENSITIZATION; VIVO GENE DELIVERY; PLASMINOGEN-ACTIVATOR;
   PARAVENTRICULAR NUCLEUS; VASOPRESSIN RECEPTOR; HYPOTHALAMIC NEURONS
AB Anxiety is believed to influence ethanol use human in alcoholics. Studies using laboratory animals suggested an interaction between oxytocin and the behavioral effects of ethanol. Our previous study implicated a potential role for the oxytocin receptor (OxtR) in regulating ethanol-conditioned place preference. Here, we examined anxiety and the behavioral responses to ethanol in C57BL/6 mice stereotaxically injected in the nucleus accumbens (NAcc) with lentiviral vectors expressing an empty vector (Mock) or the OxtR cDNA. For anxiety we used the elevated-plus maze, the open-field and the marble-burying tests and for ethanol we used the two-bottle choice paradigm, the wire-hanging and ethanol-induced loss-of-righting-reflex tests. We found that, compared to Mock, OxtR overexpression led to anxiolytic-like behavior without altering spontaneous locomotor activity. Most importantly, we found that, relative to Mock controls, increased expression of the OxtR in the NAcc led to decreased ethanol consumption and preference in the two-bottle choice protocol and increased resistance to ethanol-induced sedation. We also compared the consequence of OxtR modulation on the consumption and preference of saccharin and quinine and found that the two experimental groups did not differ for any tastant. These results provide further evidence that the oxytocin system contributes to the regulation of ethanol drinking and sensitivity and position OxtR as a central molecular mediator of ethanol's effects within the mesolimbic system. Taken together, the current findings suggest that OxtR manipulation may be a relevant strategy to address ethanol use disorders. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Bahi, Amine; Al Mansouri, Shamma; Al Maamari, Elyazia] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Anat, Al Ain, U Arab Emirates.
RP Bahi, A (reprint author), United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Anat, Al Ain, U Arab Emirates.
EM amine.bahi@gmail.com
FU United Arab Emirates University [NP/13/05, 31M082]
FX The author would like to acknowledge Prof. Jean-Luc Dreyer for the
   generous donation of the lentiviral vectors used in the current study.
   The authors are grateful to Mr. Mohamed Elwasila and Mr. Mohamed
   Shafiullah for their technical assistance and Dr. Mahmoud Hag Ali from
   the Animal Research Facility for his suggestions on animal care and
   welfare. The 1st author received salary and research funding from the
   United Arab Emirates University (Grants No. NP/13/05 and 31M082). The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al Ameri M, 2014, BRAIN RES, V1583, P122, DOI 10.1016/j.brainres.2014.07.051
   Al Maamari E, 2014, DRUG DES DEV THER, V8, P1391, DOI 10.2147/DDDT.S68636
   Al Mansouri S, 2014, PHARMACOL BIOCHEM BE, V124, P260, DOI 10.1016/j.pbb.2014.06.025
   Bahi A, 2005, EUR J NEUROSCI, V21, P3415, DOI 10.1111/j.1460-9568.2005.04157.x
   Bahi A, 2004, EUR J NEUROSCI, V20, P3473, DOI 10.1111/j.1460-9568.2004.03771.x
   Bahi A, 2004, EUR J NEUROSCI, V19, P1621, DOI 10.1111/j.1460-9568.2004.03260.x
   Bahi A, 2008, NEUROPSYCHOPHARMACOL, V33, P2726, DOI 10.1038/sj.npp.1301668
   Bahi A, 2008, PSYCHOPHARMACOLOGY, V199, P169, DOI 10.1007/s00213-008-1164-1
   Bahi A, 2015, PHYSIOL BEHAV, V151, P189, DOI 10.1016/j.physbeh.2015.07.012
   Bahi A, 2015, PHYSIOL BEHAV, V139, P321, DOI 10.1016/j.physbeh.2014.11.046
   Bahi A, 2014, ALCOHOL, V48, P677, DOI 10.1016/j.alcohol.2014.06.008
   Bahi A, 2014, ALCOHOL CLIN EXP RES, V38, P2369, DOI 10.1111/acer.12503
   Bahi A, 2014, PHYSIOL BEHAV, V135, P119, DOI 10.1016/j.physbeh.2014.06.003
   Bahi A, 2014, DRUG DES DEV THER, V8, P627, DOI 10.2147/DDDT.S63088
   Bahi A, 2014, PSYCHOPHARMACOLOGY, V231, P367, DOI 10.1007/s00213-013-3243-1
   Bahi A, 2013, NEUROPSYCHOPHARMACOL, V38, P2109, DOI 10.1038/npp.2012.122
   Bahi A, 2013, EUR J NEUROSCI, V38, P2328, DOI 10.1111/ejn.12228
   Bahi A, 2013, STRESS, V16, P441, DOI 10.3109/10253890.2012.754419
   Bahi A, 2013, PSYCHOPHARMACOLOGY, V228, P85, DOI 10.1007/s00213-013-3019-7
   Bahi A, 2013, PEPTIDES, V43, P48, DOI 10.1016/j.peptides.2013.02.008
   Bahi A, 2013, PHARMACOL BIOCHEM BE, V105, P83, DOI 10.1016/j.pbb.2013.01.023
   Bahi A, 2012, EUR NEUROPSYCHOPHARM, V22, P672, DOI 10.1016/j.euroneuro.2012.01.008
   Bahi A, 2012, PSYCHOPHARMACOLOGY, V222, P141, DOI 10.1007/s00213-011-2630-8
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Blume A, 2008, EUR J NEUROSCI, V27, P1947, DOI 10.1111/j.1460-9568.2008.06184.x
   Bolton J, 2006, J NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98
   Bowen MT, 2015, P NATL ACAD SCI USA, V112, P3104, DOI 10.1073/pnas.1416900112
   Boyce-Rustay JM, 2008, BEHAV BRAIN RES, V186, P133, DOI 10.1016/j.bbr.2007.07.031
   BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8
   Brunell Steven C, 2005, Alcohol Clin Exp Res, V29, P1641, DOI 10.1097/01.alc.0000179382.64752.13
   CAPLAN MA, 1986, PHARMACOL BIOCHEM BE, V24, P271, DOI 10.1016/0091-3057(86)90350-3
   CAPPELL H, 1972, Q J STUD ALCOHOL, V33, P33
   Coffey CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053991
   DEKEYZER Y, 1994, FEBS LETT, V356, P215, DOI 10.1016/0014-5793(94)01268-7
   dela Pena IJI, 2014, AM J DRUG ALCOHOL AB, V40, P75, DOI 10.3109/00952990.2013.846349
   Figueira RJ, 2008, BEHAV NEUROSCI, V122, P618, DOI 10.1037/0735-7044.122.3.618
   Paxinos G., 1996, MOUSE BRAIN STEREOTA
   Funk D, 2004, PSYCHOPHARMACOLOGY, V176, P82, DOI 10.1007/s00213-004-1859-x
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Grippo AJ, 2009, PSYCHONEUROENDOCRINO, V34, P1542, DOI 10.1016/j.psyneuen.2009.05.017
   Hayton SJ, 2012, ALCOHOL CLIN EXP RES, V36, P594, DOI 10.1111/j.1530-0277.2011.01668.x
   Henniger MSH, 2002, NEUROPSYCHOPHARMACOL, V26, P729, DOI 10.1016/S0893-133X(01)00408-0
   Hoyle CHV, 1999, BRAIN RES, V848, P1, DOI 10.1016/S0006-8993(99)01975-7
   Johansson A, 2012, PSYCHONEUROENDOCRINO, V37, P1546, DOI 10.1016/j.psyneuen.2012.02.009
   Kaluz S, 1996, GENE, V172, P313, DOI 10.1016/0378-1119(96)00195-3
   Klenerova V, 2010, NEUROENDOCRINOL LETT, V31, P622
   Klenerova V, 2009, NEUROENDOCRINOL LETT, V30, P335
   KOVACS GL, 1987, PHARMACOL BIOCHEM BE, V26, P57, DOI 10.1016/0091-3057(87)90533-8
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Lee HJ, 2008, ENDOCRINOLOGY, V149, P3256, DOI 10.1210/en.2007-1710
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   Logrip ML, 2012, ADDICT BIOL, V17, P920, DOI 10.1111/j.1369-1600.2012.00460.x
   Mak P, 2012, J PSYCHOPHARMACOL, V26, P532, DOI 10.1177/0269881111416687
   Marchesi C, 1997, PROG NEURO-PSYCHOPH, V21, P797, DOI 10.1016/S0278-5846(97)00080-8
   Matthews DB, 2008, ALCOHOL, V42, P469, DOI 10.1016/j.alcohol.2008.05.001
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   MERIKANGAS KR, 1994, PSYCHOL MED, V24, P69
   MURASAWA S, 1995, J BIOL CHEM, V270, P20042
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Overstreet DH, 2007, ALCOHOL CLIN EXP RES, V31, P1473, DOI 10.1111/j.1530-0277.2007.00445.x
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Peters S, 2013, ADDICT BIOL, V18, P66, DOI 10.1111/adb.12001
   Peters S. T., 2016, ADDICT BIOL
   PUCILOWSKI O, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90067-1
   Ragnauth AK, 2004, NEUROENDOCRINOLOGY, V80, P92, DOI 10.1159/000081844
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Rose JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083852
   SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P1723
   Silva SM, 2002, BRAIN RES, V925, P76, DOI 10.1016/S0006-8993(01)03261-9
   Sivukhina EV, 2006, HORM METAB RES, V38, P382, DOI 10.1055/s-2006-944522
   SOUSA N, 1995, ALCOHOL CLIN EXP RES, V19, P879, DOI 10.1111/j.1530-0277.1995.tb00962.x
   Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI 10.1007/BF02246268
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   SZABO G, 1987, ALCOHOL ALCOHOLISM, V22, P71
   SZABO G, 1985, ALCOHOL, V2, P567, DOI 10.1016/0741-8329(85)90082-5
   Tambs K, 1997, BEHAV GENET, V27, P241, DOI 10.1023/A:1025662114352
   Williams SK, 2009, NEUROTOXICOL TERATOL, V31, P291, DOI 10.1016/j.ntt.2009.06.001
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
NR 80
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD OCT 1
PY 2016
VL 164
BP 249
EP 258
DI 10.1016/j.physbeh.2016.06.009
PN A
PG 10
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DU6QM
UT WOS:000382339700030
PM 27306084
ER

PT J
AU Putnam, PT
   Roman, JM
   Zimmerman, PE
   Gothard, KM
AF Putnam, P. T.
   Roman, J. M.
   Zimmerman, P. E.
   Gothard, K. M.
TI Oxytocin enhances gaze-following responses to videos of natural social
   behavior in adult male rhesus monkeys
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Gaze following; Rhesus; Social; Natural behavior; Primate
ID AUTISM SPECTRUM DISORDERS; SUPERIOR TEMPORAL SULCUS; MACAQUE
   MACACA-MULATTA; FACIAL EXPRESSIONS; JOINT ATTENTION; AMYGDALA;
   COGNITION; RECEPTOR; NEURONS; HUMANS
AB Gaze following is a basic building block of social behavior that has been observed in multiple species, including primates. The absence of gaze following is associated with abnormal development of social cognition, such as in autism spectrum disorders (ASD). Some social deficits in ASD, including the failure to look at eyes and the inability to recognize facial expressions, are ameliorated by intranasal administration of oxytocin (IN-OT). Here we tested the hypothesis that IN-OT might enhance social processes that require active engagement with a social partner, such as gaze following. Alternatively, IN-OT may only enhance the perceptual salience of the eyes, and may not modify behavioral responses to social signals. To test this hypothesis, we presented four monkeys with videos of conspecifics displaying natural behaviors. Each video was viewed multiple times before and after the monkeys received intranasally either 50 IU of OT or saline. We found that despite a gradual decrease in attention to the repeated viewing of the same videos (habituation), IN-OT consistently increased the frequency of gaze following saccades. Further analysis confirmed that these behaviors did not occur randomly, but rather predictably in response to the same segments of the videos. These findings suggest that in response to more naturalistic social stimuli IN-OT enhances the propensity to interact with a social partner rather than merely elevating the perceptual salience of the eyes. In light of these findings, gaze following may serve as a metric for pro-social effects of oxytocin that target social action more than social perception. (C) 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
C1 [Putnam, P. T.; Roman, J. M.; Zimmerman, P. E.; Gothard, K. M.] Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.
RP Putnam, PT (reprint author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.
EM putnampt@gmail.com
FU NIH/NIMH [P50MH100023]; Undergraduate Biology Research Program;
   Neuroscience and Cognitive Science Program at the University of Arizona
FX Supported by: NIH/NIMH - P50MH100023 supported the work of the authors;
   The Undergraduate Biology Research Program and the Neuroscience and
   Cognitive Science Program at the University of Arizona supported the
   work of the undergraduate students.
CR Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Chevallier C, 2012, TRENDS COGN SCI, V16, P231, DOI 10.1016/j.tics.2012.02.007
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Dal Monte O., 2014, FRONT NEUROSCI, V8
   Dawson G, 1998, J AUTISM DEV DISORD, V28, P479, DOI 10.1023/A:1026043926488
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ebitz RB, 2013, P NATL ACAD SCI USA, V110, P11630, DOI 10.1073/pnas.1305230110
   Emery NJ, 1997, J COMP PSYCHOL, V111, P286
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hopkins W.D., 2014, SCI REP, P4
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Iidaka T, 2012, NEUROSCI LETT, V510, P154, DOI 10.1016/j.neulet.2012.01.029
   INSEL TR, 1993, J NEUROENDOCRINOL, V5, P619, DOI 10.1111/j.1365-2826.1993.tb00531.x
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Kamphuis S, 2009, EUR J NEUROSCI, V29, P1732, DOI 10.1111/j.1460-9568.2009.06730.x
   KITT CA, 1987, BRAIN RES, V406, P192, DOI 10.1016/0006-8993(87)90783-9
   Kliemann D, 2012, J NEUROSCI, V32, P9469, DOI 10.1523/JNEUROSCI.5294-11.2012
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Materna S, 2008, J COGNITIVE NEUROSCI, V20, P108, DOI 10.1162/jocn.2008.20008
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Mosher CP, 2011, BEHAV NEUROSCI, V125, P639, DOI 10.1037/a0024264
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Parr LA, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00278
   Parr LA, 2013, PSYCHONEUROENDOCRINO, V38, P1748, DOI 10.1016/j.psyneuen.2013.02.011
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Roy A, 2014, SOC COGN AFFECT NEUR, V9, P209, DOI 10.1093/scan/nss123
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Scott-Van Zeeland AA, 2010, AUTISM RES, V3, P53, DOI 10.1002/aur.122
   Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Shepherd SV, 2009, P NATL ACAD SCI USA, V106, P9489, DOI 10.1073/pnas.0900419106
   Shepherd S.V., 2010, FRONT INTEGR NEUROSC, V4
   Simpson EA, 2014, P NATL ACAD SCI USA, V111, P6922, DOI 10.1073/pnas.1402471111
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Tsao DY, 2003, NAT NEUROSCI, V6, P989, DOI 10.1038/nn1111
   Unal CT, 2015, J NEUROSCI, V35, P853, DOI 10.1523/JNEUROSCI.2706-14.2015
   Walum H., 2015, BIOL PSYCHIAT
   Xu-Wilson M, 2009, EXP BRAIN RES, V196, P475, DOI 10.1007/s00221-009-1879-1
   Yatawara C.J., 2015, MOL PSYCHIAT
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 2015, NEUROPSYCHOPHARMACOL, V40, P243, DOI 10.1038/npp.2014.186
   Young LJ, 1999, J NEUROENDOCRINOL, V11, P291
NR 52
TC 1
Z9 1
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD OCT
PY 2016
VL 72
BP 47
EP 53
DI 10.1016/j.psyneuen.2016.05.016
PG 7
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DV0FY
UT WOS:000382594600006
PM 27343726
ER

PT J
AU Bernaerts, S
   Berra, E
   Wenderoth, N
   Alaerts, K
AF Bernaerts, Sylvie
   Berra, Emmely
   Wenderoth, Nicole
   Alaerts, Kaat
TI Influence of oxytocin on emotion recognition from body language: A
   randomized placebo-controlled trial
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Emotion recognition; Point light displays; Biological motion;
   Mirror system
ID BIOLOGICAL MOTION PERCEPTION; SUPERIOR TEMPORAL SULCUS; MIRROR NEURONS;
   SIMULATION; HUMANS; AUTISM; BRAIN; FACES; GAZE; EYE
AB The neuropeptide 'oxytocin' (OT) is known to play a pivotal role in a variety of complex social behaviors by promoting a prosocial attitude and interpersonal bonding. One mechanism by which OT is hypothesized, to promote prosocial behavior is by enhancing the processing of socially relevant information from the environment. With the present study, we explored to what extent OT can alter the 'reading' of emotional body language as presented by impoverished biological motion point light displays (PLDs). To do so, a double-blind between-subjects randomized placebo-controlled trial was conducted, assessing performance on a bodily emotion recognition task in healthy adult males before and after a single-dose of intranasal OT (24 IU). Overall, a single-dose of OT administration had a significant effect of medium size on emotion recognition from body language. OT-induced improvements in emotion recognition were not differentially modulated by the emotional valence of the presented stimuli (positive versus negative) and also, the overall tendency to label an observed emotional state as 'happy' (positive) or 'angry' (negative) was not modified by the administration of OT. Albeit moderate, the present findings of OT-induced improvements in bodily emotion recognition from whole-body PLD provide further support for a link between OT and the processing of socio-communicative cues originating from the body of others. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Bernaerts, Sylvie; Berra, Emmely; Alaerts, Kaat] Katholieke Univ Leuven, Dept Rehabil Sci, Res Grp Neuromotor Rehabil, Leuven, Belgium.
   [Wenderoth, Nicole] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Inst Human Movement Sci & Sport, Neural Control Movement Lab, Zurich, Switzerland.
RP Bernaerts, S (reprint author), Katholieke Univ Leuven, Dept Rehabil Sci, Res Grp Neuromotor Rehabil, Leuven, Belgium.
EM sylvie.bernaerts@kuleuven.be; emmely.berra@student.kuleuven.be;
   nicole.wenderoth@hest.ethz.ch; kaat.alaerts@faber.kuleuven.be
FU Flanders Fund for Scientific Research (FWO) [KAN 1506716N, KAN 1521313N,
   G.0401.12]; Society in Science - ETH Zurich; Marguerite-Marie Delacroix
   foundation
FX This research was supported by grants from the Flanders Fund for
   Scientific Research (FWO projects KAN 1506716N, KAN 1521313N, &
   G.0401.12) and the Branco Weiss fellowship of the Society in Science -
   ETH Zurich granted to K.A. S.B. is supported by a fund of the
   Marguerite-Marie Delacroix foundation.
CR Alaerts K, 2014, SOC COGN AFFECT NEUR, V9, P1589, DOI 10.1093/scan/nst156
   Alaerts K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020989
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Avenanti A, 2013, CEREB CORTEX, V23, P570, DOI 10.1093/cercor/bhs040
   Bolling DZ, 2013, BRAIN TOPOGR, V26, P315, DOI 10.1007/s10548-012-0253-y
   Bos PA, 2015, NEUROIMAGE, V113, P217, DOI 10.1016/j.neuroimage.2015.03.049
   Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671
   Carruthers P., 1996, THEORIES THEORIES MI
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Cohen J., 1988, STAT POWER ANAL BEHA
   Daughters K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145104
   Davies M., 1995, MENTAL SIMULATION EV
   De Coster L, 2014, PSYCHONEUROENDOCRINO, V50, P220, DOI 10.1016/j.psyneuen.2014.08.021
   Domes G, 2013, PSYCHOL MED, V43, P1747, DOI 10.1017/S0033291712002565
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Galbally M, 2011, HARVARD REV PSYCHIAT, V19, P1, DOI 10.3109/10673229.2011.549771
   Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002
   Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5
   Gallese V, 2009, PSYCHOANAL DIALOGUES, V19, P519, DOI 10.1080/10481880903231910
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Grossman ED, 2005, VISION RES, V45, P2847, DOI 10.1016/j.visres.2005.05.027
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Harms MB, 2010, NEUROPSYCHOL REV, V20, P290, DOI 10.1007/s11065-010-9138-6
   Hurlemann R, 2016, BIOL PSYCHIAT, V79, P185, DOI 10.1016/j.biopsych.2015.05.013
   Iacoboni M, 2001, P NATL ACAD SCI USA, V98, P13995, DOI 10.1073/pnas.241474598
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Kaiser MD, 2012, DEV COGN NEUROS-NETH, V2, P25, DOI 10.1016/j.dcn.2011.05.005
   Kendrick KM, 2000, EXP PHYSIOL, V85, p111S, DOI 10.1111/j.1469-445X.2000.tb00014.x
   Keri S, 2009, COGN AFFECT BEHAV NE, V9, P237, DOI 10.3758/CABN.9.3.237
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Nackaerts E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044473
   Nave G, 2015, PERSPECT PSYCHOL SCI, V10, P772, DOI 10.1177/1745691615600138
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Pelphrey KA, 2005, CEREB CORTEX, V15, P1866, DOI 10.1093/cercor/bhi064
   Perry A, 2010, PSYCHONEUROENDOCRINO, V35, P1446, DOI 10.1016/j.psyneuen.2010.04.011
   Prince W., 2005, PERSPECTIVES IMITATI, P141
   Redcay E, 2008, NEUROSCI BIOBEHAV R, V32, P123, DOI 10.1016/j.neubiorev.2007.06.004
   Saygin AP, 2007, BRAIN, V130, P2452, DOI 10.1093/brain/awm162
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Sinigaglia C, 2010, J ANAL PSYCHOL, V55, P3, DOI 10.1111/j.1468-5922.2009.01821.x
   Strauss GP, 2015, SCHIZOPHR RES, V162, P52, DOI 10.1016/j.schres.2015.01.022
   Tollenaar MS, 2013, PSYCHONEUROENDOCRINO, V38, P1797, DOI 10.1016/j.psyneuen.2013.02.018
   Troje NF, 2006, CURR BIOL, V16, P821, DOI 10.1016/j.cub.2006.03.022
   van Kemenade BM, 2012, J COGNITIVE NEUROSCI, V24, P896, DOI 10.1162/jocn_a_00194
   Vander Wyk BC, 2012, DEV COGN NEUROS-NETH, V2, P409, DOI 10.1016/j.dcn.2012.04.004
   Vonck S, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00438
   Wigton R, 2015, J PSYCHIATR NEUROSCI, V40, pE1, DOI 10.1503/jpn.130289
   Xu L, 2015, PSYCHONEUROENDOCRINO, V62, P352, DOI 10.1016/j.psyneuen.2015.09.002
NR 52
TC 0
Z9 0
U1 24
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD OCT
PY 2016
VL 72
BP 182
EP 189
DI 10.1016/j.psyneuen.2016.07.002
PG 8
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DV0FY
UT WOS:000382594600024
PM 27442997
ER

PT J
AU Sanchez-Vidana, DI
   Chan, NMJ
   Chan, AHL
   Hui, KKY
   Lee, S
   Chan, HY
   Law, YS
   Sze, MY
   Tsui, WCS
   Fung, TKH
   Lau, BWM
   Lai, CYY
AF Sanchez-Vidana, Dalinda Isabel
   Chan, Ngai-Man Jackie
   Chan, Alan H. L.
   Hui, Katy K. Y.
   Lee, Sylvia
   Chan, Hoi-Yi
   Law, Yuen Shan
   Sze, Mei Yi
   Tsui, Wai-Ching Sarah
   Fung, Timothy K. H.
   Lau, Benson Wui-Man
   Lai, Cynthia Y. Y.
TI REPEATED TREATMENT WITH OXYTOCIN PROMOTES HIPPOCAMPAL CELL
   PROLIFERATION, DENDRITIC MATURATION AND AFFECTS SOCIO-EMOTIONAL BEHAVIOR
SO NEUROSCIENCE
LA English
DT Article
DE oxytocin; hippocampal cell proliferation; neurogenesis; dendritic
   complexity; depression-like behaviors; anxiety-like behaviors
ID DEPRESSION-LIKE BEHAVIOR; ADULT NEUROGENESIS; SOCIAL-BEHAVIOR;
   MATING-BEHAVIOR; DENTATE GYRUS; OPEN-FIELD; STRESS; CORTICOSTERONE;
   RATS; ANXIETY
AB Rewarding social behaviors including positive social interactions and sexual behaviors are shown to regulate adult neurogenesis, but the underlying biological mechanisms remain elusive. Oxytocin, a neurohypophysial hormone secreted after exposure to social interaction or sexual behaviors, has a profound role in the formation of social bonding and regulation of emotional distress. While the acute effect of oxytocin was usually studied, relatively scarce evidence showed the behavioral consequence of repeated oxytocin treatment. The purpose of the current study was to investigate the effect of repeated oxytocin treatment on hippocampal cell proliferation, dendritic maturation of new born neurons and social/emotional behaviors. Adult male Sprague-Dawley rats received treatment with either vehicle or oxytocin (1 mg/kg) daily for two weeks. Behavioral tests revealed that oxytocin increased social behaviors and reduced the anxiety-and depression-like behaviors. Cell proliferation, differentiation and the dendritic complexity of new born neurons in the hippocampus were promoted by oxytocin treatment. Depression-and anxiety-like behaviors were induced by repeated treatment of corticosterone (40 mg/kg) for two weeks while oxytocin treatment reversed the behavioral disturbances. Suppression of cell proliferation caused by corticosterone was reverted by oxytocin treatment in which cell proliferation, cell differentiation, and dendritic complexity increased. The present findings reveal that oxytocin not only enhances cell proliferation, but also promotes the development of the new neurons which is associated with the induction of positive emotional and social behaviors. The results also suggest that oxytocin may be a potential therapeutic agent for treatment of emotional and social dysfunction. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Sanchez-Vidana, Dalinda Isabel; Chan, Ngai-Man Jackie; Chan, Alan H. L.; Hui, Katy K. Y.; Lee, Sylvia; Chan, Hoi-Yi; Law, Yuen Shan; Sze, Mei Yi; Tsui, Wai-Ching Sarah; Fung, Timothy K. H.; Lau, Benson Wui-Man; Lai, Cynthia Y. Y.] Hong Kong Polytech Univ, Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.
RP Lau, BWM (reprint author), Hong Kong Polytech Univ, Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.
EM benson.lau@polyu.edu.hk
OI LAI, Yuen Yi Cynthia/0000-0001-6032-7089
FU Large Equipment Fund; Hong Kong Polytechnic University [1.51.27.DD6B];
   ECS, University Grant Council, H.K. [0112876]
FX The study was supported by the Large Equipment Fund, The Hong Kong
   Polytechnic University (1.51.27.DD6B), and ECS, University Grant
   Council, H.K. (0112876) to Lau B.W.
CR Airan RD, 2007, SCIENCE, V317, P819, DOI 10.1126/science.1144400
   Altunkaynak BZ, 2011, NEUROQUANTOLOGY, V10
   Andrews MH, 2012, ENDOCRINOLOGY, V153, P200, DOI 10.1210/en.2011-1434
   ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   Becker A, 1999, PSYCHOPHARMACOLOGY, V144, P333, DOI 10.1007/s002130051015
   Bessa JM, 2009, MOL PSYCHIATR, V14, P764, DOI 10.1038/mp.2008.119
   Blair KA, 2004, J SCHOOL PSYCHOL, V42, P419, DOI 10.1016/j.jsp.2004.10.002
   Brummelte S, 2006, HORM BEHAV, V50, P370, DOI 10.1016/j.yhbeh.2006.04.008
   CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0
   Chen Y-L, 2015, HONG KONG J OCCUP TH
   Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822
   Eisch AJ, 2008, J NEUROSCI, V28, P11785, DOI 10.1523/JNEUROSCI.3798-08.2008
   Eliava M, 2016, NEURON, V89, P1291, DOI 10.1016/j.neuron.2016.01.041
   Gamberini MT, 2015, J ETHNOPHARMACOL, V168, P45, DOI 10.1016/j.jep.2015.03.053
   Gregus A, 2005, BEHAV BRAIN RES, V156, P105, DOI 10.1016/j.bbr.2004.05.013
   Gutierrez H, 2007, J NEUROSCI METH, V163, P24, DOI 10.1016/j.jneumeth.2007.02.002
   Hattiangady B, 2010, HIPPOCAMPUS, V20, P97, DOI 10.1002/hipo.20594
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hillerer KM, 2014, HIPPOCAMPUS, V24, P673, DOI 10.1002/hipo.22258
   Jafarzadeh N, 2014, NEUROSCI LETT, V564, P105, DOI 10.1016/j.neulet.2014.02.012
   Jurek B, 2015, J NEUROSCI, V35, P12248, DOI 10.1523/JNEUROSCI.1345-14.2015
   Kalynchuk LE, 2004, BEHAV NEUROSCI, V118, P1365, DOI 10.1037/0735-7044.118.6.1365
   Kikusui T, 2006, PHILOS T R SOC B, V361, P2215, DOI 10.1098/rstb.2006.1941
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lau BWM, 2011, J SEX MED, V8, P1390, DOI 10.1111/j.1743-6109.2010.02081.x
   Lau BWM, 2011, CELL TRANSPLANT, V20, P871, DOI 10.3727/096368910X539065
   Lau BW, 2013, CHINESE SCI BULL, V58, P3188
   Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Lieberwirth C, 2012, HORM BEHAV, V62, P357, DOI 10.1016/j.yhbeh.2012.03.005
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Lussier AL, 2013, NEUROPHARMACOLOGY, V71, P174, DOI 10.1016/j.neuropharm.2013.04.012
   Mak GK, 2007, NAT NEUROSCI, V10, P1003, DOI 10.1038/nn1928
   Malberg JE, 2004, J PSYCHIATR NEUROSCI, V29, P196
   Matsuzaki M, 2012, J PHYSIOL SCI, V62, P441, DOI 10.1007/s12576-012-0232-9
   MCNEILLY AS, 1972, J ENDOCRINOL, V54, P399, DOI 10.1677/joe.0.0540399
   Meijering E, 2010, CYTOM PART A, V77A, P693, DOI 10.1002/cyto.a.20895
   Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696
   Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Nowakowska E, 2002, POL J PHARMACOL, V54, P605
   Parker KJ, 2010, PSYCHIAT RES, V178, P359, DOI 10.1016/j.psychres.2009.09.017
   Plumpe T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-77
   Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X
   Ramirez-Rodriguez G, 2011, J PINEAL RES, V50, P29, DOI 10.1111/j.1600-079X.2010.00802.x
   Rankin SL, 2003, BRAIN RES, V971, P189, DOI 10.1016/S0006-8993(03)02350-3
   Revest JM, 2009, MOL PSYCHIATR, V14, P959, DOI 10.1038/mp.2009.15
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Rotzinger S, 2010, PEPTIDES, V31, P736, DOI 10.1016/j.peptides.2009.12.015
   Ruan LH, 2014, PROG NEUROBIOL, V115, P116, DOI 10.1016/j.pneurobio.2013.12.006
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Slattery David A, 2010, Pharmaceuticals (Basel), V3, P702
   Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287
   So K F, 2012, Hong Kong Med J, V18 Suppl 3, P20
   Song J, 2012, DEV NEUROBIOL, V72, P1032, DOI 10.1002/dneu.22014
   Sousa N, 2000, NEUROSCIENCE, V97, P253, DOI 10.1016/S0306-4522(00)00050-6
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   Winner B, 2011, EUR J NEUROSCI, V33, P1139, DOI 10.1111/j.1460-9568.2011.07613.x
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   Xiao F, 2015, NEURAL REGEN RES, V10, P772, DOI 10.4103/1673-5374.156979
   Yan Y, 2014, NEUROPEPTIDES, V48, P83, DOI 10.1016/j.npep.2014.01.001
   YOUNG EA, 1995, J NEUROENDOCRINOL, V7, P37, DOI 10.1111/j.1365-2826.1995.tb00665.x
   Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629
NR 65
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 1
PY 2016
VL 333
BP 65
EP 77
DI 10.1016/j.neuroscience.2016.07.005
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA DU1BU
UT WOS:000381942000007
PM 27418343
ER

PT J
AU de Moura, AC
   da Silva, IRV
   Reinaldo, G
   Dani, C
   Elsner, VR
   Giovenardi, M
AF de Moura, Ana Carolina
   Vital da Silva, Ivy Reichert
   Reinaldo, Gustavo
   Dani, Caroline
   Elsner, Viviane Rostirola
   Giovenardi, Marcia
TI Global Histone H4 Acetylation in the Olfactory Bulb of Lactating Rats
   with Different Patterns of Maternal Behavior
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Epigenetics; Histone H4 acetylation; Gene expression; Maternal behavior;
   Licking/grooming; High/low licking mothers
ID ESTROGEN-RECEPTOR; PREFRONTAL CORTEX; OXYTOCIN RECEPTOR; CARE;
   CHROMATIN; EXPRESSION; HIPPOCAMPUS; STRESS; METHYLATION; PLASTICITY
AB In rats, variations in the levels of neuromodulatory molecules and in the expression of their receptors are observed during pregnancy and postpartum. These changes may contribute to the development and management of maternal behavior. The frequency of licking the pups is used to evaluate maternal care, having mothers with low licking (LL) and high licking (HL) frequencies. Previously, we found that HL had increased levels of transcriptional expression of the receptors for serotonin (HTR1a, HTR1b), estrogen (Er alpha), dopamine (D1a), and prolactin (Prlr) than LL in the olfactory bulb (OB); however, the molecular mechanisms behind this phenomenon are unknown. Since evidences pointed out that epigenetic marks, which may alter gene expression, are modulated by environmental factors such as exercise, diet, maternal care, and xenobiotic exposure, our objective was to verify the acetylation levels of histone-H4 in the OB of LL and HL rats. Maternal behavior was studied for the first 7 postpartum days. LL (n = 4) and HL (n = 5) mothers were selected according to the behavior of licking their pups. Acetylation levels of histone-H4 were determined using the Global Histone-H4 Acetylation Assay Kit and expressed as ng/mg protein (mean +/- SD). Analysis revealed that HL (278.36 +/- 68.95) had increased H4 acetylation levels than LL (183.24 +/- 73.05; p = 0.045). The enhanced expression of the previously studied receptors in the OB could be related, at least in part, to the hyperacetylation status of histone-H4 here observed. Afterward, the modulation of histone acetylation levels could exert a pivotal role through molecular mechanisms involved in the different patterns of maternal behavior.
C1 [de Moura, Ana Carolina; Giovenardi, Marcia] Univ Fed Ciencias Saude Porto Alegre, Dept Ciencias Basicas Saude, Sarmento Leite 245,Sala 308, BR-90050170 Porto Alegre, RS, Brazil.
   [Vital da Silva, Ivy Reichert; Dani, Caroline; Elsner, Viviane Rostirola] IPA, Programa Pos Grad Biociencias & Reabilitacao, Ctr Univ Metodista, Porto Alegre, RS, Brazil.
   [Reinaldo, Gustavo] IPA, Curso Fisioterapia, Ctr Univ Metodista, Porto Alegre, RS, Brazil.
RP de Moura, AC (reprint author), Univ Fed Ciencias Saude Porto Alegre, Dept Ciencias Basicas Saude, Sarmento Leite 245,Sala 308, BR-90050170 Porto Alegre, RS, Brazil.
EM anacarol.demoura@gmail.com; giovenardi.marcia@gmail.com
FU PROAP/UFCSPA; CAPES; FAPERGS
FX We thank PROAP/UFCSPA, CAPES and FAPERGS for financial support.
CR Beery AK, 2016, HORM BEHAV, V77, P42, DOI 10.1016/j.yhbeh.2015.05.022
   Bie BH, 2012, NEUROPSYCHOPHARMACOL, V37, P2780, DOI 10.1038/npp.2012.144
   Blaze J, 2013, INT J DEV NEUROSCI, V31, P804, DOI 10.1016/j.ijdevneu.2013.10.001
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Bredy TW, 2007, LEARN MEMORY, V14, P268, DOI 10.1101/lm.500907
   Caldji C, 1998, P NATL ACAD SCI USA, V95, P5335, DOI 10.1073/pnas.95.9.5335
   Champagne DL, 2008, J NEUROSCI, V28, P6037, DOI 10.1523/JNEUROSCI.0526-08.2008
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Champagne FA, 2003, PHYSIOL BEHAV, V79, P359, DOI 10.1016/S0031-9384(03)00149-5
   Champagne FA, 2008, FRONT NEUROENDOCRIN, V29, P386, DOI 10.1016/j.yfrne.2008.03.003
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Champagne FA, 2008, CURR OPIN PHARMACOL, V8, P735, DOI 10.1016/j.coph.2008.06.018
   Chiu K, 2007, JOVE-J VIS EXP, V7, P269, DOI DOI 10.3791/269
   de Moura AC, 2015, NEUROSCI RES, V99, P8, DOI 10.1016/j.neures.2015.05.003
   Elsner VR, 2011, NEUROSCIENCE, V192, P580, DOI 10.1016/j.neuroscience.2011.06.066
   Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023
   Lalonde ME, 2014, GENE DEV, V28, P1029, DOI 10.1101/gad.236331.113
   Lenz KM, 2009, DEV NEUROBIOL, V69, P603, DOI 10.1002/dneu.20729
   Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200
   Levy F, 2004, HORM BEHAV, V46, P284, DOI 10.1016/j.yhbeh.2004.02.005
   Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659
   Maccari S, 2014, J NEUROENDOCRINOL, V26, P707, DOI 10.1111/jne.12175
   McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739
   Mileva-Seitz VR, 2016, HORM BEHAV, V77, P211, DOI 10.1016/j.yhbeh.2015.06.003
   MYERS MM, 1989, DEV PSYCHOBIOL, V22, P29, DOI 10.1002/dev.420220104
   Parent CI, 2008, DEV PSYCHOBIOL, V50, P767, DOI 10.1002/dev.20342
   Patisaul HB, 2003, J NEUROENDOCRINOL, V15, P787, DOI 10.1046/j.1365-2826.2003.01061.x
   Pena CJ, 2014, EUR J NEUROSCI, V39, P946, DOI 10.1111/ejn.12479
   Ruthschilling CA, 2012, BEHAV BRAIN RES, V228, P176, DOI 10.1016/j.bbr.2011.12.005
   Sharma RR, 2005, SCHIZOPHR RES, V72, P79, DOI 10.1016/j.sclires.2004.03.001
   Stolzenberg DS, 2012, HORM BEHAV, V62, P128, DOI 10.1016/j.yhbeh.2012.05.012
   Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659
   Veenema AH, 2009, PSYCHONEUROENDOCRINO, V34, P463, DOI 10.1016/j.psyneuen.2008.10.017
   Warnault V, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.4
   Weaver ICG, 2007, EPIGENETICS, V2, P22
   Weaver ICG, 2006, P NATL ACAD SCI USA, V103, P3480, DOI 10.1073/pnas.0507526103
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Yamawaki Y, 2012, WORLD J BIOL PSYCHIA, V13, P458, DOI 10.3109/15622975.2011.585663
NR 40
TC 0
Z9 0
U1 10
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD OCT
PY 2016
VL 36
IS 7
BP 1209
EP 1213
DI 10.1007/s10571-015-0306-3
PG 5
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA DS3KA
UT WOS:000380680500018
PM 26620050
ER

PT J
AU Mol, BJ
   Logtenberg, SLM
   Verhoeven, CJM
   Bloemenkamp, KWM
   Papatsonis, DNM
   Bakker, JJH
   van der Post, JAM
AF Mol, Ben Willem J.
   Logtenberg, Sabine L. M.
   Verhoeven, Corine J. M.
   Bloemenkamp, Kitty W. M.
   Papatsonis, Dimitri N. M.
   Bakker, Jannet J. H.
   van der Post, Joris A. M.
TI Does measurement of intrauterine pressure have predictive value during
   oxytocin-augmented labor?
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Intrauterine pressure; mode of delivery; pressure catheter
ID ANAPHYLACTOID SYNDROME; CATHETER PLACEMENT; COMPLICATIONS
AB Objective: In a previous randomized trial that compared monitoring uterine contractions with an intrauterine pressure catheter (IUPC) versus external monitoring, we demonstrated that use of an IUPC did not improve the outcome of labor. To provide insight in the lack of a positive effect, we evaluated level of IUP in Montevideo units (MU) in correlation with dysfunctional labor and adverse neonatal outcome.Study design: Here, we present two secondary analyses on the 503 women who had IUP measured in the trial. Firstly, we assessed labor outcome in relation to the highest IUP measured at any time during labor. Secondly, we assessed labor outcome to the IUP registered at the last vaginal examination during the first stage of labor in two study groups (above and below 200 MU).Results: Women with lower IUP were statistically significant older, had pregnancies with a longer gestational age, longer labors and neonates with a higher birth weight. The risk of a cesarean section was higher in women who had low IUP during labor (Likelihood Ratio 1.6 for IUP<100 MU, 0.41 for IUP>300 MU). IUP was not associated with neonatal outcome.Conclusion: IUP is associated with mode of delivery. However, use of internal tocodynamometry does not improve birth outcomes.
C1 [Mol, Ben Willem J.] Univ Adelaide, Robinson Res Inst, Sch Paediat & Reprod Hlth, Adelaide, Australia.
   [Mol, Ben Willem J.] South Australian Hlth & Med Res Inst Adelaide, Adelaide, SA, Australia.
   [Logtenberg, Sabine L. M.] Onze Lieve Vrouw Hosp, Dept Obstet & Gynecol, Amsterdam, Netherlands.
   [Verhoeven, Corine J. M.] Maxima Med Ctr, Dept Obstet & Gynecol, Veldhoven, Netherlands.
   [Verhoeven, Corine J. M.] Vrije Univ Amsterdam Med Ctr, Dept Midwifery Sci, AVAG EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
   [Bloemenkamp, Kitty W. M.] Leiden Univ, Med Ctr, Dept Obstet & Gynecol, Leiden, Netherlands.
   [Papatsonis, Dimitri N. M.] AMPHIA Hosp Breda, Dept Obstet & Gynecol, Breda, Netherlands.
   [Bakker, Jannet J. H.; van der Post, Joris A. M.] Acad Med Ctr, Dept Obstet & Gynecol, Amsterdam, Netherlands.
RP Mol, BJ (reprint author), Univ Adelaide, Robinson Res Inst, Sch Paediat & Reprod Hlth, Adelaide, Australia.; Mol, BJ (reprint author), South Australian Hlth & Med Res Inst Adelaide, Adelaide, SA, Australia.
EM ben.mol@adelaide.edu.au
CR American College of Obstetricians and Gynecologists, 2003, ACOG PRACTICE B, V49, P1445
   ARULKUMARAN S, 1991, OBSTET GYNECOL, V78, P800
   Bakker JJH, 2010, NEW ENGL J MED, V362, P306, DOI 10.1056/NEJMoa0902748
   Bakker JJ, 2012, COCHRANE DB SYST REV, V12
   CALDEYROBARCIA R, 1957, J PHARMACOL EXP THER, V121, P18
   CHUA S, 1992, BRIT J OBSTET GYNAEC, V99, P186, DOI 10.1111/j.1471-0528.1992.tb14496.x
   DOMENICHINI Y, 1981, J GYNECOL OBST BIO R, V10, P591
   Harbison L, 2010, OBSTET GYNECOL, V115, P407, DOI 10.1097/AOG.0b013e3181b5c8cc
   HAUTH JC, 1986, OBSTET GYNECOL, V68, P305
   Lind BK, 1999, AM J OBSTET GYNECOL, V180, P1034, DOI 10.1016/S0002-9378(99)70680-0
   Lind BK., 1998, PRIM CARE UPDATE OB, V5, P185, DOI 10.1016/S1068-607X(98)00103-6
   MADANES AE, 1982, OBSTET GYNECOL, V59, P389
   Matsuo K, 2008, AM J OBSTET GYNECOL, V198, pE8, DOI 10.1016/j.ajog.2007.09.035
   TRUDINGER BJ, 1978, BRIT J OBSTET GYNAEC, V85, P567, DOI 10.1111/j.1471-0528.1978.tb14921.x
   Wilmink FA, 2008, J MATERN-FETAL NEO M, V21, P880, DOI 10.1080/14767050802220508
NR 15
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD OCT
PY 2016
VL 29
IS 20
BP 3239
EP 3242
DI 10.3109/14767058.2015.1123243
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DR8EC
UT WOS:000380130200001
PM 26699193
ER

PT J
AU Kashanian, M
   Hasankhani, S
   Sheikhansari, N
   Bahasadri, S
   Homam, H
AF Kashanian, Maryam
   Hasankhani, Samira
   Sheikhansari, Narges
   Bahasadri, Shohreh
   Homam, Homa
TI The effects of sequential use of oxytocin and sublingual nitroglycerin
   in the cases of retained placenta
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Manual removal of placenta; nitroglycerin; oxytocin; pregnancy and
   delivery; retained placenta; third stage of labor
ID INTRAVENOUS NITROGLYCERIN; INTRAUMBILICAL INJECTION; 3RD STAGE;
   MANAGEMENT; LABOR; UTEROTONICS; HEMORRHAGE; RISK
AB Objectives: To evaluate the effects of adding sublingual nitroglycerin to oxytocin, for delivery of retained placenta after vaginal delivery.Method: The study was performed as a placebo controlled clinical trial on women who did not finish delivering placenta after 30 min of active management of the third stage of labor. In case group, 1 mg nitroglycerin and in the control group, placebo was prescribed sublingually.Results: In total, 80 women finished the study. The number of manual removal of placenta did not show significant difference between the two groups [25 women (62.5%) in the case and 30 women (75%) in the control group, p=0.335]. There was no significant difference between the two groups according to duration of the third stage of labor, hemoglobin index, decline in HB index>30% and maternal vital signs after treatment. There was no significant difference between the two groups according to adverse effects [eight women (20%) in the case group and four (10%) in the control group (p=0.348)].Conclusion: The sequential use of oxytocin and sublingual nitroglycerin could not lead to delivery of more placentas and did not reduce the necessity of manual removal of placenta in comparison with placebo.
C1 [Kashanian, Maryam; Hasankhani, Samira; Bahasadri, Shohreh; Homam, Homa] Iran Univ Med Sci, Akbarabadi Teaching Hosp, Dept Obstet & Gynecol, Tehran, Iran.
   [Sheikhansari, Narges] Univ Southampton, Fac Med, Southampton, Hants, England.
RP Kashanian, M (reprint author), 9 Mostaghimi Alley,Khajeh Nasir Toosi Ave, Tehran 16117, Iran.
EM maryamkashanian@yahoo.com
OI Kashanian, Maryam/0000-0001-7181-0244
CR Abdel-Aleem H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007708.pub2
   Abdel-Aleem H, 2015, COCHRANE DB SYST REV, V11
   Bider D, 1996, EUR J OBSTET GYN R B, V64, P59, DOI 10.1016/0301-2115(95)02273-2
   Bullarbo M, 2005, INT J GYNECOL OBSTET, V91, P228, DOI 10.1016/j.ijgo.2005.08.020
   Bullarbo M, 2012, OBSTET GYNECOL INT
   Chedraui PA, 2003, GYNECOL OBSTET INVES, V56, P61, DOI 10.1159/000072734
   COMBS CA, 1991, OBSTET GYNECOL, V77, P77
   Dufour P, 1997, ARCH GYNECOL OBSTET, V261, P1, DOI 10.1007/s004040050189
   Ekerhovd E, 2008, ACTA OBSTET GYN SCAN, V87, P222, DOI 10.1080/00016340701855654
   Gazvani MR, 1998, OBSTET GYNECOL, V91, P203, DOI 10.1016/S0029-7844(97)00622-4
   Habek D, 2007, INT J GYNECOL OBSTET, V99, P105, DOI 10.1016/j.ijgo.2007.05.007
   Harara R, 2011, J OBSTET GYNAECOL RE, V37, P1203, DOI 10.1111/j.1447-0756.2010.01499.x
   Leduc Dean, 2009, J Obstet Gynaecol Can, V31, P980
   Lowenwirt IP, 1997, AUST NZ J OBSTET GYN, V37, P20, DOI 10.1111/j.1479-828X.1997.tb02212.x
   Magann EF, 2005, OBSTET GYN CLIN N AM, V32, P323, DOI 10.1016/j.ogc.2005.01.006
   Magann EF, 2008, GYNECOL OBSTET INVES, V65, P201, DOI 10.1159/000112227
   Nardin JM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001337.pub2
   Morgan Pamela J, 2002, J Obstet Gynaecol Can, V24, P403
   Owolabi AT, 2008, SINGAP MED J, V49, P532
   Sheldon WR, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-46
   Taebi Mahboubeh, 2012, Iran J Nurs Midwifery Res, V17, pS76
   Tessier V, 2004, J GYNECOL OBST BIO R, V33
   Visalyaputra S, 2011, INT J GYNECOL OBSTET, V112, P103, DOI 10.1016/j.ijgo.2010.08.021
   Weeks AD, 2008, BEST PRACT RES CL OB, V22, P1103, DOI 10.1016/j.bpobgyn.2008.07.005
   Westhoff G, 2013, COCHRANE DB SYST REV, V10, DOI [DOI 10.1002/14651858.CD001808.PUB2, 10.1002/14651858.CD001808.pub2]
   [Anonymous], 2009, WHO TECH REP SER, P17
NR 26
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD OCT
PY 2016
VL 29
IS 20
BP 3254
EP 3259
DI 10.3109/14767058.2015.1124264
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DR8EC
UT WOS:000380130200004
PM 26701364
ER

PT J
AU Stenson, D
   Wallstrom, T
   Sjostrand, M
   Akerud, H
   Gemzell-Danielsson, K
   Wiberg-Itzel, E
AF Stenson, David
   Wallstrom, Tove
   Sjostrand, Maria
   Akerud, Helena
   Gemzell-Danielsson, Kristina
   Wiberg-Itzel, Eva
TI Induction of labor in women with a uterine scar
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Induction of labor; misoprostol; PGE2; TOLAC; uterine scar
ID PREVIOUS CESAREAN DELIVERY; MISOPROSTOL; RUPTURE; CONTRACTILITY;
   OUTCOMES; TRIAL; TERM
AB Objective: To evaluate the frequency of uterine rupture following induction of labor in women with a previous cesarean section. Misoprostol was compared to other methods of induction.Methods: A retrospective cohort study of 208 women attempting induction of labor after one previous cesarean section. Delivery data were collected retrospectively and compared. Group 1(2009-2010) was compared with Group 2 (2012-2013). In Group 1, the main method of induction was vaginal PGE(2) (prostaglandin-E-2), amniotomy, oxytocin or a balloon catheter. In Group 2, the dominant method of induction was an oral solution of misoprostol. Main outcome measures: frequency of uterine rupture in the two groups.Results: Nine cases (4.3%) of uterine rupture occurred. There was no significant difference in the frequency of uterine rupture following the change of method of induction from PGE(2), amniotomy, oxytocin or mechanical dilatation with a balloon catheter to orally administered misoprostol (4.1 versus 4.6%, p=0.9). All ruptures occurred in women with no prior vaginal delivery.Conclusion: The shift to oral misoprostol as the primary method of induction in women with a previous cesarean section did not increase the frequency of uterine rupture in the cohort studied.
C1 [Stenson, David; Wallstrom, Tove; Sjostrand, Maria; Wiberg-Itzel, Eva] Karolinska Inst, Soder Hosp, Sect Obstet & Gynecol, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden.
   [Akerud, Helena] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.
   [Gemzell-Danielsson, Kristina] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.
RP Wiberg-Itzel, E (reprint author), Karolinska Inst, Soder Hosp, Sect Obstet & Gynecol, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden.
EM eva@itzel.eu
CR [Anonymous], 2010, OBSTET GYNECOL, V116, P450
   Aghideh FK, 2014, J MATERN-FETAL NEO M, V27, P592, DOI 10.3109/14767058.2013.831066
   Alfirevic Z, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001338.pub2
   Aronsson A, 2004, HUM REPROD, V19, P81, DOI 10.1093/humrep/deh005
   Aslan H, 2004, EUR J OBSTET GYN R B, V113, P45, DOI 10.1016/S0201-2115(03)00363-4
   Chauhan SP, 2003, AM J OBSTET GYNECOL, V189, P408, DOI 10.1067/S0002-9378(03)00675-6
   Crane JMG, 2006, BJOG-INT J OBSTET GY, V113, P1366, DOI 10.1111/j.1471-0528.2006.01111.x
   Crane J M G, 2004, J Matern Fetal Neonatal Med, V15, P319, DOI 10.1080/14767050410001702195
   Danielsson KG, 1999, OBSTET GYNECOL, V93, P275, DOI 10.1016/S0029-7844(98)00436-0
   Dodd JM, 2012, COCHRANE DB SYST REV, V5
   [Anonymous], 2012, AM J OBSTET GYNECOL
   Jozwiak M, 2013, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD009792.pub2, DOI 10.1002/14651858.CD009792.PUB2]
   Landon MB, 2004, NEW ENGL J MED, V351, P2581, DOI 10.1056/NEJMoa040405
   Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101
   Plaut MM, 1999, AM J OBSTET GYNECOL, V180, P1535, DOI 10.1016/S0002-9378(99)70049-9
   Ravasia DJ, 2000, AM J OBSTET GYNECOL, V183, P1176, DOI 10.1067/mob.2000.109037
   Sentilhes L, 2013, EUR J OBSTET GYN R B, V170, P25, DOI 10.1016/j.ejogrb.2013.05.015
   [Anonymous], 2005, INT J GYNECOL OBSTET, V89, P319
   Stock SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060404
   Tang J, 2013, INT J GYNECOL OBSTET, V121, P186, DOI 10.1016/j.ijgo.2012.12.009
   Vogel JP, 2013, COCHRANE DB SYST REV, V9
   Wing DA, 1998, OBSTET GYNECOL, V91, P828, DOI 10.1016/S0029-7844(97)00553-X
NR 22
TC 0
Z9 0
U1 8
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD OCT
PY 2016
VL 29
IS 20
BP 3286
EP 3291
DI 10.3109/14767058.2015.1123242
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DR8EC
UT WOS:000380130200010
PM 26699657
ER

PT J
AU Ahmed, AI
   Zhu, L
   Aldhaheri, S
   Sakr, S
   Minkoff, H
   Haberman, S
AF Ahmed, Ahmed I.
   Zhu, Ling
   Aldhaheri, Sarah
   Sakr, Sharif
   Minkoff, Howard
   Haberman, Shoshana
TI Uterine tachysystole in spontaneous labor at term
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Epidural analgesia; NRFHT; spontaneous labor; uterine tachysystole
ID FETAL HEART-RATE; BREAST STIMULATION; CONTRACTIONS; PATTERNS;
   ABNORMALITIES; OXYTOCIN; WOMEN
AB Objectives: The objective of this study is to determine the incidence of uterine tachysystole and its association with spontaneous labor at term.Methods: A retrospective cohort study of 8008 women in spontaneous labor (without prostaglandins or oxytocin). Fetal heart tracings and uterine activity were recorded every 15min. Primary outcome: occurrence of tachysystole (> 5 uterine contractions /10min over 30min periods). Secondary outcomes: non-reassuring fetal heart tracings (NRFHT), NICU admissions, and cesarean deliveries.Results: About 890 patients (11.1 %) had at least one episode of tachysystole. Non-whites have higher incidence of uterine tachysystole; adjusted odds ratio (aOR) was 1.66 for Hispanics (95% CI 1.28-2.05), 1.58 for African Americans (95% CI 1.05-2.38), and 1.51 for Asians (95% CI=1.13-2.0). The use of epidural analgesia was higher in the tachysystole group (62.2% versus 40.9%, aOR 1.89, CI 1.58-2.26; p< 0.001). Tachysystole was more frequent among nulliparous women and in women carrying higher weight fetuses. Oligohydramnios (aOR 1.62, CI 0.70-3.72; p<0.004), and NRFHT were more common in the tachysystole group (4.2% versus 2.5%, p=0.002). Newborns in the tachysystole group were two times more likely to be admitted to NICU (30 /890 [3.4%] versus 122 /7118 [1.7%], OR=2, p=0.001). There was no difference in the frequency of meconium-stained amniotic fluid or Apgar scores <7 at 5min.Conclusion: Uterine tachysystole occurs in more than 10% of spontaneous labors and is associated with NRFHR, increased rate of caesarean deliveries and NICU admissions. It is not associated with low Apgar scores or meconium-stained amniotic fluid.
C1 [Ahmed, Ahmed I.; Aldhaheri, Sarah; Sakr, Sharif] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Detroit, MI 48201 USA.
   [Ahmed, Ahmed I.] Wayne State Univ, Sch Med, Dept Med Genet, Detroit, MI USA.
   [Zhu, Ling; Minkoff, Howard; Haberman, Shoshana] Maimonides Hosp, Dept Obstet & Gynecol, Brooklyn, NY 11219 USA.
   [Aldhaheri, Sarah] King Abdulaziz Univ, Dept Obstet & Gynecol, Jeddah, Saudi Arabia.
RP Ahmed, AI (reprint author), Wayne State Univ, Dept Obstet & Gynecol, 3990 John R, Detroit, MI 48201 USA.
EM aahmed2@dmc.org
CR Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6
   [Anonymous], 2009, OBSTET GYNECOL, V114, P192, DOI DOI 10.1097/AOG.0B013E3181AEF106
   ACOG Committee on Practice Bulletins-Obstetrics, 2009, OBSTET GYNECOL 1, V114, P386, DOI DOI 10.1097/AOG.0B013E3181B48EF5
   Boyle A, 2013, OBSTET GYNECOL, V122, P33, DOI 10.1097/AOG.0b013e3182952242
   CURTIS P, 1989, OBSTET GYNECOL, V73, P631
   Doyle J, 2011, JOGNN-J OBST GYN NEO, V40, P512, DOI 10.1111/j.1552-6909.2011.01275.x
   FRAGER NB, 1987, OBSTET GYNECOL, V69, P767
   Frey HA, 2014, J MATERN-FETAL NEO M, V27, P1422, DOI 10.3109/14767058.2013.866645
   Heuser CC, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.04.004
   Hutchings G, 2009, J CELL MOL MED, V13, P4268, DOI 10.1111/j.1582-4934.2009.00894.x
   IOSIF CS, 1983, ACTA OBSTET GYN SCAN, V62, P165
   Jonsson M, 2008, ACTA OBSTET GYN SCAN, V87, P745, DOI 10.1080/00016340802220352
   Kunz MK, 2013, JOGNN-J OBST GYN NEO, V42, P12, DOI 10.1111/j.1552-6909.2012.01428.x
   Macones GA, 2008, OBSTET GYNECOL, V112, P661, DOI 10.1097/AOG.0b013e3181841395
   Marshall LM, 1997, OBSTET GYNECOL, V90, P967, DOI 10.1016/S0029-7844(97)00534-6
   MARTINEZMIR I, 1990, AM J OBSTET GYNECOL, V163, P189
   PEEBLES DM, 1994, BRIT J OBSTET GYNAEC, V101, P44, DOI 10.1111/j.1471-0528.1994.tb13008.x
   ROMERO R, 1994, ANN NY ACAD SCI, V734, P414, DOI 10.1111/j.1749-6632.1994.tb21771.x
   Romero R, 2006, BJOG-INT J OBSTET GY, V113, P17, DOI 10.1111/j.1471-0528.2006.01120.x
   Sheiner E, 2004, AM J OBSTET GYNECOL, V191, P945, DOI 10.1016/j.ajog.2004.05.060
   Sheiner E, 2004, J REPROD MED, V49, P373
   Simpson KR, 2011, CLIN OBSTET GYNECOL, V54, P40, DOI 10.1097/GRF.0b013e31820a06aa
   Simpson KR, 2008, CERVICAL RIPENING IN
   Smith S, 2014, J MATERN-FETAL NEO M, V27, P709, DOI 10.3109/14767058.2013.836484
   Stewart RD, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.07.032
   Strasser SM, 2010, J MATERN-FETAL NEO M, V23, P736, DOI 10.3109/14767050903300951
   Young RC, 2015, J BIOMECH, V48, P1614, DOI 10.1016/j.jbiomech.2015.02.002
NR 27
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD OCT
PY 2016
VL 29
IS 20
BP 3335
EP 3339
DI 10.3109/14767058.2015.1125463
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DR8EC
UT WOS:000380130200018
PM 27074823
ER

PT J
AU Schwartz, L
   Holland, A
   Dykens, E
   Strong, T
   Roof, E
   Bohonowych, J
AF Schwartz, Lauren
   Holland, Anthony
   Dykens, Elisabeth
   Strong, Theresa
   Roof, Elizabeth
   Bohonowych, Jessica
TI Prader-Willi syndrome mental health research strategy workshop
   proceedings: the state of the science and future directions
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Review
DE Mental health research; Behavioral phenotype; Developmental disability;
   And intellectual disability
ID MATERNAL UNIPARENTAL DISOMY; PLACEBO-CONTROLLED-TRIAL;
   FRAGILE-X-SYNDROME; POLYVAGAL PERSPECTIVE; GENETIC SUBTYPES;
   CLINICAL-TRIALS; SKIN-PICKING; BEHAVIOR; DELETION; PEOPLE
AB This paper reports on the 'Prader-Willi Syndrome (PWS) Mental Health Research Strategy Workshop' that took place in March 2015. PWS is characterized by a complex phenotype affecting multiple systems with a high prevalence of maladaptive behaviours, and neuropsychiatric illness. Prader Willi syndrome results from the absence of paternally derived alleles located at the imprinted chromosomal locus, 15q11-13. The goal of the workshop was to highlight the state of the science of the mental health of people with this rare neurodevelopmental disorder. Mental ill health and maladaptive behaviors significantly impact quality of life for persons with PWS and their caregivers. Effective treatments and further research into this area are critically needed.
   Methods: A multidisciplinary group of scientists and health care professionals were brought together to discuss the mental health and behavioral needs of people with PWS. The workshop strategy was to integrate established work on PWS with other relevant areas of study. The meeting also focused on two neurobiological systems that research had suggested were relevant to understanding the broader mental health aspects of PWS: the autonomic nervous system and oxytocin/vasopressin pathways. Other relevant topics were considered and recommendations made.
   Results: The workshop presentations and working group discussions revealed that no one approach was sufficient to fully conceptualize the mental health challenges in PWS. Workshop discussions pointed to the need for theoretically informed studies focused on clinical characterization, measurement, and the probing of specific neurobiological systems through pharmaceutical or other interventions. Future studies in this area should explore the use of advanced neuroimaging protocols, as well as molecular studies using iPS cells in order to create more informed theories.
   Conclusions: Within this framework, workshop participants identified and prioritized key research questions, and highlighted current opportunities. Recommendations were made with respect to the development of specific resources and tools for furthering mental health research such as The Global PWS Registry, the development of effective endpoints, the use of animal models and iPS cells to aid understanding of the neurobiological underpinnings. Additionally, collaborative opportunities across disciplines and syndromes were highlighted and targeted research initiatives focused on psychological/behavioral interventions modified for use in PWS were recommended.
C1 [Schwartz, Lauren] Univ Washington, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA.
   [Holland, Anthony] Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Cambridge, England.
   [Dykens, Elisabeth; Roof, Elizabeth] Vanderbilt Univ, Vanderbilt Kennedy Ctr, Nashville, TN 37235 USA.
   [Strong, Theresa; Bohonowych, Jessica] Fdn Prader Willi Res, Los Angeles, CA USA.
   [Strong, Theresa] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
RP Schwartz, L (reprint author), Univ Washington, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA.
EM Laurenroth30@gmail.com
FU non-profit organization Foundation for Prader Willi Research [501c3]
FX The workshop was funded by a non-profit organization (501c3) The
   Foundation for Prader Willi Research (www.fpwr.org).
CR Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192
   Angkustsiri K, 2012, J DEV BEHAV PEDIATR, V33, P713, DOI 10.1097/DBP.0b013e318272dd24
   Bales KL, 2007, HORM BEHAV, V52, P274, DOI 10.1016/j.yhbeh.2007.05.004
   Beaton EA, 2011, J NEURODEV DISORD, V3, P68, DOI 10.1007/s11689-010-9069-9
   Berry-Kravis E, 2013, J DEV BEHAV PEDIATR, V34, P508, DOI 10.1097/DBP.0b013e31829d1f20
   Boer H, 2002, LANCET, V359, P135, DOI 10.1016/S0140-6736(02)07340-3
   Bull LE, 2015, J AUTISM DEV DISORD, V45, P1569, DOI 10.1007/s10803-014-2308-2
   Butler MG, 2004, PEDIATRICS, V113, P565, DOI 10.1542/peds.113.3.565
   Cassidy SB, 2012, GENET MED, V14, P10, DOI 10.1038/gim.0b013e31822bead0
   Cassidy SB, 2009, EUR J HUM GENET, V17, P3, DOI 10.1038/ejhg.2008.165
   de Souza MA, 2013, AM J MED GENET A, V161, P2453, DOI 10.1002/ajmg.a.36100
   Doe CM, 2009, HUM MOL GENET, V18, P2140, DOI 10.1093/hmg/ddp137
   Dykens EM, 2008, J CHILD PSYCHOL PSYC, V49, P1001, DOI 10.1111/j.1469-7610.2008.01913.x
   Dykens EM, 2004, AM J MENT RETARD, V109, P142, DOI 10.1352/0895-8017(2004)109<142:MACBIP>2.0.CO;2
   Einfeld S., 1999, J INTELLECT DEV DIS, V24, P349, DOI DOI 10.1080/13668259900034111
   Einfeld SL, 2014, AM J MED GENET A, V9999, P1
   Goldstone AP, 2008, J CLIN ENDOCR METAB, V93, P4183, DOI 10.1210/jc.2008-0649
   Greaves N, 2006, J INTELL DISABIL RES, V50, P92, DOI 10.1111/j.1365-2788.2005.00726.x
   Grugni G, 2013, NUTR METAB CARDIOVAS, V23, P1134, DOI 10.1016/j.numecd.2012.11.006
   Hall SS, 2014, RES DEV DISABIL, V35, P2284, DOI 10.1016/j.ridd.2014.05.025
   Hinton EC, 2006, INT J OBESITY, V30, P313, DOI 10.1038/sj.ijo.0803128
   Holland AJ, 2003, PSYCHOL MED, V33, P141, DOI 10.1017/S0033291702006736
   Jacquemont S, 2014, PSYCHOPHARMACOLOGY, V231, P1237, DOI 10.1007/s00213-013-3289-0
   Joa I, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0470-5
   Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265
   Larson FV, 2014, PSYCHOL MED, V44, P2431, DOI 10.1017/S0033291713002961
   Manning KE, 2016, J INTELL DISABIL RES, V60, P149, DOI 10.1111/jir.12203
   Miller JL, 2007, J NEUROL NEUROSUR PS, V78, P912
   Miller JL, 2014, AM J MED GENET A, V164, P421, DOI 10.1002/ajmg.a.36306
   Miller JL, 2011, AM J MED GENET A, V155A, P1040, DOI 10.1002/ajmg.a.33951
   Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009
   Porges SW, 2013, INT J PSYCHOPHYSIOL, V88, P261, DOI 10.1016/j.ijpsycho.2012.11.009
   Porges SW, 2011, INFANT CHILD DEV, V20, P106, DOI 10.1002/icd.688
   Roof E, 2000, J INTELL DISABIL RES, V44, P25, DOI 10.1046/j.1365-2788.2000.00250.x
   Sinnema M, 2011, RES DEV DISABIL, V32, P604, DOI 10.1016/j.ridd.2010.12.014
   Soni S, 2008, PSYCHOL MED, V38, P1505, DOI 10.1017/S0033291707002504
   Stauder JEA, 2005, CLIN NEUROPHYSIOL, V116, P1464, DOI 10.1016/j.clinph.2005.02.019
   Swaab DF, 1997, ACTA PAEDIATR, V86, P50
   Tauber M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-47
   Veltman MWM, 2005, PSYCHIAT GENET, V15, P243, DOI 10.1097/00041444-200512000-00006
   Vogels A, 2003, J MED GENET, V40, P72, DOI 10.1136/jmg.40.1.72
   Whittington J, 2004, J INTELL DISABIL RES, V48, P172, DOI 10.1111/j.1365-2788.2004.00556.x
   Woodcock K, 2009, J INTELL DISABIL RES, V53, P265, DOI 10.1111/j.1365-2788.2008.01122.x
   Woodcock KA, 2011, J INTELL DISABIL RES, V55, P152, DOI 10.1111/j.1365-2788.2010.01368.x
   Woodcock KA, 2010, BRAIN RES, V1363, P128, DOI 10.1016/j.brainres.2010.09.093
   Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072640
NR 46
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD SEP 29
PY 2016
VL 11
AR 131
DI 10.1186/s13023-016-0504-1
PG 7
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA DX7RG
UT WOS:000384585900003
PM 27682995
ER

PT J
AU Olszewski, PK
   Klockars, OA
   Klockars, A
   Levine, AS
AF Olszewski, Pawel K.
   Klockars, Oscar A.
   Klockars, Anica
   Levine, Allen S.
TI Central oxytocin receptor stimulation attenuates the orexigenic effects
   of butorphanol tartrate
SO NEUROREPORT
LA English
DT Article
DE butorphanol; food intake; opioids; oxytocin; paraventricular nucleus
ID FOOD-INTAKE; OPIOID ANTAGONISTS; TASTE-AVERSION; NEUROPEPTIDE-Y; RATS;
   CHOLECYSTOKININ; DEPRIVATION; RESPONSES; SYSTEMS; MU
AB Butorphanol tartrate (BT), a mixed mu// opioid receptor agonist, is one of the most potent orexigens known to date. The central mechanisms through which BT causes hyperphagia are largely unknown. Interestingly, BT suppresses meal-end activation of neurons synthesizing anorexigenic neuropeptide, oxytocin (OT), which suggests that BT promotes hyperphagia by silencing OT-derived satiety signaling. As OT terminates consumption by acting by distinct hindbrain and forebrain circuits, we investigated whether stimulation of the OT receptor in the forebrain or the hindbrain [through lateral ventricular (LV) and fourth ventricular (4V) OT injections] leads to termination of food intake induced by BT. We established effective doses of BT on chow intake in ad-libitum-fed and overnight-deprived rats as well as effective doses of LV and 4V OT in deprived animals. Then, we determined doses of LV and 4V OT that reduce hyperphagia produced by BT in sated and deprived rats. Finally, we assessed whether OT's effects on BT-induced feeding can be suppressed by an OT receptor antagonist. 4mg/kg BT increased intake in ad-libitum-fed and overnight-deprived rats, whereas LV and 4V OT at 1g caused a decrease in deprived rats. BT-induced chow intake in hungry and sated animals was suppressed by a very low, 0.1g dose of 4V OT, whereas 1g OT was effective LV. The effect of OT was attenuated by OT receptor antagonist, L-368899. Reduced activity of the OT circuit, especially its hindbrain component, is a critical factor in shaping the magnitude of consumption in response to BT treatment.
C1 [Olszewski, Pawel K.; Levine, Allen S.] Univ Minnesota, Dept Food Sci & Nutr, 1334 Eckles Ave, St Paul, MN USA.
   [Olszewski, Pawel K.; Klockars, Oscar A.; Klockars, Anica] Univ Waikato, Dept Biol Sci, Private Bag 3105, Hamilton 3240, New Zealand.
RP Olszewski, PK (reprint author), Univ Waikato, Dept Biol Sci, Private Bag 3105, Hamilton 3240, New Zealand.
EM pawel@waikato.ac.nz
FU Royal Society of New Zealand Marsden grant
FX This research was supported by the Royal Society of New Zealand Marsden
   grant.
CR ARLETTI R, 1990, PHYSIOL BEHAV, V48, P825, DOI 10.1016/0031-9384(90)90234-U
   Blevins JE, 2003, BRAIN RES, V993, P30, DOI 10.1016/j.brainres.2003.08.036
   BODNAR RJ, 1995, BRAIN RES, V700, P205, DOI 10.1016/0006-8993(95)00957-R
   Boggiano MA, 2005, BEHAV NEUROSCI, V119, P1207, DOI 10.1037/0735-7044.119.5.1207
   CHANG KJ, 1981, P NATL ACAD SCI-BIOL, V78, P4141, DOI 10.1073/pnas.78.7.4141
   Craft RM, 2003, PHARMACOL BIOCHEM BE, V75, P235, DOI 10.1016/S0091-3057(03)00076-5
   FLANAGAN LM, 1988, NEUROENDOCRINOLOGY, V48, P668, DOI 10.1159/000125080
   FLYNN FW, 1989, AM J PHYSIOL, V256, pR590
   Gosnell BA, 2009, INT J OBESITY, V33, pS54, DOI 10.1038/ijo.2009.73
   GOSNELL BA, 1986, LIFE SCI, V38, P1081, DOI 10.1016/0024-3205(86)90243-2
   Jewett DC, 2001, BRAIN RES, V909, P75, DOI 10.1016/S0006-8993(01)02624-5
   Kim EM, 2001, BRAIN RES, V907, P125, DOI 10.1016/S0006-8993(01)02322-8
   LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5
   LENG G, 1992, EXP BRAIN RES, V88, P321, DOI 10.1007/BF02259107
   LEVINE AS, 1994, BRAIN RES, V637, P242, DOI 10.1016/0006-8993(94)91239-4
   LEVINE AS, 1983, LIFE SCI, V32, P781, DOI 10.1016/0024-3205(83)90313-2
   Mitra A, 2012, PHARMACOL BIOCHEM BE, V100, P575, DOI 10.1016/j.pbb.2011.08.010
   Mitra A, 2012, PHARMACOL BIOCHEM BE, V100, P581, DOI 10.1016/j.pbb.2011.08.009
   MORLEY JE, 1985, AM J CLIN NUTR, V42, P1175
   MORLEY JE, 1983, PHARMACOL BIOCHEM BE, V19, P577, DOI 10.1016/0091-3057(83)90330-1
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Olszewski PK, 2000, AM J PHYSIOL-REG I, V279, pR1504
   Paxinos G., 1986, RAT BRAIN STEREOTAXI
   Schwartz MW, 2000, NATURE, V404, P661
NR 25
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD SEP 28
PY 2016
VL 27
IS 14
BP 1012
EP 1017
DI 10.1097/WNR.0000000000000647
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA DX5WX
UT WOS:000384454500003
PM 27471903
ER

PT J
AU Li, K
   Nakajima, M
   Ibanez-Tallon, I
   Heintz, N
AF Li, Kun
   Nakajima, Miho
   Ibanez-Tallon, Ines
   Heintz, Nathaniel
TI A Cortical Circuit for Sexually Dimorphic Oxytocin-Dependent Anxiety
   Behaviors
SO CELL
LA English
DT Article
ID VENTROMEDIAL HYPOTHALAMUS; BINDING-PROTEIN; STRESS; BRAIN;
   CORTICOTROPIN; DEPRESSION; NEURONS; AUTISM; INTERNEURONS; NEUROSCIENCE
AB The frequency of human social and emotional disorders varies significantly between males and females. We have recently reported that oxytocin receptor interneurons (OxtrINs) modulate female sociosexual behavior. Here, we show that, in male mice, OxtrINs regulate anxiety-related behaviors. We demonstrate that corticotropin-releasing-hormone-binding protein (CRHBP), an antagonist of the stress hormone CRH, is specifically expressed in OxtrINs. Production of CRHBP blocks the CRH-induced potentiation of postsynaptic layer 2/3 pyramidal cell activity of male, but not female, mice, thus producing an anxiolytic effect. Our data identify OxtrINs as critical for modulation of social and emotional behaviors in both females and males and reveal a molecular mechanism that acts on local medial prefrontal cortex (mPFC) circuits to coordinate responses to OXT and CRH. They suggest that additional studies of the impact of the OXT/OXTR and CRHBP/CRH pathways in males and females will be important in development of gender-specific therapies.
C1 [Li, Kun; Nakajima, Miho; Ibanez-Tallon, Ines; Heintz, Nathaniel] Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, 1230 York Ave, New York, NY 10065 USA.
RP Heintz, N (reprint author), Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, 1230 York Ave, New York, NY 10065 USA.
EM heintz@rockefeller.edu
FU HHMI; NIH/NIDA [1P30 DA035756-01]; Leon Black Family Foundation; HFSP
   postdoctoral fellowship [LT000271/2015-L]
FX This work was supported by the HHMI (to N.H.), the NIH/NIDA (grant 1P30
   DA035756-01 to I.I.-T and N.H.), the Leon Black Family Foundation (to
   N.H.), and the HFSP postdoctoral fellowship LT000271/2015-L (to K.L.).
   We want to thank Cuidong Wang (Rockefeller University) for technical
   assistance.
CR Altemus M, 2014, FRONT NEUROENDOCRIN, V35, P320, DOI 10.1016/j.yfrne.2014.05.004
   Aoki Y, 2015, MOL PSYCHIATR, V20, P447, DOI 10.1038/mp.2014.74
   Auer S, 2010, NAT METHODS, V7, P229, DOI [10.1038/nmeth.1425, 10.1038/NMETH.1425]
   Bangasser DA, 2015, HORM BEHAV, V76, P125, DOI 10.1016/j.yhbeh.2015.04.003
   BEERY AK, 2015, STRESS, V1, P116, DOI DOI 10.1016/J.YNSTR.2014.10.004
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028
   Insel TR, 2016, BIOL PSYCHIAT, V79, P153, DOI 10.1016/j.biopsych.2015.02.002
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Iwasaki-Sekino A, 2009, PSYCHONEUROENDOCRINO, V34, P226, DOI 10.1016/j.psyneuen.2008.09.003
   Kunwar PS, 2015, ELIFE, V4, DOI 10.7554/eLife.06633
   Labermaier C, 2014, ENDOCRINOLOGY, V155, P2500, DOI 10.1210/en.2013-1986
   Laryea Gloria, 2012, Behav Sci (Basel), V2, P135, DOI 10.3390/bs2020135
   Lee HJ, 2008, ENDOCRINOLOGY, V149, P3256, DOI 10.1210/en.2007-1710
   Lee H, 2014, NATURE, V509, P627, DOI 10.1038/nature13169
   Liu J, 2014, J CLIN INVEST, V124, P1242, DOI 10.1172/JCI72126
   MacDonald K, 2014, BRAIN RES, V1580, P22, DOI 10.1016/j.brainres.2014.01.025
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Mellen M, 2012, CELL, V151, P1417, DOI 10.1016/j.cell.2012.11.022
   Nakajima M, 2014, CELL, V159, P295, DOI 10.1016/j.cell.2014.09.020
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008
   Refojo D, 2011, SCIENCE, V333, P1903, DOI 10.1126/science.1202107
   Rubenstein E, 2015, J DEV PHYS DISABIL, V27, P119, DOI 10.1007/s10882-014-9397-x
   Sandi C, 2015, NAT REV NEUROSCI, V16, P290, DOI 10.1038/nrn3918
   Scott Niv, 2015, Nature, V525, P519, DOI 10.1038/nature15378
   Shrestha P, 2015, ELIFE, V4, DOI 10.7554/eLife.08752
   Smoller JW, 2016, NEUROPSYCHOPHARMACOL, V41, P297, DOI 10.1038/npp.2015.266
   Van Den Eede F, 2005, AGEING RES REV, V4, P213
   Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101
   Weber H., 2015, MOL PSYCHIAT
   Westphal NJ, 2006, FRONT BIOSCI, V11, P1878, DOI 10.2741/1931
   Wigton R, 2015, J PSYCHIATR NEUROSCI, V40, pE1, DOI 10.1503/jpn.130289
   Yang CF, 2014, NEURON, V82, P261, DOI 10.1016/j.neuron.2014.03.029
   Yang CF, 2013, CELL, V153, P896, DOI 10.1016/j.cell.2013.04.017
NR 40
TC 0
Z9 0
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 22
PY 2016
VL 167
IS 1
BP 60
EP +
DI 10.1016/j.cell.2016.08.067
PG 24
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA EA1GW
UT WOS:000386341500014
PM 27641503
ER

PT J
AU Westberg, L
   Henningsson, S
   Zettergren, A
   Svard, J
   Hovey, D
   Lin, T
   Ebner, NC
   Fischer, H
AF Westberg, Lars
   Henningsson, Susanne
   Zettergren, Anna
   Svard, Joakim
   Hovey, Daniel
   Lin, Tian
   Ebner, Natalie C.
   Fischer, Hakan
TI Variation in the Oxytocin Receptor Gene Is Associated with Face
   Recognition and its Neural Correlates
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE oxytocin; social cognition; face recognition; polymorphism; OXTR
ID SOCIAL RECOGNITION; INTRANASAL OXYTOCIN; AMYGDALA ACTIVITY;
   HUMAN-MEMORY; HUMAN BRAIN; OXTR; HUMANS; METAANALYSIS; BEHAVIOR;
   POLYMORPHISMS
AB The ability to recognize faces is crucial for daily social interactions. Recent studies suggest that intranasal oxytocin administration improves social recognition in humans. Oxytocin signaling in the amygdala plays an essential role for social recognition in mice, and oxytocin administration has been shown to influence amygdala activity in humans. It is therefore possible that the effects of oxytocin on human social recognition depend on mechanisms that take place in the amygdala a central region for memory processing also in humans. Variation in the gene encoding the oxytocin receptor (OXTR) has been associated with several aspects of social behavior. The present study examined the potential associations between nine OXTR polymorphisms, distributed across the gene, and the ability to recognize faces, as well as face-elicited amygdala activity measured by functional magnetic resonance imaging (fMRI) during incidental encoding of faces. The OXTR 3' polymorphism rs7632287, previously related to social bonding behavior and autism risk, was associated with participants ability to recognize faces. Carriers of the GA genotype, associated with enhanced memory, displayed higher amygdala activity during face encoding compared to carriers of the GG genotype. In line with work in rodents, these findings suggest that, in humans, naturally occurring endogenous modulation of OXTR function affects social recognition through an amygdala-dependent mechanism. These findings contribute to the understanding of how oxytocin regulates human social behaviors.
C1 [Westberg, Lars; Henningsson, Susanne; Zettergren, Anna; Hovey, Daniel] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden.
   [Zettergren, Anna] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.
   [Svard, Joakim; Fischer, Hakan] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden.
   [Lin, Tian; Ebner, Natalie C.] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA.
   [Ebner, Natalie C.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA.
   [Fischer, Hakan] Stockholm Univ, Dept Psychol, Stockholm, Sweden.
RP Westberg, L (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden.
EM lars.westberg@pharm.gu.se
FU Swedish Research Council [2009-7006, 2011-4819, 2014-3805, 2008-2356];
   Magnus Bergvalls-stiftelse; Stiftelsen Soderstrom-Konigska sjukhemmet
FX This work was supported by the Swedish Research Council under Grant
   [2009-7006; 2011-4819; 2014-3805 for LW and 2008-2356 for HF]; Magnus
   Bergvalls-stiftelse and Stiftelsen Soderstrom-Konigska sjukhemmet. We
   thank Johanna Loven for helping with data collection, and Johanna
   Milding for assisting in the statistical analyses. The funding sources
   had no role in the design and conduct of the study, preparation, review,
   or approval of the manuscript, and decision to submit the manuscript for
   publication.
CR Bakermans-Kranenburg MJ, 2014, PSYCHIAT GENET, V24, P45, DOI 10.1097/YPG.0b013e3283643684
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Belin P, 2011, BRIT J PSYCHOL, V102, P711, DOI 10.1111/j.2044-8295.2011.02041.x
   Bernstein M, 2015, NEUROSCI BIOBEHAV R, V55, P536, DOI 10.1016/j.neubiorev.2015.06.010
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Brett M, 2002, 8 INT C FUNCT MAPP H
   Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Ebner NC, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00223
   Ellingsen DM, 2014, PSYCHONEUROENDOCRINO, V39, P11, DOI 10.1016/j.psyneuen.2013.09.017
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gao S, 2016, P NATL ACAD SCI USA, V113, P7650, DOI 10.1073/pnas.1602620113
   GHEUSI G, 1994, BEHAV PROCESS, V33, P59, DOI 10.1016/0376-6357(94)90060-4
   Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Hamann SB, 1999, NAT NEUROSCI, V2, P289, DOI 10.1038/6404
   Harrison AJ, 2015, AM J MED GENET B, V168, P720, DOI 10.1002/ajmg.b.32377
   Herzmann G, 2012, BRAIN RES, V1451, P65, DOI 10.1016/j.brainres.2012.02.049
   Hovey D, 2016, MOL PSYCHIATR, V21, P983, DOI 10.1038/mp.2015.144
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Johansson A, 2012, GENES BRAIN BEHAV, V11, P214, DOI 10.1111/j.1601-183X.2011.00744.x
   Kanat M, 2015, NEUROPSYCHOPHARMACOL, V40, P287, DOI 10.1038/npp.2014.183
   Kensinger EA, 2006, J NEUROSCI, V26, P2564, DOI 10.1523/JNEUROSCI.5241-05.2006
   Li JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131820
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Loven J, 2014, SOC COGN AFFECT NEUR, V9, P1000, DOI 10.1093/scan/nst073
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Peretto P, 2014, NEURAL PLAST, DOI 10.1155/2014/497657
   Popik P, 1998, PROG BRAIN RES, V119, P415
   Rietveld CA, 2014, PSYCHOL SCI, V25, P1975, DOI 10.1177/0956797614545132
   Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Savaskan E, 2008, PSYCHONEUROENDOCRINO, V33, P368, DOI 10.1016/j.psyneuen.2007.12.004
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Shin NY, 2015, NEUROPSYCHOPHARMACOL, V40, P2286, DOI 10.1038/npp.2015.78
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704
   Tansey KE, 2010, NEUROSCI LETT, V474, P163, DOI 10.1016/j.neulet.2010.03.035
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Westberg L., 2014, OXFORD HDB MOL PSYCH, P145
   Wigton R, 2015, J PSYCHIATR NEUROSCI, V40, pE1, DOI 10.1503/jpn.130289
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
NR 49
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD SEP 22
PY 2016
VL 10
AR 178
DI 10.3389/fnbeh.2016.00178
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DW6NE
UT WOS:000383767100001
PM 27713694
ER

PT J
AU Zou, ZL
   Song, HW
   Zhang, YT
   Zhang, XC
AF Zou, Zhiling
   Song, Hongwen
   Zhang, Yuting
   Zhang, Xiaochu
TI Romantic Love vs. Drug Addiction May Inspire a New Treatment for
   Addiction
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Review
DE romantic love; social cognition system; drug addiction; oxytocin;
   resting-state functional connectivity; drug addiction treatment
ID STATE FUNCTIONAL CONNECTIVITY; ANTERIOR CINGULATE CORTEX; DORSAL
   STRIATUM; BRAIN ACTIVITY; NEURAL BASIS; ACCUMBENS DOPAMINE; SOCIAL
   ATTACHMENT; PREFRONTAL CORTEX; COCAINE ADDICTION; SUBSTANCE-ABUSE
AB Drug addiction is a complex neurological dysfunction induced by recurring drug intoxication. Strategies to prevent and treat drug addiction constitute a topic of research interest. Early-stage romantic love is characterized by some characteristics of addiction, which gradually disappear as the love relationship progresses. Therefore, comparison of the concordance and discordance between romantic love and drug addiction may elucidate potential treatments for addiction. This focused review uses the evidences from our recent studies to compare the neural alterations between romantic love and drug addiction, moreover we also compare the behavioral and neurochemical alterations between romantic love and drug addiction. From the behavioral comparisons we find that there are many similarities between the early stage of romantic love and drug addiction, and this stage romantic love is considered as a behavioral addiction, while significant differences exist between the later stage of romantic love and drug addiction, and this stage of romantic love eventually developed into a prosocial behavior. The neuroimaging comparisons suggest that romantic love and drug addiction both display the functional enhancement in reward and emotion regulation network. Except the similar neural changes, romantic love display special function enhancement in social cognition network, while drug addiction display special dysfunction in cognitive control network. The neurochemical comparisons show that there are many similarities in the dopamine (DA) system, while significant differences in oxytocin (OT) system for romantic love and drug addiction. These findings indicate that the functional alterations in reward and emotion regulation network and the DA system may be the neurophysiological basis of romantic love as a behavioral addiction, and the functional alterations in social cognition network and the OT system may be the neurophysiological basis of romantic love as a prosocial behavior. It seems that the OT system is a critical factor for the development of addiction. So we then discuss strategies to treat drug addiction with OT, and suggest that future research should further investigate OT system interventions aiming to improve cognitive control and/or social cognition functions, in order to develop strategies designed to more effectively treat drug addiction.
C1 [Zou, Zhiling; Song, Hongwen] Southwest Univ, Fac Psychol, Chongqing, Peoples R China.
   [Song, Hongwen; Zhang, Xiaochu] Chinese Acad Sci, Hefei Inst Phys Sci, Ctr Med Phys & Technol, Hefei, Peoples R China.
   [Zhang, Yuting; Zhang, Xiaochu] Chinese Acad Sci, Univ Sci & Technol China, Sch Life Sci, Key Lab Brain Funct & Dis, Hefei, Peoples R China.
   [Zhang, Xiaochu] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Peoples R China.
   [Zhang, Xiaochu] Univ Sci & Technol China, Ctr Biomed Engn, Hefei, Peoples R China.
RP Zhang, XC (reprint author), Chinese Acad Sci, Hefei Inst Phys Sci, Ctr Med Phys & Technol, Hefei, Peoples R China.; Zhang, XC (reprint author), Chinese Acad Sci, Univ Sci & Technol China, Sch Life Sci, Key Lab Brain Funct & Dis, Hefei, Peoples R China.; Zhang, XC (reprint author), Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei, Peoples R China.; Zhang, XC (reprint author), Univ Sci & Technol China, Ctr Biomed Engn, Hefei, Peoples R China.
EM zxcustc@ustc.edu.cn
FU National Natural Science Foundation of China [31230032, 31171083,
   31471071]; Fundamental Research Funds for the Central Universities of
   China [SWU 1509134, WK2070000033]; Chinese Academy of Sciences
   [KJ2070000018]; Hefei Science Center, CAS "User with Potential"
   [2015HSC-UP017]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31230032, 31171083, and 31471071), the Fundamental
   Research Funds for the Central Universities of China (SWU 1509134 and
   WK2070000033), the 100 Talents Program of the Chinese Academy of
   Sciences (KJ2070000018), and Hefei Science Center, CAS "User with
   Potential" (2015HSC-UP017).
CR Acevedo BP, 2012, SOC COGN AFFECT NEUR, V7, P145, DOI 10.1093/scan/nsq092
   Amaro H, 1999, HISPANIC J BEHAV SCI, V21, P266, DOI 10.1177/0739986399213005
   Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Asensio S, 2010, SYNAPSE, V64, P397, DOI 10.1002/syn.20741
   Association AP, 2013, DIAGN STAT MAN MENT
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Baler RD, 2006, TRENDS MOL MED, V12, P559, DOI 10.1016/j.molmed.2006.10.005
   Bartels A, 2000, NEUROREPORT, V11, P3829, DOI 10.1097/00001756-200011270-00046
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Bertran-Gonzalez J, 2008, J NEUROSCI, V28, P5671, DOI 10.1523/JNEUROSCI.1039-08.2008
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bosch OJ, 2009, NEUROPSYCHOPHARMACOL, V34, P1406, DOI 10.1038/npp.2008.154
   Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003
   Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Cisler JM, 2013, PSYCHIAT RES-NEUROIM, V213, P39, DOI 10.1016/j.pscychresns.2013.02.007
   Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555
   Cui SS, 2001, J NEUROSCI, V21, P9867
   Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591
   Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072
   Elliott R, 2003, J NEUROSCI, V23, P303
   Esch T, 2005, NEUROENDOCRINOL LETT, V26, P175
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Fisher HE, 1998, HUM NATURE-INT BIOS, V9, P23, DOI 10.1007/s12110-998-1010-5
   Fisher HE, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00687
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Fox Michael D, 2010, Front Syst Neurosci, V4, P19, DOI 10.3389/fnsys.2010.00019
   Fraley R., 2000, REV GEN PSYCHOL, V4, P132, DOI DOI 10.1037/1089-2680.4.2.132
   Frascella J, 2010, ANN NY ACAD SCI, V1187, P294, DOI 10.1111/j.1749-6632.2009.05420.x
   GIBBS DM, 1984, LIFE SCI, V35, P487, DOI 10.1016/0024-3205(84)90241-8
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Grieder TE, 2012, P NATL ACAD SCI USA, V109, P3101, DOI 10.1073/pnas.1114422109
   Grippo AJ, 2007, PSYCHOSOM MED, V69, P149, DOI 10.1097/PSY.0b013e31802f054b
   Gu H, 2010, NEUROIMAGE, V53, P593, DOI 10.1016/j.neuroimage.2010.06.066
   Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109
   HATFIELD E, 1986, J ADOLESCENCE, V9, P383, DOI 10.1016/S0140-1971(86)80043-4
   HATFIELD E, 1987, ARCH SEX BEHAV, V16, P259, DOI 10.1007/BF01541613
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   HENRY DJ, 1995, J NEUROSCI, V15, P6287
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Jarrett TM, 2006, NEUROPEPTIDES, V40, P161, DOI 10.1016/j.npep.2006.03.002
   Johns JM, 1997, NEUROPEPTIDES, V31, P439, DOI 10.1016/S0143-4179(97)90037-8
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2010, BRAIN RES, V1314, P3, DOI 10.1016/j.brainres.2009.11.008
   Koob G. F., 1999, PSYCHIATRY, V46, P1167, DOI [10.1016/S0006-3223(99)00164-X, DOI 10.1016/S0006-3223(99)00164-X]
   KOVACS GL, 1981, NEUROPHARMACOLOGY, V20, P647, DOI 10.1016/0028-3908(81)90111-8
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Liebowitz M. R., 1983, CHEM LOVE
   Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062
   Liu N, 2015, P NATL ACAD SCI USA, V112, pE3123, DOI 10.1073/pnas.1508097112
   Lv WW, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01335
   Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037
   Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5
   Marazziti D, 2004, PSYCHONEUROENDOCRINO, V29, P931, DOI 10.1016/j.psyneuen.2003.08.006
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Melis M, 2005, INT REV NEUROBIOL, V63, P101, DOI 10.1016/S0074-7742(05)63005-X
   Meloy JR, 2005, J FORENSIC SCI, V50, P1472
   MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0
   NAKAJIMA S, 1986, PHARMACOL BIOCHEM BE, V24, P919, DOI 10.1016/0091-3057(86)90437-5
   Narendran R, 2005, AM J PSYCHIAT, V162, P2352, DOI 10.1176/appi.ajp.162.12.2352
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Ortigue S, 2007, J COGNITIVE NEUROSCI, V19, P1218, DOI 10.1162/jocn.2007.19.7.1218
   Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x
   Parker KJ, 2005, PSYCHONEUROENDOCRINO, V30, P924, DOI 10.1016/j.psyneuen.2005.04.002
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   SARNYAI Z, 1992, NEUROPHARMACOLOGY, V31, P593, DOI 10.1016/0028-3908(92)90192-R
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563
   Song HW, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00071
   Starka L, 2007, Prague Med Rep, V108, P297
   STERNBERG RJ, 1986, PSYCHOL REV, V93, P119, DOI 10.1037/0033-295X.93.2.119
   Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117
   Tops M, 2014, PHARMACOL BIOCHEM BE, V119, P39, DOI 10.1016/j.pbb.2013.07.015
   van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Volkow ND, 2008, NEUROIMAGE, V42, P1537, DOI 10.1016/j.neuroimage.2008.06.002
   Volkow ND, 2007, ARCH NEUROL-CHICAGO, V64, P1575, DOI 10.1001/archneur.64.11.1575
   Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936
   Wang Y, 2016, NEUROREPORT, V27, P323, DOI 10.1097/WNR.0000000000000541
   Wei ZD, 2016, SCI REP-UK, V6, DOI 10.1038/srep21778
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816
   Xu XM, 2011, HUM BRAIN MAPP, V32, P249, DOI 10.1002/hbm.21017
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zhang XC, 2011, NEUROIMAGE, V54, P131, DOI 10.1016/j.neuroimage.2010.07.063
   Zhang XC, 2009, HUM BRAIN MAPP, V30, P896, DOI 10.1002/hbm.20552
   Zhang YJ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00675
   Zorrilla EP, 2001, PSYCHOPHARMACOLOGY, V158, P374, DOI 10.1007/s002130100773
NR 99
TC 0
Z9 0
U1 29
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD SEP 22
PY 2016
VL 7
DI 10.3389/fpsyg.2016.01436
PG 12
WC Psychology, Multidisciplinary
SC Psychology
GA DW5EB
UT WOS:000383663900002
ER

PT J
AU Preckel, K
   Kanske, P
   Singer, T
   Paulus, FM
   Krach, S
AF Preckel, Katrin
   Kanske, Philipp
   Singer, Tania
   Paulus, Frieder M.
   Krach, Soeren
TI Clinical trial of modulatory effects of oxytocin treatment on
   higher-order social cognition in autism spectrum disorder: a randomized,
   placebo-controlled, double-blind and crossover trial
SO BMC PSYCHIATRY
LA English
DT Article
DE Autism spectrum disorder; Oxytocin; Emotional reactivity; Social
   motivation; Social reward; Empathy; Theory of mind; fMRI; Oxytocin
   receptor gene
ID HIGH-FUNCTIONING AUTISM; INTRANASAL OXYTOCIN; REPETITIVE BEHAVIORS;
   NUCLEUS-ACCUMBENS; ASPERGER-SYNDROME; BRAIN RESPONSES; NEURAL-NETWORKS;
   BDI-II; REWARD; ADULTS
AB Background: Autism spectrum disorders are neurodevelopmental conditions with severe impairments in social communication and interaction. Pioneering research suggests that oxytocin can improve motivation, cognition and attention to social cues in patients with autism spectrum disorder. The aim of this clinical trial is to characterize basic mechanisms of action of acute oxytocin treatment on neural levels and to relate these to changes in different levels of socio-affective and -cognitive functioning.
   Methods: This clinical study is a randomized, double-blind, cross-over, placebo-controlled, multicenter functional magnetic resonance imaging study with two arms. A sample of 102 male autism spectrum disorder patients, diagnosed with Infantile Autistic Disorder (F84.0 according to ICD-10), Asperger Syndrome (F84.5 according to ICD-10), or Atypical Autism (F84.1 according to ICD-10) will be recruited and will receive oxytocin and placebo nasal spray on two different days. Autism spectrum disorder patients will be randomized to determine who receives oxytocin on the first and who on the second visit. Healthy control participants will be recruited and case-control matched to the autism spectrum disorder patients. The primary outcome will be neural network activity, measured with functional magnetic resonance imaging while participants perform socio-affective and -cognitive tasks. Behavioral markers such as theory of mind accuracy ratings and response times will be assessed as secondary outcomes in addition to physiological measures such as skin conductance. Trait measures for alexithymia, interpersonal reactivity, and social anxiety will also be evaluated. Additionally, we will analyze the effect of oxytocin receptor gene variants and how these potentially influence the primary and secondary outcome measures. Functional magnetic resonance imaging assessments will take place at two time points which will be scheduled at least two weeks apart to ensure a sufficient wash-out time after oxytocin treatment. The study has been approved by an ethical review board and the competent authority.
   Discussion: Revealing the mechanisms of acute oxytocin administration, especially on the socio-affective and -cognitive domains at hand, will be a further step towards novel therapeutic interventions regarding autism.
C1 [Preckel, Katrin; Kanske, Philipp; Singer, Tania] Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04107 Leipzig, Germany.
   [Paulus, Frieder M.; Krach, Soeren] Univ Klinikum Schleswig Holstein, Klin Psychiat & Psychotherapie, Campus Lubeck,Ratzeburger Allee 160, D-23562 Lubeck, Germany.
RP Preckel, K (reprint author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04107 Leipzig, Germany.
EM preckel@cbs.mpg.de
FU Bundesministerium fur Bildung und Forschung (BMBF) [01EE1409H]
FX The clinical study is financed by the Bundesministerium fur Bildung und
   Forschung (BMBF) (grant number: 01EE1409H, awarded to TS, PK, SK and
   FP).
CR Althaus M, 2015, NEUROPSYCHOLOGIA, V79, P53, DOI 10.1016/j.neuropsychologia.2015.10.025
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2016, CORTEX, V76, P79, DOI 10.1016/j.cortex.2015.12.010
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Anger H, 1968, WORTSCHATZTEST WST 7
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Barratt E. S., 1994, VIOLENCE MENTAL DISO, P61
   Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060
   Burri A, 2008, PSYCHONEUROENDOCRINO, V33, P591, DOI 10.1016/j.psyneuen.2008.01.014
   Busner J, 2009, COMPR PSYCHIAT, V50, P257, DOI 10.1016/j.comppsych.2008.08.005
   CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Davis M. H., 1980, JSAS CATALOG SELECTE, V10, P85, DOI DOI 10.1037//0022-3514.44.1.113
   Derogatis L, 1983, BRIEF SYMPTOM INVENT, V13, P595, DOI DOI 10.1017/S0033291700048017
   Di Martino A, 2009, BIOL PSYCHIAT, V65, P63, DOI 10.1016/j.biopsych.2008.09.022
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Domes G, 2014, NEUROPSYCHOPHARMACOL, V39, P698, DOI 10.1038/npp.2013.254
   Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007
   Eckstein M, 2016, NEUROPSYCHOPHARMACOL, V41, P932, DOI 10.1038/npp.2015.245
   Eckstein M, 2015, BIOL PSYCHIAT, V78, P194, DOI 10.1016/j.biopsych.2014.10.015
   Eckstein M, 2014, HUM BRAIN MAPP, V35, P4741, DOI 10.1002/hbm.22508
   Friston KJ, 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402
   Frith U, 2005, CURR BIOL, V15, pR786, DOI 10.1016/j.cub.2005.09.033
   Grabe HJ, 2012, PSYCHIAT PRAX, V39, P109, DOI 10.1055/s-0031-1298984
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hollander E, 2012, AM J PSYCHIAT, V169, P292, DOI 10.1176/appi.ajp.2011.10050764
   Janca A, 1996, SOC PSYCH PSYCH EPID, V31, P349, DOI 10.1007/BF00783424
   Kanske P, 2016, SOC COGN AFFECT NEUR, P1383
   Kanske P, 2015, NEUROIMAGE, V122, P6, DOI 10.1016/j.neuroimage.2015.07.082
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Knutson B, 2001, J NEUROSCI, V21, part. no.
   Kohls G, 2013, SOC COGN AFFECT NEUR, V8, P565, DOI 10.1093/scan/nss033
   Krach S, 2015, HUM BRAIN MAPP, V36, P4730, DOI 10.1002/hbm.22949
   Kuehner C, 2006, J AFFECT DISORDERS, V91, pS71
   Kuhner C, 2007, NERVENARZT, V78, P651, DOI 10.1007/s00115-006-2098-7
   Kumsta R, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00083
   Laux L., 1981, STATE TRAIT ANGSTINV
   Lee Seung Yup, 2015, Exp Neurobiol, V24, P312, DOI 10.5607/en.2015.24.4.312
   Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121
   Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658
   Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-7967(97)10031-6
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Nickels KC, 2008, J DEV BEHAV PEDIATR, V29, P75, DOI 10.1097/DBP.0b013e31815f24f7
   Paulus FM, 2013, RES DEV DISABIL, V34, P1312, DOI 10.1016/j.ridd.2013.01.009
   Paulus FM, 2015, CORTEX, V65, P219, DOI 10.1016/j.cortex.2015.01.018
   Preckel K, 2015, SOC COGN AFFECT NEUR, V10, P987, DOI 10.1093/scan/nsu147
   Preckel K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00191
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Rademacher L, 2016, CURR TOP BEHAV NEURO, P1
   Rademacher L, 2010, NEUROIMAGE, V49, P3276, DOI 10.1016/j.neuroimage.2009.10.089
   Schultz RT, 2005, INT J DEV NEUROSCI, V23, P125, DOI 10.1016/j.ijdevneu.2004.12.012
   Schulz Kenneth F, 2010, J Pharmacol Pharmacother, V1, P100, DOI 10.4103/0976-500X.72352
   Silani G, 2008, SOC NEUROSCI, V3, P97, DOI 10.1080/17470910701577020
   Singer T, 2008, EMOTION, V8, P781, DOI 10.1037/a0014195
   Spreckelmeyer KN, 2009, SOC COGN AFFECT NEUR, V4, P158, DOI 10.1093/scan/nsn051
   Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048
   Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8
   Trimmer E, 2016, AUTISM, P1
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181
   Yatawara CJ, 2015, MOL PSYCHIATR, P1225
   Zink CF, 2012, HORM BEHAV, V61, P400, DOI 10.1016/j.yhbeh.2012.01.016
NR 69
TC 0
Z9 0
U1 14
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD SEP 21
PY 2016
VL 16
AR 329
DI 10.1186/s12888-016-1036-x
PG 10
WC Psychiatry
SC Psychiatry
GA DX4IR
UT WOS:000384344900001
ER

PT J
AU Sun, L
   Liu, LN
   Zong, SB
   Wang, ZZ
   Zhou, J
   Xu, ZL
   Ding, G
   Xiao, W
   Kou, JP
AF Sun, Lan
   Liu, Lina
   Zong, Shaobo
   Wang, Zhengzhong
   Zhou, Jun
   Xu, Zhiliang
   Ding, Gang
   Xiao, Wei
   Kou, Junping
TI Traditional Chinese medicine Guizhi Fuling capsule used for therapy of
   dysmenorrhea via attenuating uterus contraction
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Guizhi Fuling capsule; Primary dysmenorrhea; Uterine contraction;
   Uterine smooth muscle cells; Ca2+
ID SMOOTH-MUSCLE; IN-VITRO; OXYTOCIN; WOMEN
AB Ethnopharmacological relevance: Guizhi Fuling formula, a well-known Chinese herbal formula recorded in the Eastern Han Dynasty, is composed of Cinnamomum cassia (L)J.Presl (Cassia bark), Poria cocos (Schw.) Wolf (Poria), Paeonia suffruticosa andrews (Mouton Cortex), Paeonia lactiflora Pall (Herbaceous peony), and Amygdalus persica L.(Persicae Semen). It has clinical efficacy of activating blood circulation to dissipate blood stasis and is commonly used for the treatment of primary dysmenorrhea. However, its therapeutic mechanism has not been clearly elucidated. The aim of this study is to reveal molecular mechanisms of action using in vivo and in vitro experimental models.
   Material and methods: The ICR mouse uterine contraction was induced by oxytocin exposure following estradiol benzoate pretreatment. Mice were given GZFLC (0.54, 1.08 g/kg) by gavage. The levels of NO, PGF(2 alpha), and Ca2+ in uterine tissue were determined according to instructions. Cyclooxygenase-2 (COX-2) and oxytocin receptor (OTR) proteins in uterine tissue were assessed by Western Blot. Mouse isolated uterus strips were mounted in tissue organ baths containing Locke's solution. The contractile responses were recorded with Power Lab recording system. The effect of GZFLC on spontaneous uterine contraction, and uterine contraction induced by oxytocin, PGF(2 alpha) was observed. Myometrial cells were exposed to oxytocin (5 U/L) to induce calcium release, and the effect of GZFLC and its components (PL, PGG, CA) on intracellular Ca2+ was analyzed with fluorometry imaging.
   Results: In vivo study demonstrated that GZFLC significantly reduced oxytocin-induced writhing responses with a maximal inhibition of 55%. It also decreased the levels of NO, PGF(2 alpha) and Ca2+ in oxytocin-induced mice uterine tissue. Moreover, Western blot analysis showed that COX-2 and OTR expressions in uterine tissue of dysmenorrhea mice were significantly reduced. GZFLC inhibited spontaneous uterus contractions in a dose-dependent manner, and the IC50 value was 0.99 mg/ml. The IC50 values of GZFLC on PGF(2 alpha), oxytocin-induced contractions were 1.45 mg/ml, 3.53 mg/ml, respectively. Further in vitro studies indicated that GZFLC and its components (PL, PGG, CA) could restrain intracellular calcium levels in favour of uteri relaxation.
   Conclusions: Both in vivo and in vitro results indicated that GZFLC possessed a significant spasmolytic effect on uterine tetanic contraction. The present study provides in vivo and in vitro experimental evidence to support the use of GZFLC for the clinical treatment of primary dysmenorrheal (PD). (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Sun, Lan; Kou, Junping] China Pharmaceut Univ, Jiangsu Prov Key Lab TCM Evaluat & Translat Res, 639 Longmian Rd, Nanjing 211198, Jiangsu, Peoples R China.
   [Sun, Lan; Liu, Lina; Zong, Shaobo; Wang, Zhengzhong; Zhou, Jun; Xu, Zhiliang; Ding, Gang; Xiao, Wei] Jiangsu Kan Pharmaceut Co Ltd, State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang 222001, Jiangsu, Peoples R China.
RP Kou, JP (reprint author), China Pharmaceut Univ, Jiangsu Prov Key Lab TCM Evaluat & Translat Res, 639 Longmian Rd, Nanjing 211198, Jiangsu, Peoples R China.; Xiao, W (reprint author), Jiangsu Kan Pharmaceut Co Ltd, 58 Haichang Rd, Lianyungang 222001, Jiangsu, Peoples R China.
EM sunlan2012@126.com; xw_kanion@163.com; junpingkou@cpu.edu.cn
FU National Major Scientific and Technological Special Project for
   Significant New Drugs Development [2013ZX09402203]
FX This work was financially supported by National Major Scientific and
   Technological Special Project for Significant New Drugs Development
   (2013ZX09402203).
CR Bernstein K, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.06.018
   Burton WN, 2003, J OCCUP ENVIRON MED, V45, P610, DOI 10.1097/01.jom0000069244.06498.01
   CALIXTO JB, 1991, J PHARM PHARMACOL, V43, P529
   Chen YT, 2013, PHYTOMEDICINE, V20, P1095, DOI 10.1016/j.phymed.2013.05.003
   FENAKEL K, 1990, EUR J OBSTET GYN R B, V37, P199, DOI 10.1016/0028-2243(90)90025-V
   Filler W.W., 1970, OBSTET GYNECOL SURV, V25, P778, DOI 10.1097/00006254-197008000-00020
   French L, 2005, AM FAM PHYSICIAN, V71, P285
   Fuchs AR, 2001, BIOL REPROD, V65, P1135, DOI 10.1095/biolreprod65.4.1135
   HALBERT DR, 1978, J REPROD MED, V21, P219
   He DY, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00010
   Hsu CS, 2003, PHYTOTHER RES, V17, P778, DOI 10.1002/ptr.1235
   Hu C.D., 2009, CHEM BIOENG, V8, P008
   Kaplan O, 2013, J REPROD IMMUNOL, V100, P87, DOI 10.1016/j.jri.2013.10.004
   KOKJOHN K, 1992, J MANIP PHYSIOL THER, V15, P279
   Lefebvre Guylaine, 2005, J Obstet Gynaecol Can, V27, P1117
   [柳于介 Liu Yujie], 2013, [中国中药杂志, China Journal of Chinese Materia Medica], V38, P2019
   Lumsden M.A., 1983, J OBSTET GYNAECOL, V90, P1135
   Moya RA, 2000, INT J GYNECOL OBSTET, V69, P113, DOI 10.1016/S0020-7292(00)00185-5
   POWELL AM, 1985, PROSTAGLANDINS, V29, P273, DOI 10.1016/0090-6980(85)90208-4
   Rudolph MI, 1997, J PHARMACOL EXP THER, V282, P256
   Sales KJ, 2003, REPRODUCTION, V126, P559, DOI 10.1530/rep.0.1260559
   SHIKANO K, 1987, BRIT J PHARMACOL, V92, P483
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Wray S, 2003, J SOC GYNECOL INVEST, V10, P252, DOI 10.1016/S1071-5576(03)00089-3
   Wrobel MH, 2015, TOXICOL APPL PHARM, V285, P23, DOI 10.1016/j.taap.2015.03.005
   Zahradnik HP, 2010, CONTRACEPTION, V81, P185, DOI 10.1016/j.contraception.2009.09.014
   Zhang G.H., 2012, J LIAONING U TRADIT, V14, P188
   Zhang JH, 2009, PHARM RES-DORD, V26, P2066, DOI 10.1007/s11095-009-9932-0
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
NR 29
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 15
PY 2016
VL 191
BP 273
EP 279
DI 10.1016/j.jep.2016.06.042
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA DY7OO
UT WOS:000385319100025
PM 27340106
ER

PT J
AU Sirotkin, AV
   Mertin, D
   Suvegova, K
   Lauricik, J
   Morovic, M
   Harrath, AH
   Kotwica, J
AF Sirotkin, Alexander V.
   Mertin, Dusan
   Suvegova, Karina
   Lauricik, Jozef
   Morovic, Martin
   Harrath, Abdel Halim
   Kotwica, Jan
TI Mink aging is associated with a reduction in ovarian hormone release and
   the response to FSH and ghrelin
SO THERIOGENOLOGY
LA English
DT Article
DE Aging; Ovary; Mink; FSH; Ghrelin; Ovarian hormones
ID MUSTELA-VISON; OXYTOCIN; FOLLICLES; STEROIDS; AXIS; EXPRESSION;
   SECRETION; PUBERTY; GROWTH; PROLIFERATION
AB The endocrine mechanisms of mink ovarian hormones release and reproductive aging are poorly investigated. The aims of our study were to: (1) identify hormones produced by mink ovaries (the steroids progesterone [P] and estradiol [E], the peptide hormone oxytocin [OT], and the prostaglandin F [PGF] and prostaglandin E [PGE]); (2) examine the effect of FSH and ghrelin on the release of the hormones listed previously; and (3) understand whether these hormones can be involved in the control of mink reproductive aging, i.e., whether aging can be associated with changes (a) in the basal release of P, E, OT, PGF, or PGE and (b) their response to FSH and ghrelin. Fragments of ovaries of young (yearlings) and old (3-5 years of age) minks were cultured with and without FSH and ghrelin (0, 1, 10, or 100 ng/mL), and the release of hormones was analyzed by EIA/RIA. We found that isolated ovaries were able to release P, E, OT, PGF, and PGE, and the levels of P produced in the ovaries of old animals were lower than those produced in the ovaries of young animals, whereas the levels of other hormones did not differ. FSH was able to stimulate P and E and suppress OT and PGF and did not affect PGE release. Aging was associated with the inhibition of the effect of FSH on ovarian P and E, the appearance of the inhibitory action of FSH on OT, and the disappearance of this action on ovarian PGF. PGE was not affected by FSH, irrespective of animal age. Ghrelin was able to promote E (but not P) and suppress OT, PGF, and PGE output. Aging was associated with the appearance of an inhibitory influence of ghrelin on ovarian OT and PGE and with the disappearance of this influence on PGF output. Aging did not affect the action of ghrelin on ovarian P and E. Our observations (1) confirm the production of P and E and show that OT, PGF, and PGE are released from mink ovaries, (2) confirm the involvement of FSH and demonstrate the involvement of ghrelin in the control of mink ovarian hormone release, and (3) suggest that reproductive aging in minks is due to a reduction in basal P release and alterations in the response of E, OT, PGF (but not of PGE) to FSH and ghrelin. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sirotkin, Alexander V.; Lauricik, Jozef; Morovic, Martin] Constantine Philosopher Univ, Nitra, Slovakia.
   [Sirotkin, Alexander V.; Mertin, Dusan; Suvegova, Karina] Res Inst Anim Prod, Luzianky, Slovakia.
   [Harrath, Abdel Halim] King Saud Univ, Dept Zool, Coll Sci, Riyadh, Saudi Arabia.
   [Kotwica, Jan] Polish Acad Sci, Inst Anim Reprod & Food Res, Olsztyn, Poland.
RP Sirotkin, AV (reprint author), Constantine Philosopher Univ, Nitra, Slovakia.; Sirotkin, AV (reprint author), Res Inst Anim Prod, Luzianky, Slovakia.
EM asirotkin@ukf.sk
RI Harrath, Abdul Halim/K-2166-2014
OI Harrath, Abdul Halim/0000-0002-2170-1303
FU Slovak Research and Development Agency [APVV-14-0001]; Ministry of
   Agriculture of the Slovak Republic [RUVVR 07-13]; Deanship of Scientific
   Research at King Saud University [164];  [VEGA 1/0022/15];  [VEGA
   1/0327/16];  [KEGA 001UKF-4/2016]
FX The authors express their deep gratitude to Ms. K. Tothova and Ing. Z.
   Kuklova for skilful help in analyzing the samples, Dr. T. Cervenkova for
   inspiration to writing this article, and to Professors G. Kotwica
   (University of Warmia and Mazury, Olsztyn, Poland), W.J. Silvia
   (University of Kentucky, USA), and W.W. Thatcher (University of Florida,
   Gainesville, USA) for kind donation of OT, prostaglandin F metabolite
   and prostaglandin E antisera, respectively. This work was supported by
   Slovak Research and Development Agency under the contract no.
   APVV-14-0001 and also co-funded by the projects VEGA 1/0022/15, VEGA
   1/0327/16, KEGA 001UKF-4/2016, and Ministry of Agriculture of the Slovak
   Republic, project RUVVR 07-13. The authors would also like to extend
   their sincere appreciation to the Deanship of Scientific Research at
   King Saud University for funding the Research group NO (RG#164).
CR Akande VA, 2004, J ASSIST REPROD GEN, V21, P257, DOI 10.1023/B:JARG.0000042011.67696.85
   Amstislavsky S, 2008, REPROD DOMEST ANIM, V43, P502, DOI 10.1111/j.1439-0531.2007.00950.x
   Bao Q, 2014, MOL CELL ENDOCRINOL, V394, P115, DOI 10.1016/j.mce.2014.07.005
   Berlinguer F, 2012, REPRODUCTION, V144, P245, DOI 10.1530/REP-12-0030
   Broekmans FJ, 2009, ENDOCR REV, V30, P465, DOI 10.1210/er.2009-0006
   Dias FCF, 2014, ANIM REPROD SCI, V149, P80, DOI 10.1016/j.anireprosci.2014.07.016
   Duras M, 2005, PROSTAG OTH LIPID M, V76, P105, DOI 10.1016/j.prostaglandins.2005.02.001
   EKSTROM TJ, 1993, GEN COMP ENDOCR, V90, P243, DOI 10.1006/gcen.1993.1079
   El-Eshmawy MM, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-153
   Finch CE, 2014, J STEROID BIOCHEM, V142, P132, DOI 10.1016/j.jsbmb.2013.03.010
   Greenman Y, 2009, NEUROENDOCRINOLOGY, V89, P79, DOI 10.1159/000151768
   Gupta M, 2015, GEN COMP ENDOCR, V210, P87, DOI 10.1016/j.ygcen.2014.09.013
   Hale GE, 2014, J STEROID BIOCHEM, V142, P121, DOI 10.1016/j.jsbmb.2013.08.015
   Huffmeijer R, 2013, GERONTOLOGY, V59, P32, DOI 10.1159/000341333
   Junnila RK, 2013, NAT REV ENDOCRINOL, V9, P366, DOI 10.1038/nrendo.2013.67
   KOTWICA J, 1993, J REPROD FERTIL, V97, P411
   Malhi PS, 2008, ANIM REPROD SCI, V109, P100, DOI 10.1016/j.anireprosci.2007.12.002
   Mertin D, 1994, POTREBA ZIVIN VYZIVN, P60
   MILLER FD, 1989, P NATL ACAD SCI USA, V86, P2468, DOI 10.1073/pnas.86.7.2468
   Moshtaghi-Kashanian GR, 2009, HORM-INT J ENDOCRINO, V8, P207
   PARKENING TA, 1985, EXP GERONTOL, V20, P291, DOI 10.1016/0531-5565(85)90055-5
   Rak A, 2008, J PHYSIOL PHARMACOL, V59, P781
   Rak-Mardyla A, 2013, J PHYSIOL PHARMACOL, V64, P695
   Rak-Mardyla A, 2015, REPROD SCI, V22, P469, DOI 10.1177/1933719114549854
   Semiz O, 2009, ACTA HISTOCHEM, V111, P104, DOI 10.1016/j.acthis.2008.04.007
   Sirotkin AV, 2008, PHYSIOL RES, V57, P745
   Sirotkin AV, 2008, REPRODUCTION, V136, P611, DOI 10.1530/REP-08-0229
   Sirotkin AV, 2006, MOL CELL ENDOCRINOL, V257-8, P15, DOI 10.1016/j.mce.2006.06.004
   Sirotkin AV, 2010, DOMEST ANIM ENDOCRIN, V39, P1, DOI 10.1016/j.domaniend.2009.06.001
   Sirotkin AV, 2014, FOLIA BIOL-KRAKOW, V62, P211, DOI 10.3409/fb62_3.211
   Sirotkin AV., 2014, REGULATORS OVARIAN F, P194
   Skarzynski DJ, 1999, THERIOGENOLOGY, V52, P385, DOI 10.1016/S0093-691X(99)00137-5
   SUNDQVIST C, 1989, J REPROD FERTIL, V85, P413
   Suvegova K., 2000, Scientifur, V24, P207
   Tauson AH, 2000, REPROD NUTR DEV, V40, P229, DOI 10.1051/rnd:2000128
   Tauson AH, 2001, J REP FER S, P97
   Tena-Sempere M, 2013, ENDOCR DEV, V25, P69, DOI 10.1159/000346055
NR 37
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD SEP 15
PY 2016
VL 86
IS 5
BP 1175
EP 1181
DI 10.1016/j.theriogenology.2016.04.007
PG 7
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DT1KO
UT WOS:000381241600004
PM 27160444
ER

PT J
AU Wang, J
   Tang, M
   Jiang, HD
   Wu, B
   Cai, W
   Hu, C
   Bao, RQ
   Dong, QM
   Xiao, L
   Li, G
   Zhang, CP
AF Wang, Jing
   Tang, Min
   Jiang, Huaide
   Wu, Bing
   Cai, Wei
   Hu, Chuan
   Bao, Riqiang
   Dong, Qiming
   Xiao, Li
   Li, Gang
   Zhang, Chunping
TI The role of adrenergic activation on murine luteal cell viability and
   progesterone production
SO THERIOGENOLOGY
LA English
DT Article
DE Luteal cell; Norepinephrine; Isoprenaline; Progesterone
ID BOVINE CORPUS-LUTEUM; CORPORA-LUTEA; OXYTOCIN; RECEPTOR; NOREPINEPHRINE;
   CATECHOLAMINES; NORADRENALINE; REGRESSION; APOPTOSIS; SECRETION
AB Sympathetic innervations exist in mammalian CL. The action of catecholaminergic system on luteal cells has been the focus of a variety of studies. Norepinephrine (NE) increased progesterone secretion of cattle luteal cells by activating beta-adrenoceptors. In this study, murine luteal cells were treated with NE and isoprenaline (ISO). We found that NE increased the viability of murine luteal cells and ISO decreased the viability of luteal cells. Both NE and ISO promoted the progesterone production. Nonselective beta-adrenergic antagonist, propranolol reversed the effect of ISO on cell viability but did not reverse the effect of NE on cell viability. Propranolol blocked the influence of NE and ISO on progesterone production. These results reveal that the increase of luteal cell viability induced by NE is not dependent on beta-adrenergic activation. alpha-Adrenergic activation possibly contributes to it. Both NE and ISO increased progesterone production through activating beta-adrenergic receptor. Further study showed that CyclinD2 is involved in the increase of luteal cell induced by NE. 3 beta-Hydroxysteroid dehydrogenase, LHR, steroidogenic acute regulatory protein (StAR), and PGF2 alpha contribute to the progesterone production induced by NE and ISO. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Wang, Jing] Nanchang Univ, Sch Med, Dept Microbiol, Nanchang, Jiangxi, Peoples R China.
   [Tang, Min; Cai, Wei; Hu, Chuan; Xiao, Li; Li, Gang; Zhang, Chunping] Nanchang Univ, Sch Med, Dept Cell Biol, Nanchang, Jiangxi, Peoples R China.
   [Jiang, Huaide; Wu, Bing] Nanchang Univ, Sch Med, Dept Physiol, Nanchang, Jiangxi, Peoples R China.
   [Bao, Riqiang; Dong, Qiming] Joint Programme Nanchang Univ & Queen Mary Univ L, London, England.
RP Zhang, CP (reprint author), Nanchang Univ, Sch Med, Dept Cell Biol, Nanchang, Jiangxi, Peoples R China.
EM zhangcp81@gmail.com
FU Jiangxi science and technology support project [20141BBG70065]; Health
   and family planning project of Jiangxi province [20155639]
FX This study was supported by Jiangxi science and technology support
   project (20141BBG70065) and Health and family planning project of
   Jiangxi province (20155639). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   article.
CR AULETTA FJ, 1988, ENDOCR REV, V9, P88
   BAHR J, 1974, BIOL REPROD, V10, P273, DOI 10.1095/biolreprod10.2.273
   Bogacki M, 1999, THERIOGENOLOGY, V52, P91, DOI 10.1016/S0093-691X(99)00112-0
   Bowolaksono A, 2008, BIOL REPROD, V79, P310, DOI 10.1095/biolreprod.107.066084
   BURDEN HW, 1977, ACTA ANAT, V97, P286
   FOHR KJ, 1993, J CLIN ENDOCR METAB, V76, P367, DOI 10.1210/jc.76.2.367
   HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2
   Iwai-Kanai E, 1999, CIRCULATION, V100, P305
   Jhaveri DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098736
   JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249
   Korzekwa A, 2004, J REPROD DEVELOP, V50, P411, DOI 10.1262/jrd.50.411
   Kotwica J, 2002, DOMEST ANIM ENDOCRIN, V23, P299, DOI 10.1016/S0739-7240(02)00165-0
   Mayerhofer A, 1999, MEDICINA-BUENOS AIRE, V59, P542
   Miszkiel G, 2001, ACTA VET HUNG, V49, P39
   Miszkiel G, 1999, REPROD NUTR DEV, V39, P509, DOI 10.1051/rnd:19990410
   Miyamoto A, 2009, DOMEST ANIM ENDOCRIN, V37, P159, DOI 10.1016/j.domaniend.2009.04.005
   Niswender GD, 2000, PHYSIOL REV, V80, P1
   Piccinato CA, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-95
   Skarzynski DJ, 2013, REPROD DOMEST ANIM, V48, P25, DOI 10.1111/rda.12203
   Wang J, 2015, REPROD FERT DEVELOP, V27, P1262, DOI 10.1071/RD14381
   Wang J, 2015, REPROD SCI, V22, P1243, DOI 10.1177/1933719115572480
   WHEELER AG, 1988, J ENDOCRINOL, V116, P137, DOI 10.1677/joe.0.1160137
NR 22
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD SEP 15
PY 2016
VL 86
IS 5
BP 1182
EP 1188
DI 10.1016/j.theriogenology.2016.04.008
PG 7
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DT1KO
UT WOS:000381241600005
PM 27173955
ER

PT J
AU Piccinno, M
   Rizzo, A
   Cariello, G
   Staffieri, F
   Sciorsci, RL
AF Piccinno, M.
   Rizzo, A.
   Cariello, G.
   Staffieri, F.
   Sciorsci, R. L.
TI Oxytocin plus antibiotics: A synergism of potentiation to enhance bovine
   uterine contractility
SO THERIOGENOLOGY
LA English
DT Article
DE Oxytocin; Amoxicillin; Enrofloxacin; Rifaximin; Uterus contractility;
   Bovine
ID RETAINED FETAL MEMBRANES; SENSITIVE K+ CHANNELS; IN-VITRO; CELLULAR
   MECHANISMS; METABOLITE CIPROFLOXACIN; HOLSTEIN COWS; DAIRY-COWS;
   MYOMETRIUM; UTERUS; PROSTAGLANDIN-F2-ALPHA
AB This in vitro study investigates the modulatory effect of three antibiotics (amoxicillin, enrofloxacin, and rifaximin) on contractility of the bovine uterine tissue, in follicular and luteal phases. The evaluation of the effects of these antibiotics (10(-4) M) was performed on oxytocin-induced contractility. The decision to test these antibiotics with the oxytocin (10(-6) M) comes from the reported ability of these combinations of hinder the antibiotic resistance and the formation of bacterial biofilms. The procedures were carried out in isolated organ bath, and the contractile functionality of the strip throughout the experiment was evaluated after a dose of carbachol (10(-6) M). The results demonstrate the different modulatory activity of these antibiotics, on the plateau of contraction induced by oxytocin, in both phases of the estrus cycle. The differing individual antibiotic effects of our testing made it possible to identify, only in some cases. Rifaximin in the follicular phase and enrofloxacin in both phases of the estrous cycle, induced a synergistic enhancement (potentiation) of uterine strip contraction induced by oxytocin. This result is thought important because these associations might enable, in vivo, a simultaneous increase of uterine cleaning and the antimicrobial action on bacteria in planktonic form and of those organized in biofilms. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Piccinno, M.; Rizzo, A.; Staffieri, F.; Sciorsci, R. L.] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Sect Vet Med & Anim Prod, Valenzano, BA, Italy.
   [Cariello, G.] Siav, ASL, Specialist Agreement, Bari, Italy.
RP Sciorsci, RL (reprint author), Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Sect Vet Med & Anim Prod, Valenzano, BA, Italy.
EM raffaeleluigi.sciorsci@uniba.it
CR Agarwal A, 2010, FEMS IMMUNOL MED MIC, V58, P147, DOI 10.1111/j.1574-695X.2009.00601.x
   Ahmad M., 2001, Pakistan Veterinary Journal, V21, P202
   Akar Y, 2010, PAK VET J, V30, P211
   Alanis AJ, 2005, ARCH MED RES, V36, P697, DOI 10.1016/j.arcmed.2005.06.009
   Andes D, 1998, ANTIMICROB AGENTS CH, V42, P2375
   Arrowsmith S, 2014, J NEUROENDOCRINOL, V26, P356, DOI 10.1111/jne.12154
   Asselin E, 1997, ENDOCRINOLOGY, V138, P4798, DOI 10.1210/en.138.11.4798
   Batoni G, 2011, CURR MED CHEM, V18, P256, DOI 10.2174/092986711794088399
   Becker B, 2001, BRIT J PHARMACOL, V134, P375, DOI 10.1038/sj.bjp.0704266
   Bergogne-Berezin E, 2002, CLIN PHARMACOKINET, V41, P741, DOI 10.2165/00003088-200241100-00004
   [Бухарин О.В. Bukharin О.V.], 2007, [Журнал микробиологии, эпидемиологии и иммунобиологии, Zhurnal mikrobiologii, epidemiologii i immunobiologii], P70
   BUKHARIN OV, 1984, ANTIBIOT MED BIOTEK, V29, P365
   Burns PD, 1997, DOMEST ANIM ENDOCRIN, V14, P181, DOI 10.1016/S0739-7240(97)00003-9
   Burns PD, 1998, DOMEST ANIM ENDOCRIN, V15, P477, DOI 10.1016/S0739-7240(98)00036-8
   Chenault JR, 2004, JAVMA-J AM VET MED A, V224, P1634, DOI 10.2460/javma.2004.224.1634
   COOPER MD, 1986, J ANIM SCI, V63, P151
   Davis JL, 2007, J VET PHARMACOL THER, V30, P564, DOI 10.1111/j.1365-2885.2007.00914.x
   Drillich M, 2006, J DAIRY SCI, V89, P627
   Drillich M, 2003, THERIOGENOLOGY, V59, P951, DOI 10.1016/S0093-691X(02)01132-9
   Estrela AB, 2009, CURR MED CHEM, V16, P1512
   Foldi J, 2006, ANIM REPROD SCI, V96, P265, DOI 10.1016/j.anireprosci.2006.08.006
   Gajewski Z, 1999, REPROD DOMEST ANIM, V34, P185, DOI 10.1111/j.1439-0531.1999.tb01239.x
   Gilbert P, 1997, Adv Dent Res, V11, P160
   Gilbert P, 2007, SCIENCE, V11, P160
   Gnemmi G., 2013, GESTIONE CLIN RIPROD, P121
   HYATT JM, 1995, CLIN PHARMACOKINET, V28, P143
   Jayaraman R, 2009, CURR SCI INDIA, V96, P1475
   Lewis GS, 1997, J DAIRY SCI, V80, P984, DOI 10.3168/jds.S0022-0302(97)76024-7
   Melendez P, 2004, J DAIRY SCI, V87, P3238
   Mengozzi G, 1996, AM J VET RES, V57, P1040
   MULHOLLAND MW, 1993, AM J SURG, V166, P552, DOI 10.1016/S0002-9610(05)81152-3
   Nuermberger E, 2004, EUR J CLIN MICROBIOL, V23, P243, DOI 10.1007/s10096-004-1109-5
   Olson ME, 2002, CAN J VET RES, V66, P86
   PATIL RK, 1980, NORD VET MED, V32, P474
   Perumamthadathil CS, 2014, CAN J VET RES, V78, P72
   Piccinno M, 2014, THERIOGENOLOGY, V82, P1287, DOI 10.1016/j.theriogenology.2014.08.008
   Piccinno M, 2014, FISH PHYSIOL BIOCHEM, V40, P1191, DOI 10.1007/s10695-014-9915-x
   POPESCU LM, 1985, BIOSCIENCE REP, V5, P21, DOI 10.1007/BF01117437
   Rizzo A, 2009, J VET PHARMACOL THER, V32, P548, DOI 10.1111/j.1365-2885.2009.01074.x
   Rizzo A, 2011, GYNECOL ENDOCRINOL, V27, P636, DOI 10.3109/09513590.2010.507293
   Rizzo A, 2010, THERIOGENOLOGY, V74, P1559, DOI 10.1016/j.theriogenology.2010.06.026
   Ruiz J, 2003, INT J ANTIMICROB AG, V22, P73, DOI 10.1016/S0924-8579(03)00083-9
   SERIO R, 1989, PROSTAG LEUKOTR ESS, V38, P237, DOI 10.1016/0952-3278(89)90127-0
   Sheldon IM, 2011, DAIR S PREC AUG 13 M
   Skorobogatykh Iul, 2010, ZH MIKROBIOL EPIDEMI, V6, P3
   SOLOFF MS, 1982, J BIOL CHEM, V257, P687
   Zunkler BJ, 2003, LIFE SCI, V73, P429, DOI 10.1016/S0024-3205(03)00296-0
NR 47
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD SEP 15
PY 2016
VL 86
IS 5
BP 1203
EP 1211
DI 10.1016/j.theriogenology.2016.04.011
PG 9
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DT1KO
UT WOS:000381241600008
PM 27173953
ER

PT J
AU Zimmermann, FF
   Gaspary, KV
   Siebel, AM
   Bonan, CD
AF Zimmermann, Fernanda Francine
   Gaspary, Karina Vidarte
   Siebel, Anna Maria
   Bonan, Carla Denise
TI Oxytocin reversed MK-801-induced social interaction and aggression
   deficits in zebrafish
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Aggression; MK-801; Oxytocin; Social behavior; Zebrafish
ID MALE RATS; PLASMA OXYTOCIN; DANIO-RERIO; SCHIZOPHRENIA; BEHAVIOR;
   AUTISM; MODEL; ADOLESCENT; BRAIN; VASOPRESSIN
AB Changes in social behavior occur in several neuropsychiatric disorders such as schizophrenia and autism. The interaction between individuals is an essential aspect and an adaptive response of several species, among them the zebrafish. Oxytocin is a neuroendocrine hormone associated with social behavior. The aim of the present study was to investigate the effects of MK-801, a non-competitive antagonist of glutamate NMDA receptors, on social interaction and aggression in zebrafish. We also examined the modulation of those effects by oxytocin, the oxytocin receptor agonist carbetocin and the oxytocin receptor antagonist L-368,899. Our results showed that MK-801 induced a decrease in the time spent in the segment closest to the conspecific school and in the time spent in the segment nearest to the mirror image, suggesting an effect on social behavior. The treatment with oxytocin after the exposure to MK-801 was able to reestablish the time spent in the segment closest to the conspecific school, as well as the time spent in the segment nearest to the mirror image. In addition, in support of the role of the oxytocin pathway in modulating those responses, we showed that the oxytocin receptor agonist carbetocin reestablished the social and aggressive behavioral deficits induced by MK-801. However, the oxytocin receptor antagonist L-368,899 was not able to reverse the behavioral changes induced by MK-801. This study supports the critical role for NMDA receptors and the oxytocinergic system in the regulation of social behavior and aggression which may be relevant for the mechanisms associated to autism and schizophrenia. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Zimmermann, Fernanda Francine; Gaspary, Karina Vidarte; Bonan, Carla Denise] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, Dept Biol Celular & Mol, Lab Neuroquim & Psicofarmacol,Fac Biociencias, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
   [Siebel, Anna Maria] Univ Comunitaria Regiao Chapeco, Programa Posgrad Ciencias Ambientais, Ave Senador Attilio Fontana 591E, BR-89809000 Chapeco, SC, Brazil.
RP Bonan, CD (reprint author), Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, Dept Biol Celular & Mol, Lab Neuroquim & Psicofarmacol,Fac Biociencias, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
EM cbonan@pucrs.br
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), and Fundacao de Amparo a Pesquisa do
   Estado do Rio Grande do Sul (FAPERGS). A.M.S and C.D.B. were recipients
   of fellowships from CNPq. F.F.Z and K.V.G. were the recipients of
   fellowships from Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and FAPERGS, respectively
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Amann LC, 2010, BRAIN RES BULL, V83, P147, DOI 10.1016/j.brainresbull.2010.04.008
   Anacker AMJ, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00185
   Andari E, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00224
   Arango C, 1999, SCHIZOPHRENIA BULL, V25, P493
   Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Black MP, 2004, NEUROREPORT, V15, P185, DOI 10.1097/01.wnr.0000103273.91211.7a
   Boccia ML, 2007, HORM BEHAV, V52, P344, DOI 10.1016/j.yhbeh.2007.05.009
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Braida D, 2012, PSYCHOPHARMACOLOGY, V220, P319, DOI 10.1007/s00213-011-2482-2
   Brain P F, 1988, Behav Processes, V17, P75, DOI 10.1016/0376-6357(88)90054-X
   Bshary R, 2014, TRENDS COGN SCI, V18, P465, DOI 10.1016/j.tics.2014.04.005
   BUIJS RM, 1982, BRAIN RES, V252, P71, DOI 10.1016/0006-8993(82)90979-9
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Calcagnoli F, 2013, PSYCHOPHARMACOLOGY, V229, P639, DOI 10.1007/s00213-013-3124-7
   CALDWELL JD, 1994, HORM BEHAV, V28, P288, DOI 10.1006/hbeh.1994.1024
   Canitano Roberto, 2014, Front Pediatr, V2, P61, DOI 10.3389/fped.2014.00061
   Carrillo M, 2011, BEHAV NEUROSCI, V125, P753, DOI 10.1037/a0025127
   Chen John, 2010, Int J Comp Psychol, V23, P82
   Couture SM, 2010, PSYCHOL MED, V40, P569, DOI 10.1017/S003329170999078X
   Crespi BJ, 2010, BRIT J PSYCHIAT, V196, P495, DOI 10.1192/bjp.196.6.495
   de Moura Linck Viviane, 2008, Prog Neuropsychopharmacol Biol Psychiatry, V32, P1449, DOI 10.1016/j.pnpbp.2008.04.013
   Ebner K., 2015, HORM BEHAV, V872, P87
   Echevarria DJ, 2008, INT J COMP PSYCHOL, V21, P19
   Feifel D., 2015, BIOL PSYCHIAT
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Filby AL, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-498
   Fischer-Shofty M, 2013, SCHIZOPHR RES, V146, P357, DOI 10.1016/j.schres.2013.01.006
   Gerlai R, 2000, PHARMACOL BIOCHEM BE, V67, P773, DOI 10.1016/S0091-3057(00)00422-6
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Goodson JL, 2005, HORM BEHAV, V48, P11, DOI 10.1016/j.yhbeh.2005.02.003
   Goodson JL, 2000, NATURE, V403, P769, DOI 10.1038/35001581
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Kalinine E, 2014, HORM BEHAV, V66, P383, DOI 10.1016/j.yhbeh.2014.06.005
   Kaminska K, 2015, PHARMACOL REP, V67, P1183, DOI 10.1016/j.pharep.2015.04.006
   Kraeuter A.K., 2015, SCHIZOPHR RES
   Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754
   Maaswinkel H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075955
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   Mathur P, 2010, NEUROBIOL DIS, V40, P66, DOI 10.1016/j.nbd.2010.05.016
   MCALLISTER KH, 1990, PHARMACOL BIOCHEM BE, V37, P101, DOI 10.1016/0091-3057(90)90048-M
   Mealey A, 2014, PSYCHIAT RES, V219, P380, DOI 10.1016/j.psychres.2014.05.040
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Mooney SJ, 2014, HORM BEHAV, V65, P380, DOI 10.1016/j.yhbeh.2014.02.003
   Morales M, 2014, PSYCHOPHARMACOLOGY, V231, P1797, DOI 10.1007/s00213-013-3278-3
   Moy SS, 2013, NEUROTOXICOL TERATOL, V36, P36, DOI 10.1016/j.ntt.2012.07.007
   Nagai T, 2011, BIOL PHARM BULL, V34, P1364
   Neill JC, 2010, PHARMACOL THERAPEUT, V128, P419, DOI 10.1016/j.pharmthera.2010.07.004
   Oliveira RF, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00131
   Oliveira RF, 2011, ZEBRAFISH, V8, P73, DOI 10.1089/zeb.2011.0690
   Pagnussat N, 2013, ZEBRAFISH, V10, P338, DOI 10.1089/zeb.2013.0867
   Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041
   PARNAS J, 1991, COMPR PSYCHIAT, V32, P7, DOI 10.1016/0010-440X(91)90065-K
   Romano A, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00497
   Saif M, 2013, BEHAV BRAIN RES, V243, P294, DOI 10.1016/j.bbr.2013.01.020
   Seibt KJ, 2011, BEHAV BRAIN RES, V224, P135, DOI 10.1016/j.bbr.2011.05.034
   Silvestre J S, 1997, Depress Anxiety, V5, P29, DOI 10.1002/(SICI)1520-6394(1997)5:1<29::AID-DA5>3.0.CO;2-0
   Snigdha S, 2008, BEHAV BRAIN RES, V191, P26, DOI 10.1016/j.bbr.2008.03.018
   Suraev AS, 2014, HORM BEHAV, V65, P488, DOI 10.1016/j.yhbeh.2014.03.002
   [Anonymous], 2013, PSYCHOPHARMACOLOGIA, DOI DOI 10.1089/CAP.2012.0048
   Teles MC, 2013, BEHAV BRAIN RES, V253, P17, DOI 10.1016/j.bbr.2013.07.012
   Teng BL, 2016, NEUROPHARMACOLOGY, V105, P61, DOI 10.1016/j.neuropharm.2015.12.025
   Tropepe V, 2003, GENES BRAIN BEHAV, V2, P268, DOI 10.1046/j.1601-183X.2003.00038.x
   van Loo KMJ, 2007, CURR GENOMICS, V8, P429, DOI 10.2174/138920207783591717
   Yatawara C.J., 2015, MOL PSYCHIAT
   Yu JF, 2011, BRAIN RES, V1385, P281, DOI 10.1016/j.brainres.2011.02.039
   Zhang L, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00259
NR 68
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD SEP 15
PY 2016
VL 311
BP 368
EP 374
DI 10.1016/j.bbr.2016.05.059
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DS1XJ
UT WOS:000380418200038
PM 27247142
ER

PT J
AU Chow, LH
   Chen, YH
   Wu, WC
   Chang, EP
   Huang, EYK
AF Chow, Lok-Hi
   Chen, Yuan-Hao
   Wu, Wan-Chuan
   Chang, En-Pei
   Huang, Eagle Yi-Kung
TI Sex Difference in Oxytocin-Induced Anti-Hyperalgesia at the Spinal Level
   in Rats with Intraplantar Carrageenan-Induced Inflammation
SO PLOS ONE
LA English
DT Article
ID ANGIOTENSIN-IV; MORPHINE ANTINOCICEPTION; ELECTRICAL-STIMULATION;
   CEREBROSPINAL-FLUID; INDUCED ANALGESIA; OPIOID RECEPTORS; CORD; PAIN;
   AMINOPEPTIDASE; MICE
AB Previously, we demonstrated intrathecal administration of oxytocin strongly induced anti-hyperalgesia in male rats. By using an oxytocin-receptor antagonist (atosiban), the descending oxytocinergic pathway was found to regulate inflammatory hyperalgesia in our previous study using male rats. The activity of this neural pathway is elevated during hyperalgesia, but whether this effect differs in a sex-dependent manner remains unknown. We conducted plantar tests on adult male and female virgin rats in which paw inflammation was induced using carrageenan. Exogenous (i.t.) application of oxytocin exerted no anti-hyperalgesic effect in female rats, except at an extremely high dose. Female rats exhibited similar extent of hyperalgesia to male rats did when the animals received the same dose of carrageenan. When atosiban was administered alone, the severity of hyperalgesia was not increased in female rats. Moreover, insulin-regulated aminopeptidase (IRAP) was expressed at higher levels in the spinal cords of female rats compared with those of male rats. Oxytocin-induced anti-hyperalgesia exhibits a sex-dependent difference in rats. This difference can partially result from the higher expression of IRAP in the spinal cords of female rats, because IRAP functions as an enzyme that degrades oxytocin. Our study confirms the existence of a sex difference in oxytocin-induced anti-hyperalgesia at the spinal level in rats.
C1 [Wu, Wan-Chuan; Chang, En-Pei; Huang, Eagle Yi-Kung] Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan.
   [Chow, Lok-Hi] Natl Def Med Ctr, Dept Anesthesiol, Taipei, Taiwan.
   [Chow, Lok-Hi] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.
   [Chow, Lok-Hi] Natl Yang Ming Univ, Sch Med, Dept Anesthesiol, Taipei, Taiwan.
   [Chen, Yuan-Hao] Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Neurol Surg, Taipei, Taiwan.
RP Huang, EYK (reprint author), Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan.
EM eyh58@mail.ndmctsgh.edu.tw
FU National Science Council, Taiwan, ROC [NSC 96-2320-B-016-020-MY3, NSC
   99-2320-B-016-002-MY3]
FX This study was supported by the grants (NSC 96-2320-B-016-020-MY3 and
   NSC 99-2320-B-016-002-MY3) from National Science Council, Taiwan, ROC.
CR Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200
   ARLETTI R, 1993, NEUROPEPTIDES, V24, P125, DOI 10.1016/0143-4179(93)90075-L
   Cheng BC, 2012, PEPTIDES, V36, P9, DOI 10.1016/j.peptides.2012.03.019
   Chow LH, 2004, J BIOMED SCI, V11, P717, DOI 10.1159/000081817
   Chow LH, 2004, CAN J ANAESTH, V51, P905
   Chow LH, 2013, PEPTIDES, V39, P21, DOI 10.1016/j.peptides.2012.10.012
   Condes-Lara M, 2006, BRAIN RES, V1081, P126, DOI 10.1016/j.brainres.2006.01.050
   Condes-Lara M, 2005, BRAIN RES, V1045, P124, DOI 10.1016/j.brainres.2005.03.020
   Condes-Lara M, 2007, BRAIN RES, V1160, P20, DOI 10.1016/j.brainres.2007.05.031
   Condes-Lara M, 2009, EUR J NEUROSCI, V30, P1056, DOI 10.1111/j.1460-9568.2009.06899.x
   DADDONA MM, 1994, NEUROREPORT, V5, P1833, DOI 10.1097/00001756-199409080-00037
   Eliava M, 2016, NEURON, V89, P1291, DOI 10.1016/j.neuron.2016.01.041
   Gao L, 2004, REGUL PEPTIDES, V120, P53, DOI 10.1016/j.regpep.2004.02.011
   Horio J, 1999, BIOCHEM BIOPH RES CO, V262, P269, DOI 10.1006/bbrc.1999.1184
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   Martinez-Lorenzan G, 2008, PAIN, V140, P265, DOI 10.1016/j.pain.2008.08.015
   Miranda-Cardenas Y, 2006, PAIN, V122, P182, DOI 10.1016/j.pain.2006.01.029
   Nomura M, 2002, PLACENTA, V23, P631, DOI 10.1053/plac.2002.0861
   Paxinos G., 1986, RAT BRAIN STEREOTAXI
   Petersson M, 1996, NEUROSCI LETT, V212, P87, DOI 10.1016/0304-3940(96)12773-7
   Petersson M, 2001, PEPTIDES, V22, P1479, DOI 10.1016/S0196-9781(01)00469-7
   Puder BA, 2001, J NEUROSCI RES, V64, P53, DOI 10.1002/jnr.1053
   Reeta K, 2006, REGUL PEPTIDES, V135, P85, DOI 10.1016/j.regpep.2006.04.004
   Robinson DA, 2002, J PHYSIOL-LONDON, V540, P593, DOI 10.1113/jphysiol.2001.013492
   TAKAGI T, 1985, HORM METAB RES, V17, P308, DOI 10.1055/s-2007-1013526
   Uhl-Bronner S, 2005, NEUROSCIENCE, V135, P147, DOI 10.1016/j.neuroscience.2005.05.025
   XU XJ, 1994, NEUROREPORT, V5, P750, DOI 10.1097/00001756-199403000-00003
   YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9
   Yamasue H, 2009, PSYCHIAT CLIN NEUROS, V63, P129, DOI 10.1111/j.1440-1819.2009.01944.x
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yang J, 2007, PEPTIDES, V28, P1113, DOI 10.1016/j.peptides.2007.03.003
   YIRMIYA R, 1990, BRAIN RES, V537, P169, DOI 10.1016/0006-8993(90)90354-E
   Yu SQ, 2003, BRAIN RES, V983, P13, DOI 10.1016/S0006-8993(03)03019-1
NR 35
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2016
VL 11
IS 9
AR e0162218
DI 10.1371/journal.pone.0162218
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV9JB
UT WOS:000383255600031
PM 27606886
ER

PT J
AU Asai, K
   Ivandini, TA
   Einaga, Y
AF Asai, Kai
   Ivandini, Tribidasari A.
   Einaga, Yasuaki
TI Continuous and selective measurement of oxytocin and vasopressin using
   boron-doped diamond electrodes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIRECT ELECTROCHEMICAL OXIDATION; LIQUID-CHROMATOGRAPHY; FILM
   ELECTRODES; MICROELECTRODES; SURFACES; VOLTAMMETRY; SEROTONIN;
   MECHANISM; PROTEINS; DOPAMINE
AB The electrochemical detection of oxytocin using boron-doped diamond (BDD) electrodes was studied. Cyclic voltammetry of oxytocin in a phosphate buffer solution exhibits an oxidation peak at +0.7 V (vs. Ag/AgCl), which is attributable to oxidation of the phenolic group in the tyrosyl moiety. Furthermore, the linearity of the current peaks obtained in flow injection analysis (FIA) using BDD microelectrodes over the oxytocin concentration range from 0.1 to 10.0 mu M with a detection limit of 50 nM (S/N = 3) was high (R-2 = 0.995). Although the voltammograms of oxytocin and vasopressin observed with an as-deposited BDD electrode, as well as with a cathodically-reduced BDD electrode, were similar, a clear distinction was observed with anodically-oxidized BDD electrodes due to the attractive interaction between vasopressin and the oxidized BDD surface. By means of this distinction, selective measurements using chronoamperometry combined with flow injection analysis at an optimized potential were demonstrated, indicating the possibility of making selective in situ or in vivo measurements of oxytocin.
C1 [Asai, Kai; Einaga, Yasuaki] Keio Univ, Fac Sci & Technol, Dept Chem, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.
   [Ivandini, Tribidasari A.] Univ Indonesia, Fac Math & Sci, Dept Chem, Kampus UI Depok, Jakarta 116424, Indonesia.
   [Einaga, Yasuaki] JST ACCEL, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.
RP Einaga, Y (reprint author), Keio Univ, Fac Sci & Technol, Dept Chem, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.; Einaga, Y (reprint author), JST ACCEL, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.
EM einaga@chem.keio.ac.jp
CR AGER JW, 1995, APPL PHYS LETT, V66, P616, DOI 10.1063/1.114031
   Asai K, 2016, ELECTROANAL, V28, P177, DOI 10.1002/elan.201500505
   Bales KL, 2007, HORM BEHAV, V52, P274, DOI 10.1016/j.yhbeh.2007.05.004
   Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085
   Chang CC, 2006, J PHYS CHEM B, V110, P19426, DOI 10.1021/jp062209q
   Chiku M, 2008, ANAL CHEM, V80, P5783, DOI 10.1021/ac800394n
   Chiku M, 2008, J ELECTROANAL CHEM, V612, P201, DOI 10.1016/j.jelechem.2007.09.027
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Duran B, 2014, ANALYST, V139, P3160, DOI 10.1039/c4an00506f
   Fierro S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03257
   Fierro S, 2012, SCI REP-UK, V2, DOI 10.1038/srep00901
   Fujishima A., 2005, DIAMOND ELECTROCHEMI
   Girard H, 2007, DIAM RELAT MATER, V16, P316, DOI 10.1016/j.diamond.2006.06.009
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   HATTORI T, 1990, BRAIN RES, V506, P169, DOI 10.1016/0006-8993(90)91216-4
   Honda Y, 2013, DIAM RELAT MATER, V40, P7, DOI 10.1016/j.diamond.2013.09.001
   Ishii Y, 2013, ANAL CHEM, V85, P4284, DOI 10.1021/ac400043b
   Ivandini TA, 2006, ANAL CHEM, V78, P3467, DOI 10.1021/ac0502029x
   Ivandini TA, 2003, J CHROMATOGR B, V791, P63, DOI 10.1016/S1570-0232(03)00204-6
   Koehbach J, 2013, P NATL ACAD SCI USA, V110, P21183, DOI 10.1073/pnas.1311183110
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   KRISTENSEN EW, 1986, ANAL CHEM, V58, P986, DOI 10.1021/ac00295a073
   KUNKEL HG, 1953, J BIOL CHEM, V200, P559
   LANE RF, 1976, ANAL CHEM, V48, P1287, DOI 10.1021/ac50003a009
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   Mabrouk OS, 2012, J NEUROSCI METH, V209, P127, DOI 10.1016/j.jneumeth.2012.06.006
   Macpherson JV, 2015, PHYS CHEM CHEM PHYS, V17, P2935, DOI 10.1039/c4cp04022h
   Martin HB, 1996, J ELECTROCHEM SOC, V143, pL133, DOI 10.1149/1.1836901
   Notsu H, 1999, ELECTROCHEM SOLID ST, V2, P522, DOI 10.1149/1.1390890
   Palecek E, 2005, PERSP BIOANAL, V1, P1
   Peckova K, 2009, CRIT REV ANAL CHEM, V39, P148, DOI 10.1080/10408340903011812
   Permentier HP, 2003, RAPID COMMUN MASS SP, V17, P1585, DOI 10.1002/rcm.1090
   Pino F, 2015, ANAL SCI, V31, P1061, DOI 10.2116/analsci.31.1061
   Popa E, 1999, ELECTROCHEM SOLID ST, V2, P49, DOI 10.1149/1.1390730
   Pruvost F, 2001, DIAM RELAT MATER, V10, P531, DOI 10.1016/S0925-9635(00)00378-2
   REYNAUD JA, 1980, J ELECTROANAL CHEM, V114, P195, DOI 10.1016/S0022-0728(80)80447-5
   Salazar-Banda GR, 2006, ELECTROCHIM ACTA, V51, P4612, DOI 10.1016/j.electacta.2005.12.039
   Sarada BV, 2000, ANAL CHEM, V72, P1632, DOI 10.1021/ac9908748
   Suffredini HB, 2004, ELECTROCHIM ACTA, V49, P4021, DOI 10.1016/j.electacta.2004.01.082
   Suprun EV, 2014, ELECTROCHIM ACTA, V140, P72, DOI 10.1016/j.electacta.2014.03.089
   Suzuki A, 2007, ANAL CHEM, V79, P8608, DOI 10.1021/ac071519h
   Swain GM, 1998, MRS BULL, V23, P56
   TAYLOR SP, 1953, J BIOL CHEM, V205, P45
   Terashima C, 2003, ANAL CHEM, V75, P1564, DOI 10.1021/ac020583q
   Trouillon R, 2010, ELECTROCHIM ACTA, V55, P6586, DOI 10.1016/j.electacta.2010.06.016
   Wang M, 2009, ELECTROCHIM ACTA, V54, P5818, DOI 10.1016/j.electacta.2009.05.037
   Watanabe T, 2014, PHYS STATUS SOLIDI A, V211, P2709, DOI 10.1002/pssa.201431455
   WRONA MZ, 1987, J ORG CHEM, V52, P2817, DOI 10.1021/jo00389a032
   Xu JS, 1997, ANAL CHEM, V69, pA591
   Yagi I, 1999, J ELECTROANAL CHEM, V473, P173, DOI 10.1016/S0022-0728(99)00027-3
   Yoshimi K, 2011, NEUROSCI RES, V71, P49, DOI 10.1016/j.neures.2011.05.013
NR 52
TC 0
Z9 0
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 7
PY 2016
VL 6
AR 32429
DI 10.1038/srep32429
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV3LM
UT WOS:000382823500001
PM 27599852
ER

PT J
AU Hansen, VL
   Schilkey, FD
   Miller, RD
AF Hansen, Victoria Leigh
   Schilkey, Faye Dorothy
   Miller, Robert David
TI Transcriptomic Changes Associated with Pregnancy in a Marsupial, the
   Gray Short-Tailed Opossum Monodelphis domestica
SO PLOS ONE
LA English
DT Article
ID DIFFERENTIAL EXPRESSION ANALYSIS; YOLK-SAC PLACENTA; OXYTOCIN RECEPTOR;
   GENE-EXPRESSION; SMINTHOPSIS-CRASSICAUDATA; SPATIOTEMPORAL EXPRESSION;
   PHYLOGENETIC ANALYSIS; CONVERGENT EVOLUTION; MAMMALIAN PREGNANCY;
   HOUSEKEEPING GENES
AB Live birth has emerged as a reproductive strategy many times across vertebrate evolution; however, mammals account for the majority of viviparous vertebrates. Marsupials are a mammalian lineage that last shared a common ancestor with eutherians (placental mammals) over 148 million years ago. Marsupials are noted for giving birth to highly altricial young after a short gestation, and represent humans' most distant viviparous mammalian relatives. Here we ask what insight can be gained into the evolution of viviparity in mammals specifically and vertebrates in general by analyzing the global uterine transcriptome in a marsupial. Transcriptome analyses were performed using NextGen sequencing of uterine RNA samples from the gray short-tailed opossum, Monodelphis domestica. Samples were collected from late stage pregnant, virgin, and non-pregnant experienced breeders. Three different algorithms were used to determine differential expression, and results were confirmed by quantitative PCR. Over 900 opossum gene transcripts were found to be significantly more abundant in the pregnant uterus than non-pregnant, and over 1400 less so. Most with increased abundance were genes related to metabolism, immune systems processes, and transport. This is the first study to characterize the transcriptomic differences between pregnant, non-pregnant breeders, and virgin marsupial uteruses and helps to establish a set of pregnancy-associated genes in the opossum. These observations allowed for comparative analyses of the differentially transcribed genes with other mammalian and non-mammalian viviparous species, revealing similarities in pregnancy related gene expression over 300 million years of amniote evolution.
C1 [Hansen, Victoria Leigh; Miller, Robert David] Univ New Mexico, Dept Biol, Ctr Evolutionary & Theoret Immunol, Albuquerque, NM 87131 USA.
   [Schilkey, Faye Dorothy] New Mexico IDeA Networks Biomed Res Excellence, Natl Ctr Genome Resources, Santa Fe, NM USA.
   [Hansen, Victoria Leigh] Natl Sci Fdn, Div Integrat Organismal Syst, 4201 Wilson Blvd, Arlington, VA 22230 USA.
RP Hansen, VL (reprint author), Univ New Mexico, Dept Biol, Ctr Evolutionary & Theoret Immunol, Albuquerque, NM 87131 USA.; Hansen, VL (reprint author), Natl Sci Fdn, Div Integrat Organismal Syst, 4201 Wilson Blvd, Arlington, VA 22230 USA.
EM vhansen@unm.edu
FU National Science Foundation [IOS-1353123]
FX The National Science Foundation funded this research under grant number
   IOS-1353123 (http://www.nsf.gov/awardsearch/showAward?AWD_ID=1353123).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Asahina T, 1998, HORM RES, V50, P37, DOI 10.1159/000053122
   Baardman ME, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.102442
   Baker Michelle L., 2004, Journal of Mammalian Evolution, V11, P1, DOI 10.1023/B:JOMM.0000029143.39776.ec
   Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634
   BLACKBURN DG, 1992, AM ZOOL, V32, P313
   Brandley MC, 2012, GENOME BIOL EVOL, V4, P394, DOI 10.1093/gbe/evs013
   Carter AM, 2013, ANNU REV ANIM BIOSCI, V1, P443, DOI 10.1146/annurev-animal-031412-103653
   Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35
   Chern SR, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-106
   Chern SR, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-127
   CORSO G, 1988, Archivio Italiano di Anatomia e di Embriologia, V93, P237
   Corso G, 2000, J MORPHOL, V243, P153, DOI 10.1002/(SICI)1097-4687(200002)243:2<153::AID-JMOR4>3.0.CO;2-Q
   Crespi B, 2004, AM NAT, V163, P635, DOI 10.1086/382734
   Drewlo S, 2012, PLACENTA, V33, P952, DOI 10.1016/j.placenta.2012.09.007
   Elliot MG, 2009, PLACENTA, V30, P949, DOI 10.1016/j.placenta.2009.08.004
   Enders AC, 2012, PLACENTA, V33, P319, DOI 10.1016/j.placenta.2012.02.008
   Freyer C, 2007, PLACENTA, V28, P249, DOI 10.1016/j.placenta.2006.03.007
   Freyer C, 2003, J EXP ZOOL PART A, V299A, P59, DOI 10.1002/jez.a.10291
   Freyer C, 2002, J ANAT, V201, P101, DOI 10.1046/j.1469-7580.2002.00084.x
   Freyer C, 2009, J EXP ZOOL PART B, V312B, P545, DOI 10.1002/jez.b.21239
   Furukawa S, 2014, J TOXICOL PATHOL, V27, P11, DOI [10.1293/tox.2013-0060, 10.1293/tox.27.2013-0060]
   Garratt M, 2013, P NATL ACAD SCI USA, V110, P7760, DOI 10.1073/pnas.1305018110
   Goff LA, 2012, ANALYSIS EXPLORATION
   Goytain A, 2005, BIOCHEM BIOPH RES CO, V330, P701, DOI 10.1016/j.bbrc.2005.03.037
   Hedges SB, 2003, TRENDS GENET, V19, P200, DOI 10.1016/S0168-9525(03)00053-2
   Hesse M, 2000, EMBO J, V19, P5060, DOI 10.1093/emboj/19.19.5060
   KEYS JL, 1988, BIOL REPROD, V39, P473, DOI 10.1095/biolreprod39.2.473
   Killian JK, 2001, MAMM GENOME, V12, P513, DOI 10.1007/s003350020026
   Kimura T, 1996, ENDOCRINOLOGY, V137, P780, DOI 10.1210/en.137.2.780
   Kin K, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.115139
   Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001
   Kumar S, 1998, NATURE, V392, P917
   Laird MK, 2014, J MORPHOL, V275, P1081, DOI 10.1002/jmor.20282
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]
   Langmead B, 2009, GENOME BIOL, V10, DOI [10.1186/gb-2009-10-3-r25, 10.1186/gb-2009-10-11-r134]
   Liu YW, 2014, BIOINFORMATICS, V30, P301, DOI 10.1093/bioinformatics/btt688
   Lynch VJ, 2015, CELL REP, V10, P551, DOI 10.1016/j.celrep.2014.12.052
   Maiti K, 2011, ENDOCRINOLOGY, V152, P2448, DOI 10.1210/en.2010-0979
   Matsuura W, 2009, BIOSCI BIOTECH BIOCH, V73, P1142, DOI 10.1271/bbb.80910
   Meller M, 2005, PLACENTA, V26, P601, DOI 10.1016/j.placenta.2004.09.009
   Mess A, 2006, J EXP ZOOL PART B, V306B, P140, DOI 10.1002/jez.b.21079
   Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118
   MOLL R, 1983, LAB INVEST, V49, P599
   Mossman HW, 1987, VERTEBRATE FETAL MEM
   Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179
   Okumu LA, 2010, REPRODUCTION, V140, P143, DOI 10.1530/REP-10-0113
   PADYKULA HA, 1982, J REPROD FERTIL, P95
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   RENFREE MB, 1994, J REPROD FERTIL, V102, P433
   Robbins JR, 2012, CURR OPIN MICROBIOL, V15, P36, DOI 10.1016/j.mib.2011.11.006
   Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22
   ROBERTS CT, 1994, J REPROD FERTIL, V100, P105
   ROBERTS RM, 1988, J REPROD FERTIL, V82, P875
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rose R, 2000, HORM BEHAV, V37, P163, DOI 10.1006/hbeh.1999.1568
   Samborski A, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.112177
   Shaw G, 1999, BIOL REPROD, V60, P611, DOI 10.1095/biolreprod60.3.611
   Spencer TE, 2002, FRONT BIOSCI, V7, pD1879, DOI 10.2741/spencer
   SPENCER TE, 1995, BIOL REPROD, V53, P1527, DOI 10.1095/biolreprod53.6.1527
   Spencer TE, 2008, REPRODUCTION, V135, P165, DOI [10.1530/REP-07-0327, 10.1530/RFP-07-0327]
   STONEROOK MJ, 1992, BIOL REPROD, V46, P290, DOI 10.1095/biolreprod46.2.290
   Terzidou V, 2005, J CLIN ENDOCR METAB, V90, P237, DOI 10.1210/jc.2004-0277
   Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tyndale-Biscoe H, 1987, REPROD PHYSL MAMMALS
   Umylny B, 2011, TAG BASED NEXT GENER, P449
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   VANDEBERG JL, 1990, AUST J ZOOL, V37, P235
   VandeBerg John L., 1997, ILAR J, V38, P4
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wathes DC, 1999, J ENDOCRINOL, V161, P143, DOI 10.1677/joe.0.1610143
   Whittington CM, 2015, MOL BIOL EVOL, V32, P3114, DOI 10.1093/molbev/msv177
   Wildman DE, 2006, P NATL ACAD SCI USA, V103, P3203, DOI 10.1073/pnas.0511344103
   Yamashita K, 2013, MOL PHYLOGENET EVOL, V67, P520, DOI 10.1016/j.ympev.2013.02.017
NR 75
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2016
VL 11
IS 9
AR e0161608
DI 10.1371/journal.pone.0161608
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV9IT
UT WOS:000383254800013
PM 27598793
ER

PT J
AU Ishii, M
   Hashimoto, H
   Ohkubo, J
   Ohbuchi, T
   Saito, T
   Maruyama, T
   Yoshimura, M
   Yamamoto, Y
   Kusuhara, K
   Ueta, Y
AF Ishii, Masahiro
   Hashimoto, Hirofumi
   Ohkubo, Jun-ichi
   Ohbuchi, Toyoaki
   Saito, Takeshi
   Maruyama, Takashi
   Yoshimura, Mitsuhiro
   Yamamoto, Yukiyo
   Kusuhara, Koichi
   Ueta, Yoichi
TI Transgenic approach to express the channelrhodopsin 2 gene in arginine
   vasopressin neurons of rats
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Arginine vasopressin; Channelrhodopsin 2; Rat; Salt loading; Transgene;
   Whole-cell patch-clamp recording
ID GREEN FLUORESCENT PROTEIN; POSTERIOR PITUITARY; SUPRAOPTIC NUCLEUS;
   OXYTOCIN; RELEASE; VISUALIZATION; OPTOGENETICS; NEUROSCIENCE; ACID
AB Optogenetics provides a powerful tool to regulate neuronal activity by light-sensitive ion channels such as channelrhodopsin 2 (ChR2). Arginine vasopressin (AVP; also known as the anti-diuretic hormone) is a multifunctional hormone which is synthesized in the magnocellular neurosecretory cells (MNCs) of the hypothalamus. Here, we have generated a transgenic rat that expresses an AVP-ChR2-enhanced green fluorescent protein (eGFP) fusion gene in the MNCs of the hypothalamus. The eGFP fluorescence that indicates the expression of ChR2-eGFP was observed in the supraoptic nucleus (SON) and in the magnocellular division of the paraventricular nucleus (PVN) that is known to contain AVP-secreting neurons. The eGFP fluorescence intensities in those nuclei and posterior pituitary were markedly increased after chronic salt loading (2% NaCl in drinking water for 5 days). ChR2-eGFP was localized mainly in the membrane of AVP-positive MNCs. Whole-cell patch-clamp recordings were performed from single MNCs isolated from the SON of the transgenic rats, and blue light evoked repetitive action potentials. Our work provides for the first time an optogenetic approach to selectively activate AVP neurons in the rat. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Ishii, Masahiro; Hashimoto, Hirofumi; Maruyama, Takashi; Yoshimura, Mitsuhiro; Ueta, Yoichi] Univ Occupat & Environm Hlth, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan.
   [Ishii, Masahiro; Yamamoto, Yukiyo; Kusuhara, Koichi] Univ Occupat & Environm Hlth, Dept Pediat, Kitakyushu, Fukuoka 8078555, Japan.
   [Ohkubo, Jun-ichi; Ohbuchi, Toyoaki] Univ Occupat & Environm Hlth, Dept Otorhinolaryngol Head & Neck Surg, Kitakyushu, Fukuoka 8078555, Japan.
   [Saito, Takeshi] Univ Occupat & Environm Hlth, Sch Med, Dept Neurosurg, Kitakyushu, Fukuoka 8078555, Japan.
RP Ueta, Y (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM yoichi@med.uoeh-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [23113518, 23659127, 25293055, 26860164]; Uehara Memorial Foundation;
   Salt Science Research Foundation [1127]
FX This paper was supported by Scientific Research on Innovative Areas No.
   23113518 (Y.U.), Challenging Exploratory Research No. 23659127 (Y.U.)
   and Scientific Research (B) No. 25293055 and No. 26860164 (Y.U.) from
   the Ministry of Education, Culture, Sports, Science and Technology,
   Japan and The Uehara Memorial Foundation (Y.U.) and The Salt Science
   Research Foundation, No. 1127 (Y.U.).
CR Boyden ES, 2015, NAT NEUROSCI, V18, P1200, DOI 10.1038/nn.4094
   BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132
   Choe HK, 2015, NEURON, V87, P152, DOI 10.1016/j.neuron.2015.06.022
   Deisseroth K, 2015, NAT NEUROSCI, V18, P1213, DOI 10.1038/nn.4091
   Eliava M, 2016, NEURON, V89, P1291, DOI 10.1016/j.neuron.2016.01.041
   Fujihara H, 2009, ENDOCRINOLOGY, V150, P5633, DOI 10.1210/en.2009-0796
   Fujio T, 2006, J NEUROENDOCRINOL, V18, P776, DOI 10.1111/j.1365-2826.2006.01476.x
   Ivanova E, 2009, MOL VIS, V15, P1680
   Katoh A, 2014, J NEUROENDOCRINOL, V26, P341, DOI 10.1111/jne.12150
   Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006
   KIYAMA H, 1990, J NEUROENDOCRINOL, V2, P257, DOI 10.1111/j.1365-2826.1990.tb00401.x
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Ludwig M, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0182
   Miyashita T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00008
   Ohbuchi T, 2010, J PHYSIOL-LONDON, V588, P2147, DOI 10.1113/jphysiol.2010.187625
   Ohkubo J, 2014, J NEUROENDOCRINOL, V26, P43, DOI 10.1111/jne.12128
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Shimano T, 2013, BRAIN RES, V1511, P138, DOI 10.1016/j.brainres.2012.10.030
   Ueta Y, 2005, ENDOCRINOLOGY, V146, P406, DOI 10.1210/en.2004-0830
NR 20
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD SEP 6
PY 2016
VL 630
BP 194
EP 198
DI 10.1016/j.neulet.2016.08.001
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA DV5ZG
UT WOS:000383008600031
PM 27493075
ER

PT J
AU Kunzier, NB
   Kinzler, WL
   Chavez, MR
   Adams, TM
   Brand, DA
   Vintzileos, AM
AF Kunzier, Nadia B.
   Kinzler, Wendy L.
   Chavez, Martin R.
   Adams, Tracy M.
   Brand, Donald A.
   Vintzileos, Anthony M.
TI The use of cervical sonography to differentiate true from false labor in
   term patients presenting for labor check
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE cervical length; cervical sonography; false labor; labor check; term
   gestation; true labor
ID PRETERM BIRTH; ULTRASOUND ASSESSMENT; PROLONGED PREGNANCY; LENGTH;
   DELIVERY; PREDICTION; ULTRASONOGRAPHY; PROGESTERONE; INDUCTION; ACCURACY
AB BACKGROUND: Cervical length by transvaginal ultrasound to predict preterm labor is widely used in clinical practice. Virtually no data exist on cervical length measurement to differentiate true from false labor in term patients who present for labor check. False-positive diagnosis of true labor at term may lead to unnecessary hospital admissions, obstetrical interventions, resource utilization, and cost.
   OBJECTIVE: We sought to determine if cervical length by transvaginal ultrasound can differentiate true from false labor in term patients presenting for labor check.
   STUDY DESIGN: This is a prospective observational study of women presenting to labor and delivery with labor symptoms at 37-42 weeks, singleton cephalic gestation, regular uterine contractions (>= 4/20 min), intact membranes, and cervix <= 4 cm dilated and <= 80% effaced. Those patients with placenta previa and indications for immediate delivery were excluded. The shortest best cervical length of 3 collected images was used for analysis. Providers managing labor were blinded to the cervical length. True labor was defined as spontaneous rupture of membranes or spontaneous cervical dilation <= 4 cm and >= 80% effaced within 24 hours of cervical length measurement. In the absence of these outcomes, labor status was determined as false labor. Receiver operating characteristic curves were generated to assess the predictive ability of cervical length to differentiate true from false labor and were analyzed separately for primiparous and multiparous patients. The diagnostic accuracies of various cervical length cutoffs were determined. The relationship of cervical length and time to delivery was also analyzed including both use and nonuse of oxytocin.
   RESULTS: In all, 77 patients were included in the study; the prevalence of true labor was 58.4% (45/77). Patients who were in true labor had shorter cervical length as compared to those in false labor: median 1.3 cm (range 0.5-4.1) vs 2.4 cm (range 1.0-5.0), respectively (P < .001). The area under the receiver operating characteristic curve for primiparous patients was 0.88 (P < .001) and for multiparous patients was 0.76 (P < .01), both demonstrating good correlation. The area under the receiver operating characteristic curves were not significantly different between primiparous and multiparous (P = .23). The area under the receiver operating characteristic curve for primiparous and multiparous patients combined was 0.8 (P < .0001), indicating a good overall correlation between cervical length and its ability to differentiate true from false labor. Overall, a cervical length cutoff of <= 1.5 cm to predict true labor had the highest specificity (81%), positive predictive value (83%), and positive likelihood ratio (4.2). There were no differences in cervical length prediction between primiparous and multiparous patients. Cervical length was positively correlated with time to delivery, regardless of the use of oxytocin.
   CONCLUSION: In differentiating true from false labor in term patients who present for labor check, a cervical length of <= 1.5 cm was the most clinically optimal cutoff with the lowest false positive rate-due to its highest specificity-and highest positive predictive value and positive likelihood ratios. Its use to decide admission in patients at term with labor symptoms may prevent unnecessary admissions, obstetrical interventions, resource utilization, and cost.
C1 [Kunzier, Nadia B.; Kinzler, Wendy L.; Chavez, Martin R.; Adams, Tracy M.; Vintzileos, Anthony M.] Winthrop Univ Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Mineola, NY 11501 USA.
   [Brand, Donald A.] Winthrop Univ Hosp, Off Hlth Outcomes Res, Mineola, NY 11501 USA.
   [Brand, Donald A.] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA.
   [Kinzler, Wendy L.; Adams, Tracy M.] SUNY Stony Brook, Dept Obstet & Gynecol, Div Maternal Fetal Med, Stony Brook, NY 11794 USA.
RP Kunzier, NB (reprint author), Winthrop Univ Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Mineola, NY 11501 USA.
EM nbennett@nyit.edu
CR ANDERSEN HF, 1990, AM J OBSTET GYNECOL, V163, P859
   Berghella V, 1997, AM J OBSTET GYNECOL, V177, P723, DOI 10.1016/S0002-9378(97)70259-X
   Berghella V, 2012, AM J OBSTET GYNECOL, V206, P376, DOI 10.1016/j.ajog.2012.03.010
   Comas M, 2016, J MATERN-FETAL NEO M, V1, P1
   Conde-Agudelo A, 2016, AM J OBSTET GYNECOL, V214, P235, DOI 10.1016/j.ajog.2015.09.102
   Conde-Agudelo A, 2015, AM J OBSTET GYNECOL, V213, P789, DOI 10.1016/j.ajog.2015.06.015
   Einerson BD, 2016, AM J OBSTET GYNECOL, V214, pS257
   Gordon MC, 2015, AM J OBSTET GYNECOL, V214
   Hassan SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/uog.9017
   Iam JD, 1996, NEW ENGL J MED, V334, P567
   Khalifeh A, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.017
   Miller ES, 2016, BJOG-INT J OBSTET GY, V123, P23, DOI 10.1111/1471-0528.13749
   Osmundson S, 2011, OBSTET GYNECOL, V117, P583, DOI 10.1097/AOG.0b013e31820caf12
   PHELPS JY, 1995, AM J OBSTET GYNECOL, V173, P942, DOI 10.1016/0002-9378(95)90371-2
   Porreco RP, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.09.874
   Rao A, 2008, ULTRASOUND OBST GYN, V32, P646, DOI 10.1002/uog.6211
   Romero R, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.003
   Schoen CN, 2015, AM J OBSTET GYNECOL, V213, P175, DOI 10.1016/j.ajog.2014.12.011
   SONEK JD, 1990, OBSTET GYNECOL, V76, P172
   Strobel E, 2006, ULTRASOUND OBST GYN, V28, P298, DOI 10.1002/uog.2746
   Temming LA, 2016, AM J OBSTET GYNECOL, V214
   Tsoi E, 2003, ULTRASOUND OBST GYN, V21, P552, DOI 10.1002/uog.131
   Vahanian SA, 2015, J MATERN-FETAL NEO M, P1
   Ware V, 2000, AM J OBSTET GYNECOL, V182, P1030, DOI 10.1067/mob.2000.105399
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2016
VL 215
IS 3
AR 372.e1-e5
DI 10.1016/j.ajog.2016.03.031
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DU8WA
UT WOS:000382495100042
PM 27018468
ER

PT J
AU Illmann, G
   Chaloupkova, H
   Melisova, M
AF Illmann, G.
   Chaloupkova, H.
   Melisova, M.
TI Impact of sow prepartum behavior on maternal behavior, piglet body
   weight gain, and mortality in farrowing pens and crates
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article
DE domestic pig; housing; maternal behavior; nest-building behavior; piglet
   growth; postural changes
ID POSTURAL CHANGES; PARTURIENT SOWS; DOMESTIC SOWS; SCHMID PENS; 24 H;
   NEST; RESPONSIVENESS; ENVIRONMENT; POSTPARTUM; OXYTOCIN
AB In the 24-h period prior to parturition, sows are active and motivated to perform nest-building behavior. The aim of this study was to investigate whether prepartum activity (nesting and postural changes) could predict maternal behavior 24 h postpartum, piglet mortality, and BW gain 24 h postpartum in farrowing pens and crates. Sows were randomly moved either to a farrowing pen (n = 20) or a farrowing crate (n = 18). Prepartum nest-building behavior (PRE-nesting) and prepartum postural changes (prepartum postural changes) were analyzed 24 h before the birth of the first piglet (BFP) and were divided into twelve 2-h intervals. Latency of the first suckling from the litter was observed after the birth of the last piglet. Udder accesses and piglet suckling were noted at 5-min intervals, using 1/0 sampling, during the first 24 h after BFP were counted. Piglet trapping, crushing, and total live-born mortality were measured during the first 72 h after BFP. Piglet BW gain was estimated 24 h after BFP. Increased PRE-nesting observed 2 h before BFP were associated with fewer suckling intervals in crates but not in pens (P < 0.01) as well as an increase in postural changes during parturition (P < 0.001) in both housings. A link between housing and PRE-postural changes was evident. An increase in the number of PRE-postural changes 2 h prior to BFP was associated with lower incidences of udder access in crates but not in pens (P < 0.05). A higher probability of piglet trapping was associated with increased PRE-nesting in the 2 to 4 h before BFP. No significant relationship between either PRE-nesting and postural changes and piglet BW gain and mortality was detected. Our results suggest that increased prepartum activity 2 h before parturition is associated with less suckling and less udder access in farrowing crates but not in farrowing pens. This suggests that the same sow behavior can have different consequences in pens vs. in crates. Future research should focus on nest-building activity, its relationship to endocrine indicators (e.g., oxytocin, cortisol) before parturition, and its potential long-lasting effects on subsequent maternal behaviors and piglet production.
C1 [Illmann, G.; Melisova, M.] Inst Anim Sci, Dept Ethol, Prague 10400, Czech Republic.
   [Chaloupkova, H.] Czech Univ Life Sci Prague, Dept Anim Sci & Ethol, Kamycka 129, Prague 16021, Czech Republic.
RP Illmann, G (reprint author), Inst Anim Sci, Dept Ethol, Prague 10400, Czech Republic.
EM gudrun.illmann@vuzv.cz
FU Ministry of Agriculture, Czech Republic [MZERO0716]
FX This research was supported by grant number MZERO0716 from the Ministry
   of Agriculture, Czech Republic. We would like to acknowledge Marie
   Simeckova for her statistical advice and to thank Jinhyeon Yun and
   Sebastian Goument for their helpful comments.
CR Andersen IL, 2005, APPL ANIM BEHAV SCI, V93, P229, DOI 10.1016/j.applanim.2004.11.015
   Andersen IL, 2014, APPL ANIM BEHAV SCI, V159, P29, DOI 10.1016/j.applanim.2014.07.002
   CRONIN GM, 1993, APPL ANIM BEHAV SCI, V36, P301, DOI 10.1016/0168-1591(93)90128-C
   Damm BI, 2005, APPL ANIM BEHAV SCI, V92, P45, DOI 10.1016/j.applanim.2004.10.013
   Damm BI, 2003, LIVEST PROD SCI, V80, P175, DOI 10.1016/S0301-4226(02)00186-0
   Damm BI, 2002, APPL ANIM BEHAV SCI, V76, P135, DOI 10.1016/S0168-1591(01)00212-X
   Damm BI, 2000, APPL ANIM BEHAV SCI, V69, P113, DOI 10.1016/S0168-1591(00)00122-2
   Edwards SA, 2002, LIVEST PROD SCI, V78, P3, DOI 10.1016/S0301-6226(02)00180-X
   Farmer C, 2009, J ANIM SCI, V87, P56, DOI 10.2527/jas.2008-1203
   Illmann G, 2015, APPL ANIM BEHAV SCI, V163, P80, DOI 10.1016/j.applanim.2014.11.011
   Illmann G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083529
   Jarvis S, 1999, APPL ANIM BEHAV SCI, V63, P195, DOI 10.1016/S0168-1591(99)00013-1
   Jarvis S, 2001, APPL ANIM BEHAV SCI, V71, P203, DOI 10.1016/S0168-1591(00)00183-0
   JENSEN P, 1986, APPL ANIM BEHAV SCI, V16, P131, DOI 10.1016/0168-1591(86)90105-X
   JENSEN P, 1993, ANIM BEHAV, V45, P351, DOI 10.1006/anbe.1993.1040
   LAWRENCE AB, 1994, APPL ANIM BEHAV SCI, V39, P313, DOI 10.1016/0168-1591(94)90165-1
   Melisova M, 2014, J ANIM SCI, V92, P3064, DOI 10.2527/jas.2013-7340
   Melisova M, 2011, APPL ANIM BEHAV SCI, V134, P121, DOI 10.1016/j.applanim.2011.06.015
   Oliviero C, 2008, ANIM REPROD SCI, V105, P365, DOI 10.1016/j.anireprosci.2007.03.015
   Pedersen LJ, 2006, APPL ANIM BEHAV SCI, V96, P215, DOI 10.1016/j.applanim.2005.06.016
   Pedersen LJ, 2003, APPL ANIM BEHAV SCI, V83, P109, DOI 10.1016/S0168-1591(03)00116-3
   Pokorna Z, 2008, APPL ANIM BEHAV SCI, V114, P346, DOI 10.1016/j.applanim.2008.04.011
   Thodberg K, 1999, APPL ANIM BEHAV SCI, V63, P131, DOI 10.1016/S0168-1591(99)00002-7
   Uvnas-Moberg K, 2001, APPL ANIM BEHAV SCI, V72, P225, DOI 10.1016/S0168-1591(01)00112-5
   Vasdal G, 2009, ANIMAL, V3, P1449, DOI 10.1017/S1751731109990309
   Weary DM, 1996, APPL ANIM BEHAV SCI, V49, P149, DOI 10.1016/0168-1591(96)01042-8
   Weary DM, 1996, ANIM BEHAV, V51, P619, DOI 10.1006/anbe.1996.0066
   Wischner D, 2009, LIVEST SCI, V124, P1, DOI 10.1016/j.livsci.2009.01.015
   Yun J, 2015, APPL ANIM BEHAV SCI, V162, P20, DOI 10.1016/j.applanim.2014.11.006
   Yun J, 2014, APPL ANIM BEHAV SCI, V160, P31, DOI 10.1016/j.applanim.2014.08.011
   Yun J, 2013, APPL ANIM BEHAV SCI, V148, P77, DOI 10.1016/j.applanim.2013.07.010
NR 31
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA
SN 0021-8812
EI 1525-3163
J9 J ANIM SCI
JI J. Anim. Sci.
PD SEP
PY 2016
VL 94
IS 9
BP 3978
EP 3986
DI 10.2527/jas2016-0329
PG 9
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA ED1XQ
UT WOS:000388638600036
ER

PT J
AU Chandaka, GK
   Wang, L
   Senogles, S
   Armstrong, WE
AF Chandaka, G. K.
   Wang, L.
   Senogles, S.
   Armstrong, W. E.
TI Late Pregnancy is a Critical Period for Changes in Phosphorylated
   Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase
   1/2 in Oxytocin Neurones
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE oxytocin; vasopressin; pERK1/2; supraoptic nucleus; paraventricular
   nucleus
ID MILK-EJECTION REFLEX; SUPRAOPTIC NUCLEUS; CENTRAL BLOCKADE; IN-VITRO;
   RELEASE; RAT; VASOPRESSIN; HYPOTHALAMUS; PLASTICITY; GESTATION
AB The physiological demands of parturition and lactation lead to the increased pulsatile release of oxytocin (OT) into the circulation from the neurohypophysial axons of OT neurones in the supraoptic (SON) and paraventricular (PVN) nuclei. These states of increased OT release are accompanied by a significant plasticity in magnocellular OT neurones and their synaptic connections, and many of these changes require activation of a central OT receptor. The mitogen-activated protein kinase/extracellular signal-regulated kinase pathway (MAPK/ERK) is assumed to be up-regulated in the PVN during lactation, and many of the effects of OT in peripheral and brain tissue are mediated through a MAPK/ERK pathway. The present study investigated whether this pathway is altered in the SON and PVN during late pregnancy [embryonic day (E) 20-21], which is a critical period for OT plasticity induction, and for lactation, when plastic changes are sustained. Based on immunoreactivity for phosphorylated ERK1/2 (pERK1/2), the results suggest an enhanced activation of MAPK/ERK pathway in OT neurones specifically during late pregnancy in both the SON and PVN. Although immunoblots from the SON confirm this pregnancy-associated up-regulation in late pregnancy, they also suggest enhancement into lactation as well. Together, the results suggest an important role for the MAPK/ERK pathway during reproductive changes in the SON and PVN.
C1 [Chandaka, G. K.; Wang, L.; Armstrong, W. E.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
   [Senogles, S.] Univ Tennessee, Ctr Hlth Sci, Microbiol Immunol & Biochem, Memphis, TN 38163 USA.
   [Senogles, S.; Armstrong, W. E.] Univ Tennessee, Ctr Hlth Sci, Inst Neurosci, Memphis, TN 38163 USA.
RP Chandaka, GK (reprint author), Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.
EM gchandak@uthsc.edu
FU NIH [HD R01-072056]
FX We thank Ms Li Li for providing technical support for the present study.
   This work was supported by NIH HD R01-072056 (WEA).
CR Antonijevic IA, 2000, J REPROD FERTIL, V120, P367, DOI 10.1530/reprod/120.2.367
   Armstrong WE, 2010, J NEUROENDOCRINOL, V22, P330, DOI 10.1111/j.1365-2826.2010.01989.x
   Armstrong WE, 2015, KNOBIL NEILLS PHYSL, P527
   Bealer SL, 2006, AM J PHYSIOL-REG I, V291, pR53, DOI 10.1152/ajpregu.00766.2005
   Bealer SL, 2010, AM J PHYSIOL-REG I, V299, pR452, DOI [10.1152/ajpregu.00217.2010, 10.1152/ajpregu.00217.2010.]
   Blume A, 2008, EUR J NEUROSCI, V27, P1947, DOI 10.1111/j.1460-9568.2008.06184.x
   BRIDGES RS, 1984, ENDOCRINOLOGY, V114, P930
   CROWLEY RS, 1995, ENDOCRINOLOGY, V136, P224, DOI 10.1210/en.136.1.224
   Dine J, 2014, J PHYSIOL-LONDON, V592, P1637, DOI 10.1113/jphysiol.2013.261008
   FREUNDMERCIER MJ, 1994, J PHYSIOL-LONDON, V480, P155
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Israel J- M, 2014, NEUROPHYSIOLOGY NEUR, P29
   Jankord R, 2010, AM J PHYSIOL-REG I, V299, pR343, DOI 10.1152/ajpregu.00131.2010
   Jurek B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037060
   LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275
   LAMBERT RC, 1993, NEUROSCIENCE, V57, P1027, DOI 10.1016/0306-4522(93)90046-I
   Langle SL, 2003, EUR J NEUROSCI, V18, P206, DOI 10.1046/j.1460-9568.2003.02741.x
   Lipschitz DL, 2003, J NEUROENDOCRINOL, V15, P743
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   Ludwig M, 1998, J NEUROENDOCRINOL, V10, P881
   MONTAGNESE C, 1990, J NEUROENDOCRINOL, V2, P225, DOI 10.1111/j.1365-2826.1990.tb00855.x
   MOOS F, 1989, J PHYSIOL-LONDON, V408, P1
   MOOS F, 1989, EXP BRAIN RES, V76, P593, DOI 10.1007/BF00248916
   MOOS F, 1984, J ENDOCRINOL, V102, P63, DOI 10.1677/joe.0.1020063
   NEUMANN I, 1993, NEUROSCIENCE, V53, P65, DOI 10.1016/0306-4522(93)90285-N
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Paxinos G, 2006, PAXINOS WATSONS RAT
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2
   Raggenbass M, 1998, PROG BRAIN RES, V119, P263
   Rossoni E, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000123
   Teruyama R, 2008, AM J PHYSIOL-ENDOC M, V295, pE1167, DOI 10.1152/ajpendo.90620.2008
   THEODOSIS DT, 1986, NATURE, V322, P738, DOI 10.1038/322738a0
   Theodosis DT, 2002, FRONT NEUROENDOCRIN, V23, P101, DOI 10.1006/frne.2001.0226
   Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
NR 39
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD SEP
PY 2016
VL 28
IS 9
DI 10.1111/jne.12398
PG 7
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA EB0WF
UT WOS:000387066500002
ER

PT J
AU Saito, R
   So, M
   Motojima, Y
   Matsuura, T
   Yoshimura, M
   Hashimoto, H
   Yamamoto, Y
   Kusuhara, K
   Ueta, Y
AF Saito, R.
   So, M.
   Motojima, Y.
   Matsuura, T.
   Yoshimura, M.
   Hashimoto, H.
   Yamamoto, Y.
   Kusuhara, K.
   Ueta, Y.
TI Activation of Nesfatin-1-Containing Neurones in the Hypothalamus and
   Brainstem by Peripheral Administration of Anorectic Hormones and
   Suppression of Feeding via Central Nesfatin-1 in Rats
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE CCK-8; food intake; GLP-1; leptin; nesfatin-1
ID GLUCAGON-LIKE PEPTIDE-1; CENTRAL-NERVOUS-SYSTEM; C-FOS EXPRESSION;
   FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; RECEPTOR STIMULATION;
   CHOLECYSTOKININ; LEPTIN; INHIBITION; OXYTOCIN
AB Peripheral anorectic hormones, such as glucagon-like peptide (GLP)-1, cholecystokinin (CCK)-8 and leptin, suppress food intake. The newly-identified anorectic neuropeptide, nesfatin-1, is synthesised in both peripheral tissues and the central nervous system, particularly by various nuclei in the hypothalamus and brainstem. In the present study, we examined the effects of i.p. administration of GLP-1 and CCK-8 and co-administrations of GLP-1 and leptin at subthreshold doses as confirmed by measurement of food intake, on nesfatin-1-immunoreactive (-IR) neurones in the hypothalamus and brainstem of rats by Fos immunohistochemistry. Intraperitoneal administration of GLP-1 (100 mu g/kg) caused significant increases in the number of nesfatin-1-IR neurones expressing Fos-immunoreactivity in the supraoptic nucleus (SON), the area postrema (AP) and the nucleus tractus solitarii (NTS) but not in the paraventricular nucleus (PVN), the arcuate nucleus (ARC) or the lateral hypothalamic area (LHA). On the other hand, i.p. administration of CCK-8 (50 mu g/kg) resulted in marked increases in the number of nesfatin-1-IR neurones expressing Fos-immunoreactivity in the SON, PVN, AP and NTS but not in the ARC or LHA. No differences in the percentage of nesfatin-1-IR neurones expressing Fos-immunoreactivity in the nuclei of the hypothalamus and brainstem were observed between rats treated with saline, GLP1 (33 mu g/kg) or leptin. However, co-administration of GLP-1 (33 mu g/kg) and leptin resulted in significant increases in the number of nesfatin-1-IR neurones expressing Fos-immunoreactivity in the AP and the NTS. Furthermore, decreased food intake induced by GLP-1, CCK-8 and leptin was attenuated significantly by pretreatment with i.c.v. administration of antisense nesfatin-1. These results indicate that nesfatin-1-expressing neurones in the brainstem may play an important role in sensing peripheral levels of GLP-1 and leptin in addition to CCK-8, and also suppress food intake in rats.
C1 [Saito, R.; So, M.; Motojima, Y.; Matsuura, T.; Yoshimura, M.; Hashimoto, H.; Ueta, Y.] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka, Japan.
   [Saito, R.; Yamamoto, Y.; Kusuhara, K.] Univ Occupat & Environm Hlth, Sch Med, Dept Pediat, Kitakyushu, Fukuoka, Japan.
RP Ueta, Y (reprint author), Univ Occupat & Environm Hlth, Dept Physiol, Sch Med, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM yoichi@med.uoeh-u.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [26461535, 15H06803];
   Japan Agency for Medical Research and Development (AMED); University of
   Occupational and Environmental Health, Japan
FX We thank Kanako Shoguchi and Yuki Nonaka for thier technical assistance.
   This article was supported by a Grant-in-Aid for Scientific Research (C)
   number 26461535 from the Japan Society for the Promotion of Science
   (JSPS), a Grant-in-Aid for Research Activity Start-up number 15H06803
   from the Japan Society for the Promotion of Science (JSPS), Japan Agency
   for Medical Research and Development (AMED), and a Grant-in-Aid for the
   Promotion of Occupational Health for the Post Graduate Student of the
   University of Occupational and Environmental Health, Japan.
CR Akieda-Asai S, 2014, AM J PHYSIOL-ENDOC M, V306, pE1284, DOI 10.1152/ajpendo.00664.2013
   Akieda-Asai S, 2014, J ENDOCRINOL, V220, P109, DOI 10.1530/JOE-13-0272
   Atsuchi K, 2010, NEUROREPORT, V21, P1008, DOI 10.1097/WNR.0b013e32833f7b96
   Baggio LL, 2004, BEST PRACT RES CL EN, V18, P531, DOI 10.1016/j.beem.2004.08.001
   Baggio LL, 2004, GASTROENTEROLOGY, V127, P546, DOI 10.1053/j.gastro.2004.04.063
   Baumgartner I, 2010, J NEUROENDOCRINOL, V22, P557, DOI 10.1111/j.1365-2826.2010.01995.x
   Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305
   CHEN DY, 1993, NEUROSCI LETT, V149, P91, DOI 10.1016/0304-3940(93)90355-O
   DAY HEW, 1994, NEUROPHARMACOLOGY, V33, P719, DOI 10.1016/0028-3908(94)90111-2
   DEBAS HT, 1975, GASTROENTEROLOGY, V68, P1211
   Drucker DJ, 2002, GASTROENTEROLOGY, V122, P531, DOI 10.1053/gast.2002.31068
   Gibbs J, 1997, OBES RES, V5, P284
   Goebel M, 2009, BRAIN RES, V1300, P114, DOI 10.1016/j.brainres.2009.08.082
   Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064
   GREEN GM, 1989, AM J PHYSIOL, V256, pG1016
   Gu GB, 2013, J COMP NEUROL, V521, P2235, DOI 10.1002/cne.23282
   Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046
   HAMAMURA M, 1991, J PHYSIOL-LONDON, V444, P51
   Hayes MR, 2010, PHYSIOL BEHAV, V100, P503, DOI 10.1016/j.physbeh.2010.02.029
   Holst JJ, 2006, DIABETOLOGIA, V49, P253, DOI 10.1007/s00125-005-0107-1
   Iwasaki Y, 2009, BIOCHEM BIOPH RES CO, V390, P958, DOI 10.1016/j.bbrc.2009.10.085
   Katoh A, 2014, J NEUROENDOCRINOL, V26, P341, DOI 10.1111/jne.12150
   Kim JD, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00480
   Kohno D, 2008, ENDOCRINOLOGY, V149, P1295, DOI 10.1210/en.2007-1276
   Ladenheim EE, 2005, AM J PHYSIOL-REG I, V289, pR473, DOI 10.1152/ajpregu.00835.2004
   Lo CM, 2007, AM J PHYSIOL-REG I, V293, pR1490, DOI 10.1152/ajpregu.00329.2007
   LUCKMAN SM, 1992, J NEUROENDOCRINOL, V4, P149, DOI 10.1111/j.1365-2826.1992.tb00152.x
   Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
   Monnikes H, 1997, BRAIN RES, V770, P277, DOI 10.1016/S0006-8993(97)00865-2
   MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702
   Motojima Y, 2016, NEUROSCI RES, V109, P63, DOI 10.1016/j.neures.2016.02.005
   Noetzel S, 2009, REGUL PEPTIDES, V157, P84, DOI 10.1016/j.regpep.2009.06.009
   Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162
   Okuno H, 2011, NEUROSCI RES, V69, P175, DOI 10.1016/j.neures.2010.12.007
   Parker JA, 2013, INT J OBESITY, V37, P1391, DOI 10.1038/ijo.2012.227
   Patterson CM, 2009, AM J PHYSIOL-REG I, V296, pR537, DOI 10.1152/ajpregu.90859.2008
   Poleni PE, 2012, BIOCHEM BIOPH RES CO, V420, P36, DOI 10.1016/j.bbrc.2012.02.109
   Price CJ, 2008, J NEUROENDOCRINOL, V20, P245, DOI 10.1111/j.1365-2826.2007.01641.x
   Ramanjaneya M, 2010, ENDOCRINOLOGY, V151, P3169, DOI 10.1210/en.2009-1358
   Raybould HE, 1998, AM J PHYSIOL-REG I, V274, pR1834
   Rinaman L, 2010, BRAIN RES, V1350, P18, DOI 10.1016/j.brainres.2010.03.059
   RITTER S, 1986, AM J PHYSIOL, V250, pR682
   Ronveaux CC, 2014, PHYSIOL BEHAV, V135, P222, DOI 10.1016/j.physbeh.2014.06.015
   SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P
   Shimizu H, 2009, ENDOCRINOLOGY, V150, P662, DOI 10.1210/en.2008-0598
   Shimizu H, 2009, PEPTIDES, V30, P995, DOI 10.1016/j.peptides.2009.01.002
   Stengel A, 2009, ENDOCRINOLOGY, V150, P4911, DOI 10.1210/en.2009-0578
   Suarez-Pinzon WL, 2008, DIABETES, V57, P3281, DOI 10.2337/db08-0688
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0
   Williams DL, 2006, DIABETES, V55, P3387, DOI 10.2337/db06-0558
   Yamamoto H, 2002, J CLIN INVEST, V110, P43, DOI 10.1172/JCI200215595
   Yosten GLC, 2012, J NEUROENDOCRINOL, V24, P1078, DOI 10.1111/j.1365-2826.2012.02304.x
   Yosten GLC, 2010, AM J PHYSIOL-REG I, V298, pR1642, DOI 10.1152/ajpregu.00804.2009
   Zheng HY, 2008, PHYSIOLOGY, V23, P75, DOI 10.1152/physiol.00047.2007
NR 55
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD SEP
PY 2016
VL 28
IS 9
DI 10.1111/jne.12400
PG 12
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA EB0WF
UT WOS:000387066500004
ER

PT J
AU Becker, MM
   Riesgo, RS
   Roesler, R
   Bosa, C
   Ohlweiler, L
   Backes, B
   Endres, RG
   Zanon, RB
   Marchezan, J
   Schwartsmann, G
AF Becker, Michele Michelin
   Riesgo, Rudimar S.
   Roesler, Rafael
   Bosa, Cleonice
   Ohlweiler, Lygia
   Backes, Barbara
   Endres, Renata G.
   Zanon, Regina B.
   Marchezan, Josemar
   Schwartsmann, Gilberto
TI Improvement in Symptoms of Autism Spectrum Disorder in Children With the
   Use of Gastrin-Releasing Peptide: An Open Trial
SO CLINICAL NEUROPHARMACOLOGY
LA English
DT Review
DE gastrin-releasing peptide receptor; bombesinlike peptides;
   neuropeptides; neurodevelopmental disorders; autism spectrum disorder
ID ABERRANT-BEHAVIOR-CHECKLIST; RECEPTOR BLOCKADE; ADOLESCENTS; RATS;
   PHARMACOTHERAPY; IRRITABILITY; ARIPIPRAZOLE; TRANSLATION; VALIDATION;
   OXYTOCIN
AB Objectives The aim of this study was to determine the efficacy and tolerability of gastrin-releasing peptide (GRP) for core symptoms of autism spectrum disorder.
   Methods This is a prospective, open-label study with 160 pmol/kg of GRP tested in 10 children with autism. Outcome measures used were the Clinical Global Impressions-Improvement Scale, Aberrant Behavior Checklist (ABC), Childhood Autism Rating Scale, and Autism Diagnostic Interview-Revised. Positive response was defined as a score of 1 (very much improved) or 2 (much improved) on the Clinical Global Impressions-Improvement Scale and an improvement of 25% or greater on at least 1 subscale of ABC.
   Results Six (60%) of the 10 subjects responded to GRP. Improvements were observed on the ABC irritability and hyperactivity subscales in 80% of patients, and 70% exhibited improvement on the social withdrawal subscale. On the Childhood Autism Rating Scale, there was a mean reduction of 4 points (4.3 2.9). Analysis of the Autism Diagnostic Interview-Revised results detected significant improvements in the domain that assesses social interaction, with a mean reduction of 2.4 points (2.4 +/- 2.83). Adverse effects occurred in 3 patients.
   Conclusions Gastrin-releasing peptide was safe and well tolerated by most subjects and may be effective for core symptoms of autism.
C1 [Becker, Michele Michelin; Ohlweiler, Lygia; Marchezan, Josemar] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Pediat, Child Neurol Unit, Porto Alegre, RS, Brazil.
   [Riesgo, Rudimar S.] Univ Fed Rio Grande do Sul, Sch Med, Dept Pediat, Child Neurol Unit, Porto Alegre, RS, Brazil.
   [Roesler, Rafael] Univ Fed Rio Grande do Sul, Clin Hosp CPE HCPA, Expt Res Ctr, Dept Pharmacol,Inst Basic Hlth Sci,Canc & Neurobi, Porto Alegre, RS, Brazil.
   [Bosa, Cleonice; Backes, Barbara; Endres, Renata G.; Zanon, Regina B.] Univ Fed Rio Grande do Sul, Inst Psychol, Dept Psychol, Porto Alegre, RS, Brazil.
   [Schwartsmann, Gilberto] Univ Fed Rio Grande do Sul, Clin Hosp CPE HCPA, Dept Internal Med, Sch Med,Canc & Neurobiol Lab,Expt Res Ctr, Porto Alegre, RS, Brazil.
RP Becker, MM (reprint author), Hosp Clin Porto Alegre, Dept Pediat, Child Neurol Unit, Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.
EM michelemb@terra.com.br
FU FIPE-HCPA (Research and Events Support Fund at Hospital de Clinicas de
   Porto Alegre); SOAD Foundation (South American Office for Anticancer
   Drug Development)
FX We are grateful to the funding agency FIPE-HCPA (Research and Events
   Support Fund at Hospital de Clinicas de Porto Alegre) and to the SOAD
   Foundation (South American Office for Anticancer Drug Development) for
   providing financial support for this study.
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Autism Developmental Disabilities Monitoring Network Surveillance Year Principal I Centers for Disease C Prevention, 2012, MMWR-MORBID MORTAL W, V61, P1
   Becker MM, 2012, ARQ NEURO-PSIQUIAT, V70, P185, DOI 10.1590/S0004-282X2012000300006
   Becker MM, 2016, J PEDIAT-BRAZIL, V92, P302, DOI 10.1016/j.jped.2015.08.012
   Benvenuto A, 2013, BRAIN DEV-JPN, V35, P119, DOI 10.1016/j.braindev.2012.03.015
   Chaperon F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034963
   Clive S, 2001, CLIN PHARMACOL THER, V69, P252, DOI 10.1067/mcp2.001.114888
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Garcia VA, 2010, BEHAV BRAIN RES, V214, P456, DOI 10.1016/j.bbr.2010.05.038
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   GUTZWILLER JP, 1994, GASTROENTEROLOGY, V106, P1168
   Horvath K, 1998, J Assoc Acad Minor Phys, V9, P9
   Ji NY, 2015, CURR OPIN PSYCHIATR, V28, P91, DOI 10.1097/YCO.0000000000000132
   Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0
   Kamichi S, 2005, BRAIN RES, V1032, P162, DOI 10.1016/j.brainres.2004.10.068
   Kaplan G, 2012, PEDIATR CLIN N AM, V59, P175, DOI 10.1016/j.pcl.2011.10.005
   Krishnaswami S, 2011, PEDIATRICS, V127, pE1322, DOI 10.1542/peds.2011-0428
   Losapio MF, 2011, CAD SAUDE PUBLICA, V27, P909, DOI 10.1590/S0102-311X2011000500009
   Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658
   McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171
   McGonigle P, 2012, BIOCHEM PHARMACOL, V83, P559, DOI 10.1016/j.bcp.2011.10.014
   Merali Z, 2014, BEHAV BRAIN RES, V263, P60, DOI 10.1016/j.bbr.2014.01.008
   Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362
   Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782
   Pereira A, 2008, J PEDIAT, V84, P487, DOI [10.2223/JPED.1828, 10.1590/S0021-75572008000700004]
   Presti-Torres J, 2007, NEUROPHARMACOLOGY, V52, P724, DOI 10.1016/j.neuropharm.2006.09.020
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Research Units on Pediatric Psychopharmacology Autism Network, 2005, AM J PSYCHIAT, V162, P1361, DOI 10.1176/appi.ajp.162.7.1361
   Roesler Rafael, 2012, Front Endocrinol (Lausanne), V3, P159, DOI 10.3389/fendo.2012.00159
   Rossignol DA, 2009, ANN CLIN PSYCHIATRY, V21, P213
   Shumyatsky GP, 2002, CELL, V111, P905, DOI 10.1016/S0092-8674(02)01116-9
   Williams K, 2012, COCHRANE DB SYST REV, V18, P4
NR 32
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-5664
EI 1537-162X
J9 CLIN NEUROPHARMACOL
JI Clin. Neuropharmacol.
PD SEP-OCT
PY 2016
VL 39
IS 5
BP 215
EP 219
DI 10.1097/WNF.0000000000000165
PG 5
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DZ2HT
UT WOS:000385663600001
PM 27332629
ER

PT J
AU Kehl, S
   Weiss, C
   Rath, W
AF Kehl, Sven
   Weiss, Christel
   Rath, Werner
TI Balloon catheters for induction of labor at term after previous cesarean
   section: a systematic review
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Review
DE Balloon catheter; Foley; Double-balloon catheter; Labor induction;
   Previous cesarean section
ID RANDOMIZED-CONTROLLED-TRIAL; OFF-LABEL USE; FOLEY CATHETER; UTERINE
   RUPTURE; UNFAVORABLE CERVIX; VAGINAL BIRTH; INTRAVAGINAL MISOPROSTOL;
   EXPECTANT MANAGEMENT; ELECTIVE INDUCTION; NULLIPAROUS WOMEN
AB To systematically review the application of balloon catheters for cervical ripening and labor induction at term after previous cesarean section. All pregnancies at term with previous cesarean section were included when cervical ripening or labor induction was conducted with balloon catheters. MEDLINE, Cochrane database and bibliography of identified articles were searched for English language studies. Reviews and meta-analysis, randomized and non-randomized controlled trials, prospective and retrospective cohort studies as well as case control studies were considered. A total of 48 potentially relevant studies were identified. The title and abstract were screened for eligibility and 32 articles were excluded. The remaining 16 publications included 1447 women (single balloon catheter: n = 1329, double-balloon catheter: n = 118). There were no randomized controlled trials. Most of the trials were retrospective studies (n = 10). The rate of uterine rupture after labor induction was low (n = 18, 1.2%). Meta-analysis of studies comparing the risk of uterine rupture between labor induction and spontaneous onset of labor found a higher risk after induction (OR 2.45, 95%CI 1.34-4.47, NNH 186). The average rate of oxytocin application was 68.4%, and vaginal birth was achieved in 56.4%. The risk for cesarean delivery was higher when labor was induced (OR 2.63, 95%CI 2.24-3.10). Data on balloon catheters for labor induction after previous cesarean section are limited by small sample size and retrospective analyses. The present data show a moderately increased risk for uterine rupture (OR = 2.45) compared to spontaneous onset of labor. However, for evidence based recommendations much more well-conducted trials are needed. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Kehl, Sven] Univ Hosp Erlangen, Dept Obstet & Gynaecol, Univ Str 21-23, D-91054 Erlangen, Germany.
   [Weiss, Christel] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Med Stat & Biomath, Bergheimer Str 58, D-69115 Heidelberg, Germany.
   [Rath, Werner] Univ Hosp RWTH Aachen, Fac Med Gynaecol & Obstet, Wendlingweg 2, D-52074 Aachen, Germany.
RP Kehl, S (reprint author), Univ Hosp Erlangen, Dept Obstet & Gynaecol, Univ Str 21-23, D-91054 Erlangen, Germany.; Rath, W (reprint author), Univ Hosp RWTH Aachen, Fac Med Gynaecol & Obstet, Wendlingweg 2, D-52074 Aachen, Germany.
EM sven.kehl@uk-erlangen.de; wrath@ukaachen.de
CR Al-Zirqi I, 2010, BJOG-INT J OBSTET GY, V117, P809, DOI 10.1111/j.1471-0528.2010.02533.x
   Alfirevic Z, 2009, COCHRANE DB SYST REV, V4
   Ande AB, 2012, ARCH GYNECOL OBSTET, V285, P967, DOI 10.1007/s00404-011-2094-4
   Bel S, 2014, GYNECOL OBSTET FERTI, V42, P301, DOI 10.1016/j.gyobfe.2013.11.002
   Ben-Aroya Z, 2002, J Matern Fetal Neonatal Med, V12, P42, DOI 10.1080/713605582
   Berndl Anne, 2014, J Obstet Gynaecol Can, V36, P678
   Bujold E, 2004, OBSTET GYNECOL, V103, P18, DOI 10.1097/01.AOG.0000109148.23082.C1
   Caughey AB, 2006, AM J OBSTET GYNECOL, V195, P700, DOI 10.1016/j.ajog.2006.07.003
   Cheuk QKY, 2015, HONG KONG MED J, V21, P243, DOI 10.12809/hkmj144404
   Costantine MM, 2011, AM J PERINAT, V28, P293, DOI 10.1055/s-0030-1271214
   Cromi A, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.11.029
   Ebeid E, 2013, OPEN J OBSTET GYNECO, V3, P301
   Ferradas E, 2013, OPEN J OBSTET GYNECO, V3, P212
   Fox NS, 2011, BJOG-INT J OBSTET GY, V118, P647, DOI 10.1111/j.1471-0528.2011.02905.x
   Gregg AR, 2008, AM J OBSTET GYNECOL, V199, P187
   Grobman WA, 2012, SEMIN PERINATOL, V36, P344, DOI 10.1053/j.semperi.2012.04.017
   Harper LM, 2008, OBSTET GYNECOL SURV, V63, P538, DOI 10.1097/OGX.0b013e31817f1505
   Heinemann J, 2008, AM J OBSTET GYNECOL, V199, P177, DOI 10.1016/j.ajog.2008.05.005
   Hoffman MK, 2004, AM J PERINAT, V21, P217, DOI 10.1055/s-2004-828608
   Huisman C, 2014, AM J OBSTET GYNECOL, V210, pS333
   Huisman CM, 2013, OBSTET GYNECOL INT, V2013
   Jozwiak M, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001233.PUB2
   Jozwiak M, 2013, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD009792.pub2, DOI 10.1002/14651858.CD009792.PUB2]
   Jozwiak M, 2014, ACTA OBSTET GYN SCAN, V93, P296, DOI 10.1111/aogs.12320
   Jozwiak M, 2011, LANCET, V378, P2095, DOI 10.1016/S0140-6736(11)61484-0
   Kehl S, 2015, BJOG-INT J OBSTET GY, V122, P129, DOI 10.1111/1471-0528.13116
   Kehl S, 2016, ARCH GYNECOL OBSTET, V293, P757, DOI 10.1007/s00404-015-3907-7
   Kehl S, 2011, EUR J OBSTET GYN R B, V159, P315, DOI 10.1016/j.ejogrb.2011.09.010
   Khotaba S, 2001, ACTA OBSTET GYN SCAN, V80, P1041, DOI 10.1034/j.1600-0412.2001.801114.x
   Krause E, 2011, EUR J OBSTET GYN R B, V159, P324, DOI 10.1016/j.ejogrb.2011.09.013
   Lamourdedieu C, 2015, J GYNECOL OBST BIO R, V44, P426, DOI 10.1016/j.jgyn.2014.07.014
   Landon MB, 2005, AM J OBSTET GYNECOL, V193, P1016, DOI 10.1016/j.ajog.2005.05.066
   Landon MB, 2004, NEW ENGL J MED, V351, P2581, DOI 10.1056/NEJMoa040405
   Locatelli A, 2004, BJOG-INT J OBSTET GY, V111, P1394, DOI 10.1111/j.1471-0528.2004.00287.x
   Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101
   MacKeen AD, 2014, AM OSTEOPATH ASS, V114, P686
   Macones GA, 2005, AM J OBSTET GYNECOL, V193, P1656, DOI 10.1016/j.ajog.2005.04.002
   Mei-Dan E, 2014, J MATERN-FETAL NEO M, V27, P1765, DOI 10.3109/14767058.2013.879704
   Mei-Dan E, 2012, J MATERN-FETAL NEO M, V25, P723, DOI 10.3109/14767058.2011.591459
   Miller TD, 2005, AUST NZ J OBSTET GYN, V45, P325, DOI 10.1111/j.1479-828X.2005.00421.x
   Mishanina E, 2014, CAN MED ASSOC J, V186, P665, DOI 10.1503/cmaj.130925
   Ophir E, 2012, OBSTET GYNECOL SURV, V67, P734, DOI 10.1097/OGX.0b013e318273feeb
   Osmundson S, 2011, OBSTET GYNECOL, V117, P583, DOI 10.1097/AOG.0b013e31820caf12
   PALATNIK A, 2015, AM J OBSTET GYNECOL, V212, P358
   Pennell CE, 2009, BJOG-INT J OBSTET GY, V116, P1443, DOI 10.1111/j.1471-0528.2009.02279.x
   Ravasia DJ, 2000, AM J OBSTET GYNECOL, V183, P1176, DOI 10.1067/mob.2000.109037
   Rossard L, 2013, J GYNECOL OBST BIO R, V42, P480, DOI 10.1016/j.jgyn.2013.03.010
   Rossi AC, 2015, ARCH GYNECOL OBSTET, V291, P273, DOI 10.1007/s00404-014-3444-9
   Salim R, 2011, OBSTET GYNECOL, V118, P79, DOI 10.1097/AOG.0b013e318220e4b7
   Sananes N, 2014, ARCH GYNECOL OBSTET, V290, P669, DOI 10.1007/s00404-014-3287-4
   Sanchez-Ramos L, 2000, CLIN OBSTET GYNECOL, V43, P513, DOI 10.1097/00003081-200009000-00011
   Sarreau M, 2014, J GYNECOL OBST BIO R, V43, P46, DOI 10.1016/j.jgyn.2013.06.006
   Schoorel ENC, 2014, BJOG-INT J OBSTET GY, V121, P840, DOI 10.1111/1471-0528.12605
   Schoorel ENC, 2014, BJOG-INT J OBSTET GY, V121, P194, DOI 10.1111/1471-0528.12539
   Scott JR, 2014, BJOG-INT J OBSTET GY, V121, P157, DOI 10.1111/1471-0528.12449
   Sims EJ, 2001, AM J OBSTET GYNECOL, V184, P1122, DOI 10.1067/mob.2001.115278
   Solt I, 2009, AM J OBSTET GYNECOL, V201, pS124
   Souza Alex Sandro Rolland, 2015, Rev Bras Ginecol Obstet, V37, P127, DOI 10.1590/SO100-720320150005120
   Stock SJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2838
   Vaknin Z, 2010, AM J OBSTET GYNECOL, V203, P418, DOI 10.1016/j.ajog.2010.04.038
   Voigt F, 2015, EUR J OBSTET GYN R B, V187, P85, DOI 10.1016/j.ejogrb.2014.11.026
   Wing D., 2015, CERVICAL RIPENING IN
   Ziyauddin Farah, 2013, J Clin Diagn Res, V7, P140, DOI 10.7860/JCDR/2012/5003.2689
NR 63
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD SEP
PY 2016
VL 204
BP 44
EP 50
DI 10.1016/j.ejogrb.2016.07.505
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DY7PO
UT WOS:000385321900009
PM 27521597
ER

PT J
AU Byun, SH
   Lee, SY
   Hong, SY
   Ryu, T
   Kim, BJ
   Jung, JY
AF Byun, Sung Hye
   Lee, So Young
   Hong, Seong Yeon
   Ryu, Taeha
   Kim, Baek Jin
   Jung, Jin Yong
TI Use of the GlideScope video laryngoscope for intubation during ex utero
   intrapartum treatment in a fetus with a giant cyst of the 4th branchial
   cleft: A case report
SO MEDICINE
LA English
DT Article
DE ex utero intrapartum treatment; fetal neck mass; GlideScope; video
   laryngoscope
ID PLACENTAL SUPPORT; DIFFICULT AIRWAY; MANAGEMENT; ANESTHESIA; TRIAL;
   FETAL
AB Introduction:In fetuses who are predicted to be at risk of catastrophic airway obstruction at delivery, the ex utero intrapartum treatment (EXIT) procedure is useful for securing the fetal airway while maintaining fetal oxygenation via placental circulation. Factors, including poor posture of the fetus and physician, narrow visual field, and issues of contamination in the aseptic surgical field, make fetal intubation during the EXIT procedure difficult. Herein, we report our experience of the usefulness of the GlideScope video laryngoscope (GVL) for intubation during the EXIT procedure.Symptoms and clinical findings:A 28-year-old woman presented with a fetus having a cystic neck mass diagnosed on prenatal ultrasound at 25 weeks of gestation. We planned the EXIT procedure in conjunction with cesarean delivery at 38 weeks of gestation, as the mass enlarged to 4.9cmx3.2cm, protruded externally at the neck, and subsequently resulted in polyhydramnios.Therapeutic intervention and outcomes:After induction of anesthesia using intravenous thiopental (300mg), adequate uterine relaxation was achieved with sevoflurane (2.0-3.0 vol%) combined with continuous intravenous infusion of nitroglycerin (0.5-1.0g/kg/min) for maintaining uteroplacental circulation. After hysterotomy, the head and right upper limb of the fetus were partially delivered, and fetal heart tones were monitored with a sterile Doppler probe. After oropharyngeal suctioning to improve the visual field, the fetus was intubated successfully using a sterile GVL by an anesthesiologist, and the passage of the endotracheal tube beyond the vocal cords was confirmed on the screen of the GVL system. Immediately after the fetal airway was definitely secured, the fetus was fully delivered with umbilical cord clamping. After delivery, nitroglycerine administration was ceased and sevoflurane administration was reduced to 0.5 minimum alveolar concentration. Additionally, oxytocin (10units) and carbetocin (100g) were administered for recovery of uterine contraction. Cesarean delivery was successfully performed without any problems, and the neonate successfully underwent surgery for removal of the neck mass under general anesthesia on the 7th day after delivery. The neonate is developing normally.Conclusion:The GVL approach may be a useful noninvasive approach for establishing a clear fetal airway during the EXIT procedure.
C1 [Byun, Sung Hye; Lee, So Young; Ryu, Taeha; Kim, Baek Jin; Jung, Jin Yong] Catholic Univ Daegu, Dept Anesthesiol & Pain Med, Sch Med, 33,Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.
   [Hong, Seong Yeon] Catholic Univ Daegu, Dept Obstet & Gynecol, Sch Med, Daegu, South Korea.
RP Jung, JY (reprint author), Catholic Univ Daegu, Dept Anesthesiol & Pain Med, Sch Med, 33,Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.
EM jychung@cu.ac.kr
CR Abraham RJ, 2010, J OBSTET GYNAECOL, V30, P1, DOI 10.3109/01443610903281656
   Apfelbaum JL, 2013, ANESTHESIOLOGY, V118, P767, DOI 10.1097/ALN.0b013e31828604c6
   Aziz MF, 2011, ANESTHESIOLOGY, V114, P34, DOI 10.1097/ALN.0b013e3182023eb7
   Bouchard S, 2002, J PEDIATR SURG, V37, P418, DOI 10.1053/jpsu.2002.30839
   Braden A, 2016, J CLIN ANESTH, V31, P60, DOI 10.1016/j.jclinane.2015.12.010
   Cooper RM, 2003, CAN J ANAESTH, V50, P611
   Fiadjoe JE, 2012, ANESTHESIOLOGY, V116, P622, DOI 10.1097/ALN.0b013e318246ea4d
   Grundgeiger T, 2015, ANAESTHESIA, V70, P1375, DOI 10.1111/anae.13190
   Hedrick Holly L, 2003, Semin Pediatr Surg, V12, P190, DOI 10.1016/S1055-8586(03)00026-X
   JORDAN RB, 1988, J PEDIATR SURG, V23, P583, DOI 10.1016/S0022-3468(88)80373-7
   Karsli C, 2010, ANAESTHESIA, V65, P353, DOI 10.1111/j.1365-2044.2010.06294.x
   Kerner B, 1998, PRENATAL DIAG, V18, P51, DOI 10.1002/(SICI)1097-0223(199801)18:1<51::AID-PD220>3.3.CO;2-L
   Kim JT, 2008, BRIT J ANAESTH, V101, P531, DOI 10.1093/bja/aen234
   Kuczkowski KM, 2007, J ANESTH, V21, P243, DOI 10.1007/s00540-006-0502-x
   LANGER JC, 1990, J PEDIATR SURG, V25, P58, DOI 10.1016/S0022-3468(05)80164-2
   Lazar DA, 2011, J PEDIATR SURG, V46, P817, DOI 10.1016/j.jpedsurg.2011.02.006
   Morris LM, 2009, J PEDIAT, V154
   Mychaliska GB, 1997, J PEDIATR SURG, V32, P227, DOI 10.1016/S0022-3468(97)90184-6
   Oliveira E, 2015, REV BRAS ANESTESIOL, V65, P529, DOI [10.1016/j.bjan.2015.08.001, 10.1016/j.bjane.2013.07.020]
   Sun Y, 2014, PEDIATR ANESTH, V24, P1056, DOI 10.1111/pan.12458
NR 20
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP
PY 2016
VL 95
IS 39
AR e4931
DI 10.1097/MD.0000000000004931
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA DZ0PE
UT WOS:000385541400043
PM 27684833
ER

PT J
AU Schleip, R
   Klingler, W
   Wearing, S
   Naylor, I
   Zuegel, M
   Hoppe, K
AF Schleip, R.
   Klingler, W.
   Wearing, S.
   Naylor, I.
   Zuegel, M.
   Hoppe, K.
TI Functional in vitro tension measurements of fascial tissue - a novel
   modified superfusion approach
SO JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS
LA English
DT Article
DE Fascia; Organ Bath; Mechanographic Registration; Superfusion;
   Immersionmized Mice; Bone Metabolic Marker
ID THORACOLUMBAR FASCIA; SMOOTH-MUSCLE; MYOFIBROBLAST; CONTRACTILITY;
   STIMULATION; HISTAMINE
AB Introduction: While two laboratory techniques are commonly used to assess the tensile properties of muscle tissue, emerging evidence suggests that the fascial components of these tissues also serve an active role in force generation. Hence, we investigated whether these techniques are sensitive for assessment of fascial micromechanics. Methods: Force measurements on dissected fascial tissue were performed either using the classical immersion organ bath or using an improved superfusion approach simulating pulsed pharmacological triggers. Rat deep dorsal fascial strips as well as rat testicular capsule were pharmacologically challenged either with mepyramine or oxytocin. Results: The classical immersion technique yielded a lower force response to mepyramine than the superfusion method (median: 367.4 vs. 555.4 mu N/mm(2)). Pause in irrigation before application reduced irregularities during bolus application. The superfusion approach was improved further by the following points: The high sensitivity of the superfusion method to bolus addition was voided by deviation of fluid supply during bolus addition. Conclusion: Although both methods demonstrated pharmacologically induced contractile responses in lumbar fascia samples, the modified superfusion method may improve force registrations of slow contracting fascial tissue and minimize artefacts of fluid application.
C1 [Schleip, R.; Klingler, W.; Wearing, S.] Univ Ulm, Div Neurophysiol, Albert Einstein Allee 23, D-89081 Ulm, Germany.
   [Schleip, R.; Klingler, W.] Neurosurg Univ, Dept Neuroanesthesiol, Ludwig Heilmeyerstr 2, D-89312 Gunzburg, Germany.
   [Klingler, W.; Hoppe, K.] Univ Ulm, Dept Anesthesiol Intens Care Med & Pain Therapy, Albert Einstein Allee 23, D-89081 Ulm, Germany.
   [Klingler, W.; Wearing, S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave Kelvin Grove,CRICOS 00213J, Brisbane, Qld 4001, Australia.
   [Naylor, I.] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England.
   [Zuegel, M.] Univ Ulm, Sport & Rehabil Med, Leimgrubenweg 14, D-89075 Ulm, Germany.
   [Hoppe, K.] Goethe Univ Frankfurt, Dept Anesthesia Intens Care Med & Pain Therapy, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
RP Klingler, W (reprint author), Neurosurg Univ Ulm, Bezirkskrankenhaus Guenzburg, Dept Neuroanesthesiol, Ludwig Heilmeyer Str 2, D-89312 Gunzburg, Germany.
EM werner.klingler@uni-ulm.de
CR BLACK JW, 1975, BRIT J PHARMACOL, V54, P319
   Castella LF, 2010, J CELL SCI, V123, P1751, DOI 10.1242/jcs.066795
   Naylor IL, 1985, BRIT J PHARMACOL, V86, P517
   COLEMAN RA, 1989, J PHARMACOL METHOD, V21, P71, DOI 10.1016/0160-5402(89)90023-5
   Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x
   Doe C, 2007, J PHARMACOL EXP THER, V320, P89, DOI 10.1124/jpet.106.110635
   Finkleman B, 1930, J PHYSIOL-LONDON, V70, P145
   FRANK GB, 1982, CAN J PHYSIOL PHARM, V60, P47
   Frost H. M., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P201
   Frost H. M., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P113
   Hemmati AA, 1999, LIFE SCI, V65, P2325, DOI 10.1016/S0024-3205(99)00499-3
   HOFFMAN AJ, 1986, J PHARMACOL METHOD, V16, P185, DOI 10.1016/0160-5402(86)90041-0
   Hoheisel U, 2013, PAIN, V154, P1953, DOI 10.1016/j.pain.2013.05.006
   Hoppe K, 2014, ANAESTHESIA, V69, P1002, DOI 10.1111/anae.12752
   Klingler W, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0439-y
   Liu SH, 1997, AM J SPORTS MED, V47, P54
   Masood N., 1994, British Journal of Pharmacology, V112, p416P
   Pipelzadeh MH, 1998, EUR J PHARMACOL, V357, P257, DOI 10.1016/S0014-2999(98)00588-3
   Naylor IL, 2007, JUNIDHAPUR J NATRUAL, V2, P105
   RABE KF, 1995, AM J PHYSIOL-LUNG C, V269, pL332
   Santiago-Mejia J, 2007, J PHYSIOL PHARMACOL, V58, P275
   Schilder A, 2014, PAIN, V155, P222, DOI 10.1016/j.pain.2013.09.025
   Schleip Robert, 2012, J Bodyw Mov Ther, V16, P94, DOI 10.1016/j.jbmt.2011.09.003
   Tahara A, 2000, BRIT J PHARMACOL, V129, P131, DOI 10.1038/sj.bjp.0702996
   Tesarz J, 2011, NEUROSCIENCE, V194, P302, DOI 10.1016/j.neuroscience.2011.07.066
   Tomasek JJ, 2006, WOUND REPAIR REGEN, V14, P313, DOI 10.1111/j.1743-6109.2006.00126.x
   Zenmyo M, 1995, VIRCHOWS ARCH, V427, P437
NR 27
TC 0
Z9 0
U1 0
U2 0
PU JMNI
PI NAFPLION
PA 7 SPILIADOU SQ, NAFPLION, 21 100, GREECE
SN 1108-7161
J9 J MUSCULOSKEL NEURON
JI J. Musculoskelet. Neuronal Interact.
PD SEP
PY 2016
VL 16
IS 3
BP 256
EP 260
PG 5
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA DY3VG
UT WOS:000385022800009
PM 27609040
ER

PT J
AU Unternaehrer, E
   Bolten, M
   Nast, I
   Staehli, S
   Meyer, AH
   Dempster, E
   Hellhammer, DH
   Lieb, R
   Meinlschmidt, G
AF Unternaehrer, Eva
   Bolten, Margarete
   Nast, Irina
   Staehli, Simon
   Meyer, Andrea H.
   Dempster, Emma
   Hellhammer, Dirk H.
   Lieb, Roselind
   Meinlschmidt, Gunther
TI Maternal adversities during pregnancy and cord blood oxytocin receptor
   (OXTR) DNA methylation
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE early life stress; epigenetics; intrauterine exposures delayed effect;
   intrauterine programming; psychosocial stress during pregnancy
ID PITUITARY-ADRENAL AXIS; POSTNATAL DEPRESSION SCALE; PSYCHOSOCIAL STRESS;
   BIRTH-WEIGHT; PLASMA OXYTOCIN; PRENATAL STRESS; ENVIRONMENT INTERACTION;
   PARENTING BEHAVIOR; NATIONAL COHORT; GENE NR3C1
AB The aim of this study was to investigate whether maternal adversities and cortisol levels during pregnancy predict cord blood DNA methylation of the oxytocin receptor (OXTR). We collected cord blood of 39 babies born to mothers participating in a cross-sectional study (N = 100) conducted in Basel, Switzerland (2007-10). Mothers completed the Inventory of Life Events (second trimester: T2), the Edinburgh Postnatal Depression Scale (EPDS, third trimester: T3), the Trier Inventory of Chronic Stress (TICS-K, 1-3 weeks postpartum) and provided saliva samples (T2, T3) for maternal cortisol profiles, as computed by the area under the curve with respect to ground (AUCg) or increase (AUCi) for the cortisol awakening response (CAR) and for diurnal cortisol profiles (DAY). OXTR DNA methylation was quantified using Sequenom EpiTYPER. The number of stressful life events (P = 0.032), EPDS score (P = 0.007) and cortisol AUCgs at T2 (CAR: P = 0.020; DAY: P = 0.024) were negatively associated with OXTR DNA methylation. Our findings suggest that distinct prenatal adversities predict decreased DNA methylation in a gene that is relevant for childbirth, maternal behavior and wellbeing of mother and offspring. If a reduced OXTR methylation increases OXTR expression, our findings could suggest an epigenetic adaptation to an adverse early environment.
C1 [Unternaehrer, Eva; Meyer, Andrea H.; Lieb, Roselind; Meinlschmidt, Gunther] Univ Basel, Dept Psychol, Div Clin Psychol & Epidemiol, CH-4055 Basel, Switzerland.
   [Unternaehrer, Eva; Nast, Irina; Lieb, Roselind; Meinlschmidt, Gunther] Univ Basel, NCCR, Swiss Etiol Study Adjustment & Mental Hlth Sesam, CH-4055 Basel, Switzerland.
   [Unternaehrer, Eva] McGill Univ, Douglas Mental Hlth Univ Inst, 6875 La Salle Blvd, Verdun, PQ H4H 1R3, Canada.
   [Bolten, Margarete] Univ Basel, Child & Adolescent Psychiat Hosp, CH-4058 Basel, Switzerland.
   [Bolten, Margarete] Univ Munich, Dept Psychol, D-80802 Munich, Germany.
   [Nast, Irina] Zurich Univ Appl Sci, Sch Hlth Profess, CH-8401 Winterthur, Switzerland.
   [Staehli, Simon] Univ Trier, Inst Psychobiol, D-54296 Trier, Germany.
   [Dempster, Emma] Univ Exeter, Sch Med, Exeter EX1 2LU, Devon, England.
   [Hellhammer, Dirk H.] Inst Stress Med Trier, D-54295 Trier, Germany.
   [Meinlschmidt, Gunther] Ruhr Univ Bochum, Fac Med, Univ Str 150, D-44801 Bochum, Germany.
RP Meinlschmidt, G (reprint author), Univ Basel, Dept Psychol, Missionsstr 60-62, CH-4055 Basel, Switzerland.
EM gunther.meinlschmidt@unibas.ch
FU Swiss National Science Foundation (SNSF) [51A240-104890]; University of
   Basel; Hoffmann-La Roche Corp.; Basel Scientific Society; Swiss National
   Science Foundation [P2BSP1_151913, 100014_135328]; Korea Research
   Foundation within the Global Research Network Program [2013S1A2A2035364]
FX The Swiss National Science Foundation (SNSF) (project no. 51A240-104890)
   (sesam individual project C to M.B., D.H.H. and G.M.), the University of
   Basel, the Hoffmann-La Roche Corp. and the Basel Scientific Society
   provided core support for the NCCR sesam. E.U., R.L. and G.M. receive
   funding from the Swiss National Science Foundation (E.U.: P2BSP1_151913;
   R.L. and G.M.: 100014_135328) and G.M. receives funding from the Korea
   Research Foundation within the Global Research Network Program
   (2013S1A2A2035364). The funding sources had no involvement in study
   design; the collection, analysis and interpretation of the data; in
   writing of the report; and in the decision to submit the article for
   publication.
CR Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705
   Almgren M, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.05.014
   Bergant AM, 1998, DEUT MED WOCHENSCHR, V123, P35, DOI 10.1055/s-2007-1023895
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Brune M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-38
   Buss C, 2012, P NATL ACAD SCI USA, V109, pE1312, DOI 10.1073/pnas.1201295109
   CAOLEI L, 2014, PLOS ONE, V0009
   Carter CS, 2003, PHYSIOL BEHAV, V79, P383, DOI 10.1016/S0031-9384(03)00151-3
   Cicchetti D, 2012, DEV PSYCHOPATHOL, V24, P411, DOI 10.1017/S0954579412000077
   Class QA, 2013, PSYCHOL SCI, V24, P1309, DOI 10.1177/0956797612468010
   COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782
   D'Anna-Hernandez KL, 2012, PSYCHOSOM MED, V74, P296, DOI 10.1097/PSY.0b013e318244fbde
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497
   Davis EP, 2010, CHILD DEV, V81, P131, DOI 10.1111/j.1467-8624.2009.01385.x
   de Souza MA, 2013, NEUROCHEM RES, V38, P1479, DOI 10.1007/s11064-013-1049-5
   Devlin AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012201
   Duthie L, 2013, NEUROENDOCRINOLOGY, V98, P106, DOI 10.1159/000354702
   Edwards S, 2001, LIFE SCI, V68, P2093, DOI 10.1016/S0024-3205(01)00996-1
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Francis DD, 2000, J NEUROENDOCRINOL, V12, P1145, DOI 10.1046/j.1365-2826.2000.00599.x
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   Franz MB, 2014, EUR J OBSTET GYN R B, V179, P121, DOI 10.1016/j.ejogrb.2014.05.038
   Gluckman PD, 2005, TRENDS ECOL EVOL, V20, P527, DOI 10.1016/j.tree.2005.08.001
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Grewen KM, 2011, BIOL PSYCHOL, V87, P340, DOI 10.1016/j.biopsycho.2011.04.003
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hompes T, 2013, J PSYCHIATR RES, V47, P880, DOI 10.1016/j.jpsychires.2013.03.009
   Hoyo C, 2012, CANCER CAUSE CONTROL, V23, P635, DOI 10.1007/s10552-012-9932-y
   Jack A, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00280
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Kimura T, 2003, J MOL ENDOCRINOL, V30, P109, DOI 10.1677/jme.0.0300109
   Kinsella MT, 2009, CLIN OBSTET GYNECOL, V52, P425, DOI 10.1097/GRF.0b013e3181b52df1
   KUMARESAN P, 1975, OBSTET GYNECOL, V46, P272
   Kumsta R., 2013, FRONT NEUROENDOCRIN, V7, P19
   Kusui C, 2001, BIOCHEM BIOPH RES CO, V289, P681, DOI 10.1006/bbrc.2001.6024
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Levine Ari, 2007, Peptides, V28, P1162, DOI 10.1016/j.peptides.2007.04.016
   Li J, 2012, NEUROSCI BIOBEHAV R, V36, P1085, DOI 10.1016/j.neubiorev.2011.12.006
   Li YY, 2014, AAPS J, V16, P27, DOI 10.1208/s12248-013-9538-7
   Light KC, 2000, HEALTH PSYCHOL, V19, P560, DOI 10.1037//0278-6133.19.6.560
   Lonstein JS, 2014, J NEUROENDOCRINOL, V26, P649, DOI 10.1111/jne.12188
   Lovejoy MC, 2000, CLIN PSYCHOL REV, V20, P561, DOI 10.1016/S0272-7358(98)00100-7
   Lutz PE, 2014, NEUROSCIENCE, V264, P142, DOI 10.1016/j.neuroscience.2013.07.069
   Mehler MF, 2008, PROG NEUROBIOL, V86, P305, DOI 10.1016/j.pneurobio.2008.10.001
   Meinlschmidt G, 2010, STRESS, V13, P163, DOI 10.3109/10253890903128632
   Meinlschmidtl G, 2015, EUR PSYCHOL, V20, P85, DOI 10.1027/1016-9040/a000233
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Monk C, 2012, DEV PSYCHOPATHOL, V24, P1361, DOI 10.1017/S0954579412000764
   Mulligan CJ, 2012, EPIGENETICS-US, V7, P853, DOI 10.4161/epi.21180
   Nast I, 2013, PAEDIATR PERINAT EP, V27, P313, DOI 10.1111/ppe.12051
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   NISSEN E, 1995, ACTA OBSTET GYN SCAN, V74, P530, DOI 10.3109/00016349509024384
   Oberlander TF, 2008, EPIGENETICS, V3, P97
   Pinheiro J., 2015, R PACKAGE VERSION, V3, P1
   Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7
   R Core Team, 2015, R LANG ENV STAT COMP
   Radtke KM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.21
   Reed V, 1998, INT J METH PSYCH RES, V7, P142, DOI DOI 10.1002/MPR.44
   Reynolds RM, 2013, PSYCHONEUROENDOCRINO, V38, P1843, DOI 10.1016/j.psyneuen.2013.05.018
   Sandman CA, 2012, NEUROENDOCRINOLOGY, V95, P8, DOI 10.1159/000327017
   Schlinzig T, 2009, ACTA PAEDIATR, V98, P1096, DOI 10.1111/j.1651-2227.2009.01371.x
   Schlotz W., 2005, FRAGEBOGEN SKALENBES
   Schulz P, 1999, DIAGNOSTICA, V45, P8, DOI 10.1026//0012-1924.45.1.8
   Sharp GC, 2015, INT J EPIDEMIOL, V44, P1288, DOI 10.1093/ije/dyv042
   Siegrist J., 2003, DIAGNOSTISCHE VERFAH, V2
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Tegethoff M, 2012, AM J RESP CRIT CARE, V185, P557, DOI 10.1164/rccm.201108-1482OC
   Tegethoff M, 2011, ENVIRON HEALTH PERSP, V119, P1647, DOI 10.1289/ehp.1003253
   Tegethoff M, 2011, BIOL PSYCHOL, V87, P414, DOI 10.1016/j.biopsycho.2011.05.007
   Tegethoff M, 2010, PSYCHOSOM MED, V72, P419, DOI 10.1097/PSY.0b013e3181d2f0b0
   Tegethoff M, 2009, ENDOCR REV, V30, P753, DOI 10.1210/er.2008-0014
   Turan N, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-10
   Unternaehrer E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.77
   Unternaehrer E, 2015, STRESS, V18, P451, DOI 10.3109/10253890.2015.1038992
   Wade M, 2015, SOC COGN AFFECT NEUR, V10, P1749, DOI 10.1093/scan/nsv064
   Welberg LAM, 2005, J ENDOCRINOL, V186, pR7, DOI 10.1677/joe.1.06374
   Ziegler T., 2005, P NATL ACAD SCI USA, V102, P237, DOI DOI 10.1073/PNAS.0504767102
   Witt WP, 2014, AM J PUBLIC HEALTH, V104, pS81, DOI 10.2105/AJPH.2013.301544
   Wittchen HU, 1998, SOC PSYCH PSYCH EPID, V33, P568, DOI 10.1007/s001270050095
   Wittchen H. U., 1997, DIA X INTERVIEW MANU
NR 80
TC 0
Z9 0
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD SEP
PY 2016
VL 11
IS 9
BP 1460
EP 1470
DI 10.1093/scan/nsw051
PG 11
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA DW5ZY
UT WOS:000383727400013
PM 27107296
ER

PT J
AU Chuilon, AL
   Le Ray, C
   Prunet, C
   Blondel, B
AF Chuilon, A. -L.
   Le Ray, C.
   Prunet, C.
   Blondel, B.
TI Episiotomy in France in 2010: Variations according to obstetrical
   context and place of birth
SO JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION
LA French
DT Article
DE Episiotomy; Women characteristics; Maternity unit; characteristics;
   Regional differences
ID OPERATIVE VAGINAL DELIVERY; RANDOMIZED CONTROLLED-TRIAL;
   LOGISTIC-REGRESSION; RISK; INTERVENTION; COHORT; OXYTOCIN; OUTCOMES;
   BELIEFS; IRELAND
AB Objectives. - To analyze episiotomy rates according to the characteristics of women and maternity units and to study the variability of rates between units and regions.
   Materials and methods. - Our study included all vaginal deliveries in the National Perinatal Survey 2010 (n = 11,322). We estimated the adjusted relative risk of episiotomy (aRR) according to women and maternity units characteristics, and we studied the variance between regions and hospitals using multilevel Poisson regressions, stratified on parity.
   Results. - In 2010, 44.7% of primiparous; 14.2% in multiparous had an episiotomy. The main associated factors were Asian origin (primiparae: aRR = 1.32 [1.16-1.51]; multiparae: aRR = 2.30 [1.67-3.16]), breech presentation (primiparae: aRR = 2.14 [1.87-2.21]; multiparae: aRR = 3.32 [2.52-4.38]) and operative vaginal delivery (primiparae: aRR = 2.04 [1.89-2.11]; multiparae: aRR = 3.19 [2.74-3.72]). Rates varied dramatically between regions (primiparae: 17 to 64%; multiparae: 3 to 21%). The variance was significant between regions and between maternity units after controlling for women and units characteristics.
   Conclusion. - It would be useful to study the attitudes and views of obstetricians and midwives about the protection of the perineum to better understand these differences in practice. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Chuilon, A. -L.; Le Ray, C.; Prunet, C.; Blondel, B.] Univ Paris 05, DHU Risques & Grossesse, Ctr Rech Epidemiol & Stat,Sorbonne Paris Cite, Inserm UMR 1153,Equipe Rech Epidemiol Obstet Peri, F-75014 Paris, France.
   [Le Ray, C.] Univ Paris 05, Grp Hosp Cochin, AP HP, Maternite Port Royal,Broca Hotel Dieu,DHU Risques, F-75014 Paris, France.
   [Chuilon, A. -L.] Univ Paris 05, Ecole Sages Femmes Baudelocque, AP HP, F-75014 Paris, France.
RP Chuilon, AL (reprint author), Inserm UMR 1153, Maternite Port Royal, 53 Ave Observ, F-75014 Paris, France.
EM anne-lise.chuilon@laposte.net
CR Aasheim V, 2011, COCHRANE DB SYST REV, V12
   Belghiti J, 2013, J GYNECOL OBST BIO R, V42, P662, DOI 10.1016/j.jgyn.2013.02.011
   Bernitz S, 2014, MIDWIFERY, V30, P364, DOI 10.1016/j.midw.2013.03.010
   Blondel B, 2012, J GYNECOL OBST BIO R, V41, P151, DOI 10.1016/j.jgyn.2011.11.008
   Carroli G, 2009, COCHRANE DB SYST REV
   Carroli G, 2000, COCHRANE DB SYST REV
   Chehab M, 2014, J GYNECOL OBST BIO R, V43, P463, DOI 10.1016/j.jgyn.2013.06.002
   CNGOF, 2006, J GYNECOL OBSTET BIO, V35
   Coulm B, 2010, BIRTH-ISS PERINAT C, V39, P183
   Dahlen HG, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001723
   de Leeuw JW, 2008, BJOG-INT J OBSTET GY, V115, P104, DOI 10.1111/j.1471-0528.2007.01554.x
   Eckman A, 2010, J GYNECOL OBST BIO R, V39, P37, DOI 10.1016/j.jgyn.2009.09.013
   Friedman AM, 2015, JAMA-J AM MED ASSOC, V313, P197, DOI 10.1001/jama.2014.14774
   Gossett DR, 2008, J REPROD MED, V53, P803
   KLEIN MC, 1995, CAN MED ASSOC J, V153, P769
   Laine K, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001649
   Lowenstein L, 2005, EUR J OBSTET GYN R B, V123, P179, DOI 10.1016/j.ejogrb.2005.04.006
   Lutomski JE, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-13
   Lutomski JE, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-123
   Macleod M, 2008, BJOG-INT J OBSTET GY, V115, P1688, DOI 10.1111/j.1471-0528.2008.01961.x
   Macleod M, 2008, EUR J OBSTET GYN R B, V136, P178, DOI 10.1016/j.ejogrb.2007.03.004
   Mangin M, 2010, J GYNECOL OBST BIO R, V39, P121, DOI 10.1016/j.jgyn.2010.01.002
   McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074
   Melo I, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-66
   Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454
   Ministere des Affaires sociales de la Sante et des Droits des femmes, 2010, ENQ NAT PER
   Murphy DJ, 2008, BJOG-INT J OBSTET GY, V115, P1695, DOI 10.1111/j.1471-0528.2008.01960.x
   Murphy DJ, 2008, BJOG, V115, P1702, DOI DOI 10.1111/J.1471-0528.2008.01960.X
   Olatunbosun OA, 1998, BRIT MED J, V316, P365
   Raisanen S, 2011, INT J GYNECOL OBSTET, V115, P26, DOI 10.1016/j.ijgo.2011.05.008
   Rapport Euro-Peristat 2013 Euro-Peristat Project with SCPE and EUROCAT, 2013, EUR PER PROJ SCPE EU
   Revicky V, 2010, EUR J OBSTET GYN R B, V150, P142, DOI 10.1016/j.ejogrb.2010.03.002
   Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003
   Traissac P, 1999, REV EPIDEMIOL SANTE, V47, P593
   Webb DA, 2002, BIRTH-ISS PERINAT C, V29, P132, DOI 10.1046/j.1523-536X.2002.00173.x
   Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0368-2315
EI 1773-0430
J9 J GYNECOL OBST BIO R
JI J. Gynecol. Obstet. Biol. Reprod.
PD SEP
PY 2016
VL 45
IS 7
BP 691
EP 700
DI 10.1016/j.jgyn.2015.10.005
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX9HA
UT WOS:000384703000006
PM 26996239
ER

PT J
AU Loscul, C
   Chantry, AA
   Caubit, L
   Deneux-Tharaux, C
   Goffinet, F
   Le Ray, C
AF Loscul, C.
   Chantry, A. -A.
   Caubit, L.
   Deneux-Tharaux, C.
   Goffinet, F.
   Le Ray, C.
TI Association between oxytocin augmentation intervals and the risk of
   postpartum haemorrhage
SO JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION
LA French
DT Article
DE Oxytocin; Augmentation intervals; Postpartum haemorrhage
ID RANDOMIZED-TRIAL; LABOR; INDUCTION; FRANCE
AB Objective. - To study the association between the duration of oxytocin augmentation intervals and the risk of postpartum haemorrhage (PPH) among primiparous women in spontaneous labour.
   Materials and methods. - Retrospective cohort including primiparous women in spontaneous labour who received oxytocin during labour (n = 454). Oxytocin augmentation intervals were dichotomized in intervals < 20 minutes and >= 20 minutes. Obstetrical and neonatal issues were analyzed according to the duration oxytocin augmentation intervals. The association between oxytocin augmentation intervals and PPH was analyzed using univariate and multivariate analysis.
   Results. - Oxytocin augmentation intervals were shorter than 20 minutes for 43.8% of the study population. The rate of PPH was higher (9.1% vs 3.5%; P = 0.014), and the use of sulprostone was more frequent (6.5% vs 3.5%; P = 0.013) if oxytocin augmentation intervals were shorter than 20 minutes in comparison with intervals >= 20 minutes. The association between oxytocin augmentation intervals and PPH remains significant after adjustment on other PPH risk factors (adjusted OR = 3.48, 95% CI [1.45-8.34]). The rate of adverse neonatal issue, defined by arterial pH at birth <= 7.10 and/or 5 minutes score d'Apgar <= 7, was higher if oxytocin augmentation intervals were < 20 minutes (12.1% vs 4.3%; P = 0.002).
   Conclusion. - Our study demonstrated an increased risk of PPH for primiparous women in spontaneous labour who received oxytocin with augmentation intervals shorter than 20 minutes. (C) 2016 Published by Elsevier Masson SAS.
C1 [Loscul, C.; Caubit, L.; Goffinet, F.; Le Ray, C.] Hop Cochin, AP HP, Maternite Port Royal, 53 Ave Observ, F-75014 Paris, France.
   [Loscul, C.; Chantry, A. -A.] Univ Paris 05, AP HP, Ecole Sages Femmes Baudelocque, F-75014 Paris, France.
   [Chantry, A. -A.; Deneux-Tharaux, C.; Goffinet, F.; Le Ray, C.] Univ Paris 05, Inserm UMR 1153, Equipe Rech Epidemiol Obstet Perinatale & Pediat, Ctr Rech Epidemiol & Stat,Sorbonne Paris Cite,DHU, F-75014 Paris, France.
RP Loscul, C (reprint author), Hop Cochin, AP HP, Maternite Port Royal, 53 Ave Observ, F-75014 Paris, France.; Loscul, C (reprint author), Univ Paris 05, AP HP, Ecole Sages Femmes Baudelocque, F-75014 Paris, France.
EM clemence.loscul@cch.aphp.fr
RI Deneux-Tharaux, Catherine/R-1111-2016
CR Belghiti J, 2013, J GYNECOL OBST BIO R, V42, P662, DOI 10.1016/j.jgyn.2013.02.011
   Belghiti J, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000514
   Blondel B., 2011, ENQUETE NATL PERINAT
   Cabrol D, 2008, PROTOCOLES CLIN OBST, P151
   Chantry AA, 2015, CRIT CARE MED, V43, P78, DOI 10.1097/CCM.0000000000000601
   College national des gynecologues et obstetriciens francais, 2007, REC PRAT CLIN MOD SU, P371
   Deneux-Tharaux C, 2010, BJOG-INT J OBSTET GY, V117, P1278, DOI 10.1111/j.1471-0528.2010.02648.x
   GONI S, 1995, INT J GYNECOL OBSTET, V48, P31, DOI 10.1016/0020-7292(94)02249-6
   Grotegut CA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.023
   Kenyon S, 2013, COCHRANE DB SYST REV, V7
   Knight M, 2008, OBSTET GYNECOL, V111, P97, DOI 10.1097/01.AOG.0000296658.83240.6d
   LAZOR LZ, 1993, OBSTET GYNECOL, V82, P1009
   Loscul C., 2013, UTILISATION SYNTOCIN
   MERCER B, 1991, OBSTET GYNECOL, V77, P659
   Oscarsson ME, 2006, ACTA OBSTET GYN SCAN, V85, P1094, DOI 10.1080/00016340600804530
   Saucedo M, 2013, J GYNECOL OBST BIO R, V42, P613, DOI 10.1016/j.jgyn.2013.06.011
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Simpson KR, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2007.12.015
   Xenakis EMJ, 1995, AM J OBSTET GYNECOL, V173, P1874, DOI 10.1016/0002-9378(95)90444-1
NR 19
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0368-2315
EI 1773-0430
J9 J GYNECOL OBST BIO R
JI J. Gynecol. Obstet. Biol. Reprod.
PD SEP
PY 2016
VL 45
IS 7
BP 708
EP 715
DI 10.1016/j.jgyn.2015.12.005
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DX9HA
UT WOS:000384703000008
PM 26874663
ER

PT J
AU Han, BR
   Park, KH
   Lee, SY
   Jung, EY
   Park, JW
AF Han, Bo Ryoung
   Park, Kyo Hoon
   Lee, Sung Youn
   Jung, Eun Young
   Park, Jeong Woo
TI Prediction of the risk of cesarean delivery after labor induction in
   twin gestations based on clinical and ultrasound parameters
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE cervical length; cesarean delivery; labor induction; parity; twins
ID CERVICAL LENGTH; BISHOP SCORE; SONOGRAPHIC MEASUREMENT; SINGLETON
   PREGNANCIES; MULTIPLE PREGNANCY; SUCCESS; TERM; METAANALYSIS; OUTCOMES;
   TRIAL
AB AimsTo develop a model based on clinical and ultrasound parameters to predict the risk of cesarean delivery after labor induction in near-term twin gestations.
   MethodsThis retrospective cohort study included 189 consecutive women with twin gestations at 36.0 weeks scheduled for labor induction. The Bishop score and transvaginal ultrasonographic measurements of cervical length were obtained immediately before labor induction. Parameters studied included maternal age, height, weight, parity, gestational age, Bishop score, cervical length, epidural analgesia, method of conception, chorionicity and birth weight. Prostaglandin E-2 (dinoprostone) and oxytocin were used for labor induction. Logistic regression analysis and receiver operating characteristic curve were used to generate a predictive model for cesarean delivery.
   ResultsFifty (26.5%) of the 189 women had cesarean deliveries. According to logistic regression analysis, maternal height (P = 0.004), parity (P = 0.005) and cervical length (P = 0.016), but not Bishop score (P = 0.920), were identified as independent predictors of cesarean delivery. A risk score based on a model of these three parameters was calculated for each patient. The model was shown to have an adequate goodness of fit (P = 0.201) and the area under the curve was 0.722, indicating fairly good discrimination.
   ConclusionsMaternal height, parity and cervical length were independent parameters for predicting the risk of cesarean delivery after labor induction in twin gestations. A predictive model using these parameters may provide useful information for deciding whether or not to induce labor.
C1 [Han, Bo Ryoung; Park, Kyo Hoon; Lee, Sung Youn; Jung, Eun Young] Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, Coll Med, Songnam, South Korea.
   [Park, Jeong Woo] Inje Univ, Ilsan Paik Hosp Gyeonggi, Dept Obstet & Gynecol, Coll Med, Gimhae, South Korea.
RP Park, KH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, 82,Gumi Ro 173 Beon Gil, Songnam 463707, Gyeonggi Do, South Korea.
EM pkh0419@snubh.org
CR Ayres A, 2005, OBSTET GYNECOL SURV, V60, P538, DOI 10.1097/01.ogx.0000172089.04828.d4
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Chauhan SP, 2010, AM J OBSTET GYNECOL, V203, P305, DOI 10.1016/j.ajog.2010.04.031
   Cnattingius R, 2005, ACTA OBSTET GYN SCAN, V84, P456, DOI 10.1111/j.0001-6349.2005.00620.x
   Crane JMG, 2006, CLIN OBSTET GYNECOL, V49, P573, DOI 10.1097/00003081-200609000-00017
   Cunningham FG, 2005, WILLIAMS OBSTET, P495
   Dellinger EH, 2000, AM J OBSTET GYNECOL, V182, P214, DOI 10.1016/S0002-9378(00)70515-1
   FRIEDMAN EA, 1964, OBSTET GYNECOL, V23, P164
   Ghassani A, 2014, J GYNECOL OBST BIO R
   Grobman WA, 1998, OBSTET GYNECOL, V92, P940, DOI 10.1016/S0029-7844(98)00351-2
   Grobman WA, 2012, SEMIN PERINATOL, V36, P344, DOI 10.1053/j.semperi.2012.04.017
   HANLEY JA, 1983, RADIOLOGY, V148, P839
   Hatfield AS, 2007, AM J OBSTET GYNECOL, V197, P186, DOI 10.1016/j.ajog.2007.04.050
   Kolkman DGE, 2013, AM J PERINAT, V30, P625, DOI 10.1055/s-0032-1331024
   Martin JA, 2011, DIVISION VITAL STAT, V60, P1
   Meath AI, 2005, AM J OBSTET GYNECOL, V192, P1410, DOI 10.1016/j.ajog.2005.01.033
   Okby R, 2013, J MATERN-FETAL NEO M, V26, P1804, DOI 10.3109/14767058.2013.804047
   Park KH, 2011, ULTRASOUND OBST GYN, V38, P198, DOI 10.1002/uog.9020
   Park KH, 2007, J KOREAN MED SCI, V22, P722
   Park KH, 2009, J PERINAT MED, V37, P519, DOI 10.1515/JPM.2009.099
   Peregrine E, 2006, OBSTET GYNECOL, V107, P227, DOI 10.1097/01.AOG.0000196508.11431.c0
   Pevzner L, 2009, OBSTET GYNECOL, V114, P1315, DOI 10.1097/AOG.0b013e3181bfb39f
   Rane SM, 2005, J MATERN-FETAL NEO M, V17, P315, DOI 10.1080/14767050500127690
   Rouse DJ, 2000, OBSTET GYNECOL, V96, P671, DOI 10.1016/S0029-7844(00)01010-3
   Rouse DJ, 2011, OBSTET GYNECOL, V117, P267, DOI 10.1097/AOG.0b013e318207887a
   Schiff E, 1998, AM J OBSTET GYNECOL, V179, P1181, DOI 10.1016/S0002-9378(98)70128-0
   Tan PC, 2011, J ULTRAS MED, V30, P227
   Taylor M, 2012, OBSTET GYNECOL, V120, P297, DOI 10.1097/AOG.0b013e31825f3643
   Verhoeven CJM, 2013, ULTRASOUND OBST GYN, V42, P500, DOI 10.1002/uog.12467
   Williams KP, 2003, ACTA OBSTET GYN SCAN, V82, P241, DOI 10.1034/j.1600-0412.2003.00098.x
   Wiriyasirivaj B, 1996, OBSTET GYNECOL, V87, P767, DOI 10.1016/0029-7844(96)00015-4
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD SEP
PY 2016
VL 42
IS 9
BP 1125
EP 1131
DI 10.1111/jog.13038
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DW4QY
UT WOS:000383629300008
PM 27199212
ER

PT J
AU Hewagalamulage, SD
   Clarke, IJ
   Rao, A
   Henry, BA
AF Hewagalamulage, Sakda D.
   Clarke, Iain J.
   Rao, Alexandra
   Henry, Belinda A.
TI Ewes With Divergent Cortisol Responses to ACTH Exhibit Functional
   Differences in the Hypothalamo-Pituitary-Adrenal (HPA) Axis
SO ENDOCRINOLOGY
LA English
DT Article
ID CORTICOTROPIN-RELEASING-FACTOR; FOOD-INTAKE; ARGININE-VASOPRESSIN;
   MESSENGER-RNA; ISOLATION/RESTRAINT STRESS; PORTAL CIRCULATION; CONSCIOUS
   SHEEP; EATING BEHAVIOR; RAINBOW-TROUT; OXYTOCIN
AB Within any population, the cortisol response to ACTH covers a considerable range. High responders (HRs) exhibit a greater cortisol secretory response to stress or ACTH, compared with individuals classified as low cortisol responders (LRs). We administered ACTH(0.2 mu g/kg, iv) to 160 female sheep and selected subpopulations of animals as LR and HR. In the present study, we aimed to characterize the hypothalamo-pituitary-adrenal axis in HR and LR and to identify factors that underlie the differing cortisol responses to ACTH. Hypothalami, pituitaries, and adrenals were collected from nonstressed HR and LR ewes. Expression of genes for CRH, arginine vasopressin (AVP), oxytocin, glucocorticoid receptor, and mineralocorticoid receptor were measured by in situ hybridization in the paraventricular nucleus of the hypothalamus, and proopiomelanocortin (POMC) gene expression was measured in the anterior pituitary. Expression of CRH, AVP, and POMC was higher in HR, with no differences in either glucocorticoid receptor or mineralocorticoid receptor expression. Oxytocin expression was greater in LR. In the adrenal gland, real-time PCR analysis indicated that expression of the ACTH receptor and a range of steroidogenic enzymes was similar in HR and LR. Adrenal weights, the cortex to medulla ratio and adrenal cortisol content were also similar in LR and HR. In conclusion, LR and HR display innate differences in the steady-state expression of CRH, AVP, oxytocin, and POMC, indicating that selection for cortisol responsiveness identifies distinct subpopulations that exhibit innate differences in the gene expression/function of hypothalamo-pituitary-adrenal axis markers.
C1 [Hewagalamulage, Sakda D.; Henry, Belinda A.] Monash Univ, Metab Dis & Obes Program, Melbourne, Vic 3800, Australia.
   [Clarke, Iain J.; Rao, Alexandra] Monash Univ, Monash Biomed Discovery Inst, Neurosci Program, Melbourne, Vic 3800, Australia.
   [Clarke, Iain J.; Rao, Alexandra] Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia.
RP Henry, BA (reprint author), Monash Univ, Dept Physiol, Bldg 13F, Clayton, Vic 3800, Australia.
EM belinda.henry@monash.edu
FU National Health and Medical Research Council [1005935]
FX This work was supported by the National Health and Medical Research
   Council Project Grant 1005935 (to B.A.H.).
CR Aguilera G, 2011, EXP GERONTOL, V46, P90, DOI 10.1016/j.exger.2010.08.023
   Anukulkitch C, 2010, NEUROENDOCRINOLOGY, V91, P223, DOI 10.1159/000262283
   ARONSSON M, 1988, P NATL ACAD SCI USA, V85, P9331, DOI 10.1073/pnas.85.23.9331
   BOCKING AD, 1986, J DEV PHYSIOL, V8, P237
   Brunton PJ, 2011, PROG NEURO-PSYCHOPH, V35, P1178, DOI 10.1016/j.pnpbp.2010.12.023
   Cavagnini F, 2000, INT J OBESITY, V24, pS77, DOI 10.1038/sj/ijo/0801284
   Cook CJ, 1997, J DAIRY RES, V64, P327, DOI 10.1017/S0022029997002240
   Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI 10.1073/pnas.1934666100
   de Kloet ER, 2000, KIDNEY INT, V57, P1329, DOI 10.1046/j.1523-1755.2000.00971.x
   DEBOLD CR, 1984, J CLIN INVEST, V73, P533, DOI 10.1172/JCI111240
   ENGLER D, 1989, NEUROENDOCRINOLOGY, V49, P367, DOI 10.1159/000125141
   Epel E, 2001, PSYCHONEUROENDOCRINO, V26, P37, DOI 10.1016/S0306-4530(00)00035-4
   FEVOLDEN SE, 1991, AQUACULTURE, V95, P53, DOI 10.1016/0044-8486(91)90072-F
   Giordano R, 2006, THESCIENTIFICWORLDJO, V6, P1, DOI 10.1100/tsw.2006.09
   Goncharova Nadezhda D, 2013, Front Endocrinol (Lausanne), V4, P26, DOI 10.3389/fendo.2013.00026
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Henry BA, 2011, ENDOCRINOLOGY
   Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001
   Hewagalamulage SD, 2015, J NEUROENDOCRINOL, V27, P44, DOI 10.1111/jne.12233
   Jessop DS, 2001, J CLIN ENDOCR METAB, V86, P4109, DOI 10.1210/jc.86.9.4109
   Kellendonk C, 2002, E SCHERING RES FDN W, V40, P305
   KELLERWOOD ME, 1984, ENDOCR REV, V5, P1
   Knott SA, 2008, DOMEST ANIM ENDOCRIN, V34, P261, DOI 10.1016/j.domaniend.2007.07.002
   Lee TK, 2014, PSYCHONEUROENDOCRINO, V47, P166, DOI 10.1016/j.psyneuen.2014.05.015
   Lee TK, 2014, FASEB J, V28, P35, DOI 10.1096/fj.13-238345
   LEHMAN MN, 1986, J COMP NEUROL, V244, P19, DOI 10.1002/cne.902440103
   Lightman SL, 2008, J NEUROENDOCRINOL, V20, P880, DOI 10.1111/j.1365-2826.2008.01711.x
   LIGHTMAN SL, 1988, J PHYSIOL-LONDON, V403, P511
   LIU JP, 1994, J CLIN INVEST, V93, P1439, DOI 10.1172/JCI117121
   Maejima Y, 2015, NEUROENDOCRINOLOGY, V101, P35, DOI 10.1159/000371636
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Newman E, 2007, PSYCHONEUROENDOCRINO, V32, P125, DOI 10.1016/j.psyneuen.2006.11.006
   OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Papadimitriou A, 2009, NEUROIMMUNOMODULAT, V16, P265, DOI 10.1159/000216184
   PASQUALI R, 1993, J CLIN ENDOCR METAB, V77, P341, DOI 10.1210/jc.77.2.341
   Pottinger TG, 1999, GEN COMP ENDOCR, V116, P122, DOI 10.1006/gcen.1999.7355
   RIVIER C, 1983, NATURE, V305, P325, DOI 10.1038/305325a0
   SAPOLSKY RM, 1986, ENDOCR REV, V7, P284
   SAPOLSKY RM, 1986, NEUROBIOL AGING, V7, P331, DOI 10.1016/0197-4580(86)90159-4
   SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169
   Tilbrook AJ, 2006, FRONT NEUROENDOCRIN, V27, P285, DOI 10.1016/j.yfrne.2006.06.002
   Tilbrook AJ, 2008, NEUROENDOCRINOLOGY, V87, P193, DOI 10.1159/000117576
   Touma C, 2008, PSYCHONEUROENDOCRINO, V33, P839, DOI 10.1016/j.psyneuen.2008.03.013
   Turner AI, 2010, ENDOCRINOLOGY, V151, P4324, DOI 10.1210/en.2010-0234
   Turner AI, 2006, J ENDOCRINOL, V188, P443, DOI 10.1677/joe.1.06328
   Turner AI, 2002, J ENDOCRINOL, V173, P113, DOI 10.1677/joe.0.1730113
   Uchoa ET, 2014, J NEUROENDOCRINOL, V26, P557, DOI 10.1111/jne.12157
   WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   YATES FE, 1971, ENDOCRINOLOGY, V88, P3
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2016
VL 157
IS 9
BP 3540
EP 3549
DI 10.1210/en.2016-1287
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DX1NA
UT WOS:000384132900029
PM 27414744
ER

PT J
AU Kramer, K
   Gawronski, A
   Vogeley, K
AF Kraemer, K.
   Gawronski, A.
   Vogeley, K.
TI Diagnosis and Therapeutic Interventions in Autism Spectrum Disorders in
   Adulthood
SO FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
LA German
DT Article
ID HIGH-FUNCTIONING ADULTS; ASPERGER-SYNDROME; CHILDREN; OXYTOCIN;
   PSYCHOPHARMACOLOGY; HYPERSEROTONEMIA; PREVALENCE; BEHAVIOR; NETWORK;
   MIND
AB Autism spectrum disorders (ASD) are characterized by disturbed social interaction and communication as well as stereotyped or repetitive behaviors and interests. Although adults with ASD often acquire complex compensatory strategies that help them master social situations in a rule-based fashion, they still show impairments in intuitive processing of social signals and especially nonverbal communication in complex everyday situations. This constitutes a particular challenge for the psychotherapy of ASD. Psychotherapists are required to explicitly inform and act as an agent of the non-autistic world to enable patients to acquire the ability to take different perspectives. The overall aim of cognitive behavioral therapy interventions addressing ASD in adulthood is to extend the patients' behavioral repertoire to improve their quality of life. Thus, besides psychoeducation on ASD and its frequently associated comorbidities, psychotherapy for adults with ASD should focus on the training and development of social-communicative skills. Furthermore, dealing with stress in everyday situations is an important aspect of psychotherapy of these patients.
C1 [Kraemer, K.; Gawronski, A.; Vogeley, K.] Univ Klin Koln, Klin & Poliklin Psychiat & Psychotherapie, Cologne, Germany.
RP Kramer, K (reprint author), Klinikum Univ Koln, Klin & Poliklin Psychiat & Psychotherapie, Kerpener Str 62, D-50937 Cologne, Germany.
EM Katharina.Kraemer@uk-koeln.de
CR Anderson GM, 2002, MOL PSYCHIATR, V7, P831, DOI 10.1038/sj.mp.4001099
   Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231
   Attwood T., 2008, COMPLETE GUIDE ASPER
   Bailey A, 1996, J CHILD PSYCHOL PSYC, V37, P89, DOI 10.1111/j.1469-7610.1996.tb01381.x
   Baird G, 2006, LANCET, V368, P210, DOI 10.1016/S0140-6736(06)69041-7
   Baron-Cohen S, 2001, INT REV RES MENT RET, V23, P169
   Betancur C, 2011, BRAIN RES, V1380, P42, DOI 10.1016/j.brainres.2010.11.078
   Bromley RL, 2013, J NEUROL NEUROSUR PS, V84, P637, DOI 10.1136/jnnp-2012-304270
   Burgoon JK, 1994, HDB INTERPERSONAL CO, P450
   Critchley HD, 2000, BRAIN, V123, P2203, DOI 10.1093/brain/123.11.2203
   Croen LA, 2005, ARCH PEDIAT ADOL MED, V159, P151, DOI 10.1001/archpedi.159.2.151
   David N, 2010, J AUTISM DEV DISORD, V40, P290, DOI 10.1007/s10803-009-0867-4
   de Bruin EI, 2007, J AUTISM DEV DISORD, V37, P877, DOI 10.1007/s10803-006-0215-x
   Dilling H, 1991, INT KLASSIFIKATION P
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebert D, 2013, ASPERGER AUTISMUS HO
   Falkai P, 2013, DIAGNOSTISCHES STAT
   FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x
   Frazier TW, 2012, J AM ACAD CHILD PSY, V51, P28, DOI 10.1016/j.jaac.2011.09.021
   Freitag CM, 2012, Z KINDER JUG-PSYCH, V40, P139, DOI 10.1024/1422-4917/a000164
   Freitag CM, 2010, EUR CHILD ADOLES PSY, V19, P169, DOI 10.1007/s00787-009-0076-x
   Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218
   Frith U, 2003, AUTISM EXPLAINING EN
   Gaus VL, 2007, COGNITIVE BEHAV THER
   Gaus VL., 2000, NATION ASS ALCOHOL D, V3, P62
   Gawronski A, 2011, FORTSCHR NEUROL PSYC, V79, P647, DOI 10.1055/s-0031-1281734
   Gawronski A, 2012, MANUALISIERTE GRUPPE
   Gawronski A, MODERNE KVT BEI SCHW
   Georgescu AL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00807
   Ghaziuddin M, 2002, J AUTISM DEV DISORD, V32, P299, DOI 10.1023/A:1016330802348
   Zafar S., 2008, CLIN NEUROPSYCHIATRY, V5, P9
   Grice M, CULTURE BRA IN PRESS
   Hadjikhani N, 2006, CEREB CORTEX, V16, P1276, DOI 10.1093/cercor/bh069
   Hallahan B, 2009, PSYCHOL MED, V39, P337, DOI 10.1017/S0033291708003383
   Haussler A, 2008, SOKO AUTISMUS GRUPPE
   Haussler A., 2008, TEACCH ANSATZ FORDER
   Hofvander B, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-35
   Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899
   Iarocci G, 2006, J AUTISM DEV DISORD, V36, P117, DOI 10.1007/s10803-005-0045-2
   Kamp-Becker I, 2010, J AUTISM DEV DISORD, V40, P921, DOI 10.1007/s10803-010-0939-5
   Kim YS, 2011, AM J PSYCHIAT, V168, P904, DOI 10.1176/appi.ajp.2011.10101532
   Kramer K, 2015, PSYCHOTHERAPEUTENJOU, V3, P231
   Kuzmanovic B, 2011, RES AUTISM SPECT DIS, V5, P604, DOI 10.1016/j.rasd.2010.07.005
   Lee YJ, 2014, CLIN PSYCHOPHARM NEU, V12, P19, DOI 10.9758/cpn.2014.12.1.19
   Lehnhardt FG, 2012, FORTSCHR NEUROL PSYC, V80, P88, DOI 10.1055/s-0031-1281642
   Lehnhardt FG, 2013, DTSCH ARZTEBL INT, V110, P755, DOI 10.3238/arztebl.2013.0755
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Lombardo MV, 2011, NEUROIMAGE, V56, P1832, DOI 10.1016/j.neuroimage.2011.02.067
   Lopez B, 2003, J CHILD PSYCHOL PSYC, V44, P285, DOI 10.1111/1469-7610.00121
   Lotter V., 1966, SOC PSYCHIAT, V1, P124, DOI DOI 10.1007/BF00584048
   McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142
   McNamara IM, 2008, BRAIN RES, V1189, P203, DOI 10.1016/j.brainres.2007.10.063
   Noterdaeme M., 2009, AUTISMUS SPEKTRUM UR
   Nylander L., 2008, CLIN NEUROPSYCHIATRY, V5, P43
   Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041
   Politte LC, 2014, HARVARD REV PSYCHIAT, V22, P76, DOI 10.1097/HRP.0000000000000030
   PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Reichenberg A, 2006, ARCH GEN PSYCHIAT, V63, P1026, DOI 10.1001/archpsyc.63.9.1026
   Remschmidt H, 2006, ASPERGER SYNDROM
   Ryden E., 2008, CLIN NEUROPSYCHIATRY, V5, P13
   Scheel C, 2011, NEUROIMAGE, V58, P391, DOI 10.1016/j.neuroimage.2011.06.040
   Schoofs T., 2015, THESIS
   Schuster N., 2007, GUTER TAG IST TAG WI
   Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111
   Stachnik JM, 2007, ANN PHARMACOTHER, V41, P626, DOI 10.1345/aph.1H527
   Stahlberg O, 2004, J NEURAL TRANSM, V111, P891, DOI 10.1007/s00702-004-0115-1
   Vogeley K., 2015, PSYCHIATRIE, V12, P94
   Vogeley K, 2015, VERHALTENSTHERAPIEMA, P481
   Vogeley K, 2015, THERAPIE PSYCHISCHER
   Vogeley K., 2016, ANDERS SEIN HOCHFUNK
   Young LJ, 2001, AM J MED GENET, V105, P53, DOI 10.1002/1096-8628(20010108)105:1<53::AID-AJMG1059>3.0.CO;2-U
NR 72
TC 0
Z9 0
U1 7
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0720-4299
EI 1439-3522
J9 FORTSCHR NEUROL PSYC
JI Forschritte Neurol. Psychiatr.
PD SEP
PY 2016
VL 84
IS 9
BP 578
EP 587
DI 10.1055/s-0042-114795
PG 10
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DX0BM
UT WOS:000384026500024
PM 27607072
ER

PT J
AU Oberg, AS
   D'Onofrio, BM
   Rickert, ME
   Hernandez-Diaz, S
   Ecker, JL
   Almqvist, C
   Larsson, H
   Lichtenstein, P
   Bateman, BT
AF Oberg, Anna Sara
   D'Onofrio, Brian M.
   Rickert, Martin E.
   Hernandez-Diaz, Sonia
   Ecker, Jeffrey L.
   Almqvist, Catarina
   Larsson, Henrik
   Lichtenstein, Paul
   Bateman, Brian T.
TI Association of Labor Induction With Offspring Risk of Autism Spectrum
   Disorders
SO JAMA PEDIATRICS
LA English
DT Article
ID POPULATION; OXYTOCIN; DESIGNS
AB IMPORTANCE Induction of labor is a frequently performed obstetrical intervention. It would thus be of great concern if reported associations between labor induction and offspring risk of autism spectrum disorders (ASD) reflected causal influence.
   OBJECTIVE To assess the associations of labor induction with ASD, comparing differentially exposed relatives (siblings and cousins discordant for induction).
   DESIGN, SETTING, AND PARTICIPANTS Follow-up of all live births in Sweden between 1992 and 2005, defined in the Medical Birth Register. The register was linked to population registers of familial relations, inpatient and outpatient visits, and education records. Diagnoses of ASD were from 2001 through 2013, and data were analyzed in the 2015-2016 year.
   EXPOSURES Induction of labor.
   MAIN OUTCOMES AND MEASURES Autism spectrum disorders identified by diagnoses from inpatient and outpatient records between 2001 and 2013. Hazard ratios (HRs) quantified the association between labor induction and offspring ASD. In addition to considering a wide range of measured confounders, comparison of exposure-discordant births to the same woman allowed additional control for all unmeasured factors shared by siblings.
   RESULTS The full cohort included 1 362 950 births, of which 22 077 offspring (1.6%) were diagnosed with ASD by ages 8 years through 21 years. In conventional models of the full cohort, associations between labor induction and offspring ASD were attenuated but remained statistically significant after adjustment for measured potential confounders (HR, 1.19; 95% CI, 1.13-1.24). When comparison was made within siblings whose births were discordant with respect to induction, thus accounting for all environmental and genetic factors shared by siblings, labor induction was no longer associated with offspring ASD (HR, 0.99; 95% CI, 0.88-1.10).
   CONCLUSIONS AND RELEVANCE In this nationwide sample of live births we observed no association between induction of labor and offspring ASD within sibling comparison. Our findings suggest that concern for ASD should not factor into the clinical decision about whether to induce labor.
C1 [Oberg, Anna Sara; Hernandez-Diaz, Sonia] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
   [Oberg, Anna Sara; Almqvist, Catarina; Larsson, Henrik; Lichtenstein, Paul] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [D'Onofrio, Brian M.; Rickert, Martin E.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.
   [Ecker, Jeffrey L.] Harvard Med Sch, Dept Obstet & Gynecol, Massachusetts Gen Hosp, Boston, MA USA.
   [Almqvist, Catarina] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden.
   [Bateman, Brian T.] Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Brigham & Womens Hosp, Boston, MA USA.
   [Bateman, Brian T.] Harvard Med Sch, Dept Anesthesia Crit Care & Pain Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Oberg, AS (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
EM oberg@hsph.harvard.edu
FU Swedish Initiative for Research on Microdata in the Social and Medical
   Sciences [SIMSAM] from Swedish Research Council [340-2013-5867];
   National Institutes of Health Eunice Kennedy Shriver National Institute
   of Child Health & Human Development [K08HD075831, R01HD061817];
   International Postdoctoral grant from Swedish Research Council [2012-34]
FX This study was supported by grants 2012-34 (International Postdoctoral
   grant) and 340-2013-5867 (Swedish Initiative for Research on Microdata
   in the Social and Medical Sciences [SIMSAM]) from the Swedish Research
   Council and grants K08HD075831 and R01HD061817 from the National
   Institutes of Health Eunice Kennedy Shriver National Institute of Child
   Health & Human Development.
CR Academy of Medical SciencesWorking Group, 2007, ID ENV CAUS DIS SHOU
   Barnabei VM, 2014, AM J OBSTET GYNECOL, V210, P494, DOI 10.1016/j.ajog.2014.01.020
   Centers for Disease Control and Prevention, 2012, MMWR SURVEILL SUMM, V61, P1
   CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143
   D'Onofrio BM, 2013, AM J PUBLIC HEALTH, V103, P46, DOI 10.2105/AJPH.2013.301252
   Dodds L, 2011, J AUTISM DEV DISORD, V41, P891, DOI 10.1007/s10803-010-1114-8
   Donofrio B, 2014, CHILD DEV PERSPECT, V8, P151, DOI 10.1111/cdep.12078
   Donovan SJ, 2011, INT J EPIDEMIOL, V40, P345, DOI 10.1093/ije/dyr057
   FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505
   Gardener H, 2011, PEDIATRICS, V128, P344, DOI 10.1542/peds.2010-1036
   Glasson EJ, 2004, ARCH GEN PSYCHIAT, V61, P618, DOI 10.1001/archpsyc.61.6.618
   Gregory SG, 2013, JAMA PEDIATR, V167, P959, DOI 10.1001/jamapediatrics.2013.2904
   Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121
   Idring S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041280
   Juul-Dam N, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e63
   Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y
   National Board of Health andWelfare, 2009, 200912515 NAT BOARD, P125
   National Board of Health and Welfare, 2003, SWED MED BIRTH REG S
   Saade GR, 2014, JAMA PEDIATR, V168, P190, DOI 10.1001/jamapediatrics.2013.4800
   Stavropoulos KKM, 2013, J CHILD PSYCHOL PSYC, V54, P603, DOI 10.1111/jcpp.12061
   Stitely ML, 2014, JAMA PEDIATR, V168, P189, DOI 10.1001/jamapediatrics.2013.4789
   Sullivan PF, 2012, ARCH GEN PSYCHIAT, V69, P1099, DOI 10.1001/archgenpsychiatry.2012.730
   Statistics Sweden, 2010, MULTIGENERATION REGI, P13
   Vintzileos A, 2014, JAMA PEDIATR, V168, P190, DOI 10.1001/jamapediatrics.2013.4795
   Wahl RUR, 2004, MED HYPOTHESES, V63, P456, DOI 10.1016/j.mehy.2004.03.008
   World Health Organization, 1992, INT CLASS DIS
NR 26
TC 0
Z9 0
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD SEP
PY 2016
VL 170
IS 9
AR e160965
DI 10.1001/jamapediatrics.2016.0965
PG 7
WC Pediatrics
SC Pediatrics
GA DX2PL
UT WOS:000384212700001
PM 27454803
ER

PT J
AU Garfinkel, BP
   Arad, S
   Neuner, SM
   Netser, S
   Wagner, S
   Kaczorowski, CC
   Rosen, CJ
   Gal, M
   Soreq, H
   Orly, J
AF Garfinkel, B. P.
   Arad, S.
   Neuner, S. M.
   Netser, S.
   Wagner, S.
   Kaczorowski, C. C.
   Rosen, C. J.
   Gal, M.
   Soreq, H.
   Orly, J.
TI HP1BP3 expression determines maternal behavior and offspring survival
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE Anxiety; chromatin; epigenetics; histone; HP1BP3; knockout mouse;
   maternal behavior; microRNA; social; survival
ID BRAIN-SEROTONIN; POSTPARTUM DEPRESSION; PROGESTERONE INHIBITION;
   GROWTH-RETARDATION; PREFRONTAL CORTEX; STRESS RESPONSES; SOCIAL
   BEHAVIORS; MICE DEFICIENT; FEMALE MICE; OXYTOCIN
AB Maternal care is an indispensable behavioral component necessary for survival and reproductive success in mammals, and postpartum maternal behavior is mediated by an incompletely understood complex interplay of signals including effects of epigenetic regulation. We approached this issue using our recently established mice with targeted deletion of heterochromatin protein 1 binding protein 3 (HP1BP3), which we found to be a novel epigenetic repressor with critical roles in postnatal growth. Here, we report a dramatic reduction in the survival of pups born to Hp1bp3(-/-) deficient mouse dams, which could be rescued by co-fostering with wild-type dams. Hp1bp3(-/-) females failed to retrieve both their own pups and foster pups in a pup retrieval test, and showed reduced anxiety-like behavior in the open-field and elevated-plus-maze tests. In contrast, Hp1bp3(-/-) females showed no deficits in behaviors often associated with impaired maternal care, including social behavior, depression, motor coordination and olfactory capability; and maintained unchanged anxiety-associated hallmarks such as cholinergic status and brain miRNA profiles. Collectively, our results suggest a novel role for HP1BP3 in regulating maternal and anxiety-related behavior in mice and call for exploring ways to manipulate this epigenetic process.
C1 [Garfinkel, B. P.; Soreq, H.] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, IL-91904 Jerusalem, Israel.
   [Garfinkel, B. P.; Arad, S.; Soreq, H.; Orly, J.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Jerusalem, Israel.
   [Arad, S.; Gal, M.] Hebrew Univ Jerusalem, Biomed Sci, Fac Med, Jerusalem, Israel.
   [Neuner, S. M.; Kaczorowski, C. C.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN USA.
   [Netser, S.; Wagner, S.] Univ Haifa, Sagol Dept Neurobiol, Haifa, Israel.
   [Rosen, C. J.] Maine Med Ctr, Ctr Clin & Translat Res, Res Inst, Scarborough, ME USA.
   [Gal, M.] Shaare Zedek Med Ctr, Dept Obstet & Gynecol, IVF Unit, Jerusalem, Israel.
RP Garfinkel, BP (reprint author), Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, IL-91904 Jerusalem, Israel.
EM benny.garfinkel@mail.huji.ac.il
FU United States - Israel Binational Science Foundation [2013194]; European
   Research Council [321501]; Edmond and Lilly Safra Center for Brain
   Sciences; Joint Research Fund of The Hebrew University Faculty of
   Medicine, Hadassah-Shaare Zedek-Kaplan Medical Centers
FX The authors wish to thank Professors Adi Mizrahi and Raz Yirmiya and Dr
   Yael Shlomai-Fuchs for their most helpful advice and discussions
   regarding maternal and social behavior. Ilan Friedson, Uriya Bekenstein
   and Dr Nibha Mishra, Jerusalem for help with preparation and analysis of
   deep sequencing. The sequencing was performed at the Center for Genomic
   Technologies at the Hebrew University of Jerusalem. This work was
   supported by The United States - Israel Binational Science Foundation
   (grant number 2013194 to JO and CJR), and by the European Research
   Council (Advanced Award 321501, to HS). BPG is supported by a fellowship
   from the Edmond and Lilly Safra Center for Brain Sciences. SA is a
   scholarship recipient of the Joint Research Fund of The Hebrew
   University Faculty of Medicine, Hadassah-Shaare Zedek-Kaplan Medical
   Centers. The authors have no conflicts of interest to declare.
CR Aartsma-Rus A., 2014, JOVE-J VIS EXP
   Alenina N, 2009, P NATL ACAD SCI USA, V106, P10332, DOI 10.1073/pnas.0810793106
   Angoa-Perez M, 2014, GENES BRAIN BEHAV, V13, P579, DOI 10.1111/gbb.12159
   Angoa-Perez M, 2014, ACS CHEM NEUROSCI, V5, P908, DOI 10.1021/cn500096g
   Arbel Y, 2014, MOL MED, V20, P38, DOI 10.2119/molmed.2013.00139
   Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3
   Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360
   Bishop S, 2004, NAT NEUROSCI, V7, P184, DOI 10.1038/nn1173
   Bond TLY, 2003, EPILEPSY BEHAV, V4, P57, DOI 10.1016/S1525-5050(02)00645-5
   BRIDGES RS, 1994, PSYCHONEUROENDOCRINO, V19, P611, DOI 10.1016/0306-4530(94)90045-0
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Champagne FA, 2009, BEHAV NEUROSCI, V123, P469, DOI 10.1037/a0015060
   Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572
   Curley JP, 2012, HORM BEHAV, V61, P454, DOI 10.1016/j.yhbeh.2012.01.013
   Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2
   De Crescenzo F, 2014, J AFFECT DISORDERS, V152, P39, DOI 10.1016/j.jad.2013.09.019
   Driessen TM, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-11
   Eisinger BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063824
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9
   Field T, 2010, INFANT BEHAV DEV, V33, P1, DOI 10.1016/j.infbeh.2009.10.005
   GANDELMA.R, 1971, SCIENCE, V171, P210, DOI 10.1126/science.171.3967.210
   Garfinkel BP, 2015, ENDOCRINOLOGY, V156, P4558, DOI 10.1210/en.2015-1668
   Garfinkel BP, 2015, NUCLEIC ACIDS RES, V43, P2074, DOI 10.1093/nar/gkv089
   Girirajan S, 2009, MAMM GENOME, V20, P247, DOI 10.1007/s00335-009-9180-y
   Grisaru D, 2006, J IMMUNOL, V176, P27
   Guintivano J, 2014, MOL PSYCHIATR, V19, P560, DOI 10.1038/mp.2013.62
   Haldar S, 2011, J BIOL CHEM, V286, P9308, DOI 10.1074/jbc.M110.143198
   Hayashihara K, 2010, J BIOL CHEM, V285, P6498, DOI 10.1074/jbc.M109.092833
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Ibn-Salem J, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0423-1
   Insel T R, 1997, Rev Reprod, V2, P28, DOI 10.1530/ror.0.0020028
   JONES PM, 1983, NEUROENDOCRINOLOGY, V37, P454, DOI 10.1159/000123592
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Lerch-Haner JK, 2008, NAT NEUROSCI, V11, P1001, DOI 10.1038/nn.2176
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027
   Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330
   Lucas BK, 1998, ENDOCRINOLOGY, V139, P4102, DOI 10.1210/en.139.10.4102
   Maguire J, 2008, NEURON, V59, P207, DOI 10.1016/j.neuron.2008.06.019
   Martel G, 2008, P NATL ACAD SCI USA, V105, P14620, DOI 10.1073/pnas.0807507105
   Martyn AC, 2012, MOL CELL BIOL, V32, P5140, DOI 10.1128/MCB.01142-12
   Meerson A, 2010, J MOL NEUROSCI, V40, P47, DOI 10.1007/s12031-009-9252-1
   Mileva-Seitz VR, 2016, HORM BEHAV, V77, P211, DOI 10.1016/j.yhbeh.2015.06.003
   Mosienko V, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.44
   Neuner SM, 2016, NEUROBIOL AGING, V46, P58, DOI 10.1016/j.neurobiolaging.2016.06.008
   Osborne L, 2016, NEUROPSYCHOPHARMACOL, V41, P1648, DOI 10.1038/npp.2015.333
   Pedersen CA, 2006, GENES BRAIN BEHAV, V5, P274, DOI 10.1111/j.1601-183X.2005.00162.x
   Rinaldi A, 2010, BEHAV BRAIN RES, V208, P265, DOI 10.1016/j.bbr.2009.11.012
   Sadakata T, 2012, P NATL ACAD SCI USA, V109, P21104, DOI 10.1073/pnas.1210055109
   Sailaja BS, 2012, P NATL ACAD SCI USA, V109, pE3687, DOI 10.1073/pnas.1209990110
   Satoh Y, 2011, J NEUROSCI, V31, P11953, DOI 10.1523/JNEUROSCI.2349-11.2011
   Schnutgen F, 2005, P NATL ACAD SCI USA, V102, P7221, DOI 10.1073/pnas.050227310
   Shaltiel G, 2013, BRAIN STRUCT FUNCT, V218, P59, DOI 10.1007/s00429-011-0376-z
   Shenhar-Tsarfaty S, 2015, P NATL ACAD SCI USA, V112, pE467, DOI 10.1073/pnas.1418264112
   SIEGEL HI, 1975, HORM BEHAV, V6, P223, DOI 10.1016/0018-506X(75)90009-4
   SIEGEL HI, 1978, HORM BEHAV, V11, P12, DOI 10.1016/0018-506X(78)90054-5
   Soreq H, 2015, TRENDS NEUROSCI, V38, P448, DOI 10.1016/j.tins.2015.05.007
   Stewart-Brown SL, 2011, HEALTH PROMOT INT, V26, pI10, DOI 10.1093/heapro/dar056
   Stolzenberg DS, 2016, HORM BEHAV, V77, P204, DOI 10.1016/j.yhbeh.2015.07.005
   Stolzenberg DS, 2014, ENDOCRINOLOGY, V155, P3674, DOI 10.1210/en.2013-1946
   Stolzenberg DS, 2012, HORM BEHAV, V62, P128, DOI 10.1016/j.yhbeh.2012.05.012
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Uchida S, 2010, J NEUROSCI, V30, P15007, DOI 10.1523/JNEUROSCI.1436-10.2010
   Wang ZS, 2011, NEUROPSYCHOPHARMACOL, V36, P772, DOI 10.1038/npp.2010.211
   Weiss J, 2011, NATURE, V472, P186, DOI 10.1038/nature09975
   Won H, 2012, NATURE, V486, P261, DOI 10.1038/nature11208
   Yang M., 2009, CURR PROTOC NEUROSCI, V8, P8, DOI DOI 10.1002/0471142301.NS0824S48
   Zhao CJ, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00388
NR 68
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD SEP
PY 2016
VL 15
IS 7
BP 678
EP 688
DI 10.1111/gbb.12312
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DW6QC
UT WOS:000383775000007
PM 27470444
ER

PT J
AU Zheng, HM
   Kendrick, KM
   Yu, RJ
AF Zheng, Huimin
   Kendrick, Keith M.
   Yu, Rongjun
TI Fear or greed? Oxytocin regulates inter-individual conflict by enhancing
   fear in men
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Fear; Greed; Oxytocin; Cooperation; Emotion
ID INTRANASAL OXYTOCIN; COOPERATIVE BEHAVIOR; DECISION-MAKING; VASOPRESSIN;
   INCREASES; ALTRUISM; HUMANS; COMPETITION; WOMEN
AB People may choose non-cooperation in social dilemmas either out of fear (if others choose to defect) or out of greed (when others choose to cooperate). Previous studies have shown that exogenous oxytocin motivates a "tend and defend" pattern in inter-group conflict in which oxytocin stimulates in-group cooperation and out-group defense. Using a double-blind placebo-controlled design combined with a modified Prisoner's dilemma game (PDG), we examined the effect of oxytocin on social motivations in inter-individual conflict in men. Results showed that compared with the placebo group, oxytocin-exposed participants were less cooperative in general. Specifically, oxytocin amplified the effect of fear on defection but did not influence the effect of greed. Another non-social control study confirmed participants' decisions were sensitive to social factors. Our findings suggest that even when social group conflict is removed, oxytocin promotes distrust of strangers in "me and you" inter-individual conflict by elevating social fear in men. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Zheng, Huimin; Yu, Rongjun] South China Normal Univ, Sch Psychol, Ctr Studies Psychol Applicat, Guangzhou, Guangdong, Peoples R China.
   [Zheng, Huimin; Yu, Rongjun] South China Normal Univ, Key Lab Mental Hlth & Cognit Sci Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
   [Kendrick, Keith M.] Univ Elect Sci & Technol China, Med Informat Ctr, Key Lab Neuroinformat, Chengdu, Peoples R China.
   [Yu, Rongjun] Natl Univ Singapore, Dept Psychol, Singapore, Singapore.
   [Yu, Rongjun] Natl Univ Singapore, Ctr Life Sci, Neurobiol Ageing Programme, Singapore, Singapore.
   [Yu, Rongjun] Natl Univ Singapore, Ctr Life Sci, Inst Neurotechnol SINAPSE, Singapore, Singapore.
RP Yu, RJ (reprint author), South China Normal Univ, Sch Psychol, Ctr Studies Psychol Applicat, Guangzhou, Guangdong, Peoples R China.; Yu, RJ (reprint author), South China Normal Univ, Key Lab Mental Hlth & Cognit Sci Guangdong Prov, Guangzhou, Guangdong, Peoples R China.; Yu, RJ (reprint author), Natl Univ Singapore, Dept Psychol, Singapore, Singapore.; Yu, RJ (reprint author), Natl Univ Singapore, Ctr Life Sci, Neurobiol Ageing Programme, Singapore, Singapore.; Yu, RJ (reprint author), Natl Univ Singapore, Ctr Life Sci, Inst Neurotechnol SINAPSE, Singapore, Singapore.
FU National Natural Science Foundation of China [31371128, 31530032]; MOE
   Tier 1 [R-581-000-191-112]; National University of Singapore Grant
   [WBSR-581-000-166-133]
FX This research was supported by the National Natural Science Foundation
   of China (31371128; 31530032), MOE Tier 1 (R-581-000-191-112), and the
   National University of Singapore Grant WBSR-581-000-166-133 to R. Yu.
CR Ahn TK, 2001, PUBLIC CHOICE, V106, P137, DOI 10.1023/A:1005219123532
   AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396
   Coleman J. S., 1992, RATIONAL CHOICE THEO
   Cosmides L, 2000, NEW COGNITIVE NEUROS, V2, P1259
   De Dreu CKW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046751
   De Dreu CKW, 2012, HORM BEHAV, V61, P419, DOI 10.1016/j.yhbeh.2011.12.009
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Declerck CH, 2014, SOC COGN AFFECT NEUR, V9, P802, DOI 10.1093/scan/nst040
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   De Dreu C.K., 2014, SOCIAL COGNITIVE AFF
   Delgado MR, 2008, SCIENCE, V321, P1849, DOI 10.1126/science.1158860
   [段明君 DUAN MingJun], 2006, [中国心理卫生杂志, Chinese Mental Health Journal], V20, P610
   Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043
   Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100
   Geanakoplos John, 1989, GAME ECON BEHAV, V1, P60, DOI [10.1016/0899-8256(89)90005-5, DOI 10.1016/0899-8256(89)90005-5]
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Hahn-Holbrook J, 2011, PSYCHOL SCI, V22, P1288, DOI 10.1177/0956797611420729
   Hoppensteadt F., 2006, SCHOLARPEDIA, V1, P1563
   Huang Y, 2015, PSYCHONEUROENDOCRINO, V60, P114, DOI 10.1016/j.psyneuen.2015.06.003
   Israel S, 2012, PSYCHONEUROENDOCRINO, V37, P1341, DOI 10.1016/j.psyneuen.2012.02.001
   KANDORI M, 1992, REV ECON STUD, V59, P63, DOI 10.2307/2297925
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lambert B, 2014, PSYCHONEUROENDOCRINO, V40, P60, DOI 10.1016/j.psyneuen.2013.10.015
   Ma YN, 2015, NEUROPSYCHOPHARMACOL, V40, P2379, DOI 10.1038/npp.2015.87
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   MacDonald K, 2014, BRAIN RES, V1580, P22, DOI 10.1016/j.brainres.2014.01.025
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Marsh AA, 2007, EMOTION, V7, P239, DOI 10.1037/1528-3542.7.2.239
   MORRIS MW, 1994, J PERS SOC PSYCHOL, V67, P949, DOI 10.1037/0022-3514.67.6.949
   Palgi S., 2014, SOCIAL COGNITIVE AFF
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Piff PK, 2012, P NATL ACAD SCI USA, V109, P4086, DOI 10.1073/pnas.1118373109
   Preckel K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00191
   PRUITT DG, 1977, ANNU REV PSYCHOL, V28, P363, DOI 10.1146/annurev.ps.28.020177.002051
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Roca CP, 2011, P NATL ACAD SCI USA, V108, P11370, DOI 10.1073/pnas.1101044108
   Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Simpson B, 2006, RATION SOC, V18, P443, DOI 10.1177/1043463106066381
   Stallen M., 2012, PSYCHOL SCI
   Steinel W, 2004, J PERS SOC PSYCHOL, V86, P419, DOI 10.1037/0022-3514.86.3.419
   Ten Velden FS, 2014, BRAIN RES, V1580, P172, DOI 10.1016/j.brainres.2013.09.013
   Theodoridou A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058113
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Yao SX, 2014, INT J NEUROPSYCHOPH, V17, P1785, DOI 10.1017/S146114571400090X
NR 46
TC 0
Z9 0
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD SEP
PY 2016
VL 85
BP 12
EP 18
DI 10.1016/j.yhbeh.2016.07.003
PG 7
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DW7GO
UT WOS:000383819400003
PM 27444251
ER

PT J
AU Sato, M
   Noguchi, J
   Mashima, M
   Tanaka, H
   Hata, T
AF Sato, Miki
   Noguchi, Junko
   Mashima, Masato
   Tanaka, Hirokazu
   Hata, Toshiyuki
TI 3D power Doppler ultrasound assessment of placental perfusion during
   uterine contraction in labor
SO PLACENTA
LA English
DT Article
DE Placental vascular sonobiopsy; 3D power Doppler ultrasound; Placental
   perfusion; Spontaneous uterine contraction; Induced uterine contraction;
   Labor
ID BLOOD-FLOW; VASCULAR SONOBIOPSY; CIRCULATION; OXYTOCIN; INDEXES
AB Introduction: To assess placental perfusion during spontaneous or induced uterine contraction in labor at term using placental vascular sonobiopsy (PVS) by 3D power Doppler ultrasound with the VOCAL imaging analysis program.
   Method: PVS was performed in 50 normal pregnancies (32 in spontaneous labor group [SLG], and 18 in induced labor group with oxytocin or prostaglandin F-2 alpha [ILG]) at 37-41 weeks of gestation to assess placental perfusion during uterine contraction in labor. Only pregnancies with an entirely visualized anterior placenta were included in the study. Data acquisition was performed before, during (at the peak of contraction), and after uterine contraction. 3D power Doppler indices such as the vascularization index (VI), flow index (FI), and vascularization flow index (VFI) were calculated in each placenta.
   Results: There were no abnormal fetal heart rate tracings during contraction in either group. VI and VFI values were significantly reduced during uterine contraction in both groups (SLG,-33.4% [-97.0-15.2%], and ILG,-49.6% [-78.2--4.0%]), respectively (P < 0.001). The FI value in the ILG group was significantly lower during uterine contraction (P = 0.035), whereas it did not change during uterine contraction in the SLG group. After uterine contraction, all vascular indices returned almost to the same level as that before uterine contraction. However, the FI value in ILG (-8.6%, [-19.7-16.0%]) was significantly lower than that in SLG (2.4%, [-13.4-38.1%]) after uterine contraction (P < 0.05). All 3D power Doppler indices (VI, FI, and VFI) during uterine contraction (at the peak of contraction) showed a correlation greater than 0.7, with good intra- and inter-observer agreements.
   Discussion: Our findings suggest that uterine contraction in both spontaneous and induced labors causes a significant reduction in placental perfusion. Reduced placental blood flow in induced uterine contraction has a tendency to be marked compared with that in spontaneous uterine contraction. To the best of our knowledge, this is the first study on the non-invasive assessment of placental perfusion during uterine contraction in labor using 3D power Doppler ultrasound. However, the data and their interpretation in the present study should be taken with some degree of caution because of the small number of subjects studied. Further studies involving a larger sample size are needed to assess placental perfusion and vascularity using PVS during normal and abnormal uterine contractions in normal and high-risk pregnancies. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Sato, Miki; Mashima, Masato; Tanaka, Hirokazu; Hata, Toshiyuki] Kagawa Univ, Grad Sch Med, Dept Perinatol & Gynecol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
   [Noguchi, Junko] Kagawa Prefectural Coll Hlth Sci, Dept Nursing, 281-1 Murecho Hara, Takamatsu, Kagawa 7610123, Japan.
RP Hata, T (reprint author), Kagawa Univ, Grad Sch Med, Dept Perinatol & Gynecol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM toshi28@med.kagawa-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [24119004, 25462561]
FX The work reported in this paper was supported by a Grant-in-Aid for
   scientific Research on Innovative Areas "Constructive Developmental
   Science" (No. 24119004), and a Research Grant (No. 25462561) from The
   Ministry of Education, Culture, Sports, Science and Technology, Japan.
CR BLAND JM, 1986, LANCET, V1, P307
   BORELL U, 1964, AM J OBSTET GYNECOL, V89, P881
   Hata T, 2011, PLACENTA, V32, P105, DOI 10.1016/j.placenta.2010.11.001
   Hidaka A., 1976, NIHON SANKA FUJINKA, V28, P105
   LEES MH, 1971, AM J OBSTET GYNECOL, V110, P68
   MCLAUGHLIN MK, 1978, AM J OBSTET GYNECOL, V130, P408
   Merce LT, 2004, J PERINAT MED, V32, P228, DOI 10.1515/JPM.2004.043
   Noguchi J, 2009, PLACENTA, V30, P391, DOI 10.1016/j.placenta.2009.02.010
   Noguchi J, 2015, ARCH GYNECOL OBSTET, V292, P75, DOI 10.1007/s00404-014-3603-z
   NOVY MJ, 1975, AM J OBSTET GYNECOL, V122, P419
   Raine-Fenning NJ, 2008, ULTRASOUND OBST GYN, V32, P540, DOI 10.1002/uog.6110
   RAMSEY EM, 1963, AM J OBSTET GYNECOL, V86, P213
   STUART B, 1981, BRIT J OBSTET GYNAEC, V88, P865, DOI 10.1111/j.1471-0528.1981.tb02220.x
   TRUPPIN M, 1961, AM J OBSTET GYNECOL, V82, P804
   Tuuli MG, 2010, PLACENTA, V31, P192, DOI 10.1016/j.placenta.2009.12.018
   Zalud I, 2008, J CLIN ULTRASOUND, V36, P391, DOI 10.1002/jcu.20485
NR 16
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
EI 1532-3102
J9 PLACENTA
JI Placenta
PD SEP
PY 2016
VL 45
BP 32
EP 36
DI 10.1016/j.placenta.2016.06.018
PG 5
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA DV9WX
UT WOS:000383294000005
PM 27577707
ER

PT J
AU Darragh, M
   Yow, B
   Kieser, A
   Booth, RJ
   Kydd, RR
   Consedine, NS
AF Darragh, Margot
   Yow, Boris
   Kieser, Anel
   Booth, Roger J.
   Kydd, Robert R.
   Consedine, Nathan S.
TI A take-home placebo treatment can reduce stress, anxiety and symptoms of
   depression in a non-patient population
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Anxiety; depression; placebo effect; psychological stress
ID CLINICAL-TRIALS; NOCEBO RESPONSES; SOCIAL SUPPORT; MECHANISMS;
   EXPECTATIONS; PREVALENCE; PAIN
AB Background: With a healthcare system burdened by symptomatic and mental-health related conditions, the placebo effect may represent a useful clinical tool. First, however, there is a need to broaden research attention and investigate placebo effects outside laboratories and beyond experimental pain. This study investigated the effectiveness of a take-home placebo treatment in the short-term alleviation of stress, anxiety and symptoms of depression in a non-patient population.
   Method: A sample of 77 participants was randomized to either the oxytocin' treatment group (n=22), the serotonin' treatment group (n=22) or the wait-list control group (n=33). The two treatment groups were given an anti-stress treatment spray' (placebo) to self-administer for 3 days, and completed online measures of perceived stress (Perceived Stress Scale-10), anxiety (Cognitive Somatic Anxiety Questionnaire) and symptoms of depression (Centre for Epidemiological Studies - Depression) before and after the 3-day protocol.
   Results: Both the serotonin' and oxytocin' treatment sprays were effective in reducing symptoms of depression; however, only those in the oxytocin' group reported less stress and anxiety as compared with controls. Overall, the oxytocin' was perceived as more effective.
   Conclusion: Placebo effects can be translated to a real-life setting in the short-term reduction of stress, anxiety and symptoms of depression in a non-patient population. In treating psychological distress, placebos may be useful addition to the treatment repertoire. The information given with treatment may also be an important consideration for practitioners.
C1 [Darragh, Margot; Yow, Boris; Kieser, Anel; Booth, Roger J.; Kydd, Robert R.; Consedine, Nathan S.] Univ Auckland, Fac Med & Hlth Sci, Dept Psychol Med, Auckland, New Zealand.
RP Consedine, NS (reprint author), Univ Auckland, Fac Med & Hlth Sci, Dept Psychol Med, Auckland Mail Ctr, Private Bag 92019, Auckland 1142, New Zealand.
EM n.consedine@auckland.ac.nz
CR Asberg KK, 2008, CHILD PSYCHIAT HUM D, V39, P481, DOI 10.1007/s10578-008-0102-0
   Barsky AJ, 2005, ARCH GEN PSYCHIAT, V62, P903, DOI 10.1001/archpsyc.62.8.903
   Benedetti F, 2002, EVAL HEALTH PROF, V25, P369, DOI 10.1177/0163278702238051
   Benedetti F., 2009, PLACEBO EFFECTS UNDE
   Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012
   Cascade Elisa, 2009, Psychiatry (Edgmont), V6, P16
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Colloca L, 2004, LANCET NEUROL, V3, P679, DOI 10.1016/S1474-4422(04)00908-1
   Colloca L, 2011, PHILOS T R SOC B, V366, P1922, DOI 10.1098/rstb.2010.0399
   Colloca L, 2011, CURR OPIN PSYCHIATR, V24, P149, DOI 10.1097/YCO.0b013e328343803b
   Cvetkovski S, 2012, AUST NZ J PSYCHIAT, V46, P457, DOI 10.1177/0004867411435290
   Darragh M, 2014, J PSYCHOSOM RES, V76, P414, DOI 10.1016/j.jpsychores.2014.02.011
   Dour HJ, 2014, DEPRESS ANXIETY, V31, P436, DOI 10.1002/da.22216
   Ferrari AJ, 2013, PSYCHOL MED, V43, P471, DOI 10.1017/S0033291712001511
   Finniss DG, 2005, PAIN, V114, P3, DOI 10.1016/j.pain.2004.12.012
   Gold PW, 2015, MOL PSYCHIATR, V20, P32, DOI 10.1038/mp.2014.163
   Hrobjartsson A., 2010, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD003974.pub3, DOI 10.1002/14651858.CD003974.PUB3]
   Hu XH, 2004, J CLIN PSYCHIAT, V65, P959
   Hughes S, 2009, J AFFECT DISORDERS, V118, P9, DOI 10.1016/j.jad.2009.01.027
   Santini ZI, 2015, J AFFECT DISORDERS, V175, P53, DOI 10.1016/j.jad.2014.12.049
   Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385
   Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591
   Kirsch Irving, 2010, Evid Based Ment Health, V13, P49, DOI 10.1136/ebmh.13.2.49
   Leuchter AF, 2014, BRIT J PSYCHIAT, V205, P443, DOI 10.1192/bjp.bp.113.140343
   McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412
   Milczarek M., 2009, OSH FIGURES STRESS W
   Miller FG, 2005, PLOS MED, V2, P853, DOI 10.1371/journal.pmed.0020262
   Miller FG, 2008, J ROY SOC MED, V101, P222, DOI 10.1258/jrsm.2008.070466
   Nimnuan C, 2001, J PSYCHOSOM RES, V51, P361, DOI 10.1016/S0022-3999(01)00223-9
   Pacheco-Lopez G, 2006, BRAIN BEHAV IMMUN, V20, P430, DOI 10.1016/j.bbi.2006.05.003
   Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rief W, 2011, CLIN PHARMACOL THER, V90, P722, DOI 10.1038/clpt.2011.204
   Rief W, 2009, J AFFECT DISORDERS, V118, P1, DOI 10.1016/j.jad.2009.01.029
   Schedlowski M, 2015, PHARMACOL REV, V67, P697, DOI 10.1124/pr.114.009423
   SCHWARTZ GE, 1978, PSYCHOSOM MED, V40, P321
   Smith KP, 2008, ANNU REV SOCIOL, V34, P405, DOI 10.1146/annurev.soc.34.040507.134601
   Thorsteinsson EB, 1999, PSYCHOL HEALTH, V14, P869, DOI 10.1080/08870449908407353
   WHO, 2001, WORLD HLTH REPORT 20
NR 39
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD SEP
PY 2016
VL 50
IS 9
SI SI
BP 858
EP 865
DI 10.1177/0004867415621390
PG 8
WC Psychiatry
SC Psychiatry
GA DV3UJ
UT WOS:000382848900007
PM 26681262
ER

PT J
AU Tzabazis, A
   Mechanic, J
   Miller, J
   Klukinov, M
   Pascual, C
   Manering, N
   Carson, DS
   Jacobs, A
   Qiao, YL
   Cuellar, J
   Frey, WH
   Jacobs, D
   Angst, M
   Yeomans, DC
AF Tzabazis, Alexander
   Mechanic, Jordan
   Miller, James
   Klukinov, Michael
   Pascual, Conrado
   Manering, Neil
   Carson, Dean S.
   Jacobs, Allon
   Qiao, Yanli
   Cuellar, Jason
   Frey, William H., II
   Jacobs, Daniel
   Angst, Martin
   Yeomans, David C.
TI Oxytocin receptor: Expression in the trigeminal nociceptive system and
   potential role in the treatment of headache disorders
SO CEPHALALGIA
LA English
DT Article
DE Oxytocin; pain; headache; trigeminal; CGRP; inflammation
ID GENE-RELATED PEPTIDE; DORSAL-HORN NEURONS; HUMAN BRAIN-STEM; RAT
   SPINAL-CORD; BINDING-SITES; SELECTIVE-INHIBITION; SYNTHETIC OXYTOCIN;
   PGE(2) RELEASE; CGRP RECEPTOR; DURA-MATER
AB Aims Our studies investigated the location of oxytocin receptors in the peripheral trigeminal sensory system and determined their role in trigeminal pain.
   Methods Oxytocin receptor expression and co-localization with calcitonin gene-related peptide was investigated in rat trigeminal ganglion using immunohistochemistry. Enzyme-linked immunosorbent assay was used to determine the effects of facial electrocutaneous stimulation and adjuvant-induced inflammation of the temporomandibular joint on oxytocin receptor expression in the trigeminal ganglion. Finally, the effects of oxytocin on capsaicin-induced calcitonin gene-related peptide release from dural nociceptors were investigated using isolated rat dura mater.
   Results Oxytocin receptor immunoreactivity was present in rat trigeminal neurons. The vast majority of oxytocin receptor immunoreactive neurons co-expressed calcitonin gene-related peptide. Both electrocutaneous stimulation and adjuvant-induced inflammation led to a rapid upregulation of oxytocin receptor protein expression in trigeminal ganglion neurons. Oxytocin significantly and dose-dependently decreased capsaicin-induced calcitonin gene-related peptide release from dural nociceptors.
   Conclusion Oxytocin receptor expression in calcitonin gene-related peptide containing trigeminal ganglion neurons, and the blockade of calcitonin gene-related peptide release from trigeminal dural afferents suggests that activation of these receptors may provide therapeutic benefit in patients with migraine and other primary headache disorders.
C1 [Tzabazis, Alexander; Klukinov, Michael; Manering, Neil; Qiao, Yanli; Cuellar, Jason; Angst, Martin; Yeomans, David C.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA.
   [Mechanic, Jordan; Miller, James; Pascual, Conrado; Carson, Dean S.; Jacobs, Allon; Jacobs, Daniel; Angst, Martin; Yeomans, David C.] Trigemina Inc, Moraga, CA USA.
   [Carson, Dean S.] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA.
   [Frey, William H., II] Reg Hosp, HealthPartners Ctr Memory & Aging, St Paul, MN USA.
   [Jacobs, Daniel] Kaiser Permanente Med Ctr, Dept Plast Surg, San Jose, CA USA.
RP Yeomans, DC (reprint author), Stanford Univ, Dept Anesthesia Pain & Perioperat Medicine, 300 Pasteur Dr,S258, Stanford, CA 94305 USA.
EM dcyeomans@stanford.edu
CR Antuzzi P, 1954, MINERVA GINECOL, V6, P26
   ARLETTI R, 1993, NEUROPEPTIDES, V24, P125, DOI 10.1016/0143-4179(93)90075-L
   BAINBRIDGE MN, 1956, BRIT MED J, V1, P1133
   Blanks AM, 2007, SEMIN REPROD MED, V25, P52, DOI 10.1055/s-2006-956775
   Burgos-Vega C, 2015, PROG MOL BIOL TRANSL, V131, P537, DOI 10.1016/bs.pmbts.2015.01.001
   Burstein R, 2014, CEPHALALGIA, V34, P853, DOI 10.1177/0333102414527648
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   Condes-Lara M, 2005, BRAIN RES, V1045, P124, DOI 10.1016/j.brainres.2005.03.020
   Serva WAD, 2012, ARQ NEURO-PSIQUIAT, V70, P428, DOI 10.1590/S0004-282X2012000600009
   Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   Ebersberger A, 2000, NEUROSCIENCE, V99, P171, DOI 10.1016/S0306-4522(00)00176-7
   Eftekhari S, 2015, BRAIN RES, V1600, P93, DOI 10.1016/j.brainres.2014.11.031
   Fang X, 2000, AM J REPROD IMMUNOL, V44, P65, DOI 10.1111/j.8755-8920.2000.440201.x
   Fewtrell MS, 2006, ARCH DIS CHILD-FETAL, V91, pF169, DOI 10.1136/adc.2005.081265
   FRANCIS HH, 1956, BRIT MED J, V1, P1136
   Ho TW, 2014, NEUROLOGY, V83, P958, DOI 10.1212/WNL.0000000000000771
   Hoshiyama E, 2012, INTERNAL MED, V51, P3119, DOI 10.2169/internalmedicine.51.8542
   Jiang CY, 2014, J NEUROPHYSIOL, V111, P991, DOI 10.1152/jn.00609.2013
   Jo YH, 1998, J NEUROSCI, V18, P2377
   Kramer PR, 2010, PHYSIOL BEHAV, V99, P669, DOI 10.1016/j.physbeh.2010.01.037
   KUYPERS HGJM, 1975, NEUROSCI LETT, V1, P9, DOI 10.1016/0304-3940(75)90004-X
   Leem JW, 2001, YONSEI MED J, V42, P74
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   LOUP F, 1989, BRAIN RES, V500, P223, DOI 10.1016/0006-8993(89)90317-X
   LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
   MILLAN MJ, 1984, BRAIN RES, V309, P384
   Moreno-Lopez Y, 2013, NEUROPEPTIDES, V47, P117, DOI 10.1016/j.npep.2012.09.008
   NICKERSON K, 1954, AM J OBSTET GYNECOL, V67, P1028
   NIMH, SOM SEL HIST OX VAS
   Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005
   Petersson M, 1996, NEUROSCI LETT, V212, P87, DOI 10.1016/0304-3940(96)12773-7
   Phillips William J, 2006, J Pain Palliat Care Pharmacother, V20, P25, DOI 10.1300/J354v20n03_05
   Qiu F, 2014, BRIT J PHARMACOL, V171, P3065, DOI 10.1111/bph.12635
   Raddant AC, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002067
   Rauk PN, 2001, AM J REPROD IMMUNOL, V45, P148, DOI 10.1111/j.8755-8920.2001.450305.x
   REITER MK, 1994, EUR J NEUROSCI, V6, P98, DOI 10.1111/j.1460-9568.1994.tb00251.x
   ROSENBLUM I, 1964, J PHARMACOL EXP THER, V144, P138
   RUIS H, 1981, BRIT MED J, V283, P340
   Sances G, 2003, CEPHALALGIA, V23, P197, DOI 10.1046/j.1468-2982.2003.00480.x
   Schmid B, 2001, ENDOCRINOLOGY, V142, P1380, DOI 10.1210/en.142.4.1380
   SWANSON LW, 1979, J COMP NEUROL, V188, P87, DOI 10.1002/cne.901880108
   Uhl-Bronner S, 2005, NEUROSCIENCE, V135, P147, DOI 10.1016/j.neuroscience.2005.05.025
   UNGER JW, 1991, J CHEM NEUROANAT, V4, P299, DOI 10.1016/0891-0618(91)90020-D
   VECSERNYES M, 1987, BRAIN RES, V414, P153, DOI 10.1016/0006-8993(87)91337-0
   Wang XJ, 2010, HEADACHE, V50, P579, DOI 10.1111/j.1526-4610.2010.01632.x
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yu SQ, 2003, BRAIN RES, V983, P13, DOI 10.1016/S0006-8993(03)03019-1
   Zimmermann K, 2003, PAIN, V103, P313, DOI 10.1016/S0304-3959(02)00459-1
   Zimmermann K, 2002, PAIN, V97, P259, DOI 10.1016/S0304-3959(02)00027-1
NR 50
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
EI 1468-2982
J9 CEPHALALGIA
JI Cephalalgia
PD SEP
PY 2016
VL 36
IS 10
BP 943
EP 950
DI 10.1177/0333102415618615
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DV3XR
UT WOS:000382859300005
PM 26590611
ER

PT J
AU Harden, SW
   Frazier, CJ
AF Harden, Scott W.
   Frazier, Charles J.
TI Oxytocin depolarizes fast-spiking hilar interneurons and induces GABA
   release onto mossy cells of the rat dentate gyrus
SO HIPPOCAMPUS
LA English
DT Article
DE hilus; electrophysiology; hippocampus; cellular neurophysiology; patch
   clamp
ID MEMBRANE-POTENTIAL OSCILLATIONS; AUTISM SPECTRUM DISORDER;
   FUNCTIONAL-CHARACTERIZATION; HIPPOCAMPAL INTERNEURONS; RECEPTOR DENSITY;
   VASOPRESSIN; NEURONS; SYSTEM; BRAIN; EXCITATION
AB Delivery of exogenous oxytocin (OXT) to central oxytocin receptors (OXT-Rs) is currently being investigated as a potential treatment for conditions such as post-traumatic stress disorder (PTSD), depression, social anxiety, and autism spectrum disorder (ASD). Despite significant research implicating central OXT signaling in modulation of mood, affect, social behavior, and stress response, relatively little is known about the cellular and synaptic mechanisms underlying these complex actions, particularly in brain regions which express the OXT-R but lie outside of the hypothalamus (where OXT-synthesizing neurons reside). We report that bath application of low concentrations of the selective OXT-R agonist Thr4,Gly7-OXT (TGOT) reliably and robustly drives GABA release in the dentate gyrus in an action potential dependent manner. Additional experiments led to identification of a small subset of small hilar interneurons that are directly depolarized by acute application of TGOT. From a physiological perspective, TGOT-responsive hilar interneurons have high input resistance, rapid repolarization velocity during an action potential, and a robust afterhyperpolarization. Further, they fire irregularly (or stutter) in response to moderate depolarization, and fire quickly with minimal spike frequency accommodation in response to large current injections. From an anatomical perspective, TGOT responsive hilar interneurons have dense axonal arborizations in the hilus that were found in close proximity with mossy cell somata and/or proximal dendrites, and also invade the granule cell layer. Further, they have primary dendrites that always extend into the granule cell layer, and sometimes have clear arborizations in the molecular layer. Overall, these data reveal a novel site of action for OXT in an important limbic circuit, and represent a significant step towards better understanding how endogenous OXT may modulate flow of information in hippocampal networks. (c) 2016 Wiley Periodicals, Inc.
C1 [Harden, Scott W.; Frazier, Charles J.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA.
   [Harden, Scott W.] Univ Florida, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA.
   [Frazier, Charles J.] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.
RP Frazier, CJ (reprint author), Univ Florida, Dept Pharmacodynam, 1345 Ctr Dr,JHMHC Box 100487, Gainesville, FL 32610 USA.; Frazier, CJ (reprint author), Univ Florida, Dept Neurosci, 1345 Ctr Dr,JHMHC Box 100487, Gainesville, FL 32610 USA.
EM cjfraz@ufl.edu
OI Harden, Scott/0000-0002-0757-1979
FU  [T90 DE021990-02];  [R01 MH104641]
FX Grant numbers: T90 DE021990-02, R01 MH104641.
CR Acsady L, 2000, J NEUROSCI, V20, P6907
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231
   AUDIGIER S, 1985, EMBO J, V4, P1407
   Bartos M, 2012, J PHYSIOL-LONDON, V590, P669, DOI 10.1113/jphysiol.2011.226175
   Bean BP, 2007, NAT REV NEUROSCI, V8, P451, DOI 10.1038/nrn2148
   Beets I, 2012, SCIENCE, V338, P543, DOI 10.1126/science.1226860
   Bracci E, 2003, J PHYSIOL-LONDON, V549, P121, DOI 10.1113/jphysiol.2003.040857
   BUIJS RM, 1979, CELL TISSUE RES, V204, P355
   Burton SD, 2014, J PHYSIOL-LONDON, V592, P2097, DOI 10.1113/jphysiol.2013.269886
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Carson DS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132224
   Chamberland S, 2014, J NEUROSCI, V34, P11032, DOI 10.1523/JNEUROSCI.0847-14.2014
   Chapman CA, 1999, J NEUROPHYSIOL, V81, P1296
   Clark CL, 2013, PSYCHONEUROENDOCRINO, V38, P1208, DOI 10.1016/j.psyneuen.2012.10.017
   Dager SR, 2007, AM J NEURORADIOL, V28, P672
   Danglot L, 2006, HIPPOCAMPUS, V16, P1032, DOI 10.1002/hipo.20225
   Dorval AD, 2005, J NEUROSCI, V25, P10025, DOI 10.1523/JNEUROSCI.3557-05.2005
   Dumais KM, 2016, FRONT NEUROENDOCRIN, V40, P1, DOI 10.1016/j.yfrne.2015.04.003
   Elgueta C, 2015, J NEUROSCI, V35, P4131, DOI 10.1523/JNEUROSCI.3671-14.2015
   Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I
   Fu LY, 2007, J PHYSIOL-LONDON, V579, P445, DOI 10.1113/jphysiol.2002.019356
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gravati M, 2010, J NEUROCHEM, V114, P1424, DOI 10.1111/j.1471-4159.2010.06861.x
   Grimmelikhuijzen CJP, 2012, REGUL PEPTIDES, V177, pS6, DOI 10.1016/j.regpep.2012.05.001
   Grinevich V, 2016, BIOL PSYCHIAT, V79, P155, DOI 10.1016/j.biopsych.2015.04.013
   Hammock EAD, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00195
   Hammock EAD, 2006, PHILOS T R SOC B, V361, P2187, DOI 10.1098/rstb.2006.1939
   Hofmann ME, 2011, J PHYSIOL-LONDON, V589, P3801, DOI 10.1113/jphysiol.2011.211482
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hosp JA, 2014, HIPPOCAMPUS, V24, P189, DOI 10.1002/hipo.22214
   Hsu D, 2007, PROG BRAIN RES, V163, P601, DOI 10.1016/S0079-6123(07)63032-5
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Johnson ZV, 2016, HORM BEHAV, V79, P8, DOI 10.1016/j.yhbeh.2015.11.011
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   Joshi S, 2006, J NEUROSCI METH, V156, P37, DOI 10.1016/j.jneumeth.2006.02.004
   Knobloch HS, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00031
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kombian SB, 1997, NEURON, V19, P903, DOI 10.1016/S0896-6273(00)80971-X
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Larimer P, 2008, J NEUROSCI, V28, P12212, DOI 10.1523/JNEUROSCI.3612-08.2008
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Leng G, 2008, PROG BRAIN RES, V170, P137, DOI 10.1016/S0079-6123(08)00413-5
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Lin David M., 2007, V399, P133, DOI 10.1007/978-1-59745-504-6_10
   Lindsly C, 2010, J PHYSIOL-LONDON, V588, P2801, DOI 10.1113/jphysiol.2009.184648
   Lu W, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-38
   Lubke J, 1998, J NEUROPHYSIOL, V79, P1518
   Ludwig M, 2003, TRENDS NEUROSCI, V26, P255, DOI 10.1016/S0166-2236(03)00072-9
   Lukas M, 2010, NEUROPHARMACOLOGY, V58, P78, DOI 10.1016/j.neuropharm.2009.06.020
   Maister L, 2013, NEUROPSYCHOLOGY, V27, P615, DOI 10.1037/a0034492
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Mott DD, 1997, J NEUROSCI, V17, P3990
   MUHLETHALER M, 1983, P NATL ACAD SCI-BIOL, V80, P6713, DOI 10.1073/pnas.80.21.6713
   Nicolson R, 2006, PSYCHIAT RES-NEUROIM, V148, P11, DOI 10.1016/j.pscychresns.2006.02.005
   Oh SW, 2014, NATURE, V508, P207, DOI 10.1038/nature13186
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Porter JT, 1998, EUR J NEUROSCI, V10, P3617, DOI 10.1046/j.1460-9568.1998.00367.x
   Prounis GS, 2015, P BIOL SCI ROY SOC, V282
   RAGGENBASS M, 1989, P NATL ACAD SCI USA, V86, P750
   Saitoh O, 2001, BRAIN, V124, P1317, DOI 10.1093/brain/124.7.1317
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Savanthrapadian S, 2014, J NEUROSCI, V34, P8197, DOI 10.1523/JNEUROSCI.5433-13.2014
   SCHARFMAN HE, 1989, NEUROSCI LETT, V96, P23, DOI 10.1016/0304-3940(89)90237-1
   Sivukhina EV, 2016, STEROIDS
   Spruston N, 1997, J COMP NEUROL, V385, P427
   Steinman M. Q, 2015, BIOL PSYCHIAT
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   SUNDQUIST J, 1983, J NEUROL NEUROSUR PS, V46, P14, DOI 10.1136/jnnp.46.1.14
   Taurines Regina, 2014, Atten Defic Hyperact Disord, V6, P231, DOI 10.1007/s12402-014-0145-y
   Tepper JM, 2010, FRONT NEUROANAT, V4, DOI 10.3389/fnana.2010.00150
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   TRIBOLLET E, 1989, J NEUROSCI, V9, P1764
   Uvnas-Moberg Kerstin, 2014, Front Psychol, V5, P1529, DOI 10.3389/fpsyg.2014.01529
   Viviani D, 2010, NEUROPHARMACOLOGY, V58, P62, DOI 10.1016/j.neuropharm.2009.06.039
   von Engelhardt J, 2007, J NEUROSCI, V27, P5633, DOI 10.1523/JNEUROSCI.4647-06.2007
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181
   Zaninetti M, 2000, EUR J NEUROSCI, V12, P3975, DOI 10.1046/j.1460-9568.2000.00290.x
   Zhang L, 2013, NEUROSCIENCE, V228, P139, DOI 10.1016/j.neuroscience.2012.10.010
   ZIMMERMAN EA, 1984, FED PROC, V43, P91
NR 89
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1050-9631
EI 1098-1063
J9 HIPPOCAMPUS
JI Hippocampus
PD SEP
PY 2016
VL 26
IS 9
BP 1124
EP 1139
DI 10.1002/hipo.22595
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA DV9PS
UT WOS:000383273900003
PM 27068005
ER

PT J
AU Connolly, KA
   Kohari, KS
   Rekawek, P
   Smilen, BS
   Miller, MR
   Moshier, E
   Factor, SH
   Stone, JL
   Bianco, AT
AF Connolly, Katherine A.
   Kohari, Katherine S.
   Rekawek, Patricia
   Smilen, Brooke S.
   Miller, Meredith R.
   Moshier, Erin
   Factor, Stephanie H.
   Stone, Joanne L.
   Bianco, Angela T.
TI A randomized trial of Foley balloon induction of labor trial in
   nulliparas (FIAT-N)
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE Foley balloon; induction of labor; oxytocin
ID CESAREAN DELIVERY; CATHETER; WOMEN; TERM
AB BACKGROUND: With an increasing rate of induction of labor, it is important to choose induction methods that are safe and efficient in achieving a vaginal delivery. The optimal method for inducing nulliparous women with an unfavorable cervix is not known.
   OBJECTIVE: We sought to determine if induction of labor with simultaneous use of oxytocin and Foley balloon vs sequential use of Foley balloon followed by oxytocin decreases the time to delivery in nulliparous women.
   STUDY DESIGN: We conducted a randomized controlled trial of nulliparous women presenting for induction at a single institution from December 2013 through March 2015. After decision for induction was made by their primary provider, women with gestational age >= 24 weeks with a nonanomalous, singleton fetus in vertex presentation with intact membranes were offered participation. Exclusion criteria included history of uterine surgery, unexplained vaginal bleeding, latex allergy, or contraindication to vaginal delivery. Participants were randomized to either simultaneous (oxytocin and Foley balloon) or sequential (oxytocin after expulsion of Foley balloon) induction group. The primary outcome was time from induction to delivery. Secondary outcomes included mode of delivery, estimated blood loss, postpartum hemorrhage, chorioamnionitis, and composite neonatal outcome. Maternal and neonatal outcomes were collected via chart review. Analyses were done on an intention-to-treat basis.
   RESULTS: A total of 166 patients were enrolled; 82 in the simultaneous and 84 in the sequential group. There were no differences in baseline characteristics in the 2 groups. Patients who received simultaneous oxytocin with insertion of a Foley balloon delivered significantly earlier (15.92 vs 18.87 hours, P = .004) than those in the sequential group. There was no difference in rate of cesarean delivery, estimated blood loss, postpartum hemorrhage, chorioamnionitis, or composite neonatal outcome.
   CONCLUSION: Simultaneous use of oxytocin and Foley balloon for induction of labor results in a significantly shorter interval to delivery in nulliparas.
C1 [Connolly, Katherine A.; Rekawek, Patricia; Smilen, Brooke S.; Miller, Meredith R.; Factor, Stephanie H.; Stone, Joanne L.; Bianco, Angela T.] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA.
   [Moshier, Erin] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA.
   [Factor, Stephanie H.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Kohari, Katherine S.] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
RP Connolly, KA (reprint author), Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA.
EM Katherine.connolly@mssm.edu
CR ACOG Committee on Practice Bulletins-Obstetrics, 2009, OBSTET GYNECOL, V114, P386
   Dahlke JD, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.02.023
   Delaney S, 2010, OBSTET GYNECOL, V115, P1239, DOI 10.1097/AOG.0b013e3181dec6d0
   Ekin A, 2015, ARCH GYNECOL OBSTET, V292, P1247, DOI 10.1007/s00404-015-3771-5
   Jozwiak M, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001233.PUB2
   Levy R, 2004, AM J OBSTET GYNECOL, V191, P1632, DOI 10.1016/j.ajog.2004.03.033
   Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1
   McMaster K, 2015, OBSTET GYNECOL, V126, P539, DOI 10.1097/AOG.0000000000001002
   Miller NR, 2015, OBSTET GYNECOL, V126, P1258, DOI 10.1097/AOG.0000000000001154
   Pettker CM, 2008, OBSTET GYNECOL, V111, P1320, DOI 10.1097/AOG.0b013e31817615a0
   Saccone G, 2015, AM J OBSTET GYNECOL, V213, P629, DOI 10.1016/j.ajog.2015.04.004
   Sciscione AC, 2014, CLIN OBSTET GYNECOL, V57, P369, DOI 10.1097/GRF.0000000000000023
   Simon CE, 2005, OBSTET GYNECOL, V105, P705, DOI 10.1097/01.AOG.0000157437.10998.e7
   Spong CY, 2012, OBSTET GYNECOL, V120, P1181, DOI [http://10.1097/AOG.0b013e3182704880, 10.1097/AOG.0b013e3182704880]
   Tolcher MC, 2015, OBSTET GYNECOL, V126, P1059, DOI 10.1097/AOG.0000000000001083
   von Gruenigen VE, 2013, AM J OBSTET GYNECOL, V209, P17, DOI 10.1016/j.ajog.2013.02.019
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   Zhang J, 2010, OBSTET GYNECOL, V116, P1281, DOI 10.1097/AOG.0b013e3181fdef6e
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2016
VL 215
IS 3
AR 392.e1-e6
DI 10.1016/j.ajog.2016.03.034
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DU8WA
UT WOS:000382495100053
PM 27018464
ER

PT J
AU Huang, L
   Zhang, JQ
   Li, YB
   Liu, M
   Deng, HM
   Luo, YC
   Tan, YF
   Hou, J
   Yao, GW
   Guan, WW
AF Huang, Ling
   Zhang, Jun-Qing
   Li, You-Bin
   Liu, Mi
   Deng, Hui-Ming
   Luo, Yu-Chao
   Tan, Yin-Feng
   Hou, Jie
   Yao, Gui-Wei
   Guan, Wei-Wei
TI Effect of Alpinia officinarum Hance alcohol extracts on primary
   dysmenorrheal
SO ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
LA English
DT Article
DE Alpinia officinarum Hance alcohol extracts; Relieve; Primary
   dysmenorrhea
ID DOUBLE-BLIND; ORAL-CONTRACEPTIVES; MEFENAMIC-ACID; IBUPROFEN; TRIAL;
   INHIBITION; ENDOPHYTES; EFFICACY; PLACEBO
AB Objective: To study the effect of Alpinia officinartun Hance (A. officinarum.) 80% alcohol extract on the primary dysmenorrhea. Methods: A. officinarum 80% alcohol extract were enriched by macroporous adsorption resins. Female mice of primary dysmenorrhea model were established by oxytocin induction; the effects of A. officinarum 80% alcohol extract on primary dysmenorrhea were observed by body twist method; and the homogenate level of prostaglandin F-2 alpha (PGF(2 alpha)), prostaglandin E-2 (PGE(2)) and Ca2+ in the uterus were observed in oxytocin-induced female mice. Results: The writhing frequency of primary dysmenorrhea mice was significantly decreased after treatment of A. officinarum 80% alcohol extract and the level of PGF(2 alpha), PGE(2) and Ca2+ in mice uterus was significantly decreased (P<0.05, P<0.01) in groups of mice treated with middle and high dosage of A. officinarum 80% alcohol extract compared with that of model group. Conclusions: These findings suggest that A. Officinarum. 80% alcohol extract can significantly relieve primary dysmenorrhea.
C1 [Huang, Ling; Zhang, Jun-Qing; Li, You-Bin; Liu, Mi; Deng, Hui-Ming; Luo, Yu-Chao; Tan, Yin-Feng; Hou, Jie; Yao, Gui-Wei; Guan, Wei-Wei] Hainan Med Univ, Sch Pharmaceut Sci, Haikou 571101, Hainan, Peoples R China.
RP Guan, WW (reprint author), Hainan Med Univ, Sch Pharmaceut Sci, Haikou 571101, Hainan, Peoples R China.
EM jqzhang2011@163.com; puer6@163.com
FU Hainan Province [ZDZX2013008]; Natural Science Foundation of China [2014
   81403006]
FX This study was supported by the key project supported of Hainan Province
   (Grant No. ZDZX2013008) and Natural Science Foundation of China (Grant
   No. 2014 81403006).
CR Altunyurt S, 2005, J REPROD MED, V50, P251
   Chen J, 2015, MOLECULES, V20, P18219, DOI 10.3390/molecules201018219
   Chen WH, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/385136.
   Chung D, 2006, TOXICOL SCI, V93, P172, DOI 10.1093/toxsci/kfl031
   Daitetsu S, 2002, J NAT PRODUCTS, V65, P1315
   Daniels SE, 2005, J GEN INTERN MED, V20, P62, DOI 10.1111/j.1525-1497.2004.30052.x
   Dawood MY, 2007, AM J OBSTET GYNECOL, V196, P35, DOI 10.1016/j.ajog.2006.06.091
   Dmitrovic R, 2012, OBSTET GYNECOL, V119, P1143, DOI 10.1097/AOG.0b013e318257217a
   Faramarzi M, 2014, IRAN RED CRESCENT ME, V16
   FENAKEL K, 1990, EUR J OBSTET GYN R B, V37, P199, DOI 10.1016/0028-2243(90)90025-V
   Gronier-Gouvernel H, 2014, GYNECOL OBSTET FERTI, V42, P174, DOI 10.1016/j.gyobfe.2014.01.024
   Harel Zeev, 2006, J Pediatr Adolesc Gynecol, V19, P363, DOI 10.1016/j.jpag.2006.09.001
   Heidarifar R, 2014, J RES MED SCI, V19, P326
   Hubbard M, 2014, J APPL MICROBIOL, V116, P109, DOI 10.1111/jam.12311
   Hugon-Rodin J, 2014, EUR J ENDOCRINOL, V171, pR221, DOI 10.1530/EJE-14-0527
   Kusari P, 2013, FUNGAL DIVERS, V60, P137, DOI 10.1007/s13225-012-0216-3
   Li SB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115289
   Liu Fang, 2009, Zhen Ci Yan Jiu, V34, P3
   Liu P, 2011, J ETHNOPHARMACOL, V133, P591, DOI 10.1016/j.jep.2010.10.042
   Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3
   Mirabi P, 2014, IRAN J PHARM RES, V13, P757
   Nejad V. Modaress, 2006, Eastern Mediterranean Health Journal, V12, P423
   Porras-Alfaro A, 2011, ANNU REV PHYTOPATHOL, V49, P291, DOI 10.1146/annurev-phyto-080508-081831
   Proctor M, 2002, COCHRANE DB SYST REV, V1, DOI 10.1002/14651858.CD002123
   Siemieniuch MJ, 2009, EXP BIOL MED, V234, P1056, DOI 10.3181/0901-RM-23
   Smith CA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007854.pub3
   Sugumar R, 2013, INDIAN J PHARMACOL, V45, P180, DOI 10.4103/0253-7613.108312
   Witt J, 2013, J WOMENS HEALTH, V22, P702, DOI 10.1089/jwh.2012.4180
   Wong CL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002120.pub3
   Xie X, 2013, OBSTET GYNECOLOGY
   Yang L, 2015, EXP ANIM TOKYO, V64, P295, DOI 10.1538/expanim.14-0111
   Yang Ya-qin, 2008, Zhen Ci Yan Jiu, V33, P366
NR 32
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1995-7645
J9 ASIAN PAC J TROP MED
JI Asian Pac. J. Trop. Med.
PD SEP
PY 2016
VL 9
IS 9
BP 861
EP 865
DI 10.1016/j.apjtm.2016.07.012
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DU1HD
UT WOS:000381957900011
PM 27633303
ER

PT J
AU Otero-Garcia, M
   Agustin-Pavon, C
   Lanuza, E
   Martinez-Garcia, F
AF Otero-Garcia, Marcos
   Agustin-Pavon, Carmen
   Lanuza, Enrique
   Martinez-Garcia, Fernando
TI Distribution of oxytocin and co-localization with arginine vasopressin
   in the brain of mice
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Amygdala; Bed nucleus of the stria terminalis; Accumbens; Maternal
   behaviour; Sociosexual brain; Neurosecretory cells
ID VENTRAL TEGMENTAL AREA; MUS-MUSCULUS BRAIN; HYPOTHALAMO-NEUROHYPOPHYSEAL
   SYSTEM; MESSENGER RIBONUCLEIC-ACIDS; RECEPTOR KNOCKOUT MICE; FEMALE
   PRAIRIE VOLES; MILK-EJECTION REFLEX; MEDIAL PREOPTIC AREA;
   MATERNAL-BEHAVIOR; SPINAL-CORD
AB Oxytocin (OT) and vasopressin (AVP) play a major role in social behaviours. Mice have become the species of choice for neurobiology of social behaviour due to identification of mouse pheromones and the advantage of genetically modified mice. However, neuroanatomical data on nonapeptidergic systems in mice are fragmentary, especially concerning the central distribution of OT. Therefore, we analyse the immunoreactivity for OT and its neurophysin in the brain of male and female mice (strain CD1). Further, we combine immunofluorescent detection of OT and AVP to locate cells co-expressing both peptides and their putative axonal processes. The results indicate that OT is present in cells of the neurosecretory paraventricular (Pa) and supraoptic hypothalamic nuclei (SON). From the anterior SON, OTergic cells extend into the medial amygdala, where a sparse cell population occupies its ventral anterior and posterior divisions. Co-expression of OT and AVP in these nuclei is rare. Moreover, a remarkable OTergic cell group is found near the ventral bed nucleus of the stria terminalis (BST), distributed between the anterodorsal preoptic nucleus and the nucleus of anterior commissure (ADP/AC). This cell group, the rostral edge of the Pa and the periventricular hypothalamus display frequent OT + AVP double labelling, with a general dominance of OT over AVP immunoreactivity. Fibres with similar immunoreactivity profile innervate the accumbens shell and core, central amygdala and portions of the intervening BST. These data, together with data in the literature on rats, suggest that the projections of ADP/AC nonapeptidergic cells onto these brain centres could promote pup-motivated behaviours and inhibit pup avoidance during motherhood.
C1 [Agustin-Pavon, Carmen; Martinez-Garcia, Fernando] Univ Jaume 1, Fac Ciencies Salut, Lab Funct Neuroanat NeuroFun, Unitat Predept Med, Ave Vicent Sos Baynat S-N, Castellon de La Plana 12071, Spain.
   [Otero-Garcia, Marcos; Lanuza, Enrique] Univ Valencia, Fac Ciencias Biol, Dept Biol Cellular Biol Func, Valencia, Spain.
RP Martinez-Garcia, F (reprint author), Univ Jaume 1, Fac Ciencies Salut, Lab Funct Neuroanat NeuroFun, Unitat Predept Med, Ave Vicent Sos Baynat S-N, Castellon de La Plana 12071, Spain.
EM femartin@uji.es
FU Spanish Ministry of Science-FEDER [BFU2013-47688-P]; Junta de
   Comunidades de Castilla-La Mancha/FEDER [PEIC11-0045-4490]; Universitat
   Jaume I; FPU (Formacion de Profesorado Universitario) programme of the
   Spanish Ministry of Education and Science
FX This work was funded by the Spanish Ministry of Science-FEDER
   (BFU2013-47688-P), the Junta de Comunidades de Castilla-La Mancha/FEDER
   (PEIC11-0045-4490) and the Universitat Jaume I. This work is part of the
   doctoral thesis of Marcos Otero-Garcia, granted by the FPU (Formacion de
   Profesorado Universitario) programme of the Spanish Ministry of
   Education and Science. The authors gratefully acknowledge Dr. Harold
   Gainer for his generous gift of antibodies.
CR Banczerowski P, 2003, J ENDOCRINOL INVEST, V26, P429
   Beery AK, 2008, J COMP NEUROL, V507, P1847, DOI 10.1002/cne.21638
   BELENKY M, 1992, BRAIN RES, V583, P279
   BENBARAK Y, 1985, J NEUROSCI, V5, P81
   Bielsky IF, 2005, NEURON, V47, P503, DOI 10.1016/j.neuron.2005.06.031
   Bosch OJ, 2011, HORM BEHAV, V59, P202, DOI 10.1016/j.yhbeh.2010.11.012
   Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6
   BUIJS RM, 1978, CELL TISSUE RES, V192, P423
   BUIJS RM, 1978, CELL TISSUE RES, V186, P423
   Butovsky E, 2006, MOL CELL NEUROSCI, V31, P795, DOI 10.1016/j.mcn.2006.01.008
   Bychowski ME, 2013, NEUROSCIENCE, V246, P52, DOI 10.1016/j.neuroscience.2013.04.047
   Cadiz-Moretti B, 2013, CHEM SIGNALS VERTEBR, V12, P269, DOI [10.1007/978-1-4614-5927-9, DOI 10.1007/978-1-4614-5927-9]
   CAFFE AR, 1989, J COMP NEUROL, V287, P302, DOI 10.1002/cne.902870304
   Caldwell HK, 2008, PROG BRAIN RES, V170, P65, DOI 10.1016/S0079-6123(08)00406-8
   Caldwell H.K., 2006, HDB NEUROCHEMISTRY M, P573
   Campbell P, 2009, J COMP NEUROL, V516, P321, DOI 10.1002/cne.22116
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   CASTEL M, 1988, NEUROSCIENCE, V24, P937, DOI 10.1016/0306-4522(88)90078-4
   Caughey SD, 2011, J NEUROENDOCRINOL, V23, P1113, DOI 10.1111/j.1365-2826.2011.02224.x
   Chamero P, 2007, NATURE, V450, P899, DOI 10.1038/nature05997
   Choleris E, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P379
   Condes-Lara M, 2007, BRAIN RES, V1160, P20, DOI 10.1016/j.brainres.2007.05.031
   DEVRIES GJ, 1985, J COMP NEUROL, V233, P236, DOI 10.1002/cne.902330206
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dong HW, 2006, J COMP NEUROL, V494, P75, DOI 10.1002/cne.20790
   DuboisDauphin M, 1996, BRAIN RES, V743, P32, DOI 10.1016/S0006-8993(96)01019-0
   Eaton JL, 2012, DEV PSYCHOBIOL, V54, P92, DOI 10.1002/dev.20566
   Egashira N, 2007, BEHAV BRAIN RES, V178, P123, DOI 10.1016/j.bbr.2006.12.009
   Evans DW, 2014, BRAIN IMAGING BEHAV
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Garcia-Moreno F, 2010, NAT NEUROSCI, V13, P680, DOI 10.1038/nn.2556
   Glasgow E, 1999, ENDOCRINOLOGY, V140, P5391, DOI 10.1210/en.140.11.5391
   Gregory R, 2015, HORM BEHAV, V69, P82, DOI 10.1016/j.yhbeh.2014.12.009
   Hammock EAD, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00195
   HATTON GI, 1985, BRAIN RES BULL, V14, P123, DOI 10.1016/0361-9230(85)90072-3
   HAWTHORN J, 1985, BRAIN RES, V346, P51, DOI 10.1016/0006-8993(85)91093-5
   HERMES MLHJ, 1988, J COMP NEUROL, V273, P252, DOI 10.1002/cne.902730209
   Honda K, 2010, J REPROD DEVELOP, V56, P336
   Honda K, 2010, J REPROD DEVELOP, V56, P98, DOI 10.1262/jrd.09-090E
   HOUYU A, 1986, NEUROENDOCRINOLOGY, V44, P235, DOI 10.1159/000124651
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   INSEL TR, 1993, J NEUROENDOCRINOL, V5, P619, DOI 10.1111/j.1365-2826.1993.tb00531.x
   INSEL TR, 1989, PHYSIOL BEHAV, V45, P1033, DOI 10.1016/0031-9384(89)90234-5
   Isogai Y, 2011, NATURE, V478, P241, DOI 10.1038/nature10437
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   JIRIKOWSKI GF, 1991, HORM METAB RES, V23, P476, DOI 10.1055/s-2007-1003733
   Kang N, 2009, EUR J NEUROSCI, V29, P624, DOI 10.1111/j.1460-9568.2009.06638.x
   KIYAMA H, 1990, J NEUROENDOCRINOL, V2, P257, DOI 10.1111/j.1365-2826.1990.tb00401.x
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   KRISCH B, 1976, CELL TISSUE RES, V174, P109
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lim MM, 2004, J COMP NEUROL, V468, P555, DOI 10.1002/cne.10973
   LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Markowitsch HJ, 1998, BEHAV NEUROL, V11, P233
   Martinez-Garcia F, 2012, MOUSE NERVOUS SYSTEM, P140, DOI 10.1016/B978-0-12-369497-3.10006-8
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   MERIGHI A, 1989, J HISTOCHEM CYTOCHEM, V37, P529
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   MEZEY E, 1991, ENDOCRINOLOGY, V129, P1814
   MOHR E, 1988, FEBS LETT, V242, P144, DOI 10.1016/0014-5793(88)81003-2
   Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111
   MUCHLINSKI AE, 1988, BRAIN RES BULL, V20, P267, DOI 10.1016/0361-9230(88)90189-X
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   Nephew BC, 2008, PHARMACOL BIOCHEM BE, V91, P77, DOI 10.1016/j.pbb.2008.06.013
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x
   Ni RJ, 2014, NEUROSCIENCE, V265, P124, DOI 10.1016/j.neuroscience.2014.01.034
   Nishimori K, 2008, PROG BRAIN RES, V170, P79, DOI 10.1016/S0079-6123(08)00408-1
   Nodari F, 2008, J NEUROSCI, V28, P6407, DOI 10.1523/JNEUROSCI.1425-08.2008
   Numan M, 1996, DEV PSYCHOBIOL, V29, P23, DOI 10.1002/(SICI)1098-2302(199601)29:1<23::AID-DEV2>3.0.CO;2-O
   NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381
   Numan M, 2010, BEHAV NEUROSCI, V124, P715, DOI 10.1037/a0021548
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Olazabal DE, 2002, HORM BEHAV, V41, P126, DOI 10.1006/hbeh.2001.1753
   Olucha-Bordonau FE, 2014, RAT NERVOUS SYSTEM, P441
   Otero-Garcia M, 2014, BRAIN STRUCT FUNCT, V219, P1055, DOI 10.1007/s00429-013-0553-3
   Pagani JH, 2015, GENES BRAIN BEHAV, V14, P167, DOI 10.1111/gbb.12202
   Paxinos G., 2001, MOUSE BRAIN STEREOTA
   Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010
   RHODES CH, 1981, J COMP NEUROL, V198, P45, DOI 10.1002/cne.901980106
   Roberts SA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-75
   Rood BD, 2013, J COMP NEUROL, V521, P2321, DOI 10.1002/cne.23288
   Rood BD, 2011, J COMP NEUROL, V519, P2434, DOI 10.1002/cne.22635
   Rosen GJ, 2008, NEUROSCIENCE, V155, P809, DOI 10.1016/j.neuroscience.2008.05.039
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Sabatier N, 2004, J NEUROENDOCRINOL, V16, P221, DOI 10.1111/j.0953-8194.2004.01155.x
   SANCHEZ MA, 1995, BRAIN RES BULL, V38, P313, DOI 10.1016/0361-9230(95)00094-U
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   SHIPLEY MT, 1984, BRAIN RES BULL, V12, P669, DOI 10.1016/0361-9230(84)90148-5
   Staes N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113364
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Succu S, 2008, EUR J NEUROSCI, V28, P813, DOI 10.1111/j.1460-9568.2008.06385.x
   SWANSON LW, 1980, J COMP NEUROL, V194, P555, DOI 10.1002/cne.901940306
   Takahashi A., 2013, CURR TOP BEHAV NEURO, V17, P3
   TAKANO S, 1992, NEUROSCIENCE, V50, P877, DOI 10.1016/0306-4522(92)90211-J
   Tang YM, 2014, NEUROPHARMACOLOGY, V77, P277, DOI 10.1016/j.neuropharm.2013.10.004
   Telleria-Diaz A, 2001, NEUROPEPTIDES, V35, P162, DOI 10.1054/npep.2001.0859
   Tobin V, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00261
   Toth I, 2013, CELL TISSUE RES, V354, P107, DOI 10.1007/s00441-013-1636-4
   Trueta C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00319
   Tsuneoka Y, 2013, J COMP NEUROL, V521, P1633, DOI 10.1002/cne.23251
   Valesky EM, 2012, ANAT REC, V295, P474, DOI 10.1002/ar.22414
   Veenema AH, 2008, PROG BRAIN RES, V170, P261, DOI 10.1016/S0079-6123(08)00422-6
   Veinante P, 1997, J COMP NEUROL, V383, P305
   Wang WD, 2000, DEV BIOL, V227, P432, DOI 10.1006/dbio.2000.9902
   Wang ZX, 1996, J COMP NEUROL, V366, P726
   WHITNALL MH, 1985, J NEUROSCI, V5, P98
   Xi D, 1999, ENDOCRINOLOGY, V140, P4677, DOI 10.1210/en.140.10.4677
   Xiao M, 2005, BRAIN RES, V1038, P150, DOI 10.1016/j.brainres.2005.01.032
   Xu L, 2010, NEUROSCIENCE, V169, P1235, DOI 10.1016/j.neuroscience.2010.05.064
   Yang J, 2011, PEPTIDES, V32, P1255, DOI 10.1016/j.peptides.2011.03.007
   Yayou K, 2015, ANIM SCI J, V86, P806, DOI 10.1111/asj.12363
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Young LJ, 1999, NATURE, V400, P766
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Zoli M, 1996, PROG NEUROBIOL, V49, P363, DOI 10.1016/0301-0082(96)00020-2
NR 123
TC 0
Z9 0
U1 10
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD SEP
PY 2016
VL 221
IS 7
BP 3445
EP 3473
DI 10.1007/s00429-015-1111-y
PG 29
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA DV1MR
UT WOS:000382685700007
PM 26388166
ER

PT J
AU Elbohoty, AEH
   Mohammed, WE
   Sweed, M
   Eldin, AMB
   Nabhan, A
   Abd-El-Maeboud, KHI
AF Elbohoty, Ahmed E. H.
   Mohammed, Walid E.
   Sweed, Mohamed
   Eldin, Ahmed M. Bahaa
   Nabhan, Ashraf
   Abd-El-Maeboud, Karim H. I.
TI Randomized controlled trial comparing carbetocin, misoprostol, and
   oxytocin for the prevention of postpartum hemorrhage following an
   elective cesarean delivery
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Atony; Carbetocin; Cesarean delivery; Misoprostol; Oxytocin; Postpartum
   hemorrhage
ID SUBLINGUAL MISOPROSTOL; BLOOD-LOSS; SECTION; MANAGEMENT; INFUSION
AB Objective: To compare the effectiveness and safety of carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following cesarean deliveries. Methods: A double-blind randomized controlled trial enrolled patients with a singleton pregnancy scheduled for an elective cesarean delivery at a maternity hospital in Cairo, Egypt, between October 1, 2012 and June 30, 2013. Participants were randomized using a computer generated sequence to receive treatment with carbetocin, misoprostol, or oxytocin. The primary outcome was the occurrence of uterine atony necessitating additional uterotonics. Per-protocol analyses were performed. Patients, investigators, and data analysts were masked to treatment assignments. Results: The present study enrolled 263 patients; data were analyzed from 88 patients treated with carbetocin, 89 treated with misoprostol, and 86 women treated with oxytocin. Further uterotonics were needed for the treatment of 5 (6%) patients who were treated with carbetocin, 20 (22%) patients treated with misoprostol, and 11 (13%) patients treated with oxytocin. In the prevention of uterine atony, carbetocin was comparable with oxytocin (RR 0.41, 95%Cl 0.14-1.25) and superior to misoprostol (RR 0.21, 95%Cl 0.07-0.58). Conclusion: Additional uterotonics were needed less frequently by patients treated with carbetocin. Carbetocin was comparable to oxytocin and superior to misoprostol in the prevention of uterine atony following an elective cesarean delivery. ClinicalTrials.gov: NCT02053922 (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Elbohoty, Ahmed E. H.; Mohammed, Walid E.; Sweed, Mohamed; Eldin, Ahmed M. Bahaa; Nabhan, Ashraf; Abd-El-Maeboud, Karim H. I.] Ain Shams Univ, Dept Obstet & Gynecol, Fac Med, Cairo, Egypt.
RP Sweed, M (reprint author), 4 Hosni Osman St, Cairo, Egypt.
EM drmsweed@med.asu.edu.eg
CR Arias F, 2000, CLIN OBSTET GYNECOL, V43, P455, DOI 10.1097/00003081-200009000-00006
   Attilakos G, 2010, BJOG-INT J OBSTET GY, V117, P929, DOI 10.1111/j.1471-0528.2010.02585.x
   Borruto F, 2009, ARCH GYNECOL OBSTET, V280, P707, DOI 10.1007/s00404-009-0973-8
   Conde-Agudelo A, 2013, AM J OBSTET GYNECOL, V209
   Cotter AM, 2001, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001808
   el Sharkwy IA, 2013, ARCH GYNECOL OBSTET, V288, P1231, DOI 10.1007/s00404-013-2896-7
   Elati A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2877
   Fekih M, 2009, J GYNECOL OBST BIO R, V38, P588, DOI 10.1016/j.jgyn.2009.09.006
   Grover J, 1997, OBSTET GYNECOL, V90, P1007, DOI 10.1016/S0029-7844(97)00490-0
   Hamm J, 2005, AM J OBSTET GYNECOL, V192, P1404, DOI 10.1016/j.ajog.2004.12.033
   Hofmeyr GJ, 2008, BEST PRACT RES CL OB, V22, P1025, DOI 10.1016/j.bpobgyn.2008.08.005
   Lapaire O, 2006, INT J GYNECOL OBSTET, V95, P2, DOI 10.1016/j.ijgo.2006.05.031
   Leduc Dean, 2009, J Obstet Gynaecol Can, V31, P980
   Oladapo OT, 2012, INT J GYNECOL OBSTET, V119, P105, DOI 10.1016/j.ijgo.2012.08.004
   Olefile Kabelo M, 2013, Curationis, V36, pE1, DOI 10.4102/curationis.v36i1.57
   Owonikoko KM, 2011, J OBSTET GYNAECOL RE, V37, P715, DOI 10.1111/j.1447-0756.2010.01399.x
   Prata Ndola, 2013, Int J Womens Health, V5, P737, DOI 10.2147/IJWH.S51661
   Rath W, 2009, EUR J OBSTET GYN R B, V147, P15, DOI 10.1016/j.ejogrb.2009.06.018
   Su LL, 2012, COCHRANE DB SYST REV, V2
   Tuncalp O, 2012, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD000494.PUB4
   Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7
   Vimala N, 2006, INT J GYNECOL OBSTET, V92, P106, DOI 10.1016/j.ijgo.2005.10.008
   World Health Organization, 2012, WHO REC PREV TREATM
   Winter C, 2007, BJOG-INT J OBSTET GY, V114, P845, DOI 10.1111/j.1471-0528.2007.01377.x
   Zhao Y, 1998, Zhonghua Fu Chan Ke Za Zhi, V33, P403
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD SEP
PY 2016
VL 134
IS 3
BP 324
EP 328
DI 10.1016/j.ijgo.2016.01.025
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV0FT
UT WOS:000382594100021
PM 27350226
ER

PT J
AU Wickramasinghe, DP
   Senaratne, S
   Senanayake, H
   Samarasekera, DN
AF Wickramasinghe, Dakshitha Praneeth
   Senaratne, Supun
   Senanayake, Hemantha
   Samarasekera, Dharmabandhu Nandadeva
TI Effect of vaginal delivery on anal sphincter function in Asian
   primigravida: a prospective study
SO INTERNATIONAL UROGYNECOLOGY JOURNAL
LA English
DT Article
DE Obstetric anal sphincter injuries; Primigravida; Sri Lanka
ID SEVERE PERINEAL TRAUMA; RISK-FACTORS; FECAL INCONTINENCE; CESAREAN
   DELIVERY; CHILDBIRTH; INJURY; EPISIOTOMY; MORPHOLOGY; TEARS; DIAGNOSIS
AB The true incidence of obstetric anal sphincter injuries (OASI) among Asian primigravida is not known. This study aimed to evaluate OASI in Sri Lankan primigravida.
   One hundred and one consecutive primigravida in their last trimester were recruited from antenatal clinics at a tertiary care centre in Sri Lanka and followed up 6 weeks and 6 months after delivery. They were assessed using anorectal manometry (3D-ARM) and endoanal ultrasound (3D-EAUS) on both occasions.
   Seventy-three (75.3 %) had vaginal delivery without instrumentation, whereas 3 (3.1 %) each delivered using forceps or vacuum. Twelve (12.4 %) had emergency caesarean sections and 6 (6.2 %) had elective caesarean sections. None had clinically identified anal sphincter injuries. EAUS identified IAS defects in 3 (5.1 %) and EAS defects in 28 (47.5 %). Both resting (p = 0.3) and squeeze (p = 0.001) pressures had decreased following childbirth. Multivariate analysis identified antepartum RP and postpartum EAS defects to be associated with RP reduction (chi(2)(4)=17.825, p < 0.0005) and antepartum SP and postpartum EAS defects to be associated with SP reduction (chi(2)(5)=31.517, p < 0.0005). Episiotomy was protective, whereas delivering after 40 weeks' gestation and delivering a baby with a longer length increased the risk of SP reduction. EAS defects (chi(2) (6)=23.502, p = .001) were more common in mothers who had labour augmented by oxytocin and in those who delivered a baby with a larger head circumference. Labour induction and delivering a longer baby were protective for EAS defects.
   Several risk and protective factors for the structural and functional damage of sphincters were identified. These findings will help to formulate a policy to minimize future obstetric anal sphincter injuries.
C1 [Wickramasinghe, Dakshitha Praneeth; Senaratne, Supun; Samarasekera, Dharmabandhu Nandadeva] Univ Colombo, Dept Surg, Fac Med, Colombo, Sri Lanka.
   [Senanayake, Hemantha] Univ Colombo, Dept Obstet & Gynaecol, Fac Med, Colombo, Sri Lanka.
RP Samarasekera, DN (reprint author), Univ Colombo, Dept Surg, Fac Med, Colombo, Sri Lanka.
EM samarasekera58@yahoo.co.uk
FU University of Colombo, Sri Lanka
FX This work was supported by a research grant from the University of
   Colombo, Sri Lanka.
CR Abramowitz L, 2000, DIS COLON RECTUM, V43, P590, DOI 10.1007/BF02235567
   Ampt AJ, 2013, AUST NZ J OBSTET GYN, V53, P9, DOI 10.1111/ajo.12038
   Andrews V, 2006, BJOG-INT J OBSTET GY, V113, P195, DOI 10.1111/j.1471-0528.2005.00799.x
   Baghestan E, 2010, OBSTET GYNECOL, V116, P25, DOI 10.1097/AOG.0b013e3181e2f50b
   Christianson LM, 2003, AM J OBSTET GYNECOL, V189, P255, DOI 10.1067/mob.2003.547
   Dahlen HG, 2007, MIDWIFERY, V23, P196, DOI 10.1016/j.midw.2006.04.004
   Faltin DL, 2000, OBSTET GYNECOL, V95, P643, DOI 10.1016/S0029-7844(99)00631-6
   Faridi A, 2002, J PERINAT MED, V30, P379, DOI 10.1515/JPM.2002.059
   Fynes M, 1998, OBSTET GYNECOL, V92, P496, DOI 10.1016/S0029-7844(98)00256-7
   Gerdin E, 2007, AUST NZ J OBSTET GYN, V47, P286, DOI 10.1111/j.1479-828X.2007.00739.x
   Greenberg MB, 2006, AM J OBSTET GYNECOL, V195, P743, DOI 10.1016/j.ajog.2006.06.016
   Groom KM, 2002, EUR J OBSTET GYN R B, V101, P19, DOI 10.1016/S0301-2115(01)00495-X
   Handa VL, 2001, OBSTET GYNECOL, V98, P225, DOI 10.1016/S0029-7844(01)01445-4
   Hudelist G, 2005, AM J OBSTET GYNECOL, V192, P875, DOI 10.1016/j.ajog.2004.09.035
   Jango H, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.08.043
   Lal M, 2003, OBSTET GYNECOL, V101, P305, DOI 10.1016/S0029-7844(02)02716-3
   MARCIO J, 1993, DIS COLON RECTUM, V36, P77
   MURAD-REGADAS Sthela Maria, 2014, Arq. Gastroenterol., V51, P198, DOI 10.1590/S0004-28032014000300006
   Raisanen S, 2011, SCAND J PUBLIC HEALT, V39, P457, DOI 10.1177/1403494811404276
   Registrar General's Department, 2002, STAT ABSTR 2008
   Rieger N, 1998, OBSTET GYNECOL SURV, V53, P345, DOI 10.1097/00006254-199806000-00008
   Ryhammer AM, 1997, DIS COLON RECTUM, V40, P287, DOI 10.1007/BF02050417
   SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601
   SULTAN AH, 1993, INT J COLORECTAL DIS, V8, P206, DOI 10.1007/BF00290307
   Varma A, 1999, DIS COLON RECTUM, V42, P1537, DOI 10.1007/BF02236202
   Wasserberg N, 2011, COLORECTAL DIS, V13, P449, DOI 10.1111/j.1463-1318.2010.02208.x
   Willis S, 2002, LANGENBECK ARCH SURG, V387, P101, DOI 10.1007/s00423-002-0296-8
   Zetterstrom J, 1999, DIS COLON RECTUM, V42, P1253, DOI 10.1007/BF02234209
NR 28
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-3462
EI 1433-3023
J9 INT UROGYNECOL J
JI Int. Urogynecol. J.
PD SEP
PY 2016
VL 27
IS 9
BP 1375
EP 1381
DI 10.1007/s00192-016-2986-8
PG 7
WC Obstetrics & Gynecology; Urology & Nephrology
SC Obstetrics & Gynecology; Urology & Nephrology
GA DU1PU
UT WOS:000381981500014
PM 26951430
ER

PT J
AU Lebowitz, ER
   Leckman, JF
   Silverman, WK
   Feldman, R
AF Lebowitz, Eli R.
   Leckman, James F.
   Silverman, Wendy K.
   Feldman, Ruth
TI Cross-generational influences on childhood anxiety disorders: pathways
   and mechanisms
SO JOURNAL OF NEURAL TRANSMISSION
LA English
DT Article
DE Anxiety disorders; Child; Mother-child relations; Oxytocin; Genetics
ID OBSESSIVE-COMPULSIVE DISORDER; COMORBIDITY SURVEY REPLICATION;
   RANDOMIZED CONTROLLED-TRIAL; SEROTONIN TRANSPORTER GENE; ANTENATAL
   MATERNAL ANXIETY; MOTHER-INFANT INTERACTIONS; PLASMA OXYTOCIN LEVELS;
   FAMILY ACCOMMODATION; PANIC DISORDER; SOCIAL ANXIETY
AB Anxiety disorders are common across the lifespan, cause severe distress and impairment, and usually have their onset in childhood. Substantial clinical and epidemiological research has demonstrated the existence of links between anxiety and its disorders in children and parents. Research on the pathways and mechanisms underlying these links has pointed to both behavioral and biological systems. This review synthesizes and summarizes several major aspects of this research. Behavioral systems include vicarious learning, social referencing, and modeling of parental anxiety; overly protective or critical parenting styles; and aspects of parental responses to child anxiety including family accommodation of the child's symptoms. Biological systems include aspects of the prenatal environment affected by maternal anxiety, development and functioning of the oxytocinergic system, and genetic and epigenetic transmission. Implications for the prevention and treatment of child anxiety disorders are discussed, including the potential to enhance child anxiety treatment outcomes through biologically informed parent-based interventions.
C1 [Lebowitz, Eli R.; Leckman, James F.; Silverman, Wendy K.] Yale Child Study Ctr, 230 S Frontage Rd, New Haven, CT 06515 USA.
   [Feldman, Ruth] Bar Ilan Univ, Gonda Brain Res, Ramat Gan, Israel.
RP Lebowitz, ER (reprint author), Yale Child Study Ctr, 230 S Frontage Rd, New Haven, CT 06515 USA.
EM eli.lebowitz@yale.edu
FU NIMH NIH HHS [K23 MH103555]
CR ALONSO J, 2004, ACTA PSYCHIAT SCAN S, V420, P21
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Amico JA, 2004, J NEUROENDOCRINOL, V16, P319, DOI 10.1111/j.0953-8194.2004.01161.x
   Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Askew C, 2007, BEHAV RES THER, V45, P2616, DOI 10.1016/j.brat.2007.06.008
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Bandura A., 1969, PRINCIPLES BEHAV MOD
   Barrett PM, 1996, J ABNORM CHILD PSYCH, V24, P187, DOI 10.1007/BF01441484
   Bartz JA, 2015, PSYCHOL SCI, V26, P1177, DOI 10.1177/0956797615580279
   Baxter AJ, 2013, PSYCHOL MED, V43, P897, DOI 10.1017/S003329171200147X
   Beidel DC, 1997, J AM ACAD CHILD PSY, V36, P918, DOI 10.1097/00004583-199707000-00013
   BERGER SM, 1962, PSYCHOL REV, V69, P450, DOI 10.1037/h0046466
   BEVAN JC, 1990, CAN J ANAESTH, V37, P177
   BIEDERMAN J, 1991, PSYCHIAT RES, V37, P333, DOI 10.1016/0165-1781(91)90068-Z
   Bogels SM, 2004, PERS INDIV DIFFER, V37, P1583, DOI 10.1016/j.paid.2004.02.014
   Branchi I, 2013, PSYCHONEUROENDOCRINO, V38, P522, DOI 10.1016/j.psyneuen.2012.07.010
   Brouwers EPM, 2001, INFANT BEHAV DEV, V24, P95, DOI 10.1016/S0163-6383(01)00062-5
   Burstein M, 2010, BEHAV RES THER, V48, P506, DOI 10.1016/j.brat.2010.02.006
   CALVOCORESSI L, 1995, AM J PSYCHIAT, V152, P441
   Canino G, 2004, ARCH GEN PSYCHIAT, V61, P85, DOI 10.1001/archpsyc.61.1.85
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Champagne FA, 2008, FRONT NEUROENDOCRIN, V29, P386, DOI 10.1016/j.yfrne.2008.03.003
   Chang SWC, 2013, P NATL ACAD SCI USA, V110, P10387, DOI 10.1073/pnas.1301213110
   Chen J, 2012, J NEUROENDOCRINOL, V24, P1055, DOI 10.1111/j.1365-2826.2012.02306.x
   CHIODERA P, 1991, HORM RES, V35, P119, DOI 10.1159/000181886
   Chorpita BF, 1996, J CLIN CHILD PSYCHOL, V25, P170, DOI 10.1207/s15374424jccp2502_5
   Compton SN, 2004, J AM ACAD CHILD PSY, V43, P930, DOI 10.1097/01.chi.0000127589.57468.bf
   Conroy S, 2012, J AM ACAD CHILD PSY, V51, P51, DOI 10.1016/j.jaac.2011.10.007
   Costello EJ, 2005, CHILD ADOL PSYCH CL, V14, P631, DOI 10.1016/j.chc.2005.06.003
   Costello E. J., 2011, ANXIETY DISORDERS CH, P56, DOI DOI 10.1017/CBO9780511994920
   Dadds MR, 1996, J ABNORM CHILD PSYCH, V24, P715, DOI 10.1007/BF01664736
   de Rosnay M, 2006, BEHAV RES THER, V44, P1165, DOI 10.1016/j.brat.2005.09.003
   Domschke K, 2013, PROG NEURO-PSYCHOPH, V46, P189, DOI 10.1016/j.pnpbp.2013.07.014
   EHLERS A, 1993, BEHAV RES THER, V31, P269, DOI 10.1016/0005-7967(93)90025-P
   Elmaolih A, 2014, BRAIN RES, V1580, P143, DOI 10.1016/j.brainres.2014.01.020
   Essau CA, 2000, J ANXIETY DISORD, V14, P263, DOI 10.1016/S0887-6185(99)00039-0
   Feldman R, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.6
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Feldman R, 2013, NEUROPSYCHOPHARMACOL, V38, P1154, DOI 10.1038/npp.2013.22
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Feldman R, 2011, J AM ACAD CHILD PSY, V50, P645, DOI 10.1016/j.jaac.2011.03.001
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, HORM BEHAV, V58, P669, DOI 10.1016/j.yhbeh.2010.06.005
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Field AP, 2008, J ABNORM PSYCHOL, V117, P214, DOI 10.1037/0021-843X.117.1.214
   Field AP, 2003, BEHAV RES THER, V41, P1277, DOI 10.1016/S0005-7967(03)00034-2
   Field AP, 2001, BEHAV RES THER, V39, P1259, DOI 10.1016/S0005-7967(00)00080-2
   FIELD T, 1985, DEV PSYCHOL, V21, P1152, DOI 10.1037//0012-1649.21.6.1152
   Fox AS, 2015, P NATL ACAD SCI USA, V112, P9118, DOI 10.1073/pnas.1508593112
   Frasch A, 1995, ADV EXP MED BIOL, V395, P257
   Gatt JM, 2009, MOL PSYCHIATR, V14, P681, DOI 10.1038/mp.2008.143
   Gerull FC, 2002, BEHAV RES THER, V40, P279, DOI 10.1016/S0005-7967(01)00013-4
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Ginsburg GS, 2015, AM J PSYCHIAT, V172, P1207, DOI 10.1176/appi.ajp.2015.14091178
   Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0
   Gordon I, 2014, J AM ACAD CHILD PSY, V53, P130, DOI 10.1016/j.jaac.2013.10.012
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Gunthert KC, 2007, PSYCHOSOM MED, V69, P762, DOI 10.1097/PSY.0b013e318157ad42
   HERSOV LA, 1960, J CHILD PSYCHOL PSYC, V1, P137, DOI 10.1111/j.1469-7610.1960.tb01988.x
   Hettema JM, 2001, AM J PSYCHIAT, V158, P1568, DOI 10.1176/appi.ajp.158.10.1568
   Hicks BM, 2009, J CHILD PSYCHOL PSYC, V50, P1309, DOI 10.1111/j.1469-7610.2009.02100.x
   Hu M, 2015, P NATL ACAD SCI USA, V112, P14348, DOI 10.1073/pnas.1507514112
   Hudson JL, 2001, BEHAV RES THER, V39, P1411, DOI 10.1016/S0005-7967(00)00107-8
   HYGGE S, 1976, J PERS SOC PSYCHOL, V33, P764, DOI 10.1037//0022-3514.33.6.764
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   Jones JD, 2015, J CHILD ADOLESC MENT, V27, P41, DOI 10.2989/17280583.2015.1007866
   Kain ZN, 1996, ARCH PEDIAT ADOL MED, V150, P1238
   Kang HJ, 2011, NATURE, V478, P483, DOI 10.1038/nature10523
   Kember RL, 2012, BRAIN BEHAV, V2, P455, DOI 10.1002/brb3.69
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359
   Keverne EB, 2004, CURR OPIN NEUROBIOL, V14, P777, DOI 10.1016/j.conb.2004.10.006
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Klauke B, 2011, DEPRESS ANXIETY, V28, P1048, DOI 10.1002/da.20840
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Koehl M, 2001, Neurotox Res, V3, P65
   La Greca AM, 2010, J CONSULT CLIN PSYCH, V78, P794, DOI 10.1037/a0020775
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   LaMontagne L L, 1992, Am J Crit Care, V1, P76
   Langley AK, 2014, J CLIN CHILD ADOLESC, V43, P579, DOI 10.1080/15374416.2013.817311
   LAST CG, 1987, AM J PSYCHIAT, V144, P1580
   Laucht M, 2009, INT J NEUROPSYCHOPH, V12, P737, DOI 10.1017/S1461145708009875
   Lebowitz ER, 2016, PSYCHONEUROENDOCRINO, V65, P35, DOI 10.1016/j.psyneuen.2015.12.007
   Lebowitz ER, 2015, DEPRESS ANXIETY, V32, P91, DOI 10.1002/da.22333
   Lebowitz ER, 2014, DEPRESS ANXIETY, V31, P1018, DOI 10.1002/da.22251
   Lebowitz ER, 2014, COGN BEHAV PRACT, V21, P456
   Lebowitz ER, 2013, J OBSESS-COMPULS REL, V2, P425, DOI 10.1016/j.jocrd.2013.08.004
   Lebowitz ER, 2013, DEPRESS ANXIETY, V30, P47, DOI 10.1002/da.21998
   Lebowitz ER, 2012, EXPERT REV NEUROTHER, V12, P229, DOI [10.1586/ern.11.200, 10.1586/ERN.11.200]
   Lee PR, 2005, NEUROPSYCHOPHARMACOL, V30, P1883, DOI 10.1038/sj.npp.1300722
   Lepine JP, 2002, J CLIN PSYCHIAT, V63, P4
   Levy DM, 1931, J NERV MENT DIS, V73, P65
   Li XJ, 2008, EUR ARCH PSY CLIN N, V258, P441, DOI 10.1007/s00406-008-0817-8
   Lieb R, 2000, ARCH GEN PSYCHIAT, V57, P859, DOI 10.1001/archpsyc.57.9.859
   Lovejoy MC, 2000, CLIN PSYCHOL REV, V20, P561, DOI 10.1016/S0272-7358(98)00100-7
   MacDonald K, 2014, BRAIN RES, V1580, P22, DOI 10.1016/j.brainres.2014.01.025
   Mah BL, 2015, DEPRESS ANXIETY, V32, P76, DOI 10.1002/da.22245
   Manassis K, 2014, J CONSULT CLIN PSYCH, V82, P1163, DOI 10.1037/a0036969
   Maron E, 2010, MOL PSYCHIATR, V15, P681, DOI 10.1038/mp.2009.145
   Martin RP, 1999, MERRILL PALMER QUART, V45, P370
   Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161
   Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669
   MERCKELBACH H, 1989, BEHAV RES THER, V27, P657, DOI 10.1016/0005-7967(89)90149-6
   Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017
   MINEKA S, 1986, J ABNORM PSYCHOL, V95, P307, DOI 10.1037/0021-843X.95.4.307
   Moore PS, 2004, J ABNORM PSYCHOL, V113, P471, DOI 10.1037/0021-843x.113.3.471
   Murgatroyd C, 2010, NAT NEUROSCI, V13, P649, DOI 10.1038/nn0510-649e
   Muris P, 1996, BEHAV RES THER, V34, P265, DOI 10.1016/0005-7967(95)00067-4
   Murray L, 2007, J CHILD PSYCHOL PSYC, V48, P45, DOI 10.1111/j.1469-7610.2006.01657.x
   Norman Kaila R, 2015, J Child Adolesc Psychiatr Nurs, V28, P131, DOI 10.1111/jcap.12116
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Olsson A, 2004, PSYCHOL SCI, V15, P822, DOI 10.1111/j.0956-7976.2004.00762.x
   Olsson A, 2007, NAT NEUROSCI, V10, P1095, DOI 10.1038/nn1968
   OST LG, 1985, BEHAV RES THER, V23, P683, DOI 10.1016/0005-7967(85)90066-X
   PARKER G, 1981, ACTA PSYCHIAT SCAND, V63, P33, DOI 10.1111/j.1600-0447.1981.tb00647.x
   Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x
   Pena CJ, 2013, ENDOCRINOLOGY, V154, P4340, DOI 10.1210/en.2013-1595
   Ponirakis A, 1998, DEV PSYCHOBIOL, V33, P163, DOI 10.1002/(SICI)1098-2302(199809)33:2<163::AID-DEV7>3.0.CO;2-H
   Poulton R, 2002, BEHAV RES THER, V40, P127, DOI 10.1016/S0005-7967(01)00045-6
   Poulton R, 2001, BEHAV RES THER, V39, P1395, DOI 10.1016/S0005-7967(00)00105-4
   Provencal N, 2012, J NEUROSCI, V32, P15626, DOI 10.1523/JNEUROSCI.1470-12.2012
   RACHMAN S, 1961, AM J PSYCHIAT, V118, P97
   Radke S, 2013, PSYCHOL SCI, V24, P1573, DOI 10.1177/0956797612472682
   Rapee RM, 1997, CLIN PSYCHOL REV, V17, P47, DOI 10.1016/S0272-7358(96)00040-2
   Reynolds S, 2012, CLIN PSYCHOL REV, V32, P251, DOI 10.1016/j.cpr.2012.01.005
   Rieger M, 2004, ANN NY ACAD SCI, V1032, P228, DOI 10.1196/annals.1314.026
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Rifkin-Graboi A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.133
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Scantamburlo G, 2007, PSYCHONEUROENDOCRINO, V32, P407, DOI 10.1016/j.psyneuen.2007.01.009
   Schiele MA, 2016, DEV PSYCHOBIOL, V58, P471, DOI 10.1002/dev.21393
   Shimada-Sugimoto M, 2015, PSYCHIAT CLIN NEUROS, V69, P388, DOI 10.1111/pcn.12291
   SILOVE D, 1986, AUST NZ J PSYCHIAT, V20, P365, DOI 10.3109/00048678609158884
   Silverman WK, 2008, J CLIN CHILD ADOLESC, V37, P105, DOI 10.1080/15374410701817907
   Silverman WK, 2009, J CONSULT CLIN PSYCH, V77, P474, DOI 10.1037/a0015761
   SILVERMAN WK, 1988, J AM ACAD CHILD PSY, V27, P779, DOI 10.1097/00004583-198811000-00020
   Siqueland L, 1996, J CLIN CHILD PSYCHOL, V25, P225, DOI 10.1207/s15374424jccp2502_12
   Sjostrom K, 1997, EUR J OBSTET GYN R B, V74, P149, DOI 10.1016/S0301-2115(97)00100-0
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   SORCE JF, 1985, DEV PSYCHOL, V21, P195, DOI 10.1037//0012-1649.21.1.195
   Sotnikov SV, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.127
   Stein MB, 2008, NEUROPSYCHOPHARMACOL, V33, P312, DOI 10.1038/sj.npp.1301422
   Steinhausen HC, 2009, EUR ARCH PSY CLIN N, V259, P270, DOI 10.1007/s00406-008-0865-0
   Storch EA, 2015, J ANXIETY DISORD, V35, P75, DOI 10.1016/j.janxdis.2015.09.001
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Szyf M, 2015, TRENDS MOL MED, V21, P134, DOI 10.1016/j.molmed.2014.12.004
   TAKAHASHI LK, 1992, BRAIN RES, V574, P131, DOI 10.1016/0006-8993(92)90809-N
   Teixeira JMA, 1999, BRIT MED J, V318, P153
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Thompson-Hollands J, 2014, J ANXIETY DISORD, V28, P765, DOI 10.1016/j.janxdis.2014.09.007
   TSUANG MT, 1993, EUR ARCH PSY CLIN N, V243, P131, DOI 10.1007/BF02190719
   Van den Bergh BRH, 2005, NEUROSCI BIOBEHAV R, V29, P237, DOI 10.1016/j.neubiorev.2004.10.007
   Van den Bergh BRH, 2004, CHILD DEV, V75, P1085, DOI 10.1111/j.1467-8624.2004.00727.x
   Van den Bergh B.R.H., 1990, PRE PERINATAL PSYCHO, V5, P119
   VAUGHAN KB, 1980, J PERS SOC PSYCHOL, V38, P909, DOI 10.1037/0022-3514.38.6.909
   Viaux-Savelon S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030935
   Wallace AR, 1893, NATURE, V48, P389, DOI 10.1038/048389b0
   Waszczuk MA, 2014, JAMA PSYCHIAT, V71, P905, DOI 10.1001/jamapsychiatry.2014.655
   Watt MC, 1998, BEHAV RES THER, V36, P505, DOI 10.1016/S0005-7967(97)10029-8
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Weems CF, 2006, J AFFECT DISORDERS, V91, P113, DOI 10.1016/j.jad.2006.01.009
   Weems CF, 2003, COGNITIVE THER RES, V27, P557, DOI 10.1023/A:1026307121386
   Weems CF, 2002, J PSYCHOPATHOL BEHAV, V24, P159, DOI 10.1023/A:1016058600416
   Weisman O, 2013, PSYCHONEUROENDOCRINO, V38, P694, DOI 10.1016/j.psyneuen.2012.08.011
   WEISSMAN MM, 1984, ARCH GEN PSYCHIAT, V41, P845
   Whaley SE, 1999, J CONSULT CLIN PSYCH, V67, P826, DOI 10.1037/0022-006X.67.6.826
   Wilson CA, 2013, BEHAV BRAIN RES, V238, P279, DOI 10.1016/j.bbr.2012.10.003
   Wood JJ, 2003, J CHILD PSYCHOL PSYC, V44, P134, DOI 10.1111/1469-7610.00106
   Wu YH, 2014, ENDOCRINOLOGY, V155, P1751, DOI 10.1210/en.2013-1868
   Zeng Y, 2015, STRESS, V18, P353, DOI 10.3109/10253890.2015.1055725
   Ziegler C, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.41
   Ziegler C, 2015, NEUROPSYCHOPHARMACOL, V40, P1528, DOI 10.1038/npp.2015.2
NR 174
TC 1
Z9 1
U1 11
U2 11
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0300-9564
EI 1435-1463
J9 J NEURAL TRANSM
JI J. Neural Transm.
PD SEP
PY 2016
VL 123
IS 9
SI SI
BP 1053
EP 1067
DI 10.1007/s00702-016-1565-y
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DV2KL
UT WOS:000382749200003
PM 27145763
ER

PT J
AU Kyeong, KS
   Hong, SH
   Kim, YC
   Choi, W
   Myung, SC
   Lee, MY
   You, RY
   Kim, CH
   Kwon, SY
   Suzuki, H
   Park, YJ
   Jeong, EH
   Kim, HS
   Kim, H
   Lim, SW
   Xu, WX
   Lee, SJ
   Ji, IW
AF Kyeong, Kyu-Sang
   Hong, Seung Hwa
   Kim, Young Chul
   Choi, Woong
   Myung, Sun Chul
   Lee, Moo Yeol
   You, Ra Young
   Kim, Chan Hyung
   Kwon, So Yeon
   Suzuki, Hikaru
   Park, Yeon Jin
   Jeong, Eun-Hwan
   Kim, Hak Soon
   Kim, Heon
   Lim, Seung Woon
   Xu, Wen-Xie
   Lee, Sang Jin
   Ji, Il Woon
TI Myometrial relaxation of mice via expression of two pore domain acid
   sensitive K+ (TASK-2) channels
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article
DE Longitudinal muscle; Myometrium; Relaxation; TASK-2
ID UTERINE SMOOTH-MUSCLE; INTRACELLULAR PH; POTASSIUM CHANNELS; ATP
   CHANNEL; CONTRACTION; UTERUS; PROGESTERONE; PARTURITION; TANDEM; CELLS
AB Myometrial relaxation of mouse via expression of two-pore domain acid sensitive (TASK) channels was studied. In our previous report, we suggested that two-pore domain acid-sensing K+ channels (TASK-2) might be one of the candidates for the regulation of uterine circular smooth muscles in mice. In this study, we tried to show the mechanisms of relaxation via TASK-2 channels in marine myometrium. Isometric contraction measurements and patch clamp technique were used to verify TASK conductance in murine myometrium. Western blot and immunehistochemical study under confocal microscopy were used to investigate molecular identity of TASK channel. In this study, we showed that TEA and 4-AP insensitive non-inactivating outward K+ current (NIOK) may be responsible for the quiescence of murine pregnant longitudinal myometrium. The characteristics of NIOK coincided with two pore domain acid-sensing K+ channels (TASK-2). NIOK in the presence of K+ channel blockers was inhibited further by TASK inhibitors such as quinidine, bupivacaine, lidocaine, and extracellular acidosis. Furthermore, oxytocin and estrogen inhibited NIOK in pregnant myometrium. When compared to non-pregnant myometrium, pregnant myometrium showed stronger inhibition of NIOK by quinidine and increased immunohistochemical expression of TASK-2. Finally, TASK-2 inhibitors induced strong myometrial contraction even in the presence of L-methionine, a known inhibitor of stretch-activated channels in the longitudinal myometrium of mouse. Activation of TASK-2 channels seems to play an essential role for relaxing uterus during pregnancy and it might be one of the alternatives for preventing preterm delivery.
C1 [Kyeong, Kyu-Sang; Hong, Seung Hwa; Jeong, Eun-Hwan; Kim, Hak Soon; Ji, Il Woon] Chungbuk Natl Univ, Coll Med, Dept Obstet & Gynecol, Cheongju 28644, South Korea.
   [Kim, Young Chul; You, Ra Young] Chungbuk Natl Univ, Coll Med, Dept Physiol, Cheongju 28644, South Korea.
   [Choi, Woong; Kim, Chan Hyung] Chungbuk Natl Univ, Coll Med, Dept Pharmacol, Cheongju 28644, South Korea.
   [Kim, Heon] Chungbuk Natl Univ, Coll Med, Dept Prevent Med, Cheongju 28644, South Korea.
   [Lim, Seung Woon] Chungbuk Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Cheongju 28644, South Korea.
   [Lee, Sang Jin] Chungbuk Natl Univ, Coll Med, Dept Med Educ, Cheongju 28644, South Korea.
   [Myung, Sun Chul] Chung Ang Univ, Coll Med, Dept Urol, Seoul 06974, South Korea.
   [Lee, Moo Yeol] Chung Ang Univ, Coll Med, Dept Physiol, Seoul 06974, South Korea.
   [Kwon, So Yeon] VHS Med Ctr, Seoul 05368, South Korea.
   [Suzuki, Hikaru] Nagoya City Univ, Sch Med, Dept Physiol, Nagoya, Aichi 4678601, Japan.
   [Park, Yeon Jin] Cheongju St Marys Hosp, Dept Obstet & Gynecol, Cheongju 28323, South Korea.
   [Xu, Wen-Xie] Shanghai Jiao Tong Univ, Sch Med, Dept Physiol, Shanghai 200240, Peoples R China.
RP Ji, IW (reprint author), Chungbuk Natl Univ, Coll Med, Dept Obstet & Gynecol, Cheongju 28644, South Korea.; Kim, YC (reprint author), Chungbuk Natl Univ, Coll Med, Dept Physiol, Cheongju 28644, South Korea.
EM physiokyc@chungbuk.ac.kr; iwji@chungbuk.ac.kr
FU Chungbuk National University
FX Kyu-Sang Kyeong, Seung Hwa Hong, Young Chul Kim equally contributed to
   this work. This work was supported by the research grant of the Chungbuk
   National University in 2014.
CR ANWER K, 1993, AM J PHYSIOL, V265, pC976
   Bai XL, 2005, REPRODUCTION, V129, P525, DOI 10.1530/rep.1.00442
   BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909
   Brinkman CR, 1990, UTERINE FUNCTION MOL, P519
   Buxton ILO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012372
   Cerri V, 2000, J Matern Fetal Med, V9, P204
   Che TT, 2012, J NEUROCHEM, V121, P516, DOI 10.1111/j.1471-4159.2012.07702.x
   CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206
   Druzin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020213
   Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464
   GARFIELD RE, 1977, SCIENCE, V198, P958, DOI 10.1126/science.929182
   HARRISON N, 1994, J PHYSIOL-LONDON, V476, P349
   Hong SH, 2016, J VET MED SCI, V78, P1153, DOI 10.1292/jvms.15-0700
   Hong SH, 2013, KOREAN J PHYSIOL PHA, V17, P359, DOI 10.4196/kjpp.2013.17.4.359
   Kang D, 2004, J BIOL CHEM, V279, P28063, DOI 10.1074/jbc.M402940200
   KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0
   Khan RN, 2001, EXP PHYSIOL, V86, P255, DOI 10.1113/eph8602181
   Khan RN, 1997, AM J PHYSIOL-CELL PH, V273, pC1721
   Kim YC, 2008, KOREAN J PHYSIOL PHA, V12, P323, DOI 10.4196/kjpp.2008.12.6.323
   Ma XY, 2011, J BIOL CHEM, V286, P39813, DOI 10.1074/jbc.M111.264788
   Mesiano S, 2007, SEMIN CELL DEV BIOL, V18, P321, DOI 10.1016/j.semcdb.2007.05.003
   Miller P, 2003, J PHYSIOL-LONDON, V548, P31, DOI 10.1113/jphysiol.2003.040048
   Monaghan K, 2011, J PHYSIOL-LONDON, V589, P1221, DOI 10.1113/jphysiol.2010.203869
   Naderali EK, 1999, J REPROD FERTIL, V117, P153
   O'Connell AD, 2002, BBA-BIOMEMBRANES, V1566, P152, DOI 10.1016/S0005-2736(02)00597-7
   Park JK, 2007, PFLUG ARCH EUR J PHY, V454, P307, DOI 10.1007/s00424-007-0204-8
   Parkington HC, 2001, FRONT HORM RES, V27, P179
   PARRATT JR, 1995, J REPROD FERTIL, V105, P71
   Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863
   ROOTH G, 1962, ARCH DIS CHILD, V37, P366
   SANBORN BM, 1995, SEMIN PERINATOL, V19, P31, DOI 10.1016/S0146-0005(95)80045-X
   SJOSTEDT S, 1962, AM J OBSTET GYNECOL, V84, P775
   Smith RC, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-41
   SOLOFF MS, 1983, CAN J BIOCHEM CELL B, V61, P625
   Soriano S, 2011, STEROIDS, V76, P856, DOI 10.1016/j.steroids.2011.03.017
   TAGGART M, 1993, PFLUG ARCH EUR J PHY, V423, P527, DOI 10.1007/BF00374951
   Taggart MJ, 1997, AM J OBSTET GYNECOL, V177, P959, DOI 10.1016/S0002-9378(97)70301-6
   TULCHINSKY D, 1972, AM J OBSTET GYNECOL, V112, P1095
   WALSH SW, 1984, J CLIN ENDOCR METAB, V58, P629
   Wray S, 2008, J NEUROENDOCRINOL, V20, P451, DOI 10.1111/j.1365-2826.2008.01665.x
   Wray S, 2015, ACTA PHYSIOL, V213, P417, DOI 10.1111/apha.12431
   Wray S, 2007, EXP PHYSIOL, V92, P621, DOI 10.1113/expphysiol.2007.038125
NR 42
TC 0
Z9 0
U1 0
U2 0
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA
SN 1226-4512
EI 2093-3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD SEP
PY 2016
VL 20
IS 5
BP 547
EP 556
DI 10.4196/kjpp.2016.20.5.547
PG 10
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA DV3CO
UT WOS:000382798800013
PM 27610042
ER

PT J
AU Binfa, L
   Pantoja, L
   Ortiz, J
   Cavada, G
   Schindler, P
   Burgos, RY
   Melo, CRME
   da Silva, LCFP
   Lima, MDP
   Hernandez, LV
   Schlenker, R
   Sanchez, V
   Rojas, MS
   Huaman, BC
   Chauca, MLT
   Cillo, A
   Lofeudo, S
   Zapiola, S
   Weeks, F
   Foster, J
AF Binfa, Lorena
   Pantoja, Loreto
   Ortiz, Jovita
   Cavada, Gabriel
   Schindler, Peter
   Ypania Burgos, Rosa
   Maganha e Melo, Celia Regina
   Florentino Pereira da Silva, Lucia Cristina
   Pimentel Lima, Marlise de Oliveira
   Valli Hernandez, Laura
   Schlenker, Rosana
   Sanchez, Verdun
   Solis Rojas, Mirian
   Cruz Huaman, Betty
   Torres Chauca, Maria Luisa
   Cillo, Alicia
   Lofeudo, Susana
   Zapiola, Sandra
   Weeks, Fiona
   Foster, Jennifer
TI Midwifery practice and maternity services: A multisite descriptive study
   in Latin America and the Caribbean
SO MIDWIFERY
LA English
DT Article
DE Midwifery Quality of Health Care; Maternal Health Services;
   Evidence-based practice; Global health; Latin America
ID HEALTH-SERVICES; DELIVERY; IMPLEMENTATION; RATES; MODEL; CHILE; CARE
AB Objective: over the past three decades there has been a social movement in Latin American countries (LAC) to support humanised, physiologic birth. Rates of caesarean section overall in Latin America are approximately 35%, increasing up to 85% in some cases. There are many factors related to poor outcomes with regard to maternal and newborn/infant health in LAC countries. Maternal and perinatal outcome data within and between countries is scarce and inaccurate. The aims of this study were to: i) describe selected obstetric and neonatal outcomes of women who received midwifery care, ii) identify the level of maternal well-being after experiencing midwifery care in 6 Latin America countries.
   Design: this was a cross sectional and descriptive study, conducted in selected maternity units in Argentina, Brazil, Chile, the Dominican Republic, Peru, and Uruguay. Quantitative methods were used to measure midwifery processes of care and maternal perceptions of well-being in labour and childbirth through a validated survey of maternal well-being and an adapted version of the American College of Nurse -Midwives (ACNM) standardized antepartum and intrapartum data set.
   Setting: Maternity units from 6 Latin American countries.
   Participants: the final sample was a convenience sample, and the total participants for all sites in the six countries was 3009 low risk women.
   Findings: for the countries reporting, overall, 82% of these low risk women had spontaneous vaginal deliveries. The rate of caesarean section was 16%; the Dominican Republic had the highest rate of Caesarean sections (30%) and Peru had the lowest rate (4%). The use of oxytocin in labour was widely variable, although overall there was a high proportion of women whose labour was augmented or induced. Ambulation was common, with the lowest proportion (48%) of women ambulating in labour in Chile, Uruguay (50%), Peru (65%), Brazil (85%). The presence of continuous support was highest in Uruguay (93%), Chile (75%) and Argentina (55%), and Peru had the lowest (22%). Episiotomies are still prevalent in all countries, the lowest rate was reported in the Dominican Republic (22%), and the highest rates were 52 and 53% (Chile and Peru, respectively). The Optimal Maternal well-being score had a prevalence of 43.5%, adequate score was 30.8%; 25% of the total sample of women rated their well-being during labour and childbirth as poor.
   Key conclusions: despite evidence-based guidelines and recommendations, birth is not managed accordingly in most cases. Women feel that care is adequate, although some women report mistreatment. Implications for Practice: More research is needed to understand why such high levels of intervention exist and to test the implementation of evidence-based practices in local settings. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Binfa, Lorena; Pantoja, Loreto; Ortiz, Jovita] Univ Chile, Fac Med, Sch Midwifery, Dept Womens & New Born Hlth Promot, Santiago, Chile.
   [Cavada, Gabriel] Univ Chile, Sch Publ Hlth, Fac Med, Santiago, Chile.
   [Schindler, Peter; Foster, Jennifer] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA.
   [Schindler, Peter; Foster, Jennifer] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Ypania Burgos, Rosa] Univ Autonoma Santo Domingo, Dept Nursing, San Francisco De Macoris, Dominican Rep.
   [Binfa, Lorena; Pantoja, Loreto; Ortiz, Jovita; Cavada, Gabriel; Schindler, Peter; Ypania Burgos, Rosa; Maganha e Melo, Celia Regina; Florentino Pereira da Silva, Lucia Cristina; Pimentel Lima, Marlise de Oliveira; Valli Hernandez, Laura; Schlenker, Rosana; Sanchez, Verdun; Solis Rojas, Mirian; Cruz Huaman, Betty; Torres Chauca, Maria Luisa; Cillo, Alicia; Lofeudo, Susana; Zapiola, Sandra; Weeks, Fiona; Foster, Jennifer] Univ Reg Hosp San Vicente de Paul, San Francisco De Macoris, Dominican Rep.
   [Maganha e Melo, Celia Regina; Florentino Pereira da Silva, Lucia Cristina; Pimentel Lima, Marlise de Oliveira] Univ Sao Paulo, Sch Midwifery, BR-05508 Sao Paulo, Brazil.
   [Valli Hernandez, Laura; Schlenker, Rosana; Sanchez, Verdun] Univ La Republ, Sch Midwifery, Montevideo, Uruguay.
   [Solis Rojas, Mirian] Univ Nacl Mayor San Marcos, Lima, Peru.
   [Cillo, Alicia; Lofeudo, Susana; Zapiola, Sandra] Univ Catolica La Plata, Sch Midwifery, La Plata, Buenos Aires, Argentina.
   [Cruz Huaman, Betty; Torres Chauca, Maria Luisa] Hosp Santa Rosa Lima, Lima, Peru.
   [Weeks, Fiona] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Binfa, L (reprint author), Univ Chile, Fac Med, Sch Midwifery, Dept Womens & New Born Hlth Promot, Santiago, Chile.
EM lbinfa@med.uchile.cl; lpantoja@med.uchile.cl; jortizc@med.uchile.cl;
   gcavada@med.uchile.cl; Peter.Schindler@emory.edu;
   rosaburgos90@yahoo.com; celiamelo@usp.hr; lucris@usp.br;
   mop.lima@hotmail.com; lalavalher@gmail.com; rosslenker@hotmail.com;
   vsanchez.uy@gmail.com; misolroj2@gmail.com; bcruzh@hotmail.com;
   mltorresch@hotmail.com; alicia.cillo@hotmail.com;
   sblofeudo03@yahoo.com.ar; sfz_66@yahoo.com.ar; fweeks2@jhu.edu;
   jennifer.foster@emory.edu
CR ACNM, 2010, ACNM DAT SET INTR CA
   Alfirevic Z, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006066.pub2
   Australian Institute of Health and Welfare, 2011, HEADL IND CHILDR HLT
   Ayres-De-Campos D, 2015, INT J GYNECOL OBSTET, V131, P13, DOI 10.1016/j.ijgo.2015.06.020
   Barcena A., 2016, IMPERATIVO IGUALDAD
   Belizan JM, 2005, BIRTH-ISS PERINAT C, V32, P210, DOI 10.1111/j.0730-7659.2005.00372.x
   Binfa L, 2016, MIDWIFERY, V35, P53, DOI 10.1016/j.midw.2016.01.018
   Binfa L, 2013, MIDWIFERY, V29, P1151, DOI 10.1016/j.midw.2013.07.001
   Bodner K, 2011, ARCH GYNECOL OBSTET, V283, P1193, DOI 10.1007/s00404-010-1525-y
   Ministerio Salud Chile, 2007, MAN AT PERS PROC REP
   Davis-Floyd R., 2007, MIDWIFERY TODAY INT, V84, P9
   Devane D., 2012, CARDIOTOCOGRAPHY VER
   ECLAC, 2004, OP END M PRES OFF EC
   Frankman EA, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.11.022
   Gialloreti LE, 2014, MED HYPOTHESES, V82, P713, DOI 10.1016/j.mehy.2014.03.011
   Gibbons L, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.026
   Greener D., 1991, INT J NURSING MIDWIF, V36, P174
   Hodnett ED, 2013, COCHRANE DATABASE SY, V7
   Hung H.W., 2015, J MATERN-FETAL NEO M, V10, P1
   Jaafar S.H., 2012, COCHRANE DATABASE SY, V9
   Kristensen K, 2016, J ALLERGY CLIN IMMUN, V137, P587, DOI 10.1016/j.jaci.2015.07.040
   Lalonde A, 2015, INT J GYNECOL OBSTET, V128, P95, DOI 10.1016/j.ijgo.2014.10.013
   Lawrence A, 2013, COCHRANE DB SYST REV, V8
   Maude RM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-184
   Merenstein DJ, 2011, CLIN PEDIATR, V50, P1024, DOI 10.1177/0009922811410875
   Ministerio Salud Peru, 2011, GUIA TECN PSIC OBST
   Moore E.R., 2012, COCHRANE DATABASE SY, V5
   NICE, 2014, INTR CAR CAR HLTH WO
   O'Neill SM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001670
   Odberg P., 2005, PROFILING MIDWIFERY
   OECD, 2013, HLTH GLANC 2013
   Silver RM, 2010, SEMIN PERINATOL, V34, P258, DOI 10.1053/j.semperi.2010.03.006
   Singata M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003930.pub3
   Smyth R., 2013, COCHRANE DATABASE SY, V6
   Solheim KN, 2011, J MATERN-FETAL NEO M, V24, P1341, DOI 10.3109/14767058.2011.553695
   Taljaard M, 2009, PAEDIATR PERINAT EP, V23, P574, DOI 10.1111/j.1365-3016.2009.01072.x
   Tunyalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045
   Umenai T, 2001, INT J GYNECOL OBSTET, V75, pS3, DOI 10.1016/S0020-7292(01)00508-2
   Uribe T Claudia, 2008, Rev. chil. obstet. ginecol., V73, P4, DOI 10.4067/S0717-75262008000100002
   World Health Organization, 1985, LANCET, V2, P436, DOI DOI 10.1016/S0140-6736(85)92750-3
NR 40
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0266-6138
EI 1532-3099
J9 MIDWIFERY
JI Midwifery
PD SEP
PY 2016
VL 40
BP 218
EP 225
DI 10.1016/j.midw.2016.07.010
PG 8
WC Nursing
SC Nursing
GA DU6FF
UT WOS:000382308900030
PM 27476027
ER

PT J
AU Yatawara, CJ
   Einfeld, SL
   Hickie, IB
   Davenport, TA
   Guastella, AJ
AF Yatawara, C. J.
   Einfeld, S. L.
   Hickie, I. B.
   Davenport, T. A.
   Guastella, A. J.
TI The effect of oxytocin nasal spray on social interaction deficits
   observed in young children with autism: a randomized clinical crossover
   trial
SO MOLECULAR PSYCHIATRY
LA English
DT Article
ID SPECTRUM DISORDERS; EMOTIONAL DISTURBANCE; INTRANASAL OXYTOCIN;
   MENTAL-RETARDATION; PLACEBO-RESPONSE; ADOLESCENTS; BEHAVIOR;
   RECOGNITION; PREDICTORS; ADULTS
AB Interventions for autism are limited. The synthetic hormone oxytocin may provide a potential treatment to improve core social and behavioral difficulties in autism, but its efficacy has yet to be evaluated in young children who potentially may benefit to a greater extent. We investigated the efficacy, tolerability and safety of oxytocin treatment in young children with autism using a double-blind, randomized, placebo-controlled, crossover, clinical trial. Thirty-one children with autism received 12 International Units (IU) of oxytocin and placebo nasal spray morning and night (24 IU per day) for 5 weeks, with a 4-week washout period between each treatment. Compared with placebo, oxytocin led to significant improvements on the primary outcome of caregiver-rated social responsiveness. Overall, nasal spray was well tolerated, and the most common reported adverse events were thirst, urination and constipation. This study is the first clinical trial to support the potential of oxytocin as an early intervention for young children with autism to help improve social interaction deficits.
C1 [Yatawara, C. J.; Guastella, A. J.] Univ Sydney, Fac Med, Cent Clin Sch, Autism Clin Translat Res,Brain & Mind Ctr, Sydney, NSW, Australia.
   [Einfeld, S. L.; Hickie, I. B.; Davenport, T. A.] Univ Sydney, Brain & Mind Ctr, Cent Clin Sch, Fac Med, Sydney, NSW, Australia.
   [Einfeld, S. L.] Univ Sydney, Ctr Disabil Res & Policy, Brain & Mind Ctr, Sydney, NSW, Australia.
RP Guastella, AJ (reprint author), Univ Sydney, Brain & Mind Ctr, Autism Clin Translat Res, Bldg F,94 Mallett St, Sydney, NSW 2050, Australia.
EM adam.guastella@sydney.edu.au
FU NHMRC [APP 623625, APP 1043664]; BUPA Health Foundation Grant [APP
   2012-00004]
FX We acknowledge an NHMRC Australian Fellowship (APP 511921) to IBH, an
   NHMRC Career Development Fellowship (APP 1061922) to AJG and a generous
   donation by Mr Geoff Stein toward the completion of this trial. These
   funders had no role in the design and conduct of the study; collection,
   management, analysis and interpretation of the data; preparation, review
   or approval of the manuscript; and decision to submit the manuscript for
   publication. We also thank ASPECT, Giant Steps and The Lizard Center in
   Sydney (Australia) for assistance with recruitment. This research was
   partially supported by NHMRC Grants (APP 623625; APP 1043664) and a BUPA
   Health Foundation Grant (APP 2012-00004) to AJG.
CR Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Association AP, 2000, DIAGN STAT MAN MENT
   Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P527, DOI 10.1097/00004583-199805000-00015
   Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855
   Brannan AM, 1997, J EMOT BEHAV DISORD, V5, P212
   Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y
   CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF70
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Constantino J. N, 2005, SOCIAL RESPONSIVENES
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Einfeld S, 2002, MANUAL DEV BEHAV CHE
   EINFELD SL, 1995, J AUTISM DEV DISORD, V25, P81, DOI 10.1007/BF02178498
   Gibbs TT, 2010, NEUROCHEMICAL BASIS OF AUTISM: FROM MOLECULES TO MINICOLUMNS, P245, DOI 10.1007/978-1-4419-1272-5_15
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella AJ, 2015, BIOL PSYCHIAT
   Guy W, 1976, ECDEU ASSESSMENT MAN
   Harris SL, 2000, J AUTISM DEV DISORD, V30, P137, DOI 10.1023/A:1005459606120
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Howlin P., 1999, TEACHING CHILDREN AU
   Howlin P, 2002, OUTCOMES NEURODEVELO
   JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037//0022-006X.59.1.12
   King BH, 2013, JAMA PEDIATR, V167, P1045, DOI 10.1001/jamapediatrics.2013.2698
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841
   Masi A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.143
   Miller G, 2013, SCIENCE, V339, P267, DOI 10.1126/science.339.6117.267
   Pine E, 2006, AUTISM, V10, P344, DOI 10.1177/1362361306064434
   Reichow B, 2012, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.00009260.PUB
   Rogers SJ, 1996, J AUTISM DEV DISORD, V26, P243, DOI 10.1007/BF02172020
   Roid G., 1997, LEITER INT PERFORMAN
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   Sharma A, 2012, J PEDIATR HEALTH CAR, V26, P291, DOI 10.1016/j.pedhc.2011.02.008
   Young LJ, 2013, BIOL PSYCHIAT, V74, P160, DOI 10.1016/j.biopsych.2013.05.015
NR 41
TC 10
Z9 10
U1 15
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD SEP
PY 2016
VL 21
IS 9
BP 1225
EP 1231
DI 10.1038/mp.2015.162
PG 7
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA DU6MK
UT WOS:000382328900010
PM 26503762
ER

PT J
AU Toepfer, P
   Heim, CM
   Entringer, S
   Wadhwa, PD
   Provencal, N
   Binder, EB
   Buss, C
AF Toepfer, Philipp
   Heim, Christine M.
   Entringer, Sonja
   Wadhwa, Pathik D.
   Provencal, Nadine
   Binder, Elisabeth B.
   Buss, Claudia
TI A variation in the oxytocin receptor gene moderates the relationship
   between early maternal care in childhood and interleukin 6 (IL-6)
   concentrations during pregnancy
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Conference of the
   International-Society-of-Psychoneuroendocrinology - Personalized
   Medicine in the Neurosciences - Genetics, Imaging, and Hormones
CY SEP 08-11, 2016
CL Miami, FL
SP Int Soc Psychoneuroendocrinol
C1 [Toepfer, Philipp; Heim, Christine M.; Entringer, Sonja; Buss, Claudia] Charite, Berlin, Germany.
   [Heim, Christine M.] Penn State Univ, University Pk, PA 16802 USA.
   [Entringer, Sonja; Wadhwa, Pathik D.; Buss, Claudia] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
   [Provencal, Nadine; Binder, Elisabeth B.] Max Planck Inst Psychiat, Munich, Germany.
   [Binder, Elisabeth B.] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
EM philipp.toepfer@charite.de
NR 0
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2016
VL 71
SU S
BP 15
EP 15
DI 10.1016/j.psyneuen.2016.07.049
PG 1
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DV0FX
UT WOS:000382594500039
ER

PT J
AU Boeck, C
   Krause, S
   Karabatsiakis, A
   Schury, K
   Waller, C
   Kolassa, IT
AF Boeck, Christina
   Krause, Sabrina
   Karabatsiakis, Alexander
   Schury, Katharina
   Waller, Christiane
   Kolassa, Iris-Tatjana
TI Telomere shortening in immune cell subsets of women with a history of
   child maltreatment: The role of cortisol and oxytocin
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Conference of the
   International-Society-of-Psychoneuroendocrinology - Personalized
   Medicine in the Neurosciences - Genetics, Imaging, and Hormones
CY SEP 08-11, 2016
CL Miami, FL
SP Int Soc Psychoneuroendocrinol
C1 [Boeck, Christina; Karabatsiakis, Alexander; Schury, Katharina; Kolassa, Iris-Tatjana] Univ Ulm, Clin & Biol Psychol, Inst Psychol & Educ, Ulm, Germany.
   [Krause, Sabrina; Waller, Christiane] Univ Hosp Ulm, Dept Psychosomat Med, Ulm, Germany.
EM christina.boeck@uni-ulm.de
NR 0
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2016
VL 71
SU S
BP 53
EP 53
DI 10.1016/j.psyneuen.2016.07.140
PG 1
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DV0FX
UT WOS:000382594500128
ER

PT J
AU Grund, T
   Grinevich, V
   Neumann, ID
AF Grund, Thomas
   Grinevich, Valery
   Neumann, Inga D.
TI Interaction of neuropeptide S with the endogenous oxytocin system within
   the hypothalamic PVN
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Conference of the
   International-Society-of-Psychoneuroendocrinology - Personalized
   Medicine in the Neurosciences - Genetics, Imaging, and Hormones
CY SEP 08-11, 2016
CL Miami, FL
SP Int Soc Psychoneuroendocrinol
C1 [Grund, Thomas; Neumann, Inga D.] Univ Regensburg, Dept Behav & Mol Neurobiol, Inst Zool, Regensburg, Germany.
   [Grinevich, Valery] German Canc Res Ctr, Schaller Res Grp Neuropeptides, D-69120 Heidelberg, Germany.
   [Grinevich, Valery] Heidelberg Univ, Network Cluster Excellence, D-69120 Heidelberg, Germany.
EM thomas.grund@ur.de
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2016
VL 71
SU S
BP 61
EP 62
DI 10.1016/j.psyneuen.2016.07.160
PG 2
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DV0FX
UT WOS:000382594500148
ER

PT J
AU Human, LJ
   Thorson, KR
   Mendes, WB
AF Human, Lauren J.
   Thorson, Katherine R.
   Mendes, Wendy Berry
TI Interactive Effects Between Extraversion and Oxytocin Administration:
   Implications for Positive Social Processes
SO SOCIAL PSYCHOLOGICAL AND PERSONALITY SCIENCE
LA English
DT Article
DE oxytocin administration; extraversion; social outcomes; prosocial
   behavior
ID INTRANASAL OXYTOCIN; PROSOCIAL BEHAVIOR; ADULT ATTACHMENT; INCREASES
   TRUST; HUMANS; PERSONALITY; SUPPORT; TRAITS; STRESS; WELL
AB Intranasal administration of the neuropeptide oxytocin (OT) appears to have positive social consequences, but these effects are often highly context- and person-specific. The present research examined whether the core personality trait of extraversion may be one important person-specific factor that plays a role in these associations. Across two double-blind randomized placebo-controlled studies (total ns: Study 1 = 121; Study 2 = 112), we observed significant interactions between OT administration and extraversion predicting prosocial outcomes. For individuals low in extraversion, OT administration relative to placebo led to greater perceived social connection and prosocial tendencies (Study 1) and more positive behavioral responses to help and greater trust of an interaction partner (Study 2). In contrast, OT administration was not beneficial for individuals high in extraversion. Overall, these findings contribute to growing evidence that OT administration has complex, person-specific effects on social behavior, indicating that extraversion plays an important role in these associations.
C1 [Human, Lauren J.] McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.
   [Thorson, Katherine R.] NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.
   [Mendes, Wendy Berry] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Human, LJ (reprint author), McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.
EM lauren.human@mcgill.ca
FU Lauren J. Human's Social Sciences and Humanities Research Council
   Postdoctoral Fellowship; Greater Good Science Center
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research was supported in part by Lauren J. Human's Social Sciences and
   Humanities Research Council Postdoctoral Fellowship and a Greater Good
   Science Center grant to Wendy Berry Mendes.
CR Anderson C, 2001, J PERS SOC PSYCHOL, V81, P116, DOI 10.1037//0022-3514.81.1.116
   ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037//0022-3514.63.4.596
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Bartlett MY, 2006, PSYCHOL SCI, V17, P319, DOI 10.1111/j.1467-9280.2006.01705.x
   Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Bartz JA, 2015, PSYCHOL SCI, V26, P1177, DOI 10.1177/0956797615580279
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Cardoso C, 2014, SOC NEUROSCI-UK, V9, P186, DOI 10.1080/17470919.2013.873079
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Cardoso C, 2012, PSYCHOPHARMACOLOGY, V220, P741, DOI 10.1007/s00213-011-2527-6
   Carlo G, 2005, PERS INDIV DIFFER, V38, P1293, DOI 10.1016/j.paid.2004.08.012
   Carver CS, 1997, PERS SOC PSYCHOL B, V23, P865, DOI 10.1177/0146167297238007
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Clark M. S., 2010, HDB SOCIAL PSYCHOL, V2, P898, DOI DOI 10.1002/9780470561119.S0CPSY002025
   COHEN J, 1962, J ABNORM PSYCHOL, V65, P145, DOI 10.1037/h0045186
   Conlisk J, 2011, J ECON BEHAV ORGAN, V78, P160, DOI 10.1016/j.jebo.2011.01.002
   Costa P. T., 1992, REVISED NEO PERSONAL
   De Dreu CKW, 2012, PSYCHONEUROENDOCRINO, V37, P871, DOI 10.1016/j.psyneuen.2011.10.003
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Deci EL, 2006, PERS SOC PSYCHOL B, V32, P313, DOI 10.1177/0146167205282148
   Depue RA, 1999, BEHAV BRAIN SCI, V22, P491
   DeSteno D, 2010, EMOTION, V10, P289, DOI 10.1037/a0017883
   Di Simplicio M, 2009, J PSYCHOPHARMACOL, V23, P241, DOI 10.1177/0269881108095705
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Human L. J., 2015, 2 POSITIVES MAKE NEG
   Human L. J., 2015, EFFECTS OXYTOC UNPUB
   Klackl J, 2013, BIOL PSYCHOL, V92, P387, DOI 10.1016/j.biopsycho.2012.11.010
   Kogan A, 2014, J PERS SOC PSYCHOL, V107, P1051, DOI 10.1037/a0037509
   Kogan A, 2013, EMOTION, V13, P599, DOI 10.1037/a0032725
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lucas RE, 2000, J PERS SOC PSYCHOL, V79, P452, DOI 10.1037//0022-3514.79.3.452
   Lucas RE, 2008, J PERS, V76, P385, DOI 10.1111/j.1467-6494.2008.00490.x
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Mikolajczak M, 2010, PSYCHOL SCI, V21, P1072, DOI 10.1177/0956797610377343
   Mikolajczak M, 2010, BIOL PSYCHOL, V85, P182, DOI 10.1016/j.biopsycho.2010.05.010
   Nave G, 2015, PERSPECT PSYCHOL SCI, V10, P772, DOI 10.1177/1745691615600138
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Ozer DJ, 2006, ANNU REV PSYCHOL, V57, P401, DOI 10.1146/annurev.psych.57.102904.190127
   Penner LA, 2002, J SOC ISSUES, V58, P447, DOI 10.1111/1540-4560.00270
   Riem MME, 2013, PSYCHONEUROENDOCRINO, V38, P1418, DOI 10.1016/j.psyneuen.2012.12.023
   SAUCIER G, 1994, J PERS ASSESS, V63, P506, DOI 10.1207/s15327752jpa6303_8
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Thomas PA, 2010, J GERONTOL B-PSYCHOL, V65, P351, DOI 10.1093/geronb/gbp113
   Unkelbach C, 2008, PSYCHOL SCI, V19, P1092, DOI 10.1111/j.1467-9280.2008.02206.x
   Uvnas-Moberg K, 1998, NEWS PHYSIOL SCI, V13, P22
   van Ijzendoorn MH, 2012, PSYCHONEUROENDOCRINO, V37, P438, DOI 10.1016/j.psyneuen.2011.07.008
   van IJzendoorn MH, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00258
   Vankov I, 2014, Q J EXP PSYCHOL, V67, P1037, DOI 10.1080/17470218.2014.885986
   Watson D, 2000, J PERS, V68, P413, DOI 10.1111/1467-6494.00102
   Watson D., 1997, HDB PERSONALITY PSYC, P767, DOI DOI 10.1016/B978-012134645-4/50030-5
   Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128
NR 64
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1948-5506
EI 1948-5514
J9 SOC PSYCHOL PERS SCI
JI Soc. Psychol. Personal Sci.
PD SEP
PY 2016
VL 7
IS 7
BP 735
EP 744
DI 10.1177/1948550616644964
PG 10
WC Psychology, Social
SC Psychology
GA DV1UE
UT WOS:000382705900014
ER

PT J
AU Xiao, W
   Wang, TL
   Fu, WY
   Wang, FY
   Zhao, L
AF Xiao, Wei
   Wang, Tianlong
   Fu, Wenya
   Wang, Fengying
   Zhao, Lei
TI Regional cerebral oxygen saturation guided cerebral protection in a
   parturient with Takayasu's arteritis undergoing cesarean section: a case
   report
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Editorial Material
DE Parturient; Takayasu's arteritis; Cesarean section; Anesthesia; Regional
   cerebral oxygen saturation
ID DIRECTED FLUID THERAPY; CAROTID-ENDARTERECTOMY; EPIDURAL-ANESTHESIA;
   DELIVERY; PREGNANCY; SURGERY; COMPLICATIONS; PREECLAMPSIA; DYSFUNCTION;
   OXYTOCIN
AB The objective of this case report is to present the successful use of regional cerebral oxygen saturation (rScO(2)) monitoring guided cerebral protection for cesarean delivery in a parturient with Takayasu's arteritis at 38 weeks' gestation. The parturient presented with impaired cerebral and renal perfusion. Titrated epidural anesthesia was performed. During the procedure, we used rScO(2) guided cerebral protection strategies, which helped to optimize cerebral oxygen delivery and prevent cerebral complications. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Xiao, Wei; Wang, Tianlong; Fu, Wenya; Zhao, Lei] Capital Med Univ, Xuan Wu Hosp, Dept Anesthesiol, Beijing 100053, Peoples R China.
   [Wang, Fengying] Capital Med Univ, Xuan Wu Hosp, Dept Obstet & Gynecol, Beijing 100053, Peoples R China.
RP Zhao, L (reprint author), Capital Med Univ, Xuan Wu Hosp, Dept Anesthesiol, Beijing 100053, Peoples R China.
EM kitten15@126.com; w_tl5595@hotmail.com; fuwenya@163.com;
   wfy1204@hotmail.com; zhaoalei@sina.com
CR Arulkumaran N, 2014, BRIT J ANAESTH, V112, P648, DOI 10.1093/bja/aet466
   Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd
   de Letter JAM, 1998, NEUROL RES, V20, pS23
   de Tournay-Jette E, 2011, J CARDIOTHOR VASC AN, V25, P95, DOI 10.1053/j.jvca.2010.03.019
   Dyer RA, 2011, BRIT J ANAESTH, V106, P77, DOI 10.1093/bja/aeq292
   Dyer RA, 2011, CURR OPIN ANESTHESIO, V24, P255, DOI 10.1097/ACO.0b013e328345331c
   Frassanito L, 2012, EUR REV MED PHARMACO, V16, P1123
   Gatto M, 2012, AUTOIMMUN REV, V11, pA447, DOI 10.1016/j.autrev.2011.11.019
   Guerci P, 2014, CRIT CARE MED, V42, P2379, DOI 10.1097/CCM.0000000000000519
   Hauenstein E, 2010, J PERINAT MED, V38, P55, DOI 10.1515/JPM.2009.120
   Ioscovich A, 2008, INT J OBSTET ANESTH, V17, P358, DOI 10.1016/j.ijoa.2007.12.001
   Jonas Max M, 2002, Curr Opin Crit Care, V8, P257, DOI 10.1097/00075198-200206000-00010
   KERR GS, 1994, ANN INTERN MED, V120, P919
   Lavoie A, 2015, ANESTH ANALG, V121, P159, DOI 10.1213/ANE.0000000000000781
   Lobo SM, 2011, CRIT CARE, V15, DOI 10.1186/cc10466
   Mythen Monty G, 2012, Perioper Med (Lond), V1, P2, DOI 10.1186/2047-0525-1-2
   Nakayama M, 2002, EUR J ANAESTH, V19, P808, DOI 10.1017/S0265021502001308
   Ni C, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0117-6
   Rigamonti A, 2005, J CLIN ANESTH, V17, P426, DOI 10.1016/j.jclinane.2004.09.007
   Schon J, 2011, MINERVA ANESTESIOL, V77, P952
   Trafidlo T, 2015, INT J SURG
   Xiao W, 2015, CHINESE MED J-PEKING, V128, P1922, DOI 10.4103/0366-6999.160546
   Xiao W, 2014, CHINESE MED J-PEKING, V127, P2719, DOI 10.3760/cma.j.issn.0366-6999.20140306
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD SEP
PY 2016
VL 33
BP 168
EP 172
DI 10.1016/j.jclinane.2016.02.036
PG 5
WC Anesthesiology
SC Anesthesiology
GA DU7VD
UT WOS:000382421800034
PM 27555157
ER

PT J
AU Ouzir, M
   Errami, M
AF Ouzir, Mounir
   Errami, Mohammed
TI Etiological theories of addiction: A comprehensive update on
   neurobiological, genetic and behavioural vulnerability
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Review
DE Addiction; Evolutionary theory; Brain systems; Genetic vulnerability;
   Impulsivity; Sociocultural context; Creativity
ID CORTICOTROPIN-RELEASING-FACTOR; STRESS-INDUCED REINSTATEMENT;
   INCENTIVE-SENSITIZATION THEORY; CONDITIONED PLACE PREFERENCE;
   NUCLEUS-ACCUMBENS NEURONS; ONLINE SOCIAL NETWORKING; MULTISTEP
   GENERAL-THEORY; LOCUS-COERULEUS NEURONS; GRANULAR INSULAR CORTEX;
   KAPPA-OPIOID-SYSTEM
AB Currently, about 246 million people around the world have used an illicit drug. The reasons for this use are multiple: e.g. to augment the sensation of pleasure or to reduce the withdrawal and other aversive effects of a given substance. This raises the problem of addiction, which remains a disease of modern society. This review offers a comprehensive update of the different theories about the etiology of addictive behaviors with emphasis on the neurobiological, environmental, psychopathological, behavioural and genetic aspects of addictions, discussed from an evolutionary perspective. The main conclusion of this review is that vulnerability to drug addiction suggests an interaction between many brain systems (including the reward, decision-making, serotonergic, oxytocin, interoceptive insula, CRF, norepinephrine, dynorphin/KOR, orexin and vasopressin systems), genetic predisposition, sociocultural context, impulsivity and drugs types. Further advances in biological and psychological science are needed to address the problems of addiction at its roots. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ouzir, Mounir; Errami, Mohammed] Univ Abdelmalek Essaadi, Fac Sci, Dept Biol, Mhannech 2, Tetouan 93000, Morocco.
RP Ouzir, M (reprint author), Univ Abdelmalek Essaadi, Fac Sci, Dept Biol, Mhannech 2, Tetouan 93000, Morocco.
EM m.ouzir@gmail.com
RI Ouzir, Mounir/N-3939-2015
OI Ouzir, Mounir/0000-0001-6835-9755
CR Abel E.L, 1980, MARIJUANA 1 12000 YE
   Ahmed SH, 2014, PSYCHOPHARMACOLOGY, V231, P3909, DOI 10.1007/s00213-014-3622-2
   Alavi Seyyed Salman, 2012, Int J Prev Med, V3, P290
   Andreassen CS, 2014, CURR PHARM DESIGN, V20, P4053
   Anselme P, 2013, BEHAV BRAIN RES, V256, P1, DOI 10.1016/j.bbr.2013.07.039
   Antonil T, 1978, MAMA COCA
   APA, 2000, AM PSYCH ASS DIAGN S
   Aston-Jones G, 2009, NEUROPHARMACOLOGY, V56, P112, DOI 10.1016/j.neuropharm.2008.06.060
   Badiani A, 2014, PSYCHOPHARMACOLOGY, V231, P3923, DOI 10.1007/s00213-014-3627-x
   Bauer IE, 2015, AM J ADDICTION, V24, P15, DOI 10.1111/ajad.12172
   Becker B, 2015, BRAIN, V138, P2074, DOI 10.1093/brain/awv113
   Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136
   Berg SA, 2014, ADDICT BIOL, V19, P1020, DOI 10.1111/adb.12082
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berrettini WH, 2012, MOL PSYCHIATR, V17, P856, DOI 10.1038/mp.2011.122
   Bi Y., 2016, BRAIN IMAGI IN PRESS
   Bienkowski P, 2010, NEUROSCI LETT, V478, P161, DOI 10.1016/j.neulet.2010.05.008
   Bisagno V, 2014, BEHAV PHARMACOL, V25, P445, DOI 10.1097/FBP.0000000000000049
   BLOCK RI, 1992, PHARMACOL BIOCHEM BE, V43, P907, DOI 10.1016/0091-3057(92)90424-E
   Boorse GC, 2005, ENDOCRINOLOGY, V146, P4851, DOI 10.1210/en.2005-0497
   Bourassa M, 2000, CREATIVITY RES J, V13, P411
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   Bressan RA, 2005, ACTA PSYCHIAT SCAND, V111, P14, DOI 10.1111/j.1600-0447.2005.00540.x
   Brody AL, 2007, BIOL PSYCHIAT, V62, P642, DOI 10.1016/j.biopsych.2006.10.026
   Bruchas MR, 2010, BRAIN RES, V1314, P44, DOI 10.1016/j.brainres.2009.08.062
   BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V44, P36, DOI 10.1159/000124618
   Buhler K.M., 2015, ADDICT BIOL
   Buisman-Pijlman FTA, 2014, PHARMACOL BIOCHEM BE, V119, P22, DOI 10.1016/j.pbb.2013.09.005
   Butler TR, 2014, ALCOHOL CLIN EXP RES, V38, P2199, DOI 10.1111/acer.12476
   Butti C, 2010, BRAIN STRUCT FUNCT, V214, P477, DOI 10.1007/s00429-010-0264-y
   Calhoun A.J., 2015, NEURON
   Campbell UC, 2000, EXP CLIN PSYCHOPHARM, V8, P312, DOI 10.1037//1064-1297.8.3.312
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Carroll AJ, 2015, ADDICT BIOL, V20, P377, DOI 10.1111/adb.12118
   Casey KF, 2014, BIOL PSYCHIAT, V76, P23, DOI 10.1016/j.biopsych.2013.08.033
   Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Chang LJ, 2013, CEREB CORTEX, V23, P739, DOI 10.1093/cercor/bhs065
   Clarke TK, 2013, ADDICT BIOL, V18, P702, DOI 10.1111/j.1369-1600.2011.00346.x
   Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590
   Contreras M, 2012, NEUROPSYCHOPHARMACOL, V37, P2101, DOI 10.1038/npp.2012.59
   Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031
   de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x
   Dome P, 2010, NEUROSCI BIOBEHAV R, V34, P295, DOI 10.1016/j.neubiorev.2009.07.013
   Dong Y, 2006, NAT NEUROSCI, V9, P475, DOI 10.1038/nn1661
   Drake RE, 2007, WORLD PSYCHIATRY, V6, P131
   Droutman V, 2015, TRENDS COGN SCI, V19, P414, DOI 10.1016/j.tics.2015.05.005
   Duncan J.R., 2012, INT SCH RES NETW NEU, V24
   Dunn AJ, 2004, ANN NY ACAD SCI, V1018, P25, DOI 10.1196/annals.1296.003
   Durrant R, 2009, AUST NZ J PSYCHIAT, V43, P1049, DOI 10.3109/00048670903270449
   Duva SM, 2011, PSYCHIAT RES, V186, P351, DOI 10.1016/j.psychres.2010.08.014
   Ebrahimian F, 2016, BEHAV NEUROSCI, V130, P91, DOI 10.1037/bne0000112
   Echeburua E, 2010, ADICCIONES, V22, P91
   Economidou D, 2009, BIOL PSYCHIAT, V65, P851, DOI 10.1016/j.biopsych.2008.12.008
   Edwards Scott, 2010, Future Neurol, V5, P393, DOI 10.2217/fnl.10.14
   Ehrich JM, 2014, NEUROPSYCHOPHARMACOL, V39, P3036, DOI 10.1038/npp.2014.157
   EISENMAN R, 1980, Journal of Clinical Psychology, V36, P1013, DOI 10.1002/1097-4679(198010)36:4<1013::AID-JCLP2270360434>3.0.CO;2-0
   El-Guebaly N, 2007, ANN EPIDEMIOL, V17, pS55, DOI 10.1016/j.annepidem.2007.01.013
   Engelmann JM, 2012, NEUROIMAGE, V60, P252, DOI 10.1016/j.neuroimage.2011.12.024
   Epps C, 2012, PERIOPERATIVE ADDICTION: CLINICAL MANAGEMENT OF THE ADDICTED PATIENT, P35, DOI 10.1007/978-1-4614-0170-4_2
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   Evans Elizabeth A, 2014, Subst Abuse Rehabil, V5, P107, DOI 10.2147/SAR.S37917
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Fava GA, 2015, PSYCHOTHER PSYCHOSOM, V84, P72, DOI 10.1159/000370338
   Field M, 2007, ADDICTION, V102, P579, DOI 10.1111/j.1360-0443.2007.01743.x
   Foddy Bennett, 2010, Philos Psychiatr Psychol, V17, P1
   Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI 10.1016/j.biopsych.2010.01.029
   Foroud T, 2000, ALCOHOL CLIN EXP RES, V24, P933, DOI 10.1097/00000374-200007000-00001
   Fowler Joanna S, 2007, Sci Pract Perspect, V3, P4
   Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0
   Galvan A, 2011, NEUROPSYCHOPHARMACOL, V36, P970, DOI 10.1038/npp.2010.235
   George O, 2014, PSYCHOPHARMACOLOGY, V231, P3911, DOI 10.1007/s00213-014-3623-1
   Gerald MS, 2002, ADDICTION, V97, P415, DOI 10.1046/j.1360-0443.2002.00023.x
   Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021
   Goodson JL, 2012, HORM BEHAV, V61, P239, DOI 10.1016/j.yhbeh.2012.01.005
   Green B, 2003, DRUG ALCOHOL REV, V22, P453, DOI 10.1080/09595230310001613976
   Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI DOI 10.1080/14659890500114359
   Griffiths M. D., 2013, ADDICT RES THEORY, V4, pe118
   Gschwind M., 2014, EPILEPTOLOGIE, V31, P87
   Gunderson EW, 2013, J ADDICT MED, V7, P153, DOI 10.1097/ADM.0b013e31829084b7
   HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64
   Hayashi T, 2013, P NATL ACAD SCI USA, V110, P4422, DOI 10.1073/pnas.1212185110
   Heath DB, 2001, PSYCHIAT CLIN N AM, V24, P479, DOI 10.1016/S0193-953X(05)70242-2
   Heilman KM, 2003, NEUROCASE, V9, P369, DOI 10.1076/neur.9.5.369.16553
   Herman AI, 2011, ADDICT BIOL, V16, P124, DOI 10.1111/j.1369-1600.2009.00197.x
   Hill EM, 2013, PRINCIPLES OF ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 1, P41, DOI 10.1016/B978-0-12-398336-7.00004-8
   Hill EM, 2002, ADDICTION, V97, P375, DOI 10.1046/j.1360-0443.2002.t01-1-00057.x
   Hill SL, 2013, CLIN TOXICOL, V51, P487, DOI 10.3109/15563650.2013.802795
   Hill SL, 2011, CLIN TOXICOL, V49, P705, DOI 10.3109/15563650.2011.615318
   Hogarth L, 2011, PSYCHOPHARMACOLOGY, V215, P567, DOI 10.1007/s00213-011-2172-0
   Holm-Hadulla RM, 2014, PSYCHOPATHOLOGY, V47, P167, DOI 10.1159/000354617
   Huang YH, 2008, J BIOL CHEM, V283, P2751, DOI 10.1074/jbc.M706578200
   Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Jentsch JD, 2014, ANN NY ACAD SCI, V1327, P1, DOI 10.1111/nyas.12388
   Jupp B, 2013, DIS MODEL MECH, V6, P302, DOI 10.1242/dmm.010934
   KAMALI K, 1976, INT J ADDICT, V11, P337
   Kandel ER, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-14
   Karban R, 1997, INDUCED RESPONSES HE
   Karkhanis AN, 2014, ALCOHOL CLIN EXP RES, V38, P2770, DOI 10.1111/acer.12555
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Kieffer BL, 2003, MOLECULAR BIOLOGY OF DRUG ADDICTION, P3
   Kirby LG, 2011, NEUROPHARMACOLOGY, V61, P421, DOI 10.1016/j.neuropharm.2011.03.022
   Koo JW, 2012, SCIENCE, V338, P124, DOI 10.1126/science.1222265
   Koob GF, 2008, NEURON, V59, P11, DOI 10.1016/j.neuron.2008.06.012
   Koob GF, 2015, EUR J PHARMACOL, V753, P73, DOI 10.1016/j.ejphar.2014.11.044
   Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI [10.1016/j.neuropharm.2013.05.024, 10.1016/j.neuropharm2013.05.024]
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Koob GF, 1999, ANN NY ACAD SCI, V897, P27, DOI 10.1111/j.1749-6632.1999.tb07876.x
   Koob G. F, 2007, STRESS ADDICTION BIO
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Kowal MA, 2015, PSYCHOPHARMACOLOGY, V232, P1123, DOI 10.1007/s00213-014-3749-1
   Kravets JL, 2015, BRAIN STRUCT FUNCT, V220, P541, DOI 10.1007/s00429-013-0674-8
   Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583
   Kuss Daria J, 2012, Brain Sci, V2, P347, DOI 10.3390/brainsci2030347
   Kuss DJ, 2011, INT J ENV RES PUB HE, V8, P3528, DOI 10.3390/ijerph8093528
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   LANG AR, 1984, ADDICT BEHAV, V9, P395, DOI 10.1016/0306-4603(84)90040-6
   Lang E, 2004, DRUG USE AUSTR PREVE, P1
   LAPP WM, 1994, AM J PSYCHOL, V107, P173, DOI 10.2307/1423036
   Le Foll Bernard, 2015, Curr Top Behav Neurosci, V24, P155, DOI 10.1007/978-3-319-13482-6_6
   Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009
   Lende DH, 2002, ADDICTION, V97, P447, DOI 10.1046/j.1360-0443.2002.00022.x
   Lende D.H., 2008, EVOLUTIONARY MED HLT, P277
   Levran O, 2012, HUM GENET, V131, P823, DOI 10.1007/s00439-012-1172-4
   Li CL, 2013, J PSYCHOPHARMACOL, V27, P837, DOI 10.1177/0269881113492028
   Li MD, 2009, NAT REV GENET, V10, P225, DOI 10.1038/nrg2536
   Li Zhong, 2013, J Addict Res Ther, VSuppl 7, P007
   Lieb R., 2015, COOCCURRING ADDICTIV
   Lin X., 2015, BEHAV BRAIN RES, V279, P240
   Logrip ML, 2011, CNS DRUGS, V25, P271, DOI 10.2165/11587790-000000000-00000
   Mackey S, 2013, NEUROSCI BIOBEHAV R, V37, P300, DOI 10.1016/j.neubiorev.2012.12.003
   Madsen HB, 2012, PSYCHOPHARMACOLOGY, V219, P699, DOI 10.1007/s00213-011-2406-1
   Mahler SV, 2012, PROG BRAIN RES, V198, P79, DOI 10.1016/B978-0-444-59489-1.00007-0
   Malekshahi T, 2015, J SUBST ABUSE TREAT, V48, P8, DOI 10.1016/j.jsat.2014.07.006
   Marchant NJ, 2007, J COMP NEUROL, V504, P702, DOI 10.1002/cne.21464
   Maria MMMS, 2015, ADDICT BIOL, V20, P407, DOI 10.1111/adb.12124
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200
   Mengod G., 2010, HDB BEHAV NEUROBIOLO, P319
   Mewes HW, 2010, PHARMACOPSYCHIATRY, V43, pS2, DOI 10.1055/s-0030-1249666
   Moallem NR, 2012, ADDICT BEHAV, V37, P871, DOI 10.1016/j.addbeh.2012.03.002
   Moorman D. E., 2005, BRAIN RES A, V1628, P130
   Morales AM, 2014, NEUROPSYCHOPHARMACOL, V39, P1816, DOI 10.1038/npp.2014.48
   Muller CP, 2015, BEHAV BRAIN RES, V277, P146, DOI 10.1016/j.bbr.2014.04.007
   Muller CP, 2010, HBK BEHAV NEUROSCI, V21, P507, DOI 10.1016/B978-0-12-374634-4.00031-9
   Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926
   Naqvi NH, 2014, ANN NY ACAD SCI, V1316, P53, DOI 10.1111/nyas.12415
   Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7
   Navarro G, 2015, J NEUROSCI, V35, P6639, DOI 10.1523/JNEUROSCI.4364-14.2015
   Nesse RM, 1997, SCIENCE, V278, P63, DOI 10.1126/science.278.5335.63
   NESSE RM, 1994, ETHOL SOCIOBIOL, V15, P339, DOI 10.1016/0162-3095(94)90007-8
   Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nielsen Margrethe, 2013, Int J Risk Saf Med, V25, P155, DOI 10.3233/JRS-130594
   Nielsen M, 2012, ADDICTION, V107, P900, DOI 10.1111/j.1360-0443.2011.03686.x
   NIKOLARAKIS KE, 1986, BRAIN RES, V399, P152, DOI 10.1016/0006-8993(86)90610-4
   NOVACEK J, 1991, J YOUTH ADOLESCENCE, V20, P475, DOI 10.1007/BF01540632
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Ouzir M, 2013, AGGRESS VIOLENT BEH, V18, P247, DOI 10.1016/j.avb.2012.11.014
   Palmer RHC, 2015, ADDICTION, V110, P530, DOI 10.1111/add.12815
   Pandey SC, 2005, ALCOHOL CLIN EXP RES, V29, P176, DOI 10.1097/01.ALC.0000153550.31168.ID
   Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x
   Panksepp J., 2000, EVOLUTION COGNITION, V6, P108
   Peele S, 2000, DRUG ALCOHOL DEPEN, V60, P221, DOI 10.1016/S0376-8716(00)00112-5
   PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441
   Piazza PV, 2013, PSYCHOPHARMACOLOGY, V229, P387, DOI 10.1007/s00213-013-3224-4
   POST F, 1994, BRIT J PSYCHIAT, V165, P22, DOI 10.1192/bjp.165.1.22
   Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
   Pushparaj A, 2013, NEUROPSYCHOPHARMACOL, V38, P690, DOI 10.1038/npp.2012.235
   RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7
   Redila VA, 2008, PSYCHOPHARMACOLOGY, V200, P59, DOI 10.1007/s00213-008-1122-y
   Reyes BAS, 2011, EXP NEUROL, V230, P96, DOI 10.1016/j.expneurol.2011.04.001
   Reyes BAS, 2008, ENDOCRINOLOGY, V149, P122, DOI 10.1210/en.2007-0705
   Roberts M. F., 1998, ALKALOIDS BIOCH ECOL
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rodriguez-Borrero E, 2010, NEUROPHARMACOLOGY, V58, P88, DOI 10.1016/j.neuropharm.2009.06.040
   Ross S, 2009, CLIN NEUROPHARMACOL, V32, P269, DOI 10.1097/WNF.0b013e3181a9163c
   Rothman RB, 2001, SYNAPSE, V39, P32, DOI 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3
   Saah Tammy, 2005, Harm Reduct J, V2, P8, DOI 10.1186/1477-7517-2-8
   Sakamoto F, 2004, REGUL PEPTIDES, V118, P183, DOI 10.1016/j.regpep.2003.12.014
   Sakurai T, 2014, NAT REV NEUROSCI, V15, P719, DOI 10.1038/nrn3837
   Salamone JD, 2012, NEURON, V76, P470, DOI 10.1016/j.neuron.2012.10.021
   Samaha AN, 2014, PROG NEURO-PSYCHOPH, V52, P9, DOI 10.1016/j.pnpbp.2013.06.008
   Saniotis A., 2013, HUMANITIES, V2, P278
   Sarnyai Z, 2001, PHARMACOL REV, V53, P209
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Schoenbaum G, 2008, BIOL PSYCHIAT, V63, P256, DOI 10.1016/j.biopsych.2007.06.003
   Schuckit MA, 2001, ALCOHOL CLIN EXP RES, V25, P323, DOI 10.1111/j.1530-0277.2001.tb02217.x
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2
   Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1
   Siegel R.K., 2005, INTOXICATION UNIVERS
   Sieminska A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-274
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Smith Iain, 2015, Int Rev Neurobiol, V120, P301, DOI 10.1016/bs.irn.2015.04.001
   Smith RJ, 2008, BRAIN STRUCT FUNCT, V213, P43, DOI 10.1007/s00429-008-0191-3
   Stoeckel L.E., 2015, ADDICT BIOL IN PRESS
   Subiah CO, 2012, METAB BRAIN DIS, V27, P341, DOI 10.1007/s11011-012-9297-7
   Sulzer D, 2005, PROG NEUROBIOL, V75, P406, DOI 10.1016/j.pneurobio.2005.04.003
   Sutherland MT, 2013, BIOL PSYCHIAT, V74, P538, DOI 10.1016/j.biopsych.2013.01.035
   Sutherland MT, 2013, PSYCHOPHARMACOLOGY, V228, P143, DOI 10.1007/s00213-013-3018-8
   TART CT, 1970, NATURE, V226, P701, DOI 10.1038/226701a0
   TINKLENBERG JR, 1978, J NERV MENT DIS, V166, P362, DOI 10.1097/00005053-197805000-00008
   Todkar A, 2013, TRANSL NEUROSCI, V4, P241, DOI 10.2478/s13380-013-0121-6
   Troland L.T., 1928, FUNDAMENTALS HUMAN M
   Turel O, 2014, PSYCHOL REP, V115, P675, DOI 10.2466/18.PR0.115c31z8
   United Nations Office on Drugs and Crime (UNODC), 2015, WORLD DRUG REP 2015
   Valdez GR, 2007, J PHARMACOL EXP THER, V323, P525, DOI 10.1124/jpet.107.125484
   Van Bockstaele EJ, 2010, BRAIN RES, V1314, P162, DOI 10.1016/j.brainres.2009.09.036
   Van Bockstaele EJ, 1998, J NEUROENDOCRINOL, V10, P743, DOI 10.1046/j.1365-2826.1998.00254.x
   Vargas-Perez H, 2014, J NEUROSCI, V34, P7899, DOI 10.1523/JNEUROSCI.3776-13.2014
   Vizi E.S., 2007, EUR REV, V15, P241
   Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   Walters CL, 2003, J NEUROCHEM, V87, P1237, DOI 10.1046/j.1471-4159.2003.02090.x
   Weaver Michael F, 2015, Addict Sci Clin Pract, V10, P8, DOI 10.1186/s13722-015-0024-7
   Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263
   Whitaker LR, 2013, NEURON, V77, P335, DOI 10.1016/j.neuron.2012.11.022
   Winsky-Sommerer R, 2004, J NEUROSCI, V24, P11439, DOI 10.1523/JNEUROSCI.3459-04.2004
   Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wise RA, 2014, NEUROPSYCHOPHARMACOL, V39, P254, DOI 10.1038/npp.2013.261
   Xu F, 2000, NAT NEUROSCI, V3, P465
   Yates D, 2012, NAT REV NEUROSCI, V13, P445, DOI 10.1038/nrn3252
   Yeoh JW, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00036
   Yuferov V, 2004, PHARMACOGENETICS, V14, P793, DOI 10.1097/00008571-200412000-00002
   Zhang H, 2008, MOL PSYCHIATR, V13, P531, DOI 10.1038/sj.mp.4002035
   Zhang XC, 2011, NEUROIMAGE, V54, P42, DOI 10.1016/j.neuroimage.2010.08.008
   Zhou Luyi, 2011, Pharmaceuticals (Basel), V4, P804
   Zhou Y, 2005, NEUROSCIENCE, V134, P1391, DOI 10.1016/j.neuroscience.2005.05.032
   Zhou Y, 2008, NEUROPSYCHOPHARMACOL, V33, P226, DOI 10.1038/sj.npp.1301419
   Zhou Yan, 2016, Prog Brain Res, V223, P237, DOI 10.1016/bs.pbr.2015.09.001
   Zhou Y, 2011, ALCOHOL CLIN EXP RES, V35, P1876, DOI 10.1111/j.1530-0277.2011.01532.x
   Zhu Y., 2015, BIOMED RES INT, P378
   Zorrilla EP, 2014, FRONT NEUROENDOCRIN, V35, P234, DOI 10.1016/j.yfrne.2014.01.001
NR 237
TC 0
Z9 0
U1 29
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD SEP
PY 2016
VL 148
BP 59
EP 68
DI 10.1016/j.pbb.2016.06.005
PG 10
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA DU6TP
UT WOS:000382347800009
PM 27306332
ER

PT J
AU Downing, JW
   Baysinger, CL
   Johnson, RF
   Paschall, RL
   Shotwell, MS
AF Downing, John W.
   Baysinger, Curtis L.
   Johnson, Raymond F.
   Paschall, Ray L.
   Shotwell, Matthew S.
TI The Effects of Vasopressin and Oxytocin on the Fetoplacental Distal Stem
   Arteriolar Vascular Resistance of the Dual-Perfused, Single, Isolated,
   Human Placental Cotyledon
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID HUMAN UMBILICAL ARTERY; UTERINE CONTRACTIONS; CESAREAN DELIVERY;
   RECEPTORS; VASOCONSTRICTION; FLOW; CIRCULATION; HYPOTENSION; PREGNANCY;
   5-HT
AB BACKGROUND: Vasoactive agents administered to counter maternal hypotension at cesarean delivery may theoretically intensify the hypoxemic fetoplacental vasoconstrictor response and, hence, negatively impact transplacental oxygen delivery-to the fetus. Yet, this aspect of their pharmacodynamic profiles is seldom mentioned, let alone investigated. We hypothesized that vasopressin, a potent systemic vasoconstrictor, and oxytocin, a uterotonic agent administered routinely at cesarean delivery, which, in contrast to vasopressin, possesses significant systemic vasodilator properties, would not influence distal stem villous arteriolar resistance.
   METHODS: The dual-perfused, single, isolated cotyledon, human placental perfusion model was used to examine the resistance response of the fetoplacental circulation to oxytocin and vasopressin in placentae harvested from healthy women. Twelve of a total of 17 individual experiments were conducted successfully during which either oxytocin (n = 6) or vasopressin (n = 6) was introduced into the fetal reservoir in concentration increments of 10(-1) M. Fetoplacental distal stem villous arteriolar perfusion pressure (FAP) was measured continuously. The fetal circuit concentration of either oxytocin or vasopressin was raised in a stepwise fashion from 109 to 10(-6) M or 10(-11) to 10(-6) M, respectively. Both reservoirs were then purged of drug, after which 1-mL 1.0 mM 5-hydroxytryptamine (2.5 mu M), an agent well known to manifestly increase fetoplacental distal stem villous arteriolar resistance, was introduced into the fetal circuit. A significant increase in FAP from baseline in response to exposure to 5-hydroxytryptamine confirmed that the fetoplacental vasoconstrictor response remained reactive. The primary outcome of this study was changes in FAP after incremental dosing of vasopressin and oxytocin.
   RESULTS: No changes in FAP were observed with either oxytocin or vasopressin regardless of the drug concentration tested. For each drug and concentration, a mean pressure change greater than +/- 10 mm Hg was excluded with 95% confidence. In contrast, 5-hydroXytryptamine significantly increased perfusion pressure in all 12 successful experiments.
   CONCLUSIONS: Oxytocin and vasopressin do not influence human fetoplacental' distal stem villous arteriolar resistance. The neutral impact of vasopressin noted here is thus analogous to the reported negligible influence of the drug on human pulmonary arteriolar resistance. Neither drug seems likely to adversely influence the compensatory hypoxemic fetoplacental vasoconstrictor response.
C1 [Downing, John W.; Baysinger, Curtis L.; Johnson, Raymond F.; Paschall, Ray L.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37212 USA.
   [Shotwell, Matthew S.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
RP Downing, JW (reprint author), 4202 Vanderbilt Univ Hosp, Div Obstet Anesthesia, Dept Anesthesiol, 1211 22nd Ave South, Nashville, TN 37232 USA.
EM john.downing@vanderbilt.edu
CR Alahuhta S, 1992, Int J Obstet Anesth, V1, P129, DOI 10.1016/0959-289X(92)90016-W
   ALLEN J, 1989, J HYPERTENS, V7, P529, DOI 10.1097/00004872-198907000-00004
   Bachmaier N, 2007, PLACENTA, V28, P861, DOI 10.1016/j.placenta.2007.01.001
   Butwick AJ, 2015, BRIT J ANAESTH, V114, P183, DOI 10.1093/bja/aeu267
   Byrne BM, 1997, PLACENTA, V18, P627, DOI 10.1016/S0143-4004(97)90003-5
   Chen YL, 1999, EUR J PHARMACOL, V376, P45, DOI 10.1016/S0014-2999(99)00351-9
   Clark SL, 2009, AM J OBSTET GYNECOL, V200
   Currigan DA, 2014, ANESTHESIOLOGY, V121, P930, DOI 10.1097/ALN.0000000000000430
   DEVANE GW, 1982, PEDIATR RES, V16, P504
   Dyer RA, 2010, INT J OBSTET ANESTH, V19, P313, DOI 10.1016/j.ijoa.2010.04.011
   Holcberg G, 1999, EUR J OBSTET GYN R B, V87, P147, DOI 10.1016/S0301-2115(99)00099-8
   Jakoubek V, 2006, PLACENTA, V27, P1030, DOI 10.1016/j.placenta.2005.10.006
   Jochberger Stefan, 2008, Best Pract Res Clin Anaesthesiol, V22, P383, DOI 10.1016/j.bpa.2008.04.002
   Jovanovic A, 1997, BRIT J PHARMACOL, V121, P1468, DOI 10.1038/sj.bjp.0701273
   JOVANOVIC A, 1995, BRIT J PHARMACOL, V115, P1295
   Li H, 2003, EARLY HUM DEV, V74, P47, DOI 10.1016/S0378-3782(03)00084-7
   Li H, 2006, EARLY HUM DEV, V82, P747, DOI 10.1016/j.earlhumdev.2006.03.011
   Lovren F, 1999, BRIT J PHARMACOL, V127, P1247, DOI 10.1038/sj.bjp.0702647
   MAIGAARD S, 1986, ACTA PHYSIOL SCAND, V128, P23, DOI 10.1111/j.1748-1716.1986.tb07945.x
   Minzter BH, 2010, ANESTH ANALG, V110, P857, DOI 10.1213/ANE.0b013e3181c91ebc
   Olofsson P, 1996, ULTRASOUND OBST GYN, V8, P247, DOI 10.1046/j.1469-0705.1996.08040247.x
   POHJAVUORI M, 1980, J PEDIATR-US, V97, P462, DOI 10.1016/S0022-3476(80)80206-X
   Radenkovic M, 2009, PHARMACOL REP, V61, P520
   Ramasubramanian R, 2006, ANESTH ANALG, V103, P439, DOI 10.1213/01.ane.0000222468.76942.d8
   Riley ET, 2004, BRIT J ANAESTH, V92, P459, DOI 10.1093/bja/aeh084
   Sasaki S, 2008, J AM SOC NEPHROL, V19, P189, DOI 10.1681/ASN.2007121319
   Tahara M, 2009, J OBSTET GYNAECOL RE, V35, P850, DOI 10.1111/j.1447-0756.2009.01064.x
   Thornton S, 2002, BJOG-INT J OBSTET GY, V109, P57
   Treschan TA, 2006, ANESTHESIOLOGY, V105, P599, DOI 10.1097/00000542-200609000-00026
   Tsen LC, 2010, INT J OBSTET ANESTH, V19, P243, DOI 10.1016/j.ijoa.2010.05.001
   Ugun-Klusek A, 2011, VASC PHARMACOL, V55, P157, DOI 10.1016/j.vph.2011.07.006
   Vedernikov YP, 2006, AM J OBSTET GYNECOL, V194, P252, DOI 10.1016/j.ajog.2005.05.006
   Wheeler AD, 2008, J CLIN ANESTH, V20, P139, DOI 10.1016/j.jclinane.2007.06.023
NR 33
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 2016
VL 123
IS 3
BP 698
EP 702
DI 10.1213/ANE.0000000000001449
PG 5
WC Anesthesiology
SC Anesthesiology
GA DT9RA
UT WOS:000381838800021
PM 27537759
ER

PT J
AU Brune, M
AF Bruene, Martin
TI On the role of oxytocin in borderline personality disorder
SO BRITISH JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Review
DE borderline personality disorder; oxytocin; attachment; childhood
   adversity; developmental plasticity; intergenerational transmission
ID GENE OXTR POLYMORPHISM; RECEPTOR GENE; INTRANASAL-OXYTOCIN; PROSOCIAL
   BEHAVIOR; STRESS REACTIVITY; SOCIAL-BEHAVIOR; BIOLOGICAL SENSITIVITY;
   PSYCHIATRIC-DISORDERS; AMYGDALA REACTIVITY; FAMILY ENVIRONMENT
AB ObjectivesInterpersonal dysfunction is central to borderline personality disorder (BPD). Recent research has focused on the role of oxytocin (OT) in BPD, particularly regarding associations of OT activity with symptoms, genetic polymorphisms of the oxytocin receptor coding gene (OXTR) in BPD, and experimental modification of interpersonal core problems of patients with BPD such as hypervigilance towards threat detection, mistrust, and non-verbal behaviour during social interaction by intranasal application of OT.
   MethodsA literature (medline') review was performed using the keywords oxytocin' and borderline personality disorder'. Secondary literature on trauma and attachment in relation to OT was also considered relevant.
   ResultsTogether, findings suggest that in BPD OT is associated with enhanced defensive mechanisms and avoidance behaviour. Moreover, gene-environment interaction concerning polymorphic variations of the OXTR gene and childhood adversity in BPD suggests that these genes convey developmental flexibility or differential susceptibility' to environmental contingencies, whereby BPD resides at the poor outcome end of the spectrum.
   ConclusionsIn view of the conflicting literature, it needs to be studied carefully whether OT can serve as a therapeutic agent given adjunct to psychotherapy in BPD. More research about the role of OT is also required with regard to the prevention of the non-genetic intergenerational transmission of BPD. Clarifying the role of OT in BPD may also benefit from research in non-human animals targeting the interaction between early adversity and OT availability more directly.
   Practitioner points
   The study of oxytocin can contribute to the understanding of the neurobiology of borderline personality disorder. Oxytocin is critically involved in attachment security, and methylation of the oxytocin receptor may play a role in the epigenetic modulation of early adversity. The intranasal application of oxytocin may be a useful therapeutic adjunct to psychotherapy. Insecure attachment and childhood adversity may produce differential neurobiological effects on the oxytocinergic system in borderline personality disorder. There is insufficient knowledge of how oxytocin interacts with vasopressin, testosterone, dopamine, and serotonin, which are also important key players in the experience of social reward and stress responsivity. It is unclear whether or not oxytocin could be beneficial in preventing the intergenerational (non-genetic) transmission of borderline personality traits.
C1 [Bruene, Martin] Ruhr Univ Bochum, Div Cognit Neuropsychiat & Psychiat Prevent Med, Dept Psychiat Psychotherapy & Prevent Med, LWL Univ Hosp, Alexandrinenstr 1, D-44791 Bochum, Germany.
RP Brune, M (reprint author), Ruhr Univ Bochum, Div Cognit Neuropsychiat & Psychiat Prevent Med, Dept Psychiat Psychotherapy & Prevent Med, LWL Univ Hosp, Alexandrinenstr 1, D-44791 Bochum, Germany.
EM martin.bruene@rub.de
OI Brune, Martin/0000-0002-2507-0561
CR Abi-Dargham A, 2012, BIOL PSYCHIAT, V72, P171, DOI 10.1016/j.biopsych.2012.05.007
   Ahern TH, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.017.2009
   Amad A, 2014, NEUROSCI BIOBEHAV R, V40, P6, DOI 10.1016/j.neubiorev.2014.01.003
   American Psychiatric Association (APA), 2013, DIAGN STA TMANT MENT
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Bakermans-Kranenburg MJ, 2006, DEV PSYCHOBIOL, V48, P406, DOI 10.1002/dev.20152
   Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085
   Bateman A, 2004, PSYCHOTHERAPY BORDER
   Belsky J, 2009, MOL PSYCHIATR, V14, P746, DOI 10.1038/mp.2009.44
   Bertsch K, 2013, AM J PSYCHIAT, V170, P1169, DOI 10.1176/appi.ajp.2013.13020263
   Bertsch K, 2013, HORM BEHAV, V63, P424, DOI 10.1016/j.yhbeh.2012.11.013
   Boyce WT, 2005, DEV PSYCHOPATHOL, V17, P271, DOI 10.1017/S0954579405050145
   Bradley B, 2013, EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.21659
   Bradley B, 2011, DEV PSYCHOPATHOL, V23, P439, DOI 10.1017/S0954579411000162
   Brune M, 2015, J NERV MENT DIS, V203, P107, DOI 10.1097/NMD.0000000000000240
   Brune M, 2013, HUM PSYCHOPHARM CLIN, V28, P552, DOI 10.1002/hup.2343
   Brune M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-38
   Bungert M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133693
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P3172, DOI 10.1016/j.psyneuen.2013.08.002
   Cassidy J, 2001, CLIN PSYCHOL-SCI PR, V8, P275, DOI 10.1093/clipsy/8.3.275
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Choi-Kain LW, 2008, AM J PSYCHIAT, V165, P1127, DOI 10.1176/appi.ajp.2008.07081360
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cicchetti D, 2014, DEV PSYCHOPATHOL, V26, P831, DOI 10.1017/S095457941400042X
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   Crespi BJ, 2016, BIOL REV, V91, P390, DOI 10.1111/brv.12175
   Cullen Kathryn R, 2011, Brain Connect, V1, P61, DOI 10.1089/brain.2010.0001
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P21, DOI 10.1017/S0954579413000485
   Davis MC, 2014, NEUROPSYCHOPHARMACOL, V39, P2070, DOI 10.1038/npp.2014.68
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Domes G, 2014, NEUROPSYCHOPHARMACOL, V39, P698, DOI 10.1038/npp.2013.254
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ebert A, 2013, SOC NEUROSCI-UK, V8, P305, DOI 10.1080/17470919.2013.807301
   Egert S, 2015, VERHALTENSTHERAPIE, V25, P45, DOI 10.1159/000368432
   Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134
   Ellis BJ, 2013, HORM BEHAV, V64, P215, DOI 10.1016/j.yhbeh.2013.02.012
   Ellis BJ, 2011, DEV PSYCHOPATHOL, V23, P85, DOI 10.1017/S0954579410000660
   Evans S, 2010, NEUROPSYCHOPHARMACOL, V35, P2502, DOI 10.1038/npp.2010.110
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Fonagy P, 2000, PSYCHIAT CLIN N AM, V23, P103, DOI 10.1016/S0193-953X(05)70146-5
   Franzen N, 2011, PSYCHIAT RES, V187, P224, DOI 10.1016/j.psychres.2010.11.012
   Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724
   Gilbert P, 2012, PSYCHOL PSYCHOTHER-T, V85, P374, DOI 10.1111/j.2044-8341.2011.02046.x
   Gremaud-Heitz D, 2014, COMPR PSYCHIAT, V55, P650, DOI 10.1016/j.comppsych.2013.11.021
   Grillon C, 2013, MOL PSYCHIATR, V18, P958, DOI 10.1038/mp.2012.156
   Groppe SE, 2013, BIOL PSYCHIAT, V74, P172, DOI 10.1016/j.biopsych.2012.12.023
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Gunderson JG, 2007, AM J PSYCHIAT, V164, P1637, DOI 10.1176/appi.ajp.2007.07071125
   Haller J, 2014, J NEUROENDOCRINOL, V26, P724, DOI 10.1111/jne.12182
   Hammen C, 2015, J PERS DISORD, V29, P177, DOI 10.1521/pedi_2014_28_152
   Hazlett EA, 2012, BIOL PSYCHIAT, V72, P448, DOI 10.1016/j.biopsych.2012.03.027
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hill KT, 2014, BEHAV BRAIN RES, V272, P175, DOI 10.1016/j.bbr.2014.07.001
   Huffmeijer R, 2013, HORM BEHAV, V63, P399, DOI 10.1016/j.yhbeh.2012.11.008
   Jobst A, 2014, PSYCHOTHER PSYCHOSOM, V83, P252, DOI 10.1159/000358526
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   KALIN NH, 1985, LIFE SCI, V36, P1275, DOI 10.1016/0024-3205(85)90272-3
   Kim S, 2014, PERSONAL DISORD, V5, P125, DOI 10.1037/per0000038
   King-Casas B, 2008, SCIENCE, V321, P806, DOI 10.1126/science.1156902
   Knobloch HS, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00031
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krause-Utz A, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0438-z
   Kumsta R, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00083
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Limberg A, 2011, BIOL PSYCHIAT, V69, P574, DOI 10.1016/j.biopsych.2010.10.024
   Longe O, 2010, NEUROIMAGE, V49, P1849, DOI 10.1016/j.neuroimage.2009.09.019
   Love TM, 2012, BIOL PSYCHIAT, V72, P198, DOI 10.1016/j.biopsych.2012.01.033
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   McQuaid RJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00128
   Meinlschmidt G, 2007, BIOL PSYCHIAT, V61, P1109, DOI 10.1016/j.biopsych.2006.09.007
   Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663, DOI 10.1038/nn.3083
   Montag C, 2011, BIOL PSYCHIAT, V69, P601, DOI 10.1016/j.biopsych.2010.10.026
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Newman LK, 2007, AUST NZ J PSYCHIAT, V41, P598, DOI 10.1080/00048670701392833
   Ohtsubo Y, 2014, PERS INDIV DIFFER, V69, P182, DOI 10.1016/j.paid.2014.05.033
   Olff M, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.26513
   Paris Joel, 2004, Curr Psychiatry Rep, V6, P71, DOI 10.1007/s11920-004-0042-8
   Perroud N, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.140
   Poulin MJ, 2013, HORM BEHAV, V63, P510, DOI 10.1016/j.yhbeh.2013.01.004
   Quirin M, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01074
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   Radke S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00193
   Reiner I, 2015, J PSYCHIATR RES, V65, P9, DOI 10.1016/j.jpsychires.2015.03.012
   Rich ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098839
   Riem MME, 2013, PSYCHONEUROENDOCRINO, V38, P1418, DOI 10.1016/j.psyneuen.2012.12.023
   Rockliff H, 2011, EMOTION, V11, P1388, DOI 10.1037/a0023861
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Roisman GI, 2013, ATTACH HUM DEV, V15, P384, DOI 10.1080/14616734.2013.768790
   Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976
   Sauer C, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00045
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Schulze L, 2016, BIOL PSYCHIAT, V79, P97, DOI 10.1016/j.biopsych.2015.03.027
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Simeon D, 2011, PSYCHONEUROENDOCRINO, V36, P1418, DOI 10.1016/j.psyneuen.2011.03.013
   Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535
   Stanley B, 2010, AM J PSYCHIAT, V167, P24, DOI 10.1176/appi.ajp.2009.09050744
   Stepp SD, 2012, PERSONAL DISORD, V3, P76, DOI 10.1037/a0023081
   Stoffers J, 2010, COCHRANE DB SYST REV, V6, DOI [10.1002/14651858.CD005653.pub2, DOI 10.1002/14651858]
   Stoffers JM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005652.pub2
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Taylor SE, 2006, BIOL PSYCHIAT, V60, P671, DOI 10.1016/j.biopsych.2006.04.019
   Taylor SE, 2006, CURR DIR PSYCHOL SCI, V15, P273, DOI 10.1111/j.1467-8721.2006.00451.x
   Tops Mattie, 2013, Front Psychol, V4, P761, DOI 10.3389/fpsyg.2013.00761
   Troisi A, 1999, NEUROSCI BIOBEHAV R, V23, P905, DOI 10.1016/S0149-7634(99)00024-X
   Unoka Z, 2009, J PERS DISORD, V23, P399, DOI 10.1521/pedi.2009.23.4.399
   Unternaehrer E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.77
   vansIJzendoorn M. H., 1995, J CHILD PSYCHOL PSYC, V36, P225
   vansIJzendoorn M. H., 1999, DEV PSYCHOPATHOL, V11, P225, DOI [10.1017/S0954579499002035, DOI 10.1017/S0954579499002035]
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Weisman O, 2013, PSYCHONEUROENDOCRINO, V38, P694, DOI 10.1016/j.psyneuen.2012.08.011
   Widom CS, 2006, BIOL PSYCHIAT, V60, P684, DOI 10.1016/j.biopsych.2006.03.039
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Winslow JT, 2003, NEUROPSYCHOPHARMACOL, V28, P910, DOI 10.1038/sj.npp.1300128
   Ziegler T., 2005, P NATL ACAD SCI USA, V102, P237, DOI DOI 10.1073/PNAS.0504767102
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Zhang TY, 2010, ANNU REV PSYCHOL, V61, P439, DOI 10.1146/annurev.psych.60.110707.163625
NR 128
TC 0
Z9 0
U1 16
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0144-6657
EI 2044-8260
J9 BRIT J CLIN PSYCHOL
JI Br. J. Clin. Psychol.
PD SEP
PY 2016
VL 55
IS 3
BP 287
EP 304
DI 10.1111/bjc.12100
PG 18
WC Psychology, Clinical
SC Psychology
GA DS6SB
UT WOS:000380911600005
PM 26616386
ER

PT J
AU Gimpl, G
AF Gimpl, Gerald
TI Interaction of G protein coupled receptors and cholesterol
SO CHEMISTRY AND PHYSICS OF LIPIDS
LA English
DT Article
DE Cholesterol; GPCR; Crystallization; Conformation; Receptor; Stability
ID MOLECULAR-DYNAMICS SIMULATIONS; RESOLUTION CRYSTAL-STRUCTURE; OXYTOCIN
   RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MEMBRANE CHOLESTEROL;
   BINDING-SITES; SEROTONIN(1A) RECEPTOR; STRUCTURAL INSIGHTS; LIPID
   INTERACTIONS; ACTIVATION
AB G protein coupled receptors (GPCRs) form the largest receptor superfamily in eukaryotic cells. Owing to their seven transmembrane helices, large parts of these proteins are embedded in the cholesterol-rich plasma membrane bilayer. Thus, GPCRs are always in proximity to cholesterol. Some of them are functionally dependent on the specific presence of cholesterol. Over the last years, enormous progress on receptor structures has been achieved. While lipophilic ligands other than cholesterol have been shown to bind either inside the helix bundle or at the receptor-lipid interface, the binding site of cholesterol was either a single transmembrane helix or a groove between two or more transmembrane helices. A clear preference for one of the two membrane leaflets has not been observed. Not surprisingly, many hydrophobic residues (primarily leucine and isoleucine) were found to be involved in cholesterol binding. In most cases, the rough p-face of cholesterol contacted the transmembrane helix bundle rather than the surrounding lipid matrix. The polar hydroxy group of cholesterol was localized near the water-membrane interface with potential hydrogen bonding to residues in receptor loop regions. Although a canonical motif, designated as CCM site, was detected as a specific cholesterol binding site in case of the beta 2AR, this site was not found to be occupied by cholesterol in other GPCRs possessing the same motif. Cholesterol receptor interactions can increase the compactness of the receptor structure and are able to enhance the conformational stability towards active or inactive receptor states. Overall, all current data suggest a high plasticity of cholesterol interaction sites in GPCRs. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Gimpl, Gerald] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Dept Biochem, Johann Joachim Becherweg 30, D-55128 Mainz, Germany.
RP Gimpl, G (reprint author), Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Dept Biochem, Johann Joachim Becherweg 30, D-55128 Mainz, Germany.
EM gimpl@uni-mainz.de
FU NIGMS [P41-GM103311]
FX Molecular graphics and analyses were performed with the UCSF Chimera
   package. Chimera is developed by the Resource for Biocomputing,
   Visualization, and Informatics at the University of California, San
   Francisco (supported by NIGMS P41-GM103311).
CR Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9
   Baier CJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00069
   Burg JS, 2015, SCIENCE, V347, P1113, DOI 10.1126/science.aaa5026
   Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643
   Cang XH, 2013, J PHYS CHEM B, V117, P1085, DOI 10.1021/jp3118192
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410
   Chrencik JE, 2015, CELL, V161, P1633, DOI 10.1016/j.cell.2015.06.002
   Dalrymple MB, 2008, PHARMACOL THERAPEUT, V118, P359, DOI 10.1016/j.pharmthera.2008.03.004
   Dawaliby R, 2016, NAT CHEM BIOL, V12, P35, DOI [10.1038/nchembio.1960, 10.1038/NCHEMBIO.1960]
   Deupi X, 2011, CURR OPIN STRUC BIOL, V21, P541, DOI 10.1016/j.sbi.2011.06.002
   Doumazane E, 2011, FASEB J, V25, P66, DOI 10.1096/fj.10-163147
   El M. D., 2012, P NATL ACAD SCI USA, V109, P16342
   Epand RM, 2010, SUBCELL BIOCHEM, V51, P253, DOI 10.1007/978-90-481-8622-8_9
   Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944
   Flock T, 2015, NATURE, V524, P173, DOI 10.1038/nature14663
   Gater DL, 2014, BIOPHYS J, V107, P2305, DOI 10.1016/j.bpj.2014.10.011
   Ghosh E, 2015, NAT REV MOL CELL BIO, V16, P69, DOI 10.1038/nrm3933
   Gimpl G, 2002, BBA-BIOMEMBRANES, V1564, P384, DOI 10.1016/S0005-2736(02)00475-3
   GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010
   Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w
   Gimpl G, 2010, SUBCELL BIOCHEM, V51, P1, DOI 10.1007/978-90-481-8622-8_1
   Gomes I, 2016, ANNU REV PHARMACOL, V56, P403, DOI 10.1146/annurev-pharmtox-011613-135952
   Gurevich VV, 2008, TRENDS PHARMACOL SCI, V29, P234, DOI 10.1016/j.tips.2008.02.004
   Hanson MA, 2008, STRUCTURE, V16, P897, DOI 10.1016/j.str.2008.05.001
   Hanson MA, 2012, SCIENCE, V335, P851, DOI 10.1126/science.1215904
   Hildebrand PW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004382
   Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886
   Jafurulla M, 2014, BBA-BIOMEMBRANES, V1838, P158, DOI 10.1016/j.bbamem.2013.08.015
   Joseph J.S., 2012, CHOLESTEROL REGULATI, P231
   Kang YY, 2015, NATURE, V523, P561, DOI 10.1038/nature14656
   Katritch V, 2014, TRENDS BIOCHEM SCI, V39, P233, DOI 10.1016/j.tibs.2014.03.002
   KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009
   Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003
   Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012
   Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7
   Lee SM, 2015, EUR J PHARMACOL, V763, P196, DOI 10.1016/j.ejphar.2015.05.013
   Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598
   Li LBB, 2012, BBA-BIOMEMBRANES, V1818, P135, DOI 10.1016/j.bbamem.2011.10.026
   Liu W, 2012, SCIENCE, V337, P232, DOI 10.1126/science.1219218
   Liu W, 2010, BIOPHYS J, V98, P1539, DOI 10.1016/j.bpj.2009.12.4296
   Lohse MJ, 2010, CURR OPIN PHARMACOL, V10, P53, DOI 10.1016/j.coph.2009.10.007
   Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954
   Marsh D, 2008, BBA-BIOMEMBRANES, V1778, P1545, DOI 10.1016/j.bbamem.2008.01.015
   Miller-Gallacher JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092727
   Mitchell DC, 2001, J BIOL CHEM, V276, P42801
   Mondal S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02909
   Muth S, 2011, BIOCHEM J, V437, P541, DOI 10.1042/BJ20101795
   Nygaard R, 2013, CELL, V152, P532, DOI 10.1016/j.cell.2013.01.008
   Oates J, 2011, CURR OPIN STRUC BIOL, V21, P802, DOI 10.1016/j.sbi.2011.09.007
   Paila YD, 2010, SUBCELL BIOCHEM, V51, P439, DOI 10.1007/978-90-481-8622-8_16
   Phillips R, 2009, NATURE, V459, P379, DOI 10.1038/nature08147
   Piscitelli CL, 2015, MOL PHARMACOL, V88, P536, DOI 10.1124/mol.115.099663
   Prasanna X, 2014, BIOPHYS J, V106, P1290, DOI 10.1016/j.bpj.2014.02.002
   Pucadyil TJ, 2006, PROG LIPID RES, V45, P295, DOI 10.1016/j.plipres.2006.02.002
   Pucadyil TJ, 2005, BIOCHEM BIOPH RES CO, V331, P422, DOI 10.1016/j.bbrc.2005.03.178
   Raghupathy R, 2015, CELL, V161, P581, DOI 10.1016/j.cell.2015.03.048
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Rios S, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0639-4
   Rog T, 2014, CHEM PHYS LIPIDS, V184, P82, DOI 10.1016/j.chemphyslip.2014.10.004
   Rosen H, 2009, ANNU REV BIOCHEM, V78, P743, DOI 10.1146/annurev.biochem.78.072407.103733
   Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665
   Saxena R, 2012, BBA-BIOMEMBRANES, V1818, P2936, DOI 10.1016/j.bbamem.2012.07.032
   Sengupta D, 2015, BBA-BIOMEMBRANES, V1848, P1775, DOI 10.1016/j.bbamem.2015.03.018
   Sengupta D, 2012, J PHYS CHEM B, V116, P12991, DOI 10.1021/jp309888u
   Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236
   Singh P, 2009, BBA-BIOMEMBRANES, V1788, P2169, DOI 10.1016/j.bbamem.2009.07.004
   Song YL, 2014, PROTEIN SCI, V23, P1, DOI 10.1002/pro.2385
   Srivastava A, 2014, NATURE, V513, P124, DOI 10.1038/nature13494
   Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896
   Villar VM, 2016, METHOD CELL BIOL, V132, P3, DOI 10.1016/bs.mcb.2015.11.008
   Wacker D, 2013, SCIENCE, V340, P615, DOI 10.1126/science.1232808
   Wacker D, 2010, J AM CHEM SOC, V132, P11443, DOI 10.1021/ja105108q
   Wiegand V, 2012, EUR J PHARMACOL, V676, P12, DOI 10.1016/j.ejphar.2011.11.041
   Wu HX, 2014, SCIENCE, V344, P58, DOI 10.1126/science.1249489
   Yao ZP, 2005, ANAL BIOCHEM, V343, P344, DOI 10.1016/j.ab.2005.05.002
   Zezula J, 2008, BRIT J PHARMACOL, V153, pS184, DOI 10.1038/sj.bjp.0707674
   Zhang C, 2012, NATURE, V492, P387, DOI 10.1038/nature11701
   Zhang DD, 2015, NATURE, V520, P317, DOI 10.1038/nature14287
   Zhang KH, 2014, NATURE, V509, P115, DOI 10.1038/nature13083
   Zocher M, 2012, P NATL ACAD SCI USA, V109, pE3463, DOI 10.1073/pnas.1210373109
NR 82
TC 3
Z9 3
U1 10
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-3084
EI 1873-2941
J9 CHEM PHYS LIPIDS
JI Chem. Phys. Lipids
PD SEP
PY 2016
VL 199
SI SI
BP 61
EP 73
DI 10.1016/j.chemphyslip.2016.04.006
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DT9PC
UT WOS:000381833800009
PM 27108066
ER

PT J
AU Camerlink, I
   Reimert, I
   Bolhuis, JE
AF Camerlink, Irene
   Reimert, Inonge
   Bolhuis, J. Elizabeth
TI Intranasal oxytocin administration in relationship to social behaviour
   in domestic pigs
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Oxytocin; Social behaviour; Nose contact; Pig; Welfare
ID AFFILIATIVE BEHAVIOR; NEUROENDOCRINE BASIS; EMOTIONAL CONTAGION;
   MATERNAL-BEHAVIOR; RECOGNITION; VASOPRESSIN; PIGLETS; ANIMALS; CONTEXT;
   WELFARE
AB Intranasal administration of oxytocin has been shown to alter positive and negative social behaviour. Positive social behaviour in pigs (Sus scrofa) may be expressed through gentle social nosing, and greater insight in the specific expression hereof might contribute to the current search for positive indicators of animal welfare. We investigated whether oxytocin alters social nosing and whether this is specific to nose-body or nose-nose contact. Sixty-four focal female pigs of 13 weeks of age (out of 16 groups) were given oxytocin (24 IU dose) and saline (placebo) intranasally once on two consecutive days. The frequency of nose-to-nose contact and nose-to-body contact was recorded upon pigs' return in the home pen after being for 10 min located in a separate area near pen mates undergoing a positive or negative event or not. The effect of intranasal oxytocin depended on the social context in which pigs were studied. Control pigs, which were not exposed to positively or negatively aroused pen mates, gave and received less nose-nose contact after oxytocin administration than after saline administration. Pigs exposed to positively aroused pen mates also tended to give less nose contact when given oxytocin compared to saline, whereas pigs exposed to negatively aroused pen mates and administered oxytocin tended to receive more nose contact. Nose-body contact was lowest in groups of negative social context, suggesting an effect of emotional state on social nosing. In contrast to nose-nose contact, nose-body contact was unaffected by oxytocin treatment. The relationship between social nosing and oxytocin merits further research. (C) 2016 Elsevier Inc All rights reserved.
C1 [Camerlink, Irene; Reimert, Inonge; Bolhuis, J. Elizabeth] Wageningen Univ, Dept Anim Sci, Adaptat Physiol Grp, POB 338, NL-6700 AH Wageningen, Netherlands.
   [Camerlink, Irene] Wageningen Univ, Dept Anim Sci, Anim Breeding & Genom Ctr, POB 338, NL-6700 AH Wageningen, Netherlands.
RP Camerlink, I (reprint author), Scotlands Rural Coll SRUC, Anim & Vet Sci Res Grp, Anim Behav & Welf, Edinburgh EH9 3JG, Midlothian, Scotland.
EM Irene.Camerlink@sruc.ac.uk
OI Camerlink, Irene/0000-0002-3427-2210
FU Netherlands Organization for Scientific Research (NWO); Dutch Ministry
   of Economic Affairs [827.09.010]
FX This study was part of the project 'Seeking Sociable Swine', which was
   financially supported by the Netherlands Organization for Scientific
   Research (NWO) and the Dutch Ministry of Economic Affairs (827.09.010).
CR Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Beattie VE, 2005, ANIM SCI, V80, P307, DOI 10.1079/ASC40040307
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   BLACKSHAW JK, 1990, APPL ANIM BEHAV SCI, V25, P61, DOI 10.1016/0168-1591(90)90070-T
   Boissy A, 2007, PHYSIOL BEHAV, V92, P375, DOI 10.1016/j.physbeh.2007.02.003
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   Camerlink I, 2013, APPL ANIM BEHAV SCI, V145, P84, DOI 10.1016/j.applanim.2013.02.008
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   De Dreu CKW, 2012, HORM BEHAV, V61, P419, DOI 10.1016/j.yhbeh.2011.12.009
   Dunbar RIM, 2010, NEUROSCI BIOBEHAV R, V34, P260, DOI 10.1016/j.neubiorev.2008.07.001
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Francis DD, 2000, J NEUROENDOCRINOL, V12, P1145, DOI 10.1046/j.1365-2826.2000.00599.x
   Grippo AJ, 2009, PSYCHONEUROENDOCRINO, V34, P1542, DOI 10.1016/j.psyneuen.2009.05.017
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Hansen S., 2000, THESIS
   Hatfield E., 1994, EMOTIONAL CONTAGION
   Held SDE, 2011, ANIM BEHAV, V81, P891, DOI 10.1016/j.anbehav.2011.01.007
   Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   IsHak WW, 2011, J AFFECT DISORDERS, V130, P1, DOI 10.1016/j.jad.2010.06.001
   Kristensen HH, 2001, APPL ANIM BEHAV SCI, V72, P321, DOI 10.1016/S0168-1591(00)00209-4
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   MacDonald KS, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00194
   Meynhardt H., 1978, SCHWARZWILD REPORT
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   PETERSEN V, 1990, APPL ANIM BEHAV SCI, V26, P169, DOI 10.1016/0168-1591(90)90096-V
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   Rault Jean-Loup, 2015, Animals (Basel), V5, P545, DOI 10.3390/ani5030371
   Rault JL, 2013, APPL ANIM BEHAV SCI, V148, P99, DOI 10.1016/j.applanim.2013.07.001
   Rault JL, 2013, PHYSIOL BEHAV, V112, P40, DOI 10.1016/j.physbeh.2013.02.007
   Rault J. L, 2011, THESIS
   Reimert I, 2015, ANIM COGN, V18, P517, DOI 10.1007/s10071-014-0820-6
   Reimert I, 2014, PHYSIOL BEHAV, V129, P221, DOI 10.1016/j.physbeh.2014.02.059
   Reimert I, 2013, PHYSIOL BEHAV, V109, P42, DOI 10.1016/j.physbeh.2012.11.002
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Schroder-Petersen DL, 2004, ACTA AGR SCAND A-AN, V54, P159, DOI 10.1080/09064700410003835
   SPRUIJT BM, 1992, PHYSIOL REV, V72, P825
   Stevens FL, 2013, J NEUROPSYCH CLIN N, V25, P96, DOI 10.1176/appi.neuropsych.13030061
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   VANLEEUWEN FW, 1995, NEUROSCIENCE, V64, P261, DOI 10.1016/0306-4522(94)00384-H
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Winslow JT, 2004, CURR OPIN NEUROBIOL, V14, P248, DOI 10.1016/j.conb.2004.03.009
   Yeates JW, 2008, VET J, V175, P293, DOI 10.1016/j.tvjl.2007.05.009
   Yu GZ, 1996, NEUROSCIENCE, V72, P1083, DOI 10.1016/0306-4522(95)00600-1
   Zink CF, 2012, HORM BEHAV, V61, P400, DOI 10.1016/j.yhbeh.2012.01.016
NR 51
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD SEP 1
PY 2016
VL 163
BP 51
EP 55
DI 10.1016/j.physbeh.2016.04.054
PG 5
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DS2KC
UT WOS:000380597400007
PM 27143253
ER

PT J
AU Guesdon, V
   Nowak, R
   Meurisse, M
   Boivin, X
   Cornilleau, F
   Chaillou, E
   Levy, F
AF Guesdon, Vanessa
   Nowak, Raymond
   Meurisse, Maryse
   Boivin, Xavier
   Cornilleau, Fabien
   Chaillou, Elodie
   Levy, Frederic
TI Behavioral evidence of heterospecific bonding between the lamb and the
   human caregiver and mapping of associated brain network
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Attachment; Tactile contact; Sheep; Multisensory; Recognition; Oxytocin
ID MEDIAL PREOPTIC AREA; SHEEP TEMPORAL CORTEX; MATERNAL-BEHAVIOR;
   NUCLEUS-ACCUMBENS; AFFILIATIVE BEHAVIOR; SOCIAL RECOGNITION; FOS
   EXPRESSION; C-FOS; ORBITOFRONTAL CORTEX; OXYTOCIN
AB While behavioral mechanisms of bonding between young mammals and humans have been explored, brain structures involved in the establishment of such processes are still unknown. The aim of the study was to identify brain regions activated by the presence of the caregiver. Since human positive interaction plays an important role in the bonding process, activation of specific brain structures by stroking was also examined. Twenty-four female lambs reared in groups of three were fed and stroked daily by a female caregiver between birth and 5-7 weeks of age. At 4 weeks, an isolation-reunion-separation test and a choice test revealed that lambs developed a strong bond with their caregiver. At 5-7 weeks of age, lambs were socially isolated for 90 min. They either remained isolated or met their caregiver who stroked them, or not, at regular intervals over a 90-min period. Neuronal activation was investigated at the end of the period for maximum c-Fos expression. Reunion with the caregiver appeased similarly the lambs whether stroking was provided or not. Stroking did not activate a specific brain network compared to no stroking. In both cases, brain regions associated with olfactory, visual and tactile cue processing were activated in the presence of the caregiver, suggesting a multisensory process involved. In addition, activation of the oxytocinergic system in the hypothalamic paraventricular nucleus induced by the presence of the caregiver suggests similar neuroendocrine mechanisms involved in inter-conspecific and animal-human bonding. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Guesdon, Vanessa] Grp ISA Lille, Equipe CASE, 48 Blvd Vauban, F-59046 Lille, France.
   [Guesdon, Vanessa; Nowak, Raymond; Meurisse, Maryse; Cornilleau, Fabien; Chaillou, Elodie; Levy, Frederic] INRA, Physiol Reprod & Comportements UMR85, F-37380 Nouzilly, France.
   [Guesdon, Vanessa; Nowak, Raymond; Meurisse, Maryse; Cornilleau, Fabien; Chaillou, Elodie; Levy, Frederic] CNRS, UMR7247, F-37380 Nouzilly, France.
   [Guesdon, Vanessa; Nowak, Raymond; Meurisse, Maryse; Cornilleau, Fabien; Chaillou, Elodie; Levy, Frederic] Univ Tours, F-37041 Tours, France.
   [Guesdon, Vanessa; Nowak, Raymond; Meurisse, Maryse; Cornilleau, Fabien; Chaillou, Elodie; Levy, Frederic] Inst Francais Cheval & Equitat, F-37380 Nouzilly, France.
   [Boivin, Xavier] INRA, Herbivores UMRH1213, F-63122 St Genes Champanelle, France.
   [Boivin, Xavier] Clermont Univ, VetAgro Sup, UMR Herbivores, BP 10448, F-63000 Clermont Ferrand, France.
RP Levy, F (reprint author), INRA, UMR Physiol Reprod & Comportements, F-37380 Nouzilly, France.
EM frederic.levy@tours.inra.fr
FU Agence Nationale de la Recherche [ANR BOND.007, NT09 492885];  [GDR2822]
FX We would like to thank Damien Capo, Eric Archer, Chantal Moussu and all
   the staff of the experimental farm "Unite Experimentale Physiologie
   Animale de l'Orfrasiere" (Nouzilly, INRA Val de Loire, France) for
   providing daily care to the pregnant and parturient ewes, and Nicole
   Jouanneau for her helpful assistance during immunohistochemistry study.
   This work was funded by the Agence Nationale de la Recherche (ANR
   BOND.007, no. NT09 492885) and was made possible through support from
   the GDR2822 "Ethologie". The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Afonso VM, 2013, J NEUROSCI, V33, P2305, DOI 10.1523/JNEUROSCI.2081-12.2013
   AGREN G, 1995, NEUROSCI LETT, V187, P49, DOI 10.1016/0304-3940(95)11335-T
   BAUM MJ, 1992, NEUROSCIENCE, V50, P627, DOI 10.1016/0306-4522(92)90452-8
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   Boivin X, 1997, J ANIM SCI, V75, P2892
   Boivin X, 2001, APPL ANIM BEHAV SCI, V72, P89, DOI 10.1016/S0168-1591(00)00201-X
   Boivin X, 2000, J ANIM SCI, V78, P879
   Brennan PA, 2006, PHILOS T R SOC B, V361, P2061, DOI 10.1098/rstb.2006.1931
   Broad KD, 2000, EUR J NEUROSCI, V12, P731, DOI 10.1046/j.1460-9568.2000.00934.x
   Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048
   Coulon M., 2015, PLOS ONE
   Coulon M, 2013, PSYCHONEUROENDOCRINO, V38, P499, DOI 10.1016/j.psyneuen.2012.07.008
   DaCosta APC, 1997, MOL BRAIN RES, V46, P63, DOI 10.1016/S0169-328X(96)00272-0
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Fewell GD, 2002, BRAIN RES, V941, P91, DOI 10.1016/S0006-8993(02)02613-6
   Fleming AS, 1996, BEHAV NEUROSCI, V110, P567
   Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3
   Gubernick D.J., 1981, P243
   Guesdon V, 2012, PHYSIOL BEHAV, V105, P203, DOI 10.1016/j.physbeh.2011.08.011
   Hasegawa I, 2000, REV NEUROSCIENCE, V11, P113
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jansen J, 2008, DEV REV, V28, P503, DOI 10.1016/j.dr.2008.07.001
   Keller M, 2005, NEUROSCIENCE, V133, P359, DOI 10.1016/j.neuroscience.2005.02.027
   Keller M, 2004, EUR J NEUROSCI, V20, P3433, DOI 10.1111/j.1460-9568.2004.03812.x
   Kendrick KM, 2006, PHILOS T R SOC B, V361, P2057, DOI 10.1098/rstb.2006.1930
   KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766
   KENDRICK KM, 1989, NEUROSCI LETT, V100, P193, DOI 10.1016/0304-3940(89)90683-6
   Kendrick KM, 1997, BRAIN RES BULL, V44, P383, DOI 10.1016/S0361-9230(97)00218-9
   KENDRICK KM, 1987, SCIENCE, V236, P448, DOI 10.1126/science.3563521
   Kendrick KM, 2001, NATURE, V414, P165, DOI 10.1038/35102669
   LEONARD CM, 1985, BEHAV BRAIN RES, V15, P159, DOI 10.1016/0166-4328(85)90062-2
   Levy F, 2008, ADV STUD BEHAV, V38, P399, DOI 10.1016/S0065-3454(08)(08)00008-9
   Ligout S, 2004, BEHAVIOUR, V141, P617, DOI 10.1163/1568539041166744
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Mariti C, 2013, BEHAVIOUR, V150, P1275, DOI 10.1163/1568539X-00003095
   Mitsui S, 2011, HORM BEHAV, V60, P239, DOI 10.1016/j.yhbeh.2011.05.012
   Nowak R, 2011, J NEUROENDOCRINOL, V23, P1042, DOI 10.1111/j.1365-2826.2011.02205.x
   Nowak R, 1997, BEHAV NEUROSCI, V111, P1375
   Nowak R, 2015, APPL ANIM BEHAV SCI, V164, P12, DOI 10.1016/j.applanim.2014.09.013
   Numan M, 2005, BEHAV NEUROSCI, V119, P1588, DOI 10.1037/0735-7044.119.6.1588
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Paxinos P., 1986, RAT BRAIN STEREOTAXI
   Peirce JW, 2002, NEUROREPORT, V13, P2395, DOI 10.1097/01.wnr.0000048023.74602.60
   Reefmann N, 2009, ANIM BEHAV, V78, P651, DOI 10.1016/j.anbehav.2009.06.015
   Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284
   Salamone JD, 2002, BEHAV BRAIN RES, V137, P3, DOI 10.1016/S0166-4328(02)00282-6
   Scott J.P., 1970, POSTNATAL DEV PHENOT, P21
   Stolzenberg DS, 2007, BEHAV NEUROSCI, V121, P907, DOI 10.1037/0735-7044.121.5.907
   Swann J, 2001, NEUROSCIENCE, V105, P695, DOI 10.1016/S0306-4522(01)00227-5
   Tallet C, 2005, APPL ANIM BEHAV SCI, V94, P59, DOI 10.1016/j.applanim.2005.02.007
   Tallet C, 2009, APPL ANIM BEHAV SCI, V119, P56, DOI 10.1016/j.applanim.2009.03.012
   Val-Laillet D, 2004, BRAIN RES, V1028, P203, DOI 10.1016/j.brainres.2004.09.023
   van Duuren E, 2007, LEARN MEMORY, V14, P446, DOI 10.1101/lm.546207
   VINCE MA, 1993, ADV STUD BEHAV, V22, P239, DOI 10.1016/S0065-3454(08)60408-8
   VINCE MA, 1984, BEHAVIOUR, V89, P117, DOI 10.1163/156853984X00065
   Waiblinger S, 2006, APPL ANIM BEHAV SCI, V101, P185, DOI 10.1016/j.applanim.2006.02.001
NR 58
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2016
VL 71
BP 159
EP 169
DI 10.1016/j.psyneuen.2016.05.020
PG 11
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DT0GY
UT WOS:000381163000020
PM 27286409
ER

PT J
AU Dannlowski, U
   Kugel, H
   Grotegerd, D
   Redlich, R
   Opel, N
   Dohm, K
   Zaremba, D
   Grogler, A
   Schwieren, J
   Suslow, T
   Ohrmann, P
   Bauer, J
   Krug, A
   Kircher, T
   Jansen, A
   Domschke, K
   Hohoff, C
   Zwitserlood, P
   Heinrichs, M
   Arolt, V
   Heindel, W
   Baune, BT
AF Dannlowski, Udo
   Kugel, Harald
   Grotegerd, Dominik
   Redlich, Ronny
   Opel, Nils
   Dohm, Katharina
   Zaremba, Dario
   Groegler, Anne
   Schwieren, Juliane
   Suslow, Thomas
   Ohrmann, Patricia
   Bauer, Jochen
   Krug, Axel
   Kircher, Tilo
   Jansen, Andreas
   Domschke, Katharina
   Hohoff, Christa
   Zwitserlood, Pienie
   Heinrichs, Markus
   Arolt, Volker
   Heindel, Walter
   Baune, Bernhard T.
TI Disadvantage of Social Sensitivity: Interaction of Oxytocin Receptor
   Genotype and Child Maltreatment on Brain Structure
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Amygdala; fMRI; Oxytocin; Reward dependence; VBM; Ventral striatum
ID EARLY-LIFE STRESS; VOXEL-BASED MORPHOMETRY; GENE VARIATION IMPACT;
   GRAY-MATTER VOLUME; AMYGDALA REACTIVITY; ANTERIOR CINGULATE; MAJOR
   DEPRESSION; AVERSIVE STIMULI; OXTR; POLYMORPHISM
AB BACKGROUND: Oxytocin has received much attention as a prosocial and anxiolytic neuropeptide. In human studies, the G-allele of a common variant (rs53576) in the oxytocin receptor gene (OXTR) has been associated with protective properties such as reduced stress response and higher receptiveness for social support. In contrast, recent studies suggest a detrimental role of the rs53576 G-allele in the context of childhood maltreatment. To further elucidate the role of OXTR, gene by maltreatment interactions on brain structure and function were investigated.
   METHODS: Three hundred nine healthy participants genotyped for OXTR rs53576 underwent structural as well as functional magnetic resonance imaging during a common emotional face-matching task. Childhood maltreatment was assessed with the Childhood Trauma Questionnaire (CTQ). Gray matter volumes were investigated by means of voxel-based morphometry across the entire brain.
   RESULTS: Structural magnetic resonance imaging data revealed a strong interaction of rs53576 genotype and CTQ scores, mapping specifically to the bilateral ventral striatum. GG homozygotes but not A-allele carriers showed strong gray matter reduction with increasing CTQ scores. In turn, lower ventral striatum gray matter volumes were associated with lower reward dependence, a prosocial trait. Furthermore, the G-allele was associated with increased amygdala responsiveness to emotional facial expressions.
   CONCLUSIONS: The findings suggest that the G-allele constitutes a vulnerability factor for specific alterations of limbic brain structure in individuals with adverse childhood experiences, complemented by increased limbic responsiveness to emotional interpersonal stimuli. While oxytocinergic signaling facilitates attachment and bonding in supportive social environments, this attunement for social cues may turn disadvantageous under early adverse conditions.
C1 [Dannlowski, Udo; Grotegerd, Dominik; Redlich, Ronny; Opel, Nils; Groegler, Anne; Schwieren, Juliane; Ohrmann, Patricia; Bauer, Jochen; Domschke, Katharina; Hohoff, Christa; Arolt, Volker] Univ Munster, Dept Psychiat, Albert Schweitzer Str 11, D-48149 Munster, Germany.
   [Dannlowski, Udo; Krug, Axel; Kircher, Tilo; Jansen, Andreas] Univ Marburg, Dept Psychiat, Marburg, Germany.
   [Kugel, Harald; Heindel, Walter] Univ Munster, Dept Clin Radiol, Munster, Germany.
   [Suslow, Thomas] Univ Leipzig, Dept Psychosomat & Psychotherapy, Leipzig, Germany.
   [Dohm, Katharina] Univ Wurzburg, Dept Psychiat, Wurzburg, Germany.
   [Zwitserlood, Pienie] Univ Munster, Dept Psychol, Munster, Germany.
   [Heinrichs, Markus] Univ Freiburg, Dept Psychol, Freiburg, Germany.
   [Heinrichs, Markus] Univ Freiburg, Univ Med Ctr, Freiburg Brain Imaging Ctr, Freiburg, Germany.
   [Baune, Bernhard T.] Univ Adelaide, Sch Med, Discipline Psychiat, Adelaide, SA, Australia.
RP Dannlowski, U (reprint author), Univ Munster, Dept Psychiat, Albert Schweitzer Str 11, D-48149 Munster, Germany.
EM dannlow@uni-muenster.de
OI Kugel, Harald/0000-0002-4349-1984
FU German Research Foundation [FOR 2107, DA1151/5-1, KI588/14-1, KR
   3822/5-1, JA1890/7-1]; Innovative Medizinische Forschung of the Medical
   Faculty of Munster [DA120903, DA111107, DA211012]
FX This study was supported by grants from the German Research Foundation
   (Grant Nos. FOR 2107; DA1151/5-1 to UD; KI588/14-1 to TK; KR 3822/5-1 to
   AK; and JA1890/7-1 to AJ); Innovative Medizinische Forschung of the
   Medical Faculty of Munster (Grant Nos. DA120903 to UD, DA111107 to UD,
   and DA211012 to UD).
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Ansell EB, 2012, BIOL PSYCHIAT, V72, P57, DOI 10.1016/j.biopsych.2011.11.022
   Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Baune BT, 2012, BIOL PSYCHIAT, V72, P655, DOI 10.1016/j.biopsych.2012.04.002
   Baune BT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-125
   Beck AT, 1987, BECK DEPRESSION INVE
   Belsky J, 2009, MOL PSYCHIATR, V14, P746, DOI 10.1038/mp.2009.44
   BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132
   Bradley B, 2013, EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.21659
   Canli T, 2002, SCIENCE, V296, P2191, DOI 10.1126/science.1068749
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Cloninger CR, 1987, PROPOSAL ARCH GEN PS, V44, P573
   Cohen RA, 2006, BIOL PSYCHIAT, V59, P975, DOI 10.1016/j.biopsych.2005.12.016
   Cunningham WA, 2014, SOC COGN AFFECT NEUR, V9, P760, DOI 10.1093/scan/nst045
   Dannlowski U, 2015, MOL PSYCHIATR, V20, P398, DOI 10.1038/mp.2014.39
   Dannlowski U, 2007, J PSYCHIATR NEUROSCI, V32, P423
   Dannlowski U, 2007, PSYCHIAT RES-NEUROIM, V154, P13, DOI 10.1016/j.pscychresns.2006.05.005
   Dannlowski U, 2013, HUM BRAIN MAPP, V34, P2899, DOI 10.1002/hbm.22112
   Dannlowski U, 2013, INT J NEUROPSYCHOPH, V16, P1443, DOI 10.1017/S1461145711001659
   Dannlowski U, 2012, BIOL PSYCHIAT, V71, P286, DOI 10.1016/j.biopsych.2011.10.021
   Dannlowski U, 2011, NEUROPSYCHOPHARMACOL, V36, P1879, DOI 10.1038/npp.2011.73
   Domschke K, 2012, NEUROIMAGE, V60, P2222, DOI 10.1016/j.neuroimage.2012.02.039
   Edmiston EE, 2011, ARCH PEDIAT ADOL MED, V165, P1069, DOI 10.1001/archpediatrics.2011.565
   Ekman P., 1976, PICTURES FACIAL AFFE
   Fan Y, 2015, NEUROPSYCHOPHARMACOL, V40, P2736, DOI 10.1038/npp.2015.123
   Fan Y, 2014, HUM BRAIN MAPP, V35, P5328, DOI 10.1002/hbm.22553
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Hostinar CE, 2014, DEV PSYCHOPATHOL, V26, P465, DOI 10.1017/S0954579414000066
   Ihme K, 2013, BRAIN RES, V1491, P60, DOI 10.1016/j.brainres.2012.10.044
   Koelkebeck K, 2013, SOC NEUROSCI-UK, V8, P631, DOI 10.1080/17470919.2013.837094
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Laux L., 1981, STATE TRAIT ANGSTINV
   Lehrl S, 1995, GOTTINGEN
   Lichev V, 2015, SOC COGN AFFECT NEUR, V10, P680, DOI 10.1093/scan/nsu104
   Lucht MJ, 2009, PROG NEURO-PSYCHOPH, V33, P860, DOI 10.1016/j.pnpbp.2009.04.004
   McCrory EJ, 2013, BRIT J PSYCHIAT, V202, P269, DOI 10.1192/bjp.bp.112.116624
   McQuaid RJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00128
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018
   Oeth P, 2011, IPLEX ASSAY INCREASE
   Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463
   Puglia MH, 2015, P NATL ACAD SCI USA
   Redlich R, 2015, NEUROPSYCHOPHARMACOL, V40, P2623
   Redlich R, 2014, JAMA PSYCHIAT, V71, P1222, DOI 10.1001/jamapsychiatry.2014.1100
   Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Saphire-Bernstein S, 2011, P NATL ACAD SCI USA, V108, P15118, DOI 10.1073/pnas.1113137108
   Satzger W, 2002, Z DIFFERENTIELLE DIA, V23, P159, DOI 10.1024//0170-1789.23.2.159
   Scher CD, 2004, CHILD ABUSE NEGLECT, V28, P167, DOI 10.1016/j.chiabu.2003.09.012
   Sehlmeyer C, 2011, PSYCHOL MED, V41, P789, DOI 10.1017/S0033291710001248
   Somerville LH, 2004, BIOL PSYCHIAT, V55, P897, DOI 10.1016/j.biopsych.2004.01.007
   Stanley B, 2010, AM J PSYCHIAT, V167, P24, DOI 10.1176/appi.ajp.2009.09050744
   Stuhrmann A, 2013, J PSYCHIATR NEUROSCI, V38, P249, DOI 10.1503/jpn.120060
   Suslow T, 2010, BIOL PSYCHIAT, V67, P155, DOI 10.1016/j.biopsych.2009.07.023
   Teicher MH, 2013, AM J PSYCHIAT, V170, P1114, DOI 10.1176/appi.ajp.2013.12070957
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Tottenham N, 2011, DEVELOPMENTAL SCI, V14, P190, DOI 10.1111/j.1467-7687.2010.00971.x
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   van Harmelen AL, 2013, SOC COGN AFFECT NEUR, V8, P362, DOI 10.1093/scan/nss007
   van Roekel E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077689
   Vargas-Martinez F, 2014, PROG NEUROBIOL, V123, P37, DOI 10.1016/j.pneurobio.2014.10.001
   Walker EA, 1999, ARCH GEN PSYCHIAT, V56, P609, DOI 10.1001/archpsyc.56.7.609
   Wang JP, 2014, BRAIN STRUCT FUNCT, V219, P1543, DOI 10.1007/s00429-013-0584-9
   WEYERS P, 1995, PERS INDIV DIFFER, V19, P853, DOI 10.1016/S0191-8869(95)00128-X
   Wittchen H-U, 1997, GOTTINGEN
   Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058
   Ziegler C, 2015, NEUROPSYCHOPHARMACOL, V40, P1528, DOI 10.1038/npp.2015.2
NR 71
TC 0
Z9 0
U1 14
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD SEP 1
PY 2016
VL 80
IS 5
BP 398
EP 405
DI 10.1016/j.biopsych.2015.12.010
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DS5RR
UT WOS:000380840500012
PM 26858213
ER

PT J
AU Steinman, MQ
   Duque-Wilckens, N
   Greenberg, GD
   Hao, R
   Campi, KL
   Laredo, SA
   Laman-Maharg, A
   Manning, CE
   Doig, IE
   Lopez, EM
   Walch, K
   Bales, KL
   Trainor, BC
AF Steinman, Michael Q.
   Duque-Wilckens, Natalia
   Greenberg, Gian D.
   Hao, Rebecca
   Campi, Katharine L.
   Laredo, Sarah A.
   Laman-Maharg, Abigail
   Manning, Claire E.
   Doig, Ian E.
   Lopez, Eduardo M.
   Walch, Keenan
   Bales, Karen L.
   Trainor, Brian C.
TI Sex-Specific Effects of Stress on Oxytocin Neurons Correspond With
   Responses to Intranasal Oxytocin
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Anxiety; Bed nucleus of the stria terminalis; Mood disorders; Oxytocin;
   Paraventricular nucleus; Peromyscus; Posttraumatic stress disorder; Sex
   differences; Social behavior
ID MALE PRAIRIE VOLES; SOCIAL DEFEAT; CENTRAL AMYGDALA; BRAIN OXYTOCIN;
   DEPRESSION; ANXIETY; FEAR; VASOPRESSIN; FEMALE; MALES
AB BACKGROUND: Oxytocin (OT) is considered to be a stress-buffering hormone, dampening the physiologic effects of stress. However, OT can also be anxiogenic. We examined acute and long-lasting effects of social defeat on OT neurons in male and female California mice.
   METHODS: We used immunohistochemistry for OT and c-fos cells to examine OT neuron activity immediately after defeat (n = 6-9) and 2 weeks (n = 6-9) and 10 weeks (n = 4-5) later. We quantified Oxt messenger RNA with quantitative polymerase chain reaction (n = 5-9). Intranasal OT was administered to naive and stressed mice tested in social interaction and resident-intruder tests (n = 8-14).
   RESULTS: Acute exposure to a third episode of defeat increased OT/c-fos colocalizations in the paraventricular nucleus of both sexes. In the medioventral bed nucleus of the stria terminalis, defeat increased Oxt messenger RNA, total OT neurons, and OT/c-fos colocalizations in female mice but not male mice. Intranasal OT failed to reverse stress-induced social withdrawal in female mice and reduced social interaction behavior in female mice naive to defeat. In contrast, intranasal OT increased social interaction in stressed male mice and reduced freezing in the resident-intruder test.
   CONCLUSIONS: Social defeat induces long-lasting increases in OT production and OT/c-fos cells in the medioventral bed nucleus of the stria terminalis of female mice but not male mice. Intranasal OT largely reversed the effects of stress on behavior in male mice, but effects were mixed in female mice. These results suggest that changes in OT-sensitive networks contribute to sex differences in behavioral responses to stress.
C1 [Steinman, Michael Q.] Univ Calif Davis, Mol Cellular Integrat Physiol Grad Grp, Davis, CA 95616 USA.
   [Steinman, Michael Q.; Duque-Wilckens, Natalia; Greenberg, Gian D.; Hao, Rebecca; Campi, Katharine L.; Laredo, Sarah A.; Laman-Maharg, Abigail; Manning, Claire E.; Doig, Ian E.; Lopez, Eduardo M.; Walch, Keenan; Bales, Karen L.; Trainor, Brian C.] Univ Calif Davis, Dept Psychol, 1 Shields Ave, Davis, CA 95616 USA.
   [Duque-Wilckens, Natalia; Laredo, Sarah A.; Trainor, Brian C.] Univ Calif Davis, Anim Behav Grad Grp, Davis, CA 95616 USA.
   [Greenberg, Gian D.; Laman-Maharg, Abigail; Trainor, Brian C.] Univ Calif Davis, Neurosci Grad Grp, Davis, CA 95616 USA.
RP Trainor, BC (reprint author), Univ Calif Davis, Dept Psychol, 1 Shields Ave, Davis, CA 95616 USA.
EM bctrainor@ucdavis.edu
RI Trainor, Brian/L-3618-2016
OI Trainor, Brian/0000-0002-4627-5478
FU National Institutes of Health (NIH) National Research Service Award [F31
   MH095253]; NIH [R01 MH085069]
FX This work was supported by the National Institutes of Health (NIH)
   National Research Service Award F31 MH095253 (MQS) and NIH Grant No. R01
   MH085069 (BCT).
CR Alvares GA, 2012, PSYCHONEUROENDOCRINO, V37, P2022, DOI 10.1016/j.psyneuen.2012.04.018
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Campi KL, 2014, NEUROPHARMACOLOGY, V77, P208, DOI 10.1016/j.neuropharm.2013.09.026
   Cohen H, 2010, J NEUROENDOCRINOL, V22, P889, DOI 10.1111/j.1365-2826.2010.02003.x
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   Dillon DG, 2014, DEPRESS ANXIETY, V31, P233, DOI 10.1002/da.22202
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Dumont EC, 2004, J NEUROSCI, V24, P8198, DOI 10.1523/JNEUROSCI.0425-04.2004
   Eckstein M, 2014, HUM BRAIN MAPP, V35, P4741, DOI 10.1002/hbm.22508
   Greenberg GD, 2014, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00223
   Grillon C, 2013, MOL PSYCHIATR, V18, P958, DOI 10.1038/mp.2012.156
   Grippo AJ, 2007, PSYCHONEUROENDOCRINO, V32, P966, DOI 10.1016/j.psyneuen.2007.07.004
   Grippo AJ, 2012, STRESS, V15, P149, DOI 10.3109/10253890.2011.605486
   Guzman YF, 2014, PSYCHOPHARMACOLOGY, V231, P2097, DOI 10.1007/s00213-013-3356-6
   Hamilton JP, 2015, SOC COGN AFFECT NEUR, V10, P552, DOI 10.1093/scan/nsu084
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Holt-Lunstad J, 2011, PSYCHONEUROENDOCRINO, V36, P1249, DOI 10.1016/j.psyneuen.2011.03.007
   Huhman KL, 2005, BIOL AGGRESSION, P295
   Jennings JH, 2013, NATURE, V496, P224, DOI 10.1038/nature12041
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Krishnan V, 2007, CELL, V131, P391, DOI 10.1016/j.cell.2007.09.018
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Laredo SA, 2015, EUR J NEUROSCI, V41, P434, DOI 10.1111/ejn.12824
   Litvin Y, 2011, PHYSIOL BEHAV, V103, P393, DOI 10.1016/j.physbeh.2011.03.007
   Lukas M, 2014, J NEUROSCI METH, V234, P101, DOI 10.1016/j.jneumeth.2014.03.013
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   MacDonald K, 2014, BRAIN RES, V1580, P22, DOI 10.1016/j.brainres.2014.01.025
   MacDonald K, 2013, PSYCHONEUROENDOCRINO, V38, P2831, DOI 10.1016/j.psyneuen.2013.05.014
   Millan MJ, 2013, NEUROSCI BIOBEHAV R, V37, P2166, DOI 10.1016/j.neubiorev.2013.09.012
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   O'Connell LA, 2012, SCIENCE, V336, P1154, DOI 10.1126/science.1218889
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Pierrehumbert B, 2010, NEUROSCIENCE, V166, P168, DOI 10.1016/j.neuroscience.2009.12.016
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Silva AL, 2010, BEHAV BRAIN RES, V208, P528, DOI 10.1016/j.bbr.2009.12.038
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   Steinman MQ, 2015, PSYCHONEUROENDOCRINO, V51, P122, DOI 10.1016/j.psyneuen.2014.09.009
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Trainor BC, 2013, HORM BEHAV, V63, P543, DOI 10.1016/j.yhbeh.2013.01.011
   Trainor BC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017405
   Trainor BC, 2010, HORM BEHAV, V58, P506, DOI 10.1016/j.yhbeh.2010.04.008
   Ulrich-Lai YM, 2011, J COMP NEUROL, V519, P1301, DOI 10.1002/cne.22571
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 48
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD SEP 1
PY 2016
VL 80
IS 5
BP 406
EP 414
DI 10.1016/j.biopsych.2015.10.007
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DS5RR
UT WOS:000380840500013
PM 26620251
ER

PT J
AU Ruan, C
   Zhang, ZB
AF Ruan, Chao
   Zhang, Zhibin
TI Laboratory domestication changed the expression patterns of oxytocin and
   vasopressin in brains of rats and mice
SO ANATOMICAL SCIENCE INTERNATIONAL
LA English
DT Article
DE Neurochemical; Medial preoptic area; Anterior hypothalamus; Social
   behaviors; Domestication
ID MEDIAL PREOPTIC AREA; VOLES MICROTUS-OCHROGASTER; FEMALE SEXUAL
   RECEPTIVITY; AGGRESSIVE-BEHAVIOR; PRAIRIE VOLES; MUS-MUSCULUS;
   SOCIAL-ORGANIZATION; SPECIES-DIFFERENCES; PATERNAL BEHAVIOR;
   RECEPTOR-BINDING
AB The process of domestication is recognized to exert significant effects on the social behaviors of various animal species, including defensive and cognitive behaviors that are closely linked to the expression of oxytocin (OT) and vasopressin (AVP) in selected areas of the brain. However, it is still unclear whether the behavioral changes observed under domestication have resulted in differences in the neurochemical systems that regulate them. In this study, we compared the differences in distribution patterns and regional quantities of OT and/or AVP staining in the forebrains of wild and laboratory strains of rats and mice. Our results indicated that, in the anterior hypothalamus (AH), laboratory strains showed significantly higher densities of OT-ir (immunoreactive) and AVP-ir cells than wild strains, while no significant difference in the densities of those cells in the lateral hypothalamus (LH) was detected between wild and laboratory strains. Laboratory strains showed higher densities of OT-ir and AVP-ir cells than wild strains in the medial preoptic area (MPOA), and differed in almost every MPOA subnucleus. Our results suggest that domestication significantly alters the expression of OT and AVP in related brain areas of laboratory rats and mice, an observation that could explain the identified changes in behavioral patterns.
C1 [Ruan, Chao; Zhang, Zhibin] Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, 1 Beichen West Rd, Beijing 100101, Peoples R China.
   [Ruan, Chao] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Zhang, ZB (reprint author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, 1 Beichen West Rd, Beijing 100101, Peoples R China.
EM zhangzb@ioz.ac.cn
FU Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDB11050300]; State Key Laboratory of Integrated Management on Pest
   Insects and Rodents [Chinese IPM1204]; Science and Technology Service
   (STS) project of the Chinese Academy of Sciences [KFJ-EW-STS-068-3]
FX The authors would like to thank Drs. Linxi Xu and Yongliang Pan for
   their help with the experimental studies, and they express their
   gratitude to Dr. Dawei Wang for his help in the field trapping of
   animals, Prof. Zuoxin Wang for his help in improving the manuscript, and
   Dr. Sarita Maree (Department of Genetics, University of Pretoria, South
   Africa) for her help in improving the paper and polishing the English.
   This paper is partially supported by the Strategic Priority Research
   Program of the Chinese Academy of Sciences (grant no. XDB11050300), a
   grant from the State Key Laboratory of Integrated Management on Pest
   Insects and Rodents (grant no. Chinese IPM1204), and The Science and
   Technology Service (STS) project of the Chinese Academy of Sciences
   (KFJ-EW-STS-068-3).
CR Barnett S. A., 1963, RAT STUDY BEHAV
   Bester-Meredith JK, 2003, BEHAV NEUROSCI, V117, P455, DOI 10.1037/0735-7044.117.3.455
   Bester-Meredith JK, 2001, HORM BEHAV, V40, P51, DOI 10.1006/hbeh.2001.1666
   Bester-Meredith JK, 1999, HORM BEHAV, V36, P25, DOI 10.1006/hbeh.1999.1522
   BOICE R, 1981, BEHAV GENET, V11, P545, DOI 10.1007/BF01070009
   Boice R, 1972, BEHAVIOUR, V42, P3
   BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132
   Burbach JPH, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P3055
   Caldwell HK, 2004, HORM BEHAV, V46, P444, DOI 10.1016/j.yhbeh.2004.04.006
   CALDWELL JD, 1989, BEHAV NEUROSCI, V103, P655, DOI 10.1037/0735-7044.103.3.655
   CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794
   Caldwell JD, 1999, HORM BEHAV, V35, P38, DOI 10.1006/hbeh.1998.1494
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   CASTLE WE, 1947, P NATL ACAD SCI USA, V33, P109, DOI 10.1073/pnas.33.5.109
   Chalfin L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5569
   Chernigovskaia E V, 2001, Zh Evol Biokhim Fiziol, V37, P144
   Consiglio AR, 1996, PHYSIOL BEHAV, V59, P591, DOI 10.1016/0031-9384(95)02117-5
   DANTZER R, 1988, BRAIN RES, V457, P143, DOI 10.1016/0006-8993(88)90066-2
   DASILVA RKP, 1995, J AUTONOM NERV SYST, V53, P195, DOI 10.1016/0165-1838(94)00176-K
   De Vries GJ, 2006, NEUROSCIENCE, V138, P947, DOI 10.1016/j.neuroscience.2005.07.050
   de Vries GJ, 1998, PROG BRAIN RES, V119, P3
   DELGADO JMR, 1953, AM J PHYSIOL, V172, P162
   EDMUNDS R, 1962, SURG GYNECOL OBSTET, V114, P458
   FERRIS CF, 1988, PHYSIOL BEHAV, V44, P235, DOI 10.1016/0031-9384(88)90144-8
   Ferris CF, 1999, BEHAV NEUROSCI, V113, P804, DOI 10.1037/0735-7044.113.4.804
   Ferris CF, 1997, J NEUROSCI, V17, P4331
   FERRIS CF, 1994, PSYCHONEUROENDOCRINO, V19, P593, DOI 10.1016/0306-4530(94)90043-4
   Frazer KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067
   FREEMAN LC, 1985, THERIOGENOLOGY, V23, P481, DOI 10.1016/0093-691X(85)90020-2
   Gerlai R, 2002, TRENDS NEUROSCI, V25, P506, DOI 10.1016/S0166-2236(02)02250-6
   Giuliano F, 1996, NEUROSCI LETT, V209, P1, DOI 10.1016/0304-3940(96)12594-5
   Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106
   GRAY P, 1984, BEHAV NEUROSCI, V98, P703, DOI 10.1037/0735-7044.98.4.703
   Harker KT, 2002, BEHAV BRAIN RES, V134, P467
   HENNESSEY AC, 1994, PHYSIOL BEHAV, V55, P905, DOI 10.1016/0031-9384(94)90078-7
   Holmes A, 2002, GENES BRAIN BEHAV, V1, P55, DOI 10.1046/j.1601-1848.2001.00005.x
   HUCK UW, 1975, J COMP PHYSIOL PSYCH, V89, P892, DOI 10.1037/h0077160
   INSEL TR, 1994, J NEUROSCI, V14, P5381
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Jing MD, 2014, MOL ECOL, V23, P4387, DOI 10.1111/mec.12873
   Kruska D, 1975, J Hirnforsch, V16, P469
   Le Roy I, 1998, BEHAV BRAIN RES, V95, P135, DOI 10.1016/S0166-4328(97)00218-0
   Leon VA, 2013, INTEGR ZOOL, V8, P18, DOI 10.1111/j.1749-4877.2012.00290.x
   LINDVALL O, 1984, BRAIN RES, V306, P19, DOI 10.1016/0006-8993(84)90352-4
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   McGinnis MY, 2002, BRAIN RES BULL, V59, P227, DOI 10.1016/S0361-9230(02)00869-9
   Michael VS, 1983, PROG BRAIN RES, V60, P101
   MOOS F, 1982, BRAIN RES, V241, P249, DOI 10.1016/0006-8993(82)91061-7
   Ness RW, 2012, G3-GENES GENOM GENET, V2, P1661, DOI 10.1534/g3.112.004713
   NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013
   Parker KJ, 2001, BEHAV NEUROSCI, V115, P1349, DOI 10.1037//0735-7044.115.6.1349
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Popik P, 1991, Eur Neuropsychopharmacol, V1, P555, DOI 10.1016/0924-977X(91)90010-R
   POPIK P, 1992, BEHAV PHARMACOL, V3, P351
   Reuss S, 1999, NEUROSCI LETT, V266, P29, DOI 10.1016/S0304-3940(99)00245-1
   Riters LV, 1997, ANN NY ACAD SCI, V807, P478, DOI 10.1111/j.1749-6632.1997.tb51943.x
   Rosen GJ, 2008, NEUROSCIENCE, V155, P809, DOI 10.1016/j.neuroscience.2008.05.039
   Waldherr M, 2007, P NATL ACAD SCI USA, V104, P16681, DOI 10.1073/pnas.0705860104
   Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065807
   Wang ZX, 1997, ANN NY ACAD SCI, V807, P510, DOI 10.1111/j.1749-6632.1997.tb51954.x
   Wang ZX, 1996, J COMP NEUROL, V366, P726
   WANG ZX, 1995, BEHAV NEUROSCI, V109, P305
   WEITZMAN RE, 1979, WESTERN J MED, V131, P373
   WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0
   Xu L, 2010, NEUROSCIENCE, V169, P1235, DOI 10.1016/j.neuroscience.2010.05.064
   Young KA, 2008, COMP BIOCHEM PHYS C, V148, P401, DOI 10.1016/j.cbpc.2008.02.004
NR 66
TC 0
Z9 0
U1 14
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1447-6959
EI 1447-073X
J9 ANAT SCI INT
JI Anat. Sci. Int.
PD SEP
PY 2016
VL 91
IS 4
BP 358
EP 370
DI 10.1007/s12565-015-0311-0
PG 13
WC Anatomy & Morphology; Developmental Biology
SC Anatomy & Morphology; Developmental Biology
GA DS3NS
UT WOS:000380690300007
PM 26553093
ER

PT J
AU Bukovskaya, O
   Shmukler, A
AF Bukovskaya, Oksana
   Shmukler, Alexander
TI Oxytocin and Social Cognitions in Schizophrenia: A Systematic Review
SO PSYCHIATRIC QUARTERLY
LA English
DT Review
DE Oxytocin; Schizophrenia; Cognition
ID INTRANASAL OXYTOCIN; PLASMA OXYTOCIN; EMOTION RECOGNITION; NEURAL
   CIRCUITRY; HUMAN AMYGDALA; OUT-GROUP; IN-GROUP; HUMANS; TRUST;
   PERCEPTION
AB Schizophrenia is a chronic multifactorial disorder. Over the last years, there has been a growing interest in cognitive deficits in schizophrenia, which is considered by many as the core abnormality of the disease. In the systematic review we focus on the social cognition and its correlation with the neuropeptide oxytocin, which is shown to be involved in the emotion recognizing processes, in the trust behavior and many other aspects of social functioning. The systematic review was performed in order to summarize the data on the liaison of oxytocin with the social cognition impairment in schizophrenia patients. Oxytocin is assumed to be a potential therapeutic agent for schizophrenia, with a special link to social cognitive functions. The oxytocinergic system is a promising neuromodulator of emotion recognition that may have the potential to normalize the social dysfunction seen in schizophrenia. Further studies are required to provide more data on the correlations between oxytocin and socialcognition as well as other schizophrenia symptoms.
C1 [Bukovskaya, Oksana; Shmukler, Alexander] Minist Hlth Russian Federat, Moscow Res Inst Psychiat, Fed Med Res Ctr Psychiat & Narcol, Moscow, Russia.
RP Bukovskaya, O (reprint author), Minist Hlth Russian Federat, Moscow Res Inst Psychiat, Fed Med Res Ctr Psychiat & Narcol, Moscow, Russia.
EM boukovskaya@mail.ru
CR Abu-Akel A, 2014, PSYCHOL MED, V44, P3523, DOI 10.1017/S003329171400097X
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Bakharev V D, 1986, Neurosci Behav Physiol, V16, P160, DOI 10.1007/BF01186517
   Barch DM, 2010, SCHIZOPHRENIA BULL, V36, P43, DOI 10.1093/schbul/sbp139
   Barraza JA, 2009, ANN NY ACAD SCI, V1167, P182, DOI 10.1111/j.1749-6632.2009.04504.x
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Brown EC, 2014, PSYCHIAT RES, V219, P436, DOI 10.1016/j.psychres.2014.06.038
   BUJANOW W, 1972, BRIT MED J, V4, P298
   BUJANOW W, 1974, CAN PSYCHIAT ASSOC J, V19, P323
   Cacciotti-Saija C., 2014, SCHIZOPHR B, V41, P483
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   Davis MC, 2014, NEUROPSYCHOPHARMACOL, V39, P2070, DOI 10.1038/npp.2014.68
   Davis MC, 2013, SCHIZOPHR RES, V147, P393, DOI 10.1016/j.schres.2013.04.023
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Domes G, 2013, PSYCHOL MED, V43, P1747, DOI 10.1017/S0033291712002565
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Engell AD, 2007, J COGNITIVE NEUROSCI, V19, P1508, DOI 10.1162/jocn.2007.19.9.1508
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Fischer-Shofty M, 2010, NEUROPSYCHOLOGIA, V48, P179, DOI 10.1016/j.neuropsychologia.2009.09.003
   Fischer-Shofty M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00127
   Gannon RL, 2014, EUR NEUROPSYCHOPHARM, V24, P964, DOI [10.1016/j.euroneuro.2013.12.007, 10.1016/j.euroneuro.2014.03.008]
   Gibson CM, 2014, SCHIZOPHR RES, V156, P261, DOI 10.1016/j.schres.2014.04.009
   Goldman M, 2008, SCHIZOPHR RES, V98, P247, DOI 10.1016/j.schres.2007.09.019
   Goldman MB, 2011, PSYCHOPHARMACOLOGY, V216, P101, DOI 10.1007/s00213-011-2193-8
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Jackson PL, 2005, NEUROIMAGE, V24, P771, DOI 10.1016/j.neuroimage.2004.09.006
   Keri S, 2009, SOC NEUROSCI-UK, V4, P287, DOI 10.1080/17470910802319710
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kiss Alexander, 2005, Endocr Regul, V39, P97
   Koscik TR, 2011, NEUROPSYCHOLOGIA, V49, P602, DOI 10.1016/j.neuropsychologia.2010.09.023
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krueger F, 2013, SOC COGN AFFECT NEUR, V8, P494, DOI 10.1093/scan/nss026
   Liedman R, 2008, GYNECOL ENDOCRINOL, V24, P508, DOI 10.1080/09513590802306218
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   MacEwan TH, 1997, ACTA PSYCHIAT SCAND, V95, P254, DOI 10.1111/j.1600-0447.1997.tb09628.x
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Perez-Rodrigueza MM, 2015, EUR NEUROPSYCHOPHARM, V25, P265
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Millan MJ, 2013, NEUROSCI BIOBEHAV R, V37, P2166, DOI 10.1016/j.neubiorev.2013.09.012
   Mohamed S, 1999, ARCH GEN PSYCHIAT, V56, P749, DOI 10.1001/archpsyc.56.8.749
   Pedersen CA, AM COLL NEUR
   Pedersen CA, 2014, BRAIN RES, V1580, P1, DOI 10.1016/j.brainres.2014.07.033
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Penn DL, 2008, SCHIZOPHRENIA BULL, V34, P408, DOI 10.1093/schbul/sbn014
   Reichenberg A, PSYCHOL B, V133, P833
   Rosenfeld AJ, 2011, SCHIZOPHRENIA BULL, V37, P1077, DOI 10.1093/schbul/sbq015
   Rubin LH, 2011, SCHIZOPHR RES, V130, P266, DOI 10.1016/j.schres.2011.06.002
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Stallen M, 2012, PSYCHOL SCI, V23, P1288, DOI 10.1177/0956797612446026
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Tops M, 2007, PSYCHOPHYSIOLOGY, V44, P444, DOI 10.1111/j.1469-8986.2007.00510.x
   van Ijzendoorn MH, 2012, PSYCHONEUROENDOCRINO, V37, P438, DOI 10.1016/j.psyneuen.2011.07.008
   Walss-Bass C, 2013, SCHIZOPHR RES, V147, P387, DOI 10.1016/j.schres.2013.04.003
   Wittchen HU, EUROPEAN NEUROPSYCHO, V21, P655
   Woolley JD, 2014, PSYCHONEUROENDOCRINO, V47, P116, DOI 10.1016/j.psyneuen.2014.04.024
NR 66
TC 2
Z9 2
U1 11
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-2720
EI 1573-6709
J9 PSYCHIAT QUART
JI Psychiatr. Q.
PD SEP
PY 2016
VL 87
IS 3
BP 521
EP 543
DI 10.1007/s11126-015-9407-x
PG 23
WC Psychiatry
SC Psychiatry
GA DR6IL
UT WOS:000380005500012
PM 26689706
ER

PT J
AU Liu, CB
   Wang, JL
   Zhan, B
   Cheng, GC
AF Liu, Chaobao
   Wang, Jianli
   Zhan, Bo
   Cheng, Guangchao
TI Neuronal activity and the expression of hypothalamic oxytocin and
   vasopressin in social versus cocaine conditioning
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Cocaine; Neuropeptide; Conditioned place preference; Reward
ID FEMALE PRAIRIE VOLES; PLACE PREFERENCE; NUCLEUS-ACCUMBENS; MANDARIN
   VOLES; TYROSINE-HYDROXYLASE; REWARDING PROPERTIES; SEEKING BEHAVIOR;
   MALE-MICE; RATS; DOPAMINE
AB Although drug rewards and natural rewards share neural substrates, the neuronal activation patterns and mechanisms behind the interaction between cocaine and social reward are poorly understood. Here, we investigated the conditioned place preference (CPP) in social (conspecific) vs cocaine conditioning, and the expression of central c-Fos, hypothalamic oxytocin (OT) and vasopressin (AVP) in ICR mice. We found that the mice produced CPP when conditioned with unfamiliar conspecific or cocaine alone. However, the mice failed to produce CPP when the two stimuli were concurrently conditioned. Compared to conditioning with conspecific alone, the mice decreased preference for conspecific when conditioning with social vs cocaine. We observed differential expression of c-Fos-immunoreactive neurons in the ventral anterior cingulate cortex, posterior cingulate cortex, accumbens (shell and core), medial nucleus of the amygdale and the ventral pallidum when comparing the control (CK), social (SC) or cocaine conditioning (CC) group, and social vs cocaine conditioning (SCC) group. Compared to the CK group, the SC or CC group had higher OT expression in the paraventricular nucleus (PVN) and lower AVP expression in the PVN and supraoptic nucleus. The SCC group showed lower OT expression compared to the SC group, and higher OT and AVP expression in the PVN compared to the CC group. These results indicate that cocaine impairs social preference through competing with social reward. The differential activations of neurons within specific reward areas, and differential expression of OT and AVP are likely to play an important role in mediating the interaction between social and cocaine rewards. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Liu, Chaobao; Wang, Jianli; Zhan, Bo; Cheng, Guangchao] Beifang Univ Nationalities, Coll Biol Sci & Engn, Ningxia 750021, Yinchuan, Peoples R China.
RP Wang, JL (reprint author), Beifang Univ Nationalities, Coll Biol Sci & Engn, Ningxia 750021, Yinchuan, Peoples R China.
EM wang_jianli@163.com
FU National Natural Science Foundation of China [31260513, 31460565]
FX This research was supported by the National Natural Science Foundation
   of China (Grants 31260513 and 31460565).
CR Banks ML, 2010, NEUROPSYCHOPHARMACOL, V35, P493, DOI 10.1038/npp.2009.154
   Bardo MT, 2013, PHARMACOL REV, V65, P255, DOI 10.1124/pr.111.005124
   Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569
   Barrot M, 1999, EUR J NEUROSCI, V11, P1155, DOI 10.1046/j.1460-9568.1999.00525.x
   Beery AK, 2010, NEUROSCIENCE, V169, P665, DOI 10.1016/j.neuroscience.2010.05.023
   BROWN EE, 1992, J NEUROSCI, V12, P4112
   Cain ME, 2004, PSYCHOPHARMACOLOGY, V176, P129, DOI 10.1007/s00213-004-1870-2
   Campbell A, 2008, BIOL PSYCHOL, V77, P1, DOI 10.1016/j.biopsycho.2007.09.001
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Chauvet C, 2011, NEUROSCIENCE, V184, P88, DOI 10.1016/j.neuroscience.2011.03.068
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Chui J., 1998, EUR J PHARMACOL, V355, P11
   Cole SL, 2013, ADDICT BIOL, V18, P274, DOI 10.1111/j.1369-1600.2011.00426.x
   Delgado MR, 2007, ANN NY ACAD SCI, V1104, P70, DOI 10.1196/annals.1390.002
   DEVRY J, 1988, LIFE SCI, V42, P2709, DOI 10.1016/0024-3205(88)90247-0
   Eisener-Dorman AF, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-29
   El Rawas R, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00008
   Estelles J, 2004, DRUG ALCOHOL DEPEN, V76, P115, DOI 10.1016/j.drugalcdep.2004.04.019
   Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229
   Fritz M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026761
   Fritz M, 2011, ADDICT BIOL, V16, P273, DOI 10.1111/j.1369-1600.2010.00285.x
   Fritz M, 2011, PHARMACOLOGY, V87, P45, DOI 10.1159/000322534
   Hu JH, 2015, HUM BRAIN MAPP, V36, P2132, DOI 10.1002/hbm.22760
   Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560
   Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3
   Jackson D, 2005, NEUROSCIENCE, V133, P635, DOI 10.1016/j.neuroscience.2005.02.047
   Johnson ZV, 2010, PHYSIOL BEHAV, V99, P412, DOI 10.1016/j.physbeh.2009.12.013
   Kahlig KM, 2003, EUR J PHARMACOL, V479, P153, DOI 10.1016/j.ejphar.2003.08.065
   Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6
   Kummer K, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00080
   Kummer KK, 2015, PHARMACOLOGY, V95, P42, DOI 10.1159/000370314
   Kummer KK, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00363
   Lippard ETC, 2015, BEHAV BRAIN RES, V278, P176, DOI 10.1016/j.bbr.2014.09.045
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Liu Y, 2011, J NEUROSCI, V31, P7960, DOI 10.1523/JNEUROSCI.1006-11.2011
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   Mattson BJ, 2005, NEUROSCIENCE, V135, P315, DOI 10.1016/j.neuroscience.2005.06.045
   McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McMurray MS, 2008, NEUROPEPTIDES, V42, P641, DOI 10.1016/j.npep.2008.05.003
   Miller CA, 2005, EUR J NEUROSCI, V21, P1385, DOI 10.1111/j.1460-9568.2005.03974.x
   Morales-Rivera A, 2014, PSYCHOPHARMACOLOGY, V231, P4145, DOI 10.1007/s00213-014-3553-y
   Murakami G, 2011, EUR J NEUROSCI, V34, P469, DOI 10.1111/j.1460-9568.2011.07761.x
   Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x
   Neisewander JL, 2000, J NEUROSCI, V20, P798
   Pitchers KK, 2014, J NEUROSCI, V34, P8825, DOI 10.1523/JNEUROSCI.0133-14.2014
   Prast JM, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00441
   Prast JM, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00317
   Ramos L, 2015, PSYCHOPHARMACOLOGY, V232, P2631, DOI 10.1007/s00213-015-3899-9
   Razzoli M, 2003, HORM BEHAV, V43, P549, DOI 10.1016/S0018-506X(03)00064-3
   Rodriguez-Borrero E, 2010, NEUROPHARMACOLOGY, V58, P88, DOI 10.1016/j.neuropharm.2009.06.040
   SARNYAI Z, 1992, NEUROPEPTIDES, V23, P27, DOI 10.1016/0143-4179(92)90006-I
   Sarnyai Z, 1998, PROG BRAIN RES, V119, P449
   Seip KM, 2009, BEHAV NEUROSCI, V123, P1325, DOI 10.1037/a0017666
   Skuse DH, 2009, TRENDS COGN SCI, V13, P27, DOI 10.1016/j.tics.2008.09.007
   Thiel KJ, 2008, DRUG ALCOHOL DEPEN, V96, P202, DOI 10.1016/j.drugalcdep.2008.02.013
   Trezza V, 2009, EUR NEUROPSYCHOPHARM, V19, P659, DOI 10.1016/j.euroneuro.2009.03.006
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   VANREE JM, 1988, LIFE SCI, V42, P1091, DOI 10.1016/0024-3205(88)90565-6
   Varlinskaya EI, 2001, ALCOHOL CLIN EXP RES, V25, P377, DOI 10.1111/j.1530-0277.2001.tb02224.x
   [Anonymous], 2014, ZOOL RES
   Wang JL, 2014, NEUROPEPTIDES, V48, P29, DOI 10.1016/j.npep.2013.10.016
   Wang JL, 2012, BEHAV PHARMACOL, V23, P693, DOI 10.1097/FBP.0b013e328358603c
   Wang JL, 2012, BEHAV BRAIN RES, V230, P149, DOI 10.1016/j.bbr.2012.02.005
   Young KA, 2011, NEUROSCI BIOBEHAV R, V35, P498, DOI 10.1016/j.neubiorev.2010.06.004
   Zernig G, 2015, BEHAV PHARMACOL, V26, P580, DOI 10.1097/FBP.0000000000000167
   Zernig Gerald, 2013, Front Psychiatry, V4, P100, DOI 10.3389/fpsyt.2013.00100
   Zhang L, 2012, NEUROSCIENCE, V215, P135, DOI 10.1016/j.neuroscience.2012.03.046
   Ziegler DR, 2002, INTEGR COMP BIOL, V42, P541, DOI 10.1093/icb/42.3.541
NR 70
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD SEP 1
PY 2016
VL 310
BP 84
EP 92
DI 10.1016/j.bbr.2016.05.010
PG 9
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DQ1KB
UT WOS:000378958800011
PM 27163750
ER

PT J
AU Stanic, D
   Plecas-Solarovic, B
   Petrovic, J
   Bogavac-Stanojevic, N
   Sopic, M
   Kotur-Stevuljevic, J
   Ignjatovic, S
   Pesic, V
AF Stanic, Dusanka
   Plecas-Solarovic, Bosiljka
   Petrovic, Jelena
   Bogavac-Stanojevic, Natasa
   Sopic, Miron
   Kotur-Stevuljevic, Jelena
   Ignjatovic, Svetlana
   Pesic, Vesna
TI Hydrogen peroxide-induced oxidative damage in peripheral blood
   lymphocytes from rats chronically treated with corticosterone: The
   protective effect of oxytocin treatment
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Chronic stress; Corticosterone; Oxytocin; Genotoxicity; Comet test;
   Oxidative stress
ID DNA-DAMAGE; IN-VITRO; GENOTOXICITY EVALUATION; HORMONAL DRUGS; ADRENAL
   AXIS; COMET ASSAY; STRESS; INJURY; REPAIR; BRAIN
AB Contemporary lifestyle is commonly associated with chronic stress, an environmental factor contributing to development of various psychological and somatic disorders. Increased levels of glucocorticoids, observed in the chronic stress, induce the production of reactive oxygen species leading to genotoxicity. The aim of this study was to investigate whether chronic administration of oxytocin (OXY) 10 IU/400 mu L/day, s.c., for 14 days, a hormone presumed to exert antioxidant effect, may prevent DNA damage in the comet assay of peripheral blood lymphocytes of Wistar rats treated chronically with corticosterone (CORT) 100 mg/L ad libitum, per os, for 21 days, as well as, to influence some plasma oxidative stress parameters, i.e. levels of total lipid hydroperoxide (LOOH), and malondialdehyde (MDA), and the activity of antioxidative enzyme superoxide dismutase (SOD). Even though there was no reduction in overall number of damaged cells after oxytocin treatment only, the marked increase in total comet score (TCS) after incubation with H2O2 in CORT group compared to controls, was absent in the CORT + OXY experimental group. Furthermore, significant decrease of highly damaged cells compared to corticosterone group was noted. Chronic oxytocin administration thus protected lymphocytes from high intensity damage that leads to cellular death. In addition, treatment with OXY along with CORT, significantly decreased concentration of LOOH in plasma, and increased SOD compared to CORT treatment only. This finding corresponds well with current reports on beneficial effects of OXY in conditions of HPA axis hyperactivity, and supports the hypothesis of OXY-mediated antioxidant action. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Stanic, Dusanka; Plecas-Solarovic, Bosiljka; Petrovic, Jelena; Pesic, Vesna] Univ Belgrade, Fac Pharm, Dept Physiol, Vojvode Stepe 450, Belgrade 11121, Serbia.
   [Bogavac-Stanojevic, Natasa; Sopic, Miron; Kotur-Stevuljevic, Jelena; Ignjatovic, Svetlana] Univ Belgrade, Dept Med Biochem, Fac Pharm, Belgrade, Serbia.
RP Stanic, D (reprint author), Univ Belgrade, Fac Pharm, Dept Physiol, Vojvode Stepe 450, Belgrade 11121, Serbia.
EM dusanka.zogovic@pharmacy.bg.ac.rs
FU Ministry of Education, Science and Technological Development, Republic
   of Serbia [175036]
FX The work was supported entirely by a grant from the Ministry of
   Education, Science and Technological Development, Republic of Serbia,
   grant no. 175036.
CR Akman T, 2015, BIOMED RES INT, DOI 10.1155/2015/167235
   Aljanabi S., 2013, ASIAN J PHARM CLIN R, V6, P82
   Andersen ML, 2009, PROG NEURO-PSYCHOPH, V33, P562, DOI 10.1016/j.pnpbp.2009.02.014
   ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X
   Andrade V., 2012, 58 C BRAS GEN 11 14
   Ashok BT, 1997, BIOCHEM MOL BIOL INT, V43, P1219
   Ayala A, 2014, OXID MED CELL LONGEV, DOI 10.1155/2014/360438
   BALI D, 1990, ENVIRON MOL MUTAGEN, V16, P250, DOI 10.1002/em.2850160406
   Biyikli NK, 2006, PEPTIDES, V27, P2249, DOI 10.1016/j.peptides.2006.03.029
   Bouayed J, 2009, J MED FOOD, V12, P861, DOI 10.1089/jmf.2008.0165
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   Chen X, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-73
   Collins A. R., 2004, BIOCHIM BIOPHYS ACTA, V1840, P794
   Consiglio AR, 2010, PROG NEURO-PSYCHOPH, V34, P652, DOI 10.1016/j.pnpbp.2010.03.004
   da Silva J, 2000, GENET MOL BIOL, V23, P241
   Djelic N, 1996, MUTAT RES-FUND MOL M, V356, P265, DOI 10.1016/0027-5107(96)00071-1
   Donner NC, 2012, PSYCHONEUROENDOCRINO, V37, P645, DOI 10.1016/j.psyneuen.2011.08.008
   Dronjak S, 2005, ACTA VET-BEOGRAD, V55, P121, DOI 10.2298/AVB0503121D
   Fahmy M. A., 2014, Comunicata Scientiae, V5, P213
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Flint MS, 2007, PSYCHONEUROENDOCRINO, V32, P470, DOI 10.1016/j.psyneuen.2007.02.013
   Gay CA, 2003, ANAL BIOCHEM, V315, P29, DOI 10.1016/S0003-2697(02)00606-1
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gonzalez-Reyes A, 2015, MOL CELL ENDOCRINOL, V412, P170, DOI 10.1016/j.mce.2015.04.028
   Gupta D, 2015, STEROIDS, V96, P95, DOI 10.1016/j.steroids.2015.01.021
   Houshmand F, 2015, HEART LUNG CIRC, V24, P86, DOI 10.1016/j.hlc.2014.05.023
   HU JJ, 1995, MUTAT RES-DNA REPAIR, V336, P193, DOI 10.1016/0921-8777(94)00054-A
   Imani Alireza, 2015, Acta Med Iran, V53, P491
   Iseri SO, 2008, BURNS, V34, P361, DOI 10.1016/j.burns.2007.03.022
   Iseri SO, 2005, J SURG RES, V126, P73, DOI 10.1016/j.jss.2005.01.021
   Joergensen A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020795
   Koroglu P, 2015, PEPTIDES, V63, P47, DOI 10.1016/j.peptides.2014.10.012
   Liu JK, 1996, FASEB J, V10, P1532
   McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154
   Misra H. P., J BIOL CHEM, P247
   Moosmann B, 2002, MOL PHARMACOL, V61, P260, DOI 10.1124/mol.61.2.260
   Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS
   Orzechowski A, 2002, J VET MED A, V49, P256, DOI 10.1046/j.1439-0442.2002.00443.x
   Roy MD, 2007, BIOTECHNIQUES, V42, P425, DOI 10.2144/000112441
   Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10-58
   SINGH H, 1994, MUTAT RES, V308, P89, DOI 10.1016/0027-5107(94)90201-1
   Singh NP, 2005, METH MOLEC MED, V111, P55
   Singh N. P., EXP CELL RES, P175
   Sopic M, 2014, J SPORT MED PHYS FIT, V54, P354
   Spiers Jereme G, 2014, Front Neurosci, V8, P456, DOI 10.3389/fnins.2014.00456
   Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008
   Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J
   Tilbrook AJ, 2006, FRONT NEUROENDOCRIN, V27, P285, DOI 10.1016/j.yfrne.2006.06.002
   Torbergsen AC, 2000, EUR J NUTR, V39, P80, DOI 10.1007/s003940050006
   Tugtepe H, 2007, REGUL PEPTIDES, V140, P101, DOI 10.1016/j.regpep.2006.11.026
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   Uvnas-Moberg K., Z PSYCHOSOM MED PSYC, P51
   Vargas-Martinez F, 2014, PROG NEUROBIOL, V123, P37, DOI 10.1016/j.pneurobio.2014.10.001
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Yegen B., 2010, MARMARA PHARM J, V14, P61
   Zafir A, 2009, STRESS, V12, P167, DOI 10.1080/10253890802234168
   Zhao Y, 2008, EUR J PHARMACOL, V581, P113, DOI 10.1016/j.ejphar.2007.12.005
NR 57
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD AUG 25
PY 2016
VL 256
BP 134
EP 141
DI 10.1016/j.cbi.2016.07.006
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA DU6RA
UT WOS:000382341100015
PM 27402529
ER

PT J
AU Dumais, KM
   Alonso, AG
   Bredewold, R
   Veenema, AH
AF Dumais, Kelly M.
   Alonso, Andrea G.
   Bredewold, Remco
   Veenema, Alexa H.
TI ROLE OF THE OXYTOCIN SYSTEM IN AMYGDALA SUBREGIONS IN THE REGULATION OF
   SOCIAL INTEREST IN MALE AND FEMALE RATS
SO NEUROSCIENCE
LA English
DT Article
DE oxytocin; oxytocin receptor; central amygdala; medial amygdala; social
   interest; sex differences
ID BORDERLINE PERSONALITY-DISORDER; MATERNAL AGGRESSIVE-BEHAVIOR; AUTISM
   SPECTRUM DISORDER; MEDIAL AMYGDALA; SEX-DIFFERENCES; INTRANASAL
   OXYTOCIN; ANXIETY DISORDER; STRIA TERMINALIS; CENTRAL NUCLEUS; BRAIN
   OXYTOCIN
AB We previously found that oxytocin (OT) receptor (OTR) binding density in the medial amygdala (MeA) correlated positively with social interest (i.e., the motivation to investigate a conspecific) in male rats, while OTR binding density in the central amygdala (CeA) correlated negatively with social interest in female rats. Here, we determined the causal involvement of OTR in the MeA and CeA in the sex-specific regulation of social interest in adult rats by injecting an OTR antagonist (5 ng/0.5 mu l/side) or OT (100 pg/0.5 mu l/side) before the social interest test (4-min same-sex juvenile exposure). OTR blockade in the CeA decreased social interest in males but not females, while all other treatments had no behavioral effect. To further explore the sex-specific involvement of the OT system in the CeA in social interest, we used in vivo microdialysis to determine possible sex differences in endogenous OT release in the CeA during social interest. Interestingly, males and females showed similar levels of extracellular OT release at baseline and during social interest, suggesting that factors other than local OT release mediate the sex-specific role of CeA-OTR in social interest. Moreover, we found a positive correlation between CeA-OT release and social investigation time in females. This was further reflected by reduced CeA-OT release during social interest in females that expressed low compared to high social interest. We discuss the possibility that this reduction in OT release may be a consequence, rather than a cause, of exposure to a social stimulus. Overall, our findings show for the first time that extracellular OT release in the CeA is similar between males and females and that OTR in the CeA plays a causal role in the regulation of social interest toward juvenile conspecifics in males. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Dumais, Kelly M.; Alonso, Andrea G.; Bredewold, Remco; Veenema, Alexa H.] Boston Coll, Dept Psychol, Neurobiol Social Behav Lab, 140 Commonwealth Ave,300 McGuinn, Chestnut Hill, MA 02467 USA.
RP Dumais, KM (reprint author), Boston Coll, Dept Psychol, Neurobiol Social Behav Lab, 140 Commonwealth Ave,300 McGuinn, Chestnut Hill, MA 02467 USA.
EM kelly.dumais@bc.edu
FU NRSA Predoctoral Fellowship [F31MH100891]; NIMH [R15MH102807]
FX We would like to thank the Veenema Lab for critically reading the
   manuscript, and Marisa Immormino, Daniel Cho, and Tessa Gillespie for
   technical assistance. We would also like to thank the animal caretakers
   at Boston College for excellent animal care, and Dr. Maurice Manning for
   kindly providing the OTR antagonist. This research is supported by NRSA
   Predoctoral Fellowship F31MH100891 to KMD and NIMH R15MH102807 to AHV.
CR Arakawa H, 2010, NEUROSCIENCE, V171, P1141, DOI 10.1016/j.neuroscience.2010.10.013
   Bale TL, 2001, J NEUROSCI, V21, P2546
   Balleine BW, 2006, TRENDS NEUROSCI, V29, P272, DOI 10.1016/j.tins.2006.03.002
   Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7
   Bergan JF, 2014, ELIFE, V3, DOI 10.7554/eLife.02743
   Bertsch K, 2013, AM J PSYCHIAT, V170, P1169, DOI 10.1176/appi.ajp.2013.13020263
   BLUTHE RM, 1990, BRAIN RES, V535, P301, DOI 10.1016/0006-8993(90)91613-L
   Bosch OJ, 2005, J NEUROSCI, V25, P6807, DOI 10.1523/JNEUROSCI.1342-05.2005
   Bredewold R., 2014, FRONT BEHAV NEUROSCI, V8, P1
   Bruhl AB, 2014, NEUROSCI BIOBEHAV R, V47, P260, DOI 10.1016/j.neubiorev.2014.08.003
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Consiglio AR, 2005, PHYSIOL BEHAV, V85, P354, DOI 10.1016/j.physbeh.2005.05.002
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Donegan NH, 2003, BIOL PSYCHIAT, V54, P1284, DOI 10.1016/S0006-3223(03)00636-X
   Dong HW, 2001, BRAIN RES REV, V38, P192, DOI 10.1016/S0165-0173(01)00079-0
   Dumais KM, 2016, PSYCHONEUROENDOCRINO, V64, P79, DOI 10.1016/j.psyneuen.2015.11.007
   Dumais KM, 2013, HORM BEHAV, V64, P693, DOI 10.1016/j.yhbeh.2013.08.012
   Dumais K. M., 2015, FRONT NEUROENDOCRIN, V40, P1, DOI DOI 10.1016/J.YFME.2015.04.003
   Dumais KM, 2016, SEX DIFFERENCES CENT, P247
   Evans KC, 2008, DEPRESS ANXIETY, V25, P496, DOI 10.1002/da.20347
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Gimpl G, 2001, PHYSIOL REV, V81, P630
   Goldin PR, 2009, BIOL PSYCHIAT, V66, P1091, DOI 10.1016/j.biopsych.2009.07.014
   Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106
   Guastella A. J., 2012, HORM BEHAV, V61, P410, DOI DOI 10.1016/J.YHBEH.2012.01.002
   Guthman EM, 2016, J NEUROSCI, V36, P2083, DOI 10.1523/JNEUROSCI.4304-15.2016
   Guzman YF, 2014, PSYCHOPHARMACOLOGY, V231, P2097, DOI 10.1007/s00213-013-3356-6
   Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465
   Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5
   Herpertz SC, 2001, BIOL PSYCHIAT, V50, P292, DOI 10.1016/S0006-3223(01)01075-7
   Horn TFW, 2001, METHODS, V23, P41, DOI 10.1006/meth.2000.1104
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Joels M, 2000, EUR J PHARMACOL, V405, P207, DOI 10.1016/S0014-2999(00)00554-9
   JOHNSTON AL, 1991, PHYSIOL BEHAV, V49, P245, DOI 10.1016/0031-9384(91)90039-Q
   Kim SY, 2015, PSYCHIAT INVEST, V12, P37, DOI 10.4306/pi.2015.12.1.37
   Kleinhans NM, 2016, J AUTISM DEV DISORD, V46, P232, DOI 10.1007/s10803-015-2565-8
   Knobloch S.H., 2012, NEURON, V73, P553
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lahoud N, 2013, PSYCHONEUROENDOCRINO, V38, P2184, DOI 10.1016/j.psyneuen.2013.04.006
   Laszlo K, 2016, BEHAV BRAIN RES, V296, P279, DOI 10.1016/j.bbr.2015.09.021
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Lubin DA, 2003, BEHAV NEUROSCI, V117, P195, DOI 10.1037/0735-7044.117.2.195
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   MANNING M, 1989, J MED CHEM, V32, P382, DOI 10.1021/jm00122a016
   Manning M, 2008, PROG BRAIN RES, V170, P473, DOI 10.1016/S0079-6123(08)00437-8
   Murakami G, 2011, EUR J NEUROSCI, V34, P469, DOI 10.1111/j.1460-9568.2011.07761.x
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Noack J, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00152
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Petrovich GD, 2001, BRAIN RES REV, V38, P247, DOI 10.1016/S0165-0173(01)00080-7
   Petrovich GD, 1997, BRAIN RES, V763, P247, DOI 10.1016/S0006-8993(96)01361-3
   Qiu F, 2014, BRIT J PHARMACOL, V171, P3065, DOI 10.1111/bph.12635
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   Stefanova N, 1998, NEUROSCI LETT, V255, P175, DOI 10.1016/S0304-3940(98)00735-6
   THOR DH, 1980, J COMP PHYSIOL PSYCH, V94, P970, DOI 10.1037/h0077831
   Varlinskaya EI, 2013, DEV PSYCHOBIOL, V55, P684, DOI 10.1002/dev.21064
   Veenema AH, 2008, PROG BRAIN RES, V170, P260
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Viviani D, 2008, PROG BRAIN RES, V170, P207, DOI 10.1016/S0079-6123(08)00418-4
   WALLACE DM, 1992, BRAIN RES BULL, V28, P447, DOI 10.1016/0361-9230(92)90046-Z
   Zahm DS, 1999, EUR J NEUROSCI, V11, P1119, DOI 10.1046/j.1460-9568.1999.00524.x
NR 71
TC 1
Z9 1
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD AUG 25
PY 2016
VL 330
BP 138
EP 149
DI 10.1016/j.neuroscience.2016.05.036
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA DP5GD
UT WOS:000378523400014
PM 27235738
ER

PT J
AU Kosaka, H
   Okamoto, Y
   Munesue, T
   Yamasue, H
   Inohara, K
   Fujioka, T
   Anme, T
   Orisaka, M
   Ishitobi, M
   Jung, M
   Fujisawa, TX
   Tanaka, S
   Arai, S
   Asano, M
   Saito, DN
   Sadato, N
   Tomoda, A
   Omori, M
   Sato, M
   Okazawa, H
   Higashida, H
   Wada, Y
AF Kosaka, H.
   Okamoto, Y.
   Munesue, T.
   Yamasue, H.
   Inohara, K.
   Fujioka, T.
   Anme, T.
   Orisaka, M.
   Ishitobi, M.
   Jung, M.
   Fujisawa, T. X.
   Tanaka, S.
   Arai, S.
   Asano, M.
   Saito, D. N.
   Sadato, N.
   Tomoda, A.
   Omori, M.
   Sato, M.
   Okazawa, H.
   Higashida, H.
   Wada, Y.
TI Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype
   in young adults with high-functioning autism: a 24-week randomized
   clinical trial
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; INTRANASAL OXYTOCIN; SPECTRUM DISORDER; RANDOM
   FORESTS; OXTR GENE; JAPANESE POPULATION; VARIABLE IMPORTANCE; SOCIAL
   BEHAVIORS; PLASMA OXYTOCIN; PRAIRIE VOLES
AB Recent studies have suggested that long-term oxytocin administration can alleviate the symptoms of autism spectrum disorder (ASD); however, factors influencing its efficacy are still unclear. We conducted a single-center phase 2, pilot, randomized, double-blind, placebo-controlled, parallel-group, clinical trial in young adults with high-functioning ASD, to determine whether oxytocin dosage and genetic background of the oxytocin receptor affects oxytocin efficacy. This trial consisted of double-blind (12 weeks), open-label (12 weeks) and follow-up phases (8 weeks). To examine dose dependency, 60 participants were randomly assigned to high-dose (32 IU per day) or low-dose intranasal oxytocin (16 IU per day), or placebo groups during the double-blind phase. Next, we measured single-nucleotide polymorphisms (SNPs) in the oxytocin receptor gene (OXTR). In the intention-to-treat population, no outcomes were improved after oxytocin administration. However, in male participants, Clinical Global Impression-Improvement (CGI-I) scores in the high-dose group, but not the low-dose group, were significantly higher than in the placebo group. Furthermore, we examined whether oxytocin efficacy, reflected in the CGI-I scores, is influenced by estimated daily dosage and OXTR polymorphisms in male participants. We found that 421 IU per day oxytocin was more effective than. 21 IU per day, and that a SNP in OXTR (rs6791619) predicted CGI-I scores for. 21 IU per day oxytocin treatment. No severe adverse events occurred. These results suggest that efficacy of long-term oxytocin administration in young men with high-functioning ASD depends on the oxytocin dosage and genetic background of the oxytocin receptor, which contributes to the effectiveness of oxytocin treatment of ASD.
C1 [Kosaka, H.; Okamoto, Y.; Jung, M.; Fujisawa, T. X.; Arai, S.; Asano, M.; Saito, D. N.; Sato, M.; Okazawa, H.; Wada, Y.] Univ Fukui, Res Ctr Child Mental Dev, Eiheiji, Fukui 9101193, Japan.
   [Kosaka, H.; Inohara, K.; Fujioka, T.; Ishitobi, M.; Asano, M.; Wada, Y.] Univ Fukui, Dept Neuropsychiat, Fac Med Sci, Eiheiji, Japan.
   [Kosaka, H.; Okamoto, Y.; Arai, S.; Asano, M.; Saito, D. N.; Tomoda, A.; Sato, M.; Okazawa, H.; Wada, Y.] Osaka Univ, United Grad Sch Child Dev, Dept Child Dev, Div Dev Higher Brain Funct, Suita, Osaka 565, Japan.
   [Kosaka, H.; Okamoto, Y.; Jung, M.; Fujisawa, T. X.; Arai, S.; Asano, M.; Saito, D. N.; Tomoda, A.; Sato, M.; Okazawa, H.; Wada, Y.] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan.
   [Kosaka, H.; Okamoto, Y.; Jung, M.; Fujisawa, T. X.; Arai, S.; Asano, M.; Saito, D. N.; Tomoda, A.; Sato, M.; Okazawa, H.; Wada, Y.] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka, Japan.
   [Kosaka, H.; Okamoto, Y.; Jung, M.; Fujisawa, T. X.; Arai, S.; Asano, M.; Saito, D. N.; Tomoda, A.; Sato, M.; Okazawa, H.; Wada, Y.] Chiba Univ, Chiba, Japan.
   [Kosaka, H.; Okamoto, Y.; Jung, M.; Fujisawa, T. X.; Arai, S.; Asano, M.; Saito, D. N.; Tomoda, A.; Sato, M.; Okazawa, H.; Wada, Y.] Univ Fukui, Eiheiji, Japan.
   [Munesue, T.; Higashida, H.] Kanazawa Univ, Res Ctr Child Mental Dev, Kanazawa, Ishikawa, Japan.
   [Yamasue, H.] Univ Tokyo, Sch Med, Dept Neuropsychiat, Tokyo, Japan.
   [Inohara, K.] Univ Electrocommun, Dept Informat, Grad Sch Informat & Engn, Chofu, Tokyo, Japan.
   [Anme, T.] Univ Tsukuba, Fac Med, Int Community Care & Lifespan Dev, Empowerment Sci, Tsukuba, Ibaraki, Japan.
   [Orisaka, M.] Univ Fukui, Dept Obstet & Gynecol, Eiheiji, Japan.
   [Ishitobi, M.] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Child & Adolescent Mental Hlth, Kodaira, Tokyo, Japan.
   [Saito, D. N.; Okazawa, H.] Univ Fukui, Biomed Imaging Res Ctr, Eiheiji, Japan.
   [Sadato, N.] Natl Inst Physiol Sci, Dept Cerebral Res, Okazaki, Aichi, Japan.
   [Omori, M.] Fukui Prefectural Univ, Fac Nursing & Social Welf Sci, Eiheiji, Japan.
   [Sato, M.] Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka, Japan.
   [Sato, M.] Osaka Univ, Div Dev Neurosci, Dept Child Dev, United Grad Sch Child Dev, Suita, Osaka 565, Japan.
   [Sato, M.] Univ Fukui, Suita, Osaka, Japan.
RP Kosaka, H (reprint author), Univ Fukui, Res Ctr Child Mental Dev, Eiheiji, Fukui 9101193, Japan.
EM hirotaka@u-fukui.ac.jp
FU Japan Society for the Promotion of Science [21220005, 21791120,
   25293248, 15K08093, 15H01846]; Japan Research Foundation for Clinical
   Pharmacology; SENSHIN Medical Research Foundation; Takeda Science
   Foundation
FX We express our sincere appreciation to the participants and their
   families who generously and courageously participated in this research.
   Professor Yoshio Minabe from Kanazawa University helped in recruiting
   the participants. The placebo spray was prepared at the Department of
   Pharmacy, University of Fukui Hospital. Kentaro Tokutake and Shiori
   Arioka from the University of Tsukuba helped with the analysis.
   Technical help was provided by Kayo Mita from the University of Fukui
   and Teruko Yuhi from Kanazawa University. Writing assistance was
   provided by Reiko Fujisawa from the University of Fukui. This trial was
   performed under the 'Integrated research on neuropsychiatric disorders'
   and 'Development of biomarker candidates for social behavior' performed
   under the Strategic Research Program for Brain Sciences from MEXT and
   AMED. This research was funded in part by Grants-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science (21220005,
   21791120, 25293248, 15K08093 and 15H01846), the Japan Research
   Foundation for Clinical Pharmacology, SENSHIN Medical Research
   Foundation, and the Takeda Science Foundation.
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Anme T, 2011, ISRN PEDIAT, V2011, DOI DOI 10.5402/2011/272913
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Bales KL, 2007, HORM BEHAV, V52, P274, DOI 10.1016/j.yhbeh.2007.05.004
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924
   Di Napoli A, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-48
   Dmitrienko A, 2011, BIOMETRICAL J, V53, P875, DOI 10.1002/bimj.201100036
   Feifel D, 2015, BEHAV BRAIN RES, V278, P424, DOI 10.1016/j.bbr.2014.10.023
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Feng C, 2015, GENES BRAIN BEHAV, V14, P516, DOI 10.1111/gbb.12234
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goldman MB, 2011, PSYCHOPHARMACOLOGY, V216, P101, DOI 10.1007/s00213-011-2193-8
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guy W, 1976, CLIN GLOBAL IMPRESSI
   Hall SS, 2012, PSYCHONEUROENDOCRINO, V37, P509, DOI 10.1016/j.psyneuen.2011.07.020
   Harris JC, 2013, J AM ACAD CHILD PSY, V52, P998, DOI 10.1016/j.jaac.2013.08.001
   Hofmann SG, 2015, PSYCHIAT RES, V228, P708, DOI 10.1016/j.psychres.2015.05.039
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Jovanovic A, 1997, BRIT J PHARMACOL, V121, P1468, DOI 10.1038/sj.bjp.0701273
   Kosaka H, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-110
   Le Couteur AN, 2003, AUTISM DIAGNOSTIC IN
   LEGROS JJ, 1984, J CLIN ENDOCR METAB, V58, P105
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   MacDonald K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00035
   MacDonald KS, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00194
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Munesue T, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00002
   Okamoto Y, 2016, CNS NEUROL DISORD-DR, V15, P564, DOI 10.2174/1871527315666160413120845
   Orisaka M, 2007, EUR J OBSTET GYN R B, V135, P111, DOI 10.1016/j.ejogrb.2006.07.040
   Renner DB, 2012, J PHARM PHARMACOL, V64, P1709, DOI 10.1111/j.2042-7158.2012.01555.x
   Renner DB, 2012, NEUROSCI LETT, V513, P193, DOI 10.1016/j.neulet.2012.02.037
   Ross TM, 2004, J NEUROIMMUNOL, V151, P66, DOI 10.1016/j.jneuroim.2004.02.011
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Strobl C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-25
   Strobl C, 2009, PSYCHOL METHODS, V14, P323, DOI 10.1037/a0016973
   Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307
   Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Watanabe Y, 2012, PSYCHIAT CLIN NEUROS, V66, P622, DOI 10.1111/j.1440-1819.2012.02396.x
   Wermter AK, 2010, AM J MED GENET B, V153B, P629, DOI 10.1002/ajmg.b.31032
   Wing L, 2002, J CHILD PSYCHOL PSYC, V43, P307, DOI 10.1111/1469-7610.00023
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Yatawara C.J., 2015, MOL PSYCHIAT
NR 59
TC 0
Z9 0
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD AUG 23
PY 2016
VL 6
AR e872
DI 10.1038/tp.2016.152
PG 8
WC Psychiatry
SC Psychiatry
GA DW1SJ
UT WOS:000383422600001
PM 27552585
ER

PT J
AU Zunhammer, M
   Geis, S
   Busch, V
   Eichhammer, P
   Greenlee, MW
AF Zunhammer, Matthias
   Geis, Sandra
   Busch, Volker
   Eichhammer, Peter
   Greenlee, Mark W.
TI Pain modulation by intranasal oxytocin and emotional picture viewing - a
   randomized double-blind fMRI study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CLINICAL-TRIALS; HUMAN BRAIN; RESPONSES; VALENCE; HUMANS; ATTENTION;
   STIMULI; RECOMMENDATIONS; POTENTIALS; PERCEPTION
AB The hormone oxytocin has been hypothesized to influence the emotional dimension of pain. This randomized, placebo-controlled, double-blind, crossover study explored whether intranasal oxytocin and emotional context can affect heat pain perception in 30 healthy male volunteers. After receiving 36 IU oxytocin or placebo, participants underwent functional Magnetic Resonance Imaging (fMRI) during which noxious and non-noxious thermode heat stimuli were applied. Simultaneously, scenes from the International Affective Pictures System (IAPS) with positive, neutral, and negative emotional valence were shown. Heat intensity and unpleasantness ratings were obtained. The activity of whole-brain correlates of heat processing was quantified via multi-voxel pattern analysis. We observed no appreciable main effects of oxytocin on ratings or neural pain correlates. Effects of emotional picture valence on ratings were smaller than reported in previous studies. Nevertheless, oxytocin was found to significantly enhance the influence of picture valence on unpleasantness ratings at noxious heat levels. No corresponding changes in whole-brain correlates of heat intensity processing were found. Our study provides evidence that intranasal oxytocin increases the effects of emotional context on the subjective unpleasantness of experimental heat pain. Future studies are needed to determine whether this effect can be utilized in clinical settings.
C1 [Zunhammer, Matthias] Univ Klinikum Essen, Neurol Klin, Hufelandstr 55, D-45147 Essen, Germany.
   [Geis, Sandra; Greenlee, Mark W.] Univ Regensburg, Lehrstuhl Expt Psychol, Univ Str 31, D-93053 Regensburg, Germany.
   [Busch, Volker; Eichhammer, Peter] Univ Regensburg, Klin Psychiat & Psychotherapie, Univ Str 84, D-93053 Regensburg, Germany.
RP Zunhammer, M (reprint author), Univ Klinikum Essen, Neurol Klin, Hufelandstr 55, D-45147 Essen, Germany.; Greenlee, MW (reprint author), Univ Regensburg, Lehrstuhl Expt Psychol, Univ Str 31, D-93053 Regensburg, Germany.
EM matthias.zunhammer@uk-essen.de;
   mark.greenlee@psychologie.uni-regensburg.de
FU German National Merit Foundation
FX The authors thank Benedict Wild for his help with data-acquisition.
   Author M.Z. was supported by a scholarship of the "German National Merit
   Foundation". The study medication was provided at no cost by sigma-tau
   s.p.a. (Italy). This investigator initiated research project received no
   other specific grant from any funding agency in the public, commercial,
   or not-for-profit sectors.
CR Ashburner J., 2014, SPM12 MANUAL FIL MET
   Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001
   Bates D, 2015, J STAT SOFTW, V67, P1
   Bethlehem RAI, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00048
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Brodersen KH, 2012, NEUROIMAGE, V63, P1162, DOI 10.1016/j.neuroimage.2012.08.035
   Brown JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024124
   Buhle JT, 2013, SOC COGN AFFECT NEUR, V8, P609, DOI 10.1093/scan/nss038
   Corradi-Dell'Acqua C, 2011, J NEUROSCI, V31, P17996, DOI 10.1523/JNEUROSCI.2686-11.2011
   Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966
   Dannecker EA, 2008, BRIT J HEALTH PSYCH, V13, P537, DOI 10.1348/135910707X230985
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Duerden EG, 2013, HUM BRAIN MAPP, V34, P109, DOI 10.1002/hbm.21416
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Goodin BR, 2015, CLIN J PAIN, V31, P757, DOI 10.1097/AJP.0000000000000166
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Horjales-Araujo E, 2013, PAIN, V154, P1469, DOI 10.1016/j.pain.2013.05.011
   Kamping S, 2013, PAIN, V154, P1846, DOI 10.1016/j.pain.2013.06.003
   Kenntner-Mabiala R, 2005, PSYCHOPHYSIOLOGY, V42, P559, DOI 10.1111/j.1469-8986.2005.00310.x
   Kenntner-Mabiala R, 2008, BIOL PSYCHOL, V78, P114, DOI 10.1016/j.biopsycho.2008.01.007
   Kessner S, 2013, JAMA-J AM MED ASSOC, V310, P1733, DOI 10.1001/jama.2013.277446
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kuhberger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105825
   LANG PJ, 1995, AM PSYCHOL, V50, P372, DOI 10.1037//0003-066X.50.5.372
   Lang P. J., 1997, INT AFFECTIVE PICTUR
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Loggia ML, 2008, J PAIN, V9, P784, DOI 10.1016/j.jpain.2008.03.014
   Marquand A, 2010, NEUROIMAGE, V49, P2178, DOI 10.1016/j.neuroimage.2009.10.072
   Meagher MW, 2001, PSYCHOSOM MED, V63, P79
   Morin C, 1998, PAIN, V74, P67, DOI 10.1016/S0304-3959(97)00152-8
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Ogino Y, 2007, CEREB CORTEX, V17, P1139, DOI 10.1093/cercor/bhl023
   Paloyelis Y, 2016, BIOL PSYCHIAT, V79, P693, DOI 10.1016/j.biopsych.2014.10.005
   Rainer G, 2002, NEUROIMAGE, V16, P607, DOI 10.1006/nimg.2002.1086
   Rash J. A., 2013, CLIN J PAIN, V00, P1
   Rash JA, 2014, PSYCHOSOM MED, V76, P422, DOI 10.1097/PSY.0000000000000068
   Rhudy JL, 2008, PAIN, V136, P250, DOI 10.1016/j.pain.2007.06.031
   Rhudy JL, 2006, PAIN, V126, P221, DOI 10.1016/j.pain.2006.06.027
   Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003
   Roy M, 2008, PAIN, V134, P140, DOI 10.1016/j.pain.2007.04.003
   Roy M, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.11.013
   Roy M, 2009, P NATL ACAD SCI USA, V106, P20900, DOI 10.1073/pnas.0904706106
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Singer T, 2008, EMOTION, V8, P781, DOI 10.1037/a0014195
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Villemure C, 2009, J NEUROSCI, V29, P705, DOI 10.1523/JNEUROSCI.3822-08.2009
   Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471
   Wiech K, 2009, NEUROIMAGE, V47, P987, DOI 10.1016/j.neuroimage.2009.05.059
   Zunhammer M, 2015, PSYCHOSOM MED, V77, P156, DOI 10.1097/PSY.0000000000000142
NR 55
TC 0
Z9 0
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 22
PY 2016
VL 6
AR 31606
DI 10.1038/srep31606
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT7XD
UT WOS:000381700700001
PM 27546446
ER

PT J
AU Gong, LP
   Li, J
   Tang, Y
   Han, T
   Wei, CF
   Yu, X
   Li, JX
   Wang, R
   Ma, XL
   Liu, KJ
   Geng, LY
   Liu, SZ
   Yan, B
   Liu, CY
AF Gong, Liping
   Li, Jing
   Tang, Yan
   Han, Ting
   Wei, Chuanfei
   Yu, Xiao
   Li, Jingxin
   Wang, Rong
   Ma, Xuelian
   Liu, Kejing
   Geng, Lingyun
   Liu, Shaozhuang
   Yan, Bing
   Liu, Chuanyong
TI The antinociception of oxytocin on colonic hypersensitivity in rats was
   mediated by inhibition of mast cell degranulation via Ca2+-NOS pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IRRITABLE-BOWEL-SYNDROME; INDUCED VISCERAL HYPERSENSITIVITY; PRIMARY
   AFFERENT NEURONS; OXIDE-LIKE-FACTOR; NITRIC-OXIDE; INTESTINAL
   EPITHELIUM; DIRECT ACTIVATION; IMMUNE-SYSTEM; SUBSTANCE-P; PAIN
AB This study was conducted to investigate the effects of oxytocin (OT) on visceral hypersensitivity/pain and mast cell degranulation and the underlying mechanisms. We found that oxytocin receptor (OTR) was expressed in colonic mast cells in humans and rats, as well as in human mast cell line-1 (HMC-1), rat basophilic leukemia cell line (RBL-2H3) and mouse mastocytoma cell line (P815). OT decreased 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced visceral hypersensitivity, colonic mast cell degranulation and histamine release after mast cell degranulation in rats. Also, OT attenuated the compound 48/80 (C48/80)-evoked histamine release in P815 cells and inward currents, responsible for the mast cell degranulation, in HMC-1, RBL-2H3 and P815 cells. Moreover, these protective effects of OT against visceral hypersensitivity and mast cell degranulation were eliminated by coadministration of OTR antagonist atosiban or a nonselective inhibitor of nitric oxide synthase (NOS), NG-Methyl-L-arginine acetate salt (L-NMMA). Notably, OT evoked a concentration-dependent increase of intracellular Ca2+ in HMC-1, RBL-2H3 and P815 cells, which was responsible for the activation of neuronal NOS (NOS1) and endothelial NOS (NOS3). Our findings strongly suggest that OT might exert the antinociception on colonic hypersensitivity through inhibition of mast cell degranulation via Ca2+-NOS pathway.
C1 [Gong, Liping; Tang, Yan; Han, Ting; Yu, Xiao; Li, Jingxin; Wang, Rong; Ma, Xuelian; Liu, Kejing; Liu, Chuanyong] Shandong Univ, Sch Med, Dept Physiol, Jinan, Peoples R China.
   [Li, Jing] Cent Hosp Zibo, Zibo, Peoples R China.
   [Wei, Chuanfei] Liaocheng Peoples Hosp, Liaocheng, Peoples R China.
   [Geng, Lingyun] Shandong Univ, Shandong Prov Hosp, Jinan, Peoples R China.
   [Liu, Shaozhuang] Shandong Univ, Qilu Hosp, Jinan, Peoples R China.
   [Yan, Bing] Shandong Univ, Jinan Cent Hosp, Jinan, Peoples R China.
   [Liu, Chuanyong] Shandong Univ, Sch Med, Prov Key Lab Mental Disorder, Jinan, Peoples R China.
RP Liu, CY (reprint author), Shandong Univ, Sch Med, Dept Physiol, Jinan, Peoples R China.; Liu, CY (reprint author), Shandong Univ, Sch Med, Prov Key Lab Mental Disorder, Jinan, Peoples R China.
EM liucy@sdu.edu.cn
FU Natural Scientific Foundation of China (NSFC) [31271237, 31471098]
FX This work was supported by the Natural Scientific Foundation of China
   (NSFC, No. 31271237 and 31471098).
CR Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782
   ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909
   Ashmole I, 2013, CLIN EXP ALLERGY, V43, P491, DOI 10.1111/cea.12043
   Barbara G, 2004, GASTROENTEROLOGY, V126, P693, DOI 10.1053/j.gastro.2003.11.055
   Barbara G, 2007, GASTROENTEROLOGY, V132, P26, DOI 10.1053/j.gastro.2006.11.039
   Bell A, 2015, PFLUG ARCH EUR J PHY, V467, P1809, DOI 10.1007/s00424-014-1609-9
   Black LV, 2009, J PAIN, V10, P1065, DOI 10.1016/j.jpain.2009.04.007
   Buhner S, 2009, GASTROENTEROLOGY, V137, P1425, DOI 10.1053/j.gastro.2009.07.005
   Bundoc VG, 2007, EXP EYE RES, V85, P575, DOI 10.1016/j.exer.2007.07.005
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   Cattaneo MG, 2008, BRIT J PHARMACOL, V153, P728, DOI 10.1038/sj.bjp.0707609
   Cenac N, 2007, J CLIN INVEST, V117, P636, DOI 10.1172/JCI29255
   Chadwick VS, 2002, GASTROENTEROLOGY, V122, P1778, DOI 10.1053/gast.2002.33579
   Chau JY, 2013, INFECT IMMUN, V81, P3515, DOI 10.1128/IAI.00380-13
   Che TT, 2012, J NEUROCHEM, V121, P516, DOI 10.1111/j.1471-4159.2012.07702.x
   Chen DW, 2015, SCI REP-UK, V5, DOI 10.1038/srep11731
   Csaba G, 2007, INFLAMM RES, V56, P447, DOI 10.1007/s00011-007-7021-6
   Duridanova DB, 1997, EUR J ENDOCRINOL, V136, P531
   Feng M, 2009, AM J PHYSIOL-ENDOC M, V296, pE1059, DOI 10.1152/ajpendo.90609.2008
   Fowler CJ, 2003, INFLAMM RES, V52, P461, DOI 10.1007/s00011-003-1202-8
   Fu Y. S., 2015, HISTOCHEM CELL BIOL
   Gebhart GF, 2000, GUT, V47, P54
   Gebhart G. F., 2000, GUT S4, V47, piv58
   Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gong L, 2015, NEUROSCIENCE, V289, P417, DOI 10.1016/j.neuroscience.2014.12.058
   Gossen A, 2012, NEUROPEPTIDES, V46, P211, DOI 10.1016/j.npep.2012.07.001
   KANWAR S, 1994, AM J PHYSIOL, V266, pG222
   Klooker TK, 2010, GUT, V59, P1213, DOI 10.1136/gut.2010.213108
   KOIBUCHI Y, 1985, EUR J PHARMACOL, V115, P171
   KUNO M, 1989, AM J PHYSIOL, V256, pC560
   KUROSE I, 1994, CIRC RES, V74, P376
   LEAKE RD, 1981, J CLIN ENDOCR METAB, V53, P730
   LEAKE RD, 1983, OBSTET GYNECOL, V62, P565
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Li J, 2015, NEUROGASTROENT MOTIL, V27, P51, DOI 10.1111/nmo.12469
   Louvel D, 1996, GUT, V39, P741, DOI 10.1136/gut.39.5.741
   MANNAIONI PF, 1991, INT J TISSUE REACT, V13, P271
   MASINI E, 1991, AGENTS ACTIONS, V33, P61, DOI 10.1007/BF01993127
   Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x
   Melis MR, 1997, REGUL PEPTIDES, V69, P105, DOI 10.1016/S0167-0115(97)00002-5
   MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C
   Ohashi K, 2008, LIFE SCI, V82, P419, DOI 10.1016/j.lfs.2007.11.027
   Ohashi K, 2007, J VET MED SCI, V69, P1223, DOI 10.1292/jvms.69.1223
   Ohlsson B, 2006, REGUL PEPTIDES, V135, P7, DOI 10.1016/j.regpep.2006.03.008
   Overman EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039935
   Parikh V, 2001, PHARMACOL RES, V43, P39, DOI 10.1006/phrs.2000.0750
   PEARCE FL, 1982, J IMMUNOL, V128, P2481
   Ray Katrina, 2014, Nat Rev Gastroenterol Hepatol, V11, P202, DOI 10.1038/nrgastro.2014.20
   Reeta K, 2006, REGUL PEPTIDES, V135, P85, DOI 10.1016/j.regpep.2006.04.004
   Rettori V, 1997, P NATL ACAD SCI USA, V94, P2741, DOI 10.1073/pnas.94.6.2741
   SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314
   Sekar Y, 2005, IMMUNOL RES, V33, P223, DOI 10.1385/IR:33:3:223
   Senturk GE, 2013, PEPTIDES, V40, P82, DOI 10.1016/j.peptides.2012.12.006
   Suzuki Y, 2010, MOL IMMUNOL, V47, P640, DOI 10.1016/j.molimm.2009.10.013
   Thompson WG, 1999, GUT, V45, pII43
   Wang YL, 2013, NEUROPEPTIDES, V47, P93, DOI 10.1016/j.npep.2012.12.003
   Welch MG, 2014, AM J PHYSIOL-GASTR L, V307, pG848, DOI 10.1152/ajpgi.00176.2014
   Welch MG, 2009, J COMP NEUROL, V512, P256, DOI 10.1002/cne.21872
   Wouters M. M., 2015, GUT
   Yaksh TL, 2014, ANESTHESIOLOGY, V120, P951, DOI 10.1097/ALN.0000000000000148
   Yan YY, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0713-y
   Yu Q, 2011, CELL TISSUE RES, V344, P227, DOI 10.1007/s00441-011-1155-0
   Yue JX, 2014, CNS NEUROSCI THER, V20, P883, DOI 10.1111/cns.12305
NR 64
TC 0
Z9 0
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 19
PY 2016
VL 6
AR 31452
DI 10.1038/srep31452
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT7JL
UT WOS:000381662800001
PM 27538454
ER

PT J
AU Corbett, BA
   Bales, KL
   Swain, D
   Sanders, K
   Weinstein, TAR
   Muglia, LJ
AF Corbett, Blythe A.
   Bales, Karen L.
   Swain, Deanna
   Sanders, Kevin
   Weinstein, Tamara A. R.
   Muglia, Louis J.
TI Comparing oxytocin and cortisol regulation in a double-blind,
   placebo-controlled, hydrocortisone challenge pilot study in children
   with autism and typical development
SO JOURNAL OF NEURODEVELOPMENTAL DISORDERS
LA English
DT Article
DE Oxytocin; Cortisol; Hydrocortisone; Autism; Hormone; Stress; Arginine
   vasopressin; Stress; Autism spectrum disorder; LHPA axis
ID DEXAMETHASONE SUPPRESSION TEST; PITUITARY-ADRENAL AXIS; RECEPTOR GENE
   OXTR; RANDOMIZED CONTROLLED-TRIAL; MALE PRAIRIE VOLES; SPECTRUM
   DISORDERS; PLASMA OXYTOCIN; INTRANASAL OXYTOCIN; SOCIAL-BEHAVIOR; BRAIN
   OXYTOCIN
AB Background: Children with autism spectrum disorder (ASD) show marked impairment in social functioning and poor adaptation to new and changing contexts, which may be influenced by underlying regulatory processes. Oxytocin (OT) and cortisol are key neuromodulators of biological and behavioral responses, show a synergistic effect, and have been implicated in the neuropathological profile in ASD. However, they are rarely investigated together. The purpose of the pilot study was to evaluate the relationship between cortisol and OT in children with ASD under baseline and physiological stress (hydrocortisone challenge) conditions. Arginine vasopressin (AVP), structurally similar to OT, was also examined.
   Methods: A double-blind, placebo-controlled, randomly assigned, crossover design was employed in 25 children 8-to-12 years with ASD (N = 14) or typical development (TD, N = 11). A low dose of hydrocortisone and placebo were administered via liquid suspension. Analysis of variance (ANOVA) was used to examine the within-subject factor "Condition" (hydrocortisone/ placebo) and "Time" (pre and post) and the between-subject factor "Group" (ASD vs. TD). Pearson correlations examined the relationship between hormone levels and clinical profile.
   Results: There was a significant Time x Condition x Group interaction F (1.23) = 4.18, p = 0.05 showing a rise in OT during the experimental condition (hydrocortisone) and a drop during the placebo condition for the TD group but not the ASD group. There were no group differences for AVP. Hormone levels were associated with social profiles.
   Conclusions: For the TD group, an inverse relationship was observed. OT increased during physiological challenge suggesting that OT played a stress-buffering role during cortisol administration. In contrast for the ASD group, OT remained unchanged or decreased during both the physiological challenge and the placebo condition, suggesting that OT failed to serve as a stress buffer under conditions of physiological stress. While OT has been tied to the social ability of children with ASD, the diminished moderating effect of OT on cortisol may also play a contributory role in the heightened stress often observed in children with ASD. These results contribute to our understanding of the growing complexity of the effects of OT on social behavior as well as the functional interplay and differential regulation OT may have on stress modulation.
C1 [Corbett, Blythe A.; Sanders, Kevin] Vanderbilt Univ, Dept Psychiat & Behav Sci, PMB 40,230 Appleton Pl, Nashville, TN 37203 USA.
   [Corbett, Blythe A.] Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN USA.
   [Corbett, Blythe A.] Vanderbilt Univ, Dept Psychol, Nasvhille, TN USA.
   [Bales, Karen L.] Univ Calif Davis, Davis, CA 95616 USA.
   [Swain, Deanna] Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA.
   [Muglia, Louis J.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Perinatal Inst, Cincinnati, OH USA.
RP Corbett, BA (reprint author), Vanderbilt Univ, Dept Psychiat & Behav Sci, PMB 40,230 Appleton Pl, Nashville, TN 37203 USA.; Corbett, BA (reprint author), Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN USA.
EM blythe.corbett@vanderbilt.edu
FU Vanderbilt Institute Clinical Translational Research (VICTR) [VR1460];
   CTSA from National Center for Advancing Translational Sciences
   [UL1TR000445]; National Institute of Child and Human Development (NICHD)
   (Vanderbilt University Medical Center) [U54 HD83211]
FX This work was supported in part by a Vanderbilt Institute Clinical
   Translational Research (VICTR) grant VR1460 (Corbett), and supported by
   CTSA award No. UL1TR000445 from the National Center for Advancing
   Translational Sciences. Its contents are solely the responsibility of
   the authors and do not necessarily represent official views of the
   National Center for Advancing Translational Sciences or the National
   Institutes of Health; however, members did not contribute to the design,
   analysis, or interpretation of the study data. Additionally, support was
   provided by the National Institute of Child and Human Development
   (NICHD) U54 HD83211 (Vanderbilt University Medical Center).
CR Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Aoki Y, 2015, MOL PSYCHIATR, V20, P447, DOI 10.1038/mp.2014.74
   Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231
   APA, 2013, DIAGN STAT MAN MENT
   Ashwin C, 2007, NEUROPSYCHOLOGIA, V45, P2, DOI 10.1016/j.neuropsychologia.2006.04.014
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Bales KL, 2005, AM J PRIMATOL, V66, P73
   Bales KL, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.117
   Bales KL, 2004, HORM BEHAV, V45, P354, DOI 10.1016/j.yhbeh.2004.01.004
   Bales KL, 2003, BEHAV NEUROSCI, V117, P854, DOI 10.1037/0735-7044.117.4.854
   Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7
   Bartz JA, 2008, PROG BRAIN RES, V170, P451, DOI 10.1016/S0079-6123(08)00435-4
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Bitsika V, 2014, PHYSIOL BEHAV, V127, P1, DOI 10.1016/j.physbeh.2013.12.011
   Brandtzaeg OK, 2016, BIORXIV
   Campbell Donald, 1963, EXPT QUASIEXPERIMENT
   Cardoso C, 2014, PSYCHONEUROENDOCRINO, V49, P161, DOI 10.1016/j.psyneuen.2014.07.014
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Carter CS, 2007, ANN NY ACAD SCI, V1098, P312, DOI 10.1196/annals.1384.006
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   [Anonymous], 2015, CHILD TEEN BMI IS BM
   Charmandari E, 2003, HORM RES, V59, P161, DOI 10.1159/000069325
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Constantino J. N, 2005, SOCIAL RESPONSIVENES
   Corbett BA, CORTISOL CIRCADIAN R
   Corbett BA, 2008, J PSYCHIATR NEUROSCI, V33, P227
   Corbett BA, 2014, J CHILD PSYCHOL PSYC, V55, P924, DOI 10.1111/jcpp.12184
   Corbett BA, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-13
   Corbett BA, 2010, MOL AUTISM, V1, DOI 10.1186/2040-2392-1-13
   Corbett BA, 2009, PSYCHIAT RES-NEUROIM, V173, P196, DOI 10.1016/j.pscychresns.2008.08.005
   Dayas CV, 1999, EUR J NEUROSCI, V11, P2312, DOI 10.1046/j.1460-9568.1999.00645.x
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Egawa J, 2013, PSYCHIAT RES, V208, P99, DOI 10.1016/j.psychres.2012.11.007
   Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Fietta P, 2009, PSYCHIAT CLIN NEUROS, V63, P613, DOI 10.1111/j.1440-1819.2009.02005.x
   Goldman M, 2008, SCHIZOPHR RES, V98, P247, DOI 10.1016/j.schres.2007.09.019
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2001, J CLIN ENDOCR METAB, V86, P4798, DOI 10.1210/jc.86.10.4798
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hennessey JW, 1979, STRESS AROUSAL PITUI
   Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2
   Hienrichs M, 2007, CURR OPIN PSYCHIATR, V20, P158
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   HOSHINO Y, 1987, JPN J PSYCHIAT NEUR, V41, P227
   HOSHINO Y, 1984, FOLIA PSYCHIAT NEU J, V38, P445
   Insel TR, 1999, BIOL PSYCHIAT, V45, P145, DOI 10.1016/S0006-3223(98)00142-5
   Insel TR, 1997, AM J PSYCHIAT, V154, P726
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   JENSEN JB, 1985, J AM ACAD CHILD PSY, V24, P263, DOI 10.1016/S0002-7138(09)61085-2
   Kanner L, 1943, NERV CHILD, V2, P217
   KENDRICK KM, 1991, BRAIN RES BULL, V26, P803, DOI 10.1016/0361-9230(91)90178-M
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kramer KM, 2004, CAN J ZOOL, V82, P1194, DOI 10.1139/Z04-098
   Legros JJ, 2001, PSYCHONEUROENDOCRINO, V26, P649, DOI 10.1016/S0306-4530(01)00018-X
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   LEVINE S, 1993, PSYCHOTHER PSYCHOSOM, V60, P33
   Lipari EF, 2001, EUR J HISTOCHEM, V45, P163
   Lopata C, 2008, J AUTISM DEV DISORD, V38, P1866, DOI 10.1007/s10803-008-0575-5
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   Mager DE, 2003, J PHARM SCI, V92, P1521, DOI 10.1002/jps.10402
   Marinovic-Curin J, 2008, EUR CHILD ADOLES PSY, V17, P39, DOI 10.1007/s00787-007-0632-1
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Martin WL, 2013, 10 WORLD C NEUR HORM
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Mendoza SP, 2000, BIOLOGY OF ANIMAL STRESS, P227, DOI 10.1079/9780851993591.0227
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098
   Naber FBA, 2007, J AUTISM DEV DISORD, V37, P1123, DOI 10.1007/s10803-006-0255-2
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   Neumann ID, 2000, REGUL PEPTIDES, V96, P31, DOI 10.1016/S0167-0115(00)00197-X
   Neumann ID, 2001, EUR J NEUROSCI, V13, P1016, DOI 10.1046/j.0953-816x.2001.01460.x
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   Posey DJ, 2008, CHILD ADOL PSYCH CL, V17, P787, DOI 10.1016/j.chc.2008.06.010
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   RICHDALE AL, 1992, J AUTISM DEV DISORD, V22, P433, DOI 10.1007/BF01048245
   Robinson KJ, 2014, J NEUROSCI METH, V226, P73, DOI 10.1016/j.jneumeth.2014.01.019
   Rubin LH, 2014, SCHIZOPHRENIA BULL, V40, P1374, DOI 10.1093/schbul/sbu027
   Rubin LH, 2013, SCHIZOPHR RES, V146, P138, DOI 10.1016/j.schres.2013.01.019
   Rutter M., 2003, SOCIAL COMMUNICATION
   SAPOLSKY RM, 1986, ENDOCR REV, V7, P284
   Schupp CW, 2013, J AUTISM DEV DISORD, V43, P2405, DOI 10.1007/s10803-013-1790-2
   Simon DM, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-32
   Skuse DH, 2009, TRENDS COGN SCI, V13, P27, DOI 10.1016/j.tics.2008.09.007
   Soravia LM, 2006, P NATL ACAD SCI USA, V103, P5585, DOI 10.1073/pnas.0509184103
   Spratt EG, 2012, J AUTISM DEV DISORD, V42, P75, DOI 10.1007/s10803-011-1214-0
   Steven KH, 1997, DRUG FACTS COMP, P122
   Taurines Regina, 2014, Atten Defic Hyperact Disord, V6, P231, DOI 10.1007/s12402-014-0145-y
   Taylor JL, 2014, PSYCHONEUROENDOCRINO, V49, P207, DOI 10.1016/j.psyneuen.2014.07.015
   Taylor SE, 2006, PSYCHOSOM MED, V68, P238, DOI 10.1097/01.psy.0000203242.95990.74
   Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038
   Tordjman S, 1997, J CHILD PSYCHOL PSYC, V38, P705, DOI 10.1111/j.1469-7610.1997.tb01697.x
   Turner RA, 1999, PSYCHIATRY, V62, P97
   Wechsler D., 1999, WECHSLER ABBREVIATED
   Weisman O, 2012, BIOL PSYCHIAT, V72, P982, DOI 10.1016/j.biopsych.2012.06.011
   Weisman O, 2012, PSYCHONEUROENDOCRINO, V37, P1582, DOI 10.1016/j.psyneuen.2012.02.014
   Welch MG, 2005, INT REV NEUROBIOL, V71, P273, DOI 10.1016/S0074-7742(05)71012-6
   Wermter AK, 2010, AM J MED GENET B, V153B, P629, DOI 10.1002/ajmg.b.31032
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   WINSLOW JT, 1993, PSYCHOPHARMACOL BULL, V29, P409
   WINTERER J, 1985, J PEDIATR-US, V106, P137, DOI 10.1016/S0022-3476(85)80486-8
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Young LJ, 1998, TRENDS NEUROSCI, V21, P71, DOI 10.1016/S0166-2236(97)01167-3
   Young LJ, 2002, MOL PSYCHIATR, V7, pS38, DOI 10.1038/sj.mp.4001175
   Yrigollen CM, 2008, BIOL PSYCHIAT, V63, P911, DOI 10.1016/j.biopsych.2007.11.015
NR 120
TC 0
Z9 0
U1 4
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1866-1947
EI 1866-1955
J9 J NEURODEV DISORD
JI J. Neurodev. Disord.
PD AUG 18
PY 2016
VL 8
AR 32
DI 10.1186/s11689-016-9165-6
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DV8SQ
UT WOS:000383207400001
PM 27540420
ER

PT J
AU Sasaki, T
   Hashimoto, K
   Oda, Y
   Ishima, T
   Yakita, M
   Kurata, T
   Kunou, M
   Takahashi, J
   Kamata, Y
   Kimura, A
   Niitsu, T
   Komatsu, H
   Hasegawa, T
   Shiina, A
   Hashimoto, T
   Kanahara, N
   Shimizu, E
   Iyo, M
AF Sasaki, Tsuyoshi
   Hashimoto, Kenji
   Oda, Yasunori
   Ishima, Tamaki
   Yakita, Madoka
   Kurata, Tsutomu
   Kunou, Masaru
   Takahashi, Jumpei
   Kamata, Yu
   Kimura, Atsushi
   Niitsu, Tomihisa
   Komatsu, Hideki
   Hasegawa, Tadashi
   Shiina, Akihiro
   Hashimoto, Tasuku
   Kanahara, Nobuhisa
   Shimizu, Eiji
   Iyo, Masaomi
TI Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in
   Adolescents (TRDIA)' Group
SO PLOS ONE
LA English
DT Article
ID BIPOLAR DISORDER; RATING-SCALE; VALIDITY; OUTCOMES; CHILDREN; TORDIA;
   RELIABILITY; VASOPRESSIN; BEHAVIOR
AB Objective
   'Treatment-resistant depression' is depression that does not respond to an adequate regimen of evidence-based treatment. Treatment-resistant depression frequently becomes chronic. Children with treatment-resistant depression might also develop bipolar disorder (BD). The objective of this study was to determine whether serum levels of oxytocin (OXT) in treatment-resistant depression in adolescents (TRDIA) differ from non-treatment-resistant depression in adolescents (non-TRDIA) or controls. We also investigated the relationships between serum OXT levels and the clinical symptoms, severity, and familial histories of adolescent depressive patients.
   Methods
   We measured serum OXT levels: TRDIA (n = 10), non-TRDIA (n = 27), and age-and sex-matched, neurotypical controls (n = 25). Patients were evaluated using the Children's Depression Rating Scale-Revised (CDRS-R) and the Depression Self-Rating Scale for Children-Japanese Version (DSRS-C-J). The patients were also assessed retrospectively using the following variables: familial history of major depressive disorder and BD (1st degree or 2nd degree), history of disruptive mood dysregulation disorder, recurrent depressive disorder (RDD), history of antidepressant activation.
   Results
   Serum levels of OXT among the TRDIA and non-TRDIA patients and controls differed significantly. Interestingly, the rates of a family history of BD (1st or 2nd degree), RDD and a history of antidepressant activation in our TRDIA group were significantly higher than those of the non-TRDIA group.
   Conclusions
   Serum levels of OXT may play a role in the pathophysiology of TRDIA.
C1 [Sasaki, Tsuyoshi; Yakita, Madoka; Kurata, Tsutomu; Kunou, Masaru; Takahashi, Jumpei; Iyo, Masaomi] Chiba Univ Hosp, Dept Child Psychiat, Chiba, Japan.
   [Sasaki, Tsuyoshi; Oda, Yasunori; Kamata, Yu; Kimura, Atsushi; Niitsu, Tomihisa; Komatsu, Hideki; Hasegawa, Tadashi; Shiina, Akihiro; Hashimoto, Tasuku; Iyo, Masaomi] Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba, Japan.
   [Hashimoto, Kenji; Ishima, Tamaki; Iyo, Masaomi] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba, Japan.
   [Kanahara, Nobuhisa; Iyo, Masaomi] Chiba Univ, Ctr Forens Mental Hlth, Div Med Treatment & Rehabil, Chiba, Japan.
   [Kunou, Masaru; Shimizu, Eiji] Chiba Univ, Grad Sch Med, Dept Cognit Behav Physiol, Chiba, Japan.
RP Sasaki, T (reprint author), Chiba Univ Hosp, Dept Child Psychiat, Chiba, Japan.; Sasaki, T (reprint author), Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba, Japan.
EM sasaki@faculty.chiba-u.jp
OI Sasaki, Tsuyoshi/0000-0001-8502-6469
FU Health Labour Sciences Research Grant [KAKENHI 201419072A]; Astellas;
   Dainippon Sumitomo; Eli Lilly; Janssen; Mochida; Otsuka; Shionogi;
   Taisho; Yoshitomi; Novartis; Abbvie; Ministry of Health, Labour and
   Welfare; Non-Profit Organization of dependence research; General
   Association for Justice; Sumitomo Dainippon Phama; Chiba-ken
   Bengoshi-kai (Chiba Lawyers Association); Chugai; Pfizer;
   Daiichi-Sankyo; Eizai; Glaxosmithkline; MSD; Takeda; Asahi Kasei; Sanofi
FX This study was supported in part by a Health Labour Sciences Research
   Grant [KAKENHI 201419072A]
   (https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=20141907
   2A). TS has received research support or speakers' honoraria from
   Astellas, Dainippon Sumitomo, Eli Lilly, Janssen, Mochida, Otsuka,
   Shionogi, Taisho, and Yoshitomi and he has also received research
   support from Novartis, Otsuka, and Taisho. KH has served as a scientific
   consultant to Taisho, and he has also received research support from
   Abbvie, Dainippon Sumitomo, Mochida, Otsuka, and Taisho. TK has received
   speakers' honoraria from Astellas, Eli Lilly, Janssen, Takeda, and
   Otsuka. MK has received speakers' honoraria from Eli Lilly. YK has
   received speakers' honoraria from Dainippon Sumitomo and Otsuka. TN has
   received honoraria from Eli Lilly and Dainippon Sumitomo. HK has
   received research support or speakers' honoraria from Dainippon
   Sumitomo, Eli Lilly, and Novartis. T. Hasegawa has received speakers'
   honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, Mochida, Otsuka,
   and Shionogi. AS has received research support from Ministry of Health,
   Labour and Welfare, Non-Profit Organization of dependence research and
   General Association for Justice, a lecture fee from Sumitomo Dainippon
   Phama and Chiba-ken Bengoshi-kai (Chiba Lawyers Association). T.
   Hashimoto has received honoraria as speaker/consultant from Astellas,
   Glaxosmithkline, Meiji Seika, Mochida, Otsuka, Tanabe Mitsubishi,
   Yoshitomiyakuhin, and received research/grant support from Astellas,
   Chugai, Otsuka, Pfizer, and Shionogi. NK has received honoraria from Eli
   Lilly, Janssen, and Otsuka. ES has received speaking honoraria from MSD,
   Meiji Seika, Mochida, Eli Lilly, Janssen, and Yoshitomi. MI has received
   research support and honoraria from Astellas, Daiichi-Sankyo, Dainippon
   Sumitomo, Eizai, Glaxosmithkline, Janssen, Mochida, MSD, Novartis,
   Otsuka, Takeda, and Yoshitomi, and received research support from Asahi
   Kasei, Pfizer, Sanofi, Shionogi, Taisho, and received honoraria from
   Chugai-Nissin Pharmaceutical, Eli Lilly, Hisamitsu, Kyowa-Hakko Kirin,
   Meiji, Ono, and Tsumura. YO, TI, MY, JT, and AK, report no biomedical
   financial interests or potential conflicts of interest. The funders
   along with any other relevant declarations relating to employment,
   consultancy, patents, products in development, marketed products had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. This does not alter the authors'
   adherence to PLOS ONE policies on sharing data and materials.
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   American Psychiatric Association, 2013, DIAGNOSTIC AND STATI
   BIRLESON P, 1981, J CHILD PSYCHOL PSYC, V22, P73, DOI 10.1111/j.1469-7610.1981.tb00533.x
   Birmaher B, 2007, J AM ACAD CHILD PSY, V46, P1503, DOI 10.1097/chi.0b013e318145ae1c
   Brent D., TREATMENT RESISTANT
   Brent DA, 2009, J CHILD PSYCHOL PSYC, V50, P143, DOI 10.1111/j.1469-7610.2008.02037.x
   Emslie GJ, 2010, AM J PSYCHIAT, V167, P782, DOI 10.1176/appi.ajp.2010.09040552
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Kennard BD, 2009, J AM ACAD CHILD PSY, V48, P186, DOI 10.1097/CHI.0b013e31819176f9
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Maalouf FT, 2012, J AFFECT DISORDERS, V138, P86, DOI 10.1016/j.jad.2011.12.021
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   March J, 2004, JAMA-J AM MED ASSOC, V292, P807
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Murata T, 1996, JPN J PSYCHIAT, V1, P131
   Pitchot W, 2008, J PSYCHIATR RES, V42, P684, DOI 10.1016/j.jpsychires.2007.07.007
   POZNANSKI EO, 1984, J AM ACAD CHILD PSY, V23, P191, DOI 10.1097/00004583-198403000-00011
   Reid JM, 2010, CHILD YOUTH CARE FOR, V39, P113, DOI 10.1007/s10566-010-9095-5
   Sakolsky DJ, 2011, J CLIN PSYCHOPHARM, V31, P92, DOI 10.1097/JCP.0b013e318204b117
   Sasaki T, 2011, OPEN CLIN CHEM J, V4, P28
   Sasaki T, 2015, PSYCHIAT RES, V228, P746, DOI 10.1016/j.psychres.2015.05.029
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Smith Donald F, 2013, Front Psychiatry, V4, P57, DOI 10.3389/fpsyt.2013.00057
   Stavropoulos KKM, 2013, J CHILD PSYCHOL PSYC, V54, P603, DOI 10.1111/jcpp.12061
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   Turan T, 2013, PSYCHONEUROENDOCRINO, V38, P2890, DOI 10.1016/j.psyneuen.2013.07.017
   World Health Organization, ICD 10 CLASS MENT BE
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Youngstrom EA, 2012, ISR J PSYCHIATR REL, V49, P15
NR 30
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2016
VL 11
IS 8
AR e0160767
DI 10.1371/journal.pone.0160767
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT6ES
UT WOS:000381577000030
ER

PT J
AU Liu, HX
   Ma, S
   Nan, Y
   Yang, WH
AF Liu, Hong-Xiang
   Ma, Shuang
   Nan, Yong
   Yang, Wan-Hua
TI Transient receptor potential melastatin-2 and temperature participate in
   the process of CD38-regulated oxytocin secretion
SO NEUROREPORT
LA English
DT Article
DE agonist; antagonist; CD38; oxytocin; temperature; transient receptor
   potential melastatin-2
ID CYCLIC-ADP-RIBOSE; MULTIFUNCTIONAL ION-CHANNEL; OXIDATIVE STRESS; TRPM2;
   DISORDER; BEHAVIOR
AB In recent studies, oxytocin showed potential for the treatment of mental diseases. CD38 is essential for oxytocin release, and hence plays a critical role in social behavior. CD38 catalyzes beta-NAD(+) into cyclic ADP ribose (cADPR), which could elevate the intracellular Ca2+ by Ca2+-permeable channels for oxytocin secretion. The temperature-sensitive cation channel, transient receptor potential melastatin-2 (TRPM2), is a cation-nonselective cation and has been shown to affect oxytocin indirectly. The aim of the present study was to verify the participation of temperature and TRPM2 in CD38-regulated oxytocin release. The crude membranes were prepared to isolate the nerve terminals from the posterior pituitary. At 34 degrees C, 37 degrees C, and 39 degrees C, agonists (beta-NAD(+), ADPR, cADPR) and antagonists (8-Br-cADPR, 2-APB) were used to stimulate the nerve terminals. Oxytocin releases were investigated by enzyme-linked immunosorbent assay. In addition, the expression of TRPM2 and CD38 in the hypothalamus and pituitary was detected by western blotting and quantitative PCR. CD38 agonists (beta-NAD(+), cADPR) and antagonist (8-Br-cADPR) could increase or reduce the oxytocin release, respectively. TRPM2 agonist (ADPR) and antagonist (2-APB) alone could also regulate oxytocin release. Furthermore, temperature could increase agonist stimulation and attenuate the antagonist inhibition on oxytocin release. In addition, CD38 and TRPM2 were expressed in the hypothalamus and pituitary at both the mRNA and the protein level. TRPM2 in pituitary nerve terminals plays a role in oxytocin release. Temperature-enhanced oxytocin release by CD38 and TRPM2. TRPM2 might be involved in the process of CD38-regulated oxytocin release. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Liu, Hong-Xiang; Ma, Shuang; Nan, Yong; Yang, Wan-Hua] Shanghai Jiao Tong Univ, Peoples Hosp 1, Songjiang Branch, Dept Emergency Crit Care Unit, 748 Middle Zhongshan Rd, Shanghai 201699, Peoples R China.
RP Liu, HX (reprint author), Shanghai Jiao Tong Univ, Peoples Hosp 1, Songjiang Branch, Dept Emergency Crit Care Unit, 748 Middle Zhongshan Rd, Shanghai 201699, Peoples R China.
EM snakerjnyy@163.com
FU National Natural Science Foundation of China [31200619]
FX This work was supported by the National Natural Science Foundation of
   China (31200619).
CR Amina S, 2010, J NEUROENDOCRINOL, V22, P460, DOI 10.1111/j.1365-2826.2010.01978.x
   Baez David, 2014, Curr Top Membr, V74, P51, DOI 10.1016/B978-0-12-800181-3.00003-8
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Higashida H, 2015, J PHYSIOL SCI, V66, P275
   HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   LECKMAN JF, 1994, PSYCHONEUROENDOCRINO, V19, P723, DOI 10.1016/0306-4530(94)90021-3
   Liu H. X., 2012, MESSENGER, V1, P150, DOI DOI 10.1166/MSR.2012.1015
   Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140
   Lopatina O, 2010, NEUROPHARMACOLOGY, V58, P50, DOI 10.1016/j.neuropharm.2009.06.012
   Matsuzaki M, 2012, J PHYSIOL SCI, V62, P441, DOI 10.1007/s12576-012-0232-9
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Naziroglu M, 2011, J MEMBRANE BIOL, V241, P51, DOI 10.1007/s00232-011-9356-8
   RU XC, 2014, ACTA PHYSIOL SINICA, V66, P7
   Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083
NR 18
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD AUG 17
PY 2016
VL 27
IS 12
BP 935
EP 939
DI 10.1097/WNR.0000000000000634
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA DQ8GG
UT WOS:000379446500009
PM 27348016
ER

PT J
AU Ma, YN
   Li, SY
   Wang, CB
   Liu, Y
   Li, WX
   Yan, XY
   Chen, Q
   Han, SH
AF Ma, Yina
   Li, Shiyi
   Wang, Chenbo
   Liu, Yi
   Li, Wenxin
   Yan, Xinyuan
   Chen, Qiang
   Han, Shihui
TI Distinct oxytocin effects on belief updating in response to desirable
   and undesirable feedback
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE oxytocin; social adaptation; confidence; belief updating; optimism
ID DISPOSITIONAL OPTIMISM; PSYCHOLOGICAL RESOURCES; HUMANS; AVOIDANCE;
   BEHAVIOR; ANXIETY; HEALTH; TRUST; UNCERTAINTY; ADAPTATION
AB Humans update their beliefs upon feedback and, accordingly, modify their behaviors to adapt to the complex, changing social environment. However, people tend to incorporate desirable (better than expected) feedback into their beliefs but to discount undesirable (worse than expected) feedback. Such optimistic updating has evolved as an advantageous mechanism for social adaptation. Here, we examine the role of oxytocin (OT). an evolutionary ancient neuropeptide pivotal for social adaptation. in belief updating upon desirable and undesirable feedback in three studies (n = 320). Using a double-blind, placebo-controlled between-subjects design, we show that intranasally administered OT (IN-OT) augments optimistic belief updating by facilitating updates of desirable feedback but impairing updates of undesirable feedback. The IN-OT-induced impairment in belief updating upon undesirable feedback is more salient in individuals with high, rather than with low, depression or anxiety traits. IN-OT selectively enhances learning rate (the strength of association between estimation error and subsequent update) of desirable feedback. IN-OT also increases participants' confidence in their estimates after receiving desirable but not undesirable feedback, and the OT effect on confidence updating upon desirable feedback mediates the effect of IN-OT on optimistic belief updating. Our findings reveal distinct functional roles of OT in updating the first-order estimation and second-order confidence judgment in response to desirable and undesirable feedback, suggesting a molecular substrate for optimistic belief updating.
C1 [Ma, Yina; Li, Shiyi; Yan, Xinyuan] Beijing Normal Univ, McGovern Inst Brain Res, IDG, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.
   [Wang, Chenbo; Liu, Yi; Li, Wenxin; Han, Shihui] Peking Univ, Beijing Key Lab Behav & Mental Hlth, McGovern Inst Brain Res, Sch Psychol & Cognit Sci,IDG, Beijing 100080, Peoples R China.
   [Chen, Qiang] Lieber Inst Brain Dev, Baltimore, MD 21205 USA.
RP Ma, YN (reprint author), Beijing Normal Univ, McGovern Inst Brain Res, IDG, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.; Han, SH (reprint author), Peking Univ, Beijing Key Lab Behav & Mental Hlth, McGovern Inst Brain Res, Sch Psychol & Cognit Sci,IDG, Beijing 100080, Peoples R China.
EM yma@bnu.edu.cn; shan@pku.edu.cn
FU State Key Laboratory of Cognitive Neuroscience and Learning,
   IDG/McGovern Institute for Brain Research; Open Research Fund of the
   State Key Laboratory of Cognitive Neuroscience and Learning; Beijing
   Municipal Science & Technology Commission [Z151100003915122]; National
   Natural Science Foundation of China [31470986, 31421003, 91332125];
   Ministry of Education of China [20130001110049]
FX We acknowledge Drs. M. Crockett, A. Kappes, S. Shamay-Tsoory, and C.
   Zink for their valuable comments on an early draft; B. Li for OT
   preparation; and Dr. K. Woodcock for proofreading. This work was
   supported by startup funding from the State Key Laboratory of Cognitive
   Neuroscience and Learning, IDG/McGovern Institute for Brain Research;
   Open Research Fund of the State Key Laboratory of Cognitive Neuroscience
   and Learning (Y.M.); Beijing Municipal Science & Technology Commission
   (Z151100003915122) (to Y.M.); National Natural Science Foundation of
   China Projects 31470986, 31421003, and 91332125; and Ministry of
   Education of China Project 20130001110049 (to S.H.).
CR Alvares GA, 2012, PSYCHONEUROENDOCRINO, V37, P2022, DOI 10.1016/j.psyneuen.2012.04.018
   Andersson MA, 2012, SOCIOL QUART, V53, P92, DOI 10.1111/j.1533-8525.2011.01227.x
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carver CS, 2014, TRENDS COGN SCI, V18, P293, DOI 10.1016/j.tics.2014.02.003
   Choe HK, 2015, NEURON, V87, P152, DOI 10.1016/j.neuron.2015.06.022
   De Dreu CKW, 2012, PSYCHONEUROENDOCRINO, V37, P871, DOI 10.1016/j.psyneuen.2011.10.003
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   De Martino B, 2013, NAT NEUROSCI, V16, P105, DOI 10.1038/nn.3279
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Eil D, 2011, AM ECON J-MICROECON, V3, P114, DOI 10.1257/mic.3.2.114
   Garrett N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00639
   Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Hirsch JK, 2012, INT PSYCHOGERIATR, V24, P1614, DOI 10.1017/S1041610212000762
   IsHak WW, 2011, J AFFECT DISORDERS, V130, P1, DOI 10.1016/j.jad.2010.06.001
   Korn CW, 2014, PSYCHOL MED, V44, P579, DOI 10.1017/S0033291713001074
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lebreton M, 2015, NAT NEUROSCI, V18, P1159, DOI 10.1038/nn.4064
   Leknes S, 2013, SOC COGN AFFECT NEUR, V8, P741, DOI 10.1093/scan/nss062
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Ma WJ, 2014, ANNU REV NEUROSCI, V37, P205, DOI 10.1146/annurev-neuro-071013-014017
   Ma Y, 2016, TRENDS COGN SCI, V20, P133, DOI 10.1016/j.tics.2015.10.009
   Ma YN, 2015, NEUROPSYCHOPHARMACOL, V40, P2379, DOI 10.1038/npp.2015.87
   MacDonald K, 2013, PSYCHONEUROENDOCRINO, V38, P2831, DOI 10.1016/j.psyneuen.2013.05.014
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   McKay RT, 2009, BEHAV BRAIN SCI, V32, P493, DOI 10.1017/S0140525X09990975
   Perez-Rodrigueza MM, 2015, EUR NEUROPSYCHOPHARM, V25, P265
   Nave G, 2015, PERSPECT PSYCHOL SCI, V10, P772, DOI 10.1177/1745691615600138
   Palminteri S, 2012, NEURON, V76, P998, DOI 10.1016/j.neuron.2012.10.017
   Puskar K R, 1999, Issues Ment Health Nurs, V20, P115
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   Radke S, 2015, PSYCHONEUROENDOCRINO, V60, P75, DOI 10.1016/j.psyneuen.2015.06.006
   Radke S, 2013, PSYCHOL SCI, V24, P1573, DOI 10.1177/0956797612472682
   Riem MME, 2014, PROG NEURO-PSYCHOPH, V51, P105, DOI 10.1016/j.pnpbp.2014.01.014
   Ruiz JM, 2006, J PERS SOC PSYCHOL, V91, P255, DOI 10.1037/0022-3514.91.2.255
   Saphire-Bernstein S, 2011, P NATL ACAD SCI USA, V108, P15118, DOI 10.1073/pnas.1113137108
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Sharot T, 2016, TRENDS COGN SCI, V20, P25, DOI 10.1016/j.tics.2015.11.002
   Sharot T, 2012, CURR BIOL, V22, P1477, DOI 10.1016/j.cub.2012.05.053
   Sharot T, 2011, CURR BIOL, V21, pR941, DOI 10.1016/j.cub.2011.10.030
   Sharot T, 2011, NAT NEUROSCI, V14, P1475, DOI 10.1038/nn.2949
   Spielberger C.D., 1983, STATE TRAIT ANXIETY
   Stavropoulos KKM, 2013, J CHILD PSYCHOL PSYC, V54, P603, DOI 10.1111/jcpp.12061
   Taylor SE, 2000, AM PSYCHOL, V55, P99, DOI 10.1037//0003-066X.55.1.99
   Taylor SE, 2011, ADV EXP SOC PSYCHOL, V44, P1, DOI 10.1016/B978-0-12-385522-0.00001-9
   Taylor ZE, 2012, J FAM PSYCHOL, V26, P133, DOI 10.1037/a0026755
   Toth I, 2012, PSYCHOPHARMACOLOGY, V223, P149, DOI 10.1007/s00213-012-2702-4
   Unkelbach C, 2008, PSYCHOL SCI, V19, P1092, DOI 10.1111/j.1467-9280.2008.02206.x
   Varki A, 2009, NATURE, V460, P684, DOI 10.1038/460684c
   Vilares I, 2012, CURR BIOL, V22, P1641, DOI 10.1016/j.cub.2012.07.010
   Vollmann M, 2011, EUR J PERSONALITY, V25, P146, DOI 10.1002/per.803
   Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181
   WEINSTEIN ND, 1995, HEALTH PSYCHOL, V14, P132, DOI 10.1037/0278-6133.14.2.132
NR 59
TC 0
Z9 0
U1 10
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP 9256
EP 9261
DI 10.1073/pnas.1604285113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200051
PM 27482087
ER

PT J
AU Sciabola, S
   Goetz, GH
   Bai, G
   Rogers, BN
   Gray, DL
   Duplantier, A
   Fonseca, KR
   Vanase-Frawley, MA
   Kablaoui, NM
AF Sciabola, Simone
   Goetz, Gilles H.
   Bai, Guoyun
   Rogers, Bruce N.
   Gray, David L.
   Duplantier, Allen
   Fonseca, Kari R.
   Vanase-Frawley, Michelle A.
   Kablaoui, Natasha M.
TI Systematic N-methylation of oxytocin: Impact on pharmacology and
   intramolecular hydrogen bonding network
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Intramolecular hydrogen bond; Hydrogen bonding; Polarity; Hidden
   polarity; SFC; NMR; Oxytocin; Cyclic peptide; Peptide
ID PEPTIDE-HORMONE-OXYTOCIN; HIGHLY POTENT ANALOGUE; DIMETHYL-SULFOXIDE;
   ORAL BIOAVAILABILITY; INTRANASAL DELIVERY; CYCLIC-PEPTIDES; NMR;
   PERMEABILITY; CONFORMATION; HUMANS
AB Oxytocin (OT) is a peptide hormone agonist of the OT receptor (OTR) that plays an important role in social behaviors such as pair bonding, maternal bonding and trust. The pharmaceutical development of OT as an oral peptide therapeutic has been hindered historically by its unfavorable physicochemical properties, including molecular weight, polarity and number of hydrogen bond donors, which determines poor cell permeability. Here we describe the first systematic study of single and multiple N-methylations of OT and their effect on physicochemical properties as well as potency at the OT receptor. The agonist EC50 and percent effect for OTR are reported and show that most N-methylations are tolerated but with some loss in potency compared to OT. The effect of N-methylation on exposed polarity is assessed through the EPSA chromatographic method and the results validated against NMR temperature coefficient experiments and the determination of NMR solution structures. We found that backbone methylation of residues not involved in IMHB and removal of the N-terminal amine can significantly reduce the exposed polarity of peptides, and yet retain a significant OTR agonist activity. The results of this study also expose the potential challenge of using the N-methylation strategy for the OT system; while exposed polarity is reduced, in some cases backbone methylation produces a significant conformational change that compromises agonist activity. The data presented provides useful insights on the SAR of OT and suggests future design strategies that can be used to develop more permeable OTR agonists based on the OT framework. (C) 2016 Published by Elsevier Ltd.
C1 [Goetz, Gilles H.; Bai, Guoyun; Vanase-Frawley, Michelle A.] Pfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA.
   [Sciabola, Simone; Rogers, Bruce N.; Gray, David L.; Duplantier, Allen; Kablaoui, Natasha M.] Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USA.
   [Fonseca, Kari R.] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Cambridge, MA 02139 USA.
RP Kablaoui, NM (reprint author), Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USA.
EM Natasha.M.Kablaoui@pfizer.com
CR Alex A, 2011, MEDCHEMCOMM, V2, P669, DOI 10.1039/c1md00093d
   BALLARDIN A, 1978, BIOCHEMISTRY-US, V17, P4443, DOI 10.1021/bi00614a014
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Beck JG, 2012, J AM CHEM SOC, V134, P12125, DOI 10.1021/ja303200d
   BHASKARAN R, 1992, BIOPOLYMERS, V32, P1599, DOI 10.1002/bip.360321203
   Biron E, 2008, ANGEW CHEM INT EDIT, V47, P2595, DOI 10.1002/anie.200705797
   Bock JE, 2013, ACS CHEM BIOL, V8, P488, DOI 10.1021/cb300515u
   Bockus AT, 2015, J MED CHEM, V58, P4581, DOI 10.1021/acs.jmedchem.5b00128
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Budesinsky M, 2005, PROTEIN PEPTIDE LETT, V12, P343, DOI 10.2174/0929866053765752
   Chatterjee J, 2008, ACCOUNTS CHEM RES, V41, P1331, DOI 10.1021/ar8000603
   Choc MG, 1997, INT J DERMATOL, V36, P1, DOI 10.1046/j.1365-4362.36.s1.2.x
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   DEBER CM, 1970, J AM CHEM SOC, V92, P6191, DOI 10.1021/ja00724a016
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   DUVIGNEAUD V, 1960, J BIOL CHEM, V235, pPC64
   Fasinu P, 2011, BIOPHARM DRUG DISPOS, V32, P185, DOI 10.1002/bdd.750
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030
   Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3
   Goetz GH, 2014, ACS MED CHEM LETT, V5, P1167, DOI 10.1021/ml500239m
   Goetz GH, 2014, J MED CHEM, V57, P2920, DOI 10.1021/jm401859b
   Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   HOPE DB, 1962, J BIOL CHEM, V237, P1563
   KATO T, 1993, J BIOMOL NMR, V3, P653
   Liu XF, 2011, EXPERT OPIN DRUG DEL, V8, P1681, DOI 10.1517/17425247.2011.633508
   LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319
   Malerba F, 2011, EXPERT OPIN DRUG DEL, V8, P1277, DOI 10.1517/17425247.2011.588204
   Manning M., PROGR BRAIN RES
   Ohno A, 2010, MAGN RESON CHEM, V48, P168, DOI 10.1002/mrc.2557
   Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033
   Ovadia O, 2011, MOL PHARMACEUT, V8, P479, DOI 10.1021/mp1003306
   PITMAN RK, 1993, PSYCHIAT RES, V48, P107, DOI 10.1016/0165-1781(93)90035-F
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   Tang L, 2004, J PHARM SCI-US, V93, P2184, DOI 10.1002/jps.20125
   URRY DW, 1971, P NATL ACAD SCI USA, V68, P956, DOI 10.1073/pnas.68.5.956
   URRY DW, 1970, P NATL ACAD SCI USA, V66, P111, DOI 10.1073/pnas.66.1.111
   Wittelsberger A, 2005, J MED CHEM, V48, P6553, DOI 10.1021/jm049205z
   WOOD SP, 1986, SCIENCE, V232, P633, DOI 10.1126/science.3008332
   Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128
NR 43
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 15
PY 2016
VL 24
IS 16
BP 3513
EP 3520
DI 10.1016/j.bmc.2016.05.062
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DS2AF
UT WOS:000380515700020
PM 27297999
ER

PT J
AU Robinson, N
   Brennan, M
AF Robinson, Natalie
   Brennan, Marnie
CA BestBET Vets
TI Oxytocin versus carbetocin administered to cows after uncomplicated
   calvings and subsequent fertility
SO VETERINARY RECORD
LA English
DT Editorial Material
C1 [Robinson, Natalie; Brennan, Marnie] Univ Nottingham, Nottingham NG7 2RD, England.
RP Robinson, N (reprint author), Univ Nottingham, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD AUG 13
PY 2016
VL 179
IS 7
BP 175
EP U65
DI 10.1136/vr.i3834
PG 2
WC Veterinary Sciences
SC Veterinary Sciences
GA DX5TO
UT WOS:000384445300020
ER

PT J
AU Busnelli, M
   Kleinau, G
   Muttenthaler, M
   Stoev, S
   Manning, M
   Bibic, L
   Howell, LA
   McCormick, PJ
   Di Lascio, S
   Braida, D
   Sala, M
   Rovati, GE
   Bellini, T
   Chini, B
AF Busnelli, Marta
   Kleinau, Gunnar
   Muttenthaler, Markus
   Stoev, Stoytcho
   Manning, Maurice
   Bibic, Lucka
   Howell, Lesley A.
   McCormick, Peter J.
   Di Lascio, Simona
   Braida, Daniela
   Sala, Mariaelvina
   Rovati, G. Enrico
   Bellini, Tommaso
   Chini, Bice
TI Design and Characterization of Superpotent Bivalent Ligands Targeting
   Oxytocin Receptor Dimers via a Channel-Like Structure
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PROTEIN-COUPLED RECEPTORS; SINGLE-MOLECULE ANALYSIS; CRYSTAL-STRUCTURE;
   ALLOSTERIC INTERACTIONS; BETA(2)-ADRENERGIC RECEPTOR; ERK1/2 ACTIVATION;
   SOCIAL-BEHAVIOR; IN-VITRO; AGONISTS; GPCR
AB Dimeric/oligomeric states of G-protein coupled receptors have been difficult to target. We report here bivalent ligands consisting of two identical oxytocin-mimetics that induce a three order magnitude boost in G-protein signaling of oxytocin receptors (OTRs) in vitro and a 100- and 40-fold gain in potency in vivo in the social behavior of mice and zebrafish. Through receptor mutagenesis and interference experiments with synthetic peptides mimicking transmembrane helices (TMH), we show that such superpotent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-TMH2 interface. Moreover, in this arrangement, only the analogues with a well-defined spacer length (similar to 25 angstrom) precisely fit inside a channel-like passage between the two protomers of the dimer. The newly discovered oxytocin bivalent ligands represent a powerful tool for targeting dimeric OTR in neurodevelopmental and psychiatric disorders and, in general, provide a framework to untangle specific arrangements of G-protein coupled receptor dimers.
C1 [Busnelli, Marta; Sala, Mariaelvina; Chini, Bice] CNR, Inst Neurosci, I-20129 Milan, Italy.
   [Busnelli, Marta; Di Lascio, Simona; Braida, Daniela; Sala, Mariaelvina; Bellini, Tommaso] Univ Milan, Dept Med Biotechnol & Translat Med, I-20129 Milan, Italy.
   [Kleinau, Gunnar] Charite, Inst Expt Pediat Endocrinol, D-13353 Berlin, Germany.
   [Muttenthaler, Markus] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   [Stoev, Stoytcho; Manning, Maurice] Univ Toledo, Dept Biochem & Canc Biol, Toledo, OH 43614 USA.
   [Bibic, Lucka; Howell, Lesley A.; McCormick, Peter J.] Univ East Anglia, Sch Pharm, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.
   [Rovati, G. Enrico] Univ Milan, Dept Pharmacol & Biomol Sci, I-20133 Milan, Italy.
RP Chini, B (reprint author), CNR, Inst Neurosci, I-20129 Milan, Italy.
EM b.chini@in.cnr.it
FU Telethon Foundation [GGP12207]; CNR Research Project on Aging; Regione
   Lombardia (Project MbMM) [18099/RCC]; European Union [254897,
   2013-BP-B-00109]; Secretary of Universities and Research of the Economy
   and Knowledge Department of the Government of Catalonia; ARC DECRA
   [DE150100784]; DFG [KL2334/2-2]; EKFS project [2014_A114]; National
   Institute of General Medical Sciences [GM-25280]; BBSRC DTP funding
   [MCCORMICK_U15DTP1]; Foundation Umberto Veronesi postdoctoral fellowship
FX This work was supported by the Telethon Foundation (grant GGP12207), CNR
   Research Project on Aging and Regione Lombardia (Project
   MbMM-convenzione no18099/RCC) to B.C.; European Union Seventh Framework
   Program (Marie Curie grant 254897 and 2013-BP-B-00109), the Secretary of
   Universities and Research of the Economy and Knowledge Department of the
   Government of Catalonia and ARC DECRA (DE150100784) to M.Mu.; DFG (grant
   KL2334/2-2) and EKFS project 2014_A114 to G.K.; the National Institute
   of General Medical Sciences (grant GM-25280) to M.Ma.; and BBSRC DTP
   funding to P.J.M. and L.A.H. (MCCORMICK_U15DTP1). M.B. is the recipient
   of a Foundation Umberto Veronesi postdoctoral fellowship. We thank Dr.
   C. Gales, INSERM, France who provided the BRET biosensor cDNAs and
   Fondazione Monzino for gifting the LSM510 META confocal laser-scanning
   microscope (Zeiss, Jena, Germany).
CR Akgun E, 2015, J MED CHEM, V58, P8647, DOI 10.1021/acs.jmedchem.5b01245
   Albizu L, 2006, MOL PHARMACOL, V70, P1783, DOI 10.1124/mol.106.025684
   Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/nchembio.396, 10.1038/NCHEMBIO.396]
   Ambrosio M, 2010, CELL MOL LIFE SCI, V67, P2979, DOI 10.1007/s00018-010-0368-9
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Birnkammer T, 2012, J MED CHEM, V55, P1147, DOI 10.1021/jm201128q
   Bonaventura J, 2015, P NATL ACAD SCI USA, V112, pE3609, DOI 10.1073/pnas.1507704112
   Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575
   Braida D, 2012, PSYCHOPHARMACOLOGY, V220, P319, DOI 10.1007/s00213-011-2482-2
   Busnelli M, 2013, J PHARMACOL EXP THER, V346, P318, DOI 10.1124/jpet.113.202994
   Busnelli M, 2012, J BIOL CHEM, V287, P3617, DOI 10.1074/jbc.M111.277178
   Calebiro D, 2013, P NATL ACAD SCI USA, V110, P743, DOI 10.1073/pnas.1205798110
   CHINI B, 1995, EMBO J, V14, P2176
   Chini B, 2003, BRIT J CANCER, V89, P930, DOI 10.1038/sj.bjc.6601189
   Cottet M, 2010, CURR OPIN PHARMACOL, V10, P59, DOI 10.1016/j.coph.2009.10.003
   Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102
   Decker M, 2009, J MED CHEM, V52, P7389, DOI 10.1021/jm900379p
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Fanelli F, 1999, MOL PHARMACOL, V56, P214
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Ferre S, 2014, PHARMACOL REV, V66, P413, DOI 10.1124/pr.113.008052
   Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743
   Gera L, 1996, IMMUNOPHARMACOLOGY, V33, P178, DOI 10.1016/0162-3109(96)00099-9
   Guitart X, 2014, MOL PHARMACOL, V86, P417, DOI 10.1124/mol.114.093096
   HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351
   Hiller C, 2013, J MED CHEM, V56, P6542, DOI 10.1021/jm4004335
   Jastrzebska B, 2015, J BIOL CHEM, V290, P25728, DOI 10.1074/jbc.M115.662684
   Johnston JM, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002649
   Jonas KC, 2015, J BIOL CHEM, V290, P3875, DOI 10.1074/jbc.M114.622498
   Kasai RS, 2011, J CELL BIOL, V192, P463, DOI 10.1083/jcb.201009128
   Koehbach J, 2013, P NATL ACAD SCI USA, V110, P21183, DOI 10.1073/pnas.1311183110
   Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227
   Lane JR, 2013, TRENDS PHARMACOL SCI, V34, P59, DOI 10.1016/j.tips.2012.10.003
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lee LTO, 2014, FASEB J, V28, P2632, DOI 10.1096/fj.13-246868
   Lensing CJ, 2016, J MED CHEM, V59, P3112, DOI 10.1021/acs.jmedchem.5b01894
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Navarro G, 2015, J NEUROSCI, V35, P6639, DOI 10.1523/JNEUROSCI.4364-14.2015
   Nimczick M, 2014, BIOORGAN MED CHEM, V22, P3938, DOI 10.1016/j.bmc.2014.06.008
   Numata J, 2012, J PHYS CHEM B, V116, P2595, DOI 10.1021/jp211383s
   Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063
   Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6
   Russo O, 2007, J MED CHEM, V50, P4482, DOI 10.1021/jm070552t
   Sala M, 2013, J NEUROENDOCRINOL, V25, P107, DOI 10.1111/j.1365-2826.2012.02385.x
   Salahpour Ali, 2012, Front Endocrinol (Lausanne), V3, P105, DOI 10.3389/fendo.2012.00105
   Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103
   Sauliere A, 2012, NAT CHEM BIOL, V8, P622, DOI [10.1038/nchembio.961, 10.1038/NCHEMBIO.961]
   Scarselli M, 2016, FEBS J, V283, P1197, DOI 10.1111/febs.13577
   Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330
   Shonberg J, 2011, CHEMMEDCHEM, V6, P963, DOI 10.1002/cmdc.201100101
   Smeester BA, 2014, EUR J PHARMACOL, V743, P48, DOI [10.1016/j.ejphar.2014.09.008, 10.1016/j.ejphan.2014.09.008]
   Soulier JL, 2005, J MED CHEM, V48, P6220, DOI 10.1021/jm050234z
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222
   Valant C, 2012, ANNU REV PHARMACOL, V52, P153, DOI 10.1146/annurev-pharmtox-010611-134514
   Vinals X, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002194
   Wrzal PK, 2012, CELL SIGNAL, V24, P342, DOI 10.1016/j.cellsig.2011.09.020
   Wrzal PK, 2012, CELL SIGNAL, V24, P333, DOI 10.1016/j.cellsig.2011.09.019
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939
   Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Zhang B, 2011, BIOORGAN MED CHEM, V19, P2808, DOI 10.1016/j.bmc.2011.03.052
NR 68
TC 0
Z9 0
U1 5
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 11
PY 2016
VL 59
IS 15
BP 7152
EP 7166
DI 10.1021/acs.jmedchem.6b00564
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DT4LM
UT WOS:000381452600012
PM 27420737
ER

PT J
AU King, LB
AF King, Lanikea B.
TI Specialized Networks for Social Cognition: A Defining Role for the
   Oxytocin Receptor
SO JOURNAL OF NEUROSCIENCE
LA English
DT Editorial Material
ID FEMALE PRAIRIE VOLES; NUCLEUS-ACCUMBENS; BEHAVIOR; INTERNEURONS;
   ATTACHMENT; AUTISM; SYSTEM
C1 [King, Lanikea B.] Scripps Res Inst, Dept Neurosci, Jupiter, FL 33458 USA.
RP King, LB (reprint author), 130 Scripps Way,C376, Jupiter, FL 33458 USA.
EM king.lanikea@gmail.com
CR Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Gigliucci Valentina, 2014, Front Pediatr, V2, P91, DOI 10.3389/fped.2014.00091
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Hammock EAD, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00195
   Keebaugh AC, 2015, SOC NEUROSCI-UK, V10, P561, DOI 10.1080/17470919.2015.1040893
   King LB, 2016, BIOL PSYCHIAT, V80, P160, DOI 10.1016/j.biopsych.2015.12.008
   Letzkus JJ, 2015, NEURON, V88, P264, DOI 10.1016/j.neuron.2015.09.024
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Mitre M, 2016, J NEUROSCI, V36, P2517, DOI 10.1523/JNEUROSCI.2409-15.2016
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   Nakajima M, 2014, CELL, V159, P295, DOI 10.1016/j.cell.2014.09.020
   Oettl LL, 2016, NEURON, V90, P609, DOI 10.1016/j.neuron.2016.03.033
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Rich ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098839
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Venkatesh B, 1997, P NATL ACAD SCI USA, V94, P12462, DOI 10.1073/pnas.94.23.12462
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 23
TC 0
Z9 0
U1 6
U2 6
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 10
PY 2016
VL 36
IS 32
BP 8283
EP 8285
DI 10.1523/JNEUROSCI.1446-16.2016
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA DU6GQ
UT WOS:000382312700001
PM 27511002
ER

PT J
AU Khoshneviszadeh, M
   Rahimian, R
   Fakhfouri, G
   Payandemehr, B
   Khodagholi, F
   Mehr, SE
   Dehpour, AR
AF Khoshneviszadeh, Mahsima
   Rahimian, Reza
   Fakhfouri, Gohar
   Payandemehr, Borna
   Khodagholi, Fariba
   Mehr, Shahram Ejtemaei
   Dehpour, Ahmad Reza
TI Oxytocin is involved in the proconvulsant effects of Sildenafil:
   Possible role of CREB
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Sildenafil; Oxytocin; Seizure; CREB phosphorylation; Mice
ID ELEMENT-BINDING PROTEIN; ANTICONVULSANT DRUGS; MOUSE MODEL; BEHAVIOR;
   MICE; EXPRESSION; STRESS; PENTYLENETETRAZOL; ANTIDEPRESSANT; RECEPTORS
AB Sildenafil is a phosphodiesterase type 5 inhibitor mainly used for male erectile dysfunction. One of rare yet serious adverse effects of Sildenafil is its potential to decrease seizure threshold. Ample evidence suggests that Sildenafil exerts central effects through induction of Oxytocin (OT) secretion and CREB phosphorylation. The aim of the present study is to evaluate potential roles of OT and CREB in the proconvulsant effects of Sildenafil.
   The Pentylenetetrazole-induced seizure was used as a standard convulsion model in this study. OT release and pCREB expression were evaluated in the hippocampus of mice using ELISA and western blot assays, respectively.
   Our results showed that Sildenafil at the dose of 10 mg kg(-1) or higher, significantly decreased seizure threshold. Pretreatment with a non-effective dose of OT, potentiated while OT receptor antagonist, Atosiban, reversed fully the proconvulsant effects of Sildenafil (5 mg kg(-1)). At biochemical inspection, Sildenafil markedly increased CREB which was attenuated by coadministration of Atosiban.
   The present study shows for the first time that OT release and the subsequent CREB phosphorylation are involved in the proconvulsant effects of acute Sildenafil treatment in an experimental model of seizure. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Khoshneviszadeh, Mahsima; Rahimian, Reza; Payandemehr, Borna; Mehr, Shahram Ejtemaei; Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
   [Rahimian, Reza; Fakhfouri, Gohar] Univ Laval, Res Ctr, Mental Hlth Inst Quebec, Dept Psychiat & Neurosci,Fac Med, Quebec City, PQ G1J 2G3, Canada.
   [Khodagholi, Fariba] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran.
   [Dehpour, Ahmad Reza] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
RP Rahimian, R; Dehpour, AR (reprint author), Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
EM rahimian78@gmail.com; gfakhfouri@yahoo.com; dehpour@yahoo.com
FU research deputy, School of Medicine, Tehran University of Medical
   Sciences [23097]
FX This study is supported by a grant (23097) from research deputy, School
   of Medicine, Tehran University of Medical Sciences.
CR Ambriz-Tututi M, 2005, EUR J PHARMACOL, V512, P121, DOI 10.1016/j.ejphar.2005.01.055
   Bale TL, 2001, J NEUROSCI, V21, P2546
   Bali A, 2015, NEUROSCI BIOBEHAV R, V51, P138, DOI 10.1016/j.neubiorev.2014.12.018
   BURBACH JPH, 1983, EUR J PHARMACOL, V94, P125, DOI 10.1016/0014-2999(83)90449-1
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Clark-Elford R, 2014, INT J NEUROPSYCHOPH, V17, P199, DOI 10.1017/S1461145713001120
   Croiset G, 1997, BRAIN RES, V759, P18, DOI 10.1016/S0006-8993(97)00070-X
   Cuadrado-Tejedor M, 2011, BRIT J PHARMACOL, V164, P2029, DOI 10.1111/j.1476-5381.2011.01517.x
   de Armentia ML, 2007, J NEUROSCI, V27, P13909
   Duenes SL, 2010, NEUROSCI LETT, V486, P207, DOI 10.1016/j.neulet.2010.09.054
   Erbas O, 2013, PEPTIDES, V40, P141, DOI 10.1016/j.peptides.2012.12.003
   Farooq MU, 2008, CLIN NEUROPHARMACOL, V31, P353, DOI [10.1097/WNF.0b013e31815cd94c, 10.1097/WNF.0B013E31815CD94C]
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Garcia-Barroso C, 2014, J ALZHEIMERS DIS, V42, pS561, DOI 10.3233/JAD-141341
   Gholipour T, 2009, EUR J PHARMACOL, V617, P79, DOI 10.1016/j.ejphar.2009.06.061
   Gilad R, 2002, BRIT MED J, V325, P869, DOI 10.1136/bmj.325.7369.869
   Han WY, 2014, PHARMACOL BIOCHEM BE, V119, P80, DOI 10.1016/j.pbb.2013.11.014
   Herdegen T, 1997, NEUROSCIENCE, V81, P199, DOI 10.1016/S0306-4522(97)00170-X
   HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4
   HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0
   Jindal A, 2012, EUR J PHARMACOL, V689, P125, DOI 10.1016/j.ejphar.2012.05.051
   KAPLAN E, 1978, S AFR MED J, V53, P27
   Lopatina O, 2011, J NEUROENDOCRINOL, V23, P1125, DOI 10.1111/j.1365-2826.2011.02136.x
   Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6
   LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K
   Loyens E, 2012, BRAIN RES, V1436, P43, DOI 10.1016/j.brainres.2011.11.059
   MacDonald K.S., 2012, FRONT NEUROSCI, V6
   Matsushita H, 2012, NEUROSCIENCE, V200, P13, DOI 10.1016/j.neuroscience.2011.11.001
   MENS WBJ, 1982, NEUROENDOCRINOLOGY, V35, P418, DOI 10.1159/000123417
   Milman HA, 2002, ANN PHARMACOTHER, V36, P1129
   Montaser-Kouhsari L, 2011, SEIZURE-EUR J EPILEP, V20, P409, DOI 10.1016/j.seizure.2011.01.014
   Moreira SG, 2000, UROLOGY, V56, P474, DOI 10.1016/S0090-4295(00)00649-X
   Nieoczym D, 2012, J NEURAL TRANSM, V119, P923, DOI 10.1007/s00702-012-0767-1
   Nowakowska E, 2002, POL J PHARMACOL, V54, P605
   OLSEN RW, 1981, MOL CELL BIOCHEM, V39, P261, DOI 10.1007/BF00232579
   Palmeri A, 2013, BEHAV BRAIN RES, V240, P11, DOI 10.1016/j.bbr.2012.10.060
   Paxinos G, 2004, MOUSE BRAIN STEREOTA
   Payandemehr B, 2015, PROG NEURO-PSYCHOPH, V57, P140, DOI 10.1016/j.pnpbp.2014.11.005
   Perez KM, 2015, CLIN THER, V37, P2598, DOI 10.1016/j.clinthera.2015.07.019
   Pi XJ, 2004, MOL BRAIN RES, V127, P60, DOI 10.1016/j.molbraines.2004.05.006
   Pont JNA, 2012, MOL ENDOCRINOL, V26, P1743, DOI 10.1210/me.2012-1057
   Rakhade SN, 2005, ANN NEUROL, V58, P736, DOI 10.1002/ana.20633
   Riazi K, 2006, BRIT J PHARMACOL, V147, P935, DOI 10.1038/sj.bjp.0706680
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Tahsili-Fahadan P, 2006, PSYCHOPHARMACOLOGY, V185, P201, DOI 10.1007/s00213-005-0302-2
   Tanis KQ, 2008, BIOL PSYCHIAT, V63, P710, DOI 10.1016/j.biopsych.2007.08.003
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   Wang C., 2014, MOL SIMULAT, DOI [10.1002/mma.3325, DOI 10.1002/MMA.3325]
   Wang QM, 2013, AM J PHYS MED REHAB, V92, P143, DOI 10.1097/PHM.0b013e3182643f1a
   Wang Y., 2015, CLIN EXP PHARM PHYSL
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Xu Y, 2011, HANDB EXP PHARMACOL, V204, P447, DOI 10.1007/978-3-642-17969-3_19
   Zhang ZJ, 2007, J PHYSIOL-LONDON, V584, P137, DOI 10.1113/jphysiol.2007.139303
   Zhu XJ, 2012, NEUROBIOL DIS, V45, P253, DOI 10.1016/j.nbd.2011.08.009
NR 54
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD AUG 10
PY 2016
VL 256
BP 44
EP 52
DI 10.1016/j.toxlet.2016.05.018
PG 9
WC Toxicology
SC Toxicology
GA DO8RA
UT WOS:000378049900005
PM 27220266
ER

PT J
AU Sun, P
   Zheng, L
   Li, L
   Guo, XY
   Zhang, WD
   Zheng, YJ
AF Sun, Peng
   Zheng, Li
   Li, Lin
   Guo, Xiuyan
   Zhang, Weidong
   Zheng, Yijie
TI The Neural Responses to Social Cooperation in Gain and Loss Context
SO PLOS ONE
LA English
DT Article
ID MEDIAL PREFRONTAL CORTEX; INTRANASAL OXYTOCIN; HUMAN BRAIN; REWARD;
   TRUST; SELF; ENFORCEMENT; PREFERENCES; VASOPRESSIN; CIRCUITRY
AB Cooperation is pervasive and constitutes the core behavioral principle of human social life. Previous studies have revealed that mutual cooperation was reliably correlated with two reward-related brain regions, the ventral striatum and the orbitofrontal cortex. Using functional magnetic resonance imaging (fMRI), this study sought to investigate how the loss and gain contexts modulated the neural responses to mutual cooperation. Twenty-five female participants were scanned when they played a series of one-shot prisoner's dilemma games in the loss and gain contexts. Specifically, participants and partners independently chose to either cooperate with each other or not, and each was awarded or deprived of (in the gain context or the loss context, respectively) a sum of money which depended upon the interaction of their choices. Behavioral results indicated that participants cooperated in nearly half of the experiment trials and reported higher level of positive emotions for mutual cooperation in both contexts, but they cooperated more in the gain than in the loss context. At the neural level, stronger activities in the orbitofrontal cortex were observed for mutual cooperation compared with the other three outcomes in both contexts, while stronger activation in ventral striatum associated with mutual cooperation was observed in the gain context only. Together, our data indicated that, even in the one-shot interaction under loss context, participants still exhibited preference for cooperation and the rewarding experience from a mutually cooperative social interaction activated the ventral striatum and the orbitofrontal cortex, but the loss context weakened the association between the ventral striatum activation and mutual cooperation.
C1 [Sun, Peng; Li, Lin; Zhang, Weidong] East China Normal Univ, Sch Psychol & Cognit Sci, Shanghai, Peoples R China.
   [Zheng, Li] East China Normal Univ, Key Lab Brain Funct Genom, Shanghai Key Lab Brain Funct Genom, Sch Psychol & Cognit Sci,Minist Educ, Shanghai, Peoples R China.
   [Guo, Xiuyan] East China Normal Univ, Shanghai Key Lab Magnet Resonance, Sch Psychol & Cognit Sci, Shanghai, Peoples R China.
   [Guo, Xiuyan] East China Normal Univ, Key Lab Brain Funct Genom, Shanghai Key Lab Brain Funct Genom, Minist Educ, Shanghai, Peoples R China.
   [Zheng, Yijie] East China Normal Univ, Shanghai Key Lab Magnet Resonance, Dept Phys, Shanghai, Peoples R China.
RP Zhang, WD (reprint author), East China Normal Univ, Sch Psychol & Cognit Sci, Shanghai, Peoples R China.; Guo, XY (reprint author), East China Normal Univ, Shanghai Key Lab Magnet Resonance, Sch Psychol & Cognit Sci, Shanghai, Peoples R China.; Guo, XY (reprint author), East China Normal Univ, Key Lab Brain Funct Genom, Shanghai Key Lab Brain Funct Genom, Minist Educ, Shanghai, Peoples R China.
EM wlkc_xyguo@126.com; wdzhang@psy.ecnu.edu.cn
FU National Natural Science Foundation of China [31271090, 71371180]; Key
   Program of the National Social Science Foundation of China [14AZD106];
   Shanghai Leading talent Plan
FX This research was supported by the National Natural Science Foundation
   of China (31271090; 71371180; http://www.nsfc.gov.cn/); the Key Program
   of the National Social Science Foundation of China (14AZD106;
   http://www.npopss-cn.gov.cn/); and the Shanghai Leading talent Plan
   (www.shrcw.gov.cn). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018
   Berns GS, 2001, J NEUROSCI, V21, P2793
   Brown S, 2011, NEUROIMAGE, V58, P250, DOI 10.1016/j.neuroimage.2011.06.012
   Camerer C.F., 2003, BEHAV GAME THEORY, V19, P7
   Carmichael ST, 1996, J COMP NEUROL, V371, P179, DOI 10.1002/(SICI)1096-9861(19960722)371:2<179::AID-CNE1>3.0.CO;2-#
   Delgado MR, 2005, NAT NEUROSCI, V8, P1611, DOI 10.1038/nn1575
   Emonds G, 2014, SOC NEUROSCI-UK, V9, P10, DOI 10.1080/17470919.2013.858080
   Fehr E, 2002, HUM NATURE-INT BIOS, V13, P1, DOI 10.1007/s12110-002-1012-7
   Fehr E, 2007, TRENDS COGN SCI, V11, P419, DOI 10.1016/j.tics.2007.09.002
   Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349
   [龚栩 Gong Xu], 2011, [中国心理卫生杂志, Chinese Mental Health Journal], V25, P40
   Grabenhorst F, 2010, NEUROIMAGE, V51, P1265, DOI 10.1016/j.neuroimage.2010.03.043
   Greene J, 2002, TRENDS COGN SCI, V6, P517, DOI 10.1016/S1364-6613(02)02011-9
   Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129
   Han SH, 2010, SOC COGN AFFECT NEUR, V5, P332, DOI 10.1093/scan/nsp027
   Henrich J, 2005, BEHAV BRAIN SCI, V28, P795
   Hsu M, 2008, SCIENCE, V320, P1092, DOI 10.1126/science.1153651
   Jian L, 2009, P NATL ACAD SCI USA, V106, P16835, DOI [10.1073/pnas.0908855106, DOI 10.1073/PNAS.0908855106]
   King-Casas B, 2005, SCIENCE, V308, P78, DOI 10.1126/science.1108062
   Korn CW, 2012, J NEUROSCI, V32, P16832, DOI 10.1523/JNEUROSCI.3016-12.2012
   Montague PR, 1996, J NEUROSCI, V16, P1936
   Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002
   O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7
   Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206
   Ongur D, 2003, J COMP NEUROL, V460, P425, DOI 10.1002/cne.10609
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Rilling JK, 2011, ANNU REV PSYCHOL, V62, P23, DOI 10.1146/annurev.psych.121208.131647
   Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9
   Rilling JK, 2004, NEUROREPORT, V15, P2539, DOI 10.1097/00001756-200411150-00022
   Tricomi E, 2010, NATURE, V463, P1089, DOI 10.1038/nature08785
   Tsukiura T, 2011, SOC COGN AFFECT NEUR, V6, P138, DOI 10.1093/scan/nsq025
   Wang TT, 2015, SOC COGN AFFECT NEUR, V10, P814, DOI 10.1093/scan/nsu123
   Wise RA, 2002, NEURON, V36, P229, DOI 10.1016/S0896-6273(02)00965-0
   Wu Y, 2014, SOC COGN AFFECT NEUR, V9, P1862, DOI 10.1093/scan/nst187
NR 35
TC 0
Z9 0
U1 10
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 5
PY 2016
VL 11
IS 8
AR e0160503
DI 10.1371/journal.pone.0160503
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GR
UT WOS:000381369500050
ER

PT J
AU Balazova, L
   Krskova, K
   Suski, M
   Sisovsky, V
   Hlavacova, N
   Olszanecki, R
   Jezova, D
   Zorad, S
AF Balazova, L.
   Krskova, K.
   Suski, M.
   Sisovsky, V.
   Hlavacova, N.
   Olszanecki, R.
   Jezova, D.
   Zorad, S.
TI METABOLIC EFFECTS OF SUBCHRONIC PERIPHERAL OXYTOCIN ADMINISTRATION IN
   LEAN AND OBESE ZUCKER RATS
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE adipose tissue; skeletal muscle; liver insulin resistance; obesity;
   oxytocin
ID INSULIN-RECEPTOR SUBSTRATE-1; FOOD-INTAKE; SKELETAL-MUSCLE;
   ADIPOSE-TISSUE; FAT; LEPTIN; RESISTANCE; EXPRESSION; MICE;
   PHOSPHORYLATION
AB Increasing evidence indicates a role of oxytocin in controlling energy metabolism. The aim of his study was to investigate oxytocin effects on obese phenotype in leptin-resistant Zucker fatty rats, focusing on glucose and lipid metabolism. Zucker fatty rats and their lean controls were treated with oxytocin (3.6 mu g/100g body weight/day) by osmotic minipumps implanted subcutaneously for 2 weeks. Two-hours intraperitoneal glucose tolerance test was performed in fasting rats. Oxytocin decreased food intake in both phenotypes while body weight gain reduced only in obese animals. In obese rats oxytocin impaired hepatic insulin extraction and enhanced liver triglyceride accumulation. Moreover, in the skeletal muscle of lean rats oxytocin treatment downregulated insulin signal transduction by decreasing of insulin receptor substrate 1 protein level and stimulating of its serine phosphorylation. Concurrently, the gene expression of insulin receptor substrate 1 in the skeletal muscle and adipose tissue was downregulated by oxytocin. In obese rats, oxytocin reduced adipocyte size and normalised mRNA levels of both fatty acid binding protein 4 and fatty acid synthase but attenuated gene expression of glucose transporter 4. The present study in Zucker fatty rats demonstrated ambivalent effects of oxytocin treatment with predominantly negative impact on skeletal muscle insulin pathway in lean animals.
C1 [Balazova, L.; Krskova, K.; Hlavacova, N.; Jezova, D.; Zorad, S.] Slovak Acad Sci, Biomed Res Ctr, Inst Expt Endocrinol, Dubravska Cesta 9, Bratislava 84505, Slovakia.
   [Krskova, K.] Slovak Acad Sci, Biomed Res Ctr, Inst Clin & Translat Res, Bratislava, Slovakia.
   [Suski, M.; Olszanecki, R.] Jagiellonian Univ, Coll Med, Chair Pharmacol, Krakow, Poland.
   [Sisovsky, V.] Comenius Univ, Univ Hosp, Fac Med, Inst Pathol Anat, Bratislava, Slovakia.
RP Balazova, L (reprint author), Slovak Acad Sci, Biomed Res Ctr, Inst Expt Endocrinol, Dubravska Cesta 9, Bratislava 84505, Slovakia.
EM balazova.luc@gmail.com
FU Ministry of Health of the Slovak Republic [2012/51-SAV-1]; Polish
   National Science Centre grant [2011/01/N/NZ4/03752];  [APVV-0028-10]; 
   [VEGA 2/0174/14]
FX This study was supported by grants APVV-0028-10, VEGA 2/0174/14,
   Ministry of Health of the Slovak Republic 2012/51-SAV-1 and by Polish
   National Science Centre grant No. 2011/01/N/NZ4/03752.
CR Aguirre L, 2013, J PHYSIOL PHARMACOL, V64, P281
   Alameddine A, 2015, J PHYSIOL PHARMACOL, V66, P249
   Altirriba J, 2014, ENDOCRINOLOGY, V155, P4189, DOI 10.1210/en.2014-1466
   Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13
   ARINO J, 1989, BIOCHEM J, V261, P827
   ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   Blevins JE, 2004, AM J PHYSIOL-REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003
   BOBBIONIHARSCH E, 1995, ENDOCRINE, V3, P55, DOI 10.1007/BF02917449
   Carvalho E, 1999, FASEB J, V13, P2173
   Danevova V, 2013, HORM METAB RES, V45, P845, DOI 10.1055/s-0033-1348265
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   Denroche HC, 2012, J DIABETES INVEST, V3, P115, DOI 10.1111/j.2040-1124.2012.00203.x
   Eckertova M, 2011, BRIT J PHARMACOL, V162, P452, DOI 10.1111/j.1476-5381.2010.01037.x
   Elabd C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5082
   Gajdosechova L, 2015, HORM METAB RES, V47, P600, DOI 10.1055/s-0034-1395677
   Gajdosechova L, 2014, J ENDOCRINOL, V220, P333, DOI 10.1530/JOE-13-0417
   HANIF K, 1982, MOL PHARMACOL, V22, P381
   Hew-Butler T, 2008, EUR J ENDOCRINOL, V159, P729, DOI 10.1530/EJE-08-0064
   Ho JM, 2014, ENDOCRINOLOGY, V155, P2845, DOI 10.1210/en.2014-1148
   Jezova D, 1995, ANN NY ACAD SCI, V771, P192, DOI 10.1111/j.1749-6632.1995.tb44681.x
   Maejima Y, 2011, AGING-US, V3, P1169
   Morino K, 2008, DIABETES, V57, P2644, DOI 10.2337/db06-0454
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Mothe I, 1996, J BIOL CHEM, V271, P11222
   Ondrejcakova M, 2010, STRESS, V13, P315, DOI 10.3109/10253891003596822
   Ondrejcakova M, 2012, GEN PHYSIOL BIOPHYS, V31, P261, DOI 10.4149/gpb_2012_030
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Perello M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059625
   Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18
   Plante E, 2015, ENDOCRINOLOGY, V156, P1416, DOI 10.1210/en.2014-1718
   Roh S, 2014, ANIM SCI J, V85, P286, DOI 10.1111/asj.12142
   Rose AJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE766
   Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028
   STOCK S, 1985, ACTA PHYSIOL SCAND, V125, P205, DOI 10.1111/j.1748-1716.1985.tb07708.x
   Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200
   Wierucka-Rybak M, 2014, J PHYSIOL PHARMACOL, V65, P487
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
   Zhang H, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003080
NR 38
TC 0
Z9 0
U1 0
U2 0
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867-5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD AUG
PY 2016
VL 67
IS 4
BP 531
EP 541
PG 11
WC Physiology
SC Physiology
GA ED2DH
UT WOS:000388653300006
PM 27779474
ER

PT J
AU Segarra, AB
   Hernandez, J
   Prieto, I
   de Gasparo, M
   Ramirez-Sanchez, M
AF Belen Segarra, Ana
   Hernandez, Joaquin
   Prieto, Isabel
   de Gasparo, Marc
   Ramirez-Sanchez, Manuel
TI Neuropeptidase activities in plasma after acute restraint stress.
   Interaction with cortico-limbic areas
SO ACTA NEUROPSYCHIATRICA
LA English
DT Article
DE cortico-limbic regions; enkephalinase activity; oxytocinase activity;
   plasma; stress
ID MET-ENKEPHALIN; BLOOD-PRESSURE; WATER-BALANCE; RATS; OXYTOCIN;
   NEUROENDOCRINE; BRAIN; MODEL; INTEGRATION; VASOPRESSIN
AB Objective: To evaluate the influence of acute restraint stress (ARS) on plasma enkephalinase and oxytocinase activities. ARS modifies basal activities in cortico-limbic regions of rats and induces changes in the correlations observed between these regions. The interactions between plasma and cortico-limbic activities will be also evaluated.
   Methods: Enkephalinase (AlaAP and LeuAP) and oxytocinase (P-LeuAP) activities were fluorometrically determined in plasma of control and stressed rats using aminoacyl-beta-naphthylamides (aaNNap), AlaNNap and LeuNNap as substrates.
   Results: No differences in enzymatic activities were observed between control and stressed animals in plasma. In contrast, highly significant positive and negative correlations between plasma and cortico-limbic regions were demonstrated in controls. Stress conditions significantly alter the pattern of these correlations.
   Conclusion: The present results clearly support a connection between plasma and brain involving certain neuropeptidase activities that change under stress conditions.
C1 [Belen Segarra, Ana; Hernandez, Joaquin; Prieto, Isabel; Ramirez-Sanchez, Manuel] Univ Jaen, Unit Physiol, Bldg B3-263, Jaen 23071, Spain.
   [de Gasparo, Marc] Cardiovasc & Metab Syndrome, Rossemaison, Switzerland.
RP Ramirez-Sanchez, M (reprint author), Univ Jaen, Unit Physiol, Bldg B3-263, Jaen 23071, Spain.
EM msanchez@ujaen.es
FU Junta de Andalucia [P10-CVI6476]
FX This work was supported by the Junta de Andalucia through project no.
   P10-CVI6476.
CR Babygirija R, 2012, AUTON NEUROSCI-BASIC, V167, P56, DOI 10.1016/j.autneu.2011.12.005
   Banegas I, 2009, NEUROPHARMACOLOGY, V56, P573, DOI 10.1016/j.neuropharm.2008.10.011
   BARRON BA, 1990, J NEUROENDOCRINOL, V2, P381, DOI 10.1111/j.1365-2826.1990.tb00422.x
   Segarra AB, 2012, BEHAV BRAIN RES, V230, P423, DOI 10.1016/j.bbr.2012.02.039
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Carrasco GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8
   Goldstein DS, 2007, STRESS, V10, P109, DOI 10.1080/10253890701288935
   Hernandez J, 2015, BEHAV BRAIN RES, V287, P42, DOI 10.1016/j.bbr.2015.03.036
   Hernandez J, 2009, NEUROPSYCHOBIOLOGY, V59, P184, DOI 10.1159/000219306
   Laguna-Abreu MTC, 2005, HORM METAB RES, V37, P84, DOI 10.1055/s-2005-861159
   LANG RE, 1983, NEUROENDOCRINOLOGY, V37, P314, DOI 10.1159/000123566
   Loyens E, 2013, INT J NEUROPSYCHOPH, V16, P1153, DOI 10.1017/S1461145712001149
   PIERZCHALA K, 1990, J CLIN INVEST, V85, P861, DOI 10.1172/JCI114513
   Prieto I, 2015, LIFE SCI, V134, P73, DOI 10.1016/j.lfs.2015.04.023
   Prieto I, 2014, NEUROENDOCRINOLOGY, V100, P198, DOI 10.1159/000368835
   Ramirez M, 2011, METHODS MOL BIOL, V789, P287, DOI 10.1007/978-1-61779-310-3_18
   Sanchez MM, 1998, ENDOCRINOLOGY, V139, P579, DOI 10.1210/en.139.2.579
   Saravia F, 1998, NEUROPEPTIDES, V32, P351, DOI 10.1016/S0143-4179(98)90058-0
   SEGARRA AB, 2013, INT J HYPERTENS, V2013
   Sterling P, 2012, PHYSIOL BEHAV, V106, P5, DOI 10.1016/j.physbeh.2011.06.004
   Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004
NR 21
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1601-5215
J9 ACTA NEUROPSYCHIATR
JI Acta Neuropsychiatr.
PD AUG
PY 2016
VL 28
IS 4
BP 239
EP 243
DI 10.1017/neu.2016.2
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA EC0WR
UT WOS:000387822800008
PM 26882874
ER

PT J
AU Waldinger, MD
AF Waldinger, Marcel D.
TI The pathophysiology of lifelong premature ejaculation
SO TRANSLATIONAL ANDROLOGY AND UROLOGY
LA English
DT Review
DE Lifelong premature ejaculation (lifelong PE); ejaculatio praecox;
   erectio praecox; detumescentia praecox; hypererotic state; genetic
   polymorphism
ID INDUCED DELAYED EJACULATION; GENERAL MALE-POPULATION; AD-HOC COMMITTEE;
   LATENCY TIME; INTRAVAGINAL EJACULATION; SEXUAL-BEHAVIOR;
   INTERNATIONAL-SOCIETY; PENILE ERECTION; MALE-RAT; OXYTOCIN
AB For many decades it has been thought that lifelong premature ejaculation (PE) is only characterized by persistent early ejaculations. Despite enormous progress of in vivo animal research, and neurobiological, genetic and pharmacological research in men with lifelong PE, our current understanding of the mechanisms behind early ejaculations is far from complete. The new classification of PE into four PE subtypes has shown that the symptomatology of lifelong PE strongly differs from acquired PE, subjective PE and variable PE. The phenotype of lifelong PE and therefore also the pathophysiology of lifelong PE is much more complex. A substantial number of men with lifelong PE not only have PE, but also premature erection and premature penile detumescence as part of an acute hypertonic or hypererotic state when engaged in an erotic situation or when making love. As both erectio praecox, ejaculatio praecox, detumescentia praecox, and the hypererotic state are part of the phenotype lifelong PE, it is argued that lifelong PE is not only a disturbance of the timing of ejaculation but also a disturbance of the timing of erection, detumescence and arousal. Since 1998, the pathophysiology of lifelong PE was thought to be mainly mediated by the central serotonergic system in line with genetic polymorphisms of specific serotonergic genes. However, by accepting that lifelong PE is characterized by the reversible hypertonic state the hypothesis of mainly serotonergic dysfunction is no longer tenable. Instead, it has been postulated that the pathophysiology of lifelong PE is mediated by a very complex interplay of central and peripheral serotonergic, dopaminergic, oxytocinergic, endocrinological, genetic and probably also epigenetic factors. Progress in research of lifelong PE can only be accomplished when a stopwatch is used to measure the IELT and the cut-off point of 1 minute for the definition of lifelong PE is maintained. Current use of validated questionnaires, neglect of stopwatch research, clinically inexperienced investigators and inclusion of anonymous men in a study performed by the Internet endanger the continuation of objective research of lifelong PE.
C1 [Waldinger, Marcel D.] Drexel Univ, Coll Med, Dept Pharmacol & Physiol, Philadelphia, PA 19104 USA.
   [Waldinger, Marcel D.] Private Practice Psychiat & Neurosexol, Amstelveen, Netherlands.
RP Waldinger, MD (reprint author), Drexel Univ, Coll Med, Pharmacol & Physiol, Philadelphia, PA 19103 USA.
EM info@praktijkwaldinger.nl
CR AHLENIUS S, 1981, PHARMACOL BIOCHEM BE, V15, P785, DOI 10.1016/0091-3057(81)90023-X
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   BERENDSEN HHG, 1987, EUR J PHARMACOL, V135, P279, DOI 10.1016/0014-2999(87)90676-5
   Carani C, 2005, J CLIN ENDOCR METAB, V90, P6472, DOI 10.1210/jc.2005-1135
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   Chen KK, 2001, UROLOGY, V58, P107, DOI 10.1016/S0090-4295(01)01000-7
   Corona G, 2012, NAT REV UROL, V9, P508, DOI 10.1038/nrurol.2012.147
   de Jong TR, 2007, J SEX MED, V4, P14, DOI 10.1111/j.1743-6109.2006.00394.x
   Foreman MM, 1988, SOC NEUROSCIENCE, V14
   Gao JJ, 2013, J SEX MED, V10, P1874, DOI 10.1111/jsm.12180
   GODPODINOFF ML, 1989, J SEX MARITAL THER, V15, P130
   Gross S, 1887, PRACTICAL TREATISE I
   HUGHES AM, 1987, BRAIN RES, V414, P133, DOI 10.1016/0006-8993(87)91333-3
   Jannini EA, 2005, INT J ANDROL, V28, P40, DOI 10.1111/j.1365-2605.2005.00593.x
   Janssen PKC, 2016, INVESTIG CLIN UROL, V57, P119, DOI 10.4111/icu.2016.57.2.119
   Janssen PKC, 2014, ASIAN J ANDROL, V16, P607, DOI 10.4103/1008-682X.126371
   Janssen PKC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088031
   Janssen PKC, 2009, J SEX MED, V6, P276, DOI 10.1111/j.1743-6109.2008.01033.x
   Janssen PK, 2013, PHARM BIOCH BEHAV
   Jern P, 2013, ARCH SEX BEHAV, V42, P45, DOI 10.1007/s10508-012-9991-x
   Jern P, 2012, J SEX MED, V9, P866, DOI 10.1111/j.1743-6109.2011.02618.x
   Kruger THC, 2003, J ENDOCRINOL, V177, P57, DOI 10.1677/joe.0.1770057
   Luo Shun-wen, 2011, Beijing Da Xue Xue Bao, V43, P514
   McMahon CG, 2008, J SEX MED, V5, P1590, DOI 10.1111/j.1743-6109.2008.00901.x
   MELIS MR, 1986, BRAIN RES, V398, P259, DOI 10.1016/0006-8993(86)91485-X
   MURPHY MR, 1987, J CLIN ENDOCR METAB, V65, P738
   Olivier B, 1998, INT CLIN PSYCHOPHARM, V13, pS9, DOI 10.1097/00004850-199807006-00003
   Ozbek E, 2009, ASIAN J ANDROL, V11, P351, DOI 10.1038/aja.2008.3
   Peeters M, 2008, NEUROSCI BIOBEHAV R, V32, P438, DOI 10.1016/j.neubiorev.2007.07.013
   Safarinejad MR, 2009, J UROLOGY, V181, P2656, DOI 10.1016/j.juro.2009.01.105
   Schapiro B, 1943, J UROLOGY, V50, P374
   Screponi E, 2001, UROLOGY, V58, P198, DOI 10.1016/S0090-4295(01)01151-7
   Serefoglu EC, 2011, J SEX MED, V8, P1177, DOI 10.1111/j.1743-6109.2010.02183.x
   Serefoglu EC, 2014, J SEX MED, V11, P1423, DOI 10.1111/jsm.12524
   Serefoglu EC, 2010, J SEX MED, V7, P810, DOI 10.1111/j.1743-6109.2009.01570.x
   STONEHAM MD, 1985, J ENDOCRINOL, V107, P97, DOI 10.1677/joe.0.1070097
   Uckert S, 2002, WORLD J UROL, V20, P323, DOI 10.1007/s00345-002-0300-5
   Ventus D, 2016, EUR UROL FOCUS
   Waldinger M D, 1998, Int J Psychiatry Clin Pract, V2, P287, DOI 10.3109/13651509809115376
   Waldinger MD, 2008, J SEX MED, V5, P1079, DOI 10.1111/j.1743-6109.2008.00789.x
   Waldinger MD, 2008, J SEX MARITAL THER, V34, P1, DOI 10.1080/00926230701640355
   Waldinger MD, 2007, DRUGS, V67, P547, DOI 10.2165/00003495-200767040-00005
   Waldinger MD, 2015, EXPERT OPIN PHARMACO, V16, P2615, DOI 10.1517/14656566.2015.1096928
   Waldinger MD, 2014, PHARMACOL BIOCHEM BE, V121, P189, DOI 10.1016/j.pbb.2013.12.004
   Waldinger MD, 2009, J SEX MED, V6, P2888, DOI 10.1111/j.1743-6109.2009.01392.x
   Waldinger MD, 2005, J SEX MED, V2, P492, DOI 10.1111/j.1743-6109.2005.00070.x
   Waldinger MD, 1998, PSYCHIATR GENET, V8, P37, DOI 10.1097/00041444-199800810-00007
   Waldinger MD, 2002, J UROLOGY, V168, P2359, DOI 10.1097/01.ju.0000035599.35887.8f
   Waldinger MD, 1998, BEHAV BRAIN RES, V92, P111, DOI 10.1016/S0166-4328(97)00183-6
   WALDINGER MD, 1994, AM J PSYCHIAT, V151, P1377
   Waldinger MD, 2013, PREMATURE EJACULATIO, P111
   Waldinger MD, 2016, EUR UROL FOCUS
   Waldinger MD, 2013, PREMATURE EJACULATIO, P5
   Zhang XH, 2005, J ENDOCRINOL, V184, P567, DOI 10.1677/joe.1.05885
   Zhang XS, 2013, J SEX MED, V10, P1603, DOI 10.1111/jsm.12123
   Zhu LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054994
   Zuccarello D, 2012, J SEX MED, V9, P1659, DOI 10.1111/j.1743-6109.2012.02715.x
NR 57
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-4683
EI 2223-4691
J9 TRANSL ANDROL UROL
JI Transl. Androl. Urol.
PD AUG
PY 2016
VL 5
IS 4
BP 424
EP 433
DI 10.21037/tau.2016.06.04
PG 10
WC Andrology
SC Endocrinology & Metabolism
GA EB1HY
UT WOS:000387101700005
PM 27652215
ER

PT J
AU McMahon, CG
AF McMahon, Chris G.
TI Emerging and investigational drugs for premature ejaculation
SO TRANSLATIONAL ANDROLOGY AND UROLOGY
LA English
DT Review
DE Premature ejaculation (PE); treatment; investigational
ID BENIGN PROSTATIC HYPERPLASIA; DORSAL PENILE NERVE; PLACEBO-CONTROLLED
   MULTICENTER; SEROTONIN REUPTAKE INHIBITOR; RANDOMIZED CONTROLLED-TRIALS;
   INDUCED DELAYED EJACULATION; URINARY-TRACT SYMPTOMS; MALE
   SEXUAL-BEHAVIOR; AD-HOC COMMITTEE; DOUBLE-BLIND
AB Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with alpha 1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.
C1 [McMahon, Chris G.] Australian Ctr Sexual Hlth, Sydney, NSW 2065, Australia.
RP McMahon, CG (reprint author), Australian Ctr Sexual Hlth, Sydney, NSW 2065, Australia.
EM chrisgmcmahon@gmail.com
CR Abdel-Hamid IA, 2001, INT J IMPOT RES, V13, P41, DOI 10.1038/sj.ijir.3900630
   Adams EH, 2006, J PAIN SYMPTOM MANAG, V31, P465, DOI 10.1016/j.jpainsymman.2005.10.006
   AHLENIUS S, 1981, PHARMACOL BIOCHEM BE, V15, P785, DOI 10.1016/0091-3057(81)90023-X
   Akin Y, 2013, IRAN RED CRESCENT ME, V15, DOI 10.5812/ircmj.13805
   Alghobary M, 2010, J SEX MED, V7, P2860, DOI 10.1111/j.1743-6109.2010.01789.x
   Althof SE, 2014, J SEX MED, V11, P1392, DOI 10.1111/jsm.12504
   ARGIOLAS A, 1989, PHARMACOL BIOCHEM BE, V33, P81, DOI 10.1016/0091-3057(89)90433-4
   ARLETTI R, 1990, EUR J PHARMACOL, V179, P377, DOI 10.1016/0014-2999(90)90178-9
   ARLETTI R, 1985, HORM BEHAV, V19, P14, DOI 10.1016/0018-506X(85)90002-9
   Asimakopoulos AD, 2012, J SEX MED, V9, P2404, DOI 10.1111/j.1743-6109.2011.02628.x
   Atan A, 2006, UROLOGY, V67, P388, DOI 10.1016/j.urology.2005.09.002
   Aversa A, 2009, INT J IMPOT RES, V21, P221, DOI 10.1038/ijir.2009.21
   Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554
   Bar-Or D, 2012, EUR UROL, V61, P736, DOI 10.1016/j.eururo.2011.08.039
   Basar M. Murad, 2005, International Urology and Nephrology, V37, P773, DOI 10.1007/s11255-005-3616-4
   Baskerville TA, 2009, EUR J NEUROSCI, V30, P2151, DOI 10.1111/j.1460-9568.2009.06999.x
   BERKOVITCH M, 1995, J UROLOGY, V154, P1360, DOI 10.1016/S0022-5347(01)66861-7
   Busato W, 2004, BJU INT, V93, P1018, DOI 10.1111/j.1464-410X.2004.04773.x
   Buvat J, 2009, EUR UROL, V55, P957, DOI 10.1016/j.eururo.2009.01.025
   Byers ES, 2003, ARCH SEX BEHAV, V32, P261, DOI 10.1023/A:1023417718557
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   Carson C, 2010, J SEX MED, V7, P3179, DOI 10.1111/j.1743-6109.2010.01913.x
   CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9
   Castiglione F, 2016, EUR UROL, V69, P904, DOI 10.1016/j.eururo.2015.12.028
   CAVALLINI G, 1995, EUR UROL, V28, P126
   Cepeda MS, 2007, J RHEUMATOL, V34, P543
   Chapple CR, 2011, EUR UROL, V59, P342, DOI 10.1016/j.eururo.2010.10.046
   Chapple CR, 2004, BJU INT, V94, P738, DOI 10.1111/j.1464-410X.2004.05022.x
   CHAPPLE CR, 1994, BRIT J UROL, V74, P50, DOI 10.1111/j.1464-410X.1994.tb16546.x
   Chen J, 2007, EUR UROL, V52, P1331, DOI 10.1016/j.eururo.2007.08.005
   Chia SJ, 2002, INT J ANDROL, V25, P301, DOI 10.1046/j.1365-2605.2002.00368.x
   Cho Hee Ju, 2014, Res Rep Urol, V6, P113, DOI 10.2147/RRU.S41618
   Choi Jae Hwi, 2014, World J Mens Health, V32, P99, DOI 10.5534/wjmh.2014.32.2.99
   Clement P, 2008, BRIT J PHARMACOL, V154, P1150, DOI 10.1038/bjp.2008.176
   Clement P, 2013, BRIT J PHARMACOL, V169, P1477, DOI 10.1111/bph.12198
   Cormio L, 2015, J SEX MED, V12, P1609, DOI 10.1111/jsm.12925
   Cossmann M, 1997, DRUGS, V53, P50
   de Jong TR, 2007, J SEX MED, V4, P14, DOI 10.1111/j.1743-6109.2006.00394.x
   Debruyne FMJ, 2000, UROLOGY, V56, P20, DOI 10.1016/S0090-4295(00)00744-5
   DEWIED D, 1993, FRONT NEUROENDOCRIN, V14, P251, DOI 10.1006/frne.1993.1009
   Dinsmore WW, 2009, BJU INT, V103, P940, DOI 10.1111/j.1464-410X.2009.08456.x
   Dinsmore WW, 2007, BJU INT, V99, P369, DOI 10.1111/j.1464-410X.2006.06583.x
   Dominguez JM, 2005, PHYSIOL BEHAV, V86, P356, DOI 10.1016/j.physbeh.2005.08.006
   Dresser MJ, 2006, J CLIN PHARMACOL, V46, P1023, DOI 10.1177/0091270006291033
   Dresser MJ, 2006, INT J IMPOT RES, V18, P104, DOI 10.1038/sj.ijir.3901420
   Dresser MJ, 2004, CLIN PHARMACOL THER, V75, P113
   Eassa BI, 2013, ASIAN J ANDROL, V15, P138, DOI 10.1038/aja.2012.96
   ElMazoudy R, 2015, Int J Impot Res, V27, P206, DOI 10.1038/ijir.2015.16
   Erenpreiss J, 2002, INT J IMP RES S4, V14, pS33
   Ferraro L, 2000, NEUROPHARMACOLOGY, V39, P1974, DOI 10.1016/S0028-3908(00)00019-8
   Ferraro L, 2005, SYNAPSE, V55, P230, DOI 10.1002/syn.20111
   Ferraro L, 2002, J NEUROSCI RES, V68, P107, DOI 10.1002/jnr.10196
   Filippi S, 2002, MOL CELL ENDOCRINOL, V193, P89, DOI 10.1016/S0303-7207(02)00101-6
   Frink MC, 1996, ARZNEIMITTEL-FORSCH, V46, P1029
   Furuya Ryoji, 2005, Hinyokika Kiyo, V51, P763
   Garrett PM, 2004, ANAESTH INTENS CARE, V32, P575
   Gil M, 2011, HORM BEHAV, V59, P435, DOI 10.1016/j.yhbeh.2010.12.012
   Giuliano F, 2012, PHARMACOL REV, V64, P621, DOI 10.1124/pr.111.004952
   Gupta J, 2008, BRIT J PHARMACOL, V155, P118, DOI 10.1038/bjp.2008.226
   Hallbeck M, 2001, J COMP NEUROL, V433, P222, DOI 10.1002/cne.1137
   HATANO A, 1994, BRIT J PHARMACOL, V113, P723
   Hellstrom W, 2004, J SEX MED, V1, P59
   Hellstrom WJG, 2005, J UROLOGY, V173, P238
   Henry R, 2008, EXPERT OPIN DRUG DEL, V5, P251, DOI 10.1517/17425247.5.2.251
   Hisasue S, 2006, INT J UROL, V13, P1311, DOI 10.1111/j.1442-2042.2006.01535.x
   Homma Y, 2010, UROLOGY, V76, P1446, DOI 10.1016/j.urology.2010.03.015
   Honda K, 1999, BRAIN RES BULL, V48, P309, DOI 10.1016/S0361-9230(98)00180-4
   Hull EM, 2004, PHYSIOL BEHAV, V83, P291, DOI 10.1016/j.physbeh.2004.08.018
   Hytrin, 2008, HYTR TER HC1 TABL
   Jannini EA, 2011, J SEX MED, V8, P2135, DOI 10.1111/j.1743-6109.2011.02401.x
   Jeon HJ, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.11.046
   Jern P, 2015, INT J IMPOT RES, V27, P75, DOI [10.1038/ijir.2014.37, 10.1038/ijir.201437]
   Jiann BP, 2015, INT J CLIN PRACT, V69, P1326, DOI 10.1111/ijcp.12700
   Kang KK, 2014, INT J UROL, V21, P325, DOI 10.1111/iju.12256
   Kang KK, 2013, UROLOGY, V81, DOI 10.1016/j.urology.2012.12.006
   Kaufman JM, 2009, BJU INT, V103, P651, DOI 10.1111/j.1464-410X.2008.08165.x
   Kawabe K, 2006, BJU INT, V98, P1019, DOI 10.1111/j.1464-410X.2006.06448.x
   Kaynar M, 2012, UROLOGY, V79, P145, DOI 10.1016/j.urology.2011.09.031
   Kirby EW, 2015, INT J IMPOT RES, V27, P121, DOI 10.1038/ijir.2015.7
   Kobayashi K, 2009, INT J IMPOT RES, V21, P306, DOI 10.1038/ijir.2009.27
   Kobayashi K, 2008, J SEX MED, V5, P2185, DOI 10.1111/j.1743-6109.2008.00779.x
   Korotkova TM, 2007, NEUROPHARMACOLOGY, V52, P626, DOI 10.1016/j.neuropharm.2006.09.005
   Koyuncu H, 2012, INT J IMPOT RES, V24, P171, DOI 10.1038/ijir.2012.12
   Lee WK, 2013, J SEX MED, V10, P2832, DOI 10.1111/jsm.12287
   LEPOR H, 1992, J UROLOGY, V148, P1467
   Lepor Herbert, 2006, Rev Urol, V8 Suppl 4, pS3
   Levine L, 2006, M SMSNA
   Li JH, 2014, CLIN THER, V36, P2003, DOI 10.1016/j.clinthera.2014.09.011
   Linn R, 2002, INT J IMP RES, V14
   Lozano AF, 2003, INT J IMP RES, V15, pS11
   Mamas MA, 2003, UROLOGY, V61, P1079, DOI 10.1016/S0090-4295(03)00131-6
   Marson L, 2010, J SEX MED, V7, P70, DOI 10.1111/j.1743-6109.2009.01509.x
   Martyn-St James M, 2015, BMC UROL, V15, DOI 10.1186/1471-2490-15-6
   Mathers MJ, 2009, ANDROLOGIA, V41, P169, DOI 10.1111/j.1439-0272.2008.00910.x
   Mattos RM, 2008, UROL INT, V80, P162, DOI 10.1159/000112607
   McDiarmid Todd, 2005, J Fam Pract, V54, P72
   McMahon CG, 2005, J SEX MED, V2, P368, DOI 10.1111/j.1743-6109.2005.20351.x
   McMahon C, 2010, J SEX MED, V7, P256, DOI 10.1111/j.1743-6109.2009.01560.x
   McMahon CG, 2004, J SEX MED, V1, P58, DOI 10.1111/j.1743-6109.2004.10109.x
   McMahon CG, 2008, J SEX MED, V5, P1590, DOI 10.1111/j.1743-6109.2008.00901.x
   McMahon CG, 2008, J SEX MED, V5, P1817, DOI 10.1111/j.1743-6109.2008.00837.x
   McMahon CG, 2013, J SEX MED, V10, P2312, DOI 10.1111/jsm.12236
   McMahon CG, 2011, J SEX MED, V8, P524, DOI 10.1111/j.1743-6109.2010.02097.x
   McMahon CG, 2006, BJU INT, V98, P259, DOI 10.1111/j.1464-410X.2006.06290.x
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Metz ME, 2000, J SEX MARITAL THER, V26, P293, DOI 10.1080/009262300438715
   Michel MC, 2007, BRIT J PHARMACOL, V152, P289, DOI 10.1038/sj.bjp.0707369
   Mirone V, 2014, EUR UROL, V65, P733, DOI 10.1016/j.eururo.2013.08.018
   Mittino D, 2004, CLIN NEUROPHARMACOL, V27, P150, DOI 10.1097/00002826-200405000-00012
   Modi NB, 2006, J CLIN PHARMACOL, V46, P301, DOI 10.1177/0091270005284850
   Mondaini N, 2013, UROLOGY, V82, P620, DOI 10.1016/j.urology.2013.05.018
   Moore R Andrew, 2005, BMC Urol, V5, P18, DOI 10.1186/1471-2490-5-18
   Park HS, 2014, UROLOGY, V84
   Pastore AL, 2012, INT J ANDROL, V35, P528, DOI 10.1111/j.1365-2605.2011.01243.x
   PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687
   Porst H, 2010, J SEX MED, V7, P2231, DOI 10.1111/j.1743-6109.2010.01820.x
   Pryor JL, 2006, LANCET, V368, P929, DOI 10.1016/S0140-6736(06)69373-2
   Qu WM, 2008, J NEUROSCI, V28, P8462, DOI 10.1523/JNEUROSCI.1819-08.2008
   Regenthal R, 2009, PSYCHOPHARMACOLOGY, V204, P627, DOI 10.1007/s00213-009-1493-8
   Roehrborn CG, 2011, PROSTATE CANCER P D, V14, P143, DOI 10.1038/pcan.2010.46
   Salem EA, 2008, J SEX MED, V5, P188, DOI 10.1111/j.1743-6109.2006.00424.x
   Salonia A, 2009, J SEX MED, V6, P2868, DOI 10.1111/j.1743-6109.2009.01404.x
   Sato Y, 2012, INT J UROL, V19, P268, DOI 10.1111/j.1442-2042.2011.02941.x
   Schapiro B, 1943, J UROLOGY, V50, P374
   Serefoglu EC, 2014, J SEX MED, V11, P1657, DOI 10.1111/jsm.12553
   Serefoglu EC, 2014, SEX MED-UK, V2, P41, DOI 10.1002/sm2.27
   Serefoglu EC, 2010, MED HYPOTHESES, V74, P83, DOI 10.1016/j.mehy.2009.07.038
   Shinghal R, 2013, J SEX MED, V10, P2506, DOI 10.1111/jsm.12272
   SIMPSON LL, 1981, PHARMACOL REV, V33, P155
   Simsek A, 2014, ASIAN J ANDROL, V16, P725, DOI 10.4103/1008-682X.128467
   Sommer F, 2005, J UROLOGY, V173, P202
   Sorbera LA, 2004, DRUG FUTURE, V29, P1201, DOI 10.1358/dof.2004.029.12.865936
   STONEHAM MD, 1985, J ENDOCRINOL, V107, P97, DOI 10.1677/joe.0.1070097
   Sun Xiang-Zhou, 2007, Zhonghua Nan Ke Xue, V13, P610
   Sun Y, 2015, UROLOGY, V86, P947, DOI 10.1016/j.urology.2015.06.051
   Symonds T, 2003, J SEX MARITAL THER, V29, P361, DOI 10.1080/00926230390224738
   Szkutnik-Fiedler D, 2012, PHARMACOL REP, V64, P1350
   Takeshita Junji, 2009, Prim Care Companion J Clin Psychiatry, V11, P273, DOI 10.4088/PCC.08l00690
   Tang Wenhao, 2004, Zhonghua Nan Ke Xue, V10, P366
   Tanrikut C, 2010, FERTIL STERIL, V94, P1021, DOI 10.1016/j.fertnstert.2009.04.039
   Uckert S, 2002, WORLD J UROL, V20, P323, DOI 10.1007/s00345-002-0300-5
   Vignozzi L, 2004, ENDOCRINOLOGY, V145, P1823, DOI 10.1210/en.2003-0962
   Waldinger MD, 2002, J UROLOGY, V168, P2359, DOI 10.1097/01.ju.0000035599.35887.8f
   Waldinger MD, 1998, BEHAV BRAIN RES, V92, P111, DOI 10.1016/S0166-4328(97)00183-6
   Waldinger MD, 2005, WORLD J UROL, V23, P115, DOI 10.1007/s00345-004-0493-x
   Wieder JA, 2000, UROLOGY, V55, P915, DOI 10.1016/S0090-4295(99)00608-1
   WITT DM, 1994, J NEUROENDOCRINOL, V6, P13, DOI 10.1111/j.1365-2826.1994.tb00549.x
   Wu T, 2012, UROLOGY, V80, P618, DOI 10.1016/j.urology.2012.05.035
   Xin Zhong Cheng, 1997, Yonsei Medical Journal, V38, P91
   Xiong Guo-Gen, 2011, Zhonghua Nan Ke Xue, V17, P538
   Yanagimoto M, 1996, BRAIN RES, V733, P292, DOI 10.1016/0006-8993(96)00800-1
   Yang L, 2013, UROL INT, V91, P197, DOI 10.1159/000348826
   Yoshida M, 2011, CLIN INTERV AGING, V6, P161, DOI 10.2147/CIA.S13803
   Yue FG, 2015, UROLOGY, V85, P856, DOI 10.1016/j.urology.2015.01.009
   Gaxiola GM, 2012, USA, Patent No. [US 8329193 B2, 8329193]
NR 155
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-4683
EI 2223-4691
J9 TRANSL ANDROL UROL
JI Transl. Androl. Urol.
PD AUG
PY 2016
VL 5
IS 4
BP 487
EP 501
DI 10.21037/tau.2016.04.02
PG 15
WC Andrology
SC Endocrinology & Metabolism
GA EB1HY
UT WOS:000387101700012
PM 27652222
ER

PT J
AU Abdel-Hamid, IA
   Elsaied, MA
   Mostafa, T
AF Abdel-Hamid, Ibrahim A.
   Elsaied, Moustafa A.
   Mostafa, Taymour
TI The drug treatment of delayed ejaculation
SO TRANSLATIONAL ANDROLOGY AND UROLOGY
LA English
DT Review
DE Ejaculation; delayed ejaculation (DE); inhibited ejaculation; drugs;
   treatment
ID RAT SEXUAL-BEHAVIOR; SPINAL-CORD-INJURY; MEDIAL PREOPTIC AREA; SEROTONIN
   REUPTAKE INHIBITORS; FLUOXETINE-INDUCED ANORGASMIA; DOPAMINE-RECEPTOR
   AGONIST; MALE COPULATORY-BEHAVIOR; VAS-DEFERENS; PENILE ERECTION;
   OXYTOCIN RECEPTOR
AB Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It is often quite concerning to patients and it can affect psychosocial well-being. Here we reviewed how DE is treated pharmacologically. We also highlighted specific settings where drugs could be introduced to medical practice. Electronic databases were searched from 1966 to February 2016, including PubMed MEDLINE, EMBASE, EBCSO Academic Search Complete, Cochrane Systematic Reviews Database, and Google Scholar using key words; delayed ejaculation, retarded ejaculation, inhibited ejaculation, drugs, treatment, or pharmacology. To achieve the maximum sensitivity of the search strategy and to identify all studies, we combined "delayed ejaculation" as Medical Subject Headings (MeSH) terms or keywords with each of "testosterone" or "cabergoline" or "bupropion" or "amantadine" or "cyproheptadine" or "midodrine" or "imipramine" or "ephedrine" or "pseudoephedrine" or "yohimbine" or "buspirone" or "oxytocin" or "bethanechol" as MeSH terms or keywords. There are a number of drugs to treat patients with DE including: testosterone, cabergoline, bupropion, amantadine, cyproheptadine, midodrine, imipramine, ephedrine, pseudoephedrine, yohimbine, buspirone, oxytocin, and bethanechol. Although there are many pharmacological treatment options, the evidence is still limited to small trials, case series or case reports. Review of literature showed that evidence level 1 (Double blind randomized clinical trial) studies were performed with testosterone, oxytocin, buspirone or bethanechol treatment. It is concluded that successful drug treatment of DE is still in its infancy. The clinicians need to be aware of the pathogenesis of DE and the pharmacological basis underlying the use of different drugs to extend better care for these patients. Various drugs are available to address such problem, however their evidence of efficacy is still limited and their choice needs to be individualized to each specific case.
C1 [Abdel-Hamid, Ibrahim A.; Elsaied, Moustafa A.] Mansoura Fac Med, Div Androl, Mansoura, Egypt.
   [Mostafa, Taymour] Cairo Univ, Dept Androl & Sexol, Fac Med, Cairo 11562, Egypt.
RP Abdel-Hamid, IA (reprint author), Mansoura Fac Med, Div Androl, Androl & Reprod, POB 35516, Mansoura, Egypt.
EM ibrahamid2007@yahoo.com
CR Abdel-Hamid IA, 2011, J SEX MED, V8, P1772, DOI 10.1111/j.1743-6109.2010.02131.x
   Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139
   ABRAHAM EM, 1988, BEHAV BRAIN RES, V30, P251, DOI 10.1016/0166-4328(88)90167-2
   Adeniyi AA, 2007, ASIAN J ANDROL, V9, P403, DOI 10.1111/j.1745-7262.2007.00276.x
   Ahlenius S, 1997, NEUROCHEM RES, V22, P1065, DOI 10.1023/A:1022443413745
   AHLENIUS S, 1995, PHARMACOL BIOCHEM BE, V51, P545, DOI 10.1016/0091-3057(94)00390-5
   Althof SE, 2012, INT J IMPOT RES, V24, P131, DOI 10.1038/ijir.2012.2
   Althof SE, 2013, J SEX MED, V10, P26, DOI 10.1111/j.1743-6109.2012.02823.x
   Alwaal A, 2015, FERTIL STERIL, V104, P1051, DOI 10.1016/j.fertnstert.2015.08.033
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   ARGIOLAS A, 1988, EUR J PHARMACOL, V149, P389, DOI 10.1016/0014-2999(88)90675-9
   ARLETTI R, 1990, EUR J PHARMACOL, V179, P377, DOI 10.1016/0014-2999(90)90178-9
   ARNOTT S, 1994, BRIT J PSYCHIAT, V164, P838, DOI 10.1192/bjp.164.6.838
   Ashton AK, 1997, J SEX MARITAL THER, V23, P165
   BALOGH S, 1992, J CLIN PSYCHIAT, V53, P212
   BARALDI M, 1974, LIFE SCI, V14, P1231, DOI 10.1016/0024-3205(74)90430-5
   BERLIN I, 1995, BRIT J CLIN PHARMACO, V39, P243
   Bernik Marcio, 2004, Rev Hosp Clin Fac Med Sao Paulo, V59, P357, DOI 10.1590/S0041-87812004000600008
   Bidaki R, 2012, HEALTHMED, V6, P4066
   BITRAN D, 1989, PHARMACOL BIOCHEM BE, V34, P453, DOI 10.1016/0091-3057(89)90540-6
   Burri A, 2008, PSYCHONEUROENDOCRINO, V33, P591, DOI 10.1016/j.psyneuen.2008.01.014
   Butcher MJ, 2015, ANDROLOGY-US, V3, P626, DOI 10.1111/andr.12041
   Canseco-Alba A, 2013, J SEX MED, V10, P686, DOI 10.1111/j.1743-6109.2012.02890.x
   Cantor JM, 1999, PSYCHOPHARMACOLOGY, V144, P355, DOI 10.1007/s002130051018
   Carro-Juarez M, 2006, INT J IMPOT RES, V18, P32, DOI 10.1038/sj.ijir.3901393
   Carro-Juareza M, 2003, BEHAV BRAIN RES, V141, P43, DOI 10.1016/S0166-4328(02)00324-8
   Cavariani MM, 2015, J APPL TOXICOL, V35, P1007, DOI 10.1002/jat.3089
   CHARLES MA, 1992, PHARMACOL BIOCHEM BE, V43, P1087, DOI 10.1016/0091-3057(92)90486-Y
   Clayton AH, 2003, INT CLIN PSYCHOPHARM, V18, P151, DOI 10.1097/01.yic.0000066456.73432.09
   Clement P, 2013, BRIT J PHARMACOL, V169, P1477, DOI 10.1111/bph.12198
   COHEN AJ, 1992, J CLIN PSYCHIAT, V53, P174
   Corona G, 2006, J ANDROL, V27, P453, DOI 10.2164/jandrol.05154
   Corona G, 2008, J SEX MED, V5, P1991, DOI 10.1111/j.1743-6109.2008.00803.x
   Corona G, 2012, NAT REV UROL, V9, P508, DOI 10.1038/nrurol.2012.147
   Courtois F, 2008, J SEX MED, V5, P2419, DOI 10.1111/j.1743-6109.2008.00857.x
   Courtois FJ, 2008, BJU INT, V101, P331, DOI 10.1111/j.1464-410X.2007.07254.x
   Dabaja AA, 2014, ASIAN J ANDROL, V16, P618, DOI 10.4103/1008-682X.123681
   Kiguti LRD, 2012, J SEX MED, V9, P159, DOI 10.1111/j.1743-6109.2011.02410.x
   DECASTRO RM, 1985, AM J PSYCHIAT, V142, P783
   Devaangam Sheshadri Shekar, 2011, Oman Med J, V26, P404, DOI 10.5001/omj.2011.104
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Dominguez JM, 2005, PHYSIOL BEHAV, V86, P356, DOI 10.1016/j.physbeh.2005.08.006
   Duran I, 2000, EXP BRAIN RES, V134, P490, DOI 10.1007/s002210000488
   Evrensel A, 2014, TURK PSIKIYATR DERG, V25, P291
   FEDER R, 1991, J CLIN PSYCHIAT, V52, P163
   Ferraz Marcia Martins Dias, 2007, Pharmacol Biochem Behav, V86, P616, DOI 10.1016/j.pbb.2007.02.003
   FERRAZ MR, 1995, PHARMACOL BIOCHEM BE, V51, P709, DOI 10.1016/0091-3057(95)00011-K
   Filippi S, 2002, MOL CELL ENDOCRINOL, V193, P89, DOI 10.1016/S0303-7207(02)00101-6
   Filippi S, 2005, ENDOCRINOLOGY, V146, P3506, DOI 10.1210/en.2004-1628
   Filippi S, 2003, J Endocrinol Invest, V26, P82
   Frayne J, 1998, MOL HUM REPROD, V4, P527, DOI 10.1093/molehr/4.6.527
   FUCHS AR, 1981, J ENDOCRINOL, V90, P245, DOI 10.1677/joe.0.0900245
   Gil M, 2013, PSYCHONEUROENDOCRINO, V38, P1688, DOI 10.1016/j.psyneuen.2013.02.002
   Gil M, 2011, HORM BEHAV, V59, P435, DOI 10.1016/j.yhbeh.2010.12.012
   Gomez-Martinez LE, 2009, BEHAV BRAIN RES, V203, P247, DOI 10.1016/j.bbr.2009.05.010
   Gorzalka BB, 2008, PSYCHOPHARMACOLOGY, V198, P479, DOI 10.1007/s00213-007-0901-1
   Graudins A, 1998, J Emerg Med, V16, P615, DOI 10.1016/S0736-4679(98)00057-2
   Harvey K V, 1995, Ann Clin Psychiatry, V7, P189, DOI 10.3109/10401239509149625
   HEDLUND H, 1985, J AUTON PHARMACOL, V5, P261, DOI 10.1111/j.1474-8673.1985.tb00127.x
   Hillegaart V, 1998, PEPTIDES, V19, P39, DOI 10.1016/S0196-9781(97)00250-7
   Hisasue S, 2006, INT J UROL, V13, P1311, DOI 10.1111/j.1442-2042.2006.01535.x
   Hosenbocus Sheik, 2013, J Can Acad Child Adolesc Psychiatry, V22, P55
   Hsieh TC, 2012, J UROLOGY, V187, pE605
   Hueletl-Soto ME, 2014, INT J IMPOT RES, V26, P205, DOI 10.1038/ijir.2014.12
   Hull EM, 2007, HORM BEHAV, V52, P45, DOI 10.1016/j.yhbeh.2007.03.030
   Ishak WW, 2008, J SEX MED, V5, P1022, DOI 10.1111/j.1743-6109.2007.00691.x
   Isola M, 2010, J REPROD DEVELOP, V56, P94, DOI 10.1262/jrd.09-063E
   JEFFRIES JJ, 1987, CAN J PSYCHIAT, V32, P79
   Jen PYP, 1999, J ANAT, V195, P481, DOI 10.1046/j.1469-7580.1999.19540481.x
   Kacker R, 2014, NEW ENGL SECT AM UR
   Kamischke A, 2002, INT J ANDROL, V25, P333, DOI 10.1046/j.1365-2605.2002.00379.x
   Keast JR, 2000, J AUTONOM NERV SYST, V79, P67, DOI 10.1016/S0165-1838(99)00087-9
   Killian LM, 2014, EUR J PHARMACOL, V735, P32, DOI 10.1016/j.ejphar.2014.03.059
   Kitrey ND, 2007, NEUROSCIENCE, V149, P636, DOI 10.1016/j.neuroscience.2007.06.051
   Kleven MS, 1997, J PHARMACOL EXP THER, V282, P747
   KORNHUBER J, 1994, J NEURAL TRANSM-SUPP, P91
   Kravos M, 2010, PHARMACOPSYCHIATRY, V43, P156, DOI 10.1055/s-0030-1249034
   Kruger THC, 2003, J ENDOCRINOL, V179, P357, DOI 10.1677/joe.0.1790357
   Kruger THC, 2005, WORLD J UROL, V23, P130, DOI 10.1007/s00345-004-0496-7
   Labbate L A, 1997, Ann Clin Psychiatry, V9, P241, DOI 10.1023/A:1022356427242
   Landen M, 1999, J CLIN PSYCHOPHARM, V19, P268, DOI 10.1097/00004714-199906000-00012
   Lauerma H, 1996, ACTA PSYCHIAT SCAND, V93, P69, DOI 10.1111/j.1600-0447.1996.tb10621.x
   Leduc BE, 2015, J SPINAL CORD MED, V38, P57, DOI 10.1179/2045772314Y.0000000225
   LEE RL, 1990, PHYSIOL BEHAV, V47, P665, DOI 10.1016/0031-9384(90)90075-F
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lentz A, 2007, J SEX MED, V4, P332, DOI 10.1111/j.1743-6109.2007.00437.x
   Lewis RW, 2004, ENDOCRINE, V23, P101, DOI 10.1385/ENDO:23:2-3:101
   MacDonald K, 2012, J SEX MED, V9, P1407, DOI 10.1111/j.1743-6109.2012.02703.x
   MAHALATI K, 1991, PHARMACOL BIOCHEM BE, V39, P219, DOI 10.1016/0091-3057(91)90426-3
   Malloy BJ, 1998, J UROLOGY, V160, P937, DOI 10.1016/S0022-5347(01)62836-2
   Martinez-Raga J, 2004, J CLIN PSYCHOPHARM, V24, P460, DOI 10.1097/01.jcp.0000130560.31867.90
   MATHES CW, 1990, PHARMACOL BIOCHEM BE, V36, P63, DOI 10.1016/0091-3057(90)90126-3
   Matuszewich L, 1999, BRAIN RES, V820, P55, DOI 10.1016/S0006-8993(98)01331-6
   MCCORMICK S, 1990, J CLIN PSYCHIAT, V51, P383
   McMahon CG, 2013, J SEX MED, V10, P204, DOI 10.1111/j.1743-6109.2012.02824.x
   Millan MJ, 2000, SYNAPSE, V35, P79, DOI 10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X
   Mir S, 1998, PSYCHIAT B, V22, P438, DOI 10.1192/pb.22.7.438
   MIZOGUCHI K, 1994, BRAIN RES, V662, P255, DOI 10.1016/0006-8993(94)90821-4
   Modell JG, 1997, CLIN PHARMACOL THER, V61, P476
   Modell JG, 2000, J SEX MARITAL THER, V26, P231, DOI 10.1080/00926230050084623
   Montorsi F, 2003, INT J IMPOT RES, V15, P203, DOI 10.1038/sj.ijir.3900999
   Moore TJ, 2014, JAMA INTERN MED, V174, P1930, DOI 10.1001/jamainternmed.2014.5262
   MORITOKI H, 1986, J PHARM PHARMACOL, V38, P737
   MURPHY MR, 1990, J CLIN ENDOCR METAB, V71, P1056
   Norden M.J., 1994, DEPRESSION, V2, P109, DOI 10.1002/depr.3050020208
   O'Flynn R, 2000, BRIT J PSYCHIAT, V177, P567
   Olivier B, 2006, INT J IMPOT RES, V18, pS14, DOI 10.1038/sj.ijir.3901330
   Outhoff K, 2009, SA FAM PRACT, V51, P298
   Paduch DA, 2015, J CLIN ENDOCR METAB, V100, P2956, DOI 10.1210/jc.2014-4434
   PAGLIETTI E, 1978, PHYSIOL BEHAV, V20, P559, DOI 10.1016/0031-9384(78)90247-0
   Palmer CW, 2004, ANIM REPROD SCI, V80, P213, DOI 10.1016/j.anireprosci.2003.07.003
   PEHEK EA, 1989, PSYCHOPHARMACOLOGY, V99, P304, DOI 10.1007/BF00445548
   Pereira VM, 2014, CNS NEUROL DISORD-DR, V13, P1079
   Piekarski DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012749
   Rehman J, 1999, BRAIN RES, V821, P414, DOI 10.1016/S0006-8993(98)01129-9
   REMY DC, 1977, J MED CHEM, V20, P836, DOI 10.1021/jm00216a020
   RETANAMARQUEZ S, 1993, NEUROPSYCHOPHARMACOL, V9, P267
   RETANAMARQUEZ S, 1993, PHARMACOL BIOCHEM BE, V44, P913, DOI 10.1016/0091-3057(93)90024-N
   RILEY AJ, 1986, BRIT J PSYCHIAT, V148, P217, DOI 10.1192/bjp.148.2.217
   Rodriguez-Manzo G, 2015, J SEX MED, V12, P1128, DOI 10.1111/jsm.12866
   Safarinejad MR, 2009, INT J IMPOT RES, V21, P213, DOI 10.1038/ijir.2009.19
   Saito T R, 1991, Jikken Dobutsu, V40, P337
   SALA M, 1990, PHYSIOL BEHAV, V47, P165, DOI 10.1016/0031-9384(90)90057-B
   Sanna F, 2014, PHARMACOL BIOCHEM BE, V124, P211, DOI 10.1016/j.pbb.2014.06.012
   SEGRAVES RT, 1987, AM J PSYCHIAT, V144, P1243
   Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223
   Shannon HE, 2000, PSYCHOPHARMACOLOGY, V149, P93, DOI 10.1007/s002139900343
   Sharma V, 2012, J ETHNOPHARMACOL, V143, P201, DOI 10.1016/j.jep.2012.06.024
   SHRIVASTAVA RK, 1995, J CLIN PSYCHOPHARM, V15, P83, DOI 10.1097/00004714-199502000-00014
   SMITH ER, 1987, PHYSIOL BEHAV, V41, P7, DOI 10.1016/0031-9384(87)90123-5
   SMITH ER, 1987, PHYSIOL BEHAV, V41, P15, DOI 10.1016/0031-9384(87)90124-7
   Soler JM, 2007, J UROLOGY, V178, P2082, DOI 10.1016/j.juro.2007.07.047
   Soler JM, 2011, EUR J PHYS REHAB MED, V47, P677
   SORSCHER SM, 1986, J CLIN PSYCHOPHARM, V6, P53
   STEELE TE, 1986, J CLIN PSYCHOPHARM, V6, P326
   STONEHAM MD, 1985, J ENDOCRINOL, V107, P97, DOI 10.1677/joe.0.1070097
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Suresh S, 2009, J ETHNOPHARMACOL, V122, P497, DOI 10.1016/j.jep.2009.01.032
   Tran T, 2015, CNS DRUGS, V29, P985, DOI 10.1007/s40263-015-0293-4
   Valevski A, 1998, CLIN NEUROPHARMACOL, V21, P355
   Vargas VM, 2004, INT J IMPOT RES, V16, P86, DOI 10.1038/sj.ijir.3901169
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Walch K, 2001, J ASSIST REPROD GEN, V18, P655, DOI 10.1023/A:1013115301159
   Waldinger MD, 2002, J UROLOGY, V168, P2359, DOI 10.1097/01.ju.0000035599.35887.8f
   WINTER JC, 1992, J PHARMACOL EXP THER, V263, P682
   YAGER J, 1986, J CLIN PSYCHIAT, V47, P210
   Yeh KY, 2008, HORM BEHAV, V53, P225, DOI 10.1016/j.yhbeh.2007.10.001
   YONEZAWA A, 1991, LIFE SCI, V48, pPL103
   Yonezawa A, 2005, BIOMED RES-TOKYO, V26, P201, DOI 10.2220/biomedres.26.201
   YONEZAWA A, 1992, LIFE SCI, V51, P1999, DOI 10.1016/0024-3205(92)90117-8
   YONEZAWA A, 1986, J PHARMACOBIO-DYNAM, V9, P1032
   Yonezawa A, 2001, PHARMACOL BIOCHEM BE, V70, P141, DOI 10.1016/S0091-3057(01)00584-6
   Yonezawa A, 2008, PHARMACOL BIOCHEM BE, V88, P367, DOI 10.1016/j.pbb.2007.09.009
   Yonezawa A, 2009, BIOMED RES-TOKYO, V30, P71
   YOSHIDA S, 1986, JPN J PHARMACOL, V41, P315, DOI 10.1254/jjp.41.315
   Zanoli P, 2005, INT J IMPOT RES, V17, P513, DOI 10.1038/sj.ijir.3901346
   Zanoli P, 2009, J ETHNOPHARMACOL, V126, P308, DOI 10.1016/j.jep.2009.08.021
   Zanoli P, 2008, ASIAN J ANDROL, V10, P937, DOI 10.1111/j.1745-7262.2008.00437.x
   Zhang XH, 2005, J ENDOCRINOL, V184, P567, DOI 10.1677/joe.1.05885
NR 159
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-4683
EI 2223-4691
J9 TRANSL ANDROL UROL
JI Transl. Androl. Urol.
PD AUG
PY 2016
VL 5
IS 4
BP 576
EP 591
DI 10.21037/tau.2016.05.05
PG 16
WC Andrology
SC Endocrinology & Metabolism
GA EB1HY
UT WOS:000387101700019
PM 27652229
ER

PT J
AU van IJzendoorn, MH
   Bakermans-Kranenburg, MJ
AF van IJzendoorn, M. H.
   Bakermans-Kranenburg, M. J.
TI The Role of Oxytocin in Parenting and as Augmentative Pharmacotherapy:
   Critical Issues and Bold Conjectures
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Review
DE oxytocin; parenting; pharmacotherapy; autism; statistical power;
   multisite multiple replications
ID INTRANASALLY ADMINISTERED OXYTOCIN; 4-WAY CROSSOVER TRIAL; PLASMA
   OXYTOCIN; INFANT FACES; RESPONSES; BEHAVIOR; HUMANS; BRAIN; STRESS;
   AMYGDALA
AB Despite the sometimes heated debate about the validity of human oxytocin studies, experimental oxytocin research with intranasal administration is a growing field with promising preliminary findings. The effects of intranasally administered oxytocin compared to placebo on brain neural activity have been supported in animal studies and in human studies of neural resting state. In several studies, oxytocin sniffs have been shown to lead to down-regulation of amygdala activation in response to infant attachment vocalisations. Meta-analytic evidence shows that oxytocin enhances the salience of (emotional) stimuli, lowers stress and arousal, and elevates empathic concern and tender care, in particular for offspring and in-group members. Less firm evidence points at the amnestic effects of oxytocin. We also note that the average effect sizes of oxytocin experiments are small to modest, and that most studies include a small number of subjects and thus are seriously underpowered, which implies a high risk for publication bias and nonreplicability. Nevertheless, we argue that the power of within-subjects experiments with oxytocin has been underestimated. Much more work is needed, however, to create a firm knowledge base of the neural and behavioural effects of oxytocin. Human oxytocin research is still taking place in the context of discovery, in which bold conjectures are being generated. In the context of justification, these conjectures should subsequently be subjected to stringent attempts at refutations before we jump to theoretical or clinical conclusions. For this context of justification, we propose a multisite multiple replications project on the social stimuli salience enhancing effect of oxytocin. Clinical application of oxytocin is premature. Meta-analytically, the use of oxytocin in clinical groups tends to show only effectiveness in changing symptomatology in individuals with autism spectrum disorders but, even then, it is not yet a validated therapy and its use is premature because safety and long-term side-effects have not been sufficiently studied, in particular in children.
C1 [van IJzendoorn, M. H.; Bakermans-Kranenburg, M. J.] Leiden Univ, Ctr Child & Family Studies, Wassenaarseweg 52, NL-2333 AK Leiden, Netherlands.
RP van IJzendoorn, MH (reprint author), Leiden Univ, Ctr Child & Family Studies, Wassenaarseweg 52, NL-2333 AK Leiden, Netherlands.
EM vanijzen@fsw.leidenuniv.nl
FU Netherlands Organization for Scientific Research [452-04-306,
   453-09-003]; European Research Council [ERC AdG 669249]
FX MJBK and MHvIJ were supported by awards from the Netherlands
   Organization for Scientific Research (MJBK: VIDI grant no. 452-04-306,
   VICI grant no. 453-09-003; MHvIJ: SPINOZA prize) and the European
   Research Council (MJBK: ERC AdG 669249). This paper is based on an
   invited talk at ISPNE 2015 Edinburgh, UK.
CR Adams RB, 2010, J COGNITIVE NEUROSCI, V22, P97, DOI 10.1162/jocn.2009.21187
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bhandari R, 2014, PHYSIOL BEHAV, V131, P123, DOI 10.1016/j.physbeh.2014.04.028
   Biringen Z, 1998, ATTACHMENT HUMAN DEV, V2, P257
   Bowlby J., 1969, ATTACHMENT LOSS ATTA, V1
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Darwin C., 1872, EXPRESSION EMOTIONS
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134
   Emde RN, 1993, IFEEL PICTURES NEW I
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Fox NA, 2015, PSYCHOL B
   Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Grewen KM, 2011, BIOL PSYCHOL, V87, P340, DOI 10.1016/j.biopsycho.2011.04.003
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Heinrichs M, 2004, PHYSIOL BEHAV, V83, P31, DOI 10.1016/j.physbeh.2004.07.020
   Heinrichs M, 2001, J CLIN ENDOCR METAB, V86, P4798, DOI 10.1210/jc.86.10.4798
   Heinrichs M, 2002, STRESS, V5, P195, DOI 10.1080/1025389021000010530
   Joosen KJ, 2013, INFANCY, V18, P414, DOI 10.1111/j.1532-7078.2012.00122.x
   Juffer F, 2008, PROMOTING POSITIVE P, P11
   Klein RA, 2014, SOC PSYCHOL-GERMANY, V45, P142, DOI 10.1027/1864-9335/a000178
   Lane A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137000
   Leitman DI, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00096
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Logan DM, 2014, J CLIN EXP NEUROPSYC, V36, P528, DOI 10.1080/13803395.2014.912614
   MacDonald K, 2013, PSYCHONEUROENDOCRINO, V38, P2831, DOI 10.1016/j.psyneuen.2013.05.014
   Mah BL, 2013, PROG NEURO-PSYCHOPH, V40, P267, DOI 10.1016/j.pnpbp.2012.10.005
   Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438
   Naber FBA, 2013, J AUTISM DEV DISORD, V43, P224, DOI 10.1007/s10803-012-1536-6
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Pincus David, 2010, Front Psychiatry, V1, P134, DOI 10.3389/fpsyt.2010.00134
   Pine DS, 2005, AM J PSYCHIAT, V162, P291, DOI 10.1176/appi.ajp.162.2.291
   Popper K., 2014, CONJECTURES REFUTATI
   Quintana DS, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.93
   Quintana DS, 2015, BIOL PSYCHIAT, V77, p368S
   Quintana DS, 2015, NEUROSCI BIOBEHAV R, V49, P182, DOI 10.1016/j.neubiorev.2014.12.011
   Radke S, 2013, PSYCHOL SCI, V24, P1573, DOI 10.1177/0956797612472682
   Reijneveld SA, 2004, NED TIJDSCHR GENEES, V148, P2227
   Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2
   Riem MME, 2014, DEVELOPMENTAL SCI, V17, P248, DOI 10.1111/desc.12103
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Riem MME, 2012, ATTACH HUM DEV, V14, P533, DOI 10.1080/14616734.2012.727252
   Riem MME, 2012, NEUROPSYCHOPHARMACOL, V37, P1257, DOI 10.1038/npp.2011.313
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Sripada CS, 2013, INT J NEUROPSYCHOPH, V16, P255, DOI 10.1017/S1461145712000533
   Sroufe L. A., 2005, DEV PERSON MINNESOTA
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   van IJzendoorn MH, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00174
   Voorthuis A, 2014, BRAIN RES, V1580, P151, DOI 10.1016/j.brainres.2013.10.051
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   Young KS, 2012, EMOTION, V12, P1200, DOI 10.1037/a0028705
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
NR 63
TC 0
Z9 0
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD AUG
PY 2016
VL 28
IS 8
SI SI
DI 10.1111/jne.12355
PG 8
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DW3VE
UT WOS:000383570400002
ER

PT J
AU Brian, J
   Doyle-Thomas, K
   Baribeau, D
   Anagnostou, E
AF Brian, Jessica
   Doyle-Thomas, Krissy
   Baribeau, Danielle
   Anagnostou, Evdokia
TI Novel Mechanisms and Treatment Approaches in Autism Spectrum Disorder
SO DISCOVERY MEDICINE
LA English
DT Article
ID PERVASIVE DEVELOPMENTAL DISORDERS; RANDOMIZED CONTROLLED-TRIAL; SIBLINGS
   RESEARCH CONSORTIUM; HIGH-FUNCTIONING AUTISM; CORTICAL THICKNESS;
   WHITE-MATTER; OPEN-LABEL; FAMILIAL AGGREGATION; INTRANASAL OXYTOCIN;
   6-MONTH-OLD INFANTS
AB Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by marked heterogeneity in biology, expression, and response to treatment. The past decade has yielded considerable progress in understanding the underlying biological mechanisms, in characterizing the earliest behavioral phenotype(s), and in developing and evaluating effective treatments for ASD. This review highlights recent research advances in genetics and neuroimaging, as well as in novel behavioral and psychopharmacological treatment approaches, arguing for the value of trans-disciplinary initiatives to move the field forward exponentially. Despite considerable complexity, patterns are beginning to emerge that can inform the identification of novel treatment targets and approaches. The next generation of major innovations in ASD research will involve collaborations across genetics/genomics, neuroimaging, and intervention science. Such efforts, currently under way, hold tremendous promise for exponentially increasing our capacity to understand the mechanisms that contribute to the emergence of ASD and to develop and evaluate personalized interventions that yield maximal impact in a meaningful way.
C1 [Brian, Jessica; Doyle-Thomas, Krissy; Baribeau, Danielle; Anagnostou, Evdokia] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON M4G 1R8, Canada.
   [Brian, Jessica; Doyle-Thomas, Krissy; Anagnostou, Evdokia] Univ Toronto, Dept Paediat, Toronto, ON M5G 1X8, Canada.
   [Baribeau, Danielle] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada.
RP Brian, J (reprint author), Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON M4G 1R8, Canada.; Brian, J (reprint author), Univ Toronto, Dept Paediat, Toronto, ON M5G 1X8, Canada.
EM jbrian@hollandbloorview.ca
FU SanofiCanada; SynapDx
FX E.A. has served as a consultant to Roche and Novartis. She has received
   grant funding from SanofiCanada and SynapDx. The other authors have
   nothing to disclose.
CR Abbott AE, CEREB CORTEX
   Accordino RE, 2016, EXPERT OPIN PHARMACO, P1
   AlSagob M, 2015, DISCOV MED, V19, P367
   Althaus M, 2015, NEUROPSYCHOLOGIA, V79, P53, DOI 10.1016/j.neuropsychologia.2015.10.025
   Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005
   Anagnostou E, 2014, CAN MED ASSOC J, V186, P509, DOI 10.1503/cmaj.121756
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Anagnostou E, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-4
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   APA, 2013, DIAGN STAT MAN MENT
   Baranek GT, 2015, AUTISM RES TREAT, V2015, DOI DOI 10.1155/2015/386951
   Baribeau DA, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0437-0
   Barnea-Goraly N, 2004, BIOL PSYCHIAT, V55, P323, DOI 10.1016/j.biopsych.2003.10.022
   Bolton PF, 1998, PSYCHOL MED, V28, P385, DOI 10.1017/S0033291797006004
   Brian JA, 2015, CURR OPIN NEUROL, V28, P117, DOI 10.1097/WCO.0000000000000182
   Carter AS, 2011, J CHILD PSYCHOL PSYC, V52, P741, DOI 10.1111/j.1469-7610.2011.02395.x
   Chawarska K, 2013, BIOL PSYCHIAT, V74, P195, DOI 10.1016/j.biopsych.2012.11.022
   Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6503a1
   Constantino JN, 2010, AM J PSYCHIAT, V167, P1349, DOI 10.1176/appi.ajp.2010.09101470
   Cortese S, 2012, EXPERT REV NEUROTHER, V12, P461, DOI [10.1586/ern.12.23, 10.1586/ERN.12.23]
   Courchesne E, 2004, CURR OPIN NEUROL, V17, P489, DOI 10.1097/01.wco.0000137542.14610.b4
   Courchesne E, 2001, NEUROLOGY, V57, P245
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018
   De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772
   Doyle-Thomas KAR, 2015, ANN NEUROL, V77, P866, DOI 10.1002/ana.24391
   Doyle-Thomas KAR, 2013, J CHILD NEUROL, V28, P729, DOI 10.1177/0883073812451496
   Doyle-Thomas KAR, 2013, RES AUTISM SPECT DIS, V7, P141, DOI 10.1016/j.rasd.2012.08.004
   Elsabbagh M, 2012, CURR BIOL, V22, P338, DOI 10.1016/j.cub.2011.12.056
   Erickson CA, 2013, PSYCHOPHARMACOLOGY B
   Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9
   Erickson CA, 2014, J AUTISM DEV DISORD, V44, P958, DOI 10.1007/s10803-013-1963-z
   Erickson CA, 2011, J CHILD ADOL PSYCHOP, V21, P565, DOI 10.1089/cap.2011.0034
   Fein D, 2013, J CHILD PSYCHOL PSYC, V54, P195, DOI 10.1111/jcpp.12037
   Flanagan JE, 2012, AM J OCCUP THER, V66, P577, DOI 10.5014/ajot.2012.004192
   Georgiades S, 2013, JAMA PSYCHIAT, V70, P42, DOI 10.1001/2013.jamapsychiatry.1
   Ghanizadeh A, 2013, CHILD PSYCHIAT HUM D
   Green J, 2015, LANCET PSYCHIAT, V2, P133, DOI 10.1016/S2215-0366(14)00091-1
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hardan AY, 2009, BIOL PSYCHIAT, V66, P320, DOI 10.1016/j.biopsych.2009.04.024
   Hardan AY, 2006, AM J PSYCHIAT, V163, P1290, DOI 10.1176/appi.ajp.163.7.1290
   Hardan AY, 2004, PSYCHIAT RES-NEUROIM, V131, P263, DOI 10.1016/j.pscychresns.2004.06.001
   Hazlett HC, 2013, EARLY BRAIN DEV INFA
   Hazlett HC, 2012, AM J PSYCHIAT, V169, P601, DOI 10.1176/appi.ajp.2012.11091425
   Herbert MR, 2003, BRAIN, V126, P1182, DOI 10.1093/brain/awg110
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Jones EJH, 2014, NEUROSCI BIOBEHAV R, V39, P1, DOI 10.1016/j.neubiorev.2013.12.001
   Jones W, 2013, NATURE, V504, P427, DOI 10.1038/nature12715
   Just MA, 2004, BRAIN, V127, P1811, DOI 10.1093/brain/awh199
   Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5
   Keller TA, 2007, NEUROREPORT, V18, P23, DOI 10.1097/01.wnr.0000239965.21685.99
   Kennedy DP, 2008, NEUROIMAGE, V39, P1877, DOI 10.1016/j.neuroimage.2007.10.052
   Krumm N, 2015, NAT GENET, V47, P582, DOI 10.1038/ng.3303
   Lainhart JE, 1999, INT REV PSYCHIATR, V11, P278, DOI 10.1080/09540269974177
   Lavelle TA, 2014, PEDIATRICS, V133, pE520, DOI 10.1542/peds.2013-0763
   Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124
   Levitt JG, 2003, CEREB CORTEX, V13, P728, DOI 10.1093/cercor/13.7.728
   Mahajan R, 2015, CNS SPECTRUMS, V20, P412, DOI 10.1017/S1092852915000371
   Marcus RN, 2011, J CLIN PSYCHIAT, V72, P1270, DOI 10.4088/JCP.09m05933
   Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009
   McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171
   Messinger D, 2013, J AM ACAD CHILD ADOL, V52, P300
   Monk CS, 2009, NEUROIMAGE, V47, P764, DOI 10.1016/j.neuroimage.2009.04.069
   Munesue T, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00002
   Nordahl CW, 2007, J NEUROSCI, V27, P11725, DOI 10.1523/JNEUROSCI.0777-07.2007
   Orsmond GI, 2007, MENT RETARD DEV D R, V13, P313, DOI 10.1002/mrdd.20171
   Ozonoff S, 2011, PEDIATRICS, V128, pE488, DOI 10.1542/peds.2010-2825
   Persico AM, 2013, BEHAV BRAIN RES, V251, P95, DOI 10.1016/j.bbr.2013.06.012
   Piven J, 1997, AM J PSYCHIAT, V154, P185
   Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028
   QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289
   Raznahan A, 2010, CEREB CORTEX, V20, P1332, DOI 10.1093/cercor/bhp198
   Reichow B, 2012, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.00009260.PUB
   Reichow B, 2012, J AUTISM DEV DISORD, V42, P512, DOI 10.1007/s10803-011-1218-9
   Rogers SJ, 2012, J AM ACAD CHILD PSY, V51, P1052, DOI 10.1016/j.jaac.2012.08.003
   Sacco R, 2015, PSYCHIAT RES-NEUROIM, V234, P239, DOI 10.1016/j.pscychresns.2015.08.016
   Scherer SW, 2011, HUM GENET, V130, P123, DOI 10.1007/s00439-011-1037-2
   Schertz HH, 2013, EARLY CHILD RES Q, V28, P249, DOI 10.1016/j.ecresq.2012.06.006
   Schreibman L, 2015, J AUTISM DEV DISORD, V45, P2411, DOI 10.1007/s10803-015-2407-8
   Sharma A, 2012, J PEDIATR HEALTH CAR, V26, P291, DOI 10.1016/j.pedhc.2011.02.008
   Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F
   Szatmari P, 2000, J CHILD PSYCHOL PSYC, V41, P579, DOI 10.1017/S0021963099005831
   Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048
   Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249
   Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757
   Yatawara C.J., 2015, MOL PSYCHIAT
   Yuen Ryan K C, 2015, Nat Med, V21, P185, DOI 10.1038/nm.3792
   Zwaigenbaum L, 2014, J AM ACAD CHILD PSY, V53, P1053, DOI 10.1016/j.jaac.2014.07.007
NR 89
TC 0
Z9 0
U1 5
U2 5
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD AUG
PY 2016
VL 22
IS 119
BP 48
EP 55
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DX2KE
UT WOS:000384197100005
ER

PT J
AU Brejchova, J
   Vosahlikova, M
   Roubalova, L
   Parenti, M
   Mauri, M
   Chernyavskiy, O
   Svoboda, P
AF Brejchova, Jana
   Vosahlikova, Miroslava
   Roubalova, Lenka
   Parenti, Marco
   Mauri, Mario
   Chernyavskiy, Oleksandr
   Svoboda, Petr
TI Plasma membrane cholesterol level and agonist-induced internalization of
   delta-opioid receptors; colocalization study with intracellular membrane
   markers of Rab family
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article
DE Cholesterol; Plasma membrane; delta-opioid receptor; Internalization;
   Rab proteins
ID CHAIN PHOSPHATIDYLCHOLINE VESICLES; ADENYLYL-CYCLASE SUPERACTIVATION;
   PROTEIN-COUPLED RECEPTORS; HIGHER-ORDER ANALYSIS; LONG-TERM ADAPTATION;
   LIPID RAFTS; MORPHINE-TOLERANCE; HEK293 CELLS; OXYTOCIN RECEPTOR;
   KNOCKOUT MICE
AB Decrease of cholesterol level in plasma membrane of living HEK293 cells transiently expressing FLAG-delta-OR by beta-cyclodextrin (beta-CDX) resulted in a slight internalization of delta-OR. Massive internalization of delta-OR induced by specific agonist DADLE was diminished in cholesterol-depleted cells. These results suggest that agonist-induced internalization of delta-OR, which has been traditionally attributed exclusively to clathrin-mediated pathway, proceeds at least partially via membrane domains. Identification of internalized pools of FLAG-delta-OR by colocalization studies with proteins of Rab family indicated the decreased presence of receptors in early endosomes (Rab5), late endosomes and lysosomes (Rab7) and fast recycling vesicles (Rab4). Slow type of recycling (Rab11) was unchanged by cholesterol depletion. As expected, agonist-induced internalization of oxytocin receptors was totally suppressed in beta-CDX-treated cells. Determination of average fluorescence lifetime of TMA-DPH, the polar derivative of hydrophobic membrane probe diphenylhexatriene, in live cells by FLIM indicated a significant alteration of the overall PM structure which may be interpreted as an increased "water-accessible space" within PM area. Data obtained by studies of HEK293 cells transiently expressing FLAG-delta-OR by "antibody feeding" method were extended by analysis of the effect of cholesterol depletion on distribution of FLAG-delta-OR in sucrose density gradients prepared from HEK293 cells stably expressing FLAG-delta-OR. Major part of FLAG-delta-OR was co-localized with plasma membrane marker Na,K-ATPase and beta-CDX treatment resulted in shift of PM fragments containing both FLAG-delta-OR and Na,K-ATPase to higher density. Thus, the decrease in content of the major lipid constituent of PM resulted in increased density of resulting PM fragments.
C1 [Brejchova, Jana; Vosahlikova, Miroslava; Roubalova, Lenka; Chernyavskiy, Oleksandr; Svoboda, Petr] Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Lab Biochem Membrane Receptors, Videnska 1083, Prague 14220, Czech Republic.
   [Parenti, Marco; Mauri, Mario] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy.
RP Svoboda, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Lab Biochem Membrane Receptors, Videnska 1083, Prague 14220, Czech Republic.
EM svobodap@biomed.cas.cz
RI Brejchova, Jana/L-9368-2015
OI Brejchova, Jana/0000-0002-2126-6671
FU Czech Science Foundation [P207/12/0919]; PROGRAM EXTRAPLUS - Fondazione
   Cariplo;  [RVO: 67985823]
FX This work was supported by Czech Science Foundation (P207/12/0919) and
   with institutional support RVO: 67985823. The stay of Jana Brejchova in
   the laboratory of Prof. Marco Parenti (University of Milano-Bicocca,
   Monza, Italy) was supported by PROGRAM EXTRAPLUS financed by Fondazione
   Cariplo. The authors thank to Francesca Guzzi for the preparation of the
   cell line stably expressing FLAG-delta-OR, valuable advices, and kind
   help in the course of J.B. stay in Monza.
CR ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299
   Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g
   Ammer H, 1998, J PHARMACOL EXP THER, V286, P855
   Ammer H, 1997, MOL PHARMACOL, V52, P993
   Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Arancibia-Carcamo IL, 2006, DYNAMIC SYNAPSE MOL, P92
   AvidorReiss T, 1996, J BIOL CHEM, V271, P21309
   AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732
   Babiychuk EB, 2006, BIOCHEM J, V397, P407, DOI 10.1042/BJ20060056
   Becker W, 2012, J MICROSC-OXFORD, V247, P119, DOI 10.1111/j.1365-2818.2012.03618.x
   Becker W, 2004, MICROSC RES TECHNIQ, V63, P58, DOI 10.1002/jemt.10421
   Bourova L, 2010, MED SCI MONITOR, V16, pBR260
   Brejchova J, 2015, BBA-BIOMEMBRANES, V1848, P781, DOI 10.1016/j.bbamem.2014.11.029
   Brejchova J, 2011, BBA-BIOMEMBRANES, V1808, P2819, DOI 10.1016/j.bbamem.2011.08.010
   Broom DC, 2002, PSYCHOPHARMACOLOGY, V164, P42, DOI 10.1007/s00213-002-1179-y
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200
   Chung PCS, 2013, PHARMACOL THERAPEUT, V140, P112, DOI 10.1016/j.pharmthera.2013.06.003
   Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005
   Dlouha K, 2013, PHYSIOL RES, V62, P547
   Filliol D, 2000, NAT GENET, V25, P195
   FUNDYTUS ME, 1995, EUR J PHARMACOL, V286, P105, DOI 10.1016/0014-2999(95)00554-X
   Gaveriaux-Ruff C, 2008, EUR J NEUROSCI, V27, P2558, DOI 10.1111/j.1460-9568.2008.06223.x
   Gimpl G, 2002, BBA-BIOMEMBRANES, V1564, P384, DOI 10.1016/S0005-2736(02)00475-3
   Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w
   Gimpl G, 2000, EXP PHYSIOL, V85, p41S, DOI 10.1111/j.1469-445X.2000.tb00006.x
   Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398
   He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X
   Huang P, 2007, BRAIN RES, V1184, P46, DOI 10.1016/j.brainres.2007.09.096
   Huang P, 2007, BIOCHEM PHARMACOL, V73, P534, DOI 10.1016/j.bcp.2006.10.032
   Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009
   Keith DE, 1996, J BIOL CHEM, V271, P19021
   Kest B, 1996, BRAIN RES BULL, V39, P185, DOI 10.1016/0361-9230(95)02092-6
   Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4
   KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009
   KLEIN U, 1994, EUR J BIOCHEM, V220, P559, DOI 10.1111/j.1432-1033.1994.tb18656.x
   Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7
   Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0
   Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417
   Lee YS, 2011, J MED CHEM, V54, P382, DOI 10.1021/jm100982d
   MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375
   Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500
   MIYAMOTO Y, 1993, J PHARMACOL EXP THER, V265, P1325
   Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191
   Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200
   Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200
   Nadal X, 2006, EUR J NEUROSCI, V23, P830, DOI 10.1111/j.1460-9568.2006.04569.x
   Oh P, 2001, MOL BIOL CELL, V12, P685
   Ostasov P, 2008, CELL BIOCHEM FUNCT, V26, P264, DOI 10.1002/cbf.1453
   Ostasov P, 2007, J RECEPT SIG TRANSD, V27, P335, DOI 10.1080/10799890701684142
   Ostasov P, 2013, CHEM PHYS LIPIDS, V167, P62, DOI 10.1016/j.chemphyslip.2013.02.006
   Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407
   Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930
   Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200
   Perrine SA, 2006, BRIT J PHARMACOL, V147, P864, DOI 10.1038/sj.bjp.0706686
   Pradhan AA, 2011, TRENDS PHARMACOL SCI, V32, P581, DOI 10.1016/j.tips.2011.06.008
   Pradhan AAA, 2010, J NEUROSCI, V30, P16459, DOI 10.1523/JNEUROSCI.3748-10.2010
   PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002
   QI J, 1990, J PHARMACOL EXP THER, V254, P683
   Rodal SK, 1999, MOL BIOL CELL, V10, P961
   Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200
   Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546
   Saitoh A, 2004, J PHARMACOL SCI, V95, P374, DOI 10.1254/jphs.FPJ04014X
   Savi P, 2006, P NATL ACAD SCI USA, V103, P11069, DOI 10.1073/pnas.0510446103
   SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130
   Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.3.CO;2-C
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Smart EJ, 1999, MOL CELL BIOL, V19, P7289
   Somsel RJ, 2000, J CELL SCI, V113, P183
   STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034
   STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033
   Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775
   SVOBODA P, 1988, J MEMBRANE BIOL, V104, P211, DOI 10.1007/BF01872323
   Trapaidze N, 1996, J BIOL CHEM, V271, P29279
   Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130
   Ujcikova H, 2014, PROTEOME SCI, V12, DOI 10.1186/1477-5956-12-11
   Ujcikova H, 2011, BBA-GEN SUBJECTS, V1810, P1220, DOI 10.1016/j.bbagen.2011.09.017
   Varga EV, 2003, J PHARMACOL EXP THER, V306, P109, DOI 10.1124/jpet.103.049643
   VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86
   Vosahlikova M, 2014, N-S ARCH PHARMACOL, V387, P487, DOI 10.1007/s00210-014-0962-8
   Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308
   Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914
   Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507
   YEAGLE PL, 1986, J BIOL CHEM, V261, P8175
   YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhao GM, 2002, J PHARMACOL EXP THER, V302, P188, DOI 10.1124/jpet.302.1.188
   Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024
   Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105
   Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3
NR 90
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145-479X
EI 1573-6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD AUG
PY 2016
VL 48
IS 4
BP 375
EP 396
DI 10.1007/s10863-016-9667-7
PG 22
WC Biophysics; Cell Biology
SC Biophysics; Cell Biology
GA DX5QP
UT WOS:000384436600004
PM 27412703
ER

PT J
AU Ison, SH
   Jarvis, S
   Rutherford, KMD
AF Ison, S. H.
   Jarvis, S.
   Rutherford, K. M. D.
TI A survey of sow management at farrowing in the UK
SO ANIMAL WELFARE
LA English
DT Article
DE animal welfare; farrowing; pain; pig; sow management; survey
ID PIGLET MORTALITY; PARTURIENT SOWS; UTERINE ACTIVITY; OXYTOCIN; PAIN;
   PIGS; PERFORMANCE; FETAL; KETOPROFEN; ASPHYXIA
AB Farrowing is an important period in pig production, with sow health and piglet mortality representing a welfare issue and an economic loss. Sow health and welfare is critical for piglet survival and good management can improve welfare and productivity. This study investigated the management of sows around farrowing and attitudes of UK pig farmers towards sow pain and difficulty farrowing. Farmers were asked how often they provided night checks, used farrowing induction and administered pharmaceutical products during and after farrowing. Farmers and veterinarians were asked if they used or prescribed anti-inflammatories for farrowing-related health issues. Farmers were asked if pain at farrowing was a problem for gilts and sows and what percentage they considered to have difficulty farrowing. Convenience sampling using a number of distribution methods was used. Sixty-one farmers and 52 veterinarians responded. Of the farmer respondents, ten worked on outdoor and 51 on indoor farms. Night checks were reported as frequently provided and farrowing induction was rare. Many respondents reported using oxytocin substitutes at least sometimes during (74%) or after (54%) farrowing. Azaperone was reported to be used at least sometimes by 45% of respondents during and 33% after farrowing. Farmers indicated that pain at farrowing was more often a problem for gilts than sows and 5% of gilts and 4% of sows were considered to have farrowing difficulty. The high level of supervision around farrowing, with the use of night checks, is encouraging and could improve welfare. Frequent use of oxytocin substitutes, which promote farrowing and milk let-down may negatively impact sow and piglet welfare and could be masking poor mothers that fail to perform well without intervention. This study provides interesting information regarding the management of sows around farrowing, which could inform future research and education to improve sow and piglet welfare in the periparturient period.
C1 [Ison, S. H.] Michigan State Univ, Dept Anim Sci, E Lansing, MI 48824 USA.
   [Ison, S. H.; Jarvis, S.; Rutherford, K. M. D.] Scotlands Rural Coll, SRUC, Anim Behav & Welf Anim & Vet Sci Res Grp, West Mains Rd, Edinburgh EH9 3JG, Midlothian, Scotland.
   [Ison, S. H.; Jarvis, S.; Rutherford, K. M. D.] Univ Edinburgh, Easter Bush Vet Ctr, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland.
RP Ison, SH (reprint author), Michigan State Univ, Dept Anim Sci, E Lansing, MI 48824 USA.; Ison, SH (reprint author), Scotlands Rural Coll, SRUC, Anim Behav & Welf Anim & Vet Sci Res Grp, West Mains Rd, Edinburgh EH9 3JG, Midlothian, Scotland.; Ison, SH (reprint author), Univ Edinburgh, Easter Bush Vet Ctr, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland.
EM shison@msu.edu
RI Rutherford, Kenneth/I-7638-2014
OI Rutherford, Kenneth/0000-0003-1944-3023
FU BBSRC; Zoetis
FX The authors would like to thank BBSRC and Zoetis for funding this study.
   The authors are grateful to all those who helped with the questionnaire
   design and distribution. Finally, the authors would like to thanks all
   respondents to the questionnaire.
CR Alonso-Spilsbury M, 2004, ANIM REPROD SCI, V84, P157, DOI 10.1016/jl.anireprosci.2003.11.002
   Arey DS, 1997, ANIM WELFARE, V6, P217
   Baxter EM, 2008, THERIOGENOLOGY, V69, P773, DOI 10.1016/j.theriogenology.2007.12.007
   Baxter EM, 2013, ANIM WELFARE, V22, P219, DOI 10.7120/09627286.22.2.219
   Baxter EM, 2012, ANIMAL, V6, P96, DOI 10.1017/S1751731111001224
   Baxter EM, 2011, ANIMAL, V5, P580, DOI 10.1017/S1751731110002272
   BPEX, 2014, BRIT PIT EX YB 2013
   Cipolla M, 2015, RES VET SCI, V99, P60, DOI 10.1016/j.rvsc.2015.02.004
   Defra, 2014, STRUCT AGR IND ENGL
   Gonzalez-Lozano M, 2010, J VET PHARMACOL THER, V33, P28, DOI 10.1111/j.1365-2885.2009.01094.x
   Herskin MS, 2011, ANIMAL, V5, P757, DOI 10.1017/S175173111000203X
   Homedes J, 2014, VET J, V201, P435, DOI 10.1016/j.tvjl.2014.05.038
   Huhn U, 2004, ARCH TIERZUCHT, V47, P575
   Ison SH, 2014, VET J, V202, P622, DOI 10.1016/j.tvjl.2014.10.003
   Jaaskelainen T, 2014, ANIM WELFARE, V23, P435, DOI 10.7120/09627286.23.4.435
   Jarvis S, 1999, APPL ANIM BEHAV SCI, V63, P195, DOI 10.1016/S0168-1591(99)00013-1
   Kirkden RD, 2013, J ANIM SCI, V91, P3361, DOI 10.2527/jas.2012-5637
   Kirkden RD, 2013, ANIM REPROD SCI, V138, P14, DOI 10.1016/j.anireprosci.2013.02.009
   Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427
   Mainau E, 2012, ANIMAL, V6, P494, DOI 10.1017/S1751731111001790
   Mainau E, 2010, THERIOGENOLOGY, V74, P1279, DOI 10.1016/j.theriogenology.2010.05.034
   Mainau E, 2011, APPL ANIM BEHAV SCI, V135, P241, DOI 10.1016/j.applanim.2011.10.020
   Martel G, 2008, LIVEST SCI, V116, P96, DOI 10.1016/j.livsci.2007.09.012
   Miquet J, 2010, P 21 IPVS VANC CAN, P160
   Mota-Rojas D, 2006, ANIM REPROD SCI, V92, P123, DOI 10.1016/j.anireprosci.2005.04.012
   Mota-Rojas D, 2005, ANIM REPROD SCI, V86, P131, DOI 10.1016/j.anireprosci.2004.06.004
   Mota-Rojas D, 2002, AM J VET RES, V63, P1571, DOI 10.2460/ajvr.2002.63.1571
   Mota-Rojas D, 2007, BIOL RES, V40, P55, DOI 10.4067/S0716-97602007000100006
   NOAH, 2014, VET MED CLASS
   Papadopoulos GA, 2010, VET J, V184, P167, DOI 10.1016/j.tvjl.2009.01.010
   Raekallio M, 2003, VET J, V165, P131, DOI 10.1016/S1090-0233(02)00186-7
   Ruediger K, 2012, J ANIM SCI, V90, P2331, DOI 10.2527/jas.2011-4661
   Sabate D., 2012, Pig Journal, V67, P19
   Straw BE, 2000, J AM VET MED ASSOC, V216, P510, DOI 10.2460/javma.2000.216.510
   Tenbergen R, 2014, J SWINE HEALTH PROD, V22, P10
   Vanderhaeghe C, 2013, ANIM REPROD SCI, V139, P76, DOI 10.1016/j.anireprosci.2013.03.007
   Viitasaari E, 2014, APPL ANIM BEHAV SCI, V158, P16, DOI 10.1016/j.applanim.2014.06.005
   Viitasaari E, 2013, VET J, V198, P153, DOI 10.1016/j.tvjl.2013.06.013
NR 38
TC 0
Z9 0
U1 7
U2 7
PU UNIV FEDERATION ANIMAL WELFARE
PI WHEATHAMPSTEAD
PA OLD SCHOOL, BREWHOUSE HILL, WHEATHAMPSTEAD AL4 8AN, HERTS, ENGLAND
SN 0962-7286
J9 ANIM WELFARE
JI Anim. Welf.
PD AUG
PY 2016
VL 25
IS 3
BP 309
EP 317
DI 10.7120/09627286.25.3.309
PG 9
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA DW7CC
UT WOS:000383807800002
ER

PT J
AU Ashar, YK
   Andrews-Hanna, JR
   Yarkoni, T
   Sills, J
   Halifax, J
   Dimidjian, S
   Wager, TD
AF Ashar, Yoni K.
   Andrews-Hanna, Jessica R.
   Yarkoni, Tal
   Sills, Jenifer
   Halifax, Joan
   Dimidjian, Sona
   Wager, Tor D.
TI Effects of Compassion Meditation on a Psychological Model of Charitable
   Donation
SO EMOTION
LA English
DT Article
DE empathy; prosocial; placebo; loving-kindness meditation; desensitization
ID RECURRENT DEPRESSION; CONFIDENCE-INTERVALS; EMOTION REGULATION;
   COGNITIVE THERAPY; LOVING-KINDNESS; EMPATHY; ALTRUISM; RESPONSES;
   PLACEBO; MINDFULNESS
AB Compassion is critical for societal wellbeing. Yet, it remains unclear how specific thoughts and feelings motivate compassionate behavior, and we lack a scientific understanding of how to effectively cultivate compassion. Here, we conducted 2 studies designed to a) develop a psychological model predicting compassionate behavior, and b) test this model as a mediator of a Compassion Meditation (CM) intervention and identify the "active ingredients" of CM. In Study 1, we developed a model predicting compassionate behavior, operationalized as real-money charitable donation, from a linear combination of self-reported tenderness, personal distress, perceived blamelessness, and perceived instrumental value of helping with high cross-validated accuracy, r = .67, p < .0001. Perceived similarity to suffering others did not predict charitable donation when controlling for other feelings and attributions. In Study 2, a randomized controlled trial, we tested the Study 1 model as a mediator of CM and investigated active ingredients. We compared a smartphone-based CM program to 2 conditions-placebo oxytocin and a Familiarity intervention-to control for expectancy effects, demand characteristics, and familiarity effects. Relative to control conditions, CM increased charitable donations, and changes in the Study 1 model of feelings and attributions mediated this effect (p(ab) = .002). The Familiarity intervention led to decreases in primary outcomes, while placebo oxytocin had no significant effects on primary outcomes. Overall, this work contributes a quantitative model of compassionate behavior, and informs our understanding of the change processes and intervention components of CM.
C1 [Ashar, Yoni K.; Sills, Jenifer] Univ Colorado, Dept Psychol & Neurosci, 345 UCB, Boulder, CO 80309 USA.
   [Andrews-Hanna, Jessica R.] Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA.
   [Yarkoni, Tal] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
   [Halifax, Joan] Upaya Inst, Santa Fe, NM USA.
   [Halifax, Joan] Zen Ctr, Santa Fe, NM USA.
   [Dimidjian, Sona; Wager, Tor D.] Univ Colorado, Boulder, CO 80309 USA.
RP Ashar, YK (reprint author), Univ Colorado, Dept Psychol & Neurosci, 345 UCB, Boulder, CO 80309 USA.
EM yoniashar@gmail.com
RI Emchi, Karma/Q-1952-2016
CR ADAIR JG, 1984, J APPL PSYCHOL, V69, P334, DOI 10.1037/0021-9010.69.2.334
   Adler NE, 2000, HEALTH PSYCHOL, V19, P586, DOI 10.1037/0278-6133.19.6.586
   ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037//0022-3514.63.4.596
   Ashar Y. K., POSITIVE NE IN PRESS, P1
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   BATSON CD, 1987, J PERS, V55, P19, DOI 10.1111/j.1467-6494.1987.tb00426.x
   BATSON CD, 1995, J PERS SOC PSYCHOL, V68, P300, DOI 10.1037//0022-3514.68.2.300
   Batson CD, 2005, BASIC APPL SOC PSYCH, V27, P15, DOI 10.1207/s15324834basp2701_2
   Batson CD, 2011, ALTRUISM HUMANS
   Bennett R, 2003, INT J NONPROFIT VOLU, V8, P12, DOI [10.1002/nvsm.198, DOI 10.1002/NVSM.198]
   Boot WR, 2013, PERSPECT PSYCHOL SCI, V8, P445, DOI 10.1177/1745691613491271
   Cameron CD, 2011, J PERS SOC PSYCHOL, V100, P1, DOI 10.1037/a0021643
   Cialdini RB, 1997, J PERS SOC PSYCHOL, V73, P481, DOI 10.1037/0022-3514.73.3.481
   CIALDINI RB, 1987, J PERS SOC PSYCHOL, V52, P749, DOI 10.1037/0022-3514.52.4.749
   Condon P, 2013, PSYCHOL SCI, V24, P2125, DOI 10.1177/0956797613485603
   Cox CL, 2012, SOC COGN AFFECT NEUR, V7, P727, DOI 10.1093/scan/nsr051
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   de Waal FBM, 2008, ANNU REV PSYCHOL, V59, P279, DOI 10.1146/annurev.psych.59.103006.093625
   Decety J, 2011, EMOT REV, V3, P92, DOI 10.1177/1754073910374662
   DELMONTE MM, 1981, PSYCHOL REP, V49, P699
   DELMONTE MM, 1985, BIOL PSYCHOL, V21, P107, DOI 10.1016/0301-0511(85)90009-2
   DiCiccio TJ, 1996, STAT SCI, V11, P189
   Dunn EW, 2014, CURR DIR PSYCHOL SCI, V23, P41, DOI 10.1177/0963721413512503
   Efron B., 1994, INTRO BOOTSTRAP, V57
   EISENBERG N, 1989, J PERS SOC PSYCHOL, V57, P55, DOI 10.1037//0022-3514.57.1.55
   Engen HG, 2013, CURR OPIN NEUROBIOL, V23, P275, DOI 10.1016/j.conb.2012.11.003
   Fan Y, 2011, NEUROSCI BIOBEHAV R, V35, P903, DOI 10.1016/j.neubiorev.2010.10.009
   Galante J, 2014, J CONSULT CLIN PSYCH, V82, P1101, DOI 10.1037/a0037249
   Gonzalez-Liencres C, 2013, NEUROSCI BIOBEHAV R, V37, P1537, DOI 10.1016/j.neubiorev.2013.05.001
   Halifax J, 2012, CURR OPIN SUPPORT PA, V6, P228, DOI 10.1097/SPC.0b013e3283530fbe
   Halifax J, 2011, J PAIN SYMPTOM MANAG, V41, P146, DOI 10.1016/j.jpainsymman.2010.08.010
   HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90038-4
   Hastie T., 2009, ELEMENTS STAT LEARNI
   Hofmann SG, 2011, CLIN PSYCHOL REV, V31, P1126, DOI 10.1016/j.cpr.2011.07.003
   Hutcherson CA, 2008, EMOTION, V8, P720, DOI 10.1037/a0013237
   Singer T., 2011, PATHOLOGICAL ALTRUIS, P368
   Klimecki OM, 2013, CEREB CORTEX, V23, P1552, DOI 10.1093/cercor/bhs142
   Koban L., 2015, EMOTION
   Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827
   Koopmann-Holm B, 2013, EMOTION, V13, P497, DOI 10.1037/a0031070
   KREBS D, 1975, J PERS SOC PSYCHOL, V32, P1134, DOI 10.1037//0022-3514.32.6.1134
   Loewenstein G, 2007, REV GEN PSYCHOL, V11, P112, DOI 10.1037/1089-2680.11.2.112
   MacCoon Donal G, 2012, Behav Res Ther, V50, P3, DOI 10.1016/j.brat.2011.10.011
   MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037//1082-989X.7.1.83
   McCambridge J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039116
   McCray LW, 2008, FAM MED, V40, P626
   Meade AW, 2012, PSYCHOL METHODS, V17, P437, DOI 10.1037/a0028085
   Mehl MR, 2001, BEHAV RES METH INS C, V33, P517, DOI 10.3758/BF03195410
   Milborrow S., 2010, P PATT REC ASS S AFR
   Miller FG, 2008, J ROY SOC MED, V101, P222, DOI 10.1258/jrsm.2008.070466
   Minear M, 2004, BEHAV RES METH INS C, V36, P630, DOI 10.3758/BF03206543
   Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035
   Odgaard EC, 2010, J CONSULT CLIN PSYCH, V78, P287, DOI 10.1037/a0019294
   Orne M. T., 2000, ENCY PSYCHOL, V2, P469
   Oveis C, 2010, J PERS SOC PSYCHOL, V98, P618, DOI 10.1037/a0017628
   Pace TWW, 2010, PSYCHONEUROENDOCRINO, V35, P310, DOI 10.1016/j.psyneuen.2009.06.008
   PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037
   Penner LA, 2005, ANNU REV PSYCHOL, V56, P365, DOI 10.1146/annurev.psych.56.091103.070141
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Raudenbush S. W., 2002, ADV QUANTITATIVE TEC, V1
   Raz G, 2014, SOC COGN AFFECT NEUR, V9, P30, DOI 10.1093/scan/nst052
   Reniers RLEP, 2011, J PERS ASSESS, V93, P84, DOI 10.1080/00223891.2010.528484
   Rudolph U, 2004, COGNITION EMOTION, V18, P815, DOI 10.1080/02699930341000248
   SCHWARZ N, 1983, J PERS SOC PSYCHOL, V45, P513, DOI 10.1037//0022-3514.45.3.513
   Segal ZV, 2010, ARCH GEN PSYCHIAT, V67, P1256, DOI 10.1001/archgenpsychiatry.2010.168
   Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279
   Sobel Michael E., 1982, SOCIOL METHODOL, V13, P290, DOI DOI 10.2307/270723
   Stellar JE, 2012, EMOTION, V12, P449, DOI 10.1037/a0026508
   Stotland E., 1969, ADV EXPT SOCIAL PSYC, V4, P271, DOI 10.1016/S0065-2601(08)60080-5
   Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833
   Vollhardt JR, 2011, AM J ORTHOPSYCHIAT, V81, P307, DOI 10.1111/j.1939-0025.2011.01099.x
   Vroom V.H, 1964, WORK MOTIVATION
   Wager TD, 2008, NEURON, V59, P1037, DOI 10.1016/j.neuron.2008.09.006
   Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976
   Wallmark E, 2013, MINDFULNESS, V4, P223, DOI 10.1007/s12671-012-0115-4
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Williams JMG, 2014, J CONSULT CLIN PSYCH, V82, P275, DOI 10.1037/a0035036
   Woolfolk R L, 1981, Biofeedback Self Regul, V6, P483, DOI 10.1007/BF00998733
   Yarkoni T., 2015, PEERJ PREPRINTS
   Zajonc RB, 2001, CURR DIR PSYCHOL SCI, V10, P224, DOI 10.1111/1467-8721.00154
   Zaki J, 2014, PSYCHOL BULL, V140, P1608, DOI 10.1037/a0037679
   Zaki J, 2012, NAT NEUROSCI, V15, P675, DOI 10.1038/nn.3085
   Zeidan F, 2010, J ALTERN COMPLEM MED, V16, P867, DOI 10.1089/acm.2009.0321
NR 84
TC 0
Z9 0
U1 16
U2 16
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1528-3542
EI 1931-1516
J9 EMOTION
JI Emotion
PD AUG
PY 2016
VL 16
IS 5
BP 691
EP 705
DI 10.1037/emo0000119
PG 15
WC Psychology, Experimental
SC Psychology
GA DV7ER
UT WOS:000383099500013
PM 27018610
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Which method is best for the induction of labour? A systematic review,
   network meta-analysis and cost-effectiveness analysis
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIAL; PROSTAGLANDIN E-2 GEL; PLACEBO-CONTROLLED
   TRIAL; DOUBLE-BLIND TRIAL; DONOR ISOSORBIDE MONONITRATE; DINOPROSTONE
   VAGINAL INSERT; 41 WEEKS GESTATION; EXTRAAMNIOTIC SALINE INFUSION;
   TITRATED ORAL MISOPROSTOL; LOW-DOSE OXYTOCIN
AB Background: More than 150,000 pregnant women in England and Wales have their labour induced each year. Multiple pharmacological, mechanical and complementary methods are available to induce labour.
   Objective: To assess the relative effectiveness, safety and cost-effectiveness of labour induction methods and, data permitting, effects in different clinical subgroups.
   Methods: We carried out a systematic review using Cochrane methods. The Cochrane Pregnancy and Childbirth Group's Trials Register was searched (March 2014). This contains over 22,000 reports of controlled trials (published from 1923 onwards) retrieved from weekly searches of OVID MEDLINE (1966 to current); Cochrane Central Register of Controlled Trials (The Cochrane Library); EMBASE (1982 to current); Cumulative Index to Nursing and Allied Health Literature (1984 to current); ClinicalTrials. gov; the World Health Organization International Clinical Trials Registry Portal; and hand-searching of relevant conference proceedings and journals. We included randomised controlled trials examining interventions to induce labour compared with placebo, no treatment or other interventions in women eligible for third-trimester induction. We included outcomes relating to efficacy, safety and acceptability to women. In addition, for the economic analysis we searched the Database of Abstracts of Reviews of Effects, and Economic Evaluations Databases, NHS Economic Evaluation Database and the Health Technology Assessment database. We carried out a network meta-analysis (NMA) using all of the available evidence, both direct and indirect, to produce estimates of the relative effects of each treatment compared with others in a network. We developed a de novo decision tree model to estimate the cost-effectiveness of various methods. The costs included were the intervention and other hospital costs incurred (price year 2012-13). We reviewed the literature to identify preference-based utilities for the health-related outcomes in the model. We calculated incremental cost-effectiveness ratios, expected costs, utilities and net benefit. We represent uncertainty in the optimal intervention using cost-effectiveness acceptability curves.
   Results: We identified 1190 studies; 611 were eligible for inclusion. The interventions most likely to achieve vaginal delivery (VD) within 24 hours were intravenous oxytocin with amniotomy [ posterior rank 2; 95% credible intervals (CrLs) 1 to 9] and higher-dose (>= 50 mu g) vaginal misoprostol (rank 3; 95% Crl 1 to 6). Compared with placebo, several treatments reduced the odds of caesarean section, but we observed considerable uncertainty in treatment rankings. For uterine hyperstimulation, double-balloon catheter had the highest probability of being among the best three treatments, whereas vaginal misoprostol (>= 50 mu g) was most likely to increase the odds of excessive uterine activity. For other safety outcomes there were insufficient data or there was too much uncertainty to identify which treatments performed 'best'. Few studies collected information on women's views. Owing to incomplete reporting of the VD within 24 hours outcome, the cost-effectiveness analysis could compare only 20 interventions. The analysis suggested that most interventions have similar utility and differ mainly in cost. With a caveat of considerable uncertainty, titrated (low-dose) misoprostol solution and buccal/sublingual misoprostol had the highest likelihood of being cost-effective.
   Limitations: There was considerable uncertainty in findings and there were insufficient data for some planned subgroup analyses.
   Conclusions: Overall, misoprostol and oxytocin with amniotomy (for women with favourable cervix) is more successful than other agents in achieving VD within 24 hours. The ranking according to safety of different methods was less clear. The cost-effectiveness analysis suggested that titrated (low-dose) oral misoprostol solution resulted in the highest utility, whereas buccal/sublingual misoprostol had the lowest cost. There was a high degree of uncertainty as to the most cost-effective intervention.
FU National Institute for Health Research Health Technology Assessment
   programme
FX The National Institute for Health Research Health Technology Assessment
   programme.
CR Aalami-Harandi Rezvan, 2013, Rev Bras Ginecol Obstet, V35, P60, DOI 10.1590/S0100-72032013000200004
   Abdul M A, 2007, West Afr J Med, V26, P213
   Abedi-Asl Z, 2007, ACTA MED IRANICA, V45, P443
   Abramovici H, 1994, INT J OBSTET GYNECOL, V46, P7
   Adair C. D., 1998, American Journal of Obstetrics and Gynecology, V178, pS93
   Adair CD, 1998, OBSTET GYNECOL, V92, P810, DOI 10.1016/S0029-7844(98)00278-6
   Adam I, 2005, INT J GYNECOL OBSTET, V89, P142, DOI 10.1016/j.ijgo.2004.11.033
   Adeniji A O, 2005, Afr J Med Med Sci, V34, P377
   Adeniji A O, 2005, West Afr J Med, V24, P334
   Adeniji AO, 2006, INT J GYNECOL OBSTET, V92, P130, DOI 10.1016/j.ijgo.2005.10.010
   Adeniji O A, 2005, J Obstet Gynaecol, V25, P134
   Agarwal K, 2012, INT J GYNECOL OBSTET, V118, P205, DOI 10.1016/j.ijgo.2012.04.017
   Agarwal N, 2003, J OBSTET GYNAECOL RE, V29, P147, DOI 10.1046/j.1341-8076.2003.00091.x
   Ajori L, 2013, ARCH GYNECOL OBSTET, V287, P887, DOI 10.1007/s00404-012-2674-y
   Akay NO, 2012, GYNECOL OBSTET INVES, V73, P242, DOI 10.1159/000334404
   Akyol D, 1999, AUST NZ J OBSTET GYN, V39, P291, DOI 10.1111/j.1479-828X.1999.tb03399.x
   Al-Hussaini TK, 2003, INT J GYNECOL OBSTET, V82, P73, DOI 10.1016/S0020-7292(03)00136-X
   Al-Malt A., 1995, American Journal of Obstetrics and Gynecology, V172, P297, DOI 10.1016/0002-9378(95)90819-6
   Al-Sebai M. A. H., 1993, Journal of Obstetrics and Gynaecology (Abingdon), V13, P112, DOI 10.3109/01443619309151795
   Al-Taani M I, 2004, East Mediterr Health J, V10, P547
   Alcalay M, 1996, EUR J OBSTET GYN R B, V70, P129, DOI 10.1016/S0301-2115(95)02586-3
   Alcoseba-Lim W, 1992, PHILIPPINES J SURG S, V47, P139
   Alfirevic Z, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001338.pub2
   Alfirevic Z, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003246.pub2
   ALLOTT HA, 1993, BRIT J OBSTET GYNAEC, V100, P898, DOI 10.1111/j.1471-0528.1993.tb15103.x
   Allouche C, 1993, Rev Fr Gynecol Obstet, V88, P492
   Amador LAV, 2007, PROGR OBSTETRICIA GI, V50, P473
   Anand AK, 2012, JK SCI, V14, P115
   ANDERSEN K, 1990, Ugeskrift for Laeger, V152, P3705
   ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585
   Arias F., 1997, American Journal of Obstetrics and Gynecology, V176, pS141, DOI 10.1016/S0002-9378(97)80554-6
   Asher GN, 2009, J MATERN-FETAL NEO M, V22, P843, DOI 10.1080/14767050902906386
   Ashrafunnessa, 1997, Bangladesh Med Res Counc Bull, V23, P66
   Atad J, 1996, OBSTET GYNECOL, V87, P223, DOI 10.1016/0029-7844(95)00389-4
   Atad J, 1999, 1 WORLD C CONTR OBST
   Ayad I A A, 2002, East Mediterr Health J, V8, P515
   Ayaz A, 2008, TAIWAN J OBSTET GYNE, V47, P192, DOI 10.1016/S1028-4559(08)60079-0
   Ayaz A, 2010, TAIWAN J OBSTET GYNE, V49, P151, DOI 10.1016/S1028-4559(10)60032-0
   BAGRATEE JS, 1990, S AFR MED J, V78, P738
   BAKOS O, 1987, ACTA OBSTET GYN SCAN, V66, P537, DOI 10.3109/00016348709015731
   Balci O, 2011, J MATERN-FETAL NEO M, V24, P1084, DOI 10.3109/14767058.2010.531798
   Balci O, 2010, INT J GYNECOL OBSTET, V110, P64, DOI 10.1016/j.ijgo.2010.02.004
   Barcaite E, 2006, 35 NORD C OBST GYN 2
   Barrilleaux P., 2002, American Journal of Obstetrics and Gynecology, V187, pS174
   Bartha JL, 2000, OBSTET GYNECOL, V96, P465, DOI 10.1016/S0029-7844(00)00954-6
   Bartusevicius A, 2006, BJOG-INT J OBSTET GY, V113, P1431, DOI 10.1111/j.1471-0528.2006.01108.x
   Beer AM, 1999, GEBURTSH FRAUENHEILK, V59, P431
   Beigi A, 2003, INT J GYNECOL OBSTET, V83, P251, DOI 10.1016/S0020-7292(03)00275-3
   BELL RJ, 1993, OBSTET GYNECOL, V82, P328
   Benedetto C, 1987, GIORNALE ITALIANO OB, V5, P447
   Bennett K, 1998, SOC OBST GYN CAN 54
   Bennett KA, 1998, OBSTET GYNECOL, V92, P481, DOI 10.1016/S0029-7844(98)00226-9
   Benzineb N, 1996, REV FRANCAISE GYNECO, V91, P173
   Berghella V, 1996, OBSTET GYNECOL, V87, P927, DOI 10.1016/0029-7844(96)00046-4
   Berghella V, 1994, 14 WORLD C GYN OBST
   Berkane N, 2005, AM J OBSTET GYNECOL, V192, P114, DOI 10.1016/j.ajog.2004.05.084
   Bernstein EP, 1991, P ANN M SOC OBST GYN
   BERNSTEIN P, 1991, CAN MED ASSOC J, V145, P1249
   BERNSTEIN P, 1987, AM J OBSTET GYNECOL, V156, P336
   Bezircioglu I, 2012, CLIN EXP OBSTET GYN, V39, P356
   Bilgin T., 1998, Clinical and Experimental Obstetrics and Gynecology, V25, P46
   Bilgin T, 1996, PRENATAL NEONATAL S1, V1, P89
   Biron-Shental T, 2004, INT J GYNECOL OBSTET, V85, P159, DOI 10.1016/j.ijgo.2003.08.006
   Bollapragada SS, 2009, BJOG-INT J OBSTET GY, V116, P1185, DOI 10.1111/j.1471-0528.2009.02216.x
   Bollapragada Shrikant, 2006, BMC Pregnancy Childbirth, V6, P25, DOI 10.1186/1471-2393-6-25
   Bollapragada SS, 2007, J OBSTET GYNAECOL S1, V27, P22
   Bolnick Jay, 2002, American Journal of Obstetrics and Gynecology, V187, pS175
   Boulvain M, 1998, BRIT J OBSTET GYNAEC, V105, P34, DOI 10.1111/j.1471-0528.1998.tb09347.x
   Boulvain M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006971
   Boulvain M, 1997, ACTA OBSTET GYN SCAN, V76, P32
   Boulvain M, 2005, COCHRANE DB SYST REV, V1
   Bounyasong S, 2000, THAI J OBSTET GYNECO, V12, P21
   Brandel E, 1998, J GYNECOL OBST BIO R, V27, P111
   Brazier J, 2007, MEASURING VALUING HL
   BREMME K, 1984, GYNECOL OBSTET INVES, V17, P120
   Bremme K, 1980, Acta Obstet Gynecol Scand Suppl, V92, P23
   Bremme K, 1980, Acta Obstet Gynecol Scand Suppl, V92, P31
   Bremme K, 1982, P 8 EUR C PER MED 7
   Brennan MC, 2011, AM J PERINAT, V28, P479, DOI 10.1055/s-0030-1271208
   Brennand JE, 1997, BRIT J OBSTET GYNAEC, V104, P775, DOI 10.1111/j.1471-0528.1997.tb12019.x
   Bricker L, 2008, BJOG-INT J OBSTET GY, V115, P1503, DOI 10.1111/j.1471-0528.2008.01890.x
   Bricker L, 2000, COCHRANE DB SYST REV, V4
   Briggs A, 2006, DECISION MODELLING H
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Browning J, 2000, OBSTET GYNECOL, V95, P76
   BUCHANAN D, 1984, OBSTET GYNECOL, V63, P659
   Budden A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009701.pub2
   Bullarbo M, 2007, EUR J OBSTET GYN R B, V130, P160, DOI 10.1016/j.ejorb.2006.01.021
   Bullarbo M, 2007, AM J OBSTET GYNECOL, V196, P50, DOI 10.1016/j.ajog.2006.08.034
   BUNG P, 1986, GEBURTSH FRAUENHEILK, V46, P93, DOI 10.1055/s-2008-1036170
   Buser D, 1997, OBSTET GYNECOL, V89, P581, DOI 10.1016/S0029-7844(97)00015-X
   Butt KD, 1999, OBSTET GYNECOL, V94, P994, DOI 10.1016/S0029-7844(99)00423-8
   BUTTINO L, 1990, J REPROD MED, V35, P155
   Byrne CM, 2007, DIS COLON RECTUM, V50, P586, DOI 10.1007/s10350-006-0847-0
   Byrne James D, 2004, J Perinatol, V24, P416, DOI 10.1038/sj.jp.7211127
   CABROL D, 1988, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V17, P527
   CAHILL DJ, 1988, IRISH J MED SCI, V157, P113, DOI 10.1007/BF02950366
   Caldwell DM, 2005, BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Cammu H, 1998, BRIT J OBSTET GYNAEC, V105, P41, DOI 10.1111/j.1471-0528.1998.tb09348.x
   Campbell J M, 1984, Clin Exp Obstet Gynecol, V11, P1
   Campos G A, 1994, Rev Chil Obstet Ginecol, V59, P190
   Cararach V, 1996, 3 WORLD C PER MED 20
   Cararach V, 1994, P 14 EUR C PER MED 5
   CARDOZO L, 1986, BRIT MED J, V293, P1059
   Carlan SJ, 2002, AM J OBSTET GYNECOL, V186, P229, DOI 10.1067/mob.2002.119630
   Carlan SJ, 2001, OBSTET GYNECOL, V98, P107, DOI 10.1016/S0029-7844(01)01369-2
   Caughey AB, 2006, AM J OBSTET GYNECOL, V195, P700, DOI 10.1016/j.ajog.2006.07.003
   Cecatti JG, 2000, 16 FIGO WORLD C OBST, V4, P28
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chang CH, 1997, J FORMOS MED ASSOC, V96, P366
   Chang P., 1997, American Journal of Obstetrics and Gynecology, V176, pS148, DOI 10.1016/S0002-9378(97)80580-7
   Chanrachakul B, 2000, OBSTET GYNECOL, V96, P549, DOI 10.1016/S0029-7844(00)00990-X
   Chanrachakul B, 2002, INT J GYNECOL OBSTET, V78, P139, DOI 10.1016/S0020-7292(02)00128-5
   Chanrachakul B, 2003, EUR J OBSTET GYN R B, V106, P154, DOI 10.1016/S0301-2115(02)00243-9
   Chanrachakul B, 2000, INT J GYNECOL OBSTET, V71, P217, DOI 10.1016/S0020-7292(00)00284-8
   Chanrachakul B, 2000, 16 FIGO WORLD C OBST, P68
   Chanrachakul B, 2010, REPROD SCI, V17, p352A
   Charoenkul Suntana, 2000, Journal of the Medical Association of Thailand, V83, P1026
   CHATTERJEE MS, 1991, EUR J OBSTET GYN R B, V38, P197, DOI 10.1016/0028-2243(91)90291-R
   Chaudhuri S, 2011, J OBSTET GYNAECOL RE, V37, P1564, DOI 10.1111/j.1447-0756.2011.01575.x
   CHAYEN B, 1986, J REPROD MED, V31, P116
   Chen TM, 2000, J ZHENIANG MED COLL, V4, P652
   Cheng SY, 2008, OBSTET GYNECOL, V111, P119, DOI 10.1097/01.AOG.0000297313.68644.71
   Cheung PC, 2006, ACTA OBSTET GYN SCAN, V85, P1128, DOI 10.1080/00016340600589636
   Chitrakar N S, 2012, J Nepal Health Res Counc, V10, P10
   Christilaw J, 1986, P ANN M SOC OBST GYN
   Chua S, 1997, J Obstet Gynaecol Res, V23, P171
   CHUA S, 1991, OBSTET GYNECOL, V77, P664
   CHUA S, 1995, OBSTET GYNECOL, V86, P550, DOI 10.1016/S0029-7844(95)80014-X
   CHUA S M, 1988, SMJ Singapore Medical Journal, V29, P379
   Chuck F., 1995, American Journal of Obstetrics and Gynecology, V172, P424
   CHUCK FJ, 1995, AM J OBSTET GYNECOL, V173, P1137, DOI 10.1016/0002-9378(95)91340-8
   Chung JH, 2003, AM J OBSTET GYNECOL, V189, P1031, DOI 10.1067/S0002-9378(03)00842-1
   CHUNG T, 1992, AUST NZ J OBSTET GYN, V32, P25, DOI 10.1111/j.1479-828X.1992.tb01892.x
   Chyu JK, 1997, AM J OBSTET GYNECOL, V177, P606, DOI 10.1016/S0002-9378(97)70153-4
   Clark A., 1998, American Journal of Obstetrics and Gynecology, V178, pS30
   Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9
   Coeytaux RR, 2007, J ALTERN COMPLEM MED, V13, P886
   Cohen S. B., 1997, American Journal of Obstetrics and Gynecology, V176, pS191, DOI 10.1016/S0002-9378(97)80746-6
   Collingham J, 2008, AM J OBSTET GYNECOL, V199, pS53, DOI 10.1016/j.ajog.2008.09.172
   Colon I, 2004, AM J OBSTET GYNECOL, V191, pS15, DOI 10.1016/j.ajog.2004.09.068
   Colon I, 2005, AM J OBSTET GYNECOL, V192, P747, DOI 10.1016/j.ajog.2004.12.051
   Corrado F, 2001, INT J GYNECOL OBSTET, V75, P195, DOI 10.1016/S0020-7292(01)00503-3
   Crane J, 1997, OBSTET GYNECOL, V89, P586, DOI 10.1016/S0029-7844(97)00004-5
   Crane J, 2001, AM J OBSTET GYNECOL, V185, pS168, DOI 10.1016/S0002-9378(01)80345-8
   Crane J, 1996, SOC OBST GYN GAN M
   Crane JMG, 2003, AM J OBSTET GYNECOL, V189, P720, DOI 10.1067/S0002-9378(03)00768-3
   Cromi A, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.05.020
   Culver J, 2001, AM J OBSTET GYNECOL, V185, pS203, DOI 10.1016/S0002-9378(01)80474-9
   CURET LB, 1989, INT J GYNECOL OBSTET, V28, P221, DOI 10.1016/0020-7292(89)90722-4
   Dallen-Bach P, 2001, AM J OBSTET GYNECOL, V185, pS108, DOI 10.1016/S0002-9378(01)80130-7
   Dallenbach P, 2003, AM J OBSTET GYNECOL, V188, P162, DOI 10.1067/mob.2003.108
   Dalui R, 2005, ACTA OBSTET GYN SCAN, V84, P362, DOI 10.1111/j.0001-6349.2005.00662.x
   Damania K K, 1992, J Postgrad Med, V38, P58
   Danielian P, 1999, BRIT J OBSTET GYNAEC, V106, P793, DOI 10.1111/j.1471-0528.1999.tb08399.x
   Danielian PJ, 1998, J OBSTET GYNAECOL S1, V18, P18
   Dare F O, 2002, J Obstet Gynaecol, V22, P283
   Darroca RJA, 1996, OBSTET GYNECOL, V87, P228, DOI 10.1016/0029-7844(95)00409-2
   DAVEY DA, 1979, S AFR MED J, V55, P837
   Davies NJ, 1991, P 2 EUR C PROST REPR
   DAY A, 1985, AUST NZ J OBSTET GYN, V25, P252, DOI 10.1111/j.1479-828X.1985.tb00738.x
   Day AR, 1986, P 24 BRIT C OBST GYN
   De A, 2006, AUST NZ J OBSTET GYN, V46, P323, DOI 10.1111/j.1479-828X.2006.00600.x
   de Aquino Marcia Maria Auxiliadora, 2003, Sao Paulo Med J, V121, P102, DOI 10.1590/S1516-31802003000300003
   de la Torre S, 2001, J Matern Fetal Med, V10, P85, DOI 10.1080/714052723
   de Miranda E, 2006, BJOG-INT J OBSTET GY, V113, P402, DOI 10.1111/j.1471-0528.2006.00870.x
   Delaney S, 2009, AM J OBSTET GYNECOL, V201, pS23
   Deng LL, 1999, J NURSING SCI, V14, P67
   Denguezli Walid, 2007, Archives of Gynecology and Obstetrics, V276, P119, DOI 10.1007/s00404-006-0313-1
   Deo S, 2012, BIOMED RES, V23, P247
   Department of Health. National Audit Office, 2013, MAT SERV ENGL SESS 2
   Deshmukh V L, 2011, J Obstet Gynaecol India, V61, P418, DOI 10.1007/s13224-011-0063-2
   Deshmukh Varsha Laxmikant, 2013, J Obstet Gynaecol India, V63, P321, DOI 10.1007/s13224-012-0337-3
   Department of Health (DH), 2013, NHS REF COSTS 2012 2
   Di Cecco Robert, 1998, American Journal of Obstetrics and Gynecology, V178, pS30
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Dias S, 2011, 2 NICE DEC SUPP U EV
   Dias S, 2011, NICE DSU TECHNICAL S
   Dias S, 2013, MED DECIS MAKING, V33, P641, DOI 10.1177/0272989X12455847
   Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724
   Diro M, 1999, J Matern Fetal Med, V8, P114
   Doany W, 1997, J Matern Fetal Med, V6, P71
   Doany Waleed, 1996, American Journal of Obstetrics and Gynecology, V174, P351
   Dodd J, 2005, AUSTR NZ J OBSTET GY, V45, P347
   Dodd JM, 2006, BRIT MED J, V332, P509, DOI 10.1136/bmj.38729.513819.63
   Dodd JM, 2006, PER SOC AUSTR NZ 10
   DOMMISSE J, 1987, S AFR MED J, V71, P506
   DOMMISSE J, 1980, S AFR MED J, V58, P518
   DUFF P, 1984, OBSTET GYNECOL, V63, P697
   Dyar T. R., 2000, American Journal of Obstetrics and Gynecology, V182, pS135
   Eddama O, 2009, BJOG-INT J OBSTET GY, V116, P1196, DOI 10.1111/j.1471-0528.2009.02236.x
   Edwards R, 2014, AM J OBSTET GYNECOL, V210, pS292
   Edwards R, 2014, AM J OBSTET GYNECOL, V210, pS278
   Edwards R, 2014, AM J OBSTET GYNECOL, V210, pS39
   EGARTER C, 1989, GYNECOL OBSTET INVES, V27, P6
   EGARTER C, 1988, ZBL GYNAKOL, V110, P345
   EGARTER C, 1987, GEBURTSH FRAUENHEILK, V47, P337, DOI 10.1055/s-2008-1035832
   EKMAN G, 1986, ACTA OBSTET GYN SCAN, V65, P857
   EKMAN G, 1983, AM J OBSTET GYNECOL, V147, P657
   EKMANORDEBERG G, 1985, OBSTET GYNECOL, V66, P307
   El-Azeem S., 1997, American Journal of Obstetrics and Gynecology, V176, pS113, DOI 10.1016/S0002-9378(97)80446-2
   El-Shawarby S A, 2006, J Obstet Gynaecol, V26, P627
   El-Sherbiny MT, 2001, INT J GYNECOL OBSTET, V72, P25, DOI 10.1016/S0020-7292(00)00308-8
   El-Din NMN, 2000, 16 FIGO WORLD C OBST
   Elhassan EM, 2007, INT J GYNECOL OBSTET, V97, P153, DOI 10.1016/j.ijgo.2007.02.014
   Elhassan EM, 2005, INT J GYNECOL OBSTET, V91, P254, DOI 10.1016/j.ijgo.2005.08.003
   Elhassan EM, 2005, INT J GYNECOL OBSTET, V90, P234, DOI 10.1016/j.ijgo.2005.03.026
   Elhassan M, 2004, INT J GYNECOL OBSTET, V85, P285, DOI 10.1016/j.ijgo.2003.11.016
   Elliot CL, 1995, 27 BRIT C OBST GYN 4
   ELMARDI AA, 1991, INT J GYNECOL OBSTET, V35, P221, DOI 10.1016/0020-7292(91)90289-H
   El-Sherbiny M, 2000, 16 FIGO WORLD C OBST
   ELTORKEY M, 1992, BRIT J OBSTET GYNAEC, V99, P455, DOI 10.1111/j.1471-0528.1992.tb13780.x
   Eroglu D, 2007, CLIN EXP OBSTET GYN, V34, P102
   Escudero F, 1997, INT J GYNECOL OBSTET, V57, P139, DOI 10.1016/S0020-7292(97)02873-7
   Esteve JLC, 2006, PROG OBSTET GINECOL, V49, P369
   Ezechi OC, 2008, IRAN J REPROD MED, V6, P83
   Facchinetti F, 2005, EUR J OBSTET GYN R B, V119, P189, DOI 10.1016/j.ejorgb.2004.06.039
   Facchinetti F, 2007, J REPROD MED, V52, P945
   Farah LA, 1997, AM J OBSTET GYNECOL, V177, P364, DOI 10.1016/S0002-9378(97)70199-6
   Fassett MJ, 2008, REPROD SCI, V15, P394, DOI 10.1177/1933719107310305
   Fassett MJ, 2008, GYNECOL OBSTET INVES, V65, P112, DOI 10.1159/000109167
   Fassett MJ, 2001, AM J OBSTET GYNECOL, V185, pS210, DOI 10.1016/S0002-9378(01)80503-2
   Feitosa Francisco Edson de Lucena, 2006, Rev. Bras. Ginecol. Obstet., V28, P566, DOI 10.1590/S0100-72032006000900012
   FENTON DW, 1985, ACTA OBSTET GYN SCAN, V64, P27
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   Ferguson JE, 2002, AM J OBSTET GYNECOL, V187, P273, DOI 10.1067/mob.2002.126202
   Ferraiolo A, 2010, J REPROD MED, V55, P423
   Fettosa FEL, 2006, INT J GYNECOL OBSTET, V94, P91, DOI 10.1016/j.ijgo.2006.04.031
   Filho OBM, 2002, REV BRAS GINECOL OBS, V24, P685
   Fisher SA, 2001, AM J OBSTET GYNECOL, V185, P906, DOI 10.1067/mob.2001.117303
   Fisher Stephanie, 2001, American Journal of Obstetrics and Gynecology, V184, pS117
   FLETCHER H, 1994, OBSTET GYNECOL, V83, P244
   FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x
   Fonseca L, 2007, AM J OBSTET GYNECOL, V197, pS106, DOI 10.1016/j.ajog.2007.10.364
   Fonseca L, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.014
   Foong LC, 1999, P 4 INT SCI M ROYAL
   Foradada C, 1996, 3 WORLD C PER MED 19, P51
   Frass KA, 2011, SAUDI MED J, V32, P679
   French L, 2001, COCHRANE DATABASE SY
   Frohn WE, 2002, OBSTET GYNECOL, V99, P206, DOI 10.1016/S0029-7844(01)01677-5
   FRYDMAN R, 1992, OBSTET GYNECOL, V80, P972
   FRYDMAN R, 1992, CONTRACEPT FERTIL S, V20, P1133
   FRYDMAN R, 1991, LANCET, V337, P488, DOI 10.1016/0140-6736(91)93421-5
   Frydman R, 1993, INT J GYNECOL OBSTET, V42, P220, DOI 10.1016/0020-7292(93)90660-O
   Gafni A, 1997, CAN MED ASSOC J, V157, P1519
   Gagnon-Gervais K, 2012, J MATERN-FETAL NEO M, V25, P2326, DOI 10.3109/14767058.2012.695819
   Gagnon-Gervais K, 2011, AM J OBSTET GYNECOL, V204, pS127, DOI 10.1016/j.ajog.2010.10.327
   De Koning Gans GHJ, 1988, COMMUNICATION
   Garry D, 2003, J Matern Fetal Neonatal Med, V13, P254, DOI 10.1080/jmf.13.4.254.259
   Garry D, 2000, ALTERN THER HEALTH M, V6, P77
   Gaudernack LC, 2006, ACTA OBSTET GYN SCAN, V85, P1348, DOI 10.1080/00016340600935839
   Gaudet Laura M, 2008, J Obstet Gynaecol Can, V30, P1118
   Gelisen O, 2005, EUR J OBSTET GYN R B, V120, P164, DOI 10.1016/j.ejogrb.2004.08.013
   Gelman A, 1992, STAT SCI, V7, P457, DOI DOI 10.1214/SS/1177011136
   Getgan M, 2003, THAI J OBSTET GYNAEC, V15, P276
   Gherman RB, 2001, J REPROD MED, V46, P641
   Gherman RB, 2002, OBSTET GYNECOL S4, V99, P47
   Giacalone PL, 1998, OBSTET GYNECOL, V92, P487, DOI 10.1016/S0029-7844(98)00225-7
   Gibson K, 2013, AM J OBSTET GYNECOL, V208, pS145
   GIHWALA N, 1987, S AFR MED J, V72, P615
   Gihwala N, 1986, P 23 C OBST GYN 23 2
   GILSON G J, 1992, American Journal of Obstetrics and Gynecology, V166, P423
   GILSON G J, 1991, American Journal of Obstetrics and Gynecology, V164, P405
   Gilson GJ, 1996, AM J OBSTET GYNECOL, V175, P145, DOI 10.1016/S0002-9378(96)70264-8
   GILSON GJ, 1993, WESTERN J MED, V159, P149
   Girija S, 2011, J OBSTET GYN INDIA, V61, P153
   Girija Shivarudraiah, 2009, J Turk Ger Gynecol Assoc, V10, P220
   Gittens L., 1996, American Journal of Obstetrics and Gynecology, V174, P354
   Glagoleva EA, 1999, EUROPEAN J OBSTET GY, V86, pS67
   Glenny AM, 2005, HLTH TECHNOL ASSESS, V9
   Goel G, 2011, 54 ALL IND C OBST GY
   GOESCHEN K, 1989, AM J PERINAT, V6, P181, DOI 10.1055/s-2007-999572
   GOLBUS MS, 1977, PROSTAGLANDINS, V14, P577, DOI 10.1016/0090-6980(77)90272-6
   Goldenberg M, 1996, EUR J OBSTET GYN R B, V66, P129, DOI 10.1016/0301-2115(96)02405-0
   GONEN R, 1994, AM J PERINAT, V11, P436, DOI 10.1055/s-2007-994615
   Gottschall D., 1997, American Journal of Obstetrics and Gynecology, V176, pS141, DOI 10.1016/S0002-9378(97)80553-4
   Gottschall DS, 1997, AM J OBSTET GYNECOL, V177, P1067, DOI 10.1016/S0002-9378(97)70016-4
   GOWER RH, 1982, OBSTET GYNECOL, V60, P617
   GRANT JM, 1992, BRIT J OBSTET GYNAEC, V99, P557, DOI 10.1111/j.1471-0528.1992.tb13820.x
   Grant JM, 1993, COMMUNICATION
   GRAVES GR, 1985, AM J OBSTET GYNECOL, V151, P178
   Green C, 1998, BR J OBSTET GYNA S17, V105, P82
   GREER IA, 1989, J OBSTET GYNAECOL, V10, P18, DOI 10.3109/01443618909151086
   Greer IA, 1990, ACTA OBSTET GYN SCAN, V69, P621, DOI 10.3109/00016349009028707
   Gregson S, 2005, BJOG-INT J OBSTET GY, V112, P438, DOI 10.1111/j.1471-0528.2004.00496.x
   Gregson S, 2004, COMPARE SAFETY EFFIC
   Greybush M, 2001, J REPROD MED, V46, P11
   Gribel GPC, 2011, ARCH GYNECOL OBSTET, V283, P1233, DOI 10.1007/s00404-010-1526-x
   Griffith-Jones MD, 1990, OBSTET GYNAECOLOGY T, V1, P104
   GRUNBERGER W, 1986, ARCH GYNECOL OBSTET, V239, P93, DOI 10.1007/BF02133968
   Guinn DA, 1997, AM J OBSTET GYNECOL, V177, P814, DOI 10.1016/S0002-9378(97)70274-6
   Guinn Debra, 2002, American Journal of Obstetrics and Gynecology, V187, pS169
   Guise JM, 2004, BRIT MED J, V329, P19, DOI 10.1136/bmj.329.7456.19
   Gulmezoglu AM, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD004945.PUB3
   Gungorduk K, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.035
   Gupta HP, 2010, J OBSTET GYNAECOL IN, V60, P51
   Gupta N, 2006, J OBSTET GYNAECOL S2, V56, P149
   Gupta R, 1998, INT J GYNECOL OBSTET, V60, P115, DOI 10.1016/S0020-7292(97)00249-X
   Haas DM, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6226
   Haas S., 1993, American Journal of Obstetrics and Gynecology, V168, P361
   Habib SM, 2008, INT J GYNECOL OBSTET, V101, P57, DOI 10.1016/j.ijgo.2007.09.027
   Haghighi L, 2006, INT J GYNECOL OBSTET, V94, P121, DOI 10.1016/j.ijgo.2006.02.018
   Haitsma V, 1996, 15 EUR PER MED 10 13
   Hales K, 1994, AM J OBSTET GYNECOL, V170, P365
   HALES KA, 1994, AM J OBSTET GYNECOL, V171, P1087
   Hall R, 2002, OBSTET GYNECOL, V99, P1044, DOI 10.1016/S0029-7844(02)01995-6
   Hallak M, 1997, CONT REV OBSTET GYNA, V9, P99
   Hamdan M, 2009, OBSTET GYNECOL, V114, P745, DOI 10.1097/AOG.0b013e3181b8fa00
   Hannah M., 1997, American Journal of Obstetrics and Gynecology, V176, pS32, DOI 10.1016/S0002-9378(97)80145-7
   Hannah M, 1996, P 15 C PRIOR PER CAR
   Hannah ME, 1997, AM J OBSTET GYNECOL, V177, P780, DOI 10.1016/S0002-9378(97)70268-0
   Hannah ME, 1996, NEW ENGL J MED, V334, P1005, DOI 10.1056/NEJM199604183341601
   Hapangama D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002865.pub2
   Harper TC, 2005, AM J OBSTET GYNECOL, V193, pS43, DOI 10.1016/j.ajog.2005.10.123
   Harper TC, 2006, J MATERN-FETAL NEO M, V19, P465, DOI 10.1080/14767050600730740
   Has R, 2002, GYNECOL OBSTET INVES, V53, P16, DOI 10.1159/000049405
   Haugland B, 2012, ACTA OBSTET GYN SCAN, V91, P85
   HAUTH JC, 1977, OBSTET GYNECOL, V49, P523
   Hay D, 1995, 27 BRIT C OBST GYN 4
   Hayashi R, 1983, COMMUNICATION
   Heden L, 1991, INT J FETO MAT MED, V4, P148
   HEINZL S, 1980, Z GEBURTSH PERINATOL, V184, P395
   Hemlin J, 1998, ACTA OBSTET GYN SCAN, V77, P45, DOI 10.1080/00016349808565810
   Henrich W, 2008, Z Geburtshilfe Neonatol, V212, P183, DOI 10.1055/s-2008-1077027
   Henry A, 2011, AUST NZ J OBSTET GYN, V51, P474
   HERABUTYA Y, 1988, Journal of the Medical Association of Thailand, V71, P269
   HERABUTYA Y, 1992, INT J GYNECOL OBSTET, V37, P253, DOI 10.1016/0020-7292(92)90325-D
   HERABUTYA Y, 1991, Journal of the Medical Association of Thailand, V74, P92
   Herabutya Y, 1993, J Med Assoc Thai, V76 Suppl 1, P63
   Herabutya Y, 1997, INT J OBSTET GYNA S4, V23, P369, DOI DOI 10.1111/J.1447-0756.1997.TB00860.X
   Hidar S, 2000, J Gynecol Obstet Biol Reprod (Paris), V29, P607
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1136/BMJ.D5928
   Hill MJ, 2008, OBSTET GYNECOL, V111, P1313, DOI 10.1097/AOG.0b013e31816fdcf3
   Hill MJ, 2008, OBSTET GYNECOL, V111, p11S
   Hjertberg R, 1996, ACTA OBSTET GYN SCAN, V75, P48, DOI 10.3109/00016349609033283
   Hjertberg R, 1994, P 14 EUR C PER MED 5
   Hodnett ED, 1997, BIRTH-ISS PERINAT C, V24, P214, DOI 10.1111/j.1523-536X.1997.tb00593.x
   Hosli I, 2008, GEBURTSH FRAUENHEILK, V68, P147, DOI 10.1055/s-2007-989479
   Hoffmann RAM, 2001, INT J GYNECOL OBSTET, V72, P215, DOI 10.1016/S0020-7292(00)00337-4
   Hoffmann RAM, 1999, P 4 INT SCI M ROYAL
   Hofmeyr G, 2000, COCHRANE DB SYST REV, V2
   Hofmeyr GJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000941.pub2
   Hofmeyr GJ, 2001, BRIT J OBSTET GYNAEC, V108, P952, DOI 10.1111/j.1471-0528.2001.00231.x
   How Helen, 2001, American Journal of Obstetrics and Gynecology, V184, pS118
   How HY, 2001, AM J OBSTET GYNECOL, V185, P911, DOI 10.1067/mob.2001.117358
   Howarth G. R., 1996, Journal of Obstetrics and Gynaecology (Abingdon), V16, P474, DOI 10.3109/01443619609030076
   Howarth GR, 2001, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003250
   Howarth GR, 1996, 15 C PRIOR PER CAR S
   Huang Wilson, 2002, American Journal of Obstetrics and Gynecology, V187, pS57
   Hudon L., 1999, American Journal of Obstetrics and Gynecology, V180, pS126
   HUSSLEIN P, 1986, GEBURTSH FRAUENHEILK, V46, P83, DOI 10.1055/s-2008-1036167
   Hutchon D J, 1980, Int J Gynaecol Obstet, V17, P604
   Hutchon DJR, 1980, ACTA OBSTET GYN SCAN, V59, P83
   Hutton E, 2001, COCHRANE DB SYST REV, V2
   Incerpi Marc, 2001, American Journal of Obstetrics and Gynecology, V184, pS120
   Incerpi MH, 2001, AM J OBSTET GYNECOL, V185, P916, DOI 10.1067/mob.2001.117306
   Irion O, 1998, OBSTET GYNECOL, V91, P65, DOI 10.1016/S0029-7844(97)00608-X
   Irion O, 2000, COCHRANE DB SYST REV, V2
   ISKANDER MN, 1978, J INT MED RES, V6, P144
   Jackson G. M., 1994, American Journal of Obstetrics and Gynecology, V170, P379
   JACKSON GM, 1994, AM J OBSTET GYNECOL, V171, P1092
   Jackson N, 2000, BRIT J OBSTET GYNAEC, V107, P1181, DOI 10.1111/j.1471-0528.2000.tb11130.x
   JAGANI N, 1984, OBSTET GYNECOL, V63, P225
   JAGANI N, 1982, OBSTET GYNECOL, V59, P21
   Janakiraman V, 2011, AM J OBSTET GYNECOL, V204, pS41
   Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159
   JEEVA MA, 1982, S AFR MED J, V61, P402
   Jindal Promila, 2011, J Obstet Gynaecol India, V61, P538
   JOHNSON IR, 1985, AM J OBSTET GYNECOL, V151, P604
   Joint Formulary Committee, BRIT NATL FORMULARY
   Jozwiak M, 2014, AM J PERINAT, V31, P145, DOI 10.1055/s-0033-1341573
   Jozwiak M, 2013, EUR J OBSTET GYN R B, V170, P137, DOI 10.1016/j.ejogrb.2013.06.017
   Jozwiak M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001233.pub2
   Jozwiak M, 2012, AM J OBSTET GYNECOL, V206, pS146
   Jozwiak M, 2011, LANCET, V378, P2095, DOI 10.1016/S0140-6736(11)61484-0
   Kadanali S, 1996, INT J GYNECOL OBSTET, V55, P99, DOI 10.1016/S0020-7292(96)02710-5
   Kadian ND, 2008, BJOG-INT J OBSTET GY, V115, P76
   Kaimal AJ, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.012
   Kalkat RK, 2008, J OBSTET GYNAECOL, V28, P695, DOI 10.1080/01443610802462522
   Kalkat RKB, 2007, 31 BRIT INT C OBST G
   KAMINSKI K, 1994, AUST NZ J OBSTET GYN, V34, P409, DOI 10.1111/j.1479-828X.1994.tb01258.x
   Kandil M, 2012, ARCH GYNECOL OBSTET, V286, P303, DOI 10.1007/s00404-012-2292-8
   Kanhai HHH, 1988, P 1 EUR C PROST REPR
   Kanhai HHH, 1988, 12 FIGO WORLD C GYN, P201
   Kashanian M, 2006, INT J GYNECOL OBSTET, V92, P79, DOI 10.1016/j.ijgo.2005.09.010
   Kashanian M, 2010, J MAT FETAL NEONA S1, V23, P616
   Kashanian M, 2007, 31 BRIT INT C OBST G
   Kashanian M, 2010, J MAT FETAL NEONA S1, V23, P226
   Kashanian M, 2009, INT J GYNECOL OBS S2, V107, P481
   Kashanian M, 2008, J MAT FETAL NEONA S1, V21, P73
   Kashanian M, 2006, J KASHAN U MED SCI, V10, P7
   Kashanian M, 2008, INT J GYNECOL OBSTET, V102, P259, DOI 10.1016/j.ijgo.2008.04.009
   Kashanian M, 2006, GYNECOL OBSTET INVES, V62, P41, DOI 10.1159/000091842
   KATZ Z, 1983, EUR J OBSTET GYN R B, V15, P71, DOI 10.1016/0028-2243(83)90175-2
   Kaul V, 2004, INT J GYNECOL OBSTET, V86, P388, DOI 10.1016/j.ijgo.2004.04.035
   Kavanagh J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003097.pub2
   Kavanagh J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003100.pub2
   Kavanagh J, 2005, COCHRANE DB SYST REV, V3
   Kavanagh J, 2001, COCHRANE DB SYST REV, V2
   Kehl S, 2012, ARCH GYNECOL OBSTE S, V286, P145
   Kehl S, 2013, EUR J OBSTET GYN R B, V168, P30, DOI 10.1016/j.ejogrb.2012.12.018
   [Anonymous], 1991, P 2 EUR C PROST REPR
   Keirse M, 1987, A STATE OF THE ART, P53
   Keirse M, 1985, ROLE PROSTAGLANDINS, P93
   Keirse MJNC, 1995, AM J OBSTET GYNECOL, V173, P1859, DOI 10.1016/0002-9378(95)90441-7
   Kelly AJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003099.pub2
   Kelly AJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006901.pub2
   Kelly AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003101.pub2
   Kelly Anthony J, 2001, COCHRANE DB SYST REV, V2
   Kemp B, 2000, INT J GYNECOL OBSTET, V71, P13, DOI 10.1016/S0020-7292(00)00253-8
   KENNEDY JH, 1982, BRIT J OBSTET GYNAEC, V89, P704, DOI 10.1111/j.1471-0528.1982.tb05094.x
   KENNEDY JH, 1978, PROSTAGLANDINS, V15, P169, DOI 10.1016/S0090-6980(78)80015-X
   Khazardoost S, 2011, TEHRAN U MED J, V68, P595
   Khoury A N, 2001, J Matern Fetal Med, V10, P186, DOI 10.1080/714052744
   Khoury Alfred, 2001, American Journal of Obstetrics and Gynecology, V184, pS118
   Kidanto HL, 2007, INT J GYNECOL OBSTET, V96, P30, DOI 10.1016/j.ijgo.2006.09.015
   KIEBACK DG, 1986, PROSTAGLANDINS, V32, P81, DOI 10.1016/0090-6980(86)90145-0
   Kim JH, 2000, KOREAN J OBSTET GYNE, V43, P243
   KIMBALL FA, 1986, PROSTAGLANDINS, V32, P527, DOI 10.1016/0090-6980(86)90035-3
   Kipikasa JH, 2005, INT J GYNECOL OBSTET, V88, P108, DOI 10.1016/j.ijgo.2004.10.006
   Koc O, 2013, J OBSTET GYNAECOL RE, V39, P790, DOI 10.1111/j.1447-0756.2012.02045.x
   Kolderup L, 1999, AM J OBSTET GYNECOL, V180, P1543, DOI 10.1016/S0002-9378(99)70050-5
   Komala Kambhampati, 2013, J Clin Diagn Res, V7, P2866, DOI 10.7860/JCDR/2013/5825.3779
   Kovavisarach E, 1997, THAI J OBSTET GYNAEC, V9, P175
   Kovavisarach E, 1998, THAI J OBSTET GYNAEC, V10, P27
   Kramer R. L., 1997, American Journal of Obstetrics and Gynecology, V176, pS111
   Kramer RL, 1997, OBSTET GYNECOL, V89, P387, DOI 10.1016/S0029-7844(97)00363-3
   KRAMMER J, 1995, OBSTET GYNECOL, V85, P614, DOI 10.1016/0029-7844(95)00013-H
   Krammer J, 1993, AM J OBSTET GYNECOL, V70, P408
   Krammer J, 1993, AM J OBSTET GYNECOL, V170, P403
   KRISTOFFERSEN M, 1986, INT J GYNECOL OBSTET, V24, P297, DOI 10.1016/0020-7292(86)90087-1
   Krithika KS, 2008, J OBSTET GYNAECOL, V28, P294, DOI 10.1080/01443610802054972
   Krupa FD, 2005, BJOG-INT J OBSTET GY, V112, P1284, DOI 10.1111/j.1471-0528.2005.00700.x
   Kulshreshtha S, 2007, Indian J Physiol Pharmacol, V51, P55
   [Anonymous], 2001, ACAD MANAGEMENT P
   Kunt C, 2010, TAIWAN J OBSTET GYNE, V49, P57, DOI 10.1016/S1028-4559(10)60010-1
   Kwon J. S., 1999, American Journal of Obstetrics and Gynecology, V180, pS128
   Kwon JS, 2001, BRIT J OBSTET GYNAEC, V108, P23, DOI 10.1111/j.1471-0528.2001.00007.x
   LACKRITZ R, 1979, AM J OBSTET GYNECOL, V134, P349
   Ladfors L., 1998, American Journal of Obstetrics and Gynecology, V178, pS197
   Ladfors L, 1996, BRIT J OBSTET GYNAEC, V103, P755, DOI 10.1111/j.1471-0528.1996.tb09869.x
   LAMKI H, 1974, IRISH MED J, V67, P515
   LANGE AP, 1981, ACTA OBSTET GYN SCAN, V60, P207
   Lange I, 1994, INT J GYNECOL OBSTET, V46, P7
   LANGE IR, 1984, AM J OBSTET GYNECOL, V148, P621
   Langenegger EJ, 2005, INT J GYNECOL OBSTET, V88, P242, DOI 10.1016/j.ijgo.2004.12.005
   Larmon J E, 2002, J Matern Fetal Neonatal Med, V11, P113, DOI 10.1080/713605466
   LAUBE DW, 1986, OBSTET GYNECOL, V68, P54
   le Roux PA, 2002, OBSTET GYNECOL, V99, P201, DOI 10.1016/S0029-7844(01)01681-7
   Lee H. Y., 1997, SMJ, V38, P292
   LEGARTH J, 1988, EUR J OBSTET GYN R B, V27, P93, DOI 10.1016/0028-2243(88)90001-9
   LEGARTH J, 1987, EUR J OBSTET GYN R B, V26, P233
   LEGARTH J, 1985, Archives of Gynecology, V237, P103
   LELAIDIER C, 1994, BRIT J OBSTET GYNAEC, V101, P501, DOI 10.1111/j.1471-0528.1994.tb13150.x
   Lelaidier C., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P91
   Lemancewicz A, 1999, INT J GYNECOL OBSTET, V67, P139, DOI 10.1016/S0020-7292(99)00160-5
   Lemke M., 1996, American Journal of Obstetrics and Gynecology, V174, P482
   Lemyre M, 2006, AM J OBSTET GYNECOL, V195, P105
   Levy R, 2005, AM J OBSTET GYNECOL, V193, pS44, DOI 10.1016/j.ajog.2005.10.127
   Levy R, 2007, J PERINAT MED, V35, P126, DOI 10.1515/JPM.2007.026
   LEWIS GJ, 1983, J OBSTET GYNAECOL, V3, P173, DOI 10.3109/01443618309081139
   Li XH, 1996, J BEIJING U TRADITIO, V19, P38
   Lien JM, 1998, AM J OBSTET GYNECOL, V179, P453, DOI 10.1016/S0002-9378(98)70378-3
   LIGGINS GC, 1979, PROSTAGLANDINS, V18, P167, DOI 10.1016/S0090-6980(79)80035-0
   Lin M, 2006, AM J OBSTET GYNECOL, V195, pS109, DOI 10.1016/j.ajog.2006.10.363
   Lin M, 2006, AM J OBSTET GYNECOL, V195, pS30, DOI 10.1016/j.ajog.2006.10.079
   Livingstone I, 2004, J OBSTET GYNAECOLOGY, V24, P106
   Lo JY, 2003, OBSTET GYNECOL, V101, P685, DOI 10.1016/S0029-7844(02)03157-5
   Lo JY, 2001, AM J OBSTET GYNE S6, V185, P204
   LO L, 1994, AUST NZ J OBSTET GYN, V34, P149, DOI 10.1111/j.1479-828X.1994.tb02678.x
   Lo L, 1993, 2 INT SCI M ROYAL CO
   Lo T. K., 2006, Hong Kong Medical Journal, V12, P345
   Lokugamage AU, 2003, ACTA OBSTET GYN SCAN, V82, P133
   LOPES P, 1991, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V20, P827
   Lopes P, 1991, P 2 EUR C PROST REPR
   Lopes P, 1990, J GYNECOL OBST BIO R, V19, P505
   Lopez-Farfan Jose Angel, 2010, Ginecol Obstet Mex, V78, P110
   Lucas MJ, 1986, P ANN M SOC PER OBST, P240
   Luckas M, 2000, COCHRANE DATABASE SY, V4
   Lughmani S, 2009, INT J GYNECOLOGY S2, V107, P250
   LUTHER ER, 1980, AM J OBSTET GYNECOL, V137, P351
   LYKKESFELDT G, 1979, ACTA OBSTET GYN SCAN, V58, P321
   LYNDRUP J, 1990, EUR J OBSTET GYN R B, V37, P111, DOI 10.1016/0028-2243(90)90104-9
   LYNDRUP J, 1989, EUR J OBSTET GYN R B, V30, P205, DOI 10.1016/0028-2243(89)90002-6
   LYNDRUP J, 1994, EUR J OBSTET GYN R B, V53, P189, DOI 10.1016/0028-2243(94)90118-X
   Lyndrup J, 1996, ACTA OBSTET GYN SCAN, V75, P86, DOI 10.3109/00016349609033293
   LYNDRUP J, 1991, EUR J OBSTET GYN R B, V42, P101
   Lyndrup J, 1988, P 1 EUR C PROST REPR
   Lyndrup J, 1991, INT J GYNECOL OBST S, V36, P70
   MCNELLIS D, 1994, AM J OBSTET GYNECOL, V170, P716
   Moraes Filho Olímpio Barbosa de, 2005, Rev. Bras. Ginecol. Obstet., V27, P24, DOI 10.1590/S0100-72032005000100006
   National Collaborating Centre for Women and Children's Health, 2008, IND LAB CLIN GUID
   National Institute for Health and Care Excellence, 2014, IND LAB CLIN GUID 70
   National Institute for Health and Care Excellence, 2004, GUID METH TECHN APPR
   NHS, 2012, WELSH GOV MAT STAT M
   NHS, 2011, NHS MAT STAT ENGL 20
   Office for National Statistics, 2013, BIRTHS ENGL WAL 2012
   Rayburn W, 2001, AM J OBSTET GYNECOL, V185, pS184, DOI 10.1016/S0002-9378(01)80408-7
   University of Sheffeld, 2015, ACC VAL INF REL VERS
   Uccella S, 2011, AM J OBSTET GYNECOL, V205, pE6, DOI 10.1016/j.ajog.2011.08.013
   Adair CD, 1996, AM J OBSTET GYNECOL, V174, P966, DOI 10.1016/S0002-9378(96)70334-4
   LANG J, 1988, BRIT MED J, V297, P715
   MACER J, 1984, OBSTET GYNECOL, V63, P664
   MACKENZIE IZ, 1981, AM J OBSTET GYNECOL, V141, P158
   MACKENZIE IZ, 1979, BRIT J OBSTET GYNAEC, V86, P167, DOI 10.1111/j.1471-0528.1979.tb10588.x
   MACLENNAN A, 1989, AUST NZ J OBSTET GYN, V29, P124, DOI 10.1111/j.1479-828X.1989.tb01700.x
   MACLENNAN AH, 1979, LANCET, V1, P117
   MACLENNAN AH, 1980, AUST NZ J OBSTET GYN, V20, P80
   MACLENNAN AH, 1980, AUST NZ J OBSTET GYN, V20, P87, DOI 10.1111/j.1479-828X.1980.tb00100.x
   MACLENNAN AH, 1986, OBSTET GYNECOL, V68, P598
   MACLENNAN AH, 1980, LANCET, V1, P220
   MacLennan AH, 1988, P 1 EUR C PROST REPR
   Macones G, 2011, AM J OBSTET GYNECOL, V204, pS5
   MacPherson M, 1984, J OBSTET GYNAECOLOGY, V4, P205
   Magann E F, 1999, J Perinatol, V19, P88, DOI 10.1038/sj.jp.7200133
   MAGANN EF, 1995, AM J OBSTET GYNECOL, V172, P1702, DOI 10.1016/0002-9378(95)91401-3
   Magann EF, 1998, AM J OBSTET GYNECOL, V178, P1279, DOI 10.1016/S0002-9378(98)70334-5
   Magann EF, 1998, AM J OBSTET GYNECOL, V179, P890, DOI 10.1016/S0002-9378(98)70184-X
   [Anonymous], 1986, COLLOQ INSE
   MAGOS AL, 1983, BRIT J OBSTET GYNAEC, V90, P726, DOI 10.1111/j.1471-0528.1983.tb09302.x
   Magtibay P., 1996, American Journal of Obstetrics and Gynecology, V174, P327
   Magtibay P M, 1998, J Matern Fetal Med, V7, P15
   MAHMOOD TA, 1989, EUR J OBSTET GYN R B, V33, P169, DOI 10.1016/0028-2243(89)90210-4
   MAHMOOD TA, 1995, OBSTET GYNECOL, V85, P71, DOI 10.1016/0029-7844(94)00316-6
   MAHMOOD TA, 1992, BRIT J OBSTET GYNAEC, V99, P112, DOI 10.1111/j.1471-0528.1992.tb14466.x
   MAHMOOD TA, 1989, LANCET, V1, P721
   Mahmood TA, 1992, P 26 BRIT C OBST GYN
   Mahmood TA, 1988, P 1 EUR C PROST REPR
   Mahmood TA, 1991, P 2 EUR C PROST REPR
   Mahmood Tahir A., 1995, European Journal of Obstetrics and Gynecology and Reproductive Biology, V58, P111, DOI 10.1016/0028-2243(94)01962-2
   Majoko F, 2002, Cent Afr J Med, V48, P123
   Majoko F, 2002, INT J GYNECOL OBSTET, V76, P127, DOI 10.1016/S0020-7292(01)00570-7
   Malik HZ, 2010, JCPSP-J COLL PHYSICI, V20, P242, DOI 04.2010/JCPSP.242245
   Malik N, 1996, OBSTET GYNECOL, V88, P540, DOI 10.1016/0029-7844(96)00266-9
   Manley J., 1999, American Journal of Obstetrics and Gynecology, V180, pS76
   MARGULIES M, 1992, LANCET, V339, P64, DOI 10.1016/0140-6736(92)90194-8
   MASSIL HY, 1988, ACTA OBSTET GYN SCAN, V67, P703, DOI 10.3109/00016349809004293
   Matonhodze B, 2000, J OBSTET GYNAECOL S1, V20, P19
   Matonhodze B, 2000, PRENAT NEONAT MED, V5, P148
   Matonhodze BB, 2003, SAMJ S AFR MED J, V93, P375
   Mawire CJ, 1999, INT J GYNECOL OBSTET, V64, P35, DOI 10.1016/S0020-7292(98)00174-X
   MCCAUL J F, 1992, American Journal of Obstetrics and Gynecology, V166, P275
   McCaul JF, 1997, SOUTHERN MED J, V90, P1229
   MCCOLGIN SW, 1990, OBSTET GYNECOL, V76, P678
   MCCOLGIN SW, 1990, J REPROD MED, V35, P811
   McColgin SW, 1989, P 9 ANN M SOC PER OB
   McKenna DS, 1999, OBSTET GYNECOL, V94, P11, DOI 10.1016/S0029-7844(99)00244-6
   McKenna DS, 2004, OBSTET GYNECOL, V104, P579, DOI 10.1097/01.AOG.0000136479.72777.56
   McLaren M, 1987, Prog Clin Biol Res, V242, P199
   MCQUEEN D, 1990, Journal of Obstetrics and Gynaecology (Abingdon), V10, P495, DOI 10.3109/01443619009151252
   McQueen D, 1992, COMMUNICATION
   Medearis AL, 1990, P 10 ANN M SOC PER O
   Megalo A, 2004, EUR J OBSTET GYN R B, V116, P34, DOI 10.1016/j.ejogrb.2004.01.038
   Mei-Dan E, 2012, REPROD SCI, V19, p229A
   Mei-Dan E, 2012, J MATERN-FETAL NEO M, V25, P723, DOI 10.3109/14767058.2011.591459
   Mei-Dan E, 2009, AM J OBSTET GYNECOL, V201, pS125
   Melchior J, 1989, Rev Fr Gynecol Obstet, V84, P747
   Mercer B, 1990, P 10 ANN M SOC PER O
   MERCER BM, 1993, AM J OBSTET GYNECOL, V169, P775
   MERCER BM, 1995, AM J OBSTET GYNECOL, V173, P1321, DOI 10.1016/0002-9378(95)91379-3
   Meydanli MM, 2003, INT J GYNECOL OBSTET, V81, P249
   Meyer M, 2005, OBSTET GYNECOL, V105, P466, DOI 10.1097/01.AOG.0000152341.31873.d9
   Meyer Marjorie, 2002, American Journal of Obstetrics and Gynecology, V187, pS167
   Milchev N, 2003, Akush Ginekol (Sofiia), V42, P9
   MILLER A, 1991, American Journal of Obstetrics and Gynecology, V164, P317
   MILLER AM, 1991, AM J OBSTET GYNECOL, V165, P1006
   MISRA M, 1994, AUST NZ J OBSTET GYN, V34, P511, DOI 10.1111/j.1479-828X.1994.tb01097.x
   Moberger B, 1994, P 14 EUR C PER MED 5
   Modarres M, 2000, MED J ISLAMIC REPUBL, V14, P211
   Modlock J, 2010, BJOG-INT J OBSTET GY, V117, P1255, DOI 10.1111/j.1471-0528.2010.02647.x
   Moini A, 2003, INT J GYNECOL OBSTET, V83, P211, DOI 10.1016/S0020-7292(03)00266-2
   Mol BW, 2011, AM J OBSTET GYNECOL, V204, pS3
   Moldin PG, 1996, BRIT J OBSTET GYNAEC, V103, P306, DOI 10.1111/j.1471-0528.1996.tb09733.x
   MOLLER M, 1987, ACTA OBSTET GYN SCAN, V66, P103, DOI 10.3109/00016348709083028
   Moller M, 1991, COMMUNICATION
   Montealegre JA, 1999, REV COLOMB OBSTET GI, V50, P133
   Moodley J, 2003, SAMJ S AFR MED J, V93, P371
   Moraes OB, 2010, ACTA OBSTET GYN SCAN, V89, P1045, DOI 10.3109/00016349.2010.499447
   MORALES WJ, 1986, SOUTHERN MED J, V79, P955, DOI 10.1097/00007611-198608000-00010
   Mosquera J, 1999, REV COLOMB OBSTET GI, V50, P7
   Mozurkewich E, 2003, AM J OBSTET GYNECOL, V189, P1026, DOI 10.1067/S0002-9378(03)00845-7
   Mozurkewich Ellen, 2002, American Journal of Obstetrics and Gynecology, V187, pS168
   Mullin P, 2001, AM J OBSTET GYNECOL, V185, pS203, DOI 10.1016/S0002-9378(01)80475-0
   MURPHY AJ, 1980, AUST NZ J OBSTET GYN, V20, P84, DOI 10.1111/j.1479-828X.1980.tb00099.x
   MURRAY HG, 1995, OBSTET GYNECOL, V86, P880, DOI 10.1016/0029-7844(95)00302-8
   Murray HG, 1996, P 14 ANN C AUSTR PER
   Murthy BK, 2006, J OBSTET GYNAECOL IN, V56, P413
   Muzonzini G, 2004, COCHRANE DB SYST REV, V4
   Naef R. W. Iii, 1994, American Journal of Obstetrics and Gynecology, V170, P340
   Naef RW, 1998, AM J OBSTET GYNECOL, V178, P126, DOI 10.1016/S0002-9378(98)70638-6
   Nager C W, 1987, J Perinatol, V7, P189
   Nagpal MB, 2009, INT J GYNECOL OBSTET, V106, P23, DOI 10.1016/j.ijgo.2009.03.014
   NAISMITH WC, 1973, J OBSTET GYN BR COMM, V80, P531
   Nanda S, 2007, TROP DOCT, V37, P21, DOI 10.1258/004947507779952032
   Nasir S, 2012, BJOG S1, V119, P11
   NATALE R, 1994, AM J OBSTET GYNECOL, V171, P936
   Natale R., 1994, American Journal of Obstetrics and Gynecology, V170, P285
   Neiger R, 2001, Tenn Med, V94, P25
   NEILSON DR, 1983, AM J OBSTET GYNECOL, V146, P526
   Netta Denise, 2002, American Journal of Obstetrics and Gynecology, V187, pS221
   Newman M., 1997, American Journal of Obstetrics and Gynecology, V176, pS112, DOI 10.1016/S0002-9378(97)80444-9
   Ngai CSW, 1995, 27 BRIT C OBST GYN 4
   Ngai SW, 2000, BRIT J OBSTET GYNAEC, V107, P222, DOI 10.1111/j.1471-0528.2000.tb11693.x
   Ngai SW, 1996, OBSTET GYNECOL, V87, P923
   Ngai SW, 1998, BRIT J OBSTET GYNA S, V105, P82
   Nguyen VT, 2012, INT J GYNECOL OBS S3, V119, P802
   Nicoll AE, 2001, AM J OBSTET GYNECOL, V184, P958, DOI 10.1067/mob.2001.111797
   Nigam A, 2004, INT J GYNECOL OBSTET, V86, P398, DOI 10.1016/j.ijgo.2004.05.010
   Nigam A, 2010, TROP DOCT, V40, P53, DOI 10.1258/td.2009.090203
   NIMROD C, 1984, OBSTET GYNECOL, V64, P476
   Niromanesh S, 2003, INT J GYNECOL OBSTET, V81, P23, DOI 10.1016/S0020-7292(02)00392-2
   NOAH M L, 1985, Archives of Gynecology, V237, P8
   NOAH ML, 1987, ACTA OBSTET GYN SCAN, V66, P3, DOI 10.3109/00016348709092944
   Nopdonrattakoon L, 2003, J OBSTET GYNAECOL RE, V29, P87
   Norman J, 2001, PHARMACOKINETICS NIT
   Norzilawati MN, 2010, J MAT FETAL NEONA S1, V23, P244
   Ntsaluba A, 1997, O G FORUM, P17
   Nunes F, 1999, AM J OBSTET GYNECOL, V181, P626, DOI 10.1016/S0002-9378(99)70503-X
   Nuutila M, 1996, ACTA OBSTET GYN SCAN, V75, P135, DOI 10.3109/00016349609033305
   NUUTILA M, 1995, HYPERTENS PREGNANCY, V14, P313, DOI 10.3109/10641959509015677
   Nuutila M, 1995, ACTA OBSTET GYN SCAN, V73, P110
   Oboro VO, 2005, ACTA OBSTET GYN SCAN, V84, P628, DOI 10.1111/j.0001-6349.2005.00655.x
   OBRIEN JM, 1995, AM J OBSTET GYNECOL, V172, P1565, DOI 10.1016/0002-9378(95)90497-2
   OBrien JM, 1995, AM J OBSTET GYNECOL, V173, P1855, DOI 10.1016/0002-9378(95)90440-9
   Oliveira Maria Virginia de Oliveira e, 2010, Rev Bras Ginecol Obstet, V32, P346, DOI 10.1590/S0100-72032010000700007
   Olmo I, 2001, J PERINATAL 1 S1, V29, P14
   Omar NS, 2013, BJOG-INT J OBSTET GY, V120, P338, DOI 10.1111/1471-0528.12054
   Ophir E, 1992, INT J FETO MATERNAL, V5, P101
   ORHUE AAE, 1995, EUR J OBSTET GYN R B, V58, P119, DOI 10.1016/0028-2243(94)01963-0
   Morgan Ortiz F, 2002, GINECOL OBSTET MEX, V70, P469
   Osman I, 2006, AM J OBSTET GYNECOL, V194, P1012, DOI 10.1016/j.ajog.2005.10.812
   Osman I, 2004, AM J OBSTET GYNECOL, V191, pS184, DOI 10.1016/j.ajog.2004.10.561
   Osman I, 2004, J OBSTET GYNAECOL S1, V24, P67
   Osman I, 2005, BJOG-INT J OBSTET GY, V112, P512
   Ottervanger HP, 1996, J PERINAT MED, V24, P237, DOI 10.1515/jpme.1996.24.3.237
   Ottervanger HP, 1992, J PERINAT MED, V20, P223
   Ottervanger HP, 1991, INT J GYNECOL OBST S, V36, P432
   Ottinger WS, 1998, AM J OBSTET GYNECOL, V179, P349, DOI 10.1016/S0002-9378(98)70363-1
   OWEN J, 1991, AM J OBSTET GYNECOL, V165, P991
   OWEN J, 1991, AM J OBSTET GYNECOL, V164, P236
   Owolabi A T, 2005, J Obstet Gynaecol, V25, P565, DOI 10.1080/01443610500231450
   Ozkan S, 2009, ARCH GYNECOL OBSTET, V280, P19, DOI 10.1007/s00404-008-0843-9
   Paisarntantiwong R, 2005, J MED ASS THAI S2, V88, P56
   Pandis GK, 2001, ULTRASOUND OBST GYN, V18, P629, DOI 10.1046/j.0960-7692.2001.00595.x
   PAPAGEORGIOU I, 1992, GYNECOL OBSTET INVES, V34, P92
   Papanikolaou Evangelos G, 2004, Reprod Biol Endocrinol, V2, P70, DOI 10.1186/1477-7827-2-70
   Parazzini F, 1998, EUR J OBSTET GYN R B, V81, P15, DOI 10.1016/S0301-2115(98)00148-1
   Parewijck W, 1986, P 10 EUR C PER MED L
   Parikh SC, 2001, J OBSTET GYNECOLOGY, V51, P57
   Parisaei M, 2008, J OBSTET GYNAECOL, V28, P290, DOI 10.1080/01443610802042951
   Parisaei MP, 2005, J OBSTET GYNAECOL S1, V25, P69
   Patil PK, 2005, J OBSTET GYNAECOLOGY, V55, P128
   Paul S, 1992, COMMUNICATION, P1
   Paungmora N, 2004, J OBSTET GYNAECOL RE, V30, P358, DOI 10.1111/j.1447-0756.2004.00215.x
   Paungmora N, 2003, THAI J OBSTET GYNAEC, V15, P272
   Peccerillo J. A., 1995, American Journal of Obstetrics and Gynecology, V172, P298
   Pedrazzoli J., 1997, American Journal of Obstetrics and Gynecology, V176, pS111, DOI 10.1016/S0002-9378(97)80439-5
   Pedrazzoli J, 1997, 20 C SWISS GYN OBST
   Peedicayil A, 1998, J CLIN EPIDEMIOL S1, V51, P21
   Pennell CE, 2009, BJOG-INT J OBSTET GY, V116, P1443, DOI 10.1111/j.1471-0528.2009.02279.x
   Pennell CE, 2013, AM J OBSTET GYNECOL, V189, P207
   Perry MY, 2004, OBSTET GYNECOL, V103, P13, DOI 10.1097/01.AOG.0000109217.24211.9D
   Perry MY, 2003, OBSTET GYNECOL, V101, p11S, DOI 10.1016/S0029-7844(02)02813-2
   Perry MY, 2003, OBSTET GYNECOLOGY, V101, p35S
   PERRYMAN D, 1992, OBSTET GYNECOL, V79, P670
   Perryman D, 1991, P 39 ANN CLIN M AM C
   Petrou S, 2011, BJOG-INT J OBSTET GY, V118, P726, DOI 10.1111/j.1471-0528.2011.02902.x
   Pevzner L, 2011, EUR J OBSTET GYN R B, V156, P144, DOI 10.1016/j.ejogrb.2011.01.015
   Pevzner L, 2009, AM J OBSTET GYNECOL, V201, pS124
   Pevzner L, 2009, OBSTET GYNECOL, V114, P261, DOI 10.1097/AOG.0b013e3181ad9377
   Pevzner L, 2008, AM J OBSTET GYNECOL, V199, pS72, DOI 10.1016/j.ajog.2008.09.245
   Pezvner L, 2011, REPROD SCI, V18, p182A
   Pham CT, 2003, BJOG-INT J OBSTET GY, V110, P121
   Pi Pixiang, 1999, Hunan Yike Daxue Xuebao, V24, P195
   Perez Picanol E, 1992, J PERINAT MED, V20, P353
   Perez Picanol E, 1990, P 12 EUR C PER MED 1
   PINTO RM, 1967, AM J OBSTET GYNECOL, V98, P540
   Pixiang P, 1999, B HUNAN MED U, V24, P195
   Plunkett BA, 2005, AM J OBSTET GYNECOL, V192, P1153, DOI 10.1016/j.ajog.2004.10.600
   Pollnow DM, 1996, AM J OBSTET GYNECOL, V174, P1910, DOI 10.1016/S0002-9378(96)70228-4
   Pongsatha S, 2005, INT J GYNECOL OBSTET, V88, P140, DOI 10.1016/j.ijgo.2004.10.011
   Poornima B, 2011, J Obstet Gynaecol India, V61, P516
   Poulsen H K, 1991, Acta Obstet Gynecol Scand, V70, P549, DOI 10.3109/00016349109007915
   Powers B, 2011, AM J OBSTET GYNECOL, V204, pS48
   Prager M, 2008, BJOG-INT J OBSTET GY, V115, P1443, DOI 10.1111/j.1471-0528.2008.01843.x
   PRASAD RNV, 1989, PROSTAG LEUKOTR ESS, V36, P185, DOI 10.1016/0952-3278(89)90060-4
   PRINS RP, 1983, OBSTET GYNECOL, V61, P459
   Puertas A, 1997, PROGR OBSTET GINECOL, V40, P13
   Puertas A, 1996, PRENATAL NEONATAL S1, V1, P89
   Puga Oscar, 2001, American Journal of Obstetrics and Gynecology, V184, pS85
   PULLE C, 1986, ACTA THERAP, V12, P5
   Putnam Kathleen, 2011, Int J Womens Health, V3, P287, DOI 10.2147/IJWH.S23436
   QUINN MA, 1981, BRIT J OBSTET GYNAEC, V88, P644, DOI 10.1111/j.1471-0528.1981.tb01223.x
   Rabl M, 2002, J REPROD MED, V47, P115
   Rabl M, 2001, WIEN KLIN WOCHENSCHR, V113, P942
   Rahman Hafizur, 2013, J Obstet Gynaecol Can, V35, P408
   Rameez MFM, 2007, J OBSTET GYNAECOL RE, V33, P452, DOI 10.1111/j.1447-0756.2007.00573.x
   Ramsey P., 1998, American Journal of Obstetrics and Gynecology, V178, pS94
   Ramsey Patrick, 2001, American Journal of Obstetrics and Gynecology, V184, pS115
   Ramsey PS, 2005, OBSTET GYNECOL, V105, P85, DOI 10.1097/01.AOG.0000146638.51536.09
   Ramsey PS, 2003, AM J OBSTET GYNECOL, V188, P560, DOI 10.1067/mob.2003.150
   Rasmussen CE, 2005, ADAPT COMPUT MACH LE, P1
   Rath DM, 2007, J OBSTET GYNECOLOGY, V57, P505
   Rath W, 1999, GEBURTSH FRAUENHEILK, V59, P323, DOI 10.1055/s-1999-15369
   Rath W, 1998, PERINAT MED, V10, P81, DOI 10.1007/s001520050089
   RATNAM SS, 1974, AUST NZ J OBSTET GYN, V14, P26, DOI 10.1111/j.1479-828X.1974.tb00818.x
   RAY DA, 1992, AM J OBSTET GYNECOL, V166, P836
   RAYBURN W, 1988, AM J OBSTET GYNECOL, V158, P1417
   Rayburn W, 1998, PRIMARY CARE UPDATE, V5, P182, DOI 10.1016/S1068-607X(98)00096-1
   Rayburn W, 1991, P 39 ANN CLIN M AM C
   RAYBURN WF, 1992, OBSTET GYNECOL, V79, P374
   Rayburn WF, 1999, OBSTET GYNECOL, V94, P250, DOI 10.1016/S0029-7844(99)00300-2
   Richardson C. J., 1991, AM J OBSTET GYNECOL, V164, P403
   Rix P, 1996, ACTA OBSTET GYN SCAN, V75, P45, DOI 10.3109/00016349609033282
   Rix P, 1988, P 1 EUR C PROST REPR
   Rizvi S, 2007, ANN KE MED J, V13, P119
   Roach VJ, 1997, INT J GYNECOL OBSTET, V59, P19, DOI 10.1016/S0020-7292(97)00179-3
   Roberts WE, 1986, J PERINATOLOGY, V6, P16
   Romer A, 1998, DZA, V41, P93
   Romero-Gutierrez Gustavo, 2011, Ginecol Obstet Mex, V79, P285
   ROUBEN D, 1993, OBSTET GYNECOL, V82, P290
   Roudsari FV, 2011, IRAN J PHARM RES, V10, P149
   Roudsari FV, 2010, J ISFAHAN MED SCH, V28, P177
   Rouzi AA, 2011, RANDOMIZED CLIN TRIA
   Rouzi AA, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.08.033
   Rowlands S, 2001, AUST NZ J OBSTET GYN, V41, P145, DOI 10.1111/j.1479-828X.2001.tb01199.x
   Rozenberg P, 2004, AM J OBSTET GYNECOL, V191, P247, DOI 10.1016/j.ajog.2003.12.038
   Rozenberg P, 2001, BRIT J OBSTET GYNAEC, V108, P1255, DOI 10.1111/j.1471-0528.2001.00270.x
   Roztocil A, 1998, Ceska Gynekol, V63, P3
   Roztocil A, 2013, J PERINATAL MED S1, V41, P557
   Russell Z, 2007, AM J OBSTET GYNECOL, V197, pS37, DOI 10.1016/j.ajog.2007.10.095
   Rust O. A., 1999, American Journal of Obstetrics and Gynecology, V180, pS126
   Rydhstrom H, 1991, Acta Obstet Gynecol Scand, V70, P543, DOI 10.3109/00016349109007914
   RYMER J, 1992, AUST NZ J OBSTET GYN, V32, P22, DOI 10.1111/j.1479-828X.1992.tb01891.x
   Saeed GA, 2011, TAIWAN J OBSTET GYNE, V50, P15, DOI 10.1016/j.tjog.2009.08.001
   Saggaf A, 2001, SAUDI J OBSTET GYNEC, V1, P89
   Sahraoui W, 2005, J Gynecol Obstet Biol Reprod (Paris), V34, P454
   Sahu L, 2004, J OBSTET GYN INDIA, V54, P139
   Salamalekis E, 2000, GYNECOL OBSTET INVES, V49, P240, DOI 10.1159/000010267
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Saleem Samina, 2006, J Coll Physicians Surg Pak, V16, P276
   SALEH YZ, 1975, AUST NZ J OBSTET GYN, V15, P80, DOI 10.1111/j.1479-828X.1975.tb00077.x
   Dominguez Salgado CR, 1999, GINECOLOGIA OBSTET M, V67, P461
   Salim R, 2011, OBSTET GYNECOL, V118, P79, DOI 10.1097/AOG.0b013e318220e4b7
   SALMON YM, 1986, OBSTET GYNECOL, V67, P21
   Sanchez-Ramos L, 1998, OBSTET GYNECOL, V91, P401, DOI 10.1016/S0029-7844(97)00673-X
   SANCHEZRAMOS L, 1992, J REPROD MED, V37, P355
   SanchezRamos L, 1997, OBSTET GYNECOL, V89, P909, DOI 10.1016/S0029-7844(97)00113-0
   Sanchez-Ramos L, 1990, P 10 ANN M SOC PER O
   Sanchez-Ramos L, 1994, AM J OBSTET GYNECOL, V170, P377
   SANDE HA, 1983, INT J GYNECOL OBSTET, V21, P333, DOI 10.1016/0020-7292(83)90025-5
   SATIN A J, 1991, American Journal of Obstetrics and Gynecology, V164, P307
   SAWAI S K, 1992, American Journal of Obstetrics and Gynecology, V166, P400
   SAWAI SK, 1994, OBSTET GYNECOL, V84, P807
   SAWAI SK, 1991, OBSTET GYNECOL, V78, P19
   Saxena P, 2011, EUR REV MED PHARMACO, V15, P759
   Schmitz T, 2014, AM J OBSTET GYNECOL, V210, pS19
   Schneider M, 2004, AM J OBSTET GYNECOL, V191, pS73, DOI 10.1016/j.ajog.2004.10.135
   Sciscione A., 1997, American Journal of Obstetrics and Gynecology, V176, pS142, DOI 10.1016/S0002-9378(97)80555-8
   Sciscione AC, 2001, OBSTET GYNECOL, V97, P603, DOI 10.1016/S0029-7844(00)01186-8
   Sciscione AC, 1999, AM J OBSTET GYNECOL, V180, P55, DOI 10.1016/S0002-9378(99)70149-3
   Seaward PGR, 1998, AM J OBSTET GYNECOL, V179, P635, DOI 10.1016/S0002-9378(98)70056-0
   SECHER NJ, 1981, ACTA OBSTET GYN SCAN, V60, P237
   SEERAS RC, 1995, INT J GYNECOL OBSTET, V48, P163, DOI 10.1016/0020-7292(94)02260-6
   Sellers SM, 1988, P 1 EUR C PROST REPR
   Selmer-Olsen T, 2007, ACTA OBSTET GYN SCAN, V86, P1447, DOI 10.1080/00016340701645287
   Selo-Ojeme DO, 2009, ARCH GYNECOL OBSTET, V279, P813, DOI 10.1007/s00404-008-0818-x
   Selo-Ojeme D, 2007, RANDOMISED CONTROLLE
   Shakya R, 2010, J NEPAL MED ASSOC, V49, P33
   Sharma Y, 2005, J OBSTET GYNAECOL RE, V31, P210, DOI 10.1111/j.1447-0756.2005.00271.x
   Shechter-Maor G, 2013, AM J OBSTET GYNECOL, V208, pS78
   Sheela CN, 2007, J OBSTET GYNAECOLOGY, V57, P327
   Sheikher C, 2009, JK SCI, V11, P75
   SHEPHERD J, 1976, LANCET, V2, P709
   Sherman DJ, 2001, OBSTET GYNECOL, V97, P375, DOI 10.1016/S0029-7844(00)01168-6
   Shetty A, 2005, EUR J OBSTET GYN R B, V123, P56, DOI 10.1016/j.ejogrb.2005.03.004
   Shetty A, 2000, BRIT J OBSTET GYNAEC, V107, P813
   Shetty A, 2004, BJOG-INT J OBSTET GY, V111, P436, DOI 10.1111/j.1741-0528.2004.00107.x
   Shetty A, 2003, ACTA OBSTET GYN SCAN, V82, P1103, DOI 10.1046/j.1600-0412.2003.00246.x
   Shetty A, 2002, BJOG-INT J OBSTET GY, V109, P1354, DOI 10.1016/S1470-0328(02)02982-8
   Shetty A, 2002, AM J OBSTET GYNECOL, V186, P72, DOI 10.1067/mob.2002.118917
   Shetty A, 2002, BJOG-INT J OBSTET GY, V109, P645, DOI 10.1016/S1470-0328(02)01459-3
   Shetty A, 2001, BRIT J OBSTET GYNAEC, V108, P238, DOI 10.1111/j.1471-0528.2001.00073.x
   Shetty A, 2001, J OBSTET GYNAECOLOGY, V21, P91
   Shetty A, 2001, J OBSTET GYNAECOL S1, V21, P51
   Shetty A, 2000, J OBSTET GYNAECOL S1, V20, P19
   Shetty A, 2003, BJOG-INT J OBSTET GY, V110, P963
   Shetty A, 2000, 16 FIGO WORLD C OBST, V4, P28
   Shoaib F, 1994, PAK J MED SCI, V10, P227
   Sifakis S., 2007, Archives of Gynecology and Obstetrics, V275, P263, DOI 10.1007/s00404-006-0258-4
   SILVACRUZ A, 1988, PHARMATHERAPEUTICA, V5, P228
   Sitthiwattanawong W, 2000, THAI J OBSTET GYNAEC, V12, P352
   Sitthiwattanawong W, 1999, THAI J OBSTET GYNAEC, V11, P87
   Skupski D, 2007, AM J OBSTET GYNECOL, V197, pS99, DOI 10.1016/j.ajog.2007.10.338
   Smith C, 2000, COMMUNICATION
   Smith CA, 2013, COCHRANE DB SYST REV, V8
   Smith CA, 2003, COCHRANE DB SYST REV, V4
   Smith CA, 2008, OBSTET GYNECOL, V112, P1067, DOI 10.1097/AOG.0b013e31818b46bb
   SMITH CV, 1990, AM J OBSTET GYNECOL, V163, P845
   SMITH CV, 1994, J REPROD MED, V39, P381
   Smith CV, 1990, P 10 ANN M SOC PER O
   SORENSEN SS, 1992, ACTA OBSTET GYN SCAN, V71, P201, DOI 10.3109/00016349209009919
   Stampe Sorenson S, 1988, 12 FIGO WORLD C GYN
   Stampe Sorensen S, 1991, INT J GYNECOL OBST S, V36, P34
   Souza ASR, 2013, INT J GYNECOL OBSTET, V123, P207, DOI 10.1016/j.ijgo.2013.06.028
   Souza Alex Sandro Rolland, 2011, Rev. Bras. Ginecol. Obstet., V33, P270, DOI 10.1590/S0100-72032011000900010
   Spallicci MDB, 2007, EUR J OBSTET GYN R B, V130, P46, DOI 10.1016/j.ejogrb.2005.10.028
   Spallicci Maria Delizete Bentivegna, 2003, Rev. Bras. Ginecol. Obstet., V25, P67, DOI 10.1590/S0100-72032003000100010
   Sparks T, 2011, AM J OBSTET GYNECOL, V204, pS78
   SPELLACY WN, 1973, OBSTET GYNECOL, V41, P14
   Spellacy WN, 1972, PROSTAGLANDINS CLIN, P107
   SPERLING LS, 1993, ACTA OBSTET GYN SCAN, V72, P627, DOI 10.3109/00016349309021155
   Spiegelhalter DJ, 2002, J ROY STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353
   Srisomboon J, 1996, J Obstet Gynaecol Res, V22, P119
   Srisomboon Jatupol, 1998, Journal of the Medical Association of Thailand, V81, P779
   St Onge Rick D., 1995, American Journal of Obstetrics and Gynecology, V172, P687, DOI 10.1016/0002-9378(95)90594-4
   Stempel JE, 1997, AM J OBSTET GYNECOL, V176, P1305, DOI 10.1016/S0002-9378(97)70350-8
   Stenlund PM, 1999, ACTA OBSTET GYN SCAN, V78, P793, DOI 10.1034/j.1600-0412.1999.780910.x
   Stenlund PM, 1994, ACTA OBSTET GYNECO S, V73, pFP50
   Stephenson ML, 2013, J MATERN-FETAL NEO M, V26, P127, DOI 10.3109/14767058.2012.703715
   Stephenson ML, 2011, REPROD SCI, V18, p183A
   Stewart J. D., 1998, American Journal of Obstetrics and Gynecology, V178, pS92
   STEWART P, 1983, J OBSTET GYNAECOL, V4, P90, DOI 10.3109/01443618309071252
   Steytler P, 1995, P 14 C PRIOR PER CAR, P167
   Stitely ML, 2000, OBSTET GYNECOL, V96, P684, DOI 10.1016/S0029-7844(00)01034-6
   Strobelt N, 2006, ACTA OBSTET GYN SCAN, V85, P302, DOI 10.1080/00016340500523685
   Strobelt N, 2003, AM J OBSTET GYNECOL, V189, pS206, DOI 10.1016/j.ajog.2003.10.544
   Su H, 1996, Zhonghua Fu Chan Ke Za Zhi, V31, P676
   Sultana N, 2006, J BANGLADESH COLL SU, V24, P44
   Surbek D. V., 1997, American Journal of Obstetrics and Gynecology, V176, pS112, DOI 10.1016/S0002-9378(97)80443-7
   Surbek DV, 1997, AM J OBSTET GYNECOL, V177, P1018, DOI 10.1016/S0002-9378(97)70006-1
   Surbek DV, 1997, ACTA OBSTET GYN SCAN, V76, P36
   Surbek DV, 1997, 20 C SWISS GYN OBST
   Surita FGC, 2005, INT J GYNECOL OBSTET, V88, P258, DOI 10.1016/j.ijgo.2004.12.006
   Suvobrata S, 2011, 54 ALL IND C OBST GY
   Suzuki S, 2000, GYNECOL OBSTET INVES, V49, P24, DOI 10.1159/000010207
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Tabasi Z, 2007, Pak J Biol Sci, V10, P920
   Tabor B., 1995, American Journal of Obstetrics and Gynecology, V172, P425
   Tabowei T O, 2003, East Afr Med J, V80, P91
   Taechakraichana N, 1996, THAI J OBSTET GYNAEC, V8, P9
   Taher S, 2008, ARCH DIS CHILD S, V93, pF51
   Taher S, 2008, BJOG S1, V115, P59
   Taher SE, 2011, BJOG-INT J OBSTET GY, V118, P719, DOI 10.1111/j.1471-0528.2011.02901.x
   TAMSEN L, 1990, GYNECOL OBSTET INVES, V29, P128
   Tan PC, 2009, SINGAP MED J, V50, P1062
   Tan PC, 2007, OBSTET GYNECOL, V110, P820, DOI 10.1097/01.AOG.0000267201.70965.ec
   Tan PC, 2013, OBSTET GYNECOL, V121, P253, DOI [http://10.1097/AOG.0b013e31827e7fd9, 10.1097/AOG.0b013e31827e7fd9]
   Tan TC, 2010, BJOG-INT J OBSTET GY, V117, P1270, DOI 10.1111/j.1471-0528.2010.02602.x
   Tang J, 2013, INT J GYNECOL OBSTET, V121, P186, DOI 10.1016/j.ijgo.2012.12.009
   Tannirandorn Yuen, 1999, Journal of the Medical Association of Thailand, V82, P229
   Taylor A. V. G., 1993, Journal of Obstetrics and Gynaecology (Abingdon), V13, P333, DOI 10.3109/01443619309151705
   ten Eikelder MLG, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-67
   Tessier F., 1997, American Journal of Obstetrics and Gynecology, V176, pS111, DOI 10.1016/S0002-9378(97)80441-3
   Tessier F, 1997, COMMUNICATION
   Tey A., 1995, American Journal of Obstetrics and Gynecology, V172, P293
   Thaisomboon A, 2012, INT J GYNECOL OBSTET, V116, P13, DOI 10.1016/j.ijgo.2011.07.027
   Thakur V, 2005, ULTRASOUND OBST GYN, V26, P452, DOI 10.1002/uog.2514
   THAVARASHA A S, 1990, International Journal of Feto-Maternal Medicine, V3, P177
   THIERY M, 1978, LANCET, V2, P835
   THIERY M, 1984, PROSTAGLANDINS, V27, P429, DOI 10.1016/0090-6980(84)90201-6
   Thigpen B, 2004, AM J OBSTET GYNECOL, V191, pS18, DOI 10.1016/j.ajog.2004.09.076
   THOMAS IL, 1986, AUST NZ J OBSTET GYN, V26, P30, DOI 10.1111/j.1479-828X.1986.tb01524.x
   Thomas N., 2000, American Journal of Obstetrics and Gynecology, V182, pS136
   Tomlinson A J, 2001, J Obstet Gynaecol, V21, P239
   Tomlinson AJ, 2000, J OBSTET GYNAECOL S1, V20, P58
   Toppozada MK, 1997, INT J GYNECOL OBSTET, V56, P135, DOI 10.1016/S0020-7292(96)02805-6
   Torrance GW, 2001, MED DECIS MAKING, V21, P329, DOI 10.1177/02729890122062622
   Trabelsi Haikel, 2012, Tunis Med, V90, P362
   TREMEAU M L, 1992, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V21, P375
   Triglia MT, 2010, ACTA OBSTET GYN SCAN, V89, P651, DOI 10.3109/00016340903575998
   Trofatter K, 2013, J PERINATAL MED S1, V41, P710
   TROFATTER KF, 1985, AM J OBSTET GYNECOL, V153, P268
   TROFATTER KF, 1993, CLIN THER, V15, P838
   TROMANS PM, 1981, BRIT MED J, V282, P679
   TROOSTWIJK AL, 1992, EUR J OBSTET GYN R B, V43, P105, DOI 10.1016/0028-2243(92)90066-8
   Turner CE, 2008, BJOG-INT J OBSTET GY, V115, P1494, DOI 10.1111/j.1471-0528.2008.01892.x
   TYLLESKAR J, 1979, ACTA OBSTET GYN SCAN, V58, P513
   Tylleskar J, 1978, P 6 EUR C PER MED 29
   Ugwu EO, 2013, J OBSTET GYNAECOL, V33, P572, DOI 10.3109/01443615.2013.786030
   Ugwu EO, 2014, ARCH GYNECOL OBSTET, V289, P29, DOI 10.1007/s00404-013-2918-5
   ULMSTEN U, 1979, OBSTET GYNECOL, V54, P581
   ULMSTEN U, 1985, ARCH GYNECOL, V236, P243, DOI 10.1007/BF02133942
   ULMSTEN U, 1982, OBSTET GYNECOL, V59, P336
   Uludag S, 2005, EUR J OBSTET GYN R B, V122, P57, DOI 10.1016/j.ejogrb.2004.11.028
   Urban R, 2003, EUR J OBSTET GYN R B, V106, P20, DOI 10.1016/S0301-2115(02)00198-7
   VAKHARIYA VR, 1972, AM J OBSTET GYNECOL, V113, P212
   Valadan M, 2005, ACTA MED IRANICA, V43, P259
   VALENTINE BH, 1977, BRIT J OBSTET GYNAEC, V84, P846, DOI 10.1111/j.1471-0528.1977.tb12506.x
   van Baaren GJ, 2012, AM J OBSTET GYNECOL, V206, pS139
   van Gemund N, 2004, BJOG-INT J OBSTET GY, V111, P42, DOI 10.1046/j.1471-0528.2003.00010.x
   Vandenbussche FPHA, 1999, BIRTH-ISS PERINAT C, V26, P178, DOI 10.1046/j.1523-536x.1999.00178.x
   VANDERWALT D, 1989, S AFR MED J, V75, P54
   VARAKLIS K, 1995, OBSTET GYNECOL, V86, P541, DOI 10.1016/S0029-7844(95)80012-3
   Vernant M, 1993, P 2 WORLD PER MED RO
   Vijgen SMC, 2010, BJOG-INT J OBSTET GY, V117, P1577, DOI 10.1111/j.1471-0528.2010.02710.x
   WAGNER MV, 1989, OBSTET GYNECOL, V74, P93
   Wang H, 1998, Zhonghua Fu Chan Ke Za Zhi, V33, P469
   Welton N, 2012, HEALTH ECON, V21, P1196, DOI 10.1002/hec.1797
   Welton N.J., 2012, EVIDENCE SYNTHESIS D
   Weston J, 1993, CONTROLLED CLIN TRIA, V14, P401, DOI 10.1016/0197-2456(93)90072-L
   Wieland D, 1999, J REPROD MED, V44, P724
   Wielgos M, 2007, NEUROENDOCRINOL LETT, V28, P513
   Williams MC, 1997, OBSTET GYNECOL, V90, P784, DOI 10.1016/S0029-7844(97)00415-8
   Williams MG, 1990, P 10 ANN M SOC PER O
   WILSON PD, 1978, BRIT J OBSTET GYNAEC, V85, P941, DOI 10.1111/j.1471-0528.1978.tb15858.x
   Wing D, 2003, AM J OBSTET GYNECOL, V189, pS204, DOI 10.1016/j.ajog.2003.10.536
   Wing D. A., 1997, American Journal of Obstetrics and Gynecology, V176, pS113, DOI 10.1016/S0002-9378(97)80447-4
   Wing D. A., 1999, American Journal of Obstetrics and Gynecology, V180, pS127
   Wing DA, 2000, OBSTET GYNECOL, V96, P543, DOI 10.1016/S0029-7844(00)00947-9
   Wing DA, 1998, AM J OBSTET GYNECOL, V179, P94, DOI 10.1016/S0002-9378(98)70256-X
   Wing DA, 2000, OBSTET GYNECOL, V95, P905, DOI 10.1016/S0029-7844(00)00815-2
   Wing DA, 2005, AM J OBSTET GYNECOL, V192, P445, DOI 10.1016/j.ajog.2004.07.058
   Wing DA, 2004, AM J OBSTET GYNECOL, V190, P1689, DOI 10.1016/j.ajog.2004.02.045
   WING DA, 1995, AM J OBSTET GYNECOL, V172, P1811, DOI 10.1016/0002-9378(95)91416-1
   Wing DA, 1997, AM J OBSTET GYNECOL, V177, P612, DOI 10.1016/S0002-9378(97)70154-6
   WING DA, 1995, AM J OBSTET GYNECOL, V172, P1804, DOI 10.1016/0002-9378(95)91415-3
   Wing DA, 1999, AM J OBSTET GYNECOL, V180, P1155, DOI 10.1016/S0002-9378(99)70610-1
   Wing DA, 1998, OBSTET GYNECOL, V91, P828, DOI 10.1016/S0029-7844(97)00553-X
   Wing DA, 2000, AM J OBSTET GYNECOL, V182, P1437, DOI 10.1067/mob.2000.106135
   Wing D, 2013, AM J OBSTET GYNECOL, V208, pS49
   Wing Deborah A., 1998, American Journal of Obstetrics and Gynecology, V178, pS93
   Wing DA, 2008, OBSTET GYNECOL, V112, P801, DOI 10.1097/AOG.0b013e318187042e
   Wing DA, 2013, OBSTET GYNECOL, V122, P201, DOI 10.1097/AOG.0b013e31829a2dd6
   WINGERUP L, 1978, ACTA OBSTET GYN SCAN, V57, P403
   Wingerup L, 1979, 9 WORLD C GYN OBST 2
   WIQVIST I, 1986, ACTA OBSTET GYN SCAN, V65, P485
   Wiriyasirivaj B, 1996, OBSTET GYNECOL, V87, P767, DOI 10.1016/0029-7844(96)00015-4
   Witter F R, 1996, J Matern Fetal Med, V5, P64
   WITTER FR, 1992, AM J OBSTET GYNECOL, V166, P830
   WITTER FR, 1987, AM J PERINAT, V4, P206, DOI 10.1055/s-2007-999774
   Witter FR, 1996, PRENATAL NEONATAL S1, V1, P249
   Wong SF, 2002, BJOG-INT J OBSTET GY, V109, P632, DOI 10.1016/S1470-0328(02)01193-X
   Yang Z Y, 1994, Zhonghua Fu Chan Ke Za Zhi, V29, P273
   Yazdani SH, 2012, J BABOL U MED SCI, V14, P7
   Yazdizadeh Hamideh, 2013, Iran J Nurs Midwifery Res, V18, P246
   Yildirim G, 2008, J MAT FETAL NEONA S1, V21, P36
   Yildirim G, 2010, J MATERN-FETAL NEO M, V23, P681, DOI 10.3109/14767050903387078
   Yin Chun-yan, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P182
   Yonekura M L, 1985, Am J Perinatol, V2, P305, DOI 10.1055/s-2007-999976
   Yuen PM, 1996, AUST NZ J OBSTET GYN, V36, P291, DOI 10.1111/j.1479-828X.1996.tb02713.x
   Yuen PM, 1993, P 2 INT SCI M ROYAL
   ZAHRADNIK HP, 1987, GEBURTSH FRAUENHEILK, V47, P190, DOI 10.1055/s-2008-1035805
   Zahran KM, 2009, J OBSTET GYNAECOL RE, V35, P1054, DOI 10.1111/j.1447-0756.2009.01030.x
   Zanconato G, 2011, J MATERN-FETAL NEO M, V24, P728, DOI 10.3109/14767058.2011.557108
   ZANINI A, 1990, OBSTET GYNECOL, V76, P681
   Zanini A, 1989, Ann Ostet Ginecol Med Perinat, V110, P209
   Zeteroglu S, 2006, J MATERN-FETAL NEO M, V19, P283, DOI 10.1080/14767050600589807
   Zeteroglu S, 2006, EUR J OBSTET GYN R B, V126, P27, DOI 10.1016/j.ejogrb.2005.07.012
   Zeteroglu S, 2004, INT J GYNECOL OBSTET, V87, P155, DOI 10.1016/j.ijgo.2004.06.021
   Zeteroglu S, 2006, EUR J OBSTET GYN R B, V129, P140, DOI 10.1016/j.ejogrb.2005.11.040
   Ziaei S, 2003, J PERINAT MED, V31, P134, DOI 10.1515/JPM.2003.018
   Zvandasara P, 2008, Cent Afr J Med, V54, P43
NR 953
TC 0
Z9 0
U1 2
U2 2
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD AUG
PY 2016
VL 20
IS 65
BP 1
EP +
DI 10.3310/hta20650
PG 585
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA DW8EK
UT WOS:000383886700001
ER

PT J
AU Lammoglia, MA
   Garcez, N
   Cabrera, A
   Lopez, RD
   Renteria, IDD
   Rojas-Ronquillo, R
AF Angel Lammoglia, Miguel
   Garcez, Nora
   Cabrera, Amalia
   Dario Lopez, Ruben
   Daniel Renteria, Iliana del Carmen
   Rojas-Ronquillo, Rebeca
TI Behavior affected by routine oxytocin injection in crossbred cows in the
   tropics
SO REVISTA BRASILEIRA DE ZOOTECNIA-BRAZILIAN JOURNAL OF ANIMAL SCIENCE
LA English
DT Article
DE animal welfare; dairy cow; stress
ID AUTOMATIC MILKING SYSTEM; DAIRY-COWS; ANIMAL-WELFARE; STRESS;
   INDICATORS; YIELD
AB The objective of the study was to determine the effect of routine intramuscular injection of oxytocin to induce milk ejection on behavior assessed in terms of stress and rectal temperature in crossbred cows (Bos indicus x Bos taurus) in the tropics of Veracruz, Mexico. Immediately after calving, cows were milked twice a day (n = 210) and randomly assigned to receive at each milking: 10 IU (0.5 mL) of oxytocin intramuscularly (n = 70); 0.5 mL of saline solution intramuscularly (n = 70); or no injection (n = 70). The following behavioral indicators of stress were observed: trampling, kicking, tail movement, failure to eat, jumping to avoid injection, vocalization, urination, and defecation. After milking, rectal temperature (RT) was measured. Statistical analysis was performed using ANOVA and chi-square. There were no differences in terms of behavioral stress indicators or rectal temperature in cows injected with oxytocin or saline solution, but both groups had greater behavioral indicators of stress and RT compared with non-injected cows. Cows injected with oxytocin or saline solution manifested a higher percentage of animals that trampled (96.8%), kicked (32%), ceased eating (61.2%), moved the tail (81.2%), jumped (20.9%) and avoided the injection (78.2%), compared with non-injected cows. Cows injected with oxytocin and saline solution had higher rectal temperature (39.13 +/- 0.08 degrees C) compared with non-injected cows (38.96 +/- 0.12 degrees C). All injected cows had higher behavioral indicators of stress measurements and rectal temperature regardless of the solution, suggesting that cows injected routinely and intramuscularly do not become habituated to this, even though some cows were injected more than 600 times throughout lactation.
C1 [Angel Lammoglia, Miguel; Garcez, Nora; Cabrera, Amalia; Dario Lopez, Ruben; Daniel Renteria, Iliana del Carmen; Rojas-Ronquillo, Rebeca] Univ Veracruzana, Fac Ciencias Biol & Agr, Tuxpan, Veracruz, Mexico.
RP Rojas-Ronquillo, R (reprint author), Univ Veracruzana, Fac Ciencias Biol & Agr, Tuxpan, Veracruz, Mexico.
EM rebrojas@uv.mx
CR Albarran-Portillo B, 2015, TROP ANIM HEALTH PRO, V47, P519, DOI 10.1007/s11250-014-0753-8
   Berman A, 2011, J DAIRY SCI, V94, P2147, DOI 10.3168/jds.2010-3962
   BRUCKMAIER RM, 1994, J DAIRY RES, V61, P323
   Callejo R. A., 2009, COW COMFORT BIENESTA
   de Vries M, 2011, J DAIRY SCI, V94, P3213, DOI 10.3168/jds.2011-4169
   Garcez N., 2013, P 16 LAT AM C BUIATR, P246
   Villa Godoy A., 2003, P 17 NAT C BUIATR VI
   Grandin T, 2014, MEAT SCI, V98, P461, DOI 10.1016/j.meatsci.2014.05.011
   Jacobs JA, 2012, J DAIRY SCI, V95, P1575, DOI 10.3168/jds.2011-4710
   Kaskous SH, 2006, J DAIRY RES, V73, P28, DOI 10.1017/S0022029905001329
   Kielland C, 2010, J DAIRY SCI, V93, P2998, DOI 10.3168/jds.2009-2899
   Lusk R. H., 1989, Textbook of veterinary internal medicine: diseases of the dog and cat. Volume 1., P23
   McDermott JJ, 2010, LIVEST SCI, V130, P95, DOI 10.1016/j.livsci.2010.02.014
   Munksgaard L, 2001, APPL ANIM BEHAV SCI, V73, P15, DOI 10.1016/S0168-1591(01)00119-8
   NOSTRAND SD, 1991, J DAIRY SCI, V74, P2119
   Rousing T, 2004, LIVEST PROD SCI, V88, P1, DOI 10.1016/j.livprodsci.2003.12.001
   Rushen J, 2001, APPL ANIM BEHAV SCI, V73, P1, DOI 10.1016/S0168-1591(01)00105-8
   Santurtun E, 2015, RES VET SCI, V100, P303, DOI 10.1016/j.rvsc.2015.03.018
   Scholten MCT, 2013, NJAS-WAGEN J LIFE SC, V66, P3, DOI 10.1016/j.njas.2013.05.009
   Sherwin CM, 2003, APPL ANIM BEHAV SCI, V81, P291, DOI 10.1016/S0168-1591(02)00288-5
   Spiers D. E., 2001, LIVESTOCK ENV, P45
   STOTT GH, 1981, J ANIM SCI, V52, P150
   von Keyserlingk MAG, 2009, J DAIRY SCI, V92, P4101, DOI 10.3168/jds.2009-2326
   Wenzel C, 2003, LIVEST PROD SCI, V83, P237, DOI 10.1016/S0301-6226(03)00109-X
NR 24
TC 0
Z9 0
U1 1
U2 1
PU REVISTA BRASILEIRA ZOOTECNIA BRAZILIAN JOURNAL ANIMAL SCI
PI VICOSA-MG
PA UNIVERSIDADE FEDERAL VICOSA,, 36571-000 VICOSA-MG, BRAZIL
SN 1806-9290
J9 REV BRAS ZOOTECN
JI Rev. Bras. Zootecn.
PD AUG
PY 2016
VL 45
IS 8
BP 478
EP 482
DI 10.1590/S1806-92902016000800008
PG 5
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA DW0LP
UT WOS:000383332200008
ER

PT J
AU Csanyi, A
   Bota, J
   Falkay, G
   Gaspar, R
   Ducza, E
AF Csanyi, Adrienn
   Bota, Judit
   Falkay, George
   Gaspar, Robert
   Ducza, Eszter
TI The Effects of Female Sexual Hormones on the Expression of Aquaporin 5
   in the Late-Pregnant Rat Uterus
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE aquaporin 5; pregnancy; estrogen; gestagen
ID ESTROUS-CYCLE; IN-VITRO; RECEPTOR SUBTYPES; PROGESTERONE;
   IDENTIFICATION; IMPLANTATION; ESTRADIOL; REDISTRIBUTION; OXYTOCIN; GENES
AB Thirteen mammalian aquaporin (AQP) water channels are known, and few of them play a role in the mammalian reproductive system. In our earlier study, the predominance of AQP5 in the late-pregnant rat uterus was proven. Our current aim was to investigate the effect of estrogen-and gestagen-related compounds on the expression of the AQP5 channel in the late-pregnant rat uterus. Furthermore, we examined the effect of hormonally-induced preterm delivery on the expression of AQP5 in the uterus. We treated pregnant Sprague-Dawley rats subcutaneously with 17 beta-estradiol, clomiphene citrate, tamoxifen citrate, progesterone, levonorgestrel, and medroxyprogesterone acetate. Preterm delivery was induced by subcutaneous mifepristone and intravaginal prostaglandin E2. Reverse-transcriptase PCR and Western blot techniques were used for the detection of the changes in AQP5 mRNA and protein expressions. The amount of AQP5 significantly increased after progesterone and progesterone analogs treatment on 18 and 22 days of pregnancy. The 17 beta-estradiol and estrogen receptor agonists did not influence the AQP5 mRNA level; however, estradiol induced a significant increase in the AQP5 protein level on the investigated days of gestation. Tamoxifen increased the AQP5 protein expression on day 18, while clomiphene citrate was ineffective. The hormonally-induced preterm birth significantly decreased the AQP5 level similarly to the day of delivery. We proved that AQP5 expression is influenced by both estrogen and progesterone in the late-pregnant rat uterus. The influence of progesterone on AQP5 expression is more predominant as compared with estrogen.
C1 [Csanyi, Adrienn; Bota, Judit; Falkay, George; Gaspar, Robert; Ducza, Eszter] Univ Szeged, Fac Pharm, Dept Pharmacodynam & Biopharm, H-6720 Szeged, Hungary.
RP Ducza, E (reprint author), Univ Szeged, Fac Pharm, Dept Pharmacodynam & Biopharm, H-6720 Szeged, Hungary.
EM csanyi.adrienn@pharm.u-szeged.hu; bota.judit@pharm.u-szeged.hu;
   falkay@pharm.u-szeged.hu; gaspar@pharm.u-szeged.hu;
   ducza@pharm.u-szeged.hu
OI Csanyi, Adrienn/0000-0001-6905-6334
CR Aralla M, 2009, THERIOGENOLOGY, V72, P310, DOI 10.1016/j.theriogenology.2009.01.023
   Bharti S, 2013, FERTIL STERIL, V99, P140, DOI 10.1016/j.fertnstert.2012.08.050
   BORODITSKY RS, 1978, OBSTET GYNECOL, V51, P686
   Bota J, 2015, EUR J PHARMACOL, V769, P177, DOI 10.1016/j.ejphar.2015.11.015
   BRANDON JM, 1979, EUR J PHARMACOL, V57, P171, DOI 10.1016/0014-2999(79)90362-5
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Cyr M, 2000, NEUROPSYCHOPHARMACOL, V23, P69, DOI 10.1016/S0893-133X(00)00085-3
   DENKER BM, 1988, J BIOL CHEM, V263, P15634
   Dickey R. P., 2015, UNEXPLAINED INFERTIL, P261
   Ducza E, 2014, MOL REPROD DEV, V81, P524, DOI 10.1002/mrd.22320
   Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431
   Elovitz MA, 2004, TRENDS ENDOCRIN MET, V15, P479, DOI 10.1016/j.tem.2004.10.009
   Graham BM, 2013, BIOL PSYCHIAT, V73, P371, DOI 10.1016/j.biopsych.2012.09.018
   Hajagos-Toth J, 2016, REPROD BIOL ENDOCRIN, V14, DOI 10.1186/s12958-016-0166-9
   Hajagos-Toth J, 2016, CROAT MED J, V57, P100, DOI 10.3325/cmj.2016.57.100
   Hara-Chikuma M, 2006, CELL MOL LIFE SCI, V63, P1386, DOI 10.1007/s00018-006-6028-4
   He RH, 2006, LIFE SCI, V79, P423, DOI 10.1016/j.lfs.2006.01.020
   Hodi A, 2014, LIFE SCI, V105, P48, DOI 10.1016/j.lfs.2014.04.023
   Ishibashi K, 2011, AM J PHYSIOL-REG I, V300, pR566, DOI 10.1152/ajpregu.90464.2008
   Itoh T, 2005, BIOCHEM BIOPH RES CO, V330, P832, DOI 10.1016/j.bbrc.2005.03.046
   Jablonski EM, 2003, BIOL REPROD, V69, P1481, DOI 10.1095/biolreprod.103.019927
   Kobayashi K, 2010, CELL TISSUE RES, V342, P307, DOI 10.1007/s00441-010-1065-6
   Kobayashi M, 2006, GENES CELLS, V11, P1133, DOI 10.1111/j.1365-2443.2006.01009.x
   Lindsay LA, 2006, REPRODUCTION, V131, P369, DOI 10.1530/rep.1.00914
   Lindsay LA, 2004, ACTA HISTOCHEM, V106, P299, DOI 10.1016/j.acthis.2004.05.004
   Lindsay LA, 2007, J MOL HISTOL, V38, P87, DOI 10.1007/s10735-007-9083-8
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   MORISHIG.WK, 1973, ENDOCRINOLOGY, V92, P1527
   Nutu M, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.03.039
   Philibert D, 1999, GYNECOL ENDOCRINOL, V13, P316
   Richard C, 2003, ENDOCRINOLOGY, V144, P1533, DOI 10.1010/en.2002-0033
   Salleh N, 2015, J MEMBRANE BIOL, V248, P1097, DOI 10.1007/s00232-015-9823-8
   Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014
   Sha XY, 2011, ACTA PHARMACOL SIN, V32, P840, DOI 10.1038/aps.2011.45
   SHAIKH AA, 1971, BIOL REPROD, V5, P297
   Skowronska A, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0004-5
   Telleria CM, 1996, CONTRACEPTION, V53, P185, DOI 10.1016/0010-7824(96)00009-1
   Thomas J., 2014, COCHRANE DATABASE SY
   TULCHINSKY D, 1972, AM J OBSTET GYNECOL, V112, P1095
   Yakata K, 2007, BBA-BIOMEMBRANES, V1768, P688, DOI 10.1016/j.bbamem.2006.11.005
   Zhang D, 2012, MOL ASPECTS MED, V33, P676, DOI 10.1016/j.mam.2012.02.002
   Zhang Y, 2015, CELL RES, V25, P139, DOI 10.1038/cr.2014.139
   Zheng Z, 2014, J MATERN-FETAL NEO M, V27, P505, DOI 10.3109/14767058.2013.820697
   Zhu C, 2015, FRONT BIOSCI-LANDMRK, V20, P838, DOI 10.2741/4341
   Zou LB, 2011, J CLIN ENDOCR METAB, V96, pE1399, DOI 10.1210/jc.2011-0426
NR 45
TC 0
Z9 0
U1 1
U2 1
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2016
VL 17
IS 8
AR 1300
DI 10.3390/ijms17081300
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA DU6PU
UT WOS:000382337900112
ER

PT J
AU Finger, E
   Feldman, H
   Cummings, J
   Boxer, A
AF Finger, E.
   Feldman, H.
   Cummings, J.
   Boxer, A.
TI Study design of a phase 2 randomized controlled trial of intranasal
   oxytocin for symptomatic treatment in FTD
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 10th International Conference on Frontotemporal Dementias
CY AUG 31-SEP 02, 2016
CL Munich, GERMANY
C1 [Finger, E.] Western Univ, Clin Neurol Sci, London, ON, Canada.
   [Finger, E.] Parkwood Inst, London, ON, Canada.
   [Feldman, H.] Univ Calif San Diego, San Diego, CA USA.
   [Feldman, H.] UBC, Neurol, Vancouver, WA USA.
   [Cummings, J.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA.
   [Boxer, A.] UCSF, Neurol, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD AUG
PY 2016
VL 138
SU 1
SI SI
MA P477
BP 428
EP 428
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DU9WI
UT WOS:000382568400526
ER

PT J
AU Kawakita, T
   Reddy, UM
   Iqbal, SN
   Landy, HJ
   Huang, CC
   Hoffman, M
   Sciscione, AC
   Grantz, KL
AF Kawakita, Tetsuya
   Reddy, Uma M.
   Iqbal, Sara N.
   Landy, Helain J.
   Huang, Chun-Chih
   Hoffman, Matthew
   Sciscione, Anthony C.
   Grantz, Katherine L.
TI Duration of Oxytocin and Rupture of the Membranes Before Diagnosing a
   Failed Induction of Labor
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 36th Annual Pregnancy Meeting of the Society-for-Maternal-Fetal-Medicine
CY FEB 01-07, 2016
CL Atlanta, GA
SP Soc Maternal Fetal Med
AB OBJECTIVE: To compare maternal and neonatal outcomes based on length of the latent phase during induction with rupture of membranes before 6 cm dilation.
   METHODS: This is a retrospective cohort study using data from the Consortium of Safe Labor study, including 9,763 nulliparous and 8,379 multiparous women with singleton, term pregnancies undergoing induction at 2 cm dilation or less with rupture of membranes before 6 cm dilation after which the latent phase ended. Outcomes were evaluated according to duration of oxytocin and rupture of membranes.
   RESULTS: At time points from 6 to 18 hours of oxytocin and rupture of membranes, the rates of nulliparous women remaining in the latent phase declined (35.9-1.4%) and the rates of vaginal delivery for those remaining in the latent phase at these time periods decreased (54.1-29.9%) Nulliparous women remaining in the latent phase for 12 hours compared with women who had exited the latent phase had significantly increased rates of chorioamnionitis (12.1% compared with 4.1%) and endometritis (3.6% compared with 1.3%) and increased rates of neonatal intensive care unit admission (8.7% compared with 6.3%). Similar patterns were present for multiparous women at 15 hours.
   CONCLUSION: Based on when neonatal morbidity increased, in an otherwise uncomplicated induction of labor with rupture of membranes, a latent phase after initiation of oxytocin of at least 12 hours for nulliparous women and 15 hours in multiparous women is a reasonable criterion for diagnosing a failed induction.
C1 MedStar Washington Hosp Ctr, Dept Obstet, Washington, DC USA.
   MedStar Washington Hosp Ctr, Dept Gynecol, Washington, DC USA.
   MedStar Georgetown Univ Hosp, Washington, DC USA.
   Georgetown Howard Univ Ctr Clin & Translat Sci, Washington, DC USA.
   MedStar Hlth Res Inst, Dept Biostat & Bioinformat, Hyattsville, MD USA.
   Christiana Care Hlth Syst, Dept Maternal Fetal Med, Newark, DE USA.
RP Kawakita, T (reprint author), 101 Irving St NW,5B63, Washington, DC 20010 USA.
EM tetsuya.x.kawakita@gmail.com
FU Intramural NIH HHS [Z99 HD999999, ZIA HD008794-07, ZIA HD008794-08];
   NCATS NIH HHS [UL1 TR000101]; NCRR NIH HHS [UL1 RR031975]; NICHD NIH HHS
   [HHSN267200603425]
CR Laughon SK, 2012, AM J OBSTET GYNECOL, V206, pS47
   Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1
   Rouse DJ, 2000, OBSTET GYNECOL, V96, P671, DOI 10.1016/S0029-7844(00)01010-3
   Rouse DJ, 2011, OBSTET GYNECOL, V117, P267, DOI 10.1097/AOG.0b013e318207887a
   Simon CE, 2005, OBSTET GYNECOL, V105, P705, DOI 10.1097/01.AOG.0000157437.10998.e7
   Zhang J, 2010, AM J OBSTET GYNECOL, V203, P326, DOI DOI 10.1016/J.AJ0G.2010.06.058
   Zhang J, 2010, OBSTET GYNECOL, V116, P1281, DOI 10.1097/AOG.0b013e3181fdef6e
   [Anonymous], 2014, OBSTET GYNECOL, V123, P693
NR 8
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD AUG
PY 2016
VL 128
IS 2
BP 373
EP 380
DI 10.1097/AOG.0000000000001527
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DS6UO
UT WOS:000380918500023
PM 27400012
ER

PT J
AU Frolich, MA
   Banks, C
   Warren, W
   Robbins, M
   Ness, T
AF Frolich, Michael A.
   Banks, Catiffaney
   Warren, William
   Robbins, Meredith
   Ness, Timothy
TI The Association Between Progesterone, Estradiol, and Oxytocin and Heat
   Pain Measures in Pregnancy: An Observational Cohort Study
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID RECURRENT ABDOMINAL-PAIN; PERIPHERAL-NERVE INJURY; INDUCED ANALGESIA;
   POSTPARTUM PERIOD; NEUROPATHIC PAIN; UP-REGULATION; THRESHOLD; LABOR;
   RAT; RESPONSES
AB BACKGROUND: Hormonal action has been implicated as a possible mechanism for pregnancy-induced analgesia. Previous investigators have reported an increase in heat pain tolerance during labor compared with nonpregnant controls and postulated it was because of the hormonal changes during pregnancy. However, these previous reports did not include measurement of hormonal values. The purpose of our study was to quantitatively test if changes in pregnancy hormone concentrations correlated with changes in temperature ratings.
   METHODS: This was a prospective cohort study consisting of 32 women scheduled for elective cesarean delivery at term between July 2010 and January 2013. Heat pain threshold and tolerance, estrogen, progesterone, and oxytocin levels were measured twice in each patient at term and again 4 to 8 weeks postpartum.
   RESULTS: All hormone levels decreased significantly between term pregnancy and the postpartum visit (all P values < 0.029). However, there were no statistically significant differences between term and postpartum heat pain measurements. The mean baseline heat pain threshold was 40.9 degrees C at term compared with 40.3 degrees C degrees postpartum (P = 0.47; mean change, -0.6 degrees C; 95% confidence interval of change, -1.8 degrees C to + 0.7 degrees C). The mean baseline heat pain tolerance was 46.1 degrees C at term and 46.0 degrees C postpartum (P = 0.59; mean change, -0.1 degrees C; 95% confidence interval of change, -0.8 degrees C degrees to + 0.6 degrees C).
   CONCLUSIONS: Our findings show that amounts of estradiol and progesterone changed significantly between the term and the postpartum visit; however, the thermal pain tolerance did not significantly change. In summary, we did not observe an association between hormonal changes and changes in pain threshold measures. This finding argues against the concept of simple progesterone-or estrogen-induced analgesia in humans.
C1 [Frolich, Michael A.; Banks, Catiffaney; Warren, William; Robbins, Meredith; Ness, Timothy] Univ Alabama Birmingham, Dept Anesthesiol, Jefferson Tower,Room 868C, Birmingham, AL 35249 USA.
RP Frolich, MA (reprint author), Univ Alabama Birmingham, Dept Anesthesiol, Jefferson Tower,Room 868C, Birmingham, AL 35249 USA.
EM froelich@uab.edu
CR Alfven G, 2004, J PEDIATR GASTR NUTR, V38, P513, DOI 10.1097/00005176-200405000-00010
   ALFVEN G, 1994, ACTA PAEDIATR, V83, P1076, DOI 10.1111/j.1651-2227.1994.tb12989.x
   BARON SA, 1984, BRAIN RES, V321, P341, DOI 10.1016/0006-8993(84)90190-2
   Black LV, 2009, J PAIN, V10, P1065, DOI 10.1016/j.jpain.2009.04.007
   Carvalho B, 2006, ANESTH ANALG, V103, P1283, DOI 10.1213/01.ane.0000239224.48719.28
   Dawson-Basoa M, 1998, BRAIN RES, V794, P61, DOI 10.1016/S0006-8993(98)00192-9
   DAWSONBASOA MB, 1993, BRAIN RES, V601, P241, DOI 10.1016/0006-8993(93)91716-6
   DawsonBasoa ME, 1996, PAIN, V64, P607, DOI 10.1016/0304-3959(96)00032-2
   Draisci G, 2012, EUR J PAIN, V16, P1389, DOI 10.1002/j.1532-2149.2012.00139.x
   DUNBAR AH, 1988, PAIN, V35, P265, DOI 10.1016/0304-3959(88)90136-4
   Engle MP, 2012, REGION ANESTH PAIN M, V37, P515, DOI 10.1097/AAP.0b013e318266352d
   Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x
   GINTZLER AR, 1980, SCIENCE, V210, P193, DOI 10.1126/science.7414330
   Goodin BR, 2015, CLIN J PAIN, V31, P757, DOI 10.1097/AJP.0000000000000166
   Grewen KM, 2008, ETHNIC HEALTH, V13, P219, DOI 10.1080/13557850701837310
   Gutierrez S, 2013, ANESTHESIOLOGY, V118, P152, DOI 10.1097/ALN.0b013e318278cd21
   Haukoos JS, 2005, ACAD EMERG MED, V12, P360, DOI 10.1197/j.aem.2004.11.018
   Hobo S, 2011, NEUROSCI LETT, V502, P52, DOI 10.1016/j.neulet.2011.07.023
   Jarahi M, 2014, NEUROSCIENCE, V256, P403, DOI 10.1016/j.neuroscience.2013.10.043
   Jarvis S, 1997, PAIN, V72, P153, DOI 10.1016/S0304-3959(97)00027-4
   Louvel D, 1996, GUT, V39, P741, DOI 10.1136/gut.39.5.741
   Lu YC, 2009, J PHARMACOL EXP THER, V331, P1104, DOI 10.1124/jpet.109.158402
   Ohel I, 2007, PAIN, V132, pS104, DOI 10.1016/j.pain.2007.05.007
   Ohlsson B, 2005, NEUROGASTROENT MOTIL, V17, P697, DOI 10.1111/j.1365-2982.2005.00679.x
   Prevost Marie, 2014, Front Public Health, V2, P1, DOI 10.3389/fpubh.2014.00001
   PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3
   Ralya A, 2014, NEUROSCI LETT, V575, P91, DOI 10.1016/j.neulet.2014.05.035
   Rash JA, 2014, CLIN J PAIN, V30, P453, DOI 10.1097/AJP.0b013e31829f57df
   Saisto T, 2001, PAIN, V93, P123, DOI 10.1016/S0304-3959(01)00302-5
   SANDER HW, 1987, BRAIN RES, V408, P389, DOI 10.1016/0006-8993(87)90412-4
   SENGUPTA P, 1984, ANAESTHESIA, V39, P982, DOI 10.1111/j.1365-2044.1984.tb08886.x
   SHAPIRA SC, 1995, EUR J ANAESTH, V12, P495
   Staikou C, 2006, Acta Anaesthesiol Belg, V57, P277
   Uryvaev YV, 1996, B EXP BIOL MED+, V122, P1071, DOI 10.1007/BF02447648
   Verdi J, 2013, EUR J PHARMACOL, V699, P207, DOI 10.1016/j.ejphar.2012.11.052
   WHIPPLE B, 1990, INT J NURS STUD, V27, P213, DOI 10.1016/0020-7489(90)90036-I
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yang J, 2007, PEPTIDES, V28, P1113, DOI 10.1016/j.peptides.2007.03.003
NR 38
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD AUG
PY 2016
VL 123
IS 2
BP 396
EP 401
DI 10.1213/ANE.0000000000001259
PG 6
WC Anesthesiology
SC Anesthesiology
GA DS5JX
UT WOS:000380819200014
PM 27028773
ER

PT J
AU Johnsen, JF
   Zipp, KA
   Kalber, T
   de Passille, AM
   Knierim, U
   Barth, K
   Mejdell, CM
AF Johnsen, Julie Foske
   Zipp, Katharina A.
   Kaelber, Tasja
   de Passille, Anne Marie
   Knierim, Ute
   Barth, Kerstin
   Mejdell, Cecilie Marie
TI Is rearing calves with the dam a feasible option for dairy farms?
   Current and future research
SO APPLIED ANIMAL BEHAVIOUR SCIENCE
LA English
DT Article; Proceedings Paper
CT Congress of the International-Society-for-Applied-Ethology (ISAE)
CY 2014
CL Vitoria Gasteiz, SPAIN
SP Int Soc Appl Ethol
DE Dairy calves; Alternative calf rearing; Suckling; Welfare
ID SKELETAL GROWTH-RATE; MILK EJECTION; UDDER HEALTH; WEIGHT-GAIN; OXYTOCIN
   RELEASE; SOCIAL-BEHAVIOR; CROSS-SUCKING; CALF GROWTH; FEED-INTAKE;
   REPRODUCTIVE-PERFORMANCE
AB In the dairy industry it is common practice to separate cow and calf shortly after birth but this practice is disputed because of animal welfare concerns. Some producers, in many countries, milk cows that also nurse dairy calves. These cow calf systems allow nursing as well as affiliative and other natural behaviours. In this review paper we describe cow calf systems used in practice and/or in research, discuss the benefits and challenges documented by research, and identify areas where more research is needed. Four cow calf systems are described: (1) free contact systems where cow and calf have unrestricted access to each other; (2) restricted suckling systems allowing short daily contact only to nurse; (3) half day contact where cow and calf are housed together during the day or night; and (4) foster cow systems where one cow nurses 2-4 calves usually without milking. In free and half day cow calf contact systems the calf drinks large amounts of milk and has high daily weight gains. High pre-weaning calf weight gains have been shown to lead to higher milk yield during that animal's first lactation. One issue with cow calf systems is the depressed weight gain of calves at weaning. The premature separation of cow and calf, compared to the natural situation, may cause stress especially in free contact systems. Weaning and separation should therefore occur in two steps. Half day contact seems particularly promising because animals get used to being separated, they experience positive human handling, and calves can learn to use a milk feeder which will prevent the growth check following weaning. Nursing cows yield less saleable milk during the suckling period, can have problems with milk ejection during machine milking and have a lower fat content of the milk, compared to non-nursing cows. Udder health of the cow may be positively affected by nursing. A rich social rearing environment has recently been shown to improve cognitive skills of calves. Still, studies on long term effects of dam rearing on behaviour, health, production and farm economics are few. There is also a need to address ways to control transmissible diseases when dairy cattle are kept in mixed age groups. Increased knowledge will help us design functional high tech dairy management systems that respect the natural behaviour of cows and calves during the calf rearing period. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Johnsen, Julie Foske; Mejdell, Cecilie Marie] Norwegian Vet Inst, Dept Hlth Surveillance, POB 750, N-0106 Oslo, Norway.
   [Zipp, Katharina A.; Knierim, Ute] Univ Kassel, Farm Anim Behav & Husb Sect, Nordbahnhofstr 1a, D-37213 Witzenhausen, Germany.
   [Kaelber, Tasja; Barth, Kerstin] Thunen Inst Organ Farming, Trenthorst 32, D-23847 Westerau, Germany.
   [de Passille, Anne Marie] Univ British Columbia, Fac Land & Food Syst, 2357 Main Mall, Vancouver, BC V6T 1Z4, Canada.
RP Mejdell, CM (reprint author), Norwegian Vet Inst, Dept Hlth Surveillance, POB 750, N-0106 Oslo, Norway.
EM julie.johnsen@vetinst.no; zipp@uni-kassel.de; tasja.kaelber@ti.bund.de;
   passille@mail.ubc.ca; uknierim@uni-kassel.de; kerstin.barth@ti.bund.de;
   cecilie.mejdell@vetinst.no
CR AKERS RM, 1984, J DAIRY SCI, V67, P115
   AKERS RM, 1982, HORM BEHAV, V16, P87, DOI 10.1016/0018-506X(82)90009-5
   Albright J.L., 1982, 21 INT DAIRY C, V1, P37
   Appleby MC, 2001, APPL ANIM BEHAV SCI, V74, P191, DOI 10.1016/S0168-1591(01)00171-X
   BarPeled U, 1997, J DAIRY SCI, V80, P2523
   Barth K., 2007, ZWISCHEN TRADITION G, P581
   Barth K, 2009, LANDBAUFORSCH SH, V326, P11
   Barth K., 2010, AKTUELLE ARBEITEN AR, P31
   Belo CJ, 2010, J DAIRY SCI, V93, P63, DOI 10.3168/jds.2009-2084
   Blowey R, 2010, MASTITIS CONTROL IN DAIRY HERDS, 2ND EDITION, P1, DOI 10.1079/9781845935504.0000
   Boden R. F., 1994, Animal Production, V58, P463
   Boe KE, 2003, APPL ANIM BEHAV SCI, V80, P175, DOI 10.1016/S0168-1591(02)00217-4
   BROUCEK J, 1995, ZIVOCISNA VYROBA, V40, P59
   Broucek J., 2006, J ANIM SCI, V19, P672
   Bruckmaier RM, 2008, J ANIM SCI, V86, P15, DOI 10.2527/jas.2007-0335
   BRUCKMAIER RM, 1992, J DAIRY RES, V59, P479
   Butler G, 2011, J DAIRY SCI, V94, P24, DOI 10.3168/jds.2010-3331
   Carbonneau E, 2012, J DAIRY SCI, V95, P6503, DOI 10.3168/jds.2012-5643
   Clarke T, 2004, J DAIRY RES, V71, P419, DOI 10.1017/S0022029904000421
   Costa J.H.C., 2014, J DAIRY SCI, P97
   Cozma A, 2013, DAIRY SCI TECHNOL, V93, P99, DOI 10.1007/s13594-012-0094-1
   Das SM, 2001, APPL ANIM BEHAV SCI, V72, P263, DOI 10.1016/S0168-1591(01)00116-2
   Das SM, 1999, ACTA VET SCAND, V40, P57
   de Passille AM, 2008, J DAIRY SCI, V91, P1416, DOI 10.3168/jds.2007-0504
   de Passille AM, 2001, APPL ANIM BEHAV SCI, V72, P175, DOI 10.1016/S0168-1591(01)00108-3
   Duve LR, 2012, J DAIRY SCI, V95, P6571, DOI 10.3168/jds.2011-5170
   Edwards JP, 2013, J DAIRY SCI, V96, P3766, DOI 10.3168/jds.2012-6394
   Ellingsen K., 2015, VETERINAERINSTITUTTE
   EVERITT G C, 1971, Proceedings of the New Zealand Society of Animal Production, V31, P22
   Froberg S, 2008, APPL ANIM BEHAV SCI, V113, P1, DOI 10.1016/j.applanim.2007.12.001
   Froberg S, 2007, TROP ANIM HEALTH PRO, V39, P71, DOI 10.1007/s11250-006-4418-0
   Froberg S, 2011, ACTA AGR SCAND A-AN, V61, P145, DOI 10.1080/09064702.2011.632433
   Froberg S, 2009, APPL ANIM BEHAV SCI, V117, P150, DOI 10.1016/j.applanim.2008.12.015
   Gaillard C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090205
   Grondahl A.M., 2007, ACTA VET SCAND, P49
   Haley DB, 2005, J ANIM SCI, V83, P2205
   Haug A, 2007, LIPIDS HEALTH DIS, V6, DOI [10.1186/1476-511X-6-25, 10.1186/1476-511X-6-29]
   Hepola H, 2007, ACTA AGR SCAND A-AN, V57, P121, DOI 10.1080/09064700701867961
   Herskin MS, 2010, J DAIRY SCI, V93, P2053, DOI 10.3168/jds.2009-2554
   Jago JG, 2010, J DAIRY SCI, V93, P2541, DOI 10.3168/jds.2009-2949
   Jainudeen MR, 2000, REPROD FARM ANIMALS, P159
   Jensen MB, 2011, APPL ANIM BEHAV SCI, V134, P92, DOI 10.1016/j.applanim.2011.06.017
   Johnsen JF, 2015, J DAIRY SCI, V98, P4800, DOI 10.3168/jds.2014-9128
   Johnsen J.F., 2015, SUCKLING DAIRY PRODU
   Johnsen JF, 2015, APPL ANIM BEHAV SCI, V166, P11, DOI 10.1016/j.applanim.2015.03.002
   Johnsen JF, 2015, APPL ANIM BEHAV SCI, V163, P50, DOI 10.1016/j.applanim.2014.12.003
   Jonasen B., 2001, COW CALF RELATIONS
   Jung J, 2001, APPL ANIM BEHAV SCI, V72, P201, DOI 10.1016/S0168-1591(01)00110-1
   Junqueira FS, 2005, LIVEST PROD SCI, V97, P241, DOI 10.1016/j.livprodsci.2005.05.005
   Kalber T., 2014, APPL AGR FORESTRY RE, V64, P45
   Kalber T., 2013, KTBL SCHRIFT S, V503, P230
   Kalber T., 2014, 48 C INT SOC APPL ET, P273
   Kaskous SH, 2006, J DAIRY RES, V73, P28, DOI 10.1017/S0022029905001329
   Kendrick KM, 2000, EXP PHYSIOL, V85, p111S, DOI 10.1111/j.1469-445X.2000.tb00014.x
   Khan MA, 2011, J DAIRY SCI, V94, P1071, DOI 10.3168/jds.2010-3733
   Kiley-Worthington M., 1983, BEHAV BEEF SUCKLER C
   Kilgour R., 1984, LIVESTOCK BEHAV PRAC
   Kisac P, 2011, CZECH J ANIM SCI, V56, P261
   Kraetzl WD, 2001, APPL ANIM BEHAV SCI, V72, P247, DOI 10.1016/S0168-1591(01)00114-9
   Krohn CC, 2001, APPL ANIM BEHAV SCI, V72, P271, DOI 10.1016/S0168-1591(01)00117-4
   Krohn C.C., 2001, COW CALF RELATIONS
   Krohn C.C., 1999, EFFECT RESTRICTED SU
   Kusche D, 2015, J SCI FOOD AGR, V95, P529, DOI 10.1002/jsfa.6768
   Langbein J, 2000, ARCH TIERZUCHT, V43, P203
   Latham NR, 2008, APPL ANIM BEHAV SCI, V110, P84, DOI 10.1016/j.applanim.2007.03.026
   LENEINDRE P, 1984, APPL ANIM BEHAV SCI, V12, P43, DOI 10.1016/0168-1591(84)90095-9
   LENEINDRE P, 1989, APPL ANIM BEHAV SCI, V23, P117, DOI 10.1016/0168-1591(89)90012-9
   Lidfors L., 2005, OLIKA SYSTEM UPPFODN
   Lidfors LM, 1996, APPL ANIM BEHAV SCI, V49, P269, DOI 10.1016/0168-1591(96)01053-2
   LITTLE DA, 1991, TROP ANIM HEALTH PRO, V23, P108, DOI 10.1007/BF02361194
   Loberg J, 2001, APPL ANIM BEHAV SCI, V74, P97, DOI 10.1016/S0168-1591(01)00157-5
   Loberg JM, 2007, J ANIM SCI, V85, P1522, DOI 10.2527/jas.2006-813
   Loberg JM, 2008, APPL ANIM BEHAV SCI, V111, P222, DOI 10.1016/j.applanim.2007.06.011
   Loberg J.M., 2007, BEHAV FOSTER COWS CA
   Lucht A., 2009, ANNAHERUNG PROBLEMAT
   Lupoli B, 2001, J DAIRY RES, V68, P175, DOI 10.1017/S0022029901004721
   Macuhova J, 2004, J DAIRY SCI, V87, P1236
   Margerison JK, 2003, APPL ANIM BEHAV SCI, V80, P277, DOI 10.1016/S0168-1591(02)00231-9
   Margerison JK, 2002, J ANIM SCI, V80, P1663
   McNamara S, 2008, LIVEST SCI, V117, P70, DOI 10.1016/j.livsci.2007.11.013
   Meagher R.K., 2014, 48 C INT SOC APPL ET, P96
   Mendoza A, 2010, LIVEST SCI, V127, P60, DOI 10.1016/j.livsci.2009.08.006
   METZ J, 1986, APPL ANIM BEHAV SCI, V16, P325, DOI 10.1016/0168-1591(86)90004-3
   Moallem U, 2010, J DAIRY SCI, V93, P2639, DOI 10.3168/jds.2009-3007
   Negrao JA, 2002, REPROD NUTR DEV, V42, P373, DOI 10.1051/rnd:2002032
   Newberry RC, 2008, APPL ANIM BEHAV SCI, V110, P3, DOI 10.1016/j.applanim.2007.03.021
   Oldham J.D., 1979, FEEDING STRATEGY HIG
   Ontsouka CE, 2003, J DAIRY SCI, V86, P2005, DOI 10.3168/jds.S0022-0302(03)73789-8
   Patton J, 2006, J DAIRY SCI, V89, P1478
   PEETERS G, 1973, ZBL VET MED A, V20, P531
   Putzmann I., 2014, AUSWIRKUNGEN AUFZUCH
   REINHARDT V, 1981, J AGR SCI, V96, P309
   Reinhardt V., 1977, P 28 ANN M EUR ASS A
   Roth BA, 2008, APPL ANIM BEHAV SCI, V111, P251, DOI 10.1016/j.applanim.2007.06.007
   Roth BA, 2009, APPL ANIM BEHAV SCI, V119, P143, DOI 10.1016/j.applanim.2009.03.004
   Ryle M., 2015, LIVEST RES RURAL DEV, V2
   Sandoval-Castro CA, 1999, ANIM SCI, V69, P287
   Schneider RA, 2007, KTBL SCHR, V461, P48
   Shamay A, 2005, J DAIRY SCI, V88, P1460
   Soberon F, 2012, J DAIRY SCI, V95, P783, DOI 10.3168/jds.2011-4391
   Szabo S, 2013, J DAIRY SCI, V96, P5644, DOI 10.3168/jds.2012-5556
   Tancin V, 2001, VET MED-CZECH, V46, P108
   Tournadre H., 2008, Rencontres Autour des Recherches sur les Ruminants, V15, P159
   Tzamaloukas O, 2015, J DAIRY SCI, V98, P1739, DOI 10.3168/jds.2014-8540
   Ufer I., 2014, THESIS
   Uvnas-Moberg K, 2001, APPL ANIM BEHAV SCI, V72, P225, DOI 10.1016/S0168-1591(01)00112-5
   Vaughan A., 2012, QUALITY LIFE DESIGNE, P104
   Veissier I, 2013, APPL ANIM BEHAV SCI, V147, P11, DOI 10.1016/j.applanim.2013.05.002
   Vieira AD, 2010, J DAIRY SCI, V93, P3079, DOI 10.3168/jds.2009-2516
   VITALE AF, 1986, APPL ANIM BEHAV SCI, V16, P217, DOI 10.1016/0168-1591(86)90115-2
   von Keyserlingk MAG, 2008, J DAIRY SCI, V91, P1011, DOI 10.3168/jds.2007-0532
   von Keyserlingk MAG, 2007, HORM BEHAV, V52, P106, DOI 10.1016/j.yhbeh.2007.03.015
   Wagenaar JP, 2011, NJAS-WAGEN J LIFE SC, V58, P157, DOI 10.1016/j.njas.2011.06.001
   Wagenaar J.P., 2007, NETH J AGR SCI, P375
   Wagner K, 2015, APPL ANIM BEHAV SCI, V164, P1, DOI 10.1016/j.applanim.2014.12.010
   Wagner K, 2013, APPL ANIM BEHAV SCI, V147, P43, DOI 10.1016/j.applanim.2013.04.010
   Wagner K, 2012, APPL ANIM BEHAV SCI, V141, P117, DOI 10.1016/j.applanim.2012.08.011
   WALSH JP, 1974, IRISH J AGR RES, V13, P77
   Wathes DC, 2008, ANIMAL, V2, P1135, DOI 10.1017/S1751731108002322
   Wellnitz O, 2001, LIVEST PROD SCI, V70, P135
   WILLIAMS GL, 1993, BIOL REPROD, V49, P1328, DOI 10.1095/biolreprod49.6.1328
   WILLIS GL, 1983, APPL ANIM ETHOL, V9, P231, DOI 10.1016/0304-3762(83)90003-2
   Zipp K., 2015, TIERHALTUNG SPANNUNG, P131
   Zipp K.A., 2014, MOVING ON, P274
   Zipp K.A., 2013, IDEAL WIRKLICHKEIT P, P462
   Zumbrunnen M., 2012, MUTTERGEBUNDENE KALB
NR 126
TC 0
Z9 0
U1 19
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1591
EI 1872-9045
J9 APPL ANIM BEHAV SCI
JI Appl. Anim. Behav. Sci.
PD AUG
PY 2016
VL 181
BP 1
EP 11
DI 10.1016/j.applanim.2015.11.011
PG 11
WC Agriculture, Dairy & Animal Science; Behavioral Sciences; Veterinary
   Sciences
SC Agriculture; Behavioral Sciences; Veterinary Sciences
GA DT0KB
UT WOS:000381171300001
ER

PT J
AU Collins, J
   Kempe, K
   Wilson, P
   Blindauer, CA
   McIntosh, MP
   Davis, TP
   Whittaker, MR
   Haddleton, DM
AF Collins, Jennifer
   Kempe, Kristian
   Wilson, Paul
   Blindauer, Claudia A.
   McIntosh, Michelle P.
   Davis, Thomas P.
   Whittaker, Michael R.
   Haddleton, David M.
TI Stability Enhancing N-Terminal PEGylation of Oxytocin Exploiting
   Different Polymer Architectures and Conjugation Approaches
SO BIOMACROMOLECULES
LA English
DT Article
ID LIVING RADICAL POLYMERIZATION; HIGHLY POTENT ANALOGUE; DIVALENT
   METAL-IONS; POLYETHYLENE-GLYCOL; POLY(ETHYLENE GLYCOL); PROTEIN
   PEGYLATION; RAFT POLYMERIZATION; DRUG-DELIVERY; COVALENT ATTACHMENT;
   DESAMINO-OXYTOCIN
AB Oxytocin, a cyclic nine amino acid neurohypophyseal hormone therapeutic, is effectively used in the control of postpartum hemorrhaging (PPH) and is on the WHO List of Essential Medicines. However, oxytocin has limited shelf life stability in aqueous solutions, particularly at temperatures in excess of 25 degrees C and injectable aqueous oxytocin formulations require refrigeration (<8 degrees C). This is particularly problematic in the hot climates often found in many developing countries where daytime temperatures can exceed 40 degrees C and where reliable cold-chain storage is not always achievable. The purpose of this study was to develop N-terminal amine targeted PEGylation strategies utilizing both linear PEG and polyPEG "comb" polymers as an effective method for stabilizing solution formulations of this peptide for prolonged storage in the absence of efficient cold-chain storage. The conjugation chemistries investigated herein include irreversible amine targeted conjugation methods utilizing NHS ester and aldehyde reductive amination chemistry. Additionally, one reversible conjugation method using a Schiff base approach was explored to allow for the release of the native peptide, thus, ensuring that biological activity remains unaffected. The reversibility of this approach was investigated for the different polymer architectures, alongside a nonpolymer oxytocin analogue to monitor how pH can tune native peptide release. Elevated temperature degradation studies of the polymer conjugates were evaluated to assess the stability of the PEGylated analogues in comparison to the native peptide in aqueous formulations to mimic storage conditions in developing nations and regions where storage under appropriate conditions is challenging.
C1 [Collins, Jennifer; Kempe, Kristian; Wilson, Paul; Blindauer, Claudia A.; Haddleton, David M.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
   [Kempe, Kristian; Wilson, Paul; McIntosh, Michelle P.; Davis, Thomas P.; Whittaker, Michael R.; Haddleton, David M.] Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, Parkville, Vic 3052, Australia.
RP Haddleton, DM (reprint author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.; Whittaker, MR; Haddleton, DM (reprint author), Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, Parkville, Vic 3052, Australia.
EM michael.whittaker@monash.edu; d.m.haddleton@warwick.ac.uk
RI Whittaker, Michael/C-2449-2008; Blindauer, Claudia/G-3237-2011; Davis,
   Thomas/B-6395-2008
OI Blindauer, Claudia/0000-0001-8396-9332; Davis,
   Thomas/0000-0003-2581-4986
FU EPSRC DTA award; Australian Research Council (ARC) Centre of Excellence
   in Convergent Bio-Nano Science and Technology [CE140100036]; Australian
   Laureate Fellowship from the ARC
FX J.C. is funded via an EPSRC DTA award. The authors wish to acknowledge
   the facilities and personnel (P.W., D.M.H., T.P.D., M.R.W.) enabled by
   the Monash-Warwick Alliance. This collaborative research was carried out
   by the Australian Research Council (ARC) Centre of Excellence in
   Convergent Bio-Nano Science and Technology (Project No. CE140100036). We
   would like to thank Mengxue Jia for assistance with MALDI-TOF. D.M.H. is
   a Wolfson/Royal Society Fellow. T.P.D. is grateful for the award of an
   Australian Laureate Fellowship from the ARC. Oxytocin was donated by
   PolyPeptide Laboratories (Hillerod, Denmark).
CR ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
   ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578
   ATKE A, 1987, ACTA ENDOCRINOL-COP, V115, P155
   Avanti C, 2012, MOL PHARMACEUT, V9, P554, DOI 10.1021/mp200622z
   Avanti C, 2011, AAPS J, V13, P284, DOI 10.1208/s12248-011-9268-7
   Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g
   Balan S, 2007, BIOCONJUGATE CHEM, V18, P61, DOI 10.1021/bc0601471
   Bays E, 2009, BIOMACROMOLECULES, V10, P1777, DOI 10.1021/bm9001987
   Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1006/toxs.1997.2396
   BERDE B, 1957, BRIT J PHARM CHEMOTH, V12, P209
   Canalle LA, 2010, CHEM SOC REV, V39, P329, DOI 10.1039/b807871h
   CHAN WY, 1962, ENDOCRINOLOGY, V71, P977
   Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1
   Chenal M, 2011, POLYM CHEM-UK, V2, P1523, DOI 10.1039/c1py00028d
   CIAMPOLINI M, 1966, INORG CHEM, V5, P41, DOI 10.1021/ic50035a010
   Collins J, 2015, BIOCONJUGATE CHEM, V26, P633, DOI 10.1021/bc5006202
   Dansereau J, 1999, AM J OBSTET GYNECOL, V180, P670, DOI 10.1016/S0002-9378(99)70271-1
   de Araujo AD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4165
   DUVIGNEAUD V, 1954, J AM CHEM SOC, V76, P3115, DOI 10.1021/ja01641a004
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   EMBREY MP, 1965, J ENDOCRINOL, V31, P185, DOI 10.1677/joe.0.0310185
   FERRIER BM, 1965, J BIOL CHEM, V240, P4264
   Filpula David, 2008, Adv Drug Deliv Rev, V60, P29, DOI 10.1016/j.addr.2007.02.001
   [Anonymous], 2002, J OBSTET GYNECOL
   GARMAN AJ, 1987, FEBS LETT, V223, P361, DOI 10.1016/0014-5793(87)80319-8
   Gauthier MA, 2008, CHEM COMMUN, P2591, DOI 10.1039/b719689j
   Gauthier MA, 2011, BIOMACROMOLECULES, V12, P482, DOI 10.1021/bm101272g
   Gong YH, 2015, BIOCONJUGATE CHEM, V26, P1172, DOI 10.1021/bc500611k
   Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1
   Greenwald RB, 2003, BIOCONJUGATE CHEM, V14, P395, DOI 10.1021/bc025652m
   Greenwald RB, 1999, J MED CHEM, V42, P3657, DOI 10.1021/jm990166e
   Hamley IW, 2014, BIOMACROMOLECULES, V15, P1543, DOI 10.1021/bm500246w
   Hawe A, 2009, PHARM RES-DORD, V26, P1679, DOI 10.1007/s11095-009-9878-2
   Heredia KL, 2007, MACROMOLECULES, V40, P4772, DOI 10.1021/ma070432v
   HOPE DB, 1962, J BIOL CHEM, V237, P3146
   HOPE DB, 1962, J BIOL CHEM, V237, P1563
   Jones MW, 2012, J AM CHEM SOC, V134, P7406, DOI 10.1021/ja211855q
   Jones MW, 2012, CHEM COMMUN, V48, P4064, DOI 10.1039/c2cc30259d
   Jones MW, 2012, J AM CHEM SOC, V134, P1847, DOI 10.1021/ja210335f
   Jones MW, 2009, CHEM COMMUN, P5272, DOI 10.1039/b906865a
   Kamigaito M, 2001, CHEM REV, V101, P3689, DOI 10.1021/cr9901182
   Kinstler OB, 1996, PHARMACEUT RES, V13, P996, DOI 10.1023/A:1016042220817
   Kozlowski A, 2001, J CONTROL RELEASE, V72, P217, DOI 10.1016/S0168-3659(01)00277-2
   Kubetzko S, 2005, MOL PHARMACOL, V68, P1439, DOI 10.1124/mol.105.014910
   Lecolley F, 2004, CHEM COMMUN, P2026, DOI 10.1039/b407712a
   Liu YK, 2011, AUST J CHEM, V64, P1602, DOI 10.1071/CH11312
   Lutz JF, 2008, J POLYM SCI POL CHEM, V46, P3459, DOI 10.1002/pola.22706
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Mantovani G, 2005, J AM CHEM SOC, V127, P2966, DOI 10.1021/ja0430999
   Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g
   Maughan KL, 2006, AM FAM PHYSICIAN, V73, P1025
   Moir C, 1939, Proc R Soc Med, V32, P928
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Muttenthaler M, 2010, J MED CHEM, V53, P8585, DOI 10.1021/jm100989w
   Nauka PC, 2016, POLYM CHEM-UK, V7, P2352, DOI 10.1039/c6py00080k
   Nicolas J, 2007, CHEM COMMUN, P1722, DOI 10.1039/b617596a
   Pasut G, 2007, PROG POLYM SCI, V32, P933, DOI 10.1016/j.progpolymsci.2007.05.008
   Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037
   Peleg-Shulman T, 2004, J MED CHEM, V47, P4897, DOI 10.1021/jm0497693
   Percec V, 2006, J AM CHEM SOC, V128, P14156, DOI 10.1021/ja065484z
   Podobnik B, 2015, BIOCONJUGATE CHEM, V26, P452, DOI 10.1021/bc500523t
   Poole RA, 2011, J PHARM SCI-US, V100, P3018, DOI 10.1002/jps.22495
   Roberts MJ, 1998, J PHARM SCI, V87, P1440, DOI 10.1021/js9800634
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Robin MP, 2013, J AM CHEM SOC, V135, P2875, DOI 10.1021/ja3105494
   Rosen BM, 2009, CHEM REV, V109, P5069, DOI 10.1021/cr900024j
   Roth PJ, 2011, MACROMOL RAPID COMM, V32, P1123, DOI 10.1002/marc.201100127
   Ryan SM, 2009, J CONTROL RELEASE, V135, P51, DOI 10.1016/j.jconrel.2008.12.014
   Sayers CT, 2009, SOFT MATTER, V5, P3038, DOI 10.1039/b905335b
   Simula A, 2015, POLYM CHEM-UK, V6, P5940, DOI 10.1039/c5py00887e
   Tao L, 2004, J AM CHEM SOC, V126, P13220, DOI 10.1021/ja0456454
   Thordarson P, 2006, APPL MICROBIOL BIOT, V73, P243, DOI 10.1007/s00253-006-0574-4
   Tsubery H, 2004, J BIOL CHEM, V279, P38118, DOI 10.1074/jbc.M405155200
   Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   VANDONGEN PWJ, 1991, PHARM WEEKBLAD, V13, P238
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   WALTER R, 1971, P NATL ACAD SCI USA, V68, P1355, DOI 10.1073/pnas.68.6.1355
   Wang YS, 2002, ADV DRUG DELIVER REV, V54, P547, DOI 10.1016/S0169-409X(02)00027-3
   Wilson P, 2015, J AM CHEM SOC, V137, P4215, DOI 10.1021/jacs.5b01140
   Wisniewski K, 2014, J MED CHEM, V57, P5306, DOI 10.1021/jm500365s
   Wisniewski K, 2013, BIOPOLYMERS, V100, P408, DOI 10.1002/bip.22260
   Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n
   Zarafshani Z, 2010, BIOMACROMOLECULES, V11, P2130, DOI 10.1021/bm1005036
   Zhao WG, 2015, POLYMER, V66, pA1, DOI 10.1016/j.polymer.2015.03.054
NR 84
TC 0
Z9 0
U1 9
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD AUG
PY 2016
VL 17
IS 8
BP 2755
EP 2766
DI 10.1021/acs.biomac.6b00919
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA DT1HF
UT WOS:000381231600027
PM 27419537
ER

PT J
AU Shah, P
   Hall, R
   Catmur, C
   Bird, G
AF Shah, Punit
   Hall, Richard
   Catmur, Caroline
   Bird, Geoffrey
TI Alexithymia, not autism, is associated with impaired interoception
SO CORTEX
LA English
DT Article
DE Autism; Alexithymia; Interoception; Interoceptive awareness; Body
   awareness
ID SPECTRUM DISORDER; EMOTIONAL AWARENESS; BODY AWARENESS; PERCEPTION;
   OXYTOCIN; SYMPTOMS; INSULA; BRAIN
AB It has been proposed that Autism Spectrum Disorder (ASD) is associated with difficulties perceiving the internal state of one's body (i.e., impaired interoception), causing the socio-emotional deficits which are a diagnostic feature of the condition. However, research indicates that alexithymia - characterized by difficulties in recognizing emotions from internal bodily sensations - is also linked to atypical interoception. Elevated rates of alexithymia in the autistic population have been shown to underpin several socio-emotional impairments thought to be symptomatic of ASD, raising the possibility that interoceptive difficulties in ASD are also due to co-occurring alexithymia. Following this line of inquiry, the present study examined the relative impact of alexithymia and autism on interoceptive accuracy (IA). Across two experiments, it was found that alexithymia, not autism, was associated with atypical interoception. Results indicate that interoceptive impairments should not be considered a feature of ASD, but instead due to co-occurring alexithymia. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Shah, Punit; Hall, Richard; Bird, Geoffrey] Univ London, Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC,Social Genet & Dev Psychiat Ctr, London SE5 8AF, England.
   [Hall, Richard] Birkbeck Coll, Dept Psychol Sci, London, England.
   [Catmur, Caroline] Univ London, Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, London WC1E 7HU, England.
   [Bird, Geoffrey] UCL, Inst Cognit Neurosci, London WC1E 6BT, England.
RP Shah, P; Bird, G (reprint author), Univ London, Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC,Social Genet & Dev Psychiat Ctr, London SE5 8AF, England.
EM punit.shah@kcl.ac.uk; geoff.bird@kcl.ac.uk
OI Shah, Punit/0000-0001-5497-4765; Catmur, Caroline/0000-0001-6996-4295
FU Medical Research Council; Experimental Psychology Society; Baily Thomas
   Charitable Fund "Interoception and Autism Spectrum Disorders"
FX P.S. is supported by a doctoral studentship from the Medical Research
   Council. R.H. was supported by an Undergraduate Bursary from the
   Experimental Psychology Society. G.B. is supported by a grant from the
   Baily Thomas Charitable Fund "Interoception and Autism Spectrum
   Disorders". We thank Aaron Dettner and Adam Skinner for their assistance
   with data collection.
CR Ainley V, 2014, NEUROPSYCHOLOGIA, V60, P21, DOI 10.1016/j.neuropsychologia.2014.05.010
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Barrett LF, 2015, NAT REV NEUROSCI, V16, P419, DOI 10.1038/nrn3950
   Beck AT, 1996, BECK DEPRESSION INVE
   Bird G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.61
   Bird G, 2011, J AUTISM DEV DISORD, V41, P1556, DOI 10.1007/s10803-011-1183-3
   Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060
   Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Clark A, 2013, BEHAV BRAIN SCI, V36, P181, DOI [10.1017/S0140525X12000477, 10.1017/S0140525X12002440]
   Cook R, 2013, PSYCHOL SCI, V24, P723, DOI 10.1177/0956797612463582
   Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176
   Ernst J, 2014, SOC COGN AFFECT NEUR, V9, P857, DOI 10.1093/scan/nst058
   Farb N, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00763
   Fiene L, 2015, AUTISM RES, V8, P709, DOI 10.1002/aur.1486
   Fitzgerald M, 2004, AM J PSYCHIAT, V161, P2134, DOI 10.1176/appi.ajp.161.11.2134
   Foulkes L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121018
   Garfinkel SN, 2016, BIOL PSYCHOL, V114, P117, DOI 10.1016/j.biopsycho.2015.12.003
   Garfinkel SN, 2015, BIOL PSYCHOL, V104, P65, DOI 10.1016/j.biopsycho.2014.11.004
   Happe F., 2008, RES AUTISM SPECTRUM, V2, P447
   Herbert BM, 2011, J PERS, V79, P1149, DOI 10.1111/j.1467-6494.2011.00717.x
   Hill E, 2004, J AUTISM DEV DISORD, V34, P229, DOI 10.1023/B:JADD.0000022613.41399.14
   Kenny L., 2015, AUTISM
   Khalsa SS, 2009, NAT NEUROSCI, V12, P1494, DOI 10.1038/nn.2411
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   Luminet O, 2011, BIOL PSYCHOL, V87, P401, DOI 10.1016/j.biopsycho.2011.05.005
   Paulus MP, 2010, BRAIN STRUCT FUNCT, V214, P451, DOI 10.1007/s00429-010-0258-9
   Quattrocki E, 2014, NEUROSCI BIOBEHAV R, V47, P410, DOI 10.1016/j.neubiorev.2014.09.012
   Ricciardi L, 2015, J NEUROPSYCH CLIN N, V27, P179, DOI 10.1176/appi.neuropsych.14070169
   Ruzich E, 2015, MOL AUTISM, V6, P1, DOI DOI 10.1186/2040-2392-6-2
   Salminen JK, 1999, J PSYCHOSOM RES, V46, P75, DOI 10.1016/S0022-3999(98)00053-1
   Schaefer M, 2014, BIOL PSYCHOL, V101, P69, DOI [10.1016/j.biopsycho.2014.05.012, 10.1016/j.biopsycho.2014.06.012]
   SCHANDRY R, 1981, PSYCHOPHYSIOLOGY, V18, P483, DOI 10.1111/j.1469-8986.1981.tb02486.x
   Schauder KB, 2015, J EXP CHILD PSYCHOL, V131, P193, DOI 10.1016/j.jecp.2014.11.002
   Seth AK, 2013, TRENDS COGN SCI, V17, P565, DOI 10.1016/j.tics.2013.09.007
   Silani G, 2008, SOC NEUROSCI, V3, P97, DOI 10.1080/17470910701577020
   Spielberger C., 1983, MANUAL STATE TRAIT A
   [Anonymous], 2013, NEUROSCIENCE, V18, P442
   [Anonymous], 2005, CURRENT OPINION NEUR
NR 39
TC 7
Z9 7
U1 7
U2 7
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0010-9452
EI 1973-8102
J9 CORTEX
JI Cortex
PD AUG
PY 2016
VL 81
BP 215
EP 220
DI 10.1016/j.cortex.2016.03.021
PG 6
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DT0HH
UT WOS:000381163900019
PM 27253723
ER

PT J
AU Pan, YJ
   Wang, DX
   Yang, J
   He, XL
   Xiao, NM
   Ma, RQ
   Wang, CH
   Lin, BC
AF Pan, Yang-Juan
   Wang, Da-Xin
   Yang, Jun
   He, Xue-Ling
   Xiao, Nai-Min
   Ma, Rui-Qing
   Wang, Chang-Hong
   Lin, Bao-Cheng
TI Oxytocin in hypothalamic supraoptic nucleus is transferred to the
   caudate nucleus to influence pain modulation
SO NEUROPEPTIDES
LA English
DT Article
DE Oxytocin; Pain modulation; Hypothalamic supraoptic nucleus; Caudate
   nucleus; Rat
ID CENTRAL-NERVOUS-SYSTEM; BINDING-SITES; RAT-BRAIN; ACUPUNCTURE ANALGESIA;
   CHOLINERGIC NEURONS; VASOPRESSIN; FOREBRAIN; EXPRESSION; PLASTICITY;
   RELEASE
AB Oxytocin (OXT), which is synthesized and secreted in the hypothalamic supraoptic nucleus (SON), is the most important bioactive substance in SON regulating pain process. Our previous study has pointed that OXT in the caudate nucleus (CdN) plays a role in pain modulation. The communication was designed to investigate the source of OXT in the rat CdN during pain process using the methods of push-pull perfusion and radioimmunoassay. The results showed that (1) pain stimulation increased the OXT concentration in the CdN perfusion liquid; (2) SON cauterization inhibited the increase of OXT concentration in CdN perfusion liquid induced by the pain stimulation, which role in both sides of SON cauterization was stronger than that in one side of SON cauterization; and (3) SON microinjection of L-glutamate sodium, which excited the SON neurons, increased OXT concentration in the CdN perfusion liquid. The data suggested that OXT in the CdN was influenced by SON during pain process, i.e., OXT in the SON might be transferred to the CdN to influence pain modulation. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Wang, Da-Xin; Yang, Jun] Yangzhou Univ, Clin Coll, Jiangsu Su Bei Peoples Hosp, Yangzhou 225001, Jiangsu, Peoples R China.
   [Yang, Jun; He, Xue-Ling] Xinxiang Inst New Med, 219 Muye Rd, Xinxiang 435003, Henan, Peoples R China.
   [Pan, Yang-Juan; Wang, Chang-Hong] Xinxiang Med Univ, Affiliated Hosp 2, Henan Prov Mental Hosp, Xinxiang 453002, Henan, Peoples R China.
   [Xiao, Nai-Min] Xinjiang Hongda Food & Beverage Co Ltd, Xinjiang 043112, Shanxi, Peoples R China.
   [Yang, Jun; Ma, Rui-Qing] Stand Technol Co Ltd, 219 Muye Rd, Xinxiang 435003, Henan, Peoples R China.
   [Lin, Bao-Cheng] Second Mil Med Univ, Dept Neurobiol, Shanghai 200433, Peoples R China.
RP Yang, J (reprint author), Xinxiang Inst New Med, 219 Muye Rd, Xinxiang 435003, Henan, Peoples R China.; Yang, J (reprint author), Stand Technol Co Ltd, 219 Muye Rd, Xinxiang 435003, Henan, Peoples R China.
EM bcd2009@126.com
FU Jiangsu Su Bei People's Hospital, Xinxiang Institute for New Medicine;
   National Natural Science Foundation of China [81241053]
FX This work was supported by Jiangsu Su Bei People's Hospital, Xinxiang
   Institute for New Medicine and the grants from the National Natural
   Science Foundation of China (81241053).
CR ALONSO G, 1986, NEUROSCI LETT, V66, P251, DOI 10.1016/0304-3940(86)90027-3
   ANTUNES JL, 1978, J COMP NEUROL, V181, P539
   Brown DC, 1998, VET SURG, V27, P607
   Burbach JPH, 2001, PHYSIOL REV, V81, P1197
   Cocchi R, 1983, Minerva Med, V74, P969
   CONDESLARA M, 1994, BRAIN RES, V637, P277, DOI 10.1016/0006-8993(94)91245-9
   DEVRIES GJ, 1983, BRAIN RES, V273, P307, DOI 10.1016/0006-8993(83)90855-7
   Dussor GO, 2004, PAIN, V107, P22, DOI 10.1016/j.pain.2003.09.022
   FREUNDMERCIER MJ, 1987, NEUROSCIENCE, V20, P599, DOI 10.1016/0306-4522(87)90113-8
   Hagelberg N, 2002, PAIN, V99, P273, DOI 10.1016/S0304-3959(02)00121-5
   Hatton GI, 2004, PEPTIDES, V25, P403, DOI 10.1016/j.peptides.2003.12.001
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lin B.C., 1979, CHINESE SCI BULL, V17, P813
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   Maeda L, 2011, J ANESTH, V25, P523, DOI 10.1007/s00540-011-1173-9
   McEwen B.B., 2004, ROLE VASOPRESSIN OXY
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Nusbaum F, 2011, INT J CLIN EXP HYP, V59, P27, DOI 10.1080/00207144.2011.522874
   Oda Y, 2000, HISTOL HISTOPATHOL, V15, P825
   OH JD, 1992, NEUROSCIENCE, V47, P807, DOI 10.1016/0306-4522(92)90031-V
   Pellegrino L, 1979, STEREOTAXIC ATLAS RA
   QuinonesJenab V, 1997, NEUROENDOCRINOLOGY, V65, P9, DOI 10.1159/000127160
   Rabhi M, 1999, BRAIN RES BULL, V48, P147, DOI 10.1016/S0361-9230(98)00158-0
   Robinson MB, 2006, HANDB EXP PHARM, V175, P251
   SARNYAI Z, 1991, NEUROPEPTIDES, V19, P51, DOI 10.1016/0143-4179(91)90073-R
   SUZUKI T, 1991, NEUROSCI RES, V11, P71, DOI 10.1016/0168-0102(91)90068-A
   SWANSON LW, 1981, J COMP NEUROL, V196, P271, DOI 10.1002/cne.901960207
   Tasker JG, 2002, PROG BRAIN RES, V139, P113
   Theodosis DT, 2002, FRONT NEUROENDOCRIN, V23, P101, DOI 10.1006/frne.2001.0226
   Uvnas-Moberg K, 1998, PEDIATR RES, V43, P344
   Vellucci SV, 1997, NEUROPEPTIDES, V31, P431, DOI 10.1016/S0143-4179(97)90036-6
   Wang YL, 2013, NEUROPEPTIDES, V47, P93, DOI 10.1016/j.npep.2012.12.003
   Weng N.Q., 1988, PAIN AND ANALGESIA
   Wunderlich A.P., 2001, OPEN NEUROIMAGING J, V5, P1
   Xu G, 1993, Zhen Ci Yan Jiu, V18, P1
   YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
   Yang J, 2008, LIFE SCI, V82, P166, DOI 10.1016/j.lfs.2007.10.023
   Yang J, 2007, PEPTIDES, V28, P1113, DOI 10.1016/j.peptides.2007.03.003
   Yang J, 2007, NEUROPEPTIDES, V41, P285, DOI 10.1016/j.npep.2007.05.004
   Yang J, 2011, PEPTIDES, V32, P2104, DOI 10.1016/j.peptides.2011.08.021
   YETERIAN EH, 1995, J COMP NEUROL, V352, P436, DOI 10.1002/cne.903520309
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 44
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4179
EI 1532-2785
J9 NEUROPEPTIDES
JI Neuropeptides
PD AUG
PY 2016
VL 58
BP 61
EP 65
DI 10.1016/j.npep.2016.03.003
PG 5
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DU7SI
UT WOS:000382414500008
PM 27045802
ER

PT J
AU Minhas, S
   Liu, C
   Galdamez, J
   So, VM
   Romeo, RD
AF Minhas, Sumeet
   Liu, Clarissa
   Galdamez, Josselyn
   So, Veronica M.
   Romeo, Russell D.
TI Stress-induced oxytocin release and oxytocin cell number and size in
   prepubertal and adult male and female rats
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT 3rd Biennial Meeting of the
   North-American-Society-for-Comparative-Endocrinology (NASCE)
CY JUN 21-25, 2015
CL Univ Ottawa, Ottawa, CANADA
SP N Amer Soc Comparat Endocrinol, Univ Ottawa, Off Vice President Res, Univ Ottawa, Fac Sci, Univ Ottawa, Fac Social Sci, Univ Ottawa, Dept Biol, Univ Ottawa, Sch Psychol
HO Univ Ottawa
DE Adolescence; HPA axis; PVN; Sex differences; SON
ID HYPOTHALAMIC SUPRAOPTIC NUCLEUS; PITUITARY-ADRENAL AXIS;
   SEXUAL-DIMORPHISM; NEUROENDOCRINE RESPONSES; GLUCOCORTICOID-RECEPTOR;
   PUBERTAL MATURATION; PERIPHERAL RELEASE; MESSENGER-RNA; VASOPRESSIN;
   SECRETION
AB Studies indicate that adolescent exposure to stress is a potent environmental factor that contributes to psychological and physiological disorders, though the mechanisms that mediate these dysfunctions are not well understood. Periadolescent animals display greater stress-induced hypothalamic-pituitary-adrenal (HPA) axis responses than adults, which may contribute to these vulnerabilities. In addition to the HPA axis, the hypothalamo-neurohypophyseal tract (HNT) is also activated in response to stress. In adults, stress activates this system resulting in secretion of oxytocin from neurons in the supraoptic (SON) and paraventricular (PVN) nuclei. However, it is currently unknown whether a similar or different response occurs in prepubertal animals. Given the influence of these hormones on a variety of emotional behaviors and physiological systems known to change as an animal transitions into adulthood, we investigated stress-induced HPA and HNT hormonal responses before and after stress, as well as the number and size of oxytocin-containing cells in the SON and PVN of prepubertal (30d) and adult (70d) male and female rats. Though we found the well-established protracted adrenocorticotropic hormone and corticosterone response in prepubertal males and females, only adult males and prepubertal females showed a significant stress induced increase in plasma oxytocin levels. Moreover, though we found no pubertal changes in the number of oxytocin cells, we did find a pubertal-related increase in oxytocin somal size in both the SON and PVN of males and females. Taken together, these data indicate that neuroendocrine systems can show different patterns of stress reactivity before and after adolescent development and that these responses can be further modified by sex. Given the impact of these hormones on a variety of systems, it will be imperative to further explore these changes in hormonal stress reactivity and their role in adolescent health. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Romeo, Russell D.] Columbia Univ Barnard Coll, Dept Psychol, New York, NY 10027 USA.
   Columbia Univ Barnard Coll, Neurosci & Behav Program, New York, NY 10027 USA.
RP Romeo, RD (reprint author), Columbia Univ Barnard Coll, Dept Psychol, New York, NY 10027 USA.
EM rromeo@barnard.edu
CR Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8
   Benarroch EE, 2013, NEUROLOGY, V80, P1521, DOI 10.1212/WNL.0b013e31828cfb15
   Bulbul M, 2011, BRAIN RES, V1387, P39, DOI 10.1016/j.brainres.2011.02.091
   CARTER DA, 1987, BRAIN RES, V406, P313, DOI 10.1016/0006-8993(87)90798-0
   CARTER DA, 1986, NEUROSCI LETT, V71, P252, DOI 10.1016/0304-3940(86)90568-9
   CHIBBAR R, 1990, MOL ENDOCRINOL, V4, P2030
   Dahl RE, 2009, DEV PSYCHOPATHOL, V21, P1, DOI 10.1017/S0954579409000017
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Douglas AJ, 2000, J NEUROENDOCRINOL, V12, P343
   Eiland L, 2013, NEUROSCIENCE, V249, P162, DOI 10.1016/j.neuroscience.2012.10.048
   Engelmann M, 1999, J NEUROENDOCRINOL, V11, P867
   Flak JN, 2011, PHYSIOL BEHAV, V104, P228, DOI 10.1016/j.physbeh.2011.03.002
   Foilb AR, 2011, J ENDOCRINOL, V210, P391, DOI 10.1530/JOE-11-0206
   Frazier CJ, 2013, ENDOCRINOLOGY, V154, P2457, DOI 10.1210/en.2013-1049
   GIBBS DM, 1984, LIFE SCI, V35, P487, DOI 10.1016/0024-3205(84)90241-8
   GIBBS DM, 1984, LIFE SCI, V34, P2245, DOI 10.1016/0024-3205(84)90212-1
   HASHIMOTO K, 1989, ACTA MED OKAYAMA, V43, P161
   Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001
   Jezova D, 1995, ANN NY ACAD SCI, V771, P192, DOI 10.1111/j.1749-6632.1995.tb44681.x
   KADEKARO M, 1995, AM J PHYSIOL-REG I, V268, pR651
   KISS A, 1994, BRAIN RES, V663, P84, DOI 10.1016/0006-8993(94)90465-0
   KISS JZ, 1988, ENDOCRINOLOGY, V122, P444
   Klein ZA, 2010, DEV PSYCHOBIOL, V52, P62, DOI 10.1002/dev.20413
   Laguna-Abreu MTC, 2005, HORM METAB RES, V37, P84, DOI 10.1055/s-2005-861159
   Lin SH, 1996, ZOOL SCI, V13, P161, DOI 10.2108/zsj.13.161
   Lui P, 2012, PHYSIOL BEHAV, V107, P104, DOI 10.1016/j.physbeh.2012.06.011
   McCormick CM, 2013, NEUROSCIENCE, V249, P242, DOI 10.1016/j.neuroscience.2012.08.063
   McCormick CM, 2007, PHARMACOL BIOCHEM BE, V86, P220, DOI 10.1016/j.pbb.2006.07.012
   McCormick CM, 2010, BRAIN COGNITION, V72, P73, DOI 10.1016/j.bandc.2009.06.003
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   MILLER FD, 1989, P NATL ACAD SCI USA, V86, P2468, DOI 10.1073/pnas.86.7.2468
   Morimoto M, 1996, NEUROSCI RES, V26, P235, DOI 10.1016/S0168-0102(96)01105-4
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   ONAKA T, 1988, NEUROSCI RES, V6, P143, DOI 10.1016/0168-0102(88)90016-8
   Ondrejcakova M, 2010, STRESS, V13, P315, DOI 10.3109/10253891003596822
   Paxinos G., 2005, RAT BRAIN STEREOTAXI
   Raymond AD, 2006, BRAIN RES, V1102, P44, DOI 10.1016/j.brainres.2006.04.113
   Romeo RD, 2006, ENDOCRINOLOGY, V147, P1664, DOI 10.1210/en.2005-1432
   Romeo RD, 2005, VITAM HORM, V71, P1, DOI 10.1016/S0083-6729(05)71001-3
   Romeo RD, 2004, NEUROENDOCRINOLOGY, V80, P387, DOI 10.1159/000084203
   Romeo RD, 2004, NEUROENDOCRINOLOGY, V79, P125, DOI 10.1159/000077270
   Romeo RD, 2006, HORM BEHAV, V50, P463, DOI 10.1016/j.yhbeh.2006.06.002
   Romeo RD, 2010, FRONT NEUROENDOCRIN, V31, P232, DOI 10.1016/j.yfrne.2010.02.004
   Romeo RD, 2010, DEV PSYCHOBIOL, V52, P244, DOI 10.1002/dev.20437
   Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647
   WILLIAMS TDM, 1985, ENDOCRINOLOGY, V116, P738
   Wotjak CT, 1998, NEUROSCIENCE, V85, P1209, DOI 10.1016/S0306-4522(97)00683-0
   Yoshida M, 2014, ENDOCRINOLOGY, V155, P2996, DOI 10.1210/en.2013-1411
   Zhang B, 2001, J NEUROENDOCRINOL, V13, P29, DOI 10.1046/j.1365-2826.2001.00593.x
   Zheng J, 2010, AM J PHYSIOL-GASTR L, V299, pG946, DOI 10.1152/ajpgi.00483.2009
NR 50
TC 0
Z9 0
U1 3
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0016-6480
EI 1095-6840
J9 GEN COMP ENDOCR
JI Gen. Comp. Endocrinol.
PD AUG 1
PY 2016
VL 234
BP 103
EP 109
DI 10.1016/j.ygcen.2016.03.014
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DU3FL
UT WOS:000382096100013
PM 26972154
ER

PT J
AU Korb, S
   Malsert, J
   Strathearn, L
   Vuilleumier, P
   Niedenthal, P
AF Korb, Sebastian
   Malsert, Jennifer
   Strathearn, Lane
   Vuilleumier, Patrik
   Niedenthal, Paula
TI Sniff and mimic - Intranasal oxytocin increases facial mimicry in a
   sample of men
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Facial mimicry; Oxytocin; Facial expressions; Facial feedback;
   Caregiving
ID AUTISM SPECTRUM DISORDERS; HIGH-FUNCTIONING AUTISM; RANDOMIZED
   CONTROLLED-TRIAL; EMOTION RECOGNITION; SOCIAL-BEHAVIOR; HUMAN BRAIN;
   ADMINISTERED OXYTOCIN; ASPERGER-SYNDROME; EXPRESSIONS; HUMANS
AB The neuropeptide oxytocin (OT) has many potential social benefits. For example, intranasal administration of OT appears to trigger caregiving behavior and to improve the recognition of emotional facial expressions. But the mechanism for these effects is not yet clear. Recent findings relating OT to action imitation and to the visual processing of the eye region of faces point to mimicry as a mechanism through which OT improves processing of emotional expression. To test the hypothesis that increased levels of OT in the brain enhance facial mimicry, 60 healthy male participants were administered, in a double-blind between-subjects design, 24 international units (IUs) of OT or placebo (PIA) through nasal spray. Facial mimicry and emotion judgments were recorded in response to movie clips depicting changing facial expressions. As expected, facial mimicry was increased in the OT group, but effects were strongest for angry infant faces. These findings provide further evidence for the importance of OT in social cognitive skills, and suggest that facial mimicry mediates the effects of OT on improved emotion recognition. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Korb, Sebastian; Malsert, Jennifer] Swiss Ctr Affect Sci, Campus Biotech,9 Chemin Mines, CH-1202 Geneva, Switzerland.
   [Malsert, Jennifer] Univ Geneva, Dept Psychol, 40 Bd Pont dArve, CH-1205 Geneva, Switzerland.
   [Strathearn, Lane] Univ Iowa, Stead Family Dept Pediat, 213F CDD Ctr Disabilities & Dev,100 Hawkins Dr, Iowa City, IA 52246 USA.
   [Vuilleumier, Patrik] Univ Geneva, Dept Fundamental Neurosci, 1 Rue Michel Servet, CH-1205 Geneva, Switzerland.
   [Korb, Sebastian; Niedenthal, Paula] Univ Wisconsin, Dept Psychol, 1202 West Johnson St, Madison, WI 53706 USA.
RP Korb, S (reprint author), Int Sch Adv Studies SISSA, Neurosci Area, Via Bonomea 265, I-34136 Trieste, Italy.
EM skorb@sissa.it; Jennifer.Malsert@unige.ch; lane-strathearn@uiowa.edu;
   Patrik.Vuilleumier@unige.ch; niedenthal@wisc.edu
RI Korb, Sebastian/A-6294-2016
OI Korb, Sebastian/0000-0002-3517-3783
FU Early Postdoc Mobility scholarship by the Swiss National Science
   Foundation [PBGEP1-139870]; National Science Foundation [BCS-1251101];
   Open Research Area (ORA) [ANR-10-ORAR-010-01]
FX Sebastian Korb was partly supported by an Early Postdoc Mobility
   scholarship by the Swiss National Science Foundation (PBGEP1-139870).
   Paula Niedenthal was supported by a grant (BCS-1251101) from the
   National Science Foundation and by a grant from Open Research Area (ORA)
   (ANR-10-ORAR-010-01) in Europe for the Social Sciences
   (ANR-DFG-ESRC-NOW).
CR Achaibou A, 2008, NEUROPSYCHOLOGIA, V46, P1104, DOI 10.1016/j.neuropsychologia.2007.10.019
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00
   Barsalou LW, 2008, ANNU REV PSYCHOL, V59, P617, DOI 10.1146/annurev.psych.59.103006.093639
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bates D., 2014, J STAT SOFTWAR UNPUB, DOI DOI 10.18637/JSS.V067.I01
   Beall PM, 2008, J EXP CHILD PSYCHOL, V101, P206, DOI 10.1016/j.jecp.2008.04.004
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Campbell A, 2014, NEUROBIOL AGING, V35, P2246, DOI 10.1016/j.neurobiolaging.2014.04.021
   Campbell A, 2008, BIOL PSYCHOL, V77, P1, DOI 10.1016/j.biopsycho.2007.09.001
   Cannon PR, 2009, COGNITION EMOTION, V23, P918, DOI 10.1080/02699930802234864
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dalton KM, 2005, NAT NEUROSCI, V8, P519, DOI 10.1038/nn1421
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   De Coster L, 2014, PSYCHONEUROENDOCRINO, V50, P220, DOI 10.1016/j.psyneuen.2014.08.021
   de Wied M, 2006, J PSYCHIAT RES, V40, P112, DOI 10.1016/j.jpsychires.2005.08.003
   Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009
   Development Core Team R., 2008, R LANG ENV STAT COMP
   DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dunbar RIM, 1998, EVOL ANTHROPOL, V6, P178, DOI 10.1002/(SICI)1520-6505(1998)6:5<178::AID-EVAN5>3.0.CO;2-8
   EKMAN P, 1983, SCIENCE, V221, P1208, DOI 10.1126/science.6612338
   Ekman P., 2005, WHAT FACE REVEALS
   Evans S, 2010, NEUROPSYCHOPHARMACOL, V35, P2502, DOI 10.1038/npp.2010.110
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   FIELD TM, 1982, SCIENCE, V218, P179, DOI 10.1126/science.7123230
   Fischer-Shofty M, 2010, NEUROPSYCHOLOGIA, V48, P179, DOI 10.1016/j.neuropsychologia.2009.09.003
   Flack WF, 2006, COGNITION EMOTION, V20, P177, DOI 10.1080/02699930500359617
   Freeman S. M., 2016, SOC NEUROSCI, P1
   Fridlund A. J., 1986, J PSYCHOPHYSIOL, V23, P567, DOI DOI 10.1111/J.1469-8986.1986.TB00676.X
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Glocker ML, 2009, P NATL ACAD SCI USA, V106, P9115, DOI 10.1073/pnas.0811620106
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Halberstadt JB, 2001, J PERS SOC PSYCHOL, V81, P587, DOI 10.1037//0022-3514.81.4.587
   Hatfield E., 1993, CURRENT DIRECTIONS P, V2, P96, DOI DOI 10.1111/1467-8721.EP10770953
   HELLER H, 1949, J PHYSIOL-LONDON, V109, P162
   Hennenlotter A, 2009, CEREB CORTEX, V19, P537, DOI 10.1093/cercor/bhn104
   Hermans EJ, 2006, PSYCHONEUROENDOCRINO, V31, P859, DOI 10.1016/j.psyneuen.2006.04.002
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Judd CM, 2012, J PERS SOC PSYCHOL, V103, P54, DOI 10.1037/a0028347
   Kim S, 2014, BRAIN RES, V1580, P133, DOI 10.1016/j.brainres.2013.10.050
   Korb S., 2009, OXFORD COMPANION EMO, P173
   Korb S, 2015, CORTEX, V70, P101, DOI 10.1016/j.cortex.2015.06.025
   Korb S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099194
   Korb S, 2010, BIOL PSYCHOL, V85, P347, DOI 10.1016/j.biopsycho.2010.07.012
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Likowski KU, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00214
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Liu N, 2015, P NATL ACAD SCI USA, V112, pE3123, DOI 10.1073/pnas.1508097112
   LOUP F, 1989, BRAIN RES, V500, P223, DOI 10.1016/0006-8993(89)90317-X
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Maringer M, 2011, EMOTION, V11, P181, DOI 10.1037/a0022596
   Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4
   Mathersul D., 2013, BIOL PSYCHOL
   McIntosh DN, 2006, DEVELOPMENTAL SCI, V9, P295, DOI 10.1111/j.1467-7687.2006.00492.x
   MELTZOFF AN, 1977, SCIENCE, V198, P75, DOI 10.1126/science.198.4312.75
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mitchell IJ, 2015, NEUROSCI BIOBEHAV R, V55, P98, DOI 10.1016/j.neubiorev.2015.04.018
   Naber FBA, 2013, J AUTISM DEV DISORD, V43, P224, DOI 10.1007/s10803-012-1536-6
   Ne'eman R, 2016, HORM BEHAV, V80, P125, DOI 10.1016/j.yhbeh.2016.01.015
   Neufeld J., 2015, AUTISM RES
   Niedenthal PM, 2010, BEHAV BRAIN SCI, V33, P417, DOI 10.1017/S0140525X10000865
   Niedenthal PM, 2001, COGNITION EMOTION, V15, P853
   Oberman LM, 2007, SOC NEUROSCI, V2, P167, DOI 10.1080/17470910701391943
   Oberman LM, 2009, DEVELOPMENTAL SCI, V12, P510, DOI 10.1111/j.1467-7687.2008.00796.x
   Oostenbroek J, 2016, CURR BIOL, V26, P1334, DOI 10.1016/j.cub.2016.03.047
   Oster H., 2005, EMOTIONAL DEV, P261
   Paloyelis Y., 2014, BIOL PSYCHIAT
   Quintana DS, 2015, NEUROSCI BIOBEHAV R, V49, P182, DOI 10.1016/j.neubiorev.2014.12.011
   RINN WE, 1984, PSYCHOL BULL, V95, P52, DOI 10.1037/0033-2909.95.1.52
   Rump KM, 2009, CHILD DEV, V80, P1434, DOI 10.1111/j.1467-8624.2009.01343.x
   Rutherford MD, 2007, VISION RES, V47, P2099, DOI 10.1016/j.visres.2007.01.029
   Rychlowska M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090876
   Schrammel F, 2009, PSYCHOPHYSIOLOGY, V46, P922, DOI 10.1111/j.1469-8986.2009.00831.x
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   Seibt B, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01122
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Simpson EA, 2014, P NATL ACAD SCI USA, V111, P6922, DOI 10.1073/pnas.1402471111
   Stel M, 2008, PSYCHOL SCI, V19, P984, DOI 10.1111/j.1467-9280.2008.02188.x
   Strathearn L, 2011, J NEUROENDOCRINOL, V23, P1054, DOI 10.1111/j.1365-2826.2011.02228.x
   Strathearn L, 2008, PEDIATRICS, V122, P40, DOI 10.1542/peds.2007-1566
   Strathearn L, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00176
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Sullivan MW, 2003, DEV PSYCHOL, V39, P693, DOI 10.1037/0012-1649.39.4.693
   Tamietto M, 2009, P NATL ACAD SCI USA, V106, P17661, DOI 10.1073/pnas.0908994106
   TASSINARY LG, 1992, PSYCHOL SCI, V3, P28, DOI 10.1111/j.1467-9280.1992.tb00252.x
   Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6
   Tracy JL, 2011, J AUTISM DEV DISORD, V41, P102, DOI 10.1007/s10803-010-1030-y
   van IJzendoorn MH, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00174
   van Ijzendoorn MH, 2012, PSYCHONEUROENDOCRINO, V37, P438, DOI 10.1016/j.psyneuen.2011.07.008
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Vuilleumier P, 2005, TRENDS COGN SCI, V9, P585, DOI 10.1016/j.tics.2005.10.011
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Weisman O, 2014, PROG NEURO-PSYCHOPH, V49, P47, DOI 10.1016/j.pnpbp.2013.11.006
   Wood A., 2015, PSYCHON B REV
   Wood A, 2016, TRENDS COGN SCI, V20, P227, DOI 10.1016/j.tics.2015.12.010
   Young KA, 2008, COMP BIOCHEM PHYS C, V148, P401, DOI 10.1016/j.cbpc.2008.02.004
NR 111
TC 1
Z9 1
U1 9
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD AUG
PY 2016
VL 84
BP 64
EP 74
DI 10.1016/j.yhbeh.2016.06.003
PG 11
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DU7TJ
UT WOS:000382417200008
PM 27283377
ER

PT J
AU Roney, JR
AF Roney, James R.
TI Theoretical frameworks for human behavioral endocrinology
SO HORMONES AND BEHAVIOR
LA English
DT Review
DE Human endocrinology; Testosterone; Oxytocin; Estradiol; Progesterone
ID NATURAL MENSTRUAL CYCLES; FEMALE SEXUAL-BEHAVIOR; OVARIAN-FUNCTION;
   TESTOSTERONE LEVELS; HORMONAL PREDICTORS; RHESUS-MONKEYS; LACTATIONAL
   AMENORRHEA; SALIVARY TESTOSTERONE; BODY-COMPOSITION; SOCIAL-BEHAVIOR
AB How can we best discover the ultimate, evolved functions of endocrine signals within the field of human behavioral endocrinology? Two related premises will guide my proposed answer. First, hormones typically have multiple, simultaneous effects distributed throughout the brain and body, such that in an abstract sense their prototypical function is the coordination of diverse outcomes. Second, coordinated output effects are often evolved, functional responses to specific eliciting conditions that cause increases or decreases in the relevant hormones. If we accept these premises, then a natural way to study hormones is to hypothesize and test how multiple eliciting conditions are mapped into coordinated output effects via hormonal signals. I will call these input output mappings "theoretical frameworks." As examples, partial theoretical frameworks for gonadal hormones will be proposed, focusing on the signaling roles of testosterone in men and on estradiol and progesterone in women. Recent research on oxytocin in humans will also be considered as an example in which application of the theoretical framework approach could be especially helpful in making functional sense of the diverse array of findings associated with this hormone. The theoretical framework approach is not especially common in the current literature, with many theories having eschewed explicit consideration of input output mappings in favor of parsimony-based arguments that attempt to find the one main thing that a hormone does with respect to psychology or behavior. I will argue that these parsimony-based models have many shortcomings, and conclude that the construction and testing of theoretical frameworks provides a better means of discovering the evolved functions of human endocrine signals. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Roney, James R.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA.
RP Roney, JR (reprint author), Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA.
EM roney@psych.ucsb.edu
FU National Science Foundation [BCS-1349023]
FX I thank James Higham, Aaron Lukaszewski, and Kim Wallen for comments on
   a previous version of this manuscript, and John Tooby for helpful
   discussion of issues related to the main themes of the article. This
   material is based upon work supported by the National Science Foundation
   under Grant Number BCS-1349023.
CR Adkins-Regan E., 2005, HORMONES ANIMAL SOCI
   Alexander JL, 2004, MENOPAUSE, V11, P749, DOI 10.1097/01.GME.0000142887.31811.97
   Alonso-Alvarez C, 2007, BIOLOGY LETT, V3, P271, DOI 10.1098/rsbl.2007.0020
   Alvarado LC, 2015, AM J PHYS ANTHROPOL, V158, P19, DOI 10.1002/ajpa.22771
   Alvergne A, 2009, HORM BEHAV, V56, P491, DOI 10.1016/j.yhbeh.2009.07.013
   Andersson M., 1994, SEXUAL SELECTION
   Archer J, 2006, NEUROSCI BIOBEHAV R, V30, P319, DOI 10.1016/j.neubiorev.2004.12.007
   Arslanian S, 1997, J CLIN ENDOCR METAB, V82, P3213, DOI 10.1210/jc.82.10.3213
   Asarian L, 2006, PHILOS T R SOC B, V361, P1251, DOI 10.1098/rstb.2006.1860
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   BEACH FA, 1974, BIOL REPROD, V10, P2, DOI 10.1095/biolreprod10.1.2
   BEACH FA, 1976, HORM BEHAV, V7, P105, DOI 10.1016/0018-506X(76)90008-8
   Beall AT, 2013, PSYCHOL SCI, V24, P1837, DOI 10.1177/0956797613476045
   Bentley GR, 1998, EUR J CLIN NUTR, V52, P261, DOI 10.1038/sj.ejcn.1600547
   Bhasin S., 2001, AM J PHYSIOL-ENDOC M, V281
   BIELERT C, 1983, PHYSIOL BEHAV, V30, P103, DOI 10.1016/0031-9384(83)90045-8
   Blaustein JD, 2008, ANNU REV PSYCHOL, V59, P93, DOI 10.1146/annurev.psych.59.103006.093556
   BOOTH A, 1993, STEROIDS, V58, P348, DOI 10.1016/0039-128X(93)90036-M
   Booth A, 2006, SOC FORCES, V85, P167, DOI 10.1353/sof.2006.0116
   Bosch O.J., 2013, PHILOS T R SOC B, V368
   Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008
   BREEDLOVE S M, 1992, P39
   Bribiescas RG, 2001, YEARB PHYS ANTHROPOL, V44, P148, DOI 10.1002/ajpa.10025
   BUFFENSTEIN R, 1995, PHYSIOL BEHAV, V58, P1067, DOI 10.1016/0031-9384(95)02003-9
   BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103
   BUSS DM, 1989, BEHAV BRAIN SCI, V12, P1
   Campbell B, 2003, AM J HUM BIOL, V15, P697, DOI 10.1002/ajhb.10203
   Cappelletti M, 2016, HORM BEHAV, V78, P178, DOI 10.1016/j.yhbeh.2015.11.003
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   Carre JM, 2015, NEUROSCIENCE, V286, P171, DOI 10.1016/j.neuroscience.2014.11.029
   Carre JM, 2013, PSYCHONEUROENDOCRINO, V38, P2034, DOI 10.1016/j.psyneuen.2013.03.008
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carter CS, 1997, ANN NY ACAD SCI, V807, P164, DOI 10.1111/j.1749-6632.1997.tb51918.x
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   COLLAER ML, 1995, PSYCHOL BULL, V118, P55, DOI 10.1037//0033-2909.118.1.55
   Cook CJ, 2012, HORM BEHAV, V61, P17, DOI 10.1016/j.yhbeh.2011.09.006
   Crespi BJ, 2016, BIOL REV, V91, P390, DOI 10.1111/brv.12175
   Crockford C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00068
   CUNNINGHAM ET, 1991, TRENDS NEUROSCI, V14, P406, DOI 10.1016/0166-2236(91)90032-P
   CZAJA JA, 1975, HORM BEHAV, V6, P329, DOI 10.1016/0018-506X(75)90003-3
   Daly M., 1983, SEX EVOLUTION BEHAV
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   DENNERSTEIN L, 1994, PSYCHONEUROENDOCRINO, V19, P293, DOI 10.1016/0306-4530(94)90067-1
   Dennerstein L, 2005, FERTIL STERIL, V84, P174, DOI 10.1016/j.fernstert.2005.01.119
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Durante KM, 2008, PERS SOC PSYCHOL B, V34, P1451, DOI 10.1177/0146167208323103
   Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607
   Eisenbruch AB, 2015, PSYCHOL SCI, V26, P1332, DOI 10.1177/0956797615586403
   Eisenegger C, 2011, TRENDS COGN SCI, V15, P263, DOI 10.1016/j.tics.2011.04.008
   Elliot AJ, 2008, J PERS SOC PSYCHOL, V95, P1150, DOI 10.1037/0022-3514.95.5.1150
   Ellison PT, 2007, AM J PHYS ANTHROPOL, V134, P513, DOI 10.1002/ajpa.20698
   Ellison PT, 2003, FERTIL STERIL, V80, P1279, DOI 10.1016/S0015-0282(03)02158-7
   ELLISON PT, 1989, AM J PHYS ANTHROPOL, V78, P519, DOI 10.1002/ajpa.1330780407
   ELLISON PT, 1985, NEW ENGL J MED, V313, P825
   ELLISON PT, 1994, ANN NY ACAD SCI, V709, P287, DOI 10.1111/j.1749-6632.1994.tb30417.x
   Ellison P.T., 2001, FERTILE GROUND
   Ellison P.T., 2009, ENDOCRINOLOGY SOCIAL, P54
   Engelmann M, 2004, FRONT NEUROENDOCRIN, V25, P132, DOI 10.1016/j.yfrne.2004.09.001
   Evans Matthew R., 2010, Open Ornithology Journal, V3, P21
   Fessler DMT, 2003, Q REV BIOL, V78, P3, DOI 10.1086/367579
   Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168
   Flinn MV, 2012, HUM NATURE-INT BIOS, V23, P68, DOI 10.1007/s12110-012-9135-y
   FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346
   Gettler LT, 2014, EVOL ANTHROPOL, V23, P146, DOI 10.1002/evan.21412
   Gettler LT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041559
   Gettler LT, 2011, P NATL ACAD SCI USA, V108, P16194, DOI 10.1073/pnas.1105403108
   Gettler LT, 2010, AM J PHYS ANTHROPOL, V142, P590, DOI 10.1002/ajpa.21282
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goetz SMM, 2014, BIOL PSYCHIAT, V76, P324, DOI 10.1016/j.biopsych.2014.01.016
   Gray PB, 2003, AM J PHYS ANTHROPOL, V122, P279, DOI 10.1002/ajpa.10293
   Gray P. B., 2009, ENDOCRINOLOGY SOCIAL, P270
   Gray PB, 2007, CURR ANTHROPOL, V48, P750, DOI 10.1086/522061
   Grillon C, 2013, MOL PSYCHIATR, V18, P958, DOI 10.1038/mp.2012.156
   Hall J. E., 2004, YEN JAFFES REPROD EN, P195
   Halpern CT, 1998, ARCH SEX BEHAV, V27, P445, DOI 10.1023/A:1018700529128
   Haselton MG, 2007, HORM BEHAV, V51, P40, DOI 10.1016/j.yhbeh.2006.07.007
   Haselton MG, 2011, CURR DIR PSYCHOL SCI, V61, P157
   HEGNER RE, 1987, AUK, V104, P462
   Hermans EJ, 2006, BIOL PSYCHIAT, V59, P872, DOI 10.1016/j.biopsych.2005.11.015
   Hill AK, 2013, EVOL HUM BEHAV, V34, P334, DOI 10.1016/j.evolhumbehav.2013.05.004
   Jasienska G, 1998, P ROY SOC B-BIOL SCI, V265, P1847, DOI 10.1098/rspb.1998.0511
   KEMNITZ JW, 1989, HORM BEHAV, V23, P235, DOI 10.1016/0018-506X(89)90064-0
   KENDRICK KM, 1985, PHYSIOL BEHAV, V34, P123, DOI 10.1016/0031-9384(85)90089-7
   KETTERSON ED, 1992, AM NAT, V140, pS33, DOI 10.1086/285396
   Kimura D., 2000, SEX COGNITION
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   KONISHI M, 1989, NEURON, V3, P541, DOI 10.1016/0896-6273(89)90264-X
   LAGER C, 1990, AM J HUM BIOL, V2, P303, DOI 10.1002/ajhb.1310020312
   Lassek WD, 2009, EVOL HUM BEHAV, V30, P322, DOI 10.1016/j.evolhumbehav.2009.04.002
   Lessey B.A., 2014, YEN JAFFES REPROD EN, P157
   Li NP, 2002, J PERS SOC PSYCHOL, V82, P947, DOI 10.1037//0022-3514.82.6.947
   Lipson SF, 1996, HUM REPROD, V11, P2090
   LUNN PG, 1981, LANCET, V1, P1428
   Marlowe FW, 1999, BEHAV ECOL SOCIOBIOL, V46, P57, DOI 10.1007/s002650050592
   Mazur A, 1998, SOC FORCES, V77, P315, DOI 10.2307/3006019
   Mazur A, 1998, BEHAV BRAIN SCI, V21, P353
   Mazur A., 2016, HORM BEHAV
   McClintock MK, 1996, DEV PSYCHOL SCI, V5, P178
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McIntyre M, 2006, J PERS SOC PSYCHOL, V91, P642, DOI 10.1037/0022-3514.91.4.642
   MEANEY MJ, 1986, BRAIN RES, V398, P324, DOI 10.1016/0006-8993(86)91492-7
   Mehta PH, 2006, HORM BEHAV, V50, P684, DOI 10.1016/j.yhbeh.2006.07.001
   Mehta PH, 2010, HORM BEHAV, V58, P898, DOI 10.1016/j.yhbeh.2010.08.020
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   MORRIS NM, 1987, ARCH SEX BEHAV, V16, P27, DOI 10.1007/BF01541839
   Muehlenbein MP, 2005, AM J HUM BIOL, V17, P527, DOI 10.1002/ajhb.20419
   Muehlenbein MP, 2005, AM J TROP MED HYG, V73, P178
   Muller MN, 2009, P R SOC B, V276, P347, DOI 10.1098/rspb.2008.1028
   Nave G, 2015, PERSPECT PSYCHOL SCI, V10, P772, DOI 10.1177/1745691615600138
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   PANTERBRICK C, 1994, ANN NY ACAD SCI, V709, P234, DOI 10.1111/j.1749-6632.1994.tb30412.x
   PERSKY H, 1978, PSYCHOSOM MED, V40, P523
   PERSKY H, 1978, ARCH SEX BEHAV, V7, P157, DOI 10.1007/BF01542376
   Peters M, 2008, ANIM BEHAV, V76, P297, DOI 10.1016/j.anbehav.2008.02.008
   Pfaff D., 1998, PHYSL REPROD, P1487
   PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369
   Pollet TV, 2011, HORM BEHAV, V60, P72, DOI 10.1016/j.yhbeh.2011.03.005
   Prokop P, 2013, ETHOLOGY, V119, P605, DOI 10.1111/eth.12102
   Puts DA, 2013, HORM BEHAV, V63, P13, DOI 10.1016/j.yhbeh.2012.11.007
   Rogol AD, 2002, J ADOLESCENT HEALTH, V31, P192, DOI 10.1016/S1054-139X(02)00485-8
   Roney JR, 2007, HORM BEHAV, V52, P326, DOI 10.1016/j.yhbeh.2007.05.008
   Roney JR, 2016, HORM BEHAV, V81, P45, DOI 10.1016/j.yhbeh.2016.03.008
   Roney JR, 2015, CURR OPIN PSYCHOL, V1, P81, DOI 10.1016/j.copsyc.2014.11.003
   Roney JR, 2015, EVOL PSYCHOL-SER, P99, DOI 10.1007/978-3-319-09384-0_6
   Roney JR, 2013, HORM BEHAV, V63, P636, DOI 10.1016/j.yhbeh.2013.02.013
   Roney JR, 2010, P R SOC B, V277, P57, DOI 10.1098/rspb.2009.1538
   Roney JR, 2003, EVOL HUM BEHAV, V24, P365, DOI 10.1016/S1090-5138(03)00053-9
   Roney J.R., 2015, ADAP HUM BEHAV PHYSL, V1, P30
   Roney J. R., 2009, ENDOCRINOLOGY SOCIAL, P246
   Roney J. R., 2016, HDB EVOLUTIONARY PSY, P1067
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Round JM, 1999, ANN HUM BIOL, V26, P49, DOI 10.1080/030144699282976
   Schneider JE, 2013, HORM BEHAV, V64, P702, DOI 10.1016/j.yhbeh.2013.07.005
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   SCHWEIGER U, 1988, FERTIL STERIL, V49, P447
   Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016
   Simmons ZL, 2009, AM J HUM BIOL, V21, P133, DOI 10.1002/ajhb.20837
   Stearns S.C., 1992, EVOLUTION LIFE HIST
   STRASSMANN BI, 1981, ETHOL SOCIOBIOL, V2, P31, DOI 10.1016/0162-3095(81)90020-0
   Symons D., 1979, EVOLUTION HUMAN SEXU
   TAKEDA H, 1990, J ENDOCRINOL, V126, P17, DOI 10.1677/joe.0.1260017
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Emery Thompson M., 2009, ENDOCRINOLOGY SOCIAL, P196
   Thornhill R., 2008, EVOLUTIONARY BIOL HU
   Tooby J., 1992, ADAPTED MIND EVOLUTI, P19
   Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004
   Trumble BC, 2010, AM J HUM BIOL, V22, P775, DOI 10.1002/ajhb.21079
   Tsai LW, 1996, AGGRESSIVE BEHAV, V22, P357
   Uvnas-Moberg K, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01529
   UvnasMoberg K, 1997, ANN NY ACAD SCI, V807, P146, DOI 10.1111/j.1749-6632.1997.tb51917.x
   Valeggia C, 2004, J BIOSOC SCI, V36, P573, DOI 10.1017/S0021932003006382
   van Anders SM, 2007, HORM BEHAV, V51, P454, DOI 10.1016/j.yhbeh.2007.01.002
   van der Meij L, 2008, HORM BEHAV, V54, P640, DOI 10.1016/j.yhbeh.2008.07.001
   van der Meij L, 2012, P ROY SOC B-BIOL SCI, V279, P202, DOI 10.1098/rspb.2011.0764
   VanGoozen SHM, 1997, ARCH SEX BEHAV, V26, P359, DOI 10.1023/A:1024587217927
   Vitzthum VJ, 2002, HUM REPROD, V17, P1906, DOI 10.1093/humrep/17.7.1906
   von Rueden C, 2011, P ROY SOC B-BIOL SCI, V278, P2223, DOI 10.1098/rspb.2010.2145
   Wakefield J. C., 2016, HDB EVOLUTIONARY PSY, P988
   WALLEN K, 1990, NEUROSCI BIOBEHAV R, V14, P233, DOI 10.1016/S0149-7634(05)80223-4
   Wallen K, 2001, HORM BEHAV, V40, P339, DOI 10.1006/hbeh.2001.1696
   WALLEN K, 1984, HORM BEHAV, V18, P431, DOI 10.1016/0018-506X(84)90028-X
   WALLEN K, 1995, CHIC SEX HIST SOC, P57
   Wallen K, 2013, HORM BEHAV, V63, P634, DOI 10.1016/j.yhbeh.2013.03.009
   WASSER S K, 1986, Journal of Psychosomatic Obstetrics and Gynecology, V5, P153, DOI 10.3109/01674828609016754
   Wilcox AJ, 2004, HUM REPROD, V19, P1539, DOI 10.1093/humrep/deh305
   Wilcox AJ, 1998, HUM REPROD, V13, P394, DOI 10.1093/humrep/13.2.394
   WILLIAMS CL, 1990, BEHAV NEUROSCI, V104, P84, DOI 10.1037/0735-7044.104.1.84
   Williams G.C., 1966, ADAPTATION NATURAL S
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   Yesilova Z, 2000, J CLIN ENDOCR METAB, V85, P66, DOI 10.1210/jc.85.1.66
   Young W. C, 1961, SEX INTERNAL SECRETI, P1173
   Zehr JL, 1998, HORM BEHAV, V33, P95, DOI 10.1006/hbeh.1998.1440
   Zeleznik Anthony J, 2004, Reprod Biol Endocrinol, V2, P31, DOI 10.1186/1477-7827-2-31
NR 175
TC 0
Z9 0
U1 7
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD AUG
PY 2016
VL 84
BP 97
EP 110
DI 10.1016/j.yhbeh.2016.06.004
PG 14
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DU7TJ
UT WOS:000382417200011
PM 27320181
ER

PT J
AU Hicks, KD
   Sullivan, AW
   Cao, JY
   Sluzas, E
   Rebuli, M
   Patisaul, HB
AF Hicks, Kimani D.
   Sullivan, Alana W.
   Cao, Jinyan
   Sluzas, Emily
   Rebuli, Meghan
   Patisaul, Heather B.
TI Interaction of bisphenol A (BPA) and soy phytoestrogens on sexually
   dimorphic sociosexual behaviors in male and female rats
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Endocrine disruption; Neuroendocrine disruption; Neuropeptides; Social;
   Diet; Open field; Affiliation; Activity; Environment
ID SEX-DIFFERENCES; DEVELOPMENTAL TOXICITY; PERINATAL EXPOSURE; SOCIAL
   RECOGNITION; RODENT DIETS; OXYTOCIN; AUTISM; MICE; AGE; HYPERACTIVITY
AB Concerns have been raised regarding the potential for endocrine disrupting compounds (EDCs) to alter brain development and behavior. Developmental exposure to bisphenol A (BPA), a ubiquitous EDC, has been linked to altered sociosexual and mood-related behaviors in various animal models and children but effects are inconsistent across laboratories and animal models creating confusion about potential risk in humans. Exposure to endocrine active diets, such as soy, which is rich in phytoestrogens, may contribute to this variability. Here, we tested the individual and combined effects of low dose oral BPA and soy diet or the individual isoflavone genistein (GEN; administered as the aglycone genistin (GIN)) on rat sociosexual behaviors with the hypothesis that soy would obfuscate any BPA-related effects. Social and activity levels were unchanged by developmental exposure to BPA but soy diet had sex specific effects including suppressed novelty preference, and open field exploration in females. The data presented here reinforce that environmental factors, including anthropogenic chemical exposure and hormone active diets, can shape complex behaviors and even reverse expected sex differences. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hicks, Kimani D.] North Carolina State Univ, Dept Psychol, Raleigh, NC 27695 USA.
   [Sullivan, Alana W.; Cao, Jinyan; Sluzas, Emily; Rebuli, Meghan; Patisaul, Heather B.] North Carolina State Univ, Biol Sci, Raleigh, NC 27695 USA.
   [Sullivan, Alana W.; Patisaul, Heather B.] WM Keck Ctr Behav Biol, Raleigh, NC 27695 USA.
RP Patisaul, HB (reprint author), Dept Biol Sci, Raleigh, NC 27695 USA.
EM hbpatisa@ncsu.edu
FU NCSU undergraduate research program; NIEHS [R21ES021233]
FX These experiments constitute the undergraduate research project of
   K.D.H. and the authors gratefully acknowledge the support of the NCSU
   undergraduate research program. This work was also supported by NIEHS
   R21ES021233. We also thank Brian Horman and Emily Cox for their
   assistance with various aspects of data collection and analysis. We also
   appreciate Kylie Rock for assisting with the Cleversys analysis.
CR Aguiar A, 2010, ENVIRON HEALTH PERSP, V118, P1646, DOI 10.1289/ehp.1002326
   Anderson OS, 2013, FASEB J, V27, P1784, DOI 10.1096/fj.12-223545
   Becker JB, 2005, ENDOCRINOLOGY, V146, P1650, DOI 10.1210/en.2004-1142
   Beronius A, 2013, TOXICOLOGY, V311, P13, DOI 10.1016/j.tox.2013.02.012
   Beronius A, 2010, REPROD TOXICOL, V29, P132, DOI 10.1016/j.reprotox.2009.11.007
   Cao JY, 2015, REPROD TOXICOL, V58, P282, DOI 10.1016/j.reprotox.2015.07.077
   Cao JY, 2012, NEUROTOXICOLOGY, V33, P23, DOI 10.1016/j.neuro.2011.11.002
   Chadman KK, 2009, AM J MED GENET B, V150B, P1, DOI 10.1002/ajmg.b.30777
   Chapin RE, 2008, BIRTH DEFECTS RES B, V83, P157, DOI 10.1002/bdrb.20147
   Cohen J., 1988, STAT POWER ANAL BEHA
   Cox KH, 2010, HORM BEHAV, V58, P754, DOI 10.1016/j.yhbeh.2010.07.008
   Crawley JN, 2007, NEUROPEPTIDES, V41, P145, DOI 10.1016/j.npep.2007.02.002
   de Cock M, 2012, ACTA PAEDIATR, V101, P811, DOI 10.1111/j.1651-2227.2012.02693.x
   FAO/WHO, 2011, TOX HLTH ASP BISPH J
   [FDA Administration F.a.D.], 2012, BISPH A BPA US FOOD
   Frye CA, 2000, PHARMACOL BIOCHEM BE, V67, P587, DOI 10.1016/S0091-3057(00)00392-0
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gioiosa L, 2013, HORM BEHAV, V63, P598, DOI 10.1016/j.yhbeh.2013.02.016
   Gore AC, 2014, ENDOCR REV, V35, P961, DOI 10.1210/er.2013-1122
   Gould T.D.D., 2010, MOOD ANXIETY RELATED
   Grandjean P, 2014, LANCET NEUROL, V13, P330, DOI 10.1016/S1474-4422(13)70278-3
   Insel TR, 1999, BIOL PSYCHIAT, V45, P145, DOI 10.1016/S0006-3223(98)00142-5
   Jasarevic E, 2011, P NATL ACAD SCI USA, V108, P11715, DOI 10.1073/pnas.1107958108
   Jefferson WN, 2009, ENVIRON HEALTH PERSP, V117, P1883, DOI 10.1289/ehp.0900923
   Kalkbrenner AE, 2014, CURR PROB PEDIATR AD, V44, P277, DOI 10.1016/j.cppeds.2014.06.001
   Kinch CD, 2015, P NATL ACAD SCI USA, V112, P1475, DOI 10.1073/pnas.1417731112
   Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110
   Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863
   Li AA, 2008, NEUROTOXICOLOGY, V29, P504, DOI 10.1016/j.neuro.2008.02.015
   MASUR J, 1980, DEV PSYCHOBIOL, V13, P107, DOI 10.1002/dev.420130202
   Matsuda S, 2012, PROG NEURO-PSYCHOPH, V39, P273, DOI 10.1016/j.pnpbp.2012.06.016
   Mustieles V, 2015, NEUROTOXICOLOGY, V49, P174, DOI 10.1016/j.neuro.2015.06.002
   Patisaul HB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043890
   Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003
   Patisaul HB, 2009, NEUROTOXICOLOGY, V30, P350, DOI 10.1016/j.neuro.2009.02.010
   Rebuli M.E., 2015, TOXICOL SCI
   SLOB AK, 1986, PHYSIOL BEHAV, V37, P313
   Sullivan AW, 2014, ENDOCRINOLOGY, V155, P3867, DOI 10.1210/en.2014-1379
   Sullivan AW, 2011, HORM BEHAV, V60, P185, DOI 10.1016/j.yhbeh.2011.04.006
   Thigpen JE, 1999, ENVIRON HEALTH PERSP, V107, pA182, DOI 10.2307/3434577
   Thigpen JE, 2013, J AM ASSOC LAB ANIM, V52, P130
   VALLE FP, 1976, ANIM LEARN BEHAV, V4, P457, DOI 10.3758/BF03214439
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Wolstenholme JT, 2013, HORM BEHAV, V64, P833, DOI 10.1016/j.yhbeh.2013.09.007
   Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001
NR 45
TC 0
Z9 0
U1 7
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD AUG
PY 2016
VL 84
BP 121
EP 126
DI 10.1016/j.yhbeh.2016.06.010
PG 6
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DU7TJ
UT WOS:000382417200013
PM 27373758
ER

PT J
AU Ivars, J
   Garabedian, C
   Devos, P
   Therby, D
   Carlier, S
   Deruelle, P
   Subtil, D
AF Ivars, Joanna
   Garabedian, Charles
   Devos, Patrick
   Therby, Denis
   Carlier, Sabine
   Deruelle, Philippe
   Subtil, Damien
TI Simplified Bishop score including parity predicts successful induction
   of labor
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Labor induction; Bishop's score; Parity; Simplified Bishop's score
ID INTRAVAGINAL MISOPROSTOL APPLICATION; CESAREAN DELIVERY; NULLIPAROUS
   WOMEN; ELECTIVE INDUCTION; UNFAVORABLE CERVIX; DIAGNOSTIC-TEST; RISK;
   TERM; LIKELIHOOD; ULTRASOUND
AB Objective: Our objectives were to confirm the predictiveness of parity for successful labor induction and propose an improvement in the Bishop's score to take parity into account and simultaneously simplify the original Bishop score.
   Study design: Retrospective study of 326 deliveries induced by oxytocin and amniotomy before prostaglandins between January 1, 1987, and June 30, 1988. We conducted a univariate and then a multivariate analysis of the relation between successful labor induction - defined by vaginal delivery and the components of Bishop's score and parity.
   Results: Nulliparous accounted for 38% of the studied population. The mean Bishop at induction was 5.75 +/- 1.4. Fetal station, cervical effacement, and parity were the only factors associated with the success of induction in this study. Removing the cervical position and consistency from the score as well as adding parity significantly improved the prediction of success (ROC curves, AUC 0.88 vs 0.68, p < 0.001). By taking 5% as the maximum risk of induction failure, a cutoff point of 4 for the new score makes it possible to induce labor in 90% of the women that were considered in the study (vs 26% or 60%, according to whether the cutoff point of the original Bishop's score is set, respectively, at 7 or 6, p < 0.001).
   Conclusion: Cervical position and consistency are not necessary for predicting successful labor induction by oxytocin and amniotomy. We confirmed the usefulness of a simplified Bishop score that considers parity. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Ivars, Joanna; Garabedian, Charles; Deruelle, Philippe; Subtil, Damien] Jeanne de Flandre Hosp, Dept Obstet, F-59045 Lille, France.
   [Devos, Patrick; Subtil, Damien] CHU Lille, EA 2694, UDSL, Univ Lille North France, F-59045 Lille, France.
   [Therby, Denis; Carlier, Sabine] Ctr Hosp, Paul Gelle Hosp, Dept Obstet, 91 Ave Lagache, F-59100 Roubaix, France.
   [Deruelle, Philippe] Univ Lille North France, EA 4489, F-59045 Lille, France.
RP Garabedian, C (reprint author), Univ Lille Nord France, Hop Jeanne de Flandre, 1 Rue Eugene Avinee, F-59037 Lille, France.
EM charles.garabedian@chru-lille.fr
RI Deruelle, Philippe/O-3689-2016; Devos, Patrick/A-8167-2008; 
OI Deruelle, Philippe/0000-0003-4273-6553; Devos,
   Patrick/0000-0001-7803-9552; Garabedian, Charles/0000-0003-2105-9784
CR ACOG, 2009, IND LAB CLIN GUID OB
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Blondel B, 2006, J Gynecol Obstet Biol Reprod (Paris), V35, P373
   Blondel B, 2012, J GYNECOL OBST BIO R, V41, P151, DOI 10.1016/j.jgyn.2011.11.008
   Crane JMG, 2006, CLIN OBSTET GYNECOL, V49, P573, DOI 10.1097/00003081-200609000-00017
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   DHALL K, 1987, AUST NZ J OBSTET GYN, V27, P309, DOI 10.1111/j.1479-828X.1987.tb01015.x
   Edwards RK, 2000, CLIN OBSTET GYNECOL, V43, P440, DOI 10.1097/00003081-200009000-00004
   Ezebialu IU, 2015, COCHRANE DB SYST REV, V6
   FRIEDMAN EA, 1967, OBSTET GYNECOL, V29, P539
   Goffinet F, 2003, J Gynecol Obstet Biol Reprod (Paris), V32, P638
   Gonen R, 1998, Eur J Ultrasound, V7, P183, DOI 10.1016/S0929-8266(98)00042-1
   Haute Autorite de Sante, 2008, DECL ART TRAV PART
   Hendrix NW, 1998, SOUTHERN MED J, V91, P248
   HUGHEY MJ, 1976, OBSTET GYNECOL, V48, P635
   Johnson DP, 2003, AM J OBSTET GYNECOL, V188, P1565, DOI 10.1067/mob.2003.458
   Kehila M, 2016, J NEONATALPERINAT ME
   LANGE AP, 1982, OBSTET GYNECOL, V60, P137
   Laughon SK, 2011, OBSTET GYNECOL, V117, P805, DOI 10.1097/AOG.0b013e3182114ad2
   Parer J, 2002, AM J OBSTET GYNECOL, V186, P1240
   Pereira S, 2014, ULTRASOUND OBST GYN, V44, P468, DOI 10.1002/uog.13411
   Perneger T, 2004, REV MAL RESPIR, V21, P398
   Pevzner L, 2009, OBSTET GYNECOL, V114, P261, DOI 10.1097/AOG.0b013e3181ad9377
   Rane SM, 2004, ULTRASOUND OBST GYN, V24, P538, DOI 10.1002/uog.1100
   Reis FM, 2003, AM J OBSTET GYNECOL, V189, P1361, DOI 10.1067/S0002-9378(03)00725-7
   SAUERBREI W, 1992, STAT MED, V11, P2093, DOI 10.1002/sim.4780111607
   Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4
   Turnbull A C, 1967, J Obstet Gynaecol Br Commonw, V74, P849
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   Watson WJ, 1996, OBSTET GYNECOL, V88, P990
   Wing DA, 2002, AM J OBSTET GYNECOL, V186, P1237, DOI 10.1067/mob.2002.123740
   Yeast JD, 1999, AM J OBSTET GYNECOL, V180, P628, DOI 10.1016/S0002-9378(99)70265-6
   Zhang J, 2002, J REPROD MED, V47, P120
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD AUG
PY 2016
VL 203
BP 309
EP 314
DI 10.1016/j.ejogrb.2016.06.007
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DU1EQ
UT WOS:000381951400058
PM 27423032
ER

PT J
AU Shum, M
   Ren, Z
   Achar, K
   Jerschow, E
AF Shum, Mili
   Ren, Zhen
   Achar, Keshav
   Jerschow, Elina
TI Intraoperative anaphylaxis to latex possibly facilitated by the
   administration of oxytocin and vasopressin
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID CESAREAN DELIVERY; SPINAL-ANESTHESIA; ALLERGY; SYNTOCINON; SECTION
C1 [Shum, Mili] Suny Downstate Med Ctr, Ctr Allergy & Asthma Res, Brooklyn, NY 11203 USA.
   [Ren, Zhen; Achar, Keshav; Jerschow, Elina] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.
RP Shum, M (reprint author), 2 Wellington Pl, Greenwich, CT 06830 USA.
EM mshum118@yahoo.com
CR Cabestrero D, 2003, CRIT CARE, V7, P392, DOI 10.1186/cc2348
   Deusch E, 1996, OBSTET GYNECOL, V88, P727, DOI 10.1016/0029-7844(96)00256-6
   Draisci G, 2007, INT J OBSTET ANESTH, V16, P63, DOI 10.1016/j.ijoa.2006.08.006
   Draisci G, 2011, ANESTHESIOLOGY, V114, P565, DOI 10.1097/ALN.0b013e318206ff50
   Ebo DG, 1997, J ALLERGY CLIN IMMUN, V100, P618, DOI 10.1016/S0091-6749(97)70165-9
   Helmer H, 1998, AM J OBSTET GYNECOL, V179, P1572, DOI 10.1016/S0002-9378(98)70027-4
   Hepner DL, 2003, ANESTH ANALG, V96, P1219, DOI 10.1213/01.ANE.0000050768.04953.16
   HOFMANN H, 1986, CONTACT DERMATITIS, V15, P241, DOI 10.1111/j.1600-0536.1986.tb01344.x
   Ikeda Nahomi, 2010, Masui, V59, P1294
   Liccardi G, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-67
   Lieberman P, 2002, J ALLERGY CLIN IMMUN, V110, pS64, DOI 10.1067/mai.2002.124970
   Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003
   MORRISS WW, 1994, ANAESTHESIA, V49, P41, DOI 10.1111/j.1365-2044.1994.tb03312.x
   Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15
   Ogata J, 2007, BRIT J ANAESTH, V98, P845, DOI 10.1093/bja/aem113
   Pant D, 2009, INT J OBSTET ANESTH, V18, P85, DOI 10.1016/j.ijoa.2008.09.004
   Shimo Tomohiro, 2006, Masui, V55, P447
   SLATER RM, 1985, ANAESTHESIA, V40, P655, DOI 10.1111/j.1365-2044.1985.tb10944.x
   Yamamoto Kaori, 2012, Masui, V61, P1080
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD AUG
PY 2016
VL 4
IS 4
BP 773
EP 776
DI 10.1016/j.jaip.2016.02.011
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA DU0SZ
UT WOS:000381916100039
PM 27039235
ER

PT J
AU Faucett, AM
   Allshouse, AA
   Donnelly, M
   Metz, TD
AF Faucett, Allison M.
   Allshouse, Amanda A.
   Donnelly, Meghan
   Metz, Torri D.
TI Do Obese Women Receive the Necessary Interventions to Achieve Vaginal
   Birth after Cesarean?
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE arrest disorder; obesity; trial of labor after cesarean; vaginal birth
   after cesarean
ID BODY-MASS INDEX; WEIGHT-BASED OUTCOMES; NORMAL 1ST STAGE; UTERINE
   CONTRACTILITY; NULLIPAROUS WOMEN; MATERNAL OBESITY; MORBID-OBESITY;
   LABOR; DELIVERY; SECTION
AB Objective We aimed to determine if obese women undergoing trial of labor after cesarean (TOLAC) were more likely to undergo repeat cesarean for arrest disorders prior to active labor, and whether this was due to decreased use of standard interventions to achieve vaginal birth.
   Study Design This was a secondary analysis of a prospective registry. Women undergoing TOLAC with one prior cesarean and a singleton, term gestation who had a repeat cesarean for an arrest disorder were included. The primary outcome was repeat cesarean prior to active labor (cervical dilation < 6 cm). Obese (body mass index >= 30 kg/m(2)) and nonobese women were compared. Multivariable logistic regression was used to estimate the association between obesity and repeat cesarean prior to active labor. Clinical interventions were compared between groups using t-test and chi(2) test.
   Results Among 2,098 women undergoing TOLAC, 1,454 (69%) were obese. Obese women were more likely to undergo repeat cesarean for an arrest disorder prior to active labor (odds ratio, 1.4; 95% confidence interval, 1.1-1.7) despite being allowed longer labors and receiving higher maximum doses of oxytocin for a longer duration than nonobese women.
   Conclusion Obese women were more likely to undergo repeat cesarean prior to active labor despite more clinical interventions to achieve vaginal birth.
C1 [Faucett, Allison M.; Donnelly, Meghan; Metz, Torri D.] Univ Colorado, Div Maternal Fetal Med, Dept Obstet & Gynecol, Sch Med, Aurora, CO USA.
   [Allshouse, Amanda A.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
   [Metz, Torri D.] Denver Hlth Med Ctr, Dept Obstet & Gynecol, Denver, CO USA.
RP Faucett, AM (reprint author), 12631 East 17th Ave,Room 4109,Mail Stop B198-5, Aurora, CO 80045 USA.
EM allison.faucett@ucdenver.edu
FU Agency for Healthcare Research and Quality [R24 HS022143-01]; National
   Institutes of Health/National Center for Research Resources Colorado
   CCTSI [UL1 RR025780]
FX This work was supported in part by the Agency for Healthcare Research
   and Quality grant number R24 HS022143-01 and National Institutes of
   Health/National Center for Research Resources Colorado CCTSI grant
   number UL1 RR025780.
CR Abenhaim Haim A, 2011, J Obstet Gynaecol Can, V33, P443
   Alexander JM, 1999, OBSTET GYNECOL, V94, P274, DOI 10.1016/S0029-7844(99)00256-2
   Carlhall S, 2013, EUR J OBSTET GYN R B, V171, P49, DOI 10.1016/j.ejogrb.2013.08.021
   Carlson NS, 2014, J MIDWIFERY WOM HEAL, V59, P43, DOI 10.1111/jmwh.12073
   Carroll CS, 2003, AM J OBSTET GYNECOL, V188, P1516, DOI 10.1067/mob.2003.472
   Chin JR, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.044
   Conner SN, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.05.054
   Durnwald CP, 2004, AM J OBSTET GYNECOL, V191, P954, DOI 10.1016/j.ajog.2004.05.051
   Garabedian MJ, 2011, AM J PERINAT, V28, P729, DOI 10.1055/s-0031-1280852
   Girsen AI, 2014, OBSTET GYNECOL, V124, P684, DOI 10.1097/AOG.0000000000000462
   Graseck AS, 2012, OBSTET GYNECOL, V119, P732, DOI 10.1097/AOG.0b013e31824c096c
   Henry DEM, 2008, OBSTET GYNECOL, V112, P1109, DOI 10.1097/AOG.0b013e31818b46a2
   Hibbard JU, 2006, OBSTET GYNECOL, V108, P125, DOI 10.1097/01.AOG.0000223871.69852.31
   Juhasz G, 2005, OBSTET GYNECOL, V106, P741, DOI 10.1097/01.AOG.0000177972.32941.65
   Kominiarek MA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.014
   Landon MB, 2005, AM J OBSTET GYNECOL, V193, P1016, DOI 10.1016/j.ajog.2005.05.066
   Lowe NK, 2011, MED HYPOTHESES, V76, P755, DOI 10.1016/j.mehy.2011.02.018
   Metz TD, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.011
   Moynihan AT, 2006, AM J OBSTET GYNECOL, V195, P504, DOI 10.1016/j.ajog.2006.01.106
   Mumtaz S, 2015, LIFE SCI, V125, P57, DOI 10.1016/j.lfs.2015.01.020
   National NIH; National Institutes of Health, 1998, OBES RES S2, V6, p51S
   Pevzner L, 2009, OBSTET GYNECOL, V114, P1315, DOI 10.1097/AOG.0b013e3181bfb39f
   Zhang J, 2007, BJOG-INT J OBSTET GY, V114, P343, DOI 10.1111/j.1471-0528.2006.01233.x
   Zhang J, 2010, OBSTET GYNECOL, V115, P705, DOI 10.1097/AOG.0b013e3181d55925
NR 24
TC 0
Z9 0
U1 1
U2 1
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
EI 1098-8785
J9 AM J PERINAT
JI Am. J. Perinatol.
PD AUG
PY 2016
VL 33
IS 10
BP 991
EP 997
DI 10.1055/s-0036-1580609
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DS4TN
UT WOS:000380774600011
PM 27120477
ER

PT J
AU Ducloy-Bouthors, AS
   Mignon, A
   Huissoud, C
   Grouin, JM
   Mercier, FJ
AF Ducloy-Bouthors, Anne-Sophie
   Mignon, Alexandre
   Huissoud, Cyril
   Grouin, Jean-Marie
   Mercier, Frederic J.
TI Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced
   coagulopathy: A study protocol for a randomised multicentre controlled
   trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Article
DE Postpartum haemorrhage; Fibrinogen concentrate; Blood transfusion
ID MAJOR OBSTETRIC HEMORRHAGE; MANAGEMENT; CRYOPRECIPITATE; SEVERITY;
   SOCIETY; LEVEL
AB Background: Postpartum haemorrhage (PPH) remains the leading cause for maternal mortality worldwide. Hypofibrinogenaemia has been identified as a major risk factor for progress towards severe PPH. The efficacy of fibrinogen concentrate supplementation in PPH has been shown in various clinical settings but the level of evidence is not sufficient to prove the benefit, evaluate the risks, and determine the value, timing and dose of fibrinogen supplementation in PPH. The FIDEL trial objective is to evaluate the impact of a therapeutic strategy based on the early administration of human fibrinogen concentrate compared to the current practice based on late administration in severe PPH patients requiring second line uterotonics.
   Methods/design: This is a prospective multicentre, randomised, double-blind, placebo-controlled trial. A total of 412 patients will be randomised if they meet the following criteria: female patients >= 18 years old, vaginal delivery, PPH requiring IV administration of prostaglandins (sulprostone) after 20 to 30 minutes of oxytocin failure. The participants are assigned to receive either fibrinogen 3 g or placebo infusions. The primary endpoint is a composite endpoint defined as the percentage of patients losing at least 4 g/dL of Hb, and/or requiring a transfusion of at least 2 units of packed red blood cells, within the 48 hours following fibrinogen administration.
   Discussion: The purpose of this study is to demonstrate the efficacy and safety of an early fibrinogen concentrate infusion in uncontrolled active PPH. (C) 2016 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.
C1 [Ducloy-Bouthors, Anne-Sophie] Acad Hosp, Maternite Jeanne de Flandre, Pole Anesthesie Reanimat, Ave Oscar Lambret, F-59037 Lille, France.
   [Mignon, Alexandre] AP HP, Pole Anesthesie Reanimat, Maternite Cochin Port Royal, 53 Ave Observ, F-75014 Paris, France.
   [Huissoud, Cyril] Hop Croix Rousse, Hosp Civils, Pole Obstet & Gynecol, 103 Grande Rue Croix Rousse, F-69004 Lyon, France.
   [Grouin, Jean-Marie] Univ Rouen, Inserm U657, 72 Rue Pre des Coulons, F-78810 Feucherolles, France.
   [Mercier, Frederic J.] Hop Univ Paris Sud, Hop Antoine Beclere, AP HP, Dept Anesthesie Reanimat, 157 Rue Porte Trivaux, F-92140 Clamart, France.
RP Ducloy-Bouthors, AS (reprint author), Acad Hosp, Maternite Jeanne de Flandre, Pole Anesthesie Reanimat, Ave Oscar Lambret, F-59037 Lille, France.
EM anne-sophie.ducloy@chru-lille.fr; alexandre.mignon@me.com;
   cyril.huissoud@chu-lyon.fr; jean-marie.grouin@univ-rouen.fr;
   frederic.mercier@abc.aphp.fr
CR Aawar N, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0670-9
   Ahmed S, 2012, TRANSFUSION MED, V22, P344, DOI 10.1111/j.1365-3148.2012.01178.x
   Bonnet MP, 2011, EUR J OBSTET GYN R B, V158, P183, DOI 10.1016/j.ejogrb.2011.04.042
   Charbit B, 2007, J THROMB HAEMOST, V5, P266, DOI 10.1111/j.1538-7836.2007.02297.x
   Chauleur C, 2008, THROMB HAEMOSTASIS, V100, P773, DOI 10.1160/TH08-06-0376
   Collins PW, 2014, BLOOD, V124, P1727, DOI 10.1182/blood-2014-04-567891
   Collis RE, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12913
   Cortet M, 2012, BRIT J ANAESTH, V108, P984, DOI 10.1093/bja/aes096
   de Lloyd L, 2011, INT J OBSTET ANESTH, V20, P135, DOI 10.1016/j.ijoa.2010.12.002
   Ducloy-Bouthors AS, 2015, ANESTH ANALG, V120, P494, DOI 10.1213/ANE.0000000000000602
   Fenger-Eriksen C, 2013, THROMB RES, V131, pE210, DOI 10.1016/j.thromres.2013.02.009
   Gayat E, 2011, INTENS CARE MED, V37, P1816, DOI 10.1007/s00134-011-2315-0
   Goffinet F, 2005, Gynecol Obstet Fertil, V33, P268, DOI 10.1016/j.gyobfe.2005.03.016
   Goffinet F, 2005, Gynecol Obstet Fertil, V33, P266, DOI 10.1016/j.gyobfe.2005.03.012
   Grottke O, 2010, CRIT CARE, V14, DOI 10.1186/cc8960
   Hellgren M, 2003, SEMIN THROMB HEMOST, V29, P125, DOI 10.1055/s-2003-38897
   Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1
   Huissoud C, 2009, BJOG-INT J OBSTET GY, V116, P1097, DOI 10.1111/j.1471-0528.2009.02187.x
   Jacobsen AF, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.041
   Karlsson O, 2014, INT J OBSTET ANESTH, V23, P10, DOI 10.1016/j.ijoa.2013.07.003
   Kikuchi M, 2013, J OBSTET GYNAECOL RE, V39, P770, DOI 10.1111/j.1447-0756.2012.02058.x
   Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55
   Kozek-Langenecker SA, 2013, EUR J ANAESTH, V30, P270, DOI 10.1097/EJA.0b013e32835f4d5b
   Levy JH, 2014, TRANSFUSION, V54, P1389, DOI 10.1111/trf.12431
   Makino S, 2015, J OBSTET GYNAECOL RE, V41, P1155, DOI 10.1111/jog.12708
   Mallaiah S, 2015, ANAESTHESIA, V70, P166, DOI 10.1111/anae.12859
   Mercier Frederic J, 2008, Anesthesiol Clin, V26, P53, DOI 10.1016/j.anclin.2007.11.008
   Onwuemene O, 2012, INT J GYNECOL OBSTET, V119, P3, DOI 10.1016/j.ijgo.2012.07.001
   Wikkelso A, 2013, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD008864.PUB2
   Wikkelso AJ, 2015, BRIT J ANAESTH, V114, P623, DOI 10.1093/bja/aeu444
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD AUG
PY 2016
VL 35
IS 4
BP 293
EP 298
DI 10.1016/j.accpm.2015.10.011
PG 6
WC Anesthesiology
SC Anesthesiology
GA DT8PP
UT WOS:000381753500010
PM 27004917
ER

PT J
AU Moura, D
   Canavarro, MC
   Figueiredo-Braga, M
AF Moura, Diana
   Canavarro, Maria Cristina
   Figueiredo-Braga, Margarida
TI Oxytocin and depression in the perinatal period-a systematic review
SO ARCHIVES OF WOMENS MENTAL HEALTH
LA English
DT Review
DE Postpartum depression; Perinatal depression; Oxytocin; Depressive
   symptoms
ID POSTPARTUM DEPRESSION; MATERNAL-CARE; PREGNANCY; PREVALENCE; STRESS;
   WOMEN; AXIS; DISORDERS; MOOD; DYSREGULATION
AB Postpartum depression (PPD) is the most common postnatal psychiatric disorder, and it represents a considerable problem to the health and well-being of women and their families. Several pathogenic mechanisms have been identified in PPD, and recently, oxytocin (OT), known to be involved in childbirth and lactation, has drawn attention as a possible diagnostic and therapeutic tool in this disorder. The aim of this review was to assess and summarize the current literature on the relationship between OT as a potential depressive biomarker and depression in the perinatal period. We conducted a literature search on four electronic databases (Pubmed, PsycINFO, Web of Science, and Science Direct) by applying the following search terms: oxytocin AND (postpartum OR postnatal OR perinatal OR peripartum) AND (depression OR depressive). Six studies were included and a total of 620 pregnant women were recruited and completed the follow-up. Depressive symptoms were evaluated using self-report scales, and in three studies, the diagnosis of major depression was additionally confirmed using semi-structured interviews. Peripheral OT levels and depression were assessed during pregnancy and/or after delivery. Higher OT levels were associated with lower depressive symptoms, even if this association lacked statistical significance in two studies. Although some studies are beginning to shed light upon the complex nature of OT's effect in depression, its role as a diagnostic and therapeutic tool in PPD is still unclear. Future research is needed to clarify the neuroendocrinological and psychosocial particularities of mothers with PPD and to define a specific profile associated with OT dysfunction.
C1 [Moura, Diana; Figueiredo-Braga, Margarida] Univ Porto, Fac Med, Dept Clin Neurosci & Mental Hlth, P-4200319 Oporto, Portugal.
   [Canavarro, Maria Cristina] Univ Coimbra, Fac Psychol & Educ Sci, Rua Colegio Novo,Apart 6153, P-3001802 Coimbra, Portugal.
   [Figueiredo-Braga, Margarida] Univ Porto, I3S, R Alfredo Allen, P-4200135 Oporto, Portugal.
RP Figueiredo-Braga, M (reprint author), Univ Porto, Fac Med, Dept Clin Neurosci & Mental Hlth, P-4200319 Oporto, Portugal.; Figueiredo-Braga, M (reprint author), Univ Porto, I3S, R Alfredo Allen, P-4200135 Oporto, Portugal.
EM mimed09032@med.up.pt; mccanavarro@fpce.uc.pt; mmfb@med.up.pt
CR Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Bale TL, 2006, HORM BEHAV, V50, P529, DOI 10.1016/j.yhbeh.2006.06.033
   Banti S, 2011, COMPR PSYCHIAT, V52, P343, DOI 10.1016/j.comppsych.2010.08.003
   Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004
   Beck CT, 2002, JOGNN, V31, P394, DOI 10.1111/j.1552-6909.2002.tb00061.x
   Bloch M, 2005, J CLIN ENDOCR METAB, V90, P695, DOI 10.1210/jc.2004-1388
   Blom EA, 2010, BJOG-INT J OBSTET GY, V117, P1390, DOI 10.1111/j.1471-0528.2010.02660.x
   Bobo WV, 2014, MAYO CLIN PROC, V89, P835, DOI 10.1016/j.mayocp.2014.01.027
   Boyd RC, 2005, ARCH WOMEN MENT HLTH, V8, P141, DOI 10.1007/s00737-005-0096-6
   Brummelte S, 2010, PROG NEURO-PSYCHOPH, V34, P766, DOI 10.1016/j.pnpbp.2009.09.006
   Brummelte S, 2016, HORM BEHAV, V77, P153, DOI 10.1016/j.yhbeh.2015.08.008
   Cox EQ, 2015, PSYCHONEUROENDOCRINO, V55, P164, DOI 10.1016/j.psyneuen.2015.02.009
   Dennis CL, 2009, PEDIATRICS, V123, pE736, DOI 10.1542/peds.2008-1629
   Eapen V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107745
   Evans J, 2001, BRIT MED J, V323, P257, DOI 10.1136/bmj.323.7307.257
   Frokjaer VG, 2015, BIOL PSYCHIAT, V78, P534, DOI 10.1016/j.biopsych.2015.04.015
   Gale S, 2003, J PSYCHOSOM OBST GYN, V24, P257, DOI 10.3109/01674820309074690
   Garfield L, 2014, BRAIN BEHAV IMM SE46, V40, pe46
   Garfield L, 2015, ARCH WOMEN MENT HLTH, V18, P123, DOI 10.1007/s00737-014-0437-4
   Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db
   Gaynes B N, 2005, Evid Rep Technol Assess (Summ), P1
   Glynn LM, 2013, NEUROPEPTIDES, V47, P363, DOI 10.1016/j.npep.2013.10.007
   Goodman SH, 2007, ANNU REV CLIN PSYCHO, V3, P107, DOI 10.1146/annurev.clinpsy.3.022806.091401
   Grace S L, 2003, Arch Womens Ment Health, V6, P263, DOI 10.1007/s00737-003-0024-6
   Jolley SN, 2007, BIOL RES NURS, V8, P210, DOI 10.1177/1099800406294598
   Josefsson A, 2001, ACTA OBSTET GYN SCAN, V80, P251
   Kim S, 2014, BRAIN RES, V1580, P219, DOI 10.1016/j.brainres.2013.11.009
   Lindahl V, 2005, ARCH WOMEN MENT HLTH, V8, P77, DOI 10.1007/s00737-005-0080-1
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   O'Hara MW, 2014, BEST PRACT RES CL OB, V28, P3, DOI 10.1016/j.bpobgyn.2013.09.002
   Oates M, 2003, BRIT MED BULL, V67, P219, DOI 10.1093/bmb/ldg011
   OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801
   Pearlstein T, 2009, AM J OBSTET GYNECOL, V200, P357, DOI 10.1016/j.ajog.2008.11.033
   Perfetti Jennifer, 2004, WMJ, V103, P56
   Ramchandani PG, 2011, DEPRESS ANXIETY, V28, P471, DOI 10.1002/da.20814
   Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006
   Sit D, 2006, J WOMENS HEALTH, V15, P352, DOI 10.1089/jwh.2006.15.352
   Sit DKY, 2009, CLIN OBSTET GYNECOL, V52, P456, DOI 10.1097/GRF.0b013e3181b5a57c
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Slattery David A, 2010, Pharmaceuticals (Basel), V3, P702
   Steiner M, 2002, FAM PRACT, V19, P469, DOI 10.1093/fampra/19.5.469
   Stuebe AM, 2013, J WOMENS HEALTH, V22, P352, DOI 10.1089/jwh.2012.3768
   Wisner KL, 2013, JAMA PSYCHIAT, V70, P490, DOI 10.1001/jamapsychiatry.2013.87
   Workman JL, 2015, PSYCHONEUROENDOCRINO, V57, P37, DOI 10.1016/j.psyneuen.2015.03.001
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Zbozinek TD, 2012, DEPRESS ANXIETY, V29, P1065, DOI 10.1002/da.22026
   Zelkowitz P, 2014, HORM BEHAV, V66, P351, DOI 10.1016/j.yhbeh.2014.06.014
NR 48
TC 0
Z9 0
U1 12
U2 12
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 1434-1816
EI 1435-1102
J9 ARCH WOMEN MENT HLTH
JI Arch. Womens Ment. Health
PD AUG
PY 2016
VL 19
IS 4
BP 561
EP 570
DI 10.1007/s00737-016-0643-3
PG 10
WC Psychiatry
SC Psychiatry
GA DS3VT
UT WOS:000380711500001
PM 27295067
ER

PT J
AU Jobst, A
   Krause, D
   Maiwald, C
   Hartl, K
   Myint, AM
   Kastner, R
   Obermeier, M
   Padberg, F
   Brucklmeier, B
   Weidinger, E
   Kieper, S
   Schwarz, M
   Zill, P
   Muller, N
AF Jobst, Andrea
   Krause, Daniela
   Maiwald, Carina
   Haertl, Kristin
   Myint, Aye-Mu
   Kaestner, Ralph
   Obermeier, Michael
   Padberg, Frank
   Bruecklmeier, Benedikt
   Weidinger, Elif
   Kieper, Susann
   Schwarz, Markus
   Zill, Peter
   Mueller, Norbert
TI Oxytocin course over pregnancy and postpartum period and the association
   with postpartum depressive symptoms
SO ARCHIVES OF WOMENS MENTAL HEALTH
LA English
DT Article
DE Postpartum depression; Oxytocin; Prediction of depressive symptoms;
   Breastfeeding; Mother-infant bonding
ID PLASMA OXYTOCIN; PERINATAL DEPRESSION; MATERNAL DEPRESSION;
   RATING-SCALE; WOMEN; ATTACHMENT; PATTERNS; RISK; NEUROSCIENCE;
   VASOPRESSIN
AB During the postpartum period, women are at higher risk of developing a mental disorder such as postpartum depression (PPD), a disorder that associates with mother-infant bonding and child development. Oxytocin is considered to play a key role in mother-infant bonding and social interactions and altered oxytocin plasma concentrations were found to be associated with PPD. In the present study, we evaluated oxytocin plasma levels and depressive symptoms during pregnancy and the postpartum period in healthy women. We evaluated 100 women twice during pregnancy (weeks 35 and 38) and three times in the postpartum period (within 2 days and 7 weeks and 6 months after delivery) by measuring oxytocin plasma levels with enzyme-linked immunosorbent assay (ELISA) and assessing depressive symptoms with the Montgomery-Asberg Depression Rating Scale. Oxytocin plasma levels significantly increased from the 35th week of gestation to 6 months postpartum in all women. However, levels decreased from the 38th week of gestation to 2 days after delivery in participants with postpartum depressive symptoms, whereas they continuously increased in the group without postpartum depressive symptoms; the difference between the course of oxytocin levels in the two groups was significant (Delta t2-t3: t = 2.14; p = 0.036*). Previous depressive episodes and breastfeeding problems predicted postpartum depressive symptoms. Our results indicate that alterations in the oxytocin system during pregnancy might be specific for women who develop postpartum depressive symptoms. Future studies should investigate whether oxytocin plasma levels might have predictive value in women at high risk for PPD.
C1 [Jobst, Andrea; Krause, Daniela; Maiwald, Carina; Myint, Aye-Mu; Obermeier, Michael; Padberg, Frank; Bruecklmeier, Benedikt; Weidinger, Elif; Kieper, Susann; Zill, Peter; Mueller, Norbert] Univ Munich, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
   [Haertl, Kristin] Univ Appl Sci, Hsch Fresenius, Infanteriestr 11 A, D-80797 Munich, Germany.
   [Kaestner, Ralph] Univ Munich, Dept Obstet & Gynecol, Maistr 11, D-80337 Munich, Germany.
   [Schwarz, Markus] Univ Munich, Med Ctr, Inst Lab Med, Munich, Germany.
RP Jobst, A (reprint author), Univ Munich, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
EM A.Jobst@med.uni-muenchen.de
FU Ludwig Maximilian University
FX The authors would like to thank all study participants. This study is
   part of C. Maiwald's MD thesis at the Faculty of Medicine of the Ludwig
   Maximilian University, Munich (in preparation). The authors thank
   Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for
   editing assistance with the manuscript. This study was funded solely by
   funds from the Ludwig Maximilian University and no outside grant money
   was used.
CR Abdollahi Fatemeh, 2014, Iran J Psychiatry Behav Sci, V8, P11
   Aceti F, 2012, RIV PSICHIATR, V47, P214, DOI 10.1708/1128.12443
   Appleby L, 1998, BRIT J PSYCHIAT, V173, P209, DOI 10.1192/bjp.173.3.209
   Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004
   Bloch M, 2000, AM J PSYCHIAT, V157, P924, DOI 10.1176/appi.ajp.157.6.924
   Bloch M, 2003, COMPR PSYCHIAT, V44, P234, DOI 10.1053/comp.2003.50014
   Brockington I, 2004, LANCET, V363, P303, DOI 10.1016/S0140-6736(03)15390-1
   Chaudron LH, 2001, J PSYCHOSOM OBST GYN, V22, P103, DOI 10.3109/01674820109049960
   Cyranowski JM, 2008, PSYCHOSOM MED, V70, P967, DOI 10.1097/PSY.0b013e318188ade4
   DEGEEST K, 1985, J PERINAT MED, V13, P3, DOI 10.1515/jpme.1985.13.1.3
   Dennis CL, 2009, PEDIATRICS, V123, pE736, DOI 10.1542/peds.2008-1629
   Engedal K, 2012, J AFFECT DISORDERS, V141, P227, DOI 10.1016/j.jad.2012.02.042
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Field T, 2010, INFANT BEHAV DEV, V33, P1, DOI 10.1016/j.infbeh.2009.10.005
   Figueiredo B, 2014, PSYCHOL MED, V44, P927, DOI 10.1017/S0033291713001530
   Forsling ML, 1998, EXP PHYSIOL, V83, P409
   Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db
   Gaynes B. N., 2005, AGENCY HLTH RES QUAL, V119, P1
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Grace S L, 2003, Arch Womens Ment Health, V6, P263, DOI 10.1007/s00737-003-0024-6
   Handlin L, 2009, BREASTFEED MED, V4, P207, DOI 10.1089/bfm.2009.0001
   Hawley CJ, 2002, J AFFECT DISORDERS, V72, P177, DOI 10.1016/S0165-0327(01)00451-7
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jonas W, 2008, ARCH WOMEN MENT HLTH, V11, P335, DOI 10.1007/s00737-008-0027-4
   Kim S, 2014, BRAIN RES, V1580, P133, DOI 10.1016/j.brainres.2013.10.050
   Kim S, 2014, BRAIN RES, V1580, P219, DOI 10.1016/j.brainres.2013.11.009
   Kirkan TS, 2015, INT J SOC PSYCHIATR, V61, P343, DOI 10.1177/0020764014543713
   KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35
   Kumsta R, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00083
   Lindahl V, 2005, ARCH WOMEN MENT HLTH, V8, P77, DOI 10.1007/s00737-005-0080-1
   Mah BL, 2015, DEPRESS ANXIETY, V32, P76, DOI 10.1002/da.22245
   Mah BL, 2013, PROG NEURO-PSYCHOPH, V40, P267, DOI 10.1016/j.pnpbp.2012.10.005
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
   Murray L, 2006, DEV PSYCHOPATHOL, V18, P489, DOI 10.1017/S0954579406060263
   Nissen E, 1996, EARLY HUM DEV, V45, P103, DOI 10.1016/0378-3782(96)01725-2
   Ohoka H, 2014, PSYCHIAT CLIN NEUROS, V68, P631, DOI 10.1111/pcn.12171
   Ozsoy S, 2009, PSYCHIAT RES, V169, P249, DOI 10.1016/j.psychres.2008.06.034
   Pang WW, 2007, J MAMMARY GLAND BIOL, V12, P211, DOI 10.1007/s10911-007-9054-4
   PEDERSEN CA, 1979, P NATL ACAD SCI USA, V76, P6661, DOI 10.1073/pnas.76.12.6661
   Silberman CD, 2006, ARQ NEURO-PSIQUIAT, V64, P407, DOI 10.1590/S0004-282X2006000300011
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Stuebe AM, 2013, J WOMENS HEALTH, V22, P352, DOI 10.1089/jwh.2012.3768
   Stuebe AM, 2012, J WOMENS HEALTH, V21, P264, DOI 10.1089/jwh.2011.3083
   Taveras EM, 2003, PEDIATRICS, V112, P108, DOI 10.1542/peds.112.1.108
   Watkins S, 2011, OBSTET GYNECOL, V118, P214, DOI 10.1097/AOG.0b013e3182260a2d
   Wisner KL, 2010, ARCH WOMEN MENT HLTH, V13, P37, DOI 10.1007/s00737-009-0119-9
   Yim IS, 2009, ARCH GEN PSYCHIAT, V66, P162, DOI 10.1001/archgenpsychiatry.2008.533
NR 49
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 1434-1816
EI 1435-1102
J9 ARCH WOMEN MENT HLTH
JI Arch. Womens Ment. Health
PD AUG
PY 2016
VL 19
IS 4
BP 571
EP 579
DI 10.1007/s00737-016-0644-2
PG 9
WC Psychiatry
SC Psychiatry
GA DS3VT
UT WOS:000380711500002
PM 27320943
ER

PT J
AU He, Y
   Wu, H
   He, XJ
   Xing, Q
   Zhou, P
   Cao, YX
   Wei, ZL
AF He, Ye
   Wu, Huan
   He, Xiaojin
   Xing, Qiong
   Zhou, Ping
   Cao, Yunxia
   Wei, Zhaolian
TI Administration of atosiban in patients with endometriosis undergoing
   frozen-thawed embryo transfer: a prospective, randomized study
SO FERTILITY AND STERILITY
LA English
DT Article
DE Atosiban; clinical pregnancy rate; endometriosis; oxytocin; uterine
   contractility
ID OXYTOCIN GENE-EXPRESSION; IN-VITRO FERTILIZATION; UTERINE PERISTALSIS;
   STROMAL CELLS; AROMATASE EXPRESSION; OVARIAN STIMULATION; PREGNANCY
   RATES; RECEPTOR; INFERTILITY; WOMEN
AB Objective: To examine the effects of atosiban, given before transfer of frozen-thawed embryo to women with endometriosis (EMs).
   Design: A randomized, controlled clinical trial.
   Setting: University hospital and IVF center.
   Patient(s): One hundred twenty women with endometriosis undergoing frozen-thawed embryo transfer were randomly allocated into the atosiban treatment and the control groups. Another 120 women with infertility due to tubal factor were enrolled into a tubal factor group, to compare serum oxytocin (OT) and prostaglandin (PG)F-2 alpha levels and uterine contractions with the endometriosis group.
   Intervention(s): In the endometriosis treatment group, a single bolus (6.75 mg, 0.9 mL per vial) of atosiban was administrated before ET.
   Main Outcome Measure(s): Implantation rate and pregnancy rate.
   Result(s): Serum OT level (1.89 +/- 0.33 vs. 1.66 +/- 0.32 ng/L), PGF(2 alpha) (2.83 +/- 0.34 vs. 2.36 +/- 0.35 ng/L) level, and uterine contractions (2.5 +/- 1.2 vs. 1.8 +/- 1.0 waves per minute) in the endometriosis group were all significantly higher than in the tubal factor group. The clinical pregnancy rate per cycle and implantation rate per transfer were 58.3% and 41.0%, respectively, in the atosiban treatment group, significantly higher than in the control group (38.3% and 23.4%, respectively).
   Conclusion(s): Women with endometriosis showed higher serum OT level, PGF(2 alpha) level, and uterine contractions. Atosiban treatment before ET in endometriosis is effective in the priming of the uterus, suitable for embryo implantation. This is the first study to evaluate the effect of atosiban treatment in patients with endometriosis.
C1 [He, Ye; Wu, Huan; He, Xiaojin; Xing, Qiong; Zhou, Ping; Cao, Yunxia; Wei, Zhaolian] Anhui Med Univ, Affiliated Hosp 1, Reprod Med Ctr, Dept Obstet & Gynecol, 218 Jixi Rd, Hefei, Peoples R China.
RP Wei, ZL (reprint author), Anhui Med Univ, Affiliated Hosp 1, Reprod Med Ctr, Dept Obstet & Gynecol, 218 Jixi Rd, Hefei, Peoples R China.
EM weizhaolian_1@126.com
CR Asselin E, 1996, BIOL REPROD, V54, P371, DOI 10.1095/biolreprod54.2.371
   Barnhart K, 2002, FERTIL STERIL, V77, P1148, DOI 10.1016/S0015-0282(02)03112-6
   Braileanu GT, 2001, REPRODUCTION, V121, P605, DOI 10.1530/rep.0.1210605
   DANETDESNOYERS G, 1994, REPROD FERT DEVELOP, V6, P193, DOI 10.1071/RD9940193
   de Ziegler D, 2010, LANCET, V376, P730, DOI 10.1016/S0140-6736(10)60490-4
   Defendini R, 1978, Res Publ Assoc Res Nerv Ment Dis, V56, P137
   Fanchin R, 2000, HUM REPROD, V15, P90
   Fanchin R, 1998, HUM REPROD, V13, P1968, DOI 10.1093/humrep/13.7.1968
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   GONEN Y, 1990, J IN VITRO FERTIL EM, V7, P146, DOI 10.1007/BF01135678
   Gryparis I, 2011, Minerva Ginecol, V63, P571
   Huddleston HG, 2011, FERTIL STERIL, V96, P797, DOI 10.1016/j.fertnstert.2011.06.023
   Husslein P, 2003, INT J CLIN PRACT, V57, P121
   Krikun G, 2009, THROMB RES, V124, P393, DOI 10.1016/j.thromres.2009.06.013
   Lan Vuong Thi Ngoc, 2012, Reprod Biomed Online, V25, P254, DOI 10.1016/j.rbmo.2012.05.014
   LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2556, DOI 10.1210/en.134.6.2556
   LEFEBVRE DL, 1994, ENDOCRINOLOGY, V134, P2562, DOI 10.1210/en.134.6.2562
   Leyendecker G, 1996, HUM REPROD, V11, P1542
   Leyendecker G, 1998, HUM REPROD UPDATE, V4, P752, DOI 10.1093/humupd/4.5.752
   Macer ML, 2012, OBSTET GYN CLIN N AM, V39, P535, DOI 10.1016/j.ogc.2012.10.002
   Mechsner SV, 2005, FERTIL STERIL, V83, P1220, DOI 10.1016/j.fertnstert.2004.11.038
   Mizumoto Y, 1995, ADV EXP MED BIOL, V395, P491
   Noble LS, 1997, J CLIN ENDOCR METAB, V82, P600, DOI 10.1210/jc.82.2.600
   Noble LS, 1996, J CLIN ENDOCR METAB, V81, P174, DOI 10.1210/jc.81.1.174
   Pierzynski P, 2007, FERTIL STERIL, V88, DOI 10.1016/j.fertnstert.2006.09.017
   The Practice Committee of the American Society for Reproductive Medicine, 2006, FERTIL STERIL, V86, pS156
   Purcell K, 2007, FERTIL STERIL, V87, P297, DOI 10.1016/j.fertnstert.2006.06.031
   Rickes D, 2002, FERTIL STERIL, V78, P757, DOI 10.1016/S0015-0282(02)03338-1
   Sales KJ, 2003, REPRODUCTION, V126, P559, DOI 10.1530/rep.0.1260559
   Simsek Y, 2012, ARCH GYNECOL OBSTET, V286, P777, DOI 10.1007/s00404-012-2390-7
   Steinwall M, 2004, BJOG-INT J OBSTET GY, V111, P266, DOI 10.1111/j.1471-0528.2004.00049.x
   Stormshak Fredrick, 2003, Reprod Biol Endocrinol, V1, P92, DOI 10.1186/1477-7827-1-92
   Surrey ES, 2015, BIOMED RES INT, DOI 10.1155/2015/482959
   Taylor RN, 2002, ANN NY ACAD SCI, V955, P89
   Taylor RN, 2002, ANN NY ACAD SCI, V955, P396
   Taylor RN, 2002, ANN NY ACAD SCI, V955, P18
   VASICKA A, 1977, AM J OBSTET GYNECOL, V127, P171
   Vedernikov Y, 2006, J SOC GYNECOL INVEST, V13, p192A
   Zhu L, 2014, HUM REPROD, V29, P1238, DOI 10.1093/humrep/deu058
   Zhu L, 2014, HUM REPROD, V29, P279, DOI 10.1093/humrep/det429
   Zhu L, 2012, HUM REPROD, V27, P2684, DOI 10.1093/humrep/des257
   ZINGG HH, 1995, RECENT PROG HORM RES, V50, P255
   [Anonymous], 1985, FERTIL STERIL, V43, P351
NR 43
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2016
VL 106
IS 2
BP 416
EP 422
DI 10.1016/j.fertnstert.2016.04.019
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DS4PQ
UT WOS:000380763400033
PM 27143518
ER

PT J
AU Dogra, S
   Sona, C
   Kumar, A
   Yadav, PN
AF Dogra, Shalini
   Sona, Chandan
   Kumar, Ajeet
   Yadav, Prem N.
TI Epigenetic regulation of G protein coupled receptor signaling and its
   implications in psychiatric disorders
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Epigenetic; HDAC; Histone methylation; Histone acetylation; DNA
   methylation; GPCR; CRH; CRHR1; Oxytocin; mGluR2; Endothelin receptors;
   CGRP; Opioids; Amygdala; VTA; DRG; GAD65; Depression; Addiction;
   Neuropathic pain
ID CORTICOTROPIN-RELEASING-FACTOR; HISTONE DEACETYLASE INHIBITORS; ADULT
   HIPPOCAMPAL NEUROGENESIS; SQUAMOUS-CELL CARCINOMA; ANXIETY-LIKE
   BEHAVIOR; FREELY MOVING RATS; DNA-METHYLATION; OPIOID RECEPTOR;
   NEUROPATHIC PAIN; NUCLEUS-ACCUMBENS
AB G protein-coupled receptors (GPCRs) act as a relay center through which extracellular signals, in the form of neurotransmitters or therapeutics, are converted into an intracellular response, which ultimately shapes the overall response at the tissue and behavioral level. Remarkably in similar ways, epigenetic mechanisms also modulate the expression pattern of a large number of genes in response to the dynamic environment inside and outside of the body, and consequently overall response. Emerging evidences from the pharmacogenomics and preclinical studies clearly suggest that these two distinct mechanisms crisscross each other in several neurological disorders. At one hand such cross-talks between two distinct mechanisms make disease etiology more challenging to understand, while on the other hand if dealt appropriately, such situations might provide an opportunity to find novel druggable target and strategy for the treatment of complex diseases. In this review article, we have summarized and highlighted the main findings that tie epigenetic mechanisms to GPCR mediated signaling in the pathophysiology of central nervous system (CNS) disorders, including depression, addiction and pain. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Dogra, Shalini; Sona, Chandan; Kumar, Ajeet; Yadav, Prem N.] CSIR Cent Drug Res Inst, Div Pharmacol, Lucknow 226031, Uttar Pradesh, India.
RP Yadav, PN (reprint author), CSIR Cent Drug Res Inst, Div Pharmacol, Sect 10,Sitapur Rd, Lucknow 226021, Uttar Pradesh, India.
EM pn.yadav@cdri.res.in
FU Ramanujan Fellowship; CSIR Network Grant THUNDER [BSC0102]; CSIR Network
   Grant UNDOO [BSC0103]; CSIR-SRF fellowship; UGC-SRF fellowship
FX This work is supported by Ramanujan Fellowship, and CSIR Network Grant
   THUNDER (BSC0102) and UNDOO (BSC0103) to PNY, CSIR-SRF fellowship to CS
   and UGC-SRF fellowship to SD and AK.
CR Albert PR, 2012, PHILOS T R SOC B, V367, P2402, DOI 10.1098/rstb.2011.0376
   Andria ML, 1999, MOL BRAIN RES, V70, P54, DOI 10.1016/S0169-328X(99)00126-6
   Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025
   Anzalone A, 2012, J NEUROSCI, V32, P9023, DOI 10.1523/JNEUROSCI.0918-12.2012
   Arborelius L, 1999, J ENDOCRINOL, V160, P1, DOI 10.1677/joe.0.1600001
   Ardayfio P, 2006, BEHAV NEUROSCI, V120, P249, DOI 10.1037/0735-7044.120.2.249
   ARO S, 1995, BRIT J PSYCHIAT, V166, P759, DOI 10.1192/bjp.166.6.759
   Artigas F, 2015, EUR NEUROPSYCHOPHARM, V25, P657, DOI 10.1016/j.euroneuro.2013.04.013
   Ayanwuyi LO, 2015, BRIT J PHARMACOL, V172, P5136, DOI 10.1111/bph.13280
   Bagot RC, 2012, P NATL ACAD SCI USA, V109, P17200, DOI 10.1073/pnas.1204599109
   Bai GA, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-51
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Barbier E, 2013, NEUROPSYCHOPHARMACOL, V38, P976, DOI 10.1038/npp.2012.261
   Bertaina-Anglade V, 2006, BEHAV PHARMACOL, V17, P703, DOI 10.1097/FBP.0b013e3280116e5c
   Bie BH, 2012, NEUROPSYCHOPHARMACOL, V37, P2780, DOI 10.1038/npp.2012.144
   Binshtok AM, 2008, J NEUROSCI, V28, P14062, DOI 10.1523/JNEUROSCI.3795-08.2008
   Bosker FJ, 2011, MOL PSYCHIATR, V16, P516, DOI 10.1038/mp.2010.38
   Boue J, 2014, GASTROENTEROLOGY, V146, P166, DOI 10.1053/j.gastro.2013.09.020
   Boulle F, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.125
   Bowery NG, 2006, CURR OPIN PHARMACOL, V6, P37, DOI 10.1016/j.coph.2005.10.002
   BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8
   Brami-Cherrier K, 2014, MOL PSYCHIATR, V19, P1193, DOI 10.1038/mp.2014.67
   Buchheit T, 2012, PAIN MED, V13, P1474, DOI 10.1111/j.1526-4637.2012.01488.x
   Buckholtz JW, 2010, SCIENCE, V329, P532, DOI 10.1126/science.1185778
   Butelman ER, 2012, TRENDS NEUROSCI, V35, P587, DOI 10.1016/j.tins.2012.05.005
   Caberlotto L, 2001, NEUROPSYCHOPHARMACOL, V25, P91, DOI 10.1016/S0893-133X(00)00231-1
   CARLIER M, 1982, BEHAV NEURAL BIOL, V35, P205, DOI 10.1016/S0163-1047(82)91213-4
   Carreira EU, 2013, EUR J PAIN, V17, P654, DOI 10.1002/j.1532-2149.2012.00240.x
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Celada P, 2004, J PSYCHIATR NEUROSCI, V29, P252
   Charbogne P, 2014, NEUROPHARMACOLOGY, V76, P204, DOI 10.1016/j.neuropharm.2013.08.028
   Chen YC, 2004, P NATL ACAD SCI USA, V101, P15782, DOI 10.1073/pnas.0403975101
   Cherng CH, 2014, J FORMOS MED ASSOC, V113, P513, DOI 10.1016/j.jfma.2013.04.007
   Chiechio S, 2002, MOL PHARMACOL, V61, P989, DOI 10.1124/mol.61.5.989
   Chiechio S, 2009, MOL PHARMACOL, V75, P1014, DOI 10.1124/mol.108.054346
   Chiechio S, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-20
   Chiechio S, 2010, TRENDS PHARMACOL SCI, V31, P153, DOI 10.1016/j.tips.2009.12.003
   Comings DE, 1996, PHARMACOGENETICS, V6, P223, DOI 10.1097/00008571-199606000-00004
   Connelly ST, 2004, J PAIN, V5, P505, DOI 10.1016/j.jpain.2004.09.002
   Covington HE, 2011, NEURON, V71, P656, DOI 10.1016/j.neuron.2011.06.007
   Covington HE, 2009, J NEUROSCI, V29, P11451, DOI 10.1523/JNEUROSCI.1758-09.2009
   Crow M, 2015, FASEB J, V29, P3370, DOI 10.1096/fj.14-264440
   Cuccurazzu B, 2013, NEUROPSYCHOPHARMACOL, V38, P2220, DOI 10.1038/npp.2013.121
   D'Addario C, 2013, J MOL NEUROSCI, V49, P312, DOI 10.1007/s12031-012-9829-y
   D'Addario C, 2011, FASEB J, V25, P1069, DOI 10.1096/fj.10-168534
   de Bodinat C, 2010, NAT REV DRUG DISCOV, V9, P628, DOI 10.1038/nrd3140
   Delis F, 2012, ALCOHOL CLIN EXP RES, V36, P815, DOI 10.1111/j.1530-0277.2011.01667.x
   DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   DICKENSON AH, 1987, NEUROPHARMACOLOGY, V26, P1235, DOI 10.1016/0028-3908(87)90275-9
   DiNieri JA, 2011, BIOL PSYCHIAT, V70, P763, DOI 10.1016/j.biopsych.2011.06.027
   Doehring A, 2013, PAIN, V154, P15, DOI 10.1016/j.pain.2012.06.011
   Dogra S, 2015, EUR J PHARMACOL, V763, P184, DOI 10.1016/j.ejphar.2015.07.018
   Dong Y, 2006, NAT NEUROSCI, V9, P475, DOI 10.1038/nn1661
   Doze VA, 2012, PHARMACOL REV, V64, P645, DOI 10.1124/pr.111.004762
   DUNCAN MJ, 1993, DEV BRAIN RES, V73, P205, DOI 10.1016/0165-3806(93)90140-6
   Ebner K, 2009, CURR PHARM DESIGN, V15, P1647
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrich E, 2015, NEUROPSYCHOPHARMACOL, V40, P1448, DOI 10.1038/npp.2014.330
   Ehrich JM, 2014, NEUROPSYCHOPHARMACOL, V39, P3036, DOI 10.1038/npp.2014.157
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Elhwuegi AS, 2004, PROG NEURO-PSYCHOPH, V28, P435, DOI 10.1016/j.pnpbp.2003.11.018
   Elliott E, 2010, NAT NEUROSCI, V13, P1351, DOI 10.1038/nn.2642
   Entringer S, 2009, HORM BEHAV, V55, P292, DOI 10.1016/j.yhbeh.2008.11.006
   Falkenberg VR, 2011, NEUROMOL MED, V13, P66, DOI 10.1007/s12017-010-8138-2
   Fan JM, 2009, NEUROSCIENCE, V159, P1363, DOI 10.1016/j.neuroscience.2009.02.009
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Frisch P, 2010, BEHAV BRAIN RES, V213, P103, DOI 10.1016/j.bbr.2010.04.044
   Gaillard S, 2014, NEURON, V84, P123, DOI 10.1016/j.neuron.2014.08.056
   Germain A, 2008, HUM PSYCHOPHARM CLIN, V23, P571, DOI 10.1002/hup.964
   GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143
   Gold PW, 2015, MOL PSYCHIATR, V20, P32, DOI 10.1038/mp.2014.163
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Goudet C, 2009, BRAIN RES REV, V60, P43, DOI 10.1016/j.brainresrev.2008.12.007
   Gourley SL, 2008, BIOL PSYCHIAT, V63, P353, DOI 10.1016/j.biopsych.2007.07.016
   Gozen O, 2013, SYNAPSE, V67, P545, DOI 10.1002/syn.21659
   Graeff J, 2011, PHYSIOL REV, V91, P603, DOI 10.1152/physrev.00012.2010
   Gundersen BB, 2009, NEUROPHARMACOLOGY, V57, P67, DOI 10.1016/j.neuropharm.2009.04.008
   Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389
   Hanack C, 2015, CELL, V160, P759, DOI 10.1016/j.cell.2015.01.022
   Harony-Nicolas H, 2014, PSYCHONEUROENDOCRINO, V39, P121, DOI 10.1016/j.psyneuen.2013.10.004
   Harwood AJ, 2003, CURR MOL MED, V3, P472, DOI 10.2174/1566524033479672
   Heuser I, 1998, Depress Anxiety, V8, P71, DOI 10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.3.CO;2-E
   Hickie IB, 2011, LANCET, V378, P621, DOI 10.1016/S0140-6736(11)60095-0
   Hillemacher T, 2015, PROG NEURO-PSYCHOPH, V63, P30, DOI 10.1016/j.pnpbp.2015.05.013
   Hodes GE, 2015, J NEUROSCI, V35, P16362, DOI 10.1523/JNEUROSCI.1392-15.2015
   Huang GJ, 2005, NEUROSCIENCE, V135, P803, DOI 10.1016/j.neuroscience.2005.05.056
   Husum H, 2008, INT J NEUROPSYCHOPH, V11, P93, DOI 10.1017/S146114570700778X
   Hwang CK, 2007, MOL CELL BIOL, V27, P4720, DOI 10.1128/MCB.00073-07
   Hwang CK, 2010, MOL PHARMACOL, V78, P58, DOI 10.1124/mol.110.064311
   Hwang CK, 2009, J CELL MOL MED, V13, P3591, DOI 10.1111/j.1582-4934.2008.00535.x
   Hwang JH, 1997, PAIN, V70, P15
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ishida Y, 2009, J NEURAL TRANSM-SUPP, P129, DOI 10.1007/978-3-211-92660-4_10
   Jack A, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00280
   Jha S, 2008, NEUROSCI LETT, V441, P210, DOI 10.1016/j.neulet.2008.06.028
   Jiao J, 2013, MOL PSYCHIATR, V18, P1273, DOI 10.1038/mp.2012.136
   Johnston JD, 2015, J ENDOCRINOL, V226, pT187, DOI 10.1530/JOE-15-0119
   Kalda Anti, 2015, Int Rev Neurobiol, V120, P85, DOI 10.1016/bs.irn.2015.02.010
   KALIVAS PW, 1984, NEUROSCI LETT, V48, P55, DOI 10.1016/0304-3940(84)90288-X
   Kallupi M, 2013, BIOL PSYCHIAT, V74, P520, DOI 10.1016/j.biopsych.2013.04.028
   Karg K, 2011, ARCH GEN PSYCHIAT, V68, P444, DOI 10.1001/archgenpsychiatry.2010.189
   Karpova NN, 2014, NEUROPHARMACOLOGY, V76, P709, DOI 10.1016/j.neuropharm.2013.04.002
   KEEGAN CE, 1994, ENDOCRINOLOGY, V134, P2547, DOI 10.1210/en.134.6.2547
   Kendler KS, 2007, ARCH GEN PSYCHIAT, V64, P1313, DOI 10.1001/archpsyc.64.11.1313
   Kiguchi N, 2012, J PHARMACOL EXP THER, V340, P577, DOI 10.1124/jpet.111.187724
   Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200
   Kim T.K., 2015, MOL NEUROBIOL
   Klengel T, 2013, NAT NEUROSCI, V16, P33, DOI 10.1038/nn.3275
   Koehl M, 1997, BRAIN RES, V759, P317, DOI 10.1016/S0006-8993(97)00394-6
   Koenig JI, 2005, BEHAV BRAIN RES, V156, P251, DOI 10.1016/j.bbr.2004.05.030
   Kombian SB, 2003, J NEUROPHYSIOL, V89, P728, DOI 10.1152/jn.00854.2002
   Koutmani Y, 2013, MOL PSYCHIATR, V18, P300, DOI 10.1038/mp.2012.198
   Kubo K, 2009, J PHARMACOL EXP THER, V331, P162, DOI 10.1124/jpet.109.156034
   Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8
   Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231
   Kyzar EJ, 2015, NEUROSCI LETT, V601, P11, DOI 10.1016/j.neulet.2015.01.051
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Laviola G, 2004, PSYCHOPHARMACOLOGY, V175, P196, DOI 10.1007/s00213-004-1800-3
   Le Francois B, 2015, NEUROBIOL DIS, V82, P332, DOI 10.1016/j.nbd.2015.07.002
   Lee JH, 2002, MOL CELL BIOL, V22, P7658, DOI 10.1128/MCB.22.21.7658-7666.2002
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905
   Malan TP, 2002, ANESTHESIOLOGY, V96, P1161, DOI 10.1097/00000542-200205000-00020
   Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234
   Malberg JE, 2000, J NEUROSCI, V20, P9104
   Manjavachi MN, 2014, NEUROPHARMACOLOGY, V79, P17, DOI 10.1016/j.neuropharm.2013.10.026
   McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Mehta D, 2013, P NATL ACAD SCI USA, V110, P8302, DOI 10.1073/pnas.1217750110
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Murgatroyd C, 2009, NAT NEUROSCI, V12, P1559, DOI 10.1038/nn.2436
   Murray F, 2008, EUR J PHARMACOL, V583, P115, DOI 10.1016/j.ejphar.2008.01.014
   Nagre NN, 2015, J NEUROCHEM, V132, P429, DOI 10.1111/jnc.13006
   NEMEROFF CB, 1991, BRIT J PSYCHIAT, V158, P59, DOI 10.1192/bjp.158.1.59
   NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362
   Nestler Eric J, 2005, Sci Pract Perspect, V3, P4
   Nestler Eric J, 2013, Dialogues Clin Neurosci, V15, P431
   Neugebauer V, 2001, NEUROTHERAPEUTICS, V1, P207, DOI [10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.0.CO;2-3, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.0.CO;2-3]
   Nielsen DA, 2009, NEUROPSYCHOPHARMACOL, V34, P867, DOI 10.1038/npp.2008.108
   Nielson DA, 2012, PHARMACOGENOMICS, V13, P1149, DOI [10.2217/pgs.12.94, 10.2217/PGS.12.94]
   Osikowicz M, 2013, EXP PHYSIOL, V98, P372, DOI 10.1113/expphysiol.2012.069922
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Paquette AG, 2013, EPIGENETICS-US, V8, P796, DOI 10.4161/epi.25358
   Park SW, 2008, NEUROSCIENCE, V151, P1034, DOI 10.1016/j.neuroscience.2007.12.015
   Patel S, 2001, PAIN, V90, P217, DOI 10.1016/S0304-3959(00)00404-8
   Pena CJ, 2014, J MOL BIOL, V426, P3389, DOI 10.1016/j.jmb.2014.03.016
   Peter CJ, 2011, TRENDS MOL MED, V17, P372, DOI 10.1016/j.molmed.2011.02.003
   Pevet Paul, 2002, Dialogues Clin Neurosci, V4, P57
   Puglia MH, 2015, P NATL ACAD SCI USA, V112, P3308, DOI 10.1073/pnas.1422096112
   RAADSHEER FC, 1995, AM J PSYCHIAT, V152, P1372
   Radley JJ, 2002, BRAIN RES, V955, P264, DOI 10.1016/S0006-8993(02)03477-7
   Reiner I, 2015, J PSYCHIATR RES, V65, P9, DOI 10.1016/j.jpsychires.2015.03.012
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Renthal William, 2009, Dialogues Clin Neurosci, V11, P257
   Revest JM, 2009, MOL PSYCHIATR, V14, P959, DOI 10.1038/mp.2009.15
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Ruhe HG, 2007, MOL PSYCHIATR, V12, P331, DOI 10.1038/sj.mp.4001949
   Ruiz-Velasco V, 2002, PHYSIOL GENOMICS, V8, P41
   Sanchis-Segura C, 2009, NEUROPSYCHOPHARMACOL, V34, P2642, DOI 10.1038/npp.2009.125
   Sandman CA, 2011, INT J PEPT, V2011, DOI DOI 10.1155/2011/837596
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Schank JR, 2014, NEUROPSYCHOPHARMACOL, V39, P1093, DOI 10.1038/npp.2013.309
   Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019
   Schmidt BL, 2007, EUR J PAIN, V11, P406, DOI 10.1016/j.ejpain.2006.05.007
   Schroeder FA, 2008, NEUROPSYCHOPHARMACOL, V33, P2981, DOI 10.1038/npp.2008.15
   Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2
   SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2
   SIVILOTTI L, 1994, J NEUROPHYSIOL, V72, P169
   Sotnikov SV, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.127
   Soumier A., 2009, MECH CONTRIBUTING PH
   Sterrenburg L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028128
   Subbanna S., 2014, INT J NEUROPSYCHOPHA, V18
   Suderman M, 2012, P NATL ACAD SCI USA, V109, P17266, DOI 10.1073/pnas.1121260109
   Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552
   Sun Y, 2014, J PAIN, V15, P856, DOI 10.1016/j.jpain.2014.05.003
   Sun Y, 2013, ANESTHESIOLOGY, V119, P1198, DOI 10.1097/ALN.0b013e31829ce340
   Suri D, 2013, BIOL PSYCHIAT, V73, P658, DOI 10.1016/j.biopsych.2012.10.023
   Taqi MM, 2011, ADDICT BIOL, V16, P499, DOI 10.1111/j.1369-1600.2011.00323.x
   Tarantino Lisa M, 2011, Front Psychiatry, V2, P44, DOI 10.3389/fpsyt.2011.00044
   Tepper JM, 1997, J NEUROSCI, V17, P2519
   Tournier BB, 2013, INT J NEUROPSYCHOPH, V16, P1819, DOI 10.1017/S1461145713000205
   Tran L, 2015, MOL PSYCHIATR, V20, P1219, DOI 10.1038/mp.2014.122
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659
   Uchida H, 2010, J NEUROSCI, V30, P4806, DOI 10.1523/JNEUROSCI.5541-09.2010
   Ulrich D, 2007, CURR OPIN NEUROBIOL, V17, P298, DOI 10.1016/j.conb.2007.04.001
   Unternaehrer E, 2015, STRESS, V18, P451, DOI 10.3109/10253890.2015.1038992
   Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5
   VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699
   van der Doelen RHA, 2015, DEV PSYCHOPATHOL, V27, P123, DOI 10.1017/S0954579414001345
   Velasquez JC, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00047
   Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001
   Viet CT, 2011, PAIN, V152, P2323, DOI 10.1016/j.pain.2011.06.025
   Volkow ND, 2011, P NATL ACAD SCI USA, V108, P15037, DOI 10.1073/pnas.1010654108
   WADDINGTON HK, 1957, AM J OBSTET GYNECOL, V73, P816
   Walker BM, 2011, ADDICT BIOL, V16, P116, DOI 10.1111/j.1369-1600.2010.00226.x
   Wallace-Boone TL, 2008, NEUROPSYCHOPHARMACOL, V33, P1919, DOI 10.1038/sj.npp.1301586
   Wan QR, 2014, BEHAV BRAIN RES, V271, P1, DOI 10.1016/j.bbr.2014.05.031
   Wang X, 2013, MOL NEUROBIOL, V48, P544, DOI 10.1007/s12035-013-8444-4
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Winkler I, 2005, BRIT J PHARMACOL, V146, P198, DOI 10.1038/sj.bjp.0706310
   Wise RA, 2009, TRENDS NEUROSCI, V32, P517, DOI 10.1016/j.tins.2009.06.004
   Wockner LF, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.111
   WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Wortwein G, 2006, PROG NEURO-PSYCHOPH, V30, P684, DOI 10.1016/j.pnpbp.2006.01.027
   YAKSH TL, 1989, PAIN, V37, P111, DOI 10.1016/0304-3959(89)90160-7
   Yu JM, 2006, MOL CELL BIOCHEM, V288, P17, DOI 10.1007/s11010-005-9113-3
   Zhang TY, 2010, J NEUROSCI, V30, P13130, DOI 10.1523/JNEUROSCI.1039-10.2010
   Zhang Z, 2011, NAT MED, V17, P1448, DOI 10.1038/nm.2442
   Zhang ZJ, 2013, PAIN, V154, P2185, DOI 10.1016/j.pain.2013.07.002
NR 216
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD AUG
PY 2016
VL 77
BP 226
EP 239
DI 10.1016/j.biocel.2016.03.012
PN B
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DT7EN
UT WOS:000381650000008
PM 27046448
ER

PT J
AU Cook, N
   Miller, J
   Hart, J
AF Cook, Naomi
   Miller, Jennifer
   Hart, John
TI Parent observed neuro-behavioral and pro-social improvements with
   oxytocin following surgical resection of craniopharyngioma
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE craniopharyngioma; intra-nasal oxytocin; panhypopituitarism; pro-social
   behavior; quality of life
ID QUALITY-OF-LIFE; CHILDHOOD CRANIOPHARYNGIOMA; INTRANASAL OXYTOCIN;
   CHILDREN; SYSTEM
AB Social and emotional impairment, school dysfunction, and neurobehavioral impairment are highly prevalent in survivors of childhood craniopharyngioma and negatively affect quality of life. As surgical resection of craniopharyngioma typically impairs hypothalamic/pituitary function, it has been postulated that perhaps post- operative deficiency of the hormone oxytocin may be the etiology of social/emotional impairment. Research on the benefits of oxytocin treatment as a hormone facilitating social interaction is well established. However, no research has yet been conducted on patients with known pituitary/hypothalamic dysfunction due to structural lesions or surgery. This case report investigates the effects of oxytocin therapy on a youngster with pituitary/hypothalamic dysfunction after craniopharyngioma removal. In this individual, treatment with low dose intranasal oxytocin resulted in increased desire for socialization and improvement in affection towards family. In light of these findings, the authors believe that further research into the potential benefits of intranasal oxytocin therapy for patients with panhypopituitarism is necessary to determine whether a broader population may also benefit from intranasal oxytocin therapy.
C1 [Miller, Jennifer] Univ Florida, Dept Pediat, Gainesville, FL 32611 USA.
   [Cook, Naomi] Nurse Naomi Press, Sydney, NSW, Australia.
   [Hart, John] Elevate Sydney Clin, Sydney, NSW, Australia.
RP Miller, J (reprint author), Univ Florida, Dept Pediat, Gainesville, FL 32611 USA.
EM millejl@peds.ufl.edu
CR Caldwell HK, 2015, HORM BEHAV, V75, P150
   Dolson EP, 2009, PEDIATR BLOOD CANCER, V52, P860, DOI 10.1002/pbc.21947
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   IsHak WW, 2011, J AFFECT DISORDERS, V130, P1, DOI 10.1016/j.jad.2010.06.001
   Kosaka H, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-110
   Lancaster K, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00132
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Muller HL, 2013, PITUITARY, V16, P56, DOI 10.1007/s11102-012-0401-0
   Muller HL, 2012, J CLIN ENDOCR METAB, V97, P3935, DOI 10.1210/jc.2012-2069
   Pedreira CC, 2006, J PEDIATR ENDOCR MET, V19, P15
   Poretti A, 2004, DEV MED CHILD NEUROL, V46, P220, DOI 10.1017/S0012162204000374
   Sobota R, 2015, BEHAV NEUROSCI, V129, P389, DOI 10.1037/bne0000074
   Stoop R, 2014, CURR OPIN NEUROBIOL, V29, P187, DOI 10.1016/j.conb.2014.09.012
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Wirth MM, 2015, NEUROPSYCHOBIOLOGY, V71, P202, DOI 10.1159/000381023
   Yatawara C.J., 2015, MOL PSYCHIAT
   Zada G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076562
NR 18
TC 1
Z9 1
U1 1
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0334-018X
EI 2191-0251
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD AUG
PY 2016
VL 29
IS 8
BP 995
EP 1000
DI 10.1515/jpem-2015-0445
PG 6
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA DS4ND
UT WOS:000380756900018
PM 27166717
ER

PT J
AU Dobrzynski, A
   Max, A
   Jurka, P
AF Dobrzynski, Artur
   Max, Andrzej
   Jurka, Piotr
TI Methods of prolonging a pregnancy threatened with preterm labour
SO MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE
LA Polish
DT Review
DE pregnancy; premature delivery; pathologies of the bearing; progesterone;
   terbutaline
ID OXYTOCIN RECEPTOR; INDUCED PARTURITION; EXPRESSION; ATOSIBAN; UTERINE;
   BITCHES; CANINE; PROGESTERONE; WOMEN; RECOMMENDATIONS
AB Both prolonged and shortened pregnancies carry the risk of increased mortality of the offspring. The main causes of early delivery are genetic factors, bacterial and viral infections, corpus luteum insufficiency and pathologies of the placenta. Antepartum luteolysis is due to the activity of prostaglandin F2 alpha. A decrease in the progesterone concentration activates the sensitivity of the uterine muscles to oxytocin. Calcium ions move into the myocytes and bind to calmodulin, starting enzymatic reactions necessary for muscle contraction. Oxytocin promotes prostaglandin F2 alpha release. Cholesterol and magnesium stimulate the binding of oxytocin to its receptors. A premature delivery is caused by a disorder of the balance between contractility and relaxation of the myometrium, which is regulated by many signalling pathways. Birth in humans can be postponed by the use of many different tocolytic medications, beta-adrenergic drugs (ritodrine, hexoprenaline, fenoterol, terbutaline), magnesium salts, prostaglandin synthesis inhibitors (indomethacin, naproxen), pentoxifylline, metoprolol, calcium antagonists - calcium channel blockers (nifedipine), oxytocine antagonists (atosiban), nitric oxide donors (nitroglycerin) as well as progesterone and its synthetic analogs. In dogs and cats, in the presence of endogenous hormone deficiency, progesterone and its derivatives (gestagens) are recommended. In small animals with the risk of premature delivery, terbutaline has successfully been used. Premature delivery is a serious problem in both human and veterinary medicine, and experience from human medicine is being gradually introduced into veterinary practice.
C1 [Dobrzynski, Artur; Max, Andrzej; Jurka, Piotr] Szkola Glowna Gospodarstwa Wiejskiego Warszawie, Katedra Chorob Malych Zwierzat & Klin, Wydzial Med Weterynaryjnej, Ul Nowoursynowska 159c, PL-02776 Warsaw, Poland.
RP Dobrzynski, A (reprint author), Ul Nowoursynowska 159 C, PL-02776 Warsaw, Poland.
EM artur_dobrzynski@sggw.pl
CR Aissi A., 2008, American Journal of Animal and Veterinary Sciences, V3, P32
   Beccaglia M, 2012, REPROD DOMEST ANIM, V47, P194, DOI 10.1111/rda.12006
   Blencowe H, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-S1-S2
   Borthwick AD, 2011, MED RES REV, V31, P576, DOI 10.1002/med.20193
   Bresciani KDS, 2009, PARASITOL RES, V104, P1213, DOI 10.1007/s00436-008-1317-5
   Bresciani KDS, 1999, VET PARASITOL, V86, P143, DOI 10.1016/S0304-4017(99)00136-3
   Brizot ML, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.02.021
   Buxton I. L., 2011, ACTA PHARMACOL SIN, P758
   Buxton ILO, 2004, MOL PHARMACOL, V65, P1051, DOI 10.1124/mol.65.5.1051
   Cabrol D, 2001, EUR J OBSTET GYN R B, V98, P177
   CHAMBERLAIN DM, 1953, P SOC EXP BIOL MED, V82, P198
   CONCANNON PW, 1989, J REPROD FERTIL, P3
   Cushing TL, 2011, J COMP PATHOL, V145, P352, DOI 10.1016/j.jcpa.2011.03.007
   Davidson A. P., 2012, P 7 INT S CAN FEL RE, P12
   Martinez de Tejada B., 2015, BJOG, V122, P80
   Franczak A, 2005, ANIM REPROD SCI, V88, P325, DOI 10.1016/j.antireprosci.2004.12.011
   FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gorlinger S, 2005, THERIOGENOLOGY, V64, P213, DOI 10.1016/j.theriogenology.2004.12.011
   Gram A, 2014, REPROD DOMEST ANIM, V49, P41, DOI 10.1111/rda.12295
   Johnson CA, 2008, THERIOGENOLOGY, V70, P1424, DOI 10.1016/j.theriogenology.2008.09.010
   Kimber-Trojnar Z, 2010, GINEKOL POL, V81, P120
   KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0
   Kimura T, 1996, ENDOCRINOLOGY, V137, P780, DOI 10.1210/en.137.2.780
   Kis A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083993
   Klarenbeek M, 2007, THERIOGENOLOGY, V68, P1169, DOI 10.1016/j.theriogenology.2007.08.017
   Kowalewski MP, 2010, REPRODUCTION, V139, P655, DOI 10.1530/REP-09-0140
   Lopate C, 2008, THERIOGENOLOGY, V70, P397, DOI 10.1016/j.theriogenology.2008.05.034
   Marx Peter, 2011, Neuropsychopharmacol Hung, V13, P139
   Michel E, 2011, REPROD DOMEST ANIM, V46, P926, DOI 10.1111/j.1439-0531.2011.01763.x
   Mitsuya K, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113209
   Otaibi M A., 2014, CALCIUM SIGNALING, V1, P70
   Reinheimer Torsten M, 2007, BMC Pregnancy Childbirth, V7 Suppl 1, pS15, DOI 10.1186/1471-2393-7-S1-S15
   Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965
   Romero Roberto, 2011, Womens Health (Lond), V7, P501, DOI 10.2217/whe.11.60
   Saleh SS, 2013, J OBSTET GYNAECOL, V33, P43, DOI 10.3109/01443615.2012.721822
   Shim JY, 2006, BJOG-INT J OBSTET GY, V113, P1228, DOI 10.1111/j.1471-0528.2006.01053.x
   Siemieniuch MJ, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/364787
   Siemieniuch MJ, 2011, ANIM REPROD SCI, V123, P89, DOI 10.1016/j.anireprosci.2010.10.015
   Slager J, 2012, J MIDWIFERY WOM HEAL, V57, P12, DOI 10.1111/j.1542-2011.2012.00210.x
   Socha P, 2011, B VET I PULAWY, V55, P71
   Sotiriadis A, 2012, ULTRASOUND OBST GYN, V40, P257, DOI 10.1002/uog.11178
   Thornton S, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.015
   Tita ATN, 2009, AM J OBSTET GYNECOL, V200, P219, DOI 10.1016/j.ajog.2008.12.035
   Tsatsaris V, 2004, DRUGS, V64, P375, DOI 10.2165/00003495-200464040-00003
   Ulrich C, 2013, AM J PHYSIOL-CELL PH, V305, pC803, DOI 10.1152/ajpcell.00198.2013
   Veiga GAL, 2015, BRAZ J MED BIOL RES, V48, P339, DOI 10.1590/1414-431X20143969
   Vogel J. P., 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006169, DOI 10.1002/14651858.CD006169]
   Wanke MM, 2006, THERIOGENOLOGY, V66, P1579, DOI 10.1016/j.theriogenology.2006.01.013
   Wiebe VJ, 2009, TOP COMPANION ANIM M, V24, P71, DOI 10.1053/j.tcam.2008.12.004
   Wielgos M, 2014, GINEKOL POL, V85, P332
   Wood S, 2012, J PERINAT MED, V40, P593, DOI 10.1515/jpm-2012-0057
   Worldwide Atosiban versus Beta-agonists Study Group, 2001, BJOG, V108, P133
   Yuan W, 2007, BMC PREGNANCY CHI S1, V7
NR 54
TC 0
Z9 0
U1 7
U2 7
PU POLISH SOC VETERINARY SCIENCES EDITORIAL OFFICE
PI LUBLIN
PA AKADEMICKA 12, 20-950 LUBLIN, POLAND
SN 0025-8628
J9 MED WETER
JI Med. Weter.
PD AUG
PY 2016
VL 72
IS 8
BP 479
EP 483
DI 10.21521/mw.5550
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA DS8XH
UT WOS:000381065800003
ER

PT J
AU Motojima, Y
   Kawasaki, M
   Matsuura, T
   Saito, R
   Yoshimura, M
   Hashimoto, H
   Ueno, H
   Maruyama, T
   Suzuki, H
   Ohnishi, H
   Sakai, A
   Ueta, Y
AF Motojima, Yasuhito
   Kawasaki, Makoto
   Matsuura, Takanori
   Saito, Reiko
   Yoshimura, Mitsuhiro
   Hashimoto, Hirofumi
   Ueno, Hiromichi
   Maruyama, Takashi
   Suzuki, Hitoshi
   Ohnishi, Hideo
   Sakai, Akinori
   Ueta, Yoichi
TI Effects of peripherally administered cholecystokinin-8 and secretin on
   feeding/drinking and oxytocin-mRFP1 fluorescence in transgenic rats
SO NEUROSCIENCE RESEARCH
LA English
DT Article
DE Brainstem; Cholecystokinin-8; Fluorescent protein; Hypothalamus;
   Oxytocin; Secretin
ID FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; BRAIN-STEM; GLUTAMATERGIC NEURONS;
   FOS EXPRESSION; KNOCKOUT MICE; INHIBITS FOOD; HYPOTHALAMUS; RECEPTOR;
   BEHAVIOR
AB Peripheral administration of cholecystokinin (CCK)-8 or secretin activates oxytocin (OXT)-secreting neurons in the hypothalamus. Although OXT is involved in the regulation of feeding behavior, detailed mechanism remains unclear. In the present study, we examined the central OXTergic pathways after intraperitoneally (i.p.) administration of CCK-8 and secretin using male OXT-monomeric red fluorescent protein 1 (mRFP1) transgenic rats and male Wistar rats. I.p. administration of CCK-8 (50 mu g/kg) and secretin (100 mu g/kg) decreased food intake in these rats. While i.p. administration of CCK-8 decreased water intake, i.p. administration of secretin increased water intake. Immunohistochemical study revealed that Fos-Like-Immunoreactive cells were observed abundantly in the brainstem and in the OXT neurons in the dorsal division of the parvocellular paraventricular nucleus (dpPVN). We could observe marked increase of mRFP1 fluorescence, as an indicator for OXT, in the dpPVN and mRFP1-positive granules in axon terminals of the dpPVN OXT neurons in the nucleus tractus solitarius (NTS) after i.p. administration of CCK-8 and secretin. These results provide us the evidence that, at least in part, i.p. administration of CCK-8 or secretin might be involved in the regulation of feeding/drinking via a OXTergic pathway from the dpPVN to the NTS. (C) 2016 Elsevier Ireland Ltd and Japan Neuroscience Society. All rights reserved.
C1 [Motojima, Yasuhito; Matsuura, Takanori; Saito, Reiko; Yoshimura, Mitsuhiro; Hashimoto, Hirofumi; Ueno, Hiromichi; Maruyama, Takashi; Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan.
   [Motojima, Yasuhito; Kawasaki, Makoto; Matsuura, Takanori; Ohnishi, Hideo; Sakai, Akinori] Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed, Kitakyushu, Fukuoka 8078555, Japan.
   [Suzuki, Hitoshi] Univ Occupat & Environm Hlth, Wakamatsu Hosp, Dept Orthopaed, Kitakyushu, Fukuoka 8080024, Japan.
RP Ueta, Y (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM yoichi@med.uoeh-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [25113721]; Japan Society for the Promotion of Science (JSPS) [25293055,
   26860164, 25462391, 15K10500]; University of Occupational and
   Environmental Health (UOEH) Research Grant for Advanced Research from
   UOEH, Japan; University of Occupational and Environmental Health
   Research Grant for the Promotion of Occupational Health from UOEH, Japan
FX We thank Dr. Roger Tsien (University of California, San Diego, CA, USA)
   for supplying the mRFP1 clone and Ms. Kanako Shoguchi and Ms. Yuki
   Nonaka (University of Occupational and Environmental Health, Kitakyushu,
   Japan) for their technical assistance. This work was supported by a
   Grant-in-Aid for Scientific Research on Innovative Areas 'fluorescence
   live imaging' number 25113721 of the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT), Grants-in-Aid for Scientific
   Research (B) number 25293055, (B) number 26860164, (C) number 25462391,
   and (C) number 15K10500 from the Japan Society for the Promotion of
   Science (JSPS), a University of Occupational and Environmental Health
   (UOEH) Research Grant for Advanced Research from UOEH, Japan, and a
   University of Occupational and Environmental Health Research Grant for
   the Promotion of Occupational Health to M.K. from UOEH, Japan,
CR ARLETTI R, 1990, PHYSIOL BEHAV, V48, P825, DOI 10.1016/0031-9384(90)90234-U
   ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   Blevins JE, 2003, BRAIN RES, V993, P30, DOI 10.1016/j.brainres.2003.08.036
   Cheng CYY, 2011, NEUROPSYCHOPHARMACOL, V36, P459, DOI 10.1038/npp.2010.178
   Chu JYS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064859
   Chu JYS, 2011, KIDNEY INT, V79, P280, DOI 10.1038/ki.2010.397
   Chu JYS, 2009, P NATL ACAD SCI USA, V106, P15961, DOI 10.1073/pnas.0903695106
   CUNNINGHAM ET, 1988, J COMP NEUROL, V274, P60, DOI 10.1002/cne.902740107
   DAY HEW, 1994, NEUROPHARMACOLOGY, V33, P719, DOI 10.1016/0028-3908(94)90111-2
   Dogrukol-Ak D, 2004, CURR PHARM DESIGN, V10, P1325, DOI 10.2174/1381612043384934
   Ebenezer IS, 1996, P ROY SOC B-BIOL SCI, V263, P491, DOI 10.1098/rspb.1996.0074
   Higashida H, 2010, J NEUROENDOCRINOL, V22, P373, DOI 10.1111/j.1365-2826.2010.01976.x
   Ho JM, 2014, ENDOCRINOLOGY, V155, P2845, DOI 10.1210/en.2014-1148
   Katoh A, 2014, J NEUROENDOCRINOL, V26, P341, DOI 10.1111/jne.12150
   Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006
   Kublaoui BM, 2008, MOL ENDOCRINOL, V22, P1723, DOI 10.1210/me.2008-0067
   Leng G, 2008, PROG BRAIN RES, V170, P137, DOI 10.1016/S0079-6123(08)00413-5
   LUCKMAN SM, 1992, J NEUROENDOCRINOL, V4, P149, DOI 10.1111/j.1365-2826.1992.tb00152.x
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002
   Matsuura T, 2015, J NEUROENDOCRINOL, V27, P636, DOI 10.1111/jne.12290
   MCCANN MJ, 1988, J AUTONOM NERV SYST, V23, P265, DOI 10.1016/0165-1838(88)90101-4
   OLSON BR, 1991, ENDOCRINOLOGY, V129, P785
   OLSON BR, 1992, BRAIN RES, V569, P238, DOI 10.1016/0006-8993(92)90635-M
   Ong ZY, 2015, AM J PHYSIOL-REG I, V308, pR800, DOI 10.1152/ajpregu.00534.2014
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Pedersen CA, 2006, GENES BRAIN BEHAV, V5, P274, DOI 10.1111/j.1601-183X.2005.00162.x
   POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2
   RENAUD LP, 1987, AM J PHYSIOL, V253, pR661
   Rinaman L, 2002, AM J PHYSIOL-REG I, V283, pR99, DOI 10.1152/ajpregu.00008.2002
   RITTER RC, 1985, AM J PHYSIOL, V248, pR501
   Sabatier N, 2003, ANN NY ACAD SCI, V994, P218
   Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016
   Shah BP, 2014, P NATL ACAD SCI USA, V111, P13193, DOI 10.1073/pnas.1407843111
   Siljee JE, 2013, EUR J ENDOCRINOL, V168, P361, DOI 10.1530/EJE-12-0750
   Singru PS, 2012, ENDOCRINOLOGY, V153, P3804, DOI 10.1210/en.2012-1235
   SMITH GP, 1981, PEPTIDES, V2, P409, DOI 10.1016/S0196-9781(81)80096-4
   SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475
   Ueta Y, 2000, J AUTONOM NERV SYST, V78, P69, DOI 10.1016/S0165-1838(99)00049-1
   Velmurugan S, 2010, ENDOCRINOLOGY, V151, P2681, DOI 10.1210/en.2009-1440
   VERBALIS JG, 1986, SCIENCE, V232, P1417, DOI 10.1126/science.3715453
   Yang H, 2004, NEUROSCIENCE, V128, P131, DOI 10.1016/j.neuroscience.2004.06.027
NR 42
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD AUG
PY 2016
VL 109
BP 63
EP 69
DI 10.1016/j.neures.2016.02.005
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DT7DD
UT WOS:000381646400008
PM 26919961
ER

PT J
AU French, CA
   Cong, XM
   Chung, KS
AF French, Cynthia A.
   Cong, Xiaomei
   Chung, Keun Sam
TI Labor Epidural Analgesia and Breastfeeding: A Systematic Review
SO JOURNAL OF HUMAN LACTATION
LA English
DT Review
DE breastfeeding; epidural analgesia; labor
ID FULL-TERM NEWBORNS; INTRAPARTUM FEVER; HUMAN-MILK; DELIVERY; ANESTHESIA;
   IMPACT; TEMPERATURE; DURATION; BEHAVIOR; MOTHER
AB Despite widespread use of epidural analgesia during labor, no consensus has been reached among obstetric and anesthesia providers regarding its effects on breastfeeding. The purpose of this review was to examine the relationship between labor epidural analgesia and breastfeeding in the immediate postpartum period. PubMed, Cochrane Library, and Cumulative Index to Nursing and Allied Health Literature were searched for articles published in 1990 or thereafter, using the search term breastfeeding combined with epidural, labor epidural analgesia, labor analgesia, or epidural analgesia. Of 117 articles, 23 described empirical studies specific to labor epidural analgesia and measured a breastfeeding outcome. Results were conflicting: 12 studies showed negative associations between epidural analgesia and breastfeeding success, 10 studies showed no effect, and 1 study showed a positive association. Most studies were observational. Of 3 randomized controlled studies, randomization methods were inadequate in 2 and not evaluable in 1. Other limitations were related to small sample size or inadequate study power; variation and lack of information regarding type and dosage of analgesia or use of other intrapartum interventions; differences in timing, definition, and method of assessing breastfeeding success; or failure to consider factors such as mothers' intention to breastfeed, social support, siblings, or the mother's need to return to work or school. It is also unclear to what extent results are mediated through effects on infant neurobehavior, maternal fever, oxytocin release, duration of labor, and need for instrumental delivery. Clinician awareness of factors affecting breastfeeding can help identify women at risk for breastfeeding difficulties in order to target support and resources effectively.
C1 [French, Cynthia A.] Columbia Univ, Grad Program Nurse Anesthesia, New York, NY USA.
   [French, Cynthia A.] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA.
   [Cong, Xiaomei] Univ Connecticut, Sch Nursing, Storrs, CT USA.
   [Chung, Keun Sam] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
RP French, CA (reprint author), Columbia Univ, Grad Program Nurse Anesthesia, Nursing, 617 West 168th St, New York, NY 10032 USA.
EM cf2608@cumc.columbia.edu
CR Albani A, 1999, Minerva Anestesiol, V65, P625
   American College of Obstetricians and Gynecologists, 2007, OBSTET GYNECOL, V109, P479
   AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340
   Anim-Somuah M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub2
   Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3
   Armani Marta, 2013, Acta Biomed, V84, P117
   Baumgarder DJ, 2003, J AM BOARD FAM PRACT, V16, P7
   Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016
   Bell AF, 2010, JOGNN-J OBST GYN NEO, V39, P178, DOI 10.1111/j.1552-6909.2010.01100.x
   Bystrova K, 2009, BIRTH-ISS PERINAT C, V36, P97, DOI 10.1111/j.1523-536X.2009.00307.x
   CAMANN WR, 1991, BRIT J ANAESTH, V67, P565, DOI 10.1093/bja/67.5.565
   Cambic CR, 2010, BRIT J ANAESTH, V105, pI50, DOI 10.1093/bja/aeq311
   Chang ZM, 2005, J HUM LACT, V21, P305, DOI 10.1177/0890334405277604
   Chen Yong-mei, 2008, Zhonghua Fu Chan Ke Za Zhi, V43, P502
   Curtin WM, 2015, J PERINATOL, V35, P396, DOI 10.1038/jp.2014.235
   Dozier AM, 2013, MATERN CHILD HLTH J, V17, P689, DOI 10.1007/s10995-012-1045-4
   Eidelman AI, 2012, BREASTFEED MED, V7, P323, DOI 10.1089/bfm.2012.0067
   Gizzo S, 2012, BREASTFEED MED, V7, P262, DOI 10.1089/bfm.2011.0099
   Greenwell EA, 2012, PEDIATRICS, V129, pE447, DOI 10.1542/peds.2010-2301
   Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x
   Hasegawa J, 2013, J ANESTH, V27, P43, DOI 10.1007/s00540-012-1480-9
   HAWKINS JL, 1995, REGION ANESTH, V20, P50
   Henderson JJ, 2003, AUST NZ J OBSTET GYN, V43, P372, DOI 10.1046/j.0004-8666.2003.t01-1-00117.x
   Ip S, 2007, EVID REP TECHNOL ASS, V153, P1, DOI DOI 10.1542/GR.18-2-15
   Ip S, 2009, BREASTFEED MED, V4, pS17, DOI 10.1089/bfm.2009.0050
   Jensen D, 1994, J Obstet Gynecol Neonatal Nurs, V23, P27, DOI 10.1111/j.1552-6909.1994.tb01847.x
   Jones L, 2012, COCHRANE DB SYST REV, V3
   Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x
   Jordan S, 2009, BJOG-INT J OBSTET GY, V116, P1622, DOI 10.1111/j.1471-0528.2009.02256.x
   Kramer MS, 2008, ARCH GEN PSYCHIAT, V65, P578, DOI 10.1001/archpsyc.65.5.578
   Leff E W, 1994, J Hum Lact, V10, P99, DOI 10.1177/089033449401000216
   Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1016/j.jclinepi.2009.06.006]
   Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415
   Matthews M K, 1988, Midwifery, V4, P154, DOI 10.1016/S0266-6138(88)80071-8
   Montgomery A, 2012, BREASTFEED MED, V7, P547, DOI 10.1089/bfm.2012.9977
   Moore ER, 2012, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD003519.PUB3
   Nguyen USDT, 2010, MATERN CHILD HLTH J, V14, P705, DOI 10.1007/s10995-009-0515-9
   Nyqvist K H, 1996, J Hum Lact, V12, P207, DOI 10.1177/089033449601200318
   PATERSON CM, 1992, BRIT J OBSTET GYNAEC, V99, P377, DOI 10.1111/j.1471-0528.1992.tb13752.x
   Radzyminski S, 2005, JOGNN-J OBST GYN NEO, V34, P335, DOI 10.1177/0884217505276283
   Radzyminski S, 2003, JOGNN, V32, P322, DOI 10.1177/0884217503253440
   RAJAN L, 1994, MIDWIFERY, V10, P87, DOI 10.1016/S0266-6138(05)80250-5
   Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x
   Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103
   SALARIYA EM, 1978, LANCET, V2, P1141
   Schwarz EB, 2009, OBSTET GYNECOL, V113, P974, DOI 10.1097/01.AOG.0000346884.67796.ca
   Sng BL, 2014, COCHRANE DB SYST REV, V10
   Stuebe AM, 2009, ARCH INTERN MED, V169, P1364, DOI 10.1001/archinternmed.2009.231
   Sullivan S, 2010, J PEDIATR-US, V156, P562, DOI 10.1016/j.jpeds.2009.10.040
   Szabo AL, 2013, ANESTH ANALG, V116, P399, DOI 10.1213/ANE.0b013e318273f63c
   Torvaldsen Siranda, 2006, Int Breastfeed J, V1, P24, DOI 10.1186/1746-4358-1-24
   Volmanen P, 2004, INT J OBSTET ANESTH, V13, P1, DOI 10.1016/j.ijos.2003.10.002
   Wang BP Li QL Hu YF, 2005, DI YI JUN YI DA XUE, V25, P118
   Wang BP, 2005, DI YI JUN YI DA XUE, V25, P114
   WESTGREN M, 1986, J PERINAT MED, V14, P235, DOI 10.1515/jpme.1986.14.4.235
   WIBERG B, 1989, SCAND J SOC MED, V17, P181
   Wieczorek PM, 2010, INT J OBSTET ANESTH, V19, P273, DOI 10.1016/j.ijoa.2010.02.001
   Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005
   Wilson MJA, 2010, ANAESTHESIA, V65, P145, DOI 10.1111/j.1365-2044.2009.06136.x
   Wright JG, 2003, J BONE JOINT SURG AM, V85A, P1
NR 60
TC 0
Z9 0
U1 12
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-3344
EI 1552-5732
J9 J HUM LACT
JI J. Hum. Lact.
PD AUG
PY 2016
VL 32
IS 3
BP 507
EP 520
DI 10.1177/0890334415623779
PG 14
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA DS0HI
UT WOS:000380275800021
PM 27121239
ER

PT J
AU Smith, AS
   Avram, SKW
   Cymerblit-Sabba, A
   Song, J
   Young, WS
AF Smith, A. S.
   Avram, S. K. Williams
   Cymerblit-Sabba, A.
   Song, J.
   Young, W. S.
TI Targeted activation of the hippocampal CA2 area strongly enhances social
   memory
SO MOLECULAR PSYCHIATRY
LA English
DT Article
ID VASOPRESSIN 1B RECEPTOR; ARGININE-VASOPRESSIN; MALE-RATS; LATERAL
   SEPTUM; MUS-MUSCULUS; RECOGNITION; OXYTOCIN; MICE; INNERVATION;
   RETRIEVAL
AB Social cognition enables individuals to understand others' intentions. Social memory is a necessary component of this process, for without it, subsequent encounters are devoid of any historical information. The CA2 area of the hippocampus, particularly the vasopressin 1b receptor (Avpr1b) expressed there, is necessary for memory formation. We used optogenetics to excite vasopressin terminals, originating from the hypothalamic paraventricular nucleus, in the CA2 of mice. This markedly enhanced their social memory if the stimulation occurred during memory acquisition, but not retrieval. This effect was blocked by an Avpr1b antagonist. Finally, this enhanced memory is resistant to the social distraction of an introduced second mouse, important for socially navigating populations of individuals. Our results indicate the CA2 can increase the salience of social signals. Targeted pharmacotherapy with Avpr1b agonists or deep brain stimulation of the CA2 are potential avenues of treatment for those with declining social memory as in various dementias.
C1 [Smith, A. S.; Avram, S. K. Williams; Cymerblit-Sabba, A.; Song, J.; Young, W. S.] NIMH, Sect Neural Gene Express, NIH, 9000 Rockville Pike,Bldg 49,Room 5A56, Bethesda, MD 20892 USA.
RP Smith, AS; Young, WS (reprint author), NIMH, Sect Neural Gene Express, NIH, 9000 Rockville Pike,Bldg 49,Room 5A56, Bethesda, MD 20892 USA.
EM adam.smith@nih.gov; wsy@mail.nih.gov
FU NIMH [ZIA-MH-002498-24]
FX We thank Emily Shepard for assistance with mouse colony maintenance and
   genotyping. We are grateful for the gifts of the vasopressin antibody
   from Harold Gainer and HSV from Ted Usdin. Alex Avram kindly wrote the
   software we used to control the optogenetic stimulations. We also thank
   Stafford Lightman and Michael Brownstein for their comments on a
   previous version of this manuscript. This research was supported by the
   intramural research program of the NIMH (ZIA-MH-002498-24).
CR Abel T, 2001, CURR OPIN NEUROBIOL, V11, P180, DOI 10.1016/S0959-4388(00)00194-X
   AlescioLautier B, 1995, EUR J PHARMACOL, V294, P763, DOI 10.1016/0014-2999(95)00632-X
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   BLUTHE RM, 1993, PSYCHONEUROENDOCRINO, V18, P323, DOI 10.1016/0306-4530(93)90028-J
   CAFFE AR, 1987, J COMP NEUROL, V261, P237, DOI 10.1002/cne.902610206
   Chevaleyre V, 2010, NEURON, V66, P560, DOI 10.1016/j.neuron.2010.04.013
   Cohen NJ, 1993, MEMORY AMNESIA HIPPO
   Cui ZZ, 2013, J COMP NEUROL, V521, P1844, DOI 10.1002/cne.23263
   DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192
   DANTZER R, 1988, BRAIN RES, V457, P143, DOI 10.1016/0006-8993(88)90066-2
   Davidson PSR, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00531
   de No RL, 1934, J PSYCHOL NEUROL, V46, P113
   Denny CA, 2014, NEURON, V83, P189, DOI 10.1016/j.neuron.2014.05.018
   DeVito LM, 2009, J NEUROSCI, V29, P2676, DOI 10.1523/JNEUROSCI.5488-08.2009
   DEVRIES GJ, 1983, BRAIN RES, V273, P307, DOI 10.1016/0006-8993(83)90855-7
   Dluzen DE, 1998, PEPTIDES, V19, P999, DOI 10.1016/S0196-9781(98)00047-3
   Duff MC, 2008, J CLIN EXP NEUROPSYC, V30, P931, DOI 10.1080/13803390801894681
   Eichenbaum H, 2014, NEURON, V83, P764, DOI 10.1016/j.neuron.2014.07.032
   Engelmann M, 2009, NEUROBIOL LEARN MEM, V91, P58, DOI 10.1016/j.nlm.2008.08.009
   Engelmann M, 2008, PROG BRAIN RES, V170, P389, DOI 10.1016/S0079-6123(08)00432-9
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007
   Greidanus TBV, 1996, BRAIN RES, V713, P153
   Griffin AL, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00054
   Hartley T, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2012.0510
   Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028
   Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6
   LANDGRAF R, 1991, NEUROENDOCRINOLOGY, V54, P378, DOI 10.1159/000125917
   LASHLEY KS, 1950, SYM SOC EXP BIOL, V4, P454
   Lein ES, 2005, J COMP NEUROL, V485, P1, DOI 10.1002/cne.20426
   LEMOAL M, 1987, NEUROSCI LETT, V77, P353, DOI 10.1016/0304-3940(87)90527-1
   Liu X, 2012, NATURE, V484, P381, DOI 10.1038/nature11028
   McNamara CG, 2014, NAT NEUROSCI, V17, P1658, DOI 10.1038/nn.3843
   O'Keefe J, 1978, HIPPOCAMPUS COGNITIV
   [Anonymous], 2014, PSYCHIATRY
   Ramirez S, 2013, SCIENCE, V341, P387, DOI 10.1126/science.1239073
   Redondo RL, 2014, NATURE, V513, P426, DOI 10.1038/nature13725
   Reijmers Leon, 2009, Front Mol Neurosci, V2, P27, DOI 10.3389/neuro.02.027.2009
   Rood BD, 2013, J COMP NEUROL, V521, P2321, DOI 10.1002/cne.23288
   Semon Richard Wolfgang, 1921, THE MNEME
   Stevenson EL, 2014, EUR J NEUROSCI, V40, P3294, DOI 10.1111/ejn.12689
   Tanaka KZ, 2014, NEURON, V84, P347, DOI 10.1016/j.neuron.2014.09.037
   Tavares RM, 2015, NEURON, V87, P231, DOI 10.1016/j.neuron.2015.06.011
   Warren DE, 2012, CLIN NEUROPSYCHOL, V26, P335, DOI 10.1080/13854046.2012.655781
   Wersinger SR, 2008, ENDOCRINOLOGY, V149, P116, DOI 10.1210/en.2007-1056
   Wersinger SR, 2002, MOL PSYCHIATR, V7, P975, DOI 10.1038/sj.mp.4001195
   WOODHAMS PL, 1993, HIPPOCAMPUS, V3, P303
   Yiu AP, 2014, NEURON, V83, P722, DOI 10.1016/j.neuron.2014.07.017
   Young WS, 2006, NEUROSCIENCE, V143, P1031, DOI 10.1016/j.neuroscience.2006.08.040
   Zhang L, 2013, NEUROSCIENCE, V228, P139, DOI 10.1016/j.neuroscience.2012.10.010
   Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406
   Zynyuk L, 2012, HIPPOCAMPUS, V22, P1405, DOI 10.1002/hipo.20977
NR 52
TC 4
Z9 4
U1 8
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD AUG
PY 2016
VL 21
IS 8
BP 1137
EP 1144
DI 10.1038/mp.2015.189
PG 8
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA DS4GN
UT WOS:000380739500018
PM 26728562
ER

PT J
AU Oya, K
   Matsuda, Y
   Matsunaga, S
   Kishi, T
   Iwata, N
AF Oya, Kazuto
   Matsuda, Yuki
   Matsunaga, Shinji
   Kishi, Taro
   Iwata, Nakao
TI Efficacy and safety of oxytocin augmentation therapy for schizophrenia:
   an updated systematic review and meta-analysis of randomized,
   placebo-controlled trials
SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
LA English
DT Review
DE Oxytocin; Schizophrenia; Systematic review; Meta-analysis
ID INTRANASAL OXYTOCIN; SOCIAL-PERCEPTION; DOUBLE-BLIND; PSYCHOTIC
   SYMPTOMS; HUMANS; RECOGNITION; VASOPRESSIN; COGNITION; SKILLS; SCALE
AB The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients' data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = -0.44, 95 % CI -0.82 to -0.06, p = 0.02, I (2) = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = -0.46, 95 % CI -1.20 to 0.28, p = 0.22, I (2) = 80 %, N = 6, n = 162), positive symptoms (SMD = -0.18, 95 % CI -0.87 to 0.51, p = 0.60, I (2) = 81 %, N = 6, n = 192), and negative symptoms (SMD = -0.34, 95 % CI -0.76 to 0.08, p = 0.12, I (2) = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = -0.44, 95 % CI -0.87 to -0.01, p = 0.04, I (2) = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.
C1 [Oya, Kazuto; Matsuda, Yuki; Matsunaga, Shinji; Kishi, Taro; Iwata, Nakao] Fujita Hlth Univ, Dept Psychiat, Sch Med, Toyoake, Aichi 4701192, Japan.
RP Kishi, T (reprint author), Fujita Hlth Univ, Dept Psychiat, Sch Med, Toyoake, Aichi 4701192, Japan.
EM tarok@fujita-hu.ac.jp
CR Andreasen N, 1984, SCALE ASSESSMENT NEG
   Averbeck BB, 2012, PSYCHOL MED, V42, P259, DOI 10.1017/S0033291711001413
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Cacciotti-Saija C, 2015, SCHIZOPHRENIA BULL, V41, P483, DOI 10.1093/schbul/sbu094
   Chapman CD, 2013, PHARM RES-DORDR, V30, P2475, DOI 10.1007/s11095-012-0915-1
   Davis MC, 2014, NEUROPSYCHOPHARMACOL, V39, P2070, DOI 10.1038/npp.2014.68
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Fischer-Shofty M, 2013, SCHIZOPHR RES, V146, P357, DOI 10.1016/j.schres.2013.01.006
   Fischer-Shofty M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00127
   Forbes C, 2010, SCHIZOPHR RES, V124, P36, DOI 10.1016/j.schres.2010.08.039
   Gibson CM, 2014, SCHIZOPHR RES, V156, P261, DOI 10.1016/j.schres.2014.04.009
   Goldman MB, 2011, PSYCHOPHARMACOLOGY, V216, P101, DOI 10.1007/s00213-011-2193-8
   Green S., 2005, SMJ Singapore Medical Journal, V46, P270
   Green S, 2005, SINGAP MED J, V46, P274
   Gumley A, 2014, BRIT J CLIN PSYCHOL, V53, P42, DOI 10.1111/bjc.12041
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Holka-Pokorska J, 2014, PSYCHIATR POL, V48, P19
   KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lee MR, 2013, SCHIZOPHR RES, V145, P110, DOI 10.1016/j.schres.2013.01.001
   Leucht S, 2009, LANCET, V373, P31, DOI [10.1016/S0140-6736(08)61764-X, 10.1016/S01406736(08)61764-X]
   MacDonald AW, 2009, SCHIZOPHRENIA BULL, V35, P493, DOI 10.1093/schbul/sbp017
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   Meltzer HY, 2004, CNS SPECTRUMS, V9, P15
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Miyamoto S, 2012, MOL PSYCHIATR, V17, P1206, DOI 10.1038/mp.2012.47
   Modabbernia A, 2013, CNS DRUGS, V27, P57, DOI 10.1007/s40263-012-0022-1
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   OVERALL JE, 1962, PSYCHOL REP, V10, P799
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Penn DL, 2009, SCHIZOPHR RES, V115, P17, DOI 10.1016/j.schres.2009.08.016
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Walters Yasmin, 2014, Psychiatr Danub, V26 Suppl 1, P285
NR 34
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0940-1334
EI 1433-8491
J9 EUR ARCH PSY CLIN N
JI Eur. Arch. Psych. Clin. Neurosci.
PD AUG
PY 2016
VL 266
IS 5
BP 439
EP 450
DI 10.1007/s00406-015-0634-9
PG 12
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DR2LQ
UT WOS:000379736400007
PM 26303414
ER

PT J
AU Milewski, M
   Goodey, A
   Lee, D
   Rimmer, E
   Saklatvala, R
   Koyama, S
   Iwashima, M
   Haruta, S
AF Milewski, Mikolaj
   Goodey, Adrian
   Lee, Dinah
   Rimmer, Eric
   Saklatvala, Robert
   Koyama, Shuzo
   Iwashima, Mic
   Haruta, Shunji
TI Rapid Absorption of Dry-Powder Intranasal Oxytocin
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE intranasal absorption; peptide; pharmacokinetics; preclinical; stability
ID DIVALENT METAL-IONS; STABILIZE OXYTOCIN; DELIVERY; STRATEGY; CITRATE
AB To probe the suitability of a dry-powder oxytocin formulation containing a carrier (mu co (TM); SNBL, Ltd.) for intranasal (IN) administration to treat post-partum hemorrhage in the developing world. Specifically, to investigate (1) whether IN administration can achieve rapid systemic absorption in cynomolgus monkeys, and (2) whether the formulation exhibits sufficient physical and chemical stability. This study was conducted to support Merck for Mothers, Merck's 10-year global initiative to end preventable maternal deaths.
   A partial-crossover pharmacokinetic (PK) study in cynomolgus monkeys (n = 6) was utilized to compare in vivo absorption of dry-powder IN oxytocin at three dose levels against an IM injection of an aqueous oxytocin formulation. Particle size distribution, delivered dose and chemical assay were monitored over a 12 month stability study.
   IN administration of oxytocin resulted in short (5 min) T-max and good dose linearity in AUC and C-max over the dose range tested (10-80 IU per animal). The relative bioavailability (BA) of IN oxytocin to IM injection was approximately 12%. The 80 IU formulation exhibited good physical stability and consistent dosing. After 12 months at 30A degrees C/65%RH, pouched samples retained 86.0% of their original assay value.
   The PK and stability data suggests that IN administration of oxytocin formulated in the mu co (TM) carrier may represent a viable option for rapid systemic absorption in humans and a product compatible with resource-scarce regions.
C1 [Milewski, Mikolaj; Goodey, Adrian; Lee, Dinah; Rimmer, Eric; Saklatvala, Robert] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ 07033 USA.
   [Koyama, Shuzo; Iwashima, Mic; Haruta, Shunji] Shin Nippon Biomed Labs Ltd, TR Div, Kagoshima, Japan.
RP Milewski, M (reprint author), Merck & Co Inc, Merck Res Labs, Kenilworth, NJ 07033 USA.
EM mikolaj.milewski@merck.com
FU Merck & Co., Inc., Kenilworth, NJ through its Merck for Mothers program
FX The authors would like to thank Pastorus Pharma, LLC owner of the
   license for the dry-powder oxytocin formulation for making it available
   for Merck-for-Mothers study and sharing pharmacokinetic data of an
   independent study involving intranasal oxytocin. This research was
   supported by funding from Merck & Co., Inc., Kenilworth, NJ through its
   Merck for Mothers program, a $500 Million, 10-year initiative to
   reducing maternal mortality.
CR Avanti C, 2012, MOL PHARMACEUT, V9, P554, DOI 10.1021/mp200622z
   Avanti C, 2011, AAPS J, V13, P284, DOI 10.1208/s12248-011-9268-7
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   DEGROOT ANJA, 1995, J PHARM PHARMACOL, V47, P571
   Dina Abbas JD, 2015, PROPOSAL INCLUSION M
   Fabio K, 2015, AAPS PHARMSCITECH
   HARKEMA JR, 1991, TOXICOL PATHOL, V19, P321
   Mousaand HA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003249
   OHAGAN DT, 1990, CRIT REV THER DRUG, V7, P35
   Ozsoy Y, 2009, MOLECULES, V14, P3754, DOI 10.3390/molecules14093754
   Prankerd RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082965
   Suman JD, 2003, EXPERT OPIN BIOL TH, V3, P519, DOI 10.1517/14712598.3.3.519
   United Nations, 2015, WE CAN END POV MILL
   WHO UNICEF UNFPA World Bank Group and United Nations Population Division, 2015, TRENDS MAT MORT 1990
NR 15
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD AUG
PY 2016
VL 33
IS 8
BP 1936
EP 1944
DI 10.1007/s11095-016-1929-x
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DR5EK
UT WOS:000379925700011
PM 27194003
ER

PT J
AU Young, RC
AF Young, Roger C.
TI Mechanotransduction mechanisms for coordinating uterine contractions in
   human labor
SO REPRODUCTION
LA English
DT Review
ID PREGNANT HUMAN UTERUS; ELECTRICAL-ACTIVITY; PROPAGATION VELOCITY;
   GAP-JUNCTIONS; MYOMETRIUM; SYNCHRONIZATION; PARTURITION; OXYTOCIN;
   VOLUME; MUSCLE
AB This review presents evolving concepts of how the human uterus contracts in pregnancy, with emphasis on the mechanisms of long-distance signaling. Action potential propagation has historically been assumed to be the sole mechanism for signaling and tissue recruitment over both short and long distances. However, data in animals and humans indicate that a single action potential does not travel distances greater than a few centimeters. To address this enigma, a long-distance signaling mechanism based on hydraulic signaling and mechanotransduction is developed. By combining this mechanism for long-distance signaling with the action potential propagation mechanism for signaling over short distances, a comprehensive dual mechanism model (or 'dual model') of uterine function is formulated. Mechanotransduction is an accepted phenomenon of myometrium, but the dual model identifies mechanotransduction as relevant to normal labor. For hydraulic signaling, a local contraction slightly increases intrauterine pressure, which globally increases wall tension. Increased wall tension then mechanically induces additional local contractions that further raise pressure. This leads to robust, positive feedback recruitment that explains the emergence of consistently strong contractions of human labor. Three key components of the dual model - rapid long-distance signaling, mechanical triggering, and electrical activity converge with the concept of mechanically sensitive electrogenic pacemakers distributed throughout the wall. The dual model retains excitation-contraction coupling and action potential propagation for signaling over short distances (<10 cm) and hence is an extension of the action potential model rather than a replacement.
C1 [Young, Roger C.] PreTel Inc, Memphis, TN 38120 USA.
   [Young, Roger C.] Univ Newcastle, Newcastle, NSW, Australia.
   [Young, Roger C.] Imperial Coll London, Chelsea & Westminster Hosp, London, England.
RP Young, RC (reprint author), PreTel Inc, Memphis, TN 38120 USA.; Young, RC (reprint author), Univ Newcastle, Newcastle, NSW, Australia.; Young, RC (reprint author), Imperial Coll London, Chelsea & Westminster Hosp, London, England.
EM ryoung@pretelhealth.com
CR ALVAREZ H, 1950, SURG GYNECOL OBSTET, V91, P1
   Banney D, 2015, SYMMETRY-BASEL, V7, P1981, DOI 10.3390/sym7041981
   Barclay M, 2010, REPROD SCI, V17, P948, DOI 10.1177/1933719110376544
   BOZLER E, 1947, AM J PHYSIOL, V149, P299
   CALDEYROBARCIA R, 1959, ANN NY ACAD SCI, V75, P813, DOI 10.1111/j.1749-6632.1959.tb44593.x
   CALDEYROBARCIA R, 1957, J PHARMACOL EXP THER, V121, P18
   Caldeyro-Barcia R, 1952, BRIT J OBSTET GYNAEC, V59, P646
   Csapo A, 1970, Obstet Gynecol Surv, V25, P515, DOI 10.1097/00006254-197006000-00001
   Csapo A, 1970, Obstet Gynecol Surv, V25, P403, DOI 10.1097/00006254-197005000-00001
   CSAPO A, 1957, P NATL ACAD SCI USA, V43, P278, DOI 10.1073/pnas.43.3.278
   CSAPO A, 1959, ANN NY ACAD SCI, V81, P453, DOI 10.1111/j.1749-6632.1959.tb49327.x
   CSAPO AI, 1963, AM J OBSTET GYNECOL, V85, P819
   CSAPO AI, 1963, AM J OBSTET GYNECOL, V85, P806
   CSAPO AI, 1965, AM J OBSTET GYNECOL, V91, P221
   CSAPO ARPAD I., 1963, NATURE, V200, P680, DOI 10.1038/200680a0
   Embrey M P, 1967, J Obstet Gynaecol Br Commonw, V74, P44
   GARFIELD RE, 1977, SCIENCE, V198, P958, DOI 10.1126/science.929182
   GARFIELD RE, 1995, SEMIN PERINATOL, V19, P41, DOI 10.1016/S0146-0005(95)80046-8
   JEFFCOATE TNA, 1948, CAN MED ASSOC J, V58, P42
   Lammers WJEP, 2008, AM J PHYSIOL-REG I, V294, pR919, DOI 10.1152/ajpregu.00704.2007
   Lammers WJEP, 2013, REPROD SCI, V20, P182, DOI 10.1177/1933719112446082
   Lucovnik M., 2011, AM J OBSTET GYNECOL, V204, P228
   Mikkelsen E, 2013, ACTA OBSTET GYN SCAN, V92, P1070, DOI 10.1111/aogs.12190
   MIRONNEAU J, 1973, J PHYSIOL-LONDON, V233, P127
   PARKINGTON HC, 1988, J REPROD FERTIL, V82, P697
   Rabotti C, 2015, ACTA PHYSIOL, V213, P406, DOI 10.1111/apha.12424
   Rabotti C, 2011, AM J OBSTET GYNECOL, V205, pE9, DOI 10.1016/j.ajog.2011.06.071
   Rabotti C, 2010, IEEE T BIO-MED ENG, V57, P2178, DOI 10.1109/TBME.2010.2049111
   Ramon Ceon, 2005, Biomed Eng Online, V4, P55, DOI 10.1186/1475-925X-4-55
   SIGGER JN, 1984, J REPROD FERTIL, V70, P103
   Smith R, 2015, AM J OBSTET GYNECOL, V213, P181, DOI 10.1016/j.ajog.2015.06.040
   TAKEDA H, 1965, FERTIL STERIL, V16, P113
   WOLFS G, 1971, OBSTET GYNECOL, V37, P241
   Wolfs G M, 1979, Acta Obstet Gynecol Scand Suppl, V90, P1
   Wray S, 2015, ACTA PHYSIOL, V213, P417, DOI 10.1111/apha.12431
   Young RC, 2015, J BIOMECH, V48, P1614, DOI 10.1016/j.jbiomech.2015.02.002
   Young RC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003850
   Young RC, 2011, REPROD SCI, V18, P64, DOI 10.1177/1933719110379637
NR 38
TC 0
Z9 0
U1 4
U2 4
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD AUG
PY 2016
VL 152
IS 2
BP R51
EP R61
DI 10.1530/REP-16-0156
PG 11
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA DR7DA
UT WOS:000380059000003
PM 27165050
ER

PT J
AU Uzefovsky, F
   Doring, AK
   Knafo-Noam, A
AF Uzefovsky, Florina
   Doring, Anna K.
   Knafo-Noam, Ariel
TI Values in Middle Childhood: Social and Genetic Contributions
SO SOCIAL DEVELOPMENT
LA English
DT Article
DE children's values; value priorities; genetics; twin study
ID ENVIRONMENTAL-INFLUENCES; VALUE SOCIALIZATION; PROSOCIAL BEHAVIOR;
   OXYTOCIN RECEPTOR; VALUE PRIORITIES; SEX-DIFFERENCES; GENDER; CHILDREN;
   ISRAEL; TRANSMISSION
AB Theories of value development often identify adolescence as the period for value formation, and cultural and familial factors as the sources for value priorities. However, recent research suggests that value priorities can be observed as early as in middle childhood, and several studies, including one on preadolescents, have suggested a genetic contribution to individual differences in values. In the current study, 174 pairs of monozygotic and dizygotic seven-year-old Israeli twins completed the Picture-based Value Survey for Children (PBVS-C). We replicated basic patterns of relations between value priorities and variables of socializationgender, religiosity, and socioeconomic statusthat have been found in studies with adults. Most important, values of Self-transcendence, Self-enhancement, and Conservation, were found to be significantly affected by genetic factors (29 percent, 47 percent, and 31 percent, respectively), as well as non-shared environment (71 percent, 53 percent, and 69 percent, respectively). Openness to change values, in contrast, were found to be unaffected by genetic factors at this age and were influenced by shared (19 percent) and non-shared (81 percent) environment. These findings support the recent view that values are formed at earlier ages than had been assumed previously, and they further our understanding of the genetic and environmental factors involved in value formation at young ages.
C1 [Uzefovsky, Florina; Knafo-Noam, Ariel] Hebrew Univ Jerusalem, IL-91905 Jerusalem, Israel.
   [Uzefovsky, Florina] Univ Cambridge, Cambridge CB2 1TN, England.
   [Doring, Anna K.] Univ Westminster, London W1R 8AL, England.
RP Doring, AK (reprint author), Royal Holloway Univ London, Egham, Surrey, England.
EM Anna.Doering@rhul.ac.uk
FU Science of Generosity Initiative; John Templeton Foundation; Israel
   Science Foundation [1670/13, 449/14]; Ariane de Rothschild fellowship;
   British Friends of Hebrew University; Joseph Levy fellowship
FX The authors are indebted to the parents and twins in the LIST for making
   the study possible. We also thank the research assistants who helped
   collect the data. Data collection was supported by a grant from The
   Science of Generosity Initiative, funded by the John Templeton
   Foundation to Ariel Knafo. Preparation of this manuscript was supported
   by grant No. 1670/13 from the Israel Science Foundation to Ariel Knafo.
   Florina Uzefovsky was supported by the Ariane de Rothschild fellowship,
   by the Israel Science Foundation (grant No. 449/14), by the British
   Friends of Hebrew University and by the Joseph Levy fellowship.
CR Avinun R., 2013, TWIN RES HUM GENET, V1, P1
   Bardi A, 2003, PERS SOC PSYCHOL B, V29, P1207, DOI 10.1177/0146167203254602
   Bardi A, 2011, J CROSS CULT PSYCHOL, V42, P271, DOI 10.1177/0022022110396916
   Beam CR, 2013, DEV PSYCHOPATHOL, V25, P7, DOI 10.1017/S0954579412000867
   Benish-Weisman M, 2015, SOC DEV, V24, P766, DOI 10.1111/sode.12122
   Bilsky W, 2013, SWISS J PSYCHOL, V72, P123, DOI 10.1024/1421-0185/a000106
   Boehnke K, 2001, J CROSS CULT PSYCHOL, V32, P241, DOI 10.1177/0022022101032002010
   Boker S, 2011, PSYCHOMETRIKA, V76, P306, DOI 10.1007/s11336-010-9200-6
   Borg I., 2005, MODERN MULTIDIMENSIO
   Brislin RW, 1980, HDB CROSS CULTURAL P, V2, p[2, 349]
   Button TMM, 2011, BEHAV GENET, V41, P201, DOI 10.1007/s10519-010-9388-3
   CASHMORE JA, 1986, J CROSS CULT PSYCHOL, V17, P441, DOI 10.1177/0022002186017004004
   Chick K. A., 2002, EARLY CHILDHOOD ED J, V29, P149, DOI 10.1023/a:1014528424032
   Cieciuch J., SOCIAL DEV IN PRESS
   Cieciuch J, 2013, EUR J DEV PSYCHOL, V10, P625, DOI 10.1080/17405629.2012.707779
   Daniel E., SOCIAL DEV IN PRESS
   Doring AK, 2010, J PERS ASSESS, V92, P439, DOI 10.1080/00223891.2010.497423
   Doring A.K., BRIT J PSYC IN PRESS
   Frable DES, 1997, ANNU REV PSYCHOL, V48, P139, DOI 10.1146/annurev.psych.48.1.139
   GRUSEC JE, 1994, DEV PSYCHOL, V30, P4, DOI 10.1037//0012-1649.30.1.4
   Haworth CMA, 2010, MOL PSYCHIATR, V15, P1112, DOI 10.1038/mp.2009.55
   Hofstede G., 2001, CULTURE ORG COMP VAL
   Israel S, 2008, PROG BRAIN RES, V170, P435, DOI 10.1016/S0079-6123(08)00434-2
   Kasser T, 2002, PERS SOC PSYCHOL B, V28, P826, DOI 10.1177/0146167202289011
   Knafo A, 2003, PERS RELATIONSHIP, V10, P371, DOI 10.1111/1475-6811.00055
   Knafo A, 2001, J CROSS CULT PSYCHOL, V32, P213, DOI 10.1177/0022022101032002008
   Knafo A., 2004, NAT COUNC JEW WOM RE
   Knafo A., 2009, CULTURAL TRANSMISSIO, P240
   Knafo A, 2008, CHILD DEV, V79, P652, DOI 10.1111/j.1467-8624.2008.01149.x
   Knafo A, 2006, DEV PSYCHOL, V42, P771, DOI 10.1073/0012-1649.42.5.771
   Knafo A, 2013, DEV PSYCHOPATHOL, V25, P1, DOI 10.1017/S0954579412000855
   Knafo A, 2011, DEV PSYCHOL, V47, P726, DOI 10.1037/a0021910
   Knafo A, 2008, EMOTION, V8, P737, DOI 10.1037/a0014179
   Kohn M., 1989, CLASS CONFORMITY STU
   Kohn M. L., 1983, WORK PERSONALITY INQ
   Longest KC, 2013, SOC FORCES, V91, P1499, DOI 10.1093/sf/sot045
   MACCOBY EE, 1992, DEV PSYCHOL, V28, P1006, DOI 10.1037//0012-1649.28.6.1006
   MARINI Z, 1994, CHILD DEV, V65, P147, DOI 10.1111/j.1467-8624.1994.tb00741.x
   Martin CL, 2002, PSYCHOL BULL, V128, P903, DOI 10.1037//0033-2909.128.6.903
   NUCCI LP, 1982, REV EDUC RES, V52, P93
   Parks-Leduc L, 2015, PERS SOC PSYCHOL REV, V19, P3, DOI 10.1177/1088868314538548
   Plomin R., 1999, HDB PERSONALITY THEO, V2, P251
   Plomin R, 2008, BEHAV GENETICS
   Price T S, 2000, Twin Res, V3, P129, DOI 10.1375/136905200320565391
   Ranieri S., 2012, FAMILY SCI, V3, P1, DOI DOI 10.1080/19424620.2012.714591
   Renner W, 2012, PERS INDIV DIFFER, V52, P89, DOI 10.1016/j.paid.2011.09.003
   ROTHBART MK, 1981, CHILD DEV, V52, P569, DOI 10.1111/j.1467-8624.1981.tb03082.x
   Saroglou V, 2004, PERS INDIV DIFFER, V37, P721, DOI 10.1016/j.paid.2003.10.005
   Saroglou V, 2012, JACOBS FOUND SER ADO, P391
   Schermer JA, 2008, TWIN RES HUM GENET, V11, P531, DOI 10.1375/twin.11.5.531
   Schonpflug U, 2001, J CROSS CULT PSYCHOL, V32, P174, DOI 10.1177/0022022101032002005
   Schwartz SH, 2005, J PERS SOC PSYCHOL, V89, P1010, DOI 10.1037/0022-3514.89.6.1010
   SCHWARTZ SH, 1995, SOC PSYCHOL QUART, V58, P88, DOI 10.2307/2787148
   SCHWARTZ SH, 1992, ADV EXP SOC PSYCHOL, V25, P1, DOI 10.1016/S0065-2601(08)60281-6
   Schwartz S. H., 2010, PROSOCIAL MOTIVES EM, V14, P221, DOI DOI 10.1037/12061-012
   Schwartz SH, 2012, JACOBS FOUND SER ADO, P97
   Schwartz SH, 2012, J PERS SOC PSYCHOL, V103, P663, DOI 10.1037/a0029393
   Schwartz SH, 2009, J PERS SOC PSYCHOL, V97, P171, DOI 10.1037/a0015546
   SPENCE I, 1973, MULTIVAR BEHAV RES, V8, P511, DOI 10.1207/s15327906mbr0804_8
   Steca P., 2012, FAMILY SCI, V3, P34, DOI [10.1080/19424620.2011.704772, DOI 10.1080/19424620.2011.704772]
   Struch N, 2002, PERS SOC PSYCHOL B, V28, P16, DOI 10.1177/0146167202281002
   Thompson RA, 2006, HANDBOOK OF MORAL DEVELOPMENT, P267
   Uzefovsky F, 2015, HORM BEHAV, V67, P60, DOI 10.1016/j.yhbeh.2014.11.007
   Vecchione M., SOCIAL DEV IN PRESS
   Verplanken B, 2002, J PERS SOC PSYCHOL, V82, P434, DOI 10.1037//0022-3514.82.3.434
   WALLER NG, 1990, PSYCHOL SCI, V1, P138, DOI 10.1111/j.1467-9280.1990.tb00083.x
   Wray-Lake L, 2014, SOC DEV, V23, P573, DOI 10.1111/sode.12065
   WRIGHT JD, 1976, AM SOCIOL REV, V41, P527, DOI 10.2307/2094258
   Zimmer-Gembeck MJ, 2005, J EARLY ADOLESCENCE, V25, P421, DOI 10.1177/0272431605279841
NR 69
TC 2
Z9 2
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-205X
EI 1467-9507
J9 SOC DEV
JI Soc. Dev.
PD AUG
PY 2016
VL 25
IS 3
BP 482
EP 502
DI 10.1111/sode.12155
PG 21
WC Psychology, Developmental
SC Psychology
GA DR5MQ
UT WOS:000379947500002
ER

PT J
AU Modi, ME
   Majchrzak, MJ
   Fonseca, KR
   Doran, A
   Osgood, S
   Vanase-Frawley, M
   Feyfant, E
   McInnes, H
   Darvari, R
   Buhl, DL
   Kablaoui, NM
AF Modi, Meera E.
   Majchrzak, Mark J.
   Fonseca, Kari R.
   Doran, Angela
   Osgood, Sarah
   Vanase-Frawley, Michelle
   Feyfant, Eric
   McInnes, Heather
   Darvari, Ramin
   Buhl, Derek L.
   Kablaoui, Natasha M.
TI Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor
   Agonist Inhibits Fear-Induced Freezing
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID SOCIAL COGNITION; CENTRAL AMYGDALA; BRAIN-REGIONS; RAT-BRAIN;
   VASOPRESSIN; BINDING; BEHAVIORS; ANXIETY; DRUGS; EXPRESSION
AB Oxytocin (OT) modulates the expression of social and emotional behaviors and consequently has been proposed as a pharmacologic treatment of psychiatric diseases, including autism spectrum disorders and schizophrenia; however, endogenous OT has a short half-life in plasma and poor permeability across the blood-brain barrier. Recent efforts have focused on the development of novel drug delivery methods to enhance brain penetration, but few efforts have aimed at improving its half-life. To explore the behavioral efficacy of an OT analog with enhanced plasma stability, we developed PF-06655075 (PF1), a novel non-brain-penetrant OT receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability. PF-06478939 was generated with only increased stability to disambiguate changes to selectivity versus stability. The efficacy of these compounds in evoking behavioral effects was tested in a conditioned fear paradigm. Both central and peripheral administration of PF1 inhibited freezing in response to a conditioned fear stimulus. Peripheral administration of PF1 resulted in a sustained level of plasma concentrations for greater than 20 hours but no detectable accumulation in brain tissue, suggesting that plasma or cerebrospinal fluid exposure was sufficient to evoke behavioral effects. Behavioral efficacy of peripherally administered OT receptor agonists on conditioned fear response opens the door to potential peripheral mechanisms in other behavioral paradigms, whether they are mediated by direct peripheral activation or feed-forward responses. Compound PF1 is freely available as a tool compound to further explore the role of peripheral OT in behavioral response.
C1 [Modi, Meera E.; Majchrzak, Mark J.; Buhl, Derek L.] Pfizer Inc, Worldwide Res & Dev, Neurosci & Pain Res Unit, Cambridge, MA USA.
   [Fonseca, Kari R.] Pfizer Inc, Worldwide Res & Dev, Dept Pharmacokinet Dynam & Metab, Cambridge, MA USA.
   [Feyfant, Eric] Pfizer Inc, Worldwide Res & Dev, Global Biotherapeut Technol, Cambridge, MA USA.
   [Kablaoui, Natasha M.] Pfizer Inc, Worldwide Res & Dev, Worldwide Med Chem, Cambridge, MA USA.
   [Doran, Angela; Osgood, Sarah; Vanase-Frawley, Michelle] Pfizer Inc, Dept Pharmacokinet Dynam & Metab, Worldwide Res & Dev, Groton, CT USA.
   [McInnes, Heather; Darvari, Ramin] Pfizer Inc, Worldwide Res & Dev, Biotherapuet Pharmaceut Res & Dev, Andover, MA USA.
RP Kablaoui, NM (reprint author), Pfizer Worldwide Med Chem, Worldwide Res & Dev, 610 Main St, Cambridge, MA 02139 USA.
EM Natasha.M.Kablaoui@pfizer.com
FU Pfizer Neuroscience Research Unit
FX This work is entirely funded by the research and development budget of
   the Pfizer Neuroscience Research Unit.
CR Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Ayers LW, 2011, NEUROPSYCHOPHARMACOL, V36, P2488, DOI 10.1038/npp.2011.138
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
   Chitkara D, 2006, MACROMOL BIOSCI, V6, P977, DOI 10.1002/mabi.200600129
   Chugh BP, 2009, NEUROIMAGE, V47, P1312, DOI 10.1016/j.neuroimage.2009.03.083
   DEWIED D, 1987, J PHARMACOL EXP THER, V241, P268
   Di L, 2012, J PHARM SCI-US, V101, P1327, DOI 10.1002/jps.23013
   Di L, 2011, DRUG METAB DISPOS, V39, P1270, DOI 10.1124/dmd.111.038778
   ERMISCH A, 1985, ENDOCRINOL EXP, V19, P29
   FABIAN M, 1969, J PHYSIOL-LONDON, V204, P653
   Favory R, 2009, EXPERT OPIN INV DRUG, V18, P1119, DOI 10.1517/13543780903066764
   Gimpl G, 2008, PROG BRAIN RES, V170, P193, DOI 10.1016/S0079-6123(08)00417-2
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Klenerova V, 2008, ANN NY ACAD SCI, V1148, P415, DOI 10.1196/annals.1410.043
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   LANDGRAF R, 1981, ENDOKRINOLOGIE, V78, P191
   LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629
   Llewellyn-Smith IJ, 2012, NEUROGASTROENT MOTIL, V24, pE136, DOI 10.1111/j.1365-2982.2011.01851.x
   MacNamara A, 2015, BEHAV BRAIN RES, V287, P34, DOI 10.1016/j.bbr.2015.03.035
   McEwen Barbara B, 2004, Adv Pharmacol, V50, P531
   MEIJER DKF, 1987, PHARM WEEKBLAD, V9, P65, DOI 10.1007/BF01960738
   Mizuno A, 2015, BRAIN SCI, V5, P3, DOI 10.3390/brainsci5010003
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Neumann I, 1996, J NEUROENDOCRINOL, V8, P227, DOI 10.1046/j.1365-2826.1996.04557.x
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Quintana DS, 2015, NEUROSCI BIOBEHAV R, V49, P182, DOI 10.1016/j.neubiorev.2014.12.011
   Rodriguez-Romaguera J, 2009, BIOL PSYCHIAT, V65, P887, DOI 10.1016/j.biopsych.2009.01.009
   STOEHR JD, 1993, ANN NY ACAD SCI, V689, P674, DOI 10.1111/j.1749-6632.1993.tb55625.x
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   TILLEMENT JP, 1988, FUNDAM CLIN PHARM, V2, P223
   Toth I, 2012, PSYCHOPHARMACOLOGY, V223, P149, DOI 10.1007/s00213-012-2702-4
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Viviani D, 2008, PROG BRAIN RES, V170, P207, DOI 10.1016/S0079-6123(08)00418-4
   Wehner JM, 2004, CURR PROTOC NEUROSCI, V8, DOI [10.1002/0471142301.ns0805cs27, DOI 10.1002/0471142301.NS0805CS27]
   Yang F, 2014, INT J MOL SCI, V15, P3580, DOI 10.3390/ijms15033580
   YOSHIMURA R, 1993, ENDOCRINOLOGY, V133, P1239, DOI 10.1210/en.133.3.1239
   Thuresson K, 2005, Patent No. [WO/2005/117830, 2005117830]
NR 40
TC 0
Z9 0
U1 10
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD AUG
PY 2016
VL 358
IS 2
BP 164
EP 172
DI 10.1124/jpet.116.232702
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DQ7RW
UT WOS:000379406400001
PM 27217590
ER

PT J
AU Fuller, DR
   Glover, MS
   Pierson, NA
   Kim, D
   Russell, DH
   Clemmer, DE
AF Fuller, Daniel R.
   Glover, Matthew S.
   Pierson, Nicholas A.
   Kim, DoYong
   Russell, David H.
   Clemmer, David E.
TI Cis -> Trans Isomerization of Pro(7) in Oxytocin Regulates Zn2+ Binding
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
DE Cis-trans isomerization; Oxytocin; Ion-mobility
ID IONIZATION MASS-SPECTROMETRY; ION MOBILITY SPECTROMETRY; GAS-PHASE;
   ELECTROSPRAY-IONIZATION; ARGININE-VASOPRESSIN; PENULTIMATE PROLINE;
   HORMONE OXYTOCIN; LIGAND-BINDING; PEPTIDE-BONDS; GRAMICIDIN-S
AB Ion mobility/mass spectrometry techniques are employed to investigate the binding of Zn2+ to the nine-residue peptide hormone oxytocin (OT, Cys(1)-Tyr(2)-Ile(3)-Gln(4)-Asn(5)-Cys(6)-Pro(7)-Leu(8)-Gly(9)-NH2, having a disulfide bond between Cys(1) and Cys(6) residues). Zn2+ binding to OT is known to increase the affinity of OT for its receptor [Pearlmutter, A. F., Soloff, M. S.: Characterization of the metal ion requirement for oxytocin-receptor interaction in rat mammary gland membranes. J. Biol. Chem. 254, 3899-3906 (1979)]. In the absence of Zn2+, we find evidence for two primary OT conformations, which arise because the Cys(6)-Pro(7) peptide bond exists in both the trans- and cis-configurations. Upon addition of Zn2+, we determine binding constants in water of K-A = 1.43 +/- 0.24 and 0.42 +/- 0.12 mu M-1, for the trans- and cis-configured populations, respectively. The Zn2+ bound form of OT, having a cross section of Omega = 235 (2), has Pro(7) in the trans-configuration, which agrees with a prior report [Wyttenbach, T., Liu, D., Bowers, M. T.: Interactions of the hormone oxytocin with divalent metal ions. J. Am. Chem. Soc. 130, 5993-6000 (2008)], in which it was proposed that Zn2+ binds to the peptide ring and is further coordinated by interaction of the C-terminal, Pro(7)-Leu(8)-Gly(9)-NH2, tail. The present work shows that the cis-configuration of OT isomerizes to the trans-configuration upon binding Zn2+. In this way, the proline residue regulates Zn2+ binding to OT and, hence, is important in receptor binding.
C1 [Fuller, Daniel R.; Glover, Matthew S.; Pierson, Nicholas A.; Clemmer, David E.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   [Pierson, Nicholas A.] Merck Res Labs, Rahway, NJ 07065 USA.
   [Kim, DoYong; Russell, David H.] Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA.
RP Clemmer, DE (reprint author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
EM clemmer@indiana.edu
RI Russell, David/C-3618-2015
OI Russell, David/0000-0003-0830-3914
FU NIH [R01 GM103725]
FX The authors acknowledge David Smiley and the DiMarchi research group at
   Indiana University for assistance with the peptide synthesis. This work
   is supported by a grant from the NIH (R01 GM103725).
CR Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Barnes CAS, 2003, J PHYS CHEM A, V107, P10566, DOI 10.1021/jp030519s
   Bohrer BC, 2008, ANNU REV ANAL CHEM, V1, P293, DOI 10.1146/annurev.anchem.1.031207.113001
   Clemmer DE, 1997, J MASS SPECTROM, V32, P577
   Counterman AE, 2002, ANAL CHEM, V74, P1946, DOI 10.1021/ac011083k
   Cubrilovic D, 2012, J AM SOC MASS SPECTR, V23, P1768, DOI 10.1007/s13361-012-0451-6
   Di Marco VB, 2009, J MASS SPECTROM, V44, P120, DOI 10.1002/jms.1481
   DUVIGNEAUD V, 1954, J AM CHEM SOC, V76, P3115, DOI 10.1021/ja01641a004
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   Gao H, 2005, ANAL CHEM, V77, P5596, DOI 10.1021/ac050549m
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Glover MS, 2015, ANAL CHEM, V87, P8466, DOI 10.1021/acs.analchem.5b01889
   Glover MS, 2015, J AM SOC MASS SPECTR, V26, P444, DOI 10.1007/s13361-014-1049-y
   Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005
   Hoaglund CS, 1998, ANAL CHEM, V70, P2236, DOI 10.1021/ac980059c
   Illes-Toth E, 2013, J AM SOC MASS SPECTR, V24, P1346, DOI 10.1007/s13361-013-0676-z
   Kempen EC, 2000, ANAL CHEM, V72, P5411, DOI 10.1021/ac000540e
   Kim E, 2013, NAT CHEM BIOL, V9, P313, DOI [10.1038/nchembio.1213, 10.1038/NCHEMBIO.1213]
   Kleinnijenhuis AJ, 2006, INT J MASS SPECTROM, V253, P217, DOI 10.1016/j.ijms.2006.03.005
   Koeniger SL, 2006, ANAL CHEM, V78, P4161, DOI 10.1021/ac051060w
   KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98
   LARIVE CK, 1992, J AM CHEM SOC, V114, P7331, DOI 10.1021/ja00045a001
   LARIVE CK, 1993, J AM CHEM SOC, V115, P2833, DOI 10.1021/ja00060a033
   Lee SW, 1998, J AM CHEM SOC, V120, P11758, DOI 10.1021/ja982075x
   Liu DF, 2005, J AM CHEM SOC, V127, P2024, DOI 10.1021/ja046042v
   LIVERMORE AH, 1949, J BIOL CHEM, V180, P365
   Loo JA, 1997, J AM SOC MASS SPECTR, V8, P234, DOI 10.1016/S1044-0305(96)00238-3
   Mason E. A., 1988, TRANSPORT PROPERTIES, P1
   Merenbloom SI, 2006, ANAL CHEM, V78, P2802, DOI 10.1021/ac052208e
   MONOD J, 1965, J MOL BIOL, V12, P88
   PEARLMUTTER AF, 1979, J BIOL CHEM, V254, P3899
   Pierson NA, 2013, J AM CHEM SOC, V135, P3186, DOI 10.1021/ja3114505
   Pierson NA, 2011, J AM CHEM SOC, V133, P13810, DOI 10.1021/ja203895j
   Pierson NA, 2010, J PHYS CHEM B, V114, P7777, DOI 10.1021/jp102478k
   RodriguezCruz SE, 1997, J AM SOC MASS SPECTR, V8, P565, DOI 10.1016/S1044-0305(97)00020-2
   Ruotolo BT, 2004, J AM SOC MASS SPECTR, V15, P870, DOI 10.1016/S1044-0305(04)00152-7
   Shi LQ, 2014, J AM CHEM SOC, V136, P12702, DOI 10.1021/ja505899g
   Silveira JA, 2013, J AM CHEM SOC, V135, P19147, DOI 10.1021/ja4114193
   STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J
   STLOUIS RH, 1990, CRIT REV ANAL CHEM, V21, P321
   [Anonymous], 2014, SIGM VERS 13 0
   Tang K, 2005, ANAL CHEM, V77, P3330, DOI 10.1021/ac048315a
   Valentine SJ, 1999, J PHYS CHEM B, V103, P1203, DOI 10.1021/jp983906o
   Voet D., 1995, BIOCHEMISTRY
   Vogt AD, 2013, BIOCHEMISTRY-US, V52, P5723, DOI 10.1021/bi400929b
   Wilcox JM, 2008, ANAL CHEM, V80, P2365, DOI 10.1021/ac701903w
   Winslow J. T., 1993, NATURE, V365, P7
   Wyttenbach T, 2001, INT J MASS SPECTROM, V212, P13, DOI 10.1016/S1387-3806(01)00517-6
   Wyttenbach T, 1997, J AM SOC MASS SPECTR, V8, P275, DOI 10.1016/S1044-0305(96)00236-X
   Wyttenbach T, 2008, J AM CHEM SOC, V130, P5993, DOI 10.1021/ja8002342
   Wyttenbach T, 2014, ANNU REV PHYS CHEM, V65, P175, DOI 10.1146/annurev-physchem-040513-103644
   Wyttenbach T, 2011, J PHYS CHEM B, V115, P12266, DOI 10.1021/jp206867a
NR 53
TC 0
Z9 0
U1 20
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1044-0305
EI 1879-1123
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD AUG
PY 2016
VL 27
IS 8
BP 1376
EP 1382
DI 10.1007/s13361-016-1410-4
PG 7
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA DR2XN
UT WOS:000379767300010
PM 27154022
ER

PT J
AU Ulmer-Yaniv, A
   Avitsur, R
   Kanat-Maymon, Y
   Schneiderman, I
   Zagoory-Sharon, O
   Feldman, R
AF Ulmer-Yaniv, Adi
   Avitsur, Ronit
   Kanat-Maymon, Yaniv
   Schneiderman, Inna
   Zagoory-Sharon, Orna
   Feldman, Ruth
TI Affiliation, reward, and immune biomarkers coalesce to support social
   synchrony during periods of bond formation in humans
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Bonding; Oxytocin; Beta-endorphin; Interleukin-6; Synchrony;
   Affiliation; Reward
ID PARENT-INFANT SYNCHRONY; A VIRUS-INFECTION; NUCLEUS-ACCUMBENS; MARITAL
   CONFLICT; BETA-ENDORPHIN; PROINFLAMMATORY CYTOKINES; OXYTOCIN LEVELS;
   BLOOD-PRESSURE; ROMANTIC LOVE; DEVELOPMENTAL OUTCOMES
AB Social bonds are critical for survival and adaptation and periods of bond formation involve reorganization of neurobiological systems as mediated by social behavior. Theoretical accounts and animal studies suggest similarity between parent-infant and pair bonding, a hypothesis not yet directly tested in humans. In this study, we recruited three groups of human adults (N = 189); parents who had their firstborn child in the last 4-6 months, new lovers who began a romantic relationship within the past 4 months, and non-attached singles. We measured plasma oxytocin (OT), beta endorphin (beta-End), and interlukin-6 (IL-6), biomarkers of the affiliation, reward, and stress-response systems, and micro-coded gaze and affect synchrony between parents and infants and among new lovers during social interaction. OT significantly increased during periods of parental and romantic bonding and was highest in new lovers. In contrast, IL-6 and beta-End were highest in new parents and lowest in singles. Biomarkers became more tightly coupled during periods of bond formation and inter-correlation among hormones was highest during romantic bonding. Structural equation modeling indicated that the effects of IL-6 and beta-End on behavioral synchrony were mediated by their impact on OT, highlighting the integrative role of the oxytocinergic system in supporting human social affiliation. Findings suggest that periods of bond formation are accompanied by increased activity, as well as tighter cross-talk among systems underpinning affiliation, reward, and stress management and that research on the multidimensional process of bonding may shed further light on the effects of attachment on health. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ulmer-Yaniv, Adi; Schneiderman, Inna; Zagoory-Sharon, Orna; Feldman, Ruth] Bar Ilan Univ, Gonda Multidisciplinary Ctr, IL-52900 Ramat Gan, Israel.
   [Avitsur, Ronit] Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel.
   [Kanat-Maymon, Yaniv] Interdisciplinary Ctr Herzlia, Herzliyya, Israel.
   [Feldman, Ruth] Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.
RP Feldman, R (reprint author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.; Feldman, R (reprint author), Bar Ilan Univ, Gonda Brain Sci Ctr, IL-52900 Ramat Gan, Israel.
EM feldman.ruth@gmail.com
FU German-Israeli Foundation [1114-101.4/2010]; I-CORE Program of the
   Planning and Budgeting Committee; Israel Science Foundation [51/11];
   Simms-Mann Foundation
FX The study was supported by the German-Israeli Foundation
   (#1114-101.4/2010), the I-CORE Program of the Planning and Budgeting
   Committee and The Israel Science Foundation (Grant No. 51/11) and the
   Simms-Mann Foundation.
CR Abraham E, 2014, P NATL ACAD SCI USA, V111, P9792, DOI 10.1073/pnas.1402569111
   AKIRA S, 1990, FASEB J, V4, P2860
   Apter-Levy Y., 2013, AM J PSYCHIAT
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Atzil S, 2011, NEUROPSYCHOPHARMACOL, V36, P2603, DOI 10.1038/npp.2011.172
   Bales KL, 2016, HORM BEHAV, V77, P249, DOI 10.1016/j.yhbeh.2015.05.021
   Barendregt H. P., 2015, FLUIDS BARRIERS CNS, V12
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Beck AT, 1996, MANUAL BECK DEPRESSI, P1
   Blackmore ER, 2014, J PSYCHOSOM OBST GYN, V35, P8, DOI 10.3109/0167482X.2013.868879
   Bowlby J, 1969, ATTACHMENT LOSS, V1
   Broad KD, 2006, PHILOS T R SOC B, V361, P2199, DOI 10.1098/rstb.2006.1940
   Brydon L, 2004, BRAIN BEHAV IMMUN, V18, P281, DOI 10.1016/j.bbi.2003.09.011
   Byrnes EM, 2000, BEHAV NEUROSCI, V114, P797, DOI 10.1037//0735-7044.114.4.797
   Champagne DL, 2008, J NEUROSCI, V28, P6037, DOI 10.1523/JNEUROSCI.0526-08.2008
   Christenfeld N, 1997, PSYCHOSOM MED, V59, P388
   Clodi M, 2008, AM J PHYSIOL-ENDOC M, V295, pE686, DOI 10.1152/ajpendo.90263.2008
   Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69
   Coussons-Read ME, 2007, BRAIN BEHAV IMMUN, V21, P343, DOI 10.1016/j.bbi.2006.08.006
   Curley JP, 2005, TRENDS ECOL EVOL, V20, P561, DOI 10.1016/j.tree.2005.05.018
   DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009
   Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019
   DAY JA, 1987, PHYS THER, V67, P926
   Depue RA, 2005, BEHAV BRAIN SCI, V28, P313
   Ditzen B, 2007, PSYCHONEUROENDOCRINO, V32, P565, DOI 10.1016/j.psyneuen.2007.03.011
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dunbar RIM, 2010, NEUROSCI BIOBEHAV R, V34, P260, DOI 10.1016/j.neubiorev.2008.07.001
   Eklund CM, 2009, ADV CLIN CHEM, V48, P111, DOI 10.1016/S0065-2423(09)48005-3
   Feldman R, 2004, DEV PSYCHOL, V40, P1133, DOI 10.1037/0012-1649.40.6.1133
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2007, CURR DIR PSYCHOL SCI, V16, P340, DOI 10.1111/j.1467-8721.2007.00532.x
   Feldman R, 2007, DEV PSYCHOBIOL, V49, P290, DOI 10.1002/dev.20220
   Feldman R, 2007, J CHILD PSYCHOL PSYC, V48, P329, DOI 10.1111/j.1469-7610.2006.01701.x
   Feldman R, 2015, TRENDS NEUROSCI, V38, P387, DOI 10.1016/j.tins.2015.04.004
   Feldman R, 2015, DEV PSYCHOPATHOL, V27, P369, DOI 10.1017/S0954579415000048
   Feldman R, 2012, PARENT-SCI PRACT, V12, P154, DOI 10.1080/15295192.2012.683342
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Forsling ML, 1998, EXP PHYSIOL, V83, P409
   Gentile D, 1998, CLIN DIAGN LAB IMMUN, V5, P604
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Graham E., 2009, HEALTH PSYCHOL, V28, P621
   Graham JE, 2009, HEALTH PSYCHOL, V28, P621, DOI 10.1037/a0015208
   Grewen KM, 2005, PSYCHOSOM MED, V67, P531, DOI 10.1097/01.psy.0000170341.88395.47
   Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0
   Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355
   Heffner KL, 2004, J BEHAV MED, V27, P233, DOI 10.1023/B:JOBM.0000028497.79129.ad
   Hegadoren KM, 2009, NEUROPEPTIDES, V43, P341, DOI 10.1016/j.npep.2009.06.004
   Hofer M A, 1994, Monogr Soc Res Child Dev, V59, P192, DOI 10.2307/1166146
   Holt-Lunstad J, 2008, PSYCHOSOM MED, V70, P976, DOI 10.1097/PSY.0b013e318187aef7
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148
   Iyengar SR, 2012, J PEDIATR GASTR NUTR, V55, P641, DOI 10.1097/MPG.0b013e3182617a9d
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   KAADA B, 1989, GEN PHARMACOL, V20, P487, DOI 10.1016/0306-3623(89)90200-0
   KALIN NH, 1989, SCIENCE, V243, P1718, DOI 10.1126/science.2564702
   Kammerer M, 2006, ARCH WOMEN MENT HLTH, V9, P187, DOI 10.1007/s00737-006-0131-2
   KEVERNE EB, 1989, PSYCHONEUROENDOCRINO, V14, P155, DOI 10.1016/0306-4530(89)90065-6
   Kiecolt-Glaser JK, 2001, PSYCHOL BULL, V127, P472, DOI 10.1037//0033-2909.127.4.472
   Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100
   KiecoltGlaser JK, 1996, J CONSULT CLIN PSYCH, V64, P324, DOI 10.1037/0022-006X.64.2.324
   Glaser R., 2005, NAT REV, V5, P243
   Kim P, 2010, BEHAV NEUROSCI, V124, P695, DOI 10.1037/a0020884
   Kringelbach ML, 2009, TRENDS COGN SCI, V13, P479, DOI 10.1016/j.tics.2009.08.006
   Kudielka BM, 2010, STRESS, V13, P1, DOI 10.3109/10253890902874913
   Kunz C, 1999, CLIN PERINATOL, V26, P307
   Light KC, 2005, BIOL PSYCHOL, V69, P5, DOI 10.1016/j.biopsycho.2004.11.002
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659
   Loving TJ, 2004, J MARRIAGE FAM, V66, P595, DOI 10.1111/j.0022-2445.2004.00040.x
   Machin AJ, 2011, BEHAVIOUR, V148, P985, DOI 10.1163/000579511X596624
   Marazziti D, 2004, PSYCHONEUROENDOCRINO, V29, P931, DOI 10.1016/j.psyneuen.2003.08.006
   MARTEL FL, 1993, PSYCHONEUROENDOCRINO, V18, P307, DOI 10.1016/0306-4530(93)90027-I
   Champagne F. A., 2001, PROG BRAIN RES, V133, P287
   Mika J, 2013, EUR J PHARMACOL, V716, P106, DOI [10.1016/j.ejphar.2013.01.072, 10.1016/j.ebhar.2013.01.072]
   Minniti F, 2014, ENDOCR METAB IMMUNE, V14, P9, DOI 10.2174/1871530314666140121145045
   Morag M, 1998, PSYCHONEUROENDOCRINO, V23, P337, DOI 10.1016/S0306-4530(98)00012-2
   Morhenn V, 2012, ALTERN THER HEALTH M, V18, P11
   Musser ED, 2012, DEV COGN NEUROS-NETH, V2, P428, DOI 10.1016/j.dcn.2012.04.003
   Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3
   Numan M, 1997, ANN NY ACAD SCI, V807, P101, DOI 10.1111/j.1749-6632.1997.tb51915.x
   Numan M., 1985, REPRODUCTION, P537
   Numan Michael, 2006, Behav Cogn Neurosci Rev, V5, P163, DOI 10.1177/1534582306288790
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Osborne LM, 2013, PSYCHONEUROENDOCRINO, V38, P1929, DOI 10.1016/j.psyneuen.2013.03.019
   Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630
   Palm M, 2013, ACTA OBSTET GYN SCAN, V92, P601, DOI 10.1111/aogs.12093
   Panksepp J, 1994, Acta Paediatr Suppl, V397, P40
   Panksepp J, 1997, ANN NY ACAD SCI, V807, P78, DOI 10.1111/j.1749-6632.1997.tb51914.x
   PANKSEPP J, 1986, ANNU REV PSYCHOL, V37, P77
   Pike JL, 1997, PSYCHOSOM MED, V59, P447
   Rosenblatt JS, 2003, SCAND J PSYCHOL, V44, P265, DOI 10.1111/1467-9450.00344
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Schmid B, 2001, ENDOCRINOLOGY, V142, P1380, DOI 10.1210/en.142.4.1380
   Schneiderman I, 2014, SOC COGN AFFECT NEUR, V9, P1524, DOI 10.1093/scan/nst142
   Schneiderman I, 2014, SOC NEUROSCI-UK, V9, P337, DOI 10.1080/17470919.2014.893925
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   Silk JB, 2007, PHILOS T R SOC B, V362, P539, DOI 10.1098/rstb.2006.1994
   Slavish DC, 2015, BRAIN BEHAV IMMUN, V44, P253, DOI 10.1016/j.bbi.2014.08.008
   SPANAGEL R, 1990, EUR J PHARMACOL, V190, P177, DOI 10.1016/0014-2999(90)94124-G
   Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928
   Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038
   Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Trezza V, 2011, J NEUROSCI, V31, P6362, DOI 10.1523/JNEUROSCI.5492-10.2011
   Vaanholt LM, 2003, BRAIN RES, V978, P169, DOI 10.1016/S0006-8993(03)02805-1
   Weaver ICG, 2009, BIRTH DEFECTS RES C, V87, P314, DOI 10.1002/bdrc.20164
   Weisman O, 2013, EUR NEUROPSYCHOPHARM, V23, P1724, DOI 10.1016/j.euroneuro.2013.06.006
   Weisman O, 2012, BIOL PSYCHIAT, V72, P982, DOI 10.1016/j.biopsych.2012.06.011
   Weller A, 2003, PEPTIDES, V24, P779, DOI 10.1016/S0196-9781(03)00118-9
   White-Traut R, 2009, DEV PSYCHOBIOL, V51, P367, DOI 10.1002/dev.20376
   Wieck A, 2014, NEUROIMMUNOMODULAT, V21, P145, DOI 10.1159/000356552
   Wilson E. O., 2012, HUMAN NATURE
   WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1
   Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 124
TC 0
Z9 0
U1 9
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD AUG
PY 2016
VL 56
BP 130
EP 139
DI 10.1016/j.bbi.2016.02.017
PG 10
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DQ1UJ
UT WOS:000378985600014
PM 26902915
ER

PT J
AU Stricker, EM
AF Stricker, Edward M.
TI 2015 Distinguished career award Reflections on a career in science
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article; Proceedings Paper
CT 24th Annual Meeting of the Society-for-the-Study-of-Ingestive-Behavior
   (SSIB)
CY JUL 07-11, 2015
CL Denver, CO
SP Soc Study Ingest Behav
DE SSIB; Career; Food and fluid ingestion
ID LATERAL HYPOTHALAMIC-LESIONS; ACUTE HOMEOSTATIC IMBALANCES; RATS DRINK
   WATER; VASOPRESSIN SECRETION; OXYTOCIN SECRETION; SODIUM APPETITE;
   SOLITARY TRACT; SALT APPETITE; FLUID VOLUME; THIRST
AB I was very pleased to receive the 2015 Distinguished Career Award from SSIB. This brief manuscript contains reminisces that might stir up pleasant memories in the older members of SSIB and also some general thoughts that I hope will be of value to the younger investigators who are closer to the beginning of their scientific careers. Although the organization has chosen to honor me with this special award, my own career was shaped by a great many people who have influenced my scientific career and I want to acknowledge them. They include Neal Miller, my doctoral mentor at Yale; Joe Holmes and Alan Epstein, my postdoctoral mentors; George Wolf and Reed Hainsworth, graduate student colleagues; John Brobeck, Paul Rozin, and Phil Teitelbaum, Michael Zigmond, Joe Verbalis, Jim Smith, and Alan Sved, faculty colleagues; Derek Denton, Paul McHugh, and James Fitzsimons, scientific role models; John Bruno, Steve Fluharty, and Linda Rinaman, post-doctoral trainees at Pitt; and Lori Flanagan, Math Curtis, Michael Bushey, Mike Bykowski, Reza Manesh, Carrie Smith, Jennifer Vaughan, and Myriam Stricker, student trainees at Pitt. I thank them all and also my colleagues in SSIB not only for the honor of this award but for providing an abundant supply of insights and discoveries that have stimulated me throughout my adult life, in addition to being an attentive community in supporting my own work. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Stricker, Edward M.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Stricker, EM (reprint author), Univ Pittsburgh, Pittsburgh, PA USA.
FU NIMH NIH HHS [R01 MH025140]
CR BRUNO JP, 1986, BEHAV NEUROSCI, V100, P125, DOI 10.1037//0735-7044.100.1.125
   Bykowski MR, 2007, PHYSIOL BEHAV, V92, P781, DOI 10.1016/j.physbeh.2007.06.007
   Curtis KS, 1999, AM J PHYSIOL-REG I, V277, pR209
   FLANAGAN LM, 1992, BRAIN RES, V578, P256, DOI 10.1016/0006-8993(92)90255-8
   FLUHARTY SJ, 1983, BRAIN RES, V267, P384, DOI 10.1016/0006-8993(83)90895-8
   FRIEDMAN MI, 1976, PSYCHOL REV, V83, P409, DOI 10.1037//0033-295X.83.6.409
   Hainsworth F.R., 1970, PHYSL BEHAVIORAL TEM, P611
   Hoffmann ML, 2006, AM J PHYSIOL-REG I, V290, pR1199, DOI 10.1152/ajpregu.00715.2005
   Manesh R, 2006, AM J PHYSIOL-REG I, V290, pR1742, DOI 10.1152/ajpregu.00865.2005
   Rinaman L, 1998, AM J PHYSIOL-REG I, V275, pR262
   Schreihofer AM, 2000, AM J PHYSIOL-REG I, V279, pR239
   Schreihofer AM, 1999, AM J PHYSIOL-REG I, V276, pR251
   Smith CA, 2007, AM J PHYSIOL-REG I, V292, pR2089, DOI 10.1152/ajpregu.00595.2006
   Stedenfeld K.A., 1970, EXPT BIOL 2008 M SAN
   Sticker E.M., 2004, HDB BEHAV NEUROBIOLO, V14
   Sticker E.M., 1986, AM J PHYSIOL, V250, pR267
   Sticker E.M., 1992, PHYSIOL BEHAV, V51, P27
   Sticker E.M., 1970, AM J PHYSIOL, V218, P191
   Stocker SD, 2002, AM J PHYSIOL-REG I, V282, pR1718, DOI 10.1152/ajpregu.00651.2001
   Stocker SD, 2001, AM J PHYSIOL-REG I, V280, pR214
   Stocker SD, 2000, AM J PHYSIOL-REG I, V279, pR576
   Stricker EM, 2007, AM J PHYSIOL-REG I, V292, pR652, DOI 10.1152/ajpregu.00055.2006
   STRICKER EM, 1966, AM J PHYSIOL, V211, P232
   STRICKER EM, 1969, AM J PHYSIOL, V217, P98
   STRICKER EM, 1967, P SOC EXP BIOL MED, V124, P816
   STRICKER EM, 1976, J COMP PHYSIOL PSYCH, V90, P127, DOI 10.1037/h0077202
   STRICKER EM, 1979, J COMP PHYSIOL PSYCH, V93, P512, DOI 10.1037/h0077591
   Stricker EM, 2005, AM J PHYSIOL-REG I, V289, pR1238, DOI 10.1152/ajpregu.00182.2005
   Stricker EM, 2003, PHYSIOL BEHAV, V79, P621, DOI 10.1016/S0031-9384(03)00172-0
   STRICKER EM, 1987, BEHAV NEUROSCI, V101, P560, DOI 10.1037/0735-7044.101.4.560
   STRICKER EM, 1975, SCIENCE, V189, P895, DOI 10.1126/science.1154028
   STRICKER EM, 1969, ANN NY ACAD SCI, V157, P553, DOI 10.1111/j.1749-6632.1969.tb12907.x
   Stricker E.M., 1976, PROGR PSYCHOBIOLOGY, V6, P121
   TEITELBAUM P, 1994, PSYCHOL REV, V101, P312, DOI 10.1037//0033-295X.101.2.312
   VERBALIS JG, 1986, BEHAV NEUROSCI, V100, P466, DOI 10.1037//0735-7044.100.4.466
   VERBALIS JG, 1986, SCIENCE, V232, P1417, DOI 10.1126/science.3715453
   Woods S.C., 2012, FUNDAMENTAL NEUROSCI, P767
   ZIGMOND MJ, 1990, TRENDS NEUROSCI, V13, P290, DOI 10.1016/0166-2236(90)90112-N
NR 38
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD AUG 1
PY 2016
VL 162
SI SI
BP 196
EP 200
DI 10.1016/j.physbeh.2015.09.028
PG 5
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA DQ1OH
UT WOS:000378969800025
PM 26434784
ER

PT J
AU Cardoso, C
   Valkanas, H
   Serravalle, L
   Ellenbogen, MA
AF Cardoso, Christopher
   Valkanas, Helen
   Serravalle, Lisa
   Ellenbogen, Mark A.
TI Oxytocin and social context moderate social support seeking in women
   during negative memory recall
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Intranasal oxytocin; Autobiographical memory; Tend-and-befriend; Social
   support; Distress
ID TEND-AND-BEFRIEND; INTRANASAL OXYTOCIN; AUTOBIOGRAPHICAL MEMORY;
   SEX-DIFFERENCES; RESPONSES; STRESS; DEPRESSION; HUMANS; PATHWAYS;
   BEHAVIOR
AB Background: Oxytocin is theorized to promote social support seeking under stress an alternate biobehavioural response to challenge known as the tend-and-befriend response. These effects may be context dependent, however, and no study has evaluated this effect in the presence and absence of social support. The aim of this study was to evaluate the effects of oxytocin on the experience of recalling emotional autobiographical memories in two contexts with and without social contact with an experimenter.
   Method: Sixty-three individuals (32 female) participated in this randomized, double-blind, placebo controlled, and within-subject study.
   Results: During recall of negative memories in the absence of social contact, oxytocin decreased perceived emotional support relative to placebo F(1,62)= 10.75, p = 0.002. In this same context, women who were motivated to affiliate with the experimenter following oxytocin administration showed this effect in greater magnitude t(57) = p = 0.047, but showed the reverse effect (i.e. increased perceived support in response to oxytocin) when social contact with the experimenter was available t(57) = 2.78, p = 0.007. Male participants did not evidence this pattern.
   Conclusion: These findings support the role of oxytocin in social support seeking in distressed women, and highlight the negative consequences of increasing oxytocin bioavailability in the absence of social support. Supportive relationships may be necessary to elicit the prosocial effects oxytocin. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Cardoso, Christopher; Valkanas, Helen; Serravalle, Lisa; Ellenbogen, Mark A.] Concordia Univ, Dept Psychol, Ctr Res Human Dev, Montreal, PQ, Canada.
RP Ellenbogen, MA (reprint author), Concordia Univ, Dept Psychol, 7141 Sherbrooke St West, Montreal, PQ H4B 1R6, Canada.
EM mark.ellenbogen@concordia.ca
FU Canada Institutes of Health Research [201403]; Fonds de recherche du
   Quebec-Sante (FRQS) [26012]
FX This research was supported by grants to Dr. Ellenbogen from the Canada
   Institutes of Health Research (201403). Christopher Cardoso is supported
   by a scholarship from the Fonds de recherche du Quebec-Sante (FRQS;
   26012).
CR Bartz Jennifer, 2011, Soc Cogn Affect Neurosci, V6, P556, DOI 10.1093/scan/nsq085
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Cardoso C, 2014, PSYCHONEUROENDOCRINO, V49, P161, DOI 10.1016/j.psyneuen.2014.07.014
   Cardoso C, 2014, SOC NEUROSCI-UK, V9, P186, DOI 10.1080/17470919.2013.873079
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P2800, DOI 10.1016/j.psyneuen.2013.05.006
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Ditzen B, 2013, SOC COGN AFFECT NEUR, V8, P897, DOI 10.1093/scan/nss083
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Huffmeijer R, 2013, HORM BEHAV, V63, P399, DOI 10.1016/j.yhbeh.2012.11.008
   Kendler KS, 2014, AM J PSYCHIAT, V171, P426, DOI 10.1176/appi.ajp.2013.13101375
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lane A, 2013, INT J PSYCHOL, V48, P676, DOI 10.1080/00207594.2012.677540
   MacDonald K, 2013, PSYCHONEUROENDOCRINO, V38, P2831, DOI 10.1016/j.psyneuen.2013.05.014
   MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037//0033-2909.114.2.376
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Seltzer LJ, 2010, P ROY SOC B-BIOL SCI, V277, P2661, DOI 10.1098/rspb.2010.0567
   Striepens N., 2013, SCI REP, V3, P3340
   Taylor SE, 2006, PSYCHOSOM MED, V68, P238, DOI 10.1097/01.psy.0000203242.95990.74
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   WILLIAMS JMG, 1986, J ABNORM PSYCHOL, V95, P144, DOI 10.1037/0021-843X.95.2.144
   Yao SX, 2014, INT J NEUROPSYCHOPH, V17, P1785, DOI 10.1017/S146114571400090X
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
NR 31
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD AUG
PY 2016
VL 70
BP 63
EP 69
DI 10.1016/j.psyneuen.2016.05.001
PG 7
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DQ1MP
UT WOS:000378965400008
PM 27164224
ER

PT J
AU Grazia, R
   Matteo, R
   Yannis, P
   James, G
   Alberto, S
   Marco, C
   Erika, P
   Liliana, D
   Edgardo, C
   Pierluigi, P
   Philip, M
   Paolo, FP
AF Grazia, Rutigliano
   Matteo, Rocchetti
   Yannis, Paloyelis
   James, Gilleen
   Alberto, Sardella
   Marco, Cappucciati
   Erika, Palombini
   Liliana, Dell'Osso
   Edgardo, Caverzasi
   Pierluigi, Politi
   Philip, McGuire
   Paolo, Fusar-Poli
TI Peripheral oxytocin and vasopressin: Biomarkers of psychiatric
   disorders? A comprehensive systematic review and preliminary
   meta-analysis
SO PSYCHIATRY RESEARCH
LA English
DT Review
DE Psychosis; Autism spectrum disorder; Bipolar disorder; Major depressive
   disorder; Obsessive-compulsive disorder; Anorexia nervosa; Bulimia
   nervosa
ID AUTISM SPECTRUM DISORDERS; CORTICOTROPIN-RELEASING HORMONE;
   OBSESSIVE-COMPULSIVE DISORDER; ATRIAL-NATRIURETIC-PEPTIDE;
   CEREBROSPINAL-FLUID LEVELS; SOCIAL ANXIETY DISORDER;
   ARGININE-VASOPRESSIN; PLASMA OXYTOCIN; SCHIZOPHRENIC-PATIENTS;
   ANOREXIA-NERVOSA
AB A large array of studies have investigated peripheral oxytocin (OT) and vasopressin (ADH) as potential biomarkers of psychiatric disorders, with highly conflicting and heterogenous findings. We searched Web of KnowledgeSM and Scopus (R) for English original articles investigating OT and/or ADH levels in different biological fluids (plasma/serum, saliva, urine and cerebrospinal fluid) across several psychiatric disorders. Sixty-four studies were included. We conducted 19 preliminary meta-analyses addressing OT alterations in plasma/serum, saliva, urine and cerebrospinal fluid of 7 psychiatric disorders and ADH alterations in plasma/serum, saliva, urine and cerebrospinal fluid of 6 psychiatric disorders compared to controls. Hedge's g was used as effect size measure, together with heterogeneity analyses, test of publication biases and quality control. None of them (except serum OT in anorexia nervosa) revealed significant differences. There is no convincing evidence that peripheral ADH or OT might be reliable biomarkers in psychiatric disorders. However, the lack of significant results was associated with high methodological heterogeneity, low quality of the studies, small sample size, and scarce reliability of the methods used in previous studies, which need to be validated and standardized. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Grazia, Rutigliano; Matteo, Rocchetti; James, Gilleen; Alberto, Sardella; Marco, Cappucciati; Erika, Palombini; Philip, McGuire; Paolo, Fusar-Poli] Kings Coll London, Inst Psychiatiy Psychol & Neurosci, Dept Psychosis Studies, PO63,De Crespigny Pk, London SE5 8AF, England.
   [Grazia, Rutigliano; Liliana, Dell'Osso] Univ Pisa, Dept Clin & Expt Med, Via Roma 67, I-56126 Pisa, Italy.
   [Matteo, Rocchetti; Marco, Cappucciati; Erika, Palombini; Edgardo, Caverzasi; Pierluigi, Politi] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy.
   [Yannis, Paloyelis] Kings Coll London, Inst Psychiat Psychol & Neurosci, Neuroimaging Dept, PO89,De Crespigny Pk, London SE5 8AF, England.
   [Paolo, Fusar-Poli] SLaM NHS Fdn Trust, OASIS Clin, 190 Kennington Lane, London SE11 5DL, England.
   [James, Gilleen] Univ Roehampton, Dept Psychol, London, England.
RP Paolo, FP (reprint author), Inst Psychiat, Dept Psychosis Studies, PO63,De Crespigny Pk, London SE5 8AF, England.
EM paolo.fusar-poli@kcl.ac.uk
RI Politi, Pierluigi/G-5070-2012
OI Paloyelis, Yannis/0000-0002-4029-3720; Rocchetti,
   Matteo/0000-0001-5016-057X; Politi, Pierluigi/0000-0002-4602-2032
FU ESRC fellowship [ES/K009400/1]; NARSAD Young Investigator Award
FX The authors have declared that there are no conflicts of interest in
   relation to the subject of this study. This work was supported with the
   resources of the Department of Psychosis Studies; Institute of
   Psychiatry, Psychology and Neuroscience; King's College London, UK. Y.P.
   was supported in part by an ESRC fellowship [Grant number ES/K009400/1].
   Dr P.F.P. was supported in part by a 2014 NARSAD Young Investigator
   Award.
CR Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47
   Alabdali A., 2014, J NEUROINFLAMM, V11
   Altemus M, 2004, BIOL PSYCHIAT, V56, P386, DOI 10.1016/j.biopsych.2004.06.002
   ALTEMUS M, 1992, BRAIN RES, V593, P311, DOI 10.1016/0006-8993(92)91326-A
   Altemus M, 1999, BIOL PSYCHIAT, V45, P931, DOI 10.1016/S0006-3223(98)00263-7
   ALTEMUS M, 1992, ARCH GEN PSYCHIAT, V49, P9
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   APPELGREN B, 1982, ACTA PHYSIOL SCAND, P1
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   BECKMANN H, 1985, PSYCHONEUROENDOCRINO, V10, P187, DOI 10.1016/0306-4530(85)90056-3
   Bendz H, 1996, NEPHROL DIAL TRANSPL, V11, P457
   Bendz H, 1999, DRUG SAFETY, V21, P449, DOI 10.2165/00002018-199921060-00002
   Bertsch K, 2013, HORM BEHAV, V63, P424, DOI 10.1016/j.yhbeh.2012.11.013
   Blevins JE, 2013, REV ENDOCR METAB DIS, V14, P311, DOI 10.1007/s11154-013-9260-x
   Borenstein M., 2005, COMPREHENSIVE METAAN
   Boso M, 2007, ARCH MED RES, V38, P70, DOI 10.1016/j.arcmed.2006.08.003
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15
   Cervantes P, 2001, J PSYCHIATR NEUROSCI, V26, P411
   Chang SWC, 2014, BRAIN RES, V1580, P57, DOI 10.1016/j.brainres.2013.11.006
   Christensen JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116172
   Cooper H., 2009, HDB RES SYNTHESIS ME
   Crowley WR, 2015, COMPR PHYSIOL, V5, P255, DOI 10.1002/cphy.c140029
   Cui SS, 2001, J NEUROSCI, V21, P9867
   Daban C, 2005, PSYCHIAT CLIN N AM, V28, P469, DOI 10.1016/j.psc.2005.01.005
   DEMITRACK MA, 1990, AM J PSYCHIAT, V147, P882
   DINAN TG, 1994, BRIT J PSYCHIAT, V164, P365, DOI 10.1192/bjp.164.3.365
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Elman I, 2003, J PSYCHOPHARMACOL, V17, P317, DOI 10.1177/02698811030173014
   EMSLEY R, 1989, AM J PSYCHIAT, V146, P250
   Evans S, 2010, NEUROPSYCHOPHARMACOL, V35, P2502, DOI 10.1038/npp.2010.110
   Evrard F, 2004, NEPHROL DIAL TRANSPL, V19, P3034, DOI 10.1093/ndt/gfh507
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513
   Frank GK, 2000, BIOL PSYCHIAT, V48, P315, DOI 10.1016/S0006-3223(00)00243-2
   Fujisawa TX, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00295
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GLOVINSKY D, 1994, SCHIZOPHR RES, V11, P273, DOI 10.1016/0920-9964(94)90021-3
   Goekoop JG, 2006, PSYCHIAT RES, V141, P201, DOI 10.1016/j.psychres.2005.09.003
   GOLD PW, 1983, NEW ENGL J MED, V308, P1117, DOI 10.1056/NEJM198305123081902
   Goldman M, 2008, SCHIZOPHR RES, V98, P247, DOI 10.1016/j.schres.2007.09.019
   Goldman MB, 2009, BRAIN RES REV, V61, P210, DOI 10.1016/j.brainresrev.2009.06.004
   Goldstein G, 2000, BIOL PSYCHIAT, V48, P65, DOI 10.1016/S0006-3223(00)00246-8
   Griebel G, 2012, J CLIN PSYCHIAT, V73, P1403, DOI 10.4088/JCP.12m07804
   Grinevich V., 2015, BIOL PSYCHIAT
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P1220, DOI 10.1016/j.biopsych.2010.03.014
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Gumley A, 2014, BRIT J CLIN PSYCHOL, V53, P42, DOI 10.1111/bjc.12041
   Hashimoto Hirofumi, 2012, Pathophysiology, V19, P283, DOI 10.1016/j.pathophys.2012.07.005
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Heuser I, 1998, Depress Anxiety, V8, P71, DOI 10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.3.CO;2-E
   Higgins J., 2011, COCHRANE HDB SYSTEMA
   Hillerer KM, 2014, NEURAL PLAST, DOI 10.1155/2014/574159
   Hoffman ER, 2012, EAT BEHAV, V13, P256, DOI 10.1016/j.eatbeh.2012.02.004
   Hoge EA, 2008, CNS NEUROSCI THER, V14, P165, DOI 10.1111/j.1755-5949.2008.00051.x
   Hoge EA, 2012, DEPRESS ANXIETY, V29, P924, DOI 10.1002/da.21973
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7
   Husslein P, 1984, Wien Klin Wochenschr Suppl, V155, P1
   Inder WJ, 1997, BIOL PSYCHIAT, V42, P744, DOI 10.1016/S0006-3223(97)00301-6
   Jobst A, 2014, ACTA NEUROPSYCHIATR, V26, P347, DOI 10.1017/neu.2014.20
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Keri S, 2009, SOC NEUROSCI-UK, V4, P287, DOI 10.1080/17470910802319710
   Knafo A, 2008, GENES BRAIN BEHAV, V7, P266, DOI 10.1111/j.1601-183X.2007.00341.x
   Kudoh A, 1998, NEUROPSYCHOBIOLOGY, V37, P169, DOI 10.1159/000026498
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lawson EA, 2012, J CLIN ENDOCR METAB, V97, pE1898, DOI 10.1210/jc.2012-1702
   Lawson EA, 2011, J CLIN PSYCHIAT, V72, P1546, DOI 10.4088/JCP.10m06617
   LECKMAN JF, 1994, ARCH GEN PSYCHIAT, V51, P782
   LEGROS JJ, 1992, PROG BRAIN RES, V93, P455
   Leng G, 2015, BIOL PSYCHIAT
   Leng G., 2015, J ENDOCRINOL
   Lipsey M, 2000, PRACTICAL METAANALYS
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   LUDWIG M, 1994, J NEUROENDOCRINOL, V6, P369, DOI 10.1111/j.1365-2826.1994.tb00595.x
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Marazziti D, 2008, CURR MED CHEM, V15, P698, DOI 10.2174/092986708783885291
   Martin A, 1998, BIOL PSYCHIAT, V44, P1349, DOI 10.1016/S0006-3223(98)00190-5
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Merali Z, 2006, BIOL PSYCHIAT, V59, P594, DOI 10.1016/j.biopsych.2005.08.008
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   MOOS F, 1989, EXP BRAIN RES, V76, P593, DOI 10.1007/BF00248916
   Neumann ID, 2007, BIOCHEM SOC T, V35, P1252, DOI 10.1042/BST0351252
   Nomura S, 2005, BBA-PROTEINS PROTEOM, V1751, P19, DOI 10.1016/j.bbapap.2005.04.006
   OHSAWA H, 1993, ACTA PSYCHIAT SCAND, V88, P130, DOI 10.1111/j.1600-0447.1993.tb03426.x
   Ozsoy S, 2009, PSYCHIAT RES, V169, P249, DOI 10.1016/j.psychres.2008.06.034
   PADFIELD PL, 1977, BRIT J PSYCHIAT, V130, P144, DOI 10.1192/bjp.130.2.144
   Pagani J.H., 2014, MOL PSYCHIAT
   Pagel T, 2013, BIPOLAR DISORD, V15, P229, DOI 10.1111/bdi.12057
   Paulson JF, 2010, JAMA-J AM MED ASSOC, V303, P1961, DOI 10.1001/jama.2010.605
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   PITTS AF, 1995, BIOL PSYCHIAT, V38, P330, DOI 10.1016/0006-3223(95)00229-A
   RASKIND MA, 1987, BIOL PSYCHIAT, V22, P453, DOI 10.1016/0006-3223(87)90167-3
   Rilling J.K., 2014, PSYCHONEUROENDOCRINO, V39, P237
   Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, P671, DOI 10.1016/S0889-8529(05)70207-3
   Rocchetti M, 2014, PSYCHIAT CLIN NEUROS, V68, P733, DOI 10.1111/pcn.12185
   Rubin LH, 2014, SCHIZOPHRENIA BULL, V40, P1374, DOI 10.1093/schbul/sbu027
   Rubin LH, 2013, SCHIZOPHR RES, V146, P138, DOI 10.1016/j.schres.2013.01.019
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Rubin RT, 1999, PSYCHIAT RES, V89, P1, DOI 10.1016/S0165-1781(99)00085-2
   Ryan MCM, 2004, PSYCHONEUROENDOCRINO, V29, P1065, DOI 10.1016/j.psyneuen.2003.08.011
   SARAI M, 1989, BIOL PSYCHIAT, V26, P576, DOI 10.1016/0006-3223(89)90082-6
   Sasayama D, 2012, SCHIZOPHR RES, V139, P201, DOI 10.1016/j.schres.2012.06.016
   Silva SM, 2002, BRAIN RES, V925, P76, DOI 10.1016/S0006-8993(01)03261-9
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50
   SPRUCE BA, 1985, CLIN ENDOCRINOL, V22, P37, DOI 10.1111/j.1365-2265.1985.tb01062.x
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Strauss GP, 2015, SCHIZOPHR RES, V162, P47, DOI 10.1016/j.schres.2015.01.034
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Taurines Regina, 2014, Atten Defic Hyperact Disord, V6, P231, DOI 10.1007/s12402-014-0145-y
   Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6
   Thompson RR, 2006, P NATL ACAD SCI USA, V103, P7889, DOI 10.1073/pnas.0600406103
   Turan T, 2013, PSYCHONEUROENDOCRINO, V38, P2890, DOI 10.1016/j.psyneuen.2013.07.017
   Uvanas-Moberg Kerstin, 2005, Int J Behav Med, V12, P59
   Uzunova G., 2015, WORLD J BIOL PSYCHIA, P1
   van Londen L, 1998, BIOL PSYCHIAT, V43, P196, DOI 10.1016/S0006-3223(97)80433-7
   Veenema AH, 2008, PROG BRAIN RES, V170, P261, DOI 10.1016/S0079-6123(08)00422-6
   Walsh P, 2005, PSYCHONEUROENDOCRINO, V30, P431, DOI 10.1016/j.psyneuen.2004.11.003
   Walss-Bass C, 2013, SCHIZOPHR RES, V147, P387, DOI 10.1016/j.schres.2013.04.003
   Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105
   WATHES DC, 1982, NATURE, V297, P225, DOI 10.1038/297225a0
   Watson S, 2007, PSYCHONEUROENDOCRINO, V32, P464, DOI 10.1016/j.psyneuen.2007.02.010
   Wersinger SR, 2002, MOL PSYCHIATR, V7, P975, DOI 10.1038/sj.mp.4001195
   Wotjak CT, 1998, NEUROSCIENCE, V85, P1209, DOI 10.1016/S0306-4522(97)00683-0
   You ZD, 2001, NEUROSCI RES, V41, P143, DOI 10.1016/S0168-0102(01)00272-3
   Yuen KW, 2014, J PSYCHIATR RES, V51, P30, DOI 10.1016/j.jpsychires.2013.12.012
   Zak PJ, 2005, HORM BEHAV, V48, P522, DOI 10.1016/j.yhbeh.2005.07.009
NR 139
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD JUL 30
PY 2016
VL 241
BP 207
EP 220
DI 10.1016/j.psychres.2016.04.117
PG 14
WC Psychiatry
SC Psychiatry
GA DQ7EY
UT WOS:000379370900035
ER

PT J
AU Huetter, FK
   Bachmann, HS
   Reinders, A
   Siffert, D
   Stelmach, P
   Knop, D
   Horn, PA
   Siffert, W
AF Huetter, Franz Korbinian
   Bachmann, Hagen Sjard
   Reinders, Anette
   Siffert, Doris
   Stelmach, Patrick
   Knop, Dietmar
   Horn, Peter Alexander
   Siffert, Winfried
TI Association of a Common Oxytocin Receptor Gene Polymorphism with
   Self-Reported 'Empathic Concern' in a Large Population of Healthy
   Volunteers
SO PLOS ONE
LA English
DT Article
ID ASPERGER-SYNDROME; OXTR; STRESS; AFFILIATION; REACTIVITY; INTERACT;
   BEHAVIOR; HUMANS
AB Background
   Previous research has linked genomic variations of the oxytocin receptor (OXTR) gene with individual differences in empathy. The impact of these variations on specific cognitive and emotional aspects of empathy, however, remains to be clarified.
   Methods
   We analysed associations of a common OXTR polymorphism (rs53576) with trait empathy in a sample of 421 blood donors (231 M, 190 F; age 18-74) using the Interpersonal Reactivity Index (IRI) as an established multidimensional self-report measure of empathy.
   Results
   Female sex was significantly associated with higher empathy scores in all IRI scales (p<0.001) with the exception of the cognitive perspective taking scale (p = 0.09). The overall trait empathy score was significantly associated with rs53576 (p = 0.01), with mean scores increasing from AA to GG genotypes. An analysis of the IRI subscores revealed that the polymorphism was especially associated with the emotional empathic concern scale (p = 0.02). Separate analysis of the male and female subgroup revealed a significant association of the polymorphism with female (p = 0.04), but not with male (p = 0.20) empathic concern. A comparison of effect sizes between the groups showed greater effects for women compared to men although effect size differences did not become significant in our sample.
   Conclusions
   Our findings suggest a significant association of the rs53576 OXTR gene polymorphism with trait empathy and especially with emotional aspects of empathy. This association is possibly weaker or absent in men compared to women.
C1 [Huetter, Franz Korbinian; Bachmann, Hagen Sjard; Reinders, Anette; Siffert, Doris; Stelmach, Patrick; Siffert, Winfried] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pharmakogenet, D-45122 Essen, Germany.
   [Knop, Dietmar; Horn, Peter Alexander] Univ Duisburg Essen, Univ Klinikum Essen, Inst Transfus Med, D-45122 Essen, Germany.
RP Siffert, W (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Inst Pharmakogenet, D-45122 Essen, Germany.
EM winfried.siffert@uk-essen.de
CR 1000 Genomes, DEEP CAT HUM GEN VAR
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Bakermans-Kranenburg MJ, 2006, DEV PSYCHOBIOL, V48, P406, DOI 10.1002/dev.20152
   Brune M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-38
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Choi D, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-4
   Davis MH, 1980, JSAS CAT SEL DOCS PS, V10, P85
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   Devroye L., 1986, NONUNIFORM RANDOM VA
   Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Fisher R. A., 1921, METRON, V1, P3
   Flandre P, 2005, ANTIVIR THER, V10, P479
   Haas BW, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00801
   HOFFMAN ML, 1977, PSYCHOL BULL, V84, P712, DOI 10.1037//0033-2909.84.4.712
   Tello FP, 2013, CHILD PSYCHIAT HUM D, V44, P320, DOI 10.1007/s10578-012-0327-9
   Kendall M., 1990, RANK CORRELATION MET
   Keysers C, 2014, UNSER EMPATHISCHES G
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Klahr AM, 2015, J FAM PSYCHOL, V29, P91, DOI 10.1037/fam0000034
   Li JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131820
   LitvackMiller W, 1997, GENET SOC GEN PSYCH, V123, P303
   MacDonald KS, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00194
   Maoz H, 2014, J PSYCHOPHARMACOL, V28, P212, DOI 10.1177/0269881113492030
   Montag C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051882
   Moons WG, 2014, EMOTION, V14, P562, DOI 10.1037/a0035503
   Motomura Y, 2015, J PHYSIOL ANTHROPOL, V34, DOI 10.1186/s40101-015-0053-7
   O'Brien E, 2013, J GERONTOL B-PSYCHOL, V68, P168, DOI 10.1093/geronb/gbs055
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Rogers K, 2007, J AUTISM DEV DISORD, V37, P709, DOI 10.1007/s10803-006-0197-8
   Sauer C, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00045
   Seidel EM, 2013, PSYCHIAT RES, V210, P1168, DOI 10.1016/j.psychres.2013.08.027
   Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGY, V21, P431, DOI 10.1037/0894-4105.21.4.431
   Smith KE, 2014, SOC NEUROSCI-UK, V9, P1, DOI 10.1080/17470919.2013.863223
   Soper DS, SIGNIFICANCE DIFFERE
   Stankova T, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-17
   Tabak Benjamin A, 2013, Front Neurosci, V7, P199, DOI 10.3389/fnins.2013.00199
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Uzefovsky F, 2015, HORM BEHAV, V67, P60, DOI 10.1016/j.yhbeh.2014.11.007
   Wang JP, 2013, NEUROIMAGE, V81, P199, DOI 10.1016/j.neuroimage.2013.05.029
   Wu N, 2012, J AFFECT DISORDERS, V138, P468, DOI 10.1016/j.jad.2012.01.009
   Zak PJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00211
NR 43
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 28
PY 2016
VL 11
IS 7
AR e0160059
DI 10.1371/journal.pone.0160059
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5IL
UT WOS:000381516100101
PM 27467763
ER

PT J
AU Kyrgiou, M
   Athanasiou, A
   Paraskevaidi, M
   Mitra, A
   Kalliala, I
   Martin-Hirsch, P
   Arbyn, M
   Bennett, P
   Paraskevaidis, E
AF Kyrgiou, Maria
   Athanasiou, Antonios
   Paraskevaidi, Maria
   Mitra, Anita
   Kalliala, Ilkka
   Martin-Hirsch, Pierre
   Arbyn, Marc
   Bennett, Phillip
   Paraskevaidis, Evangelos
TI Adverse obstetric outcomes after local treatment for cervical
   preinvasive and early invasive disease according to cone depth:
   systematic review and meta-analysis
SO BMJ-British Medical Journal
LA English
DT Review
ID LOOP ELECTROSURGICAL EXCISION; COLD-KNIFE CONIZATION; SPONTANEOUS
   PRETERM DELIVERY; LONG-TERM OUTCOMES; INTRAEPITHELIAL NEOPLASIA CIN;
   DIOXIDE LASER CONIZATION; POPULATION-BASED COHORT; CARCINOMA IN-SITU;
   TRANSFORMATION ZONE; PREGNANCY OUTCOMES
AB OBJECTIVE
   To assess the effect of treatment for cervical intraepithelial neoplasia (CIN) on obstetric outcomes and to correlate this with cone depth and comparison group used.
   Design
   Systematic review and meta-analysis.
   Data sources
   CENTRAL, Medline, Embase from 1948 to April 2016 were searched for studies assessing obstetric outcomes in women with or without previous local cervical treatment.
   DATA EXTRACTION AND SYNTHESIS
   Independent reviewers extracted the data and performed quality assessment using the Newcastle-Ottawa criteria. Studies were classified according to method and obstetric endpoint. Pooled risk ratios were calculated with a random effect model and inverse variance. Heterogeneity between studies was assessed with I-2 statistics.
   Main outcome measures
   Obstetric outcomes comprised preterm birth (including spontaneous and threatened), premature rupture of the membranes, chorioamnionitis, mode of delivery, length of labour, induction of delivery, oxytocin use, haemorrhage, analgesia, cervical cerclage, and cervical stenosis. Neonatal outcomes comprised low birth weight, admission to neonatal intensive care, stillbirth, APGAR scores, and perinatal mortality.
   Results
   71 studies were included (6 338 982 participants: 65 082 treated/6 292 563 untreated). Treatment significantly increased the risk of overall (<37 weeks; 10.7% v 5.4%; relative risk 1.78, 95% confidence interval 1.60 to 1.98), severe (<32-34 weeks; 3.5% v 1.4%; 2.40, 1.92 to 2.99), and extreme (<28-30 weeks; 1.0% v 0.3%; 2.54, 1.77 to 3.63) preterm birth. Techniques removing or ablating more tissue were associated with worse outcomes. Relative risks for delivery at <37 weeks were 2.70 (2.14 to 3.40) for cold knife conisation, 2.11 (1.26 to 3.54) for laser conisation, 2.02 (1.60 to 2.55) for excision not otherwise specified, 1.56 (1.36 to 1.79) for large loop excision of the transformation zone, and 1.46 (1.27 to 1.66) for ablation not otherwise specified. Compared with no treatment, the risk of preterm birth was higher in women who had undergone more than one treatment (13.2% v 4.1%; 3.78, 2.65 to 5.39) and with increasing cone depth (<= 10-12 mm; 7.1% v 3.4%; 1.54, 1.09 to 2.18; >= 10-12 mm: 9.8% v 3.4%, 1.93, 1.62 to 2.31; <= 15-17 mm: 10.1% v 3.4%; 2.77, 1.95 to 3.93; >= 20 mm: 10.2% v 3.4%; 4.91, 2.06 to 11.68). The choice of comparison group affected the magnitude of effect. This was higher for external comparators, followed by internal comparators, and ultimately women with disease who did not undergo treatment. In women with untreated CIN and in pregnancies before treatment, the risk of preterm birth was higher than the risk in the general population (5.9% v 5.6%; 1.24, 1.14 to 1.35). Spontaneous preterm birth, premature rupture of the membranes, chorioamnionitis, low birth weight, admission to neonatal intensive care, and perinatal mortality were also significantly increased after treatment.
   Conclusions
   Women with CIN have a higher baseline risk for prematurity. Excisional and ablative treatment further increases that risk. The frequency and severity of adverse sequelae increases with increasing cone depth and is higher for excision than for ablation.
C1 [Kyrgiou, Maria; Paraskevaidi, Maria; Mitra, Anita; Kalliala, Ilkka; Bennett, Phillip] Imperial Coll, Inst Reprod & Dev Biol, Dept Surg & Canc, Fac Med, London, England.
   [Kyrgiou, Maria; Mitra, Anita; Bennett, Phillip] Imperial Healthcare NHS Trust, Queen Charlottes & Chelsea Hammersmith Hosp, London, England.
   [Athanasiou, Antonios; Paraskevaidis, Evangelos] Univ Hosp Ioannina, Ioannina, Greece.
   [Martin-Hirsch, Pierre] Lancashire Teaching Hosp, Dept Gynaecol Oncol, Preston, Lancs, England.
   [Martin-Hirsch, Pierre] Univ Lancaster, Dept Biophoton, Lancaster, England.
   [Arbyn, Marc] Sci Inst Publ Hlth, Unit Canc Epidemiol, Brussels, Belgium.
RP Kyrgiou, M (reprint author), Imperial Coll, Inst Reprod & Dev Biol, Dept Surg & Canc, Fac Med, London, England.
EM m.kyrgiou@imperial.ac.uk
FU British Society of Colposcopy Cervical Pathology Jordan/Singer Award
   [P47773]; Imperial College Healthcare Charity [P47907]; Genesis Research
   Trust [P55549]; Sigrid Juselius Fellowship [P52483]; Imperial Healthcare
   NHS Trust NIHR Biomedical Research Centre [P45272]; COHEAHR Network -
   Seventh Framework Programme of DG Research of the European Commission
   (Brussels) [603019]; Institut National du Cancer (Paris) through the
   COSPCC study (Consequences obstetricales du (sur) traitement des
   precurseurs du cancer du col); European Federation of Colposcopy
   (Birmingham); Joint Action CANCON
FX This work was supported by the British Society of Colposcopy Cervical
   Pathology Jordan/Singer Award (P47773) (MK); the Imperial College
   Healthcare Charity (P47907) (AM and MK); Genesis Research Trust (P55549)
   (MK); Sigrid Juselius Fellowship (P52483 to IK and MK), and the Imperial
   Healthcare NHS Trust NIHR Biomedical Research Centre (P45272) (MK, PRB).
   MA received support from the COHEAHR Network (grant No 603019), funded
   by Seventh Framework Programme of DG Research of the European Commission
   (Brussels); Institut National du Cancer (Paris) through the COSPCC study
   (Consequences obstetricales du (sur) traitement des precurseurs du
   cancer du col); the European Federation of Colposcopy (Birmingham); and
   the Joint Action CANCON. None of the funders has any influence on the
   study design; in the collection, analysis, and interpretation of data;
   in the writing of the report; and in the decision to submit the article
   for publication.
CR Acharya Ganesh, 2005, Archives of Gynecology and Obstetrics, V272, P109, DOI 10.1007/s00404-005-0727-1
   Al-Halal H, 2013, ARCH GYNECOL OBSTET, V287, P245, DOI 10.1007/s00404-012-2475-3
   Albrechtsen S, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1343
   Althuisius SM, 2001, INT J GYNECOL OBSTET, V72, P31, DOI 10.1016/S0020-7292(00)00326-X
   Andersen ES, 1999, J GYNECOL SURG, V15, P7, DOI 10.1089/gyn.1999.15.7
   Anderson MC, 1984, J GYNECOLOGIC SURG, V1, P35, DOI DOI 10.1089/GYN.1984.1.35
   Andia D, 2011, INT J GYNECOL OBSTET, V112, P225, DOI 10.1016/j.ijgo.2010.10.015
   Anwar A, 2016, J MATERN-FETAL NEO M, V29, P477, DOI 10.3109/14767058.2015.1006619
   Arbyn M, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7700
   Arbyn M, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1284
   Armarnik S, 2011, ARCH GYNECOL OBSTET, V283, P765, DOI 10.1007/s00404-011-1848-3
   Bekassy Z, 1996, ARCH GYNECOL OBSTET, V258, P75, DOI 10.1007/BF00626027
   Berghella V, 2004, AM J OBSTET GYNECOL, V191, P1393, DOI 10.1016/j.ajog.2004.06.087
   Berretta R, 2013, DIS MARKERS, DOI 10.1155/2013/686027
   BLOMFIELD PI, 1993, AM J OBSTET GYNECOL, V169, P620
   Braet P. G., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, P79, DOI 10.3109/01443619409030016
   Bruinsma F, 2007, BJOG-INT J OBSTET GY, V114, P70, DOI 10.1111/j.1471-0528.2006.01107.x
   Bruinsma FJ, 2011, BJOG-INT J OBSTET GY, V118, P1031, DOI 10.1111/j.1471-0528.2011.02944.x
   BULLER RE, 1982, AM J OBSTET GYNECOL, V142, P506
   Castanon A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6223
   Castanon A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5174
   Ciavattini A, 2015, FERTIL STERIL, V103, P1043, DOI 10.1016/j.fertnstert.2014.12.112
   Ciavattini A, 2014, J MATERN-FETAL NEO M, V27, P1169, DOI 10.3109/14767058.2013.850483
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Conner SN, 2014, OBSTET GYNECOL, V123, P752, DOI 10.1097/AOG.0000000000000174
   Conner SN, 2013, OBSTET GYNECOL, V122, P1154, DOI 10.1097/01.AOG.0000435454.31850.79
   Crane JMG, 2006, OBSTET GYNECOL, V107, P37, DOI 10.1097/01.AOG.0000192169.44775.76
   Crane JMG, 2003, OBSTET GYNECOL, V102, P1058, DOI 10.1016/S0029-7844(03)00741-5
   CRUICKSHANK ME, 1995, BRIT J OBSTET GYNAEC, V102, P467, DOI 10.1111/j.1471-0528.1995.tb11319.x
   Danhof NA, 2015, EUR J OBSTET GYN R B, V188, P24, DOI 10.1016/j.ejogrb.2015.02.033
   Deeks J, 2001, STAT METHODS EXAMINI, DOI [10.1002/9780470693926.ch15, DOI 10.1002/9780470693926.CH15]
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ehsanipoor RM, 2014, J MATERN-FETAL NEO M, V27, P821, DOI 10.3109/14767058.2013.836178
   El-Bastawissi AY, 1999, OBSTET GYNECOL, V93, P207, DOI 10.1016/S0029-7844(98)00386-X
   Fischer RL, 2010, ULTRASOUND OBST GYN, V36, P613, DOI 10.1002/uog.7682
   Forsmo S, 1996, ACTA OBSTET GYN SCAN, V75, P139, DOI 10.3109/00016349609033306
   Founta C, 2010, BJOG-INT J OBSTET GY, V117, P1468, DOI 10.1111/j.1471-0528.2010.02709.x
   Frega A, 2013, INT J GYNECOL OBSTET, V122, P145, DOI 10.1016/j.ijgo.2013.03.013
   Frey HA, 2013, OBSTET GYNECOL, V121, P39, DOI [http://10.1097/AOG.0b013e318278f904, 10.1097/AOG.0b013e318278f904]
   Gentry DJ, 2000, AM J OBSTET GYNECOL, V182, P516, DOI 10.1067/mob.2000.104209
   GRONROOS M, 1979, ACTA OBSTET GYN SCAN, V58, P477
   Gunasekera P. C., 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P291, DOI 10.3109/01443619209015508
   Guo HJ, 2013, EUR J GYNAECOL ONCOL, V34, P79
   HAFFENDEN DK, 1993, BRIT J OBSTET GYNAEC, V100, P1059, DOI 10.1111/j.1471-0528.1993.tb15153.x
   HAGEN B, 1993, BRIT J OBSTET GYNAEC, V100, P717, DOI 10.1111/j.1471-0528.1993.tb14261.x
   Heinonen A, 2013, OBSTET GYNECOL, V121, P1063, DOI 10.1097/AOG.0b013e31828caa31
   HEMMINGSSON E, 1982, BRIT J OBSTET GYNAEC, V89, P675, DOI 10.1111/j.1471-0528.1982.tb04725.x
   Henk HJ, 2010, J LOW GENIT TRACT DI, V14, P29, DOI 10.1097/LGT.0b013e3181ac05e9
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Himes KP, 2007, OBSTET GYNECOL, V109, P314, DOI 10.1097/01.AOG.0000251497.55065.74
   Jakobsson M, 2007, OBSTET GYNECOL, V109, P309, DOI 10.1097/01.AOG.0000253239.87040.23
   Jakobsson M, 2009, OBSTET GYNECOL, V114, P504, DOI 10.1097/AOG.0b013e3181b052de
   Jin Gong, 2014, Arch Gynecol Obstet, V289, P85, DOI 10.1007/s00404-013-2955-0
   JONES JM, 1979, BRIT J OBSTET GYNAEC, V86, P913, DOI 10.1111/j.1471-0528.1979.tb11237.x
   Kalliala I, 2012, BJOG-INT J OBSTET GY, V119, P227, DOI 10.1111/j.1471-0528.2011.03042.x
   Khalid S, 2012, BJOG-INT J OBSTET GY, V119, P685, DOI 10.1111/j.1471-0528.2011.03252.x
   Kim M, 2016, ARCH GYNECOL OBSTET, V293, P651, DOI 10.1007/s00404-015-3860-5
   Kindinger L, 2013, BJOG-INT J OBSTET GY, V120, P50
   Kindinger L, PLOS ONE IN PRESS
   Kirn V, 2015, ARCH GYNECOL OBSTET, V291, P599, DOI 10.1007/s00404-014-3463-6
   Kitson SJ, 2014, EUR J OBSTET GYN R B, V180, P51, DOI 10.1016/j.ejogrb.2014.06.011
   Klaritsch P, 2006, GYNECOL ONCOL, V103, P604, DOI 10.1016/j.ygyno.2006.04.003
   KRISTENSEN GB, 1985, ARCH GYNECOL, V236, P127, DOI 10.1007/BF02133954
   KRISTENSEN J, 1993, OBSTET GYNECOL, V81, P1005
   KULLANDER S, 1971, ACTA OBSTET GYN SCAN, V50, P153
   KUOPPALA T, 1986, ARCH GYNECOL OBSTET, V237, P149, DOI 10.1007/BF02133858
   Kyrgiou M, 2006, LANCET, V367, P489, DOI 10.1016/S0140-6736(06)68181-6
   Kyrgiou M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5847
   Kyrgiou Maria, 2014, BMJ, V349, pg6192, DOI 10.1136/bmj.g6192
   Kyrgiou M, 2015, INT J GYNECOL OBSTET, V128, P141, DOI 10.1016/j.ijgo.2014.07.038
   LARSSON G, 1982, ACTA OBSTET GYN SCAN, V61, P461
   LEIMAN G, 1980, AM J OBSTET GYNECOL, V136, P14
   Lima AF, 2011, J LOW GENIT TRACT DI, V15, P276, DOI 10.1097/LGT.0b013e31821a6823
   Liu Y, 2014, GYNECOL OBSTET INVES, V77, P240, DOI 10.1159/000360538
   LUDVIKSSON K, 1982, EUR J OBSTET GYN R B, V14, P135, DOI 10.1016/0028-2243(82)90088-0
   Macvicar J, 1968, J Obstet Gynaecol Br Commonw, V75, P355
   Martin-Hirsch PP, 2013, COCHRANE DB SYST REV, V12, DOI 10.1002/14651858.CD001318.pub3
   Martyn FM, 2015, EUR J OBSTET GYN R B, V185, P114, DOI 10.1016/j.ejogrb.2014.12.004
   Masamoto H, 2008, J OBSTET GYNAECOL RE, V34, P838, DOI 10.1111/j.1447-0756.2008.00852.x
   Michelin MA, 2009, CLIN EXP OBSTET GYN, V36, P17
   Miller ES, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.06.036
   Mitsuhashi A, 2000, INT J GYNECOL OBSTET, V71, P237, DOI 10.1016/S0020-7292(99)00173-3
   Moher David, 2009, Open Med, V3, pe123
   MOINIAN M, 1982, ACTA OBSTET GYN SCAN, V61, P101
   MONAGHAN JM, 1982, BRIT J OBSTET GYNAEC, V89, P387, DOI 10.1111/j.1471-0528.1982.tb05082.x
   Naleway AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117525
   Nam KH, 2010, J GYNECOL ONCOL, V21, P225, DOI 10.3802/jgo.2010.21.4.225
   Noehr B, 2009, OBSTET GYNECOL, V114, P1232, DOI 10.1097/AOG.0b013e3181bf1ef2
   Noehr B, 2009, OBSTET GYNECOL, V114, P511, DOI 10.1097/AOG.0b013e3181b1377b
   Noehr B, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.02.004
   Novikova EG, 1994, AKUSH GINEKOL MOSK, V2, P44
   Ortoft G, 2010, BJOG-INT J OBSTET GY, V117, P258, DOI 10.1111/j.1471-0528.2009.02438.x
   Paraskevaidis E, 2007, BJOG-INT J OBSTET GY, V114, P3, DOI 10.1111/j.1471-0528.2006.01178.x
   Paraskevaidis E, 2002, GYNECOL ONCOL, V86, P10, DOI 10.1006/gyno.2002.6650
   Parikh R, 2008, J REPROD MED, V53, P909
   Patrelli T S, 2008, Minerva Ginecol, V60, P295
   Petry KU, 2008, EUR J GYNAECOL ONCOL, V29, P345
   Phadnis SV, 2011, BJOG-INT J OBSTET GY, V118, P1585, DOI 10.1111/j.1471-0528.2011.03085.x
   Pils S, 2014, BJOG-INT J OBSTET GY, V121, P457, DOI 10.1111/1471-0528.12390
   Pinborg A, 2015, HUM REPROD, V30, P197, DOI 10.1093/humrep/deu260
   Poon LCY, 2012, BJOG-INT J OBSTET GY, V119, P692, DOI 10.1111/j.1471-0528.2011.03203.x
   Radha Bai Prabhu T, 2010, J OBSTET GYNAECOL IN, V60, P149, DOI [10.1007/s13224-010-0022-3, DOI 10.1007/S13224-010-0022-3]
   Rafaeli-Yehudai T, 2014, J MATERN-FETAL NEO M, V27, P1594, DOI 10.3109/14767058.2013.871254
   Raio L, 1997, OBSTET GYNECOL, V90, P978, DOI 10.1016/S0029-7844(97)00489-4
   Reilly R, 2012, BJOG-INT J OBSTET GY, V119, P236, DOI 10.1111/j.1471-0528.2011.03052.x
   RICCIOTTI HA, 1995, INT J GYNECOL OBSTET, V50, P175, DOI 10.1016/0020-7292(95)02432-C
   ROSEN A, 1991, GEBURTSH FRAUENHEILK, V51, P208, DOI 10.1055/s-2007-1023705
   Sadler L, 2004, JAMA-J AM MED ASSOC, V291, P2100, DOI 10.1001/jama.291.17.2100
   SAGOT P, 1995, EUR J OBSTET GYN R B, V58, P53, DOI 10.1016/0028-2243(94)01986-H
   Samson SLA, 2005, OBSTET GYNECOL, V105, P325, DOI 10.1097/01.AOG.0000151991.09124.bb
   Sangkarat S, 2014, ASIAN PAC J CANCER P, V15, P1035, DOI 10.7314/APJCP.2014.15.2.1035
   Saunders N, 1986, GYNECOLOGIC LASER SU, P121
   Seki N, 2010, EUR J GYNAECOL ONCOL, V31, P399
   Shanbhag S, 2009, OBSTET GYNECOL, V114, P727, DOI 10.1097/AOG.0b013e3181b5cba3
   Shin MY, 2010, J GYNECOL ONCOL, V21, P230, DOI 10.3802/jgo.2010.21.4.230
   Simoens C, 2012, BJOG-INT J OBSTET GY, V119, P1247, DOI 10.1111/j.1471-0528.2012.03429.x
   Sjoborg KD, 2007, ACTA OBSTET GYN SCAN, V86, P423, DOI 10.1080/11038120701208158
   Sljivancanin D, 2013, SRP ARK CELOK LEK, V141, P192, DOI 10.2298/SARH13041925
   Smaldone GMM, 2010, J WOMENS HEALTH, V19, P969, DOI 10.1089/jwh.2009.1574
   Sozen H, 2014, J REPROD MED, V59, P81
   SPITZER M, 1995, OBSTET GYNECOL, V86, P504, DOI 10.1016/S0029-7844(95)80005-0
   Spracklen CN, 2013, BJOG-INT J OBSTET GY, V120, P960, DOI 10.1111/1471-0528.12209
   Stout MJ, 2015, BJOG-INT J OBSTET GY, V122, P545, DOI 10.1111/1471-0528.13252
   Strander B, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7361
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan Linda, 2004, J Obstet Gynaecol, V24, P25
   Turlington WT, 1996, J REPROD MED, V41, P815
   van de Vijver A, 2010, BJOG-INT J OBSTET GY, V117, P268, DOI 10.1111/j.1471-0528.2009.02437.x
   Van Hentenryck M, 2012, EUR J OBSTET GYN R B, V162, P16, DOI 10.1016/j.ejogrb.2012.01.019
   van Rooijen M, 1999, ACTA OBSTET GYN SCAN, V78, P346
   Wakita K, 1990, J Clin Laser Med Surg, V8, P71
   WEBER T, 1979, ACTA OBSTET GYN SCAN, V58, P347
   Wells GA, NEWCASTLE OTTAWA SCA
   Werner CL, 2010, OBSTET GYNECOL, V115, P605, DOI 10.1097/AOG.0b013e3181d068a3
   Wongtiraporn W, 2014, ASIAN PAC J CANCER P, V15, P7757, DOI 10.7314/APJCP.2014.15.18.7757
   Wuntakal R, 2013, INT J GYNECOL CANCER, V23, P710, DOI 10.1097/IGC.0b013e3182885496
   Zuo Z, 2011, AM J CLIN PATHOL, V136, P260, DOI 10.1309/AJCP93JMIUEKRPIW
NR 137
TC 2
Z9 3
U1 7
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUL 28
PY 2016
VL 354
AR i3633
DI 10.1136/bmj.i3633
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS6ZO
UT WOS:000380932300001
PM 27469988
ER

PT J
AU Arthi, PN
   Jalakandan, B
AF Arthi, P. Nivedhana
   Jalakandan, B.
TI EVALUATION OF MATERNAL AND FOETAL OUTCOME IN TERM PREMATURE RUPTURE OF
   MEMBRANES MANAGED WITH EARLY INDUCTION
SO JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS
LA English
DT Article
DE Premature Rupture of Membranes; Chorioamnionitis; Perinatal Asphyxia;
   Neonatal Sepsis; Bishop Score
ID PRELABOR RUPTURE; AMNIOTIC MEMBRANES; RISK-FACTORS; INFECTION; TRIAL;
   FLUID; WOMEN; LABOR
AB BACKGROUND
   Premature Rupture of Membranes (PROM) occurs in 10% of all pregnancies. The significance of PROM lies in the fact that it has obscure aetiology with difficulties in diagnosis and is associated with significant maternal and neonatal risks. There is still no universally accepted policy for the management of PROM at term.
   OBJECTIVES
   To identify the risk factors causing PROM and to study the labour outcomes and the maternal and perinatal morbidity and mortality in cases of PROM at term.
   METHODS
   This prospective descriptive study was conducted on seventy five patients with spontaneous rupture of membranes with gestational age >= 37 weeks and managed with early induction. A detailed history and examination were carried out. All parameters of maternal and foetal wellbeing were recorded. A sterile speculum examination and amniotic fluid culture were done. Labour was induced with intravenous oxytocin. Data was collected using a structured questionnaire. Neonates with poor Apgar score were admitted in Neonatology Intensive Care Unit (NICU). Observations for signs of infection were continued in puerperium. Data regarding mode of delivery, foetal weight, foetal Apgar score, weight, and neonatal outcome were recorded.
   RESULTS
   PROM occurs more frequently in unbooked, nulliparous women of low socioeconomic class. Incidence of LSCS (44%) and instrumental delivery (28%) were higher. E. coli (42.5%) was the most common pathogen isolated from vagina followed by commensals (17.5%). Puerperal pyrexia (10.7%) was a major cause for maternal morbidity followed by wound infection (2.7%) and chorioamnionitis (1.3%). 27.6% of the neonates required NICU observation for mild respiratory distress. 5.3% of neonates were admitted for perinatal asphyxia and 2.6% of neonates were admitted for neonatal sepsis. No perinatal deaths were there. Infections have increased with increasing period of latency.
   CONCLUSION
   Overall incidence of maternal and neonatal infectious complications were very less in our study. The early induction of patients in our study by reducing the duration of latency had contributed for the reduction in the incidence of infectious complications.
C1 [Arthi, P. Nivedhana] Sri Lakshmi Narayana Inst Med Sci, Dept Obstet & Gynaecol, Pondicherry 605502, India.
   [Jalakandan, B.] Sri Lakshmi Narayana Inst Med Sci, Dept Anaesthesiol & Crit Care, Pondicherry, India.
RP Arthi, PN (reprint author), Sri Lakshmi Narayana Inst Med Sci, Dept Obstet & Gynaecol, Pondicherry 605502, India.
EM sujanjala@gmail.com
CR ALGER LS, 1988, AM J OBSTET GYNECOL, V159, P397
   [Anonymous], 1998, ACOG PRACTICE B
   [Anonymous], 2009, ANNALS
   AMSTEY M S, 1976, Journal of the American Venereal Disease Association, V3, P14
   Andrews WW, 2003, OBSTET GYNECOL, V101, P1183, DOI 10.1016/S0029-7844(03)00016-4
   BOURESLI MN, 1981, CELL TISSUE RES, V220, P263
   Chaim W, 2000, Infect Dis Obstet Gynecol, V8, P77
   [Anonymous], 1999, FOETAL DAUGHTER
   Dare MR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005302.pub2
   EKWO EE, 1993, INT J EPIDEMIOL, V22, P495, DOI 10.1093/ije/22.3.495
   Erdemoglu E, 2004, ACTA OBSTET GYN SCAN, V83, P622, DOI 10.1111/j.0001-6349.2004.00343.x
   GIBBS RS, 1982, J INFECT DIS, V145, P1
   GRANT JM, 1992, BRIT J OBSTET GYNAEC, V99, P557, DOI 10.1111/j.1471-0528.1992.tb13820.x
   Hannah ME, 1996, NEW ENGL J MED, V334, P1005, DOI 10.1056/NEJM199604183341601
   HARGER JH, 1990, AM J OBSTET GYNECOL, V163, P130
   [Anonymous], 2011, MACED J MED SCI
   Imseis HM, 1999, AM J OBSTET GYNECOL, V180, P578, DOI 10.1016/S0002-9378(99)70257-7
   Ladfors L, 1998, J PERINAT MED, V26, P94, DOI 10.1515/jpme.1998.26.2.94
   Ladfors L, 1996, BRIT J OBSTET GYNAEC, V103, P755, DOI 10.1111/j.1471-0528.1996.tb09869.x
   LINN S, 1983, AM J OBSTET GYNECOL, V146, P136
   MILLS JL, 1981, LANCET, V2, P136
   NAEYE RL, 1980, LANCET, V1, P192
   Noor Shehla, 2010, J Ayub Med Coll Abbottabad, V22, P164
   Ottervanger HP, 1996, J PERINAT MED, V24, P237, DOI 10.1515/jpme.1996.24.3.237
   POLZIN WJ, 1991, CLIN OBSTET GYNECOL, V34, P702, DOI 10.1097/00003081-199112000-00006
   Ratanakorn Woranart, 2005, Journal of the Medical Association of Thailand, V88, P973
   Romero R, 2003, J NUTR, V133, p1668S
   RYDSTROM H, 1986, ACTA OBSTET GYN SCAN, V65, P587
   Seaward PGR, 1998, AM J OBSTET GYNECOL, V179, P635, DOI 10.1016/S0002-9378(98)70056-0
   SKINNER SJM, 1981, OBSTET GYNECOL, V57, P487
   SPINILLO A, 1994, INT J GYNECOL OBSTET, V47, P7, DOI 10.1016/0020-7292(94)90454-5
   Tavassoli Fatemeh, 2010, Oman Med J, V25, P118, DOI 10.5001/omj.2010.32
   Vaishnav J, 2012, MED SCI, V1, P118
   WAGNER MV, 1989, OBSTET GYNECOL, V74, P93
   Yancey NK, 1996, OBSTET GYNECOL, V87, P188
NR 35
TC 0
Z9 0
U1 3
U2 3
PU JOURNAL EVOLUTION MEDICAL & DENTAL SCIENCES
PI KARNATAKA
PA C/O AKSHANTALA ENTERPRISES, NO 65, 1ST FL, SAHUKAR CHENNIAH RD, MYSORE,
   KARNATAKA, 570 009, INDIA
SN 2278-4748
EI 2278-4802
J9 J EVOL MED DENT SCI-
JI J. Evol. Med. Dent. Sci.-JEMDS
PD JUL 25
PY 2016
VL 5
IS 59
BP 4092
EP 4099
DI 10.14260/jemds/2016/936
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS0HL
UT WOS:000380276100008
ER

PT J
AU Zhong, J
   Amina, S
   Liang, M
   Akther, S
   Yuhi, T
   Nishimura, T
   Tsuji, C
   Tsuji, T
   Liu, HX
   Hashii, M
   Furuhara, K
   Yokoyama, S
   Yamamoto, Y
   Okamoto, H
   Zhao, YJ
   Lee, HC
   Tominaga, M
   Lopatina, O
   Higashida, H
AF Zhong, Jing
   Amina, Sarwat
   Liang, Mingkun
   Akther, Shirin
   Yuhi, Teruko
   Nishimura, Tomoko
   Tsuji, Chiharu
   Tsuji, Takahiro
   Liu, Hong-Xiang
   Hashii, Minako
   Furuhara, Kazumi
   Yokoyama, Shigeru
   Yamamoto, Yasuhiko
   Okamoto, Hiroshi
   Zhao, Yong Juan
   Lee, Hon Cheung
   Tominaga, Makoto
   Lopatina, Olga
   Higashida, Haruhiro
TI Cyclic ADP-Ribose and Heat Regulate Oxytocin Release via CD38 and TRPM2
   in the Hypothalamus during Social or Psychological Stress in Mice
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE oxytocin; secretion; hyperthermia; NAD; cyclic ADP-ribose; stress;
   autism
ID AUTISM SPECTRUM DISORDERS; C-FOS EXPRESSION; INSULIN-SECRETION; INDUCED
   HYPERTHERMIA; COMMUNICATIVE INTERACTION; NEURAL MECHANISMS; MATERNAL
   MATES; OPEN-FIELD; MOUSE; BEHAVIOR
AB Hypothalamic oxytocin (01) is released into the brain by cyclic ADP ribose (cADPR) with or without depolarizing stimulation. Previously, we showed that the intracellular free calcium concentration ([Ca2+](i)) that seems to trigger OT release can be elevated by beta-NAD(+), cADPR, and ADP in mouse oxytocinergic neurons. As these beta-NAD(+) metabolites activate warm sensitive TRPM2 cation channels, when the incubation temperature is increased, the [Ca2+](i), in hypothalamic neurons is elevated. However, it has not been determined whether OT release is facilitated by heat in vitro or hyperthermia in vivo in combination with cADPR. Furthermore, it has not been examined whether CD38 and TRPM2 exert their functions on OT release during stress or stress-induced hyperthermia in relation to the anxiolytic roles and social behaviors of OT under stress conditions. Here, we report that OT release from the isolated hypothalami of male mice in culture was enhanced by extracellular application of cADPR or increasing the incubation temperature from 35 degrees C to 38.5 degrees C, and simultaneous stimulation showed a greater effect. This release was inhibited by a cADPR-dependent ryanodine receptor inhibitor and a nonspecific TRPM2 inhibitor. The facilitated release by heat and cADPR was suppressed in the hypothalamus isolated from CD38 knockout mice and CD38- or TRPM2 knockdown mice. In the course of these experiments, we noted that OT release differed markedly between individual mice under stress with group housing. That is, when male mice received cage switch stress and eliminated due to their social subclass, significantly higher levels of OT release were found in subordinates compared with ordinates. In mice exposed to anxiety stress in an open field, the cerebrospinal fluid (CSF) OT level increased transiently at 5 min after exposure, and the rectal temperature also increased from 36.6 degrees C to 37.8 degrees C. OT levels in the CSF of mice with lipopolysaccharide-induced fever (+0.8'degrees C) were higher than those of control mice. The TRPM2 mRNA levels and immunoreactivities increased in the subordinate group with cage-switch stress. These results showed that cADPR/CD38 and heat/TRPM2 are co-regulators of OT secretion and suggested that CD38 and TRPM2 are potential therapeutic targets for OT release in psychiatric diseases caused by social stress.
C1 [Zhong, Jing; Amina, Sarwat; Liang, Mingkun; Akther, Shirin; Yuhi, Teruko; Nishimura, Tomoko; Tsuji, Chiharu; Tsuji, Takahiro; Liu, Hong-Xiang; Hashii, Minako; Furuhara, Kazumi; Yokoyama, Shigeru; Lopatina, Olga; Higashida, Haruhiro] Kanazawa Univ, Res Ctr Child Dev Dev, Dept Basic Res Social Recognit & Memory, Kanazawa, Ishikawa, Japan.
   [Yamamoto, Yasuhiko; Okamoto, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa, Japan.
   [Okamoto, Hiroshi] Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi, Japan.
   [Zhao, Yong Juan; Lee, Hon Cheung] Peking Univ, Grad Sch, Sch Chem Biol & Biotechnol, Shenzhen, Peoples R China.
   [Tominaga, Makoto] Natl Inst Nat Sci, Natl Inst Physiol Sci, Okazaki Inst Integrat Biosci, Div Cell Signaling, Okazaki, Aichi, Japan.
   [Lopatina, Olga; Higashida, Haruhiro] Krasnoyarsk State Med Univ, Res Inst Mol Med & Pathobiochem, Krasnoyarsk, Russia.
   [Zhong, Jing] Guangxi Univ Chinese Med, Dept Physiol, Nanning, Peoples R China.
   [Liang, Mingkun] Guangxi Univ Chinese Med, Ruikang Hosp, China Neurol Dept, Nanning, Peoples R China.
RP Higashida, H (reprint author), Kanazawa Univ, Res Ctr Child Dev Dev, Dept Basic Res Social Recognit & Memory, Kanazawa, Ishikawa, Japan.; Higashida, H (reprint author), Krasnoyarsk State Med Univ, Res Inst Mol Med & Pathobiochem, Krasnoyarsk, Russia.
EM haruhiro@med.kanazawa-u.ac.jp
RI Lee, Hon Cheung/C-4329-2009
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   (MEXT); Japan Agency for Medical Research and Development (AMED);
   industry-Academia Collaborative R&D Programs (COI) from MEXT; National
   Science Foundation of China [31301156, 31571438, 31470815, 91413114];
   Shenzhen government [JCYJ20150331100801849]
FX This work was supported by grant-in-aid from "Integrated research on
   neuropsychiatric disorders" carried out under the Strategic Research
   Program for Brain Sciences by the Ministry of Education, Culture,
   Sports, Science and Technology of Japan (MEXT) and from the Japan Agency
   for Medical Research and Development (AMED) and also by the
   industry-Academia Collaborative R&D Programs (COI) from MEXT, and grants
   from National Science Foundation of China (#31301156, #31571438 to YZ;
   #31470815, #91413114 to HL; and a grant from Shenzhen government
   (#JCYJ20150331100801849 to YZ).
CR Amina S, 2010, J NEUROENDOCRINOL, V22, P460, DOI 10.1111/j.1365-2826.2010.01978.x
   Baez David, 2014, Curr Top Membr, V74, P51, DOI 10.1016/B978-0-12-800181-3.00003-8
   Borges BC, 2006, NEUROSCI LETT, V404, P227, DOI 10.1016/j.neulet.2006.05.052
   Bouwknecht JA, 2007, BRAIN RES BULL, V72, P32, DOI 10.1016/j.brainresbull.2006.12.009
   Bouwknecht JA, 2007, NEUROSCI BIOBEHAV R, V31, P41, DOI 10.1016/j.neubiorev.2006.02.002
   Brunton PJ, 2008, NAT REV NEUROSCI, V9, P11, DOI 10.1038/nrn2280
   Butterweck V, 2003, BEHAV BRAIN RES, V144, P49, DOI 10.1016/S0166-4328(03)00059-7
   Carter CS, 2009, DEV NEUROSCI-BASEL, V31, P332, DOI 10.1159/000216544
   Curran LK, 2007, PEDIATRICS, V120, pE1386, DOI 10.1542/peds.2007-0360
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dulac C, 2014, SCIENCE, V345, P765, DOI 10.1126/science.1253291
   Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607
   Ebstein R. P., 2010, HDB EXP PHARM, V65, P831, DOI [10.1016/j.neuron.2010.02.020, DOI 10.1016/J.NEUR0N.2010.02.020]
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   FLEMING JO, 1983, J NEUROIMMUNOL, V4, P129, DOI 10.1016/0165-5728(83)90017-6
   Frank KA, 2008, EDUC EVAL POLICY AN, V30, P3, DOI 10.3102/0162373707313781
   Good P, 2013, MED HYPOTHESES, V80, P1, DOI 10.1016/j.mehy.2012.08.035
   Good P, 2011, NEUROPSYCHOL REV, V21, P66, DOI 10.1007/s11065-011-9157-y
   Grinevich V, 2015, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00164
   HANSEN EW, 1992, PHARMACOL TOXICOL, V70, P389
   Hashimoto H, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00213
   Higashida H, 2016, J PHYSIOL SCI, V66, P275, DOI 10.1007/s12576-015-0425-0
   Higashida H, 2012, HORM BEHAV, V61, P351, DOI 10.1016/j.yhbeh.2011.12.011
   Higashida H, 2011, BIOL PHARM BULL, V34, P1369
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Kashio M, 2015, J BIOL CHEM, V290, P12435, DOI 10.1074/jbc.M115.649913
   Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869
   Kim UH, 2014, MESSENGER, V3, P6, DOI DOI 10.1166/MSR.2014.1030
   Kirsch P., 2015, DIALOGUES CLIN NEURO, V7, P463, DOI [10.1093/ijnp/pyu012, DOI 10.1093/IJNP/PYU012]
   KLUGER MJ, 1987, PHYSIOL BEHAV, V39, P763, DOI 10.1016/0031-9384(87)90263-0
   LANDGRAF R, 1990, AM J PHYSIOL, V259, pR1056
   Lee HC, 1997, METHOD ENZYMOL, V280, P331
   LEMAY LG, 1990, PHYSIOL BEHAV, V47, P957, DOI 10.1016/0031-9384(90)90024-X
   Leng G, 2015, J ENDOCRINOL, V226, pT173, DOI 10.1530/JOE-15-0087
   LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0
   Liu HX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2336
   Liu H. X., 2012, MESSENGER, V1, P150, DOI DOI 10.1166/MSR.2012.1015
   Liu L., 2008, JOVE-J VIS EXP, V21, P960, DOI [10.3791/960, DOI 10.3791/960]
   Lkhagvasuren B, 2011, EUR J NEUROSCI, V34, P1442, DOI 10.1111/j.1460-9568.2011.07863.x
   LONG NC, 1990, AM J PHYSIOL, V258, pR591
   Lopatina O, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00133
   Lopatina O, 2010, NEUROPHARMACOLOGY, V58, P50, DOI 10.1016/j.neuropharm.2009.06.012
   Megremi ASF, 2013, MED HYPOTHESES, V80, P391, DOI 10.1016/j.mehy.2013.01.007
   Mehler MF, 2009, BRAIN RES REV, V59, P388, DOI 10.1016/j.brainresrev.2008.11.001
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   Morrison SF, 2011, FRONT BIOSCI-LANDMRK, V16, P74, DOI 10.2741/3677
   Munesue T, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00002
   Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004
   NAKAYAMA T, 1985, JPN J PHYSIOL, V35, P375, DOI 10.2170/jjphysiol.35.375
   Naviaux JC, 2015, MOL AUTISM, V6, DOI 10.1186/2040-2392-6-1
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Norton E., 2014, SCIENCE
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   Oka T, 2003, J PHYSIOL-LONDON, V551, P945, DOI 10.1113/jphysiol.2003.048140
   Okamoto H, 2014, MESSENGER, V3, P27, DOI DOI 10.1166/MSR.2014.1032
   Onaka T, 2012, J NEUROENDOCRINOL, V24, P587, DOI 10.1111/j.1365-2826.2012.02300.x
   Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100
   Quirin M, 2011, PSYCHONEUROENDOCRINO, V36, P898, DOI 10.1016/j.psyneuen.2010.12.005
   Rasmussen S, 2011, J AM ASSOC LAB ANIM, V50, P479
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   SINGER R, 1986, PHYSIOL BEHAV, V36, P1179, DOI 10.1016/0031-9384(86)90497-X
   Stabile AM, 2010, PEPTIDES, V31, P706, DOI 10.1016/j.peptides.2009.11.004
   Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048
   TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083
   Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079
   Uchida K, 2011, ENDOCR J, V58, P1021
   Uchida K, 2011, DIABETES, V60, P119, DOI 10.2337/db10-0276
   Vinkers CH, 2008, EUR J PHARMACOL, V585, P407, DOI 10.1016/j.ejphar.2008.02.097
   Wang F, 2014, TRENDS NEUROSCI, V37, P674, DOI 10.1016/j.tins.2014.07.005
   [Anonymous], 2015, BRAIN 11, DOI DOI 10.1093/BRAIN/AWV249
   Yamasue H, 2016, PSYCHIAT CLIN NEUROS, V70, P89, DOI 10.1111/pcn.12364
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162
   Yirmiya R, 2001, NEUROPSYCHOPHARMACOL, V24, P531, DOI 10.1016/S0893-133X(00)00226-8
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Zhao YJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002700
   Zhong J, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0066-x
NR 85
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUL 22
PY 2016
VL 10
AR 304
DI 10.3389/fnins.2016.00304
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA DR6FC
UT WOS:000379996600001
PM 27499729
ER

PT J
AU Livingston, LA
   Livingston, LM
AF Livingston, Lucy A.
   Livingston, Louise M.
TI Commentary: Alexithymia, not autism, is associated with impaired
   interoception
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Editorial Material
DE autism; autism spectrum disorder; interoception; alexithymia; emotional
   symptoms
ID SPECTRUM DISORDER; OXYTOCIN; EMOTION; INSULA; BRAIN
C1 [Livingston, Lucy A.] Univ London, Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England.
   [Livingston, Louise M.] Univ London, Birkbeck Coll, Dept Psychol Sci, London, England.
RP Livingston, LA (reprint author), Univ London, Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England.
EM lucy.livingston@kcl.ac.uk
FU Medical Research Council
FX LAL is funded by the Medical Research Council.
CR Bethlehem RAI, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00048
   Bird G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.61
   Bird G, 2011, J AUTISM DEV DISORD, V41, P1556, DOI 10.1007/s10803-011-1183-3
   Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060
   Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Cook R, 2013, PSYCHOL SCI, V24, P723, DOI 10.1177/0956797612463582
   Craig AD, 2014, DO YOU FEEL INTEROCE
   Garfinkel SN, 2013, SOC COGN AFFECT NEUR, V8, P231, DOI 10.1093/scan/nss140
   Griffin C, 2016, AUTISM RES, V9, P773, DOI 10.1002/aur.1569
   Happe F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770
   Herbert BM, 2011, J PERS, V79, P1149, DOI 10.1111/j.1467-6494.2011.00717.x
   Hill E, 2004, J AUTISM DEV DISORD, V34, P229, DOI 10.1023/B:JADD.0000022613.41399.14
   Milosavljevic B, 2016, J AUTISM DEV DISORD, V46, P1354, DOI 10.1007/s10803-015-2670-8
   Nemiah J. C., 1976, MODERN TRENDS PSYCHO, V3, P430
   Quattrocki E, 2014, NEUROSCI BIOBEHAV R, V47, P410, DOI 10.1016/j.neubiorev.2014.09.012
   Quirin M, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01074
   Samur D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00861
   Seth AK, 2013, TRENDS COGN SCI, V17, P565, DOI 10.1016/j.tics.2013.09.007
   Shah P, 2016, CORTEX, V81, P215, DOI 10.1016/j.cortex.2016.03.021
   Zaki J, 2012, NEUROIMAGE, V62, P493, DOI 10.1016/j.neuroimage.2012.05.012
NR 20
TC 1
Z9 1
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD JUL 22
PY 2016
VL 7
AR 1103
DI 10.3389/fpsyci.2016.01103
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA DR6ME
UT WOS:000380015200001
PM 27501009
ER

PT J
AU Yuan, GY
   Qian, WY
   Pan, RR
   Jia, J
   Jiang, D
   Yang, QC
   Wang, S
   Liu, YX
   Yu, SQ
   Hu, H
   Sun, WJ
   Ye, JJ
   Mao, CM
   Zhuang, R
   Zhou, LB
AF Yuan, Guoyue
   Qian, Weiyun
   Pan, Ruirong
   Jia, Jue
   Jiang, Dan
   Yang, Qichao
   Wang, Su
   Liu, Yuanxin
   Yu, Shuqin
   Hu, Hao
   Sun, Wenjun
   Ye, Jingjing
   Mao, Chaoming
   Zhuang, Ruo
   Zhou, Libin
TI Reduced circulating oxytocin and High-Molecular-Weight adiponectin are
   risk factors for metabolic syndrome
SO ENDOCRINE JOURNAL
LA English
DT Article
DE Oxytocin; High-molecular-weight adiponectin; Metabolic syndrome
ID TYPE-2 DIABETIC-PATIENTS; ADIPOSE-TISSUE; FOOD-INTAKE;
   INSULIN-RESISTANCE; DEFICIENT MICE; OBESITY; SECRETION; RATS; FORM; MEN
AB The neurohypophysial hormone, oxytocin, is involved in the regulation of energy metabolism. Adiponectin (APN) is an adipose tissue-specific serum protein that inversely associates with metabolic syndrome (MetS). High molecular-weight adiponectin (HMW APN) is considered the active form. In the present study, we aimed to determine the relationships of oxytocin and HMW APN to MetS and investigate whether or not the combination of oxytocin and BMW APN is associated with further metabolic abnormalities compared to each of them alone. A total of 170 subjects (75 with MetS and 95 non-MetS) were enrolled. Anthropometric parameters, oral glucose tolerance test (OGTT), blood lipids, hs-CRP, oxytocin and HMW APN levels were measured. Compared with non-MetS subjects, serum oxytocin and HMW APN levels were significantly lower in subjects with MetS (P<0.01). We then classified the subjects into three groups: high oxytocin and high BMW APN levels (high score group), low oxytocin and low HMW APN levels (low score group) and others. Participants in low score group showed the worst metabolic profiles and were more likely to have MetS compared to the other two group. In Spearman rank correlation coefficient, the classification by the combination of oxytocin and HMW APN was significantly correlated with a larger number of metabolic risk factors compared with classification by each of them alone. Individuals with low circulating oxytocin levels coupled with low HMW APN levels were at significantly increased risk of MetS. The combination of both markers would be useful for identifying MetS high risk patients.
C1 [Yuan, Guoyue; Pan, Ruirong; Jia, Jue; Jiang, Dan; Yang, Qichao; Wang, Su; Liu, Yuanxin; Yu, Shuqin; Hu, Hao; Sun, Wenjun; Ye, Jingjing; Mao, Chaoming; Zhuang, Ruo] Jiangsu Univ, Dept Endocrinol, Affiliated Hosp, 438 Jiefang Rd, Zhenjiang 212001, Jiangsu, Peoples R China.
   [Qian, Weiyun] Soochow Univ, Dept Geriatr, Affiliated Hosp 3, Changzhou 213003, Jiangsu, Peoples R China.
   [Zhou, Libin] Shanghai Jiao Tong Univ, Shanghai Inst Endocrine & Metab Dis, Ruijin Hosp, Sch Med,Ctr Mol Med,State Key Lab Med Genom, 197,Ruijin Rd 2, Shanghai 200025, Peoples R China.
RP Yuan, GY (reprint author), Jiangsu Univ, Dept Endocrinol, Affiliated Hosp, 438 Jiefang Rd, Zhenjiang 212001, Jiangsu, Peoples R China.; Zhou, LB (reprint author), Shanghai Jiao Tong Univ, Shanghai Inst Endocrine & Metab Dis, Ruijin Hosp, Sch Med,Ctr Mol Med,State Key Lab Med Genom, 197,Ruijin Rd 2, Shanghai 200025, Peoples R China.
EM yuanguoyue@hotmail.com; libin_zhou@yahoo.com
FU National Natural Science Foundation of China [81570721, 81370965,
   81370889]; Natural Science Foundation of Jiangsu Province, China
   [BK20151331, BK2009208]; Medical Science and Technology Development
   Foundation; International Exchange Program of Jiangsu Province
   Department of Health [H201247]; Science and Technology Commission of
   Zhenjiang City, Jiangsu Province [SH2015028, SH2013035, SH2012027,
   SHW2015017]; Six talent peaks project in Jiangsu Province [2015-WSN-006]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (81570721, 81370965, 81370889), the Natural
   Science Foundation of Jiangsu Province, China (BK20151331, BK2009208),
   the Medical Science and Technology Development Foundation and
   International Exchange Program of the Jiangsu Province Department of
   Health (H201247), the Science and Technology Commission of Zhenjiang
   City, Jiangsu Province (SH2015028, SH2013035, SH2012027, SHW2015017),
   and Six talent peaks project in Jiangsu Province (2015-WSN-006).
CR Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   Aso Y, 2006, DIABETES, V55, P1954, DOI 10.2337/db05-1525
   Blevins JE, 2015, AM J PHYSIOL-REG I, V308, pR431, DOI 10.1152/ajpregu.00441.2014
   Bobbert T, 2005, DIABETES, V54, P2712, DOI 10.2337/diabetes.54.9.2712
   Cai Dongsheng, 2013, Drug Discov Today Dis Mech, V10, pe63
   Camerino C, 2009, OBESITY, V17, P980, DOI 10.1038/oby.2009.12
   Chaves VE, 2013, PEPTIDES, V45, P9, DOI 10.1016/j.peptides.2013.04.010
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   Devaraj S, 2008, ARTERIOSCL THROM VAS, V28, P1368, DOI 10.1161/ATVBAHA.108.163303
   Eckertova M, 2001, BRIT J PHARMACOL, V162, P452
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Hara K, 2006, DIABETES CARE, V29, P1357, DOI 10.2337/dc05-1801
   Kaneko H, 2011, CARDIOVASC RES, V91, P546, DOI 10.1093/cvr/cvr088
   Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709
   Liu ML, 2014, BEST PRACT RES CL EN, V28, P25, DOI 10.1016/j.beem.2013.06.003
   Liu ML, 2010, BIOCHEM J, V425, P41, DOI 10.1042/BJ20091045
   Maejima Y, 2011, AGING-US, V3, P1169
   McGown C, 2014, CLIN LIVER DIS, V18, P41, DOI 10.1016/j.cld.2013.09.012
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Oki K, 2007, ENDOCR J, V54, P431, DOI 10.1507/endocrj.K06-172
   Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200
   Petersson M, 1997, J AUTONOM NERV SYST, V66, P15, DOI 10.1016/S0165-1838(97)00040-4
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   Ryo M, 2004, CIRC J, V68, P975, DOI 10.1253/circj.68.975
   Seino Y, 2007, METABOLISM, V56, P1493, DOI 10.1016/j.metabol.2007.06.015
   Szeto A, 2013, PSYCHONEUROENDOCRINO, V38, P685, DOI 10.1016/j.psyneuen.2012.08.009
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Yuan GY, 2007, J ENDOCRINOL, V194, P275, DOI 10.1677/JOE-07-0133
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
NR 29
TC 1
Z9 1
U1 0
U2 0
PU JAPAN ENDOCRINE SOC
PI KYOTO
PA 75  YANAGINOBANBA NISHIIRU-MASUYA-CHO, SANJOU-DORI, NAKAGYOU-KU, KYOTO,
   604-8111, JAPAN
SN 0918-8959
EI 1348-4540
J9 ENDOCR J
JI Endocr. J.
PD JUL 20
PY 2016
VL 63
IS 7
BP 655
EP 662
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DV3CC
UT WOS:000382797600008
PM 27237400
ER

PT J
AU McQuaid, RJ
   McInnis, OA
   Matheson, K
   Anisman, H
AF McQuaid, Robyn J.
   McInnis, Opal A.
   Matheson, Kimberly
   Anisman, Hymie
TI Oxytocin and Social Sensitivity: Gene Polymorphisms in Relation to
   Depressive Symptoms and Suicidal Ideation
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE depression; suicidal ideation; oxytocin; polymorphism; social
   connectedness; trauma
ID INTRANASAL OXYTOCIN; RECEPTOR GENE; MAJOR DEPRESSION; PERIPHERAL
   OXYTOCIN; STRESS REACTIVITY; PLASMA OXYTOCIN; LIFE EVENTS; LOW-INCOME;
   HUMANS; BEHAVIOR
AB Although the neuropeptide oxytocin has been associated with enhanced prosocial behaviors, it has also been linked to aggression and mental health disorders. Thus, it was suggested that oxytocin might act by increasing the salience of social stimuli, irrespective of whether these are positive or negative, thus increasing vulnerability to negative mental health outcomes. The current study (N = 243), conducted among white university students, examined the relation of trauma, depressive symptoms including suicidal ideation in relation to a single nucleotide polymorphism (SNP) within the oxytocin receptor gene (OXTR), rs53576, and a SNP on the CD38 gene that controls oxytocin release, rs3796863. Individuals with the polymorphism on both alleles (AA genotype) of the CD38 SNP had previously been linked to elevated plasma oxytocin levels. Consistent with the social sensitivity perspective, however, in the current study, individuals carrying the AA genotype displayed elevated feelings of alienation from parents and peers as well as increased levels of suicidal ideation. Moreover, they tended to report elevated depressive symptoms compared to CC homozygotes. It was also observed that the CD38 genotype moderated the relation between trauma and suicidal ideation scores, such that high levels of trauma were associated with elevated suicidal ideation among all CD38 genotypes, but this relationship was stronger among individuals with the AA genotype. In contrast, there was no relationship between the OXTR SNP, rs53576, depression or suicidal ideation. These findings support a social sensitivity hypothesis of oxytocin, wherein the AA genotype of the CD38 SNP, which has been considered the "protective allele" was associated with increased sensitivity and susceptibility to disturbed social relations and suicidal ideation.
C1 [McQuaid, Robyn J.; McInnis, Opal A.; Matheson, Kimberly; Anisman, Hymie] Carleton Univ, Dept Neurosci, Ottawa, ON, Canada.
RP McQuaid, RJ (reprint author), Carleton Univ, Dept Neurosci, Ottawa, ON, Canada.
EM robyn_mcquaid@carleton.ca
FU Canadian Institutes of Health Research (CIHR); Natural Sciences and
   Engineering Research Council of Canada (NSERC)
FX This research was supported by the Canadian Institutes of Health
   Research (CIHR) and the Natural Sciences and Engineering Research
   Council of Canada (NSERC). The funding sources had no further role in
   the study or in the writing of this article.
CR Anisman H., 2012, NEUROBIOLOGICAL BASI
   ARMSDEN GC, 1987, J YOUTH ADOLESCENCE, V16, P427, DOI 10.1007/BF02202939
   Averbeck BB, 2010, P NATL ACAD SCI USA, V107, P9033, DOI 10.1073/pnas.1004892107
   Bartz Jennifer, 2011, Soc Cogn Affect Neurosci, V6, P556, DOI 10.1093/scan/nsq085
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   Belsky J, 2009, PSYCHOL BULL, V135, P885, DOI 10.1037/a0017376
   Boyce WT, 2005, DEV PSYCHOPATHOL, V17, P271, DOI 10.1017/S0954579405050145
   Bradley B, 2011, DEV PSYCHOPATHOL, V23, P439, DOI 10.1017/S0954579411000162
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Caspi A, 2010, AM J PSYCHIAT, V167, P509, DOI 10.1176/appi.ajp.2010.09101452
   COMPAS BE, 1986, AM J COMMUN PSYCHOL, V14, P241, DOI 10.1007/BF00911173
   Compton MT, 2005, SOC PSYCH PSYCH EPID, V40, P175, DOI 10.1007/s00127-005-0865-6
   Cruwys T, 2013, SOC SCI MED, V98, P179, DOI 10.1016/j.socscimed.2013.09.013
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   DeWall CN, 2014, SOC PSYCHOL PERS SCI, V5, P691, DOI 10.1177/1948550613516876
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089
   Dwivedi Y, 2012, NEUROBIOLOGICAL BASI
   Evans SJ, 2004, P NATL ACAD SCI USA, V101, P15506, DOI 10.1076/pnas.0406788101
   Feifel D, 2012, SCHIZOPHR RES, V139, P207, DOI 10.1016/j.schres.2012.05.018
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465
   Heim C, 2008, MOL PSYCHIATR, V14, P954, DOI DOI 10.1038/MP.2008.112
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Jia R, 2008, PHYSIOL BEHAV, V95, P56, DOI 10.1016/j.physbeh.2008.04.015
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   Kent P, 2016, PSYCHONEUROENDOCRINO, V64, P123, DOI 10.1016/j.psyneuen.2015.11.019
   Kidder K., 2000, HLTH CANADAS CHILDRE, P199
   Kim JM, 2015, INT J PSYCHIAT MED, V49, P75, DOI [10.1177/0091217415574439, 10.2190/PM.49.1.f]
   Kim JM, 2014, AM J GERIAT PSYCHIAT, V22, P980, DOI 10.1016/j.jagp.2013.06.001
   Kiss I, 2011, BIOL PSYCHOL, V88, P223, DOI 10.1016/j.biopsycho.2011.08.005
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krueger F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00004
   Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Lerer E, 2010, AUTISM RES, V3, P293, DOI 10.1002/aur.156
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Mann JJ, 2003, NAT REV NEUROSCI, V4, P819, DOI 10.1038/nrn1220
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McInnis OA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01133
   McQuaid RJ, 2015, SOC COGN AFFECT NEUR, V10, P1153, DOI 10.1093/scan/nsu166
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   McQuaid RJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00128
   Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0
   Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004
   Preacher KJ, 2006, J EDUC BEHAV STAT, V31, P437, DOI 10.3102/10769986031004437
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Riem MME, 2013, PSYCHONEUROENDOCRINO, V38, P1418, DOI 10.1016/j.psyneuen.2012.12.023
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Saphire-Bernstein S, 2011, P NATL ACAD SCI USA, V108, P15118, DOI 10.1073/pnas.1113137108
   Sauer C, 2012, NEUROPSYCHOPHARMACOL, V37, P1474, DOI 10.1038/npp.2011.333
   Scantamburlo G, 2007, PSYCHONEUROENDOCRINO, V32, P407, DOI 10.1016/j.psyneuen.2007.01.009
   Scantamburlo G, 2011, J NEUROPSYCH CLIN N, V23, pE5, DOI 10.1176/appi.neuropsych.23.2.E5
   Seedat Soraya, 2005, Violence Vict, V20, P87, DOI 10.1891/vivi.2005.20.1.87
   Shalvi S, 2014, P NATL ACAD SCI USA, V111, P5503, DOI 10.1073/pnas.1400724111
   Shamay-Tsoory SG, 2013, PSYCHONEUROENDOCRINO, V38, P3139, DOI 10.1016/j.psyneuen.2013.09.015
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Smith KE, 2014, SOC NEUROSCI-UK, V9, P1, DOI 10.1080/17470919.2013.863223
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tabak Benjamin A, 2016, Clin Psychol Sci, V4, P17
   Wang S, 2009, PSYCHIAT RES, V170, P204, DOI 10.1016/j.psychres.2008.12.006
   Winfree LT, 2010, YOUTH VIOLENCE JUV J, V8, P19, DOI 10.1177/1541204009338252
   Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128
NR 69
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUL 19
PY 2016
VL 10
AR 358
DI 10.3389/fnhum.2016.00358
PG 9
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA DR4PA
UT WOS:000379882400001
PM 27486392
ER

PT J
AU Rashid, S
   Overton, S
   Mazigh, B
   Mayer, PM
AF Rashid, Shaan
   Overton, Sean
   Mazigh, Bihac
   Mayer, Paul M.
TI Dual-spray hydrogen/deuterium exchange (HDX) reactions: A new method of
   probing protein structure
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID IONIZATION MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; CYTOCHROME-C;
   CONFORMATIONAL-CHANGES; MOBILE PHASES; UBIQUITIN; RESOLUTION;
   DISSOCIATION; SENSITIVITY; DYNAMICS
AB RATIONALE: Traditionally, hydrogen/deuterium exchange (HDX) reactions are done in the solution phase. This usually involves incubating the protein with a suitable deuterating agent then acidifying the solution to quench the reaction. A more efficient method may be to conduct the reaction within the ion source of a mass spectrometer and subsequently analyze the products.
   METHODS: Using the two electrospray emitters equipped on the Waters Synapt G1 mass spectrometer, HDX reactions were conducted within the ion source region in a controlled fashion ('dual-spray'). Peptide and protein solutions were electrosprayed through one emitter and the deuterating agent D2O through the secondary electrospray emitter. For the relatively small peptides, Phe-Leu-Glu-Glu-Leu and oxytocin, the yield of products was calculated using deconvolution functions. Electrospray ionization (ESI) charge-state distributions and average number of deuterium exchanges were used to probe secondary and tertiary structures of ubiquitin, lysozyme, and cytochrome c in their native and unfolded states.
   RESULTS: Clear shifts in isotope distributions indicated HDX occurring within the ion source. By ion mobility, simultaneous deuterium exchange for two isobaric species, the oxytocin monomer and dimer, was observed. For denatured ubiquitin, the 12+ and 13+ charge states have a lower average number of exchanges relative to the lower charge states which indicates that these charge states have segments which restrict the access of D2O. Lysozyme has a linear relationship between the charge state and the average number of exchanges, indicating that lysozyme becomes increasingly unfolded as the charge state increases. The dual-spray HDX method was paired to high-performance liquid chromatography (HPLC) to demonstrate the applicability of the technique for probing gas-phase structures in protein mixtures.
   CONCLUSIONS: ESI droplets formed from a secondary emitter penetrate primary ESI droplets and change the solvent composition. Dual-spray HDX is demonstrated to be a more efficient method for probing the structure of proteins than solution-phase HDX since the acid quenching step can be surpassed. Copyright (C) 2016 John Wiley & Sons, Ltd.
C1 [Rashid, Shaan; Overton, Sean; Mazigh, Bihac; Mayer, Paul M.] Univ Ottawa, Dept Chem, 10 Marie Curie, Ottawa, ON K1N 6N5, Canada.
RP Mayer, PM (reprint author), Univ Ottawa, Dept Chem, 10 Marie Curie, Ottawa, ON K1N 6N5, Canada.
EM pmmayer@uottawa.ca
CR APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M
   BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0
   Brutscher B, 1997, BIOCHEMISTRY-US, V36, P13043, DOI 10.1021/bi971538t
   BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6
   Chen HW, 2006, CHEM COMMUN, P2042, DOI 10.1039/b602614a
   Chen H., 2007, ANGEW CHEM, V119, P586, DOI 10.1002/ange.200602942
   Cotham VC, 2015, ANAL CHEM, V87, P9396, DOI 10.1021/acs.analchem.5b02242
   Harrison AG, 2006, J AM CHEM SOC, V128, P10364, DOI 10.1021/ja062440h
   KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415
   Konermann L, 1998, J AM SOC MASS SPECTR, V9, P1248, DOI 10.1016/S1044-0305(98)00103-2
   Konermann L, 2003, MASS SPECTROM REV, V22, P1, DOI 10.1002/mas.10044
   Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u
   Konermann L, 2011, CHEM SOC REV, V40, P1224, DOI 10.1039/c0cs00113a
   Kostyukevich Y, 2014, J MASS SPECTROM, V49, P989, DOI 10.1002/jms.3409
   Marcsisin SR, 2010, ANAL BIOANAL CHEM, V397, P967, DOI 10.1007/s00216-010-3556-4
   Rand KD, 2009, ANAL CHEM, V81, P10019, DOI 10.1021/ac901897x
   Shen J, 1999, J MASS SPECTROM, V34, P137, DOI 10.1002/(SICI)1096-9888(199902)34:2<137::AID-JMS776>3.3.CO;2-S
   Shi HL, 2012, J PHYS CHEM B, V116, P3344, DOI 10.1021/jp210797x
   Shou WZ, 2005, J CHROMATOGR B, V825, P186, DOI 10.1016/j.jchromb.2005.01.011
   Valentine SJ, 1997, J PHYS CHEM B, V101, P3891, DOI 10.1021/jp970217o
   VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6
   Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064
   Williams DK, 2007, ANAL CHEM, V79, P7916, DOI 10.1021/ac071444h
   WOOD TD, 1995, P NATL ACAD SCI USA, V92, P2451, DOI 10.1073/pnas.92.7.2451
   Xia Y, 2005, J AM SOC MASS SPECTR, V16, P1750, DOI 10.1016/j.jasms.2005.07.013
   ZHANG Y, 1990, J BIOL CHEM, V265, P16330
NR 26
TC 0
Z9 0
U1 11
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-4198
EI 1097-0231
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD JUL 15
PY 2016
VL 30
IS 13
BP 1505
EP 1512
DI 10.1002/rcm.7591
PG 8
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA DR5XA
UT WOS:000379974500008
PM 27321838
ER

PT J
AU Friston, K
AF Friston, Karl
TI The Bayesian Savant
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID AUTISM SPECTRUM DISORDERS; INTEROCEPTION; OXYTOCIN; ACCOUNT
C1 [Friston, Karl] UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England.
RP Friston, K (reprint author), UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England.
EM k.friston@ucl.ac.uk
CR Brewer R, 2015, NEUROSCI BIOBEHAV R, V56, P348, DOI 10.1016/j.neubiorev.2015.07.006
   Davis G, 2015, AUTISM, V19, P351, DOI 10.1177/1362361314552198
   Happe F, 2006, J AUTISM DEV DISORD, V36, P5, DOI 10.1007/s10803-005-0039-0
   Lawson RP, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00302
   Palmer CJ, 2015, CONSCIOUS COGN, V36, P376, DOI 10.1016/j.concog.2015.04.007
   Pellicano E, 2012, TRENDS COGN SCI, V16, P504, DOI 10.1016/j.tics.2012.08.009
   Quattrocki E, 2014, NEUROSCI BIOBEHAV R, V47, P410, DOI 10.1016/j.neubiorev.2014.09.012
   Sevgi M, 2016, BIOL PSYCHIAT, V80, P112, DOI 10.1016/j.biopsych.2015.11.025
   Thomas MSC, 2016, DEVELOPMENTAL SCI, V19, P284, DOI 10.1111/desc.12303
   Van de Cruys S, 2014, PSYCHOL REV, V121, P649
NR 10
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JUL 15
PY 2016
VL 80
IS 2
BP 87
EP 89
DI 10.1016/j.biopsych.2016.05.006
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DP5IT
UT WOS:000378530200003
PM 27346080
ER

PT J
AU King, LB
   Walum, H
   Inoue, K
   Eyrich, NW
   Young, LJ
AF King, Lanikea B.
   Walum, Hasse
   Inoue, Kiyoshi
   Eyrich, Nicholas W.
   Young, Larry J.
TI Variation in the Oxytocin Receptor Gene Predicts Brain Region-Specific
   Expression and Social Attachment
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Allelic imbalance; Autism; Individual differences; Prairie vole; Social
   behavior; Striatum
ID FEMALE PRAIRIE VOLES; PARTNER PREFERENCE FORMATION; AUTISM SPECTRUM
   DISORDER; NUCLEUS-ACCUMBENS; TRANSCRIPTIONAL REGULATION; OXTR
   POLYMORPHISM; MESSENGER-RNA; MENTAL-HEALTH; BEHAVIOR; MECHANISMS
AB BACKGROUND: Oxytocin (OXT) modulates several aspects of social behavior. Intranasal OXT is a leading candidate for treating social deficits in patients with autism spectrum disorder, and common genetic variants in the human OXTR gene are associated with emotion recognition, relationship quality, and autism spectrum disorder. Animal models have revealed that individual differences in Oxtr expression in the brain drive social behavior variation. Our understanding of how genetic variation contributes to brain OXTR expression is very limited.
   METHODS: We investigated Oxtr expression in monogamous prairie voles, which have a well-characterized OXT system. We quantified brain region-specific levels of Oxtr messenger RNA and oxytocin receptor protein with established neuroanatomic methods. We used pyrosequencing to investigate allelic imbalance of Oxtr mRNA, a molecular signature of polymorphic genetic regulatory elements. We performed next-generation sequencing to discover variants in and near the Oxtr gene. We investigated social attachment using the partner preference test.
   RESULTS: Our allelic imbalance data demonstrate that genetic variants contribute to individual differences in Oxtr expression, but only in particular brain regions, including the nucleus accumbens, where oxytocin receptor signaling facilitates social attachment. Next-generation sequencing identified one polymorphism in the Oxtr intron, near a putative cis-regulatory element, explaining 74% of the variance in striatal Oxtr expression specifically. Males homozygous for the high expressing allele display enhanced social attachment.
   CONCLUSIONS: Taken together, these findings provide convincing evidence for robust genetic influence on Oxtr expression and provide novel insights into how noncoding polymorphisms in OXTR might influence individual differences in human social cognition and behavior.
C1 [King, Lanikea B.; Walum, Hasse; Inoue, Kiyoshi; Eyrich, Nicholas W.; Young, Larry J.] Emory Univ, Yerkes Natl Primate Res Ctr, Dept Psychiat & Behav Sci, Silvio O Conte Ctr Oxytocin & Social Cognit,Ctr T, Atlanta, GA 30329 USA.
RP Young, LJ (reprint author), Emory Univ, Yerkes Natl Primate Res Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.
EM lyoun03@emory.edu
FU National Institutes of Health [R01MH096983, 1P50MH100023, 5T32GM008605,
   5T32DA015040]; Swedish Brain Foundation; National Institutes of Health
   Office of Research Infrastructure Programs [OD P51OD11132]
FX This work was supported by the National Institutes of Health Grant Nos.
   R01MH096983 (to LJY), 1P50MH100023 (to LJY), 5T32GM008605 (to LBK), and
   5T32DA015040 (to LBK) and the Swedish Brain Foundation (to HW).
   Additional funding was provided by the National Institutes of Health
   Office of Research Infrastructure Programs/OD P51OD11132 to the Yerkes
   National Primate Research Center.
CR Abi-Dargham Anissa, 2014, J Clin Psychiatry, V75, pe31, DOI 10.4088/JCP.13078tx2c
   Ahern TH, 2009, J NEUROSCI METH, V182, P180, DOI 10.1016/j.jneumeth.2009.06.010
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   BALE TL, 1995, ENDOCRINOLOGY, V136, P5135, DOI 10.1210/en.136.11.5135
   Barrett CE, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.73
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Beery AK, 2016, HORM BEHAV, V77, P42, DOI 10.1016/j.yhbeh.2015.05.022
   Bendesky A, 2011, NAT REV GENET, V12, P809, DOI 10.1038/nrg3065
   Chen FS, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.163
   Cretekos CJ, 2008, GENE DEV, V22, P141, DOI 10.1101/gad.1620408
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Dekker J, 2013, NAT REV GENET, V14, P390, DOI 10.1038/nrg3454
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Donaldson ZR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003729
   Feng C, 2015, GENES BRAIN BEHAV, V14, P516, DOI 10.1111/gbb.12234
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gaur U, 2013, J APPL GENET, V54, P271, DOI 10.1007/s13353-013-0148-y
   Goodson JL, 2012, HORM BEHAV, V61, P239, DOI 10.1016/j.yhbeh.2012.01.005
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   Harony-Nicolas H, 2014, PSYCHONEUROENDOCRINO, V39, P121, DOI 10.1016/j.psyneuen.2013.10.004
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Inoue K, 2004, EUR J NEUROSCI, V20, P2909, DOI 10.1111/j.1460-9568.2004.03763.x
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   INSEL TR, 1993, J NEUROENDOCRINOL, V5, P619, DOI 10.1111/j.1365-2826.1993.tb00531.x
   Johnson AD, 2005, PHARMACOL THERAPEUT, V106, P19, DOI 10.1016/j.pharmthera.2004.11.001
   Johnson ZV, 2016, HORM BEHAV, V79, P8, DOI 10.1016/j.yhbeh.2015.11.011
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Keebaugh AC, 2015, SOC NEUROSCI-UK, V10, P561, DOI 10.1080/17470919.2015.1040893
   Keebaugh AC, 2011, HORM BEHAV, V60, P498, DOI 10.1016/j.yhbeh.2011.07.018
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Linnen CR, 2013, SCIENCE, V339, P1312, DOI 10.1126/science.1233213
   Liu Xiaoxi, 2015, Hum Genome Var, V2, P15024, DOI 10.1038/hgv.2015.24
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   Loth E, 2014, BIOL PSYCHIAT, V76, P367, DOI 10.1016/j.biopsych.2013.07.043
   Lucas-Thompson RG, 2013, HORM BEHAV, V63, P615, DOI 10.1016/j.yhbeh.2013.02.015
   Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   McGraw LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029345
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0
   Modi ME, 2015, NEUROPSYCHOPHARMACOL, V40, P1856, DOI 10.1038/npp.2015.35
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   Montag C, 2013, EUR ARCH PSY CLIN N, V263, pS169, DOI 10.1007/s00406-013-0452-x
   Mouse ENCODE Consortium, 2012, GENOME BIOL, V13, P418, DOI DOI 10.1186/GB-2012-13-8-418
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   O'Connell LA, 2011, J COMP NEUROL, V519, P3599, DOI 10.1002/cne.22735
   Odom DT, 2007, NAT GENET, V39, P730, DOI 10.1038/ng2047
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Oleksiak MF, 2002, NAT GENET, V32, P261, DOI 10.1038/ng983
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Paredes UM, 2013, GENES BRAIN BEHAV, V12, P282, DOI 10.1111/j.1601-183X.2012.00857.x
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Reiner I, 2015, J PSYCHIATR RES, V65, P9, DOI 10.1016/j.jpsychires.2015.03.012
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Smearman EL, 2015, DEV PSYCHOPATHOL, V27, P309, DOI 10.1017/S0954579414000649
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Tost H, 2011, BIOL PSYCHIAT, V70, pE37, DOI [10.1016/j.biopsych.2011.06.034, 10.1016/j.biopsych.2011.07.021]
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007
   Visser M, 2015, HUM MOL GENET, V24, P2649, DOI 10.1093/hmg/ddv029
   Walum H, 2016, BIOL PSYCHIAT, V79, P251, DOI 10.1016/j.biopsych.2015.06.016
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Wilkins JM, 2007, HUM MOL GENET, V16, P537, DOI 10.1093/hmg/ddl488
   Wittkopp PJ, 2012, NAT REV GENET, V13, P59, DOI 10.1038/nrg3095
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 2015, NEUROPSYCHOPHARMACOL, V40, P243, DOI 10.1038/npp.2014.186
   Young LJ, 1996, J NEUROENDOCRINOL, V8, P777, DOI 10.1046/j.1365-2826.1996.05188.x
   Young LJ, 1997, ANN NY ACAD SCI, V807, P514, DOI 10.1111/j.1749-6632.1997.tb51955.x
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
   Zhang K, 2009, NAT METHODS, V6, P613, DOI 10.1038/nmeth.1357
NR 84
TC 4
Z9 4
U1 13
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JUL 15
PY 2016
VL 80
IS 2
BP 160
EP 169
DI 10.1016/j.biopsych.2015.12.008
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DP5IT
UT WOS:000378530200013
PM 26893121
ER

PT J
AU Israel, S
AF Israel, Salomon
TI Toward a Mechanistic Understanding of How Variation in the Oxytocin
   Receptor Gene Shapes Individual Differences in Brain and Social Behavior
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
C1 [Israel, Salomon] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.
RP Israel, S (reprint author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.
EM salomon.israel@mail.huji.ac.il
CR Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   King LB, 2016, BIOL PSYCHIAT, V80, P160, DOI 10.1016/j.biopsych.2015.12.008
   Kumsta R, 2013, FRONT NEUROSCI, V7, P1
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Ma W-J, 2013, MOL AUTISM, V4, P1
   Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Puglia MH, 2015, P NATL ACAD SCI USA, V112, P3308, DOI 10.1073/pnas.1422096112
NR 10
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JUL 15
PY 2016
VL 80
IS 2
BP E7
EP E9
DI 10.1016/j.biopsych.2016.05.008
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DP5IT
UT WOS:000378530200001
PM 27346083
ER

PT J
AU de Amorim, MD
   Nielsen, K
   Cruz, RKS
   Card, C
AF de Amorim, Mariana Diel
   Nielsen, Kayla
   Salgueiro Cruz, Raissa Karolliny
   Card, Claire
TI Progesterone levels and days to luteolysis in mares treated with
   intrauterine fractionated coconut oil
SO THERIOGENOLOGY
LA English
DT Article
DE Coconut oil; Days to luteolysis; Mare; Progesterone
ID LUTEAL FUNCTION; OXYTOCIN; DIESTRUS; SUPPRESSION; EXPRESSION; ESTRUS
AB Intrauterine plant oil infusion, including fractionated coconut oil, has been previously found to be a safe, inexpensive, and reversible method of prolonging the luteal phase in mares when administered on Day 10 of the estrous cycle. Our objective was to understand the uteroovarian response to the administration of fractionated coconut oil infusion in the uterus of diestrous mares. We hypothesized that intrauterine coconut oil administration on Day 10 would prolong luteal life span in a dose-dependent fashion and would result in higher serum progesterone levels than untreated mares at the expected time of luteolysis. Light-horse mares (n = 18) were examined using transrectal palpation and ultrasonography to determine if they had a normal interovulatory interval and were then examined daily in estrus until the day of ovulation (Day 0) and then every other day during an estrous cycle. Jugular blood was drawn on Day 11, Day 13, Day 15, and Day 17, centrifuged, and serum stored until assayed for progesterone (P4; Siemens Coat-a-Count Progesterone RIA, Los Angeles, CA, USA). Mares were randomly assigned to treatment and studied over one to two estrous cycles with a rest cycle after each treatment cycle. Groups were: control (n = 5), fractionated coconut oil 1.0 mL (Miglyol 810; Sasol Oil, Witten, Germany) infused in the uterus with an artificial insemination pipette on Day 10 (Group 1; n = 5) and fractionated coconut oil 0.5 mL infused in the uterus with an embryo transfer gun, on Day 10 (Group 2; n = 5). All statistical analyses were performed using analytical software (Stata SE, version 13.1, College Station, TX, USA) at P < 0.05. Data were first evaluated using the Shapiro-Wilk test for normality. Differences between groups in days to luteolysis (DTL) were examined using analysis of variance and Bonferroni, and the effect of day and treatment on P4 levels were examined using the Kruskal-Wallis and Dunn's all pairwise test. There was a significant difference in DTL between the groups (P = 0.0083), with fewer DTL in Group 1 compared to control (P = 0.011) and to Group 2 (P = 0.034). There was a significant effect of day (P < 0.0001) on P4 levels with Day 11 P4 levels higher than Day 15 and Day 17 and Day 13 P4 levels higher than Day 15 or Day 17 (P < 0.03). There was a significant effect of treatment group (P = 0.0098) on P4 levels with control and Group 2 levels higher than Group 1 mares (P= 0.0012, P = 0.0495, respectively). We concluded that intrauterine administration of 1 mL of fractionated coconut oil lowered P4 levels in diestrus in a dose-dependent fashion and did not prolonged the luteal phase of the mares. (c) 2016 Elsevier Inc. All rights reserved.
C1 [de Amorim, Mariana Diel; Nielsen, Kayla; Card, Claire] Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, Saskatoon, SK S7N 0W0, Canada.
   [Salgueiro Cruz, Raissa Karolliny] Sao Paulo State Univ UNESP, Sch Vet Med & Anim Sci, Dept Vet Sci, Botucatu, SP, Brazil.
   [de Amorim, Mariana Diel] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Hlth Management, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.
RP de Amorim, MD (reprint author), Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, Saskatoon, SK S7N 0W0, Canada.; de Amorim, MD (reprint author), Univ Prince Edward Isl, Atlantic Vet Coll, Dept Hlth Management, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.
EM mariana.dieldeamorim@usask.ca
FU Equine Health Research Fund at the University of Saskatchewan, Western
   College of Veterinary Medicine [414568]
FX Funding for this paper was from the Equine Health Research Fund (grant
   number: 414568) at the University of Saskatchewan, Western College of
   Veterinary Medicine. We would like to thank to Susan Cook for performing
   the progesterone analysis.
CR Argo CM, 2010, VET J, V186, P39, DOI 10.1016/j.tvjl.2009.07.013
   Rivera de Alamo MM, 2010, ANIM REPROD SCI, V121S, ps227
   Diel de Amorim MA, 2014, P ANN CONV AM ASS EQ, V60, P317
   Diet de Amorim M, 2016, THERIOGENOLOGY, P1030
   Freeman CE, 2015, EQUINE VET EDUC, V27, P469, DOI 10.1111/eve.12408
   Gee EK, 2012, NEW ZEAL VET J, V60, P189, DOI 10.1080/00480169.2011.651095
   Ginther O. J., 1990, Equine Veterinary Journal, V22, P194
   Hedberg Y, 2006, ACTA VET SCAND, V48, DOI 10.1186/1751-0147-48-12
   Jorgensen JS, 1996, P AM ASS EQUINE PRAC, V42, P98
   Keith L, 2013, THERIOGENOLOGY, V79, P616, DOI 10.1016/j.theriogenology.2012.11.015
   Kim PY, 2012, PLOS ONE, V7, P1
   Klabnik-Bradford J., 2013, CLIN THERIOGENOL, V5, P410
   Lefranc AC, 2004, EQUINE VET J, V36, P183, DOI 10.2746/0425164044868675
   Nie GJ, 2003, J EQUINE VET SCI, V23, P266, DOI 10.1053/jevs.2003.75
   Nie GJ, 2001, P P ANN CONV AM ASS, V41, P246
   Penrod LV, 2013, DOMEST ANIM ENDOCRIN, V44, P46, DOI 10.1016/j.domaniend.2012.09.002
   del Alamo MMR, 2008, ANIM REPROD SCI, V107, P94, DOI 10.1016/j.anireprosci.2007.06.010
   Schulman ML, 2013, EQUINE VET J, V45, P111, DOI 10.1111/j.2042-3306.2012.00577.x
   Stout TAE, 1999, J REPROD FERTIL, V116, P315
   Turner RM, 2015, EQUINE VET EDUC, V27, P340, DOI 10.1111/eve.12311
   Vanderwall DK, 2007, JAVMA-J AM VET MED A, V231, P1864, DOI 10.2460/javma.231.12.1864
   Vanderwall DK, 2016, J EQUINE VET SCI, V36, P1, DOI 10.1016/j.jevs.2015.09.007
   Vanderwall DK, 2012, J EQUINE VET SCI, V32, P536, DOI 10.1016/j.jevs.2011.12.011
   Vanderwall DK, 2013, EQUINE PRACT, P342
   Wilsher S, 2011, EQUINE VET J, V43, P99, DOI 10.1111/j.2042-3306.2010.00131.x
NR 25
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD JUL 15
PY 2016
VL 86
IS 2
BP 545
EP 550
DI 10.1016/j.theriogenology.2016.02.002
PG 6
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DO5SP
UT WOS:000377843400010
ER

PT J
AU Smith, AL
   Freeman, SM
   Barnhart, TE
   Abbott, DH
   Ahlers, EO
   Kukis, DL
   Bales, KL
   Goodman, MM
   Young, LJ
AF Smith, Aaron L.
   Freeman, Sara M.
   Barnhart, Todd E.
   Abbott, David H.
   Ahlers, Elizabeth O.
   Kukis, David L.
   Bales, Karen L.
   Goodman, Mark M.
   Young, Larry J.
TI Initial investigation of three selective and potent small molecule
   oxytocin receptor PET ligands in New World monkeys
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Oxytocin; Oxytocin receptor; Vasopressin; Vasopressin receptor; PET
   imaging; Marmoset; Titi monkey
ID RANDOMIZED CONTROLLED-TRIAL; AUTISM SPECTRUM DISORDERS; NEUROANATOMICAL
   DISTRIBUTION; INTRANASAL OXYTOCIN; SALIVARY-GLAND; MESSENGER-RNA; GENE
   OXTR; VASOPRESSIN; EXPRESSION; BEHAVIOR
AB The neuropeptide oxytocin is part of a neuroendocrine system that has physiological effects ranging from ensuring uterine myometrial contractions at parturition and post-partum mammary gland milk ejection to the modulation of neural control of social relationships. This initial study was performed to investigate the potential use of positron emission tomography (PET) for localizing oxytocin receptors in two New World primates. Three biomarkers for PET (1-3) that are known to have high affinity and selectivity for the human oxytocin receptor were investigated in the common marmoset (Callithrix jacchus) via PET imaging. Brain penetration, and uptake in the salivary gland area were both observed with biomarkers 2 and 3. No brain penetration was observed with 1, but uptake was observed more specifically in several peripheral endocrine glands compared to 2 or 3. Biomarker 2, which displayed the best brain penetration of the three biomarkers in the marmoset, was then investigated in the monogamous coppery titi monkey (Callicebus cupreus) in a brain scan and a limited full body scan. No significant brain penetration of 2 was observed in the titi monkey, but significant uptake was observed in various locations throughout the periphery. Metabolism of 2 was suspected to have been significant based upon HPLC analysis of blood draws, but parent compound was still present near the end of the scan. Follow-up investigations will focus on next generation biomarkers bearing improved binding characteristics and brain penetrability as well as investigating tissue in regions where biomarker uptake was observed. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Smith, Aaron L.; Goodman, Mark M.; Young, Larry J.] Emory Univ, Silvio O Conte Ctr Oxytocin & Social Cognit, Dept Psychiat & Behav Sci, Ctr Translat Social Neurosci,Yerkes Natl Primate, 954 Gatewood Rd, Atlanta, GA 30329 USA.
   [Smith, Aaron L.; Goodman, Mark M.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
   [Freeman, Sara M.; Bales, Karen L.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.
   [Barnhart, Todd E.] Univ Wisconsin, Dept Med Phys, Madison, WI 53705 USA.
   [Abbott, David H.] Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53715 USA.
   [Abbott, David H.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   [Ahlers, Elizabeth O.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI 53715 USA.
   [Kukis, David L.] Univ Calif Davis, Ctr Mol & Genom Imaging, Davis, CA 95616 USA.
RP Young, LJ (reprint author), Emory Univ, Silvio O Conte Ctr Oxytocin & Social Cognit, Dept Psychiat & Behav Sci, Ctr Translat Social Neurosci,Yerkes Natl Primate, 954 Gatewood Rd, Atlanta, GA 30329 USA.
EM lyoun03@emory.edu
OI Freeman, Sara/0000-0001-7422-3440
FU NIH [1P50MH100023-01]; Good Nature Institute; Office of Research
   Infrastructure Programs [P51OD01107]; Office of Research Infrastructure
   Programs/OD [P51OD011132];  [NIMH-R21MH090776]
FX We would like to acknowledge the funding support for this research from
   NIMH-R21MH090776 and NIH 1P50MH100023-01 to L.J.Y. The titi monkey work
   was funded by the Good Nature Institute to KLB, and the Office of
   Research Infrastructure Programs P51OD01107 to the California National
   Primate Research Center. Additional support was provided by the Office
   of Research Infrastructure Programs/OD P51OD011132 to YNPRC. We would
   also like to acknowledge the veterinary staff involved in the imaging
   studies for providing excellent services.
CR Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   BARBER A, 1983, COMP BIOCHEM PHYS C, V75, P161, DOI 10.1016/0742-8413(83)90027-0
   Bosch OJ, 2016, PSYCHONEUROENDOCRINO, V64, P66, DOI 10.1016/j.psyneuen.2015.11.011
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Chen X., 2015, BRAIN IMAGING BEHAV
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Feczko E, 2015, ANIM BEHAV, V107, P115, DOI 10.1016/j.anbehav.2015.05.014
   Feng CL, 2015, BRAIN IMAGING BEHAV, V9, P754, DOI 10.1007/s11682-014-9333-9
   Francis SM, 2014, BRAIN RES, V1580, P199, DOI 10.1016/j.brainres.2014.01.021
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   GEISSMANN T, 1987, INT J PRIMATOL, V8, P1, DOI 10.1007/BF02737111
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   Hammock EAD, 2006, PHILOS T R SOC B, V361, P2187, DOI 10.1098/rstb.2006.1939
   Hicks C, 2015, PSYCHOPHARMACOLOGY, V232, P2659, DOI 10.1007/s00213-015-3902-5
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Jankowski M, 2004, P NATL ACAD SCI USA, V101, P13074, DOI 10.1073/pnas.0405324101
   King L. E. A., 2016, BIOL PSYCHI IN PRESS
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   Mascaro JS, 2014, PSYCHONEUROENDOCRINO, V46, P153, DOI 10.1016/j.psyneuen.2014.04.014
   Monstein HJ, 2004, REGUL PEPTIDES, V119, P39, DOI 10.1016/j.regpep.2003.12.017
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Perkeybile AM, 2015, PHYSIOL BEHAV, V147, P149, DOI 10.1016/j.physbeh.2015.04.024
   Pournajafi-Nazarloo H, 2007, ENDOCRINE, V31, P154, DOI 10.1007/s12020-007-0023-x
   QuinonesJenab V, 1997, NEUROENDOCRINOLOGY, V65, P9, DOI 10.1159/000127160
   Ren D., 2015, PLOS ONE, V10
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   SATO M, 1984, CANCER, V54, P2959, DOI 10.1002/1097-0142(19841215)54:12<2959::AID-CNCR2820541225>3.0.CO;2-5
   Schorscher-Petcu A, 2009, NEUROSCI LETT, V461, P217, DOI 10.1016/j.neulet.2009.06.016
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Smearman EL, 2015, DEV PSYCHOPATHOL, V27, P309, DOI 10.1017/S0954579414000649
   Smith AL, 2013, BIOORG MED CHEM LETT, V23, P5415, DOI 10.1016/j.bmcl.2013.07.045
   Smith AL, 2013, BIOORG MED CHEM LETT, V23, P902, DOI 10.1016/j.bmcl.2012.10.116
   Smith AL, 2012, BIOORGAN MED CHEM, V20, P2721, DOI 10.1016/j.bmc.2012.02.019
   Striepens N., 2013, SCI REP, V3
   Tyagi Manoj G., 2007, Biomedical Research (Aligarh), V18, P103
   Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105
   Wright PC, 2013, CAM S BIO EVOL ANTHR, V65, P232
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 1998, TRENDS NEUROSCI, V21, P71, DOI 10.1016/S0166-2236(97)01167-3
NR 45
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 15
PY 2016
VL 26
IS 14
BP 3370
EP 3375
DI 10.1016/j.bmcl.2016.04.097
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA DO0LW
UT WOS:000377471400034
PM 27209233
ER

PT J
AU Heifets, BD
   Malenka, RC
AF Heifets, Boris D.
   Malenka, Robert C.
TI MDMA as a Probe and Treatment for Social Behaviors
SO CELL
LA English
DT Editorial Material
ID TRANSLATION; OXYTOCIN; ECSTASY; HUMANS
AB MDMA, better known as the recreational drug "ecstasy,'' is well known for stimulating a feeling of closeness and empathy in its users. We advocate that exploring its mechanism of action could lead to new treatments for psychiatric conditions characterized by impairments in social behavior.
C1 [Heifets, Boris D.] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Sch Med, Stanford, CA 94305 USA.
   [Malenka, Robert C.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
RP Malenka, RC (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
EM malenka@stanford.edu
CR Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Danforth AL, 2016, PROG NEURO-PSYCHOPH, V64, P237, DOI 10.1016/j.pnpbp.2015.03.011
   Green AR, 2012, BRIT J PHARMACOL, V166, P1523, DOI 10.1111/j.1476-5381.2011.01819.x
   Greer G. R., 1990, ECSTASY CLIN PHARM N, P21
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jonas DE, 2013, COMP EFFECTIVENESS R
   Kamilar-Britt P, 2015, NEUROSCI BIOBEHAV R, V57, P433, DOI 10.1016/j.neubiorev.2015.08.016
   Kirkpatrick MG, 2014, PSYCHOPHARMACOLOGY, V231, P3899, DOI 10.1007/s00213-014-3528-z
   Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438
   Mithoefer M., 2013, MAPS B, V23, P10
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611
   Ricaurte GA, 2002, SCIENCE, V297, P2260, DOI 10.1126/science.1074501
   Roberts CA, 2016, NEUROSCI BIOBEHAV R, V63, P158, DOI 10.1016/j.neubiorev.2016.02.003
   Shulgin A. T., 1990, ECSTASY CLIN PHARM N, P1
   Zakzanis KK, 2007, HUM PSYCHOPHARM CLIN, V22, P427, DOI 10.1002/hup.873
NR 15
TC 0
Z9 0
U1 11
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUL 14
PY 2016
VL 166
IS 2
BP 269
EP 272
DI 10.1016/j.cell.2016.06.045
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DR9ZR
UT WOS:000380255400004
PM 27419864
ER

PT J
AU Corradi-Dell'Acqua, C
   Koban, L
   Leiberg, S
   Vuilleumier, P
AF Corradi-Dell'Acqua, Corrado
   Koban, Leonie
   Leiberg, Susanne
   Vuilleumier, Patrik
TI Editorial: What Determines Social Behavior? Investigating the Role of
   Emotions, Self-Centered Motives, and Social Norms
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Editorial Material
DE social behavior; ultimatum game; emotions; decision making; contextual
   appraisal; medial prefrontal cortex (mPFC); autism spectrum disorders
   (ASD); oxytocin receptor gene
ID SEROTONIN TRANSPORTER GENE; PREFRONTAL CORTEX; CINGULATE CORTEX;
   INDIVIDUALISM-COLLECTIVISM; MORAL JUDGMENT; LOCAL PATTERNS; NEURAL
   BASIS; PAIN; COEVOLUTION; RESPONSES
C1 [Corradi-Dell'Acqua, Corrado; Koban, Leonie; Vuilleumier, Patrik] Univ Geneva, Swiss Ctr Affect Sci, Geneva, Switzerland.
   [Corradi-Dell'Acqua, Corrado; Koban, Leonie; Vuilleumier, Patrik] Univ Med Ctr, Dept Neurosci & Clin Neurol, Lab Neurol & Imaging Cognit, Geneva, Switzerland.
   [Corradi-Dell'Acqua, Corrado] Univ Geneva, Fac Psychol & Sci Educ, Dept Psychol, Geneva, Switzerland.
   [Koban, Leonie] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA.
   [Leiberg, Susanne] Univ Zurich, Dept Econ, Zurich, Switzerland.
RP Corradi-Dell'Acqua, C (reprint author), Univ Geneva, Swiss Ctr Affect Sci, Geneva, Switzerland.; Corradi-Dell'Acqua, C (reprint author), Univ Med Ctr, Dept Neurosci & Clin Neurol, Lab Neurol & Imaging Cognit, Geneva, Switzerland.; Corradi-Dell'Acqua, C (reprint author), Univ Geneva, Fac Psychol & Sci Educ, Dept Psychol, Geneva, Switzerland.
EM corrado.corradi@unige.ch
CR ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0
   Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536
   Chiao JY, 2010, P R SOC B, V277, P529, DOI 10.1098/rspb.2009.1650
   Corradi-Dell'Acqua C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10904
   Corradi-Dell'Acqua C, 2015, CORTEX, V70, P21, DOI 10.1016/j.cortex.2015.02.011
   Corradi-Dell'Acqua C, 2014, SOC COGN AFFECT NEUR, V9, P1175, DOI 10.1093/scan/nst097
   Corradi-Dell'Acqua C, 2011, J NEUROSCI, V31, P17996, DOI 10.1523/JNEUROSCI.2686-11.2011
   Eisenberg DTA, 2011, P ROY SOC B-BIOL SCI, V278, P329, DOI 10.1098/rspb.2010.0714
   Eskine KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041159
   Eskine KJ, 2011, PSYCHOL SCI, V22, P295, DOI 10.1177/0956797611398497
   Forbes CE, 2010, ANNU REV NEUROSCI, V33, P299, DOI 10.1146/annurev-neuro-060909-153230
   Grossmann T, 2010, BIOL LETTERS, V6, P540, DOI 10.1098/rsbl.2009.1069
   Hare Robert D, 2005, Curr Psychiatry Rep, V7, P57, DOI 10.1007/s11920-005-0026-3
   Koban L, 2014, NEUROSCI BIOBEHAV R, V46, P71, DOI 10.1016/j.neubiorev.2014.02.014
   Krishnan A, 2016, ELIFE, V5, DOI 10.7554/eLife.15166
   Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654
   Manstead A. S. R., 2001, SERIES AFFECTIVE SCI, P221
   Moll J, 2008, ANN NY ACAD SCI, V1124, P161, DOI 10.1196/annals.1440.005
   Phelps EA, 2014, ANNU REV NEUROSCI, V37, P263, DOI 10.1146/annurev-neuro-071013-014119
   Sarlo M, 2013, INT J PSYCHOL, V48, P263, DOI 10.1080/00207594.2012.656127
   Scherer KR, 2009, COGNITION EMOTION, V23, P1307, DOI 10.1080/02699930902928969
   Scherer K. R., 1984, APPROACHES EMOTION, P293
   Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994
   Walton KE, 2008, J PERS, V76, P1623, DOI 10.1111/j.1467-6494.2008.00533.x
NR 24
TC 0
Z9 0
U1 15
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUL 7
PY 2016
VL 10
AR 342
DI 10.3389/fnhum.2016.00342
PG 5
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA DQ3QK
UT WOS:000379116600001
PM 27458361
ER

PT J
AU Hostetler, CM
   Phillips, TJ
   Ryabinin, AE
AF Hostetler, Caroline M.
   Phillips, Tamara J.
   Ryabinin, Andrey E.
TI Methamphetamine Consumption Inhibits Pair Bonding and Hypothalamic
   Oxytocin in Prairie Voles
SO PLOS ONE
LA English
DT Article
ID NUCLEUS-ACCUMBENS DOPAMINE; MICROTUS-OCHROGASTER; PARTNER PREFERENCE;
   MONOGAMOUS RODENT; SEX-DIFFERENCES; MOUSE-BRAIN; DRUG; AMPHETAMINE;
   VASOPRESSIN; BEHAVIOR
AB Methamphetamine (MA) abuse has been linked to violence, risk-taking behaviors, decreased sexual inhibition, and criminal activity. It is important to understand mechanisms underlying these drug effects for prevention and treatment of MA-associated social problems. Previous studies have demonstrated that experimenter-administered amphetamine inhibits pair bonding and increases aggression in monogamous prairie voles. It is not currently known whether similar effects on social behaviors would be obtained under conditions during which the drug is voluntarily (actively) administered. The current study investigated whether MA drinking affects pair bonding and what neurocircuits are engaged. In Experiment 1, we exposed male and female voles to 4 days each of 20 and 40 mg/L MA under a continuous 2-bottle choice (2BC) procedure. Animals were housed either singly or in mesh-divided cages with a social partner. Voles consumed MA in a drinking solution, but MA drinking was not affected by either sex or housing condition. In Experiment 2, we investigated whether MA drinking disrupts social bonding by measuring aggression and partner preference formation following three consecutive days of 18-hour/day access to 100 mg/L MA in a 2BC procedure. Although aggression toward a novel opposite-sex animal was not affected by MA exposure, partner preference was inhibited in MA drinking animals. Experiment 3 examined whether alterations in hypothalamic neuropeptides provide a potential explanation for the inhibition of partner preference observed in Experiment 2. MA drinking led to significant decreases in oxytocin, but not vasopressin, in the paraventricular nucleus of the hypothalamus. These experiments are the first investigation into how voluntary pre-exposure to MA affects the development of social attachment in a socially monogamous species and identify potential neural circuits involved in these effects.
C1 [Hostetler, Caroline M.; Phillips, Tamara J.; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
   [Hostetler, Caroline M.; Phillips, Tamara J.] Vet Affairs Portland Hlth Care Syst, Portland, OR 97239 USA.
   [Phillips, Tamara J.; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA.
RP Hostetler, CM (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.; Hostetler, CM (reprint author), Vet Affairs Portland Hlth Care Syst, Portland, OR 97239 USA.
EM Caroline.Hostetler@gmail.com
FU National Institutes of Health [RO1 AA019793, P50DA018165]; Department of
   Veterans Affairs
FX Funding was provided by National Institutes of Health RO1 AA019793 (to
   AER), Department of Veterans Affairs (to TJP), and National Institutes
   of Health P50DA018165 (to TJP). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anacker AMJ, 2014, P NATL ACAD SCI USA, V111, P6052, DOI 10.1073/pnas.1320879111
   Anacker AMJ, 2011, ADDICT BIOL, V16, P92, DOI 10.1111/j.1369-1600.2010.00234.x
   Anderson Peter D, 2012, J Pharm Pract, V25, P41, DOI 10.1177/0897190011431150
   Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Aragona BJ, 2007, NEUROSCI LETT, V418, P190, DOI 10.1016/j.neulet.2007.03.019
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003
   CARTER CS, 1995, NEUROSCI BIOBEHAV R, V19, P303
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   CUNNINGHAM CL, 1992, ANN NY ACAD SCI, V654, P431, DOI 10.1111/j.1749-6632.1992.tb25989.x
   Darke S, 2008, DRUG ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702
   Deng XL, 2007, BIOL PSYCHIAT, V61, P1235, DOI 10.1016/j.biopsych.2006.09.010
   Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X
   DeVries AC, 1997, CAN J ZOOL, V75, P295, DOI 10.1139/z97-037
   Eastwood EC, 2014, ADDICT BIOL, V19, P370, DOI 10.1111/adb.12003
   Fattore Liana, 2008, Womens Health (Lond), V4, P51, DOI 10.2217/17455057.4.1.51
   GETZ LL, 1981, BEHAV ECOL SOCIOBIOL, V8, P189, DOI 10.1007/BF00299829
   Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106
   Grilly DM, 2001, PSYCHOPHARMACOLOGY, V153, P155, DOI 10.1007/s002130000580
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   Hammock EAD, 2002, EUR J NEUROSCI, V16, P399, DOI 10.1046/j.1460-9568.2002.02083.x
   Harkness JH, 2015, NEUROPSYCHOPHARMACOL, V40, P2175, DOI 10.1038/npp.2015.61
   Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365
   Hostetler CM, 2012, PSYCHOPHARMACOLOGY, V224, P121, DOI 10.1007/s00213-012-2836-4
   Hostetler CM, 2012, NEUROSCIENCE
   Knafo A, 2008, GENES BRAIN BEHAV, V7, P266, DOI 10.1111/j.1601-183X.2007.00341.x
   Liu Y, 2011, J NEUROSCI, V31, P7960, DOI 10.1523/JNEUROSCI.1006-11.2011
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   Lynch WJ, 2006, EXP CLIN PSYCHOPHARM, V14, P34, DOI 10.1037/1064-1297.14.1.34
   McCutcheon JE, 2011, J NEUROSCI, V31, P5737, DOI 10.1523/JNEUROSCI.0350-11.2011
   McFarland K, 2003, J NEUROSCI, V23, P3531
   McKetin R, 2014, ADDICTION, V109, P798, DOI 10.1111/add.12474
   Phillips TJ, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00327
   Quality CfBHSa, 2015, NSDUH SER H, VH-50
   Ryabinin AE, 2000, ACTA NEUROBIOL EXP, V60, P547
   Semple SJ, 2002, J SUBST ABUSE TREAT, V22, P149, DOI 10.1016/S0740-5472(02)00223-4
   Shabani S, 2011, GENES BRAIN BEHAV, V10, P625, DOI 10.1111/j.1601-183X.2011.00700.x
   Shabani S, 2012, NEUROPHARMACOLOGY, V62, P2169, DOI 10.1016/j.neuropharm.2012.01.002
   Shi X, PLOS ONE
   Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105
   Wheeler JM, 2009, GENES BRAIN BEHAV, V8, P758, DOI 10.1111/j.1601-183X.2009.00522.x
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   Young KA, 2014, J NEUROSCI, V34, P8499, DOI 10.1523/JNEUROSCI.4275-13.2014
   Young KA, 2011, BRAIN RES, V1367, P213, DOI 10.1016/j.brainres.2010.09.109
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Zanos P, 2014, PHARMACOL BIOCHEM BE, V119, P72, DOI 10.1016/j.pbb.2013.05.009
   Zhu JPQ, 2006, NEUROTOXICOLOGY, V27, P131, DOI 10.1016/j.neuro.2005.05.014
NR 48
TC 0
Z9 0
U1 8
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 5
PY 2016
VL 11
IS 7
AR e0158178
DI 10.1371/journal.pone.0158178
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR3JE
UT WOS:000379798700021
PM 27380172
ER

PT J
AU Gao, S
   Becker, B
   Luo, LZ
   Geng, YY
   Zhao, WH
   Yin, Y
   Hu, JH
   Gao, Z
   Gong, QY
   Hurlemann, R
   Yao, DZ
   Kendrick, KM
AF Gao, Shan
   Becker, Benjamin
   Luo, Lizhu
   Geng, Yayuan
   Zhao, Weihua
   Yin, Yu
   Hu, Jiehui
   Gao, Zhao
   Gong, Qiyong
   Hurlemann, Rene
   Yao, Dezhong
   Kendrick, Keith M.
TI Oxytocin, the peptide that bonds the sexes also divides them
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE oxytocin; sex differences; amygdala; functional imaging; social
   cognition
ID INTRANASAL OXYTOCIN; AMYGDALA REACTIVITY; SOCIAL COGNITION; NEURAL
   CIRCUITRY; HUMANS; FEMALES; BRAIN; VASOPRESSIN; RESPONSES; BEHAVIOR
AB Facilitation of social attraction and bonding by the evolutionarily conserved neuropeptide oxytocin is well-established in female mammals. However, accumulating behavioral evidence suggests that oxytocin may have evolved sex-specific functional roles in the domain of human social cognition. A critical question is how oxytocin differentially modulates neural processing of social information in men and women, leading to divergent behavioral responses. Here we show that intranasal oxytocin treatment produces sex-and valence-dependent increases in amygdala activation when women view individuals identified as praising others but in men those who criticize them. Women subsequently show increased liking for the faces of these individuals, whereas in men it is reduced. Thus, oxytocin may act differentially via the amygdala to enhance the salience of positive social attributes in women but negative ones in men. We hypothesize that oxytocin may have evolved different but complementary roles to help ensure successful reproduction by encouraging mothers to promote a prosocial rearing environment for offspring and fathers to protect against antisocial influences.
C1 [Gao, Shan; Becker, Benjamin; Luo, Lizhu; Geng, Yayuan; Zhao, Weihua; Yin, Yu; Hu, Jiehui; Gao, Zhao; Yao, Dezhong; Kendrick, Keith M.] Univ Elect Sci & Technol China, Med Informat Ctr, Key Lab NeuroInformat, Minist Educ, Chengdu 611731, Peoples R China.
   [Gao, Shan; Hu, Jiehui; Gao, Zhao] Univ Elect Sci & Technol China, Sch Linguist & Literature, Chengdu 611731, Peoples R China.
   [Gong, Qiyong] Sichuan Univ, West China Hosp, Dept Radiol, Huaxi Magnet Resonance Res Ctr, Chengdu 610041, Peoples R China.
   [Hurlemann, Rene] Univ Bonn, Dept Psychiat & Psychotherapy, Div Med Psychol, D-53105 Bonn, Germany.
RP Kendrick, KM (reprint author), Univ Elect Sci & Technol China, Med Informat Ctr, Key Lab NeuroInformat, Minist Educ, Chengdu 611731, Peoples R China.
EM kkendrick@uestc.edu.cn
FU National Natural Science Foundation of China [31530032]
FX We thank Xiaole Ma, Zhiying Zhao, and Shuxia Yao for assistance with
   data acquisition and analysis. K.M.K. was supported by National Natural
   Science Foundation of China Grant 31530032.
CR Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x
   Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5
   Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Bliss-Moreau E, 2008, EMOTION, V8, P479, DOI 10.1037/1528-3542.8.4.479
   Camm AJ, 1996, CIRCULATION, V93, P1043
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Ditzen B, 2013, SOC COGN AFFECT NEUR, V8, P897, DOI 10.1093/scan/nss083
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034
   Eickhoff SB, 2007, NEUROIMAGE, V36, P511, DOI 10.1016/j.neuroimage.2007.03.060
   Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   Frijling JL, 2016, SOC COGN AFFECT NEUR, V11, P327, DOI 10.1093/scan/nsv116
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   Guastella A. J., 2012, HORM BEHAV, V61, P410, DOI DOI 10.1016/J.YHBEH.2012.01.002
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Hoge EA, 2014, HUM PSYCHOPHARM CLIN, V29, P299, DOI 10.1002/hup.2402
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Kanat M, 2015, NEUROPSYCHOPHARMACOL, V40, P2632, DOI 10.1038/npp.2015.111
   Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547
   Kendrick KM, 2000, EXP PHYSIOL, V85, P111
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   McLaren DG, 2012, NEUROIMAGE, V61, P1277, DOI 10.1016/j.neuroimage.2012.03.068
   Peled-Ayron L, 2016, PSYCHONEUROENDOCRINO, V66, P159, DOI 10.1016/j.psyneuen.2016.01.015
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Preckel K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00191
   Riem MME, 2012, NEUROPSYCHOPHARMACOL, V37, P1257, DOI 10.1038/npp.2011.313
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Schiller D, 2009, NAT NEUROSCI, V12, P508, DOI 10.1038/nn.2278
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Stevens JS, 2012, NEUROPSYCHOLOGIA, V50, P1578, DOI 10.1016/j.neuropsychologia.2012.03.011
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Todorov A, 2008, SOC COGN AFFECT NEUR, V3, P119, DOI 10.1093/scan/nsn009
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 47
TC 1
Z9 1
U1 6
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 5
PY 2016
VL 113
IS 27
BP 7650
EP 7654
DI 10.1073/pnas.1602620113
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DQ2GW
UT WOS:000379021700089
PM 27325780
ER

PT J
AU Haas, BW
   Filkowski, MM
   Cochran, RN
   Denison, L
   Ishak, A
   Nishitani, S
   Smith, AK
AF Haas, Brian W.
   Filkowski, Megan M.
   Cochran, R. Nick
   Denison, Lydia
   Ishak, Alexandra
   Nishitani, Shota
   Smith, Alicia K.
TI Epigenetic modification of OXT and human sociability
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE epigenetics; oxytocin; OXT; sociability; social cognition
ID OXYTOCIN RECEPTOR GENE; VOXEL-BASED MORPHOMETRY; SUPERIOR TEMPORAL
   SULCUS; DNA METHYLATION; EMOTION RECOGNITION; FACIAL EXPRESSIONS;
   SOCIAL-PERCEPTION; I OXT; BEHAVIOR; BRAIN
AB Across many mammalian species there exist genetic and biological systems that facilitate the tendency to be social. Oxytocin is a neuropeptide involved in social-approach behaviors in humans and others mammals. Although there exists a large, mounting body of evidence showing that oxytocin signaling genes are associated with human sociability, very little is currently known regarding the way the structural gene for oxytocin (OXT) confers individual differences in human sociability. In this study, we undertook a comprehensive approach to investigate the association between epigenetic modification of OXT via DNA methylation, and overt measures of social processing, including self-report, behavior, and brain function and structure. Genetic data were collected via saliva samples and analyzed to target and quantify DNA methylation across the promoter region of OXT. We observed a consistent pattern of results across sociability measures. People that exhibit lower OXT DNA methylation (presumably linked to higher OXT expression) display more secure attachment styles, improved ability to recognize emotional facial expressions, greater superior temporal sulcus activity during two social-cognitive functional MRI tasks, and larger fusiform gyrus gray matter volume than people that exhibit higher OXT DNA methylation. These findings provide empirical evidence that epigenetic modification of OXT is linked to several overt measures of sociability in humans and serve to advance progress in translational social neuroscience research toward a better understanding of the evolutionary and genetic basis of normal and abnormal human sociability.
C1 [Haas, Brian W.; Filkowski, Megan M.; Cochran, R. Nick] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
   [Haas, Brian W.] Univ Georgia, Interdisciplinary Neurosci Grad Program, Athens, GA 30602 USA.
   [Denison, Lydia; Nishitani, Shota; Smith, Alicia K.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Ishak, Alexandra] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Ctr Interdisciplinary Brain Sci Res, Stanford, CA 94305 USA.
   [Nishitani, Shota] Nagasaki Univ, Grad Sch Biomed Sci, Course Med & Dent Sci, Dept Neurobiol & Behav,Unit Basic Med Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
RP Haas, BW (reprint author), Univ Georgia, Dept Psychol, Athens, GA 30602 USA.; Haas, BW (reprint author), Univ Georgia, Interdisciplinary Neurosci Grad Program, Athens, GA 30602 USA.
EM bhaas@uga.edu
CR Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003
   Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582
   Baggio HC, 2012, NEUROPSYCHOLOGIA, V50, P2121, DOI 10.1016/j.neuropsychologia.2012.05.020
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Essex MJ, 2013, CHILD DEV, V84, P58, DOI 10.1111/j.1467-8624.2011.01641.x
   Feeney JA, 1994, ATTACHEMENT ADULTS C
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001
   Furman DJ, 2011, PSYCHONEUROENDOCRINO, V36, P891, DOI 10.1016/j.psyneuen.2010.12.004
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guo JJU, 2011, NAT NEUROSCI, V14, P1345, DOI 10.1038/nn.2900
   Haas BW, 2015, EMOTION, V15, P390, DOI 10.1037/emo0000053
   Haas BW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120639
   Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041
   Hein G, 2008, J COGNITIVE NEUROSCI, V20, P2125, DOI 10.1162/jocn.2008.20148
   Higashida H, 2010, J NEUROENDOCRINOL, V22, P373, DOI 10.1111/j.1365-2826.2010.01976.x
   Hovey D, 2014, SOC NEUROSCI-UK, V9, P378, DOI 10.1080/17470919.2014.897995
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Jack A, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00280
   Jonas W, 2013, GENES BRAIN BEHAV, V12, P681, DOI 10.1111/gbb.12069
   Kanwisher N, 1997, J NEUROSCI, V17, P4302
   Karantzas GC, 2010, J SOC PERS RELAT, V27, P749, DOI 10.1177/0265407510373756
   Kascheike B, 1997, DNA CELL BIOL, V16, P1237, DOI 10.1089/dna.1997.16.1237
   Kim YR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088673
   King LB, 2015, BIOL PSYCHI IN PRESS
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Love TM, 2012, BIOL PSYCHIAT, V72, P198, DOI 10.1016/j.biopsych.2012.01.033
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   Mileva-Seitz V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061443
   Niedenthal PM, 2001, COGNITION EMOTION, V15, P853
   Onitsuka T, 2003, ARCH GEN PSYCHIAT, V60, P349, DOI 10.1001/archpsyc.60.4.349
   Puglia MH, 2015, P NATL ACAD SCI USA, V112, P3308, DOI 10.1073/pnas.1422096112
   RAO VVNG, 1992, CYTOGENET CELL GENET, V61, P271
   Rubin LH, 2015, BIOL PSYCHIAT COGN N, V1, P141
   Rusch N, 2003, NEUROIMAGE, V20, P385, DOI 10.1016/S1053-8119(03)00297-0
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Silver M, 2011, NEUROIMAGE, V54, P992, DOI 10.1016/j.neuroimage.2010.08.049
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Smith AK, 2015, AM J MED GENET B, V168, P36, DOI 10.1002/ajmg.b.32278
   Smith AK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-145
   Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Teltsh O, 2012, INT J NEUROPSYCHOPH, V15, P309, DOI 10.1017/S1461145711001374
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Tottenham N, 2009, PSYCHIAT RES, V168, P242, DOI 10.1016/j.psychres.2008.05.006
   Unternaehrer E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.77
   Valente AA, 2005, BIOL PSYCHIAT, V58, P479, DOI 10.1016/j.biopsych.2005.04.021
   Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058
   Xu Y, 2008, J HUM GENET, V53, P637, DOI 10.1007/s10038-008-0292-0
   Yrigollen CM, 2008, BIOL PSYCHIAT, V63, P911, DOI 10.1016/j.biopsych.2007.11.015
   Ziegler C, 2015, NEUROPSYCHOPHARMACOL, V40, P1528, DOI 10.1038/npp.2015.2
   Zilbovicius M, 2006, TRENDS NEUROSCI, V29, P359, DOI 10.1016/j.tins.2006.06.004
NR 62
TC 0
Z9 0
U1 11
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 5
PY 2016
VL 113
IS 27
BP E3816
EP E3823
DI 10.1073/pnas.1602809113
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DQ2GW
UT WOS:000379021700005
PM 27325757
ER

PT J
AU Saleh, N
   Saladino, G
   Gervasio, FL
   Haensele, E
   Banting, L
   Whitley, DC
   Santos, JSD
   Bureau, R
   Clark, T
AF Saleh, Noureldin
   Saladino, Giorgio
   Gervasio, Francesco L.
   Haensele, Elke
   Banting, Lee
   Whitley, David C.
   Santos, Jana Sopkova-de Oliveira
   Bureau, Ronan
   Clark, Timothy
TI A Three-Site Mechanism for Agonist/Antagonist Selective Binding to
   Vasopressin Receptors
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE G-protein coupled receptors; hormones; metadynamics; molecular dynamics;
   receptors
ID MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; MOLECULAR
   PHARMACOLOGY; FUNNEL-METADYNAMICS; ADRENERGIC-RECEPTOR;
   CRYSTAL-STRUCTURE; COMPLEX; ANTAGONISTS; OXYTOCIN; NEUROPHYSIN
AB Molecular-dynamics simulations with metadynamics enhanced sampling reveal three distinct binding sites for arginine vasopressin (AVP) within its V-2-receptor (V2R). Two of these, the vestibule and intermediate sites, block (antagonize) the receptor, and the third is the orthosteric activation (agonist) site. The contacts found for the orthosteric site satisfy all the requirements deduced from mutagenesis experiments. Metadynamics simulations for V2R and its V1aR-analog give an excellent correlation with experimental binding free energies by assuming that the most stable binding site in the simulations corresponds to the experimental binding free energy in each case. The resulting three-site mechanism separates agonists from antagonists and explains subtype selectivity.
C1 [Saleh, Noureldin; Clark, Timothy] Univ Erlangen Nurnberg, Comp Chem Ctr, Nagelsbachstr 25, D-91052 Erlangen, Germany.
   [Saladino, Giorgio; Gervasio, Francesco L.] UCL, Dept Chem, London WC1E 6BT, England.
   [Saladino, Giorgio; Gervasio, Francesco L.] UCL, Inst Struct & Mol Biol, London WC1E 6BT, England.
   [Haensele, Elke; Banting, Lee; Whitley, David C.; Clark, Timothy] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England.
   [Santos, Jana Sopkova-de Oliveira; Bureau, Ronan] Normandie Univ, CERMN, UNICAEN, UPRES EA 4258,FR CNRS INC3M 3038, Blvd Becquerel, F-14032 Caen, France.
RP Clark, T (reprint author), Univ Erlangen Nurnberg, Comp Chem Ctr, Nagelsbachstr 25, D-91052 Erlangen, Germany.
EM Tim.Clark@fau.de
RI Saladino, Giorgio/O-6411-2015
OI Clark, Timothy/0000-0001-7931-4659; Saladino,
   Giorgio/0000-0002-3234-5762
FU Deutsche Forschungsgemeinschaft [GK1910]; European Union project
   "Peptide Research Network of Excellence" PeReNE as part of the Interreg
   IVA France (Channel)-England program (Interreg EU); EPSRC [EP/
   M013898/1]
FX This work was supported by the Deutsche Forschungsgemeinschaft as part
   of GK1910 "Medicinal Chemistry of Selective GPCR Ligands", by the
   European Union project "Peptide Research Network of Excellence" PeReNE
   as part of the Interreg IVA France (Channel)-England 2007-2014 program
   (Interreg EU) and by a generous grant of computer time on SuperMUC at
   the Leibniz Rechenzentrum, Munich. G.S. and F.L.G. acknowledge the EPSRC
   [grant: EP/ M013898/1] for financial support.
CR Barducci A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.020603
   Boukharta L, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003585
   Branduardi D, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2432340
   Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1327.2000.01472.x
   Crombie AL, 2010, BIOORG MED CHEM LETT, V20, P3742, DOI 10.1016/j.bmcl.2010.04.068
   Darve E, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2829861
   DELEAN A, 1980, J BIOL CHEM, V255, P7108
   Dror RO, 2013, NATURE, V503, P295, DOI 10.1038/nature12595
   Dror RO, 2011, P NATL ACAD SCI USA, V108, P18684, DOI 10.1073/pnas.1110499108
   Dror RO, 2011, P NATL ACAD SCI USA, V108, P13118, DOI 10.1073/pnas.1104614108
   Egloff P, 2014, P NATL ACAD SCI USA, V111, pE655, DOI 10.1073/pnas.1317903111
   Filmore D., 2004, MOD DRUG DISCOV, P24
   Grazioso G, 2012, J AM CHEM SOC, V134, P453, DOI 10.1021/ja208485w
   Gruber CW, 2010, CURR PHARM DESIGN, V16, P3071
   Haensele Elke, 2014, J Mol Model, V20, P2485, DOI 10.1007/s00894-014-2485-0
   Haga K, 2012, NATURE, V482, P547, DOI 10.1038/nature10753
   Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400
   Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674
   HOWL J, 1995, GEN PHARMACOL, V26, P1143, DOI 10.1016/0306-3623(95)00016-T
   Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886
   Jean-Alphonse F, 2009, J AM SOC NEPHROL, V20, P2190, DOI 10.1681/ASN.2008121289
   Juraszek J, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.108106
   Kappel K, 2015, Q REV BIOPHYS, V48, P479, DOI 10.1017/S0033583515000153
   KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020
   Kruse AC, 2012, NATURE, V482, P552, DOI 10.1038/nature10867
   Laio A, 2002, P NATL ACAD SCI USA, V99, P12562, DOI 10.1073/pnas.202427399
   Lemmens-Gruber R, 2006, CELL MOL LIFE SCI, V63, P1766, DOI 10.1007/s00018-006-6054-2
   Limongelli V, 2013, P NATL ACAD SCI USA, V110, P6358, DOI 10.1073/pnas.1303186110
   Limongelli V, 2010, P NATL ACAD SCI USA, V107, P5411, DOI 10.1073/pnas.0913377107
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Matthews JM, 2004, BIOORG MED CHEM LETT, V14, P2747, DOI 10.1016/j.bmcl.2004.03.083
   PAN Y, 1994, J BIOL CHEM, V269, P31933
   Raiteri P, 2006, J PHYS CHEM B, V110, P3533, DOI 10.1021/jp054359r
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Ring AM, 2013, NATURE, V502, P575, DOI 10.1038/nature12572
   Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163
   Saladino G, 2012, J CHEM THEORY COMPUT, V8, P1165, DOI 10.1021/ct3001377
   Serradeil-Le Gal C., 2001, Cardiovascular Drug Reviews, V19, P201
   Thibonnier M, 2002, PROG BRAIN RES, V139, P179
   Troussicot L, 2015, J AM CHEM SOC, V137, P1273, DOI 10.1021/ja511336z
   Wheatley M, 2012, BRIT J PHARMACOL, V165, P1688, DOI 10.1111/j.1476-5381.2011.01629.x
   Wu CK, 2001, PROTEIN SCI, V10, P1869, DOI 10.1110/ps.10601
NR 42
TC 0
Z9 0
U1 4
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD JUL 4
PY 2016
VL 55
IS 28
BP 8008
EP 8012
DI 10.1002/anie.201602729
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA DV9IC
UT WOS:000383253100020
PM 27184628
ER

PT J
AU Garba, I
   Muhammed, AS
   Muhammad, Z
   Galadanci, HS
   Ayyuba, R
   Abubakar, IS
AF Garba, Ibrahim
   Muhammed, Abubakar Shehu
   Muhammad, Zakari
   Galadanci, Hadiza Shehu
   Ayyuba, Rabiu
   Abubakar, Idris Sulaiman
TI Induction to delivery interval using transcervical Foley catheter plus
   oxytocin and vaginal misoprostol: A comparative study at Aminu Kano
   Teaching Hospital, Kano, Nigeria
SO ANNALS OF AFRICAN MEDICINE
LA English
DT Article
DE Induction delivery interval; Kano; misoprostol; postdatism;
   transcervical catheter
ID PROLONGED PREGNANCY; POSTDATE PREGNANCY; LABOR; MANAGEMENT; MORTALITY
AB Background: Induction of labor (IOL) is an artificial initiation of labor before its spontaneous onset for the purpose of delivery of the fetoplacental unit. Many factors are associated with its success in postdatism.
   Objective: To compare the induction delivery intervals using transcervical Foley catheter plus oxytocin and vaginal misoprostol, and to identify the factors associated with successful induction among postdate singleton multiparae.
   Materials and Methods: The study was a prospective randomized controlled trial of singleton multiparous pregnant women. They were randomized into two groups, one group for intravaginal misoprostol and the other group for transcervical Foley catheter insertion as a method of cervical ripening and IOL. The data were analyzed using SPSS version 17 computer software (SPSS Inc., IL, Chicago, USA). Comparisons of categorical variables were done using Chi-squared test, with P < 0.05 considered as significant. Student's t-test was used for continuous variables.
   Results: The incidence of postdatism was found to be 136 (13.1%). The mean induction delivery time interval was shorter in the misoprostol group 70 (5.54 +/- 1.8 h) than in the Foley catheter oxytocin infusion group 66 (6.65 +/- 1.7 h) (P = 0.035). There was, however, no statistically significant difference in the maternal and neonatal outcomes when these two agents were used for cervical ripening and IOL. Higher parity and higher Bishop's score were the factors found to be associated with high success rate of IOL (P < 0.001).
   Conclusion: Vaginal misoprostol resulted in shorter induction delivery time interval as compared to transcervical Foley catheter. High parity and high Bishop's scores were the factors found to be associated with the success of IOL.
C1 [Garba, Ibrahim; Muhammad, Zakari; Galadanci, Hadiza Shehu; Ayyuba, Rabiu; Abubakar, Idris Sulaiman] Bayero Univ, Aminu Kano Teaching Hosp, Dept Obstet & Gynaecol, Kano, Nigeria.
   [Muhammed, Abubakar Shehu] Aminu Kano Teaching Hosp, Dept Obstet & Gynaecol, Kano, Nigeria.
RP Ayyuba, R (reprint author), Bayero Univ, Aminu Kano Teaching Hosp, Dept Obstet & Gynaecol, Kano, Nigeria.
EM ayyubarabiu@yahoo.com
CR Bako B G, 2008, Niger J Med, V17, P139
   Bartusevicius A, 2005, INT J GYNECOL OBSTET, V91, P2, DOI 10.1016/j.ijgo.2005.07.002
   BEISCHER NA, 1969, AM J OBSTET GYNECOL, V103, P476
   Choy-Hee L, 2001, AM J OBSTET GYNECOL, V184, P1115, DOI 10.1067/mob.2001.115177
   Cotzias CS, 1999, BRIT MED J, V319, P287
   Crowley P, 2000, COCHRANE DB SYST REV, V2
   Ekele B A, 2002, Afr J Reprod Health, V6, P98, DOI 10.2307/3583262
   Ekele B A, 2007, Niger J Clin Pract, V10, P234
   Ferdous J, 2009, J BANGLADESH COLL PH, V27, P1
   FLETCHER H, 1994, OBSTET GYNECOL, V83, P244
   Gonen R, 1998, Eur J Ultrasound, V7, P183, DOI 10.1016/S0929-8266(98)00042-1
   HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402
   Hilder L, 1998, BRIT J OBSTET GYNAEC, V105, P169, DOI 10.1111/j.1471-0528.1998.tb10047.x
   Hofmeyr GJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000941
   Hovi M, 2006, ACTA OBSTET GYN SCAN, V85, P805, DOI 10.1080/00016340500442472
   Jindal P, 2007, J OBSTET GYNAECOLOGY, V57, P42
   Lawani OL, 2014, OBSTET GYNECOL INT, V2014, P1
   Martin Joyce A, 2011, Natl Vital Stat Rep, V60, P1
   Mbele AM, 2007, SAMJ S AFR MED J, V97, P289
   NAEYE RL, 1978, AM J EPIDEMIOL, V108, P429
   Owolabi A T, 2005, J Obstet Gynaecol, V25, P565, DOI 10.1080/01443610500231450
   Rand L, 2000, OBSTET GYNECOL, V96, P779, DOI 10.1016/S0029-7844(00)01002-4
   RAYBURN WF, 1981, J REPROD MED, V26, P93
   Roudsari FV, 2011, IRAN J PHARM RES, V10, P149
   SACHS BP, 1986, J REPROD MED, V31, P162
NR 25
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1596-3519
EI 0975-5764
J9 ANN AFR MED
JI Ann. Afr. Med.
PD JUL-SEP
PY 2016
VL 15
IS 3
BP 114
EP 119
DI 10.4103/1596-3519.188890
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA1KN
UT WOS:000386351100004
PM 27549415
ER

PT J
AU Di Renzo, GC
   Giardina, I
   Clerici, G
   Brillo, E
   Gerli, S
AF Di Renzo, Gian Carlo
   Giardina, Irene
   Clerici, Graziano
   Brillo, Eleonora
   Gerli, Sandro
TI Progesterone in normal and pathological pregnancy
SO HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION
LA English
DT Article
DE pathological pregnancy; pregnancy; preterm birth; progesterone;
   tocolysis
ID LUTEAL-PHASE SUPPORT; ORAL DYDROGESTERONE TREATMENT; PLACEBO-CONTROLLED
   TRIAL; MICRONIZED PROGESTERONE; PRETERM LABOR; DOUBLE-BLIND; VAGINAL
   PROGESTERONE; HUMAN MYOMETRIUM; RECURRENT MISCARRIAGE; CYTOKINE
   PRODUCTION
AB Progesterone is an essential hormone in the process of reproduction. It is involved in the menstrual cycle, implantation and is essential for pregnancy maintenance. It has been proposed and extensively used in the treatment of different gynecological pathologies as well as in assisted reproductive technologies and in the maintenance of pregnancy. Called "the pregnancy hormone", natural progesterone is essential before pregnancy and has a crucial role in its maintenance based on different mechanisms such as: modulation of maternal immune response and suppression of inflammatory response (the presence of progesterone and its interaction with progesterone receptors at the decidua level appears to play a major role in the maternal defense strategy), reduction of uterine contractility (adequate progesterone concentrations in myometrium are able to counteract prostaglandin stimulatory activity as well as oxytocin), improvement of utero-placental circulation and luteal phase support (it has been demonstrated that progesterone may promote the invasion of extravillous trophoblasts to the decidua by inhibiting apoptosis of extravillous trophoblasts). Once the therapeutic need of progesterone is established, the key factor is the decision of the best route to administer the hormone and the optimal dosage determination. Progesterone can be administered by many different routes, but the most utilized are oral, the vaginal and intramuscular administration. The main uses of progesterone are represented by: threatened miscarriage, recurrent miscarriage and preterm birth (in the prevention strategy, as a tocolytic agent and also in the maintenance of uterine quiescence).
C1 [Di Renzo, Gian Carlo] Santa Maria Misericordia Univ Hosp, Ctr Perinatal & Reprod Med, Dept Obstet & Gynaecol, I-06132 Perugia, Italy.
   [Giardina, Irene; Clerici, Graziano; Brillo, Eleonora; Gerli, Sandro] Univ Perugia, Dept Obstet & Gynaecol, Perugia, Italy.
   [Giardina, Irene; Clerici, Graziano; Brillo, Eleonora; Gerli, Sandro] Univ Perugia, Ctr Perinatal & Reprod Med, Perugia, Italy.
RP Di Renzo, GC (reprint author), Santa Maria Misericordia Univ Hosp, Ctr Perinatal & Reprod Med, Dept Obstet & Gynaecol, I-06132 Perugia, Italy.
EM giancarlo.direnzo@unipg.it
CR Aghsa MM, 2012, ARCH GYNECOL OBSTET, V286, P1049, DOI 10.1007/s00404-012-2410-7
   Barentsen R, 1996, EUR MENOPAUSE J, V3, P266
   Barton JR, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.039
   Baumbach J, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.011
   Berghella V, 2012, AM J OBSTET GYNECOL, V206, P376, DOI 10.1016/j.ajog.2012.03.010
   Borna S, 2008, AUST NZ J OBSTET GYN, V48, P58, DOI [10.1111/j.1479-828X.2007.00803.x, 10.1111/j.1479-82SX.2007.00803.x]
   Bouckaert Y, 2004, HUM REPROD, V19, P1806, DOI 10.1093/humrep/deh316
   BOURGAIN C, 1990, HUM REPROD, V5, P537
   Bulletti C, 1997, HUM REPROD, V12, P1073
   Campbell S, 2011, ULTRASOUND OBST GYN, V38, P1, DOI 10.1002/uog.9073
   Chanrachakul B, 2005, AM J OBSTET GYNECOL, V192, P458, DOI 10.1016/j.ajog.2004.07.077
   Cicinelli E, 2000, OBSTET GYNECOL, V95, P403, DOI 10.1016/S0029-7844(99)00542-6
   Combs CA, 2011, AM J OBSTET GYNECOL, V204
   Coomarasamy A, 2015, NEW ENGL J MED, V373, P2141, DOI 10.1056/NEJMoa1504927
   Czajkowski K, 2007, FERTIL STERIL, V87, P613, DOI 10.1016/j.fertnstert.2006.07.1506
   da Fonseca EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/mob.2003.41
   Daya S, 2009, MATURITAS, V65, pS29, DOI 10.1016/j.maturitas.2009.09.012
   de Tejada BM, 2015, BJOG-INT J OBSTET GY, V122, P80, DOI 10.1111/1471-0528.13061
   Devoto L, 2009, REPROD BIOMED ONLINE, V18, pS19
   Di Renzo GC, 2005, CURR OPIN OBSTET GYN, V17, P598, DOI 10.1097/01.gco.0000191899.84567.4d
   Di Renzo GC, 2005, BJOG-INT J OBSTET GY, V112, P57
   Di Renzo GC, 2015, INT J GYNECOL OBSTET, V128, P80, DOI 10.1016/j.ijgo.2014.10.011
   Di Renzo GC, 2012, GYNECOL ENDOCRINOL, V28, P925, DOI 10.3109/09513590.2012.730576
   Di Renzo GC, 2011, J MATERN-FETAL NEO M, V24, P659, DOI 10.3109/14767058.2011.553694
   Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010
   Fanchin R, 2000, HUM REPROD, V15, P90
   Farine Dan, 2008, J Obstet Gynaecol Can, V30, P67
   Fatemi HM, 2007, HUM REPROD UPDATE, V13, P581, DOI 10.1093/humupd/dmm021
   Fitzpatrick LA, 1999, FERTIL STERIL, V72, P389, DOI 10.1016/S0015-0282(99)00272-1
   Furcron AE, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.010
   Grobman WA, 2012, AM J OBSTET GYNECOL, V207, pe1
   Haas DM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003511.pub2
   Haas DM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003511.pub3
   HARTIKAINENSORRI AL, 1980, OBSTET GYNECOL, V56, P692
   Heyborne KD, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.014
   Kamat S, 2014, J Obstet Gynaecol, V34, P322, DOI 10.3109/01443615.2013.874407
   Karteris E, 2006, MOL ENDOCRINOL, V20, P1519, DOI 10.1210/me.2005-0243
   KEIRSE MJNC, 1990, BRIT J OBSTET GYNAEC, V97, P149, DOI 10.1111/j.1471-0528.1990.tb01740.x
   Kuhl H, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500148875
   Kumar A, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.1251
   Kurjak A, 2006, MANAGMENT PRETERM LA, P1394
   Liu J, 2007, MOL HUM REPROD, V13, P869, DOI 10.1093/molehr/gam078
   Maher MA, 2013, ACTA OBSTET GYN SCAN, V92, P215, DOI 10.1111/aogs.12017
   Merlino AA, 2007, J CLIN ENDOCR METAB, V92, P1927, DOI 10.1210/jc.2007-0077
   MILES RA, 1994, FERTIL STERIL, V62, P485
   NAHOUL K, 1987, J STEROID BIOCHEM, V26, P241, DOI 10.1016/0022-4731(87)90078-1
   Nakamura O, 2009, J TOXICOL SCI, V34, pSP331
   NILLIUS SJ, 1971, AM J OBSTET GYNECOL, V110, P470
   NOBLOT G, 1991, EUR J OBSTET GYN R B, V40, P203, DOI 10.1016/0028-2243(91)90118-5
   Perusquia M, 2001, LIFE SCI, V68, P2933, DOI 10.1016/S0024-3205(01)01089-X
   Raghupathy R, 2009, J REPROD IMMUNOL, V80, P91, DOI 10.1016/j.jri.2009.01.004
   Raghupathy R, 2008, INDIAN J BIOCHEM BIO, V45, P229
   Renthal NE, 2010, P NATL ACAD SCI USA, V107, P20828, DOI 10.1073/pnas.1008301107
   Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816
   Romero R, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.003
   Ruan XY, 2014, MATURITAS, V79, P248, DOI 10.1016/j.maturitas.2014.07.009
   Ruddock NK, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.085
   Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014
   Schuit E, 2015, BJOG-INT J OBSTET GY, V122, P27, DOI 10.1111/1471-0528.13032
   Schwartz N, 2009, AM J OBSTET GYNECOL, V201
   Siew JY, 2015, OBSTET GYNECOL, p104S
   Sotiriadis A, 2004, BRIT MED J, V329, P152, DOI 10.1136/bmj.329.7458.152
   Stricker N, 2015, AM J OBSTET GYNECOL, V214
   Suhag A, 2015, AM J OBSTET GYNECOL, V213, P479, DOI 10.1016/j.ajog.2015.03.031
   Szekeres-Bartho J, 2009, IMMUNOTHERAPY, V1, P873, DOI [10.2217/imt.09.54, 10.2217/IMT.09.54]
   Szekeres-Bartho J, 2001, INT IMMUNOPHARMACOL, V1, P1037, DOI 10.1016/S1567-5769(01)00035-2
   Szekeres-Bartho Julia, 2002, Int Rev Immunol, V21, P471, DOI 10.1080/08830180215017
   SzekeresBartho J, 1997, CELL IMMUNOL, V177, P194, DOI 10.1006/cimm.1997.1090
   Verhaegen J, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6077
   Wahabi HA, 2011, COCHRANE DATABASE SY
   Walch K, 2005, J MATERN-FETAL NEO M, V18, P265, DOI 10.1080/14767050500246243
   Walch KT, 2008, BEST PRACT RES CL OB, V22, P375, DOI 10.1016/j.bpobgyn.2007.08.009
   Winer N, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.10.1097
   Zakar T, 2011, NEW ENGL J MED, V364, P972, DOI 10.1056/NEJMcibr1100071
   Zava DT, 1998, P SOC EXP BIOL MED, V217, P369
NR 75
TC 0
Z9 0
U1 2
U2 2
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1868-1883
EI 1868-1891
J9 HORM MOL BIOL CLIN I
JI Horm. Mol. Biol. Clin. Investig.
PD JUL
PY 2016
VL 27
IS 1
SI SI
BP 35
EP 48
DI 10.1515/hmbci-2016-0038
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DX8PL
UT WOS:000384650900005
PM 27662646
ER

PT J
AU Rasouli, M
   Keramat, A
   Khosravi, A
   Mohabatpour, Z
AF Rasouli, Masoumeh
   Keramat, Afsaneh
   Khosravi, Ahmad
   Mohabatpour, Zahra
TI Prevalence and Factors Associated With Episiotomy in Shahroud City,
   Northeast of Iran
SO INTERNATIONAL JOURNAL OF WOMENS HEALTH AND REPRODUCTION SCIENCES
LA English
DT Article
DE Complications; Epidemiology; Episiotomy; Parturition
ID RISK-FACTORS; DELIVERY; INJURY; RATES
AB Objectives: Episiotomy is the most common surgical incision in midwifery. Given its questionable benefits, the present study aimed to determine the frequency of episiotomy and its associated factors in women with vaginal childbirth.
   Materials and Methods: This descriptive cross-sectional study was conducted on a population consisting of all women that had vaginal childbirth over a six-month period (from October 2014 to April 2015) in Fatemieh Teaching hospital in Shahroud city. Participants were selected by census. Data were collected using a researcher-made questionnaire consisting of four parts, whose validity and reliability had been confirmed. Data were analyzed in SPSS 21 using descriptive statistics and chi-square, t test and logistic regression analysis.
   Results: Of the 978 cases of vaginal childbirth, 406 (41.5%) had undergone episiotomy. Mean age of participating women was 27.32 +/- 5.14 years. Episiotomy was found to have significant relationships with mother's age, parity, first and fifth minute Apgar scores, duration of the second stage of labor, birth spacing, use of oxytocin, vacuum deliveries and use of analgesics (P < 0.05). Overall, prevalence of intact perinea was 34.7%. In the final logistic regression analysis, among significant variables and variables with P<0.1 in univariate analysis, parity, use of oxytocin, first minute Apgar score and infant's head circumference with P < 0.0001 and birth spacing with P = 0.043 were considered predictors of episiotomy.
   Conclusion: The overall rate of episiotomy in this study was 41.5%, which is much higher than the standards set by the World Health Organization (WHO). Further research is required to provide appropriate solutions to reduce episiotomy.
C1 [Rasouli, Masoumeh] Shahroud Univ Med Sci, Shahroud, Iran.
   [Keramat, Afsaneh] Shahroud Univ Med Sci, Fac Nursing & Midwifery, Shahroud, Iran.
   [Khosravi, Ahmad] Shahroud Univ Med Sci, Ctr Hlth Related Social & Behav Sci, Shahroud, Iran.
   [Mohabatpour, Zahra] Shahroud Univ Med Sci, Student Res Comm, Shahroud, Iran.
RP Keramat, A (reprint author), Shahroud Univ Med Sci, Sch Nursing & Midwifery, Dept Reprod Hlth, Shahroud, Iran.
EM keramat1@yahoo.com
CR Ahmadi Z, 2015, IRAN J OBSTET GYNECO, V18, P19
   Asali R, 2009, OBSTET GYNACOL INFER, V2, P43
   Boran Saadet Unsal, 2013, Eurasian J Med, V45, P176, DOI 10.5152/eajm.2013.36
   Braga GC, 2014, REV ASSOC MED BRAS, V60, P465, DOI 10.1590/1806-9282.60.05.015
   Carroli G, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000081.pub2
   Christianson LM, 2003, AM J OBSTET GYNECOL, V189, P255, DOI 10.1067/mob.2003.547
   Cunningham F, 2010, WILLIAMS OBSTET
   Ekwempu CC, 2006, TXB OBSTET GYNAECOLO, P477
   Escuriet R, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0753-z
   Golmakany A, 2005, J MAZANDARAN U MED S, V15, P57
   Graham ID, 2005, BIRTH-ISS PERINAT C, V32, P219, DOI 10.1111/j.0730-7659.2005.00373.x
   Gupta JK, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005073.pub3
   Hueston WJ, 1996, OBSTET GYNECOL, V87, P1001, DOI 10.1016/0029-7844(96)00068-3
   Izuka Eo, 2014, Ann Med Health Sci Res, V4, P928, DOI 10.4103/2141-9248.144916
   Jovanovic NS, 2011, CENT EUR J MED, V6, P685, DOI 10.2478/s11536-011-0088-z
   Khani S, 2012, IRAN J NURS, V24, P45
   Khani S, 2001, MODRAES J MED SCI, V4, P9
   Kropp N, 2005, INT J GYNECOL OBSTET, V91, P157, DOI 10.1016/j.ijgo.2005.07.013
   LaCross A, 2015, J MIDWIFERY WOM HEAL, V60, P37, DOI 10.1111/jmwh.12283
   de Carvalho CCM, 2010, REV ASSOC MED BRAS, V56, P333, DOI 10.1590/S0104-42302010000300020
   Motevasselian M, 2002, J YAZD U MED SCI, V10, P25
   Sekhavat L, 2009, J GORGAN U MED SCI, V11, P33
   Khajavi Shojae K, 2009, QOM U MED SCI J, V3, P47
   World Health Organization, 1996, CAR NORM BIRTH PRACT
NR 24
TC 0
Z9 0
U1 3
U2 3
PU ARAS PART MEDICAL INT PRESS
PI TABRIZ
PA NO 1, S SHAREATI ST, 5138815941, TABRIZ, 00000, IRAN
SN 2330-4456
J9 INT J WOMENS HEALTH
JI Int. J. Womens Health Reprod. Sci.
PD JUL
PY 2016
VL 4
IS 3
BP 125
EP 129
DI 10.15296/ijwhr.2016.29
PG 5
WC Reproductive Biology
SC Reproductive Biology
GA DX6YT
UT WOS:000384532700008
ER

PT J
AU Aebi, M
   van Donkelaar, MMJ
   Poelmans, G
   Buitelaar, JK
   Sonuga-Barke, EJS
   Stringaris, A
   Faraone, SV
   Franke, B
   Steinhausen, HC
   van Hulzen, KJE
AF Aebi, Marcel
   van Donkelaar, Marjolein M. J.
   Poelmans, Geert
   Buitelaar, Jan K.
   Sonuga-Barke, Edmund J. S.
   Stringaris, Argyris
   Faraone, Stephen V.
   Franke, Barbara
   Steinhausen, Hans-Christoph
   van Hulzen, Kimm J. E.
CA IMAGE Consortium
TI Gene-Set and Multivariate Genome-Wide Association Analysis of
   Oppositional Defiant Behavior Subtypes in
   Attention-Deficit/Hyperactivity Disorder
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE ODD; GWAS; irritability; beta-catenin; neurite outgrowth
ID DEFICIT HYPERACTIVITY DISORDER; CALLOUS-UNEMOTIONAL TRAITS; CHILD
   PSYCHIATRIC-PATIENTS; LARGE MULTICENTER ADHD; CONDUCT DISORDER;
   AGGRESSIVE-BEHAVIOR; SEROTONIN TRANSPORTER; ANTISOCIAL-BEHAVIOR;
   DIAGNOSTIC-APPROACH; OXTR POLYMORPHISMS
AB Oppositional defiant disorder (ODD) is a frequent psychiatric disorder seen in children and adolescents with attention-deficit-hyperactivity disorder (ADHD). ODD is also a common ante-cedent to both affective disorders and aggressive behaviors. Although the heritability of ODD has been estimated to be around 0.60, there has been little research into the molecular genetics of ODD. The present study examined the association of irritable and defiant/vindictive dimensions and categorical subtypes of ODD(based on latent class analyses) with previously described specific polymorphisms (DRD4 exon3 VNTR, 5-HTTLPR, and seven OXTR SNPs) as well as with dopamine, serotonin, and oxytocin genes and pathways in a clinical sample of children and adolescents with ADHD. In addition, we performed a multivariate genome-wide association study (GWAS) of the aforementioned ODD dimensions and subtypes. Apart from adjusting the analyses for age and sex, we controlled for "parental ability to cope with disruptive behavior." None of the hypothesis-driven analyses revealed a significant association with ODD dimensions and subtypes. Inadequate parenting behavior was significantly associated with all ODD dimensions and subtypes, most strongly with defiant/vindictive behaviors. In addition, the GWAS did not result in genome-wide significant findings but bioinformatics and literature analyses revealed that the proteins encoded by 28 of the 53 top-ranked genes functionally interact in a molecular landscape centered around Beta-catenin signaling and involved in the regulation of neurite outgrowth. Our findings provide new insights into the molecular basis of ODD and inform future genetic studies of oppositional behavior. (C) 2015 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley Periodicals, Inc.
C1 [Aebi, Marcel; IMAGE Consortium] Univ Hosp Psychiat, Dept Forens Psychiat Child & Youth Forens Serv, Neptunstr 60, CH-8032 Zurich, Switzerland.
   [Aebi, Marcel; Steinhausen, Hans-Christoph] Univ Zurich, Dept Child & Adolescent Psychiat, Zurich, Switzerland.
   [van Donkelaar, Marjolein M. J.; Poelmans, Geert; Franke, Barbara; van Hulzen, Kimm J. E.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Poelmans, Geert; Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Nijmegen, Netherlands.
   [Poelmans, Geert] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Donders Inst Brain Cognit & Behav, Dept Mol Anim Physiol, Nijmegen, Netherlands.
   [Sonuga-Barke, Edmund J. S.] Univ Southampton, Dept Psychol, Dev Brain Behav Lab, Southampton, Hants, England.
   [Sonuga-Barke, Edmund J. S.] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium.
   [Stringaris, Argyris] Kings Coll London, Inst Psychiat, London, England.
   [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
   [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
   [Faraone, Stephen V.] Univ Bergen, KG Jebsen Ctr Psychiat Disorders, Dept Biomed, Bergen, Norway.
   [Franke, Barbara] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Psychiat, Nijmegen, Netherlands.
   [Steinhausen, Hans-Christoph] Univ Basel, Dept Psychol Clin Psychol & Epidemiol, Basel, Switzerland.
   [Steinhausen, Hans-Christoph] Aalborg Univ Hosp, Hosp Psychiat, Res Unit Child & Adolescent Psychiat, Aalborg, Denmark.
RP Aebi, M (reprint author), Univ Hosp Psychiat, Dept Forens Psychiat Child & Youth Forens Serv, Neptunstr 60, CH-8032 Zurich, Switzerland.
EM marcel.aebi@uzh.ch
RI Franke, Barbara/D-4836-2009; 
OI Franke, Barbara/0000-0003-4375-6572; Faraone,
   Stephen/0000-0002-9217-3982
FU NIH [R01MH62873, R01MH081803]; European Union [602805, 603016, 278948];
   Wellcome Trust; Biomedical Research Centre of the National Institute of
   Health Research; K.G. Jebsen Centre for Research on Neuropsychiatric
   Disorders, University of Bergen, Bergen, Norway; European Community
   [602805]; NIMH [R13MH059126, R01MH094469]; Netherlands Organisation for
   Scientific Research (NWO) [016-130-669]
FX Grant sponsor: NIH; Grant numbers: R01MH62873, R01MH081803; Grant
   sponsor: European Union's Seventh Framework Programme for research,
   technological development and demonstration; Grant numbers: no 602805
   (AGGRESSOTYPE), no 603016 (MATRICS), no 278948 (TACTICS); Grant sponsor:
   Wellcome Trust and the Biomedical Research Centre of the National
   Institute of Health Research; Grant sponsor: K.G. Jebsen Centre for
   Research on Neuropsychiatric Disorders, University of Bergen, Bergen,
   Norway; Grant sponsor: European Community's Seventh Framework Programme
   (FP7/2007-2013); Grant number: no 602805; Grant sponsor: NIMH; Grant
   numbers: R13MH059126, R01MH094469; Grant sponsor: Netherlands
   Organisation for Scientific Research (NWO); Grant number: 016-130-669.
CR Aebi M, 2010, PSYCHOL MED, V40, P2089, DOI 10.1017/S0033291710000590
   Aebi M, 2013, J CHILD PSYCHOL PSYC, V54, P941, DOI 10.1111/jcpp.12039
   Alliey-Rodriguez N, 2011, PSYCHIAT GENET, V21, P190, DOI 10.1097/YPG.0b013e3283457a31
   Althoff RR, 2014, J CHILD PSYCHOL PSYC, V55, P1162, DOI 10.1111/jcpp.12233
   Angold A, 1999, J CHILD PSYCHOL PSYC, V40, P57, DOI 10.1017/S0021963098003448
   Anholt RRH, 2012, ANNU REV GENET, V46, P145, DOI 10.1146/annurev-genet-110711-155514
   Anney RJL, 2008, AM J MED GENET B, V147B, P1369, DOI 10.1002/ajmg.b.30871
   Beitchman JH, 2012, EUR CHILD ADOLES PSY, V21, P125, DOI 10.1007/s00787-012-0240-6
   Blair RJR, 2013, NAT REV NEUROSCI, V14, P786, DOI 10.1038/nrn3577
   Blom G, 1958, STAT ESTIMATES TRANS, P176
   Bralten J, 2013, J AM ACAD CHILD PSY, V52, P1204, DOI 10.1016/j.jaac.2013.08.020
   Brookes K, 2006, MOL PSYCHIATR, V11, P934, DOI 10.1038/sj.mp.4001869
   BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186
   Burke JD, 2008, J ABNORM CHILD PSYCH, V36, P679, DOI 10.1007/s10802-008-9219-7
   Burke JD, 2012, J CHILD PSYCHOL PSYC, V53, P1176, DOI 10.1111/j.1469-7610.2012.02598.x
   Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2
   Chen W, 2006, ATTENTION DEFICIT HY, P3, DOI 10.1016/B978-0-7506-7574-1.50008-6
   Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621
   Conners CK, 1997, CONNERS RATING SCALE, P217
   Coolidge FL, 2000, DEV NEUROPSYCHOL, V17, P273, DOI 10.1207/S15326942DN1703_1
   Copeland WE, 2009, ARCH GEN PSYCHIAT, V66, P764, DOI 10.1001/archgenpsychiatry.2009.85
   Fernandez de la Cruz L, 2015, J AM ACAD CHILD ADOL, V54, P62
   Dick DM, 2011, MOL PSYCHIATR, V16, P800, DOI 10.1038/mp.2010.73
   Dick DM, 2005, J ABNORM CHILD PSYCH, V33, P219, DOI 10.1007/s10802-005-1829-8
   DiLalla LF, 2009, DEV PSYCHOBIOL, V51, P451, DOI 10.1002/dev.20384
   Dowell RD, 2010, SCIENCE, V328, P469, DOI 10.1126/science.1189015
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   Duke AA, 2013, PSYCHOL BULL, V139, P1148, DOI 10.1037/a0031544
   Ebejer JL, 2013, TWIN RES HUM GENET, V16, P560, DOI 10.1017/thg.2013.12
   Ezpeleta L, 2012, J CHILD PSYCHOL PSYC, V53, P1128, DOI 10.1111/j.1469-7610.2012.02545.x
   FARAONE SV, 1991, PSYCHOL MED, V21, P109
   Ferreira MAR, 2009, BIOINFORMATICS, V25, P132, DOI 10.1093/bioinformatics/btn563
   Fetissov SO, 2006, BIOL PSYCHIAT, V60, P799, DOI 10.1016/j.biopsych.2006.03.081
   Ficks CA, 2014, BEHAV GENET, V44, P427, DOI 10.1007/s10519-014-9661-y
   Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196
   FRICK PJ, 1992, J CONSULT CLIN PSYCH, V60, P49, DOI 10.1037//0022-006X.60.1.49
   Galesloot TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095923
   Gherman Adrian, 2009, Human Genomics, V3, P143
   Gizer IR, 2009, HUM GENET, V126, P51, DOI 10.1007/s00439-009-0694-x
   Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x
   Haller J, 2013, BRAIN RES BULL, V93, P97, DOI 10.1016/j.brainresbull.2012.10.003
   Heils A, 1996, J NEUROCHEM, V66, P2621
   Hibar DP, 2015, NATURE, V520, P224, DOI 10.1038/nature14101
   Hinney A, 2011, AM J MED GENET B, V156B, P888, DOI 10.1002/ajmg.b.31246
   Holmans P, 2009, AM J HUM GENET, V85, P13, DOI 10.1016/j.ajhg.2009.05.011
   Holmes J, 2002, AM J MED GENET, V114, P150, DOI 10.1002/ajmg.10149
   Johansson A, 2012, GENES BRAIN BEHAV, V11, P214, DOI 10.1111/j.1601-183X.2011.00744.x
   Johansson A, 2012, PSYCHONEUROENDOCRINO, V37, P1546, DOI 10.1016/j.psyneuen.2012.02.009
   Kirley A, 2004, AM J MED GENET B, V131B, P38, DOI 10.1002/ajmg.b.30072
   Kolko DJ, 2010, J ABNORM PSYCHOL, V119, P713, DOI 10.1037/a0020910
   Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj.cdd.4400934
   Krieger FV, 2013, J AM ACAD CHILD PSY, V52, P389, DOI 10.1016/j.jaac.2013.01.004
   Kuny AV, 2013, J AM ACAD CHILD PSY, V52, P172, DOI 10.1016/j.jaac.2012.10.005
   Langbehn DR, 1998, ARCH GEN PSYCHIAT, V55, P821, DOI 10.1001/archpsyc.55.9.821
   Lavigne JV, 2013, DEV PSYCHOPATHOL, V25, P555, DOI 10.1017/S0954579412001241
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Lee SH, 2013, NAT GENET, V45, P984, DOI 10.1038/ng.2711
   Li HM, 2013, NAT CELL BIOL, V15, P773, DOI 10.1038/ncb2791
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Linzer DA, 2011, J STAT SOFTW, V42, P1
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Mandy W, 2014, J ABNORM CHILD PSYCH, V42, P291, DOI 10.1007/s10802-013-9778-0
   Mick E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087257
   Montoya ER, 2012, MOTIV EMOTION, V36, P65, DOI 10.1007/s11031-011-9264-3
   Muller UC, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-55
   Muller UC, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-54
   Nadder TS, 1998, BEHAV GENET, V28, P83, DOI 10.1023/A:1021686906396
   Neale BM, 2010, J AM ACAD CHILD PSY, V49, P884, DOI 10.1016/j.jaac.2010.06.008
   Neale BM, 2008, AM J MED GENET B, V147B, P1337, DOI 10.1002/ajmg.b.30866
   Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888
   Nimmrich I, 2001, CANCER LETT, V165, P71, DOI 10.1016/S0304-3835(01)00390-1
   Park J, 2010, PROG NEURO-PSYCHOPH, V34, P697, DOI 10.1016/j.pnpbp.2010.03.029
   Patterson GR., 1982, COERCIVE FAMILY PROC, P368
   Pavlov KA, 2012, J APPL GENET, V53, P61, DOI 10.1007/s13353-011-0069-6
   Penzes P, 2011, NAT NEUROSCI, V14, P285, DOI 10.1038/nn.2741
   Petty CR, 2009, J PSYCHIATR RES, V43, P345, DOI 10.1016/j.jpsychires.2008.03.010
   Pickrell JK, 2010, NATURE, V464, P768, DOI 10.1038/nature08872
   Poelmans G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.48
   Poelmans G, 2011, MOL PSYCHIATR, V16, P365, DOI 10.1038/mp.2010.105
   Poelmans G, 2011, AM J PSYCHIAT, V168, P365, DOI 10.1176/appi.ajp.2010.10070948
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   R Development Core Team, 2011, R LANG ENV STAT COMP, P3604
   Ramklint M, 2001, EUR J PSYCHIAT, V15, P245
   Rusch N, 2007, NEUROIMAGE, V35, P738, DOI 10.1016/j.neuroimage.2006.12.007
   Ryding E, 2008, PROG BRAIN RES, V172, P307, DOI 10.1016/S0079-6123(08)00915-1
   Sagazio A, 2011, GROWTH HORM IGF RES, V21, P76, DOI 10.1016/j.ghir.2011.01.002
   Sanchez-Mora C, 2015, NEUROPSYCHOPHARMACOL, V40, P915, DOI 10.1038/npp.2014.267
   Saxena K, 2012, J CHILD ADOL PSYCHOP, V22, P112, DOI 10.1089/cap.2011.0063
   Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774
   Sneddon LU, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018181
   Stalenheim EG, 2004, PSYCHIAT RES, V121, P281, DOI 10.1016/j.psychres.2003.07.002
   Stergiakouli E, 2012, AM J PSYCHIAT, V169, P186, DOI 10.1176/appi.ajp.2011.11040551
   Stringaris A, 2012, AM J PSYCHIAT, V169, P47, DOI 10.1176/appi.ajp.2011.10101549
   Stringaris A, 2009, AM J PSYCHIAT, V166, P1048, DOI 10.1176/appi.ajp.2009.08121849
   Stringaris A, 2009, J CHILD PSYCHOL PSYC, V50, P216, DOI 10.1111/j.1469-7610.2008.01989.x
   Stringaris A, 2009, J AM ACAD CHILD PSY, V48, P404, DOI 10.1097/CHI.0b013e3181984f30
   TAYLOR E, 1986, BRIT J PSYCHIAT, V149, P760, DOI 10.1192/bjp.149.6.760
   Thissen AJAM, 2015, AM J MED GENET B, V9999B, P1
   Tielbeek JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045086
   Trent S, 2009, EUR NEUROPSYCHOPHARM, V19, P876, DOI 10.1016/j.euroneuro.2009.07.003
   Valzelli L., 1981, PSYCHOBIOLOGY AGGRES
   Vassos E, 2014, MOL PSYCHIATR, V19, P471, DOI 10.1038/mp.2013.31
   Veyrieras JB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000214
   Yang L, 2013, AM J MED GENET B, V162B, P419, DOI 10.1002/ajmg.b.32169
   Zai CC, 2012, PSYCHIAT RES, V200, P784, DOI 10.1016/j.psychres.2012.07.031
   Zayats T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122501
NR 107
TC 1
Z9 1
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUL
PY 2016
VL 171
IS 5
SI SI
BP 573
EP 588
DI 10.1002/ajmg.b.32346
PG 16
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA DV4DA
UT WOS:000382873900003
PM 26184070
ER

PT J
AU LoParo, D
   Johansson, A
   Walum, H
   Westberg, L
   Santtila, P
   Waldman, I
AF LoParo, Devon
   Johansson, Ada
   Walum, Hasse
   Westberg, Lars
   Santtila, Pekka
   Waldman, Irwin
TI Rigorous Tests of Gene-Environment Interactions in a Lab Study of the
   Oxytocin Receptor Gene (OXTR), Alcohol Exposure, and Aggression
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE oxytocin; aggression; alcohol
ID LABORATORY AGGRESSION; REACTIVE AGGRESSION; CONDUCT DISORDER;
   SOCIAL-BEHAVIOR; TRAIT ANGER; MALE RATS; HUMANS; PROVOCATION;
   VASOPRESSIN; ATTENTION
AB Naturalistic studies of gene-environment interactions (G X E) have been plagued by several limitations, including difficulty isolating specific environmental risk factors from other correlated aspects of the environment, gene-environment correlation (r(GE)), and the use of a single genetic variant to represent the influence of a gene. We present results from 235 Finnish young men in two lab studies of aggression and alcohol challenge that attempt to redress these limitations of the extant G X E literature. Specifically, we use a latent variable modeling approach in an attempt to more fully account for genetic variation across the oxytocin receptor gene (OXTR) and to robustly test its main effects on aggression and its interaction with alcohol exposure. We also modeled aggression as a latent variable comprising various indices, including the average and maximum levels of aggression, the earliest trial on which aggression was expressed, and the proportion of trials on which the minimum and maximum levels of aggression were expressed. The best fitting model for the genetic variation across OXTR included six factors derived from an exploratory factor analysis, roughly corresponding to six haplotype blocks. Aggression levels were higher on trials in which participants were administered alcohol, won, or were provoked. There was a significant main effect of OXTR on aggression across studies after controlling for covariates. The interaction of OXTR and alcohol was also significant across studies, such that OXTR had stronger effects on aggression in the alcohol administration condition. (C) 2015 Wiley Periodicals, Inc.
C1 [LoParo, Devon; Walum, Hasse; Waldman, Irwin] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA.
   [Johansson, Ada; Westberg, Lars] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden.
   [Johansson, Ada; Santtila, Pekka] Abo Akad Univ, Dept Psychol & Logoped, Turku, Finland.
   [Walum, Hasse] Emory Univ, Yerkes Natl Primate Res Ctr, Ctr Translat Social Neurosci, Atlanta, GA 30322 USA.
RP LoParo, D (reprint author), 36 Eagle Row, Atlanta, GA 30306 USA.
EM dloparo@emory.edu
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Anderson CA, 1999, CURR DIR PSYCHOL SCI, V8, P3, DOI 10.1111/1467-8721.00002
   Anderson C. A., 1997, REV GEN PSYCHOL, V1, P19, DOI [10.1037/1089-2680.1.1.19, DOI 10.1037/1089-2680.1.1.19]
   Bakermans-Kranenburg MJ, 2008, DEV PSYCHOL, V44, P293, DOI 10.1037/0012-1649.44.1.293
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bettencourt BA, 1996, PSYCHOL BULL, V119, P422, DOI 10.1037/0033-2909.119.3.422
   Blair RJR, 2001, J NEUROL NEUROSUR PS, V71, P727, DOI 10.1136/jnnp.71.6.727
   BOND A, 1986, BIOL PSYCHOL, V22, P69, DOI 10.1016/0301-0511(86)90021-9
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005
   Burt SA, 2009, PSYCHOL BULL, V135, P608, DOI 10.1037/a0015702
   BUSHMAN BJ, 1990, PSYCHOL BULL, V107, P341, DOI 10.1037//0033-2909.107.3.341
   Bushman B. J., 1998, HUMAN AGGRESSION THE, P23, DOI 10.1016/B978-012278805-5/50003-1
   Calcagnoli F, 2014, HORM BEHAV, V65, P427, DOI 10.1016/j.yhbeh.2014.03.008
   Calcagnoli F, 2013, PSYCHOPHARMACOLOGY, V229, P639, DOI 10.1007/s00213-013-3124-7
   Caldwell HK, 2012, ADV EXP MED BIOL, V739, P187, DOI 10.1007/978-1-4614-1704-0_12
   Carlson M, 1989, SOCIAL PSYCHOL B, V15, P377
   CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9
   Chen FS, 2012, SOC PSYCHOL PERS SCI, V3, P93, DOI 10.1177/1948550611410325
   Cherek DR, 2000, AGGRESSIVE BEHAV, V26, P291, DOI 10.1002/1098-2337(2000)26:4<291::AID-AB2>3.0.CO;2-9
   Chermack ST, 1997, CLIN PSYCHOL REV, V17, P621, DOI 10.1016/S0272-7358(97)00038-X
   Clutton-Brock T., 1988, REPROD SUCCESS STUDI
   Coccaro EF, 2010, NEUROPSYCHOPHARMACOL, V35, P435, DOI 10.1038/npp.2009.148
   Consiglio AR, 2005, PHYSIOL BEHAV, V85, P354, DOI 10.1016/j.physbeh.2005.05.002
   Cosgrove VE, 2011, J ABNORM CHILD PSYCH, V39, P109, DOI 10.1007/s10802-010-9444-8
   Cuthbert BN, 2014, WORLD PSYCHIATRY, V13, P28, DOI 10.1002/wps.20087
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   DeVries AC, 1997, J NEUROENDOCRINOL, V9, P363, DOI 10.1046/j.1365-2826.1997.t01-1-00589.x
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   DREWS C, 1993, BEHAVIOUR, V125, P283, DOI 10.1163/156853993X00290
   Duncan LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Exum ML, 2006, J CRIM JUST, V34, P131, DOI 10.1016/jjcrimjus.2006.01.008
   Ferguson CJ, 2009, J EXP CRIMINOL, V5, P121, DOI 10.1007/s11292-009-9069-5
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Fetissov SO, 2006, BIOL PSYCHIAT, V60, P799, DOI 10.1016/j.biopsych.2006.03.081
   FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592
   Giancola PR, 2008, AGGRESSIVE BEHAV, V34, P214, DOI 10.1002/ab.20235
   GIANCOLA PR, 1995, AGGRESSIVE BEHAV, V21, P199, DOI 10.1002/1098-2337(1995)21:3<199::AID-AB2480210303>3.0.CO;2-Q
   Grunebaum MF, 2006, BIPOLAR DISORD, V8, P496, DOI 10.1111/j.1399-5618.2006.00349.x
   Harmon AC, 2002, J NEUROENDOCRINOL, V14, P963, DOI 10.1046/j.1365-2826.2002.00863.x
   HARTMANN DP, 1969, J PERS SOC PSYCHOL, V11, P280, DOI 10.1037/h0027071
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hoaken PNS, 2000, ALCOHOL ALCOHOLISM, V35, P471, DOI 10.1093/alcalc/35.5.471
   Ito TA, 1996, PSYCHOL BULL, V120, P60, DOI 10.1037//0033-2909.120.1.60
   Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258
   Johansson A, 2012, GENES BRAIN BEHAV, V11, P214, DOI 10.1111/j.1601-183X.2011.00744.x
   Johansson A, 2013, TWIN RES HUM GENET, V16, P150, DOI 10.1017/thg.2012.108
   Johansson A, 2012, PSYCHONEUROENDOCRINO, V37, P1546, DOI 10.1016/j.psyneuen.2012.02.009
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   Keller MC, 2014, BIOL PSYCHIAT, V75, P18, DOI 10.1016/j.biopsych.2013.09.006
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kramer UM, 2008, J COGNITIVE NEUROSCI, V20, P1464, DOI 10.1162/jocn.2008.20103
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Li MX, 2011, AM J HUM GENET, V88, P283, DOI 10.1016/j.ajhg.2011.01.019
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Lubin DA, 2003, BEHAV NEUROSCI, V117, P195, DOI 10.1037/0735-7044.117.2.195
   MALAMUTH NM, 1983, J PERS SOC PSYCHOL, V45, P432, DOI 10.1037/0022-3514.45.2.432
   MALAMUTH NM, 1986, AGGRESSIVE BEHAV, V12, P129, DOI 10.1002/1098-2337(1986)12:2<129::AID-AB2480120207>3.0.CO;2-P
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037//0033-2909.114.2.376
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McMurray MS, 2008, NEUROTOXICOL TERATOL, V30, P475, DOI 10.1016/j.ntt.2008.07.001
   MURPHY DA, 1992, J ABNORM CHILD PSYCH, V20, P451, DOI 10.1007/BF00916809
   Muthen L.K., 1998, MPLUS USERS GUIDE
   Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901
   Nelson RJ, 2007, NAT REV NEUROSCI, V8, P536, DOI 10.1038/nrn2174
   Parrott DJ, 2002, J STUD ALCOHOL, V63, P196
   Parrott DJ, 2004, ALCOHOL CLIN EXP RES, V28, P855, DOI 10.1097/01.ALC.0000128226.92708.21
   PELHAM WE, 1991, J ABNORM CHILD PSYCH, V19, P407, DOI 10.1007/BF00919086
   Ragnauth AK, 2005, GENES BRAIN BEHAV, V4, P229, DOI 10.1111/j.1601-183X.2005.00118.x
   Reidy DE, 2007, J RES PERS, V41, P1244, DOI 10.1016/j.jrp.2007.03.001
   Rhee SH, 2011, HUMAN AGGRESSION VIO, P143, DOI 10.1037/12346-008
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Sakai JT, 2012, PSYCHIAT GENET, V22, P99, DOI 10.1097/YPG.0b013e32834c0cb2
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774
   SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972
   Tackett JL, 2005, J ABNORM PSYCHOL, V114, P483, DOI 10.1037/0021-843X.114.3.483
   Tauber M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-47
   TAYLOR SP, 1967, J PERS, V35, P297, DOI 10.1111/j.1467-6494.1967.tb01430.x
   van IJzendoorn MH, 2011, NAT REV GENET, V12, DOI 10.1038/nrg2764-c1
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Von Der Pahlen B, 2008, J STUD ALCOHOL DRUGS, V69, P616
   Waldman ID, 2007, DEV PSYCHOPATHOL, V19, P1117, DOI 10.1017/S0954579407000570
   Walum H, 2011, DNA SOCIAL COGNITION
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Waschbusch DA, 2002, J ABNORM CHILD PSYCH, V30, P641, DOI 10.1023/A:1020867831811
   WHO, 2000, GUIDELINES COMMUNITY
   Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   WOLFE BM, 1971, PSYCHON SCI, V24, P193
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young SW, 1998, ADV EXP MED BIOL, V449, P231
   Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128
   Zeichner A, 1999, PSYCHOL REP, V85, P1229, DOI 10.2466/PR0.85.7.1229-1237
NR 102
TC 2
Z9 2
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUL
PY 2016
VL 171
IS 5
SI SI
BP 589
EP 602
DI 10.1002/ajmg.b.32359
PG 14
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA DV4DA
UT WOS:000382873900004
PM 26250573
ER

PT J
AU Fernandez-Castillo, N
   Cormand, B
AF Fernandez-Castillo, Noelia
   Cormand, Bru
TI Aggressive Behavior in Humans: Genes and Pathways Identified Through
   Association Studies
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Review
DE aggression; genetics; association studies; GWAS; candidate genes
ID SEROTONIN TRANSPORTER PROMOTER; MONOAMINE-OXIDASE-A; ANTISOCIAL
   PERSONALITY-DISORDER; GENOME-WIDE ASSOCIATION; OXYTOCIN RECEPTOR GENE;
   CHILDHOOD-ONSET AGGRESSION; ANGER-RELATED TRAITS; OPPOSITIONAL DEFIANT
   DISORDER; FAMILY-BASED ASSOCIATION; MAOA-LPR GENOTYPE
AB Aggressive behavior has both genetic and environmental components. Many association studies have been performed to identify genetic factors underlying aggressive behaviors in humans. In this review we summarize the previous work performed in this field, considering both candidate gene (CGAS) and genome-wide association studies (GWAS), excluding those performed in samples where the primary diagnosis is a psychiatric or neurological disorder other than an aggression-related phenotype. Subsequently, we have studied the enrichment of pathways and functions in GWAS data. The results of our searches show that most CGAS have identified associations with genes involved in dopaminergic and serotonergic neurotransmission and in hormone regulation. On the other hand, GWAS have not yet identified genome-wide significant associations, but top nominal findings are related to several signaling pathways, such as axon guidance or estrogen receptor signaling, and also to neurodevelopmental processes and synaptic plasticity. Future studies should use larger samples, homogeneous phenotypes and standardized measurements to identify genes that underlie aggressive behaviors in humans. (C) 2016 Wiley Periodicals, Inc.
C1 [Fernandez-Castillo, Noelia; Cormand, Bru] Univ Barcelona, Fac Biol, Dept Genet, Avinguda Diagonal 643,Edifici Prevosti,3a Planta, E-08028 Barcelona, Catalonia, Spain.
   [Fernandez-Castillo, Noelia; Cormand, Bru] IBUB, Catalonia, Spain.
   [Fernandez-Castillo, Noelia; Cormand, Bru] CIBERER, Barcelona, Spain.
RP Fernandez-Castillo, N; Cormand, B (reprint author), Univ Barcelona, Fac Biol, Dept Genet, Avinguda Diagonal 643,Edifici Prevosti,3a Planta, E-08028 Barcelona, Catalonia, Spain.
EM noefernandez@ub.edu; bcormand@ub.edu
FU Centro de Investigacion Biomedica en Red de Enfermedades Raras
   (CIBERER); Spanish "Ministerio de Economia y Competitividad"
   [SAF2012-33484]; AGAUR [2014SGR932]; European Community [602805]
FX Grant sponsor: Centro de Investigacion Biomedica en Red de Enfermedades
   Raras (CIBERER); Grant sponsor: Spanish "Ministerio de Economia y
   Competitividad"; Grant number: SAF2012-33484; Grant sponsor: AGAUR;
   Grant number: 2014SGR932; Grant sponsor: European Community's Seventh
   Framework Programme; Grant number: 602805.
CR Albaugh MD, 2010, J AM ACAD CHILD PSY, V49, P841, DOI 10.1016/j.jaac.2010.05.015
   Anholt RRH, 2012, ANNU REV GENET, V46, P145, DOI 10.1146/annurev-genet-110711-155514
   Anney RJL, 2008, AM J MED GENET B, V147B, P1369, DOI 10.1002/ajmg.b.30871
   Antypa N, 2013, EUR ARCH PSY CLIN N, V263, P393, DOI 10.1007/s00406-012-0378-8
   Armstrong TA, 2014, PSYCHIAT GENET, V24, P164, DOI 10.1097/YPG.0000000000000033
   Aslund C, 2013, AGGRESSIVE BEHAV, V39, P52, DOI 10.1002/ab.21451
   Baca-Garcia E, 2004, PSYCHIAT RES, V126, P99, DOI 10.1016/j.psychres.2003.10.007
   Bagri A, 2002, NEURON, V33, P233, DOI 10.1016/S0896-6273(02)00561-5
   Banlaki Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117792
   Basoglu C, 2011, CAN J PSYCHIAT, V56, P341
   Beach SRH, 2010, J FAM PSYCHOL, V24, P12, DOI 10.1037/a0018074
   Beaver KM, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-30
   Beaver KM, 2014, PSYCHIAT QUART, V85, P257, DOI 10.1007/s11126-013-9287-x
   Beaver KM, 2010, COMPR PSYCHIAT, V51, P130, DOI 10.1016/j.comppsych.2009.03.010
   Beaver Kevin M, 2008, Biodemography Soc Biol, V54, P47, DOI 10.1080/19485565.2008.9989131
   Beaver KM, 2010, INT J OFFENDER THER, V54, P22, DOI 10.1177/0306624X08325349
   Beaver KM, 2009, J GENET PSYCHOL, V170, P101, DOI 10.3200/GNTP.170.2.101-114
   Beitchman JH, 2006, AM J PSYCHIAT, V163, P1103, DOI 10.1176/appi.ajp.163.6.1103
   Beitchman JH, 2012, EUR CHILD ADOLESC PS
   Berggard C, 2003, NEUROSCI LETT, V347, P196, DOI 10.1016/S0304-3940(03)00699-2
   Bevilacqua L, 2012, ARCH GEN PSYCHIAT, V69, P62, DOI 10.1001/archgenpsychiatry.2011.152
   Boutwell Brian B, 2008, Crim Behav Ment Health, V18, P59, DOI 10.1002/cbm.678
   Brody GH, 2011, DEV PSYCHOPATHOL, V23, P617, DOI 10.1017/S0954579411000046
   BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186
   Buchmann AF, 2014, PSYCHOPHARMACOLOGY, V231, P3089, DOI 10.1007/s00213-014-3484-7
   Burt SA, 2008, AGGRESSIVE BEHAV, V34, P437, DOI 10.1002/ab.20251
   Burt SA, 2009, CLIN PSYCHOL REV, V29, P163, DOI 10.1016/j.cpr.2008.12.004
   Byrd AL, 2014, BIOL PSYCHIAT, V75, P9, DOI 10.1016/j.biopsych.2013.05.004
   Cadoret RJ, 2003, COMPR PSYCHIAT, V44, P88, DOI 10.1053/comp.2003.50018
   Calati R, 2011, J PSYCHIATR RES, V45, P309, DOI 10.1016/j.jpsychires.2010.07.004
   CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602
   Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290
   Caspi A, 2008, ARCH GEN PSYCHIAT, V65, P203, DOI 10.1001/archgenpsychiatry.2007.24
   Chen BF, 2014, J MOL NEUROSCI, V52, P481, DOI 10.1007/s12031-013-0160-z
   Chen TJH, 2005, MED HYPOTHESES, V65, P703, DOI 10.1016/j.mehy.2005.04.037
   Cheng D, 2006, PSYCHONEUROENDOCRINO, V31, P548, DOI 10.1016/j.psyneuen.2005.11.004
   Cicchetti D, 2012, DEV PSYCHOPATHOL, V24, P907, DOI 10.1017/S0954579412000442
   Comings DE, 2000, PSYCHIATR GENET, V10, P39, DOI 10.1097/00041444-200010010-00007
   Conner TS, 2010, AM J MED GENET B, V153B, P67, DOI 10.1002/ajmg.b.30955
   Conway CC, 2012, J CLIN CHILD ADOLESC, V41, P53, DOI 10.1080/15374416.2012.632351
   Craig IW, 2007, BIOESSAYS, V29, P227, DOI 10.1002/bies.20538
   Craig IW, 2009, HUM GENET, V126, P101, DOI 10.1007/s00439-009-0695-9
   Arias JMC, 2011, PSYCHIAT GENET, V21, P115, DOI 10.1097/YPG.0b013e3283437175
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P21, DOI 10.1017/S0954579413000485
   Dadds MR, 2013, PSYCHIAT GENET, V23, P251, DOI 10.1097/YPG.0b013e3283650f83
   Damberg M, 2000, MOL PSYCHIATR, V5, P220, DOI 10.1038/sj.mp.4000691
   Davidge KM, 2004, PSYCHIAT GENET, V14, P143, DOI 10.1097/00041444-200409000-00004
   Derringer J, 2010, BEHAV GENET, V40, P639, DOI 10.1007/s10519-010-9358-9
   DeYoung CG, 2010, PSYCHIAT GENET, V20, P20, DOI 10.1097/YPG.0b013e32833511e4
   Dick DM, 2008, ARCH GEN PSYCHIAT, V65, P310
   Dick DM, 2011, PSYCHOL SCI, V22, P481, DOI 10.1177/0956797611403318
   Dick DM, 2009, ARCH GEN PSYCHIAT, V66, P649, DOI 10.1001/archgenpsychiatry.2009.48
   Dijkstra JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054821
   Dmitrieva J, 2011, SOC COGN AFFECT NEUR, V6, P82, DOI 10.1093/scan/nsq020
   Edwards AC, 2010, J CHILD PSYCHOL PSYC, V51, P679, DOI 10.1111/j.1469-7610.2009.02196.x
   Eisenberger NI, 2007, BIOL PSYCHIAT, V61, P1100, DOI 10.1016/j.biopsych.2006.08.007
   Evans J, 2000, PSYCHOL MED, V30, P1327, DOI 10.1017/S0033291799002822
   Farbiash T, 2014, J ABNORM CHILD PSYCH, V42, P489, DOI 10.1007/s10802-013-9791-3
   Fergusson DM, 2012, BRIT J PSYCHIAT, V200, P116, DOI 10.1192/bjp.bp.111.093328
   Fergusson DM, 2011, BRIT J PSYCHIAT, V198, P457, DOI 10.1192/bjp.bp.110.086991
   Ficks CA, 2014, BEHAV GENET, V44, P427, DOI 10.1007/s10519-014-9661-y
   Flory JD, 2007, PSYCHIAT GENET, V17, P344
   Fogel BL, 2012, HUM MOL GENET, V21, P4171, DOI 10.1093/hmg/dds240
   Foley DL, 2004, ARCH GEN PSYCHIAT, V61, P738, DOI 10.1001/archpsyc.61.7.738
   Fowler T, 2009, PSYCHIAT GENET, V19, P312, DOI 10.1097/YPG.0b013e3283328df4
   Frazzetto G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000486
   Gallardo-Pujol D, 2013, GENES BRAIN BEHAV, V12, P140, DOI 10.1111/j.1601-183X.2012.00868.x
   Garcia LF, 2010, PSYCHIAT RES, V177, P161, DOI 10.1016/j.psychres.2008.12.018
   Gerra G, 2005, J NEURAL TRANSM, V112, P1397, DOI 10.1007/s00702-004-0268-y
   Giegling I, 2008, AM J MED GENET B, V147B, P308, DOI 10.1002/ajmg.b.30599
   Giegling I, 2006, J AFFECT DISORDERS, V96, P75, DOI 10.1016/j.jad.2006.05.016
   Gietl A, 2007, EUR NEUROPSYCHOPHARM, V17, P410, DOI 10.1016/j.euroneuro.2006.11.004
   Gonda X, 2009, EUR ARCH PSY CLIN N, V259, P106, DOI 10.1007/s00406-008-0842-7
   Gorodetsky E, 2014, GENES BRAIN BEHAV, V13, P543, DOI 10.1111/gbb.12140
   Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018
   Greenberg BD, 2000, AM J MED GENET, V96, P202, DOI 10.1002/(SICI)1096-8628(20000403)96:2<202::AID-AJMG16>3.0.CO;2-J
   Gunter TD, 2010, BEHAV SCI LAW, V28, P148, DOI 10.1002/bsl.923
   Guo G, 2008, EUR J HUM GENET, V16, P626, DOI 10.1038/sj.ejhg.5201999
   Guo G, 2007, HUM GENET, V121, P125, DOI 10.1007/s00439-006-0244-8
   Gyurak A, 2013, EMOTION, V13, P25, DOI 10.1037/a0029616
   Haberstick BC, 2005, AM J MED GENET B, V135B, P59, DOI 10.1002/ajmg.b.30176
   Haberstick BC, 2006, BIOL PSYCHIAT, V59, P836, DOI 10.1016/j.biopsych.2005.10.008
   Haberstick BC, 2014, BIOL PSYCHIAT, V75, P25, DOI 10.1016/j.biopsych.2013.03.028
   Haenold R, 2014, J CELL SCI, V127, P3052, DOI 10.1242/jcs.140731
   Hakulinen C, 2013, J BEHAV MED, V36, P583, DOI 10.1007/s10865-012-9452-y
   Hamshere ML, 2013, AM J PSYCHIAT, V170, P909, DOI 10.1176/appi.ajp.2013.12081129
   Hennig J, 2005, BEHAV NEUROSCI, V119, P16, DOI 10.1037/0735-7044.119.1.16
   Hess C, 2009, J NEURAL TRANSM, V116, P121, DOI 10.1007/s00702-008-0138-0
   Hirata Y, 2013, AGGRESSIVE BEHAV, V39, P45, DOI 10.1002/ab.21448
   Hohmann S, 2009, J NEURAL TRANSM, V116, P1621, DOI 10.1007/s00702-009-0290-1
   Huizinga D, 2006, BIOL PSYCHIAT, V60, P677, DOI 10.1016/j.biopsych.2005.12.022
   Jensen KP, 2009, MOL PSYCHIATR, V14, P381, DOI 10.1038/mp.2008.15
   Jonsson EG, 2001, PSYCHIATR GENET, V11, P19, DOI 10.1097/00041444-200103000-00004
   Jorm AF, 2001, AM J MED GENET, V105, P346, DOI 10.1002/ajmg.1355
   Kang JI, 2008, NEUROSCI LETT, V430, P252, DOI 10.1016/j.neulet.2007.11.005
   Keltikangas-Jarvinen L, 2008, GENES BRAIN BEHAV, V7, P46, DOI 10.1111/j.1601-183X.2007.00324.x
   Kieling C, 2013, J CHILD PSYCHOL PSYC, V54, P298, DOI 10.1111/jcpp.12022
   Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851
   Kirley A, 2004, AM J MED GENET B, V131B, P38, DOI 10.1002/ajmg.b.30072
   Kourmouli N, 2013, PSYCHIAT GENET, V23, P188, DOI 10.1097/YPG.0b013e3283643629
   Kretschmer T, 2014, J RES ADOLESCENCE, V24, P177, DOI 10.1111/jora.12050
   Kuepper Y, 2013, BEHAV BRAIN RES, V247, P73, DOI 10.1016/j.bbr.2013.03.002
   Kulikova MA, 2008, B EXP BIOL MED+, V145, P62, DOI 10.1007/s10517-008-0006-9
   Latendresse SJ, 2011, CHILD DEV, V82, P1797, DOI 10.1111/j.1467-8624.2011.01640.x
   Lee SS, 2007, AM J MED GENET B, V144B, P310, DOI 10.1002/ajmg.b.30447
   Liao DL, 2004, NEUROPSYCHOBIOLOGY, V50, P284, DOI 10.1159/000080953
   Lin L, 2005, MOL CELL NEUROSCI, V28, P547, DOI 10.1016/j.mcn.2004.11.009
   Logue MW, 2013, PSYCHONEUROENDOCRINO, V38, P2249, DOI 10.1016/j.psyneuen.2013.04.013
   Lopez-Castroman J, 2014, PSYCHOL MED, V44, P3059, DOI 10.1017/S0033291714000646
   Luppino D, 2014, PSYCHIAT GENET, V24, P185, DOI 10.1097/YPG.0000000000000036
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Malik AI, 2014, PSYCHIAT GENET, V24, P201, DOI 10.1097/YPG.0000000000000044
   Malmberg K, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-28
   Mann JJ, 2008, J AFFECT DISORDERS, V106, P117, DOI 10.1016/j.jad.2007.05.031
   Manuck SB, 1999, BIOL PSYCHIAT, V45, P603, DOI 10.1016/S0006-3223(98)00375-8
   Manuck SB, 2002, PHYSIOL BEHAV, V77, P705, DOI 10.1016/S0031-9384(02)00922-8
   Manuck SB, 2000, PSYCHIAT RES, V95, P9, DOI 10.1016/S0165-1781(00)00162-1
   Marsman R, 2013, PSYCHIAT RES, V209, P66, DOI 10.1016/j.psychres.2012.10.022
   Martel MM, 2011, J ABNORM CHILD PSYCH, V39, P1, DOI 10.1007/s10802-010-9439-5
   McGrath LM, 2012, ARCH WOMEN MENT HLTH, V15, P269, DOI 10.1007/s00737-012-0286-y
   Merjonen P, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.13
   Mick E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087257
   Mick E, 2011, J AM ACAD CHILD PSY, V50, P807, DOI 10.1016/j.jaac.2011.05.001
   Mik HM, 2007, PSYCHIAT GENET, V17, P11, DOI 10.1097/YPG.0b013e3280114103
   Miodovnik A, 2012, PSYCHIAT GENET, V22, P115, DOI 10.1097/YPG.0b013e328351850b
   Moons WG, 2014, EMOTION, V14, P562, DOI 10.1037/a0035503
   Moul C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056619
   Musci RJ, 2014, PREV SCI, V15, P831, DOI 10.1007/s11121-013-0441-3
   Nikitopoulos J, 2014, J PSYCHIATR RES, V59, P53, DOI 10.1016/j.jpsychires.2014.08.012
   Nilsson KW, 2006, BIOL PSYCHIAT, V59, P121, DOI 10.1016/j.biopsych.2005.06.024
   Nobile M, 2007, DEV PSYCHOPATHOL, V19, P1147, DOI 10.1017/S0954579407000594
   Pavlov KA, 2012, J APPL GENET, V53, P61, DOI 10.1007/s13353-011-0069-6
   Perroud N, 2010, GENES BRAIN BEHAV, V9, P193, DOI 10.1111/j.1601-183X.2009.00547.x
   Persson ML, 2000, PSYCHIAT RES, V95, P1, DOI 10.1016/S0165-1781(00)00160-8
   Philibert RA, 2011, BIOL PSYCHOL, V87, P366, DOI 10.1016/j.biopsycho.2011.04.007
   Pickles A, 2013, J CHILD PSYCHOL PSYC, V54, P1308, DOI 10.1111/jcpp.12081
   Pingault JB, 2013, MOL PSYCHIATR, V18, P1151, DOI 10.1038/mp.2012.173
   Prichard ZM, 2007, PSYCHIAT GENET, V17, P299, DOI 10.1097/YPG.0b013e32816ebc9e
   Prom-Wormley EC, 2009, PSYCHOL MED, V39, P579, DOI 10.1017/S0033291708004170
   Qian QJ, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-8
   Rajender S, 2008, INT J LEGAL MED, V122, P367, DOI 10.1007/s00414-008-0225-7
   Reif A, 2007, NEUROPSYCHOPHARMACOL, V32, P2375, DOI 10.1038/sj.npp.1301359
   Reif A, 2009, ARCH GEN PSYCHIAT, V66, P41, DOI 10.1001/archgenpsychiatry.2008.510
   Reti IM, 2011, COMPR PSYCHIAT, V52, P188, DOI 10.1016/j.comppsych.2010.05.005
   Retz W, 2004, BEHAV SCI LAW, V22, P415, DOI 10.1002/bsl.589
   Retz W, 2003, J NEURAL TRANSM, V110, P561, DOI 10.1007/s00702-002-0805-5
   Retz W, 2010, J NEURAL TRANSM, V117, P321, DOI 10.1007/s00702-009-0352-4
   Reuter M, 2005, AM J MED GENET B, V134B, P20, DOI 10.1002/ajmg.30153
   Reuter M, 2009, BEHAV BRAIN RES, V202, P179, DOI 10.1016/j.bbr.2009.03.032
   Richter S, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00175
   Robinson MD, 2010, J PERS, V78, P1, DOI 10.1111/j.1467-6494.2009.00606.x
   Rotondo A, 1999, MOL PSYCHIATR, V4, P360, DOI 10.1038/sj.mp.4000578
   Rujescu D, 2002, MOL PSYCHIATR, V7, P1023, DOI 10.1038/sj.mp.4001128
   Rujescu D, 2003, BIOL PSYCHIAT, V54, P34, DOI 10.1016/S0006-3223(03)01831-0
   Sadeh N, 2013, J ABNORM PSYCHOL, V122, P167, DOI 10.1037/a0029866
   Sakai JT, 2007, PSYCHIAT GENET, V17, P207, DOI 10.1097/YPG.0b013e32809913c8
   Sakai JT, 2006, AM J MED GENET B, V141B, P825, DOI 10.1002/ajmg.b.30278
   Sakai JT, 2012, PSYCHIAT GENET, V22, P99, DOI 10.1097/YPG.0b013e32834c0cb2
   Sakai JT, 2010, PSYCHIAT GENET, V20, P199, DOI 10.1097/YPG.0b013e32833a20f1
   Schlomer GL, 2015, J YOUTH ADOLESCENCE, V44, P581, DOI 10.1007/s10964-014-0198-4
   Serretti A, 2007, AM J MED GENET B, V144B, P291, DOI 10.1002/ajmg.b.30432
   Shehzad Z, 2012, NEUROIMAGE, V60, P2158, DOI 10.1016/j.neuroimage.2012.01.097
   Sjoberg RL, 2007, AM J MED GENET B, V144B, P159, DOI 10.1002/ajmg.b.30360
   Smearman EL, 2015, DEV PSYCHOPATHOL, V27, P309, DOI 10.1017/S0954579414000649
   Sokolowski M, 2010, MOL PSYCHIATR, V15, P10, DOI 10.1038/mp.2009.70
   Sonuga-Barke EJS, 2008, AM J MED GENET B, V147B, P1359, DOI 10.1002/ajmg.b.30860
   Stephens SH, 2012, BEHAV GENET, V42, P402, DOI 10.1007/s10519-011-9514-x
   Sysoeva OV, 2009, INT J PSYCHOPHYSIOL, V72, P173, DOI 10.1016/j.ijpsycho.2008.12.005
   Terracciano A, 2009, AM J MED GENET B, V150B, P1070, DOI 10.1002/ajmg.b.30932
   Tielbeek JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045086
   Tiihonen J, 2015, MOL PSYCHIATR, V20, P786, DOI 10.1038/mp.2014.130
   Tuvblad C, 2011, ADV GENET, V75, P171, DOI 10.1016/B978-0-12-380858-5.00007-1
   van der Vegt EJM, 2009, PSYCHIAT GENET, V19, P209, DOI 10.1097/YPG.0b013e32832a5084
   Vassos E, 2014, MOL PSYCHIATR, V19, P471, DOI 10.1038/mp.2013.31
   Verhoeven FEA, 2012, BRAIN BEHAV, V2, P806, DOI 10.1002/brb3.96
   Vermeersch H, 2013, HORM BEHAV, V63, P447, DOI 10.1016/j.yhbeh.2012.11.017
   Verona E, 2006, BIOL PSYCHOL, V71, P33, DOI 10.1016/j.biopsycho.2005.02.001
   Veroude K, 2015, AM J MED GENET B
   Viding E, 2010, J CHILD PSYCHOL PSYC, V51, P780, DOI 10.1111/j.1469-7610.2010.02236.x
   Wakschlag LS, 2010, MOL PSYCHIATR, V15, P928, DOI 10.1038/mp.2009.22
   Wang TY, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-18
   Wasserman D, 2007, GENES BRAIN BEHAV, V6, P321, DOI 10.1111/j.1601-183X.2006.00259.x
   Weder N, 2009, BIOL PSYCHIAT, V65, P417, DOI 10.1016/j.biopsych.2008.09.013
   Westberg L, 2003, MOL PSYCHIATR, V8, P118, DOI 10.1038/sj.mp.4001192
   Widom CS, 2006, BIOL PSYCHIAT, V60, P684, DOI 10.1016/j.biopsych.2006.03.039
   Williams LM, 2009, NEUROPSYCHOPHARMACOL, V34, P1797, DOI 10.1038/npp.2009.1
   Willoughby MT, 2013, DEV PSYCHOPATHOL, V25, P903, DOI 10.1017/S0954579413000266
   Yang JW, 2007, NEUROPSYCHOBIOLOGY, V56, P19, DOI 10.1159/000109973
   Yang J, 2010, NEUROPSYCHOBIOLOGY, V62, P158, DOI 10.1159/000318572
   Yoon HK, 2012, BEHAV BRAIN RES, V231, P105, DOI 10.1016/j.bbr.2012.03.001
   Young SE, 2006, AM J PSYCHIAT, V163, P1019, DOI 10.1176/appi.ajp.163.6.1019
   Young SE, 2002, AM J MED GENET, V114, P144, DOI 10.1002/ajmg.10155
   Zai CC, 2012, PSYCHIAT RES, V200, P784, DOI 10.1016/j.psychres.2012.07.031
   Zai CC, 2012, WORLD J BIOL PSYCHIA, V13, P65, DOI 10.3109/15622975.2010.543431
   Zalsman G, 2001, AM J MED GENET, V105, P239, DOI 10.1002/ajmg.1261
   Zimmermann P, 2009, J CHILD PSYCHOL PSYC, V50, P1339, DOI 10.1111/j.1469-7610.2009.02158.x
   Zohsel K, 2014, J CHILD PSYCHOL PSYC, V55, P69, DOI 10.1111/jcpp.12138
   Zouk H, 2007, AM J MED GENET B, V144B, P996, DOI 10.1002/ajmg.b.30521
NR 198
TC 1
Z9 1
U1 12
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUL
PY 2016
VL 171
IS 5
SI SI
BP 676
EP 696
DI 10.1002/ajmg.b.32419
PG 21
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA DV4DA
UT WOS:000382873900008
PM 26773414
ER

PT J
AU Barengolts, E
AF Barengolts, Elena
TI OXYTOCIN - AN EMERGING TREATMENT FOR OBESITY AND DYSGLYCEMIA: REVIEW OF
   RANDOMIZED CONTROLLED TRIALS AND COHORT STUDIES
SO ENDOCRINE PRACTICE
LA English
DT Review
ID FOOD-INTAKE; INTRANASAL OXYTOCIN; PERIPHERAL OXYTOCIN; BODY-WEIGHT;
   PLASMA OXYTOCIN; DEFICIENT MICE; HUMANS; RATS; VASOPRESSIN; BEHAVIOR
AB Objective: The psychotropic mediator and neuropeptide hormone oxytocin (OXT) is emerging as a promising treatment of metabolic disorders (obesity and dysglycemia). This review focuses on studies relevant to OXT use and its mechanisms of action in metabolic disorders and wellness behavior motivation.
   Methods: Randomized controlled trials (RCTs) and cohort and preclinical studies identified in electronic databases were reviewed.
   Results: There were only a few RCTs and cohort studies related to OXT and metabolic disorders. Anorexigenic and weight-loss effects of intranasal OXT (IOXT) were evaluated in 3 double-blind RCTs involving 85 subjects. A single dose of 24 IU reduced caloric intake by 122 kcal. The 24 IU 4-times daily dose for 8 weeks produced similar to 9-kg weight loss (P<.001 vs. placebo) and a trend toward reduced postprandial glucose and insulin levels. Similarly, in a double-blind RCT IOXT versus placebo increased the willingness to cooperate and the expectation that others will cooperate at prosocial tasks. A cohort study showed lower serum OXT level in obese versus normal-weight subjects and a negative correlation with body mass index. Circulating OXT was also lower in type 2 diabetes versus normoglycemic subjects and negatively correlated with glycosylated hemoglobin A1C and insulin resistance.
   Conclusion: The gap of knowledge remains on the efficacy of OXT for metabolic indications. It is a challenge to the scientific community to provide data that can be disseminated to inform the scientific community, medical personnel, and the public about the potential benefits and risks of chronic OXT use.
C1 [Barengolts, Elena] Univ Illinois, Endocrinol Sect, Dept Med, Med Ctr, MC 640 1819 West Polk St, Chicago, IL 60612 USA.
RP Barengolts, E (reprint author), Univ Illinois, Endocrinol Sect, Dept Med, Med Ctr, MC 640 1819 West Polk St, Chicago, IL 60612 USA.
EM eibareng@uic.edu
CR Al-Mamun HA, 2015, GENET SEL EVOL, V47, DOI 10.1186/s12711-015-0142-4
   Altirriba J, 2014, ENDOCRINOLOGY, V155, P4189, DOI 10.1210/en.2014-1466
   Bakos J, 2014, NEUROPEPTIDES, V48, P281, DOI 10.1016/j.npep.2014.06.004
   Blevins JE, 2016, AM J PHYSIOL-REG I, V310, pR640, DOI 10.1152/ajpregu.00220.2015
   Blevins JE, 2015, PHYSIOL BEHAV, V152, P438, DOI 10.1016/j.physbeh.2015.05.023
   Blevins JE, 2015, AM J PHYSIOL-REG I, V308, pR431, DOI 10.1152/ajpregu.00441.2014
   Borg J, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-17
   Brown SL, 2015, NEUROSCI BIOBEHAV R, V55, P1, DOI 10.1016/j.neubiorev.2015.04.004
   Camerino C, 2009, OBESITY, V17, P980, DOI 10.1038/oby.2009.12
   Chaviaras S, 2010, PSYCHOPHARMACOLOGY, V210, P35, DOI 10.1007/s00213-010-1815-x
   Chicharro JL, 2001, HORM RES, V55, P155, DOI 10.1159/000049988
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   Areias MFC, 2015, BEHAV BRAIN RES, V282, P209, DOI 10.1016/j.bbr.2015.01.003
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   Desbonnet L, 2015, BRAIN BEHAV IMMUN, V48, P165, DOI 10.1016/j.bbi.2015.04.004
   Devost D, 2008, PROG BRAIN RES, V170, P167, DOI 10.1016/S0079-6123(08)00415-9
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   DZEWALTOWSKI DA, 1990, J SPORT EXERCISE PSY, V12, P388
   Elabd S K, 2014, Endocr Regul, V48, P87
   Erdman SE, 2014, BENEF MICROBES, V5, P109, DOI 10.3920/BM2013.0042
   FLIERS E, 1983, PEPTIDES, V4, P165, DOI 10.1016/0196-9781(83)90108-0
   Frey HA, 2015, J MATERN-FETAL NEO M, V28, P1614, DOI 10.3109/14767058.2014.963046
   Gajdosechova L, 2014, J ENDOCRINOL, V220, P333, DOI 10.1530/JOE-13-0417
   GAO ZY, 1991, BIOCHEM J, V276, P169
   Giusti-Paiva A, 2010, NEUROENDOCRINOL LETT, V31, P87
   GOREN HJ, 1986, REGUL PEPTIDES, V16, P125, DOI 10.1016/0167-0115(86)90056-X
   Gossen A, 2012, NEUROPEPTIDES, V46, P211, DOI 10.1016/j.npep.2012.07.001
   Hill M, 2015, J PERINAT MED, V43, P703, DOI 10.1515/jpm-2014-0134
   Israel S, 2012, PSYCHONEUROENDOCRINO, V37, P1341, DOI 10.1016/j.psyneuen.2012.02.001
   Iwasaki Y, 2015, AM J PHYSIOL-REG I, V308, pR360, DOI 10.1152/ajpregu.00344.2014
   Kirkpatrick MG, 2014, PSYCHONEUROENDOCRINO, V46, P23, DOI 10.1016/j.psyneuen.2014.04.006
   Konstantinos L, ENDOTEXT
   Kontoangelos K, 2013, Curr Diabetes Rev, V9, P450
   Kontoangelos K, 2012, EXP DIABETES RES, DOI 10.1155/2012/560864
   Koroglu P, 2015, PEPTIDES, V63, P47, DOI 10.1016/j.peptides.2014.10.012
   Kujath AS, 2015, DIABETES-METAB RES, V31, P102, DOI 10.1002/dmrr.2577
   Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069
   Lawson EA, 2014, J CLIN ENDOCR METAB, V99, pE881, DOI 10.1210/jc.2013-4136
   Liberati A, 2009, ANN INTERN MED, V151, pW65
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Matsuura T, 2015, J NEUROENDOCRINOL, V27, P636, DOI 10.1111/jne.12290
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Morley JE, 2001, J GERONTOL A-BIOL, V56, P81
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   MUCHMORE DB, 1981, J BIOL CHEM, V256, P365
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Petra AI, 2015, CLIN THER, V37, P984, DOI 10.1016/j.clinthera.2015.04.002
   Plante E, 2015, ENDOCRINOLOGY, V156, P1416, DOI 10.1210/en.2014-1718
   Poutahidis T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078898
   Prada PO, 2005, ENDOCRINOLOGY, V146, P1576, DOI 10.1210/en.2004-0767
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   Qureshi S, 2014, ENDOCRINOLOGY, V155, P4605, DOI 10.1210/en.2014-1385
   Reagan LP, 2008, EUR J PHARMACOL, V585, P64, DOI 10.1016/j.ejphar.2008.02.050
   Schroeder M, 2010, HORM BEHAV, V57, P455, DOI 10.1016/j.yhbeh.2010.02.002
   STOCK S, 1989, INT J OBESITY, V13, P213
   STOCK S, 1993, GYNECOL OBSTET INVES, V36, P81
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   SUMMAR ML, 1990, MOL ENDOCRINOL, V4, P947
   Suzuki M, 2013, REGUL PEPTIDES, V183, P42, DOI 10.1016/j.regpep.2013.03.019
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660
   Welch MG, 2014, AM J PHYSIOL-GASTR L, V307, pG848, DOI 10.1152/ajpgi.00176.2014
   Welch MG, 2009, J COMP NEUROL, V512, P256, DOI 10.1002/cne.21872
   Wu ZF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045167
   Yi JQ, 2015, BEHAV BRAIN RES, V286, P58, DOI 10.1016/j.bbr.2015.02.008
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
   Zhang G, 2011, NEURON, V69, P523, DOI 10.1016/j.neuron.2010.12.036
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
NR 71
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
EI 1934-2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD JUL
PY 2016
VL 22
IS 7
BP 885
EP 894
DI 10.4158/EP151192.RA
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DX3NI
UT WOS:000384279400012
PM 27018619
ER

PT J
AU Gammie, SC
   Driessen, TM
   Zhao, CJ
   Saul, MC
   Eisinger, BE
AF Gammie, Stephen C.
   Driessen, Terri M.
   Zhao, Changjiu
   Saul, Michael C.
   Eisinger, Brian E.
TI Genetic and neuroendocrine regulation of the postpartum brain
SO FRONTIERS IN NEUROENDOCRINOLOGY
LA English
DT Review
DE Maternal; Postpartum; Depression; Addiction; Reward; Social behavior;
   Mental health; MicroRNA; Oxytocin; Prolactin
ID DEPRESSION-LIKE BEHAVIOR; CENTRAL-NERVOUS-SYSTEM; MEDIAL PREOPTIC AREA;
   REV-ERB-ALPHA; MATERNAL-BEHAVIOR; HIPPOCAMPAL NEUROGENESIS; SOCIAL
   DEFICITS; LATERAL SEPTUM; FUNCTIONAL IMPLICATIONS; PSYCHIATRIC-DISORDERS
AB Changes in expression of hundreds of genes occur during the production and function of the maternal brain that support a wide range of processes. In this review, we synthesize findings from four microarray studies of different maternal brain regions and identify a core group of 700 maternal genes that show significant expression changes across multiple regions. With those maternal genes, we provide new insights into reward-related pathways (maternal bonding), postpartum depression, social behaviors, mental health disorders, and nervous system plasticity/developmental events. We also integrate the new genes into well-studied maternal signaling pathways, including those for prolactin, oxytocin/vasopressin, endogenous opioids, and steroid receptors (estradiol, progesterone, cortisol). A newer transcriptional regulation model for the maternal brain is provided that incorporates recent work on maternal microRNAs. We also compare the top 700 genes with other maternal gene expression studies. Together, we highlight new genes and new directions for studies on the postpartum brain. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Gammie, Stephen C.; Driessen, Terri M.; Zhao, Changjiu; Saul, Michael C.; Eisinger, Brian E.] Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.
   [Gammie, Stephen C.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA.
RP Gammie, SC (reprint author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.; Gammie, SC (reprint author), Univ Wisconsin, 430 Lincoln Dr, Madison, WI 53706 USA.
EM scgammie@wisc.edu
FU United States National Institutes of Health [R01 MH 085642]
FX This work was supported by the United States National Institutes of
   Health Grant R01 MH 085642 to Stephen Gammie.
CR Akbari EM, 2013, BEHAV NEUROSCI, V127, P913, DOI 10.1037/a0034884
   Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0
   Arai Y, 2005, J NEUROSCI, V25, P9752, DOI 10.1523/JNEUROSCI.2512-05.2005
   Arbabi L, 2014, BEHAV BRAIN RES, V271, P65, DOI 10.1016/j.bbr.2014.05.036
   Banerjee S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6759
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Belfort MA, 2001, ACTA OBSTET GYN SCAN, V80, P104, DOI 10.1034/j.1600-0412.2001.080002104.x
   Belluardo N, 2005, NEUROSCIENCE, V133, P787, DOI 10.1016/j.neuroscience.2005.01.061
   Berger WT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050968
   Berkel S, 2012, HUM MOL GENET, V21, P344, DOI 10.1093/hmg/ddr470
   Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/er.19.3.225
   BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181
   Brandstatter JH, 2004, J COMP NEUROL, V475, P551, DOI 10.1002/cne.20194
   Bridges RS, 2015, FRONT NEUROENDOCRIN, V36, P178, DOI 10.1016/j.yfrne.2014.11.007
   Brockington I, 2004, LANCET, V363, P303, DOI 10.1016/S0140-6736(03)15390-1
   Burris TP, 2008, MOL ENDOCRINOL, V22, P1509, DOI 10.1210/me.2007-0519
   Byrnes EM, 2007, NEUROPSYCHOPHARMACOL, V32, P1021, DOI 10.1038/sj.npp.1301222
   Cartmell J, 2000, J NEUROCHEM, V75, P889, DOI 10.1046/j.1471-4159.2000.0750889.x
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Cipolla MJ, 2004, AM J PHYSIOL-HEART C, V286, pH2127, DOI 10.1152/ajpheart.01154.2003
   Couto Tiago Castro E, 2015, World J Psychiatry, V5, P103, DOI 10.5498/wjp.v5.i1.103
   D'Anna KL, 2006, J NEUROENDOCRINOL, V18, P553, DOI 10.1111/j.1365-2826.2006.01448.x
   de Bartolomeis A, 2004, INT REV NEUROBIOL, V59, P221
   de Moura AC, 2015, NEUROSCI RES, V99, P8, DOI 10.1016/j.neures.2015.05.003
   De Vriese SR, 2003, LIFE SCI, V73, P3181, DOI 10.1016/j.lfs.2003.02.001
   Dean B, 2015, CURR MOL MED, V15, P253
   Driessen T., 2014, PLOS ONE
   Driessen TM, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-11
   Eisinger B.E., 2014, FRONT BEHAV NEUROSCI, V8
   Eisinger BE, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-147
   Eisinger BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063824
   Eshel N, 2010, BIOL PSYCHIAT, V68, P118, DOI 10.1016/j.biopsych.2010.01.027
   Espana RA, 2004, PEPTIDES, V25, P1927, DOI 10.1016/j.peptides.2004.06.006
   Etain B, 2011, EUR NEUROPSYCHOPHARM, V21, pS676, DOI 10.1016/j.euroneuro.2011.07.007
   Febo M, 2005, J NEUROSCI, V25, P11637, DOI 10.1523/JNEUROSCI.3604-05.2005
   Febo M, 2011, J NEUROENDOCRINOL, V23, P1009, DOI 10.1111/j.1365-2826.2011.02184.x
   Ferris CF, 2005, J NEUROSCI, V25, P149, DOI 10.1523/JNEUROSCI.3156-04.2005
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   Frank MJ, 2009, NAT NEUROSCI, V12, P1062, DOI 10.1038/nn.2342
   Galea LAM, 2013, J NEUROENDOCRINOL, V25, P1039, DOI 10.1111/jne.12070
   Gammie Stephen C, 2005, Brain Res Mol Brain Res, V139, P201
   Goldstein TR, 2006, BIPOLAR DISORD, V8, P350, DOI 10.1111/j.1399-5618.2006.00321.x
   Gregg C, 2009, J NEUROL SCI, V285, P22, DOI 10.1016/j.jns.2009.06.040
   Grubb SC, 2014, NUCLEIC ACIDS RES, V42, pD825, DOI 10.1093/nar/gkt1159
   Guillaumond F, 2005, J BIOL RHYTHM, V20, P391, DOI 10.1177/0748730405277232
   HAFNER H, 1995, EUR ARCH PSY CLIN N, V246, P17, DOI 10.1007/BF02191811
   HAUSER H, 1985, HORM BEHAV, V19, P454, DOI 10.1016/0018-506X(85)90041-8
   Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405
   Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028
   Henriques JB, 2000, COGNITION EMOTION, V14, P711
   Higham JP, 2011, BEHAV NEUROSCI, V125, P131, DOI 10.1037/a0022695
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ida T, 2005, ENDOCRINOLOGY, V146, P4217, DOI 10.1210/en.2005-0107
   Jia W., 2014, PLOS ONE, V9
   Kaczocha M, 2009, P NATL ACAD SCI USA, V106, P6375, DOI 10.1073/pnas.0901515106
   Kaimal V, 2010, NUCLEIC ACIDS RES, V38, pW96, DOI 10.1093/nar/gkq418
   Kazi AA, 2009, BIOL REPROD, V81, P378, DOI 10.1095/biolreprod.109.076117
   Keebaugh A.C., 2015, SOC NEUROSCI, P1
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kiessling S, 2010, J CLIN INVEST, V120, P2600, DOI 10.1172/JCI41192
   Kikuchi Y, 2015, NEUROSCIENCE COMMUNI, V1, P1
   Kinsley CH, 2008, ARCH SEX BEHAV, V37, P43, DOI 10.1007/s10508-007-9277-x
   Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0
   Kripke Daniel F, 2009, J Circadian Rhythms, V7, P2, DOI 10.1186/1740-3391-7-2
   Kuroda KO, 2011, PROG NEURO-PSYCHOPH, V35, P1205, DOI 10.1016/j.pnpbp.2011.02.008
   KURTZ A, 1994, DEVELOPMENT, V120, P2637
   Larsen CM, 2012, BRAIN BEHAV IMMUN, V26, P201, DOI 10.1016/j.bbi.2011.07.233
   Larsen CM, 2008, HORM BEHAV, V53, P509, DOI 10.1016/j.yhbeh.2007.11.020
   Laufer Benjamin I, 2012, Microrna, V1, P59
   Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191
   Leblond CS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002521
   Lee A, 1999, BEHAV BRAIN RES, V100, P15, DOI 10.1016/S0166-4328(98)00109-0
   Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453
   Leuner B, 2016, FRONT NEUROENDOCRIN, V41, P99, DOI 10.1016/j.yfrne.2016.02.004
   Leuner B, 2010, J NEUROSCI, V30, P13499, DOI 10.1523/JNEUROSCI.3388-10.2010
   Levy F, 2011, J NEUROENDOCRINOL, V23, P984, DOI 10.1111/j.1365-2826.2011.02203.x
   Li JZ, 2013, P NATL ACAD SCI USA, V110, P9950, DOI 10.1073/pnas.1305814110
   Liu RZ, 2010, INT J DEV BIOL, V54, P1229, DOI [10.1387/ijdb.092976rl, 10.1387/ijdb.092976r1]
   Lonstein JS, 2000, NEUROSCI BIOBEHAV R, V24, P669, DOI 10.1016/S0149-7634(00)00036-1
   Ma XM, 2001, J COMP NEUROL, V429, P388, DOI 10.1002/1096-9861(20010115)429:3<388::AID-CNE3>3.0.CO;2-I
   Maina G., 2014, ARCH WOMEN MENT HLTH, P1
   Mandela P, 2014, HORM BEHAV, V66, P430, DOI 10.1016/j.yhbeh.2014.07.001
   Maniam J, 2010, BEHAV BRAIN RES, V208, P72, DOI 10.1016/j.bbr.2009.11.005
   Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505
   Matsumata M, 2012, STEM CELLS, V30, P1532, DOI 10.1002/stem.1124
   Mattson BJ, 2005, NEUROSCIENCE, V135, P315, DOI 10.1016/j.neuroscience.2005.06.045
   Mattson BJ, 2003, PSYCHOPHARMACOLOGY, V167, P1, DOI 10.1007/s00213-002-1351-4
   Mattson BJ, 2001, BEHAV NEUROSCI, V115, P683, DOI 10.1037//0735-7044.115.3.683
   Mead AN, 2005, PSYCHOPHARMACOLOGY, V179, P164, DOI 10.1007/s00213-004-2071-8
   Mileva-Seitz V, 2012, GENES BRAIN BEHAV, V11, P684, DOI 10.1111/j.1601-183X.2012.00804.x
   Mileva-Seitz VR, 2016, HORM BEHAV, V77, P211, DOI 10.1016/j.yhbeh.2015.06.003
   Miller LJ, 2002, JAMA-J AM MED ASSOC, V287, P762, DOI 10.1001/jama.287.6.762
   Miyamoto A., 2010, PHYSIOL GENOMICS, V42, P290
   Mossner R, 2008, EUR NEUROPSYCHOPHARM, V18, P768, DOI 10.1016/j.euroneuro.2008.05.007
   Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128
   MUNDY P, 1986, J CHILD PSYCHOL PSYC, V27, P657, DOI 10.1111/j.1469-7610.1986.tb00190.x
   Munoz C, 2014, CELL PHYSIOL BIOCHEM, V33, P491, DOI 10.1159/000358629
   Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018
   Nicolas Ob, 2013, JAKSTAT, V2, DOI DOI 10.4161/JKST.22925
   Noriuchi M, 2008, BIOL PSYCHIAT, V63, P415, DOI 10.1016/j.biopsych.2007.05.018
   Numan M, 2003, NEUROBIOLOGY PARENTA
   Numan M, 2007, DEV PSYCHOBIOL, V49, P12, DOI 10.1002/dev.20198
   Numan M, 2012, PARENT-SCI PRACT, V12, P105, DOI 10.1080/15295192.2012.680406
   O'Brien NL, 2014, PSYCHIAT GENET, V24, P277, DOI 10.1097/YPG.0000000000000050
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8
   Olazabal DE, 2013, NEUROSCI BIOBEHAV R, V37, P1860, DOI 10.1016/j.neubiorev.2013.04.003
   Oliveros J. C., 2007, VENNY INTERACTIVE TO
   Otto S., 2003, ESSENT FATTY ACIDS, V69, P237
   PANKSEPP J, 1994, ACTA PAEDIATR, V83, P40, DOI 10.1111/j.1651-2227.1994.tb13264.x
   Pappa I., 2015, ATTACH HUM DEV, P1
   Parada M, 2008, BEHAV NEUROSCI, V122, P368, DOI 10.1037/0735-7044.122.2.368
   Pawluski JL, 2007, NEUROSCIENCE, V149, P53, DOI 10.1016/j.neuroscience.2007.07.031
   Perlmann T, 2004, CELL TISSUE RES, V318, P45, DOI 10.1007/s00441-004-0974-7
   Piechota M, 2012, GENES BRAIN BEHAV, V11, P404, DOI 10.1111/j.1601-183X.2012.00777.x
   Pletscher-Frankild S, 2015, METHODS, V74, P83, DOI 10.1016/j.ymeth.2014.11.020
   Rappaport N., 2013, DATABASE J BIOL DATA
   Ray S, 2016, G3-GENES GENOM GENET, V6, P221, DOI 10.1534/g3.115.020982/-/DC1
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Sakamoto T, 2008, BIOCHEM BIOPH RES CO, V375, P49, DOI 10.1016/j.bbrc.2008.07.124
   Salzberg HC, 2002, NEUROSCIENCE, V114, P675, DOI 10.1016/S0306-4522(02)00358-5
   Saul MC, 2016, NEUROSCIENCE, V312, P130, DOI 10.1016/j.neuroscience.2015.11.019
   Scheich B, 2016, NEUROPHARMACOLOGY, V101, P204, DOI 10.1016/j.neuropharm.2015.09.021
   Schlaepfer TE, 2008, NEUROPSYCHOPHARMACOL, V33, P368, DOI 10.1038/sj.npp.1301408
   Seip KM, 2007, PSYCHOPHARMACOLOGY, V194, P309, DOI 10.1007/s00213-007-0841-9
   Shams S, 2012, BEHAV BRAIN RES, V233, P79, DOI 10.1016/j.bbr.2012.04.048
   Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505
   Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647
   Sommer JE, 2009, J NEUROSCI, V29, P5367, DOI 10.1523/JNEUROSCI.0235-09.2009
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Stansberg C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-94
   Stolzenberg DS, 2011, NEUROSCI BIOBEHAV R, V35, P826, DOI 10.1016/j.neubiorev.2010.10.003
   Strathearn L, 2008, PEDIATRICS, V122, P40, DOI 10.1542/peds.2007-1566
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083
   Thomas M, 2010, NAT STRUCT MOL BIOL, V17, P1169, DOI 10.1038/nsmb.1921
   Torner L, 2009, J NEUROSCI, V29, P1826, DOI 10.1523/JNEUROSCI.3178-08.2009
   Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799
   Trabzuni D., 2013, NAT COMMUN, V4
   Tsunoka T., 2009, BIOL PSYCHIAT, V33, P875
   Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504
   Wang J, 2008, GENES BRAIN BEHAV, V7, P78, DOI 10.1111/j.1601-183X.2007.00328.x
   Wang J, 2004, J NEUROSCI RES, V76, P306, DOI 10.1002/jnr.20076
   Wang Y, 2009, OMICS, V13, P313, DOI 10.1089/omi.2009.0040
   Wang YZ, 2011, MOL ENDOCRINOL, V25, P72, DOI 10.1210/me.2010-0294
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Wettschureck N, 2004, MOL CELL BIOL, V24, P8048, DOI 10.1128/MCB.24.18.8048-8054.2004
   Wilsoncroft W., 1968, BEHAV RES METHODS, V1, P229, DOI DOI 10.3758/BF03208105
   Won H, 2012, NATURE, V486, P261, DOI 10.1038/nature11208
   Wongchitrat P, 2013, NEUROSCI LETT, V542, P126, DOI 10.1016/j.neulet.2013.03.009
   Xia Y., 2014, ALCOHOL ALCOHOLISM
   Xiao XQ, 2005, ENDOCRINOLOGY, V146, P4391, DOI 10.1210/en.2005-0561
   Yun SW, 2012, P NATL ACAD SCI USA, V109, P10214, DOI 10.1073/pnas.1200817109
   Zerbino DR, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0621-5
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]
   Zhao C., 2014, BRAIN RES
   Zhao CJ, 2015, J HISTOCHEM CYTOCHEM, V63, P417, DOI 10.1369/0022155415578283
   Zhao CJ, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00388
   Zhao CJ, 2012, BRAIN RES, V1470, P35, DOI 10.1016/j.brainres.2012.06.002
   Zhao CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038602
   Zucchi S, 2013, ENVIRON SCI TECHNOL, V47, P12548, DOI 10.1021/es403800y
NR 161
TC 0
Z9 0
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-3022
EI 1095-6808
J9 FRONT NEUROENDOCRIN
JI Front. Neuroendocrinol.
PD JUL
PY 2016
VL 42
BP 1
EP 17
DI 10.1016/j.yfrne.2016.05.002
PG 17
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DX4ZI
UT WOS:000384389200002
PM 27184829
ER

PT J
AU French, JA
   Taylor, JH
   Mustoe, AC
   Cavanaugh, J
AF French, Jeffrey A.
   Taylor, Jack H.
   Mustoe, Aaryn C.
   Cavanaugh, Jon
TI Neuropeptide diversity and the regulation of social behavior in New
   World primates
SO FRONTIERS IN NEUROENDOCRINOLOGY
LA English
DT Review
DE Oxytocin; Vasopressin; New World monkey; Social behavior; Monogamy;
   Oxytocin receptor; Vasopressin receptor
ID VASOPRESSIN V1A RECEPTORS; HUMAN OXYTOCIN RECEPTOR; UPPER SPINAL-CORD;
   NEUROHYPOPHYSEAL HORMONE GENES; MARMOSETS CALLITHRIX-JACCHUS; FEMALE
   COMMON MARMOSETS; SEX-SPECIFIC REGULATION; HUMAN-BRAIN; MOLECULAR
   EVOLUTION; LATERAL SEPTUM
AB Oxytocin (OT) and vasopressin (AVP) are important hypothalamic neuropeptides that regulate peripheral physiology, and have emerged as important modulators of brain function, particularly in the social realm. OT structure and the genes that ultimately determine structure are highly conserved among diverse eutherian mammals, but recent discoveries have identified surprising variability in OT and peptide structure in New World monkeys (NWM), with five new OT variants identified to date. This review explores these new findings in light of comparative OT/AVP ligand evolution, documents coevolutionary changes in the oxytocin and vasopressin receptors (OTR and V1aR), and highlights the distribution of neuropeptidergic neurons and receptors in the primate brain. Finally, the behavioral consequences of OT and AVP in regulating NWM sociality are summarized, demonstrating important neuromodulatory effects of these compounds and OT ligand-specific influences in certain social domains. (C) 2016 Elsevier Inc. All rights reserved.
C1 [French, Jeffrey A.; Taylor, Jack H.; Mustoe, Aaryn C.; Cavanaugh, Jon] Univ Nebraska, Program Neurosci & Behav, Omaha, NE 68182 USA.
RP French, JA (reprint author), Univ Nebraska, Neurosci Program, Allwine Hall 419,6001 Dodge St, Omaha, NE 68182 USA.
EM jfrench@unomaha.edu
FU National Institutes of Health [HD042882]; Nebraska Foundation; Office of
   Research and Creative Activity at UNO
FX We thank members of the Callitrichid Research Center at the University
   of Nebraska at Omaha for support and comments on the materials and ideas
   covered in this paper. Elizabeth Genne-Bacon provided important impetus
   for pursuing the oxytocin system in New World monkeys. The research from
   the CRC described in this review was supported in part by funds from the
   National Institutes of Health (HD042882), the Nebraska Foundation, and
   from the Office of Research and Creative Activity at UNO.
CR Acher R, 1996, GEN COMP ENDOCR, V102, P157, DOI 10.1006/gcen.1996.0057
   ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7
   Acher R, 1995, ADV EXP MED BIOL, V395, P615
   Agmo A, 2012, BEHAVIOUR, V149, P407, DOI 10.1163/156853912X638454
   Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Babb P.L., 2015, MOL PHYLOGENET
   Bankir L, 2001, CARDIOVASC RES, V51, P372, DOI 10.1016/S0008-6363(01)00328-5
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Barrett CE, 2013, HORM BEHAV, V63, P518, DOI 10.1016/j.yhbeh.2013.01.005
   Beery A.K., 2015, CURR OPIN BEHAV SCI, V6, P174
   Beery AK, 2008, J COMP NEUROL, V507, P1847, DOI 10.1002/cne.21638
   Beets I., 2013, WORM
   Bethlehem R.A., 2014, FRONT BEHAV NEUROSCI, V8
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Boccia ML, 2001, NEUROREPORT, V12, P1723, DOI 10.1097/00001756-200106130-00041
   BOINSKI S, 1987, BEHAV ECOL SOCIOBIOL, V21, P13, DOI 10.1007/BF00324430
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Brosnan SF, 2014, SCIENCE, V346, P314, DOI 10.1126/science.1251776
   Brosnan S.F., 2011, FRONT NEUROSCI, V5
   Brosnan S.F., 2015, BEHAVIOUR
   Burkart JM, 2007, P NATL ACAD SCI USA, V104, P19762, DOI 10.1073/pnas.0710310104
   CAFFE AR, 1989, J COMP NEUROL, V287, P302, DOI 10.1002/cne.902870304
   CAFFE AR, 1987, J COMP NEUROL, V261, P237, DOI 10.1002/cne.902610206
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Caldwell H.K., 2006, HDB NEUROCHEMISTRY M, P573
   Cavanaugh Jon, 2016, Psychoneuroendocrinology, V66, P22, DOI 10.1016/j.psyneuen.2015.12.027
   Cavanaugh J, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00251
   Cavanaugh J, 2014, PSYCHONEUROENDOCRINO, V49, P1, DOI 10.1016/j.psyneuen.2014.06.020
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Chapais B, 2013, EVOL ANTHROPOL, V22, P52, DOI 10.1002/evan.21345
   CHINI B, 1995, EMBO J, V14, P2176
   Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0
   Crockford C, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2765
   Cronin KA, 2012, ANIM BEHAV, V84, P1085, DOI 10.1016/j.anbehav.2012.08.009
   Cronin KA, 2010, P ROY SOC B-BIOL SCI, V277, P3845, DOI 10.1098/rspb.2010.0879
   De Vries GJ, 2006, NEUROSCIENCE, V138, P947, DOI 10.1016/j.neuroscience.2005.07.050
   Devost D, 2004, J NEUROENDOCRINOL, V16, P372, DOI 10.1111/j.0953-8194.2004.01188.x
   DeVries AC, 2003, PHYSIOL BEHAV, V79, P399, DOI 10.1016/S0031-9384(03)00152-5
   DEVRIES GJ, 1983, BRAIN RES, V273, P307, DOI 10.1016/0006-8993(83)90855-7
   Diaz-Munoz SL, 2016, AM J PRIMATOL, V78, P372, DOI 10.1002/ajp.22431
   Diaz-Munoz SL, 2016, AM J PRIMATOL, V78, P283, DOI 10.1002/ajp.22463
   DIETZ JM, 1993, ANIM BEHAV, V46, P1067, DOI 10.1006/anbe.1993.1297
   DIGBY LJ, 1995, PRIMATES, V36, P361, DOI 10.1007/BF02382859
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Dumais KM, 2016, FRONT NEUROENDOCRIN, V40, P1, DOI 10.1016/j.yfrne.2015.04.003
   Dumais KM, 2016, PSYCHONEUROENDOCRINO, V64, P79, DOI 10.1016/j.psyneuen.2015.11.007
   Ebitz R.B., 2013, FRONT BEHAV NEUROSCI, V7
   Epple G., 1972, International Zoo Yearbook, V12, P36, DOI 10.1111/j.1748-1090.1972.tb02261.x
   Everts HGJ, 1997, BRAIN RES, V760, P1, DOI 10.1016/S0006-8993(97)00269-2
   FEDIGAN L, 1993, INT J PRIMATOL, V14, P853, DOI 10.1007/BF02220256
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Fernandez-Duque E, 2009, ANNU REV ANTHROPOL, V38, P115, DOI 10.1146/annurev-anthro-091908-164334
   Fernandez-Duque E., 2007, PRIMATES PERSPECTIVE, P139
   Ferris CF, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00245
   Finkenwirth C, 2015, PHYSIOL BEHAV, V151, P246, DOI 10.1016/j.physbeh.2015.07.034
   FLIERS E, 1985, BRAIN RES, V342, P45, DOI 10.1016/0006-8993(85)91351-4
   FLIERS E, 1986, BRAIN RES, V375, P363, DOI 10.1016/0006-8993(86)90759-6
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   FRENCH JA, 1989, ANIM BEHAV, V37, P487, DOI 10.1016/0003-3472(89)90095-X
   [Anonymous], 2008, THE PARENTAL BRAIN
   Fuxe K, 2012, BRAIN RES, V1476, P119, DOI 10.1016/j.brainres.2012.01.062
   Geisler I, 2009, CHEM BIOL DRUG DES, V73, P39, DOI 10.1111/j.1747-0285.2008.00759.x
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GOLDIZEN AW, 1988, TRENDS ECOL EVOL, V3, P36, DOI 10.1016/0169-5347(88)90045-6
   Goodson JL, 2013, PSYCHONEUROENDOCRINO, V38, P465, DOI 10.1016/j.psyneuen.2012.12.005
   Goodson JL, 2009, FRONT NEUROENDOCRIN, V30, P429, DOI 10.1016/j.yfrne.2009.05.007
   Goodson JL, 2008, PROG BRAIN RES, V170, P3, DOI 10.1016/S0079-6123(08)00401-9
   Griebel Guy, 2003, Current Drug Targets - CNS and Neurological Disorders, V2, P191, DOI 10.2174/1568007033482850
   Grinevich V., 2015, BIOL PSYCHIAT
   Gruber CW, 2014, EXP PHYSIOL, V99, P55, DOI 10.1113/expphysiol.2013.072561
   Gruber CW, 2012, FUTURE MED CHEM, V4, P1791, DOI [10.4155/fmc.12.108, 10.4155/FMC.12.108]
   Gwee PC, 2008, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-47
   Gwee PC, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-93
   Hawtin SR, 2005, MOL ENDOCRINOL, V19, P2871, DOI 10.1210/me.2005-0148
   HENNESSY MB, 1995, PHYSIOL BEHAV, V57, P331, DOI 10.1016/0031-9384(94)00250-9
   Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682
   Hofmann HA, 2014, TRENDS ECOL EVOL, V29, P581, DOI 10.1016/j.tree.2014.07.008
   ICHIMIYA Y, 1988, MOL BRAIN RES, V4, P81, DOI 10.1016/0169-328X(88)90022-8
   Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Ishunina TA, 1999, J CLIN ENDOCR METAB, V84, P4637, DOI 10.1210/jc.84.12.4637
   Janson C.H., 1986, PRIMATE ECOLOGY CONS, V2, P169
   Jarcho MR, 2011, GENES BRAIN BEHAV, V10, P375, DOI 10.1111/j.1601-183X.2010.00677.x
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   KAWATA M, 1982, ANAT EMBRYOL, V165, P151, DOI 10.1007/BF00305474
   Kelly Aubrey M, 2015, Curr Opin Behav Sci, V6, P97
   Kelly AM, 2014, FRONT NEUROENDOCRIN, V35, P512, DOI 10.1016/j.yfrne.2014.04.005
   Kenakin T, 2007, MOL PHARMACOL, V72, P1393, DOI 10.1124/mol.107.040352
   Kendrick KM, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P183
   Kiss Alexander, 2005, Endocr Regul, V39, P97
   KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721
   Knobloch HS, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00031
   Koehbach J, 2013, BIOCHEM SOC T, V41, P197, DOI 10.1042/BST20120256
   Kozorovitskiy Y, 2006, NAT NEUROSCI, V9, P1094, DOI 10.1038/nn1753
   Lakshminarayanan VR, 2008, CURR BIOL, V18, pR999, DOI 10.1016/j.cub.2008.08.057
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lee AG, 2011, BIOL LETTERS, V7, P584, DOI 10.1098/rsbl.2011.0107
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Leng G, 2015, BIOL PSYCHIAT
   Lim MM, 2004, J COMP NEUROL, V468, P555, DOI 10.1002/cne.10973
   Liutkeviciute Z., 2015, MOL NEUROENDOCRINOLO
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   LOUP F, 1989, BRAIN RES, V500, P223, DOI 10.1016/0006-8993(89)90317-X
   Loyens E, 2012, BRAIN RES, V1436, P43, DOI 10.1016/j.brainres.2011.11.059
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Lukas D, 2013, SCIENCE, V341, P526, DOI 10.1126/science.1238677
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Markov GV, 2008, MOL CELL ENDOCRINOL, V293, P5, DOI 10.1016/j.mce.2008.06.011
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mooney SJ, 2015, NEUROSCIENCE, V303, P261, DOI 10.1016/j.neuroscience.2015.06.043
   Mota MTD, 2006, HORM BEHAV, V49, P293, DOI 10.1016/j.yhbeh.2005.07.012
   MOUILLAC B, 1995, J BIOL CHEM, V270, P25771
   Mustoe AC, 2016, ANIM BEHAV, V114, P69, DOI 10.1016/j.anbehav.2016.01.025
   Mustoe AC, 2015, HORM BEHAV, V71, P83, DOI 10.1016/j.yhbeh.2015.04.015
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x
   Nievergelt CM, 2000, INT J PRIMATOL, V21, P1, DOI 10.1023/A:1005411227810
   Nunes S, 2001, HORM BEHAV, V39, P70, DOI 10.1006/hbeh.2000.1631
   Nunes S, 2000, ANIM BEHAV, V60, P857, DOI 10.1006/anbe.2000.1524
   O'Connell LA, 2012, SCIENCE, V336, P1154, DOI 10.1126/science.1218889
   O'Connell LA, 2011, J COMP NEUROL, V519, P3599, DOI 10.1002/cne.22735
   Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200
   Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607
   Ophir AG, 2008, ANIM BEHAV, V75, P1143, DOI 10.1016/j.anbehav.2007.09.022
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Parker KJ, 2005, PSYCHONEUROENDOCRINO, V30, P924, DOI 10.1016/j.psyneuen.2005.04.002
   Perelman P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001342
   Platt ML, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0096
   Ren DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125775
   Ren DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111638
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   ROSENBERGER AL, 1992, AM J PHYS ANTHROPOL, V88, P525, DOI 10.1002/ajpa.1330880408
   Ross CN, 2004, PHYSIOL BEHAV, V83, P437, DOI 10.1016/j.physbeh.2004.08.036
   Ross CN, 2011, AM J PRIMATOL, V73, P1072, DOI 10.1002/ajp.20975
   Rukstalis M, 2005, HORM BEHAV, V47, P1, DOI 10.1016/yhbeh.2004.09.004
   Saito A, 2011, J COMP PHYSIOL A, V197, P329, DOI 10.1007/s00359-010-0617-2
   Saltzman W, 2009, P R SOC B, V276, P389, DOI 10.1098/rspb.2008.1374
   SAWYER WH, 1977, AM ZOOL, V17, P727
   SCHAFFNER CM, 1995, AM J PRIMATOL, V36, P185, DOI 10.1002/ajp.1350360303
   Schneider H, 2015, MOL PHYLOGENET EVOL, V82, P348, DOI 10.1016/j.ympev.2013.10.017
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Schorscher-Petcu A, 2009, NEUROSCI LETT, V461, P217, DOI 10.1016/j.neulet.2009.06.016
   Shamay-Tsoory S, 2016, BIOL PSYCHIAT, V79, P150, DOI 10.1016/j.biopsych.2015.10.014
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   Smith AS, 2012, HORM BEHAV, V61, P320, DOI 10.1016/j.yhbeh.2011.11.010
   Smith AS, 2010, HORM BEHAV, V57, P255, DOI 10.1016/j.yhbeh.2009.12.004
   Smith A.S., 2016, MOL PSYCHIAT
   Smith RJ, 1997, J HUM EVOL, V32, P523, DOI 10.1006/jhev.1996.0122
   Smith TE, 2001, CHEM SENSES, V26, P449, DOI 10.1093/chemse/26.5.449
   Smith TE, 1998, HORM BEHAV, V34, P211, DOI 10.1006/hbeh.1998.1469
   Snowdon CT, 2010, HORM BEHAV, V58, P614, DOI 10.1016/j.yhbeh.2010.06.014
   SOFRONIEW MV, 1983, PROG BRAIN RES, V60, P101
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   Spence-Aizenberg A., 2015, PRIMATES
   Stevenson EL, 2012, HORM BEHAV, V61, P277, DOI 10.1016/j.yhbeh.2011.11.009
   Stoop R, 2014, CURR OPIN NEUROBIOL, V29, P187, DOI 10.1016/j.conb.2014.09.012
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Storey A.E., 2015, HORM BEHAV
   SUKHOV RR, 1993, J COMP NEUROL, V337, P295, DOI 10.1002/cne.903370210
   Taghert PH, 2012, NEURON, V76, P82, DOI 10.1016/j.neuron.2012.08.035
   Taylor JH, 2015, HORM BEHAV, V75, P154, DOI 10.1016/j.yhbeh.2015.10.002
   Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195
   Toloczko DM, 1997, ANN NY ACAD SCI, V807, P506, DOI 10.1111/j.1749-6632.1997.tb51953.x
   UEDA S, 1983, CELL TISSUE RES, V234, P237, DOI 10.1007/BF00213766
   van Anders SM, 2013, ARCH SEX BEHAV, V42, P1115, DOI 10.1007/s10508-013-0134-9
   Vargas-Pinilla P, 2015, P NATL ACAD SCI USA, V112, P88, DOI 10.1073/pnas.1419399112
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   Waite Gabi N, 2014, Biomed Sci Instrum, V50, P1
   Wallis M, 2012, GEN COMP ENDOCR, V179, P313, DOI 10.1016/j.ygcen.2012.07.030
   Walum H., 2015, BIOL PSYCHIAT
   Wang ZX, 1997, BRAIN RES, V768, P147, DOI 10.1016/S0006-8993(97)00636-7
   Wang ZX, 1997, SYNAPSE, V27, P14, DOI 10.1002/(SICI)1098-2396(199709)27:1<14::AID-SYN2>3.0.CO;2-G
   Wesley VJ, 2002, BIOCHEMISTRY-US, V41, P5086, DOI 10.1021/bi015990v
   WIERDA M, 1991, NEUROBIOL AGING, V12, P511, DOI 10.1016/0197-4580(91)90081-T
   Wildman DE, 2009, MOL PHYLOGENET EVOL, V53, P694, DOI 10.1016/j.ympev.2009.07.019
   Wircer E., 2015, MOL NEUROENDOCR GENO, V301
   Wittig RM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.3096
   Woller MJ, 2012, J NEUROENDOCRINOL, V24, P413, DOI 10.1111/j.1365-2826.2011.02252.x
   Yamashita K, 2013, MOL PHYLOGENET EVOL, V67, P520, DOI 10.1016/j.ympev.2013.02.017
   Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 1999, J NEUROENDOCRINOL, V11, P291
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young WS, 2003, NEUROENDOCRINOLOGY, V78, P185, DOI 10.1159/000073702
   Young W.S., 2009, ENCY NEUROSCIENCE, P51
   Zak P. J., 2012, MORAL MOL SOURCE LOV
   Zhang JZ, 2000, J MOL EVOL, V50, P56
   Ziegler TE, 2013, AM J PRIMATOL, V75, P202, DOI 10.1002/ajp.22061
   Zik JB, 2015, PSYCHIAT RES, V226, P31, DOI 10.1016/j.psychres.2014.11.048
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8
   Zoicas L, 2014, NEUROPSYCHOPHARMACOL, V39, P3027, DOI 10.1038/npp.2014.156
NR 200
TC 0
Z9 0
U1 10
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-3022
EI 1095-6808
J9 FRONT NEUROENDOCRIN
JI Front. Neuroendocrinol.
PD JUL
PY 2016
VL 42
BP 18
EP 39
DI 10.1016/j.yfrne.2016.03.004
PG 22
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DX4ZI
UT WOS:000384389200003
PM 27020799
ER

PT J
AU Milton, M
   Ouellette-Kuntz, H
   Liu, X
AF Milton, M.
   Ouellette-Kuntz, H.
   Liu, X.
TI The differential impact of oxytocin receptor genotypes on the risk of
   autism spectrum disorder and resulting social communication deficits
SO JOURNAL OF INTELLECTUAL DISABILITY RESEARCH
LA English
DT Meeting Abstract
C1 [Milton, M.] Queens Univ, Kingston, ON K7L 3N6, Canada.
EM 14mm62@queensu.ca
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0964-2633
EI 1365-2788
J9 J INTELL DISABIL RES
JI J. Intell. Disabil. Res.
PD JUL-AUG
PY 2016
VL 60
IS 7-8
SI SI
BP 800
EP 800
PG 1
WC Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry;
   Rehabilitation
SC Education & Educational Research; Genetics & Heredity; Neurosciences &
   Neurology; Psychiatry; Rehabilitation
GA DW2GX
UT WOS:000383462000885
ER

PT J
AU Smallwood, M
   Sareen, A
   Baker, E
   Hannusch, R
   Kwessi, E
   Williams, T
AF Smallwood, Melissa
   Sareen, Ashley
   Baker, Emma
   Hannusch, Rachel
   Kwessi, Eddy
   Williams, Tyisha
TI Increased Risk of Autism Development in Children Whose Mothers
   Experienced Birth Complications or Received Labor and Delivery Drugs
SO ASN NEURO
LA English
DT Article
DE autism; ASD; birth complications; induction; Pitocin
ID SPECTRUM DISORDERS; OXYTOCIN; INDUCTION; BUPIVACAINE; POPULATION;
   ANALGESIA; PITOCIN; TWIN
AB Autism spectrum disorder (ASD) is a perplexing and pervasive developmental disorder characterized by social difficulties, communicative deficits, and repetitive behavior. The increased rate of ASD diagnosis has raised questions concerning the genetic and environmental factors contributing to the development of this disorder; meanwhile, the cause of ASD remains unknown. This study surveyed mothers of ASD and non-ASD children to determine possible effects of labor and delivery (L&D) drugs on the development of ASD. The survey was administered to mothers; however, the results were analyzed by child, as the study focused on the development of autism. Furthermore, an independent ASD dataset from the Southwest Autism Research and Resource Center was analyzed and compared. Indeed, L&D drugs are associated with ASD (p = .039). Moreover, the Southwest Autism Research and Resource Center dataset shows that the labor induction drug, Pitocin, is significantly associated with ASD (p = .004). We also observed a synergistic effect between administrations of L&D drugs and experiencing a birth complication, in which both obstetrics factors occurring together increased the likelihood of the fetus developing ASD later in life (p = .0003). The present study shows the possible effects of L&D drugs, such as Pitocin labor-inducing and analgesic drugs, on children and ASD.
C1 [Smallwood, Melissa; Sareen, Ashley; Baker, Emma; Hannusch, Rachel; Williams, Tyisha] Trinity Univ, Neurosci Program, San Antonio, TX 78212 USA.
   [Kwessi, Eddy] Trinity Univ, Dept Math, San Antonio, TX 78212 USA.
   [Williams, Tyisha] Trinity Univ, Dept Biol, San Antonio, TX 78212 USA.
RP Williams, T (reprint author), Trinity Univ, One Trinity Pl, San Antonio, TX 78212 USA.
EM twilliam@trinity.edu
FU Howard Hughes Medical Institute (HHMI)
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: The Howard
   Hughes Medical Institute (HHMI) is also acknowledged for financial
   support of this work via the HHMI Initiatives and Sustainability Program
   at Trinity University.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Baio J., 2014, MMWR SURVEILL SUM S2, V63, P1
   Capogna G, 1999, BRIT J ANAESTH, V82, P371
   Deth R, 2008, NEUROTOXICOLOGY, V29, P190, DOI 10.1016/j.neuro.2007.09.010
   Gale S, 2003, J AUTISM DEV DISORD, V33, P205, DOI 10.1023/A:1022951829477
   Gialloreti LE, 2014, MED HYPOTHESES, V82, P713, DOI 10.1016/j.mehy.2014.03.011
   Glasson EJ, 2004, ARCH GEN PSYCHIAT, V61, P618, DOI 10.1001/archpsyc.61.6.618
   Gregory SG, 2013, JAMA PEDIATR, V167, P959, DOI 10.1001/jamapediatrics.2013.2904
   Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76
   Infante-Rivard C, 2000, AM J EPIDEMIOL, V152, P480, DOI 10.1093/aje/152.5.480
   JOHNSON RF, 1995, ANESTHESIOLOGY, V82, P459, DOI 10.1097/00000542-199502000-00016
   Juul-Dam N, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e63
   Kenkel WM, 2014, J NEUROENDOCRINOL, V26, P739, DOI 10.1111/jne.12186
   Kolevzon A, 2007, ARCH PEDIAT ADOL MED, V161, P326, DOI 10.1001/archpedi.161.4.326
   Leighton BL, 2002, AM J OBSTET GYNECOL, V186, pS69, DOI 10.1067/mob.2002.121813
   Newschaffer CJ, 2007, ANNU REV PUBL HEALTH, V28, P235, DOI 10.1146/annurev.publhealth.28.021406.144007
   RICE RD, 1961, OBSTET GYNECOL, V17, P297
   Rodier P, 2011, AM J OBSTET GYNECOL, V204, P91, DOI 10.1016/j.ajog.2010.11.030
   Ronald A, 2006, J AM ACAD CHILD PSY, V45, P691, DOI 10.1097/01.chi.0000215325.13058.9d
   Rosenstein MG, 2014, AM J OBSTET GYNECOL, V210, P495, DOI 10.1016/j.ajog.2014.02.015
   Wahl RUR, 2004, MED HYPOTHESES, V63, P456, DOI 10.1016/j.mehy.2004.03.008
   Weisman O, 2015, BEHAV BRAIN RES, V284, P207, DOI 10.1016/j.bbr.2015.02.028
NR 22
TC 0
Z9 0
U1 7
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759-0914
J9 ASN NEURO
JI ASN Neuro
PD JUL-AUG
PY 2016
VL 8
IS 4
DI 10.1177/1759091416659742
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DU1RO
UT WOS:000381986700003
ER

PT J
AU Zhao, WH
   Yao, SX
   Li, Q
   Geng, YY
   Ma, XL
   Luo, LZ
   Xu, L
   Kendrick, KM
AF Zhao, Weihua
   Yao, Shuxia
   Li, Qin
   Geng, Yayuan
   Ma, Xiaole
   Luo, Lizhu
   Xu, Lei
   Kendrick, Keith M.
TI Oxytocin Blurs the Self-Other Distinction During Trait Judgments and
   Reduces Medial Prefrontal Cortex Responses
SO HUMAN BRAIN MAPPING
LA English
DT Article
DE self-referential effect; self- vs. other processing; oxytocin; cortical
   midline structures; self-esteem; medial prefrontal cortex
ID DEFAULT-MODE NETWORK; CORTICAL MIDLINE STRUCTURES; FUNCTIONAL
   CONNECTIVITY; INTRANASAL OXYTOCIN; SOCIAL COGNITION; PSYCHOPHYSIOLOGICAL
   INTERACTIONS; INDIVIDUAL-DIFFERENCES; NEURAL RESPONSE; FRONTAL-CORTEX;
   EXTENDED SELF
AB The neuropeptide oxytocin (OXT) may act either to increase or blur the distinction between self and other and thereby promote either more selfish or altruistic behaviors. To attempt to distinguish between these two possibilities we performed a double-blind, between-subject, placebo-controlled design study to investigate the effect of intranasal OXT on self and other (mother, classmate, or stranger) trait judgments in conjunction with functional magnetic resonance imaging. Results showed that OXT reduced response times for making both self and other judgments, but also reduced the accuracy of their subsequent recall, thereby abolishing the normal self-bias observed in this task. OXT also abolished the positive correlation between response and self-esteem scale scores seen in the PLC group, suggesting that its effects were strongest in individuals with higher levels of self-esteem. A whole-brain functional magnetic resonance imaging analysis revealed that OXT also reduced responses during both self and other trait judgments in the dorsal (dmPFC) and ventral (vmPFC) medial prefrontal cortex. A subsequent region of interest analysis revealed that behavioral performance and self-esteem scale scores were associated with dmPFC activation and its functional connectivity with the anterior cingulate and between the vmPFC and posterior cingulate. Thus overall, while OXT may improve speed of decision making in self -vs. other trait judgments it also blunts the normal bias towards remembering self-attributes and reduces mPFC responses and connectivity with other cortical midline regions involved in self-processing. This is consistent with the view that OXT can reduce self-centered behavior. (C) 2016 Wiley Periodicals, Inc.
C1 [Zhao, Weihua; Yao, Shuxia; Li, Qin; Geng, Yayuan; Ma, Xiaole; Luo, Lizhu; Xu, Lei; Kendrick, Keith M.] Univ Elect Sci & Technol China, Med Informat Ctr, Sch Life Sci & Technol, Key Lab Neuroinformat, Chengdu, Peoples R China.
RP Kendrick, KM (reprint author), 4,Sect 2,North Jianshe Rd, Chengdu 610054, Peoples R China.
EM k.kendrick.uestc@gmail.com
FU National Natural Science Foundation of China (NSFC) [31530032]
FX Contract grant sponsor: National Natural Science Foundation of China
   (NSFC) (to K.M.K.); Contract grant number: 31530032
CR Abu-Akel A, 2015, SOC NEUROSCI-UK, V10, P7, DOI 10.1080/17470919.2014.948637
   Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884
   ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037//0022-3514.63.4.596
   Aron A, 2004, EUROPEAN REV SOCIAL, V15, P101, DOI DOI 10.1080/10463280440000008
   Bartz JA, 2015, PSYCHOL SCI, V26, P1177, DOI 10.1177/0956797615580279
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Baumeister RF, 2003, PSYCHOL SCI, P1
   Beer JS, 2010, J COGNITIVE NEUROSCI, V22, P2108, DOI 10.1162/jocn.2009.21359
   BELK RW, 1988, J CONSUM RES, V15, P139, DOI 10.1086/209154
   Berkovich-Ohana A, 2012, CLIN NEUROPHYSIOL, V123, P700, DOI 10.1016/j.clinph.2011.07.048
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Blair K, 2008, ARCH GEN PSYCHIAT, V65, P1176, DOI 10.1001/archpsyc.65.10.1176
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Brett M., 2002, NEUROIMAGE, V16, pS497, DOI 10.1016/S1053-8119(02)90013-3
   Brown JD, 2010, J CROSS CULT PSYCHOL, V41, P116, DOI 10.1177/0022022109349509
   Bzdok D, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00232
   Cardoso C, 2012, PSYCHOPHARMACOLOGY, V220, P741, DOI 10.1007/s00213-011-2527-6
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   Cikara M, 2014, NEUROIMAGE, V96, P36, DOI 10.1016/j.neuroimage.2014.03.080
   Colonnello V, 2014, J PSYCHOSOM RES, V77, P415, DOI 10.1016/j.jpsychores.2014.06.016
   Colonnello V, 2013, PSYCHONEUROENDOCRINO, V38, P2996, DOI 10.1016/j.psyneuen.2013.08.010
   McCrae RR, 1989, NEO PI NEO FFI MAN S, P105
   D'Argembeau A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00372
   D'Argembeau A, 2012, ADV EXP MED BIOL, V739, P276, DOI 10.1007/978-1-4614-1704-0_18
   D'Argembeau A, 2012, CEREB CORTEX, V22, P659, DOI 10.1093/cercor/bhr144
   Ellenbogen MA, 2012, PSYCHOPHYSIOLOGY, V49, P128, DOI 10.1111/j.1469-8986.2011.01278.x
   Feng TY, 2013, BEHAV BRAIN RES, V248, P74, DOI 10.1016/j.bbr.2013.04.005
   Frewen PA, 2013, SOC COGN AFFECT NEUR, V8, P546, DOI 10.1093/scan/nss032
   Friston KJ, 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Gyurak A, 2012, SOC COGN AFFECT NEUR, V7, P322, DOI 10.1093/scan/nsr014
   Heatherton TF, 2000, J PERS SOC PSYCHOL, V78, P725, DOI 10.1037//0022-3514.78.4.725
   Hu JH, 2015, HUM BRAIN MAPP, V36, P2132, DOI 10.1002/hbm.22760
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kim K, 2014, SOC COGN AFFECT NEUR, V9, P1006, DOI 10.1093/scan/nst082
   Kim K, 2012, SOC COGN AFFECT NEUR, V7, P199, DOI 10.1093/scan/nsq096
   Kim MJ, 2011, BEHAV BRAIN RES, V223, P403, DOI 10.1016/j.bbr.2011.04.025
   Levy DJ, 2012, CURR OPIN NEUROBIOL, V22, P1027, DOI 10.1016/j.conb.2012.06.001
   Liu Y, 2013, BIOL PSYCHOL, V94, P380, DOI 10.1016/j.biopsycho.2013.08.003
   Macrae CN, 2004, CEREB CORTEX, V14, P647, DOI 10.1093/cercor/bhh025
   MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224
   Martinelli P, 2013, HUM BRAIN MAPP, V34, P1515, DOI 10.1002/hbm.22008
   McLaren DG, 2012, NEUROIMAGE, V61, P1277, DOI 10.1016/j.neuroimage.2012.03.068
   Meffert H, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00046
   Molnar-Szakacs I, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00571
   Moran JM, 2006, J COGNITIVE NEUROSCI, V18, P1586, DOI 10.1162/jocn.2006.18.9.1586
   Mu Y, 2010, NEUROIMAGE, V53, P757, DOI 10.1016/j.neuroimage.2010.07.008
   Murray RJ, 2012, NEUROSCI BIOBEHAV R, V36, P1043, DOI 10.1016/j.neubiorev.2011.12.013
   Neisser U., 1988, PHILOS PSYCHOL, V1, P35, DOI [10.1080/09515088808572924, DOI 10.1080/09515088808572924]
   Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002
   O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055
   Onoda K, 2010, SOC COGN AFFECT NEUR, V5, P385, DOI 10.1093/scan/nsq002
   Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087
   Phan KL, 2004, NEUROIMAGE, V21, P768, DOI 10.1016/j.neuroimage.2003.09.072
   Qin PM, 2011, NEUROIMAGE, V57, P1221, DOI 10.1016/j.neuroimage.2011.05.028
   ROGERS TB, 1977, J PERS SOC PSYCHOL, V35, P677, DOI 10.1037//0022-3514.35.9.677
   Rosenberg M, 1989, SOC ADOLESCENT SELF
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Schneider F, 2008, NEUROSCIENCE, V157, P120, DOI 10.1016/j.neuroscience.2008.08.014
   Sescousse G, 2013, NEUROSCI BIOBEHAV R, V37, P681, DOI 10.1016/j.neubiorev.2013.02.002
   Shamay-Tsoory SG, 2016, BIOL PSYCHIAT, V79, P194, DOI 10.1016/j.biopsych.2015.07.020
   Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106
   SINGELIS TM, 1994, PERS SOC PSYCHOL B, V20, P580, DOI 10.1177/0146167294205014
   Somerville LH, 2010, CEREB CORTEX, V20, P3005, DOI 10.1093/cercor/bhq049
   Spielberger C. D., 1970, MANUAL STATE TRAIT A
   Sripada CS, 2013, INT J NEUROPSYCHOPH, V16, P255, DOI 10.1017/S1461145712000533
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   Symons CS, 1997, PSYCHOL BULL, V121, P371, DOI 10.1037/0033-2909.121.3.371
   Tao R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047103
   Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001
   Uddin LQ, 2009, HUM BRAIN MAPP, V30, P625, DOI 10.1002/hbm.20531
   van der Meer L, 2010, NEUROSCI BIOBEHAV R, V34, P935, DOI 10.1016/j.neubiorev.2009.12.004
   Wagner G, 2013, SOC COGN AFFECT NEUR, V8, P828, DOI 10.1093/scan/nss074
   Cui H., 2005, EXPLORATIONS CHINESE
   Wang G, 2012, SOC COGN AFFECT NEUR, V7, P222, DOI 10.1093/scan/nsr002
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Xu L, 2015, PSYCHONEUROENDOCRINO, V62, P352, DOI 10.1016/j.psyneuen.2015.09.002
   Yang J, 2014, SOC COGN AFFECT NEUR, V9, P1814, DOI 10.1093/scan/nst181
   Yang J, 2012, NEUROPSYCHOLOGIA, V50, P1267, DOI 10.1016/j.neuropsychologia.2012.02.010
   Yao SX, 2014, INT J NEUROPSYCHOPH, V17, P1785, DOI 10.1017/S146114571400090X
   Zhu Y, 2007, NEUROIMAGE, V34, P1310, DOI 10.1016/j.neuroimage.2006.07.047
NR 87
TC 0
Z9 0
U1 3
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
EI 1097-0193
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUL
PY 2016
VL 37
IS 7
BP 2512
EP 2527
DI 10.1002/hbm.23190
PG 16
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DU8TV
UT WOS:000382488800012
PM 27016006
ER

PT J
AU Wang, JP
   Qin, W
   Liu, F
   Liu, B
   Zhou, Y
   Jiang, TZ
   Yu, CS
AF Wang, Junping
   Qin, Wen
   Liu, Feng
   Liu, Bing
   Zhou, Yuan
   Jiang, Tianzi
   Yu, Chunshui
TI Sex-Specific Mediation Effect of the Right Fusiform Face Area Volume on
   the Association Between Variants in Repeat Length of AVPR1A RS3 and
   Altruistic Behavior in Healthy Adults
SO HUMAN BRAIN MAPPING
LA English
DT Article
DE autism spectrum disorder; arginine vasopressin receptor 1A; fusiform
   face area; gray matter volume; microsatellite; mediation analysis
ID STATE FUNCTIONAL CONNECTIVITY; SPECTRUM DISORDER; PROMOTER REGION;
   FLANKING REGION; BRAIN RESPONSES; MESSENGER-RNA; RECEPTOR GENE;
   VASOPRESSIN; AUTISM; OXYTOCIN
AB Microsatellite variants in the arginine vasopressin receptor 1A gene (AVPR1A) RS3 have been associated with normal social behaviors variation and autism spectrum disorders (ASDs) in a sex-specific manner. However, neural mechanisms underlying these associations remain largely unknown. We hypothesized that AVPR1A RS3 variants affect altruistic behavior by modulating the gray matter volume (GMV) of specific brain regions in a sex-specific manner. We investigated 278 young healthy adults using the Dictator Game to assess altruistic behavior. All subjects were genotyped and main effect of AVPR1A RS3 repeat polymorphisms and interaction of genotype-by-sex on the GMV were assessed in a voxel-wise manner. We observed that male subjects with relatively short repeats allocated less money to others and exhibited a significantly smaller GMV in the right fusiform face area (FFA) compared with male long homozygotes. In male subjects, the GMV of the right FFA exhibited a significant positive correlation with altruistic behavior. A mixed mediation and moderation analysis further revealed both a significant mediation effect of the GMV of the right FFA on the association between AVPR1A RS3 repeat polymorphisms and allocation sums and a significant moderation effect of sex (only in males) on the mediation effect. Post hoc analysis showed that the GMV of the right FFA was significantly smaller in male subjects carrying allele 426 than in non-426 carriers. These results suggest that the GMV of the right FFA may be a potential mediator whereby the genetic variants in AVPR1A RS3 affect altruistic behavior in healthy male subjects. (C) 2016 Wiley Periodicals, Inc.
C1 [Wang, Junping; Qin, Wen; Liu, Feng; Yu, Chunshui] Tianjin Med Univ, Gen Hosp, Dept Radiol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
   [Wang, Junping; Qin, Wen; Liu, Feng; Yu, Chunshui] Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Funct Imaging, Tianjin 300052, Peoples R China.
   [Liu, Bing; Jiang, Tianzi] Chinese Acad Sci, Inst Automat, Brainnetome Ctr, Beijing, Peoples R China.
   [Liu, Bing; Jiang, Tianzi] Chinese Acad Sci, Inst Automat, Natl Lab Pattern Recognit, Beijing, Peoples R China.
   [Zhou, Yuan] Chinese Acad Sci, Inst Psychol, Ctr Social & Econ Behav, Beijing, Peoples R China.
RP Yu, CS (reprint author), Tianjin Med Univ, Gen Hosp, Dept Radiol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
EM chun-shuiyu@tijmu.edu.cn
RI Qin, Wen/G-3266-2014
OI Qin, Wen/0000-0002-9121-8296
CR Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007
   Avinun R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025274
   Barton JJS, 2002, NEUROLOGY, V58, P71
   Bisceglia R, 2012, GENES BRAIN BEHAV, V11, P262, DOI 10.1111/j.1601-183X.2012.00769.x
   Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5
   Chakrabarti S, 2005, AM J PSYCHIAT, V162, P1133, DOI 10.1176/appi.ajp.162.6.1133
   Chen Q, 2000, NEUROSCIENCE, V101, P19, DOI 10.1016/S0306-4522(00)00323-7
   Chen Q, 2000, NEUROPEPTIDES, V34, P173, DOI 10.1054/npep.2000.0809
   CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   Hammock EAD, 2002, EUR J NEUROSCI, V16, P399, DOI 10.1046/j.1460-9568.2002.02083.x
   Hibar DP, 2015, NATURE, V520, P224, DOI 10.1038/nature14101
   Hopkins WD, 2012, GENES BRAIN BEHAV, V11, P552, DOI 10.1111/j.1601-183X.2012.00799.x
   Kanwisher N, 1999, NEUROREPORT, V10, P183, DOI 10.1097/00001756-199901180-00035
   Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125
   Knafo A, 2008, GENES BRAIN BEHAV, V7, P266, DOI 10.1111/j.1601-183X.2007.00341.x
   Kruschwitz JD, 2015, BRAIN STRUCT FUNCT, V220, P2373, DOI 10.1007/s00429-014-0782-0
   Kruschwitz JD, 2015, HUM BRAIN MAPP, V36, P4089, DOI 10.1002/hbm.22900
   Kwon H, 2004, DEV MED CHILD NEUROL, V46, P760, DOI 10.1017/S0012162204001306
   Lauvin M-A, 2012, Diagn Interv Imaging, V93, P139, DOI 10.1016/j.diii.2012.01.007
   Levin R, 2009, PSYCHONEUROENDOCRINO, V34, P901, DOI 10.1016/j.psyneuen.2008.12.014
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Meyer-Lindenberg A, 2009, MOL PSYCHIATR, V14, P968, DOI 10.1038/mp.2008.54
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Parker RI, 2007, BEHAV THER, V38, P95, DOI 10.1016/j.beth.2006.05.002
   Penner LA, 2005, ANNU REV PSYCHOL, V56, P365, DOI 10.1146/annurev.psych.56.091103.070141
   Pitcher D, 2007, CURR BIOL, V17, P1568, DOI 10.1016/j.cub.2007.07.063
   Sato W, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-99
   Singer T, 2004, NEURON, V41, P653, DOI 10.1016/S0896-6273(04)00014-5
   Tansey KE, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-3
   Thompson PM, 2001, NAT NEUROSCI, V4, P1253, DOI 10.1038/nn758
   Thompson RR, 2006, P NATL ACAD SCI USA, V103, P7889, DOI 10.1073/pnas.0600406103
   Toal F, 2010, PSYCHOL MED, V40, P1171, DOI 10.1017/S0033291709991541
   Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105
   Wang JP, 2014, BRAIN STRUCT FUNCT, V219, P1543, DOI 10.1007/s00429-013-0584-9
   Wang ZX, 1997, J COMP NEUROL, V378, P535
   Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503
   Weisberg J, 2014, CEREB CORTEX, V24, P37, DOI 10.1093/cercor/bhs276
   Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816
   Yang SY, 2010, PSYCHIAT RES, V178, P199, DOI 10.1016/j.psychres.2009.11.007
   Yirmiya N, 2006, MOL PSYCHIATR, V11, P488, DOI 10.1038/sj.mp.4001812
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 45
TC 1
Z9 1
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
EI 1097-0193
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUL
PY 2016
VL 37
IS 7
BP 2700
EP 2709
DI 10.1002/hbm.23203
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DU8TV
UT WOS:000382488800024
PM 27027249
ER

PT J
AU Hashemian, F
   Shafigh, F
   Roohi, E
AF Hashemian, F.
   Shafigh, F.
   Roohi, E.
TI Regulatory role of prolactin in paternal behavior in male parents: A
   narrative review
SO JOURNAL OF POSTGRADUATE MEDICINE
LA English
DT Review
DE Parental behavior; paternal behavior; prolactin
ID MATERNAL-BEHAVIOR; PEROMYSCUS-CALIFORNICUS; NONHUMAN-PRIMATES; HORMONAL
   CHANGES; FEMALE RAT; RESPONSIVENESS; FATHERS; CARE; OXYTOCIN;
   SUPPRESSION
AB In all mammalian species, a combination of neuroendocrine and experiential factors contributes to the emergence of remarkable behavioral changes observed in parental behavior. Yet, our understanding of neuroendocrine bases of paternal behavior in humans is still preliminary and more research is needed in this area. In the present review, the authors summarized hormonal bases of paternal behavior in both human and nonhuman mammalian species and focused on studies on the regulatory role of prolactin in occurrence of paternal behavior. All peer-reviewed journal articles published before 2015 for each area discussed ( parental brain, hormonal bases of maternal behavior, hormonal bases of paternal behavior and the role of prolactin in regulation of paternal behavior in nonhuman mammalian species, hormonal bases of paternal behavior and the role of prolactin in regulation of paternal behavior in humans) were searched by PubMed, Medline, and Scopus for original research and review articles. Publications between 1973 and 2015 were included. Similar to female parents, elevated prolactin levels in new fathers most probably contribute to child-caring behavior and facilitate behavioral and emotional states attributed to child care. Moreover, elevated parental prolactin levels after childbirth decrease the parents' libidos so that they invest more in parental care than in fertility behavior. According to the available clinical studies, elevation in the amounts of prolactin levels after childbirth in male parents are probably associated with paternal behavior observed in humans.
C1 [Hashemian, F.; Shafigh, F.; Roohi, E.] Islamic Azad Univ, Fac Pharm, Dept Clin Pharm, Pharmaceut Sci Branch, Tehran, Iran.
RP Hashemian, F (reprint author), Islamic Azad Univ, Fac Pharm, Dept Clin Pharm, Pharmaceut Sci Branch, Tehran, Iran.
EM Hashemian.f@iaups.ac.ir
CR Almond REA, 2006, HORM BEHAV, V49, P673, DOI 10.1016/j.yhbeh.2005.12.009
   BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639
   Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/er.19.3.225
   Bridges RS, 2008, NEUROBIOLOGY OF THE PARENTAL BRAIN, P1
   BRIDGES RS, 1990, P NATL ACAD SCI USA, V87, P8003, DOI 10.1073/pnas.87.20.8003
   Bridges RS, 1990, MAMMALIAN PARENTING, P93
   Bridges RS., 1996, ADV STUD BEHAV, V25, P215
   Brooks PL, 2005, HORM BEHAV, V47, P358, DOI 10.1016/j.yhbeh.2004.10.003
   BROWN RE, 1986, J COMP PSYCHOL, V100, P155, DOI 10.1037/0735-7036.100.2.155
   Cabrera NJ, 2013, HDB FATHER INVOLVEME, P91
   Carlson AA, 2006, HORM BEHAV, V50, P94, DOI 10.1016/j.yhbeh.2006.01.009
   Clutton-brock TH., 1991, EVOLUTION PARENTAL C, P7
   de Jong TR, 2009, HORM BEHAV, V56, P220, DOI 10.1016/j.yhbeh.2009.05.001
   DIXSON AF, 1982, NATURE, V299, P551, DOI 10.1038/299551a0
   Feldman R, 2013, ATTACH HUM DEV, V15, P407, DOI 10.1080/14616734.2013.782650
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Fernandez-Duque E, 2009, ANNU REV ANTHROPOL, V38, P115, DOI 10.1146/annurev-anthro-091908-164334
   Fleming AS, 1997, HORM BEHAV, V31, P145, DOI 10.1006/hbeh.1997.1376
   Fleming AS, 2002, HORM BEHAV, V42, P399, DOI 10.1006/hbeh.2002.1840
   Freeman ME, 2000, PHYSIOL REV, V80, P1523
   Gerhardt S., 2004, WHY LOVE MATTERS AFF, P193
   Gettler LT, 2012, AM J PHYS ANTHROPOL, V148, P362, DOI 10.1002/ajpa.22058
   Gettler LT, 2011, HORM BEHAV, V60, P599, DOI 10.1016/j.yhbeh.2011.08.009
   Gettler LT, 2010, AM ANTHROPOL, V112, P7, DOI 10.1111/j.1548-1433.2009.01193.x
   Gordon I, 2010, HORM BEHAV, V58, P513, DOI 10.1016/j.yhbeh.2010.04.007
   Gray PB, 2010, FATHERHOOD EVOLUTION, P26
   GUBERNICK DJ, 1989, HORM BEHAV, V23, P203, DOI 10.1016/0018-506X(89)90061-5
   Hashemian F, 2013, P 13 AS C CLIN PHARM, P606
   Insel TR, 1990, OXYTOCIN MATERNAL BE, P60
   Kennett JE, 2012, J NEUROENDOCRINOL, V24, P403, DOI 10.1111/j.1365-2826.2011.02263.x
   KINSLEY CH, 1988, HORM BEHAV, V22, P49, DOI 10.1016/0018-506X(88)90030-X
   KIRKPATRICK B, 1994, BRAIN RES, V658, P112
   Kleiman D.G., 1981, P347
   Lamb M. E., 2010, ROLE FATHER CHILD DE, P94
   Leuner B, 2010, TRENDS NEUROSCI, V33, P465, DOI 10.1016/j.tins.2010.07.003
   Lonstein JS, 2001, BEHAV NEUROSCI, V115, P58, DOI 10.1037//0735-7044.115.1.58
   Lonstein JS, 2000, NEUROSCI BIOBEHAV R, V24, P669, DOI 10.1016/S0149-7634(00)00036-1
   Maestripieri D, 1999, NEUROSCI BIOBEHAV R, V23, P411, DOI 10.1016/S0149-7634(98)00042-6
   Muehlenbein MP, 2010, HUMAN EVOLUTIONARY B, P338
   Numan M, 2003, NEUROBIOLOGY PARENTA, P8
   Numan M, 2007, DEV PSYCHOBIOL, V49, P12, DOI 10.1002/dev.20198
   Pryce CR, 1995, MOTHERHOOD HUMAN NON, P69
   Pyrce CR, 1996, ADV STUD BEHAV, V25, P423
   QUADAGNO DM, 1973, PHYSIOL BEHAV, V11, P251, DOI 10.1016/0031-9384(73)90357-0
   Reburn CJ, 1999, HORM BEHAV, V35, P163, DOI 10.1006/hbeh.1998.1509
   Riley A, 2000, J SEX MARITAL THER, V26, P269, DOI 10.1080/00926230050084669
   Rilling JK, 2013, NEUROPSYCHOLOGIA, V51, P731, DOI 10.1016/j.neuropsychologia.2012.12.017
   Rosenblatt JS, 1998, HORM BEHAV, V33, P104, DOI 10.1006/hbeh.1998.1441
   Schradin C, 1999, NEWS PHYSIOL SCI, V14, P223
   Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928
   Storey AE, 2000, EVOL HUM BEHAV, V21, P79, DOI 10.1016/S1090-5138(99)00042-2
   Turna B, 2005, INT J IMPOT RES, V17, P148, DOI 10.1038/sj.ijir.3901294
   Wang ZX, 2000, J NEUROENDOCRINOL, V12, P111, DOI 10.1046/j.1365-2826.2000.00435.x
   Wylie K, 2010, MATURITAS, V67, P275, DOI 10.1016/j.maturitas.2010.07.011
   Wynne-Edwards KE, 2001, HORM BEHAV, V40, P139, DOI 10.1006/hbeh.2001.1699
   WYNNEEDWARDS KE, 1989, PHYSIOL BEHAV, V45, P465, DOI 10.1016/0031-9384(89)90059-0
   Ziegler TE, 2000, HORM BEHAV, V38, P159, DOI 10.1006/hbeh.2000.1617
   Ziegler TE, 2009, HORM BEHAV, V56, P436, DOI 10.1016/j.yhbeh.2009.07.012
NR 59
TC 0
Z9 0
U1 4
U2 4
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0022-3859
J9 J POSTGRAD MED
JI J. Postgrad. Med.
PD JUL-SEP
PY 2016
VL 62
IS 3
BP 182
EP 187
DI 10.4103/0022-3859.186389
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU7OG
UT WOS:000382403700009
PM 27424551
ER

PT J
AU Reis, AR
   Jacobs, S
   Menegotto, PR
   Silveira, PP
   Lucion, AB
AF Reis, Adolfo R.
   Jacobs, Silvana
   Menegotto, Pamela R.
   Silveira, Patricia P.
   Lucion, Aldo B.
TI Neonatal Handling Alters Maternal Emotional Response to Stress
SO DEVELOPMENTAL PSYCHOBIOLOGY
LA English
DT Article
DE neonatal intervention; stress response; depression; lactating females;
   adrenal weight
ID PITUITARY-ADRENAL AXIS; MILK-EJECTION REFLEX; NEUROENDOCRINE RESPONSES;
   POSTPARTUM DEPRESSION; ANXIETY DISORDERS; OXYTOCIN NEURONS; CHILDHOOD
   TRAUMA; SWIMMING TEST; HUMAN MOTHERS; FEMALE RATS
AB Neonatal handling is an experimental procedure used to analyze the effects of environmental interventions during early postpartum days (PPD). Long-lasting effects of repeated stress exposure in the neonatal period on the maternal side are poorly studied in this model. The aim of this study was to verify if handling the pups induces enduring effects on damsstress responses, increasing their risk for depression. Dams were divided into two groups (NHNon-handled and H-Handled) based on the handling procedure (pups were handled for 1 min/per day from PPD1-PPD10) and then subdivided into four groups (NH, NH +/- S, H, and H +/- S) based on the exposure or not to restraint stress after weaning (1 hr/per day for 7 days, PPD22-PPD28). We analyzed damsbehavior in the forced swimming test (FST PPD29-PPD30), plasma basal corticosterone and BDNF levels, as well as adrenal weight (PPD31). The results show that handling alters the stress response of dams to acute and chronic stress, as evidenced by dams of the H group having increased immobility in the first day of FST (p<.001), similar to NH +/- S (p<.01). Dams of the H and H +/- S groups show decreased levels of corticosterone when compared to NH and NH +/- S groups (p<.05), but the H + S group shows an increased adrenal weight, suggesting an increased sensibility of the maternal organism to the chronic stress applied after weaning (p<.05). We show that handling may induce a long-lasting effect on maternal stress response; these changes in the damsemotional reactivity increase their susceptibility for the development of psychiatric disorders such as depression. (C) 2016 Wiley Periodicals, Inc.
C1 [Reis, Adolfo R.; Jacobs, Silvana; Menegotto, Pamela R.; Lucion, Aldo B.] Univ Fed Rio Grande do Sul, Dept Fisiol, Inst Ciencias Basicas Saude, Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.
   [Reis, Adolfo R.; Silveira, Patricia P.; Lucion, Aldo B.] Univ Fed Rio Grande do Sul, Programa Posgrad Neurociencias, Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.
   [Silveira, Patricia P.] Univ Fed Rio Grande do Sul, Dept Pediat, Fac Med, Ramiro Barcelos 2350, BR-90035003 Porto Alegre, RS, Brazil.
RP Reis, AR (reprint author), Univ Fed Rio Grande do Sul, Dept Fisiol, Inst Ciencias Basicas Saude, Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.; Reis, AR (reprint author), Univ Fed Rio Grande do Sul, Programa Posgrad Neurociencias, Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.
EM bioadolfo@gmail.com
FU Coordination of Improvement of Higher Education Personnel (CAPES);
   National Research Council of Brazil (CNPq); FAPERGS-PRONEX [10/0018.3]
FX Contract grant sponsor: Coordination of Improvement of Higher Education
   Personnel (CAPES); Contract grant sponsor: National Research Council of
   Brazil (CNPq); Contract grant sponsor: FAPERGS-PRONEX; Contract grant
   number: 10/0018.3
CR Angelucci F, 2004, PROG BRAIN RES, V146, P151, DOI 10.1016/S0079-6123(03)46011-1
   Barrett J, 2011, J CHILD PSYCHOL PSYC, V52, P368, DOI 10.1111/j.1469-7610.2010.02306.x
   Beck CT, 2001, NURS RES, V50, P275, DOI 10.1097/00006199-200109000-00004
   BLANCHARD DC, 1995, PSYCHONEUROENDOCRINO, V20, P117, DOI 10.1016/0306-4530(94)E0045-B
   Bogdanova OV, 2013, PHYSIOL BEHAV, V118, P227, DOI 10.1016/j.physbeh.2013.05.012
   Brenes JC, 2008, PHARMACOL BIOCHEM BE, V89, P85, DOI 10.1016/j.pbb,2007.11.004
   Bridges RS, 2015, FRONT NEUROENDOCRIN, V36, P178, DOI 10.1016/j.yfrne.2014.11.007
   Caldwell EE, 2010, ALCOHOL, V44, P265, DOI 10.1016/j.alcohol.2010.02.012
   CERVO L, 1988, J PHARM PHARMACOL, V40, P155
   Detke MJ, 1996, BEHAV BRAIN RES, V73, P43
   Douglas AJ, 2005, STRESS, V8, P5, DOI 10.1080/10253890500044380
   Douglas AJ, 2003, ENDOCRINOLOGY, V144, P5268, DOI 10.1210/en.2003-0461
   Elfving B, 2010, INT J NEUROPSYCHOPH, V13, P563, DOI 10.1017/S1461145709990721
   Fleming AS, 1997, HORM BEHAV, V32, P85, DOI 10.1006/hbeh.1997.1407
   Fleming AS, 1997, HORM BEHAV, V31, P145, DOI 10.1006/hbeh.1997.1376
   FREUNDMERCIER MJ, 1984, J PHYSIOL-LONDON, V352, P447
   Gomes CM, 1999, BRAZ J MED BIOL RES, V32, P1239, DOI 10.1590/S0100-879X1999001000010
   Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X
   Hillerer KM, 2012, NEUROENDOCRINOLOGY, V95, P22, DOI 10.1159/000330445
   Hillerer KM, 2011, ENDOCRINOLOGY, V152, P3930, DOI 10.1210/en.2011-1091
   LAMBERT RC, 1993, NEUROSCIENCE, V54, P361, DOI 10.1016/0306-4522(93)90258-H
   LAMBERT RC, 1993, NEUROSCIENCE, V57, P1027, DOI 10.1016/0306-4522(93)90046-I
   LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405
   Lightman S L, 2001, Prog Brain Res, V133, P111
   Liu D, 2000, J NEUROENDOCRINOL, V12, P5
   Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659
   Llewellyn AM, 1997, J CLIN PSYCHIAT, V58, P26
   Lucion AB, 2003, BEHAV NEUROSCI, V117, P894, DOI 10.1037/0735-7044.117.5.894
   Madruga C, 2006, BEHAV BRAIN RES, V166, P241, DOI 10.1016/j.bbr.2005.08.005
   Mastorakos G, 2000, ANN NY ACAD SCI, V900, P95
   Nemeroff CB, 2004, J CLIN PSYCHIAT, V65, P18
   Nemeroff CB Charles B, 2004, Psychopharmacol Bull, V38, P14
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 2003, DEPRESS ANXIETY, V17, P111, DOI 10.1002/da.10070
   Neumann ID, 1998, J PHYSIOL-LONDON, V508, P289
   Padoin MJ, 2001, BEHAV NEUROSCI, V115, P1332, DOI 10.1037//0735-7044.115.6.1332
   PEARLMAN WH, 1983, ENDOCRINOL EXP, V17, P165
   PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V
   PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8
   Raineki C, 2009, NEUROSCIENCE, V159, P31, DOI 10.1016/j.neuroscience.2008.12.012
   Raineki C, 2008, NEUROENDOCRINOLOGY, V87, P151, DOI 10.1159/000112230
   Raineki C, 2013, DEV PSYCHOBIOL, V55, P496, DOI 10.1002/dev.21053
   Reis AR, 2014, BEHAV BRAIN RES, V265, P216, DOI 10.1016/j.bbr.2014.02.036
   Reus GZ, 2011, NEUROCHEM RES, V36, P460, DOI 10.1007/s11064-010-0364-3
   Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006
   Severino GS, 2004, PHYSIOL BEHAV, V81, P489, DOI 10.1016/j.physbeh.2004.02.019
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Silveira PP, 2013, BRAZ J MED BIOL RES, V46, P426, DOI 10.1590/1414-431X20132784
   Silveira PP, 2006, BEHAV BRAIN RES, V173, P205, DOI 10.1016/j.bbr.2006.06.031
   STEINER M, 1979, ACTA PSYCHIAT SCAND, V60, P449, DOI 10.1111/j.1600-0447.1979.tb00555.x
   Todeschin AS, 2009, HORM BEHAV, V56, P93, DOI 10.1016/j.yhbeh.2009.03.006
   Westdahl C, 2007, OBSTET GYNECOL, V110, P134, DOI 10.1097/01.AOG.0000265352.61822.1b
   Winkelmann-Duarte EC, 2011, EXP BRAIN RES, V215, P163, DOI 10.1007/s00221-011-2881-y
   Yan J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1267
NR 54
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1630
EI 1098-2302
J9 DEV PSYCHOBIOL
JI Dev. Psychobiol.
PD JUL
PY 2016
VL 58
IS 5
BP 614
EP 622
DI 10.1002/dev.21405
PG 9
WC Developmental Biology; Psychology
SC Developmental Biology; Psychology
GA DS8GX
UT WOS:000381022600006
PM 27020142
ER

PT J
AU Zhu, J
   Chen, ZJ
   Zhu, LT
   Meng, ZH
   Wu, GC
   Tian, ZZ
AF Zhu, Jing
   Chen, Zhejun
   Zhu, LiTing
   Meng, ZeHui
   Wu, GenCheng
   Tian, ZhanZhuang
TI Arginine Vasopressin and Arginine Vasopressin Receptor 1b Involved in
   Electroacupuncture-Attenuated Hypothalamic-Pituitary-Adrenal Axis
   Hyperactivity in Hepatectomy Rats
SO NEUROMODULATION
LA English
DT Article
DE Arginine vasopressin; AVPR1b; electroacupuncture; hepatectomy; HPA axis
ID NERVE-STIMULATION; ADULT RATS; STRESS; ACUPUNCTURE; OXYTOCIN; PAIN;
   EXPRESSION; NEURONS; MODEL; NEUROMODULATION
AB Objective: The study aims to know the effect of electroacupuncture (EA) in maintenance of the homeostasis of the neuroendocrine system in hepatectomy rats and the involvement of arginine vasopressin (AVP) signaling in hypothalamus after EA was observed.
   Materials and Methods: Rats were randomly assigned to four groups, including the intact group, model group, sham-EA group, and EA group. EA was given during the perioperative period at the Zusanli (ST36) and Sanyinjiao (SP6) points after hepatectomy. The serum adrenocorticotropic hormone (ACTH) and corticosterone (CORT) levels were detected via radioimmunoassay. The expression of AVP, arginine vasopressin receptor 1a (AVPR1a), arginine vasopressin receptor 1b (AVPR1b), and glucocorticoid receptor (GR) was detected by Western blot after surgery.
   Results: Compared with the intact group, the ACTH and CORT levels in the serum of model group were increased, whereas the ACTH and CORT levels were decreased in the EA group compared with the model group. Moreover, AVP and AVPR1b protein levels in the pituitary gland were increased in the model group and decreased in the EA group. Further, a distinct increase in the AVP and AVPR1a protein levels was observed in the model group, whereas they were significantly decreased in the EA group. Blockade of AVPR1b by nelivaptan reduced the increase of ACTH and CORT. D [Leu(4), Lys(8)] vasopressin can inhibit the effect of EA in rectification of the hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis.
   Conclusions: EA application at ST36 and SP6 can ameliorate the hyperactivity of the HPA axis via AVP signaling during the perioperative period.
C1 [Zhu, Jing; Chen, Zhejun; Zhu, LiTing; Meng, ZeHui; Wu, GenCheng; Tian, ZhanZhuang] Fudan Univ, Collaborat Innovat Ctr Brain Sci Inst Acupuncture, WHO Collaborating Ctr Tradit Med, Dept Integrat Med & Neurobiol,State Key Lab Med N, Shanghai 200032, Peoples R China.
RP Tian, ZZ (reprint author), Fudan Univ, Collaborat Innovat Ctr Brain Sci Inst Acupuncture, WHO Collaborating Ctr Tradit Med, Dept Integrat Med & Neurobiol,State Key Lab Med N, Shanghai 200032, Peoples R China.
EM tianvv@shmu.edu.cn
FU National Key Program of Basic Science (973) [2013CB531906]; National
   Natural Science Fund of China [81573712]
FX This project was supported by the National Key Program of Basic Science
   (973) 2013CB531906 and the National Natural Science Fund of China
   (81573712).
CR Acar O, 2015, NEUROMODULATION, V18, P324, DOI 10.1111/ner.12246
   Badowska-Szalewska E, 2014, J NEUROSCI RES, V92, P1446, DOI 10.1002/jnr.23428
   Barsegyan A, 2015, NEUROPSYCHOPHARMACOL, V40, P1979, DOI 10.1038/npp.2015.48
   BONDY CA, 1987, NEUROENDOCRINOLOGY, V46, P258, DOI 10.1159/000124829
   Cipriano C, 2003, MECH AGEING DEV, V124, P877, DOI 10.1016/S0047-6374(03)00146-5
   de Souza MA, 2013, NEUROCHEM RES, V38, P1479, DOI 10.1007/s11064-013-1049-5
   Eshkevari L, 2013, J ENDOCRINOL, V217, P95, DOI 10.1530/JOE-12-0404
   Feng XM, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-225
   Gibbison B, 2013, BRIT J ANAESTH, V111, P347, DOI 10.1093/bja/aet077
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Jasnic N, 2013, J EXP BIOL, V216, P2302, DOI 10.1242/jeb.082842
   Johnson S, 2015, NEUROMODULATION, V18, P384, DOI 10.1111/ner.12244
   Liu RP, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/789674
   LU GW, 1983, AM J PHYSIOL, V245, pR606
   Newson MJF, 2009, J ENDOCRINOL, V202, P123, DOI 10.1677/JOE-09-0093
   Pena A, 2007, ENDOCRINOLOGY, V148, P4136, DOI 10.1210/en.2006-1633
   Slusarz MJ, 2015, EXPERT OPIN THER PAT, V25, P711, DOI 10.1517/13543776.2015.1026257
   Song MJ, 2009, BRAIN RES BULL, V78, P335, DOI 10.1016/j.brainresbull.2008.10.009
   Sood R, 2014, PSYCHONEUROENDOCRINO, V49, P62, DOI 10.1016/j.psyneuen.2014.06.015
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   Tabosa A, 2002, BRAZ J MED BIOL RES, V35, P731, DOI 10.1590/S0100-879X2002000600015
   Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x
   Tanoue A, 2004, J CLIN INVEST, V113, P302, DOI 10.1172/JCI200419656
   Tian N, 2006, PEPTIDES, V27, P2313, DOI 10.1016/j.peptides.2006.03.010
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Wang K, 2012, J NEUROSCI RES, V90, P1464, DOI 10.1002/jnr.23028
   Wang LX, 2009, BRAIN RES, V1247, P79, DOI 10.1016/j.brainres.2008.09.094
   Wang Q, 2015, INT J CARDIOL, V194, P28, DOI 10.1016/j.ijcard.2015.05.043
   Wang XW, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-21
   Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094696
   WITEKJANUSEK L, 1984, AVIAT SPACE ENVIR MD, V55, P538
   Xu J, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0667-7
   Yao Y, 2015, EVID-BASED COMPL ALT, V2015, DOI [DOI 10.1155/2015/324360, 10.1155/2015/324360]
   Yi WM, 2014, EVID-BASED COMPL ALT, V2014
   Yoon SS, 2012, PSYCHOPHARMACOLOGY, V222, P303, DOI 10.1007/s00213-012-2683-3
   Yuan ST, 2014, BRAIN RES, V1593, P19, DOI 10.1016/j.brainres.2014.10.005
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD JUL
PY 2016
VL 19
IS 5
BP 498
EP 505
DI 10.1111/ner.12366
PG 8
WC Medicine, Research & Experimental; Clinical Neurology
SC Research & Experimental Medicine; Neurosciences & Neurology
GA DS6NP
UT WOS:000380899000017
PM 26573696
ER

PT J
AU Yamaguchi, ET
   Siaulys, MM
   Torres, MLA
AF Yamaguchi, Eduardo Tsuyoshi
   Siaulys, Monica Maria
   Abramides Torres, Marcelo Luis
TI Oxytocin in cesarean-sections. What's new?
SO REVISTA BRASILEIRA DE ANESTESIOLOGIA
LA English
DT Review
DE Oxytocin; Cesarean section; Desensitization; Dose
ID DOUBLE-BLIND; RANDOMIZED-TRIAL; BLOOD-LOSS; DELIVERY; BOLUS; WOMEN;
   CARBETOCIN; INFUSION; HEMORRHAGE; ANESTHESIA
AB Oxytocin is the uterotonic agent of choice in the prevention and treatment of postpartum uterine atony. Nevertheless, there is no consensus on the optimal dose and rate for use in cesarean sections. The use of high bolus doses (e.g., 10 IU of oxytocin) can determine deleterious cardiovascular changes for the patient, especially in situations of hypovolemia or low cardiac reserve. Furthermore, high doses of oxytocin for prolonged periods may lead to desensitization of oxytocin receptors in myometrium, resulting in clinical inefficiency. (C) 2016 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.
C1 [Yamaguchi, Eduardo Tsuyoshi] HU USP, Sao Paulo, SP, Brazil.
   [Siaulys, Monica Maria] Hosp Maternidade Santa Joana, Sao Paulo, SP, Brazil.
   [Abramides Torres, Marcelo Luis] Univ Sao Paulo, Dept Surg, Fac Med, Sao Paulo, SP, Brazil.
RP Yamaguchi, ET (reprint author), HU USP, Sao Paulo, SP, Brazil.
EM eduardo@hu.usp.br
CR Archer TL, 2008, INT J OBSTET ANESTH, V17, P247, DOI 10.1016/j.ijoa.2008.03.003
   Balki M, 2006, OBSTET GYNECOL, V107, P45, DOI 10.1097/01.AOG.0000191529.52596.c0
   Balki M, 2010, REPROD SCI, V17, P269, DOI 10.1177/1933719109351934
   Butwick AJ, 2012, INT J OBSTET ANESTH, V21, P348, DOI 10.1016/j.ijoa.2012.08.005
   Butwick AJ, 2010, BRIT J ANAESTH, V104, P338, DOI 10.1093/bja/aeq004
   Carvalho JCA, 2004, OBSTET GYNECOL, V104, P1005, DOI 10.1097/01.AOG.0000142709.04450.bd
   Cordovani D, 2012, CAN J ANESTH, V59, P751, DOI 10.1007/s12630-012-9728-2
   Dyer RA, 2010, INT J OBSTET ANESTH, V19, P313, DOI 10.1016/j.ijoa.2010.04.011
   Dyer RA, 2009, ANESTHESIOLOGY, V111, P753, DOI 10.1097/ALN.0b013e3181b437e0
   Frolich MA, 2011, INT J OBSTET ANESTH, V20, P30, DOI 10.1016/j.ijoa.2010.08.002
   George RB, 2010, CAN J ANAESTH, V57, P578, DOI 10.1007/s12630-010-9297-1
   King KJ, 2010, ANESTH ANALG, V111, P1460, DOI 10.1213/ANE.0b013e3181f8930a
   Langesaeter E, 2006, INT J GYNECOL OBSTET, V95, P46, DOI 10.1016/j.ijgo.2006.05.032
   Langesaeter E, 2011, INT J OBSTET ANESTH, V20, P26, DOI 10.1016/j.ijoa.2010.10.004
   McLeod G, 2010, INT J OBSTET ANESTH, V19, P155, DOI 10.1016/j.ijoa.2009.08.005
   Ministerio da Saude (Brasil) Secretaria de Vigilancia em Saude, 2011, MORT MAT BRAS PRINC
   Moertl MG, 2011, BJOG-INT J OBSTET GY, V118, P1349, DOI 10.1111/j.1471-0528.2011.03022.x
   Pursche T, 2012, ARCH GYNECOL OBSTET, V286, P633, DOI 10.1007/s00404-012-2334-2
   Roach MK, 2013, AM J PERINAT, V30, P523, DOI 10.1055/s-0032-1329184
   Rosaeg OP, 1998, ANESTH ANALG, V86, P40, DOI 10.1097/00000539-199801000-00008
   Rosseland LA, 2013, ANESTHESIOLOGY, V119, P541, DOI 10.1097/ALN.0b013e31829416dd
   Sartain JB, 2008, BRIT J ANAESTH, V101, P822, DOI 10.1093/bja/aen273
   Sheehan SR, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4661
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
   Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301
   Thomas JS, 2007, BRIT J ANAESTH, V98, P116, DOI 10.1093/bja/ael302
   Tsen LC, 2010, INT J OBSTET ANESTH, V19, P243, DOI 10.1016/j.ijoa.2010.05.001
   Wedisinghe L, 2008, EUR J OBSTET GYN R B, V137, P27, DOI 10.1016/j.ejogrb.2007.04.007
   Yamaguchi ET, 2011, INT J OBSTET ANESTH, V20, P224, DOI 10.1016/j.ijoa.2011.03.004
   Yamaguchi Eduardo Tsuyoshi, 2007, Rev Bras Anestesiol, V57, P324, DOI 10.1590/S0034-70942007000300011
   [Anonymous], 2001, WHY MOTHERS DIE CONF
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0034-7094
EI 1806-907X
J9 REV BRAS ANESTESIOL
JI Rev. Bras. Anestesiol.
PD JUL-AUG
PY 2016
VL 66
IS 4
BP 402
EP 407
DI 10.1016/j.bjane.2014.11.015
PG 6
WC Anesthesiology
SC Anesthesiology
GA DS5SU
UT WOS:000380843400012
PM 26626317
ER

PT J
AU Tsikouras, P
   Koukouli, Z
   Manav, B
   Soilemetzidis, M
   Liberis, A
   Csorba, R
   Trypsianis, G
   Galazios, G
AF Tsikouras, P.
   Koukouli, Z.
   Manav, B.
   Soilemetzidis, M.
   Liberis, A.
   Csorba, R.
   Trypsianis, G.
   Galazios, G.
TI Induction of Labor in Post-Term Nulliparous and Parous Women - Potential
   Advantages of Misoprostol over Dinoprostone
SO GEBURTSHILFE UND FRAUENHEILKUNDE
LA English
DT Article
DE misoprostol; dinoprostone; labor induction; post-term pregnancy
ID RANDOMIZED-CONTROLLED-TRIAL; OFF-LABEL USE; 50 MU-G; VAGINAL
   MISOPROSTOL; OXYTOCIN; INSERT
AB Introduction: We undertook a prospective cohort study to compare the effectiveness and safety of 50 mu g misoprostol versus 3 mg dinoprostone in two vaginal doses 6 hours apart, followed if necessary by oxytocin for labor induction in low-risk post-term (>40 weeks) pregnancies with unfavorable cervix (Bishop score <= 6).
   Methods: Labor induction and subsequent management were conducted using a standardized protocol. The primary outcome of the study was labor induction rate. Secondary outcomes included mode of delivery, time interval from induction to delivery, maternal complications and neonatal outcome.
   Results: 107 patients received misoprostol (Group A) and 99 patients received dinoprostone (Group B). Compared with group A, more women in Group B needed a second vaginal dose of prostaglandin or oxytocin infusion in order to proceed to labor (21.5 vs. 43.4%; p = 0.01). Misoprostol alone as a single or double vaginal dose was more effective than dinoprostone alone in inducing labor without oxytocin administration (85.0 vs. 50.4%; p = 0.04). Overall, the rate of successful induction of labor did not differ between groups (91.6 vs. 85.8%; p = 0.75). Vaginal delivery, operative vaginal delivery and Caesarean section rates were not significantly different. Time interval from induction to delivery however, was shorter for Group A (median 11 hours vs. 14.1 hours; p < 0.001). Though emergency Caesarean section due to fetal distress was more frequent in Group A (16.8 vs. 4.0%; p = 0.007), low Apgar scores <7 and NICU admissions did not differ significantly. Maternal complications, mostly not serious, were higher in Group A (31.8 vs. 2.0, p < 0.001).
   Conclusion: Misoprostol is a more effective agent than dinoprost in post-term pregnancy for labor induction with few maternal adverse effects.
C1 [Tsikouras, P.; Koukouli, Z.; Manav, B.; Soilemetzidis, M.; Liberis, A.; Galazios, G.] Democritus Univ Thrace, Dept Obstet & Gynecol, Lysimachou Petrina 6 Km Alexandroupolis Makri, Alexandroupolis, Greece.
   [Csorba, R.] Univ Wurzburg, Teaching Hosp, Clinicum Aschaffenburg, Dept Obstet & Gynecol, Wurzburg, Germany.
   [Trypsianis, G.] Democritus Univ Thrace, Dept Med Stat, Alexandroupolis, Greece.
RP Tsikouras, P (reprint author), Democritus Univ Thrace, Dept Obstet & Gynecol, Lysimachou Petrina 6 Km Alexandroupolis Makri, Alexandroupolis, Greece.
EM ptsikour@med.duth.gr
CR ACOG Committee on Practice Bulletins-Obstetrics, 2009, OBSTET GYNECOL 1, V114, P386, DOI DOI 10.1097/AOG.0B013E3181B48EF5
   Adair CD, 1998, OBSTET GYNECOL, V92, P810, DOI 10.1016/S0029-7844(98)00278-6
   American College of Obstetricians and Gynecologists; Society for Maternal- Fetal Medicine, 2014, OBSTET GYNECOL, V123, P693, DOI DOI 10.1097/01.AOG.0000444441.04111.1D
   Austin SC, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.03.014
   Cohen WR, 1983, MANAGEMENT OF LABOR
   Crane JMG, 2006, BJOG-INT J OBSTET GY, V113, P1366, DOI 10.1111/j.1471-0528.2006.01111.x
   EMTE, 2014, HELL SOC OBST GYN GU, P71
   Hofmeyr GJ, 2010, COCHRANE DB SYST REV, V10
   Kramer RL, 1997, OBSTET GYNECOL, V89, P387, DOI 10.1016/S0029-7844(97)00363-3
   Krause E, 2011, EUR J OBSTET GYN R B, V159, P324, DOI 10.1016/j.ejogrb.2011.09.013
   Leduc Dean, 2013, J Obstet Gynaecol Can, V35, P840
   Loto OM, 2012, J MATERN-FETAL NEO M, V25, P2359, DOI 10.3109/14767058.2012.696160
   Martin Joyce A, 2012, Natl Vital Stat Rep, V61, P1
   Papanikolaou Evangelos G, 2004, Reprod Biol Endocrinol, V2, P70, DOI 10.1186/1477-7827-2-70
   Plaut MM, 1999, AM J OBSTET GYNECOL, V180, P1535, DOI 10.1016/S0002-9378(99)70049-9
   Rahman Hafizur, 2013, J Obstet Gynaecol Can, V35, P408
   Rasheed Rozina, 2007, J Pak Med Assoc, V57, P404
   Rouse DJ, 1999, OBSTET GYNECOL, V93, P323, DOI 10.1016/S0029-7844(98)00448-7
   Rouzi AA, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.08.033
   Sanchez-Ramos L, 2002, OBSTET GYNECOL, V99, P145, DOI 10.1016/S0029-7844(01)01644-1
   Santo S, 2009, GYNECOL OBSTET INVES, V68, P272, DOI 10.1159/000242427
   Silfeler D, 2011, ARCH GYNECOL OBSTET, V284, P1331, DOI 10.1007/s00404-011-1844-7
   Talaulikar VS, 2011, OBSTET GYNECOL SURV, V66, P717, DOI 10.1097/OGX.0b013e31823e0c69
   Tang J, 2013, INT J GYNECOL OBSTET, V121, P186, DOI 10.1016/j.ijgo.2012.12.009
   Voigt F, 2015, EUR J OBSTET GYN R B, V187, P85, DOI 10.1016/j.ejogrb.2014.11.026
   Weeks AD, 2005, BJOG-INT J OBSTET GY, V112, P269, DOI 10.1111/j.1471-0528.2004.00490.x
   World Health Organization, 2011, WHO REC IND LAB
   Wing DA, 2013, OBSTET GYNECOL, V122, P201, DOI 10.1097/AOG.0b013e31829a2dd6
   Wing DA, 2011, OBSTET GYNECOL, V117, P533, DOI 10.1097/AOG.0b013e318209d669
   Zeng Xianling, 2015, Drug Discov Ther, V9, P165, DOI 10.5582/ddt.2015.01033
NR 30
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0016-5751
EI 1438-8804
J9 GEBURTSH FRAUENHEILK
JI Geburtshilfe Frauenheilkd.
PD JUL
PY 2016
VL 76
IS 7
BP 785
EP 792
DI 10.1055/s-0042-105287
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DS5BQ
UT WOS:000380795900011
ER

PT J
AU Kleinau, G
   Muller, A
   Biebermann, H
AF Kleinau, Gunnar
   Mueller, Anne
   Biebermann, Heike
TI Oligomerization of GPCRs involved in endocrine regulation
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Review
DE G-protein-coupled receptors; homomers; heteromers; homooligomerization;
   heterooligomerization; dimers; oligomers; endocrine regulation;
   endocrine diseases; signaling
ID PROTEIN-COUPLED-RECEPTORS; RESONANCE ENERGY-TRANSFER; GLYCOPROTEIN
   HORMONE-RECEPTORS; V2 VASOPRESSIN RECEPTORS; SINGLE-MOLECULE ANALYSIS;
   LIGAND-BINDING SITES; WILD-TYPE RECEPTORS; MU-OPIOID RECEPTOR; OXYTOCIN
   RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR
AB More than 800 different human membrane-spanning G-protein-coupled receptors ( GPCRs) serve as signal transducers at biological barriers. These receptors are activated by a wide variety of ligands such as peptides, ions and hormones, and are able to activate a diverse set of intracellular signaling pathways. GPCRs are of central importance in endocrine regulation, which underpins the significance of comprehensively studying these receptors and interrelated systems. During the last decade, the capacity for multimerization of GPCRs was found to be a common and functionally relevant property. The interaction between GPCR monomers results in higher order complexes such as homomers ( identical receptor subtype) or heteromers ( different receptor subtypes), which may be present in a specific and dynamic monomer/oligomer equilibrium. It is widely accepted that the oligomerization of GPCRs is a mechanism for determining the fine-tuning and expansion of cellular processes by modification of ligand action, expression levels, and related signaling outcome. Accordingly, oligomerization provides exciting opportunities to optimize pharmacological treatment with respect to receptor target and tissue selectivity or for the development of diagnostic tools. On the other hand, GPCR heteromerization may be a potential reason for the undesired side effects of pharmacological interventions, faced with numerous and common mutual signaling modifications in heteromeric constellations. Finally, detailed deciphering of the physiological occurrence and relevance of specific GPCR/ GPCR-ligand interactions poses a future challenge. This review will tackle the aspects of GPCR oligomerization with specific emphasis on family A GPCRs involved in endocrine regulation, whereby only a subset of these receptors will be discussed in detail.
C1 [Kleinau, Gunnar; Mueller, Anne; Biebermann, Heike] Charite, IEPE, Berlin, Germany.
RP Biebermann, H (reprint author), Charite, IEPE, Berlin, Germany.
EM heike.biebermann@charite.de
FU Deutsche Forschungsgemeinschaft [BI893/2-2, BI893/5-2, BI893/6-6,
   BI893/8-1]; Helmholtz Alliance 'Imaging and Curing Environmental
   Metabolic Diseases' (ICEMED) [WP19]; Else-Kroner-Fresenius-Stiftung
   [2014_A114]
FX This work was supported by the Deutsche Forschungsgemeinschaft
   BI893/2-2, BI893/5-2, BI893/6-6 and BI893/8-1, the Helmholtz Alliance
   'Imaging and Curing Environmental Metabolic Diseases' (ICEMED), WP19 (H
   Biebermann), and by the Else-Kroner-Fresenius-Stiftung (G Kleinau and H
   Biebermann, 2014_A114).
CR AbdAlla S, 2000, NATURE, V407, P94
   AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003
   AbdAlla S, 2009, J BIOL CHEM, V284, P6566, DOI 10.1074/jbc.M808277200
   Ahuja S, 2009, TRENDS PHARMACOL SCI, V30, P494, DOI 10.1016/j.tips.2009.06.003
   Albizu L, 2006, MOL PHARMACOL, V70, P1783, DOI 10.1124/mol.106.025684
   Albizu L, 2010, CNS NEUROL DISORD-DR, V9, P636
   Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/nchembio.396, 10.1038/NCHEMBIO.396]
   Allen MD, 2011, FASEB J, V25, P3687, DOI 10.1096/fj.11-188961
   Ardura JA, 2011, PHARMACOL REV, V63, P882, DOI 10.1124/pr.110.004176
   ARGIOLAS A, 1992, ANN NY ACAD SCI, V652, P194, DOI 10.1111/j.1749-6632.1992.tb34355.x
   Bakker RA, 2004, J PHARMACOL EXP THER, V311, P131, DOI 10.1124/jpet.104.067041
   Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35047145
   Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642
   Beaumont KA, 2005, HUM MOL GENET, V14, P2145, DOI 10.1093/hmg/ddi219
   Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603
   Benleulmi-Chaachoua A, 2016, J PINEAL RES, V60, P95, DOI 10.1111/jpi.12294
   Bianco AC, 2014, THYROID, V24, P88, DOI 10.1089/thy.2013.0109
   Biebermann H, 2003, DIABETES, V52, P2984, DOI 10.2337/diabetes.52.12.2984
   Biebermann H, 2012, HDB EXPT PHARM, V209, P47, DOI [DOI 10.1007/978-3-642-24716-3_, 10.1007/978-3-642-24716-3_3]
   Biebermann H, 2012, J CLIN ENDOCR METAB, V97, pE228, DOI 10.1210/jc.2011-2106
   Bilek R, 2000, PHYSIOL RES, V49, pS19
   Bonomi M, 2013, METHOD ENZYMOL, V521, P367, DOI 10.1016/B978-0-12-391862-8.00020-X
   Bonomi M, 2012, ASIAN J ANDROL, V14, P49, DOI 10.1038/aja.2011.68
   Borroto-Escuela DO, 2014, INT J MOL SCI, V15, P8570, DOI 10.3390/ijms15058570
   Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575
   Brezillon S, 2001, BRAIN RES, V921, P21, DOI 10.1016/S0006-8993(01)03068-2
   Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091
   Calebiro D, 2005, HUM MOL GENET, V14, P2991, DOI 10.1093/hmg/ddi329
   Calebiro D, 2013, P NATL ACAD SCI USA, V110, P743, DOI 10.1073/pnas.1205798110
   Cao J, 1998, J BIOL CHEM, V273, P32281, DOI 10.1074/jbc.273.48.32281
   Carlsson J, 2011, NAT CHEM BIOL, V7, P769, DOI 10.1038/nchembio.662
   Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586
   Chaly AL, 2016, ELIFE, V5, DOI 10.7554/eLife.12397
   Chen JC, 2005, MOL PHARMACOL, V67, P2070, DOI 10.1124/mol.105.011619
   Ciruela F, 2014, ACS CHEM BIOL, V9, P1918, DOI 10.1021/cb5004042
   Ciruela F, 2010, TRENDS BIOTECHNOL, V28, P407, DOI 10.1016/j.tibtech.2010.05.002
   Cohen BD, 2004, MOL CELL ENDOCRINOL, V220, P1, DOI 10.1016/j.mce.2004.04.012
   Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455
   CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0
   CONN PM, 1982, ENDOCRINOLOGY, V111, P335
   Cooray SN, 2011, MOL CELL ENDOCRINOL, V331, P215, DOI 10.1016/j.mce.2010.07.015
   Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200
   Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234
   De Moerlooze L, 2000, CYTOGENET CELL GENET, V90, P146, DOI 10.1159/000015650
   Decaillot FM, 2008, P NATL ACAD SCI USA, V105, P16045, DOI 10.1073/pnas.0804106105
   Dehvari N, 2012, BRIT J PHARMACOL, V165, P1442, DOI 10.1111/j.1476-5381.2011.01647.x
   Deupi X, 2011, CURR OPIN STRUC BIOL, V21, P541, DOI 10.1016/j.sbi.2011.06.002
   Dinger MC, 2003, J BIOL CHEM, V278, P10562, DOI 10.1074/jbc.M205747200
   Dinter Juliane, 2015, Eur Thyroid J, V4, P21, DOI 10.1159/000381801
   Dinter J, 2015, J MOL ENDOCRINOL, V54, P205, DOI 10.1530/JME-15-0003
   Dode C, 2006, PLOS GENET, V2, P1648, DOI 10.1371/journal.pgen.0020175
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Doupnik CA, 2008, J RECEPT SIG TRANSD, V28, P83, DOI 10.1080/10799890801941970 
   Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509
   Durroux T, 2005, TRENDS PHARMACOL SCI, V26, P376, DOI 10.1016/j.tips.2005.05.006
   Ebner NC, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00487
   Ellis J, 2006, J BIOL CHEM, V281, P38812, DOI 10.1074/jbc.M602494200
   Fanelli F, 2007, MOL CELL ENDOCRINOL, V260, P59, DOI 10.1016/j.mce.2005.12.054
   Farooqi S, 2014, MAMM GENOME, V25, P377, DOI 10.1007/s00335-014-9541-z
   Feng XY, 2013, ENDOCRINOLOGY, V154, P3925, DOI 10.1210/en.2013-1407
   Ferre S, 2015, TRENDS PHARMACOL SCI, V36, P145, DOI 10.1016/j.tips.2015.01.002
   Ferre S, 2010, CURR OPIN PHARMACOL, V10, P1, DOI 10.1016/j.coph.2009.11.002
   Frederick AL, 2015, MOL PSYCHIATR, V20, P1373, DOI 10.1038/mp.2014.166
   Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Fuxe K, 2012, CURR MED CHEM, V19, P356
   Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/i.tips.2007.06.005
   Garcia-Jimenez C, 2007, ARQ BRAS ENDOCRINOL, V51, P654, DOI 10.1590/S0004-27302007000500003
   Garfield AS, 2015, NAT NEUROSCI, V18, P863, DOI 10.1038/nn.4011
   Garland SL, 2013, J BIOMOL SCREEN, V18, P947, DOI 10.1177/1087057113498418
   George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244
   George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gomes I, 2000, J NEUROSCI, V20, part. no.
   Gomes I, 2016, ANNU REV PHARMACOL, V56, P403, DOI 10.1146/annurev-pharmtox-011613-135952
   Gomes I, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00268
   Gomes I, 2013, PROG MOL BIOL TRANSL, V117, P207, DOI 10.1016/B978-0-12-386931-9.00009-X
   Gonzalez S, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001347
   Gonzalez-Maeso J, 2008, NATURE, V452, P93, DOI 10.1038/nature06612
   Gorinski N, 2012, MOL PHARMACOL, V82, P448, DOI 10.1124/mol.112.079137
   Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305
   Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102
   Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200
   Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153
   Hague C, 2006, MOL PHARMACOL, V69, P45, DOI 10.1124/mol.105.014985
   Hall RA, 1998, NATURE, V392, P626
   Hanson MA, 2009, STRUCTURE, V17, P8, DOI 10.1016/j.str.2008.12.003
   Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200
   Harikumar KG, 2008, J MOL NEUROSCI, V36, P279, DOI 10.1007/s12031-008-9060-z
   Harmeier A, 2015, EUR NEUROPSYCHOPHARM, V25, P2049, DOI 10.1016/j.euroneuro.2015.08.011
   HARRIGAN MT, 1991, MOL ENDOCRINOL, V5, P1331
   HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438
   Hay DL, 2006, PHARMACOL THERAPEUT, V109, P173, DOI 10.1016/j.pharmthera.2005.06.015
   Hebert TE, 1996, J BIOL CHEM, V271, P16384
   Heng BC, 2013, BIOTECHNOL ADV, V31, P1676, DOI 10.1016/j.biotechadv.2013.08.017
   Hern JA, 2010, P NATL ACAD SCI USA, V107, P2693, DOI 10.1073/pnas.0907915107
   Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027
   Herrick-Davis K, 2013, MOL PHARMACOL, V84, P630, DOI 10.1124/mol.113.087072
   Heuer H, 1999, ACTA MED AUST, V26, P119
   Hink MA, 2013, METHOD CELL BIOL, V117, P197, DOI 10.1016/B978-0-12-408143-7.00011-6
   Ho M K C, 2009, Curr Mol Pharmacol, V2, P19
   Hofmann KP, 2009, TRENDS BIOCHEM SCI, V34, P540, DOI 10.1016/j.tibs.2009.07.005
   Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892
   Hu JX, 2013, J BIOL CHEM, V288, P34777, DOI 10.1074/jbc.M113.503714
   Hutchings CJ, 2010, MABS-AUSTIN, V2, P594, DOI 10.4161/mabs.2.6.13420
   Ibrahim S, 2010, ARTERIOSCL THROM VAS, V30, P1802, DOI 10.1161/ATVBAHA.110.208900
   Jackson DS, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00213
   Ji I, 2004, MOL ENDOCRINOL, V18, P968, DOI 10.1210/me.2003-0443
   Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299
   Jiang H, 2006, MOL ENDOCRINOL, V20, P1772, DOI 10.1210/me.2005-0084
   Jonas KC, 2015, J BIOL CHEM, V290, P3875, DOI 10.1074/jbc.M114.622498
   Juhasz JR, 2008, EUR J PHARMACOL, V581, P235, DOI 10.1016/j.ejphar.2007.11.060
   Kasahara Y, 2013, ENDOCRINOLOGY, V154, P4305, DOI 10.1210/en.2012-2206
   Kasai RS, 2011, J CELL BIOL, V192, P463, DOI 10.1083/jcb.201009128
   Kern A, 2015, CELL, V163, P1176, DOI 10.1016/j.cell.2015.10.062
   Kern A, 2012, NEURON, V73, P317, DOI 10.1016/j.neuron.2011.10.038
   Khelashvili G, 2010, BIOINFORMATICS, V26, P1804, DOI 10.1093/bioinformatics/btq264
   Kilpatrick LE, 2015, MOL PHARMACOL, V87, P718, DOI 10.1124/mol.114.095356
   Kleinau G, 2013, ENDOCR REV, V34, P691, DOI 10.1210/er.2012-1072
   Kleinau G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027073
   Kleinau G, 2009, ENDOCR REV, V30, P133, DOI 10.1210/er.2008-0044
   Kobilka B, 2008, TRENDS PHARMACOL SCI, V29, P79, DOI 10.1016/j.tips.2007.11.009
   Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003
   Kontoyianni M, 2012, CURR MED CHEM, V19, P544
   Kopanchuk S, 2006, NEUROCHEM INT, V49, P533, DOI 10.1016/j.neuint.2006.04.006
   Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002
   Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200
   KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5
   Laffray S, 2012, EMBO J, V31, P3239, DOI 10.1038/emboj.2012.161
   Lambert NA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115pe12
   Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200
   Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329
   Levoye A, 2006, EMBO REP, V7, P1094, DOI 10.1038/sj.embor.7400838
   Levoye A, 2006, EMBO J, V25, P3012, DOI 10.1038/sj.emboj.7601193
   Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199
   Li X, 2013, CURR DRUG TARGETS, V14, P899
   Libri DV, 2014, J CLIN ENDOCR METAB, V99, pE458, DOI 10.1210/jc.2013-2431
   Limbird LE, 2004, MOL INTERV, V4, P326, DOI 10.1124/mi.4.6.6
   Lodowski DT, 2009, PHOTOCHEM PHOTOBIOL, V85, P425, DOI 10.1111/j.1751-1097.2008.00516.x
   Lohse MJ, 2012, PHARMACOL REV, V64, P299, DOI 10.1124/pr.110.004309
   Lohse MJ, 2010, CURR OPIN PHARMACOL, V10, P53, DOI 10.1016/j.coph.2009.10.007
   Magalhaes AC, 2010, NAT NEUROSCI, V13, P622, DOI 10.1038/nn.2529
   Maldonado-Perez D, 2007, TRENDS ENDOCRIN MET, V18, P66, DOI 10.1016/j.tem.2006.12.002
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Mancia F, 2008, EMBO REP, V9, P363, DOI 10.1038/embor.2008.27
   Mandrika I, 2005, BIOCHEM BIOPH RES CO, V326, P349, DOI 10.1016/j.bbrc.2004.11.036
   Marsango S, 2011, CELL MOL LIFE SCI, V68, P2919, DOI 10.1007/s00018-010-0601-6
   Mason JS, 2012, TRENDS PHARMACOL SCI, V33, P249, DOI 10.1016/j.tips.2012.02.005
   Matsumoto S, 2006, P NATL ACAD SCI USA, V103, P4140, DOI 10.1073/pnas.0508881103
   Maurice P, 2011, ADV PHARMACOL, V62, P349, DOI 10.1016/B978-0-12-385952-5.00001-4
   Maurice P, 2011, TRENDS PHARMACOL SCI, V32, P514, DOI 10.1016/j.tips.2011.05.006
   Mazurkiewicz JE, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.125781
   McLatchie LM, 1998, NATURE, V393, P333
   McMillin SM, 2011, J BIOL CHEM, V286, P28584, DOI 10.1074/jbc.M111.259788
   Metherell LA, 2005, NAT GENET, V37, P166, DOI 10.1038/ng1501
   Mohr K, 2013, ANGEW CHEM INT EDIT, V52, P508, DOI 10.1002/anie.201205315
   Muller A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053347
   Muller TD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2968
   Murat B, 2012, MOL ENDOCRINOL, V26, P502, DOI 10.1210/me.2011-1202
   Navarro G, 2008, THESCIENTIFICWORLDJO, V8, P1088, DOI 10.1100/tsw.2008.136
   Negri L, 2007, LIFE SCI, V81, P1103, DOI 10.1016/j.1s.2007.08.011
   Ng HKH, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00010
   Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103
   Ng Stephanie Y L, 2012, Front Endocrinol (Lausanne), V3, P175, DOI 10.3389/fendo.2012.00175
   Nijmeijer S, 2010, J BIOL CHEM, V285, P29632, DOI 10.1074/jbc.M110.115618
   Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006
   O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521
   White JF, 2007, PNAS, V104, P12199, DOI [10.1073/ pnas. 0705312104, DOI 10.1073/PNAS.0705312104]
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006
   Oswal A, 2007, OBES REV, V8, P293, DOI 10.1111/j.1467-789X.2007.00378.x
   Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9
   Park S, 2012, P NATL ACAD SCI USA, V109, P19003, DOI 10.1073/pnas.1209590109
   Pei L, 2010, NAT MED, V16, P1393, DOI 10.1038/nm.2263
   Pellissier LP, 2011, J BIOL CHEM, V286, P9985, DOI 10.1074/jbc.M110.201939
   Perreault ML, 2014, NEUROPSYCHOPHARMACOL, V39, P156, DOI 10.1038/npp.2013.148
   Persani L, 2007, NAT CLIN PRACT ENDOC, V3, P180, DOI 10.1038/ncpendmet0401
   Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200
   Piechowski CL, 2013, J MOL ENDOCRINOL, V51, P109, DOI 10.1530/JME-13-0061
   Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5
   Piscitelli CL, 2015, MOL PHARMACOL, V88, P536, DOI 10.1124/mol.115.099663
   Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1
   Raivio T, 2012, J CLIN ENDOCR METAB, V97, pE694, DOI 10.1210/jc.2011-2938
   Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251
   Rashid AJ, 2007, P NATL ACAD SCI USA, V104, P654, DOI 10.1073/pna5.0604049104
   RAYMOND JR, 1995, AM J PHYSIOL-RENAL, V269, pF141
   Rediger A, 2012, NEUROENDOCRINOLOGY, V95, P277, DOI 10.1159/000334903
   Rediger A, 2011, J BIOL CHEM, V286, P39623, DOI 10.1074/jbc.M111.287607
   Rediger A, 2009, OBESITY FACTS, V2, P80, DOI 10.1159/000209862
   Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040
   Reynaud R, 2012, J CLIN ENDOCR METAB, V97, pE1068, DOI 10.1210/jc.2011-3056
   Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757
   Ritter SL, 2009, NAT REV MOL CELL BIO, V10, P819, DOI 10.1038/nrm2803
   Rivero-Muller A, 2010, P NATL ACAD SCI USA, V107, P2319, DOI 10.1073/pnas.0906695106
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144
   Rozenfeld R, 2011, BIOCHEM J, V433, P11, DOI 10.1042/BJ20100458
   Sakai T, 2008, ACTA BIOL HUNG, V59, P241, DOI 10.1556/ABiol.59.2008.Suppl.34
   Sakai T, 2012, ENDOCRINOLOGY, V153, P1841, DOI 10.1210/en.2011-1668
   Satake Honoo, 2013, Front Endocrinol (Lausanne), V4, P100, DOI 10.3389/fendo.2013.00100
   Sbai O, 2014, FASEB J, V28, P3734, DOI 10.1096/fj.13-243402
   Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330
   Scheerer P, 2009, P NATL ACAD SCI USA, V106, P10660, DOI 10.1073/pnas.0900072106
   Schellekens H, 2013, J BIOL CHEM, V288, P181, DOI 10.1074/jbc.M112.382473
   Schelshorn D, 2012, MOL PHARMACOL, V81, P309, DOI 10.1124/mol.111.074757
   Schertler GFX, 2008, NATURE, V453, P292, DOI 10.1038/453292a
   Schlyer S, 2006, DRUG DISCOV TODAY, V11, P481, DOI 10.1016/j.drudis.2006.04.008
   Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008
   Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218
   Seeman P, 2005, P NATL ACAD SCI USA, V102, P3513, DOI 10.1073/pnas.0409766102
   Seeman P, 2007, SYNAPSE, V61, P303, DOI 10.1002/syn.20368
   Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0
   Shoichet BK, 2012, TRENDS PHARMACOL SCI, V33, P268, DOI 10.1016/j.tips.2012.03.007
   Shonberg J, 2011, CHEMMEDCHEM, V6, P963, DOI 10.1002/cmdc.201100101
   Skieterska K, 2013, METHOD CELL BIOL, V117, P323, DOI 10.1016/B978-0-12-408143-7.00017-7
   Smit MJ, 2007, ANNU REV PHARMACOL, V47, P53, DOI 10.1146/annurev.pharmtox.47.120505.105126
   Smith NJ, 2010, PHARMACOL REV, V62, P701, DOI 10.1124/pr.110.002667
   Smits G, 2003, NEW ENGL J MED, V349, P760, DOI 10.1056/NEJMoa030064
   Song GJ, 2005, MOL ENDOCRINOL, V19, P2859, DOI 10.1210/me.2005-0133
   Song GJ, 2007, P NATL ACAD SCI USA, V104, P18303, DOI 10.1073/pnas.0702857104
   Sposini S, 2015, MOL CELL ENDOCRINOL, V399, P362, DOI 10.1016/j.mce.2014.10.024
   Sun Y, 2003, J MOL ENDOCRINOL, V30, P87, DOI 10.1677/jme.0.0300087
   Surgand JS, 2006, PROTEINS, V62, P509, DOI 10.1002/prot.20768
   Svendsen AM, 2008, ENDOCRINOLOGY, V149, P1113, DOI 10.1210/en.2007-0412
   Svendsen AM, 2009, ANN NY ACAD SCI, V1160, P54, DOI 10.1111/j.1749-6632.2009.03835.x
   Tadagaki K, 2012, BLOOD, V119, P4908, DOI 10.1182/blood-2011-08-372516
   Tadagaki K, 2012, NEUROENDOCRINOLOGY, V95, P223, DOI 10.1159/000330000
   Tao YX, 2006, PHARMACOL THERAPEUT, V111, P949, DOI 10.1016/j.pharmthera.2006.02.008
   Tao YX, 2010, CURR OPIN INVEST DR, V11, P1092
   Tao YX, 2004, J BIOL CHEM, V279, P5904, DOI 10.1074/jbc.M311162200
   Tarnow P, 2008, OBESITY FACTS, V1, P155, DOI 10.1159/000138251
   Tate CG, 2009, CURR OPIN STRUC BIOL, V19, P386, DOI 10.1016/j.sbi.2009.07.004
   Teichmann A, 2014, J BIOL CHEM, V289, P24250, DOI 10.1074/jbc.M114.553644
   Teichmann A, 2012, J BIOL CHEM, V287, P27265, DOI 10.1074/jbc.M112.360594
   Teitler M, 2012, PHARMACOL THERAPEUT, V133, P205, DOI 10.1016/j.pharmthera.2011.10.007
   Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101
   Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222
   Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551
   Tripathi A, 2015, P NATL ACAD SCI USA, V112, pE1659, DOI 10.1073/pnas.1417564112
   Troppmann B, 2013, HUM REPROD UPDATE, V19, P583, DOI 10.1093/humupd/dmt023
   Tschische P, 2011, BIOCHEM PHARMACOL, V82, P610, DOI 10.1016/j.bcp.2011.06.009
   Tyndall JDA, 2005, MED CHEM, V1, P405, DOI 10.2174/1573406054368675
   Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541
   Uddin MS, 2012, J RECEPT SIG TRANSD, V32, P65, DOI 10.3109/10799893.2011.647352
   Urizar E, 2005, EMBO J, V24, P1954, DOI 10.1038/sj.emboj.7600686
   van Unen J, 2015, MOL PHARMACOL, V88, P589, DOI 10.1124/mol.115.098897
   Vassart G, 2014, ENDOTEXT
   Vassart G, 2011, NAT REV ENDOCRINOL, V7, P362, DOI 10.1038/nrendo.2011.20
   Veldhuis NA, 2015, PHARMACOL REV, V67, P36, DOI 10.1124/pr.114.009555
   Vidi PA, 2009, MOL PHARMACOL, V75, P733, DOI 10.1124/mol.108.053819
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Vilardaga JP, 2008, NAT CHEM BIOL, V4, P126, DOI 10.1038/nchembio.64
   Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102
   Walther C, 2015, MOL ENDOCRINOL, V29, P814, DOI 10.1210/me.2015-1091
   Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8
   Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wichard JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016811
   Wilson SJ, 2007, BIOCHEM BIOPH RES CO, V352, P397, DOI 10.1016/j.bbrc.2006.11.040
   Wrzal PK, 2012, CELL SIGNAL, V24, P342, DOI 10.1016/j.cellsig.2011.09.020
   Wrzal PK, 2012, CELL SIGNAL, V24, P333, DOI 10.1016/j.cellsig.2011.09.019
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939
   Xie ZH, 2008, J PHARMACOL EXP THER, V325, P629, DOI 10.1124/jpet.107.135079
   Yanagawa M, 2011, J BIOL CHEM, V286, P22971, DOI 10.1074/jbc.M110.206870
   Yekkirala AS, 2013, LIFE SCI, V92, P438, DOI 10.1016/j.lfs.2012.06.021
   Young SF, 2007, CELL MOL NEUROBIOL, V27, P439, DOI 10.1007/s10571-006-9135-8
   Yuan YY, 2013, MEDCHEMCOMM, V4, P847, DOI 10.1039/c3md00080j
   Zhao Q, 2012, ACTA PHARMACOL SIN, V33, P324, DOI 10.1038/aps.2011.187
   Zhou WB, 2012, REGUL PEPTIDES, V179, P84, DOI 10.1016/j.regpep.2012.08.003
   Zhu CC, 2002, J BIOL CHEM, V277, P28228, DOI 10.1074/jbc.M204221200
   Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z
   Zoenen M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1991
NR 273
TC 0
Z9 0
U1 2
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952-5041
EI 1479-6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD JUL
PY 2016
VL 57
IS 1
BP R59
EP R80
DI 10.1530/JME-16-0049
PG 22
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DS3YB
UT WOS:000380717500007
PM 27151573
ER

PT J
AU Ishiguro, T
   Takeda, J
   Fang, X
   Bronson, H
   Olson, DM
AF Ishiguro, Tomohito
   Takeda, Jun
   Fang, Xin
   Bronson, Heather
   Olson, David M.
TI Interleukin (IL)-1 in rat parturition: IL-1 receptors 1 and 2 and
   accessory proteins abundance in pregnant rat uterus at term - regulation
   by progesterone
SO PHYSIOLOGICAL REPORTS
LA English
DT Article
DE IL-1 receptor; IL-1 receptor accessory protein; IL-1 receptor accessory
   protein - brain dominant; parturition; uterus
ID INDUCED PRETERM LABOR; SMOOTH-MUSCLE-CELLS; LATE-GESTATION;
   PROINFLAMMATORY CYTOKINES; ACTIVATOR PROTEIN-1; OXYTOCIN RECEPTOR; BLOOD
   MONOCYTES; FETAL MEMBRANES; EXPRESSION; MYOMETRIUM
AB The role of interleukin-1 (IL-1), a pro-inflammatory cytokine, in parturition is typically noted by changes in its concentrations. Studying the expression of its receptor family, IL-1 receptor (IL-1R) 1, IL-1R2, IL-1R accessory protein (IL-1RAcP), and its predominantly brain isoform, IL-1RAcPb, during late gestation in the uterus in the Long-Evans rat is another. We assessed changes in their mRNA and protein relative abundance in the uterus and compared IL-1RAcP and IL-1RAcPb mRNA abundance in uterus, cervix, ovaries, placenta, and whole blood of Long-Evans rats during late gestation or in RU486 and progesterone-treated dams using quantitative real-time PCR and western immunoblotting. IL-1R1, IL-1RAcP, and IL-1RAcPb mRNA abundance significantly increased in the uterus at delivery whereas IL-1R2 mRNA abundance significantly decreased. IL-1R1 protein increased at term and IL-1R2 protein decreased at term compared to nonpregnant uteri. IL1-RAcPb mRNA abundance was less than IL-1RAcP, but in the lower uterine segment it was the highest of all tissues examined. RU486 stimulated preterm delivery and an increase in IL-1R1 mRNA abundance whereas progesterone administration extended pregnancy and suppressed the increase in IL-1R1. These data suggest that changes in uterine sensitivity to IL-1 occur during late gestation and suggest another level of regulation for the control of delivery. The roles for IL-1RAcP and IL-1RAcPb need to be determined, but may relate to different intracellular signaling pathways.
C1 [Ishiguro, Tomohito; Takeda, Jun; Fang, Xin; Bronson, Heather; Olson, David M.] Univ Alberta, Dept Obstet & Gynecol, 227 HMRC, Edmonton, AB T6G 2S2, Canada.
   [Ishiguro, Tomohito; Takeda, Jun; Fang, Xin; Bronson, Heather; Olson, David M.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada.
   [Ishiguro, Tomohito; Takeda, Jun; Fang, Xin; Bronson, Heather; Olson, David M.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
   [Ishiguro, Tomohito; Takeda, Jun] Juntendo Univ, Fac Med, Dept Obstet, Tokyo, Japan.
   [Ishiguro, Tomohito; Takeda, Jun] Juntendo Univ, Fac Med, Dept Gynecol, Tokyo, Japan.
   [Ishiguro, Tomohito] Koshigaya Municipal Hosp, Dept Obstet, Koshigaya, Japan.
   [Ishiguro, Tomohito] Koshigaya Municipal Hosp, Dept Gynecol, Koshigaya, Japan.
RP Olson, DM (reprint author), Univ Alberta, Dept Obstet & Gynecol, 227 HMRC, Edmonton, AB T6G 2S2, Canada.
EM david.olson@ualberta.ca
CR Adams Waldorf K M, 2011, BJOG, V118, P136, DOI 10.1111/j.1471-0528.2010.02728.x
   Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x
   Bartlett SR, 1999, J PHYSIOL-LONDON, V520, P399, DOI 10.1111/j.1469-7793.1999.00399.x
   Bennett WA, 2000, AM J OBSTET GYNECOL, V182, P1496, DOI 10.1067/mob.2000.106848
   Bollapragada S, 2009, AM J OBSTET GYNECOL, V200, P101
   Christiaens I, 2008, J REPROD IMMUNOL, V79, P50, DOI 10.1016/j.jri.2008.04.002
   Fang X, 1997, ENDOCRINOLOGY, V138, P2763, DOI 10.1210/en.138.7.2763
   Fang X, 2000, AM J REPROD IMMUNOL, V44, P65, DOI 10.1111/j.8755-8920.2000.440201.x
   Gomez-Lopez N, 2016, IMMUNOL CELL BIOL, V94, P79, DOI 10.1038/icb.2015.63
   Gomez-Lopez N, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S8
   Hirsch E, 2002, AM J OBSTET GYNECOL, V186, P523, DOI 10.1067/mob.2002.120278
   Hirsch Emmet, 2009, J Negat Results Biomed, V8, P1, DOI 10.1186/1477-5751-8-1
   Huang YY, 2011, J NEUROSCI, V31, P18048, DOI 10.1523/JNEUROSCI.4067-11.2011
   Kim J, 2012, J REPROD IMMUNOL, V94, P190, DOI 10.1016/j.jri.2012.02.002
   Lan L, 1999, MOL CELL ENDOCRINOL, V155, P123, DOI 10.1016/S0303-7207(99)00066-0
   LIGGINS GC, 1977, BIOL REPROD, V16, P39, DOI 10.1095/biolreprod16.1.39
   MacIntyre DA, 2014, FASEB J, V28, P2358, DOI 10.1096/fj.13-247783
   Mitchell BF, 2005, AM J PHYSIOL-ENDOC M, V289, pE658, DOI 10.1152/ajpendo.00058.2005
   Mitchell JA, 2002, BIOL REPROD, V67, P240, DOI 10.1095/biolreprod67.1.240
   Montalbano AP, 2013, ENDOCRINOLOGY, V154, P483, DOI 10.1210/en.2012-1797
   Nadeau-Vallee M, 2015, J IMMUNOL, V195, P3402, DOI 10.4049/jimmunol.1500758
   OPSJON SL, 1993, AM J OBSTET GYNECOL, V169, P397
   Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/humrep/gag001
   Paris JJ, 2011, STRESS, V14, P652, DOI 10.3109/10253890.2011.628719
   Parker L C, 2000, Brain Res Mol Brain Res, V79, P156
   Pawelczyk E, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-66
   Robertson SA, 2010, ENDOCRINOLOGY, V151, P3996, DOI 10.1210/en.2010-0063
   ROMERO R, 1992, AM J OBSTET GYNECOL, V167, P1041
   ROMERO R, 1991, AM J OBSTET GYNECOL, V165, P969
   ROMERO R, 1989, AM J OBSTET GYNECOL, V160, P1117
   ROMERO R, 1992, AM J REPROD IMMUNOL, V27, P117
   Romero R, 2006, SEMIN FETAL NEONAT M, V11, P317, DOI 10.1016/j.siny.2006.05.001
   Sadowsky DR, 2000, AM J OBSTET GYNECOL, V183, P173, DOI 10.1067/mob.2000.105968
   Schober L, 2012, IMMUNOL CELL BIOL, V90, P935, DOI 10.1038/icb.2012.33
   Shynlova O, 2005, BIOL REPROD, V73, P773, DOI 10.1095/biolreprod.105.040006
   Shynlova O, 2004, BIOL REPROD, V70, P986, DOI 10.1095/biolreprod.103.023648
   Shynlova O, 2008, J IMMUNOL, V181, P1470
   Shynlova O, 2007, REPRODUCTION, V134, P503, DOI 10.1530/REP-07-0004
   Shynlova O, 2007, BIOL REPROD, V76, P571, DOI 10.1095/biolreprod.106.056929
   Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691
   Smith DE, 2009, IMMUNITY, V30, P817, DOI 10.1016/j.immuni.2009.03.020
   Taishi P, 2012, J APPL PHYSIOL, V112, P1015, DOI 10.1152/japplphysiol.01307.2011
   Terzidou V, 2006, J CLIN ENDOCR METAB, V91, P2317, DOI 10.1210/jc.2005.2649
   Verstraeten B, 2015, REPROD SCI, V22, p141A
   Wakabayashi A, 2013, MOL HUM REPROD, V19, P718, DOI 10.1093/molehr/gat057
   Waldorf KMA, 2008, REPROD SCI, V15, P121, DOI 10.1177/1933719107310992
   Xu C, 2015, MOL HUM REPROD, V21, P603, DOI 10.1093/molehr/gav018
   Yao YL, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0121-6
   Yoshida T, 2012, J NEUROSCI, V32, P2588, DOI 10.1523/JNEUROSCI.4637-11.2012
   Young A, 2002, BIOL REPROD, V66, P445, DOI 10.1095/biolreprod66.2.445
NR 50
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2051-817X
J9 PHYSIOL REP
JI PHYSIOL. REP.
PD JUL
PY 2016
VL 4
IS 14
AR e12866
DI 10.14814/phy2.12866
PG 12
WC Physiology
SC Physiology
GA DS3XK
UT WOS:000380715800007
ER

PT J
AU Jackson, DB
AF Jackson, Dylan B.
TI The Association Between Breastfeeding Duration and Attachment: A
   Genetically Informed Analysis
SO Breastfeeding Medicine
LA English
DT Article
ID MOTHER-INFANT RELATIONSHIP; MATERNAL SENSITIVITY; SIBLING COMPARISONS;
   OXYTOCIN RESPONSE; Q-SORT; SECURITY; BEHAVIOR; CHILDHOOD; BRAIN;
   DISORDER
AB Introduction: A growing body of research explores whether breastfeeding during infancy influences the development of attachment security in offspring. Studies to date have generally yielded inconsistent results, with some studies detecting an association between breastfeeding and attachment security, and others failing to do so. The purpose of this study is to empirically consider whether (1) any association between breastfeeding and offspring attachment security is robust to both familial and genetic confounding and (2) whether the breastfeeding-attachment relationship is significant for both male and female offspring.
   Materials and Methods: The present study uses data from the Early Childhood Longitudinal Study: Birth Cohort (ECLS-B) to examine whether twins who differ in their extent of exposure to breastfeeding exhibit different attachment patterns by the time they reach toddlerhood.
   Results: The results suggest that, independent of genetic and shared environmental influences, breastfeeding duration increases the security of attachment in offspring, but only among females.
   Conclusions: A longer duration of breastfeeding may help to facilitate a secure attachment among female offspring.
C1 [Jackson, Dylan B.] Univ Texas San Antonio, Dept Criminal Justice, 501 W Cesar E Chavez Blvd, San Antonio, TX 78207 USA.
RP Jackson, DB (reprint author), Univ Texas San Antonio, Dept Criminal Justice, 501 W Cesar E Chavez Blvd, San Antonio, TX 78207 USA.
EM dylan.jackson@utsa.edu
CR Andreassen C, 2007, METHODOLOGY REPORT
   Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002
   BOWLBY J, 1982, AM J ORTHOPSYCHIAT, V52, P664
   Bowlby J., 1969, ATTACHMENT LOSS ATTA, VI
   Britton JR, 2006, PEDIATRICS, V118, pE1436, DOI 10.1542/peds.2005-2916
   Bronte-Tinkew J, 2009, J MARRIAGE FAM, V71, P1001
   Cable N, 2012, EUR J PUBLIC HEALTH, V22, P653, DOI 10.1093/eurpub/ckr135
   Colen CG, 2014, SOC SCI MED, V109, P55, DOI 10.1016/j.socscimed.2014.01.027
   Else-Quest NM, 2003, MERRILL PALMER QUART, V49, P495, DOI 10.1353/mpq.2003.0020
   Evenhouse E, 2005, HEALTH SERV RES, V40, P1781, DOI 10.1111/j.1475-6773.2005.00453.x
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Foroushani A. R., 2010, Eastern Mediterranean Health Journal, V16, P202
   Gribble KD., 2006, INT BREASTFEED J, V1, P1
   Jansen J, 2008, DEV REV, V28, P503, DOI 10.1016/j.dr.2008.07.001
   Kim P, 2011, J CHILD PSYCHOL PSYC, V52, P907, DOI 10.1111/j.1469-7610.2011.02406.x
   Kohler HP, 2001, BEHAV GENET, V31, P179, DOI 10.1023/A:1010253411274
   Kramer MS, 2008, PEDIATRICS, V121, pE435, DOI 10.1542/peds.2007-1248
   Kramer MS, 2011, PAEDIATR PERINAT EP, V25, P500, DOI 10.1111/j.1365-3016.2011.01211.x
   Lai YL, 2015, APPL NURS RES, V28, P116, DOI 10.1016/j.apnr.2014.08.002
   Leerkes EM, 2011, INFANT BEHAV DEV, V34, P443, DOI 10.1016/j.infbeh.2011.04.006
   Liu JH, 2014, NUTRIENTS, V6, P76, DOI 10.3390/nu6010076
   Lonnerdal B, 2013, J PAEDIATR CHILD H, V49, P1, DOI 10.1111/jpc.12104
   Mathews ME, 2014, J HUM LACT, V30, P480, DOI 10.1177/0890334414537707
   Minnis H, 2007, BRIT J PSYCHIAT, V190, P490, DOI 10.1192/bjp.bp.105.019745
   Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3
   PEDERSON DR, 1990, CHILD DEV, V61, P1974, DOI 10.1111/j.1467-8624.1990.tb03579.x
   Quinn PJ, 2001, J PAEDIATR CHILD H, V37, P465, DOI 10.1046/j.1440-1754.2001.00702.x
   Raby KL, 2012, PSYCHOL SCI, V23, P1016, DOI 10.1177/0956797612438265
   Rodgers JL, 2001, J QUANT CRIMINOL, V17, P145, DOI 10.1023/A:1011097929954
   Roisman GI, 2008, DEV PSYCHOL, V44, P831, DOI 10.1037/0012-1649.44.3.831
   Schulze PA, 2008, EPIDEMIOL INFECT, V180, P703, DOI 10.1080/03004430802263870
   Schwartz JA, 2015, J INTERPERS VIOLENCE, DOI 0886260515576970
   Schwarze CE, 2015, J PERS DISORD, V29, P610, DOI 10.1521/pedi_2014_28_160
   Shapiro DL, 1999, CHILD ABUSE NEGLECT, V23, P1175, DOI 10.1016/S0145-2134(99)00085-X
   Shelton KH, 2011, EUR CHILD ADOLES PSY, V20, P571, DOI 10.1007/s00787-011-0224-y
   Strathearn L, 2012, HORM BEHAV, V61, P429, DOI 10.1016/j.yhbeh.2012.01.014
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Tharner A, 2012, J DEV BEHAV PEDIATR, V33, P396, DOI 10.1097/DBP.0b013e318257fac3
   van Ijzendoorn MH, 2004, CHILD DEV, V75, P1188, DOI 10.1111/j.1467-8624.2004.00733.x
   WATERS E, 1985, MONOGR SOC RES CHILD, V50, P41, DOI 10.2307/3333826
NR 40
TC 2
Z9 2
U1 6
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1556-8253
EI 1556-8342
J9 BREASTFEED MED
JI Breastfeed. Med.
PD JUL-AUG
PY 2016
VL 11
IS 6
BP 297
EP 304
DI 10.1089/bfm.2016.0036
PG 8
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA DS4LG
UT WOS:000380752000009
ER

PT J
AU Fujiwara, T
   Sanada, M
   Kofuji, T
   Akagawa, K
AF Fujiwara, Tomonori
   Sanada, Masumi
   Kofuji, Takefumi
   Akagawa, Kimio
TI Unusual social behavior in HPC-1/syntaxinlA knockout mice is caused by
   disruption of the oxytocinergic neural system
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE HPC-1/syntaxin 1A; in vivo microdialysis; knockout mice; oxytocin; SNARE
   protein; social behavior
ID SYNAPTIC PLASTICITY; MEDIAL AMYGDALA; OUT MICE; 1A; RECOGNITION; GENE;
   EXPRESSION; AUTISM; MOUSE; FEAR
AB HPC-1/syntaxin1A (STX1A), a neuronal soluble N-ethylmaleimide-sensitive fusion attachment protein receptor, contributes to neural function in the CNS by regulating transmitter release. Recent studies reported that STX1A is associated with human neuropsychological disorders, such as autism spectrum disorder and attention deficit hyperactivity disorder. Previously, we showed that STX1A null mutant mice (STX1A KO) exhibit neuropsychological abnormalities, such as fear memory deficits, attenuation of latent inhibition, and unusual social behavior. These observations suggested that STX1A may be involved in the neuropsychological basis of these abnormalities. Here, to study the neural basis of social behavior, we analyzed the profile of unusual social behavior in STX1A KO with a social novelty preference test, which is a useful method for quantification of social behavior. Interestingly, the unusual social behavior in STX1A KO was partially rescued by intracerebroventricular administration of oxytocin (OXT). In vivo microdialysis studies revealed that the extracellular OXT concentration in the CNS of STX1A KO was significantly lower compared with wild- type mice. Furthermore, dopamine-induced OXT release was reduced in STX1A KO. These results suggested that STX1A plays an important role in social behavior through regulation of the OXTergic neural system.
C1 [Fujiwara, Tomonori; Sanada, Masumi; Kofuji, Takefumi; Akagawa, Kimio] Kyorin Univ, Sch Med, Dept Cell Physiol, Shinkawa 6-20-2, Mitaka, Tokyo 1818611, Japan.
   [Kofuji, Takefumi] Kyorin Univ, Sch Med, Radioisotope Lab, Mitaka, Tokyo 1818611, Japan.
RP Fujiwara, T (reprint author), Kyorin Univ, Sch Med, Dept Cell Physiol, Shinkawa 6-20-2, Mitaka, Tokyo 1818611, Japan.
EM tfuj@ks.kyorin-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [22500338, 24300142]; Promotion and Mutual Aid Cooperation for Private
   Schools of Japan
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research (C) to T.F. (grant no. 22500338), Grant-in-Aid for Scientific
   Research (B) to K.A. (grant no. 24300142) from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan, and a
   Grant-in-Aid from the Promotion and Mutual Aid Cooperation for Private
   Schools of Japan to K.A.
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Burket JA, 2011, BRAIN RES BULL, V86, P152, DOI 10.1016/j.brainresbull.2011.08.001
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Espana RA, 2008, NEUROSCIENCE, V155, P250, DOI 10.1016/j.neuroscience.2008.05.022
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Fujiwara T, 2006, J NEUROSCI, V26, P5767, DOI 10.1523/JNEUROSCI.0289-06.2006
   Fujiwara T, 2011, J NEUROENDOCRINOL, V23, P1222, DOI 10.1111/j.1365-2826.2011.02214.x
   Fujiwara T, 2010, EUR J NEUROSCI, V32, P99, DOI 10.1111/j.1460-9568.2010.07269.x
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gaier ED, 2014, J NEUROPHYSIOL, V111, P1927, DOI 10.1152/jn.00631.2013
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gould BR, 2003, NEUROSCIENCE, V122, P155, DOI 10.1016/S0306-4522(03)00283-5
   Greidanus TBV, 1996, BRAIN RES, V713, P153
   Gur R, 2014, BIOL PSYCHIAT, V76, P377, DOI 10.1016/j.biopsych.2014.03.022
   Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028
   INOUE A, 1992, J BIOL CHEM, V267, P10613
   Jack A., 2012, FRONT HUM NEUROSCI, V10, P280
   Kenar ANI, 2014, PSYCHIAT INVEST, V11, P76, DOI 10.4306/pi.2014.11.1.76
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Mishima T, 2012, J NEUROSCI, V32, P381, DOI 10.1523/JNEUROSCI.2911-11.2012
   Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x
   Nakamura K, 2008, INT J NEUROPSYCHOPH, V11, P1073, DOI 10.1017/S1461145708009036
   Paxions G., 1997, MOUSE BRAIN STEREOTA
   ROELING TAP, 1993, NEUROSCIENCE, V56, P199, DOI 10.1016/0306-4522(93)90574-Y
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Scott Niv, 2015, Nature, V525, P519, DOI 10.1038/nature15378
   Sudhof TC, 2009, SCIENCE, V323, P474, DOI 10.1126/science.1161748
   Tobin V, 2012, J NEUROENDOCRINOL, V24, P629, DOI 10.1111/j.1365-2826.2011.02237.x
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Toth I, 2013, CELL TISSUE RES, V354, P107, DOI 10.1007/s00441-013-1636-4
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
NR 37
TC 0
Z9 0
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD JUL
PY 2016
VL 138
IS 1
BP 117
EP 123
DI 10.1111/jnc.13634
PG 7
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DS0CO
UT WOS:000380263200008
PM 27059771
ER

PT J
AU Hong, SH
   Kyeong, KS
   Kim, CH
   Kim, YC
   Choi, W
   Yoo, RY
   Kim, HS
   Park, YJ
   Ji, IW
   Jeong, EH
   Kim, HS
   Xu, WX
   Lee, SJ
AF Hong, Seung Hwa
   Kyeong, Kyu-Sang
   Kim, Chan Hyung
   Kim, Young Chul
   Choi, Woong
   Yoo, Ra Young
   Kim, Hun Sik
   Park, Yeon Jin
   Ji, Il Woon
   Jeong, Eun-Hwan
   Kim, Hak Soon
   Xu, Wen-Xie
   Lee, Sang Jin
TI Regulation of myometrial contraction by ATP-sensitive potassium (K-ATP)
   channel via activation of SUR2B and Kir 6.2 in mouse
SO JOURNAL OF VETERINARY MEDICAL SCIENCE
LA English
DT Article
DE ATP-sensitive potassium (K-ATP); Kir6.2; myometrium; relaxation; SUR2B
ID MUSCLE; EXPRESSION; SUBUNITS; MYOCYTES; ARTERIES; SEGMENT; UTERUS;
   LABOR; MICE
AB ATP-sensitive potassium (K-ATP) channels are well characterized in cardiac, pancreatic and many other muscle cells. In the present study, functional expression of the K-ATP channel was examined in non-pregnant murine longitudinal myometrium. Isometric contraction measurements and Western blot were used. K-ATP channel openers (KCOs), such as pinacidil, cromakalim, diazoxide and nicorandil, inhibited spontaneous myometrial contractions in a reversible and glibenclamide-sensitive manner. KCOs inhibited oxytocin (OXT)- and prostaglandin F-2 alpha, (PGF(2 alpha))-induced phasic contractions in a glibenclamide-sensitive manner. SUR2B and Kir6.2 were detected by Western blot, whereas SUR1, SUR2A and Kir6.1 were not. These results show that pinacidl, cromakalim, diazoxide and nicorandil-sensitive K-ATP channels exist in murine myometrium, which are composed of SUR2B and Kir6.2. Based on the modulatory effects of the K-ATP channel on spontaneous contraction, OXT- and PGF(2 alpha)-induced contractions, K-ATP channels seem to play an essential role in murine myometrial motility via activation of SUR2B and Kir6.2.
C1 [Hong, Seung Hwa; Kyeong, Kyu-Sang; Park, Yeon Jin; Ji, Il Woon; Jeong, Eun-Hwan; Kim, Hak Soon] Chungbuk Natl Univ CBNU, Dept Obstet & Gynecol, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.
   [Kim, Chan Hyung; Choi, Woong; Kim, Hun Sik] CBNU, Dept Pharmacol, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.
   [Kim, Young Chul; Yoo, Ra Young] CBNU, Coll Med, Dept Physiol, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.
   [Xu, Wen-Xie] Shanghai Jiao Tong Univ, Coll Medcine, Dept Physiol, 800 Dongchun Rd, Shanghai 200240, Peoples R China.
   [Lee, Sang Jin] CBNV, Coll Med, Dept Med Educ, Chungdae Ro 1, Heongju 28644, Chungbuk, Peoples R China.
RP Kim, YC (reprint author), CBNU, Coll Med, Dept Physiol, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.; Lee, SJ (reprint author), CBNV, Coll Med, Dept Med Educ, Chungdae Ro 1, Heongju 28644, Chungbuk, Peoples R China.
EM physiokyc@chungbuk.ac.kr; drsangjin@chungbuk.ac.kr
FU Chungbuk National University
FX Seung Hwa Hong, Kyu-Sang Kyeong and Chan Hyung Kim equally contributed
   to this work. This work was supported by the research grant of the
   Chungbuk National University in 2013. We give special thanks for
   experimental assistance to Hee Sun Park.
CR Adebiyi A, 2011, AM J PHYSIOL-HEART C, V301, pH1360, DOI 10.1152/ajpheart.00406.2011
   Bryan J, 2007, PFLUG ARCH EUR J PHY, V453, P703, DOI 10.1007/s00424-006-0116-z
   Burke MA, 2008, CIRC RES, V102, P164, DOI 10.1161/CIRCRESAHA.107.165324
   COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0
   Creasy R. K., 2009, CREASY RESNIKS MATER, P521
   Cunningham F. G., 1997, WILLIAMS OBSTET, P817
   Curley M, 2002, MOL HUM REPROD, V8, P941, DOI 10.1093/molehr/8.10.941
   Du QY, 2013, MECH AGEING DEV, V134, P98, DOI 10.1016/j.mad.2013.01.003
   Du RH, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-35
   Hong SH, 2013, KOREAN J PHYSIOL PHA, V17, P359, DOI 10.4196/kjpp.2013.17.4.359
   Ishii H, 2007, AM J CARDIOL, V99, P1203, DOI 10.1016/j.amjcard.2006.12.034
   Jovanovic S, 2008, CTS-CLIN TRANSL SCI, V1, P71, DOI 10.1111/j.1752-8062.2008.00007.x
   Khan RN, 1997, AM J PHYSIOL-CELL PH, V273, pC1721
   Kostrzewska A, 1996, ACTA OBSTET GYN SCAN, V75, P886, DOI 10.3109/00016349609055022
   Monaghan K, 2011, J PHYSIOL-LONDON, V589, P1221, DOI 10.1113/jphysiol.2010.203869
   NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0
   Novakovic R, 2007, BASIC CLIN PHARMACOL, V101, P181, DOI 10.1111/j.1742-7843.2007.00096.x
   PINTO RM, 1967, AM J OBSTET GYNECOL, V98, P547
   SANBORN BM, 1995, SEMIN PERINATOL, V19, P31, DOI 10.1016/S0146-0005(95)80045-X
   Sawada K, 2005, EUR J OBSTET GYN R B, V122, P49, DOI 10.1016/j.ejogrb.2004.11.026
   Schwarz MK, 2003, CURR MED CHEM, V10, P1441, DOI 10.2174/0929867033457331
   Sim JH, 2002, AM J PHYSIOL-GASTR L, V282, pG137
   Smith RC, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-41
   STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869
   Wray S, 2008, J NEUROENDOCRINOL, V20, P451, DOI 10.1111/j.1365-2826.2008.01665.x
   Wray S, 2015, EXP PHYSIOL, V100, P1468, DOI 10.1113/EP085131
NR 26
TC 1
Z9 1
U1 2
U2 2
PU JAPAN SOC VET SCI
PI TOKYO
PA UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN
SN 0916-7250
EI 1347-7439
J9 J VET MED SCI
JI J. Vet. Med. Sci.
PD JUL
PY 2016
VL 78
IS 7
BP 1153
EP 1159
DI 10.1292/jvms.15-0700
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA DS2NY
UT WOS:000380622000009
PM 27086859
ER

PT J
AU Dudai, Y
   Edelson, MG
AF Dudai, Yadin
   Edelson, Micah G.
TI Personal memory: Is it personal, is it memory?
SO MEMORY STUDIES
LA English
DT Article
DE episodic memory; self; social conformity; retrieval; reconsolidation
ID SOCIAL DECISION-MAKING; LONG-TERM-MEMORY; COGNITIVE NEUROSCIENCE;
   EPISODIC MEMORY; CONFORMITY; AMYGDALA; BRAIN; RECONSOLIDATION;
   NEUROBIOLOGY; OXYTOCIN
AB Recollection of personal events is a major activity of the human mind and is considered essential for maintaining the cohesiveness of the self-concept. Yet evidence from cognitive psychology and brain research converge to raise doubts concerning the veridicality of the events recalled. Furthermore, even information encoded and recalled correctly seems to be prone to significant and long-lasting distortion by exposure to new input at the time of retrieval. A major source of such new input is inter-personal. From early infancy, we tend to look to others as a primary source of information and may reevaluate our own perceptions, preferences, and memories when they contradict a larger consensus. Circuits in our brain can modify our memory in response to such information even under conditions in which our original memory is accurate and our confidence is strong. Part of what we believe we know is in fact a product of the amalgamation of the internal representations originating in multiple brains. Personal memory may hence be considered conceptually as a node in a highly distributed multi-dimensional memory space, in which the contribution of the individual is only part of an informational syncytium that transcends the personal. This may provide our species with a phylogenetic advantage ensuring that, on one hand, accumulated information can be fitted to the real-time requirements of the locale, but on the other hand, that the storage capacity and availability of information markedly exceeds the capacity and the life span of the individual brain. In consequence, however, individuals may be unreliable narrators of their own history.
C1 [Dudai, Yadin] Weizmann Inst Sci, Neurobiol, Rehovot, Israel.
   [Dudai, Yadin] NYU, Neural Sci, New York, NY 10003 USA.
   [Edelson, Micah G.] Univ Zurich, Dept Econ, CH-8006 Zurich, Switzerland.
RP Dudai, Y (reprint author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
EM yadin.dudai@weizmann.ac.il
CR Adolphs R, 2003, ANN NY ACAD SCI, V985, P326
   ALLEN VL, 1965, ADV EXP SOC PSYCHOL, V2, P133
   Asch S, 1951, GROUPS LEADERSHIP ME, P39
   Assmann J, 2008, MEDIEN KULT ERINNERU, V8, P109
   Ben-Yakov A, 2011, J NEUROSCI, V31, P9032, DOI 10.1523/JNEUROSCI.0702-11.2011
   Berns GS, 2005, BIOL PSYCHIAT, V58, P245, DOI 10.1016/j.biopsych.2005.04.012
   Boyd R., 1988, P29
   Boyd R., 2004, ORIGIN EVOLUTION CUL
   Byrne R. W., 1989, MACHIAVELLIAN INTELL
   Chambers KL, 2001, MEM COGNITION, V29, P1120, DOI 10.3758/BF03206381
   Christoff K, 2000, PSYCHOBIOLOGY, V28, P168
   De Martino B, 2013, NAT NEUROSCI, V16, P105, DOI 10.1038/nn.3279
   DEUTSCH MORTON, 1955, JOUR ABNORMAL AND SOCIAL PSYCHOL, V51-31, P629, DOI 10.1037/h0046408
   Dolan RJ, 2003, ANN NY ACAD SCI, V985, P348
   Dolan RJ, 2002, SCIENCE, V298, P1191, DOI 10.1126/science.1076358
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Dudai Y, 2005, NATURE, V434, P567, DOI 10.1038/434567a
   Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050
   Dudai Y, 2012, ANNU REV NEUROSCI, V35, P227, DOI 10.1146/annurev-neuro-062111-150500
   Dunbar RIM, 2007, SCIENCE, V317, P1344, DOI 10.1126/science.1145463
   Echterhoff G, 2005, MEM COGNITION, V33, P770, DOI 10.3758/BF03193073
   Edelson M, 2011, SCIENCE, V333, P108, DOI 10.1126/science.1203557
   Edelson MG, 2015, NEUROPSYCHOPHARMACOL, V40, P966, DOI 10.1038/npp.2014.273
   Edelson MG, 2014, J NEUROSCI, V34, P7744, DOI 10.1523/JNEUROSCI.4720-13.2014
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Fivush R, 2016, MEM STUD, V9, P305, DOI 10.1177/1750698016645264
   Furman O, 2007, LEARN MEMORY, V14, P457, DOI 10.1101/lm.550407
   Gabbert F, 2006, PSYCHON B REV, V13, P480, DOI 10.3758/BF03193873
   Hasson U, 2008, NEURON, V57, P452, DOI 10.1016/j.neuron.2007.12.009
   Haun DBM, 2013, DEV COGN NEUROS-NETH, V3, P61, DOI 10.1016/j.dcn.2012.09.003
   Hirst W, 2012, ANNU REV PSYCHOL, V63, P55, DOI 10.1146/annurev-psych-120710-100340
   Hirst W, 2011, GROUNDING SOCIALITY: NEURONS, MIND, AND CULTURE, P95
   Izuma K, 2013, CURR OPIN NEUROBIOL, V23, P456, DOI 10.1016/j.conb.2013.03.009
   KELMAN HC, 1961, PUBLIC OPIN QUART, V25, P57, DOI 10.1086/266996
   Klucharev V, 2009, NEURON, V61, P140, DOI 10.1016/j.neuron.2008.11.027
   Kluver H., 1937, AM J PHYSIOL, V119, P352
   Koechlin E, 2007, SCIENCE, V318, P594, DOI 10.1126/science.1142995
   Loftus EF, 2005, LEARN MEMORY, V12, P361, DOI 10.1101/lm.94705
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   McKenzie S, 2011, NEURON, V71, P224, DOI 10.1016/j.neuron.2011.06.037
   Meade ML, 2002, MEM COGNITION, V30, P995, DOI 10.3758/BF03194318
   Mendelsohn A, 2008, NEURON, V57, P159, DOI 10.1016/j.neuron.2007.11.022
   Mitchell JP, 2009, J COGNITIVE NEUROSCI, V21, P594, DOI 10.1162/jocn.2009.21033
   Morris RG., 2007, HIPPOCAMPUS BOOK, P581
   Muller G. E., 1900, Z PSYCHOL, V1, P1
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015
   Reysen MB, 2005, MEMORY, V13, P87, DOI 10.1080/09658210344000602
   Roediger HL, 2001, PSYCHON B REV, V8, P365, DOI 10.3758/BF03196174
   Roediger III H. L., 2012, MEMORY LAW, P84
   Ruff CC, 2014, NAT REV NEUROSCI, V15, P549, DOI 10.1038/nrn3776
   Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014
   Sara SJ, 2000, LEARN MEMORY, V7, P73, DOI 10.1101/lm.7.2.73
   Schacter DL, 2007, NAT REV NEUROSCI, V8, P657, DOI 10.1038/nrn2213
   Schacter DL, 2016, MEM STUD, V9, P245, DOI 10.1177/1750698016645230
   Schacter DL, 2013, NAT NEUROSCI, V16, P119, DOI 10.1038/nn.3294
   Schacter DL, 2011, TRENDS COGN SCI, V15, P467, DOI 10.1016/j.tics.2011.08.004
   SCHWARTZ B, 1982, SOC FORCES, V61, P374, DOI 10.2307/2578232
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   Sherif M., 1936, PSYCHOL SOCIAL NORMS
   Simonsen A, 2014, PSYCHOPHARMACOLOGY, V231, P2759, DOI 10.1007/s00213-014-3444-2
   Smith E., 2007, SOCIAL PSYCHOL
   Squire LR, 2011, ANNU REV NEUROSCI, V34, P259, DOI 10.1146/annurev-neuro-061010-113720
   Stone CB, 2012, PERSPECT PSYCHOL SCI, V7, P39, DOI 10.1177/1745691611427303
   Striepens N, 2011, FRONT NEUROENDOCRIN, V32, P426, DOI 10.1016/j.yfrne.2011.07.001
   VICKERS D, 1970, Ergonomics, V13, P37, DOI 10.1080/00140137008931117
   Wagner AD, 1999, PHILOS T ROY SOC B, V354, P1307, DOI 10.1098/rstb.1999.0481
   Wang Q, 2016, MEM STUD, V9, P295, DOI 10.1177/1750698016645238
   Wright DB, 2009, CURR DIR PSYCHOL SCI, V18, P174
   Zhu LS, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00128
NR 70
TC 6
Z9 6
U1 16
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1750-6980
EI 1750-6999
J9 MEM STUD
JI Mem. Stud.
PD JUL
PY 2016
VL 9
IS 3
SI SI
BP 275
EP 283
DI 10.1177/1750698016645234
PG 9
WC Cultural Studies; History
SC Cultural Studies; History
GA DR6NI
UT WOS:000380018200005
ER

PT J
AU Jones-Mason, K
   Allen, IE
   Bush, N
   Hamilton, S
AF Jones-Mason, Karen
   Allen, Isabel Elaine
   Bush, Nicole
   Hamilton, Steve
TI Epigenetic marks as the link between environment and development:
   examination of the associations between attachment, socioeconomic
   status, and methylation of the SLC6A4 gene
SO BRAIN AND BEHAVIOR
LA English
DT Article
DE Attachment; socioeconomic status; methylation; SLC6A4 and 5-HTTLPR
ID TRANSPORTER PROMOTER POLYMORPHISM; POSTTRAUMATIC-STRESS-DISORDER;
   OXYTOCIN RECEPTOR GENE; IOWA ADOPTEE SAMPLE; SEROTONIN TRANSPORTER; DNA
   METHYLATION; INFANT ATTACHMENT; EARLY EXPERIENCE; MATERNAL-CARE;
   INDIVIDUAL-DIFFERENCES
AB Background: Epigenetic processes act as a link between environment and individual development. This pilot study examined the association between socioeconomic status (SES), attachment, and methylation of the promoter region of the serotonin transportergene (SLC6A4). Methods: Attachment classification and SLC6A4 methylation was determined in 100 late adolescents. We hypothesized that (1) SES would interact with methylation to predict higher unresolved loss (UL) or trauma scores on the Adult Attachment Interview; (2) across SES, participants with unresolved attachment would have lower levels of methylation than organized or secure participants; and (3) within the unresolved classification, SES would predict methylation. Results: Results showed that lower methylation and low-SES were associated with higher UL, and higher methylation and low-SES were associated with higher unresolved trauma. Across SES, unresolved participants had lower levels ofmethylation than organized participants. Within the unresolved category, low-SES unresolved participants had higher levels of methylation than mid/upper-SES participants. SES was unrelated to methylation within the secure and organized categories. Conclusions: These results suggest that the quality of attachment relationships may impact epigenetic processes.
C1 [Jones-Mason, Karen] Univ Calif Berkeley, Dept Social Welf, Berkeley, CA 94720 USA.
   [Allen, Isabel Elaine] Univ Calif San Francisco, Dept Stat, San Francisco, CA 94143 USA.
   [Bush, Nicole] Univ Calif San Francisco, Dept Psychiat & Pediat, San Francisco, CA 94143 USA.
   [Hamilton, Steve] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Hamilton, Steve] Kaiser Permanente San Francisco Med Ctr, Dept Psychiat, San Francisco, CA USA.
   [Jones-Mason, Karen] Univ Calif San Francisco, Ctr Hlth & Community, San Francisco, CA 94143 USA.
RP Jones-Mason, K (reprint author), Univ Calif San Francisco, POB 472091, San Francisco, CA 94147 USA.
EM Karen.Jones-Mason@ucsf.edu
CR Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Allis C.D., 2007, EPIGENETICS
   Bakermans-Kranenburg MJ, 2009, ATTACH HUM DEV, V11, P223, DOI 10.1080/14616730902814762
   Barry RA, 2008, J CHILD PSYCHOL PSYC, V49, P1313, DOI 10.1111/j.1469-7610.2008.01935.x
   Beach SRH, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00676
   Beach SRH, 2014, DEV PSYCHOPATHOL, V26, P289, DOI 10.1017/S0954579413000990
   Beach SRH, 2014, BIOL PSYCHOL, V96, P28, DOI 10.1016/j.biopsycho.2013.10.006
   Beach SRH, 2011, PSYCHOSOM MED, V73, P83, DOI 10.1097/PSY.0b013e3181fdd074
   Beach SRH, 2010, AM J MED GENET B, V153B, P710, DOI 10.1002/ajmg.b.31028
   BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   Beck A. T., 1996, MANUAL BECK DEPRESSI
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Bock J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00011
   Booij L, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0251
   Borghol N, 2012, INT J EPIDEMIOL, V41, P62, DOI 10.1093/ije/dyr147
   Boyce WT, 2015, DEVELOPMENTAL SCI, V18, P1, DOI 10.1111/desc.12282
   Brody GH, 2013, J FAM PSYCHOL, V27, P22, DOI 10.1037/a0027829
   Caspers KM, 2009, DEV PSYCHOL, V45, P64, DOI 10.1037/a0014026
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925
   Chen E, 2011, MOL PSYCHIATR, V16, P729, DOI 10.1038/mp.2010.53
   Crowell J. A., 1999, HDB ATTACHMENT THEOR, P434
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497
   Danese A, 2007, P NATL ACAD SCI USA, V104, P1319, DOI 10.1073/pnas.0610362104
   Dozier M., 2008, HDB ATTACHMENT THEOR, V2, P718
   Duncan LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191
   Eisenberger NI, 2012, NAT NEUROSCI, V15, P669, DOI 10.1038/nn.3086
   Ellis BJ, 2011, DEV PSYCHOPATHOL, V23, P7, DOI 10.1017/S0954579410000611
   Fish EW, 2004, ANN NY ACAD SCI, V1036, P167, DOI 10.1196/annals.1330.011
   Francis DD, 1999, BIOL PSYCHIAT, V46, P1153, DOI 10.1016/S0006-3223(99)00237-1
   Francis DD, 1999, ANN NY ACAD SCI, V896, P66, DOI 10.1111/j.1749-6632.1999.tb08106.x
   FYDRICH T, 1992, J ANXIETY DISORD, V6, P55, DOI 10.1016/0887-6185(92)90026-4
   George C., 1984, ADULT ATTACHME UNPUB
   Gouin JP, 2009, BRAIN BEHAV IMMUN, V23, P898, DOI 10.1016/j.bbi.2008.09.016
   Graham AM, 2013, PSYCHOL SCI, V24, P782, DOI 10.1177/0956797612458803
   Hernandez L. M., 2006, GENES BEHAV SOCIAL E
   Hesse E., 1999, HDB ATTACHMENT THEOR, P395
   Hollingshead A. B., 1975, 4 FACTOR INDEX UNPUB
   Ichise M, 2006, J NEUROSCI, V26, P4638, DOI 10.1523/JNEUROSCI.5199-05.2006
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Kang HJ, 2013, PROG NEURO-PSYCHOPH, V44, P23, DOI 10.1016/j.pnpbp.2013.01.006
   Kinnally EL, 2008, GENES BRAIN BEHAV, V7, P481, DOI 10.1111/j.1601-183X.2007.00383.x
   Kochanska G, 2009, J CHILD PSYCHOL PSYC, V50, P1331, DOI 10.1111/j.1469-7610.2008.02050.x
   Koenen KC, 2011, DEPRESS ANXIETY, V28, P639, DOI 10.1002/da.20825
   Kogan SM, 2010, HEALTH PSYCHOL, V29, P471, DOI 10.1037/a0020594
   Kraft JB, 2007, BIOL PSYCHIAT, V61, P734, DOI 10.1016/j.biopsych.2006.07.017
   Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109
   Lesch KP, 2007, EMBO REP, V8, pS24, DOI 10.1038/sj.embor.7401008
   Loman MM, 2010, NEUROSCI BIOBEHAV R, V34, P867, DOI 10.1016/j.neubiorev.2009.05.007
   Luijk MPCM, 2011, J CHILD PSYCHOL PSYC, V52, P1295, DOI 10.1111/j.1469-7610.2011.02440.x
   Lyons-Ruth Karlen, 2003, Attach Hum Dev, V5, P330, DOI 10.1080/14616730310001633410
   Lyons-Ruth K., 2003, ATTACHMENT HUMAN DEV, V5, P409
   Main M., 2003, ADULT ATTACHME UNPUB
   McDade TW, 2006, PSYCHOSOM MED, V68, P376, DOI 10.1097/01.psy.0000221371.43607.64
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   McWilliams LA, 2010, HEALTH PSYCHOL, V29, P446, DOI 10.1037/a0020061
   Meaney MJ, 2005, TRENDS NEUROSCI, V28, P456, DOI 10.1016/j.tins.2005.07.006
   Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106
   Mitchell C, 2014, P NATL ACAD SCI USA, V111, P5944, DOI 10.1073/pnas.1404293111
   Munafo MR, 2009, BIOL PSYCHIAT, V65, P211, DOI 10.1016/j.biopsych.2008.06.009
   Murgatroyd Chris, 2011, Front Psychiatry, V2, P16, DOI 10.3389/fpsyt.2011.00016
   Nolte T, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00055
   Peters MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9570
   Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463
   Philibert R, 2007, AM J MED GENET B, V144B, P101, DOI 10.1002/ajmg.b.30414
   Puig J, 2013, HEALTH PSYCHOL, V32, P409, DOI 10.1037/a0028889
   Raby KL, 2013, J CHILD PSYCHOL PSYC, V54, P1223, DOI 10.1111/jcpp.12093
   Raby KL, 2012, PSYCHOL SCI, V23, P1016, DOI 10.1177/0956797612438265
   Reiner I, 2015, J PSYCHIATR RES, V65, P9, DOI 10.1016/j.jpsychires.2015.03.012
   Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878
   Roisman GI, 2013, ATTACH HUM DEV, V15, P384, DOI 10.1080/14616734.2013.768790
   Rutter M., 2006, GENES BEHAV NATURE N
   SAGI A, 1994, DEV PSYCHOL, V30, P771, DOI 10.1037/0012-1649.30.5.771
   Sale A, 2014, PHYSIOL REV, V94, P189, DOI 10.1152/physrev.00036.2012
   Shannon C, 2005, AM J PSYCHIAT, V162, P1658, DOI 10.1176/appi.ajp.162.9.1658
   Spangler G, 2009, J CHILD PSYCHOL PSYC, V50, P952, DOI 10.1111/j.1469-7610.2008.02054.x
   Szyf M, 2013, CHILD DEV, V84, P49, DOI 10.1111/j.1467-8624.2012.01793.x
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   Tammen SA, 2013, MOL ASPECTS MED, V34, P753, DOI 10.1016/j.mam.2012.07.018
   Taylor SE, 2006, BIOL PSYCHIAT, V60, P671, DOI 10.1016/j.biopsych.2006.04.019
   Tehranifar P, 2013, EPIGENETICS-US, V8, P23, DOI 10.4161/epi.22989
   Uddin M, 2013, BIODEMOGR SOC BIOL, V59, P68, DOI 10.1080/19485565.2013.774627
   Uher R, 2008, MOL PSYCHIATR, V13, P131, DOI 10.1038/sj.mp.4002067
   Uher R, 2010, MOL PSYCHIATR, V15, P18, DOI 10.1038/mp.2009.123
   Umer M, 2013, ANTIOXID REDOX SIGN, V18, P1972, DOI 10.1089/ars.2012.4923
   Van Emmichoven IAZ, 2003, DEV PSYCHOPATHOL, V15, P219, DOI 10.1017/S0954579403000129
   vansIJzendoorn M. H., 2012, TRANSL PSYCHIAT, V2, pe147, DOI DOI 10.1038/TP.2012.73
   vansIJzendoorn M. H., 1996, J CONSULT CLIN PSYCH, V64, P8
   vansIJzendoorn M. H., 2010, BIOL PSYCHIAT, V68, P405
   vansIJzendoorn M. H., 1995, PSYCHOL BULL, V117, P387, DOI [10.1037/0033-2909.117.3.387, DOI 10.1037/0033-2909.117.3.387]
   Vijayendran Meeshanthini, 2012, Front Psychiatry, V3, P55, DOI 10.3389/fpsyt.2012.00055
   Wampler KS, 2003, FAM PROCESS, V42, P497, DOI 10.1111/j.1545-5300.2003.00497.x
   Ward MJ, 2006, ATTACH HUM DEV, V8, P327, DOI 10.1080/14616730601048241
   Xie PX, 2012, AM J MED GENET B, V159B, P644, DOI 10.1002/ajmg.b.32068
   Yin HS, 2012, ACAD PEDIATR, V12, P117, DOI 10.1016/j.acap.2012.01.001
   Zhang FF, 2011, EPIGENETICS-US, V6, P623
   Zilberman D, 2007, DEVELOPMENT, V134, P3959, DOI 10.1242/dev.001131
   Sweatt JD, 2013, EPIGENETIC REGULATION IN THE NERVOUS SYSTEM: BASIC MECHANISMS AND CLINICAL IMPACT, P1
NR 100
TC 0
Z9 0
U1 4
U2 4
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2162-3279
J9 BRAIN BEHAV
JI Brain Behav.
PD JUL
PY 2016
VL 6
IS 7
AR e00480
DI 10.1002/brb3.480
PG 18
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DR6VP
UT WOS:000380039700010
PM 27458544
ER

PT J
AU Achong, N
   McIntyre, HD
   Callaway, L
   Duncan, EL
AF Achong, N.
   McIntyre, H. D.
   Callaway, L.
   Duncan, E. L.
TI Glycaemic behaviour during breastfeeding in women with Type 1 diabetes
SO DIABETIC MEDICINE
LA English
DT Article
ID GLUCOSE-UPTAKE; LACTATION; HYPOGLYCEMIA; PREGNANCY; OXYTOCIN; MILK;
   RESPONSES; MELLITUS; REQUIREMENTS; PROLACTIN
AB AimTo describe glycaemia in both breastfeeding women and artificially feeding women with Type 1 diabetes, and the changes in glycaemia induced by suckling.
   MethodsA blinded continuous glucose monitor was applied for up to 6 days in eight breastfeeding and eight artificially feeding women with Type 1 diabetes 2-4 months postpartum. Women recorded glucose levels, insulin dosages, oral intake and breastfeeding episodes. A standardized breakfast was consumed on 2 days. A third group (clinic controls) were identified from a historical database.
   ResultsCarbohydrate intake tended to be higher in breastfeeding than artificially feeding women (P = 0.09) despite similar insulin requirements. Compared with breastfeeding women, the high blood glucose index and standard deviation of glucose were higher in artificially feeding women (P = 0.02 and 0.06, respectively) and in the clinical control group (P = 0.02 and 0.05, respectively). The low blood glucose index and hypoglycaemia were similar. After suckling, the low blood glucose index increased compared with before (P < 0.01) and during (P < 0.01) suckling. Hypoglycaemia (blood glucose < 4.0 mmol/l) occurred within 3 h of suckling in 14% of suckling episodes, and was associated with time from last oral intake (P = 0.04) and last rapid-acting insulin (P = 0.03). After a standardized breakfast, the area under the glucose curve was positive. In breastfeeding women the area under the glucose curve was positive if suckling was avoided for 1 h after eating and negative if suckling occurred within 30 min of eating.
   ConclusionsBreastfeeding women with Type 1 diabetes had similar hypoglycaemia but lower glucose variability than artificially feeding women. Suckling reduced maternal glucose levels but did not cause hypoglycaemia in most episodes.
C1 [Achong, N.; McIntyre, H. D.; Callaway, L.; Duncan, E. L.] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Achong, N.; Callaway, L.; Duncan, E. L.] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
   [McIntyre, H. D.] Mater Med Res Inst, Brisbane, Qld, Australia.
   [Duncan, E. L.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia.
   [Duncan, E. L.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia.
RP Achong, N (reprint author), Univ Queensland, Sch Med, Brisbane, Qld, Australia.; Achong, N (reprint author), Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
EM naomiachong.endo@gmail.com
FU Royal Brisbane and Women's Hospital Foundation; National Health and
   Medical Research Council
FX The study was funded by a grant from the Royal Brisbane and Women's
   Hospital Foundation and the National Health and Medical Research Council
   (N.A.).
CR ARTHUR PG, 1991, J PEDIATR GASTR NUTR, V13, P260, DOI 10.1097/00005176-199110000-00004
   Arumugam R, 2008, ENDOCRINOLOGY, V149, P5401, DOI 10.1210/en.2008-0051
   Bentley-Lewis R, 2007, DIABETES CARE, V30, P2792, DOI 10.2337/dc07-1243
   BORCHJOHNSEN K, 1984, LANCET, V2, P1083
   Brown Catherine R L, 2013, CMAJ Open, V1, pE9, DOI 10.9778/cmajo.20120011
   Butte NF, 2005, PUBLIC HEALTH NUTR, V8, P1010, DOI 10.1079/PHN2005793
   Colatrella A, 2012, DIABETES TECHNOL THE, V14, P576, DOI 10.1089/dia.2011.0266
   DALY SEJ, 1992, EXP PHYSIOL, V77, P79
   Daly SEJ, 1996, EXP PHYSIOL, V81, P861
   DAVIES HA, 1989, BRIT MED J, V298, P1357
   Feig DS, 2011, J MATERN-FETAL NEO M, V24, P511, DOI 10.3109/14767058.2010.500711
   FERRIS AM, 1988, J AM DIET ASSOC, V88, P317
   Florian M, 2010, ENDOCRINOLOGY, V151, P482, DOI 10.1210/en.2009-0624
   Group DS, 2003, BMC, V325, P746
   Gunderson EP, 2012, DIABETES CARE, V35, P50, DOI 10.2337/dc11-1409
   Hummel S, 2009, DIABETES CARE, V32, P921, DOI 10.2337/dc08-1943
   Khan S, 2013, J HUM LACT, V29, P81, DOI 10.1177/0890334412448841
   Kovatchev BP, 1997, DIABETES CARE, V20, P1655, DOI 10.2337/diacare.20.11.1655
   LEAKE RD, 1983, OBSTET GYNECOL, V62, P565
   Lee ES, 2008, REGUL PEPTIDES, V151, P71, DOI 10.1016/j.regpep.2008.05.001
   Linne Y, 2004, OBES RES, V12, P1166, DOI 10.1038/oby.2004.146
   Liu DT, 1996, CLIN INVEST MED, V19, P71
   LORENZI M, 1984, WESTERN J MED, V141, P467
   Maia FFR, 2007, DIABETES RES CLIN PR, V75, P30, DOI 10.1016/j.diabres.2006.05.009
   MURTAUGH M A, 1989, FASEB Journal, V3, pA769
   Nilsson LA, 2009, HORM METAB RES, V41, P747, DOI 10.1055/s-0029-1224181
   PAOLISSO G, 1988, HORM RES, V30, P10, DOI 10.1159/000181018
   Rayburn W, 1985, Am J Perinatol, V2, P271, DOI 10.1055/s-2007-999968
   Riviello C, 2009, ENDOCR PRACT, V15, P187
   Saez-de-Ibarra L, 2003, PRACT DIAB INT, V20, P271, DOI 10.1002/pdi.529
   Schoen S, 2008, BREASTFEED MED, V3, P171, DOI 10.1089/bfm.2007.0027
   Seaquist ER, 2013, J CLIN ENDOCR METAB, V98, P1845, DOI 10.1210/jc.2012-4127
   Stage E, 2006, DIABETES CARE, V29, P771, DOI 10.2337/diacare.29.04.06.dc05-1103
   WHICHELOW MJ, 1983, BRIT MED J, V287, P649
   [Anonymous], 2003, GLOB STRAT INF YOUNG
NR 35
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD JUL
PY 2016
VL 33
IS 7
BP 947
EP 955
DI 10.1111/dme.12993
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DR5GG
UT WOS:000379930900012
PM 26479263
ER

PT J
AU Han, RT
   Lee, H
   Lee, J
   Lee, SB
   Kim, HJ
   Back, SK
   Na, HS
AF Han, Rafael Taeho
   Lee, Hyunkyoung
   Lee, JaeHee
   Lee, Sat-Byol
   Kim, Hee Jin
   Back, Seung Keun
   Na, Heung Sik
TI Brief Isolation Changes Nociceptive Behaviors and Compromises Drug Tests
   in Mice
SO PAIN PRACTICE
LA English
DT Article
DE analgesics; drug testing; pain assessment; pain behaviors; animal
   models; isolation; rodent
ID STRESS-INDUCED ANALGESIA; SOCIAL-ISOLATION; PAIN; OXYTOCIN; RECEPTOR;
   MORPHINE; RATS; HYPERALGESIA; MODULATION; SEROTONIN
AB Herding with a litter is known to comfort rodents, whereas isolation and grouping with noncagemates provoke stress. The effects of stress induced by isolation and grouping with noncagemates on pain responses, and their underlying mechanisms remain elusive. We assessed the effect of isolation, a common condition during behavioral tests, and of grouping on defecation and pain behaviors of mice. Fecal pellets were counted 2hours after exposure to the test chamber. It is significantly more in the isolated mice than in the grouped mice. Hindpaw withdrawal threshold and withdrawal latency were adopted as the indicatives of mechanical and thermal pain sensitivities, respectively. Interestingly, isolated mice showed higher pain thresholds than mice grouping with cagemates, and even those with noncagemates, indicating analgesic effects. Such effects were reduced by intrathecal injection of 0.01mg/kg of naloxone (opioid receptor antagonist), atosiban (oxytocin and vasopressin receptor antagonist), and ketanserin (5-HT receptor antagonist). Intraperitoneal delivery of 1mg/kg of naloxone and atosiban, but not ketanserin, also alleviated the isolation-induced analgesic effects. In contrast, these drugs at the same dose had no significant effect on the mice grouping with cagemates. In addition, the effect of morphine on thermal pain was more robust in the mice grouping with cagemates than in the isolated mice. These data demonstrated that brief isolation caused analgesia, mediated by endogenous opioidergic, oxytocinergic, and serotonergic pathways. These results indicate that isolation during pain behavioral tests can affect pain responses and the efficacy of drugs; thus, nociception tests should be conducted in grouping.
C1 [Han, Rafael Taeho; Lee, Hyunkyoung; Lee, JaeHee; Lee, Sat-Byol; Na, Heung Sik] Korea Univ, Coll Med, Neurosci Res Inst, Seoul, South Korea.
   [Han, Rafael Taeho; Lee, Hyunkyoung; Lee, JaeHee; Lee, Sat-Byol; Na, Heung Sik] Korea Univ, Coll Med, Dept Physiol, 73 Inchon Ro, Seoul 136705, South Korea.
   [Kim, Hee Jin] Yonsei Univ, Div Biol Sci & Technol, Coll Sci & Technol, Wonju Campus, Wonju, South Korea.
   [Back, Seung Keun] Konyang Univ, Coll Med Engn, Dept Pharmaceut & Biotechnol, Chungnam, South Korea.
RP Back, SK; Na, HS (reprint author), Korea Univ, Coll Med, Dept Physiol, 73 Inchon Ro, Seoul 136705, South Korea.
EM skback@korea.ac.kr; hsna@korea.ac.kr
OI Han, Rafael Taeho/0000-0002-0127-2396
FU Public Welfare & Safety research program through the National Research
   Foundation of Korea (NRF) - Ministry of Education, Science, and
   Technology [NRF-2012-0009675]
FX This research was supported by the Public Welfare & Safety research
   program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education, Science, and Technology
   (NRF-2012-0009675).
CR BARONE FC, 1990, AM J PHYSIOL, V258, pG329
   BERGE OG, 1983, PHARMACOL BIOCHEM BE, V19, P873, DOI 10.1016/0091-3057(83)90096-5
   BONAZ B, 1994, BRAIN RES, V641, P21, DOI 10.1016/0006-8993(94)91810-4
   Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003
   CARMODY JJ, 1979, LIFE SCI, V24, P1149, DOI 10.1016/0024-3205(79)90050-X
   DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398
   HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5
   Hobo S, 2012, ANESTH ANALG, V114, P442, DOI [10.1213/ANE.0b013e31823b1bc8, 10.1213/ANE.0b013e31823blbc8]
   Juif PE, 2013, PAIN, V154, P1449, DOI 10.1016/j.pain.2013.05.003
   Langford DJ, 2011, J PAIN, V12, P125, DOI 10.1016/j.jpain.2010.06.003
   Langford DJ, 2006, SCIENCE, V312, P1967, DOI 10.1126/science.1128322
   Lau BK, 2014, CURR OPIN NEUROBIOL, V29, P159, DOI 10.1016/j.conb.2014.07.010
   Le Roy C, 2011, J PAIN, V12, P1069, DOI 10.1016/j.jpain.2011.04.011
   LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
   Mckee DT, 2007, ENDOCRINOLOGY, V148, P4649, DOI 10.1210/en.2007-0646
   MIYATA K, 1992, J PHARMACOL EXP THER, V261, P297
   Moreno-Lopez Y, 2013, NEUROPEPTIDES, V47, P117, DOI 10.1016/j.npep.2012.09.008
   PANKSEPP J, 1980, PSYCHOPHARMACOLOGY, V72, P111, DOI 10.1007/BF00433816
   PUGLISIALLEGRA S, 1983, PHARMACOL BIOCHEM BE, V19, P679, DOI 10.1016/0091-3057(83)90344-1
   Quintero L, 2011, PAIN, V152, P1909, DOI 10.1016/j.pain.2011.04.017
   RAMABADRAN K, 1989, PSYCHOPHARMACOLOGY, V97, P169, DOI 10.1007/BF00442244
   Rao SSC, 1998, AM J GASTROENTEROL, V93, P985, DOI 10.1016/S0002-9270(98)00174-9
   Robinson DA, 2002, J PHYSIOL-LONDON, V540, P593, DOI 10.1113/jphysiol.2001.013492
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   SCHUL R, 1991, BRAIN RES, V553, P353, DOI 10.1016/0006-8993(91)90849-Q
   Sehgal N, 2011, PAIN PHYSICIAN, V14, P249
   Seo YJ, 2011, ARCH PHARM RES, V34, P269, DOI 10.1007/s12272-011-0213-1
   Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/nmeth.2935, 10.1038/NMETH.2935]
   TULI JS, 1995, LAB ANIM, V29, P132, DOI 10.1258/002367795780740249
   Vanegas H, 2004, BRAIN RES REV, V46, P295, DOI 10.1016/j.brainresrev.2004.07
   Weiss IC, 2004, BEHAV BRAIN RES, V152, P279, DOI 10.1016/j.bbr.2003.10.015
   Wu DF, 1997, DRUG METAB DISPOS, V25, P768
   Zollner C., 2007, HDB EXP PHARM, P31, DOI DOI 10.1007/978-3-540-33823-9_2
NR 33
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1530-7085
EI 1533-2500
J9 PAIN PRACT
JI Pain Pract.
PD JUL
PY 2016
VL 16
IS 6
BP 749
EP 757
DI 10.1111/papr.12325
PG 9
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA DR4TH
UT WOS:000379895100012
PM 26212903
ER

PT J
AU Sivukhina, EV
   Jirikowski, GF
AF Sivukhina, Elena V.
   Jirikowski, Gustav F.
TI Magnocellular hypothalamic system and its interaction with the
   hypothalamo-pituitary-adrenal axis
SO STEROIDS
LA English
DT Article; Proceedings Paper
CT 9th International Meeting on Rapid Responses to Steroid Hormones (RRSH)
   / 1st Asian Meeting on Rapid Responses to Steroid Hormones (RRSH)
CY JUN 07-10, 2015
CL Natl Yang Ming Univ, Taipei, TAIWAN
HO Natl Yang Ming Univ
DE Vasopressin; Oxytocin; Corticotropin-releasing hormone; Glucocorticoids;
   Stress
ID CORTICOSTEROID-BINDING GLOBULIN; ATRIAL-NATRIURETIC-PEPTIDE; VASOPRESSIN
   MESSENGER-RNA; CONGESTIVE-HEART-FAILURE; DEXAMETHASONE SUPPRESSION TEST;
   CORTICOTROPIN-RELEASING-FACTOR; PARAVENTRICULAR NUCLEUS;
   ARGININE-VASOPRESSIN; SUPRAOPTIC NUCLEUS; CHRONIC STRESS
AB The hypothalamo-neurohypophyseal system plays a key role in maintaining homeostasis and in regulation of numerous adaptive reactions, e.g., endocrine stress response. Nonapeptides vasopressin and oxytocin are the major hormones of this system. They are synthesized by magnocellular neurons of the paraventricular and supraoptic hypothalamic nuclei. Magnocellular vasopressin is known to be one of the main physiological regulators of water-electrolyte balance. Its importance for control of the hypothalamo-pituitary-adrenal axis has been widely described. Magnocellular oxytocin is secreted predominantly during lactation and parturition. The complex actions of oxytocin within the brain include control of reproductive behavior and its involvement in central stress response to different stimuli. It's neuroendocrine basis is activation of the hypothalamo-pituitary-adrenal axis: corticotropin-releasing hormone is synthesized in parvocellular neurons of the paraventricular hypothalamic nuclei. The transitory coexpression of vasopressin in these cells upon stress has been described. Glucocorticoids, the end products of the hypothalamo-pituitary-adrenal axis have both central and peripheral actions. Their availability to target tissues is mainly dependent on systemic levels of corticosteroid-binding globulin. Intrinsic expression of this protein in different brain regions in neurons and glial cells has been recently demonstrated. Regulation of the hypothalamo-pituitary-adrenal axis and hypothalamo-neurohypophyseal system is highly complex. The role of both systems in the pathogenesis of various chronic ailments in humans has extensively been studied. Their disturbed functioning seems to be linked to various psychiatric, autoimmune and cardiovascular pathologies. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sivukhina, Elena V.; Jirikowski, Gustav F.] Jena Univ Hosp, Inst Anat 2, Teichgraben 7, D-07743 Jena, Germany.
RP Jirikowski, GF (reprint author), Jena Univ Hosp, Inst Anat 2, Teichgraben 7, D-07743 Jena, Germany.
EM Gustav.Jirikowski@med.uni-jena.de
CR AGUILERA G, 1994, FRONT NEUROENDOCRIN, V15, P321, DOI 10.1006/frne.1994.1013
   ANTONI FA, 1993, FRONT NEUROENDOCRIN, V14, P76, DOI 10.1006/frne.1993.1004
   BAILLY D, 1989, HORM RES, V31, P72, DOI 10.1159/000181090
   BITO K, 1980, JPN CIRC J, V44, P117
   BUIJS RM, 1979, CELL TISSUE RES, V204, P355
   Bundzikova J, 2008, CELL MOL NEUROBIOL, V28, P1033, DOI 10.1007/s10571-008-9306-x
   Burbach JPH, 2001, PHYSIOL REV, V81, P1197
   Burrell LM, 2000, EXP PHYSIOL, V85, p259S, DOI 10.1111/j.1469-445X.2000.tb00031.x
   CALDWELL JD, 1989, BEHAV NEUROSCI, V103, P655, DOI 10.1037/0735-7044.103.3.655
   Caldwell J.D., 2012, HUMAN HYPOTHALAMUS A, P1
   CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78
   CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF70
   Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106
   Chu I, 2005, J APPL TOXICOL, V25, P193, DOI 10.1002/jat.1051
   COLLINS GB, 1992, ALCOHOL CLIN EXP RES, V16, P228, DOI 10.1111/j.1530-0277.1992.tb01368.x
   Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529
   DACKIS CA, 1986, ALCOHOL CLIN EXP RES, V10, P59, DOI 10.1111/j.1530-0277.1986.tb05615.x
   DE GOEIJ DCE, 1991, NEUROENDOCRINOLOGY, V53, P150, DOI 10.1159/000125712
   Dobsa L, 2013, BIOCHEM MEDICA, V23, P172, DOI 10.11613/BM.2013.021
   DUDAEV VA, 1986, KARDIOLOGIYA, V26, P98
   Engelmann M, 2004, FRONT NEUROENDOCRIN, V25, P132, DOI 10.1016/j.yfrne.2004.09.001
   FAHRBACH SE, 1985, NEUROENDOCRINOLOGY, V40, P526, DOI 10.1159/000124125
   Fehm-Wohlsdorf G., 2001, PSYCHONEUROENDOCRINO, V9, P285
   Francis Gary S., 2001, American Journal of Medicine, V110, p37S
   Glasgow E, 2000, AM J PHYSIOL-REG I, V279, pR1239
   Goldsmith Steven R, 2006, Cleve Clin J Med, V73 Suppl 2, pS20
   Goncharuk VD, 2007, J COMP NEUROL, V503, P148, DOI 10.1002/cne.21387
   Goncharuk VD, 2002, J COMP NEUROL, V443, P321, DOI 10.1002/cne.10124
   Grinevich V, 2001, J NEUROENDOCRINOL, V13, P711
   Guder G, 2007, CIRCULATION, V115, P1754, DOI 10.1161/CIRCULATIONAHA.106.653964
   GULYA K, 1991, BRAIN RES, V557, P129, DOI 10.1016/0006-8993(91)90125-F
   HAANWINCKEL MA, 1995, P NATL ACAD SCI USA, V92, P7902, DOI 10.1073/pnas.92.17.7902
   HAMMOND GL, 1990, ENDOCR REV, V11, P65
   Hazell GGJ, 2012, FRONT NEUROENDOCRIN, V33, P45, DOI 10.1016/j.yfrne.2011.07.002
   Herman JP, 2012, BRAZ J MED BIOL RES, V45, P292, DOI 10.1590/S0100-879X2012007500041
   Herman JP, 2008, PROG BRAIN RES, V170, P353, DOI 10.1016/S0079-6123(08)00429-9
   Herman JP, 2004, ANN NY ACAD SCI, V1018, P35, DOI 10.1196/annals.1296.004
   HODGES JR, 1984, BRIT J ANAESTH, V56, P701, DOI 10.1093/bja/56.7.701
   Huitinga I, 2004, ANN NEUROL, V55, P37, DOI 10.1002/ana.10766
   Hundt W, 2001, ALCOHOL CLIN EXP RES, V25, P687, DOI 10.1111/j.1530-0277.2001.tb02268.x
   Ishunina TA, 1999, J CLIN ENDOCR METAB, V84, P4637, DOI 10.1210/jc.84.12.4637
   Jedrzejewska E A, 1984, Ann Univ Mariae Curie Sklodowska Med, V39, P293
   Jezova D, 1995, ANN NY ACAD SCI, V771, P192, DOI 10.1111/j.1749-6632.1995.tb44681.x
   KASATKINA L V, 1979, Kardiologiya, V19, P93
   KISS A, 1993, BRAIN RES, V630, P262, DOI 10.1016/0006-8993(93)90665-A
   Kjaer A, 2001, CLIN PHYSIOL, V21, P661, DOI 10.1046/j.1365-2281.2001.00371.x
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Laguna-Abreu MTC, 2005, HORM METAB RES, V37, P84, DOI 10.1055/s-2005-861159
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   LANG RE, 1983, NEUROENDOCRINOLOGY, V37, P314, DOI 10.1159/000123566
   Lauand F, 2007, NEUROSCIENCE, V147, P247, DOI 10.1016/j.neuroscience.2007.04.021
   LeJemtel TH, 2007, INT J CARDIOL, V120, P1, DOI 10.1016/j.ijcard.2006.11.113
   Lightman S. L., 2002, Archives of Physiology and Biochemistry, V110, P90, DOI 10.1076/apab.110.1.90.899
   Lu Liang, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P489
   Madeira MD, 1999, BRAIN RES BULL, V48, P3, DOI 10.1016/S0361-9230(98)00131-2
   Maier T, 1998, HYPERTENSION, V31, P480
   MAJUMDAR SK, 1988, DRUG ALCOHOL DEPEN, V21, P231, DOI 10.1016/0376-8716(88)90074-9
   Martocchia Antonio, 2013, Recent Pat CNS Drug Discov, V8, P79
   Maxime V, 2009, CLIN CHEST MED, V30, P17, DOI 10.1016/j.ccm.2008.10.003
   MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093
   Mejer O.C., 2005, ENDOCRINOLOGY, V146, P1372
   MEZEY E, 1991, ENDOCRINOLOGY, V129, P1814
   Minguell ER, 2004, REV ESP CARDIOL, V57, P347
   Moriyama Y, 2000, J CLIN ENDOCR METAB, V85, P1834, DOI 10.1210/jc.85.5.1834
   Murphy D, 2012, J NEUROENDOCRINOL, V24, P539, DOI 10.1111/j.1365-2826.2011.02241.x
   Nakamura T, 2006, INT J CARDIOL, V106, P191, DOI 10.1016/j.ijcard.2005.01.043
   PACKER M, 1993, AM J CARDIOL, V71, pC3, DOI 10.1016/0002-9149(93)90081-M
   PATEL KP, 1993, AM J PHYSIOL, V265, pR923
   Paukov V. S., 2001, Arkhiv Patologii, V63, P21
   PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605
   PITTMAN QJ, 1982, ENDOCRINOLOGY, V110, P1058
   Pyner S, 2009, J CHEM NEUROANAT, V38, P197, DOI 10.1016/j.jchemneu.2009.03.005
   RAADSHEER FC, 1993, BRAIN RES, V615, P50, DOI 10.1016/0006-8993(93)91113-7
   RAADSHEER FC, 1994, NEUROENDOCRINOLOGY, V60, P436, DOI 10.1159/000126778
   RAFF H, 1993, ANN NY ACAD SCI, V689, P411, DOI 10.1111/j.1749-6632.1993.tb55564.x
   Rai A, 2006, AM J NEPHROL, V26, P579, DOI 10.1159/000098028
   Ramos AT, 2006, NEUROENDOCRINOLOGY, V84, P309, DOI 10.1159/000097587
   Robertson G L, 1987, Kidney Int Suppl, V21, pS20
   Roper JA, 2011, STRESS, V14, P98, DOI 10.3109/10253890.2010.512376
   Sanghi P, 2005, EUR HEART J, V26, P538, DOI 10.1093/eurheartj/ehi145
   SANNA PP, 1993, MOL BRAIN RES, V19, P241, DOI 10.1016/0169-328X(93)90035-N
   Saper C.B., 1990, HUMAN NERVOUS SYSTEM, P389
   SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306
   Scott LV, 1998, LIFE SCI, V62, P1985, DOI 10.1016/S0024-3205(98)00027-7
   Sivukhina EV, 2006, HORM METAB RES, V38, P382, DOI 10.1055/s-2006-944522
   Sivukhina E. V., 2010, Sudebno-Meditsinskaya Ekspertiza, V53, P7
   Sivukhina EV, 2010, HORM METAB RES, V42, P56, DOI 10.1055/s-0029-1234081
   Sivukhina EV, 2009, HORM METAB RES, V41, P778, DOI 10.1055/s-0029-1224182
   Sivukhina E, 2013, ANN ANAT, V195, P219, DOI 10.1016/j.aanat.2012.10.008
   Sivukhina E, 2013, J EXP BIOL, V216, P245, DOI 10.1242/jeb.076893
   Sivukhina EV, 2014, STEROIDS, V81, P70, DOI 10.1016/j.steroids.2013.11.001
   Sivukhina EV, 2006, HORM METAB RES, V38, P253, DOI 10.1055/s-2006-925346
   Smith Sean M, 2006, Dialogues Clin Neurosci, V8, P383
   Sofroniew M.V., 1981, Acta Histochemica Supplementband, V24, P79
   Stetler C, 2011, PSYCHOSOM MED, V73, P114, DOI 10.1097/PSY.0b013e31820ad12b
   SUEMARU S, 1990, ACTA MED OKAYAMA, V44, P233
   SWAAB DF, 1994, J NEUROENDOCRINOL, V6, P681, DOI 10.1111/j.1365-2826.1994.tb00635.x
   Swaab D.F., 1997, HAND CHEM N, V13, P39
   TARGUM SD, 1982, J AFFECT DISORDERS, V4, P347, DOI 10.1016/0165-0327(82)90030-1
   Telleria-Diaz A, 2001, NEUROPEPTIDES, V35, P162, DOI 10.1054/npep.2001.0859
   Ventura RR, 2002, BRAZ J MED BIOL RES, V35, P1101, DOI 10.1590/S0100-879X2002000900011
   Volpi S, 2004, STRESS, V7, P75, DOI 10.1080/102538900410001733535
   VONBARDELEBEN U, 1989, PSYCHONEUROENDOCRINO, V14, P441, DOI 10.1016/0306-4530(89)90043-7
   WAND GS, 1991, J CLIN ENDOCR METAB, V72, P1290
   Westphal U, 1986, Monogr Endocrinol, V27, P1
   Windle RJ, 2006, ENDOCRINOLOGY, V147, P2423, DOI 10.1210/en.2005-1079
   Wotjak CT, 2001, EUR J NEUROSCI, V13, P2273, DOI 10.1046/j.0953-816x.2001.01613.x
   Wsol A, 2009, STRESS, V12, P517, DOI 10.3109/10253890802687688
   Xi D, 1999, ENDOCRINOLOGY, V140, P4677, DOI 10.1210/en.140.10.4677
   Zhang ZH, 2002, AM J PHYSIOL-HEART C, V283, pH423, DOI 10.1152/ajpheart.00685.2001
   Zhuo J.N., 1999, MICROSC RES TECHNIQ, V44, P36
   Zimmermann U, 2003, BIOL PSYCHIAT, V53, P75, DOI 10.1016/S0006-3223(02)01444-0
NR 113
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-128X
EI 1878-5867
J9 STEROIDS
JI Steroids
PD JUL
PY 2016
VL 111
SI SI
BP 21
EP 28
DI 10.1016/j.steroids.2016.01.008
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DQ9VS
UT WOS:000379558000005
PM 26827626
ER

PT J
AU Gribble, K
AF Gribble, Karleen
TI Promoting attachment in foster parents: what we can learn from the
   experience of parents of premature infants
SO ADOPTION AND FOSTERING
LA English
DT Article
DE Attachment; foster care; premature infants; grief; loss
ID BIRTH-WEIGHT INFANTS; INTENSIVE-CARE-UNIT; PRETERM INFANTS;
   YOUNG-CHILDREN; MOTHERS; OXYTOCIN; INTERVENTION; COMMITMENT; PREGNANCY;
   KANGAROO
AB It is advantageous for children in foster care to have caregivers who are strongly attached to them. However, foster parents may have difficulty attaching to the children placed in their care because they fear the grief that they will feel if a child is removed. The parents of premature babies are another group who may face difficulty attaching to their children owing to the fear of loss. Research has found that parent-premature infant attachment can be assisted via the promotion of close proximity and nurturing touch, aiding parents to interpret their child's cues and understand their needs, and through providing caregiving. These findings may be applied to foster parenting and provide guidance in the methods by which foster parent-to-child attachment can be promoted. While foster parents who attach to their foster children will grieve if children leave their care, the careful facilitation of moves, providing feedback on children's well-being and offering support through the grieving process will assist them to retain an ability to attach to subsequent foster children and to continue fostering.
C1 [Gribble, Karleen] Univ Western Sydney, Sch Nursing & Midwifery, Locked Bag 1797, Penrith, NSW 2751, Australia.
RP Gribble, K (reprint author), Univ Western Sydney, Sch Nursing & Midwifery, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM karleeng@uws.edu.au
CR Ackerman JP, 2005, J APPL DEV PSYCHOL, V26, P507, DOI 10.1016/j.appdev.2005.06.003
   Affonso D, 1993, Neonatal Netw, V12, P25
   Amankwaa L. C., 2007, NEWBORN INFANT NURSI, V7, P25, DOI DOI 10.1053/J.NAINR.2006.12.001
   ANISFELD E, 1990, CHILD DEV, V61, P1617, DOI 10.1111/j.1467-8624.1990.tb02888.x
   Ayling P, 2013, ADOPTION FOSTERING, V37, P130
   Bernard K, 2011, INFANT MENT HEALTH J, V32, P251, DOI 10.1002/imhj.20293
   Bialoskurski M, 1999, J PERINAT NEONAT NUR, V13, P66
   Bick J, 2013, CHILD DEV, V84, P826, DOI 10.1111/cdev.12008
   Blythe SL, 2013, CONTEMP NURSE, V44, P87, DOI 10.5172/conu.2013.44.1.87
   Bond Cherry, 2002, Semin Neonatol, V7, P477, DOI 10.1053/siny.2002.0149
   Booth P. B., 2010, THERAPLAY HELPING PA
   Bradley RH, 1997, J MARRIAGE FAM, V59, P77, DOI 10.2307/353663
   Brisch Karl Heinz, 2003, Attach Hum Dev, V5, P120, DOI 10.1080/1461673031000108504
   Brockington I, 2011, PSYCHOPATHOLOGY, V44, P329, DOI 10.1159/000325058
   Cairns K., 2002, ADOPTION FOSTERING, V26, P6
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Christos JA, 1977, THE BULLETIN, V5, P295
   Crnic K. A., 1986, INFANT MENT HEALTH J, V7, P19, DOI 10.1002/1097-0355(198621)7:1<19::AID-IMHJ2280070104>3.0.CO;2-1
   Doka K., 1989, DISENFRANCHISED GRIE
   Dozier M, 2004, INF MENTAL HLTH J, V25, P368, DOI 10.1002/imhj.20011
   Dozier M, 2002, INFANT MENT HEALTH J, V23, P541, DOI 10.1002/imhj.10032
   Dozier M, 2001, CHILD DEV, V72, P1467, DOI 10.1111/1467-8624.00360
   Dozier M, 2006, CHILD MALTREATMENT, V11, P338, DOI 10.1177/1077559506291263
   Dozier Mary, 2011, Zero Three, V31, P17
   Duhn Lenora, 2010, Adv Neonatal Care, V10, P294, DOI 10.1097/ANC.0b013e3181fd2263
   Edelstein SB, 2001, CHILD WELFARE, V80, P5
   FANAROFF AA, 1972, PEDIATRICS, V49, P287
   Fegran L, 2008, J CLIN NURS, V17, P810, DOI 10.1111/j.1365-2702.2007.02125.x
   Feijo L, 2006, INFANT BEHAV DEV, V29, P476, DOI 10.1016/j.infbeh.2006.02.003
   Feldman R, 1999, J CHILD PSYCHOL PSYC, V40, P929, DOI 10.1017/S0021963099004308
   Feldman R, 2002, PEDIATRICS, V110, P16, DOI 10.1542/peds.110.1.16
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Ferber SG, 2005, INFANT BEHAV DEV, V28, P74, DOI 10.1016/j.infbeh.2004.07.004
   Field T, 1996, J APPL DEV PSYCHOL, V17, P37, DOI 10.1016/S0193-3973(96)90004-0
   Fisher PA, 2000, J AM ACAD CHILD PSY, V39, P1356, DOI 10.1097/00004583-200011000-00009
   Flacking R, 2006, SOC SCI MED, V62, P70, DOI 10.1016/j.sociscimed.2005.05.026
   Gathwala G, 2008, INDIAN J PEDIATR, V75, P43, DOI 10.1007/s12098-008-0005-x
   Gaudet C, 2010, J REPROD INFANT PSYC, V28, P240, DOI 10.1080/02646830903487342
   Glover Vivette, 2002, Semin Neonatol, V7, P495, DOI 10.1053/siny.2002.0154
   GOLDBERG S, 1977, MERRILL PALMER QUART, V23, P163
   Golding K, 2007, ADOPTION FOSTERING, V31, P39
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Goulet C, 1998, J ADV NURS, V28, P1071
   Green J, 2002, J CHILD PSYCHOL PSYC, V43, P835, DOI 10.1111/1469-7610.00102
   Gribble Karleen D, 2007, J Child Adolesc Psychiatr Nurs, V20, P14, DOI 10.1111/j.1744-6171.2007.00076.x
   Handlin L, 2012, BREASTFEED MED, V7, P93, DOI 10.1089/bfm.2010.0099
   Harris CH, 1986, NURSING ASSESSMENT S, P61
   Hebert C, 2013, ADOPTION FOSTERING, V37, P253
   Heermann J A, 2000, Neonatal Netw, V19, P23
   Holmes B, 2010, ADOPTION FOSTERING, V34, P65
   Johnson AN, 2007, JOGNN-J OBST GYN NEO, V36, P568, DOI 10.1111/J.1152-6909.2007.00187.x
   Johnson S H, 1975, JOGN Nurs, V4, P15, DOI 10.1111/j.1552-6909.1975.tb00612.x
   Korja R, 2008, EARLY HUM DEV, V84, P257, DOI 10.1016/j.earlhumdev.2007.06.006
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kramer MS, 2000, PAEDIATR PERINAT EP, V14, P194, DOI 10.1046/j.1365-3016.2000.00266.x
   Kretchmar MD, 2005, ATTACH HUM DEV, V7, P31, DOI 10.1080/14616730500048102
   Lappin G., 2005, RE VIEW REHABILITATI, V37, P87, DOI 10.3200/REVU.37.2.87-94
   Lindhiem O, 2007, CHILD ABUSE NEGLECT, V31, P361, DOI 10.1016/j.chiabu.2006.12.003
   Lupton D, 2001, SOC SCI MED, V53, P1011, DOI 10.1016/S0277-9536(00)00396-8
   MCGEHEE LJ, 1983, INFANT BEHAV DEV, V6, P461, DOI 10.1016/S0163-6383(83)90271-0
   McHugh M, 2007, COSTS CONSEQUENCES U
   Meijssen DE, 2011, CHILD CARE HLTH DEV, V37, P195, DOI 10.1111/j.1365-2214.2010.01119.x
   Melnyk BM, 2001, RES NURS HEALTH, V24, P373, DOI 10.1002/nur.1038
   MERCER RT, 1990, J ADV NURS, V15, P268, DOI 10.1111/j.1365-2648.1990.tb01813.x
   Minnis H., 2001, ADOPTION FOSTERING, V25, P44
   Morhenn V, 2012, ALTERN THER HEALTH M, V18, P11
   Nagasawa M., 2012, FRONT HUM NEUROSCI, V6, P1
   Netzer D, 1999, Twin Res, V2, P258, DOI 10.1375/136905299320565744
   Nyqvist KH, 2010, ACTA PAEDIATR, V99, P820, DOI 10.1111/j.1651-2227.2010.01787.x
   Perry B. D., 2006, WORKING TRAUMATIZED, P27
   Porter Luz S, 2004, Pediatr Nurs, V30, P363
   Riggs DW, 2009, BRIT J SOC WORK, V39, P789, DOI 10.1093/bjsw/bcm156
   Schofield G, 2005, ATTACH HUM DEV, V7, P3, DOI 10.1080/14616730500049019
   Schore AN, 2001, INFANT MENT HEALTH J, V22, P7, DOI 10.1002/1097-0355(200101/04)22:1<7::AID-IMHJ2>3.0.CO;2-N
   Schormans AF, 2004, OMEGA-J DEATH DYING, V49, P347, DOI 10.2190/PMPX-5JWW-7LAB-C9LE
   Solomon J., 2011, DISORGANIZED ATTACHM, P25
   Spencer N, 2006, J EPIDEMIOL COMMUN H, V60, P337, DOI 10.1136/jech.2005.042085
   Stovall KC, 2000, DEV PSYCHOPATHOL, V12, P133, DOI 10.1017/S0954579400002029
   Stovall-McClough KC, 2004, DEV PSYCHOPATHOL, V16, P253, DOI 10.1017/S0954579404044505
   Sutton C, 2001, BEHAV COGN PSYCHOTH, V29, P357, DOI 10.1017/S1352465801003083
   Thompson H., 2011, ADOPTION FOSTERING, V35, P49
   Thomson J, 2007, AUSTR SOCIAL WORK, V60, P336, DOI DOI 10.1080/03124070701519694
   Thomson L, 2010, COMMUNITIES CHILDREN, V5, P48
   Trombini E, 2008, ACTA PAEDIATR, V97, P894, DOI 10.1111/j.1651-2227.2008.00849.x
   Urquhart LR, 1989, CHILD ADOLESCENT SOC, V6, P193, DOI 10.1007/BF00755847
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   VANBEEK Y, 1994, BEHAVIOUR, V129, P35, DOI 10.1163/156853994X00343
   Wilson K, 2000, BRIT J SOC WORK, V30, P193, DOI 10.1093/bjsw/30.2.193
   Woodroffe I., 2006, J NEONATAL NURSING, V12, P144, DOI 10.1016/j.jnn.2006.03.004
   Wozniak D, 2001, THEYRE ALL MY CHILDR
   Zeanah CH, 2011, J AM ACAD CHILD PSY, V50, P1199, DOI 10.1016/j.jaac.2011.08.001
NR 91
TC 0
Z9 0
U1 13
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0308-5759
EI 1740-469X
J9 ADOPT FOSTER
JI Adopt. Foster.
PD JUL
PY 2016
VL 40
IS 2
BP 113
EP 127
DI 10.1177/0308575916643923
PG 15
WC Family Studies
SC Family Studies
GA DQ2NN
UT WOS:000379039200002
ER

PT J
AU Tietjen, GE
   Buse, DC
   Collins, SA
AF Tietjen, Gretchen E.
   Buse, Dawn C.
   Collins, Stuart A.
TI Childhood Maltreatment in the Migraine Patient
SO CURRENT TREATMENT OPTIONS IN NEUROLOGY
LA English
DT Review
DE Childhood maltreatment; Abuse; Adverse childhood experiences; Stress;
   Migraine; Genetics; Epigenetics; Cognitive behavioral therapy
ID EARLY-LIFE STRESS; COMMUNITY SAMPLE; PHYSICAL ABUSE;
   PSYCHIATRIC-DISORDERS; RECURRENT HEADACHE; EMOTIONAL ABUSE;
   SEXUAL-ABUSE; CHRONIC PAIN; 5-HTT GENE; METAANALYSIS
AB Maltreatment during childhood increases vulnerability to a host of health disorders, including migraine. Putative mechanisms linking maltreatment and migraine include stress-induced dysregulation of the hypothalamic-pituitary-adrenal ( HPA) axis, as well as disruption of other stress-mediating homeostatic systems, including those involving endocannabinoids, monoamine neurotransmitters, oxytocin, and inflammation. Prolonged elevation of glucocorticoids alters the neural architecture of the limbic system, resulting in the structural as well as functional changes described in both maltreatment and in migraine. Although treatment trials for migraine have not stratified participants by abuse history, strategies, such as cognitive behavioral therapy, which alter stress responsivity, may be particularly effective in this subgroup. Some therapies involving the endocannabinoid, serotonergic, oxytonergic, and inflammatory systems are under investigation for migraine. Anti-epileptic drugs such as valproate and topiramate, which are FDA approved for migraine treatment, are also known to interfere with epigenetic changes induced by stress. Discerning the role for this mechanism in treatment of maltreated migraineurs may introduce another therapeutic avenue.
C1 [Tietjen, Gretchen E.; Collins, Stuart A.] Univ Toledo, Coll Med & Life Sci, Dept Neurol, 3000 Arlington Ave,MS 1195, Toledo, OH 43615 USA.
   [Buse, Dawn C.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Buse, Dawn C.] Montefiore Headache Ctr, Bronx, NY USA.
RP Tietjen, GE (reprint author), Univ Toledo, Coll Med & Life Sci, Dept Neurol, 3000 Arlington Ave,MS 1195, Toledo, OH 43615 USA.
EM gretchen.tietjen@utoledo.edu
FU Allergan Pharmaceuticals; Dr. Reddy's Pharmaceuticals; Avanir
   Pharmaceuticals
FX Dawn C. Buse is an advisory board member of Eli Lilly and has received
   research support from Allergan Pharmaceuticals, Dr. Reddy's
   Pharmaceuticals, and Avanir Pharmaceuticals.
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Anda R, 2010, HEADACHE, V50, P1473, DOI 10.1111/j.1526-4610.2010.01756.x
   Andersen SL, 2008, J NEUROPSYCH CLIN N, V20, P292, DOI 10.1176/appi.neuropsych.20.3.292
   Andrasik F, 2007, NEUROL SCI, V28, pS70, DOI 10.1007/s10072-007-0754-8
   Beck AT, 1979, COGNITIVE THERAPY DE
   Bernstein DA, 2000, NEW DIRECTIONS PROGR
   Brennenstuhl S, 2015, HEADACHE, V55, P973, DOI 10.1111/head.12614
   BRESLAU N, 1993, J PSYCHIAT RES, V27, P211, DOI 10.1016/0022-3956(93)90009-Q
   Brown ES, 1999, NEUROPSYCHOPHARMACOL, V21, P474, DOI 10.1016/S0893-133X(99)00054-8
   Brown J, 2005, CLIN J PAIN, V21, P374, DOI 10.1097/01.ajp.0000149797.16370.dc
   Buse DC, 2010, J NEUROL NEUROSUR PS, V81, P428, DOI 10.1136/jnnp.2009.192492
   Buse DC, 2015, CEPHALALGIA, V35, P844, DOI 10.1177/0333102414567382
   Buse DC, 2013, J NEUROL, V260, P1960, DOI 10.1007/s00415-012-6725-x
   Campbell JK, 2000, EVIDENCE BASED GUIDE
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Coelho R, 2014, ACTA PSYCHIAT SCAND, V129, P180, DOI 10.1111/acps.12217
   Cohen Judith A., 2006, TREATING TRAUMA TRAU
   Couch JR, 2011, HEADACHE, V51, P33, DOI 10.1111/j.1526-4610.2010.01800.x
   Dai Z, 2015, NEUROSCIENCE, V299, P88, DOI 10.1016/j.neuroscience.2015.04.066
   De Bellis MD, 2014, CHILD ADOL PSYCH CL, V23, P185, DOI 10.1016/j.chc.2014.01.002
   De Brito SA, 2013, J CHILD PSYCHOL PSYC, V54, P105, DOI 10.1111/j.1469-7610.2012.02597.x
   Dias A, 2015, EUR CHILD ADOLES PSY, V24, P767, DOI 10.1007/s00787-014-0621-0
   Edvinsson L, 2015, BRIT J CLIN PHARMACO, V80, P193, DOI 10.1111/bcp.12618
   Eising E, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-26
   Eyal S, 2004, EPILEPSIA, V45, P737, DOI 10.1111/j.0013-9580.2004.00104.x
   Fan Y, 2015, NEUROPSYCHOPHARMACOL, V40, P2736, DOI 10.1038/npp.2015.123
   Fan Y, 2014, HUM BRAIN MAPP, V35, P5328, DOI 10.1002/hbm.22553
   Fang XM, 2015, B WORLD HEALTH ORGAN, V93, P176, DOI 10.2471/BLT.14.140970
   Fang X, 2015, CHILD ABUSE NEGLECT, V42, P146, DOI 10.1016/j.chiabu.2015.02.012
   FELITTI VJ, 1991, SOUTHERN MED J, V84, P328
   Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8
   Fuller-Thomson E, 2010, HEADACHE, V50, P749, DOI 10.1111/j.1526-4610.2010.01626.x
   Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7
   Golding JM, 1999, J NERV MENT DIS, V187, P624, DOI 10.1097/00005053-199910000-00006
   Goodwin RD, 2003, AM J PUBLIC HEALTH, V93, P1065, DOI 10.2105/AJPH.93.7.1065
   Gutman David A, 2002, Semin Clin Neuropsychiatry, V7, P89, DOI 10.1053/scnp.2002.31781
   Hall H., 2007, PAIN MANAGEMENT, V2, P1025
   Hart H, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00052
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Heim C, 2010, DEV PSYCHOBIOL, V52, P671, DOI 10.1002/dev.20494
   Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621
   HOLROYD KA, 1988, J CONSULT CLIN PSYCH, V56, P218, DOI 10.1037/0022-006X.56.2.218
   Holroyd KA, 1982, ADV COGNITIVE BEHAVI, V1, P275
   Irby MB, 2016, HEADACHE, V56, P357, DOI 10.1111/head.12738
   Jacobson E., 1938, PROGR RELAXATION
   Jawahar MC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0156-3
   Jette N, 2008, HEADACHE, V48, P501, DOI 10.1111/j.1526-4610.2007.00993.x
   Kim H, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-65
   Kopec JA, 2004, CAN J PUBLIC HEALTH, V95, P361
   Lee MA, 2015, CHILD ABUSE NEGLECT, V44, P130, DOI 10.1016/j.chiabu.2015.03.016
   Leenarts LEW, 2013, EUR CHILD ADOLES PSY, V22, P269, DOI 10.1007/s00787-012-0367-5
   Lemstra M, 2002, HEADACHE, V42, P845, DOI 10.1046/j.1526-4610.2002.02202.x
   Linehan MM, 2006, ARCH GEN PSYCHIAT, V63, P757, DOI 10.1001/archpsyc.63.7.757
   Linton SJ, 2002, PAIN, V96, P347, DOI 10.1016/S0304-3959(01)00480-8
   Liu H, 2011, J NEUROL SCI, V305, P57, DOI 10.1016/j.jns.2011.03.016
   Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102
   Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537
   Maizels M, 2006, HEADACHE, V46, pS98, DOI 10.1111/j.1526-4610.2006.00561.x
   Maizels M, 2012, HEADACHE, V52, P1553, DOI 10.1111/j.1526-4610.2012.02209.x
   Mandelli L, 2015, EUR PSYCHIAT, V30, P665, DOI 10.1016/j.eurpsy.2015.04.007
   Martsolf Donna S, 2005, Issues Ment Health Nurs, V26, P801, DOI 10.1080/01612840500184012
   MATHEW NT, 1981, HEADACHE, V21, P105, DOI 10.1111/j.1526-4610.1981.hed2103105.x
   Matthews K, 2001, SYNAPSE, V40910, P1
   McCarran MS, 1987, ANXIETY STRESS DISOR, P465
   McCauley J, 1997, JAMA-J AM MED ASSOC, V277, P1362, DOI 10.1001/jama.277.17.1362
   McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086
   Mitra R, 2008, P NATL ACAD SCI USA, V105, P5573, DOI 10.1073/pnas.0705615105
   Moore SE, 2015, CHILD ABUSE NEGLECT, V48, P208, DOI 10.1016/j.chiabu.2015.05.006
   Nestoriuc Y, 2007, PAIN, V128, P111, DOI 10.1016/j.pain.2006.09.007
   Opel N, 2014, NEUROPSYCHOPHARMACOL, V39, P2724
   Pagliaccio D, 2014, NEUROPSYCHOPHARMACOL, V39, P1245, DOI 10.1038/npp.2013.327
   PENZIEN DB, 1994, BEHAV MED, V20, P64
   Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004
   Raphael KG, 2011, PAIN, V152, P163, DOI 10.1016/j.pain.2010.10.014
   Raphael KG, 2001, PAIN, V92, P283, DOI 10.1016/S0304-3959(01)00270-6
   Rime C, 2007, PAIN MANAGEMENT, V2, P1021
   RIMSZA ME, 1988, CHILD ABUSE NEGLECT, V12, P201, DOI 10.1016/0145-2134(88)90028-2
   Romans S, 2002, PSYCHOTHER PSYCHOSOM, V71, P141, DOI 10.1159/000056281
   Sachs-Ericsson N, 2007, CHILD ABUSE NEGLECT, V31, P531, DOI 10.1016/j.chiabu.2006.12.007
   Sarchielli P, 2006, HEADACHE, V46, P200, DOI 10.1111/j.1526-4610.2006.00337.x
   Schramm SH, 2015, CEPHALALGIA, V35, P853, DOI 10.1177/0333102414563087
   Schurks M, 2010, CEPHALALGIA, V30, P1296, DOI 10.1177/0333102410362929
   Schurks M, 2010, HEADACHE, V50, P588, DOI 10.1111/j.1526-4610.2009.01570.x
   Schwedt TJ, 2015, HEADACHE, V55, P762, DOI 10.1111/head.12584
   Shyti R, 2015, EXP NEUROL, V263, P214, DOI 10.1016/j.expneurol.2014.10.015
   Smearman EL, 2016, CHILD DEV, V87, P122, DOI 10.1111/cdev.12493
   Smith SC, 2014, NEUROENDOCRINOL LETT, V35, P198
   Smitherman TA, 2013, HEADACHE, V53, P775, DOI 10.1111/head.12063
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stensland SO, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-35
   Stranahan AM, 2008, NEUROMOL MED, V10, P118, DOI 10.1007/s12017-008-8027-0
   Tietjen G, 2016, NEUROLOGY IN PRESS
   Tietjen GE, 2015, NEUROLOGY, V84, P132, DOI 10.1212/WNL.0000000000001120
   Tietjen GE, 2012, HEADACHE, V52, P920, DOI [10.1111/j.1526-4610.2012.02165.x, 10.1111/j.1526-4610.2012.02179.x]
   Tietjen GE, 2009, STROKE, V40, P2977, DOI 10.1161/STROKEAHA.109.547901
   Tzabazis A, 2015, CEPHALALGIA
   Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033
   Varkey E, 2011, CEPHALALGIA, V31, P1428, DOI 10.1177/0333102411419681
   Waeber C, 2005, NEUROLOGY, V64, pS9
   Walker EA, 1999, AM J MED, V107, P332, DOI 10.1016/S0002-9343(99)00235-1
   Walsh CA, 2007, J INTERPERS VIOLENCE, V22, P1536, DOI 10.1177/0886260507306484
   Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x
   Wildeman C, 2014, JAMA PEDIATR, V168, P706, DOI 10.1001/jamapediatrics.2014.410
   Wolpe J., 1958, PSYCHOTHERAPY RECIPR
   Yeomans DC, 2013, CEPHALALGIA S59, V33
NR 105
TC 0
Z9 0
U1 3
U2 3
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1092-8480
EI 1534-3138
J9 CURR TREAT OPTION NE
JI Curr. Treat. Options Neurol.
PD JUL
PY 2016
VL 18
IS 7
AR 31
DI 10.1007/s11940-016-0415-4
PG 15
WC Clinical Neurology
SC Neurosciences & Neurology
GA DQ2DU
UT WOS:000379012600003
PM 27194425
ER

PT J
AU Ergul, M
   Turgut, NH
   Sarac, B
   Altun, A
   Yildirim, S
   Bagcivan, I
AF Ergul, Merve
   Turgut, Nergiz H.
   Sarac, Bulent
   Altun, Ahmet
   Yildirim, Sahin
   Bagcivan, Ihsan
TI Investigating the effects of the Rho-kinase enzyme inhibitors AS1892802
   and fasudil hydrochloride on the contractions of isolated pregnant rat
   myometrium
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Rho-kinase inhibitor; AS1892802; Fasudil hydrochloride; Myometrium;
   Tocolysis
ID CANCER-THERAPY; PRETERM BIRTH; GTPASES; CALCIUM; CELLS; LABOR
AB Objectives: Rho-kinases (ROCKs), are one of the dynamic structures of the actin cytoskeleton and they mediate different biological processes, including regulation of calcium sensitivity of smooth muscle contraction. The activation of Rho A/ROCK system is thought to be effective on the termination time of the pregnancy process. The aim of this study, was to investigate in vitro effects of the ROCK enzyme inhibitors, clinically available fasudil hydrochloride, and a new promising inhibitor AS1892802, on the contractions of isolated pregnant rat myometrium.
   Study design: Term pregnant Wistar albino rats (n = 12), weighing 200-220 g, were used in this study. Myometrial tissues obtained from rats were dissected into four full-thickness longitudinal muscle strips and then myometrial tension was recorded isometrically. The inhibitory effects of cumulative concentrations of AS1892802 and of fasudil hydrochloride in the presence and absence of ODQ (guanylate cyclase inhibitor), L-NAME (nitric oxide synthase inhibitor) and L-NNA (endothelial nitric oxide synthase inhibitor) on oxytocin-induced myometrial contractions were measured, and values for -log10 EC50 (pD(2)) and mean maximal inhibition (E-max) were compared.
   Results: Both ROCK inhibitors, AS1892802 and fasudil hydrochloride starting from the concentrations of 10(-6) M reached statistical significance on contraction amplitude and frequency of myometrial strips (p < 0.05). The inhibition of the amplitude and frequency of myometrial contractions was antagonized with ODQ (10(-5) M; only amplitude), L-NAME (3 x 10(-5) M) and L-NNA (10(-5) M) (p < 0.05).
   Conclusion: These results suggest that fasudil hydrochloride and AS1892802 may contribute to the development of new tocolytic drugs. We conclude that AS1892802 and fasudil hydrochloride perform this inhibitory effect partially through ROCK inhibition and the NO/cGMP pathway. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Ergul, Merve; Turgut, Nergiz H.] Cumhuriyet Univ, Fac Pharm, Dept Pharmacol, PK 848, TR-58140 Sivas, Turkey.
   [Sarac, Bulent; Altun, Ahmet; Yildirim, Sahin; Bagcivan, Ihsan] Cumhuriyet Univ, Fac Med, Dept Pharmacol, TR-58140 Sivas, Turkey.
RP Turgut, NH (reprint author), Cumhuriyet Univ, Fac Pharm, Dept Pharmacol, PK 848, TR-58140 Sivas, Turkey.
EM nergizht@yahoo.com
FU Cumhuriyet University Scientific Research Project (CUBAP, Sivas, Turkey)
   [T-587]
FX This study was supported by Cumhuriyet University Scientific Research
   Project T-587 (CUBAP, Sivas, Turkey).
CR Albersen M, 2010, EXPERT OPIN EMERG DR, V15, P467, DOI 10.1517/14728214.2010.480973
   American College of Obstetricians and Gynecologists, 2012, OBSTET GYNECOL, V119, P1308, DOI DOI 10.1097/A0G.0B013E31825AF2F0
   Bernal AL, 2003, BJOG-INT J OBSTET GY, V110, P39, DOI 10.1016/S1470-0328(03)00023-5
   Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145
   Friel M, 2005, J SOC GYNECOL INVEST, V12, P20
   Gao Jie, 2009, Zhonghua Fu Chan Ke Za Zhi, V44, P345
   Garnock-Jones P., 2014, DRUGS, V74, P2211
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Goupil E, 2010, J BIOL CHEM, V13, P25624
   Grewal S, 2010, BIOL REPROD, V83, P75, DOI 10.1095/biolreprod.109.080630
   Howson C, 2012, BORN TOO SOON GLOBAL
   Hudson A, 2012, BIOCHEM SOC T, V40, P262
   Hudson A, 2012, MOL HUM REPROD, V18, P265
   Komers R, 2011, KIDNEY INT, V79, P432, DOI 10.1038/ki.2010.428
   Kramer MS, 2012, AM J OBSTET GYNECOL, V206, P108, DOI 10.1016/j.ajog.2011.10.864
   Kupittayanant S, 2001, PFLUG ARCH EUR J PHY, V443, P112
   Lartey J, 2007, BIOL REPROD, V76, P971, DOI 10.1095/biolreprod.106.058982
   Lartey J, 2009, REPRODUCTION, V138, P407, DOI 10.1530/REP-09-0160
   Lee DH, 2009, J BIOL CHEM, V284, P11776, DOI 10.1074/jbc.C900014200
   Loirand G, 2015, PHARMACOL REV, V67, P1074, DOI 10.1124/pr.115.010595
   Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547
   Malik M, 2014, REPROD SCI, V21, P1126, DOI 10.1177/1933719114545240
   Mehats C, 2004, EUR J OBSTET GYN R B, V117, pS15, DOI 10.1016/j.ejogrb.2004.07.010
   Moran CJ, 2002, MOL HUM REPROD, V8, P196, DOI 10.1093/molehr/8.2.196
   Mueller AK, 2005, NAT REV DRUG DISCOV, V4, P387
   Olson F, 2008, CURR OPIN CELL BIOL, V20, P242
   Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127
   Schaafsma A, 2008, EUR J PHARMACOL, V585, P398
   Sharp PE, 1998, LAB RAT, P104
   Smith V, 2009, EUR J OBSTET GYN R B, V142, P3, DOI 10.1016/j.ejogrb.2008.09.008
   Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920
   TAKAYASU M, 1986, J NEUROSURG, V65, P80, DOI 10.3171/jns.1986.65.1.0080
   Takeshita N, 2011, J PHARMACOL SCI, V115, P481, DOI 10.1254/jphs.10319FP
   Tamura M, 2005, BBA-PROTEINS PROTEOM, V1754, P245, DOI 10.1021/j.bbapap.2005.06.015
   Tsuno A, 2011, J CLIN ENDOCR METAB, V96, pE1944, DOI 10.1210/jc.2011-1503
   Vicari RM, 2005, J AM COLL CARDIOL, V46, P1803, DOI 10.1016/j.jacc.2005.07.047
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Voipio HM, 1998, SCAND J LAB ANIM SCI, V25, P5
   Yoshimi E, 2010, J PHARMACOL EXP THER, V1, P955
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD JUL
PY 2016
VL 202
BP 45
EP 50
DI 10.1016/j.ejogrb.2016.04.031
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DQ3IF
UT WOS:000379095300009
PM 27160814
ER

PT J
AU Childs, E
   Bershad, AK
   de Wit, H
AF Childs, Emma
   Bershad, Anya K.
   de Wit, Harriet
TI Effects of d-amphetamine upon psychosocial stress responses
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE d-amphetamine; cortisol; stress; emotion; cardiovascular
ID METHAMPHETAMINE; HUMANS; MDMA; BEHAVIOR; METHYLPHENIDATE;
   CORTICOSTERONE; BUPRENORPHINE; SENSITIZATION; OXYTOCIN; AMYGDALA
AB Psychostimulant drugs alter the salience of stimuli in both laboratory animals and humans. In animals, stimulants increase rates of responding to conditioned incentive stimuli, and in humans, amphetamine increases positive ratings of emotional images. However, the effects of stimulants on real-life emotional events have not been studied in humans. In this study, we examined the effect of d-amphetamine on responses to acute psychosocial stress using a public speaking task. Healthy volunteers (N=56) participated in two experimental sessions, one with a psychosocial stressor (the Trier Social Stress Test) and one with a non-stressful control task. They were randomly assigned to receive d-amphetamine (5 mg n=18, 10 mg n=20) or placebo (n=18) on both sessions under double blind conditions. Salivary cortisol, subjective mood, and vital signs were measured at regular intervals during the session. Subjects also provided cognitive appraisals of the tasks before and after their performances. Amphetamine produced its expected mood and physiological effects, and the Trier Social Stress Test produced its expected effects on cortisol and mood. Although neither dose of amphetamine altered cardiovascular or hormonal responses to stress, amphetamine (10 mg) increased participants' pre-task appraisals of how challenging the task would be, and it increased post-task ratings of self-efficacy. Paradoxically, it also increased ratings of how stressful the task was, and prolonged aversive emotional responses. These findings suggest that amphetamine differentially affects stress response components: it may increase participants' appraisals of self-efficacy without dampening the direct emotional or physiological responses to the stress.
C1 [Childs, Emma; Bershad, Anya K.; de Wit, Harriet] Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 South Maryland Ave,MC3077, Chicago, IL 60637 USA.
RP Childs, E (reprint author), Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 South Maryland Ave,MC3077, Chicago, IL 60637 USA.
EM echilds@psych.uic.edu
RI Childs, Emma/K-6775-2014
OI Childs, Emma/0000-0003-1747-5208
FU National Institutes of Health: National Institute of Drug Abuse
   [DA02812]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Institutes of Health: National Institute of
   Drug Abuse (grant number DA02812).
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Angrist B M, 1970, Biol Psychiatry, V2, P95
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Ballard ME, 2012, J PSYCHOPHARMACOL, V26, P1289, DOI 10.1177/0269881112446530
   Bedi G, 2010, BIOL PSYCHIAT, V68, P1134, DOI 10.1016/j.biopsych.2010.08.003
   Bedi G, 2009, PSYCHOPHARMACOLOGY, V207, P73, DOI 10.1007/s00213-009-1635-z
   Bershad AK, 2016, PSYCHONEUROENDOCRINO, V63, P43, DOI 10.1016/j.psyneuen.2015.09.011
   Bershad AK, 2015, PSYCHONEUROENDOCRINO, V52, P281, DOI 10.1016/j.psyneuen.2014.12.004
   CANTOR JR, 1975, J PERS SOC PSYCHOL, V32, P69, DOI 10.1037/h0076784
   Childs E, 2006, PSYCHOPHARMACOLOGY, V185, P514, DOI 10.1007/s00213-006-0341-3
   Childs E, 2006, PSYCHOPHYSIOLOGY, V43, P366, DOI 10.1111/j.1469-8986.2006.00414.x
   Childs E, 2011, ALCOHOL CLIN EXP RES, V35, P1794, DOI 10.1111/j.1530-0277.2011.01522.x
   Childs E, 2010, EXP CLIN PSYCHOPHARM, V18, P78, DOI 10.1037/a0018060
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Corr PJ, 2013, PSYCHOPHARMACOLOGY, V225, P373, DOI 10.1007/s00213-012-2824-8
   DEWIT H, 1986, DRUG ALCOHOL DEPEN, V16, P341, DOI 10.1016/0376-8716(86)90068-2
   DUTTON DG, 1974, J PERS SOC PSYCHOL, V30, P510, DOI 10.1037/h0037031
   ELLINWOOD EH, 1973, AM J PSYCHIAT, V130, P1088
   FOLSTEIN MF, 1973, PSYCHOL MED, V3, P479
   Fries E, 2006, PSYCHONEUROENDOCRINO, V31, P1278, DOI 10.1016/j.psyneuen.2006.09.009
   Frye CG, 2014, PHARMACOL BIOCHEM BE, V117, P1, DOI 10.1016/j.pbb.2013.11.030
   Gaab J, 2005, PSYCHONEUROENDOCRINO, V30, P599, DOI 10.1016/j.psyneuen.2005.02.001
   Hall R C, 1988, Psychiatr Med, V6, P73
   Hariri AR, 2002, NEUROPSYCHOPHARMACOL, V27, P1036, DOI 10.1016/S0893-133X(02)00373-1
   Hart CL, 2002, PSYCHOPHARMACOLOGY, V164, P376, DOI 10.1007/s00213-002-1225-9
   Heal DJ, 2013, J PSYCHOPHARMACOL, V27, P479, DOI 10.1177/0269881113482532
   Het S, 2007, BEHAV NEUROSCI, V121, P11
   Hysek CM, 2014, INT J NEUROPSYCHOPH, V17, P371, DOI 10.1017/S1461145713001132
   Hysek CM, 2012, PSYCHOPHARMACOLOGY, V222, P293, DOI 10.1007/s00213-012-2645-9
   JOHANSON CE, 1980, PSYCHOPHARMACOLOGY, V71, P275, DOI 10.1007/BF00433062
   Kirkpatrick MG, 2008, PSYCHOPHARMACOLOGY, V197, P137, DOI 10.1007/s00213-007-1018-2
   Kirkpatrick MG, 2014, NEUROPSYCHOPHARMACOL, V39, P1654, DOI 10.1038/npp.2014.12
   KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004
   KNYCH ET, 1979, NEUROENDOCRINOLOGY, V29, P110, DOI 10.1159/000122912
   MARTIN WR, 1971, CLIN PHARMACOL THER, V12, P245
   McCloskey M, 2010, PSYCHOPHARMACOLOGY, V208, P201, DOI 10.1007/s00213-009-1719-9
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Morean ME, 2013, PSYCHOPHARMACOLOGY, V227, P177, DOI 10.1007/s00213-012-2954-z
   Ostrander MM, 2003, BRAIN RES, V990, P209, DOI 10.1016/j.brainres.2003.07.001
   Phan KL, 2008, J NEUROSCI, V28, P2313, DOI 10.1523/JNEUROSCI.5603-07.2008
   Schachter S, 1962, PSYCHOL REV, V69, P378
   Schlotz W, 2011, PSYCHOL ASSESSMENT, V23, P80, DOI 10.1037/a0021148
   Schmidt ED, 2001, EUR J NEUROSCI, V13, P1923, DOI 10.1046/j.0953-816x.2001.01569.x
   Shalev I, 2011, HORM BEHAV, V60, P121, DOI 10.1016/j.yhbeh.2011.04.005
   Silber BY, 2006, PSYCHOPHARMACOLOGY, V187, P154, DOI 10.1007/s00213-006-0410-7
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   Spielberger CD., 1989, STATE TRAIT ANXIETY
   VOGEL WH, 1984, NEUROPHARMACOLOGY, V23, P1105, DOI 10.1016/0028-3908(84)90136-9
   Wachtel SR, 2002, DRUG ALCOHOL DEPEN, V68, P23, DOI 10.1016/S0376-8716(02)00104-7
   Wardle MC, 2014, PSYCHOPHARMACOLOGY, V231, P4219, DOI 10.1007/s00213-014-3570-x
   Wardle MC, 2012, PSYCHOPHARMACOLOGY, V223, P199, DOI 10.1007/s00213-012-2708-y
   Wardle MC, 2012, PSYCHOPHARMACOLOGY, V220, P143, DOI 10.1007/s00213-011-2498-7
   White TL, 2007, EXP CLIN PSYCHOPHARM, V15, P599, DOI 10.1037/1064-1297.15.6.599
   White TL, 2002, PHARMACOL BIOCHEM BE, V73, P729, DOI 10.1016/S0091-3057(02)00818-3
   Wiegmann DA, 1996, INT J AVIAT PSYCHOL, V6, P379
NR 55
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
EI 1461-7285
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD JUL
PY 2016
VL 30
IS 7
BP 608
EP 615
DI 10.1177/0269881116650388
PG 8
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DQ4LP
UT WOS:000379175700005
PM 27235381
ER

PT J
AU Xue, X
   Yang, JY
   He, Y
   Wang, LR
   Liu, P
   Yu, LS
   Bi, GH
   Zhu, MM
   Liu, YY
   Xiang, RW
   Yang, XT
   Fan, XY
   Wang, XM
   Qi, J
   Zhang, HJ
   Wei, T
   Cui, W
   Ge, GL
   Xi, ZX
   Wu, CF
   Liang, XJ
AF Xue, Xue
   Yang, Jing-Yu
   He, Yi
   Wang, Li-Rong
   Liu, Ping
   Yu, Li-Sha
   Bi, Guo-Hua
   Zhu, Ming-Ming
   Liu, Yue-Yang
   Xiang, Rong-Wu
   Yang, Xiao-Ting
   Fan, Xin-Yu
   Wang, Xiao-Min
   Qi, Jia
   Zhang, Hong-Jie
   Wei, Tuo
   Cui, Wei
   Ge, Guang-Lu
   Xi, Zheng-Xiong
   Wu, Chun-Fu
   Liang, Xing-Jie
TI Aggregated single-walled carbon nanotubes attenuate the behavioural and
   neurochemical effects of methamphetamine in mice
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID ELECTROCHEMICAL SENSORS; CEREBRAL-CORTEX; DOPAMINE; RECEPTORS; RAT;
   BIOMOLECULES; PLASTICITY; OXYTOCIN; NEURONS; COCAINE
AB Methamphetamine (METH) abuse is a serious social and health problem worldwide. At present, there are no effective medications to treat METH addiction(1). Here, we report that aggregated single-walled carbon nanotubes (aSWNTs) significantly inhibited METH self-administration, METH-induced conditioned place preference and METH- or cue-induced relapse to drug-seeking behaviour in mice. The use of aSWNTs alone did not significantly alter the mesolimbic dopamine system, whereas pretreatment with aSWNTs attenuated METH-induced increases in extracellular dopamine in the ventral striatum. Electrochemical assays suggest that aSWNTs facilitated dopamine oxidation. In addition, aSWNTs attenuated METH-induced increases in tyrosine hydroxylase or synaptic protein expression. These findings suggest that aSWNTs may have therapeutic effects for treatment of METH addiction by oxidation of METH-enhanced extracellular dopamine in the striatum.
C1 [Xue, Xue; Wang, Li-Rong; Wei, Tuo; Ge, Guang-Lu; Liang, Xing-Jie] Chinese Acad Sci, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China.
   [Xue, Xue; Wang, Li-Rong; Wei, Tuo; Ge, Guang-Lu; Liang, Xing-Jie] Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China.
   [Yang, Jing-Yu; Liu, Ping; Yu, Li-Sha; Zhu, Ming-Ming; Liu, Yue-Yang; Yang, Xiao-Ting; Fan, Xin-Yu; Wang, Xiao-Min; Cui, Wei; Wu, Chun-Fu] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China.
   [He, Yi; Bi, Guo-Hua; Qi, Jia; Xi, Zheng-Xiong] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Wang, Li-Rong; Ge, Guang-Lu] Natl Ctr Nanosci & Technol China, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing 100190, Peoples R China.
   [Xiang, Rong-Wu] Shenyang Pharmaceut Univ, Dept Biopharmaceut Informat, Shenyang 110016, Peoples R China.
   [Zhang, Hong-Jie] Chinese Acad Sci, Inst Biophys, State Key Lab Biomacromol, Beijing 100101, Peoples R China.
   [Wei, Tuo; Liang, Xing-Jie] Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
RP Xi, ZX (reprint author), NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
EM zxi@mail.nih.gov; wucf@syphu.edu.cn; liangxj@nanoctr.cn
FU National Key Scientific Project for New Drug Discovery and Development
   [2013ZX09301305]; National Natural Science Foundation key project
   [31430031]; National Distinguished Young Scholars grant [31225009];
   National Natural Science Foundation in China [81373383]; State High-Tech
   Development Plan [2012AA020804, SS2014AA020708]; National Institute on
   Drug Abuse (NIDA), Intramural Research Program (IRP), National
   Institutes of Health (NIH) in the United States of America; Chinese
   Academy of Sciences (CAS), Hundred Talents Program [07165111ZX]; CAS
   Knowledge Innovation Program; Strategic Priority Research Program of the
   Chinese Academy of Sciences [XDA09030301]; external collaboration
   program of BIC, Chinese Academy of Science [121D11KYSB20130006]
FX This work was supported by the National Key Scientific Project for New
   Drug Discovery and Development (2013ZX09301305), the National Natural
   Science Foundation key project (31430031), the National Distinguished
   Young Scholars grant (31225009) and the National Natural Science
   Foundation (No. 81373383) in China. This work was also supported by
   State High-Tech Development Plan (2012AA020804 and SS2014AA020708) and
   the National Institute on Drug Abuse (NIDA), Intramural Research Program
   (IRP), National Institutes of Health (NIH) in the United States of
   America. We also gratefully acknowledge support from the Chinese Academy
   of Sciences (CAS), Hundred Talents Program (07165111ZX), the CAS
   Knowledge Innovation Program, the Strategic Priority Research Program of
   the Chinese Academy of Sciences (XDA09030301) and the external
   collaboration program of BIC, Chinese Academy of Science
   (121D11KYSB20130006). We thank I. Hanson for English editing services.
CR Arnold MS, 2006, NAT NANOTECHNOL, V1, P60, DOI 10.1038/nnano.2006.52
   Bardi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080964
   Chiu Veronica M, 2012, Curr Drug Abuse Rev, V5, P227
   COLONNIER M, 1985, J COMP NEUROL, V231, P175, DOI 10.1002/cne.902310205
   DeFelipe J, 1999, CEREB CORTEX, V9, P722, DOI 10.1093/cercor/9.7.722
   Edwards SL, 2009, EXPERT REV MED DEVIC, V6, P499, DOI [10.1586/erd.09.29, 10.1586/ERD.09.29]
   Figueiredo LCS, 2014, ANALYST, V139, P2842, DOI 10.1039/c4an00229f
   Giraldo JP, 2015, SMALL, V11, P3973, DOI 10.1002/smll.201403276
   Han WY, 2013, PHARM BIOCH BEHAV, V119, P80
   Keefer EW, 2008, NAT NANOTECHNOL, V3, P434, DOI 10.1038/nnano.2008.174
   Keller CM, 2011, PSYCHOPHARMACOLOGY, V215, P513, DOI 10.1007/s00213-011-2301-9
   Khan AA, 2015, NANOSCALE, V7, P330, DOI 10.1039/c4nr04466e
   Lee HJ, 2011, NAT NANOTECHNOL, V6, P120, DOI 10.1038/nnano.2010.281
   Ma XW, 2012, ACS NANO, V6, P10486, DOI 10.1021/nn302457v
   O'Brien CP, 2005, PHARMACOL THERAPEUT, V108, P18, DOI 10.1016/j.pharmthera.2005.06.018
   Pickens CL, 2011, TRENDS NEUROSCI, V34, P411, DOI 10.1016/j.tins.2011.06.001
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Qi J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6390
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
   Shepard JD, 2006, PSYCHOPHARMACOLOGY, V185, P505, DOI 10.1007/s00213-006-0316-4
   Song R, 2012, P NATL ACAD SCI USA, V109, P17675, DOI 10.1073/pnas.1205297109
   Suzuki I, 2013, BIOSENS BIOELECTRON, V49, P270, DOI 10.1016/j.bios.2013.05.023
   Tiwari JN, 2016, ACS NANO, V10, P46, DOI 10.1021/acsnano.5b05690
   Vocci FJ, 2007, ADDICTION, V102, P96, DOI 10.1111/j.1360-0443.2007.01772.x
   Wang LR, 2014, SMALL, V10, P2859, DOI 10.1002/smll.201303342
   Wang LR, 2012, NANOSCALE, V4, P3983, DOI 10.1039/c2nr30346a
   Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
   Xue X, 2014, NANO LETT, V14, P5110, DOI 10.1021/nl501839q
   Yang C, 2015, ANAL CHIM ACTA, V887, P17, DOI 10.1016/j.aca.2015.05.049
   Zhu J, 2012, J NEUROSCI RES, V90, P895, DOI 10.1002/jnr.22821
NR 32
TC 5
Z9 5
U1 15
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD JUL
PY 2016
VL 11
IS 7
BP 613
EP +
DI 10.1038/NNANO.2016.23
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA DQ9BY
UT WOS:000379506600012
PM 26974957
ER

PT J
AU Miyoshi, H
   Konishi, H
   Teraoka, Y
   Urabe, S
   Furusho, H
   Miyauchi, M
   Takata, T
   Kudo, Y
AF Miyoshi, Hiroshi
   Konishi, Haruhisa
   Teraoka, Yuko
   Urabe, Satoshi
   Furusho, Hisako
   Miyauchi, Mutsumi
   Takata, Takashi
   Kudo, Yoshiki
TI Enhanced Expression of Contractile-Associated Proteins and Ion Channels
   in Preterm Delivery Model Mice With Chronic Odontogenic Porphyromonas
   Gingivalis Infection
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE preterm delivery; odontogenic infection; contractile-associated protein;
   P2X7 receptor; chronic inflammation
ID PREGNANT RAT MYOMETRIUM; LOW-BIRTH-WEIGHT; INTRAAMNIOTIC INFECTION;
   FUNCTIONAL EXPRESSION; GAP-JUNCTIONS; MUSCLE-CELLS; LABOR; PARTURITION;
   RECEPTOR; MECHANISM
AB Inflammation and infection have been reported to induce preterm delivery. We have studied the relationship between inflammation and various ion channels, including the L-type Ca2+ channel and P2X7 receptor, during acute inflammation of the pregnant rat uterus induced by lipopolysaccharides. Recently, we found that mice with odontogenic Porphyromonas gingivalis (P.g, an important odontogenic pathogen) infection delivered at day 18.3 of gestation (vs. day 20.5 in normal mice). The purpose of this study was to investigate the expression of myometrial contractile-associated proteins inducing contractions and confirm that these mice are useful as a model for preterm delivery induced by chronic inflammation. We examined the expression of the oxytocin receptor, connexin 43, prostaglandin F receptors, L-type Ca2+ channel, and P2X7 receptor in the myometrium at day 18 of gestation by real-time PCR and western blot analyses. We also measured TNF- and IL-1 levels in the blood serum, placenta, fetal membrane and myometrium on the same day. mRNA expression of the oxytocin receptor, connexin 43, prostaglandin F receptors, L-type Ca2+ channel, and P2X7 receptor was elevated by 5.4, 3.2, 2.4, 2.5, and 1.7 fold, respectively, in the P.g-infected mice. Protein levels of the oxytocin receptor and connexin 43 also increased. Serum levels of TNF- and IL-1 were elevated, showing that systemic inflammation continued during pregnancy. IL-1 levels in the placenta and fetal membrane also increased, suggesting inflammatory reactions were induced. Thus, mice with odontogenic infection may be useful as a model of chronic inflammation-induced preterm delivery.
C1 [Miyoshi, Hiroshi; Konishi, Haruhisa; Teraoka, Yuko; Urabe, Satoshi; Kudo, Yoshiki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Obstet & Gynecol, Hiroshima, Japan.
   [Furusho, Hisako; Miyauchi, Mutsumi; Takata, Takashi] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Basic Life Sci, Hiroshima, Japan.
RP Miyoshi, H (reprint author), Hiroshima Univ Biomed Sci & Hlth, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM miyo36@hiroshima-u.ac.jp
FU general incorporated foundation Ryokufu-kai
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported in part by a young researchers grant from the general
   incorporated foundation Ryokufu-kai.
CR Ao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137249
   Barbera-Cremades M, 2012, FASEB J, V26, P2951, DOI 10.1096/fj.12-205765
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   Chang EY, 2012, J MATERN-FETAL NEO M, V25, P2395, DOI 10.3109/14767058.2012.697942
   Chiao CW, 2013, CLIN SCI, V125, P131, DOI [10.1042/CS20120479, 10.1042/C520120479]
   Choi HB, 2007, J NEUROSCI, V27, P4957, DOI 10.1523/JNEUROSCI.5417-06.2007
   Davenport ES, 2002, J DENT RES, V81, P313
   Dudley DJ, 1997, J REPROD IMMUNOL, V36, P93, DOI 10.1016/S0165-0378(97)00065-X
   Elovitz MA, 2004, TRENDS ENDOCRIN MET, V15, P479, DOI 10.1016/j.tem.2004.10.009
   Fang X, 2000, AM J REPROD IMMUNOL, V44, P65, DOI 10.1111/j.8755-8920.2000.440201.x
   FIDEL PL, 1994, AM J OBSTET GYNECOL, V170, P1467
   Furusho H, 2013, J GASTROENTEROL, V48, P1259, DOI 10.1007/s00535-012-0738-1
   GARFIELD RE, 1977, SCIENCE, V198, P958, DOI 10.1126/science.929182
   GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515
   GOMEZ R, 1995, CLIN PERINATOL, V22, P281
   Hasegawa K, 2003, J PERIODONTOL, V74, P1762
   Hasegawa-Nakamura K, 2011, J PERIODONTAL RES, V46, P497, DOI 10.1111/j.1600-0765.2011.01366.x
   Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008
   KASAI Y, 1994, BRIT J PHARMACOL, V112, P1132
   Katz J, 2009, J DENT RES, V88, P575, DOI 10.1177/0022034509338032
   Kawarabayashi T, 1997, GYNECOL OBSTET INVES, V43, P145
   KNOX IC, 1950, AM J OBSTET GYNECOL, V59, P190
   Kurashima Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2023
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Mendelson CR, 2009, MOL ENDOCRINOL, V23, P947, DOI 10.1210/me.2009-0016
   Miyoshi H, 1996, BIOPHYS J, V71, P1324
   Miyoshi H, 2004, PFLUG ARCH EUR J PHY, V447, P457, DOI 10.1007/s00424-003-1175-z
   Miyoshi H, 2012, REPROD SCI, V19, P1285, DOI 10.1177/1933719112450333
   Miyoshi H, 2010, AM J PHYSIOL-REG I, V298, pR1117, DOI 10.1152/ajpregu.00507.2009
   Morandini Ana Carolina, 2014, Biomed J, V37, P169, DOI 10.4103/2319-4170.127803
   Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103
   Pizzo G, 2010, EUR J INTERN MED, V21, P496, DOI 10.1016/j.ejim.2010.07.011
   Romero R, 2006, BJOG-INT J OBSTET GY, V113, P17, DOI 10.1111/j.1471-0528.2006.01120.x
   ROMERO R, 1989, AM J OBSTET GYNECOL, V160, P1117
   ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817
   Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816
   Seymour GJ, 2007, CLIN MICROBIOL INFEC, V13, P3, DOI 10.1111/j.1469-0691.2007.01798.x
   Tonon R, 2000, J BONE MINER RES, V15, P1669, DOI 10.1359/jbmr.2000.15.9.1669
   Urabe S, 2009, REPROD SCI, V16, P1186, DOI 10.1177/1933719109344630
NR 39
TC 1
Z9 1
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD JUL
PY 2016
VL 23
IS 7
BP 838
EP 846
DI 10.1177/1933719115620497
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DQ2KH
UT WOS:000379030700003
PM 26692542
ER

PT J
AU Welch, MG
AF Welch, Martha G.
TI Nurture in the neonatal intensive care unit
SO ACTA PAEDIATRICA
LA English
DT Editorial Material
ID OXYTOCIN
C1 [Welch, Martha G.] Columbia Univ, Med Ctr, New York, NY USA.
RP Welch, MG (reprint author), Columbia Univ, Med Ctr, New York, NY USA.
EM mgw13@columbia.edu
CR Grunau Ruth Eckstein, 2013, Rambam Maimonides Med J, V4, pe0025, DOI 10.5041/RMMJ.10132
   Hofer M A, 1994, Monogr Soc Res Child Dev, V59, P192, DOI 10.2307/1166146
   Kommers D, 2016, ACTA PAEDIATR, V105, P738, DOI 10.1111/apa.13254
   Lynch J, 1997, AM J PUBLIC HEALTH, V87, P617, DOI 10.2105/AJPH.87.4.617
   Morelius E, 2015, EARLY HUM DEV, V91, P63, DOI 10.1016/j.earlhumdev.2014.12.005
   Sullivan R, 2011, CLIN PERINATOL, V38, P643, DOI 10.1016/j.clp.2011.08.011
   Todeschin AS, 2009, HORM BEHAV, V56, P93, DOI 10.1016/j.yhbeh.2009.03.006
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Welch MG, 2014, AM J PHYSIOL-GASTR L, V307, pG848, DOI 10.1152/ajpgi.00176.2014
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0803-5253
EI 1651-2227
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD JUL
PY 2016
VL 105
IS 7
BP 730
EP 731
DI 10.1111/apa.13294
PG 2
WC Pediatrics
SC Pediatrics
GA DP5VC
UT WOS:000378565100009
PM 27272626
ER

PT J
AU Culbert, KM
   Racine, SE
   Klump, KL
AF Culbert, Kristen M.
   Racine, Sarah E.
   Klump, Kelly L.
TI Hormonal Factors and Disturbances in Eating Disorders
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Review
DE Eating disorders; Eating pathology; Hormones; Endocrine; Review
ID CORTISOL AWAKENING RESPONSE; BULIMIA-NERVOSA PATIENTS; PRESSOR STRESS
   TEST; BODY-MASS INDEX; ANOREXIA-NERVOSA; OVARIAN HORMONES;
   MENSTRUAL-CYCLE; PSYCHOLOGICAL STRESS; SYMPTOMATIC PATIENTS; OBESE WOMEN
AB This review summarizes the current state of the literature regarding hormonal correlates of, and etiologic influences on, eating pathology. Several hormones (e.g., ghrelin, CCK, GLP-1, PYY, leptin, oxytocin, cortisol) are disrupted during the ill state of eating disorders and likely contribute to the maintenance of core symptoms (e.g., dietary restriction, binge eating) and/or co-occurring features (e.g., mood symptoms, attentional biases). Some of these hormones (e.g., ghrelin, cortisol) may also be related to eating pathology via links with psychological stress. Despite these effects, the role of hormonal factors in the etiology of eating disorders remains unknown. The strongest evidence for etiologic effects has emerged for ovarian hormones, as changes in ovarian hormones predict changes in phenotypic and genetic influences on disordered eating. Future studies would benefit from utilizing etiologically informative designs (e.g., high risk, behavioral genetic) and continuing to explore factors (e.g., psychological, neural responsivity) that may impact hormonal influences on eating pathology.
C1 [Culbert, Kristen M.] Univ Nevada, Dept Psychol, 4505 Maryland Pkwy Mail Stop 5030, Las Vegas, NV 89154 USA.
   [Racine, Sarah E.] Ohio Univ, Dept Psychol, Athens, OH 45701 USA.
   [Klump, Kelly L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA.
RP Culbert, KM (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy Mail Stop 5030, Las Vegas, NV 89154 USA.
EM kristen.culbert@unlv.edu
CR Adami G, 2002, PHYSIOL BEHAV, V75, P189, DOI 10.1016/S0031-9384(01)00639-4
   Adamo KB, 2014, ISRN OBES, V2014, P1
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Baker Jessica H, 2012, Expert Rev Obstet Gynecol, V7, P573
   Becker JB, 2009, HORM BEHAV, V55, P646, DOI 10.1016/j.yhbeh.2009.03.014
   Bello NT, 2010, PHYSIOL BEHAV, V99, P611, DOI 10.1016/j.physbeh.2010.01.033
   Buss J, 2014, APPETITE, V76, P84, DOI 10.1016/j.appet.2014.01.011
   Culbert KM, 2014, PSYCHOL MED, V44, P2271, DOI 10.1017/S0033291713003073
   Culbert KM, 2015, BEHAV NEUROSCI, V129, P18, DOI 10.1037/bne0000034
   Culbert KM, 2013, J ABNORM PSYCHOL, V122, P420, DOI 10.1037/a0031791
   Cuntz U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054457
   Devlin MJ, 2012, PHYSIOL BEHAV, V106, P238, DOI 10.1016/j.physbeh.2012.02.009
   Dossat AM, 2015, INT J EAT DISORDER, V48, P199, DOI 10.1002/eat.22264
   Edler C, 2007, PSYCHOL MED, V37, P131, DOI 10.1017/S0033291706008956
   Elran-Barak R, 2015, EAT BEHAV, V18, P192, DOI 10.1016/j.eatbeh.2015.05.012
   FICHTER MM, 1986, PSYCHIAT RES, V17, P61, DOI 10.1016/0165-1781(86)90042-9
   FICHTER MM, 1986, PSYCHONEUROENDOCRINO, V11, P295, DOI 10.1016/0306-4530(86)90015-6
   Fries E, 2009, INT J PSYCHOPHYSIOL, V72, P67, DOI 10.1016/j.ijpsycho.2008.03.014
   Geliebter A., 2008, American Journal of Lifestyle Medicine, V2, P305, DOI 10.1177/1559827608317358
   Geliebter A, 2013, INT J OBESITY, V37, P1104, DOI 10.1038/ijo.2012.166
   Geliebter A, 2005, J NUTR, V135, P1326
   Ginty AT, 2012, PSYCHONEUROENDOCRINO, V37, P715, DOI 10.1016/j.psyneuen.2011.09.004
   Gluck ME, 2014, PSYCHOSOM MED, V76, P74, DOI 10.1097/PSY.0000000000000018
   Hannon-Engel SL, 2013, PHYSIOL BEHAV, V122, P56, DOI 10.1016/j.physbeh.2013.08.014
   Het S, 2015, J PSYCHOSOM RES, V78, P260, DOI 10.1016/j.jpsychores.2014.11.001
   Hildebrandt BA, 2015, INT J EAT DISORDER, V48, P477, DOI 10.1002/eat.22326
   Hildebrandt T, 2016, INT J EAT DISORDER, V49, P69, DOI 10.1002/eat.22456
   Hilterscheid E, 2015, EAT WEIGHT DISORD-ST, V20, P435, DOI 10.1007/s40519-015-0185-0
   Holsen LM, 2014, PSYCHIAT RES-NEUROIM, V223, P94, DOI 10.1016/j.pscychresns.2014.04.015
   KAYE WH, 1989, BIOL PSYCHIAT, V25, P768, DOI 10.1016/0006-3223(89)90248-5
   Keel PK, 2007, ARCH GEN PSYCHIAT, V64, P1058, DOI 10.1001/archpsyc.64.9.1058
   Kim YR, 2014, PSYCHONEUROENDOCRINO, V44, P133, DOI 10.1016/j.psyneuen.2014.02.019
   Klump KL, 2015, PSYCHOL MED, V45, P3227, DOI 10.1017/S0033291715001221
   Klump KL, 2010, PSYCHOL MED, V40, P1745, DOI 10.1017/S0033291709992236
   Klump KL, 2008, PSYCHOL MED, V38, P1749, DOI 10.1017/S0033291708002997
   Klump Kelly L, 2014, Clin Psychol Sci, V2, P545
   Klump KL, 2013, INT J EAT DISORDER, V46, P256, DOI 10.1002/eat.22084
   Klump KL, 2013, J ABNORM PSYCHOL, V122, P131, DOI 10.1037/a0029524
   Kojima S, 2005, CLIN ENDOCRINOL, V62, P74, DOI 10.1111/j.1365-2265.2004.02176.x
   Larsen JK, 2009, INT J BEHAV MED, V16, P311, DOI 10.1007/s12529-009-9036-6
   Lavagnino L, 2014, APPETITE, V83, P112, DOI 10.1016/j.appet.2014.08.020
   Lawson EA, 2013, EUR J ENDOCRINOL, V169, P639, DOI 10.1530/EJE-13-0433
   Lawson EA, 2013, J CLIN PSYCHIAT, V74, pE451, DOI 10.4088/JCP.12m08154
   Lawson EA, 2012, J CLIN ENDOCR METAB, V97, pE1898, DOI 10.1210/jc.2012-1702
   Lawson EA, 2011, EUR J ENDOCRINOL, V164, P253, DOI 10.1530/EJE-10-0523
   Martins C, 2010, APPETITE, V55, P208, DOI 10.1016/j.appet.2010.05.091
   Miller K, 2004, J CLIN ENDOCR METAB, V90, P1428, DOI 10.1210/jc.2004-1181
   Miller KK, 2007, J CLIN PSYCHIAT, V68, P959
   Miller R, 2014, INT J OBESITY, V38, P397, DOI 10.1038/ijo.2013.126
   Monteleone AM, 2015, INT J EAT DISORDER, V48, P615, DOI 10.1002/eat.22375
   Monteleone P, 2005, PSYCHONEUROENDOCRINO, V30, P243, DOI 10.1016/j.psyneuen.2004.07.004
   Monteleone P, 2014, PSYCHOL MED, V44, P2653, DOI 10.1017/S0033291714000270
   Monteleone P, 2003, PSYCHOL MED, V33, P1387, DOI 10.1017/S0033291703008316
   Monteleone P, 2001, PSYCHOSOM MED, V63, P62
   Monteleone P, 2008, J CLIN ENDOCR METAB, V93, P4418, DOI 10.1210/jc.2008-1138
   Monteleone P, 2012, NEUROPSYCHOBIOLOGY, V66, P230, DOI 10.1159/000341877
   Monteleone P, 2010, PSYCHONEUROENDOCRINO, V35, P284, DOI 10.1016/j.psyneuen.2009.07.001
   Myhre R, 2014, PHYSIOL BEHAV, V129, P50, DOI 10.1016/j.physbeh.2014.02.008
   Oskis A, 2012, STRESS, V15, P601, DOI 10.3109/10253890.2012.661493
   Ostlund H, 2003, ANN NY ACAD SCI, V1007, P54, DOI 10.1196/annals.1286.006
   Pike KM, 2006, PSYCHIAT RES, V142, P19, DOI 10.1016/j.psychres.2005.10.006
   Racine SE, 2013, EAT BEHAV, V14, P161, DOI 10.1016/j.eatbeh.2013.02.007
   Raspopow K, 2014, APPETITE, V74, P35, DOI 10.1016/j.appet.2013.11.018
   Raspopow K, 2010, HORM BEHAV, V58, P677, DOI 10.1016/j.yhbeh.2010.06.003
   Rigamonti AE, 2014, NEUROPSYCHOBIOLOGY, V70, P228, DOI 10.1159/000368160
   Rosenberg N, 2013, PSYCHIAT RES, V208, P156, DOI 10.1016/j.psychres.2012.09.050
   Rouach V, 2007, PSYCHONEUROENDOCRINO, V32, P693, DOI 10.1016/j.psyneuen.2007.04.010
   Sabatier N, 2013, FRONT ENDOCRINOL, V4, P1
   Sedlackova D, 2011, PHYSIOL RES, V60, P165
   Sedlackova D, 2012, NUTR METAB, V9, P1186
   Smyth JM, 2007, J CONSULT CLIN PSYCH, V75, P629, DOI 10.1037/0022-006X.75.4.629
   SUNDBLAD C, 1994, ACTA PSYCHIAT SCAND, V90, P397, DOI 10.1111/j.1600-0447.1994.tb01613.x
   van Strien T, 2013, PSYCHONEUROENDOCRINO, V38, P677, DOI 10.1016/j.psyneuen.2012.08.008
   Welch SL, 1997, PSYCHOL MED, V27, P515, DOI 10.1017/S0033291796004370
   WELTZIN TE, 1991, BIOL PSYCHIAT, V30, P37, DOI 10.1016/0006-3223(91)90068-W
   Wild B, 2014, INT J PSYCHOPHYSIOL, V94, P272, DOI 10.1016/j.ijpsycho.2014.09.010
   Zoccola P, SAGE ENCY ABNORMAL C
NR 77
TC 0
Z9 0
U1 16
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
EI 1535-1645
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD JUL
PY 2016
VL 18
IS 7
AR 65
DI 10.1007/s11920-016-0701-6
PG 16
WC Psychiatry
SC Psychiatry
GA DQ0BP
UT WOS:000378862900004
PM 27222139
ER

PT J
AU Leppanen, J
   Cardi, V
   Ng, KW
   Stein, D
   Tchanturia, K
   Treasure, J
   Paloyelis, Y
AF Leppanen, Jenni
   Cardi, Valentina
   Ng, Kah Wee
   Stein, Daniel
   Tchanturia, Kate
   Treasure, Janet
   Paloyelis, Yannis
TI Oxytocin in Eating Disorders: A New Target for Treatment?
SO EUROPEAN EATING DISORDERS REVIEW
LA English
DT Meeting Abstract
C1 [Leppanen, Jenni; Cardi, Valentina; Tchanturia, Kate; Treasure, Janet; Paloyelis, Yannis] Kings Coll London, London WC2R 2LS, England.
   [Ng, Kah Wee] Singapore Gen Hosp, Singapore, Singapore.
   [Stein, Daniel] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1072-4133
EI 1099-0968
J9 EUR EAT DISORD REV
JI Eur. Eat. Disord. Rev.
PD JUL
PY 2016
VL 24
IS 4
MA 5.3
BP E6
EP E6
PG 1
WC Psychology, Clinical
SC Psychology
GA DP8BL
UT WOS:000378722800028
ER

PT J
AU Angioni, L
   Cocco, C
   Ferri, GL
   Argiolas, A
   Melis, MR
   Sanna, F
AF Angioni, Laura
   Cocco, Cristina
   Ferri, Gian-Luca
   Argiolas, Antonio
   Melis, Maria Rosaria
   Sanna, Fabrizio
TI Involvement of nigral oxytocin in locomotor activity: A behavioral,
   immunohistochemical and lesion study in male rats
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Oxytocin; Dopamine; Glutamic acid; Substantia nigra; Oxytocin-saporin;
   Locomotor activity
ID VENTRAL TEGMENTAL AREA; SUBSTANTIA-NIGRA; PARKINSONS-DISEASE;
   PARAVENTRICULAR NUCLEUS; PARS RETICULATA; PENILE ERECTION; BASAL
   GANGLIA; HUMAN BRAIN; GLUTAMATE NEURONS; GLOBUS-PALLIDUS
AB Oxytocin is involved in the control of different behaviors, from sexual behavior and food consumption to empathy, social and affective behaviors. An imbalance of central oxytocinergic neurotransmission has been also associated with different mental pathologies, from depression, anxiety and anorexia/bulimia to schizophrenia, autism and drug dependence. This study shows that oxytocin may also play a role in the control of locomotor activity. Accordingly, intraperitoneal oxytocin (0.5-2000 mu g/kg) reduced locomotor activity of adult male rats. This effect was abolished by d(CH2)(5)Tyr(Me)(2)-Orn(8)-vasotocin, an oxytocin receptor antagonist, given into the lateral ventricles at the dose of 2 mu g/rat, which was ineffective on locomotor activity. Oxytocin (50-200 ng/site) also reduced and d(CH2)(5)Tyr(Me)(2)-Orn(8)-vasotocin (2 mu g/site) increased locomotor activity when injected bilaterally into the substantia nigra, a key area in the control of locomotor activity. Conversely, the destruction of nigral neurons bearing oxytocin receptors by the recently characterized neurotoxin oxytocin-saporin injected into the substantia nigra, increased basal locomotor activity. Since oxytocin-saporin injected into the substantia nigra caused a marked reduction of neurons immunoreactive for tyrosine hydroxylase (e.g., nigrostriatal dopaminergic neurons) and for vesicular glutamate transporters VGluT1, VGluT2 and VGluT3 (e.g., glutamatergic neurons), but not for glutamic acid decarboxylase (e.g., GABAergic neurons), together these findings suggest that oxytocin influences locomotor activity by acting on receptors localized presynaptically in nigral glutamatergic nerve terminals (which control the activity of nigral GABAergic efferent neurons projecting to brain stem nuclei controlling locomotor activity), rather than on receptors localized in the cell bodies/dendrites of nigrostriatal dopaminergic neurons. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license.
C1 [Angioni, Laura; Cocco, Cristina; Ferri, Gian-Luca] Univ Cagliari, NEF Lab, Sect Cytomorphol, Dept Biomed Sci, I-09042 Cagliari, Italy.
   [Argiolas, Antonio; Melis, Maria Rosaria; Sanna, Fabrizio] Univ Cagliari, Neuropsychobiol Lab, Sect Neurosci & Clin Pharmacol, Dept Biomed Sci, I-09042 Cagliari, Italy.
RP Sanna, F (reprint author), Cittadella Univ, Univ Cagliari, Dept Biomed Sci, Sect Neurosci & Clin Pharmacol, SS 554,Km 4-500, I-09042 Cagliari, Italy.
EM fabrizio.sanna@unica.it
FU University of Cagliari [CAR 2013-2014]; ARS (Autonomous Region of
   Sardinia) [L.R. 7/2007, CRP-26206, CRP-60834]; MIUR (Ministero
   dell'Istruzione, dell'Universita e della Ricerca Scientifica)
   [RBSI14IUX7]
FX This work was partially supported by grants from the University of
   Cagliari (CAR 2013-2014) to AA, MRM, GLF and CC, from ARS (Autonomous
   Region of Sardinia) (L.R. 7/2007, "Promotion of Scientific Research and
   technological innovation in Sardinia", European Social Fund, 2007-2013,
   Projects Code No. CRP-26206 and CRP-60834 to GLC and CC, and by a MIUR
   (Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica)
   grant (SIR 2014, Code no. RBSI14IUX7) to FS. All the authors contributed
   equally to the work.
CR ADAN RAH, 1995, ENDOCRINOLOGY, V136, P4022, DOI 10.1210/en.136.9.4022
   Antal M, 2014, J NEUROSCI, V34, P8032, DOI 10.1523/JNEUROSCI.0236-14.2014
   Argiolas A, 2004, PHYSIOL BEHAV, V83, P309, DOI 10.1016/j.physbeh.2004.08.019
   Argiolas A, 2013, PROG NEUROBIOL, V108, P80, DOI 10.1016/j.pneurobio.2013.06.006
   BANKOWSKI K, 1980, INT J PEPT PROT RES, V16, P382
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Baskin DG, 2010, ENDOCRINOLOGY, V151, P4207, DOI 10.1210/en.2010-0295
   Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006
   BUIJS RM, 1978, CELL TISSUE RES, V192, P423
   Cocco C, 2003, APPL IMMUNOHISTO M M, V11, P274
   COSTALL B, 1972, NEUROPHARMACOLOGY, V11, P317, DOI 10.1016/0028-3908(72)90017-2
   Crespi B.J., 2015, BIOL REV CAMB PHILOS
   CRINE AF, 1983, REGUL PEPTIDES, V5, P145, DOI 10.1016/0167-0115(83)90122-2
   DOGTEROM J, 1978, NEUROSCI LETT, V9, P341, DOI 10.1016/0304-3940(78)90206-9
   Erbas O, 2013, GEN PHYSIOL BIOPHYS, V32, P517, DOI 10.4149/gpb_2013055
   Erbas O, 2012, PEPTIDES, V38, P312, DOI 10.1016/j.peptides.2012.05.026
   Feeser M., 2012, PSYCHONEUROENDOCRINO, V53, P223
   Fremeau RT, 2004, TRENDS NEUROSCI, V27, P98, DOI 10.1016/j.tins.2003.11.005
   Gil M, 2013, PSYCHONEUROENDOCRINO, V38, P1688, DOI 10.1016/j.psyneuen.2013.02.002
   Grieb B., 2013, FRONT SYST NEUROSCI, V27, P7
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   von Bohlen Und Halbach O., 2004, CELL TISSUE RES, V318, P3, DOI DOI 10.1007/S00441-004-0963-X
   Hauber W, 1998, PROG NEUROBIOL, V56, P507, DOI 10.1016/S0301-0082(98)00041-0
   Hodaie M, 2007, NEUROSURGERY, V60, P17, DOI 10.1227/01.NEU.0000249209.11967.CB
   Kaneda K, 2005, EUR J NEUROSCI, V22, P3241, DOI 10.1111/j.1460-9568.2005.04488.x
   Klenerova V, 2009, NEUROENDOCRINOL LETT, V30, P335
   Lee CR, 2013, J NEUROSCI, V33, P1157, DOI 10.1523/JNEUROSCI.2832-12.2013
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   LOUP F, 1989, BRAIN RES, V500, P223, DOI 10.1016/0006-8993(89)90317-X
   Love TM, 2014, PHARMACOL BIOCHEM BE, V119, P49, DOI 10.1016/j.pbb.2013.06.011
   Maejima Y, 2015, NEUROENDOCRINOLOGY, V101, P35, DOI 10.1159/000371636
   Maguire S, 2013, EUR EAT DISORD REV, V21, P475, DOI 10.1002/erv.2252
   Mai J K, 1993, J Hirnforsch, V34, P133
   MARSHALL JF, 1977, SCIENCE, V198, P62, DOI 10.1126/science.897683
   Martin-Ibanez R, 2006, EUR J NEUROSCI, V23, P1063, DOI 10.1111/j.1460-9568.2006.04601.x
   Melis M R, 1984, Brain Res, V295, P387
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Melis MR, 2011, NEUROSCI BIOBEHAV R, V35, P939, DOI 10.1016/j.neubiorev.2010.10.014
   MELIS MR, 1984, N-S ARCH PHARMACOL, V326, P83, DOI 10.1007/BF00518784
   MELIS MR, 1983, J PHARMACOL EXP THER, V226, P425
   Morales M, 2014, NEUROSCIENCE, V282, P60, DOI 10.1016/j.neuroscience.2014.05.032
   Parker JA, 2012, NEUROPHARMACOLOGY, V63, P18, DOI 10.1016/j.neuropharm.2012.02.004
   Paxinos G, 2007, RAT BRAIN STEREOTAXI
   PURBA JS, 1994, NEUROLOGY, V44, P84
   Radnikow G, 1998, J NEUROSCI, V18, P2009
   Sanna F, 2012, HORM BEHAV, V62, P505, DOI 10.1016/j.yhbeh.2012.08.010
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   SOFRONIEW MV, 1983, PROG BRAIN RES, V60, P101
   SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475
   Stefanik P, 2015, PHARMACOL BIOCHEM BE, V131, P42, DOI 10.1016/j.pbb.2015.01.021
   Succu S, 2008, EUR J NEUROSCI, V28, P813, DOI 10.1111/j.1460-9568.2008.06385.x
   Takakusaki K, 2003, NEUROSCIENCE, V119, P293, DOI 10.1016/S0306-4522(03)00095-2
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   UVNASMOBERG K, 1992, ACTA PHYSIOL SCAND, V145, P429, DOI 10.1111/j.1748-1716.1992.tb09385.x
   Vaccari C, 1998, ENDOCRINOLOGY, V139, P5015, DOI 10.1210/en.139.12.5015
   Windels F, 2006, NEUROSCIENCE, V140, P1289, DOI 10.1016/j.neuroscience.2006.03.064
   Yague JG, 2013, EXP NEUROL, V247, P1, DOI 10.1016/j.expneurol.2013.03.023
   Yamaguchi T, 2013, EUR J NEUROSCI, V38, P3602, DOI 10.1111/ejn.12359
   ZIMMERMAN EA, 1984, FED PROC, V43, P91
NR 61
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD JUL
PY 2016
VL 83
BP 23
EP 38
DI 10.1016/j.yhbeh.2016.05.012
PG 16
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DQ1SU
UT WOS:000378981500004
PM 27189764
ER

PT J
AU Spencer, TE
   Forde, N
   Lonergan, P
AF Spencer, Thomas E.
   Forde, Niamh
   Lonergan, Patrick
TI The role of progesterone and conceptus-derived factors in uterine
   biology during early pregnancy in ruminants
SO JOURNAL OF DAIRY SCIENCE
LA English
DT Article
DE progesterone; interferon; prostaglandin; uterus; pregnancy
ID CROSS-REACTIVE PROTEIN; IN-VITRO CULTURE; INTERFERON-TAU; OVINE UTERUS;
   BOVINE ENDOMETRIUM; ESTROUS-CYCLE; GENE-EXPRESSION; PREIMPLANTATION
   CONCEPTUS; EMBRYO DEVELOPMENT; ARACHIDONIC-ACID
AB This review integrates established and new information on the role of progesterone, interferon tau (IFNT), and prostaglandins in uterine biology of ruminants. Establishment of pregnancy in ruminants encompasses growth of the posthatching blastocyst, elongation of the conceptus (embryo and extraembryonic membranes), and suppression of the endometrial luteolytic mechanism to maintain progesterone production by the ovary. Conceptus elongation involves exponential increases in length of the trophectoderm for pregnancy recognition signaling, implantation, and establishment of pregnancy. Pregnancy recognition signaling is accomplished by IFNT from the trophectoderm that has a paracrine antiluteolytic effect to inhibit upregulation of oxytocin receptors in the endometrial epithelia, thereby inhibiting production of luteobrqic PGF(2 alpha), pulses by the uterus. Survival and growth of the preimplantation blastocyst and elongating conceptus clearly requires embryotrophic factors (AA, carbohydrates, proteins, lipids, and other substances) in the uterine lumen. Individual, interactive, and coordinated actions of progesterone, IFNT, and prostaglandins regulate expression of elongation-and implantation-related genes in the endometrial epithelia that, in turn alter the uterine luminal histotroph and govern conceptus survival and growth. An increased knowledge of progesterone biology and conceptus-endometrial interactions is necessary to understand and elucidate the causes of pregnancy loss and provide a basis for new strategies to improve pregnancy outcome and reproductive efficiency in ruminants.
C1 [Spencer, Thomas E.] Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA.
   [Forde, Niamh] Univ Leeds, Leeds Inst Cardiovasc & Mol Med, Div Reprod & Early Dev, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.
   [Lonergan, Patrick] Sch Agr & Food Sci, Dublin 4, Ireland.
RP Spencer, TE (reprint author), Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA.
EM spencerte@missouri.edu
FU AFRI from the USDA National Institute of Food and Agriculture
   (Washington, DC) [2009-01722, 2012-67015-30173]; Science Foundation
   Ireland (Dublin, Ireland) [07/SRC/B1156, 10/IN.1/B3011, 13/IA/1983]
FX Support for the work of the authors described in this review paper was
   provided, in part, by AFRI competitive grants 2009-01722 and
   2012-67015-30173 from the USDA National Institute of Food and
   Agriculture (Washington, DC) and grants from Science Foundation Ireland
   (Dublin, Ireland; 07/SRC/B1156, 10/IN.1/B3011 and 13/IA/1983).
CR Alexopoulos NI, 2005, REPROD FERT DEVELOP, V17, P799, DOI 10.1071/RD04104
   Antoniazzi AQ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.105684
   Arosh JA, 2004, ENDOCRINOLOGY, V145, P5280, DOI 10.1210/en.2004-0587
   Austin KJ, 2004, ENDOCRINOLOGY, V145, P967, DOI 10.1210/en.2003-1087
   Bauersachs S, 2006, REPRODUCTION, V132, P319, DOI 10.1530/rep.1.00996
   Bauersachs S, 2015, ANNU REV ANIM BIOSCI, V3, P489, DOI 10.1146/annurev-animal-022114-110639
   Bauersachs S, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.094771
   Bazer F W, 1991, J Reprod Fertil Suppl, V43, P39
   Bazer FW, 2012, MOL CELL ENDOCRINOL, V354, P22, DOI 10.1016/j.mce.2011.08.026
   Bazer FW, 2010, MOL HUM REPROD, V16, P135, DOI 10.1093/molehr/gap095
   Bazer FW, 2009, SEMIN REPROD MED, V27, P90, DOI 10.1055/s-0028-1108013
   BAZER FW, 1975, J ANIM SCI, V41, P1376
   Beltman ME, 2009, THERIOGENOLOGY, V72, P986, DOI 10.1016/j.theriogenology.2009.06.018
   Beltman ME, 2009, THERIOGENOLOGY, V71, P1173, DOI 10.1016/j.theriogenology.2008.12.014
   Berg DK, 2010, THERIOGENOLOGY, V73, P250, DOI 10.1016/j.theriogenology.2009.09.005
   BETTERIDGE KJ, 1980, J REPROD FERTIL, V59, P205
   BETTERIDGE KJ, 1988, THERIOGENOLOGY, V29, P155, DOI 10.1016/0093-691X(88)90038-6
   Bisinotto RS, 2015, J DAIRY SCI, V98, P2472, DOI 10.3168/jds.2014-8954
   Brandao DO, 2004, BIOL REPROD, V71, P2048, DOI 10.1095/biolreprod.103.025916
   Brooks K, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.130757
   Brooks K, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.124156
   Brooks K, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-53
   Brooks KE, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.123877
   Burns G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090913
   Cammas L, 2006, REPRODUCTION, V131, P917, DOI 10.1530/rep.1.00799
   Carter F, 2008, REPROD FERT DEVELOP, V20, P368, DOI 10.1071/RD07204
   Cerri RLA, 2012, J DAIRY SCI, V95, P5657, DOI 10.3168/jds.2011-5114
   Charpigny G, 1997, ENDOCRINOLOGY, V138, P2163, DOI 10.1210/en.138.5.2163
   Charpigny G, 1997, BIOL REPROD, V57, P1032, DOI 10.1095/biolreprod57.5.1032
   Choi Y, 2003, BIOL REPROD, V68, P1703, DOI 10.1095/biolreprod.102.012708
   Choi YS, 2001, BIOL REPROD, V65, P1038, DOI 10.1095/biolreprod65.4.1038
   Clemente M, 2009, REPRODUCTION, V138, P507, DOI 10.1530/REP-09-0152
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Diskin MG, 2008, REPROD DOMEST ANIM, V43, P260, DOI 10.1111/j.1439-0531.2008.01171.x
   Dorniak P, 2013, J ANIM SCI, V91, P1627, DOI 10.2527/jas.2012-5845
   Dorniak P, 2013, ENDOCRINOLOGY, V154, P931, DOI 10.1210/en.2012-1909
   Dorniak P, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100487
   Dorniak P, 2011, BIOL REPROD, V84, P1119, DOI 10.1095/biolreprod.110.089979
   El-Sayed A, 2006, PHYSIOL GENOMICS, V28, P84, DOI 10.1152/physiolgenomics.00111.2006
   ELLINWOOD WE, 1979, BIOL REPROD, V21, P845, DOI 10.1095/biolreprod21.4.845
   Emond V, 2004, BIOL REPROD, V70, P54, DOI 10.1095/biolreprod.103.018689
   Erdem H, 2010, REPROD DOMEST ANIM, V45, P625, DOI 10.1111/j.1439-0531.2008.01317.x
   FLECHON JE, 1986, REPROD NUTR DEV, V26, P1017, DOI 10.1051/rnd:19860609
   Forde N, 2012, PHYSIOL GENOMICS, V44, P799, DOI 10.1152/physiolgenomics.00067.2012
   Forde N, 2011, BIOL REPROD, V85, P144, DOI 10.1095/biolreprod.110.090019
   Forde N, 2011, BIOL REPROD, V84, P266, DOI 10.1095/biolreprod.110.085910
   Forde N, 2010, PHYSIOL GENOMICS, V41, P53, DOI 10.1152/physiolgenomics.00162.2009
   Forde N, 2009, BIOL REPROD, V81, P784, DOI 10.1095/biolreprod.108.074336
   Forde N, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.115.129296
   Forde N, 2014, REPRODUCTION, V147, P575, DOI 10.1530/REP-13-0010
   Forde N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-321
   Forde N, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103424
   Forde N, 2012, J REPROD DEVELOP, V58, P189, DOI 10.1262/jrd.2011-021
   Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289
   Gray CA, 2001, BIOL REPROD, V64, P1608, DOI 10.1095/biolreprod64.6.1608
   Gray CA, 2001, BIOL REPROD, V65, P1311, DOI 10.1095/biolreprod65.5.1311
   Guillomot M, 1995, J Reprod Fertil Suppl, V49, P39
   Hansen TR, 2010, SOC REPROD FERTIL, V67, P325
   Hansen TR, 1999, J REPROD FERTIL, P329
   Hue I, 2012, ANIM REPROD SCI, V134, P19, DOI 10.1016/j.anireprosci.2012.08.007
   Johnson GA, 1999, BIOL REPROD, V61, P312, DOI 10.1095/biolreprod61.1.312
   Johnson GA, 1999, ENDOCRINE, V10, P243, DOI 10.1007/BF02738623
   Johnson GA, 2001, BIOL REPROD, V64, P1392, DOI 10.1095/biolreprod64.5.1392
   Johnson GA, 2000, BIOL REPROD, V62, P622, DOI 10.1095/biolreprod62.3.622
   Kim S, 2003, ENDOCRINOLOGY, V144, P5203, DOI 10.1210/en.2003-0665
   Larson JE, 2011, REPROD FERT DEVELOP, V23, P311, DOI 10.1071/RD10106
   Lewis G S, 1989, J Reprod Fertil Suppl, V37, P261
   LEWIS GS, 1982, BIOL REPROD, V27, P431, DOI 10.1095/biolreprod27.2.431
   LEWIS GS, 1985, PROSTAGLANDINS, V30, P263, DOI 10.1016/0090-6980(85)90190-X
   LEWIS GS, 1983, PROSTAGLANDINS, V25, P881, DOI 10.1016/0090-6980(83)90011-4
   Lewis SK, 2007, BIOL REPROD, V77, P1027, DOI 10.1095/biolreprod.107.063594
   Lonergan P, 2007, REPROD FERT DEVELOP, V19, P861, DOI 10.1071/RD07089
   Lonergan P, 2014, ANIMAL, V8, P64, DOI 10.1017/S1751731114000470
   Lonergan P, 2011, THERIOGENOLOGY, V76, P1594, DOI 10.1016/j.theriogenology.2011.06.012
   Mamo S, 2012, ANIM REPROD SCI, V134, P56, DOI 10.1016/j.anireprosci.2012.08.011
   Mann GE, 2006, VET J, V171, P500, DOI 10.1016/j.tvjl.2004.12.005
   Mansouri-Attia N, 2009, PHYSIOL GENOMICS, V39, P14, DOI 10.1152/physiolgenomics.90404.2008
   MARCUS GJ, 1981, BIOL REPROD, V25, P56, DOI 10.1095/biolreprod25.1.56
   Meier S, 2011, J DAIRY RES, V78, P263, DOI 10.1017/S0022029911000173
   Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/M300470200
   Nagaoka K, 2003, BIOL REPROD, V68, P1413, DOI 10.1095/biolreprod.102.008912
   NEPHEW KP, 1991, BIOL REPROD, V44, P536, DOI 10.1095/biolreprod44.3.536
   O'Hara L, 2012, REPRODUCTION, V143, P673, DOI 10.1530/REP-11-0505
   O'Hara L, 2014, THERIOGENOLOGY, V81, P1123, DOI 10.1016/j.theriogenology.2014.01.041
   Okumu LA, 2010, REPRODUCTION, V140, P143, DOI 10.1530/REP-10-0113
   Ott TL, 2010, AM J REPROD IMMUNOL, V64, P245, DOI 10.1111/j.1600-0897.2010.00912.x
   Parr MH, 2014, ANIM REPROD SCI, V150, P7, DOI 10.1016/j.anireprosci.2014.08.008
   Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700042200
   Pursley J Richard, 2011, Reprod Fertil Dev, V24, P267, DOI 10.1071/RD11917
   Rivera FA, 2011, REPRODUCTION, V141, P333, DOI 10.1530/REP-10-0375
   Roberts RM, 2003, REPRODUCTION, P239
   Salilew-Wondim D, 2010, PHYSIOL GENOMICS, V42, P201, DOI 10.1152/physiolgenomics.00047.2010
   Satterfield MC, 2006, BIOL REPROD, V75, P289, DOI 10.1095/biolreprod.106.052944
   Simmons RM, 2010, BIOL REPROD, V82, P35, DOI 10.1095/biolreprod.109.079608
   Simmons RM, 2009, ENDOCRINOLOGY, V150, P4295, DOI 10.1210/en.2009-0060
   Song G, 2007, REPRODUCTION, V133, P285, DOI 10.1530/REP-06-0092
   Spencer T E, 2007, Soc Reprod Fertil Suppl, V64, P379
   Spencer TE, 2006, METH MOLEC MED, V121, P85
   Spencer TE, 2002, FRONT BIOSCI, V7, pD1879, DOI 10.2741/spencer
   Spencer TE, 2008, REPRODUCTION, V135, P165, DOI [10.1530/REP-07-0327, 10.1530/RFP-07-0327]
   Spencer TE, 2007, REPROD FERT DEVELOP, V19, P65, DOI 10.1071/RD06102
   Spencer TE, 2013, REPRODUCTION, V146, P377, DOI 10.1530/REP-13-0165
   Spencer Thomas E, 2004, Reprod Biol Endocrinol, V2, P49, DOI 10.1186/1477-7827-2-49
   Tan WF, 2013, P NATL ACAD SCI USA, V110, P16526, DOI 10.1073/pnas.1310478110
   Thatcher W. W., 1989, Journal of Reproduction and Fertility, P91
   Thatcher W, 2011, THERIOGENOLOGY, V76, P1619, DOI 10.1016/j.theriogenology.2011.06.005
   Ulbrich SE, 2009, REPRODUCTION, V138, P371, DOI 10.1530/REP-09-0081
   Ulbrich SE, 2013, METHODS, V59, P108, DOI 10.1016/j.ymeth.2012.10.013
   WALES RG, 1989, REPROD FERT DEVELOP, V1, P31, DOI 10.1071/RD9890031
   Wang JH, 2009, CR BIOL, V332, P986, DOI 10.1016/j.crvi.2009.09.004
   Wang XQ, 2014, FASEB J, V28, P2852, DOI 10.1096/fj.13-248757
   Wiltbank MC, 2014, ANIMAL, V8, P70, DOI 10.1017/S1751731114000585
   Wiltbank Milo C, 2011, Reprod Fertil Dev, V24, P238, DOI 10.1071/RD11913
NR 113
TC 2
Z9 2
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-0302
EI 1525-3198
J9 J DAIRY SCI
JI J. Dairy Sci.
PD JUL
PY 2016
VL 99
IS 7
BP 5941
EP 5950
DI 10.3168/jds.2015-10070
PG 10
WC Agriculture, Dairy & Animal Science; Food Science & Technology
SC Agriculture; Food Science & Technology
GA DO7XA
UT WOS:000377995100089
PM 26387021
ER

PT J
AU Woolley, JD
   Arcuni, PA
   Stauffer, CS
   Fulford, D
   Carson, DS
   Batki, S
   Vinogradov, S
AF Woolley, Josh D.
   Arcuni, Peter A.
   Stauffer, Christopher S.
   Fulford, Daniel
   Carson, Dean S.
   Batki, Steve
   Vinogradov, Sophia
TI The effects of intranasal oxytocin in opioid-dependent individuals and
   healthy control subjects: a pilot study
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Oxytocin; Heroin; Opioid; Addiction; Tolerability; Craving; Implicit;
   Social; RMET; Clinical
ID SOCIAL COGNITION; NEURAL SYSTEMS; WITHDRAWAL; TOLERANCE; ADDICTION;
   HUMANS; ALCOHOLICS; METHADONE; IMPLICIT; RELAPSE
AB Rationale There has been an explosion of research on the potential benefits of the social neuropeptide oxytocin for a number of mental disorders including substance use disorders. Recent evidence suggests that intranasal oxytocin has both direct anti-addiction effects and pro-social effects that may facilitate engagement in psychosocial treatment for substance use disorders.
   Objectives We aimed to assess the tolerability of intranasal oxytocin and its effects on heroin craving, implicit association with heroin and social perceptual ability in opioid-dependent patients receiving opioid replacement therapy (ORT) and healthy control participants.
   Methods We performed a randomized, double-blind, placebo-controlled, within-and between-subjects, crossover, proof-of-concept trial to examine the effects of oxytocin (40 international units) on a cue-induced craving task (ORT patients only), an Implicit Association Task (IAT), and two social perception tasks: the Reading the Mind in the Eyes Task (RMET) and The Awareness of Social Inference Test (TASIT).
   Results Oxytocin was well tolerated by patients receiving ORT but had no significant effects on craving or IAT scores. There was a significant reduction in RMET performance after oxytocin administration versus placebo in the patient group only, and a significant reduction in TASIT performance after oxytocin in both the patient and healthy control groups.
   Conclusions A single dose of intranasal oxytocin is well tolerated by patients receiving ORT, paving the way for future investigations. Despite no significant improvement in craving or IAT scores after a single dose of oxytocin and some evidence that social perception was worsened, further investigation is required to determine the role oxytocin may play in the treatment of opioid use disorder.
C1 [Woolley, Josh D.; Stauffer, Christopher S.; Batki, Steve; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.
   [Woolley, Josh D.; Arcuni, Peter A.; Stauffer, Christopher S.; Batki, Steve; Vinogradov, Sophia] San Francisco VA Med Ctr, Dept Mental Hlth, 4150 Clement St 116C-1, San Francisco, CA 94121 USA.
   [Fulford, Daniel] Boston Univ, Sargent Coll Hlth & Rehabil Sci, 635 Commonwealth Ave,SAR 512, Boston, MA 02215 USA.
   [Carson, Dean S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
RP Woolley, JD (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.; Woolley, JD (reprint author), San Francisco VA Med Ctr, Dept Mental Hlth, 4150 Clement St 116C-1, San Francisco, CA 94121 USA.
EM Josh.Woolley@ucsf.edu
FU San Francisco Treatment Research Center at the University of California,
   San Francisco from the National Institute on Drug Abuse [P50 DA009253]
FX This project was supported by the San Francisco Treatment Research
   Center at the University of California, San Francisco, via grant number
   P50 DA009253 from the National Institute on Drug Abuse.
CR BABOR TF, 1976, ARCH GEN PSYCHIAT, V33, P363
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   BOND A, 1974, BRIT J MED PSYCHOL, V47, P211
   Bonson KR, 2002, NEUROPSYCHOPHARMACOL, V26, P376, DOI 10.1016/S0893-133X(01)00371-2
   Bora E, 2009, ACTA PSYCHIAT SCAND, V120, P253, DOI 10.1111/j.1600-0447.2009.01414.x
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   De Vries TJ, 2002, J NEUROSCI, V22, P3321
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Gordon I, 2011, DEV COGN NEUROS-NETH, V1, P471, DOI 10.1016/j.dcn.2011.07.007
   GOSSOP M, 1989, BRIT J PSYCHIAT, V154, P348, DOI 10.1192/bjp.154.3.348
   Gossop M, 2002, ADDICTION, V97, P1259, DOI 10.1046/j.1360-0443.2002.00227.x
   Greenwald AG, 2009, J PERS SOC PSYCHOL, V97, P17, DOI 10.1037/a0015575
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   HAERTZEN CA, 1969, J NERV MENT DIS, V148, P606, DOI 10.1097/00005053-196906000-00004
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   INTURRISI CE, 1972, CLIN PHARMACOL THER, V13, P923
   JENNINGS JR, 1992, PSYCHOPHYSIOLOGY, V29, P742
   Kelly JF, 2009, ADDICT RES THEORY, V17, P236, DOI 10.1080/16066350902770458
   Knight DK, 1996, J SUBST ABUSE, V8, P417, DOI 10.1016/S0899-3289(96)90003-6
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kornreich C, 2003, PSYCHIAT RES, V119, P251, DOI 10.1016/S0165-1781(03)00130-6
   KOVACS GL, 1985, BRAIN RES, V328, P158, DOI 10.1016/0006-8993(85)91336-8
   KOVACS GL, 1985, NEUROPHARMACOLOGY, V24, P413, DOI 10.1016/0028-3908(85)90026-7
   KOVACS GL, 1985, LIFE SCI, V37, P17, DOI 10.1016/0024-3205(85)90620-4
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   KRIVAN M, 1992, PHARMACOL BIOCHEM BE, V43, P187, DOI 10.1016/0091-3057(92)90656-Z
   Lane K. A., 2007, IMPLICIT MEASURES AT, P59
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   Lindgren KP, 2014, J STUD ALCOHOL DRUGS, V75, P290
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Marhe R, 2013, J CONSULT CLIN PSYCH, V81, P1, DOI 10.1037/a0030754
   McGregor IS, 2008, BRIT J PHARMACOL, V154, P358, DOI 10.1038/bjp.2008.132
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modabbernia A, 2013, CNS DRUGS, V27, P57, DOI 10.1007/s40263-012-0022-1
   MONTI PM, 1987, J ABNORM PSYCHOL, V96, P122, DOI 10.1037/0021-843X.96.2.122
   Mueller SE, 2009, INT J ENV RES PUB HE, V6, P3010, DOI 10.3390/ijerph6123010
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   NIDA 2012. Mental Health Services Administration, 2012, NSDUH SER H, VH- 44
   NIDA, 2012, HHS PUBL, V12- 4713
   Norman GJ, 2011, J PSYCHOPHARMACOL, V25, P1313, DOI 10.1177/0269881110367452
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   Radke S, 2015, PSYCHONEUROENDOCRINO, V60, P75, DOI 10.1016/j.psyneuen.2015.06.006
   Raisch DW, 2002, ANN PHARMACOTHER, V36, P312
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   Schulteis G, 2000, NATURE, V405, P1013
   Shany-Ur T, 2012, CORTEX, V48, P1329, DOI 10.1016/j.cortex.2011.08.003
   Shi J, 2008, EUR J PHARMACOL, V579, P160, DOI 10.1016/j.ejphar.2007.09.042
   Stein Dan J, 2007, CNS Spectr, V12, P669
   Stoller KB, 2001, PSYCHOPHARMACOLOGY, V154, P230, DOI 10.1007/s002130000637
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Veilleux JC, 2010, CLIN PSYCHOL REV, V30, P155, DOI 10.1016/j.cpr.2009.10.006
   Woolley JD, 2014, PSYCHONEUROENDOCRINO, V47, P116, DOI 10.1016/j.psyneuen.2014.04.024
   OKAZAKI S, 1999, BLACK TAR HEROIN DAR
NR 62
TC 0
Z9 0
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUL
PY 2016
VL 233
IS 13
BP 2571
EP 2580
DI 10.1007/s00213-016-4308-8
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DP5ZE
UT WOS:000378575900015
PM 27137199
ER

PT J
AU Althaus, M
   Groen, Y
   Wijers, AA
   Noltes, H
   Tucha, O
   Sweep, FC
   Calcagnoli, F
   Hoekstra, PJ
AF Althaus, Monika
   Groen, Yvonne
   Wijers, Albertus A.
   Noltes, Henriette
   Tucha, Oliver
   Sweep, Fred C.
   Calcagnoli, Federica
   Hoekstra, Pieter J.
TI Do blood plasma levels of oxytocin moderate the effect of nasally
   administered oxytocin on social orienting in high-functioning male
   adults with autism spectrum disorder?
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Baseline plasma oxytocin; Post-oxytocin treatment plasma oxytocin;
   Social orienting; Autism spectrum disorder; Electrocortical and cardiac
   evoked responses
ID CEREBROSPINAL-FLUID OXYTOCIN; SEX-DIFFERENCES; INTRANASAL OXYTOCIN;
   ASPERGER-SYNDROME; MALE RATS; PREGNANCY; EMPATHY; HUMANS; BRAIN;
   RESPONSES
AB The study investigated whether baseline plasma oxytocin (OXT) concentrations might moderate the effects of nasally administered OXT on social orienting.
   Thirty-one males with Autism spectrum disorder (ASD) and thirty healthy males participated in a double-blind placebo-controlled crossover trial. After administration of the compound, participants were viewing pictures from the International Affective Picture System that represented a systematic variation of pleasant, unpleasant and neutral scenes with and without humans. The outcome measures were a cardiac evoked response (ECR) and a cortical evoked long latency parietal positivity (LPP).
   Males with ASD had significantly higher plasma baseline levels than the controls. In the absence of general treatment effects, higher baseline concentrations were found to be associated with larger treatment effects, particularly in the group of males with ASD. Higher post-treatment plasma OXT concentrations were found to be associated with smaller treatment effects and larger orienting responses in the placebo situation in the group of controls.
   We interpret our findings as suggesting that it is the central availability of OXT determining how much of the nasally administered OXT will become centrally absorbed and how much of it will become released into the bloodstream.
C1 [Althaus, Monika; Hoekstra, Pieter J.] Univ Groningen, Univ Med Ctr Groningen, Dept Child & Adolescent Psychiat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   [Groen, Yvonne; Tucha, Oliver] Univ Groningen, Dept Clin & Dev Neuropsychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
   [Wijers, Albertus A.] Univ Groningen, Dept Expt & Work Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
   [Noltes, Henriette] Lentis, Autism Team North Netherlands ATN, Laan Corpus den Hoorn 102-2, NL-9728 JR Groningen, Netherlands.
   [Sweep, Fred C.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Geert Grootepl 8, NL-6525 GA Nijmegen, Netherlands.
   [Calcagnoli, Federica] Univ Groningen, Dept Behav Physiol, Nijenborg 7, NL-9747 AG Groningen, Netherlands.
RP Althaus, M (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Child & Adolescent Psychiat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM m.althaus@accare.nl
FU Accare foundation
FX We give our special thanks to the Accare foundation for the financial
   support of this investigation. We are further grateful for the kind
   support by the Autism Team of the North of the Netherlands and the Jonx
   Team of Lentis, Groningen, in recruiting our participants.
CR Altemus M, 2004, BIOL PSYCHIAT, V56, P386, DOI 10.1016/j.biopsych.2004.06.002
   Althaus M, 2015, NEUROPSYCHOLOGIA
   Althaus M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108224
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   American Psychiatric Association, 2004, DIAGN STAT MAN MENT
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Arrindell W. A., 1986, SCL 90 HANDLEIDING B
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319
   Cochran DM, 2013, HARVARD REV PSYCHIAT, V21, P219, DOI 10.1097/HRP.0b013e3182a75b7d
   Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Fries ABW, 2005, P NATL ACAD SCI USA, V102, P17237, DOI 10.1073/pnas.0504767102
   Gray J. A., 2000, NEUROPSYCHOLOGY ANXI
   Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8
   Groen Y, 2013, NEUROPSYCHOLOGIA, V51, P142, DOI 10.1016/j.neuropsychologia.2012.11.012
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella A. J., 2012, HORM BEHAV, V61, P410, DOI DOI 10.1016/J.YHBEH.2012.01.002
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Hoge EA, 2008, CNS NEUROSCI THER, V14, P165, DOI 10.1111/j.1755-5949.2008.00051.x
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Jansen LMC, 2006, J AUTISM DEV DISORD, V36, P891, DOI 10.1007/s10803-006-0124-z
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Lang PJ, 2008, INT AFFECTIVE PICTUR, pA
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   Luteijn F, 2005, HERZIENING GIT HANDL
   Marazziti Donatella, 2006, Clin Pract Epidemiol Ment Health, V2, P28, DOI 10.1186/1745-0179-2-28
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Onaka T, 2004, J NEUROENDOCRINOL, V16, P308, DOI 10.1111/j.0953-8194.2004.01186.x
   Proverbio AM, 2009, NEUROPSYCHOLOGIA, V47, P2374, DOI 10.1016/j.neuropsychologia.2008.10.030
   Rubin Leah H, 2010, Schizophr Res, V124, P13, DOI 10.1016/j.schres.2010.09.014
   Shamay-Tsoory Simone G, 2011, Neuroscientist, V17, P18, DOI 10.1177/1073858410379268
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Spielberger CD, 1973, MANUAL STATE TRAIT A
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   TAKAGI T, 1985, HORM METAB RES, V17, P308, DOI 10.1055/s-2007-1013526
   Winslow JT, 2003, NEUROPSYCHOPHARMACOL, V28, P910, DOI 10.1038/sj.npp.1300128
   Yuen KW, 2014, J PSYCHIATR RES, V51, P30, DOI 10.1016/j.jpsychires.2013.12.012
NR 52
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUL
PY 2016
VL 233
IS 14
BP 2737
EP 2751
DI 10.1007/s00213-016-4339-1
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DQ0FR
UT WOS:000378874600010
PM 27256356
ER

PT J
AU Woodside, B
AF Woodside, Barbara
TI Mood, Food, and Fertility: Adaptations of the Maternal Brain
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; PITUITARY-ADRENAL AXIS; MESSENGER-RNA
   EXPRESSION; BREAST-FEEDING WOMEN; PULSATILE LUTEINIZING-HORMONE;
   OVARIECTOMIZED LACTATING RATS; FOLLICLE-STIMULATING-HORMONE; INDUCED
   PROLACTIN-RELEASE; NEUROPEPTIDE-Y NPY; TUBEROINFUNDIBULAR DOPAMINERGIC
   SYSTEM
AB Successfully rearing young places multiple demands on the mammalian female. These are met by a wide array of alterations in maternal physiology and behavior that are coordinated with the needs of the developing young, and include adaptations in neuroendocrine systems not directly involved in maternal behavior or lactation. In this article, attenuations in the behavioral and neuroendocrine responses to stressors, the alterations in metabolic pathways facilitating both increased food intake and conservation of energy, and the changes in fertility that occur postpartum are described. The mechanisms underlying these processes as well as the factors that contribute to them and the relative contributions of these stimuli at different times postpartum are also reviewed. The induction and maintenance of the adaptations observed in the postpartum maternal brain are dependent on mother-young interaction and, in most cases, on suckling stimulation and its consequences for the hormonal profile of the mother. The peptide hormone prolactin acting on receptors within the brain makes a major contribution to changes in metabolic pathways, suppression of fertility and the attenuation of the neuroendocrine response to stress during lactation. Oxytocin is also released, both into the circulation and in some hypothalamic nuclei, in response to suckling stimulation and this hormone has been implicated in the decrease in anxiety behavior seen in the early postpartum period. The relative importance of these hormones changes across lactation and it is becoming increasingly clear that many of the adaptations to motherhood reviewed here reflect the outcome of multiple influences. (C) 2016 American Physiological Society.
C1 [Woodside, Barbara] Concordia Univ, Dept Psychol, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.
RP Woodside, B (reprint author), Concordia Univ, Dept Psychol, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.
EM barbara.woodside@concordia.ca
FU Natural Sciences and Engineering Research Council, Canada [7938];
   Canadian Institutes for Health Research; Fonds de la Recherche en Sante
   du Quebec
FX B. W. received funding from the Natural Sciences and Engineering
   Research Council, Canada (Grant # 7938), the Canadian Institutes for
   Health Research and from the Fonds de la Recherche en Sante du Quebec
   through an infrastructure grant to the Center for Studies in Behavioral
   Neurobiology/Groupe de recherche en neurobiologie comportementale.
CR ABELENDA M, 1987, PFLUG ARCH EUR J PHY, V409, P314
   Abizaid A, 2008, NEUROSCI LETT, V440, P206, DOI 10.1016/j.neulet.2008.05.105
   Abizaid A, 2004, BRAIN RES, V1001, P72, DOI 10.1016/j.brainres.2003.10.069
   Abizaid A, 2004, AM J PHYSIOL-REG I, V286, pR217, DOI 10.1152/ajpregu.00128.2003
   Abizaid A, 2003, J NEUROENDOCRINOL, V15, P1037, DOI 10.1046/j.1365-2826.2003.01091.x
   Abizaid A, 2002, PHYSIOL BEHAV, V75, P483, DOI 10.1016/S0031-9384(02)00658-3
   Abizaid A, 1997, BRAIN RES, V761, P306, DOI 10.1016/S0006-8993(97)00351-X
   Abizaid A, PHYSL BEHAV, V74, P77
   Abizaid A, 2008, REGUL PEPTIDES, V149, P3, DOI 10.1016/j.regpep.2007.10.006
   Abizaid A, 2006, J CLIN INVEST, V116, P3229, DOI 10.1172/JCI29867
   Abizaid A, 2006, NEURON, V51, P691, DOI 10.1016/j.neuron.2006.08.025
   Abizaid A, 2009, J NEUROENDOCRINOL, V21, P787, DOI 10.1111/j.1365-2826.2009.01896.x
   Adamantidis A, 2008, CELL MOL LIFE SCI, V65, P1475, DOI 10.1007/s00018-008-7521-8
   Afonso VM, 2009, HORM BEHAV, V56, P11, DOI 10.1016/j.yhbeh.2009.02.003
   Agrati D, 2015, ARCH WOMENS MENT HLT
   ALTEMUS M, 1995, J CLIN ENDOCR METAB, V80, P2954, DOI 10.1210/jc.80.10.2954
   Altemus M, 2001, PSYCHOSOM MED, V63, P814
   Araujo-Lopes R, 2014, ENDOCRINOLOGY, V155, P1010, DOI 10.1210/en.2013-1889
   Asarian L, 2006, PHILOS T R SOC B, V361, P1251, DOI 10.1098/rstb.2006.1860
   Augustine RA, 2008, ENDOCRINOLOGY, V149, P1049, DOI 10.1210/en.2007-1018
   Augustine RA, 2008, J PHYSIOL-LONDON, V586, P387, DOI 10.1113/jphysiol.2007.146316
   BAIRD DT, 1979, J CLIN ENDOCR METAB, V49, P500
   Bakowska JC, 1997, J COMP NEUROL, V386, P161, DOI 10.1002/(SICI)1096-9861(19970922)386:2<161::AID-CNE1>3.0.CO;2-#
   BARASH I, 1992, RECEPTOR, V2, P39
   Barbosa-Vargas E, 2009, HORM BEHAV, V56, P246, DOI 10.1016/j.yhbeh.2009.05.004
   Bechtold DA, 2006, ENDOCRINOLOGY, V147, P4723, DOI 10.1210/en.2006-0753
   Bellefontaine N, 2014, HORM BEHAV, V66, P7, DOI 10.1016/j.yhbeh.2014.04.007
   Bernard V, 2015, NAT REV ENDOCRINOL, V11, P265, DOI 10.1038/nrendo.2015.36
   Bhatnagar S, 1998, FERTIL STERIL, V70, P461
   Blume A, 2009, ENDOCRINOLOGY, V150, P1841, DOI 10.1210/en.2008-1023
   BONGAARTS J, 1980, SCIENCE, V208, P564, DOI 10.1126/science.7367878
   Bosch OJ, 2007, PSYCHONEUROENDOCRINO, V32, P267, DOI 10.1016/j.psyneuen.2006.12.012
   Bosch OJ, 2011, HORM BEHAV, V59, P202, DOI 10.1016/j.yhbeh.2010.11.012
   BOWEN WD, 1985, CAN J ZOOL, V63, P2841
   BOYNE R, 1966, J PHYSIOL-LONDON, V183, P570
   Brandao ML, 2003, EUR J PHARMACOL, V463, P225, DOI 10.1016/S0014-2999(03)01284-6
   BRIDGES R, 1972, DEV PSYCHOBIOL, V5, P123, DOI 10.1002/dev.420050205
   Bridges RS, 2015, FRONT NEUROENDOCRIN, V36, P178, DOI 10.1016/j.yfrne.2014.11.007
   BRIDGES RS, 1990, P NATL ACAD SCI USA, V87, P8003, DOI 10.1073/pnas.87.20.8003
   BROAD KD, 1993, J NEUROENDOCRINOL, V5, P435, DOI 10.1111/j.1365-2826.1993.tb00505.x
   Brogan RS, 1999, ENDOCRINOLOGY, V140, P2621, DOI 10.1210/en.140.6.2621
   Brogan RS, 2000, J NEUROENDOCRINOL, V12, P1077, DOI 10.1046/j.1365-2826.2000.00559.x
   BROMMAGE R, 1989, J NUTR, V119, P428
   Bronson F, 1985, FUNCT ORTHOD, V2, P11
   BRONSON FH, 1990, AM J PHYSIOL, V259, pR25
   BRONSON FH, 1986, ENDOCRINOLOGY, V118, P2483
   Brown RSE, 2014, J NEUROENDOCRINOL, V26, P898, DOI 10.1111/jne.12223
   Brown RSE, 2010, J COMP NEUROL, V518, P92, DOI 10.1002/cne.22208
   Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122
   Brunton PJ, 2008, J NEUROENDOCRINOL, V20, P764, DOI 10.1111/j.1365-2826.2008.01735.x
   Brunton PJ, 2008, NAT REV NEUROSCI, V9, P11, DOI 10.1038/nrn2280
   Budin RE, 2010, FUNCTIONAL ROLE GHRE
   Buonfiglio DC, 2015, HORM BEHAV, V71, P60, DOI 10.1016/j.yhbeh.2015.04.004
   Butte NF, 2005, PUBLIC HEALTH NUTR, V8, P1010, DOI 10.1079/PHN2005793
   Butte NF, 2003, AM J OBSTET GYNECOL, V189, P1423, DOI 10.1067/S0002-9378(03)00596-9
   CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794
   Campbell RE, 2001, NEUROENDOCRINOLOGY, V74, P106, DOI 10.1159/000054676
   Carter C S, 2001, Prog Brain Res, V133, P241
   Chalivoix S, 2010, J NEUROENDOCRINOL, V22, P110, DOI 10.1111/j.1365-2826.2009.01939.x
   Chen PL, 1999, ENDOCRINOLOGY, V140, P2645, DOI 10.1210/en.140.6.2645
   Chen PL, 2004, ENDOCRINOLOGY, V145, P823, DOI 10.1210/en.2003-1255
   Cheung CC, 2001, NEUROENDOCRINOLOGY, V74, P12, DOI 10.1159/000054666
   CIOFI P, 1993, J NEUROENDOCRINOL, V5, P599, DOI 10.1111/j.1365-2826.1993.tb00528.x
   Clarke IJ, 2014, HORM BEHAV, V66, P15, DOI 10.1016/j.yhbeh.2014.02.005
   Clarke PE, 2005, ANN HUM BIOL, V32, P247, DOI 10.1080/03014460500049915
   Clarkson J, 2009, ENDOCRINOLOGY, V150, P3214, DOI 10.1210/en.2008-1733
   Clegg DJ, 2007, DIABETES, V56, P1051, DOI 10.2337/db06-0015
   Clegg DJ, 2006, DIABETES, V55, P978, DOI 10.2337/diabetes.55.04.06.db05-1339
   COHEN LR, 1989, APPETITE, V12, P119, DOI 10.1016/0195-6663(89)90101-3
   CRIPPS AW, 1975, BRIT J NUTR, V33, P17, DOI 10.1079/BJN19750005
   Crowley WR, 2007, PEPTIDES, V28, P447, DOI 10.1016/j.peptides.2006.09.025
   Crowley WR, 2015, COMPR PHYSIOL, V5, P255, DOI 10.1002/cphy.c140029
   CROWLEY WR, 1992, ENDOCR REV, V13, P33, DOI 10.1210/er.13.1.33
   Crowley WR, 2004, J NEUROENDOCRINOL, V16, P637, DOI 10.1111/j.1365-2826.2004.01213.x
   Crowley WR, 2003, PHARMACOL BIOCHEM BE, V74, P417, DOI 10.1016/S0091-3057(02)01006-7
   Cservenak M, 2010, ENDOCRINOLOGY, V151, P5830, DOI 10.1210/en.2010-0767
   Cui JG, 2011, AM J PHYSIOL-REG I, V300, pR447, DOI 10.1152/ajpregu.00121.2010
   CUMMINGS S, 1988, NEUROENDOCRINOLOGY, V47, P523, DOI 10.1159/000124965
   Curley JP, 2012, HORM BEHAV, V61, P454, DOI 10.1016/j.yhbeh.2012.01.013
   da Costa APC, 2001, MOL BRAIN RES, V91, P119, DOI 10.1016/S0169-328X(01)00137-1
   daCosta APC, 1996, BRAIN RES, V742, P177, DOI 10.1016/S0006-8993(96)00962-6
   DaCosta APC, 1997, BRAIN RES, V770, P151, DOI 10.1016/S0006-8993(97)00764-6
   DELGADO H, 1979, AM J OBSTET GYNECOL, V135, P303
   DELGADO HL, 1982, AM J CLIN NUTR, V35, P1468
   Denis RGP, 2003, J ENDOCRINOL, V176, P193, DOI 10.1677/joe.0.1760193
   Deschamps S, 2003, J NEUROENDOCRINOL, V15, P486
   DiVall SA, 2010, J CLIN INVEST, V120, P2900, DOI 10.1172/JCI41069
   Dobolyi A, 2011, J NEUROENDOCRINOL, V23, P1002, DOI 10.1111/j.1365-2826.2011.02127.x
   Donato Jose Jr, 2011, Front Endocrinol (Lausanne), V2, P57, DOI 10.3389/fendo.2011.00057
   Donato J, 2011, J CLIN INVEST, V121, P355, DOI 10.1172/JCI45106
   Donner N, 2007, EUR J NEUROSCI, V25, P1804, DOI 10.1111/j.1460-9568.2007.05416.x
   Douglas AJ, 2007, EUR J NEUROSCI, V25, P1599, DOI 10.1111/j.1460-9568.2007.05380.x
   Douglas AJ, 2005, STRESS, V8, P5, DOI 10.1080/10253890500044380
   Douglas AJ, 2002, J NEUROENDOCRINOL, V14, P768, DOI 10.1046/j.1365-2826.2002.00837.x
   Douglas AJ, 2007, PHYSIOL BEHAV, V91, P352, DOI 10.1016/j.physbeh.2007.04.012
   Ellison PT, 2003, FERTIL STERIL, V80, P1279, DOI 10.1016/S0015-0282(03)02158-7
   Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0
   Eriksson M, 1996, NEUROENDOCRINOLOGY, V63, P356, DOI 10.1159/000126976
   ERIKSSON M, 1994, ACTA PHYSIOL SCAND, V151, P453, DOI 10.1111/j.1748-1716.1994.tb09767.x
   ERMISCH A, 1985, ENDOCRINOL EXP, V19, P29
   Evans JJ, 2012, HUM REPROD UPDATE, V18, P313, DOI 10.1093/humupd/dms004
   Evans MC, 2014, J NEUROENDOCRINOL, V26, P468, DOI 10.1111/jne.12166
   Fabic MS, 2013, STUD FAMILY PLANN, V44, P205, DOI 10.1111/j.1728-4465.2013.00353.x
   FENELON VS, 1994, BRAIN RES, V662, P165, DOI 10.1016/0006-8993(94)90809-5
   Fernandez-Fernandez R, 2005, NEUROENDOCRINOLOGY, V82, P245, DOI 10.1159/000092753
   Fernandez-Fernandez R, 2004, NEUROSCI LETT, V362, P103, DOI 10.1016/j.neulet.2004.03.003
   Figueira RJ, 2008, BEHAV NEUROSCI, V122, P618, DOI 10.1037/0735-7044.122.3.618
   FLEMING AS, 1981, PHYSIOL BEHAV, V27, P863, DOI 10.1016/0031-9384(81)90054-8
   FLINT DJ, 1985, BIOCHEM SOC T, V13, P828
   FLINT DJ, 1979, BIOCHEM J, V182, P421
   Flugge G, 2004, CELL TISSUE RES, V315, P1, DOI 10.1007/s00441-003-0807-0
   FOX SR, 1984, ENDOCRINOLOGY, V115, P2045
   Frazao R, 2014, AM J PHYSIOL-ENDOC M, V306, pE606, DOI 10.1152/ajpendo.00211.2013
   Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378
   Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532
   FREUNDMERCIER MJ, 1994, J PHYSIOL-LONDON, V480, P155
   Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878
   Friedman JM, 2002, NUTR REV, V60, P85, DOI DOI 10.1301/002966402320634878
   Friedman JM, 2002, NUTR REV, V60, pS68, DOI DOI 10.1301/002966402320634878
   Frontera M, 2005, CELL PHYSIOL BIOCHEM, V15, P203, DOI 10.1159/000086407
   Fulton S, 2002, BEHAV NEUROSCI, V116, P651, DOI 10.1037//0735-7044.116.4.651
   Fulton S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006
   Furuta M, 2001, BIOCHEM BIOPH RES CO, V288, P780, DOI 10.1006/bbrc.2001.5854
   Gale S, 2003, J PSYCHOSOM OBST GYN, V24, P257, DOI 10.3109/01674820309074690
   Gao Q, 2008, AM J PHYSIOL-ENDOC M, V294, pE817, DOI 10.1152/ajpendo.00733.2007
   Gao Q, 2007, NAT MED, V13, P89, DOI 10.1038/nm1525
   GLASIER A, 1986, CLIN ENDOCRINOL, V24, P243, DOI 10.1111/j.1365-2265.1986.tb03264.x
   GLASIER A, 1984, CLIN ENDOCRINOL, V20, P415, DOI 10.1111/j.1365-2265.1984.tb03437.x
   Grattan DR, 2008, J NEUROENDOCRINOL, V20, P752, DOI 10.1111/j.1365-2826.2008.01736.x
   Grattan D R, 2001, Prog Brain Res, V133, P153
   Grattan DR, 2008, J NEUROENDOCRINOL, V20, P497, DOI 10.1111/j.1365-2826.2008.01661.x
   Grattan DR, 2007, ENDOCRINOLOGY, V148, P4344, DOI 10.1210/en.2007-0403
   Grattan DR, 2002, REPRODUCTION, V123, P497, DOI 10.1530/rep.0.1230497
   Grattan DR, 2001, HORM BEHAV, V40, P115, DOI 10.1006/hbeh.2001.1698
   Grill HJ, 2009, INT J OBESITY, V33, pS11, DOI 10.1038/ijo.2009.10
   Grill HJ, 2001, INT J OBESITY, V25, pS73, DOI 10.1038/sj/ijo/0801917
   Grill HJ, 2002, FRONT NEUROENDOCRIN, V23, P2, DOI 10.1006/frne.2001.0224
   Grosvenor C E, 1971, J Anim Sci, V32 Suppl 1, P115
   GROTA LJ, 1974, HORM BEHAV, V5, P275, DOI 10.1016/0018-506X(74)90014-2
   GROTA LJ, 1967, J REPROD FERTIL, V13, P83
   Guyon A, 2009, PEPTIDES, V30, P2031, DOI 10.1016/j.peptides.2009.05.028
   Gyengesi E, 2010, ENDOCRINOLOGY, V151, P5395, DOI 10.1210/en.2010-0681
   HANSEN S, 1985, PSYCHOPHARMACOLOGY, V86, P344, DOI 10.1007/BF00432226
   HANSEN S, 1983, J ENDOCRINOL, V99, P173, DOI 10.1677/joe.0.0990173
   HANSEN S, 1986, BEHAV NEUROSCI, V100, P410, DOI 10.1037//0735-7044.100.3.410
   HARD E, 1985, PHYSIOL BEHAV, V35, P641, DOI 10.1016/0031-9384(85)90155-6
   HAYSSEN V, 1993, J DAIRY SCI, V76, P3213
   Heinrichs M, 2001, J CLIN ENDOCR METAB, V86, P4798, DOI 10.1210/jc.86.10.4798
   Heinrichs M, 2002, STRESS, V5, P195, DOI 10.1080/1025389021000010530
   Herbison AE, 2008, BRAIN RES REV, V57, P277, DOI 10.1016/j.brainresrev.2007.OS.006
   Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006
   Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001
   HIGUCHI T, 1988, J ENDOCRINOL, V116, P225, DOI 10.1677/joe.0.1160225
   HIGUCHI T, 1989, J ENDOCRINOL, V122, P495, DOI 10.1677/joe.0.1220495
   Hillerer KM, 2012, NEUROENDOCRINOLOGY, V95, P22, DOI 10.1159/000330445
   Hillerer KM, 2011, ENDOCRINOLOGY, V152, P3930, DOI 10.1210/en.2011-1091
   Hommel JD, 2006, NEURON, V51, P801, DOI 10.1016/j.neuron.2006.08.023
   HOWIE PW, 1981, BRIT MED J, V283, P757
   ILLINGWORTH PJ, 1995, HUM REPROD, V10, P1671
   IMAIMATSUMARA K, 1990, J PHYSIOL-LONDON, V425, P271
   INSEL TR, 1986, NEUROENDOCRINOLOGY, V44, P515, DOI 10.1159/000124694
   INSEL TR, 1990, J NEUROENDOCRINOL, V2, P539, DOI 10.1111/j.1365-2826.1990.tb00445.x
   ISLER D, 1984, ANN NUTR METAB, V28, P101, DOI 10.1159/000176789
   JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976
   JAHN GA, 1986, J ENDOCRINOL, V110, P423, DOI 10.1677/joe.0.1100423
   JENNESS R, 1986, J DAIRY SCI, V69, P869
   JOHNSTON JM, 1986, J CLIN ENDOCR METAB, V62, P653
   Johnstone L E, 2001, Prog Brain Res, V133, P215
   Jonas K, 2009, Breastfeed Med, V4, P71, DOI 10.1089/bfm.2008.0002
   Jonas W, 2008, BREASTFEED MED, V3, P103, DOI 10.1089/bfm.2007.0031
   Jonas W, 2008, ARCH WOMEN MENT HLTH, V11, P335, DOI 10.1007/s00737-008-0027-4
   Jurek B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037060
   Kalra PS, 2000, METHOD ENZYMOL, V314, P184
   Kaye J, 2004, CLIN ENDOCRINOL, V61, P582, DOI 10.1111/j.1365-2265.2004.02133.x
   Kennedy KI, 1996, INT J GYNECOL OBSTET, V54, P55, DOI 10.1016/0020-7292(96)02670-7
   KENT S, 1991, PHYSIOL BEHAV, V49, P1079, DOI 10.1016/0031-9384(91)90334-K
   Kim JD, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00480
   KNOLLEMA S, 1992, J NEUROENDOCRINOL, V4, P709, DOI 10.1111/j.1365-2826.1992.tb00222.x
   Kokay IC, 2005, J NEUROENDOCRINOL, V17, P827, DOI 10.1111/j.1365-2826.2005.01374.x
   Kokay IC, 2006, AM J PHYSIOL-REG I, V290, pR1216, DOI 10.1152/ajpregu.00730.2005
   Ladyman SR, 2014, REPRODUCTION, V147, P743, DOI 10.1530/REP-13-0426
   Ladyman SR, 2009, PHYSIOL BEHAV, V97, P91, DOI 10.1016/j.physbeh.2009.02.008
   Ladyman SR, 2005, ENDOCRINOLOGY, V146, P3868, DOI 10.1210/en.2005-0194
   Ladyman SR, 2004, ENDOCRINOLOGY, V145, P3704, DOI 10.1210/en.2004-0338
   Lamming G., 1978, CONTROL OF OVULATION
   Larsen CM, 2010, ENDOCRINOLOGY, V151, P3805, DOI 10.1210/en.2009-1385
   Lehman MN, 2013, ADV EXP MED BIOL, V784, P27, DOI 10.1007/978-1-4614-6199-9_3
   Lehman MN, 2010, BRAIN RES, V1364, P90, DOI 10.1016/j.brainres.2010.09.020
   Lehman MN, 2010, ENDOCRINOLOGY, V151, P3479, DOI 10.1210/en.2010-0022
   Leng G., 2015, BIOL PSYCHIAT, V79, P243, DOI DOI 10.1016/J.BIOPSYCH.2015.05.003
   Leng G, 2008, CURR OPIN PHARMACOL, V8, P731, DOI 10.1016/j.coph.2008.07.001
   Li C, 1999, NEUROSCIENCE, V94, P117, DOI 10.1016/S0306-4522(99)00236-5
   Li C, 1998, REGUL PEPTIDES, V75-6, P93, DOI 10.1016/S0167-0115(98)00057-3
   Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645
   Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382
   Li G, 2007, AM J PHYSIOL-ENDOC M, V293, pE252, DOI 10.1152/ajpendo.00451.2006
   Lightman S L, 2001, Prog Brain Res, V133, P111
   LIGHTMAN SL, 1989, ENDOCRINOLOGY, V124, P2358
   LINCOLN DW, 1982, J REPROD FERTIL, V65, P571
   LINDEN A, 1990, J ENDOCRINOL, V127, P257, DOI 10.1677/joe.0.1270257
   Linden A, 1989, Acta Physiol Scand Suppl, V585, pi
   Liu X, 2014, ENDOCRINOLOGY, V155, P193, DOI 10.1210/en.2013-1621
   Liu XH, 2015, ENDOCRINOLOGY, V156, P1815, DOI 10.1210/en.2014-1845
   Lof M, 2006, BRIT J NUTR, V95, P296, DOI 10.1079/BJN20051497
   Lonstein JS, 2014, J NEUROENDOCRINOL, V26, P649, DOI 10.1111/jne.12188
   Lonstein JS, 2007, FRONT NEUROENDOCRIN, V28, P115, DOI 10.1016/j.yfrne.2007.05.002
   Lonstein JS, 2005, HORM BEHAV, V47, P241, DOI 10.1016/j.yhbeh.2004.11.001
   Lonstein JS, 1997, J NEUROSCI, V17, P3364
   LOUDON ASI, 1983, NATURE, V302, P145, DOI 10.1038/302145a0
   Louis GW, 2011, ENDOCRINOLOGY, V152, P2302, DOI 10.1210/en.2011-0096
   Luo N, 2011, ENDOCRINOLOGY, V152, P883, DOI 10.1210/en.2010-1135
   MAEDA K, 1987, ENDOCRINOL JAPON, V34, P709
   MAEDA KI, 1990, ENDOCRINOL JAPON, V37, P405
   Maestripieri D, 2011, AM J PRIMATOL, V73, P516, DOI 10.1002/ajp.20882
   Mann PE, 1997, MOL BRAIN RES, V46, P9, DOI 10.1016/S0169-328X(96)00267-7
   Marshall JC, 1991, RECENT PROG HORM RES, V47, P188
   [Anonymous], 1991, RECENT PROG HORM RES
   Martin C, 2014, J NEUROSCI, V34, P6047, DOI 10.1523/JNEUROSCI.3003-13.2014
   MARTIN RH, 1981, CLIN ENDOCRINOL, V14, P363, DOI 10.1111/j.1365-2265.1981.tb00621.x
   MATTHEIJ JAM, 1984, HORM RES, V20, P261, DOI 10.1159/000180006
   MATTHEIJ JAM, 1979, HORM RES, V11, P325, DOI 10.1159/000179070
   Mattson BJ, 2001, BEHAV NEUROSCI, V115, P683, DOI 10.1037//0735-7044.115.3.683
   McNeilly A S, 2001, Prog Brain Res, V133, P207
   MCNEILLY AS, 1982, CLIN ENDOCRINOL, V17, P609, DOI 10.1111/j.1365-2265.1982.tb01634.x
   McNeilly AS, 2001, REPROD FERT DEVELOP, V13, P583, DOI 10.1071/RD01056
   MCNEILLY AS, 1983, CLIN ENDOCRINOL, V19, P167, DOI 10.1111/j.1365-2265.1983.tb02978.x
   McNeilly AS, 2001, MATERNAL BRAIN NEURO, P207
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Mezzacappa ES, 2005, J PSYCHOSOM RES, V58, P351, DOI 10.1016/j.jpsychores.2004.11.004
   MILLELIRE L, 1989, PHYSIOL BEHAV, V46, P429, DOI 10.1016/0031-9384(89)90015-2
   MILLER SC, 1986, BONE, V7, P283, DOI 10.1016/8756-3282(86)90209-7
   Miller SM, 2010, PHARMACOL BIOCHEM BE, V95, P457, DOI 10.1016/j.pbb.2010.03.007
   MISAKI N, 1992, NEUROCHEM INT, V21, P185, DOI 10.1016/0197-0186(92)90145-H
   Mitchell J B, 1994, Rev Neurosci, V5, P317
   Morales T, 2003, NEUROSCIENCE, V121, P771, DOI 10.1016/S0306-4522(03)00522-0
   Naef L, 2007, ENDOCRINOLOGY, V148, P5977, DOI 10.1210/en.2007-0442
   Nagatani S, 1998, NEUROENDOCRINOLOGY, V67, P370, DOI 10.1159/000054335
   NAGY G, 1986, J ENDOCRINOL, V111, P137, DOI 10.1677/joe.0.1110137
   NAISMITH DJ, 1976, BRIT J NUTR, V36, P563, DOI 10.1079/BJN19760109
   NAISMITH DJ, 1982, BRIT J NUTR, V48, P433, DOI 10.1079/BJN19820125
   Nephew BC, 2009, BEHAV NEUROSCI, V123, P949, DOI 10.1037/a0016734
   NEUMANN I, 1994, ENDOCRINOLOGY, V134, P141, DOI 10.1210/en.134.1.141
   Neumann I, 1995, ADV EXP MED BIOL, V395, P173
   Neumann ID, 2000, NEUROSCIENCE, V95, P567
   Neumann ID, 2000, REGUL PEPTIDES, V96, P31, DOI 10.1016/S0167-0115(00)00197-X
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Nissen E, 1998, J PSYCHOSOM OBST GYN, V19, P49, DOI 10.3109/01674829809044221
   NOEL MB, 1993, PHYSIOL BEHAV, V54, P151, DOI 10.1016/0031-9384(93)90057-M
   Numan M, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P1921
   Numan M, 2003, NEUROBIOLOGY PARENTA
   Numan M, 2010, BEHAV NEUROSCI, V124, P715, DOI 10.1037/a0021548
   Oftedal OT, 2000, P NUTR SOC, V59, P99, DOI 10.1017/S0029665100000124
   Ohkura S, 2009, PEPTIDES, V30, P49, DOI 10.1016/j.peptides.2008.08.004
   Okamura H, 2013, ADV EXP MED BIOL, V784, P297, DOI 10.1007/978-1-4614-6199-9_14
   OLTMANS GA, 1977, BRAIN RES, V128, P293, DOI 10.1016/0006-8993(77)90996-9
   Palkovits M, 2010, NEUROCHEM RES, V35, P2078, DOI 10.1007/s11064-010-0292-2
   PAUL AA, 1979, P NUTR SOC, V38, pA28
   Pawluski JL, 2009, PHYSIOL BEHAV, V96, P108, DOI 10.1016/j.physbeh.2008.09.004
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776
   Perheentupa A, 2000, J CLIN ENDOCR METAB, V85, P4280, DOI 10.1210/jc.85.11.4280
   Peterson AE, 2000, CONTRACEPTION, V62, P221, DOI 10.1016/S0010-7824(00)00171-2
   Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010
   PLOTSKY PM, 1987, LIFE SCI, V41, P1311, DOI 10.1016/0024-3205(87)90211-6
   PLOTSKY PM, 1987, ANN NY ACAD SCI, V512, P205, DOI 10.1111/j.1749-6632.1987.tb24962.x
   PLOTSKY PM, 1987, ENDOCRINOLOGY, V121, P924
   Popeski N, 2001, J NEUROENDOCRINOL, V13, P596, DOI 10.1046/j.1365-2826.2001.00673.x
   Quennell JH, 2009, ENDOCRINOLOGY, V150, P2805, DOI 10.1210/en.2008-1693
   Radley JJ, 2011, J NEUROSCI, V31, P9683, DOI 10.1523/JNEUROSCI.6040-10.2011
   Radley JJ, 2009, J NEUROSCI, V29, P7330, DOI 10.1523/JNEUROSCI.5924-08.2009
   Radley JJ, 2006, J NEUROSCI, V26, P12967, DOI 10.1523/JNEUROSCI.4297-06.2006
   Ragan CM, 2014, NEUROSCIENCE, V256, P433, DOI 10.1016/j.neuroscience.2013.10.014
   Ramos MP, 2003, AM J PHYSIOL-ENDOC M, V285, pE318, DOI 10.1152/ajpendo.00456.2002
   Richter CP, 1938, ENDOCRINOLOGY, V23, P15
   Riediger T, 2012, P NUTR SOC, V71, P463, DOI 10.1017/S0029665112000778
   RITTER RC, 1981, SCIENCE, V213, P451, DOI 10.1126/science.6264602
   Ritter S, 2000, BRAIN RES, V856, P37, DOI 10.1016/S0006-8993(99)02327-6
   Ritter S, 2001, J COMP NEUROL, V432, P197, DOI 10.1002/cne.1097
   Roa J, 2006, ENDOCRINOLOGY, V147, P2864, DOI 10.1210/en.2005-1463
   Roa J, 2012, ENDOCRINOLOGY, V153, P5587, DOI 10.1210/en.2012-1470
   ROBINSON CJ, 1982, J ENDOCRINOL, V94, P443, DOI 10.1677/joe.0.0940443
   Romano N, 2013, J NEUROSCI, V33, P4424, DOI 10.1523/JNEUROSCI.4415-12.2013
   Rondini TA, 2010, J CHEM NEUROANAT, V39, P51, DOI 10.1016/j.jchemneu.2009.10.005
   ROTHCHILD I, 1960, ENDOCRINOLOGY, V67, P9
   Roy AF, 2007, J ENDOCRINOL, V195, P341, DOI 10.1677/JOE-07-0321
   SALAMONE JD, 1990, NEUROSCIENCE, V39, P17, DOI 10.1016/0306-4522(90)90218-S
   SALAMONE JD, 1993, PHARMACOL BIOCHEM BE, V44, P605, DOI 10.1016/0091-3057(93)90174-R
   Santos NR, 2003, PHARMACOL BIOCHEM BE, V75, P25, DOI 10.1016/S0091-3057(03)00033-9
   SAR M, 1969, NEUROENDOCRINOLOGY, V4, P25, DOI 10.1159/000121735
   Sauve D, 1996, BRAIN RES, V729, P75
   SCHLEIN PA, 1974, J ENDOCRINOL, V62, P93, DOI 10.1677/joe.0.0620093
   Schneider JE, 2004, PHYSIOL BEHAV, V81, P289, DOI 10.1016/j.physbeh.2004.02.007
   Segal-Lieberman G, 2003, AM J PHYSIOL-ENDOC M, V284, pE1131, DOI 10.1152/ajpendo.00491.2002
   Shanks N, 1999, J NEUROENDOCRINOL, V11, P857
   Slattery DA, 2008, J PHYSIOL-LONDON, V586, P377, DOI 10.1113/jphysiol.2007.145896
   Slonaker JR, 1925, AM J PHYSIOL, V71, P362
   Smith JT, 2013, PEPTIDES, V47, P45, DOI 10.1016/j.peptides.2013.06.012
   Smith JT, 2006, J NEUROENDOCRINOL, V18, P298, DOI 10.1111/j.1365-2826.2006.01417.x
   SMITH MS, 1993, ENDOCRINOLOGY, V133, P1258, DOI 10.1210/en.133.3.1258
   Smith MS, 2002, FRONT NEUROENDOCRIN, V23, P225, DOI 10.1016/S0091-3022(02)00002-X
   SMITH MS, 1977, BIOL REPROD, V17, P255, DOI 10.1095/biolreprod17.2.255
   SMITH MS, 1978, ENDOCRINOLOGY, V102, P114
   SMITH MS, 1978, ENDOCRINOLOGY, V102, P121
   SMITH MS, 1984, ARCH BIOL MED EXP, V17, P231
   SMITH MS, 1985, ENDOCRINOLOGY, V116, P1826
   SMITH MS, 1978, BIOL REPROD, V19, P77, DOI 10.1095/biolreprod19.1.77
   SMOTHERMAN WP, 1977, HORM BEHAV, V8, P242, DOI 10.1016/0018-506X(77)90041-1
   SODERSTEN P, 1984, J ENDOCRINOL, V102, P251, DOI 10.1677/joe.0.1020251
   Stern J M, 1974, Prog Brain Res, V41, P433
   STERN JM, 1973, NEUROENDOCRINOLOGY, V12, P179, DOI 10.1159/000122167
   STERN JM, 1972, HORM BEHAV, V3, P237, DOI 10.1016/0018-506X(72)90037-2
   Steyn FJ, 2007, J NEUROENDOCRINOL, V19, P788, DOI 10.1111/j.1365-2826.2007.01590.x
   Stolzenberg DS, 2011, NEUROSCI BIOBEHAV R, V35, P826, DOI 10.1016/j.neubiorev.2010.10.003
   STRUBBE JH, 1980, PHYSIOL BEHAV, V25, P775, DOI 10.1016/0031-9384(80)90383-2
   Stuebe AM, 2013, J WOMENS HEALTH, V22, P352, DOI 10.1089/jwh.2012.3768
   Sullivan SD, 2004, ENDOCRINOLOGY, V145, P1194, DOI 10.1210/en.2003-1374
   Suzuki Y, 2010, J ENDOCRINOL, V207, P105, DOI 10.1677/JOE-09-0463
   Szabo FK, 2010, ENDOCRINE, V37, P62, DOI 10.1007/s12020-009-9266-z
   Tay CCK, 1996, HUM REPROD, V11, P950
   TAY CCK, 1993, HUM REPROD, V8, P532
   TAY CCK, 1992, HUM REPROD, V7, P951
   TAYA K, 1982, ENDOCRINOL JAPON, V29, P453
   THOMAN EB, 1970, J COMP PHYSIOL PSYCH, V70, P364, DOI 10.1037/h0028710
   TOMOGANE H, 1975, J ENDOCRINOL, V65, P155, DOI 10.1677/joe.0.0650155
   TOMOGANE H, 1976, J REPROD FERTIL, V47, P347
   Torner L, 2004, EUR J NEUROSCI, V19, P1601, DOI 10.1111/j.1460-9568.2004.03264.x
   Torner L, 2002, EUR J NEUROSCI, V15, P1381, DOI 10.1046/j.1460-9568.2002.01965.x
   Torner L, 2001, J NEUROSCI, V21, P3207
   Torner L, 2002, STRESS, V5, P249, DOI 10.1080/1025389021000048638
   Toufexis DJ, 1998, J NEUROENDOCRINOL, V10, P417, DOI 10.1046/j.1365-2826.1998.00223.x
   Toufexis DJ, 2002, J NEUROENDOCRINOL, V14, P492, DOI 10.1046/j.1365-2826.2002.00805.x
   Toufexis DJ, 1999, BEHAV NEUROSCI, V113, P176, DOI 10.1037//0735-7044.113.1.176
   Toufexis DJ, 1999, J NEUROENDOCRINOL, V11, P757
   Toufexis DJ, 1996, BRAIN RES, V737, P71, DOI 10.1016/0006-8993(96)00627-0
   TRAYHURN P, 1985, INT J OBESITY, V9, P81
   TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P370
   Treece BR, 2000, BRAIN RES, V872, P37, DOI 10.1016/S0006-8993(00)02432-X
   True C, 2011, J NEUROENDOCRINOL, V23, P1099, DOI 10.1111/j.1365-2826.2011.02144.x
   True C, 2011, J NEUROENDOCRINOL, V23, P52, DOI 10.1111/j.1365-2826.2010.02076.x
   TSUKAMURA H, 1988, J ENDOCRINOL, V118, P311, DOI 10.1677/joe.0.1180311
   Tsukamura H, 2001, Prog Brain Res, V133, P187
   Tu MT, 2006, J NEUROENDOCRINOL, V18, P494, DOI 10.1111/j.1635-2826.2006.01441.x
   TUCKER HA, 1977, J ANIM SCI, V45, P627
   Uenoyama Y, 2009, J NEUROENDOCRINOL, V21, P299, DOI 10.1111/j.1365-2826.2009.01853.x
   Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647
   UVNASMOBERG K, 1994, PSYCHONEUROENDOCRINO, V19, P687, DOI 10.1016/0306-4530(94)90050-7
   Valeggia C, 2004, J BIOSOC SCI, V36, P573, DOI 10.1017/S0021932003006382
   Valeggia C, 2009, AM J HUM BIOL, V21, P559, DOI 10.1002/ajhb.20907
   Van Look PFA, 1999, FERTIL STERIL, V72, P431
   Vernon RG, 1997, J MAMMARY GLAND BIOL, V2, P231, DOI 10.1023/A:1026380220364
   Voogt J L, 2001, Prog Brain Res, V133, P173
   Wade GN, 1996, AM J PHYSIOL-ENDOC M, V270, pE1
   WADE GN, 1982, PHYSIOL BEHAV, V29, P701, DOI 10.1016/0031-9384(82)90242-6
   Wahab F, 2011, HORM METAB RES, V43, P81, DOI 10.1055/s-0030-1269852
   WAKERLEY JB, 1971, NATURE-NEW BIOL, V233, P180
   Wakerley JB, 1995, ADV EXP MED BIOL, V395, P117
   Walker C D, 2001, Prog Brain Res, V133, P99
   Walker CD, 2004, J PSYCHIATR NEUROSCI, V29, P364
   WALKER CD, 1995, J NEUROENDOCRINOL, V7, P615, DOI 10.1111/j.1365-2826.1995.tb00799.x
   WALKER CD, 1992, ENDOCRINOLOGY, V130, P115, DOI 10.1210/en.130.1.115
   Walker CD, 2001, J NEUROENDOCRINOL, V13, P74, DOI 10.1046/j.1365-2826.2001.00589.x
   WALKER CD, 1995, J ENDOCRINOL, V146, P95, DOI 10.1677/joe.0.1460095
   WALSH RJ, 1987, ENDOCRINOLOGY, V120, P1846
   WANG HJ, 1993, ENDOCRINOLOGY, V133, P1657, DOI 10.1210/en.133.4.1657
   Wang YF, 2004, J NEUROPHYSIOL, V91, P2312, DOI 10.1152/jn.00697.2003
   Wellman M, 2015, PEPTIDES, V70, P17, DOI 10.1016/j.peptides.2015.05.007
   WIDSTROM AM, 1988, J PEDIATR GASTR NUTR, V7, P517, DOI 10.1097/00005176-198807000-00007
   WIDSTROM AM, 1988, ACTA PAEDIATR SCAND, V77, P502, DOI 10.1111/j.1651-2227.1988.tb10691.x
   Windle RJ, 2013, ENDOCRINOLOGY, V154, P749, DOI 10.1210/en.2012-1779
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P3741, DOI 10.1210/en.138.9.3741
   Windle RJ, 2004, J NEUROSCI, V24, P2974, DOI 10.1523/JNEUROSCI.3432-03.2004
   Windle RJ, 1997, J NEUROENDOCRINOL, V9, P407, DOI 10.1046/j.1365-2826.1997.00587.x
   Wood CE, 2015, COMPR PHYSL, V6, P33
   Woodside B, 1998, AM J PHYSIOL-REG I, V274, pR1653
   Woodside B, 2000, HORM BEHAV, V37, P353, DOI 10.1006/hbeh.2000.1598
   WOODSIDE B, 1991, HORM BEHAV, V25, P70, DOI 10.1016/0018-506X(91)90040-O
   Woodside B, 1999, PHYSIOL BEHAV, V65, P711
   Woodside B, 2008, THE PARENTAL BRAIN
   Woodside B, 2007, PHYSIOL BEHAV, V91, P375, DOI 10.1016/j.physbeh.2007.04.015
   Woodside C, 1995, Horm Behav, V29, P154
   Wu Q, 2008, P NATL ACAD SCI USA, V105, P2687, DOI 10.1073/pnas.0712062105
   Wu Q, 2012, NATURE, V483, P594, DOI 10.1038/nature10899
   Wu Q, 2011, EUR J PHARMACOL, V660, P21, DOI 10.1016/j.ejphar.2010.10.110
   Wu Q, 2009, CELL, V137, P1225, DOI 10.1016/j.cell.2009.04.022
   Xiao XQ, 2004, ENDOCRINOLOGY, V145, P5344, DOI 10.1210/en.2004-0721
   Xiao XQ, 2004, ENDOCRINOLOGY, V145, P830, DOI 10.1210/en.2003-0836
   Xu J, 2009, ENDOCRINOLOGY, V150, P333, DOI 10.1210/en.2008-0962
   Xu J, 2009, ENDOCRINOLOGY, V150, P4231, DOI 10.1210/en.2009-0190
   Yamada S, 2007, ENDOCRINOLOGY, V148, P2226, DOI 10.1210/en.2006-1529
   Yamada S, 2012, J NEUROENDOCRINOL, V24, P1234, DOI 10.1111/j.1365-2826.2012.02330.x
   ZIGMOND MJ, 1972, SCIENCE, V177, P1211
   ZINAMAN MJ, 1995, J CLIN ENDOCR METAB, V80, P2088, DOI 10.1210/jc.80.7.2088
   Zuure WA, 2013, J NEUROSCI, V33, P17874, DOI 10.1523/JNEUROSCI.2278-13.2013
NR 393
TC 0
Z9 0
U1 2
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040-4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD JUL
PY 2016
VL 6
IS 3
BP 1493
EP 1518
DI 10.1002/cphy.c150036
PG 26
WC Physiology
SC Physiology
GA DP1EB
UT WOS:000378232200012
PM 27347899
ER

PT J
AU James, N
   Liu, XC
   Bell, A
AF James, Noelle
   Liu, Xiaochen
   Bell, Alison
TI A fluorescence in situ hybridization (FISH) protocol for stickleback
   tissue
SO EVOLUTIONARY ECOLOGY RESEARCH
LA English
DT Article
DE fluorescence in situ hybridization; fluorescence methods; Gasterosteus
   aculeatus; gene expression; gene localization; in situ hybridization;
   RNA; threespine stickleback
ID THREESPINE STICKLEBACKS; PARALLEL EVOLUTION; PELVIC REDUCTION;
   EXPRESSION; EMBRYOS; RNAS
AB Background: Threespine stickleback are an important model for behaviour and evolutionary studies. A growing number of quantitative trait loci (QTL) and gene expression studies are identifying genes related to ecologically important traits in sticklebacks. In order to visualize the expression of candidate genes, we developed a fluorescence in situ hybridization (FISH) protocol.
   Methods: We present a protocol for FISH on fresh or flash-frozen dissected tissue, using either cryo-or paraffin embedding. The protocol covers probe design guidelines and synthesis, sample embedding, sectioning, and the hybridization process. The protocol is optimized for brain tissue. Key steps for modifying the protocol for other tissues are noted.
   Results: The FISH protocol resulted in specific labelling under all combinations of dissection and embedding conditions. Paraffin embedding preserved morphology better than cryo-embedding. We provide representative results showing the expression of glial fibrillary acidic protein (GFAP), oxytocin receptor (OXTR), and tyrosine hydroxylase (TH) in the brain.
C1 [James, Noelle; Bell, Alison] Univ Illinois, Neurosci Program, 505 South Goodwin Ave, Urbana, IL 61801 USA.
   [Liu, Xiaochen] Univ Illinois, Carl R Woese Inst Genom Biol, Urbana, IL USA.
   [Bell, Alison] Univ Illinois, Sch Integrat Biol, Urbana, IL USA.
RP James, N (reprint author), Univ Illinois, Neurosci Program, 505 South Goodwin Ave, Urbana, IL 61801 USA.
EM nholmes3@life.illinois.edu
FU NSF [IOS 1121980]; NIH [R01 GM082937]; UIUC; Simons Foundation
FX We thank Lisa Stubbs and Chris Seward for generous use of equipment and
   advice. Most imaging was done on the Zeiss Axiovert 200M from the Core
   Facilities at the Carl R. Woese Institute for Genomic Biology. Funding
   was provided by NSF (IOS 1121980), NIH (R01 GM082937), UIUC and the
   Simons Foundation.
CR Barroso-Chinea P, 2007, J NEUROSCI METH, V162, P119, DOI 10.1016/j.jneumeth.2006.12.017
   Chan YF, 2010, SCIENCE, V327, P302, DOI 10.1126/science.1182213
   Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239
   Eisel D, 2008, DIG APPL MANUAL NONR
   Greenwood AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137726
   Greenwood AK, 2013, CURR BIOL, V23, P1884, DOI 10.1016/j.cub.2013.07.058
   Kitano J, 2010, CURR BIOL, V20, P2124, DOI 10.1016/j.cub.2010.10.050
   Kuhn E., 2010, COLD SPRING HARB PRO, V2010
   Liu J, 2014, G3-GENES GENOM GENET, V4, P595, DOI 10.1534/g3.114.010389
   Miller CT, 2007, CELL, V131, P1179, DOI 10.1016/j.cell.2007.10.055
   Rittschof CC, 2014, P NATL ACAD SCI USA, V111, P17929, DOI 10.1073/pnas.1420369111
   Sanogo YO, 2012, P ROY SOC B-BIOL SCI, V279, P4929, DOI 10.1098/rspb.2012.2087
   Sanogo YO, 2011, BRAIN BEHAV EVOLUT, V77, P270, DOI 10.1159/000328221
   Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415
   TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   Zimmerman SG, 2013, NAT PROTOC, V8, P2158, DOI 10.1038/nprot.2013.136
NR 17
TC 1
Z9 1
U1 4
U2 4
PU EVOLUTIONARY ECOLOGY LTD
PI TUCSON
PA UNIV ARIZONA, 321 BIOSCIENCES WEST, TUCSON, AZ 85721 USA
SN 1522-0613
EI 1937-3791
J9 EVOL ECOL RES
JI Evol. Ecol. Res.
PD JUL
PY 2016
VL 17
IS 4
BP 603
EP 617
PG 15
WC Ecology; Evolutionary Biology; Genetics & Heredity
SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics &
   Heredity
GA DP0HA
UT WOS:000378168800009
ER

PT J
AU Hussien, NI
   Mousa, AM
AF Hussien, Noha I.
   Mousa, Ayman M.
TI Could nitric oxide be a mediator of action of oxytocin on myocardial
   injury in rats? (Biochemical, histological and immunohistochemical
   study)
SO GENERAL PHYSIOLOGY AND BIOPHYSICS
LA English
DT Article
DE Myocardial injury; Isoprenaline; Oxytocin; Atosiban; Nitric oxide;
   Apoptosis
ID CELL-DEATH; REPERFUSION INJURY; HEART-DISEASE; PROTECTION; INFARCTION;
   APOPTOSIS; PATHWAY
AB Oxytocin (OT) was revisited recently as a hormone of cardiovascular system with several new functions in cardiovascular regulation. But less is known about its role in acute myocardial injury (MI). The aim of our study was to investigate the possible protective effect of OT on the biochemical, histological and immunohistochemical changes of MI induced by isoprenaline (ISO) in adult male albino rats and studying the possible role of nitric oxide (NO) in its action. Forty male albino rats were divided into 5 groups: control rats (Group I), acute MI rats (Group II), rats pretreated with OT prior to induction of MI (Group III), rats injected with a combination of OT and atosiban (ATO, OT receptor antagonist) prior to induction of MI (Group IV). In Group V, a combination of OT and nitric oxide synthase inhibitor (L-NAME) were injected to the rats prior to induction of MI. The heart wall in all groups were taken and processed for histological, immunohistochemical, morpho-metrical and biochemical studies. We concluded that OT has antioxidant, anti-inflammatory and anti-apoptotic effects on MI and its effects is mediated through NO.
C1 [Hussien, Noha I.] Benha Univ, Benha Fac Med, Dept Physiol, Cairo, Egypt.
   [Mousa, Ayman M.] Benha Univ, Benha Fac Med, Dept Histol & Cell Biol, Cairo, Egypt.
   [Mousa, Ayman M.] Qassim Univ, Dept Basic Hlth Sci, Coll Appl Med Sci, Buraydah, Saudi Arabia.
RP Hussien, NI (reprint author), Benha Univ, Dept Physiol, Fac Med, Banha, Egypt.
EM drnohaibrahim79@gmail.com
CR Alizadeh AM, 2011, REGUL PEPTIDES, V167, P86, DOI 10.1016/j.regpep.2010.11.004
   Bae S., 2010, AM J PHYSIOL, V299, P1374
   Bancroft J. D., 2013, BANCROFTS THEORY PRA, P187
   Biondi-Zoccai GGL, 2004, INT J CARDIOL, V94, P105, DOI 10.1016/j.ijcard.2003.07.001
   BORIES PN, 1995, CLIN CHEM, V41, P904
   Buytaert E, 2006, AUTOPHAGY, V2, P238
   Cai L, 2002, DIABETES, V51, P1938, DOI 10.2337/diabetes.51.6.1938
   Palacios Callender M., 2004, P NATL ACAD SCI USA, V101, P7630
   Faghihi M, 2012, PEPTIDES, V37, P314, DOI 10.1016/j.peptides.2012.08.001
   Fariba H., 2015, HEART LUNG CIRC, V24, P86
   FORSTERMANN U, 1994, HYPERTENSION, V23, P1121
   Francis J., 2004, AM J PHYSIOL-HEART C, V286, P2264
   Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5
   Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI [10.1016/j.cpcardiol.2009.10.002, 10.1016/j.cpcardio1.2009.10.002]
   Gurgun C, 2008, INT J CARDIOL, V123, P102, DOI 10.1016/j.ijcard.2006.11.152
   Gutkowska J, 2014, BRAZ J MED BIOL RES, V47, P206, DOI 10.1590/1414-431X20133309
   Houshmand F, 2009, PEPTIDES, V30, P2301, DOI 10.1016/j.peptides.2009.09.010
   IWAMOTO K, 1987, J PHARMACOBIO-DYNAM, V10, P280
   John L. W., 2005, MEM I O CRUZ RIO DE, V100, P5
   Kewalramani G, 2009, CARDIOVASC RES, V84, P42, DOI 10.1093/cvr/cvp166
   Khatua TN, 2012, NITRIC OXIDE-BIOL CH, V27, P9, DOI 10.1016/j.niox.2012.03.004
   King J, 1965, PRACTICAL CLIN ENZYM
   Lee Y, 2009, APOPTOSIS, V14, P536, DOI 10.1007/s10495-008-0302-x
   Madhesh M., 2011, INDIAN J PHARM, V43, P516
   Kodidhela L. D., 2013, INT RES J PHARM, V5, P26
   Menaouar A, 2014, INT J CARDIOL, V175, P38, DOI 10.1016/j.ijcard.2014.04.174
   Moghimian M, 2012, STRESS, V15, P385, DOI 10.3109/10253890.2011.630436
   Ndiaye K, 2008, BIOL REPROD, V78, P786, DOI 10.1095/biolreprod.107.065938
   Offerman E. L., 1972, J HAEMATOL, V23, P713
   OKINAKA S, 1961, ARCH NEUROL-CHICAGO, V4, P520
   Ovize M, 2010, CARDIOVASC RES, V87, P406, DOI 10.1093/cvr/cvq129
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Paul-Clark MJ, 2003, J IMMUNOL, V171, P3245
   Rajadurai M, 2006, J BIOCHEM MOL TOXIC, V20, P191, DOI 10.1002/jbt.20136
   Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297
   Szeto A., 2008, AM J PHYSIOL-ENDOC M, V295, P1495
   Szeto A, 2013, PSYCHONEUROENDOCRINO, V38, P685, DOI 10.1016/j.psyneuen.2012.08.009
   Tawfik MK, 2010, EUR REV MED PHARMACO, V14, P499
   Upaganlawar Aman, 2010, J Pharmacol Pharmacother, V1, P24, DOI 10.4103/0976-500X.64532
   Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111
   Wsol A., 2008, J PHYSIOL PHARMACOL, V8, P123
NR 41
TC 0
Z9 0
U1 0
U2 0
PU GENERAL PHYSIOL AND BIOPHYSICS
PI BRATISLAVA
PA INST OF MOLEC PHYSIOL GENETICS SLOVAK ACAD OF SCI VLARSKA 5, 83334
   BRATISLAVA, SLOVAKIA
SN 0231-5882
EI 1338-4325
J9 GEN PHYSIOL BIOPHYS
JI Gen. Physiol. Biophys.
PD JUL
PY 2016
VL 35
IS 3
BP 353
EP 362
DI 10.4149/gpb_2015049
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Physiology
SC Biochemistry & Molecular Biology; Biophysics; Physiology
GA DO9JJ
UT WOS:000378102200011
PM 27226256
ER

PT J
AU Pruimboom, L
   Reheis, D
AF Pruimboom, L.
   Reheis, D.
TI Intermittent drinking, oxytocin and human health
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Thirst; Addiction; Craving; Collaboration; Health; Evolution; Oxytocin
ID ALLOSTATIC LOAD; TIME-COURSE; HYDRATION; DISEASE; STRESS; BEHAVIOR;
   NEUROBIOLOGY; EXPRESSION; SYSTEM; LOVE
AB Looking at a waterhole, it is surprising that so many animals share the same space without visible signs of anxiety or aggression. Although waterholes are the preferred feeding locations of large carnivores, water holes are shared by all type of herbivores of all sizes and shapes, including elephants. Recent research shows that the homeostatic disturbances leading to the "thirst feeling" not only activate specific substances regulating water and mineral household, but also the "trust and love" hormone oxytocin, while decreasing the production of the typical stress hormone cortisol. People using drugs, seem to be in search for oxytocin, as evidenced in studies with individuals on drugs such as ecstasy and gamma-hydroxybyturate. Hot environment, drought and increased sweating also activate specific oxytocin-producing parts of the hypothalamus, just as breastfeeding does in mother and infant. Water homeostasis is the only allostatic system activating trust neuro-anatomy and we suggest that this is due to the fact that all animals depend on water, whereas food type is species specific. Our hypothesis; regulating drinking behaviour through intermittent bulk drinking could increase oxytocin signalling, recover human trust and increase health by down-regulation of stress axis activity and inflammatory activity of the immune system. Intermittent bulk drinking should be defined as water (including tea and coffee) drinking up to a feeling of satiety and regulated by a mild feeling of thirst. This would mean that people would not drink less quantity but less frequently and that's how all animals, but also human newborns behave. It is the latter group, which is probably the only group of humans with a normal fluid homeostasis. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Pruimboom, L.; Reheis, D.] Natura Fdn, Edisonstr 66, NL-3281 NC Numansdorp, Netherlands.
   [Pruimboom, L.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, POB 30-001, NL-9700 RB Groningen, Netherlands.
RP Pruimboom, L (reprint author), Burgemeester Marijnenlaan 98, NL-2585 DR The Hague, Netherlands.
EM cpni.pruimboom@icloud.com
OI Pruimboom, Leo/0000-0003-2955-4675
CR Arueti M, 2013, J COGN NEUROSCI
   Barraza JA, 2009, ANN NY ACAD SCI, V1167, P182, DOI 10.1111/j.1749-6632.2009.04504.x
   Benarroch EE, 2013, NEUROLOGY, V80, P1521, DOI 10.1212/WNL.0b013e31828cfb15
   Bhattarai N, 2010, BMJ CASE REP, V2010
   Biswas M, 2007, POSTGRAD MED J, V83, P373, DOI 10.1136/pgmj.2006.056515
   Blecha L, 2010, ARCH PEDIATRIE, V17, P191, DOI 10.1016/j.arcped.2009.09.018
   Blum K, 2011, IIOAB J, V2
   Bobakova D, 2012, ADDICT BEHAV, V37, P1063, DOI 10.1016/j.addbeh.2012.04.014
   Calay ES, 2013, NAT MED, V19, P265, DOI 10.1038/nm.3114
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Cevenini E, 2013, CURR OPIN CLIN NUTR, V16, P14, DOI 10.1097/MCO.0b013e32835ada13
   Charnetski CJ, 2004, PSYCHOL REP, V95, P1087, DOI 10.2466/pr0.95.3f.1087-1091
   Cloninger C Robert, 2013, Mens Sana Monogr, V11, P16, DOI 10.4103/0973-1229.109288
   Coelho JS, 2008, BEHAV RES THER, V46, P219, DOI 10.1016/j.brat.2007.11.004
   CORNELL CE, 1989, PHYSIOL BEHAV, V45, P695, DOI 10.1016/0031-9384(89)90281-3
   da Silva AL, 2013, ALCOHOL ALCOHOLISM, V48, P495, DOI 10.1093/alcalc/agt040
   Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019
   Egger G, 2011, OBES REV, V12, P339, DOI 10.1111/j.1467-789X.2010.00795.x
   Egger Garry, 2012, Prev Chronic Dis, V9, pE95
   Epstein JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003955
   Esch T, 2004, NEUROENDOCRINOL LETT, V25, P235
   Esch T, 2005, NEUROENDOCRINOL LETT, V26, P175
   Esch T, 2011, MED SCI MONITOR, V17, pRA65
   Esch T, 2010, NEUROENDOCRINOL LETT, V31, P19
   da Silveira LTG, 2007, CELL MOL NEUROBIOL, V27, P575, DOI 10.1007/s10571-007-9144-2
   Gilbert P, 2006, CLIN PSYCHOL PSYCHOT, V13, P353, DOI 10.1002/cpp.507
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goodson JL, 2013, PSYCHONEUROENDOCRINO, V38, P465, DOI 10.1016/j.psyneuen.2012.12.005
   GOPINATHAN PM, 1988, ARCH ENVIRON HEALTH, V43, P15
   Gordis EB, 2006, PSYCHONEUROENDOCRINO, V31, P976, DOI 10.1016/j.psyneuen.2006.05.010
   Grandjean A, 2007, J AM COLL NUTR, V26, P549, DOI DOI 10.1080/07315724.2007.10719657
   Jankowski M, 2010, BASIC RES CARDIOL, V105, P205, DOI 10.1007/s00395-009-0076-5
   Koerner BI., 2010, WIRED, V18
   Korte SM, 2009, VET J, V182, P378, DOI 10.1016/j.tvjl.2009.08.023
   Korte SM, 2005, NEUROSCI BIOBEHAV R, V29, P3, DOI 10.1016/j.neubiorev.2004.08.009
   Krause EG, 2011, J NEUROSCI, V31, P5470, DOI 10.1523/JNEUROSCI.6078-10.2011
   Kubera Britta, 2012, Front Neuroenergetics, V4, P4, DOI 10.3389/fnene.2012.00004
   Lindseth PD, 2013, MIL MED, V178, P792, DOI 10.7205/MILMED-D-13-00013
   Malmkvist J, 2009, J ANIM SCI, V87, P2796, DOI 10.2527/jas.2008-1592
   Manz F, 2007, J AM COLL NUTR, V26, p562S
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   Millar JR, 2011, PSYCHIATR REHABIL J, V35, P141, DOI 10.2975/35.2.2011.141.144
   Millard-Stafford M, 2012, NUTR REV, V70, pS147, DOI 10.1111/j.1753-4887.2012.00527.x
   Mullis K, 2013, BRAIN RES, V1513, P85, DOI 10.1016/j.brainres.2013.03.026
   Murphy D, 2012, J NEUROENDOCRINOL, V24, P539, DOI 10.1111/j.1365-2826.2011.02241.x
   Nakamura K, 2008, BEHAV BRAIN RES, V187, P442, DOI 10.1016/j.bbr.2007.10.002
   Nettle D, 2013, BEHAV ECOL
   Olszewski PK, 2010, PHARMACOL BIOCHEM BE, V97, P47, DOI 10.1016/j.pbb.2010.05.026
   Olszewski PK, 2010, ENDOCRINOLOGY, V151, P4736, DOI 10.1210/en.2010-0151
   Perez-Leighton CE, 2012, AM J PHYSIOL-ENDOC M, V303, pE865, DOI 10.1152/ajpendo.00119.2012
   Perillan C, 2012, PSICOTHEMA, V24, P422
   Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005
   Pittman D. Q. J., 2011, J NEUROENDOCRINOL, V23, P1296, DOI [10.1111/j.1365-2826.2011.02176.x, DOI 10.1111/J.1365-2826.2011.02176.X]
   Popkin BM, 2010, NUTR REV, V68, P439, DOI 10.1111/j.1753-4887.2010.00304.x
   Prescott JW, 2005, PSYCHOTHERAPY POLITI, V3, P194, DOI 10.1002/ppi.6
   Pruimboom L, 2011, MED HYPOTHESES, V77, P708, DOI 10.1016/j.mehy.2011.07.022
   Qiu J, 2011, ENDOCRINOLOGY, V152, P3483, DOI 10.1210/en.2011-1044
   Raudino A, 2013, J ADOLESCENCE, V36, P331, DOI 10.1016/j.adolescence.2012.12.002
   Ruiz-Nunez B, 2013, J NUTR BIOCH
   Scott-Phillips C, 2011, PERSPECT PSYCHOL SCI, V6, P38
   Stein DJ, 2009, CNS SPECTRUMS, V14, P239
   Sterns RH, 2009, SEMIN NEPHROL, V29, P282, DOI 10.1016/j.semnephrol.2009.03.002
   Straub RH, 2012, J MOL MED, V90, P523, DOI 10.1007/s00109-012-0861-8
   Thornton SN, 2010, PHYSIOL BEHAV, V100, P15, DOI 10.1016/j.physbeh.2010.02.026
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   Valeix M, 2007, OECOLOGIA, V153, P739, DOI 10.1007/s00442-007-0764-5
   Valtin H, 2002, AM J PHYSIOL-REG I, V283, pR993, DOI 10.1152/ajpregu.00365.2002
   Veening JG, 2013, NEUROSCI BIOBEHAV RE
   Ventegodt Soren, 2004, ScientificWorldJournal, V4, P362
   Wallner B, 2009, PROG NEURO-PSYCHOPH, V33, P391, DOI 10.1016/j.pnpbp.2009.02.006
   Winslow JT, 2005, INT J DEV NEUROSCI, V23, P245, DOI 10.1016/j.ijdevneu.2004.03.003
   Young KA, 2010, FRONT NEUROENDOCRINO
NR 72
TC 0
Z9 0
U1 14
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2016
VL 92
BP 80
EP 83
DI 10.1016/j.mehy.2016.04.043
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DP0LZ
UT WOS:000378182600021
PM 27241263
ER

PT J
AU Kim, TK
   Lee, JE
   Kim, JE
   Park, JY
   Choi, J
   Kim, H
   Lee, EH
   Han, PL
AF Kim, Tae-Kyung
   Lee, Jung-Eun
   Kim, Ji-Eun
   Park, Jin-Young
   Choi, Juli
   Kim, Hannah
   Lee, Eun-Hwa
   Han, Pyung-Lim
TI G9a-Mediated Regulation of OXT and AVP Expression in the Basolateral
   Amygdala Mediates Stress-Induced Lasting Behavioral Depression and Its
   Reversal by Exercise
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Exercise; Depression; BLA; G9a; Dimethylation; Oxytocin; Vasopressin
ID LONG-TERM POTENTIATION; MAJOR DEPRESSION; IN-VIVO; ARGININE-VASOPRESSIN;
   OXYTOCIN RECEPTOR; PHYSICAL-ACTIVITY; SOCIAL BEHAVIORS; KNOCKOUT MOUSE;
   ANIMAL-MODELS; RAT MODEL
AB Chronic stress produces behavioral depression. Conversely, physical exercise is held to be beneficial in the treatment of depression. Although genomic mechanisms are likely involved in these behavioral changes, underlying mechanisms are not clearly understood. In the present study, we investigated whether stress effects and their reversal by exercise occur via genomic mechanisms in the amygdala, a core part of the limbic system important for regulating mood states. Mice treated with chronic restraint showed lasting depression-like behaviors, which were counteracted by treatment with scheduled forceful exercise. Microarray analysis identified a number of genes whose expression in the amygdala was either upregulated or downregulated after repeated stress, and these changes were reversed by exercise. Of these genes, the neuropeptides oxytocin (OXT) and arginine vasopressin (AVP) were selected as representative stress-induced and exercise-responded genes in the BLA. Stereotaxic injection of OXT or AVP receptor agonists within the BLA in normal mice produced depression-like behaviors, whereas small interfering RNA (siRNA)-mediated suppression of the OXT or AVP transcripts in the BLA was sufficient to block stress-induced depressive behaviors. Stress-induced depression-like behaviors were accompanied by a global reduction of G9a histone methyltransferase and H3K9me2 at the OXT and AVP promoters. Conversely, repeated exercise increased the levels of G9a and H3K9me2 at the OXT and AVP promoters in the BLA, which was associated with the suppression of OXT and AVP expressions. These results identify G9a-induced histone methylation at the OXT and AVP promoters in the BLA as a mechanism for mediating stress-induced lasting behavioral depression and its reversal by exercise.
C1 [Kim, Tae-Kyung; Lee, Jung-Eun; Kim, Ji-Eun; Park, Jin-Young; Choi, Juli; Kim, Hannah; Lee, Eun-Hwa; Han, Pyung-Lim] Ewha Womans Univ, Dept Brain & Cognit Sci, 11-1 Daehyun Dong, Seoul 120750, South Korea.
   [Han, Pyung-Lim] Ewha Womans Univ, Dept Chem & Nano Sci, Seoul, South Korea.
   [Han, Pyung-Lim] Ewha Womans Univ, Brain Dis Res Inst, Seoul, South Korea.
RP Han, PL (reprint author), Ewha Womans Univ, Dept Brain & Cognit Sci, 11-1 Daehyun Dong, Seoul 120750, South Korea.; Han, PL (reprint author), Ewha Womans Univ, Dept Chem & Nano Sci, Seoul, South Korea.; Han, PL (reprint author), Ewha Womans Univ, Brain Dis Res Inst, Seoul, South Korea.
EM plhan@ewha.ac.kr
OI Han, Pyung-Lim/0000-0002-1735-6746
FU Ministry of Science, ICT and Future Planning, Republic of Korea
   [2012R1A2A1A03010177]
FX This research was supported by a grant (2012R1A2A1A03010177) from the
   Ministry of Science, ICT and Future Planning, Republic of Korea.
CR ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   Babyak M, 2000, PSYCHOSOM MED, V62, P633
   Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042
   Caldwell HK, 2008, PROG BRAIN RES, V170, P65, DOI 10.1016/S0079-6123(08)00406-8
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200
   Cooney GM, 2013, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD004366.PUB6
   Covington HE, 2011, NEURON, V71, P656, DOI 10.1016/j.neuron.2011.06.007
   Danielsson L, 2013, PHYSIOTHER THEOR PR, V29, P573, DOI 10.3109/09593985.2013.774452
   Davis S, 2000, J NEUROSCI, V20, P4563
   Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Greenwood BN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046118
   Griebel G, 2002, P NATL ACAD SCI USA, V99, P6370, DOI 10.1073/pnas.092012099
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Josefsson T, 2014, SCAND J MED SCI SPOR, V24, P259, DOI 10.1111/sms.12050
   Kim KS, 2008, J NEUROCHEM, V107, P105, DOI 10.1111/j.1471-4159.2008.05592.x
   Kim KS, 2009, J NEUROSCI RES, V87, P2983, DOI 10.1002/jnr.22119
   Kim TK, 2015, ENDOCRINOL METAB, V30, pe2
   Kmietowicz Z, 2013, BMJ-BRIT MED J, V13, P347
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   Krishnan V., 2011, AM J PSYCHIAT, V167, P1305
   Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu
   Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Lee HJ, 2008, ENDOCRINOLOGY, V149, P3256, DOI 10.1210/en.2007-1710
   Lee KW, 2009, J NEUROCHEM, V108, P165, DOI 10.1111/j.1471-4159.2008.05769.x
   Mammen G, 2013, AM J PREV MED, V45, P649, DOI 10.1016/j.amepre.2013.08.001
   Mlynarik M, 2007, HORM BEHAV, V51, P395, DOI 10.1016/j.yhbeh.2006.12.007
   Murray EA, 2011, BIOL PSYCHIAT, V69, pE43, DOI 10.1016/j.biopsych.2010.09.041
   Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI 10.1038/nn.2647
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Park Jin-Young, 2014, Exp Neurobiol, V23, P215, DOI 10.5607/en.2014.23.3.215
   Peng S, 2010, INT J MOL SCI, V11, P222, DOI 10.3390/ijms11010222
   Raveendran R, 2009, J NEUROCHEM, V110, P92, DOI 10.1111/j.1471-4159.2009.06108.x
   Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003
   Schaefer A, 2009, NEURON, V64, P678, DOI 10.1016/j.neuron.2009.11.019
   Seo JS, 2012, J NEUROSCI, V32, P9690, DOI 10.1523/JNEUROSCI.0794-12.2012
   Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcb.2005.01.006
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Strohle A, 2009, J NEURAL TRANSM, V116, P777, DOI 10.1007/s00702-008-0092-x
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad989402
   Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192
   Thomas MG, 2004, NAT REV NEUROSCI, V5, P173
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   vanLonden L, 1997, NEUROPSYCHOPHARMACOL, V17, P284, DOI 10.1016/S0893-133X(97)00054-7
   Vialou V, 2013, ANNU REV PHARMACOL, V53, P59, DOI 10.1146/annurev-pharmtox-010611-134540
   Viviani D, 2008, PROG BRAIN RES, V170, P207, DOI 10.1016/S0079-6123(08)00418-4
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   Yan Y, 2014, NEUROPEPTIDES, V48, P83, DOI 10.1016/j.npep.2014.01.001
   Yang J, 2012, NEUROPEPTIDES, V46, P141, DOI 10.1016/j.npep.2012.03.003
   Young WS, 2003, NEUROENDOCRINOLOGY, V78, P185, DOI 10.1159/000073702
   Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100
NR 55
TC 1
Z9 1
U1 8
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JUL
PY 2016
VL 53
IS 5
BP 2843
EP 2856
DI 10.1007/s12035-015-9160-z
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA DO7AU
UT WOS:000377935400009
PM 25863961
ER

PT J
AU Schneider-Hassloff, H
   Straube, B
   Jansen, A
   Nuscheler, B
   Wemken, G
   Witt, SH
   Rietschel, M
   Kircher, T
AF Schneider-Hassloff, H.
   Straube, B.
   Jansen, A.
   Nuscheler, B.
   Wemken, G.
   Witt, S. H.
   Rietschel, M.
   Kircher, T.
TI Oxytocin receptor polymorphism and childhood social experiences shape
   adult personality, brain structure and neural correlates of mentalizing
SO NEUROIMAGE
LA English
DT Article
DE rs53576; Attachment; Alexithymia; fMRI; VBM; Social cognition;
   Theory-of-mind
ID TORONTO-ALEXITHYMIA-SCALE; INTRANASAL OXYTOCIN; ATTACHMENT STYLE; GENE
   OXTR; MATERNAL-CARE; GENDER-DIFFERENCES; PLASMA OXYTOCIN;
   SELF-AWARENESS; HUMAN AMYGDALA; HUMANS
AB Introduction: The oxytocin system is involved in human social behavior and social cognition such as attachment, emotion recognition and mentalizing (i.e. the ability to represent mental states of oneself and others). It is shaped by social experiences in early life, especially by parent-infant interactions. The single nucleotid polymorphism rs53576 in the oxytocin receptor (OXTR) gene has been linked to social behavioral phenotypes.
   Method: In 195 adult healthy subjects we investigated the interaction of OXTR rs53576 and childhood attachment security (CAS) on the personality traits "adult attachment style" and "alexithymia" (i.e. emotional self-awareness), on brain structure (voxel-based morphometry) and neural activation (fMRI) during an interactive mentalizing paradigm (prisoner's dilemma game; subgroup: n = 163).
   Results: We found that in GG-homozygotes, but not in A-allele carriers, insecure childhood attachment is - in adulthood -associated with a) higher attachment-related anxiety and alexithymia, b) higher brain gray matter volume of left amygdala and lower volumes in right superior parietal lobule (SPL), left temporal pole (TP), and bilateral frontal regions, and c) higher mentalizing-related neural activity in bilateral TP and precunei, and right middle and superior frontal gyri. Interaction effects of genotype and CAS on brain volume and/ or function were associated with individual differences in alexithymia and attachment-related anxiety. Interactive effects were in part sexually dimorphic.
   Conclusion: The interaction of OXTR genotype and CAS modulates adult personality as well as brain structure and function of areas implicated in salience processing and mentalizing. Rs53576 GG-homozygotes are partially more susceptible to childhood attachment experiences than A-allele carriers. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Schneider-Hassloff, H.; Straube, B.; Jansen, A.; Nuscheler, B.; Kircher, T.] Univ Marburg, Dept Psychiat & Psychotherapy, Rudolf Bultmann St 8, D-35039 Marburg, Germany.
   [Wemken, G.] Univ Marburg, Inst Psychol, Social Psychol, D-35039 Marburg, Germany.
   [Witt, S. H.; Rietschel, M.] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Bergheimer Str 58, D-69115 Heidelberg, Germany.
   [Schneider-Hassloff, H.] Univ Ulm, ZNL TransferCtr Neurosci & Learning, Pk St 11, D-89073 Ulm, Germany.
RP Schneider-Hassloff, H (reprint author), Univ Marburg, Dept Psychiat & Psychotherapy, Rudolf Bultmann St 8, D-35039 Marburg, Germany.; Schneider-Hassloff, H (reprint author), Univ Ulm, ZNL TransferCtr Neurosci & Learning, Pk St 11, D-89073 Ulm, Germany.
EM schneid5@staff.uni-marburg.de
FU LOEWE initiative - State of Hesse; DFG [FOR 2107, KI 588/14-1, JA
   1890/7-1, RI 908/11-1, WI 3439/3-1, KI 588/16-1, STR 1146/4-1, STR
   1146/8-1]
FX We thank Ulrich Wagner for valuable input on theoretical background and
   on the experimental setup in the early project phase. We thank Jens
   Sommer and Mechthild Wallnig for technical support in the preparation of
   and during the fMRI data acquisition. We further thank Rebecca Drexler,
   Johannes Krautheim and Sabine Frenzel for their assistance during data
   collection. This research was supported by the LOEWE initiative funded
   by the State of Hesse. TK, AJ, MR, BS and SW are in part supported by
   the DFG (FOR 2107: KI 588/14-1, JA 1890/7-1, RI 908/11-1, WI 3439/3-1;
   KI 588/16-1; STR 1146/4-1 and STR 1146/8-1).
CR Abu-Akel A, 2011, NEUROPSYCHOLOGIA, V49, P2971, DOI 10.1016/j.neuropsychologia.2011.07.012
   Ackenheil M., 1999, MINI MINIINTERNATION
   Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5
   Andari E., 2012, CEREB CORTEX, P1
   Bach M, 1996, PSYCHOTHER PSYCH MED, V46, P23
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Bales KL, 2007, NEUROSCIENCE, V144, P38, DOI 10.1016/j.neuroscience.2006.09.009
   Bales KL, 2012, HORM BEHAV, V61, P313, DOI 10.1016/j.yhbeh.2011.12.013
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   Belsky J, 2009, MOL PSYCHIATR, V14, P746, DOI 10.1038/mp.2009.44
   Benetti S, 2010, HUM BRAIN MAPP, V31, P1482, DOI 10.1002/hbm.20954
   Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Bowlby J., 1969, ATTACHMENT
   Bradley B, 2013, EUR J PSYCHOTRAUMATO, V4, P1
   Bradley B, 2011, DEV PSYCHOPATHOL, V23, P439, DOI 10.1017/S0954579411000162
   Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Carter CS, 2009, DEV NEUROSCI-BASEL, V31, P332, DOI 10.1159/000216544
   Cattaneo L, 2009, ARCH NEUROL-CHICAGO, V66, P557, DOI 10.1001/archneurol.2009.41
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Champagne FA, 2009, NEUROSCI BIOBEHAV R, V33, P593, DOI 10.1016/j.neubiorev.2007.10.009
   Chang WH, 2014, PSYCHONEUROENDOCRINO, V47, P212, DOI 10.1016/j.psyneuen.2014.05.020
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   COLLINS NL, 1990, J PERS SOC PSYCHOL, V58, P644, DOI 10.1037/0022-3514.58.4.644
   Cook R, 2013, PSYCHOL SCI, V24, P723, DOI 10.1177/0956797612463582
   Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755
   Costa B, 2009, PSYCHONEUROENDOCRINO, V34, P1506, DOI 10.1016/j.psyneuen.2009.05.006
   Crawford TN, 2007, EUR J PERSONALITY, V21, P191, DOI 10.1002/per.602
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   Dempfle A, 2008, EUR J HUM GENET, V16, P1164, DOI 10.1038/ejhg.2008.106
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Donges US, 2012, NEUROSCIENCE, V220, P149, DOI 10.1016/j.neuroscience.2012.06.036
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034
   Fonagy P, 2007, J CHILD PSYCHOL PSYC, V48, P288, DOI 10.1111/j.1469-7610.2007.01727.x
   Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x
   Fries ABW, 2005, P NATL ACAD SCI USA, V102, P17237, DOI 10.1073/pnas.0504767102
   Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6
   Gamer M, 2010, P NATL ACAD SCI USA, V107, P9400, DOI 10.1073/pnas.1000985107
   Gillath O, 2008, PERS SOC PSYCHOL B, V34, P1396, DOI [10.1177/0146167208321484, 10.1177/1046167208321484]
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GRIFFIN D, 1994, J PERS SOC PSYCHOL, V67, P430, DOI 10.1037//0022-3514.67.3.430
   Grossmann K, 2004, BINDUNGEN GEFUGE PSY
   Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008
   Hammen C, 2015, J PERS DISORD, V29, P177, DOI 10.1521/pedi_2014_28_152
   Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112
   Henson R., 2005, ANOVAS SPM SECONDARY, P1
   HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383
   Hostinar CE, 2014, DEV PSYCHOPATHOL, V26, P465, DOI 10.1017/S0954579414000066
   Insausti R., 2012, HUMAN NERVOUS SYSTEM, P896
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Jack A, 2012, FRONT HUM NEUROSCI, V6, P1
   Karlsson H, 2008, BRIT J PSYCHIAT, V192, P32, DOI 10.1192/bjp.bp.106.034728
   Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910
   Kircher T, 2009, NEUROSCI LETT, V454, P176, DOI 10.1016/j.neulet.2009.03.026
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krach S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002597
   Kramer KM, 2004, CAN J ZOOL, V82, P1194, DOI 10.1139/Z04-098
   Kriegeskorte N, 2010, J CEREBR BLOOD F MET, V30, P1551, DOI 10.1038/jcbfm.2010.86
   Krueger F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00004
   Krug A, 2010, NEUROIMAGE, V53, P985, DOI 10.1016/j.neuroimage.2009.12.062
   Kumsta R, 2013, FRONT NEUROSCI, V7, P1
   Kurdek LA, 2002, J SOC PERS RELAT, V19, P811, DOI 10.1177/0265407502196005
   Kusui C, 2001, BIOCHEM BIOPH RES CO, V289, P681, DOI 10.1006/bbrc.2001.6024
   Lemche E, 2004, PSYCHOTHER PSYCHOSOM, V73, P366, DOI 10.1159/000080390
   Levant RF, 2009, PSYCHOL MEN MASCULIN, V10, P190, DOI 10.1037/a0015652
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   Lindquist KA, 2012, BEHAV BRAIN SCI, V35, P121, DOI 10.1017/S0140525X11000446
   Lucht MJ, 2013, NORD J PSYCHIAT, V67, P15, DOI 10.3109/08039488.2012.700731
   Lucht MJ, 2009, PROG NEURO-PSYCHOPH, V33, P860, DOI 10.1016/j.pnpbp.2009.04.004
   Lukas M, 2010, NEUROPHARMACOLOGY, V58, P78, DOI 10.1016/j.neuropharm.2009.06.020
   Luminet O, 2006, J RES PERS, V40, P713, DOI 10.1016/j.jrp.2005.09.001
   Luminet O, 2011, BIOL PSYCHOL, V87, P401, DOI 10.1016/j.biopsycho.2011.05.005
   Mar RA, 2011, ANNU REV PSYCHOL, V62, P103, DOI 10.1146/annurev-psych-120709-145406
   McInnis O.A., 2015, FRONT PSYCHOL, V6, P1
   McQuaid RJ, 2015, SOC COGN AFFECT NEUR, V10, P1153, DOI 10.1093/scan/nsu166
   McQuaid RJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00128
   Meinlschmidt G, 2007, BIOL PSYCHIAT, V61, P1109, DOI 10.1016/j.biopsych.2006.09.007
   Meins E, 1998, SOC DEV, V7, P1, DOI 10.1111/1467-9507.00047
   Mikulincer M., 2007, ATTACHMENT ADULTHOOD
   Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0
   Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1
   Moriguchi Y, 2009, HUM BRAIN MAPP, V30, P2063, DOI 10.1002/hbm.20653
   Moriguchi Y, 2006, NEUROIMAGE, V32, P1472, DOI 10.1016/j.neuroimage.2006.04.186
   Neumann E., 2002, Z FAM, V3, P234
   O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052
   Olson IR, 2013, SOC COGN AFFECT NEUR, V8, P123, DOI 10.1093/scan/nss119
   Paulus FM, 2013, HUM BRAIN MAPP, V34, P304, DOI 10.1002/hbm.21434
   PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515
   Quirin M, 2010, SOC COGN AFFECT NEUR, V5, P39, DOI 10.1093/scan/nsp042
   Raby KL, 2013, J CHILD PSYCHOL PSYC, V54, P1223, DOI 10.1111/jcpp.12093
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Rilling JK, 2004, NEUROIMAGE, V22, P1694, DOI 10.1016/j.neuroimage.2004.04.015
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Ross L.A., 2010, NEUROIMAGE, V49, P1
   Savaskan E, 2008, PSYCHONEUROENDOCRINO, V33, P368, DOI 10.1016/j.psyneuen.2007.12.004
   Schmahmann JD, 2007, CEREBELLUM, V6, P254, DOI 10.1080/14734220701490995
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   SIMPSON JA, 1992, J PERS SOC PSYCHOL, V62, P434, DOI 10.1037/0022-3514.62.3.434
   Skuse DH, 2009, TRENDS COGN SCI, V13, P27, DOI 10.1016/j.tics.2008.09.007
   Skuse D. H., 2011, PEDIATR RES, V69, p85R, DOI [10.1203/PDR.0b013e318212f562, DOI 10.1203/PDR.0B013E318212F562]
   Smeltzer MD, 2006, NEUROSCI LETT, V394, P146, DOI 10.1016/j.neulet.2005.10.019
   Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928
   Stellmacher J., AUTHORITARIANI UNPUB
   Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008
   Symons DK, 2000, SOC DEV, V9, P3, DOI 10.1111/1467-9507.00108
   Tops M, 2007, PSYCHOPHYSIOLOGY, V44, P444, DOI 10.1111/j.1469-8986.2007.00510.x
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789
   Vrticka P, 2012, SOC NEUROSCI-UK, V7, P473, DOI 10.1080/17470919.2011.647410
   Vrticka P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002868
   Ward MJ, 2006, ATTACH HUM DEV, V8, P327, DOI 10.1080/14616730601048241
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Xu GF, 2009, BRAIN, V132, P383, DOI 10.1093/brain/awn254
   Zak PJ, 2005, HORM BEHAV, V48, P522, DOI 10.1016/j.yhbeh.2005.07.009
   Zhang TY, 2010, ANNU REV PSYCHOL, V61, P439, DOI 10.1146/annurev.psych.60.110707.163625
NR 131
TC 1
Z9 1
U1 14
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD JUL 1
PY 2016
VL 134
BP 671
EP 684
DI 10.1016/j.neuroimage.2016.04.009
PG 14
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DO8PP
UT WOS:000378045900062
PM 27109357
ER

PT J
AU Bernal, A
   Mahia, J
   Puerto, A
AF Bernal, Antonio
   Mahia, Javier
   Puerto, Amadeo
TI Animal models of Central Diabetes Insipidus: Human relevance of acquired
   beyond hereditary syndromes and the role of oxytocin
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Brattleboro rat; Hereditary and traumatic diabetes insipidus; Arginine
   vasopressin; Oxytocin; Water intake; Urine volume; Natriuresis;
   Polydipsia; Synergic hormonal effects
ID ATRIAL-NATRIURETIC-PEPTIDE; CORTICOTROPIN-RELEASING HORMONE; POSTERIOR
   PITUITARY-HORMONES; MEDIAN-EMINENCE POLYDIPSIA; C-FOS EXPRESSION;
   BRATTLEBORO RATS; COLLECTING DUCT; WATER-INTAKE; ARGININE-VASOPRESSIN;
   OSMOTIC STIMULATION
AB The aim of this study was to review different animal models of Central Diabetes Insipidus, a neurobiological syndrome characterized by the excretion of copious amounts of diluted urine (polyuria), a consequent water intake (polydipsia), and a rise in the serum sodium concentration (hypernatremia). In rodents, Central Diabetes Insipidus can be caused by genetic disorders (Brattleboro rats) but also by various traumatic/surgical interventions, including neurohypophysectomy, pituitary stalk compression, hypophysectomy, and median eminence lesions. Regardless of its etiology, Central Diabetes Insipidus affects the neuroendocrine system that secretes arginine vasopressin, a neurohormone responsible for antidiuretic functions that acts trough the renal system. However, most Central Diabetes Insipidus models also show disorders in other neurobiological systems, specifically in the secretion of oxytocin, a neurohormone involved in body sodium excretion.
   Although the hydromineral behaviors shown by the different Central Diabetes Insipidus models have usually been considered as very similar, the present review highlights relevant differences with respect to these behaviors as a function of the individual neurobiological systems affected. Increased understanding of the relationship between the neuroendocrine systems involved and the associated hydromineral behaviors may allow appropriate action to be taken to correct these behavioral neuroendocrine deficits. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Bernal, Antonio; Mahia, Javier; Puerto, Amadeo] Univ Granada, Dept Psychobiol & Mind, Brain & Behav Res Ctr CIMCYC, Granada 18071, Spain.
RP Bernal, A (reprint author), Dept Psychobiol, Campus Cartuja S-N, Granada 18071, Spain.
EM antoniobernal@ugr.es
FU University of Granada; Spanish Ministry of Education and Culture
   (national R+D Plan) [PSI2010-17400]
FX This study was supported in part by the University of Granada and
   Spanish Ministry of Education and Culture (national R+D Plan
   PSI2010-17400). The authors are grateful to Richard Davies for his
   assistance with the English version of this paper.
CR Adams Jessica R, 2006, Pituitary, V9, P93, DOI 10.1007/s11102-006-9276-2
   Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107
   ANDERSEN SE, 1992, ACTA PHYSIOL SCAND, V145, P267, DOI 10.1111/j.1748-1716.1992.tb09364.x
   Antunes-Rodrigues J, 2004, PHYSIOL REV, V84, P169, DOI 10.1152/physrev.00017.2003
   ANTUNESRODRIGUES J, 1991, P NATL ACAD SCI USA, V88, P2956, DOI 10.1073/pnas.88.7.2956
   Armstrong W. E., 2014, RAT NERVOUS SYSTEM, P369
   AUBRY RH, 1965, J CLIN ENDOCR METAB, V25, P1481
   Babey M, 2011, NAT REV ENDOCRINOL, V7, P701, DOI 10.1038/nrendo.2011.100
   Babina AV, 2014, B EXP BIOL MED+, V156, P605, DOI 10.1007/s10517-014-2405-4
   Bacic A, 1999, MIL MED, V164, P214
   BAKKER HR, 1976, J ENDOCRINOL, V69, P149, DOI 10.1677/joe.0.0690149
   Ball S., 2005, MEDICINE, V33, P18, DOI 10.1383/medc.2005.33.11.18
   BALMENT RJ, 1984, J PHYSIOL-LONDON, V352, P517
   BALMENT RJ, 1980, J PHYSIOL-LONDON, V308, P439
   BALMENT RJ, 1986, J PHYSIOL-LONDON, V381, P453
   BALMENT RJ, 1986, J PHYSIOL-LONDON, V381, P439
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Macias Batista A., 1999, AN MED INT, V16, P87
   Baturina GS, 2013, DOKL BIOCHEM BIOPHYS, V449, P102, DOI 10.1134/S1607672913020130
   BAYLIS PH, 1987, AM J PHYSIOL, V253, pR671
   BENNETT T, 1987, J PHYSIOL-LONDON, V385, P35
   BENNETT T, 1986, J PHYSIOL-LONDON, V381, P407
   Bernal A, 2007, HORM BEHAV, V52, P289, DOI 10.1016/j.yhbeh.2007.05.005
   Bernal A, 2013, BRAIN RES BULL, V94, P40, DOI 10.1016/j.brainresbull.2013.02.003
   Bernal A, 2010, J NEUROENDOCRINOL, V22, P1043, DOI 10.1111/j.1365-2826.2010.02050.x
   Bernal A, 2015, PHYSIOL BEHAV, V141, P135, DOI 10.1016/j.physbeh.2015.01.022
   Bernal A, 2010, HORM BEHAV, V57, P284, DOI 10.1016/j.yhbeh.2009.12.009
   Betley JN, 2015, NATURE, V521, P180, DOI 10.1038/nature14416
   Binkley S. A., 1995, ENDOCRINOLOGY, P87
   Birk J, 2009, J CELL SCI, V122, P3994, DOI 10.1242/jcs.051136
   BLACKBURN RE, 1995, AM J PHYSIOL-REG I, V269, pR245
   BLACKBURN RE, 1992, NEUROENDOCRINOLOGY, V56, P255, DOI 10.1159/000126236
   BLACKBURN RE, 1992, AM J PHYSIOL, V263, pR1347
   BLEVINS LS, 1992, CRIT CARE MED, V20, P69, DOI 10.1097/00003246-199201000-00019
   Bourque CW, 2008, NAT REV NEUROSCI, V9, P519, DOI 10.1038/nrn2400
   BRIMBLE MJ, 1991, J ENDOCRINOL, V129, P49, DOI 10.1677/joe.0.1290049
   Bronstein MD, 2000, NEUROENDOCRINOLOGY IN PHYSIOLOGY AND MEDICINE, P475
   BROOKS FP, 1958, J PHYSIOL-LONDON, V142, P468
   BROWNSTEIN MJ, 1983, ANNU REV PHYSIOL, V45, P129, DOI 10.1146/annurev.ph.45.030183.001021
   BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132
   BRUNNER H, 1956, N-S ARCH EX PATH PH, V228, P457
   BUMA P, 1988, CELL TISSUE RES, V252, P107
   Bundzikova J, 2008, CELL MOL NEUROBIOL, V28, P1033, DOI 10.1007/s10571-008-9306-x
   Cheetham Tim, 2002, Paediatr Drugs, V4, P785, DOI 10.2165/00148581-200204120-00003
   CHENG SWT, 1987, NEUROENDOCRINOLOGY, V45, P93, DOI 10.1159/000124709
   Chiodera P, 1998, METABOLISM, V47, P893, DOI 10.1016/S0026-0495(98)90339-0
   CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78
   CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF70
   Chriguer RS, 2001, BRAIN RES, V889, P239, DOI 10.1016/S0006-8993(00)03096-1
   Christensen JH, 2013, CLIN GENET, V83, P44, DOI 10.1111/j.1399-0004.2011.01833.x
   Christensen JH, 2006, SEMIN NEPHROL, V26, P209, DOI 10.1016/j.semnephrol.2006.03.003
   CONRAD KP, 1986, AM J PHYSIOL, V251, pF290
   CONRAD KP, 1993, ANN NY ACAD SCI, V689, P346, DOI 10.1111/j.1749-6632.1993.tb55559.x
   Curtis GM, 1924, ARCH INTERN MED, V34, P801
   Czernichow P, 2000, HORM RES, V53, P61, DOI 10.1159/000023536
   DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421
   Del Tredici AL, 2008, BIOCHEM PHARMACOL, V76, P1134, DOI 10.1016/j.bcp.2008.08.004
   DEMUNBRUN TW, 1954, AM J PHYSIOL, V179, P429
   lorgi N Di, 2012, HORM RES PAEDIAT, V77, P69
   DLOUHA H, 1982, ANN NY ACAD SCI, V394, P10, DOI 10.1111/j.1749-6632.1982.tb37406.x
   DOGTEROM J, 1977, NEUROENDOCRINOLOGY, V24, P108, DOI 10.1159/000122702
   DOHANICS J, 1992, BRAIN RES, V575, P215, DOI 10.1016/0006-8993(92)90082-K
   DORN J, 1970, AM J PHYSIOL, V219, P1292
   Dumont Aaron S, 2005, J Intensive Care Med, V20, P127, DOI 10.1177/0885066605275247
   DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521
   DUVIGNEAUD V, 1953, J AM CHEM SOC, V75, P4879
   DYBALL REJ, 1968, BRIT J PHARMACOL, V33, P319
   DYBALL REJ, 1971, J PHYSIOL-LONDON, V214, P245
   EDWARDS BR, 1984, AM J PHYSIOL, V247, pF453
   Elias LLK, 1997, J CLIN ENDOCR METAB, V82, P1243, DOI 10.1210/jc.82.4.1243
   Elias PCL, 2004, J ENDOCRINOL, V180, P297, DOI 10.1677/joe.0.1800297
   Fenske W, 2012, J CLIN ENDOCR METAB, V97, P3426, DOI 10.1210/jc.2012-1981
   FISHER AWF, 1982, ANN NY ACAD SCI, V394, P96, DOI 10.1111/j.1749-6632.1982.tb37415.x
   Fisher C, 1936, ENDOCRINOLOGY, V20, P762
   Fitts DA, 2003, AM J PHYSIOL-REG I, V285, pR1331, DOI 10.1152/ajpregu.00254.2003
   FJELLESTADPAULSEN A, 1993, REGUL PEPTIDES, V45, P303, DOI 10.1016/0167-0115(93)90225-W
   FREGLY MJ, 1989, PHYSIOL BEHAV, V45, P825, DOI 10.1016/0031-9384(89)90302-8
   FRIEDMAN SM, 1958, AM J PHYSIOL, V192, P401
   FRIEDMAN SM, 1962, AM J PHYSIOL, V203, P697
   Fujisawa I, 2004, J NEUROENDOCRINOL, V16, P297, DOI 10.1111/j.0953-8194.2004.01183.x
   Fujiwara TM, 2005, J AM SOC NEPHROL, V16, P2836, DOI 10.1681/ASN.2005040371
   FULLER LM, 1988, AM J PHYSIOL, V255, pR217
   FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   GIOVANNELLI L, 1992, BRAIN RES, V588, P41, DOI 10.1016/0006-8993(92)91342-C
   Gonzales-Portillo G, 1998, NEUROSURGERY, V42, P917, DOI 10.1097/00006123-199804000-00131
   GREGER NG, 1986, AM J DIS CHILD, V140, P551
   HAANWINCKEL MA, 1995, P NATL ACAD SCI USA, V92, P7902, DOI 10.1073/pnas.92.17.7902
   Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017
   Haller J, 1996, J NEUROENDOCRINOL, V8, P361, DOI 10.1046/j.1365-2826.1996.04654.x
   HAN JS, 1993, AM J PHYSIOL, V265, pF26
   Hansell P, 2000, KIDNEY INT, V58, P2061
   HARRIS HW, 1991, AM J PHYSIOL, V261, pC143
   Heinbecker P, 1941, AM J PHYSIOL, V133, P0582
   HENDY GN, 1995, BAILLIERE CLIN ENDOC, V9, P509, DOI 10.1016/S0950-351X(95)80570-2
   Hensen J, 1999, CLIN ENDOCRINOL, V50, P431, DOI 10.1046/j.1365-2265.1999.00666.x
   HERMAN JP, 1987, J NEUROSCI, V7, P2564
   Holcomb Susan Simmons, 2002, Dimens Crit Care Nurs, V21, P94, DOI 10.1097/00003465-200205000-00004
   HOLLINSHEAD WH, 1964, MAYO CLIN PROC, V39, P92
   HORN AM, 1985, J ENDOCRINOL, V104, P211, DOI 10.1677/joe.0.1040211
   HUANG W, 1995, AM J PHYSIOL-REG I, V268, pR634
   Huang YS, 1996, BRAIN RES, V732, P95
   Ikkos D., 1954, J CLIN ENDOCR METAB, V15, P553
   Ivanova LN, 2008, B EXP BIOL MED+, V146, P642, DOI 10.1007/s10517-009-0359-8
   Jackson LF, 2005, COMP BIOCHEM PHYS B, V140, P211, DOI 10.1016/j.cbpc.2004.10.004
   Jard S., 1988, ADV EXP MED BIOL, V449, P1
   Johns EJ, 2002, CLIN AUTON RES, V12, P256, DOI 10.1007/s10286-002-0050-x
   Joo KW, 2004, NEPHROL DIAL TRANSPL, V19, P2480, DOI 10.1093/ndt/gfh413
   KADEKARO M, 1992, AM J PHYSIOL, V262, pR310
   KADEKARO M, 1995, AM J PHYSIOL-REG I, V268, pR651
   KADEKARO M, 1992, J NEUROENDOCRINOL, V4, P217, DOI 10.1111/j.1365-2826.1992.tb00162.x
   Kadekaro M, 1997, AM J PHYSIOL-REG I, V273, pR1024
   KAMOI K, 1990, J CLIN ENDOCR METAB, V70, P1385
   Kavelaars J, 2001, NETH J MED, V58, P150, DOI 10.1016/S0300-2977(01)00083-3
   KIEM DT, 1995, NEUROENDOCRINOLOGY, V61, P152, DOI 10.1159/000126835
   Kim JK, 1998, P ASSOC AM PHYSICIAN, V110, P380
   King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.physiol.58.1.619
   Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253
   Kolmodin L, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-35
   Kostoglou-Athanassiou I., 1994, J ENDOCRINOL SO, V143
   Kurokawa H, 1998, RADIOLOGY, V207, P79
   LANDGRAF R, 1988, BRAIN RES, V457, P219, DOI 10.1016/0006-8993(88)90689-0
   LANG RE, 1981, LIFE SCI, V29, P1425, DOI 10.1016/0024-3205(81)90005-9
   LASZLO FA, 1966, J ENDOCRINOL, V36, P125, DOI 10.1677/joe.0.0360125
   LAULIN JP, 1990, REGUL PEPTIDES, V31, P157, DOI 10.1016/0167-0115(90)90002-E
   Lavrinenko VA, 2014, B EXP BIOL MED+, V156, P624, DOI 10.1007/s10517-014-2410-7
   Layton AT, 2010, AM J PHYSIOL-RENAL, V298, pF973, DOI 10.1152/ajprenal.00249.2009
   LEGROS JJ, 1992, HORM RES, V37, P16, DOI 10.1159/000182396
   Leng G, 2005, VITAM HORM, V71, P27, DOI 10.1016/S0083-6729(05)71002-5
   Li C, 2008, J AM SOC NEPHROL, V19, P225, DOI 10.1681/ASN.2007010029
   LICHARDUS B, 1973, ENDOKRINOLOGIE, V61, P403
   Lindholm Jorgen, 2004, Pituitary, V7, P33, DOI 10.1023/B:PITU.0000044633.52516.e1
   Lippert TH, 2003, HORM RES, V60, P262, DOI 10.1159/000074243
   LIPSETT MB, 1956, J CLIN ENDOCR METAB, V16, P183
   Loh JA, 2007, NAT CLIN PRACT ENDOC, V3, P489, DOI 10.1038/ncpendmet0513
   LYNESS J, 1985, EXPERIENTIA, V41, P1444, DOI 10.1007/BF01950026
   Maghnie M, 2000, NEW ENGL J MED, V343, P998, DOI 10.1056/NEJM200010053431403
   Mahia J, 2007, EXP BRAIN RES, V183, P27, DOI 10.1007/s00221-007-1018-9
   Mahia J, 2007, BEHAV BRAIN RES, V181, P147, DOI 10.1016/j.bbr.2007.03.026
   Mahia J, 2006, EUR J NEUROSCI, V23, P1321, DOI 10.1111/j.1460-9568.2006.04644.x
   Mahia J., 2007, INT J CLIN HLTH PSYC, V7, P511
   Mahia J, 2013, ACTA NEUROBIOL EXP, V73, P326
   Mahia J, 2008, NEUROSCI LETT, V447, P7, DOI 10.1016/j.neulet.2008.09.072
   Mahia J, 2009, EUR J NEUROSCI, V29, P1440, DOI 10.1111/j.1460-9568.2009.06686.x
   MAHON JM, 1995, NEUROSCIENCE, V69, P199, DOI 10.1016/0306-4522(95)00238-E
   Makara G B, 2001, Stress, V4, P25
   Makara GB, 1996, ENDOCRINOLOGY, V137, P580, DOI 10.1210/en.137.2.580
   MAKARA GB, 1995, ENDOCRINOLOGY, V136, P1864, DOI 10.1210/en.136.5.1864
   Makaryus AN, 2006, CLEV CLIN J MED, V73, P65
   Man S., 1992, CRITICAL CARE MED, V20, P94
   MAZZA E, 1994, EUR J ENDOCRINOL, V130, P121
   McCann SM, 1997, BRAZ J MED BIOL RES, V30, P427
   MCKINLEY MJ, 1992, PROG BRAIN RES, V91, P395
   Mirsky A., 1954, AM J PHYSIOL, V54, P691
   Morris JF, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P621, DOI 10.1016/B978-012369442-3/50091-X
   MORRIS M, 1984, NEUROENDOCRINOLOGY, V39, P377, DOI 10.1159/000124008
   MORRIS M, 1976, P SOC EXP BIOL MED, V152, P95
   Morrissey SE, 2001, EUR J ENDOCRINOL, V145, P65, DOI 10.1530/eje.0.1450065
   MOSES AM, 1992, AM J NEURORADIOL, V13, P1273
   Mundschenk J, 2001, EXP CLIN ENDOCR DIAB, V109, P406, DOI 10.1055/s-2001-18994
   MURPHY HM, 1991, PEPTIDES, V12, P319, DOI 10.1016/0196-9781(91)90019-L
   Nakamura S, 2000, J PHARMACOL EXP THER, V295, P1005
   Nakamura S, 2000, BRIT J PHARMACOL, V129, P1700, DOI 10.1038/sj.bjp.0703221
   Nemergut EC, 2005, J NEUROSURG, V103, P448, DOI 10.3171/jns.2005.103.3.0448
   Nielsen S, 2002, PHYSIOL REV, V82, P205
   NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013
   Nishi EE, 2015, EXP PHYSIOL, V100, P479, DOI 10.1113/expphysiol.2014.079889
   NORTH WG, 1982, ANN NY ACAD SCI, V394, P167, DOI 10.1111/j.1749-6632.1982.tb37424.x
   O'Connor W. J., 1946, QUART JOUR EXPTL PHYSIOL, V33, P149
   OCONNOR WJ, 1952, Q J EXP PHYSIOL CMS, V37, P1
   OCONNOR WJ, 1950, Q J EXP PHYSIOL CMS, V36, P21
   Oka Y, 2015, NATURE, V520, P349, DOI 10.1038/nature14108
   PAGE RB, 1984, J COMP NEUROL, V226, P274, DOI 10.1002/cne.902260211
   PALMIERI GM, 1969, J COMP PHYSIOL PSYCH, V68, P38, DOI 10.1037/h0027667
   Paxinos G., 1986, RAT BRAIN STEREOTAXI
   Phulwani N., 2011, DIABETES INSIPIDUS, P109
   PICKFORD M, 1945, J PHYSIOL-LONDON, V104, P105
   Pittman J.G., 1963, NEW ENGL J MED, V68, P481
   Pivonello R., 2000, CLIN ENDOCRINOL, V54, P97
   POTTER RR, 1964, OBSTET GYNECOL, V23, P699
   Pouzet B, 2001, NEPHROL DIAL TRANSPL, V16, P725, DOI 10.1093/ndt/16.4.725
   POW DV, 1990, J NEUROENDOCRINOL, V2, P233, DOI 10.1111/j.1365-2826.1990.tb00856.x
   Price TG, 2000, J EMERG MED, V19, P153, DOI 10.1016/S0736-4679(00)00201-8
   Qureshi S, 2014, ENDOCRINOLOGY, V155, P4605, DOI 10.1210/en.2014-1385
   RAISMAN G, 1973, BRAIN RES, V55, P245, DOI 10.1016/0006-8993(73)90294-1
   Rajaratnam S, 2003, BRIT J NEUROSURG, V17, P437, DOI 10.1080/02688690310001611233
   RAO VVNG, 1992, CYTOGENET CELL GENET, V61, P271
   Rasmussen M. S., 2003, Journal of Physiology (Cambridge), V546, P591, DOI 10.1113/jphysiol.2002.027425
   Rasmussen MS, 2004, ACTA PHYSIOL SCAND, V181, P247, DOI 10.1111/j.1365-201X.2004.01286.x
   Rembratt A, 2004, EUR J CLIN PHARMACOL, V60, P397, DOI 10.1007/s00228-004-0781-9
   RENAUD LP, 1991, PROG NEUROBIOL, V36, P131, DOI 10.1016/0301-0082(91)90020-2
   Richter CP, 1935, AM J PHYSIOL, V113, P578
   Rivkees SA, 2007, J PEDIATR ENDOCR MET, V20, P459
   Robertson G L, 1987, Kidney Int Suppl, V21, pS20
   ROBERTSON GL, 1995, ENDOCRIN METAB CLIN, V24, P549
   ROBERTSON GL, 1983, J LAB CLIN MED, V101, P351
   ROLLS BJ, 1970, PHYSIOL BEHAV, V5, P1385, DOI 10.1016/0031-9384(70)90124-1
   Rose B. D., 2015, CLIN PHYSL ACID BASE
   Saborio P, 2000, Pediatr Rev, V21, P122, DOI 10.1542/pir.21-4-122
   Sasaki S, 2008, J AM SOC NEPHROL, V19, P189, DOI 10.1681/ASN.2007121319
   SAUL GB, 1968, J HERED, V59, P113
   SAWYER WH, 1952, AM J PHYSIOL, V169, P583
   [Anonymous], 1997, AM J PHYSIOL-REG I
   SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0
   SCHMIDT A, 1990, AM J PHYSIOL, V259, pF872
   SCHRAMM LP, 1993, BRAIN RES, V616, P251, DOI 10.1016/0006-8993(93)90216-A
   Schreckinger M, 2013, CLIN NEUROL NEUROSUR, V115, P121, DOI 10.1016/j.clineuro.2012.08.009
   SECKL J, 1989, BRIT MED J, V298, P2
   SECKL JR, 1992, DRUGS, V44, P216, DOI 10.2165/00003495-199244020-00006
   SECKL JR, 1987, BRAIN, V110, P737, DOI 10.1093/brain/110.3.737
   Sheehan JM, 2006, ACTA NEUROCHIR, V148, P287, DOI 10.1007/s00701-005-0686-0
   SHERMAN TG, 1988, J NEUROSCI, V8, P3785
   Si-Hoe SL, 2000, FASEB J, V14, P1680
   Singer I, 1997, ARCH INTERN MED, V157, P1293, DOI 10.1001/archinte.157.12.1293
   Singer PA, 2003, NEUROSURG CLIN N AM, V14, P123, DOI 10.1016/S1042-3680(02)00032-3
   SMITH RW, 1962, AM J PHYSIOL, V203, P366
   SNYDER HM, 1992, AM J PHYSIOL, V263, pC147
   Song JK, 1999, J NEUROSURG, V90, P1141, DOI 10.3171/jns.1999.90.6.1141
   STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534
   STOECKEL ME, 1989, AM J PHYSIOL, V257, pF310
   STRANGE K, 1987, SCIENCE, V235, P1068, DOI 10.1126/science.3823867
   STRICKER EM, 1966, AM J PHYSIOL, V211, P232
   STRICKER EM, 1986, AM J PHYSIOL, V250, pR267
   STRICKER EM, 1987, BEHAV NEUROSCI, V101, P560, DOI 10.1037/0735-7044.101.4.560
   SWAAB DF, 1993, ANAT EMBRYOL, V187, P317
   SWAAB DF, 1975, J NEURAL TRANSM, V36, P195, DOI 10.1007/BF01253126
   Swann HG, 1939, SCIENCE, V90, P67, DOI 10.1126/science.90.2325.67-a
   Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f
   TITLEBAUM LF, 1960, AM J PHYSIOL, V199, P22
   Treschan TA, 2006, ANESTHESIOLOGY, V105, P599, DOI 10.1097/00000542-200609000-00026
   TRIBOLLET E, 1992, ANN NY ACAD SCI, V652, P29, DOI 10.1111/j.1749-6632.1992.tb34343.x
   VALTIN H, 1965, ENDOCRINOLOGY, V77, P701
   VALTIN H, 1964, AM J PHYSIOL, V206, P425
   VALTIN H, 1982, ANN NY ACAD SCI, V394, P1, DOI 10.1111/j.1749-6632.1982.tb37405.x
   VALTIN H, 1974, NEW ENGL J MED, V290, P670
   VALTIN H, 1967, AM J MED, V42, P814, DOI 10.1016/0002-9343(67)90098-8
   VANDESANDE F, 1976, CELL TISSUE RES, V165, P307
   Vega C, 2010, AM J PHYSIOL-REG I, V299, pR1701, DOI 10.1152/ajpregu.00575.2010
   Verbalis JG, 2003, BEST PRACT RES CL EN, V17, P471, DOI 10.1016/S1521-690X(03)00049-6
   VERBALIS JG, 1986, AM J PHYSIOL, V250, pR444
   VERBALIS JG, 1991, ENDOCRINOLOGY, V128, P1317
   VERBALIS JG, 1991, AM J PHYSIOL, V261, pR1028
   Walter MF, 2000, J ENDOCRINOL, V165, P19, DOI 10.1677/joe.0.1650019
   Wang JY, 2000, NEPHRON, V86, P342, DOI 10.1159/000045791
   Wells T, 1998, MOL CELL ENDOCRINOL, V136, P103, DOI 10.1016/S0303-7207(97)00219-0
   White HL, 1938, AM J PHYSIOL, V123, P566
   WIDEMAN CH, 1991, PEPTIDES, V12, P285, DOI 10.1016/0196-9781(91)90013-F
   WIEGAND SJ, 1980, J COMP NEUROL, V192, P1, DOI 10.1002/cne.901920102
   Wilke C, 2005, KIDNEY INT, V67, P201, DOI 10.1111/j.1523-1755.2005.00071.x
   WILLIAMS TDM, 1986, J ENDOCRINOL, V108, P163, DOI 10.1677/joe.0.1080163
   WINDLE RJ, 1993, J ENDOCRINOL, V137, P311, DOI 10.1677/joe.0.1370311
   WINDLE RJ, 1995, J ENDOCRINOL, V144, P441, DOI 10.1677/joe.0.1440441
   Windle RJ, 1997, J ENDOCRINOL, V152, P257, DOI 10.1677/joe.0.1520257
   WYNDHAM JR, 1987, ARCH GERONTOL GERIAT, V6, P323, DOI 10.1016/0167-4943(87)90012-4
   Xiong JJ, 1996, BRAIN RES, V719, P143, DOI 10.1016/0006-8993(95)01466-7
   Yang Z, 2007, EXP PHYSIOL, V92, P109, DOI 10.1113/expphysiol.2006.034884
   Ye L, 2005, J CLIN ENDOCR METAB, V90, P4388, DOI 10.1210/jc.2004-2000
   YIRMIYA R, 1988, BEHAV NEUROSCI, V102, P574
   Zelena D, 2006, AM J PHYSIOL-ENDOC M, V290, pE243, DOI 10.1152/ajpendo.00118.2005
   Zelena D, 2013, J NEUROENDOCRINOL, V25, P711, DOI 10.1111/jne.12047
   Zelena D, 2009, J ENDOCRINOL, V202, P263, DOI 10.1677/JOE-09-0096
   Zimmeman M. B., 1984, FEED P, V43, P91
   ZIMMERMAN EA, 1976, KIDNEY INT, V10, P12, DOI 10.1038/ki.1976.75
NR 263
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD JUL
PY 2016
VL 66
BP 1
EP 14
DI 10.1016/j.neubiorev.2016.02.023
PG 14
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DP0KD
UT WOS:000378177800001
PM 27118135
ER

PT J
AU Terbeck, S
   Savulescu, J
   Chesterman, LP
   Cowen, PJ
AF Terbeck, S.
   Savulescu, J.
   Chesterman, L. P.
   Cowen, P. J.
TI Noradrenaline effects on social behaviour, intergroup relations, and
   moral decisions
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
ID PLAY-BEHAVIOR; PROPRANOLOL TREATMENT; SELECTIVE SEROTONIN; AMYGDALA
   ACTIVATION; HEALTHY-VOLUNTEERS; NEURAL BASIS; WHITE FACES; RAT-BRAIN;
   STRESS; JUDGMENT
AB Recent research has begun to elucidate the neural basis of higher order social concepts, such as the mechanisms involved in intergroup relations, and moral judgments. Most theories have concentrated on higher order emotions, such as guilt, shame, or empathy, as core mechanisms. Accordingly, psychopharmacological and neurobiological studies have investigated the effects of manipulating serotonin or oxytocin activity on moral and social decisions and attitudes. However, recently it has been determined that changes in more basic emotions, such as fear and anger, might also have a significant role in social and moral cognition. This article summarizes psychopharmacological and fMRI research on the role of noradrenaline in higher order social cognition suggesting that indeed noradrenergic mediated affective changes might play key- and probably causal- role in certain social attitudes and moral judgments. Social judgments may also be directly influenced by numerous neurotransmitter manipulations but these effects could be mediated by modulation of basic emotions which appear to play an essential role in the formation of social concepts and moral behaviour. (C) 2016 Published by Elsevier Ltd.
C1 [Terbeck, S.] Univ Plymouth, Dept Psychol, Plymouth PL4 8AA, Devon, England.
   [Savulescu, J.] Univ Oxford, Oxford Ctr Neuroeth, Littlegate House,St Ebbes St, Oxford OX1 1PT, England.
   [Cowen, P. J.] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.
   [Chesterman, L. P.] Cygnet Hosp Stevenage, Graveley Rd, Stevenage SG1 4YS, Herts, England.
RP Terbeck, S (reprint author), Univ Plymouth, Dept Psychol, Plymouth PL4 8AA, Devon, England.
EM sylvia.terbeck@plymouth.ac.uk
FU Wellcome Trust [086041]
CR Achterberg EJM, 2016, NEUROPSYCHOPHARMACOL, V41, P858, DOI 10.1038/npp.2015.212
   Achterberg EJM, 2015, J NEUROSCI, V35, P161, DOI 10.1523/JNEUROSCI.2945-14.2015
   Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514
   AX AF, 1953, PSYCHOSOM MED, V15, P433
   BEATTY WW, 1984, PHARMACOL BIOCHEM BE, V20, P747, DOI 10.1016/0091-3057(84)90194-1
   BEATTY WW, 1982, PHARMACOL BIOCHEM BE, V16, P417, DOI 10.1016/0091-3057(82)90445-2
   Bechara A., 2005, SCIENCE, V257, P1293
   BLISS EL, 1968, J PHARMACOL EXP THER, V164, P122
   Brunello N, 2003, INT CLIN PSYCHOPHARM, V18, P191, DOI 10.1097/01.yic.0000073880.93678.68
   Buffalari DM, 2007, J NEUROSCI, V27, P12358, DOI 10.1523/JNEUROSCI.2007-07.2007
   CARLSON M, 1988, J PERS SOC PSYCHOL, V55, P211, DOI 10.1037//0022-3514.55.2.211
   Casebeer WD, 2003, BIOL PHILOS, V18, P169, DOI 10.1023/A:1023380907603
   CASSEL JC, 1995, NEUROSCIENCE, V69, P1, DOI 10.1016/0306-4522(95)00241-A
   CORRODI H, 1968, LIFE SCI PT 1 PHYSI, V7, P107, DOI 10.1016/0024-3205(68)90368-8
   Crockett M. J., 2014, PHILOS PSYCHIAT PSYC, V21, P131
   Crockett MJ, 2010, P NATL ACAD SCI USA, V107, P17433, DOI 10.1073/pnas.1009396107
   Cunningham WA, 2004, PSYCHOL SCI, V15, P806, DOI 10.1111/j.0956-7976.2004.00760.x
   Damasio A. R., 1994, DESCARTES ERROR EMOT
   Darke S., 1988, COGNITION EMOTION, V2, P145, DOI DOI 10.1080/02699938808408071
   DAVIS M, 1993, BEHAV BRAIN RES, V58, P175, DOI 10.1016/0166-4328(93)90102-V
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   De Houwer J, 2009, PSYCHOL BULL, V135, P347, DOI 10.1037/a0014211
   Eisenberg N, 2000, ANNU REV PSYCHOL, V51, P665, DOI 10.1146/annurev.psych.51.1.665
   FRY PS, 1975, DEV PSYCHOL, V11, P466, DOI 10.1037/h0076678
   Galvin G., 1985, NEUROSCI BIOBEHAV R, V9, P233
   Gibbard Alan, 1990, WISE CHOICES APT FEE
   Golby AJ, 2001, NAT NEUROSCI, V4, P845, DOI 10.1038/90565
   GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005
   Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872
   Greene J. D., 2008, MORAL PSYCHOL, V3
   Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464
   Haidt J, 2003, SER AFFECTIVE SCI, P852
   Haidt J., 2008, MORAL PSYCHOL, V2, P1
   Harmer CJ, 2004, AM J PSYCHIAT, V161, P1256, DOI 10.1176/appi.ajp.161.7.1256
   Hurlemann R, 2010, PSYCHOL MED, V40, P1839, DOI 10.1017/S0033291709992376
   Ibsen A. M., 1992, MOTIV EMOTION, V16, P65
   Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148
   ISEN AM, 1987, J PERS SOC PSYCHOL, V52, P1122, DOI 10.1037//0022-3514.52.6.1122
   JOHNSON EJ, 1983, J PERS SOC PSYCHOL, V45, P20, DOI 10.1037/0022-3514.45.1.20
   Knutson KM, 2007, HUM BRAIN MAPP, V28, P915, DOI 10.1002/hbm.20320
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Leonard B. E., 2003, FUNDAMENTALS PSYCHOP
   Levy Neil, 2014, Philos Psychiatr Psychol, V21, P111
   Lieberman MD, 2005, NAT NEUROSCI, V8, P720, DOI 10.1038/nn1465
   MILLS PJ, 1991, PSYCHOSOMATICS, V32, P209
   Moll J., 2008, MORAL PSYCHOL, V3
   Montgomery S. A., 1997, J PSYCHOPHARMACOL S4, V11, P9
   Moretto G, 2010, J COGNITIVE NEUROSCI, V22, P1888, DOI 10.1162/jocn.2009.21367
   Morilak DA, 2005, PROG NEURO-PSYCHOPH, V29, P1214, DOI 10.1016/j.pnpbp.2005.08.007
   Nichols S, 2006, COGNITION, V100, P530, DOI 10.1016/j.cognition.2005.07.005
   Norbury R, 2008, MOL PSYCHIATR, V13, P1011, DOI 10.1038/sj.mp.4002091
   Nosek B. A., 2007, AUTOMATIC PROCESSES, P265
   Onaka T, 2012, J NEUROENDOCRINOL, V24, P587, DOI 10.1111/j.1365-2826.2012.02300.x
   PALVIMAKI EP, 1994, PSYCHOPHARMACOLOGY, V115, P543, DOI 10.1007/BF02245579
   Pham MT, 2007, REV GEN PSYCHOL, V11, P155, DOI 10.1037/1089-2680.11.2.155
   Phelps EA, 2000, J COGNITIVE NEUROSCI, V12, P729, DOI 10.1162/089892900562552
   Pitman RK, 2005, CNS SPECTRUMS, V10, P99
   Poehlman T. A., 2004, EUR J SOC PSYCHOL, V38, P922
   Richeson JA, 2003, NAT NEUROSCI, V6, P1323, DOI 10.1038/nn1156
   Salmina AB, 2010, J NEUROENDOCRINOL, V22, P380, DOI 10.1111/j.1365-2826.2010.01970.x
   Scher SJ, 1997, PERS SOC PSYCHOL B, V23, P482, DOI 10.1177/0146167297235004
   Silver JM, 1999, J NEUROPSYCH CLIN N, V11, P328
   Stanley D, 2008, CURR DIR PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-8721.2008.00568.x
   Stein MB, 2007, J TRAUMA STRESS, V20, P923, DOI 10.1002/jts.20270
   Szabo ST, 2000, INT J NEUROPSYCHOPH, V3, P1, DOI 10.1017/S1461145700001772
   Terbeck S, 2015, PSYCHOPHARMACOLOGY, V232, P2951, DOI 10.1007/s00213-015-3929-7
   Terbeck Sylvia, 2013, Biol Psychol, V92, P323, DOI 10.1016/j.biopsycho.2012.09.005
   Terbeck S, 2012, PSYCHOPHARMACOLOGY, V222, P723, DOI 10.1007/s00213-012-2768-z
   Terbeck S, 2012, PSYCHOPHARMACOLOGY, V222, P419, DOI 10.1007/s00213-012-2657-5
   Tse WS, 2002, PSYCHOPHARMACOLOGY, V161, P324, DOI 10.1007/s00213-002-1049-7
   TYRER PJ, 1974, BMJ-BRIT MED J, V2, P14
   van Stegeren AH, 2005, NEUROIMAGE, V24, P898, DOI 10.1016/j.neuroimage.2004.09.011
   Vanderschuren LJMJ, 1997, NEUROSCI BIOBEHAV R, V21, P309, DOI 10.1016/S0149-7634(96)00020-6
   Vanderschuren LJMJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2946, DOI 10.1038/npp.2008.10
   WEISS JM, 1971, J COMP PHYSIOL PSYCH, V77, P22, DOI 10.1037/h0031581
   Wheatley T, 2005, PSYCHOL SCI, V16, P780, DOI 10.1111/j.1467-9280.2005.01614.x
   Wheeler ME, 2005, PSYCHOL SCI, V16, P56, DOI 10.1111/j.0956-7976.2005.00780.x
NR 77
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD JUL
PY 2016
VL 66
BP 54
EP 60
DI 10.1016/j.neubiorev.2016.03.031
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DP0KD
UT WOS:000378177800004
PM 27126289
ER

PT J
AU Hovey, D
   Lindstedt, M
   Zettergren, A
   Jonsson, L
   Johansson, A
   Melke, J
   Kerekes, N
   Anckarsater, H
   Lichtenstein, P
   Lundstrom, S
   Westberg, L
AF Hovey, D.
   Lindstedt, M.
   Zettergren, A.
   Jonsson, L.
   Johansson, A.
   Melke, J.
   Kerekes, N.
   Anckarsater, H.
   Lichtenstein, P.
   Lundstrom, S.
   Westberg, L.
TI Antisocial behavior and polymorphisms in the oxytocin receptor gene:
   findings in two independent samples
SO MOLECULAR PSYCHIATRY
LA English
DT Article
ID CALLOUS-UNEMOTIONAL TRAITS; CHILDHOOD-ONSET AGGRESSION; MALE RATS;
   INTRANASAL OXYTOCIN; OXTR POLYMORPHISMS; BRAIN OXYTOCIN; LIFE-HISTORY;
   FOLLOW-UP; VARIANTS; HUMANS
AB The quantitative genetic contribution to antisocial behavior is well established, but few, if any, genetic variants are established as risk factors. Emerging evidence suggests that the neuropeptide oxytocin (OXT) may modulate interpersonal aggression. We here investigated whether single-nucleotide polymorphisms (SNPs) in the OXT receptor gene (OXTR) are associated with the expression of antisocial behavior. A discovery sample, including both sexes, was drawn from the Child and Adolescent Twin Study in Sweden (CATSS; n = 2372), and a sample from the Twin Study of Child and Adolescent Development (TCHAD; n = 1232) was used for replication. Eight SNPs in OXTR, selected on previous associations with social and antisocial behavior, were genotyped in the participants of CATSS. Significant polymorphisms were subsequently genotyped in TCHAD for replication. Participants completed self-assessment questionnaires-Life History of Aggression (LHA; available only in CATSS), and Self-Reported Delinquency (SRD; available in both samples)-designed to capture antisocial behavior as continuous traits. In the discovery sample, the rs7632287 AA genotype was associated with higher frequency of antisocial behavior in boys, and this was then replicated in the second sample. In particular, overt aggression (directly targeting another individual) was strongly associated with this genotype in boys (P = 6.2 x 10(-7) in the discovery sample). Meta-analysis of the results for antisocial behavior from both samples yielded P = 2.5 x 10(-5). Furthermore, an association between rs4564970 and LHA (P = 0.00013) survived correction in the discovery sample, but there was no association with the SRD in the replication sample. We conclude that the rs7632287 and rs4564970 polymorphisms in OXTR may independently influence antisocial behavior in adolescent boys. Further replication of our results will be crucial to understanding how aberrant social behavior arises, and would support the OXT receptor as one potential target in the treatment of aggressive antisocial behavior.
C1 [Hovey, D.; Lindstedt, M.; Zettergren, A.; Jonsson, L.; Johansson, A.; Melke, J.; Westberg, L.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Box 431, Gothenburg, Sweden.
   [Zettergren, A.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.
   [Johansson, A.] Univ Turku, Dept Behav Sci & Philosophy, Turku, Finland.
   [Kerekes, N.; Anckarsater, H.; Lundstrom, S.] Univ Gothenburg, Ctr Eth Law & Mental Hlth CELAM, Molndal, Sweden.
   [Kerekes, N.; Lundstrom, S.] Swedish Prison & Probat Serv, R&D Unit, Gothenburg, Sweden.
   [Lichtenstein, P.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Lundstrom, S.] Univ Gothenburg, Gillberg Neuropsychiat Ctr, Gothenburg, Sweden.
RP Westberg, L (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Box 431, Gothenburg, Sweden.
EM lars.westberg@pharm.gu.se
OI lichtenstein, paul/0000-0003-3037-5287
FU Swedish Research Council; Swedish Research Council for Working Life and
   Social Research; Society of Swedish Literature in Finland;
   Soderstrom-Konigska Foundation; European Union [602768]
FX This research was supported by grants from the Swedish Research Council,
   Swedish Research Council for Working Life and Social Research, The
   Society of Swedish Literature in Finland and the Soderstrom-Konigska
   Foundation. The research leading to these results has also received
   funding from the European Union Seventh Framework Programme
   (FP7/2007-2013) under grant agreement no 602768.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anckarsater H, 2011, TWIN RES HUM GENET, V14, P495, DOI 10.1375/twin.14.6.495
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Beitchman JH, 2012, EUR CHILD ADOLES PSY, V21, P125, DOI 10.1007/s00787-012-0240-6
   Blanks AM, 2007, SEMIN REPROD MED, V25, P52, DOI 10.1055/s-2006-956775
   Calcagnoli F, 2015, NEUROPHARMACOLOGY, V90, P74, DOI 10.1016/j.neuropharm.2014.11.012
   Calcagnoli F, 2015, PSYCHONEUROENDOCRINO, V51, P112, DOI 10.1016/j.psyneuen.2014.09.019
   Calcagnoli F, 2014, HORM BEHAV, V65, P427, DOI 10.1016/j.yhbeh.2014.03.008
   Calcagnoli F, 2014, BEHAV BRAIN RES, V261, P315, DOI 10.1016/j.bbr.2013.12.050
   Calcagnoli F, 2013, PSYCHOPHARMACOLOGY, V229, P639, DOI 10.1007/s00213-013-3124-7
   Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Cecil CAM, 2014, MOL PSYCHIATR, V19, P1071, DOI 10.1038/mp.2014.95
   Christ CC, 2014, J PERS
   Clark CL, 2013, PSYCHONEUROENDOCRINO, V38, P1208, DOI 10.1016/j.psyneuen.2012.10.017
   Coccaro EF, 1998, COMPR PSYCHIAT, V39, P368, DOI 10.1016/S0010-440X(98)90050-5
   Coccaro EF, 1997, PSYCHIAT RES, V73, P147, DOI 10.1016/S0165-1781(97)00119-4
   Colman I, 2009, BRIT MED J, V338, DOI 10.1136/bmj.a2981
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P21, DOI 10.1017/S0954579413000485
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497
   DeVries AC, 1997, J NEUROENDOCRINOL, V9, P363, DOI 10.1046/j.1365-2826.1997.t01-1-00589.x
   Dorfman Hayley M, 2014, Curr Top Behav Neurosci, V17, P297, DOI 10.1007/7854_2013_272
   Feng C, 2014, BRAIN IMAGING BEHAV
   FERRIS CF, 1992, ANN NY ACAD SCI, V652, P456, DOI 10.1111/j.1749-6632.1992.tb34382.x
   Fetissov SO, 2006, BIOL PSYCHIAT, V60, P799, DOI 10.1016/j.biopsych.2006.03.081
   Ge D, 2009, METAP SOFTWARE
   Hannelius U, 2007, TWIN RES HUM GENET, V10, P604, DOI 10.1375/twin.10.4.604
   Harmon AC, 2002, J NEUROENDOCRINOL, V14, P963, DOI 10.1046/j.1365-2826.2002.00863.x
   Hofvander B, 2011, PSYCHIAT RES, V185, P280, DOI 10.1016/j.psychres.2010.05.008
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Israel S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005535
   Johansson A, 2012, GENES BRAIN BEHAV, V11, P214, DOI 10.1111/j.1601-183X.2011.00744.x
   Johansson A, 2012, PSYCHONEUROENDOCRINO, V37, P1546, DOI 10.1016/j.psyneuen.2012.02.009
   Junger-Tas J, 1994, DELIQUENT BEHAV YOUN
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125
   Laursen HR, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00423
   Lee R, 2009, PSYCHONEUROENDOCRINO, V34, P1567, DOI 10.1016/j.psyneuen.2009.06.002
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Lichtenstein P, 2007, TWIN RES HUM GENET, V10, P67, DOI 10.1375/twin.10.1.67
   [Anonymous], 2014, MOL PSYCHIATR, DOI DOI 10.1038/MP.2014.77
   Loth E, 2014, BIOL PSYCHIAT, V76, P367, DOI 10.1016/j.biopsych.2013.07.043
   Lubin DA, 2003, BEHAV NEUROSCI, V117, P195, DOI 10.1037/0735-7044.117.2.195
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   Malik AI, 2014, PSYCHIAT GENET, V24, P201, DOI 10.1097/YPG.0000000000000044
   Melchers M, 2013, BEHAV NEUROSCI, V127, P780, DOI 10.1037/a0033748
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Pagani JH, 2015, GENES BRAIN BEHAV, V14, P167, DOI 10.1111/gbb.12202
   Plomin R, 2009, NAT REV GENET, V10, P872, DOI 10.1038/nrg2670
   Ragnauth AK, 2005, GENES BRAIN BEHAV, V4, P229, DOI 10.1111/j.1601-183X.2005.00118.x
   Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009
   Ring J., 1999, HEM SKOLA KAMRATER B
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Savaskan E, 2008, PSYCHONEUROENDOCRINO, V33, P368, DOI 10.1016/j.psyneuen.2007.12.004
   Scott S, 2001, BRIT MED J, V323, P191, DOI 10.1136/bmj.323.7306.191
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Smearman EL, 2015, DEV PSYCHOPATHOL, V27, P309, DOI 10.1017/S0954579414000649
   Tansey KE, 2010, NEUROSCI LETT, V474, P163, DOI 10.1016/j.neulet.2010.03.035
   Tiihonen J, 2014, MOL PSYCHIATR, V20, P786, DOI DOI 10.1038/MP.2014.130
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Tuvblad C, 2011, BEHAV GENET, V41, P629, DOI 10.1007/s10519-011-9463-4
   Vassos E, 2014, MOL PSYCHIATR, V19, P471, DOI 10.1038/mp.2013.31
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Wang K, 2009, NATURE, V459, P528, DOI 10.1038/nature07999
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Westberg L, 2015, OXFORD HDB MOL PSYCH, P145
   Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566
   Wu N, 2012, J AFFECT DISORDERS, V138, P468, DOI 10.1016/j.jad.2012.01.009
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 73
TC 1
Z9 1
U1 7
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JUL
PY 2016
VL 21
IS 7
BP 983
EP 988
DI 10.1038/mp.2015.144
PG 6
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA DO9DX
UT WOS:000378085600015
PM 26390829
ER

PT J
AU Koch, SBJ
   van Zuiden, M
   Nawijn, L
   Frijling, JL
   Veltman, DJ
   Olff, M
AF Koch, Saskia B. J.
   van Zuiden, Mirjam
   Nawijn, Laura
   Frijling, Jessie L.
   Veltman, Dick J.
   Olff, Miranda
TI Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in
   Posttraumatic Stress Disorder
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COGNITIVE-BEHAVIOR THERAPY;
   SOCIAL ANXIETY DISORDER; ANTERIOR CINGULATE; TREATMENT RESPONSE; FEAR
   INHIBITION; DSM-IV; HUMANS; PTSD; CORTEX
AB The neuropeptide oxytocin (OT) has been suggested as a promising pharmacological agent for medication-enhanced psychotherapy in posttraumatic stress disorder (PTSD) because of its anxiolytic and prosocial properties. We therefore investigated the behavioral and neurobiological effects of a single intranasal OT administration (40 IU) in PTSD patients. We conducted a randomized, placebo-controlled, cross-over resting-state fMRI study in male and female police officers with (n = 37, 21 males) and without PTSD (n = 40, 20 males). We investigated OT administration effects on subjective anxiety and functional connectivity of basolateral (BLA) and centromedial (CeM) amygdala subregions with prefrontal and salience processing areas. In PTSD patients, OT administration resulted in decreased subjective anxiety and nervousness. Under placebo, male PTSD patients showed diminished right CeM to left ventromedial prefrontal cortex (vmPFC) connectivity compared with male trauma-exposed controls, which was reinstated after OT administration. Additionally, female PTSD patients showed enhanced right BLA to bilateral dorsal anterior cingulate cortex (dACC) connectivity compared with female trauma-exposed controls, which was dampened after OT administration. Although caution is warranted, our findings tentatively suggest that OT has the potential to diminish anxiety and fear expression of the amygdala in PTSD, either via increased control of the vmPFC over the CeM (males) or via decreased salience processing of the dACC and BLA (females). Our findings add to accumulating evidence that OT administration could potentially enhance treatment response in PTSD.
C1 [Koch, Saskia B. J.; van Zuiden, Mirjam; Nawijn, Laura; Frijling, Jessie L.; Olff, Miranda] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.
   [Koch, Saskia B. J.; Nawijn, Laura; Frijling, Jessie L.] Univ Amsterdam, Acad Med Ctr, Brain Imaging Ctr, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.
   [Veltman, Dick J.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
   [Olff, Miranda] Arq Psychotrauma Expert Ctr, Diemen, Netherlands.
RP Koch, SBJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.
EM s.b.koch@amc.uva.nl
FU ZonMw; Netherlands organization for Health Research and Development
   [91210041]; Academic Medical Center Research Council [40-00812-98-10041]
FX The study is supported by grants from ZonMw, the Netherlands
   organization for Health Research and Development (grant no. 91210041),
   and the Academic Medical Center Research Council (grant no.
   40-00812-98-10041). All authors declare that they have no biomedical
   financial interests and no potential conflicts of interest.
CR Acheson DT, 2015, DEPRESS ANXIETY, V32, P400, DOI 10.1002/da.22362
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bertsch K, 2013, AM J PSYCHIAT, V170, P1169, DOI 10.1176/appi.ajp.2013.13020263
   BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408
   Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214
   Bremner JD, 2007, J NERV MENT DIS, V195, P211, DOI 10.1097/01.nmd.0000243824.84651.6c
   Brown VM, 2014, NEUROPSYCHOPHARMACOL, V39, P351, DOI 10.1038/npp.2013.197
   Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231
   Bryant RA, 2008, HUM BRAIN MAPP, V29, P517, DOI 10.1002/hbm.20415
   CALDWELL JD, 1994, PEPTIDES, V15, P1079, DOI 10.1016/0196-9781(94)90073-6
   Carlier I, 1992, PSYCHIAT FENNICA S, V23, P59
   Chao-Gan Yan, 2010, Front Syst Neurosci, V4, P13, DOI 10.3389/fnsys.2010.00013
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   de Vries GJ, 2009, J TRAUMA STRESS, V22, P259, DOI 10.1002/jts.20429
   de Kleine RA, 2013, EUR J PSYCHOTRAUMATO, V4
   Dodhia S, 2014, NEUROPSYCHOPHARMACOL, V39, P2061, DOI 10.1038/npp.2014.53
   Eckstein M., 2014, BIOL PSYCHIAT, V78, P194, DOI [10.1016/j.biopsych, DOI 10.1016/J.BIOPSYCH]
   Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034
   Fani N, 2012, BIOL PSYCHOL, V90, P134, DOI 10.1016/j.biopsycho.2012.03.001
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Felmingham K, 2007, PSYCHOL SCI, V18, P127, DOI 10.1111/j.1467-9280.2007.01860.x
   First M.B., 2012, STRUCTURED CLIN INTE
   Foa EB, 2009, EFFECTIVE TREATMENTS
   Hayes Jasmeet P, 2012, Biol Mood Anxiety Disord, V2, P9, DOI 10.1186/2045-5380-2-9
   Jovanovic T, 2010, AM J PSYCHIAT, V167, P648, DOI 10.1176/appi.ajp.2009.09071074
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Koch SBJ, 2016, NEUROPSYCHOPHARMACOL, V41, P1495, DOI 10.1038/npp.2015.299
   Koch SBJ, 2014, PSYCHONEUROENDOCRINO, V40, P242, DOI 10.1016/j.psyneuen.2013.11.018
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0
   Li Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035925
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011
   Milad MR, 2006, BEHAV NEUROSCI, V120, P1196, DOI 10.1037/0735-7044.120.5.1196
   Nawijn L, 2016, PSYCHONEUROENDOCRINO
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Olff M, 2010, CNS SPECTRUMS, V15, P522, DOI 10.1017/S109285290000047X
   Paloyelis Y, 2016, BIOL PSYCHIAT, V79, P693, DOI 10.1016/j.biopsych.2014.10.005
   Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003
   Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012
   Roy AK, 2009, NEUROIMAGE, V45, P614, DOI 10.1016/j.neuroimage.2008.11.030
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Sripada CS, 2013, INT J NEUROPSYCHOPH, V16, P255, DOI 10.1017/S1461145712000533
   Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33
   Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069
   Stefanacci L, 2002, J COMP NEUROL, V451, P301, DOI 10.1002/cne.10339
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   van Rooij SJH, 2015, NEUROPSYCHOPHARMACOL
   Yan CG, 2013, NEUROIMAGE, V76, P183, DOI 10.1016/j.neuroimage.2013.03.004
   Zoicas Iulia, 2014, Neuropsychopharmacology, V39, P3027, DOI 10.1038/npp.2014.156
NR 52
TC 0
Z9 0
U1 10
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUL
PY 2016
VL 41
IS 8
BP 2041
EP 2051
DI 10.1038/npp.2016.1
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DO5SJ
UT WOS:000377842800012
PM 26741286
ER

PT J
AU Muroy, SE
   Long, KLP
   Kaufer, D
   Kirby, ED
AF Muroy, Sandra E.
   Long, Kimberly L. P.
   Kaufer, Daniela
   Kirby, Elizabeth D.
TI Moderate Stress-Induced Social Bonding and Oxytocin Signaling are
   Disrupted by Predator Odor in Male Rats
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID DOMINANCE; HIPPOCAMPUS; EXPRESSION; RESPONSES; SUPPORT; ANXIETY; MEMORY;
   3,4-METHYLENEDIOXYMETHAMPHETAMINE; AFFILIATION; ENVIRONMENT
AB In times of stress, social support can serve as a potent buffering mechanism that enhances resilience. In humans, stress can promote protective affiliative interactions and prosocial behavior. Yet, stress also precipitates psychopathologies characterized by social withdrawal such as post-traumatic stress disorder (PTSD) and depression. The factors that drive adaptive vs maladaptive social responses to stress are not yet clear. Rodent studies have focused on pair-bonded, opposite-sex mates and suggest that a variety of stressors can induce social support-like behaviors. However, between same-sex conspecffics-particularly males-stress effects on social bonding are less understood and often associated with aggression and social unrest We thus sought to investigate if a moderate stressor-3 h of acute immobilization impacts social-support behaviors differently when experienced in a neutral vs more innately threatening context (ie, paired with predator odor). We found that moderate stress increased social support-seeking behavior in rat cagemates and facilitated long-term sharing of a limited water resource, decreased aggression, and strongly defined dominance ranks (an indicator of home cage stability). In contrast, experiencing the same stressor in the presence of predator odor eliminated the positive behavioral effects of moderate stress. Importantly, hypothalamic oxytocin (OT) signaling increased coincident with stress in a neutral but not a predator odor context. Our results define a novel rodent model of divergent stress effects on social affiliation and OT signaling dependent on odor context with particularly strong relevance to stress-related disorders such as PTSD, which are characterized by a disrupted ability to seek and maintain social bonds.
C1 [Muroy, Sandra E.; Kaufer, Daniela; Kirby, Elizabeth D.] Univ Calif Berkeley, Dept Integrat Biol, 430E Li Ka Shing Ctr, Berkeley, CA 94720 USA.
   [Long, Kimberly L. P.; Kaufer, Daniela; Kirby, Elizabeth D.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Integrat Biol, 430E Li Ka Shing Ctr, Berkeley, CA 94720 USA.
   [Kaufer, Daniela] Canadian Inst Adv Res, CIFAR Program Child & Brain Dev, Toronto, ON, Canada.
   [Kirby, Elizabeth D.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
RP Kaufer, D; Kirby, ED (reprint author), Univ Calif Berkeley, Dept Integrat Biol, 430E Li Ka Shing Ctr, Berkeley, CA 94720 USA.; Kaufer, D; Kirby, ED (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Integrat Biol, 430E Li Ka Shing Ctr, Berkeley, CA 94720 USA.
EM danielak@berkeley.edu; lizkirby@stanford.edu
FU NIMH BRAINS innovator award
FX SEM and EDK designed and performed experiments, analyzed data, and wrote
   the manuscript. KLPL performed experiments. DK designed experiments and
   wrote the manuscript. We thank IB Bartal, K Taravosh-Lahn, and AK Beery
   for helpful comments on the manuscript and DK Hernandez, MC Goff and JM
   Castellano for technical assistance. This work was supported by the NIMH
   BRAINS innovator award to DK.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Aragona BJ, 2004, ILAR J, V45, P35
   BEERY AK, 2015, STRESS, V1, P116, DOI DOI 10.1016/J.YNSTR.2014.10.004
   BERDOY M, 1995, BEHAVIOUR, V132, P193, DOI 10.1163/156853995X00694
   Blanchard RJ, 2001, PHYSIOL BEHAV, V73, P261, DOI 10.1016/S0031-9384(01)00449-8
   Bowen MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068483
   Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Carpenter CR, 1942, BIOL S, V8, P177
   CARTER CS, 1986, ADV STUD BEHAV, V16, P109, DOI 10.1016/S0065-3454(08)60189-8
   Champagne FA, 2003, PHYSIOL BEHAV, V79, P359, DOI 10.1016/S0031-9384(03)00149-5
   Choleris E, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P1, DOI 10.1017/CBO9781139017855
   Conrad CD, 1999, NEUROBIOL LEARN MEM, V72, P39, DOI 10.1006/nlme.1998.3898
   Desmedt A, 2015, BIOL PSYCHIAT, V78, P290, DOI 10.1016/j.biopsych.2015.06.017
   Dettmer AM, 2014, ILAR J, V55, P361, DOI 10.1093/ilar/ilu025
   DEWAAL FBM, 1986, Q REV BIOL, V61, P459, DOI 10.1086/415144
   Ditzen B, 2008, J PSYCHOSOM RES, V64, P479, DOI 10.1016/j.jpsychores.2007.11.011
   Dumont GJH, 2006, J PSYCHOPHARMACOL, V20, P176, DOI 10.1177/0269881106063271
   Gavrilets S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4526
   Gunnar MR, 2000, MINN SYM CHILD PSYCH, V31, P163
   Hebb ALO, 2004, EUR J NEUROSCI, V20, P2415, DOI 10.1111/j.1460-9568.2004.03704.x
   HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889
   Janitzky K, 2015, BRAIN RES, V1599, P1, DOI 10.1016/j.brainres.2014.12.030
   Kikusui T, 2006, PHILOS T R SOC B, V361, P2215, DOI 10.1098/rstb.2006.1941
   Kim EJ, 2015, LEARN MEMORY, V22, P411, DOI 10.1101/lm.037291.114
   Kirby ED, 2013, ELIFE, V2, DOI 10.7554/eLife.00362
   KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P23
   Koolhaas JM, 2013, JOVE-J VIS EXP, DOI 10.3791/4367
   LATANE B, 1969, J EXP SOC PSYCHOL, V5, P61, DOI 10.1016/0022-1031(69)90006-7
   LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0
   McEwen BS, 2001, ANN NY ACAD SCI, V933, P265
   Morrow BA, 2000, BRAIN RES BULL, V52, P519, DOI 10.1016/S0361-9230(00)00290-2
   Nosjean Anne, 2014, Front Behav Neurosci, V8, P447, DOI 10.3389/fnbeh.2014.00447
   Parker KJ, 2006, P NATL ACAD SCI USA, V103, P3000, DOI 10.1073/pnas.0506571103
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   Sandi C, 2015, NAT REV NEUROSCI, V16, P290, DOI 10.1038/nrn3918
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   SMITH MA, 1995, J NEUROSCI, V15, P1768
   Stefanik P, 2015, PHARMACOL BIOCHEM BE, V131, P42, DOI 10.1016/j.pbb.2015.01.021
   Takahashi T, 2007, NEUROENDOCRINOL LETT, V28, P662
   Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411
   Taylor SE, 2011, OXFORD HDB HLTH PSYC, P189, DOI DOI 10.1093/OXFORDHB/9780195342819.013.0009
   ULRICH RE, 1962, J EXP ANAL BEHAV, V5, P511, DOI 10.1901/jeab.1962.5-511
   VANKREVE.D, 1970, GENET PSYCHOL MONOGR, V81, P143
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   von Dawans B, 2012, PSYCHOL SCI, V23, P651, DOI 10.1177/0956797611431576
   West SA, 2007, CURR BIOL, V17, pR661, DOI 10.1016/j.cub.2007.06.004
   Yee JR, 2008, PSYCHOSOM MED, V70, P1050, DOI 10.1097/PSY.0b013e31818425fb
   [Anonymous], 2005, COMPREHENSIVE ALGORI
   ZUCKER RA, 1968, J PERS SOC PSYCHOL, V8, P354, DOI 10.1037/h0025574
NR 50
TC 1
Z9 1
U1 10
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUL
PY 2016
VL 41
IS 8
BP 2160
EP 2170
DI 10.1038/npp.2016.16
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DO5SJ
UT WOS:000377842800023
PM 26830961
ER

PT J
AU Ebner, NC
   Chen, HH
   Porges, E
   Lin, T
   Fischer, H
   Feifel, D
   Cohen, RA
AF Ebner, Natalie C.
   Chen, Huaihou
   Porges, Eric
   Lin, Tian
   Fischer, Hakan
   Feifel, David
   Cohen, Ronald A.
TI Oxytocin's effect on resting-state functional connectivity varies by age
   and sex
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Aging; Sex; Resting-state functional connectivity; Amygdala;
   Medial prefrontal cortex
ID AUTISM SPECTRUM DISORDERS; SOCIAL ANXIETY DISORDER; INTRANASAL OXYTOCIN;
   MATERNAL-BEHAVIOR; ESTROGEN-RECEPTOR; NEURAL CIRCUITRY; FRONTAL-CORTEX;
   HUMAN BRAIN; FEMALE RAT; AMYGDALA
AB The neuropeptide oxytocin plays a role in social cognition and affective processing. The neural processes underlying these effects are not well understood. Modulation of connectivity strength between subcortical and cortical regions has been suggested as one possible mechanism. The current study investigated effects of intranasal oxytocin administration on resting-state functional connectivity between amygdala and medial prefrontal cortex (mPFC), as two regions involved in social-cognitive and affective processing. Going beyond previous work that largely examined young male participants, our study comprised young and older men and women to identify age and sex variations in oxytocin's central processes. This approach was based on known hormonal differences among these groups and emerging evidence of sex differences in oxytocin's effects on amygdala reactivity and age-by-sex-modulated effects of oxytocin in affective processing. In a double-blind design, 79 participants were randomly assigned to self-administer either intranasal oxytocin or placebo before undergoing resting-state functional magnetic resonance imaging. Using a targeted region-to-region approach, resting-state functional connectivity strength between bilateral amygdala and mPFC was examined. Participants in the oxytocin compared to the placebo group and men compared to women had overall greater amygdala-mPFC connectivity strength at rest. These main effects were qualified by a significant three-way interaction: while oxytocin compared to placebo administration increased resting-state amygdala-mPFC connectivity for young women, oxytocin did not significantly influence connectivity in the other age-by-sex subgroups. This study provides novel evidence of age-by-sex differences in how oxytocin modulates resting-state brain connectivity, furthering our understanding of how oxytocin affects brain networks at rest. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Ebner, Natalie C.; Lin, Tian] Univ Florida, Dept Psychol, POB 112250, Gainesville, FL 32611 USA.
   [Ebner, Natalie C.; Chen, Huaihou; Porges, Eric; Cohen, Ronald A.] Univ Florida, Inst Aging, Clin Translat Res Program CAM CTRP, Cognit Aging & Memory Program,Dept Aging & Geriat, 2004 Mowry Rd, Gainesville, FL 32611 USA.
   [Chen, Huaihou] Univ Florida, Dept Biostat, 2004 Mowry Rd, Gainesville, FL 32611 USA.
   [Fischer, Hakan] Stockholm Univ, Dept Psychol, Frescati Hagvag 14,Room 320, SE-10691 Stockholm, Sweden.
   [Feifel, David] Univ Calif San Diego, Dept Psychiat, 200 W Arbor Dr, San Diego, CA 92103 USA.
RP Ebner, NC (reprint author), Univ Florida, Dept Psychol, POB 112250, Gainesville, FL 32611 USA.
EM natalie.ebner@ufl.edu; huaihouchen@phhp.ufl.edu; eporges@ufl.edu;
   lintian0527@ufl.edu; hakan.fischer@psychology.su.se; dfeifel@ucsd.edu;
   roncohen@ufl.edu
FU Department of Psychology at University of Florida; McKnight Brain
   Research Foundation; University of Florida Center for Cognitive Aging
   and Memory; University of Florida Clinical and Translational Science
   pilot award (NIH/NCATS) [UL1 TR000064]; Scientific Research Network on
   Decision Neuroscience and Aging pilot award (NIH/NIA) [R24 AG039350]
FX This work was supported by the Department of Psychology at University of
   Florida, the McKnight Brain Research Foundation, and the University of
   Florida Center for Cognitive Aging and Memory, as well as a University
   of Florida Clinical and Translational Science pilot award (NIH/NCATS;
   UL1 TR000064), and a Scientific Research Network on Decision
   Neuroscience and Aging pilot award (NIH/NIA, R24 AG039350) to NCE.
CR AKAISHI T, 1985, BRAIN RES, V335, P302, DOI 10.1016/0006-8993(85)90481-0
   Altemus M, 1999, BIOL PSYCHIAT, V45, P931, DOI 10.1016/S0006-3223(98)00263-7
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Bale TL, 1997, ENDOCRINOLOGY, V138, P1151, DOI 10.1210/en.138.3.1151
   Banks SJ, 2007, SOC COGN AFFECT NEUR, V2, P303, DOI 10.1093/scan/nsm029
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Bickart KC, 2012, J NEUROSCI, V32, P14729, DOI 10.1523/JNEUROSCI.1599-12.2012
   Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bos PA, 2012, FRONT NEUROENDOCRIN, V33, P17, DOI 10.1016/j.yfrne.2011.01.002
   Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678
   Braun U, 2012, NEUROIMAGE, V59, P1404, DOI 10.1016/j.neuroimage.2011.08.044
   Campbell A, 2014, NEUROBIOL AGING, V35, P2246, DOI 10.1016/j.neurobiolaging.2014.04.021
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497
   De Dreu C.K.W., 2014, MECH SOCIAL CONNECTI, P391, DOI DOI 10.1037/14250-022
   Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021
   Dodhia S, 2014, NEUROPSYCHOPHARMACOL, V39, P2061, DOI 10.1038/npp.2014.53
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Dunbar RIM, 1998, EVOL ANTHROPOL, V6, P178, DOI 10.1002/(SICI)1520-6505(1998)6:5<178::AID-EVAN5>3.0.CO;2-8
   Ebner NC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00175
   Ebner NC, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01595
   Ebner NC, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00487
   Ellenbogen MA, 2014, PSYCHOPHYSIOLOGY, V51, P1169, DOI 10.1111/psyp.12263
   Fan Y, 2014, HUM BRAIN MAPP, V35, P5328, DOI 10.1002/hbm.22553
   Farmer J, 2013, AUST J RURAL HEALTH, V21, P20, DOI 10.1111/ajr.12004
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027
   Gosling SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   GUR RC, 1995, SCIENCE, V267, P528, DOI 10.1126/science.7824953
   Huang CC, 2015, CNS NEUROSCI THER, V21, P817, DOI 10.1111/cns.12396
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   Huffmeijer R, 2013, GERONTOLOGY, V59, P32, DOI 10.1159/000341333
   Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Kanat M, 2014, BRAIN RES, V1580, P160, DOI 10.1016/j.brainres.2013.11.003
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kovacs B, 2015, EUR PSYCHIAT, V30, P542, DOI 10.1016/j.eurpsy.2015.02.010
   Kumar J., 2015, INT J NEUROPSYCHOPH, V18, P1
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   MacDonald K, 2012, ACTA NEUROPSYCHIATR, V24, P130, DOI 10.1111/j.1601-5215.2011.00634.x
   MacDonald KS, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00194
   Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Pessoa L, 2008, NAT REV NEUROSCI, V9, P148, DOI 10.1038/nrn2317
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018
   Prater KE, 2013, DEPRESS ANXIETY, V30, P234, DOI 10.1002/da.22014
   QuinonesJenab V, 1997, NEUROENDOCRINOLOGY, V65, P9, DOI 10.1159/000127160
   Rey A., 1964, EXAMEN CLIN PSYCHOL
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Sergerie K, 2008, NEUROSCI BIOBEHAV R, V32, P811, DOI 10.1016/j.neubiorev.2007.12.002
   Sripada CS, 2013, INT J NEUROPSYCHOPH, V16, P255, DOI 10.1017/S1461145712000533
   Vasudevan N, 2001, NEUROENDOCRINOLOGY, V74, P309, DOI 10.1159/000054698
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Wechsler D., 1981, WAIS R MANUAL WECHSL
   Wei MF, 2007, J PERS ASSESS, V88, P187
   Whitfield-Gabrieli Susan, 2012, Brain Connect, V2, P125, DOI 10.1089/brain.2012.0073
   Young LJ, 1998, NEUROREPORT, V9, P933, DOI 10.1097/00001756-199803300-00031
NR 70
TC 2
Z9 2
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUL
PY 2016
VL 69
BP 50
EP 59
DI 10.1016/j.psyneuen.2016.03.013
PG 10
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DO4CH
UT WOS:000377728900007
PM 27032063
ER

PT J
AU Rault, JL
AF Rault, Jean-Loup
TI Effects of positive and negative human contacts and intranasal oxytocin
   on cerebrospinal fluid oxytocin
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Behavior; Brain; Central; CSF; Human-animal relationship; Neuropeptide
ID BLOOD-BRAIN-BARRIER; PLASMA OXYTOCIN; SOCIAL-BEHAVIOR; RHESUS MACAQUES;
   VASOPRESSIN; PIGS; NEUROPEPTIDES; PARTURITION; CLEARANCE; PEPTIDES
AB Despite the popularity of oxytocin (OT) research for its role in social behavior, the relationship between the social environment and endogenous central OT remains poorly understood. This study investigated the effects of positive and negative human contacts and intranasal OT administration on OT concentration in the cerebrospinal fluid (CSF). The pig was used as a model, with repeated CSF sampling through a spinal catheter using a within-subject design. Positive human contact led to sustained CSF OT elevation in pigs over 120 min which outlasted the 15 min interaction. Furthermore, the frequency of positive interactions was correlated with CSF OT increase. This provides a neurophysiological basis to positive human-animal relationships, with OT preserving bonds within but also between species through interactions. Conversely, CSF OT concentration did not vary during or after negative contact with an unfamiliar person, supporting CSF OT as a biomarker of positive valence in the human-animal relationship context. Intranasal OT administration resulted in peak CSF OT within 10 min, with approximately 0.001% of the administered dose reaching the CSF. The sensitivity of the oxytocinergic system to variations in the social environment is a worthy area of investigation for its scientific and clinical implications. In particular, positive interactions result in outlasting central OT release. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Rault, Jean-Loup] Univ Melbourne, Fac Vet & Agr Sci, Anim Welf Sci Ctr, Parkville, Vic 3010, Australia.
RP Rault, JL (reprint author), Univ Melbourne, Fac Vet & Agr Sci, Anim Welf Sci Ctr, Parkville, Vic 3010, Australia.
EM raultj@unimelb.edu.au
FU University of Melbourne [601692]
FX This research was partly funded by a University of Melbourne Early
   Career Researcher Grant (# 601692).
CR AMICO JA, 1990, J CLIN ENDOCR METAB, V71, P1531
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bernards CM, 2006, ANESTHESIOLOGY, V105, P169, DOI 10.1097/00000542-200607000-00027
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Christensen JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116172
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Coulon M, 2013, PSYCHONEUROENDOCRINO, V38, P499, DOI 10.1016/j.psyneuen.2012.07.008
   Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677
   DARPA-Defense Advanced Research Project Agency, 2013, SB132001 DARPA SMALL
   ERMISCH A, 1985, ENDOCRINOL EXP, V19, P29
   Hemsworth PH, 2011, HUMAN-LIVESTOCK INTERACTIONS, 2ND EDITION: THE STOCKPERSON AND THE PRODUCTIVITY AND WELFARE OF INTENSIVELY FARMED ANIMALS, P1, DOI 10.1079/9781845936730.0000
   Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016
   JONES PM, 1982, NEUROENDOCRINOLOGY, V34, P297, DOI 10.1159/000123316
   Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
   Kang YS, 2000, ARCH PHARM RES, V23, P391, DOI 10.1007/BF02975453
   KENDRICK KM, 1991, BRAIN RES BULL, V26, P803, DOI 10.1016/0361-9230(91)90178-M
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   McEwen B. B., 2004, ADV PHARMACOL, P531
   MENS WBJ, 1983, BRAIN RES, V262, P143, DOI 10.1016/0006-8993(83)90478-X
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Neumann I, 1996, J NEUROENDOCRINOL, V8, P227, DOI 10.1046/j.1365-2826.1996.04557.x
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Neumann ID, 2009, FRONT NEUROENDOCRIN, V30, P483, DOI 10.1016/j.yfrne.2009.04.012
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Parker KJ, 2010, BEHAV NEUROSCI, V124, P428, DOI 10.1037/a0019576
   Perlow K.J., 1982, SCIENCE, V216, P1416
   Rault JL, 2013, PHYSIOL BEHAV, V112, P40, DOI 10.1016/j.physbeh.2013.02.007
   Rault JL, 2012, APPL ANIM BEHAV SCI, V136, P1, DOI 10.1016/j.applanim.2011.10.002
   Rault J.-L., 2015, ANIMALS, V5, P0371
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Veening JG, 2010, PHYSIOL BEHAV, V101, P193, DOI 10.1016/j.physbeh.2010.05.004
   WACHS EA, 1984, DOMEST ANIM ENDOCRIN, V1, P121, DOI 10.1016/0739-7240(84)90026-2
   Watson PMD, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-59
   Winslow JT, 2003, NEUROPSYCHOPHARMACOL, V28, P910, DOI 10.1038/sj.npp.1300128
NR 42
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUL
PY 2016
VL 69
BP 60
EP 66
DI 10.1016/j.psyneuen.2016.03.015
PG 7
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DO4CH
UT WOS:000377728900008
PM 27032064
ER

PT J
AU Kimmel, M
   Clive, M
   Gispen, F
   Guintivano, J
   Brown, T
   Cox, O
   Beckmann, MW
   Kornhuber, J
   Fasching, PA
   Osborne, LM
   Binder, E
   Payne, JL
   Kaminsky, Z
AF Kimmel, Mary
   Clive, Makena
   Gispen, Fiona
   Guintivano, Jerry
   Brown, Tori
   Cox, Olivia
   Beckmann, Matthias W.
   Kornhuber, Johannes
   Fasching, Peter A.
   Osborne, Lauren M.
   Binder, Elisabeth
   Payne, Jennifer L.
   Kaminsky, Zachary
TI Oxytocin receptor DNA methylation in postpartum depression
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Postpartum depression; Trauma; DNA methylation; OXTR; Allopregnanolone;
   Estradiol
ID BETA(2)-ADRENERGIC RECEPTOR; ERK1/2 ACTIVATION; LATE PREGNANCY;
   ALLOPREGNANOLONE; GENE; SYMPTOMS; HISTORY; RISK; ESTROGEN; WOMEN
AB The oxytocin receptor (OXTR) is a key regulator of stress and anxiety and may be regulated by both psychosocial risk factors and gonadal hormones, making it an attractive candidate for study in postpartum depression (PPD). The objective of this study was to investigate both serum hormone and PPD specific DNA methylation variation in the OXTR. Illumina HM450 microarray data generated in a prospective PPD cohort identified significant associations (P = 0.014) with PPD in an intronic region in the OXTR located 4 bp proximal to an estrogen receptor (ER) binding region. Pyrosequencing confirmed moderate evidence for an interaction of CpGs in the region with childhood abuse status to mediate PPD. These CpGs located on chr3 at positions 8810078 and 8810069 exhibited significant associations with postpartum depression scores from an independent cohort of 240 women with no prior psychiatric history. Hormone analysis suggested a PPD specific negative correlation of DNA methylation in the region with serum estradiol levels. Estradiol levels and OXTR DNA methylation exhibited a significant interaction to associate with the ratio of allopregnanolone to progesterone. Cumulatively, the data corroborate our previous hypotheses of a PPD specific increased sensitivity of epigenetic reprogramming at estrogen target genes and suggests that OXTR epigenetic variation may be an important mediator of mood relevant neuroactive steroid production. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kimmel, Mary; Clive, Makena; Gispen, Fiona; Guintivano, Jerry; Brown, Tori; Cox, Olivia; Osborne, Lauren M.; Payne, Jennifer L.; Kaminsky, Zachary] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA.
   [Kaminsky, Zachary] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21287 USA.
   [Binder, Elisabeth] Max Planck Inst Psychiat, Dept Translat Res Psychiat, D-80804 Munich, Germany.
   [Beckmann, Matthias W.; Fasching, Peter A.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, D-91054 Erlangen, Germany.
   [Kornhuber, Johannes] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Psychiat, D-91054 Erlangen, Germany.
   [Kimmel, Mary] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA.
RP Kaminsky, Z (reprint author), Johns Hopkins Univ, Mood Disorder Ctr, 720 Rutland Ave,Ross Res Bldg 1070, Baltimore, MD 21205 USA.
EM zkamins1@jhmi.edu
FU Solomon R. & Rebecca D. Baker Foundation; NARSAD Young Investigator
   Award; National Institute of Mental Health (NIMH) [K23 MH074799-01A2]
FX We would like to thank Dr. Summer Rosenstock Ph.D. of the Johns Hopkins
   Bloomberg School of Public Health, Department of International Health,
   for guidance on visual presentation of statistical models in this work.
   We would like to thank The Solomon R. & Rebecca D. Baker Foundation for
   their generous support of this research. This work was funded in part by
   a NARSAD 2010 Young Investigator Award to Dr. Kaminsky and by National
   Institute of Mental Health (NIMH) Grant K23 MH074799-01A2 to Dr. Payne.
   Prospective human subjects research was conducted under IRB protocol #
   00008149 and # 00049309.
CR Ammerman R. T., 2012, PSYCHOL TRAUMA THEOR, V4
   Andreen L, 2009, PSYCHONEUROENDOCRINO, V34, P1121, DOI 10.1016/j.psyneuen.2009.02.003
   Aswathi A, 2015, Asian J Psychiatr, V17, P85, DOI 10.1016/j.ajp.2015.08.008
   Backstrom T, 2011, NEUROSCIENCE, V191, P46, DOI 10.1016/j.neuroscience.2011.03.061
   Bakermans-Kranenburg MJ, 2012, SOC COGN AFFECT NEUR, V7, P951, DOI 10.1093/scan/nsr067
   Bali A, 2014, PROG NEURO-PSYCHOPH, V48, P64, DOI 10.1016/j.pnpbp.2013.09.005
   Bartella V, 2012, BREAST CANCER RES TR, V134, P569, DOI 10.1007/s10549-012-2090-9
   Bell AF, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00243
   Berretti R, 2014, HORM BEHAV, V65, P142, DOI 10.1016/j.yhbeh.2013.12.009
   Bloch M, 2000, AM J PSYCHIAT, V157, P924, DOI 10.1176/appi.ajp.157.6.924
   Brunton PJ, 2014, PROG NEUROBIOL, V113, P106, DOI 10.1016/j.pneurobio.2013.08.005
   Bunevicius R, 2009, WORLD J BIOL PSYCHIA, V10, P324, DOI 10.3109/15622970903144038
   Colantuoni C, 2011, NATURE, V478, P519, DOI 10.1038/nature10524
   Cuijpers P, 2008, J CLIN PSYCHOL, V64, P103, DOI 10.1002/jclp.20432
   Deligiannidis KM, 2013, J PSYCHIATR RES, V47, P816, DOI 10.1016/j.jpsychires.2013.02.010
   Devost D, 2008, PROG BRAIN RES, V170, P167, DOI 10.1016/S0079-6123(08)00415-9
   Field T, 2011, INFANT BEHAV DEV, V34, P1, DOI 10.1016/j.infbeh.2010.09.008
   Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI [10.1210/en.2005-1120, 10.1210/en.2006-0349]
   Franczak A, 2002, REPROD NUTR DEV, V42, P327, DOI 10.1051/rnd:2002029
   Gagnidze K, 2013, J NEUROENDOCRINOL, V25, P939, DOI 10.1111/jne.12085
   Girdler SS, 2012, PSYCHONEUROENDOCRINO, V37, P543, DOI 10.1016/j.psyneuen.2011.08.004
   Guintivano J, 2014, MOL PSYCHIATR, V19, P560, DOI 10.1038/mp.2013.62
   Harony-Nicolas H, 2014, PSYCHONEUROENDOCRINO, V39, P121, DOI 10.1016/j.psyneuen.2013.10.004
   Hellgren C, 2014, NEUROPSYCHOBIOLOGY, V69, P147, DOI 10.1159/000358838
   Hirst KP, 2010, AM FAM PHYSICIAN, V82, P926
   Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96
   Huffmeijer R, 2011, BIOL PSYCHOL, V86, P307, DOI 10.1016/j.biopsycho.2011.01.003
   Jeong HG, 2013, GEN HOSP PSYCHIAT, V35, P354, DOI 10.1016/j.genhosppsych.2013.02.009
   Josefsson A, 2001, ACTA OBSTET GYN SCAN, V80, P251
   Juif PE, 2013, J NEUROSCI, V33, P16617, DOI 10.1523/JNEUROSCI.3084-12.2013
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Lightman SL, 2014, NAT REV ENDOCRINOL, V10, P71, DOI 10.1038/nrendo.2013.257
   Magiakou MA, 1996, J CLIN ENDOCR METAB, V81, P1912, DOI 10.1210/jc.81.5.1912
   Mamrut S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056869
   McCoy SJB, 2011, SOUTH MED J, V104, P128, DOI 10.1097/SMJ.0b013e318200c221
   Mehta D., 2014, PSYCHOL MED, P1
   Mehta D, 2012, J AFFECT DISORDERS, V136, P1192, DOI 10.1016/j.jad.2011.11.042
   Meltzer-Brody S., 2013, AM J OBSTET GYNECOL, V208, pe211
   Miller LJ, 2002, JAMA-J AM MED ASSOC, V287, P762, DOI 10.1001/jama.287.6.762
   Miranda TB, 2013, CANCER RES, V73, P5130, DOI 10.1158/0008-5472.CAN-13-0742
   Myers AJ, 2014, J PSYCHIATR RES, V59, P93, DOI 10.1016/j.jpsychires.2014.08.021
   O'Hara MW, 2009, J CLIN PSYCHOL, V65, P1258, DOI 10.1002/jclp.20644
   Osborne L., 2015, NEUROPSYCHOPHARMACOL, V41, P1648
   Pearlstein T, 2009, AM J OBSTET GYNECOL, V200, P357, DOI 10.1016/j.ajog.2008.11.033
   Pedersen CA, 2007, PSYCHONEUROENDOCRINO, V32, P235, DOI 10.1016/j.psyneuen.2006.12.010
   Perroud N, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.60
   Provencal N, 2015, EXP NEUROL, V268, P10, DOI 10.1016/j.expneurol.2014.09.001
   QuinonesJenab V, 1997, NEUROENDOCRINOLOGY, V65, P9, DOI 10.1159/000127160
   Reiner I, 2015, J PSYCHIATR RES, V65, P9, DOI 10.1016/j.jpsychires.2015.03.012
   Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006
   Schiller CE, 2014, PSYCHOPHARMACOLOGY, V231, P3557, DOI 10.1007/s00213-014-3599-x
   Skrundz M, 2011, NEUROPSYCHOPHARMACOL, V36, P1886, DOI 10.1038/npp.2011.74
   Smith A.S., 2015, PSYCHONEUROENDOCRINO, V63, P50
   Soufia M, 2010, ENCEPHALE, V36, P513, DOI 10.1016/j.encep.2010.02.003
   Studd J. W., 2011, CLIMACTERIC
   Stuebe AM, 2012, J WOMENS HEALTH, V21, P264, DOI 10.1089/jwh.2011.3083
   Sundaram S, 2014, WOMEN HEALTH ISS, V24, pE381, DOI 10.1016/j.whi.2014.05.001
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Unternaehrer E., 2015, STRESS, P1, DOI DOI 10.3109/10253890.2015.1038992
   Viguera AC, 2011, AM J PSYCHIAT, V168, P1179, DOI 10.1176/appi.ajp.2011.11010148
   Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116
   Windle RJ, 2006, ENDOCRINOLOGY, V147, P2423, DOI 10.1210/en.2005-1079
   Wrzal PK, 2012, CELL SIGNAL, V24, P342, DOI 10.1016/j.cellsig.2011.09.020
   Wrzal PK, 2012, CELL SIGNAL, V24, P333, DOI 10.1016/j.cellsig.2011.09.019
   Yim IS, 2015, ANNU REV CLIN PSYCHO, V11, P99, DOI 10.1146/annurev-clinpsy-101414-020426
   Yim IS, 2010, J AFFECT DISORDERS, V125, P128, DOI 10.1016/j.jad.2009.12.009
NR 66
TC 1
Z9 1
U1 22
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUL
PY 2016
VL 69
BP 150
EP 160
DI 10.1016/j.psyneuen.2016.04.008
PG 11
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DO4CH
UT WOS:000377728900018
PM 27108164
ER

PT J
AU Quintana, DS
   Westlye, LT
   Alnaes, D
   Rustan, OG
   Kaufmann, T
   Smerud, KT
   Mahmoud, RA
   Djupesland, PG
   Andreassen, OA
AF Quintana, Daniel S.
   Westlye, Lars T.
   Alnaes, Dag
   Rustan, Oyvind G.
   Kaufmann, Tobias
   Smerud, Knut T.
   Mahmoud, Ramy A.
   Djupesland, Per G.
   Andreassen, Ole A.
TI Low dose intranasal oxytocin delivered with Breath Powered device
   dampens amygdala response to emotional stimuli: A peripheral
   effect-controlled within-subjects randomized dose-response fMRI trial
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Intranasal; Intravenous; Dose-response; fMRI
ID SOCIAL COGNITION; SUMATRIPTAN POWDER; HUMAN BRAIN; NASAL; FEAR;
   REACTIVITY; DISORDERS; ANXIETY; AUTISM; SCHIZOPHRENIA
AB It is unclear if and how exogenous oxytocin (OT) reaches the brain to improve social behavior and cognition and what is the optimal dose for OT response. To better understand the delivery routes of intranasal OT administration to the brain and the dose-response, we compared amygdala response to facial stimuli by means of functional magnetic resonance imaging (fMRI) in four treatment conditions, including two different doses of intranasal OT using a novel Breath Powered device, intravenous (IV) OT, which provided similar concentrations of blood plasma OT, and placebo. We adopted a randomized, double-blind, double-dummy, crossover design, with 16 healthy male adults administering a single-dose of these four treatments. We observed a treatment effect on right amygdala activation during the processing of angry and happy face stimuli, with pairwise comparisons revealing reduced activation after the 8IU low dose intranasal treatment compared to placebo. These data suggest the dampening of amygdala activity in response to emotional stimuli occurs via direct intranasal delivery pathways rather than across the blood-brain barrier via systemically circulating OT. Trial registration: This trial is registered at the U.S. National Institutes of Health clinical trial registry (www.clinicaltrials.gov; NCT01983514) and as EudraCT no. 2013-001608-12. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Quintana, Daniel S.; Westlye, Lars T.; Alnaes, Dag; Rustan, Oyvind G.; Kaufmann, Tobias; Andreassen, Ole A.] Univ Oslo, Oslo Univ Hosp, Div Hlth & Addict, NORMENT,KG Jebsen Ctr Psychosis Res, Oslo, Norway.
   [Westlye, Lars T.] Univ Oslo, Dept Psychol, Oslo, Norway.
   [Smerud, Knut T.] Smerud Med Res Int AS, Oslo, Norway.
   [Mahmoud, Ramy A.] OptiNose US Inc, Yardley, PA USA.
   [Djupesland, Per G.] OptiNose AS, Oslo, Norway.
RP Andreassen, OA (reprint author), Oslo Univ Hosp, KG Jebsen Ctr Psychosis Res, NORMENT, Bldg 49,Kirkeveien 166,POB 4956 Nydalen, N-0424 Oslo, Norway.
EM o.a.andreassen@medisin.uio.no
OI Westlye, Lars T./0000-0001-8644-956X
FU Research Council of Norway; OptiNose AS [BIA 219483]
FX This study was supported by the Research Council of Norway and OptiNose
   AS (Grant no. BIA 219483). The Research Council of Norway had no
   influence in the ideas contained in the manuscript and no role in the
   writing of the manuscript.
CR Bakke H, 2006, SCAND J IMMUNOL, V63, P223, DOI 10.1111/j.1365-3083.2006.01730.x
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   BENELLI A, 1995, NEUROPEPTIDES, V28, P251, DOI 10.1016/0143-4179(95)90029-2
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Bethlehem RAI, 2013, PSYCHONEUROENDOCRINO, V38, P962, DOI 10.1016/j.psyneuen.2012.10.011
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Dale O, 2006, J PHARM PHARMACOL, V58, P1311, DOI 10.1211/jpp.58.10.0003
   Davis MC, 2013, SCHIZOPHR RES, V147, P393, DOI 10.1016/j.schres.2013.04.023
   Djupesland Per G, 2014, Ther Deliv, V5, P709, DOI 10.4155/tde.14.41
   Djupesland P.G., 2012, DRUG DELIV TRANSL RE, V3, P42
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Frijling JL, 2016, NEUROPSYCHOPHARMACOL, V41, P1286, DOI 10.1038/npp.2015.278
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gouin JP, 2010, PSYCHONEUROENDOCRINO, V35, P1082, DOI 10.1016/j.psyneuen.2010.01.009
   Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060
   Guastella AJ, 2016, BIOL PSYCHIAT, V79, P234, DOI 10.1016/j.biopsych.2015.06.028
   Guastella AJ, 2015, SCHIZOPHR RES, V168, P628, DOI 10.1016/j.schres.2015.06.005
   Guastella AJ, 2013, PSYCHONEUROENDOCRINO, V38, P612, DOI 10.1016/j.psyneuen.2012.11.019
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Guastella A. J., 2012, HORM BEHAV, V61, P410, DOI DOI 10.1016/J.YHBEH.2012.01.002
   Hall SS, 2012, PSYCHONEUROENDOCRINO, V37, P509, DOI 10.1016/j.psyneuen.2011.07.020
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Insel TR, 2016, BIOL PSYCHIAT, V79, P153, DOI 10.1016/j.biopsych.2015.02.002
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   Kanat M, 2015, NEUROPSYCHOPHARMACOL, V40, P287, DOI 10.1038/npp.2014.183
   Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Koch SBJ, 2014, PSYCHONEUROENDOCRINO, V40, P242, DOI 10.1016/j.psyneuen.2013.11.018
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lane A, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12384
   Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8
   LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629
   Legios J.-J., 2001, PSYCHONEUROENDOCRINO, V26, P649
   Leknes S, 2012, SOC COGN AFFECT NEUR, V8, P741
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Lundqvist D., 1998, KAROLINSKA DIRECTED
   MayerHubner B, 1996, LANCET, V347, P623, DOI 10.1016/S0140-6736(96)91325-2
   McEwen Barbara B, 2004, Adv Pharmacol, V50, P531
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Merlcus P., 2003, NEUROLOGY, V60, P1669
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Obaidi M, 2013, HEADACHE, V53, P1323, DOI 10.1111/head.12167
   Ousdal OT, 2008, NEUROSCIENCE, V156, P450, DOI 10.1016/j.neuroscience.2008.07.066
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   Quintana DS, 2016, MOL PSYCHIATR, V21, P29, DOI 10.1038/mp.2015.166
   Quintana DS, 2016, BIOL PSYCHIAT, V79, pE49, DOI 10.1016/j.biopsych.2015.06.021
   Quintana DS, 2015, NEUROSCI BIOBEHAV R, V49, P182, DOI 10.1016/j.neubiorev.2014.12.011
   Quintana DS, 2015, TRANSL PSYCHIAT, V5, P1
   Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007
   Smith SM, 1997, INT J COMPUT VISION, V23, P45, DOI 10.1023/A:1007963824710
   Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051
   Sosulski D.L., 2012, NATURE, V472, P213
   Tepper SJ, 2015, HEADACHE, V55, P621, DOI 10.1111/head.12583
   Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029
   Wechsler D., 1999, WESCHSLER ABBREVIATE
   Wetzels R, 2012, PSYCHON B REV, V19, P1057, DOI 10.3758/s13423-012-0295-x
   Whalen PJ, 2007, TRENDS COGN SCI, V11, P499, DOI 10.1016/j.tics.2007.08.016
   Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931
   Yamasue H, 2016, PSYCHIAT CLIN NEUROS, V70, P89, DOI 10.1111/pcn.12364
   Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162
NR 71
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUL
PY 2016
VL 69
BP 180
EP 188
DI 10.1016/j.psyneuen.2016.04.010
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DO4CH
UT WOS:000377728900021
PM 27107209
ER

PT J
AU Santos, JEP
   Bisinotto, RS
   Ribeiro, ES
AF Santos, J. E. P.
   Bisinotto, R. S.
   Ribeiro, E. S.
TI Mechanisms underlying reduced fertility in anovular dairy cows
SO THERIOGENOLOGY
LA English
DT Review
DE Anovular; Conceptus; Corpus luteum; Disease; Progesterone
ID NEGATIVE-ENERGY-BALANCE; ARTIFICIAL-INSEMINATION PROTOCOL;
   LUTEINIZING-HORMONE SECRETION; NONESTERIFIED-FATTY-ACIDS; CELL SIGNALING
   PATHWAYS; PROGESTERONE SUPPLEMENTATION; OVULATORY FOLLICLE; ESTROUS
   CYCLES; BOVINE-OOCYTES; CORPUS-LUTEUM
AB Resumption of ovulation after parturition is a coordinated process that involves recoupling of the GH/insulin-like growth factor 1 axis in the liver, increase in follicular development and steroidogenesis, and removal of negative feedback from estradiol in the hypothalamus. Infectious diseases and metabolic disorders associated with extensive negative energy balance during early lactation disrupt this pathway and delay first ovulation postpartum. Extended periods of anovulation postpartum exert long-lasting effects on fertility in dairy cows including the lack of spontaneous estrus, reduced pregnancy per artificial insemination (P/AI), and increased risk of pregnancy loss. Concentrations of progesterone in anovular cows subjected to synchronized programs for AI are insufficient to optimize follicular maturation, oocyte competence, and subsequent fertility to AI. Ovulation of first wave follicles, which develop under low concentrations of progesterone, reduces embryo quality in the first week after fertilization and P/AI in dairy cows. Although the specific mechanisms by which anovulation and low concentrations of progesterone impair oocyte quality have not been defined, studies with persistent follicles support the involvement of premature resumption of meiosis and degradation of maternal RNA. Suboptimal concentrations of progesterone before ovulation also increase the synthesis of PGF(2 alpha) in response to oxytocin during the subsequent estrous cycle, which explains the greater incidence of short luteal phases after the first AI postpartum in anovular cows compared with estrous cyclic herd mates. It is suggested that increased spontaneous luteolysis early in the estrous cycle is one of the mechanisms that contributes to early embryonic losses in anovular cows. Anovulation also leads to major shifts in gene expression in elongated conceptuses during preimplantation stages of pregnancy. Transcripts involved with control of energy metabolism and DNA repair were downregulated, whereas genes linked to apoptosis and autophagy were upregulated in Day 15 conceptuses collected from anovular cows compared with estrous cyclic counterparts. Similar changes in conceptus transcriptome were not observed in estrous cyclic cows induced to ovulate follicles that grew under low and high concentrations of progesterone, indicating an effect of anovulation on embryonic development that is not mediated solely by progesterone concentrations before ovulation. Finally, risk factors for anovulation have direct effects on embryo development and uterine receptivity to pregnancy that complement those determined by insufficient concentrations of progesterone during follicular growth. One approach to minimize the impact of anovulation on fertility is supplementation with progesterone during recruitment, selection and final stages of development of the preovulatory follicle. It is suggested that a minimum of 2.0 ng/mL of progesterone is needed during growth of the preovulatory follicle to achieve P/AI similar to that of cows growing the preovulatory follicle during diestrus. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Santos, J. E. P.] Univ Florida, Dept Anim Sci, DH Barron Reprod & Perinatal Biol Res Program, Gainesville, FL 32611 USA.
   [Bisinotto, R. S.] Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA.
   [Ribeiro, E. S.] Univ Guelph, Dept Anim Biosci, Guelph, ON N1G 2W1, Canada.
RP Santos, JEP (reprint author), Univ Florida, Dept Anim Sci, DH Barron Reprod & Perinatal Biol Res Program, Gainesville, FL 32611 USA.
EM jepsantos@ufl.edu
FU Southeast Milk Inc. Checkoff Program (Belleview, FL, USA); National
   Institute of Food and Agriculture, United States Department of
   Agriculture [2015-67015-23313]
FX Funding for experiments conducted by the authors and presented in this
   review was provided by grants from the Southeast Milk Inc. Checkoff
   Program (Belleview, FL, USA) and from the National Institute of Food and
   Agriculture, United States Department of Agriculture award number
   2015-67015-23313.
CR Aparicio IM, 2011, BIOL REPROD, V84, P910, DOI 10.1095/biolreprod.110.087411
   Badinga L, 1992, BIOL REPROD, V47, P871
   Bazer FW, 2008, REPROD BIOL, V8, P179
   BELL AW, 1995, J ANIM SCI, V73, P2804
   Bisinotto RS, 2015, J DAIRY SCI, V98, P2515, DOI 10.3168/jds.2014-9058
   Bisinotto RS, 2015, J DAIRY SCI, V98, P2472, DOI 10.3168/jds.2014-8954
   Bisinotto RS, 2013, J DAIRY SCI, V96, P2214, DOI 10.3168/jds.2012-6038
   Bisinotto RS, 2010, J DAIRY SCI, V93, P3578, DOI 10.3168/jds.2010-3047
   Bisinotto RS, BIOL REPROD UNPUB
   Bleach ECL, 2004, REPRODUCTION, V127, P621, DOI 10.1530/rep.1.00190
   Butler ST, 2003, J ENDOCRINOL, V176, P205, DOI 10.1677/joe.0.1760205
   Butler ST, 2004, REPRODUCTION, V127, P537, DOI 10.1530/rep.1.00079
   Butler WR, 2003, LIVEST PROD SCI, V83, P211, DOI 10.1016/S0301-6226(03)00112-X
   Cerri RLA, 2011, J DAIRY SCI, V94, P3352, DOI 10.3168/jds.2010-3735
   Cerri RLA, 2009, REPRODUCTION, V137, P813, DOI 10.1530/REP-08-0242
   Cetica P, 2002, REPRODUCTION, V124, P675, DOI 10.1530/rep.0.1240675
   Chang E, 2009, MOL CELL ENDOCRINOL, V307, P77, DOI 10.1016/j.mce.2009.03.024
   Clarke Iain J., 2005, Animal Reproduction Science, V88, P29, DOI 10.1016/j.anireprosci.2005.05.003
   Contreras GA, 2010, J DAIRY SCI, V93, P2508, DOI 10.3168/jds.2009-2876
   Cunha AP, 2008, J DAIRY SCI S1, V91, P246
   De Vries A, 2006, J DAIRY SCI, V89, P3876
   DEKEL N, 1995, TRENDS ENDOCRIN MET, V6, P165, DOI 10.1016/1043-2760(95)00079-W
   Dumon-Jones V, 2003, CANCER RES, V63, P7263
   Dungan HM, 2006, ENDOCRINOLOGY, V147, P1154, DOI 10.1210/en.2005-1282
   Endo N, 2012, ANIM REPROD SCI, V134, P112, DOI 10.1016/j.anireprosci.2012.08.018
   Gumen A, 2003, J DAIRY SCI, V86, P3184, DOI 10.3168/jds.S0022-0302(03)73921-6
   Herlihy MM, 2012, J DAIRY SCI, V95, P7003, DOI 10.3168/jds.2011-5260
   Kadokawa H, 2006, J DAIRY SCI, V89, P3020
   Kim J, 2010, MATRIX BIOL, V29, P369, DOI 10.1016/j.matbio.2010.04.001
   Kinder JE, 1996, J ANIM SCI, V74, P1424
   Leroy JLMR, 2006, REPROD DOMEST ANIM, V41, P119, DOI 10.1111/j.1439-0531.2006.00650.x
   Leroy JLMR, 2005, REPRODUCTION, V130, P485, DOI 10.1530/rep.1.00735
   Leroy JLMR, 2004, THERIOGENOLOGY, V62, P1131, DOI 10.1016/j.theriogenology.2003.12.017
   LUCY MC, 1992, REPROD NUTR DEV, V32, P331, DOI 10.1051/rnd:19920403
   Martinez N, 2014, J DAIRY SCI, V97, P874, DOI 10.3168/jds.2013-7408
   Martinez N, 2012, J DAIRY SCI, V95, P7158, DOI 10.3168/jds.2012-5812
   McCracken JA, 1999, PHYSIOL REV, V79, P263
   Mehlmann LM, 2005, REPRODUCTION, V130, P791, DOI 10.1530/rep.1.00793
   Meirelles FV, 2004, ANIM REPROD SCI, V82-3, P13, DOI 10.1016/j.anireprosci.2004.05.012
   Morham SG, 1996, MOL CELL BIOL, V16, P6804
   Norman HD, 2009, J DAIRY SCI, V92, P3517, DOI 10.3168/jds.2008-1768
   Revah I, 1996, J REPROD FERTIL, V106, P39
   Ribeiro ES, 2016, J DAIRY SCI, V99, P4761, DOI 10.3168/jds.2015-10315
   Ribeiro ES, 2016, J DAIRY SCI, V99, P2201, DOI 10.3168/jds.2015-10337
   Ribeiro ES, 2014, J DAIRY SCI, V97, P6888, DOI 10.3168/jds.2014-7908
   Ribeiro ES, 2013, J DAIRY SCI, V96, P5682, DOI 10.3168/jds.2012-6335
   Ribeiro ES, 2014, BIOL REPROD, V90, P1
   Rivera FA, 2011, REPRODUCTION, V141, P333, DOI 10.1530/REP-10-0375
   Robinson RS, 2001, REPRODUCTION, V122, P965, DOI 10.1530/rep.0.1220965
   Guerra D, 2009, J DAIRY SCI S1, V92, P441
   Santos JEP, 2010, SOC REPROD FERTIL, V67, P387
   Santos JEP, 2010, J DAIRY SCI, V93, P2976, DOI 10.3168/jds.2009-2870
   Santos JEP, 2009, ANIM REPROD SCI, V110, P207, DOI 10.1016/j.anireprosci.2008.01.014
   Santos JEP, 2004, ANIM REPROD SCI, V82-3, P513, DOI 10.1016/j.anireprosci.2004.04.015
   SCHILLO KK, 1992, J ANIM SCI, V70, P1271
   Schmitt EJP, 1996, J ANIM SCI, V74, P154
   Shaham-Albalancy A, 2001, REPRODUCTION, V122, P643, DOI 10.1530/rep.0.1220643
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022
   Smith JT, 2007, ENDOCRINOLOGY, V148, P1150, DOI 10.1210/en.2006-1435
   Thatcher W. W., 1989, Journal of Reproduction and Fertility, P91
   Toder V, 2002, AM J REPROD IMMUNOL, V48, P235, DOI 10.1034/j.1600-0897.2002.01130.x
   Tripathi A, 2010, J CELL PHYSIOL, V223, P592, DOI 10.1002/jcp.22108
   Walsh RB, 2007, J DAIRY SCI, V90, P315
   Wathes DC, 2009, PHYSIOL GENOMICS, V39, P1, DOI 10.1152/physiolgenomics.00064.2009
   Wiltbank MC, 2014, ANIMAL, V8, P70, DOI 10.1017/S1751731114000585
   Wiltbank MC, 2002, THERIOGENOLOGY, V57, P21, DOI 10.1016/S0093-691X(01)00656-2
   Yu JY, 2001, BIOL REPROD, V65, P1260, DOI 10.1095/biolreprod65.4.1260
   Yu JY, 2004, DEV BIOL, V268, P195, DOI 10.1016/j.ydbio.2003.12.020
   Zhang MJ, 2009, MOL HUM REPROD, V15, P399, DOI 10.1093/molehr/gap031
   Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7
   ZOLLERS WG, 1993, J REPROD FERTIL, V97, P329
NR 71
TC 0
Z9 0
U1 20
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0093-691X
EI 1879-3231
J9 THERIOGENOLOGY
JI Theriogenology
PD JUL 1
PY 2016
VL 86
IS 1
SI SI
BP 254
EP 262
DI 10.1016/j.theriogenology.2016.04.038
PG 9
WC Reproductive Biology; Veterinary Sciences
SC Reproductive Biology; Veterinary Sciences
GA DO2XG
UT WOS:000377643700029
PM 27160451
ER

PT J
AU Higashida, H
AF Higashida, Haruhiro
TI Somato-axodendritic release of oxytocin into the brain due to calcium
   amplification is essential for social memory
SO JOURNAL OF PHYSIOLOGICAL SCIENCES
LA English
DT Review
DE Oxytocin; Hypothalamus; Social behavior; CD38; TRPM2
ID CYCLIC-ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; AUTISM SPECTRUM
   DISORDER; CD38 GENE; INTRACELLULAR CALCIUM; POSTERIOR PITUITARY;
   SUPRAOPTIC NUCLEUS; PEPTIDE RELEASE; ANIMAL-MODELS; RAT-BRAIN
AB Oxytocin (OT) is released into the brain from the cell soma, axons, and dendrites of neurosecretory cells in the hypothalamus. Locally released OT can activate OT receptors, form inositol-1,4,5-trisphosphate and elevate intracellular free calcium (Ca2+) concentrations [(Ca2+) (i) ] in self and neighboring neurons in the hypothalamus, resulting in further OT release: i.e., autocrine or paracrine systems of OT-induced OT release. CD38-dependent cyclic ADP-ribose (cADPR) is also involved in this autoregulation by elevating [Ca2+] (i) via Ca2+ mobilization through ryanodine receptors on intracellular Ca2+ pools that are sensitive to both Ca2+ and cADPR. In addition, it has recently been reported that heat stimulation and hyperthermia enhance [Ca2+] (i) increases by Ca2+ influx, probably through TRPM2 cation channels, suggesting that cADPR and TRPM2 molecules act as Ca2+ signal amplifiers. Thus, OT release is not simply due to depolarization-secretion coupling. Both of these molecules play critical roles not only during labor and milk ejection in reproductive females, but also during social behavior in daily life in both genders. This was clearly demonstrated in CD38 knockout mice in that social behavior was impaired by reduction of [Ca2+] (i) elevation and subsequent OT secretion. Evidence for the associations of CD38 with social behavior and psychiatric disorder is discussed, especially in subjects with autism spectrum disorder.
C1 [Higashida, Haruhiro] Kanazawa Univ, Dept Basic Res Social Recognit, Res Ctr Child Mental Dev, Kanazawa, Ishikawa 9208640, Japan.
   [Higashida, Haruhiro] Osaka Univ, United Grad Sch Child, Kanazawa Branchi, Div Sociocognit Neurosci, Takara Machi 13-1, Kanazawa, Ishikawa 9208640, Japan.
RP Higashida, H (reprint author), Kanazawa Univ, Dept Basic Res Social Recognit, Res Ctr Child Mental Dev, Kanazawa, Ishikawa 9208640, Japan.; Higashida, H (reprint author), Osaka Univ, United Grad Sch Child, Kanazawa Branchi, Div Sociocognit Neurosci, Takara Machi 13-1, Kanazawa, Ishikawa 9208640, Japan.
EM haruhiro@med.kanazawa-u.ac.jp
RI higashida, haruhiro/L-3773-2015
OI higashida, haruhiro/0000-0002-1779-0606
FU Integrated Research on Neuropsychiatric Disorders under the Strategic
   Research Program for Brain Sciences
FX This work was supported by a grant-in-aid from Integrated Research on
   Neuropsychiatric Disorders carried out under the Strategic Research
   Program for Brain Sciences.
CR ADAN RAH, 1995, ENDOCRINOLOGY, V136, P4022, DOI 10.1210/en.136.9.4022
   Algoe SB, 2014, SOC COGN AFFECT NEUR, V9, P1855, DOI 10.1093/scan/nst182
   Amina S, 2010, J NEUROENDOCRINOL, V22, P460, DOI 10.1111/j.1365-2826.2010.01978.x
   AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247
   Bealer SL, 2010, AM J PHYSIOL-REG I, V299, pR452, DOI [10.1152/ajpregu.00217.2010, 10.1152/ajpregu.00217.2010.]
   Beck A, 2006, FASEB J, V20, P962, DOI 10.1096/fj.05-5538fje
   Boittin FX, 2003, J BIOL CHEM, V278, P9602, DOI 10.1074/jbc.M204891200
   BOURQUE CW, 1991, TRENDS NEUROSCI, V14, P28, DOI 10.1016/0166-2236(91)90180-3
   Brunton PJ, 2010, BRAIN RES, V1364, P198, DOI 10.1016/j.brainres.2010.09.062
   Carter CS, 2003, PHYSIOL BEHAV, V79, P383, DOI 10.1016/S0031-9384(03)00151-3
   Ceni C, 2006, BIOCHEM J, V395, P417, DOI 10.1042/BJ20051321
   Chang SC, 2014, PSYCHONEUROENDOCRINO, V39, P257, DOI 10.1016/j.psyneuen.2013.09.024
   Choleris E, 2009, FRONT NEUROENDOCRIN, V30, P4424
   De Flora A, 2004, ANN NY ACAD SCI, V1028, P176, DOI 10.1196/annals.1322.021
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Douglas AJ, 2002, REPRODUCTION, V123, P543, DOI 10.1530/rep.0.1230543
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Ebstein RP, 2011, FEBS LETT, V585, P1529, DOI 10.1016/j.febslet.2011.05.004
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   Endo M, 2009, PHYSIOL REV, V9, P1153
   Faouzi M, 2014, HANDB EXP PHARMACOL, V222, P403, DOI 10.1007/978-3-642-54215-2_16
   Feldman R, 2015, BIOL PSYCHIAT
   Feldman R, 2015, DEV PSYCHOPATHOL, V27, P369, DOI 10.1017/S0954579415000048
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002
   Franco L, 2001, J BIOL CHEM, V276, P21642
   FREUNDMERCIER MJ, 1994, J PHYSIOL-LONDON, V480, P155
   Gainer H, 2012, J NEUROENDOCRINOL, V24, P528, DOI 10.1111/j.1365-2826.2011.02236.x
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118
   Grinevich V., 2015, BIOL PSYCHIAT
   Guastella AJ, 2015, BIOL PSYCHIAT
   Higashida C, 2013, MESSENGER, V2, P33
   Higashida H, 2010, J NEUROENDOCRINOL, V22, P373, DOI 10.1111/j.1365-2826.2010.01976.x
   Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348
   Higashida H, 2007, NEUROCHEM INT, V51, P192, DOI 10.1016/j.neuint.2007.06.023
   Higashida H, 2007, NEUROSCI RES, V57, P339, DOI 10.1016/j.neures.2006.11.008
   Higashida H, 2012, NEUROCHEM INT, V61, P828, DOI 10.1016/j.neuint.2012.01.030
   Higashida H, 2012, HORM BEHAV, V61, P351, DOI 10.1016/j.yhbeh.2011.12.011
   Higashida H, 2011, BIOL PHARM BULL, V34, P1369
   Hovey D, 2014, SOC NEUROSCI-UK, V9, P378, DOI 10.1080/17470919.2014.897995
   Hoyle CHV, 1998, REGUL PEPTIDES, V73, P1, DOI 10.1016/S0167-0115(97)01073-2
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526
   Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006
   Katz B, 1969, SHERR LECT, P47
   Kim SY, 2010, J BIOL CHEM, V285, P576, DOI 10.1074/jbc.M109.076216
   Kim UH, 2014, MESSENGER, V3, P6, DOI DOI 10.1166/MSR.2014.1030
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Krol KM, 2015, P NATL ACAD SCI USA, V112, pE5434, DOI 10.1073/pnas.1506352112
   LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275
   Lee H. C., 2012, MESSENGER, V1, P16, DOI DOI 10.1166/MSR.2012.1005
   Leng G, 2015, J ENDOCRINOL, V226, pT173, DOI 10.1530/JOE-15-0087
   Lerer E, 2010, AUTISM RES, V3, P293, DOI 10.1002/aur.156
   Liu H. X., 2012, MESSENGER, V1, P150, DOI DOI 10.1166/MSR.2012.1015
   Lopatina O, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00182
   Lopatina O, 2010, NEUROPHARMACOLOGY, V58, P50, DOI 10.1016/j.neuropharm.2009.06.012
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Ludwig M, 2015, PHILOS T R SOC LON B, V370
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   MOOS F, 1984, J ENDOCRINOL, V102, P63, DOI 10.1677/joe.0.1020063
   Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   NEUMANN I, 1994, ENDOCRINOLOGY, V134, P141, DOI 10.1210/en.134.1.141
   Neumann I, 1996, J NEUROENDOCRINOL, V8, P227, DOI 10.1046/j.1365-2826.1996.04557.x
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2007, BIOCHEM SOC T, V35, P1252, DOI 10.1042/BST0351252
   NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503
   NUMA S, 1990, COLD SPRING HARB SYM, V55, P1
   Okamoto H, 2014, MESSENGER, V3, P27, DOI DOI 10.1166/MSR.2014.1032
   Onaka T, 2012, J NEUROENDOCRINOL, V24, P587, DOI 10.1111/j.1365-2826.2012.02300.x
   Rah SY, 2005, J BIOL CHEM, V280, P2888, DOI 10.1074/jbc.M409592200
   RICHARD P, 1991, PHYSIOL REV, V71, P331
   Riebold M, 2011, MOL MED, V17, P799, DOI 10.2119/molmed.2011.00080
   Salmina AB, 2010, J NEUROENDOCRINOL, V22, P380, DOI 10.1111/j.1365-2826.2010.01970.x
   Salmina AB, 2013, CURR TOP MED CHEM, V13, P2965
   Sauer C, 2012, NEUROPSYCHOPHARMACOL, V37, P1474, DOI 10.1038/npp.2011.333
   Sternfeld L, 2003, J BIOL CHEM, V278, P33629, DOI 10.1074/jbc.M301043200
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Tobin VA, 2008, ENDOCRINOLOGY, V149, P6136, DOI 10.1210/en.2008-0178
   Uchida K, 2014, CELL CALCIUM, V56, P332, DOI 10.1016/j.ceca.2014.07.001
   Watanabe T, 2015, BRAIN, V138, P3400
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Yoshimura M, 2015, J PHYSIOL SCI, V65, P385, DOI 10.1007/s12576-015-0386-3
   Young LJ, 1997, J NEUROENDOCRINOL, V9, P859, DOI 10.1046/j.1365-2826.1997.00654.x
   Zhao YJ, 2015, BBA-MOL CELL RES, V1853, P2095, DOI 10.1016/j.bbamcr.2014.10.028
   Zhao YJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002700
NR 88
TC 1
Z9 1
U1 5
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 1880-6546
EI 1880-6562
J9 J PHYSIOL SCI
JI J. Physiol. Sci.
PD JUL
PY 2016
VL 66
IS 4
BP 275
EP 282
DI 10.1007/s12576-015-0425-0
PG 8
WC Physiology
SC Physiology
GA DN9OX
UT WOS:000377410200001
PM 26586001
ER

PT J
AU Harrison, N
   Lopes, PC
   Konig, B
AF Harrison, Nicola
   Lopes, Patricia C.
   Konig, Barbara
TI Oxytocin and Social Preference in Female House Mice (Mus musculus
   domesticus)
SO ETHOLOGY
LA English
DT Article
DE behavioural observations; house mice; partner preference; peripheral
   oxytocin; social behaviour
ID VOLES MICROTUS-OCHROGASTER; PRAIRIE VOLES; REPRODUCTIVE SUCCESS; PARTNER
   PREFERENCES; BEHAVIOR; RATS; VASOPRESSIN; RECOGNITION; AFFILIATION;
   MOUSE
AB In social species, same-sex individuals may form social bonds behaviourally expressed as individual preferences, resulting in fitness benefits such as increased offspring survival, longevity and group cohesion. As a result of individual preferences, female house mice (Mus musculus domesticus) form social affiliations while communally nursing and may do so with kin or non-kin. However, the mechanisms behind the formation of such preferences are unknown. Oxytocin has been linked to a range of social behaviours including bond facilitation, social memory and parental care. Here, we experimentally increased oxytocin in pairs of unfamiliar, unrelated females and predicted that females with elevated oxytocin would demonstrate increased affiliative behaviours compared against a control. Subsequently, we tested for the formation of a social preference, using a preference test with the previous partner and a new unfamiliar female. Our results indicated no significant effect of treatment on positive and negative behaviours between females during the three initial cohabitation days. In both treatments, females demonstrated increased socio-positive behaviours and cohabitation time with their partner and decreased socio-negative behaviours and latency to meet, over the 3-d period. During the partner preference test, control but not oxytocin females demonstrated a significant preference for their cohabitation partner, and oxytocin females spent similar amounts of time with both stimulus females. Therefore, increasing peripheral oxytocin appears not to be involved in the facilitation of initial encounters with a stranger but may hinder the formation of a preference for this new partner.
C1 [Harrison, Nicola; Lopes, Patricia C.; Konig, Barbara] Univ Zurich, Dept Evolutionary Biol & Environm Studies, Winterthurerstr 190, CH-8057 Zurich, Switzerland.
RP Harrison, N (reprint author), Univ Zurich, Dept Evolutionary Biol & Environm Studies, Winterthurerstr 190, CH-8057 Zurich, Switzerland.
EM nicola.harrison@ieu.uzh.ch
FU University of Zurich
FX We would like to thank Gabi Stichel and Sally Steinert for animal
   husbandry and members of our research group for statistical advice. We
   also thank Jamie Samson and two anonymous referees for their comments on
   the manuscript and Carel van Schaik for discussions. We are grateful for
   funding from the University of Zurich and the authors declare no
   conflict of interests.
CR Anacker AMJ, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00185
   Bates D., 2014, LME4 LINEAR MIXED EF
   Beery AK, 2010, NEUROSCIENCE, V169, P665, DOI 10.1016/j.neuroscience.2010.05.023
   Beery A.K., 2015, CURR OPIN BEHAV SCI, V6, P174
   Bowen MT, 2014, INT J NEUROPSYCHOPH, V17, P1621, DOI 10.1017/S1461145714000388
   Busnelli M, 2013, J PHARMACOL EXP THER, V346, P318, DOI 10.1124/jpet.113.202994
   Cameron EZ, 2009, P NATL ACAD SCI USA, V106, P13850, DOI 10.1073/pnas.0900639106
   Campbell A, 2008, BIOL PSYCHOL, V77, P1, DOI 10.1016/j.biopsycho.2007.09.001
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Choleris E, 2003, P NATL ACAD SCI USA, V100, P6192, DOI 10.1073/pnas.0631699100
   Choleris E, 2009, FRONT NEUROENDOCRIN, V30, P442, DOI 10.1016/j.yfrne.2009.05.003
   Crawley M.J., 2007, R BOOK
   Crockford C., 2013, P ROY SOC B, V280, P1
   Crockford C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00068
   Cushing BS, 2000, HORM BEHAV, V37, P49, DOI 10.1006/hbeh.1999.1558
   De Dreu CKW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046751
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   Dharmadhikari A, 1997, ANN NY ACAD SCI, V807, P610, DOI 10.1111/j.1749-6632.1997.tb51982.x
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   Freeman SM, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12382
   Frere CH, 2010, P NATL ACAD SCI USA, V107, P19949, DOI 10.1073/pnas.1007997107
   Hayes LD, 2000, ANIM BEHAV, V59, P677, DOI 10.1006/anbe.1999.1390
   Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425
   HURST JL, 1990, ANIM BEHAV, V40, P233, DOI 10.1016/S0003-3472(05)80918-2
   Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Ismail N., 2007, HANDLING OVERDISPERS
   KONIG B, 1989, ETHOL ECOL EVOL, V1, P99
   KONIG B, 1994, BEHAV ECOL SOCIOBIOL, V34, P275, DOI 10.1007/s002650050043
   Konig B., 2012, EVOLUTION HOUSE MOUS, P114
   Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Mackintosh J.H., 1981, S ZOOL SOC LOND, V47, P337
   Madden JR, 2011, P ROY SOC B-BIOL SCI, V278, P1189, DOI 10.1098/rspb.2010.1675
   MANNING CJ, 1995, ANIM BEHAV, V50, P741
   MCCARTHY MM, 1990, HORM BEHAV, V24, P365, DOI 10.1016/0018-506X(90)90015-P
   Mooney SJ, 2014, HORM BEHAV, V65, P380, DOI 10.1016/j.yhbeh.2014.02.003
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   PACKER C, 1992, ANIM BEHAV, V43, P265, DOI 10.1016/S0003-3472(05)80222-2
   Penagarikano O., 2015, SCI TRANSL MED, V7, P1
   R Core Team, 2015, R LANG ENV STAT COMP
   [Anonymous], 2012, FRONT HUM NEUROSCI
   Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004
   Schulke O, 2010, CURR BIOL, V20, P2207, DOI 10.1016/j.cub.2010.10.058
   Seyfarth RM, 2012, ANNU REV PSYCHOL, V63, P153, DOI 10.1146/annurev-psych-120710-100337
   Silk JB, 2003, SCIENCE, V302, P1231, DOI 10.1126/science.1088580
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Venables W. N., 2002, MODERN APPL STAT S
   Weidt A., 2007, THESIS U ZURICH ZURI
   Weidt A, 2008, ANIM BEHAV, V75, P801, DOI 10.1016/j.anbehav.2007.06.017
   Weidt A, 2014, NATURWISSENSCHAFTEN, V101, P73, DOI 10.1007/s00114-013-1130-6
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909
   WITT DM, 1990, PHARMACOL BIOCHEM BE, V37, P63, DOI 10.1016/0091-3057(90)90042-G
   Wittig RM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.3096
   Yamamoto Y, 2004, NEUROSCIENCE, V125, P947, DOI 10.1016/j.neuroscience.2004.02.028
   Yee JR, 2008, PSYCHOSOM MED, V70, P1050, DOI 10.1097/PSY.0b013e31818425fb
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 65
TC 0
Z9 0
U1 11
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0179-1613
EI 1439-0310
J9 ETHOLOGY
JI Ethology
PD JUL
PY 2016
VL 122
IS 7
BP 571
EP 581
DI 10.1111/eth.12505
PG 11
WC Psychology, Biological; Behavioral Sciences; Zoology
SC Psychology; Behavioral Sciences; Zoology
GA DN7ZB
UT WOS:000377297600006
ER

PT J
AU Opendak, M
   Offit, L
   Monari, P
   Schoenfeld, TJ
   Sonti, AN
   Cameron, HA
   Gould, E
AF Opendak, Maya
   Offit, Lily
   Monari, Patrick
   Schoenfeld, Timothy J.
   Sonti, Anup N.
   Cameron, Heather A.
   Gould, Elizabeth
TI Lasting Adaptations in Social Behavior Produced by Social Disruption and
   Inhibition of Adult Neurogenesis
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE dominance hierarchy; GFAP-TK transgenic rats; hippocampus; neurogenesis;
   oxytocin; social behavior
ID ELEVATED PLUS-MAZE; POSTTRAUMATIC-STRESS-DISORDER; BORN
   HIPPOCAMPAL-NEURONS; NEURAL STEM-CELLS; DENTATE GYRUS; VICARIOUS TRIAL;
   MALE-RATS; INSTABILITY STRESS; DECISION-MAKING; ERROR BEHAVIOR
AB Research on social instability has focused on its detrimental consequences, but most people are resilient and respond by invoking various coping strategies. To investigate cellular processes underlying such strategies, a dominance hierarchy of rats was formed and then destabilized. Regardless of social position, rats from disrupted hierarchies had fewer new neurons in the hippocampus compared with rats from control cages and those from stable hierarchies. Social disruption produced a preference for familiar over novel conspecifics, a change that did not involve global memory impairments or increased anxiety. Using the neuropeptide oxytocin as a tool to increase neurogenesis in the hippocampus of disrupted rats restored preference for novel conspecifics to predisruption levels. Conversely, reducing the number of new neurons by limited inhibition of adult neurogenesis in naive transgenic GFAP-thymidine kinase rats resulted in social behavior similar to disrupted rats. Together, these results provide novel mechanistic evidence that social disruption shapes behavior in a potentially adaptive way, possibly by reducing adult neurogenesis in the hippocampus.
C1 [Opendak, Maya; Offit, Lily; Monari, Patrick; Gould, Elizabeth] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08540 USA.
   [Offit, Lily; Monari, Patrick; Gould, Elizabeth] Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA.
   [Schoenfeld, Timothy J.; Sonti, Anup N.; Cameron, Heather A.] NIMH, NIH, Bethesda, MD 20892 USA.
   [Opendak, Maya] Nathan S Kline Inst Psychiat Res, Emot Brain Inst, Orangeburg, NY USA.
   [Opendak, Maya] NYU, Sch Med, Ctr Child Study, Child & Adolescent Psychiat, New York, NY USA.
RP Gould, E (reprint author), Princeton Univ, Princeton Neurosci Inst, Dept Psychol, Princeton, NJ 08540 USA.
EM goulde@princeton.edu
RI Cameron, Heather/E-6221-2011
OI Cameron, Heather/0000-0002-3245-5777
FU Intramural Program of the National Institutes of Health/National
   Institute of Mental Health [ZIAMH002784]
FX This work was supported in part by the Intramural Program of the
   National Institutes of Health/National Institute of Mental Health (Grant
   ZIAMH002784 to H.A.C.).
CR Albeck DS, 1997, J NEUROSCI, V17, P4895
   Alonso R, 2004, MOL PSYCHIATR, V9, P278, DOI 10.1038/sj.mp.4001464
   Banasr M, 2006, BIOL PSYCHIAT, V59, P1087, DOI 10.1016/j.biopsych.2005.11.025
   Bannerman DM, 2012, NAT NEUROSCI, V15, P1153, DOI 10.1038/nn.3166
   Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011
   BARNETT S. A., 1958, PROC ZOOL SOC LONDON, V130, P107
   Bett D, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00070
   Blanchard DC, 2013, NEUROSCI BIOBEHAV R, V37, P1567, DOI 10.1016/j.neubiorev.2013.06.008
   BLANCHARD DC, 1995, PSYCHONEUROENDOCRINO, V20, P117, DOI 10.1016/0306-4530(94)E0045-B
   BLANCHARD DC, 1991, BRAIN RES, V568, P61, DOI 10.1016/0006-8993(91)91379-F
   Bossarte RM, 2013, AM J PUBLIC HEALTH, V103, pS213, DOI 10.2105/AJPH.2013.301277
   Bourke CH, 2014, BEHAV BRAIN RES, V270, P295, DOI 10.1016/j.bbr.2014.05.035
   Branchi I, 2013, HORM BEHAV, V63, P503, DOI 10.1016/j.yhbeh.2013.01.003
   Branchi I, 2013, PSYCHONEUROENDOCRINO, V38, P522, DOI 10.1016/j.psyneuen.2012.07.010
   Breton YA, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00041
   Brudzynski SM, 2013, CURR OPIN NEUROBIOL, V23, P310, DOI 10.1016/j.conb.2013.01.014
   Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013
   Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197
   Clark PJ, 2012, HIPPOCAMPUS, V22, P1860, DOI 10.1002/hipo.22020
   Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x
   Cutuli JJ, 2013, CHILD DEV, V84, P841, DOI 10.1111/cdev.12013
   Czeh B, 2002, BIOL PSYCHIAT, V52, P1057, DOI 10.1016/S0006-3223(02)01457-9
   Daniels Willie Mark Uren, 2008, Neuropsychiatr Dis Treat, V4, P451
   Deng W, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00034
   Doll BB, 2015, NEUROBIOL LEARN MEM, V117, P4, DOI 10.1016/j.nlm.2014.04.014
   Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959
   Eagle AL, 2013, BEHAV BRAIN RES, V256, P591, DOI 10.1016/j.bbr.2013.09.014
   ENGELMANN M, 1995, PHYSIOL BEHAV, V58, P315, DOI 10.1016/0031-9384(95)00053-L
   FILE SE, 1988, NEUROPSYCHOBIOLOGY, V20, P82, DOI 10.1159/000118478
   Fries E, 2005, PSYCHONEUROENDOCRINO, V30, P1010, DOI 10.1016/j.psyneuen.2005.04.006
   Garrett L, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00302
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Glasper ER, 2012, BEHAV BRAIN RES, V227, P380, DOI 10.1016/j.bbr.2011.05.013
   Gunnar MR, 2009, PSYCHONEUROENDOCRINO, V34, P953, DOI 10.1016/j.psyneuen.2009.02.010
   Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3
   HU D, 1995, P NATL ACAD SCI USA, V92, P5506, DOI 10.1073/pnas.92.12.5506
   Hu D, 1997, BEHAV BRAIN RES, V86, P67, DOI 10.1016/S0166-4328(96)02247-4
   Sandoval CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017689
   Johnson A, 2007, CURR OPIN NEUROBIOL, V17, P692, DOI 10.1016/j.conb.2008.01.003
   Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203
   Khoshaba D. M., 1999, CONSULTING PSYCHOL J, V51, P106, DOI [10.1037/1061-4087.51.2.106, DOI 10.1037/1061-4087.51.2.106]
   Koolhaas JM, 2010, FRONT NEUROENDOCRIN, V31, P307, DOI 10.1016/j.yfrne.2010.04.001
   Korte SM, 1996, BRAIN RES, V736, P338, DOI 10.1016/0006-8993(96)00723-8
   Kozorovitskiy Y, 2004, J NEUROSCI, V24, P6755, DOI 10.1523/JNEUROSCI.0345-04.2004
   KRAMES L, 1969, PSYCHON SCI, V16, P11
   KREMARIK P, 1995, BRAIN RES BULL, V36, P195, DOI 10.1016/0361-9230(94)00196-8
   Kuhn HG, 1996, J NEUROSCI, V16, P2027
   Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107
   Lee PR, 2007, BRAIN RES, V1156, P152, DOI 10.1016/j.brainres.2007.04.042
   Leuner B., 2010, ANNU REV PSYCHOL, V61, pC1, DOI DOI 10.1146/ANNUREV.PSYCH.093008.100359
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Leuner B, 2010, ANNU REV PSYCHOL, V61, P111, DOI 10.1146/annurev.psych.093008.100359
   Leuner B, 2009, J COMP NEUROL, V517, P123, DOI 10.1002/cne.22107
   Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P411, DOI 10.1016/S0306-4530(97)00045-0
   LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180
   Lugert S, 2010, CELL STEM CELL, V6, P445, DOI 10.1016/j.stem.2010.03.017
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Mak GK, 2010, NAT NEUROSCI, V13, P753, DOI 10.1038/nn.2550
   Marrone DF, 2012, HIPPOCAMPUS, V22, P1134, DOI 10.1002/hipo.20959
   McCormick CM, 2013, NEUROSCIENCE, V249, P242, DOI 10.1016/j.neuroscience.2012.08.063
   McCormick CM, 2015, DEV COGN NEUROS-NETH, V11, P2, DOI 10.1016/j.dcn.2014.04.002
   McCormick CM, 2012, HIPPOCAMPUS, V22, P1300, DOI 10.1002/hipo.20966
   McDonald HY, 2005, NEUROSCI LETT, V385, P70, DOI 10.1016/j.neulet.2005.05.022
   McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x
   McHugh SB, 2004, BEHAV NEUROSCI, V118, P63, DOI 10.1037/0735-7044.118.1.63
   Meconi A, 2015, NEUROSCI LETT, V603, P66, DOI 10.1016/j.neulet.2015.07.029
   Morris AM, 2013, HIPPOCAMPUS, V23, P162, DOI 10.1002/hipo.22078
   Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-183X.2004.00076.x
   Opendak M, 2015, TRENDS COGN SCI, V19, P151, DOI 10.1016/j.tics.2015.01.001
   Palombo DJ, 2015, NEUROBIOL LEARN MEM, V125, P93, DOI 10.1016/j.nlm.2015.08.005
   PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6
   Petrik D, 2012, NEUROPHARMACOLOGY, V62, P21, DOI 10.1016/j.neuropharm.2011.09.003
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   Redish AD, 2016, NAT REV NEUROSCI, V17, P147, DOI 10.1038/nrn.2015.30
   Rohleder N, 2004, BIOL PSYCHIAT, V55, P745, DOI 10.1016/j.biopsych.2003.11.018
   Schoenfeld TJ, 2014, J NEUROSCI, V34, P15679, DOI 10.1523/JNEUROSCI.3234-13.2014
   Seo DO, 2015, J NEUROSCI, V35, P11330, DOI 10.1523/JNEUROSCI.0483-15.2015
   SIEGEL SJ, 1993, BRAIN RES, V619, P299, DOI 10.1016/0006-8993(93)91624-2
   Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287
   Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009
   Snyder JS, 2016, ENEURO, DOI [10.1523/ENEURO.0064-16.2016, DOI 10.1523/ENEURO.0064-16.2016]
   Staples LG, 2014, HORM BEHAV, V65, P294, DOI 10.1016/j.yhbeh.2013.12.014
   Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002
   Sun HL, 2013, BEHAV BRAIN RES, V257, P1, DOI 10.1016/j.bbr.2013.08.044
   Swan AA, 2014, HIPPOCAMPUS, V24, P1581, DOI 10.1002/hipo.22337
   THOR DH, 1982, J COMP PHYSIOL PSYCH, V96, P1000, DOI 10.1037//0735-7036.96.6.1000
   Tolman EC, 1938, PSYCHOL REV, V45, P1, DOI 10.1037/h0062733
   TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0
   Tsai CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9373
   van der Kooij MA, 2012, NEUROSCI BIOBEHAV R, V36, P1763, DOI 10.1016/j.neubiorev.2011.10.006
   Veenema AH, 2007, BRAIN BEHAV EVOLUT, V70, P274, DOI 10.1159/000105491
   Vega CJ, 2005, NAT METHODS, V2, P167, DOI 10.1038/NMETH741
   Vives A, 2011, INT J HEALTH SERV, V41, P625, DOI 10.2190/HS.41.4.b
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   WITT DM, 1992, PHARMACOL BIOCHEM BE, V43, P855, DOI 10.1016/0091-3057(92)90418-F
   YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004
NR 96
TC 0
Z9 0
U1 2
U2 2
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 29
PY 2016
VL 36
IS 26
BP 7027
EP 7038
DI 10.1523/JNEUROSCI.4435-15.2016
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA DQ2GJ
UT WOS:000379020200017
PM 27358459
ER

PT J
AU Soylu-Kucharz, R
   Baldo, B
   Petersen, A
AF Soylu-Kucharz, Rana
   Baldo, Barbara
   Petersen, Asa
TI Metabolic and behavioral effects of mutant huntingtin deletion in Sim1
   neurons in the BACHD mouse model of Huntington's disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TRANSCRIPTION FACTOR; MICE; ANXIETY; REPEAT; TESTOSTERONE; VASOPRESSIN;
   DYSFUNCTION; EXPRESSION; OXYTOCIN; HORMONE
AB Hypothalamic pathology, metabolic dysfunction and psychiatric symptoms are part of Huntington disease (HD), which is caused by an expanded CAG repeat in the huntingtin (HTT) gene. Inactivation of mutant HTT selectively in the hypothalamus prevents the development of metabolic dysfunction and depressive-like behavior in the BACHD mouse model. The hypothalamic paraventricular nucleus (PVN) is implicated in metabolic and emotional control, therefore we here tested whether inactivation of mutant HTT in the PVN affects metabolic and psychiatric manifestations of HD in BACHD mice. BACHD mice were crossed with mice expressing Cre-recombinase under the Sim1 promoter (Sim1Cre) to inactivate mutant HTT in Sim1 expressing cells, i.e. the PVN of the hypothalamus. We found that inactivation of mutant HTT in Sim1 cells had a sex-specific effect on both the metabolic and the psychiatric phenotype, as these phenotypes were no longer different in male BACHD/Sim1-Cre mice compared to wild-type littermates. We also found a reduced number of GnRH neurons specifically in the anterior hypothalamus and an increased testes weight in male BACHD mice compared to wildtype littermates. Taken together, expression of mutant HTT in Sim1 cells may play a role for the development of metabolic dysfunction and depressive-like behavior in male BACHD mice.
C1 [Soylu-Kucharz, Rana; Baldo, Barbara; Petersen, Asa] Lund Univ, Dept Expt Med Sci, Translat Neuroendocrine Res Unit, BMC D11, SE-22184 Lund, Sweden.
RP Soylu-Kucharz, R (reprint author), Lund Univ, Dept Expt Med Sci, Translat Neuroendocrine Res Unit, BMC D11, SE-22184 Lund, Sweden.
EM rana.soylu@med.lu.se
FU Swedish Medical Research Council [2010-4500, 2013-3537]; Ragnar
   Soderberg Foundation; Province of Skane State Grants; Swedish
   Association of Persons with Neurological Disabilities (NHR)
FX We thank Anneli Josefsson, Ulla Samuelsson, Ulrika Sparrhult-Bjork and
   Bjorn Anzelius for excellent technical assistance. We would like to
   acknowledge Krzysztof Kucharz for his assistance with the illustrations.
   This work was supported by grants from the Swedish Medical Research
   Council to A.P. [grant numbers 2010-4500 and 2013-3537]; the Ragnar
   Soderberg Foundation to A.P.; the Province of Skane State Grants (ALF)
   to A.P.; The Swedish Association of Persons with Neurological
   Disabilities (NHR) to AP.
CR Aziz A, 2008, BRAIN PATHOL, V18, P474, DOI 10.1111/j.1750-3639.2008.00135.x
   Baldo B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107691
   Balthasar N, 2005, CELL, V123, P493, DOI 10.1016/j.cell.2005.08.035
   BIRD ED, 1976, NATURE, V260, P536, DOI 10.1038/260536a0
   Du X, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.58
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Gabery S, 2015, NEUROPATH APPL NEURO, V41, P843, DOI 10.1111/nan.12236
   Gabery S, 2010, ACTA NEUROPATHOL, V120, P777, DOI 10.1007/s00401-010-0742-6
   Gray M, 2008, J NEUROSCI, V28, P6182, DOI 10.1523/JNEUROSCI.0857-08.2008
   Hult S, 2011, CELL METAB, V13, P428, DOI 10.1016/j.cmet.2011.02.013
   Hult S, 2010, CURR DRUG TARGETS, V11, P1237
   Jastroch M, 2014, BEST PRACT RES CL EN, V28, P661, DOI 10.1016/j.beem.2014.02.002
   Kalliolia E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138848
   Kotliarova S, 2005, J NEUROCHEM, V93, P641, DOI 10.1111/j.1471-4159.2005.03035.x
   Lee EB, 2014, ACTA NEUROPATHOL, V127, P3, DOI 10.1007/s00401-013-1190-x
   Lloret A, 2006, HUM MOL GENET, V15, P2015, DOI 10.1093/hmg/ddl125
   Lundh SH, 2013, HUM MOL GENET, V22, P3485, DOI 10.1093/hmg/ddt203
   Lundh SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051168
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Markianos M, 2005, ANN NEUROL, V57, P520, DOI 10.1002/ana.20428
   Menalled L, 2009, NEUROBIOL DIS, V35, P319, DOI 10.1016/j.nbd.2009.05.007
   Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Orvoen S, 2012, NEUROSCI LETT, V507, P127, DOI 10.1016/j.neulet.2011.11.063
   Papalexi E, 2005, EUR J NEUROSCI, V22, P1541, DOI 10.1111/j.1460-9568.2005.04324.x
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Petersen A, 2005, HUM MOL GENET, V14, P39, DOI 10.1093/hmg/ddi004
   Petersen Asa, 2012, J Huntingtons Dis, V1, P5, DOI 10.3233/JHD-2012-120006
   Pietropaolo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019965
   Politis M, 2008, BRAIN, V131, P2860, DOI 10.1093/brain/awn244
   PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327
   Renoir T, 2014, PHARMACOL BIOCHEM BE, V127, P15, DOI 10.1016/j.pbb.2014.10.004
   Renoir Thibault, 2012, J Huntingtons Dis, V1, P261, DOI 10.3233/JHD-120039
   Ross CA, 2014, NAT REV NEUROL, V10, P204, DOI 10.1038/nrneurol.2014.24
   Saleh N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004962
   Soneson C, 2010, NEUROBIOL DIS, V40, P531, DOI 10.1016/j.nbd.2010.07.013
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4
   Traish AM, 2014, CURR OPIN ENDOCRINOL, V21, P313, DOI 10.1097/MED.0000000000000086
   Van Raamsdonk JM, 2007, NEUROBIOL DIS, V26, P512, DOI 10.1016/j.nbd.2007.01.006
   Van Raamsdonk JM, 2007, NEUROBIOL DIS, V26, P189, DOI 10.1016/j.nbd.2006.12.010
   WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037//0033-2909.83.3.482
   WEST MJ, 1991, ANAT REC, V231, P482, DOI 10.1002/ar.1092310411
   Yamanaka T, 2010, HUM MOL GENET, V19, P2099, DOI 10.1093/hmg/ddq087
   Yeoh JW, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00036
NR 44
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 23
PY 2016
VL 6
AR 28322
DI 10.1038/srep28322
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DP2KD
UT WOS:000378316400001
PM 27334347
ER

PT J
AU Huang, XC
   Su, SL
   Duan, JA
   Sha, XX
   Zhu, KY
   Guo, JM
   Yu, L
   Liu, P
   Shang, EX
   Qian, DW
AF Huang, Xiaochen
   Su, Shulan
   Duan, Jin-Ao
   Sha, Xiuxiu
   Zhu, Kavin Yue
   Guo, Jianming
   Yu, Li
   Liu, Pei
   Shang, Erxin
   Qian, Dawei
TI Effects and mechanisms of Shaofu-Zhuyu decoction and its major bioactive
   component for Cold - Stagnation and Blood - Stasis primary dysmenorrhea
   rats
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Review
DE Primary dysmenorrhea (PD); Shaofu Zhuyu decoction (SFZYD);
   UPLC-QTOF-MS/MS; metabolomics; potential biomarkers; MAPK signaling
   pathway
ID IN-VITRO; INFLAMMATION; THERAPY; CANCER; CONTRACTION; CYTOKINE; PLASMA;
   URINE; TRIAL; TNF
AB Ethnopharmacological relevance: Traditional Chinese medicine (TCM) is used under the guidance of the theory of traditional Chinese medical sciences in clinical application. The Chinese herbal formula, Shaofu Zhuyu decoction (SFZYD), is considered as an effective prescription for treating Cold- Stagnation and Blood- Stasis (CSBS) primary dysmenorrhea. The previous studies showed the SFZYD exhibited significant anti-inflammation and analgesic effect. In this present study the metabolomics of CSBS primary dysmenorrhea diseased rats and the cytokine transcription in PHA stimulated-PBMC were investigated to explore the effects and mechanisms.
   Aim of the study: Explore a valuable insight into the effects and mechanisms of SFZYD on Cold - Stagnation and Blood- Stasis primary dysmenorrhea rats.
   Materials and methods: We established CSBS primary dysmenorrhea diseased rats according the clinical symptoms. A targeted tandem mass spectrometry (MS/MS)-based metabolomic platform was used to evaluate the metabolic profiling changes and the intervention effects by SFZYD. The PBMC cell was adopted to explore the mechanisms by analyzing the signaling pathway evaluated by expression of inflammatory cytokines, c-jun and c-fos and corresponding phosphorylation levels.
   Results: Estradiol, oxytocin, progesterone, endothelin, beta-endorphin and PGF(2 alpha), were restored back to the normal level after the treatment of SFZYD. Total twenty-five metabolites (10 in plasma and 15 in urine), up-regulated or down-regulated, were identified. These identified biomarkers underpinning the metabolic pathway including pentose and glucuronate interconversions, steroid hormone biosynthesis, and glycerophospholipid metabolism are disturbed in model rats. Among these metabolites, twenty one potential biomarkers were regulated after SFZYD treated. The compound of paeoniflorin, a major bioactive compound in SFZYD, was proved to regulate the MAPK signaling pathway by inhibiting the expression of IL-1 beta, IL-2, IL-10, IL-12, TNF alpha, INF gamma, c-jun and c-fos in PHA stimulated-PBMC.
   Conclusion: These findings indicated that SFZYD improved the metabolic profiling and biochemical indicators on CSBS primary dysmenorrhea rats. And the mechanisms were closely related with the regulation of the MAPK pathway by reduction in phosphorylated forms of the three MAPK (ERK1/2, p38 and JNK) and down regulation of c-jun and c-fos by paeoniflorin. The data could be provided the guidance for further research and new drug discovery. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Huang, Xiaochen; Su, Shulan; Duan, Jin-Ao; Sha, Xiuxiu; Zhu, Kavin Yue; Guo, Jianming; Yu, Li; Liu, Pei; Shang, Erxin; Qian, Dawei] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing 210023, Jiangsu, Peoples R China.
   [Huang, Xiaochen] Nanjing Univ Chinese Med, Hanlin Coll, Taizhou 225300, Peoples R China.
RP Su, SL; Duan, JA (reprint author), Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Jiangsu Key Lab High Technol Res TCM Formulae, Nanjing 210023, Jiangsu, Peoples R China.
EM sushulan1974@163.com; duanja@163.com
FU Key Research Project in Basic Science of Jiangsu College and University
   [11KJA360002]; National Natural Science Foundation of China [81373889];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions [ysxk-2014]; Ministry of Education; 333 High-level Talents
   Training Project - Jiangsu Province; Six Talents Project - Jiangsu
   Province [2012-YY-010]
FX This work was supported by the Key Research Project in Basic Science of
   Jiangsu College and University (No. 11KJA360002) and the National
   Natural Science Foundation of China (No. 81373889). This work was also
   supported by a project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (ysxk-2014). This
   work also supported by 2013' Program for New Century Excellent Talents
   by the Ministry of Education (Grant NCET-13-0873), 333 High-level
   Talents Training Project Funded by Jiangsu Province, and Six Talents
   Project Funded by Jiangsu Province (2012-YY-010).
CR Baggio V, 2005, VET IMMUNOL IMMUNOP, V107, P27, DOI 10.1016/j.vetiinm.2005.02.019
   Bahman N., 2012, J MOL SCI, V13, P2119
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Chan W Y, 1980, Adv Prostaglandin Thromboxane Res, V8, P1443
   Cheng Q.Q., 2011, J CHIN MED, V16, P1249
   Cornel K M, 2012, J CLIN ENDOCR METAB, V97, P591
   Davis AR, 2005, OBSTET GYNECOL, V106, P97, DOI 10.1097/01.AOG.0000165826.03915.65
   Fan M., 2011, BEIJING J TRAD CHIN, V30, P455
   French L, 2005, AM FAM PHYSICIAN, V71, P285
   Harel Z. A., 2002, PEDIATR DRUGS, V12, P797
   Hommes DW, 2003, GUT, V52, P144, DOI 10.1136/gut.52.1.144
   Hougee S, 2005, BIOCHEM PHARMACOL, V69, P241, DOI 10.1016/j.bcp.2004.10.002
   Hsu CS, 2006, PHYTOMEDICINE, V13, P94, DOI 10.1016/j.phymed.2004.06.016
   Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895
   Liu P, 2013, MOL BIOSYST, V9, P77, DOI 10.1039/c2mb25238d
   Moss SF, 2005, NAT CLIN PRACT ONCOL, V2, P90, DOI 10.1038/ncponc0081
   Nicholson JK, 2012, EXPERT OPIN DRUG MET, V8, P135, DOI 10.1517/17425255.2012.646987
   Ostad SN, 2001, J ETHNOPHARMACOL, V76, P299, DOI 10.1016/S0378-8741(01)00249-5
   Pevin R., 2015, POL J MICROBIOL, V64, P69
   Proctor M. L., 2001, COCHRANE DB SYST REV, P4
   Rao KMK, 2002, J TOXICOL ENV HEAL A, V65, P757, DOI 10.1080/00984100290071027
   Schmittgen T. D., 2002, ANAL BIOCHEM, V85, P194
   Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050
   Stener-Victorin E, 2010, J CLIN ENDOCR METAB, V95, P810, DOI 10.1210/jc.2009-1908
   SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6
   Su SL, 2013, J PROTEOME RES, V12, P852, DOI 10.1021/pr300935x
   Su SL, 2010, AM J CHINESE MED, V38, P777, DOI 10.1142/S0192415X10008238
   Su SL, 2010, J CHROMATOGR B, V878, P355, DOI 10.1016/j.jchromb.2009.11.048
   Swantek JL, 1997, MOL CELL BIOL, V17, P6274
   Doubova SV, 2007, J ETHNOPHARMACOL, V110, P305, DOI 10.1016/j.jep.2006.09.033
   White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852
   Wolf L L, 1999, J Am Acad Nurse Pract, V11, P125, DOI 10.1111/j.1745-7599.1999.tb00549.x
   Yan L, 2006, EUR J CANCER, V42, P793, DOI 10.1016/j.ejca.2006.01.013
   Zahradnik HP, 2010, CONTRACEPTION, V81, P185, DOI 10.1016/j.contraception.2009.09.014
NR 34
TC 0
Z9 0
U1 17
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 20
PY 2016
VL 186
BP 234
EP 243
DI 10.1016/j.jep.2016.03.067
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA DO5OI
UT WOS:000377832000025
PM 27060631
ER

PT J
AU Buffington, SA
   Di Prisco, GV
   Auchtung, TA
   Ajami, NJ
   Petrosino, JF
   Costa-Mattioli, M
AF Buffington, Shelly A.
   Di Prisco, Gonzalo Viana
   Auchtung, Thomas A.
   Ajami, Nadim J.
   Petrosino, Joseph F.
   Costa-Mattioli, Mauro
TI Microbial Reconstitution Reverses Maternal Diet-Induced Social and
   Synaptic Deficits in Offspring
SO CELL
LA English
DT Article
ID VENTRAL TEGMENTAL AREA; NEURODEVELOPMENTAL DISORDERS; SPECTRUM
   DISORDERS; NUCLEUS-ACCUMBENS; GUT MICROBIOME; VAGUS NERVE; AUTISM;
   OXYTOCIN; BEHAVIOR; BRAIN
AB Maternal obesity during pregnancy has been associated with increased risk of neurodevelopmental disorders, including autism spectrum disorder (ASD), in offspring. Here, we report that maternal high-fat diet (MHFD) induces a shift in microbial ecology that negatively impacts offspring social behavior. Social deficits and gut microbiota dysbiosis in MHFD offspring are prevented by co-housing with offspring of mothers on a regular diet (MRD) and transferable to germ-free mice. In addition, social interaction induces synaptic potentiation (LTP) in the ventral tegmental area (VTA) of MRD, but not MHFD offspring. Moreover, MHFD offspring had fewer oxytocin immunoreactive neurons in the hypothalamus. Using metagenomics and precision microbiota reconstitution, we identified a single commensal strain that corrects oxytocin levels, LTP, and social deficits in MHFD offspring. Our findings causally link maternal diet, gut microbial imbalance, VTA plasticity, and behavior and suggest that probiotic treatment may relieve specific behavioral abnormalities associated with neurodevelopmental disorders.
C1 [Buffington, Shelly A.; Di Prisco, Gonzalo Viana; Costa-Mattioli, Mauro] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
   [Buffington, Shelly A.; Di Prisco, Gonzalo Viana; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
   [Auchtung, Thomas A.; Ajami, Nadim J.; Petrosino, Joseph F.] Baylor Coll Med, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA.
   [Auchtung, Thomas A.; Ajami, Nadim J.; Petrosino, Joseph F.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
RP Costa-Mattioli, M (reprint author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; Costa-Mattioli, M (reprint author), Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA.
EM costamat@bcm.edu
FU NIH [NIMH 096816, NINDS 076708]; Alkek Foundation; Baylor College of
   Medicine
FX We thank members of the Costa-Mattioli laboratory, K. Krnjevic, M.
   Beauchamp, and H. Dierick for comments on the manuscript; A. Swennes, J.
   Garcia, D. Quach and J. Auchtung for technical advice. This work was
   supported by funding from the NIH (NIMH 096816, NINDS 076708) to M. C.-M
   and the Alkek Foundation and Baylor College of Medicine to the Alkek
   Center for Meta-genomics and Microbiome Research to J.F.P.
CR Aye ILMH, 2015, P NATL ACAD SCI USA, V112, P12858, DOI 10.1073/pnas.1515484112
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Bilder DA, 2013, PEDIATRICS, V132, pE1276, DOI 10.1542/peds.2013-1188
   Bolton Jessica L, 2014, Dialogues Clin Neurosci, V16, P307
   Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108
   Bresnahan M, 2015, JAMA PSYCHIAT, V72, P466, DOI 10.1001/jamapsychiatry.2014.3034
   Connolly N, 2016, AUTISM RES
   Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346
   Davari S, 2013, NEUROSCIENCE, V240, P287, DOI 10.1016/j.neuroscience.2013.02.055
   Desbonnet L, 2014, MOL PSYCHIATR, V19, P146, DOI 10.1038/mp.2013.65
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Galley JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113026
   Groppe SE, 2013, BIOL PSYCHIAT, V74, P172, DOI 10.1016/j.biopsych.2012.12.023
   Gunaydin LA, 2014, CELL, V157, P1535, DOI 10.1016/j.cell.2014.05.017
   Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76
   Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024
   Huang W., 2016, ELIFE, V5, P5
   Huang YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003281
   Human Microbiome Project Consortium, 2012, NATURE, V486, P215, DOI DOI 10.1038/NATURE11209
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   King JC, 2006, ANNU REV NUTR, V26, P271, DOI 10.1146/annurev.nutr.24.012003.132249
   Krakowiak P, 2012, PEDIATRICS, V129, pE1121, DOI 10.1542/peds.2011-2583
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Ma J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4889
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Mathers JC, 2009, ADV EXP MED BIOL, V646, P119, DOI 10.1007/978-1-4020-9173-5_13
   Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304
   Mayer EA, 2014, BIOESSAYS, V36, P933, DOI 10.1002/bies.201400075
   McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217
   Mefford HC, 2012, NEW ENGL J MED, V366, P733, DOI 10.1056/NEJMra1114194
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   Moss BG, 2014, AM J HEALTH PROMOT, V28, P181, DOI 10.4278/ajhp.120705-QUAN-325
   Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Poutahidis T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078898
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214
   Sabatier Nancy, 2013, Front Endocrinol (Lausanne), V4, P35, DOI 10.3389/fendo.2013.00035
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/nmeth.2066, 10.1038/NMETH.2066]
   Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851
   Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458
   Sullivan EL, 2014, PHYSIOL BEHAV, V123, P236, DOI 10.1016/j.physbeh.2012.07.014
   Tang YM, 2014, NEUROPHARMACOLOGY, V77, P277, DOI 10.1016/j.neuropharm.2013.10.004
   Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Uvnas-Moberg Kerstin, 2014, Front Psychol, V5, P1529, DOI 10.3389/fpsyg.2014.01529
   Wang X, 2002, WORLD J GASTROENTERO, V8, P540
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053
NR 55
TC 12
Z9 13
U1 35
U2 35
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUN 16
PY 2016
VL 165
IS 7
BP 1762
EP 1775
DI 10.1016/j.cell.2016.06.001
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DO8VD
UT WOS:000378062000025
PM 27315483
ER

PT J
AU Gupta, SL
   Dhiman, V
   Jayasekharan, T
   Sahoo, NK
AF Gupta, Shyam L.
   Dhiman, Vikas
   Jayasekharan, T.
   Sahoo, N. K.
TI Analysis of argentinated peptide complexes using matrix-assisted laser
   desorption/ionization time-of-flight mass spectrometry: Peptide =
   oxytocin, arg(8)-vasopressin, bradykinin, bombesin, somatostatin,
   neurotensin
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID ELECTRON-CAPTURE DISSOCIATION; NONAPEPTIDE HORMONE OXYTOCIN; METAL-ION
   SELECTIVITY; ARGININE-VASOPRESSIN; COORDINATION ABILITY;
   RAMAN-SPECTROSCOPY; BINDING-SITES; HUMAN-PLASMA; AMINO-ACIDS; RECEPTORS
AB RATIONALE: The increased use of silver nanoparticles (AgNPs) for various biological applications, and over-expression of various peptide receptors in different tumors/cancer cells, necessitate the need for dedicated investigations on the intrinsic binding ability of Ag with various biologically important peptides for better understanding of AgNPs-peptide interactions and for the future development of contrasting agents as well as drugs for imaging/biomedical applications.
   METHODS: The [M+(Ag)(n)](+) complexes are prepared and characterized using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS).
   RESULTS: Silver complexes of the peptides [M+(Ag)(n)](+), where M = oxytocin, arg(8)-vasopressin, bradykinin, bombesin, somatostatin, and neurotensin, have been investigated for their intrinsic Ag+-binding ability. Unusual binding of up to seven Ag+ with these small peptides is observed. The mass spectra show n = 1-5 for bombesin and somatostatin, n = 1-6 for bradykinin and arg(8)-vasopressin, and n = 1-7 for oxytocin and neurotensin. In addition, oxytocin and arg(8)-vasopressin show the formation of dimers and their complexes [M-2+(Ag)(n)](+) with n = 1-8 and n = 1-5, respectively. The possible amino acid residues responsible for Ag+ binding in each peptide have been identified on the basis of density functional theory (DFT)-calculated binding energy values of Ag+ towards individual amino acids.
   CONCLUSIONS: Mass spectrometric evidence indicates that the peptides, viz., oxytocin, arg(8)-vasopressin, bradykinin, bombesin, somatostatin, and neurotensin, show greater affinity for Ag+. Hence, they may be used as carriers for AgNPs in targeted drug delivery as well as an alternative for iodinated contrasting agents in dual energy X-ray imaging techniques. Radio-labeled Ag with these peptides can also be used in radio-pharmaceuticals for diagnostic and therapeutic applications. Copyright (C) 2016 John Wiley & Sons, Ltd.
C1 [Gupta, Shyam L.; Dhiman, Vikas; Jayasekharan, T.; Sahoo, N. K.] Bhabha Atom Res Ctr, Phys Grp, Atom & Mol Phys Div, Bombay 400085, Maharashtra, India.
RP Jayasekharan, T (reprint author), Bhabha Atom Res Ctr, Phys Grp, Atom & Mol Phys Div, Bombay 400085, Maharashtra, India.
EM jsekhar@barc.gov.in
CR Avanti C, 2011, AAPS J, V13, P284, DOI 10.1208/s12248-011-9268-7
   Blasiak B, 2013, J NANOMATER, DOI 10.1155/2013/148578
   Bras G, 2013, PEPTIDES, V48, P114, DOI 10.1016/j.peptides.2013.08.003
   Cassoni P, 2001, ANN ONCOL, V12, pS37
   Cerda BA, 1999, INT J MASS SPECTROM, V193, P205, DOI 10.1016/S1387-3806(99)00164-5
   Chiba T., 1994, PHYSL GASTROINTESTIN
   Chu IK, 2002, ANAL CHEM, V74, P2072, DOI 10.1021/ac0111006
   Cotter R. J., 1997, TIME FLIGHT MASS SPE
   Deng HF, 2015, MOL PHARMACEUT, V12, P3054, DOI 10.1021/acs.molpharmaceut.5b00325
   Drochioiu G., 2013, ENCY METALLOPROTEINS, P2063
   Dudev T, 2014, CHEM REV, V114, P538, DOI 10.1021/cr4004665
   Eckhardt S, 2013, CHEM REV, V113, P4708, DOI 10.1021/cr300288v
   EVERS BM, 1992, ANN SURG, V216, P423, DOI 10.1097/00000658-199210000-00005
   Fani M, 2012, THERANOSTICS, V2, P481, DOI 10.7150/thno.4024
   FONG CTO, 1960, P NATL ACAD SCI USA, V46, P1273, DOI 10.1073/pnas.46.10.1273
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gniazdowska E, 2014, J MED CHEM, V57, P5986, DOI 10.1021/jm500272r
   Golias Ch, 2007, Hippokratia, V11, P124
   Gonzalez N, 2008, CURR OPIN ENDOCRINOL, V15, P58, DOI 10.1097/MED.0b013e3282f3709b
   Hofland LJ, 2001, ANN ONCOL, V12, pS31
   Hohla F, 2010, CELL CYCLE, V9, P1738
   Homan K, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3365937
   Homan KA, 2012, ACS NANO, V6, P641, DOI 10.1021/nn204100n
   Hornig B, 1997, CIRCULATION, V95, P1115
   HUMMERICH W, 1983, KLIN WOCHENSCHR, V61, P203, DOI 10.1007/BF01488976
   Ivanova B, 2012, INORG CHIM ACTA, V392, P211, DOI 10.1016/j.ica.2012.06.028
   Jamous M, 2013, MOLECULES, V18, P3379, DOI 10.3390/molecules18033379
   Jayasekharan T, 2010, RAPID COMMUN MASS SP, V24, P3562, DOI 10.1002/rcm.4811
   Jia YN, 2015, NUCL MED BIOL, V42, P816, DOI 10.1016/j.nucmedbio.2015.07.010
   Jover J, 2008, DALTON T, P6441, DOI 10.1039/b805860a
   Karunamuni R., 2012, LECT NOTES COMPUT SC, V7361, P418
   Kastin A., 2013, HDB BIOL ACTIVE PEPT
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-89
   Kitabgi P, 2002, CURR OPIN DRUG DI DE, V5, P764
   Kocher T, 2005, ANAL CHEM, V77, P172, DOI 10.1021/ac0489115
   Korner M., 2015, EJNMMI RES, V5, P1
   Kozik Andrzej, 2015, BMC Microbiol, V15, P60, DOI 10.1186/s12866-015-0394-8
   KOZLOWSKI H, 1989, J CHEM SOC DALTON, P173, DOI 10.1039/dt9890000173
   Lippard S. J., 1994, PRINCIPLES BIOINORGA
   Liu DF, 2005, J AM CHEM SOC, V127, P2024, DOI 10.1021/ja046042v
   Liu HC, 2007, J AM SOC MASS SPECTR, V18, P2007, DOI 10.1016/j.jasms.2007.08.015
   Lu Y, 2009, NATURE, V460, P855, DOI 10.1038/nature08304
   Manning MC, 2010, PHARM RES-DORDR, V27, P544, DOI 10.1007/s11095-009-0045-6
   Maschauer S., 2014, BIOORGAN MED CHEM, V23, P4026
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   MILEWICZ A, 1994, GYNECOL ENDOCRINOL, V8, P45, DOI 10.3109/09513599409028457
   Mitric R, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2772630
   Morones-Ramirez J. R., 2013, SCI TRANSL MED, V5, P190, DOI DOI 10.1126/SCITRANSLMED.3006276
   [Anonymous], 2015, NTS NEUR HOM HUM
   Nishino H, 1998, AM J PHYSIOL-GASTR L, V274, pG525
   North WG, 1998, CANCER RES, V58, P1866
   Okarvi SM, 2008, CANCER TREAT REV, V34, P13, DOI 10.1016/j.ctrv.2007.07.017
   Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183
   Podstawka E, 2006, BIOPOLYMERS, V83, P193, DOI 10.1002/bip.20545
   Podstawka E, 2009, J PHYS CHEM B, V113, P4978, DOI 10.1021/jp8110716
   Prudent M, 2008, J AM SOC MASS SPECTR, V19, P560, DOI 10.1016/j.jasms.2008.01.008
   Rapson TD, 2015, ACS BIOMATER SCI ENG, V1, P1114, DOI 10.1021/acsbiomaterials.5b00239
   Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007
   RHOLAM M, 1985, BIOCHEMISTRY-US, V24, P3345, DOI 10.1021/bi00334a040
   SAITO H, 1982, HORM METAB RES, V14, P71, DOI 10.1055/s-2007-1018927
   Schimpff RM, 2001, J NEUROL NEUROSUR PS, V70, P784, DOI 10.1136/jnnp.70.6.784
   Sharman A, 2008, BRIT J ANAESTH, V8, P134
   Shoeib T, 2002, J PHYS CHEM A, V106, P6121, DOI 10.1021/jp013662z
   Shvartsburg AA, 2004, J AM SOC MASS SPECTR, V15, P406, DOI 10.1016/j.jasms.2003.11.005
   Sovago I, 2006, DALTON T, P3841, DOI 10.1039/b607515k
   St-Gelais F, 2006, J PSYCHIATR NEUROSCI, V31, P229
   Starck M, 2015, INORG CHEM, V54, P11557, DOI 10.1021/acs.inorgchem.5b02249
   Swiech D, 2015, PHYS CHEM CHEM PHYS, V17, P17140, DOI 10.1039/c5cp02319j
   Tabarin T, 2009, EUR PHYS J D, V52, P191, DOI 10.1140/epjd/e2008-00272-2
   TU AT, 1979, J BIOL CHEM, V254, P3272
   Valliant JF, 2001, INORG CHIM ACTA, V325, P155, DOI 10.1016/S0020-1693(01)00637-5
   van der Burgt YEM, 2009, RAPID COMMUN MASS SP, V23, P31, DOI 10.1002/rcm.3849
   VERMA PS, 1980, CLIN CHEM, V26, P429
   Wang J, 2015, MOL PHARMACEUT, V12, P966, DOI 10.1021/mp500809f
   Weber HC, 2009, CURR OPIN ENDOCRINOL, V16, P66, DOI 10.1097/MED.0b013e32831cf5aa
   Wei H, 2000, J CHEM SOC DALTON, P4196, DOI 10.1039/b004254o
   White JF, 2012, NATURE, V490, P508, DOI 10.1038/nature11558
   Wu J, 2002, INT J CANCER, V98, P29, DOI 10.1002/ijc.10142
   Wyttenbach T, 2008, J AM CHEM SOC, V130, P5993, DOI 10.1021/ja8002342
   Xu XE, 2010, J PHYS CHEM B, V114, P1417, DOI 10.1021/jp907436p
   Yang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057358
   Zelenka K, 2011, BIOCONJUGATE CHEM, V22, P958, DOI 10.1021/bc2000269
NR 82
TC 0
Z9 0
U1 9
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-4198
EI 1097-0231
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD JUN 15
PY 2016
VL 30
IS 11
BP 1313
EP 1322
DI 10.1002/rcm.7562
PG 10
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA DR5VW
UT WOS:000379971500007
PM 27173113
ER

PT J
AU Theofanopoulou, C
AF Theofanopoulou, Constantina
TI Implications of Oxytocin in Human Linguistic Cognition: From Genome to
   Phenome
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE oxytocin; language; alpha rhythm; OXTR; POU3F2; LNPEP; FOXP2; CNTNAP2
ID AUTISM SPECTRUM DISORDERS; WHITE-MATTER DEVELOPMENT; SOCIAL-BEHAVIOR;
   INTRANASAL OXYTOCIN; FACTOR BRN-2; BREAST-MILK; HUMAN BRAIN; VITAMIN-D;
   RECEPTOR; SPEECH
AB The neurohormone oxytocin (OXT) has been found to mediate the regulation of complex socioemotional cognition in multiple ways both in humans and other animals. Recent studies have investigated the effects of OXT in different levels of analysis (from genetic to behavioral) chiefly targeting its impact on the social component and only indirectly indicating its implications in other components of our socio-interactive abilities. This article aims at shedding light onto how OXT might be modulating the multimodality that characterizes our higher-order linguistic abilities (vocal-auditory-attentional-memory-social systems). Based on evidence coming from genetic, EEG, fMRI, and behavioral studies, I attempt to establish the promises of this perspective with the goal of stressing the need for neuropeptide treatments to enter clinical practice.
C1 [Theofanopoulou, Constantina] Univ Barcelona, Dept Gen Linguist, Barcelona, Spain.
RP Theofanopoulou, C (reprint author), Univ Barcelona, Dept Gen Linguist, Barcelona, Spain.
EM constantinaki@hotmail.com
FU Spanish Ministry of Economy and Competitiveness [FFI2013-43823-P];
   Generalitat de Catalunya
FX Preparation of this work was supported by funds from the Spanish
   Ministry of Economy and Competitiveness (grant FFI2013-43823-P), as well
   as funds from the Generalitat de Catalunya (FI-grant-2016-2019).
CR Al-Farsi Yahya M, 2012, Nutrition, V28, pe27, DOI 10.1016/j.nut.2012.01.007
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Benitez-Burraco A, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00794
   Benitez-Burraco Antonio, 2014, Front Cell Neurosci, V8, P387, DOI 10.3389/fncel.2014.00387
   Berra I., 2015, RETI SAPERI LINGUAGG, V1, P167, DOI 10.12832/81296
   Boeckx C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00291
   Brimacombe M, 2007, MATERN CHILD HLTH J, V11, P73, DOI 10.1007/s10995-006-0142-7
   Burbach JPH, 2001, PHYSIOL REV, V81, P1197
   Cannell JJ, 2008, MED HYPOTHESES, V70, P750, DOI 10.1016/j.mehy.2007.08.016
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Carter CS, 2003, PHYSIOL BEHAV, V79, P383, DOI 10.1016/S0031-9384(03)00151-3
   De Berardis D, 2013, CNS NEUROL DISORD-DR, V12, P252
   Deoni SCL, 2013, NEUROIMAGE, V82, P77, DOI 10.1016/j.neuroimage.2013.05.090
   Di Benedetto A, 2014, P NATL ACAD SCI USA, V111, P16502, DOI 10.1073/pnas.1419349111
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebitz RB, 2014, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00225
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Ellenbogen MA, 2014, PSYCHOPHYSIOLOGY, V51, P1169, DOI 10.1111/psyp.12263
   Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025
   Fisher S. E., 2015, FUTURE BRAIN ESSAYS, P149
   Gallup GG, 2011, MED HYPOTHESES, V77, P345, DOI 10.1016/j.mehy.2011.05.010
   Gamer M, 2010, J NEUROSCI, V30, P9347, DOI 10.1523/JNEUROSCI.2847-10.2010
   Gascoyne DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128513
   Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62
   Grinevich V, 2015, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00164
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026
   Haas BW, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00028
   Hammock EAD, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00195
   Han MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083584
   Hepker M, 2016, EFFECT OXYTOCIN ADM
   Holler J, 2014, COGNITION, V133, P692, DOI 10.1016/j.cognition.2014.08.008
   Holler J, 2015, SOC COGN AFFECT NEUR, V10, P255, DOI 10.1093/scan/nsu047
   Isaacs EB, 2010, PEDIATR RES, V67, P357, DOI 10.1203/PDR.0b013e3181d026da
   Kafouri S, 2013, INT J EPIDEMIOL, V42, P150, DOI 10.1093/ije/dys172
   Keri S, 2009, COGN AFFECT BEHAV NE, V9, P237, DOI 10.3758/CABN.9.3.237
   Khedr EHM, 2004, ACTA PAEDIATR, V93, P734, DOI 10.1080/08035250410029407
   Klimesch W, 2012, TRENDS COGN SCI, V16, P606, DOI 10.1016/j.tics.2012.10.007
   Lange J, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00043
   LECKMAN JF, 1994, PSYCHONEUROENDOCRINO, V19, P723, DOI 10.1016/0306-4530(94)90021-3
   Lee HJ, 2010, BRAIN RES, V1364, P216, DOI 10.1016/j.brainres.2010.08.042
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Levinson SC, 2016, TRENDS COGN SCI, V20, P6, DOI 10.1016/j.tics.2015.10.010
   Lopatina Olga, 2012, Front Neurosci, V6, P182, DOI 10.3389/fnins.2012.00182
   Ma Y, 2016, TRENDS COGN SCI, V20, P133, DOI 10.1016/j.tics.2015.10.009
   Maricic T, 2013, MOL BIOL EVOL, V30, P844, DOI 10.1093/molbev/mss271
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Moran LV, 2011, SCHIZOPHRENIA BULL, V37, P659, DOI 10.1093/schbul/sbr056
   Murphy JW, 2014, AUTISM RES, V7, P442, DOI 10.1002/aur.1374
   Muthukumaraswamy SD, 2004, PSYCHOPHYSIOLOGY, V41, P152, DOI 10.1046/j.1469-8986.2003.00129.x
   Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109
   Neumann D, 2006, SOC COGN AFFECT NEUR, V1, P194, DOI 10.1093/scan/nsl030
   Oberman LM, 2008, NEUROPSYCHOLOGIA, V46, P1558, DOI 10.1016/j.neuropsychologia.2008.01.010
   Oberman Lindsay M, 2005, Brain Res Cogn Brain Res, V24, P190
   Obleser J, 2012, CEREB CORTEX, V22, P2466, DOI 10.1093/cercor/bhr325
   Orekhova EV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039906
   Patrick RP, 2014, FASEB J, V28, P2398, DOI 10.1096/fj.13-246546
   Pelphrey KA, 2005, BRAIN, V128, P1038, DOI 10.1093/brain/awh404
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Perry A, 2010, PSYCHONEUROENDOCRINO, V35, P1446, DOI 10.1016/j.psyneuen.2010.04.011
   Pineda JA, 2005, BRAIN RES REV, V50, P57, DOI 10.1016/j.brainresrev.2005.04.005
   Prufer K, 1997, CELL MOL BIOL, V43, P543
   Puglia MH, 2015, P NATL ACAD SCI USA, V112, P3308, DOI 10.1073/pnas.1422096112
   Ripolles P, 2014, CURR BIOL, V24, P2606, DOI 10.1016/j.cub.2014.09.044
   Roberts TPL, 2010, AUTISM RES, V3, P8, DOI 10.1002/aur.111
   Rodenas-Cuadrado P, 2014, EUR J HUM GENET, V22, P171, DOI 10.1038/ejhg.2013.100
   Schaschl H, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0372-7
   Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122
   Seltzer LJ, 2010, P ROY SOC B-BIOL SCI, V277, P2661, DOI 10.1098/rspb.2010.0567
   Simonyan K, 2012, BRAIN LANG, V122, P142, DOI 10.1016/j.bandl.2011.12.009
   Singh F, 2016, EUR NEUROPSYCHOPHARM, V26, P626, DOI 10.1016/j.euroneuro.2015.12.026
   Steinman G, 2013, MED HYPOTHESES, V81, P999, DOI 10.1016/j.mehy.2013.09.013
   TAKEDA S, 1986, ENDOCRINOL JAPON, V33, P821
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Theodosis DT, 2002, FRONT NEUROENDOCRIN, V23, P101, DOI 10.1006/frne.2001.0226
   Theofanopoulou C., 2016, EVOLAND 11 WORKSH RH
   Theofanopoulou Constantina, 2015, Front Cell Dev Biol, V3, P64, DOI 10.3389/fcell.2015.00064
   Theofanopoulou C, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01355
   Uvnas-Moberg K, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01529
   Vernes SC, 2007, AM J HUM GENET, V81, P1232, DOI 10.1086/522238
   Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181
   Williams P G, 2000, Pediatr Nurs, V26, P259
   Yamasue H, 2013, BRAIN DEV-JPN, V35, P111, DOI 10.1016/j.braindev.2012.08.010
   Yau SH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00208
   Yoshimura R, 1996, NEUROSCI RES, V24, P291, DOI 10.1016/0168-0102(95)01003-3
   Zhao HX, 2015, DEV BIOL, V398, P242, DOI 10.1016/j.ydbio.2014.12.007
   Zheng JJ, 2014, NAT NEUROSCI, V17, P391, DOI 10.1038/nn.3634
NR 88
TC 0
Z9 0
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUN 14
PY 2016
VL 10
AR 271
DI 10.3389/fnins.2016.00271
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DO3FL
UT WOS:000377665900001
PM 27378840
ER

PT J
AU Bartal, IB
   Shan, HZ
   Molasky, NMR
   Murray, TM
   Williams, JZ
   Decety, J
   Mason, P
AF Bartal, Inbal Ben-Ami
   Shan, Haozhe
   Molasky, Nora M. R.
   Murray, Teresa M.
   Williams, Jasper Z.
   Decety, Jean
   Mason, Peggy
TI Anxiolytic Treatment Impairs Helping Behavior in Rats
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE emotional contagion; midazolam; empathy; helping; rodent; altruism
ID PROSOCIAL BEHAVIOR; SOCIAL-BEHAVIOR; INVERTED-U; EMPATHY; STRESS;
   BENZODIAZEPINES; OXYTOCIN; VASOPRESSIN; REACTIVITY; 5-HTTLPR
AB Despite decades of research with humans, the biological mechanisms that motivate an individual to help others remain poorly understood. In order to investigate the roots of pro-sociality in mammals, we established the helping behavior test, a paradigm in which rats are faced with a conspecific trapped in a restrainer that can only be opened from the outside. Over the course of repeated test sessions, rats exposed to a trapped cagemate learn to open the door to the restrainer, thereby helping the trapped rat to escape (Ben-Ami Bartal et al., 2011). The discovery of this natural behavior provides a unique opportunity to probe the motivation of rodent helping behavior, leading to a deeper understanding of biological influences on human pro-sociality. To determine if an affective response motivates door-opening, rats receiving midazolam, a benzodiazepine anxiolytic, were tested in the helping behavior test. Midazolam-treated rats showed less helping behavior than saline-treated rats or rats receiving no injection. Yet, midazolam-treated rats opened a restrainer containing chocolate, highlighting the socially specific effects of the anxiolytic. To determine if midazolam interferes with helping through a sympatholytic effect, the peripherally restricted beta-adrenergic receptor antagonist nadolol was administered; nadolol did not interfere with helping. The corticosterone response of rats exposed to a trapped cagemate was measured and compared to the rats' subsequent helping behavior. Rats with the greatest corticosterone responses showed the least helping behavior and those with the smallest responses showed the most consistent helping at the shortest latency. These results are discussed in terms of their implications for the interaction between stress and pro-social behavior. Finally, we observed that door-opening appeared to be reinforcing. A novel analytical tool was designed to interrogate the pattern of door-opening for signs that a rat's behavior on one session influenced his behavior on the next session. Results suggest that helping a trapped rat has a greater motivational value than does chocolate. In sum, this series of experiments clearly demonstrates the fundamental role of affect in motivating pro-social behavior in rodents and the need for a helper to resonate with the affect of a victim.
C1 [Bartal, Inbal Ben-Ami; Shan, Haozhe; Molasky, Nora M. R.; Williams, Jasper Z.; Mason, Peggy] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA.
   [Murray, Teresa M.; Decety, Jean] Univ Chicago, Pritzker Sch Med, Dept Psychol, Chicago, IL 60637 USA.
   [Decety, Jean] Univ Chicago, Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
RP Mason, P (reprint author), Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA.
EM pmason@uchicago.edu
FU Pritzker Medical School; Biological Sciences Division
FX Funds from the Pritzker Medical School and the Biological Sciences
   Division supported this work.
CR Anacker AMJ, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00185
   Bartal IB, 2014, ELIFE, V3, DOI 10.7554/eLife.01385
   Bartal IBA, 2011, SCIENCE, V334, P1427, DOI 10.1126/science.1210789
   BATSON CD, 1987, J PERS, V55, P19, DOI 10.1111/j.1467-6494.1987.tb00426.x
   Beery Annaliese K, 2015, Neurobiol Stress, V1, P116
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   CHRISTMAS AJ, 1970, NEUROPHARMACOLOGY, V9, P17, DOI 10.1016/0028-3908(70)90044-4
   Clay Z, 2013, P NATL ACAD SCI USA, V110, P18121, DOI 10.1073/pnas.1316449110
   Cronin KA, 2012, ANIM BEHAV, V84, P1085, DOI 10.1016/j.anbehav.2012.08.009
   Febo M, 2014, BRAIN RES, V1580, P8, DOI 10.1016/j.brainres.2014.01.019
   Gotlib IH, 2008, BIOL PSYCHIAT, V63, P847, DOI 10.1016/j.biopsych.2007.10.008
   GRAY RW, 1995, PHYSIOL BEHAV, V58, P853, DOI 10.1016/0031-9384(95)00115-Y
   Hernandez-Lallement J, 2016, NEUROBIOL LEARN MEM, V127, P1, DOI 10.1016/j.nlm.2015.11.004
   Hernandez-Lallement J, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00443
   Joels M, 2006, TRENDS PHARMACOL SCI, V27, P244, DOI 10.1016/j.tips.2006.03.007
   Kikusui T, 2006, PHILOS T R SOC B, V361, P2215, DOI 10.1098/rstb.2006.1941
   Marquez C, 2015, CURR BIOL, V25, P1736, DOI 10.1016/j.cub.2015.05.018
   Martin LJ, 2015, CURR BIOL, V25, P326, DOI 10.1016/j.cub.2014.11.028
   Muroy S. E., 2016, NEUROPSYCHOPHARMACOL, DOI [10.1038/npp.2016.16, DOI 10.1038/NPP.2016.16[]
   Panksepp JB, 2011, NEUROSCI BIOBEHAV R, V35, P1864, DOI 10.1016/j.neubiorev.2011.05.013
   Salehi Basira, 2010, Learn Mem, V17, P522, DOI 10.1101/lm.1914110
   Sapolsky RM, 2015, NAT NEUROSCI, V18, P1344, DOI 10.1038/nn.4109
   Sato N, 2015, ANIM COGN, V18, P1039, DOI 10.1007/s10071-015-0872-2
   Schilling TM, 2013, PSYCHONEUROENDOCRINO, V38, P1565, DOI 10.1016/j.psyneuen.2013.01.001
   Silberberg A, 2014, ANIM COGN, V17, P609, DOI 10.1007/s10071-013-0692-1
   Stoltenberg SF, 2013, SOC NEUROSCI-UK, V8, P400, DOI 10.1080/17470919.2013.807874
   WEERTS EM, 1993, PSYCHOPHARMACOLOGY, V110, P451, DOI 10.1007/BF02244652
   Welt T, 2006, NEUROPSYCHOPHARMACOL, V31, P2573, DOI 10.1038/sj.npp.1301006
   Yagi K, 1996, NEUROSCI LETT, V203, P49, DOI 10.1016/0304-3940(95)12262-1
NR 29
TC 0
Z9 0
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD JUN 8
PY 2016
VL 7
AR 850
DI 10.3389/fpsyg.2016.00850
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA DN7LD
UT WOS:000377256400001
ER

PT J
AU Jankowski, M
   Broderick, TL
   Gutkowska, J
AF Jankowski, Marek
   Broderick, Tom L.
   Gutkowska, Jolanta
TI Oxytocin and cardioprotection in diabetes and obesity
SO BMC ENDOCRINE DISORDERS
LA English
DT Review
DE Oxytocin; Heart; Cardiomyocyte; Differentiation; Stem cells;
   Cardioprotection
ID MESENCHYMAL STEM-CELLS; ATRIAL-NATRIURETIC-PEPTIDE; CARDIAC PROGENITOR
   CELLS; DIET-FED RATS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION;
   GENE-EXPRESSION; ADIPOSE-TISSUE; HEART-FAILURE; FOOD-INTAKE
AB Oxytocin (OT) emerges as a drug for the treatment of diabetes and obesity. The entire OT system is synthesized in the rat and human heart. The direct myocardial infusion with OT into an ischemic or failing heart has the potential to elicit a variety of cardioprotective effects. OT treatment attenuates cardiomyocyte (CMs) death induced by ischemia-reperfusion by activating pro-survival pathways within injured CMs in vivo and in isolated cells. OT treatment reduces cardiac apoptosis, fibrosis, and hypertrophy. The OT/OT receptor (OTR) system is downregulated in the db/db mouse model of type 2 diabetes which develops genetic diabetic cardiomyopathy (DC) similar to human disease. We have shown that chronic OT treatment prevents the development of DC in the db/db mouse. In addition, OT stimulates glucose uptake in both cardiac stem cells and CMs, and increases cell resistance to diabetic conditions. OT may help replace lost CMs by stimulating the in situ differentiation of cardiac stem cells into functional mature CMs. Lastly, adult stem cells amenable for transplantation such as MSCs could be preconditioned with OT ex vivo and implanted into the injured heart to aid in tissue regeneration through direct differentiation, secretion of protective and cardiomyogenic factors and/or their fusion with injured CMs.
C1 [Jankowski, Marek; Gutkowska, Jolanta] CRCHUM 7 134, Cardiovasc Biochem Lab, 900 St Denis St, Montreal, PQ H2X 0A9, Canada.
   [Jankowski, Marek; Gutkowska, Jolanta] Univ Montreal, Fac Med, Dept Med, Montreal, PQ, Canada.
   [Broderick, Tom L.] Midwestern Univ, Lab Diabet & Exercise Metab, Dept Physiol, Agave Hall,Off 217-B,19555 North 59th Ave, Glendale, AZ 85308 USA.
RP Jankowski, M (reprint author), CRCHUM 7 134, Cardiovasc Biochem Lab, 900 St Denis St, Montreal, PQ H2X 0A9, Canada.; Jankowski, M (reprint author), Univ Montreal, Fac Med, Dept Med, Montreal, PQ, Canada.; Broderick, TL (reprint author), Midwestern Univ, Lab Diabet & Exercise Metab, Dept Physiol, Agave Hall,Off 217-B,19555 North 59th Ave, Glendale, AZ 85308 USA.
EM marek.jankowski@umontreal.ca; tbrode@midwestern.edu
FU Canadian Institutes of Health Research; Canadian Heart and Stroke
   Foundation
FX this study was supported in part by the Canadian Institutes of Health
   Research and the Canadian Heart and Stroke Foundation.
CR Adams V, 2008, J MOL BIOL, V384, P48, DOI 10.1016/j.jmb.2008.08.087
   Akerlund M, 1999, BRIT J OBSTET GYNAEC, V106, P1047, DOI 10.1111/j.1471-0528.1999.tb08112.x
   Alizadeh AM, 2013, PEPTIDES, V45, P66, DOI 10.1016/j.peptides.2013.04.016
   Altirriba J, 2014, ENDOCRINOLOGY, V155, P4189, DOI 10.1210/en.2014-1466
   Bassuk SS, 2005, J APPL PHYSIOL, V99, P1193, DOI 10.1152/japplphysiol.00160.2005
   Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303
   Bisping E, 2006, P NATL ACAD SCI USA, V103, P14471, DOI 10.1073/pnas.0602543103
   Blevins JE, 2016, AM J PHYSIOL-REG I, V310, pR640, DOI 10.1152/ajpregu.00220.2015
   Blevins JE, 2015, AM J PHYSIOL-REG I, V308, pR431, DOI 10.1152/ajpregu.00441.2014
   Bollini S, 2011, J MOL CELL CARDIOL, V50, P296, DOI 10.1016/j.yjmcc.2010.07.006
   Broderick TL, 2010, ACTA PHYSIOL, V200, P147, DOI 10.1111/j.1748-1716.2010.02134.x
   Broderick TL, 2012, ISRN ENDOCRINOL, V2012
   Broderick TL, 2014, REGUL PEPTIDES, V188, P52, DOI 10.1016/j.regpep.2013.12.005
   Cai Dongsheng, 2013, Drug Discov Today Dis Mech, V10, pe63
   Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109
   D'Amario D, 2014, CIRCULATION, V129, P157, DOI 10.1161/CIRCULATIONAHA.113.006591
   Mukaddam-Daher S, 2001, HYPERTENSION, V38, P292
   Daiber A, 2010, BBA-BIOENERGETICS, V1797, P897, DOI 10.1016/j.bbabio.2010.01.032
   Danalache BA, 2007, STEM CELLS, V25, P679, DOI 10.1634/stemcells.2005-0610
   Das B, 2012, LIFE SCI, V90, P763, DOI 10.1016/j.lfs.2012.03.030
   Deblon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025565
   Dombret C, 2012, HUM MOL GENET, V21, P4703, DOI 10.1093/hmg/dds310
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   Elabd S, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00121
   Emmert MY, 2013, EUR HEART J, V34, P2830, DOI 10.1093/eurheartj/ehs156
   Florian M, 2010, ENDOCRINOLOGY, V151, P482, DOI 10.1210/en.2009-0624
   Forbes JM, 2013, PHYSIOL REV, V93, P137, DOI 10.1152/physrev.00045.2011
   Gajdosechova L, 2014, J ENDOCRINOL, V220, P333, DOI 10.1530/JOE-13-0417
   Garlid KD, 2009, J MOL CELL CARDIOL, V46, P858, DOI 10.1016/j.yjmcc.2008.11.019
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gimpl G, 2008, EXPERT OPIN THER PAT, V18, P1239, DOI 10.1517/13543770802493409
   Gollisch KSC, 2009, AM J PHYSIOL-ENDOC M, V297, pE495, DOI 10.1152/ajpendo.90424.2008
   Gonzalez-Reyes A, 2015, MOL CELL ENDOCRINOL, V412, P170, DOI 10.1016/j.mce.2015.04.028
   Gossen A, 2012, NEUROPEPTIDES, V46, P211, DOI 10.1016/j.npep.2012.07.001
   Grewen KM, 2011, BIOL PSYCHOL, V87, P340, DOI 10.1016/j.biopsycho.2011.04.003
   Gutkowska J, 2000, BRAZ J MED BIOL RES, V33, P625, DOI 10.1590/S0100-879X2000000600003
   Gutkowska J, 2012, J NEUROENDOCRINOL, V24, P599, DOI 10.1111/j.1365-2826.2011.02235.x
   Gutkowska J, 1997, P NATL ACAD SCI USA, V94, P11704, DOI 10.1073/pnas.94.21.11704
   Gutkowska J, 2009, J PHYSIOL-LONDON, V587, P4725, DOI 10.1113/jphysiol.2009.176461
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Heusch G, 2008, CIRCULATION, V118, P1915, DOI 10.1161/CIRCULATIONAHA.108.805242
   INGALLS AM, 1950, J HERED, V41, P317
   Jankowski M, 1998, P NATL ACAD SCI USA, V95, P14558, DOI 10.1073/pnas.95.24.14558
   Jankowski M, 2004, P NATL ACAD SCI USA, V101, P13074, DOI 10.1073/pnas.0405324101
   Jankowski M, 2010, BASIC RES CARDIOL, V105, P205, DOI 10.1007/s00395-009-0076-5
   Jialal I, 2010, AM J CARDIOL, V106, P1606, DOI 10.1016/j.amjcard.2010.07.039
   Kajstura J, 2008, CTS-CLIN TRANSL SCI, V1, P80, DOI 10.1111/j.1752-8062.2008.00030.x
   Kasama S, 2008, EUR HEART J, V29, P1485, DOI 10.1093/eurheartj/ehn206
   Kim YS, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-38
   Kim YS, 2010, ARTIF ORGANS, V34, P453, DOI 10.1111/j.1525-1594.2009.00894.x
   Kobayashi S, 2007, J BIOL CHEM, V282, P21945, DOI 10.1074/jbc.M703048200
   Kujath AS, 2015, DIABETES-METAB RES, V31, P102, DOI 10.1002/dmrr.2577
   Kung G, 2011, CIRC RES, V108, P1017, DOI 10.1161/CIRCRESAHA.110.225730
   Lavie CJ, 2015, CIRC RES, V117, P207, DOI 10.1161/CIRCRESAHA.117.305205
   Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1
   Ludwig M, 2013, J NEUROENDOCRINOL, V25, P655, DOI 10.1111/jne.12046
   Maejima Y, 2011, AGING-US, V3, P1169
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155
   Manolescu DC, 2014, APPL PHYSIOL NUTR ME, V39, P1127, DOI 10.1139/apnm-2014-0005
   Martin SS, 2008, J AM COLL CARDIOL, V52, P1201, DOI 10.1016/j.jacc.2008.05.060
   Mazzone T, 2010, CIRCULATION, V122, P2201, DOI 10.1161/CIRCULATIONAHA.109.913350
   MELVILLE KI, 1961, BRIT J PHARM CHEMOTH, V17, P218
   Menaouar A, 2014, INT J CARDIOL, V175, P38, DOI 10.1016/j.ijcard.2014.04.174
   Meredith ME, 2015, AAPS J, V17, P780, DOI 10.1208/s12248-015-9719-7
   Messina E, 2006, CIRC RES, V99, P1, DOI 10.1161/01.RES.0000233141.65522.3e
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mohsin S, 2013, CIRC RES, V113, P1169, DOI 10.1161/CIRCRESAHA.113.302302
   Moien-Afshari F, 2008, DIABETOLOGIA, V51, P1327, DOI 10.1007/s00125-008-0996-x
   Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Morton GJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE392, DOI 10.1152/ajpendo.00546.2010
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Noiseux N, 2012, ENDOCRINOLOGY, V153, P5361, DOI 10.1210/en.2012-1402
   Ondrejcakova M, 2012, GEN PHYSIOL BIOPHYS, V31, P261, DOI 10.4149/gpb_2012_030
   Ondrejcakova M, 2009, CAN J PHYSIOL PHARM, V87, P137, DOI 10.1139/Y08-108
   Perrelli Maria-Giulia, 2011, World J Cardiol, V3, P186, DOI 10.4330/wjc.v3.i6.186
   Phie J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138048
   Plante E, 2015, ENDOCRINOLOGY, V156, P1416, DOI 10.1210/en.2014-1718
   Plante E, 2014, DIABETOLOGIA, V57, P1257, DOI 10.1007/s00125-014-3201-4
   Qian WY, 2014, J CLIN ENDOCR METAB, V99, P4683, DOI 10.1210/jc.2014-2206
   Rabe K, 2008, MOL MED, V14, P741, DOI 10.2119/2008-00058.Rabe
   Romero-Corral A, 2008, NAT CLIN PRACT CARD, V5, P418, DOI 10.1038/ncpcardio1218
   Rota M, 2006, CIRC RES, V99, P42, DOI 10.1016/01.RES.0000231289.634683.08
   Sabatier Nancy, 2013, Front Endocrinol (Lausanne), V4, P35, DOI 10.3389/fendo.2013.00035
   Sakurai T, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/801743
   Schrier RW, 2009, KIDNEY INT, V76, P137, DOI 10.1038/ki.2009.103
   Schwartz MW, 1997, DIABETES CARE, V20, P1476, DOI 10.2337/diacare.20.9.1476
   Shah Ankur, 2003, Rev Cardiovasc Med, V4 Suppl 6, pS50
   Spetter MS, 2015, MOL PHARMACEUT, V12, P2767, DOI 10.1021/acs.molpharmaceut.5b00047
   Stevens FL, 2013, J NEUROPSYCH CLIN N, V25, P96, DOI 10.1176/appi.neuropsych.13030061
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77
   Tolson KP, 2010, J NEUROSCI, V30, P3803, DOI 10.1523/JNEUROSCI.5444-09.2010
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Vest AR, 2013, CIRCULATION, V127, P945, DOI 10.1161/CIRCULATIONAHA.112.103275
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Zabala S, 2008, J CLIN PHARM THER, V33, P79, DOI 10.1111/j.1365-2710.2008.00881.x
   Zachwieja JJ, 1997, DIABETES, V46, P1159, DOI 10.2337/diabetes.46.7.1159
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
   Zhang G, 2011, NEURON, V69, P523, DOI 10.1016/j.neuron.2010.12.036
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
NR 102
TC 0
Z9 0
U1 6
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD JUN 7
PY 2016
VL 16
AR 34
DI 10.1186/s12902-016-0110-1
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DN6DD
UT WOS:000377161100001
PM 27268060
ER

PT J
AU Katte, TA
   Reekie, TA
   Jorgensen, WT
   Kassiou, M
AF Katte, Timothy A.
   Reekie, Tristan A.
   Jorgensen, William T.
   Kassiou, Michael
TI The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler
   Conditions: A Route to Pyrazolo[3,4]benzodiazepines
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID OXYTOCIN RECEPTOR AGONIST; CYCLIZATION REACTIONS; CONDENSATION;
   VASOPRESSIN; DERIVATIVES; MODEL; RING
AB Reported is a method for the synthesis of seven-membered heterocycles via a Pictet-Spengler condensation reaction under very mild conditions. High substrate scope allows for use of aldehydes using catalytic amounts of acetic: acid yielding 39-90% and ketones using catalytic amounts of trifluoroacetic acid yielding 25-83%.
C1 [Katte, Timothy A.; Reekie, Tristan A.; Jorgensen, William T.; Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.
RP Kassiou, M (reprint author), Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.
EM michael.kassiou@sydney.edu.au
RI Reekie, Tristan/M-5091-2015; Jorgensen, William/R-5621-2016
OI Reekie, Tristan/0000-0003-1415-8880; Jorgensen,
   William/0000-0002-9990-6894
FU Australian National Health and Medical Research Council
FX This work was supported by the Australian National Health and Medical
   Research Council.
CR Badiola KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111782
   Deaudelin P, 2008, ORG LETT, V10, P2841, DOI 10.1021/ol8009978
   Denoyelle S., 2015, EUR J ORG CHEM, V32, P7146
   Dong WF, 2011, J ORG CHEM, V76, P5363, DOI 10.1021/jo200758r
   Dunetz JR, 2005, CHEM COMMUN, P4465, DOI 10.1039/b508151c
   Dzvinchuk I. B., 2006, CHEM HETEROCYCL COMP, V42, P798, DOI 10.1007/s10593-006-0164-5
   Fandrick DR, 2015, ORG LETT, V17, P2964, DOI 10.1021/acs.orglett.5b01248
   Frantz MC, 2010, J MED CHEM, V53, P1546, DOI 10.1021/jm901084f
   Hicks C, 2014, BRIT J PHARMACOL, V171, P2868, DOI 10.1111/bph.12613
   Jorgensen WT, 2016, EUR J MED CHEM, V108, P730, DOI 10.1016/j.ejmech.2015.11.050
   Kojima N, 2013, EUR J MED CHEM, V63, P833, DOI 10.1016/j.ejmech.2013.03.009
   Kundu B, 2005, J ORG CHEM, V70, P4889, DOI 10.1021/jo050384h
   Li XF, 2000, TETRAHEDRON LETT, V41, P4069, DOI 10.1016/S0040-4039(00)00592-X
   Manini P, 2000, J ORG CHEM, V65, P4269, DOI 10.1021/jo991969c
   Nakamura S, 2003, ORG LETT, V5, P2087, DOI 10.1021/ol034526a
   Otto R, 2014, EUR J MED CHEM, V87, P63, DOI 10.1016/j.ejmech.2014.09.048
   Pictet A, 1911, BER DTSCH CHEM GES, V44, P2030, DOI 10.1002/cber.19110440309
   Reekie TA, 2013, SYNTHESIS-STUTTGART, V45, P3211, DOI 10.1055/s-0033-1338549
   Rose MD, 2007, J ORG CHEM, V72, P538, DOI 10.1021/jo0619783
   Shumaila AMA, 2011, TETRAHEDRON, V67, P936, DOI 10.1016/j.tet.2010.12.003
   Sim F, 2015, J PSYCHOPHARMACOL, V29, P212, DOI 10.1177/0269881114541013
   [Anonymous], 2015, MED CHEM LETT, DOI DOI 10.1016/J.BMCL.2015.04.018
   Thigulla Y, 2016, ORG BIOMOL CHEM, V14, P876, DOI 10.1039/c5ob01650a
NR 23
TC 0
Z9 0
U1 14
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD JUN 3
PY 2016
VL 81
IS 11
BP 4883
EP 4889
DI 10.1021/acs.joc.6b00710
PG 7
WC Chemistry, Organic
SC Chemistry
GA DN8HJ
UT WOS:000377319500050
PM 27159074
ER

PT J
AU Devi, VA
   Rajini, P
AF Devi, V. Aruna
   Rajini, P.
TI INDUCTION OF LABOUR IN INTRAUTERINE FOETAL DEATH WITH INTRAVAGINAL
   MISOPROSTOL
SO JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS
LA English
DT Article
DE Induction of Labour; Intrauterine Foetal Death; Misoprostol
AB OBJECTIVES
   To optimize the dose of misoprostol in induction of labour in IUDs. To evaluate the effectiveness and safety of intravaginal misoprostol.
   METHOD he prospective study conducted at Gandhi Medical College/Hospital, Secunderabad, during Jan 2015 to Dec 2015; 500 patients with intrauterine foetal deaths between 18 to 40 weeks were taken for the study after conforming IUD with ultrasound.
   INDUCTION PROTOCOL
   After admission and selection for the study, 100 mu g (Half tablet) misoprostol was introduced into the posterior vaginal fornix. If the patient was not in labour after 12 hours, the dose was repeated every 12 hours for up to 48 hours. During the period of induction, there were always obstetricians on duty to manage any complications or side effects if developed. No further medication nor artificial rupture of membranes was allowed during study.
   RESULTS
   Most of the patients studied were in the age group of 21 to 25 years, few between 26-30 years and very few in 31-35 years. Most of the patients were primigravidas and the Bishop score is <5.60% of the patients aborted/delivered within 12 hours of induction; 86% of the patients delivered within 18 hours of induction, 96% of the patients delivered within 24 hours of induction.
   CONCLUSION
   With the introduction of prostaglandins, the induction delivery interval is drastically reduced from other methods like Oxytocin infusion and extra-amniotic instillation of Ethacridine lactate. In this study, administration of relatively low dose of misoprostol 100 mu g (12th hourly) intravaginally proved to be highly effective in induction of labour in intrauterine foetal deaths.
C1 [Devi, V. Aruna; Rajini, P.] Gandhi Med Coll Hosp, Dept Obstet & Gynaecol, New Bhoiguda, Secunderabad, India.
RP Devi, VA (reprint author), Flat 204,Priyanka Towers, New Bhoiguda 500003, Secunderabad, India.
EM avinjamoori@yahoo.com
CR Blanchette HA, 1999, AM J OBSTET GYNECOL, V180, P1551, DOI 10.1016/S0002-9378(99)70051-7
   BUGALHO A, 1994, AM J OBSTET GYNECOL, V171, P538
   BUGALHO A, 1995, ACTA OBSTET GYN SCAN, V74, P194, DOI 10.3109/00016349509008937
   Bugalho Antonio, 1995, CONNECTING WORLD BIO, V39, P252
   Easmin S, 2011, Mymensingh Med J, V20, P566
   Nvende L, 2004, E AFR MED J, V81, P179
NR 6
TC 0
Z9 0
U1 1
U2 1
PU JOURNAL EVOLUTION MEDICAL & DENTAL SCIENCES
PI KARNATAKA
PA C/O AKSHANTALA ENTERPRISES, NO 65, 1ST FL, SAHUKAR CHENNIAH RD, MYSORE,
   KARNATAKA, 570 009, INDIA
SN 2278-4748
EI 2278-4802
J9 J EVOL MED DENT SCI-
JI J. Evol. Med. Dent. Sci.-JEMDS
PD JUN 2
PY 2016
VL 5
IS 44
BP 2846
EP 2849
DI 10.14260/jemds/2016/641
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DO7MS
UT WOS:000377967300006
ER

PT J
AU Raber, J
   Weber, SJ
   Kronenberg, A
   Turker, MS
AF Raber, Jacob
   Weber, Sydney J.
   Kronenberg, Amy
   Turker, Mitchell S.
TI Sex- and dose-dependent effects of calcium ion irradiation on behavioral
   performance of B6D2F1 mice during contextual fear conditioning training
SO LIFE SCIENCES IN SPACE RESEARCH
LA English
DT Article
DE Hippocampus; Irradiation; Fear memory; Contextual; Extinction
ID FE-56 IRRADIATION; HIPPOCAMPUS; OXYTOCIN; STRESS; MEMORY; RADIATION;
   RATS
AB The space radiation environment includes energetic charged particles that may impact behavioral and cognitive performance. The relationship between the dose and the ionization density of the various types of charged particles (expressed as linear energy transfer or LET), and cognitive performance is complex. In our earlier work, whole body exposure to Si-28 ions (263 MeV/n, LET = 78 keV/mu m; 1.6 Gy) affected contextual fear memory in C57BL/6J xDBA2/J F1 (B6D2F1) mice three months following irradiation but this was not the case following exposure to 48 Ti ions (1 GeV/n, LET = 107 keV/mu m; 0.2 or 0.4 Gy). As an increased understanding of the impact of charged particle exposures is critical for assessment of risk to the CNS of astronauts during and following missions, in this study we used Ca-40 ion beams (942 MeV/n, LET = 90 keV/mu m) to determine the behavioral and cognitive effects for the LET region between that of Si ions and Ti ions. Ca-40 ion exposure reduced baseline activity in a novel environment in a dose-dependent manner, which suggests reduced motivation to explore and/or a diminished level of curiosity in a novel environment. In addition, exposure to Ca-40 ions had sex-dependent effects on response to shock. Ca-40 ion irradiation reduced the response to shock in female, but not male, mice. In contrast, Ca-40 ion irradiation did not affect fear learning, memory, or extinction of fear memory for either gender at the doses employed in this study. Thus Ca-40 ion irradiation affected behavioral, but not cognitive, performance. The effects of Ca-40 ion irradiation on behavioral performance are relevant, as a combination of novelty and aversive environmental stimuli is pertinent to conditions experienced by astronauts during and following space missions. (C) 2016 The Committee on Space Research (COSPAR). Published by Elsevier Ltd. All rights reserved.
C1 [Raber, Jacob; Weber, Sydney J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, L470,3181SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
   [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Radiat Med, Div Neurosci ONPRC, Portland, OR 97239 USA.
   [Kronenberg, Amy] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.
   [Turker, Mitchell S.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97239 USA.
   [Turker, Mitchell S.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
RP Raber, J (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, L470,3181SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM raberj@ohsu.edu
CR Aljanabi S., 2013, ASIAN J PHARM CLIN R, V6, P82
   Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8
   Anagnostaras SG, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00158
   Carmack SA, 2010, NEUROSCI LETT, V468, P18, DOI 10.1016/j.neulet.2009.10.049
   Carter CS, 2007, BEHAV BRAIN RES, V176, P170, DOI 10.1016/j.bbr.2006.08.025
   Chang YJ, 2009, HIPPOCAMPUS, V19, P1142, DOI 10.1002/hipo.20581
   Davis MJ, 2013, NEUROPHARMACOLOGY, V66, P365, DOI 10.1016/j.neuropharm.2012.07.038
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Garcia-Ovejero D, 2001, DEV BRAIN RES, V130, P191, DOI 10.1016/S0165-3806(01)00236-X
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Indovina I, 2011, NEURON, V69, P563, DOI 10.1016/j.neuron.2010.12.034
   Inslicht SS, 2013, J PSYCHIATR RES, V47, P64, DOI 10.1016/j.jpsychires.2012.08.027
   Johnson LA, 2015, NEUROPSYCHOPHARMACOL, V40, P2443, DOI 10.1038/npp.2015.95
   Keil L., 1985, J APPL PHYSIOL, V73, p166S
   Kronenberg A, 2009, RADIAT RES, V172, P550, DOI 10.1667/RR1804.1
   Kugelman T, 2016, BEHAV BRAIN RES, V298, P1, DOI 10.1016/j.bbr.2015.10.050
   Lebron-Milad K., 2012, BIOL MOOD ANXIETY DI, V2, P2, DOI DOI 10.1186/2045-5380-2-7
   Lesniewski LA, 2009, J GERONTOL A-BIOL, V64, P9, DOI 10.1093/gerona/gln049
   Milad MR, 2010, NEUROSCIENCE, V168, P652, DOI 10.1016/j.neuroscience.2010.04.030
   Milad MR, 2009, NEUROSCIENCE, V164, P887, DOI 10.1016/j.neuroscience.2009.09.011
   Milad MR, 2011, NEUROMETHODS, V50, P111, DOI 10.1007/978-1-60761-883-6_5
   Missig G, 2010, NEUROPSYCHOPHARMACOL, V35, P2607, DOI 10.1038/npp.2010.155
   NATARAJAN S, 1963, INT J RADIAT BIOL RE, V7, P315, DOI 10.1080/09553006314551241
   Olsen RHJ, 2012, GENES BRAIN BEHAV, V11, P806, DOI 10.1111/j.1601-183X.2012.00833.x
   Olsen RHJ, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00231
   PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037//0735-7044.106.2.274
   Raber J, 2016, BEHAV BRAIN RES, V302, P263, DOI 10.1016/j.bbr.2016.01.035
   Raber Jacob, 2015, Life Sci Space Res (Amst), V7, P61, DOI 10.1016/j.lssr.2015.10.004
   Raber J, 2015, RADIAT RES, V183, P708, DOI 10.1667/RR13951.1
   Raber J, 2014, RADIAT RES, V181, P362, DOI 10.1667/RR13347.1
   Raber J, 2013, BEHAV BRAIN RES, V246, P162, DOI 10.1016/j.bbr.2013.02.022
   RABIN BM, 2014, J BEHAV BRAIN SCI, V4, P297
   Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103
   Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492
   Villasana L, 2010, HIPPOCAMPUS, V20, P19, DOI 10.1002/hipo.20659
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2214-5524
EI 2214-5532
J9 LIFE SCI SPACE RES
JI Life Sci. Space Res.
PD JUN
PY 2016
VL 9
BP 56
EP 61
DI 10.1016/j.lssr.2016.03.002
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC3GN
UT WOS:000388014300006
PM 27345201
ER

PT J
AU Dahlke, JD
   Mendez-Figueroa, H
   Sperling, JD
   Maggio, L
   Connealy, BD
   Chauhan, SP
AF Dahlke, Joshua D.
   Mendez-Figueroa, Hector
   Sperling, Jeffrey D.
   Maggio, Lindsay
   Connealy, Brendan D.
   Chauhan, Suneet P.
TI Evidence-Based Cesarean Delivery for the Nonobstetrician
SO SURGERY JOURNAL-NEW YORK
LA English
DT Review
DE cesarean delivery; surgical technique; evidence-based
ID RANDOMIZED-CONTROLLED-TRIAL; EVIDENCE-BASED SURGERY; MISGAV-LADACH;
   SECTION; PREGNANCY; MORTALITY; BLADDER
AB Cesarean delivery (CD) is one of the most common major surgeries performed in the United States and worldwide. Surgical techniques evaluated in well-designed randomized controlled trials (RCTs) that demonstrate maternal benefit should be incorporated into practice. The objective of this review is to provide a summary of surgical techniques of the procedure and review the evidence basis for them for the nonobstetrician. The following techniques with the strongest evidence should be commonly performed, when feasible: (1) prophylactic antibiotics with a single dose of ampicillin or first-generation cephalosporin prior to skin incision; (2) postpartum hemorrhage prevention with oxytocin infusion of 10 to 40 IU in 1 L crystalloid over 4 to 8 hours; (3) low transverse skin incision; (4) blunt or sharp subcutaneous and fascial expansion; (5) blunt, cephalad-caudad uterine incision expansion; (6) spontaneous placental removal; (7) blunt-tip needle usage during closure; (8) subcutaneous suture closure (running or interrupted) if thickness is >= 2 cm; and (9) skin closure with suture. Although the number of RCTs designed to optimize maternal and neonatal outcomes of this common procedure is encouraging, further work is needed to minimize surgical morbidity. Optimal methods for postpartum hemorrhage prevention, adhesion prevention, and venous thromboembolism prophylaxis remain ongoing areas of active research, with outcomes that could markedly improve maternal morbidity and mortality. If evidence of a surgical technique appears preferred over another, clinicians should be comfortable adopting the evidence-based technique when performing and teaching CD.
C1 [Dahlke, Joshua D.; Connealy, Brendan D.] Nebraska Methodist Womens Hosp & Perinatal Ctr, Div Maternal Fetal Med, Omaha, NE USA.
   [Mendez-Figueroa, Hector; Chauhan, Suneet P.] UT Hlth Univ Texas Med Sch Houston, Dept Obstet Gynecol & Reprod Sci, Div Maternal Fetal Med, Houston, TX USA.
   [Sperling, Jeffrey D.] Brown Univ, Women & Infants Hosp Rhode Isl, Warren Alpert Med Sch, Dept Obstet & Gynecol, Providence, RI 02912 USA.
   [Maggio, Lindsay] Univ S Florida, Dept Obstet & Gynecol, Morsani Coll Med, Div Maternal Fetal Med, Tampa, FL 33620 USA.
RP Dahlke, JD (reprint author), 717 N 190th Plaza,Suite 2400, Omaha, NE 68022 USA.
EM joshuadahlke@gmail.com
CR Abalos E, 2013, LANCET, V382, P234, DOI DOI 10.1016/S0140-6736(13)60441-9
   Barber EL, 2011, OBSTET GYNECOL, V118, P29, DOI 10.1097/AOG.0b013e31821e5f65
   Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11
   Berghella V, 2005, AM J OBSTET GYNECOL, V193, P1607, DOI 10.1016/j.ajog.2005.03.063
   Boyle A, 2012, SEMIN PERINATOL, V36, P308, DOI 10.1053/j.semperi.2012.04.012
   Brocklehurst P, 2010, BJOG-INT J OBSTET GY, V117, P1366, DOI 10.1111/j.1471-0528.2010.02686.x
   Caughey AB, 2014, AM J OBSTET GYNECOL, V210, P179, DOI 10.1016/j.ajog.2014.01.026
   Costantine MM, 2008, AM J OBSTET GYNECOL, V199
   Dahlke JD, 2013, AM J OBSTET GYNECOL, V209, P294, DOI 10.1016/j.ajog.2013.02.043
   Dodd JM, 2008, COCHRANE DB SYST REV, V3
   Haas DM, 2010, COCHRANE DB SYST REV, V3
   Hofmeyr JG, 2009, AM J OBSTET GYNECOL, V201, P431, DOI 10.1016/j.ajog.2009.03.018
   James AH, 2006, AM J OBSTET GYNECOL, V194, P1311, DOI 10.1016/j.ajog.2005.11.008
   Li L, 2011, BJOG-INT J OBSTET GY, V118, P400, DOI 10.1111/j.1471-0528.2010.02802.x
   Mackeen AD, 2015, AM J OBSTET GYNECOL, V212
   Marnai M, 2007, COCHRANE DB SYST REV, V2
   Naki MM, 2011, J MATERN-FETAL NEO M, V24, P239, DOI 10.3109/14767058.2010.482612
   O'Neill HA, 2014, EUR J OBSTET GYN R B, V174, P20, DOI 10.1016/j.ejogrb.2013.12.020
   Parantainen A, 2011, COCHRANE DB SYST REV, V11
   Sullivan S, 2009, OBSTET GYNECOL, V114, P211, DOI 10.1097/AOG.0b013e3181ae9b4a
   Viney R, 2012, OBSTET GYNECOL, V119, P1106, DOI 10.1097/AOG.0b013e3182460d09
   Walsh CA, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.009
   Wilkinson C, 2000, COCHRANE DB SYST REV, V2
   Xavier P, 2005, ACTA OBSTET GYN SCAN, V84, P878, DOI 10.1111/j.0001-6349.2005.00631.x
   Zhang J, 2010, AM J OBSTET GYNECOL, V203, P326, DOI DOI 10.1016/J.AJ0G.2010.06.058
NR 25
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 2378-5136
EI 2378-5128
J9 SURG J-NY
JI Surg. J.-NY
PD JUN
PY 2016
VL 2
IS 1
BP E1
EP E6
DI 10.1055/s-0035-1570316
PG 6
WC Surgery
SC Surgery
GA EB0MM
UT WOS:000387037900001
ER

PT J
AU Yang, L
   Yao, XL
   Li, SJ
   Chen, K
   Wang, YX
   Chen, L
   Zhang, LY
AF Yang, Ling
   Yao, Xiaolei
   Li, Shujing
   Chen, Kai
   Wang, Yongxiang
   Chen, Long
   Zhang, Leying
TI Expression of Genes Associated With Luteolysis in Peripheral Blood
   Mononuclear Cells During Early Pregnancy in Cattle
SO MOLECULAR REPRODUCTION AND DEVELOPMENT
LA English
DT Article
ID BOVINE CORPUS-LUTEUM; INTERFERON-STIMULATED GENES; BINDING-PROTEIN 1;
   ESTROUS-CYCLE; 1ST TRIMESTER; DAIRY-COWS; PROSTAGLANDIN; PROGESTERONE;
   RECEPTOR; ENDOMETRIUM
AB The conceptus-derived signals that initiate maternal recognition of pregnancy act primarily on the endometrium to inhibit the development of luteolysis, thus modifying the expression of genes in the corpus luteum. The involvement of peripheral blood mononuclear cells (PBMCs) in the formation of this anti-luteolytic mechanism during early pregnancy is uncertain. In this study, PBMCs from non-pregnant and earlypregnant cows were sampled to explore the expression of genes associated with luteolysis, including AKR1B1 (aldo-keto reductase family 1, member B1; a bovine prostaglandin F synthase), PTGFR(PGF2a receptor), OXT(oxytocin), PTGES(PGE synthase), PTGER1 (PGE2 receptor 1), and PGR (progesterone receptor). OXT and PTGFR transcript abundance was low in PBMCs at Day 18 in pregnant individuals. PGR and PTGER1 mRNA abundance was significantly higher at Day 30 in pregnant individuals. AKR1B1 and PTGES transcript abundance was significantly higher at Day 18 in PBMCs from non-pregnant individuals, yet AKR1B1 and PTGES protein abundance was elevated at Day 30 in pregnant individuals - althoughAKR1B1 dimer maybe significantly higher atDay 18 in non-pregnantPBMCs. In conclusion, changes in bovine PBMC gene expression are associated with luteolysis during early pregnancy,
C1 [Yang, Ling; Yao, Xiaolei; Chen, Kai; Wang, Yongxiang; Zhang, Leying] Hebei Univ Engn, Dept Anim Sci, Coll Agr, Handan 056021, Peoples R China.
   [Li, Shujing; Chen, Long] Hebei Prov Engn Technol Res Ctr Dairy Cattle Bree, Shijiazhuang, Peoples R China.
RP Yang, L (reprint author), Hebei Univ Engn, Dept Anim Sci, Coll Agr, Handan 056021, Peoples R China.
EM yangling@hebeu.edu.cn
FU Natural Science Foundation of Hebei Province, China [C2014402015];
   Science and Technology Project of Hebei Province, China [14236602D-12]
FX Grant sponsor: Natural Science Foundation of Hebei Province, China;
   Grant number: C2014402015; Grant sponsor: Science and Technology Project
   of Hebei Province, China; Grant number: 14236602D-12
CR Arosh JA, 2004, ENDOCRINOLOGY, V145, P5280, DOI 10.1210/en.2004-0587
   Austin KJ, 1996, BIOL REPROD, V54, P600, DOI 10.1095/biolreprod54.3.600
   Bazer FW, 2010, MOL HUM REPROD, V16, P135, DOI 10.1093/molehr/gap095
   Bazer FW, 2009, SEMIN REPROD MED, V27, P90, DOI 10.1055/s-0028-1108013
   BAZER FW, 1991, J REPROD FERTIL, P39
   Blesson CS, 2014, RECEPT CLIN INVEST, V1, P127
   Bott RC, 2010, BIOL REPROD, V82, P725, DOI 10.1095/biolreprod.109.079467
   Brooks K, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-53
   Brozos CN, 2012, J VET SCI, V13, P67, DOI 10.4142/jvs.2012.13.1.67
   Dorniak P, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100487
   DuBay KM, 2010, DIFFERENTIAL GENE EX, P47
   Gifford CA, 2007, J DAIRY SCI, V90, P274
   Gu G, 2012, BIOL REPROD, V86, P1
   Ideta A, 2010, MOL REPROD DEV, V77, P954, DOI 10.1002/mrd.21243
   Kizaki K, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-6
   Kowalik MK, 2014, THERIOGENOLOGY, V82, P1086, DOI 10.1016/j.theriogenology.2014.07.021
   Kowalik MK, 2013, REPROD BIOL, V13, P15, DOI 10.1016/j.repbio.2013.01.170
   Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326
   Lemaster JW, 1999, PROSTAG OTH LIPID M, V57, P259, DOI 10.1016/S0090-6980(99)00007-6
   MacIntyre DM, 2002, BIOL REPROD, V66, P1430, DOI 10.1095/biolreprod66.5.1430
   Madore E, 2003, J BIOL CHEM, V278, P11205, DOI 10.1074/jbc.M208318200
   MCDONALD LE, 1953, AM J VET RES, V14, P539
   Niswender G D, 2007, Soc Reprod Fertil Suppl, V64, P191
   Penning TM, 2003, ALDOKETO REDUCTASES, P3
   Pepin NL, 2013, PROSTAG OTH LIPID M, V106, P124, DOI 10.1016/j.prostaglandins.2013.05.005
   ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432
   Romero JJ, 2013, PHYSIOL GENOMICS, V45, P1095, DOI 10.1152/physiolgenomics.00082.2013
   SAKAMOTO K, 1995, J REPROD FERTIL, V103, P99
   Sakumoto R, 2014, REPROD BIOL, V14, P115, DOI 10.1016/j.repbio.2013.12.003
   Sakumoto R, 2015, J REPROD DEVELOP, V61, P42, DOI 10.1262/jrd.2014-101
   Shirasuna K, 2012, DOMEST ANIM ENDOCRIN, V43, P198, DOI 10.1016/j.domaniend.2012.03.007
   Shirasuna K, 2012, J REPROD DEVELOP, V58, P84, DOI 10.1262/jrd.11-094K
   Spencer TE, 2013, REPRODUCTION, V146, P377, DOI 10.1530/REP-13-0165
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Thatcher W. W., 1989, Journal of Reproduction and Fertility, P91
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yang L., 2014, Asian Journal of Animal and Veterinary Advances, V9, P610, DOI 10.3923/ajava.2014.610.620
   Yang L, 2010, J DAIRY SCI, V93, P1000, DOI 10.3168/jds.2009-2529
   Yang L, 2010, J ANIM VET ADV, V9, P3016
NR 39
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1040-452X
EI 1098-2795
J9 MOL REPROD DEV
JI Mol. Reprod. Dev.
PD JUN
PY 2016
VL 83
IS 6
BP 509
EP 515
DI 10.1002/mrd.22647
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology
SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology
GA DY7EH
UT WOS:000385291900004
PM 27061007
ER

PT J
AU Driver, RL
AF Driver, Robin Lynn
TI Use of Oxytocin in Labor
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Meeting Abstract
DE labor; induction; oxytocin
C1 [Driver, Robin Lynn] Mt Carmel Hlth Syst, Columbus, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0884-2175
EI 1552-6909
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD JUN
PY 2016
VL 45
IS 3
SU S
BP S46
EP S46
PG 1
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA DY3NH
UT WOS:000385000000090
ER

PT J
AU Robinson, AK
   Heale, PA
AF Robinson, Aydrien K.
   Heale, Patricia A.
TI An Educational Pathway to Successful Induction With Oxytocin
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Meeting Abstract
DE oxytocin; labor dystocia; needs assessment
C1 [Robinson, Aydrien K.] Childrens Mem Hermann Hosp, Texas City, TX USA.
   [Heale, Patricia A.] Childrens Mem Hermann Hosp, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0884-2175
EI 1552-6909
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD JUN
PY 2016
VL 45
IS 3
SU S
BP S15
EP S15
PG 1
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA DY3NH
UT WOS:000385000000030
ER

PT J
AU Ayadi, M
   Musaad, A
   Aljumaah, R
   Matar, A
   Faye, B
AF Ayadi, Moez
   Musaad, Abdelgader
   Aljumaah, Riyadh
   Matar, Abdelkarim
   Faye, Bernard
TI EFFECTS OF MANUAL UDDER STIMULATION ON MILK PARTITIONING AND FLOW TRAITS
   DURING THE MACHINE MILKING IN DAIRY CAMELS (Camelus dromedarius)
SO JOURNAL OF CAMEL PRACTICE AND RESEARCH
LA English
DT Article
DE Camels; cistern; machine milking; milk partitioning; udder stimulation
ID OXYTOCIN RELEASE; REMOVAL; EJECTION; SYSTEM; COWS
AB A total of 9 multiparous dromedary camels in late stage of lactation (287 +/- 8 DIM; 3.8 +/- 0.8 kg/d) were used to study the effect of manual udder stimulation on machine milking efficiency of dairy camels under intensive management condition. Experimental design consisted of 3x3 Latin square with 9 animals allocated randomly and equally to 3 treatment (T-1=60 s, T-2=90 s and T-3=120 s). All camels were machine milked twice daily. Milk yield and milk flow parameters were recorded by Lactocorder (R) milk meters. Udder health was evaluated by California mastitis test (CMT) and somatic cell counts (SCC). Cisternal milk was determined 14 h after milking using Atosiban (R). Volumes of machine milk (MM), machine stripping milk (MSM) and residual milk (RM) were recorded in duplicate. No subclinical mastitis was detected during the experimental period as indicated by the CMT (<1) and SCC (279x10(3)+/- 58 cells/mL). Camels were characterised by relatively small cistern (8.84 +/- 3.10%). There was a large variation in the proportion of RM (average= 25.1 +/- 10.2%; max: 83.4%, min: 2.1%) between camels due to the duration of udder preparation. Consequently, camels were classified into easy milked camels (G(1): RM<25%) and hard milked camels (G(2)=RM>25%). The increase of udder stimulation from T-1, to T-3 decreased (p<0.05) the lag time (LT) (3.83 to 2.24 sec) in camels of G(1) and the MSM (26.6 to 14.8%) as well as RM (46.1 to 31.4%) in camels of G(2). Bimodal curves tended (P=0.08) to decrease from 43.6% to 28.1% when duration of udder stimulation increased from T-1, to T-3 in camels of G(2). In conclusion, increase duration of manual udder stimulation to 90-120 s ameliorate the machine milking efficiency in harder milked camels at late stage of lactation.
C1 [Ayadi, Moez; Aljumaah, Riyadh; Matar, Abdelkarim] King Saud Univ, Dept Anim Prod, Coll Food & Agr Sci, POB 2460, Riyadh 11451, Saudi Arabia.
   [Ayadi, Moez] Univ Jendouba, Dept Biotechnol Anim, Inst Super Biotechnol Beja, BP 382,Av Habib Bourguiba, Beja 9000, Tunisia.
   [Musaad, Abdelgader; Faye, Bernard] Camel Project Ctr, Conservat & Genet Improvement Ctr, Al Kharj 11942, Saudi Arabia.
RP Ayadi, M (reprint author), King Saud Univ, Dept Anim Prod, Coll Food & Agr Sci, POB 2460, Riyadh 11451, Saudi Arabia.; Ayadi, M (reprint author), Univ Jendouba, Dept Biotechnol Anim, Inst Super Biotechnol Beja, BP 382,Av Habib Bourguiba, Beja 9000, Tunisia.
EM mayadi@ksu.edu.sa
FU FAO project of improvement of research for sustainable development of
   camel production in the KSA [UTF/SAU/021/SAU]; Deanship of Scientific
   Research at King Saud University, Saudi Arabia [RGP-042]
FX Study was supported by the FAO project of improvement of research for
   sustainable development of camel production in the KSA (UTF/SAU/021/SAU)
   and the Deanship of Scientific Research at King Saud University, Saudi
   Arabia through the Research Group Project No. RGP-042.
CR Aljumaah S, 2011, TROPICAL ANIMAL HLTH, V43, P1605
   Ambord S, 2010, J DAIRY RES, V77, P468, DOI 10.1017/S0022029910000518
   Atigui M, 2014, J DAIRY RES, V81, P494, DOI 10.1017/S002202991400051X
   Atigui M, 2014, J DAIRY RES, V81, P173, DOI 10.1017/S0022029914000089
   Ayadi M, 2013, SPAN J AGRIC RES, V11, P790, DOI 10.5424/sjar/2013113-4060
   Ayadi M, 2009, J DAIRY SCI, V92, P1452, DOI 10.3168/jds.2008-1447
   Ayadi M, 2014, INT LIV C WILDL AR D, P76
   Borghese A, 2007, ITAL J ANIM SCI, V6, P39
   Bruckmaier RM, 1998, J DAIRY SCI, V81, P939
   Bruckmaier RM, 2001, J DAIRY RES, V68, P369, DOI 10.1017/S0022029901005015
   Caja G, 2011, P 62 ANN M EAAP STAV, P363
   DEWHURST RJ, 1994, ANIM PROD, V58, P181
   Dzidic A, 2004, J DAIRY SCI, V87, P4163
   Hammadi M., 2010, Journal of Camel Practice and Research, V17, P1
   Juhasz J, 2008, P WBC ICAR 2008 SAT, P84
   Labussiere J, 1999, MIEUX COMPR, P307
   Wemery U, 2004, J CAMEL PRACT RES, V11, P51
   Yagil R, 1999, J CAMEL PRACT RES, V6, P27
NR 18
TC 0
Z9 0
U1 0
U2 0
PU CAMEL PUBL HOUSE
PI BIKANER
PA 67 GANDHI NAGAR WEST, NEAR LALGARH PALACE, BIKANER 334001, INDIA
SN 0971-6777
J9 J CAMEL PRACT RES
JI J. Camel Pract. Res.
PD JUN
PY 2016
VL 23
IS 1
BP 85
EP 89
DI 10.5958/2277-8934.2016.00012.6
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA DY1QD
UT WOS:000384868600013
ER

PT J
AU Niasari-Naslaji, A
   Pezeshk, H
   Atakpour, AB
   Ghaffari, S
   Nickchi, P
   Safi, S
   Shirazi-Beheshtiha, SH
   Arabha, H
   Samiei, R
   Amjadi, M
   Moradlou, AAH
   Narimani, I
   Moosavi-Movahedi, AA
AF Niasari-Naslaji, A.
   Pezeshk, H.
   Atakpour, A. B.
   Ghaffari, S.
   Nickchi, P.
   Safi, S.
   Shirazi-Beheshtiha, S. H.
   Arabha, H.
   Samiei, R.
   Amjadi, M.
   Moradlou, A. A. Haji
   Narimani, I.
   Moosavi-Movahedi, A. A.
TI ESTIMATION OF SOMATIC CELL COUNT, AS GOLD STANDARD TO DETECT SUBCLINICAL
   MASTITIS, IN DROMEDARY CAMEL
SO JOURNAL OF CAMEL PRACTICE AND RESEARCH
LA English
DT Article
DE Dromedary camel; SCC; subclinical mastitis
ID DAIRY GOATS; MILK; PREVALENCE; ETHIOPIA
AB The objective of the present study was to estimate cut-off point of somatic cell count (SCC) to detect subclinical mastitis using mathematical modelling in dromedary camel. Camel milk samples were collected from individual quarters (n=243) of 95 milking camels. Approximately five minutes prior to milking, camel received oxytocin (20 I.U, IM), the teat was washed and the camel calf was released to stimulate the dam. After 2 minutes, the suckling was interrupted and the teat was dried with tissue and sampling was conducted to perform CMT, and to collect milk for SCC. The range of SCC corresponding with CMT scores of 0, T, 1, 2 and 3 were 0-51000, 57000-108000,116000-306000, 3420004830000 and 2129000-8435000, respectively. The threshold values for SCC to detect subclinical mastitis in camel were calculated by considering two different approaches: frequentist analysis (306000 cells/ml) and Bayesian analysis (390000 cells/ml). In conclusion, SCC values beyond 306000 cells/ml could be considered as subclinical mastitis in camel.
C1 [Niasari-Naslaji, A.; Atakpour, A. B.; Ghaffari, S.; Arabha, H.] Univ Tehran, Fac Vet Med, Dept Theriogenol, Tehran, Iran.
   [Pezeshk, H.; Nickchi, P.] Univ Tehran, Sch Math Stat & Comp Sci, Tehran, Iran.
   [Moosavi-Movahedi, A. A.] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran.
   [Safi, S.] Islamic Azad Univ, Sci & Res Branch, Fac Specialised Vet Sci, Dept Pathol & Clin Pathol, Tehran, Iran.
   [Shirazi-Beheshtiha, S. H.] Islamic Azad Univ, Karaj Branch, Fac Vet Med, Dept Clin Sci, Karaj, Iran.
   [Moradlou, A. A. Haji] Pegah Milk Co, Golestan, Iran.
   [Amjadi, M.] Int Dairy Federat, Tehran, Iran.
   [Narimani, I.] Minist Jahad E Agr, Ctr Anim Breeding, Tehran, Iran.
RP Niasari-Naslaji, A (reprint author), Univ Tehran, Fac Vet Med, Dept Theriogenol, Tehran, Iran.
EM niasari@ut.ac.ir
CR Abdurahman OAS, 1995, ACTA VET SCAND, V36, P423
   Abera M, 2010, TROP ANIM HEALTH PRO, V42, P341, DOI 10.1007/s11250-009-9424-6
   Alamin MA, 2013, IOSR J AGR VET SCI, V2, P7
   Almaw G, 2000, J CAMEL PRACT RES, V7, P97
   Behrens CN, 2004, STAT MODEL, V4, P227, DOI 10.1191/1471082X04st075oa
   Bergonier D, 2003, LIVEST PROD SCI, V79, P1, DOI 10.1016/S0301-6226(02)00145-8
   Burvenich C, 2003, VET RES, V34, P521, DOI 10.1051/vetres:2003023
   Contreras A, 2007, SMALL RUMINANT RES, V68, P145, DOI 10.1016/j.smallrumres.2006.09.011
   Contreras A, 2003, LIVEST PROD SCI, V79, P273, DOI 10.1016/S0301-6226(02)00172-0
   DOHOO IR, 1982, CAN VET J, V23, P119
   Hatmi EI- H, 2007, SMALL RUMINANT RES, V70, P267
   Halasa T, 2007, VET QUART, V29, P18
   Jones GM, 2009, UNDERSTANDING BASICS, p[404, 233]
   Lehmann E. L., 1998, THEORY POINT ESTIMAT
   Lenin Bhatt, 2004, Veterinary Practitioner, V5, P61
   Manefield GW, 1996, CAMELS COMPENDIUM, P152
   Nagy P, 2013, J DAIRY SCI, V96, P5625, DOI 10.3168/jds.2013-6990
   O'Mahony MC, 2006, RES VET SCI, V80, P155, DOI 10.1016/j.rvsc.2005.05.005
   Perrin GG, 1997, SMALL RUMINANT RES, V26, P167, DOI 10.1016/S0921-4488(96)00990-X
   Plozza K, 2011, AUST VET J, V89, P41, DOI 10.1111/j.1751-0813.2010.00649.x
   Regassa A, 2013, TROP ANIM HEALTH PRO, V45, P1589, DOI 10.1007/s11250-013-0403-6
   Salami M, 2010, J AGR FOOD CHEM, V58, P3297, DOI 10.1021/jf9033283
   SCHALM O. W., 1957, JOUR AMER VET MED ASSOC, V130, P199
   Schepers AJ, 1997, J DAIRY SCI, V80, P1833
   Seifu E., 2010, ETHIOPIAN VET J, V14, P103
   Sibtain Ahmad, 2012, Tropical Animal Health and Production, V44, P107, DOI 10.1007/s11250-011-9895-0
   Suheir I, 2005, SUDAN J VET RES, V20, P23
   Wernery U, 2002, INFECT DIS CAMELIDS
   Yagil R, 1982, CAMELS CAMEL MILK AN
   Younan M, 2001, PREV VET MED, V51, P307, DOI 10.1016/S0167-5877(01)00228-8
NR 30
TC 0
Z9 0
U1 0
U2 0
PU CAMEL PUBL HOUSE
PI BIKANER
PA 67 GANDHI NAGAR WEST, NEAR LALGARH PALACE, BIKANER 334001, INDIA
SN 0971-6777
J9 J CAMEL PRACT RES
JI J. Camel Pract. Res.
PD JUN
PY 2016
VL 23
IS 1
BP 175
EP 178
DI 10.5958/2277-8934.2016.00033.3
PG 4
WC Veterinary Sciences
SC Veterinary Sciences
GA DY1QD
UT WOS:000384868600031
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Higher Oxytocin Levels Found to Predict Severity of Postpartum
   Depression
SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES
LA English
DT News Item
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0279-3695
EI 1938-2413
J9 J PSYCHOSOC NURS MEN
JI J. Psychosoc. Nurs. Ment. Health Serv.
PD JUN
PY 2016
VL 54
IS 6
BP 55
EP 55
PG 1
WC Nursing
SC Nursing
GA DY1YJ
UT WOS:000384890000011
ER

PT J
AU See, R
   Chun, YC
   See, R
AF See, Ronald
   Chun, Young Chul
   See, Ronald
TI Oxytocin attenuates drug seeking in a model of psychostimulant addiction
   and relapse
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
CR Cox BM, 2013, PSYCHONEUROENDOCRINO, V38, P2343, DOI 10.1016/j.psyneuen.2013.05.005
   Leong KC, 2015, EXPT CLIN P IN PRESS
   Zhou L, 2014, INT J NEUROPSYCHOPH, V18, P1
NR 3
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
BP 38
EP 39
PG 2
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600097
ER

PT J
AU Kim, YR
AF Kim, Youl-Ri
TI Oxytocin as a multidimensional pharmacotherapy in psychiatric disorders
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
BP 39
EP 39
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600099
ER

PT J
AU Lee, J
AF Lee, Junghee
TI Oxytocin facilitation of social cognition skills training.
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
BP 39
EP 40
PG 2
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600100
ER

PT J
AU Neumann, ID
AF Neumann, Inga D.
TI Chronic effects of oxytocin: Are we ready for its therapeutic use?
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
CR Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   Toth I, 2012, NEUROPSYCHOPHARMACOL, V37, P1433, DOI 10.1038/npp.2011.329
   Zoicas Iulia, 2014, Neuropsychopharmacology, V39, P3027, DOI 10.1038/npp.2014.156
NR 3
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
BP 39
EP 39
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600098
ER

PT J
AU Kasahara, Y
   Suzuki, S
   Onouchi, Y
   Yoshida, A
   Ono, C
   Kikuchi, Y
   Yu, ZQ
   Tomita, H
AF Kasahara, Yoshiyuki
   Suzuki, Sachie
   Onouchi, Yuji
   Yoshida, Ayaka
   Ono, Chiaki
   Kikuchi, Yoshie
   Yu, Zhiqian
   Tomita, Hiroaki
TI Pregnant mice exposure to extreme level of oxytocin influences emotional
   and social behaviors of the offsprings after growing up
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
C1 [Kasahara, Yoshiyuki; Suzuki, Sachie; Onouchi, Yuji; Yoshida, Ayaka; Ono, Chiaki; Kikuchi, Yoshie; Yu, Zhiqian; Tomita, Hiroaki] Tohoku Univ, Int Res Inst Disaster Sci, Dept Disaster Psychiat, Sendai, Miyagi 980, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
MA PS09
BP 50
EP 50
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600128
ER

PT J
AU Lien, YJ
   Chang, HH
   Yang, YK
   Lu, RB
   Chen, PS
AF Lien, Yueh-Ju
   Chang, Hui Hua
   Yang, Yen Kuang
   Lu, Ru-Band
   Chen, Po See
TI The serum oxytocin levels among major depressive and bipolar II disorder
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
C1 [Lien, Yueh-Ju; Yang, Yen Kuang; Lu, Ru-Band; Chen, Po See] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Psychiat, Coll Med, Tainan, Taiwan.
   [Chang, Hui Hua] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan.
   [Chang, Hui Hua] Natl Cheng Kung Univ, Sch Pharm, Coll Med, Tainan, Taiwan.
CR Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Turan T, 2013, PSYCHONEUROENDOCRINO, V38, P2890, DOI 10.1016/j.psyneuen.2013.07.017
NR 2
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
MA PS50
BP 64
EP 64
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600168
ER

PT J
AU Marazziti, D
   Baroni, S
   Mucci, F
   Dell'Osso, L
AF Marazziti, Donatella
   Baroni, Stefano
   Mucci, Federico
   Dell'Osso, Liliana
TI Plasma oxytocin levels in OCD patients
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 30th Seoul World Congress of the
   International-College-of-Neuropsychopharmacology (CINP)
CY JUL 03-07, 2016
CL Seoul, SOUTH KOREA
SP Int Coll Neuropsychopharmacol
C1 [Marazziti, Donatella; Baroni, Stefano; Mucci, Federico; Dell'Osso, Liliana] Univ Pisa, Sect Psychiat, Dipartimento Med Clin & Sperimentale, I-56100 Pisa, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2016
VL 19
SU 1
MA PT617
BP 272
EP 272
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW8PI
UT WOS:000383917600730
ER

PT J
AU Chen, X
   Hackett, PD
   DeMarco, AC
   Feng, CL
   Stair, S
   Haroon, E
   Ditzen, B
   Pagnoni, G
   Rilling, JK
AF Chen, Xu
   Hackett, Patrick D.
   DeMarco, Ashley C.
   Feng, Chunliang
   Stair, Sabrina
   Haroon, Ebrahim
   Ditzen, Beate
   Pagnoni, Giuseppe
   Rilling, James K.
TI Effects of oxytocin and vasopressin on the neural response to
   unreciprocated cooperation within brain regions involved in stress and
   anxiety in men and women
SO BRAIN IMAGING AND BEHAVIOR
LA English
DT Article
DE Amygdala; Anterior insula; Anxiety; Oxytocin; Social cooperation;
   Functional magnetic resonance imaging (fMRI)
ID BORDERLINE PERSONALITY-DISORDER; INTRANASAL OXYTOCIN; SOCIAL ANXIETY;
   PSYCHOSOCIAL STRESS; CENTRAL AMYGDALA; PLASMA OXYTOCIN; HUMANS; RATS;
   BEHAVIOR; ROBUST
AB Anxiety disorders are characterized by hyperactivity in both the amygdala and the anterior insula. Interventions that normalize activity in these areas may therefore be effective in treating anxiety disorders. Recently, there has been significant interest in the potential use of oxytocin (OT), as well as vasopressin (AVP) antagonists, as treatments for anxiety disorders. In this double-blind, placebo-controlled, pharmaco-fMRI study, 153 men and 151 women were randomized to treatment with either 24 IU intranasal OT, 20 IU intranasal AVP, or placebo and imaged with fMRI as they played the iterated Prisoner's Dilemma game with same-sex human and computer partners. In men, OT attenuated the fMRI response to unreciprocated cooperation (CD), a negative social interaction, within the amygdala and anterior insula. This effect was specific to interactions with human partners. In contrast, among women, OT unexpectedly attenuated the amygdala and anterior insula response to unreciprocated cooperation from computer but not human partners. Among women, AVP did not significantly modulate the response to unreciprocated cooperation in either the amygdala or the anterior insula. However, among men, AVP attenuated the BOLD response to CD outcomes with human partners across a relatively large cluster including the amygdala and the anterior insula, which was contrary to expectations. Our results suggest that OT may decrease the stress of negative social interactions among men, whereas these effects were not found in women interacting with human partners. These findings support continued investigation into the possible efficacy of OT as a treatment for anxiety disorders.
C1 [Chen, Xu; Hackett, Patrick D.; Feng, Chunliang; Rilling, James K.] Emory Univ, Dept Anthropol, 1557 Dickey Dr, Atlanta, GA 30322 USA.
   [Chen, Xu; Stair, Sabrina; Haroon, Ebrahim; Ditzen, Beate; Rilling, James K.] Emory Univ, Dept Psychiat & Behav Sci, 201 Dowman Dr, Atlanta, GA 30322 USA.
   [Ditzen, Beate; Rilling, James K.] Emory Univ, Ctr Behav Neurosci, Atlanta, GA 30322 USA.
   [Rilling, James K.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
   [Rilling, James K.] Emory Univ, Ctr Translat Social Neurosci, Atlanta, GA 30322 USA.
   [DeMarco, Ashley C.] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA.
   [Ditzen, Beate] Univ Zurich, Dept Psychol, Zurich, Switzerland.
   [Pagnoni, Giuseppe] Univ Modena & Reggio Emilia, Dept Neural Biomed & Metab Sci, Modena, Italy.
RP Rilling, JK (reprint author), Emory Univ, Dept Anthropol, 1557 Dickey Dr, Atlanta, GA 30322 USA.; Rilling, JK (reprint author), Emory Univ, Dept Psychiat & Behav Sci, 201 Dowman Dr, Atlanta, GA 30322 USA.; Rilling, JK (reprint author), Emory Univ, Ctr Behav Neurosci, Atlanta, GA 30322 USA.; Rilling, JK (reprint author), Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.; Rilling, JK (reprint author), Emory Univ, Ctr Translat Social Neurosci, Atlanta, GA 30322 USA.
EM jrillin@emory.edu
FU NCATS NIH HHS [UL1 TR000454]; NIMH NIH HHS [R01 MH084068]
CR Altemus M, 1999, BIOL PSYCHIAT, V45, P931, DOI 10.1016/S0006-3223(98)00263-7
   Anderson IM, 2008, NEUROPHARMACOLOGY, V55, P1029, DOI 10.1016/j.neuropharm.2008.06.029
   AXELROD R., 1984, EVOLUTION COOPERATIO
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Bertsch K, 2013, AM J PSYCHIAT, V170, P1169, DOI 10.1176/appi.ajp.2013.13020263
   Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Cosmides L, 2000, NEW COGNITIVE NEUROS, P1259
   Costa P. T., 1992, REVISED NEO PERSONAL
   De Dreu CKW, 2012, PSYCHONEUROENDOCRINO, V37, P871, DOI 10.1016/j.psyneuen.2011.10.003
   Declerck CH, 2014, SOC COGN AFFECT NEUR, V9, P802, DOI 10.1093/scan/nst040
   DEGOEIJ DCE, 1992, ENDOCRINOLOGY, V131, P847, DOI 10.1210/en.131.2.847
   Del-Ben CM, 2012, J PSYCHOPHARMACOL, V26, P443, DOI 10.1177/0269881110389092
   Dell'osso B, 2013, EUR PSYCHIAT, V28, P7, DOI 10.1016/j.eurpsy.2011.11.003
   Derick S, 2002, ENDOCRINOLOGY, V143, P4655, DOI 10.1210/en.2002-220363
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134
   Engelmann M, 2000, EXP PHYSIOL, V85, p125S
   Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504
   Falk A, 2008, GAME ECON BEHAV, V62, P287, DOI 10.1016/j.geb.2007.06.001
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060
   Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005
   Hall SS, 2012, PSYCHONEUROENDOCRINO, V37, P509, DOI 10.1016/j.psyneuen.2011.07.020
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   King-Casas B, 2008, SCIENCE, V321, P806, DOI 10.1126/science.1156902
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Koen Nastassja, 2011, Dialogues Clin Neurosci, V13, P423
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kubzansky LD, 2012, BIOL PSYCHOL, V90, P1, DOI 10.1016/j.biopsycho.2012.02.010
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   LAKEY B, 1994, J SOC CLIN PSYCHOL, V13, P42, DOI 10.1521/jscp.1994.13.1.42
   Lee Royce J, 2013, Front Syst Neurosci, V7, P100, DOI 10.3389/fnsys.2013.00100
   Liebsch G, 1996, NEUROSCI LETT, V217, P101, DOI 10.1016/0304-3940(96)13069-X
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Macdonald K., 2014, BRAIN RES
   MacDonald K, 2013, PSYCHONEUROENDOCRINO, V38, P2831, DOI 10.1016/j.psyneuen.2013.05.014
   Mak P, 2012, J PSYCHOPHARMACOL, V26, P532, DOI 10.1177/0269881111416687
   McClure EB, 2007, J ABNORM CHILD PSYCH, V35, P567, DOI 10.1007/s10802-007-9113-8
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P282, DOI 10.1001/archpsyc.62.3.282
   PITMAN RK, 1993, PSYCHIAT RES, V48, P107, DOI 10.1016/0165-1781(93)90035-F
   Rilling JK, 2008, NEUROPSYCHOLOGIA, V46, P1256, DOI 10.1016/j.neuropsychologia.2007.11.033
   Rilling JK, 2007, BIOL PSYCHIAT, V61, P1260, DOI 10.1016/j.biopsych.2006.07.021
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Rilling JK, 2012, PSYCHONEUROENDOCRINO, V37, P447, DOI 10.1016/j.psyneuen.2011.07.013
   Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976
   Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Surget A, 2008, EUR J PHARMACOL, V583, P340, DOI 10.1016/j.ejphar.2007.11.065
   Thompson RR, 2006, P NATL ACAD SCI USA, V103, P7889, DOI 10.1073/pnas.0600406103
   TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755
   Uzefovsky F, 2012, PSYCHONEUROENDOCRINO, V37, P576, DOI 10.1016/j.psyneuen.2011.07.018
   Veenema AH, 2013, PSYCHONEUROENDOCRINO, V38, P2554, DOI 10.1016/j.psyneuen.2013.06.002
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Weisman O, 2013, PSYCHONEUROENDOCRINO, V38, P694, DOI 10.1016/j.psyneuen.2012.08.011
   Wigton R, 2015, J PSYCHIATR NEUROSCI, V40, pE1, DOI 10.1503/jpn.130289
   Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058
   Zelena D, 2008, ENDOCRINOLOGY, V149, P2576, DOI 10.1210/en.2007-1537
   Zink CF, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.2
NR 70
TC 0
Z9 0
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7557
EI 1931-7565
J9 BRAIN IMAGING BEHAV
JI Brain Imaging Behav.
PD JUN
PY 2016
VL 10
IS 2
BP 581
EP 593
DI 10.1007/s11682-015-9411-7
PG 13
WC Neuroimaging
SC Neurosciences & Neurology
GA DU7JK
UT WOS:000382390000024
PM 26040978
ER

PT J
AU Condes-Lara, M
   Zayas-Gonzalez, H
   Manzano-Garcia, A
   Cordova-Quiroz, E
   Granados-Mortera, J
   Garcia-Cuevas, M
   Morales-Gomez, J
   Gonzalez-Hernandez, A
AF Condes-Lara, Miguel
   Zayas-Gonzalez, Hector
   Manzano-Garcia, Alfredo
   Cordova-Quiroz, Estefania
   Granados-Mortera, Juan
   Garcia-Cuevas, Marco
   Morales-Gomez, Julio
   Gonzalez-Hernandez, Abimael
TI Successful Pain Management with Epidural Oxytocin
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Letter
ID ELECTRICAL-STIMULATION; INTRATHECAL OXYTOCIN; RATS
C1 [Condes-Lara, Miguel; Zayas-Gonzalez, Hector; Manzano-Garcia, Alfredo; Gonzalez-Hernandez, Abimael] Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Desarrollo & Neurofisiol, Blvd Juriquilla 3001, Queretaro 76230, Mexico.
   [Zayas-Gonzalez, Hector; Cordova-Quiroz, Estefania; Granados-Mortera, Juan; Garcia-Cuevas, Marco; Morales-Gomez, Julio] Hosp Reg Petr Mexicanos, Guanajuato, Mexico.
RP Gonzalez-Hernandez, A (reprint author), Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Desarrollo & Neurofisiol, Blvd Juriquilla 3001, Queretaro 76230, Mexico.
EM abimaelgh@gmail.com
RI Gonzalez-Hernandez, Abimael/B-4746-2013
OI Gonzalez-Hernandez, Abimael/0000-0002-6472-1419
CR Eisenach JC, 2015, ANESTHESIOLOGY, V122, P407, DOI 10.1097/ALN.0000000000000539
   Gonzalez-Hernandez A, 2014, TRENDS PHARMACOL SCI, V35, P5, DOI 10.1016/j.tips.2014.09.004
   Goodin BR, 2015, CLIN J PAIN, V31, P757, DOI 10.1097/AJP.0000000000000166
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   Martinez-Lorenzan G, 2008, PAIN, V140, P265, DOI 10.1016/j.pain.2008.08.015
   Miranda-Cardenas Y, 2006, PAIN, V122, P182, DOI 10.1016/j.pain.2006.01.029
   Rash JA, 2014, CLIN J PAIN, V30, P453, DOI 10.1097/AJP.0b013e31829f57df
   Schorscher-Petcu A, 2009, NEUROSCI LETT, V461, P217, DOI 10.1016/j.neulet.2009.06.016
   Wrobel L, 2011, NEUROSCI LETT, V495, P49, DOI 10.1016/j.neulet.2011.03.033
   Yaksh TL, 2014, ANESTHESIOLOGY, V120, P951, DOI 10.1097/ALN.0000000000000148
NR 10
TC 2
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
EI 1755-5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD JUN
PY 2016
VL 22
IS 6
BP 532
EP 534
DI 10.1111/cns.12551
PG 3
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DS8DH
UT WOS:000381012800012
PM 27080720
ER

PT J
AU Lestanova, Z
   Bacova, Z
   Kiss, A
   Havranek, T
   Strbak, V
   Bakos, J
AF Lestanova, Z.
   Bacova, Z.
   Kiss, A.
   Havranek, T.
   Strbak, V.
   Bakos, J.
TI Oxytocin Increases Neurite Length and Expression of Cytoskeletal
   Proteins Associated with Neuronal Growth
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Oxytocin; Neurite elongation; Actin-binding proteins;
   Microtubule-associated proteins
ID MICROTUBULE-ASSOCIATED PROTEINS; INTERMEDIATE-FILAMENT PROTEIN;
   CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; GENE-EXPRESSION; NEURAL
   DIFFERENTIATION; NEUROBLASTOMA-CELLS; ACTIN CYTOSKELETON;
   CEREBRAL-CORTEX; NESTIN
AB Neuropeptide oxytocin acts as a growth and differentiation factor; however, its effects on neurite growth are poorly understood. The aims of the present study were (1) to evaluate time effects of oxytocin on expression of nestin and MAP2; (2) to measure the effect of oxytocin on gene expression of beta-actin, vimentin, cofilin, and drebrin; and (3) to measure changes in neurite length and number in response to oxytocin/oxytocin receptor antagonist L-371,257. Exposure of SH-SY5Y cells to 1 mu M oxytocin resulted in a significant increase in gene expression and protein levels of nestin after 12, 24, and 48 h. Oxytocin treatment induced no changes in gene expression of MAP2; however, a decrease of protein beta-actin, vimentin, and drebrin increased in response to oxytocin. Oxytocin induced significant elongation of neurites after 12, 24, and 48 h. No change in neurite length was observed in the presence of the combination of retinoic acid and oxytocin receptor antagonist L-371,257. Oxytocin treatment for 12 h increased the number of neurites. Overall, the present data suggest that oxytocin contributes to the regulation of expression of cytoskeletal proteins associated with growth of neuronal cones and induces neurite elongation mediated by oxytocin receptors at least in certain types of neuronal cells.
C1 [Lestanova, Z.; Bacova, Z.; Kiss, A.; Havranek, T.; Strbak, V.; Bakos, J.] Slovak Acad Sci, Inst Expt Endocrinol, Vlarska 3, Bratislava, Slovakia.
   [Bakos, J.] Comenius Univ, Fac Med, Inst Physiol, Bratislava, Slovakia.
   [Bacova, Z.; Strbak, V.] Slovak Med Univ, Fac Med, Dept Normal & Pathol Physiol, Bratislava, Slovakia.
RP Bakos, J (reprint author), Slovak Acad Sci, Inst Expt Endocrinol, Vlarska 3, Bratislava, Slovakia.; Bakos, J (reprint author), Comenius Univ, Fac Med, Inst Physiol, Bratislava, Slovakia.
EM j.bakos@savba.sk
FU Grant Agency of Ministry of Education and Slovak Academy of Sciences
   (VEGA) [2/0119/15]; Slovak Research and Development Agency
   [APVV-0253-10]
FX The work was supported by project 2/0119/15 of the Grant Agency of
   Ministry of Education and Slovak Academy of Sciences (VEGA), by the
   Slovak Research and Development Agency project APVV-0253-10.
CR Ahn HH, 2014, INT J MOL SCI, V15, P2075, DOI 10.3390/ijms15022075
   Bakos J, 2014, NEUROPEPTIDES, V48, P281, DOI 10.1016/j.npep.2014.06.004
   Bakos J, 2013, J MOL NEUROSCI, V50, P462, DOI 10.1007/s12031-013-9960-4
   Bakos J, 2012, CELL MOL NEUROBIOL, V32, P891, DOI 10.1007/s10571-012-9799-1
   Bhoopathi P, 2011, CANCER RES, V71, P4908, DOI 10.1158/0008-5472.CAN-10-3395
   Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.3.CO;2-Z
   CHAMAK B, 1987, J NEUROSCI, V7, P3163
   Chen Q, 2000, NEUROSCIENCE, V101, P19, DOI 10.1016/S0306-4522(00)00323-7
   Chini B, 2007, BIOCHEM SOC T, V35, P737
   Choi SA, 2011, NEURO-ONCOLOGY, V13, P61, DOI 10.1093/neuonc/noq147
   Chou YH, 2003, MOL BIOL CELL, V14, P1468, DOI 10.1091/mbc.E02-08-0545
   Chou YH, 2009, FASEB J, V23, P3734, DOI 10.1096/fj.09-137455
   Colaianni G, 2012, J BIOL CHEM, V287, P29159, DOI 10.1074/jbc.M112.365049
   Cotta-Grand N, 2009, PEPTIDES, V30, P2014, DOI 10.1016/j.peptides.2009.06.015
   Danalache BA, 2014, J ENDOCRINOL, V220, P277, DOI 10.1530/JOE-13-0305
   Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI DOI 10.1016/J.NTT.2004.02.006
   de Wit NCJ, 2010, REPROD SCI, V17, P40, DOI 10.1177/1933719109345287
   Dehmelt L, 2004, J NEUROBIOL, V58, P18, DOI 10.1002/neu.10284
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008-0127
   Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996
   Galkin VE, 2011, P NATL ACAD SCI USA, V108, P20568, DOI 10.1073/pnas.1110109108
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goldberg JL, 2003, GENE DEV, V17, P941, DOI 10.1101/gad.1062303
   Guo H, 2014, J NEUROSCI RES, V92, P1374, DOI 10.1002/jnr.23403
   Hammerle B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076761
   Hao HN, 2003, J HEMATOTH STEM CELL, V12, P389, DOI 10.1089/152581603322286024
   Havranek T, 2015, J NEUROSCI RES, V93, P893, DOI 10.1002/jnr.23559
   Hayashi K, 1996, J NEUROSCI, V16, P7161
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Hendrickson ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018535
   Hobson SA, 2013, J NEUROCHEM, V127, P199, DOI 10.1111/jnc.12379
   Jafarzadeh N, 2014, NEUROSCI LETT, V564, P105, DOI 10.1016/j.neulet.2014.02.012
   Jankowski Marek, 2012, Recent Pat Cardiovasc Drug Discov, V7, P81
   Jin ZG, 2009, J BIOL CHEM, V284, P8160, DOI 10.1074/jbc.M805632200
   Kiss Alexander, 2005, Endocr Regul, V39, P97
   Letourneau PC, 2009, RESULTS PROBL CELL D, V48, P65, DOI 10.1007/400_2009_15
   Leuner B, 2012, HIPPOCAMPUS, V22, P861, DOI 10.1002/hipo.20947
   Lin WC, 1995, J NEUROSCI, V15, P8331
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lothian C, 1999, EXP CELL RES, V248, P509, DOI 10.1006/excr.1999.4417
   Lucotte B, 2014, MOL NEUROBIOL
   Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501
   MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6
   McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771
   McLaughlin D, 2006, J NEUROSCI RES, V83, P1190, DOI 10.1002/jnr.20828
   Melino M, 2012, WORLD J GASTROENTERO, V18, P1732, DOI 10.3748/wjg.v18.i15.1732
   Mikati MA, 2013, J BIOL CHEM, V288, P19926, DOI 10.1074/jbc.M113.472647
   Nitti M, 2010, CELL SIGNAL, V22, P828, DOI 10.1016/j.cellsig.2010.01.007
   Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U
   Paulikova H, 2008, NEOPLASMA, V55, P338
   Przyborski S A, 1995, Brain Res Dev Brain Res, V89, P187
   REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558
   Sasaki Y, 2010, J NEUROSCI, V30, P9349, DOI 10.1523/JNEUROSCI.0499-10.2010
   Schulpen SHW, 2015, TOXICOL IN VITRO, V29, P449, DOI 10.1016/j.tiv.2014.12.001
   Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881
   Stiess M, 2010, SCIENCE, V327, P704, DOI 10.1126/science.1182179
   Takahashi H, 2003, J NEUROSCI, V23, P6586
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Uvnas-Moberg K, 1998, PEDIATR RES, V43, P344
   Vasavda N, 2006, J ALLERGY CLIN IMMUN, V118, P1090, DOI 10.1016/j.jaci.2006.07.039
   Vaskova M, 2011, LEUKEMIA RES, V35, P1111, DOI 10.1016/j.leukres.2011.03.028
   Wang YF, 2007, J NEUROSCI, V27, P13822, DOI 10.1523/JNEUROSCI.4119-07.2007
   Wen AY, 2013, BIOCHEM BIOPH RES CO, V432, P638, DOI 10.1016/j.bbrc.2013.02.031
   Yan Y, 2001, NEUROSCI LETT, V302, P89, DOI 10.1016/S0304-3940(01)01664-0
NR 64
TC 0
Z9 0
U1 7
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD JUN
PY 2016
VL 59
IS 2
BP 184
EP 192
DI 10.1007/s12031-015-0664-9
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DS3ZG
UT WOS:000380720600002
PM 26474566
ER

PT J
AU Yong, CY
   Chen, S
   Chen, H
   Chu, X
   Zhang, C
   Tan, C
   Ye, L
   Li, JS
AF Yong, Chun-yan
   Chen, Shu
   Chen, Heng
   Chu, Xiao
   Zhang, Chao
   Tan, Cheng
   Ye, Lan
   Li, Jiang-shan
TI Central neuromechanisms underlying control of intragastric pressure
   through acupuncture at Zusanli (ST36) in rats: the upper cervical cord
   is the key link between the ascending and descending pathways
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE nerve regeneration; traditional Chinese medicine; acupuncture; Zusanli
   (ST36); upper cervical cord; dorsolateral funiculus; dorsal cord;
   hypothalamic paraventricular nucleus; intragastric pressure;
   immunohistochemical double staining; nervous pathway; neural
   regeneration
ID C-1-C-2 SPINAL NEURONS; PARAVENTRICULAR NUCLEUS; AFFERENT PATHWAYS;
   GASTRIC-MOTILITY; ELECTROACUPUNCTURE; STIMULATION; RESPONSES; OXYTOCIN
AB Sensory inputs stimulated by Zusanli (ST36) acupuncture in the abdomen are known to converge in the upper cervical cord. However, it is unclear whether these inputs are subsequently conveyed to the hypothalamic paraventricular nucleus and what kind of afferent fibers are involved. We focused on the upper cervical cord, where afferent inputs converge, and detected c-fos expression in oxytocinergic neurons. We found that Zusanli acupuncture therapy effectively elevated intragastric pressure, but inhibited expression of c-fos in oxytocinergic neurons of the paraventricular nucleus in upper cervical cord injured rats. These Zusanli acupuncture effects remained even after complete dorsal cord transection. However, after complete transection of the spinal cord or dorsolateral funiculus, the effects were significantly attenuated and even disappeared. These findings suggest that the paraventricular nucleus is responsible for pooling and integrating signals from the Zusanli acupuncture and sensory information from the intragastric pressure variation, thereby contributing to the regulation of intragastric pressure. The upper cervical cord serves as the key link between ascending and descending pathways, which conveys afferent inputs to the paraventricular nucleus through the dorsolateral funiculus.
C1 [Yong, Chun-yan] Cent S Univ, Xiangya Hosp, Dept Integrat Med, Changsha, Hunan, Peoples R China.
   [Chen, Shu; Chen, Heng; Chu, Xiao; Zhang, Chao; Tan, Cheng; Ye, Lan; Li, Jiang-shan] Hunan Univ Chinese Med, Sch Acupuncture & Massage, Changsha, Hunan, Peoples R China.
RP Li, JS (reprint author), Hunan Univ Chinese Med, Sch Acupuncture & Massage, Changsha, Hunan, Peoples R China.
EM ljs8268@126.com
FU National Natural Science Foundation of China [81273677]; Postgraduate
   Innovation Topics of Hunan University of Chinese Medicine in China
   [2014CX01]
FX This study was supported by the National Natural Science Foundation of
   China, No. 81273677; and a grant from the Postgraduate Innovation Topics
   of Hunan University of Chinese Medicine in China in 2014, No. 2014CX01.
CR Benarroch EE, 2005, CLIN AUTON RES, V15, P254, DOI 10.1007/s10286-005-0290-7
   Chen S, 2014, ZHONGGUO ZUZHI GONGC, V18, P675
   Chen Y, 2013, AM J CHINESE MED, V41, P1233, DOI 10.1142/S0192415X13500833
   Condes-Lara M, 2007, BRAIN RES, V1160, P20, DOI 10.1016/j.brainres.2007.05.031
   FLANAGAN LM, 1992, BRAIN RES, V578, P256, DOI 10.1016/0006-8993(92)90255-8
   Gerald G, 2001, PHYSIOL REV, V81, P629
   ZR Li, 2007, EXPT ACUPUNCTURE SCI
   Liu JH, 2004, NEUROSCI LETT, V356, P99, DOI 10.1016/j.neulet.2003.11.044
   Llewellyn-Smith IJ, 2012, NEUROGASTROENT MOTIL, V24, pE136, DOI 10.1111/j.1365-2982.2011.01851.x
   Miyano Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064777
   National Neurosurgery Acupuncture Anesthesia Cooperation, 1986, ACUPUNCT ANESTHESIA, V663, P670
   Qin C, 2004, J NEUROPHYSIOL, V91, P2227, DOI 10.1152/jn.00971.2003
   Qin C, 2003, AUTON NEUROSCI-BASIC, V104, P128, DOI 10.1016/S1566-0702(03)00002-X
   Silva ML, 2010, EUR J PAIN, V14, P249, DOI 10.1016/j.ejpain.2009.05.007
   Singru PS, 2012, ENDOCRINOLOGY, V153, P3804, DOI 10.1210/en.2012-1235
   Wang HJ, 2010, YIXUE XINXI, V23, P153
   Wessel MU, 1997, PAIN, V73, P309
   Li JS, 2009, ZHONGGUO XIANDAI YIS, V45, P62
   Yang Q, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-137
   Yang Zong-Bao, 2013, Zhongguo Zhen Jiu, V33, P1017
   Yin WH, 2008, ZHONGGUO LINCHUANG J, V26, P647
   Zhang J, 2008, NEUROSCI RES, V62, P262, DOI 10.1016/j.neures.2008.09.004
   Zhou HC, 2013, ZHONGHUA XINGWEI YIX, V22, P788
NR 23
TC 0
Z9 0
U1 4
U2 4
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JUN
PY 2016
VL 11
IS 6
BP 971
EP 976
DI 10.4103/1673-5374.184497
PG 6
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA DS9QU
UT WOS:000381119200031
PM 27482227
ER

PT J
AU MacFadyen, K
   Smith, J
   de Kloet, A
   Krause, E
   Peris, J
AF MacFadyen, K.
   Smith, J.
   de Kloet, A.
   Krause, E.
   Peris, J.
TI OXYTOCIN REGULATION OF ETHANOL INTAKE AND ACCUMBAL GLUTAMATE LEVELS IN
   MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA)
CY JUN 25-29, 2016
CL New Orleans, LA
SP Res Soc Alcoholism
C1 [MacFadyen, K.; Smith, J.; de Kloet, A.; Krause, E.; Peris, J.] Univ Florida, Dept Pharmacodynam, Gainesville, FL 32610 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2016
VL 40
SU 1
SI SI
MA 491
BP 138A
EP 138A
PG 1
WC Substance Abuse
SC Substance Abuse
GA DR3PH
UT WOS:000379814601489
ER

PT J
AU Tunstall, BJ
   Vendruscolo, JCM
   Lee, MR
   Koob, GF
   Vendruscolo, LF
AF Tunstall, B. J.
   Vendruscolo, J. C. M.
   Lee, M. R.
   Koob, G. F.
   Vendruscolo, L. F.
TI OXYTOCIN BLOCKS COMPULSIVE-LIKE ALCOHOL DRINKING IN RATS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA)
CY JUN 25-29, 2016
CL New Orleans, LA
SP Res Soc Alcoholism
C1 [Tunstall, B. J.; Vendruscolo, J. C. M.; Lee, M. R.; Koob, G. F.; Vendruscolo, L. F.] NIDA, NIH, Baltimore, MD 21224 USA.
RI koob, george/P-8791-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2016
VL 40
SU 1
SI SI
MA 528
BP 147A
EP 147A
PG 1
WC Substance Abuse
SC Substance Abuse
GA DR3PH
UT WOS:000379814601526
ER

PT J
AU Mohiyeddini, C
   Opacka-Juffry, J
AF Mohiyeddini, C.
   Opacka-Juffry, J.
TI PLASMA OXYTOCIN EXPLAINS THE LINK BETWEEN EARLY-CHILDHOOD TRAUMA AND
   HEAVY DRINKING IN ADULT MEN
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA)
CY JUN 25-29, 2016
CL New Orleans, LA
SP Res Soc Alcoholism
C1 [Mohiyeddini, C.; Opacka-Juffry, J.] Northeastern Univ, Dept Appl Psychol, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2016
VL 40
SU 1
SI SI
MA 602
BP 166A
EP 166A
PG 1
WC Substance Abuse
SC Substance Abuse
GA DR3PH
UT WOS:000379814601600
ER

PT J
AU Young, KA
   O'Bryan, CM
   Pesarchick, BF
   Francomacaro, LM
   Bohidar, AE
   Stevenson, JR
AF Young, K. A.
   O'Bryan, C. M.
   Pesarchick, B. F.
   Francomacaro, L. M.
   Bohidar, A. E.
   Stevenson, J. R.
TI ALCOHOL DRINKING DECREASES OXYTOCIN EXPRESSION IN THE PARAVENTRICULAR
   NUCELUS OF THE HYPOTHALAMUS IN PRAIRIE VOLES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA)
CY JUN 25-29, 2016
CL New Orleans, LA
SP Res Soc Alcoholism
C1 [Young, K. A.; O'Bryan, C. M.; Pesarchick, B. F.; Francomacaro, L. M.; Bohidar, A. E.; Stevenson, J. R.] Bucknell Univ, Dept Psychol, Program Neurosci, Lewisburg, PA 17837 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2016
VL 40
SU 1
SI SI
MA 750
BP 203A
EP 203A
PG 1
WC Substance Abuse
SC Substance Abuse
GA DR3PH
UT WOS:000379814601748
ER

PT J
AU Love, TM
   Cranford, JA
   Burmeister, M
   Wojnar, M
   Zucker, RA
   Brower, K
AF Love, T. M.
   Cranford, J. A.
   Burmeister, M.
   Wojnar, M.
   Zucker, R. A.
   Brower, K.
TI IMPACT OF SOCIAL SUPPORT ON PSYCHIATRIC SYMPTOM SEVERITY IS MODERATED BY
   OXYTOCIN GENOTYPE IN ALCOHOL DEPENDENT PATIENTS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA)
CY JUN 25-29, 2016
CL New Orleans, LA
SP Res Soc Alcoholism
C1 [Love, T. M.; Cranford, J. A.; Burmeister, M.; Wojnar, M.; Zucker, R. A.; Brower, K.] Univ Michigan, Dept Psychiat, Addict Res Ctr, Ann Arbor, MI 48108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2016
VL 40
SU 1
SI SI
MA 136
BP 282A
EP 282A
PG 1
WC Substance Abuse
SC Substance Abuse
GA DR3PH
UT WOS:000379814602136
ER

PT J
AU Vannuccini, S
   Bocchi, C
   Severi, FM
   Challis, JR
   Petraglia, F
AF Vannuccini, Silvia
   Bocchi, Caterina
   Severi, Filiberto M.
   Challis, John R.
   Petraglia, Felice
TI Endocrinology of human parturition
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Parturition; Placenta; Estrogens; Progesterone; CRH; Urocortin;
   Prostaglandins; Relaxin
ID CORTICOTROPIN-RELEASING HORMONE; HUMAN PLACENTAL TROPHOBLASTS; HUMAN
   PREGNANT MYOMETRIUM; FACTOR-BINDING PROTEIN; FETAL MEMBRANES;
   PROGESTERONE WITHDRAWAL; PROSTAGLANDIN RELEASE; INTRAUTERINE TISSUES;
   CONTRACTILE ACTIVITY; PRETERM LABOR
AB The mechanisms involved in human pregnancy maintenance and parturition are highly complex and involve mother, fetus and placenta. The "final common pathway" to delivery is composed by inflammatory and endocrine interactive paths that tip the balance in favor of coordinated uterine contractility and cervical dilation. These mechanisms involve a shift from progesterone to estrogen dominance, CRH action, increased sensitivity to oxytocin, gap junction formation, and increased prostaglandins activity. Complementary changes in the cervix involve a decrease in progesterone dominance and the actions of prostaglandins and relaxin, via connective tissue alterations, leading to cervical softening and dilation. Neuronal, hormonal, inflammatory and immune pathways participate in initiation of labor and the utero-placental unit plays a major role in the synthesis and release of parturition mediators. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Vannuccini, Silvia; Bocchi, Caterina; Severi, Filiberto M.; Petraglia, Felice] Univ Siena S Maria Scotte, Dept Mol & Dev Med, Obstet & Gynecol, Viale Bracci, I-53100 Siena, Italy.
   [Challis, John R.] Univ Western Australia, M460A,35,Stirling Highway, Crawley, WA 6009, Australia.
RP Petraglia, F (reprint author), Univ Siena S Maria Scotte, Dept Mol & Dev Med, Obstet & Gynecol, Viale Bracci, I-53100 Siena, Italy.
EM felice.petraglia@unisi.it
RI BOCCHI, Caterina/L-7674-2016; Vannuccini, Silvia/L-9140-2016; PETRAGLIA,
   Felice/K-6535-2016; SEVERI, Filiberto Maria/K-6586-2016
OI BOCCHI, Caterina/0000-0002-4546-8526; Vannuccini,
   Silvia/0000-0001-5790-587X; PETRAGLIA, Felice/0000-0002-8851-625X;
   SEVERI, Filiberto Maria/0000-0002-0892-4561
CR Aguilar HN, 2010, HUM REPROD UPDATE, V16, P725, DOI 10.1093/humupd/dmq016
   Andersson S, 2008, J CLIN ENDOCR METAB, V93, P2366, DOI 10.1210/jc.2007-2813
   Bernal AL, 2003, BJOG-INT J OBSTET GY, V110, P39, DOI 10.1016/S1470-0328(03)00023-5
   Blanks AM, 2003, BJOG-INT J OBSTET GY, V110, P46, DOI 10.1016/S1470-0328(03)00024-7
   Blanks AM, 2003, J CLIN ENDOCR METAB, V88, P3392, DOI 10.1210/jc.2002-021212
   Byrns MC, 2014, J STEROID BIOCHEM, V139, P173, DOI 10.1016/j.jsbmb.2013.01.015
   CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054
   Carbillon L, 2000, FETAL DIAGN THER, V15, P308, DOI 10.1159/000021027
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   Challis JRG, 2005, J OBSTET GYNAECOL RE, V31, P492, DOI 10.1111/j.1447-0756.2005.00342.x
   Challis JRG, 2002, REPRODUCTION, V124, P1
   Challis JRG, 1997, ANN NY ACAD SCI, V828, P254, DOI 10.1111/j.1749-6632.1997.tb48546.x
   Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100
   Florio P, 2005, J CLIN ENDOCR METAB, V90, P5361, DOI 10.1210/jc.2005-0109
   Florio P, 2004, PEPTIDES, V25, P1751, DOI 10.1016/j.2004.05.026
   Fuentes A, 1996, PROSTAGLANDINS, V52, P261, DOI 10.1016/S0090-6980(96)00088-3
   Gao L, 2008, ENDOCRINOLOGY, V149, P2866, DOI 10.1210/en.2007-1377
   Gao L, 2012, ENDOCRINOLOGY, V153, P4918, DOI 10.1210/en.2012-1453
   Gibb W, 2002, J OBSTET GYNAECOL, V24, P873
   Goldsmith LT, 2009, ANN NY ACAD SCI, V1160, P130, DOI 10.1111/j.1749-6632.2008.03800.x
   Golightly E, 2011, MOL CELL ENDOCRINOL, V335, P52, DOI 10.1016/j.mce.2010.08.005
   Grammatopoulos DK, 1999, LANCET, V354, P1546, DOI 10.1016/S0140-6736(99)03418-2
   Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076
   Guo CM, 2012, ENDOCRINOLOGY, V153, P4938, DOI 10.1210/en.2012-1441
   Iliodromiti Z, 2012, HORM-INT J ENDOCRINO, V11, P397
   Kamel RM, 2010, ARCH GYNECOL OBSTET, V281, P975, DOI 10.1007/s00404-010-1365-9
   Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948
   Li W, 2005, J CLIN ENDOCR METAB, V90, P6569, DOI 10.1210/jc.2005-1445
   Li XQ, 2014, PLACENTA, V35, P291, DOI 10.1016/j.placenta.2014.03.005
   Lockwood CJ, 2004, OBSTET GYN CLIN N AM, V31, P935, DOI 10.1016/j.ogc.2004.08.012
   Rivera J, 1995, ADV EXP MED BIOL, V395, P435
   McLean M, 2001, REPRODUCTION, V121, P493
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Mesiano S, 2007, SEMIN CELL DEV BIOL, V18, P321, DOI 10.1016/j.semcdb.2007.05.003
   Mesiano S, 2011, REPROD SCI, V18, P6, DOI 10.1177/1933719110382922
   MITCHELL BF, 1993, AM J OBSTET GYNECOL, V168, P1377
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Norwitz ER, 1999, NEW ENGL J MED, V341, P660, DOI 10.1056/NEJM199908263410906
   Palejwala S, 2001, ENDOCRINOLOGY, V142, P3405, DOI 10.1210/en.142.8.3405
   PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0
   Petraglia F, 1999, J CLIN ENDOCR METAB, V84, P1420, DOI 10.1210/jc.84.4.1420
   Petraglia F, 1996, ENDOCR REV, V17, P156, DOI 10.1210/er.17.2.156
   Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P3807, DOI 10.1210/jc.81.10.3807
   PETRAGLIA F, 1995, J CLIN ENDOCR METAB, V80, P3073, DOI 10.1210/jc.80.10.3073
   PETRAGLIA F, 1993, J CLIN ENDOCR METAB, V77, P919, DOI 10.1210/jc.77.4.919
   PETRAGLIA F, 1990, OBSTET GYNECOL, V75, P784
   Petraglia F, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P2847
   Petraglia F, 2010, ENDOCR REV, V31, P783, DOI 10.1210/er.2009-0019
   Phillips RJ, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-241
   Ravanos K, 2015, GYNECOL ENDOCRINOL, V31, P679, DOI 10.3109/09513590.2015.1076783
   Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398
   ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P657
   Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013
   Simpkin JC, 1999, BRIT J OBSTET GYNAEC, V106, P439, DOI 10.1111/j.1471-0528.1999.tb08297.x
   Sirianni R, 2005, J CLIN ENDOCR METAB, V90, P279, DOI 10.1210/jc.2004-0865
   Smith R, 1998, J CLIN ENDOCR METAB, V83, P2916, DOI 10.1210/jc.83.8.2916
   Smith R, 2007, NEW ENGL J MED, V356, P271, DOI 10.1056/NEJMra061360
   Smith R, 2009, J CLIN ENDOCR METAB, V94, P2066, DOI 10.1210/jc.2008-2257
   Snegovskikh V, 2006, ENDOCRIN METAB CLIN, V35, P173, DOI 10.1016/j.ecl.2005.09.012
   Terzidou Vasso, 2007, Best Pract Res Clin Obstet Gynaecol, V21, P729, DOI 10.1016/j.bpobgyn.2007.05.001
   Thijssen JHH, 2005, J STEROID BIOCHEM, V97, P397, DOI 10.1016/j.jsbmb.2005.08.011
   Torricelli M, 2011, AM J OBSTET GYNECOL, V204
   VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0
   Vitoratos N, 2006, ANN NY ACAD SCI, V1092, P310, DOI 10.1196/annals.1365.029
   Voltolini C, 2015, ENDOCRINOLOGY, V156, P670, DOI 10.1210/en.2014-1432
   Voltolini C, 2014, HAND CLINIC, V124, P17, DOI 10.1016/B978-0-444-59602-4.00002-2
   Wang W, 2012, ENDOCRINOLOGY, V15
   Weiss G, 2000, J CLIN ENDOCR METAB, V85, P4421, DOI 10.1210/jc.85.12.4421
   Weiss G, 2001, FRONT HORM RES, V27, P105
   Yang RF, 2006, J MOL ENDOCRINOL, V37, P533, DOI 10.1677/jme.1.02119
   You XJ, 2006, BIOL REPROD, V74, P1067, DOI 10.1095/biolreprod.105.049361
   You XJ, 2014, J CLIN ENDOCR METAB, V99, pE199, DOI 10.1210/jc.2013-3366
   Zakar T, 2007, AM J OBSTET GYNECOL, V196, P289, DOI 10.1016/j.ajog.2006.09.005
NR 73
TC 0
Z9 0
U1 8
U2 8
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4266
EI 2213-3941
J9 ANN ENDOCRINOL-PARIS
JI Ann Endocrinol.
PD JUN
PY 2016
VL 77
IS 2
BP 105
EP 113
DI 10.1016/j.ando.2016.04.025
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DQ8HP
UT WOS:000379451100009
PM 27155774
ER

PT J
AU Levy, F
AF Levy, Frederic
TI Neuroendocrine control of maternal behavior in non-human and human
   mammals
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Maternal care; Steroids; Oxytocin; Prolactin; Hypothalamus
ID MULTIPAROUS PARTURIENT EWES; MESSENGER-RNA EXPRESSION; NULLIPAROUS
   FEMALE RATS; ZEALAND WHITE-RABBITS; VAGINOCERVICAL STIMULATION;
   AMNIOTIC-FLUID; LATE PREGNANCY; SEX STEROIDS; PARAVENTRICULAR NUCLEUS;
   CEREBROSPINAL-FLUID
AB Mammalian parental care is essentially provided by the mother and it occupies most of the reproductive period for female. The synchronization of maternal behavior with parturition and lactation ensures that the mother responds to the needs of the young at the appropriate time. This temporal synchrony is accomplished by hormonal changes that underly both the onset of maternal behavior and of parturition and lactation. The aim of this review is to describe and compare the hormonal mechanisms that regulate the onset of maternal behavior across a variety of mammals, including humans, that represent different behavioral strategies. Are involved the steroid hormones, estradiol and progesterone synthesized by the ovaries which primed the future mother to repond maternally. In response to these steroids, oxytocin release induced by vaginocervical stimulation and prolactin release affect the maternal brain. The medial preoptic area integrates the hormonal signals to regulate maternal behavior. The hormonal cocktail that stimulates maternal behavior varies across mammalian species. Because most of the studies in humans are correlative and because human environment is complex, direct causality between hormones and maternal behavior is unclear. However, one can reasonably think that hormones create a positive bias towards the baby increasing the occurrence of maternal behavior. (C) 2016 Published by Elsevier Masson SAS.
C1 [Levy, Frederic] Univ F Rabelais, Physiol Reprod & Comportements, IFCE, INRA,UMR85,CNRS,UMR7247, F-37380 Nouzilly, France.
RP Levy, F (reprint author), Univ F Rabelais, Physiol Reprod & Comportements, IFCE, INRA,UMR85,CNRS,UMR7247, F-37380 Nouzilly, France.
EM levy@tours.inra.fr
CR ANDERSON CO, 1971, HORM BEHAV, V2, P183, DOI 10.1016/0018-506X(71)90015-8
   Apter-Levi Y, 2014, BRAIN RES, V1580, P124, DOI 10.1016/j.brainres.2013.10.052
   Bahr NI, 1998, PHYSIOL BEHAV, V64, P429, DOI 10.1016/S0031-9384(98)00057-2
   Bahr NI, 2001, HORM BEHAV, V40, P533, DOI 10.1006/hbeh.2001.1722
   BARANCZUK R, 1974, J ENDOCRINOL, V63, P125, DOI 10.1677/joe.0.0630125
   Bardi M, 2003, GEN COMP ENDOCR, V133, P323, DOI 10.1016/S0016-6480(03)00193-X
   Barth M, 2001, INT J PRIMATOL, V22, P647
   BAST JD, 1974, J ENDOCRINOL, V63, P527, DOI 10.1677/joe.0.0630527
   BECKWITH BE, 1983, PHARMACOL BIOCHEM BE, V19, P431, DOI 10.1016/0091-3057(83)90115-6
   Benassayag C, 1999, AM J PHYSIOL-ENDOC M, V276, pE1112
   Blanks AM, 2003, BJOG-INT J OBSTET GY, V110, P46, DOI 10.1016/S1470-0328(03)00024-7
   Brazelton T. Berry, 1977, CULTURE INFANCY VARI, P151
   BRIDGES RS, 1975, BIOL REPROD, V13, P617, DOI 10.1095/biolreprod13.5.617
   Bridges RS, 1997, ENDOCRINOLOGY, V138, P756, DOI 10.1210/en.138.2.756
   BRIDGES RS, 1984, ENDOCRINOLOGY, V114, P930
   BRIDGES RS, 1990, ENDOCRINOLOGY, V126, P837
   BRIDGES RS, 1990, P NATL ACAD SCI USA, V87, P8003, DOI 10.1073/pnas.87.20.8003
   Bridges RS, 1996, NEUROENDOCRINOLOGY, V64, P57, DOI 10.1159/000127098
   BRIDGES RS, 1985, SCIENCE, V227, P782, DOI 10.1126/science.3969568
   Bridges RS, 2001, ENDOCRINOLOGY, V142, P730, DOI 10.1210/en.142.2.730
   Bridges RS, 1990, MAMMALIAN PARENTING, P93
   Bridges RS., 1996, ADV STUD BEHAV, V25, P215
   BROAD KD, 1993, J NEUROENDOCRINOL, V5, P711, DOI 10.1111/j.1365-2826.1993.tb00544.x
   Broad KD, 1999, EUR J NEUROSCI, V11, P3725, DOI 10.1046/j.1460-9568.1999.00782.x
   BROAD KD, 1995, MOL BRAIN RES, V29, P310, DOI 10.1016/0169-328X(94)00260-L
   CAUDILL W, 1969, PSYCHIATR, V32, P12
   Chaim W, 1998, ARCH GYNECOL OBSTET, V262, P43, DOI 10.1007/s004040050226
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   CHALLIS JRG, 1971, J REPROD FERTIL, V26, P401
   CHAMLEY WA, 1973, BIOL REPROD, V9, P30
   Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598
   Corter C, 2002, HDB PARENTING BIOL E, P141
   DaCosta APC, 1996, J NEUROENDOCRINOL, V8, P163, DOI 10.1046/j.1365-2826.1996.04411.x
   DAVIS SL, 1971, BIOL REPROD, V4, P145
   DOERR HK, 1981, BEHAV NEURAL BIOL, V32, P35, DOI 10.1016/S0163-1047(81)90242-9
   Dwyer CM, 1999, PHYSIOL BEHAV, V67, P443, DOI 10.1016/S0031-9384(99)00089-X
   FAHRBACH SE, 1985, NEUROENDOCRINOLOGY, V40, P526, DOI 10.1159/000124125
   FAHRBACH SE, 1986, PHYSIOL BEHAV, V37, P135, DOI 10.1016/0031-9384(86)90396-3
   FAHRBACH SE, 1984, HORM BEHAV, V18, P267, DOI 10.1016/0018-506X(84)90016-3
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   FERNANDES PA, 1995, J SOC GYNECOL INVEST, V2, P597, DOI 10.1016/1071-5576(95)00004-X
   Fite JE, 2000, HORM BEHAV, V38, P1, DOI 10.1006/hbeh.2000.1607
   Fleming AS, 1997, HORM BEHAV, V32, P85, DOI 10.1006/hbeh.1997.1407
   Fleming AS, 1997, HORM BEHAV, V31, P145, DOI 10.1006/hbeh.1997.1376
   Fleming A. S., 1987, J REPRODUCTION INFAN, V5, P193, DOI DOI 10.1080/02646838708403495
   Fleming AS, 1996, ADV STUD BEHAV, P295
   FRIEDMAN MI, 1981, J COMP PHYSIOL PSYCH, V95, P26, DOI 10.1037/h0077753
   FUCHS AR, 1991, AM J OBSTET GYNECOL, V165, P1515
   Gonzalez-Mariscal G, 2003, HORM BEHAV, V43, P312, DOI 10.1016/S0018-506X(02)00046-6
   Gonzalez-Mariscal G, 2000, J NEUROENDOCRINOL, V12, P983, DOI 10.1046/j.1365-2826.2000.00544.x
   Gonzalez-Mariscal Gabriela, 2002, P215
   Gonzalez-Mariscal G, 1996, PARENTAL CARE EVOLUT, P333
   GONZALEZMARISCAL G, 1994, PHYSIOL BEHAV, V55, P1081, DOI 10.1016/0031-9384(94)90391-3
   GONZALEZMARISCAL G, 1994, BIOL REPROD, V50, P373, DOI 10.1095/biolreprod50.2.373
   Grattan D R, 2001, Prog Brain Res, V133, P153
   HAUSER H, 1985, HORM BEHAV, V19, P454, DOI 10.1016/0018-506X(85)90041-8
   HENNESSY MB, 1977, HORM BEHAV, V9, P222, DOI 10.1016/0018-506X(77)90058-7
   Henry JP, 1998, PSYCHONEUROENDOCRINO, V23, P863
   HERSHER LEONARD, 1963, BEHAVIOUR, V20, P311, DOI 10.1163/156853963X00059
   HUDSON R, 1986, PHYSIOL BEHAV, V37, P123, DOI 10.1016/0031-9384(86)90394-X
   HUDSON S, 1975, J DAIRY SCI, V58, P30
   HUDSON SJ, 1977, APPL ANIM ETHOL, V3, P271, DOI 10.1016/0304-3762(77)90008-6
   Hydbring E, 1999, J ENDOCRINOL, V160, P75, DOI 10.1677/joe.0.1600075
   INSEL TR, 1990, ENDOCRINOLOGY, V126, P1849
   Insel T, 1990, MAMMALIAN PARENTING, P260, DOI DOI 10.1111/J.1749-6632.1992.TB34350.X
   Jilge B, 2001, CHRONOBIOL INT, V18, P1, DOI 10.1081/CBI-100001275
   KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766
   KENDRICK KM, 1988, BRAIN RES, V442, P171, DOI 10.1016/0006-8993(88)91447-3
   KENDRICK KM, 1993, J NEUROENDOCRINOL, V5, P13, DOI 10.1111/j.1365-2826.1993.tb00359.x
   KENDRICK KM, 1991, BRAIN RES BULL, V26, P803, DOI 10.1016/0361-9230(91)90178-M
   KENDRICK KM, 1986, NEUROENDOCRINOLOGY, V44, P149, DOI 10.1159/000124638
   KENDRICK KM, 1992, BRAIN RES, V569, P199, DOI 10.1016/0006-8993(92)90631-I
   KENDRICK KM, 1991, PHYSIOL BEHAV, V50, P595, DOI 10.1016/0031-9384(91)90551-X
   KENDRICK KM, 1991, PHYSIOL BEHAV, V49, P745, DOI 10.1016/0031-9384(91)90313-D
   KENDRICK KM, 1987, NEUROENDOCRINOLOGY, V46, P56, DOI 10.1159/000124796
   Kendrick KM, 2000, EXP PHYSIOL, V85, P111
   KEVERNE EB, 1991, BRAIN RES, V540, P55, DOI 10.1016/0006-8993(91)90492-E
   KEVERNE EB, 1992, ANN NY ACAD SCI, V652, P83, DOI 10.1111/j.1749-6632.1992.tb34348.x
   KEVERNE EB, 1983, SCIENCE, V219, P81, DOI 10.1126/science.6849123
   Klopfer PH, 1964, P NATL ACAD SCI USA, V52, P588
   KOCH M, 1989, PHYSIOL BEHAV, V45, P771, DOI 10.1016/0031-9384(89)90293-X
   Konner M, 1977, CULTURE INFANCY VARI, P287
   KREHBIEL D, 1987, PHYSIOL BEHAV, V40, P463, DOI 10.1016/0031-9384(87)90031-X
   KUBOTA T, 1989, ACTA ENDOCRINOL-COP, V121, P297
   LANDGRAF R, 1991, NEUROENDOCRINOLOGY, V54, P378, DOI 10.1159/000125917
   Leiderman P. H., 1977, CULTURE INFANCY VARI
   LEVY F, 1990, CHEM SIGNAL, V5, P162
   LEVY F, 1992, BEHAV NEUROSCI, V106, P427
   LEVY F, 1995, PHYSIOL BEHAV, V57, P97, DOI 10.1016/0031-9384(94)00200-O
   LISK RD, 1969, ANIM BEHAV, V17, P730, DOI 10.1016/S0003-3472(69)80020-5
   Lucas BK, 1998, ENDOCRINOLOGY, V139, P4102, DOI 10.1210/en.139.10.4102
   LUNDBLAD EG, 1980, LAB ANIM SCI, V30, P913
   Maestripieri D, 1998, HORM BEHAV, V34, P223, DOI 10.1006/hbeh.1998.1470
   Maestripieri D, 2000, PHYSIOL BEHAV, V71, P43, DOI 10.1016/S0031-9384(00)00338-3
   Maletinska J, 2002, BEHAVIOUR, V139, P975, DOI 10.1163/156853902320387927
   Mastorakos G, 2003, ANN NY ACAD SCI, V997, P136, DOI 10.1196/annals.1290.016
   MAZOR M, 1994, AM J OBSTET GYNECOL, V171, P231
   MEIER GW, 1965, NATURE, V206, P492, DOI 10.1038/206492a0
   Melamed S, 1999, J PSYCHOSOM RES, V46, P591, DOI 10.1016/S0022-3999(99)00007-0
   MOSS HA, 1967, MERRILL-PALMER Q BEH, V13, P19
   Negatu Z, 2002, ANIM REPROD SCI, V72, P125, DOI 10.1016/S0378-4320(02)00070-2
   NEUMANN I, 1993, NEUROENDOCRINOLOGY, V58, P637, DOI 10.1159/000126604
   NEUMANN I, 1994, ENDOCRINOLOGY, V134, P141, DOI 10.1210/en.134.1.141
   Neumann I D, 2001, Prog Brain Res, V133, P143
   NOLTEN WE, 1981, AM J OBSTET GYNECOL, V139, P492
   Nowak R, 2010, ENCYCLOPEDIA OF BEHAVIORAL NEUROSCIENCE, VOL 2: H-O, P163
   Numan M, 1994, Acta Paediatr Suppl, V397, P19
   Numan M, 2003, NEUROBIOLOGY PARENTA
   OLSSON K, 1995, COMP BIOCHEM PHYS A, V110, P309, DOI 10.1016/0300-9629(94)00186-W
   PEDERSEN CA, 1979, P NATL ACAD SCI USA, V76, P6661, DOI 10.1073/pnas.76.12.6661
   PEDERSEN CA, 1985, NEUROPEPTIDES, V6, P175, DOI 10.1016/0143-4179(85)90108-8
   Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x
   PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605
   Pedersen CA, 2003, PHYSIOL BEHAV, V80, P233, DOI 10.1016/j.physbeh.2003.07.011
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   POINDRON P, 1988, PSYCHONEUROENDOCRINO, V13, P99, DOI 10.1016/0306-4530(88)90009-1
   POINDRON P, 1979, PHYSIOL BEHAV, V23, P1081, DOI 10.1016/0031-9384(79)90300-7
   [Anonymous], 1980, ADV STUD BEHAV
   Pryce Christopher R., 1996, Advances in the Study of Behavior, V25, P423
   PRYCE CR, 1988, PHYSIOL BEHAV, V44, P717, DOI 10.1016/0031-9384(88)90052-2
   PRYCE CR, 1993, J COMP PSYCHOL, V107, P99, DOI 10.1037//0735-7036.107.1.99
   Rees SL, 2004, HORM BEHAV
   REYES FI, 1975, ENDOCRINOLOGY, V96, P1447
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Riem M. M., 2011, NEUROPSYCHOPHARMACOL, V37, P1257, DOI DOI 10.1038/NPP.2011.313
   ROBERTSON MC, 1981, ENDOCRINOLOGY, V108, P2388
   ROMERO R, 1987, OBSTET GYNECOL, V70, P849
   Rosenblatt J S, 1994, Acta Paediatr Suppl, V397, P3
   Rosenblatt J.S., 1990, P40
   Rosenblatt JS, 2002, HDB PARENTING, P31
   Rosenblatt JS, 1963, MATERNAL BEHAV MAMMA, P8
   RUBIANES E, 1992, APPL ANIM BEHAV SCI, V35, P35, DOI 10.1016/0168-1591(92)90014-3
   Russell JA, 2003, FRONT NEUROENDOCRIN, V24, P27, DOI 10.1016/S0091-3022(02)00104-8
   Schaal B, 2003, NATURE, V424, P68, DOI 10.1038/nature01739
   SHIPKA MP, 1991, APPL ANIM BEHAV SCI, V31, P91, DOI 10.1016/0168-1591(91)90156-R
   SIEGEL HI, 1980, NEUROSCI BIOBEHAV R, V4, P17, DOI 10.1016/0149-7634(80)90023-8
   SIEGEL HI, 1975, PHYSIOL BEHAV, V14, P465, DOI 10.1016/0031-9384(75)90012-8
   SIEGEL HI, 1978, HORM BEHAV, V11, P12, DOI 10.1016/0018-506X(78)90054-5
   SMITH FV, 1966, ANIM BEHAV, V14, P120, DOI 10.1016/S0003-3472(66)80019-2
   SOARES MJ, 1982, J ENDOCRINOL, V95, P29, DOI 10.1677/joe.0.0950029
   Stallings J, 2001, PARENT-SCI PRACT, V1, P71, DOI 10.1207/S15327922PAR011&2_5
   STERN JM, 1990, NEUROSCI BIOBEHAV R, V14, P183, DOI 10.1016/S0149-7634(05)80219-2
   STERN JM, 1992, PSYCHOBIOLOGY, V20, P71
   Stern JM, 1989, PSYCHOENDOCRINOLOGY, P105
   STROTT CA, 1974, ENDOCRINOLOGY, V95, P1327
   SWANSON LJ, 1979, BEHAV NEURAL BIOL, V26, P364, DOI 10.1016/S0163-1047(79)91344-X
   TAKAGI T, 1985, HORM METAB RES, V17, P308, DOI 10.1055/s-2007-1013526
   TAVERNE MAM, 1988, ANIM REPROD SCI, V17, P51, DOI 10.1016/0378-4320(88)90044-9
   THOMAN EB, 1970, PHYSIOL BEHAV, V5, P1417, DOI 10.1016/0031-9384(70)90129-0
   TRONICK EZ, 1992, DEV PSYCHOL, V28, P568, DOI 10.1037//0012-1649.28.4.568
   VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275
   VOCI VE, 1973, J COMP PHYSIOL PSYCH, V83, P388, DOI 10.1037/h0034663
   WAMBOLDT MZ, 1987, BEHAV NEUROSCI, V101, P439, DOI 10.1037/0735-7044.101.3.439
   Wang S, 1997, Acta Physiol Scand Suppl, V640, P164
   Williams GL, 2001, BIOL REPROD, V65, P295, DOI 10.1095/biolreprod65.1.295
   YEO JAG, 1986, PHYSIOL BEHAV, V37, P23, DOI 10.1016/0031-9384(86)90378-1
   Yu GZ, 1996, NEUROSCIENCE, V72, P1073, DOI 10.1016/0306-4522(95)00599-4
   Yu GZ, 1996, NEUROSCIENCE, V72, P1083, DOI 10.1016/0306-4522(95)00600-1
   ZARROW MX, 1971, HORM BEHAV, V2, P343, DOI 10.1016/0018-506X(71)90009-2
   Ziegler TE, 2000, HORM BEHAV, V38, P111, DOI 10.1006/hbeh.2000.1606
NR 161
TC 0
Z9 0
U1 5
U2 5
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4266
EI 2213-3941
J9 ANN ENDOCRINOL-PARIS
JI Ann Endocrinol.
PD JUN
PY 2016
VL 77
IS 2
BP 114
EP 125
DI 10.1016/j.ando.2016.04.002
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DQ8HP
UT WOS:000379451100010
PM 27130073
ER

PT J
AU Salles, JP
AF Salles, Jean Pierre
TI Bone metabolism during pregnancy
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Pregnancy; Osteoporosis; Lactation; Newborn; Parathyroid hormone-related
   protein
ID CALCIUM-SENSING-RECEPTOR; HORMONE-RELATED PROTEIN; MAMMARY-GLAND;
   INTESTINAL CALCIUM; OSTEOPOROSIS; LACTATION; MINERALIZATION; OXYTOCIN;
   TURNOVER; DENSITY
AB During pregnancy, mineral concentrations, of calcium and phosphorus in particular, are maintained at a high level in fetal blood so that the developing skeleton may accrete adequate mineral content. The placenta actively transports minerals for this purpose. Maternal intestinal absorption increases in order to meet the fetal demand for calcium, which is only partly dependent on calcitriol. Mineral regulation is essentially dependent on parathyroid hormone (PTH) and PTH-related protein (PTHrP). The calcium-sensing receptor (CaSR) regulates PTH and PTHrP production. If calcium intake is insufficient, the maternal skeleton will undergo resorption due to PTHrP. After birth, a switch from fetal to neonatal homeostasis occurs through increase in PTH and calcitriol, and developmental adaptation of the kidneys and intestines with bone turnover contributing additional mineral to the circulation. Calcium absorption becomes progressively active and dependent on calcitriol. The postnatal skeleton can transiently present with osteoposis but adequate mineral diet usually allows full restoration. Cases of primary osteoporosis must be identified. Loss of trabecular mineral content occurs during lactation in order to provide calcium to the newborn. This programmed bone loss is dependent on a "brain-breast-bone" circuit. The physiological bone resorption during reproduction does not normally cause fractures or persistent osteoporosis. Women who experience fracture are likely to have other causes of bone loss. (C) 2016 Published by Elsevier Masson SAS.
C1 [Salles, Jean Pierre] CHU Toulouse, Hop Enfants, Unite Endocrinol Malad Osseuses Genet & Gynecol, TSA 70034, F-31059 Toulouse 9, France.
   [Salles, Jean Pierre] Univ Toulouse 3, Inserm UMR 1043, CPTP, F-31059 Toulouse, France.
RP Salles, JP (reprint author), CHU Toulouse, Hop Enfants, Unite Endocrinol Malad Osseuses Genet & Gynecol, TSA 70034, F-31059 Toulouse 9, France.
EM salles.jp@chu-toulouse.fr
CR Ardeshirpour L, 2006, BONE, V38, P787, DOI 10.1016/j.bone.2005.11.009
   Baird J, 2011, OSTEOPOROSIS INT, V22, P1323, DOI 10.1007/s00198-010-1344-9
   Black AJ, 2000, J BONE MINER RES, V15, P557, DOI 10.1359/jbmr.2000.15.3.557
   BROMMAGE R, 1990, AM J PHYSIOL, V259, pG631
   Colaianni G, 2014, J NEUROENDOCRINOL, V26, P53, DOI 10.1111/jne.12120
   Colaianni G, 2012, J BIOL CHEM, V287, P29159, DOI 10.1074/jbc.M112.365049
   Colaianni G, 2011, BIOCHEM BIOPH RES CO, V411, P512, DOI 10.1016/j.bbrc.2011.06.158
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198-005-2039-5
   Eller-Vainicher C, 2012, EUR J ENDOCRINOL, V166, P753, DOI 10.1530/EJE-11-1050
   Fudge NJ, 2010, ENDOCRINOLOGY, V151, P886, DOI 10.1210/en.2009-1010
   Gafni RI, 2002, FASEB J, V16, P736, DOI 10.1096/fj.01-0640fje
   Hernandez LL, 2012, AM J PHYSIOL-ENDOC M, V302, pE1009, DOI 10.1152/ajpendo.00666.2011
   Horseman ND, 2014, TRENDS ENDOCRIN MET, V25, P34, DOI 10.1016/j.tem.2013.08.004
   Hovi P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000135
   Kampe AJ, 2015, HORM RES PAEDIAT, V84, P361, DOI 10.1159/000439566
   Karaplis AC, 1998, ENDOCRINOLOGY, V139, P5255, DOI 10.1210/en.139.12.5255
   Korakaki E, 2007, J BONE MINER METAB, V25, P172, DOI 10.1007/s00774-006-0742-8
   Kovacs CS, 2015, OSTEOPOROSIS INT, V26, P2223, DOI 10.1007/s00198-015-3149-3
   Kovacs CS, 2015, EARLY HUM DEV, V91, P623, DOI 10.1016/j.earlhumdev.2015.08.007
   Kovacs CS, 2014, PHYSIOL REV, V94, P1143, DOI 10.1152/physrev.00014.2014
   Kovacs CS, 1998, J CLIN INVEST, V101, P2812, DOI 10.1172/JCI2940
   Kovacs CS, 2001, ENDOCRINOLOGY, V142, P4983, DOI 10.1210/en.142.11.4983
   Land C, 2008, BEST PRACT RES CL EN, V22, P107, DOI 10.1016/j.beem.2007.09.005
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lips MA, 2007, J RHEUMATOL, V34, P769
   Liu XS, 2012, J BONE MINER RES, V27, P865, DOI 10.1002/jbmr.1503
   Mastaglia SR, 2010, OSTEOPOROSIS INT, V21, P1959, DOI 10.1007/s00198-009-1138-0
   Moller UK, 2012, OSTEOPOROSIS INT, V23, P1213, DOI 10.1007/s00198-011-1654-6
   Nakano K, 2006, BONE, V38, P249, DOI 10.1016/j.bone.2005.07.017
   NAMGUNG R, 1993, J PEDIATR-US, V122, P269, DOI 10.1016/S0022-3476(06)80132-0
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Rauchenzauner M, 2007, J CLIN ENDOCR METAB, V92, P443, DOI 10.1210/jc.2006-1706
   Reh CMS, 2011, J CLIN ENDOCR METAB, V96, pE707, DOI 10.1210/jc.2010-1306
   REID IR, 1992, CLIN ENDOCRINOL, V37, P298, DOI 10.1111/j.1365-2265.1992.tb02325.x
   Salles JP, 2015, SUBCELL BIOCHEM, V76, P3, DOI 10.1007/978-94-017-7197-9_1
   Shahtaheri SM, 1999, BRIT J OBSTET GYNAEC, V106, P432, DOI 10.1111/j.1471-0528.1999.tb08296.x
   VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2015, J CLIN ENDOCR METAB
   Wysolmerski JJ, 2010, ANN NY ACAD SCI, V1192, P161, DOI 10.1111/j.1749-6632.2009.05249.x
NR 40
TC 0
Z9 0
U1 6
U2 6
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4266
EI 2213-3941
J9 ANN ENDOCRINOL-PARIS
JI Ann Endocrinol.
PD JUN
PY 2016
VL 77
IS 2
BP 163
EP 168
DI 10.1016/j.ando.2016.04.004
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DQ8HP
UT WOS:000379451100017
PM 27157104
ER

PT J
AU Gaballa, Z
   Sukumaran, S
   Rose, P
   Lines, K
AF Gaballa, Z.
   Sukumaran, S.
   Rose, P.
   Lines, K.
TI Postpartum haemorrhage (PPH) - oxytocin or syntometrine? Is it nice to
   follow NICE (National Institute of Clinical Excellence)?
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Meeting Abstract
C1 [Gaballa, Z.; Sukumaran, S.; Rose, P.; Lines, K.] Warwick Hosp, Warwick, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
PD JUN
PY 2016
VL 123
SU 2
SI SI
MA EP8.272
BP 167
EP 167
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DQ4DF
UT WOS:000379153200316
ER

PT J
AU Bansal, V
   Fisher, TE
AF Bansal, V.
   Fisher, T. E.
TI Na+-Activated K+ Channels in Rat Supraoptic Neurones
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE Slack; Slick; K-Na current; magnocellular neurosecretory cells;
   osmoregulation; AHP
ID ROOT GANGLION NEURONS; CENTRAL-NERVOUS-SYSTEM; POTASSIUM CHANNEL;
   IN-VITRO; SLOW AFTERHYPERPOLARIZATION; FUNCTIONAL-ROLE; SLACK;
   VASOPRESSIN; SLICK; OXYTOCIN
AB The magnocellular neurosecretory cells (MNCs) of the hypothalamus secrete the neurohormones vasopressin and oxytocin. The systemic release of these hormones depends on the rate and pattern of MNC firing and it is therefore important to identify the ion channels that contribute to the electrical behaviour of MNCs. In the present study, we report evidence for the presence of Na+-activated K+ (K-Na) channels in rat MNCs. K-Na channels mediate outwardly rectifying K+ currents activated by the increases in intracellular Na+ that occur during electrical activity. Although the molecular identity of native K-Na channels is unclear, their biophysical properties are consistent with those of expressed Slick (slo 2.1) and Slack (slo 2.2) proteins. Using immunocytochemistry and Western blot experiments, we found that both Slick and Slack proteins are expressed in rat MNCs. Using whole cell voltage clamp techniques on acutely isolated rat MNCs, we found that inhibiting Na+ influx by the addition of the Na+ channel blocker tetrodotoxin or the replacement of Na+ in the external solution with Li+ caused a significant decrease in sustained outward currents. Furthermore, the evoked outward current density was significantly higher in rat MNCs using patch pipettes containing 60mm Na+ than it was when patch pipettes containing 0mm Na+ were used. Our data show that functional K-Na channels are expressed in rat MNCs. These channels could contribute to the activity-dependent afterhyperpolarisations that have been identified in the MNCs and thereby play a role in the regulation of their electrical behaviour.
C1 [Bansal, V.; Fisher, T. E.] Univ Saskatchewan, Coll Med, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
RP Fisher, TE (reprint author), Univ Saskatchewan, Coll Med, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
EM thomas.fisher@usask.ca
FU Natural Sciences and Engineering Research Council of Canada
FX The work in the present study was supported by a grant from the Natural
   Sciences and Engineering Research Council of Canada to TEF. The authors
   thank Xuan Thanh Vo for his excellent technical assistance. The authors
   of the manuscript have no conflicts of interest to declare.
CR ALTSTEIN M, 1988, PEPTIDES, V9, P87, DOI 10.1016/0196-9781(88)90014-9
   Bhattacharjee A, 2005, TRENDS NEUROSCI, V28, P422, DOI 10.1016/j.tins.2005.06.003
   Bhattacharjee A, 2003, J NEUROSCI, V23, P11681
   Bhattacharjee A, 2002, J COMP NEUROL, V454, P241, DOI 10.1002/cne.10439
   Bhattacharjee Arin, 2005, J Comp Neurol, V484, P80, DOI 10.1002/cne.20462
   BICKNELL RJ, 1988, J EXP BIOL, V139, P51
   Bischoff U, 1998, J PHYSIOL-LONDON, V510, P743, DOI 10.1111/j.1469-7793.1998.743bj.x
   Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601
   Brown CH, 2013, J NEUROENDOCRINOL, V25, P678, DOI 10.1111/jne.12051
   Brown MR, 2008, J PHYSIOL-LONDON, V586, P5161, DOI 10.1113/jphysiol.2008.160861
   Cangiano L, 2002, J NEUROPHYSIOL, V88, P289, DOI 10.1152/jn.00641.2001
   Cervantes B, 2013, NEUROSCIENCE, V240, P163, DOI 10.1016/j.neuroscience.2013.02.052
   Chen HJ, 2009, J NEUROSCI, V29, P5654, DOI 10.1523/JNEUROSCI.5978-08.2009
   CONRAD KP, 1993, ANN NY ACAD SCI, V689, P346, DOI 10.1111/j.1749-6632.1993.tb55559.x
   Del Burgo LS, 2008, J COMP NEUROL, V510, P581, DOI 10.1002/cne.21810
   Dopico AM, 1999, J PHYSIOL-LONDON, V519, P101, DOI 10.1111/j.1469-7793.1999.0101o.x
   DRYER SE, 1989, J PHYSIOL-LONDON, V410, P283
   Faber ESL, 2003, NEUROSCIENTIST, V9, P181, DOI 10.1177/107385840325673
   Gao SB, 2008, ACTA PHARMACOL SIN, V29, P899, DOI 10.1111/j.1745-7254.2008.00842.x
   Ghamari-Langroudi M, 2004, J NEUROSCI, V24, P7718, DOI 10.1523/JNEUROSCI.1240-04.2004
   Greffrath W, 2004, J NEUROENDOCRINOL, V16, P577, DOI 10.1111/j.1365-2826.2004.01204.x
   Hess D, 2007, J NEUROPHYSIOL, V97, P3484, DOI 10.1152/jn.00742.2006
   HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637
   Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x
   Kim GE, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/fncel.2014.00209, 10.3389/fnce1.2014.00209]
   Kirkpatrick K, 1996, J PHYSIOL-LONDON, V494, P389
   Li JH, 2001, NEUROREPORT, V12, P1007, DOI 10.1097/00001756-200104170-00028
   Liu XH, 2005, J PHYSIOL-LONDON, V568, P61, DOI 10.1113/jphysiol.2005.093773
   Liu XH, 2004, BRAIN RES, V1023, P185, DOI 10.1016/j.brainres.2004.07.017
   Lu SQ, 2010, J NEUROPHYSIOL, V103, P3311, DOI 10.1152/jn.00607.2009
   Markham MR, 2013, J NEUROPHYSIOL, V109, P1713, DOI 10.1152/jn.00875.2012
   Naeini RS, 2006, NAT NEUROSCI, V9, P93, DOI 10.1038/nn1614
   NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013
   Ohbuchi T, 2010, NEUROSCI LETT, V484, P26, DOI 10.1016/j.neulet.2010.08.010
   OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291
   OLIET SHR, 1993, NATURE, V364, P341, DOI 10.1038/364341a0
   POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6
   Richard D, 1995, J PHYSIOL-LONDON, V489, P567
   Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7
   Sanchez-Vives MV, 2000, J NEUROSCI, V20, P4286
   Santi CM, 2006, J NEUROSCI, V26, P5059, DOI 10.1523/JNEUROSCI.3372-05.2006
   Tamsett TJ, 2009, J NEUROSCI, V29, P5127, DOI 10.1523/JNEUROSCI.0859-09.2009
   Thomson SJ, 2015, J BIOL CHEM, V290, P14528, DOI 10.1074/jbc.M115.653089
   Wallen P, 2007, J PHYSIOL-LONDON, V585, P75, DOI 10.1113/jphysiol.2007.138156
   Yang B, 2007, J NEUROSCI, V27, P2617, DOI 10.1523/JNEUROSCI5308-06.2007
   Yuan A, 2003, NEURON, V37, P765, DOI 10.1016/S0896-6273(03)00096-5
   Zaelzer C, 2015, CELL REP, V13, P23, DOI 10.1016/j.celrep.2015.08.061
NR 47
TC 0
Z9 0
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD JUN
PY 2016
VL 28
IS 6
DI 10.1111/jne.12394
PG 10
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DR1TR
UT WOS:000379688300004
ER

PT J
AU Matsuura, T
   Kawasaki, M
   Hashimoto, H
   Yoshimura, M
   Motojima, Y
   Saito, R
   Ueno, H
   Maruyama, T
   Ishikura, T
   Sabanai, K
   Mori, T
   Ohnishi, H
   Onaka, T
   Sakai, A
   Ueta, Y
AF Matsuura, T.
   Kawasaki, M.
   Hashimoto, H.
   Yoshimura, M.
   Motojima, Y.
   Saito, R.
   Ueno, H.
   Maruyama, T.
   Ishikura, T.
   Sabanai, K.
   Mori, T.
   Ohnishi, H.
   Onaka, T.
   Sakai, A.
   Ueta, Y.
TI Possible Involvement of the Rat Hypothalamo-Neurohypophysial/-Spinal
   Oxytocinergic Pathways in Acute Nociceptive Responses
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE oxytocin; fluorescent protein; acute nociception
ID GREEN FLUORESCENT PROTEIN; PERIPHERAL-NERVE INJURY;
   ELECTRICAL-STIMULATION; TRANSGENIC RATS; DORSAL-HORN; NEURONS; CORD;
   RECEPTOR; INNERVATION; VASOPRESSIN
AB Oxytocin (OXT)-containing neurosecretory cells in the parvocellular divisions of the paraventricular nucleus (PVN), which project to the medulla and spinal cord, are involved in various physiological functions, such as sensory modulation and autonomic processes. In the present study, we examined OXT expression in the hypothalamo-spinal pathway, as well as the hypothalamo-neurohypophysial system, which includes the magnocellular neurosecretory cells in the PVN and the supraoptic nucleus (SON), after s.c. injection of saline or formalin into the hindpaws of transgenic rats that express the OXT and monomeric red fluorescent protein 1 (mRFP1) fusion gene. (i) The numbers of OXT-mRFP1 neurones that expressed Fos-like immunoreactivity (-IR) and OXT-mRFP1 intensity were increased significantly in the magnocellular/parvocellular PVN and SON after s.c. injection of formalin. (ii) OXT-mRFP1 neurones in the anterior parvocellular PVN, which may project to the dorsal horn of the spinal cord, were activated by s.c. injection of formalin, as indicated by a significant increases of Fos-IR and mRFP1 intensity intensity. (iii) Formalin injection caused a significant transient increase in plasma OXT. (iv) OXT, mRFP1 and corticotrophin-releasing hormone mRNAs in the PVN were significantly increased after s.c. injection of formalin. (v) An intrathecal injection of OXT-saporin induced hypersensitivity in conscious rats. Taken together, these results suggest that the hypothalamo-neurohypophysial/-spinal OXTergic pathways may be involved in acute nociceptive responses in rats.
C1 [Matsuura, T.; Hashimoto, H.; Yoshimura, M.; Motojima, Y.; Saito, R.; Ueno, H.; Maruyama, T.; Ueta, Y.] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka, Japan.
   [Matsuura, T.; Kawasaki, M.; Motojima, Y.; Ishikura, T.; Sabanai, K.; Mori, T.; Ohnishi, H.; Sakai, A.] Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed, Kitakyushu, Fukuoka, Japan.
   [Onaka, T.] Jichi Med Univ, Dept Physiol, Div Brain & Neurophysiol, Shimotsuke, Tochigi, Japan.
RP Ueta, Y (reprint author), Univ Occupat & Environm Hlth, Dept Physiol, Sch Med, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM yoichi@med.uoeh-u.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology (MEXT)
   [25113721]; Japan Society for the Promotion of Science (JSPS), Japan
   [25293055, 26860164, 15K10500, 25462391]; University of Occupational and
   Environmental Health (UOEH) Research Grant for Advanced Research from
   the UOEH; UOEH Research Grant for the Promotion of Occupational Health
FX We thank Dr Roger Tsien (University of California, San Diego, CA, USA)
   for supplying the RFP1 clone, as well as Ms Yuki Nonaka and Kanako
   Shoguchi (University of Occupational and Environmental Health,
   Kitakyushu, Japan) for their technical assistance. This work was
   supported by a Grant-in-Aid for Scientific Research on Innovative Areas
   'Fluorescence Live Imaging' No. 25113721 of the Ministry of Education,
   Culture, Sports, Science, and Technology (MEXT); Grants-in-Aid for
   Scientific Research (B) No. 25293055, (B) No. 26860164, (C) No. 15K10500
   and (C) No. 25462391 from the Japan Society for the Promotion of Science
   (JSPS), Japan; a University of Occupational and Environmental Health
   (UOEH) Research Grant for Advanced Research from the UOEH; and a UOEH
   Research Grant for the Promotion of Occupational Health to MK. The
   authors declare that they have no conflicts of interests or other
   competing interests to disclose.
CR Aloisi AM, 1996, PROG BRAIN RES, V110, P33
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Baskin DG, 2010, ENDOCRINOLOGY, V151, P4207, DOI 10.1210/en.2010-0295
   Blevins JE, 2003, BRAIN RES, V993, P30, DOI 10.1016/j.brainres.2003.08.036
   Breton JD, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-19
   Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27
   CARMICHAEL MS, 1994, ARCH SEX BEHAV, V23, P59, DOI 10.1007/BF01541618
   Chini B, 2007, BIOCHEM SOC T, V35, P737
   Condes-Lara M, 2009, EUR J NEUROSCI, V30, P1056, DOI 10.1111/j.1460-9568.2009.06899.x
   Condes-Lara M, 2009, BRAIN RES, V1247, P38, DOI 10.1016/j.brainres.2008.10.030
   DeLaTorre S, 2009, PAIN, V144, P320, DOI 10.1016/j.pain.2009.05.002
   desAraujo AD, 2014, NATURE COMMUNICATION, V5, P3165
   DUBUISSON D, 1977, PAIN, V4, P161
   Gutierrez S, 2013, ANESTHESIOLOGY, V118, P152, DOI 10.1097/ALN.0b013e318278cd21
   Han Y, 2009, NEUROSCI LETT, V454, P101, DOI 10.1016/j.neulet.2009.02.062
   HIGUCHI T, 1985, J ENDOCRINOL, V106, P311, DOI 10.1677/joe.0.1060311
   HOSOYA Y, 1995, EXP BRAIN RES, V107, P9
   Juif PE, 2013, PAIN, V154, P1449, DOI 10.1016/j.pain.2013.05.003
   Katoh A, 2014, J NEUROENDOCRINOL, V26, P341, DOI 10.1111/jne.12150
   Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509
   LECKMAN JF, 1994, PSYCHONEUROENDOCRINO, V19, P723, DOI 10.1016/0306-4530(94)90021-3
   Long JZ, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-20
   Lund I, 2002, EUR J NEUROSCI, V16, P330, DOI 10.1046/j.1460-9568.2002.02087.x
   Matsuura T, 2015, J NEUROENDOCRINOL, V27, P636, DOI 10.1111/jne.12290
   MESTRE C, 1994, J PHARMACOL TOXICOL, V32, P197, DOI 10.1016/1056-8719(94)90087-6
   Miranda-Cardenas Y, 2006, PAIN, V122, P182, DOI 10.1016/j.pain.2006.01.029
   Moreno-Lopez Y, 2013, NEUROPEPTIDES, V47, P117, DOI 10.1016/j.npep.2012.09.008
   ONAKA T, 1990, EXP BRAIN RES, V81, P53
   Paxinos G., 1998, RAT BRAIN STEREOTAXI
   Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005
   Puder BA, 2001, J NEUROSCI RES, V64, P53, DOI 10.1002/jnr.1053
   Raghavendra V, 2003, PAIN, V104, P655, DOI 10.1016/S0304-3959(03)00138-6
   REITER MK, 1994, EUR J NEUROSCI, V6, P98, DOI 10.1111/j.1460-9568.1994.tb00251.x
   Rojas-Piloni Gerardo, 2010, Neurosci Lett, V476, P32, DOI 10.1016/j.neulet.2010.03.076
   Russell JA, 1998, J ENDOCRINOL, V157, P343, DOI 10.1677/joe.0.1570343
   SAPER CB, 1976, BRAIN RES, V117, P305, DOI 10.1016/0006-8993(76)90738-1
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   STOCK S, 1988, ACTA PHYSIOL SCAND, V132, P29, DOI 10.1111/j.1748-1716.1988.tb08294.x
   Suzuki H, 2009, J NEUROSCI, V29, P13182, DOI 10.1523/JNEUROSCI.2624-09.2009
   SWANSON LW, 1979, J COMP NEUROL, V188, P87, DOI 10.1002/cne.901880108
   Tobin VA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025366
   Tribollet E, 1997, NEUROSCIENCE, V78, P499, DOI 10.1016/S0306-4522(96)00591-X
   UETA Y, 1995, ENDOCRINOLOGY, V136, P4182, DOI 10.1210/en.136.10.4182
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   Veronneau-Longueville F, 1999, NEUROSCIENCE, V93, P1437, DOI 10.1016/S0306-4522(99)00262-6
   Wrobel L, 2011, NEUROSCI LETT, V495, P49, DOI 10.1016/j.neulet.2011.03.033
   Zhang BJ, 2002, ENDOCRINOLOGY, V143, P1036, DOI 10.1210/en.143.3.1036
NR 50
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD JUN
PY 2016
VL 28
IS 6
DI 10.1111/jne.12396
PG 13
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DR1TR
UT WOS:000379688300005
ER

PT J
AU Stabile, AM
   Moreto, V
   Batalhao, ME
   Rocha, MJ
   Antunes-Rodrigues, J
   Carnio, EC
AF Stabile, A. M.
   Moreto, V.
   Batalhao, M. E.
   Rocha, M. J.
   Antunes-Rodrigues, J.
   Carnio, E. C.
TI Differential Role of Neurohypophysial Hormones in Hypotension and Nitric
   Oxide Production During Endotoxaemia
SO JOURNAL OF NEUROENDOCRINOLOGY
LA English
DT Article
DE vasopressin; oxytocin; nitric oxide; endotoxaemia; arterial pressure
ID SEPTIC SHOCK; VASOPRESSIN RELEASE; MOUSE MACROPHAGES; IMMUNE-SYSTEM; V-1
   RECEPTOR; LATE-PHASE; SEPSIS; CELLS; RATS; LIPOPOLYSACCHARIDE
AB Besides their well-established endocrine roles, vasopressin and oxytocin are also important regulators of immune function, participating in a complex neuroendocrine-immune network. In the present study, we investigated whether and how vasopressin and oxytocin could modulate lipopolysaccharide (LPS)-induced nitric oxide (NO) production in a well-established model of experimental endotoxaemia. Male Wistar rats were previously treated i.v. with vasopressin V-1 or oxytocin receptor antagonists and then received either an i.v. LPS injection to induce endotoxaemia or a saline imjection as a control. The animals were divided into two groups: in the first group, blood was collected at 2, 4 and 6h after LPS injection; in the second group, mean arterial blood pressure (MABP) and heart rate (HR) were recorded over 6h. Plasma vasopressin and oxytocin values were higher in LPS- compared to saline-injected animals at 2 and 4h but returned to basal levels at 6h. NO levels exhibited an opposite pattern, showing a progressive increase over the entire period. The previous administration of a vasopressin V-1 receptor antagonist significantly reduced NO plasma concentrations at 2 and 4h but not at 6h. By contrast, oxytocin receptor agonist pre-treatment had no effect on the NO plasma concentration. In relation to MABP, previous treatment with vasopressin V-1 receptor antagonist reversed the LPS-induced hypotension at 4h, although this was not the case for oxytocin antagonist-treated animals. None of the antagonists affected HR. Our findings indicate that vasopressin (but not oxytocin) has effects on NO production during endotoxaemia in rats, although they do not lend support to the proposed anti-inflammatory actions of vasopressin during endotoxaemia.
C1 [Stabile, A. M.; Moreto, V.; Batalhao, M. E.; Carnio, E. C.] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Ribeirao Preto, SP, Brazil.
   [Rocha, M. J.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [Antunes-Rodrigues, J.] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil.
RP Stabile, AM (reprint author), Ribeirao Preto Coll Nursing, Ave Bandeirantes 3900, BR-14040902 Ribeirao Preto, SP, Brazil.
EM angelita@eerp.usp.br
RI Rocha, Maria Jose/J-4441-2012
FU Sao Paulo State Research Foundation - FAPESP [N 2005/5125-3]
FX We thank Dr Klaus Hartfelder for reviewing the English in the manuscript
   submitted for publication. The authors have no conflicts of interest to
   report. This work was founded by the Sao Paulo State Research Foundation
   - FAPESP (grant number N 2005/5125-3).
CR Bai XW, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0532-y
   Batalhao ME, 2008, REGUL PEPTIDES, V147, P67, DOI 10.1016/j.regpep.2008.01.001
   BELL J, 1993, LIFE SCI, V52, P95, DOI 10.1016/0024-3205(93)90292-B
   Bucher M, 2002, AM J PHYSIOL-REG I, V282, pR979, DOI 10.1152/ajpregu.00520.2001
   Chini B, 2007, BIOCHEM SOC T, V35, P737
   Csaba G, 2014, ACTA MICROBIOL IMM H, V61, P241, DOI 10.1556/AMicr.61.2014.3.1
   Correa PBF, 2007, J NEUROIMMUNOL, V183, P17, DOI 10.1016/j.jneuroim.2006.10.021
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Giusti-Paiva A, 2003, PFLUG ARCH EUR J PHY, V447, P175, DOI 10.1007/s00424-003-1164-2
   Giusti-Paiva A, 2002, CRIT CARE MED, V30, P1306, DOI 10.1097/00003246-200206000-00025
   Hofstetter C, 2007, INT J MOL MED, V20, P597
   Ieri SO, 2005, J SURG RES, V126, P73
   Khegai II, 2003, B EXP BIOL MED+, V136, P448, DOI 10.1023/B:BEBM.0000017089.28428.1c
   Kimmoun A, 2013, CURR VASC PHARMACOL, V11, P139
   Kusano E, 1997, J HYPERTENS, V15, P627, DOI 10.1097/00004872-199715060-00009
   Landry DW, 1997, CIRCULATION, V95, P1122
   Lerman Yelena V., 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P19
   LORSBACH RB, 1993, J BIOL CHEM, V268, P1908
   Martins TF, 2011, J NEUROIMMUNOL, V238, P52, DOI 10.1016/j.jneuroim.2011.08.001
   Moreto V, 2006, SHOCK, V26, P472, DOI 10.1097/01.shk.0000230301.86139.6a
   Nardi GM, 2014, CRIT CARE MED, V42, P391
   Nemzek JA, 2008, COMPARATIVE MED, V58, P120
   Nicholas C, 2007, J IMMUNOL, V179, P7121
   Oliveira-Pelegrin GR, 2014, J NEUROIMMUNOL, V267, P28, DOI 10.1016/j.jneuroim.2013.12.006
   Oliveira-Pelegrin GR, 2013, NEUROIMMUNOMODULAT, V20, P65, DOI 10.1159/000345044
   Oliveira-Pelegrin GR, 2010, PEPTIDES, V31, P1847, DOI 10.1016/j.peptides.2010.06.031
   Ramachandran G, 2014, VIRULENCE, V5, P213, DOI 10.4161/viru.27024
   RAYMOND V, 1985, FEBS LETT, V182, P196, DOI 10.1016/0014-5793(85)81183-2
   Russell JA, 2011, CRIT CARE, V15, DOI 10.1186/cc8224
   Sharshar T, 2003, CRIT CARE MED, V31, P1752, DOI 10.1097/01.CCM.0000063046.82359.4A
   Stabile AM, 2010, PEPTIDES, V31, P706, DOI 10.1016/j.peptides.2009.11.004
   Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008
   Takayama K, 2005, NAT MED, V11, P562, DOI 10.1038/nm1231
   Umino T, 1999, AM J PHYSIOL-RENAL, V276, pF433
   Vayssettes-Courchay C, 2005, AUTON NEUROSCI-BASIC, V120, P35, DOI 10.1016/j.autneu.2005.03.002
   Wahab F, 2015, ENDOCRINE, V49, P215, DOI 10.1007/s12020-014-0452-2
   XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522
   Yamamoto K, 1997, HYPERTENSION, V30, P1112
   Zik JB, 2015, PSYCHIAT RES, V226, P31, DOI 10.1016/j.psychres.2014.11.048
NR 39
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-8194
EI 1365-2826
J9 J NEUROENDOCRINOL
JI J. Neuroendocrinol.
PD JUN
PY 2016
VL 28
IS 6
DI 10.1111/jne.12391
PG 6
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA DR1TR
UT WOS:000379688300001
ER

PT J
AU Gilfeather, CL
   Lemley, CO
AF Gilfeather, C. L.
   Lemley, C. O.
TI Effects of Interferon-Tau and Steroids on Cytochrome P450 Activity in
   Bovine Endometrial Epithelial Cells
SO REPRODUCTION IN DOMESTIC ANIMALS
LA English
DT Article
ID HUMAN LIVER-MICROSOMES; ARACHIDONIC-ACID; ENZYME-ACTIVITY; CLEARANCE
   RATE; DAIRY-COWS; PROGESTERONE; METABOLISM; INHIBITORS; MECHANISMS;
   PREGNANCY
AB The objective of the current study was to examine cyclooxygenase (COX), cytochrome P450 1A (CYP1A) and 2C (CYP2C) activity in bovine endometrial cell cultures following exposure to oxytocin (OT), interferon-tau (IFN), estradiol (E2) and/or progesterone (P4). Bovine endometrial epithelial cells were treated with OT, IFN, a combination of OT+IFN or control (CON) media for 24 h. For the second experiment, cells were treated with E2, P4, a combination of E2 + P4 or CON media for 24 h. Treatments were performed in triplicate, and the experiment was repeated four times (n = 12 per treatment). Treatment with OT alone increased (p < 0.01) activity of COX compared with CON; however, OT alone did not alter activity of CYP1A (p = 0.55) or CYP2C (p = 0.46) compared with CON. Activity of CYP1A and CYP2C was decreased in cells exposed to IFN (p < 0.01) or OT+ IFN (p < 0.01) compared with CON. Treatment with E2 alone did not alter activity of CYP1A (p = 0.64) or CYP2C (p = 0.06) compared with CON. Activity of CYP1A and CYP2C was decreased (p < 0.01) in P4 vs CON. In summary, IFN exposure, irrespective of OT treatment, decreased the activity of CYP1A and CYP2C. Activity of CYP1A was decreased following P4 treatment alone, while that of CYP2C was decreased following both P4 and E2 + P4 treatment. The mixed function monooxygenase enzymes, CYP1A and CYP2C, have been implicated in synthesizing embryotoxic compounds; therefore, downregulation in the endometrium may be necessary during maternal recognition of pregnancy.
C1 [Gilfeather, C. L.; Lemley, C. O.] Mississippi State Univ, Dept Anim & Dairy Sci, Box 9815, Mississippi State, MS 39762 USA.
RP Lemley, CO (reprint author), Mississippi State Univ, Dept Anim & Dairy Sci, Box 9815, Mississippi State, MS 39762 USA.
EM caleb.lemley@msstate.edu
FU United State Department of Agriculture, Agricultural Research Service,
   Biophotonic Initiative [58-6402-3-0120]
FX This project was funded through the United State Department of
   Agriculture, Agricultural Research Service, Biophotonic Initiative
   number 58-6402-3-0120.
CR Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897
   Asselin E, 1997, ENDOCRINOLOGY, V138, P4798, DOI 10.1210/en.138.11.4798
   Bazer FW, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-23
   Bogacki M, 2002, BIOL REPROD, V67, P184, DOI 10.1095/biolreprod67.1.184
   Doostdar H, 2000, TOXICOLOGY, V144, P31, DOI 10.1016/S0300-483X(99)00215-2
   Hahn ME, 1998, COMP BIOCHEM PHYS C, V121, P23, DOI 10.1016/S0742-8413(98)10028-2
   Hart CG, 2014, DOMEST ANIM ENDOCRIN, V49, P31, DOI 10.1016/j.domaniend.2014.05.003
   Lattanzi ML, 2003, BIOL REPROD, V69, P1793, DOI 10.1095/biolreprod.103.020743
   Lemley CO, 2008, J DAIRY SCI, V91, P641, DOI 10.3168/jds.2007-0636
   Lemley CO, 2010, J DAIRY SCI, V93, P4613, DOI 10.3168/jds.2010-3165
   Lemley CO, 2010, J ENDOCRINOL, V205, P233, DOI 10.1677/JOE-10-0042
   Mannisto PT, 1999, PHARMACOL REV, V51, P593
   PARR RA, 1993, RES VET SCI, V55, P306, DOI 10.1016/0034-5288(93)90099-2
   RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3
   Roman RJ, 2002, PHYSIOL REV, V82, P131
   Sangsritavong S, 2002, J DAIRY SCI, V85, P2831, DOI 10.3168/jds.S0022-0302(02)74370-1
   Tithof PK, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-16
   WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F
   Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V346, P161, DOI 10.1006/abbi.1997.0302
   Yueh MF, 2005, TOXICOL IN VITRO, V19, P275, DOI 10.1016/j.tiv.2004.10.003
   Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1
NR 21
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0936-6768
EI 1439-0531
J9 REPROD DOMEST ANIM
JI Reprod. Domest. Anim.
PD JUN
PY 2016
VL 51
IS 3
BP 415
EP 420
DI 10.1111/rda.12695
PG 6
WC Agriculture, Dairy & Animal Science; Reproductive Biology; Veterinary
   Sciences
SC Agriculture; Reproductive Biology; Veterinary Sciences
GA DR4YS
UT WOS:000379910300011
PM 27103466
ER

PT J
AU Atramentova, LA
   Luchko, EN
AF Atramentova, L. A.
   Luchko, E. N.
TI Aggression and empathy as genetic differentiation factors of urban
   population
SO RUSSIAN JOURNAL OF GENETICS
LA English
DT Article
DE marriage structure; aggression; empathy; MAO-A rs2235186 SNP
ID OXYTOCIN RECEPTOR; DONETSK POPULATION; MONOAMINE-OXIDASE; GENOTYPE;
   1990S; ASSOCIATION; DEMOGRAPHY; BEHAVIOR; SCHIZOPHRENIA; POLYMORPHISM
AB Permanent residents of Kharkiv (637 men and 856 women at the age of 45-65 years) are tested on the level of aggression and empathy. The average aggression level (41.7 points) is higher in migrants (born outside Kharkiv) than in indigenous people (36.3 points); the average empathy level is lower in migrants (3.2 points) than in indigenous people (5.5 points). The average values of the aggression and empathy indices are not associated with ethnicity and degree of miscegenation. The correlation between spouses (r) by these personal features is within 0.20-0.31; the marriage conjugation index (K) is 0.13-0.18. Genotyping of the married couples for the rs2235186 SNP of X-linked monoaminooxidase (MAO-A) gene detected a positive marriage assortativeness: the C x CC and T x TT pairs are developed more frequently than during panmixia; the C x TT and T x CC pairs, less frequently. The T allele is coupled with increased aggression level and decreased empathy level. The phenotypes of heterozygous women indicate the intermediate inheritance of these traits.
C1 [Atramentova, L. A.; Luchko, E. N.] Kharkov Natl Univ, Dept Genet & Cytol, UA-61022 Kharkov, Ukraine.
RP Atramentova, LA (reprint author), Kharkov Natl Univ, Dept Genet & Cytol, UA-61022 Kharkov, Ukraine.
EM atramentova@yandex.ru; ekaterina_luchko@mail.ru
CR Alia-Klein N., 2008, BIOL PSYCHOL, P5099, DOI [10.1523/JNEUROSCI.0925-08.2008, DOI 10.1523/JNEUROSCI.0925-08.2008]
   Altukhov Yu. P., 2004, DINAMIKA POPULYATSIO
   Atramentova LA, 2000, RUSS J GENET+, V36, P81
   Atramentova LA, 2002, RUSS J GENET+, V38, P816, DOI 10.1023/A:1016399823573
   Atramentova LA, 2002, RUSS J GENET+, V38, P1189, DOI 10.1023/A:1020609006063
   Atramentova LA, 2002, RUSS J GENET+, V38, P1082, DOI 10.1023/A:1020200100784
   Balabanova L.M., 1998, SUDEBNAYA PATOPSIKHO
   Baron R. A., 1994, HUMAN AGGRESSION
   Beach SRH, 2010, J FAM PSYCHOL, V24, P12, DOI 10.1037/a0018074
   Berkovits L., 1993, AGGRESSION ITS CAUSE
   Berman M.E., 2009, PSYCHOL SCI, V24, P74
   Bulaeva K.B., 1991, GENETICHESKIE OSNOVY
   Coplan A., 2011, EMPATHY PHILOS PSYCH, V5, P3
   Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187
   Falconer D.S., 1960, INTRO QUANTITATIVE G
   Filiptsova O V, 2015, Indian J Psychol Med, V37, P305, DOI 10.4103/0253-7176.162958
   Filiptsova O.V., 2015, EGYPT J MED HUM GENE, V16
   Filiptsova O.V., 2014, EGYPT J MED HUM GENE, V15, P347
   Filiptsova O.V., 2009, THESIS
   Guo G, 2007, HUM GENET, V121, P125, DOI 10.1007/s00439-006-0244-8
   Hallikainen T, 1999, MOL PSYCHIATR, V4, P385, DOI 10.1038/sj.mp.4000526
   Hennig J, 2005, BEHAV NEUROSCI, V119, P16, DOI 10.1037/0735-7044.119.1.16
   Hess C.A., 2009, HUM GENET, V126, P101
   Hur YM, 2013, PERS INDIV DIFFER, V55, P247, DOI 10.1016/j.paid.2012.05.016
   Jones G, 2001, BRIT J PSYCHIAT, V179, P351, DOI 10.1192/bjp.179.4.351
   Karelin A.A., 2002, PSIKHOLOGICHESKIE TE, V1
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kreuger R.F., 1998, BEHAV GENET, V28, P173
   Kurbatova O.L., 2014, THESIS
   Malik AI, 2012, GENES BRAIN BEHAV, V11, P545, DOI 10.1111/j.1601-183X.2012.00776.x
   New AS, 2001, BIOL PSYCHIAT, V50, P62, DOI 10.1016/S0006-3223(01)01108-8
   Nilsson KW, 2006, BIOL PSYCHIAT, V59, P121, DOI 10.1016/j.biopsych.2005.06.024
   Plomin R., 2001, PSYCHOLOGIST, V14, P68
   Prom-Wormley EC, 2009, PSYCHOL MED, V39, P579, DOI 10.1017/S0033291708004170
   Ronald L., 2011, AM SOCIOL REV, V76, P883, DOI [10.1177/0003122411427580, DOI 10.1177/0003122411427580]
   Strous RD, 1997, PSYCHIAT RES, V69, P71, DOI 10.1016/S0165-1781(96)03111-3
   Tuvblad C, 2011, ADV GENET, V75, P171, DOI 10.1016/B978-0-12-380858-5.00007-1
   Uzefovsky F, 2015, HORM BEHAV, V67, P60, DOI 10.1016/j.yhbeh.2014.11.007
   Yan Xiu-juan, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P1354
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1022-7954
EI 1608-3369
J9 RUSS J GENET+
JI Russ. J. Genet.
PD JUN
PY 2016
VL 52
IS 6
BP 615
EP 621
DI 10.1134/S1022795416050021
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA DR0IZ
UT WOS:000379592500009
ER

PT J
AU Kori, S
   Pascual, CR
   Klukinov, M
   Yeomans, DC
AF Kori, S.
   Pascual, C. R.
   Klukinov, M.
   Yeomans, D. C.
TI Intranasal oxytocin produces oxytocin receptor specific analgesia in the
   trigeminal system by local uptake and not by systemic absorption
SO HEADACHE
LA English
DT Meeting Abstract
CT 58th Annual Scientific Meeting of the American-Headache-Society
CY JUN 09-12, 2016
CL San Diego, CA
SP Amer Headache Soc
C1 [Kori, S.] Trigemina Inc, Moraga, CA USA.
   [Pascual, C. R.] Trigemina, Santa Clara, CA USA.
   [Klukinov, M.] Stanford Univ, Stanford, CA 94305 USA.
   [Yeomans, D. C.] Stanford Univ, Sunnyvale, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD JUN
PY 2016
VL 56
SU 1
SI SI
MA OR17
BP 11
EP 11
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA DQ4ER
UT WOS:000379157200018
ER

PT J
AU Yeomans, DC
   Tzabazis, AZ
   Carson, D
   Klukinov, M
   Kori, S
AF Yeomans, D. C.
   Tzabazis, A. Z.
   Carson, D.
   Klukinov, M.
   Kori, S.
TI Oxytocin blocks CGRP release in the dura in situ: a potential mechanism
   of action for frequency reduction in migraine
SO HEADACHE
LA English
DT Meeting Abstract
CT 58th Annual Scientific Meeting of the American-Headache-Society
CY JUN 09-12, 2016
CL San Diego, CA
SP Amer Headache Soc
C1 [Yeomans, D. C.] Stanford Univ, Sunnyvale, CA USA.
   [Tzabazis, A. Z.; Klukinov, M.] Stanford Univ, Stanford, CA 94305 USA.
   [Carson, D.; Kori, S.] Trigemina Inc, Moraga, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD JUN
PY 2016
VL 56
SU 1
SI SI
MA OR18
BP 11
EP 12
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA DQ4ER
UT WOS:000379157200019
ER

PT J
AU Chappell, AR
   Freeman, SM
   Lin, YK
   LaPrairie, JL
   Inoue, K
   Young, LJ
   Hayes, LD
AF Chappell, A. R.
   Freeman, S. M.
   Lin, Y. K.
   LaPrairie, J. L.
   Inoue, K.
   Young, L. J.
   Hayes, L. D.
TI Distributions of oxytocin and vasopressin 1a receptors in the Taiwan
   vole and their role in social monogamy
SO JOURNAL OF ZOOLOGY
LA English
DT Article
DE Oxytocin; Vasopressin; neuropeptide distribution; mating systems; social
   monogamy; vole; pairing; social behavior
ID PRAIRIE VOLES; MICROTUS-OCHROGASTER; PARTNER PREFERENCE; BINDING-SITES;
   NEUROANATOMICAL DISTRIBUTION; AFFILIATIVE BEHAVIORS; ATTACHMENT;
   DENSITY; SYSTEM; BRAIN
AB Social monogamy is a mating strategy rarely employed by mammalian species. Laboratory studies in socially monogamous prairie voles Microtus ochrogaster demonstrate that oxytocin and vasopressin act within the mesolimbic dopamine pathway to facilitate pair-bond formation. Species differences in oxytocin receptor (OTR) and vasopressin 1a receptor (V1aR) distribution in this pathway are associated with species differences in mating strategy. Here, we characterize the neuroanatomical distribution of OTR and V1aR binding sites in naturally occurring populations of Taiwan voles Microtus kikuchii, which purportedly display social monogamy. Live trapping was conducted at two sites in 2009-2010 and receptor autoradiography for OTR and V1aR was performed on brains from 24 animals. OTR binding in two brain regions where OTR signaling regulates pair-bonding were directly compared with that of prairie voles. Our results show that like prairie voles, Taiwan voles exhibit OTR in the prefrontal cortex, insular cortex, claustrum, nucleus accumbens, caudate-putamen, dorsal lateral septal nucleus, central amygdala and ventromedial hypothalamus. Unlike prairie voles, Taiwan voles exhibit OTR binding in the CA3 field of the hippocampus, as well as the indusium griseum, which has only previously been documented in tuco-tucos Ctenomys haigi, Ctenomys sociabilis, Syrian hamsters Mesocricetus auratus and naked mole-rats Heterocephalus glaber. V1aR binding was present in the ventral pallidum, lateral septum, nucleus basalis, bed nucleus of the stria terminalis, hippocampus, medial amygdala, and anterior, ventromedial and dorsomedial hypothalamus. Marked individual differences in V1aR binding were noted in the cingulate cortex and several thalamic nuclei, remarkably similar to prairie voles. While pharmacological studies are needed to determine whether oxytocin and vasopressin are involved in pair-bond formation in this species, our results lay a foundation for future investigations into the role of these neuropeptides in Taiwan vole social behavior.
C1 [Chappell, A. R.; Hayes, L. D.] Univ Louisiana Monroe, Dept Biol, Monroe, LA USA.
   [Freeman, S. M.; LaPrairie, J. L.; Inoue, K.; Young, L. J.] Emory Univ, Yerkes Natl Primate Res Ctr, Dept Psychiat & Behav Sci, Silvio O Conte Ctr Oxytocin & Social Cognit,Ctr T, Atlanta, GA 30322 USA.
   [Freeman, S. M.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.
   [Lin, Y. K.] Natl Taiwan Univ, Coll Life Sci, Dept Life Sci, Taipei 10764, Taiwan.
   [Hayes, L. D.] Univ Tennessee, Dept Biol Geol & Environm Sci, Chattanooga, TN 37403 USA.
RP Hayes, LD (reprint author), Univ Tennessee, Dept Biol Geol & Environm Sci, Chattanooga, TN 37403 USA.
EM loren-hayes@utc.edu
FU National Science Foundation (NSF) Office of International Science and
   Engineering [0901056, 0836799]; Louisiana Board of Regents Pfund [NSF
   0836776]; NSF Eastern Asia and Pacific Summer Institutes [1015256];
   National Institutes of Health [P50MH100023, P51OD011132]; American
   Society of Mammalogists
FX We thank the Endemic Species Alpine Research Station on Hehuanshan,
   Taiwan for providing facilities and equipment to conduct our research,
   Phebe Quan for field assistance and Joydeep Bhattacharjee and David Tao
   for statistical advice. This project was funded by National Science
   Foundation (NSF) Office of International Science and Engineering
   (0901056 to LDH; 0836799 to LJY), Louisiana Board of Regents Pfund (NSF
   0836776 to LDH), NSF Eastern Asia and Pacific Summer Institutes (1015256
   to ARC), National Institutes of Health (P50MH100023 to LJY and
   P51OD011132 to Yerkes National Primate Research Center) and American
   Society of Mammalogists Grant-in-Aid (to ARC).
CR Ahern TH, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.017.2009
   Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007
   Bales KL, 2007, BRAIN RES, V1184, P245, DOI 10.1016/j.brainres.2007.09.087
   Barrett CE, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.73
   Beery AK, 2008, J COMP NEUROL, V507, P1847, DOI 10.1002/cne.21638
   Brashares JS, 2002, J ANIM ECOL, V71, P626, DOI 10.1046/j.1365-2656.2002.00633.x
   Cushing BS, 2001, HORM BEHAV, V39, P48, DOI 10.1006/hbeh.2000.1633
   DUBOISDAUPHIN M, 1992, NEUROREPORT, V3, P797, DOI 10.1097/00001756-199209000-00019
   EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542
   FOLTZ DW, 1981, AM NAT, V117, P665, DOI 10.1086/283751
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   Gillette JR, 2000, ANIM BEHAV, V59, P1241, DOI 10.1006/anbe.2000.1437
   Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Goodson JL, 2003, J COMP NEUROL, V462, P1, DOI 10.1002/cne.10679
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   INSEL TR, 1991, NEUROSCIENCE, V43, P623, DOI 10.1016/0306-4522(91)90321-E
   Jia R, 2008, NEUROPEPTIDES, V42, P525, DOI 10.1016/j.npep.2008.06.001
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Kalamatianos T, 2010, J COMP NEUROL, V518, P1792, DOI 10.1002/cne.22302
   King LB, 2016, BIOL PSYCHIAT, V80, P160, DOI 10.1016/j.biopsych.2015.12.008
   Lack D, 1968, ECOLOGICAL ADAPTATIO
   Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Lim MM, 2004, J COMP NEUROL, V468, P555, DOI 10.1002/cne.10973
   Lu M. S., 1991, THESIS
   Lukas D, 2012, P ROY SOC B-BIOL SCI, V279, P2151, DOI 10.1098/rspb.2011.2468
   Marfori MA, 1997, J MAMMAL, V78, P715, DOI 10.2307/1382930
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Oldfield RG, 2011, PHYSIOL BEHAV, V102, P296, DOI 10.1016/j.physbeh.2010.11.022
   Ophir AG, 2008, P NATL ACAD SCI USA, V105, P1249, DOI 10.1073/pnas.0709116105
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Paxinos G, 2006, RAT BRAIN STEREOTAXI
   PERRONE M JR, 1978, Environmental Biology of Fishes, V3, P193, DOI 10.1007/BF00691943
   Phelps SM, 2003, J COMP NEUROL, V466, P564, DOI 10.1002/cne.10902
   RIBBLE DO, 1991, BEHAV ECOL SOCIOBIOL, V29, P161, DOI 10.1007/BF00166397
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Schamel D, 2004, BEHAV ECOL SOCIOBIOL, V57, P110, DOI 10.1007/s00265-004-0825-2
   Schorscher-Petcu A, 2009, NEUROSCI LETT, V461, P217, DOI 10.1016/j.neulet.2009.06.016
   Smith AS, 2010, HORM BEHAV, V57, P255, DOI 10.1016/j.yhbeh.2009.12.004
   Solomon NG, 2009, MOL ECOL, V18, P4680, DOI 10.1111/j.1365-294X.2009.04361.x
   Solomon NG, 2004, CAN J ZOOL, V82, P1667, DOI 10.1139/Z04-142
   Streatfeild CA, 2011, ANIM BEHAV, V82, P1387, DOI 10.1016/j.anbehav.2011.09.023
   Turner LM, 2010, MOL BIOL EVOL, V27, P1269, DOI 10.1093/molbev/msq013
   While GM, 2009, BEHAV ECOL, V20, P245, DOI 10.1093/beheco/arp015
   Wu J., 2007, THESIS
   Wu JS, 2012, ZOOL STUD, V51, P204
   Wu P. J., 1998, THESIS
   Wu RY, 2011, J COMP PHYSIOL A, V197, P267, DOI 10.1007/s00359-010-0609-2
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
   YU HT, 1994, J ZOOL, V234, P577
   Zhao Y., 2002, ACTA ZOOL SINICA, V48, P167
NR 55
TC 0
Z9 0
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-8369
EI 1469-7998
J9 J ZOOL
JI J. Zool.
PD JUN
PY 2016
VL 299
IS 2
BP 106
EP 115
DI 10.1111/jzo.12332
PG 10
WC Zoology
SC Zoology
GA DP5OJ
UT WOS:000378546600005
PM 27453637
ER

PT J
AU Fuzesi, T
   Daviu, N
   Cusulin, JIW
   Bonin, RP
   Bains, JS
AF Fuzesi, Tamas
   Daviu, Nuria
   Cusulin, Jaclyn I. Wamsteeker
   Bonin, Robert P.
   Bains, Jaideep S.
TI Hypothalamic CRH neurons orchestrate complex behaviours after stress
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CENTRAL AMYGDALA; RAT; STIMULATION; OXYTOCIN; BRAIN; ORGANIZATION;
   RESPONSES; CIRCUITS; CELLS; LINES
AB All organisms possess innate behavioural and physiological programmes that ensure survival. In order to have maximum adaptive benefit, these programmes must be sufficiently flexible to account for changes in the environment. Here we show that hypothalamic CRH neurons orchestrate an environmentally flexible repertoire of behaviours that emerge after acute stress in mice. Optical silencing of CRH neurons disrupts the organization of individual behaviours after acute stress. These behavioural patterns shift according to the environment after stress, but this environmental sensitivity is blunted by activation of PVN CRH neurons. These findings provide evidence that PVN CRH cells are part of a previously unexplored circuit that matches precise behavioural patterns to environmental context following stress. Overactivity in this network in the absence of stress may contribute to environmental ambivalence, resulting in context-inappropriate behavioural strategies.
C1 [Fuzesi, Tamas; Daviu, Nuria; Cusulin, Jaclyn I. Wamsteeker; Bains, Jaideep S.] Univ Calgary, Hotchkiss Brain Inst, Cumming Sch Med, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Bonin, Robert P.] Univ Toronto, Leslie Dan Sch Pharm, 144 Coll St, Toronto, ON M5S 3M2, Canada.
RP Bains, JS (reprint author), Univ Calgary, Hotchkiss Brain Inst, Cumming Sch Med, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM jsbains@ucalgary.ca
FU Hotchkiss Brain Institute in creating the HBI Advance Light and
   Optogenetics core facility; Canadian Institutes for Health Research
   [CIHR 86501]; Brain Canada; Alberta Innovates-Health Solutions (AIHS);
   UCalgary Eyes High Fellowship; AIHS; HBI (Fong Award)
FX We thank Dinara Baimoukhametova, Cheryl Sank, Mio Tsutsui and Rodney
   Barasi for technical assistance with tissue processing, behavioural
   assessment and mouse colony maintenance. We are grateful to Drs Wataru
   Inoue and Carlo Cusulin for critical comments and also thank Amy Li and
   Alexander Morley for assisting with immunohistochemistry and cell
   counts. We acknowledge Dr Karl Deisseroth for kindly providing the virus
   constructs. We are grateful for the support of the Hotchkiss Brain
   Institute in creating the HBI Advance Light and Optogenetics core
   facility. This research was funded by operating grants to J.S.B. from
   the Canadian Institutes for Health Research (CIHR 86501) and Brain
   Canada. T.F. was supported by a Fellowship from Alberta Innovates-Health
   Solutions (AIHS). N.D. is supported by a UCalgary Eyes High Fellowship.
   J.I.W.C. was supported by studentships from AIHS and the HBI (Fong
   Award).
CR Ahmari SE, 2013, SCIENCE, V340, P1234, DOI 10.1126/science.1234733
   American Psychiatric Association, DIAGN STAT MAN MENT
   Blanchard DC, 2011, NEUROSCI BIOBEHAV R, V35, P991, DOI 10.1016/j.neubiorev.2010.10.016
   Blanchard D. C., 2005, CURR PROTOC NEUROSCI, DOI DOI 10.1002/0471142301.NS0819S30
   Bressers WMA, 1995, BEHAV NEUROSCI, V109, P1158, DOI 10.1037//0735-7044.109.6.1158
   BRESSERS WMA, 1995, BEHAV NEUROSCI, V109, P955, DOI 10.1037/0735-7044.109.5.955
   Cannon W. B., 1915, BODILY CHANGES PAIN
   Chow BY, 2010, NATURE, V463, P98, DOI 10.1038/nature08652
   Ciocchi S, 2015, SCIENCE, V348, P560, DOI 10.1126/science.aaa3245
   Wamsteeker Cusulin JI, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064943, DOI 10.1371/J0URNAL.P0NE.0064943]
   Denver RJ, 2009, ANN NY ACAD SCI, V1163, P1, DOI 10.1111/j.1749-6632.2009.04433.x
   Dietrich MO, 2015, CELL, V160, P1222, DOI 10.1016/j.cell.2015.02.024
   Droste SK, 2008, ENDOCRINOLOGY, V149, P3244, DOI 10.1210/en.2008-0103
   Dunn AJ, 1999, BRAIN RES, V845, P14, DOI 10.1016/S0006-8993(99)01912-5
   Felix-Ortiz AC, 2014, J NEUROSCI, V34, P586, DOI 10.1523/JNEUROSCI.4257-13.2014
   Henson SM, 2012, J BIOL DYNAM, V6, P17, DOI 10.1080/17513758.2011.605913
   Hong WZ, 2014, CELL, V158, P1348, DOI 10.1016/j.cell.2014.07.049
   Hrabovszky E, 2005, ENDOCRINOLOGY, V146, P341, DOI 10.1210/en.2004-0856
   Hull C, 2009, J NEUROSCI, V29, P8991, DOI 10.1523/JNEUROSCI.5717-08.2009
   Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379
   Jennings JH, 2015, CELL, V160, P516, DOI 10.1016/j.cell.2014.12.026
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kruk MR, 1998, NEUROSCI BIOBEHAV R, V23, P163, DOI 10.1016/S0149-7634(98)00018-9
   LAMMERS JHCM, 1987, BRAIN RES, V418, P1, DOI 10.1016/0006-8993(87)90956-5
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Mongeau R, 2003, J NEUROSCI, V23, P3855
   Nieh EH, 2015, CELL, V160, P528, DOI 10.1016/j.cell.2015.01.003
   Petreanu L, 2009, NATURE, V457, P1142, DOI 10.1038/nature07709
   RHO JH, 1987, BRAIN RES, V436, P143, DOI 10.1016/0006-8993(87)91566-6
   Rodaros D, 2007, NEUROSCIENCE, V150, P8, DOI 10.1016/j.neuroscience.2007.09.043
   Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0
   Singer HS, 2009, SEMIN PEDIATR NEUROL, V16, P77, DOI 10.1016/j.spen.2009.03.008
   SPRUIJT BM, 1992, PHYSIOL REV, V72, P825
   Sternson SM, 2013, NEURON, V77, P810, DOI 10.1016/j.neuron.2013.02.018
   Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
   SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454
   Taniguchi H, 2011, NEURON, V71, P995, DOI 10.1016/j.neuron.2011.07.026
   Tinbergen N., 1989, STUDY INSTINCT
   Troisi Alfonso, 2002, Stress, V5, P47, DOI 10.1080/102538902900012378
   VANERP AMM, 1995, PHYSIOL BEHAV, V57, P887, DOI 10.1016/0031-9384(94)00335-3
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   Wiltschko AB, 2015, NEURON, V88, P1121, DOI 10.1016/j.neuron.2015.11.031
   Witten IB, 2011, NEURON, V72, P721, DOI 10.1016/j.neuron.2011.10.028
   Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936
NR 44
TC 2
Z9 2
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2016
VL 7
AR 11937
DI 10.1038/ncomms11937
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DP9KI
UT WOS:000378814700001
PM 27306314
ER

PT J
AU Wade, M
   Hoffmann, TJ
   Knafo-Noam, A
   O'Connor, TG
   Jenkins, JM
AF Wade, Mark
   Hoffmann, Thomas J.
   Knafo-Noam, Ariel
   O'Connor, Thomas G.
   Jenkins, Jennifer M.
TI Oxytocin and vasopressin hormone genes in children's externalizing
   problems: A cognitive endophenotype approach
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Externalizing problems; Oxytocin; Vasopressin; Molecular genetic; Theory
   of mind; Executive functioning; Endophenotype
ID GENOME-WIDE ASSOCIATION; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;
   DEFICIT HYPERACTIVITY DISORDER; ANXIETY-RELATED BEHAVIOR; ONSET MOOD
   DISORDERS; EXECUTIVE FUNCTION; CONDUCT DISORDER; PRION PROTEIN;
   INDIVIDUAL-DIFFERENCES; QUANTITATIVE TRAITS
AB Externalizing problems are among the most common mental health problems of children. Research suggests that these problems are heritable, yet little is known about the specific genes involved in their pathophysiology. The current study examined a genotype-endophenotype-phenotype model of externalizing problems in 320 preschool-aged children. Markers of the oxytocin (OXT) and arginine vasopressin (AVP) hormone genes were selected as candidates owing to their known association with psychopathology in other domains. We tested whether OXT and AVP variants were related to children's externalizing problems, as well as two cognitive endophenotypes presumed to underlie these problems: theory of mind (ToM) and executive functioning (EF). Externalizing problems were assessed at age 4.5 using a previously-validated rating scale. ToM and EF were measured with age-appropriate tasks. Using a family-based association design and controlling for non-genomic confounds, support was found for an association between a two-marker OXT haplotype (rs2740210-rs2770378) and a two-marker AVP haplotype (rs1887854-rs3761249) and externalizing problems. Specific associations of these haplotypes with ToM and EF were also observed. Further, ToM and EF were shown to independently and jointly predict externalizing problems, and to partially mediate the effects of OXT and AVP on externalizing problems. This study provides the first evidence that genetic variation in OXT and AVP may contribute to individual differences in childhood externalizing problems, and that these effects may operate through emerging neurocognitive abilities in the preschool period. (C). 2016 Elsevier Inc. All rights reserved.
C1 [Wade, Mark; Jenkins, Jennifer M.] Univ Toronto, Dept Appl Psychol & Human Dev, 252 Bloor St West, Toronto, ON M5S 1V6, Canada.
   [Hoffmann, Thomas J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Hoffmann, Thomas J.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
   [Knafo-Noam, Ariel] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.
   [O'Connor, Thomas G.] Univ Rochester, Dept Psychiat, Rochester, NY 14627 USA.
RP Jenkins, JM (reprint author), Univ Toronto, Dept Appl Psychol & Human Dev, 252 Bloor St West, Toronto, ON M5S 1V6, Canada.
EM m.wade@utoronto.ca; jenny.jenkins@utoronto.ca
FU Canadian Institutes of Health Research [70334]
FX We are grateful to the families who give so generously of their time, to
   the Hamilton and Toronto Public Health Units for facilitating
   recruitment of the sample, and to Mira Boskovic for project management.
   The grant 'Transactional Processes in Emotional and Behavioral
   Regulation: Individuals in Context' was awarded to Jennifer M. Jenkins
   and Michael Boyle from the Canadian Institutes of Health Research
   (Funding Reference #70334) and covered data collection. The study team,
   beyond the current authors includes: Cathy Barr, Kathy Georgiades, Greg
   Moran, Michal Perlman, Hildy Ross, and Louis Schmidt.
CR Allen-Brady K, 2009, MOL PSYCHIATR, V14, P590, DOI 10.1038/mp.2008.14
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Beitchman JH, 2012, EUR CHILD ADOLES PSY, V21, P125, DOI 10.1007/s00787-012-0240-6
   Benke KS, 2014, J AM ACAD CHILD PSY, V53, P667, DOI 10.1016/j.jaac.2013.12.028
   Bernier A, 2012, DEVELOPMENTAL SCI, V15, P12, DOI 10.1111/j.1467-7687.2011.01093.x
   Bisceglia R, 2014, INFANT CHILD DEV, V23, P249, DOI 10.1002/icd.1866
   BOYLE MH, 1993, J CHILD PSYCHOL PSYC, V34, P189, DOI 10.1111/j.1469-7610.1993.tb00979.x
   Bunck M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005129
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Caspi A, 2008, ARCH GEN PSYCHIAT, V65, P203, DOI 10.1001/archgenpsychiatry.2007.24
   Cohen J., 2013, APPL MULTIPLE REGRES
   Comings DE, 2000, CLIN GENET, V58, P31, DOI 10.1034/j.1399-0004.2000.580106.x
   Criado JR, 2005, NEUROBIOL DIS, V19, P255, DOI 10.1016/j.nbd.2004.01.001
   Croes EA, 2003, ANN NEUROL, V54, P275, DOI 10.1002/ana.10658
   Cuthbert BN, 2014, PSYCHOPHYSIOLOGY, V51, P1205, DOI 10.1111/psyp.12342
   Deater-Deckard K, 2012, J CHILD PSYCHOL PSYC, V53, P1084, DOI 10.1111/j.1469-7610.2012.02582.x
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   Dempster EL, 2009, EUR J NEUROSCI, V30, P1615, DOI 10.1111/j.1460-9568.2009.06930.x
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Dunn L. M., 1997, PEABODY PICTURE VOCA
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   Ensink K, 2016, CAN J BEHAV SCI, V48, P9, DOI 10.1037/cbs0000030
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Fahie CM, 2003, J APPL DEV PSYCHOL, V24, P51, DOI 10.1016/S0193-3973(03)00024-8
   Faraone SV, 2005, BIOL PSYCHIAT, V57, P1313, DOI 10.1016/j.biopsych.2004.11.024
   Farrant B.M., 2014, CHILD DEV RES, V2014
   Frick PJ, 2012, ANNU REV CLIN PSYCHO, V8, P77, DOI 10.1146/annurev-clinpsy-032511-143150
   Gabreels BATF, 1998, J CLIN ENDOCR METAB, V83, P591, DOI 10.1210/jc.83.2.591
   Gatt Justine M., 2007, Journal of Integrative Neuroscience, V6, P75, DOI 10.1142/S0219635207001398
   Gaustella AJ, 2012, HORM BEHAV, V61, P410
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goos LM, 2009, AM J PSYCHIAT, V166, P711, DOI 10.1176/appi.ajp.2009.08040621
   Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636
   Hardiman A, 2005, J MOL ENDOCRINOL, V34, P739, DOI 10.1677/jme.1.01812
   Hovey D, 2014, SOC NEUROSCI-UK, V9, P378, DOI 10.1080/17470919.2014.897995
   Hughes C, 2006, J CHILD PSYCHOL PSYC, V47, P488, DOI 10.1111/j.1469-7610.2005.01519.x
   Jonas W, 2013, GENES BRAIN BEHAV, V12, P681, DOI 10.1111/gbb.12069
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P242, DOI 10.1046/j.1365-2826.2003.00978.x
   Kachiwala SJ, 2005, NEUROSCI LETT, V386, P116, DOI 10.1016/j.neulet.2005.05.067
   Kebir O, 2011, EUR ARCH PSY CLIN N, V261, P583, DOI 10.1007/s00406-011-0207-5
   Kessler MS, 2007, EUR J NEUROSCI, V26, P2857, DOI 10.1111/j.1460-9568.2007.05917.x
   Kim-Cohen J, 2003, ARCH GEN PSYCHIAT, V60, P709, DOI 10.1001/archpsyc.60.7.709
   Kimhi Y, 2014, J AUTISM DEV DISORD, V44, P2341, DOI 10.1007/s10803-014-2104-z
   Laird NM, 2008, ADV GENET, V60, P219, DOI 10.1016/S0065-2660(07)00410-5
   Lange C, 2002, AM J HUM GENET, V71, P1330, DOI 10.1086/344696
   Lasky-Su J, 2008, AM J MED GENET B, V147B, P1345, DOI 10.1002/ajmg.b.30867
   Lee A.G., 2011, BIOL LETT
   Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Malik AI, 2014, PSYCHIAT GENET, V24, P201, DOI 10.1097/YPG.0000000000000044
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mick E, 2011, J AM ACAD CHILD PSY, V50, P807, DOI 10.1016/j.jaac.2011.05.001
   Mileva-Seitz V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061443
   Murgatroyd C, 2004, J NEUROSCI, V24, P7762, DOI 10.1523/JNEUROSCI.1614-04.2004
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Olson SL, 2011, DEV PSYCHOPATHOL, V23, P253, DOI 10.1017/S0954579410000775
   Pappa I, 2015, J AM ACAD CHILD PSY, V54, P737, DOI 10.1016/j.jaac.2015.06.004
   Pennington BF, 2006, COGNITION, V101, P385, DOI 10.1016/j.cognition.2006.04.008
   Plomin R, 2013, CHILD DEV, V84, P104, DOI 10.1111/j.1467-8624.2012.01757.x
   Preacher KJ, 2011, PSYCHOL METHODS, V16, P93, DOI 10.1037/a0022658
   Raaijmakers MAJ, 2008, J ABNORM CHILD PSYCH, V36, P1097, DOI 10.1007/s10802-008-9235-7
   REED MA, 1984, MERRILL PALMER QUART, V30, P131
   Ren DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125775
   Ren DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111638
   Rommelse NNJ, 2008, PSYCHOL MED, V38, P1595, DOI 10.1017/S0033291708002869
   Salatino-Oliveira A, 2015, AM J MED GENET B, V168, P162, DOI 10.1002/ajmg.b.32293
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Slutske WS, 1997, J ABNORM PSYCHOL, V106, P266, DOI 10.1037/0021-843X.106.2.266
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Strauss JS, 2010, PSYCHONEUROENDOCRINO, V35, P1422, DOI 10.1016/j.psyneuen.2010.04.008
   Teltsh O, 2012, INT J NEUROPSYCHOPH, V15, P309, DOI 10.1017/S1461145711001374
   Thapar A, 2001, BRIT J PSYCHIAT, V179, P224, DOI 10.1192/bjp.179.3.224
   Uhl GR, 2008, ARCH GEN PSYCHIAT, V65, P345, DOI 10.1001/archpsyc.65.3.345
   Vacher CM, 2002, J NEUROSCI, V22, P1513
   Vansteelandt S, 2009, GENET EPIDEMIOL, V33, P394, DOI 10.1002/gepi.20393
   Vargas-Pinilla P, 2015, P NATL ACAD SCI USA, V112, P88, DOI 10.1073/pnas.1419399112
   Viding E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065789
   Wade M, 2014, GENES BRAIN BEHAV, V13, P603, DOI 10.1111/gbb.12148
   Wade M., 2015, SOC COGN AFFECT NEUR
   Wade M, 2014, BRAIN COGNITION, V90, P116, DOI 10.1016/j.bandc.2014.06.002
   Wellman HM, 2004, CHILD DEV, V75, P523, DOI 10.1111/j.1467-8624.2004.00691.x
   Xu Y, 2008, J HUM GENET, V53, P637, DOI 10.1007/s10038-008-0292-0
   Young AF, 2006, AUST NZ J PUBL HEAL, V30, P353, DOI 10.1111/j.1467-842X.2006.tb00849.x
   Yuan KH, 2000, SOCIOL METHODOL, V30, P165
   Zelazo PD, 2006, NAT PROTOC, V1, P297, DOI 10.1038/nprot.2006.46
NR 85
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD JUN
PY 2016
VL 82
BP 78
EP 86
DI 10.1016/j.yhbeh.2016.05.002
PG 9
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DP0OB
UT WOS:000378188000009
PM 27155104
ER

PT J
AU Adanu, RMK
AF Adanu, Richard M. K.
TI Announcing the winner of the John J. Sciarra IJGO Prize Paper Award for
   2015
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Editorial Material
ID CESAREAN DELIVERY; CONTROLLED-TRIAL; POSTPARTUM HEMORRHAGE; WOMEN;
   MISOPROSTOL; MANAGEMENT; PREGNANCY; OXYTOCIN; OUTCOMES
CR Chaudhuri P, 2015, INT J GYNECOL OBSTET, V128, P48, DOI 10.1016/j.ijgo.2014.07.029
   Gopimohan R, 2015, INT J GYNECOL OBSTET, V129, P114, DOI 10.1016/j.ijgo.2014.11.023
   Laban M, 2015, INT J GYNECOL OBSTET, V128, P246, DOI 10.1016/j.ijgo.2014.09.018
   Maged AM, 2015, INT J GYNECOL OBSTET, V131, P265, DOI 10.1016/j.ijgo.2015.05.027
   Mazhar SB, 2015, INT J GYNECOL OBSTET, V129, P30, DOI 10.1016/j.ijgo.2014.10.017
   Moini A, 2015, INT J GYNECOL OBSTET, V131, P129, DOI 10.1016/j.ijgo.2015.06.032
   Musa AO, 2015, INT J GYNECOL OBSTET, V129, P227, DOI 10.1016/j.ijgo.2015.01.008
   Okafor II, 2015, INT J GYNECOL OBSTET, V128, P110, DOI 10.1016/j.ijgo.2014.08.015
   Sakhavar N, 2015, INT J GYNECOL OBSTET, V128, P122, DOI [10.1016/j.ijgo.2014.08.020, 10.1016/j.ijgo2014.08.020]
   Topcu HO, 2015, INT J GYNECOL OBSTET, V130, P244, DOI 10.1016/j.ijgo.2015.03.035
   Ukah M, 2015, INT J GYNECOL OBSTET, V131, P41, DOI 10.1016/j.ijgo.2015.05.009
   Zhu YN, 2015, INT J GYNECOL OBSTET, V130, P49, DOI 10.1016/j.ijgo.2015.01.010
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUN
PY 2016
VL 133
IS 3
BP 259
EP 260
DI 10.1016/j.ijgo.2016.03.003
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DO5OZ
UT WOS:000377833800001
PM 27108690
ER

PT J
AU Vlassoff, M
   Diallo, A
   Philbin, J
   Kost, K
   Bankole, A
AF Vlassoff, Michael
   Diallo, Alioune
   Philbin, Jesse
   Kost, Kathryn
   Bankole, Akin
TI Cost-effectiveness of two interventions for the prevention of postpartum
   hemorrhage in Senegal
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE CEA; Cost-effectiveness; Misoprostol; Oxytocin; PPH; Postpartum
   hemorrhage; Senegal
ID COMMUNITY-LEVEL; MISOPROSTOL; TRIAL
AB Objective: To compare, at the community level, the cost-effectiveness of oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH). Methods: The present cost-effectiveness study used data collected during a randomized trial that compared the prophylactic effectiveness of misoprostol and oxytocin for the prevention of PPH in a rural setting in Senegal between June 6 and September 21 2013. The two interventions were compared, with referral to a higher level facility owing to PPH being the outcome measure. The costs and effects were calculated for two hypothetical cohorts of patients delivering during a 1-year period, with each cohort receiving one intervention. A comparison with a third hypothetical cohort receiving the current standard of care was included. A sensitivity analysis was performed to estimate the impact of variations in model assumptions. Results: The cost per PPH referral averted was US$ 38.96 for misoprostol and US$ 119.15 for oxytocin. In all the scenarios modeled the misoprostol intervention dominated, except in the worst-case scenario, where the oxytocin intervention demonstrated slightly better cost-effectiveness. Conclusion: The use of misoprostol for PPH prophylaxis could be cost effective and improve maternal outcomes in low-income settings. (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
C1 [Vlassoff, Michael; Philbin, Jesse; Kost, Kathryn; Bankole, Akin] Guttmacher Inst, 125 Maiden Lane, New York, NY 10038 USA.
RP Vlassoff, M (reprint author), Guttmacher Inst, Div Res, 125 Maiden Lane, New York, NY 10038 USA.
EM mvlassoff@guttmacher.org
FU Gynuity Health Projects through Bill and Melinda Gates Foundation;
   Guttmacher Center for Population Research Innovation and Dissemination
   (NIH grant) [5 R24 HD074034]
FX The study was funded by Gynuity Health Projects through a grant from the
   Bill and Melinda Gates Foundation. Additional support was provided by
   the Guttmacher Center for Population Research Innovation and
   Dissemination (NIH grant 5 R24 HD074034).
CR Agence Nationale de la Statistique et de la Demographie, 2012, DEM HLTH MULT IND CL
   Bradley SEK, 2007, INT J GYNECOL OBSTET, V97, P52, DOI 10.1016/j.ijgo.2006.12.005
   Bruns B, 2007, J TRAUMA, V63, P312, DOI 10.1097/TA.0b013e31812389d6
   Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004
   Diadhiou M, 2011, INT J GYNECOL OBSTET, V115, P251, DOI 10.1016/j.ijgo.2011.08.002
   Diop A, 2016, LANCET GLOB HEALTH, V4, pE37, DOI 10.1016/S2214-109X(15)00219-3
   Gizzo S, 2013, REPROD SCI, V20, P1011, DOI 10.1177/1933719112468951
   Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4
   Hofmeyr GJ, 2013, COCHRANE DB SYST REV, V7
   KNOTTENBELT JD, 1991, J TRAUMA, V31, P1396, DOI 10.1097/00005373-199110000-00015
   Oladapo OT, 2012, INT J GYNECOL OBSTET, V119, P105, DOI 10.1016/j.ijgo.2012.08.004
   Pazarli Pinar, 2007, Tuberk Toraks, V55, P323
   Pichon-Riviere A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129044
   Prata N, 2013, HEALTH POLICY PLANN, V28, P339, DOI 10.1093/heapol/czs068
   Rajaei M, 2014, J PREGNANCY, V2014
   Rath WH, 2011, ACTA OBSTET GYN SCAN, V90, P421, DOI 10.1111/j.1600-0412.2011.01107.x
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Smith JM, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-44
   Stanton CK, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001524
   Sutherland T, 2009, INT J GYNECOL OBSTET, V104, P189, DOI 10.1016/j.ijgo.2008.10.011
   Tuncalp O, 2013, INT J GYNECOL OBSTET, V123, P254, DOI 10.1016/j.ijgo.2013.06.024
   United Nations Department of Economic and Social Affairs Population Division, 2015, WORLD POP PROSP 2015
   WHO UNICEF UNFPA The World Bank and the United Nation Population Division, 2014, TRENDS MAT MORT 1990
   World Health Organization, 2010, WHO CHOOS INT AR COS
   Zelop CM, 2011, OBSTET GYNECOL, V117, P3, DOI 10.1097/AOG.0b013e318202ec9a
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUN
PY 2016
VL 133
IS 3
BP 307
EP 311
DI 10.1016/j.ijgo.2015.10.015
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DO5OZ
UT WOS:000377833800012
PM 26952348
ER

PT J
AU Sujata, N
   Tobin, R
   Kaur, R
   Aneja, A
   Khanna, M
   Hanjoora, VM
AF Sujata, Nambiath
   Tobin, Raj
   Kaur, Ranjeet
   Aneja, Anjila
   Khanna, Mona
   Hanjoora, Vijay M.
TI Randomized controlled trial of tranexamic acid among parturients at
   increased risk for postpartum hemorrhage undergoing cesarean delivery
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Cesarean delivery; High-risk pregnancy; Postpartum hemorrhage;
   Tranexamic acid
ID REDUCING BLOOD-LOSS; OXYTOCIN; SECTION; EFFICACY
AB Objective: To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage. Methods: Between August 1, 2012, and April 30, 2013, a randomized controlled trial was performed at a tertiary care center in India. Women undergoing an elective or emergency cesarean delivery who were at high risk for postpartum hemorrhage were enrolled. They were randomly assigned using sealed, opaque envelopes to receive 10 mg/kg tranexamic acid or normal saline 10 min before skin incision. Anesthesiologists were not masked to group assignment, but patients and obstetricians were. The primary outcome was need for additional uterotonic drugs within 24 h after delivery. Analyses were by intention to treat. Results: Thirty patients were assigned to each group. Additional uterotonic drugs were required in 7 (23%) patients assigned to tranexamic acid and 25 (83%) patients in the control group (P < 0.001). Conclusion: Intravenous tranexamic acid, administered before skin incision, significantly reduced the requirement for additional uterotonics among women at increased risk for postpartum hemorrhage. (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Sujata, Nambiath; Tobin, Raj; Kaur, Ranjeet; Khanna, Mona; Hanjoora, Vijay M.] Max Hosp, Dept Anaesthesia, A 325, New Delhi 110017, India.
   [Aneja, Anjila] Fortis Hosp, Dept Obstet & Gynecol, New Delhi, India.
RP Sujata, N (reprint author), Max Hosp, Dept Anaesthesia, A 325, New Delhi 110017, India.
EM drnambiath@yahoo.com
CR Balki M, 2006, OBSTET GYNECOL, V107, P45, DOI 10.1097/01.AOG.0000191529.52596.c0
   Bhattacharya Susmita, 2013, J Anaesthesiol Clin Pharmacol, V29, P32, DOI 10.4103/0970-9185.105790
   Bouwmeester FW, 2005, CURR PHARM DESIGN, V11, P759, DOI 10.2174/1381612053381882
   Gungorduk K, 2011, AM J PERINAT, V28, P233, DOI 10.1055/s-0030-1268238
   Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1
   Ibrahim SM, 2008, J INT MED RES, V36, P1129
   Lethaby A, 2004, COCHRANE DB SYST REV, V4
   Mayer DC, 2009, CHESTNUTS OBSTET ANE, P811
   Munn MB, 2001, OBSTET GYNECOL, V98, P386, DOI 10.1016/S0029-7844(01)01479-X
   Novikova N, 2015, COCHRANE DB SYST REV, V6
   Peitsidis P, 2011, EXPERT OPIN PHARMACO, V12, P503, DOI 10.1517/14656566.2011.545818
   Sarna MC, 1997, ANESTH ANALG, V84, P753, DOI 10.1097/00000539-199704000-00010
   Sekhavat L, 2009, J MATERN-FETAL NEO M, V22, P72, DOI 10.1080/14767050802353580
   Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5
   Stahl DL, 2012, ANAESTHESIA, V67, P479, DOI 10.1111/j.1365-2044.2011.06916.x
   Walfish M, 2009, BR J ANAESTH S1, V103, pi47, DOI DOI 10.1093/BJA/AEP303
NR 16
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUN
PY 2016
VL 133
IS 3
BP 312
EP 315
DI 10.1016/j.ijgo.2015.09.032
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DO5OZ
UT WOS:000377833800013
PM 26952346
ER

PT J
AU Koga, K
   Yoshinaga, M
   Uematsu, Y
   Nagai, Y
   Miyakoshi, N
   Shimoda, Y
   Fujinaga, M
   Minamimoto, T
   Zhang, MR
   Higuchi, M
   Ohtake, N
   Suhara, T
   Chaki, S
AF Koga, Kazumi
   Yoshinaga, Mitsukane
   Uematsu, Yoshikatsu
   Nagai, Yuji
   Miyakoshi, Naoki
   Shimoda, Yoko
   Fujinaga, Masayuki
   Minamimoto, Takafumi
   Zhang, Ming-Rong
   Higuchi, Makoto
   Ohtake, Norikazu
   Suhara, Tetsuya
   Chaki, Shigeyuki
TI TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand
   for Vasopressin V-1B Receptor
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID PITUITARY-ADRENAL AXIS; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION;
   OXYTOCIN RECEPTOR; RESEARCH TOOLS; BINDING-SITES; V1B RECEPTORS; 1B
   RECEPTOR; RAT-BRAIN; ANTAGONIST
AB A novel pyridopyrimidin-4-one derivative, N-tert-butyl-2-[2-(3methoxyphenyl)- 6-[3-(morpholin-4-yl) propoxy]-4-oxopyrido[2,3d] pyrimidin-3(4H)-yl] acetamide (TASP0434299), was characterized as a radioligand candidate for arginine vasopressin 1B (V-1B) receptor. TASP0434299 exhibited high binding affinities for human and rat V-1B receptors with IC50 values of 0.526 and 0.641 nM, respectively, and potent antagonistic activity at the human V-1B receptor with an IC50 value of 0.639 nM without apparent binding affinities for other molecules at 1 mM. [H-3] TASP0434299 bound to membranes expressing the human V-1B receptor as well as those prepared from the rat anterior pituitary in a saturable manner. The binding of [H-3] TASP0434299 to the membranes was dose-dependently displaced by several ligands for the V-1B receptor. In addition, the intravenous administration of [H-3] TASP0434299 to rats produced a saturable radioactive accumulation in the anterior pituitary where the V-1B receptor is enriched, and it was dosedependently blocked by the oral administration of 2-[2-(3-chloro-4fluorophenyl)- 6-[3-(morpholin-4-yl) propoxy]-4-oxopyrido[2,3-d] pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride, a V-1B receptor antagonist, indicating that [H-3] TASP0434299 can be used as an in vivo radiotracer to measure the occupancy of the V-1B receptor. Finally, the intravenous administration of [C-11] TASP0434299 provided positron emission tomographic images of the V-1B receptor in the pituitary in an anesthetized monkey, and the signal was blocked by pretreatment with an excess of unlabeled TASP0434299. These results indicate that radiolabeled TASP0434299 is the first radioligand to be capable of quantifying the V-1B receptor selectively in both in vitro and in vivo studies and will provide a clinical biomarker for determining the occupancy of the V-1B receptor during drug development or for monitoring the levels of the V-1B receptor in diseased conditions.
C1 [Koga, Kazumi; Uematsu, Yoshikatsu; Chaki, Shigeyuki] Taisho Pharmaceut Co Ltd, Pharmacol Labs, Saitama, Japan.
   [Yoshinaga, Mitsukane; Miyakoshi, Naoki; Ohtake, Norikazu] Taisho Pharmaceut Co Ltd, Chem Labs, Saitama, Japan.
   [Nagai, Yuji; Shimoda, Yoko; Fujinaga, Masayuki; Minamimoto, Takafumi; Zhang, Ming-Rong; Higuchi, Makoto; Suhara, Tetsuya] Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 260, Japan.
RP Chaki, S (reprint author), Taisho Pharmaceut Co Ltd, Kita Ku, 1-403 Yoshino Cho, Saitama, Japan.
EM s-chaki@so.taisho.co.jp
RI Minamimoto, Takafumi/D-6610-2012
OI Minamimoto, Takafumi/0000-0003-4305-0174
FU Taisho Pharmaceutical Co., Ltd.; Japan Agency for Medical Research and
   Development; Ministry of Education, Culture, Sports, Science and
   Technology, Japan [23111009]
FX This study was funded by Taisho Pharmaceutical Co., Ltd. This study was
   supported in part by the Brain Mapping by Integrated Neurotechnologies
   for Disease Studies (to T.S.) from the Japan Agency for Medical Research
   and Development, and by Grants-in-Aid for Scientific Research on
   Innovative Areas [Brain Environment Grant 23111009] (to M.H.) from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan.
CR Aguilera G, 2000, REGUL PEPTIDES, V96, P23, DOI 10.1016/S0167-0115(00)00196-8
   Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   deKeyzer Y, 1996, J CLIN INVEST, V97, P1311, DOI 10.1172/JCI118547
   DUPASQUIER D, 1991, J ENDOCRINOL, V129, P197, DOI 10.1677/joe.0.1290197
   FREUNDMERCIER MJ, 1991, J NEUROENDOCRINOL, V3, P285, DOI 10.1111/j.1365-2826.1991.tb00277.x
   Griebel G, 2012, J CLIN PSYCHIAT, V73, P1403, DOI 10.4088/JCP.12m07804
   Griffante C, 2005, BRIT J PHARMACOL, V146, P744, DOI 10.1038/sj.bjp.0706383
   Guillon G, 2004, J NEUROENDOCRINOL, V16, P356, DOI 10.1111/j.0953-8194.2004.01163.x
   Hargreaves RJ, 2014, NEUROBIOL DIS, V61, P32, DOI 10.1016/j.nbd.2013.08.017
   Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659
   Iijima M, 2014, BRIT J PHARMACOL, V171, P3511, DOI 10.1111/bph.12699
   The Japanese Association for Laboratory Animal Science, 1987, EXP ANIM, V36, P285
   Katz DA, 2016, PSYCHOPHARMACOLOGY, V233, P71, DOI 10.1007/s00213-015-4089-5
   KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0
   Koga K, 2016, EJNMMI RES, V6, DOI 10.1186/s13550-016-0170-2
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0
   LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Manning M, 2008, PROG BRAIN RES, V170, P473, DOI 10.1016/S0079-6123(08)00437-8
   Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037
   Nakamura M, 2006, DRUG METAB DISPOS, V34, P369, DOI 10.1124/dmd.105.006213
   Oshikawa S, 2004, MOL PHARMACOL, V65, P623, DOI 10.1124/mol.65.3.623
   RabadanDiehl C, 1997, ENDOCRINOLOGY, V138, P5189, DOI 10.1210/en.138.12.5189
   Rene P, 2000, GENE, V241, P57, DOI 10.1016/S0378-1119(99)00468-0
   Roper J, 2011, THESIS
   SAITO M, 1995, BIOCHEM BIOPH RES CO, V212, P751, DOI 10.1006/bbrc.1995.2033
   Schonberger M, 2010, BIOORG MED CHEM LETT, V20, P3103, DOI 10.1016/j.bmcl.2010.03.108
   Scott LV, 1998, LIFE SCI, V62, P1985, DOI 10.1016/S0024-3205(98)00027-7
   Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122
   Serradeil-Le Gal C, 2007, AM J PHYSIOL-REG I, V293, pR938, DOI 10.1152/ajpregu.00062.2007
   SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088
   THIBONNIER M, 1994, J BIOL CHEM, V269, P3304
   TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0
   Vaccari C, 1998, ENDOCRINOLOGY, V139, P5015, DOI 10.1210/en.139.12.5015
   Yoshinaga M, 2013, INT, Patent No. PCT/JP2013/066950
   Young WS, 2006, NEUROSCIENCE, V143, P1031, DOI 10.1016/j.neuroscience.2006.08.040
NR 38
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUN
PY 2016
VL 357
IS 3
BP 495
EP 508
DI 10.1124/jpet.116.232942
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DO3OP
UT WOS:000377691200006
PM 27029585
ER

PT J
AU Marnet, PG
   Atigui, M
   Hammadi, M
AF Marnet, Pierre Guy
   Atigui, Moufida
   Hammadi, Mohamed
TI Developing mechanical milking in camels? Some main steps to takeaEuro
   broken vertical bar
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE Milking; Camels; Machine milking; Milk production; Development
ID INTENSIVE FARMING SYSTEM; DAIRY DROMEDARY CAMELS; FLOW TRAITS;
   MACHINE-MILKING; COWS; EJECTION; OXYTOCIN; UDDER; MANAGEMENT; REMOVAL
AB After a first phase of development in the ex-Soviet Union in the 1940s, camel mechanical milking is now developing again in the Arabic peninsula, North and East Africa, Asia, Australia and even in the USA and Europe in a lesser extent, because of the great demand and important health value of camel milk. Nevertheless, such a development remains empirical and uses trial and error methodology, which is generally more time-consuming and more expensive and could create a deadlock in the situation. Nevertheless, developing mechanical milking of camels could be done throughout a step by step well-designed approach rather than this empirical approach. It is the only way to understand the animal/machine interaction and to give us the means to adapt machine milking to the different situations encountered in the world and to animal specificities.
   After describing the different essential and ancillary steps of this development (knowledge of animal physiology, udder and teat shapes, teat functional characteristics, first functional data of milking including teat reaction, milk emission kinetic, efficiency of milk extraction, weaning procedure, milking procedure, milking behavior of animals, adaptation of material and settingsaEuro broken vertical bar), we aim to relate, as example, the first results obtained in Tunisian dromedary camels in the last 4 years as basis for more adapted or even specific materials and setting evolution.
C1 [Marnet, Pierre Guy] AGROCAMPUS OUEST, 65 Rue St Brieuc, F-35042 Rennes, France.
   [Atigui, Moufida; Hammadi, Mohamed] Gabes Univ, Inst Arid Reg, Lab Breeding & Wildlife, Medenine 4119, Tunisia.
RP Marnet, PG (reprint author), AGROCAMPUS OUEST, 65 Rue St Brieuc, F-35042 Rennes, France.
EM marnet@agrocampus-ouest.fr
FU Tunisian and French governmental authorities; European Union; PROCAMED
   project [IB/1.1/493]
FX Many thanks to the Tunisian and French governmental authorities for
   their experimental facilities and financial and technical support, and
   to the European Union and the PROCAMED project IB/1.1/493 for financial
   support for mobility.
CR Allain C., 2010, Rencontres Autour des Recherches sur les Ruminants, V17, P447
   ALSHAIKH MA, 1994, J DAIRY RES, V61, P451
   Atigui M., 2014, 21 RENC AUT RECH RUM, p[21, 340]
   Atigui M., 2014, THESIS, P46
   Atigui M, 2015, TROP ANIM HEALTH PRO, V47, P201, DOI 10.1007/s11250-014-0708-0
   Atigui M, 2014, J DAIRY RES, V81, P494, DOI 10.1017/S002202991400051X
   Atigui M, 2014, J DAIRY RES, V81, P173, DOI 10.1017/S0022029914000089
   Ayadi M, 2004, J DAIRY RES, V71, P304, DOI 10.1017/S0022029904000329
   Ayadi M, 2009, J DAIRY SCI, V92, P1452, DOI 10.3168/jds.2008-1447
   Ayadi M., 2015, P 4 INT SOC CAM RES, P110
   Ayadi M., 2013, SPAN J AGRIC RES, V1, P790
   Ayadi M., 2014, RES SEM INT EL FAUN, P76
   Bava L, 2007, ITAL J ANIM SCI, V6, P500
   Billon P., 1999, MILKING MILK PRODUCT, p[95, 51]
   Borghese A, 2007, ITAL J ANIM SCI, V6, P39
   Boselli C., 2010, REV VET S1, V21, P576
   BRUCKMAIER RM, 1994, J DAIRY RES, V61, P323
   Bruckmaier RM, 1998, J DAIRY SCI, V81, P939
   BRUCKMAIER RM, 1995, J ANIM BREED GENET, V112, P293
   Bruckmaier RM, 1997, J DAIRY RES, V64, P315, DOI 10.1017/S002202999700232X
   Bruckmaier R. M., 2007, J ANIM SCI, V86, P15
   Buchenauer D, 1999, GENETICS OF CATTLE, P365
   Corbet V., 2010, 001031006 I EL
   de Passille AM, 2008, J DAIRY SCI, V91, P1416, DOI 10.3168/jds.2007-0504
   Eisa M. M. O., 2012, THESIS
   GRINDAL RJ, 1991, J DAIRY RES, V58, P383
   Hamann J., 1990, WORLD REV ANIMAL PRO, V15, P17
   Hammadi M., 2010, Journal of Camel Practice and Research, V17, P1
   Hernandez H, 2002, HORM BEHAV, V42, P232, DOI 10.1006/hbeh.2002.1812
   Knight C. H., 1994, Journal of Dairy Science, V77, P84
   Komara M., 2009, Rencontres Autour des Recherches sur les Ruminants, V16, P179
   LABUSSIE.J, 1969, ANN ZOOTECH, V18, P5, DOI 10.1051/animres:19690101
   Labussiere J., 1964, ANN ZOOTECH, V13, P199, DOI 10.1051/animres:19640207
   LABUSSIERE J, 1988, LIVEST PROD SCI, V18, P253, DOI 10.1016/0301-6226(88)90035-8
   Labussiere J., 1983, 3 INT S MACH MILK SM, P780
   Marnet PG, 2008, J ANIM SCI, V86, P47, DOI 10.2527/jas.2007-0285
   Marnet PG, 2001, LIVEST PROD SCI, V70, P125, DOI 10.1016/S0301-6226(01)00205-6
   Marnet PG, 1999, EAAP PUBLIC, P41
   Marnet PG, 2000, REPROD NUTR DEV, V40, P271, DOI 10.1051/rnd:2000131
   Marnet P. G., 1996, P S MILK SYNTH SECR, P114
   Marnet P.G., 2001, RENC RECH RUMIN, V8, P321
   Martinet J., 1963, P S 1 MACH MILK HAMR, P114
   Weber F., 1989, P 4 INT S MACH MILK, P564
   McKusick BC, 2002, J DAIRY SCI, V85, P2521, DOI 10.3168/jds.S0022-0302(02)74335-X
   Mein G., 2003, IDF S 100 YEARS LIN
   MOCQUOT J C, 1974, Annales de Genetique et de Selection Animale, V6, P463, DOI 10.1186/1297-9686-6-4-463
   Nagy P., 2015, P 4 INT SOC CAM RES, P134
   Rasmussen MD, 2000, J DAIRY SCI, V83, P77
   Salimei E., 2013, Milk and dairy products in human nutrition: production, composition and health, P594
   Sandrucci A, 2007, J DAIRY SCI, V90, P1159
   Shehadeh K., 2014, Scientific Journal of Review, V3, P1004
   SPENCER SB, 1991, J DAIRY SCI, V74, P429
   Stelwagen K., 2001, J DAIRY SCI, V84, P204
   Tancin V, 2007, CZECH J ANIM SCI, V52, P117
   Tancin V, 2006, J DAIRY SCI, V89, P978
   Tancin V, 2001, VET MED-CZECH, V46, P108
   Uppal S.K., 1994, BUFFALO J, V2, P125
   Vanbergue E., 2013, 20 RENC AUT RECH RUM, V20, P281
   Wellnitz O, 2001, LIVEST PROD SCI, V70, P135
   Wernery U, 2004, J CAMEL PRACT RES, V11, P51
   Wilde C. J., 1996, PROGR DAIRY SCI, P311
NR 61
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
EI 1573-7438
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD JUN
PY 2016
VL 48
IS 5
BP 889
EP 896
DI 10.1007/s11250-016-1024-7
PG 8
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA DO5EP
UT WOS:000377806700003
PM 26936275
ER

PT J
AU Atigui, M
   Marnet, PG
   Harrabi, H
   Bessalah, S
   Khorchani, T
   Hammadi, M
AF Atigui, Moufida
   Marnet, Pierre-Guy
   Harrabi, Hager
   Bessalah, Salma
   Khorchani, Touhami
   Hammadi, Mohamed
TI Relationship between external and internal udder and teat measurements
   of machine milked dromedary camels
SO TROPICAL ANIMAL HEALTH AND PRODUCTION
LA English
DT Article
DE Ultrasonography; Udder measurements; Milk partitioning; Camels
ID DAIRY-COWS; CISTERNAL MILK; MORPHOLOGY TRAITS; FLOW TRAITS; LACTATION;
   EJECTION; INTERVAL; SYSTEM; SHEEP; SIZE
AB This study aims to determine the relationship between internal and external udder and teat measurements and evaluate their correlation with milk yield and milk partitioning in the udder of dromedary camels. Six Maghrebi camels reared under intensive conditions were monitored at early, middle, and late lactation. Udder measurements included udder depth, udder horizontal circumference, fore and rear teat length and diameter. Besides, scans of the left fore and rear quarters were taken in duplicate before morning milking (16 h) using an oxytocin receptor blocking agent (Atosiban) to determine teat and gland distension before milk ejection. Cisternal and alveolar milk volumes were then evaluated. Correlation coefficients were calculated between the performed udder external and ultrasonographical measurements and cisternal and daily milk production on the measurement day. Significant effect of lactation stage was observed in all measured traits. All internal and external measurements decreased significantly at late lactation as well as cisternal and total milk yield. The quarter cisternal area averaged 16.3 +/- 2.2 cm(2) and decreased about three times at late lactation compared to early and middle lactation. All external and internal measurements were positively and highly correlated (P < 0.001). The knowledge of the relationship between udder internal and external morphological traits would permit to predict udder cisternal storage capacity and can ultimately be adopted to improve milk storage capacity of dromedary camels.
C1 [Atigui, Moufida; Harrabi, Hager; Bessalah, Salma; Khorchani, Touhami; Hammadi, Mohamed] Univ Gabes, Arid Lands Inst, Livestock & Wildlife Lab, Medenine 4119, Tunisia.
   [Marnet, Pierre-Guy] AGROCAMPUS OUEST, PEGASE UMR1348, F-35042 Rennes, France.
   [Marnet, Pierre-Guy] INRA, PEGASE UMR1348, F-35042 Rennes, France.
RP Atigui, M (reprint author), Univ Gabes, Arid Lands Inst, Livestock & Wildlife Lab, Medenine 4119, Tunisia.
EM atigui2009@gmail.com
FU Tunisian Authority; Foundation L'Oreal/UNESCO for Women in Science;
   French Authority
FX This work was carried out in collaboration between Arid Lands Institute
   (IRESA, Tunisia) and Agrocampus Ouest-INRA (France). Authors would like
   to thank the Tunisian and French Authorities for the financial support
   and Mr Bechir Saafi and Mr Lassaad Khalfalli for their careful
   assistance to animal management. M. A. acknowledges the Foundation
   L'Oreal/UNESCO for Women in Science for financial support (Maghreb
   fellowships L'Oreal-UNESCO for women in science 2015).
CR Abshenas J., 2007, Journal of the Faculty of Veterinary Medicine, University of Tehran, V62, P27
   Al-Saiady M. Y., 2012, Emirates Journal of Food and Agriculture, V24, P85
   Aljumaah RS, 2012, J ANIM VET ADV, V11, P141, DOI 10.3923/javaa.2012.141.147
   ALSHAIKH MA, 1994, J DAIRY RES, V61, P451
   Alwan O. A., 2014, INT J ENG APPL SCI, V4, P1
   Atigui M, 2015, TROP ANIM HEALTH PRO, V47, P201, DOI 10.1007/s11250-014-0708-0
   Atigui M, 2014, J DAIRY RES, V81, P173, DOI 10.1017/S0022029914000089
   Ayadi M, 2003, J DAIRY RES, V70, P1, DOI 10.1017/S0022029902005873
   Ayadi M, 2009, J DAIRY SCI, V92, P1452, DOI 10.3168/jds.2008-1447
   Ayadi M., 2013, SPAN J AGRIC RES, V1, P790
   Babiker WIA, 2014, EMIR J FOOD AGR, V26, P333, DOI 10.9755/ejfa.y26i4.17664
   BRUCKMAIER RM, 1992, J DAIRY RES, V59, P151
   BRUCKMAIER RM, 1994, MILCHWISSENSCHAFT, V49, P543
   Caja G, 2004, J DAIRY SCI, V87, P2409
   Caja G, 2011, P 62 ANN M EAAP STAV, P363
   Eisa M. O., 2009, Pakistan Journal of Nutrition, V8, P1868
   Eisa M. O., 2010, LIVESTOCK RES RURAL, V22, P2010
   Hammadi M., 2010, Journal of Camel Practice and Research, V17, P1
   Ishag I. A., 2011, LIVESTOCK RES RURAL, V23
   KNIGHT CH, 1993, LIVEST PROD SCI, V35, P3, DOI 10.1016/0301-6226(93)90178-K
   KNIGHT CH, 1994, J DAIRY RES, V61, P167
   Lopez-Fontana CM, 2012, REPROD FERT DEVELOP, V24, P704, DOI 10.1071/RD11160
   Marnet P. G., 2015, SCI PRACTICAL J VET, V2, P131
   McKusick B. C., 2000, P 6 GREAT LAK DAIR S
   Milerski M, 2006, CZECH J ANIM SCI, V51, P383
   Molenaar A., 2013, Proceedings of the New Zealand Society of Animal Production, V73, P114
   Musaad A, 2013, TROP ANIM HEALTH PRO, V45, P1039, DOI 10.1007/s11250-012-0331-x
   Nagy P., 2015, P 4 C ISOCARD SILK R, P51
   Nagy P., 2015, P 4 INT SOC CAM RES, P134
   Nickerson S. C., 1992, Machine milking and lactation., P37
   Peris S, 1999, SMALL RUMINANT RES, V33, P171, DOI 10.1016/S0921-4488(99)00017-6
   Pfeilsticker HU, 1996, J DAIRY RES, V63, P509
   Prasad R. M. V., 2010, LIVESTOCK RES RURAL, V22
   ROGERS GW, 1991, J DAIRY SCI, V74, P4189
   Rovai M, 1999, EAAP PUBLIC, P107
   Rovai M, 2004, P 10 GREAT LAK DAIR, P79
   Sadeghi S., 2013, LIVESTOCK RES RURAL, V25
   Stefanon B, 2002, J DAIRY RES, V69, P37, DOI 10.1017/S0022029901005246
   Stelwagen K., 2001, Journal of Dairy Science, V84, pE204
   Szymanowska A., 2010, ANN U M CURIE SKLODO, V27, P36
   Thomas CS, 2004, J DAIRY RES, V71, P162, DOI 10.1017/S0022029904000081
   Weiss D, 2004, J DAIRY SCI, V87, P3280
   Zwertvaegher I, 2012, J DAIRY SCI, V95, P4978, DOI 10.3168/jds.2011-5296
NR 43
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-4747
EI 1573-7438
J9 TROP ANIM HEALTH PRO
JI Trop. Anim. Health Prod.
PD JUN
PY 2016
VL 48
IS 5
BP 935
EP 942
DI 10.1007/s11250-016-1059-9
PG 8
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA DO5EP
UT WOS:000377806700008
PM 27129886
ER

PT J
AU Saxton, A
   Fahy, K
   Hastie, C
AF Saxton, A.
   Fahy, K.
   Hastie, C.
TI Pronurturance Plus at birth: A risk reduction strategy for preventing
   postpartum haemorrhage
SO WOMEN AND BIRTH
LA English
DT Article
DE Theory; Cognitive neuroscience; Mindfulness psychology; Postpartum
   haemorrhage; Third stage of labour
ID TO-SKIN CONTACT; LIFE-THREATENING EVENTS; ATTENTIONAL NETWORKS; HEALTHY
   NEWBORNS; MINDFULNESS; SYSTEM; NEUROSCIENCE; MECHANISM; OXYTOCIN;
   EMOTION
AB Background: Postpartum haemorrhage (PPH) rates continue to rise in the developed world. A recent study found that any skin-to-skin contact and breastfeeding within 30 min of birth was associated with an almost 50% reduction in PPH rates. Improved oxytocin release is the biological reason proposed to explain this. The combination of skin-to-skin contact and breastfeeding within 30 min of birth is termed 'Pronurturance'. Midwifery theory and research claims that optimal third stage care is more holistic than simple Pronurturnace which suggests that further reductions in PPH rates may be possible.
   Question: What can midwives and women do to minimise blood loss in the third and fourth stages of labour?
   Method: We present a new theory that describes and explains how to optimise the woman's reproductive psychophysiology in the third and fourth stages of labour to ensure a well contracted uterus which inhibits excessive bleeding regardless of risk status or whether active management was used. In developing the Pronurturance Plus theory we expand upon what is already known about oxytocin in relation to simple pronurturance to integrate concepts from birth territory theory, cognitive neuroscience, mindfulness psychology and the autonomic nervous system to develop an holistic understanding of how to optimise care and minimise PPH.
   Conclusion: Pronurturance Plus is a psycho-biologically grounded theory which is consistent with existing evidence. It is free, natural and socially desirable. (C) 2015 Australian College of Midwives. Published by Elsevier Ltd. All rights reserved.
C1 [Saxton, A.] So Cross Univ, Sch Hlth & Human Sci, Southern Cross Dr, Bilinga, Qld 4225, Australia.
   [Fahy, K.] So Cross Univ, Gold Coast Campus, Bilinga, Qld 4225, Australia.
   [Hastie, C.] So Cross Univ, Sch Hlth & Human Sci, Locked Bag 4, Coolangatta, Qld 4225, Australia.
RP Saxton, A (reprint author), 17 Cypress Grove, Aberglasslyn, NSW 2320, Australia.
EM Dfars1@pacific.net.au
CR Akerlund A, 1985, ACTA OBSTET GYNECOL, V64, P499
   Andres V, 2011, PEDIATRICS, V127, pE1073, DOI 10.1542/peds.2009-3095
   Arrowsmith S, 2014, J NEUROENDOCRINOL, V26, P356, DOI 10.1111/jne.12154
   Becher JC, 2012, ARCH DIS CHILD-FETAL, V97, pF30, DOI 10.1136/adc.2010.208736
   Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Bystrova K, 2003, ACTA PAEDIATR, V92, P320
   Cacioppo JT, 2007, HANDBOOK OF PSYCHOPHYSIOLOGY, 3RD EDITION, P1, DOI 10.2277/ 0521844711
   Cacioppo JT, 2010, SOC COGNITION, V28, P675
   Cohen N, 2011, EXP PSYCHOL, V58, P171, DOI 10.1027/1618-3169/a000083
   Crenshaw J., 2010, KEEPING MOTHER BABY
   Dixon L, 2013, NZ COLL MIDWIVES J, V28, P15
   Fahy K, 2011, THEORY MIDWIFERY PRA, P215
   Fahy K., 2008, BIRTH TERRITORY MIDW
   Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004
   Fan J, 2004, PSYCHIAT PRAX, V31, pS210, DOI 10.1055/s-2004-828484
   Fulton P, 2013, MINDFULNESS PYSCHOTH, P36
   Gangal P, 2007, BREAST CRAWL
   Germer Christopher K, 2013, MINDFULNESS PSYCHOTH
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Handy TC, 2015, CAN J EXP PSYCHOL, V69, P183, DOI 10.1037/cep0000051
   Hastie C., 2008, PUTTING WOMEN 1 INTE
   Hastie Carolyn, 2009, Women Birth, V22, P89, DOI 10.1016/j.wombi.2009.02.004
   Hugill K., 2015, BR J MIDWIFERY, V23, P238
   Kennell JH, 2003, ACTA PAEDIATR, V92, P272
   Klaus M, 1998, Pediatrics, V102, P1244
   Leon-Cava N, 2002, QUANTIFYING EC BENEF, P1
   Markovic S, 2012, I-PERCEPTION, V3, P1, DOI 10.1068/i0450aap
   Odent M, 2001, INT J GYNECOL OBSTET, V75, pS39, DOI 10.1016/S0020-7292(01)00512-4
   Odent M., 2001, SCI LOVE
   Odent Michel, 2002, Midwifery Today Int Midwife, P9
   Olendzki A., 2013, MINDFULNESS PSYCHOTH, P261
   Pert C., 1999, MOL EMOTION WHY YOU
   Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525
   Phillips R., 2013, NEWBORN INFANT NURSI, V13, P67, DOI DOI 10.1053/J.NAINR.2013.04.001
   Poets A, 2011, PEDIATRICS, V127, pE869, DOI 10.1542/peds.2010-2189
   Posner M. I., 2008, TOPICS INTEGRATIVE N, P31, DOI 10.1017/CBO9780511541681.005
   Posner M.I., 2011, COGNITIVE NEUROSCIEN
   Raffone A, 2010, ZYGON, V45, P627
   Rothbart MK, 2001, DEV COGN NEUROSCI, P353
   Saxton A, 2015, MIDWIFERY IN PRESS
   Saxton A, 2014, WOMEN BIRTH, V27, P250, DOI 10.1016/j.wombi.2014.06.004
   Trevathan W, 2013, EVOLUTION EARLY EXPE, P221
   [World Health Organisation UNICEF], 2009, BAB FRIENDL HOSP IN, P1
   Uvnas-Moberg K, 2005, INT J BEHAV MED, V12, P59, DOI 10.1207/s15327558ijbm1202_3
   Uvnas-Moberg K., 2013, HORMONE CLOSENESS RO, P1
   Uvnas-Moberg K, 2013, EVOLUTION EARLY EXPE, P298
   van den Hurk PAM, 2010, Q J EXP PSYCHOL, V63, P1168, DOI 10.1080/17470210903249365
   Vincent Sarah, 2011, Pract Midwife, V14, P44
   Vincent Sarah, 2011, Pract Midwife, V14, P40
NR 50
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1871-5192
EI 1878-1799
J9 WOMEN BIRTH
JI Women Birth
PD JUN
PY 2016
VL 29
IS 3
BP 279
EP 284
DI 10.1016/j.wombi.2015.11.007
PG 6
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA DO7VI
UT WOS:000377990700017
PM 26724899
ER

PT J
AU Jameson, H
   Bateman, R
   Byrne, P
   Dyavanapalli, J
   Wang, X
   Jain, V
   Mendelowitz, D
AF Jameson, Heather
   Bateman, Ryan
   Byrne, Peter
   Dyavanapalli, Jhansi
   Wang, Xin
   Jain, Vivek
   Mendelowitz, David
TI Oxytocin neuron activation prevents hypertension that occurs with
   chronic intermittent hypoxia/hypercapnia in rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE paraventricular nucleus of hypothalamus; oxytocin; hypoxia
ID OBSTRUCTIVE SLEEP-APNEA; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS;
   BLOOD-PRESSURE; BRAIN-STEM; BAROREFLEX SENSITIVITY; HYPOXIA; MODULATION;
   RESPONSES; NEUROTRANSMISSION; EXPRESSION
AB Hypertension is a common outcome associated with obstructive sleep apnea (OSA), a prevalent yet poorly treated cardiovascular disease. Recent studies showed oxytocin (OXT), released from hypothalamic paraventricular nucleus (PVN) neurons, activates cardiac vagal neurons in the dorsal motor nucleus of the vagus (DMNX) and may blunt cardiovascular responses to stress. This study tests whether the release of OXT from PVN fibers in the DMNX is diminished with chronic intermittent hypoxia-hypercapnia (CIH/H) exposure, an animal model of OSA, and whether activation of PVN OXT neurons restores OXT release in the DMNX and prevents the hypertension resulting from CIH/H. To assess OXT release from PVN fibers, Chinese hamster ovarian (CHO) cells were engineered to be highly sensitive to OXT by stable expression of the human recombinant OXT receptor and the calcium indicator R-GECO1. PVN fibers in the DMNX were selectively photoactivated in vitro by expression of channelrhodopsin. The release of OXT onto CHO cells in the DMNX was blunted in rats exposed to 21 days of CIH/H. Chronic activation of PVN OXT neurons in vivo, using designer receptors exclusively activated by designer drugs, restored the release of OXT onto CHO cells in the DMNX. Chronic PVN OXT neuron activation in vivo also prevented the hypertension that occurred in conscious unrestrained telemetry-equipped sham rats exposed to 3 wk of CIH/H. These results demonstrate that chronic activation of OXT neurons restores the release of OXT from PVN fibers in the DMNX and prevents the hypertension that occurs with 3 wk of CIH/H exposure.
C1 [Jameson, Heather; Bateman, Ryan; Byrne, Peter; Dyavanapalli, Jhansi; Wang, Xin; Mendelowitz, David] George Washington Univ, Dept Physiol & Pharmacol, 2300 I St NW, Washington, DC 20037 USA.
   [Jameson, Heather; Wang, Xin; Mendelowitz, David] George Washington Univ, Inst Biomed Sci, Washington, DC 20037 USA.
   [Jain, Vivek] George Washington Univ, Dept Med, Washington, DC 20037 USA.
RP Mendelowitz, D (reprint author), George Washington Univ, Dept Physiol & Pharmacol, 2300 I St NW, Washington, DC 20037 USA.
EM dmendel@gwu.edu
FU NIH [HL49965, HL59895, HL72006]; AHA
FX This work was supported by NIH grant HL49965, HL59895, and HL72006 to D.
   Mendelowitz and a predoctoral fellowship from the AHA to H. Jameson.
CR Andresen Michael C, 2012, Front Neurosci, V6, P191, DOI 10.3389/fnins.2012.00191
   Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175
   Blume A, 2009, BRAIN RES, V1302, P34, DOI 10.1016/j.brainres.2009.09.047
   Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0
   Carlson JT, 1996, AM J RESP CRIT CARE, V154, P1490
   Choi JW, 2013, J NEUROCHEM, V126, P331, DOI 10.1111/jnc.12308
   Coleman CG, 2010, J NEUROSCI, V30, P12103, DOI 10.1523/JNEUROSCI.3367-10.2010
   Dergacheva O, 2014, HYPERTENSION, V64, P597, DOI 10.1161/HYPERTENSIONAHA.114.03603
   Dyavanapalli J, 2014, J PHYSIOL-LONDON, V592, P2799, DOI 10.1113/jphysiol.2014.273482
   Gamer M, 2012, PSYCHONEUROENDOCRINO, V37, P87, DOI 10.1016/j.psyneuen.2011.05.007
   da Silva AQG, 2011, BRAIN RES, V1368, P231, DOI 10.1016/j.brainres.2010.10.087
   de Oliveira DCG, 2012, HUM PSYCHOPHARM CLIN, V27, P378, DOI 10.1002/hup.2237
   Grippo AJ, 2012, STRESS, V15, P149, DOI 10.3109/10253890.2011.605486
   Grippo AJ, 2009, PSYCHONEUROENDOCRINO, V34, P1542, DOI 10.1016/j.psyneuen.2009.05.017
   Higa-Taniguchi KT, 2009, EXP PHYSIOL, V94, P1103, DOI 10.1113/expphysiol.2009.049262
   Holmes GM, 2013, J PHYSIOL-LONDON, V591, P3081, DOI 10.1113/jphysiol.2013.253732
   Holst S, 2002, AUTON NEUROSCI-BASIC, V99, P85, DOI 10.1016/S1566-0702(02)00134-0
   Kc P, 2010, RESP PHYSIOL NEUROBI, V174, P55, DOI 10.1016/j.resp.2010.08.001
   Kc P, 2010, J PHYSIOL-LONDON, V588, P725, DOI 10.1113/jphysiol.2009.184580
   Knight WD, 2011, AM J PHYSIOL-REG I, V301, pR131, DOI 10.1152/ajpregu.00830.2010
   Lai CJ, 2006, J APPL PHYSIOL, V100, P1974, DOI 10.1152/japplphysiol.01051.2005
   Leung RST, 2009, PROG CARDIOVASC DIS, V51, P324, DOI 10.1016/j.pcad.2008.06.002
   Loke YK, 2012, CIRC-CARDIOVASC QUAL, V5, P720, DOI 10.1161/CIRCOUTCOMES.111.964783
   Marcus NJ, 2010, RESP PHYSIOL NEUROBI, V171, P36, DOI 10.1016/j.resp.2010.02.003
   Parish JM, 2004, MAYO CLIN PROC, V79, P1036
   Petersson M, 2002, PROG BRAIN RES, V139, P281
   Petersson M, 1997, J AUTONOM NERV SYST, V66, P15, DOI 10.1016/S0165-1838(97)00040-4
   Pinol RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112138
   Pinol RA, 2012, J NEUROSCI METH, V210, P238, DOI 10.1016/j.jneumeth.2012.07.022
   Tobin VA, 2007, J PHYSIOL-LONDON, V582, P1337, DOI 10.1113/jphysiol.2007.132639
   Wang J, 2002, NEUROSCIENCE, V111, P699
NR 31
TC 1
Z9 1
U1 1
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD JUN 1
PY 2016
VL 310
IS 11
BP H1549
EP H1557
DI 10.1152/ajpheart.00808.2015
PG 9
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Physiology
GA DN9XQ
UT WOS:000377434400019
PM 27016581
ER

PT J
AU Teng, BL
   Nikolova, VD
   Riddick, NV
   Agster, KL
   Crowley, JJ
   Baker, LK
   Koller, BH
   Pedersen, CA
   Jarstfer, MB
   Moy, SS
AF Teng, Brian L.
   Nikolova, Viktoriya D.
   Riddick, Natallia V.
   Agster, Kara L.
   Crowley, James J.
   Baker, Lorinda K.
   Koller, Beverly H.
   Pedersen, Cort A.
   Jarstfer, Michael B.
   Moy, Sheryl S.
TI Reversal of social deficits by subchronic oxytocin in two autism mouse
   models
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Autism spectrum disorders; Clozapine; Oxytocin; Risperidone;
   Schizophrenia; Sociability
ID RANDOMIZED CONTROLLED-TRIAL; NMDA RECEPTOR HYPOFUNCTION; INTRANASAL
   OXYTOCIN; SPECTRUM DISORDERS; REPETITIVE BEHAVIOR; GENETIC MODEL;
   GLUTAMATE RECEPTORS; PLASMA OXYTOCIN; ANIMAL-MODELS; SCHIZOPHRENIA
AB Social deficits are a hallmark feature of autism spectrum disorder (ASD) and related developmental syndromes. Although there is no standard treatment for social dysfunction, clinical studies have identified oxytocin as a potential therapeutic with prosocial efficacy. We have previously reported that peripheral oxytocin treatment can increase sociability and ameliorate repetitive stereotypy in adolescent mice from the C58/J model of ASD-like behavior. In the present study, we determined that prosocial oxytocin effects were not limited to the adolescent period, since C58/J mice, tested in adulthood, demonstrated significant social preference up to 2 weeks following subchronic oxytocin treatment. Oxytocin was also evaluated in adult mice with underexpression of the N-methyl-D-aspartate receptor NR1 subunit (encoded by Grin1), a genetic model of autism- and schizophrenia-like behavior. Subchronic oxytocin had striking prosocial efficacy in male Grin1 knockdown mice; in contrast, chronic regimens with clozapine (66 mg/kg/day) or risperidone (2 mg/kg/day) failed to reverse deficits in sociability. Neither the subchronic oxytocin regimen, nor chronic treatment with clozapine or risperidone, reversed impaired prepulse inhibition in the Grin1 knockdown mice. Overall, these studies demonstrate oxytocin can enhance sociability in mouse models with divergent genotypes and behavioral profiles, adding to the evidence that this neurohormone could have therapeutic prosocial efficacy across a spectrum of developmental disorders. (C) 2015 The Authors. Published by Elsevier Ltd.
C1 [Teng, Brian L.; Nikolova, Viktoriya D.; Riddick, Natallia V.; Agster, Kara L.; Baker, Lorinda K.; Pedersen, Cort A.; Jarstfer, Michael B.; Moy, Sheryl S.] Univ N Carolina, Sch Med, Carolina Inst Dev Disabil, CB 7146, Chapel Hill, NC 27599 USA.
   [Teng, Brian L.; Jarstfer, Michael B.] Univ N Carolina, Sch Med, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Nikolova, Viktoriya D.; Riddick, Natallia V.; Agster, Kara L.; Baker, Lorinda K.; Pedersen, Cort A.; Moy, Sheryl S.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA.
   [Crowley, James J.; Koller, Beverly H.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   [Teng, Brian L.] Biogen Idec Inc, Corp Strategy Div, Cambridge, MA 02142 USA.
   [Agster, Kara L.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA.
RP Moy, SS (reprint author), Univ N Carolina, Sch Med, Carolina Inst Dev Disabil, CB 7146, Chapel Hill, NC 27599 USA.
EM ssmoy@med.unc.edu
OI Teng, Brian/0000-0002-3721-6732; Crowley, James/0000-0001-9051-1557;
   Baker, Lorinda/0000-0002-4541-5109
FU Department of Defense [AR1002312P1, AR1002312P2, AR100231P3]; National
   Institute for Mental Health [RO1 MH080069, K01 MH094406]; National
   Institute of Child Health & Human Development [P30 HD03110, U54
   HD079124]; Autism Speaks Translational Postdoctoral Fellowship [7952]
FX We sincerely thank Rebecca Dye and Tamara T. Davis for their valuable
   contributions to this research. Support for this project was provided by
   the Department of Defense (AR1002312P1, AR1002312P2, and AR100231P3),
   the National Institute for Mental Health (RO1 MH080069 and K01
   MH094406), and the National Institute of Child Health & Human
   Development (P30 HD03110; U54 HD079124). Dr. Teng was supported by an
   Autism Speaks Translational Postdoctoral Fellowship (#7952). These
   funding sources were not involved in the study design, the collection,
   analysis or interpretation of data, writing of the report, or in the
   decision to submit the article for publication.
CR Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346
   Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   Bales KL, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.117
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   Billingslea EN, 2014, NEUROPSYCHOPHARMACOL, V39, P1603, DOI 10.1038/npp.2014.7
   Bowen MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027237
   Brodkin ES, 2004, BRAIN RES, V1002, P151, DOI 10.1016/j.brainres.2003.12.013
   Budreck EC, 2013, P NATL ACAD SCI USA, V110, P725, DOI 10.1073/pnas.1214718110
   Burnashev N, 2015, CURR OPIN PHARMACOL, V20, P73, DOI 10.1016/j.coph.2014.11.008
   Cacciotti-Saija C, 2015, SCHIZOPHRENIA BULL, V41, P483, DOI 10.1093/schbul/sbu094
   Chadman KK, 2014, EXPERT OPIN DRUG DIS, V9, P1389, DOI 10.1517/17460441.2014.962511
   Chadman KK, 2011, PHARMACOL BIOCHEM BE, V97, P586, DOI 10.1016/j.pbb.2010.09.012
   Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3
   Davis MC, 2013, SCHIZOPHR RES, V147, P393, DOI 10.1016/j.schres.2013.04.023
   Duffney LJ, 2013, J NEUROSCI, V33, P15767, DOI 10.1523/JNEUROSCI.1175-13.2013
   Duncan GE, 2006, PHARMACOL BIOCHEM BE, V85, P481, DOI 10.1016/j.pbb.2006.09.017
   Duncan GE, 2006, PSYCHOPHARMACOLOGY, V184, P190, DOI 10.1007/s00213-005-0214-1
   Duncan GE, 2004, BEHAV BRAIN RES, V153, P507, DOI 10.1016/j.bbr.2004.01.008
   Ernst M, 2006, PSYCHOL MED, V36, P299, DOI 10.1017/S0033291705005891
   Feifel D, 2012, EUR NEUROPSYCHOPHARM, V22, P374, DOI 10.1016/j.euroneuro.2011.09.004
   Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039
   Finlay JM, 2015, BRAIN RES, V1600, P70, DOI 10.1016/j.brainres.2014.10.037
   Fischer-Shofty M, 2013, SCHIZOPHR RES, V146, P357, DOI 10.1016/j.schres.2013.01.006
   Gandal MJ, 2012, GENES BRAIN BEHAV, V11, P740, DOI 10.1111/j.1601-183X.2012.00816.x
   Gould GG, 2011, J NEUROCHEM, V116, P291, DOI 10.1111/j.1471-4159.2010.07104.x
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hall SS, 2012, PSYCHONEUROENDOCRINO, V37, P509, DOI 10.1016/j.psyneuen.2011.07.020
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.bipsych.2006.05.030
   Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310
   Kapur S, 2003, J PHARMACOL EXP THER, V305, P625, DOI 10.1124/jpet.102.046987
   Lee EJ, 2015, CURR OPIN PHARMACOL, V20, P8, DOI 10.1016/j.coph.2014.10.007
   Mahajan R, 2012, PEDIATRICS, V130, pS125, DOI 10.1542/peds.2012-0900J
   Mielnik CA, 2014, GENES BRAIN BEHAV, V13, P592, DOI 10.1111/gbb.12155
   Milenkovic M, 2014, GENES BRAIN BEHAV, V13, P850, DOI 10.1111/gbb.12183
   Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8
   Morales M, 2014, PSYCHOPHARMACOLOGY, V231, P1797, DOI 10.1007/s00213-013-3278-3
   Moy SS, 2008, BEHAV BRAIN RES, V191, P118, DOI 10.1016/j.bbr.2008.03.015
   Moy SS, 2008, BEHAV BRAIN RES, V188, P178, DOI 10.1016/j.bbr.2007.10.029
   Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030
   Moy SS, 2014, BEHAV BRAIN RES, V259, P200, DOI 10.1016/j.bbr.2013.10.052
   Moy SS, 2012, DEV NEUROSCI-BASEL, V34, P159, DOI 10.1159/000337984
   Muehlmann AM, 2012, BEHAV BRAIN RES, V235, P143, DOI 10.1016/j.bbr.2012.07.041
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Pedersen CA, 2014, BRAIN RES, V1580, P102, DOI 10.1016/j.brainres.2014.01.050
   Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027
   Penagarikano O., 2011, CELL, V147, P235
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Penn DL, 2009, SCHIZOPHR RES, V115, P17, DOI 10.1016/j.schres.2009.08.016
   Perez-Costas E, 2008, J NEURAL TRANSM, V115, P745, DOI 10.1007/s00702-007-0004-5
   Peters S, 2014, PSYCHONEUROENDOCRINO, V42, P225, DOI 10.1016/j.psyneuen.2014.01.021
   Ring RH, 2010, NEUROPHARMACOLOGY, V58, P69, DOI [10.1016/j.neuropharm.2009.08.015, 10.1016/j.neuropharm.2009.07.016]
   Roberts DL, 2010, PSYCHIAT RES, V178, P46, DOI 10.1016/j.psychres.2010.04.006
   Ryan BC, 2010, BEHAV BRAIN RES, V208, P178, DOI 10.1016/j.bbr.2009.11.031
   Sanders SJ, 2015, NEURON, V87, P1215, DOI 10.1016/j.neuron.2015.09.016
   Sankoorikal GMV, 2006, BIOL PSYCHIAT, V59, P415, DOI 10.1016/j.biopsych.2005.07.026
   Saunders John A, 2013, Autism Res, V6, P69, DOI 10.1002/aur.1264
   Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201
   Silverman JL, 2012, SCI TRANSL MED, V4, P131
   Sobota R, 2015, BEHAV NEUROSCI, V129, P389, DOI 10.1037/bne0000074
   Spear L P, 2011, DEV COGN NEUROSCI, V1, P392, DOI DOI 10.1016/J.DCN.2011.08
   Suraev AS, 2014, HORM BEHAV, V65, P488, DOI 10.1016/j.yhbeh.2014.03.002
   Tarabeux J, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.52
   Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038
   Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110
   Wadenberg MLG, 2001, NEUROPSYCHOPHARMACOL, V25, P633, DOI 10.1016/S0893-133X(01)00261-5
   West L, 2009, J SPEC PEDIATR NURS, V14, P183, DOI 10.1111/j.1744-6155.2009.00196.x
   Woolley JD, 2014, PSYCHONEUROENDOCRINO, V47, P116, DOI 10.1016/j.psyneuen.2014.04.024
   Yatawara C.J., 2015, MOL PSYCHIAT
   Zeidan-Chulia F., 2014, CELL DEATH DIS, V22, pe1250
NR 71
TC 1
Z9 1
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JUN
PY 2016
VL 105
BP 61
EP 71
DI 10.1016/j.neuropharm.2015.12.025
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DN8EF
UT WOS:000377311300007
PM 26748053
ER

PT J
AU Georgiou, P
   Zanos, P
   Garcia-Carmona, JA
   Hourani, S
   Kitchen, I
   Laorden, ML
   Bailey, A
AF Georgiou, Polymnia
   Zanos, Panos
   Garcia-Carmona, Juan-Antonio
   Hourani, Susanna
   Kitchen, Ian
   Laorden, Maria-Luisa
   Bailey, Alexis
TI Methamphetamine abstinence induces changes in mu-opioid receptor,
   oxytocin and CRF systems: Association with an anxiogenic phenotype
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Methamphetamine withdrawal; Oxytocin; mu-opioid receptor; CRF; Anxiety
ID CONDITIONED PLACE PREFERENCE; INDUCED BEHAVIORAL SENSITIZATION;
   CORTICOTROPIN-RELEASING-FACTOR; MEDIAL PREFRONTAL CORTEX; INDUCED
   REINSTATEMENT; SEEKING BEHAVIOR; LATERAL SEPTUM; UP-REGULATION; HPA
   AXIS; MICE
AB The major challenge in treating methamphetamine addicts is the maintenance of a drug free-state since they experience negative emotional symptoms during abstinence, which may trigger relapse. The neuronal mechanisms underlying long-term withdrawal and relapse are currently not well-understood. There is evidence suggesting a role of the oxytocin (OTR), mu-opioid receptor (MOPr), dopamine D-2 receptor (D2R), corticotropin-releasing factor (CRF) systems and the hypothalamic-pituitary-adrenal (HPA)-axis in the different stages of methamphetamine addiction. In this study, we aimed to characterize the behavioral effects of methamphetamine withdrawal in mice and to assess the modulation of the OTR, MOPr, D2R, CRF and HPA-axis following chronic methamphetamine administration and withdrawal. Tenday methamphetamine administration (2 mg/kg) increased OTR binding in the amygdala, whilst 7 days of withdrawal induced an upregulation of this receptor in the lateral septum. Chronic methamphetamine treatment increased plasma OT levels that returned to control levels following withdrawal. In addition, methamphetamine administration and withdrawal increased striatal MOPr binding, as well as c-Fos(+)/CRF+ neuronal expression in the amygdala, whereas an increase in plasma corticosterone levels was observed following METH administration, but not withdrawal. No differences were observed in the D2R binding following METH administration and withdrawal. The alterations in the OTR, MOPr and CRF systems occurred concomitantly with the emergence of anxiety-related symptoms and the development of psychomotor sensitization during withdrawal. Collectively, our findings indicate that chronic meth amphetamine use and abstinence can induce brain-region specific neuroadaptations of the OTR, MOPr and CRF systems, which may, at least, partly explain the withdrawal-related anxiogenic effects. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Georgiou, Polymnia; Zanos, Panos; Hourani, Susanna; Kitchen, Ian; Bailey, Alexis] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Guildford GU2 7XH, Surrey, England.
   [Garcia-Carmona, Juan-Antonio; Laorden, Maria-Luisa] Univ Murcia, Sch Med, Dept Pharmacol, E-30001 Murcia, Spain.
   [Bailey, Alexis] St Georges Univ London, Inst Med & Biomed Educ, London SW17 0RE, England.
   [Georgiou, Polymnia; Zanos, Panos] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.
RP Bailey, A (reprint author), St Georges Univ London, Inst Med & Biomed Educ, London SW17 0RE, England.
EM abailey@sgul.ac.uk
FU Royal Society grant [RG120556]; Lilia and Charalambos Georgiou;
   Fundacion Seneca, Agencia de Ciencia y Tecnologia de la Region de Murcia
   [15519/FPI/10]
FX Funding for this study was provided by a Royal Society grant (RG120556;
   P.I. Alexis Bailey) and by Lilia and Charalambos Georgiou. JAGC was in
   receipt of a pre-doctoral fellowship from Fundacion Seneca, Agencia de
   Ciencia y Tecnologia de la Region de Murcia (15519/FPI/10). The sponsors
   had no involvement in the design of the study and in the collection,
   analyses and interpretation of the data, nor in the writing of the
   manuscript and the decision to submit this article for publication.
CR Arai S, 2008, NEUROPSYCHOPHARMACOL, V33, P3164, DOI 10.1038/npp.2008.41
   Bale TL, 2002, INTEGR COMP BIOL, V42, P552, DOI 10.1093/icb/42.3.552
   Baracz SJ, 2012, BEHAV BRAIN RES, V228, P185, DOI 10.1016/j.bbr.2011.11.038
   Baracz S. J., 2014, ADDICT BIOL, V21, P316
   Bershad AK, 2015, J CLIN PSYCHOPHARM, V35, P308, DOI 10.1097/JCP.0000000000000314
   Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Chiu CT, 2006, J BIOMED SCI, V13, P797, DOI 10.1007/s11373-006-9102-x
   Clemens KJ, 2007, DRUG ALCOHOL DEPEN, V86, P183, DOI 10.1016/j.drugalcdep.2006.06.004
   Cox BM, 2013, PSYCHONEUROENDOCRINO, V38, P2343, DOI 10.1016/j.psyneuen.2013.05.005
   Craft RM, 2010, PHARMACOL BIOCHEM BE, V96, P402, DOI 10.1016/j.pbb.2010.06.012
   Eslami-Shahrbabaki Mahin, 2015, Addict Health, V7, P37
   Faravelli C, 2012, CURR PHARM DESIGN, V18, P5663
   Forrest Alexandra D, 2014, Curr Behav Neurosci Rep, V1, P100
   Garcia-Carmona JA, 2013, INT J NEUROPSYCHOPH, V16, P1999, DOI 10.1017/S1461145713000588
   Georgiou P, 2015, EUR NEUROPSYCHOPHARM, V25, P2459, DOI 10.1016/j.euroneuro.2015.09.015
   Georgiou P, 2015, ADDICT BIOL, V20, P902, DOI 10.1111/adb.12208
   Gorelick DA, 2008, PSYCHOPHARMACOLOGY, V200, P475, DOI 10.1007/s00213-008-1225-5
   Grace CE, 2010, NEUROTOXICOL TERATOL, V32, P346, DOI 10.1016/j.ntt.2010.01.006
   Han WY, 2014, PHARMACOL BIOCHEM BE, V119, P80, DOI 10.1016/j.pbb.2013.11.014
   Hicks C., 2014, ADDICT BIOL
   Jang CG, 2013, PSYCHOPHARMACOLOGY, V225, P753, DOI 10.1007/s00213-012-2864-0
   King G, 2010, J NEUROIMMUNE PHARM, V5, P582, DOI 10.1007/s11481-010-9206-y
   Kitanaka N, 2010, NEUROCHEM RES, V35, P749, DOI 10.1007/s11064-010-0132-4
   LANDGRAF R, 1981, ENDOKRINOLOGIE, V78, P191
   Lever C, 2006, REV NEUROSCIENCE, V17, P111
   London ED, 2004, ARCH GEN PSYCHIAT, V61, P73, DOI 10.1001/archpsyc.61.1.73
   Lu P, 2010, BEHAV BRAIN RES, V207, P387, DOI 10.1016/j.bbr.2009.10.024
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   Mancino MJ, 2011, AM J DRUG ALCOHOL AB, V37, P131, DOI 10.3109/00952990.2010.543998
   MARTI J, 1993, EUR J PHARMACOL, V236, P295, DOI 10.1016/0014-2999(93)90601-D
   Martin TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034236
   Moffett MC, 2007, PSYCHOPHARMACOLOGY, V190, P171, DOI 10.1007/s00213-006-0625-7
   Nawata Y, 2012, PHARMACOL BIOCHEM BE, V101, P297, DOI 10.1016/j.pbb.2012.01.003
   Panenka WJ, 2013, DRUG ALCOHOL DEPEN, V129, P167, DOI 10.1016/j.drugalcdep.2012.11.016
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   Reeves R, 2003, PHARMACOL BIOCHEM BE, V76, P315, DOI 10.1016/j.pbb.2003.08.003
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   Ron Dorit, 2005, Sci STKE, V2005, pre14, DOI 10.1126/stke.3092005re14
   SARNYAI Z, 1992, NEUROPEPTIDES, V23, P27, DOI 10.1016/0143-4179(92)90006-I
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   SATO M, 1983, BIOL PSYCHIAT, V18, P429
   SATO M, 1992, ANN NY ACAD SCI, V654, P160, DOI 10.1111/j.1749-6632.1992.tb25965.x
   Sheehan TP, 2004, BRAIN RES REV, V46, P71, DOI 10.1016/j.brainresrev.2004.04.009
   Shen XE, 2010, J NEUROSCI RES, V88, P2294, DOI 10.1002/jnr.22386
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   Wang GJ, 2012, MOL PSYCHIATR, V17, P918, DOI 10.1038/mp.2011.86
   Wright S.R., 2015, ADDICT BIOL
   Yamamoto H, 2011, CURR NEUROPHARMACOL, V9, P73, DOI 10.2174/157015911795017056
   Zanos P, 2015, J PHARMACOL EXP THER, V355, P76, DOI 10.1124/jpet.115.225664
   Zanos P, 2015, NEUROSCI LETT, V600, P33, DOI 10.1016/j.neulet.2015.05.054
   Zanos P, 2014, PHARMACOL BIOCHEM BE, V119, P72, DOI 10.1016/j.pbb.2013.05.009
   Zanos P, 2014, NEUROPSYCHOPHARMACOL, V39, P855, DOI 10.1038/npp.2013.285
   Zoicas Iulia, 2014, Neuropsychopharmacology, V39, P3027, DOI 10.1038/npp.2014.156
   Zombeck JA, 2009, PSYCHOPHARMACOLOGY, V201, P589, DOI 10.1007/s00213-008-1327-0
   Zorick T, 2010, ADDICTION, V105, P1809, DOI 10.1111/j.1360-0443.2010.03066.x
   Zorrilla EP, 2014, FRONT NEUROENDOCRIN, V35, P234, DOI 10.1016/j.yfrne.2014.01.001
NR 60
TC 2
Z9 2
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JUN
PY 2016
VL 105
BP 520
EP 532
DI 10.1016/j.neuropharm.2016.02.012
PG 13
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DN8EF
UT WOS:000377311300049
PM 26896754
ER

PT J
AU Meng, XL
   Shen, F
   Li, CL
   Li, YH
   Wang, XW
AF Meng, Xiaolu
   Shen, Fang
   Li, Chunlu
   Li, Yonghui
   Wang, Xuewei
TI Depression-like behaviors in tree shrews and comparison of the effects
   of treatment with fluoxetine and carbetocin
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE Depression-like behaviors; Tree shrews; Uncontrollable foot shocks;
   Chronic unpredictable stress; Carbetocin
ID CHRONIC PSYCHOSOCIAL STRESS; LEARNED HELPLESSNESS; TUPAIA-BELANGERI;
   MAJOR DEPRESSION; SEXUAL-BEHAVIOR; BRAIN OXYTOCIN; MALE-RATS;
   ANTIDEPRESSANT; SYSTEM; VASOPRESSIN
AB Tree shrews, a species phylogenetically close to primates, are regarded as a suitable and naturalistic animal model for depression studies. However, psychological symptoms that are essential for depression diagnosis and treatment, such as helplessness and social withdrawal, have not been studied in this model. Therefore, in this study, we first investigated learned helplessness, social interaction and sucrose preference induced by two chronic stress paradigms: uncontrollable foot shocks (1-week foot shocks) and multiple unpredictable stimuli (1-week foot shocks and 3-week unpredictable stressors) in tree shrews. Our results showed that uncontrollable foot shocks could only induce learned helplessness in animals; whereas animals treated with multiple unpredictable stimuli exhibited more depression-like behaviors including social withdrawal, anhedonia and learned helplessness. These findings suggested that multiple unpredictable stimuli could effectively induce various depression-like behaviors in tree shrews. More importantly, we compared the antidepressant effects of fluoxetine and carbetocin, a long-acting oxytocin analog, on specific depression-like behaviors. Our present data displayed that, compared with fluoxetine, carbetocin was also effective in reversing learned helplessness, elevating sucrose preference and improving social interaction behaviors in depression-like animals. Therefore, carbetocin might be a potential antidepressant with applications in humans. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Meng, Xiaolu; Shen, Fang; Li, Chunlu; Li, Yonghui] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, 16 Lin Cui Rd, Beijing 100101, Peoples R China.
   [Meng, Xiaolu; Li, Chunlu] Univ Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China.
   [Wang, Xuewei] Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD USA.
RP Shen, F (reprint author), Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, 16 Lin Cui Rd, Beijing 100101, Peoples R China.
EM shenf@psych.ac.cn
FU National Basic Research Program [2015CB553501]; National Natural Science
   Foundation [31170988]; Natural Science Foundation Major Research Plan
   program [91332115]; Natural Science Foundation Youth program [31500893];
   Key Laboratory of Mental Health, Institute of Psychology, Chinese
   Academy of Sciences
FX This work was supported by grants from the National Basic Research
   Program Grants (2015CB553501), the National Natural Science Foundation
   (31170988), the Natural Science Foundation Major Research Plan program
   (91332115), the Natural Science Foundation Youth program (31500893) and
   the Key Laboratory of Mental Health, Institute of Psychology, Chinese
   Academy of Sciences.
CR ARLETTI R, 1987, LIFE SCI, V41, P1725, DOI 10.1016/0024-3205(87)90600-X
   Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410
   Branchi I, 2010, PSYCHONEUROENDOCRINO, V35, P743, DOI 10.1016/j.psyneuen.2009.10.016
   CAFFE AR, 1989, J COMP NEUROL, V287, P302, DOI 10.1002/cne.902870304
   CALDWELL JD, 1986, NEUROPEPTIDES, V7, P175, DOI 10.1016/0143-4179(86)90093-4
   Carter C.S., 2002, P299
   CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Catena-Dell'Osso M, 2013, MINI-REV MED CHEM, V13, P2
   Chaviaras S, 2010, PSYCHOPHARMACOLOGY, V210, P35, DOI 10.1007/s00213-010-1815-x
   Chuang JC, 2011, J CLIN INVEST, V121, P2684, DOI 10.1172/JCI57660
   Czeh B, 2006, NEUROPSYCHOPHARMACOL, V31, P1616, DOI 10.1038/sj.npp.1300982
   Dalla C, 2008, NEUROPSYCHOPHARMACOL, V33, P1559, DOI 10.1038/sj.npp.1301533
   De Bonis M, 2012, J MATERN-FETAL NEO M, V25, P732, DOI 10.3109/14767058.2011.587920
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Fan Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2416
   Macedo GVF, 2013, PSYCHOPHARMACOLOGY, V225, P647, DOI 10.1007/s00213-012-2859-x
   Flugge G, 2001, PHYSIOL BEHAV, V73, P293, DOI 10.1016/S0031-9384(01)00450-4
   FOELIX RF, 1987, CELL TISSUE RES, V247, P287
   Fuchs E, 1996, PHARMACOL BIOCHEM BE, V54, P219, DOI 10.1016/0091-3057(95)02166-3
   Furukawa TA, 2011, INT J SOC PSYCHIATR, V57, P501, DOI 10.1177/0020764010371273
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Golden SA, 2011, NAT PROTOC, V6, P1183, DOI 10.1038/nprot.2011.361
   Gulati K., 2015, THER TARGETS NEUROL, V2
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   HUGHES AM, 1987, BRAIN RES, V414, P133, DOI 10.1016/0006-8993(87)91333-3
   Hyttel J., 1994, INT CLIN PSYCHOPHARM
   Kampen M, 2002, STRESS, V5, P36, DOI 10.1080/10253890290012396
   Kramer M, 1999, NEUROSCI BIOBEHAV R, V23, P937, DOI 10.1016/S0149-7634(99)00027-5
   Landry M, 2005, SYNAPSE, V58, P102, DOI 10.1002/syn.20187
   Larsen MH, 2010, J PSYCHIATR RES, V44, P808, DOI 10.1016/j.jpsychires.2010.01.005
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Levis DJ., 1976, LEARNED HELPLESSNESS
   Liberzon I, 1997, NEUROPSYCHOPHARMACOL, V17, P353, DOI 10.1016/S0893-133X(97)00070-5
   LIU SY, 1982, ACTA ZOOL SINICA, V28, P399
   Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234
   Martin R. D., 1968, Zeitschrift fuer Tierpsychologie, V25, P409
   Matsushita H, 2012, NEUROSCIENCE, V200, P13, DOI 10.1016/j.neuroscience.2011.11.001
   Matsuzaki M, 2012, J PHYSIOL SCI, V62, P441, DOI 10.1007/s12576-012-0232-9
   McQuaid RJ, 2014, NEUROSCI BIOBEHAV R, V45, P305, DOI 10.1016/j.neubiorev.2014.07.005
   Melis MR, 2007, EUR J NEUROSCI, V26, P1026, DOI 10.1111/j.1460-9568.2007.05721.x
   Michaelis T, 2001, J PSYCHIAT RES, V35, P231, DOI 10.1016/S0022-3956(01)00025-5
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2002, PROG BRAIN RES, V139, P147
   Ni RJ, 2014, NEUROSCIENCE, V265, P124, DOI 10.1016/j.neuroscience.2014.01.034
   Nowakowska E, 2002, POL J PHARMACOL, V54, P605
   Nutt D, 2007, J PSYCHOPHARMACOL, V21, P461, DOI 10.1177/0269881106069938
   Ohl F, 1999, LAB ANIM, V33, P269, DOI 10.1258/002367799780578237
   Peng YZ, 1991, BIOL CHINESE TREE SH
   PETTY F, 1994, PSYCHIAT RES, V52, P285, DOI 10.1016/0165-1781(94)90074-4
   Poveda A, 2009, J CHEM NEUROANAT, V37, P214, DOI 10.1016/j.jchemneu.2009.03.006
   Radke S, 2014, PSYCHIAT RES, V219, P513, DOI 10.1016/j.psychres.2014.07.011
   Rath W, 2009, EUR J OBSTET GYN R B, V147, P15, DOI 10.1016/j.ejogrb.2009.06.018
   ROTHSCHILD AJ, 1995, AM J PSYCHIAT, V152, P1514
   Rotzinger S, 2010, PEPTIDES, V31, P736, DOI 10.1016/j.peptides.2009.12.015
   Slattery David A, 2010, Pharmaceuticals (Basel), V3, P702
   Tse WS, 2004, J NERV MENT DIS, V192, P260, DOI 10.1097/01.nmd.0000120884.60002.2b
   Turan T, 2013, PSYCHONEUROENDOCRINO, V38, P2890, DOI 10.1016/j.psyneuen.2013.07.017
   Vollmayr B, 2013, CELL TISSUE RES, V354, P171, DOI 10.1007/s00441-013-1654-2
   Wang JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052954
   Wang ZX, 1997, SYNAPSE, V27, P14, DOI 10.1002/(SICI)1098-2396(199709)27:1<14::AID-SYN2>3.0.CO;2-G
   Wu JH, 1999, J PSYCHIAT RES, V33, P17, DOI 10.1016/S0022-3956(98)00041-7
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
NR 64
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD JUN
PY 2016
VL 145
BP 1
EP 8
DI 10.1016/j.pbb.2016.03.006
PG 8
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA DN8JZ
UT WOS:000377326300001
PM 26987370
ER

PT J
AU Kortus, S
   Srinivasan, C
   Forostyak, O
   Ueta, Y
   Sykova, E
   Chvatal, A
   Zapotocky, M
   Verkhratsky, A
   Dayanithi, G
AF Kortus, Stepan
   Srinivasan, Chinnapaiyan
   Forostyak, Oksana
   Ueta, Yoichi
   Sykova, Eva
   Chvatal, Alexandr
   Zapotocky, Martin
   Verkhratsky, Alexei
   Dayanithi, Govindan
TI Physiology of spontaneous [Ca2+](i) oscillations in the isolated
   vasopressin and oxytocin neurones of the rat supraoptic nucleus
SO CELL CALCIUM
LA English
DT Article
DE Hypothalamus; Magnocellular neurosecretory cells; Supraoptic nucleus;
   Vasopressin; Oxytocin; Transgenic rats; Enhanced green fluorescence
   protein; Monomeric red fluorescence protein; Osmoregulation;
   Hyper-osmolarity; Hypo-osmolarity; Dehydration; Lactation; Electrical
   activity; Ca2+ oscillations; Fura-2; Fluorescence spectrofluorimetry;
   Spationtemporal dynamics; Skewness
ID INTRACELLULAR TRANSDUCTION SIGNALS; MAGNOCELLULAR NEURONS;
   HORMONE-RELEASE; NERVE-TERMINALS; NEURAL LOBE; CA2+ INFLUX;
   NEUROHYPOPHYSIS; ACTIVATION; INCREASE; OSMOSENSITIVITY
AB The magnocellular vasopressin (AVP) and oxytocin (OT) neurones exhibit specific electrophysiological behaviour, synthesise AVP and OT peptides and secrete them into the neurohypophysial system in response to various physiological stimulations. The activity of these neurones is regulated by the very same peptides released either somato-dendritically or when applied to supraoptic nucleus (SON) preparations in vitro. The AVP and OT, secreted somato-dendritically (i.e. in the SON proper) act through specific autoreceptors, induce distinct Ca2+ signals and regulate cellular events. Here, we demonstrate that about 70% of freshly isolated individual SON neurones from the adult non-transgenic or transgenic rats bearing AVP (AVP-eGFP) or OT (OT-mRFP1) markers, produce distinct spontaneous [Ca2+](i) oscillations. In the neurones identified (through specific fluorescence), about 80% of AVP neurones and about 60% of OT neurones exhibited these oscillations. Exposure to AVP triggered [Ca2+](i) oscillations in silent AVP neurones, or modified the oscillatory pattern in spontaneously active cells. Hyper-and hypo-osmotic stimuli (325 or 275 mOsmol/l) respectively intensified or inhibited spontaneous [Ca2+](i) dynamics. In rats dehydrated for 3 or 5 days almost 90% of neurones displayed spontaneous [Ca2+](i) oscillations. More than 80% of OT-mRFP1 neurones from 3 to 6-day-lactating rats were oscillatory vs. about 44% (OT-mRFP1 neurones) in virgins. Together, these results unveil for the first time that both AVP and OT neurones maintain, via Ca2+ signals, their remarkable intrinsic in vivo physiological properties in an isolated condition. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kortus, Stepan; Srinivasan, Chinnapaiyan; Forostyak, Oksana; Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
   [Kortus, Stepan; Zapotocky, Martin] Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CR-14220 Prague, Czech Republic.
   [Kortus, Stepan; Zapotocky, Martin] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Salmovska 1, Prague 12000, Czech Republic.
   [Forostyak, Oksana; Sykova, Eva; Chvatal, Alexandr] Charles Univ Prague, Fac Med 2, Dept Neurosci, V Uvalu 84, Prague 15006, Czech Republic.
   [Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan.
   [Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220, Czech Republic.
   [Chvatal, Alexandr] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220, Czech Republic.
   [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, D-4417 Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Verkhratsky, Alexei] Ikerbasque, Basque Fdn Sci, Achucarro Ctr Neurosci, E-48011 Bilbao, Spain.
   [Verkhratsky, Alexei] Univ Basque Country UPV EHU, Dept Neurosci, Leioa, Spain.
   [Verkhratsky, Alexei] CIBERNED, Leioa, Spain.
   [Verkhratsky, Alexei] Univ Nizhny Novgorod, Nizhnii Novgorod 603022, Russia.
   [Dayanithi, Govindan] Univ Montpellier 2, INSERM, Unite Rech U1198, F-34095 Montpellier, France.
   [Dayanithi, Govindan] Ecole Prat Hautes Etud, Sorbonne, F-75014 Paris, France.
RP Dayanithi, G (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.; Verkhratsky, A (reprint author), Univ Manchester, Sch Biol Sci, D-4417 Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM Alexej.Verkhratsky@manchester.ac.uk; gdaya@univ-montp2.fr
RI Zapotocky, Martin/B-8225-2008; Verkhratsky, Alexei/J-4527-2013
OI Zapotocky, Martin/0000-0002-0437-2528; Verkhratsky,
   Alexei/0000-0003-2592-9898
FU Grant Agency of the Czech Republic [14-34077S, GACR P304/12/G069]; Grant
   Agency of Charles University in Prague [GAUK 22214]; FP7 Initial
   Training Network Edu-GLIA program [PITN-GA-2009-237956]; "Advanced
   Bioimaging of Living Tissues" project [CZ.2.16/3.1.00/21527]; European
   Regional Development Fund; Wellcome Trust; Alzheimer's research
   foundation (UK); Ministry of Education and Science of the Russian
   Federation [02.B.49.21.0003]; Lobachevsky State University of Nizhny
   Novgorod [02.B.49.21.0003]; Russian Scientific Foundation [14-15-00633];
   Ministry of Education of the Russian Federation [RFMEFI57814X0079]
FX This work was supported by the grants 14-34077S and GACR P304/12/G069
   from the Grant Agency of the Czech Republic, GAUK 22214 from the Grant
   Agency of Charles University in Prague, and by institutional support
   RVO#67985823. CS and GD were supported in part by the FP7 Initial
   Training Network Edu-GLIA program (PITN-GA-2009-237956). This
   publication is partly a result of the "Advanced Bioimaging of Living
   Tissues" project, registration number #CZ.2.16/3.1.00/21527, which was
   financed from the budget of the European Regional Development Fund and
   public budgets of the Czech Republic through the Operational Programme
   Prague-Competitiveness. AV was supported by the Wellcome Trust, by the
   Alzheimer's research foundation (UK) and by the grant (agreement from
   August 27, 2013 no. 02.B.49.21.0003) between The Ministry of Education
   and Science of the Russian Federation and Lobachevsky State University
   of Nizhny Novgorod, by the grant of the Russian Scientific Foundation
   No14-15-00633 and by the Ministry of Education of the Russian
   Federation, unique identity number RFMEFI57814X0079. Govindan Dayanithi
   belongs to the "Centre National de la Recherche Scientifique-The French
   Ministry of Research and Higher Education-Paris", France. We are
   grateful to Kip Allan Bauersfeld, IEM ASCR, for critical reading and
   helpful comments on the manuscript.
CR BOURQUE CW, 1984, J PHYSIOL-LONDON, V349, P631
   BRETHES D, 1987, P NATL ACAD SCI USA, V84, P1439, DOI 10.1073/pnas.84.5.1439
   CAZALIS M, 1987, J PHYSIOL-LONDON, V390, P55
   CAZALIS M, 1987, J PHYSIOL-LONDON, V390, P71
   CAZALIS M, 1985, J PHYSIOL-LONDON, V369, P45
   Chevaleyre V, 2000, J NEUROSCI, V20, P5813
   Dayanithi G, 1996, J PHYSIOL-LONDON, V490, P713
   Dayanithi G, 2006, CELL CALCIUM, V39, P237, DOI 10.1016/j.ceca.2005.10.011
   DAYANITHI G, 1987, NATURE, V325, P813, DOI 10.1038/325813a0
   Dayanithi G, 2000, EXP PHYSIOL, V85, p75S, DOI 10.1111/j.1469-445X.2000.tb00010.x
   Dayanithi G, 2012, CELL CALCIUM, V51, P293, DOI 10.1016/j.ceca.2012.02.002
   Forostyak O, 2013, STEM CELLS DEV, V22, P1506, DOI 10.1089/scd.2012.0624
   Gouzenes L, 1999, J PHYSIOL-LONDON, V517, P771, DOI 10.1111/j.1469-7793.1999.0771s.x
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HUANG WC, 1982, AM J PHYSIOL, V243, pF553
   Jamen F, 2003, J NEUROENDOCRINOL, V15, P871, DOI 10.1046/j.1365-2826.2003.01075.x
   Katoh A, 2011, ENDOCRINOLOGY, V152, P2768, DOI 10.1210/en.2011-0006
   Knight WD, 2010, AM J PHYSIOL-REG I, V299, pR1232, DOI 10.1152/ajpregu.00066.2010
   Komori Y, 2010, CELL CALCIUM, V48, P324, DOI 10.1016/j.ceca.2010.10.002
   LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275
   Ludwig M, 2005, J PHYSIOL-LONDON, V564, P515, DOI 10.1113/jphysiol.2005.083931
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   MASON WT, 1980, NATURE, V287, P154, DOI 10.1038/287154a0
   Moos F, 1998, ADV EXP MED BIOL, V449, P153
   Moos FC, 1997, NEUROSCIENCE, V77, P993, DOI 10.1016/S0306-4522(96)00536-2
   Moriya T, 2015, CELL CALCIUM, V57, P25, DOI 10.1016/j.ceca.2014.11.003
   NORDMAN JJ, 1986, CELL TISSUE RES, V246, P177
   OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291
   OLIET SHR, 1993, NATURE, V364, P341, DOI 10.1038/364341a0
   Prager-Khoutorsky M, 2010, TRENDS NEUROSCI, V33, P76, DOI 10.1016/j.tins.2009.11.004
   Sabatier N, 1997, J PHYSIOL-LONDON, V503, P253, DOI 10.1111/j.1469-7793.1997.253bh.x
   Sabatier N, 2004, J NEUROENDOCRINOL, V16, P221, DOI 10.1111/j.0953-8194.2004.01155.x
   Sabatier N, 1998, J PHYSIOL-LONDON, V513, P699, DOI 10.1111/j.1469-7793.1998.699ba.x
   Trudel E, 2012, J NEUROENDOCRINOL, V24, P577, DOI 10.1111/j.1365-2826.2012.02298.x
   Ueta Y, 2005, ENDOCRINOLOGY, V146, P406, DOI 10.1210/en.2004-0830
   Ueta Y, 2011, HORM BEHAV, V59, P221, DOI 10.1016/j.yhbeh.2010.12.007
   Viero C, 2006, CELL CALCIUM, V40, P383, DOI 10.1016/j.ceca.2006.04.007
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   WAKERLEY JB, 1978, BRAIN RES, V148, P425, DOI 10.1016/0006-8993(78)90730-8
NR 39
TC 0
Z9 0
U1 10
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
EI 1532-1991
J9 CELL CALCIUM
JI Cell Calcium
PD JUN
PY 2016
VL 59
IS 6
BP 280
EP 288
DI 10.1016/j.ceca.2016.04.001
PG 9
WC Cell Biology
SC Cell Biology
GA DN1ND
UT WOS:000376831800002
PM 27072326
ER

PT J
AU Kortus, S
   Srinivasan, C
   Forostyak, O
   Zapotocky, M
   Ueta, Y
   Sykova, E
   Chvatal, A
   Verkhratsky, A
   Dayanithi, G
AF Kortus, Stepan
   Srinivasan, Chinnapaiyan
   Forostyak, Oksana
   Zapotocky, Martin
   Ueta, Yoichi
   Sykova, Eva
   Chvatal, Alexandr
   Verkhratsky, Alexei
   Dayanithi, Govindan
TI Sodium-calcium exchanger and R-type Ca2+ channels mediate spontaneous
   [Ca2+](i) oscillations in magnocellular neurones of the rat supraoptic
   nucleus
SO CELL CALCIUM
LA English
DT Article
DE Ca2+ signalling; Voltage-gated Ca2+ channels; Ca2+ homeostasis; Ca2+
   imaging; Ca2+ oscillations; Ca2+ clearance; Transgenic rats;
   Vasopressin; Oxytocin; Hypothalamus; Supraoptic nucleus; Na+/Ca2+
   exchanger; Mitochondria; Plasma membrane calcium pump; Sarcoendoplasmic
   reticulum; Ca2+-ATPase; GABA; Glutamate; 1,4,5-Trisphosphate;
   Tetrodotoxin; Ca2+ channel toxins
ID SOMATODENDRITIC VASOPRESSIN RELEASE; INTRACELLULAR TRANSDUCTION SIGNALS;
   NEUROHYPOPHYSEAL TERMINALS; NERVE-TERMINALS; RECEPTOR; MECHANISMS;
   OXYTOCIN; CELLS; ACTIVATION; INCREASE
AB Isolated supraoptic neurones generate spontaneous [Ca2+](i) oscillations in isolated conditions. Here we report in depth analysis of the contribution of plasmalemmal ion channels (Ca2+, Na+),Na+/Ca2+ exchanger (NCX), intracellular Ca2+ release channels (InsP(3)Rs and RyRs), Ca2+ storage organelles, plasma membrane Ca2+ pump and intracellular signal transduction cascades into spontaneous Ca2+ activity. While removal of extracellular Ca2+ or incubation with non-specific voltage-gated Ca2+ channel (VGCC) blocker Cd2+ suppressed the oscillations, neither Ni2+ nor TTA-P2, the T-type VGCC blockers, had an effect. Inhibitors of VGCC nicardipine, omega-conotoxin GVIA, omega-conotoxin MVIIC, omega-agatoxin IVA (for L-, N-, P and P/Q-type channels, respectively) did not affect [Ca2+](i) oscillations. In contrast, a specific R-type VGCC blocker SNX-482 attenuated [Ca2+](i) oscillations. Incubation with TTX had no effect, whereas removal of the extracellular Na+ or application of an inhibitor of the reverse operation mode of Na+/Ca2+ exchanger KB-R7943 blocked the oscillations. The mitochondrial uncoupler CCCP irreversibly blocked spontaneous [Ca2+](i) activity. Exposure of neurones to Ca2+ mobilisers (thapsigargin, cyclopiazonic acid, caffeine and ryanodine); 4-aminopyridine (A-type K+ current blocker); phospholipase C and adenylyl cyclase pathways blockers U-73122, Rp-cAMP, SQ-22536 and H-89 had no effect. Oscillations were blocked by GABA,but not by glutamate, apamin or dynorphin. In conclusion, spontaneous oscillations in magnocellular neurones are mediated by a concerted action of R-type Ca2+ channels and the NCX fluctuating between forward and reverse modes. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kortus, Stepan; Srinivasan, Chinnapaiyan; Forostyak, Oksana; Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
   [Kortus, Stepan; Zapotocky, Martin] Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CR-14220 Prague, Czech Republic.
   [Kortus, Stepan; Zapotocky, Martin] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Salmovska 1, Prague 12000, Czech Republic.
   [Forostyak, Oksana; Sykova, Eva; Chvatal, Alexandr] Charles Univ Prague, Fac Med 2, Dept Neurosci, V Uvalu 84, Prague 15006, Czech Republic.
   [Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan.
   [Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220, Czech Republic.
   [Chvatal, Alexandr] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220, Czech Republic.
   [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, D-4417 Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Verkhratsky, Alexei] Ikerbasque, Basque Fdn Sci, Achucarro Ctr Neurosci, E-48011 Bilbao, Spain.
   [Verkhratsky, Alexei] Univ Basque Country UPV EHU, Dept Neurosci, Leioa, Spain.
   [Verkhratsky, Alexei] CIBERNED, Leioa, Spain.
   [Verkhratsky, Alexei] Univ Nizhny Novgorod, Nizhnii Novgorod 603022, Russia.
   [Dayanithi, Govindan] Univ Montpellier, INSERM, Unite Rech U1198, F-34095 Montpellier, France.
   [Dayanithi, Govindan] Ecole Prat Hautes Etud, Sorbonne, F-75014 Paris, France.
RP Dayanithi, G (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.; Verkhratsky, A (reprint author), Univ Manchester, Sch Biol Sci, D-4417 Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM Alexej.Verkhratsky@manchester.ac.uk; gdaya@univ-montp2.fr
RI Zapotocky, Martin/B-8225-2008; Verkhratsky, Alexei/J-4527-2013
OI Zapotocky, Martin/0000-0002-0437-2528; Verkhratsky,
   Alexei/0000-0003-2592-9898
FU Grant Agency of the Czech Republic [14-34077S, GACR P304/12/G069]; Grant
   Agency of Charles University in Prague [GAUK 22214]; FP7 Initial
   Training Network Edu-GLIA program [PITN-GA-2009-237956]; "Advanced
   Bioimaging of Living Tissues" project [CZ.2.16/3.1.00/21527]; European
   Regional Development Fund; Wellcome Trust; Alzheimer's research
   foundation (UK); Ministry of Education and Science of the Russian
   Federation [02.B.49.21.0003]; Lobachevsky State University of Nizhny
   Novgorod [02.B.49.21.0003]; Russian Scientific Foundation [14-15-00633];
   Ministry of Education of the Russian Federation [RFMEFI57814X0079]
FX This work was supported by the grants 14-34077S and GACR P304/12/G069
   from the Grant Agency of the Czech Republic and GAUK 22214 from the
   Grant Agency of Charles University in Prague, and by institutional
   support RVO#67985823. CS and GD were supported in part by the FP7
   Initial Training Network Edu-GLIA program (PITN-GA-2009-237956). This
   publication is partly a result of the "Advanced Bioimaging of Living
   Tissues" project, registration number #CZ.2.16/3.1.00/21527, which was
   financed from the budget of the European Regional Development Fund and
   public budgets of the Czech Republic through the Operational Programme
   Prague-Competitiveness. AV was supported by the Wellcome Trust, by the
   Alzheimer's research foundation (UK) and by a grant (agreement from
   August 27 2013 No 02.B.49.21.0003) between The Ministry of Education and
   Science of the Russian Federation and Lobachevsky State University of
   Nizhny Novgorod, by a grant of the Russian Scientific Foundation No
   14-15-00633 and by the Ministry of Education of the Russian Federation,
   unique identity number RFMEFI57814X0079. Govindan Dayanithi belongs to
   the "Centre National de la Recherche Scientifique-The French Ministry of
   Research and Higher Education-Paris", France. We are grateful to Kip
   Allan Bauersfeld, IEM ASCR, for critical reading and helpful comments on
   the manuscript.
CR Armstrong WE, 1995, PROG NEUROBIOL, V47, P291, DOI 10.1016/0301-0082(95)00025-9
   BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97
   Bourinet E, 2001, BIOPHYS J, V81, P79
   Brown CH, 2013, J NEUROENDOCRINOL, V25, P678, DOI 10.1111/jne.12051
   Brown CH, 2000, J NEUROENDOCRINOL, V12, P711, DOI 10.1046/j.1365-2826.2000.00547.x
   Brustovetsky T, 2011, BRIT J PHARMACOL, V162, P255, DOI 10.1111/j.1476-5381.2010.01054.x
   CAZALIS M, 1985, J PHYSIOL-LONDON, V369, P45
   Dayanithi G, 1996, J PHYSIOL-LONDON, V490, P713
   Dayanithi G, 2006, CELL CALCIUM, V39, P237, DOI 10.1016/j.ceca.2005.10.011
   Dayanithi G, 2000, EXP PHYSIOL, V85, p75S, DOI 10.1111/j.1469-445X.2000.tb00010.x
   Dayanithi G, 2012, CELL CALCIUM, V51, P293, DOI 10.1016/j.ceca.2012.02.002
   Dreyfus FM, 2010, J NEUROSCI, V30, P99, DOI 10.1523/JNEUROSCI.4305-09.2010
   Fujihara H, 2012, ENDOCRINOLOGY, V153, P1377, DOI 10.1210/en.2011-1539
   Fujihara H, 2009, ENDOCRINOLOGY, V150, P5633, DOI 10.1210/en.2009-0796
   Gouzenes L, 1999, J PHYSIOL-LONDON, V517, P771, DOI 10.1111/j.1469-7793.1999.0771s.x
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hattori Y, 1998, J NEUROENDOCRINOL, V10, P383, DOI 10.1046/j.1365-2826.1998.00219.x
   Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143-4160(03)00069-1
   Komori Y, 2010, CELL CALCIUM, V48, P324, DOI 10.1016/j.ceca.2010.10.002
   LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275
   Ludwig M, 2005, J PHYSIOL-LONDON, V564, P515, DOI 10.1113/jphysiol.2005.083931
   Ludwig M, 2002, NATURE, V418, P85, DOI 10.1038/nature00822
   Moriya T, 2015, CELL CALCIUM, V57, P25, DOI 10.1016/j.ceca.2014.11.003
   Ortiz-Miranda S, 2005, J NEUROENDOCRINOL, V17, P583, DOI 10.1111/j.1365-2826.2005.01346.x
   Richard P, 1997, BIOL CELL, V89, P555, DOI 10.1016/S0248-4900(98)80159-7
   Roper P, 2003, J COMPUT NEUROSCI, V15, P367, DOI 10.1023/A:1027424128972
   Sabatier N, 1997, J PHYSIOL-LONDON, V503, P253, DOI 10.1111/j.1469-7793.1997.253bh.x
   Sabatier N, 2004, J NEUROENDOCRINOL, V16, P221, DOI 10.1111/j.0953-8194.2004.01155.x
   Sabatier N, 1998, J PHYSIOL-LONDON, V513, P699, DOI 10.1111/j.1469-7793.1998.699ba.x
   Sasaki N, 2005, CELL CALCIUM, V37, P45, DOI 10.1016/j.ceca.2004.06.007
   Shibuya I, 2000, EXP PHYSIOL, V85, p145S, DOI 10.1111/j.1469-445X.2000.tb00018.x
   Shibuya I, 1998, J NEUROENDOCRINOL, V10, P31, DOI 10.1046/j.1365-2826.1998.00168.x
   Sneyd J, 2004, P NATL ACAD SCI USA, V101, P1392, DOI 10.1073/pnas.0303472101
   SNEYD J, 1995, FASEB J, V9, P1463
   TOESCU EC, 1991, J PHYSIOL-LONDON, V433, P127
   Ueta Y, 2005, ENDOCRINOLOGY, V146, P406, DOI 10.1210/en.2004-0830
   Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004
   Viero C, 2006, CELL CALCIUM, V40, P383, DOI 10.1016/j.ceca.2006.04.007
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9
   Wanaverbecq N, 2003, J PHYSIOL-LONDON, V550, P83, DOI 10.1113/jphysiol.2002.035782
   Wang G, 1999, J NEUROSCI, V19, P9235
NR 42
TC 0
Z9 0
U1 11
U2 12
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
EI 1532-1991
J9 CELL CALCIUM
JI Cell Calcium
PD JUN
PY 2016
VL 59
IS 6
BP 289
EP 298
DI 10.1016/j.ceca.2016.03.010
PG 10
WC Cell Biology
SC Cell Biology
GA DN1ND
UT WOS:000376831800003
PM 27052156
ER

PT J
AU Nakata, M
   Gantulga, D
   Santoso, P
   Zhang, BY
   Masuda, C
   Mori, M
   Okada, T
   Yada, T
AF Nakata, Masanori
   Gantulga, Darambazar
   Santoso, Putra
   Zhang, Boyang
   Masuda, Chiaki
   Mori, Masatomo
   Okada, Takashi
   Yada, Toshihiko
TI Paraventricular NUCB2/Nesfatin-1 Supports Oxytocin and Vasopressin
   Neurons to Control Feeding Behavior and Fluid Balance in Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID SYMPATHETIC-NERVE ACTIVITY; FOOD-INTAKE; NESFATIN-1 NEURONS; SUPRAOPTIC
   NUCLEI; BLOOD-PRESSURE; RATS; OBESITY; BRAIN; LEPTIN; IMMUNOREACTIVITY
AB Nesfatin-1, derived from nucleobindin-2 (NUCB2), is expressed in the hypothalamus, including the paraventricular nucleus (PVN), an integrative center for energy homeostasis. However, precise role of the NUCB2/nesfatin-1 in PVN remains less defined. The present study aimed to clarify physiological and/or pathophysiological roles of endogenous NUCB2/nesfatin-1 in PVN by using adeno-associated virus vectors encoding short hairpin RNAs targeting NUCB2 in mice. PVN-specific NUCB2 knockdown primarily increased food intake and decreased plasma oxytocin level specifically in light phase, leading to increased body weight gain without affecting energy expenditure. Furthermore, high-salt diet increased the systolic blood pressure, plasma arginine vasopressin (AVP) and AVP mRNA expression in PVN, and all these changes were blunted by PVN-specific NUCB2 knockdown. These results reveal that the endogenous NUCB2/nesfatin-1 in PVN regulates PVN AVP and oxytocin and consequently the fluid and energy balance.
C1 [Nakata, Masanori; Gantulga, Darambazar; Santoso, Putra; Zhang, Boyang; Yada, Toshihiko] Jichi Med Univ, Sch Med, Div Integrat Physiol, Shimotsuke, Tochigi 3290498, Japan.
   [Masuda, Chiaki; Okada, Takashi] Nippon Med Sch, Res Ctr Adv Med Technol, Div Gene Therapy, Dept Biochem & Mol Biol, Tokyo 1138603, Japan.
   [Mori, Masatomo] Metab & Obese Res Inst, Maebashi, Gunma 3710037, Japan.
   [Yada, Toshihiko] Natl Inst Nat Sci, Natl Inst Physiol Sci, Dept Dev Physiol, Div Adaptat Dev, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.
RP Yada, T (reprint author), Jichi Med Univ, Div Integrat Physiol, Dept Physiol, Yakushiji 3311-1, Shimotsuke, Tochigi 3290498, Japan.
EM tyada@jichi.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [24592277, 15K09442];
   Japan Diabetes Foundation; JSPS [26670453]; Ministry of Education,
   Culture, Sports, Science and Technology of Japan (MEXT) [10036069];
   MEXT-Supported Programs for Strategic Research Foundation at Private
   Universities; Ministry of Health, Labor, and Welfare, Japan; grant for
   Collaborative Research in Cooperation with Universities; grant for Joint
   Researches in National Institute for Physiological Sciences; Ono
   Pharmaceutical Co.; JKA through promotion funds from KEIRIN RACE
FX This work was supported by Grants-in-Aid for Scientific Research (C)
   (24592277 and 15K09442) from Japan Society for the Promotion of Science
   (JSPS) and a grant from Japan Diabetes Foundation (M.N.). Apart of this
   work was supported by Grant-in-Aid for Challenging Exploratory Research
   26670453 from JSPS; Strategic Research Program for Brain Sciences Grant
   10036069 by the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (MEXT); MEXT-Supported Programs for Strategic
   Research Foundation at Private Universities 2011-2015 (Cooperative Basic
   and Clinical Research on Circadian Medicine) and 2013-2017; a
   Grant-in-Aid from Health Labor Sciences Research Grants from the
   Ministry of Health, Labor, and Welfare, Japan; a grant for Collaborative
   Research in Cooperation with Universities; a grant for Joint Researches
   in National Institute for Physiological Sciences; and grants from Japan
   Diabetes Foundation and from Ono Pharmaceutical Co. (T.Y.). This study
   was subsidized by JKA through its promotion funds from KEIRIN RACE
   (T.Y.).
CR ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P739
   Darambazar G, 2015, BIOCHEM BIOPH RES CO, V456, P913, DOI 10.1016/j.bbrc.2014.12.065
   Fitts DA, 2004, AM J PHYSIOL-REG I, V287, pR1325, DOI 10.1152/ajpregu.00391.2004
   Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054
   Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064
   Goebel-Stengel M, 2011, BRAIN RES, V1396, P20, DOI 10.1016/j.brainres.2011.04.031
   HERVEY GR, 1953, NATURE, V171, P1125, DOI 10.1038/1711125a0
   Ishida E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050918
   Kohno D, 2008, ENDOCRINOLOGY, V149, P1295, DOI 10.1210/en.2007-1276
   LINCOLN DW, 1973, J ENDOCRINOL, V57, P459, DOI 10.1677/joe.0.0570459
   Maejima Y, 2011, AGING-US, V3, P1169
   Maejima Y, 2009, CELL METAB, V10, P355, DOI 10.1016/j.cmet.2009.09.002
   Mariman ECM, 2015, PHYSIOL GENOMICS, V47, P225, DOI 10.1152/physiolgenomics.00006.2015
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Nakata M, 2016, INT J OBESITY, V40, P425, DOI 10.1038/ijo.2015.201
   Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162
   Okada T, 2005, HUM GENE THER, V16, P1212, DOI 10.1089/hum.2005.16.1212
   Palasz A, 2012, NEUROPEPTIDES, V46, P105, DOI 10.1016/j.npep.2011.12.002
   Perello M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059625
   PITTMAN QJ, 1982, ENDOCRINOLOGY, V110, P1058
   Sedbazar U, 2013, BIOCHEM BIOPH RES CO, V434, P434, DOI 10.1016/j.bbrc.2013.03.090
   SOKOL HW, 1967, NATURE, V214, P314, DOI 10.1038/214314a0
   Stengel A, 2011, OBES REV, V12, P261, DOI 10.1111/j.1467-789X.2010.00770.x
   SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Tanida M, 2015, DIABETES, V64, P3725, DOI 10.2337/db15-0282
   Tanida M, 2011, NEUROREPORT, V22, P309, DOI 10.1097/WNR.0b013e328346107f
   Tragante V, 2014, AM J HUM GENET, V94, P349, DOI 10.1016/j.ajhg.2013.12.016
   VERNEY EB, 1947, PROC R SOC SER B-BIO, V135, P25, DOI 10.1098/rspb.1947.0037
   Yilmaz MS, 2015, AUTON NEUROSCI-BASIC, V193, P63, DOI 10.1016/j.autneu.2015.07.009
   Yoshimura M, 2014, AM J PHYSIOL-REG I, V307, pR225, DOI 10.1152/ajpregu.00488.2013
   Yosten GLC, 2014, AM J PHYSIOL-REG I, V306, pR722, DOI 10.1152/ajpregu.00396.2013
   Yosten GLC, 2009, AM J PHYSIOL-REG I, V297, pR330, DOI 10.1152/ajpregu.90867.2008
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
NR 34
TC 1
Z9 1
U1 7
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2016
VL 157
IS 6
BP 2322
EP 2332
DI 10.1210/en.2015-2082
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DN6VM
UT WOS:000377214600013
PM 27105386
ER

PT J
AU Mahovetz, LM
   Young, LJ
   Hopkins, WD
AF Mahovetz, L. M.
   Young, L. J.
   Hopkins, W. D.
TI The influence of AVPR1A genotype on individual differences in behaviors
   during a mirror self-recognition task in chimpanzees (Pan troglodytes)
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE AVPR1A; chimpanzee; genetics; mark test; mirror self-recognition;
   nonhuman primates; scratching; social behavior; social cognition;
   vasopressin
ID NONHUMAN-PRIMATES; FLANKING REGION; VASOPRESSIN; OXYTOCIN;
   MICROSATELLITE; ANXIETY; AWARENESS; GENE; ASSOCIATION; EXPRESSION
AB The mark/rouge test has been used to assess mirror self-recognition (MSR) in many species. Despite consistent evidence of MSR in great apes, genetic or non-genetic factors may account for the individual differences in behavioral responses that have been reported. We examined whether vasopressin receptor gene (AVPR1A) polymorphisms are associated with MSR-related behaviors in chimpanzees since vasopressin has been implicated in the development and evolution of complex social relations and cognition and chimpanzees are polymorphic for the presence of the RS3-containing DupB region. We compared a sample of DupB+/- and DupB-/- chimpanzees on a mark test to assess its role on social behavior toward a mirror. Chimpanzees were administered two, 10-min sessions where frequencies of mirror-guided self-directed behaviors, contingent actions and other social behaviors were recorded. Approximately one-third showed evidence of MSR and these individuals exhibited more mirror-guided self-exploratory behaviors and mouth contingent actions than chimpanzees not classified as passers. Moreover, DupB+/- males exhibited more scratching and agonistic behaviors than other male and female cohorts. Our findings support previous studies demonstrating individual differences in MSR abilities in chimpanzees and suggest that AVPR1A partly explains individual differences in MSR by influencing the behavioral reactions of chimpanzees in front of a mirror.
C1 [Mahovetz, L. M.] Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA.
   [Young, L. J.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA.
   [Young, L. J.] Emory Univ, Yerkes Primate Natl Res Ctr, Atlanta, GA 30322 USA.
   [Young, L. J.] Emory Univ, Silvio O Conte Ctr Oxytocin & Social Cognit, Ctr Translat Social Neurosci, Atlanta, GA 30322 USA.
   [Hopkins, W. D.] Georgia State Univ, Inst Neurosci, POB 5030, Atlanta, GA 30302 USA.
   [Hopkins, W. D.] Georgia State Univ, Language Res Ctr, Atlanta, GA 30303 USA.
   [Hopkins, W. D.] Yerkes Natl Primate Res Ctr, Div Dev & Cognit Neurosci, Atlanta, GA USA.
RP Hopkins, WD (reprint author), Georgia State Univ, Inst Neurosci, POB 5030, Atlanta, GA 30302 USA.
EM whopkins4@gsu.edu
FU NIH [MH-92923, NS-42867, NS-73134, HD-60563]; Office of Research
   Infrastructure Programs/OD [P51OD11132]
FX American Psychological Association and Institute of Medicine guidelines
   for the treatment of chimpanzees in research were followed during all
   aspects of this study. This research was supported by NIH -grants
   MH-92923, NS-42867, NS-73134 and HD-60563 to WDH and Office of Research
   Infrastructure Programs/OD P51OD11132 to YNPRC. There are no potential
   sources of conflict of interest regarding this research. We would like
   to thank Stephanie Bogart, Heidi Lyn, Jamie Russell and Jennifer
   Schaeffer for assisting with data collection.
CR Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007
   Allen M, 2008, J INTEGR BIOSCI, V5, P19
   Anderson JR, 2015, PRIMATES, V56, P317, DOI 10.1007/s10329-015-0488-9
   Anderson JR, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001024
   Aureli F, 1997, AGGRESSIVE BEHAV, V23, P315, DOI 10.1002/(SICI)1098-2337(1997)23:5<315::AID-AB2>3.0.CO;2-H
   Baker KC, 1997, BEHAVIOUR, V134, P1031, DOI 10.1163/156853997X00386
   Bard KA, 2006, INFANCY, V9, P191, DOI 10.1207/s15327078in0902_6
   Barrett CE, 2013, HORM BEHAV, V63, P518, DOI 10.1016/j.yhbeh.2013.01.005
   Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360
   CALHOUN S, 1988, AM J PRIMATOL, V15, P361, DOI 10.1002/ajp.1350150409
   Castles DL, 1999, ANIM BEHAV, V58, P1207, DOI 10.1006/anbe.1999.1250
   Chang LT, 2015, CURR BIOL, V25, P212, DOI 10.1016/j.cub.2014.11.016
   Crockford C, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2765
   de Veer MW, 1999, ANIM BEHAV, V58, P459, DOI 10.1006/anbe.1999.1166
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Donaldson ZR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003729
   Donaldson ZR, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-180
   Ebstein RP, 2012, HORM BEHAV, V61, P359, DOI 10.1016/j.yhbeh.2011.12.014
   GALLUP GC, 1971, PSYCHOL REC, V21, P69
   GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86
   GALLUP GG, 1982, AM J PRIMATOL, V2, P237, DOI 10.1002/ajp.1350020302
   Gallup Jr G. G., 2011, OXFORD HDB SELF, P80
   Gallup Jr G. G., 2002, COGNITIVE ANIMAL EMP, P327
   Goodson JL, 2001, BRAIN RES REV, V35, P246, DOI 10.1016/S0165-0173(01)00043-1
   Hammock EAD, 2005, GENES BRAIN BEHAV, V4, P289, DOI 10.1111/j.1601-183X.2005.00119.x
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   Hammock EAD, 2006, PHILOS T R SOC B, V361, P2187, DOI 10.1098/rstb.2006.1939
   Heschl A, 2006, PRIMATES, V47, P187, DOI 10.1007/s10329-005-0170-8
   Hopkins WD, 2012, GENES BRAIN BEHAV, V11, P552, DOI 10.1111/j.1601-183X.2012.00799.x
   Hopkins W. D., 2014, SCI REP, V4, P1
   Hyatt Charles W., 1994, P248, DOI 10.1017/CBO9780511565526.017
   Hyatt CW, 1998, AM J PRIMATOL, V45, P307, DOI 10.1002/(SICI)1098-2345(1998)45:3<307::AID-AJP7>3.0.CO;2-#
   Keenan J. P., 2003, FACE MIRROR SEARCH O
   Latzman RD, 2016, PSYCHOPHYSIOLOGY, V53, P355, DOI 10.1111/psyp.12449
   Latzman RD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095741
   Leavens DA, 2004, BEHAVIOUR, V141, P979, DOI 10.1163/1568539042360189
   LIN AC, 1992, J COMP PSYCHOL, V106, P120, DOI 10.1037//0735-7036.106.2.120
   MAESTRIPIERI D, 1992, ANIM BEHAV, V44, P967, DOI 10.1016/S0003-3472(05)80592-5
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mitchell RW, 1997, ANN NY ACAD SCI, V818, P39, DOI 10.1111/j.1749-6632.1997.tb48245.x
   Parker S., 1994, SELF AWARENESS ANIMA
   Plotnik JM, 2006, P NATL ACAD SCI USA, V103, P17053, DOI 10.1073/pnas.0608062103
   Posada S, 2007, AM J PRIMATOL, V69, P576, DOI 10.1002/ajp.20355
   POVINELLI DJ, 1989, J COMP PSYCHOL, V103, P122, DOI 10.1037/0735-7036.103.2.122
   POVINELLI DJ, 1993, J COMP PSYCHOL, V107, P347, DOI 10.1037/0735-7036.107.4.347
   Povinelli DJ, 1997, ANIM BEHAV, V53, P1083, DOI 10.1006/anbe.1996.0303
   Prior H, 2008, PLOS BIOL, V6, P1642, DOI 10.1371/journal.pbio.0060202
   Rajala AZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012865
   Reiss D, 2001, P NATL ACAD SCI USA, V98, P5937, DOI 10.1073/pnas.101086398
   Shaffer VA, 2000, INT J COMP PSYCHOL, V13, P154
   Soler M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086193
   Staes N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113364
   SUAREZ SD, 1981, J HUM EVOL, V10, P175, DOI 10.1016/S0047-2484(81)80016-4
   Suddendorf T, 2009, P R SOC B, V276, P1671, DOI 10.1098/rspb.2008.1754
   SWARTZ KB, 1991, PRIMATES, V32, P483, DOI 10.1007/BF02381939
   TROISI A, 1991, BEHAV NEURAL BIOL, V56, P307, DOI 10.1016/0163-1047(91)90469-7
   Wade M, 2014, GENES BRAIN BEHAV, V13, P603, DOI 10.1111/gbb.12148
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
NR 58
TC 1
Z9 1
U1 8
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD JUN
PY 2016
VL 15
IS 5
BP 445
EP 452
DI 10.1111/gbb.12291
PG 8
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DN6VV
UT WOS:000377215500001
PM 27058969
ER

PT J
AU Patak, J
   Zhang-James, Y
   Faraone, SV
AF Patak, Jameson
   Zhang-James, Yanli
   Faraone, Stephen V.
TI Endosomal system genetics and autism spectrum disorders: A literature
   review
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE Autism spectrum disorder (ASD); Genetics; Endosomal system; Endosome
   dysregulation; Recycling; Trafficking; mTOR
ID DEFICIT HYPERACTIVITY DISORDER; OXYTOCIN RECEPTOR GENE; DE-NOVO
   MUTATIONS; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; NA+/H+ EXCHANGER
   NHE6; ENDOCYTIC RECYCLING COMPARTMENT; TRANSPORTER CODING VARIANT;
   GENOME-WIDE ASSOCIATION; CELL-ADHESION MOLECULE; LONG-TERM POTENTIATION
AB Autism spectrum disorders (ASDs) are a group of debilitating neurodevelopmental disorders thought to have genetic etiology, due to their high heritability. The endosomal system has become increasingly implicated in ASD pathophysiology. In an attempt to summarize the association between endosomal system genes and ASDs we performed a systematic review of the literature. We searched PubMed for relevant articles. Simons Foundation Autism Research Initiative (SFARI) gene database was used to exclude articles regarding genes with less than minimal evidence for association with ASDs. Our search retained 55 articles reviewed in two categories: genes that regulate and genes that are regulated by the endosomal system. Our review shows that the endosomal system is a novel pathway implicated in ASDs as well as other neuropsychiatric disorders. It plays a central, role in aspects of cellular physiology on which neurons and glial cells are particularly reliant, due to their unique metabolic and functional demands. The system shows potential for biomarkers and pharmacological intervention and thus more research into this pathway is warranted. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Patak, Jameson; Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, 750 E Adams St, Syracuse, NY 13210 USA.
   [Zhang-James, Yanli; Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA.
   [Faraone, Stephen V.] Univ Bergen, KG Jebsen Ctr Neuropsychiat Disorders, Dept Biomed, Bergen, Norway.
RP Faraone, SV (reprint author), SUNY Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA.
EM patakj@upstate.edu; zhangy@upstate.edu; sfaraone@childpsychresearch.org
FU K.G. Jebsen Centre for Research on Neuropsychiatric Disorders,
   University of Bergen, Bergen, Norway; European Community [602805]; NIMH
   [R01MH094469]
FX Dr. Faraone is supported by the K.G. Jebsen Centre for Research on
   Neuropsychiatric Disorders, University of Bergen, Bergen, Norway, the
   European Community's Seventh Framework Programme (FP7/2007-2013) under
   grant agreement no. 602805 and NIMH grant R01MH094469.
CR Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005
   Amr M, 2012, RES AUTISM SPECT DIS, V6, P240, DOI 10.1016/j.rasd.2011.05.005
   Anney R, 2010, HUM MOL GENET, V19, P4072, DOI 10.1093/hmg/ddq307
   Antshel KM, 2013, EXPERT REV NEUROTHER, V13, P1117, DOI 10.1586/14737175.2013.840417
   Ao X, 2014, CELL DEATH DIFFER, V21, P348, DOI 10.1038/cdd.2013.187
   Aoto J, 2013, CELL, V154, P75, DOI 10.1016/j.cell.2013.05.060
   Ascano M, 2009, J NEUROSCI, V29, P11674, DOI 10.1523/JNEUROSCI.1542-09.2009
   Barreirinho M S, 2001, Rev Neurol, V32, P812
   Barrow SL, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-17
   Basu SN, 2009, NUCLEIC ACIDS RES, V37, pD832, DOI 10.1093/nar/gkn835
   Bel C, 2009, J CELL SCI, V122, P3403, DOI 10.1242/jcs.050526
   Ben-Shachar S, 2009, J MED GENET, V46, P382, DOI 10.1136/jmg.2008.064378
   Betancur C, 2011, BRAIN RES, V1380, P42, DOI 10.1016/j.brainres.2010.11.078
   Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356
   Ayhan Bilgic K. G., 2010, RES AUTISM SPECT DIS, V4, P639
   Bonaglia MC, 2006, J MED GENET, V43, P822, DOI 10.1136/jmg.2005.038604
   Bowton E, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.90
   BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W
   Calero M, 2001, J BIOL CHEM, V276, P12100, DOI 10.1074/jbc.M008439200
   Casanova MF, 2006, ACTA NEUROPATHOL, V112, P287, DOI 10.1007/s00401-006-0085-5
   Casanova MF, 2002, J CHILD NEUROL, V17, P692, DOI 10.1177/088307380201700908
   Castermans D, 2003, J MED GENET, V40, P352, DOI 10.1136/jmg.40.5.352
   Castermans D, 2007, EUR J HUM GENET, V15, P422, DOI 10.1038/sj.ejhg.5201785
   Castermans D, 2010, HUM MOL GENET, V19, P1368, DOI 10.1093/hmg/ddq013
   Chanda S., 2015, MOL PSYCHIAT
   Chapleau CA, 2009, J NEURODEV DISORD, V1, P185, DOI 10.1007/s11689-009-9027-6
   Chen CK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5246
   Chen JY, 2015, ONCOTARGET, V6, P12405
   Chow ML, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002592
   Christianson AL, 1999, J MED GENET, V36, P759
   Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004
   Cortese S, 2012, EXPERT REV NEUROTHER, V12, P1227, DOI [10.1586/ern.12.116, 10.1586/ERN.12.116]
   Cota D, 2009, PHYSIOL BEHAV, V97, P520, DOI 10.1016/j.physbeh.2009.03.006
   Courchesne E, 2007, NEURON, V56, P399, DOI 10.1016/j.neuron.2007.10.016
   Dager SR, 2007, AM J NEURORADIOL, V28, P672
   De Jaco A, 2008, CHEM-BIOL INTERACT, V175, P349, DOI 10.1016/j.cbi.2008.04.023
   De Jaco A, 2010, J BIOL CHEM, V285, P28674, DOI 10.1074/jbc.M110.139519
   De Rubeis S, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0553-1
   de Silva MG, 2003, J MED GENET, V40, P733, DOI 10.1136/jmg.40.10.733
   Deane EC, 2013, J NEUROSCI, V33, P595, DOI 10.1523/JNEUROSCI.2583-12.2013
   del Pino I, 2011, BIOCHEM BIOPH RES CO, V412, P435, DOI 10.1016/j.bbrc.2011.07.110
   Devlin B, 2012, CURR OPIN GENET DEV, V22, P229, DOI 10.1016/j.gde.2012.03.002
   Di Martino A, 2014, MOL PSYCHIATR, V19, P659, DOI 10.1038/mp.2013.78
   Di Nardo A, 2014, HUM MOL GENET, V23, P3865, DOI 10.1093/hmg/ddu101
   Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0
   Dong HL, 1999, ANN NY ACAD SCI, V868, P535, DOI 10.1111/j.1749-6632.1999.tb11323.x
   Donowitz M, 2013, MOL ASPECTS MED, V34, P236, DOI 10.1016/j.mam.2012.05.001
   Dosman CF, 2006, DEV MED CHILD NEUROL, V48, P1008, DOI 10.1017/S0012162206232225
   Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029
   Dudova I, 2014, NEUROPSYCH DIS TREAT, V10, P2201, DOI 10.2147/NDT.S72921
   Dudova I, 2014, NEUROPSYCH DIS TREAT, V10, P277, DOI 10.2147/NDT.S57057
   Dunlop EA, 2013, BIOCHEM SOC T, V41, P939, DOI 10.1042/BST20130030
   Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933
   El Achkar CM, 2015, EPILEPSY BEHAV, V47, P183, DOI 10.1016/j.yebeh.2014.12.022
   Falivelli G, 2012, HUM MOL GENET, V21, P4761, DOI 10.1093/hmg/dds320
   Faraone SV, 2014, MOL PSYCHIATR, V19, P880, DOI 10.1038/mp.2013.126
   Faraone SV, 1999, AM J PSYCHIAT, V156, P768
   Farzana F., 2015, MOL NEUROBIOL
   Folsch H, 2009, TRAFFIC, V10, P972, DOI 10.1111/j.1600-0854.2009.00927.x
   Freche Dominik, 2012, Commun Integr Biol, V5, P448, DOI 10.4161/cib.20818
   Fujita E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.23
   Fujiwara M, 2013, J PHARMACOL SCI, V122, P71, DOI 10.1254/jphs.12194FP
   Garbern JY, 2010, BRAIN, V133, P1391, DOI 10.1093/brain/awq071
   Gauglerl T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039
   Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293
   Gilfillan GD, 2008, AM J HUM GENET, V82, P1003, DOI 10.1016/j.ajhg.2008.01.013
   GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J
   Graber TE, 2013, LEARN MEMORY, V20, P518, DOI 10.1101/lm.027664.112
   Groenman AP, 2013, ADDICTION, V108, P1503, DOI 10.1111/add.12188
   Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775
   Guterman M., 2013, BIOLOGY, P49
   Hamilton PJ, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0002-7
   Hao Yi-Heng, 2015, Mol Cell, V59, P956, DOI 10.1016/j.molcel.2015.07.033
   Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051
   Herguner S, 2012, EUR J PEDIATR, V171, P143, DOI 10.1007/s00431-011-1506-6
   Hill JK, 2006, J NEUROSCI, V26, P9944, DOI 10.1523/JNEUROSCI.2990-06.2006
   Ilie A, 2014, NEUROCHEM INT, V73, P192, DOI 10.1016/j.neuint.2013.09.020
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908
   Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009
   Peter Ishola E. G., 2015, ANAT PHYSL, V5
   Iwata K, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-33
   Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136
   Jeste S. S., 2015, J CHILD NEUROL
   Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99
   Kana RK, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00349
   Kliemann D, 2012, J NEUROSCI, V32, P9469, DOI 10.1523/JNEUROSCI.5294-11.2012
   Kondapalli KC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7289
   Kondapalli KC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00172
   Kondapalli KC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3510
   Kovtun O, 2015, ACS CHEM NEUROSCI, V6, P526, DOI 10.1021/cn500202c
   Krakowiak P, 2012, PEDIATRICS, V129, pE1121, DOI 10.1542/peds.2011-2583
   Krumm N, 2014, TRENDS NEUROSCI, V37, P95, DOI 10.1016/j.tins.2013.11.005
   Kurisu J, 2010, J NEUROCHEM, V113, P1598, DOI 10.1111/j.1471-4159.2010.06714.x
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lasky-Su J, 2008, AM J MED GENET B, V147B, P1345, DOI 10.1002/ajmg.b.30867
   Latif A, 2002, AUTISM, V6, P103, DOI 10.1177/1362361302006001008
   Lee Kyung-Min, 2013, Exp Neurobiol, V22, P133, DOI 10.5607/en.2013.22.3.133
   Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224
   Lodish H. F., 2013, MOL CELL BIOL
   Luo ZC, 2013, OBESITY, V21, P210, DOI [10.1002/oby.20250, 10.1038/oby.2012.182]
   Ma DQ, 2007, MOL PSYCHIATR, V12, P376, DOI 10.1038/sj.mp.4001927
   Ma WJ, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-22
   Magdaleno S, 2002, NEURON, V33, P573, DOI 10.1016/S0896-6273(02)00582-2
   Malo ME, 2006, CAN J PHYSIOL PHARM, V84, P1081, DOI 10.1139/Y06-065
   Arlene Mannion M. B., 2014, REV J AUTISM DEV DIS, V1, P124
   Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   Maximo JO, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00605
   Mayle KM, 2012, BBA-GEN SUBJECTS, V1820, P264, DOI 10.1016/j.bbagen.2011.09.009
   Mazei-Robison MS, 2008, J NEUROSCI, V28, P7040, DOI [10.1523/JNEUROSCI.0473-08.2008, 10.1523/JNEUROSCI.473-08.2008]
   McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171
   McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993
   Medrihan L, 2009, J PHYSIOL-LONDON, V587, P5095, DOI 10.1113/jphysiol.2009.178236
   Mejias R, 2011, P NATL ACAD SCI USA, V108, P4920, DOI 10.1073/pnas.1102233108
   Miles JH, 2011, GENET MED, V13, P278, DOI 10.1097/GIM.0b013e3181ff67ba
   Miller AC, 2015, CURR BIOL, V25, P16, DOI 10.1016/j.cub.2014.10.071
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morrow EM, 2008, SCIENCE, V321, P218, DOI 10.1126/science.1157657
   Moseley RL, 2015, NEUROIMAGE-CLIN, V9, P140, DOI 10.1016/j.nicl.2015.07.015
   Muhle R, 2004, PEDIATRICS, V113, pE472, DOI 10.1542/peds.113.5.e472
   Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106
   Nair R, 2013, J CELL BIOL, V200, P61, DOI 10.1083/jcb.201207113
   Nakamura N, 2005, J BIOL CHEM, V280, P1561, DOI 10.1074/jbc.M410041200
   Nava C, 2014, EUR J HUM GENET, V22, P71, DOI 10.1038/ejhg.2013.88
   Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011
   Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113
   Nuytens K, 2013, NEUROBIOL DIS, V51, P144, DOI 10.1016/j.nbd.2012.11.004
   O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989
   O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835
   Ohgaki R, 2010, MOL BIOL CELL, V21, P1293, DOI 10.1091/mbc.E09-09-0767
   Otomo A., 2012, NEUROL RES INT, V2012, DOI DOI 10.1155/2012/498428
   Ouyang Q, 2013, NEURON, V80, P97, DOI 10.1016/j.neuron.2013.07.043
   Park M, 2006, NEURON, V52, P817, DOI 10.1016/j.neuron.2006.09.040
   Penagarikano O, 2011, CELL, V147, P235, DOI 10.1016/j.cell.2011.08.040
   Pescosolido MF, 2014, ANN NEUROL, V76, P581, DOI 10.1002/ana.24225
   Pescosolido Matthew F, 2012, Dialogues Clin Neurosci, V14, P239
   Pinto D, 2014, AM J HUM GENET, V94, P677, DOI 10.1016/j.ajhg.2014.03.018
   Pirooznia Mehdi, 2007, Bioinformation, V1, P420
   Poultney CS, 2013, AM J HUM GENET, V93, P607, DOI 10.1016/j.ajhg.2013.09.001
   Prasad H, 2015, FUTURE ONCOL, V11, P1847, DOI [10.2217/fon.15.93, 10.2217/FON.15.93]
   Prasad HC, 2009, PHILOS T R SOC B, V364, P163, DOI 10.1098/rstb.2008.0143
   Prevention C. f. D. C. a, 2015, AUT SPECTR DIS ASD
   Prevention C. f. D. C. a., 2014, MMWR-MORBID MORTAL W, P22
   Raynaud F, 2013, J NEUROSCI, V33, P9699, DOI 10.1523/JNEUROSCI.2725-12.2013
   Razi M, 2009, J CELL BIOL, V185, P305, DOI 10.1083/jcb.200810098
   Alvarez Retuerto AI, 2008, HUM MOL GENET, V17, P3887, DOI DOI 10.1093/HMG/DDN291.PUBMED:18782849
   Reynolds A, 2012, PEDIATRICS, V130, pS154, DOI 10.1542/peds.2012-0900M
   Rivera HM, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00194
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945
   Savelyeva L, 2006, HUM GENET, V118, P551, DOI 10.1007/s00439-005-0083-z
   Schaaf CP, 2013, NAT GENET, V45, P1405, DOI 10.1038/ng.2776
   Schmidt MR, 2007, BIOL CELL, V99, P333, DOI 10.1042/BC20070007
   Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004
   Schwede M, 2014, MOL PSYCHIATR, V19, P277, DOI 10.1038/mp.2013.28
   Shehata M, 2014, REV NEUROSCIENCE, V25, P543, DOI 10.1515/revneuro-2014-0002
   Shehata M, 2012, J NEUROSCI, V32, P10413, DOI 10.1523/JNEUROSCI.4533-11.2012
   Shen DN, 2015, NEUROSCI BULL, V31, P416, DOI 10.1007/s12264-015-1536-6
   Shen W, 2009, J CELL BIOL, V187, P71, DOI 10.1083/jcb.200907109
   Sheng G, 2008, J CLIN INVEST, V118, P2785, DOI 10.1172/JCI35339
   Sheng M, 2007, ANNU REV BIOCHEM, V76, P823, DOI 10.1146/annurev.biochem.76.060805.160029
   Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Speaks A., 2015, AUTISM EPILEPSY RESO
   Stromme P, 2011, BRAIN, V134, P3369, DOI 10.1093/brain/awr250
   Supekar K, 2013, CELL REP, V5, P738, DOI 10.1016/j.celrep.2013.10.001
   Tang GM, 2014, NEURON, V83, P1131, DOI 10.1016/j.neuron.2014.07.040
   Tarpey PS, 2009, NAT GENET, V41, P535, DOI 10.1038/ng.367
   Tessier DR, 2013, PLACENTA, V34, P205, DOI 10.1016/j.placenta.2012.11.035
   Thomas M. S., 2015, DEV SCI
   Tottenham N, 2014, SOC COGN AFFECT NEUR, V9, P106, DOI 10.1093/scan/nst050
   Traer CJ, 2007, NAT CELL BIOL, V9, P1370, DOI 10.1038/ncb1656
   Trahey M., 2010, BIOL REP, V2, P47
   Trotman M, 2014, BRAIN RES, V1546, P53, DOI 10.1016/j.brainres.2013.12.027
   Uchino S, 2013, BRAIN DEV-JPN, V35, P106, DOI 10.1016/j.braindev.2012.05.013
   Uhlmann EJ, 2002, ANN NEUROL, V52, P285, DOI 10.1002/ana.10283
   Valleau JC, 2014, J CHEM NEUROANAT, V61-62, P221, DOI 10.1016/j.jchemneu.2014.05.001
   van de Glind G, 2014, DRUG ALCOHOL DEPEN, V134, P158, DOI 10.1016/j.drugalcdep.2013.09.026
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   van Emmerik-van Oortmerssen K, 2014, ADDICTION, V109, P262, DOI 10.1111/add.12370
   Varea O, 2015, P NATL ACAD SCI USA, V112, P6176, DOI 10.1073/pnas.1423205112
   Vink JM, 2009, AM J HUM GENET, V84, P367, DOI 10.1016/j.ajhg.2009.02.001
   Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797
   Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047
   Volders K, 2012, J NEUROSCI, V32, P15193, DOI 10.1523/JNEUROSCI.6424-11.2012
   Wagle M., 2014, NEUROLOGY, V82, P338
   WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424
   Wang JC, 2013, MOL PSYCHIATR, V18, P1218, DOI 10.1038/mp.2012.143
   Wang XL, 2000, J NEUROSCI, V20, P8551
   Washington SD, 2014, HUM BRAIN MAPP, V35, P1284, DOI 10.1002/hbm.22252
   Watts Timothy John, 2008, Clin Med Pathol, V1, P99
   Website, 2015, ALL BRAIN ATL
   Wilson JM, 2000, MOL BIOL CELL, V11, P2657
   Wise A., 2015, J NEUROGENET, P1
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   Xiao GH, 1997, J BIOL CHEM, V272, P6097
   Xu XS, 2010, P NATL ACAD SCI USA, V107, P19126, DOI 10.1073/pnas.1013032107
   Lina Yang Y. Z.-J., 2014, AUTISM SPECTRU UNPUB
   Yap CC, 2012, NEURON, V74, P440, DOI 10.1016/j.neuron.2012.04.015
   Zhang-James Y, 2014, BEHAV BRAIN RES, V269, P103, DOI 10.1016/j.bbr.2014.04.035
   Zhang-James Y, 2012, DEV NEUROSCI-BASEL, V34, P218, DOI 10.1159/000338813
   Zhang-James Y, 2011, AM J MED GENET B, V156B, P835, DOI 10.1002/ajmg.b.31229
   Yanli Zhang-James F. S. B., 2015, EFFECT DIS ASS UNPUB
   Zhao H, 2014, J NEUROSCI, V34, P10085, DOI 10.1523/JNEUROSCI.2156-14.2014
   Zhiling Y, 2008, BIOCHEM BIOPH RES CO, V377, P926, DOI 10.1016/j.bbrc.2008.10.107
NR 207
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD JUN
PY 2016
VL 65
BP 95
EP 112
DI 10.1016/j.neubiorev.2016.03.022
PG 18
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DN0WJ
UT WOS:000376787400005
PM 27048963
ER

PT J
AU Cheng, ZR
   Abudureyimu, A
   Oguejiofor, CF
   Ellis, R
   Barry, AT
   Chen, X
   Anstaett, OL
   Brownlie, J
   Wathes, DC
AF Cheng, Zhangrui
   Abudureyimu, Ayimuguli
   Oguejiofor, Chike F.
   Ellis, Rebekah
   Barry, Amy Teresa
   Chen, Xing
   Anstaett, Olivia L.
   Brownlie, Joe
   Wathes, D. Claire
TI BVDV alters uterine prostaglandin production during pregnancy
   recognition in cows
SO REPRODUCTION
LA English
DT Article
ID VIRAL DIARRHEA VIRUS; ENDOMETRIAL IMMUNE-RESPONSE; OVINE TROPHOBLAST
   PROTEIN-1; POLYUNSATURATED FATTY-ACIDS; INTERFERON-TAU;
   EPITHELIAL-CELLS; PROGESTERONE; OXYTOCIN; EXPRESSION; CATTLE
AB Embryonic mortality in cows is at least in part caused by failure of pregnancy recognition (PR). Evidence has shown that bovine viral diarrhoea virus (BVDV) infection can disrupt pregnancy. Prostaglandins (PG) play important roles in many reproductive processes, such as implantation. The aim of this study was to investigate the effect of BVDV infection on uterine PG production and PR using an in vitro PR model. Bovine uterine endometrial cells isolated from ten BVDV-free cows were cultured and treated with 0 or 100 ng/mL interferon-tau (IFNT) in the absence or presence of non-cytopathic BVDV (ncpBVDV). PGF(2 alpha) and PGE(2) concentrations in the spent medium were measured using radioimmunoassays, and in the treated cells expression of the genes associated with PG production and signalling was quantified using qPCR. The results showed that the IF NT challenge significantly stimulated PTGS1 and PTGER3 mRNA expression and PGE(2) production; however, these stimulatory effects were neutralised in the presence of ncpBVDV infection. ncpBVDV infection significantly increased PTGS1 and mPGES1 mRNA expression and decreased AKR1B1 expression, leading to increased PGE(2) and decreased PGF(2 alpha) concentrations and an increased PGE(2):PGF(2 alpha) ratio. The other tested genes, including PGR, ESR1, OXTR, PTGS2, PTGER2 and PTGFR, were not significantly altered by IFNT, ncpBVDV or their combination. Our study suggests that BVDV infection may impair PR by (1) inhibiting the effect of IFNT on uterine PG production and (2) inducing an endocrine switch of PG production from PGF(2 alpha) to PGE(2) to decrease uterine immunity, thereby predisposing the animals to uterine disease.
C1 [Cheng, Zhangrui; Oguejiofor, Chike F.; Ellis, Rebekah; Barry, Amy Teresa; Chen, Xing; Wathes, D. Claire] Royal Vet Coll, Dept Prod & Populat Hlth, N Mymms, Herts, England.
   [Abudureyimu, Ayimuguli] Northwest Univ Nationalities, Life Sci & Engn Coll, Lanzhou, Peoples R China.
   [Chen, Xing] Huazhong Agr Univ, Coll Anim Sci & Technol, Key Lab Agr Anim Genet Breeding & Reprod, Educ Minist China, Wuhan, Peoples R China.
   [Anstaett, Olivia L.; Brownlie, Joe] Royal Vet Coll, Dept Pathol & Pathogen Biol, N Mymms, Herts, England.
RP Cheng, ZR (reprint author), Royal Vet Coll, Dept Prod & Populat Hlth, N Mymms, Herts, England.
EM zcheng@rvc.ac.uk
CR Bazer FW, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-23
   Bazer FW, 2008, REPROD BIOL, V8, P179
   Charpigny G, 1999, J REPROD FERTIL, V117, P315, DOI 10.1530/jrf.0.1170315
   Cheng Z, 2001, J ENDOCRINOL, V171, P463, DOI 10.1677/joe.0.1710463
   Cheng ZR, 2013, ANIM REPROD SCI, V143, P38, DOI 10.1016/j.anireprosci.2013.10.015
   DANETDESNOYERS G, 1994, REPROD FERT DEVELOP, V6, P193, DOI 10.1071/RD9940193
   De Vries A, 2006, J DAIRY SCI, V89, P3876
   Diskin MG, 2011, REPROD FERT DEVELOP, V24, P244, DOI [DOI 10.1071/RD11914, 10.1071/RD11914]
   Dorniak P, 2013, J ANIM SCI, V91, P1627, DOI 10.2527/jas.2012-5845
   Dorniak P, 2012, BIOL REPROD, V87, P1, DOI [10.1095/biolreprod.112.101691, DOI 10.1095/BIOLREPROD.112]
   Forde N, 2011, BIOL REPROD, V85, P144, DOI 10.1095/biolreprod.110.090019
   Fortier MA, 2008, J PHYSIOL PHARMACOL, V59, P65
   Gilbert Robert O, 2011, Reprod Fertil Dev, V24, P252, DOI 10.1071/RD11915
   Grooms DL, 2004, VET CLIN N AM-FOOD A, V20, P5, DOI 10.1016/j.cvfa.2003.11.006
   Herath S, 2009, ENDOCRINOLOGY, V150, P1912, DOI 10.1210/en.2008-1379
   Jabbour HN, 2009, REPRODUCTION, V138, P903, DOI 10.1530/REP-09-0247
   Kimura K, 2004, MOL REPROD DEV, V67, P193, DOI 10.1002/mrd.10389
   Kohara J, 2012, JPN J VET RES, V60, P63
   Lanyon SR, 2014, VET J, V199, P201, DOI 10.1016/j.tvjl.2013.07.024
   Leung ST, 2000, J REPROD FERTIL, V119, P287, DOI 10.1530/reprod/119.2.287
   Lewis GS, 2003, J ANIM SCI, V81, P285
   Lonergan P, 2014, ANIMAL, V8, P64, DOI 10.1017/S1751731114000470
   Mann GE, 2013, MOL CELL ENDOCRINOL, V376, P1, DOI 10.1016/j.mce.2013.06.001
   Mann G E, 1999, J Reprod Fertil Suppl, V54, P317
   McCracken JA, 1999, PHYSIOL REV, V79, P263
   Oguejiofor CF, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.128868
   Oguejiofor CF, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.128876
   de Oliveira TFP, 2013, BIOLOGICALS, V41, P407, DOI 10.1016/j.biologicals.2013.08.005
   PONTZER CH, 1991, CANCER RES, V51, P5304
   PONTZER CH, 1988, BIOCHEM BIOPH RES CO, V152, P801, DOI 10.1016/S0006-291X(88)80109-8
   POYSER NL, 1995, PROSTAG LEUKOTR ESS, V53, P147, DOI 10.1016/0952-3278(95)90115-9
   PRATT BR, 1977, J ANIM SCI, V45, P784
   Robinson RS, 1999, J ENDOCRINOL, V160, P21, DOI 10.1677/joe.0.1600021
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Song G, 2007, REPRODUCTION, V133, P285, DOI 10.1530/REP-06-0092
   Spencer TE, 2013, REPRODUCTION, V146, P377, DOI 10.1530/REP-13-0165
   Tithof PK, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-16
   VILCEK S, 1994, ARCH VIROL, V136, P309, DOI 10.1007/BF01321060
   Wathes D C, 1995, J Reprod Fertil Suppl, V49, P53
   Wathes DC, 2007, BIOL REPROD, V77, P190, DOI 10.1095/biolreprod.107.060558
   Wathes DC, 1996, J ENDOCRINOL, V151, P375, DOI 10.1677/joe.0.1510375
   WATHES DC, 1993, J ENDOCRINOL, V138, P479, DOI 10.1677/joe.0.1380479
   Weems CW, 2006, VET J, V171, P206, DOI 10.1016/j.tvjl.2004.11.014
   WELSH MD, 1995, VET IMMUNOL IMMUNOP, V46, P195, DOI 10.1016/0165-2427(94)05366-Z
   ZARCO L, 1988, J REPROD FERTIL, V83, P527
NR 45
TC 0
Z9 0
U1 3
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD JUN
PY 2016
VL 151
IS 6
BP 605
EP 614
DI 10.1530/REP-15-0583
PG 10
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA DN4EP
UT WOS:000377016300007
PM 26952097
ER

PT J
AU Temamogullari, NE
   Nijhout, HF
   Reed, MC
AF Temamogullari, N. Ezgi
   Nijhout, H. Frederik
   Reed, Michael C.
TI Mathematical modeling of perifusion cell culture experiments on GnRH
   signaling
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Mathematical model; Perifusion cell culture; GnRH; LH
ID GONADOTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS;
   ANTERIOR-PITUITARY GLAND; LUTEINIZING-HORMONE; GENE-EXPRESSION;
   DIFFERENTIAL REGULATION; SECRETION; PULSATILE; STIMULATION; LH
AB The effects of pulsatile GnRH stimulation on anterior pituitary cells are studied using perifusion cell cultures, where constantly moving culture medium over the immobilized cells allows intermittent GnRH delivery. The LH content of the outgoing medium serves as a readout of the GnRH signaling pathway activation in the cells. The challenge lies in relating the LH content of the medium leaving the chamber to the cellular processes producing LH secretion. To investigate this relation we developed and analyzed a mathematical model consisting of coupled partial differential equations describing LH secretion in a perifusion cell culture. We match the mathematical model to three different data sets and give cellular mechanisms that explain the data. Our model illustrates the importance of the negative feedback in the signaling pathway and receptor desensitization. We demonstrate that different LH outcomes in oxytocin and GnRH stimulations might originate from different receptor dynamics and concentration. We analyze the model to understand the influence of parameters, like the velocity of the medium flow or the fraction collection time, on the LH outcomes. We show that slow velocities lead to high LH outcomes. Also, we show that fraction collection times, which do not divide the GnRH pulse period evenly, lead to irregularities in the data. We examine the influence of the rate of binding and dissociation of GnRH on the GnRH movement down the chamber. Our model serves as an important tool that can help in the design of perifusion experiments and the interpretation of results. Published by Elsevier Inc.
C1 [Temamogullari, N. Ezgi; Reed, Michael C.] Duke Univ, Dept Math, Durham, NC 27706 USA.
   [Nijhout, H. Frederik] Duke Univ, Dept Biol, Durham, NC USA.
RP Temamogullari, NE (reprint author), Duke Univ, Dept Math, Durham, NC 27706 USA.
EM ezgi@math.duke.edu; hfn@duke.edu; reed@math.duke.edu
FU NIH [R01 ES019876]; NSF [EF-1038593]; DARPA [D12AP00001]
FX This work was supported by Grants R01 ES019876 from NIH (HFN, MCR) and
   EF-1038593 from NSF (MCR,HFN) and D12AP00001 (J Harer) from DARPA.
CR Bedecarrats GY, 2003, ENDOCRINOLOGY, V144, P1802, DOI 10.1210/en.2002-221140
   Bertram R, 2008, B MATH BIOL, V70, P2211, DOI 10.1007/s11538-008-9341-2
   Blum JJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE263
   Cantor HC, 1996, ENDOCRINOLOGY, V137, P2782, DOI 10.1210/en.137.7.2782
   Ciccone NA, 2009, CURR OPIN ENDOCRINOL, V16, P321, DOI 10.1097/MED.0b013e32832d88fb
   Dobkin-Bekman M, 2006, MOL CELL ENDOCRINOL, V252, P184, DOI 10.1016/j.mce.2006.03.035
   Evans J., 2013, INT J ENDOCRINOL, V2013
   Evans JJ, 1999, ENDOCR REV, V20, P46, DOI 10.1210/er.20.1.46
   Evans JJ, 2001, NEUROENDOCRINOLOGY, V73, P408, DOI 10.1159/000054659
   Fournier RL, 2011, BASIC TRANSPORT PHEN
   Garrel G, 2010, BIOL REPROD, V82, P1170, DOI 10.1095/biolreprod.109.082925
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gonzalez-Iglesias A.E., 2014, ENDOCRINOLOGY, V156, P600
   Haisenleder DJ, 2008, ENDOCRINOLOGY, V149, P139, DOI 10.1210/en.2007-1113
   HEINRICH N, 1985, PHARMACEUT RES, P198
   Heinze K, 1998, AM J PHYSIOL-ENDOC M, V275, pE1061
   Kanasaki H., 2012, J SIGNAL TRANSDUCT, V2012, P1
   Krsmanovic LZ, 2000, ENDOCRINOLOGY, V141, P1187, DOI 10.1210/en.141.3.1187
   Leng G, 2008, NEUROCHEM RES, V33, P668, DOI 10.1007/s11064-007-9500-0
   LI CH, 1952, J GEN PHYSIOL, V35, P629, DOI 10.1085/jgp.35.4.629
   Magill JC, 2013, MATH BIOSCI, V246, P38, DOI 10.1016/j.mbs.2013.09.006
   McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001
   McArdle CA, 1999, MOL CELL ENDOCRINOL, V151, P129, DOI 10.1016/S0303-7207(99)00024-6
   MCINTOSH JEA, 1984, MED BIOL ENG COMPUT, V22, P259, DOI 10.1007/BF02442753
   MCINTOSH JEA, 1986, J ENDOCRINOL, V109, P155, DOI 10.1677/joe.0.1090155
   MCINTOSH RP, 1985, ENDOCRINOLOGY, V117, P169
   Midgley A., 1995, METHODS NEUROSCI, V28, P188
   [Anonymous], 1994, METH NEUROSCI
   Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5
   Pemberton JG, 2014, GEN COMP ENDOCR, V205, P268, DOI 10.1016/j.ygcen.2014.03.011
   Perrett Rebecca M, 2013, Front Endocrinol (Lausanne), V4, P180, DOI 10.3389/fendo.2013.00180
   Purwana IN, 2010, BIOL REPROD, V82, P352, DOI 10.1095/biolreprod.109.080440
   REED MC, 1990, SIAM J APPL MATH, V50, P167, DOI 10.1137/0150011
   Reed M.C., 1994, LECT MATH LIFE SCI, V24, P1
   Ruf F, 2004, TRENDS ENDOCRIN MET, V15, P331, DOI 10.1016/j.tem.2004.07.008
   Scullion S, 2004, J NEUROENDOCRINOL, V16, P265, DOI 10.1111/j.0953-8194.2004.01169.x
   SMITH WR, 1991, AM J PHYSIOL, V261, pR247
   Thackray VG, 2010, MOL CELL ENDOCRINOL, V314, P192, DOI 10.1016/j.mce.2009.09.003
   Thompson IR, 2014, MOL CELL ENDOCRINOL, V385, P28, DOI 10.1016/j.mce.2013.09.012
   Veldhuis JD, 2008, ENDOCR REV, V29, P823, DOI 10.1210/er.2008-0005
   Washington Talitha M, 2004, Theor Biol Med Model, V1, P9, DOI 10.1186/1742-4682-1-9
   WEISS J, 1993, ENDOCRINOLOGY, V132, P2307, DOI 10.1210/en.132.6.2307
   Zhang T, 2006, J MOL ENDOCRINOL, V36, P41, DOI 10.1677/jme.1.01881
NR 43
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD JUN
PY 2016
VL 276
BP 121
EP 132
DI 10.1016/j.mbs.2016.03.016
PG 12
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA DM9TL
UT WOS:000376708500012
PM 27067630
ER

PT J
AU Colonnello, V
   Domes, G
   Heinrichs, M
AF Colonnello, Valentina
   Domes, Gregor
   Heinrichs, Markus
TI As time goes by: Oxytocin influences the subjective perception of time
   in a social context
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Social cognition; Subjectivity; Sociability
ID INTRANASAL OXYTOCIN; INTERNAL CLOCK; FACIAL EXPRESSIONS; NEURAL
   MECHANISMS; HUMAN BRAIN; EMOTION; RECOGNITION; VALIDATION; SELF; MEN
AB Time perception depends on an event's emotional relevance to the beholder; a subjective time dilation effect is associated with self-relevant, emotionally salient stimuli. Previous studies have revealed that oxytocin modulates the salience of social stimuli and attention to social cues. However, whether the oxytocin system is involved in human subjective time perception is unknown. The aim of the present study was to investigate whether increased oxytocin levels would induce a time dilation effect for self relevant, positive social cues.
   In a double-blind, placebo-controlled, between-subject design, heterosexual men were administered intranasal oxytocin or placebo. After about 50 min, participants completed a time-bisection task in which they estimated lengths of exposure to happy female faces (self-relevant positive stimuli, based on sexual orientation), emotionally neutral and negative female faces (control), and happy, neutral, and negative male faces (control). Oxytocin induced a subjective time dilation effect for happy female faces and a time compression effect for happy male faces.
   Our results provide evidence that oxytocin influences time perception, a primary form of human subjectivity. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Colonnello, Valentina; Domes, Gregor; Heinrichs, Markus] Univ Freiburg, Lab Biol & Personal Psychol, Dept Psychol, D-79104 Freiburg, Germany.
   [Domes, Gregor; Heinrichs, Markus] Univ Freiburg, Univ Med Ctr, Freiburg Brain Imaging Ctr, D-79106 Freiburg, Germany.
RP Colonnello, V (reprint author), Univ Freiburg, Lab Biol & Personal Psychol, Dept Psychol, D-79104 Freiburg, Germany.
EM valentina.colonnello@psychologie.uni-freiburg.de
FU Deutsche Forschungsgemeinschaft [He5310/1-1]
FX Source: This work was supported by grants from the Deutsche
   Forschungsgemeinschaft to M.H. (He5310/1-1).
CR Allman MJ, 2014, ANNU REV PSYCHOL, V65, P743, DOI 10.1146/annurev-psych-010213-115117
   BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1
   Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471
   Bernieri F. J., 1991, FUNDAMENTALS NONVERB, P401
   Boccia ML, 2013, NEUROSCIENCE, V253, P155, DOI 10.1016/j.neuroscience.2013.08.048
   Buhusi CV, 2005, NAT REV NEUROSCI, V6, P755, DOI 10.1038/nrn1764
   Burri A, 2008, PSYCHONEUROENDOCRINO, V33, P591, DOI 10.1016/j.psyneuen.2008.01.014
   COLLINS NL, 1990, J PERS SOC PSYCHOL, V58, P644, DOI 10.1037/0022-3514.58.4.644
   Colonnello V, 2014, J PSYCHOSOM RES, V77, P415, DOI 10.1016/j.jpsychores.2014.06.016
   Colonnello V, 2013, PSYCHONEUROENDOCRINO, V38, P2996, DOI 10.1016/j.psyneuen.2013.08.010
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   Di Simplicio M., 2008, J PSYCHOPHARMACOL, V23, P241
   Domes G, 2013, PSYCHOL MED, V43, P1747, DOI 10.1017/S0033291712002565
   Droit-Volet S, 2004, COGNITION EMOTION, V18, P849, DOI 10.1080/02699930341000194
   Droit-Volet S, 2007, TRENDS COGN SCI, V11, P504, DOI 10.1016/j.tics.2007.09.008
   Ebner NC, 2010, BEHAV RES METHODS, V42, P351, DOI 10.3758/BRM.42.1.351
   Effron DA, 2006, EMOTION, V6, P1, DOI 10.1037/1528-3542.6.1.1
   Fahrenberg J., 1984, FREIBURGER PERSON LI
   Haggard P, 2008, NAT REV NEUROSCI, V9, P934, DOI 10.1038/nrn2497
   Hagura N, 2012, P ROY SOC B-BIOL SCI, V279, P4399, DOI 10.1098/rspb.2012.1339
   Heinrichs M, 2004, PHYSIOL BEHAV, V83, P31, DOI 10.1016/j.physbeh.2004.07.020
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Ivry RB, 2008, TRENDS COGN SCI, V12, P273, DOI 10.1016/j.tics.2008.04.002
   Kranz F, 2006, CURR BIOL, V16, P63, DOI 10.1016/j.cub.2005.10.070
   Lewis PA, 2003, CURR OPIN NEUROBIOL, V13, P250, DOI 10.1016/S0959-4388(03)00036-9
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015
   Livesey AC, 2007, NEUROPSYCHOLOGIA, V45, P321, DOI 10.1016/j.neuropsychologia.2006.06.033
   Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-7967(97)10031-6
   Meck WH, 2006, BRAIN RES, V1109, P93, DOI 10.1016/j.brainres.2006.06.031
   Meck WH, 2005, BRAIN COGNITION, V58, P1, DOI 10.1016/j.bandc.2004.09.004
   MECK WH, 1987, BEHAV BRAIN RES, V23, P147, DOI 10.1016/0166-4328(87)90051-9
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Oaten M, 2009, PSYCHOL BULL, V135, P303, DOI 10.1037/a0014823
   Panksepp J, 2009, BIOL PSYCHIAT, V65, P725, DOI 10.1016/j.biopsych.2009.02.004
   Prehn K, 2013, PSYCHOPHYSIOLOGY, V50, P528, DOI 10.1111/psyp.12042
   Sandstrom NJ, 2007, BEHAV NEUROSCI, V121, P422, DOI 10.1037/0735-7044.121.2.422
   Schmidt K.-H., 1992, WORTSCHATZTEST WST
   Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Spielberger CD, 1991, STATE TRAIT ANGER EX
   STEYER R, 1994, DIAGNOSTICA, V40, P320
   Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019
   Thienel M, 2014, PSYCHONEUROENDOCRINO, V39, P194, DOI 10.1016/j.psyneuen.2013.09.013
   Thornhill R, 1999, TRENDS COGN SCI, V3, P452, DOI 10.1016/S1364-6613(99)01403-5
   Tipples J, 2008, EMOTION, V8, P127, DOI 10.1037/1528-3542.8.1.127
   Tracy JL, 2011, EMOTION, V11, P1379, DOI 10.1037/a0022902
   TRIBOLLET E, 1992, ANN NY ACAD SCI, V652, P29, DOI 10.1111/j.1749-6632.1992.tb34343.x
   Unkelbach C, 2008, PSYCHOL SCI, V19, P1092, DOI 10.1111/j.1467-9280.2008.02206.x
   Wittmann M, 2015, CONSCIOUS COGN, V38, P172, DOI 10.1016/j.concog.2015.06.008
   Wittmann M, 2009, PHILOS T R SOC B, V364, P1809, DOI 10.1098/rstb.2009.0025
NR 51
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUN
PY 2016
VL 68
BP 69
EP 73
DI 10.1016/j.psyneuen.2016.02.015
PG 5
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DM3AF
UT WOS:000376218500009
PM 26945451
ER

PT J
AU Anacker, AMJ
   Christensen, JD
   LaFlamme, EM
   Grunberg, DM
   Beery, AK
AF Anacker, Allison M. J.
   Christensen, Jennifer D.
   LaFlamme, Elyssa M.
   Grunberg, Diana M.
   Beery, Annaliese K.
TI Septal oxytocin administration impairs peer affiliation via V1 a
   receptors in female meadow voles
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxytocin; Vasopressin; Vasopressin 1a receptor; Meadow vole; Social
   behavior; Lateral septum
ID SOCIAL-BEHAVIOR NETWORK; PAIR BOND FORMATION; MALE PRAIRIE VOLES;
   MICROTUS-PENNSYLVANICUS; LATERAL SEPTUM; NUCLEUS-ACCUMBENS; MEDIAL
   AMYGDALA; SEASONAL DIFFERENCES; PARTNER PREFERENCES; PATERNAL BEHAVIOR
AB The peptide hormone oxytocin (OT) plays an important role in social behaviors, including social bond formation. In different contexts, however, OT is also associated with aggression, social selectivity, and reduced affiliation. Female meadow voles form social preferences for familiar same-sex peers under short, winter-like day lengths in the laboratory, and provide a means of studying affiliation outside the context of reproductive pair bonds. Multiple lines of evidence suggest that the actions of OT in the lateral septum (LS) may decrease affiliative behavior, including greater density of OT receptors in the LS of meadow voles that huddle less. We infused OT into the LS of female meadow voles immediately prior to cohabitation with a social partner to determine its effects on partner preference formation. OT prevented the formation of preferences for the partner female. Co-administration of OT with a specific OT receptor antagonist did not reverse the effect, but co-administration of OT with a specific vasopressin la receptor (V1 aR) antagonist did, indicating that OT in the LS likely acted through V1aRs to decrease partner preference. Receptor autoradiography revealed dense V1 aR binding in the LS of female meadow voles. These results suggest that the LS is a brain region that may be responsible for inhibitory effects of OT administration on affiliation, which will be important to consider in therapeutic administrations of OT. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Anacker, Allison M. J.; Christensen, Jennifer D.; LaFlamme, Elyssa M.; Grunberg, Diana M.; Beery, Annaliese K.] Smith Coll, Clark Sci Ctr, Program Neurosci, 44 Coll Lane, Northampton, MA 01063 USA.
   [Beery, Annaliese K.] Smith Coll, Clark Sci Ctr, Dept Biol, Dept Psychol, 44 Coll Lane, Northampton, MA 01063 USA.
   [Anacker, Allison M. J.] Columbia Univ, NYSPI Unit 78,1051 Riverside Dr, New York, NY 10032 USA.
RP Beery, AK (reprint author), Smith Coll, Clark Sci Ctr, 44 Coll Lane, Northampton, MA 01063 USA.
EM allison.anacker@gmail.com; j3nnchrstnsn@gmail.com; eml97@georgetown.edu;
   diana.ms.grunberg@gmail.com; abeery@smith.edu
FU National Science Foundation; National Institutes of Health; Eveillard
   Postdoctoral Fellowship at Smith College
FX This work was supported by grants from the National Science Foundation,
   the National Institutes of Health, and the Eveillard Postdoctoral
   Fellowship at Smith College. Funding sources played no further role in
   study design, data collection, data analysis, or decision to publish.
CR Ahern TH, 2009, J NEUROSCI METH, V182, P180, DOI 10.1016/j.jneumeth.2009.06.010
   Anacker AMJ, 2016, HORM BEHAV, V79, P52, DOI 10.1016/j.yhbeh.2016.01.004
   Anacker AMJ, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00185
   Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025
   BAMSHAD M, 1993, J NEUROENDOCRINOL, V5, P247, DOI 10.1111/j.1365-2826.1993.tb00480.x
   Beery AK, 2010, NEUROSCIENCE, V169, P665, DOI 10.1016/j.neuroscience.2010.05.023
   Beery A. K., 2015, CURR OPIN BEHAV SCI
   Beery AK, 2008, HORM BEHAV, V54, P153, DOI 10.1016/j.yhbeh.2008.02.007
   Beery AK, 2008, J COMP NEUROL, V507, P1847, DOI 10.1002/cne.21638
   Beery AK, 2014, HORM BEHAV, V66, P779, DOI 10.1016/j.yhbeh.2014.08.014
   Beery AK, 2009, PHYSIOL BEHAV, V97, P52, DOI 10.1016/j.physbeh.2009.01.020
   BOONSTRA R, 1993, BEHAV ECOL, V4, P83, DOI 10.1093/beheco/4.1.83
   Bredewold R, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00216
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Caughey SD, 2011, J NEUROENDOCRINOL, V23, P1113, DOI 10.1111/j.1365-2826.2011.02224.x
   Chan WY, 1996, J PHARMACOL EXP THER, V277, P999
   Curley JP, 2012, HORM BEHAV, V61, P454, DOI 10.1016/j.yhbeh.2012.01.013
   De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Declerck CH, 2014, SOC COGN AFFECT NEUR, V9, P802, DOI 10.1093/scan/nst040
   DEVRIES GJ, 1992, ANN NY ACAD SCI, V652, P387
   DEVRIES GJ, 1981, BRAIN RES, V218, P67, DOI 10.1016/0006-8993(81)90989-6
   Dumais KM, 2016, PSYCHONEUROENDOCRINO, V64, P79, DOI 10.1016/j.psyneuen.2015.11.007
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   FERKIN MH, 1991, J REPROD FERTIL, V92, P433
   Getz L. L., 1972, J MAMMAL, V53
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Goodson JL, 2005, HORM BEHAV, V48, P11, DOI 10.1016/j.yhbeh.2005.02.003
   Goodson JL, 1999, J NEUROENDOCRINOL, V11, P19
   Gur R, 2014, BIOL PSYCHIAT, V76, P377, DOI 10.1016/j.biopsych.2014.03.022
   Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465
   INSEL TR, 1994, J NEUROSCI, V14, P5381
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Keebaugh AC, 2015, SOC NEUROSCI-UK, V10, P561, DOI 10.1080/17470919.2015.1040893
   LANDGRAF R, 1995, J NEUROSCI, V15, P4250
   Leonard ST, 2005, PHYSIOL BEHAV, V85, P461, DOI 10.1016/j.physbeh.2005.05.011
   Leonard ST, 1999, PHYSIOL BEHAV, V68, P139, DOI 10.1016/S0031-9384(99)00161-4
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   MADISON DM, 1984, BEHAV ECOL SOCIOBIOL, V15, P9, DOI 10.1007/BF00310209
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   MANNING M, 1995, INT J PEPT PROT RES, V46, P244
   MCSHEA WJ, 1990, ANIM BEHAV, V39, P346, DOI 10.1016/S0003-3472(05)80880-2
   Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Ondrasek NR, 2015, PHYSIOL BEHAV, V140, P118, DOI 10.1016/j.physbeh.2014.12.021
   Parker KJ, 2003, J COMP PSYCHOL, V117, P283, DOI 10.1037/0735-7036.117.3.283
   Parker KJ, 2001, BEHAV NEUROSCI, V115, P1341, DOI 10.1037/0735-7044.115.6.1341
   Qiu F, 2014, BRIT J PHARMACOL, V171, P3065, DOI 10.1111/bph.12635
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Shen Helen, 2015, Nature, V522, P410, DOI 10.1038/522410a
   Sheng F, 2013, BIOL PSYCHOL, V92, P380, DOI 10.1016/j.biopsycho.2012.11.018
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   van Anders SM, 2013, ARCH SEX BEHAV, V42, P1115, DOI 10.1007/s10508-013-0134-9
   Veenema AH, 2012, HORM BEHAV, V61, P50, DOI 10.1016/j.yhbeh.2011.10.002
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   WANG ZX, 1993, BRAIN RES, V631, P156, DOI 10.1016/0006-8993(93)91203-5
   WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F
   Yong E, 2012, NEW SCI, V213, P39
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
   Zik JB, 2015, PSYCHIAT RES, V226, P31, DOI 10.1016/j.psychres.2014.11.048
   Zoicas Iulia, 2014, Neuropsychopharmacology, V39, P3027, DOI 10.1038/npp.2014.156
NR 67
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUN
PY 2016
VL 68
BP 156
EP 162
DI 10.1016/j.psyneuen.2016.02.025
PG 7
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DM3AF
UT WOS:000376218500019
PM 26974500
ER

PT J
AU Cardoso, C
   Kalogeropoulos, C
   Brown, CA
   Orlando, MA
   Ellenbogen, MA
AF Cardoso, Christopher
   Kalogeropoulos, Christopher
   Brown, Christopher A.
   Orlando, Mark Anthony
   Ellenbogen, Mark A.
TI Memory response to oxytocin predicts relationship dissolution over 18
   months
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Intranasal oxytocin; Autobiographical memory; Self-referential
   processing; Romantic relationships; Relationship dissolution
ID INTRANASAL OXYTOCIN; MENTAL-HEALTH; AUTOBIOGRAPHICAL MEMORY;
   SOCIAL-BEHAVIOR; RECEPTOR GENE; DEPRESSION; HUMANS; COMMITMENT; PARTNER;
   CONTEXT
AB Background: Oxytocin is known for its role in pair bonding in non-human animals. To examine the role of oxytocin in human romantic bonding, we examined its effect on recall of memories of past and current romantic experiences as predictors of relationship dissolution.
   Method: In a placebo-controlled, within-subject, randomized experiment, 48 participants (249;16 single) self-administered intranasal oxytocin and completed an autobiographical memory test. Participants in a current romantic relationship reported on their relationship status 18 months later.
   Results: Participants in a relationship recalled fewer memories of past romantic partners following oxytocin administration relative to placebo. Participants who responded to oxytocin by recalling more conflict memories of their current romantic partner, relative to placebo, were more likely to have ended their relationship over 18 months than those who did not show this response.
   Conclusion: These results suggest that the memory response to an intranasal oxytocin challenge may represent an index of relationship outcome over time. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Cardoso, Christopher; Kalogeropoulos, Christopher; Brown, Christopher A.; Orlando, Mark Anthony; Ellenbogen, Mark A.] Concordia Univ, Dept Psychol, Ctr Res Human Dev, Montreal, PQ H3G 1M8, Canada.
RP Ellenbogen, MA (reprint author), Concordia Univ, Dept Psychol, Ctr Res Human Dev, Montreal, PQ H3G 1M8, Canada.
EM mark.ellenbogen@concordia.ca
FU Canada Research Chair program (Social Sciences and Humanities Research
   Council of Canada; SSHRC); Fonds de recherche du Quebec - Sante (FRQS);
   SSHRC; Canadian Institutes of Health Research (CIHR)
FX This research was supported by grants to Dr. Ellenbogen from the Canada
   Research Chair program (supported by the Social Sciences and Humanities
   Research Council of Canada; SSHRC). Christopher Cardoso is supported by
   a scholarship from the Fonds de recherche du Quebec - Sante (FRQS). Mark
   Anthony Orlando is supported by a scholarship from SSHRC. Christopher
   Kalogeropoulos is supported by a scholarship from the Canadian
   Institutes of Health Research (CIHR).
CR Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   Beck A. T., 1996, MANUAL BECK DEPRESSI
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Cardoso C, 2014, PSYCHONEUROENDOCRINO, V49, P161, DOI 10.1016/j.psyneuen.2014.07.014
   Cardoso C, 2014, SOC NEUROSCI-UK, V9, P186, DOI 10.1080/17470919.2013.873079
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Cardoso C, 2012, PSYCHOPHARMACOLOGY, V220, P741, DOI 10.1007/s00213-011-2527-6
   Carter CS, 2014, ANNU REV PSYCHOL, V65, P17, DOI 10.1146/annurev-psych-010213-115110
   Cavanaugh J, 2014, PSYCHONEUROENDOCRINO, V49, P1, DOI 10.1016/j.psyneuen.2014.06.020
   Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003
   Colonnello V, 2013, PSYCHONEUROENDOCRINO, V38, P2996, DOI 10.1016/j.psyneuen.2013.08.010
   Conway MA, 2005, J MEM LANG, V53, P594, DOI 10.1016/j.jml.2005.08.005
   Conway MA, 2001, J MEM LANG, V45, P493, DOI 10.1006/jmla.2001.2781
   Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011
   Ellenbogen M.A., 2012, PSYCHOPHYSIOLOGY, V49, P127
   Ellenbogen MA, 2013, PSYCHONEUROENDOCRINO, V38, P387, DOI 10.1016/j.psyneuen.2012.06.016
   Fergusson DM, 2005, ARCH GEN PSYCHIAT, V62, P66, DOI 10.1001/archpsyc.62.1.66
   Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008
   Guastella A.J., 2013, PSYCHONEUROENDOCRINO, V38, P612
   Lilja G, 2012, SCAND J CARING SCI, V26, P245, DOI 10.1111/j.1471-6712.2011.00925.x
   Olff M, 2013, PSYCHONEUROENDOCRINO, V38, P1883, DOI 10.1016/j.psyneuen.2013.06.019
   Pincus David, 2010, Front Psychiatry, V1, P134, DOI 10.3389/fpsyt.2010.00134
   Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009
   Rockliff H, 2011, EMOTION, V11, P1388, DOI 10.1037/a0023861
   RUSBULT CE, 1993, J SOC PERS RELAT, V10, P175, DOI 10.1177/026540759301000202
   RUSBULT CE, 1983, J PERS SOC PSYCHOL, V45, P101, DOI 10.1037/0022-3514.45.1.101
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   Shahrestani S, 2013, NEUROPSYCHOPHARMACOL, V38, P1929, DOI 10.1038/npp.2013.86
   Smith AS, 2010, HORM BEHAV, V57, P255, DOI 10.1016/j.yhbeh.2009.12.004
   Striepens N., 2013, SCI REP, V3, P3340
   Taylor SE, 2010, PSYCHOL SCI, V21, P3, DOI 10.1177/0956797609356507
   Thompson SM, 2014, PSYCHONEUROENDOCRINO, V43, P11, DOI 10.1016/j.psyneuen.2014.01.012
   Walum H, 2012, BIOL PSYCHIAT, V71, P419, DOI 10.1016/j.biopsych.2011.09.002
   Wang SS, 2008, MOL PSYCHIATR, V13, P786, DOI 10.1038/mp.2008.38
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Zelkowitz P, 2014, HORM BEHAV, V66, P351, DOI 10.1016/j.yhbeh.2014.06.014
NR 40
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD JUN
PY 2016
VL 68
BP 171
EP 176
DI 10.1016/j.psyneuen.2016.03.005
PG 6
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA DM3AF
UT WOS:000376218500021
PM 26986091
ER

PT J
AU Antonazzo, P
   Laoreti, A
   Personeni, C
   Grossi, E
   Martinelli, A
   Cetin, I
AF Antonazzo, Patrizio
   Laoreti, Arianna
   Personeni, Carlo
   Grossi, Elena
   Martinelli, Anna
   Cetin, Irene
TI Vaginal Dinoprostone Versus Intravenous Oxytocin for Labor Induction in
   Patients Not Responsive to a First Dose of Dinoprostone: A Randomized
   Prospective Study
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE labor induction; cervical ripening; dinoprostone
ID CONTROLLED-TRIAL; COMPARATIVE EFFICACY; UNFAVORABLE CERVIX; BISHOP
   SCORE; MISOPROSTOL; TERM; INSERT; PREINDUCTION; CONCURRENT; METAANALYSIS
AB Objective: To evaluate the efficacy of 2 different regimens for labor induction in patients with unfavorable cervix not responsive to a first dose of dinoprostone vaginal insert.
   Methods: Between November, 2011 and June, 2014, 338 patients underwent induction of labor. After standard 24 hours treatment, 94 singleton term pregnancies remained with a Bishop score 6 and were randomized into 2 different regimens: repeated vaginal dinoprostone (group A, n = 47) or intravenous oxytocin (group B, n = 47). Primary outcome was vaginal delivery, and the secondary outcomes were interval between labor induction and delivery and operative delivery rates.
   Results: Vaginal deliveries were significantly higher (group A: 26/47 (55.3%) and group B 16/47 (34.0%), P < .05), and cesarean sections were significantly lower (group A 21/47 (44.7%) and group B 31/47 (66%), P < .05) in patients who received a double dose of dinoprostone. The intervals between labor induction and onset of labor and between labor induction and delivery were lower in the group treated with oxytocin. Neonatal outcomes were similar in the 2 groups.
   Conclusion: A second dinoprostone vaginal insert is an effective and safe choice for patients with unfavorable cervix not responsive to a first 24 hours administration of dinoprostone for cervical ripening, and its use is associated with lower cesarean section rates.
C1 [Antonazzo, Patrizio; Laoreti, Arianna; Personeni, Carlo; Grossi, Elena; Martinelli, Anna; Cetin, Irene] Univ Milan, Hosp L Sacco, Unit Obstet & Gynecol, Dept Biomed & Clin Sci, Via GB Grassi 74, I-20157 Milan, Italy.
   [Antonazzo, Patrizio; Laoreti, Arianna; Personeni, Carlo; Grossi, Elena; Martinelli, Anna; Cetin, Irene] Univ Milan, Ctr Fetal Res Giorgio Pardi, I-20157 Milan, Italy.
RP Antonazzo, P (reprint author), Univ Milan, Hosp L Sacco, Unit Obstet & Gynecol, Dept Biomed & Clin Sci, Via GB Grassi 74, I-20157 Milan, Italy.
EM patrizio.antonazzo@guest.unimi.it
CR ACOG Committee on Practice Bulletins-Obstetrics, 2009, OBSTET GYNECOL 1, V114, P386
   American College of Obstetricians and Gynecologists, 2010, OBSTET GYNECOL, V116, P1232
   ARULKUMARAN S, 1985, AUST NZ J OBSTET GYN, V25, P190, DOI 10.1111/j.1479-828X.1985.tb00641.x
   Barbitch MP, 2013, GYNECOL OBSTET FERTI, V41, P346, DOI 10.1016/j.gyobfe.2013.02.008
   Bebbington M, 2003, AM J OBSTET GYNECOL, V189, pS211, DOI 10.1016/j.ajog.2003.10.565
   BISHOP EH, 1964, OBSTET GYNECOL, V24, P266
   Bolnick JM, 2004, AM J OBSTET GYNECOL, V190, P124, DOI 10.1016/S0002-9378(03)00952-9
   Christensen FC, 2002, AM J OBSTET GYNECOL, V186, P61, DOI 10.1067/mob.2002.118309
   Facchinetti F, 2012, J MATERN-FETAL NEO M, V25, P1965, DOI 10.3109/14767058.2012.668584
   Garry D, 2003, J Matern Fetal Neonatal Med, V13, P254, DOI 10.1080/jmf.13.4.254.259
   Keirse MJNC, 2006, CLIN OBSTET GYNECOL, V49, P609, DOI 10.1097/00003081-200609000-00020
   Khan RA, 2007, INT J GYNECOL OBSTET, V96, P94, DOI 10.1016/j.ijgo.2006.10.002
   Macones GA, 2008, OBSTET GYNECOL, V112, P661, DOI 10.1097/AOG.0b013e3181841395
   Marconi AM, 2008, EUR J OBSTET GYN R B, V138, P135, DOI 10.1016/j.ejogrb.2007.08.009
   Ozkan S, 2009, ARCH GYNECOL OBSTET, V280, P19, DOI 10.1007/s00404-008-0843-9
   Pevzner L, 2009, OBSTET GYNECOL, V114, P261, DOI 10.1097/AOG.0b013e3181ad9377
   Ramsey PS, 2003, AM J OBSTET GYNECOL, V188, P560, DOI 10.1067/mob.2003.150
   Rozenberg P, 2004, AM J OBSTET GYNECOL, V191, P247, DOI 10.1016/j.ajog.2003.12.038
   Sanchez-Ramos L, 1998, OBSTET GYNECOL, V91, P401, DOI 10.1016/S0029-7844(97)00673-X
   Sanchez-Ramos L, 1999, OBSTET GYNECOL, V94, P878, DOI 10.1016/S0029-7844(99)00320-8
   Smith JG, 2006, CLIN OBSTET GYNECOL, V49, P594, DOI 10.1097/00003081-200609000-00019
   Tan PC, 2009, OBSTET GYNECOL, V113, P1059, DOI 10.1097/AOG.0b013e3181a1f605
   Tanir HM, 2008, CLIN EXP OBSTET GYN, V35, P65
   Thomas J, 2014, COCHRANE DB SYST REV, V6
   Timmons B, 2010, TRENDS ENDOCRIN MET, V21, P353, DOI 10.1016/j.tem.2010.01.011
   Triglia MT, 2010, ACTA OBSTET GYN SCAN, V89, P651, DOI 10.3109/00016340903575998
   Vrouenraets FPJM, 2005, OBSTET GYNECOL, V105, P690, DOI 10.1097/01.AOG.0000152338.76759.38
   Wing DA, 1997, AM J OBSTET GYNECOL, V177, P612, DOI 10.1016/S0002-9378(97)70154-6
   Xenakis EMJ, 1997, OBSTET GYNECOL, V90, P235, DOI 10.1016/S0029-7844(97)00259-7
   Zanconato G, 2011, J MATERN-FETAL NEO M, V24, P728, DOI 10.3109/14767058.2011.557108
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD JUN
PY 2016
VL 23
IS 6
BP 779
EP 784
DI 10.1177/1933719115618272
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DM3YB
UT WOS:000376281500013
PM 26626794
ER

PT J
AU Loytved-Hardegg, JJ
   Brunner, M
   Ries, JJ
   von Felten, S
   Heugel, C
   Lapaire, O
   Voekt, C
   Hosli, I
AF Loytved-Hardegg, Julia J.
   Brunner, Mirjam
   Ries, Jean-Jacques
   von Felten, Stefanie
   Heugel, Christina
   Lapaire, Olav
   Voekt, Cora
   Hosli, Irene
TI Replacement of oxytocin bolus administration by infusion: influences on
   postpartum outcome
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Oxytocin; Post partum haemorrhage; Third stage of labour
ID ELECTIVE CESAREAN DELIVERY; LABOR; HEMORRHAGE; PARTURITION; ANESTHESIA;
   DURATION; SECTION
AB Postpartum haemorrhage (PPH) represents a leading cause of maternal morbidity and mortality. Giving oxytocin after birth reduces the risk for PPH. It has never been tested whether different methods of oxytocin administration affect the maternal outcome. This study aims to compare the infusion versus the bolus application of oxytocin after singleton vaginal delivery.
   This retrospective monocentre study compares the incidence of clinically relevant postpartum complications in women receiving 5 IE of oxytocin as a bolus or as a 100 ml-infusion over 5 min, given immediately after birth. Included were women delivering singletons vaginally at term. We used propensity score weighting to compare outcomes between women receiving bolus and infusion and to minimize the selection bias in this retrospective cohort.
   1765 patients were included. Patient characteristics were balanced. We found no significant differences for the combined overall postpartum adverse outcome (the incidence of PPH, manual removal of the placenta and/or curettage). For the single outcomes, we observed a significantly higher frequency of manual removal of the placenta (Odds ratio 1.47, 95 % CI 1.02-2.13) and a slightly higher but clinically not relevant estimated blood loss (Relative effect 1.05, 95 % CI 1.01-1.10) in the infusion group.
   The data show a tendency towards more complications in the infusion group. It is related to a more frequent need for manual removal of the placenta.
C1 [Loytved-Hardegg, Julia J.; Brunner, Mirjam; Heugel, Christina; Lapaire, Olav; Hosli, Irene] Univ Basel Hosp, Dept Obstet, Spitalstr 21, CH-4031 Basel, Switzerland.
   [Ries, Jean-Jacques] Womens Hosp Med Ctr, Cantonal Hosp Aarau, Tellstr, CH-5001 Aarau, Switzerland.
   [von Felten, Stefanie] Univ Basel Hosp, Clin Trial Unit, Schanzenstr 55, CH-4031 Basel, Switzerland.
   [Voekt, Cora] Womens Hosp Med Ctr, Hosp Grabs, Spitalstr 44, CH-9472 Grabs, Switzerland.
RP Hosli, I (reprint author), Univ Basel Hosp, Dept Obstet, Spitalstr 21, CH-4031 Basel, Switzerland.
EM Irene.hoesli@usb.ch
CR American College of Obstetricians and Gynecologists, 2006, OBSTET GYNECOL, V108, P1039
   Balki M, 2006, OBSTET GYNECOL, V107, P45, DOI 10.1097/01.AOG.0000191529.52596.c0
   Bateman BT, 2010, ANESTH ANALG, V110, P1368, DOI 10.1213/ANE.0b013e3181d74898
   Begley CM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007412.pub3
   Carvalho JCA, 2004, OBSTET GYNECOL, V104, P1005, DOI 10.1097/01.AOG.0000142709.04450.bd
   Cheung WMC, 2011, J OBSTET GYNAECOL, V31, P37, DOI 10.3109/01443615.2010.531301
   Development Core Team R., 2013, R LANG ENV STAT COMP
   Dyer RA, 2011, CURR OPIN ANESTHESIO, V24, P255, DOI 10.1097/ACO.0b013e328345331c
   Dyer RA, 2009, ANESTHESIOLOGY, V111, P753, DOI 10.1097/ALN.0b013e3181b437e0
   Ekin A, 2015, ARCH GYNECOL OBSTET
   FUCHS AR, 1991, AM J OBSTET GYNECOL, V165, P1515
   Grotegut CA, 2011, AM J OBSTET GYNECOL, V204, P56
   Hernan MA, 2006, J EPIDEMIOL COMMUN H, V60, P578, DOI 10.1136/jech.2004.029496
   Kramer MS, 2013, AM J OBSTET GYNECOL, V209, P449, DOI DOI 10.1016/J.AJ0G.2013.07.007
   Langesaeter E, 2009, BRIT J ANAESTH, V103, P260, DOI 10.1093/bja/aep137
   Lutomski JE, 2012, BJOG-INT J OBSTET GY, V119, P306, DOI 10.1111/j.1471-0528.2011.03198.x
   Nordstrom L, 1997, BRIT J OBSTET GYNAEC, V104, P781, DOI 10.1111/j.1471-0528.1997.tb12020.x
   Phaneuf S, 2000, J REPROD FERTIL, V120, P91, DOI 10.1530/reprod/120.1.91
   Prendiville W, 1988, BRIT J OBSTET GYNAEC, V1, P3
   Pursche T, 2012, ARCH GYNECOL OBSTET, V286, P633, DOI 10.1007/s00404-012-2334-2
   Ridgeway G., 2013, TWANG TOOLKIT WEIGHT
   Roach MK, 2013, AM J PERINAT, V30, P523, DOI 10.1055/s-0032-1329184
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Sheehan SR, 2011, BMJ-BRIT MED J, V343, P4661
   Svanstrom MC, 2008, BRIT J ANAESTH, V100, P683, DOI 10.1093/bja/aen071
   Thomas TA, 2002, BRIT J ANAESTH, V89, P499, DOI 10.1093/bja/aef193
   National Collaborating Centre for Women's and Childrens Health (UK), 2007, INTR CAR CAR HLTH WO, V55
   Westhoff G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001808.pub2
   World Health Organization, 2000, MAN COMPL PREGN CHIL
   World Health Organization, 2012, WHO REC PREV TREATM
   Zeeman GG, 1997, OBSTET GYNECOL, V89, P873, DOI 10.1016/S0029-7844(97)00056-2
NR 31
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD JUN
PY 2016
VL 293
IS 6
BP 1219
EP 1225
DI 10.1007/s00404-015-3916-6
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DM1HX
UT WOS:000376097400008
PM 26538357
ER

PT J
AU Sumikura, H
   Inada, E
AF Sumikura, Hiroyuki
   Inada, Eiichi
TI Uterotonics and tocolytics for anesthesiologists
SO CURRENT OPINION IN ANESTHESIOLOGY
LA English
DT Review
DE carbetocin; misoprostol; oxytocin; tocolytics; uterotonics
ID ELECTIVE CESAREAN DELIVERY; RANDOMIZED CONTROLLED-TRIAL; INTRAPARTUM
   FETAL DISTRESS; PLACEBO-CONTROLLED TRIAL; IN-VITRO; UTERINE RELAXATION;
   RETAINED PLACENTA; MYOMETRIAL STRIPS; TERM LABOR; OXYTOCIN
AB Purpose of review
   Obstetric anesthesiologists are supposed to understand the uterotonics and tocolytics used in the perinatal period to provide a better clinical practice. This review describes current consensus of uterotonics and tocolytics used in the perinatal period that an obstetric anesthesiologist should know.
   Recent findings
   Rational use of uterotonics for cesarean section has been well studied in the past decades. Oxytocin remained as a first line uterotonics for cesarean section. For continuous infusion, it is reported that ED90 is higher for laboring parturients than for nonlaboring parturients (6.2 vs. 44.2 IU/h) implying that protocol for oxytocin infusion should be different between laboring patients with prior exposure to oxytocin and nonlaboring patients. For bolus administration, 'rule of three' has been proposed and its efficacy has been reported. When oxytocin fails to achieve sufficient uterine contraction, second-line agents must be administered, and it has been reported that methylergonovine is a superior second-line uterotonic to carboprost. On the other hand, the role of tocolytic agents in obstetric anesthesia has not been well studied.
   Summary
   Anesthesiologists involved in obstetric anesthesia should be able to determine the appropriate uterotonic for cesarean section and know the indication of tocolytics in perinatal period.
C1 [Sumikura, Hiroyuki; Inada, Eiichi] Juntendo Univ, Dept Anesthesiol & Pain Med, Fac Med, Tokyo, Japan.
RP Sumikura, H (reprint author), Juntendo Univ, Dept Anesthesiol & Pain Med, Fac Med, Bunkyo Ku, 3-1-3 Hongo, Tokyo, Japan.
EM hiroyuki.sumikura@gmail.com
CR Abdel-Aleem H, 2015, COCHRANE DB SYST REV, V11
   ABOULEISH E, 1995, BRIT J ANAESTH, V75, P486
   Anandakrishnan S, 2013, CAN J ANESTH, V60, P1054, DOI 10.1007/s12630-013-0028-2
   Anotayanonth S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004352.PUB2
   Balki M, 2006, OBSTET GYNECOL, V107, P45, DOI 10.1097/01.AOG.0000191529.52596.c0
   Balki M, 2015, ANESTH ANALG, V120, P1074, DOI 10.1213/ANE.0000000000000682
   Balki M, 2014, CAN J ANESTH, V61, P808, DOI 10.1007/s12630-014-0190-1
   Bateman BT, 2014, ANESTH ANALG, V119, P1344, DOI 10.1213/ANE.0000000000000398
   Bullarbo M, 2005, INT J GYNECOL OBSTET, V91, P228, DOI 10.1016/j.ijgo.2005.08.020
   Bullens LM, 2015, OBSTET GYNECOL SURV, V70, P524, DOI 10.1097/OGX.0000000000000215
   Butwick AJ, 2010, BRIT J ANAESTH, V104, P338, DOI 10.1093/bja/aeq004
   Butwick AJ, 2015, AM J OBSTET GYNECOL, V212
   CALDEYROBARCIA R, 1992, EARLY HUM DEV, V29, P27, DOI 10.1016/0378-3782(92)90054-K
   Carvalho JCA, 2004, OBSTET GYNECOL, V104, P1005, DOI 10.1097/01.AOG.0000142709.04450.bd
   Chaudhuri P, 2015, INT J GYNECOL OBSTET, V128, P48, DOI 10.1016/j.ijgo.2014.07.029
   Cluver C, 2015, COCHRANE DB SYST REV, V2
   Cole NM, 2016, ANESTHESIOLOGY, V124, P378, DOI 10.1097/ALN.0000000000000940
   Conde-Agudelo A, 2013, AM J OBSTET GYNECOL, V209
   Cordovani D, 2012, CAN J ANESTH, V59, P751, DOI 10.1007/s12630-012-9728-2
   Crowther CA, 2014, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001060.PUB2
   de Hens R, 2008, OBSTET GYNECOL SURV, V63, P383, DOI 10.1097/OGX.0b013e31816ff75b
   Duffy JMN, 2015, OBSTET GYNECOL, V125, P711, DOI 10.1097/AOG.0000000000000697
   Dyer RA, 2011, CURR OPIN ANESTHESIO, V24, P255, DOI 10.1097/ACO.0b013e328345331c
   Farber MK, 2015, INT J OBSTET ANESTH, V24, P217, DOI 10.1016/j.ijoa.2015.03.007
   Flenady V, 2014, COCHRANE DB SYST REV, V6
   Flenady V, 2014, COCHRANE DB SYST REV, V6
   Harnett MJP, 2000, ANESTH ANALG, V91, P1043, DOI 10.1097/00000539-200010000-00069
   Hernandez-Castro F, 2016, INT J GYNECOL OBSTET, V132, P184, DOI 10.1016/j.ijgo.2015.06.060
   Hong RW, 2006, ANESTH ANALG, V103, P511, DOI 10.1213/01.ANE.0000227115.35626.09
   Hua J, 2013, BJOG-INT J OBSTET GY, V120, P531, DOI 10.1111/1471-0528.12134
   HUTCHON DJR, 1982, BRIT J OBSTET GYNAEC, V89, P671, DOI 10.1111/j.1471-0528.1982.tb04724.x
   Khan M, 2014, CAN J ANESTH, V61, P242, DOI 10.1007/s12630-013-0082-9
   Khaw KS, 2015, BRIT J ANAESTH, V114, P944, DOI 10.1093/bja/aev107
   Kovacheva VP, 2015, ANESTHESIOLOGY, V123, P92, DOI 10.1097/ALN.0000000000000682
   Lavoie A, 2015, ANESTH ANALG, V121, P159, DOI 10.1213/ANE.0000000000000781
   Lee AI, 2014, INT J OBSTET ANESTH, V23, P18, DOI 10.1016/j.ijoa.2013.09.004
   LIPSHITZ J, 1977, AM J OBSTET GYNECOL, V129, P31
   Mackeen AD, 2014, COCHRANE DB SYST REV, V2
   Manuck TA, 2015, OBSTET GYNECOL, V126, P954, DOI 10.1097/AOG.0000000000001095
   Mercier FJ, 1997, ANESTH ANALG, V84, P1117, DOI 10.1097/00000539-199705000-00030
   Nguyen-Lu Nhathien, 2015, Can J Anaesth, V62, P866, DOI 10.1007/s12630-015-0375-2
   O'Grady J P, 2000, J Perinatol, V20, P27, DOI 10.1038/sj.jp.7200303
   Pullen KM, 2007, AM J OBSTET GYNECOL, V197, P414
   Segal S, 1998, ANESTH ANALG, V86, P304
   SHEYBANY S, 1982, BRIT J OBSTET GYNAEC, V89, P723, DOI 10.1111/j.1471-0528.1982.tb05098.x
   Su LL, 2012, COCHRANE DB SYST REV, V4
   Tsen LC, 2010, INT J OBSTET ANESTH, V19, P243, DOI 10.1016/j.ijoa.2010.05.001
NR 47
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0952-7907
EI 1473-6500
J9 CURR OPIN ANESTHESIO
JI Curr. Opin. Anesthesiol.
PD JUN
PY 2016
VL 29
IS 3
BP 282
EP 287
DI 10.1097/ACO.0000000000000332
PG 6
WC Anesthesiology
SC Anesthesiology
GA DL9EC
UT WOS:000375943300005
PM 26974052
ER

PT J
AU Tu, XZ
   Xiong, J
   Li, ZJ
   Zhou, LH
   Emmanouil, C
   Zeng, QL
AF Tu, Xingzhao
   Xiong, Jing
   Li, Zhijie
   Zhou, Lihong
   Emmanouil, Christina
   Zeng, Qingle
TI CuI-catalyzed synthesis of 2-(tert-butyldisulfanyl) heterocycles from
   2-mercaptoheterocycles and tert-butanesulfinamide
SO MONATSHEFTE FUR CHEMIE
LA English
DT Article
DE 2-(tert-Butyldisulfanyl)heterocycles; Copper catalysis;
   2-Mercaptoheterocycles; tert-Butanesulfinamide; Condensation
ID BOND FORMATION; DISULFIDE; SULFINAMIDES; SOMATOSTATIN; ANTAGONISTS;
   COMPLEXES; OXYTOCIN; HYDROGEN; HALIDES
AB The valuable 2-(tert-butyldisulfanyl)heterocycles were effectively synthesized from 2-mercaptoheterocycles and tert-butanesulfinamide via unusual condensation. The reaction between 2-mercapto sulfur-containing heterocycles and tert-butanesulfinamide was performed under ligand-free CuI-catalyzed conditions. The synthetic processes described herein are simple, cost-efficient, and practical. Furthermore, a plausible mechanism is proposed for this transformation.
C1 [Tu, Xingzhao; Xiong, Jing; Li, Zhijie; Zhou, Lihong; Zeng, Qingle] Chengdu Univ Technol, Inst Green Catalysis & Synth, Coll Mat & Chem & Chem Engn, Chengdu 610059, Peoples R China.
   [Emmanouil, Christina] Aristotle Univ Thessaloniki, Sch Rural & Surveying Engn, Thessaloniki 54124, Greece.
RP Zeng, QL (reprint author), Chengdu Univ Technol, Inst Green Catalysis & Synth, Coll Mat & Chem & Chem Engn, Chengdu 610059, Peoples R China.
EM qinglezeng@hotmail.com
OI Emmanouil, Christina/0000-0003-0101-9531
FU National Natural Science Foundation of China [21372034]; Ministry of
   Science and Technology of the People's Republic of China [2013DFA21690];
   Science & Technology Department of Sichuan Province [2016HH0074];
   Cultivating Program for Excellent Innovation Team of Chengdu University
   of Technology [HY0084]; Specialized Research Fund for the Doctoral
   Program of Higher Education [20135122120002]
FX We thank the National Natural Science Foundation of China (No.
   21372034), Ministry of Science and Technology of the People's Republic
   of China (No. 2013DFA21690), Science & Technology Department of Sichuan
   Province (No. 2016HH0074), and the Cultivating Program for Excellent
   Innovation Team of Chengdu University of Technology (No. HY0084) for the
   financial support. Dr. Zhou thanks the grants from the Specialized
   Research Fund for the Doctoral Program of Higher Education (New
   Teachers) (No. 20135122120002).
CR Ajiki K, 2005, ORG LETT, V7, P4193, DOI 10.1021/ol051588n
   Chen L, 1997, J MED CHEM, V40, P864, DOI 10.1021/jm9607156
   FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320
   Gaowa A, 2015, EUR J PHARM BIOPHARM, V92, P228, DOI 10.1016/j.ejpb.2015.03.015
   Gerland B, 2007, ORG LETT, V9, P3021, DOI 10.1021/ol071088p
   Grossi L, 2001, EUR J ORG CHEM, P131
   Han M, 2011, TETRAHEDRON LETT, V52, P236, DOI 10.1016/j.tetlet.2010.11.042
   Hipler F, 2003, J MOL STRUCT, V658, P179, DOI 10.1016/S0022-2860(03)00386-7
   Hocart SJ, 1999, J MED CHEM, V42, P1863, DOI 10.1021/jm9806289
   Iranpoor N, 2005, SYNLETT, P1447, DOI 10.1055/s-2005-868488
   LASSNER E, 1968, TALANTA, V15, P623, DOI 10.1016/0039-9140(68)80147-X
   Leino R, 2004, TETRAHEDRON LETT, V45, P8489, DOI 10.1016/j.tetlet.2004.09.100
   Lv XR, 2014, ORG PREP PROCED INT, V46, P164, DOI 10.1080/00304948.2014.884373
   Lv XR, 2013, FRESEN ENVIRON BULL, V22, P3854
   Mandal B, 2014, RSC ADV, V4, P13854, DOI 10.1039/c3ra45997g
   Martin RE, 2007, J MED CHEM, V50, P6291, DOI 10.1021/jm701143p
   McDonnell NB, 1997, J MED CHEM, V40, P1969, DOI 10.1021/jm970147+
   Musiejuk M, 2015, ORG PREP PROCED INT, V47, P95, DOI 10.1080/00304948.2015.1005981
   Muttenthaler M, 2010, J MED CHEM, V53, P8585, DOI 10.1021/jm100989w
   Robak MT, 2010, CHEM REV, V110, P3600, DOI 10.1021/cr900382t
   Ryu EK, 2004, BIOORGAN MED CHEM, V12, P859, DOI 10.1016/j.bmc.2004.01.002
   Sun Xiaofei, 2012, Acta Crystallogr Sect E Struct Rep Online, V68, po1728, DOI 10.1107/S1600536812020673
   Sun XF, 2012, J ORG CHEM, V77, P4454, DOI 10.1021/jo3003584
   Tanaka K, 2004, TETRAHEDRON LETT, V45, P5677, DOI 10.1016/j.tetlet.2004.05.092
   WIEGHARDT K, 1980, CHEM BER-RECL, V113, P629, DOI 10.1002/cber.19801130221
   Witt D, 2008, SYNTHESIS-STUTTGART, P2491, DOI 10.1055/s-2008-1067188
   Xiao HL, 2009, PHOSPHORUS SULFUR, V184, P2553, DOI 10.1080/10426500802529051
   Yuan JW, 2015, ORG CHEM FRONT, V2, P677, DOI 10.1039/c5qo00027k
NR 28
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-9247
EI 1434-4475
J9 MONATSH CHEM
JI Mon. Chem.
PD JUN
PY 2016
VL 147
IS 6
BP 1101
EP 1105
DI 10.1007/s00706-015-1618-1
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA DM0XY
UT WOS:000376070500015
ER

PT J
AU Stewart, MJ
   Harding, BI
   Adamson, KJ
   Wang, T
   Storey, KB
   Cummins, SF
AF Stewart, M. J.
   Harding, B. I.
   Adamson, K. J.
   Wang, T.
   Storey, K. B.
   Cummins, S. F.
TI Characterisation of two conopressin precursor isoforms in the land
   snail, Theba pisana
SO PEPTIDES
LA English
DT Article; Proceedings Paper
CT Invertebrate Neuropeptide Conference 2015 (INC2015).
CY 2015
CL Bagan, MYANMAR
DE Conopressin; Neurophysin; CNS; Dart sac; Theba pisana; Land snail
ID VASOPRESSIN OXYTOCIN SUPERFAMILY; CENTRAL-NERVOUS-SYSTEM; ACCESSORY
   SEX-ORGANS; DORSAL-BODY HORMONE; LYMNAEA-STAGNALIS; CRYSTAL-STRUCTURE;
   FRESHWATER SNAIL; HELIX-ASPERSA; NEUROPEPTIDES; NEUROPHYSIN
AB Increased understanding of the molecular components involved in mollusc reproduction may assist in understanding the evolutionary adaptations used by animals, including hermaphrodites, to produce off-spring. The neuropeptide conopressin, a member of the vasopressin/oxytocin-like peptide family, can modulate various reproductive activities in invertebrates. In this study, we used the hermaphroditic land snail, Theba pisana, to investigate the presence and tissue-specific distribution of a conopressin gene. Our transcriptomic analysis of T. pisana CNS sheath tissue has revealed two conopressin gene transcripts (Tpiconopressin-1 and Tpi-conopressin-2), each encoding for precursors containing an identical conopressin nonapeptide and a variable neurophysin. T. pisana conopressins share high identity with other land snails and slugs, as well as other mollusc and vertebrate vasopressin/oxytocin, supported by phylogenetic analysis. Conserved residues in the T. pisana neurophysin are important for peptide binding, and we present molecular dynamic models demonstrating the most likely stable structure of the Tpi-conopressin-1 peptide when associated with neurophysin. RT-PCR shows that Tpi-conopressin-1 is additionally expressed in reproductive tissues, including the dart sac, where abundant spatial expression throughout the sac region is found; this implies a role in 'love' dart synthesis or dart injection during mating. The presence of a conopressin receptor in the CNS sheath indicates CNS neural excitation. In summary, this study represents a detailed molecular analysis of conopressin in a land snail. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Stewart, M. J.; Harding, B. I.; Adamson, K. J.; Wang, T.; Cummins, S. F.] Univ Sunshine Coast, Fac Sci Hlth Educ & Engn, Genecol Res Ctr, Maroochydore, Qld 4558, Australia.
   [Storey, K. B.] Carleton Univ, Inst Biochem, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.
   [Storey, K. B.] Carleton Univ, Dept Biol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.
RP Cummins, SF (reprint author), Univ Sunshine Coast, Fac Sci Hlth Educ & Engn, Genecol Res Ctr, Maroochydore, Qld 4558, Australia.
EM scummins@usc.edu.au
FU Grains Research and Development Corporation (GRDC) Innovation and
   Investment Grants [USU00001]; GRDC Scholarship; Australian Research
   Council
FX This work is supported by the Grains Research and Development
   Corporation (GRDC) Innovation and Investment Grants (USU00001; MJS, TW,
   SFC), GRDC Scholarship (BIH), and the Australian Research Council (SFC).
   We wish to extend also our gratitude to Mr. Graham Hayes, we thank for
   supplying the snails used in this study.
CR Adamson KJ, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1510-8
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   BARKER JL, 1975, BRAIN RES, V84, P501
   Beitz E, 2000, BIOINFORMATICS, V16, P135, DOI 10.1093/bioinformatics/16.2.135
   Boer H., 1975, NETH J ZOOL, V26, P94, DOI 10.1163/002829676X00073
   Boer P., 1997, J EXP BIOL, V200, P941
   BROADWELL RD, 1979, P NATL ACAD SCI USA, V76, P5999, DOI 10.1073/pnas.76.11.5999
   Bruce-Gregorios J., 1974, HISTOPHATOLOGIC TECH
   Casadio A, 2004, J NEUROSCI RES, V75, P32, DOI 10.1002/jnr.10841
   Case D. A., 2010, AMBER 11
   Chakir K, 2003, MOL PHARMACOL, V64, P1048, DOI 10.1124/mol.64.5.1048
   Chase R, 2002, BEHAV ITS NEURAL CON
   CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240
   CRUZ LJ, 1987, J BIOL CHEM, V262, P15821
   Cummins SF, 2009, INT J DEV BIOL, V53, P1081, DOI 10.1387/ijdb.082791sc
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   GERAERTS WPM, 1975, GEN COMP ENDOCR, V27, P450, DOI 10.1016/0016-6480(75)90065-9
   GERAERTS WPM, 1976, GEN COMP ENDOCR, V29, P109, DOI 10.1016/0016-6480(76)90012-5
   Howl J, 1996, BIOCHEM J, V317, P577
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Koene JM, 1998, J EXP BIOL, V201, P2313
   Koene JM, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00167
   Koene JM, 2009, ANIM BIOL, V59, P435, DOI 10.1163/157075509X12499949744306
   LAMBERT RC, 1993, NEUROSCIENCE, V57, P1027, DOI 10.1016/0306-4522(93)90046-I
   Leonard E, 2003, BASHEM BURNEM BAITEM
   Min XJ, 2005, NUCLEIC ACIDS RES, V33, pW677, DOI 10.1093/nar/gki394
   Moraes GD, 2010, BRAZ J BIOL, V70, P341, DOI 10.1590/S1519-69842010005000017
   OUMI T, 1994, BIOCHEM BIOPH RES CO, V198, P393, DOI 10.1006/bbrc.1994.1055
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   PROUX JP, 1987, BIOCHEM BIOPH RES CO, V149, P180, DOI 10.1016/0006-291X(87)91621-4
   REICH G, 1992, NEUROSCI LETT, V134, P191, DOI 10.1016/0304-3940(92)90514-8
   Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6
   Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Saleuddin ASM, 1997, TISSUE CELL, V29, P267, DOI 10.1016/S0040-8166(97)80002-X
   SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x
   Satake H, 1999, J BIOL CHEM, V274, P5605, DOI 10.1074/jbc.274.9.5605
   Southey BR, 2006, NUCLEIC ACIDS RES, V34, pW267, DOI 10.1093/nar/gkl161
   Stewart MJ, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-840
   Takuwa-Kuroda K, 2003, REGUL PEPTIDES, V115, P139, DOI 10.1016/S0167-0115(03)00151-4
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   VANGOLEN FA, 1995, NEUROSCIENCE, V69, P1275, DOI 10.1016/0306-4522(95)00311-6
   VANKESTEREN RE, 1995, NEURON, V15, P897, DOI 10.1016/0896-6273(95)90180-9
   VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989
   VANKESTEREN RE, 1992, P NATL ACAD SCI USA, V89, P4593, DOI 10.1073/pnas.89.10.4593
   Veenstra JA, 2010, GEN COMP ENDOCR, V167, P86, DOI 10.1016/j.ygcen.2010.02.010
   Watt S., 2012, GROUND COVER, V97, P37
   WIJDENES J, 1987, GEN COMP ENDOCR, V68, P224, DOI 10.1016/0016-6480(87)90033-5
NR 48
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
EI 1873-5169
J9 PEPTIDES
JI Peptides
PD JUN
PY 2016
VL 80
BP 32
EP 39
DI 10.1016/j.peptides.2015.12.009
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA DL9BM
UT WOS:000375936400006
PM 26752717
ER

PT J
AU Ayers, L
   Agostini, A
   Schulkin, J
   Rosen, JB
AF Ayers, Luke
   Agostini, Andrew
   Schulkin, Jay
   Rosen, Jeffrey B.
TI Effects of oxytocin on background anxiety in rats with high or low
   baseline startle
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Startle; Oxytocin; Fear; Anxiety
ID FEAR-POTENTIATED STARTLE; POSTTRAUMATIC-STRESS-DISORDER; CONDITIONED
   FEAR; ACOUSTIC STARTLE; DEFICIENT MICE; ANIMAL-MODEL; HETEROGENEOUS
   RATS; BLOOD-PRESSURE; BEHAVIOR; RESPONSES
AB Oxytocin has antianxiety properties in humans and rodents. However, the antianxiety effects have been variable.
   To reduce variability and to strengthen the antianxiety effect of oxytocin in fear-potentiated startle, two experiments were performed. First, different amounts of light-shock pairings were given to determine the optimal levels of cue-specific fear conditioning and non-predictable startle (background anxiety). Second, the antianxiety effects of oxytocin were examined in rats with high and low pre-fear conditioning baseline startle to determine if oxytocin differentially affects high and low trait anxiety rats.
   Baseline pre-fear conditioning startle responses were first measured. Rats then received 1, 5, or 10 light-shock pairings. Fear-potentiated startle was then tested with two trial types: light-cued startle and non-cued startle trials. In the second experiment, rats fear conditioned with 10 light-shock pairings were administered either saline or oxytocin before a fear-potentiated startle test. Rats were categorized as low or high startlers by their pre-fear conditioning startle amplitude.
   Ten shock pairings produced the largest non-cued startle responses (background anxiety), without increasing cue-specific fear-potentiated startle compared to one and five light-shock pairings. Cue-specific fear-potentiated startle was unaffected by oxytocin. Oxytocin reduced background anxiety only in rats with low pre-fear startle responses.
   Oxytocin has population selective antianxiety effects on non-cued unpredictable threat, but only in rats with low pre-fear baseline startle responses. The low startle responses are reminiscent of humans with low startle responses and high trait anxiety.
C1 [Ayers, Luke] Widener Univ, Dept Psychol, Chester, PA 19013 USA.
   [Agostini, Andrew; Rosen, Jeffrey B.] Univ Delaware, Dept Psychol & Brain Sci, Newark, DE USA.
   [Schulkin, Jay] Georgetown Univ, Dept Neurosci, Washington, DC USA.
RP Rosen, JB (reprint author), Univ Delaware, Dept Psychol & Brain Sci, Newark, DE USA.
EM jrosen@udel.edu
FU NIMH [1R01MH094812-01A1]
FX This study was supported by NIMH grant 1R01MH094812-01A1 to J.B.R.
CR Acheson D, 2013, PSYCHOPHARMACOLOGY, V229, P199, DOI 10.1007/s00213-013-3099-4
   Amico JA, 2004, J NEUROENDOCRINOL, V16, P319, DOI 10.1111/j.0953-8194.2004.01161.x
   Ayers LW, 2011, NEUROPSYCHOPHARMACOL, V36, P2488, DOI 10.1038/npp.2011.138
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Blaszczyk JW, 2000, PHYSIOL BEHAV, V70, P471
   Cohen H, 2010, J NEUROENDOCRINOL, V22, P889, DOI 10.1111/j.1365-2826.2010.02003.x
   Cohen H, 2004, ANN NY ACAD SCI, V1032, P167, DOI 10.1196/annals.1314.014
   Cohen H, 2008, BIOL PSYCHIAT, V64, P708, DOI 10.1016/j.biopsych.2008.05.025
   DAVIS M, 1986, BEHAV NEUROSCI, V100, P814, DOI 10.1037/0735-7044.100.6.814
   DAVIS M, 1979, PSYCHOPHARMACOLOGY, V65, P111, DOI 10.1007/BF00433036
   de Oliveira DCG, 2012, J PSYCHOPHARMACOL, V26, P497, DOI 10.1177/0269881111400642
   Eckstein M, 2015, BIOL PSYCHIAT, V78, P194, DOI 10.1016/j.biopsych.2014.10.015
   Ellenbogen MA, 2014, PSYCHOPHYSIOLOGY, V51, P1169, DOI 10.1111/psyp.12263
   Eskandarian Sharaf, 2013, Basic Clin Neurosci, V4, P315
   Feifel D, 2012, EUR NEUROPSYCHOPHARM, V22, P374, DOI 10.1016/j.euroneuro.2011.09.004
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   de Oliveira LF, 2007, NEUROBIOL LEARN MEM, V87, P67, DOI 10.1016/j.nlm.2006.05.006
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   de Oliveira DCG, 2012, HUM PSYCHOPHARM CLIN, V27, P378, DOI 10.1002/hup.2237
   Grewen KM, 2011, BIOL PSYCHOL, V87, P340, DOI 10.1016/j.biopsycho.2011.04.003
   Grillon C, 2013, MOL PSYCHIATR, V18, P958, DOI 10.1038/mp.2012.156
   Grillon C, 2003, CLIN NEUROPHYSIOL, V114, P1557, DOI 10.1016/S1388-2457(03)00202-5
   Grillon C, 2009, BIOL PSYCHIAT, V66, P47, DOI 10.1016/j.biopsych.2008.12.028
   Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465
   Holst S, 2002, AUTON NEUROSCI-BASIC, V99, P85, DOI 10.1016/S1566-0702(02)00134-0
   Jovanovic T, 2010, PSYCHONEUROENDOCRINO, V35, P846, DOI 10.1016/j.psyneuen.2009.11.009
   Jovanovic T, 2010, DEPRESS ANXIETY, V27, P244, DOI 10.1002/da.20663
   KING MG, 1985, PEPTIDES, V6, P567, DOI 10.1016/0196-9781(85)90122-6
   Lopez-Aumatell R, 2009, BEHAV BRAIN RES, V202, P92, DOI 10.1016/j.bbr.2009.03.024
   Lopez-Aumatell R, 2009, PSICOTHEMA, V21, P27
   Mantella RC, 2003, ENDOCRINOLOGY, V144, P2291, DOI 10.1210/en.2002-0197
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Miles L, 2011, NEUROPSYCHOPHARMACOL, V36, P1563, DOI 10.1038/npp.2011.29
   Missig G, 2010, NEUROPSYCHOPHARMACOL, V35, P2607, DOI 10.1038/npp.2010.155
   Nair HP, 2005, J NEUROSCI, V25, P11479, DOI 10.1523/JNEUROSCI.2524-05.2005
   Norrholm SD, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00077
   Pardon MC, 2002, NEUROSCIENCE, V115, P229, DOI 10.1016/S0306-4522(02)00364-0
   Park PE, 2013, INT J NEUROPSYCHOPH, V16, P1867, DOI 10.1017/S1461145713000308
   Petersson M, 1999, NEUROSCI LETT, V264, P41, DOI 10.1016/S0304-3940(99)00159-7
   Petersson M, 1996, PHYSIOL BEHAV, V60, P1311
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   PITMAN RK, 1993, PSYCHIAT RES, V48, P107, DOI 10.1016/0165-1781(93)90035-F
   Plappert CF, 2002, GENES BRAIN BEHAV, V1, P178, DOI 10.1034/j.1601-183X.2002.10306.x
   Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z
   SERVATIUS RJ, 1994, PHYSIOL BEHAV, V56, P945, DOI 10.1016/0031-9384(94)90328-X
   SERVATIUS RJ, 1995, BIOL PSYCHIAT, V38, P539, DOI 10.1016/0006-3223(94)00369-E
   Shum FWF, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-22
   Slattery DA, 2010, NEUROPHARMACOLOGY, V58, P56, DOI 10.1016/j.neuropharm.2009.06.038
   Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109
   Toth M, 2013, BEHAV PHARMACOL, V24, P1, DOI 10.1097/FBP.0b013e32835cf408
   Uvnas-Moberg K, 1999, REGUL PEPTIDES, V80, P75, DOI 10.1016/S0167-0115(99)00014-2
   UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6
   Vicens-Costa E, 2011, PHYSIOL BEHAV, V103, P148, DOI 10.1016/j.physbeh.2010.12.009
   Waters AM, 2014, PSYCHIAT RES, V217, P93, DOI 10.1016/j.psychres.2014.01.047
   Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
   Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566
   Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941
   Yen YC, 2012, NEUROBIOL LEARN MEM, V98, P56, DOI 10.1016/j.nlm.2012.04.009
   Young LJ, 2015, SCIENCE, V347, P825, DOI 10.1126/science.aaa8120
NR 59
TC 0
Z9 0
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
EI 1432-2072
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUN
PY 2016
VL 233
IS 11
BP 2165
EP 2172
DI 10.1007/s00213-016-4267-0
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DM1JS
UT WOS:000376102100014
PM 27004789
ER

PT J
AU Li, BQ
   Jiang, YQ
   Sun, JL
   Liang, J
   Jin, YL
AF Li, Baoqing
   Jiang, Yuqing
   Sun, Jinlei
   Liang, Jie
   Jin, Yulian
TI MR spectroscopy for assessing the effects of oxytocin on marrow
   adipogenesis induced by glucocorticoid in rabbits
SO ACTA RADIOLOGICA
LA English
DT Article
DE Magnetic resonance (MR) spectroscopy; glucocorticoid-induced
   osteoporosis; marrow fat content; oxytocin
ID MESENCHYMAL STEM-CELLS; INDUCED OSTEOPOROSIS; OVARIECTOMIZED RATS; BONE;
   FAT; DIFFERENTIATION; MODEL; ADIPOCYTES; MICE; CT
AB Background: Previous studies suggest that oxytocin (OT) negatively modulates adipogenesis while promoting osteogenesis in vitro. Because of its effects on marrow stromal cells, OT might have potential utility in therapy for glucocorticoid-induced osteoporosis (GIO).
   Purpose: To explore the effects of OT on marrow adipogenesis in a rabbit model of GIO.
   Material and Methods: Thirty-six-month-old female New Zealand rabbits were randomly assigned to the control, GIO, and GIO + OT groups. Magnetic resonance (MR) spectroscopy and multi-detector computed tomography (MDCT) were performed to detect marrow fat content (MFC) and bone mineral density (BMD) at baseline, and 1, 2, and 3 months. After 3 months of treatment, marrow adipocytes were quantitatively evaluated by histopathology.
   Results: In the GIO group, MFC substantially increased from 34.1% to 43.2% at month 1, and it was maintained until month 3 (by 59.2%, all P <0.01). MFC values in the GIO group were significantly different from the control and OT-treated groups over time. Early OT treatment reversed marrow adiposity to levels of the controls. BMD values were significantly lower in the GIO group at months 2 and 3 compared to the controls; however, partial recovery of vertebral BMD (87.1% of baseline) and femoral BMD (89.3% of baseline) in the OT-treated group were observed. The mean diameter and density of adipocyte and percentage of adipocyte area increased by 30.0%, 70.1%, and 88.9%, respectively (all P <0.05) in the GIO group, but remained unchanged in the OT-treated group.
   Conclusion: Early OT treatment was sufficient to eliminate glucocorticoid-induced marrow adiposity.
C1 [Li, Baoqing; Sun, Jinlei; Liang, Jie; Jin, Yulian] Shijingshan Hosp, Dept Radiol, 24 Shijingshan Rd, Beijing 100043, Peoples R China.
   [Jiang, Yuqing] Peking Univ, Affiliated Coll 1, Beijing Hosp, Clin Lab, Beijing 100871, Peoples R China.
RP Li, BQ (reprint author), Shijingshan Hosp, Dept Radiol, 24 Shijingshan Rd, Beijing 100043, Peoples R China.
EM lbqradiology@163.com
CR Beranger GE, 2014, ENDOCRINOLOGY, V155, P1340, DOI 10.1210/en.2013-1688
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018-013-1440-z
   Breuil V, 2014, J CLIN ENDOCR METAB, V99, pE634, DOI 10.1210/jc.2013-4126
   Bultink IEM, 2013, EXPERT OPIN PHARMACO, V14, P185, DOI 10.1517/14656566.2013.761975
   Castaneda S, 2008, J BONE MINER METAB, V26, P53, DOI 10.1007/s00774-007-0797-1
   Duque G, 2011, OSTEOPOROSIS INT, V22, P1547, DOI 10.1007/s00198-010-1353-8
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008-0127
   Li GW, 2014, ENDOCRINOLOGY, V155, P4731, DOI 10.1210/en.2014-1359
   Li GW, 2013, SKELETAL RADIOL, V42, P1235, DOI 10.1007/s00256-013-1659-7
   Li GW, 2013, SKELETAL RADIOL, V42, P195, DOI 10.1007/s00256-012-1473-7
   Li GW, 2012, EUR RADIOL, V22, P923, DOI 10.1007/s00330-011-2325-x
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Luppen CA, 2002, J BONE MINER RES, V17, P301, DOI 10.1359/jbmr.2002.17.2.301
   Patel JJ, 2014, CELL BIOCHEM FUNCT, V32, P368, DOI 10.1002/cbf.3025
   Qiu Y, 2015, OSTEOPOROSIS INT, V26, P1081, DOI 10.1007/s00198-014-2933-9
   Schwartz AV, 2013, J CLIN ENDOCR METAB, V98, P2294, DOI 10.1210/jc.2012-3949
   Shin YH, 2012, J KOREAN NEUROSURG S, V52, P1, DOI 10.3340/jkns.2012.52.1.1
   Vidal C, 2012, STEM CELLS, V30, P1042, DOI 10.1002/stem.1063
   Wang YXJ, 2009, EUR RADIOL, V19, P882, DOI 10.1007/s00330-008-1219-z
NR 21
TC 0
Z9 0
U1 7
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0284-1851
EI 1600-0455
J9 ACTA RADIOL
JI Acta Radiol.
PD JUN
PY 2016
VL 57
IS 6
BP 701
EP 707
DI 10.1177/0284185115599804
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DL6CQ
UT WOS:000375726300011
PM 26297728
ER

PT J
AU Ondrasek, NR
AF Ondrasek, Naomi R.
TI Emerging Frontiers in Social Neuroendocrinology and the Study of
   Nonapeptides
SO ETHOLOGY
LA English
DT Review
DE environment; individual differences; mating systems; nonapeptides; sex
   differences; social behavior
ID VOLES MICROTUS-OCHROGASTER; OXYTOCIN RECEPTOR DENSITY; SEX AFFILIATIVE
   BEHAVIOR; DECISION-MAKING NETWORK; TREEFROGS HYLA-CINEREA; FEMALE
   PRAIRIE VOLES; MEADOW VOLES; REPRODUCTIVE SUCCESS; ARGININE-VASOTOCIN;
   VASOPRESSIN INNERVATION
AB Social neuroendocrinology, which elucidates the physiological mediators of social behavior, has undergone numerous advances since its inception more than 20yrs ago. Among these was the discovery that the nonapeptidesa family of homologous peptides that includes oxytocin and vasopressinplay a significant role in mediating a variety of affiliative behaviors. However, important gaps remain in our understanding of how the non-apeptide systems contribute to variations in behavior at several levels, including among species, between the sexes, and within different environmental contexts. This study acknowledges the work and foresight of the late James Goodson by examining emerging trends in social neuroendocrinology.
C1 [Ondrasek, Naomi R.] Univ Calif Davis, Dept Neurobiol Physiol & Behav, 196 Briggs Hall, Davis, CA 95616 USA.
RP Ondrasek, NR (reprint author), Univ Calif Davis, Dept Neurobiol Physiol & Behav, 196 Briggs Hall, Davis, CA 95616 USA.
EM nondrasek@ucdavis.edu
FU National Science Foundation Postdoctoral Research Fellowship in Biology
   [NSF 1202895]
FX I thank James Goodson not only for his contributions to the field, but
   for his efforts to foster the early careers of young ethologists and
   neuroendocrinologists. Rebecca Calisi, Annaliese Beery, Redouan Bshary,
   and two anonymous reviewers provided insightful advice that much
   improved this manuscript. Finally, I also thank Mark Hauber for
   providing the original invitation to write this review. This material is
   based upon work supported by the National Science Foundation
   Postdoctoral Research Fellowship in Biology under Grant No. (NSF
   1202895).
CR Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Alexander R.D., 1974, Annual Rev Ecol Syst, V5, P325, DOI 10.1146/annurev.es.05.110174.001545
   Almeida O, 2012, HORM BEHAV, V61, P212, DOI 10.1016/j.yhbeh.2011.12.008
   Anacker A.M.J., 2013, BEHAV NEUROSCI, V7, P1
   BAMSHAD M, 1993, J NEUROENDOCRINOL, V5, P247, DOI 10.1111/j.1365-2826.1993.tb00480.x
   BAMSHAD M, 1994, PHYSIOL BEHAV, V56, P751, DOI 10.1016/0031-9384(94)90238-0
   Beery AK, 2010, NEUROSCIENCE, V169, P665, DOI 10.1016/j.neuroscience.2010.05.023
   Beery AK, 2008, HORM BEHAV, V54, P153, DOI 10.1016/j.yhbeh.2008.02.007
   Beery AK, 2008, J COMP NEUROL, V507, P1847, DOI 10.1002/cne.21638
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Beery AK, 2009, PHYSIOL BEHAV, V97, P52, DOI 10.1016/j.physbeh.2009.01.020
   Bentley GE, 1999, P NATL ACAD SCI USA, V96, P4674, DOI 10.1073/pnas.96.8.4674
   Blumstein DT, 2010, FRONT BEHAV NEUROSCI, V4, P1
   Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785
   Caldwell H., 2015, CURR TOPICS BEHAV NE, V1, P53, DOI [10.1007/7854_2015_390, DOI 10.1007/7854_2015_390]
   Cameron EZ, 2009, P NATL ACAD SCI USA, V106, P13850, DOI 10.1073/pnas.0900639106
   CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x
   Carter SC, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Cowley AW, 2000, EXP PHYSIOL, V85, p223S, DOI 10.1111/j.1469-445X.2000.tb00027.x
   Cushing BS, 2005, ACTA THERIOL SIN, V25, P182
   Cushing BS, 2001, HORM BEHAV, V39, P48, DOI 10.1006/hbeh.2000.1633
   DAVIES NB, 1986, J ANIM ECOL, V55, P139, DOI 10.2307/4698
   DesDreu CK, 2011, P NATL ACAD SCI USA, V108, P1262
   desVries GJ, 2008, PROG BRAIN RES, V170, P17
   DesVries GJ, 2006, NEUROSCIENCE, V138, P947
   DeVries AC, 1996, P NATL ACAD SCI USA, V93, P11980, DOI 10.1073/pnas.93.21.11980
   Dumais K. M., 2015, FRONT NEUROENDOCRIN, V40, P1, DOI DOI 10.1016/J.YFME.2015.04.003
   Faulkes CG, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0347
   Ferrier L, 2010, AM J PHYSIOL-GASTR L, V299, pG1298, DOI 10.1152/ajpgi.00022.2010
   Ferris CF, 1997, J NEUROSCI, V17, P4331
   GETZ LL, 1993, J MAMMAL, V74, P44, DOI 10.2307/1381904
   GETZ LL, 1981, BEHAV ECOL SOCIOBIOL, V8, P189, DOI 10.1007/BF00299829
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goodson JL, 2006, HORM BEHAV, V50, P223, DOI 10.1016/j.yhbeh.2006.03.005
   Goodson JL, 2013, HORM BEHAV, V64, P103, DOI 10.1016/j.yhbeh.2013.05.006
   Goodson JL, 2013, PSYCHONEUROENDOCRINO, V38, P465, DOI 10.1016/j.psyneuen.2012.12.005
   Goodson JL, 2012, P NATL ACAD SCI USA, V109, P10685, DOI 10.1073/pnas.1203394109
   Goodson JL, 2012, HORM BEHAV, V61, P239, DOI 10.1016/j.yhbeh.2012.01.005
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Goodson JL, 2009, SCIENCE, V325, P862, DOI 10.1126/science.1174929
   Goodson JL, 2008, PROG BRAIN RES, V170, P3, DOI 10.1016/S0079-6123(08)00401-9
   Goodson JL, 2005, HORM BEHAV, V48, P11, DOI 10.1016/j.yhbeh.2005.02.003
   Goodson JL, 2000, NATURE, V403, P769, DOI 10.1038/35001581
   Goodson JL, 2001, BRAIN RES REV, V35, P246, DOI 10.1016/S0165-0173(01)00043-1
   Goodson J.L., 2011, FRONT NEUROANAT, V5, P1
   Hammock EAD, 2005, SCIENCE, V308, P1630, DOI 10.1126/science.1111427
   HANIF K, 1982, SCIENCE, V216, P1010, DOI 10.1126/science.7079746
   Hayes UL, 2007, HORM BEHAV, V51, P265, DOI 10.1016/j.yhbeh.2006.10.011
   Hofmann HA, 2014, TRENDS ECOL EVOL, V29, P581, DOI 10.1016/j.tree.2014.07.008
   Holmes CL, 2003, CRIT CARE, V7, P427, DOI 10.1186/cc2337
   HORN AM, 1988, BRAIN RES, V455, P18, DOI 10.1016/0006-8993(88)90108-4
   Howard CM, 2015, J NEUROENDOCRINOL, V27, P670, DOI 10.1111/jne.12292
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   INSEL TR, 1992, PSYCHONEUROENDOCRINO, V17, P3, DOI 10.1016/0306-4530(92)90073-G
   Jankowski M, 2000, P NATL ACAD SCI USA, V97, P6207, DOI 10.1073/pnas.110137497
   Johnson Zachary V, 2015, Curr Opin Behav Sci, V3, P38
   Kelly AM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00242
   Kelly AM, 2013, HORM BEHAV, V64, P840, DOI 10.1016/j.yhbeh.2013.09.006
   KLEIMAN DG, 1977, Q REV BIOL, V52, P39, DOI 10.1086/409721
   Kleszczynska A, 2012, GEN COMP ENDOCR, V175, P290, DOI 10.1016/j.ygcen.2011.11.022
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Lema SC, 2006, HORM BEHAV, V50, P183, DOI 10.1016/j.yhbeh.2006.02.010
   Ludwig M, 2006, NAT REV NEUROSCI, V7, P126, DOI 10.1038/nrn1845
   Lutterschmidt DI, 2012, BRAIN BEHAV EVOLUT, V80, P222, DOI 10.1159/000341238
   Mabry KE, 2011, ANIM BEHAV, V81, P11, DOI 10.1016/j.anbehav.2010.09.021
   MADISON DM, 1987, AM ZOOL, V27, P899
   McGraw LA, 2010, TRENDS NEUROSCI, V33, P103, DOI 10.1016/j.tins.2009.11.006
   MEIDAN R, 1985, ENDOCRINOLOGY, V116, P416
   Michopoulos V, 2011, HORM BEHAV, V59, P528, DOI 10.1016/j.yhbeh.2011.02.002
   Mustoe AC, 2015, HORM BEHAV, V71, P83, DOI 10.1016/j.yhbeh.2015.04.015
   Neumann ID, 2013, PSYCHONEUROENDOCRINO, V38, P1985, DOI 10.1016/j.psyneuen.2013.03.003
   Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x
   O'Connell LA, 2012, SCIENCE, V336, P1154, DOI 10.1126/science.1218889
   Okhovat M, 2015, SCIENCE, V350, P1371, DOI 10.1126/science.aac5791
   Olazabal DE, 2006, NEUROSCIENCE, V141, P559, DOI 10.1016/j.neuroscience.2006.04.017
   Olazabal DE, 2006, HORM BEHAV, V49, P681, DOI 10.1016/j.yhbeh.2005.12.010
   Ondrasek NR, 2015, PHYSIOL BEHAV, V140, P118, DOI 10.1016/j.physbeh.2014.12.021
   Ophir AG, 2008, P NATL ACAD SCI USA, V105, P1249, DOI 10.1073/pnas.0709116105
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Ophir AG, 2011, HORM BEHAV, V60, P22, DOI 10.1016/j.yhbeh.2011.03.012
   Parker KJ, 2001, BEHAV NEUROSCI, V115, P1349, DOI 10.1037//0735-7044.115.6.1349
   Phelps SM, 2003, J COMP NEUROL, V466, P564, DOI 10.1002/cne.10902
   Phelps SM, 2010, NEUROPHARMACOLOGY, V58, P17, DOI 10.1016/j.neuropharm.2009.06.043
   PHILLIPS PA, 1990, ENDOCRINOLOGY, V126, P1478
   Prendergast BJ, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P507
   Reddon AR, 2014, BEHAVIOUR, V151, P1389, DOI 10.1163/1568539X-00003190
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Roberts RL, 1998, ANIM BEHAV, V55, P1131, DOI 10.1006/anbe.1997.0659
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Szentirmai I, 2007, J EVOLUTION BIOL, V20, P1739, DOI 10.1111/j.1420-9101.2007.01392.x
   Taborsky M, 2015, TRENDS NEUROSCI, V38, P189, DOI 10.1016/j.tins.2015.01.004
   Tahara A, 1998, NEUROPEPTIDES, V32, P281, DOI 10.1016/S0143-4179(98)90049-X
   Tang Y, 2012, NEUROSCIENCE, V219, P10, DOI 10.1016/j.neuroscience.2012.05.063
   THIBONNIER M, 1986, AM J PHYSIOL, V251, pH115
   Thompson RR, 2008, EUR J NEUROSCI, V27, P2285, DOI 10.1111/j.1460-9568.2008.06210.x
   Thompson RR, 2004, BEHAV NEUROSCI, V118, P620, DOI 10.1037/0735-7044.118.3.620
   Turner LM, 2010, MOL BIOL EVOL, V27, P1269, DOI 10.1093/molbev/msq013
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Verbalis JG, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P1599
   WANG ZX, 1994, BRAIN RES, V650, P212, DOI 10.1016/0006-8993(94)91784-1
   Wang ZX, 2000, J NEUROENDOCRINOL, V12, P111, DOI 10.1046/j.1365-2826.2000.00435.x
   WANG ZX, 1992, J COMP PSYCHOL, V106, P163, DOI 10.1037/0735-7036.106.2.163
   Welch MG, 2009, J COMP NEUROL, V512, P256, DOI 10.1002/cne.21872
   Merritt J. F., 1984, SPECIAL PUBLICATION, V10, P293
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   WILLIAMS JR, 1992, ANN NY ACAD SCI, V652, P487, DOI 10.1111/j.1749-6632.1992.tb34393.x
   Wittig RM, 2008, HORM BEHAV, V54, P170, DOI 10.1016/j.yhbeh.2008.02.009
   Yasukawa K., 1995, BIRDS N AM ONLINE, DOI [10.2173/bna.184, DOI 10.2173/BNA.184]
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Zheng DJ, 2013, BEHAV BRAIN RES, V246, P139, DOI 10.1016/j.bbr.2013.02.024
NR 112
TC 0
Z9 0
U1 14
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0179-1613
EI 1439-0310
J9 ETHOLOGY
JI Ethology
PD JUN
PY 2016
VL 122
IS 6
BP 443
EP 455
DI 10.1111/eth.12493
PG 13
WC Psychology, Biological; Behavioral Sciences; Zoology
SC Psychology; Behavioral Sciences; Zoology
GA DK8CC
UT WOS:000375153800001
ER

PT J
AU Calanchini, C
AF Calanchini, Carlo
TI Switch from distress to well-being by strong emotions: Speculations on
   three clinical vignettes
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Review
DE clinical cases; oxytocinergic and dopaminergic circuits; positive
   emotions
ID INFANT-MOTHER ATTACHMENT; SOCIAL ATTACHMENT; LOVE; NEUROBIOLOGY;
   ADDICTION; OXYTOCIN; SYSTEMS; STRESS; REWARD; BRAIN
AB Starting from three clinical vignettes representing two mental disorders and different approaches to their treatment, we ask whether and how an unexpected event occurring at a particular time in a person's life could provoke such strong emotions as to determine a sudden transition from a state of severe distress to one of well-being. In this transition, we postulate that a major role is played by biological tendencies and brain plasticity under the influence of psychotherapy and positive emotions, emotionsespecially trust, the sense of being cared for, and falling in lovethat are awakened by openness to novelty and to the Other. Neurobiologically, a sudden improvement could be ascribed to an oxytocinergic action that, combined with dopaminergic circuits, can restore a state of well-being, safe attachment, and gratification. J. Comp. Neurol. 524:1687-1694, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Calanchini, Carlo] Osped Malcantonese, CH-6980 Castelrotto, Switzerland.
RP Calanchini, C (reprint author), Via Luvini 7, CH-6900 Lugano, Switzerland.
EM c.calanchini@oscam.ch
CR AINSWORTH MDS, 1979, AM PSYCHOL, V34, P932, DOI 10.1037//0003-066X.34.10.932
   Aristotle, 1986, ANIMA SOUL
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Bowlby J, 1978, Adolesc Psychiatry, V6, P5
   Cardoso C, 2013, PSYCHONEUROENDOCRINO, V38, P399, DOI 10.1016/j.psyneuen.2012.07.013
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Coria-Avila GA, 2014, NEUROSCI BIOBEHAV R, V43, P173, DOI 10.1016/j.neubiorev.2014.04.004
   Damasio A. R., 1994, DESCARTES ERROR EMOT
   de Boer A, 2012, NEUROSCIENCE, V201, P114, DOI 10.1016/j.neuroscience.2011.11.017
   Esch T, 2004, NEUROENDOCRINOL LETT, V25, P235
   Gabbard G. O., 1995, BOUNDARIES BOUNDARY
   Hostetler CM, 2012, PSYCHOPHARMACOLOGY, V224, P27, DOI 10.1007/s00213-012-2858-y
   James W., 1884, MIND, V9, P188, DOI DOI 10.1093/MIND/OS-IX.34.188
   McGraw LA, 2010, TRENDS NEUROSCI, V33, P103, DOI 10.1016/j.tins.2009.11.006
   Panksepp J., 2012, ARCHEOLOGY MIND
   Tarlaci S, 2012, NEUROQUANTOLOGY, V10, P744
   Tops M, 2014, PHARMACOL BIOCHEM BE, V119, P39, DOI 10.1016/j.pbb.2013.07.015
   TRACY RL, 1981, CHILD DEV, V52, P1341, DOI 10.1111/j.1467-8624.1981.tb03189.x
   Winnicott DW, 1971, PLAYING REALITY
   Young LJ, 2009, NATURE, V457, P148, DOI 10.1038/457148a
   Zak PJ, 2005, HORM BEHAV, V48, P522, DOI 10.1016/j.yhbeh.2005.07.009
   Zeki S, 2007, FEBS LETT, V581, P2575, DOI 10.1016/j.febslet.2007.03.094
NR 22
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD JUN 1
PY 2016
VL 524
IS 8
SI SI
BP 1687
EP 1694
DI 10.1002/cne.23849
PG 8
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA DH9UH
UT WOS:000373140900015
PM 26174585
ER

PT J
AU Burgdorf, C
   Rinn, C
   Stemmler, G
AF Burgdorf, Christin
   Rinn, Constanze
   Stemmler, Gerhard
TI Effects of personality on the opioidergic modulation of the emotion
   warmth-liking
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE cyberball; naltrexone; positive emotion; psychophysiology; autonomic
   response patterns
ID IMPEDANCE CARDIOGRAPHY; POSITIVE EMOTIONS; SOCIAL EXCLUSION;
   NERVOUS-SYSTEM; ATTACHMENT; OSTRACISM; REACTIVITY; RECEPTORS;
   NEUROBIOLOGY; METAANALYSIS
AB Neurobiological research suggests there are discrete emotion systems, which are based on separate neural pathways with specific neurotransmitters (i.e., oxytocin, opioids). So far, autonomic regulation patterns of different positive emotions could not be unambiguously characterized. Warmth-liking, as an emotion system, is activated during interpersonal interactions and close relationships. We postulated that warmth-liking has a specific somatovisceral signature, which is, however, qualified by individual differences in personality and attachment style. Individual differences in personality and attachment style are postulated to contribute to -opiate functioning. Forty-eight females in a heterosexual relationship, selected on the basis of attachment reports, took part in a virtual ball-tossing game with their partners and two confederates. Participants received either the competitive -opioid antagonist naltrexone (25 mg) or a placebo in a randomized double-blind design. Social exclusion during the game reduced feelings of warmth, increased feelings of anger, and increased blood pressure and left-ventricular contractibility, whereas social inclusion was characterized by physiological quiescence. Further analyses revealed differential effects in self-reported feelings as well as in cardiovascular parameters as a function of attachment style. Secure attachment predicted higher levels of warmth-liking, physiological quiescence, and less negative feelings even during social exclusion. These findings can be interpreted as evidence for psychophysiological resilience. Furthermore, naltrexone reduced feelings of warmth and increased vasoconstriction during social inclusion, especially for securely bonded participants. These findings are remarkable hints for an opioidergic modulation of the interaction between emotion and personality. J. Comp. Neurol. 524:1712-1726, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Burgdorf, Christin; Rinn, Constanze; Stemmler, Gerhard] Univ Marburg, D-35037 Marburg, Germany.
RP Burgdorf, C (reprint author), Univ Marburg, Dept Psychol, Gutenbergstr 18, D-35037 Marburg, Germany.
EM christin.burgdorf@staff.uni-marburg.de
FU Deutsche Forschungsgemeinschaft (DFG) [Ste405/15-1]
FX Grant sponsor: Deutsche Forschungsgemeinschaft (DFG); Grant number:
   Ste405/15-1 (to G.S.).
CR Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Armario P, 2003, J HUM HYPERTENS, V17, P181, DOI 10.1038/sj.jhh.1001530
   AX AF, 1953, PSYCHOSOM MED, V15, P433
   Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018
   Belsley D.A., 1980, REGRESSION DIAGNOSTI
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   Bowlby J., 1969, ATTACHMENT LOSS
   Boyes ME, 2009, PERS INDIV DIFFER, V47, P396, DOI 10.1016/j.paid.2009.04.005
   Burgdorf J, 2006, NEUROSCI BIOBEHAV R, V30, P173, DOI 10.1016/j.neubiorev.2005.06.001
   Cacioppo JT, 2000, HDB EMOTIONS, V2
   Cannon WB, 1927, AM J PSYCHOL, V39, P106, DOI 10.2307/1415404
   Depue RA, 2005, BEHAV BRAIN SCI, V28, P313
   Depue RA, 1999, BEHAV BRAIN SCI, V22, P491
   Dhawan BN, 1996, PHARMACOL REV, V48, P567
   Diamond LM, 2001, PERS SOC PSYCHOL REV, V5, P276, DOI 10.1207/S15327957PSPR0504_1
   EKMAN P, 1983, SCIENCE, V221, P1208, DOI 10.1126/science.6612338
   Fraley RC, 2002, PERS SOC PSYCHOL REV, V6, P123, DOI 10.1207/S15327957PSPR0602_03
   Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218
   Gramer M, 2014, BIOL PSYCHOL, V101, P1, DOI 10.1016/j.biopsycho.2014.06.002
   Grau I, 1994, ENTWICKLUNG VALIDIER
   Gregson-Williams R, 2006, FAMILY AWAKES HEDGE
   Harmon-Jones E, 2009, EMOTION, V9, P113, DOI 10.1037/a0014117
   Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255
   Holt-Lunstad J, 2014, INT J PSYCHOPHYSIOL, V93, P381, DOI 10.1016/j.ijpsycho.2014.05.014
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   Ijzerman H, 2012, ACTA PSYCHOL, V140, P283, DOI 10.1016/j.actpsy.2012.05.002
   James W., 1884, MIND, V9, P188, DOI DOI 10.1093/MIND/OS-IX.34.188
   Kelly M, 2012, INT J PSYCHOPHYSIOL, V83, P309, DOI 10.1016/j.ijpsycho.2011.11.008
   Keverne EB, 1996, J PSYCHOPHARMACOL, V10, P16, DOI 10.1177/026988119601000104
   Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010
   Krill AL, 2008, PERS INDIV DIFFER, V45, P684, DOI 10.1016/j.paid.2008.07.016
   KUBICEK WG, 1966, AEROSPACE MED, V37, P1208
   Lau G, 2009, EMOTION, V9, P430, DOI 10.1037/a0015350
   Lee Raby K., 2013, J CHILD PSYCHOL PSYC, V54, P1223, DOI [10.1111/jcpp.12093, DOI 10.1111/JCPP.12093]
   Machin AJ, 2011, BEHAVIOUR, V148, P985, DOI 10.1163/000579511X596624
   Margraf J, 1994, MINIDIPS DIAGNOSTISC
   Menken A, 1991, BEAUTY BEAST WALT DI
   Moore SR, 2014, FRONT PSYCHOL, V5, P1
   Moutsiana C, 2014, J CHILD PSYCHOL PSYC, V55, P999, DOI 10.1111/jcpp.12198
   Murray-Close D, 2011, INT J PSYCHOPHYSIOL, V80, P28, DOI 10.1016/j.ijpsycho.2011.01.007
   Nitsche A, OBJECTIVE ASSE UNPUB
   Nitschke JB, 2004, NEUROIMAGE, V21, P583, DOI 10.1016/j.neuroimaging.2003.10.005
   Ostendorf F., 2004, NEO PERSOENLICHKEITS
   Panksepp J, 2005, CONSCIOUS COGN, V14, P30, DOI 10.1016/j.concog.2004.10.004
   Panksepp J., 1998, AFFECTIVE NEUROSCIEN
   Panksepp J, 2014, J CLIN PSYCHOL, V2, P472, DOI DOI 10.1177/2167702614535913
   Panksepp J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021236
   Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138
   Plutchik R., 1962, EMOTIONS FACTS THEOR
   Puig J, 2013, HEALTH PSYCHOL, V32, P409, DOI 10.1037/a0028889
   Raaijmakers E, 1998, MED BIOL ENG COMPUT, V36, P592, DOI 10.1007/BF02524429
   Stemmler G, 2004, REGULATION OF EMOTION, P33
   Stemmler G, 2001, PSYCHOPHYSIOLOGY, V38, P275, DOI 10.1017/S0048577201991668
   Stemmler G, 2002, PERSONLICHKEIT EMOTI, P115
   Stemmler G., 1992, DIFFERENTIAL PSYCHOP
   Stemmler G, 2010, BIOL PSYCHOL, V84, P541, DOI 10.1016/j.biopsycho.2009.09.012
   STERNBACH RA, 1962, J PSYCHOSOM RES, V6, P87, DOI 10.1016/0022-3999(62)90059-4
   Strobel A., 2001, Z DIFFERENTIELLE DIA, V22, P216, DOI DOI 10.1024//0170-1789.22.3.216
   Tellegen A, 2008, HDB PERSONALITY THEO, P261, DOI DOI 10.4135/9781849200479.N13
   Uchino BN, 2011, BIOL PSYCHOL, V86, P137, DOI 10.1016/j.biopsycho.2010.04.003
   Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0
   UvnasMoberg K, 1997, ANN NY ACAD SCI, V807, P146, DOI 10.1111/j.1749-6632.1997.tb51917.x
   WALLACE RK, 1971, AM J PHYSIOL, V221, P795
   Westermann R, 1996, EUR J SOC PSYCHOL, V26, P557, DOI 10.1002/(SICI)1099-0992(199607)26:4<557::AID-EJSP769>3.0.CO;2-4
   Williams KD, 2006, BEHAV RES METHODS, V38, P174, DOI 10.3758/BF03192765
   Williams KD, 2007, ANNU REV PSYCHOL, V58, P425, DOI 10.1146/annurev.psych.58.110405.085641
   Williams LE, 2008, SCIENCE, V322, P606, DOI 10.1126/science.1162548
   Woltjer HH, 1996, MED BIOL ENG COMPUT, V34, P84, DOI 10.1007/BF02637027
   Zadro L, 2004, J EXP SOC PSYCHOL, V40, P560, DOI 10.1016/j.jesp.2003.11.006
NR 69
TC 0
Z9 0
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD JUN 1
PY 2016
VL 524
IS 8
SI SI
BP 1712
EP 1726
DI 10.1002/cne.23847
PG 15
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA DH9UH
UT WOS:000373140900018
PM 26135853
ER

PT J
AU Singh, N
   Uikey, P
   Bagga, C
AF Singh, Nitu
   Uikey, Prashant
   Bagga, Chandni
TI ROLE OF ORAL MISOPROSTOL 25 MG (MICROGRAM) IN PREMATURE RUPTURE OF
   MEMBRANE IN PATIENT AT TERM
SO JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS
LA English
DT Article
DE PROM; Misoprostol; Induction Delivery Interval
ID PRELABOR RUPTURE; UNFAVORABLE CERVIX; MANAGEMENT; INDUCTION; LABOR;
   OXYTOCIN; TRIAL
AB BACKGROUND
   Premature rupture of membranes is a potential hazard in obstetrics. It causes significant maternal and neonatal morbidity. 1,2 It complicates 5-10% of all pregnancies at term. 3 and therefore warrants intervention; 25 microgram misoprostol is a promising agent for induction of labour in PROM.
   METHODS
   A prospective study was carried out in 100 cases with premature rupture of membranes at term satisfying the inclusion and exclusion criteria. They were divided into study and control group. Study group was given 25 microgram misoprostol orally, which was repeated every 4 hourly till maximum of 6 doses till onset of active labour. Control group was managed by traditional method (Oxytocin infusion for augmentation of labour). The mode of delivery and the induction delivery time was noted. The maternal and neonatal morbidity was also noted.
   RESULT
   Average induction delivery interval in misoprostol group was 10.01+/-3.08 hrs. and 14.15+/-5.30 hrs. in control groups (P=0.0006). Average PROM delivery interval in misoprostol group was 13.58+/-3.49 hrs. and 18.19+/-5.62 hrs. in control group (P=0.000); 64% of patients delivered vaginally as compared to 70% in control group and caesarean rate was 28% as compared to 24% in control group.
   CONCLUSION
   Tab Misoprostol in a dose of 25 micrograms in cases of premature rupture of membrane at term reduces the induction delivery interval and thus reduces maternal and perinatal morbidity associated with PROM.
C1 [Singh, Nitu; Uikey, Prashant; Bagga, Chandni] Indira Gandhi Govt Med Coll & Hosp, Dept Obstet & Gynaecol, Nagpur, Maharashtra, India.
RP Singh, N (reprint author), B6,Nanak Shilp Soc,Smruti Nagar,Koradi Rd, Nagpur 441111, Maharashtra, India.
EM ajayneetu@rediffmail.com
CR Cheung PC, 2006, ACTA OBSTET GYN SCAN, V85, P1128, DOI 10.1080/00016340600589636
   Datta MR, 2007, J OBSTET GYNAECOL IN, V57, P505
   Duff P, 1996, NEW ENGL J MED, V334, P1053, DOI 10.1056/NEJM199604183341609
   FAYEZ JA, 1978, OBSTET GYNECOL, V52, P17
   GOESCHEN K, 1989, AM J PERINAT, V6, P181, DOI 10.1055/s-2007-999572
   GRANSTROM L, 1987, ACTA OBSTET GYN SCAN, V66, P429, DOI 10.3109/00016348709022048
   GUISE JM, 1992, AM J PERINAT, V9, P56, DOI 10.1055/s-2007-994671
   Krishnamma BS, 2002, J OBSTET GYNAECOL IN, V52, P64
   Krupa G, 2005, BJOG, V112, P1284
   Mozurkewich E, 2003, AM J OBSTET GYNECOL, V189, P1026, DOI 10.1067/S0002-9378(03)00845-7
   NATALE R, 1994, AM J OBSTET GYNECOL, V171, P936
   Ozden S, 2002, INT J GYNECOL OBSTET, V77, P109, DOI 10.1016/S0020-7292(02)00030-9
   Shetty A, 2002, BJOG-INT J OBSTET GY, V109, P1354, DOI 10.1016/S1470-0328(02)02982-8
   SPERLING LS, 1993, ACTA OBSTET GYN SCAN, V72, P627, DOI 10.3109/00016349309021155
NR 14
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL EVOLUTION MEDICAL & DENTAL SCIENCES
PI KARNATAKA
PA C/O AKSHANTALA ENTERPRISES, NO 65, 1ST FL, SAHUKAR CHENNIAH RD, MYSORE,
   KARNATAKA, 570 009, INDIA
SN 2278-4748
EI 2278-4802
J9 J EVOL MED DENT SCI-
JI J. Evol. Med. Dent. Sci.-JEMDS
PD MAY 30
PY 2016
VL 5
IS 43
BP 2769
EP 2772
DI 10.14260/jemds/2016/625
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DO7MN
UT WOS:000377966800006
ER

PT J
AU Hinzey, A
   Gaudier-Diaz, MM
   Lustberg, MB
   DeVries, AC
AF Hinzey, Adam
   Gaudier-Diaz, Monica M.
   Lustberg, Maryam B.
   DeVries, A. Courtney
TI Breast cancer and social environment: getting by with a little help from
   our friends
SO BREAST CANCER RESEARCH
LA English
DT Review
DE Social isolation; Breast cancer; Oxytocin; Catecholamines;
   Glucocorticoids
ID GENE-EXPRESSION; GLUCOCORTICOID-RECEPTOR; PSYCHOSOCIAL FACTORS; OXYTOCIN
   RECEPTORS; OVARIAN-CARCINOMA; TUMOR-GROWTH; ENDOTHELIAL-CELLS;
   BETA-BLOCKERS; STAGE-II; SURVIVAL
AB Social environment is a well-recognized determinant in health and wellbeing. Among breast cancer patients, inadequate social support is associated with a substantial increase in cancer-related mortality. A common explanation is that socially isolated individuals fare worse due to reduced instrumental support (i.e., assistance meeting the demands of treatment). However, the ability to replicate the detrimental effects of social isolation on mammary tumor growth in rodents strongly suggests an alternative explanation; i.e., socially isolated individuals have a physiological milieu that promotes tumor growth. This review summarizes the clinical and basic science literature supporting social influences on breast cancer, and provides a conceptual physiological framework for these effects. We propose that social environment contributes to the vast individual differences in prognosis among breast cancer survivors because social environment is capable of altering basic physiological processes, which in turn can modulate tumor growth. Appreciation of the role of social environment in breast cancer progression could promote the identification of patients at increased risk for poor outcomes. In addition, characterization of the underlying physiological mechanisms could lead to targeted disruption of detrimental pathways that promote tumor progression in socially isolated individuals, or exploitation of protective pathways activated through social engagement as novel therapeutic complements to contemporary treatments.
C1 [Hinzey, Adam; Gaudier-Diaz, Monica M.; DeVries, A. Courtney] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA.
   [Lustberg, Maryam B.] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Lustberg, Maryam B.] Ohio State Univ, Stephanie Spielman Breast Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA.
   [DeVries, A. Courtney] 614 Biomed Res Tower,460 West 12th Ave, Columbus, OH 43210 USA.
RP DeVries, AC (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA.; DeVries, AC (reprint author), 614 Biomed Res Tower,460 West 12th Ave, Columbus, OH 43210 USA.
EM devries.14@osu.edu
FU Pelotonia; NCI [1R01CA194924]
FX We thank Jose Mendez for providing the art for the figures and Alison
   Butler and David Paternite for providing feedback on an early version of
   the manuscript. This work was supported by Pelotonia (Graduate
   Fellowship to AH, Idea Grant to ACD and MBL) and NCI (1R01CA194924 to
   ACD).
CR Adam EK, 2006, P NATL ACAD SCI USA, V103, P17058, DOI 10.1073/pnas.060503103
   Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422
   Beasley JM, 2010, J CANCER SURVIV, V4, P372, DOI 10.1007/s11764-010-0139-5
   BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186
   Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4
   Bussolati G, 1996, AM J PATHOL, V148, P1895
   Cassoni P, 2006, MOL CANCER RES, V4, P351, DOI 10.1158/1541-7786
   Cassoni P, 2006, INT J ONCOL, V28, P1263
   CASSONI P, 1994, VIRCHOWS ARCH, V425, P467
   Chan DS, 2014, ANN ONCOL, V10, P1901
   COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310
   Cole SW, 2008, BRAIN BEHAV IMMUN, V22, P1049, DOI 10.1016/j.bbi.2008.02.006
   Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189
   Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641
   Copland JA, 1999, ENDOCRINOLOGY, V140, P2258, DOI 10.1210/en.140.5.2258
   de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
   ELL K, 1992, J PSYCHOSOM RES, V36, P531, DOI 10.1016/0022-3999(92)90038-4
   Falagas ME, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1744
   Feng ZH, 2012, P NATL ACAD SCI USA, V109, P7013, DOI 10.1073/pnas.1203930109
   Filiano AJ, 2014, SOC NEUR ANN M 2014
   FUNCH DP, 1983, J PSYCHOSOM RES, V27, P77, DOI 10.1016/0022-3999(83)90112-5
   Garssen B, 1999, PSYCHIAT RES, V85, P51, DOI 10.1016/S0165-1781(99)00008-6
   Giese-Davis J, 2015, PSYCHOSOM MED, V77, P346, DOI 10.1097/PSY.0000000000000167
   Grant N, 2009, ANN BEHAV MED, V37, P29, DOI 10.1007/s12160-009-9081-z
   Gundisch S, 2012, ANTICANCER RES, V32, P4251
   Hermes GL, 2009, P NATL ACAD SCI USA, V106, P22393, DOI 10.1073/pnas.0910753106
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889
   Izano M, 2015, CANC MED, V2, P315
   JEMMOTT JB, 1984, PSYCHOL BULL, V95, P78, DOI 10.1037//0033-2909.95.1.78
   Karelina K, 2011, PSYCHOSOM MED, V73, P67, DOI 10.1097/PSY.0b013e3182002116
   Kroenke CH, 2013, BREAST CANCER RES TR, V137, P261, DOI 10.1007/s10549-012-2253-8
   Kroenke CH, 2012, BREAST CANCER RES TR, V133, P375, DOI 10.1007/s10549-012-1962-3
   Kroenke CH, 2006, J CLIN ONCOL, V24, P1105, DOI 10.1200/JCO.2005.04.2846
   Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656
   Lang K, 2004, INT J CANCER, V112, P231, DOI 10.1002/ijc.20410
   Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704
   Leung J, 2014, PSYCHO-ONCOLOGY, V23, P1014, DOI 10.1002/pon.3523
   LEVY SM, 1990, PSYCHOSOM MED, V52, P73
   LEVY SM, 1991, BEHAV MED, V17, P67
   Lietzen LW, 2014, ANN ONCOL, V25, P2419, DOI 10.1093/annonc/mdu453
   Lutgendorf SK, 2005, J CLIN ONCOL, V23
   Lutgendorf SK, 2015, AM PSYCHOL, V70, P186, DOI 10.1037/a0035730
   Lutgendorf SK, 2012, J CLIN ONCOL, V30, P2885, DOI 10.1200/JCO.2011.39.4411
   Lutgendorf SK, 2011, BRAIN BEHAV IMMUN, V25, P250, DOI 10.1016/j.bbi.2010.10.012
   Madden KS, 2013, BRAIN BEHAV IMMUN, V30, pS135, DOI 10.1016/j.bbi.2012.05.003
   Masur K, 2001, CANCER RES, V61, P2866
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441
   Nausheen B, 2009, J PSYCHOSOM RES, V67, P403, DOI 10.1016/j.jpsychores.2008.12.012
   Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200
   Oliveira-Pelegrin GR, 2013, NEUROIMMUNOMODULAT, V20, P65, DOI 10.1159/000345044
   Pang D, 2006, CANCER BIOL THER, V5, P933
   Powe DG, 2010, ONCOTARGET, V1, P628
   Reeder A, 2015, BRIT J CANCER, V112, P1461, DOI 10.1038/bjc.2015.133
   Sephton SE, 2000, J NATL CANCER I, V92, P994, DOI 10.1093/jnci/92.12.994
   Shahzad MM, 2010, J BIOL CHEM, V12, P35462
   Skor MN, 2013, CLIN CANCER RES, V19, P6163, DOI 10.1158/1078-0432.CCR-12-3826
   Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522
   Smith AS, 2014, BIOL PSYCHIAT, V76, P281, DOI 10.1016/j.biopsych.2013.09.017
   Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698
   Sorensen GV, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3106
   Steptoe A, 2013, P NATL ACAD SCI USA, V110, P5797, DOI 10.1073/pnas.1219686110
   Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008
   Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447
   Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301
   Tomaka J, 2006, J AGING HEALTH, V18, P359, DOI 10.1177/0898264305280993
   UMBERSON D, 1987, J HEALTH SOC BEHAV, V28, P306, DOI 10.2307/2136848
   Volden PA, 2013, CANCER PREV RES, V6, P634, DOI 10.1158/1940-6207.CAPR-12-0458
   Wang JC, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-19
   Weihs KL, 2008, PSYCHOSOM MED, V70, P117, DOI 10.1097/PSY.0b013e31815c25cf
   Weihs KL, 2005, J PSYCHOSOM RES, V59, P299, DOI 10.1016/j.jpsychores.2004.12.002
   Williams JB, 2009, CANCER PREV RES, V2, P850, DOI 10.1158/1940-6207.CAPR-08-0238
   WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801
   Wu W, 2005, J BIOL CHEM, V280, P4117, DOI 10.1074/jbc.M411200200
NR 75
TC 1
Z9 1
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD MAY 26
PY 2016
VL 18
AR 54
DI 10.1186/s13058-016-0700-x
PG 9
WC Oncology
SC Oncology
GA DN7QX
UT WOS:000377273500001
PM 27225892
ER

PT J
AU van Vliet, EOG
   Nijman, TAJ
   Schuit, E
   Heida, KY
   Opmeer, BC
   Kok, M
   Gyselaers, W
   Porath, MM
   Woiski, M
   Bax, CJ
   Bloemenkamp, KWM
   Scheepers, HCJ
   Jacquemyn, Y
   van Beek, E
   Duvekot, JJ
   Franssen, MTM
   Papatsonis, DN
   Kok, JH
   van der Post, JAM
   Franx, A
   Mol, BW
   Oudijk, MA
AF van Vliet, Elvira O. G.
   Nijman, Tobias A. J.
   Schuit, Ewoud
   Heida, Karst Y.
   Opmeer, Brent C.
   Kok, Marjolein
   Gyselaers, Wilfried
   Porath, Martina M.
   Woiski, Mallory
   Bax, Caroline J.
   Bloemenkamp, Kitty W. M.
   Scheepers, Hubertina C. J.
   Jacquemyn, Yves
   van Beek, Erik
   Duvekot, Johannes J.
   Franssen, Maureen T. M.
   Papatsonis, Dimitri N.
   Kok, Joke H.
   van der Post, Joris A. M.
   Franx, Arie
   Mol, Ben W.
   Oudijk, Martijn A.
TI Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a
   multicentre, randomised controlled trial
SO LANCET
LA English
DT Article
ID MATERNAL HEMODYNAMICS; TOCOLYTIC TREATMENT; BLOOD-FLOW; WAVE-FORMS;
   FETAL; LABOR; THERAPY; DELIVERY; METAANALYSIS; PREGNANCY
AB Background In women with threatened preterm birth, delay of delivery by 48 h allows antenatal corticosteroids to improve neonatal outcomes. For this reason, tocolytics are often administered for 48 h; however, there is no consensus about which drug results in the best maternal and neonatal outcomes. In the APOSTEL III trial we aimed to compare the effectiveness and safety of the calcium-channel blocker nifedipine and the oxytocin inhibitor atosiban in women with threatened preterm birth.
   Methods We did this multicentre, randomised controlled trial in ten tertiary and nine teaching hospitals in the Netherlands and Belgium. Women with threatened preterm birth (gestational age 25-34 weeks) were randomly assigned (1:1) to either oral nifedipine or intravenous atosiban for 48 h. An independent data manager used a web-based computerised programme to randomly assign women in permuted block sizes of four, with groups stratified by centre. Clinicians, outcome assessors, and women were not masked to treatment group. The primary outcome was a composite of adverse perinatal outcomes, which included perinatal mortality, bronchopulmonary dysplasia, sepsis, intraventricular haemorrhage, periventricular leukomalacia, and necrotising enterocolitis. Analysis was done in all women and babies with follow-up data. The study is registered at the Dutch Clinical Trial Registry, number NTR2947.
   Findings Between July 6, 2011, and July 7, 2014, we randomly assigned 254 women to nifedipine and 256 to atosiban. Primary outcome data were available for 248 women and 297 babies in the nifedipine group and 255 women and 294 babies in the atosiban group. The primary outcome occurred in 42 babies (14%) in the nifedipine group and in 45 (15%) in the atosiban group (relative risk [RR] 0.91, 95% CI 0.61-1.37). 16 (5%) babies died in the nifedipine group and seven (2%) died in the atosiban group (RR 2.20, 95% CI 0.91-5.33); all deaths were deemed unlikely to be related to the study drug. Maternal adverse events did not differ between groups.
   Interpretation In women with threatened preterm birth, 48 h of tocolysis with nifedipine or atosiban results in similar perinatal outcomes. Future clinical research should focus on large placebo-controlled trials, powered for perinatal outcomes.
C1 [van Vliet, Elvira O. G.; Nijman, Tobias A. J.; Heida, Karst Y.; Bloemenkamp, Kitty W. M.; Franx, Arie; Oudijk, Martijn A.] Univ Med Ctr Utrecht, Dept Obstet, Wilhelmina Hosp, Birth Ctr,Div Woman & Baby, Utrecht, Netherlands.
   [Schuit, Ewoud] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Schuit, Ewoud] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
   [Opmeer, Brent C.] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Kok, Marjolein; van der Post, Joris A. M.; Oudijk, Martijn A.] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynecol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Kok, Joke H.] Univ Amsterdam, Acad Med Ctr, Dept Neonatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Gyselaers, Wilfried] Ziekenhuis Oost Limburg, Dept Obstet & Gynecol, Genk, Belgium.
   [Gyselaers, Wilfried] Hasselt Univ, Dept Physiol, Diepenbeek, Belgium.
   [Porath, Martina M.] Maxima Med Ctr, Dept Obstet & Gynaecol, Veldhoven, Netherlands.
   [Woiski, Mallory] Univ Med Ctr Nijmegen, Dept Obstet & Gynaecol, Nijmegen, Netherlands.
   [Bax, Caroline J.] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynaecol, Amsterdam, Netherlands.
   [Bloemenkamp, Kitty W. M.] Leiden Univ, Med Ctr, Dept Obstet, Leiden, Netherlands.
   [Scheepers, Hubertina C. J.] Maastricht Univ, Med Ctr, Dept Obstet & Gynecol, NL-6200 MD Maastricht, Netherlands.
   [Jacquemyn, Yves] Univ Antwerp Hosp, Dept Gynecol & Obstet, Antwerp, Belgium.
   [van Beek, Erik] St Antonius Hosp, Dept Obstet & Gynaecol, Nieuwegein, Netherlands.
   [Duvekot, Johannes J.] Erasmus Univ, Med Ctr, Dept Obstet & Gynecol, Rotterdam, Netherlands.
   [Franssen, Maureen T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet, Groningen, Netherlands.
   [Papatsonis, Dimitri N.] Amphia Hosp, Dept Obstet & Gynecol, Breda, Netherlands.
   [Mol, Ben W.] Univ Adelaide, Robinson Res Inst, Sch Paediat & Reprod Hlth, Adelaide, SA, Australia.
   [Mol, Ben W.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
RP Oudijk, MA (reprint author), Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands.
EM m.a.oudijk@amc.uva.nl
FU ZonMw (the Netherlands Organisation for Health Research and
   Development); ZonMw, the Netherlands Organization for Health Research
   and Development Healthcare Rational Medicine program [836011005]
FX ZonMw (the Netherlands Organisation for Health Research and
   Development).r This study was funded by ZonMw, the Netherlands
   Organization for Health Research and Development Healthcare Rational
   Medicine program, project number 836011005. We thank the research
   nurses, midwives, and administrative assistants of our consortium; and
   the residents, nurses, midwives, and gynaecologists of the participating
   centres for their help with participant recruitment and data collection.
   We give special thanks to the members of the data safety monitoring
   committee J G P Tijssen, F M Helmerhorst, T R de Haan, and J H van der
   Lee, for monitoring the trial and evaluating the interim analysis. We
   thank H A A Brouwers, J J H M Erwich, L van Toledo, and A C C Evers for
   their evaluation of perinatal mortality in our study. We give many
   thanks to all the women who participated in this study.
CR Al-Omari WR, 2006, EUR J OBSTET GYN R B, V128, P129, DOI 10.1016/j.ejogrb.2005.12.010
   Alfirevic Z, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6531
   Ananth A, 2006, J MATERN-FETAL NEO M, V19, P773
   BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001
   Berkman ND, 2003, AM J OBSTET GYNECOL, V188, P1648, DOI 10.1067/mob.2003.356
   Blea CW, 1997, AM J OBSTET GYNECOL, V176, P922, DOI 10.1016/S0002-9378(97)70622-7
   Blencowe H, 2013, REPROD HLTH, V10, P1, DOI DOI 10.1186/1742-4755-10-S1-S2
   Bolisetty S, 2006, AUST NZ J OBSTET GYN, V46, P189, DOI 10.1111/j.1479-828X.2006.00564.x
   De Heus R, 2009, J MATERN-FETAL NEO M, V22, P485, DOI 10.1080/14767050802702349
   de Heus R, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b744
   DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5
   Flenady V, 2014, COCHRANE DB SYST REV, V6
   Flenady V, 2014, COCHRANE DB SYST REV, V6
   FURUHASHI N, 1991, GYNECOL OBSTET INVES, V32, P1
   Gates S, 2004, BJOG-INT J OBSTET GY, V111, P213, DOI 10.1111/j.1471-0528.2004.00059.x
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Guclu S, 2004, ULTRASOUND OBST GYN, V24, P761, DOI 10.1002/uog.1770
   Haas DM, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6226
   Haas DM, 2009, OBSTET GYNECOL, V113, P585, DOI 10.1097/AOG.0b013e318199924a
   Hammers AL, 2015, AM J OBSTET GYNECOL, V212, P505
   HARAKE B, 1987, AM J OBSTET GYNECOL, V157, P1003
   Hehir MP, 2012, J MATERN-FETAL NEO M, V25, P2234, DOI 10.3109/14767058.2012.684171
   HOLBROOK RH, 1987, OBSTET GYNECOL, V69, P83
   Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723
   Kashanian M, 2005, INT J GYNECOL OBSTET, V91, P10, DOI 10.1016/j.ijgo.2005.06.005
   Keirse MJNC, 2003, BJOG-INT J OBSTET GY, V110, P94, DOI 10.1016/S1470-0328(03)00051-X
   Khan K, 2010, J MATERN-FETAL NEO M, V23, P1030, DOI 10.3109/14767050903572182
   American College of Obstetricians and Gynecologist; Committee on Practice Bulletins, 2012, OBSTET GYNECOL, V119, P1308
   MARI G, 1989, AM J OBSTET GYNECOL, V161, P1514
   Ment LR, 2002, NEUROLOGY, V58, P1726
   Meyboom RHB, 1997, DRUG SAFETY, V17, P374, DOI 10.2165/00002018-199717060-00004
   PIRHONEN JP, 1990, OBSTET GYNECOL, V76, P807
   RCOG, 2011, TOC WOM PRET LAB
   Reinebrant HE, 2015, COCHRANE DB SYST REV, V6
   Salim R, 2012, OBSTET GYNECOL, V120, P1323, DOI [http://10.1097/AOG.0b013e3182755dff, 10.1097/AOG.0b013e3182755dff]
   SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239
   Simhan HN, 2007, NEW ENGL J MED, V357, P477, DOI 10.1056/NEJMra050435
   Treyvaud K, 2014, J PEDIATR-US, V164, P515, DOI 10.1016/j.jpeds.2013.11.001
   van Veen AJ, 2005, BJOG-INT J OBSTET GY, V112, P509, DOI 10.1111/j.1471-0528.2004.00480.x
   van Vliet EOG, 2014, EXPERT OPIN PHARMACO, V15, P787, DOI 10.1517/14656566.2014.889684
   van Vliet EOG, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-93
   Vogel JP, 2015, LANCET GLOB HEALTH, V3, pE589, DOI 10.1016/S2214-109X(15)00183-7
NR 42
TC 2
Z9 2
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 21
PY 2016
VL 387
IS 10033
BP 2117
EP 2124
DI 10.1016/S0140-6736(16)00548-1
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA DM6HC
UT WOS:000376450800035
PM 26944026
ER

PT J
AU Vaudry, H
AF Vaudry, Hubert
TI Editorial: Trends in Neuroendocrinology
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Editorial Material
DE editorial; neuroendocrinology; ICN2014; oxytocin; circadian rhythm;
   neuroendocrine factors
ID HYPOTHALAMIC CONTROL; ENERGY HOMEOSTASIS; GLUCOSE; METABOLISM
C1 [Vaudry, Hubert] INSERM, Mont St Aignan, France.
   [Vaudry, Hubert] Normandy Univ, IRIB, Mont St Aignan, France.
   [Vaudry, Hubert] Univ Rouen, Lab Neuronal & Neuroendocrine Differentiat & Comm, Mont St Aignan, France.
   [Vaudry, Hubert] Int Associated Lab Samuel de Champlain, Mont St Aignan, France.
RP Vaudry, H (reprint author), INSERM, Mont St Aignan, France.; Vaudry, H (reprint author), Normandy Univ, IRIB, Mont St Aignan, France.; Vaudry, H (reprint author), Univ Rouen, Lab Neuronal & Neuroendocrine Differentiat & Comm, Mont St Aignan, France.; Vaudry, H (reprint author), Int Associated Lab Samuel de Champlain, Mont St Aignan, France.
EM hubert.vaudry@univ-rouen.fr
CR Gargantini E, 2013, HORM METAB RES, V45, P1002, DOI 10.1055/s-0033-1351325
   Knauf C, 2013, HORM METAB RES, V45, P928, DOI 10.1055/s-0033-1351321
   Murray S, 2014, NAT REV ENDOCRINOL, V10, P540, DOI 10.1038/nrendo.2014.91
   Primeaux SD, 2013, HORM METAB RES, V45, P967, DOI 10.1055/s-0033-1353181
   Sekar R, 2013, HORM METAB RES, V45, P945, DOI 10.1055/s-0033-1353155
   Stengel A, 2013, HORM METAB RES, V45, P975, DOI 10.1055/s-0033-1351324
   Tonon MC, 2013, HORM METAB RES, V45, P955, DOI 10.1055/s-0033-1355357
NR 7
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 18
PY 2016
VL 7
AR 41
DI 10.3389/fendo.2016.00041
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DP5AW
UT WOS:000378509400001
PM 27242665
ER

PT J
AU Lee, JH
   Espinera, AR
   Chen, DD
   Choi, KE
   Caslin, AY
   Won, S
   Pecoraro, V
   Xu, GY
   Wei, L
   Yu, SP
AF Lee, Jin Hwan
   Espinera, Alyssa R.
   Chen, Dongdong
   Choi, Ko-Eun
   Caslin, Asha Yoshiko
   Won, Soonmi
   Pecoraro, Valentina
   Xu, Guang-Yin
   Wei, Ling
   Yu, Shan Ping
TI Neonatal inflammatory pain and systemic inflammatory responses as
   possible environmental factors in the development of autism spectrum
   disorder of juvenile rats
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Inflammatory pain; Social behavior; Cell death; Autism spectrum
   disorder; NRXN1; FMR1; Oxytocin
ID HIPPOCAMPAL NEUROGENESIS; POSTMORTEM BRAIN; IMMUNE-RESPONSE; CHILDREN;
   OXYTOCIN; DYSFUNCTION; MEMORY; STRESS; MICE; MECHANISMS
AB Background: Autism spectrum disorder (ASD) affects many children and juveniles. The pathogenesis of ASD is not well understood. Environmental factors may play important roles in the development of ASD. We examined a possible relationship of inflammatory pain in neonates and the development of ASD in juveniles.
   Methods: Acute inflammation pain was induced by 5 % formalin (5 mu l/day) subcutaneous injection into two hindpaws of postnatal day 3 to 5 (P3-P5) rat pups. Western blot, immunohistochemical, and behavioral examinations were performed at different time points after the insult.
   Results: Formalin injection caused acute and chronic inflammatory responses including transient local edema, increased levels of inflammatory cytokines, TNF-alpha, and IL-1 beta in the blood as well as in the brain, and increased microglia in the brain. One day after the pain insult, there was significant cell death in the cortex and hippocampus. Two weeks later, although the hindpaw local reaction subsided, impaired axonal growth and demyelization were seen in the brain of P21 juvenile rats. The number of bromodeoxyuridine (BrdU) and doublecortin (DCX) double-positive cells in the hippocampal dentate gyrus of P21 rats was significantly lower than that in controls, indicating reduced neurogenesis. In the P21 rat's brain of the formalin group, the expression of autism-related gene neurexin 1 (NRXN1), fragile X mental retardation 1 (FMR1), and oxytocin was significantly downregulated, consistent with the gene alteration in ASD. Juvenile rats in the formalin group showed hyperalgesia, repetitive behaviors, abnormal locomotion, sleep disorder, and distinct deficits in social memory and social activities. These alterations in neuroinflammatory reactions, gene expression, and behaviors were more evident in male than in female rats. Importantly, an anti-inflammation treatment using indomethacin (10 mg/kg, i.p.) at the time of formalin injections suppressed inflammatory responses and neuronal cell death and prevented alterations in ASD-related genes and the development of abnormal behaviors.
   Conclusions: These novel observations indicate that severe inflammatory pain in neonates and persistent inflammatory reactions may predispose premature infants to development delays and psychiatric disorders including ASD. The prevention of pain stimuli and prompt treatments of inflammation during development appear vitally important in disrupting possible evolution of ASD syndromes.
C1 [Lee, Jin Hwan; Espinera, Alyssa R.; Chen, Dongdong; Choi, Ko-Eun; Caslin, Asha Yoshiko; Won, Soonmi; Pecoraro, Valentina; Wei, Ling; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.
   [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.
   [Chen, Dongdong; Xu, Guang-Yin] Soochow Univ, Inst Neurosci, Lab Translat Pain Med, Suzhou 215123, Jiangsu, Peoples R China.
   [Yu, Shan Ping] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Atlanta, GA 30033 USA.
   [Yu, Shan Ping] Emory Univ, Sch Med, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.
RP Yu, SP (reprint author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.; Yu, SP (reprint author), Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Atlanta, GA 30033 USA.; Yu, SP (reprint author), Emory Univ, Sch Med, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.
EM spyu@emory.edu
FU NIH [NS062097, NS073378, NS075338]; American Heart Association (AHA)
   [12GRNT12060222]; AHA Established Investigator Award; O. Wayne Rollins
   Endowed Chair fund; Emory Neuroscience Initiative Seed Grant
FX This work was supported by the NIH grants NS062097, NS073378, NS075338,
   American Heart Association (AHA) Grant-in-Aid grant 12GRNT12060222, and
   AHA Established Investigator Award. It was also supported by the O.
   Wayne Rollins Endowed Chair fund to SPY. Preliminary experiments were
   supported by an Emory Neuroscience Initiative Seed Grant.
CR Allik H, 2006, BMC PSYCHIATRY, V6, P6
   Ambalavanan N, 2012, AM J PERINAT, V29, P731, DOI 10.1055/s-0032-1316443
   Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197
   Anand KJS, 2000, PROG BRAIN RES, V122, P117
   Anello A, 2009, J AUTISM DEV DISORD, V39, P1487, DOI 10.1007/s10803-009-0755-y
   Angelidou A, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-89
   Association AP, 2013, DIAGN STAT MAN MENT
   Bandstra NF, 2012, CLIN J PAIN, V28, P715, DOI 10.1097/AJP.0b013e318243ecf6
   Brimberg L, 2013, MOL PSYCHIATR, V18, P1171, DOI 10.1038/mp.2013.101
   Broek JAC, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-41
   Brown AS, 2014, MOL PSYCHIATR, V19, P259, DOI 10.1038/mp.2012.197
   Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60
   Casey KL, 1999, P NATL ACAD SCI USA, V96, P7668, DOI 10.1073/pnas.96.14.7668
   Chen D, 2015, ASN NEURO, V7
   Chen JL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00276
   Chez MG, 2007, PEDIATR NEUROL, V36, P361, DOI 10.1016/j.pediatrneurol.2007.01.012
   Croonenberghs J, 2002, NEUROPSYCHOBIOLOGY, V45, P1, DOI 10.1159/000048665
   Davis EP, 2014, PSYCHONEUROENDOCRINO, V49, P11, DOI 10.1016/j.psyneuen.2014.06.014
   De Felipe C, 1998, NATURE, V392, P394
   Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC), 2014, MMWR SURVEILL SUMM, V63, P1
   Diz-Chaves Y, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-71
   Duric V, 2005, NEUROSCIENCE, V133, P999, DOI 10.1016/j.neuroscience.2005.04.002
   Fatemi SH, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-6
   Feng JN, 2006, NEUROSCI LETT, V409, P10, DOI 10.1016/j.neulet.2006.08.017
   Fitzgerald M, 2001, NEUROSCIENTIST, V7, P246
   Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37
   Ghaleiha A, 2013, INT J NEUROPSYCHOPH, V16, P783, DOI 10.1017/S1461145712000880
   Ghiani CA, 2011, ASN NEURO, V3, P233, DOI 10.1042/AN20110027
   Giannoni E, 2011, INFECT IMMUN, V79, P2690, DOI 10.1128/IAI.00076-11
   Hansen-Pupp I, 2007, ACTA PAEDIATR, V96, P830, DOI 10.1111/j.1651-2227.2007.00276.x
   Happe F, 2008, NEUROPSYCHOL REV, V18, P287, DOI 10.1007/s11065-008-9076-8
   Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028
   Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021
   Jeste SS, 2014, NAT REV NEUROL, V10, P74, DOI 10.1038/nrneurol.2013.278
   Jeste SS, 2011, CURR OPIN NEUROL, V24, P132, DOI 10.1097/WCO.0b013e3283446450
   Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041
   Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0
   Kim SH, 2013, NEUROSCI AUTISM SPEC, P25
   Kuijper EAM, 2013, REPROD BIOMED ONLINE, V27, P33, DOI 10.1016/j.rbmo.2013.03.009
   Laarakker MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031503
   Leslie ATFS, 2011, NEUROSCI LETT, V501, P78, DOI 10.1016/j.neulet.2011.06.047
   Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002
   Malik M, 2011, IMMUNOBIOLOGY, V216, P80, DOI 10.1016/j.imbio.2010.03.001
   Malow BA, 2012, PEDIATRICS, V130, pS106, DOI 10.1542/peds.2012-0900I
   McCarthy MM, 2010, J NEUROENDOCRINOL, V22, P736, DOI 10.1111/j.1365-2826.2010.02021.x
   McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x
   Mezzelani A, 2015, NUTR NEUROSCI, V18, P145, DOI 10.1179/1476830513Y.0000000108
   Miano Silvia, 2010, Paediatr Drugs, V12, P75, DOI 10.2165/11316140-000000000-00000
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010
   Mohamad O, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-51
   Moore GS, 2012, AM J OBSTET GYNECOL, V206, P314
   Onore C, 2012, BRAIN BEHAV IMMUN, V26, P383, DOI 10.1016/j.bbi.2011.08.007
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Page Gayle Giboney, 2004, J Perinat Educ, V13, P10, DOI 10.1624/105812404X1725
   Pardo Carlos A, 2005, Int Rev Psychiatry, V17, P485, DOI 10.1080/02646830500381930
   Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612
   Rattaz C, 2013, PAIN, V154, P2007, DOI 10.1016/j.pain.2013.06.011
   Ren Ke, 1999, ILAR J, V40, P111
   Ricci S, 2013, NEUROTOX RES, V24, P491, DOI 10.1007/s12640-013-9393-4
   Ronemus M, 2014, NAT REV GENET, V15, P133, DOI 10.1038/nrg3585
   Salmaso N, 2014, NAT NEUROSCI, V17, P341, DOI 10.1038/nn.3604
   Siegel C, 2010, J NEUROSCI RES, V88, P2765, DOI 10.1002/jnr.22406
   Sizonenko SV, 2003, PEDIATR RES, V54, P263, DOI 10.1203/01.PDR.0000072517.01207.87
   Spencer CM, 2005, GENES BRAIN BEHAV, V4, P420, DOI 10.1111/j.1601-183X.00123.x
   Suzuki K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020470
   Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221
   Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0
   Tanis JC, 2012, PEDIATR RES, V72, P641, DOI 10.1038/pr.2012.130
   Tirko NNMM, 2014, SOC NEUR ABSTR, V300, pB58
   TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T
   Uekita T, 2011, BEHAV BRAIN RES, V219, P302, DOI 10.1016/j.bbr.2011.01.042
   Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315
   Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116
   Wasley Annemarie, 2007, MMWR Surveill Summ, V56, P1
   Watt N, 2008, J AUTISM DEV DISORD, V38, P1518, DOI 10.1007/s10803-007-0532-8
   Wegiel J, 2010, ACTA NEUROPATHOL, V119, P755, DOI 10.1007/s00401-010-0655-4
   Wei HG, 2014, INT J DEV NEUROSCI, V36, P13, DOI 10.1016/j.ijdevneu.2014.04.004
   White LD, 2001, CELL DEATH DIFFER, V8, P345, DOI 10.1038/sj.cdd.4400816
   Williams DL, 2006, NEUROPSYCHOLOGY, V20, P21, DOI 10.1037/0894-4105.20.1.21
   Williams DL, 2005, ARCH CLIN NEUROPSYCH, V20, P1, DOI 10.1016/j.acn.2002.08.001
   Wu MD, 2012, BRAIN BEHAV IMMUN, V26, P292, DOI 10.1016/j.bbi.2011.09.012
   Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012
   Zablotsky B., 2014, NATL HLTH STAT REP, P1
   Zikopoulos B, 2010, J NEUROSCI, V30, P14595, DOI 10.1523/JNEUROSCI.2257-10.2010
   [Anonymous], 2013, DIAGN STAT MAN MENT
NR 86
TC 1
Z9 1
U1 7
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD MAY 16
PY 2016
VL 13
AR 109
DI 10.1186/s12974-016-0575-x
PG 20
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DL8OT
UT WOS:000375902000002
PM 27184741
ER

PT J
AU Matsuura, T
   Kawasaki, M
   Hashimoto, H
   Yoshimura, M
   Motojima, Y
   Saito, R
   Ueno, H
   Maruyama, T
   Sabanai, K
   Mori, T
   Ohnishi, H
   Sakai, A
   Ueta, Y
AF Matsuura, Takanori
   Kawasaki, Makoto
   Hashimoto, Hirofumi
   Yoshimura, Mitsuhiro
   Motojima, Yasuhito
   Saito, Reiko
   Ueno, Hiromichi
   Maruyama, Takashi
   Sabanai, Ken
   Mori, Toshiharu
   Ohnishi, Hideo
   Sakai, Akinori
   Ueta, Yoichi
TI Effects of central administration of oxytocin-saporin cytotoxin on
   chronic inflammation and feeding/drinking behaviors in adjuvant
   arthritic rats
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Oxytocin; Saporin; Adjuvant arthritis; Feeding
ID GREEN FLUORESCENT PROTEIN; SPINAL-CORD; FOOD-INTAKE; IN-VITRO; NEURONS;
   RECEPTOR; VISUALIZATION; HYPOTHALAMUS; STIMULATION; INHIBITION
AB An increase in the arthritis index as a marker of chronic inflammation and suppression of food intake are observed in adjuvant arthritic (AA) rats. Our previous study demonstrated that central oxytocin (OXT)-ergic pathways were activated potently in AA rats. In the present study, OXT-saporin (SAP) cytotoxin, which chemically disrupts OXT signaling was administered centrally to determine whether central OXT may be involved in the developments of chronic inflammation and alteration of feeding/drinking behavior in AA rats. The arthritis index was significantly enhanced in AA rats pretreated with OXT-SAP administered intrathecally (i.t.) but not intracerebroventricularly (i.c.v.). Suppression of food intake was significantly attenuated transiently in AA rats pretreated with OXT-SAP administered i.c.v. but not i.t. Suppression of drinking behavior was not affected by i.t. or i.c.v. administration of OXT-SAP in AA rats. In addition, intraperitoneal administration of an OXT receptor antagonist did not change the arthritis index or feeding/drinking behavior in AA rats. These results suggest that central OXT-ergic pathways may be involved in anti-inflammation at the spinal level and suppression of feeding behavior at the forebrain-brainstem level in AA rats. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Matsuura, Takanori; Hashimoto, Hirofumi; Yoshimura, Mitsuhiro; Motojima, Yasuhito; Saito, Reiko; Ueno, Hiromichi; Maruyama, Takashi; Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 8078555, Japan.
   [Matsuura, Takanori; Kawasaki, Makoto; Motojima, Yasuhito; Sabanai, Ken; Mori, Toshiharu; Ohnishi, Hideo; Sakai, Akinori] Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed, Kitakyushu, Fukuoka 8078555, Japan.
RP Ueta, Y (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM yoichi@med.uoeh-u.ac.jp
FU Japan Society for the Promotion of Science (JSPS), Japan [26860164,
   25293055, 15K10500, 25462391]; University of Occupational and
   Environmental Health (UOEH) Research Grant for Advanced Research from
   the UOEH
FX We thank. Ms. Yuki Nonaka and Kanako Shoguchi and University of
   Occupational and Environmental Health, (Kitakyushu, Japan) for their
   technical assistances. This work was supported by a Grant-in-Aid for
   Scientific Grants-in-Aid for Scientific Research (B) No. 26860164, (B)
   No. 25293055, (C) No. 15K10500 and (C) No. 25462391 from the Japan
   Society for the Promotion of Science (JSPS), Japan and a University of
   Occupational and Environmental Health (UOEH) Research Grant for Advanced
   Research from the UOEH to M.K. The authors declare no conflicts of
   interests or other competing interests to disclose.
CR ARLETTI R, 1989, PEPTIDES, V10, P89, DOI 10.1016/0196-9781(89)90082-X
   Baird JP, 2009, ENDOCRINOLOGY, V150, P1202, DOI 10.1210/en.2008-0293
   Baskin DG, 2010, ENDOCRINOLOGY, V151, P4207, DOI 10.1210/en.2010-0295
   Blevins JE, 2003, BRAIN RES, V993, P30, DOI 10.1016/j.brainres.2003.08.036
   Breton JD, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-19
   Hashimoto H, 2010, J PHYSIOL SCI, V60, P19, DOI 10.1007/s12576-009-0062-6
   HOGERVORST EJM, 1992, INT IMMUNOL, V4, P719, DOI 10.1093/intimm/4.7.719
   Izeboud CA, 1999, INFLAMM RES, V48, P497, DOI 10.1007/s000110050493
   Kasai M, 2001, NEUROSCI RES, V41, P345, DOI 10.1016/S0168-0102(01)00291-7
   Katoh A, 2014, J NEUROENDOCRINOL, V26, P341, DOI 10.1111/jne.12150
   Kimura T, 1995, ADV EXP MED BIOL, V395, P259
   KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509
   Maejima Y, 2011, AGING-US, V3, P1169
   Matsuura T, 2015, J NEUROENDOCRINOL, V27, P636, DOI 10.1111/jne.12290
   MESTRE C, 1994, J PHARMACOL TOXICOL, V32, P197, DOI 10.1016/1056-8719(94)90087-6
   OLSON BR, 1991, ENDOCRINOLOGY, V129, P785
   Olszewski PK, 2010, ENDOCRINOLOGY, V151, P4736, DOI 10.1210/en.2010-0151
   PEARSON CM, 1964, ARTHRITIS RHEUM, V7, P80, DOI 10.1002/art.1780070111
   PEARSON CM, 1963, AM J PATHOL, V42, P73
   Petersson M, 2001, PEPTIDES, V22, P1479, DOI 10.1016/S0196-9781(01)00469-7
   Puder BA, 2001, J NEUROSCI RES, V64, P53, DOI 10.1002/jnr.1053
   Sansone GR, 2001, BRAIN RES, V898, P265, DOI 10.1016/S0006-8993(01)02192-8
   SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306
   SPANGELO BL, 1994, ENDOCRINOLOGY, V135, P556, DOI 10.1210/en.135.2.556
   Suzuki H, 2009, J NEUROENDOCRINOL, V21, P183, DOI [10.1111/j.1365-2826.2009.01818.x, 10.1111/j.1365-2826.2009.01841.x]
   SWANSON LW, 1979, J COMP NEUROL, V188, P87, DOI 10.1002/cne.901880108
   Tanaka H, 1996, BRAIN RES BULL, V39, P33, DOI 10.1016/0361-9230(95)02037-3
   UVNASMOBERG K, 1993, ACTA PHYSIOL SCAND, V149, P199, DOI 10.1111/j.1748-1716.1993.tb09612.x
   WILLIAMS KI, 1980, PROSTAGLANDINS, V19, P31, DOI 10.1016/0090-6980(80)90151-3
   Wrobel L, 2011, NEUROSCI LETT, V495, P49, DOI 10.1016/j.neulet.2011.03.033
   Yoon SY, 2007, NEUROPHARMACOLOGY, V53, P677, DOI 10.1016/j.neuropharm.2007.07.011
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD MAY 16
PY 2016
VL 621
BP 104
EP 110
DI 10.1016/j.neulet.2016.04.010
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DM2XK
UT WOS:000376211200016
PM 27060190
ER

PT J
AU Mahadevan, V
   Woodin, MA
AF Mahadevan, Vivek
   Woodin, Melanie A.
TI Regulation of neuronal chloride homeostasis by neuromodulators
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Review
ID CL COTRANSPORTER KCC2; PROTEIN-COUPLED-RECEPTOR; METABOTROPIC GLUTAMATE
   RECEPTORS; PLASMA OXYTOCIN LEVELS; GROUP-I MGLURS; NEUROPATHIC PAIN;
   HIPPOCAMPAL-NEURONS; FEEDFORWARD INHIBITION; FUNCTION PREDICTION;
   MORPHINE-TOLERANCE
AB KCC2 is the central regulator of neuronal Cl-homeostasis, and is critical for enabling strong hyperpolarizing synaptic inhibition in the mature brain. KCC2 hypofunction results in decreased inhibition and increased network hyperexcitability that underlies numerous disease states including epilepsy, neuropathic pain and neuropsychiatric disorders. The current holy grail of KCC2 biology is to identify how we can rescue KCC2 hypofunction in order to restore physiological levels of synaptic inhibition and neuronal network activity. It is becoming increasingly clear that diverse cellular signals regulate KCC2 surface expression and function including neurotransmitters and neuromodulators. In the present review we explore the existing evidence that G-protein-coupled receptor (GPCR) signalling can regulate KCC2 activity in numerous regions of the nervous system including the hypothalamus, hippocampus and spinal cord. We present key evidence from the literature suggesting that GPCR signalling is a conserved mechanism for regulating chloride homeostasis. This evidence includes: (1) the activation of group 1 metabotropic glutamate receptors and metabotropic Zn2+ receptors strengthens GABAergic inhibition in CA3 pyramidal neurons through a regulation of KCC2; (2) activation of the 5-hydroxytryptamine type 2A serotonin receptors upregulates KCC2 cell surface expression and function, restores endogenous inhibition in motoneurons, and reduces spasticity in rats; and (3) activation of A3A-type adenosine receptors rescues KCC2 dysfunction and reverses allodynia in a model of neuropathic pain. We propose that GPCR-signals are novel endogenous Cl-extrusion enhancers that may regulate KCC2 function.
C1 [Mahadevan, Vivek; Woodin, Melanie A.] Univ Toronto, Dept Cell & Syst Biol, 25 Harbord St, Toronto, ON M5S 3G5, Canada.
RP Woodin, MA (reprint author), Univ Toronto, Dept Cell & Syst Biol, 25 Harbord St, Toronto, ON M5S 3G5, Canada.
EM m.woodin@utoronto.ca
FU Canadian Institutes of Health Research (CIHR)
FX This work was supported by a grant to M.A.W. from the Canadian
   Institutes of Health Research (CIHR).
CR Alvarez-Leefmans FJ, 2010, PHYSL PATHOLOGY CHLO
   Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2
   Atherton JF, 2010, J NEUROSCI, V30, P16025, DOI 10.1523/JNEUROSCI.3898-10.2010
   Banke TG, 2008, J PHYSIOL-LONDON, V586, P4925, DOI 10.1113/jphysiol.2008.157024
   Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006
   Biel M, 2009, PHYSIOL REV, V89, P847, DOI 10.1152/physrev.00029.2008
   Bos R, 2013, P NATL ACAD SCI USA, V110, P348, DOI 10.1073/pnas.1213680110
   Brustein E, 2005, J NEUROSCI, V25, P10607, DOI 10.1523/JNEUROSCI.2017-05.2005
   BUZSAKI G, 1984, PROG NEUROBIOL, V22, P131, DOI 10.1016/0301-0082(84)90023-6
   Chamma I., 2012, FRONTIERS CELLULAR N, V6, P1
   Chamma I, 2013, J NEUROSCI, V33, P15488, DOI 10.1523/JNEUROSCI.5889-12.2013
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Chorin E, 2011, J NEUROSCI, V31, P12916, DOI 10.1523/JNEUROSCI.2205-11.2011
   Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760
   Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868
   Deeb TZ, 2013, EUR J NEUROSCI, V38, P2453, DOI 10.1111/ejn.12241
   Delpire E, 2012, BIOORG MED CHEM LETT, V22, P4532, DOI 10.1016/j.bmcl.2012.05.126
   Delpire E, 2009, P NATL ACAD SCI USA, V106, P5383, DOI 10.1073/pnas.0812756106
   Farr CD, 2004, J NEUROCHEM, V91, P438, DOI 10.1111/j.1471-4159.2004.02735.x
   Ferrini F, 2013, NAT NEUROSCI, V16, P183, DOI 10.1038/nn.3295
   Fiumelli H, 2005, NEURON, V48, P773, DOI 10.1016/j.neuron.2005.10.025
   Ford A, 2015, J NEUROSCI, V35, P6057, DOI 10.1523/JNEUROSCI.4495-14.2015
   Frederickson CJ, 2000, J NUTR, V130, P1471
   Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356
   Gauvain G, 2011, P NATL ACAD SCI USA, V108, P15474, DOI 10.1073/pnas.1107893108
   Gilad D, 2015, NEUROBIOL DIS, V81, P4, DOI 10.1016/j.nbd.2014.12.020
   Goldman M, 2008, SCHIZOPHR RES, V98, P247, DOI 10.1016/j.schres.2007.09.019
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Grunewald E, 2009, MOL CELL NEUROSCI, V42, P363, DOI 10.1016/j.mcn.2009.08.007
   Gulyas AI, 2001, EUR J NEUROSCI, V13, P2205, DOI 10.1046/j.0953-816x.2001.01600.x
   He Q, 2014, J NEUROSCI, V34, P446, DOI 10.1523/JNEUROSCI.4447-13.2014
   Hewitt SA, 2009, NAT NEUROSCI, V12, P438, DOI 10.1038/nn.2274
   Huang X, 2015, NATURE, V526, P277, DOI 10.1038/nature14972
   Huang Z, 2009, J NEUROSCI, V29, P10979, DOI 10.1523/JNEUROSCI.1531-09.2009
   Hubner CA, 2014, EMBO REP, V15, P732, DOI 10.15252/embr.201439039
   Isaacson JS, 2011, NEURON, V72, P231, DOI 10.1016/j.neuron.2011.09.027
   Ivakine EA, 2013, P NATL ACAD SCI USA, V110, P3561, DOI 10.1073/pnas.1212907110
   Kahle KT, 2013, TRENDS NEUROSCI, V36, P726, DOI [10.1016/j.tins.2013.08.006, 10.1016/i.tins.2013.08.006]
   Kaila K, 2014, NAT REV NEUROSCI, V15, P637, DOI 10.1038/nrn3819
   Kato AS, 2012, J NEUROSCI, V32, P15296, DOI 10.1523/JNEUROSCI.0705-12.2012
   Kopp-Scheinpflug C, 2011, NEURON, V71, P911, DOI 10.1016/j.neuron.2011.06.028
   Lee HHC, 2007, J BIOL CHEM, V282, P29777, DOI 10.1074/jbc.M705053200
   Lee HHC, 2011, NAT NEUROSCI, V14, P736, DOI 10.1038/nn.2806
   Lee HHC, 2010, MOL CELL NEUROSCI, V45, P173, DOI 10.1016/j.mcn.2010.06.008
   Li H, 2007, NEURON, V56, P1019, DOI 10.1016/j.neuron.2007.10.039
   Llano O, 2015, J CELL BIOL, V209, P671, DOI 10.1083/jcb.201411008
   Mahadevan V, 2014, CELL REP, V7, P1762, DOI 10.1016/j.celrep.2014.05.022
   MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2
   Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731
   McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815
   McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X
   Medina I, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00027
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Ormond J, 2011, FRONT CELL NEUROSCI, V5, P1
   Ormond J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007224
   Pavlov I, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1202
   Penagarikano O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010257
   Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908
   Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342
   Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731
   Puskarjov M, 2012, J NEUROSCI, V32, P11356, DOI 10.1523/JNEUROSCI.6265-11.2012
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1046/j.1601-183X.2003.00037.x
   Saadi RA, 2012, NEUROSCIENCE, V210, P38, DOI 10.1016/j.neuroscience.2012.03.001
   Scantamburlo G, 2007, PSYCHONEUROENDOCRINO, V32, P407, DOI 10.1016/j.psyneuen.2007.01.009
   Schomberg SL, 2001, J NEUROPHYSIOL, V85, P2563
   Shaffer PL, 2009, SCIENCE, V325, P1010, DOI 10.1126/science.1176088
   Shah MM, 2014, J PHYSIOL-LONDON, V592, P2711, DOI 10.1113/jphysiol.2013.270058
   Shah MM, 2004, NEURON, V44, P495, DOI 10.1016/j.neuron.2004.10.011
   Silayeva L, 2015, P NATL ACAD SCI USA, V112, P3523, DOI 10.1073/pnas.1415126112
   Sivakumaran S, 2015, J NEUROSCI, V35, P8291, DOI 10.1523/JNEUROSCI.5205-14.2015
   STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197
   Sun DD, 1999, J NEUROPHYSIOL, V81, P1939
   Takkala P, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00016
   Tao R, 2012, J NEUROSCI, V32, P5216, DOI 10.1523/JNEUROSCI.4626-11.2012
   Tora AS, 2015, FASEB J, V29, P4174, DOI 10.1096/fj.14-269746
   Tyzio R, 2006, SCIENCE, V314, P1788, DOI 10.1126/science.1133212
   Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190
   Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100
   Warmuth S, 2009, STRUCTURE, V17, P538, DOI 10.1016/j.str.2009.02.009
   Woodin MA, 2003, NEURON, V39, P807, DOI 10.1016/S0896-6273(03)00507-5
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhou HY, 2012, J BIOL CHEM, V287, P33853, DOI 10.1074/jbc.M112.395830
NR 84
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD MAY 15
PY 2016
VL 594
IS 10
BP 2593
EP 2605
DI 10.1113/JP271593
PG 13
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA DQ4PN
UT WOS:000379185900007
PM 26876607
ER

PT J
AU Colloca, L
   Pine, DS
   Ernst, M
   Miller, FG
   Grillon, C
AF Colloca, Luana
   Pine, Daniel S.
   Ernst, Monique
   Miller, Franklin G.
   Grillon, Christian
TI Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized
   Trial
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Anxiety; Expectancy; Pain; Sexual dimorphism; Stress; Verbal suggestions
ID SOCIAL BRAIN; INTERMALE AGGRESSION; INTRANASAL OXYTOCIN; NEURAL
   CIRCUITRY; OPIOID ACTIVITY; OUT-GROUP; BEHAVIOR; PAIN; HUMANS; RESPONSES
AB BACKGROUND: Social cues and interpersonal interactions strongly contribute to evoke placebo effects that are pervasive in medicine and depend upon the activation of endogenous modulatory systems. Here, we explore the possibility to boost placebo effects by targeting pharmacologically the vasopressin system, characterized by a sexually dimorphic response and involved in the regulation of human and nonhuman social behaviors.
   METHODS: We enrolled 109 healthy participants and studied the effects of intranasal administration of an arginine vasopressin 1A and 1B receptor agonist against 1) no treatment, 2) oxytocin, and 3) saline in a randomized, placebo-controlled, double-blind, parallel design trial using a well-established model of placebo analgesia while controlling for sex differences.
   RESULTS: Vasopressin agonists boosted placebo effects in women but had no effect in men. The effects of vasopressin on expectancy-induced analgesia were significantly larger than those observed in the no-treatment (p < .004), oxytocin (p < .001), and saline (p < .015) groups. Moreover, women with lower dispositional anxiety and cortisol levels showed the largest vasopressin-induced modulation of placebo effects, suggesting a moderating interplay between pre-existing psychological factors and treatment cortisol changes.
   CONCLUSIONS: This is the first study that demonstrates that arginine vasopressin boosts placebo effects and that the effect of vasopressin depends upon a significant sex by treatment interaction. These findings are novel and might open up new avenues for clinically relevant research due to the therapeutic potentials of vasopressin as well as the possibility to systematically control for influences of placebo responses in clinical trials.
C1 [Colloca, Luana] Univ Maryland, Baltimore, MD 21201 USA.
   [Pine, Daniel S.; Ernst, Monique; Grillon, Christian] NIMH, Bethesda, MD 20892 USA.
   [Miller, Franklin G.] Weill Cornell Med Coll, New York, NY USA.
RP Colloca, L (reprint author), Univ Maryland, Sch Nursing, 655 W Lombard St,Room 729A, Baltimore, MD 21201 USA.
EM colloca@son.umaryland.edu
OI Colloca, Luana/0000-0002-6503-4709
FU Intramural Program of the National Institute of Mental Health;
   University of Maryland Baltimore; International Association for Study of
   Pain; International Association for Study of Pain (IASP); Georgetown
   University (United States); National Center for Complementary and
   Integrative Health
FX This project was partially supported by the Intramural Program of the
   National Institute of Mental Health, the National Center for
   Complementary and Integrative Health (LC), University of Maryland
   Baltimore (LC), and International Association for Study of Pain (Early
   Research Grant [LC]).; Dr. Colloca reports having received research
   funding from the International Association for Study of Pain (IASP) and
   University of Maryland Baltimore; travel reimbursements from different
   institutions, including the German Research Foundation Research Program
   (Germany), French Chapter of IASP, Scuola Internazionale Superiore di
   Studi Avanzati (Italy), Center of Biomedical Research Excellence (United
   States), Center for Pain Research and Innovation (North Carolina, United
   States), Brocher Foundation (Switzerland), University of Sydney
   (Australia), and IASP (United States); and lecture fees from Georgetown
   University (United States). All other authors reported no biomedical
   financial interests or potential conflicts of interest.
CR Abu-Akel A, 2014, PSYCHOL MED, V44, P3523, DOI 10.1017/S003329171400097X
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Amanzio M, 1999, J NEUROSCI, V19, P484
   Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009
   Beiderbeck DI, 2007, EUR J NEUROSCI, V26, P3597, DOI 10.1111/j.1460-9568.2007.05974.x
   Benedetti F, 2014, NEURON, V84, P623, DOI 10.1016/j.neuron.2014.10.023
   Benedetti F, 2011, NAT MED, V17, P1228, DOI 10.1038/nm.2435
   Bielsky IE, 2005, BEHAV BRAIN RES, V164, P132, DOI 10.1016/j.bbr.2005.06.005
   Bolborea M, 2010, NEUROSCIENCE, V165, P819, DOI 10.1016/j.neuroscience.2009.11.006
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bosch OJ, 2008, P NATL ACAD SCI USA, V105, P17139, DOI 10.1073/pnas.0807412105
   Bosch OJ, 2010, EUR J NEUROSCI, V31, P883, DOI 10.1111/j.1460-9568.2010.07115.x
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   Colloca L, 2008, PAIN, V136, P211, DOI 10.1016/j.pain.2008.02.006
   Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705
   Colloca L, 2004, LANCET NEUROL, V3, P679, DOI 10.1016/S1474-4422(04)00908-1
   Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005
   Colloca L, 2010, PAIN, V151, P430, DOI 10.1016/j.pain.2010.08.007
   Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033
   Dolen G, 2015, J NEUROENDOCRINOL, V27, P516, DOI 10.1111/jne.12284
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014
   Enck P, 2009, NEUROGASTROENT MOTIL, V21, P347, DOI 10.1111/j.1365-2982.2009.01285.x
   Feng CL, 2015, BRAIN IMAGING BEHAV, V9, P754, DOI 10.1007/s11682-014-9333-9
   Ferris CF, 1997, J NEUROSCI, V17, P4331
   Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0
   Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106
   Goodin BR, 2015, CLIN J PAIN, V31, P757, DOI 10.1097/AJP.0000000000000166
   Goodson JL, 2010, CURR OPIN NEUROBIOL, V20, P784, DOI 10.1016/j.conb.2010.08.020
   Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Kanat M, 2014, BRAIN RES, V1580, P160, DOI 10.1016/j.brainres.2013.11.003
   Kessner S, 2013, JAMA-J AM MED ASSOC, V310, P1733, DOI 10.1001/jama.2013.277446
   Kirk R. E., 2012, EXPT DESIGN PROCEDUR
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kogan A, 2011, P NATL ACAD SCI USA, V108, P19189, DOI 10.1073/pnas.1112658108
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003
   LEVINE JD, 1978, LANCET, V2, P654
   Martin AL, 2010, PAIN, V149, P208, DOI 10.1016/j.pain.2009.12.004
   Meissner K, 2011, J NEUROSCI, V31, P16117, DOI 10.1523/JNEUROSCI.4099-11.2011
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Miller FG, 2005, PLOS MED, V2, P853, DOI 10.1371/journal.pmed.0020262
   Moerman DE, 2002, ANN INTERN MED, V136, P471
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Norman GJ, 2012, SOC NEUROSCI-UK, V7, P18, DOI 10.1080/17470919.2011.568702
   Pecina M, 2014, MOL PSYCHIATR, V19, P385, DOI 10.1038/mp.2013.124
   Pecina M, 2015, NEUROPSYCHOPHARMACOL, V40, P957, DOI 10.1038/npp.2014.272
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34
   Spielberger CD., 1989, STATE TRAIT ANXIETY
   Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6
   Thompson RR, 2006, P NATL ACAD SCI USA, V103, P7889, DOI 10.1073/pnas.0600406103
   Thompson RR, 2004, BEHAV NEUROSCI, V118, P620, DOI 10.1037/0735-7044.118.3.620
   van Ijzendoorn MH, 2012, PSYCHONEUROENDOCRINO, V37, P438, DOI 10.1016/j.psyneuen.2011.07.008
   Veenema AH, 2010, HORM BEHAV, V58, P273, DOI 10.1016/j.yhbeh.2010.03.006
   Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104
   Yamasue H, 2009, PSYCHIAT CLIN NEUROS, V63, P129, DOI 10.1111/j.1440-1819.2009.01944.x
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Zink CF, 2012, HORM BEHAV, V61, P400, DOI 10.1016/j.yhbeh.2012.01.016
   Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005
   [Anonymous], 1992, ANN N Y ACAD SCI, V652, P1
NR 68
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2016
VL 79
IS 10
BP 794
EP 802
DI 10.1016/j.biopsych.2015.07.019
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DK6ZJ
UT WOS:000375074200008
PM 26321018
ER

PT J
AU Bayerl, DS
   Honig, JN
   Bosch, OJ
AF Bayerl, Doris S.
   Hoenig, Jennifer N.
   Bosch, Oliver J.
TI Vasopressin V1a, but not V1b, receptors within the PVN of lactating rats
   mediate maternal care and anxiety-related behaviour
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE d(CH2)(5)Tyr(Me)(2)AVP; Maternal care; Maternal motivation; mRNA;
   Protein; SSR149415
ID HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; CORTICOTROPIN-RELEASING-FACTOR;
   ARGININE-VASOPRESSIN; SOCIAL BEHAVIORS; BRAIN OXYTOCIN; AGGRESSION;
   INVOLVEMENT; ANTAGONISTS; ACTIVATION; DEFENSE
AB The brain neuropeptide arginine-vasopressin (AVP) mediates a wide range of social behaviours via its V1a (V1aR) but also its V1b receptor (V1bR). With respect to maternal behaviour, V1bR are still less investigated, whereas V1aR have been shown repeatedly to trigger maternal behaviour, depending on the brain region. Here, we aimed to study the role of both V1aR and V1bR within the hypothalamic paraventricular nucleus (PVN), a major source of AVP, in maternal care (lactation day (LD) 1), maternal motivation in the pup retrieval test (LD 3) and anxiety-related behaviour on the elevated plus maze (EPM; LD 5) by acute local infusion of receptor subtype-specific antagonists for V1aR (d(CH2)(5)Tyr(Me)(2)AVP) or V1bR (SSR149415). Furthermore, we compared V1bR expression in the PVN of virgin versus lactating rats (LD 4).
   Our results demonstrate that within the PVN neither V1bR mRNA (qPCR) nor protein (Western Blot) content differed between virgin and lactating rats. Regarding behaviour, acute antagonism of V1aR, but not of V1bR, decreased the occurrence of nursing as well as anxiety-related behaviour as reflected by higher percentage of time spent on and of entries into the open arms of the EPM. Maternal motivation was not affected by any treatment. In summary, we demonstrate subtype-specific involvement of V1 receptors within the PVN in mediating various maternal behaviours. The lack of effects after V1bR blockade reveals that AVP acts mainly via V1aR in the PVN, at least in lactating rats, to mediate maternal care and anxiety. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Bayerl, Doris S.; Hoenig, Jennifer N.; Bosch, Oliver J.] Univ Regensburg, Dept Behav & Mol Neurobiol, D-93053 Regensburg, Germany.
RP Bosch, OJ (reprint author), Univ Regensburg, Univ Str 31, D-93053 Regensburg, Germany.
EM doris.bayerl@ur.de; jennifer.hoenig@live.de; oliver.bosch@ur.de
FU Deutsche Forschungsgemeinschaft (DFG) [BO1958/6-1]
FX This study was supported by the Deutsche Forschungsgemeinschaft (DFG
   BO1958/6-1 to OJB).
CR Bayerl DS, 2014, J NEUROENDOCRINOL, V26, P918, DOI 10.1111/jne.12226
   Bayerl DS, 2016, HORM BEHAV, V79, P18, DOI 10.1016/j.yhbeh.2015.12.003
   Blume A, 2008, EUR J NEUROSCI, V27, P1947, DOI 10.1111/j.1460-9568.2008.06184.x
   Bosch OJ, 2010, J NEUROENDOCRINOL, V22, P420, DOI 10.1111/j.1365-2826.2010.01984.x
   Bosch OJ, 2008, P NATL ACAD SCI USA, V105, P17139, DOI 10.1073/pnas.0807412105
   Bosch OJ, 2007, PSYCHONEUROENDOCRINO, V32, P267, DOI 10.1016/j.psyneuen.2006.12.012
   Bosch OJ, 2012, HORM BEHAV, V61, P293, DOI 10.1016/j.yhbeh.2011.11.002
   Bosch OJ, 2011, HORM BEHAV, V59, P202, DOI 10.1016/j.yhbeh.2010.11.012
   Bosch OJ, 2010, EUR J NEUROSCI, V31, P883, DOI 10.1111/j.1460-9568.2010.07115.x
   CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794
   Griebel G, 2005, CURR PHARM DESIGN, V11, P1549, DOI 10.2174/1381612053764797
   Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659
   INSEL TR, 1989, PHYSIOL BEHAV, V45, P1033, DOI 10.1016/0031-9384(89)90234-5
   Klampfl SM, 2013, EUR J NEUROSCI, V38, P2742, DOI 10.1111/ejn.12274
   KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003
   Nephew BC, 2008, PHARMACOL BIOCHEM BE, V91, P77, DOI 10.1016/j.pbb.2008.06.013
   Neumann ID, 2001, EUR J NEUROSCI, V13, P1016, DOI 10.1046/j.0953-816x.2001.01460.x
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   NUMAN M, 1985, PHYSIOL BEHAV, V35, P417, DOI 10.1016/0031-9384(85)90318-X
   Numan M, 2003, NEUROBIOLOGY PARENTA
   Paxinos G, 2007, RAT BRAIN STEREOTAXI
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122
   Toufexis DJ, 1999, J NEUROENDOCRINOL, V11, P757
   Veenema AH, 2008, PROG BRAIN RES, V170, P261, DOI 10.1016/S0079-6123(08)00422-6
   Walker C D, 2001, Prog Brain Res, V133, P99
   Wigger A, 2004, NEUROPSYCHOPHARMACOL, V29, P1, DOI 10.1038/sj.npp.1300290
NR 27
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD MAY 15
PY 2016
VL 305
BP 18
EP 22
DI 10.1016/j.bbr.2016.02.020
PG 5
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA DK0OZ
UT WOS:000374613400003
PM 26909846
ER

PT J
AU Almeida-Pereira, G
   Coletti, R
   Mecawi, AS
   Reis, LC
   Elias, LLK
   Antunes-Rodrigues, J
AF Almeida-Pereira, G.
   Coletti, R.
   Mecawi, A. S.
   Reis, L. C.
   Elias, L. L. K.
   Antunes-Rodrigues, J.
TI ESTRADIOL AND ANGIOTENSIN II CROSSTALK IN HYDROMINERAL BALANCE: ROLE OF
   THE ERK1/2 AND JNK SIGNALING PATHWAYS
SO NEUROSCIENCE
LA English
DT Article
DE sodium intake; water intake; vasopressin secretion; oxytocin secretion;
   ovariectomized rats
ID ACTIVATED PROTEIN-KINASE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS;
   SUBFORNICAL ORGAN; SODIUM APPETITE; FEMALE RATS; TYPE-1 RECEPTORS;
   VASOPRESSINERGIC NEURONS; ESTROGEN DECREASES; COUPLED RECEPTORS; VOLUME
   EXPANSION
AB The angiotensin II (ANGII) receptor AT1 plays an important role in the control of hydromineral balance, mediating the dipsogenic and natriorexigenic effects and neuroendocrine responses of ANGII. While estradiol (E2) is known to modulate several actions of ANGII in the brain, the molecular and cellular mechanisms of the interaction between E2 and ANGII and its physiological role in the control of body fluids remain unclear. We investigated the influence of E2 (40 mu g/kg) pretreatment and extracellular-signal-regulated kinase (ERK1/2) and c-Jun N-terminal kinase (JNK) cell signaling on the dipsogenic and natriorexigenic effects, as well as the neuroendocrine responses to angiotensinergic central stimulation in ovariectomized rats (OVX). We showed that the inhibitory effect of E2 on ANGII-induced water and sodium intake requires the ERK1/2 and JNK signaling pathways. On the other hand, E2 pretreatment prevents the ANGII-induced phosphorylation of ERK and JNK in the lamina terminalis. E2 therapy decreased oxytocin (OT) and vasopressin (AVP) secretion and decreased ERK1/2 phosphorylation in the supraoptic and paraventricular nuclei (SON and PVN, respectively). We found that the AVP secretion induced by ANGII required ERK1/2 signaling, but OT secretion did not involve ERK1/2 signaling. Taken together, these results demonstrate that E2 modulates ANGII-induced water and sodium intake and AVP secretion by affecting the ERK1/2 and JNK pathways in the lamina terminalis and ERK1/2 signaling in the hypothalamic nuclei (PVN and SON) in OVX rats. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Almeida-Pereira, G.; Coletti, R.; Elias, L. L. K.; Antunes-Rodrigues, J.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Physiol, BR-14049900 Ribeirao Preto, Brazil.
   [Mecawi, A. S.; Reis, L. C.] Univ Fed Rural Rio de Janeiro, Inst Biol, Dept Physiol Sci, BR-23890000 Seropedica, Brazil.
RP Almeida-Pereira, G (reprint author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Physiol, BR-14049900 Ribeirao Preto, Brazil.
EM g.almeidapereira@gmail.com
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (FAPESP);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   FAPESP [2012/04620-0]
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo, Brazil (FAPESP), Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). Gislaine Almeida-Pereira is fellowship
   from FAPESP (#2012/04620-0). We thank Maria Valci dos Santos and Milene
   Mantovani for their excellent technical assistance; and Kaue Machado
   Costa for valuable assistance in final revision of the manuscript.
CR ABDELLATIF MM, 1991, CIRC RES, V69, P800
   Almeida-Pereira G, 2013, HORM BEHAV, V64, P847, DOI 10.1016/j.yhbeh.2013.10.009
   Antunes-Rodrigues J, 2004, PHYSIOL REV, V84, P169, DOI 10.1152/physrev.00017.2003
   ANTUNESRODRIGUES J, 1985, P NATL ACAD SCI USA, V82, P8720, DOI 10.1073/pnas.82.24.8720
   Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856
   BARTANUSZ V, 1994, FUNDAM CLIN PHARM, V8, P539
   BERESFORD MJ, 1992, EXP PHYSIOL, V77, P761
   BLACKBURN RE, 1993, P NATL ACAD SCI USA, V90, P10380, DOI 10.1073/pnas.90.21.10380
   Bold MLK, 1999, CARDIOVASC RES, V41, P524
   Caunt CJ, 2012, FEBS J, V280, P489
   Coble JP, 2014, AM J PHYSIOL-REG I, V308, pR238
   Dai SY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0261-4
   Daniels D, 2005, ENDOCRINOLOGY, V146, P5552, DOI 10.1210/en.2005-0774
   Daniels D, 2008, EXP PHYSIOL, V94, P130
   Daniels D, 2007, EXP PHYSIOL, V92, P523, DOI 10.1113/expphysiol.2006.036897
   de Gasparo M, 2000, PHARMACOL REV, V52, P415
   DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009
   Dominguez R, 2009, J NEUROSCI, V29, P4228, DOI 10.1523/JNEUROSCI.0550-09.2009
   Elias PCL, 1998, ARQ BRAS ENDOCRINOL, V42, P198
   Felgendreger LA, 2013, J NEUROENDOCRINOL, V25, P97, DOI 10.1111/j.1365-2826.2012.02376.x
   Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32
   FERGUSON AV, 1986, AM J PHYSIOL, V251, pR712
   FERGUSON AV, 1986, AM J PHYSIOL, V251, pR425
   FERGUSON AV, 1984, NEUROENDOCRINOLOGY, V39, P423, DOI 10.1159/000124015
   Fitzsimons JT, 1998, PHYSIOL REV, V78, P583
   Grafe LA, 2014, J NEUROSCI, V34, P9249, DOI 10.1523/JNEUROSCI.3979-13.2014
   HAANWINCKEL MA, 1995, P NATL ACAD SCI USA, V92, P7902, DOI 10.1073/pnas.92.17.7902
   Hines J, 2003, BIOCHEM PHARMACOL, V66, P251, DOI 10.1016/S0006-2952(03)00257-0
   HOHLE S, 1995, EUR J PHARMACOL, V275, P277, DOI 10.1016/0014-2999(95)00005-6
   Huang CY, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-24
   Huang XC, 1996, J BIOL CHEM, V271, P15635
   Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536
   Iglesias AG, 2001, AM J PHYSIOL-ENDOC M, V280, pE462
   JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H
   JONKLAAS J, 1985, BRAIN RES, V326, P239, DOI 10.1016/0006-8993(85)90033-2
   Khalil RA, 2005, HYPERTENSION, V46, P249, DOI 10.1161/01.HYP.0000172945.06681.a4
   Kisley LR, 1999, BRAIN RES, V844, P34, DOI 10.1016/S0006-8993(99)01815-6
   Kisley LR, 2000, NEUROENDOCRINOLOGY, V72, P306, DOI 10.1159/000054599
   Krause EG, 2006, J PHYSIOL-LONDON, V573, P251, DOI 10.1113/jphysiol.2006.106740
   Krause EG, 2003, PHYSIOL BEHAV, V79, P267, DOI 10.1016/S0031-9384(03)00095-7
   Landgren BM, 2004, J CLIN ENDOCR METAB, V89, P2763, DOI 10.1210/jc.2003-030824
   Lawan A, 2013, CELL MOL LIFE SCI, V70, P223, DOI 10.1007/s00018-012-1041-2
   Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155
   Lo Presti A, 2004, EUR J OBSTET GYN R B, V113, pS33, DOI 10.1016/j.ejogrb.2003.11.008
   Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898
   Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006
   Oktem O, 2009, SEMIN REPROD MED, V27, P486, DOI 10.1055/s-0029-1241059
   Paxinos G., 1997, RAT BRAIN STEREOTAXI
   Reis WL, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-64
   SADOSHIMA J, 1995, CIRC RES, V76, P1
   Sandberg K, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-7
   Setalo G, 2002, J NEUROBIOL, V50, P1, DOI 10.1002/neu.10000
   SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0
   STRICKER EM, 1991, AM J PHYSIOL, V260, pR1082
   SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2
   Takeda-Matsubara Y, 2002, HYPERTENSION, V39, P41, DOI 10.1161/hy1201.097197
   Tanaka J, 2003, EXP NEUROL, V179, P83, DOI 10.1006/exnr.2002.8054
   Tanaka J, 2001, NEUROSCI LETT, V307, P155, DOI 10.1016/S0304-3940(01)01940-1
   TANG H, 1995, CIRC RES, V77, P239
   Theodosiou A, 2002, GENOME BIOL, V3, P3009
   Thomas WG, 2003, TRENDS ENDOCRIN MET, V14, P130, DOI 10.1016/S1043k-2760(03)00023-7
   Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3
   Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200
   Vento PJ, 2012, EXP PHYSIOL, V97, P1305, DOI 10.1113/expphysiol.2012.065771
   Vilhena-Franco T, 2011, J NEUROENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2826.2011.02133.x
   Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200
   Wei SG, 2008, HYPERTENSION, V52, P679, DOI 10.1161/HYPERTENSIONAHA.108.113639
   Zhu Q, 2005, NEUROSCI LETT, V380, P12, DOI 10.1016/j.neulet.2005.01.007
NR 68
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAY 13
PY 2016
VL 322
BP 525
EP 538
DI 10.1016/j.neuroscience.2016.02.067
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA DG8QX
UT WOS:000372349800045
PM 26951941
ER

PT J
AU Francis, SM
   Kistner-Griffin, E
   Yan, ZY
   Guter, S
   Cook, EH
   Jacob, S
AF Francis, Sunday M.
   Kistner-Griffin, Emily
   Yan, Zhongyu
   Guter, Stephen
   Cook, Edwin H.
   Jacob, Suma
TI Variants in Adjacent Oxytocin/Vasopressin Gene Region and Associations
   with ASD Diagnosis and Other Autism Related Endophenotypes
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE oxytocin; vasopressin; ASD; genetics; polymorphisms; biomarkers;
   phenotypes; IQ
ID OXYTOCIN-RECEPTOR GENE; SPECTRUM DISORDER; PLASMA OXYTOCIN;
   SOCIAL-BEHAVIOR; MATERNAL-BEHAVIOR; PUBERTAL CHANGES; CANDIDATE GENES;
   SEROTONIN; VASOPRESSIN; OXTR
AB Background: There has been increasing interest in oxytocin (peptide: OT, gene: OXT) as a treatment pathway for neurodevelopmental disorders such as Autism Spectrum Disorder (ASD). Neurodevelopmental disorders affect functional, social, and intellectual abilities. With advances in molecular biology, research has connected multiple gene regions to the clinical presentation of ASD. Studies have also shown that the neuropeptide hormones OT and arginine vasopressin (AVP) influence mammalian social and territorial behaviors and may have treatment potential for neurodevelopmental disorders. Published data examining molecular and phenotypic variation in ASD, such as cognitive abilities, are limited. Since most studies have focused on the receptors in the OT-AVP system, we investigated genetic variation within peptide genes for association with phenotypic ASD features that help identify subgroups within the spectrum.
   Methods: In this study, TDT analysis was carried out utilizing FBAT in 207 probands (156 trios) and a European Ancestry (EA) subsample (108 trios). The evolutionarily related and adjacent genes of OXT and AVP were studied for associations between the tagged single nucleotide polymorphisms and ASD diagnosis, social abilities, restrictive and repetitive behaviors, and IQ for cognitive abilities. Additionally, relationships with whole blood serotonin (WB5HT) were explored because of the developmental relationships connecting plasma levels of OT and WB5HT within ASD.
   Results: Results indicate significant association between OXT rs6084258 (p = 0.001) and ASD. Associations with several endophenotypes were also noted: OXT rs6133010 was associated with IQ (full scale IQ, p = 0.008; nonverbal 10, p = 0.010, verbal IQ, p = 0.006); and OXT rs4813625 and OXT rs877172 were associated with WB5HT levels (EA, p = 0.027 and p = 0.033, respectively). Additionally, we measured plasma OT (pOT) levels in a subsample (N = 54). Results show the three polymorphisms, OXT rs6084258, OXT rs11697250, and OXT rs877172, have significant association with pOT (EA, p = 0.011, p = 0.010, and p = 0.002, respectively).
   Conclusions: These findings suggest that SNPs near OXT and AVP are associated with diagnosis of ASD, social behaviors, restricted and repetitive behaviors, IQ, pOT, and WB5HT. Future studies need to replicate these findings and examine gene-interactions in other neurodevelopmental disorders. Mechanisms of action may influence early social and cognitive development that may or may not be limited to ASD diagnosis.
C1 [Francis, Sunday M.; Jacob, Suma] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   [Kistner-Griffin, Emily] Med Univ S Carolina, Hollings Canc Ctr, Biostat Shared Resource, Charleston, SC 29425 USA.
   [Yan, Zhongyu] Dow AgroSci LLC, Indianapolis, IN USA.
   [Guter, Stephen; Cook, Edwin H.] Univ Illinois, Dept Psychiat, Inst Juvenile Res, Chicago, IL 60612 USA.
RP Jacob, S (reprint author), Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
EM sjacob@umn.edu
FU NIMH [K23MH082121]; NARSAD Young Investigator Award [3K23MH082121-03S1];
   Leadership Education in Neurodevelopmental and Related Disorders (LEND)
   Training Program [T73MC12835]; NICHD/NINDS/NIEHS [P50HD055751]
FX This work was supported by NIMH K23MH082121 and NARSAD Young
   Investigator Award (SJ), 3K23MH082121-03S1 and Leadership Education in
   Neurodevelopmental and Related Disorders (LEND) Training Program
   T73MC12835 (SF) and NICHD/NINDS/NIEHS P50HD055751 (EC, EK, SG). The
   authors would like to acknowledge: Dr. Marianna Morris for her
   assistance with oxytocin measurement and Dr. George Anderson for his
   expertise in whole-blood serotonin measurement. We are very grateful to
   Dr. Sue C. Carter for her ongoing guidance and support with many aspects
   of investigating the oxytocin and vasopressin systems. We appreciate the
   time and effort Dr. Lea Davis put into the eQTL analysis. We value
   laboratory assistance from Kathy Hennessy, Kelly Moore, and Zengping
   Hao. Jacob Cogen also helped with genotyping a subset of samples. Also,
   the authors would like to thank Emma Shankland, Diksha Srishyla, and
   Lucinda Wasserburg for their assistance in reviewing the manuscript.
CR Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346
   Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   AMAN MG, 1985, AM J MENT DEF, V89, P492
   Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049
   Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107
   ANDERSON GM, 1981, CLIN CHEM, V27, P775
   BAILEY A, 1995, PSYCHOL MED, V25, P63
   Bales KL, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.117
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Carter CS, 2007, BIOL PSYCHIAT, V62, P709, DOI 10.1016/j.biopsych.2007.07.012
   Carter CS, 1995, ANN NY ACAD SCI, V771, P82, DOI 10.1111/j.1749-6632.1995.tb44672.x
   Carter C. S., 2012, AUTISMS MOL MODEL SY, P334
   Ceroni F, 2014, AUTISM RES, V7, P254, DOI 10.1002/aur.1365
   Chapman NH, 2011, HUM GENET, V129, P59, DOI 10.1007/s00439-010-0899-z
   Chen C, 2013, MOL PSYCHIATR, V18, P1308, DOI 10.1038/mp.2012.146
   Clark CL, 2013, PSYCHONEUROENDOCRINO, V38, P1208, DOI 10.1016/j.psyneuen.2012.10.017
   Constantino JN, 2000, AM J PSYCHIAT, V157, P2043, DOI 10.1176/appi.ajp.157.12.2043
   Davis LK, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-3
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   Elliot C. D., 2006, DIFFERENTIAL ABILITY
   Emiliano ABF, 2007, NEUROPSYCHOPHARMACOL, V32, P977, DOI 10.1038/sj.npp.1301206
   Feldman R, 2016, BIOL PSYCHIAT, V79, P174, DOI 10.1016/j.biopsych.2015.08.008
   Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513
   Ferguson GD, 2001, MOL NEUROBIOL, V23, P173
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Francis SM, 2014, BRAIN RES, V1580, P199, DOI 10.1016/j.brainres.2014.01.021
   Francis S. M., 2014, OBSESSIVE COMPULSIVE, P261
   Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644
   Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636
   Hammock E, 2012, J AM ACAD CHILD PSY, V51, P712, DOI 10.1016/j.jaac.2012.04.010
   Harrison AJ, 2015, AM J MED GENET B, V168, P720, DOI 10.1002/ajmg.b.32377
   Hovey D, 2014, SOC NEUROSCI-UK, V9, P378, DOI 10.1080/17470919.2014.897995
   Jacob S., 2011, NEUROPSYCHOLOGY AUTI, P451
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Jansen LMC, 2006, J AUTISM DEV DISORD, V36, P891, DOI 10.1007/s10803-006-0124-z
   Jorgensen H, 2003, J NEUROENDOCRINOL, V15, P242, DOI 10.1046/j.1365-2826.2003.00978.x
   Kendrick KM, 1997, BRAIN RES BULL, V44, P383, DOI 10.1016/S0361-9230(97)00218-9
   Kranz TM, 2016, AUTISM RES, V9, P1036, DOI 10.1002/aur.1597
   Kumar AM, 1998, GERONTOLOGY, V44, P211, DOI 10.1159/000022012
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M
   Lakatosova S., 2013, AUTISM, V3, P121, DOI [10.4172/2165-7890.1000121, DOI 10.4172/2165-7890.1000121]
   Lee R, 2003, PSYCHIAT RES, V118, P129, DOI 10.1016/S0165-1781(03)00070-2
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Lerer E, 2010, AUTISM RES, V3, P293, DOI 10.1002/aur.156
   Levin-Decanini T, 2013, AUTISM RES, V6, P621, DOI 10.1002/aur.1322
   LINCOLN AJ, 1988, J AUTISM DEV DISORD, V18, P505, DOI 10.1007/BF02211870
   LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   Love TM, 2012, BIOL PSYCHIAT, V72, P198, DOI 10.1016/j.biopsych.2012.01.033
   MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291
   MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13
   McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mileva-Seitz V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061443
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111
   Mullen EM, 1995, MULLEN SCALES EARLY
   Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004
   Munson J, 2008, AM J MENT RETARD, V113, P439, DOI 10.1352/2008.113:439-452
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Romero-Fernandez W, 2013, MOL PSYCHIATR, V18, P849, DOI 10.1038/mp.2012.103
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   SAWCHENKO PE, 1983, BRAIN RES, V277, P355, DOI 10.1016/0006-8993(83)90945-9
   Souza RP, 2010, SCHIZOPHR RES, V121, P279, DOI 10.1016/j.schres.2010.04.019
   Souza RP, 2010, INT J NEUROPSYCHOPH, V13, P793, DOI 10.1017/S1461145710000167
   Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2
   Tansey KE, 2010, NEUROSCI LETT, V474, P163, DOI 10.1016/j.neulet.2010.03.035
   Taurines Regina, 2014, Atten Defic Hyperact Disord, V6, P231, DOI 10.1007/s12402-014-0145-y
   Teltsh O, 2012, INT J NEUROPSYCHOPH, V15, P309, DOI 10.1017/S1461145711001374
   Wang Z, 1997, Brain Res Dev Brain Res, V104, P191
   Wechsler D., 1999, WECHSLER ABBREVIATED
   Weiss LA, 2009, NATURE, V461, P802, DOI 10.1038/nature08490
   Werling DM, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-13
   Wermter AK, 2010, AM J MED GENET B, V153B, P629, DOI 10.1002/ajmg.b.31032
   Yang CJ, 2015, RES AUTISM SPECT DIS, V18, P12, DOI 10.1016/j.rasd.2015.07.002
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Young LJ, 2001, AM J MED GENET, V105, P53, DOI 10.1002/1096-8628(20010108)105:1<53::AID-AJMG1059>3.0.CO;2-U
   Yrigollen CM, 2008, BIOL PSYCHIAT, V63, P911, DOI 10.1016/j.biopsych.2007.11.015
NR 85
TC 1
Z9 1
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD MAY 12
PY 2016
VL 10
AR 195
DI 10.3389/fnins.2016.00195
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA DL7NY
UT WOS:000375828600001
PM 27242401
ER

PT J
AU Calvo, P
   Fortuny, JR
   Guzman, S
   Macias, C
   Bowen, J
   Garcia, ML
   Orejas, O
   Molins, F
   Tvarijonaviciute, A
   Ceron, JJ
   Bulbena, A
   Fatjo, J
AF Calvo, Paula
   Fortuny, Joan R.
   Guzman, Sergio
   Macias, Cristina
   Bowen, Jonathan
   Garcia, Maria L.
   Orejas, Olivia
   Molins, Ferran
   Tvarijonaviciute, Asta
   Ceron, Jose J.
   Bulbena, Antoni
   Fatjo, Jaume
TI Animal Assisted Therapy (AAT) Program As a Useful Adjunct to
   Conventional Psychosocial Rehabilitation for Patients with
   Schizophrenia: Results of a Small-scale Randomized Controlled Trial
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE animal-assisted therapy; psychosocial rehabilitation; adherence to
   treatment; schizophrenia; PANSS; EuroQol-5 dimensions; salivary
   cortisol; salivary alpha-amylase
ID QUALITY-OF-LIFE; SALIVARY ALPHA-AMYLASE; PSYCHIATRIC-PATIENTS; DOG;
   OXYTOCIN; CORTISOL; BIOMARKERS; INPATIENTS; DISORDERS; SYMPTOMS
AB Currently, one of the main objectives of human-animal interaction research is to demonstrate the benefits of animal assisted therapy (AAT) for specific profiles of patients or participants. The aim of this study is to assess the effect of an MT program as an adjunct to a conventional 6-month psychosocial rehabilitation program for people with schizophrenia. Our hypothesis is that the inclusion of MT into psychosocial rehabilitation would contribute positively to the impact of the overall program on symptomology and quality of life, and that MT would be a positive experience for patients. To test these hypotheses, we compared pre-program with post-program scores for the Positive and Negative Syndrome Scale (PANSS) and the EuroQoL-5 dimensions questionnaire (EuroQol-5D), pre-session with post-session salivary cortisol and alpha-amylase for the last four MT sessions, and adherence rates between different elements of the program. We conducted a randomized, controlled study in a psychiatric care center in Spain. Twenty-two institutionalized patients with chronic schizophrenia completed the 6-month rehabilitation program, which included individual psychotherapy, group therapy, a functional program (intended to improve daily functioning), a community program (intended to facilitate community reintegration) and a family program. Each member of the control group (n = 8) participated in one activity from a range of therapeutic activities that were part of the functional program. In place of this functional program activity, the MT-treatment group (n = 14) participated in twice-weekly 1-h sessions of MT. All participants received the same weekly total number of hours of rehabilitation. At the end of the program, both groups (control and AAT-treatment) showed significant improvements in positive and overall symptomatology, as measured with PANSS, but only the MT-treatment group showed a significant improvement in negative symptomatology. Adherence to the MT-treatment was significantly higher than overall adherence to the control group's functional rehabilitation activities. Cortisol level was significantly reduced after participating in an MT session, which could indicate that interaction with the therapy dogs reduced stress. In conclusion, the results of this small-scale RCT suggest that MT could be considered a useful adjunct to conventional psychosocial rehabilitation for people with schizophrenia.
C1 [Calvo, Paula; Bowen, Jonathan; Bulbena, Antoni; Fatjo, Jaume] Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Chair Affin Fdn Anim & Hlth, Bellaterra, Spain.
   [Calvo, Paula; Bulbena, Antoni; Fatjo, Jaume] Hosp del Mar, Med Res Inst, Barcelona, Spain.
   [Fortuny, Joan R.; Guzman, Sergio; Macias, Cristina; Garcia, Maria L.; Orejas, Olivia; Molins, Ferran; Bulbena, Antoni] Inst Neuropsiquiatria & Addicc, Ctr Assistencials Emili Mira, Parc Salut Mar, Santa Coloma De Gramenet, Spain.
   [Bowen, Jonathan] Univ London Royal Vet Coll, Queen Mother Hosp Small Anim, London NW1 0TU, England.
   [Tvarijonaviciute, Asta; Ceron, Jose J.] Univ Murcia, Interlab UMU, Campus Excelencia Mare Nostrum, Murcia, Spain.
   [Tvarijonaviciute, Asta] Univ Autonoma Barcelona, Dept Med & Anim Surg, Bellaterra, Spain.
RP Calvo, P (reprint author), Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Chair Affin Fdn Anim & Hlth, Bellaterra, Spain.; Calvo, P (reprint author), Hosp del Mar, Med Res Inst, Barcelona, Spain.
EM paula.calvo@uab.cat
FU Affinity Foundation
FX This study was supported by the Affinity Foundation.
CR American Psychiatric Association, 2000, DSM 4 TR DIAGNOSTIC
   Armijo-Olivo S, 2009, PHYS THER REV, V14, P36, DOI DOI 10.1179/174328809X405928
   Barak Y, 2001, AM J GERIAT PSYCHIAT, V9, P439
   Barker SB, 1998, PSYCHIATR SERV, V49, P797
   Beebe Lora Humphrey, 2005, Issues Ment Health Nurs, V26, P661, DOI 10.1080/01612840590959551
   Beetz A, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00352
   Beetz A, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00234
   Berget B, 2008, J PSYCHIATR MENT HLT, V15, P576, DOI 10.1111/j.1365-2850.2008.01268.x
   Bobes J., 2005, EUR PSYCHIAT, V20, P313, DOI 10.1016/S0924-9338(05)80182-8
   Boutron I, 2008, ANN INTERN MED, V148, P295
   Chu CI, 2009, J PSYCHOSOC NURS, V47, P42, DOI 10.3928/02793695-20091103-96
   Dwyer F, 2006, ANTHROZOOS, V19, P243, DOI 10.2752/089279306785415592
   Fine AH, 2010, HANDBOOK ON ANIMAL-ASSISTED THERAPY: THEORETICAL FOUNDATIONS AND GUIDELINES FOR PRACTICE, 3RD EDITION, P1
   Fortunato CK, 2008, DEV PSYCHOBIOL, V50, P807, DOI 10.1002/dev.20326
   Granger DA, 2007, PHYSIOL BEHAV, V92, P583, DOI 10.1016/j.physbeh.2007.05.004
   Granger DA, 2007, DEV PSYCHOBIOL, V49, P692, DOI 10.1002/dev.20247
   Grawe RW, 2001, ACTA PSYCHIAT SCAND, V104, P60, DOI 10.1034/j.1600-0447.2001.104s408060.x
   HAMMER MA, 1995, BIOL PSYCHIAT, V37, P828, DOI 10.1016/0006-3223(95)00040-N
   Hayhurst KP, 2014, BMC PSYCHIATRY, V14, DOI [10.1186/s12888-014-0365-x, 10.1186/s12884-014-0365-x]
   Holt-Lunstad J, 2008, PSYCHOSOM MED, V70, P976, DOI 10.1097/PSY.0b013e318187aef7
   Hsu YY, 2003, J AM VET MED ASSOC, V223, P1293, DOI 10.2460/javma.2003.223.1293
   Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002
   Julius H., 2013, ATTACHMENT PETS INTE
   Kamioka H, 2014, COMPLEMENT THER MED, V22, P371, DOI 10.1016/j.ctim.2013.12.016
   Kaplan H. I., 1989, COMPREHENSIVE TXB PS, V1
   Kaplan H. I., 1989, COMPREHENSIVE TXB PS, V2
   KAY S R, 1989, British Journal of Psychiatry, V155, P59
   Klainin-Yobas P, 2016, BIOL RES NURS, V18, P213, DOI 10.1177/1099800415595877
   Konig HH, 2007, EUR PSYCHIAT, V22, P177, DOI 10.1016/j.eurpsy.2006.08.004
   Kovacs Z, 2004, CLIN REHABIL, V18, P483, DOI 10.1191/0269215504cr765oa
   Kovacs Z, 2006, ANTHROZOOS, V19, P353, DOI 10.2752/089279306785415475
   Lang UE, 2010, EUR J INTEGR MED, V2, P123, DOI 10.1016/j.eujim.2010.07.002
   Liddle PF, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1111/j.0065-1591.2000.007s021[dash]3.x
   Lucidi P, 2005, APPL ANIM BEHAV SCI, V95, P103, DOI 10.1016/j.applanim.2005.04.006
   Margariti M, 2015, PSYCHIAT RES, V225, P695, DOI 10.1016/j.psychres.2014.11.016
   Medici CR, 2016, INT J SOC PSYCHIATR, V62, P12, DOI 10.1177/0020764015585330
   Monteleone AM, 2015, NEUROPSYCHOBIOLOGY, V72, P1, DOI 10.1159/000437437
   Nagasawa M, 2015, SCIENCE, V348, P333, DOI 10.1126/science.1261022
   Nathans-Barel I, 2005, PSYCHOTHER PSYCHOSOM, V74, P31, DOI 10.1159/00082024
   Nepps P, 2014, J EVID BASED COMPLEM, V19, P211, DOI DOI 10.1177/2156587214533570
   Neumann ID, 2000, J NEUROENDOCRINOL, V12, P235
   Nimer J, 2007, ANTHROZOOS, V20, P225, DOI 10.2752/089279307X224773
   Owen WE, 2011, CLIN CHIM ACTA, V412, P480, DOI 10.1016/j.cca.2010.11.023
   Payne LA, 2014, J CHILD ADOLESC BEHA, V2, DOI DOI 10.4172/JCALB.1000129
   Pedersen I., 2011, HLTH NURS, V32, P493, DOI DOI 10.3109/01612840.2011.566982
   PERALTA V, 1994, PSYCHIAT RES, V53, P31, DOI 10.1016/0165-1781(94)90093-0
   Rae J, 2015, J DUAL DIAGN, V11, P42, DOI 10.1080/15504263.2014.992096
   Rohleder N, 2006, PSYCHOPHYSIOLOGY, V43, P645, DOI 10.1111/j.1469-8986.2006.00457.x
   Rossetti J, 2010, J PSYCHOSOC NURS MEN, V48, P44, DOI 10.3928/02793695-20100831-05
   Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18
   Tecles F, 2014, J VET MED EDUC, V41, P37, DOI 10.3138/jvme.0513-073R1
   Uggerby P, 2011, SCHIZOPHR RES, V131, P120, DOI 10.1016/j.schres.2011.03.001
   Velligan DI, 1997, SCHIZOPHR RES, V25, P21, DOI 10.1016/S0920-9964(97)00010-8
   Viau R, 2010, PSYCHONEUROENDOCRINO, V35, P1187, DOI 10.1016/j.psyneuen.2010.02.004
   Villalta-Gil V, 2009, ANTHROZOOS, V22, P149, DOI 10.2752/175303709X434176
   Ochoa S., 2007, PAPELES PSICOLOGO, V28, P49
   Warren KR, 2011, BIOL RES NURS, V13, P383, DOI 10.1177/1099800410393272
   Wilson-d'Almeida K, 2013, EUR PSYCHIAT, V28, P185, DOI 10.1016/j.eurpsy.2011.10.002
   Zasloff RL, 1996, APPL ANIM BEHAV SCI, V47, P43, DOI 10.1016/0168-1591(95)01009-2
   Zik JB, 2015, PSYCHIAT RES, V226, P31, DOI 10.1016/j.psychres.2014.11.048
NR 60
TC 0
Z9 0
U1 26
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD MAY 6
PY 2016
VL 7
AR 631
DI 10.3389/fpsyg.2016.00631
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA DL1GN
UT WOS:000375380700001
PM 27199859
ER

PT J
AU Stoop, R
AF Stoop, Ron
TI Sniffing and Oxytocin: Effects on Olfactory Memories
SO NEURON
LA English
DT Editorial Material
ID VASOPRESSIN; RECOGNITION; AMYGDALA; SYSTEM; BULB
AB In this issue of Neuron, Oettl et al. (2016) show how oxytocin can boost processing of olfactory information in female rats by a top-downregulation from the anterior olfactory nucleus onto the main olfactory bulb. As a result, interactions with juvenile conspecifics receive more attention and are longer memorized.
C1 [Stoop, Ron] Lausanne Univ Hosp Ctr, Ctr Psychiat Neurosci, Dept Psychiat, CH-1008 Prilly, Switzerland.
RP Stoop, R (reprint author), Lausanne Univ Hosp Ctr, Ctr Psychiat Neurosci, Dept Psychiat, CH-1008 Prilly, Switzerland.
EM rstoop@unil.ch
CR Choe HK, 2015, NEURON, V87, P152, DOI 10.1016/j.neuron.2015.06.022
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Fang LY, 2008, NEUROSCI LETT, V438, P133, DOI 10.1016/j.neulet.2007.12.070
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Mitre M, 2016, J NEUROSCI, V36, P2517, DOI 10.1523/JNEUROSCI.2409-15.2016
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   Stoop R, 2015, ANNU REV NEUROSCI, V38, P369, DOI 10.1146/annurev-neuro-071714-033904
   Stoop R, 2014, CURR OPIN NEUROBIOL, V29, P187, DOI 10.1016/j.conb.2014.09.012
   Tobin VA, 2010, NATURE, V464, P413, DOI 10.1038/nature08826
   Wacker DW, 2012, HORM BEHAV, V61, P259, DOI 10.1016/j.yhbeh.2011.08.014
   Zheng JJ, 2014, NAT NEUROSCI, V17, P391, DOI 10.1038/nn.3634
NR 12
TC 0
Z9 0
U1 6
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAY 4
PY 2016
VL 90
IS 3
BP 431
EP 433
DI 10.1016/j.neuron.2016.04.033
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA DM3NZ
UT WOS:000376254500004
PM 27151635
ER

PT J
AU Oettl, LL
   Ravi, N
   Schneider, M
   Scheller, MF
   Schneider, P
   Mitre, M
   Gouveia, MD
   Froemke, RC
   Chao, MV
   Young, WS
   Meyer-Lindenberg, A
   Grinevich, V
   Shusterman, R
   Kelsch, W
AF Oettl, Lars-Lennart
   Ravi, Namasivayam
   Schneider, Miriam
   Scheller, Max F.
   Schneider, Peggy
   Mitre, Mariela
   Gouveia, Miriam da Silva
   Froemke, Robert C.
   Chao, Moses V.
   Young, W. Scott
   Meyer-Lindenberg, Andreas
   Grinevich, Valery
   Shusterman, Roman
   Kelsch, Wolfgang
TI Oxytocin Enhances Social Recognition by Modulating Cortical Control of
   Early Olfactory Processing
SO NEURON
LA English
DT Article
ID BULB GRANULE CELLS; CENTRAL AMYGDALA; RAT-BRAIN; NEUROANATOMICAL
   DISTRIBUTION; ADULT NEUROGENESIS; MATERNAL-BEHAVIOR; MEDIAL AMYGDALA;
   BINDING-SITES; MITRAL CELLS; SYSTEM
AB Oxytocin promotes social interactions and recognition of conspecifics that rely on olfaction in most species. The circuit mechanisms through which oxytocin modifies olfactory processing are incompletely understood. Here, we observed that optogenetically induced oxytocin release enhanced olfactory exploration and same-sex recognition of adult rats. Consistent with oxytocin's function in the anterior olfactory cortex, particularly in social cue processing, region-selective receptor deletion impaired social recognition but left odor discrimination and recognition intact outside a social context. Oxytocin transiently increased the drive of the anterior olfactory cortex projecting to olfactory bulb interneurons. Cortical top-down recruitment of interneurons dynamically enhanced the inhibitory input to olfactory bulb projection neurons and increased the signal-to-noise of their output. In summary, oxytocin generates states for optimized information extraction in an early cortical top-down network that is required for social interactions with potential implications for sensory processing deficits in autism spectrum disorders.
C1 [Oettl, Lars-Lennart; Ravi, Namasivayam; Schneider, Miriam; Scheller, Max F.; Schneider, Peggy; Meyer-Lindenberg, Andreas; Grinevich, Valery; Kelsch, Wolfgang] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, D-68159 Mannheim, Germany.
   [Mitre, Mariela; Froemke, Robert C.; Chao, Moses V.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA.
   [Gouveia, Miriam da Silva; Grinevich, Valery] German Canc Res Ctr, Schaller Res Grp Neuropeptides, D-69120 Heidelberg, Germany.
   [Young, W. Scott] NIMH, Sect Neural Gene Express, NIH, Bethesda, MD 20892 USA.
   [Shusterman, Roman] Univ Haifa, Sagol Dept Neurobiol, IL-3498838 Haifa, Israel.
   [Shusterman, Roman] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
RP Kelsch, W (reprint author), Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, D-68159 Mannheim, Germany.
EM wolfgang.kelsch@zi-mannheim.de
RI Young, W Scott/A-9333-2009; 
OI Young, W Scott/0000-0001-6614-5112; Froemke, Robert/0000-0002-1230-6811
FU DFG [KE1661/1-1, SFB 1134]; DFG Collaborative Research Center [(SFB)
   636]; Schaller Research Foundation; NIMH [ZIA-MH-002498-24]
FX We thank Patrick Jendritza for help with recordings, Drs. Heike Tost and
   Georg Kohr for discussions, Dr. Marina Eliava for histology, Cathrin
   Huber and Christian Gluch for technical assistance, and Dr. Wolfgang
   Weber-Fahr and Felix Hoerner for structural MRI imaging. The project was
   funded by DFG KE1661/1-1 and DFG Collaborative Research Center (SFB) 636
   to W.K. and the Schaller Research Foundation and DFG SFB 1134 to V.G.
   and to W.K. W.S.Y. was supported by the intramural research program of
   the NIMH (ZIA-MH-002498-24).
CR Alonso M, 2012, NAT NEUROSCI, V15, P897, DOI 10.1038/nn.3108
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Angelo K, 2012, NATURE, V488, P375, DOI 10.1038/nature11291
   Asperger H, 1944, ARCH PSYCHIAT NERVEN, V117, P76, DOI 10.1007/BF01837709
   Balu R, 2007, J NEUROSCI, V27, P5621, DOI 10.1523/JNEUROSCI.4630-06.2007
   Balu R, 2007, J NEUROPHYSIOL, V97, P1959, DOI 10.1152/jn.01115.2006
   Barlow HB, 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013
   Beier KT, 2015, CELL, V162, P622, DOI 10.1016/j.cell.2015.07.015
   Boyd AM, 2015, CELL REP, V10, P1032, DOI 10.1016/j.celrep.2015.01.047
   Boyd AM, 2012, NEURON, V76, P1161, DOI 10.1016/j.neuron.2012.10.020
   Ramon y Cajal S., 1911, HISTOLOGIE SYSTEME N, V2
   Cang JH, 2003, J NEUROSCI, V23, P4108
   Carey RM, 2011, J NEUROSCI, V31, P10615, DOI 10.1523/JNEUROSCI.1805-11.2011
   Choe HK, 2015, NEURON, V87, P152, DOI 10.1016/j.neuron.2015.06.022
   Crane L, 2009, AUTISM, V13, P215, DOI 10.1177/1362361309103794
   DANTZER R, 1990, BEHAV BRAIN RES, V40, P53, DOI 10.1016/0166-4328(90)90042-D
   DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192
   DAVIS BJ, 1978, BRAIN RES BULL, V3, P59, DOI 10.1016/0361-9230(78)90062-X
   DEOLMOS J, 1978, J COMP NEUROL, V181, P213, DOI 10.1002/cne.901810202
   De Saint JD, 2009, J NEUROSCI, V29, P2043
   Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007
   Doucette W, 2011, NEURON, V69, P1176, DOI 10.1016/j.neuron.2011.02.024
   ELANDS J, 1988, AM J PHYSIOL, V254, pE31
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   FLEMING A, 1979, SCIENCE, V203, P372, DOI 10.1126/science.760196
   Freeman SM, 2014, NEUROSCIENCE, V273, P12, DOI 10.1016/j.neuroscience.2014.04.055
   Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023
   FREUNDMERCIER MJ, 1987, NEUROSCIENCE, V20, P599, DOI 10.1016/0306-4522(87)90113-8
   HABERLY LB, 1978, J COMP NEUROL, V181, P781, DOI 10.1002/cne.901810407
   Hayar A, 2004, J NEUROSCI, V24, P6676, DOI 10.1523/JNEUROSCI.1367-04.2004
   Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636
   Igarashi KM, 2012, J NEUROSCI, V32, P7970, DOI 10.1523/JNEUROSCI.0154-12.2012
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Kay LM, 1999, NAT NEUROSCI, V2, P1003
   Kelsch W, 2008, P NATL ACAD SCI USA, V105, P16803, DOI 10.1073/pnas.0807970105
   KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766
   KERR DIB, 1955, J NEUROPHYSIOL, V18, P362
   Kim Y, 2015, CELL REP, V10, P292, DOI 10.1016/j.celrep.2014.12.014
   Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030
   Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6
   Laaris N, 2007, J NEUROPHYSIOL, V97, P296, DOI 10.1152/jn.00823.2006
   Lee HJ, 2008, ENDOCRINOLOGY, V149, P3256, DOI 10.1210/en.2007-1710
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Linster C, 2014, CURR OPIN NEUROBIOL, V29, P82, DOI 10.1016/j.conb.2014.05.010
   Lukas M, 2013, BEHAV BRAIN RES, V251, P85, DOI 10.1016/j.bbr.2012.08.011
   Lukas M, 2013, PSYCHONEUROENDOCRINO, V38, P916, DOI 10.1016/j.psyneuen.2012.09.018
   Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95
   LUSKIN MB, 1983, J COMP NEUROL, V216, P264, DOI 10.1002/cne.902160305
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Markopoulos F, 2012, NEURON, V76, P1175, DOI 10.1016/j.neuron.2012.10.028
   Markram K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00224
   Marlin BJ, 2015, NATURE, V520, P499, DOI 10.1038/nature14402
   Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663, DOI 10.1038/nn.3083
   Miczek K.A., 2005, BEHAV LAB RAT HDB TE, P344, DOI DOI 10.1093/ACPROF:OSO/9780195162851.001.0001
   MYKYTOWYCZ R, 1974, J INVEST DERMATOL, V62, P124, DOI 10.1111/1523-1747.ep12676776
   NATYNCZUK SE, 1994, J CHEM ECOL, V20, P1843, DOI 10.1007/BF02066226
   Nissant A, 2009, NAT NEUROSCI, V12, P728, DOI 10.1038/nn.2298
   Numan M, 2003, NEUROBIOLOGY PARENTA
   Olshausen BA, 2004, CURR OPIN NEUROBIOL, V14, P481, DOI 10.1016/j.conb.2004.07.007
   Otazu GH, 2015, NEURON, V86, P1461, DOI 10.1016/j.neuron.2015.05.023
   Otazu GH, 2009, NAT NEUROSCI, V12, P646, DOI 10.1038/nn.2306
   Owen SF, 2013, NATURE, V500, P458, DOI 10.1038/nature12330
   PAGER J, 1972, PHYSIOL BEHAV, V9, P573, DOI 10.1016/0031-9384(72)90014-5
   Popik Piotr, 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P315
   Raggenbass M, 2001, PROG NEUROBIOL, V64, P307, DOI 10.1016/S0301-0082(00)00064-2
   Rinberg D, 2006, J NEUROSCI, V26, P8857, DOI 10.1523/JNEUROSCI.0884-06.2006
   Robertson CE, 2014, BRAIN, V137, P2588, DOI 10.1093/brain/awu189
   Rothermel M, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00073
   Sanchez-Andrade G, 2005, J REPROD DEVELOP, V51, P547, DOI 10.1262/jrd.17031
   Sanchez-Andrade G, 2009, BEHAV BRAIN RES, V200, P323, DOI 10.1016/j.bbr.2008.12.021
   Schoppa NE, 2006, J NEUROSCI, V26, P12996, DOI 10.1523/JNEUROSCI.3503-06.2006
   SHIPLEY MT, 1984, BRAIN RES BULL, V12, P669, DOI 10.1016/0361-9230(84)90148-5
   Shusterman R, 2011, NAT NEUROSCI, V14, P1039, DOI 10.1038/nn.2877
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Soria-Gomez E, 2014, NAT NEUROSCI, V17, P407, DOI 10.1038/nn.3647
   Sosulski DL, 2011, NATURE, V472, P213, DOI 10.1038/nature09868
   Stopka P, 2007, PHYSIOL BEHAV, V91, P667, DOI 10.1016/j.physbeh.2007.03.030
   TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0
   Vaccari C, 1998, ENDOCRINOLOGY, V139, P5015, DOI 10.1210/en.139.12.5015
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   WALLENBERG A., 1928, DEUTSCHE ZEITSCHR NERVENHEILK, V101, P111, DOI 10.1007/BF01652688
   Wesson DW, 2013, CURR BIOL, V23, P575, DOI 10.1016/j.cub.2013.02.012
   Wiesner B. P., 1933, MATERNAL BEHAV RAT
   Willmore B, 2001, NETWORK-COMP NEURAL, V12, P255, DOI 10.1088/0954-898X/12/3/302
   Wolff SBE, 2014, NATURE, V509, P453, DOI 10.1038/nature13258
   Yamaguchi M, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00132
   YOSHIMURA R, 1993, ENDOCRINOLOGY, V133, P1239, DOI 10.1210/en.133.3.1239
   Yu GZ, 1996, NEUROSCIENCE, V72, P1073, DOI 10.1016/0306-4522(95)00599-4
NR 88
TC 3
Z9 3
U1 8
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAY 4
PY 2016
VL 90
IS 3
BP 609
EP 621
DI 10.1016/j.neuron.2016.03.033
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA DM3NZ
UT WOS:000376254500019
PM 27112498
ER

PT J
AU Watanabe, S
   Wei, FY
   Matsunaga, T
   Matsunaga, N
   Kaitsuka, T
   Tomizawa, K
AF Watanabe, Sayaka
   Wei, Fan-Yan
   Matsunaga, Tomomi
   Matsunaga, Nanami
   Kaitsuka, Taku
   Tomizawa, Kazuhito
TI Oxytocin Protects against Stress-Induced Cell Death in Murine Pancreatic
   beta-Cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ISCHEMIA-REPERFUSION; DEFICIENT MICE; MATERNAL RISK; RAT PANCREAS;
   VASOPRESSIN; BINDING; AUTOIMMUNITY; METAANALYSIS; MODULATION; APOPTOSIS
AB Oxytocin (Oxt) is a key neuropeptide that regulates maternal behaviors as well as social behaviors in mammals. Interestingly, recent studies have shown that the impairment of Oxt signaling is associated with the disturbance of metabolic homeostasis, resulting in obesity and diabetes. However, the molecular mechanism by which Oxt signaling controls metabolic responses is largely unknown. Here, we report that Oxt signaling attenuates the death of pancreatic beta cells in islets exposed to cytotoxic stresses. The protective effect of Oxt was diminished in islets isolated from oxytocin receptor knockout (Oxtr(-/-)) mice. Oxtr(-/-) mice developed normally, but exhibited impaired insulin secretion and showed glucose intolerance under a high-fat diet. Mechanistically, the deficiency of Oxtr impaired MAPK/ ERK-CREB signaling, which exaggerated the endoplasmic reticulum stress response and ultimately increased the death of beta cells in pancreatic islets under stressed conditions. These results reveal that Oxt protects pancreatic beta cells against death caused by metabolic stress, and Oxt signaling may be a potential therapeutic target.
C1 [Watanabe, Sayaka; Wei, Fan-Yan; Matsunaga, Tomomi; Matsunaga, Nanami; Kaitsuka, Taku; Tomizawa, Kazuhito] Kumamoto Univ, Fac Life Sci, Dept Mol Physiol, Kumamoto 8608556, Japan.
RP Tomizawa, K (reprint author), Kumamoto Univ, Fac Life Sci, Dept Mol Physiol, Kumamoto 8608556, Japan.
EM tomikt@kumamoto-u.ac.jp
CR Akerlund M, 1999, BRIT J OBSTET GYNAEC, V106, P1047, DOI 10.1111/j.1471-0528.1999.tb08112.x
   Alizadeh AM, 2012, PEPTIDES, V36, P71, DOI 10.1016/j.peptides.2012.03.023
   Altirriba J, 2014, ENDOCRINOLOGY, V155, P4189, DOI 10.1210/en.2014-1466
   AMICO JA, 1988, AM J MED SCI, V296, P303, DOI 10.1097/00000441-198811000-00003
   Antonelli A, 2002, DIABETOLOGIA, V45, P1298, DOI 10.1007/s00125-002-0886-6
   ARGIOLAS A, 1991, NEUROSCI BIOBEHAV R, V15, P217, DOI 10.1016/S0149-7634(05)80002-8
   Aune D, 2014, NUTR METAB CARDIOVAS, V24, P107, DOI 10.1016/j.numecd.2013.10.028
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019
   Blevins J. E., 2015, PHYSIOL BEHAV
   Camerino C, 2009, OBESITY, V17, P980, DOI 10.1038/oby.2009.12
   Chen J, 2006, J IMMUNOL, V176, P4590
   Dale HH, 1906, J PHYSIOL-LONDON, V34, P163
   Darling N.J., 2014, SCI REP-UK, V1843, P2150
   de la Monte SM, 2008, J DIABETES SCI TECHN, V2, P1101, DOI DOI 10.1177/193229680800200619
   DUNNING BE, 1984, PEPTIDES, V5, P871, DOI 10.1016/0196-9781(84)90109-8
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gonzalez-Reyes A, 2015, MOL CELL ENDOCRINOL, V412, P170, DOI 10.1016/j.mce.2015.04.028
   HANIF K, 1982, SCIENCE, V216, P1010, DOI 10.1126/science.7079746
   INSEL TR, 1992, ANN NY ACAD SCI, V652, P122, DOI 10.1111/j.1749-6632.1992.tb34350.x
   Jager S, 2014, DIABETOLOGIA, V57, P1355, DOI 10.1007/s00125-014-3247-3
   Johnson JD, 2006, DIABETES, V55, P2737, DOI 10.2337/db05-1455
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   LOUP F, 1991, BRAIN RES, V555, P220, DOI 10.1016/0006-8993(91)90345-V
   Maejima Y, 2011, AGING-US, V3, P1169
   Matsushita H, 2012, NEUROSCIENCE, V200, P13, DOI 10.1016/j.neuroscience.2011.11.001
   McCarthy MM, 1997, MOL MED TODAY, V3, P269, DOI 10.1016/S1357-4310(97)01058-7
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Plante E, 2015, ENDOCRINOLOGY, V156, P1416, DOI 10.1210/en.2014-1718
   Ristow M, 2003, J CLIN INVEST, V112, P527, DOI 10.1172/JCI200318107
   Sanborn BM, 1998, ADV EXP MED BIOL, V449, P277
   Takayanagi Y, 2008, NEUROREPORT, V19, P951, DOI 10.1097/WNR.0b013e3283021ca9
   Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023
   Tu SC, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-48
   Wang YG, 2009, NATURE, V460, P534, DOI 10.1038/nature08111
   Wei FY, 2011, J CLIN INVEST, V121, P3598, DOI 10.1172/JCI58056
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061477
NR 37
TC 1
Z9 1
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 4
PY 2016
VL 6
AR 25185
DI 10.1038/srep25185
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DL1OX
UT WOS:000375402700001
PM 27143105
ER

PT J
AU Martinetz, S
   Neumann, ID
AF Martinetz, Stefanie
   Neumann, Inga D.
TI The potential of oxytocin as a therapeutic target for psychiatric
   disorders
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Editorial Material
ID SOCIAL BEHAVIORS; RECEPTOR; ANXIETY; TRANSCRIPTION; VASOPRESSIN
C1 [Martinetz, Stefanie; Neumann, Inga D.] Univ Regensburg, Dept Behav & Mol Neurobiol, D-93053 Regensburg, Germany.
RP Neumann, ID (reprint author), Univ Regensburg, Dept Behav & Mol Neurobiol, D-93053 Regensburg, Germany.
EM Inga.Neumann@ur.de
CR Amina S, 2010, J NEUROENDOCRINOL, V22, P460, DOI 10.1111/j.1365-2826.2010.01978.x
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Bowen MT, 2015, P NATL ACAD SCI USA, V112, P3104, DOI 10.1073/pnas.1416900112
   Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310
   Jong Trynke R de, 2015, Psychoneuroendocrinology, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027
   Jurek B, 2015, J NEUROSCI, V35, P12248, DOI 10.1523/JNEUROSCI.1345-14.2015
   Jurek B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037060
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Lane A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137000
   Mesic I, 2015, NEUROPSYCHOPHARMACOL, V40, P2337, DOI 10.1038/npp.2015.81
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111
   Neumann ID, 2016, BIOL PSYCHIAT, V79, P213, DOI 10.1016/j.biopsych.2015.06.004
   Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004
   Peters S, 2014, PSYCHONEUROENDOCRINO, V42, P225, DOI 10.1016/j.psyneuen.2014.01.021
   Riebold M, 2011, MOL MED, V17, P799, DOI 10.2119/molmed.2011.00080
   Sarnyai Z, 2014, PHARMACOL BIOCHEM BE, V119, P3, DOI 10.1016/j.pbb.2013.11.019
   Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190
   van den Burg EH, 2015, NEUROPSYCHOPHARMACOL, V40, P2938, DOI 10.1038/npp.2015.147
   Ziegler C, 2015, NEUROPSYCHOPHARMACOL, V40, P1528, DOI 10.1038/npp.2015.2
NR 20
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD MAY 3
PY 2016
VL 20
IS 5
BP 515
EP 518
DI 10.1517/14728222.2016.1129403
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DI9AG
UT WOS:000373793100001
PM 26641928
ER

PT J
AU Muller, CL
   Anacker, J
   Veenstra-Vanderweele, J
AF Muller, C. L.
   Anacker, J.
   Veenstra-Vanderweele, J.
TI THE SEROTONIN SYSTEM IN AUTISM SPECTRUM DISORDER: FROM BIOMARKER TO
   ANIMAL MODELS
SO NEUROSCIENCE
LA English
DT Review
DE genetic; monoamine; reuptake; platelet; neurodevelopment; multisensory
ID WHOLE-BLOOD SEROTONIN; ACUTE-TRYPTOPHAN-DEPLETION; PLATELET-POOR PLASMA;
   RANDOMIZED CONTROLLED-TRIAL; RECEPTOR KNOCKOUT MICE; BRAIN-SEROTONIN;
   1ST-DEGREE RELATIVES; SOCIAL-BEHAVIOR; SOMATOSENSORY CORTEX;
   MONOAMINE-OXIDASE
AB Elevated whole blood serotonin, or hyperserotonemia, was the first biomarker identified in autism spectrum disorder (ASD) and is present in more than 25% of affected children. The serotonin system is a logical candidate for involvement in ASD due to its pleiotropic role across multiple brain systems both dynamically and across development. Tantalizing clues connect this peripheral biomarker with changes in brain and behavior in ASD, but the contribution of the serotonin system to ASD pathophysiology remains incompletely understood. Studies of whole blood serotonin levels in ASD and in a large founder population indicate greater heritability than for the disorder itself and suggest an association with recurrence risk. Emerging data from both neuroimaging and postmortem samples also indicate changes in the brain serotonin system in ASD. Genetic linkage and association studies of both whole blood serotonin levels and of ASD risk point to the chromosomal region containing the serotonin transporter (SERT) gene in males but not in females. In ASD families with evidence of linkage to this region, multiple rare SERT amino acid variants lead to a convergent increase in serotonin uptake in cell models. A knock-in mouse model of one of these variants, SERT Gly56Ala, recapitulates the hyperserotonemia biomarker and shows increased brain serotonin clearance, increased serotonin receptor sensitivity, and altered social, communication, and repetitive behaviors. Data from other rodent models also suggest an important role for the serotonin system in social behavior, in cognitive flexibility, and in sensory development. Recent work indicates that reciprocal interactions between serotonin and other systems, such as oxytocin, may be particularly important for social behavior. Collectively, these data point to the serotonin system as a prime candidate for treatment development in a subgroup of children defined by a robust, heritable biomarker.
   This article is part of a Special Issue entitled: Neuropsychiatric Disease. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Muller, C. L.] Vanderbilt Univ, Vanderbilt Brain Inst, 465 21st Ave South, Nashville, TN 37232 USA.
   [Anacker, J.] Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
   [Veenstra-Vanderweele, J.] Columbia Univ, Dept Psychiat, Sackler Inst Dev Psychobiol, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
   [Veenstra-Vanderweele, J.] New York Presbyterian Hosp, Ctr Autism & Dev Brain, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
   [Veenstra-Vanderweele, J.] New York State Psychiat Inst & Hosp, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
RP Veenstra-Vanderweele, J (reprint author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.; Veenstra-Vanderweele, J (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr,Mail Unit 78, New York, NY 10032 USA.
EM christopher.l.muller@vanderbilt.edu; aanacke@nyspi.columbia.edu;
   veenstr@nyspi.columbia.edu
RI Veenstra-VanderWeele, Jeremy/K-1935-2015
OI Veenstra-VanderWeele, Jeremy/0000-0002-6349-1076
FU NIH [MH094604]; New York State Psychiatric Institute; Mortimer D.
   Sackler Chair Fund; Columbia University Department of Psychiatry
FX Critical insights into the serotonin system and its relationship with
   autism spectrum disorder were provided by Ed Cook, Randy Blakely, George
   Anderson, Suma Jacob, Ana Carneiro, and Carissa Cascio. Support for this
   work was provided by NIH MH094604, New York State Psychiatric Institute,
   the Mortimer D. Sackler Chair Fund, and the Columbia University
   Department of Psychiatry.
CR Abney M, 2001, AM J HUM GENET, V68, P1302, DOI 10.1086/320112
   ABRAMSON RK, 1989, J AUTISM DEV DISORD, V19, P397, DOI 10.1007/BF02212938
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Amodeo DA, 2014, AUTISM RES, V7, P555, DOI 10.1002/aur.1395
   Anderson GM, 2007, PEDIATR NEUROL, V36, P138, DOI 10.1016/j.pediatrneurol.2006.11.007
   Anderson GM, 2012, J AUTISM DEV DISORD, V42, P1510, DOI 10.1007/s10803-011-1371-1
   ANDERSON GM, 1987, LIFE SCI, V40, P1063, DOI 10.1016/0024-3205(87)90568-6
   Anderson GM, 2002, MOL PSYCHIATR, V7, P831, DOI 10.1038/sj.mp.4001099
   ANDERSON GM, 1984, PSYCHIAT RES, V11, P133, DOI 10.1016/0165-1781(84)90097-0
   ANDERSON GM, 1987, J CHILD PSYCHOL PSYC, V28, P885, DOI 10.1111/j.1469-7610.1987.tb00677.x
   Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678
   Aoki Y, 2015, MOL PSYCHIATR, V20, P447, DOI 10.1038/mp.2014.74
   Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231
   Atladottir HO, 2012, PEDIATRICS, V130, pE1447, DOI 10.1542/peds.2012-1107
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Azmitia EC, 2011, NEUROPHARMACOLOGY, V60, P1347, DOI 10.1016/j.neuropharm.2011.02.002
   Baganz NL, 2013, ACS CHEM NEUROSCI, V4, P48, DOI 10.1021/cn300186b
   Bailey A, 1998, HUM MOL GENET, V7, P571
   Bengel D, 1998, MOL PHARMACOL, V53, P649
   BENNETTCLARKE CA, 1995, BRAIN RES, V702, P255, DOI 10.1016/0006-8993(95)00867-5
   BENNETTCLARKE CA, 1994, J NEUROSCI, V14, P7594
   Blakely RD, 2005, PHYSIOLOGY, V20, P225, DOI 10.1152/physiol.00013.2005
   BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0
   Blakely RD, 2012, COLD SPRING HARBOR P, V4
   Boccuto L, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-16
   Bonnin A, 2006, NEUROSCIENCE, V141, P781, DOI 10.1016/j.neuroscience.2006.04.036
   Bonnin A, 2007, NAT NEUROSCI, V10, P588, DOI 10.1038/nn1896
   Bonnin A, 2011, NATURE, V472, P347, DOI 10.1038/nature09972
   Bortolato M, 2013, INT J NEUROPSYCHOPH, V16, P869, DOI 10.1017/S1461145712000715
   Boulougouris V, 2010, J NEUROSCI, V30, P930, DOI 10.1523/JNEUROSCI.4312-09.2010
   Brown AS, 2012, DEV NEUROBIOL, V72, P1272, DOI 10.1002/dneu.22024
   Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0
   Carneiro AMD, 2009, P NATL ACAD SCI USA, V106, P2047, DOI 10.1073/pnas.0809449106
   Carneiro AMD, 2008, J CLIN INVEST, V118, P1544, DOI 10.1172/JCI33374
   Carter MD, 2011, AUTISM RES, V4, P57, DOI 10.1002/aur.180
   Cases O, 1996, NEURON, V16, P297, DOI 10.1016/S0896-6273(00)80048-3
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290
   Chadman KK, 2011, PHARMACOL BIOCHEM BE, V97, P586, DOI 10.1016/j.pbb.2010.09.012
   Chen X, 2015, CELL REP
   Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9
   Clarke HF, 2004, SCIENCE, V304, P878, DOI 10.1126/science.1094987
   CONRAD LCA, 1974, J COMP NEUROL, V156, P179, DOI 10.1002/cne.901560205
   Cook E H Jr, 1990, J Neuropsychiatry Clin Neurosci, V2, P268
   COOK EH, 1988, J AUTISM DEV DISORD, V18, P553, DOI 10.1007/BF02211873
   COOK EH, 1993, LIFE SCI, V52, P2005, DOI 10.1016/0024-3205(93)90685-V
   COOK EH, 1988, BIOL PSYCHIAT, V24, P488, DOI 10.1016/0006-3223(88)90192-8
   Cools R, 2008, TRENDS COGN SCI, V12, P31, DOI 10.1016/j.tics.2007.10.01
   Cote F, 2007, P NATL ACAD SCI USA, V104, P329, DOI 10.1073/pnas.0606722104
   Courchesne E, 2001, NEUROLOGY, V57, P245
   Coutinho AM, 2004, MOL PSYCHIATR, V9, P264, DOI 10.1038/sj.mp.4001409
   Coutinho AM, 2007, HUM GENET, V121, P243, DOI 10.1007/s00439-006-0301-3
   Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73
   Croonenberghs J, 2000, NEUROPSYCHOPHARMACOL, V22, P275, DOI 10.1016/S0893-133X(99)00131-1
   Cross S, 2008, NEUROPSYCHOPHARMACOL, V33, P353, DOI 10.1038/sj.npp.1301406
   Dahlstroem A., 1964, ACTA PHYSL SCAND S, V232, P231
   Daly E, 2014, BRAIN, V137, P2600, DOI 10.1093/brain/awu178
   Daly EM, 2012, ARCH GEN PSYCHIAT, V69, P1003, DOI 10.1001/archgenpsychiatry.2012.513
   DAMATO RJ, 1987, P NATL ACAD SCI USA, V84, P4322, DOI 10.1073/pnas.84.12.4322
   Dawson N, 2009, J NEUROSCI RES, V87, P2375, DOI 10.1002/jnr.22062
   De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772
   de Theije CGM, 2014, BRAIN BEHAV IMMUN, V37, P197, DOI 10.1016/j.bbi.2013.12.005
   Del'Guidice T, 2014, NEUROPSYCHOPHARMACOL, V39, P1125, DOI 10.1038/npp.2013.313
   DEUFEMIA P, 1995, BIOMED PHARMACOTHER, V49, P288, DOI 10.1016/0753-3322(96)82645-X
   Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC), 2014, MMWR SURVEILL SUMM, V63, P1
   Devlin B, 2005, MOL PSYCHIATR, V10, P1110, DOI 10.1038/sj.mp.4001724
   Dolen G, 2015, SOC NEUROSCI-UK, V10, P450, DOI 10.1080/17470919.2015.1087875
   Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518
   Dougherty JD, 2013, J NEUROSCI, V33, P2732, DOI 10.1523/JNEUROSCI.4762-12.2013
   Dufour-Rainfray D, 2010, NEUROSCI LETT, V470, P55, DOI 10.1016/j.neulet.2009.12.054
   Eaton JL, 2012, DEV PSYCHOBIOL, V54, P92, DOI 10.1002/dev.20566
   Edwards DJ, 2006, J CLIN PHARMACOL, V46, P508, DOI 10.1177/0091270006286903
   Esaki T, 2005, P NATL ACAD SCI USA, V102, P5582, DOI 10.1073/pnas.0501509102
   Farook MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043030
   File SE, 1996, J NEUROSCI, V16, P4810
   FOLK GE, 1988, COMP BIOCHEM PHYS C, V91, P251, DOI 10.1016/0742-8413(88)90193-4
   FUJIMIYA M, 1986, J COMP NEUROL, V246, P191, DOI 10.1002/cne.902460205
   Gabriele S, 2014, EUR NEUROPSYCHOPHARM, V24, P919, DOI 10.1016/j.euroneuro.2014.02.004
   Gauglerl T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039
   Gershon MD, 2013, CURR OPIN ENDOCRINOL, V20, P14, DOI 10.1097/MED.0b013e32835bc703
   Girgis RR, 2011, PSYCHIAT RES-NEUROIM, V194, P230, DOI 10.1016/j.pscychresns.2011.04.007
   Gleason G, 2010, P NATL ACAD SCI USA, V107, P7592, DOI 10.1073/pnas.0914805107
   Goldberg J, 2009, J AUTISM DEV DISORD, V39, P97, DOI 10.1007/s10803-008-0604-4
   GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441
   Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110
   Gorrindo P, 2012, AUTISM RES, V5, P101, DOI 10.1002/aur.237
   Gould GG, 2014, PSYCHONEUROENDOCRINO, V39, P158, DOI 10.1016/j.psyneuen.2013.09.003
   Gould GG, 2011, J NEUROCHEM, V116, P291, DOI 10.1111/j.1471-4159.2010.07104.x
   Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305
   Hammock E, 2012, J AM ACAD CHILD PSY, V51, P712, DOI 10.1016/j.jaac.2012.04.010
   HANLEY HG, 1977, ARCH GEN PSYCHIAT, V34, P521
   HANNA GL, 1991, BIOL PSYCHIAT, V29, P738, DOI 10.1016/0006-3223(91)90193-P
   Hannon J, 2008, BEHAV BRAIN RES, V195, P198, DOI 10.1016/j.bbr.2008.03.020
   HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Harrington RA, 2014, PEDIATRICS, V133, pE1241, DOI 10.1542/peds.2013-3406
   Harrington RA, 2013, AUTISM RES, V6, P149, DOI 10.1002/aur.1288
   Hay-Schmidt A, 2000, P ROY SOC B-BIOL SCI, V267, P1071, DOI 10.1098/rspb.2000.1111
   Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627
   Hollander E, 2012, AM J PSYCHIAT, V169, P292, DOI 10.1176/appi.ajp.2011.10050764
   Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024
   Hunt GE, 2011, BRAIN RES BULL, V86, P65, DOI 10.1016/j.brainresbull.2011.06.011
   Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449
   Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   JACOBS BL, 1992, PHYSIOL REV, V72, P165
   Janusonis S, 2006, J NEUROCHEM, V99, P1019, DOI 10.1111/j.1471-4159.2006.04150.x
   Jitsuki S, 2011, NEURON, V69, P780, DOI 10.1016/j.neuron.2011.01.016
   Kane MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048975
   Kanner L, 1943, NERV CHILD, V2, P217
   Kepser LJ, 2015, BEHAV BRAIN RES, V277, P3, DOI 10.1016/j.bbr.2014.05.022
   Kerr TM, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-35
   Kim H, 2010, NAT MED, V16, P804, DOI 10.1038/nm.2173
   King BH, 2013, JAMA PEDIATR, V167, P1045, DOI 10.1001/jamapediatrics.2013.2698
   King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30
   Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265
   Kistner-Griffin E, 2011, AM J MED GENET B, V156B, P139, DOI 10.1002/ajmg.b.31146
   Kolevzon A, 2010, PSYCHIAT RES, V175, P274, DOI 10.1016/j.psychres.2009.02.008
   Korade Z, 2013, PHARM BIOCH BEHAV
   KUPERMAN S, 1985, J AM ACAD CHILD PSY, V24, P186, DOI 10.1016/S0002-7138(09)60446-5
   Kuteykin-Teplyakov K, 2014, EUR NEUROPSYCHOPHARM, V24, P1773, DOI 10.1016/j.euroneuro.2014.08.007
   Langridge AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050963
   Leboyer M, 1999, BIOL PSYCHIAT, V45, P158, DOI 10.1016/S0006-3223(97)00532-5
   Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9
   LEVENTHAL BL, 1990, J AUTISM DEV DISORD, V20, P499, DOI 10.1007/BF02216055
   Levitt P, 2011, ARCH GEN PSYCHIAT, V68, P1093, DOI 10.1001/archgenpsychiatry.2011.98
   Lidow Michael S., 1992, Cerebral Cortex, V2, P401, DOI 10.1093/cercor/2.5.401
   LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217
   Madden AMK, 2014, PHYSIOL BEHAV, V128, P260, DOI 10.1016/j.physbeh.2014.01.036
   Makkonen I, 2008, DEV MED CHILD NEUROL, V50, P593, DOI 10.1111/j.1469-8749.2008.03027.x
   Margolis KG, 2014, GUT, V63, P928, DOI 10.1136/gutjnl-2013-304901
   Marler S, J AUTISM DE IN PRESS
   Martin MM, 2012, PHYSIOL BEHAV, V105, P529, DOI 10.1016/j.physbeh.2011.09.015
   McBride P. Anne, 1998, Journal of the American Academy of Child and Adolescent Psychiatry, V37, P767, DOI 10.1097/00004583-199807000-00017
   McBride PA, 1989, ARCH GEN PSYCHIAT, V46, P205
   McCauley JL, 2004, AM J MED GENET B, V127B, P104, DOI 10.1002/ajmg.b.20151
   McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171
   McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142
   MCDOUGLE CJ, 1993, BIOL PSYCHIAT, V33, P547, DOI 10.1016/0006-3223(93)90011-2
   McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993
   McNamara IM, 2008, BRAIN RES, V1189, P203, DOI 10.1016/j.brainres.2007.10.063
   Mei H, 2007, AM J HUM GENET, V81, P1251, DOI 10.1086/522307
   MELTZER HY, 1988, PSYCHIAT RES, V24, P263, DOI 10.1016/0165-1781(88)90108-4
   Millan MJ, 2008, TRENDS PHARMACOL SCI, V29, P454, DOI 10.1016/j.tips.2008.06.007
   Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270
   Miller VM, 2013, BRAIN BEHAV IMMUN, V33, P153, DOI 10.1016/j.bbi.2013.07.002
   MINDERAA RB, 1994, BIOL PSYCHIAT, V36, P237, DOI 10.1016/0006-3223(94)90605-X
   Miyazaki K, 2005, INT J DEV NEUROSCI, V23, P287, DOI 10.1016/j.ijdevneu.2004.05.004
   Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3
   Montag C, 2011, BIOL PSYCHIAT, V69, P601, DOI 10.1016/j.biopsych.2010.10.026
   Mosienko V, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0003-6
   Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111
   Moy SS, 2008, GENES BRAIN BEHAV
   Mulder EJ, 2004, J AM ACAD CHILD PSY, V43, P491, DOI 10.1097/01.chi.0000111365.94169.b0
   Mulder EJ, 2010, NEUROPSYCHOBIOLOGY, V61, P27, DOI 10.1159/000258640
   Murphy DL, 2008, NAT REV NEUROSCI, V9, P85, DOI 10.1038/nrn2284
   Murphy DGM, 2006, AM J PSYCHIAT, V163, P934, DOI 10.1176/appi.ajp.163.5.934
   Nakamura K, 2010, ARCH GEN PSYCHIAT, V67, P59, DOI 10.1001/archgenpsychiatry.2009.137
   Nakatani J, 2009, CELL, V137, P1235, DOI 10.1016/j.cell.2009.04.024
   Neumeyer AM, 2013, J AUTISM DEV DISORD, V43, P1623, DOI 10.1007/s10803-012-1709-3
   Nyffeler Johanna, 2014, J Mol Psychiatry, V2, P1, DOI 10.1186/2049-9256-2-1
   Oblak A, 2013, AUTISM RES, V6, P571, DOI 10.1002/aur.1317
   OHEARN E, 1984, BRAIN RES BULL, V13, P709, DOI 10.1016/0361-9230(84)90232-6
   Ohkawara T, 2015, BRAIN DEV-JPN, V37, P88, DOI 10.1016/j.braindev.2014.03.007
   Olivier B, 1995, PHARMACOPSYCHIATRY, V28, P80, DOI 10.1055/s-2007-979624
   Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365
   Pagan C, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.120
   Pagani JH, 2015, GENES BRAIN BEHAV, V14, P167, DOI 10.1111/gbb.12202
   Page DT, 2009, P NATL ACAD SCI USA, V106, P1989, DOI 10.1073/pnas.0804428106
   Panksepp JB, 2007, GENES BRAIN BEHAV, V6, P661, DOI 10.1111/j.1601-183X.2006.00295.x
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   PARTINGTON MW, 1973, DEV MED CHILD NEUROL, V15, P616
   Patrick RP, 2014, FASEB J, V28, P2398, DOI 10.1096/fj.13-246546
   PERRY BD, 1991, BIOL PSYCHIAT, V30, P121, DOI 10.1016/0006-3223(91)90165-I
   Persico AM, 2001, J NEUROSCI, V21, P6862
   Persico AM, 2000, CEREB CORTEX, V10, P181, DOI 10.1093/cercor/10.2.181
   PIVEN J, 1991, J AUTISM DEV DISORD, V21, P51, DOI 10.1007/BF02206997
   Prasad HC, 2009, PHILOS T R SOC B, V364, P163, DOI 10.1098/rstb.2008.0143
   Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040
   Proulx E, 2010, J NEURODEV DISORD, V2, P99, DOI 10.1007/s11689-010-9044-5
   QIAN Y, 1995, J NEUROSCI, V15, P1261
   Rai D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2059
   Raznahan A, 2009, PSYCHIAT GENET, V19, P147, DOI 10.1097/YPG.0b013e32832a505a
   Rebello TJ, 2014, J NEUROSCI, V34, P12379, DOI 10.1523/JNEUROSCI.1020-13.2014
   REISS AL, 1985, J PEDIATR-US, V106, P247, DOI 10.1016/S0022-3476(85)80296-1
   Riccio O, 2009, MOL PSYCHIATR, V14, P280, DOI 10.1038/mp.2008.89
   Robinson EB, 2014, P NATL ACAD SCI USA, V111, P15161, DOI 10.1073/pnas.1409204111
   Sacco R, 2010, AUTISM RES, V3, P237, DOI 10.1002/aur.151
   Sakurai T, 2008, AUTISM RES, V1, P251, DOI 10.1002/aur.30
   Salichon N, 2001, J NEUROSCI, V21, P884
   Sanders SJ, 2015, NEURON, V87, P1215, DOI 10.1016/j.neuron.2015.09.016
   SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214
   SCHAIN RJ, 1961, J PEDIATR-US, V58, P315, DOI 10.1016/S0022-3476(61)80261-8
   Schauder KB, 2015, RES AUTISM SPECT DIS, V10, P93, DOI 10.1016/j.rasd.2014.11.008
   Shoaf SE, 2000, J CEREBR BLOOD F MET, V20, P244
   Simpson KL, 2011, P NATL ACAD SCI USA, V108, P18465, DOI 10.1073/pnas.1109353108
   Skuse DH, 2014, P NATL ACAD SCI USA, V111, P1987, DOI 10.1073/pnas.1302985111
   Smit-Rigter LA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00169
   Spivak B, 2004, NEUROPSYCHOBIOLOGY, V50, P157, DOI 10.1159/000079108
   Stevenson RA, 2014, J NEUROSCI, V34, P691, DOI 10.1523/JNEUROSCI.3615-13.2014
   Stone JL, 2004, AM J HUM GENET, V75, P1117, DOI 10.1086/426034
   Suri D, 2014, NEUROPSYCHOPHARMACOL
   Sutcliffe JS, 2005, AM J HUM GENET, V77, P265, DOI 10.1086/432648
   Thanseem I, 2012, BIOL PSYCHIAT, V71, P410, DOI 10.1016/j.biopsych.2011.09.020
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032
   Tordjman S, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-29
   Tsujino N, 2007, NEUROSCI RES, V57, P289, DOI 10.1016/j.neures.2006.10.018
   van Kleef ESB, 2012, EUR J NEUROSCI, V35, P1563, DOI 10.1111/j.1460-9568.2012.8096.x
   Vaswani M, 2003, PROG NEURO-PSYCHOPH, V27, P85, DOI 10.1016/S0278-5846(02)00338-X
   Veenstra-VanderWeele J, 2012, P NATL ACAD SCI USA, V109, P5469, DOI 10.1073/pnas.1112345109
   Waage-Baudet H, 2003, INT J DEV NEUROSCI, V21, P451, DOI 10.1016/j.ijdevneu.2003.09.002
   Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197
   Wassink TH, 2007, ARCH GEN PSYCHIAT, V64, P709, DOI 10.1001/archpsyc.64.6.709
   Weiss LA, 2005, AM J HUM GENET, V76, P33, DOI 10.1086/426697
   Weiss LA, 2004, EUR J HUM GENET, V12, P949, DOI 10.1038/sj.ejhg.5201239
   Weiss LA, 2004, EUR J HUM GENET ADV
   Weiss LA, 2006, HUM GENET, V120, P93, DOI 10.1007/s00439-006-0196-z
   WELKER C, 1971, BRAIN RES, V26, P259
   Whyte A, 2014, NEUROCHEM INT, V73, P122, DOI 10.1016/j.neuint.2013.09.014
   Wiggins JL, 2014, SOC COGN AFFECT NEUR, V9, P832, DOI 10.1093/scan/nst039
   Wiggins Jillian Lee, 2012, Neuroimage Clin, V2, P17, DOI 10.1016/j.nicl.2012.10.008
   Winter C, 2008, EUR NEUROPSYCHOPHARM, V18, P712, DOI 10.1016/j.euroneuro.2008.06.001
   Worbe Y, 2015, MOL PSYCHIAT
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Ye R, 2014, GENES BRAIN BEHAV, V13, P247, DOI 10.1111/gbb.12092
   Yonan AL, 2003, AM J HUM GENET, V73, P886, DOI 10.1086/378778
   Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009
   Young EJ, 2008, GENES BRAIN BEHAV, V7, P224, DOI 10.1111/j.1601-183X.2007.00343.x
   Zerbo O, 2013, J AUTISM DEV DISORD
   Zerbo O, 2013, J AUTISM DEV DISORD, V43, P25, DOI 10.1007/s10803-012-1540-x
   Zhang WQ, 2015, NEUROPHARMACOLOGY, V90, P1, DOI 10.1016/j.neuropharm.2014.10.024
   Zheng JJ, 2014, NAT NEUROSCI, V17, P391, DOI 10.1038/nn.3634
NR 232
TC 4
Z9 4
U1 18
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAY 3
PY 2016
VL 321
BP 24
EP 41
DI 10.1016/j.neuroscience.2015.11.010
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA DG8QF
UT WOS:000372348000004
PM 26577932
ER

PT J
AU Riem, MME
   Bakermans-Kranenburg, MJ
   van IJzendoorn, MH
AF Riem, Madelon M. E.
   Bakermans-Kranenburg, Marian J.
   van IJzendoorn, Marinus H.
TI Intranasal administration of oxytocin modulates behavioral and amygdala
   responses to infant crying in females with insecure attachment
   representations
SO ATTACHMENT & HUMAN DEVELOPMENT
LA English
DT Article
DE amygdala; adult attachment; infant crying; fMRI; Oxytocin; AAI
ID RANDOMIZED-CONTROLLED-TRIAL; ADULT ATTACHMENT; MATERNAL SENSITIVITY;
   DEPRESSIVE SYMPTOMS; PHYSICAL ABUSE; HANDGRIP FORCE; BRAIN IMAGES;
   MOTHERS; DISTRESS; HUMANS
AB The current study examined the effects of oxytocin administration on the response to infant crying in individuals with secure or insecure attachment representations as assessed with the Adult Attachment Interview. We measured feelings of irritation and the use of excessive force as indicated by grip strength using a handgrip dynamometer during exposure to infant crying in 42 women without children who were administered intranasal oxytocin or a placebo. In addition, amygdala responses to infant crying and control sounds were measured with functional magnetic resonance imaging (fMRI). The effects of oxytocin on reactivity to crying were moderated by attachment security. Oxytocin decreased the use of excessive handgrip force and amygdala reactivity in response to crying in individuals with insecure attachment representations. Our findings indicate that insecure individuals, who show emotional, behavioral, and neural hyperreactivity to crying, benefit the most from intranasal oxytocin.
C1 [Riem, Madelon M. E.; Bakermans-Kranenburg, Marian J.; van IJzendoorn, Marinus H.] Leiden Univ, Ctr Child & Family Studies, POB 9555, NL-2300 RB Leiden, Netherlands.
   [Riem, Madelon M. E.; Bakermans-Kranenburg, Marian J.; van IJzendoorn, Marinus H.] Leiden Univ, LIBC, Leiden, Netherlands.
RP Bakermans-Kranenburg, MJ; van IJzendoorn, MH (reprint author), Leiden Univ, Ctr Child & Family Studies, POB 9555, NL-2300 RB Leiden, Netherlands.
EM bakermans@fsw.leidenuniv.nl; vanijzen@fsw.leidenuniv.nl
FU Netherlands Organization for scientific Research (NWO); Dutch Ministry
   of Education, Culture, and Science; Netherlands Organization for
   Scientific Research NWO [024.001.003]; European Research Council [ERC
   AdG 669249]
FX MJBK and MHvIJ were supported by awards from the Netherlands
   Organization for scientific Research (NWO) (MJBK: VICI Grant; MHvIJ:
   SPINOZA prize) and by the Gravitation program of the Dutch Ministry of
   Education, Culture, and Science and the Netherlands Organization for
   Scientific Research NWO [grant number 024.001.003]. MJBK was also
   supported by the European Research Council [grant number ERC AdG
   669249].
CR Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34
   Bakermans-Kranenburg MJ, 2012, SOC COGN AFFECT NEUR, V7, P951, DOI 10.1093/scan/nsr067
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   Buchheim A, 2009, PSYCHONEUROENDOCRINO, V34, P1417, DOI 10.1016/j.psyneuen.2009.04.002
   Bugental DB, 1999, DEV PSYCHOL, V35, P1367, DOI 10.1037//0012-1649.35.6.1367
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   CASANOVA GM, 1994, CHILD ABUSE NEGLECT, V18, P995, DOI 10.1016/0145-2134(94)90124-4
   Clark-Elford R., 2014, INT J NEUROPSYCHOPH, V18
   Compier-de Block LHCG, 2015, CHILD ABUSE NEGLECT, V40, P124, DOI 10.1016/j.chiabu.2014.03.006
   Crittenden P. M., 2004, PATTERNS ATTAC UNPUB
   Crouch JL, 2008, CHILD ABUSE NEGLECT, V32, P702, DOI 10.1016/j.chiabu.2007.11.002
   David SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070104
   De Dreu CKW, 2012, PSYCHONEUROENDOCRINO, V37, P871, DOI 10.1016/j.psyneuen.2011.10.003
   De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047
   Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006
   Dessureau BK, 1998, INFANT BEHAV DEV, V21, P367, DOI 10.1016/S0163-6383(98)90013-3
   Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025
   Dykas MJ, 2011, PSYCHOL BULL, V137, P19, DOI 10.1037/a0021367
   EGELAND B, 1988, CHILD DEV, V59, P1080, DOI 10.2307/1130274
   Fan Y, 2015, NEUROPSYCHOPHARMACOL, V40, P2736, DOI 10.1038/npp.2015.123
   Feldman R, 2007, PSYCHOL SCI, V18, P965, DOI 10.1111/j.1467-9280.2007.02010.x
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Galbally M, 2011, HARVARD REV PSYCHIAT, V19, P1, DOI 10.3109/10673229.2011.549771
   George C, 1985, ADULT ATTACHME UNPUB
   Grimm S, 2014, SOC COGN AFFECT NEUR, V9, P1828, DOI 10.1093/scan/nsu020
   Groh AM, 2009, DEV PSYCHOL, V45, P889, DOI 10.1037/a0014943
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Hesse E, 2008, HDB ATTACHMENT THEOR, P552
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Ioannidis JPA, 2014, TRENDS COGN SCI, V18, P235, DOI 10.1016/j.tics.2014.02.010
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Leerkes EM, 2006, ATTACH HUM DEV, V8, P11, DOI 10.1080/14616730600594450
   Leerkes EM, 2011, J FAM PSYCHOL, V25, P635, DOI 10.1037/a0023654
   Leerkes EM, 2010, PARENT-SCI PRACT, V10, P219, DOI 10.1080/15295190903290840
   Leon K, 2004, INF MENTAL HLTH J, V25, P130, DOI 10.1002/imhj.10091
   Luminet O, 2011, BIOL PSYCHOL, V87, P401, DOI 10.1016/j.biopsycho.2011.05.005
   Ma YN, 2015, NEUROPSYCHOPHARMACOL, V40, P2379, DOI 10.1038/npp.2015.87
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Mah BL, 2015, DEPRESS ANXIETY, V32, P76, DOI 10.1002/da.22245
   Goldwyn R., 1984, ADULT ATTACHME UNPUB
   Main M, 1985, MONOGRAPHS SOC RES C, V50, P66
   Meinlschmidt G, 2007, BIOL PSYCHIAT, V61, P1109, DOI 10.1016/j.biopsych.2006.09.007
   Mikolajczak M, 2010, PSYCHOL SCI, V21, P1072, DOI 10.1177/0956797610377343
   Naber F., 2012, J AUTISM DEV DISORD, V43, P1
   Naber F, 2010, PSYCHONEUROENDOCRINO, V35, P1583, DOI 10.1016/j.psyneuen.2010.04.007
   Out D, 2010, GENES BRAIN BEHAV, V9, P868, DOI 10.1111/j.1601-183X.2010.00624.x
   Out D, 2010, CHILD ABUSE NEGLECT, V34, P863, DOI 10.1016/j.chiabu.2010.05.003
   Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008
   Pierrehumbert B, 2012, ATTACH HUM DEV, V14, P453, DOI 10.1080/14616734.2012.706394
   Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2
   Riem MME, 2014, DEVELOPMENTAL SCI, V17, P248, DOI 10.1111/desc.12103
   Riem MME, 2013, EUR NEUROPSYCHOPHARM, V23, P1288, DOI 10.1016/j.euroneuro.2013.01.011
   Riem MME, 2013, PSYCHONEUROENDOCRINO, V38, P1418, DOI 10.1016/j.psyneuen.2012.12.023
   Riem MME, 2012, ATTACH HUM DEV, V14, P533, DOI 10.1080/14616734.2012.727252
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Riem MME, 2011, SOC COGN AFFECT NEUR, V6, P294, DOI 10.1093/scan/nsq035
   Rilling JK, 2013, NEUROPSYCHOLOGIA, V51, P731, DOI 10.1016/j.neuropsychologia.2012.12.017
   Roisman GI, 2007, J PERS SOC PSYCHOL, V92, P678, DOI 10.1037/0022-3514.92.4.678
   Roisman GI, 2014, MONOGR SOC RES CHILD, V79, P85, DOI 10.1111/mono.12115
   Schoenmaker C, 2015, ATTACH HUM DEV, V17, P241, DOI 10.1080/14616734.2015.1037315
   Schuetze P, 2003, INFANCY, V4, P65, DOI 10.1207/S15327078IN0401_4
   Schuetze P, 2001, INFANCY, V2, P483, DOI 10.1207/S15327078IN0204_06
   Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062
   Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051
   Soltis J, 2004, BEHAV BRAIN SCI, V27, P443
   Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103
   Straus MA, 1998, CHILD ABUSE NEGLECT, V22, P249, DOI 10.1016/S0145-2134(97)00174-9
   Swain JE, 2014, BRAIN RES, V1580, P78, DOI 10.1016/j.brainres.2014.03.007
   van IJzendoorn MH, 2014, MONOGR SOC RES CHILD, V79, P157, DOI 10.1111/mono.12120
   Waters E, 2000, CHILD DEV, V71, P678, DOI 10.1111/1467-8624.00175
   Weinfield NS, 2000, CHILD DEV, V71, P695, DOI 10.1111/1467-8624.00178
   Weisman O, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0828
   Worsley K. J., 2001, FUNCTIONAL MRI INTRO, P251, DOI DOI 10.1093/ACPROF:OSO/9780192630711.003.0014
   Zeifman DM, 2001, DEV PSYCHOBIOL, V39, P265, DOI 10.1002/dev.1005
NR 79
TC 0
Z9 0
U1 10
U2 17
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1461-6734
EI 1469-2988
J9 ATTACH HUM DEV
JI Attach. Hum. Dev.
PD MAY 3
PY 2016
VL 18
IS 3
BP 213
EP 234
DI 10.1080/14616734.2016.1149872
PG 22
WC Psychology, Developmental
SC Psychology
GA DG6LY
UT WOS:000372197400001
PM 26982874
ER

PT J
AU Rezaei, SS
   Muin, D
   Wolzt, M
   Luger, A
   Bayerle-Eder, M
AF Rezaei, Sheikh S.
   Muin, D.
   Wolzt, M.
   Luger, A.
   Bayerle-Eder, M.
TI OXYTOCIN TREATMENT OF THE FEMALE PARTNER IMPROVES SEXUAL FUNCTION AND
   DEPRESSION IN UNTREATED MEN
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Meeting Abstract
C1 [Rezaei, Sheikh S.; Muin, D.; Wolzt, M.; Luger, A.; Bayerle-Eder, M.] Med Univ Vienna, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD MAY
PY 2016
VL 13
IS 5
SU 2
MA PS-02-012
BP S87
EP S87
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DX9TU
UT WOS:000384739200029
ER

PT J
AU Alanko, K
   Gunst, A
   Mokros, A
   Santtila, P
AF Alanko, Katarina
   Gunst, Annika
   Mokros, Andreas
   Santtila, Pekka
TI Genetic Variants Associated With Male Pedophilic Sexual Interest
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Genetic Variant; Polymorphism; Twin; Pedophilic Sexual Interest;
   Pedophilia; Hormones
ID TESTOSTERONE; PARAPHILIA; DESIGN
AB Introduction: The etiology of sexual preference disorders (paraphilias) in general and pedophilia in particular remains unknown. There are some indications of biological factors related to pedophilic interest and pedophilic disorder.
   Aim: To examine single-nucleotide polymorphisms (SNPs) potentially associated with pedophilic sexual interest.
   Methods: The sample consisted of 1,672 men 18 to 45 years old from the Genetics of Sex and Aggression sample who had submitted saliva samples. Fifty-four SNPs were genotyped and relevant SNPs were analyzed.
   Main Outcome Measures: A self-report questionnaire designed specifically for the Genetics of Sex and Aggression sample was used to measure sexual interest in and sexual behavior toward children and adolescents. DNA extraction and genotyping were used to measure possible associations between male pedophilia and SNPs.
   Results: Before controlling for multiple testing, statistically significant associations were found for SNPs linked to androgen, estrogen, prolactin, corticotrophin, serotonin, and oxytocin. No associations remained significant after controlling for multiple testing.
   Conclusion: The results of the present study suggest a complex biological mechanism affecting adult sexual interest in children. Very small effect sizes characterized the findings, and several polymorphisms related to different hormonal functioning were initially related to the phenotype. Copyright (C) 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Alanko, Katarina; Santtila, Pekka] Abo Akad Univ, Fac Arts Psychol & Theol, Fabriksgatan 2, SF-20500 Turku, Finland.
   [Gunst, Annika] Univ Turku, Dept Behav Sci & Philosophy, Tirku, Finland.
   [Mokros, Andreas] Psychiat Univ Hosp Zurich, Ctr Forens Psychiat, Zurich, Switzerland.
RP Alanko, K (reprint author), Abo Akad Univ, Fac Arts Psychol & Theol, Fabriksgatan 2, SF-20500 Turku, Finland.
EM katarina.alanko@abo.fi
FU German Federal Ministry of Family Affairs, Senior Citizens, Women, and
   Youth
FX This work is part of the MiKADO project funded by the German Federal
   Ministry of Family Affairs, Senior Citizens, Women, and Youth.
CR Alanko K, 2013, J SEX MED, V10, P1090, DOI 10.1111/jsm.12067
   Bogaert AF, 2001, NEUROPSYCHOLOGIA, V39, P465, DOI 10.1016/S0028-3932(00)00134-2
   [Anonymous], 2006, Z SEXUALFORSCH, DOI DOI 10.1055/S-2006-955198
   FLORHENRY P, 1991, INT J PSYCHOPHYSIOL, V10, P253, DOI 10.1016/0167-8760(91)90036-W
   Johansson A, 2013, TWIN RES HUM GENET, V16, P150, DOI 10.1017/thg.2012.108
   Jordan K, 2011, J SEX MED, V8, P2993, DOI 10.1111/j.1743-6109.2011.02394.x
   Jordan K, 2011, J SEX MED, V8, P3008, DOI 10.1111/j.1743-6109.2011.02393.x
   Jorgensen TJ, 2009, AM J EPIDEMIOL, V170, P986, DOI 10.1093/aje/kwp242
   Kingston DA, 2012, J AM ACAD PSYCHIATRY, V40, P476
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
NR 10
TC 0
Z9 0
U1 7
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD MAY
PY 2016
VL 13
IS 5
BP 835
EP 842
DI 10.1016/j.jsxm.2016.02.170
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA DX9PP
UT WOS:000384727900009
PM 27114195
ER

PT J
AU Mitchell, JM
   Arcuni, PA
   Weinstein, D
   Woolley, JD
AF Mitchell, Jennifer M.
   Arcuni, Peter A.
   Weinstein, Dawn
   Woolley, Josh D.
TI Intranasal Oxytocin Selectively Modulates Social Perception, Craving,
   and Approach Behavior in Subjects With Alcohol Use Disorder
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE alcohol abuse; alcohol use disorder; craving; oxytocin; social
   perception
ID ADULT ATTACHMENT; HEALTHY CONTROLS; FOOD-INTAKE; EYES TEST; HUMANS;
   ADDICTION; STRESS; MIND; DEPENDENCE; RECEPTOR
AB Objectives: A pharmacotherapy that both improves social abilities and promotes abstinence may be particularly helpful for the treatment of alcohol use disorder. Recent clinical and preclinical evidence suggests that oxytocin has prosocial and antiaddiction effects. We performed a pilot, laboratory-based, preclinical trial of oxytocin in subjects with alcohol abuse (as per Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria) to evaluate therapeutic potential and assess tolerability.
   Methods: Social perceptual ability, cue-induced craving, and approach bias for alcohol and appetitive imagery were quantified after intranasal oxytocin and placebo administration to 32 nontreatment-seeking individuals with alcohol abuse in a double-blind, crossover study. Because attachment style can moderate the effects of oxytocin, we also explored whether attachment style moderated oxytocin's effects on our behavioral measures.
   Results: Oxytocin significantly improved recognition of easier items on a social perception task, but had no significant group-level effect on cue-induced craving. However, oxytocin effects on craving were moderated by attachment anxiety, with oxytocin reducing craving in more anxiously attached individuals and increasing craving in less anxiously attached individuals. Subjects did not display an approach bias to alcohol images on the placebo day, preventing meaningful analysis of this measure. Subjects did display an approach bias to appetitive images on the placebo day, which was significantly reduced by oxytocin administration. No adverse reactions were observed.
   Conclusions: Intranasal oxytocin has potential to improve social perception, reduce cue-induced alcohol cravings, and reduce appetitive approach bias in subjects with alcohol abuse, and can be safely tolerated in this population. The effects of oxytocin are complex, however, and require further investigation.
C1 [Mitchell, Jennifer M.; Weinstein, Dawn] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
   [Mitchell, Jennifer M.; Arcuni, Peter A.; Woolley, Josh D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
RP Mitchell, JM (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
EM jennifer.mitchell@ucsf.edu
FU UCSF Wheeler Center for the Neurobiology of Addiction; California State
   Funds for research on drug and alcohol abuse; United States Department
   of Veterans Affairs, Office of Research and Development, Clinical
   Science Research and Development program under Career Development Award
   [CX000758]
FX This work was supported by a grant from the UCSF Wheeler Center for the
   Neurobiology of Addiction and by California State Funds for research on
   drug and alcohol abuse. In addition, Dr. Woolley's work is supported by
   the United States Department of Veterans Affairs, Office of Research and
   Development, Clinical Science Research and Development program under
   Career Development Award (award #CX000758) and the use of facilities at
   the San Francisco Veterans Affairs Medical Center.
CR ADAN RAH, 1995, ENDOCRINOLOGY, V136, P4022, DOI 10.1210/en.136.9.4022
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107
   BOHN MJ, 1995, ALCOHOL CLIN EXP RES, V19, P600, DOI 10.1111/j.1530-0277.1995.tb01554.x
   Bora E, 2009, SCHIZOPHR RES, V109, P1, DOI 10.1016/j.schres.2008.12.020
   Bowen MT, 2015, P NATL ACAD SCI USA, V112, P3104, DOI 10.1073/pnas.1416900112
   Buckner JD, 2008, J PSYCHIATR RES, V42, P230, DOI 10.1016/j.jpsychires.2007.01.002
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   De Dreu CKW, 2012, PSYCHONEUROENDOCRINO, V37, P871, DOI 10.1016/j.psyneuen.2011.10.003
   DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607
   Fang Angela, 2014, Clin Psychol Sci, V2, P740
   Feifel D, 1999, PSYCHOPHARMACOLOGY, V141, P93, DOI 10.1007/s002130050811
   Fraley RC, 2011, PSYCHOL ASSESSMENT, V23, P615, DOI 10.1037/a0022898
   Fraley RC, 2000, J PERS SOC PSYCHOL, V78, P350, DOI 10.1037/0022-3514.78.2.350
   Guastella AJ, 2012, HORM BEHAV, V61, P773, DOI [10.1016/j.yhbeh.2012.01.002, 10.1016/j.yhbeh.2012.04.008]
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   IBRAGIMOV R, 1987, LIFE SCI, V41, P1265, DOI 10.1016/0024-3205(87)90205-0
   JENNINGS JR, 1992, PSYCHOPHYSIOLOGY, V29, P742
   Knight DK, 1996, J SUBST ABUSE, V8, P417, DOI 10.1016/S0899-3289(96)90003-6
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945
   Lee MR, 2014, EUR NEUROPSYCHOPHARM, V24, P1483, DOI 10.1016/j.euroneuro.2014.06.005
   MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015
   Mann K, 2004, CNS DRUGS, V18, P485, DOI 10.2165/00023210-200418080-00002
   Maurage P, 2011, PSYCHIAT RES, V190, P375, DOI 10.1016/j.psychres.2011.06.015
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   McNally AM, 2003, ADDICT BEHAV, V28, P1115, DOI 10.1016/S0306-4603(02)00224-1
   McRae-Clark AL, 2013, PSYCHOPHARMACOLOGY, V228, P623, DOI 10.1007/s00213-013-3062-4
   Mitchell JM, 2007, NEUROPSYCHOPHARMACOL, V32, P439, DOI 10.1038/sj.npp.1301226
   MONTI PM, 1987, J ABNORM PSYCHOL, V96, P122, DOI 10.1037/0021-843X.96.2.122
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Mueller SE, 2009, INT J ENV RES PUB HE, V6, P3010, DOI 10.3390/ijerph6123010
   Norman GJ, 2011, J PSYCHOPHARMACOL, V25, P1313, DOI 10.1177/0269881110367452
   Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663
   Pan YL, 2009, NEUROSCI LETT, V454, P67, DOI 10.1016/j.neulet.2009.02.064
   Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Savaskan E, 2008, PSYCHONEUROENDOCRINO, V33, P368, DOI 10.1016/j.psyneuen.2007.12.004
   Sinha R, 2009, NEUROPSYCHOPHARMACOL, V34, P1198, DOI 10.1038/npp.2008.78
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Stein DJ, 2007, CNS SPECTRUMS, V12, P675
   Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Wiers RW, 2009, GENES BRAIN BEHAV, V8, P101, DOI 10.1111/j.1601-183X.2008.00454.x
   Wiers RW, 2010, ADDICTION, V105, P279, DOI 10.1111/j.1360-0443.2009.02775.x
NR 51
TC 1
Z9 1
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD MAY-JUN
PY 2016
VL 10
IS 3
BP 182
EP 189
DI 10.1097/ADM.0000000000000213
PG 8
WC Substance Abuse
SC Substance Abuse
GA DS5RG
UT WOS:000380839400009
PM 27159342
ER

PT J
AU Lara-Cinisomo, S
   Girdler, SS
   Grewen, K
   Meltzer-Brody, S
AF Lara-Cinisomo, Sandraluz
   Girdler, Susan S.
   Grewen, Karen
   Meltzer-Brody, Samantha
TI A Biopsychosocial Conceptual Framework of Postpartum Depression Risk in
   Immigrant and US-born Latina Mothers in the United States
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID INTIMATE PARTNER VIOLENCE; CORTICOTROPIN-RELEASING HORMONE;
   PITUITARY-ADRENAL AXIS; MEXICAN-AMERICAN WOMEN; ACCULTURATIVE STRESS;
   SOCIAL SUPPORT; MONITORING-SYSTEM; PREGNANT LATINAS; SYMPTOMS;
   PREVALENCE
AB Objective: In this review, we offer a conceptual framework that identifies risk factors of postpartum depression (PPD) in immigrant and U.S.-born Latinas in the United States by focusing on psychosocial and neuroendocrine factors. Although the evidence of the impact psychosocial stressors have on the development of PPD has been well-documented, less is known about the biological etiology of PPD or how these complex stressors jointly increase the risk of PPD in immigrant and U. S.-born Latinas in the United States.
   Methods: Using PubMed, CINAHL, and Embase, we reviewed the literature from 2000 to 2015 regarding psychosocial and physiological risk factors associated with PPD to develop a conceptual model for Latinas.
   Results: Our search yielded 16 relevant studies. Based on our review of the literature, we developed a biopsychosocial conceptual model of PPD for Latinas in the United States. We make arguments for an integrated model designed to assess psychosocial and physiological risk factors and PPD in a high-risk population. Our framework describes the hypothesized associations between culturally and contextually relevant psychosocial stressors, neurobiological factors (e.g., hypothalamic-pituitary-adrenal [HPA] axis response systemand oxytocin signaling), and PPD in Latinas in the United States.
   Conclusions: Future studies should evaluate prospectively the impact psychosocial stressors identified here have on the development of PPD in both immigrant and U. S-born Latinas while examining neuroendocrine function, such as the HPA axis and oxytocin signaling. Our conceptual framework will allow for the reporting of main and indirect effects of psychosocial risk factors and biomarkers (e.g., HPA axis and oxytocin function) on PPD in foreign- and U. S.-born postpartum Latinas. (C) 2016 Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Lara-Cinisomo, Sandraluz; Girdler, Susan S.; Grewen, Karen; Meltzer-Brody, Samantha] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA.
   [Lara-Cinisomo, Sandraluz] Univ Illinois, Dept Kinesiol & Community Hlth, Coll Appl Hlth Sci, 1204 South Fourth St, Champaign, IL 61820 USA.
RP Lara-Cinisomo, S (reprint author), Univ Illinois, Dept Kinesiol & Community Hlth, Coll Appl Hlth Sci, 1204 South Fourth St, Champaign, IL 61820 USA.
EM laracini@illinois.edu
FU National Institute of Health [MH093315]; Foundation of Hope; North
   Carolina Translational and Clinical Sciences (NC TraCS) Institute
FX The authors acknowledge the National Institute of Health (MH093315 -
   "Postdoctoral Training in Reproductive Mood Disorders"; Drs. Girdler &
   Rubinow, PIs), the Foundation of Hope, and the North Carolina
   Translational and Clinical Sciences (NC TraCS) Institute for their
   support of Sandraluz Lara-Cinisomo's research.
CR Ahluwalia IB, 2012, J HUM LACT, V28, P167, DOI 10.1177/0890334412438403
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5
   Androff DK, 2012, SOC WORK, V57, P165, DOI 10.1093/sw/sws034
   Beck Cheryl Tatano, 2005, MCN Am J Matern Child Nurs, V30, P299
   Bloch M, 2005, J CLIN ENDOCR METAB, V90, P695, DOI 10.1210/jc.2004-1388
   Blume J, 2011, BRAIN BEHAV IMMUN, V25, P221, DOI 10.1016/j.bbi.2010.10.008
   Campos B, 2008, CULT DIVERS ETHN MIN, V14, P155, DOI 10.1037/1099-9809.14.2.155
   Centers for Disease Control and Prevention, 2011, RAT ANY EXCL BREASTF
   Christian LM, 2014, AM J OBSTET GYNECOL, V211, P275, DOI 10.1016/j.ajog.2014.06.042
   Cox EQ, 2015, PSYCHONEUROENDOCRINO, V55, P164, DOI 10.1016/j.psyneuen.2015.02.009
   D'Anna-Hernandez KL, 2015, J AFFECT DISORDERS, V176, P35, DOI 10.1016/j.jad.2015.01.036
   D'Anna-Hernandez KL, 2011, PHYSIOL BEHAV, V104, P348, DOI 10.1016/j.physbeh.2011.02.041
   Davila M, 2009, MATERN CHILD HLTH J, V13, P318, DOI 10.1007/s10995-008-0385-6
   Dawson BA, 2010, HISPANIC J BEHAV SCI, V32, P216, DOI 10.1177/0739986310364750
   Diaz MA, 2007, CULT DIVERS ETHN MIN, V13, P328, DOI 10.1037/1099-9809.13.4.328
   Donaldson-Myles F., 2012, BRIT J MIDWIFERY, V20, P88
   Garabedian MJ, 2011, J WOMENS HEALTH, V20, P447, DOI 10.1089/jwh.2010.1960
   Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db
   Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592
   Hromi-Fiedler A, 2011, MATERN CHILD NUTR, V7, P421, DOI 10.1111/j.1740-8709.2010.00266.x
   Jackson CL, 2015, J INTERPERS VIOLENCE, V30, P659, DOI 10.1177/0886260514535262
   Jolley SN, 2007, BIOL RES NURS, V8, P210, DOI 10.1177/1099800406294598
   Juruena MF, 2014, EPILEPSY BEHAV, V38, P148, DOI 10.1016/j.yebeh.2013.10.020
   Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002
   Kim S, 2014, BRAIN RES, V1580, P219, DOI 10.1016/j.brainres.2013.11.009
   Lara-Cinisomo S, 2015, J IMMIGR MINOR HEALT, V17, P1593, DOI 10.1007/s10903-015-0205-1
   Lara-Cinisomo S., 2013, PERINATAL DEPRESSION
   Lee DL, 2012, COUNS PSYCHOL, V40, P28, DOI 10.1177/0011000011403326
   Liu CH, 2013, MATERN CHILD HLTH J, V17, P1599, DOI 10.1007/s10995-012-1171-z
   Livingston G, 2012, US BIRTH RATE FALLS
   Lopez M. H., 2013, DIVERSE ORIGINS NATI
   Lucero NB, 2012, J AM ACAD NURSE PRAC, V24, P726, DOI 10.1111/j.1745-7599.2012.00744.x
   Magiakou MA, 1996, J CLIN ENDOCR METAB, V81, P1912, DOI 10.1210/jc.81.5.1912
   National Child Traumatic Stress Network (NCTSN), 2005, CULT TRAUM BRIEF
   National Poverty Center (NPC), 2009, COL POV WHY RAC ETHN
   Nylen KJ, 2013, J BEHAV MED, V36, P427, DOI 10.1007/s10865-012-9436-y
   Revollo HW, 2011, INT REV PSYCHIATR, V23, P84, DOI 10.3109/09540261.2010.545988
   Rodriguez M. A., 2009, J GEN INTERNAL MED, V24, pS505
   Rodriguez MA, 2008, ANN FAM MED, V6, P44, DOI 10.1370/afm.743
   Segre LS, 2007, SOC PSYCH PSYCH EPID, V42, P316, DOI 10.1007/s00127-007-0168-1
   Stapleton LRT, 2012, J FAM PSYCHOL, V26, P453, DOI 10.1037/a0028332
   Stuebe AM, 2013, J WOMENS HEALTH, V22, P352, DOI 10.1089/jwh.2012.3768
   Sumner LA, 2011, MATERN CHILD HLTH J, V15, P1046, DOI 10.1007/s10995-010-0649-9
   Surkan PJ, 2006, MATERN CHILD HLTH J, V10, P375, DOI 10.1007/s10995-005-0056-9
   Tomfohr L. M., 2013, THESIS
   Torres L, 2012, CULT DIVERS ETHN MIN, V18, P17, DOI 10.1037/a0026710
   Torres L, 2010, CULT DIVERS ETHN MIN, V16, P256, DOI 10.1037/a0017357
   Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4
   Valentine JM, 2011, ARCH WOMEN MENT HLTH, V14, P135, DOI 10.1007/s00737-010-0191-1
   Zeiders KH, 2015, DEV PSYCHOPATHOL, V27, P293, DOI 10.1017/S0954579414000637
NR 50
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAY-JUN
PY 2016
VL 26
IS 3
BP 336
EP 343
DI 10.1016/j.whi.2016.02.006
PG 8
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA DR2MV
UT WOS:000379739500013
PM 27052823
ER

PT J
AU Bulut, EC
   Abueid, L
   Ercan, F
   Suleymanoglu, S
   Agirbasli, M
   Yegen, BC
AF Bulut, Erman Caner
   Abueid, Leyla
   Ercan, Feriha
   Suleymanoglu, Selami
   Agirbasli, Mehmet
   Yegen, Berrak C.
TI Treatment with oestrogen-receptor agonists or oxytocin in conjunction
   with exercise protects against myocardial infarction in ovariectomized
   rats
SO EXPERIMENTAL PHYSIOLOGY
LA English
DT Article
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; ISCHEMIA-REPERFUSION INJURY;
   RANDOMIZED CONTROLLED-TRIAL; HEALTHY POSTMENOPAUSAL WOMEN;
   CORONARY-HEART-DISEASE; NITRIC-OXIDE; FEMALE RATS; NATRIURETIC-PEPTIDE;
   DEPENDENT MECHANISM; GENDER-DIFFERENCES
AB To investigate the putative protective effects of oxytocin or oestrogen receptor agonists against myocardial injury of ovariectomized sedentary or exercised rats, female Sprague-Dawley rats assigned to sham-operated control and ovariectomized (OVX) groups were kept sedentary or undertook swimming exercise for 4 weeks and were treated with saline, an oestrogen receptor (ER) beta (DPN) or ER alpha agonist (PPT) or oxytocin. Ovariectomy increased weight gain and anxiety in sedentary rats, whereas exercise prevented weight gain. When accompanied by exercise, both ER agonists and oxytocin inhibited weight gain and anxiety; oxytocin, in the absence or presence of exercise, increased the left ventricular diastolic dimensions and ejection fraction, whereas ER agonists also increased left ventricular diameter when given to exercised rats. Upon the induction of myocardial ischaemia-reperfusion in the OVX rats, plasma creatine kinase-(muscle-brain) was depressed by PPT and oxytocin, whereas DPN, PPT and OT reduced plasminogen activator inhibitor-1 concentrations. The increased tumour necrosis factor-alpha concentration in OVX rats was also suppressed by exercise or DPN, PPT or oxytocin treatments, whereas the interleukin-6 concentration was diminished by all the treatments when given in conjunction with exercise. Disorganization of cardiac muscle fibres was reduced in all exercised rats. Oestrogen receptor agonists, as well as oxytocin, in conjunction with exercise may be effective new therapeutics to protect against myocardial ischaemia in postmenopausal women.
C1 [Bulut, Erman Caner; Abueid, Leyla; Yegen, Berrak C.] Marmara Univ, Sch Med, Dept Physiol, Saglik Kampusu Basibuyuk Mah Maltepe, TR-34854 Istanbul, Turkey.
   [Ercan, Feriha] Marmara Univ, Sch Med, Dept Histol & Embryol, TR-34854 Istanbul, Turkey.
   [Suleymanoglu, Selami] Gulhane Mil Med Acad, Dept Pediat Cardiol, Istanbul, Turkey.
   [Agirbasli, Mehmet] Marmara Univ, Sch Med, Dept Cardiol, TR-34854 Istanbul, Turkey.
RP Yegen, BC (reprint author), Marmara Univ, Sch Med, Dept Physiol, Saglik Kampusu Basibuyuk Mah Maltepe, TR-34854 Istanbul, Turkey.
EM byegen@marmara.edu.tr
FU Scientific Research Project Commission of Marmara University (BAPKO)
   [SAG-C-YLP-130612-0207]
FX This work was supported by the Scientific Research Project Commission of
   Marmara University (BAPKO) project no.: SAG-C-YLP-130612-0207.
CR Al-Amran F Fadhil, 2014, Heart Views, V15, P37, DOI 10.4103/1995-705X.137493
   Al-Nakkash L, 2009, GENDER MED, V6, P488, DOI 10.1016/j.genm.2009.09.004
   Alizadeh AM, 2012, PEPTIDES, V36, P71, DOI 10.1016/j.peptides.2012.03.023
   Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701
   Aydin S, 2014, PEPTIDES, V58, P91, DOI 10.1016/j.peptides.2014.06.001
   Bagla AG, 2013, ACTA HISTOCHEM, V115, P658, DOI 10.1016/j.acthis.2013.01.005
   BARBASH GI, 1990, BRIT HEART J, V64, P241
   Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349
   Booth EA, 2005, AM J PHYSIOL-HEART C, V289, pH2039, DOI 10.1152/ajpheart.00479.2005
   Braga DC, 2000, AM J PHYSIOL-REG I, V278, pR1474
   Brown DA, 2007, J APPL PHYSIOL, V103, P1894, DOI 10.1152/japplphysiol.00464.2007
   Brown NJ, 2002, CIRCULATION, V105, P304, DOI 10.1161/hc0302.102570
   Cakir B, 2010, CELL BIOCHEM FUNCT, V28, P469, DOI 10.1002/cbf.1679
   Calvert JW, 2013, PHYSIOLOGY, V28, P216, DOI 10.1152/physiol.00011.2013
   Cetinel S, 2010, REGUL PEPTIDES, V160, P146, DOI 10.1016/j.regpep.2009.11.011
   de Lemos JA, 2001, J AM COLL CARDIOL, V38, P1283, DOI 10.1016/S0735-1097(01)01550-9
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Dimmeler S, 2003, CIRCULATION, V107, P3118, DOI 10.1161/01.CIR.0000074244.82874.A0
   Dorge H, 2002, J MOL CELL CARDIOL, V34, P51, DOI 10.1006/jmcc.2001.1489
   Everson-Rose SA, 2005, ANNU REV PUBL HEALTH, V26, P469, DOI 10.1146/annurev.publhealth.26.021304.144542
   Faghihi M, 2012, PEPTIDES, V37, P314, DOI 10.1016/j.peptides.2012.08.001
   Flues K, 2010, MATURITAS, V65, P267, DOI 10.1016/j.maturitas.2009.11.007
   Frasier CR, 2011, J APPL PHYSIOL, V111, P905, DOI 10.1152/japplphysiol.00004.2011
   Gabel Scott A, 2005, J Mol Cell Cardiol, V38, P289, DOI 10.1016/j.yjmcc.2004.11.013
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Gutkowska J, 2014, BRAZ J MED BIOL RES, V47, P206, DOI 10.1590/1414-431X20133309
   Gutkowska J, 1997, P NATL ACAD SCI USA, V94, P11704, DOI 10.1073/pnas.94.21.11704
   Gutkowska J, 2007, AM J PHYSIOL-REG I, V293, pR267, DOI 10.1152/ajpregu.00071.2007
   Hale SL, 1996, AM HEART J, V132, P258, DOI 10.1016/S0002-8703(96)90419-6
   Hou NQ, 2013, JNCI-J NATL CANCER I, V105, P1365, DOI 10.1093/jnci/djt207
   Hutchens MP, 2012, AM J PHYSIOL-RENAL, V303, pF377, DOI 10.1152/ajprenal.00354.2011
   Jankowski M, 2010, BASIC RES CARDIOL, V105, P205, DOI 10.1007/s00395-009-0076-5
   Kobayashi H, 2009, J CARDIOVASC PHARM, V54, P510, DOI 10.1097/FJC.0b013e3181bfac02
   Kudwa AE, 2014, PHYSIOL BEHAV, V129, P287, DOI 10.1016/j.physbeh.2014.03.004
   Kumral ZNO, 2014, INFLAMMATION, V37, P694, DOI 10.1007/s10753-013-9786-9
   Lavie CJ, 2009, MAYO CLIN PROC, V84, P373, DOI [10.1016/S0025-6196(11)60548-X, 10.4065/84.4.373]
   Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218
   Marco EM, 2005, BEHAV BRAIN RES, V163, P212, DOI 10.1016/j.bbr.2005.05.005
   Marini M, 2008, HISTOCHEM CELL BIOL, V129, P479, DOI 10.1007/s00418-007-0373-8
   Marini M, 2007, EUR J APPL PHYSIOL, V99, P503, DOI 10.1007/s00421-006-0369-4
   Martins AS, 2005, HYPERTENSION, V46, P1004, DOI 10.1161/01.HYP.0000175812.03322.59
   McNulty PH, 2000, AM J PHYSIOL-HEART C, V278, pH1030
   Meyer MR, 2006, HYPERTENSION, V47, P1019, DOI 10.1161/01.HYP.0000223064.62762.0b
   Mukaddam-Daher S, 2001, HYPERTENSION, V38, P292
   Node K, 1997, CIRCULATION, V96, P1953
   Novotny JL, 2009, ENDOCRINOLOGY, V150, P889, DOI 10.1210/en.2008-0708
   Orshal JM, 2004, AM J PHYSIOL-REG I, V286, pR233, DOI 10.1152/ajpregu.00338.2003
   Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499
   Pedram A, 2010, MOL ENDOCRINOL, V24, P2152, DOI 10.1210/me.2010-0154
   Pelzer T, 2005, CIRCULATION, V111, P1492, DOI 10.1161/01.CIR.0000159262.18512.46
   Rossouw Jacques E, 2002, JAMA, V288, P321
   Rozanski A, 2005, J AM COLL CARDIOL, V45, P637, DOI 10.1016/j.jac.2004.12.005
   SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N
   Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358
   Shephard RJ, 1999, CIRCULATION, V99, P963
   Shimizu T, 2016, J ATHEROSCLER THROMB, V23, P557, DOI 10.5551/jat.32300
   Sidaway Peter, 2015, Nat Rev Clin Oncol, V12, P251, DOI 10.1038/nrclinonc.2015.44
   Soares C N, 2001, Sao Paulo Med J, V119, P78
   Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m
   STEWART DE, 1992, INT J PSYCHIAT MED, V22, P213
   Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800
   Takuma K, 2007, NEUROSCIENCE, V146, P60, DOI 10.1016/j.neuroscience.2007.01.017
   Tomicek NJ, 2013, CARDIOVASC THER, V31, P32, DOI 10.1111/j.1755-5922.2011.00288.x
   Traupe T, 2007, HYPERTENSION, V49, P1364, DOI 10.1161/HYPERTENSIONAHA.106.081554
   Tugtepe H, 2007, REGUL PEPTIDES, V140, P101, DOI 10.1016/j.regpep.2006.11.026
   Gutierrez CV, 2012, J CLIN NURS, V21, P923, DOI 10.1111/j.1365-2702.2011.03972.x
   Vornehm ND, 2009, SURGERY, V146, P145, DOI 10.1016/j.surg.2009.04.026
   Walf AA, 2009, GENDER MED, V6, P300, DOI 10.1016/j.genm.2009.04.004
   Wang Y, 2010, CIRC J, V74, P634, DOI 10.1253/circj.CJ-09-0223
   Wenger NK, 2002, CARDIOVASC RES, V53, P558, DOI 10.1016/S0008-6363(01)00511-9
   Xavier D, 2016, LANCET DIABETES ENDO, V4, P244, DOI 10.1016/S2213-8587(15)00480-5
   Xiang GS, 2005, J AM COLL CARDIOL, V46, P536, DOI 10.1016/j.jcc.2005.04.047
   Zhai PY, 2000, AM J PHYSIOL-HEART C, V278, pH1640
   Zhai PY, 2000, AM J PHYSIOL-HEART C, V279, pH2766
   Zheng XP, 2011, INT J CARDIOL, V151, P290, DOI 10.1016/j.ijcard.2010.05.059
NR 75
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-0670
EI 1469-445X
J9 EXP PHYSIOL
JI Exp. Physiol.
PD MAY 1
PY 2016
VL 101
IS 5
BP 612
EP 627
DI 10.1113/EP085708
PG 16
WC Physiology
SC Physiology
GA DP6XS
UT WOS:000378643700006
PM 26958805
ER

PT J
AU Ambwani, S
   Berenson, KR
   Simms, L
   Li, A
   Corfield, F
   Treasure, J
AF Ambwani, Suman
   Berenson, Kathy R.
   Simms, Lea
   Li, Amanda
   Corfield, Freya
   Treasure, Janet
TI Seeing Things Differently: An Experimental Investigation of Social
   Cognition and Interpersonal Behavior in Anorexia Nervosa
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE social cognition; interpersonal circumplex; eating disorders; anorexia
   nervosa; experimental research
ID EATING-DISORDERS; SELF-EFFICACY; PERCEPTION; MODEL; PERSONALITY;
   ATTACHMENT; OXYTOCIN; MIND; HETEROGENEITY; INDIVIDUALS
AB Objective: Interpersonal difficulties among individuals with anorexia nervosa (AN) may stem in part due to misperceiving social cues. The current study investigated social functioning by comparing interpersonal self-efficacy, perceptions of dominance/submission (i.e., agency) and coldness/warmth (i.e., communion), and hypothetical behavioral reactions among individuals with and without AN.
   Method: Seventy-seven women (AN/Other Specified Feeding or Eating Disorder OSFED-AN n=41, nonclinical comparison group n=36 completed questionnaires assessing mood symptoms and interpersonal self-efficacy, followed by an experimental video-rating task in which they received critical feedback from job supervisors varying in degrees of agency and communion.
   Results: AN respondents perceived more coldness overall, even after adjusting for differences in depression and anxiety symptoms, and tended to respond with coldness even to videos that they perceived as being warm. However, perceptual accuracies for agency were similar across groups. Interpersonal self-efficacy moderated the relationship between diagnostic status and behavioral responses: among those who felt competent being cold-submissive, AN respondents selected cold-submissive responses more frequently than did the nonclinical comparison group.
   Discussion: Among those with AN symptoms, there may be a tendency toward social perceptual inaccuracies regarding communion and non-complementary cold behavioral responses. Results suggest that improving social perceptions may be a fruitful intervention target for enhancing interpersonal functioning among individuals with AN. (C) 2015 Wiley Periodicals, Inc.
C1 [Ambwani, Suman; Simms, Lea] Dickinson Coll, Dept Psychol, POB 1773, Carlisle, PA 17013 USA.
   [Berenson, Kathy R.] Gettysburg Coll, Dept Psychol, Gettysburg, PA 17325 USA.
   [Li, Amanda; Corfield, Freya; Treasure, Janet] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
RP Ambwani, S (reprint author), Dickinson Coll, Dept Psychol, POB 1773, Carlisle, PA 17013 USA.
EM ambwanis@dickinson.edu
FU Research and Development Committee at Dickinson College; Psychiatry
   Research Trust Fellowships; National Institute for Health Research
   (NIHR); Mental Health Biomedical Research at South London and Maudsley
   NHS Foundation Trust; King's College London
FX Supported by a Scholarly/Creative Grant from the Research and
   Development Committee at Dickinson College (to S.A.), Psychiatry
   Research Trust Fellowships to (F.C. and A.L.), The project was also
   supported by the National Institute for Health Research (NIHR), Mental
   Health Biomedical Research at South London and Maudsley NHS Foundation
   Trust, and King's College London (through salary support to J.T.).
CR Adenzato M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044414
   Adolphs Ralph, 2009, HDB NEUROSCIENCE BEH, V2, P923
   Aiken Leona S., 1991, MULTIPLE REGRESSION
   Ambwani S, 2015, INT J EAT DISORDER, V48, P715, DOI 10.1002/eat.22410
   Arcelus J, 2013, CLIN PSYCHOL REV, V33, P156, DOI 10.1016/j.cpr.2012.10.009
   Bartz JA, 2015, PSYCHOL SCI, V26, P1177, DOI 10.1177/0956797615580279
   Beadle JN, 2013, ANN CLIN PSYCHIATRY, V25, P107
   Broberg AG, 2001, EUR EAT DISORD REV, V9, P381, DOI 10.1002/erv.421
   Caglar-Nazali P, 2014, NEUROSCI BIOBEHAV R, V44, P55
   Cain AS, 2008, INT J EAT DISORDER, V41, P713, DOI 10.1002/eat.20563
   Calderoni S, 2013, NEUROPSYCH DIS TREAT, V9, P1583, DOI 10.2147/NDT.S50214
   Cardi V, 2015, PLOS ONE, V18, P1
   Cardi V, 2015, SELF HELP AID RECOVE, V16, P165
   Cardi V, 2014, INT J EAT DISORDER, V47, P543, DOI 10.1002/eat.22261
   Courty A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-222
   Curran PJ, 2011, ANNU REV PSYCHOL, V62, P583, DOI 10.1146/annurev.psych.093008.100356
   Dapelo MM, 2015, PSYCHIAT RES, V230, P70, DOI 10.1016/j.psychres.2015.08.019
   de Sampaio FTP, 2013, PSYCHIAT RES, V210, P1116, DOI 10.1016/j.psychres.2013.08.051
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Dykas MJ, 2011, PSYCHOL BULL, V137, P19, DOI 10.1037/a0021367
   Erickson TM, 2015, J PERS, V83, P429, DOI 10.1111/jopy.12117
   Erickson TM, 2009, J PERS SOC PSYCHOL, V97, P893, DOI 10.1037/a0016515
   Forand NR, 2010, PSYCHOL WOMEN QUART, V34, P380
   Goddard E, 2013, COGNITIVE THER RES, V37, P890, DOI 10.1007/s10608-013-9535-2
   Goddard E, 2013, BMC PSYCHIATRY, V13, P1
   Hartmann A, 2010, INT J EAT DISORDER, V43, P619, DOI 10.1002/eat.20747
   Horowitz LM, 2006, PERS SOC PSYCHOL REV, V10, P67, DOI 10.1207/s15327957pspr1001_4
   Huke V, 2013, EUR EAT DISORD REV, V21, P345, DOI 10.1002/erv.2244
   Joos AAB, 2009, INT J EAT DISORDER, V42, P318, DOI 10.1002/eat.20621
   Leary T., 1957, INTERPERSONAL DIAGNO
   Lindsay WR, 2009, J INTELL DISABIL RES, V53, P529, DOI 10.1111/j.1365-2788.2009.01171.x
   Locke KD, 2007, PERS SOC PSYCHOL B, V33, P94, DOI 10.1177/0146167206293375
   Moskowitz DS, 2005, PSYCHOL ASSESSMENT, V17, P218, DOI 10.1037/1040-3590.17.2.218
   Pereira T, 2006, INT J EAT DISORDER, V39, P677, DOI 10.1002/eat.20303
   Renwick B, 2013, EUR PSYCHIAT, V28, P436, DOI 10.1016/j.eurpsy.2013.03.004
   Rieger E, 2010, CLIN PSYCHOL REV, V30, P400, DOI 10.1016/j.cpr.2010.02.001
   Russell TA, 2009, PSYCHIAT RES, V168, P181, DOI 10.1016/j.psychres.2008.10.028
   Schmidt U, 2006, BRIT J CLIN PSYCHOL, V45, P343, DOI 10.1348/014466505X53902
   Spitzer MB, 1996, STRUCTURED CLIN INTE
   Steiger H, 1999, J CONSULT CLIN PSYCH, V67, P765, DOI 10.1037/0022-006X.67.5.765
   Tasca GA, 2014, INT J EAT DISORDER, V47, P710, DOI 10.1002/eat.22302
   Tchanturia K, 2013, INT J EAT DISORDER, V46, P492, DOI 10.1002/eat.22106
   Thomas KM, 2014, PSYCHOL ASSESSMENT, V26, P23, DOI 10.1037/a0034318
   Treasure J, 2013, J EAT DISORD, V1, P1, DOI DOI 10.1186/2050-2974-1-13
   Treasure J, 2012, EUR EAT DISORD REV, V20, P431, DOI 10.1002/erv.2181
   Troop NA, 2016, EUR EAT DISORD REV, V24, P75, DOI 10.1002/erv.2386
   Veening JG, 2013, NEUROSCI BIOBEHAV R, V37, P1445, DOI 10.1016/j.neubiorev.2013.04.012
   Wright AGC, 2013, J PERS DISORD, V27, P125, DOI 10.1521/pedi.2013.27.2.125
NR 48
TC 2
Z9 2
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
EI 1098-108X
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD MAY
PY 2016
VL 49
IS 5
BP 499
EP 506
DI 10.1002/eat.22498
PG 8
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA DP6ZJ
UT WOS:000378648400007
PM 26712303
ER

PT J
AU Erdman, SE
AF Erdman, Susan E.
TI Microbes and healthful longevity
SO AGING-US
LA English
DT Editorial Material
DE aging; cancer; cachexia; FoxN1; oxytocin; lifespan
ID REGENERATION
C1 [Erdman, Susan E.] MIT, Div Comparat Med, Cambridge, MA 02139 USA.
RP Erdman, SE (reprint author), MIT, Div Comparat Med, Cambridge, MA 02139 USA.
EM serdman@mit.edu
CR Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Bredenkamp N, 2014, DEVELOPMENT, V141, P1627, DOI 10.1242/dev.103614
   Elabd C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5082
   Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551
   Poutahidis T, 2013, PLOS ONE, V8, P78898
   Varian BJ, 2016, ONCOTARGET, V7, P11803, DOI 10.18632/oncotarget.7730
NR 7
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY
PY 2016
VL 8
IS 5
BP 839
EP 840
PG 2
WC Cell Biology
SC Cell Biology
GA DO5CL
UT WOS:000377801100004
PM 27223638
ER

PT J
AU Beijers, R
   Cillessen, L
   Zijlmans, MAC
AF Beijers, Roseriet
   Cillessen, Linda
   Zijlmans, Maartje A. C.
TI An experimental study on mother-infant skin-to-skin contact in
   full-terms
SO INFANT BEHAVIOR & DEVELOPMENT
LA English
DT Article
DE Skin-to-skin contact (SSC); Infancy; Stress; Cortisol; Quality of
   maternal behavior; Sensitivity
ID KANGAROO CARE; CORTISOL; RESPONSES; STRESS; BEHAVIOR; BIRTH; LIFE;
   OXYTOCIN; SALIVA; SLEEP
AB In premature infants, daily skin-to-skin contact (SSC) has various beneficial effects on the health of the infant and the mother. These beneficial effects might extend to full-term infants. This experimental within-subject study examines the immediate effects of SSC on full-terms' cortisol physiology during SSC and subsequent physiological and behavioral reactions to a mild stressor (a bathing session). Additionally, the effects of SSC on the quality of maternal behavior are examined.
   Between 5 and 7 weeks postpartum, 17 full-term infant-mother dyads were visited at home twice. During one home visit, a bathing session was proceeded by 50 min of mother-infant SSC, while during the other visit the bathing session was proceeded by 50min of the infant resting alone. The order of the home visits was counterbalanced. Infant salivary cortisol measures were taken to measure the cortisol response to the experimental condition (SSC versus solitary resting) and the bathing session. Furthermore, infant behavioral distress and the quality of maternal behavior during the bathing session were scored from videotapes.
   Two-way within-subject repeated measures ANOVA's showed that, when compared to solitary resting, full-terms' cortisol concentrations significantly decreased during SSC, followed by higher cortisol reactivity in response to the subsequent bathing session. No effects of SSC on infant behavioral distress and maternal caregiving behavior were found. Apparently, a single session of mother-infant SSC can affect infant cortisol physiology in full-term infants. Future SSC research is needed to investigate the neurobiological mechanisms and dose-response relations in full-term infants. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Beijers, Roseriet; Cillessen, Linda; Zijlmans, Maartje A. C.] Radboud Univ Nijmegen, Inst Behav Sci, Dept Dev Psychol, NL-6525 ED Nijmegen, Netherlands.
RP Beijers, R (reprint author), Radboud Univ Nijmegen, Inst Behav Sci, Dev Psychol, POB 9140, NL-6500 HE Nijmegen, Netherlands.
EM r.beijers@psych.ru.nl
FU Behavioural Science Institute, Radboud University
FX This research was supported by the Behavioural Science Institute,
   Radboud University.
CR Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT
   Albers EM, 2008, J CHILD PSYCHOL PSYC, V49, P97, DOI 10.1111/j.1469-7610.2007.01818.x
   Beijers R, 2013, STRESS, V16, P267, DOI 10.3109/10253890.2012.742057
   Beijers R, 2011, J DEV BEHAV PEDIATR, V32, P635, DOI 10.1097/DBP.0b013e318228888d
   Bigelow A, 2012, JOGNN-J OBST GYN NEO, V41, P369, DOI 10.1111/j.1552-6909.2012.01350.x
   Cong XM, 2015, EARLY HUM DEV, V91, P401, DOI 10.1016/j.earlhumdev.2015.04.012
   de Weerth C, 2007, PSYCHONEUROENDOCRINO, V32, P1144, DOI 10.1016/j.psyneuen.2007.07.005
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355
   Feldman R, 2003, J FAM PSYCHOL, V17, P94, DOI 10.1037/0893-3200.17.1.94
   Feldman R, 2002, PEDIATRICS, V110, P16, DOI 10.1542/peds.110.1.16
   Feldman R, 2014, BIOL PSYCHIAT, V75, P56, DOI 10.1016/j.biopsych.2013.08.012
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Feldman R, 2010, PSYCHONEUROENDOCRINO, V35, P1133, DOI 10.1016/j.psyneuen.2010.01.013
   Ferber SG, 2004, PEDIATRICS, V113, P858, DOI 10.1542/peds.113.4.858
   Girden E. R., 1992, ANOVA REPEATED MEASU
   Gitau R, 2002, J REPROD INFANT PSYC, V20, P83, DOI 10.1080/02646830220134595
   Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005
   Gray L, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.1.e14
   Herman J. P., 2013, FRONTIERS BEHAV NEUR, P7
   Jansen J, 2010, STRESS, V13, P491, DOI 10.3109/10253890.2010.483298
   Jansen J, 2010, PSYCHONEUROENDOCRINO, V35, P329, DOI 10.1016/j.psyneuen.2009.07.008
   Kashaninia Z, 2008, J SPEC PEDIATR NURS, V13, P275, DOI 10.1111/j.1744-6155.2008.00165.x
   KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P23
   Kostandy RR, 2008, PAIN MANAG NURS, V9, P55, DOI 10.1016/j.pmn.2007.11.004
   Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639
   Moore ER, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub3
   Moore E. R., 2007, COCHRANE DATABASE SY, P3
   Morelius E, 2015, EARLY HUM DEV, V91, P63, DOI 10.1016/j.earlhumdev.2014.12.005
   Morgan BE, 2011, BIOL PSYCHIAT, V70, P817, DOI 10.1016/j.biopsych.2011.06.018
   Roller CG, 2005, JOGNN-J OBST GYN NEO, V34, P210, DOI 10.1177/084217504273675
   Snijders T., 2012, MULTILEVEL ANAL INTR
   STERN E, 1969, PEDIATRICS, V43, P65
   Takahashi Y, 2011, EARLY HUM DEV, V87, P151, DOI 10.1016/j.earlhumdev.2010.11.012
   Tukey J. W., 1977, EXPLORATORY DATA ANA
   WILDER J, 1957, J NERV MENT DIS, V125, P73, DOI 10.1097/00005053-195701000-00009
NR 36
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-6383
EI 1879-0453
J9 INFANT BEHAV DEV
JI Infant Behav. Dev.
PD MAY
PY 2016
VL 43
BP 58
EP 65
DI 10.1016/j.infbeh.2016.01.001
PG 8
WC Psychology, Developmental
SC Psychology
GA DP2ZF
UT WOS:000378361400007
PM 27130955
ER

PT J
AU Hogberg, M
   Dahlborn, K
   Hydbring-Sandberg, E
   Hartmann, E
   Andren, A
AF Hogberg, M.
   Dahlborn, K.
   Hydbring-Sandberg, E.
   Hartmann, E.
   Andren, A.
TI Milk processing quality of suckled/milked goats: effects of milk
   accumulation interval and milking regime
SO JOURNAL OF DAIRY RESEARCH
LA English
DT Article
DE Casein; Curd yield; Goats; Milk fat; Suckling
ID THRICE-DAILY MILKING; WEANING SYSTEM; DAIRY GOATS; LAMB GROWTH; CHEESE;
   YIELD; EWES; OXYTOCIN; UDDER; ALPHA(S1)-CASEIN
AB Milk with a high concentration of fat and casein is required for cheese production, and these components have a major impact for both quality and yield of the curd. Recent observations have shown that suckling can elevate milk fat concentration in goats and our aim was therefore to check the hypothesis that animal welfare and cheese-processing properties of goat milk could be optimised by appropriate management of suckled/milked goats. Twelve Swedish dairy goats were kept together with one kid each in 4 different mixed management-systems (milking combined with partial suckling) in a cross-over design. Two milk accumulation intervals were tested; Short = dams and kids were together for 16 h (T16) and Long =; dams and kids were together for 8 h (T8 h). In addition, two milking regimes were used; Suckled Before Milking = S and Milked Before Suckling = M. Milk accumulation interval referred to how long dams and kids were separated. The milk yield available for processing (milk offtake), was weighed and analysed from each milking occasion and the suckled milk yield was estimated by a weigh-suckle-weigh method (WSW) in combination with observing the suckling behaviour during the free suckling periods. Milking managements, such as 'suckling before milking (S)', increased milk fat concentration compared to milking before suckling (M) and 'Short accumulation treatments (T16)' gave higher milk fat, casein concentration and individual curd yield (%) compared to the 'Long accumulation treatment (T8)'. The total individual curd yield (g) was the same despite treatment, but the animal welfare was most likely higher in T16 where dams and kids spent more time together.
C1 [Hogberg, M.; Dahlborn, K.; Hydbring-Sandberg, E.; Hartmann, E.] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, POB 7011, SE-75007 Uppsala, Sweden.
   [Andren, A.] Swedish Univ Agr Sci, Dept Food Sci, POB 7051, SE-75007 Uppsala, Sweden.
RP Hogberg, M (reprint author), Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, POB 7011, SE-75007 Uppsala, Sweden.
EM madeleine.hogberg@slu.se
CR Brandt L, 2009, DJURHALLNING HALSOPR
   BRUCKMAIER RM, 1994, J DAIRY RES, V61, P323
   Cameron EZ, 1998, ANIM BEHAV, V56, P521, DOI 10.1006/anbe.1998.0793
   Clark S, 2000, SMALL RUMINANT RES, V38, P123, DOI 10.1016/S0921-4488(00)00154-1
   Damian JP, 2008, ARQ BRAS MED VET ZOO, V60, P1564, DOI 10.1590/S0102-09352008000600040
   Delgadillo DA, 1997, ANIMAL APPL BEHAV SC, V55, P91
   Delgado-Pertinez M, 2009, SMALL RUMINANT RES, V84, P108, DOI 10.1016/j.smallrumres.2009.06.014
   Froberg S, 2008, APPL ANIM BEHAV SCI, V113, P1, DOI 10.1016/j.applanim.2007.12.001
   HENDERSON AJ, 1985, Q J EXP PHYSIOL CMS, V70, P557
   Hogberg M, 2014, SMALL RUMINANT RES, V121, P111, DOI 10.1016/j.smallrumres.2014.04.008
   Hogberg M, 2011, MILK YIELD COMPOSITI
   Hogberg M, 2011, FARM ANAL MILK COMPO
   Jaeggi JJ, 2008, SMALL RUMINANT RES, V79, P124, DOI 10.1016/j.smallrumres.2008.07.011
   Johansson M., 2014, Sheep & Goat Research Journal, V29, P1
   KNIGHT CH, 1993, LIVEST PROD SCI, V35, P3, DOI 10.1016/0301-6226(93)90178-K
   KNIGHT TW, 1993, NEW ZEAL J AGR RES, V36, P215
   Lollivier V, 2006, J PHYSIOL-LONDON, V570, P125
   Marnet PG, 2008, J ANIM SCI, V86, P47, DOI 10.2527/jas.2007-0285
   Marnet PG, 2001, LIVEST PROD SCI, V70, P125, DOI 10.1016/S0301-6226(01)00205-6
   Marnet PG, 2000, REPROD NUTR DEV, V40, P271, DOI 10.1051/rnd:2000131
   McKusick BC, 2002, J DAIRY SCI, V85, P2521, DOI 10.3168/jds.S0022-0302(02)74335-X
   McKusick BC, 2001, J DAIRY SCI, V84, P1660
   Miranda-de la Lama GC, 2010, SMALL RUMINANT RES, V90, P1, DOI 10.1016/j.smallrumres.2010.01.006
   Olsson K, 2009, J DAIRY RES, V75, P1
   Othmane MH, 2002, SMALL RUMINANT RES, V45, P67, DOI 10.1016/S0921-4488(02)00079-2
   Paape MJ, 2007, SMALL RUMINANT RES, V68, P114, DOI 10.1016/j.smallrumres.2006.09.014
   Persson Y, 2011, ACTA VET SCAND, V5, P1
   Pirisi A, 1994, INT DAIRY J, V4, P329, DOI 10.1016/0958-6946(94)90030-2
   Rassu SPG, 2015, SMALL RUMINANT RES, V125, P15, DOI 10.1016/j.smallrumres.2015.02.015
   Salama AAK, 2004, J DAIRY SCI, V87, P1181
   Shams D, 1984, J ENDOCRINOL, V102, P337
   Silanikove N, 2010, SMALL RUMINANT RES, V89, P110, DOI 10.1016/j.smallrumres.2009.12.033
   Skeie SB, 2014, SMALL RUMINANT RES, V122, P10, DOI 10.1016/j.smallrumres.2014.07,012
   Soryal K, 2005, SMALL RUMINANT RES, V58, P275, DOI 10.1016/j.smallrumres.2004.11.003
   Tzamaloukas O, 2015, J DAIRY SCI, V98, P1739, DOI 10.3168/jds.2014-8540
   WILDE CJ, 1987, J ANIM SCI, V64, P533
NR 36
TC 0
Z9 0
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0022-0299
EI 1469-7629
J9 J DAIRY RES
JI J. Dairy Res.
PD MAY
PY 2016
VL 83
IS 2
BP 173
EP 179
DI 10.1017/S0022029916000157
PG 7
WC Agriculture, Dairy & Animal Science; Food Science & Technology
SC Agriculture; Food Science & Technology
GA DP0HZ
UT WOS:000378171900007
PM 27056664
ER

PT J
AU Ferneborg, S
   Stadtmuller, L
   Pickova, J
   Wiking, L
   Svennersten-Sjaunja, K
AF Ferneborg, Sabine
   Stadtmueller, Larissa
   Pickova, Jana
   Wiking, Lars
   Svennersten-Sjaunja, Kerstin
TI Effects of automatic cluster removal and feeding during milking on
   milking efficiency, milk yield and milk fat quality
SO JOURNAL OF DAIRY RESEARCH
LA English
DT Article
DE Dairy cow; cluster removal; milking efficiency; milk yield; milk fat;
   FFA
ID DAIRY-COWS; ACID-COMPOSITION; UDDER HEALTH; MAMMARY-GLAND; GLOBULES;
   PROLACTIN; OXYTOCIN; SIZE; FLOW; DURATION
AB In order to increase milking efficiency, the effects of two different cluster take-off levels (200 and 800 g/min) and feeding vs. not feeding during milking were tested in a Latin square design study including 32 cows. Milk yield, milking time, milk flow and milking interval were measured and milk samples were analysed for gross composition, sodium and potassium concentration, free fatty acid (FFA) content, milk fat globule (MFG) size, MFG membrane (MFGM) material and fatty acid composition. Residual milk was harvested to evaluate udder emptying. Increasing the take-off level from 200 to 800 g/min at the whole udder level decreased milking time and increased harvest flow. Udder emptying decreased slightly, but there were no effects on milk yield, FFA content or MFGM. There were interactive effects of take-off level and feeding during milking on content of fatty acids C4:0, C6:0, C16:0, C18:3(n-3) and C20:0. Feeding during milking increased milk yield per day and decreased milking interval. Sodium and potassium concentrations in milk were unaffected by treatments, indicating no loss of tight junction integrity. From these results, it is clear that feeding during milking should be used to increase milk yield and improve milking efficiency, regardless of take-off level used, and that the effect of feeding is more pronounced when a low take-off level is used. Feeding seemed to counteract the effects of the low take-off level on milking time and milking interval. Low take-off levels can therefore be used in combination with feeding.
C1 [Ferneborg, Sabine; Stadtmueller, Larissa; Svennersten-Sjaunja, Kerstin] Swedish Univ Agr Sci, Dept Anim Nutr & Management, S-90183 Umea, Sweden.
   [Stadtmueller, Larissa] Univ Hohenheim, Livestock Syst Engn, Stuttgart, Germany.
   [Pickova, Jana] Swedish Univ Agr Sci, Dept Food Sci, S-90183 Umea, Sweden.
   [Wiking, Lars] Aarhus Univ, Dept Food Sci, DK-8000 Aarhus C, Denmark.
RP Ferneborg, S (reprint author), Swedish Univ Agr Sci, Dept Anim Nutr & Management, S-90183 Umea, Sweden.
EM sabine.ferneborg@slu.se
FU Swedish Farmers' Foundation (SLF)
FX The authors wish to acknowledge the Swedish Farmers' Foundation (SLF)
   for funding the study and DeLaval International AB for technical
   assistance and advice.
CR ARMSTRONG DV, 1970, J DAIRY SCI, V53, P658
   Briard V, 2003, EUR J LIPID SCI TECH, V105, P677, DOI 10.1002/ejlt.200300812
   Burke JK, 2011, ANIM PROD SCI, V51, P920, DOI 10.1071/AN11042
   Clarke T, 2004, J DAIRY RES, V71, P419, DOI 10.1017/S0022029904000421
   DEETH HC, 1975, AUST J DAIRY TECHNOL, V30, P109
   Edwards JP, 2013, J DAIRY SCI, V96, P1886, DOI 10.3168/jds.2012-6191
   Gomez-Cortes P, 2011, SMALL RUMINANT RES, V97, P72, DOI 10.1016/j.smallrumres.2011.01.003
   Hernandez LL, 2007, J ANIM SCI, V85, P208
   Hernandez LL, 2011, J ENDOCRINOL, V209, P45, DOI 10.1530/JOE-10-0452
   Jago JG, 2010, J DAIRY SCI, V93, P2541, DOI 10.3168/jds.2009-2949
   Johansson B, 1999, J DAIRY RES, V66, P151, DOI 10.1017/S0022029999003532
   Kennett JE, 2009, ENDOCRINOLOGY, V150, P2292, DOI 10.1210/en.2008-1611
   KERNOHAN EA, 1969, J DAIRY RES, V36, P177
   KNIGHT CH, 1994, J ENDOCRINOL, V142, P471, DOI 10.1677/joe.0.1420471
   Lacasse P, 2012, DOMEST ANIM ENDOCRIN, V43, P154, DOI 10.1016/j.domaniend.2011.12.007
   Larsen MK, 2012, J DAIRY SCI, V95, P5608, DOI 10.3168/jds.2012-5815
   Lollivier V, 2015, J DAIRY SCI, V98, P8775, DOI 10.3168/jds.2015-9853
   Lollivier V, 2002, REPROD NUTR DEV, V42, P173, DOI 10.1051/rnd:2002016
   Lopez C, 2011, FOOD CHEM, V125, P355, DOI 10.1016/j.foodchem.2010.09.005
   Magliaro AL, 2005, J DAIRY SCI, V88, P148
   NATZKE RP, 1982, J DAIRY SCI, V65, P117
   Neijenhuis F, 2000, J DAIRY SCI, V83, P2795
   Ollivier-Bousquet M, 2002, REPROD NUTR DEV, V42, P149, DOI 10.1051/rnd:2002014
   Ontsouka CE, 2003, J DAIRY SCI, V86, P2005, DOI 10.3168/jds.S0022-0302(03)73789-8
   Peaker M, 1996, J MAMMARY GLAND BIOL, V1, P307, DOI 10.1007/BF02018083
   Prescott NB, 1998, APPL ANIM BEHAV SCI, V57, P23, DOI 10.1016/S0168-1591(97)00112-3
   Rahmatyar Z, 2012, MILCHWISSENSCHAFT, V67, P34
   RASMUSSEN MD, 1993, J DAIRY RES, V60, P287
   Rasmussen MD, 2004, P 43 ANN M NAT MAST, P169
   Rushen J, 1999, J DAIRY SCI, V82, P720
   SAMUELSSON B, 1993, SWED J AGR RES, V23, P101
   Samuelsson B, 1996, LIVEST PROD SCI, V46, P49, DOI 10.1016/0301-6226(96)00020-6
   Shingfield KJ, 2003, ANIM SCI, V77, P165
   STELWAGEN K, 1995, AM J PHYSIOL-REG I, V269, pR848
   Stewart S, 2002, J DAIRY SCI, V85, P818
   SVENNERSTEN K, 1991, MILCHWISSENSCHAFT, V46, P507
   SVENNERSTEN K, 1995, ACTA PHYSIOL SCAND, V153, P309, DOI 10.1111/j.1748-1716.1995.tb09867.x
   Tancin V, 2006, J DAIRY SCI, V89, P978
   TIMMEN H, 1988, LIPIDS, V23, P685, DOI 10.1007/BF02535669
   Volden H, 2011, EAAP PUBLIC, P1, DOI 10.3920/978-90-8686-718-9
   Wiking L, 2003, INT DAIRY J, V13, P797, DOI 10.1016/S0958-6946(03)00110-9
   Wiking L, 2004, INT DAIRY J, V14, P909, DOI 10.1016/j.idairyj.2004.03.005
   Wiking L, 2005, THESIS
NR 43
TC 0
Z9 0
U1 9
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0022-0299
EI 1469-7629
J9 J DAIRY RES
JI J. Dairy Res.
PD MAY
PY 2016
VL 83
IS 2
BP 180
EP 187
DI 10.1017/S0022029916000170
PG 8
WC Agriculture, Dairy & Animal Science; Food Science & Technology
SC Agriculture; Food Science & Technology
GA DP0HZ
UT WOS:000378171900008
PM 27210491
ER

PT J
AU Bader, O
AF Bader, Oren
TI Attending to emotions is sharing of emotions - A multidisciplinary
   perspective to social attention and emotional sharing. Comment on Zahavi
   and Rochat (2015)
SO CONSCIOUSNESS AND COGNITION
LA English
DT Review
DE Dan Zahavi; Caregiving; Emotional sharing; Expression of emotions;
   Social attention; Social cognition
ID EYE CONTACT; DEVELOPMENTAL-PSYCHOLOGY; FACIAL EXPRESSIONS; SHARED
   EMOTIONS; OXYTOCIN; SELF; FACE; EXPERIENCES; INTENTIONS; PERCEPTION
AB Attending to bodily expression of emotions plays an important role in the human social world. It provides subjects with valuable information, constructs opportunities to act, and importantly, as Daniel Stern pointed out, it is involved in the constitution of the direct experience of others. Whether mutual or one-sided, these direct experiences, in which the subject can share the perspectives and attitudes of other subjects, always comprise one person's bodily expression of emotions that is available to another person. In this article I suggest that attending to other subjects' expressed emotions involves a special (social) mode of attention and emotional sharing. This suggestion challenges Dan Zahavi's view that confines the sharing of emotions solely to reciprocal experiences. (c) 2016 Elsevier Inc. All rights reserved.
C1 [Bader, Oren] Tel Aviv Univ, Sch Philosophy, Lester & Sally Entin Fac Humanities, Cohn Inst Hist & Philosophy Sci Ideas, IL-69978 Tel Aviv, Israel.
RP Bader, O (reprint author), Tel Aviv Univ, Sch Philosophy, Lester & Sally Entin Fac Humanities, Cohn Inst Hist & Philosophy Sci Ideas, IL-69978 Tel Aviv, Israel.
EM oren.bader@gmail.com
CR Abraham E, 2014, P NATL ACAD SCI USA, V111, P9792, DOI 10.1073/pnas.1402569111
   Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146
   Becchio C, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00117
   Becchio C, 2010, CURR DIR PSYCHOL SCI, V19, P183, DOI 10.1177/0963721410370131
   Bednar JA, 2003, NEURAL COMPUT, V15, P1525, DOI 10.1162/089976603321891792
   Birmingham E., 2009, ANN NEW YORK ACAD SC
   Boothby EJ, 2014, PSYCHOL SCI, V25, P2209, DOI 10.1177/0956797614551162
   Bradley MM, 2012, FRONT PSYCHOL, V3, P1
   Bronfman ZZ, 2014, PSYCHOL SCI, V25, P1394, DOI 10.1177/0956797614532656
   Brosch T., 2014, COLLECTIVE EMOTIONS, P78
   BUTTERWORTH G, 1991, BRIT J DEV PSYCHOL, V9, P55
   Cardoso C, 2014, EMOTION, V14, P43, DOI 10.1037/a0034314
   Carpenter M., 1998, MONOGRAPHS SOC RES C, V63, P255, DOI DOI 10.2307/1166214
   CARR D, 1986, MONIST, V69, P521
   Carter C. S., 2014, ANNU REV PSYCHOL, V65, P7
   Churchland PS, 2011, BRAINTRUST: WHAT NEUROSCIENCE TELLS US ABOUT MORALITY, P1
   Crouzet SM, 2010, J VISION, V10, DOI 10.1167/10.4.16
   Darwin C., 1998, EXPRESSION EMOTIONS
   Eimer M, 2015, CONSCIOUS COGN, V35, P274, DOI 10.1016/j.concog.2015.01.001
   Farroni T, 2002, P NATL ACAD SCI USA, V99, P9602, DOI 10.1073/pnas.152159999
   Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008
   Gallagher S., 2012, JOINT ATTENTION NEW, P293
   Gallagher S., 2008, SHARED MIND PERSPECT, P17, DOI DOI 10.1075/CELCR.12.04GAL
   Gallagher Shaun, 2005, BODY SHAPES MIND
   Gallese Vittorio, 2007, Novartis Found Symp, V278, P3
   Gallese V, 2010, NEUROPSYCHOLOGIA, V48, P746, DOI 10.1016/j.neuropsychologia.2009.09.038
   Girard P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016453
   Goren-Inbar N, 2011, PHILOS T R SOC B, V366, P1038, DOI 10.1098/rstb.2010.0365
   Guastella A. J., 2012, HORM BEHAV, V61, P410, DOI DOI 10.1016/J.YHBEH.2012.01.002
   Gurwitch A., 1966, PHENOMENOLOGY PSYCHO
   Hattori Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep01566
   Hepach R, 2013, J EXP CHILD PSYCHOL, V115, P16, DOI 10.1016/j.jecp.2012.12.013
   Heyes C, 2010, NEUROSCI BIOBEHAV R, V34, P575, DOI 10.1016/j.neubiorev.2009.11.007
   Hoehl S, 2010, DEVELOPMENTAL SCI, V13, P813, DOI 10.1111/j.1467-7687.2009.00944.x
   Hrdy S., 2009, MOTHERS OTHERS EVOLU
   Hrdy S., 2009, NAT HIST, P24
   Husserl E., 1970, CRISIS EUROPEAN SCI
   Husserl Edmund, 1960, CARTESIAN MEDITATION
   Isler K, 2012, CURR ANTHROPOL, V53, pS453, DOI 10.1086/667623
   Isler K, 2012, J HUM EVOL, V63, P52, DOI 10.1016/j.jhevol.2012.03.009
   Jablonka E, 2012, PHILOS T R SOC B, V367, P2152, DOI 10.1098/rstb.2012.0117
   Kaneko T, 2011, P ROY SOC B-BIOL SCI, V278, P3694, DOI 10.1098/rspb.2011.0611
   Kenkel WM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069965
   Klinnert M. D., 1983, EMOTION THEORY RES E, V2, P57, DOI DOI 10.1016/B978-0-12-558702-0.50009-1
   Knoblich G, 2008, PHILOS T R SOC B, V363, P2021, DOI 10.1098/rstb.2008.0006
   Knott C, 2001, FOUND HUM B, P429
   Krueger J, 2013, CONT PHILOS REV, V46, P509, DOI 10.1007/s11007-013-9278-5
   Krueger J, 2012, PHENOMENOL COGN SCI, V11, P149, DOI 10.1007/s11097-011-9226-y
   Lang PJ, 2013, EMOT REV, V5, P230, DOI 10.1177/1754073913477511
   Lang PJ, 2010, BIOL PSYCHOL, V84, P437, DOI 10.1016/j.biopsycho.2009.10.007
   Lang PJ, 1997, ATTENTION AND ORIENTING: SENSORY AND MOTIVATIONAL PROCESSES, P97
   Langton SRH, 2000, TRENDS COGN SCI, V4, P50, DOI 10.1016/S1364-6613(99)01436-9
   Moore C., 1995, JOINT ATTENTION ITS, P15
   Morand SM, 2014, CEREB CORTEX, V24, P898, DOI 10.1093/cercor/bhs368
   Nelson K, 2009, J CONSCIOUSNESS STUD, V16, P69
   Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x
   Peltola MJ, 2009, SOC COGN AFFECT NEUR, V4, P134, DOI 10.1093/scan/nsn046
   Pitcher D, 2012, J NEUROSCI, V32, P15877, DOI 10.1523/JNEUROSCI.2624-12.2012
   Reddy V., 2012, JOINT ATTENTION NEW, P137
   Reddy V., 2010, HDB INFANT DEV, P365
   Reddy V., 2008, INFANTS KNOW MINDS
   Reddy V, 2015, J CONSCIOUSNESS STUD, V22, P24
   Rigato S, 2013, EMOT REV, V5, P36, DOI 10.1177/1754073912457225
   Rochat P, 2000, INFANT BEHAV DEV, V23, P513, DOI 10.1016/S0163-6383(01)00055-8
   Rochat P., 2014, ORIGINS POSSESSION O
   Rochat P, 2011, CONSCIOUS COGN, V20, P204, DOI 10.1016/j.concog.2010.06.007
   Rochat P, 2010, NEUROPSYCHOLOGIA, V48, P738, DOI 10.1016/j.neuropsychologia.2009.11.021
   Salmela M., 2013, I EMOTIONS GROUP AGE, V2, P159
   Salmela M, 2012, PHILOS EXPLOR, V15, P33, DOI 10.1080/13869795.2012.647355
   Sartori L, 2011, EXP BRAIN RES, V211, P557, DOI 10.1007/s00221-011-2650-y
   Schilbach L, 2013, BEHAV BRAIN SCI, V36, P393, DOI 10.1017/S0140525X12000660
   Schmid HB, 2009, CONTRIB PHENOMENOL, V58, P1, DOI 10.1007/978-90-481-2437-4
   Schmid H. B., 2014, COLLECTIVE EMOTIONS, P3
   Schmidt KL, 2001, YEARB PHYS ANTHROPOL, V44, P3, DOI 10.1002/ajpa.20001
   Schutz A., 1967, PHENOMENOLOGY SOCIAL
   Schutz A., 2013, PHAENOMENOLOGICA, V206
   SEARLE JR, 1990, SYS DEV FDN, P401
   Shipton C., 2013, BAR INT SERIES, V2468
   Shipton C., 2009, LITHIC MAT PALEOLITH, P219
   Shteynberg G., 2014, EMOTION
   Simion F, 2001, INFANT CHILD DEV, V10, P59, DOI 10.1002/icd.247
   Sinigaglia C, 2011, CONSCIOUS COGN, V20, P64, DOI 10.1016/j.concog.2010.11.012
   Sinigaglia C, 2010, J ANAL PSYCHOL, V55, P3, DOI 10.1111/j.1468-5922.2009.01821.x
   Sinigaglia C, 2008, EMERG COMMUN-STUD NE, V10, P17
   Sterelny K, 2012, EVOLVED APPRENTICE E
   Stern D, 1985, INTERPERSONAL WORLD
   Stern DN, 1999, EARLY SOCIAL COGNITION, P67
   Striano T, 2006, SOC COGN AFFECT NEUR, V1, P87, DOI 10.1093/scan/nsl008
   Swedell L, 2012, INT J PRIMATOL, V33, P1165, DOI 10.1007/s10764-012-9600-9
   Tomasello M, 2009, WHY WE COOPERATE, P1
   Tomasello M, 2003, DEV PSYCHOL, V39, P906, DOI 10.1037/0012-1649.39.5.906
   Tomasello Michael, 2008, ORIGINS HUMAN COMMUN
   Tomasello M., 2014, NATURAL HIST HUMAN T
   Tomonaga Masaki, 2010, P42
   Van Kleef GA, 2009, CURR DIR PSYCHOL SCI, V18, P184
   Van Schaik C. P., 2004, ORANGUTANS RED APES
   Waller BM, 2014, BIOL LETTERS, V10, DOI 10.1098/rsbl.2013.0974
   Yatawara C.J., 2015, MOL PSYCHIATR, P1
   Yu C., 2013, PLOS ONE, V8
   Zahavi Dan, 2001, HUSSERL TRANSCENDENT
   Zahavi D, 2003, HUSSERLS PHENOMENOLO
   Zahavi D, 2015, CONSCIOUS COGN, V36, P543, DOI 10.1016/j.concog.2015.05.008
   Zahavi D, 2015, J CONSCIOUSNESS STUD, V22, P84
NR 103
TC 0
Z9 0
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8100
EI 1090-2376
J9 CONSCIOUS COGN
JI Conscious. Cogn.
PD MAY
PY 2016
VL 42
BP 382
EP 395
DI 10.1016/j.concog.2016.04.012
PG 14
WC Psychology, Experimental
SC Psychology
GA DO5SO
UT WOS:000377843300034
PM 27152930
ER

PT J
AU Song, ZM
   Larkin, TE
   Malley, MO
   Albers, HE
AF Song, Zhimin
   Larkin, Tony E.
   Malley, Maureen O'.
   Albers, H. Elliott
TI Oxytocin (OT) and arginine-vasopressin (AVP) act on OT receptors and not
   AVP V1a receptors to enhance social recognition in adult Syrian hamsters
   (Mesocricetus auratus)
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Social behavior; Nonapeptides; Neuropeptides; Neurohypophyseal hormones;
   Social communication; Flank marking; Chemosensory, olfaction; Odor
   recognition; Memory
ID BEHAVIOR NEURAL-NETWORK; FLANK MARKING BEHAVIOR; GOLDEN-HAMSTERS;
   MALE-RATS; OLFACTORY-BULB; BINDING-SITES; INDIVIDUAL RECOGNITION; MEDIAL
   AMYGDALA; SCENT MARKING; MEMORY
AB Social recognition is a fundamental requirement for all forms of social relationships. A majority of studies investigating the neural mechanisms underlying social recognition in rodents have investigated relatively neutral social stimuli such as juveniles or ovariectomized females over short time intervals (e.g., 2 h). The present study developed a new testing model to study social recognition among adult males using a potent social stimulus. Flank gland odors are used extensively in social communication in Syrian hamsters and convey important information such as dominance status. We found that the recognition of flank gland odors after a 3 min exposure lasted for at least 24 h, substantially longer than the recognition of other social cues in rats and mice. Intra-cerebroventricular injections of OT and AVP prolonged the recognition of flank gland odor for up to 48 h. Selective OTR but not V1aR agonists, mimicked these enhancing effects of OT and AVP. Similarly, selective OTR but not V1aR antagonists blocked recognition of the odors after 20 min. In contrast, the recognition of non-social stimuli was not blocked by either the OTR or the V1aR antagonists. Our findings suggest both OT and AVP enhance social recognition via acting on OTRs and not V1aRs and that the recognition enhancing effects of OT and AVP are limited to social stimuli. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Song, Zhimin; Larkin, Tony E.; Malley, Maureen O'.; Albers, H. Elliott] Georgia State Univ, Neurosci Inst, Ctr Behav Neurosci, POB 5030, Atlanta, GA 30302 USA.
RP Albers, HE (reprint author), Georgia State Univ, Neurosci Inst, POB 5030, Atlanta, GA 30302 USA.
EM biohea@gsu.edu
FU NSF [IOS-0923301]
FX We would like to thank Dr. Maurice Manning for his generous gifts of the
   OT and AVP receptor agonists and antagonists used in this study. This
   work was supported by NSF IOS-0923301 to HEA.
CR Albers HE, 2015, FRONT NEUROENDOCRIN, V36, P49, DOI 10.1016/j.yfrne.2014.07.001
   Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007
   ALBERS HE, 1986, J NEUROSCI, V6, P2085
   ALBERS HE, 1991, BRAIN RES, V539, P137, DOI 10.1016/0006-8993(91)90696-S
   Bielsky IF, 2005, NEURON, V47, P503, DOI 10.1016/j.neuron.2005.06.031
   Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360
   BLUTHE RM, 1993, PSYCHONEUROENDOCRINO, V18, P323, DOI 10.1016/0306-4530(93)90028-J
   Caldwell H.K., 2015, CURR TOP BEHAV NEURO
   Choleris E, 2007, P NATL ACAD SCI USA, V104, P4670, DOI 10.1073/pnas.0700670104
   Choleris E, 2009, FRONT NEUROENDOCRIN, V30, P442, DOI 10.1016/j.yfrne.2009.05.003
   DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192
   DANTZER R, 1988, BRAIN RES, V457, P143, DOI 10.1016/0006-8993(88)90066-2
   Dluzen DE, 1998, PEPTIDES, V19, P999, DOI 10.1016/S0196-9781(98)00047-3
   DUBOISDAUPHIN M, 1990, J COMP NEUROL, V300, P535, DOI 10.1002/cne.903000408
   DUBOISDAUPHIN M, 1992, NEUROREPORT, V3, P797, DOI 10.1097/00001756-199209000-00019
   ENGELMANN M, 1994, PHYSIOL BEHAV, V55, P145, DOI 10.1016/0031-9384(94)90022-1
   Engelmann M, 2011, NAT PROTOC, V6, P1152, DOI 10.1038/nprot.2011.353
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Ferguson JN, 2001, J NEUROSCI, V21, P8278
   FERRIS CF, 1984, SCIENCE, V224, P521, DOI 10.1126/science.6538700
   FERRIS CF, 1987, PHYSIOL BEHAV, V40, P661, DOI 10.1016/0031-9384(87)90114-4
   FERRIS CF, 1988, EUR J PHARMACOL, V154, P153, DOI 10.1016/0014-2999(88)90092-1
   FERRIS CF, 1995, J COMP NEUROL, V360, P589, DOI 10.1002/cne.903600404
   Ferris CF, 2013, OXYTOCIN, VASOPRESSIN AND RELATED PEPTIDES IN THE REGULATION OF BEHAVIOR, P213
   Gabor CS, 2012, BEHAV NEUROSCI, V126, P97, DOI 10.1037/a0026464
   Gattermann R, 2008, BIOL LETTERS, V4, P253, DOI 10.1098/rsbl.2008.0066
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   HALPIN ZT, 1976, BEHAVIOUR, V58, P117
   JOHNSTON RE, 1976, BEHAV BIOL, V16, P199, DOI 10.1016/S0091-6773(76)91310-9
   JOHNSTON RE, 1993, J COMP PSYCHOL, V107, P201
   Johnston RE, 2001, ANIM BEHAV, V61, P545, DOI 10.1006/anbe.2000.1637
   Johnston RE, 2008, J COMP PSYCHOL, V122, P121, DOI 10.1037/0735-7036.122.2.121
   Kavaliers M, 2005, TRENDS PARASITOL, V21, P423, DOI 10.1016/j.pt.2005.07.008
   Landgraf R, 2003, EUR J NEUROSCI, V18, P403, DOI 10.1046/j.1460-9568.2003.02750.x
   LANDGRAF R, 1995, J NEUROSCI, V15, P4250
   Larrazolo-Lopez A, 2008, NEUROSCIENCE, V152, P585, DOI 10.1016/j.neuroscience.2008.01.024
   LEMOAL M, 1987, NEUROSCI LETT, V77, P353, DOI 10.1016/0304-3940(87)90527-1
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   Lukas M, 2011, PSYCHONEUROENDOCRINO, V36, P843, DOI 10.1016/j.psyneuen.2010.11.007
   Macbeth AH, 2009, GENES BRAIN BEHAV, V8, P558, DOI 10.1111/j.1601-183X.2009.00506.x
   Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x
   Mateo JM, 2003, ANIM COGN, V6, P73, DOI 10.1007/s10071-003-0165-z
   Maybauer Marc O, 2008, Best Pract Res Clin Anaesthesiol, V22, P253, DOI 10.1016/j.bpa.2008.03.003
   Nephew BC, 2008, PHARMACOL BIOCHEM BE, V91, P77, DOI 10.1016/j.pbb.2008.06.013
   Petrulis A, 2009, BEHAV BRAIN RES, V200, P260, DOI 10.1016/j.bbr.2008.10.027
   POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591
   Qiu F, 2014, BRIT J PHARMACOL, V171, P3065, DOI 10.1111/bph.12635
   Ramos L, 2013, NEUROPSYCHOPHARMACOL, V38, P2249, DOI 10.1038/npp.2013.125
   Sala M, 2011, BIOL PSYCHIAT, V69, P875, DOI 10.1016/j.biopsych.2010.12.022
   Schorscher-Petcu A, 2010, J NEUROSCI, V30, P8274, DOI 10.1523/JNEUROSCI.1594-10.2010
   Song ZM, 2014, PSYCHONEUROENDOCRINO, V50, P14, DOI 10.1016/j.psyneuen.2014.08.005
   Tobin VA, 2010, NATURE, V464, P413, DOI 10.1038/nature08826
   Veenema AH, 2012, HORM BEHAV, V61, P50, DOI 10.1016/j.yhbeh.2011.10.002
   Veinante P, 1997, J COMP NEUROL, V383, P305
   Wersinger SR, 2007, GENES BRAIN BEHAV, V6, P540, DOI 10.1111/j.1601-183X.2006.00281.x
   Whitman DC, 1998, CELL TISSUE RES, V291, P231, DOI 10.1007/s004410050993
   Winslow JT, 2004, CURR OPIN NEUROBIOL, V14, P248, DOI 10.1016/j.conb.2004.03.009
   Zheng D.J., 2013, ANIM BEHAV, V86
NR 58
TC 0
Z9 0
U1 9
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD MAY
PY 2016
VL 81
BP 20
EP 27
DI 10.1016/j.yhbeh.2016.02.004
PG 8
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DO5TY
UT WOS:000377846900003
PM 26975586
ER

PT J
AU Duclot, F
   Wang, H
   Youssef, C
   Liu, Y
   Wang, Z
   Kabbaj, M
AF Duclot, F.
   Wang, H.
   Youssef, C.
   Liu, Y.
   Wang, Z.
   Kabbaj, M.
TI Trichostatin A (TSA) facilitates formation of partner preference in male
   prairie voles (Microtus ochrogaster)
SO HORMONES AND BEHAVIOR
LA English
DT Article
DE Partner preference; Trichostatin A; Nucleus accumbens; Oxytocin;
   Vasopressin; Prairie voles
ID PAIR BOND FORMATION; OXYTOCIN RECEPTOR DENSITY; NUCLEUS-ACCUMBENS;
   SOCIAL ATTACHMENT; POLYGAMOUS VOLES; VASOPRESSIN; ORGANIZATION;
   MECHANISMS; EXPRESSION; BEHAVIORS
AB In the socially monogamous prairie voles (Microtus ochrogaster), the development of a social bonding is indicated by the formation of partner preference, which involves a variety of environmental and neurochemical factors and brain structures. In a most recent study in female prairie voles, we found that treatment with the histone deacetylase inhibitor trichostatin A (TSA) facilitates the formation of partner preference through up-regulation of oxytocin receptor (OTR) and vasopressin V1a receptor (V1aR) genes expression in the nucleus accumbens (NAcc). In the present study, we tested the hypothesis that TSA treatment also facilitates partner preference formation and alters OTR and V1aR genes expression in the NAcc in male prairie voles. We thus observed that central injection of TSA dose-dependently promoted the formation of partner preference in the absence of mating in male prairie voles. Interestingly, TSA treatment up-regulated OTR, but not V1aR, gene expression in the NAcc similarly as they were affected by mating - an essential process for naturally occurring partner preference. These data, together with others, not only indicate the involvement of epigenetic events but also the potential role of NAcc oxytocin in the regulation of partner preference in both male and female prairie voles. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Duclot, F.; Wang, H.; Youssef, C.; Kabbaj, M.] Florida State Univ, Dept Biomed Sci, Tallahassee, FL 32306 USA.
   [Duclot, F.; Liu, Y.; Wang, Z.; Kabbaj, M.] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.
   [Wang, H.; Liu, Y.; Wang, Z.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
RP Kabbaj, M (reprint author), Florida State Univ, Coll Med, 1115 W Call St, Tallahassee, FL 32306 USA.
EM mohamed.kabbaj@med.fsu.edu
RI Kabbaj, Mohamed/M-9240-2016; Duclot, Florian/E-4669-2013
OI Duclot, Florian/0000-0003-0121-5807
FU National Institute of Mental Health (NIMH) [MHR21-083128, MHR01-087583,
   MHR01-099085, MHR01- 058616]
FX This work was supported by the National Institute of Mental Health
   (NIMH) grants.; MHR21-083128 to M.K. and Z.W., MHR01-087583 and
   MHR01-099085 to M.K., and MHR01- 058616 to Z.W.
CR Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613
   Barrett CE, 2013, HORM BEHAV, V63, P518, DOI 10.1016/j.yhbeh.2013.01.005
   INSEL TR, 1994, J NEUROSCI, V14, P5381
   INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981
   INSEL TR, 1995, PHYSIOL BEHAV, V57, P615, DOI 10.1016/0031-9384(94)00362-9
   INSEL TR, 1995, BEHAV NEUROSCI, V109, P782, DOI 10.1037//0735-7044.109.4.782
   Keebaugh AC, 2015, SOC NEUROSCI-UK, V10, P561, DOI 10.1080/17470919.2015.1040893
   Keebaugh AC, 2011, HORM BEHAV, V60, P498, DOI 10.1016/j.yhbeh.2011.07.018
   Lim MM, 2004, NEUROSCIENCE, V125, P35, DOI 10.1016/j.neuroscience.2003.12.008
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Liu Y, 2001, BEHAV NEUROSCI, V115, P910, DOI 10.1037//0735-7044.115.4.910
   Liu Y, 2010, P NATL ACAD SCI USA, V107, P1217, DOI 10.1073/pnas.0911998107
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   Ophir AG, 2012, HORM BEHAV, V61, P445, DOI 10.1016/j.yhbeh.2012.01.007
   Ross HE, 2009, NEUROSCIENCE, V162, P892, DOI 10.1016/j.neuroscience.2009.05.055
   Ross HE, 2009, J NEUROSCI, V29, P1312, DOI 10.1523/JNEUROSCI.5039-08.2009
   Wang H, 2013, NAT NEUROSCI, V16, P919, DOI 10.1038/nn.3420
   Wang ZX, 1997, J COMP NEUROL, V378, P535
   WILLIAMS JR, 1992, HORM BEHAV, V26, P339, DOI 10.1016/0018-506X(92)90004-F
   WILLIAMS JR, 1994, J NEUROENDOCRINOL, V6, P247, DOI 10.1111/j.1365-2826.1994.tb00579.x
   WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0
   Young KA, 2011, FRONT NEUROENDOCRIN, V32, P53, DOI 10.1016/j.yfrne.2010.07.006
   Young KA, 2008, COMP BIOCHEM PHYS C, V148, P401, DOI 10.1016/j.cbpc.2008.02.004
   Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691
NR 24
TC 1
Z9 1
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD MAY
PY 2016
VL 81
BP 68
EP 73
DI 10.1016/j.yhbeh.2016.04.001
PG 6
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA DO5TY
UT WOS:000377846900009
PM 27074037
ER

PT J
AU Denizot, AL
   Besson, V
   Correra, RM
   Mazzola, A
   Lopes, I
   Courbard, JR
   Marazzi, G
   Sassoon, DA
AF Denizot, Anne-Lyse
   Besson, Vanessa
   Correra, Rosa Maria
   Mazzola, Alessia
   Lopes, Izolina
   Courbard, Jean-Remy
   Marazzi, Giovanna
   Sassoon, David A.
TI A Novel Mutant Allele of Pw1/Peg3 Does Not Affect Maternal Behavior or
   Nursing Behavior
SO PLOS GENETICS
LA English
DT Article
ID EXPRESSED IMPRINTED GENE; PEG3; GROWTH; OXYTOCIN; MICE; APEG3; STEM;
   VASOPRESSIN; PROGENITOR; BRAIN
AB Parental imprinting is a mammalian-specific form of epigenetic regulation in which one allele of a gene is silenced depending on its parental origin. Parentally imprinted genes have been shown to play a role in growth, metabolism, cancer, and behavior. Although the molecular mechanisms underlying parental imprinting have been largely elucidated, the selective advantage of silencing one allele remains unclear. The mutant phenotype of the imprinted gene, Pw1/Peg3, provides a key example to illustrate the hypothesis on a coadaptation between mother and offspring, in which Pw1/Peg3 is required for a set of essential maternal behaviors, such as nursing, nest building, and postnatal care. We have generated a novel Pw1/Peg3 mutant allele that targets the last exon for the PW1 protein that contains >90% of the coding sequence resulting in a loss of Pw1/Peg3 expression. In contrast to previous reports that have targeted upstream exons, we observe that maternal behavior and lactation are not disrupted upon loss of Pw1/Peg3. Both paternal and homozygous Pw1/Peg3 mutant females nurse and feed their pups properly and no differences are detected in either oxytocin neuron number or oxytocin plasma levels. In addition, suckling capacities are normal in mutant pups. Consistent with previous reports, we observe a reduction of postnatal growth. These results support a general role for Pw1/Peg3 in the regulation of body growth but not maternal care and lactation.
C1 [Denizot, Anne-Lyse; Besson, Vanessa; Correra, Rosa Maria; Mazzola, Alessia; Lopes, Izolina; Courbard, Jean-Remy; Marazzi, Giovanna; Sassoon, David A.] Univ Paris 06, INSERM, Stem Cells & Regenerat Med, Inst Cardiometab & Nutr ICAN,UMRS 1166, Paris, France.
RP Marazzi, G; Sassoon, DA (reprint author), Univ Paris 06, INSERM, Stem Cells & Regenerat Med, Inst Cardiometab & Nutr ICAN,UMRS 1166, Paris, France.
EM giovanna.em.marazzi@gmail.com; david.a.sassoon@gmail.com
FU French Ministry of Research 'Chaire d'Excellence'; Muscular Dystrophy
   Association of America; European Community [Health-F5-2009-223098,
   241440]; Strategic Plan Support from the Association Francaise contre
   les Myopathies (AFM); EC [290123]
FX This work was supported by the French Ministry of Research 'Chaire
   d'Excellence' and the Muscular Dystrophy Association of America to DAS
   and the European Community Seventh Framework Program projects OPTISTEM
   (Optimization of stem cell therapy for degenerative epithelial and
   muscle diseases contract number Health-F5-2009-223098) and ENDOSTEM
   (Activation of vasculature associated stem cells and muscle stem cells
   for the repair and maintenance of muscle tissue-agreement number
   241440). This work was also supported by a Strategic Plan Support from
   the Association Francaise contre les Myopathies (AFM) and is affiliated
   the ANR "Laboratoire d'Excellence" program REVIVE and the IHU-ICAN
   projects and EC 290123 Ingenium (ITN) training grant. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Besson V, 2011, P NATL ACAD SCI USA, V108, P11470, DOI 10.1073/pnas.1103873108
   Bonfanti C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7364
   Broad KD, 2011, P NATL ACAD SCI USA, V108, P15237, DOI 10.1073/pnas.1106022108
   CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794
   CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0
   Champagne FA, 2009, BEHAV NEUROSCI, V123, P469, DOI 10.1037/a0015060
   Charalambous M, 2012, CELL METAB, V15, P209, DOI 10.1016/j.cmet.2012.01.006
   Chiavegatto S, 2012, BRAIN BEHAV, V2, P365, DOI 10.1002/brb3.58
   Choo JH, 2008, GENE, V409, P28, DOI 10.1016/j.gene.2007.10.036
   Cowley M, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001799
   Curley JP, 2005, FASEB J, V19, P1302, DOI 10.1096/fj.04-3216fje
   Curley JP, 2004, P ROY SOC B-BIOL SCI, V271, P1303, DOI 10.1098/rspb.2004.2725
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ferguson-Smith AC, 2011, NAT REV GENET, V12, P565, DOI 10.1038/nrg3032
   Frey WD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144459
   Frey WD, 2014, GENE, V540, P251, DOI 10.1016/j.gene.2014.02.056
   Garfield AS, 2011, NATURE, V469, P534, DOI 10.1038/nature09651
   Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828
   Glasgow E, 2005, MOL BRAIN RES, V137, P143, DOI 10.1016/j.molbrainres.2005.02.030
   Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120
   Jiang XL, 2010, J BIOL CHEM, V285, P8472, DOI 10.1074/jbc.M109.069450
   Keverne EB, 2008, FRONT NEUROENDOCRIN, V29, P398, DOI 10.1016/j.yfrne.2008.03.001
   [Anonymous], 2014, PLOS MED, DOI DOI 10.1371/JOURNAL.PONE.0083359
   Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186
   Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330
   MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1
   Mitchell KJ, 2010, NAT CELL BIOL, V12, P257, DOI 10.1038/ncb2025
   MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90040-W
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9
   Pannerec A, 2013, DEVELOPMENT, V140, P2879, DOI 10.1242/dev.089326
   PEDERSEN CA, 1979, P NATL ACAD SCI USA, V76, P6661, DOI 10.1073/pnas.76.12.6661
   Perera BPU, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119493
   Peters J, 2014, NAT REV GENET, V15, P517, DOI 10.1038/nrg3766
   Plasschaert RN, 2014, DEVELOPMENT, V141, P1805, DOI 10.1242/dev.101428
   Radford EJ, 2012, PLOS GENET, V8, P41, DOI 10.1371/journal.pgen.1002605
   Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172
   Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287
   Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897
   Rodriguez CI, 2000, NAT GENET, V25, P139
   SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0
   Thiaville MM, 2013, GENE, V512, P314, DOI 10.1016/j.gene.2012.10.005
   Varrault A, 2006, DEV CELL, V11, P711, DOI 10.1016/j.devcel.2006.09.003
   Wolf JB, 2006, PLOS BIOL, V4, P2238, DOI 10.1371/journal.pbio.0040380
   Wolf JB, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002085
   Yang Mu, 2008, Front Neurosci, V2, P186, DOI 10.3389/neuro.01.029.2008
   Ye A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108596
   Young LJ, 1997, HORM BEHAV, V31, P221, DOI 10.1006/hbeh.1997.1377
   Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393
NR 51
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2016
VL 12
IS 5
AR e1006053
DI 10.1371/journal.pgen.1006053
PG 20
WC Genetics & Heredity
SC Genetics & Heredity
GA DN6PH
UT WOS:000377197100053
PM 27187722
ER

PT J
AU Forostyak, O
   Butenko, O
   Anderova, M
   Forostyak, S
   Sykova, E
   Verkhratsky, A
   Dayanithi, G
AF Forostyak, Oksana
   Butenko, Olena
   Anderova, Miroslava
   Forostyak, Serhiy
   Sykova, Eva
   Verkhratsky, Alexei
   Dayanithi, Govindan
TI Specific profiles of ion channels and ionotropic receptors define
   adipose- and bone marrow derived stromal cells
SO STEM CELL RESEARCH
LA English
DT Article
DE Adipose derived stromal cells; Bone marrow stromal cell; Ca2+ signaling;
   Patch-clamp; Ion channels; Ionotropic receptors; Purinergic signaling;
   Ryanodine receptors; Vasopressin; Oxytocin
ID MESENCHYMAL STEM-CELLS; INTRACELLULAR CA2+ CONCENTRATION; RAT SUPRAOPTIC
   NUCLEUS; ARGININE-VASOPRESSIN; ELECTROPHYSIOLOGICAL PROPERTIES; NEURAL
   DIFFERENTIATION; MAGNOCELLULAR NEURONS; CALCIUM; OXYTOCIN; TISSUE
AB Adherent, fibroblastic cells from different tissues are thought to contain subsets of tissue-specific stem/progenitor cells (often called mesenchymal stem cells). These cells display similar cell surface characteristics based on their fibroblastic nature, but also exhibit differences in molecular phenotype, growth rate, and their ability to differentiate into various cell phenotypes. The mechanisms underlying these differences remain poorly understood. We analyzed Ca2+ signals and membrane properties in rat adipose-derived stromal cells (ADSCs) and bone marrow stromal cells (BMSCs) in basal conditions, and then following a switch into medium that contains factors known to modify their character. Modified ADSCs (mADSCs) expressed L-type Ca2+ channels whereas both L- and P/Q- channels were operational in mBMSCs. Both mADSCs and mBMSCs possessed functional endoplasmic reticulum Ca2+ stores, expressed ryanodine receptor-1 and -3, and exhibited spontaneous [Ca2+](i) oscillations. The mBMSCs expressed P2X(7) purinoceptors; the mADSCs expressed both P2X (but not P2X(7)) and P2Y (but not P2Y(1)) receptors. Both types of stromal cells exhibited [Ca2+](i) responses to vasopressin (AVP) and expressed V-1 type receptors. Functional oxytocin (OT) receptors were, in contrast, expressed only in modified ADSCs and BMSCs. AVP and OT-induced [Ca2+](i) responses were dose-dependent and were blocked by their respective specific receptor antagonists. Electrophysiological data revealed that passive ion currents dominated the membrane conductance in ADSCs and BMSCs. Medium modification led to a significant shift in the reversal potential of passive currents from -40 to -50mV in cells in basal to -80mV in modified cells. Hence membrane conductance was mediated by non-selective channels in cells in basal conditions, whereas in modified medium conditions, it was associated with K+-selective channels. Our results indicate that modification of ADSCs and BMSCs by alteration in medium formulation is associated with significant changes in their Ca2+ signaling and membrane properties. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Forostyak, Oksana; Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
   [Forostyak, Oksana; Anderova, Miroslava; Forostyak, Serhiy; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.
   [Butenko, Olena; Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220, Czech Republic.
   [Forostyak, Serhiy; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220, Czech Republic.
   [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, D-4417 Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Verkhratsky, Alexei] Basque Fdn Sci, Ikerbasque, Achucarro Ctr Neurosci, Bilbao 48011, Spain.
   [Verkhratsky, Alexei] Univ Nizhny Novgorod, Nizhnii Novgorod 603022, Russia.
   [Dayanithi, Govindan] Univ Montpellier, Inst Natl Sante & Rech Med, U1198, F-34095 Montpellier, France.
   [Dayanithi, Govindan] Ecole Prat Hautes Etud Sorbonne, 4-14 Rue Ferrus, F-75014 Paris, France.
   [Butenko, Olena] Neurosci Inst Cavalieri Ottolenghi, Reg Gonzole 10, I-10043 Turin, Italy.
RP Dayanithi, G (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
EM olena.butenko@unito.it; gdaya@univ-montp2.fr
RI Verkhratsky, Alexei/J-4527-2013
OI Verkhratsky, Alexei/0000-0003-2592-9898
FU Grant Agency of the Czech Republic [GACR 14-34077S, GACR P304/11/2373,
   GACR P304/12/G069, GACR 10504P]; European Regional Development Fund
   [CZ.2.16/3.1.00/21527]; Operational Programme Prague Competitiveness;
   Wellcome Trust; Alzheimer's research foundation (UK); Ministry of
   Education and Science of the Russian Federation [02.B.49.21.0003];
   Lobachevsky State University of Nizhny Novgorod [02.B.49.21.0003];
   Russian Scientific Foundation [14-15-00633]; Ministry of Education of
   the Russian Federation [RFMEFI57814X0079]
FX This work was supported by the grants GACR 14-34077S, GACR P304/11/2373,
   GACR P304/12/G069 and GACR 10504P from the Grant Agency of the Czech
   Republic. This publication is partly a result of the "Advanced
   Bioimaging of Living Tissues" project, registration number
   #CZ.2.16/3.1.00/21527, which was financed from the budget of the
   European Regional Development Fund and public budgets of the Czech
   Republic through the Operational Programme Prague Competitiveness. AV
   was supported by the Wellcome Trust, by the Alzheimer's research
   foundation (UK) and by the grant (agreement from August 27, 2013 no.
   02.B.49.21.0003) between The Ministry of Education and Science of the
   Russian Federation and Lobachevsky State University of Nizhny Novgorod,
   by the grant of the Russian Scientific Foundation no. 14-15-00633 and by
   the Ministry of Education of the Russian Federation, unique identity
   number RFMEFI57814X0079. Govindan Dayanithi belongs to the "Centre
   National de la Recherche Scientifique-The French Ministry of Research
   and Higher Education-Paris", France. We thank David Arboleda and Lenka
   Baranovicova for their participation in preliminary experiments. We are
   grateful to Kip Allan Bauersfeld, IEM ASCR, for critical reading and
   helpful comments on the manuscript.
CR Anderova M, 2006, J NEUROBIOL, V66, P1084, DOI 10.1002/neu.20278
   Arboleda D, 2011, CELL MOL NEUROBIOL, V31, P1113, DOI 10.1007/s10571-011-9712-3
   Bai XW, 2007, AM J PHYSIOL-CELL PH, V293, pC1539, DOI 10.1152/ajpcell.00089.2007
   BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0
   Bentley DC, 2014, AM J PHYSIOL-ENDOC M, V307, pE161, DOI 10.1152/ajpendo.00446.2013
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Choudhery MS, 2013, CYTOTHERAPY, V15, P330, DOI 10.1016/j.jcyt.2012.11.010
   Cocks G, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt220
   Coppi E, 2007, STEM CELLS, V25, P1840, DOI 10.1634/stemcells.2006-0669
   Dayanith G, 2008, J PHYSIOL PHARMACOL, V59, P7
   Dayanithi G, 1996, J PHYSIOL-LONDON, V490, P713
   Dayanithi G, 2006, CELL CALCIUM, V39, P237, DOI 10.1016/j.ceca.2005.10.011
   Dayanithi G, 2000, EXP PHYSIOL, V85, p75S, DOI 10.1111/j.1469-445X.2000.tb00010.x
   Dayanithi G, 2012, CELL CALCIUM, V51, P293, DOI 10.1016/j.ceca.2012.02.002
   Deng XL, 2006, BIOCHEM BIOPH RES CO, V348, P301, DOI 10.1016/j.bbrc.2006.07.054
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008-0127
   Florian M, 2010, ENDOCRINOLOGY, V151, P482, DOI 10.1210/en.2009-0624
   Forostyak O, 2016, CELL CALCIUM, V59, P57, DOI 10.1016/j.ceca.2016.02.001
   Forostyak O, 2013, STEM CELLS DEV, V22, P1506, DOI 10.1089/scd.2012.0624
   Forostyak S, 2011, CYTOTHERAPY, V13, P1036, DOI 10.3109/14653249.2011.592521
   Fox LE, 2010, STEM CELLS DEV, V19, P1831, DOI 10.1089/scd.2010.0089
   Fujihara H, 2009, ENDOCRINOLOGY, V150, P5633, DOI 10.1210/en.2009-0796
   Gassanov N, 2007, J BIOL CHEM, V282, P11255, DOI 10.1071/jbc.M610769200
   Glaser T, 2012, PURINERG SIGNAL, V8, P523, DOI 10.1007/s11302-011-9282-3
   Heubach JF, 2004, J PHYSIOL-LONDON, V554, P659, DOI 10.1113/jphysiol.2003.055806
   Hussy N, 2001, J NEUROSCI, V21, P7110
   Ichikawa J, 2009, J CELL PHYSIOL, V219, P372, DOI 10.1002/jcp.21680
   Jafarzadeh N, 2014, NEUROSCI LETT, V564, P105, DOI 10.1016/j.neulet.2014.02.012
   Jang S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-25
   Kawano S, 2006, CELL CALCIUM, V39, P313, DOI 10.1016/j.ceca.2005.11.008
   Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143-4160(03)00069-1
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143-4160(02)00124-0
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342
   Komori Y, 2010, CELL CALCIUM, V48, P324, DOI 10.1016/j.ceca.2010.10.002
   Kotova PD, 2014, BBA-MOL CELL RES, V1843, P1899, DOI 10.1016/j.bbamcr.2014.05.002
   LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275
   Lanner JT, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003996
   Li GR, 2005, STEM CELLS, V23, P371, DOI 10.1634/stemcells.2004-0213
   Li GR, 2006, STEM CELLS, V24, P1519, DOI 10.1634/stemcells.2005-0307
   Moriya T, 2015, CELL CALCIUM, V57, P25, DOI 10.1016/j.ceca.2014.11.003
   Moriya T, 2012, BRAIN RES, V1483, P1, DOI 10.1016/j.brainres.2012.08.028
   Nbaheen M., 2013, STEM CELL REV, V9, P32
   Neprasova H, 2007, PFLUG ARCH EUR J PHY, V453, P839, DOI 10.1007/s00424-006-0151-9
   Noiseux N, 2012, ENDOCRINOLOGY, V153, P5361, DOI 10.1210/en.2012-1402
   Resende RR, 2010, STEM CELLS DEV, V19, P379, DOI 10.1089/scd.2008.0289
   Safford KM, 2004, EXP NEUROL, V187, P319, DOI 10.1016/j.expneurol.2004.01.027
   Sauer H, 2011, J CELL PHYSIOL, V226, P1642, DOI 10.1002/jcp.22495
   Scicchitano BM, 2005, MOL BIOL CELL, V16, P3632, DOI 10.1091/mbc.E05-01-0055
   Shinoda K, 2015, NAT MED, V21, P389, DOI 10.1038/nm.3819
   Suzuki H, 2009, J NEUROSCI, V29, P13182, DOI 10.1523/JNEUROSCI.2624-09.2009
   Syed N.-i.-H., 2012, WIRES MEMBR TRANSP S, V1, P16, DOI DOI 10.1002/WMTS.1
   Todoroki M, 2010, STRESS, V13, P281, DOI 10.3109/10253890903383406
   Tran TDN, 2015, MOL CELL ENDOCRINOL, V406, P1, DOI 10.1016/j.mce.2015.02.009
   Ueta Y, 2008, J NEUROENDOCRINOL, V20, P660, DOI 10.1111/j.1365-2826.2008.01706.x
   Viero C, 2006, CELL CALCIUM, V40, P383, DOI 10.1016/j.ceca.2006.04.007
   Viero Cedric, 2014, Front Cell Dev Biol, V2, P36, DOI 10.3389/fcell.2014.00036
   Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x
   Wen L, 2012, BIOCHEM BIOPH RES CO, V424, P439, DOI 10.1016/j.bbrc.2012.06.128
   WILLINGHAM MC, 1975, J CELL BIOL, V67, P146, DOI 10.1083/jcb.67.1.146
   Yang XD, 2003, J CARDIOVASC PHARM, V42, P132, DOI 10.1097/00005344-200307000-00020
   Ye B, 2010, PHYSIOL RES, V59, P323
   Zhu TQ, 2015, CELL MOL NEUROBIOL, V35, P255, DOI 10.1007/s10571-014-0120-3
   Zippel N, 2012, STEM CELLS DEV, V21, P884, DOI 10.1089/scd.2010.0576
NR 63
TC 0
Z9 0
U1 6
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2016
VL 16
IS 3
BP 622
EP 634
DI 10.1016/j.scr.2016.03.010
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA DN9RD
UT WOS:000377416900012
PM 27062357
ER

PT J
AU Kozai, K
   Tokuyama, S
   Szostek, AZ
   Toishi, Y
   Tsunoda, N
   Taya, K
   Sakatani, M
   Takahashi, M
   Nambo, Y
   Skarzynski, DJ
   Yamamoto, Y
   Kimura, K
   Okuda, K
AF Kozai, Keisuke
   Tokuyama, Shota
   Szostek, Anna Z.
   Toishi, Yuko
   Tsunoda, Nobuo
   Taya, Kazuyoshi
   Sakatani, Miki
   Takahashi, Masashi
   Nambo, Yasuo
   Skarzynski, Dariusz J.
   Yamamoto, Yuki
   Kimura, Koji
   Okuda, Kiyoshi
TI Evidence for a PGF(2 alpha) auto-amplification system in the endometrium
   in mares
SO REPRODUCTION
LA English
DT Article
ID EQUINE CORPORA-LUTEA; CORPUS-LUTEUM; ESTROUS-CYCLE; OXYTOCIN RECEPTOR;
   STROMAL CELLS; INDUCED LUTEOLYSIS; WHOLE-BLOOD; HALF-LIFE; IN-VITRO;
   PROSTAGLANDIN-F2-ALPHA
AB In mares, prostaglandin F-2 alpha (PGF(2 alpha)) secreted from the endometrium is a major luteolysin. Some domestic animals have an auto-amplification system in which PGF(2 alpha) can stimulate its own production. Here, we investigated whether this is also the case in mares. In an in vivo study, mares at the mid-luteal phase (days 6-8 of estrous cycle) were injected i.m. with cloprostenol (250 mu g) and blood samples were collected at fixed intervals until 72 h after treatment. Progesterone (P-4) concentrations started decreasing 45 min after the injection and continued to decrease up to 24 h (P < 0.05). In turn, 13,14-dihydro-15-keto-PGF(2 alpha) (PGFM) metabolite started to increase 4h after an injection and continued to increase up to 72 h (P < 0.05). PGF receptor (PTGFR) mRNA expression in the endometrium was significantly higher in the late luteal phase than in the early and regressed luteal phases (P < 0.05). In vitro, PGF(2 alpha) significantly stimulated (P < 0.05) PGF(2 alpha) production by endometrial tissues and endometrial epithelial and stromal cells and significantly increased (P < 0.05) the mRNA expression of prostaglandin-endoperoxide synthase-2 (PTGS2), an enzyme involved in PGF(2 alpha) synthesis in endometrial cell. These findings strongly suggest the existence of an endometrial PGF(2 alpha) auto-amplification system in mares.
C1 [Kozai, Keisuke; Tokuyama, Shota; Szostek, Anna Z.; Yamamoto, Yuki; Kimura, Koji; Okuda, Kiyoshi] Okayama Univ, Grad Sch Environm & Life Sci, Reprod Physiol Lab, Okayama, Japan.
   [Szostek, Anna Z.; Skarzynski, Dariusz J.] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Reprod Immunol, Olsztyn, Poland.
   [Toishi, Yuko; Tsunoda, Nobuo; Taya, Kazuyoshi] Shadai Corp, Shiraoi, Hokkaido, Japan.
   [Sakatani, Miki; Takahashi, Masashi] Natl Agr & Food Res Org NARO, Kyushu Okinawa Agr Res Ctr, Kumamoto, Japan.
   [Takahashi, Masashi] Hokkaido Univ, Dept Anim Sci, Sapporo, Hokkaido 060, Japan.
   [Nambo, Yasuo] Japan Racing Assoc, Equine Sci Div, Hidaka Training & Res Ctr, Shiraoi, Hokkaido, Japan.
   [Nambo, Yasuo; Okuda, Kiyoshi] Obihiro Univ Agr & Vet Med, Obihiro, Hokkaido 080, Japan.
RP Okuda, K (reprint author), Okayama Univ, Grad Sch Environm & Life Sci, Reprod Physiol Lab, Okayama, Japan.; Okuda, K (reprint author), Obihiro Univ Agr & Vet Med, Obihiro, Hokkaido 080, Japan.
EM kokuda@okayama-u.ac.jp
FU Japan Society for the Promotion of Science (JSPS); Polish Academy of
   Sciences; Equine Research Institute, Japan Racing Association;
   Foundation of Polish Science (FNP, Program Start, Poland)
FX This study was supported by the Japanese-Polish Joint Research Project
   under an agreement between the Japan Society for the Promotion of
   Science (JSPS) and Polish Academy of Sciences and was supported in part
   by the Equine Research Institute, Japan Racing Association. A Szostek
   was supported by Domestic Grants for Young Scientists from Foundation of
   Polish Science (FNP, Program Start, Poland) and a JSPS post-doctoral
   fellow (P-14082).
CR Atli MO, 2010, ANIM REPROD SCI, V122, P124, DOI 10.1016/j.anireprosci.2010.08.007
   Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223
   Beg MA, 2005, ANIM REPROD SCI, V90, P273, DOI 10.1016/j.anireprosci.2005.02.008
   Betteridge KJ, 1985, EQUINE VET J S, V3, P25
   de Ruijter-Villani M, 2015, REPROD FERT DEVELOP, V27, P834, DOI 10.1071/RD13381
   Diaz FJ, 2000, BIOL REPROD, V63, P1504, DOI 10.1095/biolreprod63.5.1504
   DOUGLAS RH, 1973, J ANIM SCI, V37, P990
   Duong HT, 2012, REPROD DOMEST ANIM, V47, P238, DOI 10.1111/j.1439-0531.2011.01835.x
   ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9
   Ferreira-Dias G, 2006, DOMEST ANIM ENDOCRIN, V30, P247, DOI 10.1016/j.domaniend.2005.07.007
   FORTIER MA, 1988, J REPROD FERTIL, V83, P239
   Franklin KJ, 1989, BIOL REPROD S1, V40
   GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070
   Ginther OJ, 2008, REPROD FERT DEVELOP, V20, P684, DOI 10.1071/RD08077
   Ginther OJ, 2012, THERIOGENOLOGY, V77, P1731, DOI 10.1016/j.theriogenology.2012.01.001
   Ginther OJ, 2009, THERIOGENOLOGY, V72, P1111, DOI 10.1016/j.theriogenology.2009.06.024
   Ginther OJ, 1992, REPROD BIOL MARE BAS, P233
   GOFF AK, 1984, THERIOGENOLOGY, V21, P887, DOI 10.1016/0093-691X(84)90382-0
   Guthrie H D, 1979, Adv Exp Med Biol, V112, P627
   Handler J, 2004, THERIOGENOLOGY, V61, P1573, DOI 10.1016/j.theriogenology.2003.09.005
   KIMBALL FA, 1977, PROSTAG OTH LIPID M, V13, P553, DOI 10.1016/0090-6980(77)90032-6
   KING SS, 1987, J EQUINE VET SCI, V7, P303, DOI 10.1016/S0737-0806(87)80050-3
   KNICKERBOCKER JJ, 1988, DOMEST ANIM ENDOCRIN, V5, P91, DOI 10.1016/0739-7240(88)90011-2
   Kotwica G, 1999, ACTA VET HUNG, V47, P249
   Kotwica J, 1999, RES VET SCI, V66, P1, DOI 10.1053/rvsc.1998.0230
   Kozai K, 2014, J REPROD DEVELOP, V60, P150, DOI 10.1262/jrd.2013-120
   Kumagai A, 2014, MOL REPROD DEV, V81, P646, DOI 10.1002/mrd.22332
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7
   Lee HY, 2007, J ENDOCRINOL, V193, P127, DOI 10.1677/joe.1.06975
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McCracken JA, 1999, PHYSIOL REV, V79, P263
   MOUILLAC B, 1995, J BIOL CHEM, V270, P25771
   Neely D P, 1979, J Reprod Fertil Suppl, P181
   Paccamonti DL, 1999, EQUINE VET J, V31, P285
   Penrod LV, 2013, ANIM REPROD SCI, V139, P69, DOI 10.1016/j.anireprosci.2013.04.010
   Postina R, 1996, J BIOL CHEM, V271, P31593
   Rexroad C E Jr, 1979, Adv Exp Med Biol, V112, P639
   Sales KJ, 2008, MOL CELL ENDOCRINOL, V285, P51, DOI 10.1016/j.mce.2008.01.016
   Shand N, 2000, J REPROD FERTIL S, V56, P271
   Shrestha HK, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100776
   Siemieniuch MJ, 2011, ANIM REPROD SCI, V123, P89, DOI 10.1016/j.anireprosci.2010.10.015
   Skarzynski DJ, 2003, BIOL REPROD, V68, P1674, DOI 10.1095/biolreprod.102.008573
   Smith WL, 1996, J BIOL CHEM, V271, P33157
   Stout T. A., 2000, J REPROD FERTILITY S, V56, P281
   Sugie Y, 2011, CLIN LAB, V57, P99
   Szostek AZ, 2012, THERIOGENOLOGY, V77, P1698, DOI 10.1016/j.theriogenology.2011.12.015
   Szostek AZ, 2014, CYTOKINE, V67, P85, DOI 10.1016/j.cyto.2014.02.005
   Szostek AZ, 2014, J ENDOCRINOL, V220, P263, DOI 10.1530/JOE-13-0185
   Szostek AZ, 2013, BIOL REPROD, V89, P1
   Taniguchi K, 2010, REPRODUCTION, V140, P885, DOI 10.1530/REP-10-0240
   THIBODEAUX JK, 1991, HUM REPROD, V6, P751
   Toishi Yuko, 2013, Journal of Equine Science, V24, P47, DOI 10.1294/jes.24.47
   Tsai SJ, 1997, BIOL REPROD, V57, P1016, DOI 10.1095/biolreprod57.5.1016
   Uenoyama Y, 1997, BIOL REPROD, V57, P723, DOI 10.1095/biolreprod57.4.723
   Utt MD, 2007, ANIM REPROD SCI, V97, P63, DOI 10.1016/j.anireprosci.2006.01.009
   Vanderwall DK, 1998, J REPROD FERTIL, V112, P337
   Wade DE, 1996, DOMEST ANIM ENDOCRIN, V13, P383, DOI 10.1016/0739-7240(96)00069-0
   WATSON ED, 1992, J REPROD FERTIL, V95, P269
   Watson E. D., 2000, J REPROD FERTIL S, V56, P289
   Xu C, 2013, J CLIN ENDOCR METAB, V98, P2975, DOI 10.1210/jc.2012-2829
NR 60
TC 0
Z9 0
U1 1
U2 1
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD MAY
PY 2016
VL 151
IS 5
BP 517
EP 526
DI 10.1530/REP-15-0617
PG 10
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA DM9NO
UT WOS:000376693200009
PM 26908917
ER

PT J
AU Scheele, D
   Plota, J
   Stoffel-Wagner, B
   Maier, W
   Hurlemann, R
AF Scheele, Dirk
   Plota, Jessica
   Stoffel-Wagner, Birgit
   Maier, Wolfgang
   Hurlemann, Rene
TI Hormonal contraceptives suppress oxytocin-induced brain reward responses
   to the partner's face
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE fMRI; hormonal contraception; oxytocin; pair-bonding; women
ID FEMALE INTRASEXUAL COMPETITION; INTRANASAL OXYTOCIN; FACIAL
   ATTRACTIVENESS; SOCIAL-DEVELOPMENT; BREAST-CANCER; ROMANTIC LOVE; LIFE
   EVENTS; WOMEN; RECEPTOR; PREFERENCES
AB The hypothalamic peptide oxytocin (OXT) has been identified as a key modulator of pair-bonding in men, but its effects in women are still elusive. Moreover, there is substantial evidence that hormonal contraception (HC) influences partner preferences and sexual satisfaction, which constitute core domains of OXT function. We thus hypothesized that OXT effects on partner-related behavioral and neural responses could be significantly altered in women using HC. In this functional magnetic resonance imaging study involving 40 pair-bonded women, 21 of whom were using HC, we investigated whether a 24-IU nasal dose of OXT would modulate brain reward responses evoked by the romantic partner's face relative to the faces of familiar and unfamiliar people. Treatment with OXT increased the perceived attractiveness of the partner relative to other men, which was paralleled by elevated responses in reward-associated regions, including the nucleus accumbens. These effects of OXT were absent in women using HC. Our results confirm and extend previous findings in men that OXT interacts with the brain reward system to reinforce partner value representations, indicating a common OXT-dependent mechanism underlying partner attraction in both sexes. This mechanism may be disturbed in women using HC, suggesting that gonadal steroids could alter partner-specific OXT effects.
C1 [Scheele, Dirk; Plota, Jessica; Maier, Wolfgang; Hurlemann, Rene] Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany.
   [Scheele, Dirk; Plota, Jessica; Hurlemann, Rene] Univ Bonn, Div Med Psychol, D-53105 Bonn, Germany.
   [Stoffel-Wagner, Birgit] Univ Bonn, Dept Clin Chem & Clin Pharmacol, D-53105 Bonn, Germany.
   [Maier, Wolfgang] German Ctr Neurodegenerat Dis DZNE, D-53175 Bonn, Germany.
RP Scheele, D (reprint author), Univ Bonn, Div Med Psychol, D-53105 Bonn, Germany.
EM dirk-scheele@gmx.de
FU Starting Independent Researcher Grant ('NEMO-Neuromodulation of
   Emotion') - Ministry of Innovation, Science, Research & Technology of
   the German State of North Rhine-Westphalia (MIWFT); Starting Independent
   Researcher Grant ('NEMO-Neuromodulation of Emotion') - University of
   Bonn
FX R.H. was supported by a Starting Independent Researcher Grant
   ('NEMO-Neuromodulation of Emotion') jointly provided by the Ministry of
   Innovation, Science, Research & Technology of the German State of North
   Rhine-Westphalia (MIWFT) and the University of Bonn.
CR Abler B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054447
   Acevedo BP, 2012, SOC COGN AFFECT NEUR, V7, P145, DOI 10.1093/scan/nsq092
   Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1
   Arndorfer CL, 2008, J YOUTH ADOLESCENCE, V37, P1059, DOI 10.1007/s10964-008-9311-x
   Aron A, 2005, J NEUROPHYSIOL, V94, P327, DOI 10.1152/jn.00838.2004
   Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003
   Behnia B, 2014, HORM BEHAV, V65, P308, DOI 10.1016/j.yhbeh.2014.01.009
   CARMICHAEL MS, 1994, ARCH SEX BEHAV, V23, P59, DOI 10.1007/BF01541618
   CHIODERA P, 1991, METABOLISM, V40, P1226, DOI 10.1016/0026-0495(91)90220-Q
   Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071
   Cobey KD, 2013, EVOL HUM BEHAV, V34, P294, DOI 10.1016/j.evolhumbehav.2013.04.003
   Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016
   Feldman R, 2015, TRENDS NEUROSCI, V38, P387, DOI 10.1016/j.tins.2015.04.004
   Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100
   Fisher ML, 2004, P ROY SOC B-BIOL SCI, V271, pS283, DOI 10.1098/rsbl.2004.0160
   Geary DC, 2001, HUM NATURE-INT BIOS, V12, P299, DOI 10.1007/s12110-001-1001-2
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Goossens L, 2009, HUM BRAIN MAPP, V30, P3332, DOI 10.1002/hbm.20755
   Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   Hurlemann R, 2016, BIOL PSYCHIAT, V79, P185, DOI 10.1016/j.biopsych.2015.05.013
   Keyes KM, 2014, AM J PSYCHIAT, V171, P864, DOI 10.1176/appi.ajp.2014.13081132
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Lillberg K, 2003, AM J EPIDEMIOL, V157, P415, DOI 10.1093/aje/kwg002
   Lin Y, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-53
   Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P1431, DOI 10.1016/j.psyneuen.2012.01.011
   Little AC, 2013, PSYCHONEUROENDOCRINO, V38, P1777, DOI 10.1016/j.psyneuen.2013.02.014
   Little AC, 2012, PSYCHONEUROENDOCRINO, V37, P999, DOI 10.1016/j.psyneuen.2011.11.007
   Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101
   LUNDIN T, 1984, BRIT J PSYCHIAT, V144, P84, DOI 10.1192/bjp.144.1.84
   Lynn SK, 2014, PSYCHIAT RES, V219, P198, DOI 10.1016/j.psychres.2014.04.031
   Morhenn V, 2012, ALTERN THER HEALTH M, V18, P11
   Mostofsky E, 2012, CIRCULATION, V125, P491, DOI 10.1161/CIRCULATIONAHA.111.061770
   Numan M, 2016, HORM BEHAV, V77, P98, DOI 10.1016/j.yhbeh.2015.05.015
   Preckel K, 2015, SOC COGN AFFECT NEUR, V10, P987, DOI 10.1093/scan/nsu147
   Preckel K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00191
   QuinonesJenab V, 1997, NEUROENDOCRINOLOGY, V65, P9, DOI 10.1159/000127160
   Riem MME, 2012, NEUROPSYCHOPHARMACOL, V37, P1257, DOI 10.1038/npp.2011.313
   Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006
   Rilling JK, 2014, SCIENCE, V345, P771, DOI 10.1126/science.1252723
   Rilling JK, 2014, PSYCHONEUROENDOCRINO, V39, P237, DOI 10.1016/j.psyneuen.2013.09.022
   Roberts SC, 2008, P ROY SOC B-BIOL SCI, V275, P2715, DOI 10.1098/rspb.2008.0825
   Roberts SC, 2012, P ROY SOC B-BIOL SCI, V279, P1430, DOI 10.1098/rspb.2011.1647
   Rupp HA, 2013, HORM BEHAV, V63, P114, DOI 10.1016/j.yhbeh.2012.10.007
   Russell VM, 2014, P NATL ACAD SCI USA, V111, P17081, DOI 10.1073/pnas.1414784111
   Scheele D, 2015, EUR NEUROPSYCHOPHARM, V25, P1817, DOI 10.1016/j.euroneuro.2015.05.009
   Scheele D, 2014, HUM BRAIN MAPP, V35, P6067, DOI 10.1002/hbm.22605
   Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78
   Scheele D, 2013, P NATL ACAD SCI USA, V110, P20308, DOI 10.1073/pnas.1314190110
   Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012
   Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021
   SHAPIRO LE, 1992, ANN NY ACAD SCI, V652, P448, DOI 10.1111/j.1749-6632.1992.tb34380.x
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Sherman DK, 2009, PROG BRAIN RES, V178, P227, DOI [10.1016/S0079-6123(09)17816-0, 10.1016/S0079-6123(09)17817-2]
   Wallwiener CW, 2010, J SEX MED, V7, P2139, DOI 10.1111/j.1743-6109.2010.01742.x
   Yao SX, 2014, INT J NEUROPSYCHOPH, V17, P1785, DOI 10.1017/S146114571400090X
   Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327
   Young LJ, 1998, NEUROREPORT, V9, P933, DOI 10.1097/00001756-199803300-00031
NR 58
TC 1
Z9 1
U1 7
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD MAY
PY 2016
VL 11
IS 5
BP 767
EP 774
DI 10.1093/scan/nsv157
PG 8
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA DM9AH
UT WOS:000376655100008
PM 26722017
ER

PT J
AU McDonald, NM
   Baker, JK
   Messinger, DS
AF McDonald, Nicole M.
   Baker, Jason K.
   Messinger, Daniel S.
TI Oxytocin and Parent-Child Interaction in the Development of Empathy
   Among Children at Risk for Autism
SO DEVELOPMENTAL PSYCHOLOGY
LA English
DT Article
DE oxytocin receptor gene; parent-child interaction; empathy; autism risk
ID RECEPTOR GENE OXTR; MUTUALLY RESPONSIVE ORIENTATION; SIBLINGS RESEARCH
   CONSORTIUM; SPECTRUM DISORDER; DIFFERENTIAL SUSCEPTIBILITY; SOCIAL
   COGNITION; INFANT FACES; 5-HTT GENES; ASSOCIATION; HUMANS
AB This longitudinal study investigated whether variation in the oxytocin receptor gene (OXTR) and early parent-child interactions predicted later empathic behavior in 84 toddlers at high or low familial risk for autism spectrum disorder. Two well-studied OXTR single-nucleotide polymorphisms, rs53576 and rs2254298, were examined. Parent-child interaction was measured at 15 and 18 months of age during free play sessions. Empathy was measured at 24 and 30 months using a response to parental distress paradigm. While there was no direct association between parent-child interaction quality or OXTR and empathy, rs53576 moderated the relation between interaction quality and empathy. Results suggest that the interplay between OXTR and early parent-child interactions predicts individual differences in empathy in children at varying risk for atypical social development. Findings are consonant with a differential susceptibility model in which an OXTR variant may increase the social salience of interaction processes for specific allele carriers. These results increase our understanding of predictors of empathy development in young children with a wide range of social outcomes.
C1 [McDonald, Nicole M.; Messinger, Daniel S.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
   [Baker, Jason K.] Calif State Univ Fullerton, Dept Child & Adolescent Studies, Fullerton, CA 92634 USA.
RP McDonald, NM (reprint author), Yale Univ, Sch Med, Ctr Child Study, 230 South Frontage Rd, New Haven, CT 06520 USA.
EM n.mcdonald@yale.edu
FU National Institute of Child Health and Development [R01HD057284,
   R01HD047417]; National Institute of General Medical Sciences
   [R01GM105004]; Fred C. and Helen Donn Flipse Research Support Fund,
   Department of Psychology, University of Miami
FX The research reported in this article was supported by grants from the
   National Institute of Child Health and Development (R01HD057284 and
   R01HD047417), the National Institute of General Medical Sciences
   (R01GM105004), and the Fred C. and Helen Donn Flipse Research Support
   Fund, Department of Psychology, University of Miami. We thank the
   families who participated in this research.
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Apter-Levy Y, 2013, AM J PSYCHIAT, V170, P1161, DOI 10.1176/appi.ajp.2013.12121597
   Baker JK, 2015, J AUTISM DEV DISORD, V45, P4140, DOI 10.1007/s10803-015-2528-0
   Baker JK, 2010, J AUTISM DEV DISORD, V40, P988, DOI 10.1007/s10803-010-0948-4
   Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Bakermans-Kranenburg MJ, 2014, PSYCHIAT GENET, V24, P45, DOI 10.1097/YPG.0b013e3283643684
   Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002
   Bartz JA, 2010, PSYCHOL SCI, V21, P1426, DOI 10.1177/0956797610383439
   Belsky J, 2007, CURR DIR PSYCHOL SCI, V16, P300, DOI 10.1111/j.1467-8721.2007.00525.x
   Bhandari R, 2014, PHYSIOL BEHAV, V131, P123, DOI 10.1016/j.physbeh.2014.04.028
   Cramer D, 2003, J PSYCHOL, V137, P85
   Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Ebstein RP, 2009, ANN NY ACAD SCI, V1167, P87, DOI 10.1111/j.1749-6632.2009.04541.x
   EISENBERG N, 1987, PSYCHOL BULL, V101, P91, DOI 10.1037/0033-2909.101.1.91
   Feldman R, 2007, AM J ORTHOPSYCHIAT, V77, P582, DOI 10.1037/0002-9432.77.4.582
   Feldman R, 2012, BIOL PSYCHIAT, V72, P175, DOI 10.1016/j.biopsych.2011.12.025
   Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x
   Fenning RM, 2012, J FAM PSYCHOL, V26, P411, DOI 10.1037/a0028287
   Fenning RM, 2011, CHILD DEV, V82, P717, DOI 10.1111/j.1467-8624.2010.01569.x
   Furman DJ, 2011, PSYCHONEUROENDOCRINO, V36, P891, DOI 10.1016/j.psyneuen.2010.12.004
   Garner PW, 2003, INF MENTAL HLTH J, V24, P580, DOI 10.1002/imhj.10076
   Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3
   Gottlieb G, 2007, DEVELOPMENTAL SCI, V10, P1, DOI 10.1111/j.1467-7687.2007.00556.x
   Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hutman T, 2010, J CHILD PSYCHOL PSYC, V51, P1010, DOI 10.1111/j.1469-7610.2010.02270.x
   Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019
   INOUE T, 1994, J BIOL CHEM, V269, P32451
   Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001
   Knafo A, 2008, EMOTION, V8, P737, DOI 10.1037/a0014179
   Kochanska G, 2005, J CHILD PSYCHOL PSYC, V46, P19, DOI 10.1111/j.1469-7610.2004.00348.x
   Kochanska G, 2002, CURR DIR PSYCHOL SCI, V11, P191, DOI 10.1111/1467-8721.00198
   Kochanska G, 1999, INFANT BEHAV DEV, V22, P249, DOI 10.1016/S0163-6383(99)00009-0
   Koni AC, 2011, INT J OBESITY, V35, pS113, DOI 10.1038/ijo.2011.43
   Laursen HR, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00423
   Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087
   Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140
   Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947
   LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145
   Lucht MJ, 2013, NORD J PSYCHIAT, V67, P15, DOI 10.3109/08039488.2012.700731
   MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615
   Marsh AA, 2012, PSYCHOPHARMACOLOGY, V224, P469, DOI 10.1007/s00213-012-2775-0
   McDonald NM, 2012, J AUTISM DEV DISORD, V42, P1566, DOI 10.1007/s10803-011-1390-y
   McElwain NL, 2008, CHILD DEV, V79, P1891, DOI 10.1111/j.1467-8624.2008.01232.x
   McQuaid RJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00128
   Messinger D, 2013, J AM ACAD CHILD PSY, V52, P300, DOI 10.1016/j.jaac.2012.12.011
   Michalska Kalina J, 2014, Front Behav Neurosci, V8, P21, DOI 10.3389/fnbeh.2014.00021
   Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0
   Montag C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051882
   Moons WG, 2014, EMOTION, V14, P562, DOI 10.1037/a0035503
   Moreno AJ, 2008, SOC DEV, V17, P613, DOI 10.1111/j.1467-9507.2007.00441.x
   Mullen EM, 1995, MULLEN SCALES EARLY
   NICHD Early Child Care Research Network, 2003, INFANT BEHAV DEV, V26, P345
   Ozonoff S, 2011, PEDIATRICS, V128, pE488, DOI 10.1542/peds.2010-2825
   Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111
   Robinson J. L., 1994, SOCIAL DEV, V3, P124
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   Rueda P, 2015, EUR J DEV PSYCHOL, V12, P85, DOI 10.1080/17405629.2014.950221
   Rutter M., 2003, SOCIAL COMMUNICATION
   Schneiderman I, 2014, SOC COGN AFFECT NEUR, V9, P1524, DOI 10.1093/scan/nst142
   Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009
   SIGMAN MD, 1992, CHILD DEV, V63, P796, DOI 10.1111/j.1467-8624.1992.tb01662.x
   Slane MM, 2014, DEV COGN NEUROS-NETH, V9, P160, DOI 10.1016/j.dcn.2014.04.001
   Smearman EL, 2015, DEV PSYCHOPATHOL, V27, P309, DOI 10.1017/S0954579414000649
   Smith A, 2009, PSYCHOL REC, V59, P489
   Smith KE, 2014, SOC NEUROSCI-UK, V9, P1, DOI 10.1080/17470919.2013.863223
   Sturge-Apple ML, 2012, J FAM PSYCHOL, V26, P431, DOI 10.1037/a0028302
   Tabak Benjamin A, 2013, Front Neurosci, V7, P199, DOI 10.3389/fnins.2013.00199
   Tansey KE, 2010, NEUROSCI LETT, V474, P163, DOI 10.1016/j.neulet.2010.03.035
   Thompson RJ, 2011, PSYCHONEUROENDOCRINO, V36, P144, DOI 10.1016/j.psyneuen.2010.07.003
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
   YIRMIYA N, 1992, CHILD DEV, V63, P150, DOI 10.1111/j.1467-8624.1992.tb03603.x
   Young SK, 1999, DEV PSYCHOL, V35, P1189, DOI 10.1037//0012-1649.35.5.1189
   ZAHNWAXLER C, 1992, DEV PSYCHOL, V28, P1038, DOI 10.1037//0012-1649.28.6.1038
   ZAHNWAXLER C, 1992, DEV PSYCHOL, V28, P126, DOI 10.1037/0012-1649.28.1.126
   Zhou Q, 2002, CHILD DEV, V73, P893, DOI 10.1111/1467-8624.00446
NR 80
TC 0
Z9 0
U1 10
U2 10
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0012-1649
EI 1939-0599
J9 DEV PSYCHOL
JI Dev. Psychol.
PD MAY
PY 2016
VL 52
IS 5
BP 735
EP 745
DI 10.1037/dev0000104
PG 11
WC Psychology, Developmental
SC Psychology
GA DM2UP
UT WOS:000376203800004
PM 26998571
ER

PT J
AU Ugwu, IA
   Oluwasola, TA
   Enabor, OO
   Anayochukwu-Ugwu, NN
   Adeyemi, AB
   Olayemi, OO
AF Ugwu, Innocent A.
   Oluwasola, Timothy A.
   Enabor, Obehi O.
   Anayochukwu-Ugwu, Ngozi N.
   Adeyemi, Abolaji B.
   Olayemi, Oladapo O.
TI Randomized controlled trial comparing 200 mu g and 400 mu g sublingual
   misoprostol for prevention of primary postpartum hemorrhage
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Adverse effects; Misoprostol; Postpartum hemorrhage; Sublingual
ID ORAL MISOPROSTOL; 3RD STAGE; OXYTOCIN; MANAGEMENT; LABOR; RISK
AB Objective: To compare efficacy and adverse effects of 200 mu g and 400 mu g misoprostol for prevention of postpartum hemorrhage (PPH). Methods: In a randomized control trial, women with term singleton pregnancies in active labor attending University College Hospital, Ibadan, Nigeria, were enrolled between July 2011 and February 2012. Participants were randomly assigned using random numbers (block size four) to receive 200 mu g or 400 mu g sublingual misoprostol after delivery of the anterior shoulder, alongside intravenous oxytocin. Investigators were masked to group assignment, but participants were not. The primary outcomes were blood loss up to 1 h after delivery, PPH (blood loss >= 500 mL), and adverse effects. Results: Overall, 62 patients were assigned to each group. No significant differences between the 200-mu g and 400-mu g groups were recorded in mean peripartum blood loss (307 +/- 145 mL vs 296 +/- 151 mL; P = 0.679) and PPH occurrence (5 [8.1%] vs 6 [9.7%] women; P = 0.752). Noticeable adverse effects were reported by 16 (25.8%) women in the 200-mu g group and 42 (67.7%) in the 400-mu g group (P < 0.001). Risk of shivering was significantly lower with 200-mu g than 400-mu g (relative risk 033, 95% confidence interval 0.19-0.58). Conclusion: Blood loss and PPH occurrence did not differ by misoprostol dose, but a 200-mu g dose was associated with a reduction in adverse effects. (C) 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Ugwu, Innocent A.; Oluwasola, Timothy A.; Enabor, Obehi O.; Adeyemi, Abolaji B.; Olayemi, Oladapo O.] Univ Coll Ibadan Hosp, Dept Obstet & Gynecol, PMB 5116, Ibadan, Nigeria.
   [Oluwasola, Timothy A.; Olayemi, Oladapo O.] Univ Ibadan, Coll Med, Dept Obstet & Gynecol, Ibadan, Nigeria.
   [Anayochukwu-Ugwu, Ngozi N.] Univ Coll Ibadan Hosp, Dept Hematol, Ibadan, Nigeria.
RP Oluwasola, TA (reprint author), Univ Coll Ibadan Hosp, Dept Obstet & Gynecol, PMB 5116, Ibadan, Nigeria.
EM sesanoluwasola@yahoo.com
CR Afolabi EO, 2010, SINGAP MED J, V51, P207
   Ajenifuja KO, 2010, AFR HEALTH SCI, V10, P71
   Alfirevic Z, 2007, INT J GYNECOL OBSTET, V99, pS198, DOI 10.1016/j.ijgo.2007.09.012
   Anderson JM, 2007, AM FAM PHYSICIAN, V75, P875
   Begley CM, 2015, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD007412.PUB4
   Bellad MB, 2012, BJOG-INT J OBSTET GY, V119, P975, DOI 10.1111/j.1471-0528.2012.03341.x
   Boulant JA, 2000, CLIN INFECT DIS, V31, pS157, DOI 10.1086/317521
   Chaudhuri P, 2015, INT J GYNECOL OBSTET, V128, P48, DOI 10.1016/j.ijgo.2014.07.029
   Danielsson KG, 1999, OBSTET GYNECOL, V93, P275, DOI 10.1016/S0029-7844(98)00436-0
   Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6
   Diab K M, 1999, J Obstet Gynaecol Res, V25, P327
   Elati A, 2011, BJOG-INT J OBSTET GY, V118, P466, DOI 10.1111/j.1471-0528.2010.02821.x
   ElRefaey H, 1997, BRIT J OBSTET GYNAEC, V104, P336, DOI 10.1111/j.1471-0528.1997.tb11464.x
   Enakpene CA, 2007, J OBSTET GYNAECOL RE, V33, P810, DOI 10.1111/j.1447-0756.2007.00661.x
   Hofmeyr GJ, 2009, B WORLD HEALTH ORGAN, V87, P666, DOI 10.2471/BLT.08.055715
   Hofmeyr GJ, 2013, COCHRANE DB SYST REV, V7
   KANOSUE K, 1994, AM J PHYSIOL, V267, pR275
   Mirteimouri M, 2013, IRAN J PHARM RES, V12, P469
   Musa AO, 2015, INT J GYNECOL OBSTET, V129, P227, DOI 10.1016/j.ijgo.2015.01.008
   Oyelese Y, 2010, CLIN OBSTET GYNECOL, V53, P147, DOI 10.1097/GRF.0b013e3181cc406d
   Tuncalp O, 2012, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD000494.PUB4
   Ujah I A O, 2005, Afr J Reprod Health, V9, P27
   Westhoff G, 2013, COCHRANE DB SYST REV, V10, DOI [DOI 10.1002/14651858.CD001808.PUB2, 10.1002/14651858.CD001808.pub2]
   WHO United Nations Children's Fund United Nations Population Fund Bank TW United Nations Population Division, TRENDS MAT MORT 1990
   World Health Organization, WHO REC PREV TREATM
NR 25
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD MAY
PY 2016
VL 133
IS 2
BP 173
EP 177
DI 10.1016/j.ijgo.2015.09.026
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DL6HE
UT WOS:000375739500010
PM 26892695
ER

PT J
AU Bor, P
   Ledertoug, S
   Boie, S
   Knoblauch, NO
   Stornes, I
AF Bor, P.
   Ledertoug, S.
   Boie, S.
   Knoblauch, N. O.
   Stornes, I.
TI Continuation Versus Discontinuation of Oxytocin Infusion During the
   Active Phase of Labor: A Randomized Controlled Trial EDITORIAL COMMENT
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
C1 [Bor, P.; Ledertoug, S.; Boie, S.; Knoblauch, N. O.; Stornes, I.] Reg Hosp Randers, Dept Obstet & Gynaecol, Randers, Denmark.
RP Bor, P (reprint author), Reg Hosp Randers, Dept Obstet & Gynaecol, Randers, Denmark.
CR THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851
   2008, AM J OBSTET GYNECOL, V198
   2007, AM J OBSTET GYNECOL, V197
   1995, N ENGL J MED, V333, P745
   [Anonymous], 1994, BJOG
NR 5
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAY
PY 2016
VL 71
IS 5
BP 267
EP 269
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DM3VL
UT WOS:000376274700003
ER

PT J
AU Maged, AM
   Hassan, AMA
   Shehata, NAA
AF Maged, Ahmed Mohamed
   Hassan, AbdelGany M. A.
   Shehata, Nesreen A. A.
TI Carbetocin versus oxytocin in the management of atonic post partum
   haemorrhage (PPH) after vaginal delivery: a randomised controlled trial
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Carbetocin; Oxytocin; Atonic postpartum haemorrhage; Vaginal delivery
ID POSTPARTUM HEMORRHAGE; CESAREAN DELIVERY; PREVENTION; INCREASE; SECTION;
   TRENDS
AB The objective of this study is to compare the effectiveness and safety of carbetocin vs. oxytocin in the management of atonic post partum haemorrhage (PPH) after vaginal delivery.
   A prospective randomised study was conducted in which 100 pregnant women were randomised into 2 equal groups: group 1 received Carbetocin 100 A mu gm (Pabal(A (R)) Ferring, UK) and group 2 received oxytocin 5 IU (Syntocinon(A (R)), Novartis, Switzerland).
   The amount of blood loss and the need for other uterotonics were significantly lower in the carbetocin group (811 +/- A 389.17 vs. 1010 +/- A 525.66 and 10/50 vs. 21/50). There was no significant difference between the carbetocin and oxytocin groups regarding occurrence of major PPH (6 vs. 11), the need for blood transfusion (6 vs. 9), the difference between blood haemoglobin levels before delivery and 24 h after delivery (0.6 +/- A 0.28 vs. 0.56 +/- A 0.25), respectively. There was no significant difference between the 2 study groups regarding both systolic and diastolic blood pressure measured immediately after the drug administration and at 30 and 60 min later. Regarding the drugs side effects, there was no significant difference between the 2 groups in the occurrence of nausea, vomiting, tachycardia, flushing, dizziness, headache, shivering, metallic taste, dyspnea, palpitations and itching.
   Carbetocin is a better alternative to oxytocin in management of atonic PPH with non-significant hemodynamic changes or side effects .
C1 [Maged, Ahmed Mohamed; Hassan, AbdelGany M. A.] Cairo Univ, Kasr Aini Hosp, Dept Obstet & Gynaecol, 1 Alsaraya St, Cairo, Egypt.
   [Shehata, Nesreen A. A.] Beni Suef Univ, Dept Obstet & Gynaecol, Bani Suwayf, Egypt.
RP Maged, AM (reprint author), Cairo Univ, Kasr Aini Hosp, Dept Obstet & Gynaecol, 1 Alsaraya St, Cairo, Egypt.
EM prof.ahmedmaged@gmail.com
OI Maged, Ahmed/0000-0001-7398-474X
CR Attilakos G, 2010, BJOG-INT J OBSTET GY, V117, P929, DOI 10.1111/j.1471-0528.2010.02585.x
   Boucher Marc, 2004, J Obstet Gynaecol Can, V26, P481
   Callaghan WM, 2010, AM J OBSTET GYNECOL, V202, P353, DOI DOI 10.1016/J.AJ0G.2010.01.011
   Canadian Perinatal Surveillance System, 2013, PER HLTH IND CAN 201
   CHARD T, 1970, J ENDOCRINOL, V48, P223, DOI 10.1677/joe.0.0480223
   Chong YS, 2004, CURR OPIN OBSTET GYN, V16, P143, DOI 10.1097/01.gco.0000124170.64477cd
   Elbourne DR, 2001, COCHRANE DB SYST REV, V4
   Ford JB, 2007, INT J GYNECOL OBSTET, V98, P237, DOI 10.1016/j.ijgo.2007.03.011
   Gulmezoglu AM, 2009, WHO GUIDELINES MANAG
   HUNTER DJS, 1992, CLIN PHARMACOL THER, V52, P60
   Joseph KS, 2007, BJOG-INT J OBSTET GY, V114, P751, DOI 10.1111/j.1471-0528.2007.01316.x
   Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55
   Kramer MS, 2013, AM J OBSTET GYNECOL, V209, P449, DOI DOI 10.1016/J.AJ0G.2013.07.007
   Liabsuetrakul T, 2007, COCHRANE DB SYST REV, V2
   Maged AM, 2015, J MATERN-FETAL NEO M, P1
   Mehrabadi A, 2013, BJOG-INT J OBSTET GY, V120, P853, DOI 10.1111/1471-0528.12149
   Mehrabadi A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-108
   Moertl MG, 2011, BJOG-INT J OBSTET GY, V118, P1349, DOI 10.1111/j.1471-0528.2011.03022.x
   NAEF RW, 1994, OBSTET GYNECOL, V83, P923
   Rossen J, 2010, ACTA OBSTET GYN SCAN, V89, P1248, DOI 10.3109/00016349.2010.514324
   Samimi M, 2013, IRAN RED CRESCENT ME, V15, P817, DOI 10.5812/ircmj.7881
   Smit M, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-194
   Su LL, 2007, COCHRANE DB SYST REV, V3
   Wedisinghe L, 2008, EUR J OBSTET GYN R B, V137, P27, DOI 10.1016/j.ejogrb.2007.04.007
   World Health Organization (WHO), 2012, TRENDS MAT MORT 1990
NR 25
TC 0
Z9 0
U1 4
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAY
PY 2016
VL 293
IS 5
BP 993
EP 999
DI 10.1007/s00404-015-3911-y
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DL7DF
UT WOS:000375799300009
PM 26511939
ER

PT J
AU Kanthak, MK
   Chen, FS
   Kumsta, R
   Hill, LK
   Thayer, JF
   Heinrichs, M
AF Kanthak, Magdalena K.
   Chen, Frances S.
   Kumsta, Robert
   Hill, LaBarron K.
   Thayer, Julian F.
   Heinrichs, Markus
TI Oxytocin receptor gene polymorphism modulates the effects of social
   support on heart rate variability
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Article
DE Stress-buffering; Molecular genetics; Oxytocin; Autonomic; Heart rate
   variability; Individual differences
ID SUBJECTIVE RESPONSES; NERVOUS-SYSTEM; STRESS; OXTR; CORTISOL;
   REACTIVITY; INTERACT; CULTURE; HUMANS; HEALTH
AB A large body of empirical research has demonstrated stress-buffering effects of social support. However, recent studies suggest that genetic variation of the oxytocin system (specifically, a common single nucleotide polymorphism, rs53576, of the oxytocin receptor gene) modulates the efficacy of social support. The timing and neurobiological basis of this genetic modulation were investigated using a standardized, laboratory-based psychological stress procedure (Trier Social Stress Test for Groups, TSST-G). To index potential stress buffering effects of social support mediated by the oxytocin system, heart rate variability (HRV) was obtained before and during the TSST-G from 40 healthy participants. Results indicate that social support is associated with higher HRV only in G allele carriers. Specifically, social support increased heart rate variability during direct social interaction and only in individuals with at least one copy of the G allele of rs53576. These findings support the idea that the stress-attenuating effects of social support are modulated by genetic variation of the oxytocin system. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Kanthak, Magdalena K.; Chen, Frances S.; Heinrichs, Markus] Univ Freiburg, Dept Psychol, Lab Biol & Personal Psychol, Stefan Meier Str 8, D-79104 Freiburg, Germany.
   [Kanthak, Magdalena K.] Tech Univ Dresden, Dept Biol Psychol, Dresden, Germany.
   [Chen, Frances S.] Univ British Columbia, Dept Psychol, 3521-2136 West Mall, Vancouver, BC V6T 1Z4, Canada.
   [Kumsta, Robert] Ruhr Univ Bochum, Fac Psychol, Dept Genet Psychol, Bochum, Germany.
   [Hill, LaBarron K.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.
   [Hill, LaBarron K.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Thayer, Julian F.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA.
   [Heinrichs, Markus] Univ Freiburg, Univ Med Ctr, Freiburg Brain Imaging, D-79104 Freiburg, Germany.
RP Heinrichs, M (reprint author), Univ Freiburg, Dept Psychol, Lab Biol & Personal Psychol, Stefan Meier Str 8, D-79104 Freiburg, Germany.; Chen, FS (reprint author), Univ British Columbia, Dept Psychol, 3521-2136 West Mall, Vancouver, BC V6T 1Z4, Canada.
EM frances.chen@psych.ubc.ca; heinrichs@psychologie.uni-freiburg.de
RI Kumsta, Robert/P-9641-2016
OI Kumsta, Robert/0000-0001-6006-6958
FU Swiss National Science Foundation [SNSF PP001-114788]; Deutsche
   Forschungsgemeinschaft [HE 5310/1-1]; AXA Foundation; National Institute
   of Aginggrant [5T32AG000029-38]
FX We thank Dr. Bernadette von Dawans for assistance during study
   preparation, and Eva Bareth, Daniela Conrad, Melanie Filser, Angela
   Herwede, Irini Johann, Juliane Kant, Theresa Lueer, Maurice Mink, Maxi
   Pannicke, Marina Pohl, Anna Sartori, Katja Schlichtig, Alexandra
   Schultz, Philomena Storz, and Julia-Caroline Walther for assistance
   during data collection. This study was supported by Swiss National
   Science Foundation Research Grant SNSF PP001-114788 (to M.H.). M.H.,
   F.S.C, and R.K. gratefully acknowledge grant support from the Deutsche
   Forschungsgemeinschaft (HE 5310/1-1). F.S.C. gratefully acknowledges
   support from a research fellowship of the AXA Foundation. L.K.H. was
   supported by a National Institute of Aginggrant (5T32AG000029-38).
CR Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004
   Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779
   Chen FS, 2011, P NATL ACAD SCI USA, V108, P19937, DOI 10.1073/pnas.1113079108
   COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037//0278-6133.7.3.269
   Coote JH, 2013, J PHYSIOL-LONDON, V591, P4073, DOI 10.1113/jphysiol.2013.257758
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   Ditzen B, 2008, J PSYCHOSOM RES, V64, P479, DOI 10.1016/j.jpsychores.2007.11.011
   Fahrenberg J., 2001, FPI R FREIBURGER PER
   Friedman BH, 1998, J PSYCHOSOM RES, V44, P133, DOI 10.1016/S0022-3999(97)00202-X
   Gianaros PJ, 2004, PSYCHOPHYSIOLOGY, V41, P521, DOI 10.1111/j.1469-8986.2004.00179.x
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
   Higa KT, 2002, AM J PHYSIOL-REG I, V282, pR537
   INOUE T, 1994, J BIOL CHEM, V269, P32451
   Kim HS, 2008, AM PSYCHOL, V63, P518, DOI 10.1037/0003-066X
   Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P23
   Kok BE, 2010, BIOL PSYCHOL, V85, P432, DOI 10.1016/j.biopsycho.2010.09.005
   Kumsta R, 2013, CURR OPIN NEUROBIOL, V23, P11, DOI 10.1016/j.conb.2012.09.004
   Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001
   LEPORE SJ, 1993, PSYCHOSOM MED, V55, P518
   Looser RR, 2010, PSYCHOSOM MED, V72, P281, DOI 10.1097/PSY.0b013e3181d35065
   Lucht MJ, 2009, PROG NEURO-PSYCHOPH, V33, P860, DOI 10.1016/j.pnpbp.2009.04.004
   LUITEN PGM, 1985, BRAIN RES, V329, P374, DOI 10.1016/0006-8993(85)90554-2
   Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-7967(97)10031-6
   Maunder RG, 2012, INFLAMM BOWEL DIS, V18, P737, DOI 10.1002/ibd.21794
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Norman GJ, 2012, HORM BEHAV, V61, P134, DOI 10.1016/j.yhbeh.2011.11.006
   Porges SW, 1997, ANN NY ACAD SCI, V807, P62, DOI 10.1111/j.1749-6632.1997.tb51913.x
   Porges SW, 2001, INT J PSYCHOPHYSIOL, V42, P123, DOI 10.1016/S0167-8760(01)00162-3
   Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7
   Pruessner JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4
   Riem MME, 2011, SOC COGN AFFECT NEUR, V6, P294, DOI 10.1093/scan/nsq035
   Rodrigues SM, 2009, P NATL ACAD SCI USA, V106, P21437, DOI 10.1073/pnas.0909579106
   ROGERS RC, 1986, PEPTIDES, V7, P695, DOI 10.1016/0196-9781(86)90046-X
   Saphire-Bernstein S, 2011, P NATL ACAD SCI USA, V108, P15118, DOI 10.1073/pnas.1113137108
   Sasaki JY, 2011, J CROSS CULT PSYCHOL, V42, P1394, DOI 10.1177/0022022111412526
   Schmidt K.-H., 1992, WORTSCHATZTEST WST
   SHUMAKER SA, 1991, HEALTH PSYCHOL, V10, P102, DOI 10.1037/0278-6133.10.2.102
   Smith TW, 2011, J PERS SOC PSYCHOL, V100, P103, DOI 10.1037/a0021136
   Spielberger C., 1983, MANUAL STATE TRAIT A
   Higa-Taniguchi K. T., 2009, EXPT PHYSL, V94, P1103
   Tarvainen MP, 2009, IFMBE PROC, V22, P1022
   Taylor SE, 2007, PSYCHOL SCI, V18, P831, DOI 10.1111/j.1467-9280.2007.01987.x
   Thayer J. F., 2008, HDB PHYSL RES METHOD, P183
   Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009
   Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004
   Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107
   Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488
   Viviani D, 2011, SCIENCE, V333, P104, DOI 10.1126/science.1201043
   von Dawans B, 2011, PSYCHONEUROENDOCRINO, V36, P514, DOI 10.1016/j.psyneuen.2010.08.004
   Weihs KL, 2005, J PSYCHOSOM RES, V59, P299, DOI 10.1016/j.jpsychores.2004.12.002
   Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013
NR 57
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
EI 1873-6246
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD MAY
PY 2016
VL 117
BP 43
EP 49
DI 10.1016/j.biopsycho.2016.02.007
PG 7
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
   Experimental
SC Psychology; Behavioral Sciences
GA DL5CE
UT WOS:000375654000006
PM 26903384
ER

EF